PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	O'Brien, KL; Levine, OS; Knoll, MD; Feikin, DR; DeLuca, AN; Driscoll, AJ; Fancourt, N; Fu, W; Haddix, M; Hammitt, LL; Higdon, MM; Kagucia, EW; Karron, RA; Li, MY; Park, DE; Prosperi, C; Shi, QY; Wu, ZK; Zeger, SL; Watson, NL; Crawley, J; Murdoch, DR; Brooks, WA; Endtz, HP; Zaman, K; Goswami, D; Hossain, L; Jahan, Y; Chisti, MJ; Howie, SRC; Ebruke, BE; Antonio, M; McLellan, JL; Machuka, EM; Shamsul, A; Zaman, SMA; Mackenzie, G; Scott, JAG; Awori, JO; Morpeth, SC; Kamau, A; Kazungu, S; Ominde, MS; Kotloff, KL; Tapia, MD; Sow, SO; Sylla, M; Tamboura, B; Onwuchekwa, U; Kourouma, N; Toure, A; Sissoko, S; Madhi, SA; Moore, DP; Adrian, PV; Baillie, VL; Kuwanda, L; Mudau, A; Groome, MJ; Mahomed, N; Simoes, EAF; Baggett, HC; Thamthitiwat, S; Maloney, SA; Bunthi, C; Rhodes, J; Sawatwong, P; Akarasewi, P; Thea, DM; Mwananyanda, L; Chipeta, J; Seidenberg, P; Mwansa, J; Somwe, SW; Kwenda, G; Anderson, TP; Mitchell, JL				O'Brien, Katherine L.; Levine, Orin S.; Knoll, Maria Deloria; Feikin, Daniel R.; DeLuca, Andrea N.; Driscoll, Amanda J.; Fancourt, Nicholas; Fu, Wei; Haddix, Meredith; Hammitt, Laura L.; Higdon, Melissa M.; Kagucia, E. Wangeci; Karron, Ruth A.; Li, Mengying; Park, Daniel E.; Prosperi, Christine; Shi, Qiyuan; Wu, Zhenke; Zeger, Scott L.; Watson, Nora L.; Crawley, Jane; Murdoch, David R.; Brooks, W. Abdullah; Endtz, Hubert P.; Zaman, Khalequ; Goswami, Doli; Hossain, Lokman; Jahan, Yasmin; Chisti, Mohammod Jobayer; Howie, Stephen R. C.; Ebruke, Bernard E.; Antonio, Martin; McLellan, Jessica L.; Machuka, Eunice M.; Shamsul, Arifin; Zaman, Syed M. A.; Mackenzie, Grant; Scott, J. Anthony G.; Awori, Juliet O.; Morpeth, Susan C.; Kamau, Alice; Kazungu, Sidi; Ominde, Micah Silaba; Kotloff, Karen L.; Tapia, Milagritos D.; Sow, Samba O.; Sylla, Mamadou; Tamboura, Boubou; Onwuchekwa, Uma; Kourouma, Nana; Toure, Aliou; Sissoko, Seydou; Madhi, Shabir A.; Moore, David P.; Adrian, Peter V.; Baillie, Vicky L.; Kuwanda, Locadiah; Mudau, Azwifarwi; Groome, Michelle J.; Mahomed, Nasreen; Simoes, Eric A. F.; Baggett, Henry C.; Thamthitiwat, Somsak; Maloney, Susan A.; Bunthi, Charatdao; Rhodes, Julia; Sawatwong, Pongpun; Akarasewi, Pasakorn; Thea, Donald M.; Mwananyanda, Lawrence; Chipeta, James; Seidenberg, Phil; Mwansa, James; Somwe, Somwe Wa; Kwenda, Geoffrey; Anderson, Trevor P.; Mitchell, Joanne L.		PERCH Study Grp	Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study	LANCET			English	Article							PNEUMOCOCCAL CONJUGATE VACCINE; POLYMERASE-CHAIN-REACTION; INDUCED SPUTUM SPECIMENS; CHILDHOOD PNEUMONIA; ETIOLOGY RESEARCH; YOUNG-CHILDREN; STANDARDIZED INTERPRETATION; DEVELOPING-COUNTRIES; PEDIATRIC PNEUMONIA; RESPIRATORY VIRUSES	Background Pneumonia is the leading cause of death among children younger than 5 years. In this study, we estimated causes of pneumonia in young African and Asian children, using novel analytical methods applied to clinical and microbiological findings. Methods We did a multi-site, international case-control study in nine study sites in seven countries: Bangladesh, The Gambia, Kenya, Mali, South Africa, Thailand, and Zambia. All sites enrolled in the study for 24 months. Cases were children aged 1-59 months admitted to hospital with severe pneumonia. Controls were age-group-matched children randomly selected from communities surrounding study sites. Nasopharyngeal and oropharyngeal (NP-OP), urine, blood, induced sputum, lung aspirate, pleural fluid, and gastric aspirates were tested with cultures, multiplex PCR, or both. Primary analyses were restricted to cases without HIV infection and with abnormal chest x-rays and to controls without HIV infection. We applied a Bayesian, partial latent class analysis to estimate probabilities of aetiological agents at the individual and population level, incorporating case and control data. Findings Between Aug 15, 2011, and Jan 30, 2014, we enrolled 4232 cases and 5119 community controls. The primary analysis group was comprised of 1769 (41.8% of 4232) cases without HIV infection and with positive chest x-rays and 5102 (99.7% of 5119) community controls without HIV infection. Wheezing was present in 555 (31.7%) of 1752 cases (range by site 10.6-97.3%). 30-day case-fatality ratio was 6.4% (114 of 1769 cases). Blood cultures were positive in 56 (3.2%) of 1749 cases, and Streptococcus pneumoniae was the most common bacteria isolated (19 [33.9%] of 56). Almost all cases (98.9%) and controls (98.0%) had at least one pathogen detected by PCR in the NP-OP specimen. The detection of respiratory syncytial virus (RSV), parainfluenza virus, human metapneumovirus, influenza virus, S pneumoniae, Haemophilus influenzae type b (Hib), H influenzae non-type b, and Pneumocystis jirovecii in NP-OP specimens was associated with case status. The aetiology analysis estimated that viruses accounted for 61.4% (95% credible interval [CrI] 57.3-65.6) of causes, whereas bacteria accounted for 27.3% (2.3-31.6) and Mycobacterium tuberculosis for 5.9% (3.9-8.3). Viruses were less common (54.5%, 95% CrI 47.4-61.5 vs 68.0%, 62.7-72.7) and bacteria more common (33.7%, 27.2-40.8 vs 22.8%, 18.3-27.6) in very severe pneumonia cases than in severe cases. RSV had the greatest aetiological fraction (31.1%, 95% CrI 28.4-34.2) of all pathogens. Human rhinovirus, human metapneumovirus A or B, human parainfluenza virus, S pneumoniae, M tuberculosis, and H influenzae each accounted for 5% or more of the aetiological distribution. We observed differences in aetiological fraction by age for Bordetella pertussis, parainfluenza types 1 and 3, parechovirus-enterovirus, P jirovecii, RSV, rhinovirus, Staphylococcus aureus, and S pneumoniae, and differences by severity for RSV, S aureus, S pneumoniae, and parainfluenza type 3. The leading ten pathogens of each site accounted for 79% or more of the site's aetiological fraction. Interpretation In our study, a small set of pathogens accounted for most cases of pneumonia requiring hospital admission. Preventing and treating a subset of pathogens could substantially affect childhood pneumonia outcomes. Copyright (C) 2019 The Author(s). Published by Elsevier Ltd.	[O'Brien, Katherine L.; Levine, Orin S.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Knoll, Maria Deloria; Feikin, Daniel R.] Bill & Melinda Gates Fdn, Seattle, WA USA; [Knoll, Maria Deloria; Feikin, Daniel R.] US Ctr Dis Control & Prevent, Atlanta, GA USA; [DeLuca, Andrea N.; Driscoll, Amanda J.; Fancourt, Nicholas; Fu, Wei; Haddix, Meredith; Hammitt, Laura L.; Higdon, Melissa M.; Kagucia, E. Wangeci; Karron, Ruth A.; Li, Mengying; Park, Daniel E.; Prosperi, Christine; Shi, Qiyuan; Wu, Zhenke; Zeger, Scott L.] Emmes Corp, Rockville, MD USA; [Crawley, Jane] Univ Oxford, Nuffield Dept Clin Med, Oxford, England; [Murdoch, David R.] Univ Otago, Christchurch, New Zealand; [Brooks, W. Abdullah; Endtz, Hubert P.; Zaman, Khalequ; Goswami, Doli; Hossain, Lokman; Jahan, Yasmin; Chisti, Mohammod Jobayer] Int Ctr Diarrhoeal Dis Res, Dhaka, Bangladesh; [Howie, Stephen R. C.; Ebruke, Bernard E.; Antonio, Martin; McLellan, Jessica L.; Machuka, Eunice M.; Shamsul, Arifin; Zaman, Syed M. A.; Mackenzie, Grant] MRC, Basse, Gambia; [Scott, J. Anthony G.] KEMRI Wellcome Trust Res Programme, Kilifi, Kenya; [Scott, J. Anthony G.] London Sch Hyg & Trop Med, London, England; [Awori, Juliet O.; Morpeth, Susan C.; Kamau, Alice; Kazungu, Sidi; Ominde, Micah Silaba] Univ Maryland, Sch Med, Div Infect Dis & Trop Pediat, Dept Pediat,Ctr Vaccine Dev, Baltimore, MD 21201 USA; [Kotloff, Karen L.; Tapia, Milagritos D.; Sow, Samba O.; Sylla, Mamadou; Tamboura, Boubou; Onwuchekwa, Uma; Kourouma, Nana; Toure, Aliou; Sissoko, Seydou] Ctr Dev Vaccins CVD Mali, Bamako, Mali; [Kotloff, Karen L.; Tapia, Milagritos D.; Sow, Samba O.; Sylla, Mamadou; Tamboura, Boubou; Onwuchekwa, Uma; Kourouma, Nana; Toure, Aliou; Sissoko, Seydou] Univ Witwatersrand, MRC, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa; [Kotloff, Karen L.; Tapia, Milagritos D.; Sow, Samba O.; Sylla, Mamadou; Tamboura, Boubou; Onwuchekwa, Uma; Kourouma, Nana; Toure, Aliou; Sissoko, Seydou] Univ Witwatersrand, Natl Res Fdn, Dept Sci & Technol, Vaccine Preventable Dis, Johannesburg, South Africa; [Madhi, Shabir A.; Moore, David P.; Adrian, Peter V.; Baillie, Vicky L.; Kuwanda, Locadiah; Mudau, Azwifarwi; Groome, Michelle J.; Mahomed, Nasreen; Simoes, Eric A. F.] US Ctr Dis Control & Prevent Collaborat, Thailand Minist Publ Hlth, Nonthaburi, Thailand; [Baggett, Henry C.; Thamthitiwat, Somsak; Maloney, Susan A.; Bunthi, Charatdao; Rhodes, Julia; Sawatwong, Pongpun; Akarasewi, Pasakorn] Boston Univ, Sch Publ Hlth, Boston, MA USA; [Thea, Donald M.; Mwananyanda, Lawrence; Chipeta, James; Seidenberg, Phil; Mwansa, James; Somwe, Somwe Wa; Kwenda, Geoffrey] Univ Teaching Hosp, Lusaka, Zambia; [Thea, Donald M.; Mwananyanda, Lawrence; Chipeta, James; Seidenberg, Phil; Mwansa, James; Somwe, Somwe Wa; Kwenda, Geoffrey] Canterbury Hlth Labs, Christchurch, New Zealand	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Bill & Melinda Gates Foundation; Centers for Disease Control & Prevention - USA; Emmes Corporation; University of Oxford; University of Otago; International Centre for Diarrhoeal Disease Research (ICDDR); University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University System of Maryland; University of Maryland Baltimore; University of Witwatersrand; National Research Foundation - South Africa; University of Witwatersrand; Ministry of Public Health - Thailand; Boston University; University of Zambia; Canterbury Health Laboratories	O'Brien, KL (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Dept Int Hlth, Baltimore, MD 21231 USA.	obrienk@who.int	Ebruke, Bernard/AAX-7133-2020; Murdoch, David/A-2012-2009; Park, Daniel/R-5604-2016; Machuka, Eunice/AFK-3646-2022; Groome, Michelle Jennifer/AAI-9967-2021; Jahan, Yasmin/AFM-4321-2022; Brooks, W. Abdullah/AAD-3876-2021; Jahan, Yasmin/GOV-3711-2022; Moore, David/AAU-7186-2020; Machuka, Eunice/AAG-2443-2022; Wu, Zhenke/U-7793-2019	Park, Daniel/0000-0001-5139-5397; Machuka, Eunice/0000-0002-1142-3442; Groome, Michelle Jennifer/0000-0001-5893-3725; Jahan, Yasmin/0000-0001-9273-9651; Brooks, W. Abdullah/0000-0001-9871-5546; Moore, David/0000-0001-6091-1605; Machuka, Eunice/0000-0002-1142-3442; Wu, Zhenke/0000-0001-7582-669X; Baillie, Vicky Lynne/0000-0003-1327-9090; Mackenzie, Grant/0000-0002-4994-2627; Deloria Knoll, Maria/0000-0001-9041-2671; Thea, Donald/0000-0002-6933-1030; Kamau, Alice/0000-0001-9846-5372; Higdon, Melissa/0000-0002-1932-9442; Zeger, Scott/0000-0001-8907-1603	Bill & Melinda Gates Foundation [48968]; Wellcome Trust (UK) [098532]	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Wellcome Trust (UK)(Wellcome Trust)	Bill & Melinda Gates Foundation.; The PERCH study was supported by grant 48968 from the Bill & Melinda Gates Foundation to the International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health (Baltimore, MD, USA). JAGS was supported by a clinical fellowship from the Wellcome Trust (UK; 098532). We gratefully acknowledge the substantial contributions to the design of the study by the Pneumonia Methods Working Group (Zulfiqar A Bhutta, Robert E Black, Harry Campbell, Thomas Cherian, Derrick Crook, Menno D de Jong, Scott F Dowell, Stephen M Graham, Keith P Klugman, Claudio F Lanata, Shabir A Madhi, Paul Martin, James Nataro, Franco Piazza, Shamim Ahmed Qazi, Heather Zar) and the PERCH Site Selection Committee (David L Blazes, Robert Bollinger, Claire V Broome, John A Crump, Olivier Fontaine, Robert Gie, David Goldblatt, Patrick W Kelley, Sharon J Peacock, Mark S Riddle, Montse Soriano-Gabarro, Annelies Van Rie, Christopher W Woods). The PERCH Expert Group (William C Blackwelder, Harry Campbell, John A Crump, Menno D de Jong, Adegoke Falade, Claudio F Lanata, Kim Mulholland, Shamim Ahmed Qazi, Cynthia G Whitney) provided valuable advice during the conduct of the study and the analysis of the results for which we are indebted. We also recognise the support provided by the Institutional Review Boards for study oversight. We appreciate the helpful discussions with our many colleagues who were conducting aetiology studies of pneumonia, neonatal sepsis, and diarrhoea during the same period, including the EPIC study, the GABRIEL study, the ANISA study, and the GEMS study. We acknowledge the work of all PERCH contributors who were involved in data collection at the local sites and central laboratories, members of the PERCH Chest Radiograph Reading Panel (see appendix for the list of members in each group), and Shalika Jayawardena and Rose Watt from Canterbury Health Laboratories. Finally, we gratefully recognise the willingness and confidence in the study by the parents of the participating children and express our gratitude for their commitment to the advancement of knowledge toward better health for children of their community and those of other communities. This paper is published with the permission of the Director of the Kenya Medical Research Institute. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention, US Department of Health and Human Services, or the US Government.	Baggett HC, 2017, CLIN INFECT DIS, V64, pS317, DOI 10.1093/cid/cix100; Baggett HC, 2009, CLIN INFECT DIS, V48, pS65, DOI 10.1086/596484; BALE JR, 1990, REV INFECT DIS, V12, pS861; Barger-Kamate B, 2016, CLIN INFECT DIS, V63, pS187, DOI 10.1093/cid/ciw546; Benet T, 2017, CLIN INFECT DIS, V54, pS861; Benet T, 2017, AM J TROP MED HYG, V97, P68, DOI 10.4269/ajtmh.16-0733; Broutin H, 2005, AM J EPIDEMIOL, V161, P1159, DOI 10.1093/aje/kwi141; Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353; Cox N, 2014, B WORLD HEALTH ORGAN, V92, P311, DOI 10.2471/BLT.14.139428; Crawley J, 2017, CLIN INFECT DIS, V64, pS228, DOI 10.1093/cid/cix077; Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6; Dagan R, 1998, J CLIN MICROBIOL, V36, P669, DOI 10.1128/JCM.36.3.669-673.1998; Dawood FS, 2016, PEDIATR PULM, V51, P588, DOI 10.1002/ppul.23343; Deloria-Knoll M, 2012, CLIN INFECT DIS, V54, pS117, DOI 10.1093/cid/cir1066; DeLuca AN, 2012, CLIN INFECT DIS, V54, pS172, DOI 10.1093/cid/cir1063; Dowell SF, 2001, CLIN INFECT DIS, V32, P824, DOI 10.1086/319205; Driscoll AJ, 2017, CLIN INFECT DIS, V64, pS368, DOI 10.1093/cid/cix101; Driscoll AJ, 2017, CLIN INFECT DIS, V64, pS245, DOI 10.1093/cid/cix081; Fancourt N, 2017, CLIN INFECT DIS, V64, pS253, DOI 10.1093/cid/cix082; Fancourt N, 2017, CLIN INFECT DIS, V64, pS262, DOI 10.1093/cid/cix089; Feikin DR, 2017, CLIN INFECT DIS, V64, pS337, DOI 10.1093/cid/cix148; Feikin DR, 2017, CLIN INFECT DIS, V64, pS188, DOI 10.1093/cid/cix143; Feikin DR, 2014, LANCET, V383, P1762, DOI 10.1016/S0140-6736(13)61682-7; Feikin DR, 2016, REPROD MATERNAL NEWB, V2; Fry AM, 2006, CLIN INFECT DIS, V43, P1016, DOI 10.1086/507638; Gelman A., 2013, BAYESIAN DATA ANAL M; Gilani Z, 2012, CLIN INFECT DIS, V54, pS102, DOI 10.1093/cid/cir1053; Grant LR, 2012, CLIN INFECT DIS, V54, pS140, DOI [10.1093/cid/cir1069, 10.1093/cid/cir1073]; Hammitt LL, 2017, CLIN INFECT DIS, V64, pS197, DOI 10.1093/cid/cix147; Higdon MM, 2017, CLIN INFECT DIS, V64, pS205, DOI 10.1093/cid/cix076; Ideh RC, 2011, INT J TUBERC LUNG D, V15, P729, DOI 10.5588/ijtld.10.0468; Jain S, 2015, NEW ENGL J MED, V372, P835, DOI 10.1056/NEJMoa1405870; Johnson HL, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000348; Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060; Knoll MD, 2017, CLIN INFECT DIS, V64, pS357, DOI 10.1093/cid/cix149; Knoll MD, 2017, CLIN INFECT DIS, V64, pS213, DOI 10.1093/cid/cix144; Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2; Lee LA, 2013, VACCINE, V31, pB61, DOI 10.1016/j.vaccine.2012.11.035; Levine OS, 2012, CLIN INFECT DIS, V54, pS93, DOI 10.1093/cid/cir1052; Liu L, 2016, LANCET, V388, P3027, DOI 10.1016/S0140-6736(16)31593-8; Moore DP, 2017, CLIN INFECT DIS, V64, pS309, DOI 10.1093/cid/cix099; Morpeth SC, 2017, CLIN INFECT DIS, V64, pS347, DOI 10.1093/cid/cix145; Murdoch DR, 2017, CLIN INFECT DIS, V64, pS271, DOI 10.1093/cid/cix083; Murdoch DR, 2017, CLIN INFECT DIS, V64, pS280, DOI 10.1093/cid/cix090; Murray EL, 2012, INDOOR AIR, V22, P132, DOI 10.1111/j.1600-0668.2011.00754.x; Ngari MM, 2017, PAEDIATR PERINAT EP, V31, P233, DOI 10.1111/ppe.12348; Nicol MP, 2011, PAEDIATR RESPIR REV, V12, P16, DOI 10.1016/j.prrv.2010.09.008; Omori R, 2015, SCI REP-UK, V5, DOI 10.1038/srep14473; Park DE, 2017, CLIN INFECT DIS, V64, pS328, DOI 10.1093/cid/cix104; Piralam B, 2015, AM J TROP MED HYG, V93, P1140, DOI 10.4269/ajtmh.15-0429; Pretorius MA, 2016, J CLIN VIROL, V75, P21, DOI 10.1016/j.jcv.2015.12.004; Ram PK, 2014, AM J TROP MED HYG, V90, P968, DOI 10.4269/ajtmh.13-0532; Rhodes J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066038; Saha SK, 2018, LANCET, V392, P145, DOI 10.1016/S0140-6736(18)31127-9; Scott JAG, 2012, CLIN INFECT DIS, V54, pS109, DOI 10.1093/cid/cir1065; SELWYN BJ, 1990, REV INFECT DIS, V12, pS870; Spichak TV, 2016, EUR J PEDIATR, V175, P1951, DOI 10.1007/s00431-016-2791-x; Tang JW, 2017, LANCET INFECT DIS, V17, pE320, DOI 10.1016/S1473-3099(17)30238-4; The PERCH Study Group, 2012, PNEUM ET RES CHILD H; Thea DM, 2017, CLIN INFECT DIS, V64, pS289, DOI 10.1093/cid/cix098; Tregnaghi MW, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001657; Turner P, 2011, J CLIN MICROBIOL, V49, P1784, DOI 10.1128/JCM.00157-11; Watson NL, 2017, CLIN INFECT DIS, V64, pS238, DOI 10.1093/cid/cix080; World Health Organization, 2009, WHO ANTHROPLUS SOFTW; World Health Organization, 1991, TECHN BAS WHO REC MA; World Health Organization (WHO), 2005, POCK BOOK HOSP CAR C; Wu ZK, 2017, BIOSTATISTICS, V18, P200, DOI 10.1093/biostatistics/kxw037; Wu ZK, 2016, J R STAT SOC C-APPL, V65, P97, DOI 10.1111/rssc.12101; Zar HJ, 2016, LANCET RESP MED, V4, P463, DOI 10.1016/S2213-2600(16)00096-5	69	329	335	6	48	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 31	2019	394	10200					757	779		10.1016/S0140-6736(19)30721-4	http://dx.doi.org/10.1016/S0140-6736(19)30721-4			23	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IT6UW	31257127	Green Published, hybrid, Green Accepted			2023-01-03	WOS:000483011400029
J	Chari, A; Vogl, DT; Gavriatopoulou, M; Nooka, AK; Yee, AJ; Huff, CA; Moreau, P; Dingli, D; Cole, C; Lonial, S; Dimopoulos, M; Stewart, AK; Richter, J; Vij, R; Tuchman, S; Raab, MS; Weisel, KC; Delforge, M; Cornell, RF; Kaminetzky, D; Hoffman, JE; Costa, LJ; Parker, TL; Levy, M; Schreder, M; Meuleman, N; Frenzel, L; Mohty, M; Choquet, S; Schiller, G; Comenzo, RL; Engelhardt, M; Illmer, T; Vlummens, P; Doyen, C; Facon, T; Karlin, L; Perrot, A; Podar, K; Kauffman, MG; Shacham, S; Li, L; Tang, S; Picklesimer, C; Saint-Martin, JR; Crochiere, M; Chang, H; Parekh, S; Landesman, Y; Shah, J; Richardson, PG; Jagannath, S				Chari, Ajai; Vogl, Dan T.; Gavriatopoulou, Maria; Nooka, Ajay K.; Yee, Andrew J.; Huff, Carol A.; Moreau, Philippe; Dingli, David; Cole, Craig; Lonial, Sagar; Dimopoulos, Meletios; Stewart, A. Keith; Richter, Joshua; Vij, Ravi; Tuchman, Sascha; Raab, Marc S.; Weisel, Katja C.; Delforge, Michel; Cornell, Robert F.; Kaminetzky, David; Hoffman, James E.; Costa, Luciano J.; Parker, Terri L.; Levy, Moshe; Schreder, Martin; Meuleman, Nathalie; Frenzel, Laurent; Mohty, Mohamad; Choquet, Sylvain; Schiller, Gary; Comenzo, Raymond L.; Engelhardt, Monika; Illmer, Thomas; Vlummens, Philip; Doyen, Chantal; Facon, Thierry; Karlin, Lionel; Perrot, Aurore; Podar, Klaus; Kauffman, Michael G.; Shacham, Sharon; Li, Lingling; Tang, Shijie; Picklesimer, Carla; Saint-Martin, Jean-Richard; Crochiere, Marsha; Chang, Hua; Parekh, Samir; Landesman, Yosef; Shah, Jatin; Richardson, Paul G.; Jagannath, Sundar			Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NUCLEAR EXPORT; SELECTIVE INHIBITOR; PHASE-I; TARGET; XPO1; MUTATIONS; CONSENSUS; CRITERIA; IMPACT	BackgroundSelinexor, a selective inhibitor of nuclear export compound that blocks exportin 1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, inhibits nuclear factor kappa B, and reduces oncoprotein messenger RNA translation, is a potential novel treatment for myeloma that is refractory to current therapeutic options. MethodsWe administered oral selinexor (80 mg) plus dexamethasone (20 mg) twice weekly to patients with myeloma who had previous exposure to bortezomib, carfilzomib, lenalidomide, pomalidomide, daratumumab, and an alkylating agent and had disease refractory to at least one proteasome inhibitor, one immunomodulatory agent, and daratumumab (triple-class refractory). The primary end point was overall response, defined as a partial response or better, with response assessed by an independent review committee. Clinical benefit, defined as a minimal response or better, was a secondary end point. ResultsA total of 122 patients in the United States and Europe were included in the modified intention-to-treat population (primary analysis), and 123 were included in the safety population. The median age was 65 years, and the median number of previous regimens was 7; a total of 53% of the patients had high-risk cytogenetic abnormalities. A partial response or better was observed in 26% of patients (95% confidence interval, 19 to 35), including two stringent complete responses; 39% of patients had a minimal response or better. The median duration of response was 4.4 months, median progression-free survival was 3.7 months, and median overall survival was 8.6 months. Fatigue, nausea, and decreased appetite were common and were typically grade 1 or 2 (grade 3 events were noted in up to 25% of patients, and no grade 4 events were reported). Thrombocytopenia occurred in 73% of the patients (grade 3 in 25% and grade 4 in 33%). Thrombocytopenia led to bleeding events of grade 3 or higher in 6 patients. ConclusionsSelinexor-dexamethasone resulted in objective treatment responses in patients with myeloma refractory to currently available therapies. (Funded by Karyopharm Therapeutics; STORM ClinicalTrials.gov number, NCT02336815.) Selinexor, a drug that inhibits nuclear export of tumor suppressor proteins, was tested in a phase 2 trial involving patients with myeloma whose disease had progressed despite treatment with proteasome inhibitors, immunomodulatory agents, alkylating agents, and monoclonal antibodies. A partial response or better was observed in 26% of patients, and the median overall survival was 8.6 months.	[Chari, Ajai; Parekh, Samir; Jagannath, Sundar] Icahn Sch Med Mt Sinai, Tisch Canc Inst, 1470 Madison Ave,3rd Fl, New York, NY 10029 USA; [Kaminetzky, David] NYU, Langone Med Ctr, New York, NY USA; [Vogl, Dan T.] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA; [Gavriatopoulou, Maria; Dimopoulos, Meletios] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece; [Nooka, Ajay K.; Lonial, Sagar] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA; [Yee, Andrew J.] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA; [Comenzo, Raymond L.] Tufts Med Ctr, Boston, MA 02111 USA; [Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Kauffman, Michael G.; Shacham, Sharon; Li, Lingling; Tang, Shijie; Picklesimer, Carla; Saint-Martin, Jean-Richard; Crochiere, Marsha; Chang, Hua; Landesman, Yosef; Shah, Jatin] Karyopharm Therapeut, Newton, MA USA; [Huff, Carol A.] Johns Hopkins Univ, Baltimore, MD USA; [Moreau, Philippe] Univ Nantes, Nantes, France; [Frenzel, Laurent] Hop Necker Enfants Malad, Paris, France; [Mohty, Mohamad] Hop St Antoine, Paris, France; [Choquet, Sylvain] La Pitie Salpetriere Hosp, Paris, France; [Facon, Thierry] Univ Hosp, Lille, France; [Karlin, Lionel] Ctr Hosp Lyon Sud, Pierre Benite, France; [Perrot, Aurore] Ctr Hosp Univ Vandoeuvre Les Nancy, Nancy, France; [Dingli, David] Mayo Clin, Rochester, MN USA; [Cole, Craig] Univ Michigan, Ann Arbor, MI 48109 USA; [Stewart, A. Keith] Mayo Clin Arizona, Phoenix, AZ USA; [Richter, Joshua] Hackensack Univ, Med Ctr, Hackensack, NJ USA; [Vij, Ravi] Washington Univ, Sch Med, St Louis, MO USA; [Tuchman, Sascha] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA; [Raab, Marc S.] Heidelberg Univ, Heidelberg, Germany; [Weisel, Katja C.] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany; [Weisel, Katja C.] Univ Tubingen, Tubingen, Germany; [Schreder, Martin] Univ Hosp Wurzburg, Wurzburg, Germany; [Engelhardt, Monika] Univ Freiburg, Freiburg, Germany; [Illmer, Thomas] Gemeinschaftspraxis Hamatol Onkol, Dresden, Germany; [Delforge, Michel] Univ Leuven, Leuven, Belgium; [Meuleman, Nathalie] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium; [Vlummens, Philip; Doyen, Chantal] Univ Hosp Ghent, Ghent, Belgium; [Doyen, Chantal] Ctr Hosp Univ Univ Catholique Louvain Namur, Yvoir, Belgium; [Cornell, Robert F.] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Hoffman, James E.] Univ Miami, Sylvester Canc Ctr, Miami, FL USA; [Costa, Luciano J.] Univ Alabama Birmingham, Birmingham, AL USA; [Parker, Terri L.] Yale Sch Med, New Haven, CT USA; [Levy, Moshe] Baylor Univ, Med Ctr, Dallas, TX USA; [Schiller, Gary] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Podar, Klaus] Karl Landsteiner Univ Hlth Sci, Univ Hosp Krems, Krems, Austria	Icahn School of Medicine at Mount Sinai; New York University; NYU Langone Medical Center; University of Pennsylvania; Pennsylvania Medicine; Athens Medical School; National & Kapodistrian University of Athens; Emory University; Harvard University; Massachusetts General Hospital; Tufts Medical Center; Harvard University; Dana-Farber Cancer Institute; Johns Hopkins University; Nantes Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite de Lille - ISITE; CHU Lille; CHU Lyon; Mayo Clinic; University of Michigan System; University of Michigan; Mayo Clinic; Mayo Clinic Phoenix; Hackensack University Medical Center; Washington University (WUSTL); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Eberhard Karls University of Tubingen; University of Wurzburg; University of Freiburg; KU Leuven; Institut Jules Bordet; Universite Libre de Bruxelles; Ghent University; Ghent University Hospital; Vanderbilt University; University of Miami; University of Alabama System; University of Alabama Birmingham; Yale University; Baylor University; Baylor University Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Jagannath, S (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, 1470 Madison Ave,3rd Fl, New York, NY 10029 USA.	sundar.jagannath@mountsinai.org	Dimopoulos, Meletios Athanasios/AAD-4130-2019; Gavriatopoulou, Maria/AAD-3698-2019; choquet, sylvain/O-7952-2017; Podar, Klaus/ABD-1112-2020	choquet, sylvain/0000-0002-7791-0470; Podar, Klaus/0000-0002-7414-3632; moreau, philippe/0000-0003-1780-8746; Perrot, Aurore/0000-0003-0131-8689; Mohty, Mohamad/0000-0002-7264-808X; Gavriatopoulou, Maria/0000-0002-6244-1229; Kaminetzky, M.D., David/0000-0003-4949-6951; Vlummens, Philip/0000-0001-8275-2887	Karyopharm Therapeutics	Karyopharm Therapeutics	Supported by Karyopharm Therapeutics.	Alexander TB, 2016, J CLIN ONCOL, V34, P4094, DOI 10.1200/JCO.2016.67.5066; Alvarez MJ, 2016, NAT GENET, V48, P838, DOI 10.1038/ng.3593; Argueta Christian, 2018, Oncotarget, V9, P25529, DOI 10.18632/oncotarget.25368; Chen Y, 2017, CLIN CANCER RES, V23, P1552, DOI 10.1158/1078-0432.CCR-16-1333; CORNELL RF, 2018, BLOOD S, V132, DOI DOI 10.1182/BLOOD-2018-99-115078; Gandhi UH, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-111033; Gasparetto CJ, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-117201; Golomb L, 2012, MOL CELL, V45, P222, DOI 10.1016/j.molcel.2011.11.022; Jardin F, 2016, AM J HEMATOL, V91, P923, DOI 10.1002/ajh.24451; Kashyap T, 2016, ONCOTARGET, V7, P78883, DOI 10.18632/oncotarget.12428; Kojima K, 2013, BLOOD, V121, P4166, DOI 10.1182/blood-2012-08-447581; Kumar SK, 2017, LEUKEMIA, V31, P2443, DOI 10.1038/leu.2017.138; Kumar S, 2016, LANCET ONCOL, V17, pE328, DOI 10.1016/S1470-2045(16)30206-6; Machlus KR, 2017, BLOOD, V130, P1132, DOI 10.1182/blood-2016-11-752840; National Cancer Institute, 2010, COMM TERM CRIT ADV E; Neggers JE, 2015, CHEM BIOL, V22, P107, DOI 10.1016/j.chembiol.2014.11.015; Noske A, 2008, CANCER-AM CANCER SOC, V112, P1733, DOI 10.1002/cncr.23354; Pick M, 2018, EUR J HAEMATOL, V100, P494, DOI 10.1111/ejh.13046; Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470-2045(14)70442-5; Rajkumar SV, 2011, BLOOD, V117, P4691, DOI 10.1182/blood-2010-10-299487; Razak ARA, 2016, J CLIN ONCOL, V34, P4142, DOI 10.1200/JCO.2015.65.3949; Schmidt J, 2013, LEUKEMIA, V27, P2357, DOI 10.1038/leu.2013.172; Sonneveld P, 2016, BLOOD, V127, P2955, DOI 10.1182/blood-2016-01-631200; Sun QX, 2013, P NATL ACAD SCI USA, V110, P1303, DOI 10.1073/pnas.1217203110; Tai YT, 2014, LEUKEMIA, V28, P155, DOI 10.1038/leu.2013.115; Tan DSP, 2014, CANCER DISCOV, V4, P527, DOI 10.1158/2159-8290.CD-13-1005; Turner JG, 2016, ONCOTARGET, V7, P78896, DOI 10.18632/oncotarget.12969; Usmani S, 2016, ONCOLOGIST, V21, P1355, DOI 10.1634/theoncologist.2016-0104; Vogl DT, 2018, J CLIN ONCOL, V36, P859, DOI 10.1200/JCO.2017.75.5207; Yoshimura M, 2014, CANCER SCI, V105, P795, DOI 10.1111/cas.12430	30	298	304	2	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 22	2019	381	8					727	738		10.1056/NEJMoa1903455	http://dx.doi.org/10.1056/NEJMoa1903455			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IT9MC	31433920	Bronze			2023-01-03	WOS:000483203400008
J	Li, J; Zhu, XD; Wang, HS; Lee, CP; Chen, SJ; Qian, YY; Han, M; Bunney, R; Beiser, DG; Hoek, TLV				Li, Jing; Zhu, Xiangdong; Wang, Huashan; Lee, Chunpei; Chen, Sy-Jou; Qian, Yuanyu; Han, Mei; Bunney, Ryan; Beiser, David G.; Hoek, Terry L. Vanden			Akt1-mediated CPR cooling protection targets regulators of metabolism, inflammation and contractile function in mouse cardiac arrest	PLOS ONE			English	Article							FACTOR-KAPPA-B; THERAPEUTIC HYPOTHERMIA CARDIOPROTECTION; PYRUVATE-DEHYDROGENASE COMPLEX; MILD HYPOTHERMIA; AKT; RESUSCITATION; ACTIVATION; INHIBITION; HEART; PHOSPHOLAMBAN	Therapeutic hypothermia initiated during cardiopulmonary resuscitation (CPR) in pre-clinical studies appears to be highly protective against sudden cardiac arrest injury. Given the challenges to implementing CPR cooling clinically, insights into its critical mechanisms of protection could guide development of new CPR drugs that mimic hypothermia effects without the need for physical cooling. Here, we used Akt1-deficient mice that lose CPR hypothermia protection to identify hypothermia targets. Adult female C57BL/6 mice (Akt1(+/+) and Akt1(+/-)) underwent 8 min of KCl-induced asystolic arrest and were randomized to receive hypothermia (30 +/- 0.5 degrees C) or normothermia. Hypothermia was initiated during CPR and extended for 1 h after resuscitation. Neurologically scored survival was measured at 72 h. Other outcomes included mean arterial pressure and target measures in heart and brain related to contractile function, glucose utilization and inflammation. Compared to northothermia, hypothermia improved both 2h mean arterial pressure and 72h neurologically intact survival in Akt1(+/+) mice but not in Akt1(+/-) mice. In Akt1(+/+) mice, hypothermia increased Akt and GSK3 beta phosphorylation, pyruvate dehydrogenase activation, and NAD(+) and ATP production while decreasing I kappa B alpha degradation and NF-kappa B activity in both heart and brain at 30 min after CPR. It also increased phospholamban phosphorylation in heart tissue. Further, hypothermia reduced metabolic and inflammatory blood markers lactate and Pre-B cell Colony Enhancing Factor. Despite hypothermia treatment, all these effects were reversed in Akt1(+/-) mice. Taken together, drugs that target Akt1 and its effectors may have the potential to mimic hypothermia-like protection to improve sudden cardiac arrest survival when administered during CPR.	[Li, Jing; Zhu, Xiangdong; Wang, Huashan; Lee, Chunpei; Chen, Sy-Jou; Qian, Yuanyu; Bunney, Ryan; Hoek, Terry L. Vanden] Univ Illinois Hosp & Hlth Sci Syst, Ctr Adv Resuscitat Med, Ctr Cardiovasc Res, Chicago, IL 60612 USA; [Li, Jing; Zhu, Xiangdong; Wang, Huashan; Lee, Chunpei; Chen, Sy-Jou; Qian, Yuanyu; Bunney, Ryan; Hoek, Terry L. Vanden] Univ Illinois Hosp & Hlth Sci Syst, Dept Emergency Med, Chicago, IL 60612 USA; [Chen, Sy-Jou] Triserv Gen Hosp, Dept Emergency Med, Natl Def Med Ctr, Taipei, Taiwan; [Qian, Yuanyu] Chinese Peoples Liberat Army Gen Hosp, Emergency Dept, Beijing, Peoples R China; [Han, Mei; Beiser, David G.] Univ Chicago, Dept Med, Sect Emergency Med, 5841 S Maryland Ave, Chicago, IL 60637 USA	National Defense Medical Center; Tri-Service General Hospital; Chinese People's Liberation Army General Hospital; University of Chicago	Hoek, TLV (corresponding author), Univ Illinois Hosp & Hlth Sci Syst, Ctr Adv Resuscitat Med, Ctr Cardiovasc Res, Chicago, IL 60612 USA.; Hoek, TLV (corresponding author), Univ Illinois Hosp & Hlth Sci Syst, Dept Emergency Med, Chicago, IL 60612 USA.	tvh@uic.edu		wang, huashan/0000-0002-3662-1576; Beiser, David/0000-0001-9676-087X	National Institute of General Medical Sciences [1R01 GM120485]; National Heart, Lung, and Blood Institute [K08-HL-091184, 1R01HL147031-01]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL147031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM120485] Funding Source: NIH RePORTER	National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by National Institute of General Medical Sciences, http://dx.doi.org/10.13039/100000057, 1R01 GM120485, to Dr Terry L. Vanden Hoek; National Heart, Lung, and Blood Institute, http://dx.doi.org/10.13039/100000050, K08-HL-091184, to Dr. David G. Beiser; and National Heart, Lung and Blood Institute, 1R01HL147031-01, to Dr Terry L. Vanden Hoek. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abella BS, 2004, CIRCULATION, V109, P2786, DOI 10.1161/01.CIR.0000131940.19833.85; Adrie C, 2002, CIRCULATION, V106, P562, DOI 10.1161/01.CIR.0000023891.80661.AD; ALOIA RC, 1989, BIOCHIM BIOPHYS ACTA, V988, P123, DOI 10.1016/0304-4157(89)90007-5; Anthonsen MW, 2001, J BIOL CHEM, V276, P35344, DOI 10.1074/jbc.M105264200; Beeson CC, 2012, J VASC RES, V49, P89, DOI 10.1159/000332326; Beiser DG, 2011, RESUSCITATION, V82, P115, DOI 10.1016/j.resuscitation.2010.08.038; Beiser DG, 2010, AM J PHYSIOL-HEART C, V298, pH1761, DOI 10.1152/ajpheart.00187.2010; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Cai LP, 2016, J NEUROSCI RES, V94, P749, DOI 10.1002/jnr.23740; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Catalucci D, 2009, J BIOL CHEM, V284, P28180, DOI 10.1074/jbc.M109.036566; Chae YC, 2016, CANCER CELL, V30, P257, DOI 10.1016/j.ccell.2016.07.004; Diestel A, 2008, CRYOBIOLOGY, V57, P216, DOI 10.1016/j.cryobiol.2008.08.005; Garten A, 2009, TRENDS ENDOCRIN MET, V20, P130, DOI 10.1016/j.tem.2008.10.004; Han HS, 2003, J CEREBR BLOOD F MET, V23, P589, DOI 10.1097/01.WCB.0000059566.39780.8D; Harris RA, 2002, ADV ENZYME REGUL, V42, P249, DOI 10.1016/S0065-2571(01)00061-9; HENDRICKX HHL, 1984, RESUSCITATION, V12, P117, DOI 10.1016/0300-9572(84)90063-7; Hoshi M, 1996, P NATL ACAD SCI USA, V93, P2719, DOI 10.1073/pnas.93.7.2719; Jones AE, 2004, SHOCK, V22, P410, DOI 10.1097/01.shk.0000142186.95718.82; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Karmazyn M., 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P323, DOI 10.2174/1568006054553417; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Ketzer LA, 2009, AM J PHYSIOL-HEART C, V297, pH556, DOI 10.1152/ajpheart.00302.2009; Kilgannon JH, 2008, RESUSCITATION, V79, P410, DOI 10.1016/j.resuscitation.2008.07.019; Kloner RA, 2001, CIRCULATION, V104, P2981, DOI 10.1161/hc4801.100038; KUSUOKA H, 1991, AM J PHYSIOL, V261, pH1005, DOI 10.1152/ajpheart.1991.261.4.H1005; Laver S, 2004, INTENS CARE MED, V30, P2126, DOI 10.1007/s00134-004-2425-z; LEWANDOWSKI ED, 1995, CIRCULATION, V91, P2071, DOI 10.1161/01.CIR.91.7.2071; Li J, 2015, AM J PHYSIOL-HEART C, V308, pH1414, DOI 10.1152/ajpheart.00748.2014; Li J, 2014, CRIT CARE MED, V42, pE734, DOI 10.1097/CCM.0000000000000656; Li J, 2011, J TRAUMA, V71, P1262, DOI 10.1097/TA.0b013e31821280c5; Li J, 2011, J NEUROTRAUM, V28, P1281, DOI 10.1089/neu.2011.1751; Lim CM, 2004, INTENS CARE MED, V30, P1638, DOI 10.1007/s00134-004-2336-z; Luthra P, 2008, J VIROL, V82, P10887, DOI 10.1128/JVI.00806-08; MacLennan DH, 2003, NAT REV MOL CELL BIO, V4, P566, DOI 10.1038/nrm1151; Ning XH, 1998, AM J PHYSIOL-HEART C, V274, pH786, DOI 10.1152/ajpheart.1998.274.3.H786; NISHIJIMA MK, 1989, AM J PHYSIOL, V257, pH1860, DOI 10.1152/ajpheart.1989.257.6.H1860; Nishimura Yoshiharu, 2005, Interact Cardiovasc Thorac Surg, V4, P101, DOI 10.1510/icvts.2004.097188; Piao L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185046; Post H, 2010, ACTA PHYSIOL, V199, P43, DOI 10.1111/j.1748-1716.2010.02083.x; Randle P J, 1981, Curr Top Cell Regul, V18, P107; Ridder DA, 2009, NEUROSCIENCE, V158, P995, DOI 10.1016/j.neuroscience.2008.07.007; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Schleicher M, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000343; Shao ZH, 2010, AM J PHYSIOL-HEART C, V298, pH2164, DOI 10.1152/ajpheart.00994.2009; Sharp WW, 2014, FASEB J, V28, P316, DOI 10.1096/fj.12-226225; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Stowe DF, 1999, AM J PHYSIOL-HEART C, V277, pH2321, DOI 10.1152/ajpheart.1999.277.6.H2321; Sugden MC, 2003, AM J PHYSIOL-ENDOC M, V284, pE855, DOI 10.1152/ajpendo.00526.2002; TANI M, 1989, CIRC RES, V65, P1045, DOI 10.1161/01.RES.65.4.1045; Van der Heiden K, 2010, CLIN SCI, V118, P593, DOI 10.1042/CS20090557; Webster CM, 2009, NEUROBIOL DIS, V33, P301, DOI 10.1016/j.nbd.2008.11.001; Yannopoulos D, 2009, CIRCULATION, V120, P1426, DOI 10.1161/CIRCULATIONAHA.109.848424; YATVIN MB, 1980, INT J RADIAT BIOL, V37, P513, DOI 10.1080/09553008014550641; Zhao TC, 2001, CIRC RES, V89, P915, DOI 10.1161/hh2201.099452; Zhu XD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095622	56	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2019	14	8							e0220604	10.1371/journal.pone.0220604	http://dx.doi.org/10.1371/journal.pone.0220604			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5FL	31398213	Green Published, gold, Green Submitted			2023-01-03	WOS:000485004000011
J	Maitland, K; Kiguli, S; Olupot-Olupot, P; Engoru, C; Mallewa, M; Goncalves, PS; Opoka, RO; Mpoya, A; Alaroker, F; Nteziyaremye, J; Chagaluka, G; Kennedy, N; Nabawanuka, E; Nakuya, M; Namayanja, C; Uyoga, S; Byabazaire, DK; M'baya, B; Wabwire, B; Frost, G; Bates, I; Evans, JA; Williams, TN; George, EC; Gibb, DM; Walker, AS				Maitland, K.; Kiguli, S.; Olupot-Olupot, P.; Engoru, C.; Mallewa, M.; Goncalves, P. Saramago; Opoka, R. O.; Mpoya, A.; Alaroker, F.; Nteziyaremye, J.; Chagaluka, G.; Kennedy, N.; Nabawanuka, E.; Nakuya, M.; Namayanja, C.; Uyoga, S.; Byabazaire, D. Kyeyune; M'baya, B.; Wabwire, B.; Frost, G.; Bates, I.; Evans, J. A.; Williams, T. N.; George, E. C.; Gibb, D. M.; Walker, A. S.		TRACT Grp	Immediate Transfusion in African Children with Uncomplicated Severe Anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLOOD-TRANSFUSION; CARE	Background The World Health Organization recommends not performing transfusions in African children hospitalized for uncomplicated severe anemia (hemoglobin level of 4 to 6 g per deciliter and no signs of clinical severity). However, high mortality and readmission rates suggest that less restrictive transfusion strategies might improve outcomes. Methods In this factorial, open-label, randomized, controlled trial, we assigned Ugandan and Malawian children 2 months to 12 years of age with uncomplicated severe anemia to immediate transfusion with 20 ml or 30 ml of whole-blood equivalent per kilogram of body weight, as determined in a second simultaneous randomization, or no immediate transfusion (control group), in which transfusion with 20 ml of whole-blood equivalent per kilogram was triggered by new signs of clinical severity or a drop in hemoglobin to below 4 g per deciliter. The primary outcome was 28-day mortality. Three other randomizations investigated transfusion volume, postdischarge supplementation with micronutrients, and postdischarge prophylaxis with trimethoprim-sulfamethoxazole. Results A total of 1565 children (median age, 26 months) underwent randomization, with 778 assigned to the immediate-transfusion group and 787 to the control group; 984 children (62.9%) had malaria. The children were followed for 180 days, and 71 (4.5%) were lost to follow-up. During the primary hospitalization, transfusion was performed in all the children in the immediate-transfusion group and in 386 (49.0%) in the control group (median time to transfusion, 1.3 hours vs. 24.9 hours after randomization). The mean (+/- SD) total blood volume transfused per child was 314 +/- 228 ml in the immediate-transfusion group and 142 +/- 224 ml in the control group. Death had occurred by 28 days in 7 children (0.9%) in the immediate-transfusion group and in 13 (1.7%) in the control group (hazard ratio, 0.54; 95% confidence interval [CI], 0.22 to 1.36; P=0.19) and by 180 days in 35 (4.5%) and 47 (6.0%), respectively (hazard ratio, 0.75; 95% CI, 0.48 to 1.15), without evidence of interaction with other randomizations (P>0.20) or evidence of between-group differences in readmissions, serious adverse events, or hemoglobin recovery at 180 days. The mean length of hospital stay was 0.9 days longer in the control group. Conclusions There was no evidence of differences in clinical outcomes over 6 months between the children who received immediate transfusion and those who did not. The triggered-transfusion strategy in the control group resulted in lower blood use; however, the length of hospital stay was longer, and this strategy required clinical and hemoglobin monitoring. (Funded by the Medical Research Council and Department for International Development; TRACT Current Controlled Trials number, .) In this randomized trial, African children 2 months to 12 years of age with uncomplicated severe anemia (hemoglobin level of 4 to 6 g per deciliter and no signs of severity) were assigned to receive immediate transfusion (20 ml or 30 ml of whole-blood equivalent per kilogram of body weight) or no immediate transfusion. There was no evidence of between-group differences in clinical outcomes over 6 months.	[Maitland, K.; Williams, T. N.] Imperial Coll London, Dept Pediat, London, England; [Frost, G.] Imperial Coll London, Nutr Res Sect, London, England; [George, E. C.; Gibb, D. M.; Walker, A. S.] UCL, Med Res Council Clin Trials Unit, London, England; [Goncalves, P. Saramago] Univ York, Ctr Hlth Econ, York, N Yorkshire, England; [Kennedy, N.] Queens Univ, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland; [Bates, I.] Liverpool Sch Trop Med & Hyg, Liverpool, Merseyside, England; [Evans, J. A.] Univ Wales Hosp, Dept Pediat, Cardiff, S Glam, Wales; [Kiguli, S.; Opoka, R. O.; Nabawanuka, E.] Makerere Univ, Dept Pediat, Kampala, Uganda; [Kiguli, S.; Opoka, R. O.; Nabawanuka, E.] Mulago Hosp, Kampala, Uganda; [Byabazaire, D. Kyeyune] Natl BTS, Uganda Blood Transfus Serv BTS, Kampala, Uganda; [Olupot-Olupot, P.; Nteziyaremye, J.; Namayanja, C.] Busitema Univ, Fac Hlth Sci, Mbale Campus, Mbale, Uganda; [Olupot-Olupot, P.; Nteziyaremye, J.; Namayanja, C.] Mbale Reg Referral Hosp, Mbale Campus, Mbale, Uganda; [Wabwire, B.] Mbale BTS, Mbale, Uganda; [Engoru, C.; Alaroker, F.; Nakuya, M.] Soroti Reg Referral Hosp, Soroti, Uganda; [Mallewa, M.; Chagaluka, G.] Coll Med, Blantyre, Malawi; [Mallewa, M.; Chagaluka, G.] Malawi Liverpool Wellcome Trust Clin Res Program, Blantyre, Malawi; [M'baya, B.] Malawi BTS, Blantyre, Malawi; [Maitland, K.; Mpoya, A.; Uyoga, S.; Williams, T. N.] Kenya Med Res Inst Wellcome Trust Res Program, Kilifi, Kenya	Imperial College London; Imperial College London; Medical Research Council Clinical Trials Unit; University of London; University College London; University of York - UK; Queens University Belfast; Liverpool School of Tropical Medicine; Cardiff University; Makerere University; Mulago National Referral Hospital; University of Malawi; University of Malawi	Maitland, K (corresponding author), Imperial Coll London, Div Med, Med Sch Bldg,St Marys Campus,Norfolk Pl, London W2 1PG, England.	k.maitland@imperial.ac.uk	Nteziyaremye, Julius/ABC-1324-2020; George, Elizabeth C/V-3381-2017	George, Elizabeth C/0000-0002-2928-3580; Kennedy, Neil/0000-0002-6262-2679; Uyoga, Sophie/0000-0003-1746-7873; Frost, Gary/0000-0003-0529-6325; bates, imelda/0000-0002-0862-8199; Nabawanuka, Eva/0000-0002-8605-0951; Gibb, Diana/0000-0002-9738-5490; Maitland, Kathryn/0000-0002-0007-0645	Medical Research Council; Department for International Development; MRC [MC_UU_12023/17, MR/J012483/1, MC_U122886353, MC_PC_MR/R019258/1, MC_UU_12023/26] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department for International Development; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Funded by the Medical Research Council and Department for International Development; TRACT Current Controlled Trials number, ISRCTN84086586.	Ala F, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001309; Calis JCJ, 2008, NEW ENGL J MED, V358, P888, DOI 10.1056/NEJMoa072727; Doctor A, 2018, PEDIATR CRIT CARE ME, V19, pS98, DOI 10.1097/PCC.0000000000001590; English M, 2002, LANCET, V359, P494, DOI 10.1016/S0140-6736(02)07666-3; Kiguli S, 2015, BMC MED, V13, DOI 10.1186/s12916-014-0246-7; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O; Lacroix J, 2007, NEW ENGL J MED, V356, P1609, DOI 10.1056/NEJMoa066240; Lara AM, 2005, J CLIN PATHOL, V58, P56, DOI 10.1136/jcp.2004.018366; Loua A, 2018, GLOBAL SURG, V4, P1; Macharia AW, 2018, AM J HEMATOL, V93, P363, DOI 10.1002/ajh.24986; Maitland K, 2019, NEW ENGL J MED, V381, P420, DOI 10.1056/NEJMoa1900100; Maitland K, 2019, WELLCOME OPEN RES, V4, P27; Maitland K, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-90; Mpoya A, 2015, TRIALS, V16, DOI 10.1186/s13063-015-1112-4; NIH, 2009, COMM TERM CRIT ADV E; Olupot-Olupot P, 2019, WELLCOME OPEN RES, V3, P130; Olupot-Olupot P, 2017, CLIN INFECT DIS, V64, P939, DOI 10.1093/cid/cix003; Opoka RO, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3382-5; Pedro R, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-307; Phiri KS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002903; Staedke SG, 2016, AM J TROP MED HYG, V95, P358, DOI 10.4269/ajtmh.16-0103; Stevens GA, 2013, LANCET GLOB HEALTH, V1, pE16, DOI 10.1016/S2214-109X(13)70001-9; Uyoga S, 2019, VOX SANG, V114, P340, DOI 10.1111/vox.12764; Wambua S, 2006, BRIT J HAEMATOL, V133, P206, DOI 10.1111/j.1365-2141.2006.06006.x; Wiliamson L, 2000, VOX SANG, V78, P291; World Health Organization, 2017, GLOB STAT REP BLOOD; World Health Organization, 2013, POCK BOOK HOSP CAR C	27	38	39	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 1	2019	381	5					407	419		10.1056/NEJMoa1900105	http://dx.doi.org/10.1056/NEJMoa1900105			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IM5WH	31365799	Green Published, Bronze, Green Accepted			2023-01-03	WOS:000478064200006
J	Hollander, M; de Miranda, E; Vandenbussche, F; van Dillen, J; Holten, L				Hollander, Martine; de Miranda, Esteriek; Vandenbussche, Frank; van Dillen, Jeroen; Holten, Lianne			Addressing a need. Holistic midwifery in the Netherlands: A qualitative analysis	PLOS ONE			English	Article							PLANNED HOME BIRTH; MATERNITY CARE; MIDWIVES; CONTINUITY; WOMEN; EXPERIENCES; CHILDBIRTH; OBSTETRICIANS; EXPLORATION; ATTITUDES	The Netherlands has a maternity care system with integrated midwifery care, including the option of home birth for low risk women. A small group of Dutch (holistic) midwives is willing to assist women in high risk pregnancies during a home birth against medical advice. We examined holistic midwives' motivations and way of practice, in order to provide other maternity care professionals with insight into the way they work and to improve professional relationships between all care providers in the field. An exploratory qualitative research design with a constructivist approach and a grounded theory method were used. We performed in-depth interviews with twenty-four holistic midwives on their motivations for working outside their professional boundaries. Open, axial and selective coding of the interview data was done in order to generate themes. We held a focus group for a member check of the findings. Four main themes were found: 1) The regular system is failing women, 2) The relationship as basis for empowerment, 3) Delivering client centered care in the current system is demanding, and 4) Future directions. One core theme emerged that covered all other themes: Addressing a need. Holistic midwives explained that many of their clients had no other choice than to choose a home birth in a high risk pregnancy because they felt let down by the regular system of maternity care. Holistic midwives appear to deliver an important service. They provide continuity of care and succeed in establishing a relationship with their clients built on trust and mutual respect, truly putting their clients' needs first. Some women feel let down by the regular system, and holistic midwives may be the last resort before those women choose to deliver unattended by any medical professional. Maternity care providers should consider working with holistic midwives in the interest of good patient care.	[Hollander, Martine; Vandenbussche, Frank; van Dillen, Jeroen] Radboud Univ Nijmegen, Med Ctr, Amalia Childrens Hosp, Dept Obstet, Nijmegen, Netherlands; [de Miranda, Esteriek] Amsterdam UMC, Acad Med Ctr, Dept Obstet, Amsterdam, Netherlands; [Holten, Lianne] AVAG Sch Midwifery, Amsterdam, Netherlands; [Holten, Lianne] Amsterdam UMC, VU EMGO Res Inst, Amsterdam, Netherlands	Radboud University Nijmegen; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam	Hollander, M (corresponding author), Radboud Univ Nijmegen, Med Ctr, Amalia Childrens Hosp, Dept Obstet, Nijmegen, Netherlands.	martine.hollander@radboudumc.nl						Amelink-Verburg MP, 2010, J MIDWIFERY WOM HEAL, V55, P216, DOI 10.1016/j.jmwh.2010.01.001; [Anonymous], 2013, J PERINAT EDUC, V22, P14, DOI [10.1891/1058-1243.22.1.14, 10.1111/j.1542-2011.2012.00218.x]; [Anonymous], 2014, STATE NEWSPAPER; Bastian H, 1998, BRIT MED J, V317, P384; Boenigk Monika, 2007, Pract Midwife, V10, P18; Charmaz K., PRACTICAL GUIDE QUAL, V2; Chervenak FA, 2013, AM J OBSTET GYNECOL, V208, P31, DOI 10.1016/j.ajog.2012.10.002; Christiaens W, 2013, MIDWIFERY, V29, pE1, DOI 10.1016/j.midw.2012.08.010; Crowther S, 2018, WOMEN BIRTH, V31, pE59, DOI 10.1016/j.wombi.2017.06.019; Crowther S, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1164-9; Dahlberg U, 2013, MIDWIFERY, V29, P407, DOI 10.1016/j.midw.2012.09.006; Danerek M, 2011, BIRTH-ISS PERINAT C, V38, P71, DOI 10.1111/j.1523-536X.2010.00440.x; Davison C, 2015, MIDWIFERY, V31, P772, DOI 10.1016/j.midw.2015.04.012; de Jonge A, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-103; De Vries RG, 2012, J PERINAT EDUC, V21, P9, DOI 10.1891/1058-1243.21.1.9; Feeley C, 2019, MIDWIFERY, V72, P50, DOI 10.1016/j.midw.2019.02.009; Forster DA, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0798-y; Green JM, 2000, MIDWIFERY, V16, P186, DOI 10.1054/midw.1999.0208; Harris G, 2000, Aust Coll Midwives Inc J, V13, P10, DOI 10.1016/S1031-170X(00)80048-3; Healy S, 2017, WOMEN BIRTH, V30, P367, DOI 10.1016/j.wombi.2017.02.005; Hollander M, 2016, J PREG CHILD HLTH, V3, P2; Hollander M, 2018, WOMEN BIRTH; Hollander MH, 2017, ARCH WOMEN MENT HLTH, V20, P515, DOI 10.1007/s00737-017-0729-6; Hollander M, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1621-0; Holten L, 2018, QUAL HEALTH RES, V28, P1883, DOI 10.1177/1049732318791535; Holten L, 2016, MIDWIFERY, V38, P55, DOI 10.1016/j.midw.2016.03.010; Jefford E, 2015, INT J CHILDBIRTH, V5, P116, DOI 10.1891/2156-5287.5.3.116; Jenkinson B, 2017, MIDWIFERY, V52, P1, DOI 10.1016/j.midw.2017.05.006; Kensington M, 2018, NURSE EDUC PRACT, V31, P143, DOI 10.1016/j.nepr.2018.06.001; Lynch B, 2002, MIDWIFERY, V18, P178, DOI 10.1054/midw.2002.0319; MacDorman MF, 2013, J MIDWIFERY WOM HEAL, V58, P494, DOI 10.1111/jmwh.12092; Mills J., 2006, INT J QUAL METH, V5, P1, DOI DOI 10.1177/160940690600500103; Mitchell ED, 2002, RCM MIDWIVES S4  DEC; Offerhaus PM, 2013, BIRTH-ISS PERINAT C, V40, P192, DOI 10.1111/birt.12055; Perdok H, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-017-1615-y; Perry C, 2002, HASTINGS CENT REP, V32, P12, DOI 10.2307/3528517; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; Sandall J, 1995, MIDWIFERY, V11, P201, DOI 10.1016/0266-6138(95)90005-5; Sandall J., 1997, BR J MIDWIFERY, V5, P106, DOI [10.12968/bjom.1997.5.2.106, DOI 10.12968/BJOM.1997.5.2.106]; Sandall J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004667.pub4; Scamell M, 2012, HEALTH RISK SOC, V14, P207, DOI 10.1080/13698575.2012.661041; Shorten A, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b2210; Symon A, 2010, BIRTH-ISS PERINAT C, V37, P280, DOI 10.1111/j.1523-536X.2010.00422.x; Thompson A., BRIT J MIDWIFERY, V21, P564; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; van Stenus CMV, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1369-6; Young C. J., 2011, THESIS	47	6	6	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2019	14	7							e0220489	10.1371/journal.pone.0220489	http://dx.doi.org/10.1371/journal.pone.0220489			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4WU	31361787	Green Published, gold, Green Submitted			2023-01-03	WOS:000484981300032
J	van der Veen, DJ; Dopp, CME; Siemonsma, PC; Nijhuis-van der Sanden, MWG; de Swart, BJM; Steultjens, EM				van der Veen, Dinja J.; Dopp, Carola M. E.; Siemonsma, Petra C.; Nijhuis-van der Sanden, Maria W. G.; de Swart, Bert J. M.; Steultjens, Esther M.			Factors influencing the implementation of Home-Based Stroke Rehabilitation: Professionals' perspective	PLOS ONE			English	Article							SUPPORTED DISCHARGE; HEALTH-CARE; DISORDERS; CAREGIVERS; THERAPY; IMPACT; BRAIN	Background Stroke has a major impact on survivors and their social environment. Care delivery is advocated to become more client-centered and home-based because of their positive impact on client outcomes. The objective of this study was to explore professionals' perspectives on the provision of Home-Based Stroke Rehabilitation (HBSR) in the Netherlands and on the barriers and facilitators influencing the implementation of HBSR in daily practice. Methods Semi-structured focus groups were conducted to explore the perspectives of health and social care professionals involved in stroke rehabilitation. Directed content analysis was performed to analyze the transcripts of recorded conversations. Results Fourteen professionals participated in focus groups (n = 12) or, if unable to attend, an interview (n = 2). Participants varied in professional backgrounds and roles in treating Dutch clients post stroke. Barriers and facilitators influencing the implementation of HBSR in daily practice were identified in relation to: the innovation, the user, the organization and the socio-political context. Participants reported that HBSR can be efficient and effective to most clients because it facilitates client-and caregiver-centered rehabilitation within the clients' own environment. However, barriers in implementing HBSR were perceived in a lack of (structured) inter-professional collaboration and the transparency of expertise of primary care professionals. Also, the current financial structures for HBSR in the Netherlands are viewed as inappropriate. Discussion In line with previous studies, we found that HBSR is recognized by professionals as a promising alternative to institution-based rehabilitation for clients with sufficient capabilities (e.g. their own health and informal support). Conclusion Multiple factors influencing the implementation of HBSR were identified. Our study suggests that, in order to implement HBSR in daily practice, region specific implementation strategies need to be developed. We recommend developing strategies concerning: organized and coordinated inter-professional collaboration, transparency of the expertise of primary care professionals, and the financial structures of HBSR.	[van der Veen, Dinja J.; de Swart, Bert J. M.; Steultjens, Esther M.] Univ Appl Sci HAN, Inst Hlth Studies, Nijmegen, Netherlands; [Dopp, Carola M. E.; Siemonsma, Petra C.] TNO Leiden, Hlth Living, Leiden, Netherlands; [Siemonsma, Petra C.] Univ Appl Sci THIM, Nieuwegein, Netherlands; [Siemonsma, Petra C.] Univ Appl Sci Leiden, Fac Hlth, Leiden, Netherlands; [Nijhuis-van der Sanden, Maria W. G.] Radboud Univ Nijmegen, Res Inst Hlth Sci, IQ Healthcare, Med Ctr, Nijmegen, Netherlands; [de Swart, Bert J. M.] Radboud Univ Nijmegen, Dept Neurorehabil, Med Ctr, Nijmegen, Netherlands	Netherlands Organization Applied Science Research; Radboud University Nijmegen; Radboud University Nijmegen	van der Veen, DJ (corresponding author), Univ Appl Sci HAN, Inst Hlth Studies, Nijmegen, Netherlands.	Dinja.vanderveen@radboudumc.nl	der Sanden, Maria WG Nijhuis-van/B-3463-2012	der Sanden, Maria WG Nijhuis-van/0000-0003-2637-6877; van der Veen, Dinja/0000-0001-5891-5914				Allen LJ, 2015, COST EFFECTIVENESS S; Arya KN, 2012, TOP STROKE REHABIL, V19, P193, DOI 10.1310/tsr1903-193; Australian Commission on Safety and Quality in Health Care, 2011, PAT CAR IMPR QUAL SA; Beaulieu MD, 2013, CAN MED ASSOC J, V185, pE590, DOI 10.1503/cmaj.121802; Camak DJ, 2015, J CLIN NURS, V24, P2376, DOI 10.1111/jocn.12884; Chandra RV, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00060; Combs SA, 2010, DISABIL REHABIL, V32, P669, DOI 10.3109/09638280903242716; Cott CA, 2004, DISABIL REHABIL, V26, P1411, DOI 10.1080/09638280400000237; Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50; DePoy E, 2013, INTRO RES UNDERSTAND; Doig E, 2010, DISABIL REHABIL, V32, P2061, DOI 10.3109/09638281003797356; Dopp CME, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-131; Ellis-Hill C, 2009, DISABIL REHABIL, V31, P61, DOI 10.1080/09638280701775289; Epstein RM, 2010, HEALTH AFFAIR, V29, P1489, DOI 10.1377/hlthaff.2009.0888; Fearon P., 2012, COCHRANE DATABASE SY, V12; Freeman T, 2006, J ADV NURS, V56, P491, DOI 10.1111/j.1365-2648.2006.04043.x; General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14; Gilbertson L, 2000, BRIT MED J, V320, P603, DOI 10.1136/bmj.320.7235.603; Gustavsson A, 2011, EUR NEUROPSYCHOPHARM, V21, P718, DOI 10.1016/j.euroneuro.2011.08.008; Holmqvist LW, 2000, SCAND J REHABIL MED, V32, P173, DOI 10.1080/003655000750060922; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Jaracz K, 2014, NEUROL NEUROCHIR POL, V48, P280, DOI 10.1016/j.pjnns.2014.07.004; Jellema S, 2016, ARCH PHYS MED REHAB, V97, P991, DOI 10.1016/j.apmr.2016.01.015; Kent TA, 2001, STROKE, V32, P2318, DOI 10.1161/hs1001.096588; Klomp J., 2019, NAH EXPERTISE TEAM I; Koehler R, 2011, COGNITIVE REHABILITATION THERAPY FOR TRAUMATIC BRAIN INJURY: EVALUATING THE EVIDENCE, P59; Lamontagne ME, 2019, TOP STROKE REHABIL, V26, P39, DOI 10.1080/10749357.2018.1534453; Langhorne P, 2007, J REHABIL MED, V39, P103, DOI 10.2340/16501977-0042; Larsen T, 2006, INT J TECHNOL ASSESS, V22, P313, DOI 10.1017/S0266462306051208; Liamputtong P., 2011, FOCUS GROUP METHODOL; Lincoln NB, 2004, CLIN REHABIL, V18, P40, DOI 10.1191/0269215504cr700oa; Minkman M M N, 2005, Int J Integr Care, V5, pe14; Mulvale G, 2016, BMC FAM PRACT, V17, DOI 10.1186/s12875-016-0492-1; Nys GMS, 2007, CEREBROVASC DIS, V23, P408, DOI 10.1159/000101464; Pantoni L, 2014, CEREBRAL SMALL VESSE, VFirst; Peters M, 2000, J NURS EDUC, V39, P166; Revalidatie CG, 2013, LEIDRAAD GERIATRISCH; Rogers E. M., 2010, INTEGRATED APPROACH; Satink T, 2015, DISABIL REHABIL, V37, P1745, DOI 10.3109/09638288.2014.976717; Siemonsma P, 2014, DISABILITY REHABILIT, V13, P13; Sit JWH, 2004, J CLIN NURS, V13, P816, DOI 10.1111/j.1365-2702.2004.00943.x; Soydan Haluk, 2009, J Evid Based Med, V2, P143, DOI 10.1111/j.1756-5391.2009.01031.x; Stiekema AW I., 2018, HERVINDEN BALANS LEV; Stolee P, 2012, CLIN REHABIL, V26, P387, DOI 10.1177/0269215511423279; Supper I, 2014, J PUBLIC HLTH OXFORD; Takeuchi N, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/128641; TURNERSTOKES L, 2015, COCHRANE DATABASE SY; Vaartjes I, 2014, NEEMT AANTAL MENSEN; Vat LE, 2016, INT J INTEGR CARE, V16, DOI 10.5334/ijic.2444; Von Koch L, 1998, DISABIL REHABIL, V20, P367, DOI 10.3109/09638289809166095; Walker MF, 2013, STROKE, V44, P293, DOI 10.1161/STROKEAHA.111.639914; Weert S., 2016, GEZONDHEIDSKRANT SJG, V3, P5; Wottrich AW, 2007, PHYS THER, V87, P778, DOI 10.2522/ptj.20060152	53	13	13	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2019	14	7							e0220226	10.1371/journal.pone.0220226	http://dx.doi.org/10.1371/journal.pone.0220226			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4VN	31344103	Green Published, gold, Green Submitted			2023-01-03	WOS:000484977900071
J	Manfredi, C; Tindall, JM; Hong, JS; Sorscher, EJ				Manfredi, Candela; Tindall, Janice M.; Hong, Jeong S.; Sorscher, Eric J.			Making precision medicine personal for cystic fibrosis	SCIENCE			English	Editorial Material							IVACAFTOR		[Manfredi, Candela; Hong, Jeong S.; Sorscher, Eric J.] Emory Univ, Sch Med, Atlanta, GA 30322 USA; [Tindall, Janice M.] Univ Alabama Birmingham, Birmingham, AL USA	Emory University; University of Alabama System; University of Alabama Birmingham	Sorscher, EJ (corresponding author), Emory Univ, Sch Med, Atlanta, GA 30322 USA.	esorscher@emory.edu		Sorscher, Eric J./0000-0001-9341-3354	NIH [R01HL139876, R01HL136414]; CFF [SORSCH13XX0]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL139876, R01HL136414] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CFF; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank M. Konomos for help with the figure and H. Evans and B. Sorscher for useful suggestions. Funding was obtained through grants from NIH (R01HL139876, R01HL136414) and CFF (SORSCH13XX0). E.J.S. serves as a board member, medical advisory council chair, and consultant for the CF Foundation.	Accurso FJ, 2010, NEW ENGL J MED, V363, P1991, DOI 10.1056/NEJMoa0909825; Berkers G, 2019, CELL REP, V26, P1701, DOI 10.1016/j.celrep.2019.01.068; Durmowicz AG, 2018, ANN AM THORAC SOC, V15, P1, DOI 10.1513/AnnalsATS.201708-668PS; Haardt M, 1999, J BIOL CHEM, V274, P21873, DOI 10.1074/jbc.274.31.21873; Han ST, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121159; Hinzpeter A, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001153; Keating D, 2018, NEW ENGL J MED, V379, P1612, DOI 10.1056/NEJMoa1807120; Rowe SM, 2005, NEW ENGL J MED, V352, P1992, DOI 10.1056/NEJMra043184; Rowe SM, 2017, NEW ENGL J MED, V377, P2024, DOI 10.1056/NEJMoa1709847; Schuck RN, 2018, CLIN PHARMACOL THER, V104, P282, DOI 10.1002/cpt.1041; Veit G, 2016, MOL BIOL CELL, V27, P424, DOI 10.1091/mbc.E14-04-0935; Wainwright CE, 2015, NEW ENGL J MED, V373, P220, DOI 10.1056/NEJMoa1409547	12	15	15	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 19	2019	365	6450			SI		220	221		10.1126/science.aaw0553	http://dx.doi.org/10.1126/science.aaw0553			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IK3HD	31320522	Green Accepted			2023-01-03	WOS:000476479200027
J	Hsieh, PH; Su, HY; Lin, CY; Kang, YN; Chang, CC				Hsieh, Ping-Han; Su, Hsiu-Yueh; Lin, Chung-Yuan; Kang, Yi-No; Chang, Chun-Chao			Infection rate among nutritional therapies for acute pancreatitis: A systematic review with network meta-analysis of randomized controlled trials	PLOS ONE			English	Review							TOTAL PARENTERAL-NUTRITION; TOTAL ENTERAL NUTRITION; NIL PER-OS; BACTERIAL TRANSLOCATION; NASOGASTRIC NUTRITION; NASOJEJUNAL TUBE; MANAGEMENT; SUPPORT; COMPLICATIONS; MORTALITY	Background Infection in acute pancreatitis (AP) is associated with nutritional therapies including naso-gastric (NG), naso-jejunal (NJ), and total parenteral nutrition (TPN). To examine infections among NG, NJ, TPN, and no nutritional support (NNS) in treating patients with AP. Methods The investigators completed comprehensive search in the Cochrane library, EMBASE, PubMed, Web of Science, and ClinicalTrials.gov without restriction on language and publication date before January 21, 2019. They also searched the reference lists of relevant studies for randomized controlled trials (RCTs) comparing NG, NJ, TPN, and NNS among patients with AP. Quantitative synthesis was conducted in a contrast-based network meta-analysis. To clarify effects, a network meta-analysis was conducted to calculate the surface under the cumulative ranking curve (SUCRA). Beside of overall infections, the event rates of infected pancreatic necrosis, bacteremia, line infection, pneumonia, urinary tract infection, and other types of infections were measured. Results The network meta-analysis of 16 RCTs showed that NJ had significantly lower overall infection rates compared with TPN (risk ratio: 0.59; 95% confidence interval: 0.38, 0.90); and NG had a larger effect size and higher rank probability compared with NJ, TPN, and NNS (mean rank = 1.7; SUCRA = 75.8). TPN was the least preferred (mean rank = 3.2; SUCRA = 26.6). Conclusions NG and NJ may be preferred therapies for treating patients with AP. Clinicians may consider NG as a first-line treatment for patients with AP (including severe AP) and even in patients receiving prophylactic antibiotics. In addition, we found that NNS should be avoided when treating patients with severe AP.	[Hsieh, Ping-Han] Taipei Vet Gen Hosp, Dept Med, Taipei, Taiwan; [Hsieh, Ping-Han; Kang, Yi-No] Taipei Med Univ Hosp, Dept Educ, Ctr Evidence Based Med, Taipei, Taiwan; [Su, Hsiu-Yueh] Taipei Med Univ Hosp, Dept Dietet, Taipei, Taiwan; [Lin, Chung-Yuan] Taipei Med Univ, Sch Med, Coll Med, Taipei, Taiwan; [Kang, Yi-No] Taipei Med Univ, Wan Fang Hosp, Taipei, Taiwan; [Chang, Chun-Chao] Taipei Med Univ Hosp, Div Gastroenterol & Hepatol, Dept Internal Med, Taipei, Taiwan; [Chang, Chun-Chao] Taipei Med Univ, Sch Med, Div Gastroenterol & Hepatol, Dept Internal Med, Taipei, Taiwan	Taipei Veterans General Hospital; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University	Kang, YN (corresponding author), Taipei Med Univ Hosp, Dept Educ, Ctr Evidence Based Med, Taipei, Taiwan.; Kang, YN (corresponding author), Taipei Med Univ, Wan Fang Hosp, Taipei, Taiwan.; Chang, CC (corresponding author), Taipei Med Univ Hosp, Div Gastroenterol & Hepatol, Dept Internal Med, Taipei, Taiwan.; Chang, CC (corresponding author), Taipei Med Univ, Sch Med, Div Gastroenterol & Hepatol, Dept Internal Med, Taipei, Taiwan.	academicnono@gmail.com; chunchao@tmu.edu.tw	/AAD-5199-2021					Abou-Assi S, 2002, AM J GASTROENTEROL, V97, P2255, DOI 10.1111/j.1572-0241.2002.05979.x; Al Samaraee A, 2010, SURG-J R COLL SURG E, V8, P105, DOI 10.1016/j.surge.2009.10.006; Al-Omran M, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002837.pub2; Bakker OJ, 2014, NEW ENGL J MED, V371, P1983, DOI 10.1056/NEJMoa1404393; Besselink M, 2013, PANCREATOLOGY, V13, pE1, DOI 10.1016/j.pan.2013.07.063; Boreham B, 2003, PANCREATOLOGY, V3, P303, DOI 10.1159/000071768; Buchman Alan, 2005, Curr Gastroenterol Rep, V7, P300; Casas M, 2007, REV ESP ENFERM DIG, V99, P264; CASSIM MM, 1974, ANN SURG, V180, P228, DOI 10.1097/00000658-197408000-00017; Choudhary A, 2009, GASTROINTEST ENDOSC, V69, pAB315, DOI [10.1016/j.gie.2009.03.893, DOI 10.1016/J.GIE.2009.03.893]; DEITCH EA, 1994, GUT, V35, pS23, DOI 10.1136/gut.35.1_Suppl.S23; Dellinger EP, 2012, ANN SURG, V256, P875, DOI 10.1097/SLA.0b013e318256f778; Doley RP, 2009, J PANCREAS, V10, P157; Du ZH, 2015, PARENTERAL ENTERAL N, V22, P168; Eatock FC, 2005, AM J GASTROENTEROL, V100, P432, DOI 10.1111/j.1572-0241.2005.40587.x; Eckerwall GE, 2006, ANN SURG, V244, P959, DOI 10.1097/01.sla.0000246866.01930.58; Forsmark CE, 2016, ANN INTERN MED, V165, P523, DOI 10.7326/M16-1581; Gomes GF, 2003, CURR OPIN CLIN NUTR, V6, P327, DOI 10.1097/01.mco.0000068970.34812.8b; Gupta Kapil, 2010, Ann Intern Med, V153, pITC51, DOI 10.7326/0003-4819-153-9-201011020-01005; Gupta R, 2003, PANCREATOLOGY, V3, P406, DOI 10.1159/000073657; Harvey SE, 2014, NEW ENGL J MED, V371, P1673, DOI 10.1056/NEJMoa1409860; He XL, 2004, CLIN NUTR, P43, DOI 10.1016/j.clnu.2004.07.011; Huang YJ, 2019, ASIAN J SURG, V42, P657, DOI 10.1016/j.asjsur.2018.11.007; Huang YJ, 2018, ASIAN J SURG, V41, P431, DOI 10.1016/j.asjsur.2017.06.002; Kalfarentzos F, 1997, BRIT J SURG, V84, P1665, DOI 10.1002/bjs.1800841207; Kao CC, 2018, J CLIN MED, V7, DOI 10.3390/jcm7100314; Kotani J, 1999, ARCH SURG-CHICAGO, V134, P287, DOI 10.1001/archsurg.134.3.287; Kumar A, 2006, J CLIN GASTROENTEROL, V40, P431, DOI 10.1097/00004836-200605000-00013; Kumar S, 2010, GASTROENTEROLOGY, V138, pS888; Lin EY, 2018, INT J SURG, V60, P224, DOI 10.1016/j.ijsu.2018.11.009; Lopez Antonio, 2008, Gastroenterol Hepatol, V31, P702, DOI 10.1016/S0210-5705(08)75820-5; Lou J, 2016, J PEDIAT GASTROENTER, V62, P48, DOI [10.1097/01.mpg.0000484500.48517.e7, DOI 10.1097/01.MPG.0000484500.48517.E7]; Louie BE, 2005, CAN J SURG, V48, P298; Ma JM, 2016, NUTR CLIN PRACT, V31, P99, DOI 10.1177/0884533615603967; Mbuagbaw L, 2017, SYST REV-LONDON, V6, DOI 10.1186/s13643-017-0473-z; McClave SA, 1997, JPEN-PARENTER ENTER, V21, P14, DOI 10.1177/014860719702100114; McClave SA, 2016, JPEN-PARENTER ENTER, V40, P159, DOI [10.1177/0148607115621863, 10.1097/CCM.0000000000001525]; McKenzie SJL, 2015, J NUTR SCI, V4, DOI 10.1017/jns.2015.20; Moparty E, 2015, INDIAN J GASTROENTER, V34, pA79; Nally D, 2014, IRISH J MED SCI, V183, pS53; Nally DM, 2014, BRIT J NUTR, V112, P1769, DOI 10.1017/S0007114514002566; Olah A, 2002, NUTRITION, V18, P259, DOI 10.1016/S0899-9007(01)00755-9; Olivier N, 2013, S AFR J CLIN NUTR, V26, P212; Pendharkar SA, 2016, JPEN-PARENTER ENTER, V40, P693, DOI 10.1177/0148607115574290; Petrov MS, 2006, DIGEST SURG, V23, P336, DOI 10.1159/000097949; Petrov MS, 2013, CRIT CARE, V17, DOI 10.1186/cc12770; Petrov MS, 2013, CLIN NUTR, V32, P697, DOI 10.1016/j.clnu.2012.12.011; Petrov MS, 2013, CURR OPIN CLIN NUTR, V16, P557, DOI 10.1097/MCO.0b013e3283638ed1; Petrov MS, 2008, J PANCREAS, V9, P440; Petrov MS, 2008, ARCH SURG-CHICAGO, V143, P1111, DOI 10.1001/archsurg.143.11.1111; Powell JJ, 2000, BRIT J SURG, V87, P1375, DOI 10.1046/j.1365-2168.2000.01558.x; Reignier J, 2018, LANCET, V391, P133, DOI [10.1016/S0140-6736(17)32146-3, 10.1016/s0140-6736(17)32146-3]; Rolniak S, 2009, GASTROENTEROLOGY, V136, pA76; SAX HC, 1987, AM J SURG, V153, P117, DOI 10.1016/0002-9610(87)90211-X; Singh N, 2012, PANCREAS, V41, P153, DOI 10.1097/MPA.0b013e318221c4a8; Stimac D, 2016, PANCREATOLOGY, V16, P523, DOI 10.1016/j.pan.2016.04.003; Tenner S, 2013, AM J GASTROENTEROL, V108, P1400, DOI 10.1038/ajg.2013.218; Trinquart L, 2016, ANN INTERN MED, V164, P666, DOI 10.7326/M15-2521; van Dijk SM, 2017, GUT, V66, P2024, DOI 10.1136/gutjnl-2016-313595; Villatoro E, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002941.pub3; Wang B, 2009, INTENS CARE MED, V35, P148; Wang GL, 2013, J SURG RES, V183, P592, DOI 10.1016/j.jss.2012.12.010; WANG YZ, 2007, WORLD CHINESE J DIGE, V15, P3545; Wiesen A, 2006, AM J GASTROENTEROL, V101, pS128, DOI 10.14309/00000434-200609001-00257; Windsor J, 2014, PANCREATOLOGY OFFICI, V14, pS98; Wu XM, 2010, PANCREAS, V39, P248, DOI 10.1097/MPA.0b013e3181bd6370; Yi FM, 2012, INTERNAL MED, V51, P523, DOI 10.2169/internalmedicine.51.6685; Zhang YongSheng, 2011, Academic Journal of Second Military Medical University, V32, P737, DOI 10.3724/SP.J.1008.2011.00737	68	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2019	14	7							e0219151	10.1371/journal.pone.0219151	http://dx.doi.org/10.1371/journal.pone.0219151			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4JZ	31291306	Green Published, gold, Green Submitted			2023-01-03	WOS:000484947800051
J	Fletcher, S; Kulnik, ST; Demain, S; Jones, F				Fletcher, Simon; Kulnik, Stefan Tino; Demain, Sara; Jones, Fiona			The problem with self-management: Problematising self-management and power using a Foucauldian lens in the context of stroke care and rehabilitation	PLOS ONE			English	Article							CHRONIC ILLNESS; HEALTH; RISK; PARTICIPATION; INTERVENTION; SURVIVORS; EXERCISE; PROGRAM; SUPPORT; PEOPLE	Self-management is a concept which is now firmly established in Western healthcare policy and practice. However, the term remains somewhat ambiguous, multi-faceted and contentious. This is evident in stroke care and rehabilitation, in which a self-management approach is increasingly adopted and advocated, yet interpreted in different ways, resulting in contradictions and tensions around control, responsibility, power and discipline. This paper aims to further our understanding of tensions and contradictions in stroke self-management, by critically examining contemporary self-management practices. We use a Foucauldian theoretical lens to explore the various power dynamics in the operationalisation of self-management, in addition to the complexity of the term self-management itself. Conducting a secondary analysis of interview and focus group data from the Self-Management VOICED study, supplemented with analysis of relevant documentary evidence from policy and practice, we describe the multiple aspects of power in operation. These include rhetorical, hierarchical, personal and mutual forms of power, representing interweaving dynamics evident in the data. These aspects of power demonstrate underlying agendas and tacit and explicit understandings of self-management which exist in clinical practice. These aspects of power also give insight into the multiple identities of 'self-management', acting as a simultaneous repressor and liberator, directly in keeping with Foucauldian thinking. The findings are also consistent with Foucault's notions of bodily docility, discussions around governance and bio-power, and contemporary discipline. Our analysis positions self-management as a highly nuanced and complex concept, which can fluctuate in its conceptualisation depending on the structures, routines, and the individual. We encourage healthcare professionals, policymakers and commissioners in the field of self-management to reflect on these complexities, to make transparent their assumptions and to explicitly position their own practice accordingly.	[Fletcher, Simon; Kulnik, Stefan Tino; Jones, Fiona] Kingston Univ & St Georges Univ London, Fac Hlth Social Care & Educ, London, England; [Demain, Sara] Univ Plymouth, Sch Hlth Profess, Plymouth, Devon, England; [Jones, Fiona] Bridges Self Management Ltd, London, England	Kingston University; University of Plymouth	Kulnik, ST (corresponding author), Kingston Univ & St Georges Univ London, Fac Hlth Social Care & Educ, London, England.	s.t.kulnik@sgul.kingston.ac.uk		Jones, Fiona/0000-0002-1452-3895; Kulnik, Stefan Tino/0000-0001-5419-6713	Health Foundation	Health Foundation	This research was part-funded by an Insight 2013 award to SD and FJ from the Health Foundation (https://health.org.uk/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.	[Anonymous], 2017, STROK ASS RESP NHS E; [Anonymous], 2016, COMM GUID REH; Audulv A, 2016, J ADV NURS, V72, P2629, DOI 10.1111/jan.13037; Barlow J, 2002, PATIENT EDUC COUNS, V48, P177, DOI 10.1016/S0738-3991(02)00032-0; Barlow JH, 2002, HLTH ED J, V61, P365, DOI DOI 10.1177/001789690206100408; Boger EJ, 2015, INT J NURS STUD, V52, P175, DOI 10.1016/j.ijnurstu.2014.05.006; Damush TM, 2016, TRANSL BEHAV MED, V6, P457, DOI 10.1007/s13142-015-0348-6; Demain S, 2014, WORKING PAPERS HLTH, V1, P7; Department of Health, 2005, SELF CAR REAL CHOIC; Dobkin BH, 2017, NEUROREHAB NEURAL RE, V31, P217, DOI 10.1177/1545968316680490; Dobkin BH, 2016, CURR OPIN NEUROL, V29, P693, DOI 10.1097/WCO.0000000000000380; Ellis J, 2017, SOC SCI MED, V176, P25, DOI 10.1016/j.socscimed.2017.01.018; FOUCAULT M, 1979, IC, P5; Foucault Michel, 1977, DISCIPLINE PUNISH BI; Foucault Michel., 1980, POWER KNOWLEDGE SELE; Fryer CE, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010442.pub2; Galvin R, 2002, HEALTH-LONDON, V6, P107, DOI 10.1177/136345930200600201; Great Britain. Department of Health, 2001, EXP PAT NEW APPR CHR; Great Britain. Department of Health, 2006, SUPP PEOPL LONG TERM; Harwood M, 2012, CLIN REHABIL, V26, P493, DOI 10.1177/0269215511426017; Hill VA, 2017, J STROKE CEREBROVASC, V26, P2806, DOI 10.1016/j.jstrokecerebrovasdis.2017.06.058; Horrocks C, 2014, SOCIOL HEALTH ILL, V36, P175, DOI 10.1111/1467-9566.12114; Intercollegiate Stroke Working Party, 2016, NAT CLIN GUID STROK; Intercollegiate Stroke Working Party, 2008, NAT CLIN GUID STROK; Jones F., 2015, REHABILITATION GOAL, P265; Jones F, 2018, PHYS MANAGEMENT NEUR, P379; Jones F, 2016, NEUROREHABILITATION, V39, P471, DOI 10.3233/NRE-161379; Kendall E, 2007, DISABIL SOC, V22, P129, DOI 10.1080/09687590601141535; Kendall E, 2011, CHRONIC ILLN, V7, P87, DOI 10.1177/1742395310380281; Kulnik ST, 2019, DESIGN HLTH     0416, P1; Kulnik ST, 2019, DISABIL REHABIL, V41, P1296, DOI 10.1080/09638288.2018.1424953; Kulnik ST, 2017, J INTERPROF CARE, V31, P75, DOI 10.1080/13561820.2016.1246432; Lorig KR, 2003, ANN BEHAV MED, V26, P1, DOI 10.1207/S15324796ABM2601_01; Mansfield A, 2016, STROKE RES TREAT, V2016, DOI 10.1155/2016/9476541; Mayo NE, 2016, STROKE, V47, P1685, DOI 10.1161/STROKEAHA.116.011309; Moore SA, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1628-2; Morden A, 2012, SOC THEOR HEALTH, V10, P78, DOI 10.1057/sth.2011.20; Parke HL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131448; Pearce G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141803; Sajatovic M, 2018, AM J HEALTH PROMOT, V32, P282, DOI 10.1177/0890117117695218; Satink T, 2015, DISABIL REHABIL, V37, P223, DOI 10.3109/09638288.2014.918187; Stroke Association, 2010, STROK ASS MAN 2010 2; Stroke Association, 2015, TOG WE CAN CONQ STRO; Stroke Association, 2016, NEW ER STROK OUR CAM; Taylor D, 2007, SOCIOL HEALTH ILL, V29, P27, DOI 10.1111/j.1467-9566.2007.00516.x; The Scottish Government, 2009, IMPR SELF MAN SUPP; Tielemans NS, 2015, J REHABIL MED, V47, P901, DOI 10.2340/16501977-2020; Wolf TJ, 2016, TOP STROKE REHABIL, V23, P284, DOI 10.1080/10749357.2016.1155278; Woodman P, 2014, DISABIL REHABIL, V36, P2031, DOI 10.3109/09638288.2014.887796; World Health Organization, 2015, WHO GLOB STRAT PEOPL; Wray F, 2018, DISABIL REHABIL, V40, P1237, DOI 10.1080/09638288.2017.1294206	51	12	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2019	14	6							e0218517	10.1371/journal.pone.0218517	http://dx.doi.org/10.1371/journal.pone.0218517			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IT5EM	31216337	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000482885300051
J	Jamali, QZ; Shah, R; Shahid, F; Fatima, A; Khalsa, S; Spacek, J; Regmi, P				Jamali, Qamar Zaman; Shah, Rashed; Shahid, Farhana; Fatima, Aisha; Khalsa, Saraswati; Spacek, Jana; Regmi, Presha			Barriers and enablers for practicing kangaroo mother care (KMC) in rural Sindh, Pakistan	PLOS ONE			English	Article							BIRTH-WEIGHT BABIES; IMPLEMENTATION	Background More than 2.5 million newborns die each year, accounting for 47% of children dying worldwide before their age of five years. Complications of preterm birth are the leading cause of death among newborns. Pakistan is amongst the top ten countries with highest preterm birth rate per 1000 live births. Globally, Every Newborn Action Plan (ENAP) has emphasized on Kangaroo Mother Care (KMC) as an essential component of neonatal health initiatives. Materials and methods We conducted this qualitative study with 12 in-depth interviews (IDIs) and 14 focus group discussion (FGD) sessions, in two health facilities of Sindh, Pakistan during October-December 2016, to understand the key barriers and enablers to a mother's ability to practice KMC and the feasibility of implementing and improving these practices. Results The findings revealed that community stakeholders were generally aware of health issues especially related to maternal and neonatal health. Both the health care providers and managers were supportive of implementing KMC in their respective health facilities as well as for continuous use of KMC at household level. In order to initiate KMC at facility level, study respondents emphasized on ensuring availability of equipment, supplies, water-sanitation facility, modified patient ward (e.g., curtain, separate room) and quality of services as well as training of health providers as critical prerequisites. Also in order to continue practicing KMC at household level, engaging the community and establishing functional referral linkage between community and facilities were focused issues in facility and community level FGDs and IDIs. Conclusion The study participants considered it feasible to initiate KMC practice at health facility and to continue practicing at home after returning from facility. Ensuring facility readiness to initiate KMC, improving capacity of health providers both at facility and community levels, coupled with focusing on community mobilization strategy, targeting specific audiences, may help policy makers and program planners to initiate KMC at health facility and keep KMC practice continued at household level.	[Jamali, Qamar Zaman; Fatima, Aisha] Save Children Int, Dept Hlth, Islamabad, Pakistan; [Shah, Rashed; Khalsa, Saraswati; Spacek, Jana] Save Children US, Dept Global Hlth, Washington, DC 20002 USA; [Shahid, Farhana] Jhpiego, Tech Unit, Karachi, Pakistan; [Regmi, Presha] Jhpiego, Baltimore, MD USA	Save the Children; Save the Children; Jhpiego; Jhpiego	Shah, R (corresponding author), Save Children US, Dept Global Hlth, Washington, DC 20002 USA.	mshah@savechildren.org	Shah, Rashed Z/D-4688-2015	Shah, Rashed Z/0000-0001-9488-5134	US Agency for International Development (USAID) [AID-391-LA-13-00001]; Australian Government	US Agency for International Development (USAID)(United States Agency for International Development (USAID)); Australian Government(Australian GovernmentCGIAR)	This publication was made possible through support provided by the US Agency for International Development (USAID), under the terms of Associate Cooperative Agreement No. AID-391-LA-13-00001; Maternal, Newborn and Child Health Services Project. Also we received partial support from the Australian Government for this study. The opinions expressed herein are those of the authors and do not necessarily reflect either the views of USAID or the Australian Government. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	[Anonymous], 2018, LEVELS TRENDS CHILD; Bergh AM, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-293; Blomqvist YT, 2013, SCAND J CARING SCI, V27, P345, DOI 10.1111/j.1471-6712.2012.01040.x; Boundy EO, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2238; Chan G, 2017, HEALTH POLICY PLANN, V32, P1466, DOI 10.1093/heapol/czx098; Chan GJ, 2016, B WORLD HEALTH ORGAN, V94, P130, DOI 10.2471/BLT.15.157818; Chan GJ, 2016, J GLOB HEALTH, V6, DOI 10.7189/jogh.06.010701; Charpak N, 2005, ACTA PAEDIATR, V94, P514, DOI 10.1080/08035250510027381; Charpak N, 2006, ACTA PAEDIATR, V95, P529, DOI 10.1080/08035250600599735; Chawanpaiboon S, 2019, LANCET GLOB HEALTH, V7, pE37, DOI 10.1016/S2214-109X(18)30451-0; Conde-Agudelo A., 2014, COCHRANE DB SYST REV, V4; Conde-Agudelo A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002771.pub4; Gontijo TL, 2012, CAD SAUDE PUBLICA, V28, P935, DOI 10.1590/S0102-311X2012000500012; Haxton Dawn, 2012, Nurs Womens Health, V16, P220, DOI 10.1111/j.1751-486X.2012.01733.x; Hendricks-Munoz KD, 2014, AM J PERINAT, V31, P987, DOI 10.1055/s-0034-1371359; Hunter EC, 2014, SOC SCI MED, V122, P21, DOI 10.1016/j.socscimed.2014.10.006; Johnson AN, 2007, MCN-AM J MATERN-CHIL, V32, P25; Kambarami RA, 2002, TROP DOCT, V32, P131, DOI 10.1177/004947550203200303; Lee HC, 2012, BREASTFEED MED, V7, P79, DOI 10.1089/bfm.2011.0004; Leonard A, 2008, PARENTS LIVED EXPERI, V13, P13; Lipato T, 2012, EVALUATION KANGAROO; Moreira Jacqueline de Oliveira, 2009, Psicol. Estud., V14, P475; Program SNL, 2011, PROGR SNL SCAL KANG; Quasem Iftekhar, 2003, J Perinatol, V23, P646, DOI 10.1038/sj.jp.7210999; Rasaily R, 2017, INDIAN J MED RES, V145, P51, DOI 10.4103/ijmr.IJMR_603_15; Seidman G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125643; Smith ER, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-016-0769-5; Vesel L, 2013, TROP MED INT HEALTH, V18, P952, DOI 10.1111/tmi.12134; WHO/UNICEF, 2014, EV NEWB ACT PLAN END; Yoshida S, 2014, LANCET, V384, pE27, DOI 10.1016/S0140-6736(14)60263-4	30	9	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2019	14	6							e0213225	10.1371/journal.pone.0213225	http://dx.doi.org/10.1371/journal.pone.0213225			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW3OC	31206544	Green Published, gold, Green Submitted			2023-01-03	WOS:000484890300003
J	Lee, MT; Jang, Y; Chang, WY				Lee, Meng-Ta; Jang, Yuh; Chang, Wan-Ying			How do impairments in cognitive functions affect activities of daily living functions in older adults?	PLOS ONE			English	Article							INSTRUMENTAL-ACTIVITIES; ALZHEIMERS-DISEASE; CLINICAL-DIAGNOSIS; DEMENTIA; PERFORMANCE; VERSION	The assessment of daily living activities could provide information about daily functions and participation restrictions to develop intervention strategies. The purposes of this study were to assess the scores of the Barthel Index (BI) and Lawton Instrumental Activities of Daily Living (IADL) scale in older adults with cognitive impairment and to explore the different effects that levels of cognitive functions have on changes in IADL functions. We recruited 31 participants with dementia, 36 with mild cognitive impairment (MCI), and 35 normal controls (NCs) from the neurology outpatient department of a regional hospital. The results of the demographic and clinical characteristics through the Lawton IADL scale, BI, Quick Mild Cognitive Impairment (Qmci) screen, Montreal Cognitive Assessment (MoCA), and Mini-Mental State Examination (MMSE), were collected on the same day and compared with the Kruskal-Wallis test, Wilcoxon rank-sum test, Fisher's exact test, and a multiple linear regression analysis, as appropriate. In the BI, bathing was the most discriminating activity to differentiate patients with MCI and dementia; in the Lawton IADL scale, medication responsibility and shopping were the most discriminating activities to differentiate NCs and patients with MCI, and patients with MCI and dementia, respectively. In addition, the predictors of changes in Lawton IADL scale scores were the problem-solving score of the Clinical Dementia Rating scale, a Qmci score of >20.4 and an age of. 81.2 years, a MoCA score of <9.4 and an age of >81.2 years, and the MMSE score and an age of >81.2 years. This study adds to the evidence that the description of basic and instrumental daily activities is integrated in older adults with cognitive impairment. Notably, the Qmci is the most significant predictor of changes in IADL function for "young" older adults, as are the MoCA and MMSE for "old" older adults.	[Lee, Meng-Ta; Jang, Yuh] Natl Taiwan Univ, Sch Occupat Therapy, Coll Med, Taipei, Taiwan; [Lee, Meng-Ta; Chang, Wan-Ying] Taipei Hosp, Div Occupat Therapy, Minist Hlth & Welf, New Taipei, Taiwan; [Jang, Yuh] Natl Taiwan Univ Hosp, Div Occupat Therapy, Dept Phys Med & Rehabil, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital	Chang, WY (corresponding author), Taipei Hosp, Div Occupat Therapy, Minist Hlth & Welf, New Taipei, Taiwan.	wanying0928@gmail.com		Lee, Meng-Ta/0000-0002-5877-4792; Chang, Wan-Ying/0000-0002-8357-1807	Taipei Hospital, Ministry of Health and Welfare, Taiwan (R.O.C.) [201707]	Taipei Hospital, Ministry of Health and Welfare, Taiwan (R.O.C.)	This work was supported by the Taipei Hospital, Ministry of Health and Welfare, Taiwan (R.O.C.), to WYC (Grant Number: 201707). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BARBERGERGATEAU P, 1992, J AM GERIATR SOC, V40, P1129, DOI 10.1111/j.1532-5415.1992.tb01802.x; Cromwell DA, 2003, J CLIN EPIDEMIOL, V56, P131, DOI 10.1016/S0895-4356(02)00599-1; De Lepeleire J, 2004, AGING MENT HEALTH, V8, P52, DOI 10.1080/13607860310001613338; Guo NW, 1988, TAIWAN J PHYS MED RE, V16, P52; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Lee HC, 1993, CLIN GERONTOLOGIST, V14, P37; Lee MT, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207851; MAHONEY F I, 1965, Md State Med J, V14, P61; Mao HF, 2018, AGE AGEING, V47, P551, DOI 10.1093/ageing/afy021; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Peres K, 2008, J AM GERIATR SOC, V56, P37, DOI 10.1111/j.1532-5415.2007.01499.x; Prince M, 2013, ALZHEIMERS DEMENT, V9, P63, DOI 10.1016/j.jalz.2012.11.007; Purser JL, 2005, J AM GERIATR SOC, V53, P1966, DOI 10.1111/j.1532-5415.2005.53566.x; Rechel B, 2013, LANCET, V381, P1312, DOI 10.1016/S0140-6736(12)62087-X; Sachdev PS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142388; Tsai CF, 2012, INT PSYCHOGERIATR, V24, P651, DOI 10.1017/S1041610211002298; Yee T.W, 2015, VECTOR GEN LINEAR AD; Yee TW, 1996, J ROY STAT SOC B MET, V58, P481	21	32	34	3	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2019	14	6							e0218112	10.1371/journal.pone.0218112	http://dx.doi.org/10.1371/journal.pone.0218112			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IC0OB	31173607	Green Submitted, gold, Green Published			2023-01-03	WOS:000470658500035
J	Hou, QL; Zhang, ZG; Lei, T; Gan, MZ; Wu, XJ; Yue, WG; Li, B; Deng, L; Gong, HC				Hou, Qiliang; Zhang, Zhigang; Lei, Ting; Gan, Maozhou; Wu, Xiangjun; Yue, Weigang; Li, Bin; Deng, Lin; Gong, Hongchang			Clinical efficacy of high-flow nasal humidified oxygen therapy in patients with hypoxemia	PLOS ONE			English	Article							CARE PATIENTS; CANNULA; VENTILATION; INTUBATION; DELIVERY; FAILURE	To evaluate the effectiveness of high-flow nasal humidified oxygen (HFNHO) therapy in patients with mild hypoxemia after extubation. This study included 316 patients with mild hypoxemia after extubation from May 2016 to May 2018 from two intensive care units in China. Compare the effects of the Venturi Mask and High-Flow Nasal Humidified Oxygen (HFNHO) therapy on Heart Rate (HR), Respiratory Rate (RR), Oxygen Saturation (SpO(2)), Oxygen Partial Pressure (PO2), Partial Pressure Of Carbon Dioxide (PCO2), Oxygenation Index (PO2/FiO(2)) after extubation, the use of noninvasive mechanical ventilation and tracheal intubation after treatment failure were observed and recorded. Patients have both lower HR and RR than those who received mask treatment (75.4 +/- 18.5 vs. 83.0 +/- 20.4, p = 0.0004; 18 +/- 6.5 vs. 23.6 +/- 10.3, p<0.001, respectively). There was significant difference between those who had HFNHO and mask administration's SpO(2) and PO2 (94.1 6.4 vs. 87.5 +/- 1.5, p<0.001; 88.16 +/- 2.9 vs. 77.3 +/- 2.3, p<0.001, respectively). For the HFNHO group, patients had lower PCO2 with the mask group. (41.3 +/- 0.99 vs 42.2 +/- 1.2, p<0.001). On the other hand, the levels of PO2/FiO(2) was significantly higher in the HFNHO Group, (181.0 +/- 8.3 vs. 157.2 4.9, p<0.05). We concluded HFNHO therapy could significantly relieve the symptoms of dyspnea, improve oxygenation, reduce the use of noninvasive mechanical ventilation and reduce the rate of secondary tracheal intubation in patients with mild hypoxemia after extubation.	[Hou, Qiliang; Deng, Lin; Gong, Hongchang] Guanghan Peoples Hosp, Dept Crit Care Med, Guanghan, Sichuan, Peoples R China; [Hou, Qiliang; Zhang, Zhigang; Yue, Weigang; Li, Bin] Lanzhou Univ, Hosp 1, Dept Crit Care Med, Lanzhou, Gansu, Peoples R China; [Lei, Ting] Lanzhou Univ, Hosp 1, Dept Obstet & Gynecol, Lanzhou, Peoples R China; [Gan, Maozhou; Wu, Xiangjun] Guanghan Peoples Hosp, Guanghan, Sichuan, Peoples R China	Lanzhou University; Lanzhou University	Hou, QL (corresponding author), Guanghan Peoples Hosp, Dept Crit Care Med, Guanghan, Sichuan, Peoples R China.; Hou, QL (corresponding author), Lanzhou Univ, Hosp 1, Dept Crit Care Med, Lanzhou, Gansu, Peoples R China.	Qilianghou@outlook.com						Azoulay E, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2492-z; Brotfain E, 2014, ISR MED ASSOC J, V16, P718; Collins JA, 2015, BREATHE, V11, P195, DOI 10.1183/20734735.001415; CONWAY JH, 1992, RESP MED, V86, P109, DOI 10.1016/S0954-6111(06)80225-8; Corley A, 2011, BRIT J ANAESTH, V107, P998, DOI 10.1093/bja/aer265; Cortegiani A, 2018, BMC ANESTHESIOL, V18, DOI 10.1186/s12871-018-0623-4; Durey A, 2016, AM J EMERG MED, V34, P2222, DOI 10.1016/j.ajem.2016.06.033; Dysart K, 2009, RESP MED, V103, P1400, DOI 10.1016/j.rmed.2009.04.007; Frat JP, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.06.52; Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326; Frizzola M, 2011, PEDIATR PULM, V46, P67, DOI 10.1002/ppul.21326; Futier E, 2016, INTENS CARE MED, V42, P1888, DOI 10.1007/s00134-016-4594-y; Groves Nicole, 2007, Aust Crit Care, V20, P126; Hanouz JL, 2019, EUR J ANAESTH, V36, P335, DOI 10.1097/EJA.0000000000000954; Hasani A, 2008, Chron Respir Dis, V5, P81, DOI 10.1177/1479972307087190; Kang BJ, 2015, INTENS CARE MED, V41, P623, DOI 10.1007/s00134-015-3693-5; Keenan SP, 2011, CAN MED ASSOC J, V183, pE195, DOI 10.1503/cmaj.100071; Kim ES, 2018, J THORAC DIS, V10, P882, DOI 10.21037/jtd.2018.01.125; Lampland AL, 2009, J PEDIATR-US, V154, P177, DOI 10.1016/j.jpeds.2008.07.021; Lee JH, 2013, INTENS CARE MED, V39, P247, DOI 10.1007/s00134-012-2743-5; Lucangelo U, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/506382; Lyu Shan, 2016, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V28, P84, DOI 10.3760/cma.j.issn.2095-4352.2016.01.018; Mas A, 2014, INT J CHRONIC OBSTR, V9, P837, DOI 10.2147/COPD.S42664; Mauri T, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2039-4; Miguel-Montanes R, 2015, CRIT CARE MED, V43, P574, DOI 10.1097/CCM.0000000000000743; Moore CP, 2019, CLIN BIOMECH, V65, P73, DOI 10.1016/j.clinbiomech.2019.04.004; Peters SG, 2013, RESP CARE, V58, P597, DOI 10.4187/respcare.01887; Plotnikow GA, 2018, RESP CARE, V63, P1016, DOI 10.4187/respcare.06031; Ricard JD, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022983; Sarkar M, 2017, LUNG INDIA, V34, P47, DOI 10.4103/0970-2113.197116; Sehgal IS, 2015, INDIAN J CRIT CARE M, V19, P743, DOI 10.4103/0972-5229.171414; Shippam W, 2019, ANAESTHESIA, V74, P450, DOI 10.1111/anae.14567; Siegel MD, HYPOXEMIA HYPERCAPNE; Simon M, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0712-9; Sztrymf B, 2011, INTENS CARE MED, V37, P1780, DOI 10.1007/s00134-011-2354-6; Tiruvoipati R, 2010, J CRIT CARE, V25, P463, DOI 10.1016/j.jcrc.2009.06.050; Wagstaff TAJ, 2007, ANAESTHESIA, V62, P492, DOI 10.1111/j.1365-2044.2007.05026.x; Ward JJ, 2013, RESP CARE, V58, P98, DOI 10.4187/respcare.01941	38	2	2	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2019	14	6							e0216957	10.1371/journal.pone.0216957	http://dx.doi.org/10.1371/journal.pone.0216957			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IB4TA	31170182	Green Submitted, Green Published, gold			2023-01-03	WOS:000470263700012
J	Haun, CT; Vann, CG; Osburn, SC; Mumford, PW; Roberson, PA; Romero, MA; Fox, CD; Johnson, CA; Parry, HA; Kavazis, AN; Moon, JR; Badisa, VLD; Mwashote, BM; Ibeanusi, V; Young, KC; Roberts, MD				Haun, Cody T.; Vann, Christopher G.; Osburn, Shelby C.; Mumford, Petey W.; Roberson, Paul A.; Romero, Matthew A.; Fox, Carlton D.; Johnson, Christopher A.; Parry, Hailey A.; Kavazis, Andreas N.; Moon, Jordan R.; Badisa, Veera L. D.; Mwashote, Benjamin M.; Ibeanusi, Victor; Young, Kaelin C.; Roberts, Michael D.			Muscle fiber hypertrophy in response to 6 weeks of high-volume resistance training in trained young men is largely attributed to sarcoplasmic hypertrophy	PLOS ONE			English	Article							SKELETAL-MUSCLE; PROTEIN-SYNTHESIS; MUSCULAR ADAPTATIONS; EXERCISE; STRENGTH; LOAD; GAINS	Cellular adaptations that occur during skeletal muscle hypertrophy in response to high-volume resistance training are not well-characterized. Therefore, we sought to explore how actin, myosin, sarcoplasmic protein, mitochondrial, and glycogen concentrations were altered in individuals that exhibited mean skeletal muscle fiber cross-sectional area (fCSA) hypertrophy following 6 weeks of high-volume resistance training. Thirty previously resistance-trained, college-aged males (mean +/- standard deviation: 21 +/- 2 years, 5 +/- 3 training years) had vastus lateralis (VL) muscle biopsies obtained prior to training (PRE), at week 3 (W3), and at week 6 (W6). Muscle tissue from 15 subjects exhibiting PRE to W6 VL mean fCSA increases ranging from 320-1600 mu m(2) was further interrogated using various biochemical and histological assays as well as proteomic analysis. Seven of these individuals donated a VL biopsy after refraining from training 8 days following the last training session (W7) to determine how deloading affected biomarkers. The 15 fCSA hypertrophic responders experienced a +23% increase in mean fCSA from PRE to W6 (p<0.001) and, while muscle glycogen concentrations remained unaltered, citrate synthase activity levels decreased by 24% (p<0.001) suggesting mitochondrial volume decreased. Interestingly, repeated measures ANOVAs indicated that p-values approached statistical significance for both myosin and actin (p = 0.052 and p = 0.055, respectively), and forced post hoc tests indicated concentrations for both proteins decreased similar to 30% from PRE to W6 (p<0.05 for each target). Phalloidin-actin staining similarly revealed actin concentrations per fiber decreased from PRE to W6. Proteomic analysis of the sarcoplasmic fraction from PRE to W6 indicated 40 proteins were up-regulated (p<0.05), KEGG analysis indicated that the glycolysis/gluconeogenesis pathway was upregulated (FDR sig. <0.001), and DAVID indicated that the following functionally-annotated pathways were upregulated (FDR value <0.05): a) glycolysis (8 proteins), b) acetylation (23 proteins), c) gluconeogenesis (5 proteins) and d) cytoplasm (20 proteins). At W7, sarcoplasmic protein concentrations remained higher than PRE (+66%, p<0.05), and both actin and myosin concentrations remained lower than PRE (similar to-50%, p<0.05). These data suggest that short-term high-volume resistance training may: a) reduce muscle fiber actin and myosin protein concentrations in spite of increasing fCSA, and b) promote sarcoplasmic expansion coincident with a coordinated up-regulation of sarcoplasmic proteins involved in glycolysis and other metabolic processes related to ATP generation. Interestingly, these effects seem to persist up to 8 days following training.	[Haun, Cody T.] LaGrange Coll, Dept Exercise Sci, La Grange, GA USA; [Vann, Christopher G.; Osburn, Shelby C.; Mumford, Petey W.; Roberson, Paul A.; Romero, Matthew A.; Fox, Carlton D.; Parry, Hailey A.; Kavazis, Andreas N.; Young, Kaelin C.; Roberts, Michael D.] Auburn Univ, Sch Kinesiol, Auburn, AL 36849 USA; [Johnson, Christopher A.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA; [Moon, Jordan R.] Impedimed, Carlsbad, CA USA; [Badisa, Veera L. D.; Mwashote, Benjamin M.; Ibeanusi, Victor] Florida A&M Univ, Sch Environm, Tallahassee, FL 32307 USA; [Young, Kaelin C.; Roberts, Michael D.] Edward Via Coll Osteopath Med Auburn Campus, Dept Cell Biol & Physiol, Auburn, AL 36832 USA	Auburn University System; Auburn University; University of Alabama System; University of Alabama Birmingham; State University System of Florida; Florida A&M University	Roberts, MD (corresponding author), Auburn Univ, Sch Kinesiol, Auburn, AL 36849 USA.; Roberts, MD (corresponding author), Edward Via Coll Osteopath Med Auburn Campus, Dept Cell Biol & Physiol, Auburn, AL 36832 USA.	mdr0024@auburn.edu	Mumford, Petey/GLS-9565-2022; Moon, James/AAA-9905-2020	Moon, James/0000-0001-8071-1491; Fox, Carlton/0000-0001-6142-6062; Mumford, Petey/0000-0002-4946-9702	Impedimed, Inc.; Florida AM University	Impedimed, Inc.; Florida AM University	Funding for subject compensation and certain assays was provided through a contract awarded to KCY and MDR by Impedimed, Inc. The funder provided support in the form of salaries for one author (JRM), but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Funding for proteomic analysis was provided through a Grant in Aid to MDR and VI from Florida A&M University. Additional funding was provided as a gift in kind to CTH and MDR through Renaissance Periodization by Dr. Mike Israetel and Nick Shaw. These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Specific roles of all authors are articulated in the 'Author Contributions' section."	Abe T., 2013, INT J CLIN MED, V4, P114, DOI DOI 10.4236/IJCM.2013.42022; Brentano MA, 2011, J SPORT MED PHYS FIT, V51, P1; Brook MS, 2015, FASEB J, V29, P4485, DOI 10.1096/fj.15-273755; Burd NA, 2013, EUR J APPL PHYSIOL, V113, P267, DOI 10.1007/s00421-012-2527-1; Campos GER, 2002, EUR J APPL PHYSIOL, V88, P50, DOI 10.1007/s00421-002-0681-6; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Cohen S, 2009, J CELL BIOL, V185, P1083, DOI 10.1083/jcb.200901052; Damas F, 2015, SPORTS MED, V45, P801, DOI 10.1007/s40279-015-0320-0; Duddy W, 2015, SKELET MUSCLE, V5, DOI 10.1186/s13395-015-0041-y; Gokhin DS, 2008, J EXP BIOL, V211, P837, DOI 10.1242/jeb.014340; Haun CT, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00247; Haun CT, 2018, FRONT NUTR, V5, DOI 10.3389/fnut.2018.00084; Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183; Hyatt HW, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12619; Jenkins NDM, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00331; Jenkins NDM, 2016, J STRENGTH COND RES, V30, P2174, DOI 10.1519/JSC.0000000000001308; Kadi F, 2004, J PHYSIOL-LONDON, V558, P1005, DOI 10.1113/jphysiol.2004.065904; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kumar V, 2009, J APPL PHYSIOL, V106, P2026, DOI 10.1152/japplphysiol.91481.2008; Larsen S, 2012, J PHYSIOL-LONDON, V590, P3349, DOI 10.1113/jphysiol.2012.230185; MACDOUGALL JD, 1982, EUR J APPL PHYSIOL O, V48, P117, DOI 10.1007/BF00421171; Martin JS, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.13029; Meijer JP, 2015, EXP PHYSIOL, V100, P1331, DOI 10.1113/EP085267; Mitchell CJ, 2012, J APPL PHYSIOL, V113, P71, DOI 10.1152/japplphysiol.00307.2012; Mobley CB, 2017, NUTRIENTS, V9, DOI 10.3390/nu9090972; Mobley CB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195203; Mobley CB, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00518; Morton RW, 2016, J APPL PHYSIOL, V121, P129, DOI 10.1152/japplphysiol.00154.2016; PENMAN KA, 1969, RES QUART, V40, P764, DOI 10.1080/10671188.1969.10614916; Petrella JK, 2008, J APPL PHYSIOL, V104, P1736, DOI 10.1152/japplphysiol.01215.2007; Qaisar R, 2016, FREE RADICAL BIO MED, V98, P56, DOI 10.1016/j.freeradbiomed.2016.03.025; Reidy PT, 2017, MED SCI SPORT EXER, V49, P1197, DOI 10.1249/MSS.0000000000001224; Reidy PT, 2016, J NUTR, V146, P155, DOI 10.3945/jn.114.203208; Roberts MD, 2018, PEERJ, V6, DOI 10.7717/peerj.5338; Schoenfeld BJ, 2010, J STRENGTH COND RES, V24, P3497, DOI 10.1519/JSC.0b013e3181bac2d7; Schuenke MD, 2012, EUR J APPL PHYSIOL, V112, P3585, DOI 10.1007/s00421-012-2339-3; STARON RS, 1991, J APPL PHYSIOL, V70, P631, DOI 10.1152/jappl.1991.70.2.631; Stone M.H., 1983, STRENGTH COND J, V5, P40; Toth MJ, 2012, J PHYSIOL-LONDON, V590, P1243, DOI 10.1113/jphysiol.2011.219659; Verdijk LB, 2009, J GERONTOL A-BIOL, V64, P332, DOI 10.1093/gerona/gln050; Wilkinson DJ, 2014, AM J PHYSIOL-ENDOC M, V306, pE571, DOI 10.1152/ajpendo.00650.2013	41	30	32	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 5	2019	14	6							e0215267	10.1371/journal.pone.0215267	http://dx.doi.org/10.1371/journal.pone.0215267			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IB2GN	31166954	gold, Green Submitted, Green Published			2023-01-03	WOS:000470087800005
J	Armstrong, AJ; Gupta, S; Healy, P; Kemeny, G; Leith, B; Zalutsky, MR; Spritzer, C; Davies, C; Rothwell, C; Ware, K; Somarelli, JA; Wood, K; Ribar, T; Giannakakou, P; Zhang, JR; Gerber, D; Anand, M; Foo, WC; Halabi, S; Gregory, SG; George, DJ				Armstrong, Andrew J.; Gupta, Santosh; Healy, Patrick; Kemeny, Gabor; Leith, Beth; Zalutsky, Michael R.; Spritzer, Charles; Davies, Catrin; Rothwell, Colin; Ware, Kathryn; Somarelli, Jason A.; Wood, Kris; Ribar, Thomas; Giannakakou, Paraskevi; Zhang, Jiaren; Gerber, Drew; Anand, Monika; Foo, Wen-Chi; Halabi, Susan; Gregory, Simon G.; George, Daniel J.			Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer	PLOS ONE			English	Article							CIRCULATING TUMOR-CELLS; EPITHELIAL PLASTICITY; ALKALINE-PHOSPHATASE; DOUBLE-BLIND; DNA-REPAIR; SURVIVAL; PHASE-3; GROWTH; TRANSITION; EXPRESSION	Background Radium-223 is a targeted alpha-particle therapy that improves survival in men with metastatic castration resistant prostate cancer (mCRPC), particularly in men with elevated serum levels of bone alkaline phosphatase (B-ALP). We hypothesized that osteomimicry, a form of epithelial plasticity leading to an osteoblastic phenotype, may contribute to intralesional deposition of radium-223 and subsequent irradiation of the tumor microenvironment. Methods We conducted a pharmacodynamic study (NCT02204943) of radium-223 in men with bone mCRPC. Prior to and three and six months after radium-223 treatment initiation, we collected CTCs and metastatic biopsies for phenotypic characterization and CTC genomic analysis. The primary objective was to describe the impact of radium-223 on the prevalence of CTC B-ALP over time. We measured radium-223 decay products in tumor and surrounding normal bone during treatment. We validated genomic findings in a separate independent study of men with bone metastatic mCRPC (n = 45) and publicly accessible data of metastatic CRPC tissues. Results We enrolled 20 men with symptomatic bone predominant mCRPC and treated with radium-223. We observed greater radium-223 radioactivity levels in metastatic bone tumor containing biopsies compared with adjacent normal bone. We found evidence of persistent Cellsearch CTCs and B-ALP (+) CTCs in the majority of men over time during radium-223 therapy despite serum B-ALP normalization. We identified genomic gains in osteoblast mimicry genes including gains of ALPL, osteopontin, SPARC, OB-cadherin and loss of RUNX2, and validated genomic alterations or increased expression at the DNA and RNA level in an independent cohort of 45 men with bone-metastatic CRPC and in 150 metastatic biopsies from men with mCRPC. Conclusions Osteomimicry may contribute in part to the uptake of radium-223 within bone metastases and may thereby enhance the therapeutic benefit of this bone targeting radiotherapy.	[Armstrong, Andrew J.; Gupta, Santosh; Kemeny, Gabor; Leith, Beth; Davies, Catrin; Rothwell, Colin; Ware, Kathryn; Somarelli, Jason A.; Gerber, Drew; Anand, Monika; George, Daniel J.] Duke Univ, Dept Med, Duke Canc Inst, Div Med Oncol, Durham, NC 27708 USA; [Armstrong, Andrew J.; Wood, Kris; Ribar, Thomas] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA; [Armstrong, Andrew J.; Gupta, Santosh; Healy, Patrick; Kemeny, Gabor; Zalutsky, Michael R.; Spritzer, Charles; Davies, Catrin; Rothwell, Colin; Ware, Kathryn; Somarelli, Jason A.; Anand, Monika; Halabi, Susan; Gregory, Simon G.; George, Daniel J.] Duke Canc Inst, Duke Prostate & Urol Canc Ctr, Durham, NC 27710 USA; [Gupta, Santosh; Gregory, Simon G.] Duke Univ, Duke Mol Physiol Inst, Durham, NC USA; [Healy, Patrick; Halabi, Susan] Duke Univ, Dept Biostat, Durham, NC USA; [Zalutsky, Michael R.; Spritzer, Charles] Duke Univ, Dept Radiol, Durham, NC 27710 USA; [Giannakakou, Paraskevi; Zhang, Jiaren] Weill Cornell Med Coll, New York, NY USA; [Foo, Wen-Chi] Duke Univ, Duke Dept Pathol, Durham, NC USA	Duke University; Duke University; Duke University; Duke University; Duke University; Duke University; Cornell University; Duke University	Armstrong, AJ (corresponding author), Duke Univ, Dept Med, Duke Canc Inst, Div Med Oncol, Durham, NC 27708 USA.; Armstrong, AJ (corresponding author), Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA.; Armstrong, AJ (corresponding author), Duke Canc Inst, Duke Prostate & Urol Canc Ctr, Durham, NC 27710 USA.	andrew.armstrong@duke.edu	Halabi, Susan/AFL-7973-2022; Halabi, Susan/AAG-7938-2022	Halabi, Susan/0000-0003-4135-2777; Halabi, Susan/0000-0003-4135-2777; Gregory, Simon/0000-0002-7805-1743; Armstrong, Andrew/0000-0001-7012-1754; zalutsky, michael/0000-0002-5456-0324	Prostate Cancer Foundation; Department of Defense Prostate Cancer Clinical Trials Consortium (DOD PCCTC); Movember; Bayer	Prostate Cancer Foundation; Department of Defense Prostate Cancer Clinical Trials Consortium (DOD PCCTC); Movember; Bayer(Bayer AG)	Funded as an investigator initiated study to Duke University by Bayer. For the PROPHECY study, we acknowledge funding from the Prostate Cancer Foundation and Movember and support from the Department of Defense Prostate Cancer Clinical Trials Consortium (DOD PCCTC).	Abida W, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00029; Armenia J, 2018, NAT GENET, V50, P645, DOI 10.1038/s41588-018-0078-z; Armstrong AJ, 2011, MOLCANCER RES; Beck GR, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997; Bitting RL, 2014, CANCER METAST REV, V33, P441, DOI 10.1007/s10555-013-9483-z; Cho HJ, 2014, CANCER DISCOV, V4, P318, DOI 10.1158/2159-8290.CD-13-0346; Chu GCY, 2014, ENDOCR-RELAT CANCER, V21, P311, DOI 10.1530/ERC-13-0548; Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541-7786.MCR-08-0077; de Bono JS, 2008, CLIN CANCER RES, V14, P6302, DOI 10.1158/1078-0432.CCR-08-0872; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140-6736(10)62344-6; Flux GD, 2017, BRIT J RADIOL, V90, DOI 10.1259/bjr.20160748; Gonzalez A, 2017, PROSTATE, V77, P321, DOI 10.1002/pros.23270; Goodwin JF, 2013, CANCER DISCOV, V3, P1254, DOI 10.1158/2159-8290.CD-13-0108; Gupta S, 2017, CLIN CANCER RES, V23, P1346, DOI 10.1158/1078-0432.CCR-16-1211; Haider M, 2016, CLIN EXP METASTAS, V33, P239, DOI 10.1007/s10585-015-9773-7; Heller G, 2018, J CLIN ONCOL, V36, P572, DOI 10.1200/JCO.2017.75.2998; Hoskin P, 2014, LANCET ONCOL, V15, P1397, DOI 10.1016/S1470-2045(14)70474-7; Huang CF, 2010, CANCER RES, V70, P4580, DOI 10.1158/0008-5472.CAN-09-3016; Huggins C, 1972, CA Cancer J Clin, V22, P232, DOI 10.3322/canjclin.22.4.232; Knerr K, 2004, INT J CANCER, V111, P152, DOI 10.1002/ijc.20223; Koeneman KS, 1999, PROSTATE, V39, P246; Li P, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-55; Lin DL, 2001, PROSTATE, V47, P212, DOI 10.1002/pros.1065; Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036; Lopez-Riquelme N, 2013, APMIS, V121, P1139, DOI 10.1111/apm.12061; Mulholland DJ, 2012, CANCER RES, V72, P1878, DOI 10.1158/0008-5472.CAN-11-3132; Norgaard M, 2010, J UROLOGY, V184, P162, DOI 10.1016/j.juro.2010.03.034; Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755; Perez-Lopez R, 2016, RADIOLOGY, V280, P151, DOI 10.1148/radiol.2015150799; Polkinghorn WR, 2013, CANCER DISCOV, V3, P1245, DOI 10.1158/2159-8290.CD-13-0172; Ramskold D, 2012, NAT BIOTECHNOL, V30, P777, DOI 10.1038/nbt.2282; Rao SR, 2017, BRIT J CANCER, V116, P227, DOI 10.1038/bjc.2016.402; Reyes EE, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0313-z; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Ruscetti M, 2015, CANCER RES, V75, P2749, DOI 10.1158/0008-5472.CAN-14-3476; Sailer V, 2018, CANCER-AM CANCER SOC, V124, P1008, DOI 10.1002/cncr.31173; San Martin IA, 2009, J CELL PHYSIOL, V221, P560, DOI 10.1002/jcp.21894; Sartor O, 2017, ANN ONCOL, V28, P1090, DOI 10.1093/annonc/mdx044; Sartor O, 2014, LANCET ONCOL, V15, P738, DOI 10.1016/S1470-2045(14)70183-4; Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487; Scher HI, 2015, J CLIN ONCOL, V33, P1348, DOI 10.1200/JCO.2014.55.3487; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414; Sieh S, 2014, BONE, V63, P121, DOI 10.1016/j.bone.2014.02.001; Spritzer CE, 2013, RADIOLOGY, V269, P816, DOI 10.1148/radiol.13121782; Taichman RS, 2007, J CLIN INVEST, V117, P2351, DOI 10.1172/JCI31791; Ware KE, 2016, ONCOTARGET, V7, P50520, DOI 10.18632/oncotarget.10476; Zou M, 2017, CANCER DISCOV, V7, P736, DOI 10.1158/2159-8290.CD-16-1174	49	7	7	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2019	14	5							e0216934	10.1371/journal.pone.0216934	http://dx.doi.org/10.1371/journal.pone.0216934			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IA0CM	31136607	gold, Green Published			2023-01-03	WOS:000469224300012
J	Manley, BJ; Arnolda, GRB; Wright, IMR; Owen, LS; Foster, JP; Huang, L; Roberts, CT; Clark, TL; Fan, WQ; Fang, AYW; Marshall, IR; Pszczola, RJ; Davis, PG; Buckmaster, AG				Manley, Brett J.; Arnolda, Gaston R. B.; Wright, Ian M. R.; Owen, Louise S.; Foster, Jann P.; Huang, Li; Roberts, Calum T.; Clark, Tracey L.; Fan, Wei-Qi; Fang, Alice Y. W.; Marshall, Isaac R.; Pszczola, Rosalynn J.; Davis, Peter G.; Buckmaster, Adam G.		HUNTER Trial Investigators	Nasal High-Flow Therapy for Newborn Infants in Special Care Nurseries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITIVE AIRWAY PRESSURE; PRIMARY RESPIRATORY SUPPORT; PHARYNGEAL PRESSURE; PRETERM INFANTS; CANNULA; DISTRESS; CENTERS	Background Nasal high-flow therapy is an alternative to nasal continuous positive airway pressure (CPAP) as a means of respiratory support for newborn infants. The efficacy of high-flow therapy in nontertiary special care nurseries is unknown. Methods We performed a multicenter, randomized, noninferiority trial involving newborn infants (<24 hours of age; gestational age, >= 31 weeks) in special care nurseries in Australia. Newborn infants with respiratory distress and a birth weight of at least 1200 g were assigned to treatment with either high-flow therapy or CPAP. The primary outcome was treatment failure within 72 hours after randomization. Infants in whom high-flow therapy failed could receive CPAP. Noninferiority was determined by calculating the absolute difference in the risk of the primary outcome, with a noninferiority margin of 10 percentage points. Results A total of 754 infants (mean gestational age, 36.9 weeks, and mean birth weight, 2909 g) were included in the primary intention-to-treat analysis. Treatment failure occurred in 78 of 381 infants (20.5%) in the high-flow group and in 38 of 373 infants (10.2%) in the CPAP group (risk difference, 10.3 percentage points; 95% confidence interval [CI], 5.2 to 15.4). In a secondary per-protocol analysis, treatment failure occurred in 49 of 339 infants (14.5%) in the high-flow group and in 27 of 338 infants (8.0%) in the CPAP group (risk difference, 6.5 percentage points; 95% CI, 1.7 to 11.2). The incidences of mechanical ventilation, transfer to a tertiary neonatal intensive care unit, and adverse events did not differ significantly between the groups. Conclusions Nasal high-flow therapy was not shown to be noninferior to CPAP and resulted in a significantly higher incidence of treatment failure than CPAP when used in nontertiary special care nurseries as early respiratory support for newborn infants with respiratory distress. (Funded by the Australian National Health and Medical Research Council and Monash University; HUNTER Australian and New Zealand Clinical Trials Registry number, .) In a multicenter randomized trial comparing nasal high-flow therapy with continuous positive airway pressure (CPAP) as initial respiratory support for newborns in nontertiary special care nurseries, high-flow therapy was not noninferior to CPAP and resulted in a significantly higher incidence of treatment failure.	[Manley, Brett J.; Owen, Louise S.; Davis, Peter G.] Royal Womens Hosp, Newborn Res Ctr, Level 7,20 Flemington Rd, Parkville, Vic 3052, Australia; [Manley, Brett J.; Owen, Louise S.; Davis, Peter G.] Royal Womens Hosp, Neonatal Serv, Parkville, Vic, Australia; [Manley, Brett J.; Owen, Louise S.; Davis, Peter G.] Univ Melbourne, Dept Obstet & Gynaecol, Parkville, Vic, Australia; [Fan, Wei-Qi] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia; [Manley, Brett J.; Owen, Louise S.; Davis, Peter G.] Murdoch Childrens Res Inst, Clin Sci, Parkville, Vic, Australia; [Arnolda, Gaston R. B.] Univ New South Wales, Sydney, NSW, Australia; [Foster, Jann P.] Univ Sydney, Sydney Nursing Sch, Sydney Med Sch, Sydney, NSW, Australia; [Arnolda, Gaston R. B.] Macquarie Univ, Australian Inst Hlth Innovat, Sydney, NSW, Australia; [Wright, Ian M. R.] Univ Wollongong, Illawarra Hlth & Med Res Inst, Wollongong, NSW, Australia; [Foster, Jann P.] Western Sydney Univ, Penrith, NSW, Australia; [Foster, Jann P.] Ingham Inst, Liverpool, NSW, Australia; [Huang, Li] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Hlth Policy, Carlton, Vic, Australia; [Roberts, Calum T.] Monash Childrens Hosp, Monash Newborn, Clayton, Vic, Australia; [Roberts, Calum T.] Monash Univ, Dept Paediat, Clayton, Vic, Australia; [Clark, Tracey L.] Monash Hlth, Monash Newborn, Dandenong, Vic, Australia; [Fan, Wei-Qi] Northern Hosp, Dept Paediat, Epping, Vic, Australia; [Fang, Alice Y. W.] Eastern Hlth, Box Hill Hosp, Box Hill, Vic, Australia; [Marshall, Isaac R.] Barwon Hlth, Womens & Childrens Serv, Geelong, Vic, Australia; [Pszczola, Rosalynn J.] Western Hlth, Dept Neonatol, St Albans, Vic, Australia; [Buckmaster, Adam G.] Cent Coast Local Hlth Dist, Dept Paediat, Gosford, NSW, Australia; [Buckmaster, Adam G.] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW, Australia	University of Melbourne; University of Melbourne; Murdoch Children's Research Institute; University of New South Wales Sydney; University of Sydney; Macquarie University; University of Wollongong; Western Sydney University; Ingham Institute for Applied Medical Research; University of Melbourne; Monash University; Box Hill Hospital; University of Newcastle	Manley, BJ (corresponding author), Royal Womens Hosp, Newborn Res Ctr, Level 7,20 Flemington Rd, Parkville, Vic 3052, Australia.	brett.manley@thewomens.org.au	Foster, Jann/AAA-5739-2020; McKinlay, Christopher JD/E-6263-2018; Arnolda, Gaston R/D-8528-2017; Foster, Jann/AAD-3806-2022	McKinlay, Christopher JD/0000-0003-1088-9467; Arnolda, Gaston R/0000-0003-4948-7633; Foster, Jann/0000-0002-6957-768X; Roberts, Calum/0000-0002-9111-5027; Manley, Brett/0000-0003-0212-7956; Huang, Li/0000-0001-5365-7899	Australian National Health and Medical Research Council; Monash University; HUNTER Australian and New Zealand [ACTRN12614001203640]	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Monash University(Monash University); HUNTER Australian and New Zealand	Funded by the Australian National Health and Medical Research Council and Monash University; HUNTER Australian and New Zealand Clinical Trials Registry number, ACTRN12614001203640.	Aagaard H, 2018, NURS INQ, V25, DOI 10.1111/nin.12231; [Anonymous], 2017, CANCER DISCOV, V7, pOF12; [Anonymous], 2015, AM J PHARM BENEFITS, V7, pe141; Argus BM, 2009, J PAEDIATR CHILD H, V45, P514, DOI 10.1111/j.1440-1754.2009.01551.x; Buckmaster A, 2012, J PAEDIATR CHILD H, V48, P747, DOI 10.1111/j.1440-1754.2012.02537.x; Buckmaster AG, 2007, PEDIATRICS, V120, P509, DOI 10.1542/peds.2007-0775; Chow SSW, 2015, REPORT AUSTR NZ NEON; Collins CL, 2013, J PEDIAT, V162; Collins CL, 2013, J PAEDIATR CHILD H, V49, P554, DOI 10.1111/jpc.12277; Iyer NP, 2016, RESP CARE, V61, P285, DOI 10.4187/respcare.04317; Klingenberg C, 2014, ARCH DIS CHILD-FETAL, V99, pF134, DOI 10.1136/archdischild-2013-304525; Lampland AL, 2009, J PEDIATR-US, V154, P177, DOI 10.1016/j.jpeds.2008.07.021; Lavizzari A, 2016, JAMA PEDIAT; Manley BJ, 2013, NEW ENGL J MED, V369, P1425, DOI 10.1056/NEJMoa1300071; Mauri L, 2017, NEW ENGL J MED, V377, P1357, DOI 10.1056/NEJMra1510063; Motojima Y, 2016, PEDIATR INT, V58, P308, DOI 10.1111/ped.12903; Murki S, 2018, NEONATOLOGY, V113, P235, DOI 10.1159/000484400; Papile LA, 2012, PEDIATRICS, V130, P587, DOI 10.1542/peds.2012-1999; Roberts CT, 2016, ARCH DIS CHILD-FETAL, V101, pF401, DOI 10.1136/archdischild-2015-309328; Roberts CT, 2016, NEW ENGL J MED, V375, P1142, DOI 10.1056/NEJMoa1603694; Roberts CT, 2014, J PAEDIATR CHILD H, V50, P806, DOI 10.1111/jpc.12636; Shetty S, 2016, ARCH DIS CHILD-FETAL, V101, pF371, DOI 10.1136/archdischild-2016-310497; Shin J, 2017, J KOREAN MED SCI, V32, P650, DOI 10.3346/jkms.2017.32.4.650; Wilkinson DJ, 2008, J PERINATOL, V28, P42, DOI 10.1038/sj.jp.7211879; Yoder BA, 2013, PEDIATRICS, V131, pE1482, DOI 10.1542/peds.2012-2742	25	41	43	2	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 23	2019	380	21					2031	2040		10.1056/NEJMoa1812077	http://dx.doi.org/10.1056/NEJMoa1812077			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ3MG	31116919	Bronze, Green Published			2023-01-03	WOS:000468752200010
J	van Beusekom, I; Bakhshi-Raiez, F; de Keizer, NF; van der Schaaf, M; Termorshuizen, F; Dongelmans, DA				van Beusekom, Ilse; Bakhshi-Raiez, Ferishta; de Keizer, Nicolette F.; van der Schaaf, Marike; Termorshuizen, Fabian; Dongelmans, Dave A.			Dutch ICU survivors have more consultations with general practitioners before and after ICU admission compared to a matched control group from the general population	PLOS ONE			English	Article							CARE; RISK	Background General Practitioners (GPs) play a key role in the healthcare trajectory of patients. If the patient experiences problems that are typically non-life-threatening, such as the symptoms of post-intensive-care syndrome, the GP will be the first healthcare professional they consult. The primary aim of this study is to gain insight in the frequency of GP consultations during the year before hospital admission and the year after discharge for ICU survivors and a matched control group from the general population. The secondary aim of this study is to gain insight into differences between subgroups of the ICU population with respect to the frequency of GP consultations. Methods We conducted a retrospective cohort study, combining a national health insurance claims database and a national quality registry for ICUs. Clinical data of patients admitted to an ICU in 2013 were enriched with claims data from the years 2012, 2013 and 2014. Poisson regression was used to assess the differences in frequency of GP consultations between the ICU population and the control group. Results ICU patients have more consultations with GPs during the year before and after admission than individuals in the control group. In the last four weeks before admission, ICU patients have 3.58 (CI 3.37; 3.80) times more GP consultations than the control group, and during the first four weeks after discharge they have 4.98 (CI 4.74; 5.23) times more GP consultations. In the year after hospital discharge ICU survivors have an increased GP consultation rate compared to the year before their hospital admission. Conclusions Close to hospital admission and shortly after hospital discharge, the frequency of GP consultations substantially increases in the population of ICU survivors. Even a year after hospital discharge, ICU survivors have increased GP consultation rates. Therefore, GPs should be well informed about the problems ICU patients suffer after discharge, in order to provide suitable follow-up care.	[van Beusekom, Ilse; Bakhshi-Raiez, Ferishta; de Keizer, Nicolette F.; Termorshuizen, Fabian] Univ Amsterdam, Amsterdam UMC, Amsterdam Publ Hlth Res Inst, Dept Med Informat, Amsterdam, Netherlands; [van Beusekom, Ilse; Bakhshi-Raiez, Ferishta; de Keizer, Nicolette F.; Termorshuizen, Fabian; Dongelmans, Dave A.] Natl Intens Care Evaluat NICE Fdn, Amsterdam, Netherlands; [van der Schaaf, Marike] Univ Amsterdam, Amsterdam UMC, Dept Rehabil, Amsterdam Movement Sci, Amsterdam, Netherlands; [van der Schaaf, Marike] Amsterdam Univ Appl Sci, Fac Hlth, Ctr Appl Res, Amsterdam, Netherlands; [Dongelmans, Dave A.] Univ Amsterdam, Amsterdam UMC, Dept Intens Care Med, Amsterdam, Netherlands	University of Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam	van Beusekom, I (corresponding author), Univ Amsterdam, Amsterdam UMC, Amsterdam Publ Hlth Res Inst, Dept Med Informat, Amsterdam, Netherlands.; van Beusekom, I (corresponding author), Natl Intens Care Evaluat NICE Fdn, Amsterdam, Netherlands.	i.vanbeusekom@amc.uva.nl	Dongelmans, Dave/AAA-8974-2019	Dongelmans, Dave/0000-0001-8477-6671	National Intensive Care Evaluation (NICE) foundation	National Intensive Care Evaluation (NICE) foundation	The National Intensive Care Evaluation (NICE) foundation pays the department of Medical Informatics for processing, checking and maintaining the Dutch quality registry. Drs. van Beusekom, Dr. Bakhshi-Raiez, Professor de Keizer and Dr. Termorshuizen are employees of the department of medical informatics and work for the NICE registry. Professor de Keizer and Dr. Dongelmans are members of the NICE board. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agard AS, 2014, INTENSIVE CRIT CARE, V30, P2; Connolly B, 2012, CRIT CARE, V16, DOI [10.1186/CC11219, 10.1186/cc11219]; Glynn LG, 2011, FAM PRACT, V28, P516, DOI 10.1093/fampra/cmr013; Jeitziner MM, 2015, J CLIN NURS, V24, P9; Knol F.A, 1998, HOOG NAAR LAAG LAAG; Lamers LM, 1999, MED CARE, V37, P824, DOI 10.1097/00005650-199908000-00012; Lamers LM, 2004, HEALTH POLICY, V68, P113, DOI 10.1016/j.healthpol.2003.09.001; Lone NI, 2016, AM J RESP CRIT CARE, V194, P198, DOI 10.1164/rccm.201511-2234OC; Mehlhorn J, 2014, CRIT CARE MED, V42, P1263, DOI 10.1097/CCM.0000000000000148; Needham DM, 2012, CRIT CARE MED, V40, P502, DOI 10.1097/CCM.0b013e318232da75; Oeyen SG, 2010, CRIT CARE MED, V38, P2386, DOI 10.1097/CCM.0b013e3181f3dec5; Pandharipande PP, 2013, NEW ENGL J MED, V369, P14; Parker AM, 2015, CRIT CARE MED, V43, P5; Roos LL, 1991, METHOD INFORM MED, V30, P2; Schellevis FG, 1994, BR J GEN PRACT, V44, P383; Stevens RD, 2007, INTENS CARE MED, V33, P11, DOI [10.1007/s00134-006-0431-z, DOI 10.1007/S00134-006-0431-Z]; van Beusekom I, 2017, J CRIT CARE, V44; van Beusekom I, 2019, CRIT CARE MED, V47, P324, DOI 10.1097/CCM.0000000000003576; van Beusekom I, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021249; van der Schaaf M, 2009, J REHABIL MED, V41, P5; van der Schaaf M, 2009, J REHABIL MED, V41, P13; van der Schaaf M, 2012, CRIT CARE MED, V40, P2742, DOI 10.1097/CCM.0b013e31825ae849; Wang YY, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003320; Williams TA, 2010, ANAESTH INTENSIVE CA, V38, P4; Zimmerman JE, 2006, CRIT CARE MED, V34, P5	25	10	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2019	14	5							e0217225	10.1371/journal.pone.0217225	http://dx.doi.org/10.1371/journal.pone.0217225			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ3VE	31120959	Green Published, Green Submitted, gold			2023-01-03	WOS:000468775700072
J	Lee, S; Jang, J; Yang, S; Hahn, J; Min, KL; Jung, EH; Oh, KS; Cho, R; Chang, MJ				Lee, Sunmin; Jang, JunYoung; Yang, Seungwon; Hahn, Jongsung; Min, Kyoung Lok; Jung, Eun Hee; Oh, Kyung Sun; Cho, Raejung; Chang, Min Jung			Development and validation of the Korean version of the medication regimen complexity index	PLOS ONE			English	Article							OLDER-PEOPLE; RELIABILITY	The medication regimen complexity index (MRCI), originally developed in English, is a reliable and valid tool to assess the complexity of pharmacotherapy. This study aimed to validate the Korean version of MRCI (MRCI-K). A cross-cultural methodological study comprising 335 discharged patients of a tertiary hospital in Korea was conducted. The translation process included translation into Korean by two clinical pharmacists, back translation by two native speakers, and a pretest of the tool, culminating in the Korean version of MRCI-K. Reliability analysis was assessed using inter-rater and test-retest reliability with 25 randomly selected patients. Convergent and discriminant validity analyses were conducted by correlating MRCI scores with medication number, age, sex, adverse drug reaction (ADR) reports, and length of stay. The criterion validity was confirmed through evaluation by a nine-member expert panel that subjectively ranked these regimens. The reliability analysis demonstrated excellent internal consistency (Cronbach's alpha = 0.977), and the intraclass correlation coefficient exceeded 0.90 for all cases. The correlation coefficient for the number of medications was 0.955 (P < 0.001). Weak significant correlations were observed with age and length of stay. The MRCI-K group with ADR reports scored higher (mean, 31.8) than the group without ADR reports (mean, 27.3). The expert panel's ranking had a stronger correlation with the MRCI ranking than the medication number ranking. MRCI-K has similar reliability and validity as MRCI and is useful for analyzing therapeutic regimens with potential applications in both practice and research in Korea.	[Lee, Sunmin; Min, Kyoung Lok; Chang, Min Jung] Yonsei Univ, Coll Med, Dept Pharmaceut Med & Regulatory Sci, Incheon, South Korea; [Lee, Sunmin; Min, Kyoung Lok; Chang, Min Jung] Yonsei Univ, Coll Pharm, Dept Pharmaceut Med & Regulatory Sci, Incheon, South Korea; [Lee, Sunmin; Jung, Eun Hee; Oh, Kyung Sun; Cho, Raejung] Inha Univ Hosp, Dept Pharm, Incheon, South Korea; [Jang, JunYoung; Yang, Seungwon; Hahn, Jongsung; Chang, Min Jung] Yonsei Univ, Coll Pharm, Dept Pharm, Incheon, South Korea; [Jang, JunYoung; Yang, Seungwon; Hahn, Jongsung; Chang, Min Jung] Yonsei Univ, Coll Pharm, Yonsei Inst Pharmaceut Sci, Incheon, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Inha University; Inha University Hospital; Yonsei University; Yonsei University	Chang, MJ (corresponding author), Yonsei Univ, Coll Med, Dept Pharmaceut Med & Regulatory Sci, Incheon, South Korea.; Chang, MJ (corresponding author), Yonsei Univ, Coll Pharm, Dept Pharmaceut Med & Regulatory Sci, Incheon, South Korea.; Chang, MJ (corresponding author), Yonsei Univ, Coll Pharm, Dept Pharm, Incheon, South Korea.; Chang, MJ (corresponding author), Yonsei Univ, Coll Pharm, Yonsei Inst Pharmaceut Sci, Incheon, South Korea.	mjchang@yonsei.ac.kr		Chang, Min Jung/0000-0002-8408-5907; Lee, Sunmin/0000-0002-0528-5098				Advinha AM, 2014, INT J CLIN PHARM-NET, V36, P750, DOI 10.1007/s11096-014-9963-4; Alves-Conceicao V, 2018, ANN PHARMACOTHER, V52, P1117, DOI 10.1177/1060028018773691; Beaton DE, 2000, SPINE, V25, P3186, DOI 10.1097/00007632-200012150-00014; Bryant BM, 2016, ANN PHARMACOTHER, V50, P926, DOI 10.1177/1060028016657552; Melchiors AC, 2007, ARQ BRAS CARDIOL, V89, P210, DOI 10.1590/S0066-782X2007001600001; Chang WT, 2017, INT J CLIN PHARM-NET, V39, P867, DOI 10.1007/s11096-017-0490-y; Dierich MT, 2011, J GERONTOL NURS, V37, P45, DOI 10.3928/00989134-20111103-02; George J, 2004, ANN PHARMACOTHER, V38, P1369, DOI 10.1345/aph.1D479; Hirsch JD, 2014, PHARMACOTHERAPY, V34, P826, DOI 10.1002/phar.1452; Kim HA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098043; Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012; Lee JS, 2008, KOREAN J FAM MED, V29, P925; Libby AM, 2013, CLIN THER, V35, P385, DOI 10.1016/j.clinthera.2013.02.019; Mansur N, 2012, AM J GERIATR PHARMAC, V10, P223, DOI 10.1016/j.amjopharm.2012.06.002; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Metz KR, 2014, ANN PHARMACOTHER, V48, P1129, DOI 10.1177/1060028014539642; Okuyan B, 2016, J EVAL CLIN PRACT, V22, P732, DOI 10.1111/jep.12526; Pantuzza LL, 2017, EUR J CLIN PHARMACOL, V73, P1475, DOI 10.1007/s00228-017-2315-2; Paquin AM, 2013, EXPERT OPIN DRUG SAF, V12, P829, DOI 10.1517/14740338.2013.823944; Sluggett JK, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2417-2; Stange D, 2012, J EVAL CLIN PRACT, V18, P515, DOI 10.1111/j.1365-2753.2011.01636.x; Willson MN, 2014, ANN PHARMACOTHER, V48, P26, DOI 10.1177/1060028013510898; Wimmer BC, 2017, J AM GERIATR SOC, V65, P747, DOI 10.1111/jgs.14682; Wimmer BC, 2015, EUR J CLIN PHARMACOL, V71, P1099, DOI 10.1007/s00228-015-1883-2; Witticke D, 2013, DRUG SAFETY, V36, P31, DOI 10.1007/s40264-012-0007-5; 2016, ANN PHARMACOTHER, V50, P918, DOI DOI 10.1177/1060028016656385	26	3	3	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2019	14	5							e0216805	10.1371/journal.pone.0216805	http://dx.doi.org/10.1371/journal.pone.0216805			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY3MG	31095602	Green Published, gold, Green Submitted			2023-01-03	WOS:000468030100045
J	Cyranoski, D				Cyranoski, David			Chinese hospitals set to sell experimental cell therapies	NATURE			English	News Item																			0	4	4	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 9	2019	569	7755					170	171		10.1038/d41586-019-01161-2	http://dx.doi.org/10.1038/d41586-019-01161-2			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX5VX	31065085	Bronze			2023-01-03	WOS:000467473600019
J	Laffranchi, Z; Manasse, GC; Salzani, L; Milella, M				Laffranchi, Zita; Manasse, Giuliana; Salzani, Luciano; Milella, Marco			Patterns of funerary variability, diet, and developmental stress in a Celtic population from NE Italy (3rd-1st c BC)	PLOS ONE			English	Article							STABLE-ISOTOPE; AGE ESTIMATION; ENAMEL HYPOPLASIAS; NITROGEN ISOTOPES; CARBON ISOTOPES; PHASE-ANALYSIS; BONE-COLLAGEN; SKELETON; BOLOGNA; PERIOD	Little is known about the types of social organization characterizing the pre-Roman Celtic populations of Italy. Here, we explore the funerary variability characterizing the late Iron Age site of Seminario Vescovile (SV: Verona, Italy, 3rd-1st c. BC), and test its possible correlation to diet and relative exposure to developmental stressors. Patterns on funerary treatment (N = 125), delta C-13 and delta N-15 (N = 90), and linear enamel hypoplasia (N = 47) from SV are compared, and their possible association with sex and age-at-death further discussed. Results point to the presence at SV of variable funerary customs while at the same time demonstrating a rather homogenous diet and exposure to developmental stressors: funerary treatment is mainly correlated to age-at-death but do not appear to be associated to either isotopic patterns or hypoplasia frequencies. Accordingly, even if some weak social differentiation may have characterized the individuals buried at SV, this was not reflected in markedly differing living conditions. Our study is the first to attempt an exploration of the links between age, sex, funerary variability, and diet in a pre-Roman Celtic community from Italy. While highlighting the potential of a multifaceted approach in bioarcheology, it also points to a series of analytical and theoretical issues relevant when trying to disentangle the cultural and biological dimensions of social differentiation in the past.	[Laffranchi, Zita] Univ Granada, Dept Med Legal Toxicol & Antropol Fis, Granada, Spain; [Manasse, Giuliana; Salzani, Luciano] Sede Padova Nucleo Verona, Settore Terr, Soprintendenza & Beni Archeol Veneto, Padua, Italy; [Milella, Marco] Univ Zurich Irchel, Dept Anthropol, Zurich, Switzerland; [Milella, Marco] Univ Zurich Irchel, Anthropol Museum, Zurich, Switzerland	University of Granada; University of Zurich; University of Zurich	Milella, M (corresponding author), Univ Zurich Irchel, Dept Anthropol, Zurich, Switzerland.; Milella, M (corresponding author), Univ Zurich Irchel, Anthropol Museum, Zurich, Switzerland.	marco.milella@aim.uzh.ch	Laffranchi, Zita/H-3510-2015; Milella, Marco/D-5070-2017	Laffranchi, Zita/0000-0001-8553-771X; Milella, Marco/0000-0003-1027-6601				Ames K., 2007, HDB ARCHAEOLOGICAL T, P487; Arbizu P., 2020, PAIRWISEADONIS PAIRW; Armelagos GJ, 2009, EVOL ANTHROPOL, V18, P261, DOI 10.1002/evan.20239; Armit I., 2012, HEADHUNTING BODY IRO; Arnold B, 2016, J ARCHAEOL METHOD TH, V23, P832, DOI 10.1007/s10816-016-9289-8; Arslan EA, 2008, ARCHEOTRADE ANTICHI, P251; Arzone A., 2013, THESIS; Auguie B., 2017, GRIDEXTRA MISCELLANE; Berseneva N., 2006, ARCHAEOLOGY CULT DEA, P179; Bocherens H, 1997, QUATERNARY RES, V48, P370, DOI 10.1006/qres.1997.1927; BOCHERENS H, 1991, J HUM EVOL, V20, P481, DOI 10.1016/0047-2484(91)90021-M; Boudin S., 2014, CELTES NORD ITALIE P, P63; Brasili P, 2000, HOMO, V51, P200; Brasili P., 2003, NECROPOLI MONTE TAMB, P475; Brasili P., 2008, TRA MONDO CELTICO MO, P53; Brasili P., 1992, ANTHROPOL ANZ, V50, P53; BRAUN DP, 1981, AM ANTIQUITY, V46, P398, DOI 10.2307/280220; Brook AH, 1998, CONNECT TISSUE RES, V39, P150; Brook AH, 2009, ARCH ORAL BIOL, V54, pS3, DOI 10.1016/j.archoralbio.2009.09.005; Brooks S., 1990, HUM EVOL, V5, P227; Brown J.A, 1995, REGIONAL APPROACHES, P3; Buckberry JL, 2002, AM J PHYS ANTHROPOL, V119, P231, DOI 10.1002/ajpa.10130; Buikstra J. E., 1994, STANDARDS DATA COLLE; Capitanio MA, 1989, ATTI MEMORIE ACCAD 6, VVI, P159; Cardarelli A., 2015, PREISTORIA PROTOSTOR; Cavalieri Manasse G., 2014, RIV EPIGRAFIA ITALIC, P373; Chapman R., 2003, MORTALITY, V8, P305, DOI DOI 10.1080/13576270310001599849; Corrain C., 1987, QUADERNI SCI ANTROPO, V13, P21; Cunliffe B., 2018, THE ANCIENT CELTS, VSecond Edition; DENIRO MJ, 1978, GEOCHIM COSMOCHIM AC, V42, P495, DOI 10.1016/0016-7037(78)90199-0; DENIRO MJ, 1981, GEOCHIM COSMOCHIM AC, V45, P341, DOI 10.1016/0016-7037(81)90244-1; Ferraresi A., 1976, NOTIZIE SCAVI ANTICH, V30, P5; Fuller BT, 2006, AM J PHYS ANTHROPOL, V129, P45, DOI 10.1002/ajpa.20244; Gamble LH, 2001, AM ANTIQUITY, V66, P185, DOI 10.2307/2694605; Gelsomini S., 1991, ATLANTE BRESCIANO, V28, P70; GOODMAN AH, 1991, ADVANCES IN DENTAL ANTHROPOLOGY, P279; GOODMAN AH, 1990, YEARB PHYS ANTHROPOL, V33, P59; Gowland R., 2006, SOCIAL ARCHAEOLOGY F, P143; Gowland R.L., 2006, SOCIAL ARCHAEOLOGY F; Grassi M., 2009, I CELTI ITALIA; Halcrow SE, 2008, J ARCHAEOL METHOD TH, V15, P190, DOI 10.1007/s10816-008-9052-x; Hedges REM, 2007, J ARCHAEOL SCI, V34, P1240, DOI 10.1016/j.jas.2006.10.015; Hillson S., 1996, DENT ANTHR; Hodder I., 1980, BRIT ARCHAEOLOGICAL, V82, P161; Hollimon S. E, 2011, SOCIAL BIOARCHAEOLOG, P147; ISCAN MY, 1985, J FORENSIC SCI, V30, P853; ISCAN MY, 1984, J FORENSIC SCI, V29, P1094; James S., 1999, ATLANTIC CELTS ANCIE; Jay M, 2006, J ARCHAEOL SCI, V33, P653, DOI 10.1016/j.jas.2005.09.020; Killgrove K, 2013, J ANTHROPOL ARCHAEOL, V32, P28, DOI 10.1016/j.jaa.2012.08.002; Knipper C, 2017, ARCHAEOL ANTHROP SCI, V9, P1307, DOI 10.1007/s12520-016-0362-8; Knipper C, 2014, J ARCHAEOL SCI, V41, P818, DOI 10.1016/j.jas.2013.09.019; Kruta V, 1999, I CELTI IN ITALIA; Laffranchi Z, 2015, HOMO, V66, P216, DOI 10.1016/j.jchb.2015.01.003; Laffranchi Z., 2015, THESIS; Laffranchi Z, 2018, J ARCHAEOL SCI-REP, V17, P30, DOI 10.1016/j.jasrep.2017.10.040; Laffranchi Z, 2016, SCI REP-UK, V6, DOI 10.1038/srep38817; Larsen C.S, 2015, BIOARCHAEOLOGY INTER, DOI DOI 10.1016/j.bone.2012.05.023; Le Huray J. D., 2006, SOCIAL ARCHAEOLOGY F, P99; Le Huray JD, 2005, J ANTHROPOL ARCHAEOL, V24, P135, DOI 10.1016/j.jaa.2004.09.002; Lenth R. V., 2018, R PACKAGE VERSION; Lewis ME, 2007, CAM S BIO EVOL ANTHR, V50, P1; M?ller-Schee&beta;el N., 2013, IRREGULARE BESTATTUN; Malnati L., 2004, IBERES VENETES, P347; Marchesini S., 2018, INVISIBLE VISIBLE NE, P143; Mariotti V, 2005, INT J OSTEOARCHAEOL, V15, P311, DOI 10.1002/oa.775; Masotti S, 2013, ARCH ORAL BIOL, V58, P416, DOI 10.1016/j.archoralbio.2012.07.011; MAY RL, 1993, AM J PHYS ANTHROPOL, V92, P37, DOI 10.1002/ajpa.1330920104; Milella M, 2015, PLOS ONE, V10; Moghaddam N, 2016, ARCHAEOL ANTHROP SCI, V10, P1067; Moghaddam N, 2016, ARCHAEOL ANTHROP SCI, V8, P149, DOI 10.1007/s12520-014-0221-4; Murray M.L., 1988, TRIBE POLITY LATE PR, P155, DOI [10.1007/978-1-4899-0777-6_7, DOI 10.1007/978-1-4899-0777-6_7]; Oelze VM, 2012, AM J PHYS ANTHROPOL, V148, P406, DOI 10.1002/ajpa.22063; Oksanen J., 2018, R PACKAGE VERSION, V2, P4; Parker Pearson Michael, 1982, SYMBOLIC STRUCTURAL, P99, DOI DOI 10.1017/CBO9780511558252; Pindborg J.J., 1970, PATHOLOGY DENT HARD; PINDBORG JJ, 1982, INT DENT J, V32, P123; Rottoli M., 2014, PLANTS PEOPLE CHOICE, P75; Rufibach K, 2009, J STAT SOFTW, V31, P1; Salzani L., 1996, NECROPOLI GALLICA RO; Salzani L., 1998, NECROPOLI GALLICA CA; Salzani L., 1995, NECROPOLI GALLICA VA; Sarnat BG, 1941, J AM DENT ASS, V28; Sassatelli G., 2008, TRA MONDO CELTICO MO, P323; Schaefer M., 2009, JUVENILE OSTEOLOGY L; Scheeres M, 2013, J ARCHAEOL SCI, V40, P3614, DOI 10.1016/j.jas.2013.05.003; Scheuer L., 2000, DEV JUVENILE OSTEOLO; SCHOENINGER MJ, 1992, J WORLD PREHIST, V6, P247, DOI 10.1007/BF00975551; SCHOENINGER MJ, 1984, GEOCHIM COSMOCHIM AC, V48, P625, DOI 10.1016/0016-7037(84)90091-7; Shanks M., 1982, SYMBOLIC STRUCTURAL, P129, DOI DOI 10.1017/CB09780511558252.013; SMITH BH, 1984, AM J PHYS ANTHROPOL, V63, P39, DOI 10.1002/ajpa.1330630107; SMITH BN, 1971, PLANT PHYSIOL, V47, P380, DOI 10.1104/pp.47.3.380; Sofaer Joana, 2006, BODY MAT CULTURE THE; Sofaer JR., 2006, SOCIAL ARCHAEOLOGY F, P155; Solinas P., 2015, STUDI ETRUSCHI, V78, P373; Sorrentino R, 2018, PLOS ONE, V13, P228, DOI [10.1016/j.jchb.2015.01.003, DOI 10.1016/J.JCHB.2015.01.003]; Steckel RH, 2006, DATA COLLECTION CODE, P1; Steel Louise, 1995, OXBOW MONOGRAPHS ARC, V51, P199; STINSON S, 1985, YEARB PHYS ANTHROPOL, V28, P123, DOI 10.1002/ajpa.1330280507; Stuani R., 2017, THESIS; SUCKLING G, 1986, ARCH ORAL BIOL, V31, P427, DOI 10.1016/0003-9969(86)90016-6; Suckling G, 1984, TOOTH ENAMEL, P357; Suzuki R., PVCLUST HIERARCHICAL; Tafuri MA, 2018, INT J OSTEOARCHAEOL, V28, P131, DOI 10.1002/oa.2639; Tafuri MA, 2009, AM J PHYS ANTHROPOL, V139, P146, DOI 10.1002/ajpa.20955; Teegen WR, 2012, CELTES NORD ITALIE P, P523; Teegen WR, 2014, ANTICHI POPOLI ALPI, P217; TRINKAUS KM, 1984, CURR ANTHROPOL, V25, P674, DOI 10.1086/203206; Ubelaker D. H., 1989, HUMAN SKELETAL REMAI, V2nd; VANDERMERWE NJ, 1982, AM SCI, V70, P596; Vitali D., 2004, GUERRIERI PRINCIPI E, P315; Vitali D., 2002, ANIMALI TRA UOMINI A, P127; Vitali D., 1987, CELTI ETRUSCHI ITALI, P309; Vitali D, 2014, ANTICHI POPOLI ALPI, P199; Vitali D., 2014, MY LIFE IS SUMMER RO, P733; Vitali D., 1991, CATALOGO MOSTRA VENE, P220; Wickham H., 2016, GGPLOT2 ELEGANT GRAP, DOI [10.1007/978-3-319-24277-4, DOI 10.1007/978-3-319-24277-4]; Zhou LM, 1998, AM J HUM BIOL, V10, P723, DOI [10.1002/(SICI)1520-6300(1998)10:6<723::AID-AJHB4>3.0.CO;2-Q, 10.1002/(SICI)1520-6300(1998)10:6&lt;723::AID-AJHB4&gt;3.0.CO;2-Q]	118	9	9	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2019	14	4							e0214372	10.1371/journal.pone.0214372	http://dx.doi.org/10.1371/journal.pone.0214372			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU1CQ	30995254	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000465010000018
J	Hetz, C; Axten, JM; Patterson, JB				Hetz, Claudio; Axten, Jeffrey M.; Patterson, John B.			Pharmacological targeting of the unfolded protein response for disease intervention	NATURE CHEMICAL BIOLOGY			English	Review							ENDOPLASMIC-RETICULUM STRESS; PANCREATIC BETA-CELLS; SELECTIVE-INHIBITION; MOUSE MODEL; ALLOSTERIC INHIBITION; INSULIN-SECRETION; KINASE INHIBITOR; BREAST-CANCER; ER STRESS; IRE1-ALPHA	Accumulation of unfolded proteins at the endoplasmic reticulum (ER) is a salient attribute of many human diseases including obesity, liver disorders, cancer, diabetes and neurodegeneration. To restore ER proteostasis, cells activate the unfolded protein response (UPR), a signaling pathway that imposes adaptive programs or triggers apoptosis of damaged cells. The UPR is critical to sustain the normal function of specialized secretory cells (i.e., pancreatic beta cells and B lymphocytes) and to control the production of lipids and cholesterol in the liver. In the context of disease, adaptive UPR responses have been linked to the growth of solid tumors, whereas chronic ER stress contributes to cell dysfunction in brain diseases, metabolic syndromes, among other conditions. Here we discuss recent developments in the design and optimization of novel compounds to manipulate UPR signaling and their efficacy in various disease models.	[Hetz, Claudio] Univ Chile, Fac Med, Biomed Neurosci Inst, Santiago, Chile; [Hetz, Claudio] FONDAP Ctr Gerosci Brain Hlth & Metab, Santiago, Chile; [Hetz, Claudio] Univ Chile, Inst Biomed Sci, Program Cellular & Mol Biol, Santiago, Chile; [Hetz, Claudio] Buck Inst Res Aging, Novato, CA 94945 USA; [Hetz, Claudio] Harvard Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; [Axten, Jeffrey M.] GlaxoSmithKline, Med Design, Med Chem, Collegeville, PA 19426 USA; [Patterson, John B.] Orinove Inc, Newbury Pk, CA 91320 USA	Universidad de Chile; Universidad de Chile; Buck Institute for Research on Aging; Harvard University; Harvard T.H. Chan School of Public Health; GlaxoSmithKline	Hetz, C (corresponding author), Univ Chile, Fac Med, Biomed Neurosci Inst, Santiago, Chile.; Hetz, C (corresponding author), FONDAP Ctr Gerosci Brain Hlth & Metab, Santiago, Chile.; Hetz, C (corresponding author), Univ Chile, Inst Biomed Sci, Program Cellular & Mol Biol, Santiago, Chile.; Hetz, C (corresponding author), Buck Inst Res Aging, Novato, CA 94945 USA.; Hetz, C (corresponding author), Harvard Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.; Axten, JM (corresponding author), GlaxoSmithKline, Med Design, Med Chem, Collegeville, PA 19426 USA.; Patterson, JB (corresponding author), Orinove Inc, Newbury Pk, CA 91320 USA.	chetz@med.uchile.cl; Jeffrey.M.Axten@gsk.com; jpatterson@orinove.com	Hetz, Claudio/ABD-7514-2021	Patterson, John/0000-0002-2871-2945; Axten, Jeffrey/0000-0002-8999-3381	FONDAP program [15150012]; Millennium Institute [P09-015-F]; CONICYT-Brazil [441921/2016-7]; FONDEF [ID16I10223, D11E1007]; FONDECYT [1180186]; US Air Force Office of Scientific Research [FA9550-16-1-0384]; Muscular Dystrophy Association; US Office of Naval Research-Global (ONR-G) [N62909-16-1-2003]	FONDAP program(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDAP); Millennium Institute(Takeda Pharmaceutical Company Ltd); CONICYT-Brazil; FONDEF; FONDECYT(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); US Air Force Office of Scientific Research(United States Department of DefenseAir Force Office of Scientific Research (AFOSR)); Muscular Dystrophy Association(Muscular Dystrophy Association); US Office of Naval Research-Global (ONR-G)(Office of Naval Research)	We thank H. Urra for initial figure design. This work was directly funded by FONDAP program 15150012, Millennium Institute P09-015-F, CONICYT-Brazil 441921/2016-7, FONDEF ID16I10223, FONDEF D11E1007 and FONDECYT 1180186 (CH). In addition, we thank the support from the US Air Force Office of Scientific Research FA9550-16-1-0384, and Muscular Dystrophy Association, US Office of Naval Research-Global (ONR-G) N62909-16-1-2003 (C.H.).	Abdulkarim B, 2017, ENDOCRINOLOGY, V158, P1659, DOI 10.1210/en.2016-1773; Asada R, 2011, J BIOCHEM, V149, P507, DOI 10.1093/jb/mvr041; Atkins C, 2013, CANCER RES, V73, P1993, DOI 10.1158/0008-5472.CAN-12-3109; Axten JM, 2013, ACS MED CHEM LETT, V4, P964, DOI 10.1021/ml400228e; Axten JM, 2012, J MED CHEM, V55, P7193, DOI 10.1021/jm300713s; Batista G, 2016, ELIFE, V5, DOI 10.7554/eLife.17197; Bettigole SE, 2015, ANNU REV IMMUNOL, V33, P107, DOI 10.1146/annurev-immunol-032414-112116; Blackwood EA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08129-2; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Briggs DI, 2017, ENEURO, V4, DOI 10.1523/ENEURO.0025-17.2017; Carrara M, 2017, NAT STRUCT MOL BIOL, V24, P708, DOI 10.1038/nsmb.3443; Chan SMH, 2018, BIOCHEM J, V475, P923, DOI 10.1042/BCJ20170678; Chang TK, 2018, MOL CELL, V71, P629, DOI 10.1016/j.molcel.2018.06.038; Chou A, 2017, P NATL ACAD SCI USA, V114, pE6420, DOI 10.1073/pnas.1707661114; Colla E, 2012, J NEUROSCI, V32, P3306, DOI 10.1523/JNEUROSCI.5367-11.2012; Concha NO, 2015, MOL PHARMACOL, V88, P1011, DOI 10.1124/mol.115.100917; Crespillo-Casado A, 2018, J BIOL CHEM, V293, P7766, DOI 10.1074/jbc.RA118.002325; Crespillo-Casado A, 2017, ELIFE, V6, DOI 10.7554/eLife.26109; Cross BCS, 2012, P NATL ACAD SCI USA, V109, pE869, DOI 10.1073/pnas.1115623109; Cubillos-Ruiz JR, 2017, CELL, V168, P692, DOI 10.1016/j.cell.2016.12.004; Das I, 2015, SCIENCE, V348, P239, DOI 10.1126/science.aaa4484; Dufey E, 2014, AM J PHYSIOL-CELL PH, V307, pC582, DOI 10.1152/ajpcell.00258.2014; Falletta P, 2017, GENE DEV, V31, P18, DOI 10.1101/gad.290940.116; Feldman HC, 2016, ACS CHEM BIOL, V11, P2195, DOI 10.1021/acschembio.5b00940; Feng YX, 2014, CANCER DISCOV, V4, P702, DOI 10.1158/2159-8290.CD-13-0945; Gallagher CM, 2016, ELIFE, V5, DOI 10.7554/eLife.11880; Gallagher CM, 2016, ELIFE, V5, DOI 10.7554/eLife.11878; Ghosh R, 2014, CELL, V158, P534, DOI 10.1016/j.cell.2014.07.002; Grande V, 2018, HUM MOL GENET, V27, P2477, DOI 10.1093/hmg/ddy152; Guan BJ, 2017, MOL CELL, V68, P885, DOI 10.1016/j.molcel.2017.11.007; Halliday M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.49; Halliday M, 2017, BRAIN, V140, P1768, DOI 10.1093/brain/awx074; Hamamura K, 2014, INT J ONCOL, V44, P1980, DOI 10.3892/ijo.2014.2366; Harrington PE, 2015, ACS MED CHEM LETT, V6, P68, DOI 10.1021/ml500315b; Hearn BR, 2016, CHEMMEDCHEM, V11, P870, DOI 10.1002/cmdc.201500483; Hetz C, 2017, NAT REV NEUROL, V13, P477, DOI 10.1038/nrneurol.2017.99; Hetz C, 2015, NAT CELL BIOL, V17, P829, DOI 10.1038/ncb3184; Hetz C, 2013, NAT REV DRUG DISCOV, V12, P703, DOI 10.1038/nrd3976; Hetz C, 2009, MOL CELL, V35, P551, DOI 10.1016/j.molcel.2009.08.021; Jiang HQ, 2014, NEUROSCIENCE, V277, P132, DOI 10.1016/j.neuroscience.2014.03.047; Johnson ECB, 2016, PEERJ, V4, DOI 10.7717/peerj.2565; Kabir ZD, 2017, MOL PSYCHIATR, V22, P1096, DOI 10.1038/mp.2017.124; Karagoz GE, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a033886; Kim MJ, 2018, J ENDOCRINOL, V236, P125, DOI 10.1530/JOE-17-0497; Koh JH, 2018, J CELL SCI, V131, DOI 10.1242/jcs.217992; Kriss CL, 2012, BLOOD, V120, P1027, DOI 10.1182/blood-2011-11-394346; Larhammar M, 2017, ELIFE, V6, DOI 10.7554/eLife.20725; Lebeaupin C, 2018, J HEPATOL, V69, P927, DOI 10.1016/j.jhep.2018.06.008; Logue SE, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05763-8; Martinez G, 2018, TRENDS NEUROSCI, V41, P610, DOI 10.1016/j.tins.2018.05.009; Martinez G, 2016, CELL REP, V14, P1382, DOI 10.1016/j.celrep.2016.01.028; Mendez AS, 2015, ELIFE, V4, DOI 10.7554/eLife.05434; Mercado G, 2018, NEUROBIOL DIS, V112, P136, DOI 10.1016/j.nbd.2018.01.004; Mimura N, 2012, BLOOD, V119, P5772, DOI 10.1182/blood-2011-07-366633; Ming J, 2015, ONCOTARGET, V6, P40692, DOI 10.18632/oncotarget.5827; Moreno JA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006767; Moreno JA, 2012, NATURE, V485, P507, DOI 10.1038/nature11058; Morita S, 2017, CELL METAB, V25, P883, DOI 10.1016/j.cmet.2017.03.018; Nguyen HG, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aar2036; Oakes SA, 2015, ANNU REV PATHOL-MECH, V10, P173, DOI 10.1146/annurev-pathol-012513-104649; Ohri SS, 2013, NEUROBIOL DIS, V58, P29, DOI 10.1016/j.nbd.2013.04.021; Ounallah-Saad H, 2014, J NEUROSCI, V34, P14624, DOI 10.1523/JNEUROSCI.2117-14.2014; Pakos-Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195; Palam LR, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.264; Papandreou I, 2011, BLOOD, V117, P1311, DOI 10.1182/blood-2010-08-303099; Paxman R, 2018, ELIFE, V7, DOI 10.7554/eLife.37168; Plate L, 2016, ELIFE, V5, DOI 10.7554/eLife.15550; Rabouw HH, 2019, P NATL ACAD SCI USA, V116, P2097, DOI 10.1073/pnas.1815767116; Radford H, 2015, ACTA NEUROPATHOL, V130, P633, DOI 10.1007/s00401-015-1487-z; Ranatunga S, 2014, J MED CHEM, V57, P4289, DOI 10.1021/jm5002452; Rojas-Rivera D, 2017, CELL DEATH DIFFER, V24, P1100, DOI 10.1038/cdd.2017.58; Rubovitch V, 2015, NEUROMOL MED, V17, P58, DOI 10.1007/s12017-015-8340-3; Sanches M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5202; Sato H, 2017, CELL STRUCT FUNCT, V42, P61, DOI 10.1247/csf.17002; Sekine Y, 2015, SCIENCE, V348, P1027, DOI 10.1126/science.aaa6986; Sheng X, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08152-3; Sidrauski C, 2015, ELIFE, V4, DOI 10.7554/eLife.07314; Sidrauski C, 2015, ELIFE, V4, DOI 10.7554/eLife.05033; Sidrauski C, 2013, ELIFE, V2, DOI 10.7554/eLife.00498; Smith AL, 2015, J MED CHEM, V58, P1426, DOI 10.1021/jm5017494; Smith JA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00422; Song M, 2018, NATURE, V562, P423, DOI 10.1038/s41586-018-0597-x; Tam AB, 2018, DEV CELL, V46, P327, DOI 10.1016/j.devcel.2018.04.023; Tang CHA, 2014, J CLIN INVEST, V124, P2585, DOI 10.1172/JCI73448; Thamsen M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209824; Tsai JC, 2018, SCIENCE, V359, P1483, DOI 10.1126/science.aaq0939; Tsaytler P, 2011, SCIENCE, V332, P91, DOI 10.1126/science.1201396; Urra H, 2016, TRENDS CANCER, V2, P252, DOI 10.1016/j.trecan.2016.03.007; Valenzuela V, 2018, MOL THER, V26, P1404, DOI 10.1016/j.ymthe.2018.04.004; Vieira FG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135570; Volkmann K, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.199737; Waller DD, 2016, CHEMBIOCHEM, V17, P843, DOI 10.1002/cbic.201500485; Wang LJ, 2014, NEUROBIOL DIS, V71, P317, DOI 10.1016/j.nbd.2014.08.010; Wang LK, 2012, NAT CHEM BIOL, V8, P982, DOI [10.1038/NCHEMBIO.1094, 10.1038/nchembio.1094]; Wang M, 2016, NATURE, V529, P326, DOI 10.1038/nature17041; Way SW, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7532; Wong YL, 2019, ELIFE, V8, DOI 10.7554/eLife.42940; Xie H, 2018, J CLIN INVEST, V128, P1300, DOI 10.1172/JCI95864; Zhao N, 2018, J CLIN INVEST, V128, P1283, DOI 10.1172/JCI95873; Zyryanova AF, 2018, SCIENCE, V359, P1533, DOI 10.1126/science.aar5129	100	134	135	3	62	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	AUG	2019	15	8					764	775		10.1038/s41589-019-0326-2	http://dx.doi.org/10.1038/s41589-019-0326-2			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	IK3GW	31320759				2023-01-03	WOS:000476478500006
J	Shanafelt, TD; Wang, XV; Kay, NE; Hanson, CA; O'Brien, S; Barrientos, J; Jelinek, DF; Braggio, E; Leis, JF; Zhang, CC; Coutre, SE; Barr, PM; Cashen, AF; Mato, AR; Singh, AK; Mullane, MP; Little, RF; Erba, H; Stone, RM; Litzow, M; Tallman, M				Shanafelt, T. D.; Wang, X. V.; Kay, N. E.; Hanson, C. A.; O'Brien, S.; Barrientos, J.; Jelinek, D. F.; Braggio, E.; Leis, J. F.; Zhang, C. C.; Coutre, S. E.; Barr, P. M.; Cashen, A. F.; Mato, A. R.; Singh, A. K.; Mullane, M. P.; Little, R. F.; Erba, H.; Stone, R. M.; Litzow, M.; Tallman, M.			Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OPEN-LABEL; CYCLOPHOSPHAMIDE; FLUDARABINE; MUTATIONS; THERAPY; PHASE-3; CLL	Patients 70 years of age or younger with previously untreated CLL were randomly assigned to receive ibrutinib plus rituximab or chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab. The ibrutinib-based regimen led to prolonged progression-free and overall survival. Background Data regarding the efficacy of treatment with ibrutinib-rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients with previously untreated chronic lymphocytic leukemia (CLL) have been limited. Methods In a phase 3 trial, we randomly assigned (in a 2:1 ratio) patients 70 years of age or younger with previously untreated CLL to receive either ibrutinib and rituximab for six cycles (after a single cycle of ibrutinib alone), followed by ibrutinib until disease progression, or six cycles of chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab. The primary end point was progression-free survival, and overall survival was a secondary end point. We report the results of a planned interim analysis. Results A total of 529 patients underwent randomization (354 patients to the ibrutinib-rituximab group, and 175 to the chemoimmunotherapy group). At a median follow-up of 33.6 months, the results of the analysis of progression-free survival favored ibrutinib-rituximab over chemoimmunotherapy (89.4% vs. 72.9% at 3 years; hazard ratio for progression or death, 0.35; 95% confidence interval [CI], 0.22 to 0.56; P<0.001), and the results met the protocol-defined efficacy threshold for the interim analysis. The results of the analysis of overall survival also favored ibrutinib-rituximab over chemoimmunotherapy (98.8% vs. 91.5% at 3 years; hazard ratio for death, 0.17; 95% CI, 0.05 to 0.54; P<0.001). In a subgroup analysis involving patients without immunoglobulin heavy-chain variable region (IGHV) mutation, ibrutinib-rituximab resulted in better progression-free survival than chemoimmunotherapy (90.7% vs. 62.5% at 3 years; hazard ratio for progression or death, 0.26; 95% CI, 0.14 to 0.50). The 3-year progression-free survival among patients with IGHV mutation was 87.7% in the ibrutinib-rituximab group and 88.0% in the chemoimmunotherapy group (hazard ratio for progression or death, 0.44; 95% CI, 0.14 to 1.36). The incidence of adverse events of grade 3 or higher (regardless of attribution) was similar in the two groups (in 282 of 352 patients [80.1%] who received ibrutinib-rituximab and in 126 of 158 [79.7%] who received chemoimmunotherapy), whereas infectious complications of grade 3 or higher were less common with ibrutinib-rituximab than with chemoimmunotherapy (in 37 patients [10.5%] vs. 32 [20.3%], P<0.001). Conclusions The ibrutinib-rituximab regimen resulted in progression-free survival and overall survival that were superior to those with a standard chemoimmunotherapy regimen among patients 70 years of age or younger with previously untreated CLL. (Funded by the National Cancer Institute and Pharmacyclics; E1912 ClinicalTrials.gov number, .)	[Shanafelt, T. D.; Coutre, S. E.] Stanford Univ, Stanford, CA 94305 USA; [O'Brien, S.] Univ Calif Irvine, Med Ctr, Orange, CA USA; [Zhang, C. C.] Kaiser Permanente Natl Canc Inst, Community Oncol Res Program NCORP, Permanente Med Grp, Oakland, CA USA; [Wang, X. V.; Stone, R. M.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Kay, N. E.; Hanson, C. A.; Leis, J. F.; Litzow, M.] Mayo Clin, Rochester, MN USA; [Singh, A. K.] Minnesota Oncol, Burnsville, MN USA; [Barrientos, J.] Lake Success, Donald & Barbara Zucker Sch Med Hofstra Northwell, Northwell Hlth Canc Inst, Rochester, NY USA; [Barr, P. M.] Univ Rochester, Rochester, NY USA; [Jelinek, D. F.; Braggio, E.] Mayo Clin, Phoenix, AZ USA; [Cashen, A. F.] Washington Univ, Sch Med, St Louis, MO USA; [Mato, A. R.; Tallman, M.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Mullane, M. P.] Aurora Canc Care, W Allis, WI USA; [Little, R. F.] NCI, Bethesda, MD 20892 USA; [Erba, H.] Univ Alabama, Tuscaloosa, AL USA	Stanford University; University of California System; University of California Irvine; Permanente Medical Groups; Harvard University; Dana-Farber Cancer Institute; Mayo Clinic; University of Rochester; Mayo Clinic; Mayo Clinic Phoenix; Washington University (WUSTL); Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Alabama System; University of Alabama Tuscaloosa	Shanafelt, TD (corresponding author), Stanford Univ, Sch Med, Dept Med, Div Hematol, 300 Pasteur Dr,Rm 3215, Stanford, CA 94025 USA.	tshana@stanford.edu	Barr, Paul/V-2574-2019; Barrientos, Jacqueline/AAE-6683-2022	Barr, Paul/0000-0002-9733-401X; Coutre, Steven/0000-0001-8420-5748	National Cancer Institute; Pharmacyclics [E1912]; NATIONAL CANCER INSTITUTE [U10CA180816, U10CA180888, UG1CA233290, R01CA193541, UG1CA189828, U10CA180833, UG1CA233180, U24CA196172, U10CA180855, U10CA180794, U10CA180820, U10CA180790, UG1CA190140, UG1CA189863, U10CA180791, UG1CA233339, UG1CA189821, U10CA180821, U10CA180867] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Pharmacyclics; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by the National Cancer Institute and Pharmacyclics; E1912 ClinicalTrials.gov number, NCT02048813.	Barrio S, 2017, LEUKEMIA, V31, P170, DOI 10.1038/leu.2016.172; Benjamini O, 2015, LEUKEMIA LYMPHOMA, V56, P1643, DOI 10.3109/10428194.2014.957203; Brown JR, 2017, HAEMATOLOGICA, V102, P1796, DOI 10.3324/haematol.2017.171041; Burger JA, 2015, NEW ENGL J MED, V373, P2425, DOI 10.1056/NEJMoa1509388; Burger JA, 2019, BLOOD, V133, P1011, DOI 10.1182/blood-2018-10-879429; Byrd JC, 2014, NEW ENGL J MED, V371, P213, DOI 10.1056/NEJMoa1400376; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; Cheson BD, 2012, J CLIN ONCOL, V30, P2820, DOI 10.1200/JCO.2012.43.3748; COX DR, 1972, J R STAT SOC B, V34, P187; Edelmann J, 2017, J ONCOL PRACT, V13, P371, DOI 10.1200/JOP.2017.023291; Eichhorst B, 2016, LANCET ONCOL, V17, P928, DOI 10.1016/S1470-2045(16)30051-1; Ferrer G, 2018, MOL MED, V24, DOI 10.1186/s10020-018-0001-1; Fischer K, 2016, BLOOD, V127, P208, DOI 10.1182/blood-2015-06-651125; Goede V, 2014, NEW ENGL J MED, V370, P1101, DOI 10.1056/NEJMoa1313984; Hallek M, 2010, LANCET, V376, P1164, DOI 10.1016/S0140-6736(10)61381-5; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Hallek M, 2018, BLOOD, V131, P2745, DOI 10.1182/blood-2017-09-806398; Herman SEM, 2014, BLOOD, V123, P3286, DOI 10.1182/blood-2014-02-548610; Herman SEM, 2011, BLOOD, V117, P6287, DOI 10.1182/blood-2011-01-328484; Jain P, 2018, BRIT J HAEMATOL, V180, P33, DOI 10.1111/bjh.15018; Landau DA, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02329-y; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Shanafelt TD, 2015, J ONCOL PRACT, V11, P252, DOI 10.1200/JOP.2014.002469; Smith TJ, 2015, J CLIN ONCOL, V33, P3199, DOI 10.1200/JCO.2015.62.3488; Stilgenbauer S, 2014, BLOOD, V123, P3247, DOI 10.1182/blood-2014-01-546150; Thompson PA, 2016, BLOOD, V127, P303, DOI 10.1182/blood-2015-09-667675; Wiestner A, 2015, HAEMATOLOGICA, V100, P1495, DOI 10.3324/haematol.2014.119123; Woyach JA, 2018, NEW ENGL J MED, V379, P2517, DOI 10.1056/NEJMoa1812836; Younes A, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-112988	30	377	382	2	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 1	2019	381	5					432	443		10.1056/NEJMoa1817073	http://dx.doi.org/10.1056/NEJMoa1817073			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IM5WH	31365801	Green Accepted			2023-01-03	WOS:000478064200008
J	Edahiro, R; Kanazu, M; Kurebe, H; Mori, M; Fujimoto, D; Taniguchi, Y; Suzuki, H; Hirano, K; Yokoyama, T; Morita, M; Fukuda, Y; Uchida, J; Makio, T; Tamiya, M				Edahiro, Ryuya; Kanazu, Masaki; Kurebe, Hiroyuki; Mori, Masahide; Fujimoto, Daichi; Taniguchi, Yoshihiko; Suzuki, Hidekazu; Hirano, Katsuya; Yokoyama, Toshihide; Morita, Mitsunori; Fukuda, Yasushi; Uchida, Junji; Makio, Takeshi; Tamiya, Motohiro			Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan	PLOS ONE			English	Article							NIVOLUMAB; PD-1	Background Pembrolizumab is currently approved as a first-line therapy for advanced non-small cell lung cancer (NSCLC) patients with a programed death ligand-1 (PD-L1) expression >= 50%. However, the association between the efficacy of pembrolizumab and PD-L1 expression levels in patients with PD-L1 expression >= 50% has not been fully elucidated. Methods We retrospectively analyzed patients with advanced NSCLC and a PD-L1 tumor proportion score (TPS) of >= 50% who received pembrolizumab as a first-line therapy at 11 institutions in Japan between February 2017 and January 2018. Patients were divided into TPS 50-89% and TPS 90-100% (ultra-high PD-L1 expression) cohorts. Results In total, 149 patients were included: 99 (66.4%) and 50 (33.6%) patients were in the TPS 50-89% and TPS 90-100% cohorts, respectively. Baseline characteristics were similar between the TPS 90-100% and TPS 50-89% cohorts. The objective response rates (ORR) in the TPS 90-100% and TPS 50-89% cohorts were 58.0% and 46.5%, respectively (p = 0.23). Time to treatment failure (TTF) was longer in the TPS 90-100% cohort than in the TPS 50-89% cohort (hazard ratio [HR]: 0.67, 95% confidence interval (CI): 0.42-1.07; p = 0.09). Although TTF within 120 days after the initiation of pembrolizumab therapy was comparable between both cohorts (p = 0.54), TTF after 120 days was significantly longer in the TPS 90-100% cohort than in the TPS 50-89% cohort (HR: 0.22, 95% CI: 0.06-0.87; p = 0.031). Immune related adverse events of grade 3 or more occurred in 16.0% and 19.2% of patients in the TPS 90-100% and TPS 50-89% cohorts, respectively. Conclusions The patients with an ultra-high PD-L1 expression continued pembrolizumab therapy longer, driven by a reduced risk of treatment failure in the late phase. PD-L1 expression levels might be a predictive biomarker of a first-line immunotherapy benefit in the late phase among NSCLC patients with TPS >= 50%.	[Edahiro, Ryuya; Kanazu, Masaki; Kurebe, Hiroyuki; Mori, Masahide] Natl Hosp Org, Dept Thorac Oncol, Osaka Toneyama Med Ctr, Toyonaka, Osaka, Japan; [Fujimoto, Daichi] Kobe City Med Ctr Gen Hosp, Dept Resp Med, Kobe, Hyogo, Japan; [Taniguchi, Yoshihiko] Natl Hosp Org, Dept Internal Med, Kinki Chuo Chest Med Ctr, Osaka, Japan; [Suzuki, Hidekazu] Osaka Habikino Med Ctr, Dept Thorac Oncol, Osaka, Japan; [Hirano, Katsuya] Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Resp Med, Amagasaki, Hyogo, Japan; [Yokoyama, Toshihide] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan; [Morita, Mitsunori] Kobe City Med Ctr West Hosp, Dept Resp Med, Kobe, Hyogo, Japan; [Fukuda, Yasushi] Himeji Med Ctr, Dept Resp Med, Himeji, Hyogo, Japan; [Uchida, Junji] Osaka Gen Med Ctr, Dept Resp Med, Osaka, Japan; [Makio, Takeshi] Itami City Hosp, Dept Resp Med, Itami, Hyogo, Japan; [Tamiya, Motohiro] Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan	Kobe City Medical Center General Hospital; Kurashiki Central Hospital; Kobe City Medical Center General Hospital	Kanazu, M (corresponding author), Natl Hosp Org, Dept Thorac Oncol, Osaka Toneyama Med Ctr, Toyonaka, Osaka, Japan.	kanazu.masaki.hs@mail.hosp.go.jp						Aguiar PN, 2017, ESMO OPEN, V2, DOI 10.1136/esmoopen-2017-000200; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Chen DS, 2012, CLIN CANCER RES, V18, P6580, DOI 10.1158/1078-0432.CCR-12-1362; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Francisco LM, 2009, J EXP MED, V206, P3015, DOI 10.1084/jem.20090847; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; He J, 2015, SCI REP-UK, V5, DOI 10.1038/srep10019; McLaughlin J, 2016, JAMA ONCOL, V2, P46, DOI 10.1001/jamaoncol.2015.3638; Morgensztern D, 2010, J THORAC ONCOL, V5, P29, DOI 10.1097/JTO.0b013e3181c5920c; Okazaki T, 2007, INT IMMUNOL, V19, P813, DOI 10.1093/intimm/dxm057; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Peters S, 2017, NEW ENGL J MED, V377, P829, DOI 10.1056/NEJMoa1704795; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rizvi H, 2018, J CLIN ONCOL, V36, P633, DOI 10.1200/JCO.2017.75.3384; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736; Schuette W, 2005, J CLIN ONCOL, V23, P8389, DOI 10.1200/JCO.2005.02.3739; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444	21	12	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2019	14	7							e0220570	10.1371/journal.pone.0220570	http://dx.doi.org/10.1371/journal.pone.0220570			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4XR	31365588	Green Published, Green Submitted, gold			2023-01-03	WOS:000484983600056
J	Moodley, R; Suleman, F				Moodley, Rajatheran; Suleman, Fatima			The impact of the single exit price policy on a basket of generic medicines in South Africa, using a time series analysis from 1999 to 2014	PLOS ONE			English	Article							COUNTRIES; SUBSTITUTION	Background Regulating pharmaceutical markets have become a key strategy by most governments in ensuring the availability and accessibility of quality medicines to its citizens. The South African government, when faced with high medicine prices, implemented the Single Exit Price (SEP) in 2004. This study assessed the impact of the of the Single Exit Price (SEP) regulation introduced in South Africa in 2004 on a basket of generic. Method Private sector price data of a basket of medicines (December 1999 to December 2014) was obtained from various price files (Pharmacy Software Vendors and Community Pharmacy). The price of the medicine was expressed in a single unit dose. The medicines investigated used the WHO/HAI methodology. The Interrupted Time-Series (ITS) model was used to estimate the change in slope and level of medicines investigated (50 originator and its available generics) before and after the policy change. Results Majority of the medicines analysed reflect a substantial decrease in medicine prices immediately after implementation of the pricing regulations as reflected in both the change in level and the change in slope using the interrupted time series analysis. Discussion This study indicates that the SEP regulation had an impact on medicine pricing in South Africa in both the short (immediately on the introduction) and long term (over the study period). Most medicines investigated showed a smaller yearly increase in price compared to before regulations. Conclusion This study provides evidence of the impact of medicine pricing intervention from a middleincome country, and useful lessons can be drawn by other developing countries looking at introducing medicine price controls.	[Moodley, Rajatheran; Suleman, Fatima] Univ KwaZulu Natal, Sch Hlth Sci, Discipline Pharmaceut Sci, Durban, South Africa; [Suleman, Fatima] Univ Utrecht, Fac Sci, Utrecht, Netherlands	University of Kwazulu Natal; Utrecht University	Suleman, F (corresponding author), Univ KwaZulu Natal, Sch Hlth Sci, Discipline Pharmaceut Sci, Durban, South Africa.; Suleman, F (corresponding author), Univ Utrecht, Fac Sci, Utrecht, Netherlands.	sulemanf@ukzn.ac.za	Suleman, Fatima/GQP-0955-2022; Moodley, Rajatheran/AAR-9988-2020	Suleman, Fatima/0000-0002-8559-9168; Moodley, Rajatheran/0000-0003-0399-0460				Aitken M., 2016, PPL, V18, P55, DOI [10.3233/PPL-160432, DOI 10.3233/PPL-160432]; [Anonymous], 2017, WORLD J PHARM RES, V6; Antonanzas F, 2017, PHARMACOECONOMICS, V35, P777, DOI 10.1007/s40273-017-0514-4; Auta A, 2014, MED PRIN PRACT, V23, P53, DOI 10.1159/000355473; Bangalee V, TRANSPARENT PRICING; Bangalee V, 2016, HEALTH SA GESONDHEID, V21, DOI 10.1016/j.hsag.2015.10.004; Barron P, 2014, AFRICAN PRIVATE PHAR; Bernal JL, 2017, INT J EPIDEMIOL, V46, P348, DOI 10.1093/ije/dyw098; Cambourieu C, 2013, GENERIC DRUG PRICING; Cameron A, 2009, LANCET, V373, P240, DOI 10.1016/S0140-6736(08)61762-6; Cameron A, 2010, COST SAVINGS SWITCHI, P11; Cameron A, 2012, VALUE HEALTH, V15, P664, DOI 10.1016/j.jval.2012.04.004; Carone G, 2012, EC PAPERS, DOI [DOI 10.2765/27111, 10.2139/ssrn.2161803]; Council for Medical Schemes, 1995, CMS ANN REP 1995; Danzon PM, 2000, J LAW ECON, V43, P311, DOI 10.1086/467458; De La Maisonneuve C., 2013, OECD EC POLICY PAPER, V6, P1; Deroukakis M, 2007, SAMJ S AFR MED J, V97, P63; Dias V, 2012, MANAG SCI HLTH; Gray A, 2015, PHARM PRICES 21 CENT; Hassali MA, 2014, SAUDI PHARM J, V22, P491, DOI 10.1016/j.jsps.2013.12.017; Hollis A., 2008, GENERIC DRUG PRICING, V2; Hollis Aidan, 2015, Healthc Policy, V11, P10; IFPMA, 2021, PHARM IND GLOB HLTH; Kaplan W, 2016, HLTH ACTION INT, P1; Mediscor, 2013, MED MED REV 2013; Moreno-Torres I, 2011, EUR J HEALTH ECON, V12, P563, DOI 10.1007/s10198-010-0271-1; National Department of Health South Africa, 1996, NAT DRUG POL S AFR T; National Department of Health South Africa, 2004, REG REL TRANSP PRIC; Seeley E, 2008, PHARM POLICY COST CO, P18; South Africa N. National Department of Health, S AFR MED PRIC REG; StataCorp, 2013, STAT REL 13, V161; Vernon JA, 2005, S EC J, V73, P233; Vogler S, 2017, EXPERT REV PHARM OUT, V17, P221, DOI 10.1080/14737167.2016.1223543; Vogler S, 2012, GABI J, V1, P93, DOI 10.5639/gabij.2012.0102.020; Vogler Sabine, 2011, South Med Rev, V4, P69, DOI 10.5655/smr.v4i2.1004; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; WHO Health Action International, 2008, MEAS MED PRIC AV AFF, V2nd; World Health Organization, 2015, WHO GUID COUNTR PHAR, P134; Xiphu L, 2004, MED PRICES SURVEY GA	39	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2019	14	7							e0219690	10.1371/journal.pone.0219690	http://dx.doi.org/10.1371/journal.pone.0219690			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4XR	31365534	Green Published, gold, Green Submitted			2023-01-03	WOS:000484983600015
J	Golan, T; Hammel, P; Reni, M; Van Cutsem, E; Macarulla, T; Hall, MJ; Park, JO; Hochhauser, D; Arnold, D; Oh, DY; Reinacher-Schick, A; Tortora, G; Algul, H; O'Reilly, EM; McGuinness, D; Cui, KY; Schlienger, K; Locker, GY; Kindler, HL				Golan, Talia; Hammel, Pascal; Reni, Michele; Van Cutsem, Eric; Macarulla, Teresa; Hall, Michael J.; Park, Joon-Oh; Hochhauser, Daniel; Arnold, Dirk; Oh, Do-Youn; Reinacher-Schick, Anke; Tortora, Giampaolo; Alguel, Hana; O'Reilly, Eileen M.; McGuinness, David; Cui, Karen Y.; Schlienger, Katia; Locker, Gershon Y.; Kindler, Hedy L.			Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GEMCITABINE; FOLFIRINOX; SURVIVAL; THERAPY; BREAST	BackgroundPatients with a germline BRCA1 or BRCA2 mutation make up a small subgroup of those with metastatic pancreatic cancer. The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib has had antitumor activity in this population. MethodsWe conducted a randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy of olaparib as maintenance therapy in patients who had a germline BRCA1 or BRCA2 mutation and metastatic pancreatic cancer and disease that had not progressed during first-line platinum-based chemotherapy. Patients were randomly assigned, in a 3:2 ratio, to receive maintenance olaparib tablets (300 mg twice daily) or placebo. The primary end point was progression-free survival, which was assessed by blinded independent central review. ResultsOf the 3315 patients who underwent screening, 154 underwent randomization and were assigned to a trial intervention (92 to receive olaparib and 62 to receive placebo). The median progression-free survival was significantly longer in the olaparib group than in the placebo group (7.4 months vs. 3.8 months; hazard ratio for disease progression or death, 0.53; 95% confidence interval [CI], 0.35 to 0.82; P=0.004). An interim analysis of overall survival, at a data maturity of 46%, showed no difference between the olaparib and placebo groups (median, 18.9 months vs. 18.1 months; hazard ratio for death, 0.91; 95% CI, 0.56 to 1.46; P=0.68). There was no significant between-group difference in health-related quality of life, as indicated by the overall change from baseline in the global quality-of-life score (on a 100-point scale, with higher scores indicating better quality of life) based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (between-group difference, -2.47 points; 95% CI, -7.27 to 2.33). The incidence of grade 3 or higher adverse events was 40% in the olaparib group and 23% in the placebo group (between-group difference, 16 percentage points; 95% CI, -0.02 to 31); 5% and 2% of the patients, respectively, discontinued the trial intervention because of an adverse event. ConclusionsAmong patients with a germline BRCA mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo.	[Golan, Talia] Tel Aviv Univ, Sheba Med Ctr, Oncol Inst, IL-52621 Tel Aviv, Israel; [Hammel, Pascal] Hop Beaujon, AP HP, Clichy, France; [Hammel, Pascal] Univ Paris VII, Paris, France; [Reni, Michele] IRCCS Osped San Raffaele Sci Inst, Milan, Italy; [Tortora, Giampaolo] Azienda Osped Univ Integrata Verona, Verona, Italy; [Tortora, Giampaolo] Fdn Policlin Univ Gemelli IRCCS, Rome, Italy; [Van Cutsem, Eric] Univ Hosp Gasthuisberg, Leuven, Belgium; [Van Cutsem, Eric] Katholieke Univ Leuven, Leuven, Belgium; [Macarulla, Teresa] Vall dHebron Univ Hosp, Barcelona, Spain; [Macarulla, Teresa] Vall dHebron Inst Oncol, Barcelona, Spain; [Hall, Michael J.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Park, Joon-Oh] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea; [Oh, Do-Youn] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Canc Res Inst, Seoul, South Korea; [Hochhauser, Daniel] UCL, Canc Inst, London, England; [McGuinness, David] AstraZeneca, Cambridge, England; [Arnold, Dirk] Asklepios Tumorzentrum Hamburg Asklepios Klin Alt, Hamburg, Germany; [Reinacher-Schick, Anke] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany; [Alguel, Hana] Tech Univ Munich, Klinikum Rechts Isar, Dept Internal Med 2, Munich, Germany; [O'Reilly, Eileen M.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Cui, Karen Y.; Locker, Gershon Y.] AstraZeneca, Gaithersburg, MD USA; [Schlienger, Katia] Merck, Kenilworth, NJ USA; [Kindler, Hedy L.] Univ Chicago, Chicago, IL 60637 USA	Chaim Sheba Medical Center; Tel Aviv University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; KU Leuven; University Hospital Leuven; KU Leuven; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Fox Chase Cancer Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Seoul National University (SNU); Seoul National University Hospital; University of London; University College London; Ruhr University Bochum; Technical University of Munich; Memorial Sloan Kettering Cancer Center; AstraZeneca; Merck & Company; University of Chicago	Golan, T (corresponding author), Tel Aviv Univ, Sheba Med Ctr, Oncol Inst, IL-52621 Tel Aviv, Israel.	talia.golan@sheba.health.gov.il	Van+Cutsem, Eric/ABE-1762-2021; Macarulla, Teresa/AAG-9230-2019; Tortora, Giampaolo/AAA-1252-2019; Reni, Michele/J-8296-2016; Tortora, Giampaolo/HGB-6261-2022	Reni, Michele/0000-0002-6463-0293; O'Reilly, Eileen M./0000-0002-8076-9199; Tortora, Giampaolo/0000-0002-1378-4962; Macarulla, Teresa/0000-0002-5856-4082; Hochhauser, Daniel/0000-0001-5522-9281	AstraZeneca; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	AstraZeneca(AstraZeneca); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by AstraZeneca and others	AstraZeneca, 2016, ASTRAZENECA GLOB POL; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Dahan L, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.4000; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Friedenson Bernard, 2005, MedGenMed, V7, P60; Ghiorzo P, 2014, WORLD J GASTROENTERO, V20, P10778, DOI 10.3748/wjg.v20.i31.10778; Golan T, 2014, BRIT J CANCER, V111, P1132, DOI 10.1038/bjc.2014.418; GOLAN T, 2018, J CLIN ONCOL S, V36; Holter S, 2015, J CLIN ONCOL, V33, P3124, DOI 10.1200/JCO.2014.59.7401; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kaufman B, 2015, J CLIN ONCOL, V33, P244, DOI 10.1200/JCO.2014.56.2728; Khalique S, 2014, CURR OPIN ONCOL, V26, P521, DOI 10.1097/CCO.0000000000000110; Moore K, 2018, NEW ENGL J MED, V379, P2495, DOI 10.1056/NEJMoa1810858; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Osoba D, 1998, J CLIN ONCOL, V16, P139, DOI 10.1200/JCO.1998.16.1.139; Pujade-Lauraine E, 2017, LANCET ONCOL, V18, P1274, DOI 10.1016/S1470-2045(17)30469-2; Rawla P, 2019, WORLD J ONCOL, V10, P10, DOI 10.14740/wjon1166; Reni M, 2013, EUR J CANCER, V49, P3609, DOI 10.1016/j.ejca.2013.06.041; Robson M, 2017, NEW ENGL J MED, V377, P523, DOI 10.1056/NEJMoa1706450; Tahara J, 2018, CANCER CHEMOTH PHARM, V82, P245, DOI 10.1007/s00280-018-3611-y; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Walsh CS, 2015, GYNECOL ONCOL, V137, P343, DOI 10.1016/j.ygyno.2015.02.017; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705	24	965	993	4	89	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 25	2019	381	4					317	327		10.1056/NEJMoa1903387	http://dx.doi.org/10.1056/NEJMoa1903387			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IM4VO	31157963	Green Published, Bronze, Green Accepted			2023-01-03	WOS:000477993600007
J	Vredevoogd, DW; Kuilman, T; Ligtenberg, MA; Boshuizen, J; Stecker, KE; de Bruijn, B; Krijgsman, O; Huang, XY; Kenski, JCN; Lacroix, R; Mezzadra, R; Gomez-Eerland, R; Yildiz, M; Dagidir, I; Apriamashvili, G; Zandhuis, N; van der Noort, V; Visser, NL; Blank, CU; Altelaar, M; Schumacher, TN; Peeper, DS				Vredevoogd, David W.; Kuilman, Thomas; Ligtenberg, Maarten A.; Boshuizen, Julia; Stecker, Kelly E.; de Bruijn, Beaunelle; Krijgsman, Oscar; Huang, Xinyao; Kenski, Juliana C. N.; Lacroix, Ruben; Mezzadra, Riccardo; Gomez-Eerland, Raquel; Yildiz, Mete; Dagidir, Ilknur; Apriamashvili, Georgi; Zandhuis, Nordin; van der Noort, Vincent; Visser, Nils L.; Blank, Christian U.; Altelaar, Maarten; Schumacher, Ton N.; Peeper, Daniel S.			Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold	CELL			English	Article							NECROSIS-FACTOR RECEPTOR; CD8 T-CELLS; ACQUIRED-RESISTANCE; COMBINED NIVOLUMAB; CLINICAL-RESPONSE; ESSENTIAL GENES; PD-1 BLOCKADE; CANCER; DEATH; ACTIVATION	New opportunities are needed to increase immune checkpoint blockade (ICB) benefit. Whereas the interferon (IFN)gamma pathway harbors both ICB resistance factors and therapeutic opportunities, this has not been systematically investigated for IFN gamma-independent signaling routes. A genome-wide CRISPR/Cas9 screen to sensitize IFN gamma receptor-deficient tumor cells to CD8 T cell elimination uncovered several hits mapping to the tumor necrosis factor (TNF) pathway. Clinically, we show that TNF antitumor activity is only limited in tumors at baseline and in ICB non-responders, correlating with its low abundance. Taking advantage of the genetic screen, wedemonstrate that ablation of the top hit, TRAF2, lowers the TNF cytotoxicity threshold in tumors by redirecting TNF signaling to favor RIPK1-dependent apoptosis. TRAF2 loss greatly enhanced the therapeutic potential of pharmacologic inhibition of its interaction partner cIAP, another screen hit, thereby cooperating with ICB. Our results suggest that selective reduction of the TNF cytotoxicity threshold increases the susceptibility of tumors to immunotherapy.	[Vredevoogd, David W.; Kuilman, Thomas; Ligtenberg, Maarten A.; Boshuizen, Julia; de Bruijn, Beaunelle; Krijgsman, Oscar; Huang, Xinyao; Kenski, Juliana C. N.; Lacroix, Ruben; Mezzadra, Riccardo; Gomez-Eerland, Raquel; Yildiz, Mete; Dagidir, Ilknur; Apriamashvili, Georgi; Zandhuis, Nordin; Visser, Nils L.; Schumacher, Ton N.; Peeper, Daniel S.] Netherlands Canc Inst, Oncode Inst, Div Mol Oncol & Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands; [van der Noort, Vincent] Netherlands Canc Inst, Div Stat, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands; [Blank, Christian U.] Netherlands Canc Inst, Div Med Oncol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands; [Altelaar, Maarten] Netherlands Canc Inst, Prote Facil, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands; [Stecker, Kelly E.; Altelaar, Maarten] Univ Utrecht, Ctr Biomol Res, Biomol Mass Spectrometry & Prote, Padualaan 8, NL-3584 CH Utrecht, Netherlands; [Stecker, Kelly E.; Altelaar, Maarten] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Padualaan 8, NL-3584 CH Utrecht, Netherlands; [Kuilman, Thomas] Neogene Therapeut, Matrix 7,Sci Pk 106, NL-1098 XG Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Utrecht University; Utrecht University	Peeper, DS (corresponding author), Netherlands Canc Inst, Oncode Inst, Div Mol Oncol & Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	d.peeper@nki.nl	Peeper, Daniel/AAA-2430-2020; Schumacher, Ton/Y-2432-2019	Schumacher, Ton/0000-0003-0517-8804; Vredevoogd, David/0000-0001-6718-1422; Kuilman, Thomas/0000-0001-6724-6767; Boshuizen, Julia/0000-0002-8135-0525; de Bruijn, Beaunelle/0000-0001-5488-3695; Stecker, Kelly/0000-0002-8374-689X; Mezzadra, Riccardo/0000-0002-7737-8461	Netherlands Organization for Scientific Research (NWO) through a VIDI grant [723.012.102]; Proteins@Work, a program of the National Roadmap Large-scale Research Facilities of the Netherlands [184.032.201]; Dutch Cancer Society [NKI 2014-7241]; European Research Council under the European Union [319661 COMBATCANCER]	Netherlands Organization for Scientific Research (NWO) through a VIDI grant(Netherlands Organization for Scientific Research (NWO)); Proteins@Work, a program of the National Roadmap Large-scale Research Facilities of the Netherlands; Dutch Cancer Society(KWF Kankerbestrijding); European Research Council under the European Union(European Research Council (ERC))	We thank the Peeper lab and Blank lab members for valuable discussions. We acknowledge Ji-Ying Song for assessing immunohistochemical stainings on murine tissue, Olaf van Tellingen for help with birinapant experiments, and Alwin Huitema for providing reagents. We would like to thank the NKI-AVL Flow Cytometry Facility, Animal Laboratory Facility, Sequencing Core Facility, Animal Pathology and High-Performance Computing Facility (HPC). This work was supported by the Netherlands Organization for Scientific Research (NWO) through a VIDI grant (723.012.102) and Proteins@Work, a program of the National Roadmap Large-scale Research Facilities of the Netherlands (184.032.201 to K.E.S. and M.A.),the Dutch Cancer Society (NKI 2014-7241 to D.S.P.), the European Research Council under the European Union's Seventh Framework Programme (FP7/2007-2013)/ERC synergy (grant agreement 319661 COMBATCANCER to D.S.P.).	Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76; Ahmadzadeh M, 2009, BLOOD, V114, P1537, DOI 10.1182/blood-2008-12-195792; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; BARTH RJ, 1991, J EXP MED, V173, P647, DOI 10.1084/jem.173.3.647; Benci JL, 2016, CELL, V167, P1540, DOI 10.1016/j.cell.2016.11.022; Benetatos CA, 2014, MOL CANCER THER, V13, P867, DOI 10.1158/1535-7163.MCT-13-0798; Bertrand F, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02358-7; Beug ST, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14278; Blomen VA, 2015, SCIENCE, V350, P1092, DOI 10.1126/science.aac7557; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Boshuizen J, 2018, NAT MED, V24, P203, DOI 10.1038/nm.4472; Brincks EL, 2008, J IMMUNOL, V181, P4918, DOI 10.4049/jimmunol.181.7.4918; Cao XM, 2011, FASEB J, V25, P1353, DOI 10.1096/fj.10-170480; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Colaprico A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1507; Cox J., 2018, PERSEUS BIOINFORMATI, P133; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Gao JJ, 2016, CELL, V167, P397, DOI 10.1016/j.cell.2016.08.069; Gomez-Eerland R, 2014, HUM GENE THER METHOD, V25, P277, DOI 10.1089/hgtb.2014.004; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jacquelot N, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00608-2; Jenkins MH, 2014, PIGM CELL MELANOMA R, V27, P495, DOI 10.1111/pcmr.12220; Ji RR, 2012, CANCER IMMUNOL IMMUN, V61, P1019, DOI 10.1007/s00262-011-1172-6; Kakaradov B, 2017, NAT IMMUNOL, V18, P422, DOI 10.1038/ni.3688; Kearney CJ, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aar3451; Kearney CJ, 2017, CELL DEATH DIFFER, V24, P1705, DOI 10.1038/cdd.2017.94; Kim JY, 2011, FEBS LETT, V585, P2144, DOI 10.1016/j.febslet.2011.05.034; Kurada BRVVSN, 2009, J BIOL CHEM, V284, P13533, DOI 10.1074/jbc.M808554200; Lam ET, 2018, MOL CANCER THER, V17, P215, DOI 10.1158/1535-7163.MCT-17-0330; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mahoney DJ, 2008, P NATL ACAD SCI USA, V105, P11778, DOI 10.1073/pnas.0711122105; Manguso RT, 2017, NATURE, V547, P413, DOI 10.1038/nature23270; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Pan D, 2018, SCIENCE, V359, P770, DOI 10.1126/science.aao1710; Patel SJ, 2017, NATURE, V548, P537, DOI 10.1038/nature23477; Peng DJ, 2015, NATURE, V527, P249, DOI 10.1038/nature15520; Post H, 2017, J PROTEOME RES, V16, P728, DOI 10.1021/acs.jproteome.6b00753; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Roh W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3560; Salzmann S, 2013, J BIOL CHEM, V288, P13455, DOI 10.1074/jbc.M112.435917; Sasi SP, 2012, ONCOGENE, V31, P4117, DOI 10.1038/onc.2011.567; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Shin DS, 2017, CANCER DISCOV, V7, P188, DOI 10.1158/2159-8290.CD-16-1223; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Vince JE, 2008, J CELL BIOL, V182, P171, DOI 10.1083/jcb.200801010; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang T, 2015, SCIENCE, V350, P1096, DOI 10.1126/science.aac7041; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Wu H, 2004, ADV PROTEIN CHEM, V68, P225; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Young L, 2010, NAT PROTOC, V5, P929, DOI 10.1038/nprot.2010.43; Yurkovetsky ZR, 2007, CLIN CANCER RES, V13, P2422, DOI 10.1158/1078-0432.CCR-06-1805; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958; Zhang SP, 2015, CELL MOL IMMUNOL, V12, P580, DOI 10.1038/cmi.2015.57	72	90	94	1	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 25	2019	178	3					585	+		10.1016/j.cell.2019.06.014	http://dx.doi.org/10.1016/j.cell.2019.06.014			30	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	IL0GF	31303383	Bronze			2023-01-03	WOS:000476973800009
J	Dulli, L; Field, S; Masaba, R; Ndiritu, J				Dulli, Lisa; Field, Samuel; Masaba, Rose; Ndiritu, John			Addressing broader reproductive health needs of female sex workers through integrated family planning/HIV prevention services: A non-randomized trial of a health-services intervention designed to improve uptake of family planning services in Kenya	PLOS ONE			English	Article							CONSISTENT CONDOM USE; DUAL PROTECTION; ABORTION; CONTRACEPTION; CARE; PREVALENCE; BARRIERS	Background Despite considerable efforts to prevent HIV and other sexually transmitted infections (STI) among female sex workers (FSW), other sexual and reproductive health (SRH) needs, such preventing unintended pregnancies, among FSW have received far less attention. Programs targeting FSW with comprehensive, accessible services are needed to address their broader SRH needs. This study tested the effectiveness of an intervention to increase dual contraceptive method use to prevent STIs, HIV and unintended pregnancy among FSW attending services in drop-in centers (DIC) in two cities in Kenya. The intervention included enhanced peer education, and routine screening for family planning (FP) needs plus expanded non-condom FP method availability in the DIC. Methods We conducted a two-group, pre-/posttest, quasi-experimental study with 719 FSW (360 intervention group, 359 comparison group). Participants were interviewed at baseline and 6 months later to examine changes in condom and non-condom FP method use. Results The intervention had a significant positive effect on non-condom, FP method use (OR = 1.38, 95%CI (1.04, 1.83)), but no effect on dual method use. Consistent condom use was reported to be high; however, many women also reported negotiating condom use with both paying and non-paying partners as difficult or very difficult. The strongest predictor of consistent condom use was partner type (paying versus non-paying/emotional); FSW reported both paying and non-paying partners also influence non-condom contraceptive use. Substantial numbers of FSW also reported experiencing sexual violence by both paying and non-paying partners. Conclusions Self-reported difficulties with consistent condom use and the sometimes dangerous conditions under which they work leave FSW vulnerable to unintended pregnancy STIs/HIV. Adding non-barrier FP methods to condoms is crucial to curb unintended pregnancies and their potential adverse health, social and economic consequences. Findings also highlight the need for additional strategies beyond condoms to reduce HIV and STI risk among FSW.	[Dulli, Lisa; Field, Samuel] Family Hlth Int FHI 360, Durham, NC USA; [Masaba, Rose] Elizabeth Glaser Pediat AIDS Fdn, Nairobi, Kenya; [Ndiritu, John] FHI 360, Juba, Nabari, Sudan	FHI 360	Dulli, L (corresponding author), Family Hlth Int FHI 360, Durham, NC USA.	ldulli@fhi360.org		Dulli, Lisa/0000-0002-3987-8932	United States Agency for International Development Prevention Technologies Agreement [GHO-A-00-09-00016-00]	United States Agency for International Development Prevention Technologies Agreement	This research was funded through the United States Agency for International Development Prevention Technologies Agreement, grant number GHO-A-00-09-00016-00. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aho J, 2010, AIDS BEHAV, V14, P1287, DOI 10.1007/s10461-009-9602-6; [Anonymous], 2010, SAS WIND 9 3 TS LEV; Bautista CT, 2008, CONTRACEPTION, V77, P209, DOI 10.1016/j.contraception.2007.11.013; Bradley J, 2010, SEX TRANSM INFECT, V86, pI44, DOI 10.1136/sti.2009.038398; Corneli A, 2016, CONTRACEPTION, V94, P34, DOI 10.1016/j.contraception.2016.03.004; Decker MR, 2013, INT J GYNECOL OBSTET, V120, P27, DOI 10.1016/j.ijgo.2012.07.026; Delvaux T, 2003, REPROD HEALTH MATTER, V11, P88, DOI 10.1016/S0968-8080(03)02163-3; Delvaux T, 2008, TROP MED INT HEALTH, V13, P962, DOI 10.1111/j.1365-3156.2008.02102.x; Dhana A, 2014, GLOBALIZATION HEALTH, V10, DOI 10.1186/1744-8603-10-46; Elmes J, 2014, J INFECT DIS, V210, pS569, DOI 10.1093/infdis/jiu493; Elmore-Meegan M, 2004, REPROD HEALTH MATTER, V12, P50, DOI 10.1016/S0968-8080(04)23125-1; Feldblum PJ, 2007, CONTRACEPTION, V76, P105, DOI 10.1016/j.contraception.2007.04.009; Gallo MF, 2015, SEX TRANSM DIS, V42, P160, DOI 10.1097/OLQ.0000000000000243; Kenya Ministry of Publich Health and Sanitation, 2010, NAT FAM PLANN GUID S; Kerrigan D, 2003, AIDS, V17, P415, DOI 10.1097/00002030-200302140-00016; Khan MR, 2009, CONTRACEPTION, V79, P221, DOI 10.1016/j.contraception.2008.09.011; Lance P., 2014, DO WE KNOW PROGRAM M; Mbonye M, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-741; Murray L, 2007, AIDS BEHAV, V11, P463, DOI 10.1007/s10461-006-9184-5; NASCOP KEMRI, 2015, GUIDELINES FOR CONDU; Ochako R, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-018-0601-5; Population Council, 2015, BAL COUNS STRAT PLUS; Shannon K, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2939; Sutherland EG, 2011, EUR J CONTRACEP REPR, V16, P173, DOI 10.3109/13625187.2011.564683; Tan SY, 2016, CULT HEALTH SEX, V18, P249, DOI 10.1080/13691058.2015.1077994; Thomsen SC, 2006, SEX TRANSM INFECT, V82, P397, DOI 10.1136/sti.2006.019992; Tideman RL, 2003, INT J STD AIDS, V14, P840, DOI 10.1258/095646203322556192; Todd CS, 2006, CONTRACEPTION, V74, P318, DOI 10.1016/j.contraception.2006.04.006; Van Lith LM, 2013, GLOB HEALTH-SCI PRAC, V1, P97, DOI 10.9745/GHSP-D-12-00036; Wayal S, 2011, SEX TRANSM INFECT, V87, P58, DOI 10.1136/sti.2010.043158; WHO, 2015, WHO REC ASS HIV TEST; Yam EA, 2013, INT PERSPECT SEX R H, V39, P69, DOI 10.1363/3906913; Yam EA, 2013, HEALTH CARE WOMEN IN, V34, P249, DOI 10.1080/07399332.2012.736576	33	7	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2019	14	7							e0219813	10.1371/journal.pone.0219813	http://dx.doi.org/10.1371/journal.pone.0219813			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IS7NE	31339919	Green Submitted, Green Published, gold			2023-01-03	WOS:000482335700036
J	Bender, H; Noyes, N; Annis, JL; Hitpas, A; Mollnow, L; Croak, K; Kane, S; Wagner, K; Dow, S; Zabel, M				Bender, Heather; Noyes, Noelle; Annis, Jessica L.; Hitpas, Amanda; Mollnow, Luke; Croak, Kendra; Kane, Sarah; Wagner, Kaitlyn; Dow, Steven; Zabel, Mark			PrPC knockdown by liposome-siRNA-peptide complexes (LSPCs) prolongs survival and normal behavior of prion-infected mice immunotolerant to treatment	PLOS ONE			English	Article							CREUTZFELDT-JAKOB-DISEASE; EARLY SOCIAL ENRICHMENT; PROTEIN ACCUMULATION; ANTITUMOR-ACTIVITY; INCUBATION PERIOD; SULFATED GLYCANS; RNA INTERFERENCE; COPPER-BINDING; AMPHOTERICIN-B; REPEAT REGION	Prion diseases are members of neurodegenerative protein misfolding diseases (NPMDs) that include Alzheimer's, Parkinson's and Huntington diseases, amyotrophic lateral sclerosis, tauopathies, traumatic brain injuries, and chronic traumatic encephalopathies. No known therapeutics extend survival or improve quality of life of humans afflicted with prion disease. We and others developed a new approach to NPMD therapy based on reducing the amount of the normal, host-encoded protein available as substrate for misfolding into pathologic forms, using RNA interference, a catabolic pathway that decreases levels of mRNA encoding a particular protein. We developed a therapeutic delivery system consisting of small interfering RNA (siRNA) complexed to liposomes and addressed to the central nervous system using a targeting peptide derived from rabies virus glycoprotein. These liposome-siRNA-peptide complexes (LSPCs) cross the blood-brain barrier and deliver PrP siRNA to neuronal cells to decrease expression of the normal cellular prion protein, PrPC, which acts as a substrate for prion replication. Here we show that LSPCs can extend survival and improve behavior of prion-infected mice that remain immunotolerant to treatment. LSPC treatment may be a viable therapy for prion and other NPMDs that can improve the quality of life of patients at terminal disease stages.	[Bender, Heather; Noyes, Noelle; Annis, Jessica L.; Hitpas, Amanda; Mollnow, Luke; Croak, Kendra; Kane, Sarah; Wagner, Kaitlyn; Dow, Steven; Zabel, Mark] Colorado State Univ, Coll Vet Med & Biomed Sci, Prion Res Ctr, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA; [Bender, Heather] Univ Colorado, Sch Med, Dept Pharmacol, Aurora, CO USA; [Noyes, Noelle] Univ Minnesota, Coll Vet Med, Dept Vet Populat Med, St Paul, MN 55108 USA; [Dow, Steven] Colorado State Univ, Dept Clin Sci, Ctr Immune & Regenerat Med, Ft Collins, CO 80523 USA	Colorado State University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Minnesota System; University of Minnesota Twin Cities; Colorado State University	Zabel, M (corresponding author), Colorado State Univ, Coll Vet Med & Biomed Sci, Prion Res Ctr, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.	mzabel@colostate.edu		Zabel, Mark/0000-0002-2666-9197	National Institutes of Health Institute for Neurological Disorders and Stroke [R01NS075214]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS075214] Funding Source: NIH RePORTER	National Institutes of Health Institute for Neurological Disorders and Stroke; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The National Institutes of Health Institute for Neurological Disorders and Stroke grant R01NS075214 to MZ funded this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Aguzzi A, 2008, ANNU REV PATHOL-MECH, V3, P11, DOI 10.1146/annurev.pathmechdis.3.121806.154326; Aguzzi A, 2013, NAT REV IMMUNOL, V13, P888, DOI 10.1038/nri3553; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; Belay ED, 2016, INT ENCY PUBLIC HLTH, DOI [10.1016/B978-0-12-803678-5.00469-0, DOI 10.1016/B978-0-12-803678-5.00469-0]; Bender HR, 2016, JOVE-J VIS EXP, DOI 10.3791/54106; Bian JF, 2014, P NATL ACAD SCI USA, V111, P6028, DOI 10.1073/pnas.1322377111; Bitko V, 2005, NAT MED, V11, P50, DOI 10.1038/nm1164; Boado RJ, 2010, J BIOTECHNOL, V146, P84, DOI 10.1016/j.jbiotec.2010.01.011; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; Branchi I, 2006, J NEUROSCI RES, V83, P965, DOI 10.1002/jnr.20789; Bremer J, 2010, NAT NEUROSCI, V13, P310, DOI 10.1038/nn.2483; Brini M, 2005, MOL BIOL CELL, V16, P2799, DOI 10.1091/mbc.E04-10-0915; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 2001, J NEUROCHEM, V76, P69, DOI 10.1046/j.1471-4159.2001.00009.x; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; BUELER H, 1994, MOL MED, V1, P19; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Caspi S, 1998, J BIOL CHEM, V273, P3484, DOI 10.1074/jbc.273.6.3484; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; Chen SZ, 2003, MOL CELL NEUROSCI, V22, P227, DOI 10.1016/S1044-7431(02)00014-3; Chiarini LB, 2002, EMBO J, V21, P3317, DOI 10.1093/emboj/cdf324; COCHRAN KW, 1971, J GEN VIROL, V13, P353, DOI 10.1099/0022-1317-13-2-353; Collinge J, 2009, LANCET NEUROL, V8, P334, DOI 10.1016/S1474-4422(09)70049-3; Cronier S, 2008, BIOCHEM J, V416, P297, DOI 10.1042/BJ20081235; D'Andrea I, 2007, BEHAV BRAIN RES, V183, P60, DOI 10.1016/j.bbr.2007.05.029; Daude N, 2003, J CELL SCI, V116, P2775, DOI 10.1242/jcs.00494; Dow SW, 1999, J IMMUNOL, V163, P1552; EHLERS B, 1984, J GEN VIROL, V65, P1325, DOI 10.1099/0022-1317-65-8-1325; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Enari M, 2001, P NATL ACAD SCI USA, V98, P9295, DOI 10.1073/pnas.151242598; Farquhar C, 1999, LANCET, V353, P117, DOI 10.1016/S0140-6736(98)05395-1; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Fuhrmann M, 2006, J NEUROCHEM, V98, P1876, DOI 10.1111/j.1471-4159.2006.04011.x; Gaskill BN, 2013, JOVE-J VIS EXP, DOI 10.3791/51012; Georgieva Julia V, 2014, Pharmaceutics, V6, P557, DOI 10.3390/pharmaceutics6040557; Goodyear A, 2009, INFECT IMMUN, V77, P1579, DOI 10.1128/IAI.01384-08; HAIG DA, 1968, J GEN VIROL, V3, P281, DOI 10.1099/0022-1317-3-2-281; Herms JW, 2001, NEUROBIOL DIS, V8, P324, DOI 10.1006/nbdi.2000.0369; Hill AF, 1999, J GEN VIROL, V80, P11, DOI 10.1099/0022-1317-80-1-11; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; Imran M, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-493; INGROSSO L, 1995, J VIROL, V69, P506, DOI 10.1128/JVI.69.1.506-508.1995; Jeffrey M, 2011, ACTA NEUROPATHOL, V121, P113, DOI 10.1007/s00401-010-0700-3; KIMBERLIN RH, 1983, ARCH VIROL, V78, P9, DOI 10.1007/BF01310854; KIMBERLIN RH, 1986, ANTIMICROB AGENTS CH, V30, P409, DOI 10.1128/AAC.30.3.409; Klohn PC, 2012, SCIENCE, V335, P52, DOI 10.1126/science.1215579; Kovacs GG, 2008, AM J PATHOL, V172, P555, DOI 10.2353/ajpath.2008.070442; Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; Lemke A, 2010, NANOMED-NANOTECHNOL, V6, P597, DOI 10.1016/j.nano.2009.12.004; Leske H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170503; LOCHT C, 1986, P NATL ACAD SCI USA, V83, P6372, DOI 10.1073/pnas.83.17.6372; Lotscher M, 2003, J IMMUNOL, V170, P6040, DOI 10.4049/jimmunol.170.12.6040; Mallucci GR, 2007, NEURON, V53, P325, DOI 10.1016/j.neuron.2007.01.005; MANSON J, 1992, DEVELOPMENT, V115, P117; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; Mead S, 2006, EUR J HUM GENET, V14, P273, DOI 10.1038/sj.ejhg.5201544; Miele G, 2003, GENE EXPRESSION, V11, P1, DOI 10.3727/000000003783992324; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Pang ZQ, 2008, J CONTROL RELEASE, V128, P120, DOI 10.1016/j.jconrel.2008.03.007; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460; Pardridge WM, 2002, NEURON, V36, P555, DOI 10.1016/S0896-6273(02)01054-1; Pastrana MA, 2006, BIOCHEMISTRY-US, V45, P15710, DOI 10.1021/bi0615442; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Pham NA, 2007, DIAGN PATHOL, V2, DOI 10.1186/1746-1596-2-8; POCCHIARI M, 1987, J GEN VIROL, V68, P219, DOI 10.1099/0022-1317-68-1-219; POCCHIARI M, 1989, J INFECT DIS, V160, P795, DOI 10.1093/infdis/160.5.795; Polymenidou M, 2004, P NATL ACAD SCI USA, V101, P14670, DOI 10.1073/pnas.0404772101; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; Pulford B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011085; Ragnarsson EGE, 2008, LAB INVEST, V88, P1215, DOI 10.1038/labinvest.2008.86; Regina A, 2008, BRIT J PHARMACOL, V155, P185, DOI 10.1038/bjp.2008.260; Sajnani G, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002547; Shiraishi N, 2000, BIOCHEM BIOPH RES CO, V267, P398, DOI 10.1006/bbrc.1999.1944; SHYNG SL, 1995, J BIOL CHEM, V270, P30221; Solassol J, 2004, J GEN VIROL, V85, P1791, DOI 10.1099/vir.0.19726-0; Sonati T, 2013, NATURE, V501, P102, DOI 10.1038/nature12402; Stewart LA, 2008, NEUROLOGY, V70, P1272, DOI 10.1212/01.wnl.0000308955.25760.c2; Supattapone S, 1999, P NATL ACAD SCI USA, V96, P14529, DOI 10.1073/pnas.96.25.14529; Supattapone S, 2001, BRANCHED POLYAMINES; Tagliavini F, 1997, SCIENCE, V278, P1404; TATEISHI J, 1981, J NEUROL NEUROSUR PS, V44, P723, DOI 10.1136/jnnp.44.8.723; Tobler I, 1996, NATURE, V380, P639, DOI 10.1038/380639a0; Torres-Lista V, 2013, BEHAV BRAIN RES, V247, P153, DOI 10.1016/j.bbr.2013.03.021; Vassallo N, 2003, J NEUROCHEM, V86, P538, DOI 10.1046/j.1471-4159.2003.01882.x; White AR, 2003, NATURE, V422, P80, DOI 10.1038/nature01457; White MD, 2008, P NATL ACAD SCI USA, V105, P10238, DOI 10.1073/pnas.0802759105; Wille H, 1996, J MOL BIOL, V259, P608, DOI 10.1006/jmbi.1996.0343; Winklhofer KF, 2000, BIOL CHEM, V381, P463, DOI 10.1515/BC.2000.061; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; Wroe SJ, 2006, LANCET, V368, P2061, DOI 10.1016/S0140-6736(06)69835-8; Wyckoff AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058630; Zabel MD, 2007, J IMMUNOL, V179, P6144, DOI 10.4049/jimmunol.179.9.6144; Zabel MD, 2010, STROMAL COMPLEMENT R; Zhang CC, 2006, P NATL ACAD SCI USA, V103, P2184, DOI 10.1073/pnas.0510577103; Zhang WD, 2005, NAT MED, V11, P56, DOI 10.1038/nm1174	103	8	9	4	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2019	14	7							e0219995	10.1371/journal.pone.0219995	http://dx.doi.org/10.1371/journal.pone.0219995			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4UB	31329627	gold, Green Published, Green Submitted			2023-01-03	WOS:000484974100036
J	de Almeida, MM; van Loenhout, JAF; Thapa, SS; Kumar, KC; Schluter, BS; Singh, R; Banse, X; Putineanu, D; Mahara, DP; Guha-Sapir, D				de Almeida, Maria Moitinho; van Loenhout, Joris Adriaan Frank; Thapa, Sunil Singh; Kumar, K. C.; Schluter, Benjamin-Samuel; Singh, Ravikant; Banse, Xavier; Putineanu, Dan; Mahara, Deepak Prakash; Guha-Sapir, Debarati			Clinical and demographic profile of admitted victims in a tertiary hospital after the 2015 earthquake in Nepal	PLOS ONE			English	Article							ANESTHESIA; INJURY; LENGTH; STAY	Background In 2015, an earthquake killing 9,000 and injuring 22,000 people hit Nepal. The Tribhuvan University Teaching Hospital (TUTH), a reference tertiary hospital, was operational immediately after the earthquake. We studied the profile of earthquake victims admitted in TUTH and assessed what factors could influence hospital length of stay. Methods An earthquake victim dataset was created based on patient records, with information on sex, age, date of admission and discharge, diagnosis, and surgical intervention. We performed an initial descriptive overview of the earthquake victims followed by a time-to-event analysis to compare length of hospital stay in different groups, using log rank test and cox regression to calculate Hazard Ratios. Results There were in total 501 admitted victims, with the peak of admissions occurring on the fifth day after the earthquake. About 89% had injury as main diagnosis, mostly in lower limbs, and 66% of all injuries were fractures. Nearly 69% of all patients underwent surgery. The median length of hospital stay was 10 days. Lower limb and trunk injuries had longer hospital stays than injuries in the head and neck (HR = 0.68, p = 0.009, and HR = 0.62 p = 0.005, respectively). Plastic surgeries had longer hospital stays than orthopaedic surgeries (HR = 0.57 p = 0.006). Having a crush injury and undergoing an amputation also increased time to discharge (HR = 0.57, p = 0.013, and HR = 0.65 p = 0.045 respectively). Conclusions Hospital stay was particularly long in this sample in comparison to other studies on earthquake victims, indirectly indicating the high burden TUTH had to bear to treat these patients. To strengthen resilience, tertiary hospitals should have preparedness plans to cope with a large influx of injured patients after a large-scale disaster, in particular for the initial days when there is limited external aid.	[de Almeida, Maria Moitinho; van Loenhout, Joris Adriaan Frank; Schluter, Benjamin-Samuel; Guha-Sapir, Debarati] Catholic Univ Louvain, Inst Hlth & Soc, CRED, Brussels, Belgium; [Thapa, Sunil Singh; Mahara, Deepak Prakash] Tribhuvan Univ Teaching Hosp, Inst Med, Dept Orthoped, Kathmandu, Nepal; [Kumar, K. C.] Tribhuvan Univ Teaching Hosp, Kathmandu, Nepal; [Singh, Ravikant] Doctors For You, Mumbai, Maharashtra, India; [Banse, Xavier; Putineanu, Dan] Clin Univ St Luc, Serv Orthoped & Traumatol Appareil Locomoteur, Brussels, Belgium	Universite Catholique Louvain; Tribhuvan University; Institute of Medicine (IoM) - Nepal; Tribhuvan University; Institute of Medicine (IoM) - Nepal; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	de Almeida, MM (corresponding author), Catholic Univ Louvain, Inst Hlth & Soc, CRED, Brussels, Belgium.	maria.rodrigues@uclouvain.be	Moitinho, Maria/E-8730-2017; van Loenhout, Joris/AAV-2075-2020	Moitinho, Maria/0000-0002-0668-8833; van Loenhout, Joris/0000-0001-7810-7738	University of Louvain's Special Research Funds (Fonds Speciaux de Recherche); United States Agency for International Development (USAID), Office of U.S. Disaster Assistance (OFDA) [AID-OFDA-A-15-00036]	University of Louvain's Special Research Funds (Fonds Speciaux de Recherche); United States Agency for International Development (USAID), Office of U.S. Disaster Assistance (OFDA)(United States Agency for International Development (USAID))	This work received a grant from the University of Louvain's Special Research Funds (Fonds Speciaux de Recherche) to MMA. This study is also part of the EM-DAT project, financed by the United States Agency for International Development (USAID), Office of U.S. Disaster Assistance (OFDA), agreement no AID-OFDA-A-15-00036 to DGS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asian Disaster Preparedness Center, 2014, HOPE PIV PROGR NEP F; Bewick V, 2004, CRIT CARE, V8, P389, DOI 10.1186/cc2955; Burton I, 2015, UNISDR TERMINOLOGY D; Clover AJP, 2014, WORLD J SURG, V38, P2543, DOI 10.1007/s00268-014-2607-y; Court-Brown CM, 1998, INJURY, V29, P529, DOI 10.1016/S0020-1383(98)00125-9; Della-Giustina K, 1999, EMERG MED CLIN N AM, V17, P895, DOI 10.1016/S0733-8627(05)70103-6; Doocy S, 2013, PLOS CURR, V5; FENN P, 1990, J HEALTH ECON, V9, P223, DOI 10.1016/0167-6296(90)90019-Y; Giri BR, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1008-z; Giri S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192076; Guha-Sapir D., EM DAT OFDA CRED INT; HARRIS JE, 1977, BELL J ECON, V8, P467, DOI 10.2307/3003297; He Q, 2011, J TRAUMA, V70, P1213, DOI 10.1097/TA.0b013e3182117b57; Huang KS, 2016, DISASTER MED PUBLIC, V10, P203, DOI 10.1017/dmp.2015.128; Karki KB, 2017, REV EFFECTIVENESS FO; Lachish T, 2017, J TRAVEL MED, V24; Lehavi A, 2016, EUR J ANAESTH, V33, P312, DOI 10.1097/EJA.0000000000000424; MacKenzie JS, 2017, WORLD J EMERG SURG, V12, DOI 10.1186/s13017-017-0115-8; Mirhadi S, 2013, TRAUMA, V15, P140, DOI 10.1177/1460408613486571; Missair A, 2013, ANESTH ANALG, V117, P934, DOI 10.1213/ANE.0b013e3182a0d7a7; National Planning Commission, 2015, NEP EARTHQ  2015 POS; Nikolic V, 2010, COLLEGIUM ANTROPOL, V34, P77; Noji E K, 2000, Prehosp Disaster Med, V15, P147; Parati G, 2001, HYPERTENSION, V38, P1093, DOI 10.1161/hy1101.095334; Sa C, 2007, HEALTH SERV OUTCOME, V7, P109, DOI 10.1007/s10742-007-0020-9; The World Bank, 2018, WORLD DEV IND; van Loenhout JAF, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2024-7; von Schreeb J, 2008, PREHOSPITAL DISASTER, V23, P144, DOI 10.1017/S1049023X00005768; Wang J, 2016, DISASTER MED PUBLIC, V10, P716, DOI 10.1017/dmp.2016.22; World Health Organization, EATHQ TECHN HAZ SHEE; Yang C, 2009, INJURY, V40, P488, DOI 10.1016/j.injury.2009.01.102; Yitzhak A, 2018, PREHOSP DISASTER MED, V33, P673, DOI 10.1017/S1049023X18000936; Zhao LP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061371	33	9	9	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2019	14	7							e0220016	10.1371/journal.pone.0220016	http://dx.doi.org/10.1371/journal.pone.0220016			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IS7PC	31318948	Green Published, Green Submitted, gold			2023-01-03	WOS:000482340700087
J	Costenbader, E; Zissette, S; Martinez, A; LeMasters, K; Dagadu, NA; Deepan, P; Shaw, B				Costenbader, Elizabeth; Zissette, Seth; Martinez, Andres; LeMasters, Katherine; Dagadu, Nana Apenem; Deepan, Prabu; Shaw, Bryan			Getting to intent: Are social norms influencing intentions to use modern contraception in the DRC?	PLOS ONE			English	Article							DEVELOPING-COUNTRIES; REPRODUCTIVE HEALTH; GENDER NORMS; FERTILITY; MEN	Meeting the reproductive health needs of women in post-conflict settings is a global health priority. In the Democratic Republic of the Congo, social norms perpetuate gender-based violence and contribute to low contraceptive use and high fertility. The Masculinite, Famille, et Foi (MFF) intervention is working with communities in Kinshasa to create normative environments supportive of modern contraception access and use. Our analysis uses survey data collected from 900 men and women in 17 community groups prior to the MFF intervention. We aimed to measure the extent to which social norms influence intentions to use modern contraception. Using multiple items to assess social norms and reference groups related to family planning and gender equity, we identified four distinct social norms constructs through factor analysis. Through structural equation modeling, we found that social norms influence intentions to use modern contraception overall, but that normative influence varies by gender.	[Costenbader, Elizabeth; Zissette, Seth; Martinez, Andres; LeMasters, Katherine] FHI 360, Durham, NC 27701 USA; [LeMasters, Katherine] Univ N Carolina, Gillings Sch Publ Hlth, Chapel Hill, NC 27515 USA; [Dagadu, Nana Apenem; Shaw, Bryan] Georgetown Univ, Inst Reprod Hlth, Washington, DC USA; [Deepan, Prabu] Tearfund, Teddington, Middx, England	FHI 360; University of North Carolina; University of North Carolina Chapel Hill; Georgetown University	Costenbader, E (corresponding author), FHI 360, Durham, NC 27701 USA.	bcostenbader@fhi360.org		LeMasters, Katherine/0000-0002-1754-1730; Zissette, Seth/0000-0002-6502-2986	United States Agency for International Development (USAID) [AID-OAA-A-15-0042]; USAID [AID-OAA-A-15-0042]; USAID in Washington; DRC	United States Agency for International Development (USAID)(United States Agency for International Development (USAID)); USAID(United States Agency for International Development (USAID)); USAID in Washington; DRC	This study was sponsored by the United States Agency for International Development (USAID) under Cooperative Agreement #AID-OAA-A-15-0042. Bryan Shaw was principal investigator of the award and Nana Apenem Dagadu was co-investigator. The funding agency had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study was sponsored by USAID under Cooperative Agreement #AID-OAA-A-15-0042. The content is solely the responsibility of the authors and does not necessarily represent the official views of USAID. The authors would like to acknowledge the role of the Passages Project implementing partners: Tearfund, FHI 360, IRH, Eglise de Christ au Congo, Population Services International, and Association de Sante Familiale. We also acknowledge the baseline data collection firm, Health Focus and the support of USAID in Washington and DRC. Finally, we thank the Kinshasa study participants and community members for their engagement in this survey and intervention.	Ajzen I, 1980, UNDERSTANDING ATTITU; Amin A, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-75; Bankole A, 1998, INT FAM PLAN PERSPEC, V24, P15, DOI 10.2307/2991915; Banwell S, 2014, J GENDER STUD, V23, P45, DOI 10.1080/09589236.2012.726603; Barden-O'Fallon J, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0317-2; Barot S., 2017, GUTTMACHER POLICY RE, V20, P24; Bawah AA, 1999, STUD FAMILY PLANN, V30, P54, DOI 10.1111/j.1728-4465.1999.00054.x; Casterline JB, 2000, POPUL DEV REV, V26, P691, DOI 10.1111/j.1728-4457.2000.00691.x; Cho H., 2012, HLTH COMMUNICATION M, P21; Chung A, 2016, REV COMMUN RES, V4, P1, DOI 10.12840/issn.2255-4165.2016.04.01.008; Cislaghi B, 2018, HLTH PSYCHOL; Cooper CM, 2017, MATERN CHILD HLTH J, V21, P1880, DOI 10.1007/s10995-017-2341-9; Costenbader E, 2017, STUDIES FAMILY PLANN, V48; CRAWFORD SES, 1995, AM POLIT SCI REV, V89, P582, DOI 10.2307/2082975; DOW TE, 1971, STUD FAMILY PLANN, V2, P153, DOI 10.2307/1964768; Knerr W., 2012, UNDERSTANDING ADDRES; Lasee A, 1997, INT FAM PLAN PERSPEC, V23, P15, DOI 10.2307/2950781; Levtov RG, 2014, MEN MASC, V17, P467, DOI 10.1177/1097184X14558234; Lundgren R, 2019, CULT HEALTH SEX, V21, P387, DOI 10.1080/13691058.2018.1471160; Lusey H, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5742-9; Lusey H, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0707-7; Lusey H, 2014, SAHARA J-J SOC ASP H, V11, P84, DOI 10.1080/17290376.2014.930695; Mmari K, 2009, GLOB PUBLIC HEALTH, V4, P350, DOI 10.1080/17441690701664418; Muanda M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167560; Muanda MF, 2017, CULT HEALTH SEX, V19, P1011, DOI 10.1080/13691058.2017.1286690; Murithi L, 2016, UNDERSTANDING COUPLE; Nanivazo M., 2012, SEXUAL VIOLENCE DEMO; Neighbors C, 2010, PSYCHOL ADDICT BEHAV, V24, P522, DOI 10.1037/a0019944; Nguyen GC, 2018, J ADOLESCENT HLTH S; Okigbo CC, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0056-1; Omba Kalonda J C, 2008, Med Trop (Mars), V68, P576; Pillai V, 2017, SOC WORK HEALTH CARE, V56, P28, DOI 10.1080/00981389.2016.1240134; Tearfund, 2014, TRANSF MASC GREAT LA; Tulane University School of Public Health University of Kinshasa School of Public Health and The Bill and Melinda Gates Institute for Population and Reproductive Health at the Johns Hopkins Bloomberg School of Public Health, 2017, PERF MON ACC 2020 PM; Van Lith LM, 2013, GLOB HEALTH-SCI PRAC, V1, P97, DOI 10.9745/GHSP-D-12-00036; Wegs C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153907; World Atlas, REL BEL DEM REP CONG; World Health Organization (WHO), FAM PLANN CONTR 2018	38	16	16	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2019	14	7							e0219617	10.1371/journal.pone.0219617	http://dx.doi.org/10.1371/journal.pone.0219617			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4SF	31310641	Green Published, gold, Green Submitted			2023-01-03	WOS:000484969300019
J	Panagiotou, OA; Kumar, A; Gutman, R; Keohane, LM; Rivera-Hernandez, M; Rahman, M; Gozalo, PL; Mor, V; Trivedi, AN				Panagiotou, Orestis A.; Kumar, Amit; Gutman, Roee; Keohane, Laura M.; Rivera-Hernandez, Maricruz; Rahman, Momotazur; Gozalo, Pedro L.; Mor, Vincent; Trivedi, Amal N.			Hospital Readmission Rates in Medicare Advantage and Traditional Medicare A Retrospective Population-Based Analysis	ANNALS OF INTERNAL MEDICINE			English	Article							SENSITIVITY-ANALYSIS; MEASUREMENT ERROR; PERFORMANCE; COST; CARE	Background: Medicare's Hospital Readmissions Reduction Program reports risk-standardized readmission rates for traditional Medicare but not Medicare Advantage beneficiaries. Objective: To compare readmission rates between Medicare Advantage and traditional Medicare. Design: Retrospective cohort study linking the Medicare Provider Analysis and Review (MedPAR) file with the Healthcare Effectiveness Data and Information Set (HEDIS). Setting: 4748 U.S. acute care hospitals. Patients: Patients aged 65 years or older hospitalized for acute myocardial infarction (AMI) (n = 841 613), congestive heart failure (CHF) (n = 1 458 652), or pneumonia (n = 2 020 365) between 2011 and 2014. Measurements: 30-day readmissions. Results: Among admissions for AMI, CHF, and pneumonia identified in MedPAR, 29.2%, 38.0%, and 37.2%, respectively, did not have a corresponding record in HEDIS. Of these, 18.9% for AMI, 23.7% for CHF, and 18.3% for pneumonia resulted in a readmission that was identified in MedPAR. However, among index admissions appearing in HEDIS, 14.4% for AMI, 18.4% for CHF, and 13.9% for pneumonia resulted in a readmission. Patients in Medicare Advantage had lower unadjusted readmission rates than those in traditional Medicare for all 3 conditions (16.6% vs. 17.1% for AMI, 21.4% vs. 21.7% for CHF, and 16.3% vs. 16.4% for pneumonia). However, after standardization, patients in Medicare Advantage had higher readmission rates than patients in traditional Medicare for AMI (17.2% vs. 16.9%; difference, 0.3 percentage point [95% CI, 0.1 to 0.5 percentage point]), CHF (21.7% vs. 21.4%; difference, 0.3 percentage point [CI, 0.2 to 0.5 percentage point]), and pneumonia (16.5% vs. 16.0%; difference, 0.5 percentage point [95% CI, 0.4 to 0.6 percentage point]). Rate differences increased between 2011 and 2014. Limitation: Potential unobserved differences between populations. Conclusion: The HEDIS data underreported hospital admissions for 3 common medical conditions, and readmission rates were higher among patients with underreported admissions. Medicare Advantage beneficiaries had higher risk-adjusted 30-day readmission rates than traditional Medicare beneficiaries. Primary Funding Source: National Institute on Aging.	[Panagiotou, Orestis A.; Gutman, Roee; Rivera-Hernandez, Maricruz; Rahman, Momotazur; Gozalo, Pedro L.; Mor, Vincent; Trivedi, Amal N.] Brown Univ, Sch Publ Hlth, 121 South Main St, Providence, RI 02903 USA; [Kumar, Amit] No Arizona Univ, Coll Hlth & Human Serv, 208 East Pine Knoll Dr,Bldg 66, Flagstaff, AZ 86011 USA; [Keohane, Laura M.] Vanderbilt Univ, Sch Med, 2525 West End Ave,Suite 1200, Nashville, TN 37203 USA; [Gozalo, Pedro L.; Mor, Vincent; Trivedi, Amal N.] Providence VA Med Ctr, Providence, RI USA	Brown University; Northern Arizona University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center	Panagiotou, OA (corresponding author), Brown Univ, Sch Publ Hlth, 121 South Main St, Providence, RI 02903 USA.	orestis_panagiotou@brown.edu	Panagiotou, Orestis/AAI-1268-2021; Gutman, Roee/J-2355-2014	Gutman, Roee/0000-0001-7095-3016; Kumar, Amit/0000-0002-0125-6759; Keohane, Laura/0000-0002-9400-0575	National Institute on Aging of the National Institutes of Health [R01AG047180, P01AG027296]; NATIONAL INSTITUTE ON AGING [R01AG047180, K01AG058700, P01AG027296] Funding Source: NIH RePORTER	National Institute on Aging of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	By grants R01AG047180 and P01AG027296 from the National Institute on Aging of the National Institutes of Health.	Barnett ML, 2015, JAMA INTERN MED, V175, P1803, DOI 10.1001/jamainternmed.2015.4660; Berenson RA, 2015, HEALTH AFFAIR, V34, P1289, DOI 10.1377/hlthaff.2014.1427; Brennan N, 2018, JAMA-J AM MED ASSOC, V319, P975, DOI 10.1001/jama.2017.21519; Centers for Medicare & Medicaid Services, 2012, HOSP WID ALL CAUS UN; Centers for Medicare & Medicaid Services, 2015, HOSP WID ALL CAUS UN; Cooper AL, 2013, ANN INTERN MED, V159, P456, DOI 10.7326/0003-4819-159-7-201310010-00005; Frakt AB, 2016, JAMA-J AM MED ASSOC, V315, P2387, DOI 10.1001/jama.2016.6790; Friedman B, 2012, INQUIRY-J HEALTH CAR, V49, P202, DOI 10.5034/inquiryjrnl_49.03.01; Gornick ME, 1996, NEW ENGL J MED, V335, P791, DOI 10.1056/NEJM199609123351106; Henke RM, 2018, MED CARE RES REV, V75, P434, DOI 10.1177/1077558717692103; Hines A. L., 2014, CONDITIONS LARGEST N; Huckfeldt PJ, 2017, HEALTH AFFAIR, V36, P91, DOI 10.1377/hlthaff.2016.1027; Ioannidis JPA, 2019, ANN INTERN MED, V170, P108, DOI 10.7326/M18-2159; Jacobson G, 2017, MEDICARE ADVANTAGE 2; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Keenan PS, 2008, CIRC-CARDIOVASC QUAL, V1, P29, DOI 10.1161/CIRCOUTCOMES.108.802686; Keogh RH, 2014, STAT MED, V33, P2137, DOI 10.1002/sim.6095; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Krumholz HM, 2011, CIRC-CARDIOVASC QUAL, V4, P243, DOI 10.1161/CIRCOUTCOMES.110.957498; Kumar A, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002592; Lind KD, 2019, MED CARE RES REV, V76, P229, DOI 10.1177/1077558717718026; Lindenauer PK, 2011, J HOSP MED, V6, P142, DOI 10.1002/jhm.890; Localio AR, 2017, ANN INTERN MED, V167, P285, DOI 10.7326/M17-1485; Localio AR, 2001, ANN INTERN MED, V135, P112, DOI 10.7326/0003-4819-135-2-200107170-00012; Martsolf GR, 2016, J BONE JOINT SURG AM, V98, P1385, DOI 10.2106/JBJS.15.00884; Mechanic R, 2014, NEW ENGL J MED, V370, P692, DOI 10.1056/NEJMp1315607; Medicare Payment Advisory Commission. (2017), 2020, HOSP SERV; Morgan RO, 1997, NEW ENGL J MED, V337, P169, DOI 10.1056/NEJM199707173370306; Muller CJ, 2014, INT J EPIDEMIOL, V43, P962, DOI 10.1093/ije/dyu029; Neuhaus JM, 1998, BIOMETRICS, V54, P638, DOI 10.2307/3109770; Neuman P, 2018, NEW ENGL J MED, V379, P2163, DOI 10.1056/NEJMhpr1804089; Rahman M, 2015, HEALTH AFFAIR, V34, P1675, DOI 10.1377/hlthaff.2015.0272; Research Data Assistace Center, 2016, DIFF INP MEDPAR FIL; Research Data Assistace Center, 2011, ID MED MAN CAR BEN M; Sato T, 2003, EPIDEMIOLOGY, V14, P680, DOI 10.1097/01.EDE.0000081989.82616.7d; STEFANSKI LA, 1985, ANN STAT, V13, P1335, DOI 10.1214/aos/1176349741; The Henry J. Kaiser Family Foundation, 2017, MED ADV; VanderWeele TJ, 2019, ANN INTERN MED, V170, P131, DOI 10.7326/M18-3112; VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607; Wasfy JH, 2017, ANN INTERN MED, V166, P324, DOI 10.7326/M16-0185; Williams R, 2012, STATA J, V12, P308, DOI 10.1177/1536867X1201200209; Yale New Haven Health Services Corporation/ Center for Out-comes Research & Evaluation, 2011, TEST PUBL REP 30 DAY; Yale New Haven Health Services Corporation/Center for Outcomes Research & Evaluation, 2016, 2016 PROCEDURE SPECI; Zuckerman RB, 2016, NEW ENGL J MED, V374, P1543, DOI 10.1056/NEJMsa1513024	44	26	26	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 16	2019	171	2					99	+		10.7326/M18-1795	http://dx.doi.org/10.7326/M18-1795			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	II8YC	31234205	Green Accepted			2023-01-03	WOS:000475478700016
J	Hermassi, S; Ghaith, A; Schwesig, R; Shephard, RJ; Chelly, MS				Hermassi, Souhail; Ghaith, Aloui; Schwesig, Rene; Shephard, Roy J.; Chelly, Mohamed Souhaiel			Effects of short-term resistance training and tapering on maximal strength, peak power, throwing ball velocity, and sprint performance in handball players	PLOS ONE			English	Article							VERTICAL JUMP; PROGRAM; AGILITY; VS.; ADAPTATIONS; INTENSITY; SPEED	The purpose of this study was to assess the effect of short-term resistance training and two weeks of tapering on physical performances in handball players. Following a ten-week progressive resistance training program, subjects were divided between an experimental (n = 10) and a control group (n = 10). The experimental group completed a resistance training program, followed by a two-week period when the training intensity was tapered by 60%, while the control group maintained their typical pattern of training. Muscle power (force-velocity test and squat and counter-movement jump tests), sprinting ability (10m and 30m), ability to change direction (T-half test) and throwing velocity (a 3-step throw with a run, and a jump throw) were evaluated before training, at the end of training and after tapering. The experimental group showed significantly larger interaction effects for the 10-week training period (12/15, 80%), than for the following 2 weeks of tapering (10/15, 67%), with the largest gains being in 15 m sprint times (d = 3.78) and maximal muscular strength in the snatch (d = 3.48). Although the performance of the experimental group generally continued to increase over tapering, the mean effect size for the training period was markedly higher (d = 1.92, range: 0.95-3.78) than that seen during tapering (d = 1.02, range: -0.17-2.09). Nevertheless the ten weeks of progressive resistance training followed by two weeks of tapering was an effective overall tactic to increase muscle power, sprint performance and ball throwing velocity in handball players.	[Hermassi, Souhail] Qatar Univ, Coll Arts & Sci, Sport Sci Program, Doha, Qatar; [Ghaith, Aloui; Chelly, Mohamed Souhaiel] Univ La Manouba, Higher Inst Sport & Phys Educ Ksar Said, Res Unit UR17JS01 Sport Performance Hlth & Soc, Tunis, Tunisia; [Schwesig, Rene] Martin Luther Univ Halle Wittenberg, Dept Orthopaed & Trauma Surg, Halle, Germany; [Shephard, Roy J.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Chelly, Mohamed Souhaiel] Univ La Manouba, Higher Inst Sport & Phys Educ Ksar Said, Dept Biol Sci Appl Phys Act & Sport, Tunis, Tunisia	Qatar University; Universite de la Manouba; Martin Luther University Halle Wittenberg; University of Toronto; Universite de la Manouba	Hermassi, S (corresponding author), Qatar Univ, Coll Arts & Sci, Sport Sci Program, Doha, Qatar.	shermassi@qu.edu.qa	Chelly, Souhaiel/I-6329-2019; Hermassi, Souhail/AAF-1987-2019	Chelly, Souhaiel/0000-0002-0713-1308; Hermassi, Souhail/0000-0001-9389-8937				Arabatzi F, 2012, J STRENGTH COND RES, V26, P2192, DOI 10.1519/JSC.0b013e31823b087a; Arabatzi F, 2010, J STRENGTH COND RES, V24, P2440, DOI 10.1519/JSC.0b013e3181e274ab; Ayers JL, 2016, BIOL SPORT, V33, P251, DOI 10.5604/20831862.1201814; Banister EW, 1999, EUR J APPL PHYSIOL O, V79, P182, DOI 10.1007/s004210050493; Behm DG, 2008, APPL PHYSIOL NUTR ME, V33, P547, DOI 10.1139/H08-020; Bishop D, 2005, J SCI MED SPORT, V8, P200, DOI 10.1016/S1440-2440(05)80011-8; Bortz J., 1999, STAT SOZIALWISSENSCH; BOSCO C, 1983, EUR J APPL PHYSIOL O, V50, P273, DOI 10.1007/BF00422166; Bosquet L, 2007, MED SCI SPORT EXER, V39, P1358, DOI 10.1249/mss.0b013e31806010e0; Cavaco B, 2014, J HUM KINET, V43, P105, DOI 10.2478/hukin-2014-0095; Chelly MS, 2014, J STRENGTH COND RES, V28, P1401, DOI 10.1519/JSC.0000000000000279; Chelly MS, 2010, J STRENGTH COND RES, V24, P1480, DOI 10.1519/JSC.0b013e3181d32fbf; Chelly MS, 2009, J STRENGTH COND RES, V23, P2241, DOI 10.1519/JSC.0b013e3181b86c40; COSTILL D L, 1985, Physician and Sportsmedicine, V13, P94, DOI 10.1080/00913847.1985.11708748; de Lacey J, 2014, J STRENGTH COND RES, V28, P3567, DOI 10.1519/JSC.0000000000000572; Garcia-Pinillos F, 2014, J STRENGTH COND RES, V28, P2452, DOI 10.1519/JSC.0000000000000452; GIBALA MJ, 1994, INT J SPORTS MED, V15, P492, DOI 10.1055/s-2007-1021093; Gonzalez-Badillo JJ, 2006, J STRENGTH COND RES, V20, P73; HARTMANN A, 1992, J PSYCHOSOM RES, V36, P159, DOI 10.1016/0022-3999(92)90024-V; Helland C, 2017, MED SCI SPORT EXER, V49, P736, DOI 10.1249/MSS.0000000000001145; Hermassi S, 2015, J STRENGTH COND RES, V29, P2105, DOI 10.1519/JSC.0000000000000855; Hermassi S, 2011, J STRENGTH COND RES, V25, P2424, DOI 10.1519/JSC.0b013e3182030edb; Hoffman JR, 2003, J STRENGTH COND RES, V17, P109; HOUMARD JA, 1994, SPORTS MED, V17, P224, DOI 10.2165/00007256-199417040-00003; HOUMARD JA, 1991, SPORTS MED, V12, P380, DOI 10.2165/00007256-199112060-00004; JEUKENDRUP AE, 1992, INT J SPORTS MED, V13, P534, DOI 10.1055/s-2007-1021312; JOHNS RA, 1992, MED SCI SPORT EXER, V24, P1141; Kenitzer J.R, 1998, J SWIM RES, V13, P31; Maestu J, 2003, HORM METAB RES, V35, P109, DOI 10.1055/s-2003-39053; Margaritis I, 2003, J AM COLL NUTR, V22, P147, DOI 10.1080/07315724.2003.10719288; McArdle W.D., 2007, EXERCISE PHYSL ENERG; Moore EWG, 2005, J STRENGTH COND RES, V19, P791; Mujika I, 1996, MED SCI SPORT EXER, V28, P251, DOI 10.1097/00005768-199602000-00015; Mujika I, 1998, INT J SPORTS MED, V19, P439, DOI 10.1055/s-2007-971942; Mujika I, 2003, MED SCI SPORT EXER, V35, P1182, DOI 10.1249/01.MSS.0000074448.73931.11; Mujika I, 2002, INT J SPORTS MED, V23, P582, DOI 10.1055/s-2002-35526; Mujika I, 2010, SCAND J MED SCI SPOR, V20, P24, DOI 10.1111/j.1600-0838.2010.01189.x; Mujika Inigo, 2004, Sports Med, V34, P891, DOI 10.2165/00007256-200434130-00003; Neary JP, 2003, CAN J APPL PHYSIOL, V28, P576, DOI 10.1139/h03-044; NEUFER PD, 1989, SPORTS MED, V8, P302, DOI 10.2165/00007256-198908050-00004; Polla B, 2004, THORAX, V59, P808, DOI 10.1136/thx.2003.009894; Pritchard HJ, 2018, J STRENGTH COND RES, V32, P458, DOI 10.1519/JSC.0000000000001803; Rhibi F., 2016, SCI SPORT, P93; Sassi RH, 2009, J STRENGTH COND RES, V23, P1644, DOI 10.1519/JSC.0b013e3181b425d2; Tricoli V, 2005, J STRENGTH COND RES, V19, P433; WENGER HA, 1986, SPORTS MED, V3, P346, DOI 10.2165/00007256-198603050-00004; WOMERSLEY J, 1973, HUM BIOL, V45, P281; Zaras ND, 2014, J STRENGTH COND RES, V28, P3484, DOI 10.1519/JSC.0000000000000566	48	10	10	3	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 5	2019	14	7							e0214827	10.1371/journal.pone.0214827	http://dx.doi.org/10.1371/journal.pone.0214827			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4FP	31276499	Green Submitted, gold, Green Published			2023-01-03	WOS:000484936300008
J	Chowdhury, S; Castro, S; Coker, C; Hinchliffe, TE; Arpaia, N; Danino, T				Chowdhury, Sreyan; Castro, Samuel; Coker, Courtney; Hinchliffe, Taylor E.; Arpaia, Nicholas; Danino, Tal			Programmable bacteria induce durable tumor regression and systemic antitumor immunity	NATURE MEDICINE			English	Article							CD47 BLOCKADE; CANCER; CELLS; IMMUNOTHERAPY; INNATE; TARGET	Synthetic biology is driving a new era of medicine through the genetic programming of living cells(1,2). This transformative approach allows for the creation of engineered systems that intelligently sense and respond to diverse environments, ultimately adding specificity and efficacy that extends beyond the capabilities of molecular-based therapeutics(3-6). One particular area of focus has been the engineering of bacteria as therapeutic delivery systems to selectively release therapeutic payloads in vivo(7-11). Here we engineered a non-pathogenic Escherichia coli strain to specifically lyse within the tumor microenvironment and release an encoded nanobody antagonist of CD47 (CD47nb)(12), an anti-phagocytic receptor that is commonly overexpressed in several human cancer types(13,14). We show that delivery of CD47nb by tumor-colonizing bacteria increases activation of tumor-infiltrating T cells, stimulates rapid tumor regression, prevents metastasis and leads to long-term survival in a syngeneic tumor model in mice. Moreover, we report that local injection of CD47nb-expressing bacteria stimulates systemic tumor-antigen-specific immune responses that reduce the growth of untreated tumors, providing proof-of-concept for an abscopal effect induced by an engineered bacterial immunotherapy. Thus, engineered bacteria may be used for safe and local delivery of immunotherapeutic payloads leading to systemic antitumor immunity.	[Chowdhury, Sreyan; Castro, Samuel; Coker, Courtney; Hinchliffe, Taylor E.; Danino, Tal] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA; [Chowdhury, Sreyan; Arpaia, Nicholas] Columbia Univ, Dept Microbiol & Immunol, Vagelos Coll Phys & Surg, New York, NY 10027 USA; [Arpaia, Nicholas; Danino, Tal] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10027 USA; [Danino, Tal] Columbia Univ, Data Sci Inst, New York, NY 10027 USA	Columbia University; Columbia University; Columbia University; Columbia University	Danino, T (corresponding author), Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA.; Arpaia, N (corresponding author), Columbia Univ, Dept Microbiol & Immunol, Vagelos Coll Phys & Surg, New York, NY 10027 USA.; Arpaia, N; Danino, T (corresponding author), Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10027 USA.; Danino, T (corresponding author), Columbia Univ, Data Sci Inst, New York, NY 10027 USA.	na2697@cumc.columbia.edu; td2506@columbia.edu	; Arpaia, Nicholas/R-2549-2018	Chowdhury, Sreyan/0000-0001-9995-2965; Arpaia, Nicholas/0000-0002-0657-0528	NIH Pathway to Independence Award [R00CA197649-02]; DoD Idea Development Award [LC160314]; DoD Era of Hope Scholar Award [BC160541]; NIH [R01GM069811, K22AI127847]; Searle Scholars Program [SSP-2017-2179]; Bonnie J. Addario Lung Cancer Foundation Young Investigators Team Award; Roy and Diana Vagelos Precision Medicine Pilot Grant; NATIONAL CANCER INSTITUTE [R00CA197649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K22AI127847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069811, T32GM008224] Funding Source: NIH RePORTER	NIH Pathway to Independence Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD Idea Development Award; DoD Era of Hope Scholar Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Searle Scholars Program; Bonnie J. Addario Lung Cancer Foundation Young Investigators Team Award; Roy and Diana Vagelos Precision Medicine Pilot Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the NIH Pathway to Independence Award (R00CA197649-02) (to T.D.), DoD Idea Development Award (LC160314) (to T.D.), DoD Era of Hope Scholar Award (BC160541) (to T.D.), NIH R01GM069811 (to T.D.), NIH K22AI127847 (to N.A.), Searle Scholars Program SSP-2017-2179 (to N.A.), Bonnie J. Addario Lung Cancer Foundation Young Investigators Team Award (to N.A. and T.D.) and the Roy and Diana Vagelos Precision Medicine Pilot Grant (to N.A. and T. D.). Research reported in this publication was performed in the Columbia University Department of Microbiology and Immunology Flow Cytometry Core facility. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We thank K.T. Fortson and O. Velasquez for technical assistance with flow cytometry experiments and in vivo tumor experiments, respectively; M.O. Din for input pertaining to SLC characterization experiments; and V. Yeong and members of the Obermeyer group for assistance with affinity chromatography and protein purification. We thank R.L. Vincent, T.M. Savage, K.A. Kaiser and L.F. Loffredo for critical review of the manuscript.	Advani R, 2018, NEW ENGL J MED, V379, P1711, DOI 10.1056/NEJMoa1807315; Armstrong AC, 2002, J IMMUNOL, V168, P3983, DOI 10.4049/jimmunol.168.8.3983; Basu S, 2005, NATURE, V434, P1130, DOI 10.1038/nature03461; BERENDT MJ, 1978, J EXP MED, V148, P1550, DOI 10.1084/jem.148.6.1550; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Chen YY, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002944; Chien Tiffany, 2017, Curr Opin Syst Biol, V5, P1, DOI 10.1016/j.coisb.2017.05.009; Coley W B, 1891, Ann Surg, V14, P199, DOI 10.1097/00000658-189112000-00015; Danino T, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3519; Danino T, 2010, NATURE, V463, P326, DOI 10.1038/nature08753; Derman AI, 2012, J BACTERIOL, V194, P2715, DOI 10.1128/JB.06550-11; Din MO, 2016, NATURE, V536, P81, DOI 10.1038/nature18930; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Fischbach MA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005568; Forbes NS, 2010, NAT REV CANCER, V10, P784, DOI 10.1038/nrc2934; Friedland AE, 2009, SCIENCE, V324, P1199, DOI 10.1126/science.1172005; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; GERDES K, 1986, EMBO J, V5, P2023, DOI 10.1002/j.1460-2075.1986.tb04459.x; Haldimann A, 2001, J BACTERIOL, V183, P6384, DOI 10.1128/JB.183.21.6384-6393.2001; Helmink BA, 2019, NAT MED, V25, P377, DOI 10.1038/s41591-019-0377-7; Huang YT, 2017, J THORAC DIS, V9, pE168, DOI 10.21037/jtd.2017.02.30; Ingram JR, 2017, P NATL ACAD SCI USA, V114, P10184, DOI 10.1073/pnas.1710776114; Jaiswal S, 2009, CELL, V138, P271, DOI 10.1016/j.cell.2009.05.046; Jiang SN, 2010, MOL THER, V18, P635, DOI 10.1038/mt.2009.295; Kauder SE, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201832; Kong XN, 2007, J EXP MED, V204, P2719, DOI 10.1084/jem.20062611; Lim WA, 2017, CELL, V168, P724, DOI 10.1016/j.cell.2017.01.016; Liu XJ, 2018, CELL REP, V24, P2101, DOI 10.1016/j.celrep.2018.07.062; Liu XJ, 2015, NAT MED, V21, P1209, DOI 10.1038/nm.3931; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; MALMGREN RA, 1955, CANCER RES, V15, P473; Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673; Pedrolli DB, 2019, TRENDS BIOTECHNOL, V37, P100, DOI 10.1016/j.tibtech.2018.09.005; Ruder WC, 2011, SCIENCE, V333, P1248, DOI 10.1126/science.1206843; Skinner SO, 2013, NAT PROTOC, V8, P1100, DOI 10.1038/nprot.2013.066; Sockolosky JT, 2016, P NATL ACAD SCI USA, V113, pE2646, DOI 10.1073/pnas.1604268113; Tsung K, 2006, SURG ONCOL, V15, P25, DOI 10.1016/j.suronc.2006.05.002; Veillette A, 2018, TRENDS IMMUNOL, V39, P173, DOI 10.1016/j.it.2017.12.005; Weber W, 2012, NAT REV GENET, V13, P21, DOI 10.1038/nrg3094; Willingham SB, 2012, P NATL ACAD SCI USA, V109, P6662, DOI 10.1073/pnas.1121623109; Wu MR, 2019, NAT REV CANCER, V19, P187, DOI 10.1038/s41568-019-0121-0; Zheng JH, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aak9537; Zhou SB, 2018, NAT REV CANCER, V18, P727, DOI 10.1038/s41568-018-0070-z	43	196	201	43	310	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2019	25	7					1057	+		10.1038/s41591-019-0498-z	http://dx.doi.org/10.1038/s41591-019-0498-z			17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	IH3ZC	31270504	Green Accepted, Green Submitted			2023-01-03	WOS:000474430400018
J	Driehuis, F; Hoogeboom, TJ; Nijhuis-van der Sandenid, MWG; de Bie, RA; Staal, JB				Driehuis, Femke; Hoogeboom, Thomas J.; Nijhuis-van der Sandenid, Maria W. G.; de Bie, Rob A.; Staal, J. Bart			Spinal manual therapy in infants, children and adolescents: A systematic review and meta-analysis on treatment indication, technique and outcomes	PLOS ONE			English	Review							LOW-BACK-PAIN; CHIROPRACTIC CARE; MANIPULATIVE THERAPY; MUSCULOSKELETAL CONDITIONS; ALTERNATIVE MEDICINE; ADVERSE EVENTS; QUALITY; GRADE; MANAGEMENT; EFFICACY	Background Studies on effectiveness and safety of specific spinal manual therapy (SMT) techniques in children, which distinguish between age groups, are lacking. Objective To conduct a systematic review of the evidence for effectiveness and harms of specific SMT techniques for infants, children and adolescents. Methods PubMed, Index to Chiropractic Literature, Embase, CINAHL and Cochrane Library were searched up to December 2017. Controlled studies, describing primary SMT treatment in infants (< 1 year) and children/ adolescents (1-18 years), were included to determine effectiveness. Controlled and observational studies and case reports were included to examine harms. One author screened titles and abstracts and two authors independently screened the full text of potentially eligible studies for inclusion. Two authors assessed risk of bias of included studies and quality of the body of evidence using the GRADE methodology. Data were described according to PRISMA guidelines and CONSORT and TIDieR checklists. If appropriate, random-effects meta-analysis was performed. Results Of the 1,236 identified studies, 26 studies were eligible. Infants and children/ adolescents were treated for various (non-) musculoskeletal indications, hypothesized to be related to spinal joint dysfunction. Studies examining the same population, indication and treatment comparison were scarce. Due to very low quality evidence, it is uncertain whether gentle, low-velocity mobilizations reduce complaints in infants with colic or torticollis, and whether high-velocity, low-amplitude manipulations reduce complaints in children/ adolescents with autism, asthma, nocturnal enuresis, headache or idiopathic scoliosis. Five case reports described severe harms after HVLA manipulations in four infants and one child. Mild, transient harms were reported after gentle spinal mobilizations in infants and children, and could be interpreted as side effect of treatment. Conclusions Based on GRADE methodology, we found the evidence was of very low quality; this prevented us from drawing conclusions about the effectiveness of specific SMT techniques in infants, children and adolescents. Outcomes in the included studies were mostly parent or patient-reported; studies did not report on intermediate outcomes to assess the effectiveness of SMT techniques in relation to the hypothesized spinal dysfunction. Severe harms were relatively scarce, poorly described and likely to be associated with underlying missed pathology. Gentle, low-velocity spinal mobilizations seem to be a safe treatment technique in infants, children and adolescents. We encourage future research to describe effectiveness and safety of specific SMT techniques instead of SMT as a general treatment approach.	[Driehuis, Femke; Hoogeboom, Thomas J.; Nijhuis-van der Sandenid, Maria W. G.; Staal, J. Bart] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, IQ Healthcare, Nijmegen, Netherlands; [de Bie, Rob A.] Maastricht Univ, Dept Epidemiol, Caphri Res Sch, Maastricht, Netherlands; [Staal, J. Bart] HAN Univ Appl Sci, Res Grp Musculoskeletal Rehabil, Nijmegen, Netherlands	Radboud University Nijmegen; Maastricht University	Driehuis, F (corresponding author), Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, IQ Healthcare, Nijmegen, Netherlands.	Femke.Driehuis@radboudumc.nl	der Sanden, Maria WG Nijhuis-van/B-3463-2012	der Sanden, Maria WG Nijhuis-van/0000-0003-2637-6877; Driehuis, Femke/0000-0001-6774-5646	Dutch Association for Manual Therapy (NVMT)	Dutch Association for Manual Therapy (NVMT)	This study was supported by the Dutch Association for Manual Therapy (NVMT). Funders had no role in study design, interpretation of data, writing process of the manuscript or decisions according to publication. No further funding agency in the public, commercial or not-for-profit sectors was involved.	Alcantara J., 2008, CLIN CHIROPR, V11, P193; Alcantara J, 2010, J ALTERN COMPLEM MED, V16, P621, DOI 10.1089/acm.2009.0369; Alcantara J, 2009, EXPLORE-NY, V5, P290, DOI 10.1016/j.explore.2009.06.002; Allen-Unhammer A, 2016, CHIROPR MAN THER, V24, DOI 10.1186/s12998-016-0107-x; [Anonymous], 2002, Paediatr Child Health, V7, P85; Balon J, 1998, NEW ENGL J MED, V339, P1013, DOI 10.1056/NEJM199810083391501; Bialosky JE, 2009, MANUAL THER, V14, P531, DOI 10.1016/j.math.2008.09.001; Borusiak P, 2010, HEADACHE, V50, P224, DOI 10.1111/j.1526-4610.2009.01550.x; Botelho MB, 2012, J MANIP PHYSIOL THER, V35, P38, DOI 10.1016/j.jmpt.2011.09.005; Bronfort G, 2001, J MANIP PHYSIOL THER, V24, P457, DOI 10.1016/S0161-4754(01)99423-0; Bronfort G, 2001, J MANIP PHYSIOL THER, V24, P369, DOI 10.1067/mmt.2001.116417; Bronfort G, 2012, ANN INTERN MED, V156, P1, DOI 10.7326/0003-4819-156-1-201201030-00002; Bronfort Gert, 2010, Chiropr Osteopat, V18, P3, DOI 10.1186/1746-1340-18-3; Browning M, 2008, CLIN CHIROPR, V11, P122, DOI DOI 10.1016/j.clch.2008.10.003; Chou R, 2010, J CLIN EPIDEMIOL, V63, P502, DOI 10.1016/j.jclinepi.2008.06.007; Chu E, 2005, WHO GUIDELINES BASIC; Cochrane Effective Practice and Organisation of Care (EPOC), 2017, TAK ACC ADV EFF EPOC; Delamothe T, 2004, BMJ-BRIT MED J, V328, P1, DOI 10.1136/bmj.328.7430.1; Deputy SR, 2014, SEMIN PEDIATR NEUROL, V21, P124, DOI 10.1016/j.spen.2014.04.016; Dobson D, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004796.pub2; Ernst E, 2009, INT J CLIN PRACT, V63, P1351, DOI 10.1111/j.1742-1241.2009.02133.x; Evans DW, 2010, MANUAL THER, V15, P286, DOI 10.1016/j.math.2009.12.009; Ferrance Randy J, 2010, Chiropr Osteopat, V18, P14, DOI 10.1186/1746-1340-18-14; French Simon D, 2010, Chiropr Osteopat, V18, P17, DOI 10.1186/1746-1340-18-17; Gleberzon Brian J, 2012, J Can Chiropr Assoc, V56, P128; Gotlib Allan, 2008, Chiropr Osteopat, V16, P11, DOI 10.1186/1746-1340-16-11; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Haugen EB, 2011, ACTA PAEDIATR, V100, P687, DOI 10.1111/j.1651-2227.2011.02145.x; Hayden JA, 2003, J MANIP PHYSIOL THER, V26, P1, DOI 10.1067/mmt.2003.11; Hestbaek Lise, 2010, Chiropr Osteopat, V18, P15, DOI 10.1186/1746-1340-18-15; Hestbaek L, 2009, J MANIP PHYSIOL THER, V32, P607, DOI 10.1016/j.jmpt.2009.08.024; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Holla Micha, 2009, Ned Tijdschr Geneeskd, V153, P828; Huijbregts PA, 2006, J MAN MANIP THER, V14, P7, DOI 10.1179/106698106790820881; Humphreys B Kim, 2010, Chiropr Osteopat, V18, P12, DOI 10.1186/1746-1340-18-12; Jacobi G, 2001, KLIN PADIATR, V213, P76, DOI 10.1055/s-2001-12881; Kemper KJ, 2008, PEDIATRICS, V122, P1374, DOI 10.1542/peds.2008-2173; Khorshid KA, 2006, J VERTEBRAL SUBLUXAT; Koch LE, 2002, FORENSIC SCI INT, V128, P168, DOI 10.1016/S0379-0738(02)00196-2; Koch LE, 1998, FORENSIC SCI INT, V97, P1, DOI 10.1016/S0379-0738(98)00124-8; Koch LE, 1998, MAN MED, V36, P21; LEBOEUF C, 1991, J MANIP PHYSIOL THER, V14, P110; Leboeuf-Yde Charlotte, 2010, Chiropr Osteopat, V18, P11, DOI 10.1186/1746-1340-18-11; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Marchand A., 2012, J MANIPULATIVE PHYSL; Marchand AM, 2012, J MANIP PHYSIOL THER, V35, P372, DOI 10.1016/j.jmpt.2012.04.008; Meeker WC, 2002, ANN INTERN MED, V136, P216, DOI 10.7326/0003-4819-136-3-200202050-00010; Miller J., 2010, CHIROPRACTIC OSTEOPA, V18; Miller JE, 2008, J MANIP PHYSIOL THER, V31, P419, DOI 10.1016/j.jmpt.2008.06.002; Miller JE, 2012, J MANIP PHYSIOL THER, V35, P600, DOI 10.1016/j.jmpt.2012.09.010; Miller JE, 2009, J MANIP PHYSIOL THER, V32, P670, DOI 10.1016/j.jmpt.2009.08.023; Ndetan H, 2012, J ALTERN COMPLEM MED, V18, P347, DOI 10.1089/acm.2011.0268; Nicolas-Schmid P, 2016, J CLIN CHIROPRACTIC, V15, P1236; Olafsdottir E, 2001, ARCH DIS CHILD, V84, P138, DOI 10.1136/adc.84.2.138; Owens DK, 2008, GRADING STRENGTH BOD; Paige NM, 2017, JAMA-J AM MED ASSOC, V317, P1451, DOI 10.1001/jama.2017.3086; Peterson DH, 2002, CHIROPRACTIC TECHNIQ; REED WR, 1994, J MANIP PHYSIOL THER, V17, P596; Rubinstein S, 2000, J MANIP PHYSIOL THER, V23, P557, DOI 10.1067/mmt.2000.109675; Rubinstein SM, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008112.pub2; Rubinstein SM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008880.pub2; Ryan R, 2016, GRADE QUALITY EVIDEN; Ryan R, 2016, DESCRIBING RESULTS; Schulz KF, 2010, J PHARMACOL PHARMACO, V1, P100, DOI [10.1016/j.jclinepi.2010.02.005, 10.4103/0976-500X.72352, 10.1016/j.ijsu.2011.09.004, 10.1186/1741-7015-8-18]; Seffinger MA, 2003, FDN OSTEOPATHIC MED, V2, P3; SHAFRIR Y, 1992, J PEDIATR-US, V120, P266, DOI 10.1016/S0022-3476(05)80440-8; Smith C, 2006, J PAEDIATR CHILD H, V42, P538, DOI 10.1111/j.1440-1754.2006.00918.x; Swierkosz S, 2015, J BACK MUSCULOSKELET, V28, P25, DOI 10.3233/BMR-140484; The Joanna Briggs Institute, 2016, JOANN BRIGGS I REV M; Todd AJ, 2016, J MANIP PHYSIOL THER, V39, P401, DOI 10.1016/j.jmpt.2016.05.006; Viswanathan M, 2012, J CLIN EPIDEMIOL, V65, P163, DOI 10.1016/j.jclinepi.2011.05.008; Vohra S, 2007, PEDIATRICS, V119, pE275, DOI 10.1542/peds.2006-1392; Wiberg JMM, 1999, J MANIP PHYSIOL THER, V22, P517, DOI 10.1016/S0161-4754(99)70003-5; Wilson PM, 2012, PEDIATRICS, V130, pE1359, DOI 10.1542/peds.2012-0372	76	8	8	2	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2019	14	6							e0218940	10.1371/journal.pone.0218940	http://dx.doi.org/10.1371/journal.pone.0218940			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW3BT	31237917	Green Published, gold, Green Submitted			2023-01-03	WOS:000484856000053
J	Ruospo, M; Palmer, SC; Graziano, G; Natale, P; Saglimbene, V; Petruzzi, M; De Benedittis, M; Craig, JC; Johnson, DW; Ford, P; Tonelli, M; Celia, E; Gelfman, R; Leal, MR; Torok, M; Stroumza, P; Frantzen, L; Bednarek-Skublewska, A; Dulawa, J; del Castillo, D; Schon, S; Bernat, AG; Hegbrant, J; Wollheim, C; Gargano, L; Strippoli, GFM; Rana, S; Serrano, M; Claros, S; Arias, M; Petracci, L; Arana, M; De Rosa, P; Gutierrez, A; Simon, M; Vergara, V; Tosi, M; Cernadas, M; Vilamajo, I; Gravac, D; Paulon, M; Penayo, L; Carrizo, G; Ghiani, M; Perez, G; Da Cruz, O; Galarce, D; Gravielle, M; Vescovo, E; Paparone, R; Mira, CM; Mojico, E; Hermida, O; Florio, D; Yucoswky, M; Labonia, W; Rubio, D; Di Napoli, G; Fernandez, A; Altman, H; Rodriguez, J; Serrano, S; Valle, G; Lobos, M; Acosta, V; Corpacci, G; Jofre, M; Gianoni, L; Chiesura, G; Capdevila, M; Montenegro, J; Bequi, J; Dayer, J; Gomez, A; Calderon, C; Abrego, E; Cechin, C; Garcia, J; Corral, J; Natiello, M; Coronel, A; Muniz, M; Muniz, V; Bonelli, A; Sanchez, F; Maestre, S; Olivera, S; Camargo, M; Avalos, V; Geandet, E; Canteli, M; Escobar, A; Sena, E; Tirado, S; Penalba, A; Neme, G; Cisneros, M; Oliszewski, R; Nascar, V; Daud, M; Mansilla, S; Alvarez, AP; Gamin, L; Arijon, M; Coombes, M; Zapata, M; Boriceanu, C; Frantzen-Trendel, S; Albert, K; Csaszar, I; Kiss, E; Kosa, D; Orosz, A; Redl, J; Kovacs, L; Varga, E; Szabo, M; Magyar, K; Kriza, G; Zajko, E; Bereczki, A; Csikos, J; Kuti, A; Mike, A; Steiner, K; Nemeth, E; Tolnai, K; Toth, A; Vinczene, J; Szummer, S; Tanyi, E; Toth, R; Szilvia, M; Dambrosio, N; Paparella, G; Sambati, M; Donatelli, C; Pedone, F; Cagnazzo, VA; Antinoro, R; Torsello, F; Saturno, C; Giannoccaro, G; Maldera, S; Boccia, E; Mantuano, M; Mammarella, RD; Meconizzi, M; Steri, PF; Riccardi, C; Flammini, A; Moscardelli, L; Murgo, M; San Filippo, N; Pagano, S; Marino, G; Montalto, G; Cantarella, S; Salamone, B; Randazzo, G; Rallo, D; Maniscalco, A; Fici, M; Lupo, A; Pellegrino, P; Fichera, R; D'Angelo, A; Falsitta, N; Bochenska-Nowacka, E; Jaroszynski, A; Drabik, J; Birecka, M; Daniewska, D; Drobisz, M; Doskocz, K; Wyrwicz, G; Inchaustegui, L; Outerelo, C; Mendes, DS; Mendes, A; Lopes, J; Barbas, J; Madeira, C; Fortes, A; Vizinho, R; Cortesao, A; Almeida, E; Bernat, A; De la Torre, B; Lopez, A; Martin, J; Cuesta, G; Rodriguez, RM; Ros, F; Garcia, M; Orero, E; Ros, E				Ruospo, Marinella; Palmer, Suetonia C.; Graziano, Giusi; Natale, Patrizia; Saglimbene, Valeria; Petruzzi, Massimo; De Benedittis, Michele; Craig, Jonathan C.; Johnson, David W.; Ford, Pauline; Tonelli, Marcello; Celia, Eduardo; Gelfman, Ruben; Leal, Miguel R.; Torok, Marietta; Stroumza, Paul; Frantzen, Luc; Bednarek-Skublewska, Anna; Dulawa, Jan; del Castillo, Domingo; Schon, Staffan; Bernat, Amparo G.; Hegbrant, Jorgen; Wollheim, Charlotta; Gargano, Letizia; Strippoli, Giovanni F. M.; Rana, S.; Serrano, M.; Claros, S.; Arias, M.; Petracci, L.; Arana, M.; De Rosa, P.; Gutierrez, A.; Simon, M.; Vergara, V.; Tosi, M.; Cernadas, M.; Vilamajo, I.; Gravac, D.; Paulon, M.; Penayo, L.; Carrizo, G.; Ghiani, M.; Perez, G.; Da Cruz, O.; Galarce, D.; Gravielle, M.; Vescovo, E.; Paparone, R.; Mira, C. Mato; Mojico, E.; Hermida, O.; Florio, D.; Yucoswky, M.; Labonia, W.; Rubio, D.; Di Napoli, G.; Fernandez, A.; Altman, H.; Rodriguez, J.; Serrano, S.; Valle, G.; Lobos, M.; Acosta, V.; Corpacci, G.; Jofre, M.; Gianoni, L.; Chiesura, G.; Capdevila, M.; Montenegro, J.; Bequi, J.; Dayer, J.; Gomez, A.; Calderon, C.; Abrego, E.; Cechin, C.; Garcia, J.; Corral, J.; Natiello, M.; Coronel, A.; Muniz, M.; Muniz, V.; Bonelli, A.; Sanchez, F.; Maestre, S.; Olivera, S.; Camargo, M.; Avalos, V.; Geandet, E.; Canteli, M.; Escobar, A.; Sena, E.; Tirado, S.; Penalba, A.; Neme, G.; Cisneros, M.; Oliszewski, R.; Nascar, V.; Daud, M.; Mansilla, S.; Alvarez, A. Paredes; Gamin, L.; Arijon, M.; Coombes, M.; Zapata, M.; Boriceanu, C.; Frantzen-Trendel, S.; Albert, K.; Csaszar, I.; Kiss, E.; Kosa, D.; Orosz, A.; Redl, J.; Kovacs, L.; Varga, E.; Szabo, M.; Magyar, K.; Kriza, G.; Zajko, E.; Bereczki, A.; Csikos, J.; Kuti, A.; Mike, A.; Steiner, K.; Nemeth, E.; Tolnai, K.; Toth, A.; Vinczene, J.; Szummer, Sz.; Tanyi, E.; Toth, R.; Szilvia, M.; Dambrosio, N.; Paparella, G.; Sambati, M.; Donatelli, C.; Pedone, F.; Cagnazzo, V. A.; Antinoro, R.; Torsello, F.; Saturno, C.; Giannoccaro, G.; Maldera, S.; Boccia, E.; Mantuano, M.; Mammarella, R. Di Toro; Meconizzi, M.; Steri, P. F.; Riccardi, C.; Flammini, A.; Moscardelli, L.; Murgo, M.; San Filippo, N.; Pagano, S.; Marino, G.; Montalto, G.; Cantarella, S.; Salamone, B.; Randazzo, G.; Rallo, D.; Maniscalco, A.; Fici, M.; Lupo, A.; Pellegrino, P.; Fichera, R.; D'Angelo, A.; Falsitta, N.; Bochenska-Nowacka, E.; Jaroszynski, A.; Drabik, J.; Birecka, M.; Daniewska, D.; Drobisz, M.; Doskocz, K.; Wyrwicz, G.; Inchaustegui, L.; Outerelo, C.; Sousa Mendes, D.; Mendes, A.; Lopes, J.; Barbas, J.; Madeira, C.; Fortes, A.; Vizinho, R.; Cortesao, A.; Almeida, E.; Bernat, A.; De la Torre, B.; Lopez, A.; Martin, J.; Cuesta, G.; Rodriguez, R. M.; Ros, F.; Garcia, M.; Orero, E.; Ros, E.		ORAL-D Investigators	Oral mucosal lesions and risk of all-cause and cardiovascular mortality in people treated with long-term haemodialysis: The ORAL-D multinational cohort study	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; HEALTH; PREVALENCE; ADULTS	Background Chronic kidney disease is a risk factor for oral diseases, which may be associated with premature death. We evaluated the risk of all-cause and cardiovascular mortality associated with oral mucosal lesions in adults with kidney failure treated with long-term haemodialysis. Methods Oral mucosal lesions (herpes, ulceration, neoformation, white lesion, red lesion, oral candidiasis, geographical tongue, petechial lesions, and fissured tongue) were evaluated within the Oral Diseases in Haemodialysis (ORAL-D) study, a multinational cohort study of 4726 haemodialysis adults. We conducted cox regression analyses adjusted for demographic and clinical variables to evaluate the association with all-cause and cardiovascular mortality. Results Overall, 4205 adults (mean age 61.6 +/- 15.6 years) underwent oral mucosal examination with 40% affected by at least one lesion. The prevalence of oral lesions was (in order of frequency): oral herpes 0.5%, mucosal ulceration 1.7%, neoformation 2.0%, white lesion 3.5%, red lesion 4.0%, oral candidiasis 4.6%, geographical tongue 4.9%, petechial lesions 7.9%, and fissured tongue 10.7%. During median follow-up of 3.5 years, 2114 patients died (1013 due to cardiovascular disease). No association was observed between any individual oral lesion and all-cause or cardiovascular mortality when adjusted for comorbidities, except for oral candidiasis, which was associated with all-cause mortality (adjusted hazard ratio 1.37, 95% CI 1.00 to 1.86) and cardiovascular mortality (adjusted hazard ratio 1.64, 95% CI 1.09 to 2.46). Conclusion Oral mucosal lesions are prevalent in haemodialysis patients. Oral candidiasis appears to be a risk factor for death due to cardiovascular diseases.	[Ruospo, Marinella; Graziano, Giusi; Natale, Patrizia; Saglimbene, Valeria; Celia, Eduardo; Gelfman, Ruben; Leal, Miguel R.; Torok, Marietta; Stroumza, Paul; Frantzen, Luc; Bednarek-Skublewska, Anna; Dulawa, Jan; del Castillo, Domingo; Schon, Staffan; Bernat, Amparo G.; Hegbrant, Jorgen; Wollheim, Charlotta; Gargano, Letizia; Strippoli, Giovanni F. M.] Diaverum Med Sci Off, Lund, Sweden; [Palmer, Suetonia C.] Univ Otago, Christchurch, New Zealand; [Natale, Patrizia; Petruzzi, Massimo; De Benedittis, Michele; Strippoli, Giovanni F. M.] Univ Bari, Bari, Italy; [Saglimbene, Valeria; Strippoli, Giovanni F. M.] Univ Sydney, Sydney, NSW, Australia; [Craig, Jonathan C.] Flinders Univ S Australia, Adelaide, SA, Australia; [Johnson, David W.; Ford, Pauline] Univ Queensland, Brisbane, Qld, Australia; [Johnson, David W.] Translat Res Inst, Brisbane, Qld, Australia; [Tonelli, Marcello] Univ Calgary, Calgary, AB, Canada; [Bednarek-Skublewska, Anna] Med Univ Lublin, Lublin, Poland; [Dulawa, Jan] Med Univ Silesia, Silesia, Poland	Diaverum; University of Otago; Universita degli Studi di Bari Aldo Moro; University of Sydney; Flinders University South Australia; University of Queensland; University of Calgary; Medical University of Lublin; Medical University Silesia	Strippoli, GFM (corresponding author), Diaverum Med Sci Off, Lund, Sweden.; Strippoli, GFM (corresponding author), Univ Bari, Bari, Italy.; Strippoli, GFM (corresponding author), Univ Sydney, Sydney, NSW, Australia.	gfmstrippoli@gmail.com	Muniz, Valdirene/AAW-3833-2021; Ford, Pauline/ABI-1007-2020; Petruzzi, Massimo/O-6040-2016; Craig, Jonathan/E-2813-2013; Petruzzi, Massimo/AAD-8820-2021; Szkutnik, Jacek/U-4355-2018; Tonelli, Marcello/B-3028-2009; Johnson, David/F-2897-2011	Ford, Pauline/0000-0002-0901-2863; Craig, Jonathan/0000-0002-2548-4035; Petruzzi, Massimo/0000-0002-9030-3739; Szkutnik, Jacek/0000-0002-7842-1775; Tonelli, Marcello/0000-0002-0846-3187; Johnson, David/0000-0001-5491-3460; Bednarek-Skublewska, Anna/0000-0002-1973-2135				[Anonymous], 2007, BMJ-BRIT MED J, V335, DOI [10.1136/bmj.39386.490150.94, DOI 10.1136/BMJ.39386.490150.94]; Chi AC, 2010, AM FAM PHYSICIAN, V82, P1381; Do L, 2014, AUST DENT J, V59, P114, DOI 10.1111/adj.12143; Gautam NR, 2014, J INT SOC PREV COMMU, V4, P164, DOI 10.4103/2231-0762.142006; Jansson L, 2002, J CLIN PERIODONTOL, V29, P1029, DOI 10.1034/j.1600-051X.2002.291108.x; Kato S, 2008, CLIN J AM SOC NEPHRO, V3, P1526, DOI 10.2215/CJN.00950208; Kramer I R, 1980, Community Dent Oral Epidemiol, V8, P1; Kroidl A, 2005, EUR J MED RES, V10, P448; Liu LJ, 2012, BMC ORAL HEALTH, V12, P1472; Oyetola EO, 2015, BMC ORAL HEALTH, V15, DOI 10.1186/s12903-015-0004-z; Palmer SC, 2016, NEPHROL DIAL TRANSPL, V31, P1647, DOI 10.1093/ndt/gfv413; Palmer SC, 2015, AM J KIDNEY DIS, V66, P666, DOI 10.1053/j.ajkd.2015.04.051; Ruospo M, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0574-x; Ruospo M, 2014, NEPHROL DIAL TRANSPL, V29, P364, DOI 10.1093/ndt/gft401; Shulman JD, 2004, J AM DENT ASSOC, V135, P1279, DOI 10.14219/jada.archive.2004.0403; Strippoli GFM, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-90	16	0	0	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 21	2019	14	6							e0218684	10.1371/journal.pone.0218684	http://dx.doi.org/10.1371/journal.pone.0218684			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW3PT	31226151	Green Published, Green Submitted, gold			2023-01-03	WOS:000484894700031
J	Yan, C; Brunson, DC; Tang, Q; Do, D; Iftimia, NA; Moore, JC; Hayes, MN; Welker, AM; Garcia, EG; Dubash, TD; Hong, X; Drapkin, BJ; Myers, DT; Phat, S; Volorio, A; Marvin, DL; Ligorio, M; Dershowitz, L; McCarthy, KM; Karabacak, MN; Fletcher, JA; Sgroi, DC; Iafrate, JA; Maheswaran, S; Dyson, NJ; Haber, DA; Rawls, JF; Langenau, DM				Yan, Chuan; Brunson, Dalton C.; Tang, Qin; Do, Daniel; Iftimia, Nicolae A.; Moore, John C.; Hayes, Madeline N.; Welker, Alessandra M.; Garcia, Elaine G.; Dubash, Taronish D.; Hong, Xin; Drapkin, Benjamin J.; Myers, David T.; Phat, Sarah; Volorio, Angela; Marvin, Dieuwke L.; Ligorio, Matteo; Dershowitz, Lyle; McCarthy, Karin M.; Karabacak, Murat N.; Fletcher, Jonathan A.; Sgroi, Dennis C.; Iafrate, John A.; Maheswaran, Shyamala; Dyson, Nick J.; Haber, Daniel A.; Rawls, John F.; Langenau, David M.			Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish	CELL			English	Article							ADULT ZEBRAFISH; SELF-RENEWAL; CELL HETEROGENEITY; REGULATES GROWTH; NEURAL-CREST; PATHWAY; IDENTIFICATION; COMBINATION; INSTABILITY; METASTASIS	Xenograft cell transplantation into immunodeficient mice has become the gold standard for assessing pre-clinical efficacy of cancer drugs, yet direct visualization of single-cell phenotypes is difficult. Here, we report an optically-clear prkdc(-/-), il2rga(-/-) zebrafish that lacks adaptive and natural killer immune cells, can engraft a wide array of human cancers at 37 degrees C, and permits the dynamic visualization of single engrafted cells. For example, photoconversion cell-lineage tracing identified migratory and proliferative cell slates in human rhabdomyosarcoma, a pediatric cancer of muscle. Additional experiments identified the preclinical efficacy of combination olaparib PARP inhibitor and temozolomide DNA-damaging agent as an effective therapy for rhabdomyosarcoma and visualized therapeutic responses using a four-color FUCCI cell-cycle fluorescent reporter. These experiments identified that combination treatment arrested rhabdomyosarcoma cells in the G2 cell cycle prior to induction of apoptosis. Finally, patient-derived xenografts could be engrafted into our model, opening new avenues for developing personalized therapeutic approaches in the future.	[Yan, Chuan; Brunson, Dalton C.; Tang, Qin; Do, Daniel; Iftimia, Nicolae A.; Moore, John C.; Hayes, Madeline N.; Welker, Alessandra M.; Garcia, Elaine G.; Volorio, Angela; Dershowitz, Lyle; McCarthy, Karin M.; Sgroi, Dennis C.; Iafrate, John A.; Langenau, David M.] Massachusetts Gen Hosp, Res Inst, Mol Pathol Unit, Charlestown, MA 02129 USA; [Yan, Chuan; Brunson, Dalton C.; Tang, Qin; Do, Daniel; Iftimia, Nicolae A.; Moore, John C.; Hayes, Madeline N.; Welker, Alessandra M.; Garcia, Elaine G.; Dubash, Taronish D.; Hong, Xin; Drapkin, Benjamin J.; Myers, David T.; Phat, Sarah; Volorio, Angela; Marvin, Dieuwke L.; Ligorio, Matteo; Dershowitz, Lyle; McCarthy, Karin M.; Sgroi, Dennis C.; Iafrate, John A.; Maheswaran, Shyamala; Dyson, Nick J.; Haber, Daniel A.; Langenau, David M.] Harvard Med Sch, Canc Ctr, Massachusetts Gen Hosp, Charlestown, MA 02129 USA; [Yan, Chuan; Brunson, Dalton C.; Tang, Qin; Do, Daniel; Iftimia, Nicolae A.; Moore, John C.; Hayes, Madeline N.; Welker, Alessandra M.; Garcia, Elaine G.; Dershowitz, Lyle; McCarthy, Karin M.; Langenau, David M.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA; [Yan, Chuan; Brunson, Dalton C.; Tang, Qin; Do, Daniel; Iftimia, Nicolae A.; Moore, John C.; Hayes, Madeline N.; Welker, Alessandra M.; Garcia, Elaine G.; Dershowitz, Lyle; McCarthy, Karin M.; Langenau, David M.] Harvard Stem Cell Inst, Cambridge, MA 02139 USA; [Karabacak, Murat N.] Shriners Hosp Children, Boston, MA 02114 USA; [Karabacak, Murat N.] Massachusetts Gen Hosp, Ctr Engn Med, Boston, MA 02114 USA; [Karabacak, Murat N.] Harvard Med Sch, Boston, MA 02114 USA; [Fletcher, Jonathan A.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Brunson, Dalton C.; Tang, Qin; Do, Daniel; Haber, Daniel A.] Howard Hughes Med Inst, Bethesda, MD 20815 USA; [Rawls, John F.] Duke Univ, Dept Mol Genet & Microbiol, Sch Med, Durham, NC 27710 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Duke University	Langenau, DM (corresponding author), Massachusetts Gen Hosp, Res Inst, Mol Pathol Unit, Charlestown, MA 02129 USA.; Langenau, DM (corresponding author), Harvard Med Sch, Canc Ctr, Massachusetts Gen Hosp, Charlestown, MA 02129 USA.; Langenau, DM (corresponding author), Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.; Langenau, DM (corresponding author), Harvard Stem Cell Inst, Cambridge, MA 02139 USA.	dlangenau@mgh.harvard.edu	Rawls, John F/C-9169-2009; Karabacak, Murat/AAG-2891-2019; Sgroi, Dennis/AAV-2487-2021; yan, chuan/J-6876-2017; HONG, XIN/X-8001-2019; Hong, Xin/AAI-5177-2020; Langenau, David/GXI-0197-2022	Rawls, John F/0000-0002-5976-5206; Karabacak, Murat/0000-0003-2761-5593; Hong, Xin/0000-0002-9671-0116; Langenau, David/0000-0001-6664-8318; yan, chuan/0000-0002-0449-7072; Brunson, Dalton/0000-0001-5620-4588; Do, Daniel/0000-0003-2985-6497	NIH [R24OD016761, R01CA154923, R01CA215118, R01CA211734, R01CA226926, R01CA1299933]; Liddy Shriver Sarcoma Initiative; MGH Research Scholars Program; Shriners Hospital for Children [U01CA220323]; HHMI; National Foundation for Cancer Research; Breast Cancer Foundation; Breast Cancer Research Foundation; Lung Cancer Research Foundation; ASCO Young Investigator Award; Alex's Lemonade Stand Foundation Young Investigator Award; Tosteson & Fund for Medical Discovery Fellowship from MGH; NATIONAL CANCER INSTITUTE [R01CA154923, U01CA220323, R01CA215118, R01CA211734, R01CA129933, R01CA226926] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [R24OD016761] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Liddy Shriver Sarcoma Initiative; MGH Research Scholars Program; Shriners Hospital for Children; HHMI(Howard Hughes Medical Institute); National Foundation for Cancer Research; Breast Cancer Foundation; Breast Cancer Research Foundation; Lung Cancer Research Foundation; ASCO Young Investigator Award; Alex's Lemonade Stand Foundation Young Investigator Award; Tosteson & Fund for Medical Discovery Fellowship from MGH; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Dr. Cyril Benes for helpful discussions and feedback on the work and Florence Lin at the Shriners Hospital for Children-Boston Special Shared Mass Spectrometry Facility for help with mass spectrometry studies. We thank Drs. Michael Dyer and Elizabeth Stewart and the The Childhood Solid Tumor Network (CSTN) from St. Jude Children's Research Hospital for patient-derived xenograft models. This work is supported by NIH grants R24OD016761 (D.M.L.), R01CA154923 (D.M.L.), R01CA215118, (D.M.L.), R01CA211734 (D.M.L.), R01CA226926 (D.M.L.), R01CA1299933 (D.A.H.); the Liddy Shriver Sarcoma Initiative (D.M.L. and J.A.F.); the MGH Research Scholars Program (D.M.L.); Shriners Hospital for Children (M.N.K.); U01CA220323 (N.J.D.); HHMI (D.A.H.); National Foundation for Cancer Research (D.A.H.); Breast Cancer Foundation (D.A.H.); the Breast Cancer Research Foundation (D.C.B.); the Lung Cancer Research Foundation (B.J.D.); ASCO Young Investigator Award (B.J.D.); the Tosteson & Fund for Medical Discovery Fellowship from MGH (C.Y.); and the Alex's Lemonade Stand Foundation Young Investigator Award (C.Y.).	Agarwala S S, 2000, Oncologist, V5, P144, DOI 10.1634/theoncologist.5-2-144; Bajar BT, 2016, NAT METHODS, V13, P993, DOI [10.1038/NMETH.4045, 10.1038/nmeth.4045]; Bakhoum SF, 2018, NATURE, V553, P467, DOI 10.1038/nature25432; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Beerling E, 2016, CELL REP, V14, P2281, DOI 10.1016/j.celrep.2016.02.034; Blackburn JS, 2012, LEUKEMIA, V26, P2069, DOI 10.1038/leu.2012.116; BRUCE WR, 1963, NATURE, V199, P79, DOI 10.1038/199079a0; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Chapman A, 2014, CELL REP, V8, P688, DOI 10.1016/j.celrep.2014.06.045; Chaudhuri AR, 2016, NATURE, V535, P382, DOI 10.1038/nature18325; Chen EY, 2014, P NATL ACAD SCI USA, V111, P5349, DOI 10.1073/pnas.1317731111; Chen X, 2013, CANCER CELL, V24, P710, DOI 10.1016/j.ccr.2013.11.002; Chudakov DM, 2007, NAT PROTOC, V2, P2024, DOI 10.1038/nprot.2007.291; Cox AG, 2016, NAT CELL BIOL, V18, P886, DOI 10.1038/ncb3389; Curtis SJ, 2010, CELL STEM CELL, V7, P127, DOI 10.1016/j.stem.2010.05.021; Dang M, 2016, DIS MODEL MECH, V9, P811, DOI 10.1242/dmm.024166; Das R, 2016, NAT MED, V22, P1351, DOI 10.1038/nm.4202; DAVIS RJ, 1994, CANCER RES, V54, P2869; Diez BD, 2010, CANCER CHEMOTH PHARM, V65, P727, DOI 10.1007/s00280-009-1078-6; Drapkin BJ, 2018, CANCER DISCOV, V8, P600, DOI 10.1158/2159-8290.CD-17-0935; Ellenbroek SIJ, 2014, NAT REV CANCER, V14, P406, DOI 10.1038/nrc3742; Fior R, 2017, P NATL ACAD SCI USA, V114, pE8234, DOI 10.1073/pnas.1618389114; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Gill SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140988; Goyama S, 2015, BLOOD, V125, P2630, DOI 10.1182/blood-2014-11-570218; Hayes MN, 2018, CELL STEM CELL, V22, P414, DOI 10.1016/j.stem.2018.02.002; He SN, 2016, ELIFE, V5, DOI 10.7554/eLife.14713; Ignatius MS, 2017, CELL REP, V19, P2304, DOI 10.1016/j.celrep.2017.05.061; Ignatius MS, 2012, CANCER CELL, V21, P680, DOI 10.1016/j.ccr.2012.03.043; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Kaufman CK, 2016, SCIENCE, V351, DOI 10.1126/science.aad2197; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007; Li ZD, 2019, LEUKEMIA, V33, P262, DOI 10.1038/s41375-018-0201-2; Lister JA, 1999, DEVELOPMENT, V126, P3757; Lobbardi R, 2017, CANCER DISCOV, V7, P1336, DOI 10.1158/2159-8290.CD-17-0267; Luo X, 2014, CELL REP, V7, P645, DOI 10.1016/j.celrep.2014.03.039; McMahon M, 2016, MOL CANCER RES, V14, P1195, DOI 10.1158/1541-7786.MCR-16-0108; Moore FE, 2016, J EXP MED, V213, P979, DOI 10.1084/jem.20152013; Moore JC, 2016, J EXP MED, V213, P2575, DOI 10.1084/jem.20160378; Murai J, 2014, J PHARMACOL EXP THER, V349, P408, DOI 10.1124/jpet.113.210146; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Peer CJ, 2016, Separations, V3, DOI 10.3390/chromatography3010004; Rajan A, 2012, CLIN CANCER RES, V18, P2344, DOI 10.1158/1078-0432.CCR-11-2425; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Rongvaux A, 2014, NAT BIOTECHNOL, V32, P364, DOI 10.1038/nbt.2858; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Smith ACH, 2010, BLOOD, V115, P3296, DOI 10.1182/blood-2009-10-246488; Stewart E, 2017, NATURE, V549, P96, DOI 10.1038/nature23647; Stewart E, 2014, CELL REP, V9, P829, DOI 10.1016/j.celrep.2014.09.028; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Sun Kaiming, 2018, Oncotarget, V9, P37080, DOI 10.18632/oncotarget.26354; Tang Q, 2017, J EXP MED, V214, P2875, DOI 10.1084/jem.20170976; Tang Q, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10358; Tang Q, 2014, NAT METHODS, V11, P821, DOI [10.1038/NMETH.3031, 10.1038/nmeth.3031]; Tchoghandjian A, 2012, ANN SURG ONCOL, V19, pS608, DOI 10.1245/s10434-011-2093-5; Tenente IM, 2014, JOVE-J VIS EXP, DOI 10.3791/52597; Tian L, 2017, NATURE, V544, P250, DOI 10.1038/nature21724; To TL, 2016, CELL CHEM BIOL, V23, P875, DOI 10.1016/j.chembiol.2016.06.007; Welker AM, 2017, NEUROSCIENCE, V356, P35, DOI 10.1016/j.neuroscience.2017.05.010; White RM, 2008, CELL STEM CELL, V2, P183, DOI 10.1016/j.stem.2007.11.002; White RM, 2011, NATURE, V471, P518, DOI 10.1038/nature09882; Yan C, 2015, J HEPATOL, V63, P420, DOI 10.1016/j.jhep.2015.03.024; Yu M, 2014, SCIENCE, V345, P216, DOI 10.1126/science.1253533	65	122	128	3	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	2019	177	7					1903	+		10.1016/j.cell.2019.04.004	http://dx.doi.org/10.1016/j.cell.2019.04.004			26	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	IC8UG	31031007	Bronze, Green Accepted			2023-01-03	WOS:000471256800026
J	Hancox, JE; van der Wardt, V; Pollock, K; Booth, V; Vedhara, K; Harwood, RH				Hancox, Jennie E.; van der Wardt, Veronika; Pollock, Kristian; Booth, Vicky; Vedhara, Kavita; Harwood, Rowan H.			Factors influencing adherence to home-based strength and balance exercises among older adults with mild cognitive impairment and early dementia: Promoting Activity, Independence and Stability in Early Dementia (PrAISED)	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; ALZHEIMERS-DISEASE; PEOPLE; EXPERIENCES; PROGRAM	Background Older adults with dementia are at a high risk of losing abilities and of accidental falls. Promoting Activity, Independence and Stability in Early Dementia (PrAISED) is a 12-month person-centred exercise and activity programme which aims to increase activity and independence whilst reducing falls in people with early dementia. In this patient group, as well as many others, poor adherence to exercise interventions can undermine treatment effectiveness. We aimed to explore patterns of barriers and facilitators influencing PrAISED participants' adherence to home-based strength and balance exercises. Methods Participants were a subsample of 20 individuals with mild cognitive impairment or early dementia and their carer(s) taking part in the PrAISED programme. Participants (with the support of a carer where necessary) kept a daily exercise diary. Participants' adherence were categorised based upon reported number of times a week they undertook the PrAISED strength and balance exercises over a 4 month period (<3 times a week = low adherence, 3-4 = meeting adherence expectations, >5 = exceeding adherence expectations). Semi-structured interviews were conducted in month 4 of the PrAISED programme to explore barriers and facilitators to adherence. A mixture of deductive and inductive thematic analysis was employed with themes categorised using the Theoretical Domains Framework. Findings Participants completed on average 98 minutes of home-based strength and balance exercises per week, 3.8 sessions per week, for an average of 24 minutes per session. Five participants were categorised as exceeding adherence expectations, 7 as meeting adherence expectations, and 8 as low adherers. Analysis of interview data based on self-reported adherence revealed six interacting themes: 1) routine, 2) practical and emotional support, 3) memory support, 4) purpose, 5) past experiences of sport and exercise, and 6) belief in and experience of benefits. Conclusions Identifiable cognitive, psychological, and practical factors influence adherence to exercise, and should be addressed in future development of interventions with this population.	[Hancox, Jennie E.; Vedhara, Kavita] Univ Nottingham, Sch Med, Div Primary Care, Nottingham, England; [van der Wardt, Veronika; Booth, Vicky] Univ Nottingham, Sch Med, Div Rehabil Ageing & Well Being, Nottingham, England; [Pollock, Kristian; Harwood, Rowan H.] Univ Nottingham, Sch Hlth Sci, Nottingham, England	University of Nottingham; University of Nottingham; University of Nottingham	Hancox, JE (corresponding author), Univ Nottingham, Sch Med, Div Primary Care, Nottingham, England.	jennie.hancox@nottingham.ac.uk	van der Wardt, Veronika/ABF-3836-2021; Pollock, Kristian/B-9734-2008; Hancox, Jennie/F-4551-2015	van der Wardt, Veronika/0000-0003-3995-7056; Pollock, Kristian/0000-0002-6836-8595; Vedhara, Kavita/0000-0002-9940-7534; Harwood, Rowan/0000-0002-4920-6718; Hancox, Jennie/0000-0001-5938-5265; Booth, Vicky/0000-0002-5338-0196	National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme [RP-PG-0614-20007]	National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme(National Institute for Health Research (NIHR))	This paper presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (Reference Number RP-PG-0614-20007). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funding was awarded to Professor Rowan H Harwood.	[Anonymous], 2015, WORLD ALZHEIMER REPO, P87; Atkins L, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0605-9; Barreto PD, 2015, AGEING RES REV, V24, P274, DOI 10.1016/j.arr.2015.09.001; Bollen JC, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005044; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Burton E, 2015, CLIN INTERV AGING, V10, P421, DOI 10.2147/CIA.S71691; Campbell J, 2003, OTAGO EXERCISE PROGR, P1; Cane J, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-37; CASPERSEN CJ, 1985, PUBLIC HEALTH REP, V100, P126; Cedervall Y, 2015, AGING MENT HEALTH, V19, P679, DOI 10.1080/13607863.2014.962004; Clemson L, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4547; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Dening T, 2013, OXFORD TXB OLD AGE P, V2nd; Di Lorito C, 2019, MATURITAS, V122, P8, DOI 10.1016/j.maturitas.2019.01.001; Feilzer MY, 2010, J MIX METHOD RES, V4, P6, DOI 10.1177/1558689809349691; Forbes D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006489.pub4; French SD, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-38; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Gardner B, 2011, ANN BEHAV MED, V42, P174, DOI 10.1007/s12160-011-9282-0; Graff MJL, 2006, BMJ-BRIT MED J, V333, P1196, DOI 10.1136/bmj.39001.688843.BE; Harwood Rowan H, 2018, Pilot Feasibility Stud, V4, P49, DOI 10.1186/s40814-018-0239-y; Hernandez SSS, 2015, J AGING PHYS ACTIV, V23, P659, DOI 10.1123/japa.2014-0180; Liu-Ambrose T, 2008, J AM GERIATR SOC, V56, P1821, DOI [10.1111/j.1532-5415.2008.01931.x, 10.1111/j.1532-5415.2008.01984.x]; Malthouse R, 2014, PHYSIOTHERAPY, V100, P169, DOI 10.1016/j.physio.2013.10.002; Middleton LE, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-017-0684-0; Petersen RC, 2014, J INTERN MED, V275, P214, DOI 10.1111/joim.12190; Pitkala KH, 2013, JAMA INTERN MED, V173, P894, DOI 10.1001/jamainternmed.2013.359; Power V, 2013, EUR REV AGING PHYS A, V10, P95, DOI 10.1007/s11556-012-0108-2; Sabia S, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j2709; Sherrington C, 2017, BRIT J SPORT MED, V51, P1749, DOI 10.1136/bjsports-2016-096547; Sparkes AC., 2013, QUALITATIVE RES METH; Suttanon P, 2012, INT PSYCHOGERIATR, V24, P1172, DOI 10.1017/S1041610211002729; Taylor ME, 2017, INT PSYCHOGERIATR, V29, P81, DOI 10.1017/S1041610216001629; Teri L, 2003, JAMA-J AM MED ASSOC, V290, P2015, DOI 10.1001/jama.290.15.2015; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Trombetti Andrea, 2011, Rev Med Suisse, V7, P1305; van Alphen HJM, 2016, ARCH GERONTOL GERIAT, V66, P109, DOI 10.1016/j.archger.2016.05.008; van der Wardt Veronika, 2017, Prev Med Rep, V7, P38, DOI 10.1016/j.pmedr.2017.05.007; Vertesi A, 2001, CAN FAM PHYSICIAN, V47, P2018; World Health Organization, 2012, DEM PUBL HLTH PRIOR	40	16	16	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2019	14	5							e0217387	10.1371/journal.pone.0217387	http://dx.doi.org/10.1371/journal.pone.0217387			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HZ3VE	31120953	Green Submitted, gold, Green Published			2023-01-03	WOS:000468775700096
J	Koreny, M; Demeyer, H; Arbillaga-Etxarri, A; Gimeno-Santos, E; Barberan-Garcia, A; Benet, M; Balcells, E; Borrell, E; Marin, A; Chiaradia, DAR; Vall-Casas, P; Vilaro, J; Rodriguez-Roisin, R; Garcia-Aymerich, J				Koreny, Maria; Demeyer, Heleen; Arbillaga-Etxarri, Ane; Gimeno-Santos, Elena; Barberan-Garcia, Anael; Benet, Marta; Balcells, Eva; Borrell, Eulalia; Marin, Alicia; Rodriguez Chiaradia, Diego A.; Vall-Casas, Pere; Vilaro, Jordi; Rodriguez-Roisin, Robert; Garcia-Aymerich, Judith			Determinants of study completion and response to a 12-month behavioral physical activity intervention in chronic obstructive pulmonary disease: A cohort study	PLOS ONE			English	Article							COPD; PEOPLE; LIFE; REHABILITATION; IMPUTATION; PROGRAM	Objectives Physical activity is key to improve the prognosis of chronic obstructive pulmonary disease (COPD). To help to tailor future interventions we aimed to identify the baseline characteristics of COPD patients which predict 12-month completion and response to a behavioral physical activity intervention. Methods This is a 12-month cohort study of the intervention arm of the Urban Training randomized controlled trial (NCT01897298), an intervention proven to be efficacious to increase physical activity. We considered baseline sociodemographic, interpersonal, environmental, clinical and psychological characteristics as potential determinants of completion and response. We defined completion as attending the 12-month study visit. Among completers, we defined response as increasing physical activity >= 1100 steps/day from baseline to 12 months, measured by accelerometer. We estimated the factors independently for completion and response using multivariable logistic regression models. Results Of a total of 202 patients (m (SD) 69 (9) years, 84% male), 132 (65%) completed the study. Among those, 37 (28%) qualified as responders. Higher numbers of baseline steps/day (OR [95% CI] 1.11 [1.02-1.21] per increase of 1000 steps, p<0.05) and living with a partner (2.77 [1.41-5.48], p<0.01) were related to a higher probability of completion while more neighborhood vulnerability (0.70 [0.57-0.86] per increase of 0.1 units in urban vulnerability index, p<0.01) was related to a lower probability. Among the completers, working (3.14 [1.05-9.33], p<0.05) and having an endocrino-metabolic disease (4.36 [1.49-12.80], p<0.01) were related to a higher probability of response while unwillingness to follow the intervention (0.21 [0.05-0.98], p<0.05) was related to a lower probability. Conclusions This study found that 12-month completion of a behavioral physical activity intervention was generally determined by previous physical activity habits as well as interpersonal and environmental physical activity facilitators while response was related to diverse factors thought to modify the individual motivation to change to an active lifestyle.	[Koreny, Maria; Benet, Marta; Garcia-Aymerich, Judith] ISGlobal, Barcelona, Spain; [Koreny, Maria; Benet, Marta; Balcells, Eva; Rodriguez Chiaradia, Diego A.; Garcia-Aymerich, Judith] Pompeu Fabra Univ UPF, Barcelona, Spain; [Koreny, Maria; Benet, Marta; Garcia-Aymerich, Judith] CIBERESP, Barcelona, Spain; [Demeyer, Heleen] Univ Leuven, KU Leuven, Dept Rehabil Sci, Leuven, Belgium; [Demeyer, Heleen] Univ Hosp KU Leuven, Dept Resp Dis, Leuven, Belgium; [Arbillaga-Etxarri, Ane] Univ Deusto, Phys Act & Sports Sci, Fac Psychol & Educ, Donostia San Sebastian, Spain; [Gimeno-Santos, Elena; Barberan-Garcia, Anael] Hosp Clin Barcelona, Resp Clin Inst, Barcelona, Spain; [Gimeno-Santos, Elena; Barberan-Garcia, Anael; Rodriguez-Roisin, Robert] August Pi & Sunyer Biomed Res Inst & DIBAPS, Barcelona, Spain; [Barberan-Garcia, Anael; Balcells, Eva; Marin, Alicia; Rodriguez Chiaradia, Diego A.] CIBER Enfermedades Resp CIBERES, Madrid, Spain; [Balcells, Eva; Rodriguez Chiaradia, Diego A.] Hosp Mar, Inst Hosp Mar Invest Med IMIM, Pneumol Dept, Barcelona, Spain; [Borrell, Eulalia] ICS, St Roc Primary Hlth Care Ctr, Badalona, Spain; [Marin, Alicia] Hosp Badalona Germans Trias & Pujol, Dept Pulm Med, Badalona, Spain; [Marin, Alicia] Fdn Inst Invest Ciencies Salut Germans Tria & Puj, Badalona, Spain; [Vall-Casas, Pere] Univ Int Catalunya, Barcelona, Spain; [Vilaro, Jordi] Ramon Llull Univ, Blanquerna Hlth Sci Sch, Global Res Wellbeing GRoW, Barcelona, Spain	ISGlobal; Pompeu Fabra University; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; KU Leuven; KU Leuven; University Hospital Leuven; University of Deusto; University of Barcelona; Hospital Clinic de Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Hospital Germans Trias i Pujol; Universitat Internacional de Catalunya (UIC); Universitat Ramon Llull	Garcia-Aymerich, J (corresponding author), ISGlobal, Barcelona, Spain.; Garcia-Aymerich, J (corresponding author), Pompeu Fabra Univ UPF, Barcelona, Spain.; Garcia-Aymerich, J (corresponding author), CIBERESP, Barcelona, Spain.	judith.garcia@isglobal.org	J, Garcia-Aymerich/G-6867-2014	J, Garcia-Aymerich/0000-0002-7097-4586; Demeyer, Heleen/0000-0001-8925-0564; Arbillaga-Etxarri, Ane/0000-0003-3565-0751	ERS/SEPAR Fellowship; FWO-Flanders (Fonds voor Wetenschappelijk Onderzoek - Vlaanderen); Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III (ISCIII) [NCT01897298, PI11/01283, PI14/0419]; ISCIII-Subdireccion General de Evaluacion y Fomento de la Investigacion; Fondo Europeo de Desarrollo Regional (FEDER); Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR) [147/2011, 201/2011]; Societat Catalana de Pneumologia; Generalitat de Catalunya (El programa de centres de recerca de Catalunya); AGAUR [2014-SGR-661]; Catalan Government (Agencia de Gestion de Ayudas Universitarias y de Investigacion)	ERS/SEPAR Fellowship; FWO-Flanders (Fonds voor Wetenschappelijk Onderzoek - Vlaanderen)(FWO); Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III (ISCIII)(Instituto de Salud Carlos III); ISCIII-Subdireccion General de Evaluacion y Fomento de la Investigacion; Fondo Europeo de Desarrollo Regional (FEDER)(European Commission); Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR); Societat Catalana de Pneumologia; Generalitat de Catalunya (El programa de centres de recerca de Catalunya); AGAUR(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); Catalan Government (Agencia de Gestion de Ayudas Universitarias y de Investigacion)	HD is the recipient of a joint ERS/SEPAR Fellowship (LTRF 2015) (Sociedad Espanola De Neumologia Y Cirugia Toracica (Separ) www.separ.es) and is a post-doctoral research fellow of the FWO-Flanders (Fonds voor Wetenschappelijk Onderzoek - Vlaanderen https://www.fwo.be/en).The Urban TrainingTM study (NCT01897298) was funded by grants from Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III (ISCIII, PI11/01283 and PI14/0419) (Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III http://www.isciii.es), integrated into Plan Estatal I+D+I 2013-2016 and co-funded by ISCIII-Subdireccion General de Evaluacion y Fomento de la Investigacion and Fondo Europeo de Desarrollo Regional (FEDER); Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR, 147/2011 and 201/2011), Societat Catalana de Pneumologia (Ajuts al millor projecte en fisioterapia respiratoria 2013). ISGlobal is a member of the CERCA Program, Generalitat de Catalunya (El programa de centres de recerca de Catalunya http://cerca.cat/). Anael Barberan-Garcia had personal funding from AGAUR 2014-SGR-661, Catalan Government (Agencia de Gestion de Ayudas Universitarias y de Investigacion http://agaur.gencat.cat/es). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altenburg WA, 2015, RESP MED, V109, P112, DOI 10.1016/j.rmed.2014.10.020; Arbillaga-Etxarri A, 2017, THORAX, P1; Arbillaga-Etxarri A, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00063-2018; Arbillaga-Etxarri A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146705; Arnold E, 2006, RESP MED, V100, P1716, DOI 10.1016/j.rmed.2006.02.007; Bauman AE, 2012, LANCET, V380, P258, DOI 10.1016/S0140-6736(12)60735-1; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; Centers for Disease Control and Prevention, 2012, OV BARR PHYS ACT; Demeyer H, 2017, THORAX, V72, P415, DOI 10.1136/thoraxjnl-2016-209026; Demeyer H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154587; DiClemente C.C., 2002, MOTIVATIONAL INTERVI, V2nd ed., P201; Donders ART, 2006, J CLIN EPIDEMIOL, V59, P1087, DOI 10.1016/j.jclinepi.2006.01.014; European Lung Foundation-ELF, FACTSH LIV ACT COPD; Garcia-Aymerich J., 2015, BRN REV, V1, P92; Gimeno-Santos E, 2015, EUR RESPIR J, V46, P988, DOI 10.1183/09031936.00183014; Gimeno-Santos E, 2014, THORAX, V69, P731, DOI 10.1136/thoraxjnl-2013-204763; Global Initiative for Chronic Obstructive Lung Disease, 2017, GLOB STRAT DIAGN MAN; Hartman JE, 2013, J PHYSIOTHER, V59, P117, DOI 10.1016/S1836-9553(13)70164-4; Hosmer D. J., 2013, APPL LOGISTIC REGRES, DOI DOI 10.1002/9781118548387; Kantorowski A, 2018, ERJ OPEN RES, V4, DOI 10.1183/23120541.00054-2018; Keating A, 2011, CHRON RESP DIS, V8, P89, DOI 10.1177/1479972310393756; Kosteli MC, 2017, INT J CHRONIC OBSTR, V12, DOI 10.2147/COPD.S119806; Mendoza L, 2015, EUR RESPIR J, V45, P347, DOI 10.1183/09031936.00084514; Mesquita R, 2017, CHEST, V151, P1028, DOI 10.1016/j.chest.2016.12.021; Moy ML, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5622; Moy ML, 2015, CHEST, V148, P128, DOI 10.1378/chest.14-1466; Prochaska JO, 1997, AM J HEALTH PROMOT, V12, P38, DOI 10.4278/0890-1171-12.1.38; Rabinovich RA, 2013, EUR RESPIR J, V42, P1205, DOI 10.1183/09031936.00134312; Soriano JB, 2017, LANCET RESP MED, V5, P691, DOI 10.1016/S2213-2600(17)30293-X; Thorpe O, 2014, INT J CHRONIC OBSTR, V9, P115, DOI 10.2147/COPD.S54457; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.3.CO;2-I; Van Remoortel H, 2013, THORAX, V68, P962, DOI 10.1136/thoraxjnl-2013-203534; Van Remoortel H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039198; Walsh JR, 2013, J CARDIOPULM REHABIL, V33, P249, DOI 10.1097/HCR.0b013e31829501b7; Waschki B, 2015, AM J RESP CRIT CARE, V192, P295, DOI 10.1164/rccm.201501-0081OC; World Health Organization, 2002, INNOVATIVE CARE CHRO; 2014, CHEST, V146, P318, DOI DOI 10.1378/CHEST.13-1968	37	2	2	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2019	14	5							e0217157	10.1371/journal.pone.0217157	http://dx.doi.org/10.1371/journal.pone.0217157			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY7BF	31107900	Green Accepted, gold, Green Published, Green Submitted			2023-01-03	WOS:000468285200033
J	van Deursen, JM				van Deursen, Jan M.			Senolytic therapies for healthy longevity	SCIENCE			English	Editorial Material							SENESCENT CELLS; CLEARANCE		[van Deursen, Jan M.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; [van Deursen, Jan M.] Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	van Deursen, JM (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.; van Deursen, JM (corresponding author), Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA.	vandeursen.jan@mayo.edu			Glenn Foundation for Medical Research; NIH [R01CA096985, R01AG057493]; NATIONAL CANCER INSTITUTE [R01CA096985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG057493] Funding Source: NIH RePORTER	Glenn Foundation for Medical Research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	J.M.v.D. is a cofounder of Unity Biotechnology and an inventor on patents licensed to or filed by Unity Biotechnology. J.M.v.D. is supported by the Glenn Foundation for Medical Research and NIH grants R01CA096985 and R01AG057493. J.M.v.D. thanks B. Childs, N. David, and D. Baker for helpful discussions.	Baar MP, 2017, CELL, V169, P132, DOI 10.1016/j.cell.2017.02.031; Baker DJ, 2016, NATURE, V530, P184, DOI 10.1038/nature16932; Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600; Bussian TJ, 2018, NATURE, V562, P578, DOI 10.1038/s41586-018-0543-y; Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010; Childs BG, 2016, SCIENCE, V354, P472, DOI 10.1126/science.aaf6659; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Dou ZX, 2017, NATURE, V550, P402, DOI 10.1038/nature24050; Jeon OH, 2017, NAT MED, V23, P775, DOI 10.1038/nm.4324; Munoz-Espin D, 2013, CELL, V155, P1104, DOI 10.1016/j.cell.2013.10.019; Muoz-Espin D., 2018, EMBO MOL MED, V10, pe9355; van Deursen JM, 2014, NATURE, V509, P439, DOI 10.1038/nature13193; Xu M, 2018, NAT MED, V24, P1246, DOI 10.1038/s41591-018-0092-9; Yosef R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11190; Yousefzadeh MJ, 2018, EBIOMEDICINE, V36, P18, DOI 10.1016/j.ebiom.2018.09.015	15	96	97	5	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 17	2019	364	6441					636	637		10.1126/science.aaw1299	http://dx.doi.org/10.1126/science.aaw1299			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HZ0SB	31097655	Green Accepted			2023-01-03	WOS:000468551000015
J	Boazak, EM; Greene, VK; Auguste, DT				Boazak, Elizabeth M.; Greene, Vaughn K., Jr.; Auguste, Debra T.			The effect of heterobifunctional crosslinkers on HEMA hydrogel modulus and toughness	PLOS ONE			English	Article							POLY(2-HYDROXYETHYL METHACRYLATE) HYDROGELS; TENSILE PROPERTIES; MECHANICS; TRACHEA; LINKING; CARTILAGE; SOFT	The use of hydrogels in load bearing applications is often limited by insufficient toughness. 2-Hydroxyethyl methacrylate (HEMA) based hydrogels are appealing for translational work, as they are affordable and the use of HEMA is FDA approved. Furthermore, HEMA is photopolymerizable, providing spatiotemporal control over mechanical properties. We evaluated the ability of vinyl methacrylate (VM), allyl methacrylate (AM), and 3-(Acryloyloxy)-2-hydroxypropyl methacrylate (AHPM) to tune hydrogel toughness and Young's modulus. The crosslinkers were selected due to their heterobifunctionality (vinyl and methacrylate) and similar size and structure to EGDMA, which was shown previously to increase toughness as compared to longer crosslinkers. Vinyl methacrylate incorporation into HEMA hydrogels gave rise to hydrogels with Young's moduli spanning ranges for ligament to cartilage, with a peak toughness of 519 +/- 70 kJ/m(3) under physiological conditions. We report toughness (work of extension) as a function of modulus and equilibrium water content for all formulations. The hydrogels exhibited 80%-100% cell viability, which suggests they could be used in tissue engineering applications.	[Boazak, Elizabeth M.; Greene, Vaughn K., Jr.; Auguste, Debra T.] CUNY, Dept Biomed Engn, New York, NY 10021 USA; [Auguste, Debra T.] Northeastern Univ, Dept Chem Engn, Boston, MA 02115 USA	City University of New York (CUNY) System; Northeastern University	Auguste, DT (corresponding author), CUNY, Dept Biomed Engn, New York, NY 10021 USA.; Auguste, DT (corresponding author), Northeastern Univ, Dept Chem Engn, Boston, MA 02115 USA.	d.auguste@northeastern.edu						AKIZUKI S, 1986, J ORTHOPAED RES, V4, P379, DOI 10.1002/jor.1100040401; ARIMA T, 1995, J DENT RES, V74, P1597, DOI 10.1177/00220345950740091501; Behrend M, 2001, EUR SURG RES, V33, P255, DOI 10.1159/000049715; Boazak EM, 2018, ACS BIOMATER SCI ENG, V4, P1272, DOI 10.1021/acsbiomaterials.7b00738; BRISCOE B, 1981, TRIBOL INT, V14, P231, DOI 10.1016/0301-679X(81)90050-5; Costa AMS, 2015, EUR POLYM J, V72, P344, DOI 10.1016/j.eurpolymj.2015.07.053; Elisseeff J, 1999, P NATL ACAD SCI USA, V96, P3104, DOI 10.1073/pnas.96.6.3104; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; KEAVENY TM, 1994, J BIOMECH, V27, P1137, DOI 10.1016/0021-9290(94)90054-X; Kim HD, 2012, INTEGR BIOL-UK, V4, P37, DOI 10.1039/c1ib00069a; Kyburz KA, 2013, ACTA BIOMATER, V9, P6381, DOI 10.1016/j.actbio.2013.01.026; Lin-Gibson S, 2004, BIOMACROMOLECULES, V5, P1280, DOI 10.1021/bm0498777; Liu Q, 2000, BIOMATERIALS, V21, P2163, DOI 10.1016/S0142-9612(00)00137-X; Luo F, 2017, POLYMER, V116, P487, DOI 10.1016/j.polymer.2017.02.042; Maganaris CN, 2005, TENDON INJURIES: BASIC SCIENCE AND CLINICAL MEDICINE, P14, DOI 10.1007/1-84628-050-8_2; Mansfield EG, 2016, ACTA BIOMATER, V33, P176, DOI 10.1016/j.actbio.2016.01.034; Moghadam MN, 2015, J MECH BEHAV BIOMED, V41, P161, DOI 10.1016/j.jmbbm.2014.10.010; Naficy S, 2011, AUST J CHEM, V64, P1007, DOI 10.1071/CH11156; Oveissi F, 2019, BIOMATER SCI-UK, V7, P926, DOI 10.1039/c8bm01182f; Reddy GK, 2004, EXP DIABESITY RES, V5, P143, DOI 10.1080/15438600490277860; RHO JY, 1993, J BIOMECH, V26, P111, DOI 10.1016/0021-9290(93)90042-D; Roberts CR, 1998, J BIOMECH, V31, P81, DOI 10.1016/S0021-9290(97)00112-7; SCHMIDT MB, 1990, J ORTHOPAED RES, V8, P353, DOI 10.1002/jor.1100080307; Seidi A, 2011, ACTA BIOMATER, V7, P1441, DOI 10.1016/j.actbio.2011.01.011; Smith KE, 2011, ACTA BIOMATER, V7, P558, DOI 10.1016/j.actbio.2010.09.001; Teng ZZ, 2012, J BIOMECH, V45, P1717, DOI 10.1016/j.jbiomech.2012.04.002; Vega-Avila Elisa, 2011, Proc West Pharmacol Soc, V54, P10; Wong JY, 2004, SURF SCI, V570, P119, DOI 10.1016/j.susc.2004.06.186; Xiao YH, 2013, TISSUE ENG PART B-RE, V19, P403, DOI [10.1089/ten.TEB.2012.0461, 10.1089/ten.teb.2012.0461]; Zhu JT, 2013, J MATER CHEM B, V1, P978, DOI 10.1039/c2tb00288d	30	12	12	2	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2019	14	5							e0215895	10.1371/journal.pone.0215895	http://dx.doi.org/10.1371/journal.pone.0215895			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX6ZE	31071122	Green Published, gold			2023-01-03	WOS:000467552100020
J	Erwin, K; Fitzpatrick, V; Norell, S; Gilliam, M				Erwin, Kim; Fitzpatrick, Veronica; Norell, Sarah; Gilliam, Melissa			Development of a Framework and Tool to Facilitate Cost-of-Care Conversations With Patients During Prenatal Care	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HUMAN-CENTERED DESIGN; DISCUSSIONS; THINKING; CANCER; IMPACT	Background: Studies show that patients want to engage in cost-of-care conversations and factor costs into the formulation of care plans. Low-income patients are particularly likely to defer care because of costs, suggesting that cost-of-care conversations may be an important factor in health equity. Little guidance is available to clinicians and health systems for how to integrate effective cost-of-care conversations into clinical practice or to address specific cost needs of low-income patients. Objective: To develop a framework and tool to assist cost-of-care conversations with low-income patients during prenatal care. Design: A qualitative study using human-centered design methods. Setting: University medical center-based obstetrics-gynecology (ob-gyn) practice. Participants: 20 pregnant or recently postpartum women, 16 clinicians, and 8 support and executive staff. Results: Pregnant women accumulate substantial indirect costs that interfere with treatment adherence and stress patients and their relationships. Frequency and duration of appointments are primary drivers of indirect costs; the burden is exacerbated by not knowing these costs in advance and disproportionately affects low-income patients. Working with ob-gyn clinicians, staff, and patients, a paper-based tool was developed to help patients forecast treatment demands and indirect costs, and to help clinicians introduce and standardize cost conversations. Limitations: Data were collected from a small number of stakeholders in a single clinical setting that may not be generalizable to other settings. The tool has not been tested for effects on adherence or clinical outcomes. Conclusion: A communication tool that helps pregnant patients understand their care plan and anticipate indirect costs can promote cost-of-care conversations between clinicians and low-income patients. Primary Funding Source: Robert Wood Johnson Foundation.	[Erwin, Kim; Norell, Sarah] Univ Illinois, 1220 South Wood St,Third Floor, Chicago, IL 60608 USA; [Fitzpatrick, Veronica] Sinai Urban Hlth Inst, 1500 South Fairfield Ave,K448, Chicago, IL 60608 USA; [Gilliam, Melissa] Univ Chicago, 5801 South Ellis Ave, Chicago, IL 60637 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago	Erwin, K (corresponding author), Univ Illinois, 1220 South Wood St,Third Floor, Chicago, IL 60608 USA.	kerwin4@uic.edu			Robert Wood Johnson Foundation [74126]	Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF))	By the Robert Wood Johnson Foundation (grant 74126) under the funding mechanism Can We Talk?	Alexander GC, 2005, ARCH INTERN MED, V165, P633, DOI 10.1001/archinte.165.6.633; Bengiamin MI, 2010, MATERN CHILD HLTH J, V14, P618, DOI 10.1007/s10995-009-0485-y; Boer L., 2012, P DES INT SYST C DIS, P388, DOI [DOI 10.1145/2317956.2318014, 10.1145/2317956.2318014]; Erwin K., 2017, IDJ, V23, P248, DOI [10.1075/idj.23.3.01erw, DOI 10.1075/IDJ.23.3.01ERW]; Erwin K, 2016, J COMP EFFECT RES, V5, P17, DOI 10.2217/cer.15.52; Hunter WG, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1353-2; Irazola V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183953; Lewis C, 2017, LISTENING LOW INCOME; Matheson GO, 2015, AM J PREV MED, V48, P472, DOI 10.1016/j.amepre.2014.10.014; Meluch A. L., 2015, Journal of Communication in Healthcare, V8, P151, DOI 10.1179/1753807615Y.0000000010; Mullaney T, 2012, INT J DES, V6, P27; Patel Minal R, 2014, Ann Am Thorac Soc, V11, P1538, DOI 10.1513/AnnalsATS.201408-363OC; Piette JD, 2004, ARCH INTERN MED, V164, P1749, DOI 10.1001/archinte.164.16.1749; Right Place, 2017, RIGHT PLAC RIGHT TIM; Roberts JP, 2016, HEALTHCARE-J DEL SCI, V4, P11, DOI 10.1016/j.hjdsi.2015.12.002; Shih YCT, 2017, CANCER-AM CANCER SOC, V123, P928, DOI 10.1002/cncr.30423; Wollins DS, 2016, ONCOLOGIST, V21, P1157, DOI 10.1634/theoncologist.2016-0207; Zafar SY, 2015, AM J MANAG CARE, V21, P607	18	4	4	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 7	2019	170	9		S			S62	U98		10.7326/M18-2207	http://dx.doi.org/10.7326/M18-2207			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IB1GA	31060059				2023-01-03	WOS:000470011700006
J	Yoon, W; Ro, YS; Cho, SI				Yoon, Wonjeong; Ro, Young Sun; Cho, Sung-il			A mediation analysis of the effect of practical training on the relationship between demographic factors, and bystanders' self-efficacy in CPR performance	PLOS ONE			English	Article							HOSPITAL CARDIAC-ARREST; CARDIOPULMONARY-RESUSCITATION; WILLINGNESS; ASSOCIATION; MANAGEMENT; PROVISION; AWARENESS; SURVIVAL; OUTCOMES	This study examined the mediation effect of practical training on the relationship of demographic characteristics with bystander self-efficacy in cardiopulmonary resuscitation (CPR) performance. We used nationwide, cross-sectional data from the Korea Community Health Survey and analyzed 25,082 Korean adults who participated in CPR training within the last 2 years. A mediation model was applied to explore the pathway from demographic characteristics via CPR practical training to self-efficacy in CPR performance. A multiple logistic regression analysis was performed to examine each path in the mediation model. Of the 25,082 respondents recently trained, 19,168 (76.8%) practiced on a manikin. In the unadjusted CPR practical training model, the demographic characteristics associated with high self-efficacy in CPR performance were male gender (odds ratio [OR] = 2.54); 50s age group (OR = 1.30); college or more (OR = 1.39) and high school education (OR = 1.32); white collar (OR = 1.24) and soldier (OR = 2.98) occupational statuses. The characteristics associated with low self-efficacy were 30s age group (OR = 0.69) and capital (OR = 0.79) and metropolitan (OR = 0.84) areas of residence (p < 0.05). In the adjusted CPR practical training model, the significance of the relationship between demographics and self-efficacy in CPR performance decreased in male gender, 30s age group, college or more and high school education, and soldier occupational status (i.e., partial mediation), and disappeared in metropolitan residents (i.e., complete mediation). The degree of the mediating effect of CPR practical training on self-efficacy differed for each demographic characteristic. Thus, individualized educational strategies considering recipient demographics are needed for effective practice-based CPR training and improving bystander CPR performance.	[Yoon, Wonjeong] Seoul Natl Univ, Grad Sch Publ Hlth, Dept Publ Hlth Sci, Seoul, South Korea; [Ro, Young Sun] Seoul Natl Univ Hosp, Biomed Res Inst, Lab Emergency Med Serv, Seoul, South Korea; [Cho, Sung-il] Seoul Natl Univ, Grad Sch Publ Hlth, Dept Publ Hlth Sci, Seoul, South Korea; [Cho, Sung-il] Seoul Natl Univ, Inst Hlth & Environm, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University (SNU)	Cho, SI (corresponding author), Seoul Natl Univ, Grad Sch Publ Hlth, Dept Publ Hlth Sci, Seoul, South Korea.; Cho, SI (corresponding author), Seoul Natl Univ, Inst Hlth & Environm, Seoul, South Korea.	persontime@hotmail.com	Cho, Sung-il/D-5703-2012	Cho, Sung-il/0000-0003-4085-1494				Akhu-Zaheya LM, 2013, CLIN SIMUL NURS, V9, pE335, DOI 10.1016/j.ecns.2012.05.001; [Anonymous], 2011, DEV DISTR CPR GUID; [Anonymous], 2013, SUDD CARD ARR SURV; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Becker TK, 2017, AM J BIOETHICS, V17, P51, DOI 10.1080/15265161.2016.1265173; Bhanji F, 2015, CIRCULATION, V132, pS561, DOI 10.1161/CIR.0000000000000268; Bouland AJ, 2017, PREHOSP EMERG CARE, V21, P662, DOI 10.1080/10903127.2017.1308605; Bryan A, 2007, AIDS BEHAV, V11, P365, DOI 10.1007/s10461-006-9150-2; Coons SJ, 2009, RESUSCITATION, V80, P334, DOI 10.1016/j.resuscitation.2008.11.024; Dobbie F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193391; Fairchild AJ, 2009, PREV SCI, V10, P87, DOI 10.1007/s11121-008-0109-6; Jacobs LM, 2003, J TRAUMA, V55, P471, DOI 10.1097/01.TA.0000059445.84105.26; Johnston TC, 2003, RESUSCITATION, V56, P67, DOI 10.1016/S0300-9572(02)00277-0; Kang Yang Wha, 2015, Osong Public Health Res Perspect, V6, P211, DOI 10.1016/j.phrp.2015.05.003; Kenny D.A., 2013, RES NOTE; Kim YT, 2012, J KOREAN MED ASSOC, V55, P74, DOI 10.5124/jkma.2012.55.1.74; Lee MJ, 2013, RESUSCITATION, V84, P889, DOI 10.1016/j.resuscitation.2013.01.009; MACKINNON DP, 1993, EVALUATION REV, V17, P144, DOI 10.1177/0193841X9301700202; MacKinnon DP, 2002, DRUG ALCOHOL DEPEN, V68, pS69; Mitchell MJ, 2009, PREHOSP EMERG CARE, V13, P478, DOI 10.1080/10903120903144833; Moon SW, 2014, AM J EMERG MED, V32, P1041, DOI 10.1016/j.ajem.2014.06.019; Plotnikoff RC, 2010, HEALTH EDUC BEHAV, V37, P170, DOI 10.1177/1090198109332599; Ro YS, 2016, AM J EMERG MED, V34, P1331, DOI 10.1016/j.ajem.2015.12.001; Ro YS, 2016, RESUSCITATION, V102, P17, DOI 10.1016/j.resuscitation.2016.02.004; Ro YS, 2013, RESUSCITATION, V84, P547, DOI 10.1016/j.resuscitation.2012.12.020; Samawi H, 2018, J STAT COMPUT SIM, V88, P1211, DOI 10.1080/00949655.2018.1426762; Sipsma K, 2011, RESUSCITATION, V82, P564, DOI 10.1016/j.resuscitation.2010.12.007; Stigler MH, 2011, HEALTH EDUC BEHAV, V38, P231, DOI 10.1177/1090198110372330; Straney LD, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012434; Swor R, 2006, ACAD EMERG MED, V13, P596, DOI 10.1197/j.aem.2005.12.021; Turner NM, 2008, MED EDUC, V42, P503, DOI 10.1111/j.1365-2923.2007.02950.x; Uber A, 2017, ACAD EMERG MED, V24, P930, DOI 10.1111/acem.13222; VanderWeele TJ, 2010, AM J EPIDEMIOL, V172, P1339, DOI 10.1093/aje/kwq332; Wissenberg M, 2013, JAMA-J AM MED ASSOC, V310, P1377, DOI 10.1001/jama.2013.278483; Zhao XS, 2010, J CONSUM RES, V37, P197, DOI 10.1086/651257; 2015, RESUSCITATION SUPPLE, V88, P48, DOI DOI 10.1016/J.RESUSCITATION.2014.12.006; 2015, RESUSCITATION, V89, P58, DOI DOI 10.1016/J.RESUSCITATION.2015.01.008; 2017, CRITICAL CARE MED, V45, P1184, DOI DOI 10.1097/CCM.0000000000002375; RESUSCITATION, V44, P27, DOI DOI 10.1016/S0300-9572(99)00160-4	40	0	0	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2019	14	4							e0215432	10.1371/journal.pone.0215432	http://dx.doi.org/10.1371/journal.pone.0215432			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HV6ZL	31034486	Green Submitted, Green Published, gold			2023-01-03	WOS:000466131200014
J	Cheung-Flynn, J; Alvis, BD; Hocking, KM; Guth, CM; Luo, WF; McCallister, R; Chadalavada, K; Polcz, M; Komalavilas, P; Brophy, CM				Cheung-Flynn, Joyce; Alvis, Bret D.; Hocking, Kyle M.; Guth, Christy M.; Luo, Weifeng; McCallister, Reid; Chadalavada, Kalyan; Polcz, Monica; Komalavilas, Padmini; Brophy, Colleen M.			Normal Saline solutions cause endothelial dysfunction through loss of membrane integrity, ATP release, and inflammatory responses mediated by P2X7R/p38 MAPK/MK2 signaling pathways	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASE; P2X7 RECEPTOR; UP-REGULATION; INJURY; PHOSPHORYLATION; HEMORRHAGE; TRISTETRAPROLIN; INHIBITION; ANTAGONISM; APOPTOSIS	Resuscitation with 0.9% Normal Saline (NS), a non-buffered acidic solution, leads to increased morbidity and mortality in the critically ill. The goal of this study was to determine the molecular mechanisms of endothelial injury after exposure to NS. The hypothesis of this investigation is that exposure of endothelium to NS would lead to loss of cell membrane integrity, resulting in release of ATP, activation of the purinergic receptor (P2X7R), and subsequent activation of stress activated signaling pathways and inflammation. Human saphenous vein endothelial cells (HSVEC) incubated in NS, but not buffered electrolyte solution (Plasma-Lyte, PL), exhibited abnormal morphology and increased release of lactate dehydrogenase (LDH), adenosine triphosphate (ATP), and decreased transendothelial resistance (TEER), suggesting loss of membrane integrity. Incubation of intact rat aorta (RA) or human saphenous vein in NS but not PL led to impaired endothelial-dependent relaxation which was ameliorated by apyrase (hydrolyzes ATP) or SB203580 (p38 MAPK inhibitor). Exposure of HSVEC to NS but not PL led to activation of p38 MAPK and its downstream substrate, MAPKAP kinase 2 (MK2). Treatment of HSVEC with exogenous ATP led to interleukin 113 (IL-1 beta) release and increased vascular cell adhesion molecule (VCAM) expression. Treatment of RA with IL-1 beta led to impaired endothelial relaxation. IL-1 beta treatment of HSVEC led to increases in p38 MAPK and MK2 phosphorylation, and increased levels of arginase II. Incubation of porcine saphenous vein (PSV) in PL with pH adjusted to 6.0 or less also led to impaired endothelial function, suggesting that the acidic nature of NS is what contributes to endothelial dysfunction. Volume overload resuscitation in a porcine model after hemorrhage with NS, but not PL, led to acidosis and impaired endothelial function. These data suggest that endothelial dysfunction caused by exposure to acidic, non-buffered NS is associated with loss of membrane integrity, release of ATP, and is modulated by P2X7R-mediated inflammatory responses.	[Cheung-Flynn, Joyce; Hocking, Kyle M.; Guth, Christy M.; Luo, Weifeng; McCallister, Reid; Chadalavada, Kalyan; Polcz, Monica; Komalavilas, Padmini; Brophy, Colleen M.] Vanderbilt Univ, Dept Surg, Med Ctr, Nashville, TN 37240 USA; [Alvis, Bret D.] Vanderbilt Univ, Dept Anesthesiol, Med Ctr, Nashville, TN USA; [Komalavilas, Padmini; Brophy, Colleen M.] VA Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Komalavilas, P (corresponding author), Vanderbilt Univ, Dept Surg, Med Ctr, Nashville, TN 37240 USA.; Komalavilas, P (corresponding author), VA Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA.	padmini.komalavilas@vumc.org			National Institute of Health [R01HL70715, R01HL105731-01]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070715] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This material is based upon work supported by National Institute of Health grants R01HL70715 to CMB and R01HL105731-01 to JCF. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ayee MAA, 2017, BIOPHYS J, V112, P325, DOI 10.1016/j.bpj.2016.12.002; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Chen S, 2013, CRIT CARE MED, V41, pE466, DOI 10.1097/CCM.0b013e31829a8246; CHESTER AH, 1993, EUR J CARDIO-THORAC, V7, P399, DOI 10.1016/1010-7940(93)90002-S; Chrestensen CA, 2004, J BIOL CHEM, V279, P10176, DOI 10.1074/jbc.M310486200; Crimi E, 2012, J CRIT CARE, V27, P108, DOI 10.1016/j.jcrc.2011.06.001; Davies M G, 1994, Ann Vasc Surg, V8, P150, DOI 10.1007/BF02018863; de Vries MR, 2018, FRONT CARDIOVASC MED, V5, DOI 10.3389/fcvm.2018.00003; Donnelly-Roberts DL, 2004, J PHARMACOL EXP THER, V308, P1053, DOI 10.1124/jpet.103.059600; Dubyak GR, 2002, AM J PHYSIOL-CELL PH, V282, pC242, DOI 10.1152/ajpcell.00522.2001; Feng L, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0409-2; Ferrari D, 1997, J IMMUNOL, V159, P1451; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; Gorska MM, 2007, J EXP MED, V204, P1637, DOI 10.1084/jem.20062621; Harskamp RE, 2014, JAMA SURG, V149, P798, DOI 10.1001/jamasurg.2014.87; Heming N, 2018, ANESTHESIOLOGY, V129, P1149, DOI 10.1097/ALN.0000000000002413; Hocking KM, 2016, SHOCK, V46, P447, DOI 10.1097/SHK.0000000000000615; Honore P, 2006, J PHARMACOL EXP THER, V319, P1376, DOI 10.1124/jpet.106.111559; Huang CS, 2014, MOL MED REP, V9, P57, DOI 10.3892/mmr.2013.1807; Jespersen Brian, 2015, J Vis Exp, P52324, DOI 10.3791/52324; Komalavilas P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188069; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Liang LH, 2005, AM J PHYSIOL-CELL PH, V289, pC388, DOI 10.1152/ajpcell.00491.2004; Luo WF, 2017, PURINERG SIGNAL, V13, P579, DOI 10.1007/s11302-017-9585-0; Michel AD, 2001, BRIT J PHARMACOL, V132, P1501, DOI 10.1038/sj.bjp.0703968; Papp L, 2007, BIOCHEM BIOPH RES CO, V355, P568, DOI 10.1016/j.bbrc.2007.02.014; Pernow J, 2015, BRIT J PHARMACOL, V172, P4684, DOI 10.1111/bph.13242; Reddi BAJ, 2013, INT J MED SCI, V10, P747, DOI 10.7150/ijms.5868; Ronkina N, 2010, BIOCHEM PHARMACOL, V80, P1915, DOI 10.1016/j.bcp.2010.06.021; Rousseau S, 2002, EMBO J, V21, P6505, DOI 10.1093/emboj/cdf639; Santos HAF, 2015, J CHEM THEORY COMPUT, V11, P5973, DOI 10.1021/acs.jctc.5b00956; Semler MW, 2018, NEW ENGL J MED, V378, P829, DOI 10.1056/NEJMoa1711584; Shatanawi A, 2015, EUR J PHARMACOL, V746, P106, DOI 10.1016/j.ejphar.2014.10.042; Stoecklin G, 2004, EMBO J, V23, P1313, DOI 10.1038/sj.emboj.7600163; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Wilbring M, 2011, EUR J CARDIO-THORAC, V40, P811, DOI 10.1016/j.ejcts.2011.01.024; Wise ES, 2015, SURGERY, V158, P537, DOI 10.1016/j.surg.2015.03.036; Yan YL, 2015, AM J PHYSIOL-CELL PH, V308, pC463, DOI 10.1152/ajpcell.00245.2014; Yu Y, 2009, NEUROREPORT, V20, P393, DOI 10.1097/WNR.0b013e328324ede7; Zamaraeva MV, 2005, CELL DEATH DIFFER, V12, P1390, DOI 10.1038/sj.cdd.4401661; Zeiser R, 2011, J MOL MED, V89, P833, DOI 10.1007/s00109-011-0767-x	41	8	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2019	14	8							e0220893	10.1371/journal.pone.0220893	http://dx.doi.org/10.1371/journal.pone.0220893			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5IT	31412063	Green Published, Green Submitted, gold			2023-01-03	WOS:000485012600040
J	Widmark, A; Gunnlaugsson, A; Beckman, L; Thellenberg-Karlsson, C; Hoyer, M; Lagerlund, M; Kindblom, J; Ginman, C; Johansson, B; Bjornlinger, K; Seke, M; Agrup, M; Fransson, P; Tavelin, B; Norman, D; Zackrisson, B; Anderson, H; Kjellen, E; Franzen, L; Nilsson, P				Widmark, Anders; Gunnlaugsson, Adalsteinn; Beckman, Lars; Thellenberg-Karlsson, Camilla; Hoyer, Morten; Lagerlund, Magnus; Kindblom, Jon; Ginman, Claes; Johansson, Bengt; Bjornlinger, Kirsten; Seke, Mihajl; Agrup, Mans; Fransson, Per; Tavelin, Bjorn; Norman, David; Zackrisson, Bjorn; Anderson, Harald; Kjellen, Elisabeth; Franzen, Lars; Nilsson, Per			Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial	LANCET			English	Article							QUALITY-OF-LIFE; RADIATION-THERAPY; MEN	Background Hypofractionated radiotherapy for prostate cancer has gained increased attention due to its proposed high radiation-fraction sensitivity. Recent reports from studies comparing moderately hypofractionated and conventionally fractionated radiotherapy support the clinical use of moderate hypofractionation. To date, there are no published randomised studies on ultra-hypofractionated radiotherapy. Here, we report the outcomes of the Scandinavian HYPO-RTPC phase 3 trial with the aim to show non-inferiority of ultra-hypofractionation compared with conventional fractionation. Methods In this open-label, randomised, phase 3 non-inferiority trial done in 12 centres in Sweden and Denmark, we recruited men up to 75 years of age with intermediate-to-high-risk prostate cancer and a WHO performance status between 0 and 2. Patients were randomly assigned to ultra-hypofractionation (42.7 Gy in seven fractions, 3 days per week for 2.5 weeks) or conventional fractionated radiotherapy (78.0 Gy in 39 fractions, 5 days per week for 8 weeks). No androgen deprivation therapy was allowed. The primary endpoint was time to biochemical or clinical failure, analysed in the per-protocol population. The prespecified non-inferiority margin was 4% at 5 years, corresponding to a critical hazard ratio (HR) limit of 1.338. Physician-recorded toxicity was measured according to the Radiation Therapy Oncology Group (RTOG) morbidity scale and patient-reported outcome measurements with the Prostate Cancer Symptom Scale (PCSS) questionnaire. This trial is registered with the ISRCTN registry, number ISRCTN45905321. Findings Between July 1, 2005, and Nov 4, 2015, 1200 patients were randomly assigned to conventional fractionation (n=602) or ultra-hypofractionation (n=598), of whom 1180 (591 conventional fractionation and 589 ultra-hypofractionation) constituted the per-protocol population. 1054 (89%) participants were intermediate risk and 126 (11%) were high risk. Median follow-up time was 5.0 years (IQR 3.1-7.0). The estimated failure-free survival at 5 years was 84% (95% CI 80-87) in both treatment groups, with an adjusted HR of 1.002 (95% CI 0.758-1.325; log-rank p=0.99). There was weak evidence of an increased frequency of acute physician-reported RTOG grade 2 or worse urinary toxicity in the ultra-hypofractionation group at end of radiotherapy (158 [28%] of 569 patients vs 132 [23%] of 578 patients; p=0.057). There were no significant differences in grade 2 or worse urinary or bowel late toxicity between the two treatment groups at any point after radiotherapy, except for an increase in urinary toxicity in the ultra-hypofractionation group compared to the conventional fractionation group at 1-year follow-up (32 [6%] of 528 patients vs 13 [2%] of 529 patients; (p=0.0037). We observed no differences between groups in frequencies at 5 years of RTOG grade 2 or worse urinary toxicity (11 [5%] of 243 patients for the ultra-hypofractionation group vs 12 [5%] of 249 for the conventional fractionation group; p=1.00) and bowel toxicity (three [1%] of 244 patients vs nine [4%] of 249 patients; p=0.14). Patient-reported outcomes revealed significantly higher levels of acute urinary and bowel symptoms in the ultra-hypofractionation group compared with the conventional fractionation group but no significant increases in late symptoms were found, except for increased urinary symptoms at 1-year follow-up, consistent with the physician-evaluated toxicity. Interpretation Ultra-hypofractionated radiotherapy is non-inferior to conventionally fractionated radiotherapy for intermediate-to-high risk prostate cancer regarding failure-free survival. Early side-effects are more pronounced with ultra-hypofractionation compared with conventional fractionation whereas late toxicity is similar in both treatment groups. The results support the use of ultra-hypofractionation for radiotherapy of prostate cancer. Copyright (C) 2019 Elsevier Ltd. All rights reserved.	[Widmark, Anders; Thellenberg-Karlsson, Camilla; Tavelin, Bjorn; Norman, David; Zackrisson, Bjorn; Franzen, Lars] Umea Univ, Dept Radiat Sci, Oncol, SE-90185 Umea, Sweden; [Fransson, Per] Umea Univ, Dept Nursing, Umea, Sweden; [Gunnlaugsson, Adalsteinn; Kjellen, Elisabeth; Nilsson, Per] Lund Univ, Skane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Lund, Sweden; [Anderson, Harald] Lund Univ, Dept Clin Sci Lund, Canc Epidemiol, Lund, Sweden; [Beckman, Lars] Sundsvall Hosp, Dept Oncol, Sundsvall, Sweden; [Hoyer, Morten] Aarhus Univ Hosp, Dept Oncol, Aarhus, Denmark; [Hoyer, Morten] Aarhus Univ Hosp, Danish Ctr Particle Therapy, Aarhus, Denmark; [Lagerlund, Magnus] Kalmar Hosp, Dept Oncol, Kalmar, Sweden; [Kindblom, Jon] Univ Gothenburg, Inst Clin Sci, Dept Oncol, Sahlgrenska Acad, Gothenburg, Sweden; [Ginman, Claes] Karlstad Cent Hosp, Dept Oncol, Karlstad, Sweden; [Johansson, Bengt] Orebro Univ, Orebro Univ Hosp, Dept Oncol, Orebro, Sweden; [Bjornlinger, Kirsten] Ryhov Hosp, Dept Oncol, Jonkoping, Sweden; [Seke, Mihajl] Cent Lasarettet, Dept Oncol, Vaxjo, Sweden; [Agrup, Mans] Linkoping Univ Hosp, Dept Oncol, Linkoping, Sweden	Umea University; Umea University; Lund University; Skane University Hospital; Lund University; Aarhus University; Aarhus University; University of Gothenburg; Orebro University; Linkoping University	Widmark, A (corresponding author), Umea Univ, Dept Radiat Sci, Oncol, SE-90185 Umea, Sweden.	anders.widmark@onkologi.umu.se	Fransson, Per/AAD-8906-2020; Gunnlaugsson, Adalsteinn/GSM-6999-2022; Johansson, Bengt/AAW-7862-2021; Høyer, Morten/AAT-7058-2021; Johansson, Bengt/AFT-7869-2022; Nilsson, Per/AAP-4057-2020	Fransson, Per/0000-0002-1248-5581; Høyer, Morten/0000-0001-8609-0008; Johansson, Bengt/0000-0002-0163-5062; Nilsson, Per/0000-0002-7983-9778	Nordic Cancer Union; Swedish Cancer Society; Swedish Research Council	Nordic Cancer Union; Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission)	The Nordic Cancer Union, the Swedish Cancer Society, and the Swedish Research Council.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Bergstrom P, 1998, INT J RADIAT ONCOL, V42, P305, DOI 10.1016/S0360-3016(98)00229-6; Brenner DJ, 2004, INT J RADIAT ONCOL, V60, P1013, DOI 10.1016/j.ijrobp.2004.04.014; Catton CN, 2017, J CLIN ONCOL, V35, P1884, DOI 10.1200/JCO.2016.71.7397; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; Dasu A, 2012, ACTA ONCOL, V51, P963, DOI 10.3109/0284186X.2012.719635; Dearnaley D, 2016, LANCET ONCOL, V17, P1047, DOI 10.1016/S1470-2045(16)30102-4; Ferlay J, 2018, EUR J CANCER, V103, P356, DOI 10.1016/j.ejca.2018.07.005; Fransson P, 2001, SUPPORT CARE CANCER, V9, P187; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; Hamoen EHJ, 2015, UROL ONCOL-SEMIN ORI, V33, DOI 10.1016/j.urolonc.2013.10.005; Incrocci L, 2016, LANCET ONCOL, V17, P1061, DOI 10.1016/S1470-2045(16)30070-5; Katz AJ, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00301; King CR, 2013, RADIOTHER ONCOL, V109, P217, DOI 10.1016/j.radonc.2013.08.030; King CR, 2012, INT J RADIAT ONCOL, V82, P877, DOI 10.1016/j.ijrobp.2010.11.054; Lee WR, 2016, J CLIN ONCOL, V34, P2325, DOI 10.1200/JCO.2016.67.0448; Loblaw A, 2017, CLIN ONCOL-UK, V29, P161, DOI 10.1016/j.clon.2016.10.001; McMahon SJ, 2018, PHYS MED BIOL, V63, DOI 10.1088/1361-6560/aae8a5; Morgan SC, 2018, J CLIN ONCOL, V36, P3411, DOI 10.1200/JCO.18.01097; Musunuru HB, 2016, RADIOTHER ONCOL, V118, P112, DOI 10.1016/j.radonc.2015.12.020; Reidunsdatter RJ, 2010, INT J RADIAT ONCOL, V77, P793, DOI 10.1016/j.ijrobp.2009.05.057; Roach M, 2006, INT J RADIAT ONCOL, V65, P965, DOI 10.1016/j.ijrobp.2006.04.029; Rosen RC, 1999, INT J IMPOT RES, V11, P319, DOI 10.1038/sj.ijir.3900472; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Vogelius IR, 2018, INT J RADIAT ONCOL, V100, P858, DOI 10.1016/j.ijrobp.2017.12.011; Zietman AL, 2016, J CLIN ONCOL, V34, P2323, DOI 10.1200/JCO.2016.67.3764	26	342	344	0	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 3	2019	394	10196					385	395		10.1016/S0140-6736(19)31131-6	http://dx.doi.org/10.1016/S0140-6736(19)31131-6			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IN5EI	31227373				2023-01-03	WOS:000478698300023
J	Jencks, SF; Schuster, A; Dougherty, GB; Gerovich, S; Brock, JE; Kind, AJH				Jencks, Stephen F.; Schuster, Alyson; Dougherty, Geoff B.; Gerovich, Sule; Brock, Jane E.; Kind, Amy J. H.			Safety-Net Hospitals, Neighborhood Disadvantage, and Readmissions Under Maryland's All-Payer Program An Observational Study	ANNALS OF INTERNAL MEDICINE			English	Article							SOCIOECONOMIC-STATUS; AREA DEPRIVATION; INEQUALITIES; PERFORMANCE; MORTALITY; BUDGETS; LEVEL	Background: Safety-net hospitals have higher-than-expected readmission rates. The relative roles of the mean disadvantage of neighborhoods the hospitals serve and the disadvantage of individual patients in predicting a patient's readmission are unclear. Objective: To examine the independent contributions of the patient's neighborhood and the hospital's service area to risk for 30-day readmission. Design: Retrospective observational study. Setting: Maryland. Participants: All Maryland residents discharged from a Maryland hospital in 2015. Measurements: Predictors included the disadvantage of neighborhoods for each Maryland resident (area disadvantage index) and the mean disadvantage of each hospital's discharged patients (safety-net index). The primary outcome was unplanned 30-day hospital readmission. Generalized estimating equations and marginal modeling were used to estimate readmission rates. Results were adjusted for clinical readmission risk. Results: 13.4% of discharged patients were readmitted within 30 days. Patients living in neighborhoods at the 90th percentile of disadvantage had a readmission rate of 14.1% (95% CI, 13.6% to 14.5%) compared with 12.5% (CI, 11.8% to 13.2%) for similar patients living in neighborhoods at the 10th percentile. Patients discharged from hospitals at the 90th percentile of safety-net status had a readmission rate of 14.8% (CI, 13.4% to 16.1%) compared with 11.6% (CI, 10.5% to 12.7%) for similar patients discharged from hospitals at the 10th percentile of safety-net status. The association of readmission risk with the hospital's safety-net index was approximately twice the observed association with the patient's neighborhood disadvantage status. Limitations: Generalizability outside Maryland is unknown. Confounding may be present. Conclusion: In Maryland, residing in a disadvantaged neighborhood and being discharged from a hospital serving a large proportion of disadvantaged neighborhoods are independently associated with increased risk for readmission. Primary Funding Source: National Institute on Minority Health and Health Disparities and Maryland Health Services Cost Review Commission.	[Schuster, Alyson; Dougherty, Geoff B.] Maryland Hlth Serv Cost Review Commiss, 4160 Patterson Ave, Baltimore, MD 21215 USA; [Gerovich, Sule] Math Policy Res, 7102 Ambassador Rd,Suite 100, Woodlawn, MD 21244 USA; [Brock, Jane E.] Telligen Colorado, Greenwood Village, CO USA; [Kind, Amy J. H.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA; [Kind, Amy J. H.] US Dept Vet Affairs, William S Middleton Hosp, GRECC, Madison, WI USA; [Jencks, Stephen F.] 8 Midvale Rd, Baltimore, MD 21210 USA; [Brock, Jane E.] Telligen, 7730 East Belleview Ave,Suite 300, Greenwood Village, CO 80111 USA; [Kind, Amy J. H.] William S Middleton Hosp, GRECC, 2500 Overlook Terrace, Madison, WI 53705 USA	Mathematica; University of Wisconsin System; University of Wisconsin Madison; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Geriatric Research Education & Clinical Center	Jencks, SF (corresponding author), 8 Midvale Rd, Baltimore, MD 21210 USA.	steve.jencks@comcast.net; alyson.schuster@maryland.gov		Kind, Amy/0000-0002-7183-610X	National Institute on Minority Health and Health Disparities of the National Institutes of Health [R01MD010243]; William S. Middleton Memorial Veterans Hospital Geriatric Research, Education and Clinical Center in Madison, Wisconsin (GRECC) [2016-010]; University of Wisconsin Department of Medicine; National Institute on Minority Health and Health Disparities [R01MD010243] Funding Source: NIH RePORTER	National Institute on Minority Health and Health Disparities of the National Institutes of Health; William S. Middleton Memorial Veterans Hospital Geriatric Research, Education and Clinical Center in Madison, Wisconsin (GRECC); University of Wisconsin Department of Medicine; National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	This project was supported by a National Institute on Minority Health and Health Disparities of the National Institutes of Health Award (R01MD010243 [principal investigator, Dr. Kind]. Drs. Jencks and Brock did not receive support for this work. Drs. Schuster, Dougherty, and Gerovich were employed by the MHSCRC. This material is the result of work also supported with resources and the use of facilities at the William S. Middleton Memorial Veterans Hospital Geriatric Research, Education and Clinical Center in Madison, Wisconsin (GRECC-Manuscript 2016-010), and the University of Wisconsin Department of Medicine.	3M Health Information Systems, 2012, APR DRG SOFTW; Arbaje AI, 2008, GERONTOLOGIST, V48, P495, DOI 10.1093/geront/48.4.495; Assistant Secretary for Planning and Evaluation, 2016, REP C SOC RISK FACT; Averill R, 2012, ALL PATIENT REFINED; Barnett ML, 2015, JAMA INTERN MED, V175, P1803, DOI 10.1001/jamainternmed.2015.4660; Begg MD, 2003, STAT MED, V22, P2591, DOI 10.1002/sim.1524; Bernheim SM, 2016, HEALTH AFFAIR, V35, P1461, DOI 10.1377/hlthaff.2015.0394; Boccuti C, 2017, AIMING FEWER HOSP U; Chetty R, 2018, Q J ECON, V133, P1163, DOI 10.1093/qje/qjy006; Chokshi DA, 2016, NEW ENGL J MED, V375, P1790, DOI 10.1056/NEJMhpr1608578; Department of Health and Human Services Centers for Medicare & Medicaid Services, 2018, FED REGISTER, V83, P41147; Enders CK, 2007, PSYCHOL METHODS, V12, P121, DOI 10.1037/1082-989X.12.2.121; Gilman M, 2015, HEALTH AFFAIR, V34, P398, DOI 10.1377/hlthaff.2014.1059; Hajat A, 2013, ENVIRON HEALTH PERSP, V121, P1325, DOI 10.1289/ehp.1206337; Horwitz LI, 2014, ANN INTERN MED, V161, pS66, DOI 10.7326/M13-3000; Hu JH, 2018, AM J MED QUAL, V33, P493, DOI 10.1177/1062860617753063; Institute of Medicine and National Research Council, 2009, THE PUBLIC HEALTH EF; Kansagara D, 2016, J HOSP MED, V11, P221, DOI 10.1002/jhm.2502; Kind AJH, 2018, NEW ENGL J MED, V378, P2456, DOI 10.1056/NEJMp1802313; Kind AJH, 2014, ANN INTERN MED, V161, P765, DOI 10.7326/M13-2946; Krumholz HM, 2014, ANN INTERN MED, V161, P833, DOI 10.7326/M14-2308; Kwan LY, 2017, ACCOUNTING SOCIAL RI; LaVeist T, 2011, HEALTH AFFAIR, V30, P1880, DOI 10.1377/hlthaff.2011.0640; Ludwig J, 2012, SCIENCE, V337, P1505, DOI 10.1126/science.1224648; Ludwig J, 2011, NEW ENGL J MED, V365, P1509, DOI 10.1056/NEJMsa1103216; Patel A, 2015, NEW ENGL J MED, V373, P1899, DOI 10.1056/NEJMp1508037; Phillips RL, 2016, HEALTH AFFAIR, V35, P1991, DOI 10.1377/hlthaff.2016.0709; Posey, 2016, HOUSEHOLD INCOME 201; Rajkumar R, 2014, NEW ENGL J MED, V370, P493, DOI 10.1056/NEJMp1314868; Roberts ET, 2018, JAMA INTERN MED, V178, P260, DOI 10.1001/jamainternmed.2017.7455; Rogan E., 2016, INVESTING SOCIAL SER; Sampson RJ, 2012, SCIENCE, V337, P1464, DOI 10.1126/science.1227881; Singh GK, 2003, AM J PUBLIC HEALTH, V93, P1137, DOI 10.2105/AJPH.93.7.1137; Singh GK, 2002, INT J EPIDEMIOL, V31, P600, DOI 10.1093/ije/31.3.600; Soobader MJ, 2001, AM J PUBLIC HEALTH, V91, P632, DOI 10.2105/AJPH.91.4.632; Taylor LA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160217; The Maryland Health Services Cost Review Commission, 2015, MAR HOSP AUD FIN STA; U.S. Department of Housing and Urban Development, 2018, NEIGHB VIOL CRIM; United States Census Bureau, 2018, QUICKFACTS BALT CIT; VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607; Yelland LN, 2011, AM J EPIDEMIOL, V174, P984, DOI 10.1093/aje/kwr183; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	42	36	36	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 16	2019	171	2					91	+		10.7326/M16-2671	http://dx.doi.org/10.7326/M16-2671			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	II8YC	31261378	Green Accepted			2023-01-03	WOS:000475478700015
J	Richardson, CR; Franklin, B; Moy, ML; Jackson, EA				Richardson, Caroline R.; Franklin, Barry; Moy, Marilyn L.; Jackson, Elizabeth A.			Advances in rehabilitation for chronic diseases: improving health outcomes and function	BMJ-BRITISH MEDICAL JOURNAL			English	Review							OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-LIFE; NEUROMUSCULAR ELECTRICAL-STIMULATION; RESPIRATORY SOCIETY STATEMENT; RANDOMIZED CONTROLLED-TRIAL; HOME-BASED REHABILITATION; DAILY PHYSICAL-ACTIVITY; HEART-FAILURE PATIENTS; ALL-CAUSE MORTALITY; CARDIAC REHABILITATION	Much of the burden on healthcare systems is related to the management of chronic conditions such as cardiovascular disease and chronic obstructive pulmonary disease. Although conventional outpatient cardiopulmonary rehabilitation programs significantly decrease morbidity and mortality and improve function and health related quality of life for people with chronic diseases, rehabilitation programs are underused. Barriers to enrollment are multifactorial and include failure to recommend and refer patients to these services; poor communication with patients about potential benefits; and patient factors including logistical and financial barriers, comorbidities, and competing demands that make participation in facility based programs difficult. Recent advances in rehabilitation programs that involve remotely delivered technology could help deliver services to more people who might benefit. Problems with intensity, adherence, and safety of home based programs have been investigated in recent clinical trials, and larger dissemination and implementation trials are under way. This review summarizes the evidence for benefit of in-person cardiac and pulmonary rehabilitation programs. It also reviews the literature on newer developments, such as home based remotely mediated exercise programs developed to decrease cost and improve accessibility, high intensity interval training in cardiac rehabilitation, and alternative therapies such as tai chi and yoga for people with chronic obstructive pulmonary disease.	[Richardson, Caroline R.] Univ Michigan, Dept Family Med, Ann Arbor, MI 48104 USA; [Franklin, Barry] Oakland Univ William Beaumont, Sch Med, Rochester, MI USA; [Moy, Marilyn L.] Harvard Med Sch, Boston, MA 02115 USA; [Jackson, Elizabeth A.] Univ Alabama Birmingham, Birmingham, AL USA	University of Michigan System; University of Michigan; Oakland University; Harvard University; Harvard Medical School; University of Alabama System; University of Alabama Birmingham	Richardson, CR (corresponding author), Univ Michigan, Dept Family Med, Ann Arbor, MI 48104 USA.	caroli@umich.edu		Richardson, Caroline/0000-0002-1945-6046				ADES PA, 1992, ARCH INTERN MED, V152, P1033, DOI 10.1001/archinte.152.5.1033; Alonso J, 2004, QUAL LIFE RES, V13, P283, DOI 10.1023/B:QURE.0000018472.46236.05; Balady GJ, 2011, CIRCULATION, V124, P2951, DOI 10.1161/CIR.0b013e31823b21e2; Beatty AL, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000568; Bjarnason-Wehrens B, 2010, EUR J CARDIOV PREV R, V17, P410, DOI [DOI 10.1097/HJR.0b013e328334f42d, 10.1097/HJR.0b013e328334f42d]; Bolton CE, 2013, THORAX, V68, pii1, DOI 10.1136/thoraxjnl-2013-203808; Casaburi Richard, 2011, Proc Am Thorac Soc, V8, P334, DOI 10.1513/pats.201101-001RM; Chen RC, 2016, INT J CHRONIC OBSTR, V11, P2965, DOI 10.2147/COPD.S120555; Cornelissen VA, 2017, EUR J PREV CARDIOL, V24, P1692, DOI 10.1177/2047487317734051; Dankner R, 2015, EUR J PREV CARDIOL, V22, P1121, DOI 10.1177/2047487314548815; Demeyer H, 2017, THORAX, V72, P415, DOI 10.1136/thoraxjnl-2016-209026; Demeyer H, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.02110-2017; Dibben GO, 2018, HEART, V104, P1394, DOI 10.1136/heartjnl-2017-312832; Dieleman JL, 2016, JAMA-J AM MED ASSOC, V316, P2627, DOI 10.1001/jama.2016.16885; Ding M, 2014, J ALTERN COMPLEM MED, V20, P79, DOI 10.1089/acm.2013.0087; Divo M, 2012, AM J RESP CRIT CARE, V186, P155, DOI 10.1164/rccm.201201-0034OC; Dunlay SM, 2014, AM J MED, V127, P538, DOI 10.1016/j.amjmed.2014.02.008; Egan C, 2012, RESP MED, V106, P1671, DOI 10.1016/j.rmed.2012.08.016; Eisner MD, 2008, AM J MED, V121, P789, DOI 10.1016/j.amjmed.2008.04.030; Englesbe MJ, 2015, ANN SURG, V262, P901, DOI 10.1097/SLA.0000000000001250; Fei Y, 2018, INT J CARDIOL, V254, P291, DOI 10.1016/j.ijcard.2017.12.039; Fischer MJ, 2007, CLIN REHABIL, V21, P212, DOI 10.1177/0269215506070783; Fletcher CM, 1960, BMJ-BRIT MED J, V2, P1662; Garcia-Aymerich J, 2006, THORAX, V61, P772, DOI 10.1136/thx.2006.060145; Gea J, 2015, J THORAC DIS, V7, pE418, DOI 10.3978/j.issn.2072-1439.2015.08.04; Gershon AS, 2018, CHEST, V153, P1336, DOI 10.1016/j.chest.2018.01.038; Grace SL, 2011, ARCH INTERN MED, V171, P235, DOI 10.1001/archinternmed.2010.501; Heppner Pia Santiago, 2006, J Cardiopulm Rehabil, V26, P44, DOI 10.1097/00008483-200601000-00010; Heran BS, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001800.pub3, 10.1002/14651858.CD001800.pub2]; Holland AE, 2017, THORAX, V72, P57, DOI 10.1136/thoraxjnl-2016-208514; Horton EJ, 2018, THORAX, V73, P29, DOI 10.1136/thoraxjnl-2016-208506; Houchen-Wolloff L, 2018, INT J CHRONIC OBSTR, V13, P37, DOI 10.2147/COPD.S143101; Hughes JR, 2010, AM J PREV MED, V39, P285, DOI 10.1016/j.amepre.2010.05.002; Jenkins AR, 2018, INT J CHRONIC OBSTR, V13, P257, DOI 10.2147/COPD.S150650; Jones SE, 2018, J THORAC DIS, V10, pS1390, DOI 10.21037/jtd.2018.03.18; Kaltsakas G, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.congress-2018.PA3652; Khakban A, 2017, AM J RESP CRIT CARE, V195, P287, DOI 10.1164/rccm.201606-1162PP; Kontis V, 2015, LANCET GLOB HEALTH, V3, pE746, DOI 10.1016/S2214-109X(15)00179-5; Kosacz Nicole M., 2012, Morbidity and Mortality Weekly Report, V61, P938; Kumar AM, 2018, CONTEMP CLIN TRIALS, V67, P23, DOI 10.1016/j.cct.2017.12.009; Lan C, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/502131; Lan Ching, 2008, V52, P12, DOI 10.1159/000134225; Lee AL, 2014, INT J CHRONIC OBSTR, V9, P1275, DOI 10.2147/COPD.S54925; Leung RWM, 2013, EUR RESPIR J, V41, P1051, DOI 10.1183/09031936.00036912; Li CY, 2018, COMPLEMENT THER CLIN, V30, P33, DOI 10.1016/j.ctcp.2017.11.006; Maddison R, 2015, EUR J PREV CARDIOL, V22, P701, DOI 10.1177/2047487314535076; Maltais F, 2008, ANN INTERN MED, V149, P869, DOI 10.7326/0003-4819-149-12-200812160-00006; Marmelo F, 2018, EUR J PREV CARDIOL, V25, P404, DOI 10.1177/2047487317752373; Martin LG, 2014, DISABIL HEALTH J, V7, pS4, DOI 10.1016/j.dhjo.2013.06.007; Marvasti FF, 2012, NEW ENGL J MED, V367, P889, DOI 10.1056/NEJMp1206230; McCarthy B, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003793.pub3; Mcvay G, 2017, EUR RESPIR J, V50, DOI 10.1183/1393003.congress-2017.PA3714; Melzer AC, 2018, ANN AM THORAC SOC, V15, P341, DOI 10.1513/AnnalsATS.201707-582OC; Mendoza L, 2015, EUR RESPIR J, V45, P347, DOI 10.1183/09031936.00084514; Mezzani A, 2013, EUR J PREV CARDIOL, V20, P442, DOI 10.1177/2047487312460484; Milewski K, 2018, CARDIOL J, DOI [10.5603/CJ.a2018.01, DOI 10.5603/CJ.A2018.01]; Milner SC, 2018, RESP MED, V137, P103, DOI 10.1016/j.rmed.2018.02.021; Moore E, 2016, CHEST, V150, P837, DOI 10.1016/j.chest.2016.05.038; Moy Marilyn L, 2016, ERJ Open Res, V2; Moy ML, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5622; Moy ML, 2015, CONTEMP CLIN TRIALS, V45, P458, DOI 10.1016/j.cct.2015.09.004; Moy ML, 2015, CHEST, V148, P128, DOI 10.1378/chest.14-1466; Moy ML, 2014, CHEST, V145, P542, DOI 10.1378/chest.13-1052; Moy ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060400; Mozaffarian D, 2008, CIRCULATION, V117, P3031, DOI 10.1161/CIRCULATIONAHA.107.738732; Ng LWC, 2012, CHRON RESP DIS, V9, P17, DOI 10.1177/1479972311430335; Ngai SPC, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009953.pub2; Nguyen HQ, 2015, RESP MED, V109, P238, DOI 10.1016/j.rmed.2014.12.004; Niebauer J, 2016, CIRCULATION, V133, P2529, DOI 10.1161/CIRCULATIONAHA.116.021348; Nilsson BB, 2019, DISABIL REHABIL, V41, P481, DOI 10.1080/09638288.2017.1397776; Nishi SPE, 2016, J CARDIOPULM REHABIL, V36, P375, DOI 10.1097/HCR.0000000000000194; Pan L, 2014, RESPIROLOGY, V19, P22, DOI 10.1111/resp.12200; Papp ME, 2017, EUR J PHYS REHAB MED, V53, P447, DOI 10.23736/S1973-9087.16.04374-4; Peters AE, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007664; Piepoli MF, 2014, EUR J PREV CARDIOL, V21, P664, DOI 10.1177/2047487312449597; Piepoli MF, 2010, EUR J CARDIOV PREV R, V17, P1, DOI 10.1097/HJR.0b013e3283313592; Pio CSD, 2017, MAYO CLIN PROC, V92, P1644, DOI 10.1016/j.mayocp.2017.07.019; Pitsavos C, 2008, J AM COLL CARDIOL, V51, P2034, DOI 10.1016/j.jacc.2008.01.053; Pitta F, 2005, AM J RESP CRIT CARE, V171, P972, DOI 10.1164/rccm.200407-855OC; Pleguezuelos E, 2016, LUNG, V194, P249, DOI 10.1007/s00408-015-9838-z; Polkey MI, 2018, CHEST, V153, P1116, DOI 10.1016/j.chest.2018.01.053; Price KJ, 2016, EUR J PREV CARDIOL, V23, P1715, DOI 10.1177/2047487316657669; Puhan MA, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005305.pub4; Ramon MA, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00079-2018; Reeves GR, 2017, JACC-HEART FAIL, V5, P359, DOI 10.1016/j.jchf.2016.12.019; Reeves GR, 2017, AM HEART J, V185, P130, DOI 10.1016/j.ahj.2016.12.012; Reid RD, 2012, EUR J PREV CARDIOL, V19, P1357, DOI 10.1177/1741826711422988; Richards SH, 2018, EUR J PREV CARDIOL, V25, P247, DOI 10.1177/2047487317739978; Ries AL, 2003, AM J RESP CRIT CARE, V167, P880, DOI 10.1164/rccm.200204-318OC; Riley DL, 2009, CAN J CARDIOL, V25, P187, DOI DOI 10.1016/; Ringbaek T, 2010, J CARDIOPULM REHABIL, V30, P47, DOI 10.1097/HCR.0b013e3181c9c985; Rochester CL, 2015, AM J RESP CRIT CARE, V192, P1373, DOI 10.1164/rccm.201510-1966ST; Rogliani P, 2018, PULM PHARMACOL THER, V50, P28, DOI 10.1016/j.pupt.2018.03.004; Ryrso CK, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0718-1; Sabatine MS, 2017, NEW ENGL J MED, V376, P1713, DOI [10.1056/NEJMoa1615664, 10.4997/JRCPE.2017.212]; Sandesara PB, 2015, J AM COLL CARDIOL, V65, P389, DOI 10.1016/j.jacc.2014.10.059; Sawatzky JAV, 2014, CLIN REHABIL, V28, P648, DOI 10.1177/0269215513516475; Schroeder SA, 2007, NEW ENGL J MED, V357, P1221, DOI 10.1056/NEJMsa073350; Selzler AM, 2018, CHRON RESP DIS, V15, P41, DOI 10.1177/1479972317724570; Shepherd CW, 2012, INT J NURS STUD, V49, P755, DOI 10.1016/j.ijnurstu.2011.11.019; Shields GE, 2018, HEART, V104, P1403, DOI 10.1136/heartjnl-2017-312809; Singh-Manoux A, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002571; Siu AL, 2015, ANN INTERN MED, V163, P622, DOI 10.7326/M15-2023; Smith A., 2013, SMARTPHONE OWNERSHIP; Soriano JB, 2017, LANCET RESP MED, V5, P691, DOI 10.1016/S2213-2600(17)30293-X; Spencer LM, 2010, EUR RESPIR J, V35, P571, DOI 10.1183/09031936.00073609; Spruit MA, 2013, AM J RESP CRIT CARE, V188, pE13, DOI 10.1164/rccm.201309-1634ST; Steele BG, 2008, ARCH PHYS MED REHAB, V89, P404, DOI 10.1016/j.apmr.2007.11.003; Steinhubl SR, 2015, J AM COLL CARDIOL, V66, P1489, DOI 10.1016/j.jacc.2015.08.006; Strijbos JH, 1996, CHEST, V109, P366, DOI 10.1378/chest.109.2.366; Thomas RJ, 2018, CIRC-CARDIOVASC QUAL, V11, DOI 10.1161/HCQ.0000000000000037; Thomas RJ, 2010, J AM COLL CARDIOL, V56, P1159, DOI 10.1016/j.jacc.2010.06.006; Troosters T, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010106; Tsai LLY, 2017, RESPIROLOGY, V22, P699, DOI 10.1111/resp.12966; Vaes AW, 2014, EUR RESPIR J, V44, P1199, DOI 10.1183/09031936.00023214; van den Berg MJE, 2019, AM HEART J, V213, P112, DOI 10.1016/j.ahj.2019.03.019; Van Remoortel H, 2013, THORAX, V68, P962, DOI 10.1136/thoraxjnl-2013-203534; Varnfield M, 2014, HEART, V100, P1770, DOI 10.1136/heartjnl-2014-305783; Vogelmeier CF, 2017, RESPIROLOGY, V22, P575, DOI 10.1111/resp.13012; Vorrink SNW, 2016, EUR RESPIR J, V48, P1019, DOI 10.1183/13993003.00083-2016; Walsh MN, 2017, J AM COLL CARDIOL, V70, P2719, DOI 10.1016/j.jacc.2017.10.020; Waschki B, 2011, CHEST, V140, P331, DOI 10.1378/chest.10-2521; Watz H, 2009, EUR RESPIR J, V33, P262, DOI 10.1183/09031936.00024608; Watz H, 2014, EUR RESPIR J, V44, P1521, DOI 10.1183/09031936.00046814; Wayne PM, 2014, ARCH PHYS MED REHAB, V95, P2470, DOI 10.1016/j.apmr.2014.05.005; Weingarten MN, 2011, J CARDIOPULM REHABIL, V31, P217, DOI 10.1097/HCR.0b013e318207d2fa; WHO, 2018, GLOB HLTH EST 2019 D; Widmer RJ, 2015, MAYO CLIN PROC, V90, P469, DOI 10.1016/j.mayocp.2014.12.026; Wijkstra P J, 2003, Monaldi Arch Chest Dis, V59, P335; Williams Nefyn H, 2011, BMJ, V343, pd6615, DOI 10.1136/bmj.d6615; Wisloff U, 2007, CIRCULATION, V115, P3086, DOI 10.1161/CIRCULATIONAHA.106.675041; World Health Organisation, 2018, TOP 10 CAUS DEATH; Wu WB, 2014, INT J CHRONIC OBSTR, V9, P1253, DOI 10.2147/COPD.S70862; Wuytack F, 2018, RESPIROLOGY, V23, P272, DOI 10.1111/resp.13224; Yan JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061806; Yeh GY, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-337; Zenko Z, 2016, J SPORT EXERCISE PSY, V38, P149, DOI 10.1123/jsep.2015-0286; Zwerink M, 2013, RESP MED, V107, P242, DOI 10.1016/j.rmed.2012.09.018	138	25	25	3	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 17	2019	365								l2191	10.1136/bmj.l2191	http://dx.doi.org/10.1136/bmj.l2191			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IF1MT	31208954				2023-01-03	WOS:000472843400002
J	Dillon, EL; Soman, KV; Wiktorowicz, JE; Sur, R; Jupiter, D; Danesi, CP; Randolph, KM; Gilkison, CR; Durham, WJ; Urban, RJ; Sheffield-Moore, M				Dillon, E. Lichar; Soman, Kizhake V.; Wiktorowicz, John E.; Sur, Ria; Jupiter, Daniel; Danesi, Christopher P.; Randolph, Kathleen M.; Gilkison, Charles R.; Durham, William J.; Urban, Randall J.; Sheffield-Moore, Melinda			Proteomic investigation of human skeletal muscle before and after 70 days of head down bed rest with or without exercise and testosterone countermeasures	PLOS ONE			English	Article							VASTUS-LATERALIS; S-NITROSYLATION; TIME-COURSE; VIBRATION; CELL; PHOSPHORYLATION; ACTIVATION; RESISTANCE; DOMAIN	Introduction Long-term head-down bed rest (HDBR) results in musculoskeletal losses similar to those observed during long-term space flight. Agents such as testosterone, in addition to regular exercise, are effective countermeasures for reducing loss of skeletal muscle mass and function. Objective We investigated the skeletal muscle proteome of healthy men in response to long term HDBR alone (CON) and to HDBR with exercise (PEX) or exercise plus testosterone (TEX) countermeasures. Method Biopsies were performed on the vastus lateralis before (pre) HDBR and on HDBR days 32 (mid) and 64 (post). Extracted proteins from these skeletal muscle biopsies were subjected to 2-dimensional gel electrophoresis (2DE), stained for phosphoproteins (Pro-Q Diamond dye) and total proteins (Sypro Ruby dye). Proteins showing significant fold differences (ttest p <= 0.05) in abundance or phosphorylation state at mid or post were identified by mass spectroscopy (MS). Results From a total of 932 protein spots, 130 spots were identified as potentially altered in terms of total protein or phosphoprotein levels due to HDBR and/or countermeasures, and 59 unique molecules emerged from MS analysis. Top canonical pathways identified through IPA included calcium signaling, actin cytoskeleton signaling, integrin linked kinase ( ILK) signaling, and epithelial adherens junction signaling. Data from the pre-HDBR proteome supported the potential for predicting physiological post-HDBR responses such as the individual's potential for loss vs. maintenance of muscle mass and strength. Conclusions HDBR resulted in alterations to skeletal muscle abundances and phosphorylation of several structural and metabolic proteins. Inclusion of exercise alone or in combination with testosterone treatment modulated the proteomic responses towards cellular reorganization and hypertrophy, respectively. Finally, the baseline proteome may aid in the development of personalized countermeasures to mitigate health risks in astronauts as related to loss of muscle mass and function.	[Dillon, E. Lichar; Danesi, Christopher P.; Randolph, Kathleen M.; Gilkison, Charles R.; Durham, William J.; Urban, Randall J.; Sheffield-Moore, Melinda] Univ Texas Med Branch, Dept Internal Med, Galveston, TX 77555 USA; [Soman, Kizhake V.; Wiktorowicz, John E.; Sur, Ria] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; [Jupiter, Daniel] Univ Texas Med Branch, Dept Prevent Med & Community Hlth, Galveston, TX 77555 USA; [Sheffield-Moore, Melinda] Texas A&M Univ, Dept Hlth & Kinesiol, College Stn, TX 77843 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Texas A&M University System; Texas A&M University College Station	Sheffield-Moore, M (corresponding author), Univ Texas Med Branch, Dept Internal Med, Galveston, TX 77555 USA.; Sheffield-Moore, M (corresponding author), Texas A&M Univ, Dept Hlth & Kinesiol, College Stn, TX 77843 USA.	msheffield-moore@tamu.edu	/B-2495-2008; Sheffield-Moore, Melinda/A-9794-2016	/0000-0002-0513-5399; Sheffield-Moore, Melinda/0000-0001-6579-4655	National Aeronautics and Space Administration [NNX10AP86G]; Institute for Translational Sciences at the University of Texas Medical Branch - National Center for Advancing Translational Sciences, National Institutes of Health [UL1TR000071]; National Cancer Institute [RO1CA127971]	National Aeronautics and Space Administration(National Aeronautics & Space Administration (NASA)); Institute for Translational Sciences at the University of Texas Medical Branch - National Center for Advancing Translational Sciences, National Institutes of Health; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was part of an integrated study registered with ClinicalTrials.gov (NCT00891449) and was funded by the National Aeronautics and Space Administration (#NNX10AP86G, RJU/MSM). The study was conducted with the support of the Institute for Translational Sciences at the University of Texas Medical Branch through funding by a Clinical and Translational Science Award (UL1TR000071) from the National Center for Advancing Translational Sciences, National Institutes of Health and (RO1CA127971, MSM) from the National Cancer Institute.	Arentson-Lantz EJ, 2016, J APPL PHYSIOL, V120, P965, DOI 10.1152/japplphysiol.00799.2015; BERGSTROM J, 1975, SCAND J CLIN LAB INV, V35, P606, DOI 10.3109/00365517509095787; Bhasin S, 2003, J GERONTOL A-BIOL, V58, P1103; Bolduc C, 2007, OBESITY, V15, P1107, DOI 10.1038/oby.2007.623; Boyle Sarah T, 2020, Small GTPases, V11, P354, DOI 10.1080/21541248.2017.1413496; Brocca L, 2012, J PHYSIOL-LONDON, V590, P5211, DOI 10.1113/jphysiol.2012.240267; Cho Y, 2018, PHYSIOL GENOMICS, V50, P746, DOI 10.1152/physiolgenomics.00043.2018; Cromwell RL, 2018, MED SCI SPORT EXER, V50, P1909, DOI 10.1249/MSS.0000000000001617; Dillon EL, 2018, MED SCI SPORT EXER, V50, P1929, DOI 10.1249/MSS.0000000000001616; Dillon EL, 2018, MED SCI SPORTS EXERC; EDGERTON VR, 1995, J APPL PHYSIOL, V78, P1733, DOI 10.1152/jappl.1995.78.5.1733; Fehon RG, 2010, NAT REV MOL CELL BIO, V11, P276, DOI 10.1038/nrm2866; Hamzeh M, 2010, ENDOCRINOLOGY, V151, P4504, DOI 10.1210/en.2010-0023; Hody S, 2011, MED SCI SPORT EXER, V43, P2281, DOI 10.1249/MSS.0b013e318222edf3; Holloway KV, 2009, PROTEOMICS, V9, P5155, DOI 10.1002/pmic.200900068; Kramerova I, 2008, HUM MOL GENET, V17, P3271, DOI 10.1093/hmg/ddn223; Li MX, 2015, GENE, V571, P153, DOI 10.1016/j.gene.2015.07.074; Ma XW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077926; Moriggi M, 2010, PROTEOMICS, V10, P3756, DOI 10.1002/pmic.200900817; Murach KA, 2018, MED SCI SPORT EXER, V50, P1950, DOI 10.1249/MSS.0000000000001620; Novak KD, 1998, MOL BIOL CELL, V9, P75, DOI 10.1091/mbc.9.1.75; Ploutz-Snyder LL, 2018, EXERCISE TRAINING MI; Rani SG, 2014, BBA-PROTEINS PROTEOM, V1844, P1718, DOI 10.1016/j.bbapap.2014.06.017; Rodriguez-Calvo R, 2015, PPAR RES, V2015, DOI 10.1155/2015/785783; Rodriguez-Calvo R, 2017, BBA-MOL CELL BIOL L, V1862, P541, DOI 10.1016/j.bbalip.2017.02.006; Rossetti ML, 2018, MOL CELL ENDOCRINOL, V473, P178, DOI 10.1016/j.mce.2018.01.017; Ryder JW, 2007, J BIOL CHEM, V282, P20447, DOI 10.1074/jbc.M702927200; Salanova M, 2014, FASEB J, V28, P4748, DOI 10.1096/fj.14-252825; Savidge TC, 2011, NAT MED, V17, P1136, DOI 10.1038/nm.2405; Schild M, 2015, J PROTEOMICS, V122, P119, DOI 10.1016/j.jprot.2015.03.028; Sheffield-Moore M, 2013, CTS-CLIN TRANSL SCI, V6, P463, DOI 10.1111/cts.12121; Sheffield-Moore M, 2011, J CLIN ENDOCR METAB, V96, pE1831, DOI 10.1210/jc.2011-1262; Soman KV, 2017, J PROTEOME RES, V16, P2663, DOI 10.1021/acs.jproteome.6b00367; Trappe S, 2004, J PHYSIOL-LONDON, V557, P501, DOI 10.1113/jphysiol.2004.062166; Wehland M, 2013, CELL PHYSIOL BIOCHEM, V31, P432, DOI 10.1159/000343380; Wiktorowicz JE, 2011, BIOCHEMISTRY-US, V50, P5601, DOI 10.1021/bi200008b; XU KY, 1995, CIRC RES, V77, P88, DOI 10.1161/01.RES.77.1.88	37	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2019	14	6							e0217690	10.1371/journal.pone.0217690	http://dx.doi.org/10.1371/journal.pone.0217690			38	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IC8NN	31194764	Green Submitted, gold, Green Published			2023-01-03	WOS:000471238300021
J	Maitra, A				Maitra, Amrapali			Going Home	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Maitra, Amrapali] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Maitra, A (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	amaitra@bwh.harvard.edu							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2019	321	21					2075	2076		10.1001/jama.2019.6924	http://dx.doi.org/10.1001/jama.2019.6924			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IB3HN	31162572				2023-01-03	WOS:000470158700010
J	Cook, R; Davidson, P; Martin, R				Cook, Rob; Davidson, Peter; Martin, Rosie		NIHR Dissemination Ctr	E-cigarettes helped more smokers quit than nicotine replacement therapy	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Cook, Rob; Martin, Rosie] Bazian Economist Intelligence Unit Healthcare, London, England; [Davidson, Peter] Univ Southampton, Wessex Inst, Southampton, Hants, England	University of Southampton	Cook, R (corresponding author), Bazian Economist Intelligence Unit Healthcare, London, England.	rob.cook@bazian.com		Cook, Robert/0000-0002-2210-3989				McNeill A, 2018, EVIDENCE REV E CIGAR; National Institute for Health and Care Excellence, 2018, NG92 NAT I HLTH CAR	2	6	6	2	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 10	2019	365								l2036	10.1136/bmj.l2036	http://dx.doi.org/10.1136/bmj.l2036			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY1UV	31076461	Green Accepted			2023-01-03	WOS:000467903500003
J	Schlosser, M; Sparby, T; Voros, S; Jones, R; Merchant, NL				Schlosser, Marco; Sparby, Terje; Voros, Sebastjan; Jones, Rebecca; Merchant, Natalie L.			Unpleasant meditation-related experiences in regular meditators: Prevalence, predictors, and conceptual considerations	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIALS; HEALTH INTERVIEW; MENTAL-ILLNESS; ADVERSE EVENTS; UNITED-STATES; MINDFULNESS; DISORDERS; QUESTIONNAIRE; CHALLENGES; DEPRESSION	So far, the large and expanding body of research on meditation has mostly focussed on the putative benefits of meditation on health and well-being. However, a growing number of reports indicate that psychologically unpleasant experiences can occur in the context of meditation practice. Very little is known about the prevalence and potential causes of these experiences. The aim of this study was to report the prevalence of particularly unpleasant meditation-related experiences in a large international sample of regular meditators, and to explore the association of these experiences with demographic characteristics, meditation practice, repetitive negative thinking, mindfulness, and self-compassion. Using a cross-sectional online survey, 1,232 regular meditators with at least two months of meditation experience (mean age = 44.8 years +/- 13.8, 53.6% female) responded to one question about particularly unpleasant meditation-related experiences. A total of 315 participants (25.6%, 95% CI: 23.1 to 28.0) reported having had particularly unpleasant meditation-related experiences, which they thought may have been caused by their meditation practice. Logistic regression models indicated that unpleasant meditation-related experiences were less likely to occur in female participants and religious participants. Participants with higher levels of repetitive negative thinking, those who only engaged in deconstructive types of meditation (e. g., vipassana/ insight meditation), and those who had attended a meditation retreat at any point in their life were more likely to report unpleasant meditation-related experiences. The high prevalence of particularly unpleasant meditation-related experiences reported here points to the importance of expanding the scientific conception of meditation beyond that of a (mental) health-promoting and self-regulating technique. We propose that understanding when these experiences are constitutive elements of meditative practice rather than merely negative effects could advance the field and, to that end, we conclude with an overview of methodological and conceptual considerations that could be used to inform future research.	[Schlosser, Marco; Jones, Rebecca; Merchant, Natalie L.] UCL, Fac Brain Sci, Div Psychiat, London, England; [Sparby, Terje] Witten Herdecke Univ, Fac Hlth, Dept Psychol & Psychotherapy, Witten, Germany; [Voros, Sebastjan] Univ Ljubljana, Fac Arts, Dept Philosophy, Ljubljana, Slovenia	University of London; University College London; University of Ljubljana	Schlosser, M (corresponding author), UCL, Fac Brain Sci, Div Psychiat, London, England.	marco.schlosser@ucl.ac.uk	Schlosser, Marco/AAM-8775-2020	Schlosser, Marco/0000-0002-0634-0749; Marchant, Natalie/0000-0003-0669-6910				Addis ME, 2008, CLIN PSYCHOL-SCI PR, V15, P153, DOI 10.1111/j.1468-2850.2008.00125.x; Altemus M, 2014, FRONT NEUROENDOCRIN, V35, P320, DOI 10.1016/j.yfrne.2014.05.004; Anderson T, 2016, J CHEM ECOL, P1; Baer R, 2019, CLIN PSYCHOL REV, V71, P101, DOI 10.1016/j.cpr.2019.01.001; Baer RA, 2008, ASSESSMENT, V15, P329, DOI 10.1177/1073191107313003; Bent S, 2006, ANN INTERN MED, V144, P257, DOI 10.7326/0003-4819-144-4-200602210-00007; Boorstein S., 1996, TXB TRANSPERSONAL PS, P344; Buddhaghosa B., 1991, VISUDDHIMAGGA; Burbea Rob., 2014, SEEING FREES MEDITAT; Carrington P, 1977, FREEDOM MEDITATION; CASTILLO RJ, 1990, PSYCHIATRY, V53, P158; Cebolla A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183137; Chan-Ob Tinnakorn, 1999, Journal of the Medical Association of Thailand, V82, P925; Cinnirella M, 1999, BRIT J MED PSYCHOL, V72, P505, DOI 10.1348/000711299160202; Clarke Tainya C, 2015, Natl Health Stat Report, P1; Compson J., 2018, MINDFULNESS, P1; Cramer H, 2016, SCI REP-UK, V6, DOI 10.1038/srep36760; Crawford MJ, 2016, BRIT J PSYCHIAT, V208, P260, DOI 10.1192/bjp.bp.114.162628; Dahl CJ, 2015, TRENDS COGN SCI, V19, P515, DOI 10.1016/j.tics.2015.07.001; Davidson RJ, 2018, PERSPECT PSYCHOL SCI, V13, P62, DOI 10.1177/1745691617718358; Dein S, 2011, TRANSCULT PSYCHIATRY, V48, P318, DOI 10.1177/1363461511402723; Disayavanish C, 1984, J PSYCHIAT ASS THAIL, V29, P1; Dobkin PL, 2012, MINDFULNESS, V3, P44, DOI 10.1007/s12671-011-0079-9; Dreyfus G, 2011, CONTEMP BUDDHISM, V12, P41, DOI 10.1080/14639947.2011.564815; Dunne J, 2011, CONTEMP BUDDHISM, V12, P71, DOI 10.1080/14639947.2011.564820; Dyga K, 2015, ARCH PSYCHIAT PSYCHO, V17; Ehring T, 2011, J BEHAV THER EXP PSY, V42, P225, DOI 10.1016/j.jbtep.2010.12.003; Ehring T, 2008, INT J COGN THER, V1, P192, DOI 10.1680/ijct.2008.1.3.192; Epstein M. D., 1981, J TRANSPERSONAL PSYC, V13, P137; FENWICK P, 1983, BRIT MED J, V287, P1401, DOI 10.1136/bmj.287.6403.1401; Fresco DM, 2007, BEHAV THER, V38, P234, DOI 10.1016/j.beth.2006.08.003; Goenka SN, 2012, DISCOURSE SUMMARIES; Goyal M, 2014, JAMA INTERN MED, V174, P357, DOI 10.1001/jamainternmed.2013.13018; Grabovac A, 2015, MINDFULNESS, V6, P589, DOI 10.1007/s12671-014-0294-2; Griffith J.L., 2010, RELIG HEALS RELIG HA; Gross JJ, 1999, COGNITION EMOTION, V13, P551, DOI 10.1080/026999399379186; HEIDE FJ, 1983, J CONSULT CLIN PSYCH, V51, P171, DOI 10.1037/0022-006X.51.2.171; Ioannidis JPA, 2006, ANN INTERN MED, V144, P298, DOI 10.7326/0003-4819-144-4-200602210-00013; Jacobi F, 2004, PSYCHOL MED, V34, P597, DOI 10.1017/S0033291703001399; Jonsson U, 2014, CONTEMP CLIN TRIALS, V38, P1, DOI 10.1016/j.cct.2014.02.005; Kang Y, 2018, J SCHOOL PSYCHOL, V68, P163, DOI 10.1016/j.jsp.2018.03.004; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Khoury B, 2017, J PSYCHOSOM RES, V92, P16, DOI 10.1016/j.jpsychores.2016.11.006; King BG, 2019, CURR OPIN PSYCHOL, V28, P238, DOI 10.1016/j.copsyc.2018.12.021; Koenig HG, 2009, CAN J PSYCHIAT, V54, P283, DOI 10.1177/070674370905400502; Kornfield J., 1979, J TRANSPERSONAL PSYC, V11, P41; Kuijpers HJH, 2007, PSYCHOPATHOLOGY, V40, P461, DOI 10.1159/000108125; Kuyken W., 2012, MINDFULNESS BASED CO; Levant RF., 1992, J FAM PSYCHOL, P379, DOI DOI 10.1037/0893-3200.5.3-4.379; Lindahl JR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176239; Lindahl JR., 2019, OXFORD HDB MEDITATIO, P1, DOI [10.1093/oxfordhb/9780198808640.013.51, DOI 10.1093/OXFORDHB/9780198808640.013.51]; Linden M, 2013, CLIN PSYCHOL PSYCHOT, V20, P286, DOI 10.1002/cpp.1765; Lomas T, 2015, MINDFULNESS, V6, P848, DOI 10.1007/s12671-014-0329-8; Lustyk M Kathleen B, 2009, Adv Mind Body Med, V24, P20; McMahan D., 2017, MEDITATION BUDDHISM; Menezes A, 2010, CURR PSYCHIAT REP, V12, P174, DOI 10.1007/s11920-010-0117-7; MILLER JJ, 1993, J TRANSPERSONAL PSY, V25, P169; Morone NE, 2017, J ALTERN COMPLEM MED, V23, P545, DOI 10.1089/acm.2016.0099; Nakaya M., 2010, GER J PSYCHIAT, V13, P161; Neff KD, 2017, J PERS ASSESS, P1; Neff KD, 2003, SELF IDENTITY, V2, P223, DOI 10.1080/15298860390209035; Perez-De-Albeniz A., 2000, INT J PSYCHOTHER, V5, P49, DOI DOI 10.1080/13569080050020263; Rojiani R, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00551; Santorelli S., 2014, MINDFULNESS BASED ST; Sayadaw M, 1991, PRACTICAL INSIGHT ME; Schermuly-Haupt ML, 2018, COGNITIVE THER RES, V42, P219, DOI 10.1007/s10608-018-9904-y; Sethi S, 2003, AUST NZ J PSYCHIAT, V37, P382; Shapiro D. H, 1992, INT J PSYCHOSOM, V39, P63; Shonin E., 2014, CLIN PRACTICE, V11, P389, DOI DOI 10.2217/cpr.14.23; Soler J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086622; Sparby T, 2017, J CONSCIOUSNESS STUD, V24, P226; Van Dam NT, 2018, PERSPECT PSYCHOL SCI, V13, P36, DOI 10.1177/1745691617709589; Van Gordon W, 2017, AUST NZ J PSYCHIAT, V51, P977, DOI 10.1177/0004867417716309; VanderKooi L., 1997, J TRANSPERSONAL PSY, V29, P31; Vaughan B, 2014, COMPR PSYCHIAT, V55, P849, DOI 10.1016/j.comppsych.2014.01.001; Vieten C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205740; Voros S, 2016, ASIAN STUD-AZIJSKE S, V4, P59, DOI 10.4312/as.2016.4.2.59-83; Wallace, 2006, ATTENTION REVOLUTION; WALSH R, 1979, AM J PSYCHIAT, V136, P1085; Wang C, 2019, COMPLEMENT THER MED, V43, P271, DOI 10.1016/j.ctim.2019.02.004; Wesselmann ED, 2010, J SOC CLIN PSYCHOL, V29, P402, DOI 10.1521/jscp.2010.29.4.402; Wong SY, 2018, MINDFULNESS, P1; Yorston G.A., 2001, MENTAL HLTH RELIG CU, V4, P209, DOI DOI 10.1080/713685624	83	49	49	3	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2019	14	5							e0216643	10.1371/journal.pone.0216643	http://dx.doi.org/10.1371/journal.pone.0216643			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HX6ZE	31071152	Green Published, gold, Green Submitted			2023-01-03	WOS:000467552100076
J	Owen, AM				Owen, Adrian M.			The Search for Consciousness	NEURON			English	Editorial Material							BRAIN; DISORDERS	In recent years, rapid technological developments in the field of neuroimaging have provided new methods for assessing residual cognition, detecting consciousness, and even communicating with patients who clinically appear to be in a vegetative state. Here, I highlight some of the major implications of these developments, discuss their scientific, clinical, legal, and ethical relevance, and make my own recommendations for future directions in this field.	[Owen, Adrian M.] Univ Western Ontario, Brain & Mind Inst, London, ON, Canada; [Owen, Adrian M.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; [Owen, Adrian M.] Univ Western Ontario, Dept Psychol, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Owen, AM (corresponding author), Univ Western Ontario, Brain & Mind Inst, London, ON, Canada.; Owen, AM (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada.; Owen, AM (corresponding author), Univ Western Ontario, Dept Psychol, London, ON, Canada.	uwocerc@uwo.ca			Canada Excellence Research Chairs (CERC) Program; Canadian Institute for Advanced Research (CIFAR); Canadian Institutes of Health Research (CIHR); James S. McDonnell Foundation	Canada Excellence Research Chairs (CERC) Program; Canadian Institute for Advanced Research (CIFAR)(Canadian Institute for Advanced Research (CIFAR)); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); James S. McDonnell Foundation	I am grateful for generous support from the Canada Excellence Research Chairs (CERC) Program, The Canadian Institute for Advanced Research (CIFAR), the Canadian Institutes of Health Research (CIHR), and the James S. McDonnell Foundation.	Abdalmalak A, 2017, NEUROPHOTONICS, V4, DOI 10.1117/1.NPh.4.4.040501; Coleman MR, 2009, BRAIN, V132, P2541, DOI 10.1093/brain/awp183; Di HB, 2008, CLIN MED, V8, P502, DOI 10.7861/clinmedicine.8-5-502; Kahane G, 2009, J MED PHILOS, V34, P6, DOI 10.1093/jmp/jhn038; Kondziella D, 2016, J NEUROL NEUROSUR PS, V87, P485, DOI 10.1136/jnnp-2015-310958; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Weijer C, 2016, BRAIN, V139, P292, DOI 10.1093/brain/awv272; 2013, NAT REV NEUROSCI, V14, P801, DOI DOI 10.1038/NRN3608	10	20	20	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	MAY 8	2019	102	3					526	528		10.1016/j.neuron.2019.03.024	http://dx.doi.org/10.1016/j.neuron.2019.03.024			3	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HX2MJ	31071287	Bronze			2023-01-03	WOS:000467225800008
J	Gracia-Cazana, T; Mascaraque, M; Lucena, SR; Vera-Alvarez, J; Gonzalez, S; Juarranz, A; Gilaberte, Y				Gracia-Cazana, Tamara; Mascaraque, Marta; Rocio Lucena, Silvia; Vera-Alvarez, Jesus; Gonzalez, Salvador; Juarranz, Angeles; Gilaberte, Yolanda			Biomarkers of basal cell carcinoma resistance to methyl-aminolevulinate photodynamic therapy	PLOS ONE			English	Article							BETA-CATENIN; CANCER; ACID; SKIN; P53; MECHANISMS; EXPRESSION; GUIDELINES; EFFICACY; SURGERY	Background Methyl-aminolevulinate photodynamic therapy (MAL-PDT) is an excellent option for the treatment of basal cell carcinoma (BCC). However, up to 25% of cases are resistant to this treatment modality. Objective The aim of this study was to identify potential biomarkers of BCC response to MAL-PDT. Material and methods Clinical, histological, and immunohistochemical (p53, Ki-67, CD-31, COX2, beta-catenin, EGFR, and survivin) variables were analyzed in a retrospective study of consecutive BCC patients treated with MAL-PDT at the San Jorge Hospital, Huesca, Spain between January 2006 and December 2015. To deepen on these markers, the effects on p53 and cyclin D1 expression, in vitro response to MAL-PDT of 2 murine BCC cell lines (ASZ and BSZ), was also evaluated. Results The retrospective study examined the response to MAL-PDT of 390 BCCs from 182 patients. The overall clinical response rate was 82.8%, with a mean follow-up time of 35.96 months (SD = 23.46). Immunohistochemistry revealed positive p53 in 84.6% of responders but only 15.4% of nonresponsive tumors (p = 0.011). Tumors with increased peripheral palisading of basal cell islands to immunostaining beta-catenin responded poorly to PDT (p = 0.01). In line with our findings in patients, in vitro studies revealed a better response to PDT in the p53-positive ASZ cell line than the p53-negative BSZ cell line (p<0.01). Multivariate analysis revealed that the following variables were significantly associated with response to PDT: age, nBCC, presence of peritumoral inflammatory infiltrate, and p53 immunopositivity. Patients with positive p53 immunostaining were 68.54 times more likely to achieve cure than p53-negative patients (CI95% 2.94-159.8) Conclusion Our finding suggest that certain clinicopathological and immunohistochemical variables, particularly p53 expression, may serve as indicators of BCC response to MAL-PDT, and thus facilitate the selection of patients who are most likely to benefit from this therapy.	[Gracia-Cazana, Tamara] Hosp Barbastro, Dept Dermatol, Huesca, Spain; [Mascaraque, Marta; Rocio Lucena, Silvia; Juarranz, Angeles] Univ Autonoma Madrid, Dept Biol, Madrid, Spain; [Vera-Alvarez, Jesus] Hosp San Jorge, Pathol Serv, Huesca, Spain; [Gonzalez, Salvador] Univ Alcala, Dept Med & Med Specialties, Madrid, Spain; [Gilaberte, Yolanda] Hosp Miguel Servet, Dermatol Serv, Zaragoza, Spain	Autonomous University of Madrid; Hospital Universidad San Jorge; Universidad de Alcala; Miguel Servet University Hospital	Gracia-Cazana, T (corresponding author), Hosp Barbastro, Dept Dermatol, Huesca, Spain.	tamgracaz@gmail.com	Checa, Marta Mascaraque/AAU-7389-2021; Gonzalez, Salvador/AFK-2480-2022; Lucena, Silvia Rocio/M-5703-2014	Checa, Marta Mascaraque/0000-0002-9677-921X; Gonzalez, Salvador/0000-0001-9282-4784; Lucena, Silvia Rocio/0000-0002-1803-3922	Instituto de Salud Carlos III; Fondos Feder Europeos, MINECO [FIS PI15/00974]	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Fondos Feder Europeos, MINECO	This project received support from the Instituto de Salud Carlos III and Fondos Feder Europeos, MINECO (FIS PI15/00974). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anand S, 2017, MOL CANCER THER, V16, P1092, DOI 10.1158/1535-7163.MCT-16-0608; Araki K, 2015, CELL MOL LIFE SCI, V72, P4077, DOI 10.1007/s00018-015-1989-9; Azimi F, 2012, J CLIN ONCOL, V30, P2678, DOI 10.1200/JCO.2011.37.8539; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Brash DE, 2006, BRIT J DERMATOL, V154, P8, DOI 10.1111/j.1365-2133.2006.07230.x; CALZAVARAPINTON PG, 1995, J PHOTOCH PHOTOBIO B, V29, P53; Casas A, 2011, CURR MED CHEM, V18, P2486, DOI 10.2174/092986711795843272; Christensen E, 2012, BRIT J DERMATOL, V166, P1342, DOI 10.1111/j.1365-2133.2012.10878.x; El-Bahrawy M, 2003, BRIT J DERMATOL, V148, P964, DOI 10.1046/j.1365-2133.2003.05240.x; Fantini F, 2011, J EUR ACAD DERMATOL, V25, P896, DOI 10.1111/j.1468-3083.2010.03877.x; Fernandez-Guarino M, 2014, J SKIN CANCER, V2014, DOI 10.1155/2014/849248; Fiechter S, 2012, DERMATOLOGY, V224, P346, DOI 10.1159/000339335; Foley P, 2009, INT J DERMATOL, V48, P1236, DOI 10.1111/j.1365-4632.2008.04022.x; Gilaberte Y, 2014, J INVEST DERMATOL, V134, P2428, DOI 10.1038/jid.2014.178; Gracia-Cazana T, 2018, BRIT J DERMATOL, V178, pE138, DOI 10.1111/bjd.15965; Gracia-Cazana T, 2016, ACTAS DERMO-SIFILOGR, V107, P740, DOI 10.1016/j.ad.2016.04.020; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Li ZS, 2016, AM J TRANSL RES, V8, P142; Micillo R, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050746; Morton CA, 1998, ARCH DERMATOL, V134, P248, DOI 10.1001/archderm.134.2.248; Morton C, 2015, EUR J DERMATOL, V25, P296, DOI 10.1684/ejd.2015.2570; Mosterd K, 2008, LANCET ONCOL, V9, P1149, DOI 10.1016/S1470-2045(08)70260-2; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Nissen CV, 2015, BRIT J DERMATOL, V173, P760, DOI 10.1111/bjd.13923; Oh ST, 2011, BRIT J DERMATOL, V165, P1197, DOI 10.1111/j.1365-2133.2011.10506.x; Prowald A, 2007, PROSTATE, V67, P1751, DOI 10.1002/pros.20660; Rhodes LE, 2004, ARCH DERMATOL, V140, P17, DOI 10.1001/archderm.140.1.17; Shah S, 2010, AM J CLIN DERMATOL, V11, P389, DOI 10.2165/11538940-000000000-00000; Smucler R, 2008, LASER SURG MED, V40, P153, DOI 10.1002/lsm.20606; So PL, 2006, EXP DERMATOL, V15, P742, DOI 10.1111/j.1600-0625.2006.00465.x; Soler AM, 2001, BRIT J DERMATOL, V145, P467, DOI 10.1046/j.1365-2133.2001.04407.x; Surrenti T, 2007, EUR J DERMATOL, V17, P412, DOI 10.1684/ejd.2007.0239; Talmadge JE, 2011, SEMIN CANCER BIOL, V21, P131, DOI 10.1016/j.semcancer.2010.12.002; Telfer NR, 2008, BRIT J DERMATOL, V159, P35, DOI 10.1111/j.1365-2133.2008.08666.x; Vinciullo C, 2005, BRIT J DERMATOL, V152, P765, DOI 10.1111/j.1365-2133.2005.06484.x; Worsley SD, 1997, GYNECOL ONCOL, V64, P189, DOI 10.1006/gyno.1996.4569; 2018, ACTA DERM-VENEREOL, V98, P116, DOI DOI 10.2340/00015555-2756; 2013, ROM J MORPHOL EMBRYO, V54, P939	38	6	6	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 24	2019	14	4							e0215537	10.1371/journal.pone.0215537	http://dx.doi.org/10.1371/journal.pone.0215537			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU6FU	31017970	Green Published, Green Submitted, gold			2023-01-03	WOS:000465375400049
J	Plummer, A; Mugele, H; Steffen, K; Stoll, J; Mayer, F; Muller, J				Plummer, Ashley; Mugele, Hendrik; Steffen, Kathrin; Stoll, Josefine; Mayer, Frank; Mueller, Juliane			General versus sports-specific injury prevention programs in athletes: A systematic review on the effects on performance	PLOS ONE			English	Review							PROPRIOCEPTIVE TRAINING-PROGRAM; CRUCIATE LIGAMENT INJURIES; YOUTH FEMALE FOOTBALL; JOINT IMBALANCE; SOCCER PLAYERS; FIFA 11+; STRENGTH; HANDBALL; BALANCE	Introduction Injury prevention programs (IPPs) are an inherent part of training in recreational and professional sports. Providing performance-enhancing benefits in addition to injury prevention may help adjust coaches and athletes' attitudes towards implementation of injury prevention into daily routine. Conventional thinking by players and coaches alike seems to suggest that IPPs need to be specific to one's sport to allow for performance enhancement. The systematic literature review aims to firstly determine the IPPs nature of exercises and whether they are specific to the sport or based on general conditioning. Secondly, can they demonstrate whether general, sports-specific or even mixed IPPs improve key performance indicators with the aim to better facilitate long-term implementation of these programs? Methods PubMed and Web of Science were electronically searched throughout March 2018. The inclusion criteria were randomized control trials, publication dates between Jan 2006 and Feb 2018, athletes (11-45 years), injury prevention programs and included predefined performance measures that could be categorized into balance, power, strength, speed/agility and endurance. The methodological quality of included articles was assessed with the Cochrane Collaboration assessment tools. Results Of 6619 initial findings, 22 studies met the inclusion criteria. In addition, reference lists unearthed a further 6 studies, making a total of 28. Nine studies used sports specific IPPs, eleven general and eight mixed prevention strategies. Overall, general programs ranged from 29-57% in their effectiveness across performance outcomes. Mixed IPPs improved in 80% balance outcomes but only 20-44% in others. Sports-specific programs led to larger scale improvements in balance (66%), power (83%), strength (75%), and speed/agility (62%). Conclusion Sports-specific IPPs have the strongest influence on most performance indices based on the significant improvement versus control groups. Other factors such as intensity, technical execution and compliance should be accounted for in future investigations in addition to exercise modality.	[Plummer, Ashley; Mugele, Hendrik] Univ Potsdam, Dept Sport & Hlth Sci, Clin Exercise Sci, Potsdam, Germany; [Mugele, Hendrik] Univ Innsbruck, Dept Sport Sci, Innsbruck, Austria; [Steffen, Kathrin] Oslo Sports Trauma Res Ctr, Oslo, Norway; [Stoll, Josefine; Mayer, Frank; Mueller, Juliane] Univ Potsdam, Univ Outpatient Clin, Professorship Sports Med & Orthoped, Potsdam, Germany; [Mueller, Juliane] Trier Univ Appl Sci, Professorship Physiotherapy Exercise Sci & Appl B, Trier, Germany	University of Potsdam; University of Innsbruck; University of Potsdam	Plummer, A (corresponding author), Univ Potsdam, Dept Sport & Hlth Sci, Clin Exercise Sci, Potsdam, Germany.	ashleyplummer@hotmail.com		Mueller, Juliane/0000-0002-4184-5427				Al Attar WSA, 2016, SPORTS MED, V46, P205, DOI 10.1007/s40279-015-0404-x; Asadi A, 2015, J STRENGTH COND RES; Aucouturier J, 2015, NITRIC OXIDE-BIOL CH, V49, P16, DOI 10.1016/j.niox.2015.05.004; Baeza G, 2017, REV BRAS MED ESPORTE, V23, P465, DOI 10.1590/1517-869220172306173456; Barber-Westin SD, 2010, J STRENGTH COND RES; Chelly MS, 2010, J STRENGTH COND RES, V24, P2670, DOI 10.1519/JSC.0b013e3181e2728f; Croisier JL, 2008, AM J SPORT MED, V36, P1469, DOI 10.1177/0363546508316764; Daneshjoo A, 2012, PLOS ONE, V7, P1, DOI DOI 10.HTTP://DX.D0I.0RG/10.1371/J0UMAL.P0NE.0051568; Daneshjoo A, 2013, BIOL SPORT; Ekstrand J, 2011, AM J SPORTS MED; Emery CA, 2009, PAEDIAT CHILD HLTH O; Filipa A, 2010, J ORTHOP SPORTS PHYS; Finch C, 2006, J SCI MED SPORT, V9, P3, DOI 10.1016/j.jsams.2006.02.009; Hermassi S, 2017, EFFECTS IN SEASON EX; Hermassi S, 2015, J STRENGTH COND RES; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Hoshikawa Y, 2013, J STRENGTH COND RES; Jakeman JR, 2016, J STRENGTH COND RES; Jullien H, 2008, J STRENGTH COND RES; Kang SH, 2013, J PHYS THER SCI, V25, P895, DOI 10.1589/jpts.25.895; Kilding AE, 2008, J SPORT SCI MED, V7, P320; Lindblom H, 2012, KNEE SURG SPORT TR A, V20, P2112, DOI 10.1007/s00167-011-1846-9; Lukas O, 2017, ACTA GYMNICA; Mandelbaum BR, 2005, AM J SPORT MED, V33, P1003, DOI 10.1177/0363546504272261; Martins DS, 2017, COMBINED PLYOMETRIC; Mascarin NC, 2017, J BODYW MOV THER, V21, P1017, DOI 10.1016/j.jbmt.2017.01.003; Moher David, 2010, BMJ, V340, pc869, DOI [10.1016/j.jclinepi.2010.03.004, 10.1136/bmj.c869]; Moher D, 2009, PHYS THER, V89, P873, DOI 10.1093/ptj/89.9.873; Mugele H, 2018, PLOS ONE; Myer GD, 2014, PHYS SPORTSMED; Niederbracht Y, 2008, J STRENGTH COND RES, V22, P140, DOI 10.1519/JSC.0b013e31815f5634; O'Brien J, 2017, CLIN J SPORT MED; Olsen OE, 2004, AM J SPORT MED, V32, P1002, DOI 10.1177/0363546503261724; Pickett W, 2005, INJ PREV; Piercy KL, 2015, AM J PUBLIC HLTH; Prieske O, 2016, SCAND J MED SCI SPOR; Ramirez-Campillo R, 2014, J STRENGTH COND RES; Romero-Franco N, 2012, J STRENGTH COND RES, V26, P2071, DOI 10.1519/JSC.0b013e31823b06e6; Rubley MD, 2011, J STRENGTH COND RES; Saraswat A, 2015, INT J PHYSIOTHER, V2, P798, DOI 10.15621/ijphy/2015/v2i5/78237; Soligard T, 2009, BMJ; Steffen K, 2008, SCAND J MED SCI SPOR, V18, P605, DOI 10.1111/j.1600-0838.2007.00703.x; Steffen K, 2008, SCAND J MED SCI SPOR, V18, P596, DOI 10.1111/j.1600-0838.2007.00708.x; Steffen K, 2013, BRIT J SPORT MED, V47, P794, DOI 10.1136/bjsports-2012-091886; Thorborg K, 2017, BR J SPORTS MED; Veliz RR, 2014, J STRENGTH COND RES; Vescovi JD, 2010, SCAND J MED SCI SPOR, V20, P394, DOI 10.1111/j.1600-0838.2009.00963.x; Wilmore JH, 2005, J ATHL TRAIN; Zech A, 2014, EUR J APPL PHYSIOL, V114, P395, DOI 10.1007/s00421-013-2786-5; Zouita S, 2016, J STRENGTH CONDITION	51	7	7	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2019	14	8							e0221346	10.1371/journal.pone.0221346	http://dx.doi.org/10.1371/journal.pone.0221346			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW6AB	31465458	Green Submitted, Green Published, gold			2023-01-03	WOS:000485058200015
J	Chen, YD; Agnello, M; Dinis, M; Chien, KC; Wang, J; Hu, W; Shi, WY; He, XS; Zou, J				Chen, Yandi; Agnello, Melissa; Dinis, Marcia; Chien, Kenneth C.; Wang, Jing; Hu, Wei; Shi, Wenyuan; He, Xuesong; Zou, Jing			Lollipop containing Glycyrrhiza uralensis extract reduces Streptococcus mutans colonization and maintains oral microbial diversity in Chinese preschool children	PLOS ONE			English	Article							DENTAL-CARIES; PREVENTION; CHILDHOOD; LICORICE; RISK	The anticariogenic activity of the extract of Glycyrrhiza uralensis (licorice) has been well documented. We recently developed an herbal lollipop containing licorice extracts with Glycyrrhizol A, the compound displaying strong antimicrobial activity against Streptococcus mutans. Preliminary testing showed that the herbal lollipop reduced salivary S. mutans counts in vivo. In this study, we aimed to further test the efficacy of this herbal lollipop for reducing salivary S. mutans levels, and investigate its impact on salivary microbiome. Using a well-established in vitro oral microbiome model, we showed that licorice extract displays targeted killing against S. mutans without affecting the biodiversity of the community. In vivo study corroborated in vitro findings, showing for high caries-risk children aged 3-6 with salivary S. mutans levels >5x10(5) cells/ml, daily use of 2 licorice-containing lollipops for 3 weeks significantly reduced salivary S. mutans levels compared to the control group. Salivary microbiome analysis showed either no change or even increase in phylogenetic diversity of the oral community following herbal lollipop usage. Although further study with longer term observation is needed, these results suggest that use of licorice extract-containing lollipops can be as a simple and effective way to reduce the risk of dental caries in children.	[Chen, Yandi; Zou, Jing] Sichuan Univ, Natl Clin Res Ctr Oral Dis, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China; [Agnello, Melissa; Dinis, Marcia] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA; [Chien, Kenneth C.] Univ Calif San Francisco, Sch Dent, San Francisco, CA USA; [Wang, Jing] Shandong Univ Tradit Chinese Med, Coll Pharmaceut Sci, Jinan, Shandong, Peoples R China; [Hu, Wei] Shandong Univ, Microbial Technol Inst, State Key Lab Microbial Technol, Qingdao, Shandong, Peoples R China; [Shi, Wenyuan; He, Xuesong] Forsyth Inst, Cambridge, MA 02142 USA	Sichuan University; University of California System; University of California Los Angeles; University of California System; University of California San Francisco; Shandong University of Traditional Chinese Medicine; Shandong University; Harvard University; Forsyth Institute	Zou, J (corresponding author), Sichuan Univ, Natl Clin Res Ctr Oral Dis, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China.; He, XS (corresponding author), Forsyth Inst, Cambridge, MA 02142 USA.	xhe@forsyth.org; zoujing1970@126.com	Chen, Yandi/AAF-9040-2019; SHI, wen/GPW-9531-2022; He, Xuesong/GXN-2297-2022	Zou, Jing/0000-0002-3618-9672; Chang Chien, Kenneth/0000-0001-8774-4229; He, Xuesong/0000-0002-3333-9188; Dinis, Marcia/0000-0001-8734-4276	National Institute of Dental and Craniofacial Research of the National Institutes of Health (NIH) [1R01DE023810, 1R01DE020102, 1R01DE026186]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE023810, R01DE026186, R01DE020102] Funding Source: NIH RePORTER	National Institute of Dental and Craniofacial Research of the National Institutes of Health (NIH); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This research was partly supported by the National Institute of Dental and Craniofacial Research of the National Institutes of Health (NIH) under awards 1R01DE020102, 1R01DE026186, and 1R01DE023810 to XH and WS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Research reported in this publication was partly supported by The National Institute of Dental and Craniofacial Research of the National Institutes of Health (NIH) under Awards 1R01DE023810, 1R01DE020102, 1R01DE026186 (to X.H. and W.S.).	Agnello M, 2017, J DENT RES, V96, P1378, DOI 10.1177/0022034517718819; ALALUUSUA S, 1989, CARIES RES, V23, P190, DOI 10.1159/000261176; Berkowitz Robert J, 2003, J Can Dent Assoc, V69, P304; Bowen WH, 2016, MOL ORAL MICROBIOL, V31, P228, DOI 10.1111/omi.12132; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Chen T, 2010, DATABASE-OXFORD, DOI 10.1093/database/baq013; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Edlund A, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-25; FAITH DP, 1992, BIOL CONSERV, V61, P1, DOI 10.1016/0006-3207(92)91201-3; Filstrup Sara L, 2003, Pediatr Dent, V25, P431; Gu F, 2002, HYBRIDOMA HYBRIDOM, V21, P225, DOI 10.1089/153685902760213822; Guo LH, 2015, SCI REP-UK, V5, DOI 10.1038/srep18015; Guo LH, 2015, P NATL ACAD SCI USA, V112, P7569, DOI 10.1073/pnas.1506207112; Harris Rebecca, 2004, Community Dent Health, V21, P71; He J, 2006, J NAT PROD, V69, P121, DOI 10.1021/np058069d; Hou J, 2017, JOURNAL OF INVESTIGA, V8; Hu CH, 2011, INT J ORAL SCI, V3, P13, DOI 10.4248/IJOS11005; KRISTOFFERSSON K, 1985, J DENT RES, V64, P58, DOI 10.1177/00220345850640011101; Li LN, 2010, INT J ORAL SCI, V2, P66, DOI 10.4248/IJOS10024; LOESCHE WJ, 1986, MICROBIOL REV, V50, P353, DOI 10.1128/MMBR.50.4.353-380.1986; Messier C, 2012, ORAL DIS, V18, P32, DOI 10.1111/j.1601-0825.2011.01842.x; Nase L, 2001, CARIES RES, V35, P412, DOI 10.1159/000047484; Peters MC, 2010, EUR ARCH PAEDIATR DE, V11, P274, DOI 10.1007/BF03262762; Petersen PE, 2004, COMMUNITY DENT ORAL, V32, P319, DOI 10.1111/j.1600-0528.2004.00175.x; Qin M, 2008, PEDIATR DENT, V30, P122; Sedighinia F, 2012, AVICENNA J PHYTOMEDI, V2, P118; Tanzer J M, 2001, J Dent Educ, V65, P1028; Tian Y, 2010, MOL ORAL MICROBIOL, V25, P357, DOI 10.1111/j.2041-1014.2010.00585.x; Wayne P, 2007, M100S117 CLIN LAB ST; Yost J, 2008, MCN-AM J MATERN-CHIL, V33, P17, DOI 10.1097/01.NMC.0000305652.01743.8d; Zhang XN, 2016, SCI REP-UK, V6, DOI 10.1038/srep18897	31	7	7	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 23	2019	14	8							e0221756	10.1371/journal.pone.0221756	http://dx.doi.org/10.1371/journal.pone.0221756			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5TR	31442287	Green Published, Green Submitted, gold			2023-01-03	WOS:000485041400073
J	Ge, Y; Dansokho, SC; Liao, XP				Ge, Yi; Dansokho, Selma Chipenda; Liao, Xiang-Peng			Advanced neonatal medicine in China: Is newborn ward capacity associated with inpatient antibiotic usage?	PLOS ONE			English	Article							CARE; PRESCRIPTION; INFECTIONS; GUIDELINES; PATTERNS	Previous surveys of neonatal medicine in China have not collected comprehensive information on antibiotic use in newborns. The goal of the present study was to assess the trends in antibiotic use in inpatient newborns from advanced hospitals in mainland China and to evaluate the contributing factors. We extracted retrospective data on newborn clinical units from a database containing key clinical subspecialty area indicators from provincial or ministerial (Class A level III) hospitals over three consecutive years (2008-2010) and in 25 of 31 provincial districts of mainland China. Fifty-five newborn units were included in the study. The results showed that two thirds (65.7% +/- 23.1%) of inpatient new-borns were prescribed antibiotic products. Antibiotic use rates were significantly different by newborn ward bed capacity (p = 0.023; 60.6% for d capacity (ficant65.7% +/- 23-100 beds group, and 77.1% for (ficant65.7% +/- 23.1%) of inpatient newb significantly different by type of hospital, geographic area, admission to physician or nurse ratio, or physician or nurse academic degree. Factors contributing significantly to antibiotic use included ward bed capacity, physician to nurse ratio, average hospital stay, and pneumonia to preterm infant ratio. Our data suggested that the use of antibiotics among inpatient newborns in advanced hospitals in mainland China was prevalent and should be subject to rigorous monitoring, and highlighted the need to explore how newborn ward bed capacity potentially impacts antibiotic use.	[Ge, Yi; Liao, Xiang-Peng] Second Mil Med Univ, Gongli Hosp, Dept Pediat, Shanghai, Peoples R China; [Dansokho, Selma Chipenda] Laval Univ, Fac Med, Off Educ & Continuing Profess Dev, Quebec City, PQ, Canada	Naval Medical University; Laval University	Liao, XP (corresponding author), Second Mil Med Univ, Gongli Hosp, Dept Pediat, Shanghai, Peoples R China.	lxp4848@aliyun.com	Liao, Xiangpeng/GNP-2312-2022	/0000-0002-4588-8803	Canadian Institutes of Health Research - Quebec Training Network in Perinatal Research Program	Canadian Institutes of Health Research - Quebec Training Network in Perinatal Research Program(Canadian Institutes of Health Research (CIHR))	This study was supported by a scholarship from the Canadian Institutes of Health Research - Quebec Training Network in Perinatal Research Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.; This study was supported by a scholarship from the Canadian Institutes of Health Research-Quebec Training Network in Perinatal Research Program. We are extremely thankful to the government agencies for the open access to the data, and to the physicians, nurses, information engineers, and other staffs to collect data from the participating hospitals.	Baggs J, 2016, JAMA INTERN MED, V176, P1639, DOI 10.1001/jamainternmed.2016.5651; Ballinger GA, 2004, ORGAN RES METHODS, V7, P127, DOI 10.1177/1094428104263672; Bert F, 2017, EUR J PUBLIC HEALTH, V27, P506, DOI 10.1093/eurpub/ckw209; Bianco A, 2018, INFECT DRUG RESIST, V11, P2199, DOI 10.2147/IDR.S170349; Boyle J, 2014, IEEE J BIOMED HEALTH, V18, P15, DOI 10.1109/JBHI.2013.2262053; Cantey JB, 2016, LANCET INFECT DIS, V16, P1178, DOI 10.1016/S1473-3099(16)30205-5; Cox LM, 2015, NAT REV ENDOCRINOL, V11, P182, DOI 10.1038/nrendo.2014.210; Currie J, 2011, ADV APPL MATH, V47, P116, DOI 10.1016/j.aam.2010.05.001; Ding H, 2008, ACTA PAEDIATR, V97, P100, DOI 10.1111/j.1651-2227.2007.00580.x; Dong LF, 2008, J ANTIMICROB CHEMOTH, V62, P410, DOI 10.1093/jac/dkn153; Driscoll A, 2018, EUR J CARDIOVASC NUR, V17, P6, DOI 10.1177/1474515117721561; Hauge C, 2017, ACTA PAEDIATR, V106, P1674, DOI 10.1111/apa.13935; Hecker MT, 2003, ARCH INTERN MED, V163, P972, DOI 10.1001/archinte.163.8.972; Lapin B, 2014, J ALLERGY CLIN IMMUN, V134, P728, DOI 10.1016/j.jaci.2014.05.006; Leroux S, 2015, ARCH DIS CHILD, V100, P394, DOI 10.1136/archdischild-2014-306873; Liang XY, 2014, FAM PRACT, V31, P311, DOI 10.1093/fampra/cmu001; Liao XP, 2018, J MATERN-FETAL NEO M, V31, P843, DOI 10.1080/14767058.2017.1299127; Liao XP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169970; Mendelson M, 2015, SAMJ S AFR MED J, V105, P325, DOI [10.7196/samj.9644, 10.7196/SAMJ.9644]; Napolitano F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084177; National action plan for combating antibiotic-resistant bacteria  2015, 2015, NAT ACT PLAN COMB AN; National Bureau of Statistics of China, 2014, CHIN POP EMPL STAT Y; National Health and Family Planning Commission of the People's Republic of China (NHFPC), 2010, PIL PROJ EV DEV NAT; Needleman J, 2002, NEW ENGL J MED, V346, P1715, DOI 10.1056/NEJMsa012247; Organisation for Economic Co-operation Development Staff, 2005, HLTH AT A GLANC; Poulsen MN, 2017, OBESITY, V25, P438, DOI 10.1002/oby.21719; Schulman J, 2015, PEDIATRICS, V135, P826, DOI 10.1542/peds.2014-3409; Shah PS, 2015, J PERINATOL, V35, P522, DOI 10.1038/jp.2015.4; Stoll BJ, 2002, PEDIATRICS, V110, P285, DOI 10.1542/peds.110.2.285; Sun Q, 2008, HEALTH AFFAIR, V27, P1042, DOI 10.1377/hlthaff.27.4.1042; Tarnow-Mordi WO, 2000, LANCET, V356, P185, DOI 10.1016/S0140-6736(00)02478-8; United Nations Development Programme, 2013, HUM DEV IND 2010; USA Centers for Disease Control and Prevention, 2017, ANT US US 2017 PROGR; Wang J, 2014, JAMA INTERN MED, V174, P1914, DOI 10.1001/jamainternmed.2014.5214; World Health Organization, 2004, PRACTICAL GUIDELINES; World Health Organization, 1993, SEL DRUG US IND EDM; World Health Organization, 2014, ANTIMICROBIAL RESIST; Xiao YH, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001556; Yin XX, 2013, J ANTIMICROB CHEMOTH, V68, P2445, DOI 10.1093/jac/dkt223; Zhang WS, 2008, EUR J CLIN PHARMACOL, V64, P821, DOI 10.1007/s00228-008-0489-3; 吴安华, 2002, [中华医院感染学杂志, Chinese Journal of Nosocomiology], V12, P881	41	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2019	14	8							e0219630	10.1371/journal.pone.0219630	http://dx.doi.org/10.1371/journal.pone.0219630			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5HO	31408462	Green Submitted, Green Published, gold			2023-01-03	WOS:000485009500005
J	Krug, S; Mordhorst, JP; Moser, F; Theuerkorn, K; Ruffert, C; Egidi, M; Rinke, A; Gress, TM; Michl, P				Krug, Sebastian; Mordhorst, Jan-Philipp; Moser, Fabian; Theuerkorn, Katharina; Ruffert, Claudia; Egidi, Maren; Rinke, Anja; Gress, Thomas M.; Michl, Patrick			Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells	PLOS ONE			English	Article							RECEPTOR SUBTYPE-1; EVEROLIMUS; EPIDEMIOLOGY; EXPRESSION; SURVIVAL; DISEASE	Somatostatin analogues (SSA) represent the standard of care for symptom control in patients with functional gastro-entero-pancreatic neuroendocrine tumors (GEP-NET). In addition, SSA exert significant anti-proliferative effects in mid-gut and pancreatic NET (PanNET). In parallel, molecularly targeted therapies (MTT) have been shown to improve progression free survival (PFS) in patients with PanNET. However, due to either primary or acquired resistance to MTT, their impact on overall survival (OS) remains unclear. To date, various hypotheses exist to explain differences in patient responsiveness to SSA and MTT. However, data addressing one of the most pivotal questions, whether combining SSA with novel MTT will result in synergistic or additive efficacy compared to monotherapy, are lacking. The aim of this study is to characterize the interaction, optimal sequence and dosing of SSA-based and molecularly targeted therapies in PanNET. Somatostatin receptor subtypes 1-5 (SSTR) were evaluated in the neuroendocrine cell lines Bon1, QGP1 and Ins-1 via immunoblot and qRT-PCR. The impact of the SSA-analogue lanreotide alone or in combination with the MTT sunitinib, everolimus and regorafenib on intracellular signalling, hormone secretion and cell proliferation was determined in cell lysates and supernatants. In addition, synergistic effects of SSA and MTT in various sequential therapeutic approaches were investigated. SSTR were differently expressed in the examined neuroendocrine tumor cell lines. SSTR modulation via lanreotide moderately influenced proliferation, mainly via modulating AKT and ERK signalling, which was paralleled by decreased chromogranin A (CgA) expression and secretion. Interestingly, MTT treatment with regorafenib upregulated the expression of SSTR-2 and -5, while sunitinib and everolimus did not significantly alter SSTR expression. Cell viability was significantly reduced by all MTT, with regorafenib exerting the most significant effects. However, compared to the marked effects of MTT alone, synergistic effects of combined MTT and lanreotide treatment were only modest and time-and dosedependent. SSTR are differentially expressed in various NEN cell lines. Their expression is influenced by MTT treatment. Various sequential or simultaneous combinations of lanreotide and MTT did not lead to significant synergistic effects.	[Krug, Sebastian; Mordhorst, Jan-Philipp; Moser, Fabian; Theuerkorn, Katharina; Ruffert, Claudia; Egidi, Maren; Michl, Patrick] Martin Luther Univ Halle Wittenberg, Dept Internal Med 1, Halle, Saale, Germany; [Krug, Sebastian; Rinke, Anja; Gress, Thomas M.] Philipps Univ, Dept Gastroenterol & Endocrinol, Marburg, Germany	Martin Luther University Halle Wittenberg; Philipps University Marburg	Michl, P (corresponding author), Martin Luther Univ Halle Wittenberg, Dept Internal Med 1, Halle, Saale, Germany.	patrick.michl@uk-halle.de	Krug, Sebastian/ABE-2890-2020; Michl, Patrick/HDN-4172-2022; Michl, Patrick/AAG-3987-2021	Krug, Sebastian/0000-0003-1672-7995; 	Ipsen Inc.	Ipsen Inc.(Ipsen)	The project was supported by a research grant from Ipsen Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anthony LB, 2015, NEUROENDOCRINOLOGY, V102, P18, DOI 10.1159/000381715; Arnold R, 2008, CLIN GASTROENTEROL H, V6, P820, DOI 10.1016/j.cgh.2008.02.052; Bajetta E, 2018, NEUROENDOCRINOLOGY, V106, P307, DOI 10.1159/000479587; Campana D, 2010, J NUCL MED, V51, P353, DOI 10.2967/jnumed.109.066662; Caplin ME, 2014, NEW ENGL J MED, V371, P224, DOI 10.1056/NEJMoa1316158; Ferolla P, 2017, LANCET ONCOL, V18, P1652, DOI 10.1016/S1470-2045(17)30681-2; Fjallskog ML, 2003, MED ONCOL, V20, P59, DOI 10.1385/MO:20:1:59; Fjallskog MLH, 2003, CLIN CANCER RES, V9, P1469; Halfdanarson TR, 2008, ANN ONCOL, V19, P1727, DOI 10.1093/annonc/mdn351; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; Kaemmerer D, 2011, EUR J NUCL MED MOL I, V38, P1659, DOI 10.1007/s00259-011-1846-5; Kulaksiz H, 2002, GUT, V50, P52, DOI 10.1136/gut.50.1.52; Kulke MH, 2017, ANN ONCOL, V28, P1309, DOI 10.1093/annonc/mdx078; Lawrence B, 2011, ENDOCRIN METAB CLIN, V40, P1, DOI 10.1016/j.ecl.2010.12.005; Modlin IM, 2010, ALIMENT PHARM THER, V31, P169, DOI 10.1111/j.1365-2036.2009.04174.x; Panzuto F, 2011, J CLIN ONCOL, V29, P2372, DOI 10.1200/JCO.2010.33.0688; Pavel M, 2016, NEUROENDOCRINOLOGY, V103, P172, DOI 10.1159/000443167; Pavel ME, 2017, CLIN PHARMACOL THER, V101, P462, DOI 10.1002/cpt.559; Pavel ME, 2011, LANCET, V378, P2005, DOI 10.1016/S0140-6736(11)61742-X; Pietras K, 2005, J CLIN ONCOL, V23, P939, DOI 10.1200/JCO.2005.07.093; Raymond E, 2011, NEW ENGL J MED, V364, P501, DOI 10.1056/NEJMoa1003825; Reubi JC, 2013, TRENDS PHARMACOL SCI, V34, P676, DOI 10.1016/j.tips.2013.10.001; Ripka S, 2010, GUT, V59, P1101, DOI 10.1136/gut.2009.189720; Segal NH, 2009, ANNU REV MED, V60, P207, DOI 10.1146/annurev.med.60.041807.132435; Somvanshi RK, 2012, PHARMACEUTICALS, V5, P417, DOI 10.3390/ph5050417; Strosberg J, 2017, NEW ENGL J MED, V376, P125, DOI 10.1056/NEJMoa1607427; Theodoropoulou M, 2013, FRONT NEUROENDOCRIN, V34, P228, DOI 10.1016/j.yfrne.2013.07.005; Wilson BJ, 2009, J BIOL CHEM, V284, P36, DOI 10.1074/jbc.M803808200; Woltering EA, 2003, CANCER BIOTHER RADIO, V18, P601, DOI 10.1089/108497803322287691; Yao JC, 2008, J CLIN ONCOL, V26, P3063, DOI 10.1200/JCO.2007.15.4377; Yao JC, 2011, NEW ENGL J MED, V364, P514, DOI 10.1056/NEJMoa1009290; Yao JC, 2010, J CLIN ONCOL, V28, P69, DOI 10.1200/JCO.2009.24.2669	32	7	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2019	14	6							e0218953	10.1371/journal.pone.0218953	http://dx.doi.org/10.1371/journal.pone.0218953			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW3BT	31237925	Green Submitted, Green Published, gold			2023-01-03	WOS:000484856000055
J	Dekerle, J; Greenhouse-Tucknott, A; Wrightson, JG; Schafer, L; Ansdell, P				Dekerle, Jeanne; Greenhouse-Tucknott, Aaron; Wrightson, James G.; Schafer, Lisa; Ansdell, Paul			Improving the measurement of TMS-assessed voluntary activation in the knee extensors	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; HUMAN MOTOR CORTEX; GROUP-III; METHODOLOGICAL ISSUES; NEUROMUSCULAR FATIGUE; STATISTICAL-METHODS; PERIPHERAL FATIGUE; MUSCLE AFFERENTS; EXCITABILITY; RELIABILITY	Purpose To test the accuracy, validity, reliability and sensitivity of an alternative method for the measure of TMS-assessed voluntary activation (VA(TMS)) in the knee extensors. Methods Ten healthy males (24 +/- 5 years) completed a neuromuscular assessment protocol before and after a fatiguing isometric exercise: two sets of five contractions (50%, 62.5%, 75%, 87.5%, 100% Maximal Voluntary Contraction; MVC) with superimposed TMS-evoked twitches for calculation of VATMs using either the first 5 stimulations (1x5C) or all 10 (2x5C). This was performed on two separate occasions (between-day reliability). Accuracy and validity were compared with a routinely used protocol [i.e. 50%, 75%, and 100% of MVC (1x3C) performed three times (3x3C)]. Results 95% confidence interval for estimated resting twitch, a key determinant of VA-rms, was similar between 1x5C, 2x5C, and 3x3C but improved by six-fold when compared to 1x3C (P<0.05). In a fresh state, potentiated twitch force was unchanged following 1x5C but decreased following 2x5C (P<0.05). A recovery was found post-exercise but was smaller for 1x5C compared to 2x5C (P<0.05), with no difference between the latter two (P>0.05). Absolute reliability was strong enough for both 1x5C and 2x5C to depict a true detectable change in the sample's VATMs following the fatiguing exercise (TEM < 3% at rest, <9% post-exercise) but 2x5C was marginally more sensitive to individual's changes from baseline. Conclusion Both 1x5C and 2x5C provide reliable measures of VA-rms. However, 1x5C may hold stronger internal validity. Both protocols allow detection of 'true' changes in sample's means but not individual scores following a fatiguing isometric exercise.	[Dekerle, Jeanne; Greenhouse-Tucknott, Aaron; Wrightson, James G.; Schafer, Lisa; Ansdell, Paul] Univ Brighton, Ctr Sport & Exercise Sci & Med SESAME, Fatigue & Exercise Tolerance Lab, Eastbourne, England; [Wrightson, James G.] Univ Calgary, Fac Kinesiol, Human Performance Lab, Calgary, AB, Canada; [Ansdell, Paul] Northumbria Univ, Fac Hlth & Life Sci, Dept Sport Exercise & Rehabil, Northumbria, England	University of Brighton; University of Calgary; Northumbria University	Dekerle, J (corresponding author), Univ Brighton, Ctr Sport & Exercise Sci & Med SESAME, Fatigue & Exercise Tolerance Lab, Eastbourne, England.	j.dekerle@brighton.ac.uk	Dekerle, Jeanne/M-8367-2019; Ansdell, Paul/J-2618-2019	Dekerle, Jeanne/0000-0002-4482-4576; Ansdell, Paul/0000-0001-7542-1107; Wrightson, James/0000-0001-7106-7470				Adreani CM, 1997, J APPL PHYSIOL, V82, P1811, DOI 10.1152/jappl.1997.82.6.1811; Armitage P, 2002, STAT METHODS; Atkinson G, 1998, SPORTS MED, V26, P217, DOI 10.2165/00007256-199826040-00002; Bachasson D, 2016, NEUROSCIENCE, V314, P125, DOI 10.1016/j.neuroscience.2015.11.056; Beaulieu LD, 2017, BRAIN STIMUL, V10, P196, DOI 10.1016/j.brs.2016.12.008; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Clark BC, 2007, J ELECTROMYOGR KINES, V17, P90, DOI 10.1016/j.jelekin.2005.11.008; Dekerle J, 2019, EUR J APPL PHYSIOL, V119, P991, DOI 10.1007/s00421-019-04089-7; Folland JP, 2007, J ELECTROMYOGR KINES, V17, P317, DOI 10.1016/j.jelekin.2006.04.008; Froyd C, 2013, J PHYSIOL-LONDON, V591, P1339, DOI 10.1113/jphysiol.2012.245316; Gandevia SC, 2001, PHYSIOL REV, V81, P1725, DOI 10.1152/physrev.2001.81.4.1725; Goodall S, 2009, EXP PHYSIOL, V94, P995, DOI 10.1113/expphysiol.2009.047902; Goodall S, 2018, EXP BRAIN RES, V236, P463, DOI 10.1007/s00221-017-5142-x; Goodall S, 2017, EUR J APPL PHYSIOL, V117, P687, DOI 10.1007/s00421-017-3561-9; Gruet M, 2014, EXP PHYSIOL, V99, P1053, DOI 10.1113/expphysiol.2014.078840; Hamada T, 2000, J APPL PHYSIOL, V88, P2131, DOI 10.1152/jappl.2000.88.6.2131; Hayes SG, 2005, J APPL PHYSIOL, V99, P1891, DOI 10.1152/japplphysiol.00629.2005; Hermens HJ, 2000, J ELECTROMYOGR KINES, V10, P361, DOI 10.1016/S1050-6411(00)00027-4; Hopkins WG, 2000, SPORTS MED, V30, P1, DOI 10.2165/00007256-200030010-00001; Hunter SK, 2006, J APPL PHYSIOL, V101, P1036, DOI 10.1152/japplphysiol.00103.2006; KAUFMAN MP, 1984, CARDIOVASC RES, V18, P663, DOI 10.1093/cvr/18.11.663; Kotan S, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00363; Kufel TJ, 2002, MUSCLE NERVE, V25, P438, DOI 10.1002/mus.10047; LORING SH, 1992, J APPL PHYSIOL, V73, P516, DOI 10.1152/jappl.1992.73.2.516; McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.1.30; Mira J, 2017, EUR J APPL PHYSIOL, V117, P1845, DOI 10.1007/s00421-017-3678-x; Otieno LA, 2019, J NEUROPHYSIOL, V121, P471, DOI 10.1152/jn.00628.2018; Sidhu SK, 2017, CLIN NEUROPHYSIOL, V128, P44, DOI 10.1016/j.clinph.2016.10.008; Sidhu SK, 2009, J APPL PHYSIOL, V106, P556, DOI 10.1152/japplphysiol.90911.2008; Sidhu SK, 2009, MUSCLE NERVE, V39, P186, DOI 10.1002/mus.21064; Souron R, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00519; Souron R, 2017, J APPL PHYSIOL, V122, P1504, DOI 10.1152/japplphysiol.00793.2016; Tamm AS, 2009, J BIOL RHYTHM, V24, P211, DOI 10.1177/0748730409334135; Taylor JL, 2009, J APPL PHYSIOL, V107, P357; Terwee CB, 2010, SPORTS MED, V40, P525, DOI 10.2165/11531370-000000000-00000; Thomas K, 2016, MED SCI SPORT EXER, V48, P1751, DOI 10.1249/MSS.0000000000000950; Thomas K, 2015, MED SCI SPORT EXER, V47, P537, DOI 10.1249/MSS.0000000000000448; Todd G, 2003, J PHYSIOL-LONDON, V551, P661, DOI 10.1113/jphysiol.2003.044099; Todd G, 2016, J APPL PHYSIOL, V121, P678, DOI 10.1152/japplphysiol.00293.2016; Twomey R, 2017, MED SCI SPORT EXER, V49, P2422, DOI 10.1249/MSS.0000000000001371; Yue GH, 2000, MUSCLE NERVE, V23, P376, DOI 10.1002/(SICI)1097-4598(200003)23:3<376::AID-MUS9>3.3.CO;2-U	41	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2019	14	6							e0216981	10.1371/journal.pone.0216981	http://dx.doi.org/10.1371/journal.pone.0216981			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IB4TA	31170180	Green Accepted, Green Published, Green Submitted, gold			2023-01-03	WOS:000470263700013
J	Nair, M; Tripathi, S; Mazumdar, S; Mahajan, R; Harshana, A; Pereira, A; Jimenez, C; Halder, D; Burza, S				Nair, Mohit; Tripathi, Santanu; Mazumdar, Sumit; Mahajan, Raman; Harshana, Amit; Pereira, Alan; Jimenez, Carolina; Halder, Debasish; Burza, Sakib			Knowledge, attitudes, and practices related to antibiotic use in Paschim Bardhaman District: A survey of healthcare providers in West Bengal, India	PLOS ONE			English	Article							RESPIRATORY-TRACT INFECTIONS; MEDICAL-STUDENTS; NEW-DELHI; PERCEPTIONS; RESISTANCE; BELIEFS; PATIENT; ADULTS	Introduction Antibiotic misuse is widespread and contributes to antibiotic resistance, especially in less regulated health systems such as India. Although informal providers are involved with substantial segments of primary healthcare, their level of knowledge, attitudes, and practices is not well documented in the literature. Objectives This quantitative study systematically examines the knowledge, attitudes, and practices of informal and formal providers with respect to antibiotic use. Methods We surveyed a convenience sample of 384 participants (96 allopathic doctors, 96 nurses, 96 informal providers, and 96 pharmacy shopkeepers) over a period of 8 weeks from December to February using a validated questionnaire developed in Italy. Our team created an equivalent, composite KAP score for each respondent in the survey, which was subsequently compared between providers. We then performed a multivariate logistic regression analysis to estimate the odds of having a low composite score (<80) based on occupation by comparing allopathic doctors (referent category) with all other study participants. The model was adjusted for age (included as a continuous variable) and gender. Results Doctors scored highest in questions assessing knowledge (77.3%) and attitudes (87.3%), but performed poorly in practices (67.6%). Many doctors knew that antibiotics were not indicated for viral infections, but over 87% (n = 82) reported prescribing them in this situation. Nurses, pharmacy shopkeepers, and informal providers were more likely to perform poorly on the survey compared to allopathic doctors (OR: 10.4, 95% CI 5.4, 20.0, p<0.01). 30.8% (n = 118) of all providers relied on pharmaceutical company representatives as a major source of information about antibiotics. Conclusions Our findings indicate poor knowledge and awareness of antibiotic use and functions among informal health providers, and dissonance between knowledge and practices among allopathic doctors. The nexus between allopathic doctors, pharmaceutical company representatives, and informal health providers present promising avenues for future research and intervention.	[Nair, Mohit; Mahajan, Raman; Harshana, Amit; Pereira, Alan; Burza, Sakib] Medecins Sans Frontieres, New Delhi, India; [Tripathi, Santanu; Mazumdar, Sumit] Calcutta Sch Trop Med, Kolkata, India; [Jimenez, Carolina] Medecins Sans Frontieres, Barcelona, Spain; [Halder, Debasish] Pasch Bardhaman Hlth Dist, Bardhaman, W Bengal, India	Calcutta School of Tropical Medicine (CSTM); Doctors Without Borders	Burza, S (corresponding author), Medecins Sans Frontieres, New Delhi, India.	sakib.burza@barcelona.msf.org	Jimenez, Carolina/GYD-8755-2022	Mahajan, Raman/0000-0001-6788-2835; Harshana, Amit Kumar Singh/0000-0003-1272-5087; de Lima Pereira, Alan/0000-0001-7578-3626; Burza, Sakib/0000-0001-7886-8633	MSF fundraising activities	MSF fundraising activities	Funding for the study was provided through normal MSF fundraising activities. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbo LM, 2013, CLIN INFECT DIS, V57, P631, DOI 10.1093/cid/cit370; Akkerman AE, 2004, J ANTIMICROB CHEMOTH, V54, P1116, DOI 10.1093/jac/dkh480; Anderson A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204878; [Anonymous], 2016, ANT RES GLOB REP SUR; [Anonymous], 2017, CDC ENC SAF ANT PRES; [Anonymous], 2018, FACTS ANT RES; Barker AK, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4261-4; Bashir A, 2012, JK PRACTITIONER, V17, P1; Bianco A, 2018, INFECT DRUG RESIST, V11, P2199, DOI 10.2147/IDR.S170349; Bloom G, 2011, HEALTH POLICY PLANN, V26, pi45, DOI 10.1093/heapol/czr025; Briggs GG., 2012, DRUGS PREGNANCY LACT; Centers for Disease Control and Prevention, 2017, ANT PRESCR US DOCT O; Chua KP, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.k5092; Das J, 2016, SCIENCE, V354, DOI 10.1126/science.aaf7384; Das J, 2012, HEALTH AFFAIR, V31, P2774, DOI 10.1377/hlthaff.2011.1356; Davis ME, 2017, ANTIBIOTICS-BASEL, V6, DOI 10.3390/antibiotics6040023; Dyar OJ, 2014, J ANTIMICROB CHEMOTH, V69, P842, DOI 10.1093/jac/dkt440; Gautham M, 2014, HEALTH POLICY PLANN, V29, pI20, DOI 10.1093/heapol/czt050; George S, 2019, AIDS CARE, V31, P875, DOI 10.1080/09540121.2018.1549720; Hawkings NJ, 2007, J ANTIMICROB CHEMOTH, V59, P1155, DOI 10.1093/jac/dkm103; Hersh AL, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2017-0027; Khan AKA, 2013, J CLIN DIAGN RES, V7, P1613, DOI 10.7860/JCDR/2013/6290.3230; Kotwani A, 2016, INDIAN J PHARMACOL, V48, P365, DOI 10.4103/0253-7613.186208; Kotwani A, 2014, TROP MED INT HEALTH, V19, P761, DOI 10.1111/tmi.12327; Kotwani A, 2010, FAM PRACT, V27, P684, DOI 10.1093/fampra/cmq059; Krishna BY, 2015, IOSR J DENT MED SCI, V14, P2279; Lindberg BH, 2017, SCAND J PRIM HEALTH, V35, P178, DOI 10.1080/02813432.2017.1333301; Minen MT, 2010, MICROB DRUG RESIST, V16, P285, DOI 10.1089/mdr.2010.0009; Ministry of Health and Family Welfare (MoHFW) Government of Bangladesh, 2017, NATL ACTION PLAN ANT; Napolitano F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084177; Norris P, 2013, ANTIBIOTICS-BASEL, V2, P465, DOI 10.3390/antibiotics2040465; Omaswa F, 2006, B WORLD HEALTH ORGAN, V84, P83, DOI 10.2471/BLT.05.027979; Padmanabha TS, 2016, INT J BASIC CLIN PHA, V5, P2432, DOI [10.18203/2319-2003.ijbcp20164100, DOI 10.18203/2319-2003.IJBCP20164100]; PULLA P, 2016, BMJ-BRIT MED J, V352, DOI DOI 10.1136/BMJ.I291; Sahoo KC, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-629; Sampath S., 2016, SCHOLARS J APPL MED, V4, P3294; Scaioli G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122476; Sudhinaraset M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054978; Varghese Joe, 2010, Indian J Med Ethics, V7, P70; WHO, 2015, ANT RES MULT PUBL AW; Zucco R, 2018, INT J MED INFORM, V111, P131, DOI 10.1016/j.ijmedinf.2017.12.005	41	27	27	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2019	14	5							e0217818	10.1371/journal.pone.0217818	http://dx.doi.org/10.1371/journal.pone.0217818			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IA7TI	31150515	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000469759100117
J	Alhabib, KF; Kinsara, AJ; Alghamdi, S; Al-Murayeh, M; Hussein, GA; AlSaif, S; Khalaf, H; Alfaleh, H; Hersi, A; Kashour, T; Al-saleh, A; Ali, M; Ullah, A; Mhish, H; Abdo, AN; Almutairi, F; Arafah, MR; AlKutshan, R; Aldosari, M; AlSabatien, BY; Alrazzaz, M; Maria, AM; Aref, AH; Selim, MM; Morsy, AM; AlTohari, FA; Alrifai, AA; Awaad, AA; El-Sayed, H; Mansour, S; Atwa, AA; Abdelkader, S; Altamimi, N; Saleh, E; Alhaidari, W; ElShihawy, EA; Busaleh, AH; Abdalmoutaleb, M; Fawzy, EM; Mokhtar, Z; Saleh, AM; Ahmad, MA; Almasswary, A; Alshehri, M; Abohatab, KM; AlGarni, T; Butt, M; Altaj, I; Abdullah, F; Alhosni, Y; Osman, HB; Bugti, N; Aziz, AA; Alarabi, A; AlHarbi, IA				Alhabib, Khalid F.; Kinsara, Abdulhalim J.; Alghamdi, Saleh; Al-Murayeh, Mushabab; Hussein, Gamal Abdin; AlSaif, Shukri; Khalaf, Hassan; Alfaleh, Hussam; Hersi, Ahmad; Kashour, Tarek; Al-saleh, Ayman; Ali, Mohammad; Ullah, Anhar; Mhish, Hassan; Abdo, Abdulrahman Nouri; Almutairi, Fawaz; Arafah, Mohammed R.; AlKutshan, Raed; Aldosari, Mubarak; AlSabatien, Basel Y.; Alrazzaz, Mohammad; Maria, Adel M.; Aref, Aziza H.; Selim, Muhammed M.; Morsy, Ayman M.; AlTohari, Fathi A.; Alrifai, Ammar A.; Awaad, Awatif A.; El-Sayed, Hassan; Mansour, Sherief; Atwa, Ashraf A.; Abdelkader, Salah; Altamimi, Naif; Saleh, Elnatheer; Alhaidari, Wael; ElShihawy, El Husseini A.; Busaleh, Ali H.; Abdalmoutaleb, Mohammed; Fawzy, Essam M.; Mokhtar, Zaki; Saleh, Adil M.; Ahmad, Mohammed A.; Almasswary, Adel; Alshehri, Mohammed; Abohatab, Khalid M.; AlGarni, Turki; Butt, Modaser; Altaj, Ibrahim; Abdullah, Farhan; Alhosni, Yahya; Osman, Hadia B.; Bugti, Najeebullah; Aziz, Atif A.; Alarabi, Abdulrahman; AlHarbi, Ibrahim A.			The first survey of the Saudi Acute Myocardial Infarction Registry Program: Main results and long-term outcomes (STARS-1 Program)	PLOS ONE			English	Article							ST-SEGMENT-ELEVATION; BASE-LINE CHARACTERISTICS; ACUTE CORONARY SYNDROMES; MANAGEMENT-PRACTICES; GENDER-DIFFERENCES; FRENCH REGISTRY; ESC; ASSOCIATION; GUIDELINES; THERAPY	Background Prior acute coronary syndrome (ACS) registries in Saudi Arabia might not have accurately described the true demographics and cardiac care of patients with ACS. We aimed to evaluate the clinical characteristics, management, and outcomes of a representative sample of patients with acute myocardial infarction (AMI) in Saudi Arabia. Methods We conducted a 1-month snap-shot, prospective, multi-center registry study in 50 hospitals from various health care sectors in Saudi Arabia. We followed patients for 1 month and 1 year after hospital discharge. Patients with AMI included those with or without ST-segment elevation (STEMI or NSTEMI, respectively). This program survey will be repeated every 5 years. Results Between May 2015 and January 2017, we enrolled 2233 patients with ACS (mean age was 56 [standard deviation = 13] years; 55.6% were Saudi citizens, 85.7% were men, and 65.9% had STEMI). Coronary artery disease risk factors were high; 52.7% had diabetes mellitus and 51.2% had hypertension. Emergency Medical Services (EMS) was utilized in only 5.2% of cases. Revascularization for patients with STEMI included thrombolytic therapy (29%), primary percutaneous coronary intervention (PCI); (42.5%), neither (29%), or a pharmacoinvasive approach (3%). Non-Saudis with STEMI were less likely to undergo primary PCI compared to Saudis (35.8% vs. 48.7%; respectively, p < 0.001), and women were less likely than men to achieve a door-to-balloon time of <90 min (42% vs. 65%; respectively, p = 0.003). Around half of the patients with NSTEMI did not undergo a coronary angiogram. All-cause mortality rates were 4%, 5.8%, and 8.1%, in-hospital, at 1 month, and at 1 year, respectively. These rates were significantly higher in women than in men. Conclusions There is an urgent need for primary prevention programs, improving the EMS infrastructure and utilization, and establishing organized ACS network programs. AMI care needs further improvement, particularly for women and non-Saudis.	[Alhabib, Khalid F.; Alfaleh, Hussam; Hersi, Ahmad; Kashour, Tarek; Al-saleh, Ayman; Ullah, Anhar] King Saud Univ, Dept Cardiac Sci, Coll Med, King Fahad Cardiac Ctr, Riyadh, Saudi Arabia; [Kinsara, Abdulhalim J.] King Saud bin Abdulaziz Univ Hlth Sci, Minist Natl Guard Hlth Affair, Dept Cardiol, COM WR King Abdullah Int Med Res Ctr, Jeddah, Saudi Arabia; [Alghamdi, Saleh] Madinah Cardiac Ctr, Madinah, Saudi Arabia; [Al-Murayeh, Mushabab; Alshehri, Mohammed] Armed Forces Hosp Southern Reg, Khamis Mushayt, Saudi Arabia; [Hussein, Gamal Abdin] King Salman North West Armed Forces Hosp, Tabuk, Saudi Arabia; [AlSaif, Shukri] Saud AlBabtain Cardiac Ctr, Dammam, Saudi Arabia; [Khalaf, Hassan] Prince Sultan Cardiac Ctr, Buraydah, Saudi Arabia; [Khalaf, Hassan] Hail Cardiac Ctr, Hail, Saudi Arabia; [Ali, Mohammad] Saudi Heart Assoc, Riyadh, Saudi Arabia; [Mhish, Hassan] King Fahd Med City, King Salman Heart Ctr, Riyadh, Saudi Arabia; [Abdo, Abdulrahman Nouri] Obeid Specialized Hosp, Riyadh, Saudi Arabia; [Almutairi, Fawaz] Secur Forces Hosp, Riyadh, Saudi Arabia; [Arafah, Mohammed R.] Dallah Hosp, Riyadh, Saudi Arabia; [AlKutshan, Raed] Aljazeera Hosp, Riyadh, Saudi Arabia; [Aldosari, Mubarak] King Saud Med City Riyadh Med Complex, Riyadh, Saudi Arabia; [AlSabatien, Basel Y.] Alwatani Natl Care Hosp, Riyadh, Saudi Arabia; [Alrazzaz, Mohammad] AlFalah Hosp, Riyadh, Saudi Arabia; [Maria, Adel M.] King Salman Hosp, Riyadh, Saudi Arabia; [Aref, Aziza H.] Imam Abdulrahman Faisal Hosp, Riyadh, Saudi Arabia; [Selim, Muhammed M.] King Fahad Gen Hosp Jeddah, Jeddah, Saudi Arabia; [Morsy, Ayman M.] AlNoor Specialist Hosp, Mecca, Saudi Arabia; [AlTohari, Fathi A.] Secur Forces Hosp, Mecca, Saudi Arabia; [Alrifai, Ammar A.] King Abdulaziz Hosp & Oncol Ctr, Jeddah, Saudi Arabia; [Awaad, Awatif A.] Althager Gen Hosp, Jeddah, Saudi Arabia; [El-Sayed, Hassan] King Abdulaziz Specialist Hosp, Altaif, Saudi Arabia; [Mansour, Sherief] AlZahra Hosp, Madinah, Saudi Arabia; [Atwa, Ashraf A.] Al Dar Hosp, Madinah, Saudi Arabia; [Abdelkader, Salah] AlMiqat Hosp, Madinah, Saudi Arabia; [Altamimi, Naif] King Fahad Hosp, Madinah, Saudi Arabia; [Saleh, Elnatheer] Ohud Hosp, Madinah, Saudi Arabia; [Alhaidari, Wael] Alansar Hosp, Madinah, Saudi Arabia; [ElShihawy, El Husseini A.] Prince Sultan Cardiac Ctr, Alhofuf Alhasa, Saudi Arabia; [Busaleh, Ali H.] Al Qateef Cent Hosp, Al Qateef, Saudi Arabia; [Abdalmoutaleb, Mohammed] Mohammad Dossary Hosp, Al Khobar, Saudi Arabia; [Fawzy, Essam M.] King Khalid Gen Hosp, Hafar Albatin, Saudi Arabia; [Mokhtar, Zaki] King Saud Hosp, Unizah, Saudi Arabia; [Saleh, Adil M.] Dr Sulaiman Alhabib Hosp, Buraydah, Saudi Arabia; [Ahmad, Mohammed A.] Alrass Gen Hosp, Arrass, Saudi Arabia; [Almasswary, Adel] Aseer Cent Hosp, Abha, Saudi Arabia; [Abohatab, Khalid M.] AlNamas Gen Hosp, Alnamas, Saudi Arabia; [AlGarni, Turki] Khamis Mushayt Gen Hosp, Khamis Mushayt, Saudi Arabia; [Butt, Modaser] King Khalid Civilian Hosp, Tabuk, Saudi Arabia; [Altaj, Ibrahim] Prince Abdulla bin Abdulaziz bin Musaed Cardiac C, Arar Cardiac Ctr, Ar Ar, Saudi Arabia; [Abdullah, Farhan] Prince Abdulaziz Bin Musaid Hosp, Ar Ar, Saudi Arabia; [Alhosni, Yahya] King Khalid Hosp, Prince Sultan Cardiac Ctr, Najran, Saudi Arabia; [Osman, Hadia B.] Prince Meteb Ibn Abdulaziz Hosp, Sakaka, Saudi Arabia; [Bugti, Najeebullah] King Abdullaziz Specialist Hosp, Sakaka, Saudi Arabia; [Aziz, Atif A.] Dumat AlJandal Hosp, Dumat Aljandal, Saudi Arabia; [Alarabi, Abdulrahman] King Fahad Cent Hosp, Albaha, Saudi Arabia; [AlHarbi, Ibrahim A.] King Fahad Cent Hosp, Jizan, Saudi Arabia	King Saud University; King Saud Bin Abdulaziz University for Health Sciences; Prince Sultan Cardiac Center; King Fahad Medical City; Security Forces Hospital - Saudi Arabia; King Saud Medical City; King Saud Bin Abdulaziz University for Health Sciences; Imam Abdulrahman Al Faisal Hospital - Dammam; Security Forces Hospital - Saudi Arabia; Jordan University of Science & Technology; King Abdullah University Hospital; Prince Sultan Cardiac Center; Assir Central Hospital; King Khalid Hospital; Prince Sultan Cardiac Center	Alhabib, KF (corresponding author), King Saud Univ, Dept Cardiac Sci, Coll Med, King Fahad Cardiac Ctr, Riyadh, Saudi Arabia.	khalidalhabib13@hotmail.com	Kinsara, Abdulhalim/AAL-1207-2020; Hersi, Ahmad/ABC-9266-2020; AlSaif, Shukri/GZM-0822-2022; GARNI, TURKI AL/ABI-4669-2020; Ullah, Anhar/CAJ-2116-2022	Kinsara, Abdulhalim/0000-0002-6414-8720; GARNI, TURKI AL/0000-0003-1041-9174; Ullah, Anhar/0000-0001-6768-2112; Alhabib, Khalid/0000-0002-6692-3874; King Saud Bin Abdulaziz University for Health Sciences, Jeddah, College of Medicine,/0000-0001-9073-534X	AstraZeneca (KSA); Algorithm pharmaceutical company; Saudi Heart Association; Emergency Department Support Program; Ministry of Health; College of Medicine Research Center at King Khalid University Hospital, King Saud University	AstraZeneca (KSA)(AstraZeneca); Algorithm pharmaceutical company; Saudi Heart Association; Emergency Department Support Program; Ministry of Health; College of Medicine Research Center at King Khalid University Hospital, King Saud University	This research was funded by AstraZeneca (KSA), Algorithm pharmaceutical company, Saudi Heart Association, Emergency Department Support Program, Ministry of Health, and the College of Medicine Research Center at King Khalid University Hospital, King Saud University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The STARS Program was managed under the auspices of the Saudi Heart Association. We would like to thank the study investigators and data collectors for their dedication and collaboration (see the list of Co-investigators and data collectors, Appendix), and Mohammad Ali for coordinating the study. Prof. Khalid F AlHabib (Principal Investigator) had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.	AlFaleh HF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124012; AlHabib KF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147385; AlHabib KF, 2011, J SAUDI HEART ASSOC, V23, P233, DOI 10.1016/j.jsha.2011.05.004; AlHabib KF, 2012, ANN SAUDI MED, V32, P9, DOI 10.5144/0256-4947.2012.9; Belle L, 2017, ARCH CARDIOVASC DIS, V110, P366, DOI 10.1016/j.acvd.2017.05.001; Chieffo Alaide, 2012, EuroIntervention, V8 Suppl P, pP27, DOI 10.4244/EIJV8SPA6; Danchin N, 2008, CIRCULATION, V118, P268, DOI 10.1161/CIRCULATIONAHA.107.762765; Hersi A, 2013, ANN SAUDI MED, V33, P339, DOI 10.5144/0256-4947.2013.339; Ibanez B, 2018, KARDIOL POL, V76, P229, DOI 10.5603/KP.2018.0041; Kristensen SD, 2014, EUR HEART J, V35, P1957, DOI 10.1093/eurheartj/eht529; Leurent G, 2014, ARCH CARDIOVASC DIS, V107, P291, DOI 10.1016/j.acvd.2014.04.005; Levine GN, 2016, J AM COLL CARDIOL, V68, P1082, DOI 10.1016/j.jacc.2016.03.513; Radovanovic D, 2007, HEART, V93, P1369, DOI 10.1136/hrt.2006.106781; Roffi M, 2016, EUR HEART J, V37, P267, DOI 10.1093/eurheartj/ehv320; Roth GA, 2018, LANCET, V392, P1736, DOI [10.1016/S0140-6736(18)32203-7, 10.1016/s0140-6736(18)32203-7]; Schiele F, 2011, AM J CARDIOL, V108, P789, DOI 10.1016/j.amjcard.2011.04.031; Shavadia J, 2013, CAN J CARDIOL, V29, P951, DOI 10.1016/j.cjca.2012.10.018; Shehab A, 2019, CURR VASC PHARMACOL, V17, P388, DOI 10.2174/1570161116666180315104820; Steg PG, 2012, EUR HEART J, V33, P2569, DOI 10.1093/eurheartj/ehs215; Storey RF, 2011, EUR HEART J, V32, P2945, DOI 10.1093/eurheartj/ehr231; Thygesen K, 2019, EUR HEART J, V40, P237, DOI [10.1093/eurheartj/ehy462, 10.1016/j.jacc.2018.08.1038, 10.1016/j.rec.2018.11.011]; Valgimigli M, 2018, LANCET, V392, P835, DOI 10.1016/S0140-6736(18)31714-8; Zaman MJ, 2014, EUR HEART J, V35, P1551, DOI 10.1093/eurheartj/ehu039; 2011, LANCET, V377, P1409, DOI DOI 10.1016/S0140-6736(11)60404-2; 2014, CIRCULATION, V129, P1629, DOI DOI 10.1161/CIRCULATIONAHA.113.005874	25	24	24	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2019	14	5							e0216551	10.1371/journal.pone.0216551	http://dx.doi.org/10.1371/journal.pone.0216551			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY9HS	31112586	Green Published, gold, Green Submitted			2023-01-03	WOS:000468451000016
J	Liu, XN; Zhao, ZG; Hou, WL; Polinder, S; van Beeck, EF; Zhang, Z; Zhou, Y; Liu, G; Xie, X; Cheng, JQ; Richardus, JH; Erasmus, V				Liu, Xiaona; Zhao, Zhiguang; Hou, Wanli; Polinder, Suzanne; van Beeck, Ed F.; Zhang, Zhen; Zhou, Yan; Liu, Gang; Xie, Xu; Cheng, Jinquan; Richardus, Jan Hendrik; Erasmus, Vicki			A multimodal intervention to improve hand hygiene compliance via social cognitive influences among kindergarten teachers in China	PLOS ONE			English	Article							CHILD DAY-CARE; HEALTH; DETERMINANTS; BEHAVIOR; PROMOTION	Children attending kindergarten are at high risk for contracting infections, for which hand hygiene (HH) has been recognized as the most cost-effective prevention measure globally. Kindergarten teachers' HH behavior plays a vital role in encouraging favorable hygiene techniques and environment. This study aims to evaluate the effectiveness of a multimodal intervention at changing kindergarten teachers' HH behavior and social cognitive factors that influences HH behavior in China. The intervention named "Clean Hands, Happy Life" includes HH products with refills, reminders and cues for action, a kick-off event with awards, and training programs. We evaluated the intervention using a self-administrative questionnaire with a stratified random sample of 12 kindergartens. Two surveys was completed by 176 teachers at baseline and 185 after the 6-month intervention. Compared with the baseline scores, there was a significant improvement in the overall self-reported HH compliance of teachers (9.38 vs. 9.68 out of 10, p = 0.006), as well as teachers' perceived disease susceptibility, disease severity and behavioral control after the intervention (p<0.05). We found that teachers' HH compliance was likely to be higher among those who have better HH guideline awareness (beta = 0.48, p<0.01) and perceived behavioral control (beta = 0.26, p = 0.01), which explained 24.2% of the variance of self-reported compliance of teachers at baseline. The assessed intervention may provide Chinese kindergarten teachers with behavioral skills and cognitions that associated with the compliance of HH behavior. We thus recommend future intervention studies consider our HH behavior change techniques, address multiple social cognitive determinants of HH behavior and include the change of targeted influences in the impact evaluation.	[Liu, Xiaona; Zhao, Zhiguang; Hou, Wanli; Zhang, Zhen; Zhou, Yan; Liu, Gang; Xie, Xu; Cheng, Jinquan] Shenzhen Ctr Dis Control & Prevent, Dept Community Hlth & Hlth Serv, Shenzhen, Guangdong, Peoples R China; [Liu, Xiaona; Polinder, Suzanne; van Beeck, Ed F.; Richardus, Jan Hendrik; Erasmus, Vicki] Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, Rotterdam, Zuid Holland Pr, Netherlands	Shenzhen Center for Disease Control & Prevention (SZCDC); Erasmus University Rotterdam; Erasmus MC	Liu, XN; Cheng, JQ (corresponding author), Shenzhen Ctr Dis Control & Prevent, Dept Community Hlth & Hlth Serv, Shenzhen, Guangdong, Peoples R China.; Liu, XN (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, Rotterdam, Zuid Holland Pr, Netherlands.	x.liu@erasmusmc.nl; cjinquan@szcdc.net	Liu, Xiaona/AAE-3907-2021; Richardus, Jan Hendrik/AAE-1278-2021	Richardus, Jan Hendrik/0000-0003-0564-6313; Liu, Xiaona/0000-0002-0183-8011	Health and Family Planning Commission of Shenzhen Municipality in China [201602001]; Department of Public Health, Erasmus University Medical Center Rotterdam in the Netherlands [20150401]; Essity Hygiene Corporate; Vinda China Group	Health and Family Planning Commission of Shenzhen Municipality in China; Department of Public Health, Erasmus University Medical Center Rotterdam in the Netherlands; Essity Hygiene Corporate; Vinda China Group	The study was made possible with support from the Health and Family Planning Commission of Shenzhen Municipality in China (Grant number: 201602001) to JC, and the Department of Public Health, Erasmus University Medical Center Rotterdam in the Netherlands (Grant number: 20150401) to VE. The specific roles of these authors are articulated in the 'author contributions' section. The funders played no role in the study design, data analysis, or preparation of the manuscript.; We gratefully acknowledge Daan Nieboer for valuable statistical advice. We thank the kindergartens and parents for their willingness to participate in the study, and the Nanshan District CDC and the Baoan District CDC for the assistance in the intervention and field investigation. Hand hygiene products used in this study were jointly sponsored by Essity Hygiene Corporate and Vinda China Group.	Bandura A, 2004, HEALTH EDUC BEHAV, V31, P143, DOI 10.1177/1090198104263660; Borghi J, 2002, TROP MED INT HEALTH, V7, P960, DOI 10.1046/j.1365-3156.2002.00954.x; Chen P, 2016, ANTIMICROB RESIST IN, V5, DOI 10.1186/s13756-016-0160-1; Curtis V, 2003, LANCET INFECT DIS, V3, P275, DOI 10.1016/S1473-3099(03)00606-6; Curtis VA, 2009, HEALTH EDUC RES, V24, P655, DOI 10.1093/her/cyp002; Friedrich MND, 2017, AM J TROP MED HYG, V96, P430, DOI 10.4269/ajtmh.16-0553; Huis A, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-92; Ingeborg BL, 2015, INFECT CONTROL DAY C; JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101; Kvaerner KJ, 2000, ARCH OTOLARYNGOL, V126, P1201, DOI 10.1001/archotol.126.10.1201; Lewinski P, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01832; Liu X, 2018, J INFECT; Lu CY, 2017, J FORMOS MED ASS; Luby SP, 2005, LANCET, V366, P225, DOI 10.1016/S0140-6736(05)66912-7; McEachan RRC, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-326; Mu X, 2016, BRAZ J INFECT DIS, V20, P413, DOI 10.1016/j.bjid.2016.04.009; Nesti MMM, 2007, J PEDIAT-BRAZIL, V83, P299, DOI [10.2223/JPED.1649, 10.1590/S0021-75572007000500004]; Peters-Scheffer N, 2008, RES DEV DISABIL, V29, P398, DOI 10.1016/j.ridd.2007.07.004; Redmond T., 2009, PERSPECTIVES LEARNIN, V10, P29; Seimetz E, 2016, HEALTH EDUC RES, V31, P109, DOI 10.1093/her/cyw002; Tao SY, 2013, PUBLIC HEALTH, V127, P620, DOI 10.1016/j.puhe.2013.03.005; The China's Ministry of Health, 2012, PUBL HLTH RESP PREV; van Breukelen GJP, 2012, J CLIN EPIDEMIOL, V65, P1212, DOI 10.1016/j.jclinepi.2012.06.002; Vetschera R, 2013, GROUP DECIS NEGOT, V22, P823, DOI 10.1007/s10726-012-9295-5; Xing WJ, 2014, LANCET INFECT DIS, V14, P308, DOI 10.1016/S1473-3099(13)70342-6; Zhang DM, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13060610; Zomer TP, 2016, EPIDEMIOL INFECT, V144, P2552, DOI 10.1017/S0950268816000911; Zomer TP, 2015, EPIDEMIOL INFECT, V143, P2494, DOI 10.1017/S095026881400329X; Zomer TP, 2013, AM J INFECT CONTROL, V41, P862, DOI 10.1016/j.ajic.2012.11.023	29	4	4	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2019	14	5							e0215824	10.1371/journal.pone.0215824	http://dx.doi.org/10.1371/journal.pone.0215824			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HY0ZM	31086379	Green Published, gold			2023-01-03	WOS:000467843000006
J	Alves, GDD; de Souza, RO; Rogez, HLG; Masaki, H; Fonseca, MJV				Dias Alves, Georgia de Assis; de Souza, Rebeca Oliveira; Ghislain Rogez, Herve Louis; Masaki, Hitoshi; Vieira Fonseca, Maria Jose			Cecropia obtusa extract and chlorogenic acid exhibit anti aging effect in human fibroblasts and keratinocytes cells exposed to UV radiation	PLOS ONE			English	Article							INGA-EDULIS LEAVES; DERMAL FIBROBLASTS; OPTIMIZATION; FLAVONOIDS	Cecropia obtusa is popularly used in the Amazonian region and exhibits antioxidant activity. Cosmetic formulations containing C. obtusa extract are commercially available for purchase; however, the chemical composition and the effects of the topical application of the extract are not described in the literature. Therefore, this study aimed to identify the main components of C. obtusa for the first time and to assess the anti aging effect in human fibroblasts and keratinocytes exposed to UVR. The main components in C. obtusa extract were identified by LC-DAD-MS/MS as chlorogenic acid (CGA), luteolin-C-hexoside, luteolin-C-hexose-O-deoxy-hexose, and apigenin-C-hexose-O-deoxy-hexose. C. obtusa extract and CGA decreased the metalloproteinase-1 and protein carbonyl levels and increased the collagen and hyaluronic acid contents. Overall, the extract exhibited better activity than CGA, and we demonstrated the ability of the extract to protect against the UV-induced increase in the pro inflammatory cytokines IL-1 beta and IL-6, which are potential pathways of the antioxidant and anti aging effect. The chemical characterization added important data to broaden the knowledge related to C. obtusa, and the results suggest that the extract is a promising candidate to be incorporated in topical photochemoprotective formulations.	[Dias Alves, Georgia de Assis; de Souza, Rebeca Oliveira; Vieira Fonseca, Maria Jose] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Pharmaceut Sci, Sao Paulo, Brazil; [Ghislain Rogez, Herve Louis] Fed Univ Para, Ctr Valorizat Amazonian Bioact Cpds CVACBA, Belem, Para, Brazil; [Masaki, Hitoshi] Tokyo Univ Technol, Tokyo, Japan	Universidade de Sao Paulo; Universidade Federal do Para; Tokyo University of Technology	Alves, GDD (corresponding author), Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Pharmaceut Sci, Sao Paulo, Brazil.	georgia.assis@gmail.com	Rogez, Herve L/A-1232-2013; de Souza, Rebeca ROS Oliveira/L-1205-2016	Rogez, Herve L/0000-0001-8925-8881; 	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [140091/2013-0]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo Fundo Amazonia (BNDS); Brazilian Genetic Heritage Management Council [010526/2015-3]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior [001]	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo Fundo Amazonia (BNDS); Brazilian Genetic Heritage Management Council; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This work was supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (Award Number: 140091/2013-0 Recipient: Georgia de Assis Dias Alves), Fundacao de Amparo a Pesquisa do Estado de Sao Paulo Fundo Amazonia (BNDS), Brazilian Genetic Heritage Management Council (Award number: CGEN License 010526/2015-3), and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Award Number: 001, Recipient: Georgia de Assis Dias Alves, Ph.D). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad Saheem, 2017, Front Biosci (Schol Ed), V9, P71; An F, 2012, NEURAL REGEN RES, V7, P2565, DOI 10.3969/j.issn.1673-5374.2012.33.001; Bosch R, 2015, ANTIOXIDANTS-BASEL, V4, P248, DOI 10.3390/antiox4020248; Brango-Vanegas J, 2014, PHYTOMEDICINE, V21, P670, DOI 10.1016/j.phymed.2014.01.001; Breiter T, 2011, FOOD CHEM, V128, P338, DOI 10.1016/j.foodchem.2011.03.029; Chaudhuri AR, 2006, MECH AGEING DEV, V127, P849, DOI 10.1016/j.mad.2006.08.006; Chen WC, 2013, PLANTA MED, V79, P616, DOI 10.1055/s-0032-1328364; Clifford MN, 2003, J AGR FOOD CHEM, V51, P2900, DOI 10.1021/jf026187q; Conrozier T, 2016, KNEE, V23, P842, DOI 10.1016/j.knee.2016.05.015; Costa GM, 2011, J BRAZIL CHEM SOC, V22, P1096, DOI 10.1590/S0103-50532011000600014; Courant F, 2014, PROTEOMICS, V14, P2369, DOI 10.1002/pmic.201400255; Cruz ED, 2013, PHYTOCHEMISTRY, V89, P71, DOI 10.1016/j.phytochem.2013.01.014; Deepha V, 2014, SPECTROCHIM ACTA A, V121, P737, DOI 10.1016/j.saa.2013.12.025; Alves GDD, 2016, IND CROP PROD, V94, P893, DOI 10.1016/j.indcrop.2016.09.064; Fagot D, 2004, PHOTOCHEM PHOTOBIOL, V79, P499, DOI 10.1562/YG-03-11-R1.1; Feng RT, 2005, J BIOL CHEM, V280, P27888, DOI 10.1074/jbc.M503347200; Jung H, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091449; Leiros GJ, 2017, J DERMATOL SCI, V85, P124, DOI 10.1016/j.jdermsci.2016.11.010; Lin CM, 2002, PLANTA MED, V68, P365, DOI 10.1055/s-2002-26753; Lopez-Lazaro M, 2009, MINI-REV MED CHEM, V9, P31, DOI 10.2174/138955709787001712; Martinez RM, 2015, J NAT PROD, V78, P1647, DOI 10.1021/acs.jnatprod.5b00198; Obayashi K, 2006, J DERMATOL SCI, V41, P121, DOI 10.1016/j.jdermsci.2005.08.004; Okano Y, 2002, J DERMATOL SCI, V29, P171, DOI 10.1016/S0923-1811(02)00021-X; Oliveira RR, 2003, PHYTOCHEM ANALYSIS, V14, P96, DOI 10.1002/pca.688; Pittayapruek P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060868; Silva EM, 2007, SEP PURIF TECHNOL, V55, P381, DOI 10.1016/j.seppur.2007.01.008; Silva EM, 2007, SEP PURIF TECHNOL, V53, P274, DOI 10.1016/j.seppur.2006.07.012; Silva EM, 2011, FOOD BIOPROD PROCESS, V89, P39, DOI 10.1016/j.fbp.2010.03.004; Simirgiotis MJ, 2010, J FOOD COMPOS ANAL, V23, P545, DOI 10.1016/j.jfca.2009.08.020; Singh M, 2015, CHEM-BIOL INTERACT, V234, P261, DOI 10.1016/j.cbi.2014.12.028; Zhang Y, 2015, EUR J HISTOCHEM, V59, P98, DOI 10.4081/ejh.2015.2467; 2008, NATURE PROTOCOLS, V3, P1125, DOI DOI 10.1038/NPROT.2008.75; 2014, AGE, V36, P353, DOI DOI 10.1007/S11357-013-9565-4	33	14	14	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 8	2019	14	5							e0216501	10.1371/journal.pone.0216501	http://dx.doi.org/10.1371/journal.pone.0216501			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX4MT	31067277	Green Submitted, Green Published, gold			2023-01-03	WOS:000467373000046
J	Mandal, R; Samstein, RM; Lee, KW; Havel, JJ; Wang, H; Krishna, C; Sabio, EY; Makarov, V; Kuo, FS; Blecua, P; Ramaswamy, AT; Durham, JN; Bartlett, B; Ma, XX; Srivastava, R; Middha, S; Zehir, A; Hechtman, JF; Morris, LGT; Weinhold, N; Riaz, N; Le, DT; Diaz, LA; Chan, TA				Mandal, Rajarsi; Samstein, Robert M.; Lee, Ken-Wing; Havel, Jonathan J.; Wang, Hao; Krishna, Chirag; Sabio, Erich Y.; Makarov, Vladimir; Kuo, Fengshen; Blecua, Pedro; Ramaswamy, Apoorva T.; Durham, Jennifer N.; Bartlett, Bjarne; Ma, Xiaoxiao; Srivastava, Raghvendra; Middha, Sumit; Zehir, Ahmet; Hechtman, Jaclyn F.; Morris, Luc G. T.; Weinhold, Nils; Riaz, Nadeem; Le, Dung T.; Diaz, Luis A., Jr.; Chan, Timothy A.			CANCER Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response	SCIENCE			English	Article							MICROSATELLITE INSTABILITY DETECTION; MUTATIONAL LANDSCAPE; CTLA-4 BLOCKADE; PD-1 BLOCKADE; GENERATION	Tumors with mismatch repair deficiency (MMR-d) are characterized by sequence alterations in microsatellites and can accumulate thousands of mutations. This high mutational burden renders tumors immunogenic and sensitive to programmed cell death-1 (PD-1) immune checkpoint inhibitors. Yet, despite their tumor immunogenicity, patients with MMR-deficient tumors experience highly variable responses, and roughly half are refractory to treatment. We present experimental and clinical evidence showing that the degree of microsatellite instability (MSI) and resultant mutational load, in part, underlies the variable response to PD-1 blockade immunotherapy in MMR-d human and mouse tumors. The extent of response is particularly associated with the accumulation of insertion-deletion (indel) mutational load. This study provides a rationale for the genome-wide characterization of MSI intensity and mutational load to better profile responses to anti-PD-1 immunotherapy across MMR-deficient human cancers.	[Mandal, Rajarsi] Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21287 USA; [Mandal, Rajarsi; Durham, Jennifer N.; Le, Dung T.] Johns Hopkins, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD 21287 USA; [Mandal, Rajarsi; Samstein, Robert M.; Lee, Ken-Wing; Havel, Jonathan J.; Sabio, Erich Y.; Makarov, Vladimir; Ma, Xiaoxiao; Morris, Luc G. T.; Riaz, Nadeem; Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Samstein, Robert M.; Blecua, Pedro; Weinhold, Nils; Riaz, Nadeem; Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA; [Havel, Jonathan J.; Makarov, Vladimir; Kuo, Fengshen; Srivastava, Raghvendra; Morris, Luc G. T.; Riaz, Nadeem; Diaz, Luis A., Jr.; Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Immunogen & Precis Oncol Platform, New York, NY 10065 USA; [Wang, Hao; Durham, Jennifer N.; Le, Dung T.] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA; [Krishna, Chirag] Mem Sloan Kettering Canc Ctr, Computat & Syst Biol Program, New York, NY 10065 USA; [Ramaswamy, Apoorva T.] Weill Cornell New York Presbyterian Hosp, Dept Otolaryngol Head & Neck Surg, New York, NY 10065 USA; [Durham, Jennifer N.; Bartlett, Bjarne; Le, Dung T.] Johns Hopkins, Swim Across Amer Lab, Baltimore, MD 21287 USA; [Middha, Sumit; Zehir, Ahmet; Hechtman, Jaclyn F.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA; [Morris, Luc G. T.] Mem Sloan Kettering Canc Ctr, Dept Surg, Head & Neck Serv, New York, NY 10065 USA; [Diaz, Luis A., Jr.] Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, New York, NY 10065 USA; [Mandal, Rajarsi] Johns Hopkins, Bloomberg Kimmel Inst Canc Immunotherapy, Johns Hopkins Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Johns Hopkins University; Johns Hopkins Medicine; Memorial Sloan Kettering Cancer Center; NewYork-Presbyterian Hospital; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Johns Hopkins University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Johns Hopkins University; Johns Hopkins Medicine	Chan, TA (corresponding author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA.; Chan, TA (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA.; Chan, TA (corresponding author), Mem Sloan Kettering Canc Ctr, Immunogen & Precis Oncol Platform, New York, NY 10065 USA.	chant@mskcc.org	Ma, Xiaoxiao/AFB-9086-2022; Chan, Timothy A/ABD-5850-2021; Bartlett, Bjarne/AAI-7358-2021; Blecua, Pedro/AAA-4589-2019; Zehir, Ahmet/ABE-7155-2020	Ma, Xiaoxiao/0000-0001-8661-5660; Bartlett, Bjarne/0000-0001-8579-0379; Blecua, Pedro/0000-0002-1012-0300; Zehir, Ahmet/0000-0001-5406-4104; Samstein, Robert/0000-0001-6860-2401; Havel, Jonathan/0000-0003-0951-510X; Kuo, Fengshen/0000-0003-1797-2896; Ramaswamy, Apoorva/0000-0001-9284-0645; Hechtman, Jaclyn/0000-0003-2645-0985; Riaz, Nadeem/0000-0001-9873-5862; Mandal, Rajarsi/0000-0001-6503-5966	NIH [T32 CA009685, 5P30 CA008748-50, R35 CA232097, 1R01CA205426]; ASCO Conquer Cancer Foundation; Pershing Square Sohn Cancer Research Alliance; STARR Cancer Consortium; Stand Up 2 Cancer [R35 CA232097, 1R01CA205426]; NATIONAL CANCER INSTITUTE [P30CA008748, T32CA009685, T32CA160001, R01CA205426, R35CA232097] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [K08DE024774] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ASCO Conquer Cancer Foundation; Pershing Square Sohn Cancer Research Alliance(Pershing Square Sohn Cancer Research Alliance); STARR Cancer Consortium; Stand Up 2 Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was funded in part by NIH grant T32 CA009685 (R.M.), ASCO Conquer Cancer Foundation Young Investigator Award (R.M.), the Pershing Square Sohn Cancer Research Alliance (T.A.C.), the STARR Cancer Consortium (T.A.C.), the NIH (core grant 5P30 CA008748-50), Stand Up 2 Cancer (T.A.C.), NIH R35 CA232097 (T.A.C.), and NIH 1R01CA205426 (T.A.C.).	Drost J, 2017, SCIENCE, V358, P234, DOI 10.1126/science.aao3130; Germano G, 2017, NATURE, V552, P116, DOI 10.1038/nature24673; Hanse RJ, 2016, NAT MED, V22, P1342, DOI 10.1038/nm.4191; Janjigian YY, 2018, CANCER DISCOV, V8, P49, DOI 10.1158/2159-8290.CD-17-0787; Kim TM, 2013, CELL, V155, P858, DOI 10.1016/j.cell.2013.10.015; Kohonen-Corish MRJ, 2005, J CLIN ONCOL, V23, P2318, DOI 10.1200/JCO.2005.00.109; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Middha S, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00084; Niu BF, 2014, BIOINFORMATICS, V30, P1015, DOI 10.1093/bioinformatics/btt755; Ogino S, 2008, J MOL DIAGN, V10, P13, DOI 10.2353/jmoldx.2008.070082; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Riaz N, 2016, NAT GENET, V48, P1327, DOI 10.1038/ng.3677; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Salipante SJ, 2014, CLIN CHEM, V60, P1192, DOI 10.1373/clinchem.2014.223677; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Supek F, 2015, NATURE, V521, P81, DOI 10.1038/nature14173; Turajlic S, 2017, LANCET ONCOL, V18, P1009, DOI 10.1016/S1470-2045(17)30516-8; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; 2017, SCIENCE, V357, P409, DOI DOI 10.1126/SCIENCE.AAN6733	25	254	266	5	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	2019	364	6439					485	+		10.1126/science.aau0447	http://dx.doi.org/10.1126/science.aau0447			38	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW6ON	31048490	Green Accepted			2023-01-03	WOS:000466809600034
J	Dedrick, RM; Guerrero-Bustamante, CA; Garlena, RA; Russell, DA; Ford, K; Harris, K; Gilmour, KC; Soothill, J; Jacobs-Sera, D; Schooley, RT; Hatfull, GF; Spencer, H				Dedrick, Rebekah M.; Guerrero-Bustamante, Carlos A.; Garlena, Rebecca A.; Russell, Daniel A.; Ford, Katrina; Harris, Kathryn; Gilmour, Kimberly C.; Soothill, James; Jacobs-Sera, Deborah; Schooley, Robert T.; Hatfull, Graham F.; Spencer, Helen			Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus	NATURE MEDICINE			English	Article							NONTUBERCULOUS MYCOBACTERIA; HOST-RANGE	A 15-year-old patient with cystic fibrosis with a disseminated Mycobacterium abscessus infection was treated with a three-phage cocktail following bilateral lung transplantation. Effective lytic phage derivatives that efficiently kill the infectious M. abscessus strain were developed by genome engineering and forward genetics. Intravenous phage treatment was well tolerated and associated with objective clinical improvement, including sternal wound closure, improved liver function, and substantial resolution of infected skin nodules.	[Dedrick, Rebekah M.; Guerrero-Bustamante, Carlos A.; Garlena, Rebecca A.; Russell, Daniel A.; Jacobs-Sera, Deborah; Hatfull, Graham F.] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; [Ford, Katrina; Harris, Kathryn; Gilmour, Kimberly C.; Soothill, James; Spencer, Helen] Great Ormond St Hosp Sick Children, London, England; [Schooley, Robert T.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of California System; University of California San Diego	Hatfull, GF (corresponding author), Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.; Spencer, H (corresponding author), Great Ormond St Hosp Sick Children, London, England.	gfh@pitt.edu; helen.spencer@gosh.nhs.uk		Dedrick, Rebekah/0000-0002-3666-711X; Guerrero, Carlos/0000-0002-7256-5188	National Institutes of Health [GM116884]; Howard Hughes Medical Institute [54308198]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM116884] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank T. Sampson, L. Holst, and S. Pinches for the discovery of BPs, Muddy, and ZoeJ, respectively, and the students and faculty in the Mycobacterial Genetics Course at the University of KwaZulu Natal and in the SEA-PHAGES program for their contributions in isolating and characterizing the collection of phages used here. Further information about the phages, who isolated them and from where is available at https://phagesdb.org.We thank the Great Ormond Street Hospital staff in the Departments of Microbiology, Cell Therapy, and Pharmacy for excellent technical assistance, C. Murphy for assistance with strains and sera, J. Standing and B. Margetts for assistance with figures, D. Bain at the University of Pittsburgh for the ICP-MS analysis, and A. Betsko for electron microscopy. We greatly appreciate the advice of J. Hartley on regulatory aspects, and thank C. Hamilton for help with translation. We thank T. Mavrich for comments on the manuscript and we are grateful to S. Strathdee for general advice and comments on the manuscript. This work was funded by the National Institutes of Health (grant GM116884 to G.F.H.) and the Howard Hughes Medical Institute (grant 54308198 to G.F.H.).	Adler Frederick R, 2009, Proc Am Thorac Soc, V6, P619, DOI 10.1513/pats.2009008-088TL; Bloom BR, 2017, MAJOR INFECT DIS, DOI 10.1596/978-1-4648-0524-0/ch11; Broussard GW, 2013, MOL CELL, V49, P237, DOI 10.1016/j.molcel.2012.11.012; Chan BK, 2018, EVOL MED PUBLIC HLTH, P60, DOI 10.1093/emph/eoy005; Dedrick RM, 2019, TUBERCULOSIS, V115, P14, DOI 10.1016/j.tube.2019.01.002; Furukawa BS, 2018, SEMIN RESP CRIT CARE, V39, P383, DOI 10.1055/s-0038-1651495; Griffith David E, 2014, F1000Prime Rep, V6, P107, DOI 10.12703/P6-107; Hatfull GF, 2015, J VIROL, V89, P8107, DOI 10.1128/JVI.01340-15; Honda JR, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02029; Jacobs-Sera D, 2012, VIROLOGY, V434, P187, DOI 10.1016/j.virol.2012.09.026; Kakasis A, 2019, INT J ANTIMICROB AG, V53, P16, DOI 10.1016/j.ijantimicag.2018.09.004; Koz'min-Sokolov B N, 1975, Probl Tuberk, P75; Marinelli LJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003957; Martiniano SL, 2017, PEDIATR PULM, V52, pS29, DOI 10.1002/ppul.23825; Osmani M, 2018, TRANSPL INFECT DIS, V20, DOI 10.1111/tid.12835; Russell DA, 2018, METHODS MOL BIOL, V1681, P109, DOI 10.1007/978-1-4939-7343-9_9; Rybniker J, 2006, J MED MICROBIOL, V55, P37, DOI 10.1099/jmm.0.46238-0; Schooley RT, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.00954-17; Sula L, 1981, Czech Med, V4, P209; Trigo G, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002183; 2012, J COMPUT BIOL, V19, P455, DOI DOI 10.1089/CMB.2012.0021	21	513	529	31	292	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2019	25	5					730	+		10.1038/s41591-019-0437-z	http://dx.doi.org/10.1038/s41591-019-0437-z			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	HY6NU	31068712	Green Submitted, Green Accepted			2023-01-03	WOS:000468247800014
J	Eshete, MT; Baeumler, PI; Siebeck, M; Tesfaye, M; Haileamlak, A; Michael, GG; Ayele, Y; Irnich, D				Eshete, Million Tesfaye; Baeumler, Petra I.; Siebeck, Matthias; Tesfaye, Markos; Haileamlak, Abraham; Michael, Girma G.; Ayele, Yemane; Irnich, Dominik			Quality of postoperative pain management in Ethiopia: A prospective longitudinal study	PLOS ONE			English	Article							PATIENT OUTCOME QUESTIONNAIRE; SOCIAL SUPPORT; PREVALENCE; SATISFACTION; SOCIETY; SURGERY; VALIDATION; PERCEPTION; GENDER; IMPACT	Background The annual number of surgical operations performed is increasing throughout the world. With this rise in the number of surgeries performed, so too, the challenge of effectively managing postoperative pain. In Africa, there are scanty data available that make use of multicenter data to characterize the quality of postoperative pain management. In this study using a longitudinal data, we have attempted to characterize the quality of postoperative pain management; among patients scheduled for major elective orthopedic, gynecologic and general surgery. Methods This prospective longitudinal study evaluated the quality of postoperative pain management in patients undergoing elective general, gynecologic, and orthopedic surgery. We quantified the prevalence of moderate to severe postoperative pain with the International Pain Outcome Questionnaire and the corresponding adequacy of treatment with the pain management index. At four time points after surgery, we estimated pain severity, its physical and emotional interference, and patient satisfaction. Results Moderate to severe postoperative pain was present in 88.2% of patients, and pain was inadequately treated in 58.4% of these patients. Chronic pain (beta = 0.346, 95% CI: 0.212, 0.480) predicted patients' worst pain intensity. Gender was not associated with the worst pain intensity or percentage of time spent in severe pain. Patient's pain intensity did not predicted the level of satisfaction. Conclusions The prevalence of moderate to severe postoperative pain and its functional interference is high in Ethiopian patients. The treatment provided to patients is inadequate and not in line with international recommendations and standards.	[Eshete, Million Tesfaye; Michael, Girma G.; Ayele, Yemane] Jimma Univ, Inst Hlth, Dept Anesthesiol, Fac Med, Jimma, Ethiopia; [Eshete, Million Tesfaye; Siebeck, Matthias] Univ Munich LMU, Med Ctr, CIHLMU Ctr Int Hlth, Munich, Germany; [Baeumler, Petra I.; Irnich, Dominik] LMU, Univ Hosp, Dept Anesthesiol, Ctr Multidisciplinary Pain, Munich, Germany; [Siebeck, Matthias] Univ Munich LMU, Med Ctr, Dept Gen Visceral & Transplantat Surg, Munich, Germany; [Tesfaye, Markos] St Pauls Hosp, Millennium Med Coll, Dept Psychiat, Addis Ababa, Ethiopia; [Haileamlak, Abraham] Jimma Univ, Fac Med, Inst Hlth, Dept Pediat & Child Hlth, Jimma, Ethiopia	Jimma University; University of Munich; University of Munich; University of Munich; Jimma University	Eshete, MT (corresponding author), Jimma Univ, Inst Hlth, Dept Anesthesiol, Fac Med, Jimma, Ethiopia.; Eshete, MT (corresponding author), Univ Munich LMU, Med Ctr, CIHLMU Ctr Int Hlth, Munich, Germany.	mtesfaye1@gmail.com		Tesfaye, Markos/0000-0002-3351-701X; Eshete, Million Tesfaye/0000-0002-4994-354X	Jimma University; CIHLMU Center for International Health, Ludwig-Maximilians-Universitat, Munich, Germany; German Academic Exchange Service (DAAD); DAAD-Exceed Program; German Ministry for Economic Cooperation and Development	Jimma University; CIHLMU Center for International Health, Ludwig-Maximilians-Universitat, Munich, Germany; German Academic Exchange Service (DAAD)(Deutscher Akademischer Austausch Dienst (DAAD)); DAAD-Exceed Program; German Ministry for Economic Cooperation and Development	This study was supported by the Jimma University and CIHLMU Center for International Health, Ludwig-Maximilians-Universitat, Munich, Germany.; We thank Jimma University, Department of Anesthesiology, Jimma University Medical Center, Yekatit 12 Hospital Medical College, Zewditu Memorial Hospital, the data collectors, data entry clerks, supervisors, and patients for their cooperation. We also thank the CIHLMU Center for International Health, Ludwig-Maximilians-Universitat, Munich, Germany, and its funding agencies, the German Academic Exchange Service (DAAD), the DAAD-Exceed Program, and the German Ministry for Economic Cooperation and Development for their support. In addition, we thank Jacquie Klesing, Board-certified Editor in the Life Sciences (ELS), for editing assistance with the manuscript.	Adogwa O, 2017, GLOB SPINE J, V7, P774, DOI 10.1177/2192568217696696; [Anonymous], 2011, MAN AC PAIN DEV WORL; Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; Beiranvand Siavash, 2014, Acta Med Iran, V52, P909; Brown C, 2013, PAIN MANAG NURS, V14, P184, DOI 10.1016/j.pmn.2010.12.002; Campbell CM, 2012, PAIN MANAG, V2, P219, DOI 10.2217/PMT.12.7; Carr Eloise, 2007, J Perioper Pract, V17, P200; Caumo W, 2002, ACTA ANAESTH SCAND, V46, P1265, DOI 10.1034/j.1399-6576.2002.461015.x; Centers for Disease Control and Prevention FDRoEMoH Ethiopian Public Health Association, 2011, BAS EV PAIN MAN PRAC; Chia YY, 2002, CAN J ANAESTH, V49, P249, DOI 10.1007/BF03020523; Chiu AS, 2018, J SURG EDUC, V75, P65, DOI 10.1016/j.jsurg.2017.06.020; Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008; Chung Joanne W Y, 2003, Nurs Health Sci, V5, P13, DOI 10.1046/j.1442-2018.2003.00130.x; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Cole LJ, 2010, NEUROBIOL AGING, V31, P494, DOI 10.1016/j.neurobiolaging.2008.04.012; Cui J, 2007, COMMUN STAT-SIMUL C, V36, P987, DOI 10.1080/03610910701539617; Darawad MW, 2014, PAIN MANAG NURS, V15, P116, DOI 10.1016/j.pmn.2012.07.005; Dihle A, 2006, J PAIN, V7, P272, DOI 10.1016/j.jpain.2005.11.005; du Prel JB, 2009, DTSCH ARZTEBL INT, V106, P335, DOI 10.3238/arztebl.2009.0335; EYs Macro O, 2005, ETHIOPIA DEMOGRAPHIC; Gerbershagen HJ, 2013, ANESTHESIOLOGY, V118, P934, DOI 10.1097/ALN.0b013e31828866b3; Gordon DB, 2010, J PAIN, V11, P1172, DOI 10.1016/j.jpain.2010.02.012; Gramke HF, 2009, CLIN J PAIN, V25, P455, DOI 10.1097/AJP.0b013e31819a6e34; Gupta Anita, 2009, J Pain Res, V2, P157; Joshi Girish P, 2005, Anesthesiol Clin North Am, V23, P21, DOI 10.1016/j.atc.2004.11.013; King NB, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001411; Kinjo S, 2012, J ANESTH, V26, P1, DOI 10.1007/s00540-011-1249-6; KULIK JA, 1989, HEALTH PSYCHOL, V8, P221, DOI 10.1037/0278-6133.8.2.221; Kuusniemi K, 2016, J PAIN RES, V9, P25, DOI 10.2147/JPR.S92502; Lanitis S, 2015, KOREAN J PAIN, V28, P265, DOI 10.3344/kjp.2015.28.4.265; Ma Y, 2012, REGION ANESTH PAIN M, V37, P99, DOI 10.1097/AAP.0b013e31823ebc74; Malouf J, 2006, J PAIN SYMPTOM MANAG, V32, P361, DOI 10.1016/j.jpainsymman.2006.05.006; McNeill JA, 2004, J PAIN SYMPTOM MANAG, V28, P47, DOI 10.1016/j.jpainsymman.2003.11.005; Meissner W, 2017, DTSCH ARZTEBL INT, V114, P161, DOI 10.3238/arztebl.2017.0161; Mercadante S, 2008, SUPPORT CARE CANCER, V16, P1203, DOI 10.1007/s00520-008-0456-7; Mercadante S, 2015, J CLIN ONCOL, V33, P2119, DOI 10.1200/JCO.2014.60.6152; Murray AA, 2016, SOUTH AFR J ANAESTH, V22, P19, DOI 10.1080/22201181.2015.1115608; Mwaka G, 2013, AFR HEALTH SCI, V13, P768, DOI 10.4314/ahs.v13i3.36; Oldenmenger WH, 2009, EUR J CANCER, V45, P1370, DOI 10.1016/j.ejca.2009.01.007; Pereira MP, 2015, CURR OPIN ANESTHESIO, V28, P546, DOI 10.1097/ACO.0000000000000226; Phillips S, 2013, J PAIN RES, V6, P683, DOI 10.2147/JPR.S42262; RCT, 2014, LANG ENV STAT COMP; Rothaug J, 2013, J PAIN, V14, P1361, DOI 10.1016/j.jpain.2013.05.016; Sakakibara N, 2018, BMC PALLIAT CARE, V17, DOI 10.1186/s12904-018-0355-8; Salm-Reifferscheidt L, 2018, LANCET, V391, P1982, DOI 10.1016/S0140-6736(18)31073-0; Schade V, 1999, PAIN, V80, P239, DOI 10.1016/S0304-3959(98)00210-3; Shen Q, 2008, WESTERN J NURS RES, V30, P975, DOI 10.1177/0193945908319576; Sommer M, 2008, EUR J ANAESTH, V25, P267, DOI 10.1017/S0265021507003031; Sousa VD, 2011, J EVAL CLIN PRACT, V17, P268, DOI 10.1111/j.1365-2753.2010.01434.x; Stephens J, 2003, RHEUMATOLOGY, V42, P40, DOI 10.1093/rheumatology/keg497; Strohbuecker B, 2005, J PAIN SYMPTOM MANAG, V29, P498, DOI 10.1016/j.jpainsymman.2004.08.012; Subramanian P, 2016, INT J NURS PRACT, V22, P232, DOI 10.1111/ijn.12363; Twisk JW, 2013, APPL LONGITUDINAL DA; Vargas-Schaffer G, 2010, CAN FAM PHYSICIAN, V56, P514; Weiser TG, 2016, B WORLD HEALTH ORGAN, V94, P201, DOI 10.2471/BLT.15.159293; Whelan CT, 2004, ARCH INTERN MED, V164, P175, DOI 10.1001/archinte.164.2.175; Wickham H., 2016, GGPLOT2 ELEGANT GRAP, DOI [10.1007/978-3-319-24277-4, DOI 10.1007/978-3-319-24277-4]; Woldehaimanot TE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102835; Zheng H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178659; 2004, CLIN J PAIN, V20, P331; 2014, PAIN, V155, P1401, DOI DOI 10.1016/J.PAIN.2014.04.02100006396-201407000-00031; 2008, ACTA ANAESTH SCAND, V52, P938, DOI DOI 10.1111/J.1399-6576.2008.01641.X; 1998, PAIN, V76, P167; 2008, CLIN J PAIN, V24, P399, DOI DOI 10.1097/AJP.0B013E3181671A08; 2003, PAIN, V105, P415, DOI DOI 10.1016/S0304-3959(03)00252-5; 2015, PAIN PRACT, V15, P236, DOI DOI 10.1111/PAPR.12166; 2002, PAIN, V97, P189	67	16	16	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2019	14	5							e0215563	10.1371/journal.pone.0215563	http://dx.doi.org/10.1371/journal.pone.0215563			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW0KS	31042777	Green Submitted, Green Published, gold			2023-01-03	WOS:000466370200037
J	Le Tourneau, C; Borcoman, E; Kamal, M				Le Tourneau, Christophe; Borcoman, Edith; Kamal, Maud			Molecular profiling in precision medicine oncology	NATURE MEDICINE			English	Editorial Material							TUMORS; CANCERS	Three innovative precision medicine studies show the utility of evidence beyond that from tumor DNA sequencing to guide therapy in patients with cancer.	[Le Tourneau, Christophe; Borcoman, Edith; Kamal, Maud] Inst Curie, Dept Drug Dev & Innovat D3i, Paris, France; [Le Tourneau, Christophe; Borcoman, Edith; Kamal, Maud] Inst Curie, Dept Drug Dev & Innovat D3i, St Cloud, France; [Le Tourneau, Christophe] INSERM, U900, Res Unit, St Cloud, France; [Le Tourneau, Christophe] Paris Saclay Univ, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Le Tourneau, C (corresponding author), Inst Curie, Dept Drug Dev & Innovat D3i, Paris, France.; Le Tourneau, C (corresponding author), Inst Curie, Dept Drug Dev & Innovat D3i, St Cloud, France.; Le Tourneau, C (corresponding author), INSERM, U900, Res Unit, St Cloud, France.; Le Tourneau, C (corresponding author), Paris Saclay Univ, Paris, France.	Christophe.LeTourneau@curie.fr		Le Tourneau, Christophe/0000-0001-9772-4686				Belin L, 2017, ANN ONCOL, V28, P590, DOI 10.1093/annonc/mdw666; Drilon A, 2018, NEW ENGL J MED, V378, P731, DOI 10.1056/NEJMoa1714448; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le Tourneau C, 2015, LANCET ONCOL, V16, P1324, DOI 10.1016/S1470-2045(15)00188-6; Massard C, 2017, CANCER DISCOV, V7, P586, DOI 10.1158/2159-8290.CD-16-1396; Rodon J, 2019, NAT MED, V25, P751, DOI 10.1038/s41591-019-0424-4; Rothwell DG, 2019, NAT MED, V25, P738, DOI 10.1038/s41591-019-0380-z; Sicklick JK, 2019, NAT MED, V25, P744, DOI 10.1038/s41591-019-0407-5; Stockley TL, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0364-2; Von Hoff DD, 2010, J CLIN ONCOL, V28, P4877, DOI 10.1200/JCO.2009.26.5983; Yates LR, 2018, ANN ONCOL, V29, P30, DOI 10.1093/annonc/mdx707	11	34	34	3	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2019	25	5					711	712		10.1038/s41591-019-0442-2	http://dx.doi.org/10.1038/s41591-019-0442-2			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	HY6NU	31036881				2023-01-03	WOS:000468247800010
J	Kim, IS; Gao, Y; Welte, T; Wang, H; Liu, J; Janghorban, M; Sheng, KW; Niu, YC; Goldstein, A; Zhao, N; Bado, I; Lo, HC; Toneff, MJ; Nguyen, T; Bu, W; Jiang, WY; Arnold, J; Gu, F; He, J; Jebakumar, D; Walker, K; Li, Y; Mo, QX; Westbrook, TF; Zong, CH; Rao, A; Sreekumar, A; Rosen, JM; Zhang, XHF				Kim, Ik Sun; Gao, Yang; Welte, Thomas; Wang, Hai; Liu, Jun; Janghorban, Mahnaz; Sheng, Kuanwei; Niu, Yichi; Goldstein, Amit; Zhao, Na; Bado, Igor; Lo, Hin-Ching; Toneff, Michael J.; Nguyen, Tuan; Bu, Wen; Jiang, Weiyu; Arnold, James; Gu, Franklin; He, Jian; Jebakumar, Deborah; Walker, Kimberly; Li, Yi; Mo, Qianxing; Westbrook, Thomas F.; Zong, Chenghang; Rao, Arundhati; Sreekumar, Arun; Rosen, Jeffrey M.; Zhang, Xiang H-F			Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms	NATURE CELL BIOLOGY			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; BONE-MARROW; MIR-200 FAMILY; MACROPHAGE POLARIZATION; SUPPRESSOR-CELLS; T-CELLS; TUMORS; MICROENVIRONMENT; METASTASIS; ZEB1	Cancer-induced immune responses affect tumour progression and therapeutic response. In multiple murine models and clinical datasets, we identified large variations of neutrophils and macrophages that define 'immune subtypes' of triple-negative breast cancer (TNBC), including neutrophil-enriched (NES) and macrophage-enriched subtypes (MES). Different tumour-intrinsic pathways and mutual regulation between macrophages (or monocytes) and neutrophils contribute to the development of a dichotomous myeloid compartment. MES contains predominantly macrophages that are CCR2-dependent and exhibit variable responses to immune checkpoint blockade (ICB). NES exhibits systemic and local accumulation of immunosuppressive neutrophils (or granulocytic myeloid-derived suppressor cells), is resistant to ICB, and contains a minority of macrophages that seem to be unaffected by CCR2 knockout. A MES-to-NES conversion mediated acquired ICB resistance of initially sensitive MES models. Our results demonstrate diverse myeloid cell frequencies, functionality and potential roles in immunotherapies, and highlight the need to better understand the inter-patient heterogeneity of the myeloid compartment.	[Kim, Ik Sun; Welte, Thomas; Wang, Hai; Liu, Jun; Goldstein, Amit; Bado, Igor; Lo, Hin-Ching; Bu, Wen; Jiang, Weiyu; Li, Yi; Zhang, Xiang H-F] Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Kim, Ik Sun; Sheng, Kuanwei; Lo, Hin-Ching] Integrat Mol & Biomed Sci Grad Program, Houston, TX USA; [Kim, Ik Sun; Gao, Yang; Welte, Thomas; Wang, Hai; Liu, Jun; Janghorban, Mahnaz; Sheng, Kuanwei; Niu, Yichi; Goldstein, Amit; Zhao, Na; Bado, Igor; Lo, Hin-Ching; Toneff, Michael J.; Nguyen, Tuan; Bu, Wen; Jiang, Weiyu; Arnold, James; Gu, Franklin; Li, Yi; Westbrook, Thomas F.; Zong, Chenghang; Sreekumar, Arun; Rosen, Jeffrey M.; Zhang, Xiang H-F] Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Kim, Ik Sun; Gao, Yang; Welte, Thomas; Wang, Hai; Liu, Jun; Janghorban, Mahnaz; Goldstein, Amit; Zhao, Na; Bado, Igor; Lo, Hin-Ching; Toneff, Michael J.; Nguyen, Tuan; Bu, Wen; Jiang, Weiyu; Li, Yi; Sreekumar, Arun; Rosen, Jeffrey M.; Zhang, Xiang H-F] Dept Mol & Cellular Biol, Houston, TX 77251 USA; [Sheng, Kuanwei; Niu, Yichi; Mo, Qianxing; Westbrook, Thomas F.; Zong, Chenghang] Dept Mol & Human Genet, Houston, TX USA; [Toneff, Michael J.; Walker, Kimberly] Widener Univ, Dept Biol, One Univ Pl, Chester, PA 19013 USA; [Nguyen, Tuan] Grad Program Translat Biol & Mol Med, Houston, TX USA; [Arnold, James; Gu, Franklin; Westbrook, Thomas F.] Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX USA; [He, Jian; Jebakumar, Deborah; Rao, Arundhati] Baylor Scott & White Healthcare, Scott & White Med Ctr, Temple, TX USA; [Mo, Qianxing] H Lee Moffitt Canc Ctr & Res Inst, Dept Biostat & Bioinformat, Tampa, FL USA; [Zong, Chenghang; Zhang, Xiang H-F] Baylor Coll Med, McNair Med Inst, One Baylor Plaza, Houston, TX 77030 USA	Widener University; Baylor Health Care System; Scott & White Medical Center; H Lee Moffitt Cancer Center & Research Institute; Baylor College of Medicine	Zhang, XHF (corresponding author), Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA.; Zhang, XHF (corresponding author), Dan L Duncan Canc Ctr, Houston, TX 77030 USA.; Zhang, XHF (corresponding author), Dept Mol & Cellular Biol, Houston, TX 77251 USA.; Zhang, XHF (corresponding author), Baylor Coll Med, McNair Med Inst, One Baylor Plaza, Houston, TX 77030 USA.	xiangz@bcm.edu	Bado, Igor/AAY-1214-2021; Nguyen, Tony Minh/AAH-1121-2019; Sheng, Kuanwei/F-4550-2017; Li, Yi/A-7635-2009	Bado, Igor/0000-0001-8855-4750; Nguyen, Tony Minh/0000-0003-4879-3962; Sheng, Kuanwei/0000-0002-7155-9915; Zhao, Na/0000-0002-8161-3380; jiang, weiyu/0000-0001-6199-4289; Zhang, Xiang/0000-0002-5674-8670; Li, Yi/0000-0002-9976-518X	Breast Cancer Research Foundation; NCI [CA151293]; US Department of Defense [DAMD W81XWH-16-1-0073, W81XWH-18-1-0574]; Susan G. Komen [CCR14298445]; McNair Medical Institute; NIH [P30 AI036211, P30 CA125123, S10 RR024574];  [NCI-CA16303]; NATIONAL CANCER INSTITUTE [R01CA016303, P30CA125123] Funding Source: NIH RePORTER	Breast Cancer Research Foundation; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); US Department of Defense(United States Department of Defense); Susan G. Komen(Susan G. Komen Breast Cancer Foundation); McNair Medical Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank D. Weiss for critically editing the manuscript, and A. Muscarella, S. Kurley, S. Kim, J. Kim, B. Ton, L. Ma and S.I. Abrams for providing various tumour models. X.H.-F. Z. is supported by Breast Cancer Research Foundation, NCI CA151293, US Department of Defense DAMD W81XWH-16-1-0073 and W81XWH-18-1-0574, Susan G. Komen CCR14298445, and McNair Medical Institute. J.M.R. is supported by NCI-CA16303. Flow cytometry and cell sorting was performed at the Cytometry and Cell Sorting Core at Baylor College of Medicine with funding from the NIH (P30 AI036211, P30 CA125123 and S10 RR024574) and the expert assistance of J.M. Sederstrom.	Ali HR, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002194; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Casbon AJ, 2015, P NATL ACAD SCI USA, V112, pE566, DOI 10.1073/pnas.1424927112; Catena R, 2013, CANCER DISCOV, V3, P578, DOI 10.1158/2159-8290.CD-12-0476; Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282; Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; De Henau O, 2016, NATURE, V539, P443, DOI 10.1038/nature20554; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Dongre A, 2017, CANCER RES, V77, P3982, DOI 10.1158/0008-5472.CAN-16-3292; Du ZJ, 2006, P NATL ACAD SCI USA, V103, P17396, DOI 10.1073/pnas.0608607103; Dyer DP, 2014, J IMMUNOL, V192, P2177, DOI 10.4049/jimmunol.1300194; Egeblad M, 2010, DEV CELL, V18, P884, DOI 10.1016/j.devcel.2010.05.012; Fridlender ZG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031524; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gallina G, 2006, J CLIN INVEST, V116, P2777, DOI 10.1172/JCI28828; Gautier EL, 2012, NAT IMMUNOL, V13, P1118, DOI 10.1038/ni.2419; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Iglesia MD, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw144; Iglesia MD, 2014, CLIN CANCER RES, V20, P3818, DOI 10.1158/1078-0432.CCR-13-3368; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kaneda MM, 2016, NATURE, V539, P437, DOI 10.1038/nature19834; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820; Kim IS, 2016, CANCER METAST REV, V35, P601, DOI 10.1007/s10555-016-9643-z; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; Kusmartsev S, 2006, CANCER IMMUNOL IMMUN, V55, P237, DOI 10.1007/s00262-005-0048-z; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Li B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1028-7; Lou YY, 2016, CLIN CANCER RES, V22, P3630, DOI 10.1158/1078-0432.CCR-15-1434; Mabbott NA, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-632; Maglione JE, 2001, CANCER RES, V61, P8298; Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001; Maruyama K, 2012, IMMUNITY, V37, P1024, DOI 10.1016/j.immuni.2012.08.022; Nagalla S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r34; Netherby CS, 2017, CANCER IMMUNOL IMMUN, V66, P989, DOI 10.1007/s00262-017-1963-5; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Nguyen PL, 2008, J CLIN ONCOL, V26, P2373, DOI 10.1200/JCO.2007.14.4287; Pahler J, 2008, NEOPLASIA, V10, P329, DOI 10.1593/neo.07871; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Park J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1711; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pfefferle AD, 2016, DIS MODEL MECH, V9, P749, DOI 10.1242/dmm.025239; Porta C, 2011, IMMUNOTHERAPY-UK, V3, P1185, DOI [10.2217/IMT.11.116, 10.2217/imt.11.116]; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Redig AJ, 2013, J INTERN MED, V274, P113, DOI 10.1111/joim.12084; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Semerad CL, 2002, IMMUNITY, V17, P413, DOI 10.1016/S1074-7613(02)00424-7; Sitkovsky M, 2005, NAT REV IMMUNOL, V5, P712, DOI 10.1038/nri1685; Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008-5472.CAN-07-5644; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tian L, 2017, NATURE, V544, P250, DOI 10.1038/nature21724; Toneff MJ, 2016, BMC BIOL, V14, DOI 10.1186/s12915-016-0269-y; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wculek SK, 2015, NATURE, V528, P413, DOI 10.1038/nature16140; Wellenstein MD, 2019, NATURE, V572, P538, DOI 10.1038/s41586-019-1450-6; Welte T, 2016, NAT CELL BIOL, V18, P632, DOI 10.1038/ncb3355	71	121	123	7	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2019	21	9					1113	+		10.1038/s41556-019-0373-7	http://dx.doi.org/10.1038/s41556-019-0373-7			17	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	IV6FG	31451770	Green Accepted			2023-01-03	WOS:000484363700010
J	Gele, AA; Musse, FK; Qureshi, S				Gele, Abdi A.; Musse, Fathia K.; Qureshi, Samera			Unmet needs for contraception: A comparative study among Somali immigrant women in Oslo and their original population in Mogadishu, Somalia	PLOS ONE			English	Article							INDUCED-ABORTION; NATIVE WOMEN; ATTITUDES; PERCEPTIONS	Introduction Unmet need for contraception is defined as the proportion of fertile individuals who do not use contraceptives despite wanting to space or limit their childbearing. Studies show that immigrant women in Europe, have higher rates of unintended pregnancies and abortion than native born women. Somali women, have the highest fertility rate in Norway which is much higher than the total fertility rate in Norway (4.0 vs. 1.7). This study investigates the unmet need for contraception among Somali immigrant women in Oslo, Norway, compared to their original population in Mogadishu, Somalia. Methods A community based, cross sectional study was carried out among Somali women in Oslo (N = 228) and Mogadishu (N = 229) from May to December 2018. Pre-structured questionnaires were given to women who were recruited through snow-ball sampling. Data was analyzed using SPSS version 25. We performed a chi-square test for the analyses of categorical variables, a t-test for continuous variables and multivariate logistic analysis to determine the association between exposure and outcome variable. Results The unmet needs for contraception among Somali women in Oslo was 20.2%, which is similar to unmet needs for contraception of women in many sub-Saharan African countries. The unmet needs for Somali immigrant women in Oslo (20.2) is two times lower than that of their original population in Somalia (48.5). The odds of having unmet needs for contraception was nearly, three times higher among Somali women in Mogadishu compared to those in Oslo (OR: 2.6, CI: 2.56-7.68). The mean intended fertility was 4 among the women in Oslo and 10.8 in Mogadishu. About 13.4% of study participants in Oslo and 86.6% of those in Mogadishu consider modern contraception irrelevant for women's health. Nearly 50% of women in both places had unintended childbirth on one or more occasion. Conclusion The study results show the prevalence of unmet needs for contraception among Somali immigrant women Oslo, is 4 fold higher than that of Norway (20.2 vs 5.5). Information Education Communication to both men and women, may reduce the high unmet need for contraception and also improve partner communication on family planning among Somali immigrants in Oslo. Training primary health providers for provision of tailored information about the modern contraception to immigrant women, which includes an individualized counselling may improve partners' knowledge, demand and uptake of modern contraception.	[Gele, Abdi A.] Norwegian Inst Publ Hlth, Dept Hlth Serv Res, Oslo, Norway; [Musse, Fathia K.] Oslo Municipal, Dept Family Counselling, Oslo, Norway; [Qureshi, Samera] Norwegian Inst Publ Hlth, Dept Hlth Serv Res, Oslo, Norway; [Qureshi, Samera] Nydalen, Oslo, Norway	Norwegian Institute of Public Health (NIPH); Norwegian Institute of Public Health (NIPH)	Gele, AA (corresponding author), Norwegian Inst Publ Hlth, Dept Hlth Serv Res, Oslo, Norway.	abdi.gele@fhi.no		Gele, Abdi A./0000-0002-3616-6411	Norwegian Extrastiftelsen [45523]	Norwegian Extrastiftelsen	This work was supported by Norwegian Extrastiftelsen (45523 to AG). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraha TH, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0632-2; Alkema L, 2013, LANCET, V381, P1642, DOI 10.1016/S0140-6736(12)62204-1; Alvarez-Nieto C, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0071-2; Bruckner TA, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1397-2; Cates W, 2010, CONTRACEPTION, V81, P460, DOI 10.1016/j.contraception.2010.01.002; Comerasamy Huguette, 2003, J Obstet Gynaecol, V23, P412, DOI 10.1080/01443610310001209342; Cox CM, 2019, PERSPECT SEX REPRO H, V51, P63, DOI 10.1363/psrh.12100; Degni F, 2006, EUR J CONTRACEP REPR, V11, P190, DOI 10.1080/13625180600557605; Egeh AA, 2019, SEX REPROD HEALTHC, V20, P27, DOI 10.1016/j.srhc.2019.02.003; Eskild Anne, 2002, Tidsskr Nor Laegeforen, V122, P1355; Fisher William, 2004, J Obstet Gynaecol Can, V26, P580; Gele A, 2019, ONLINE JOURNAL OF CO; Gele AA, 2012, INT J WOMENS HEALTH, V4, P7, DOI 10.2147/IJWH.S27577; Goth UGS, 2011, EUR J GEN PRACT, V17, P28, DOI 10.3109/13814788.2010.525632; Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9; Gure F, 2016, STUD FAMILY PLANN, V47, P69, DOI 10.1111/j.1728-4465.2016.00047.x; Helstrom L, 2003, SCAND J PUBLIC HEALT, V31, P405, DOI 10.1080/14034940210165181; Kingori C, 2018, ETHNIC HEALTH, V23, P339, DOI 10.1080/13557858.2016.1263285; Kiura Annet Wanjira, 2014, CONSTRAINED AGENCY O, V18; Koch E, 2014, PUBLIC HEALTH, V128, P384, DOI 10.1016/j.puhe.2014.01.008; Leeners B, 2017, EUR J CONTRACEP REPR, V22, P38, DOI 10.1080/13625187.2016.1258053; Link CF, 2011, STUD FAMILY PLANN, V42, P83, DOI 10.1111/j.1728-4465.2011.00268.x; Nketiah-Amponsah Edward, 2012, Afr J Reprod Health, V16, P155; Nyarko SH, 2019, J PREGNANCY, V2019, DOI 10.1155/2019/2920491; Omland G, 2014, BJOG-INT J OBSTET GY, V121, P1221, DOI 10.1111/1471-0528.12906; Ontiri S, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16091543; Prata N, 2017, AFR J REPROD HEALTH, V21, P35, DOI 10.29063/ajrh2017/v21i2.5; Raben LAD, 2018, FAM PRACT, V35, P468, DOI 10.1093/fampra/cmx133; Rasch V, 2008, EUR J PUBLIC HEALTH, V18, P144, DOI 10.1093/eurpub/ckm112; Rasch V, 2007, HUM REPROD, V22, P1320, DOI 10.1093/humrep/dem012; Sedgh G, 2014, STUD FAMILY PLANN, V45, P301, DOI 10.1111/j.1728-4465.2014.00393.x; Statistics Norway, 2000, SAMLET FRUKTBARHETST; The WHO's original source is Guttmacher Institute, 2017, ADDING IT UP THE COS; The World Bank, 2019, FERTILITY RATE TOTAL; Vangen S, AN INTERNATIONAL JOU, V115; Wiebe E, 2013, CAN FAM PHYSICIAN, V59, pE451; Wiebe ER, 2006, CONTRACEPTION, V73, P623, DOI 10.1016/j.contraception.2006.02.001; World Health Organization, 2018, UNMET NEED FOR FAMIL; World Health Organization, 2016, ACTION PLAN FOR SEXU	39	11	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 15	2019	14	8							e0220783	10.1371/journal.pone.0220783	http://dx.doi.org/10.1371/journal.pone.0220783			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW5KK	31415575	Green Published, Green Submitted, gold			2023-01-03	WOS:000485017200032
J	Veyron, JH; Friocourt, P; Jeanjean, O; Luquel, L; Bonifas, N; Denis, F; Belmin, J				Veyron, Jacques-Henri; Friocourt, Patrick; Jeanjean, Olivier; Luquel, Laurence; Bonifas, Nicolas; Denis, Fabrice; Belmin, Joel			Home care aides' observations and machine learning algorithms for the prediction of visits to emergency departments by older community-dwelling individuals receiving home care assistance: A proof of concept study	PLOS ONE			English	Article							TRENDS; MODEL; RISK	Background Older individuals receiving home assistance are at high risk for emergency visits and unplanned hospitalization. Anticipating their health difficulties could prevent these events. This study investigated the effectiveness of an at-home monitoring method using social workers' observations to predict risk for 7- and 14-day emergency department (ED) visits. Methods This was a prospective cohort study of persons. 75 years, living at home and receiving assistance from home care aides (HCA) at 6 French facilities. After each home visit, HCAs reported on participants' functional status using a smartphone application that recorded 27 functional items about each participant (e.g., ability to stand, move, eat, mood, loneliness). We recorded ED visits. Finally, we used machine learning techniques (i.e., leveraging random forest predictors) to develop a 7-and 14-day predictive algorithm for the risk of ED visit. Results The study included 301 participants, and the HCA made 9,987 observations. Over the mean 10-month follow-up, 97 participants (32%) had at least one ED visit. Modeling techniques identified 9 contributory factors from the longitudinal records of the HCA and developed a predictive algorithm for the risk of ED visit. The predictive performance (i.e., the area under the ROC curve) was 0.70 at 7 days and 0.67 at 14 days. Interpretation For frail elders receiving in-home care, information on functional status collected by HCA helps predict the risk of ED visits 7 to 14 days in advance. A survey system for real-time identification of risks could be developed using this exploratory work.	[Veyron, Jacques-Henri] ANAP, Paris, France; [Friocourt, Patrick] Hop Simone Veil, Serv Med Interne Geriatr, Blois, France; [Jeanjean, Olivier] Grp Hosp Nord Essonne, Soins Palliatifs, Pole Geriatrie, SSR, Longjumeau, France; [Luquel, Laurence] Hop Prive Geriatr Magnolias, Ballainvilliers, France; [Bonifas, Nicolas] Ecole Polytech, Palaiseau, France; [Denis, Fabrice] Inst Interreg Cancerol Jean Bernard, Le Mans, France; [Belmin, Joel] Hop Charles Foix, AP HP, Ivry, France; [Belmin, Joel] Sorbonne Univ, Paris, France	Institut Polytechnique de Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Charles-Foix - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite	Veyron, JH (corresponding author), ANAP, Paris, France.	Jacques-Henri.veyron@anap.fr	Belmin, Joel/V-9995-2019; Belmin, Joël/Q-3914-2017	Belmin, Joel/0000-0003-1630-9582; Belmin, Joël/0000-0003-1630-9582				Adams JG, 2013, JAMA-J AM MED ASSOC, V309, P1173, DOI 10.1001/jama.2013.2476; Basch E, 2017, JAMA-J AM MED ASSOC, V318, P197, DOI 10.1001/jama.2017.7156; Belmin J, 2007, AGE AGEING, V36, P298, DOI 10.1093/ageing/afm026; Crane SJ, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-338; de Gelder J, 2018, J AM GERIATR SOC, V66, P735, DOI 10.1111/jgs.15301; Denis F, 2019, JAMA-J AM MED ASSOC, V321, P306, DOI 10.1001/jama.2018.18085; Duong HV, 2018, PREHOSP EMERG CARE, V22, P7, DOI 10.1080/10903127.2017.1347223; Gasperini B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189925; Hao SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112944; Hartig MT, 1997, J GERONTOL A-BIOL, V52, pM142, DOI 10.1093/gerona/52A.3.M142; Horng S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174708; Hu ZK, 2015, INTERACT J MED RES, V4, P39, DOI 10.2196/ijmr.4022; Hwang U, 2007, J AM GERIATR SOC, V55, P1873, DOI 10.1111/j.1532-5415.2007.01400.x; Jin B, 2016, BMC EMERG MED, V16, DOI 10.1186/s12873-016-0074-5; Jones A, 2018, CAN MED ASSOC J, V190, pE525, DOI 10.1503/cmaj.170892; Kahn JH, 2016, EMERG MED CLIN N AM, V34, P435, DOI 10.1016/j.emc.2016.04.014; Nair NP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165757; Pishgoo B, 2011, J RES MED SCI, V16, P262; Shelton P, 2000, AM J MANAG CARE, V6, P925; Takahashi PY, 2016, AM J MANAG CARE, V22, P475; Tang N, 2010, JAMA-J AM MED ASSOC, V304, P664, DOI 10.1001/jama.2010.1112; Thome B, 2003, J CLIN NURS, V12, P860, DOI 10.1046/j.1365-2702.2003.00803.x; Uscher-Pines L, 2013, AM J MANAG CARE, V19, P47; Wolinsky FD, 2008, J GERONTOL A-BIOL, V63, P204, DOI 10.1093/gerona/63.2.204; Wong A, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.1018	25	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2019	14	8							e0220002	10.1371/journal.pone.0220002	http://dx.doi.org/10.1371/journal.pone.0220002			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW5HO	31408458	Green Submitted, Green Published, gold			2023-01-03	WOS:000485009500006
J	Wande, DP; Sangeda, RZ; Tibalinda, P; Mutta, IK; Mkumbwa, S; Bitegeko, A; Kaale, E				Wande, Dickson Pius; Sangeda, Raphael Zozimus; Tibalinda, Prosper; Mutta, Innocent Kairuki; Mkumbwa, Sonia; Bitegeko, Adonis; Kaale, Eliangiringa			Pharmaceuticals imports in Tanzania: Overview of private sector market size, share, growth and projected trends to 2021	PLOS ONE			English	Article								Background To assess the extent to which foreign pharmaceutical imports vary from year to year and identifying leading generic and branded formulations, key countries and key importers of pharmaceuticals in private sector supply chain. Methodology A systematic analysis of data for pharmaceutical imports from the Ministry of Health. Data from 2013 to 2016 fiscal years and relevant documents were accessed from the Tanzania Food and Drugs Authority (TFDA). Data cleaning was carried out to remove duplicate entries and to exclude pharmaceutical imports for individual uses, promotion purpose, donations, raw material, medical devices, government institutions and veterinary products. Results A total of 397 different suppliers imported pharmaceutical in Tanzania mainland from 2013 to 2016 fiscal years. In the 2013-2014 fiscal year, the private sector suppliers imported pharmaceutical worth 216 U.S million dollars. India ranked as the first country for exporting highest value of pharmaceutical into the country. It displays a 54% cumulative market share of total imports from 2013-2016, followed by Egypt (11.7%), Switzerland and the USA hold 4.1% of cumulative market share. By 2020-2021 fiscal years, we forecast for imported pharmaceuticals to reach a total value of 906 U.S million dollars for the private sector supply chain. All analysis in this study and the forecasted figures are limited to private sector pharmaceutical supply chain only and does not include data for government pharmaceutical supply chain. Conclusions Our result shows that the vast majority of pharmaceutical imports in the private sector supply chain are dominated by imports from India. India is competing with other countries such as Egypt, Switzerland, USA and South Africa among the top importing countries. There was almost an equal distribution of pharmaceutical for both communicable and non-communicable diseases. Data presented shows a growing trend for the market segment for medicines required for the management of non-communicable diseases. Generally, the private sector pharmaceutical market is keeping on rising at a rapid pace. By the year 2021, the growth is forecasted to increase by 28% compared to the current market value. The projected growth rate could be good news for foreign pharmaceutical companies seeking new sources of growth in international pharmaceutical trading. It is also good news to the poor patients if the availability of drugs previously unavailable in the country is significantly increased.	[Wande, Dickson Pius] Muhimbili Univ Hlth & Allied Sci, Sch Pharm, Dept Pharmaceut & Pharm Practice, Dar Es Salaam, Tanzania; [Sangeda, Raphael Zozimus] Muhimbili Univ Hlth & Allied Sci, Sch Pharm, Dept Pharmaceut Microbiol, Dar Es Salaam, Tanzania; [Tibalinda, Prosper; Kaale, Eliangiringa] Muhimbili Univ Hlth & Allied Sci, Sch Pharm, Pharmaceut R&D Lab, Dar Es Salaam, Tanzania; [Mutta, Innocent Kairuki] Hubert Kairuki Mem Univ, Dar Es Salaam, Tanzania; [Mkumbwa, Sonia; Bitegeko, Adonis] Minist Hlth, Tanzania Food & Drugs Author, Dar Es Salaam, Tanzania; [Kaale, Eliangiringa] Muhimbili Univ Hlth & Allied Sci, Sch Pharm, Dept Med Chem, Dar Es Salaam, Tanzania	Muhimbili University of Health & Allied Sciences; Muhimbili University of Health & Allied Sciences; Muhimbili University of Health & Allied Sciences; Muhimbili University of Health & Allied Sciences	Kaale, E (corresponding author), Muhimbili Univ Hlth & Allied Sci, Sch Pharm, Pharmaceut R&D Lab, Dar Es Salaam, Tanzania.; Kaale, E (corresponding author), Muhimbili Univ Hlth & Allied Sci, Sch Pharm, Dept Med Chem, Dar Es Salaam, Tanzania.	elia.kaale@gmail.com	Kaale, Eliangiringa/AAC-8561-2019; Sangeda, Raphael Zozimus/V-6624-2018	Kaale, Eliangiringa/0000-0001-6008-3539; Sangeda, Raphael Zozimus/0000-0002-6574-5308; Wande, Dickson Pius/0000-0002-1788-3650				Alba S, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-163; BOT, 2018, IND FOR EXCH MARK RA; Business Monitor International Ltd, 2016, TANZ PHARM HLTH REP, VQ3; CDC, GLOB HLTH TANZ; EAC, 2014, 2 E AFRIC COMM EAC R; Embrey M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164332; Ewen M, 2017, J Pharm Policy Pract, V10, P7, DOI 10.1186/s40545-016-0095-1; Guariguata L, 2014, DIABETES RES CLIN PR, V103, P137, DOI 10.1016/j.diabres.2013.11.002; Kaale E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165785; Kagashe LF G A, 2004, TANZANIA MED J, V19; Kengne AP, 2017, INT J EPIDEMIOL, V46, P1421, DOI 10.1093/ije/dyx078; Lee B., 2018, ANAL GOVT TANZANIAS; Losse K., 2007, VIABILITY LOCAL PHAR; Marty Francisco, 2002, Expert Opin Pharmacother, V3, P91; Mhamba RM, 2010, PHARM IND ACCESS ESS; MoHSW, 2006, NATL MED POLICY NMP; Mushi MF, 2017, TANZAN J HLTH RES, V19, P1; Mziray S, 2017, PHARM REGUL AFF, V6, P1, DOI 10.4172/2167-7689.1000191; NANRA RS, 1980, MED J AUSTRALIA, V1, P486, DOI 10.5694/j.1326-5377.1980.tb135047.x; Ogbera AO, 2014, WORLD J DIABETES, V5, P905, DOI 10.4239/wjd.v5.i6.905; Opiyo N, 2016, COCHRANE DATABASE SY; Ozioko Calistus, 2017, SOLID DOSAGE FORMS T; Rehman HA-U, 2011, PHARM DEV WORLD INDI; Sabot OJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006857; Samarasekera U, 2008, LANCET, V371, P1403, DOI 10.1016/S0140-6736(08)60611-X; Sikika, 2018, HLTH SECT BUDG AN FI; Simba Daudi, 2012, Tanzan J Health Res, V14, P89; Spyros G, 1998, FORECASTING METHODS; Stanifer JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122638; STEWART JH, 1976, AUST NZ J MED, V6, P498, DOI 10.1111/j.1445-5994.1976.tb03045.x; Tibandebage P., 2016, MAKING MED AFRICA PO, P45; UNAIDS, 2016, HIV AIDS TANZ; UNDP, 2016, LOC PROD PHARM CAN P; WHO, 2006, NAT GUID DIAGN TREAT, P105; WHO, 1990, AN THER CHEM CLASS S; WHO, 2015, UNIT REP TANZ WHO ST; Wilson R, 2012, SHAKESPEARE, V8, P1, DOI 10.1080/17450918.2012.660280; World Health Organization, 2010, GLOBAL STATUS REPORT, P176; Ziraba AK, 2009, BMC HEALTH SERV RES, V9, DOI [10.1186/1471-2458-9-465, 10.1186/1472-6963-9-46]	39	8	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 12	2019	14	8							e0220701	10.1371/journal.pone.0220701	http://dx.doi.org/10.1371/journal.pone.0220701			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5GN	31404109	Green Published, Green Submitted, gold			2023-01-03	WOS:000485006800025
J	Bailey, NW; Freedman, G; Raj, K; Sullivan, CM; Rogasch, NC; Chung, SW; Hoy, KE; Chambers, R; Hassed, C; Van Dam, NT; Koenig, T; Fitzgerald, PB				Bailey, Neil W.; Freedman, Gabrielle; Raj, Kavya; Sullivan, Caley M.; Rogasch, Nigel C.; Chung, Sung W.; Hoy, Kate E.; Chambers, Richard; Hassed, Craig; Van Dam, Nicholas T.; Koenig, Thomas; Fitzgerald, Paul B.			Mindfulness meditators show altered distributions of early and late neural activity markers of attention in a response inhibition task	PLOS ONE			English	Article							EVENT-RELATED POTENTIALS; COGNITIVE THERAPY; VISUAL-ATTENTION; PARIETAL CORTEX; ERP; MECHANISMS; CONFLICT; ALPHA; EEG; PERFORMANCE	Attention is vital for optimal behavioural performance in every-day life. Mindfulness meditation has been shown to enhance attention. However, the components of attention altered by meditation and the related neural activities are underexplored. In particular, the contributions of inhibitory processes and sustained attention are not well understood. To address these points, 34 meditators were compared to 28 age and gender matched controls during electroencephalography (EEG) recordings of neural activity during a Go/Nogo response inhibition task. This task generates a P3 event related potential, which is related to response inhibition processes in Nogo trials, and attention processes across both trial types. Compared with controls, meditators were more accurate at responding to Go and Nogo trials. Meditators showed a more frontally distributed P3 to both Go and Nogo trials, suggesting more frontal involvement in sustained attention rather than activity specific to response inhibition. Unexpectedly, meditators also showed increased positivity over the right parietal cortex prior to visual information reaching the occipital cortex (during the pre-C1 window). Both results were positively related to increased accuracy across both groups. The results suggest that meditators show altered engagement of neural regions related to attention, including both higher order processes generated by frontal regions, and sensory anticipation processes generated by poster regions. This activity may reflect an increased capacity to modulate a range of neural processes in order to meet task requirements. This increased capacity may underlie the improved attentional function observed in mindfulness meditators.	[Bailey, Neil W.; Freedman, Gabrielle; Raj, Kavya; Sullivan, Caley M.; Chung, Sung W.; Hoy, Kate E.; Fitzgerald, Paul B.] Monash Univ, Monash Alfred Psychiat Res Ctr, Cent Clin Sch, Melbourne, Vic, Australia; [Bailey, Neil W.; Fitzgerald, Paul B.] Epworth Healthcare, Epworth Ctr Innovat Mental Hlth, Epworth Clin, Camberwell, Vic, Australia; [Raj, Kavya; Rogasch, Nigel C.] Monash Univ, Sch Psychol Sci, Monash Inst Cognit & Clin Neurosci, Brain & Mental Hlth Res Hub, Clayton, Vic, Australia; [Raj, Kavya; Rogasch, Nigel C.] Monash Univ, Monash Biomed Imaging, Clayton, Vic, Australia; [Chambers, Richard] Monash Univ, Campus Community Div, Melbourne, Vic, Australia; [Hassed, Craig] Monash Univ, Dept Gen Practice, Melbourne, Vic, Australia; [Van Dam, Nicholas T.] Univ Melbourne, Sch Psychol Sci, Parkville, Vic, Australia; [Van Dam, Nicholas T.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Koenig, Thomas] Univ Bern, Univ Hosp Psychiat, Translat Res Ctr, Bern, Switzerland	Monash University; Monash University; Monash University; Monash University; Monash University; University of Melbourne; Icahn School of Medicine at Mount Sinai; University of Bern; University Hospital of Bern	Bailey, NW (corresponding author), Monash Univ, Monash Alfred Psychiat Res Ctr, Cent Clin Sch, Melbourne, Vic, Australia.; Bailey, NW (corresponding author), Epworth Healthcare, Epworth Ctr Innovat Mental Hlth, Epworth Clin, Camberwell, Vic, Australia.	neil.bailey@monash.edu	Bailey, Neil/AAB-2741-2021; Koenig, Thomas/ABD-2278-2020; Van Dam, Nicholas Thomas/G-2799-2010	Koenig, Thomas/0000-0002-1472-4638; Van Dam, Nicholas Thomas/0000-0002-1131-0739; Chung, Sung Wook/0000-0001-8022-8037; Bailey, Neil/0000-0002-8483-1068; Rogasch, Nigel/0000-0002-4484-1069; Hoy, Kate/0000-0003-0694-9674	Neuronetics; Cervel Neurotech; National Health and Medical Research Council of Australia [6069070, 1082894, 1072057]	Neuronetics; Cervel Neurotech; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	PBF has received equipment for research from MagVenture A/S, Medtronic Ltd, Cervel Neurotech and Brainsway Ltd and funding for research from Neuronetics and Cervel Neurotech. PBF is supported by a National Health and Medical Research Council of Australia Practitioner Fellowship (6069070). KEH is supported by a National Health and Medical Research Council of Australia Career Development Fellowship (1082894). NCR is supported by a National Health and Medical Research Council of Australia Fellowship (1072057). These funders supported the researchers for other projects but no funding contribution was made to this specific project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; PBF has received equipment for research from MagVenture A/S, Medtronic Ltd, Cervel Neurotech and Brainsway Ltd and funding for research from Neuronetics and Cervel Neurotech. PBF is on the scientific advisory board for Bionomics Ltd. All other authors have no conflicts to report. PBF is supported by a National Health and Medical Research Council of Australia Practitioner Fellowship (6069070). KEH is supported by a National Health and Medical Research Council of Australia Career Development Fellowship (1082894). NCR is supported by a National Health and Medical Research Council of Australia Fellowship (1072057). This does not alter our adherence to PLOS ONE policies on sharing data and materials.	Andreu CI, 2017, MINDFULNESS, V8, P1603, DOI 10.1007/s12671-017-0732-z; Baer RA, 2006, ASSESSMENT, V13, P27, DOI 10.1177/1073191105283504; BAILEY N, 2018, MINDFULNESS, P1; Bailey NW, 2014, PSYCHIAT RES-NEUROIM, V224, P324, DOI 10.1016/j.pscychresns.2014.09.008; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Beck A.T., 1996, BECK DEPRESSION INVE, DOI DOI 10.1037/T00742-000; Behrmann M, 2004, CURR OPIN NEUROBIOL, V14, P212, DOI 10.1016/j.conb.2004.03.012; Benikos N, 2013, INT J PSYCHOPHYSIOL, V87, P262, DOI 10.1016/j.ijpsycho.2012.08.005; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003; Bruin KJ, 2002, CLIN NEUROPHYSIOL, V113, P1172, DOI 10.1016/S1388-2457(02)00141-4; Cahn BR, 2006, PSYCHOL BULL, V132, P180, DOI 10.1037/0033-2909.132.2.180; Chambers R, 2008, COGNITIVE THER RES, V32, P303, DOI 10.1007/s10608-007-9119-0; Cheng KS, 2017, PEERJ, V5, DOI 10.7717/peerj.3857; Cramer AOJ, 2016, PSYCHON B REV, V23, P640, DOI 10.3758/s13423-015-0913-5; Crane RS, 2017, PSYCHOL MED, V47, P990, DOI 10.1017/S0033291716003317; Datta A, 2007, COMPUTATIONAL INTELL, V2007; Davidson RJ, 2015, AM PSYCHOL, V70, P581, DOI 10.1037/a0039512; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Di Russo F, 2003, CEREB CORTEX, V13, P486, DOI 10.1093/cercor/13.5.486; Donkers FCL, 2004, BRAIN COGNITION, V56, P165, DOI 10.1016/j.bandc.2004.04.005; du Boisgueheneuc F, 2006, BRAIN, V129, P3315, DOI 10.1093/brain/awl244; Eldar S, 2010, BIOL PSYCHOL, V85, P252, DOI 10.1016/j.biopsycho.2010.07.010; Falkenstein M, 1999, ACTA PSYCHOL, V101, P267, DOI 10.1016/S0001-6918(99)00008-6; Falkenstein M, 2006, CLIN NEUROPHYSIOL, V117, P1638, DOI 10.1016/j.clinph.2006.05.002; Fox KCR, 2014, NEUROSCI BIOBEHAV R, V43, P48, DOI 10.1016/j.neubiorev.2014.03.016; Foxe JJ, 2002, EXP BRAIN RES, V142, P139, DOI 10.1007/s00221-001-0906-7; Foxe JJ, 2005, EXP BRAIN RES, V166, P370, DOI 10.1007/s00221-005-2378-7; Foxe JJ, 1998, NEUROREPORT, V9, P3929, DOI 10.1097/00001756-199812010-00030; Fu KMG, 2001, COGNITIVE BRAIN RES, V12, P145, DOI 10.1016/S0926-6410(01)00034-9; Fu SM, 2005, COGNITIVE BRAIN RES, V23, P341, DOI 10.1016/j.cogbrainres.2004.11.014; Goyal M, 2014, JAMA INTERN MED, V174, P357, DOI 10.1001/jamainternmed.2013.13018; Gramfort A, 2010, BIOMED ENG ONLINE, V9, DOI 10.1186/1475-925X-9-45; Hartmann L, 2016, BRAIN STRUCT FUNCT, V221, P3835, DOI 10.1007/s00429-015-1131-7; Holzel BK, 2011, PERSPECT PSYCHOL SCI, V6, P537, DOI 10.1177/1745691611419671; Hong XF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08807-z; Hopf JM, 2000, CLIN NEUROPHYSIOL, V111, P1241, DOI 10.1016/S1388-2457(00)00313-8; Huster RJ, 2013, INT J PSYCHOPHYSIOL, V87, P217, DOI 10.1016/j.ijpsycho.2012.08.001; Junior R.D.M., 2014, PSYCHOL NEUROSCI, V7, P503, DOI [10.3922/j.psns.2014.4.09, DOI 10.3922/J.PSNS.2014.4.09]; Kabat-Zinn J, 2009, LIBR J; Keil A, 2007, NEUROIMAGE, V36, P472, DOI 10.1016/j.neuroimage.2007.02.048; Kelly SP, 2008, CEREB CORTEX, V18, P2629, DOI 10.1093/cercor/bhn022; Kerr CE, 2011, BRAIN RES BULL, V85, P96, DOI 10.1016/j.brainresbull.2011.03.026; Klimesch W, 2007, NEUROSCI BIOBEHAV R, V31, P1003, DOI 10.1016/j.neubiorev.2007.03.005; Koenig T., 2011, COMPUT INTEL NEUROSC, V2011, P4; Koenig T, 2014, BRAIN TOPOGR, V27, P72, DOI 10.1007/s10548-013-0310-1; Krompinger JW, 2009, BIOL PSYCHOL, V81, P153, DOI 10.1016/j.biopsycho.2009.03.007; Lao SA, 2016, CONSCIOUS COGN, V45, P109, DOI 10.1016/j.concog.2016.08.017; LAVIE N, 1995, J EXP PSYCHOL HUMAN, V21, P451, DOI 10.1037/0096-1523.21.3.451; LEHMANN D, 1987, ELECTROEN CLIN NEURO, V67, P271, DOI 10.1016/0013-4694(87)90025-3; Lin FH, 2006, NEUROIMAGE, V31, P160, DOI 10.1016/j.neuroimage.2005.11.054; Lutz A, 2008, TRENDS COGN SCI, V12, P163, DOI 10.1016/j.tics.2008.01.005; Lutz A, 2009, J NEUROSCI, V29, P13418, DOI 10.1523/JNEUROSCI.1614-09.2009; Malhotra P, 2009, BRAIN, V132, P645, DOI 10.1093/brain/awn350; Malinowski P, 2017, MINDFULNESS, V8, P78, DOI 10.1007/s12671-015-0482-8; Malinowski P, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00008; Manna A, 2010, BRAIN RES BULL, V82, P46, DOI 10.1016/j.brainresbull.2010.03.001; Martinez A, 1999, NAT NEUROSCI, V2, P364, DOI 10.1038/7274; Michel CM, 2004, CLIN NEUROPHYSIOL, V115, P2195, DOI 10.1016/j.clinph.2004.06.001; Moore A, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00018; Moore A, 2009, CONSCIOUS COGN, V18, P176, DOI 10.1016/j.concog.2008.12.008; Murray MM, 2008, BRAIN TOPOGR, V20, P249, DOI 10.1007/s10548-008-0054-5; Nieuwenhuis S, 2004, PSYCHOPHYSIOLOGY, V41, P157, DOI 10.1046/j.1469-8986.2003.00128.x; Nieuwenhuis S, 2003, COGN AFFECT BEHAV NE, V3, P17, DOI 10.3758/CABN.3.1.17; Palmer JA, 2008, AC SPEECH SIGN PROC; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P5; PERRIN F, 1989, ELECTROEN CLIN NEURO, V72, P184, DOI 10.1016/0013-4694(89)90180-6; Posner MI, 2015, CURR OPIN BEHAV SCI, V4, P1, DOI 10.1016/j.cobeha.2014.12.008; Quaglia JT, 2016, J PERS, V84, P393, DOI 10.1111/jopy.12167; Rauss KS, 2009, HUM BRAIN MAPP, V30, P1723, DOI 10.1002/hbm.20636; Sandra BK, 2011, EMOTION, V11, P299, DOI 10.1037/a0022764; Sanger KL, 2016, TRENDS NEUROSCI EDUC, V5, P1, DOI 10.1016/j.tine.2016.01.001; Schoenberg PLA, 2015, COGN NEURODYNAMICS, V9, P13, DOI 10.1007/s11571-014-9308-y; Schoenberg PLA, 2014, COGN NEURODYNAMICS, V8, P373, DOI 10.1007/s11571-014-9294-0; Schoenberg PLA, 2014, CLIN NEUROPHYSIOL, V125, P1407, DOI 10.1016/j.clinph.2013.11.031; Schroeder CE, 2001, FRONT BIOSCI-LANDMRK, V6, pD672, DOI 10.2741/Schroed; Shapiro SL, 2006, J CLIN PSYCHOL, V62, P373, DOI 10.1002/jclp.20237; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Slagter HA, 2007, PLOS BIOL, V5, P1228, DOI 10.1371/journal.pbio.0050138; Slagter HA, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00017; Slagter HA, 2009, J COGNITIVE NEUROSCI, V21, P1536, DOI 10.1162/jocn.2009.21125; Steer RA., 1997, BECK ANXIETY INVENTO; Tadel F, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/879716; Tang YY, 2015, NAT REV NEUROSCI, V16, P213, DOI 10.1038/nrn3916; Tang YY, 2009, P NATL ACAD SCI USA, V106, P8865, DOI 10.1073/pnas.0904031106; Valentine E.R., 1999, MENTAL HLTH RELIG CU, V2, P59, DOI DOI 10.1080/13674679908406332; Van der Lubbe RHJ, 2005, J COGNITIVE NEUROSCI, V17, P1829, DOI 10.1162/089892905775008634; van Leeuwen S, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00133; Vogel EK, 2005, J COGNITIVE NEUROSCI, V17, P1907, DOI 10.1162/089892905775008599; Walach H, 2006, PERS INDIV DIFFER, V40, P1543, DOI 10.1016/j.paid.2005.11.025; Wessel JR, 2018, PSYCHOPHYSIOLOGY, V55, DOI 10.1111/psyp.12871; WICKENS C, 1983, SCIENCE, V221, P1080, DOI 10.1126/science.6879207; Worden MS, 2000, J NEUROSCI, V20	93	14	14	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2019	14	8							e0203096	10.1371/journal.pone.0203096	http://dx.doi.org/10.1371/journal.pone.0203096			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW5CU	31386663	Green Published, gold, Green Submitted			2023-01-03	WOS:000484997100001
J	Barcena, C; Valdes-Mas, R; Mayoral, P; Garabaya, C; Durand, S; Rodriguez, F; Fernandez-Garcia, MT; Salazar, N; Nogacka, AM; Garatachea, N; Bossut, N; Aprahamian, F; Lucia, A; Kroemer, G; Freije, JMP; Quiros, PM; Lopez-Otin, C				Barcena, Clea; Valdes-Mas, Rafael; Mayoral, Pablo; Garabaya, Cecilia; Durand, Sylvere; Rodriguez, Francisco; Teresa Fernandez-Garcia, Maria; Salazar, Nuria; Nogacka, Alicja M.; Garatachea, Nuria; Bossut, Noelie; Aprahamian, Fanny; Lucia, Alejandro; Kroemer, Guido; Freije, Jose M. P.; Quiros, Pedro M.; Lopez-Otin, Carlos			Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice	NATURE MEDICINE			English	Article							GUT MICROBIOTA; INTESTINAL MICROBIOTA; BILE-ACIDS; METABOLITES; ACTIVATION; PHYSIOLOGY; NUTRIENT; GENETICS; SHAPE	The gut microbiome is emerging as a key regulator of several metabolic, immune and neuroendocrine pathways(1,2). Gut microbiome deregulation has been implicated in major conditions such as obesity, type 2 diabetes, cardiovascular disease, non-alcoholic fatty acid liver disease and cancer(3-6), but its precise role in aging remains to be elucidated. Here, we find that two different mouse models of progeria are characterized by intestinal dysbiosis with alterations that include an increase in the abundance of Proteobacteria and Cyanobacteria, and a decrease in the abundance of Verrucomicrobia. Consistent with these findings, we found that human progeria patients also display intestinal dysbiosis and that long-lived humans (that is, centenarians) exhibit a substantial increase in Verrucomicrobia and a reduction in Proteobacteria. Fecal microbiota transplantation from wild-type mice enhanced healthspan and lifespan in both progeroid mouse models, and transplantation with the verrucomicrobia Akkermansia muciniphila was sufficient to exert beneficial effects. Moreover, metabolomic analysis of ileal content points to the restoration of secondary bile acids as a possible mechanism for the beneficial effects of reestablishing a healthy microbiome. Our results demonstrate that correction of the accelerated aging-associated intestinal dysbiosis is beneficial, suggesting the existence of a link between aging and the gut microbiota that provides a rationale for microbiome-based interventions against age-related diseases.	[Barcena, Clea; Valdes-Mas, Rafael; Mayoral, Pablo; Garabaya, Cecilia; Rodriguez, Francisco; Freije, Jose M. P.; Quiros, Pedro M.; Lopez-Otin, Carlos] Univ Oviedo, Inst Univ Oncol IUOPA, Fac Med, Dept Bioquim & Biol Mol, Oviedo, Spain; [Durand, Sylvere; Bossut, Noelie; Aprahamian, Fanny; Kroemer, Guido] Gustave Roussy Canc Campus, Cell Biol & Metabol Platforms, Villejuif, France; [Durand, Sylvere; Bossut, Noelie; Aprahamian, Fanny; Kroemer, Guido] Ctr Rech Cordeliers, Equipe 11 Labellisee Ligue Canc, Paris, France; [Durand, Sylvere; Bossut, Noelie; Aprahamian, Fanny; Kroemer, Guido] INSERM, U1138, Paris, France; [Durand, Sylvere; Bossut, Noelie; Aprahamian, Fanny; Kroemer, Guido] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Teresa Fernandez-Garcia, Maria] Univ Oviedo, IUOPA, Unidad Histopatol Mol, Oviedo, Spain; [Salazar, Nuria; Nogacka, Alicja M.] CSIC, IPLA, Dept Microbiol & Biochem Dairy Prod, Villaviciosa, Spain; [Salazar, Nuria; Nogacka, Alicja M.] Inst Invest Sanitaria Principado Asturias ISPA, Diet Microbiota & Hlth Grp, Oviedo, Spain; [Garatachea, Nuria] Univ Zaragoza, Dept Physiatry & Nursing, Fac Hlth & Sport Sci, Huesca, Spain; [Garatachea, Nuria] Univ Zaragoza, GENUD, Zaragoza, Spain; [Lucia, Alejandro] Univ Europea Madrid, Fac Sport Sci, Madrid, Spain; [Lucia, Alejandro] Inst Invest Hosp 12 Octubre i 12, Madrid, Spain; [Lucia, Alejandro] CIBERFES, Madrid, Spain; [Kroemer, Guido] Univ Paris 06, Paris, France; [Kroemer, Guido] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France; [Kroemer, Guido] Karolinska Inst, Karolinska Univ Hosp, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Freije, Jose M. P.; Quiros, Pedro M.; Lopez-Otin, Carlos] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain	University of Oviedo; Instituto Universitario de Oncologia de Asturias; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of Oviedo; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Productos Lacteos de Asturias (IPLA); Instituto de Investigacion Sanitaria del Principado de Asturias (ISPA); University of Zaragoza; University of Zaragoza; European University of Madrid; Hospital Universitario 12 de Octubre; CIBER - Centro de Investigacion Biomedica en Red; CIBERFES; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Karolinska Institutet; Karolinska University Hospital; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC	Quiros, PM; Lopez-Otin, C (corresponding author), Univ Oviedo, Inst Univ Oncol IUOPA, Fac Med, Dept Bioquim & Biol Mol, Oviedo, Spain.; Quiros, PM; Lopez-Otin, C (corresponding author), Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain.	pmquiros@gmail.com; clo@uniovi.es	Salazar, Nuria/D-2189-2015; Garatachea, Nuria/ABF-8732-2020; KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; López-Otín, Carlos/AAB-2106-2020; Valdés-Mas, Rafael/AAC-2879-2021; Quiros, Pedro M/L-3186-2017; Freije, José M.P./A-6535-2008; Barcena, Clea/AAB-4606-2020	Salazar, Nuria/0000-0003-1435-7628; KROEMER, Guido/0000-0002-9334-4405; López-Otín, Carlos/0000-0001-6964-1904; Valdés-Mas, Rafael/0000-0002-0737-5425; Quiros, Pedro M/0000-0002-7793-6291; Freije, José M.P./0000-0002-4688-8266; Barcena, Clea/0000-0002-7452-2536; Nogacka, Alicja/0000-0001-8300-6149; Mayoral, Pablo/0000-0003-3567-3777; Lucia, Alejandro/0000-0002-5565-0997	FPI - Ministerio de Economia y Competividad (MINECO); Juan de la Cierva - Ministerio de Economia y Competividad (MINECO); Fondo de Investigaciones Sanitarias; Fondos FEDER [PI15/00558]; European Union; Ligue contre le Cancer; Agence National de la Recherche (ANR); ANR; ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; Chancelerie des universites de Paris (Legs Poix); Fondation pour la Recherche Medicale (FRM); Fundacion Bancaria Caja de Ahorros de Asturias; Ministerio de Economia y Competitividad-FEDER; Gobierno del Principado de Asturias; European Research Council; Instituto de Salud Carlos III (RTICC); Progeria Research Foundation	FPI - Ministerio de Economia y Competividad (MINECO); Juan de la Cierva - Ministerio de Economia y Competividad (MINECO); Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Fondos FEDER(European Commission); European Union(European Commission); Ligue contre le Cancer(Ligue nationale contre le cancer); Agence National de la Recherche (ANR)(French National Research Agency (ANR)); ANR(French National Research Agency (ANR)); ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Canceropole Ile-de-France(Region Ile-de-France); Chancelerie des universites de Paris (Legs Poix); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Fundacion Bancaria Caja de Ahorros de Asturias; Ministerio de Economia y Competitividad-FEDER(Spanish Government); Gobierno del Principado de Asturias(Principality of Asturias); European Research Council(European Research Council (ERC)European Commission); Instituto de Salud Carlos III (RTICC)(Instituto de Salud Carlos III); Progeria Research Foundation	The authors thank M. Stamsnijder and the Progeria Family Circle, and all the participants that have kindly engaged in our study. The authors also thank G. Velasco, Y. Espanol, A.R. Folgueras, X.M. Caravia, J.M. Fraile, I. Varela, M. Mittelbrunn and K. Iribarren for helpful comments and advice; R. Feijoo, A. Moyano, D.A. Puente, S.A. Miranda, M.S. Pitiot, V. Garcia de la Fuente and M.C. Muniz for excellent technical assistance; M. Gueimonde and C.G. de los Reyes-Gavilan (IPLA-CSIC) for providing A. muciniphila; C. Mayolas for help with logistic organization. The authors acknowledge generous support by J. I. Cabrera. A.M.N. is a recipient of a FPI predoctoral contract and N.S. is supported by a Juan de la Cierva postdoctoral contract, both granted by Ministerio de Economia y Competividad (MINECO). A.L.'s research on aging is funded by Fondo de Investigaciones Sanitarias and Fondos FEDER (PI15/00558). The metabolomics platform is supported by H2020 European Union project OncoBiome. G. K. is supported by Ligue contre le Cancer (equipe labellisee); Agence National de la Recherche (ANR) -Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; Chancelerie des universites de Paris (Legs Poix), Fondation pour la Recherche Medicale (FRM); a donation by Elior; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy Odyssea; the European Union Horizon 2020 Project Oncobiome; Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumiere; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM). The Instituto Universitario de Oncologia is supported by Fundacion Bancaria Caja de Ahorros de Asturias. J.M.P.F. is supported by Ministerio de Economia y Competitividad-FEDER and Gobierno del Principado de Asturias. C.L.-O. is supported by grants from the European Research Council (DeAge, ERC Advanced Grant), Ministerio de Economia y Competitividad-FEDER, Instituto de Salud Carlos III (RTICC) and Progeria Research Foundation.	Abubucker S, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002358; Barcena C, 2018, CELL REP, V24, P2392, DOI 10.1016/j.celrep.2018.07.089; Biagi E, 2016, CURR BIOL, V26, P1480, DOI 10.1016/j.cub.2016.04.016; Bodogai M, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4271; Breton J, 2016, CELL METAB, V23, P324, DOI 10.1016/j.cmet.2015.10.017; Buffie CG, 2015, NATURE, V517, P205, DOI 10.1038/nature13828; Cabreiro F, 2013, EMBO MOL MED, V5, P1300, DOI 10.1002/emmm.201100972; Cox LM, 2014, CELL, V158, P705, DOI 10.1016/j.cell.2014.05.052; Enot DP, 2015, CELL CYCLE, V14, P2399, DOI 10.1080/15384101.2015.1064206; Everard A, 2013, P NATL ACAD SCI USA, V110, P9066, DOI 10.1073/pnas.1219451110; Goodrich JK, 2014, CELL, V159, P789, DOI 10.1016/j.cell.2014.09.053; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Gordon LB, 2014, CELL, V156, P400, DOI 10.1016/j.cell.2013.12.028; Kalabis J, 2006, J BIOL CHEM, V281, P6434, DOI 10.1074/jbc.M512905200; Koeth RA, 2013, NAT MED, V19, P576, DOI 10.1038/nm.3145; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; Leulier F, 2017, CELL METAB, V25, P522, DOI 10.1016/j.cmet.2017.02.001; Lloyd-Price J, 2017, NATURE, V550, P61, DOI 10.1038/nature23889; Loomba R, 2017, CELL METAB, V25, P1054, DOI 10.1016/j.cmet.2017.04.001; Maharshak N, 2013, GUT MICROBES, V4, P316, DOI 10.4161/gmic.25486; O'Toole PW, 2015, SCIENCE, V350, P1214, DOI 10.1126/science.aac8469; Osorio FG, 2012, GENE DEV, V26, P2311, DOI 10.1101/gad.197954.112; Osorio FG, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002847; Pierre JF, 2016, AM J PHYSIOL-GASTR L, V311, pG286, DOI 10.1152/ajpgi.00202.2016; Plovier H, 2017, NAT MED, V23, P107, DOI 10.1038/nm.4236; Postler TS, 2017, CELL METAB, V26, P110, DOI 10.1016/j.cmet.2017.05.008; Puente XS, 2011, AM J HUM GENET, V88, P650, DOI 10.1016/j.ajhg.2011.04.010; Qin JJ, 2012, NATURE, V490, P55, DOI 10.1038/nature11450; Ridaura VK, 2013, SCIENCE, V341, P1079, DOI 10.1126/science.1241214; Rios-Covian D, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00185; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rothschild D, 2018, NATURE, V555, P210, DOI 10.1038/nature25973; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Schneeberger M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16643; Schroeder B, 2016, NAT MED, V22, P1079, DOI 10.1038/nm.4185; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Thaiss CA, 2016, NATURE, V535, P65, DOI 10.1038/nature18847; Vallim TQD, 2013, CELL METAB, V17, P657, DOI 10.1016/j.cmet.2013.03.013; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Varela I, 2005, NATURE, V437, P564, DOI 10.1038/nature04019; Vrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031; Wahlstrom A, 2016, CELL METAB, V24, P41, DOI 10.1016/j.cmet.2016.05.005; Wang CX, 2004, MECH AGEING DEV, V125, P629, DOI 10.1016/j.mad.2004.07.003; Wang YH, 2018, NAT MED, V24, P1804, DOI 10.1038/s41591-018-0238-9; Weingarden AR, 2014, AM J PHYSIOL-GASTR L, V306, pG310, DOI 10.1152/ajpgi.00282.2013; Zarrinpar A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05336-9; Zitvogel L, 2017, NAT REV MICROBIOL, V15, P465, DOI 10.1038/nrmicro.2017.44	47	189	200	21	189	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2019	25	8					1234	+		10.1038/s41591-019-0504-5	http://dx.doi.org/10.1038/s41591-019-0504-5			22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	IQ0BI	31332389	Green Submitted			2023-01-03	WOS:000480414600021
J	Leulseged, TW; Ayele, BT				Leulseged, Tigist W.; Ayele, Birhanu T.			Time to optimal glycaemic control and prognostic factors among type 2 diabetes mellitus patients in public teaching hospitals in Addis Ababa, Ethiopia	PLOS ONE			English	Article								Aim To estimate time to first optimal glycaemic control and identify prognostic factors among type 2 diabetes mellitus (T2DM) patients attending diabetes clinic of public teaching hospitals in Addis Ababa, Ethiopia. Methods A retrospective chart review study was conducted at diabetes clinic of Addis Ababa's public teaching hospitals among a randomly selected sample of 685 charts of patients with T2DMwho were on follow up from January 1, 2013 to June 30, 2017. Data was collected using data abstraction tool. Descriptive statistics, Kaplan Meier plots, median survival time, Log-rank test and Cox proportional hazard survival models were used for analysis. Results Median time to first optimal glycaemic control among the study population was 9.5 months. Factors that affect time to first optimal glycaemic control were age group (HR = 0.635, 95% CI: 0.486-0.831 for 50-59 years, HR = 0.558, 95% CI: 0.403-0.771for 60-69 years and HR = 0.495, 95% CI: 0.310-0.790 for > = 70 years), diabetes neuropathy (HR = 0.502, 95% CI: 0.375-0.672), more than one complication (HR = 0.381, 95% CI: 0.177-0.816), hypertension (HR = 0.611, 95% CI: 0.486-0.769), dyslipidemia (HR = 0.609, 95% CI: 0.450-0.824), cardiovascular disease (HR = 0.670, 95% CI: 0.458-0.979) and hospital patient being treated (HR = 1.273, 95% CI: 1.052-1.541). Conclusions Median time to first optimal glycaemic control among T2DM patients is longer than expected which might imply that patients are being exposed to more risk of complication and death.	[Leulseged, Tigist W.] Millennium Med Coll, Dept Internal Med, St Pauls Hosp, Addis Ababa, Ethiopia; [Ayele, Birhanu T.] Stellenbosch Univ, Fac Med & Hlth Sci, Div Epidemiol & Biostat, Cape Town, South Africa	Stellenbosch University	Leulseged, TW (corresponding author), Millennium Med Coll, Dept Internal Med, St Pauls Hosp, Addis Ababa, Ethiopia.	tigdolly@gmail.com	Ayele, Birhanu/AAG-4155-2019	Ayele, Birhanu/0000-0002-5589-8327; Leulseged, Tigist/0000-0002-5767-1417				Abebe SM, 2015, DIABET METAB SYND OB, V8, P65, DOI 10.2147/DMSO.S75467; ADA, 2017, STAND MED CAR DIAB G; AHMAD R, 2014, KUMAR CLARK CLIN MED, P243, DOI DOI 10.1109/BDCLOUD.2014.88; Berhane F., 2017, J DIABETES METABOLIS, V8, P729; Blonde L, 2017, DIABETES VASC DIS RE, V14, P172, DOI 10.1177/1479164116679775; CARL J, 2002, DIABETES CARE, V25, P1297, DOI [10.2337/diacare.25.8.1297, DOI 10.2337/DIACARE.25.8.1297]; David Hosmer, 2008, APPL SURVIVAL ANAL; Derbachew Asfaw Teni, 2015, Ethiopian e-Journal for Research and Innovation Foresight, V7, P20; Ewenighi Chinwe O, 2013, Indian J Med Sci, V67, P61; Fauci A, 2015, HARRISON PRINCIPLES; Gebregziabher M, 2010, AM J EPIDEMIOL, V171, P1090, DOI 10.1093/aje/kwq070; Kassahun Tefera, 2016, BMC Res Notes, V9, P78, DOI 10.1186/s13104-016-1896-7; Kibirige D, 2017, INT J GEN MED, V10, P33, DOI 10.2147/IJGM.S124548; Mohammed J, 2016, J DIABETES RES, V2108, P14; Ngoyo J, 2016, J ENDOCRINOLOGY DIAB, V3, P1; Senait M, 2015, ETHIOPIAN PHARM J, V31, P131; Su JB, 2018, CARDIOVASC DIABETOL, V17, DOI 10.1186/s12933-018-0693-0; World Health Organization, 2016, GLOB REP DIAB, P16; Xu F, 2014, DIABETOL METAB SYNDR, V6, DOI 10.1186/1758-5996-6-139	19	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2019	14	7							e0220309	10.1371/journal.pone.0220309	http://dx.doi.org/10.1371/journal.pone.0220309			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4XR	31365544	gold, Green Submitted, Green Published			2023-01-03	WOS:000484983600035
J	Boseila, AA; Abdel-Reheem, AY; Basalious, EB				Boseila, Amira A.; Abdel-Reheem, Amal Y.; Basalious, Emad B.			Design of bile-based vesicles (BBVs) for hepatocytes specific delivery of Daclatasvir: Comparison of ex-vivo transenterocytic transport, in-vitro protein adsorption resistance and HepG2 cellular uptake of charged and beta-sitosterol decorated vesicles	PLOS ONE			English	Article							WATER-SOLUBLE DRUGS; LOADED LIPOSOMES; ORAL DELIVERY; MEMBRANOUS REPLICATION; NANOPARTICLES; BILOSOMES; SALTS; NS5A; STABILITY; BIODISTRIBUTION	Daclatasvir is a new direct acting antiviral used in treatment of Hepatitis C virus, in an attempt to increase its hepatocytes specificity and uptake. It was encapsulated within bile based vesicles (BBVs) containing egg phosphatidyl choline, cholesterol and sodium deoxycholate fabricated by thin-film hydration method. A D-optimal mixture design was applied to study the effect of formulation variables on vesicular characteristics. The dependent variables picked were the particle size, polydispersity index, zeta potential and entrapment efficiency. The optimized bile based vesicles were subjected for further modifications to prepare miniaturized anionic (ABBVs), cationic (CBBVs) and Sito-G decorated BBVs (Sito-GBBVs) to be capable to penetrate liver fenestrae (<200 nm). The aim of the current work is to compare the potential of the ABBVs, CBBVs and Sito-GBBVs loaded with Daclatasvir for stability in simulated biological fluids, ex-vivo intestinal transenterocytic transport, HepG2 cellular uptake and resistance to blood protein adsorption. The miniaturized ABBVs, CBBVs and Sito-GBBVs showed acceptable stability in simulated biological fluids. CBBVs had the highest transenterocytic transport through intestinal membrane. The internalization of CBBVs into HepG2 cells was about 2.1 folds that of ABBVs and 1.45 folds that of Sito-GBBVs. ABBVs and Sito-GBBVs showed superior resistance to opsonization compared to CBBVs which showed significant increase in particle size (p>0.05) due to protein adsorption. The miniaturized Sito-GBBVs constitute a promising strategy to overcome key biological barriers facing hepatocytes specific delivery of Daclatasvir.	[Boseila, Amira A.; Abdel-Reheem, Amal Y.] Natl Org Drug Control & Res, Dept Pharmaceut, Cairo, Egypt; [Basalious, Emad B.] Cairo Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Cairo, Egypt	National Organization for Drug Control & Research (NODCAR); Egyptian Knowledge Bank (EKB); Cairo University	Boseila, AA (corresponding author), Natl Org Drug Control & Res, Dept Pharmaceut, Cairo, Egypt.	miro.boseila@hotmail.com	Boseila, Amira/GRY-7396-2022	Boseila, Amira/0000-0003-0666-5233				Abdelbary AA, 2016, INT J PHARMACEUT, V513, P688, DOI 10.1016/j.ijpharm.2016.10.006; Aburahma MH, 2016, DRUG DELIV, V23, P1847, DOI 10.3109/10717544.2014.976892; Akamatsu K, 1998, J DRUG TARGET, V6, P229, DOI 10.3109/10611869808997897; Al-Mahallawi AM, 2015, INT J PHARMACEUT, V485, P329, DOI 10.1016/j.ijpharm.2015.03.033; Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m; Ali MH, 2013, INT J PHARMACEUT, V453, P225, DOI 10.1016/j.ijpharm.2012.06.056; Andrieux K, 2009, EUR J PHARM BIOPHARM, V71, P346, DOI 10.1016/j.ejpb.2008.09.004; [Anonymous], 2018, FDA DISSOLUTION METH; Berger C, 2014, GASTROENTEROLOGY, V147, P1094, DOI 10.1053/j.gastro.2014.07.019; Berger KL, 2011, J VIROL, V85, P8870, DOI 10.1128/JVI.00059-11; Bramwell VW, 2006, J PHARM PHARMACOL, V58, P717, DOI 10.1211/jpp.58.6.0002; Chen YP, 2009, INT J PHARMACEUT, V376, P153, DOI 10.1016/j.ijpharm.2009.04.022; D'Souza AA, 2015, J CONTROL RELEASE, V203, P126, DOI 10.1016/j.jconrel.2015.02.022; DELEERS M, 1982, PHARMACOL RES COMMUN, V14, P333, DOI 10.1016/S0031-6989(82)80103-3; El-Shabouri MH, 2002, INT J PHARM, V249, P101, DOI 10.1016/S0378-5173(02)00461-1; Elmowafy M, 2013, EUR J PHARM SCI, V50, P161, DOI 10.1016/j.ejps.2013.06.012; Elnaggar YSR, 2015, INT J NANOMED, V10, P3955, DOI 10.2147/IJN.S82558; Ensign LM, 2012, ADV DRUG DELIVER REV, V64, P557, DOI 10.1016/j.addr.2011.12.009; Freag MS, 2013, INT J PHARMACEUT, V454, P462, DOI 10.1016/j.ijpharm.2013.06.039; Gangishetty H, 2015, PHARM DEV TECHNOL, V20, P641, DOI 10.3109/10837450.2014.908306; Gao M, 2010, NATURE, V465, P96, DOI 10.1038/nature08960; Gaumet M, 2008, EUR J PHARM BIOPHARM, V69, P1, DOI 10.1016/j.ejpb.2007.08.001; Gosert R, 2003, J VIROL, V77, P5487, DOI 10.1128/JVI.77.9.5487-5492.2003; Guan PP, 2011, INT J NANOMED, V6, P965, DOI 10.2147/IJN.S19259; Guhagarkar SA, 2010, INT J PHARMACEUT, V401, P113, DOI 10.1016/j.ijpharm.2010.09.012; Hanna LA, 2017, DRUG DELIV, V24, P188, DOI 10.1080/10717544.2016.1239661; Hashida M, 2001, ADV DRUG DELIVER REV, V52, P187, DOI 10.1016/S0169-409X(01)00209-5; Hashim F, 2010, DRUG DELIV, V17, P282, DOI 10.3109/10717541003706257; He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065; Hu SW, 2013, INT J PHARMACEUT, V441, P693, DOI 10.1016/j.ijpharm.2012.10.025; Jacobson IM, 2010, CLIN GASTROENTEROL H, V8, P924, DOI 10.1016/j.cgh.2010.06.032; Jain S, 2014, NANOMED-NANOTECHNOL, V10, P431, DOI 10.1016/j.nano.2013.08.012; Lankoff A, 2013, NANOTOXICOLOGY, V7, P235, DOI 10.3109/17435390.2011.649796; McGivern DR, 2014, GASTROENTEROLOGY, V147, P453, DOI 10.1053/j.gastro.2014.04.021; McMahon HT, 2011, NAT REV MOL CELL BIO, V12, P517, DOI 10.1038/nrm3151; Mohammed AR, 2004, INT J PHARMACEUT, V285, P23, DOI 10.1016/j.ijpharm.2004.07.010; Mohsen AM, 2017, DRUG DEV IND PHARM, V43, P2043, DOI 10.1080/03639045.2017.1361968; Moradpour D, 2013, CURR TOP MICROBIOL, V369, P113, DOI 10.1007/978-3-642-27340-7_5; Naguib SS, 2017, DRUG DELIV, V24, P99, DOI 10.1080/10717544.2016.1233588; Niu MM, 2014, INT J PHARMACEUT, V460, P119, DOI 10.1016/j.ijpharm.2013.11.028; Owens DE, 2006, INT J PHARMACEUT, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010; Parfieniuk A, 2007, WORLD J GASTROENTERO, V13, P5673, DOI 10.3748/wjg.v13.i43.5673; Reiss S, 2011, CELL HOST MICROBE, V9, P32, DOI 10.1016/j.chom.2010.12.002; Repetto G, 2008, NAT PROTOC, V3, P1125, DOI 10.1038/nprot.2008.75; Romero-Brey I, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003056; Shamma RN, 2014, INT J NANOMED, V9, P5449, DOI 10.2147/IJN.S73010; Shehata EMM, 2016, INT J PHARMACEUT, V511, P745, DOI 10.1016/j.ijpharm.2016.07.078; Sun JK, 2010, DRUG DELIV, V17, P164, DOI 10.3109/10717541003667764; Takakura Y, 1998, ADV DRUG DELIVER REV, V34, P93, DOI 10.1016/S0169-409X(98)00006-4; Vyas SP, 2006, J PHARM PHARMACOL, V58, P321, DOI 10.1211/jpp.58.3.0005; Walkey CD, 2012, J AM CHEM SOC, V134, P2139, DOI 10.1021/ja2084338; Wang SL, 2006, INT J PHARM, V311, P82, DOI 10.1016/j.ijpharm.2005.12.014; Wilkhu JS, 2013, J DRUG TARGET, V21, P291, DOI 10.3109/1061186X.2012.747528; Zidan AS, 2013, J LIPOSOME RES, V23, P318, DOI 10.3109/08982104.2013.810645	54	4	4	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2019	14	7							e0219752	10.1371/journal.pone.0219752	http://dx.doi.org/10.1371/journal.pone.0219752			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4SF	31310613	Green Published, gold, Green Submitted			2023-01-03	WOS:000484969300031
J	Nagano, H; Obara, H; Takayama, Y				Nagano, Hiroaki; Obara, Haruo; Takayama, Yoshihiro			A brief home-based palliative care learning experience for medical students and resident doctors in Okinawa, Japan	PLOS ONE			English	Article								Background The clinical component of medical education for students and resident doctors in Japan occurs almost entirely in the hospital setting. Because of this inpatient focus, graduate medical education clinical training often fails to expose physicians-in-training to the challenges that patients may face in the outpatient or home setting. This is a descriptive study in which we explore what participating students and resident doctors learned through our brief home-based teaching experience. Methods From June 2016 to December 2017, attending physicians on the internal medicine service had medical students and resident doctors accompany them on home care visits. Participants were selected by convenience sampling based on their rotation availability. After the home visit and the interactive discussion, the participants were expected to prepare a reflective journal on their experience and learning. Thematic analysis was applied, and key themes were developed based on Kolb's ELT (Experiential learning theory). Three months after completion of the experience, semi-structured interviews were individually conducted assessing participants' self-perceived changes. Results Thirty-two medical students(10) or residents(22) participated in a home visit. Thirty of these learners were able to complete a reflective journal. Using thematic analysis, we identified 2 domains and 6 key themes from the participants' perceptions. Participants recognized the importance of patient-centered care, inter-professional collaboration of the home care team, and reconceptualized the meaning of medical practice and their professional identity as a doctor. Three month post-experience interviews were completed on 12 of the original 30 participants who completed the reflective journal. 2 domains and 6 key themes from the residents' experiences and perceptions were generated. The participants reported an increased attention to the daily lives and social situations of their hospitalized patients, and an extension of their focus beyond the clinical medical treatment of the patient. Conclusion The experience of a brief visit to a patient's home is a novel educational approach that may potentially provide medical students and resident doctors with opportunities to learn about out-of-hospital, patient-centered, home-based medical care.	[Nagano, Hiroaki] Okinawa Chubu Hosp, Dept Resp Med, Uruma, Okinawa, Japan; [Obara, Haruo] Okinawa Chubu Hosp, Dept Gen Internal Med, Uruma, Okinawa, Japan; [Takayama, Yoshihiro] Okinawa Chubu Hosp, Dept Infect Dis, Uruma, Okinawa, Japan	Okinawa Chubu Central Hospital; Okinawa Chubu Central Hospital; Okinawa Chubu Central Hospital	Nagano, H (corresponding author), Okinawa Chubu Hosp, Dept Resp Med, Uruma, Okinawa, Japan.	hiroakinoko322violin@gmail.com		Nagano, Hiroaki/0000-0001-5587-5662				Buchman S, 2012, CAN FAM PHYSICIAN, V58, P114; Chandran Rabin, 2014, R I Med J (2013), V98, P35; Difat J, 2015, CAN FAM PHYSICIAN, V61, P189; Emanuel EJ, 2000, ANN INTERN MED, V132, P451, DOI 10.7326/0003-4819-132-6-200003210-00005; Franco P, 2010, ARCH ONCOL, V18, P31; Cardenas LAG, 2013, INTERFACE-BOTUCATU, V17, P649, DOI 10.1590/S1414-32832013000300012; Garcia-Huidobro Diego, 2014, ISRN Family Med, V2014, P631732, DOI 10.1155/2014/631732; Gomes B, 2004, J ROY SOC MED, V97, P413, DOI 10.1258/jrsm.97.9.413; Groh G, 2013, J PALLIAT MED, V16, P848, DOI 10.1089/jpm.2012.0491; Helen CR, 2005, BRIT MED J, V331, P239, DOI [10.1136/bmj.331.7528.sgp239, DOI 10.1136/BMJ.331.7528.SGP239]; Hervada-Page Maria, 2007, Care Manag J, V8, P206, DOI 10.1891/152109807782590628; Hudson P, 2009, J PAIN SYMPTOM MANAG, V38, P299, DOI 10.1016/j.jpainsymman.2008.08.010; Ivy O, 2005, J INTERPROF CARE, V1, P39; Kazuko A, 2017, BMC MED EDUC, V17, P1, DOI [10.1186/s12909-016-0842-7, DOI 10.1186/S12909-016-0842-7]; Kolb A. Y., 2009, SAGE HDB MANAGEMENT, V42, P68, DOI [DOI 10.4135/9780857021038.N3, 10.4135/9780857021038.n3]; Landers S, 2016, HOME HLTH CARE MAN P, V28, P262, DOI 10.1177/1084822316666368; Parent Kelly, 2016, AMA J Ethics, V18, P24, DOI 10.1001/journalofethics.2016.18.1.medu1-1601; Rabow M, 2013, J PALLIAT MED, V16, P1540, DOI 10.1089/jpm.2013.0153; Roane DM, 2002, GERONTOLOGIST, V42, P109, DOI 10.1093/geront/42.1.109; Sairenji Tomoko, 2017, J Grad Med Educ, V9, P90, DOI 10.4300/JGME-D-16-00249.1; Shepperd S, 2009, CAN MED ASSOC J, V180, P175, DOI 10.1503/cmaj.081491; Taro T, 2010, IGAKUKYOUIKU, V41, P161; YOUNG R, 1981, J MED EDUC, V56, P341	23	5	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2019	14	6							e0218780	10.1371/journal.pone.0218780	http://dx.doi.org/10.1371/journal.pone.0218780			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW3BT	31237900	Green Submitted, Green Published, gold			2023-01-03	WOS:000484856000039
J	Hausmann, N; Meredith-Williams, M; Douka, K; Inglis, RH; Bailey, G				Hausmann, Niklas; Meredith-Williams, Matthew; Douka, Katerina; Inglis, Robyn H.; Bailey, Geoff			Quantifying spatial variability in shell midden formation in the Farasan Islands, Saudi Arabia	PLOS ONE			English	Article							COASTAL RESOURCE USE; ACCUMULATION RATES; SUBMERGED LANDSCAPES; MOLLUSKS EMERGENT; MARINE RESOURCES; SITE FORMATION; TORRES STRAIT; PLEISTOCENE; ARCHAEOLOGY; TRENDS	During the past decade, over 3000 shell middens or shell matrix deposits have been discovered on the Farasan Islands in the southern Red Sea, dating to the period c. 7,360 to 4,700 years ago. Many of the sites are distributed along a palaeoshoreline which is now 2-3 m above present sea level. Others form clusters with some sites on the shoreline and others located inland over distances of c. 30 m to 1 km. We refer to these inland sites as 'post-shore' sites. Following Meehan, who observed a similar spatial separation in shell deposition in her ethnographic study of Anbarra shellgathering in the Northern Territory of Australia, we hypothesise that the shoreline sites are specialised sites for the processing or immediate consumption of shell food, and the post-shore sites are habitation sites used for a variety of activities. We test this proposition through a systematic analysis of 55 radiocarbon dates and measurement of shell quantities from the excavation of 15 shell matrix sites in a variety of locations including shoreline and post-shore sites. Our results demonstrate large differences in rates of shell accumulation between these two types of sites and selective removal of shoreline sites by changes in sea level. We also discuss the wider implications for understanding the differential preservation and visibility of shell-matrix deposits in coastal settings in other parts of the world extending back into the later Pleistocene in association with periods of lowersea level. Our results highlight the importance of taphonomic factors of post-depositional degradation and destruction, rates of shell accumulation, the influence on site location of factors other than shell food supply, and the relative distance of deposits from their nearest palaeoshorelines as key variables in the interpretation of shell quantities. Failure to take these variables into account when investigating shells and shell-matrix deposits in late Pleistocene and early Holocene contexts is likely to compromise interpretations of the role and significance of shell food in human evolutionary and socio-cultural development.	[Hausmann, Niklas; Douka, Katerina] Max Planck Inst Sci Human Hist, Jena, Germany; [Hausmann, Niklas; Meredith-Williams, Matthew; Inglis, Robyn H.; Bailey, Geoff] Univ York, Heslington, England; [Meredith-Williams, Matthew] La Trobe Univ, Bundoora, Vic, Australia; [Bailey, Geoff] Flinders Univ S Australia, Adelaide, SA, Australia	University of York - UK; La Trobe University; Flinders University South Australia	Hausmann, N (corresponding author), Max Planck Inst Sci Human Hist, Jena, Germany.; Hausmann, N (corresponding author), Univ York, Heslington, England.	hausmann@shh.mpg.de	Meredith-Williams, Matthew/AHB-5532-2022; Hausmann, Niklas/AAF-3539-2019; Douka, Katerina/L-3287-2014	Hausmann, Niklas/0000-0002-4381-8334; Douka, Katerina/0000-0002-0558-0011; bailey, geoffrey/0000-0003-2656-830X; Meredith-Williams, Matthew Gregory/0000-0001-5284-641X	European Research Council as part of the DISPERSE Project [269586]	European Research Council as part of the DISPERSE Project	This research was funded by the European Research Council as part of the DISPERSE Project (269586).	Alsharekh AM, 2013, COASTAL PREHISTORY S; Alvarez M, 2010, QUATERN INT, P1; ANDERSEN S. H., 2000, P PREHIST SOC, V66, P361, DOI [DOI 10.1017/S0079497X00001857, 10.1017/S0079497X00001857]; Andrus CFT, 2011, QUATERNARY SCI REV, V30, P2892, DOI 10.1016/j.quascirev.2011.07.016; Antunes M., 2000, MEMORIAS ACAD CIENCI; Bailey G., 2010, RED SEA COASTAL LAND, P15; Bailey G., 2002, FARMING; Bailey GN, 2015, QUATERN INT, V382, P42, DOI 10.1016/j.quaint.2015.01.002; Bailey G.N., 2019, GEOLOGICAL SETTING P, V79, P583; Bailey G. N., 1978, EARLY POSTGLACIAL SE; Bailey GN, 2008, QUATERNARY SCI REV, V27, P2153, DOI 10.1016/j.quascirev.2008.08.012; Bailey GN, 2003, GEOARCHAEOLOGY, V18, P175, DOI 10.1002/gea.10057; BAILEY GN, 1975, J ARCHAEOL SCI, V2, P45, DOI 10.1016/0305-4403(75)90045-X; Bailey GN., 2013, SHELL ENERGY MOLLUSC, P241; Bailey GN, 1977, SHELL MOUNDS SHELL M, V11, P132; Balbo A, 2011, QUATERN INT, V239, P147, DOI 10.1016/j.quaint.2011.03.032; Benjamin J., 2011, SUBMERGED PREHISTORY; Bird DW, 2002, J ARCHAEOL SCI, V29, P457, DOI 10.1006/jasc.2001.0734; Bird DW, 1997, J ARCHAEOL SCI, V24, P39, DOI 10.1006/jasc.1995.0095; Bovy KM, 2019, J ARCHAEOL SCI-REP, V23, P1168, DOI 10.1016/j.jasrep.2018.08.049; Bronk Ramsey, 2017, OXCAL VER4 3; Campbell G, 2008, ENVIRON ARCHAEOL, V13, P111, DOI 10.1179/174963108X343236; Campmas E, 2017, AFR ARCHAEOL REV, V34, P469, DOI 10.1007/s10437-017-9273-z; Cannon A, 2000, J ARCHAEOL SCI, V27, P725, DOI 10.1006/jasc.1999.0498; Claassen C., 1998, SHELLS; Clark JL, 2013, CURR ANTHROPOL, V54, pS269, DOI 10.1086/673386; Codding BF, 2014, J ISL COAST ARCHAEOL, V9, P238, DOI 10.1080/15564894.2013.848958; Cook Hale JW, 2019, SE ARCHAEOLOGY, V38, P1; Dibble H.L., 2012, PALEOANTHROPOLOGY, V2012, P145, DOI DOI 10.4207/PA.2012.ART74; Erlandson JM, 2001, J ARCHAEOL RES, P1; Estevez J, 2013, SHELL ENERGY MOLLUSC, P107; Fa DA, 2008, QUATERNARY SCI REV, V27, P2194, DOI 10.1016/j.quascirev.2008.07.015; Fano M.A., 2013, SHELL ENERGY MOLLUSC, P155; Fischer A., 2007, SHELL MIDDENS ATLANT, P54; Flamand JRB, 1988, MAMMALIA, P52, DOI [10.1515/mamm-1988-0422, DOI 10.1515/MAMM-1988-0422]; Gosden C, 1991, MODELS MATENKUPKUM I; Gutierrez-Zugasti I, 2011, QUATERN INT, V239, P70, DOI 10.1016/j.quaint.2011.02.031; Habu J, 2011, QUATERN INT, V239, P19, DOI 10.1016/j.quaint.2011.03.014; Hardy BL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023768; Hardy K, 2016, J ANTHROPOL ARCHAEOL, V41, P19, DOI 10.1016/j.jaa.2015.11.001; Hausmann N, 2017, QUATERN INT, V427, P115, DOI 10.1016/j.quaint.2015.08.051; Hausmann N, 2017, J ISL COAST ARCHAEOL, V12, P360, DOI 10.1080/15564894.2016.1216478; Hausmann N, 2017, J ARCHAEOL METHOD TH, V24, P776, DOI 10.1007/s10816-016-9287-x; Holdaway SJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183863; Inglis R. H., GEOLOGICAL SETTING P; Jazwa CS, 2017, WHEN LAND MEETS SEA, P163, DOI 10.1007/978-3-319-48787-8_8; Jazwa CS, 2015, J ANTHROPOL ARCHAEOL, V40, P33, DOI 10.1016/j.jaa.2015.05.005; Jerardino A, 2016, J ARCHAEOL SCI-REP, V6, P637, DOI 10.1016/j.jasrep.2015.06.005; Jerardino A, 2016, J ANTHROPOL ARCHAEOL, V41, P213, DOI 10.1016/j.jaa.2016.01.001; Jew NP, 2015, J ARCHAEOL SCI-REP, V3, P257, DOI 10.1016/j.jasrep.2015.06.022; Johnson A, 2015, J ISL COAST ARCHAEOL, V10, P232, DOI 10.1080/15564894.2014.980472; Khalidi Lamya, 2007, NATURAL RESOURCES CU, P35; Lambeck K, 2011, QUATERNARY SCI REV, V30, P3542, DOI 10.1016/j.quascirev.2011.08.008; Letham B, 2017, J ISL COAST ARCHAEOL, P1; Lovis WA, 2012, AM ANTIQUITY, V77, P591, DOI 10.7183/0002-7316.77.3.591; Marean CW, 2016, PHILOS T R SOC B, V371, DOI 10.1098/rstb.2015.0239; Marean CW, 2014, J HUM EVOL, V77, P17, DOI 10.1016/j.jhevol.2014.02.025; Marelli DC, 2001, J ARCHAEOL SCI, V28, P577, DOI 10.1006/jasc.2000.0565; Meehan B.F, 1975, SHELL BED SHELL MIDD; Meredith-Williams M, 2018, DISPERSE FIELD REPOR, P87; Meredith-Williams MG, 2014, INTERNET ARCHAEOLOGY; METCALFE D, 1992, AM ANTHROPOL, V94, P340, DOI 10.1525/aa.1992.94.2.02a00040; Milner G.R., 1998, SE ARCHAEOL, V17, P119; Mitchell P, 2008, ANTIQUITY, V82, P1093, DOI 10.1017/S0003598X00097805; Momber G, GEOLOGICAL SETTING P; Moore CR, 2012, J SOC ARCHAEOL, V12, P264, DOI 10.1177/1469605311431518; Morrison M, 2014, AUST ARCHAEOL, P1; O'Connor S, 2007, ANTIQUITY, V81, P523, DOI 10.1017/S0003598X00095569; Orquera L., 2000, RELACIONES SOC ARGEN, VXXVI, P345; Parkington J, 2012, J ARCHAEOL SCI, V39, P1521, DOI 10.1016/j.jas.2011.10.034; Pavlopoulos K, 2018, QUATERN INT, V493, P198, DOI 10.1016/j.quaint.2018.06.004; Penkman K, 2013, QUAT GEOCHRONOL, V16, P1, DOI 10.1016/j.quageo.2012.12.007; Peres TM, 2010, INTEGRATING ZOOARCHAEOLOGY AND PALEOETHNOBOTANY, P15, DOI 10.1007/978-1-4419-0935-0_2; Perles C, 2016, QUATERN INT, V407, P45, DOI 10.1016/j.quaint.2015.05.045; Pfister CA, 2016, P ROY SOC B-BIOL SCI, V283, DOI 10.1098/rspb.2016.0392; Pluckhahn TJ, 2015, J ANTHROPOL ARCHAEOL, V37, P19, DOI 10.1016/j.jaa.2014.10.004; Ramos-Munoz J, 2016, QUATERN INT, V407, P6, DOI 10.1016/j.quaint.2015.12.092; Reimer PJ, 2013, RADIOCARBON, V55, P1869, DOI 10.2458/azu_js_rc.55.16947; Rick TC, 2006, GEOARCHAEOLOGY, V21, P567, DOI 10.1002/gea.20124; Savarese M, 2016, ANTHROPOCENE, V16, P28, DOI 10.1016/j.ancene.2016.10.002; Shawcross W., 1968, Proceedings of the Prehistoric Society, V33, P107; Skriver C, 2017, SEA ARCHAEOLOGY PALA, P131; Steele TE, 2011, INTERD CONTRIB ARCH, P383, DOI 10.1007/978-1-4419-8219-3_16; Stein JK, 2003, J ARCHAEOL SCI, V30, P297, DOI 10.1006/jasc.2002.0838; Szabo K., 2013, SHELL ENERGY MOLLUSC, P277; Szabo K, 2015, J ARCHAEOL SCI, V54, P64, DOI 10.1016/j.jas.2014.11.022; Thomas KD, 2015, J ARCHAEOL SCI, V56, P159, DOI 10.1016/j.jas.2015.01.015; Thomas KD, 2015, J ARCHAEOL SCI, V56, P133, DOI 10.1016/j.jas.2015.01.024; Thompson VD, 2011, AM ANTIQUITY, V76, P315, DOI 10.7183/0002-7316.76.2.315; Villagran XS, 2019, J ARCHAEOL METHOD TH, V26, P344, DOI 10.1007/s10816-018-9374-2; Villagran XS, 2014, J ANTHROPOL ARCHAEOL, V36, P211, DOI 10.1016/j.jaa.2014.10.002; Villagran XS, 2011, ARCHAEOL ANTHROP SCI, V3, P357, DOI 10.1007/s12520-011-0074-z; Villagran XS, 2011, J ISL COAST ARCHAEOL, V6, P211, DOI 10.1080/15564894.2011.586087; Ward I, 2016, GEOL SOC SPEC PUBL, V411, P251, DOI 10.1144/SP411.4; Waselkov GA, 1987, ADV ARCHAEOL METH TH, V10, P93, DOI DOI 10.1016/B978-0-12-003110-8.50006-2; Will M, 2019, J WORLD PREHIST, V32, P33, DOI 10.1007/s10963-018-09127-4; Will M, 2016, QUATERN INT, V404, P68, DOI 10.1016/j.quaint.2015.10.021; Winder IC, 2015, J HUM EVOL, V87, P48, DOI 10.1016/j.jhevol.2015.07.002; Zangrando AFJ, 2016, ENVIRON ARCHAEOL, V21, P182, DOI 10.1080/14614103.2015.1130888	99	14	14	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2019	14	6							e0217596	10.1371/journal.pone.0217596	http://dx.doi.org/10.1371/journal.pone.0217596			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IC8MD	31188856	Green Published, gold, Green Accepted			2023-01-03	WOS:000471234500034
J	Heinrich, EC; Djokic, MA; Gilbertson, D; DeYoung, PN; Bosompra, NO; Wu, L; Anza-Ramirez, C; Orr, JE; Powell, FL; Malhotra, A; Simonson, TS				Heinrich, Erica C.; Djokic, Matea A.; Gilbertson, Dillon; DeYoung, Pamela N.; Bosompra, Naa-Oye; Wu, Lu; Anza-Ramirez, Cecilia; Orr, Jeremy E.; Powell, Frank L.; Malhotra, Atul; Simonson, Tatum S.			Cognitive function and mood at high altitude following acclimatization and use of supplemental oxygen and adaptive servoventilation sleep treatments	PLOS ONE			English	Article							DECISION-MAKING; REACTION-TIME; RISK-TAKING; HYPOXIA; PERFORMANCE; IMPAIRMENT; MEMORY; RELIABILITY; VALIDATION; EXPOSURE	Impairments in cognitive function, mood, and sleep quality occur following ascent to high altitude. Low oxygen (hypoxia) and poor sleep quality are both linked to impaired cognitive performance, but their independent contributions at high altitude remain unknown. Adaptive servoventilation (ASV) improves sleep quality by stabilizing breathing and preventing central apneas without supplemental oxygen. We compared the efficacy of ASV and supplemental oxygen sleep treatments for improving daytime cognitive function and mood in high-altitude visitors (N = 18) during acclimatization to 3,800 m. Each night, subjects were randomly provided with ASV, supplemental oxygen (SpO(2) > 95%), or no treatment. Each morning subjects completed a series of cognitive function tests and questionnaires to assess mood and multiple aspects of cognitive performance. We found that both ASV and supplemental oxygen (O-2) improved daytime feelings of confusion (ASV: p < 0.01; O-2: p < 0.05) and fatigue (ASV: p < 0.01; O-2: p < 0.01) but did not improve other measures of cognitive performance at high altitude. However, performance improved on the trail making tests (TMT) A and B (p < 0.001), the balloon analog risk test (p < 0.0001), and the psychomotor vigilance test (p < 0.01) over the course of three days at altitude after controlling for effects of sleep treatments. Compared to sea level, subjects reported higher levels of confusion (p < 0.01) and performed worse on the TMT A (p < 0.05) and the emotion recognition test (p < 0.05) on nights when they received no treatment at high altitude. These results suggest that stabilizing breathing (ASV) or increasing oxygenation (supplemental oxygen) during sleep can reduce feelings of fatigue and confusion, but that daytime hypoxia may play a larger role in other cognitive impairments reported at high altitude. Furthermore, this study provides evidence that some aspects of cognition (executive control, risk inhibition, sustained attention) improve with acclimatization.	[Heinrich, Erica C.; Djokic, Matea A.; Gilbertson, Dillon; DeYoung, Pamela N.; Bosompra, Naa-Oye; Wu, Lu; Orr, Jeremy E.; Powell, Frank L.; Malhotra, Atul; Simonson, Tatum S.] Univ Calif San Diego, Dept Med, Div Pulm Crit Care & Sleep Med, La Jolla, CA 92093 USA; [Anza-Ramirez, Cecilia] Univ Peruana Cayetano Heredia, Fac Ciencias & Filosofia, Dept Ciencias Biol & Fisiol, Lima, Peru; [Heinrich, Erica C.] Univ Calif Riverside, Div Biomed Sci, Sch Med, Riverside, CA 92521 USA; [Djokic, Matea A.] Montana State Univ, Dept Ecol, Bozeman, MT 59717 USA	University of California System; University of California San Diego; Universidad Peruana Cayetano Heredia; University of California System; University of California Riverside; Montana State University System; Montana State University Bozeman	Heinrich, EC (corresponding author), Univ Calif San Diego, Dept Med, Div Pulm Crit Care & Sleep Med, La Jolla, CA 92093 USA.; Heinrich, EC (corresponding author), Univ Calif Riverside, Div Biomed Sci, Sch Med, Riverside, CA 92521 USA.	erica.heinrich@medsch.ucr.edu	Orr, Jeremy E./T-6372-2019; Anza-Ramirez, Cecilia/AAP-6223-2021	Orr, Jeremy E./0000-0002-4498-5337; Anza-Ramirez, Cecilia/0000-0001-7364-8252	University of California San Diego Center for Physiological Genomics of Low Oxygen (CPLGO) Office of Research Affairs Support for Center Development; National Heart, Lung, and Blood Institute [F32HL131306, F32HL131218, R01HL081823, R01HL085188, K24HL132105, T32HL134632, R00HL118215]; American Physiological Society Giles Filley Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081823, R00HL118215, T32HL134632, K24HL132105, R01HL085188, F32HL131218] Funding Source: NIH RePORTER	University of California San Diego Center for Physiological Genomics of Low Oxygen (CPLGO) Office of Research Affairs Support for Center Development; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Physiological Society Giles Filley Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This research is supported by The University of California San Diego Center for Physiological Genomics of Low Oxygen (CPLGO) Office of Research Affairs Support for Center Development (TSS, AM); the National Heart, Lung, and Blood Institute (F32HL131306 to JEO, F32HL131218 to ECH, R01HL081823 to FLP, R01HL085188, K24HL132105, T32HL134632 to AM, and R00HL118215 to TSS); and the American Physiological Society Giles Filley Award to TSS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alfred R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031400; Armstrong RA, 2014, OPHTHAL PHYSL OPT, V34, P502, DOI 10.1111/opo.12131; Asmaro D, 2013, AVIAT SPACE ENVIR MD, V84, P1159, DOI 10.3357/ASEM.3661.2013; BAHRKE MS, 1993, SPORTS MED, V16, P97, DOI 10.2165/00007256-199316020-00003; Bartholomew CJ, 1999, INT J AVIAT PSYCHOL, V9, P351, DOI 10.1207/s15327108ijap0904_3; Basaran KE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146087; Basner M, 2015, AEROSP MED HUM PERF, V86, P942, DOI 10.3357/AMHP.4343.2015; Betz ME, 2011, SUICIDE LIFE-THREAT, V41, P562, DOI 10.1111/j.1943-278X.2011.00054.x; Bowie CR, 2006, NAT PROTOC, V1, P2277, DOI 10.1038/nprot.2006.390; CROWLEY JS, 1992, AVIAT SPACE ENVIR MD, V63, P696; Dewald JF, 2010, SLEEP MED REV, V14, P179, DOI 10.1016/j.smrv.2009.10.004; Dorrian J., 2005, THESIS, P39; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; FINDLEY LJ, 1986, CHEST, V90, P686, DOI 10.1378/chest.90.5.686; FOWLER B, 1987, ERGONOMICS, V30, P1475, DOI 10.1080/00140138708966040; FOWLER B, 1987, HUM FACTORS, V29, P61, DOI 10.1177/001872088702900106; Gao YX, 2015, EUR J NEUROL, V22, P1363, DOI 10.1111/ene.12507; Garrett-Bakelman FE, 2019, SCIENCE, V364, P144, DOI 10.1126/science.aau8650; Gerard A B, 2000, High Alt Med Biol, V1, P51, DOI 10.1089/152702900320685; Gray S, 2003, J COMMUN DISORD, V36, P129, DOI 10.1016/S0021-9924(03)00003-0; Grocott MPW, 2009, NEW ENGL J MED, V360, P140, DOI 10.1056/NEJMoa0801581; Harris GA, 2009, WILD ENVIRON MED, V20, P261, DOI 10.1580/08-WEME-OR-261R.1; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; HODDES E, 1973, PSYCHOPHYSIOLOGY, V10, P431, DOI 10.1111/j.1469-8986.1973.tb00801.x; HORNBEIN TF, 1989, NEW ENGL J MED, V321, P1714, DOI 10.1056/NEJM198912213212505; Ishigami Y, 2011, FRONT AGING NEUROSCI, V3, DOI 10.3389/fnagi.2011.00017; Issa AN, 2016, WILD ENVIRON MED, V27, P371, DOI 10.1016/j.wem.2016.04.008; Kemps E, 2001, MEMORY, V9, P13, DOI 10.1080/09658210042000012; Kessels RPC, 2010, APPL NEUROPSYCHOL, V4282, P37; Killgore WDS, 2011, J SLEEP RES, V20, P395, DOI 10.1111/j.1365-2869.2010.00893.x; Kim N, 2011, AM J PSYCHIAT, V168, P49, DOI 10.1176/appi.ajp.2010.10020289; LEDWITH F, 1970, ERGONOMICS, V13, P465, DOI 10.1080/00140137008931161; Lejuez CW, 2002, J EXP PSYCHOL-APPL, V8, P75, DOI 10.1037//1076-898X.8.2.75; Lemos VD, 2012, PSYCHOPHYSIOLOGY, V49, P1298, DOI 10.1111/j.1469-8986.2012.01411.x; Li X Y, 2000, Space Med Med Eng (Beijing), V13, P235; McElroy M K, 2000, High Alt Med Biol, V1, P197, DOI 10.1089/15270290050144190; McMorris T, 2017, NEUROSCI BIOBEHAV R, V74, P225, DOI 10.1016/j.neubiorev.2017.01.019; McNair D.M., 1971, MANUAL PROFILES MOOD; Morrison SA, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00410; Niedermeier M, 2017, PHYSIOL BEHAV, V173, P236, DOI 10.1016/j.physbeh.2017.02.018; Orr JE, 2018, HIGH ALT MED BIOL, V19, P178, DOI 10.1089/ham.2017.0147; Pighin S, 2014, STRESS, V17, P204, DOI 10.3109/10253890.2014.891103; Pighin S, 2012, JUDGM DECIS MAK, V7, P472; Pun M, 2018, FRONT PHYSIOL, V9, P1; REITE M, 1975, ELECTROEN CLIN NEURO, V38, P463, DOI 10.1016/0013-4694(75)90188-1; Rimoldi SF, 2016, J PEDIATR-US, V169, P238, DOI 10.1016/j.jpeds.2015.10.009; ROACH RC, 1993, HYPOXIA AND MOLECULAR MEDICINE, P272; Rosenzweig I, 2015, LANCET RESP MED, V3, P404, DOI 10.1016/S2213-2600(15)00090-9; SEVERINGHAUS JW, 1966, CIRC RES, V19, P274, DOI 10.1161/01.RES.19.2.274; Shukitt-Hale B, 1998, INT J AVIAT PSYCHOL, V8, P319, DOI 10.1207/s15327108ijap0804_1; SHUKITTHALE B, 1994, BEHAV NEURAL BIOL, V62, P244, DOI 10.1016/S0163-1047(05)80023-8; SHUKITTHALE B, 1990, AVIAT SPACE ENVIR MD, V61, P225; Smyth C., 2011, J GERONTOL NURS, V25; Strauss E., 2006, COMPENDIUM NEUROPSYC; Terry PC, 1999, J SPORT SCI, V17, P861, DOI 10.1080/026404199365425; Terry PC, 2003, PSYCHOL SPORT EXERC, V4, P125, DOI 10.1016/S1469-0292(01)00035-8; Turner CE, 2015, PHYSIOL BEHAV, V142, P104, DOI 10.1016/j.physbeh.2015.02.006; Virues-Ortega Javier, 2004, Neuropsychology Review, V14, P197; Wagner S, 2011, ARCH CLIN NEUROPSYCH, V26, P314, DOI 10.1093/arclin/acr024; Wang JY, 2013, NEUROTOXICOL TERATOL, V35, P28, DOI 10.1016/j.ntt.2012.12.003; Weil JV, 2004, HIGH ALT MED BIOL, V5, P180, DOI 10.1089/1527029041352162; White TL, 2008, EXP CLIN PSYCHOPHARM, V16, P565, DOI 10.1037/a0014083; Windsor JS, 2006, HIGH ALT MED BIOL, V7, P307, DOI 10.1089/ham.2006.7.307; Yan XA, 2011, EXP BRAIN RES, V208, P437, DOI 10.1007/s00221-010-2494-x	64	20	21	3	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2019	14	6							e0217089	10.1371/journal.pone.0217089	http://dx.doi.org/10.1371/journal.pone.0217089			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IC8MD	31188839	gold, Green Published, Green Submitted			2023-01-03	WOS:000471234500016
J	Honarmand, S; Dabirmanesh, B; Amanlou, M; Khajeh, K				Honarmand, Shokouh; Dabirmanesh, Bahareh; Amanlou, Massoud; Khajeh, Khosro			The interaction of several herbal extracts with alpha-synuclein: Fibril formation and surface plasmon resonance analysis	PLOS ONE			English	Article							AMYLOID FIBRILS; PARKINSONS-DISEASE; PLANT POLYPHENOLS; AGGREGATION; PATHOGENESIS; INHIBITION; TOXICITY; PRODUCT	Proteins from their native conformation convert into highly ordered fibrillar aggregation under particular conditions; that are described as amyloid fibrils. alpha-Synuclein (alpha-Syn) is a small natively unfolded protein that its fibrillation is the causative factor of Parkinson's disease. One important approach in the development of therapeutic agents is the use of small molecules (such as flavonoids) that could specifically and efficiently inhibit the aggregation process. In this study the effect of few herbal extract (Berberis, Quercus robur, Zizyphus vulgaris, Salix aegyptica) containing flavonoids were investigated on fibril formation of alpha-syn by using conventional methods such as ThT fluorescence, circular dichroism (CD) spectroscopy and transmission electron microscopy (TEM). The interaction of extracts were also analysed by surface plasmon resonance (SPR). Among extracts, Salix aegyptica revealed the highest inhibitory effect on fibril formation. As expected, Salix aegyptica extract also exhibited the highest affinity toward alpha-syn. Cell viability using MTT assay revealed that fibrils alone were more toxic than those containing the extract. Overall, we demonstrated that the affinity of compounds used in this study corresponds to their ability to arrest fibrillation and reduce cellular toxicity of alpha-syn fibrils.	[Honarmand, Shokouh; Dabirmanesh, Bahareh; Khajeh, Khosro] Tarbiat Modares Univ, Fac Biol Sci, Dept Biochem, Tehran, Iran; [Amanlou, Massoud] Univ Tehran Med Sci, Fac Pharm, Dept Med Chem, Tehran, Iran; [Amanlou, Massoud] Univ Tehran Med Sci, Drug Design & Dev Res Ctr, Tehran, Iran	Tarbiat Modares University; Tehran University of Medical Sciences; Tehran University of Medical Sciences	Dabirmanesh, B (corresponding author), Tarbiat Modares Univ, Fac Biol Sci, Dept Biochem, Tehran, Iran.	dabirmanesh@modares.ac.ir			research council of Tarbiat Modares University; Iran National Science Foundation (INSF) [93042561]	research council of Tarbiat Modares University; Iran National Science Foundation (INSF)(Iran National Science Foundation (INSF))	The present study was supported by grants from research council of Tarbiat Modares University and Iran National Science Foundation (INSF, project 93042561). The funders had no role in the study design, data collection and analysis, decision to publish and preparation of the manuscript.	Ahsan N, 2015, SCI REP-UK, V5, DOI 10.1038/srep09862; Asgarpanah J., 2012, African Journal of Biotechnology, V11, P7145; Bennett MJ, 2006, STRUCTURE, V14, P811, DOI 10.1016/j.str.2006.03.011; Biancalana M, 2010, BBA-PROTEINS PROTEOM, V1804, P1405, DOI 10.1016/j.bbapap.2010.04.001; Breydo L, 2012, BBA-MOL BASIS DIS, V1822, P261, DOI 10.1016/j.bbadis.2011.10.002; Bruggink KA, 2012, J ALZHEIMERS DIS, V28, P735, DOI 10.3233/JAD-2011-111421; Cairo CW, 2002, BIOCHEMISTRY-US, V41, P8620, DOI 10.1021/bi0156254; Coelho-Cerqueira E, 2013, FEBS J, V280, P4915, DOI 10.1111/febs.12471; Dehay B, 2015, LANCET NEUROL, V14, P855, DOI 10.1016/S1474-4422(15)00006-X; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Ferreira Nelson, 2015, Biochem Biophys Rep, V3, P123, DOI 10.1016/j.bbrep.2015.07.019; Fink AL, 2006, ACCOUNTS CHEM RES, V39, P628, DOI 10.1021/ar050073t; Gaeta A, 2005, BRIT J PHARMACOL, V146, P1041, DOI 10.1038/sj.bjp.0706416; Gautam S, 2017, BBA-PROTEINS PROTEOM, V1865, P589, DOI 10.1016/j.bbapap.2017.02.014; Kang T, 2006, LANGMUIR, V22, P13, DOI 10.1021/la052276w; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Meng XY, 2010, PARKINSONS DIS-US, V2010, DOI 10.4061/2010/650794; Morel B, 2010, BIOPHYS J, V99, P3801, DOI 10.1016/j.bpj.2010.10.039; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Pandey KB, 2009, OXID MED CELL LONGEV, V2, P270, DOI 10.4161/oxim.2.5.9498; Perni M, 2017, P NATL ACAD SCI USA, V114, pE1009, DOI 10.1073/pnas.1610586114; Porat Y, 2006, CHEM BIOL DRUG DES, V67, P27, DOI 10.1111/j.1747-0285.2005.00318.x; Pujols J, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030478; Qi XL, 2018, IND CROP PROD, V121, P411, DOI 10.1016/j.indcrop.2018.05.038; SCALBERT A, 1987, PHYTOCHEMISTRY, V26, P3191, DOI 10.1016/S0031-9422(00)82468-1; Shamspur T, 2011, J ESSENT OIL BEAR PL, V14, P543, DOI 10.1080/0972060X.2011.10643971; Stefani M, 2013, INT J MOL SCI, V14, P12411, DOI 10.3390/ijms140612411; Sun K, 2017, SENSOR ACTUAT B-CHEM, V245, P87, DOI 10.1016/j.snb.2017.01.171; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Tan M. C. S., 2018, Malaysian Journal of Analytical Sciences, V22, P579; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Velander P, 2017, BIOCHEM PHARMACOL, V139, P40, DOI 10.1016/j.bcp.2017.04.004; Wittenberg NJ, 2014, EXPERT REV NEUROTHER, V14, P449, DOI 10.1586/14737175.2014.896199; Xu LJ, 2016, PARKINSONS DIS-US, V2016, DOI 10.1155/2016/1720621; Zhu M, 2013, BBA-GEN SUBJECTS, V1830, P2872, DOI 10.1016/j.bbagen.2012.12.027	37	10	10	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2019	14	6							e0217801	10.1371/journal.pone.0217801	http://dx.doi.org/10.1371/journal.pone.0217801			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IC4XB	31185031	gold, Green Published, Green Submitted			2023-01-03	WOS:000470970000016
J	Fermaut, M; Fauconnier, A; Brossard, A; Razafimamonjy, J; Fritel, X; Serfaty, A				Fermaut, Marion; Fauconnier, Arnaud; Brossard, Aurelie; Razafimamonjy, Jimmy; Fritel, Xavier; Serfaty, Annie			Detection of complicated ectopic pregnancies in the hospital discharge database: A validation study	PLOS ONE			English	Article							ADMINISTRATIVE DATA; ACCURACY; SYSTEM; HEALTH; CANCER; ERRORS	Objective Complicated ectopic pregnancies with severe bleeding (CEPSB) are life-threatening situations and should be considered maternal near-miss cases. Previous studies have found an association between severe maternal morbidity secondary to CEPSB and substandard care. Almost all women with CEPSB are hospitalized, generating administrative and medical records. The objective of this study was to propose a method to measure the validity of the hospital discharge database (HDD) to detect CEPSB among hospital stays in two gynecological units. Methods We included all hospital stays of women who were 18-45 years old and hospitalized for acute pelvic pain or/and metrorrhagia in the two hospitals. The HDD was compared to medical data (gold standard). Two algorithms constructed from the International Classification of Disease (ICD-10) and Common Classification of Medical Procedures (CCAM), were applied to the HDD: a "predefined algorithm" according to coding guidelines and a "pragmatic algorithm" based on coding practices. Sensitivity, specificity and positive likelihood-ratios were calculated. False negatives and positives were analyzed to describe coding practices. Results Among 370 hospital stays included, 52 were classified as CEPSB cases. The "predefined algorithm" gave a sensitivity of 23.1% (95% CI: 11.6-34.5) and a specificity of 99.1% (95% CI: 98.0-100.0) to identify CEPSB. The "pragmatic algorithm" gave a sensitivity of 63.5% (95% CI: 50.4-76.5) and a specificity of 94.7% (95% CI: 92.2-97.5) to identify CEPSB. Coding errors (77.6%) were due to misuse of diagnosis codes and because complications were not coded. Conclusion HDD is not reliable enough to detect CEPSB due to incorrect coding practices. However, it could be an ideal tool to monitor quality of care if a culture in data quality assessment is developed to improve quality of medical information.	[Fermaut, Marion; Fauconnier, Arnaud] Intercommunal Hosp Ctr Poissy St Germain En Laye, Dept Gynecol & Obstet, Poissy, France; [Fermaut, Marion; Fauconnier, Arnaud; Serfaty, Annie] UVSQ, EA 7285, Res Unit Risk & Safety Clin Med Women & Perinatal, Montigny Le Bretonneux, France; [Brossard, Aurelie; Fritel, Xavier] Univ Hosp Ctr Poitiers, Dept Gynecol & Obstet, Poitiers, France; [Razafimamonjy, Jimmy] Intercommunal Hosp Ctr Poissy St Germain En Laye, Dept Med Informat, Poissy, France; [Fritel, Xavier] Univ Hosp Ctr Poitiers, INSERM, CIC 1402, Poitiers, France; [Serfaty, Annie] Eastern Parisian Univ Hosp, AP HP, Dept Med Informat, Paris, France; [Serfaty, Annie] Reg Agcy Hlth Paris Reg Direct Hlth Promot & Ineq, Paris, France	UDICE-French Research Universities; Universite Paris Saclay; CHU Poitiers; Universite de Poitiers; CHU Poitiers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Poitiers; Assistance Publique Hopitaux Paris (APHP)	Serfaty, A (corresponding author), UVSQ, EA 7285, Res Unit Risk & Safety Clin Med Women & Perinatal, Montigny Le Bretonneux, France.; Serfaty, A (corresponding author), Eastern Parisian Univ Hosp, AP HP, Dept Med Informat, Paris, France.; Serfaty, A (corresponding author), Reg Agcy Hlth Paris Reg Direct Hlth Promot & Ineq, Paris, France.	annieserfatydr@yahoo.fr	FRITEL, Xavier/K-8566-2012	FRITEL, Xavier/0000-0002-4987-8127; SERFATY, Annie/0000-0002-3973-5210	Woman's Health Research Institute (France)	Woman's Health Research Institute (France)	This work was supported by the Woman's Health Research Institute (France) for conducting the research.	Allanson ER, 2016, BJOG-INT J OBSTET GY, V123, P2037, DOI 10.1111/1471-0528.14246; American College of Obstetricians and Gynecologists' Committee on Practice BulletinsGynecology, 2018, Obstet Gynecol, V131, pe91, DOI 10.1097/AOG.0000000000002560; [Anonymous], 2016, BJOG, V123, pe15, DOI 10.1111/1471-0528.14189; Baldi I, 2008, J CLIN EPIDEMIOL, V61, P373, DOI 10.1016/j.jclinepi.2007.05.017; Bhattacharya AA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211265; Bouyer J, 2003, J Gynecol Obstet Biol Reprod (Paris), V32, pS8; Chantry AA, 2012, REV EPIDEMIOL SANTE, V60, P177, DOI 10.1016/j.respe.2011.11.003; Chantry AA, 2011, J CLIN EPIDEMIOL, V64, P1014, DOI 10.1016/j.jclinepi.2010.11.015; Coste J, 2004, HUM REPROD, V19, P2014, DOI 10.1093/humrep/deh399; Couris CM, 2009, J CLIN EPIDEMIOL, V62, P660, DOI 10.1016/j.jclinepi.2008.07.013; Couris CM, 2004, REV EPIDEMIOL SANTE, V52, P151, DOI 10.1016/S0398-7620(04)99036-0; DUSSAUCY A, 1994, REV EPIDEMIOL SANTE, V42, P345; Grimes DA, 2006, AM J OBSTET GYNECOL, V194, P92, DOI 10.1016/j.ajog.2005.06.070; Haesebaert J, 2013, STROKE, V44, P1770, DOI 10.1161/STROKEAHA.113.001300; HARTZ AJ, 1994, AM J PUBLIC HEALTH, V84, P1609, DOI 10.2105/AJPH.84.10.1609; Huusom LD, 2011, BJOG-INT J OBSTET GY, V118, P1, DOI 10.1111/j.1471-0528.2010.02782.x; Iezzoni LI, 1997, ANN INTERN MED, V127, P666, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00048; Kirk E, 2007, HUM REPROD, V22, P2824, DOI 10.1093/humrep/dem283; Lambert L, 2012, CAN J CARDIOL, V28, P162, DOI 10.1016/j.cjca.2011.10.005; LOMBRAIL P, 1994, REV EPIDEMIOL SANTE, V42, P334; Mavrelos D, ULTRASOUND OBSTET GY, V42, P102; Ministry of Health, 2012, B OFFICIEL, P126; Ministry of Health, 1991, J OFFICIEL REPUBLIQU; Ministry of Health, 2004, J OFFICIEL REPUBLIQU, P14277; Misset B, 2008, CRIT CARE, V12, DOI 10.1186/cc6969; Quan H, 2004, J CLIN EPIDEMIOL, V57, P366, DOI 10.1016/j.jclinepi.2003.01.002; Serfaty A, 2017, REV EPIDEMIOL SANTE, V65, pS209, DOI 10.1016/j.respe.2017.06.002; Serfaty A, 2014, LANCET, V384, P1672, DOI 10.1016/S0140-6736(14)62032-8; Serfaty A, 2011, EUR J PUBLIC HEALTH, V21, P504, DOI 10.1093/eurpub/ckq101; van Mello NM, 2012, FERTIL STERIL, V97, P623, DOI 10.1016/j.fertnstert.2011.12.021; Wedderburn CJ, 2010, HUM REPROD, V25, P328, DOI 10.1093/humrep/dep397; Yasmeen S, 2006, AM J OBSTET GYNECOL, V194, P992, DOI 10.1016/j.ajog.2005.08.058	32	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 5	2019	14	6							e0217674	10.1371/journal.pone.0217674	http://dx.doi.org/10.1371/journal.pone.0217674			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IB2GN	31166967	Green Published, gold, Green Submitted			2023-01-03	WOS:000470087800034
J	Jain, N; Keating, M; Thompson, P; Ferrajoli, A; Burger, J; Borthakur, G; Takahashi, K; Estrov, Z; Fowler, N; Kadia, T; Konopleva, M; Alvarado, Y; Yilmaz, M; DiNardo, C; Bose, P; Ohanian, M; Pemmaraju, N; Jabbour, E; Sasaki, K; Kanagal-Shamanna, R; Patel, K; Jorgensen, J; Garg, N; Wang, XM; Sondermann, K; Cruz, N; Wei, CJ; Ayala, A; Plunkett, W; Kantarjian, H; Gandhi, V; Wierda, W				Jain, Nitin; Keating, Michael; Thompson, Philip; Ferrajoli, Alessandra; Burger, Jan; Borthakur, Gautam; Takahashi, Koichi; Estrov, Zeev; Fowler, Nathan; Kadia, Tapan; Konopleva, Marina; Alvarado, Yesid; Yilmaz, Musa; DiNardo, Courtney; Bose, Prithviraj; Ohanian, Maro; Pemmaraju, Naveen; Jabbour, Elias; Sasaki, Koji; Kanagal-Shamanna, Rashmi; Patel, Keyur; Jorgensen, Jeffrey; Garg, Naveen; Wang, Xuemei; Sondermann, Katrina; Cruz, Nichole; Wei, Chongjuan; Ayala, Ana; Plunkett, William; Kantarjian, Hagop; Gandhi, Varsha; Wierda, William			Ibrutinib and Venetoclax for First-Line Treatment of CLL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; PROGRESSION-FREE; INITIAL THERAPY; RITUXIMAB; CHEMOIMMUNOTHERAPY; CYCLOPHOSPHAMIDE; FLUDARABINE; SURVIVAL	Background Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL). Preclinical investigations have indicated potential synergistic interaction of their combination. Methods We conducted an investigator-initiated phase 2 study of combined ibrutinib and venetoclax involving previously untreated high-risk and older patients with CLL. All patients had at least one of the following features: chromosome 17p deletion, mutated TP53, chromosome 11q deletion, unmutated IGHV, or an age of 65 years or older. Patients received ibrutinib monotherapy (420 mg once daily) for 3 cycles, followed by the addition of venetoclax (weekly dose escalation to 400 mg once daily). Combined therapy was administered for 24 cycles. Response assessments were performed according to International Workshop on Chronic Lymphocytic Leukemia 2008 criteria. Minimal residual disease was assessed by means of multicolor flow cytometry in bone marrow (sensitivity, 10(-4)). Results A total of 80 patients were treated. The median age was 65 years (range, 26 to 83). A total of 30% of the patients were 70 years of age or older. Overall, 92% of the patients had unmutated IGHV, TP53 aberration, or chromosome 11q deletion. With combined treatment, the proportions of patients who had complete remission (with or without normal blood count recovery) and remission with undetectable minimal residual disease increased over time. After 12 cycles of combined treatment, 88% of the patients had complete remission or complete remission with incomplete count recovery, and 61% had remission with undetectable minimal residual disease. Responses were noted in older adults and across all high-risk subgroups. Three patients had laboratory evidence of tumor lysis syndrome. The adverse-event profile was similar to what has been reported with ibrutinib and venetoclax. Conclusions In this study, combined venetoclax and ibrutinib was an effective oral regimen for high-risk and older patients with CLL.	[Jain, Nitin; Keating, Michael; Thompson, Philip; Ferrajoli, Alessandra; Burger, Jan; Borthakur, Gautam; Takahashi, Koichi; Estrov, Zeev; Kadia, Tapan; Konopleva, Marina; Alvarado, Yesid; Yilmaz, Musa; DiNardo, Courtney; Bose, Prithviraj; Ohanian, Maro; Pemmaraju, Naveen; Jabbour, Elias; Sasaki, Koji; Sondermann, Katrina; Cruz, Nichole; Wei, Chongjuan; Ayala, Ana; Kantarjian, Hagop; Wierda, William] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Fowler, Nathan] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA; [Kanagal-Shamanna, Rashmi; Patel, Keyur; Jorgensen, Jeffrey] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Garg, Naveen] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA; [Wang, Xuemei] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Plunkett, William; Gandhi, Varsha] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Jain, N (corresponding author), Univ Texas MD Derson Canc Ctr, Dept Leukemia, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030 USA.	njain@mdanderson.org	Borthakur, Gautam/AAQ-4490-2021; Yilmaz, Musa/AAG-9780-2019; Wang, Xuemei/GXF-3702-2022; Sasaki, Koji/T-1218-2019	Sasaki, Koji/0000-0002-9140-0610; Yilmaz, Musa/0000-0002-4498-4895; garg, naveen/0000-0002-0321-2813	AbbVie; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	AbbVie(AbbVie); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by AbbVie and others; ClinicalTrials. gov number, NCT02756897.	Ahn IE, 2018, BLOOD, V131, P2357, DOI 10.1182/blood-2017-12-820910; Bottcher S, 2012, J CLIN ONCOL, V30, P980, DOI 10.1200/JCO.2011.36.9348; Brown JR, 2017, HAEMATOLOGICA, V102, P1796, DOI 10.3324/haematol.2017.171041; Burger JA, 2015, NEW ENGL J MED, V373, P2425, DOI 10.1056/NEJMoa1509388; Byrd JC, 2014, NEW ENGL J MED, V371, P213, DOI 10.1056/NEJMoa1400376; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; Cairo MS, 2004, BRIT J HAEMATOL, V127, P3, DOI 10.1111/j.1365-2141.2004.05094.x; Cervantes-Gomez F, 2015, CLIN CANCER RES, V21, P3705, DOI 10.1158/1078-0432.CCR-14-2809; Chen TT, 1997, STAT MED, V16, P2701, DOI 10.1002/(SICI)1097-0258(19971215)16:23<2701::AID-SIM704>3.0.CO;2-1; Deng J, 2017, LEUKEMIA, V31, P2075, DOI 10.1038/leu.2017.32; Dimier N, 2018, BLOOD, V131, P955, DOI 10.1182/blood-2017-06-792333; Eichhorst B, 2016, LANCET ONCOL, V17, P928, DOI 10.1016/S1470-2045(16)30051-1; Goede V, 2014, NEW ENGL J MED, V370, P1101, DOI 10.1056/NEJMoa1313984; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Hallek M, 2018, LANCET, V391, P1524, DOI 10.1016/S0140-6736(18)30422-7; Herman SEM, 2011, BLOOD, V117, P6287, DOI 10.1182/blood-2011-01-328484; JAIN N, 2018, BLOOD S, V132, DOI DOI 10.1182/BLOOD-2018-185; Jain N, 2018, HEMATOL-AM SOC HEMAT, P242, DOI 10.1182/asheducation-2018.1.242; Keating MJ, 2005, J CLIN ONCOL, V23, P4079, DOI 10.1200/JCO.2005.12.051; O'Brien S, 2018, BLOOD, V131, P1910, DOI 10.1182/blood-2017-10-810044; Rawstron AC, 2007, LEUKEMIA, V21, P956, DOI 10.1038/sj.leu.2404584; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; Seymour JF, 2018, NEW ENGL J MED, V378, P1107, DOI 10.1056/NEJMoa1713976; Seymour JF, 2017, LANCET ONCOL, V18, P230, DOI 10.1016/S1470-2045(17)30012-8; SLINGER E, 2017, BLOOD S1, V130; Stilgenbauer S, 2018, J CLIN ONCOL, V36, P1973, DOI 10.1200/JCO.2017.76.6840; Tam CS, 2018, NEW ENGL J MED, V378, P1211, DOI 10.1056/NEJMoa1715519	27	286	292	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 30	2019	380	22					2095	2103		10.1056/NEJMoa1900574	http://dx.doi.org/10.1056/NEJMoa1900574			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IC6IF	31141631	Bronze			2023-01-03	WOS:000471074800007
J	Nytko, KJ; Thumser-Henner, P; Weyland, MS; Scheidegger, S; Bley, CR				Nytko, Katarzyna J.; Thumser-Henner, Pauline; Weyland, Mathias S.; Scheidegger, Stephan; Bley, Carla Rohrer			Cell line-specific efficacy of thermoradiotherapy in human and canine cancer cells in vitro	PLOS ONE			English	Article							HOMOLOGOUS RECOMBINATION; BRCA2 DEGRADATION; CHO-CELLS; HYPERTHERMIA; RADIATION; HSP70; HEAT; COMBINATION; RADIOSENSITIZATION; THERMOTOLERANCE	Objective Aims were to investigate sensitivity of various human and canine cancer cell lines to hyperthermia and the influence of particular treatment conditions, and to analyze the DNA-damage response and mode of cell death in cell line radiosensitized by hyperthermia. Additionally, we were interested in the involvement of HSP70 in radiosensitization. Methods Radiosensitization by hyperthermia was determined in a panel of human and canine cancer cell lines using clonogenic cell survival assay, as well as levels of heat shock proteins (HSPs) using immunoblotting. The influence of the hyperthermia-radiotherapy time gap, different temperatures and the order of treatments on clonogenicity of hyperthermia-sensitive A549 cells was investigated. Additionally, DNA damage and cell death were assessed by Comet assay and an apoptosis/necrosis assay. Further we induced transient knockdown in A549 cells to test HSP70's involvement in radiosensitization. Results Out of eight cell lines tested, only two (A549 and Abrams) showed significant decrease in clonogenic cell survival when pre-treated with hyperthermia at 42 degrees C. Strong induction of HSP70 upon thermoradiotherapy (HT-RT) treatment was found in all cell lines. Transient knockdown of HSP70 in A549 cells did not result in decrease of clonogenic cell survival in response to HT-RT. Conclusion Tumor cell-type, temperature and order of treatment play an important role in radiosensitization by hyperthermia. However, hyperthermia has limited potency to radiosensitize canine cancer cells grown in a 2D cell culture setting presented here. DNA damage and apoptosis/necrosis did not increase upon combined treatment and cytosolic levels of HSP70 appear not to play critical role in the radiosensitization of A549 cells.	[Nytko, Katarzyna J.; Thumser-Henner, Pauline; Bley, Carla Rohrer] Univ Zurich, Div Radiat Oncol, Vetsuisse Fac, Zurich, Switzerland; [Nytko, Katarzyna J.; Thumser-Henner, Pauline; Bley, Carla Rohrer] Univ Zurich, Ctr Appl Biotechnol & Mol Med, Zurich, Switzerland; [Nytko, Katarzyna J.; Thumser-Henner, Pauline; Bley, Carla Rohrer] Univ Zurich, Vetsuisse Fac, Ctr Clin Studies, Zurich, Switzerland; [Weyland, Mathias S.; Scheidegger, Stephan] Zurich Univ Appl Sci, ZHAW Sch Engn, Winterthur, Switzerland; [Weyland, Mathias S.] Univ Fribourg, BioNanomat Grp, Adolphe Merkle Inst, Fribourg, Switzerland	University of Zurich; University of Zurich; University of Zurich; Zurich University of Applied Sciences; University of Fribourg	Nytko, KJ (corresponding author), Univ Zurich, Div Radiat Oncol, Vetsuisse Fac, Zurich, Switzerland.; Nytko, KJ (corresponding author), Univ Zurich, Ctr Appl Biotechnol & Mol Med, Zurich, Switzerland.; Nytko, KJ (corresponding author), Univ Zurich, Vetsuisse Fac, Ctr Clin Studies, Zurich, Switzerland.	knytko@vetclinics.uzh.ch	Rohrer Bley, Carla/G-1192-2013	Rohrer Bley, Carla/0000-0002-5733-2722	MarieLouise von Muralt Stiftung fur Kleintiere, Zurich, Switzerland; Swiss National Foundation [320030_163435]	MarieLouise von Muralt Stiftung fur Kleintiere, Zurich, Switzerland; Swiss National Foundation(Swiss National Science Foundation (SNSF))	This work was supported by the MarieLouise von Muralt Stiftung fur Kleintiere, Zurich, Switzerland, to CRB; Swiss National Foundation (grant number 320030_163435 to SS and CRB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asling J, 2016, CELL STRESS CHAPERON, V21, P1065, DOI 10.1007/s12192-016-0730-4; Bergs JWJ, 2013, DNA REPAIR, V12, P38, DOI 10.1016/j.dnarep.2012.10.008; Cihoric N, 2015, INT J HYPERTHER, V31, P609, DOI 10.3109/02656736.2015.1040471; COHEN JD, 1988, CANCER RES, V48, P3576; Daugaard M, 2007, FEBS LETT, V581, P3702, DOI 10.1016/j.febsiet.2007.05.039; Dressel S, 2018, VET COMP ONCOL, V16, P202, DOI 10.1111/vco.12340; Eppink B, 2012, INT J HYPERTHER, V28, P509, DOI 10.3109/02656736.2012.695427; GILLETTE SM, 1992, INT J HYPERTHER, V8, P309, DOI 10.3109/02656739209021786; Grosse N, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-203; HENLE KJ, 1976, RADIAT RES, V66, P505, DOI 10.2307/3574455; Horsman MR, 2007, CLIN ONCOL-UK, V19, P418, DOI 10.1016/j.clon.2007.03.015; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; Hurwitz M, 2014, SEMIN ONCOL, V41, P714, DOI 10.1053/j.seminoncol.2014.09.014; Kampinga HH, 2001, INT J RADIAT BIOL, V77, P399, DOI 10.1080/09553000010024687; Kim W.J., 2017, IMPROVEMENT FOREST M, P1; Krawczyk PM, 2011, P NATL ACAD SCI USA, V108, P9851, DOI 10.1073/pnas.1101053108; LI GC, 1980, CANCER RES, V40, P4501; MANNING MR, 1982, CANCER, V49, P205, DOI 10.1002/1097-0142(19820115)49:2<205::AID-CNCR2820490202>3.0.CO;2-W; Multhoff G, 2015, CANCER LETT, V368, P179, DOI 10.1016/j.canlet.2015.02.013; Murakami N, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0461-1; Murphy ME, 2013, CARCINOGENESIS, V34, P1181, DOI 10.1093/carcin/bgt111; Oei AL, 2015, CANCER RES, V75, P5120, DOI 10.1158/0008-5472.CAN-15-0816; Oommen D, 2013, BIOCHEM BIOPH RES CO, V430, P236, DOI 10.1016/j.bbrc.2012.10.124; OVERGAARD J, 1981, CANCER-AM CANCER SOC, V48, P1116, DOI 10.1002/1097-0142(19810901)48:5<1116::AID-CNCR2820480512>3.0.CO;2-J; SAPARETO SA, 1978, RADIAT RES, V73, P221, DOI 10.2307/3574816; Schulz N, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061176; Shin JU, 2015, YONSEI MED J, V56, P1619, DOI 10.3349/ymj.2015.56.6.1619; Speit G, 2013, MUTAT RES-FUND MOL M, V747, P1, DOI 10.1016/j.mrfmmm.2013.04.008; van den Tempel N, 2018, INT J HYPERTHER, V34, P407, DOI 10.1080/02656736.2017.1355487; van den Tempel N, 2017, ONCOTARGET, V8, P44593, DOI 10.18632/oncotarget.17861; van Leeuwen CM, 2018, INT J HYPERTHER, V34, P901, DOI 10.1080/02656736.2018.1468930; van Leeuwen CM, 2018, INT J HYPERTHER, V34, P30, DOI 10.1080/02656736.2017.1320812; van Leeuwen CM, 2017, RADIAT ONCOL, V12, DOI 10.1186/s13014-017-0813-0; van Oorschot B, 2016, ONCOTARGET, V7, P65504, DOI 10.18632/oncotarget.11798; Vriend LEM, 2017, ONCOTARGET, V8, P97490, DOI 10.18632/oncotarget.22142; Xu M, 2002, INT J HYPERTHER, V18, P385, DOI 10.1080/02656730210146908	36	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2019	14	5							e0216744	10.1371/journal.pone.0216744	http://dx.doi.org/10.1371/journal.pone.0216744			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY2KH	31091255	Green Submitted, Green Published, gold, Green Accepted			2023-01-03	WOS:000467949100036
J	Goldenberg, T; Stephenson, R				Goldenberg, Tamar; Stephenson, Rob			Applying a deviance framework to understand modern contraceptive use in sub-Saharan Africa	PLOS ONE			English	Article							CONTEXTUAL INFLUENCES; FERTILITY; ETHIOPIA; HEALTH	Increasing modern contraceptive use is important for improving maternal and child health and achieving economic growth and development goals. However, pervasive high unmet need for modern contraceptives in sub-Saharan Africa warrants new understandings of the drivers of modern contraceptive use. A deviance approach (i.e., examining how women's experiences/characteristics differ from other women in their community) provides an innovative framework for capturing heterogeneity among women in a community. This framework can inform public health programming by both exploring how women avoid adverse health outcomes and understanding the needs of harder-to-reach populations who may experience health risks, despite living in communities where others do not experience vulnerability. Using data from Demographic and Health Surveys from 29 sub-Saharan African countries, we examine how a woman's deviation from community norms around socioeconomic characteristics and gender and fertility norms and behaviors is associated with modern contraceptive use. Random-effects logistic regression models were fitted for each country to examine relationships between modern contraceptive use and deviance. Some deviance factors were associated with modern contraceptive use in only a few countries, while others were significant across many countries. Cross-country consistency in the direction of the relationship between deviance and modern contraceptive use varied by the specific deviance factor, with some relationships being consistent across countries, and other relationships being more varied. For example, having more education than the community norm was associated with increased modern contraceptive use across countries; however, marrying older than other women in the community was associated with an increase in modern contraceptive use in some countries and a decrease in others. More work is needed to understand the role of deviance on modern contraceptive use; however, this study suggests that using context-specific deviance approaches may be important for further elucidating experiences of modern contraceptive use.	[Goldenberg, Tamar] Univ Michigan, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, Ann Arbor, MI 48109 USA; [Goldenberg, Tamar; Stephenson, Rob] Univ Michigan, Ctr Sexual & Hlth Dispar, Ann Arbor, MI 48109 USA; [Stephenson, Rob] Univ Michigan, Sch Nursing, Dept Syst Populat & Leadership, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Goldenberg, T (corresponding author), Univ Michigan, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, Ann Arbor, MI 48109 USA.; Goldenberg, T (corresponding author), Univ Michigan, Ctr Sexual & Hlth Dispar, Ann Arbor, MI 48109 USA.	tamargol@umich.edu		Goldenberg, Tamar/0000-0003-3998-2913				Ahmed S, 2012, LANCET, V380, P111, DOI 10.1016/S0140-6736(12)60478-4; Al Riyami Asya, 2004, Reprod Health Matters, V12, P144, DOI 10.1016/S0968-8080(04)23113-5; Alemayehu M., 2014, SCI J PUBLIC HEAL, V2, P297, DOI [10.11648/j.sjph.20140204.19, DOI 10.11648/J.SJPH.20140204.19]; [Anonymous], 2015, TRENDS CONTR US WORL; Ashraf QH, 2013, POPUL DEV REV, V39, P97, DOI 10.1111/j.1728-4457.2013.00575.x; Berggren WL., 2002, FOOD NUTR BULL, V23, P7; Bhandari TR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147473; Bronfenbrenner U, 1979, ECOLOGY HUMAN DEV EX; Canning D, 2012, LANCET, V380, P165, DOI 10.1016/S0140-6736(12)60827-7; Casterline JB, 2001, DIFFUSION PROCESSES AND FERTILITY TRANSITION: SELECTED PERSPECTIVES, P1; Cau BM, 2015, HEALTH PLACE, V31, P10, DOI 10.1016/j.healthplace.2014.10.006; Cleland J, 2001, DIFFUSION PROCESSES AND FERTILITY TRANSITION: SELECTED PERSPECTIVES, P39; Cleland J, 2012, LANCET, V380, P149, DOI 10.1016/S0140-6736(12)60609-6; Crivello Gina., 2018, MARITAL FERTILITY DE; Dynes M, 2012, HEALTH PLACE, V18, P766, DOI 10.1016/j.healthplace.2012.04.006; Ejembi C.L., 2015, CONTEXTUAL FACTORS I; Elfstrom KM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040670; Jejeebhoy S., 1995, WOMENS ED AUTONOMY R; Kaggwa EB, 2008, INT FAM PLAN PERSPEC, V34, P79, DOI [10.1363/3407908, 10.1363/ifpp.34.079.08]; Kamal SMM, 2015, ASIA-PAC J PUBLIC HE, V27, pNP2661, DOI 10.1177/1010539511421194; Marsh DR, 2004, BMJ-BRIT MED J, V329, P1177, DOI 10.1136/bmj.329.7475.1177; McClendon KA, 2018, CULT HEALTH SEX, V20, P799, DOI 10.1080/13691058.2017.1383513; OlaOlorun F, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0118-z; OlaOlorun FM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098702; Palamuleni Martin E, 2013, Afr J Reprod Health, V17, P91; Peterson HB, 2013, LANCET, V381, P1696, DOI 10.1016/S0140-6736(13)60999-X; Saleem Shabana, 2005, Reprod Health, V2, P8, DOI 10.1186/1742-4755-2-8; Spreitzer GM, 2004, AM BEHAV SCI, V47, P828, DOI 10.1177/0002764203260212; Stephenson R, 2003, AM J PUBLIC HEALTH, V93, P1820, DOI 10.2105/AJPH.93.11.1820; Stephenson R, 2008, INT FAM PLAN PERSPEC, V34, P62, DOI 10.1363/ifpp.34.062.08; Stephenson R, 2007, AM J PUBLIC HEALTH, V97, P1233, DOI 10.2105/AJPH.2005.071522; Tekelab T, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0208-z; Upadhyay UD, 2014, SOC SCI MED, V115, P111, DOI 10.1016/j.socscimed.2014.06.014; Vasa P, 2013, 2013 CONFERENCE ON LASERS AND ELECTRO-OPTICS EUROPE AND INTERNATIONAL QUANTUM ELECTRONICS CONFERENCE (CLEO EUROPE/IQEC); Walker LO, 2007, PUBLIC HEALTH NURS, V24, P571, DOI 10.1111/j.1525-1446.2007.00670.x; Wheldon MC, 2018, 2 UN DEP EC SOC AFF	36	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 8	2019	14	5							e0216381	10.1371/journal.pone.0216381	http://dx.doi.org/10.1371/journal.pone.0216381			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HX4MT	31067279	Green Submitted, Green Published, gold			2023-01-03	WOS:000467373000041
J	Vancayseele, N; Rotsaert, I; Portzky, G; van Heeringen, K				Vancayseele, Nikita; Rotsaert, Ine; Portzky, Gwendolyn; van Heeringen, Kees			Medication used in intentional drug overdose in Flanders 2008-2013	PLOS ONE			English	Article							DELIBERATE SELF-HARM; ATTEMPTED-SUICIDE; CO-PROXAMOL; TRENDS; REPETITION; DISORDERS; RISK; ANTIDEPRESSANTS; INTERVENTION; MULTICENTER	Background Intentional drug overdose is the most common method of self-harm. As psychiatric disorders are very common in self-harm patients, the medication used to treat these disorders can become the means for the self-harm act. The present study aimed at investigating an association between the use of prescribed medication (analgesics and antipyretics, anti-epileptics, antipsychotics, antidepressants and psychostimulants) as a method of self-harm and prescription rates of this medication in Flanders. We investigated the possible effect of gender, alcohol use during the self-harm act and a history of self-harm. Methods Data from the multicenter study of self-harm in Flanders between 2008 and 2013 were used. The significance of differences in percentages was calculated by GEE and the strength by odds ratios (OR). Results There was an increase in the odds of using antidepressants (0.8%) and antipsychotics (2%) among females when the rate of prescription increases. Analgesics and antipyretics (39.3/1,000) and antidepressants (124.9/1,000) were the most commonly prescribed drugs among females. Antidepressants (63.9/1,000) and antipsychotics (26.5/1,000) were the most commonly prescribed drugs among males. Antidepressants and analgesics and antipyretics were the most frequently used medications for self-harm. Analgesics and antipyretics during the self-harm act were more common among first-timers, while repeaters more commonly overdosed using antipsychotics and antidepressants. Conclusion These findings suggest that the availability of medication via prescriptions plays an important role in the choice of the medication ingested during the self-harm act. Precautions are necessary when prescribing medication, including restrictions on the number of prescriptions and the return of unused medication to pharmacies after cessation of treatment. These issues should be a focus of attention in the education and training of physicians and pharmacists.	[Vancayseele, Nikita; Rotsaert, Ine; Portzky, Gwendolyn; van Heeringen, Kees] Univ Ghent, Unit Suicide Res, Ghent, Belgium; [Rotsaert, Ine; Portzky, Gwendolyn] Univ Ghent, Flemish Ctr Expertise Suicide Prevent, Ghent, Belgium; [van Heeringen, Kees] Univ Ghent, Dept Head & Skin, Ghent, Belgium	Ghent University; Ghent University; Ghent University	Vancayseele, N (corresponding author), Univ Ghent, Unit Suicide Res, Ghent, Belgium.	Nikita.Vancayseele@UGent.be			Flemish government	Flemish government(European Commission)	NV and IR received an award for this study from the Flemish government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baca-Garcia E, 2002, EUR PSYCHIAT, V17, P466, DOI 10.1016/S0924-9338(02)00706-X; Beautrais AL, 1996, AM J PSYCHIAT, V153, P1009; Bergen H, 2010, BRIT J PSYCHIAT, V197, P493, DOI 10.1192/bjp.bp.110.077651; Bhaskaran J, 2015, J CLIN PSYCHIAT, V76, pE1583, DOI 10.4088/JCP.14m09568; Bille-Brahe U., 1994, ATTEMPTED SUICIDE EU, P3; Brown TL, 2018, J CLIN PSYCHIAT, V79, DOI 10.4088/JCP.17m11982; BUCKLEY NA, 1995, MED J AUSTRALIA, V162, P194, DOI 10.5694/j.1326-5377.1995.tb126022.x; Buykx P, 2010, AUST NZ J PUBL HEAL, V34, P401, DOI 10.1111/j.1753-6405.2010.00573.x; Chandrasekaran R, 2003, Indian J Psychiatry, V45, P45; Cooper J, 2005, AM J PSYCHIAT, V162, P297, DOI 10.1176/appi.ajp.162.2.297; Coppens E, 2014, ERVARINGEN ATTITUDES; Corcoran P, 2010, BMC CLIN PHARM, P10; Corcoran TE, 2013, EJNMMI RES, V3, DOI 10.1186/2191-219X-3-14; Crawford MJ, 2010, PSYCHOL MED, V40, P1821, DOI 10.1017/S0033291709991899; Crombie IK, 1998, BRIT J GEN PRACT, V48, P1505; Doshi A, 2005, ANN EMERG MED, V46, P369, DOI 10.1016/j.annemergmed.2005.04.018; FORSTER DP, 1985, ACTA PSYCHIAT SCAND, V71, P567, DOI 10.1111/j.1600-0447.1985.tb02550.x; Geulayov G, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010538; Griffin E, 2014, ANN REPORT 2013; Grunebaum MF, 2004, J CLIN PSYCHIAT, V65, P1456, DOI 10.4088/JCP.v65n1103; Gusmao R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066455; Haffajee RL, 2015, JAMA-J AM MED ASSOC, V313, P891, DOI 10.1001/jama.2014.18514; Haw C, 2005, SOC PSYCH PSYCH EPID, V40, P964, DOI 10.1007/s00127-005-0981-3; Haw C, 2001, BRIT J PSYCHIAT, V178, P48, DOI 10.1192/bjp.178.1.48; Hawton K, 2003, J CHILD PSYCHOL PSYC, V44, P1191, DOI 10.1111/1469-7610.00200; Hawton K, 1999, J ADOLESCENCE, V22, P369, DOI 10.1006/jado.1999.0228; Hawton K, 2009, BRIT MED J, V338; Hawton K., 2015, SELF HARM OXFORD 201; Hawton K, 2015, J AFFECT DISORDERS, V175, P147, DOI 10.1016/j.jad.2014.12.062; Hawton K, 2012, LANCET, V379, P2373, DOI 10.1016/S0140-6736(12)60322-5; Hawton K, 2009, LANCET, V373, P1372, DOI 10.1016/S0140-6736(09)60372-X; Hooper S, 2009, AUSTRALAS PSYCHIATRY, V17, P300, DOI 10.1080/10398560902998626; Isacsson G, 1996, J AFFECT DISORDERS, V41, P1, DOI 10.1016/0165-0327(96)00050-X; Kapur N, 2013, BRIT J PSYCHIAT, V202, P326, DOI 10.1192/bjp.bp.112.116111; Lo A, 2003, CAN J PSYCHIAT, V48, P232, DOI 10.1177/070674370304800406; Michel K, 2000, SOC PSYCH PSYCH EPID, V35, P156, DOI 10.1007/s001270050198; O'Connor RC, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2017.0268; O'Connor RC, 2014, LANCET PSYCHIAT, V1, P73, DOI 10.1016/S2215-0366(14)70222-6; Olfson M, 2008, ARCH GEN PSYCHIAT, V65, P94, DOI 10.1001/archgenpsychiatry.2007.5; Paulozzi LJ, 2011, PAIN MED, V12, P747, DOI 10.1111/j.1526-4637.2011.01062.x; Perry IJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031663; Sandilands EA, 2008, BRIT J CLIN PHARMACO, V66, P290, DOI 10.1111/j.1365-2125.2008.03206.x; SEGEST E, 1993, MED SCI LAW, V33, P41, DOI 10.1177/002580249303300108; Simkin S, 2005, QJM-INT J MED, V98, P159, DOI 10.1093/qjmed/hci026; Singhal A, 2014, J ROY SOC MED, V107, P194, DOI 10.1177/0141076814522033; Skegg K, 2005, LANCET, V366, P1471, DOI 10.1016/S0140-6736(05)67600-3; Stenbacka M, 2017, SUICIDOL ONLINE-SOL, V8; Tournier M, 2009, EUR ARCH PSY CLIN N, V259, P86, DOI 10.1007/s00406-008-0839-2; Townsend E, 2001, SOC PSYCH PSYCH EPID, V36, P228, DOI 10.1007/s001270170053; van Vancayseele N, 2014, JAARVERSLAG 2013; Vancayseele N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156711; Vlaams Agentschap Zorg en Gezondheid aieo, ZELFD VLAAND EUR 201; World Health Organization (WHO), FACTSH SUIC; Zalsman G, 2016, LANCET PSYCHIAT, V3, P646, DOI 10.1016/S2215-0366(16)30030-X; 2012, GEN HOSP PSYCHIAT, V34, P557, DOI DOI 10.1016/J.GENHOSPPSYCH.2012.03.020	55	4	4	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2019	14	5							e0216317	10.1371/journal.pone.0216317	http://dx.doi.org/10.1371/journal.pone.0216317			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HW2JY	31048918	Green Published, Green Submitted, gold			2023-01-03	WOS:000466511200070
J	DeMartino, ES; Sperry, BP; Doyle, CK; Chor, J; Kramer, DB; Dudzinski, DM; Mueller, PS				DeMartino, Erin S.; Sperry, Beau P.; Doyle, Cavan K.; Chor, Julie; Kramer, Daniel B.; Dudzinski, David M.; Mueller, Paul S.			US State Regulation of Decisions for Pregnant Women Without Decisional Capacity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[DeMartino, Erin S.] Mayo Clin, Div Pulm & Crit Care Med, 200 First St SW, Rochester, MN 55905 USA; [Sperry, Beau P.] Mayo Clin, Biomed Eth Res Program, Rochester, MN USA; [Doyle, Cavan K.] Loyola Univ Chicago, Stritch Sch Med, Neiswanger Inst Bioeth, Maywood, IL USA; [Chor, Julie] Univ Chicago, Dept Obstet & Gynecol, Chicago, IL 60637 USA; [Kramer, Daniel B.] Beth Israel Deaconess Med Ctr, Richard A & Susan F Smith Ctr Outcomes Res Cardio, Boston, MA 02215 USA; [Dudzinski, David M.] Massachusetts Gen Hosp, Dept Cardiol, Boston, MA 02114 USA; [Mueller, Paul S.] Mayo Clin Hlth Syst, Gen Internal Med, La Crosse, WI USA	Mayo Clinic; Mayo Clinic; Loyola University Chicago; University of Chicago; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital	DeMartino, ES (corresponding author), Mayo Clin, Div Pulm & Crit Care Med, 200 First St SW, Rochester, MN 55905 USA.	demartino.erin@mayo.edu		Sperry, Beau/0000-0002-1776-191X				Beauchamp T. L., 2013, PRINCIPLES BIOMEDICA, V7th; DeMartino ES, 2017, NEW ENGL J MED, V376, P1478, DOI 10.1056/NEJMms1611497; Manninen BA, 2016, KENNEDY INST ETHIC J, V26, P399, DOI 10.1353/ken.2016.0036; Sabatino CP, 2010, MILBANK Q, V88, P211, DOI 10.1111/j.1468-0009.2010.00596.x; Sabatino CP, 2003, PUBLIC POLICY AGING, V13, P1, DOI 10.1093/ppar/13.1.1	5	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	2019	321	16					1628	1631		10.1001/jama.2019.2587	http://dx.doi.org/10.1001/jama.2019.2587			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV7BZ	31012920	Green Published, Bronze			2023-01-03	WOS:000466137800023
J	Nicolian, S; Butel, T; Gambotti, L; Durand, M; Filipovic-Pierucci, A; Mallet, A; Kone, M; Durand-Zaleski, I; Dommergues, M				Nicolian, Stephanie; Butel, Thibault; Gambotti, Laetitia; Durand, Manon; Filipovic-Pierucci, Antoine; Mallet, Alain; Kone, Mamadou; Durand-Zaleski, Isabelle; Dommergues, Marc			Cost-effectiveness of acupuncture versus standard care for pelvic and low back pain in pregnancy: A randomized controlled trial	PLOS ONE			English	Article							QUALITY-OF-LIFE; GIRDLE PAIN; COMPARING ACUPUNCTURE; RISK-FACTORS; WOMEN; PREVALENCE; GUIDELINES; ADJUNCT	Objective To assess the cost-effectiveness of acupuncture for pelvic girdle and low back pain (PGLBP) during pregnancy. Design Pragmatic-open-label randomised controlled trial. Setting Five maternity hospitals Population Pregnant women with PGLBP Method 1:1 randomization to standard care or standard care plus acupuncture (5 sessions by an acupuncturist midwife). Main outcome measure Efficacy: proportion of days with self-assessed pain by numerical rating scale (NRS). 4/10. Cost effectiveness (societal viewpoint, time horizon: pregnancy): incremental cost per days with NRS. 4/10. Indirect non-healthcare costs included daily compensations for sick leave and productivity loss caused by absenteeism or presenteeism. Results 96 women were allocated to acupuncture and 103 to standard care (total 199). The proportion of days with NRS <= 4/10 was greater in the acupuncture group than in the standard care group (61% vs 48%, p = 0.007). The mean Oswestry disability score was lower in the acupuncture group than with standard care alone (33 versus 38, Delta = 5, 95% CI: 0.8 to 9, p = 0.02). Average total costs were higher in the control group ((sic)2947) than in the acupuncture group ((sic)2635, Delta = -(sic)312, 95% CI: -966 to +325), resulting from the higher indirect costs of absenteeism and presenteeism. Acupuncture was a dominant strategy when both healthcare and non-healthcare costs were included. Costs for the health system (employer and out-of-pocket costs excluded) were slightly higher for acupuncture ((sic)1512 versus (sic)1452, Delta = (sic)60, 95% CI: -272 to +470). Conclusion Acupuncture was a dominant strategy when accounting for employer costs. A 100% probability of cost-effectiveness was obtained for a willingness to pay of (sic)100 per days with pain NRS <= 4.	[Nicolian, Stephanie; Dommergues, Marc] Hop Univ Pitie Salpetriere Charle Foix, AP HP, Serv Gynecol Obstet, Paris, France; [Nicolian, Stephanie] Hop Univ Pitie Salpetriere Charle Foix, AP HP, Ctr Integre Med Chinoise, Paris, France; [Nicolian, Stephanie; Durand, Manon; Filipovic-Pierucci, Antoine] INSERM, Paris, France; [Nicolian, Stephanie; Durand, Manon; Filipovic-Pierucci, Antoine] Hop Univ Pitie Salpetriere Charle Foix, AP HP, CIC 1421, Paris, France; [Butel, Thibault; Durand-Zaleski, Isabelle] Hop Hotel Dieu, AP HP, Unite Rech Clin Ecom Sante, Paris, France; [Gambotti, Laetitia; Mallet, Alain; Kone, Mamadou] Hop Univ Pitie Salpetriere Charles Foix, AP HP, Unite Rech Clin, Paris, France; [Dommergues, Marc] Sorbonne Univ, Paris, France	Assistance Publique Hopitaux Paris (APHP); Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite	Dommergues, M (corresponding author), Hop Univ Pitie Salpetriere Charle Foix, AP HP, Serv Gynecol Obstet, Paris, France.; Dommergues, M (corresponding author), Sorbonne Univ, Paris, France.	marc.dommergues@aphp.fr		Nicolian, Stephanie/0000-0001-5597-189X; Dommergues, Marc/0000-0001-9800-4525	Delegation a la Recherche Clinique d'Ile de France [HAO11037/P11101]	Delegation a la Recherche Clinique d'Ile de France	The funding support received during this specific study was provided by a grant from the Delegation a la Recherche Clinique d'Ile de France (https://recherche.aphp.fr/la-delegation-a-la-recherche-clinique-a-linnovationde-lap-hp/), Award number: HAO11037/P11101, Recipient: Stephanie Nicolian The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albert H, 2000, EUR SPINE J, V9, P161, DOI 10.1007/s005860050228; BERG G, 1988, OBSTET GYNECOL, V71, P71; Briggs AH, 2001, HEALTH ECON, V10, P179, DOI 10.1002/hec.584; Clark SJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112563; Close C, 2014, J ADV NURS, V70, P1702, DOI 10.1111/jan.12360; Dorheim SK, 2013, BJOG-INT J OBSTET GY, V120, P521, DOI 10.1111/1471-0528.12035; Drummond MF., 2005, METHODS EC EVALUATIO, P55; Elden H, 2008, BJOG-INT J OBSTET GY, V115, P1655, DOI 10.1111/j.1471-0528.2008.01904.x; Elden H, 2005, BMJ-BRIT MED J, V330, P761, DOI 10.1136/bmj.38397.507014.E0; Foster NE, 2016, HEALTH TECHNOL ASSES, V20, P1, DOI 10.3310/hta20330; Galimard JE, 2016, STAT MED, V35, P2907, DOI 10.1002/sim.6902; Gatrell CJ, 2011, SOC SCI MED, V72, P478, DOI 10.1016/j.socscimed.2010.11.020; Guerreiro da Silva Joao Bosco, 2004, Acupunct Med, V22, P60; Gutke A, 2011, EUR SPINE J, V20, P440, DOI 10.1007/s00586-010-1487-6; HECKMAN JJ, 1979, ECONOMETRICA, V47, P153, DOI 10.2307/1912352; Husereau D, 2013, VALUE HEALTH, V16, P231, DOI 10.1016/j.jval.2013.02.002; Kain ZN, 2009, AM J OBSTET GYNECOL, V201, P271, DOI [DOI 10.1016/J.AJ0G.2009.04.028], DOI 10.1016/J.AJ0G.2009.04.028]; Kvorning N, 2004, ACTA OBSTET GYN SCAN, V83, P246; Lund I, 2006, ACTA OBSTET GYN SCAN, V85, P12, DOI 10.1080/00016340500317153; Noren L, 2002, EUR SPINE J, V11, P267, DOI 10.1007/s00586-001-0357-7; Olsson C, 2004, ACTA OBSTET GYN SCAN, V83, P351, DOI 10.1080/j.0001-6349.2004.00384.x; Ostelo RWJG, 2008, SPINE, V33, P90, DOI 10.1097/BRS.0b013e31815e3a10; Ostgaard HC, 1996, SEMIN PERINATOL, V20, P61, DOI 10.1016/S0146-0005(96)80058-9; OSTGAARD HC, 1991, SPINE, V16, P549, DOI 10.1097/00007632-199105000-00011; Puhani, 2002, J EC SURVEYS; Ratcliffe J, 2006, BRIT MED J, V333, P626, DOI 10.1136/bmj.38932.806134.7C; ROBINSON R, 1993, BMJ-BRIT MED J, V307, P670, DOI 10.1136/bmj.307.6905.670; The National Institute for Health and Care Excellence (NICE- UK), 2009, LOW BACK PAIN EARL M; Vermani E, 2010, PAIN PRACT, V10, P60, DOI 10.1111/j.1533-2500.2009.00327.x; Vleeming A, 2008, EUR SPINE J, V17, P794, DOI 10.1007/s00586-008-0602-4; Wang SM, 2004, OBSTET GYNECOL, V104, P65, DOI 10.1097/01.AOG.0000129403.54061.0e; Wedenberg K, 2000, ACTA OBSTET GYN SCAN, V79, P331, DOI 10.1034/j.1600-0412.2000.079005331.x; Whynes DK, 2013, VALUE HEALTH, V16, P124, DOI 10.1016/j.jval.2012.09.003; Witt CM, 2006, AM J EPIDEMIOL, V164, P487, DOI 10.1093/aje/kwj224; Wu WH, 2004, EUR SPINE J, V13, P575, DOI 10.1007/s00586-003-0615-y	35	6	8	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2019	14	4							e0214195	10.1371/journal.pone.0214195	http://dx.doi.org/10.1371/journal.pone.0214195			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HU2FT	31009470	Green Published, gold			2023-01-03	WOS:000465087500007
J	Han, D; Li, J; Tan, WH				Han, Da; Li, Juan; Tan, Weihong			CRISPR propels a smart hydrogel	SCIENCE			English	Editorial Material							PLATFORM; APTAMER		[Han, Da; Li, Juan; Tan, Weihong] Shanghai Jiao Tong Univ, IMM, Renji Hosp, Sch Med, Shanghai 200240, Peoples R China; [Han, Da; Li, Juan; Tan, Weihong] Shanghai Jiao Tong Univ, Coll Chem & Chem Engn, Shanghai 200240, Peoples R China; [Han, Da; Tan, Weihong] Chinese Acad Sci, ICBM, Hangzhou 310022, Zhejiang, Peoples R China; [Han, Da; Tan, Weihong] Univ Chinese Acad Sci, Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China; [Li, Juan; Tan, Weihong] Hunan Univ, Coll Biol, Coll Chem & Chem Engn, Mol Sci & Biomed Lab MBL,State Key Chemo Biosensi, Changsha 410082, Hunan, Peoples R China; [Tan, Weihong] Univ Florida, Dept Chem, UF Genet Inst, Ctr Res Bio Nano Interface,Hlth Canc Ctr, Gainesville, FL 32611 USA; [Tan, Weihong] Univ Florida, Dept Physiol & Funct Gen, UF Genet Inst, Ctr Res Bio Nano Interface,Hlth Canc Ctr, Gainesville, FL 32611 USA; [Tan, Weihong] Univ Florida, McKnight Brain Inst, Gainesville, FL 32611 USA	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese Academy of Sciences; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Hunan University; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Li, J (corresponding author), Shanghai Jiao Tong Univ, IMM, Renji Hosp, Sch Med, Shanghai 200240, Peoples R China.; Li, J (corresponding author), Shanghai Jiao Tong Univ, Coll Chem & Chem Engn, Shanghai 200240, Peoples R China.; Li, J (corresponding author), Hunan Univ, Coll Biol, Coll Chem & Chem Engn, Mol Sci & Biomed Lab MBL,State Key Chemo Biosensi, Changsha 410082, Hunan, Peoples R China.	lijuan@fzu.edu.cn; tan@chem.ufl.edu	Tan, Weihong/AAA-4536-2020; Han, Da/AAT-2116-2020					English MA, 2019, SCIENCE, V365, P780, DOI 10.1126/science.aaw5122; Gootenberg JS, 2018, SCIENCE, V360, P439, DOI 10.1126/science.aaq0179; Kahn JS, 2015, NANO LETT, V15, P7773, DOI 10.1021/acs.nanolett.5b04101; Knott GJ, 2018, SCIENCE, V361, P866, DOI 10.1126/science.aat5011; Li J, 2016, CHEM SOC REV, V45, P1410, DOI 10.1039/c5cs00586h; Lu CH, 2013, NANO LETT, V13, P1298, DOI 10.1021/nl400078g; Yang HH, 2008, J AM CHEM SOC, V130, P6320, DOI 10.1021/ja801339w; Zhu Z, 2010, ANGEW CHEM INT EDIT, V49, P1052, DOI 10.1002/anie.200905570	8	9	9	28	297	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 23	2019	365	6455			SI		754	755		10.1126/science.aay4198	http://dx.doi.org/10.1126/science.aay4198			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IS9JH	31439783				2023-01-03	WOS:000482464000029
J	Maitland, K; Olupot-Olupot, P; Kiguli, S; Chagaluka, G; Alaroker, F; Opoka, RO; Mpoya, A; Engoru, C; Nteziyaremye, J; Mallewa, M; Kennedy, N; Nakuya, M; Namayanja, C; Kayaga, J; Uyoga, S; Byabazaire, DK; M'baya, B; Wabwire, B; Frost, G; Bates, I; Evans, JA; Williams, TN; Goncalves, PS; George, EC; Gibb, DM; Walker, AS				Maitland, K.; Olupot-Olupot, P.; Kiguli, S.; Chagaluka, G.; Alaroker, F.; Opoka, R. O.; Mpoya, A.; Engoru, C.; Nteziyaremye, J.; Mallewa, M.; Kennedy, N.; Nakuya, M.; Namayanja, C.; Kayaga, J.; Uyoga, S.; Byabazaire, D. Kyeyune; M'baya, B.; Wabwire, B.; Frost, G.; Bates, I.; Evans, J. A.; Williams, T. N.; Goncalves, P. Saramago; George, E. C.; Gibb, D. M.; Walker, A. S.		TRACT Grp	Transfusion Volume for Children with Severe Anemia in Africa	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Severe anemia (hemoglobin level, <6 g per deciliter) is a leading cause of hospital admission and death in children in sub-Saharan Africa. The World Health Organization recommends transfusion of 20 ml of whole-blood equivalent per kilogram of body weight for anemia, regardless of hemoglobin level. Methods In this factorial, open-label trial, we randomly assigned Ugandan and Malawian children 2 months to 12 years of age with a hemoglobin level of less than 6 g per deciliter and severity features (e.g., respiratory distress or reduced consciousness) to receive immediate blood transfusion with 20 ml per kilogram or 30 ml per kilogram. Three other randomized analyses investigated immediate as compared with no immediate transfusion, the administration of postdischarge micronutrients, and postdischarge prophylaxis with trimethoprim-sulfamethoxazole. The primary outcome was 28-day mortality. Results A total of 3196 eligible children (median age, 37 months; 2050 [64.1%] with malaria) were assigned to receive a transfusion of 30 ml per kilogram (1598 children) or 20 ml per kilogram (1598 children) and were followed for 180 days. A total of 1592 children (99.6%) in the higher-volume group and 1596 (99.9%) in the lower-volume group started transfusion (median, 1.2 hours after randomization). The mean (+/- SD) volume of total blood transfused per child was 475 +/- 385 ml and 353 +/- 348 ml, respectively; 197 children (12.3%) and 300 children (18.8%) in the respective groups received additional transfusions. Overall, 55 children (3.4%) in the higher-volume group and 72 (4.5%) in the lower-volume group died before 28 days (hazard ratio, 0.76; 95% confidence interval [CI], 0.54 to 1.08; P=0.12 by log-rank test). This finding masked significant heterogeneity in 28-day mortality according to the presence or absence of fever (>37.5 degrees C) at screening (P=0.001 after Sidak correction). Among the 1943 children (60.8%) without fever, mortality was lower with a transfusion volume of 30 ml per kilogram than with a volume of 20 ml per kilogram (hazard ratio, 0.43; 95% CI, 0.27 to 0.69). Among the 1253 children (39.2%) with fever, mortality was higher with 30 ml per kilogram than with 20 ml per kilogram (hazard ratio, 1.91; 95% CI, 1.04 to 3.49). There was no evidence of differences between the randomized groups in readmissions, serious adverse events, or hemoglobin recovery at 180 days. Conclusions Overall mortality did not differ between the two transfusion strategies. (Funded by the Medical Research Council and Department for International Development, United Kingdom; TRACT Current Controlled Trials number, .) This open-label trial randomly assigned African children 2 months to 12 years of age with severe anemia to receive immediate blood transfusion with 20 ml per kilogram or 30 ml per kilogram. The primary outcome of 28-day mortality did not differ between transfusion-volume strategies.	[Maitland, K.; Williams, T. N.] Imperial Coll London, Dept Med, St Marys Campus,Norfolk Pl, London W2 1PG, England; [Frost, G.] Imperial Coll London, Nutr Res Sect, London, England; [George, E. C.; Gibb, D. M.; Walker, A. S.] UCL, Med Res Council Clin Trials Unit, London, England; [Kennedy, N.] Queens Univ, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland; [Bates, I.] Liverpool Sch Trop Med & Hyg, Liverpool, Merseyside, England; [Evans, J. A.] Univ Hosp Wales, Dept Pediat, Cardiff, S Glam, Wales; [Goncalves, P. Saramago] Univ York, Ctr Hlth Econ, York, N Yorkshire, England; [Olupot-Olupot, P.; Nteziyaremye, J.; Namayanja, C.] Busitema Univ, Fac Hlth Sci, Mbale Reg Referral Hosp, Mbale Campus, Mbale, Uganda; [Wabwire, B.] Mbale Blood Transfus Serv, Mbale, Uganda; [Kiguli, S.; Opoka, R. O.; Kayaga, J.] Makerere Univ, Dept Pediat, Kampala, Uganda; [Kiguli, S.; Opoka, R. O.; Kayaga, J.] Mulago Hosp, Kampala, Uganda; [Byabazaire, D. Kyeyune] Natl Blood Transfus Serv, Uganda Blood Transfus Serv, Kampala, Uganda; [Alaroker, F.; Engoru, C.; Nakuya, M.] Soroti Reg Referral Hosp, Soroti, Uganda; [Maitland, K.; Mpoya, A.; Uyoga, S.; Williams, T. N.] Kenya Govt Med Res Ctr, Wellcome Trust Res Program, Kilifi, Malawi; [Chagaluka, G.; Mallewa, M.; Kennedy, N.] Coll Med, Blantyre, Malawi; [Chagaluka, G.; Mallewa, M.; Kennedy, N.] Malawi Liverpool Wellcome Trust Clin Res Program, Blantyre, Malawi; [M'baya, B.] Malawi Blood Transfus Serv, Blantyre, Malawi	Imperial College London; Imperial College London; Medical Research Council Clinical Trials Unit; University of London; University College London; Queens University Belfast; Liverpool School of Tropical Medicine; Cardiff University; University of York - UK; Makerere University; Mulago National Referral Hospital; University of Malawi; University of Malawi	Maitland, K (corresponding author), Imperial Coll London, Dept Med, St Marys Campus,Norfolk Pl, London W2 1PG, England.	k.maitland@imperial.ac.uk	Nteziyaremye, Julius/ABC-1324-2020; George, Elizabeth C/V-3381-2017	Uyoga, Sophie/0000-0003-1746-7873; George, Elizabeth C/0000-0002-2928-3580; Maitland, Kathryn/0000-0002-0007-0645; Gibb, Diana/0000-0002-9738-5490; Frost, Gary/0000-0003-0529-6325; bates, imelda/0000-0002-0862-8199; Kennedy, Neil/0000-0002-6262-2679	Medical Research Council; Department for International Development, United Kingdom; MRC [MC_UU_12023/26, MR/J012483/1, MC_PC_MR/R019258/1, MC_UU_12023/17, MC_U122886353] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department for International Development, United Kingdom; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Funded by the Medical Research Council and Department for International Development, United Kingdom; TRACT Current Controlled Trials number, ISRCTN84086586.	Ala F, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001309; Bates I, 2008, BJOG-INT J OBSTET GY, V115, P1331, DOI 10.1111/j.1471-0528.2008.01866.x; Calis JCJ, 2008, NEW ENGL J MED, V358, P888, DOI 10.1056/NEJMoa072727; Doctor A, 2018, PEDIATR CRIT CARE ME, V19, pS98, DOI 10.1097/PCC.0000000000001590; Kiguli S, 2015, BMC MED, V13, DOI 10.1186/s12916-014-0246-7; Lara AM, 2005, J CLIN PATHOL, V58, P56, DOI 10.1136/jcp.2004.018366; Maitland K, 2019, NEW ENGL J MED, V381, P407, DOI 10.1056/NEJMoa1900105; Maitland K, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-90; Morris KP, 2005, ARCH DIS CHILD, V90, P724, DOI 10.1136/adc.2004.062174; Mpoya A, 2015, TRIALS, V16, DOI 10.1186/s13063-015-1112-4; Olupot-Olupot P, 2019, WELLCOME OPEN RES, V3, P130; Olupot-Olupot P, 2017, CLIN INFECT DIS, V64, P939, DOI 10.1093/cid/cix003; Olupot-Olupot P, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-67; Pedro R, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-307; Phiri KS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002903; Stevens GA, 2013, LANCET GLOB HEALTH, V1, pE16, DOI 10.1016/S2214-109X(13)70001-9; Sun X, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1553; Uyoga S, 2019, VOX SANG, V114, P340, DOI 10.1111/vox.12764; Walker RH, 1996, CLIN LAB MED, V16, P895, DOI 10.1016/S0272-2712(18)30245-2; Woods B, 2016, VALUE HEALTH, V19, P929, DOI 10.1016/j.jval.2016.02.017; World Health Organization, 2017, GLOB STAT REP BLOOD; World Health Organization, 2013, POCK BOOK HOSP CAR C	22	27	28	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 1	2019	381	5					420	431		10.1056/NEJMoa1900100	http://dx.doi.org/10.1056/NEJMoa1900100			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IM5WH	31365800	Green Accepted, Green Published			2023-01-03	WOS:000478064200007
J	Grimaldi, AE; De Giglio, L; Haggiag, S; Bianco, A; Cortese, A; Crisafulli, SG; Monteleone, F; Marfia, G; Prosperini, L; Galgani, S; Mirabella, M; Centonze, D; Pozzilli, C; Castelli, L				Grimaldi, Alessandro Enrico; De Giglio, Laura; Haggiag, Shalom; Bianco, Assunta; Cortese, Antonio; Crisafulli, Sebastiano Giuseppe; Monteleone, Fabrizia; Marfia, Gerola; Prosperini, Luca; Galgani, Simonetta; Mirabella, Massimiliano; Centonze, Diego; Pozzilli, Carlo; Castelli, Letizia			The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray)	PLOS ONE			English	Article							CANNABIS-BASED MEDICINE; VOLUNTARY EXERCISE; MANAGEMENT; SYMPTOMS	Background Nabiximols (THC/ CBD Oromucosal Spray, Sativex) is used as an add-on therapy to treat moderate to severe spasticity of Multiple Sclerosis (MS). Objectives To examine the impact of physiotherapy (PT) programs on effectiveness and persistence of nabiximols treatment in people with MS-related spasticity. Methods This is an observational multicenter study with a follow-up period of 12 weeks, conducted in routine care settings in Italy. Patients with moderate to severe MS-related spasticity who started nabiximols were included. Spasticity was evaluated by the patient-rated 0-10 numerical rating scale (NRS). Clinical data were collected at baseline (T0), 4 weeks (T1) and 12 weeks (T2) months after enrollment. Results A total of 297 MS patients were selected, 290 completed the 3 months follow-up period. Mean NRS scores were 7.6 +/- 1.1 at T0, 5.8 +/- 1.4 at T1 and 5.5 +/- 1.5 at T2. At T1, 77% of patients reached. 20% improvement (initial response, IR); 22% reached. 30% improvement (clinically relevant response, CRR). At T1, patients undergoing PT had a higher probability to reach CRR (Odds Ratio = 2.6 95% CI 1.3-5.6, p = 0.01). Nabiximols was discontinued in 30/290 (10.3%) patients at T1 (early discontinuers) and in 71/ 290 (24.5%) patients at T2 (late discontinuers). The probability of being late discontinuers was reduced in patients undergoing PT (Hazard Ratio = 0.41; 95% CI 0.23-0.69, p = 0.001). Conclusions Our real-life study confirms nabiximols' effectiveness in MS-related spasticity and suggests that the association of a PT program may improve overall response and persistence to nabiximols treatment.	[Grimaldi, Alessandro Enrico; De Giglio, Laura; Pozzilli, Carlo] Sapienza Univ Rome, MS Ctr St Andrea Hosp, Rome, Italy; [De Giglio, Laura; Cortese, Antonio; Crisafulli, Sebastiano Giuseppe; Pozzilli, Carlo] Sapienza Univ Rome, Dept Human Neurosci, Rome, Italy; [Haggiag, Shalom; Prosperini, Luca; Galgani, Simonetta] San Camillo Forlanini Hosp, Multiple Sclerosis Clin Ctr, Rome, Italy; [Bianco, Assunta; Mirabella, Massimiliano] Univ Cattolica, Fdn Policlin Univ Agostino Gemelli IRCCS, Multiple Sclerosis Unit, Rome, Italy; [Monteleone, Fabrizia; Marfia, Gerola; Centonze, Diego] Tor Vergata Univ, Dept Syst Med, MS Ctr, Rome, Italy; [Centonze, Diego] IRCCS Neuromed, Unit Neurol & Neurorehabil, Pozzilli, Italy; [Castelli, Letizia] IRCCS Fdn Don Carlo Gnocchi, Milan, Italy	Sapienza University Rome; Sapienza University Rome; Azienda Ospedaliera San Camillo-Forlanini; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Rome Tor Vergata; IRCCS Neuromed; IRCCS Fondazione Don Carlo Gnocchi Onlus	Grimaldi, AE (corresponding author), Sapienza Univ Rome, MS Ctr St Andrea Hosp, Rome, Italy.	alessandro.grimaldi.sr@gmail.com	Pozzilli, Carlo/AAC-3270-2022; Prosperini, Luca/K-5712-2016; Haggiag, Shalom/AAL-8385-2021; De Giglio, Laura/J-4796-2016; MIRABELLA, Massimiliano/AAC-4016-2020; Castelli, Letizia/AAL-7701-2020; Castelli, Letizia/AAC-2441-2019	Pozzilli, Carlo/0000-0002-6360-4798; Haggiag, Shalom/0000-0002-5569-4121; De Giglio, Laura/0000-0001-9018-7320; MIRABELLA, Massimiliano/0000-0002-7783-114X; Grimaldi, Alessandro/0000-0002-7856-0126				Amatya B, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009974.pub2; Baker D, 2000, NATURE, V404, P84, DOI 10.1038/35003583; Breiman L., 1984, CLASSIFICATION REGRE, DOI [10.2307/2530946, DOI 10.1201/9781315139470]; Collin C, 2007, EUR J NEUROL, V14, P290, DOI 10.1111/j.1468-1331.2006.01639.x; De Chiara V, 2010, NEUROPSYCHOPHARMACOL, V35, P374, DOI 10.1038/npp.2009.141; Dubreucq S, 2013, BIOL PSYCHIAT, V73, P895, DOI 10.1016/j.biopsych.2012.10.025; Etoom M, 2018, AM J PHYS MED REHAB, V97, P793, DOI 10.1097/PHM.0000000000000970; Farrar JT, 2008, CLIN THER, V30, P974, DOI 10.1016/j.clinthera.2008.05.011; Flachenecker P, 2014, EUR NEUROL, V71, P271, DOI 10.1159/000357427; Giovannelli M, 2007, CLIN REHABIL, V21, P331, DOI 10.1177/0269215507072772; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Latino P, 2017, NEUROL SCI, V38, P1841, DOI 10.1007/s10072-017-3078-3; Meuth SG, 2015, EXPERT REV NEUROTHER, V15, P909, DOI 10.1586/14737175.2015.1067607; Mori F, 2014, NEUROL-NEUROIMMUNOL, V1, DOI 10.1212/NXI.0000000000000048; Novotna A, 2011, EUR J NEUROL, V18, P1122, DOI 10.1111/j.1468-1331.2010.03328.x; Oreja-Guevara C., 2015, CLIN EXP PHARM, V5, DOI [10.4172/2161-1459.1000184, DOI 10.4172/2161-1459.1000184]; Otero-Romero S, 2016, MULT SCLER J, V22, P1386, DOI 10.1177/1352458516643600; Patti F, 2016, J NEUROL NEUROSUR PS, V87, P944, DOI 10.1136/jnnp-2015-312591; Perez J, 2006, DRUG TODAY, V42, P495, DOI 10.1358/dot.2006.42.8.1021517; Pozzilli C, 2014, EUR NEUROL, V71, P1, DOI 10.1159/000357739; Pozzilli C, 2013, EXPERT REV NEUROTHER, V13, P49, DOI 10.1586/14737175.2013.865877; Raichlen DA, 2013, EUR J APPL PHYSIOL, V113, P869, DOI 10.1007/s00421-012-2495-5; Rizzo MA, 2004, MULT SCLER, V10, P589, DOI 10.1191/1352458504ms1085oa; Rossi S, 2009, NEUROBIOL DIS, V36, P51, DOI 10.1016/j.nbd.2009.06.013; Shakespeare D T, 2001, Cochrane Database Syst Rev, pCD001332, DOI 10.1002/14651858.CD001332; Wade DT, 2006, MULT SCLER J, V12, P639, DOI 10.1177/1352458505070618	26	7	7	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2019	14	7							e0219670	10.1371/journal.pone.0219670	http://dx.doi.org/10.1371/journal.pone.0219670			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4WU	31361750	Green Submitted, gold, Green Published			2023-01-03	WOS:000484981300013
J	Beh, CY; Rasedee, A; Selvarajah, GT; Yazan, LS; Omar, AR; Foong, JN; How, CW; Foo, JB				Beh, Chaw Yee; Rasedee, Abdullah; Selvarajah, Gayathri Thevi; Yazan, Latifah Saiful; Omar, Abdul Rahman; Foong, Jia Ning; How, Chee Wun; Foo, Jhi Biau			Enhanced anti-mammary gland cancer activities of tamoxifen-loaded erythropoietin-coated drug delivery system	PLOS ONE			English	Article							TRANSLATION; EXPRESSION	Nanomedicine is an emerging area in the medical field, particularly in the treatment of cancers. Nanostructured lipid carrier (NLC) was shown to be a good nanoparticulated carrier for the delivery of tamoxifen (TAM). In this study, the tamoxifen-loaded erythropoietin-coated nanostructured lipid carriers (EPO-TAMNLC) were developed to enhance the anti-cancer properties and targetability of TAM, using EPO as the homing ligand for EPO receptors (EpoRs) on breast cancer tissue cells. Tamoxifen-loaded NLC (TAMNLC) was used for comparison. The LA7 cells and LA7 cell-induced rat mammary gland tumor were used as models in the study. Immunocytochemistry staining showed that LA7 cells express estrogen receptors (ERs) and EpoRs. EPO-TAMNLC and TAMNLC significantly (p<0.05) inhibited proliferation of LA7 in dose-and time-dependent manner. EPO-TAMNLC induced apoptosis and G(0)/G(1) cell cycle arrest of LA7 cells. Both drug delivery systems showed anti-mammary gland tumor properties. At an intravenous dose of 5 mg kg(-1) body weight, EPO-TAMNLC and TAMNLC were not toxic to rats, suggesting that both are safe therapeutic compounds. In conclusion, EPO-TAMNLC is not only a unique drug delivery system because of the dual drug-loading feature, but also potentially highly specific in the targeting of breast cancer tissues positive for ERs and EpoRs. The incorporation of TAM into NLC with and without EPO coat had significantly (p<0.05) improved specificity and safety of the drug carriers in the treatment of mammary gland tumors.	[Beh, Chaw Yee; Rasedee, Abdullah; Omar, Abdul Rahman; Foong, Jia Ning] Univ Putra Malaysia, Inst Biosci, Upm Serdang, Selangor, Malaysia; [Rasedee, Abdullah; Selvarajah, Gayathri Thevi; Omar, Abdul Rahman] Univ Putra Malaysia, Fac Vet Med, Upm Serdang, Selangor, Malaysia; [Yazan, Latifah Saiful] Univ Putra Malaysia, Fac Med, Upm Serdang, Selangor, Malaysia; [How, Chee Wun] MAHSA Univ, Fac Pharm, Ctr Preuniv Studies, Kuala Langat, Selangor, Malaysia; [How, Chee Wun] Monash Univ Malaysia, Sch Pharm, Bandar Sunway, Selangor, Malaysia; [Foo, Jhi Biau] Taylors Univ, Fac Hlth & Med Sci, Sch Pharm, Subang Jaya, Selangor, Malaysia	Universiti Putra Malaysia; Universiti Putra Malaysia; Universiti Putra Malaysia; Mahsa University; Monash University; Monash University Sunway; Taylor's University	Beh, CY; Rasedee, A (corresponding author), Univ Putra Malaysia, Inst Biosci, Upm Serdang, Selangor, Malaysia.; Rasedee, A (corresponding author), Univ Putra Malaysia, Fac Vet Med, Upm Serdang, Selangor, Malaysia.	chawyee1015@gmail.com; rasedee@upm.edu.my	Rasedee, Abdullah/E-9119-2013; Foo, Jhi Biau/J-2844-2019; HOW, CHEE WUN/AAE-2256-2019	Rasedee, Abdullah/0000-0001-6625-508X; HOW, CHEE WUN/0000-0002-5910-6542; Foo, Jhi Biau/0000-0002-5880-2220; Chaw Yee, Beh/0000-0003-1392-0589; Selvarajah, Gayathri Thevi/0000-0001-7240-9882	Graduate Research Fellowship University Putra Malaysia [GP-IPS/2017/9537700]	Graduate Research Fellowship University Putra Malaysia	Chaw Yee Beh has received the funding from Graduate Research Fellowship University Putra Malaysia with grant numbers GP-IPS/2017/9537700. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors thank Institute of Bioscience (IBS) and the Faculty of Veterinary Medicine (FVM), Universiti Putra Malaysia for the facilities provided and the staffs of Laboratory of Vaccines and Immunotherapeutics, IBS and Haematology and Clinical Biochemistry Laboratory, FVM, for their assistance. This work was funded by Graduate Research Fellowship, University Putra Malaysia with grant number GP-IPS/2017/9537700.	Abbasalipourkabir R, 2010, AFR J BIOTECHNOL, V9, P4491; Acharya S, 2009, BIOMATERIALS, V30, P5737, DOI 10.1016/j.biomaterials.2009.07.008; Al-Janabi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082576; Beh CY, 2017, DRUG DES DEV THER, V11, P771, DOI 10.2147/DDDT.S123939; Beloqui A, 2013, EUR J PHARM BIOPHARM, V84, P309, DOI 10.1016/j.ejpb.2013.01.029; Beloqui A, 2016, NANOMED-NANOTECHNOL, V12, P143, DOI 10.1016/j.nano.2015.09.004; Dalvai M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011011; Diehl KH, 2001, J APPL TOXICOL, V21, P15, DOI 10.1002/jat.727; DiFrancesco T, 2012, CLIN INVEST MED, V35, pE114; Fabbrocini G, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-50; Fasehee H, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951-016-0183-z; Fischer Andrew H, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot4986; Gargiulo S, 2012, ILAR J, V53, pE55, DOI 10.1093/ilar.53.1.55; Gewirtz DA, 2006, CLIN CANCER RES, V12, P2232, DOI 10.1158/1078-0432.CCR-05-2287; Harrington SE, 2008, JAMA-J AM MED ASSOC, V299, P2667, DOI 10.1001/jama.299.22.2667; He QL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189837; Housman G, 2014, CANCERS, V6, P1769, DOI 10.3390/cancers6031769; How CW, 2013, COLLOID SURFACE B, V112, P393, DOI 10.1016/j.colsurfb.2013.08.009; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Laugsch M, 2008, INT J CANCER, V122, P1005, DOI 10.1002/ijc.23201; Lazzeroni M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3233; Lee SH, 2008, INT J LAB HEMATOL, V30, P349, DOI 10.1111/j.1751-553X.2008.01100.x; Manshadi SD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084635; Martins NM, 2008, J APPL TOXICOL, V28, P337, DOI 10.1002/jat.1284; Narvekar M, 2014, AAPS PHARMSCITECH, V15, P822, DOI 10.1208/s12249-014-0107-x; Nounou MI, 2015, BREAST CANCER-BASIC, V9, P17, DOI 10.4137/BCBCR.S29420; Poonia N, 2016, FUTUR SCI OA, V2, DOI 10.4155/fsoa-2016-0030; Radwan EM, 2016, MOL MED REP, V13, P3945, DOI 10.3892/mmr.2016.4989; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Roger E, 2012, MOL PHARMACEUT, V9, P2103, DOI 10.1021/mp2005388; Sairah AK, 2009, AM J PHARM TOXICOL, V4, P12; Sanad R., 2014, J DRUG RES EGYPT, V35, P73; Savjani K. T., 2012, ISRN PHARM, V2012; Sulahian R, 2009, BLOOD, V113, P5287, DOI 10.1182/blood-2008-09-179572; Syahida M., 2012, International Food Research Journal, V19, P955; Talluri SV, 2016, DRUG DELIV, V23, P1291, DOI 10.3109/10717544.2015.1092183; Travlos GS, 2006, TOXICOL PATHOL, V34, P548, DOI 10.1080/01926230600939856; Trost N, 2013, INT J MOL MED, V31, P717, DOI 10.3892/ijmm.2013.1231; Wang Y, 2006, CURR CANCER THER REV, V2, P271, DOI 10.2174/157339406777934717; Xiao G, 2013, INTERNATIONAL JOURNA, V2013	40	8	9	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2019	14	7							e0219285	10.1371/journal.pone.0219285	http://dx.doi.org/10.1371/journal.pone.0219285			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4JZ	31291309	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000484947800065
J	Palstam, A; Sjodin, A; Sunnerhagen, KS				Palstam, Annie; Sjodin, Astrid; Sunnerhagen, Katharina Stibrant			Participation and autonomy five years after stroke: A longitudinal observational study	PLOS ONE			English	Article							PERCEIVED PARTICIPATION; SOCIAL-PARTICIPATION; LIFE SATISFACTION; IMPACT; DISABILITY; PREDICTORS; DEPRESSION; HANDICAP; DETERMINANTS; RECOVERY	Objective Stroke is the second most common cause of disability in the world. The purpose of this study was to evaluate the participation and autonomy of persons with stroke, five years after a stroke, and to explore potential associations between factors and perceived restrictions in participation and autonomy. Methods This five-year follow-up survey study included individuals diagnosed with a first-time stroke during 2009-2010, in Gothenburg. The survey included the Impact of Participation and Autonomy-questionnaire (IPA-E), which comprised five domains: Autonomy Indoor, Family Role, Autonomy Outdoor, Work & Education, and Social Life & Relationships. Logistic regression analyses were used to analyze factors associated with participation restrictions. Results At 5 years after a stroke, 457 patients were alive; of these, 281 responded to the follow-up survey. Participation restrictions were most pronounced in the IPA-E domains of Autonomy Outdoors, Work/Education, and Social Life and Relationships. In contrast, restrictions were less pronounced in the IPA-E domains of Autonomy Indoors and Family Role. Severe stroke, older age, and female sex predicted participation restrictions at five years after a stroke. Participation restrictions were partly explained by feelings of depression at five years after stroke. Problems associated with participation restrictions were most frequently observed in the areas of mobility, leisure, and help/support from other people. Conclusion This study showed that participation and autonomy were restricted among persons with stroke at five years after the stroke. The domains perceived as most restricted were those that required high levels of physical, social, and cognitive abilities.	[Palstam, Annie; Sjodin, Astrid; Sunnerhagen, Katharina Stibrant] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci, Gothenburg, Sweden	University of Gothenburg	Palstam, A (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci, Gothenburg, Sweden.	anme.palstam@gu.se	Sunnerhagen, Katharina Stibrant/AAE-2405-2020	Sunnerhagen, Katharina Stibrant/0000-0002-5940-4400	Swedish Research Council [VR 2012-70X-22122-01-3, VR2017-00946]; Swedish Heart Lung Foundation; Swedish Brain Foundation; Promobilia; Swedish Stroke Association; Swedish government; county councils, the ALF agreement [ALFGBG-718711]; Norrbacka-Eugenia foundation	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Heart Lung Foundation(Swedish Heart-Lung Foundation); Swedish Brain Foundation; Promobilia; Swedish Stroke Association; Swedish government; county councils, the ALF agreement; Norrbacka-Eugenia foundation	The study was supported by grants from the Swedish Research Council (VR 2012-70X-22122-01-3, VR2017-00946), The Swedish Heart Lung Foundation, The Swedish Brain Foundation, Promobilia, Norrbacka-Eugenia foundation, The Swedish Stroke Association as well as by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement (ALFGBG-718711) to KSS.	ALLEN SM, 1993, J GERONTOL, V48, pS204, DOI 10.1093/geronj/48.4.S204; Amosun SL, 2013, AFR HEALTH SCI, V13, P24, DOI 10.4314/ahs.v13i1.4; Andrenelli E, 2015, EUR J PHYS REHAB MED, V51, P575; Bergstrom AL, 2015, J REHABIL MED, V47, P508, DOI 10.2340/16501977-1964; Blomgren C, 2018, SCAND J OCCUP THER, V25, P119, DOI 10.1080/11038128.2017.1329343; Boosman H, 2011, CLIN REHABIL, V25, P460, DOI 10.1177/0269215510388314; Burton CR, 2000, J ADV NURS, V32, P301, DOI 10.1046/j.1365-2648.2000.01477.x; Cardol M, 2002, CLIN REHABIL, V16, P27, DOI 10.1191/0269215502cr464oa; Cardol M, 2002, DISABIL REHABIL, V24, P970, DOI 10.1080/09638280210151996; Cardol M, 2001, ARCH PHYS MED REHAB, V82, P210, DOI 10.1053/apmr.2001.18218; Chau JPC, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-49; Chen XM, 2017, CLIN REHABIL, V31, P1257, DOI 10.1177/0269215516684178; D'Alisa S, 2005, ACTA NEUROL SCAND, V112, P157, DOI 10.1111/j.1600-0404.2005.00466.x; de Graaf JA., 2017, DISABIL REHABIL, V5, P1; Desrosiers J, 2006, DISABIL REHABIL, V28, P221, DOI 10.1080/09638280500158372; Desrosiers J, 2004, AGING CLIN EXP RES, V16, P406; Dijkers MP, 2010, ARCH PHYS MED REHAB, V91, pS5, DOI 10.1016/j.apmr.2009.10.036; Duncan PW, 2003, ARCH PHYS MED REHAB, V84, P950, DOI 10.1016/S0003-9993(03)00035-2; Edwards Dorothy F, 2006, J Stroke Cerebrovasc Dis, V15, P151, DOI 10.1016/j.jstrokecerebrovasdis.2006.04.001; Erikson A, 2010, J REHABIL MED, V42, P831, DOI 10.2340/16501977-0608; Eriksson Gunilla, 2013, Am J Occup Ther, V67, pe131, DOI 10.5014/ajot.2013.008292; Fallahpour M, 2011, J REHABIL MED, V43, P388, DOI 10.2340/16501977-0789; Feigin VL, 2015, NEUROEPIDEMIOLOGY, V45, P161, DOI 10.1159/000441085; Gadidi V, 2011, ARCH PHYS MED REHAB, V92, P1802, DOI 10.1016/j.apmr.2011.06.014; Hadidi N, 2009, HEART LUNG, V38, P151, DOI 10.1016/j.hrtlng.2008.05.002; Hankey GJ, 2002, STROKE, V33, P1034, DOI 10.1161/01.STR.0000012515.66889.24; Harwood RH, 1997, DISABIL REHABIL, V19, P205, DOI 10.3109/09638289709166528; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Kirkevold M, 2002, DISABIL REHABIL, V24, P887, DOI 10.1080/09638280210142239; Larsson J, 2013, J REHABIL MED, V45, P765, DOI 10.2340/16501977-1184; Lund ML, 2007, J REHABIL MED, V39, P156, DOI 10.2340/16501977-0031; Pallesen H, 2014, DISABIL REHABIL, V36, P232, DOI 10.3109/09638288.2013.788217; Parker CJ, 1997, DISABIL REHABIL, V19, P1, DOI 10.3109/09638289709166438; Persson HC, 2018, ACTA NEUROL SCAND, V137, P99, DOI 10.1111/ane.12815; Persson HC, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-162; Reinhardt JD, 2007, J RHEUMATOL, V34, P1214; Schepers VP, 2005, ARCH PHYS MED REHAB, V86, P1472, DOI 10.1016/j.apmr.2004.11.039; Shi Y, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00218; Silva SM, 2016, DISABIL REHABIL, V38, P1830, DOI 10.3109/09638288.2015.1107774; Singam A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144344; Sturm JW, 2004, STROKE, V35, P715, DOI 10.1161/01.STR.0000117573.19022.66; Sturm JW, 2002, STROKE, V33, P762, DOI 10.1161/hs0302.103815; Tellier M, 2009, TOP STROKE REHABIL, V16, P454, DOI 10.1310/tsr1606-454; Tornbom K, 2017, ACTA NEUROL SCAND, V135, P649, DOI 10.1111/ane.12661; Tornbom K, 2017, J STROKE CEREBROVASC, V26, P57, DOI 10.1016/j.jstrokecerebrovasdis.2016.08.029; Turner-Stokes L, 2002, CLIN REHABIL, V16, P231, DOI 10.1191/0269215502cr487oa; Venna VR, 2015, METAB BRAIN DIS, V30, P497, DOI 10.1007/s11011-014-9544-1; Vikholmen K, 2015, ACTA NEUROL SCAND, V132, P329, DOI 10.1111/ane.12404; Wesali S, 2015, CLIN NEUROL NEUROSUR, V138, P52, DOI 10.1016/j.clineuro.2015.07.020; Woodman P, 2014, DISABIL REHABIL, V36, P2031, DOI 10.3109/09638288.2014.887796; Ytterberg C, 2017, J REHABIL MED, V49, P637, DOI 10.2340/16501977-2258	51	23	24	5	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2019	14	7							e0219513	10.1371/journal.pone.0219513	http://dx.doi.org/10.1371/journal.pone.0219513			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4GX	31283800	Green Published, Green Submitted, gold			2023-01-03	WOS:000484939800039
J	Thobani, R; Jessani, S; Azam, I; Reza, S; Sami, N; Rozi, S; Abrejo, F; Saleem, S				Thobani, Rozina; Jessani, Saleem; Azam, Iqbal; Reza, Sayyeda; Sami, Neelofar; Rozi, Shafquat; Abrejo, Farina; Saleem, Sarah			Factors associated with the discontinuation of modern methods of contraception in the low income areas of Sukh Initiative Karachi: A community-based case control study	PLOS ONE			English	Article								Introduction Discontinuation of a contraceptive method soon after its initiation is becoming a public health problem in Low middle income countries and may result in unintended pregnancy and related unwanted consequences. A better understanding of factors behind discontinuation of a modern method would help in designing interventions to continue its use till desired spacing goals are achieved. Objective To determine factors associated with the discontinuation of modern contraceptive methods within six months of its use compared to continued use of modern method for at least six months in low-income areas of Karachi, Pakistan. Methods A community-based case-control study was conducted in low-income areas of Karachi. Cases were 137 users who discontinued a modern contraceptive method within 6 months of initiation and were not using any method at the time of interview, while controls were 276 continuous users of modern method for at least last six months from the time of interview. Information was collected by using a structured questionnaire. Applied logistic regression was used to identify the associated factors for discontinuation. Results The mean ages of discontinued and continued users were 29.3 +/- 5.3 years and 29.2 +/- 5.4 years respectively. A larger proportion of the discontinued users had no formal education (43.8%) as compared to the continued users (27.9%). The factors associated with discontinuation of a modern method of contraception were belonging to Sindhi ethnicity [OR: 2.54, 95% CI 1.16-5.57], experiencing side effects [OR: 15.12; 95% CI 7.50-30.51], difficulty in accessing contraceptives by themselves [OR: 0.40, 95% CI 0.19-0.83] and difficulty in reaching clinics for management of the side effects [OR: 4.10, 95% CI 2.38-7.05]. Moreover, women having support from the husband for contraceptive use were less likely to discontinue the method [OR: 0.58, 95% CI 0.34-0.98]. Conclusions Sindhi ethnicity and side effects of modern methods of contraception were identified as major factors for discontinuation in low-income populations. Similarly, women who had difficulty in travelling to reach clinics for treatment also contributed to discontinuation. Furthermore, women using long acting methods and those supported by their husbands were less likely to discontinue the contraceptive methods. Findings emphasize a need to focus on Sindhi ethnicity and trainings of service providers on management of side effects and provision of high quality of services.	[Thobani, Rozina; Jessani, Saleem; Azam, Iqbal; Reza, Sayyeda; Sami, Neelofar; Rozi, Shafquat; Abrejo, Farina; Saleem, Sarah] Aga Khan Univ, Dept Community Hlth Sci, Karachi, Pakistan	Aga Khan University	Saleem, S (corresponding author), Aga Khan Univ, Dept Community Hlth Sci, Karachi, Pakistan.	sarah.saleem@aku.edu	; , Rozi/AAB-6281-2021	Saleem, Sarah/0000-0002-6797-8631; , Rozi/0000-0003-4117-1335	Aman Foundation	Aman Foundation	Funding for this research was recieved from Aman Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aga Khan University, 2013, INT ADV SEM FAM PLAN; Aga Khan University, 2015, SUKH IN BAS ASS; Ali M, 1999, J BIOSOC SCI, V31, P343, DOI 10.1017/S0021932099003430; Ali M, 2012, CAUSES CONSEQUENCES; Ali MM, 2011, LONG TERM CONTRACEPT; Ali MM, 2010, CONTRACEPTION, V81, P22, DOI 10.1016/j.contraception.2009.06.009; [Anonymous], 2013, POSTABORTION CARE PA; [Anonymous], 2016, WHY DO WOMEN GIRLS S; Barden-O'Fallon J, 2011, INT PERSPECT SEX R H, V37, P16, DOI 10.1363/3701611; Blanc, 1997, DHS ANAL REPORTS, V6; Blanc AK, 2002, STUD FAMILY PLANN, V33, P127, DOI 10.1111/j.1728-4465.2002.00127.x; Bracher M, 1992, FAMILY PLANNING PERS, P58; Bradley S.E.K., 2009, DHS ANAL STUDIES; Choe MK, 1991, CONTRACEPTIVE USE DI; Khan MA, 2001, CONTRACEPTION, V64, P161, DOI 10.1016/S0010-7824(01)00238-4; Laguna EP, 2000, CONTRACEPTIVE USE DY; Littlejohn KE, 2012, DEMOGRAPHY, V49, P1433, DOI 10.1007/s13524-012-0127-7; Mumah JN, 2015, STUD FAMILY PLANN, V46, P369, DOI 10.1111/j.1728-4465.2015.00038.x; National Institute of Population Studies, 2012, PAK DEM HLTH SURV 20; Parveen T, 2015, INVESTIGATING LOW MO; Rizvi Farwa, 2012, J Ayub Med Coll Abbottabad, V24, P101; Sathar Z, 2014, STUD FAMILY PLANN, V45, P471, DOI 10.1111/j.1728-4465.2014.00004.x; Tolesa Bekele, 2015, Epidemiology: Open Access, V5, P179; UNDESA, 2015, TRENDS CONTR US WORL; Vadnais D, 2006, RES FINDINGS DEMOGRA; World Health Organization, 2013, SEX REPR HLTH CONTR	26	12	12	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 3	2019	14	7							e0218952	10.1371/journal.pone.0218952	http://dx.doi.org/10.1371/journal.pone.0218952			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4CE	31269086	Green Published, gold, Green Submitted			2023-01-03	WOS:000484927300031
J	Chun, TW; Eisinger, RW; Fauci, AS				Chun, Tae-Wook; Eisinger, Robert W.; Fauci, Anthony S.			Durable Control of HIV Infection in the Absence of Antiretroviral Therapy Opportunities and Obstacles	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Chun, Tae-Wook] NIAID, Div Intramural Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Eisinger, Robert W.; Fauci, Anthony S.] NIAID, Off Director, 9000 Rockville Pike, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Fauci, AS (corresponding author), NIAID, NIH, 9000 Rockville Pike,Bldg 31,Room 7AO3, Bethesda, MD 20892 USA.	afauci@niaid.nih.gov	Chun, Tae-Wook/AAC-3101-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000851] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Davey RT, 1999, P NATL ACAD SCI USA, V96, P15109, DOI 10.1073/pnas.96.26.15109; Gupta RK, 2019, NATURE, V568, P244, DOI 10.1038/s41586-019-1027-4; Nishimura Y, 2017, NATURE, V543, P559, DOI 10.1038/nature21435; Pitman MC, 2018, LANCET HIV, V5, pE317, DOI 10.1016/S2352-3018(18)30039-0; Sengupta S, 2018, IMMUNITY, V48, P872, DOI 10.1016/j.immuni.2018.04.030; Sneller MC, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan8848	7	11	11	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	2019	322	1					27	28		10.1001/jama.2019.5397	http://dx.doi.org/10.1001/jama.2019.5397			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IH7AA	31169893				2023-01-03	WOS:000474655200012
J	Ayers, JW; Caputi, T; Leas, EC				Ayers, John W.; Caputi, Theodore; Leas, Eric C.			The Need for Federal Regulation of Marijuana Marketing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Ayers, John W.; Caputi, Theodore] Univ Calif San Diego, Dept Med, Div Infect Dis & Global Publ Hlth, La Jolla, CA 92093 USA; [Leas, Eric C.] Univ Calif San Diego, Sch Med, Dept Family Med & Publ Hlth, Div Hlth Policy, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Ayers, JW (corresponding author), 333 CRSF 9500 Gilman Dr, La Jolla, CA 92093 USA.	ayers.john.w@gmail.com						Humphreys K, 2019, JAMA-J AM MED ASSOC, V321, P639, DOI 10.1001/jama.2019.0077; Lodi M., 2018, CANNABIS CRAMPS; Lodi M., 2019, CBD CAN HELP BREAKOU; Mandelbaum DE, 2017, PEDIATR NEUROL, V66, P12, DOI 10.1016/j.pediatrneurol.2016.09.004; Owusu T., COWENS CANNABIS ANAL; Shiparo J, 2018, ALL THINGS CONSIDERE; Volkow ND, 2014, NEW ENGL J MED, V370, P2219, DOI 10.1056/NEJMra1402309	7	30	30	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2019	321	22					2163	2164		10.1001/jama.2019.4432	http://dx.doi.org/10.1001/jama.2019.4432			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IC6HB	31095243				2023-01-03	WOS:000471071200009
J	Erdeve, O; Okulu, E; Tunc, G; Celik, Y; Kayacan, U; Cetinkaya, M; Buyukkale, G; Ozkan, H; Koksal, N; Satar, M; Akcali, M; Aygun, C; Ozkiraz, S; Zubarioglu, U; Unal, S; Turgut, H; Mert, K; Gokmen, T; Akcan, B; Atasay, B; Arsan, S; Ozkan, EO; Uslu, S; Demirel, N; Gokce, IK; Vardar, G; Turkmen, M; Konak, M; Ozan, B; Kilicaslan, B; Narli, N; Demir, N; Tuncer, O; Akin, IM; Aslanoglu, S; Calkavur, S; Olukman, O; Bayraktar, BT; Bilgin, L; Guran, O; Aksu, M; Hirfanoglu, I; Ince, DA; Ecevit, AN; Narter, F				Erdeve, Omer; Okulu, Emel; Tunc, Gaffari; Celik, Yalcin; Kayacan, Ugur; Cetinkaya, Merih; Buyukkale, Gokhan; Ozkan, Hilal; Koksal, Nilgun; Satar, Mehmet; Akcali, Mustafa; Aygun, Canan; Ozkiraz, Servet; Zubarioglu, Umut; Unal, Sezin; Turgut, Hatice; Mert, Kurthan; Gokmen, Tulin; Akcan, Baris; Atasay, Begum; Arsan, Saadet; Ozkan, Elif Ozyazici; Uslu, Sinan; Demirel, Nihal; Gokce, Ismail Kursad; Vardar, Gonca; Turkmen, Munevver; Konak, Murat; Ozan, Beyza; Kilicaslan, Buket; Narli, Nejat; Demir, Nihat; Tuncer, Oguz; Akin, Ilke Mungan; Aslanoglu, Sertac; Calkavur, Sebnem; Olukman, Ozgur; Bayraktar, Bilge Tanyeri; Bilgin, Leyla; Guran, Omer; Aksu, Meltem; Hirfanoglu, Ibrahim; Ince, Deniz Anuk; Ecevit, Ayse N.; Narter, Fatma		Rescue-HFOV Trial Grp	An observational, prospective, multicenter study on rescue high-frequency oscillatory ventilation in neonates failing with conventional ventilation	PLOS ONE			English	Article							CONGENITAL DIAPHRAGMATIC-HERNIA; MECHANICAL VENTILATION; TERM INFANTS; MANAGEMENT; FAILURE; TRIAL	Background To achieve gas exchange goals and mitigate lung injury, infants who fail with conventional ventilation (CV) are generally switched to high-frequency oscillatory ventilation (HFOV). Although preferred in many neonatal intensive care units (NICUs), research on this type of rescue HFOV has not been reported recently. Methods An online registry database for a multicenter, prospective study was set to evaluate factors affecting the response of newborn infants to rescue HFOV treatment. The study population consisted of 372 infants with CV failure after at least 4 hours of treatment in 23 participating NICUs. Patients were grouped according to their final outcome as survived (Group S) or as died or received extracorporeal membrane oxygenation (ECMO) (Group D/E). Patients' demographic characteristics and underlying diseases in addition to their ventilator settings, arterial blood gas (ABG) analysis results at 0, 1, 4, and 24 hours, type of device, ventilation duration, and complications were compared between groups. Results HFOV as rescue treatment was successful in 58.1% of patients. Demographic and treatment parameters were not different between groups, except that infants in Group D/E had lower birthweight (BW) (1655 +/- 1091 vs. 1858 +/- 1027 g, p = 0.006), a higher initial FiO2 setting (83% vs. 72%, p < 0.001), and a higher rate of nitric oxide exposure (21.8% vs. 11.1%, p = 0.004) in comparison to infants who survived (Group S). The initial cut-offs for a successful response on ABG were defined as pH > 7.065 (OR: 19.74, 95% CI 4.83-80.6, p < 0.001), HCO3 > 16.35 mmol/L (OR: 1.06, 95% CI 1.01-1.1, p = 0.006), and lactate level < 3.75 mmol/L (OR: 1.09% 95 CI 1.01-1.16, p = 0.006). Rescue HFOV duration was associated with retinopathy of prematurity (p = 0.005) and moderate or severe chronic lung disease (p < 0.001), but not with patent ductus arteriosus or intraventricular hemorrhage, in survivors (p > 0.05). Conclusion Rescue HFOV as defined for this population was successful in more than half of the patients with CV failure. Although the response was not associated with gestational age, underlying disease, device used, or initial MV settings, it seemed to be more effective in patients with higher BW and those not requiring nitric oxide. Initial pH, HCO3, and lactate levels on ABG may be used as predictors of a response to rescue HFOV.	[Erdeve, Omer; Okulu, Emel; Tunc, Gaffari; Atasay, Begum; Arsan, Saadet] Ankara Univ, Sch Med, Dept Pediat, Div Neonatol, Ankara, Turkey; [Celik, Yalcin; Kayacan, Ugur] Mersin Univ, Sch Med, Dept Pediat, Div Neonatol, Mersin, Turkey; [Cetinkaya, Merih; Buyukkale, Gokhan] Univ Hlth Sci, Kanuni Training & Res Hosp, Dept Neonatol, Istanbul, Turkey; [Ozkan, Hilal; Koksal, Nilgun] Uludag Univ, Sch Med, Dept Pediat, Div Neonatol, Bursa, Turkey; [Satar, Mehmet; Akcali, Mustafa] Cukurova Univ, Sch Med, Dept Pediat, Div Neonatol, Adana, Turkey; [Aygun, Canan] Ondokuz Mayis Univ, Sch Med, Dept Pediat, Div Neonatol, Samsun, Turkey; [Ozkiraz, Servet] Medicalpk Hosp, Neonatal Intens Care Unit, Gaziantep, Turkey; [Zubarioglu, Umut] Univ Hlth Sci, Sisli Etfal Training & Res Hosp, Dept Neonatol, Istanbul, Turkey; [Unal, Sezin] Univ Hlth Sci, Etlik Zubeyde Hanim Matern Training & Res Hosp, Dept Neonatol, Ankara, Turkey; [Turgut, Hatice] Inonu Univ, Sch Med, Dept Pediat, Div Neonatol, Malatya, Turkey; [Mert, Kurthan] Adana Numune Training & Res Hosp, Neonatal Intens Care Unit, Adana, Turkey; [Gokmen, Tulin] Univ Hlth Sci, Zeynep Kamil Training & Res Hosp, Dept Neonatol, Istanbul, Turkey; [Akcan, Baris] Adnan Menderes Univ, Sch Med, Dept Pediat, Div Neonatol, Aydin, Turkey	Ankara University; Mersin University; University of Health Sciences Turkey; Uludag University; Cukurova University; Ondokuz Mayis University; Medical Park Hospitals Group; Istanbul Sisli Hamidiye Etfal Training & Research Hospital; University of Health Sciences Turkey; Etlik Zubeyde Hanim Gynecology Education & Research Hospital; University of Health Sciences Turkey; Inonu University; Adana Numune Training & Research Hospital; Ankara Numune Training & Research Hospital; Istanbul Zeynep Kamil Maternity & Children's Diseases Training & Research Hospital; University of Health Sciences Turkey; Adnan Menderes University	Erdeve, O (corresponding author), Ankara Univ, Sch Med, Dept Pediat, Div Neonatol, Ankara, Turkey.	omererdeve@yahoo.com	Uslu, Sinan/AAV-6420-2021; Celik, Yalcin/AAA-4342-2021; Unal, Sezin/G-5003-2017; aksu, meltem/AAJ-1667-2021; /AAG-8393-2021; DEMİR, NİHAT/GRY-3625-2022; Gökçe, İsmail Kürşad/ABI-8128-2020; Olukman, Özgür/AAV-5924-2021; Satar, Mehmet/E-9403-2018; Demirel, Nihal/ABI-5267-2020; Ince, Deniz Anuk/I-6746-2016; Konak, Murat/B-2334-2018; Cetinkaya, Merih/AFP-9671-2022; Atasay, Fatma Begum/AAQ-1632-2020; AKIN, Ilke Mungan/ABE-7061-2020; ERDEVE, Omer/W-1480-2017; bilgin, leyla/AAS-8299-2020; Zubarioglu, Adil Umut/AAG-3984-2019; ECEVİT, AYSE/AAJ-4616-2021; Okulu, Emel/AAH-8855-2020	Unal, Sezin/0000-0002-5124-4422; aksu, meltem/0000-0002-0045-0082; Satar, Mehmet/0000-0002-5718-0503; Ince, Deniz Anuk/0000-0002-4369-2110; Konak, Murat/0000-0001-8728-4541; Atasay, Fatma Begum/0000-0002-9114-5293; Zubarioglu, Adil Umut/0000-0001-6053-7043; ECEVİT, AYSE/0000-0002-2232-8117; ERDEVE, OMER/0000-0002-3193-0812; Celik, Yalcin/0000-0002-1357-0585; AYGUN, CANAN/0000-0002-7955-5943; Okulu, Emel/0000-0002-1101-3355	Turkish Neonatal Society [5-2016]	Turkish Neonatal Society	This study was supported by the Turkish Neonatal Society, number 5-2016, received by OE. Turkish Neonatal Society funded the study's online registry system. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ARNOLD JH, 1994, CRIT CARE MED, V22, P1530, DOI 10.1097/00003246-199422100-00006; ARNOLD JH, 1993, CRIT CARE MED, V21, P272, DOI 10.1097/00003246-199302000-00021; Ben Jaballah N, 2006, AM J PERINAT, V23, P403, DOI 10.1055/s-2006-951289; BHUTA T, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000438; Bhuta T, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002974; Cheung PY, 1996, PEDIATRICS, V97, P437; Cools F, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000104.pub4; DELEMOS R, 1992, EARLY HUM DEV, V29, P299, DOI 10.1016/0378-3782(92)90181-F; DELEMOS RA, 1992, PEDIATR PULM, V12, P29, DOI 10.1002/ppul.1950120108; DiBlasi RM, 2010, RESP CARE, V55, P1717; Ferguson ND, 2013, NEW ENGL J MED, V368, P795, DOI 10.1056/NEJMoa1215554; Gerstmann DR, 1996, PEDIATRICS, V98, P1044; Gupta P, 2014, JAMA PEDIATR, V168, P243, DOI 10.1001/jamapediatrics.2013.4463; Morcillo F, 1999, An Esp Pediatr, V50, P269; Okulu E, 2018, TURK J MED SCI, V48, P223, DOI 10.3906/sag-1707-62; PARANKA MMS, 1995, PEDIATRICS, V95, P400; Poddutoor PK, 2011, INDIAN PEDIATR, V48, P467, DOI 10.1007/s13312-011-0073-2; Rimensberger PC, 2015, PEDIATR CRIT CARE ME, V16, pS51, DOI 10.1097/PCC.0000000000000433; Snoek KG, 2016, NEONATOLOGY, V110, P66, DOI 10.1159/000444210; Snoek KG, 2016, ANN SURG, V263, P867, DOI 10.1097/SLA.0000000000001533; Sud S, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2327; Tana M, 2015, CRIT CARE MED, V43, P1685, DOI 10.1097/CCM.0000000000000967; Young D, 2013, NEW ENGL J MED, V368, P806, DOI 10.1056/NEJMoa1215716	23	10	10	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2019	14	6							e0217768	10.1371/journal.pone.0217768	http://dx.doi.org/10.1371/journal.pone.0217768			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IC3IS	31181092	gold, Green Published			2023-01-03	WOS:000470854200027
J	Di Pilato, M; Kim, EY; Cadilha, BL; Prussmann, JN; Nasrallah, MN; Seruggia, D; Usmani, SM; Misale, S; Zappulli, V; Carrizosa, E; Mani, V; Ligorio, M; Warner, RD; Medoff, BD; Marangoni, F; Villani, AC; Mempel, TR				Di Pilato, Mauro; Kim, Edward Y.; Cadilha, Bruno L.; Prussmann, Jasper N.; Nasrallah, Mazen N.; Seruggia, Davide; Usmani, Shariq M.; Misale, Sandra; Zappulli, Valentina; Carrizosa, Esteban; Mani, Vinidhra; Ligorio, Matteo; Warner, Ross D.; Medoff, Benjamin D.; Marangoni, Francesco; Villani, Alexandra-Chloe; Mempel, Thorsten R.			Targeting the CBM complex causes T-reg cells to prime tumours for immune checkpoint therapy	NATURE			English	Article							PD-1 BLOCKADE; MALT1 PROTEASE; EFFECTOR; CARMA1; REQUIREMENT; SENSITIVITY; ACTIVATION; INHIBITORS; RESPONSES; SIGNALS	Solid tumours are infiltrated by effector T cells with the potential to control or reject them, as well as by regulatory T (T-reg) cells that restrict the function of effector T cells and thereby promote tumour growth1. The anti-tumour activity of effector T cells can be therapeutically unleashed, and is now being exploited for the treatment of some forms of human cancer. However, weak tumour-associated inflammatory responses and the immune-suppressive function of T-reg cells remain major hurdles to broader effectiveness of tumour immunotherapy2. Here we show that, after disruption of the CARMA1-BCL10-MALT1 (CBM) signalosome complex, most tumour-infiltrating T-reg cells produce IFN gamma, resulting in stunted tumour growth. Notably, genetic deletion of both or even just one allele of CARMA1 (also known as Card11) in only a fraction of T-reg cells-which avoided systemic autoimmunity-was sufficient to produce this anti-tumour effect, showing that it is not the mere loss of suppressive function but the gain of effector activity by T-reg cells that initiates tumour control. The production of IFN gamma by Treg cells was accompanied by activation of macrophages and upregulation of class I molecules of the major histocompatibility complex on tumour cells. However, tumour cells also upregulated the expression of PD-L1, which indicates activation of adaptive immune resistance(3). Consequently, blockade of PD-1 together with CARMA1 deletion caused rejection of tumours that otherwise do not respond to anti-PD-1 monotherapy. This effect was reproduced by pharmacological inhibition of the CBM protein MALT1. Our results demonstrate that partial disruption of the CBM complex and induction of IFN gamma secretion in the preferentially self-reactive T-reg cell pool does not cause systemic autoimmunity but is sufficient to prime the tumour environment for successful immune checkpoint therapy.	[Di Pilato, Mauro; Kim, Edward Y.; Cadilha, Bruno L.; Prussmann, Jasper N.; Nasrallah, Mazen N.; Usmani, Shariq M.; Carrizosa, Esteban; Mani, Vinidhra; Warner, Ross D.; Medoff, Benjamin D.; Marangoni, Francesco; Villani, Alexandra-Chloe; Mempel, Thorsten R.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA; [Di Pilato, Mauro; Kim, Edward Y.; Prussmann, Jasper N.; Nasrallah, Mazen N.; Seruggia, Davide; Usmani, Shariq M.; Misale, Sandra; Carrizosa, Esteban; Mani, Vinidhra; Ligorio, Matteo; Medoff, Benjamin D.; Marangoni, Francesco; Villani, Alexandra-Chloe; Mempel, Thorsten R.] Harvard Med Sch, Boston, MA 02115 USA; [Seruggia, Davide] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA; [Misale, Sandra; Ligorio, Matteo] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA; [Zappulli, Valentina] Univ Padua, Dept Comparat Biomed & Food Sci, Padua, Italy	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts General Hospital; University of Padua	Di Pilato, M; Mempel, TR (corresponding author), Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA.; Di Pilato, M; Mempel, TR (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	mdipilato@mgh.harvard.edu; tmempel@mgh.harvard.edu	Pruessmann, Jasper/AAY-5686-2021; seruggia, davide/T-9574-2019; Cadilha, Bruno/U-3776-2017; Warner, Ross/C-6368-2019	Pruessmann, Jasper/0000-0002-1289-852X; Di Pilato, Mauro/0000-0003-3902-7406; seruggia, davide/0000-0001-5014-0499; Usmani, Shariq/0000-0002-6462-1098; Cadilha, Bruno/0000-0001-7045-3898; Warner, Ross/0000-0001-9394-0912	EMBO fellowship [ALTF534-2015]; Marie Curie Global Fellowship [750973]; DFG Fellowships [PR 1652/1-1, US 116/2-1]; NIH [T32 CA207021, AI123349]; Sara Elizabeth O'Brien Fellowship; Melanoma Research Alliance Senior Investigator Award [MRA-348693]; Bob and Laura Reynolds MGH Research Scholar Award; NATIONAL CANCER INSTITUTE [R35CA232103, T32CA207021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI123349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351] Funding Source: NIH RePORTER	EMBO fellowship(European Molecular Biology Organization (EMBO)); Marie Curie Global Fellowship; DFG Fellowships(German Research Foundation (DFG)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sara Elizabeth O'Brien Fellowship; Melanoma Research Alliance Senior Investigator Award; Bob and Laura Reynolds MGH Research Scholar Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank the MGH Pathology Flow Cytometry Core and N. Ali-Akbar for technical assistance. This study was funded by an EMBO fellowship (ALTF534-2015) and a Marie Curie Global Fellowship (750973) (M.D.P.), DFG Fellowships (PR 1652/1-1 to J.N.P and US 116/2-1 to S.M.U), NIH T32 CA207021 (V.M.), a Sara Elizabeth O'Brien Fellowship (F.M.), and Melanoma Research Alliance Senior Investigator Award MRA-348693, NIH AI123349, and the Bob and Laura Reynolds MGH Research Scholar Award (T.R.M.).	Barnes MJ, 2009, PLOS BIOL, V7, P513, DOI 10.1371/journal.pbio.1000051; Bauer CA, 2014, J CLIN INVEST, V124, P2425, DOI 10.1172/JCI66375; Bornancin F, 2015, J IMMUNOL, V194, P3723, DOI 10.4049/jimmunol.1402254; Brustle A, 2017, CELL DEATH DIFFER, V24, P1214, DOI 10.1038/cdd.2015.104; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; Fontan L, 2012, CANCER CELL, V22, P812, DOI 10.1016/j.ccr.2012.11.003; Gewies A, 2014, CELL REP, V9, P1292, DOI 10.1016/j.celrep.2014.10.044; GODFREY VL, 1991, P NATL ACAD SCI USA, V88, P5528, DOI 10.1073/pnas.88.13.5528; Grinberg-Bleyer Y, 2017, CELL, V170, P1096, DOI 10.1016/j.cell.2017.08.004; Jaworski M, 2014, EMBO J, V33, P2765, DOI 10.15252/embj.201488987; Jenkins MH, 2014, PIGM CELL MELANOMA R, V27, P495, DOI 10.1111/pcmr.12220; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Long MX, 2009, IMMUNITY, V31, P921, DOI 10.1016/j.immuni.2009.09.022; Marangoni F, 2018, J IMMUNOL, V200, P3647, DOI 10.4049/jimmunol.1701220; Marangoni F, 2013, IMMUNITY, V38, P237, DOI 10.1016/j.immuni.2012.09.012; Medoff BD, 2009, EUR J IMMUNOL, V39, P78, DOI 10.1002/eji.200838734; Meininger I, 2016, BIOL CHEM, V397, P1315, DOI 10.1515/hsz-2016-0216; Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673; Messina N, 2016, J AUTOIMMUN, V70, P52, DOI 10.1016/j.jaut.2016.03.017; Molinero LL, 2009, J IMMUNOL, V182, P6736, DOI 10.4049/jimmunol.0900498; Nagel D, 2012, CANCER CELL, V22, P825, DOI 10.1016/j.ccr.2012.11.002; Oh H, 2017, IMMUNITY, V47, P450, DOI 10.1016/j.immuni.2017.08.010; Overacre-Delgoffe AE, 2017, CELL, V169, P1130, DOI 10.1016/j.cell.2017.05.005; Pierson W, 2013, NAT IMMUNOL, V14, P959, DOI 10.1038/ni.2649; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rubtsov YP, 2008, IMMUNITY, V28, P546, DOI 10.1016/j.immuni.2008.02.017; Rubtsov YP, 2010, SCIENCE, V329, P1667, DOI 10.1126/science.1191996; Sasaki Y, 2006, IMMUNITY, V24, P729, DOI 10.1016/j.immuni.2006.04.005; Savage PA, 2014, IMMUNOL REV, V259, P245, DOI 10.1111/imr.12166; Schlauderer F, 2013, ANGEW CHEM INT EDIT, V52, P10384, DOI 10.1002/anie.201304290; Schmidt-Supprian M, 2004, P NATL ACAD SCI USA, V101, P4566, DOI 10.1073/pnas.0400885101; Smigiel KS, 2014, J EXP MED, V211, P121, DOI 10.1084/jem.20131142; SPIESS PJ, 1987, JNCI-J NATL CANCER I, V79, P1067; Spranger S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006504; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Thome M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003004; Vasanthakumar A, 2017, CELL REP, V20, P2906, DOI 10.1016/j.celrep.2017.08.068; Wang YS, 2017, CASE REP INFECT DIS, V2017, P1, DOI 10.1155/2017/7052908; Yu JY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7074; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958	44	103	104	2	91	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 6	2019	570	7759					112	+		10.1038/s41586-019-1215-2	http://dx.doi.org/10.1038/s41586-019-1215-2			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IB3DU	31092922	Green Accepted, Green Submitted			2023-01-03	WOS:000470149000049
J	Han, SY; Ogawa, A; Osada, T; Suda, A; Tanaka, M; Nanjo, H; Shimo, Y; Hattori, N; Konishi, S				Han, Shuyan; Ogawa, Akitoshi; Osada, Takahiro; Suda, Akimitsu; Tanaka, Masaki; Nanjo, Hitoshi; Shimo, Yasushi; Hattori, Nobutaka; Konishi, Seiki			More subjects are required for ventrolateral than dorsolateral prefrontal TMS because of intolerability and potential drop-out	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; THETA-BURST STIMULATION; MEMORY-GUIDED SACCADES; COGNITIVE NEUROSCIENCE; MOTOR THRESHOLD; FRONTAL-CORTEX; SAFETY; DISRUPTION; PERTURBATION; CHRONOMETRY	Transcranial magnetic stimulation (TMS) of the human lateral prefrontal cortex, particularly the ventral region, often causes considerable discomfort to subjects. To date, in contrast to abundant literature on stimulations to the dorsolateral prefrontal cortex, the ventrolateral prefrontal cortex has been less frequently stimulated, partly because some subjects are intolerable of stimulation to the ventrolateral prefrontal cortex. To predict the additional number of subjects required for the stimulation of the dorsolateral and ventrolateral prefrontal cortices, 20 young healthy subjects reported two evaluation scores: the discomfort caused by TMS and the resulting intolerability to complete the TMS experiments. Single-pulse stimulation (SPS) or theta-burst stimulation (TBS) was administered to the lateral prefrontal cortex. The high-resolution extended 10-20 system was used to provide accurate estimation of the voxelwise scores. The discomfort ratings with the SPS and TBS were relatively higher in the ventrolateral prefrontal cortex than those in the dorsolateral prefrontal cortex. Both the SPS and TBS elicited maximal discomfort at the stimulation position F8. The SPS and TBS to F8 under the standard TMS protocols were intolerable for approximately one half (11 and 10, respectively) of the subjects. The intolerability was further calculated for all voxels in the lateral prefrontal cortex, which enabled us to estimate the additional number of subjects required for specific target areas. These results suggest that prior knowledge of subjects' discomfort during stimulation of the lateral prefrontal cortex can be of practical use in the experimental planning of the appropriate number of recruited subjects and provide the database for the probability of intolerability that can be used to predict the additional number of subjects.	[Han, Shuyan; Ogawa, Akitoshi; Osada, Takahiro; Suda, Akimitsu; Tanaka, Masaki; Nanjo, Hitoshi; Konishi, Seiki] Juntendo Univ, Dept Neurophysiol, Sch Med, Tokyo, Japan; [Suda, Akimitsu; Shimo, Yasushi; Hattori, Nobutaka] Juntendo Univ, Dept Neurol, Sch Med, Tokyo, Japan; [Konishi, Seiki] Juntendo Univ, Res Inst Dis Old Age, Sch Med, Tokyo, Japan; [Konishi, Seiki] Juntendo Univ, Sportol Ctr, Sch Med, Tokyo, Japan; [Konishi, Seiki] Juntendo Univ, Adv Res Inst Hlth Sci, Sch Med, Tokyo, Japan	Juntendo University; Juntendo University; Juntendo University; Juntendo University; Juntendo University	Konishi, S (corresponding author), Juntendo Univ, Dept Neurophysiol, Sch Med, Tokyo, Japan.; Konishi, S (corresponding author), Juntendo Univ, Res Inst Dis Old Age, Sch Med, Tokyo, Japan.; Konishi, S (corresponding author), Juntendo Univ, Sportol Ctr, Sch Med, Tokyo, Japan.; Konishi, S (corresponding author), Juntendo Univ, Adv Res Inst Hlth Sci, Sch Med, Tokyo, Japan.	skonishi@juntendo.ac.jp	Ogawa, Akitoshi/AAB-6930-2020; Hattori, Nobutaka/ACR-0069-2022; Ogawa, Akitoshi/D-6287-2011; Osada, Takahiro/GLU-9088-2022	Ogawa, Akitoshi/0000-0003-1247-445X; Osada, Takahiro/0000-0002-3743-3200	JSPS KAKENHI [16K16076]; Takeda Science Foundation	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF))	This work was supported by JSPS KAKENHI to A.O. (grant number 16K16076) and a grant from Takeda Science Foundation to S.K.	Abler B, 2005, BRAIN TOPOGR, V17, P193, DOI 10.1007/s10548-005-6028-y; Anderson BS, 2009, BRAIN STIMUL, V2, P88, DOI 10.1016/j.brs.2008.09.001; Arana AB, 2008, BRAIN STIMUL, V1, P44, DOI 10.1016/j.brs.2007.08.006; Basso D, 2010, NEUROPSYCHOLOGIA, V48, P3282, DOI 10.1016/j.neuropsychologia.2010.07.011; Bilek E, 2013, J NEUROSCI, V33, P7050, DOI 10.1523/JNEUROSCI.3081-12.2013; Borckardt JJ, 2013, BRAIN STIMUL, V6, P925, DOI 10.1016/j.brs.2013.04.009; Cai WD, 2012, J NEUROSCI METH, V204, P238, DOI 10.1016/j.jneumeth.2011.11.020; CHATRIAN GE, 1988, J CLIN NEUROPHYSIOL, V5, P183, DOI 10.1097/00004691-198804000-00005; Chikazoe J, 2009, CEREB CORTEX, V19, P146, DOI 10.1093/cercor/bhn065; Chung SW, 2018, HUM BRAIN MAPP, V39, P783, DOI 10.1002/hbm.23882; D'Ardenne K, 2012, P NATL ACAD SCI USA, V109, P19900, DOI 10.1073/pnas.1116727109; De Dreu CKW, 2016, SOC COGN AFFECT NEUR, V11, P1236, DOI 10.1093/scan/nsw045; Devlin JT, 2003, J COGNITIVE NEUROSCI, V15, P71, DOI 10.1162/089892903321107837; Duecker F, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00210; Duecker F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073813; Duque J, 2012, J NEUROSCI, V32, P806, DOI 10.1523/JNEUROSCI.4299-12.2012; Gogulski J, 2017, CEREB CORTEX, V27, P5343, DOI 10.1093/cercor/bhx219; Gratton C, 2013, FRONT SYST NEUROSCI, V7, DOI 10.3389/fnsys.2013.00124; Grossheinrich N, 2009, BIOL PSYCHIAT, V65, P778, DOI 10.1016/j.biopsych.2008.10.029; Hallett M, 2007, NEURON, V55, P187, DOI 10.1016/j.neuron.2007.06.026; Hartwigsen G, 2013, P NATL ACAD SCI USA, V110, P16402, DOI 10.1073/pnas.1310190110; Hartwright CE, 2016, HUM BRAIN MAPP, V37, P3502, DOI 10.1002/hbm.23255; Herwig U, 2010, NEUROSCI LETT, V471, P30, DOI 10.1016/j.neulet.2010.01.003; Holmes NP, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.01989; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Jimura K, 2014, NEUROSCIENCE, V274, P383, DOI 10.1016/j.neuroscience.2014.05.058; Jurcak V, 2007, NEUROIMAGE, V34, P1600, DOI 10.1016/j.neuroimage.2006.09.024; Kahn I, 2005, J NEUROPHYSIOL, V94, P688, DOI 10.1152/jn.01335.2004; Loo CK, 2008, INT J NEUROPSYCHOPH, V11, P131, DOI 10.1017/S1461145707007717; Machii K, 2006, CLIN NEUROPHYSIOL, V117, P455, DOI 10.1016/j.clinph.2005.10.014; Maizey L, 2013, CLIN NEUROPHYSIOL, V124, P536, DOI 10.1016/j.clinph.2012.07.024; Meteyard L, 2018, J NEUROSCI METH, V299, P34, DOI 10.1016/j.jneumeth.2018.02.008; Miyashita Y., 2016, JUNTENDO MED J, V62, P6; Morishima Y, 2009, NAT NEUROSCI, V12, P85, DOI 10.1038/nn.2237; Mottaghy FM, 2003, NEUROIMAGE, V18, P565, DOI 10.1016/S1053-8119(03)00010-7; Mull BR, 2001, CLIN NEUROPHYSIOL, V112, P1672, DOI 10.1016/S1388-2457(01)00606-X; Muri RM, 2000, NEUROPSYCHOLOGIA, V38, P1105, DOI 10.1016/S0028-3932(00)00030-0; Narayana S, 2015, J CHILD NEUROL, V30, P1111, DOI 10.1177/0883073814553274; Nyffeler T, 2004, EXP BRAIN RES, V154, P109, DOI 10.1007/s00221-003-1663-6; Oberman L, 2011, J CLIN NEUROPHYSIOL, V28, P67, DOI 10.1097/WNP.0b013e318205135f; Osada T, 2019, J NEUROSCI, V39, P2509, DOI 10.1523/JNEUROSCI.2244-18.2019; Ott DVM, 2011, NEUROIMAGE, V57, P617, DOI 10.1016/j.neuroimage.2011.04.038; Parkin BL, 2015, NEURON, V87, P932, DOI 10.1016/j.neuron.2015.07.032; Pascual-Leone A, 2000, CURR OPIN NEUROBIOL, V10, P232, DOI 10.1016/S0959-4388(00)00081-7; Paus T, 2005, PHILOS T R SOC B, V360, P1109, DOI 10.1098/rstb.2005.1652; Peterchev AV, 2017, BRAIN STIMUL, V10, P99, DOI 10.1016/j.brs.2016.09.007; Poreisz C, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-54; Rahnev D, 2016, P NATL ACAD SCI USA, V113, P6059, DOI 10.1073/pnas.1522551113; Ro T, 1997, J COGNITIVE NEUROSCI, V9, P433, DOI 10.1162/jocn.1997.9.4.433; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Rossini PM, 2015, CLIN NEUROPHYSIOL, V126, P1071, DOI 10.1016/j.clinph.2015.02.001; Sagliano L, 2016, SOC COGN AFFECT NEUR, V11, P1992, DOI 10.1093/scan/nsw105; Schabrun SM, 2018, PAIN MED, V19, P608, DOI 10.1093/pm/pnx099; Simmons JP, 2011, PSYCHOL SCI, V22, P1359, DOI 10.1177/0956797611417632; Smalle EHM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14547-x; Smittenaar P, 2013, NEURON, V80, P914, DOI 10.1016/j.neuron.2013.08.009; Stokes MG, 2007, CLIN NEUROPHYSIOL, V118, P1617, DOI 10.1016/j.clinph.2007.04.004; Stokes MG, 2005, J NEUROPHYSIOL, V94, P4520, DOI 10.1152/jn.00067.2005; Suppa A, 2016, BRAIN STIMUL, V9, P323, DOI 10.1016/j.brs.2016.01.006; Tame L, 2016, NEUROIMAGE, V138, P184, DOI 10.1016/j.neuroimage.2016.05.056; Tarapore PE, 2016, CLIN NEUROPHYSIOL, V127, P1895, DOI 10.1016/j.clinph.2015.11.042; Thapa T, 2018, NEURAL PLAST, V2018, DOI 10.1155/2018/6207508; Thapa T, 2018, CLIN NEUROPHYSIOL, V129, P1090, DOI 10.1016/j.clinph.2018.01.060; Ubaldi S, 2015, CEREB CORTEX, V25, P1032, DOI 10.1093/cercor/bht295; Ueno T, 2018, CEREB CORTEX, V28, P3035, DOI 10.1093/cercor/bhy131; Verbruggen F, 2010, P NATL ACAD SCI USA, V107, P13966, DOI 10.1073/pnas.1001957107; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Watanabe T, 2015, J NEUROSCI, V35, P4813, DOI 10.1523/JNEUROSCI.3761-14.2015; Watanabe T, 2014, HUM BRAIN MAPP, V35, P1896, DOI 10.1002/hbm.22300; Yamasaki T, 2018, FRONT HUM NEUROSCI, V12, DOI 10.3389/fnhum.2018.00208; Yi X, 2014, EXP BRAIN RES, V232, P545, DOI 10.1007/s00221-013-3763-2; Zhao D, 2018, CEREB CORTEX, V28, P3468, DOI 10.1093/cercor/bhx213	72	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2019	14	6							e0217826	10.1371/journal.pone.0217826	http://dx.doi.org/10.1371/journal.pone.0217826			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IA9ZE	31158248	gold, Green Submitted, Green Published			2023-01-03	WOS:000469915700028
J	Krebs, E; Enns, B; Wang, L; Zang, X; Panagiotoglou, D; Rio, C; Dombrowski, J; Feaster, DJ; Golden, M; Granich, R; Marshall, B; Mehta, SH; Metsch, L; Schackman, BR; Strathdee, SA; Nosyk, B; Gebo, K; Kerr, T; Kirk, G; Montaner, J; Shoptaw, S; Small, W				Krebs, Emanuel; Enns, Benjamin; Wang, Linwei; Zang, Xiao; Panagiotoglou, Dimitra; Del Rio, Carlos; Dombrowski, Julia; Feaster, Daniel J.; Golden, Matthew; Granich, Reuben; Marshall, Brandon; Mehta, Shruti H.; Metsch, Lisa; Schackman, Bruce R.; Strathdee, Steffanie A.; Nosyk, Bohdan; Gebo, Kelly; Kerr, Thomas; Kirk, Gregory; Montaner, Julio; Shoptaw, Steven; Small, William		Localized HIV Modeling Study Grp	Developing a dynamic HIV transmission model for 6 US cities: An evidence synthesis	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DECISION-ANALYTIC MODELS; HEALTH STATE UTILITIES; INJECTING DRUG-USERS; PLASMA VIRAL LOAD; QUALITY-OF-LIFE; ANTIRETROVIRAL THERAPY; COST-EFFECTIVENESS; HETEROSEXUAL TRANSMISSION; ECONOMIC EVALUATIONS	Background Dynamic HIV transmission models can provide evidence-based guidance on optimal combination implementation strategies to treat and prevent HIV/AIDS. However, these models can be extremely data intensive, and the availability of good-quality data characterizing regional microepidemics varies substantially within and across countries. We aim to provide a comprehensive and transparent description of an evidence synthesis process and reporting framework employed to populate and calibrate a dynamic, compartmental HIV transmission model for six US cities. Methods We executed a mixed-method evidence synthesis strategy to populate model parameters in six categories: (i) initial HIV-negative and HIV-infected populations; (ii) parameters used to calculate the probability of HIV transmission; (iii) screening, diagnosis, treatment and HIV disease progression; (iv) HIV prevention programs; (v) the costs of medical care; and (vi) health utility weights for each stage of HIV disease progression. We identified parameters that required city-specific data and stratification by gender, risk group and race/ethnicity a priori and sought out databases for primary analysis to augment our evidence synthesis. We ranked the quality of each parameter using context- and domain-specific criteria and verified sources and assumptions with our scientific advisory committee. Findings To inform the 1,667 parameters needed to populate our model, we synthesized evidence from 59 peer-reviewed publications and 24 public health and surveillance reports and executed primary analyses using 11 data sets. Of these 1,667 parameters, 1,517 (91%) were city-specific and 150 (9%) were common for all cities. Notably, 1,074 (64%), 201 (12%) and 312 (19%) parameters corresponded to categories (i), (ii) and (iii), respectively. Parameters ranked as best-to moderate-quality evidence comprised 39% of the common parameters and ranged from 56%-60% across cities for the city-specific parameters. We identified variation in parameter values across cities as well as within cities across risk and race/ethnic groups. Conclusions Better integration of modelling in decision making can be achieved by systematically reporting on the evidence synthesis process that is used to populate models, and by explicitly assessing the quality of data entered into the model. The effective communication of this process can help prioritize data collection of the most informative components of local HIV prevention and care services in order to reduce decision uncertainty and strengthen model conclusions.	[Krebs, Emanuel; Enns, Benjamin; Wang, Linwei; Zang, Xiao; Panagiotoglou, Dimitra; Nosyk, Bohdan] British Columbia Ctr Excellence HIV AIDS, Hlth Econ Res Unit, Vancouver, BC, Canada; [Zang, Xiao; Nosyk, Bohdan; Small, William] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC, Canada; [Del Rio, Carlos] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Emory Ctr AIDS Res, Atlanta, GA 30322 USA; [Dombrowski, Julia; Golden, Matthew] Univ Washington, Dept Med, Div Allergy & Infect Dis Adjunct Epidemiol, Seattle, WA USA; [Feaster, Daniel J.] Univ Miami, Ctr Family Studies, Leonard M Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL USA; [Granich, Reuben] Int Assoc Providers AIDS Care, Washington, DC USA; [Marshall, Brandon] Brown Sch Publ Hlth, Dept Epidemiol, Providence, RI USA; [Mehta, Shruti H.; Gebo, Kelly; Kirk, Gregory] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Metsch, Lisa] Columbia Univ, Mailman Sch Publ Hlth, Dept Sociomed Sci, New York, NY USA; [Schackman, Bruce R.] Weill Cornell Med Coll, Dept Healthcare Policy & Res, New York, NY USA; [Strathdee, Steffanie A.] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA; [Del Rio, Carlos] Emory Univ, Rollins Sch Publ Hlth, Emory Ctr AIDS Res, Hubert Dept Global Hlth, Atlanta, GA 30322 USA; [Kerr, Thomas] British Columbia Ctr Substance Use, Vancouver, BC, Canada; [Kerr, Thomas; Montaner, Julio] Univ British Columbia, Fac Med, Vancouver, BC, Canada; [Nosyk, Bohdan; Montaner, Julio; Small, William] BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada; [Shoptaw, Steven] Univ Calif Los Angeles, Sch Med, Ctr HIV Identificat Prevent & Treatment Serv, Los Angeles, CA 90024 USA	B.C. Centre for Excellence in HIV/AIDS; Simon Fraser University; Emory University; Rollins School Public Health; University of Washington; University of Washington Seattle; University of Miami; Brown University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Columbia University; Cornell University; University of California System; University of California San Diego; Emory University; Rollins School Public Health; University of British Columbia; B.C. Centre for Excellence in HIV/AIDS; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Nosyk, B (corresponding author), British Columbia Ctr Excellence HIV AIDS, Hlth Econ Res Unit, Vancouver, BC, Canada.; Nosyk, B (corresponding author), Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC, Canada.	bnosyk@cfenet.ubc.ca	Enns, Benjamin/GYU-3276-2022; Gebo, Kelly/AHA-7533-2022; Golden, Matthew/AAE-4314-2020; Strathdee, Steffanie A/B-9042-2009	Enns, Benjamin/0000-0002-4865-1510; Gebo, Kelly/0000-0003-4010-398X; Krebs, Emanuel/0000-0002-6590-8728	National Institutes on Drug Abuse (NIDA) [R01-DA041747]; NIDA [DA12568, DA036297]; Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV [P30DA040500]; NIDA Method to Extend Research in Time (MERIT) award [R37-DA019829]; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA019829, R01DA041747, P30DA040500] Funding Source: NIH RePORTER	National Institutes on Drug Abuse (NIDA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV; NIDA Method to Extend Research in Time (MERIT) award; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This study was funded by the National Institutes on Drug Abuse (NIDA), grant no. R01-DA041747 (BN), and received additional support from NIDA grants DA12568 and DA036297. BRS received additional support from the Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (P30DA040500). SAS is supported by a NIDA Method to Extend Research in Time (MERIT) award (R37-DA019829). The funders had no direct role in the conduct of the analysis or the decision to submit the manuscript. NIDA - https://www.drugabuse.gov/. CHERISH - https://cherishresearch.org/.	Administration. DoHaMHVS, 2010, MAR VIT STAT ANN REP; Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006; Anderson SJ, 2014, LANCET, V384, P249, DOI 10.1016/S0140-6736(14)61053-9; [Anonymous], 2017, GEORGIA HLTH NEWS; [Anonymous], 2019, HIV SURVEILL REP SPE; [Anonymous], 2018, HIV SURV REP 2017; Attia S, 2009, AIDS, V23, P1397, DOI 10.1097/QAD.0b013e32832b7dca; Baggaley RF, 2013, EPIDEMIOLOGY, V24, P110, DOI 10.1097/EDE.0b013e318276cad7; Baggaley RF, 2010, INT J EPIDEMIOL, V39, P1048, DOI 10.1093/ije/dyq057; Baggaley RF, 2006, AIDS, V20, P805, DOI 10.1097/01.aids.0000218543.46963.6d; Baser O, 2011, AM J MANAG CARE, V17, pS6; Bellan SE, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001801; Bernard CL, 2016, ANN INTERN MED, V26, pM15; Blair JM, 2014, BEHAV CLIN CHARACTER; Boily MC, 2009, LANCET INFECT DIS, V9, P118, DOI 10.1016/S1473-3099(09)70021-0; Briggs AH, 2012, MED DECIS MAKING, V32, P722, DOI 10.1177/0272989X12458348; CACERES CF, 1994, AIDS, V8, P1051, DOI 10.1097/00002030-199408000-00004; Center for HIV Surveillance-Epidemiology and Evaluation-Department of Health and Mental Hygiene-Baltimore-MD, 2015, BALT CIT ANN HIV EP; Centers for Disease Control and Prevention, 2014, PUBL US DAT FIL DOC; Centers for Disease Control and Prevention, 2021, HIV SURVEILLANCE SUP; Centers for Disease Control and Prevention, 2015, 11 CDCP; Centers for Disease Control and Prevention, 2014, PREEXP PROPH PREV HI; Centers for Disease Control and Prevention, 2015, SYR SERV PROGR PERS; Centers for Disease Control and Prevention, 2014, 15 CDCP; Centers for Disease Control and Prevention, 2013, 13 CDCP; Centers for Disease Control and Prevention (CDC), 2014, BEH RISK FACT SURV S; Centers for Medicare and Medicaid Services, 2017, CLIN LAB FEE SCHED; Centers for Medicare and Medicaid Services, 2017, PHYS FEE SCHED SEARC; Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7; City of Baltimore, 2016, BALT CIT SYR EXCH PR; Claxton K, 2002, LANCET, V360, P711, DOI 10.1016/S0140-6736(02)09832-X; Claxton K, 1999, J HEALTH ECON, V18, P341, DOI 10.1016/S0167-6296(98)00039-3; Cleary S, 2009, HEALTH ECON, V19, P1166; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Cooper NJ, 2007, HEALTH ECON, V16, P1277, DOI 10.1002/hec.1297; Cooper Nicola, 2005, J Health Serv Res Policy, V10, P245, DOI 10.1258/135581905774414187; County of Los Angeles, 2011, 2010 ANN HIV SURV RE; Critchlow S, 2017, J MED ECON, V20, P129, DOI 10.1080/13696998.2016.1229671; Cuadros DF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09464-y; DEGRUTTOLA V, 1989, J CLIN EPIDEMIOL, V42, P849, DOI 10.1016/0895-4356(89)90098-X; Delva W, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001239; DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601; Dombrowski JC, 2014, JAIDS-J ACQ IMM DEF, V67, P323, DOI 10.1097/QAI.0000000000000302; Downs AM, 1996, J ACQ IMMUN DEF SYND, V11, P388, DOI 10.1097/00042560-199604010-00010; Eddy DM, 2012, MED DECIS MAKING, V32, P733, DOI 10.1177/0272989X12454579; Emanuel EJ, 2016, JAMA-J AM MED ASSOC, V316, P2604, DOI 10.1001/jama.2016.16739; Enns B, 2019, AIDS, V3; Evans E, 2015, ADDICTION, V110, P996, DOI 10.1111/add.12863; Florida Department of Health, 2018, ALL CAUS CRUD DEATH; Florida Department of Health, 2016, HIV SURV MIAM FL2015; Frieden TR, 2017, NEW ENGL J MED, V377, P465, DOI 10.1056/NEJMra1614394; Fujimoto K, 2015, AM J PUBLIC HEALTH, V105, P1128, DOI 10.2105/AJPH.2014.302474; Gaines TL, 2016, AIDS CARE, V28, P554, DOI 10.1080/09540121.2015.1131968; Ganz ML, 2015, J MED ECON, V18, P366, DOI 10.3111/13696998.2014.1001848; Garnett GP, 2011, LANCET, V378, P515, DOI 10.1016/S0140-6736(10)61505-X; Garrison LP, 2007, VALUE HEALTH, V10, P326, DOI 10.1111/j.1524-4733.2007.00186.x; Georgia Department of Public Health, 2018, AG ADJ DEATH RAT 201; Georgia Department of Public Health. HIV, 2014, HIV AIDS EP PROGR HI; Goodreau SM, 2017, LANCET HIV, V4, pE311, DOI 10.1016/S2352-3018(17)30067-X; Granich RM, 2009, LANCET, V373, P1080, DOI 10.1016/S0140-6736(09)60648-6; GRANT RM, 1987, J INFECT DIS, V156, P189, DOI 10.1093/infdis/156.1.189; Greenberg AE, 2015, JAIDS-J ACQ IMM DEF, V69, pS1, DOI 10.1097/QAI.0000000000000569; Greenhalgh T, 2005, BRIT MED J, V331, P1064, DOI 10.1136/bmj.38636.593461.68; Grey Jeremy A, 2016, JMIR Public Health Surveill, V2, pe14, DOI 10.2196/publichealth.5365; Hall HI, 2015, MMWR-MORBID MORTAL W, V64, P657; Hansen HB, 2013, J BEHAV HEALTH SER R, V40, P367, DOI 10.1007/s11414-013-9341-3; Holtgrave DR, 1997, J ACQ IMMUN DEF SYND, V16, P54, DOI 10.1097/00042560-199709010-00009; Honiden S, 2006, QUAL LIFE RES, V15, P69, DOI 10.1007/s11136-005-8485-x; Hudgens MG, 2002, AM J EPIDEMIOL, V155, P159, DOI 10.1093/aje/155.2.159; Husereau D, 2013, VALUE HEALTH, V16, pE1, DOI 10.1016/j.jval.2013.02.010; Jit M, 2014, LANCET GLOB HEALTH, V2, pE406, DOI 10.1016/S2214-109X(14)70237-2; Jones A, 2014, LANCET, V384, P272, DOI 10.1016/S0140-6736(13)62230-8; Joyce VR, 2009, JAIDS-J ACQ IMM DEF, V50, P27, DOI 10.1097/QAI.0b013e31818ce6f3; KAPLAN EH, 1990, J ACQ IMMUN DEF SYND, V3, P55; KAPLAN EH, 1992, J ACQ IMMUN DEF SYND, V5, P1116; Karnon J, 2011, PHARMACOECONOMICS, V29, P51, DOI 10.2165/11584610-000000000-00000; Kato M, 2013, JAIDS-J ACQ IMM DEF, V63, pE142, DOI 10.1097/QAI.0b013e31829b535b; Katz IT, 2017, LANCET HIV, V4, pE324, DOI 10.1016/S2352-3018(17)30086-3; Kauf TL, 2008, VALUE HEALTH, V11, P1144, DOI 10.1111/j.1524-4733.2008.00326.x; Leynaert B, 1998, AM J EPIDEMIOL, V148, P88, DOI 10.1093/oxfordjournals.aje.a009564; Liu AY, 2016, JAMA INTERN MED, V176, P75, DOI 10.1001/jamainternmed.2015.4683; Long EF, 2006, AIDS, V20, P2207, DOI 10.1097/QAD.0b013e328010c7d0; Long EF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095735; Long EF, 2010, ANN INTERN MED, V153, P778, DOI 10.7326/0003-4819-153-12-201012210-00004; Los Angeles County Department of Public Health, 2013, MORT LOS ANG COUNT 2; Low AJ, 2016, CLIN INFECT DIS, V63, P1094, DOI 10.1093/cid/ciw416; MacArthur GJ, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5945; Mangal TD, 2017, AIDS, V31, P1073, DOI 10.1097/QAD.0000000000001437; Marks G, 2005, JAIDS-J ACQ IMM DEF, V39, P446, DOI 10.1097/01.qai.0000151079.33935.79; Marmor M, 2001, J ACQ IMMUN DEF SYND, V27, P472, DOI 10.1097/00126334-200108150-00009; McCollister K, 2017, J SUBST ABUSE TREAT, V81, P25, DOI 10.1016/j.jsat.2017.07.008; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Metsch LR, 2013, JAMA-J AM MED ASSOC, V310, P1701, DOI 10.1001/jama.2013.280034; Mugavero MJ, 2013, CLIN INFECT DIS, V57, P1164, DOI 10.1093/cid/cit420; Nachega JB, 2014, CLIN INFECT DIS, V59, pS21, DOI 10.1093/cid/ciu299; Neumann P. J., 2016, Cost-effectiveness in health and medicine; New York City Department of Health and Mental Hygiene, 2011, NEW YORK CIT HIV AID; New York City Department of Health and Mental Hygiene, 2011, SUMM VIT STAT 2010 C; New York State Department of Health AIDS Institute, 2014, COMPR HARM RED REV T; NICOLOSI A, 1994, EPIDEMIOLOGY, V5, P570, DOI 10.1097/00001648-199411000-00003; Nosyk B, 2015, DRUG ALCOHOL DEPEN, V146, pe53, DOI DOI 10.1016/J.DRUGALCDEP.2014.09.516; Nosyk B, 2015, LANCET HIV, V2; Nosyk B, 2018, CLIN INFECT DIS, V66, P765, DOI 10.1093/cid/cix832; Nosyk B, 2017, LANCET HIV, V4, pE303, DOI 10.1016/S2352-3018(17)30045-0; Nosyk B, 2015, LANCET HIV, V2, pE393, DOI 10.1016/S2352-3018(15)00127-7; OBRIEN TR, 1994, J ACQ IMMUN DEF SYND, V7, P705; Oxford Centre for Evidence-Based Medicine, 2009, LEVELS EVIDENCE; Padian NS, 1997, AM J EPIDEMIOL, V146, P350, DOI 10.1093/oxfordjournals.aje.a009276; Paisley S, 2016, PHARMACOECONOMICS, V34, P597, DOI 10.1007/s40273-015-0372-x; Paisley S, 2010, INT J TECHNOL ASSESS, V26, P458, DOI 10.1017/S026646231000098X; Panagiotoglou D, 2017, AIDS BEHAV; Patel P, 2014, AIDS, V28, P1509, DOI 10.1097/QAD.0000000000000298; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; Powers KA, 2008, LANCET INFECT DIS, V8, P553, DOI 10.1016/S1473-3099(08)70156-7; Praditsitthikorn N, 2013, INFLUENZA OTHER RESP, V7, P59, DOI 10.1111/irv.12091; Public Health-Seattle and King County, HIV AIDS ANN Q REP 2; Public Health-Seattle & King County, 2017, HIV STD PROGR 2017; Raymond HF, 2009, AIDS BEHAV, V13, P630, DOI 10.1007/s10461-009-9574-6; Rebeiro PF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146119; Rodger A, 2014, 21 C RETR OPP INF 3; Rodger AJ, 2016, JAMA-J AM MED ASSOC, V316, P171, DOI 10.1001/jama.2016.5148; Saloner B, 2017, MED CARE, V55, P669, DOI 10.1097/MLR.0000000000000727; SAMHSA, 2017, NUMB DATA CERT PHYS; Sanders GD, 2005, NEW ENGL J MED, V352, P570, DOI 10.1056/NEJMsa042657; Sanders GD, 2016, JAMA-J AM MED ASSOC, V316, P1093, DOI 10.1001/jama.2016.12195; Schackman BR, 2002, MED DECIS MAKING, V22, P27, DOI 10.1177/02729890222062892; Schiller-Fruthwirth IC, 2017, APPL HEALTH ECON HEA, V15, P333, DOI 10.1007/s40258-017-0312-3; Shepherd K, 2015, NATURE, V523, P152, DOI 10.1038/523152a; Shiboski SC, 1998, J ACQ IMMUN DEF SYND, V19, P527, DOI 10.1097/00042560-199812150-00013; Smith DK, 2015, JAIDS-J ACQ IMM DEF, V68, P337, DOI 10.1097/QAI.0000000000000461; Song DL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116694; Song RG, 2017, JAIDS-J ACQ IMM DEF, V74, P3, DOI 10.1097/QAI.0000000000001151; Substance Abuse and Mental Health Services Administration, 2020, TREATM EP DAT SET TE; Suen Sze-Chuan, 2017, J Theor Biol, V428, P1, DOI 10.1016/j.jtbi.2017.06.004; Sutton AJ, 2012, EPIDEMICS-NETH, V4, P48, DOI 10.1016/j.epidem.2011.12.001; Taylor DCA, 2010, PHARMACOECONOMICS, V28, P995, DOI 10.2165/11538660-000000000-00000; Tempalski B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064789; Tengs TO, 2002, MED DECIS MAKING, V22, P475, DOI 10.1177/0272989X02238300; Timko C, 2016, J ADDICT DIS, V35, P22, DOI 10.1080/10550887.2016.1100960; Tookes H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129360; Truven Health Analytics, 2018, RED BOOK AV WHOL PRI; Hoang VP, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1368-8; Vlahov D, 1998, JAMA-J AM MED ASSOC, V279, P35, DOI 10.1001/jama.279.1.35; VLAHOV D, 1991, J DRUG ISSUES, V21, P759, DOI 10.1177/002204269102100406; Wand H, 2011, INT J HEALTH GEOGR, V10, DOI 10.1186/1476-072X-10-28; Wang L, 2019, LANCET HIV; Washington State Department of Health, 2011, AG ADJ MORT RAT; Weller S, 2002, Cochrane Database Syst Rev, pCD003255; Wiseman V, 2016, HEALTH ECON, V25, P140, DOI 10.1002/hec.3299; World Health Organization, 2011, PREVENTION TREATMENT; Zang X, 2019, DEV CALIBRATIO UNPUB; Zang X, 2019, STRUCTURAL DESIGN DA; Zechmeister-Koss I, 2014, MED DECIS MAKING, V34, P288, DOI 10.1177/0272989X13509406	153	24	24	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2019	14	5							e0217559	10.1371/journal.pone.0217559	http://dx.doi.org/10.1371/journal.pone.0217559			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IA2XG	31145752	Green Published, gold, Green Submitted			2023-01-03	WOS:000469425500022
J	Pinilla, J; Rodriguez-Caro, A				Pinilla, Jaime; Rodriguez-Caro, Alejandro			Differences in healthcare utilisation between users and non-users of homeopathic products in Spain: Results from three waves of the National Health Survey (2011-2017)	PLOS ONE			English	Article							PROPENSITY SCORE; COMPLEMENTARY; MEDICINE; EUROPE	Objective To compare the differences in the use of healthcare services: visits to the doctor and hospitalisation, performance of routine tests, and preventive influenza vaccination, between users and non-users of homeopathic products. Methods We used the microdata for adults over 15 years old from three waves of the Spanish National Health Survey, corresponding to the years 2011, 2014 and 2017. We proposed a comparative design of a quasi-experimental type, considering as the treatment group the respondents who said that they had used homeopathic products in the past two weeks; and another group, for control, comprising respondents who said that they had not used this type of products, but only conventional medicines, with observable characteristics similar to those of the treatment group. We used a model for rare events logistics regression (relogit) to estimate the probability of using homeopathy. From the propensity score and a vector of control variables, we used techniques of genetic matching to match individuals from the treatment group with similar individuals belonging to the control group. Results There are no statistically significant differences between users and non-users of homeopathy in visits to the general practitioner (P>vertical bar z vertical bar 0.387), to the specialist (P>vertical bar z vertical bar 0.52), in hospitalisations (P>vertical bar z vertical bar 0.592) or in the use of emergency services (P>vertical bar z vertical bar 0.109). Nor were there any statistically significant differences in the performance of routine tests, except for the faecal occult blood test, which is more prevalent in users of homeopathic products. 20.9% of users of homeopathy had done this test compared with 15.3% of non-users (P>vertical bar z vertical bar 0.022). There are also significant differences in vaccination against influenza with 12.6% of homeopathy users stating that they had been vaccinated in the last influenza campaign, against 21.0% of non-users (P>vertical bar z vertical bar <0.001). The health conditions which homeopathy users reported were constipation (OR: 1.65 CI: 1.16-2.36), malignant tumour (OR: 1.60 CI: 1.09-2.36) osteoporosis (OR: 1.49 CI: 1.05-2.10), varicose veins (OR: 1.35 CI: 1.05-1.74) and allergy (OR: 1.35 CI: 1.06-1.72). Conclusions Differences in the use of healthcare resources between users and non-users of homeopathic products have not been found to be statistically significant in Spain. It has been shown that most homeopathic products are used as a complement to treatment with conventional medicine. Nevertheless, our results highlight some warning signs which should raise the attention of healthcare authorities. The use of these therapies in patients with malignant tumours and the rejection of vaccines are warning signs of a possible health hazard in the long term.	[Pinilla, Jaime; Rodriguez-Caro, Alejandro] Univ Las Palmas Gran Canaria, Dept Quantitat Methods, Las Palmas Gran Canaria, Spain; [Pinilla, Jaime] Univ Pompeu Fabra, Ctr Res Hlth & Econ, Barcelona, Spain	Universidad de Las Palmas de Gran Canaria; Pompeu Fabra University	Rodriguez-Caro, A (corresponding author), Univ Las Palmas Gran Canaria, Dept Quantitat Methods, Las Palmas Gran Canaria, Spain.	alejandro.rodriguez@ulpgc.es	Pinilla, Jaime/F-8132-2016	Pinilla, Jaime/0000-0002-7126-4236; Rodriguez-Caro, Alejandro/0000-0002-8080-3094	'National Programme for Research, Development and Innovation to Address the Challenges of Society: National Plan for Scientific Research and Technical Innovation' - Ministry of Economy and Competitiveness of Spain [ECO2017-83771-C3-2-R]	'National Programme for Research, Development and Innovation to Address the Challenges of Society: National Plan for Scientific Research and Technical Innovation' - Ministry of Economy and Competitiveness of Spain	This paper forms part of the research funded by Grant ECO2017-83771-C3-2-R under the 'National Programme for Research, Development and Innovation to Address the Challenges of Society: National Plan for Scientific Research and Technical Innovation 2017-2020' funded by the Ministry of Economy and Competitiveness of Spain. Funder does not play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2015, NHMRC STAT EV WIND H; Austin PC, 2018, STAT METHODS MED RES, V27, P1240, DOI 10.1177/0962280216658920; Bleser WK, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4664; Cepeda MS, 2003, AM J EPIDEMIOL, V158, P280, DOI 10.1093/aje/kwg115; Diamond A, 2013, REV ECON STAT, V95, P932, DOI 10.1162/REST_a_00318; Dossett ML, 2016, AM J PUBLIC HEALTH, V106, P743, DOI 10.2105/AJPH.2015.303025; Eardley S, 2012, FORSCH KOMPLEMENTMED, V19, P18, DOI 10.1159/000342708; European Academies' Science Advisory Council, HOM PROD PRACT ASS E; Gale N, 2014, SOCIOL COMPASS, V8, P805, DOI 10.1111/soc4.12182; House of Commons Science and Technology Committee, 2010, EV CHECK 2 HOM 4 REP; HS Clinical Commissioners NE, 2017, IT WHICH SHOULD NOT; Huijts T, 2017, EUR J PUBLIC HEALTH, V27, P55, DOI 10.1093/eurpub/ckw231; Johnson SB, 2018, JAMA ONCOL, V4, P1375, DOI 10.1001/jamaoncol.2018.2487; Kemppainen LM, 2018, SCAND J PUBLIC HEALT, V46, P448, DOI 10.1177/1403494817733869; KING G, 2001, POLITICAL ANAL, V0009; Lewith GT, 2002, COMPLEMENT THER MED, V10, P100, DOI 10.1054/ctim.2002.0525; Lindea K, 2015, FAM PRACT, V32, P62, DOI 10.1093/fampra/cmu071; MacArtney JI, 2014, QUAL HEALTH RES, V24, P114, DOI 10.1177/1049732313518977; Menniti-Ippolito F, 2002, EUR J CLIN PHARMACOL, V58, P61, DOI 10.1007/s00228-002-0435-8; Organizacion Medica Colegial de Codigo de deontologia medica, 2011, GUIA ET MED; Ridgeway G, 2015, J CAUSAL INFERENCE, V3, P237, DOI 10.1515/jci-2014-0039; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Rubin DB, 2000, J AM STAT ASSOC, V95, P573, DOI 10.2307/2669400; Schiffman L. G., 1994, CONSUMER BEHAV; Sekhon S, 2018, PACKAGE MATCHING MUL; Stryker S, 2007, J PERS, V75, P1083, DOI 10.1111/j.1467-6494.2007.00468.x; von Ammon K, 2012, FORSCH KOMPLEMENTMED, V19, P37, DOI 10.1159/000343129; White AR, 1997, FAM PRACT, V14, P302, DOI 10.1093/fampra/14.4.302	28	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2019	14	5							e0216707	10.1371/journal.pone.0216707	http://dx.doi.org/10.1371/journal.pone.0216707			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HX9GC	31083699	Green Published, gold, Green Submitted			2023-01-03	WOS:000467714000034
J	Woods, JA; Newton, JC; Thompson, SC; Malacova, E; Ngo, HT; Katzenellenbogen, JM; Murray, K; Shahid, S; Johnson, CE				Woods, John A.; Newton, Jade C.; Thompson, Sandra C.; Malacova, Eva; Ngo, Hanh T.; Katzenellenbogen, Judith M.; Murray, Kevin; Shahid, Shaouli; Johnson, Claire E.			Indigenous compared with non-Indigenous Australian patients at entry to specialist palliative care: Cross-sectional findings from a multi-jurisdictional dataset	PLOS ONE			English	Article							ABORIGINAL PEOPLE; ACCEPTABILITY; RELIABILITY; QUALITY	Background There are few quantitative studies on palliative care provision to Indigenous Australians, a population known to experience distinctive barriers to quality healthcare and to have poorer health outcomes than other Australians. Objectives To investigate equity of specialist palliative care service provision through characterising and comparing Indigenous and non-Indigenous patients at entry to care. Methods Using data (01/01/2010-30/06/2015) from all services participating in the multi-jurisdictional Palliative Care Outcomes Collaboration, Indigenous and non-Indigenous patients entering palliative care were compared on proportions vis-a-vis those expected from national statutory datasets, demographic characteristics, and entry-to-care status across fourteen 'problem' domains (e.g., pain, functional impairment) after matching by age, sex, and specific diagnosis. Results Of 140,267 patients, 1,465 (1.0%, much lower than expected from statutory data) were Indigenous, 133,987 (95.5%) non-Indigenous, and 4,905 (3.5%) had a missing identifier. The proportion of patients with a missing identifier diminished markedly over the study period, without a corresponding increase in the proportion identified as Indigenous. Indigenous compared with non-Indigenous patients were younger (mean 62.8 versus 73.0 years, p<0.001), a higher proportion were female (51.5% versus 46.3%; p<0.001) or resided outside major cities (44.2% versus 21.5%, p<0.001). Across all domains, Indigenous compared with matched non-Indigenous patients had lower or equal risk of status requiring prompt intervention. Conclusions Indigenous patients (especially those residing outside major cities) are substantially under-represented in care by services participating in the nationwide specialist palliative care Collaboration, likely reflecting widespread access barriers. However, the similarity of status indicators among Indigenous and non-Indigenous patients at entry to care suggests that Indigenous patients who are able to access these services do not disproportionately experience clinically important impediments to care initiation.	[Woods, John A.; Thompson, Sandra C.] Univ Western Australia, Sch Populat & Global Hlth, Western Australian Ctr Rural Hlth, Nedlands, WA, Australia; [Newton, Jade C.; Johnson, Claire E.] Univ Western Australia, Sch Med, Canc & Palliat Care Res & Evaluat Unit, Nedlands, WA, Australia; [Newton, Jade C.] Curtin Univ, Sch Nursing Midwifery & Paramed, Bentley, WA, Australia; [Malacova, Eva] Curtin Univ, Sch Publ Hlth, Bentley, WA, Australia; [Malacova, Eva; Katzenellenbogen, Judith M.; Murray, Kevin] Univ Western Australia, Sch Populat & Global Hlth, Nedlands, WA, Australia; [Ngo, Hanh T.] Univ Western Australia, Rural Clin Sch, Nedlands, WA, Australia; [Ngo, Hanh T.] Univ Western Australia, Sch Med, Discipline Emergency Med, Nedlands, WA, Australia; [Katzenellenbogen, Judith M.] Univ Western Australia, Telethon Kids Inst, Nedlands, WA, Australia; [Shahid, Shaouli] Curtin Univ, Ctr Aboriginal Studies, Bentley, WA, Australia; [Johnson, Claire E.] Monash Univ, Nursing & Midwifery, Clayton, Vic, Australia; [Johnson, Claire E.] Eastern Hlth, Box Hill, Vic, Australia; [Malacova, Eva] QIMR Berghofer Med Res Inst, Stat Unit, Herston, Qld, Australia	University of Western Australia; University of Western Australia; Curtin University; Curtin University; University of Western Australia; University of Western Australia; University of Western Australia; Telethon Kids Institute; University of Western Australia; Curtin University; Monash University; QIMR Berghofer Medical Research Institute	Woods, JA (corresponding author), Univ Western Australia, Sch Populat & Global Hlth, Western Australian Ctr Rural Hlth, Nedlands, WA, Australia.	john.woods@uwa.edu.au	Johnson, Claire/H-5145-2014; Murray, Kevin/H-5503-2014; Thompson, Sandra/H-5955-2014; Woods, John/C-6541-2013	Johnson, Claire/0000-0001-9190-8441; Murray, Kevin/0000-0002-8856-6046; Thompson, Sandra/0000-0003-0327-7155; Newton, Jade/0000-0001-8688-2048; Katzenellenbogen, Judith/0000-0001-5287-5819; Woods, John/0000-0003-3006-8500	Australian National Health and Medical Research Council [1133793]; University of Western Australia Athelstan and Amy Saw Top-Up Scholarship; Australian Government Research Training Program Scholarship at The University of Western Australia; National Palliative Care Program by the Australian Government Department of Health	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); University of Western Australia Athelstan and Amy Saw Top-Up Scholarship; Australian Government Research Training Program Scholarship at The University of Western Australia(Australian Government); National Palliative Care Program by the Australian Government Department of Health	JW is funded by the Australian National Health and Medical Research Council (https://nhmrc.gov.au/: Postgraduate Research Scholarship 1133793), a University of Western Australia Athelstan and Amy Saw Top-Up Scholarship, and a University Postgraduate Award and Australian Government Research Training Program Scholarship at The University of Western Australia (www.uwa.edu.au). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The data for this study were provided by the Palliative Care Outcomes Collaboration (PCOC https://ahsri.uow.edu.au/pcoc/index.html). PCOC is funded under the National Palliative Care Program by the Australian Government Department of Health. PCOC Statistician/Data Manager Mr Samuel Allingham and former National Director Ms Karen Quinsey provided helpful advice for the researchers' investigation of data quality and data cleaning. Mr Allingham prepared the dataset and, upon request, provided refined episode sequence data based on lookback to the dataset's inception in 2005.	Abernethy Amy P, 2005, BMC Palliat Care, V4, P7; ABS, 2013, SOC IND AR; Allingham S, 2018, PATIENT OUTCOMES PAL; Aoun SM, 2011, J PALLIAT MED, V14, P315, DOI 10.1089/jpm.2010.0412; Australian Bureau of Statistics, 2017, ABS STAT DEATHS YEAR; Australian Bureau of Statistics, 2017, TABL DEATHS YEAR REG; Australian Bureau of Statistics, 2013, 3238055001 AUSTR BUR; Australian Bureau of Statistics, 2013, AUSTR STAT GEOGR STA, V5; Australian Bureau of Statistics, 2017, 2071 0 CENS POP HOUS; Australian Institute of Health and Welfare, 2016, AUSTR HLTH SER, V15; Australian Institute of Health and Welfare, 2017, ABORIGINAL TORRES ST; Australian Institute of Health and Welfare, 2016, AUSTR BURD DIS STUD, V6; Biddle N, 2009, J POPUL RES, V26, P305, DOI 10.1007/s12546-010-9026-1; Clapham S., 2017, PALLIATIVE CARE OUTC; Condon JR, 2014, POPUL HEALTH METR, V12, DOI 10.1186/1478-7954-12-1; Durey A, 2012, NURS INQ, V19, P144, DOI 10.1111/j.1440-1800.2011.00546.x; Eagar K, 2010, AUST HEALTH REV, V34, P186, DOI 10.1071/AH08718; FRIES BE, 1994, MED CARE, V32, P668, DOI 10.1097/00005650-199407000-00002; Hoy WE, 2016, NEPHROLOGY CARLTON; Masso M, 2016, PALLIATIVE MED, V30, P479, DOI 10.1177/0269216315613904; Masso M, 2015, PALLIATIVE MED, V29, P22, DOI 10.1177/0269216314551814; McGrath P, 2006, INT J PALLIAT NURS, V12, P102, DOI 10.12968/ijpn.2006.12.3.20692; McGrath Pam, 2006, Rural Remote Health, V6, P549; McGrath PD, 2007, AUST HEALTH REV, V31, P430, DOI 10.1071/AH070430; O'Brien AP, 2013, RURAL REMOTE HEALTH, V13; Palliative Care Outcomes Collaboration, 2012, PCOC VERS 3 0 DAT DA; Randall DA, 2018, MED J AUSTRALIA, V209, P19, DOI 10.5694/mja17.00878; Shahid S, 2009, MED J AUSTRALIA, V190, P574, DOI 10.5694/j.1326-5377.2009.tb02569.x; Smith K, 2008, NEUROLOGY, V71, P1470, DOI 10.1212/01.wnl.0000320508.11013.4f; StataCorp LP, STATA IC VERS 13 1; Thompson SC, 2012, BMC MED INFORM DECIS, V12, DOI 10.1186/1472-6947-12-133; To T, 2010, INTERN MED J, V40, P772, DOI 10.1111/j.1445-5994.2009.02064.x; Woods JA, 2018, BMC PALLIAT CARE, V17, DOI 10.1186/s12904-018-0380-7; Woods JA, 2012, BMC CARDIOVASC DISOR, V12, DOI 10.1186/1471-2261-12-99; World Health Organisation (WHO), 2017, WHO DEF PALL CAR; Zambas SI, 2016, CONTEMP NURSE, V52, P398, DOI 10.1080/10376178.2016.1195238; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090; 2008, LANCET ONCOL, V9, P585, DOI DOI 10.1016/S1470-2045(08)70150-5	38	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2019	14	5							e0215403	10.1371/journal.pone.0215403	http://dx.doi.org/10.1371/journal.pone.0215403			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW2JY	31048843	Green Published, gold			2023-01-03	WOS:000466511200016
J	Oga-Omenka, C; Zarowsky, C; Agbaje, A; Kuye, J; Menzies, D				Oga-Omenka, Charity; Zarowsky, Christina; Agbaje, Aderonke; Kuye, Joseph; Menzies, Dick			Rates and timeliness of treatment initiation among drug-resistant tuberculosis patients in Nigeria-A retrospective cohort study	PLOS ONE			English	Article								Background There were an estimated 580,000 new cases of multidrug/rifampicin resistant TB (DR-TB) in 2015, and only 20% were initiated on treatment. This study explored health system and patient factors associated with initiation and timeliness of treatment among DR-TB patients in Nigeria, ranked 4(th) globally for estimated TB cases in 2015. Methods A retrospective cohort study using 2015 diagnosis and treatment data from the Nigerian TB program electronic records examined "treatment ever received" (yes/no) and "treatment within 30 days" (yes/no). We compared health system and patient characteristics using binomial logistic regression, while controlling for confounders. Results Of 996 patients diagnosed nationwide in 2015 (aged 0-87 years, median 34), 47.8% were never treated. Of those treated (n = 520), 51.2% were treated within the 30 days prescribed in the National treatment guideline. Healthcare facility locations were significantly associated with ever receiving treatment and timely treatment. Predictors of timely treatment at the national level also included level of care and patient treatment history. The South-West zone, where DR-TB programs started, showed overall better access to DR-TB healthcare. Conclusions Healthcare facility geographic locations were significantly associated with treatment initiation and timeliness. Significant regional differences in access to DR-TB care in Nigeria persist, reflecting uneven contexts for national DR-TB treatment rollout.	[Oga-Omenka, Charity; Zarowsky, Christina] Univ Montreal, Sch Publ Hlth, ESPUM, Montreal, PQ, Canada; [Oga-Omenka, Charity; Zarowsky, Christina] Univ Montreal, Publ Hlth Res Inst, IRSPUM, Montreal, PQ, Canada; [Agbaje, Aderonke] Inst Human Virol, Abuja, Nigeria; [Kuye, Joseph] Fed Minist Hlth, Natl TB & Leprosy Control Program, Abuja, Nigeria; [Menzies, Dick] McGill Univ, Int TB Ctr, Montreal, PQ, Canada; [Menzies, Dick] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; McGill University; McGill University	Oga-Omenka, C (corresponding author), Univ Montreal, Sch Publ Hlth, ESPUM, Montreal, PQ, Canada.; Oga-Omenka, C (corresponding author), Univ Montreal, Publ Hlth Res Inst, IRSPUM, Montreal, PQ, Canada.	omenkac@gmail.com	Oga-Omenka, Charity/GLR-8573-2022	Oga-Omenka, Charity/0000-0003-0779-570X; Zarowsky, Christina/0000-0002-0850-6212; Kuye, Joseph Oluwatoyin/0000-0001-6840-0674	Global Fund New Funding Model MDR TB Grant (Global Fund to Fight AIDS, Tuberculosis and Malaria: NFM MDR TB Grant); IHVN	Global Fund New Funding Model MDR TB Grant (Global Fund to Fight AIDS, Tuberculosis and Malaria: NFM MDR TB Grant); IHVN	COO received funding for fieldwork through the Global Fund New Funding Model MDR TB Grant (Global Fund to Fight AIDS, Tuberculosis and Malaria: NFM MDR TB Grant), with funds provided through IHVN as the Principal Recipient. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2015, POPULATION STAT COUN; Cox H, 2014, INT J TUBERC LUNG D, V18, P441, DOI 10.5588/ijtld.13.0742; Gandhi NR, 2010, AM J RESP CRIT CARE, V181, P80, DOI 10.1164/rccm.200907-0989OC; Gehre F, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0704-5; Gidado M, 2014, J HEALTH SCI, V2, P145; Mustapha G, 2016, SAARC J TUBERC LUNG, V12, P1, DOI [10.3126/saarctb.v12i2.15948, DOI 10.3126/SAARCTB.V12I2.15948]; National Bureau of Statistics, 2016, DEM STAT B 2015; National Bureau of Statistics, 2016, NAT POP EST 2006 201; NBLCP/FMOH, 2015, 2015 ANN REP NAT TUB; NBLCP/FMOH, NAT TUB LEPR BUR ULC; NBLCP/FMOH, 2012, 1 NAT TB PREV SURV N; NBLCP/FMOH, 2014, NAT STRAT PLAN TUB C; Onyedum CC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180996; Otu AA, 2013, ANN TROP MED PUBLIC, V6, P491, DOI 10.4103/1755-6783.133685; PablosMendez A, 1996, JAMA-J AM MED ASSOC, V276, P1223, DOI 10.1001/jama.276.15.1223; Tope AT, 2014, J MICROBIOL RES, V4, P72; TURETT GS, 1995, CLIN INFECT DIS, V21, P1238, DOI 10.1093/clinids/21.5.1238; van de Water Brittney J, 2017, Glob Pediatr Health, V4, p2333794X17744140, DOI 10.1177/2333794X17744140; Van den Handel T, 2015, INT J TUBERC LUNG D, V19, P392, DOI 10.5588/ijtld.14.0653; WHO, 2016, GLOB TUB REP; World Health Organization, 2021, B WORLD HEALTH ORGAN, DOI DOI 10.2471/BLT.21.286807; World Health Organization, 2006, 924156539X WHO; World Health Organization, 2017, WHOHISHSR1713; World Health Organization, 2016, WHOHTMNTDPCT2016 WHO WHO GUIDELINES TREAT, P55; World Health Organization, 2013, DEFINITIONS REPORTIN; Zimri K, 2012, PUBLIC HEALTH ACTION, V2, P71, DOI 10.5588/pha.12.0024; 2018, PUBLIC HLTH ACTION, V8, P2, DOI DOI 10.5588/PHA.17	27	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2019	14	4							e0215542	10.1371/journal.pone.0215542	http://dx.doi.org/10.1371/journal.pone.0215542			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU8EY	31022228	Green Published, Green Submitted, gold			2023-01-03	WOS:000465519100032
J	Dadi, AF; Desyibelew, HD				Dadi, Abel Fekadu; Desyibelew, Hanna Demelash			Undernutrition and its associated factors among pregnant mothers in Gondar town, Northwest Ethiopia	PLOS ONE			English	Article								Background Regardless of significant gains and signs of progress in the last decades, maternal undernutrition remains a major public health concern in Ethiopia. Supporting the progress of interventions being taken in the country with evidence might be important to keep the sustainability of the government effort. We aimed at determining the extent of undernutrition and its associated factors among pregnant mothers in Gondar town, Northwest Ethiopia. Method A community-based cross-sectional study was conducted by including 940 selected pregnant mothers through a cluster sampling. A face-to-face interview was administered to pregnant mothers at a household level. We collected data using an Online Data collection kit (ODK) and the collected data was directly downloaded from the Google Cloud platform and finally imported to Stata 14 for further analysis. A multivariable logistic regression model was fitted to identify factors associated with undernutrition. A crude and adjusted odds ratio with their 95% confidence interval was calculated to declare the association and its significance. Model fitness was assured through the Hosmer and Lemeshow goodness of fit test and model classification accuracy. Result 14.4% (95% CI: 12.3-16.7) of pregnant mothers were undernourished. After adjusting for the main covariates; as the age of the pregnant mothers increases the odds of being undernourished decreases by 10% (AOR: 0.90; 95% CI: 0.87-0.95) and having a poor marital condition (AOR: 2.18; 95% CI: 1.03-4.59) increased the odds of undernutrition. The risk of undernutrition was also decreased by 43% among those pregnant mothers who consumed coffee sometimes (AOR: 0.57; 95% CI: 0.36-0.89) as compared to daily consumers. Conclusion A significant proportion of pregnant mother were undernourished. Integration of nutritional interventions with maternity health services would be highly important to improve the nutritional status of the mothers. It is also important to counsel pregnant mothers about a consequence of frequent coffee drinking during their pregnancy.	[Dadi, Abel Fekadu] Univ Gondar, Coll Med & Hlth Sci, Inst Publ Hlth, Dept Epidemiol & Biostat, Gondar, Ethiopia; [Desyibelew, Hanna Demelash] Bahir Dar Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Dept Publ Hlth Nutr, Bahir Dar, Ethiopia; [Dadi, Abel Fekadu] Flinders Univ S Australia, Sch Publ Hlth, Coll Med & Publ Hlth, Bedford Pk, SA, Australia	University of Gondar; Bahir Dar University; Flinders University South Australia	Desyibelew, HD (corresponding author), Bahir Dar Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Dept Publ Hlth Nutr, Bahir Dar, Ethiopia.	Hanna.de21@gmail.com	Dadi, Abel Fekadu/AAU-3433-2020	Dadi, Abel Fekadu/0000-0001-9967-7713				Abasizadeh S, 2016, INT J EPIDEMIOLOGIC, V3; Abdel-Raoufabdel-Aziz Afifi Rasha, 2013, J Egypt Soc Parasitol, V43, P125; Acharya SR, 2017, NEPAL ASIAN PAC J HL, V4, P19; Adinma J, 2017, TROP J OBSTET GYNAEC, V34, P79; Bain LE, 2013, PAN AFR MED J, V15, DOI 10.11604/pamj.2013.15.120.2535; Black R., 2013, LANCET, V2013, P1; Bye A, 2016, MIDWIFERY, V42, P38, DOI 10.1016/j.midw.2016.09.013; Dalky H., 2018, GLOBAL J HLTH SCI, V10, P1, DOI [DOI 10.5539/GJHS.V10N4P58, 10.5539/gjhs.v10n4p58]; Duru CB, PREVALENCE DETERMINA; Elmugabil A, 2017, FUTUR SCI OA, V3, DOI 10.4155/fsoa-2016-0096; FAO, 2021, STAT FOOD SEC NUTR W; Federal Democratic Republic of Ethiopia, 2016, NAT NUTR PROGR 2016; Gebre B, 2018, BMC NUTR, V4, DOI 10.1186/s40795-018-0222-2; Hanlon C, 2008, J AFFECT DISORDERS, V108, P251, DOI 10.1016/j.jad.2007.10.023; Hasan M, 2017, CUREUS, V9; Hossain B., 2013, J NUTR FOOD SCI, V03, P1; Kedir H, 2016, MATERN CHILD NUTR, V12, P51, DOI 10.1111/mcn.12136; Kuche D., 2015, J FOOD SCI ENG, V5, P85; Kumera Gemechu, 2018, Matern Health Neonatol Perinatol, V4, P18, DOI 10.1186/s40748-018-0087-z; Loudyi FM, 2016, PAN AFRICAN MED J, P24; Lukose A, 2014, MATERN CHILD HLTH J, V18, P161, DOI 10.1007/s10995-013-1249-2; Nana A, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1822-1; Neggers Y., 2016, J GYNECOLOGY NEONATA, V2; Nguyen TN, 2010, AUST NZ J PSYCHIAT, V44, P1036, DOI 10.3109/00048674.2010.503185; Nigatu M, 2018, ADV PUBLIC HLTH, V2018; Nosikov A., 2003, EUROHIS DEV COMMON I, V57, P35; Prenkert M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009119; Regassa N, 2012, J BIOSOC SCI, V44, P537, DOI 10.1017/S002193201200017X; Salunkhe AH, 2017, ONLINE J HLTH ALLIED, V16; Santana JD, 2015, NUTR HOSP, V32, P130, DOI 10.3305/nh.2015.32.1.8970; Sonko A., 2016, J EPIDEMIOLOGY PUBLI, V1, DOI [10.16966/2471-8211.102, DOI 10.16966/2471-8211.102]; Symington EA, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1943-6; Tang AM., 2016, DETERMINING GLOBAL M; Wolde T., 2014, FOOD SCI QUALITY MAN, V30, P59; World Health Organization, 2011, GLOB REC PHYS ACT HL; Zgheib C, 2017, J PREG CHILD HLTH, V4, P2	36	19	19	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2019	14	4							e0215305	10.1371/journal.pone.0215305	http://dx.doi.org/10.1371/journal.pone.0215305			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HU2FT	31009475	Green Submitted, gold, Green Published			2023-01-03	WOS:000465087500020
J	Webster, P				Webster, Paul			Canada to widen its newly opened retail cannabis market	LANCET			English	Editorial Material																			0	0	0	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 12	2019	393	10167					116	116		10.1016/S0140-6736(19)30075-3	http://dx.doi.org/10.1016/S0140-6736(19)30075-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HH0VD	31204651				2023-01-03	WOS:000455437100011
J	Samuelsson, L; Tyden, J; Herwald, H; Hultin, M; Wallden, J; Steinvall, I; Sjoberg, F; Johansson, J				Samuelsson, Line; Tyden, Jonas; Herwald, Heiko; Hultin, Magnus; Wallden, Jakob; Steinvall, Ingrid; Sjoberg, Folke; Johansson, Joakim			Renal clearance of heparin-binding protein and elimination during renal replacement therapy: Studies in ICU patients and healthy volunteers	PLOS ONE			English	Article							SERUM CYSTATIN C; ORGAN DYSFUNCTION; EARLY MARKER; INFECTION; BIOMARKER; FAILURE; HBP	Background Heparin-binding protein (HBP) is released by neutrophils upon activation, and elevated plasma levels are seen in inflammatory states like sepsis, shock, cardiac arrest, and burns. However, little is known about the elimination of HBP. We wanted to study renal clearance of HBP in healthy individuals and in burn patients in intensive care units (ICUs). We also wished to examine the levels of HBP in the effluent of renal replacement circuits in ICU patients undergoing continuous renal replacement therapy (CRRT). Methods We measured plasma and urine levels of HBP and urine flow rate in 8 healthy individuals and 20 patients in a burn ICU. In 32 patients on CRRT, we measured levels of HBP in plasma and in the effluent of the CRRT circuit. Results Renal clearance of HBP (median (IQR) ml/min) was 0.19 (0.08-0.33) in healthy individuals and 0.30 (0.01-1.04) in burn ICU patients. In ICU patients with cystatin C levels exceeding 1.44 mg/l, clearance was 0.45 (0.15-2.81), and in patients with cystatin C below 1.44 mg/l clearance was lower 0.28 (0.14-0.55) (p = 0.04). Starting CRRT did not significantly alter plasma levels of HBP (p = 0.14), and the median HBP level in the effluent on CRRT was 9.1 ng/ml (IQR 7.8-14.4 ng/ml). Conclusion In healthy individuals and critically ill burn patients, renal clearance of HBP is low. It is increased when renal function is impaired. Starting CRRT in critically ill patients does not alter plasma levels of HBP significantly, but HBP can be found in the effluent. It seems unlikely that impaired kidney function needs to be considered when interpreting concentrations of HBP in previous studies. Starting CRRT does not appear to be an effective way of reducing HBP concentrations.	[Samuelsson, Line; Tyden, Jonas; Johansson, Joakim] Umea Univ, Dept Surg & Perioperat Sci, Anesthesiol & Intens Care Med Ostersund, Umea, Sweden; [Herwald, Heiko] Lund Univ, Dept Clin Sci, Lund, Sweden; [Hultin, Magnus] Umea Univ, Dept Surg & Perioperat Sci, Anesthesiol & Intens Care Med, Umea, Sweden; [Wallden, Jakob] Umea Univ, Anesthesiol & Intens Care Med Sundsvall, Dept Surg & Perioperat Sci, Umea, Sweden; [Steinvall, Ingrid; Sjoberg, Folke] Linkoping Univ, Dept Hand Surg Plast Surg & Burns, Linkoping, Sweden; [Steinvall, Ingrid; Sjoberg, Folke] Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden; [Johansson, Joakim] Linkoping Univ, Dept Anesthesiol & Intens Care, Linkoping, Sweden	Umea University; Lund University; Umea University; Umea University; Linkoping University; Linkoping University; Linkoping University	Tyden, J (corresponding author), Umea Univ, Dept Surg & Perioperat Sci, Anesthesiol & Intens Care Med Ostersund, Umea, Sweden.	jonas.tyden@regionjh.se	Hultin, Magnus/A-1321-2010; Steinvall, Ingrid/I-5954-2019; Herwald, Heiko/AAN-3708-2021; Wallden, Jakob/AAY-4793-2020	Hultin, Magnus/0000-0003-2935-7161; Herwald, Heiko/0000-0002-8111-2842; Wallden, Jakob/0000-0002-8171-5184; Steinvall, Ingrid/0000-0002-8027-9632				Bentzer Peter, 2016, Intensive Care Med Exp, V4, P33; Cai XY, 2012, CLIN CHEM LAB MED, V50, P667, DOI 10.1515/cclm-2011-0838; Chew MS, 2012, INFLAMM RES, V61, P375, DOI 10.1007/s00011-011-0422-6; De Vriese AS, 1999, J AM SOC NEPHROL, V10, P846; Fisher J, 2017, J INTERN MED, V281, P562, DOI 10.1111/joim.12604; Fisher J, 2017, SHOCK, V48, P313, DOI 10.1097/SHK.0000000000000862; Gautam N, 2001, NAT MED, V7, P1123, DOI 10.1038/nm1001-1123; Gritters M, 2006, NEPHROL DIAL TRANSPL, V21, P153, DOI 10.1093/ndt/gfi069; Johansson J, 2013, ACTA ANAESTH SCAND, V57, P580, DOI 10.1111/aas.12070; Johansson J, 2015, J BURN CARE RES, V36, P484, DOI 10.1097/BCR.0000000000000211; Johansson J, 2009, BURNS, V35, P1185, DOI 10.1016/j.burns.2009.02.021; Kahn F, 2019, HEPARIN BINDING PRO, DOI [10.1097/SHK.0000000000001332, DOI 10.1097/SHK.0000000000001332]; Kjolvmark C, 2016, DIAGN MICR INFEC DIS, V85, P243, DOI 10.1016/j.diagmicrobio.2016.03.005; Kjolvmark C, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu004; Lin QH, 2013, CRIT CARE, V17, DOI 10.1186/cc12834; Linder A, 2015, CRIT CARE MED, V43, P2378, DOI 10.1097/CCM.0000000000001265; Linder A, 2012, CRIT CARE, V16, DOI 10.1186/cc11353; Linder A, 2009, CLIN INFECT DIS, V49, P1044, DOI 10.1086/605563; MAACK T, 1979, KIDNEY INT, V16, P251, DOI 10.1038/ki.1979.128; SHAFER WM, 1984, INFECT IMMUN, V45, P29, DOI 10.1128/IAI.45.1.29-35.1984; Sjoberg F, 2000, BURNS, V26, P553, DOI 10.1016/S0305-4179(00)00004-8; Tapper H, 2002, BLOOD, V99, P1785, DOI 10.1182/blood.V99.5.1785; Tverring J, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0330-1; Tyden J, 2017, ACTA ANAESTH SCAND, V61, P797, DOI 10.1111/aas.12913; Tyden J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152035; Yim H, 2015, EUR J CLIN INVEST, V45, P594, DOI 10.1111/eci.12452	26	7	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2019	14	8							e0221813	10.1371/journal.pone.0221813	http://dx.doi.org/10.1371/journal.pone.0221813			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW6AB	31465432	Green Published, Green Submitted, gold			2023-01-03	WOS:000485058200055
J	Ramanathan, M; Vijayan, B				Ramanathan, Mala; Vijayan, Bevin			Covariates of diarrhoea among under-five children in India: Are they level dependent?	PLOS ONE			English	Article							GLOBAL BURDEN; PREVENTION; DISEASE; HEALTH	Program interventions like access to improved water supply, sanitation and hygiene do not have a systematic response to the aggregate health outcomes. Therefore, this is an attempt at recognising the concept of level sensitivity while verifying the association between prevalence of diarrhoea in under-five children in a district and its corresponding coverage of improved water supply and sanitation and hygiene. Information obtained in the DLHS-4 including 275 districts from 19 states and 2 union territories of India forms the database for this analysis. Universal access to safe drinking water, improving coverage of sanitation in a district beyond 71 percent across the country and beyond 78 percent among the non-south DLHS districts, has the potential to realise reductions in the prevalence of diarrhoea in under-five children in a district. The effect of improved sanitation seems to work synergistically with these indicators only at better levels of prevalence of diarrhoea in under-five children in a district. This offers lessons for the Clean India Mission in terms of universalising access to safe water and coverage up to three-fourths of households with sanitation in a district for the positive externalities to manifest in reduced prevalence of diarrhoea in under-five children.	[Ramanathan, Mala; Vijayan, Bevin] Sree Chitra Tirunal Inst Med Sci & Technol, Achutha Menon Ctr Hlth Sci Studies, Trivandrum, Kerala, India	Department of Science & Technology (India); Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)	Ramanathan, M (corresponding author), Sree Chitra Tirunal Inst Med Sci & Technol, Achutha Menon Ctr Hlth Sci Studies, Trivandrum, Kerala, India.	mala@sctimst.ac.in	Ramanathan, Mala/AAI-7031-2020; Vijayan, Bevin/AAT-7953-2021	Vijayan, Bevin/0000-0001-5674-6563; Ramanathan, Mala/0000-0003-0625-109X				[Anonymous], R LANG ENV STAT COMP; Bartram J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000367; Fewtrell L, 2005, LANCET INFECT DIS, V5, P42, DOI 10.1016/S1473-3099(04)01253-8; Government of India, 2014, DISTR LEV HOUS FAC S; Kahn G, 2012, INDIAN PEDIATR, V49, P467, DOI 10.1007/s13312-012-0076-7; Keusch GT, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P371; Lodha R, 2012, INDIAN PEDIATR, V49, P441; Lumley T, 2002, ANNU REV PUBL HEALTH, V23, P151, DOI 10.1146/annurev.publhealth.23.100901.140546; Ministry of Drinking Water and Sanitation Guidelines for Swachh Bharat Mission (Gramin), 2017, GUID SWACHH BHAR MIS; Mishra US, 2006, APPL ECON LETT, V13, P519, DOI 10.1080/13504850500400413; Mishra US, 2016, EVAL PROGRAM PLANN, V58, P70, DOI 10.1016/j.evalprogplan.2016.04.002; Nathan HSK, 2017, J INT DEV, V29, P520, DOI 10.1002/jid.2898; National Sample Survey Organisation, 2012, KEY IND DRINK WAT SA; Nilima,, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6213-z; Paul S, 1996, APPL ECON LETT, V3, P677, DOI 10.1080/135048596355925; Progress of the Seasons, 2017, HAWTH VALL FARMSC EC; Schmidt AF, 2018, J CLIN EPIDEMIOL, V98, P146, DOI 10.1016/j.jclinepi.2017.12.006; SPSS Inc, 2008, IBM SPSS STAT WIND V; Troeger C, 2017, LANCET INFECT DIS, V17, P909, DOI 10.1016/S1473-3099(17)30276-1; Unicef, 2010, DIARRH WHY CHILDR AR; United Nations Children's Fund (UNICEF), 2012, PNEUM DIARRH TACKL D; Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1	23	3	3	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2019	14	8							e0221200	10.1371/journal.pone.0221200	http://dx.doi.org/10.1371/journal.pone.0221200			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW5QN	31433822	Green Submitted, gold, Green Published			2023-01-03	WOS:000485033100020
J	Barkal, AA; Brewer, RE; Markovic, M; Kowarsky, M; Barkal, SA; Zaro, BW; Krishnan, V; Hatakeyama, J; Dorigo, O; Barkal, LJ; Weissman, IL				Barkal, Amira A.; Brewer, Rachel E.; Markovic, Maxim; Kowarsky, Mark; Barkal, Sammy A.; Zaro, Balyn W.; Krishnan, Venkatesh; Hatakeyama, Jason; Dorigo, Oliver; Barkal, Layla J.; Weissman, Irving L.			CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy	NATURE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; EXPRESSION; INNATE; CD47	Ovarian cancer and triple-negative breast cancer are among the most lethal diseases affecting women, with few targeted therapies and high rates of metastasis. Cancer cells are capable of evading clearance by macrophages through the overexpression of antiphagocytic surface proteins called 'don't eat me' signals-including CD471, programmed cell death ligand 1 (PD-L1) 2 and the beta-2 microglobulin subunit of the major histocompatibility class I complex (B2M)(3). Monoclonal antibodies that antagonize the interaction of 'don't eat me' signals with their macrophage-expressed receptors have demonstrated therapeutic potential in several wcancers(4,5). However, variability in the magnitude and durability of the response to these agents has suggested the presence of additional, as yet unknown 'don't eat me' signals. Here we show that CD24 can be the dominant innate immune checkpoint in ovarian cancer and breast cancer, and is a promising target for cancer immunotherapy. We demonstrate a role for tumour-expressed CD24 in promoting immune evasion through its interaction with the inhibitory receptor sialic-acid-binding Ig-like lectin 10 (Siglec-10), which is expressed by tumour-associated macrophages. We find that many tumours overexpress CD24 and that tumour-associated macrophages express high levels of Siglec-10. Genetic ablation of either CD24 or Siglec-10, as well as blockade of the CD24-Siglec-10 interaction using monoclonal antibodies, robustly augment the phagocytosis of all CD24-expressing human tumours that we tested. Genetic ablation and therapeutic blockade of CD24 resulted in a macrophage-dependent reduction of tumour growth in vivo and an increase in survival time. These data reveal CD24 as a highly expressed, anti-phagocytic signal in several cancers and demonstrate the therapeutic potential for CD24 blockade in cancer immunotherapy.	[Barkal, Amira A.; Brewer, Rachel E.; Markovic, Maxim; Barkal, Sammy A.; Zaro, Balyn W.; Hatakeyama, Jason; Weissman, Irving L.] Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA; [Barkal, Amira A.; Brewer, Rachel E.; Markovic, Maxim; Zaro, Balyn W.; Weissman, Irving L.] Stanford Univ, Sch Med, Ludwig Ctr Canc Stem Cell Res & Med, Stanford, CA 94305 USA; [Barkal, Amira A.; Brewer, Rachel E.; Markovic, Maxim; Zaro, Balyn W.; Weissman, Irving L.] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA; [Barkal, Amira A.] Stanford Univ, Stanford Med Scientist Training Program, Stanford, CA 94305 USA; [Kowarsky, Mark] Stanford Univ, Dept Phys, Stanford, CA 94305 USA; [Krishnan, Venkatesh; Dorigo, Oliver] Stanford Univ, Sch Med, Div Gynecol Oncol, Dept Obstet & Gynecol, Stanford, CA 94305 USA; [Hatakeyama, Jason] Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA; [Barkal, Layla J.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA; [Weissman, Irving L.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford Cancer Institute; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University	Weissman, IL (corresponding author), Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA.; Weissman, IL (corresponding author), Stanford Univ, Sch Med, Ludwig Ctr Canc Stem Cell Res & Med, Stanford, CA 94305 USA.; Weissman, IL (corresponding author), Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA.; Weissman, IL (corresponding author), Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA.	irv@stanford.edu		Hatakeyama, Jason/0000-0001-8690-5107; Markovic, Maxim/0000-0001-9949-794X; Zaro, Balyn/0000-0002-8938-9889; Barkal, Sammy/0000-0002-8391-5956; Barkal, Layla/0000-0002-4734-7197	Virginia D. K. Ludwig Fund for Cancer Research [NIHR01CA086017, NIHGR01GM100315]; NIH/NCI Outstanding Investigator Award [R35CA220434]; Stanford Medical Scientist Training Program [T32GM007365]; National Cancer Institute [F30CA232472]; Program in Translational and Experimental Hematology T32 from the National Heart, Lung, and Blood Institute [1T32HL120824]; NATIONAL CANCER INSTITUTE [R35CA220434, F30CA232472, P30CA124435] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL120824] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365, R01GM100315] Funding Source: NIH RePORTER	Virginia D. K. Ludwig Fund for Cancer Research; NIH/NCI Outstanding Investigator Award; Stanford Medical Scientist Training Program; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Program in Translational and Experimental Hematology T32 from the National Heart, Lung, and Blood Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the members of the Weissman laboratory, the Stanford Stem Cell Institute, R. L. Maute and K. S. Kao for advice and discussions; A. McCarty, T. Naik and L. Quinn for technical and logistical support; I. Wapnir for providing samples from patients with breast cancer; G. Wernig for providing human ascites samples; and G. Krampitz for the APL1 cell line. The research reported in this publication was supported by the Virginia D. K. Ludwig Fund for Cancer Research (NIHR01CA086017 and NIHGR01GM100315) and the NIH/NCI Outstanding Investigator Award (R35CA220434 to I.L.W.); the Stanford Medical Scientist Training Program (T32GM007365 to A.A.B); the National Cancer Institute (F30CA232472 to A.A.B); and the Program in Translational and Experimental Hematology T32 from the National Heart, Lung, and Blood Institute (1T32HL120824 to B.W.Z.). The contents of this manuscript are solely the responsibility of the authors.	Abram CL, 2017, J LEUKOCYTE BIOL, V102, P657, DOI 10.1189/jlb.2MR0317-105R; Advani R, 2018, NEW ENGL J MED, V379, P1711, DOI 10.1056/NEJMoa1807315; Alsaab HO, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00561; Ayers M, 2019, CLIN CANCER RES, V25, P1564, DOI 10.1158/1078-0432.CCR-18-1316; Barkal AA, 2018, NAT IMMUNOL, V19, P76, DOI 10.1038/s41590-017-0004-z; Brinkman EK, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku936; Chen GY, 2014, GLYCOBIOLOGY, V24, P800, DOI 10.1093/glycob/cwu068; Chen GY, 2011, NAT BIOTECHNOL, V29, P428, DOI 10.1038/nbt.1846; Chen GY, 2009, SCIENCE, V323, P1722, DOI 10.1126/science.1168988; Chen WL, 2013, CELL, V152, P467, DOI 10.1016/j.cell.2013.01.011; Crocker PR, 2007, NAT REV IMMUNOL, V7, P255, DOI 10.1038/nri2056; Dietrich J, 2001, J IMMUNOL, V166, P2514, DOI 10.4049/jimmunol.166.4.2514; Goldman M., 2018, UCSC XENA PLATFORM C, DOI [10.1101/326470v3, DOI 10.1101/326470V3]; Gordon SR, 2017, NATURE, V545, P495, DOI 10.1038/nature22396; Karaayvaz M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06052-0; Kristiansen G, 2003, CLIN CANCER RES, V9, P4906; Liu J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137345; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Martinez FO., 2012, CURR PROTOC IMMUNOL, V28, P1; Miksa M, 2009, J IMMUNOL METHODS, V342, P71, DOI 10.1016/j.jim.2008.11.019; Nanda R, 2016, J CLIN ONCOL, V34, P2460, DOI 10.1200/JCO.2015.64.8931; OKAZAKI M, 1993, BLOOD, V81, P84; PIRRUCCELLO SJ, 1986, J IMMUNOL, V136, P3779; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Tarhriz V, 2019, J CELL PHYSIOL, V234, P2134, DOI 10.1002/jcp.27581; Toubai T, 2014, BLOOD, V123, P3512, DOI 10.1182/blood-2013-12-545335; Varga A, 2017, P SOC CLIN ONCOL S, V35, P5513, DOI DOI 10.1200/JC0.2017.35.15_; Willingham SB, 2012, P NATL ACAD SCI USA, V109, P6662, DOI 10.1073/pnas.1121623109	29	413	432	32	339	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 15	2019	572	7769					392	+		10.1038/s41586-019-1456-0	http://dx.doi.org/10.1038/s41586-019-1456-0			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IR4OM	31367043	Green Accepted, Green Submitted			2023-01-03	WOS:000481414100048
J	Huang, YH; Chen, ST; Liu, FH; Hsieh, SH; Lin, CH; Liou, MJ; Wang, CC; Huang, CH; Liu, GH; Lin, JR; Yang, LY; Hsu, TY; Lee, MC; Huang, CT; Wu, YH				Huang, Yueh-Hsiang; Chen, Szu-Tah; Liu, Feng-Hsuan; Hsieh, Sheng-Hwu; Lin, Chia-Hung; Liou, Miaw-Jene; Wang, Chih-Ching; Huang, Chung-Huei; Liu, Geng-Hao; Lin, Jr-Rung; Yang, Lan-Yan; Hsu, Tzu-Yang; Lee, Ming-Chung; Huang, Chun-Teng; Wu, Yi-Hong			The efficacy and safety of concentrated herbal extract granules, YH1, as an add-on medication in poorly controlled type 2 diabetes: A randomized, double-blind, placebo-controlled pilot trial	PLOS ONE			English	Article							BODY-MASS INDEX; ATRACTYLENOLIDE III; GUT MICROBIOTA; BASAL INSULIN; BERBERINE; MECHANISMS	Background In Asian countries, many patients with type 2 diabetes fail to achieve controlled glycated hemoglobin (HbA(1c)) levels while taking several classes of oral hypoglycemic agents (OHAs). Traditional Chinese medicine could be an alternative therapeutic option for poorly controlled type 2 diabetes. YH1 is a concentrated Chinese herbal extract formula that combines Rhizoma Coptidis and Shen-Ling-Bai-Zhu-San. This randomized, double-blind, placebo-controlled pilot study evaluated YH1 as an add-on medication for poorly controlled type 2 diabetes. Methods Forty-six patients with poorly controlled type 2 diabetes were randomly assigned 1:1 to the YH1 or placebo group. Before the trial, all subjects had received three or more classes of OHAs with HbA(1c) > 7.0% (53 mmol/mol) and a body mass index >= 23 kg/m(2). During the 12-week trial, participants continued to take OHAs without any dose or medication changes. The primary endpoint was the percentage change in HbA(1c) level. Per-protocol analysis was applied to the final evaluation. Results At week 12, there was an 11.1% reduction in HbA(1c) from baseline and a 68.9% increase in homeostatic model assessment (HOMA) of beta cell function in the YH1 group, which also exhibited significant reductions in two-hour postprandial glucose (-26.2%), triglycerides (-29.5%), total cholesterol (-21.6%), low-density lipoprotein cholesterol (-17.4%), body weight (-0.5%), and waist circumference (-1.1%). The changes in fasting plasma glucose, HOMA insulin resistance and symptom scores were not significantly different between the YH1 and placebo groups. No serious adverse events occurred during this clinical trial. Conclusions This pilot study indicates that YH1 together with OHAs can improve hypoglycemic action and beta-cell function in overweight/obese patients with poorly controlled type 2 diabetes. YH1 is a safe add-on medication for OHAs and has beneficial effects on weight control and lipid metabolism. A larger study population with longer treatment and follow-up periods is required for further verification.	[Huang, Yueh-Hsiang; Liu, Geng-Hao; Wu, Yi-Hong] Chang Gung Mem Hosp, Div Chinese Internal Med, Ctr Tradit Chinese Med, Taoyuan, Taiwan; [Huang, Yueh-Hsiang; Lin, Chia-Hung; Liu, Geng-Hao] Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, Taoyuan, Taiwan; [Chen, Szu-Tah; Liu, Feng-Hsuan; Hsieh, Sheng-Hwu; Lin, Chia-Hung; Liou, Miaw-Jene; Wang, Chih-Ching; Huang, Chung-Huei] Chang Gung Mem Hosp, Div Endocrinol & Metab, Dept Internal Med, Linkou, Taiwan; [Liu, Geng-Hao; Wu, Yi-Hong] Chang Gung Univ, Sch Tradit Chinese Med, Coll Med, Taoyuan, Taiwan; [Lin, Jr-Rung] Chang Gung Univ, Clin Informat & Med Stat Res Ctr, Taoyuan, Taiwan; [Lin, Jr-Rung] Chang Gung Univ, Grad Inst Clin Med, Taoyuan, Taiwan; [Yang, Lan-Yan; Hsu, Tzu-Yang] Chang Gung Mem Hosp, Clin Trial Ctr, Biostat & Informat Unit, Taoyuan, Taiwan; [Yang, Lan-Yan; Hsu, Tzu-Yang] Chang Gung Univ, Taoyuan, Taiwan; [Lee, Ming-Chung] Brion Res Inst Taiwan, Taipei, Taiwan; [Huang, Chun-Teng] Sanford Burnham Prebys Med Discovery Inst, La Jolla, CA USA	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Sanford Burnham Prebys Medical Discovery Institute	Wu, YH (corresponding author), Chang Gung Mem Hosp, Div Chinese Internal Med, Ctr Tradit Chinese Med, Taoyuan, Taiwan.; Wu, YH (corresponding author), Chang Gung Univ, Sch Tradit Chinese Med, Coll Med, Taoyuan, Taiwan.	mzpjih@gmail.com	yang, lan/GRJ-3120-2022	Huang, Yueh Hsiang/0000-0001-7422-120X; Huang, Chung-Huei/0000-0001-6736-1423; Yang, Lan-Yan/0000-0002-6305-540X; liu, geng hao/0000-0002-9671-2955; Huang, Chun-Teng/0000-0003-3737-7875	Chang Gung Memorial Hospital Research Program [CMRPG1F0031]; Clinical Trial Center, Chang Gung Memorial Hospital, Linkou, Taiwan [MOHW107-TDU-B-212-123005]	Chang Gung Memorial Hospital Research Program(Chang Gung Memorial Hospital); Clinical Trial Center, Chang Gung Memorial Hospital, Linkou, Taiwan	This study was supported by research grants from Chang Gung Memorial Hospital Research Program (CMRPG1F0031). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors thank all the participants for agreeing to join this study without any payment. The authors are also grateful to the nurses and research assistants, especially Wan Ling Chiu and Shu Chuan Shih, for their practical work during the study. In addition, the authors acknowledge the statistical assistance provided by the Clinical Trial Center, Chang Gung Memorial Hospital, Linkou, Taiwan, MOHW107-TDU-B-212-123005. The authors also appreciate Hsiao-Jung Tseng for providing statistical assistance.	[Anonymous], 2014, DIABETES RES CLIN PR, V104, P1, DOI 10.1016/j.diabres.2012.10.001; Bae JP, 2016, J DIABETES COMPLICAT, V30, P212, DOI 10.1016/j.jdiacomp.2015.11.016; Barba C, 2004, LANCET, V363, P157, DOI 10.1016/S0140-6736(03)15268-3; Chan WB, 2017, DIABET METAB SYND OB, V10, P521, DOI 10.2147/DMSO.S143046; Chuang LM, 2001, DIABETES RES CLIN PR, V54, pS55; Cicero AF, 2009, CLIN LIPIDOL, V4, P553, DOI 10.2217/CLP.09.41; Dong H, 2013, PLANTA MED, V79, P437, DOI 10.1055/s-0032-1328321; Dong H, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/591654; Go HK, 2015, NUTRIENTS, V7, P8532, DOI 10.3390/nu7105411; Huang C-Y, 2013, EVIDENCE BASED COMPL, V2013; Ji LN, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-602; Ji LN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056703; Kong WJ, 2004, NAT MED, V10, P1344, DOI 10.1038/nm1135; Li TH, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1155/2011/128402; Liu MJ, 2016, J TRADIT CHIN MED, V36, P555; Lv WJ, 2017, INT J BIOL MACROMOL, V105, P1622, DOI 10.1016/j.ijbiomac.2017.02.060; Ma H, 2019, FITOTERAPIA, V134, P210, DOI 10.1016/j.fitote.2019.03.003; Ogurtsova K, 2017, DIABETES RES CLIN PR, V128, P40, DOI 10.1016/j.diabres.2017.03.024; Priyadarshini M, 2016, TRENDS ENDOCRIN MET, V27, P653, DOI 10.1016/j.tem.2016.03.011; Scheen AJ, 2017, DIABETES METAB, V43, P295, DOI 10.1016/j.diabet.2017.04.009; Shishtar E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107391; Song MY, 2017, BIOL PHARM BULL, V40, P339, DOI 10.1248/bpb.b16-00853; Talley NJ, 2004, NEUROGASTROENT MOTIL, V16, P413, DOI 10.1111/j.1365-2982.2004.00530.x; Tong XL, 2012, AM J CHINESE MED, V40, P877, DOI 10.1142/S0192415X12500656; Tsai ST, 2011, J DIABETES, V3, P208, DOI 10.1111/j.1753-0407.2011.00137.x; Wang KT, 2010, J PHARM PHARMACOL, V62, P381, DOI 10.1211/jpp.62.03.0014; Wang Y, 2017, METABOLISM, V70, P72, DOI 10.1016/j.metabol.2017.02.003; Wang YW, 2014, METABOLISM, V63, P1167, DOI 10.1016/j.metabol.2014.05.013; Yin J, 2008, METABOLISM, V57, P712, DOI 10.1016/j.metabol.2008.01.013; Yin J, 2012, ACTA PHARM SIN B, V2, P327, DOI 10.1016/j.apsb.2012.06.003; Zhang Q, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-188; Zhang Y., 2013, FOOD SCI HUM WELL, V2, P167	32	19	19	4	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 15	2019	14	8							e0221199	10.1371/journal.pone.0221199	http://dx.doi.org/10.1371/journal.pone.0221199			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5KK	31415655	gold, Green Published, Green Submitted			2023-01-03	WOS:000485017200091
J	Spiegel, B; Fuller, G; Lopez, M; Dupuy, T; Noah, B; Howard, A; Albert, M; Tashjian, V; Lam, R; Ahm, J; Dailey, F; Rosen, BT; Vrahas, M; Little, M; Garlich, J; Dzubur, E; IsHak, W; Danovitch, I				Spiegel, Brennan; Fuller, Garth; Lopez, Mayra; Dupuy, Taylor; Noah, Benjamin; Howard, Amber; Albert, Michael; Tashjian, Vartan; Lam, Richard; Ahm, Joseph; Dailey, Francis; Rosen, Bradley T.; Vrahas, Mark; Little, Milton; Garlich, John; Dzubur, Eldin; IsHak, Waguih; Danovitch, Itai			Virtual reality for management of pain in hospitalized patients: A randomized comparative effectiveness trial	PLOS ONE			English	Article							EXPOSURE THERAPY; DISTRACTION; REACTIVITY	Objectives Therapeutic virtual reality (VR) has emerged as an effective, drug-free tool for pain management, but there is a lack of randomized, controlled data evaluating its effectiveness in hospitalized patients. We sought to measure the impact of on-demand VR versus "health and wellness" television programming for pain in hospitalized patients. Methods We performed a prospective, randomized, comparative effectiveness trial in hospitalized patients with an average pain score of >= 3 out of 10 points. Patients in the experimental group received a library of 21 VR experiences administered using the Samsung Gear Oculus headset; control patients viewed specialized television programming to promote health and wellness. Clinical staff followed usual care; study interventions were not protocolized. The primary outcome was patient-reported pain using a numeric rating scale, as recorded by nursing staff during usual care. Pre- and post-intervention pain scores were compared immediately after initial treatment and after 48- and 72-hours. Results There were 120 subjects (61 VR; 59 control). The mean within-subject difference in immediate pre- and post-intervention pain scores was larger in the VR group (-1.72 points; SD 3.56) than in the control group (-0.46 points; SD 3.01); this difference was significant in favor of VR (P < .04). When limited to the subgroup of patients with severe baseline pain (>= 7 points), the effect of VR was more pronounced vs. control (-3.04, SD 3.75 vs.-0.93, SD 2.16 points; P = .02). In regression analyses adjusting for pre-intervention pain, time, age, gender, and type of pain, VR yielded a.59 (P = .03) and.56 (P = .04) point incremental reduction in pain versus control during the 48- and 72-hour post-intervention periods, respectively. Conclusions VR significantly reduces pain versus an active control condition in hospitalized patients. VR is most effective for severe pain. Future trials should evaluate standardized order sets that interpose VR as an early non-drug option for analgesia.	[Spiegel, Brennan; Fuller, Garth; Lopez, Mayra; Dupuy, Taylor; Noah, Benjamin; Howard, Amber; Albert, Michael; Tashjian, Vartan; Lam, Richard; Ahm, Joseph; Dailey, Francis; Rosen, Bradley T.; Dzubur, Eldin] Cedars Sinai Hlth Syst, Dept Med, Div Hlth Serv Res, Los Angeles, CA 90048 USA; [Spiegel, Brennan] Cedars Sinai Grad Program, Div Hlth Delivery Sci, Los Angeles, CA 90048 USA; [Rosen, Bradley T.] Cedars Sinai Hlth Syst, Inpatient Specialty Program, Los Angeles, CA USA; [Vrahas, Mark; Little, Milton; Garlich, John] Cedars Sinai Hlth Syst, Dept Orthopaed, Los Angeles, CA USA; [IsHak, Waguih; Danovitch, Itai] Cedars Sinai Hlth Syst, Dept Psychiat, Los Angeles, CA USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center	Spiegel, B (corresponding author), Cedars Sinai Hlth Syst, Dept Med, Div Hlth Serv Res, Los Angeles, CA 90048 USA.; Spiegel, B (corresponding author), Cedars Sinai Grad Program, Div Hlth Delivery Sci, Los Angeles, CA 90048 USA.	brennan.spiegel@cshs.org	Garlich, John M/D-3181-2017; Danovitch, Itai/AAG-5313-2021; IsHak, Waguih William/C-1336-2011; IsHak, Waguih/O-7956-2019	Garlich, John M/0000-0002-6608-9701; Danovitch, Itai/0000-0001-9580-6450; IsHak, Waguih William/0000-0003-1970-4756; IsHak, Waguih/0000-0003-1970-4756	Cedars - Translational Science (NCATS) UCLA CTSI Grant [UL1TR001881]; Marc and Sheri Rapaport Fund for Digital Health Sciences & Precision Health; NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant [UL1TR001881]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001881] Funding Source: NIH RePORTER	Cedars - Translational Science (NCATS) UCLA CTSI Grant; Marc and Sheri Rapaport Fund for Digital Health Sciences & Precision Health; NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This study was funded, in part, through an institutional grant to Cedars - Translational Science (NCATS) UCLA CTSI Grant Number UL1TR001881. The authors have no equity or ownership with appliedVR or other VR hardware or software companies. All aspects of the study design, performance, analysis, data interpretation and writing were independently conducted by the investigators.Sinai Medical Center from appliedVR ($47,333 direct cost). The Cedars -Sinai Center for Outcomes Research and Education (CS -CORE) is supported by The Marc and Sheri Rapaport Fund for Digital Health Sciences & Precision Health. Brennan Spiegel is supported by a NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant Number UL1TR001881. The authors have no equity or ownership with appliedVR or other VR hardware or software companies. All aspects of the study design, performance, analysis, data interpretation and writing were independently conducted by the investigators.	Bird SB, 2001, ANN EMERG MED, V38, P639, DOI 10.1067/mem.2001.118012; Bordnick PS, 2008, ADDICT BEHAV, V33, P743, DOI 10.1016/j.addbeh.2007.12.010; Bordnick PS, 2012, RES SOCIAL WORK PRAC, V22, P293, DOI 10.1177/1049731511426880; Bordnick PS, 2005, CYBERPSYCHOL BEHAV, V8, P487, DOI 10.1089/cpb.2005.8.487; Brown DK, 2013, ENVIRON SCI TECHNOL, V47, P5562, DOI 10.1021/es305019p; Carrougher GJ, 2009, J BURN CARE RES, V30, P785, DOI 10.1097/BCR.0b013e3181b485d3; Dascal Julieta, 2017, Innov Clin Neurosci, V14, P14; de Kort YAW, 2006, J ENVIRON PSYCHOL, V26, P309, DOI 10.1016/j.jenvp.2006.09.001; Diette GB, 2003, CHEST, V123, P941, DOI 10.1378/chest.123.3.941; Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Fontaine D, 2005, CRITICAL CARE NURSIN, P36; Furman E, 2009, J AM DENT ASSOC, V140, P1508, DOI 10.14219/jada.archive.2009.0102; Garrett B, 2014, CLIN J PAIN, V30, P1089, DOI 10.1097/AJP.0000000000000064; Gerbershagen HJ, 2011, BRIT J ANAESTH, V107, P619, DOI 10.1093/bja/aer195; Gold JI, 2006, CYBERPSYCHOL BEHAV, V9, P207, DOI 10.1089/cpb.2006.9.207; Helfand M, 2009, PAIN MED, V10, P1183, DOI 10.1111/j.1526-4637.2009.00718.x; Hoffman HG, 2000, CLIN J PAIN, V16, P244, DOI 10.1097/00002508-200009000-00010; Hoffman HG, 2000, PAIN, V85, P305, DOI 10.1016/S0304-3959(99)00275-4; Hoffman HG, 2001, CYBERPSYCHOL BEHAV, V4, P527, DOI 10.1089/109493101750527088; Hoffman HG, 2001, CLIN J PAIN, V17, P229, DOI 10.1097/00002508-200109000-00007; Kline GA, 2009, J HOLIST NURS, V27, P159, DOI 10.1177/0898010109336138; La Viola J. J.  Jr., 2000, SIGCHI Bulletin, V32, P47, DOI 10.1145/333329.333344; Li A, 2011, PAIN MANAG, V1, P147, DOI 10.2217/PMT.10.15; Malenbaum S, 2008, PAIN, V134, P241, DOI 10.1016/j.pain.2007.12.002; Malloy KM, 2010, CLIN PSYCHOL REV, V30, P1011, DOI 10.1016/j.cpr.2010.07.001; Maples-Keller JL, 2017, NEUROTHERAPEUTICS, V14, P554, DOI 10.1007/s13311-017-0534-y; Maples-Keller JL, 2017, HARVARD REV PSYCHIAT, V25, P103, DOI 10.1097/HRP.0000000000000138; Maples-Keller JL, 2017, BEHAV THER, V48, P147, DOI 10.1016/j.beth.2016.02.011; MCCAUL KD, 1984, PSYCHOL BULL, V95, P516, DOI 10.1037/0033-2909.95.3.516; Mosadeghi S, 2016, JMIR MENT HEALTH, V3, DOI 10.2196/mental.5801; Nichols S, 2002, APPL ERGON, V33, P251, DOI 10.1016/S0003-6870(02)00020-0; Rizzo AA, 2009, STUD HEALTH TECHNOL, V142, P277, DOI 10.3233/978-1-58603-964-6-277; Salaffi F, 2004, EUR J PAIN, V8, P283, DOI 10.1016/j.ejpain.2003.09.004; Shah A, 2017, J PAIN, V18, P1374, DOI 10.1016/j.jpain.2017.06.010; Tashjian VC, 2017, JMIR MENT HEALTH, V4, DOI 10.2196/mental.7387; Turk DC, 2011, LANCET, V377, P2226, DOI 10.1016/S0140-6736(11)60402-9	37	56	61	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2019	14	8							e0219115	10.1371/journal.pone.0219115	http://dx.doi.org/10.1371/journal.pone.0219115			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW5IT	31412029	Green Submitted, Green Published, gold			2023-01-03	WOS:000485012600013
J	Barone, M; Turroni, S; Rampelli, S; Soverini, M; D'Amico, F; Biagi, E; Brigidi, P; Troiani, E; Candela, M				Barone, Monica; Turroni, Silvia; Rampelli, Simone; Soverini, Matteo; D'Amico, Federica; Biagi, Elena; Brigidi, Patrizia; Troiani, Emidio; Candela, Marco			Gut microbiome response to a modern Paleolithic diet in a Western lifestyle context	PLOS ONE			English	Article							INFLAMMATION; IMPACT	The modern Paleolithic diet (MPD), featured by the consumption of vegetables, fruit, nuts, seeds, eggs, fish and lean meat, while excluding grains, dairy products, salt and refined sugar, has gained substantial public attention in recent years because of its potential multiple health benefits. However, to date little is known about the actual impact of this dietary pattern on the gut microbiome (GM) and its implications for human health. In the current scenario where Western diets, low in fiber while rich in industrialized and processed foods, are considered one of the leading causes of maladaptive GM changes along human evolution, likely contributing to the increasing incidence of chronic non-communicable diseases, we hypothesize that the MPD could modulate the Western GM towards a more "ancestral" configuration. In an attempt to shed light on this, here we profiled the GM structure of urban Italian subjects adhering to the MPD, and compared data with other urban Italians following a Mediterranean Diet (MD), as well as worldwide traditional hunter-gatherer populations from previous publications. Notwithstanding a strong geography effect on the GM structure, our results show an unexpectedly high degree of biodiversity in MPD subjects, which well approximates that of traditional populations. The GM of MPD individuals also shows some peculiarities, including a high relative abundance of bile-tolerant and fat-loving microorganisms. The consumption of plant-based foods-albeit with the exclusion of grains and pulses-along with the minimization of the intake of processed foods, both hallmarks of the MPD, could therefore contribute to partially rewild the GM but caution should be taken in adhering to this dietary pattern in the long term.	[Barone, Monica; Turroni, Silvia; Rampelli, Simone; Soverini, Matteo; D'Amico, Federica; Biagi, Elena; Brigidi, Patrizia; Candela, Marco] Univ Bologna, Dept Pharm & Biotechnol, Unit Microbial Ecol Hlth, Bologna, Italy; [Troiani, Emidio] Social Secur Inst, Primary Care Unit, Cailungo, San Marino; [Troiani, Emidio] Social Secur Inst, Terr Hlth, Cailungo, San Marino	University of Bologna	Turroni, S (corresponding author), Univ Bologna, Dept Pharm & Biotechnol, Unit Microbial Ecol Hlth, Bologna, Italy.	silvia.turroni@unibo.it	TROIANI, EMIDIO/AHC-2826-2022; Turroni, Silvia/J-7195-2016; D'Amico, Federica/AAA-7556-2019; Rampelli, Simone/K-5675-2016; Barone, Monica/AAA-3514-2019	TROIANI, EMIDIO/0000-0002-5173-8174; Turroni, Silvia/0000-0003-2345-9482; D'Amico, Federica/0000-0002-2136-9558; Rampelli, Simone/0000-0002-5655-6695; Barone, Monica/0000-0001-5229-570X; Soverini, Matteo/0000-0002-3026-9460				Ayeni FA, 2018, CELL REP, V23, P3056, DOI 10.1016/j.celrep.2018.05.018; Biagi E, 2016, CURR BIOL, V26, P1480, DOI 10.1016/j.cub.2016.04.016; Blaser MJ, 2017, NAT REV IMMUNOL, V17, P461, DOI 10.1038/nri.2017.77; Caesar R, 2015, CELL METAB, V22, P658, DOI 10.1016/j.cmet.2015.07.026; Cani PD, 2018, NAT REV GASTRO HEPAT, V15, P671, DOI 10.1038/s41575-018-0025-6; Cani PD, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01765; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Cotillard A, 2013, NATURE, V500, P585, DOI 10.1038/nature12480; Coyte KZ, 2015, SCIENCE, V350, P663, DOI 10.1126/science.aad2602; Dall'Asta C, 2012, MOL NUTR FOOD RES, V56, P632, DOI 10.1002/mnfr.201100515; Danchin A, 2018, ENVIRON MICROBIOL, V20, P1966, DOI 10.1111/1462-2920.14255; Dao MC, 2016, GUT, V65, P426, DOI 10.1136/gutjnl-2014-308778; Davenport ER, 2017, BMC BIOL, V15, DOI 10.1186/s12915-017-0454-7; David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820; De Filippis F, 2016, GUT, V65, P1812, DOI 10.1136/gutjnl-2015-309957; De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107; Deschasaux M, 2018, NAT MED, V24, P1526, DOI 10.1038/s41591-018-0160-1; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; El Kaoutari A, 2013, NAT REV MICROBIOL, V11, P497, DOI 10.1038/nrmicro3050; Genoni A, 2016, NUTRIENTS, V8; Genoni A, 2019, BRIT J NUTR, V121, P322, DOI 10.1017/S000711451800329X; Girard C, 2017, MSPHERE, V2, DOI 10.1128/mSphere.00297-16; Gorvitovskaia A, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0160-7; Groves HT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00182; Haas BJ, 2011, GENOME RES, V21, P494, DOI 10.1101/gr.112730.110; He Y, 2018, NAT MED, V24, P1532, DOI 10.1038/s41591-018-0164-x; Johnson KVA, 2016, GUT MICROBES, V7, P455, DOI 10.1080/19490976.2016.1241933; Jonsson T, 2009, CARDIOVASC DIABETOL, V8, DOI 10.1186/1475-2840-8-35; Klindworth A, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks808; Lahti L, 2013, PEERJ, V1, DOI 10.7717/peerj.32; Lindeberg S, 2007, DIABETOLOGIA, V50, P1795, DOI 10.1007/s00125-007-0716-y; Lozupone CA, 2012, NATURE, V489, P220, DOI 10.1038/nature11550; Martin G, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01153; Masella AP, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-31; Mellberg C, 2014, EUR J CLIN NUTR, V68, P350, DOI 10.1038/ejcn.2013.290; Moeller AH, 2014, P NATL ACAD SCI USA, V111, P16431, DOI 10.1073/pnas.1419136111; Mosca A, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00455; Obregon-Tito AJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7505; Otten J, 2018, DIABETOLOGIA, V61, P1548, DOI 10.1007/s00125-018-4618-y; Otten J, 2017, DIABETES-METAB RES, V33, DOI 10.1002/dmrr.2828; Rajilic-Stojanovic M, 2014, FEMS MICROBIOL REV, V38, P996, DOI 10.1111/1574-6976.12075; Schnorr SL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4654; Smits SA, 2017, SCIENCE, V357, P802, DOI 10.1126/science.aan4834; Sonnenburg ED, 2014, CELL METAB, V20, P779, DOI 10.1016/j.cmet.2014.07.003; Whalen KA, 2016, J NUTR, V146, P1217, DOI 10.3945/jn.115.224048; Wirbel J, 2019, NAT MED, V25, P679, DOI 10.1038/s41591-019-0406-6; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Zuo T, 2018, NAT REV GASTRO HEPAT, V15, P440, DOI 10.1038/s41575-018-0003-z	48	34	37	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2019	14	8							e0220619	10.1371/journal.pone.0220619	http://dx.doi.org/10.1371/journal.pone.0220619			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5EW	31393934	Green Published, gold, Green Submitted			2023-01-03	WOS:000485002500048
J	Kang, SY; Sen, A; Bai, G; Anderson, GF				Kang, So-Yeon; Sen, Aditi; Bai, Ge; Anderson, Gerard F.			Financial Eligibility Criteria and Medication Coverage for Independent Charity Patient Assistance Programs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPROVE ADHERENCE; DRUG COUPONS; COSTS	ImportanceAlthough independent charity patient assistance programs improve patient access to costly prescription drugs, recent federal investigations have raised questions about their potential to increase pharmaceutical spending and to violate the federal Anti-Kickback Statute. Little is known about the design of the programs, patient eligibility, or drug coverage. ObjectiveTo examine the eligibility criteria of the independent charity patient assistance programs and the drugs covered by them. Design, Setting, and ParticipantsDescriptive cross-sectional study of the 6 largest independent charities offering patient assistance programs for patients including, but not limited to, Medicare beneficiaries in 2018. These charities offered 274 different disease-specific patient assistance programs. Drugs were identified for subgroup analysis that had any use reported on the Medicare Part D spending dashboard and any off-patent brand-name drugs that incurred more than $10000 in Medicare spending per beneficiary in 2016. ExposuresSupport by independent charity patient assistance programs. Main Outcomes and MeasuresThe primary outcomes were the characteristics of patient assistance programs, including assistance type, insurance coverage (vs uninsured), and income eligibility. The secondary outcomes were the cost of the drugs covered by the patient assistance programs and the coverage of expensive off-patent brand-name drugs vs substitutable generic drugs. ResultsAmong the 6 independent charity foundations included in the analysis, their total revenue in 2017 ranged from $24 million to $532 million, and expenditures on patient assistance programs ranged from $24 million to $353 million, representing on average, 86% of their revenue. Of the 274 patient assistance programs offered by these organizations, 168 (61%) provided only co-payment assistance, and the most common therapeutic area covered was cancer or cancer treatment-related symptoms (113 patient assistance programs; 41%). A total of 267 programs (97%) required insurance coverage as an eligibility criterion (ie, excluded uninsured patients). The most common income eligibility limit was 500% of the federal poverty level. The median annual cost of the drugs per beneficiary covered by the programs was $1157 (interquartile range, $247-$5609) compared with $367 (interquartile range, $100-$1500) for the noncovered drugs. Off-patent brand-name drugs (cost: >$10000) were covered by a mean of 3.1 (SD, 2.0) patient assistance programs, whereas their generic equivalents were covered by a mean of 1.2 (SD, 1.0) patient assistance programs. Conclusions and RelevanceIn 2018, among 274 patient assistance programs operated by the 6 independent charity foundations, the majority did not provide coverage for uninsured patients. Medications that were covered by the patient assistance programs were generally more expensive than those that were not covered.	[Kang, So-Yeon; Sen, Aditi; Bai, Ge; Anderson, Gerard F.] Johns Hopkins Univ, Dept Hlth Policy & Management, Bloomberg Sch Publ Hlth, 624 N Broadway, Baltimore, MD 21205 USA; [Bai, Ge] Johns Hopkins Univ, Carey Business Sch, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University	Anderson, GF (corresponding author), Johns Hopkins Univ, Dept Hlth Policy & Management, Bloomberg Sch Publ Hlth, 624 N Broadway, Baltimore, MD 21205 USA.	ganderson@jhu.edu			Arnold Ventures	Arnold Ventures	This research was funded by grants from Arnold Ventures.	Bidwal M, 2017, RES SOC ADMIN PHARM, V13, P759, DOI 10.1016/j.sapharm.2016.07.007; Centers for Medicare and Medicaid Services, PHARM MAN PAT ASS PR; Centers for Medicare & Medicaid Services, MED PRESCR DRUG BEN; Centers for Medicare & Medicaid Services, MED D; Choudhry NK, 2009, HEALTH AFFAIR, V28, P827, DOI 10.1377/hlthaff.28.3.827; Chronic Condition Data Warehouse, DOLL AM MED D; Congressional Research Service, PRESCR DR1G DISC COU; Cubanski J, CLOSING MED D; Cubanski J, NO LIMIT MED D; Dafny L, 2017, AM ECON J-ECON POLIC, V9, P91, DOI 10.1257/pol.20150588; Frerick A., 2016, TAX NOTES, V153, P1151; Friedman B, EMERGING ENFORCEMENT; HealthCare.gov, 2018 FED POV LEV CON; HealthWell Foundation, 2017 ANN REP; HealthWell Foundation, HELP UND AFF CRIT ME; Howard DH, 2014, NEW ENGL J MED, V371, P97, DOI 10.1056/NEJMp1401658; Kang SY, 2019, AM J PUBLIC HEALTH, V109, P559, DOI 10.2105/AJPH.2018.304946; Office of Inspector General, SPEC ADV B PHARM MAN; PAN Foundation, 2017 ANN REP; Patient Access Network Foundation, HIGH DED COP SHOULDN; Ross JS, 2013, NEW ENGL J MED, V369, P1188, DOI 10.1056/NEJMp1301993; Starner CI, 2014, HEALTH AFFAIR, V33, P1761, DOI 10.1377/hlthaff.2014.0497; Tigas M, NONPROFIT EXPLORER D; U.S. Food and Drug Administration, APPR DRUG PROD THER, V42; US Department of Justice, DRUG MAK ACT AGR PAY; US Department of Justice, 3 PHARM CO AGR PAY T; US Department of Justice, 2 PHARM CO AGR PAY T; US Deptartment of Health and Human Services, GEN RAR DIS INF CTR; Yezefski T, 2018, SEMIN HEMATOL, V55, P185, DOI 10.1053/j.seminhematol.2017.07.004; Zullig LL, 2017, J MANAG CARE SPEC PH, V23, P407, DOI 10.18553/jmcp.2017.23.4.407	30	21	21	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	2019	322	5					422	429		10.1001/jama.2019.9943	http://dx.doi.org/10.1001/jama.2019.9943			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IP8JR	31386135	Green Published, Bronze			2023-01-03	WOS:000480293200015
J	Manrique, G; Garcia, M; Fernandez, SN; Gonzalez, R; Solana, MJ; Lopez, J; Urbano, J; Lopez-Herce, J				Manrique, Gema; Garcia, Miriam; Fernandez, Sarah N.; Gonzalez, Rafael; Solana, Maria J.; Lopez, Jorge; Urbano, Javier; Lopez-Herce, Jesus			Comparison between synchronized and non-synchronized ventilation and between guided and non-guided chest compressions during resuscitation in a pediatric animal model after asphyxial cardiac arrest	PLOS ONE			English	Article							2017 INTERNATIONAL CONSENSUS; CARDIOVASCULAR CARE SCIENCE; CARDIOPULMONARY-RESUSCITATION; QUALITY; CPR; FEEDBACK; HYPERVENTILATION; ASSOCIATION; GUIDELINES; STANDARD	Introduction There are no studies comparing synchronized and non-synchronized ventilation with bag-valve mask ventilation (BVMV) during cardiopulmonary resuscitation (CPR) in pediatric patients. The main aim is to compare between synchronized and non-synchronized BVMV with chest compressions (CC), and between guided and non-guided CC with a real-time feedback-device in a pediatric animal model of asphyxial cardiac arrest (CA). The secondary aim is to analyze the quality of CC during resuscitation. Methods 60 piglets were randomized for CPR into four groups: Group A: guided-CC and synchronized ventilation; Group B: guided-CC and non-synchronized ventilation; Group C: non-guided CC and synchronized ventilation; Group D: non-guided CC and non-synchronized ventilation. Return of spontaneous circulation (ROSC), hemodynamic and respiratory parameters, and quality of CC were compared between all groups. Results 60 piglets were included. Twenty-six (46.5%) achieved ROSC: A (46.7%), B (66.7%), C (26.7%) and D (33.3%). Survival rates were higher in group B than in groups A+C+D (66.7% vs 35.6%, p = 0.035). ROSC was higher with guided-CC (A+B 56.7% vs C+D 30%, p = 0.037). Piglets receiving non-synchronized ventilation did not show different rates of ROSC than synchronized ventilation (B+D 50% vs A+C 36.7%, p = 0.297). Non-synchronized groups showed lower arterial pCO(2) after 3 minutes of CPR than synchronized groups: 57 vs 71 mmHg, p = 0.019. No differences were found in arterial pH and pO(2), mean arterial pressure (MAP) or cerebral blood flow between groups. Chest compressions were shallower in surviving than in non-surviving piglets (4.7 vs 5.1 cm, p = 0.047). There was a negative correlation between time without CC and MAP (r = -0.35, p = 0.038). Conclusions The group receiving non-synchronized ventilation and guided-CC obtained significantly higher ROSC rates than the other modalities of resuscitation. Guided-CC achieved higher ROSC rates than non-guided CC. Non-synchronized ventilation was associated with better ventilation parameters, with no differences in hemodynamics or cerebral flow.	[Manrique, Gema; Garcia, Miriam; Fernandez, Sarah N.; Gonzalez, Rafael; Solana, Maria J.; Lopez, Jorge; Urbano, Javier; Lopez-Herce, Jesus] Hosp Univ Gregorio Maranon, Pediat Intens Care Dept, Madrid, Spain; [Manrique, Gema; Urbano, Javier; Lopez-Herce, Jesus] Univ Complutense Madrid, Fac Med, Maternal & Child Publ Hlth Dept, Madrid, Spain; [Manrique, Gema; Garcia, Miriam; Fernandez, Sarah N.; Gonzalez, Rafael; Solana, Maria J.; Lopez, Jorge; Urbano, Javier; Lopez-Herce, Jesus] Hosp Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain; [Manrique, Gema; Garcia, Miriam; Fernandez, Sarah N.; Gonzalez, Rafael; Solana, Maria J.; Lopez, Jorge; Urbano, Javier; Lopez-Herce, Jesus] Hosp Univ Gregorio Maranon, Res Network Maternal & Child Hlth & Dev RedSAMID, Madrid, Spain	General University Gregorio Maranon Hospital; Complutense University of Madrid; General University Gregorio Maranon Hospital; General University Gregorio Maranon Hospital	Urbano, J (corresponding author), Hosp Univ Gregorio Maranon, Pediat Intens Care Dept, Madrid, Spain.; Urbano, J (corresponding author), Univ Complutense Madrid, Fac Med, Maternal & Child Publ Hlth Dept, Madrid, Spain.; Urbano, J (corresponding author), Hosp Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain.; Urbano, J (corresponding author), Hosp Univ Gregorio Maranon, Res Network Maternal & Child Hlth & Dev RedSAMID, Madrid, Spain.	javierurbanovillaescusa@gmail.com	Lopez, Jorge/AAD-4109-2022; Fernandez Lafever, Sarah Nicole/AAE-4978-2022; López, Jorge Eduardo/HJA-7565-2022; Lopez-Herce, Jesus/A-1602-2019	Lopez, Jorge/0000-0002-9942-6399; Fernandez Lafever, Sarah Nicole/0000-0003-4859-5966; Lopez-Herce, Jesus/0000-0001-6105-9178; MANRIQUE MARTIN, GEMA/0000-0002-1311-9022; Urbano, Javier/0000-0002-3511-2905; Gonzalez Cortes, Rafael/0000-0002-3259-7898	Carlos III Health Institute - European Union ERDF funds (European Regional Development Fund) [RD16/0022/0007, PI15/00743]; Mother-Child Health and Development Network (Red SAMID) - RETICS - PN I+D+I 2008-2011 (Spain), ISCIIISub-Directorate General for Research Assessment and Promotion	Carlos III Health Institute - European Union ERDF funds (European Regional Development Fund); Mother-Child Health and Development Network (Red SAMID) - RETICS - PN I+D+I 2008-2011 (Spain), ISCIIISub-Directorate General for Research Assessment and Promotion	This work was supported by the Carlos III Health Institute, responsible for Spain's Health Research and Development Strategy, co-financed by the European Union ERDF funds (European Regional Development Fund), ref. RD16/0022/0007, with reference PI15/00743 to JL-H, and the Mother-Child Health and Development Network (Red SAMID) - RETICS funded by the PN I+D+I 2008-2011 (Spain), ISCIIISub-Directorate General for Research Assessment and Promotion. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersen LW, 2016, JAMA-J AM MED ASSOC, V316, P1786, DOI 10.1001/jama.2016.14486; Atkins DL, 2018, CIRCULATION, V137, pE1, DOI 10.1161/CIR.0000000000000540; Aufderheide Tom P, 2004, Crit Care Med, V32, pS345, DOI 10.1097/01.CCM.0000134335.46859.09; Aufderheide TP, 2004, CIRCULATION, V109, P1960, DOI 10.1161/01.CIR.0000126594.79136.61; Berg RA, 2000, CIRCULATION, V101, P1743; Bobrow BJ, 2010, JAMA-J AM MED ASSOC, V304, P1447, DOI 10.1001/jama.2010.1392; Botran M, 2011, INTENS CARE MED, V37, P1873, DOI 10.1007/s00134-011-2338-6; Cortegiani A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1740-z; Ewy GA, 2007, CIRCULATION, V116, P2525, DOI 10.1161/CIRCULATIONAHA.107.711820; Gazmuri RJ, 2012, RESUSCITATION, V83, P259, DOI 10.1016/j.resuscitation.2011.07.034; Gonzalez R, 2017, WORLD J PEDIATR, V13, P544, DOI 10.1007/s12519-017-0061-2; Jones A, 2015, RESUSCITATION, V90, P50, DOI 10.1016/j.resuscitation.2015.01.036; Kill C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127759; Kill C, 2014, CRIT CARE MED, V42, pE89, DOI 10.1097/CCM.0b013e3182a63fa0; Lin S, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1371-9; Lopez J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188846; Lopez J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162185; Maconochie IK, 2015, RESUSCITATION, V95, P223, DOI 10.1016/j.resuscitation.2015.07.028; Meert KL, 2009, PEDIATR CRIT CARE ME, V10, P544, DOI 10.1097/PCC.0b013e3181a7045c; Morgan RW, 2019, RESUSCITATION, V139, P1, DOI 10.1016/j.resuscitation.2019.03.032; Nichol G, 2015, NEW ENGL J MED, V373, P2203, DOI 10.1056/NEJMoa1509139; Olasveengen TM, 2017, CIRCULATION, V136, pE424, DOI 10.1161/CIR.0000000000000541; Olasveengen TM, 2017, RESUSCITATION, V121, P201, DOI 10.1016/j.resuscitation.2017.10.021; Tanaka Shota, 2017, BMJ Open Sport Exerc Med, V3, pe000208, DOI 10.1136/bmjsem-2016-000208; Vahedian-Azimi A, 2016, CRITICAL CARE, V20, P1, DOI [10.1186/s13054-015-1178-0, DOI 10.1186/S13054-015-1178-0]; Wallace SK, 2013, CIRC-CARDIOVASC QUAL, V6, P148, DOI 10.1161/CIRCOUTCOMES.111.000041; Yang ZF, 2017, J THORAC DIS, V9, P3232, DOI 10.21037/jtd.2017.08.167; Yeung J, 2014, RESUSCITATION, V85, P898, DOI 10.1016/j.resuscitation.2014.02.018; Yeung J, 2009, RESUSCITATION, V80, P743, DOI 10.1016/j.resuscitation.2009.04.012; Zapletal B, 2014, RESUSCITATION, V85, P560, DOI 10.1016/j.resuscitation.2013.10.028	31	8	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2019	14	7							e0219660	10.1371/journal.pone.0219660	http://dx.doi.org/10.1371/journal.pone.0219660			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IS7PC	31318890	Green Published, gold, Green Submitted			2023-01-03	WOS:000482340700038
J	Sofeu, CL; Tejiokem, MC; Penda, CI; Protopopescu, C; Ndongo, FA; Ndiang, ST; Guemkam, G; Warszawski, J; Faye, A; Giorgi, R; Barre-Sinoussi, F; Scott, D; Tangy, F; Blanche, S; Dollfus, C; Baril, L; Kfutwah, A; Penda, I; Denise, E; Nomegne, E; Yuya, F; William, M; Alain, NP; Felicite, O; Ledoux, SC; Patrice, T; Juste, B; Marie, EJ; Armel, E; Patricia, M; Audrey, NJ; Felicite, N; Robinson, M; Paul, K; Ernestine, B; Louise, BM; Dieudonne, E; Gweha, D; Annie, N; Suzanne, N; Anne, NN; Yvette, O; Guillaume, W; Zeudja; Michelle, A; Jean, D; Julie, D; Valery, E; Nicaise, M; Madeleine, MP; Aurore, NS; Ngwa; Shiro, O				Sofeu, Casimir Ledoux; Tejiokem, Mathurin Cyrille; Penda, Calixte Ida; Protopopescu, Camelia; Ndongo, Francis Ateba; Ndiang, Suzie Tetang; Guemkam, Georgette; Warszawski, Josiane; Faye, Albert; Giorgi, Roch; Barre-Sinoussi, Francoise; Scott, Daniel; Tangy, Frederic; Blanche, Stephane; Dollfus, Catherine; Baril, Laurence; Kfutwah, Anfumbom; Penda, Ida; Denise, Epouner; Nomegne, Etienne; Yuya, Francis; William, Mbanzouen; Alain, Ngoupo Paul; Felicite, Owona; Ledoux, Sofeu Casimir; Patrice, Tchendjou; Juste, Bossolo; Marie, Ehongo Jean; Armel, Evouna; Patricia, Mbida; Audrey, Ndongo Jean; Felicite, Nguefack; Robinson, Mbu; Paul, Koki; Ernestine, Bekono; Louise, Belinga Marie; Dieudonne, Evoundou; Gweha, Derboise; Annie, Nga; Suzanne, Nguen; Anne, Njom Nlend; Yvette, Onono; Guillaume, Wamba; Zeudja; Michelle, Alibien; Jean, Dissongo, II; Julie, Djene; Valery, Ewane; Nicaise, Makwet; Madeleine, Mbangue Prime; Aurore, Ngo Sohna; Ngwa; Shiro, Obedat		ANRS-PEDIACAM Study Grp	Early treated HIV-infected children remain at risk of growth retardation during the first five years of life: Results from the ANRS-PEDIACAM cohort in Cameroon	PLOS ONE			English	Article							RECEIVING ANTIRETROVIRAL THERAPY; AGE; INITIATION; MALNUTRITION; BORN; ART	Background Long-term growth in HIV-infected infants treated early in resource-limited settings is poorly documented. Incidence of growth retardation, instantaneous risk of death related to malnutrition and growth parameters evolution during the first five years of life of uninfected and early treated HIV-infected children were compared and associated factors with growth retardation were identified. Methods Weight-for-age (WAZ), weight-for-length (WLZ), and length-for-age (LAZ) Z-scores were calculated. The ANRS-PEDIACAM cohort includes four groups of infants with three enrolled during the first week of life: HIV-infected (HI, n = 69), HIV-exposed uninfected (HEU, n = 205) and HIV-unexposed uninfected (HUU, n = 196). The last group included HIV-infected infants diagnosed before 7 months of age (HIL, n = 141). The multi-state Markov model was used to describe the incidence of growth retardation and identified associated factors. Results During the first 5 years, 27.5% of children experienced underweight (WAZ<-2), 60.4% stunting (LAZ<-2) and 41.1% wasting (WLZ<-2) at least once. The instantaneous risk of death observed from underweight state (35.3 [14.1-88.2], 84.0 [25.5-276.3], and 6.0 [1.5-24.1] per 1000 person-months for 0-6 months, 6-12 months, and 12-60 months respectively) was higher than from non-underweight state (9.6 [5.7-16.1], 20.1 [10.3-39.4] and 0.3 [0.1-0.9] per 1000 person-months). Compared to HEU, HIL and HI children were most at risk of wasting (adjusted HR (aHR) = 4.3 (95% CI: 1.9-9.8), P< 0.001 and aHR = 3.3 (95% CI: 1.4-7.9), P = 0.01 respectively) and stunting for HIL (aHR = 8.4 (95% CI: 2.4-29.7). The risk of underweight was higher in HEU compared to HUU children (aHR = 5.0 (CI: 1.4-10.0), P = 0.001). Others associated factors to growth retardation were chronic pathologies, small size at birth, diarrhea and CD4< 25%. Conclusions HIV-infected children remained at high risk of wasting and stunting within the first 5 years period of follow-up. There is a need of identifying suitable nutritional support and best ways to integrate it with cART in pediatric HIV infection global care.	[Sofeu, Casimir Ledoux; Tejiokem, Mathurin Cyrille] Ctr Pasteur Cameroun, Serv Epidemiol & Sante Publ, Yaounde, Cameroon; [Sofeu, Casimir Ledoux; Protopopescu, Camelia; Giorgi, Roch] Aix Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France; [Sofeu, Casimir Ledoux] Univ Bordeaux, ISPED, INSERM, Bordeaux Populat Hlth U1219 Biostat, Bordeaux, France; [Penda, Calixte Ida] Univ Douala, Fac Med Sci Pharmaceut, Douala, Cameroon; [Penda, Calixte Ida] Hop Laquintinie, Hop Jour, Douala, Cameroon; [Ndongo, Francis Ateba; Guemkam, Georgette] Fdn Chantal Biya, Ctr Mere & Enfant, Yaounde, Cameroon; [Ndiang, Suzie Tetang] Ctr Hosp Essos, Yaounde, Cameroon; [Warszawski, Josiane] INSERM, U1018, CESP, Equipe VIH & IST 4, Le Kremlin Bicetre, France; [Warszawski, Josiane] Hop Bicetre, AP HP, Serv Epidemiol & Sante Publ, Le Kremlin Bicetre, France; [Warszawski, Josiane] Univ Paris Sud 11, Paris, France; [Faye, Albert] Hop Robert Debre, AP HP, Pediat Gen, Paris, France; [Faye, Albert] Univ Paris 07, Sorbonne Paris Cite, Paris, France; [Faye, Albert] INSERM, UMR 1123, ECEVE, Paris, France; [Giorgi, Roch] Hop La Timone, AP HP, Serv Biostat & Technol Informat & Commun, Marseille, France; [Faye, Albert] Univ Paris 07, Hop Robert Debre, Paris, France; [Tejiokem, Mathurin Cyrille; Kfutwah, Anfumbom; Denise, Epouner; Nomegne, Etienne; Yuya, Francis; William, Mbanzouen; Alain, Ngoupo Paul; Felicite, Owona; Ledoux, Sofeu Casimir; Patrice, Tchendjou] Ctr Pasteur Cameroun, Yaounde, Cameroon; [Barre-Sinoussi, Francoise; Scott, Daniel] Inst Pasteur Paris, Unite Regulat Infect Retrovirales, Paris, France; [Tangy, Frederic] Inst Pasteur Paris, Unite Genom Virale & Vaccinant, Paris, France; [Blanche, Stephane] Hop Necker Enfants Malad, Serv Immunol & Hematol Pediat, Paris, France; [Dollfus, Catherine] Hop Trousseau, Paris, France; [Baril, Laurence] GSK Bio, Risenxart, Belgium; [Penda, Ida] Hop Laquintinie, Douala, Cameroon; [Juste, Bossolo; Marie, Ehongo Jean; Armel, Evouna; Patricia, Mbida; Audrey, Ndongo Jean; Felicite, Nguefack; Robinson, Mbu; Paul, Koki] Ctr Hosp Matern, Mother & Child Care Ctr Yaounde, Yaounde, Cameroon; [Ernestine, Bekono; Louise, Belinga Marie; Dieudonne, Evoundou; Gweha, Derboise; Annie, Nga; Suzanne, Nguen; Anne, Njom Nlend; Yvette, Onono; Guillaume, Wamba; Zeudja] Essos Hosp Ctr Yaounde, Yaounde, Cameroon; [Michelle, Alibien; Jean, Dissongo, II; Julie, Djene; Valery, Ewane; Nicaise, Makwet; Madeleine, Mbangue Prime; Aurore, Ngo Sohna; Ngwa; Shiro, Obedat] Laquintinie Hosp Douala, Douala, Cameroon	Centre Pasteur du Cameroun; Institut de Recherche pour le Developpement (IRD); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre Pasteur du Cameroun; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; GlaxoSmithKline	Sofeu, CL (corresponding author), Ctr Pasteur Cameroun, Serv Epidemiol & Sante Publ, Yaounde, Cameroon.; Sofeu, CL (corresponding author), Aix Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France.; Sofeu, CL (corresponding author), Univ Bordeaux, ISPED, INSERM, Bordeaux Populat Hlth U1219 Biostat, Bordeaux, France.	scl.ledoux@gmail.com	GIORGI, Roch/A-6438-2009	GIORGI, Roch/0000-0001-6135-3078; Protopopescu, Camelia/0000-0003-0164-7917; Penda, Calixte Ida/0000-0002-1070-2108; SOFEU, Casimir Ledoux/0000-0002-4304-990X	French National Agency for Research on HIV/AIDS and viral hepatitis (ANRS, France)	French National Agency for Research on HIV/AIDS and viral hepatitis (ANRS, France)	This study is funded by the French National Agency for Research on HIV/AIDS and viral hepatitis (ANRS, France). The ANRS is informed at regular intervals about the progress of the study. The ANRS had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. All the co-authors have contributed collectively to this study and have approved the final version of this manuscript and its submission to PLoS ONE.	Anaky MF, 2010, B WORLD HEALTH ORGAN, V88, P490, DOI 10.2471/BLT.09.068015; Bailey RC, 1999, INT J EPIDEMIOL, V28, P532, DOI 10.1093/ije/28.3.532; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Brian CZ, 2011, PLOS ONE, V6; Chavance M, 2000, REV EPIDEMIOL SANTE, V48, P389; Debeaudrap P, 2018, AIDS, V32, P2749, DOI 10.1097/QAD.0000000000002023; Fergusson P, 2009, T ROY SOC TROP MED H, V103, P541, DOI 10.1016/j.trstmh.2008.10.029; Heidkamp RA, 2012, J NUTR, V142, P774, DOI 10.3945/jn.111.155275; INS, 2014, ENQ GRAPP IND MULT M; Jackson CH, 2011, J STAT SOFTW, V38, P1; Jesson J, 2015, MED MALADIES INFECT, V45, P149, DOI 10.1016/j.medmal.2015.03.002; Jesson J, 2018, PEDIATR INFECT DIS J, V37, P781, DOI 10.1097/INF.0000000000001932; Jesson J, 2015, PEDIATR INFECT DIS J, V34, pE159, DOI 10.1097/INF.0000000000000734; Kfutwah AKW, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2308-x; Lee PA, 2003, PEDIATRICS, V111, P1253, DOI 10.1542/peds.111.6.1253; Lepage P, 1996, PEDIATR INFECT DIS J, V15, P479, DOI 10.1097/00006454-199606000-00003; MENG XL, 1992, BIOMETRIKA, V79, P103, DOI 10.1093/biomet/79.1.103; Miller TL, 2008, J PEDIATR GASTR NUTR, V47, P247, DOI 10.1097/MPG.0b013e318181b254; Mistler SA, 2013, SAS MACROCOMPUTING P; Mwiru Ramadhani S, 2015, J Int Assoc Provid AIDS Care, V14, P172, DOI 10.1177/2325957413500852; Mwiru RS, 2014, J TROP PEDIATRICS, V60, P179, DOI 10.1093/tropej/fmt104; Newell ML, 2004, LANCET, V364, P1236, DOI 10.1016/S0140-6736(04)17140-7; OMS, 2011, SYST INF NUTR VIT MI; Parchure RS, 2015, INDIAN J PEDIATR, V82, P519, DOI 10.1007/s12098-014-1659-1; Prendergast A, 2011, AIDS, V25, P951, DOI 10.1097/QAD.0b013e328345e56b; Protopopescu C, 2009, J ANTIMICROB CHEMOTH, V64, P599, DOI 10.1093/jac/dkp232; Rondeau V, 2007, BIOSTATISTICS, V8, P708, DOI 10.1093/biostatistics/kxl043; Rouet F, 2005, J CLIN MICROBIOL, V43, P2709, DOI 10.1128/JCM.43.6.2709-2717.2005; Shelton BJ, 2003, STAT MED, V22, P2057, DOI 10.1002/sim.1469; Shiau S, 2013, J PEDIATR-US, V162, P1138, DOI 10.1016/j.jpeds.2012.11.025; Sofeu CL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093554; Sunguya BF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-869; Tejiokem MC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021840; Teklemariam Z, 2015, HIV AIDS-RES PALLIAT, V7, P191, DOI 10.2147/HIV.S78845; UNAIDS, 2014, UNAIDS GAP REP 2014; UNAIDS/WHO, FACT SHEET WORLD AID; UNICEF, 2014, COMM CHILD SURV PROM; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; WHO, 2006, WHO GENEVA; WHO, 2015, WHO AID MEM	40	6	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2019	14	7							e0219960	10.1371/journal.pone.0219960	http://dx.doi.org/10.1371/journal.pone.0219960			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IS7PC	31318938	Green Published, gold, Green Submitted			2023-01-03	WOS:000482340700076
J	Yamada, R; Odamaki, S; Araki, M; Watanabe, T; Matsuo, K; Uchida, K; Kato, T; Ozaki-Masuzawa, Y; Takenaka, A				Yamada, Riho; Odamaki, Shizuka; Araki, Masaya; Watanabe, Tasuku; Matsuo, Keigo; Uchida, Kaito; Kato, Taku; Ozaki-Masuzawa, Yori; Takenaka, Asako			Dietary protein restriction increases hepatic leptin receptor mRNA and plasma soluble leptin receptor in male rodents	PLOS ONE			English	Article							ADIPOSE-TISSUE; CIRCULATING LEPTIN; FOOD-INTAKE; OBESE GENE; OB PROTEIN; EXPRESSION; LIVER; MALNUTRITION; ACCUMULATION; ACTIVATION	Leptin is an adipokine that regulates adipose tissue mass through membrane-anchored leptin receptor (Ob-R). Extracellular domain of Ob-R in plasma is called soluble leptin receptor (sOb-R), and is the main leptin-binding protein. Based on a previous DNA microarray analysis that showed induction of hepatic Ob-R mRNA in low-protein diet-fed mice, this study aimed to clarify the effect of dietary protein restriction on hepatic Ob-R mRNA and plasma sOb-R levels. First, the effect of protein restriction on hepatic Ob-R mRNA level was examined together with fasting and food restriction using male rats as common experimental model for nutritional research. Hepatic Ob-R mRNA level was increased by feeding low-protein diet for 7 d, although not significantly influenced by 12-h fasting and sixty percent restriction in food consumption. Then, effect of protein restriction on liver Ob-R and plasma sOb-R was investigated using male mice because specific sOb-R ELISA was more available for mice. Hepatic Ob-R mRNA level was also increased in protein restricted-mice although it did not increase in hypothalamus. Hepatic Ob-R protein was decreased, whereas plasma sOb-R was increased by protein restriction. Because the concentration of sOb-R increased without changing plasma leptin concentration, free leptin in plasma was significantly reduced. The direct effect of amino acid deprivation on Ob-R mRNA level was not observed in rat hepatoma cells H4IIE cultured in amino acid deprived medium. In conclusion, dietary protein restriction increased hepatic Ob-R mRNA, resulting in increased plasma sOb-R concentration, which in turn, reduces plasma free leptin level and may modulate leptin activity.	[Yamada, Riho; Odamaki, Shizuka; Araki, Masaya; Watanabe, Tasuku; Matsuo, Keigo; Uchida, Kaito; Kato, Taku; Ozaki-Masuzawa, Yori; Takenaka, Asako] Meiji Univ, Sch Agr, Dept Agr Chem, Kawasaki, Kanagawa, Japan; [Ozaki-Masuzawa, Yori] Nihon Univ, Coll Bioresource Sci, Dept Chem & Life Sci, Fujisawa, Kanagawa, Japan	Meiji University; Nihon University	Takenaka, A (corresponding author), Meiji Univ, Sch Agr, Dept Agr Chem, Kawasaki, Kanagawa, Japan.	takenaka@meiji.ac.jp						Adams AC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049977; Akasaka Y, 2010, BBA-MOL CELL BIOL L, V1801, P1115, DOI 10.1016/j.bbalip.2010.06.009; Bruhat A, 2002, J BIOL CHEM, V277, P48107, DOI 10.1074/jbc.M206149200; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chan JL, 2002, DIABETES, V51, P2105, DOI 10.2337/diabetes.51.7.2105; Cohen P, 2005, J BIOL CHEM, V280, P10034, DOI 10.1074/jbc.M413684200; Cohen SE, 2007, J BIOL CHEM, V282, P23672, DOI 10.1074/jbc.M704053200; Commins SP, 1999, ENDOCRINOLOGY, V140, P292, DOI 10.1210/en.140.1.292; de Franca SA, 2009, NUTRITION, V25, P1186, DOI 10.1016/j.nut.2009.03.011; Du FY, 2000, J NUTR, V130, P514, DOI 10.1093/jn/130.3.514; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; Gallardo N, 2005, ENDOCRINOLOGY, V146, P4934, DOI 10.1210/en.2005-0220; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Haynes WG, 1997, J CLIN INVEST, V100, P270, DOI 10.1172/JCI119532; Lammert A, 2001, BIOCHEM BIOPH RES CO, V283, P982, DOI 10.1006/bbrc.2001.4885; Levin N, 1996, P NATL ACAD SCI USA, V93, P1726, DOI 10.1073/pnas.93.4.1726; Lou PH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011669; Margetic S, 2002, INT J OBESITY, V26, P1407, DOI 10.1038/sj.ijo.0802142; Medici V, 2010, OBESITY, V18, P2268, DOI 10.1038/oby.2010.95; Mitchell SE, 2009, J PHYSIOL-LONDON, V587, P3573, DOI 10.1113/jphysiol.2009.173328; Monteleone P, 2002, MOL PSYCHIATR, V7, P641, DOI 10.1038/sj.mp.4001043; Myers MG, 2008, ANNU REV PHYSIOL, V70, P537, DOI 10.1146/annurev.physiol.70.113006.100707; Ogier V, 2002, INT J OBESITY, V26, P496, DOI 10.1038/sj.ijo.0801951; Ozaki Y, 2015, BRIT J NUTR, V114, P1410, DOI 10.1017/S0007114515002846; Ozaki Y, 2014, BIOSCI BIOTECH BIOCH, V78, P130, DOI 10.1080/09168451.2014.877825; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Pezeshki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep25145; Schaab M, 2015, BEST PRACT RES CL EN, V29, P661, DOI 10.1016/j.beem.2015.08.002; Schaab M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034787; Stein K, 2006, J CLIN ENDOCR METAB, V91, P1021, DOI 10.1210/jc.2005-1394; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Toyoshima Y, 2014, ENDOCR J, V61, P499, DOI 10.1507/endocrj.EJ13-0514; Wang MY, 1996, FEBS LETT, V392, P87, DOI 10.1016/0014-5793(96)00790-9; Yang GQ, 2004, MOL ENDOCRINOL, V18, P1354, DOI 10.1210/me.2004-0027; Yannakoulia M, 2003, J CLIN ENDOCR METAB, V88, P1730, DOI 10.1210/jc.2002-021604; Zhang JJ, 2009, BRIT J PHARMACOL, V158, P475, DOI 10.1111/j.1476-5381.2009.00246.x; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	39	4	5	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2019	14	7							e0219603	10.1371/journal.pone.0219603	http://dx.doi.org/10.1371/journal.pone.0219603			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4RU	31306448	Green Published, Green Submitted, gold			2023-01-03	WOS:000484968200024
J	Miyashita, Y; Ishikawa, K; Fukushima, Y; Kouwaki, T; Nakamura, K; Oshiumi, H				Miyashita, Yusuke; Ishikawa, Kana; Fukushima, Yoshimi; Kouwaki, Takahisa; Nakamura, Kimitoshi; Oshiumi, Hiroyuki			Immune-regulatory microRNA expression levels within circulating extracellular vesicles correspond with the appearance of local symptoms after seasonal flu vaccination	PLOS ONE			English	Article							CYTOKINE RESPONSES; CELLS; EXOSOMES; MIR-451; BINDING	Extracellular vesicles (EVs) contain microRNAs (miRNAs) that regulate the innate immune responses, such as the production of pro-inflammatory cytokines. The excessive production of pro-inflammatory cytokines after vaccination can cause local adverse reactions, such as pain, itching, swelling, and redness. Previous studies have shown that circulating EV miR-451a regulates innate immune responses, and miR-451a levels in serum EVs are negatively correlated with the pro-inflammatory cytokine expression levels in response to the influenza vaccine. Since excessive pro-inflammatory cytokine production is a cause of the local adverse reactions to vaccination, we investigated whether miR-451a levels in serum EVs correlate with local symptoms at the vaccination site, such as pain, itching, swelling, and redness. Interestingly, miR-451a levels in serum EVs were inversely correlated with the number of symptoms after vaccination. We determined the level of several other immuneregulatory miRNAs in serum EVs. Using the immune-regulatory miRNA levels of miR-22, miR-29a, miR-451a, and miR-107, we calculated a normalized miRNA level for each healthy donor and found that the normalized miRNA levels were significantly correlated with the number of local symptoms after vaccination. Our data indicated that immune-regulatory miRNA levels in serum EVs can be used as biomarkers to assess local symptoms after influenza vaccination.	[Miyashita, Yusuke; Ishikawa, Kana; Fukushima, Yoshimi; Kouwaki, Takahisa; Oshiumi, Hiroyuki] Kumamoto Univ, Grad Sch Med Sci, Fac Life Sci, Dept Immunol,Chuo Ku, Kumamoto, Japan; [Miyashita, Yusuke; Nakamura, Kimitoshi] Kumamoto Univ, Fac Life Sci, Dept Pediat, Chuo Ku, Kumamoto, Japan	Kumamoto University; Kumamoto University	Oshiumi, H (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Fac Life Sci, Dept Immunol,Chuo Ku, Kumamoto, Japan.	oshiumi@kumamoto-u.ac.jp		Oshiumi, Hiroyuki/0000-0003-1567-8722; , Kimitoshi/0000-0003-4903-2428	Japan Agency for Medical Research and Development (AMED); Ministry of Education, Science, and Technology (MEXT); PRESTO JST; Waksman Foundation of Japan; Shinnihon Foundation of Advanced Medical Treatment Research; Naito Foundation; Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Care; Cosmetology Research Foundation	Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Ministry of Education, Science, and Technology (MEXT); PRESTO JST(Japan Science & Technology Agency (JST)); Waksman Foundation of Japan(Waksman Foundation of Japan Inc.); Shinnihon Foundation of Advanced Medical Treatment Research; Naito Foundation(Naito Memorial Foundation); Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Care; Cosmetology Research Foundation	This work was funded by the Japan Agency for Medical Research and Development (AMED), the Ministry of Education, Science, and Technology (MEXT), PRESTO JST, the Waksman Foundation of Japan, the Shinnihon Foundation of Advanced Medical Treatment Research, the Naito Foundation, the Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Care, and the Cosmetology Research Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We would like to thank all members of our laboratory for their helpful discussions and technical assistance. This work was supported in part by Grants-in-Aid from the Japan Agency for Medical Research and Development (AMED), a grant-in-aid from the Ministry of Education, Science, and Technology (MEXT), PRESTO JST, the Waksman Foundation of Japan, the Shinnihon Foundation of Advanced Medical Treatment Research, the Naito Foundation, the Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Care, and the Cosmetology Research Foundation.	Alexander M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8321; Cha DJ, 2015, ELIFE, V4, DOI 10.7554/eLife.07197; Chen T, 2011, FEBS LETT, V585, P657, DOI 10.1016/j.febslet.2011.01.027; Christian LM, 2015, VACCINE, V33, P3360, DOI 10.1016/j.vaccine.2015.05.008; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Dinarello CA, 2004, J ENDOTOXIN RES, V10, P201, DOI 10.1179/096805104225006129; Dinarello CA, 1999, J INFECT DIS, V179, pS294, DOI 10.1086/513856; Gu W, 2017, FEBS LETT, V591, P513, DOI 10.1002/1873-3468.12565; Kawabata A, 2011, BIOL PHARM BULL, V34, P1170, DOI 10.1248/bpb.34.1170; Koppers-Lalic D, 2014, CELL REP, V8, P1649, DOI 10.1016/j.celrep.2014.08.027; Kouwaki T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030666; Kouwaki T, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00335; Okamoto M, 2018, J BIOL CHEM, V293, P18585, DOI 10.1074/jbc.RA118.003862; Pan X, 2013, MOL CANCER THER, V12, P1153, DOI 10.1158/1535-7163.MCT-12-0802; Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171; Robbins PD, 2014, NAT REV IMMUNOL, V14, P195, DOI 10.1038/nri3622; Rosenberger CM, 2012, J IMMUNOL, V189, P5965, DOI 10.4049/jimmunol.1201437; Santangelo L, 2016, CELL REP, V17, P799, DOI 10.1016/j.celrep.2016.09.031; Shurtleff MJ, 2016, ELIFE, V5, DOI 10.7554/eLife.19276; Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007; Smyth LA, 2015, IMMUNOLOGY, V144, P197, DOI 10.1111/imm.12390; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016; Villarroya-Beltri C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3980; Xue XC, 2014, EUR J IMMUNOL, V44, P673, DOI 10.1002/eji.201343717	25	8	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2019	14	7							e0219510	10.1371/journal.pone.0219510	http://dx.doi.org/10.1371/journal.pone.0219510			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IS7KI	31287847	gold, Green Submitted, Green Published			2023-01-03	WOS:000482328300026
J	Perehudoff, SK; Alexandrov, NV; Hogerzeil, HV				Perehudoff, S. Katrina; Alexandrov, Nikita V.; Hogerzeil, Hans V.			The right to health as the basis for universal health coverage: A cross-national analysis of national medicines policies of 71 countries	PLOS ONE			English	Article							DRUG POLICIES; ACCESS	Persistent barriers to universal access to medicines are limited social protection in the event of illness, inadequate financing for essential medicines, frequent stock-outs in the public sector, and high prices in the private sector. We argue that greater coherence between human rights law, national medicines policies, and universal health coverage schemes can address these barriers. We present a cross-national content analysis of national medicines policies from 71 countries published between 1990-2016. The World Health Organization's ( WHO) 2001 guidelines for developing and implementing a national medicines policy and all 71 national medicines policies were assessed on 12 principles, linking a health systems approach to essential medicines with international human rights law for medicines affordability and financing for vulnerable groups. National medicines policies most frequently contain measures for medicines selection and efficient spending/cost-effectiveness. Four principles ( legal right to health; government financing; efficient spending; and financial protection of vulnerable populations) are significantly stronger in national medicines policies published after 2004 than before. Six principles have remained weak or absent: pooling user contributions, international cooperation, and four principles for good governance. Overall, South Africa ( 1996), Indonesia and South Sudan ( 2006), Philippines ( 2011-2016), Malaysia ( 2012), Somalia ( 2013), Afghanistan ( 2014), and Uganda ( 2015) include the most relevant texts and can be used as models for other settings. We conclude that WHO's 2001 guidelines have guided the content and language of many subsequent national medicines policies. WHO and national policy makers can use these principles and the practical examples identified in our study to further align national medicines policies with human rights law and with Target 3.8 for universal access to essential medicines in the Sustainable Development Goals.	[Perehudoff, S. Katrina; Alexandrov, Nikita V.; Hogerzeil, Hans V.] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Global Hlth Unit, Groningen, Netherlands; [Perehudoff, S. Katrina] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Perehudoff, S. Katrina] Univ Ghent, Int Ctr Reprod Hlth, Dept Publ Hlth & Primary Care, Ghent, Belgium	University of Groningen; University of Toronto; Ghent University; Ghent University Hospital	Perehudoff, SK (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Global Hlth Unit, Groningen, Netherlands.; Perehudoff, SK (corresponding author), Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.; Perehudoff, SK (corresponding author), Univ Ghent, Int Ctr Reprod Hlth, Dept Publ Hlth & Primary Care, Ghent, Belgium.	katrina.perehudoff@gmail.com	Perehudoff, Katrina/G-1024-2019	Perehudoff, Katrina/0000-0003-3958-0244; Alexandrov, Nikita V./0000-0001-5526-532X				Biehl J, 2016, HEALTH HUM RIGHTS, V18, P209; Bigdeli M, 2013, HEALTH POLICY PLANN, V28, P692, DOI 10.1093/heapol/czs108; Cameron A, 2011, B WHO; Ewen M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171284; Hodgkin C, 2001, DEV IMPLEMENT NATL D; Hoebert JM, 2013, J PHARM POLICY PRACT; Hogerzeil H V, 2006, B WHO, V84; Holloway KA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152020; Holloway KA, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001724; Koon AD, 2016, HEALTH POLICY PLANN, V31, P801, DOI 10.1093/heapol/czv128; Liu Y, 2017, HEALTH POLICY PLANN, V32, P170, DOI 10.1093/heapol/czw107; Mendoza-Ruiz A, 2017, PHARM POLICY COUNTRI, P193, DOI [10.1007/978-3-319-51673-8_10, DOI 10.1007/978-3-319-51673-8_10]; Moye-Holz D, 2017, GLOBALIZATION HEALTH, V13, DOI 10.1186/s12992-017-0281-1; Office of the High Commissioner for Human Rights, 2012, HRPUB125 OFF HIGH CO, P174; Perehudoff K, 2018, GLOB PUBLIC HEALTH, P1, DOI [10.1080/17441692.2018.1515237, DOI 10.1080/17441692.2018.1515237]; Perehudoff K, HLTH POL PLAN; Perehudoff K, 2019, J HUM RIGHTS PRACT, V11, P1, DOI 10.1093/jhuman/huz013; Perehudoff K, 2016, B WORLD HEALTH ORGAN, V94, P935, DOI 10.2471/BLT.15.166371; Pizzarossa LB, 2018, HEALTH HUM RIGHTS, V20, P93; Prada SI, 2018, COST EFFECT RESOUR A, V16, DOI 10.1186/s12962-018-0092-0; Ratanawijitrasin S, 2001, SOC SCI MED, V53, P831, DOI 10.1016/S0277-9536(00)00390-7; Republic of the Philippines, PHILIPPINE MEDICINES; UN Committee on Economic Social and Cultural Rights, 2016, EC12GC22 UN COMM EC; UN Committee on Economic Social and Cultural Rights, 2000, EC2000 UN CESCR; UN Committee on Economic Social and Cultural Rights, 2008, EC12GC19 UN COMM EC; UN Committee on Economic Social and Cultural Rights, 1991, E1991231991 UN COMM; WHO, 2007, EV BUS STRENGTH HLTH, P44; Wirtz VJ, 2016, LANCET, V74; World Health Organization, 2004, EQ ACC ESS MED FRAM; World Health Organization, 2014, GOOD GOV MED MOD FRA; Yamin AE, 2009, PLOS MED, V6, P147, DOI 10.1371/journal.pmed.1000032; Yang L, 2013, HLTH POLICY PLAN; Zhang Y., 2018, ADV RIGHT HLTH CARE	33	11	11	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2019	14	6							e0215577	10.1371/journal.pone.0215577	http://dx.doi.org/10.1371/journal.pone.0215577			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW3XM	31251737	Green Submitted, Green Published, gold			2023-01-03	WOS:000484915000002
J	Hotez, PJ; Fenwick, A; Molyneux, DH				Hotez, Peter J.; Fenwick, Alan; Molyneux, David H.			Collateral Benefits of Preventive Chemotherapy - Expanding the War on Neglected Tropical Diseases	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							AZITHROMYCIN	Collateral effects of mass drug administration have reduced disease burdens on a scale exceeding the intended impact on seven neglected tropical diseases. Expanding these interventions would cost-effectively increase years of healthy life for people in affected regions.	[Hotez, Peter J.] Baylor Coll Med, Natl Sch Trop Med, Houston, TX 77030 USA; [Hotez, Peter J.] Texas Childrens Hosp, Houston, TX 77030 USA; [Fenwick, Alan] Imperial Coll London, Dept Infect Dis Epidemiol, London, England; [Molyneux, David H.] Univ Liverpool Liverpool Sch Trop Med, Liverpool, Merseyside, England	Baylor College of Medicine; Baylor College of Medicine; Imperial College London; Liverpool School of Tropical Medicine	Hotez, PJ (corresponding author), Baylor Coll Med, Natl Sch Trop Med, Houston, TX 77030 USA.; Hotez, PJ (corresponding author), Texas Childrens Hosp, Houston, TX 77030 USA.							Engelman D, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002167; Hotez PJ, 2018, PLOS NEGLECT TROP D, V12; Keenan JD, 2018, NEW ENGL J MED, V378, P1583, DOI [10.1056/NEJMoa1715474, 10.1056/nejmoa1715474]; Mitja O, 2015, NEW ENGL J MED, V372, P703, DOI 10.1056/NEJMoa1408586; Smit MR, 2018, LANCET INFECT DIS, V18, P615, DOI 10.1016/S1473-3099(18)30163-4	5	16	16	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 20	2019	380	25					2389	2391		10.1056/NEJMp1900400	http://dx.doi.org/10.1056/NEJMp1900400			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IE2LF	31067365	Bronze, Green Accepted			2023-01-03	WOS:000472215000003
J	Molero, Y; Larsson, H; D'Onofrio, BM; Sharp, DJ; Fazel, S				Molero, Yasmina; Larsson, Henrik; D'Onofrio, Brian M.; Sharp, David J.; Fazel, Seena			Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANTIEPILEPTIC DRUGS; PREGABALIN; ABUSE; MISUSE; PHARMACODYNAMICS; RISK; PHARMACOKINETICS; METAANALYSIS; EFFICACY; EPILEPSY	OBJECTIVE To examine associations between gabapentinoids and adverse outcomes related to coordination disturbances (head or body injuries, or both and road traffic incidents or offences), mental health (suicidal behaviour, unintentional overdoses), and criminality. DESING Population based cohort study. SETTING High quality prescription, patient, death, and crime registers, Sweden. PARTICIPANTS 191 973 people from the Swedish Prescribed Drug Register who collected prescriptions for gabapentinoids (pregabalin or gabapentin) during 2006 to 2013. MAIN OUTCOME MEASURES Primary outcomes were suicidal behaviour, unintentional overdoses, head/body injuries, road traffic incidents and offences, and arrests for violent crime. Stratified Cox proportional hazards regression was conducted comparing treatment periods with non-treatment periods within an individual. Participants served as their own control, thus accounting for time invariant factors (eg, genetic and historical factors), and reducing confounding by indication. Additional adjustments were made by age, sex, comorbidities, substance use, and use of other antiepileptics. RESULTS During the study period, 10 026 (5.2%) participants were treated for suicidal behaviour or died from suicide, 17144 (8.9%) experienced an unintentional overdose, 12 070 (6.3%) had a road traffic incident or offence, 70 522 (36.7%) presented with head/body injuries, and 7984 (4.1%) were arrested for a violent crime. In within-individual analyses, gabapentinoid treatment was associated with increased hazards of suicidal behaviour and deaths from suicide (age adjusted hazard ratio 1.26, 95% confidence interval 1.20 to 1.32), unintentional overdoses (1.24, 1.19 to 1.28), head/body injuries (1.22, 1.19 to 1.25), and road traffic incidents and offences (1.13, 1.06 to 1.20). Associations with arrests for violent crime were less clear (1.04, 0.98 to 1.11). When the drugs were examined separately, pregabalin was associated with increased hazards of all outcomes, whereas gabapentin was associated with decreased or no statistically significant hazards. When stratifying on age, increased hazards of all outcomes were associated with participants aged 15 to 24 years. CONCLUSIONS This study suggests that gabapentinoids are associated with an increased risk of suicidal behaviour, unintentional overdoses, head/body injuries, and road traffic incidents and offences. Pregabalin was associated with higher hazards of these outcomes than gabapentin.	[Molero, Yasmina; Fazel, Seena] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; [Molero, Yasmina; Larsson, Henrik; D'Onofrio, Brian M.] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Molero, Yasmina] Karolinska Inst, Dept Clin Neurosci, Ctr Psychiat Res, Stockholm, Sweden; [Larsson, Henrik] Orebro Univ, Sch Med Sci, Orebro, Sweden; [D'Onofrio, Brian M.] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN USA; [Sharp, David J.] Imperial Coll London, Div Brain Sci, London, England	University of Oxford; Karolinska Institutet; Karolinska Institutet; Orebro University; Indiana University System; Indiana University Bloomington; Imperial College London	Fazel, S (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.	seena.fazel@psych.ox.ac.uk	Sharp, David J/A-2119-2013; Larsson, Henrik/GYD-5161-2022; Fazel, Seena/B-5307-2008	Fazel, Seena/0000-0002-5383-5365	Wellcome Trust [202836/Z/16/Z]; Swedish Research Council through the Swedish Initiative for Research on Microdata and the Social and Medical Sciences [340-2013-5867]; Swedish Research Council for Health Working Life and Welfare [2015-0028]; Karolinska Institutet Funds [2016fobi50581]; MRC [UKDRI-7006] Funding Source: UKRI	Wellcome Trust(Wellcome Trust); Swedish Research Council through the Swedish Initiative for Research on Microdata and the Social and Medical Sciences; Swedish Research Council for Health Working Life and Welfare(Swedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte)); Karolinska Institutet Funds; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was supported by the Wellcome Trust (No 202836/Z/16/Z), Swedish Research Council through the Swedish Initiative for Research on Microdata and the Social and Medical Sciences (340-2013-5867), the Swedish Research Council for Health Working Life and Welfare (2015-0028), and Karolinska Institutet Funds (2016fobi50581). The funders had no further role in the study design; in the collection, analysis, and interpretation of data; or in the writing of the paper.	Allison Paul D., 2009, FIXED EFFECTS REGRES, DOI DOI 10.4135/9781412993869; Allison PD, 1996, SOCIOL METHOD RES, V25, P207, DOI 10.1177/0049124196025002003; Andersohn F, 2010, NEUROLOGY, V75, P335, DOI 10.1212/WNL.0b013e3181ea157e; [Anonymous], 2006, SWEDISH GOVT OFFICIA, P30; Baldwin DS, 2013, NEUROPSYCH DIS TREAT, V9, P883, DOI 10.2147/NDT.S36453; Bockbrader HN, 2010, CLIN PHARMACOKINET, V49, P661, DOI 10.2165/11536200-000000000-00000; Bonnet U, 2017, EUR NEUROPSYCHOPHARM, V27, P1185, DOI 10.1016/j.euroneuro.2017.08.430; Bowie Mark W, 2007, Am J Geriatr Pharmacother, V5, P263, DOI 10.1016/j.amjopharm.2007.10.001; Brooke HL, 2017, EUR J EPIDEMIOL, V32, P765, DOI 10.1007/s10654-017-0316-1; eHalsomyndigheten, 2014, 2014028263 EHALSOMYN; European Monitoring Centre for Drugs and Drug Addiction, 2017, EUR DRUG REP 2017 TR; Evoy KE, 2017, DRUGS, V77, P403, DOI 10.1007/s40265-017-0700-x; Fazel S, 2009, JAMA-J AM MED ASSOC, V301, P2016, DOI 10.1001/jama.2009.675; Gahr M, 2013, EUR J CLIN PHARMACOL, V69, P1335, DOI 10.1007/s00228-012-1464-6; Gajraj NM, 2007, ANESTH ANALG, V105, P1805, DOI 10.1213/01.ane.0000287643.13410.5e; Gibbons RD, 2010, PHARMACOEPIDEM DR S, V19, P1241, DOI 10.1002/pds.2036; Gibbons RD, 2009, ARCH GEN PSYCHIAT, V66, P1354, DOI 10.1001/archgenpsychiatry.2009.159; Gomes T, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002396; Goodman CW, 2017, NEW ENGL J MED, V377, P411, DOI 10.1056/NEJMp1704633; Hauser W, 2010, J PAIN, V11, P505, DOI 10.1016/j.jpain.2010.01.002; Hesdorffer DC, 2010, EPILEPSY CURR, V10, P137, DOI 10.1111/j.1535-7511.2010.01382.x; IACOBUCCI G, 2017, BMJ-BRIT MED J, V358, P1454, DOI DOI 10.1136/BMJ.J4441; Iversen L., 2016, ADVICE ANTICONVULSAN; Johansen ME, 2018, JAMA INTERN MED, V178, P292, DOI 10.1001/jamainternmed.2017.7856; Ludvigsson JF, 2016, EUR J EPIDEMIOL, V31, P125, DOI 10.1007/s10654-016-0117-y; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Mangoni AA, 2004, BRIT J CLIN PHARMACO, V57, P6, DOI 10.1046/j.1365-2125.2003.02007.x; Mathieson S, 2017, NEW ENGL J MED, V376, P1111, DOI 10.1056/NEJMoa1614292; MAYOR S, 2018, BMJ-BRIT MED J, V363, P1454, DOI DOI 10.1136/BMJ.K4364; Meymandi MS, 2013, CAN J ANESTH, V60, P44, DOI 10.1007/s12630-012-9813-6; Millar J, 2013, EMERG MED J, V30, P874, DOI DOI 10.1136/EMERMED-2013-203113.20; Mitis F, 2013, EUROPEAN FACTS GLOBA, P8; Molero Y, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001875; Molero Y, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2388; Mula M, 2007, DRUG SAFETY, V30, P555, DOI 10.2165/00002018-200730070-00001; Mula M, 2011, DRUG HEALTHC PATIENT, V3, P15, DOI 10.2147/DHPS.S13070; National Council for Crime Prevention, 2017, CRIM TRENDS SWED UNT; Norton JW, 2001, CLIN NEUROPHARMACOL, V24, P245, DOI 10.1097/00002826-200107000-00011; Olesen JB, 2010, PHARMACOEPIDEM DR S, V19, P518, DOI 10.1002/pds.1932; Patorno E, 2010, JAMA-J AM MED ASSOC, V303, P1401, DOI 10.1001/jama.2010.410; Perucca E, 2005, ACTA NEUROL SCAND, V112, P30, DOI 10.1111/j.1600-0404.2005.00506.x; Philippidis A., 2017, GENETIC ENG BIOTECHN; Pinninti NR, 2001, J NEUROPSYCH CLIN N, V13, P424, DOI 10.1176/appi.neuropsych.13.3.424; PMLIVE, PMLIVE; PMLIVE, 2017, PMLIVE; Rutherford MJ, 2015, J STAT COMPUT SIM, V85, P777, DOI 10.1080/00949655.2013.845890; Sakolsky D, 2012, CHILD ADOL PSYCH CL, V21, P313, DOI 10.1016/j.chc.2012.01.005; Schifano F, 2014, CNS DRUGS, V28, P491, DOI 10.1007/s40263-014-0164-4; Schifano F, 2011, PSYCHOTHER PSYCHOSOM, V80, P118, DOI 10.1159/000321079; Sharma T, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i65; Smith RV, 2016, ADDICTION, V111, P1160, DOI 10.1111/add.13324; Straube S, 2010, RHEUMATOLOGY, V49, P706, DOI 10.1093/rheumatology/kep432; Tallian KB, 1996, EPILEPSIA, V37, P501, DOI 10.1111/j.1528-1157.1996.tb00598.x; Toth C, 2014, THER ADV DRUG SAF, V5, P38, DOI 10.1177/2042098613505614; Turner S, 2015, FALLS OLDER ADULTS E; US Food and Drug Administration, 2008, STAT REV EV ANT DRUG; Wettermark B, 2007, PHARMACOEPIDEM DR S, V16, P726, DOI 10.1002/pds.1294; Zaccara G, 2011, EPILEPSIA, V52, P826, DOI 10.1111/j.1528-1167.2010.02966.x	58	55	56	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 12	2019	365								l2147	10.1136/bmj.l2147	http://dx.doi.org/10.1136/bmj.l2147			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IE0BD	31189556	Green Published, hybrid			2023-01-03	WOS:000472050600003
J	Moss, M; Huang, DT; Brower, RG; Ferguson, ND; Ginde, AA; Gong, MN; Grissom, CK; Gundel, S; Hayden, D; Hite, RD; Hou, PC; Hough, CL; Iwashyna, TJ; Khan, A; Liu, KD; Talmor, D; Thompson, BT; Ulysse, CA; Yealy, DM; Angus, DC				Moss, Marc; Huang, David T.; Brower, Roy G.; Ferguson, Niall D.; Ginde, Adit A.; Gong, M. N.; Grissom, Colin K.; Gundel, Stephanie; Hayden, Douglas; Hite, R. Duncan; Hou, Peter C.; Hough, Catherine L.; Iwashyna, Theodore J.; Khan, Akram; Liu, Kathleen D.; Talmor, Daniel; Thompson, B. Taylor; Ulysse, Christine A.; Yealy, Donald M.; Angus, Derek C.		Natl Heart Lung Blood Inst PETAL	Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MECHANICALLY VENTILATED PATIENTS; INTENSIVE-CARE UNIT; NONLINEAR IMPUTATION; BLOCKING-AGENTS; SEDATION; RELIABILITY; MORTALITY; ICU; AGITATION; WEAKNESS	Background The benefits of early continuous neuromuscular blockade in patients with acute respiratory distress syndrome (ARDS) who are receiving mechanical ventilation remain unclear. Methods We randomly assigned patients with moderate-to-severe ARDS (defined by a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen of <150 mm Hg with a positive end-expiratory pressure [PEEP] of >= 8 cm of water) to a 48-hour continuous infusion of cisatracurium with concomitant deep sedation (intervention group) or to a usual-care approach without routine neuromuscular blockade and with lighter sedation targets (control group). The same mechanical-ventilation strategies were used in both groups, including a strategy involving a high PEEP. The primary end point was in-hospital death from any cause at 90 days. Results The trial was stopped at the second interim analysis for futility. We enrolled 1006 patients early after the onset of moderate-to-severe ARDS (median, 7.6 hours after onset). During the first 48 hours after randomization, 488 of the 501 patients (97.4%) in the intervention group started a continuous infusion of cisatracurium (median duration of infusion, 47.8 hours; median dose, 1807 mg), and 86 of the 505 patients (17.0%) in the control group received a neuromuscular blocking agent (median dose, 38 mg). At 90 days, 213 patients (42.5%) in the intervention group and 216 (42.8%) in the control group had died before hospital discharge (between-group difference, -0.3 percentage points; 95% confidence interval, -6.4 to 5.9; P=0.93). While in the hospital, patients in the intervention group were less physically active and had more adverse cardiovascular events than patients in the control group. There were no consistent between-group differences in end points assessed at 3, 6, and 12 months. Conclusions Among patients with moderate-to-severe ARDS who were treated with a strategy involving a high PEEP, there was no significant difference in mortality at 90 days between patients who received an early and continuous cisatracurium infusion and those who were treated with a usual-care approach with lighter sedation targets. (Funded by the National Heart, Lung, and Blood Institute; ROSE ClinicalTrials.gov number, .) This trial revisited research conducted about a decade ago that showed a survival benefit with early neuromuscular blockade in patients with acute respiratory distress syndrome. The new trial did not show a benefit with neuromuscular blockade with respect to overall survival or other clinical outcomes.	[Moss, Marc] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA; [Ginde, Adit A.] Univ Colorado, Sch Med, Dept Emergency Med, Aurora, CO USA; [Huang, David T.; Angus, Derek C.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; [Yealy, Donald M.] Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA USA; [Brower, Roy G.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Ferguson, Niall D.] Univ Hlth Network, Dept Med, Interdept Div Crit Care Med, Toronto, ON, Canada; [Ferguson, Niall D.] Univ Toronto, Sinai Hlth Syst, Toronto, ON, Canada; [Gong, M. N.] Montefiore Hosp, Dept Med, New York, NY USA; [Grissom, Colin K.] Intermt Med Ctr, Dept Med, Salt Lake City, UT USA; [Grissom, Colin K.] Univ Utah, Salt Lake City, UT USA; [Gundel, Stephanie; Hough, Catherine L.] Univ Washington, Dept Med, Seattle, WA USA; [Hayden, Douglas] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA; [Thompson, B. Taylor] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Ulysse, Christine A.] Massachusetts Gen Hosp, PETAL Network Clin Coordinating Ctr, Boston, MA 02114 USA; [Hou, Peter C.] Brigham & Womens Hosp, Dept Emergency Med, Div Emergency Crit Care Med, 75 Francis St, Boston, MA 02115 USA; [Talmor, Daniel] Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02215 USA; [Hite, R. Duncan] Cleveland Clin, Resp Inst, Dept Crit Care, Cleveland, OH 44106 USA; [Iwashyna, Theodore J.] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA; [Iwashyna, Theodore J.] Vet Affairs Ctr Clin Res, Ann Arbor, MI USA; [Khan, Akram] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA; [Liu, Kathleen D.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Liu, Kathleen D.] Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Intermountain Healthcare; Intermountain Medical Center; Utah System of Higher Education; University of Utah; University of Washington; University of Washington Seattle; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Cleveland Clinic Foundation; University of Michigan System; University of Michigan; Oregon Health & Science University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Angus, DC (corresponding author), Univ Pittsburgh, 3550 Terrace St, Pittsburgh, PA 15261 USA.	angusdc@upmc.edu	Angus, Derek C/E-9671-2012; Gill, Jasreen/AAU-8351-2021; Khan, Akram/AAB-6446-2022; Ferguson, Niall/D-7619-2019; Brown, Samuel/E-6846-2015; Puskarich, Michael/N-7849-2014	Gill, Jasreen/0000-0002-1703-5379; Khan, Akram/0000-0003-3091-632X; Ferguson, Niall/0000-0002-6213-5264; Gibbs, Kevin/0000-0002-5272-2289; Brown, Samuel/0000-0003-1206-6261; Puskarich, Michael/0000-0001-6358-4670; Bajwa, Ednan/0000-0001-9026-1009; Files, Daniel Clark/0000-0002-1595-4080; Banner-Goodspeed, Valerie/0000-0002-7644-2521; Douglas, Ivor/0000-0002-4541-1431; Liu, Kathleen/0000-0003-4891-8649; Hite, Robert Duncan/0000-0002-2625-8750	National Heart, Lung, and Blood Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL123022, U01HL123023, U01HL123009, U01HL123018, U01HL123010, U01HL123008, U01HL123033, U01HL122998, U01HL123004, K23HL143053, U01HL123031, U01HL122989, U01HL123027, U01HL123020] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Funded by the National Heart, Lung, and Blood Institute; ROSE ClinicalTrials.gov number, NCT02509078.	Avidan MS, 2009, BMC ANESTHESIOL, V9, P8; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; Briel M, 2010, JAMA-J AM MED ASSOC, V303, P865, DOI 10.1001/jama.2010.218; Brower RG, 2004, NEW ENGL J MED, V351, P327; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Brown SM, 2017, CRIT CARE MED, V45, P1317, DOI 10.1097/CCM.0000000000002514; Brown SM, 2016, CHEST, V150, P307, DOI 10.1016/j.chest.2016.01.003; De Jonghe B, 2002, JAMA-J AM MED ASSOC, V288, P2859, DOI 10.1001/jama.288.22.2859; Devlin JW, 2018, CRIT CARE MED, V46, P1532, DOI [10.1097/CCM.0000000000003299, 10.1097/CCM.0000000000003259]; Devlin JW, 2018, CRIT CARE MED, V46, P1003, DOI 10.1097/CCM.0000000000003142; Ferguson ND, 2013, NEW ENGL J MED, V368, P795, DOI 10.1056/NEJMoa1215554; Ferguson ND, 2012, INTENS CARE MED, V38, P1573, DOI 10.1007/s00134-012-2682-1; Galvin JE, 2005, NEUROLOGY, V65, P559, DOI 10.1212/01.wnl.0000172958.95282.2a; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Hobson J, 2015, OCCUP MED-OXFORD, V65, P764, DOI 10.1093/occmed/kqv078; Hodgson C, 2014, HEART LUNG, V43, P19, DOI 10.1016/j.hrtlng.2013.11.003; Huang DT, 2017, ANN AM THORAC SOC, V14, P124, DOI 10.1513/AnnalsATS.201608-629OT; HUNTER JM, 1995, NEW ENGL J MED, V332, P1691, DOI 10.1056/NEJM199506223322507; KLEYWEG RP, 1991, MUSCLE NERVE, V14, P1103, DOI 10.1002/mus.880141111; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Kress JP, 2014, NEW ENGL J MED, V370, P1626, DOI 10.1056/NEJMra1209390; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Marini JJ, 2006, CRIT CARE MED, V34, P2851, DOI 10.1097/01.CCM.0000248331.36982.28; Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372; Price DR, 2016, CRIT CARE MED, V44, P2070, DOI 10.1097/CCM.0000000000001839; Puthucheary Z, 2012, AM J RESP CRIT CARE, V185, P911, DOI 10.1164/rccm.201107-1320OE; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255; RIKER RR, 1994, CRIT CARE MED, V22, P433, DOI 10.1097/00003246-199403000-00013; Schenck EJ, 2019, CHEST, V155, P474, DOI 10.1016/j.chest.2018.09.031; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Shehabi Y, 2018, CRIT CARE MED, V46, P850, DOI 10.1097/CCM.0000000000003071; Shehabi Y, 2012, AM J RESP CRIT CARE, V186, P724, DOI 10.1164/rccm.201203-0522OC; Slutsky AS, 2010, NEW ENGL J MED, V363, P1176, DOI 10.1056/NEJMe1007136; Sottile PD, 2018, CRIT CARE MED, V46, pE151, DOI 10.1097/CCM.0000000000002849; Twigg E, 2008, ACTA ANAESTH SCAND, V52, P202, DOI 10.1111/j.1399-6576.2007.01531.x; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564	43	357	365	7	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 23	2019	380	21					1997	2008		10.1056/NEJMoa1901686	http://dx.doi.org/10.1056/NEJMoa1901686			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ3MG	31112383	Bronze, Green Accepted			2023-01-03	WOS:000468752200007
J	Oliva-Moreno, J; Pena-Longobardo, LM; Garcia-Mochon, L; Lozano, MD; Metcalfe, IM; Garcia-Calvente, MD				Oliva-Moreno, Juan; Maria Pena-Longobardo, Luz; Garcia-Mochon, Leticia; del Rio Lozano, Maria; Mosquera Metcalfe, Isabel; del Mar Garcia-Calvente, Maria			The economic value of time of informal care and its determinants (The CUIDARSE Study)	PLOS ONE			English	Article							OPPORTUNITY COSTS; VALUATION; PEOPLE; SUBSTITUTION; ASSISTANCE; EMPLOYMENT; SERVICES; HEALTH; IMPACT	Objective The main aims of this paper are to analyse the monetary value of informal care time using different techniques and to identify significant variables associated with the number of care-giving hours. Data and methods A multicentre study in two Spanish regions in adult caregivers was conducted. A total sample of 604 people was available. A multivariate analysis was performed to identify the variables associated with the number of hours of caregiving time. In the monetary valuation of informal care provided, three approaches were used: replacement cost method, opportunity cost and contingent valuation (willingness to pay and willingness to accept). Results The main determinants of the amount of time of informal care provided were age, gender, the level of care receiver's dependence and the professional care services received (at home and out of home). The value estimated for informal care time ranges from EUROS 80,247 (replacement cost method) to EUROS 14,325 (willingness to pay), with intermediate values of EUROS 27,140 and EUROS 29,343 (opportunity cost and willingness to accept, respectively). Several sensitivity analyses were performed over the base cases, confirming the previous results. Conclusions Time of informal care represents a great social value, regardless of the applied technique. However, the results can differ strongly depending on the technique chosen. Therefore, the choice of technique of valuation is not neutral. Among the determinants of informal care time, the professional care received at home has a complementary character to informal care, while the formal care outside the home has a substitute character.	[Oliva-Moreno, Juan; Maria Pena-Longobardo, Luz] Univ Castilla La Mancha, Dept Econ Anal, Toledo, Spain; [Oliva-Moreno, Juan; Maria Pena-Longobardo, Luz] Univ Castilla La Mancha, Seminar Res Econ & Hlth SIES, Toledo, Spain; [Garcia-Mochon, Leticia; del Rio Lozano, Maria; del Mar Garcia-Calvente, Maria] Andalusian Sch Publ Hlth EASP, Granada, Spain; [Garcia-Mochon, Leticia; del Rio Lozano, Maria; del Mar Garcia-Calvente, Maria] Biomed Res Ctr Ibs GRANADA, Granada, Spain; [Mosquera Metcalfe, Isabel] Univ Basque Country, Dept Sociol, Gipuzkoa, Spain; [Mosquera Metcalfe, Isabel] Univ Basque Country, Res Grp Social Determinants Hlth & Demog Change O, Gipuzkoa, Spain	Universidad de Castilla-La Mancha; Universidad de Castilla-La Mancha; Escuela Andaluza de Salud Publica; University of Basque Country; University of Basque Country	Pena-Longobardo, LM (corresponding author), Univ Castilla La Mancha, Dept Econ Anal, Toledo, Spain.; Pena-Longobardo, LM (corresponding author), Univ Castilla La Mancha, Seminar Res Econ & Hlth SIES, Toledo, Spain.	luzmaria.pena@uclm.es	Oliva, Juan/A-1299-2011; Garcia, Leticia/AGV-7679-2022; del Mar Garcia-Calvente, María/AAB-8235-2020; del Mar García-Calvente, María/H-8097-2012; Pena Longobardo, Luz Maria/K-6413-2017	Oliva, Juan/0000-0002-8997-0307; del Mar Garcia-Calvente, María/0000-0003-3108-4633; Pena Longobardo, Luz Maria/0000-0001-7224-2189; Garcia-Mochon, Leticia/0000-0002-6300-2738	Instituto de Salud Carlos III; European Regional Development Fund [PI12/00498]; Ministry of Economy [ECO2017-83771-C3-1-R]	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); European Regional Development Fund(European Commission); Ministry of Economy	This work has received funding from the Instituto de Salud Carlos III and the European Regional Development Fund (PI12/00498) and Ministry of Economy (ECO2017-83771-C3-1-R). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arno PS, 1999, HEALTH AFFAIR, V18, P182, DOI 10.1377/hlthaff.18.2.182; Bauer JM, 2015, J POPUL AGEING, V8, P113, DOI 10.1007/s12062-015-9116-0; Bolin K, 2008, HEALTH ECON, V17, P393, DOI 10.1002/hec.1275; Calvente MG., 2011, GAC SANIT, V25, P100, DOI [10.1016/j.gaceta.2011.09.006, DOI 10.1016/J.GACETA.2011.09.006]; Carrera F., 2013, REFORMS LONG TERM CA; Chappell N., 1991, AGEING SOC, V11, P299, DOI [10.1017/s0144686x00004189, DOI 10.1017/S0144686X00004189]; Chari AV, 2015, HEALTH SERV RES, V50, P871, DOI 10.1111/1475-6773.12238; Commission European, 2007, HLTH AG KEYST SUST E; Courtin E, 2014, HEALTH POLICY, V118, P84, DOI 10.1016/j.healthpol.2014.07.013; del Rio Lozano M, 2017, QUALITY LIFE RES, V26; EUnetHT, METH GUID METH HLTH; European Commission, 2017, AG REP 2018 2018 AG; European Commission, 2018, REP INF CAR EUR EXPL; GREENE VL, 1983, MED CARE, V21, P609, DOI 10.1097/00005650-198306000-00003; Hoefman RJ, 2013, PHARMACOECONOMICS, V31, P1105, DOI 10.1007/s40273-013-0104-z; Hollander Marcus J, 2009, Healthc Q, V12, P42; Jimenez-Martin S, 2012, EUR J HEALTH ECON, V13, P461, DOI 10.1007/s10198-011-0317-z; Kehusmaa S, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-317; Lacey L, 2017, NEUROL THER, V6, P11, DOI 10.1007/s40120-016-0056-2; Lopez-Bastida J, 2016, EUR J HEALTH ECON, V17, P1, DOI 10.1007/s10198-016-0780-7; Lundsgaard J., 2005, OECD HLTH WORKING PA; Pena-Longobardo LM, 2016, HEALTH POLICY, V120, P1177, DOI 10.1016/j.healthpol.2016.08.012; Pena-Longobardo LM, 2015, EUR J HEALTH ECON, V16, P507, DOI 10.1007/s10198-014-0604-6; Mentzakis E, 2009, REV ECON HOUSEHOLD, V7, P283, DOI 10.1007/s11150-008-9047-0; MOSCOVICE I, 1988, MED CARE, V26, P971, DOI 10.1097/00005650-198810000-00005; Mosquera I, 2016, QUAL LIFE RES, V25, P1059, DOI 10.1007/s11136-015-1159-4; MSSSI Ministerio de Sanidad Servicios Sociales e Igualdad, 2014, INF EST INV ESTR NAC; Muramatsu N, 2002, J HEALTH SOC BEHAV, V43, P107, DOI 10.2307/3090248; Navaie-Waliser M., 2002, MED CARE, P40; Neubauer S, 2008, INT PSYCHOGERIATR, V20, P1160, DOI 10.1017/S1041610208007564; OECD.Stat, 2018, HLTH STAT 2018; Oliva-Moreno J, 2017, PHARMACOECONOMICS, V35, P331, DOI 10.1007/s40273-016-0468-y; Oliva-Moreno J, 2015, APPL HEALTH ECON HEA, V13, P223, DOI 10.1007/s40258-015-0161-x; Paraponaris A, 2012, EUR J HEALTH ECON, V13, P327, DOI 10.1007/s10198-011-0305-3; PENNING MJ, 1990, GERONTOLOGIST, V30, P220, DOI 10.1093/geront/30.2.220; Pickard L, 2012, LONG TERM CARE USE S, V116, P114; Pickard L., 2011, 94 ENEPRI; Pickard L, 2015, J SOC POLICY, V44, P567, DOI 10.1017/S0047279415000069; Pickard L, 2015, AGEING SOC, V35, P96, DOI 10.1017/S0144686X13000512; Saltman RB, 2006, INT J HEALTH SERV, V36, P719, DOI 10.2190/AUL1-4LAM-4VNB-3YH0; SMITH K, 1994, HEALTH ECON, V3, P137, DOI 10.1002/hec.4730030303; Trepel D, 2011, ECON SOC REV, V42, P479; Triantafillou J., 2010, INFORMAL CARE LONG T; van den Berg B, 2006, SOC SCI MED, V62, P835, DOI 10.1016/j.socscimed.2005.06.046; van den Berg B, 2006, HEALTH ECON, V15, P447, DOI 10.1002/hec.1075; van den Berg Bernard, 2004, Eur J Health Econ, V5, P36, DOI 10.1007/s10198-003-0189-y; van Exel Job, 2008, Expert Rev Pharmacoecon Outcomes Res, V8, P557, DOI 10.1586/14737167.8.6.557; Yabroff KR, 2009, CANCER, V115, P4362, DOI 10.1002/cncr.24588; 2013, QUALITATIVE HLTH RES, V23, P1506, DOI DOI 10.1177/1049732313507144; 1996, HEALTH ECON, V5, P13, DOI DOI 10.1002/(SICI)1099-1050(199601)5:1<13::AID	50	22	24	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2019	14	5							e0217016	10.1371/journal.pone.0217016	http://dx.doi.org/10.1371/journal.pone.0217016			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HY9HS	31112587	Green Published, Green Submitted, gold			2023-01-03	WOS:000468451000033
J	Doerken, S; Avalos, M; Lagarde, E; Schumacher, M				Doerken, Sam; Avalos, Marta; Lagarde, Emmanuel; Schumacher, Martin			Penalized logistic regression with low prevalence exposures beyond high dimensional settings	PLOS ONE			English	Article							LIKELIHOOD; SHRINKAGE; SELECTION	Estimating and selecting risk factors with extremely low prevalences of exposure for a binary outcome is a challenge because classical standard techniques, markedly logistic regression, often fail to provide meaningful results in such settings. While penalized regression methods are widely used in high-dimensional settings, we were able to show their usefulness in low-dimensional settings as well. Specifically, we demonstrate that Firth correction, ridge, the lasso and boosting all improve the estimation for low-prevalence risk factors. While the methods themselves are well-established, comparison studies are needed to assess their potential benefits in this context. This is done here using the dataset of a large unmatched case-control study from France (2005-2008) about the relationship between prescription medicines and road traffic accidents and an accompanying simulation study. Results show that the estimation of risk factors with prevalences below 0.1% can be drastically improved by using Firth correction and boosting in particular, especially for ultra-low prevalences. When a moderate number of low prevalence exposures is available, we recommend the use of penalized techniques.	[Doerken, Sam; Schumacher, Martin] Univ Freiburg, Inst Med Biometry & Stat, Fac Med, Freiburg, Germany; [Doerken, Sam; Schumacher, Martin] Univ Freiburg, Med Ctr, Freiburg, Germany; [Doerken, Sam] Univ Freiburg, Freiburg Ctr Data Anal & Modeling, Freiburg, Germany; [Avalos, Marta; Lagarde, Emmanuel] Univ Bordeaux, INSERM, Bordeaux Populat Hlth Res Ctr, UMR 1219, Bordeaux, France; [Avalos, Marta] INRIA Bordeaux Sud Ouest, SISTM Team, Talence, France	University of Freiburg; University of Freiburg; University of Freiburg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Doerken, S (corresponding author), Univ Freiburg, Inst Med Biometry & Stat, Fac Med, Freiburg, Germany.; Doerken, S (corresponding author), Univ Freiburg, Med Ctr, Freiburg, Germany.; Doerken, S (corresponding author), Univ Freiburg, Freiburg Ctr Data Anal & Modeling, Freiburg, Germany.	doerken@imbi.uni-freiburg.de	AVALOS, Marta/T-5017-2019	Doerken, Sam/0000-0002-9223-8045	French National Research Agency (ANR, DAA) [0766CO204]; French Medical Research Foundation (Equipe FRM); French National Medical Research Institute (Equipe INSERM Avenir); French Direction Generale de la Sante (DGS); University of Freiburg; German Research Foundation (DFG); Afssaps	French National Research Agency (ANR, DAA)(French National Research Agency (ANR)); French Medical Research Foundation (Equipe FRM)(Fondation pour la Recherche Medicale); French National Medical Research Institute (Equipe INSERM Avenir); French Direction Generale de la Sante (DGS); University of Freiburg; German Research Foundation (DFG)(German Research Foundation (DFG)); Afssaps	The CESIR-A project was funded by the Afssaps, the French National Research Agency (ANR, DAA no 0766CO204), the French Medical Research Foundation (Equipe FRM), the French National Medical Research Institute (Equipe INSERM Avenir) and the French Direction Generale de la Sante (DGS) to EL. The article processing charge was funded by the German Research Foundation (DFG) and the University of Freiburg in the funding program Open Access Publishing.	[Anonymous], 2008, MULTIVARIABLE MODEL; Austin PC, 2002, DRUG SAFETY, V25, P677, DOI 10.2165/00002018-200225090-00006; Avalos M, 2012, EPIDEMIOLOGY, V23, P706, DOI 10.1097/EDE.0b013e31825fa528; Cole SR, 2014, AM J EPIDEMIOL, V179, P252, DOI 10.1093/aje/kwt245; Desai RJ, 2017, EPIDEMIOLOGY, V28, P249, DOI 10.1097/EDE.0000000000000595; Devika S, 2016, J POSTGRAD MED, V62, P26, DOI 10.4103/0022-3859.173193; Doerken S, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0197-0; Ewald K, 2018, ELECTRON J STAT, V12, P1358, DOI 10.1214/18-EJS1425; Gordis L., 2013, EPIDEMIOLOGY; Hastie T., 2009, ELEMENTS STAT LEARNI, V2, P1; Hastie T., 1990, GEN ADDITIVE MODELS, DOI DOI 10.1201/9780203753781; Heinze G, 2002, STAT MED, V21, P2409, DOI 10.1002/sim.1047; Heinze G, 2006, STAT MED, V25, P4216, DOI 10.1002/sim.2687; Heinze G, 2018, BIOMETRICAL J, V60, P431, DOI 10.1002/bimj.201700067; HILDESHEIM A, 1991, INT J CANCER, V49, P335, DOI 10.1002/ijc.2910490304; HOERL AE, 1970, TECHNOMETRICS, V12, P55, DOI 10.1080/00401706.1970.10488634; Hosmer D. J., 2013, APPL LOGISTIC REGRES, DOI DOI 10.1002/9781118548387; Mansournia MA, 2018, AM J EPIDEMIOL, V187, P864, DOI 10.1093/aje/kwx299; Mayr A, 2014, METHOD INFORM MED, V53, P419, DOI 10.3414/ME13-01-0122; Orriols L, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000366; Rothman KJ, 2012, MODERN EPIDEMIOLOGY; Sauerbrei W, 2014, STAT MED, V33, P5413, DOI 10.1002/sim.6265; Schuz J, 1999, INT J EPIDEMIOL, V28, P631, DOI 10.1093/ije/28.4.631; Sullivan SG, 2013, INT J EPIDEMIOL, V42, P308, DOI 10.1093/ije/dys213; Sun H, 2012, BIOINFORMATICS, V28, P1368, DOI 10.1093/bioinformatics/bts145; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Tutz G, 2006, BIOMETRICS, V62, P961, DOI 10.1111/j.1541-0420.2006.00578.x; Yates F, 1934, J R STAT SOC, V1, P217, DOI 10.2307/2983604	28	31	32	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2019	14	5							e0217057	10.1371/journal.pone.0217057	http://dx.doi.org/10.1371/journal.pone.0217057			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY7BF	31107924	gold, Green Published, Green Submitted			2023-01-03	WOS:000468285200029
J	Majtan, T; Park, I; Cox, A; Branchford, BR; di Paola, J; Bublil, EM; Kraus, JP				Majtan, Tomas; Park, Insun; Cox, Allaura; Branchford, Brian R.; di Paola, Jorge; Bublil, Erez M.; Kraus, Jan P.			Behavior, body composition, and vascular phenotype of homocystinuric mice on methionine-restricted diet or enzyme replacement therapy	FASEB JOURNAL			English	Article						cystathionine beta-synthase; homocysteine; anxiety; endothelial dysfunction; thrombosis	CYSTATHIONINE BETA-SYNTHASE; MOUSE MODELS; DEFICIENCY; OSTEOPOROSIS; MASS	Classic homocystinuria (HCU) is an inherited disorder characterized by elevated homocysteine (Hcy) in plasma and tissues resulting from cystathionine beta-synthase (CBS) deficiency. There is no cure, and patients are predominantly managed by methionine-restricted diet (MRD) to limit the production of Hcy. In this study, we used the I278T mouse model of HCU to evaluate the long-term impact of a novel enzyme replacement therapy [truncated human CBS C155 mutant modified with linear 20-kDa N-hydroxysuccinimide ester polyethylene glycol OT-58)] on clinical end points relevant to human patients with HCU. In addition, we compared its efficacy on a background of either MRD or normal methionine intake [regular diet (REG)] to that of MRD alone. We found that, compared with untreated I278T mice, OT-58 treatment of I278T mice fed with the REG diet resulted in a 90% decrease in plasma Hcy concentrations and correction of learning/cognition, endothelial dysfunction, hemostasis, bone mineralization, and body composition. On background of the MRD, OT-58 performed equally well with plasma Hcy entirely normalized. The MRD alone decreased plasma Hcy by 67% and corrected the HCU phenotype in I278T mice. However, the MRD increased anxiety and reduced bone mineral content in both I278T mice and wild-type controls. This study shows that OT-58 is a highly efficacious novel treatment for HCU on the background of either normal or restricted methionine intake.	[Majtan, Tomas; Park, Insun; Kraus, Jan P.] Univ Colorado, Sect Genet, Aurora, CO USA; [Cox, Allaura; Branchford, Brian R.; di Paola, Jorge] Univ Colorado, Sch Med, Dept Pediat, Sect Hematol Oncol, Aurora, CO USA; [Cox, Allaura; Branchford, Brian R.; di Paola, Jorge] Univ Colorado, Hemophilia & Thrombosis Ctr, Aurora, CO USA; [Bublil, Erez M.] Orphan Technol Ltd, Rapperswil, Switzerland	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Majtan, T (corresponding author), Univ Colorado, Sch Med, 12800 E 19th Ave,Mail Stop 8313, Aurora, CO 80045 USA.	tomas.majtan@ucdenver.edu	Majtan, Tomas/AAE-8426-2021	Majtan, Tomas/0000-0002-2751-2124	American Heart Association Scientist Development Grant [16SDG30040000]; Orphan Technologies, Ltd., a private pharmaceutical company developing an enzyme replacement therapy for cystathionine b-synthase (CBS)-deficient homocystinuria; U.S. National Institutes of Health, Office of the Director [1S10OD018156-01]	American Heart Association Scientist Development Grant(American Heart Association); Orphan Technologies, Ltd., a private pharmaceutical company developing an enzyme replacement therapy for cystathionine b-synthase (CBS)-deficient homocystinuria; U.S. National Institutes of Health, Office of the Director(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank Teodoro Bottiglieri (Institute of Metabolic Disease, Baylor Scott and White Research Institute, Dallas, TX, USA) for plasma metabolites measurements; Nicolas Busquet and Stacey Zander (University of Colorado) for help with behavioral assessment; Korey Haefner, Sara Wennersten, and Maria Cavasin (University of Colorado) for assistance with flow-mediated vasodilation (FMD) measurements; and Kimberley Bruce (University of Colorado Anschutz Medical Campus, Aurora, CO, USA) for access to the dual-energy X-ray absorptiometry (DXA) scanner. T.M. is a recipient of American Heart Association Scientist Development Grant 16SDG30040000. This study was supported by research grants from Orphan Technologies, Ltd., a private pharmaceutical company developing an enzyme replacement therapy for cystathionine b-synthase (CBS)-deficient homocystinuria (to J.P.K. and T.M.). Shared resources funded by Grant 1S10OD018156-01 from the U.S. National Institutes of Health, Office of the Director were used. The authors declare the following conflicts of interest: T.M., E.M. B., and J. P.K. are inventors on patents related to the processes and products referred here (U.S. patents 9034318 and 9243239). T.M. provides consulting services to Orphan Technologies, Ltd. E.M.B. is an employee of Orphan Technologies, Ltd.	ABBOTT MH, 1987, AM J MED GENET, V26, P959, DOI 10.1002/ajmg.1320260427; Anthony TG, 2013, CURR OPIN CLIN NUTR, V16, P96, DOI 10.1097/MCO.0b013e32835b618b; Arning E, 2016, METHODS MOL BIOL, V1378, P255, DOI 10.1007/978-1-4939-3182-8_27; Ben Abdallah NMB, 2011, EXP NEUROL, V227, P42, DOI 10.1016/j.expneurol.2010.09.008; Bublil EM, 2016, J CLIN INVEST, V126, P2372, DOI 10.1172/JCI85396; Dayal S, 2006, BLOOD, V108, P2237, DOI 10.1182/blood-2006-02-005991; Dayal S, 2012, BLOOD, V119, P3176, DOI 10.1182/blood-2011-09-380568; El Bashir H, 2015, JIMD REP, V21, P89, DOI 10.1007/8904_2014_394; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; Gupta S, 2014, FASEB J, V28, P781, DOI 10.1096/fj.13-240770; Gupta S, 2009, FASEB J, V23, P883, DOI 10.1096/fj.08-120584; Kluijtmans LAJ, 1999, AM J HUM GENET, V65, P59, DOI 10.1086/302439; Kruger WD, 2016, ANN NY ACAD SCI, V1363, P80, DOI 10.1111/nyas.12967; Maclean KN, 2010, MOL GENET METAB, V101, P153, DOI 10.1016/j.ymgme.2010.06.010; Maclean KN, 2010, MOL GENET METAB, V101, P163, DOI 10.1016/j.ymgme.2010.06.007; Majtan T, 2018, LIFE SCI, V200, P15, DOI 10.1016/j.lfs.2018.03.018; Majtan T, 2018, MOL THER, V26, P834, DOI 10.1016/j.ymthe.2017.12.014; Majtan T, 2018, HUM MUTAT, V39, P210, DOI 10.1002/humu.23360; Majtan T, 2017, FASEB J, V31, P5495, DOI 10.1096/fj.201700565R; Majtan T, 2017, BIOMACROMOLECULES, V18, P1747, DOI 10.1021/acs.biomac.7b00154; Majtan T, 2016, CURR DRUG TARGETS, V17, P1455, DOI 10.2174/1389450117666160302094910; Marchi R, 2012, THROMB HAEMOSTASIS, V108, P516, DOI 10.1160/TH12-05-0355; Morris AAM, 2017, J INHERIT METAB DIS, V40, P49, DOI 10.1007/s10545-016-9979-0; Mudd S.H., 2001, METABOLIC BASIS INHE, P2007; MUDD SH, 1970, J CLIN INVEST, V49, P1762, DOI 10.1172/JCI106394; Parrot F, 2000, J INHERIT METAB DIS, V23, P338, DOI 10.1023/A:1005618927729; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Schiff M, 2012, NEUROPEDIATRICS, V43, P295, DOI 10.1055/s-0032-1329883; Schuler D, 2014, ARTERIOSCL THROM VAS, V34, P2651, DOI 10.1161/ATVBAHA.114.304699; Walter JH, 1998, EUR J PEDIATR, V157, pS71, DOI 10.1007/PL00014308; Wang LQ, 2005, HUM MOL GENET, V14, P2201, DOI 10.1093/hmg/ddi224; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585	32	12	13	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2019	33	11					12477	12486		10.1096/fj.201901203R	http://dx.doi.org/10.1096/fj.201901203R			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KC8ZX	31450979	Green Published			2023-01-03	WOS:000507461600068
J	Zhang, Y; Chen, L; Hu, GQ; Zhang, N; Zhu, XD; Yang, KY; Jin, F; Shi, M; Chen, YP; Hu, WH; Cheng, ZB; Wang, SY; Tian, Y; Wang, XC; Sun, Y; Li, JG; Li, WF; Li, YH; Tang, LL; Mao, YP; Zhou, GQ; Sun, R; Liu, X; Guo, R; Long, GX; Liang, SQ; Li, L; Huang, J; Long, JH; Zang, J; Liu, QD; Zou, L; Su, QF; Zheng, BM; Xiao, Y; Guo, Y; Han, F; Mo, HY; Lv, JW; Du, XJ; Xu, C; Liu, N; Li, YQ; Chua, MLK; Xie, FY; Sun, Y; Ma, J				Zhang, Yuan; Chen, Lei; Hu, Guo-Qing; Zhang, Ning; Zhu, Xiao-Dong; Yang, Kun-Yu; Jin, Feng; Shi, Mei; Chen, Yu-Pei; Hu, Wei-Han; Cheng, Zhi-Bin; Wang, Si-Yang; Tian, Ye; Wang, Xi-Cheng; Sun, Yan; Li, Jin-Gao; Li, Wen-Fei; Li, Yu-Hong; Tang, Ling-Long; Mao, Yan-Ping; Zhou, Guan-Qun; Sun, Rui; Liu, Xu; Guo, Rui; Long, Guo-Xian; Liang, Shao-Qiang; Li, Ling; Huang, Jing; Long, Jin-Hua; Zang, Jian; Liu, Qiao-Dan; Zou, Li; Su, Qiong-Fei; Zheng, Bao-Min; Xiao, Yun; Guo, Ying; Han, Fei; Mo, Hao-Yuan; Lv, Jia-Wei; Du, Xiao-Jing; Xu, Cheng; Liu, Na; Li, Ying-Qin; Chua, Melvin L. K.; Xie, Fang-Yun; Sun, Ying; Ma, Jun			Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTENSITY-MODULATED RADIOTHERAPY; CONCURRENT CHEMORADIOTHERAPY; CANCER; FLUOROURACIL; COMBINATION; MULTICENTER; DOCETAXEL; PHASE-3; TRIALS; HEAD	Background Platinum-based concurrent chemoradiotherapy is the standard of care for patients with locoregionally advanced nasopharyngeal carcinoma. Additional gemcitabine and cisplatin induction chemotherapy has shown promising efficacy in phase 2 trials. Methods In a parallel-group, multicenter, randomized, controlled, phase 3 trial, we compared gemcitabine and cisplatin as induction chemotherapy plus concurrent chemoradiotherapy with concurrent chemoradiotherapy alone. Patients with locoregionally advanced nasopharyngeal carcinoma were randomly assigned in a 1:1 ratio to receive gemcitabine (at a dose of 1 g per square meter of body-surface area on days 1 and 8) plus cisplatin (80 mg per square meter on day 1), administered every 3 weeks for three cycles, plus chemoradiotherapy (concurrent cisplatin at a dose of 100 mg per square meter every 3 weeks for three cycles plus intensity-modulated radiotherapy) or chemoradiotherapy alone. The primary end point was recurrence-free survival (i.e., freedom from disease recurrence [distant metastasis or locoregional recurrence] or death from any cause) in the intention-to-treat population. Secondary end points included overall survival, treatment adherence, and safety. Results A total of 480 patients were included in the trial (242 patients in the induction chemotherapy group and 238 in the standard-therapy group). At a median follow-up of 42.7 months, the 3-year recurrence-free survival was 85.3% in the induction chemotherapy group and 76.5% in the standard-therapy group (stratified hazard ratio for recurrence or death, 0.51; 95% confidence interval [CI], 0.34 to 0.77; P=0.001). Overall survival at 3 years was 94.6% and 90.3%, respectively (stratified hazard ratio for death, 0.43; 95% CI, 0.24 to 0.77). A total of 96.7% of the patients completed three cycles of induction chemotherapy. The incidence of acute adverse events of grade 3 or 4 was 75.7% in the induction chemotherapy group and 55.7% in the standard-therapy group, with a higher incidence of neutropenia, thrombocytopenia, anemia, nausea, and vomiting in the induction chemotherapy group. The incidence of grade 3 or 4 late toxic effects was 9.2% in the induction chemotherapy group and 11.4% in the standard-therapy group. Conclusions Induction chemotherapy added to chemoradiotherapy significantly improved recurrence-free survival and overall survival, as compared with chemoradiotherapy alone, among patients with locoregionally advanced nasopharyngeal carcinoma.	[Zhang, Yuan; Chen, Lei; Chen, Yu-Pei; Hu, Wei-Han; Li, Wen-Fei; Tang, Ling-Long; Mao, Yan-Ping; Zhou, Guan-Qun; Sun, Rui; Liu, Xu; Guo, Rui; Han, Fei; Lv, Jia-Wei; Du, Xiao-Jing; Xu, Cheng; Liu, Na; Li, Ying-Qin; Xie, Fang-Yun; Sun, Ying; Ma, Jun] Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, 651 Dongfeng Rd E, Guangzhou 510060, Guangdong, Peoples R China; [Li, Yu-Hong] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China; [Mo, Hao-Yuan] Sun Yat Sen Univ, Ctr Canc, Dept Nasopharyngeal Carcinoma, Guangzhou, Guangdong, Peoples R China; [Guo, Ying] Sun Yat Sen Univ, Ctr Canc, Clin Trials Ctr, Guangzhou, Guangdong, Peoples R China; [Zhang, Yuan; Chen, Lei; Chen, Yu-Pei; Hu, Wei-Han; Li, Wen-Fei; Tang, Ling-Long; Mao, Yan-Ping; Zhou, Guan-Qun; Sun, Rui; Liu, Xu; Guo, Rui; Han, Fei; Lv, Jia-Wei; Du, Xiao-Jing; Xu, Cheng; Liu, Na; Li, Ying-Qin; Xie, Fang-Yun; Sun, Ying; Ma, Jun] Collaborat Innovat Ctr Canc Med, State Key Labora Oncol South China, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Guangzhou, Guangdong, Peoples R China; [Wang, Xi-Cheng; Su, Qiong-Fei] Guangdong Pharmaceut Univ, Affiliated Hosp 1, Dept Radiat Oncol, Guangzhou, Guangdong, Peoples R China; [Hu, Guo-Qing; Long, Guo-Xian] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Ctr Canc, Wuhan, Hubei, Peoples R China; [Yang, Kun-Yu; Huang, Jing] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Ctr Canc, Wuhan, Hubei, Peoples R China; [Zhang, Ning; Liang, Shao-Qiang] First Peoples Hosp Foshan, Dept Radiat Oncol, Foshan, Peoples R China; [Zhu, Xiao-Dong; Li, Ling] Guangxi Med Univ, Affiliated Canc Hosp, Dept Radiat Oncol, Nanning, Peoples R China; [Jin, Feng; Long, Jin-Hua] Guizhou Med Univ, Guizhou Canc Hosp, Affiliated Hosp, Dept Head & Neck Oncol, Guiyang, Guizhou, Peoples R China; [Shi, Mei; Zang, Jian] Fourth Mil Med Univ, XiJing Hosp, Dept Radiat Oncol, Xian, Shaanxi, Peoples R China; [Cheng, Zhi-Bin] Sun Yat Sen Univ, Affiliated Hosp 5, Ctr Canc, Zhuhai, Peoples R China; [Wang, Si-Yang; Liu, Qiao-Dan] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Head & Neck Oncol, Zhuhai, Peoples R China; [Tian, Ye; Zou, Li] Soochow Univ, Affiliated Hosp 2, Dept Radiat Oncol, Suzhou, Peoples R China; [Sun, Yan; Zheng, Bao-Min] Peking Univ, Canc Hosp, Dept Radiat Oncol, Beijing, Peoples R China; [Li, Jin-Gao; Xiao, Yun] Jiangxi Canc Hosp, Dept Radiat Oncol, Nanchang, Jiangxi, Peoples R China; [Chua, Melvin L. K.] Natl Canc Ctr Singapore, Div Radiat Oncol, Singapore, Singapore; [Chua, Melvin L. K.] Natl Canc Ctr Singapore, Div Med Sci, Singapore, Singapore; [Chua, Melvin L. K.] Duke Natl Univ Singapore Med Sch, Oncol Acad Program, Singapore, Singapore	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Guangdong Pharmaceutical University; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Guangxi Medical University; Guizhou Medical University; Air Force Military Medical University; Sun Yat Sen University; Sun Yat Sen University; Soochow University - China; Peking University; National Cancer Centre Singapore (NCCS); National Cancer Centre Singapore (NCCS)	Ma, J (corresponding author), Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, 651 Dongfeng Rd E, Guangzhou 510060, Guangdong, Peoples R China.	majun2@mail.sysu.edu.cn	Han, Fei/AAD-7348-2021; Chen, Yu-Pei/AAY-9539-2020; Chua, Melvin LK/ABG-6045-2020	Chen, Yu-Pei/0000-0002-0010-3494; Chua, Melvin LK/0000-0002-1648-1473; Zhang, Yuan/0000-0002-7141-1208; Ma, Jun/0000-0002-1137-9349; Liu, Na/0000-0001-8654-3636; Sun, Ying/0000-0002-5888-2929; Hu, Guoqing/0000-0001-6856-7220; Liu, Xu (Steve)/0000-0003-4827-5524	Innovation Team Development Plan of the Ministry of Education	Innovation Team Development Plan of the Ministry of Education	Funded by the Innovation Team Development Plan of the Ministry of Education and others; ClinicalTrials.gov number, NCT01872962.	Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310, DOI 10.1200/JCO.1998.16.4.1310; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chan ATC, 2010, ANN ONCOL, V21, P308, DOI 10.1093/annonc/mdq277; Chen L, 2012, LANCET ONCOL, V13, P163, DOI 10.1016/S1470-2045(11)70320-5; Chow S. C., 2003, SAMPLE SIZE CALCULAT; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Fang WF, 2018, LANCET ONCOL, V19, P1338, DOI 10.1016/S1470-2045(18)30495-9; Fisher DJ, 2011, J CLIN EPIDEMIOL, V64, P949, DOI 10.1016/j.jclinepi.2010.11.016; Hong RL, 2018, ANN ONCOL, V29, P1972, DOI 10.1093/annonc/mdy249; Lai SZ, 2011, INT J RADIAT ONCOL, V80, P661, DOI 10.1016/j.ijrobp.2010.03.024; Lee AWM, 2014, RADIOTHER ONCOL, V110, P377, DOI 10.1016/j.radonc.2014.02.003; Li WF, 2019, INT J CANCER, V145, P295, DOI 10.1002/ijc.32099; Mao YP, 2009, INT J RADIAT ONCOL, V73, P1326, DOI 10.1016/j.ijrobp.2008.07.062; NEWCOMB R, 2018, J CLIN ONCOL S, V36; Ngan RKC, 2002, ANN ONCOL, V13, P1252, DOI 10.1093/annonc/mdf200; Pocock SJ, 2002, LANCET, V359, P1686, DOI 10.1016/S0140-6736(02)08594-X; Posner MR, 2007, NEW ENGL J MED, V357, P1705, DOI 10.1056/NEJMoa070956; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Sun Y, 2016, LANCET ONCOL, V17, P1509, DOI 10.1016/S1470-2045(16)30410-7; Tan T, 2015, INT J RADIAT ONCOL, V91, P952, DOI 10.1016/j.ijrobp.2015.01.002; Tang LL, 2017, J NATL COMPR CANC NE, V15, P913, DOI 10.6004/jnccn.2017.0121; Vermorken JB, 2007, NEW ENGL J MED, V357, P1695, DOI 10.1056/NEJMoa071028; Xiao WW, 2011, CANCER-AM CANCER SOC, V117, P1874, DOI 10.1002/cncr.25754; Xiayun H, 2012, EUR ARCH OTO-RHINO-L, V269, P1027, DOI 10.1007/s00405-011-1669-9; Yau TK, 2006, HEAD NECK-J SCI SPEC, V28, P880, DOI 10.1002/hed.20421; Zhang L, 2016, LANCET, V388, P1883, DOI 10.1016/S0140-6736(16)31388-5	27	372	390	17	116	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 19	2019	381	12					1124	1135		10.1056/NEJMoa1905287	http://dx.doi.org/10.1056/NEJMoa1905287			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IZ4PY	31150573	Bronze			2023-01-03	WOS:000487066900007
J	Worth, T				Worth, Tammy			EFFICACY Unpicking the entourage effect	NATURE			English	Editorial Material																		Baron EP, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194-018-0862-2; Ben-Shabat S, 1998, EUR J PHARMACOL, V353, P23, DOI 10.1016/S0014-2999(98)00392-6; Fukumoto S, 2008, STRESS HEALTH, V24, P3, DOI 10.1002/smi.1158; Johnson JR, 2010, J PAIN SYMPTOM MANAG, V39, P167, DOI 10.1016/j.jpainsymman.2009.06.008; Lewis MA, 2018, PLANTA MED, V84, P225, DOI 10.1055/s-0043-122240; Pamplona FA, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00759; Russo EB, 2017, ADV PHARMACOL, V80, P67, DOI 10.1016/bs.apha.2017.03.004; Santiago M., 2019, PREPRINT BIORXIV, DOI [10.1101/569079, DOI 10.1101/569079]; World Health Organization, 2018, WHO TECH REP SER, V1013	9	11	11	0	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 29	2019	572	7771					S12	S13		10.1038/d41586-019-02528-1	http://dx.doi.org/10.1038/d41586-019-02528-1			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IU2JG	31462791	Bronze			2023-01-03	WOS:000483405500017
J	Bikdeli, B; Wang, Y; Jimenez, D; Parikh, SA; Monreal, M; Goldhaber, SZ; Krumholz, HM				Bikdeli, Behnood; Wang, Yun; Jimenez, David; Parikh, Sahil A.; Monreal, Manuel; Goldhaber, Samuel Z.; Krumholz, Harlan M.			Pulmonary Embolism Hospitalization, Readmission, and Mortality Rates in US Older Adults, 1999-2015	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							VENOUS THROMBOEMBOLISM; TRENDS	This study uses Medicare billing codes to characterize trends in readmission and mortality rates for Medicare fee-for-service beneficiaries with pulmonary embolism (PE) between 1999 and 2015 to assess changes accompanying recent diagnostic and therapeutic changes in management of the disease.	[Bikdeli, Behnood; Parikh, Sahil A.] Columbia Univ, Med Ctr, Div Cardiol, New York, NY USA; [Wang, Yun; Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA; [Jimenez, David] Hosp Ramon & Cajal, Resp Dept, Madrid, Spain; [Monreal, Manuel] Hosp Badalona Germans Trias & Pujol, Badalona, Spain; [Goldhaber, Samuel Z.] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA	Columbia University; Hospital Germans Trias i Pujol; Harvard University; Brigham & Women's Hospital	Krumholz, HM (corresponding author), Ctr Outcomes Res & Evaluat, One Church St,Ste 200, New Haven, CT 06510 USA.	harlan.krumholz@yale.edu	, Harlan/AAI-2875-2020		NHLBI [T32 HL007854]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007854] Funding Source: NIH RePORTER	NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Dr Bikdeli was supported by grant T32 HL007854 from the NHLBI.	Berman AR, 2001, CLIN GERIATR MED, V17, P107, DOI 10.1016/S0749-0690(05)70109-9; Jimenez D, 2016, J AM COLL CARDIOL, V67, P162, DOI 10.1016/j.jacc.2015.10.060; Kearon C, 2016, CHEST, V149, P315, DOI 10.1016/j.chest.2015.11.026; Tritschler T, 2018, JAMA-J AM MED ASSOC, V320, P1583, DOI 10.1001/jama.2018.14346; White RH, 2010, THROMB RES, V126, P61, DOI 10.1016/j.thromres.2010.03.009; Wiener RS, 2011, ARCH INTERN MED, V171, P831, DOI 10.1001/archinternmed.2011.178	6	47	48	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	2019	322	6					574	576		10.1001/jama.2019.8594	http://dx.doi.org/10.1001/jama.2019.8594			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IR9XG	31408124	Bronze, Green Published			2023-01-03	WOS:000481799500023
J	Das, G; Patra, JK; Debnath, T; Ansari, A; Shin, HS				Das, Gitishree; Patra, Jayanta Kumar; Debnath, Trishna; Ansari, Abuzar; Shin, Han-Seung			Investigation of antioxidant, antibacterial, antidiabetic, and cytotoxicity potential of silver nanoparticles synthesized using the outer peel extract of Ananas comosus (L.)	PLOS ONE			English	Article							GREEN SYNTHESIS; LEAF EXTRACT; GOLD NANOPARTICLES; ESSENTIAL OIL; SEED EXTRACT; PINEAPPLE; WASTE; BIOSYNTHESIS; OXIDE	Currently, green nanotechnology-based approaches using waste materials from food have been accepted as an environmentally friendly and cost-effective approach with various biomedical applications. In the current study, AgNPs were synthesized using the outer peel extract of the fruit Ananas comosus (AC), which is a food waste material. Characterization was done using UV-visible spectroscopy, X-ray diffraction (XRD), Fourier transform infrared (FT-IR) spectroscopy, scanning electronic microscopy (SEM) and energy-dispersive X-ray spectroscopy (EDX) analyses. The formation of AgNPs has confirmed through UV-visible spectroscopy (at 485 nm) by the change of color owing to surface Plasmon resonance. Based on the XRD pattern, the crystalline property of AgNPs was established. The functional group existing in AC outer peel extract accountable for the reduction of Ag+ ion and the stabilization of AC-AgNPs was investigated through FT-IR. The morphological structures and elemental composition was determined by SEM and EDX analysis. With the growing application of AgNPs in biomedical perspectives, the biosynthesized AC-AgNPs were evaluated for their antioxidative, antidiabetic, and cytotoxic potential against HepG(2) cells along with their antibacterial potential. The results showed that AC-AgNPs are extremely effective with high antidiabetic potential at a very low concentration as well as it exhibited higher cytotoxic activity against the HepG(2) cancer cells in a dose-dependent manner. It also exhibited potential antioxidant activity and moderate antibacterial activity against the four tested foodborne pathogenic bacteria. Overall, the results highlight the effectiveness and potential applications of AC-AgNPs in biomedical fields such as in the treatment of acute illnesses as well as in drug formulation for treating various diseases such as cancer and diabetes. Further, it has applications in wound dressing or in treating bacterial related diseases.	[Das, Gitishree; Patra, Jayanta Kumar] Dongguk Univ Seoul, Res Inst Biotechnol & Med Converged Sci, Seoul, Gyeonggi Do, South Korea; [Debnath, Trishna; Shin, Han-Seung] Dongguk Univ Seoul, Dept Food Sci & Biotechnol, Seoul, Gyeonggi Do, South Korea; [Ansari, Abuzar] Ewha Womans Univ, Ewha Med Res Inst, Dept Obstet & Gynecol, Med Sch, Seoul, South Korea	Dongguk University; Dongguk University; Ewha Womans University	Shin, HS (corresponding author), Dongguk Univ Seoul, Dept Food Sci & Biotechnol, Seoul, Gyeonggi Do, South Korea.	spartan@dongguk.edu	ANSARI, ABUZAR/AAZ-2578-2020; PATRA, JAYANTA KUMAR/AEM-6689-2022	Das, Gitishree/0000-0002-5676-0768; PATRA, JAYANTA KUMAR/0000-0003-4118-4355	Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries (IPET) through High Value-added Food Technology Development Program - Ministry of Agriculture, Food and Rural Affairs (MAFRA) [118056-2]; Korea Environmental Industry & Technology Institute [A117-00197-0703-0]	Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries (IPET) through High Value-added Food Technology Development Program - Ministry of Agriculture, Food and Rural Affairs (MAFRA); Korea Environmental Industry & Technology Institute	This work was supported by the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries (IPET) through High Value-added Food Technology Development Program funded by Ministry of Agriculture, Food and Rural Affairs (MAFRA) (118056-2) and funded by Korea Environmental Industry & Technology Institute (A117-00197-0703-0) to H-SS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adedapo AA, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-54; Ahmed S, 2016, J ADV RES, V7, P17, DOI 10.1016/j.jare.2015.02.007; Anand MAV, 2019, MICROB PATHOGENESIS, V135, DOI 10.1016/j.micpath.2019.103609; Annu, 2018, J APPL BIOMED, V16, P221, DOI 10.1016/j.jab.2018.02.002; [Anonymous], 2014, J PHARMACOGNOSY PHYT; Ashraf JM, 2016, SCI REP-UK, V6, DOI 10.1038/srep20414; Balan K, 2016, RSC ADV, V6, P40162, DOI 10.1039/c5ra24391b; Baruwa Olayinka Isiaka, 2013, Journal of Horticultural Research, V21, P59, DOI 10.2478/johr-2013-0022; Basavegowda N, 2017, CATAL LETT, V147, P2630, DOI 10.1007/s10562-017-2168-4; Butala MA, 2018, STARCH-STARKE, V70, DOI 10.1002/star.201700182; Cao YW, 2001, J AM CHEM SOC, V123, P7961, DOI 10.1021/ja011342n; Chaloupka K, 2010, TRENDS BIOTECHNOL, V28, P580, DOI 10.1016/j.tibtech.2010.07.006; Cheng R, 2010, ADV MOLEC TOXICOL, V4, P157, DOI 10.1016/S1872-0854(10)04005-1; Choi SM, 2011, SYNTHETIC MET, V161, P2405, DOI 10.1016/j.synthmet.2011.09.008; Coates J., 2000, INTERPRETATION OF IN; Diao WR, 2013, J AGR FOOD CHEM, V61, P6044, DOI 10.1021/jf4007856; Faedmaleki F, 2014, IRAN J PHARM RES, V13, P235; Femi-Adepoju A, 2019, GREEN SYNTHESIS SILV; Gangula A, 2011, LANGMUIR, V27, P15268, DOI 10.1021/la2034559; Govindappa M, 2018, RESULTS PHYS, V9, P400, DOI 10.1016/j.rinp.2018.02.049; He D, 2013, ENVIRON SCI TECHNOL, V47, P9148, DOI 10.1021/es400391a; He YQ, 2018, NEW J CHEM, V42, P2882, DOI 10.1039/c7nj04224h; He YQ, 2017, RSC ADV, V7, P39842, DOI 10.1039/c7ra05286c; IALENTI A, 1993, BRIT J PHARMACOL, V110, P701, DOI 10.1111/j.1476-5381.1993.tb13868.x; Iravani S, 2014, RES PHARM SCI, V9, P385; Jagtap UB, 2013, IND CROP PROD, V46, P132, DOI 10.1016/j.indcrop.2013.01.019; Jain PK, 2008, ACCOUNTS CHEM RES, V41, P1578, DOI 10.1021/ar7002804; Kalaiyarasu T., 2016, ASIAN J PHARM CLIN R, V9, P1; Kalpana M. B., 2014, Der Pharmacia Lettre, V6, P22; Kargutkar S, 2016, PHARM BIOL, V54, P2616, DOI 10.3109/13880209.2016.1173066; Kumar B, 2017, SAUDI J BIOL SCI, V24, P45, DOI 10.1016/j.sjbs.2015.09.006; Li T, 2014, INT J FOOD PROP, V17, P1805, DOI 10.1080/10942912.2012.732168; Mittal AK, 2013, BIOTECHNOL ADV, V31, P346, DOI 10.1016/j.biotechadv.2013.01.003; Mousavi Bita, 2018, Artif Cells Nanomed Biotechnol, V46, P499, DOI 10.1080/21691401.2018.1430697; Naganathan K, 2017, IOP C SERIES MAT SCI; de Barros CHN, 2018, NANOTECHNOL SCI APPL, V11, P1, DOI 10.2147/NSA.S156115; Naz S, 2017, IET NANOBIOTECHNOL, V11, P1040, DOI 10.1049/iet-nbt.2017.0082; Nguyen NHA, 2018, NANOSCALE RES LETT, V13, DOI 10.1186/s11671-018-2575-5; Omran BA, 2018, ENERG SOURCE PART A, V40, P227, DOI 10.1080/15567036.2017.1410597; Oves M, 2018, MAT SCI ENG C-MATER, V89, P429, DOI 10.1016/j.msec.2018.03.035; P Patil Shriniwas, 2017, Biochem Biophys Rep, V10, P76, DOI 10.1016/j.bbrep.2017.03.002; Parveen M, 2016, APPL NANOSCI, V6, P267, DOI 10.1007/s13204-015-0433-7; Patil S, 2017, 3 BIOTECH, V7, DOI 10.1007/s13205-016-0589-1; Patra J. K., 2017, MICROBIOL, V8, P167, DOI [10.3389/fmicb.2017.00167, DOI 10.3389/FMICB.2017.00167]; Patra JK, 2018, J PHOTOCH PHOTOBIO B, V188, P116, DOI 10.1016/j.jphotobiol.2018.08.004; Patra JK, 2016, IET NANOBIOTECHNOL, V10, P326, DOI 10.1049/iet-nbt.2015.0102; Patra JK, 2015, INT J NANOMED, V10, P7253, DOI 10.2147/IJN.S95483; Patra JK, 2015, J FOOD BIOCHEM, V39, P80, DOI 10.1111/jfbc.12110; Pirtarighat S, 2019, J NANOSTRUCTURE CHEM, V9, P1, DOI 10.1007/s40097-018-0291-4; Poadang S, 2017, SYNTHESIS CHARACTERI; Poadang Sarinya, 2017, Chiang Mai University Journal of Natural Sciences, V16, P123, DOI 10.12982/cmujns.2017.0010; Prakash P, 2013, COLLOID SURFACE B, V108, P255, DOI 10.1016/j.colsurfb.2013.03.017; Prasannaraj Govindaraj, 2017, Advances in Natural Sciences: Nanoscience & Nanotechnology, V8, DOI 10.1088/2043-6254/aa6d2c; Punbusayakul N., 2018, P INN FUNCT FOODS AS; Putri D A, 2018, MAL J FUND APPL SCI, V14, P307; Rai M, 2009, BIOTECHNOL ADV, V27, P76, DOI 10.1016/j.biotechadv.2008.09.002; Rajeshkumar S., 2014, BIOINORGANIC CHEM AP, V2014; Rajkumar T, 2019, J PHOTOCH PHOTOBIO B, V193, P1, DOI 10.1016/j.jphotobiol.2019.01.008; Ramesh PS, 2015, SPECTROCHIM ACTA A, V142, P339, DOI 10.1016/j.saa.2015.01.062; Rashad M M, 2015, INT J TOXICOL PHARM, V7, P287; Reenaa M., 2017, INT J CURRENT MICROB, V6, P2358, DOI DOI 10.20546/IJCMAS.2017.607.337; Rehan M, 2018, ACS SUSTAIN CHEM ENG, V6, P5911, DOI 10.1021/acssuschemeng.7b04302; Riya MP, 2014, J SCI FOOD AGR, V94, P943, DOI 10.1002/jsfa.6340; Romelle FD, 2016, EUROPEAN J FOOD SCI, V4, P12, DOI DOI 10.2527/JAS2012-5761.; Sah BNP, 2016, J FOOD SCI TECH MYS, V53, P1698, DOI 10.1007/s13197-015-2100-0; Santiso R, 2012, MUTAT RES-FUND MOL M, V734, P41, DOI 10.1016/j.mrfmmm.2012.03.006; Saraswaty V, 2017, IOP C SERIES EARTH E; Shafiya Rafiq, 2018, Journal of the Saudi Society of Agricultural Sciences, V17, P351; Sharma D., 2015, ARABIAN J CHEM; Shen WN, 2011, CHEM ENG J, V175, P592, DOI 10.1016/j.cej.2011.09.121; Sivaranjani K., 2013, INT RES J PHARM, V4, P225; Soto KM, 2019, LWT-FOOD SCI TECHNOL, V103, P293, DOI 10.1016/j.lwt.2019.01.023; Sre PRR, 2015, SPECTROCHIM ACTA A, V135, P1137, DOI 10.1016/j.saa.2014.08.019; Tashi T., 2016, J CHEM PHARM RES, V8, P526; Vanaja M, 2013, APPL NANOSCI, V3, P217, DOI 10.1007/s13204-012-0121-9; Wypij M, 2018, WORLD J MICROB BIOT, V34, DOI 10.1007/s11274-017-2406-3; Zhou Y, 2001, CHEM COMMUN, P613, DOI 10.1039/b100636n; Zhou Y, 2012, J NANOBIOTECHNOL, V10, DOI 10.1186/1477-3155-10-19	78	82	83	6	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 12	2019	14	8							e0220950	10.1371/journal.pone.0220950	http://dx.doi.org/10.1371/journal.pone.0220950			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5GN	31404086	Green Published, Green Submitted, gold			2023-01-03	WOS:000485006800045
J	Liu, A; Kline, DM; Brock, GN; Bonsu, BK				Liu, Anqi; Kline, David M.; Brock, Guy N.; Bonsu, Bema K.			Multistate model of the patient flow process in the pediatric emergency department	PLOS ONE			English	Article							LENGTH-OF-STAY; WAITING-TIMES; PREDICTION; VARIABLES; TRIAGE	Objectives The main purpose of this paper was to model the process by which patients enter the ED, are seen by physicians, and discharged from the Emergency Department at Nationwide Children's Hospital, as well as identify modifiable factors that are associated with ED lengths of stay through use of multistate modeling. Methods In this study, 75,591 patients admitted to the ED from March 1st, 2016 to February 28th, 2017 were analyzed using a multistate model of the ED process. Cox proportional hazards models with transition-specific covariates were used to model each transition in the multistate model and the Aalen-Johansen estimator was used to obtain transition probabilities and state occupation probabilities in the ED process. Results Acuity level, season, time of day and number of ED physicians had significant and varying associations with the six transitions in the multistate model. Race and ethnicity were significantly associated with transition to left without being seen, but not with the other transitions. Conversely, age and gender were significantly associated with registration to room and subsequent transitions in the model, though the magnitude of association was not strong. Conclusions The multistate model presented in this paper decomposes the overall ED length of stay into constituent transitions for modeling covariate-specific effects on each transition. This allows physicians to understand the ED process and identify which potentially modifiable covariates would have the greatest impact on reducing the waiting times in each state in the model.	[Liu, Anqi; Kline, David M.; Brock, Guy N.] Ohio State Univ, Coll Med, Dept Biomed Informat, Columbus, OH 43210 USA; [Liu, Anqi; Kline, David M.; Brock, Guy N.] Ohio State Univ, Coll Publ Hlth, Div Biostat, Columbus, OH 43210 USA; [Liu, Anqi; Kline, David M.; Brock, Guy N.] Ohio State Univ, Wexner Med Ctr, Ctr Biostat, Columbus, OH 43210 USA; [Brock, Guy N.; Bonsu, Bema K.] NCH, Dept Pediat, Columbus, OH 43205 USA; [Brock, Guy N.; Bonsu, Bema K.] Ohio State Univ, Columbus, OH 43210 USA; [Brock, Guy N.] Nationwide Childrens Hosp, Biostat Resource NCH BRANCH, Columbus, OH 43205 USA; [Bonsu, Bema K.] Nationwide Childrens Hosp, Div Emergency Med, Columbus, OH USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University System of Ohio; Ohio State University; Nationwide Childrens Hospital	Kline, DM; Brock, GN (corresponding author), Ohio State Univ, Coll Med, Dept Biomed Informat, Columbus, OH 43210 USA.; Kline, DM; Brock, GN (corresponding author), Ohio State Univ, Coll Publ Hlth, Div Biostat, Columbus, OH 43210 USA.; Kline, DM; Brock, GN (corresponding author), Ohio State Univ, Wexner Med Ctr, Ctr Biostat, Columbus, OH 43210 USA.; Brock, GN (corresponding author), NCH, Dept Pediat, Columbus, OH 43205 USA.; Brock, GN (corresponding author), Ohio State Univ, Columbus, OH 43210 USA.; Brock, GN (corresponding author), Nationwide Childrens Hosp, Biostat Resource NCH BRANCH, Columbus, OH 43205 USA.	david.kline@osumc.edu; guy.brock@osumc.edu	Kline, David/K-8372-2019	Kline, David/0000-0001-6183-3303	National Institutes of Health/National Center for Advancing Translational Sciences [UL1TR002733]; Nationwide Children's Hospital; National Institutes of Health (NIH)/National Center for Advancing Translational Science (NCATS) [UL1TR002733]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002733] Funding Source: NIH RePORTER	National Institutes of Health/National Center for Advancing Translational Sciences; Nationwide Children's Hospital(Ohio State University); National Institutes of Health (NIH)/National Center for Advancing Translational Science (NCATS); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	GNB was partially supported by National Institutes of Health/National Center for Advancing Translational Sciences grant UL1TR002733. AL was partially supported by funding from Nationwide Children's Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported in part by funding from Nationwide Children's Hospital and by National Institutes of Health (NIH)/National Center for Advancing Translational Science (NCATS) grant UL1TR002733.	AALEN OO, 1978, SCAND J STAT, V5, P141; Alver SK, 2016, LIVER TRANSPLANT, V22, P1343, DOI 10.1002/lt.24503; Bobrovitz N, 2017, BMC EMERG MED, V17, DOI 10.1186/s12873-017-0145-2; Boudreaux ED, 2000, AM J EMERG MED, V18, P394, DOI 10.1053/ajem.2000.7316; Bruijns SR, 2008, EMERG MED J, V25, P395, DOI 10.1136/emj.2007.049411; Chang AM, 2018, ANN EMERG MED, V71, P497, DOI 10.1016/j.annemergmed.2017.07.022; Choi YF, 2006, EMERG MED J, V23, P262, DOI 10.1136/emj.2005.025254; Clark DE, 2016, HEALTH SERV RES, V51, P1074, DOI 10.1111/1475-6773.12400; Cross KP, 2010, ACAD EMERG MED, V17, P1197, DOI 10.1111/j.1553-2712.2010.00908.x; de Wreede LC, 2011, J STAT SOFTW, V38, P1; Doan Q, 2014, JAAPA-J AM ACAD PHYS, V27, P35, DOI 10.1097/01.JAA.0000451860.95151.e1; Georgio G, 2017, J EMERG MED, V53, P418, DOI 10.1016/j.jemermed.2017.05.004; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Gran JM, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2408-8; Hosmer DW, 2002, STATA J, V2, P331, DOI 10.1177/1536867X0200200401; James CA, 2005, PEDIATRICS, V115, pE310, DOI 10.1542/peds.2004-1541; Jouriles N, 2013, ACAD EMERG MED, V20, P421, DOI 10.1111/acem.12107; Keiding N, 2001, STAT MED, V20, P1871, DOI 10.1002/sim.810; Lambe S, 2003, ANN EMERG MED, V41, P35, DOI 10.1067/mem.2003.2; Lateef A, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2491-x; Liu SW, 2009, ANN EMERG MED, V54, P381, DOI 10.1016/j.annemergmed.2009.02.001; Mason S, 2017, EMERG MED J, V34, P46, DOI 10.1136/emermed-2015-205201; Michelson KA, 2016, PEDIATR EMERG CARE, V32, P599, DOI 10.1097/PEC.0000000000000892; Newton AS, 2014, EMERG MED INT, V2014, P10; Park CY, 2009, HEALTH SERV RES, V44, P2022, DOI 10.1111/j.1475-6773.2009.01020.x; Qiu SS, 2015, HEALTH CARE MANAG SC, V18, P67, DOI 10.1007/s10729-014-9283-1; Rathlev NK, 2007, ANN EMERG MED, V49, P265, DOI 10.1016/j.annemergmed.2006.11.007; Schull MJ, 2007, ANN EMERG MED, V49, P257, DOI 10.1016/j.annemergmed.2006.06.027; Sethuraman U, 2011, PEDIATR EMERG CARE, V27, P295, DOI 10.1097/PEC.0b013e318217b503; Smith CJ, 2015, J HOSP MED, V10, P711, DOI 10.1002/jhm.2431; Sun Y, 2012, ANN EMERG MED, V60, P299, DOI 10.1016/j.annemergmed.2012.03.011; Vashi AA, 2019, MIL MED, V184, pE169, DOI 10.1093/milmed/usy165; Yiadom MYAB, 2018, ACAD EMERG MED, V25, P65, DOI 10.1111/acem.13319	33	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2019	14	7							e0219514	10.1371/journal.pone.0219514	http://dx.doi.org/10.1371/journal.pone.0219514			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4JZ	31291345	Green Published, Green Submitted, gold			2023-01-03	WOS:000484947800101
J	Chang, Y; Chusri, S; Sangthong, R; McNeil, E; Hu, JQ; Du, W; Li, D; Fan, XY; Zhou, HN; Chongsuvivatwong, V; Tang, L				Chang, Yue; Chusri, Sarunyou; Sangthong, Rassamee; McNeil, Edward; Hu, Jiaqi; Du, Wei; Li, Duan; Fan, Xingying; Zhou, Hanni; Chongsuvivatwong, Virasakdi; Tang, Lei			Clinical pattern of antibiotic overuse and misuse in primary healthcare hospitals in the southwest of China	PLOS ONE			English	Article							RESPIRATORY-TRACT INFECTIONS; PRESCRIBING PATTERNS; PRESCRIPTION	Purpose Overuse and misuse of antibiotics are the primary risk factors for antibiotics resistance. Inadequate professional competence of primary care physicians might exacerbate these problems in China. This retrospective study aims to document the clinical pattern of antibiotics use and its overuse and misuse rates in rural primary care institutions and to evaluate the association between antibiotics use and characteristics of physicians and their patients. Methods Medical records from 16 primary care hospitals in rural areas of Guizhou province, China were obtained from the Health Information System in 2018. Classification of unnecessary use, incorrect spectrum of antibiotic, escalated use of extended spectrum and combined antibiotics use was based on the Guiding Principle of Clinical Use of Antibiotics (2015, China) and guidelines from the US Centers for Disease Control and Prevention. Generalized Estimating Equations were employed to determine predictive factors for inappropriate antibiotics use. Results A total of 74,648 antibiotics prescriptions were retrieved. Uncomplicated respiratory infection was the most common disease accounting for 58.6% of all prescriptions. The main antibiotic group used was penicillins (51.5%) followed by cephalosporins and macrolides (14% each). Of 57,009 patient visits, only 8.7% of the antibiotic prescriptions were appropriate. Combined use, escalated use of extended spectrum antibiotics, incorrect spectrum and unnecessary antibiotics use was found in 7.8%, 1.9%, 4.3% and 77.3% of patient visits, respectively, of which 28.7% were given intravenously. Antibiotics misuse was significantly more likely among newly employed physicians with lower levels of professional education. Adult patients and those who had public insurance had a higher risk of being prescribed unnecessary antibiotics. Conclusion Overuse of antibiotics for uncomplicated respiratory infection and use of cephalosporins, macrolides and injection antibiotics in primary care are the major problems of clinical practice in rural areas of Guizhou.	[Chang, Yue; Hu, Jiaqi; Du, Wei; Li, Duan; Fan, Xingying; Zhou, Hanni; Tang, Lei] Guizhou Med Univ, Sch Med & Hlth Management, Guiyang, Guizhou, Peoples R China; [Chang, Yue; Sangthong, Rassamee; McNeil, Edward; Chongsuvivatwong, Virasakdi] Prince Songkla Univ, Fac Med, Epidemiol Unit, Hat Yai, Songkhla, Thailand; [Chusri, Sarunyou] Prince Songkla Univ, Dept Internal Med, Div Infect Dis, Hat Yai, Songkhla, Thailand; [Chusri, Sarunyou] Prince Songkla Univ, Dept Biomed Sci, Hat Yai, Songkhla, Thailand	Guizhou Medical University; Prince of Songkla University; Prince of Songkla University; Prince of Songkla University	Tang, L (corresponding author), Guizhou Med Univ, Sch Med & Hlth Management, Guiyang, Guizhou, Peoples R China.; Chongsuvivatwong, V (corresponding author), Prince Songkla Univ, Fac Med, Epidemiol Unit, Hat Yai, Songkhla, Thailand.	cvirasak@medicine.psu.ac.th; tlei1974@163.com		Chongsuvivatwong, Virasakdi/0000-0002-9850-4463; McNeil, Edward Braddon/0000-0002-9492-1040	Guizhou innovative talent foundation [2016-4015]	Guizhou innovative talent foundation	This study is part of author YC's thesis in partial fulfillment of the requirements for a PhD at Prince of Songkla University, Thailand, and the China Medical Board under the project "A second collaborative program to improve the health research capacity of western medical universities in China and Prince of Songkla University (PSU)". This study was also possible due to a grant obtained from Guizhou innovative talent foundation (2016-4015) to LT.	Anderson A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204878; Batzing-Feigenbaum J, 2016, DTSCH ARZTEBL INT, V113, P454, DOI 10.3238/arztebl.2016.0454; Bhartiy S S, 2008, Kathmandu Univ Med J (KUMJ), V6, P55; Bianco A, 2018, INFECT DRUG RESIST, V11, P2199, DOI 10.2147/IDR.S170349; Butt AA, 2017, INT J INFECT DIS, V55, P20, DOI 10.1016/j.ijid.2016.12.004; Center for Disease Dynamics, 2015, EC POL STAT WORLDS A; Centers for Disease Control and Prevention, 2017, ANT PRESCR US DOCT O; Centers for Disease Control and Prevention, 2018, ANT PRESCR US; Choi KH, 2012, J KOREAN MED SCI, V27, P120, DOI 10.3346/jkms.2012.27.2.120; Dancer SJ, 2004, LANCET INFECT DIS, V4, P611, DOI 10.1016/S1473-3099(04)01145-4; Davis ME, 2017, ANTIBIOTICS-BASEL, V6, DOI 10.3390/antibiotics6040023; Dong HJ, 1999, HEALTH POLICY, V48, P29, DOI 10.1016/S0168-8510(99)00026-3; Durkin MJ, 2018, INFECT CONT HOSP EP, V39, P584, DOI 10.1017/ice.2018.26; Segura-Egea JJ, 2017, INT DENT J, V67, P197, DOI 10.1111/idj.12287; Li YB, 2012, HEALTH AFFAIR, V31, P1075, DOI 10.1377/hlthaff.2010.0965; Lindberg BH, 2017, SCAND J PRIM HEALTH, V35, P178, DOI 10.1080/02813432.2017.1333301; Mao WH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117710; Milder E, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.016; Napolitano F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084177; National Health and Family Planning Commission of China, 2015, CHIN HLTH FAM PLANN; Qu XY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196668; Sharma P, 2017, PLOS ONE, V12, P181; Sun Q, 2015, BMC PHARMACOL TOXICO, V16, DOI 10.1186/s40360-015-0009-x; Van Boeckel TP, 2014, LANCET INFECT DIS, V14, P742, DOI 10.1016/S1473-3099(14)70780-7; Wang J, 2014, JAMA INTERN MED, V174, P1914, DOI 10.1001/jamainternmed.2014.5214; Wang YY, 2016, INT J ANTIMICROB AG, V48, P666, DOI 10.1016/j.ijantimicag.2016.09.008; WHO, 2014, INT STAT CLASS DIS R; World Health Organization, 2017, ANT PRESCR RES VIEWS; Xiao YH, 2016, INT J ANTIMICROB AG, V48, P409, DOI 10.1016/j.ijantimicag.2016.06.017; Zucco R, 2018, INT J MED INFORM, V111, P131, DOI 10.1016/j.ijmedinf.2017.12.005	30	28	28	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 26	2019	14	6							e0214779	10.1371/journal.pone.0214779	http://dx.doi.org/10.1371/journal.pone.0214779			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IT5DV	31242185	Green Submitted, gold, Green Published			2023-01-03	WOS:000482883600004
J	Gaeta, JM				Gaeta, Jessie M.			A Pitiful Sanctuary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Gaeta, Jessie M.] Boston Univ, Sch Med, Boston Hlth Care Homeless Program, 780 Albany St, Boston, MA 02118 USA	Boston University	Gaeta, JM (corresponding author), Boston Univ, Sch Med, Boston Hlth Care Homeless Program, 780 Albany St, Boston, MA 02118 USA.	jgaeta@bhchp.org							0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	2019	321	24					2407	2408		10.1001/jama.2019.7998	http://dx.doi.org/10.1001/jama.2019.7998			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IF3UX	31237648				2023-01-03	WOS:000473009700017
J	Houlihan, AJ; Conlin, P; Chee-Sanford, JC				Houlihan, Adam J.; Conlin, Peter; Chee-Sanford, Joanne C.			Water-soluble exudates from seeds of Kochia scoparia exhibit antifungal activity against Colletotrichum graminicola	PLOS ONE			English	Article							ANTIMICROBIAL ACTIVITY; MICROBIAL DIVERSITY; PHENOLIC-COMPOUNDS; PLANT; SOIL; DYNAMICS; GROWTH; L.; PATHOGENICITY; SPERMOSPHERE	Plant seed exudates are composed of complex mixtures of chemicals with potential for bioactive compounds with antimicrobial properties. This study focused on kochia (Kochia scoparia), one of many weedy plant species considered invasive in many agricultural systems. Extraction of compounds in water yielded an exudate mass equivalent to 7% of the original seed mass used. Water-soluble exudates were tested against 16 known plant pathogens in disk diffusion assays and kochia exudates were found to inhibit Colletotrichum graminicola, the fungal causative agent of anthracnose and stalk rot in maize. The narrow range of fungi found as targets suggested the mechanism of inhibition may be specific rather than broadly antifungal. A decline in viability of cells over four orders of magnitude occurred within six hours of exposure to exudate. The minimum inhibitory concentration was 3.125 mg L-1. Hyphae formation in C. graminicola appeared inhibited following exposure to the exudate. Small molecular weight compounds as determined by GC/MS analysis showed high relative amounts of the sugars fructose, galactopyranose, glucose, and sorbitol, along with moderate proportions of organic acids and amino acids. Protein content averaged 0.7% in the standard concentration (100 mg mL(-1)) used for inhibition assays. Size fractionation of the exudate and subsequent disk diffusion assays revealed bioactive fractions with compounds in the MW range <5 kDa. To the best of our knowledge, this study is the first to show promising bioactivity against C. graminicola that was associated with water-extractable compounds from a common weed species. The results suggest that seeds of persistent plant species with long-lived seed banks like kochia may have potential for use in the discovery of compounds active in inhibiting fungal pathogens.	[Houlihan, Adam J.; Chee-Sanford, Joanne C.] USDA ARS, Urbana, IL 61801 USA; [Houlihan, Adam J.; Conlin, Peter; Chee-Sanford, Joanne C.] Univ Illinois, Dept Crop Sci, Urbana, IL 61801 USA; [Chee-Sanford, Joanne C.] Univ Illinois, Dept Nat Resources & Environm Sci, Urbana, IL 61801 USA	United States Department of Agriculture (USDA); University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Chee-Sanford, JC (corresponding author), USDA ARS, Urbana, IL 61801 USA.; Chee-Sanford, JC (corresponding author), Univ Illinois, Dept Crop Sci, Urbana, IL 61801 USA.; Chee-Sanford, JC (corresponding author), Univ Illinois, Dept Nat Resources & Environm Sci, Urbana, IL 61801 USA.	Joanne.Cheesanford@ars.usda.gov		Conlin, Peter/0000-0002-2793-7624	U.S. Dept. of Agriculture	U.S. Dept. of Agriculture(United States Department of Agriculture (USDA))	The authors received no specific funding for this work, but wish to acknowledge general funding by U.S. Dept. of Agriculture. The funders had no role in study, data collection and analysis, decision to publish, or preparation of the manuscript.	Balouiri M, 2016, J PHARM ANAL, V6, P71, DOI 10.1016/j.jpha.2015.11.005; Bergstrom GC, 1999, PLANT DIS, V83, P596, DOI 10.1094/PDIS.1999.83.7.596; Bouaziz F, 2017, INT J BIOL MACROMOL, V95, P667, DOI 10.1016/j.ijbiomac.2016.11.104; Buhler DD, 1997, WEED SCI, V45, P329, DOI 10.1017/S0043174500092948; Cano J, 2004, J CLIN MICROBIOL, V42, P2450, DOI 10.1128/JCM.42.6.2450-2454.2004; Casey CE, 1998, J CHROMATOGR A, V804, P311, DOI 10.1016/S0021-9673(97)01297-1; Chee-Sanford J, 2010, CURRENT RES TECHNOLO, P257; Chee-Sanford JC, 2006, WEED SCI, V54, P575, DOI 10.1614/WS-05-055R.1; Coskun D, 2017, TRENDS PLANT SCI, V22, P661, DOI 10.1016/j.tplants.2017.05.004; de Lucca AJ, 1999, ANTIMICROB AGENTS CH, V43, P1, DOI 10.1093/jac/43.1.1; Dean R, 2012, MOL PLANT PATHOL, V13, P414, DOI 10.1111/j.1364-3703.2011.00783.x; Dille JA, 2017, WEED SCI, V65, P614, DOI 10.1017/wsc.2017.18; Duke SO, 2003, PEST MANAG SCI, V59, P708, DOI 10.1002/ps.633; Eisenhauer N, 2017, SCI REP-UK, V7, DOI 10.1038/srep44641; FORCELLA F, 1992, WEED SCI, V40, P636, DOI 10.1017/S0043174500058240; FRAVEL DR, 1988, ANNU REV PHYTOPATHOL, V26, P75, DOI 10.1146/annurev.py.26.090188.000451; Friesen LF, 2009, CAN J PLANT SCI, V89, P141, DOI 10.4141/CJPS08057; Garbeva P, 2004, ANNU REV PHYTOPATHOL, V42, P243, DOI 10.1146/annurev.phyto.42.012604.135455; Gruiz K, 1996, ADV EXP MED BIOL, V404, P527; Haring SC, 2018, PEST MANAG SCI, V74, P2412, DOI 10.1002/ps.5068; Heidtmann-Bemvenuti R, 2016, J SCI FOOD AGR, V96, P3998, DOI 10.1002/jsfa.7591; Hibbett DS, 2007, MYCOL RES, V111, P509, DOI 10.1016/j.mycres.2007.03.004; Iqbal A, 2012, J EXP BOT, V63, P2595, DOI 10.1093/jxb/err436; Kitanaka S, 1998, CHEM PHARM BULL, V46, P1650, DOI 10.1248/cpb.46.1650; Lange M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096182; Lanoue A, 2010, PLANT SIGNAL BEHAV, V5, P1037, DOI [10.4161/psb.5.8.12337, 10.1111/j.1469-8137.2009.03066.x]; Legaz ME, 2011, PLANT SIGNAL BEHAV, V6, P1132, DOI 10.4161/psb.6.8.15810; Ling N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063383; Lukman AI, 2011, J COLLOID INTERF SCI, V353, P433, DOI 10.1016/j.jcis.2010.09.088; Manthey FA, 1996, WEED TECHNOL, V10, P522, DOI 10.1017/S0890037X00040379; Martins SJ, 2018, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02631; Mims CW, 2002, PHYTOPATHOLOGY, V92, P803, DOI 10.1094/PHYTO.2002.92.7.803; Montesinos E, 2008, CHEM BIODIVERS, V5, P1225, DOI 10.1002/cbdv.200890111; Naveed M, 2017, EUR J SOIL SCI, V68, P806, DOI 10.1111/ejss.12487; Nawrot R, 2014, FOLIA MICROBIOL, V59, P181, DOI 10.1007/s12223-013-0280-4; NCCLS, 1998, PROPOSED STANDARD M3; Nelson EB, 2004, ANNU REV PHYTOPATHOL, V42, P271, DOI 10.1146/annurev.phyto.42.121603.131041; NELSON EB, 1994, PHYTOPATHOLOGY, V84, P677, DOI 10.1094/Phyto-84-677; Ngai PHK, 2007, APPL MICROBIOL BIOT, V74, P366, DOI 10.1007/s00253-006-0685-y; Nohynek LJ, 2006, NUTR CANCER, V54, P18, DOI 10.1207/s15327914nc5401_4; O'Connell RJ, 2012, NAT GENET, V44, P1060, DOI 10.1038/ng.2372; Penfield S, 2017, CURR BIOL, V27, pR874, DOI 10.1016/j.cub.2017.05.050; Ramirez-Sanchez O, 2016, GENOM PROTEOM BIOINF, V14, P357, DOI 10.1016/j.gpb.2016.06.003; Roessner U, 2000, PLANT J, V23, P131, DOI 10.1046/j.1365-313x.2000.00774.x; Rose TL, 2006, PLANT SOIL, V286, P181, DOI 10.1007/s11104-006-9036-0; Rossi V, 2007, PHYTOPATHOLOGY, V97, P352, DOI 10.1094/PHYTO-97-3-0352; Roy S, 2018, CURR MICROBIOL, V75, P550, DOI 10.1007/s00284-017-1415-7; Schiltz S, 2015, J APPL MICROBIOL, V119, P1467, DOI 10.1111/jam.12946; SIEMENS DH, 1992, ECOLOGY, V73, P2152, DOI 10.2307/1941463; Simin K, 2001, PHYTOTHER RES, V15, P437, DOI 10.1002/ptr.756; Soares AMS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200848; Soares MH, 2017, CHEM BIODIVERS, V14, DOI 10.1002/cbdv.201700149; Soni Priyanka, 2012, Asian Pacific Journal of Tropical Biomedicine, V2, P1002, DOI 10.1016/S2221-1691(13)60014-3; Tambalo DD, 2014, CAN J MICROBIOL, V60, P15, DOI 10.1139/cjm-2013-0723; Thabet AA, 2018, J PHARM PHARMACOL, V70, P450, DOI 10.1111/jphp.12876; van Elsas JD, 2002, BIODEGRADATION, V13, P29, DOI 10.1023/A:1016393915414; Vargas-Arispuro I, 2005, IND CROP PROD, V22, P101, DOI 10.1016/j.indcrop.2004.06.003; Vurro M, 2018, CURR MED CHEM, V25, P268, DOI 10.2174/0929867324666170426152331; WEATHERS.DM, 1969, WEED SCI, V17, P464, DOI 10.1017/S0043174500054564; Werner S, 2007, MOL PLANT MICROBE IN, V20, P1555, DOI 10.1094/MPMI-20-12-1555; Windstam S, 2008, APPL ENVIRON MICROB, V74, P4292, DOI 10.1128/AEM.00264-08; Zhang RF, 2017, CURR OPIN MICROBIOL, V37, P8, DOI 10.1016/j.mib.2017.03.008	62	6	6	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2019	14	6							e0218104	10.1371/journal.pone.0218104	http://dx.doi.org/10.1371/journal.pone.0218104			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IT5EM	31216294	Green Submitted, gold, Green Published			2023-01-03	WOS:000482885300031
J	Honeyford, K; Bell, D; Chowdhury, F; Quint, J; Aylin, P; Bottle, A				Honeyford, Kate; Bell, Derek; Chowdhury, Faiza; Quint, Jennifer; Aylin, Paul; Bottle, Alex			Unscheduled hospital contacts after inpatient discharge: A national observational study of COPD and heart failure patients in England	PLOS ONE			English	Article							EMERGENCY-DEPARTMENT; DIAGNOSIS	Introduction Readmissions are a recognised challenge for providers of healthcare and incur financial penalties in a growing number of countries. However, the scale of unscheduled hospital contacts including attendances at emergency departments that do not result in admission is not well known. In addition, little is known about the route to readmission for patients recently discharged from an emergency hospital stay. Methods This is an observational study of national hospital administration data for England. In this retrospective cohort study, we tracked patients for 30 days after discharge from an emergency admission for heart failure (HF) or chronic obstructive pulmonary disorder (COPD). Results The majority of patients (COPD: 79%; HF: 75%) had no unscheduled contact with secondary health care within 30 days of discharge. Of those who did have unscheduled contact, the most common first unscheduled contact was emergency department (ED) attendance (COPD: 16%; HF: 18%). A further 5% of COPD patients and 4% of HF patients were admitted for an emergency inpatient stay, but not through the ED. A small percentage of patients (COPD:<1%, HF: 2%) died without any known contact with secondary care. ED conversion rates at first attendance for both COPD and HF were high: 75% and 79% respectively. A quarter of patients who were not admitted during this first ED attendance attended the ED again within the 30-day follow-up period, and around half (COPD: 56%; HF: 63%) of these were admitted at this point. Patients who live alone, had an index admission which included an overnight stay and were comorbid had higher odds of being admitted through the ED than via other routes. Conclusion While the majority of patients did not have unscheduled contact with secondary care in the 30 days after index discharge, many patients attended the ED, often multiple times, and many were admitted to hospital, not always via the ED. More frail patients were more likely to be admitted through the ED, suggesting a possible area of focus as discharge bundles are developed.	[Honeyford, Kate] Imperial Coll, Dept Primary Care & Publ Hlth, Digital Hlth Unit, London, England; [Bell, Derek] Imperial Coll London, Sch Publ Hlth, Chelsea & Westminster Campus, London, England; [Chowdhury, Faiza] Imperial Coll London, NIHR CLAHRC North West London, Chelsea & Westminster Campus, London, England; [Quint, Jennifer] Imperial Coll London, Natl Heart & Lung Inst, Royal Brompton Campus, London, England; [Aylin, Paul; Bottle, Alex] Imperial Coll, Dr Foster Unit, Dept Primary Care & Publ Hlth, London, England	Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London	Honeyford, K (corresponding author), Imperial Coll, Dept Primary Care & Publ Hlth, Digital Hlth Unit, London, England.	K.Honeyford@imperial.ac.uk	quint, jennifer/ABE-3384-2020	Honeyford, Kate/0000-0002-5533-7693; Aylin, Paul/0000-0003-4589-1743; Quint, Jennifer/0000-0003-0149-4869	National Institute for Health Research (NIHR) Health Services and Delivery Research programme [14/19/50]; National Institute for Health Research (NIHR) under the Collaborations for Leadership in Applied Health Research and Care (CLAHRC) programme North West London; Dr Foster(R), a private healthcare information company; National Institute for Health Research Health Services Research	National Institute for Health Research (NIHR) Health Services and Delivery Research programme(National Institute for Health Research (NIHR)); National Institute for Health Research (NIHR) under the Collaborations for Leadership in Applied Health Research and Care (CLAHRC) programme North West London(National Institute for Health Research (NIHR)); Dr Foster(R), a private healthcare information company; National Institute for Health Research Health Services Research	This project was funded by the National Institute for Health Research (NIHR) Health Services and Delivery Research programme (project number 14/19/50). Dr Alex Bottle was the grant holder and Dr Kate Honeyford's salary came from this grant. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the HS&DR programme, NIHR, NHS or the Department of Health. F. S. Chowdhury receives support from the National Institute for Health Research (NIHR) under the Collaborations for Leadership in Applied Health Research and Care (CLAHRC) programme North West London. The Dr Foster Unit at Imperial College London is partially funded by a grant from Dr Foster (R), a private healthcare information company. The Dr Foster Unit at Imperial College London is partly funded by research grants from the National Institute for Health Research Health Services Research.	Balicer RD, 2013, ISR J HEALTH POLICY, V2, DOI 10.1186/2045-4015-2-2; Barker I, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j84; Bolton CE, 2013, THORAX, V68, pii1, DOI 10.1136/thoraxjnl-2013-203808; Bottle A, 2018, HLTH SERVICES DELIVE, V6.26, DOI [10.3310/hsdr062602018, DOI 10.3310/HSDR062602018]; Bottle A, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010669; Bottle A, 2014, EUR J HEART FAIL, V16, P846, DOI 10.1002/ejhf.129; Cowling TE, 2016, BMJ QUAL SAF, V25, P432, DOI 10.1136/bmjqs-2015-004338; Cowling TE, 2014, J ROY SOC MED, V107, P432, DOI 10.1177/0141076814542669; Daniels J, 2018, BRIT J PAIN, V12, P10, DOI 10.1177/2049463717720635; Dharmarajan K, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h411; Guarascio AJ, 2013, CLINICOECONOMIC OUTC, V5, P235, DOI 10.2147/CEOR.S34321; Inamdar AA, 2016, J CLIN MED, V5, DOI 10.3390/jcm5070062; Jencks SF, 2009, NEW ENGL J MED, P360; Joynt KE, 2012, NEW ENGL J MED, V366, P1366, DOI 10.1056/NEJMp1201598; Kocher KE, 2013, HEALTH AFFAIR, V32, P1600, DOI 10.1377/hlthaff.2013.0067; Laverty AA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116187; Lewis EF, 2013, EVAL HEALTH PROF, V36, P330, DOI 10.1177/0163278713496565; Morganti Kristy Gonzalez, 2013, Rand Health Q, V3, P3; NHS England Pricing Team, 2016, 05995 NHS ENGL PRIC, V05995; NICE, 2010, CHRON HEART FAIL AD; Rising K, 2013, ANN EMERGENCY MED, V62; Trueman D., 2017, ESTIMATING EC BURDEN; van Walraven C, 2012, J EVAL CLIN PRACT, V18, P1211, DOI 10.1111/j.1365-2753.2011.01773.x	23	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2019	14	6							e0218128	10.1371/journal.pone.0218128	http://dx.doi.org/10.1371/journal.pone.0218128			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IC8NN	31194792	Green Published, Green Submitted, gold			2023-01-03	WOS:000471238300050
J	Sullivan, RJ; Hamid, O; Gonzalez, R; Infante, JR; Patel, MR; Hodi, FS; Lewis, KD; Tawbi, HA; Hernandez, G; Wongchenko, MJ; Chang, YM; Roberts, L; Ballinger, M; Yan, YB; Cha, E; Hwu, P				Sullivan, Ryan J.; Hamid, Omid; Gonzalez, Rene; Infante, Jeffrey R.; Patel, Manish R.; Hodi, F. Stephen; Lewis, Karl D.; Tawbi, Hussein A.; Hernandez, Genevive; Wongchenko, Matthew J.; Chang, YiMeng; Roberts, Louise; Ballinger, Marcus; Yan, Yibing; Cha, Edward; Hwu, Patrick			Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients	NATURE MEDICINE			English	Article							SIGNALING PATHWAY; T-CELL; DOUBLE-BLIND; OPEN-LABEL; INHIBITION; PEMBROLIZUMAB; DABRAFENIB; COMBINATION; IPILIMUMAB; EXPRESSION	Melanoma treatment has progressed in the past decade with the development and approval of immune checkpoint inhibitors targeting programmed death 1 (PD-1) or its ligand (PD-L1) and cytotoxic T lymphocyte-associated antigen 4, as well as small molecule inhibitors of BRAF and/or MEK for the subgroup of patients with BRAF(V600) mutations(1-9). BRAF/MEK-targeted therapies have effects on the tumor microenvironment that support their combination with PD-1/PD-L1 inhibitors(10-20). This phase Ib study (ClinicalTrials.gov, number NCT01656642) evaluated the safety and anti-tumor activity of combining atezolizumab (anti-PD-L1) with vemurafenib (BRAF inhibitor), or cobimetinib (MEK inhibitor) + vemurafenib, in patients with BRAF(V600)-mutated metastatic melanoma. Triple combination therapy with atezolizumab + cobimetinib + vemurafenib, after a 28-d run-in period with cobimetinib + vemurafenib, had substantial but manageable toxicity. Exploratory biomarker data show that the cobimetinib + vemurafenib run-in was associated with an increase in proliferating CD4(+) T-helper cells but not with an increase in T-regulatory cells, as observed in the vemurafenib-only runin period. The confirmed objective response rate was 71.8% (95% confidence interval 55.1-85.0). The estimated median duration of response was 17.4 months (95% confidence interval 10.6-25.3) with ongoing response in 39.3% of patients after 29.9 months of follow-up. Further investigation in a phase III trial is underway.	[Sullivan, Ryan J.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; [Hamid, Omid] Angeles Clin & Res Inst, Los Angeles, CA USA; [Gonzalez, Rene; Lewis, Karl D.] Univ Colorado, Ctr Canc, Aurora, CO USA; [Infante, Jeffrey R.] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA; [Patel, Manish R.] Florida Canc Specialists & Res Inst, Sarah Cannon Res Inst, Sarasota, FL USA; [Hodi, F. Stephen] Dana Farber Canc Inst, Boston, MA 02115 USA; [Tawbi, Hussein A.; Hwu, Patrick] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Hernandez, Genevive; Wongchenko, Matthew J.; Chang, YiMeng; Roberts, Louise; Ballinger, Marcus; Yan, Yibing; Cha, Edward] Genentech Inc, San Francisco, CA 94080 USA	Harvard University; Massachusetts General Hospital; Angeles Clinic & Research Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; Sarah Cannon Research Institute; Tennessee Oncology; Florida Cancer Specialists; Sarah Cannon Research Institute; Harvard University; Dana-Farber Cancer Institute; University of Texas System; UTMD Anderson Cancer Center; Roche Holding; Genentech	Sullivan, RJ (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.	rsullivan7@mgh.harvard.edu	gonzález, rene/W-2081-2019		S. Lecagoonporn (MD Anderson Cancer Center, Houston, TX, USA); F. Hoffmann-La Roche Ltd.	S. Lecagoonporn (MD Anderson Cancer Center, Houston, TX, USA); F. Hoffmann-La Roche Ltd.(Hoffmann-La Roche)	Research support was provided by S. Lecagoonporn (MD Anderson Cancer Center, Houston, TX, USA). Medical writing support was provided by M. Sweetlove and J. Sah (ApotheCom, San Francisco, CA, USA) and was funded by F. Hoffmann-La Roche Ltd.	Ascierto PA, 2016, LANCET ONCOL, V17, P1248, DOI 10.1016/S1470-2045(16)30122-X; Ascierto PA, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-85; Boni A, 2010, CANCER RES, V70, P5213, DOI 10.1158/0008-5472.CAN-10-0118; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cooper ZA, 2014, CANCER IMMUNOL RES, V2, P643, DOI 10.1158/2326-6066.CIR-13-0215; Cooper ZA, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26615; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Daud AI, 2016, J CLIN ONCOL, V34, P4102, DOI 10.1200/JCO.2016.67.2477; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Ebert PJR, 2016, IMMUNITY, V44, P609, DOI 10.1016/j.immuni.2016.01.024; Frederick DT, 2013, CLIN CANCER RES, V19, P1225, DOI 10.1158/1078-0432.CCR-12-1630; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Hamid O., 2015, PIGM CELL MELANOMA R, V28, P778; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hu-Lieskovan S, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4691; Khalili JS, 2012, CLIN CANCER RES, V18, P5329, DOI 10.1158/1078-0432.CCR-12-1632; Kono M, 2006, MOL CANCER RES, V4, P779, DOI 10.1158/1541-7786.MCR-06-0077; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Long GV, 2017, EUR J CANCER, V72, pS122, DOI 10.1016/S0959-8049(17)30482-3; Long GV, 2016, LANCET ONCOL, V17, P1743, DOI 10.1016/S1470-2045(16)30578-2; Long GV, 2015, LANCET, V386, P444, DOI 10.1016/S0140-6736(15)60898-4; Long GV, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12098; RAPISUWON S, 2018, J CLIN ONCOL S, V36; Ribas A, 2017, ANN ONCOL, V28, P428, DOI [10.1093/annonc/mdx377, DOI 10.1093/ANNONC/MDX377]; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Sapkota B, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22890; Schilling B, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.25218; Sullivan R, 2016, J TRANSL MED, V14; Sumimoto H, 2006, J EXP MED, V203, P1651, DOI 10.1084/jem.20051848; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Vella LJ, 2014, CANCER IMMUNOL RES, V2, P351, DOI 10.1158/2326-6066.CIR-13-0181; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Weber JS, 2015, LANCET ONCOL, V16, P375, DOI 10.1016/S1470-2045(15)70076-8; Wilmott JS, 2012, CLIN CANCER RES, V18, P1386, DOI 10.1158/1078-0432.CCR-11-2479; Wongchenko MJ, 2017, CLIN CANCER RES, V23, P5238, DOI 10.1158/1078-0432.CCR-17-0172	40	139	142	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2019	25	6					929	+		10.1038/s41591-019-0474-7	http://dx.doi.org/10.1038/s41591-019-0474-7			19	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	IC3FK	31171876				2023-01-03	WOS:000470844400023
J	Asada, S; Yoshida, K; Fukuma, S; Nomura, T; Wada, M; Onishi, Y; Kurita, N; Fukagawa, M; Fukuhara, S; Akizawa, T				Asada, Shinji; Yoshida, Kazuki; Fukuma, Shingo; Nomura, Takanobu; Wada, Michihito; Onishi, Yoshihiro; Kurita, Noriaki; Fukagawa, Masafumi; Fukuhara, Shunichi; Akizawa, Tadao			Effectiveness of cinacalcet treatment for secondary hyperparathyroidism on hospitalization: Results from the MBD-5D study	PLOS ONE			English	Article							MARGINAL STRUCTURAL MODELS; CHRONIC KIDNEY-DISEASE; CLINICAL-PRACTICE GUIDELINE; CARDIOVASCULAR-DISEASE; HEMODIALYSIS-PATIENTS; CHRONIC DIALYSIS; EVENTS; MANAGEMENT; MORTALITY; SURVIVAL	Objectives To elucidate the effect of cinacalcet use on all-cause and cause-specific hospitalization outcomes using a prospective cohort of maintenance hemodialysis patients. Methods We used data from a prospective cohort of Japanese hemodialysis patients with secondary hyperparathyroidism and examined baseline characteristics as well as longitudinal changes. All patients were cinacalcet-naive at study enrollment. Further, we used a marginal structural model to account for time-varying confounders on cinacalcet initiation and hospitalization outcomes, and an Andersen-Gill-type recurrent event model to account for any recurring events of hospitalization in the outcome analysis using the weighted dataset. Results Among the 3,276 patients, cinacalcet treatment was initiated in 1,384 patients during the entire follow-up. Cinacalcet users were slightly younger, included more patients with chronic glomerulonephritis and fewer patients with diabetes, were more likely to have a history of parathyroidectomy, and were more often used receiving vitamin D receptor activator, phosphate binders, and iron supplements. The overall hospitalization analysis yielded a hazard ratio (HR) of 0.97 (95% confidence interval [CI]: 0.80, 1.18). A trend toward a mild protective association was observed for cardiovascular-related hospitalizations (HR: 0.85; 95% CI: 0.64, 1.14). In the subgroup analysis, a protective association was seen due to cinacalcet use for infection-related hospitalizations in the lowest intact parathyroid hormone group (HR: 0.36; 95% CI: 0.14, 0.95). Conclusions Cinacalcet initiation in patients on maintenance hemodialysis had no effect on all-cause and cause-specific hospitalizations. Although the overall association was statistically not significant, cinacalcet may have a protective association on cardiovascular-related hospitalization in all patients and infection-related hospitalization in patient with low intact parathyroid hormone.	[Asada, Shinji; Nomura, Takanobu; Wada, Michihito] Kyowa Hakko Kirin, Med Affairs Dept, Chiyoda Ku, Tokyo, Japan; [Yoshida, Kazuki] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Yoshida, Kazuki] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Fukuma, Shingo] Kyoto Univ, Human Hlth Sci, Grad Sch Med, Kyoto, Japan; [Fukuma, Shingo] Keihanshin Consortium Fostering Next Generat Glob, Kyoto, Japan; [Onishi, Yoshihiro] Inst Hlth Outcomes & Proc Evaluat Res iHope Int, Kyoto, Japan; [Kurita, Noriaki] Fukushima Med Univ, Ctr Innovat Res Commun & Clin Excellence CiRC 2, Fukushima, Japan; [Kurita, Noriaki] Fukushima Med Univ Hosp, Dept Innovat Res & Educ Clinicians & Trainees DiR, Fukushima, Japan; [Fukagawa, Masafumi] Tokai Univ, Sch Med, Div Nephrol Endocrinol & Metab, Tokyo, Japan; [Fukuhara, Shunichi] Kyoto Univ, Sch Publ Hlth, Dept Healthcare Epidemiol, Fac Med, Kyoto, Japan; [Akizawa, Tadao] Showa Univ, Shinagawa Ku, Tokyo, Japan	Kyowa Kirin Ltd; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Kyoto University; Fukushima Medical University; Fukushima Medical University; Tokai University; Kyoto University; Showa University	Asada, S (corresponding author), Kyowa Hakko Kirin, Med Affairs Dept, Chiyoda Ku, Tokyo, Japan.	shinji.asada@kyowa-kirin.co.jp	Kurita, Noriaki/I-6023-2019	Kurita, Noriaki/0000-0003-4127-7500; Asada, Shinji/0000-0002-7717-8945; Fukuma, Shingo/0000-0002-8379-8761	Kyowa Hakko Kirin	Kyowa Hakko Kirin(Kyowa Kirin Ltd)	The MBD-5D study was funded by Kyowa Hakko Kirin.	Akizawa T, 2016, SCI REP-UK, V6, DOI 10.1038/srep19612; Amorim LDAF, 2015, INT J EPIDEMIOL, V44, P324, DOI 10.1093/ije/dyu222; ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Block GA, 2010, KIDNEY INT, V78, P578, DOI 10.1038/ki.2010.167; Chertow GM, 2012, NEW ENGL J MED, V367, P2482, DOI 10.1056/NEJMoa1205624; Choi SR, 2012, NEPHRON CLIN PRACT, V122, P1, DOI 10.1159/000347145; Cole SR, 2005, AM J EPIDEMIOL, V162, P471, DOI 10.1093/aje/kwi216; Cunningham J, 2005, KIDNEY INT, V68, P1793, DOI 10.1111/j.1523-1755.2005.00596.x; Fewell Z, 2004, STATA J, V4, P402, DOI 10.1177/1536867X0400400403; Fukagawa M, 2014, AM J KIDNEY DIS, V63, P979, DOI 10.1053/j.ajkd.2013.08.011; Fukagawa M, 2013, THER APHER DIAL, V17, P247, DOI 10.1111/1744-9987.12058; Fukagawa M, 2008, THER APHER DIAL, V12, P514, DOI 10.1111/j.1744-9987.2008.00648.x; Fukuhara S, 2011, THER APHER DIAL, V15, P169, DOI 10.1111/j.1744-9987.2010.00906.x; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Hernan MA, 2000, EPIDEMIOLOGY, V11, P561, DOI 10.1097/00001648-200009000-00012; Hernan MARJ., 2018, CAUSAL INFERENCE; Komaba H, 2015, SEMIN DIALYSIS, V28, P594, DOI 10.1111/sdi.12413; Komaba H, 2012, NAT REV NEPHROL, V8, P484, DOI 10.1038/nrneph.2012.116; Komaba H, 2011, CLIN EXP NEPHROL, V15, P797, DOI 10.1007/s10157-011-0502-5; Masakane I., 2018, RENAL REPLACEMENT TH, V4, P45, DOI DOI 10.1186/S41100-018-0183-6; Mieno MN, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-80; Moe SM, 2015, CIRCULATION, V132, P27, DOI 10.1161/CIRCULATIONAHA.114.013876; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; Nishikawa K, 2017, CLIN EXP NEPHROL, V21, P316, DOI 10.1007/s10157-016-1293-5; Raggi P, 2011, NEPHROL DIAL TRANSPL, V26, P1327, DOI 10.1093/ndt/gfq725; Ray WA, 2003, AM J EPIDEMIOL, V158, P915, DOI 10.1093/aje/kwg231; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; Taniguchi M, 2013, THER APHER DIAL, V17, P221, DOI 10.1111/1744-9987.12030; van Buuren S, 2011, J STAT SOFTW, V45, P1; Yoshida K, 2015, NAT REV RHEUMATOL, V11, P437, DOI 10.1038/nrrheum.2015.30; Zhang Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048070	31	1	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2019	14	5							e0216399	10.1371/journal.pone.0216399	http://dx.doi.org/10.1371/journal.pone.0216399			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IA1LO	31141505	Green Submitted, Green Published, gold			2023-01-03	WOS:000469323000007
J	Kaur, N; Sinha, PK; Sahni, G				Kaur, Navneet; Sinha, Prakash Kumar; Sahni, Girish			Site-specific PEGylation of micro-plasmin for improved thrombolytic therapy through engineering enhanced resistance against serpin mediated inhibition	PLOS ONE			English	Article							POLYETHYLENE-GLYCOL MODIFICATION; PROTEIN PEGYLATION; ANTIBODY FRAGMENTS; MOLECULAR-WEIGHT; PEG; MICROPLASMIN; SUBSTRATE; CHEMISTRY; PEPTIDE; DOMAIN	The relatively rapid inhibition of microplasmin by alpha(2)-AP leads to short functional half-life of the molecule in vivo, causing inefficient clot dissolution, even after site-specific, local catheter-based delivery. Here, we describe a PEGylation approach for improving the therapeutic potential via improving the survival of microplasmin in presence of its cognate inhibitor, alpha(2)-AP, wherein a series of strategically designed cysteine analogs of micro-plasminogen were prepared and expressed in E. coli, and further modified by covalent grafting in vitro with PEG groups of different molecular sizes so as to select single or double PEG chains that increase the molecular weight and hydrodynamic radii of the conjugates, but with a minimal discernible effect on intrinsic plasmin activity and structural framework, as explored by amidolytic activity and CD-spectroscopy, respectively. Interestingly, some of the purified PEG-coupled proteins after conversion to their corresponding proteolytically active forms were found to exhibit significantly reduced inhibition rates (up to 2-fold) by alpha(2)-AP relative to that observed with wild-type microplasmin. These results indicate an interesting, and not often observed, effect of PEG groups through reduced/altered dynamics between protease and inhibitor, likely through a steric hindrance mechanism. Thus, the present study successfully identifies single- and double-site PEGylated muteins of microplasmin with significantly enhanced functional half-life through enhanced resistance to inactivation by its in vivo plasma inhibitor. Such an increased survival of bioactivity in situ, holds unmistakable potential for therapeutic exploitation, especially in ischemic strokes where a direct, catheter-based deposition within the cranium has been shown to be promising, but is currently limited by the very short in vivo bioactive half-life of the fibrin dissolving agent/s.	[Kaur, Navneet; Sinha, Prakash Kumar; Sahni, Girish] CSIR Inst Microbial Technol, Chandigarh, India; [Kaur, Navneet; Sinha, Prakash Kumar] Panjab Univ, Chandigarh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH); Panjab University	Sahni, G (corresponding author), CSIR Inst Microbial Technol, Chandigarh, India.	girishsahni@gmail.com	Sinha, Prakash Kumar/K-6048-2013	Sinha, Prakash Kumar/0000-0002-2067-5676	Council of Scientific and Industrial Research (CSIR), New Delhi, India; ICMR Junior Research fellowship	Council of Scientific and Industrial Research (CSIR), New Delhi, India(Council of Scientific & Industrial Research (CSIR) - India); ICMR Junior Research fellowship	R and D funding was provided by the Council of Scientific and Industrial Research (CSIR), New Delhi, India. GS is a Bhatnagar Research Fellow of the CSIR and a Honorary Professor, Punjab University, Chandigarh, India. NK was supported by ICMR Junior Research fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3582; Adivitiya, 2017, BIOENGINEERED, V8, P331, DOI 10.1080/21655979.2016.1229718; AMBRUS JL, 1957, ANN NY ACAD SCI, V68, P97, DOI 10.1111/j.1749-6632.1957.tb42616.x; Aneja R, 2009, J BIOL CHEM, V284, P32642, DOI 10.1074/jbc.M109.046573; Aoki N, 2005, J THROMB HAEMOST, V3, P623, DOI 10.1111/j.1538-7836.2004.01055.x; Bailon P, 1998, PHARM SCI TECHNOL TO, V1, P352, DOI 10.1016/S1461-5347(98)00086-8; BOYLES PW, 1960, AM J CARDIOL, V6, P439, DOI 10.1016/0002-9149(60)90337-4; Chapman AP, 1999, NAT BIOTECHNOL, V17, P780, DOI 10.1038/11717; Chapman AP, 2002, ADV DRUG DELIVER REV, V54, P531, DOI 10.1016/S0169-409X(02)00026-1; Chaudhary A, 1999, PROTEIN SCI, V8, P2791; CLIFFTON EE, 1957, ANN NY ACAD SCI, V68, P209, DOI 10.1111/j.1749-6632.1957.tb42627.x; Collen D, 2000, CIRCULATION, V102, P1766; COLLEN D, 1991, BLOOD, V78, P3114; Crumrine R Christian, 2012, Exp Transl Stroke Med, V4, P10, DOI 10.1186/2040-7378-4-10; DELGADO C, 1992, CRIT REV THER DRUG, V9, P249; Doherty DH, 2005, BIOCONJUGATE CHEM, V16, P1291, DOI 10.1021/bc050172r; Dong XB, 2018, MEMBRANES-BASEL, V8, DOI 10.3390/membranes8020023; DREBORG S, 1990, CRIT REV THER DRUG, V6, P315; Erel O, 2014, CLIN BIOCHEM, V47, P326, DOI 10.1016/j.clinbiochem.2014.09.026; Fishburn CS, 2008, J PHARM SCI-US, V97, P4167, DOI 10.1002/jps.21278; Gaberc-Porekar V, 2008, CURR OPIN DRUG DISC, V11, P242; GEIER GE, 1979, J BIOL CHEM, V254, P1408; Gladysheva IP, 2002, J BIOL CHEM, V277, P26846, DOI 10.1074/jbc.M202999200; Greenwald RB, 2003, ADV DRUG DELIVER REV, V55, P217, DOI 10.1016/S0169-409X(02)00180-1; Hao Y, 2006, BIODRUGS, V20, P357, DOI 10.2165/00063030-200620060-00006; Harris JM, 2003, ADV DRUG DELIVER REV, V55, P1259, DOI 10.1016/S0169-409X(03)00107-8; Harris JM, 1997, ACS SYM SER, P680; Hoefer IE, 2009, J VASC INTERV RADIOL, V20, P951, DOI 10.1016/j.jvir.2009.03.043; Hu Y, 2007, J CONTROL RELEASE, V118, P7, DOI 10.1016/j.jconrel.2006.11.028; Hunt JA, 2008, THROMB HAEMOSTASIS, V100, P413, DOI 10.1160/TH08-04-0225; Jahan R, 2008, STROKE, V39, P1613, DOI 10.1161/STROKEAHA.107.507376; Jensen VJ, 1976, US patent, Patent No. 3950513; Joshi KK, 2010, PROCESS BIOCHEM, V45, P1251, DOI 10.1016/j.procbio.2010.04.014; KATRE NV, 1993, ADV DRUG DELIVER REV, V10, P91, DOI 10.1016/0169-409X(93)90005-O; Kerwin BA, 2002, PROTEIN SCI, V11, P1825, DOI 10.1110/ps.0208102; Kubetzko S, 2005, MOL PHARMACOL, V68, P1439, DOI 10.1124/mol.105.014910; Kusterle M, 2008, ACTA CHIM SLOV, V55, P594; Lapchak PA, 2002, STROKE, V33, P2279, DOI 10.1161/01.STR.0000028267.09604.7B; Law RHP, 2008, BLOOD, V111, P2049, DOI 10.1182/blood-2007-09-114215; Lawrence PB, 2016, CURR OPIN CHEM BIOL, V34, P88, DOI 10.1016/j.cbpa.2016.08.006; Lee P, 2015, MACROMOL BIOSCI, V15, P1332, DOI 10.1002/mabi.201500143; Lin XT, 2013, THROMB J, V11, DOI 10.1186/1477-9560-11-2; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; Marder VJ, 2011, J THROMB HAEMOST, V9, P364, DOI 10.1111/j.1538-7836.2011.04370.x; Marder VJ, 2010, J THROMB HAEMOST, V8, P433, DOI 10.1111/j.1538-7836.2009.03701.x; MAXFIELD J, 1975, POLYMER, V16, P505, DOI 10.1016/0032-3861(75)90008-7; Milla P, 2012, CURR DRUG METAB, V13, P105, DOI 10.2174/138920012798356934; Mok H, 2005, MOL THER, V11, P66, DOI 10.1016/j.ymthe.2004.09.015; Morgenstern J, 2017, INT J PHARMACEUT, V519, P408, DOI 10.1016/j.ijpharm.2017.01.040; Mu QM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068559; Nagai N, 2003, J THROMB HAEMOST, V1, P307, DOI 10.1046/j.1538-7836.2003.00078.x; Nagai N, 2001, BLOOD, V97, P3086, DOI 10.1182/blood.V97.10.3086; Nagai N, 1999, CIRCULATION, V99, P2440, DOI 10.1161/01.CIR.99.18.2440; Neffendorf JE, 2018, ACTA OPHTHALMOL, V96, P685, DOI 10.1111/aos.13547; Ozbakir HF, 2018, AICHE J, V64, P12, DOI 10.1002/aic.15893; PETERSEN TE, 1990, J BIOL CHEM, V265, P6104; Roberts MJ, 2002, ADV DRUG DELIVER REV, V54, P459, DOI 10.1016/S0169-409X(02)00022-4; Rodriguez-Martinez JA, 2008, BIOTECHNOL BIOENG, V101, P1142, DOI 10.1002/bit.22014; Sadeghi S, 2003, J THROMB HAEMOST, V1, P2621, DOI 10.1046/j.1538-7836.2003.00441.x; Sawhney P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155831; SEHON AH, 1991, ADV DRUG DELIVER REV, V6, P203, DOI 10.1016/0169-409X(91)90041-A; Suzuki Y, 2004, STROKE, V35, P2402, DOI 10.1161/01.STR.0000140628.00927.1a; Tovchigrechko A, 2006, NUCLEIC ACIDS RES, V34, pW310, DOI 10.1093/nar/gkl206; Turecek PL, 2016, J PHARM SCI-US, V105, P460, DOI 10.1016/j.xphs.2015.11.015; Turner RB, 2002, J BIOL CHEM, V277, P33068, DOI 10.1074/jbc.M203782200; Veronese FM, 2005, DRUG DISCOV TODAY, V10, P1451, DOI 10.1016/S1359-6446(05)03575-0; Veronese FM, 2001, BIOMATERIALS, V22, P405, DOI 10.1016/S0142-9612(00)00193-9; Wang XQ, 2000, J MOL BIOL, V295, P903, DOI 10.1006/jmbi.1999.3397; WIMAN B, 1978, EUR J BIOCHEM, V87, P143, DOI 10.1111/j.1432-1033.1978.tb12360.x; WIMAN B, 1979, BIOCHIM BIOPHYS ACTA, V579, P142, DOI 10.1016/0005-2795(79)90094-1; WIMAN B, 1979, J BIOL CHEM, V254, P9291; WU HL, 1987, P NATL ACAD SCI USA, V84, P8292, DOI 10.1073/pnas.84.23.8292; Wu YP, 2000, J CELL BIOL, V148, P1295, DOI 10.1083/jcb.148.6.1295; Yang C, 2011, BIOCHEMISTRY-US, V50, P2585, DOI 10.1021/bi101926u; Yang K, 2003, PROTEIN ENG, V16, P761, DOI 10.1093/protein/gzg093; ZALIPSKY S, 1995, ADV DRUG DELIVER REV, V16, P157, DOI 10.1016/0169-409X(95)00023-Z; Zheng JC, 2012, IMMUNOPHARM IMMUNOT, V34, P866, DOI 10.3109/08923973.2012.666979	78	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2019	14	5							e0217234	10.1371/journal.pone.0217234	http://dx.doi.org/10.1371/journal.pone.0217234			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IA1LO	31141522	Green Published, Green Submitted, gold			2023-01-03	WOS:000469323000045
J	Somma, F; Stoia, V; Serra, N; D'Angelo, R; Gatta, G; Fiore, F				Somma, Francesco; Stoia, Vincenzo; Serra, Nicola; D'Angelo, Roberto; Gatta, Gianluca; Fiore, Francesco			Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival	PLOS ONE			English	Article							UNRESECTABLE HEPATOCELLULAR-CARCINOMA; TRANSARTERIAL CHEMOEMBOLIZATION; LIVER-TRANSPLANTATION; MICROSPHERES; CANCER; TERM; SORAFENIB; BRACHYTHERAPY; DESIGN; SAFETY	Purpose Portal vein thrombosis (PVT) is generally recognized as a prognostic factor in HCC. Our purpose is to assess and compare the survival of patients with PVT and without PVT, after Y-90 Trans-Arterial Radio-Embolization (TARE) of unresectable HCC, unresponsive to other loco-regional treatments. Materials and methods Between November 2005 and November 2012, Y-90 resin-based TARE was performed in an IRB-approved prospective protocol, on 89 patients with unresectable HCC. 33/89 patients had PVT, the remaining 56 were resistant-to-cTACE or underwent TARE as a downstaging therapy. All patients were studied with Multi-Detector Computed Tomography (MDCT), angiography, 99m Tc-MAA-scintigraphy and liver biopsy. Gastro-duodenal artery was embolized in most cases. Proton-Pump Inhibitors were administered to prevent gastritis and ulcers..2 test with Yates correction and log rank test were used to compare the two proportions and Kaplan-Meier survival curves, respectively. Results The average activity administered was 1.7 +/- 0.4 GBq. After the treatment, CTCAE grade 2 adverse events occurred in 46% (41/89) patients: in particular, fever and abdominal pain were found in 25 and 16 patients, respectively. No major side-effect was observed. According to mRECIST criteria, partial response or complete response was found in 70% of patient three months after the treatment, and in 90.5% nine months after the treatment. No significant difference was found in survival of patients with PVT compared to those without PVT (p-value = 0.672). A complete regression of PVT was observed in almost half patients (13/27, 48.1%). Conclusions Portal vein invasion does not affect survival in advanced stage HCC-patients undergoing TARE using Y-90 resin-based microspheres. Y90 procedure is associated with regression of portal vein tumor thrombus.	[Somma, Francesco; Stoia, Vincenzo; Serra, Nicola; D'Angelo, Roberto; Gatta, Gianluca; Fiore, Francesco] Ist Nazl Tumori IRCCS Fdn G Pascale, Dipartimento Radiol Interventist, Naples, Italy	IRCCS Fondazione Pascale	Somma, F (corresponding author), Ist Nazl Tumori IRCCS Fdn G Pascale, Dipartimento Radiol Interventist, Naples, Italy.	fra1585@hotmail.it	Somma, Francesco/AAA-9462-2021; , vincenzo/AAY-6364-2021	, vincenzo/0000-0002-8919-861X; GATTA, Gianluca/0000-0003-0874-8294; Somma, Francesco/0000-0002-8193-3050				Barbier L, 2011, INT J HEPATOL, V2011, DOI 10.4061/2011/791013; BREEDIS C, 1954, AM J PATHOL, V30, P969; Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933; Bruix J, 2012, J HEPATOL, V57, P821, DOI 10.1016/j.jhep.2012.06.014; Camma C, 2002, RADIOLOGY, V224, P47, DOI 10.1148/radiol.2241011262; Carr BI, 2016, ONCOLOGY-BASEL, V90, P215, DOI 10.1159/000444394; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Chow P, 2017, P AN M AM SOC CLIN, V35, P4002, DOI DOI 10.1200/JC0.201735.15.3UPPL.4002; Chung GE, 2011, RADIOLOGY, V258, P627, DOI 10.1148/radiol.10101058; Clayton D, 1993, STAT MODELS EPIDEMIO, p[27, 146]; Costentin CE, 2017, LIVER CANCER, V6, P360, DOI 10.1159/000481315; D'Avola D, 2009, HEPATO-GASTROENTEROL, V56, P1683; Dai QS, 2014, MOL CLIN ONCOL, V2, P1047, DOI 10.3892/mco.2014.391; FARMER DG, 1994, ANN SURG, V219, P236, DOI 10.1097/00000658-199403000-00003; Fiore F, 2014, ENDOCRINE; Gondolesi GE, 2004, ANN SURG, V239, P142, DOI 10.1097/01.sla.0000109022.32391.eb; Hilgard P, 2010, HEPATOLOGY, V52, P1741, DOI 10.1002/hep.23944; Ho S, 1997, BRIT J RADIOL, V70, P823, DOI 10.1259/bjr.70.836.9486047; Ho S, 1996, EUR J NUCL MED, V23, P947, DOI 10.1007/BF01084369; Jeong SW, 2013, GUT LIVER, V7, P696, DOI 10.5009/gnl.2013.7.6.696; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kennedy AS, 2006, INT J RADIAT ONCOL, V65, P412, DOI 10.1016/j.ijrobp.2005.12.051; Lammer J, 2010, CARDIOVASC INTER RAD, V33, P41, DOI 10.1007/s00270-009-9711-7; Lau WY, 2013, ONCOLOGY-BASEL, V84, P311, DOI 10.1159/000348325; Lencioni R, 2005, RADIOLOGY, V234, P961, DOI 10.1148/radiol.2343040350; Lencioni R, 2010, SEMIN LIVER DIS, V30, P52, DOI 10.1055/s-0030-1247132; Lewandowski RJ, 2009, AM J TRANSPLANT, V9, P1920, DOI 10.1111/j.1600-6143.2009.02695.x; Lewandowski RJ, 2007, CARDIOVASC INTER RAD, V30, P571, DOI 10.1007/s00270-007-9064-z; Lewandowski RJ, 2010, RADIOLOGY, V255, P955, DOI 10.1148/radiol.10091473; Liapi E, 2007, J CLIN ONCOL, V25, P978, DOI 10.1200/JCO.2006.09.8657; Liu DM, 2005, J VASC INTERV RADIOL, V16, P911, DOI 10.1097/01.RVI.0000164324.79242.B2; Llovet JM, 1999, HEPATOLOGY, V29, P62, DOI 10.1002/hep.510290145; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2008, JNCI-J NATL CANCER I, V100, P698, DOI 10.1093/jnci/djn134; Llovet JM, 2012, J HEPATOL, V56, P908, DOI 10.1016/j.jhep.2011.12.001; Luo J, 2011, ANN SURG ONCOL, V18, P413, DOI 10.1245/s10434-010-1321-8; Manghisi G, 1998, HEPATOLOGY, V28, P751; Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104; Mazzaferro V, 2013, HEPATOLOGY, V57, P1826, DOI 10.1002/hep.26014; Memon K, 2012, CURR TREAT OPTION ON, V13, P403, DOI 10.1007/s11864-012-0200-x; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pinter M, 2012, RADIOLOGY, V263, P590, DOI 10.1148/radiol.12111550; Pirisi M, 1998, J CANCER RES CLIN, V124, P397, DOI 10.1007/s004320050189; Salem R, 2002, J VASC INTERV RADIOL, V13, pS223, DOI 10.1016/S1051-0443(07)61790-4; Salem R, 2007, TECH VASC INTERV RAD, V10, P12, DOI 10.1053/j.tvir.2007.08.001; Salem R, 2006, J VASC INTERV RADIOL, V17, P1251, DOI 10.1097/01.RVI.0000233785.75257.9A; Salem R, 2010, GASTROENTEROLOGY, V138, P52, DOI 10.1053/j.gastro.2009.09.006; Sangro B, 2012, J HEPATOL, V56, P464, DOI 10.1016/j.jhep.2011.07.012; Sangro B, 2011, HEPATOLOGY, V54, P868, DOI 10.1002/hep.24451; Sato K, 2006, CARDIOVASC INTER RAD, V29, P522, DOI 10.1007/s00270-005-0171-4; Shi J, 2010, ANN SURG ONCOL, V17, P2073, DOI 10.1245/s10434-010-0940-4; SOKAL RR, 1995, BIOMETRY PRINCIPLES, P724; Somma F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129573; Syha R, 2012, EUR J GASTROEN HEPAT, V24, P1325, DOI 10.1097/MEG.0b013e32835724bc; Vilgrain V, 2017, J HEPATOL, V66, pS85, DOI 10.1016/S0168-8278(17)30436-1	57	20	21	3	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2019	14	5							e0216935	10.1371/journal.pone.0216935	http://dx.doi.org/10.1371/journal.pone.0216935			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IA1LO	31141552	Green Published, Green Submitted, gold			2023-01-03	WOS:000469323000029
J	Bintabara, D; Nakamura, K; Ntwenya, J; Seino, K; Mpondo, BCT				Bintabara, Deogratius; Nakamura, Keiko; Ntwenya, Julius; Seino, Kaoruko; Mpondo, Bonaventura C. T.			Adherence to standards of first-visit antenatal care among providers: A stratified analysis of Tanzanian facility-based survey for improving quality of antenatal care	PLOS ONE			English	Article							HEALTH-CARE; PREGNANT-WOMEN; CHILD HEALTH; SERVICES; NEWBORN	Introduction Despite the benefits of early antenatal care visits for early prevention, detection, and treatment of potential complications in pregnancy, a high level of provider adherence to first-visit antenatal care standards is needed. However, little information is available regarding provider adherence to antenatal care in Tanzania. This study was performed to assess provider adherence to first-visit antenatal care standards and to apply stratified analysis to identify associated factors in Tanzania. Methods Data from the 2014-2015 Tanzania Service Provision Assessment Survey were used in this study. Provider adherence to first-visit antenatal care standards was measured using 10 domains: client history; aspects of prior pregnancies; danger signs of the current pregnancy; physical examination; routine tests; HIV testing and counseling; maintaining a healthy pregnancy; iron/folate supplements; tetanus toxoid vaccination, and preparation for delivery. A composite score was then created in which the highest quantile (corresponding to. 60.5%) considered to provider adhering to first-visit antenatal care standards. Initially, a series of unadjusted logistic regression analyses according to the type of facility and managing authority were performed separately at each level (i.e., facility, provider, and client). Thereafter, all variables with P < 0.2 were fitted into the respective stratified multivariable logistic regression analysis using a 5% significance level. Results A total of 1756 first-visit antenatal care consultations performed by 822 providers in 648 health facilities were analyzed. The overall median [Interquartile range, IQR] adherence to first-visit antenatal care was relatively low at 47.1% [35.7%-60.5%]. After adjusting for selected variables from each level in specific strata, at dispensary; female providers [AOR = 5.5; 95% CI, 1.8-16.4], at health centre; performance of quality assurance [AOR = 2.2; 95% CI, 1.3-3.9], at hospital; availability of routine tests [AOR = 2.5; 95% CI, 1.3-4.8] and basic medicine [AOR = 2.8; 95% CI, 1.4-5.7], at public facilities; availability of medicine [AOR = 1.8; 95% CI, 1.1-3.2] and receiving refresher training [AOR = 1.8; 95% CI, 1.1-3.1], and at private facility; receiving external fund from government [AOR = 3.0; 95% CI, 1.1-8.4] were significantly associated with better adherence to first-visit antenatal care standards. Conclusions The study highlighted the important factors, including the provision of refresher training, regular distribution of basic medicines, and diagnostics equipment which may influence provider adherence to first-visit ANC standards.	[Bintabara, Deogratius; Nakamura, Keiko; Seino, Kaoruko] Tokyo Med & Dent Univ, Grad Sch, Div Publ Hlth, Dept Global Hlth Entrepreneurship, Tokyo, Japan; [Bintabara, Deogratius; Ntwenya, Julius] Univ Dodoma, Coll Hlth Sci, Dept Publ Hlth, Dodoma, Tanzania; [Seino, Kaoruko] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA; [Mpondo, Bonaventura C. T.] Univ Dodoma, Coll Hlth Sci, Dept Internal Med, Dodoma, Tanzania	Tokyo Medical & Dental University (TMDU); University of Michigan System; University of Michigan	Nakamura, K (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Div Publ Hlth, Dept Global Hlth Entrepreneurship, Tokyo, Japan.	nakamura.ith@tmd.ac.jp		Seino, Kaoruko/0000-0003-3145-6396; NTWENYA, JULIUS/0000-0002-4719-1970				Abou-Zahr I, 2014, ANTENATAL CARE DEV C, V2003, P1; Adam T, 2005, BMJ-BRIT MED J, V331, P1107, DOI 10.1136/bmj.331.7525.1107; Afulani PA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117996; Alkema L., 2015, GLOBAL, V6736, P13; Amoakoh-Coleman M, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1167-6; Amoakoh-Coleman M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157542; Annie K, 2014, FOCUSED ANTENATAL CA; [Anonymous], 2016, SERV AV READ ASS SAR; [Anonymous], 2011, TANZ DEM HLTH SURV 2; Atinga RA, 2013, INT J SOC ECON, V40, P852, DOI 10.1108/IJSE-2011-0075; Bhutta ZA, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-S1-S7; Bintabara D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192942; Bintabara D, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2809-8; Bintabara D, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1469-3; Bintabara D, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0041-8; Boller C, 2003, B WORLD HEALTH ORGAN, V81, P116; Busari J., 2012, ADV MED ED PRACT, V121; Cancedda C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001840; Carolan M, 2010, MIDWIFERY, V26, P189, DOI 10.1016/j.midw.2008.03.005; Carroli G, 2001, LANCET, V357, P1565, DOI 10.1016/S0140-6736(00)04723-1; Choi Y, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-266; DALE DC, 1981, SOC SCI MED-MED ECON, V15, P199, DOI 10.1016/0160-7995(81)90039-3; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; de Jonge V, 2011, BEST PRACT RES CL GA, V25, P337, DOI 10.1016/j.bpg.2011.05.001; de Jongh TE, 2016, BJOG-INT J OBSTET GY, V123, P549, DOI 10.1111/1471-0528.13898; Desalegn Daniel Melese, 2016, BMC Res Notes, V9, P403, DOI 10.1186/s13104-016-2207-z; Di Mario S, 2005, WHAT IS EFFECTIVEN S, V25; Donabedian A, 1997, ARCH PATHOL LAB MED, V121, P1145; Duysburgh E, 2014, BJOG-INT J OBSTET GY, V121, P117, DOI 10.1111/1471-0528.12905; Fagbamigbe AF, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0081-0; Gammal HA, 2014, J FAMILY MED PRIM CA, V3, P238, DOI [10.4103/2249-4863.141617, DOI 10.4103/2249-4863.141617]; Gross K, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-16; Gross K, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-36; Gupta S, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000410; Halm EA, 2000, ARCH INTERN MED, V160, P98, DOI 10.1001/archinte.160.1.98; Heredia-Pi I, 2016, B WORLD HEALTH ORGAN, V94, P452, DOI 10.2471/BLT.15.168302; James White, 2013, TANZANIA PRIVATE HLT; JHPIEGO, 2004, MAT NEON HLTH FOC AN; Johns Hopkins Bloomberg School of Public Health Family Care International Maternal and Neonatal Health Program., 2004, MON BIRTH PREP COMP; Joshi C, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-94; Kaaya EE, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001284; Kanyangarara M, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.021101; Kerber KJ, 2007, LANCET, V370, P1358, DOI 10.1016/S0140-6736(07)61578-5; KOBLINSKY MA, 1994, HEALTH POLICY PLANN, V9, P252, DOI 10.1093/heapol/9.3.252; Kruk ME, 2017, B WORLD HEALTH ORGAN, V95, P408, DOI [10.2471/BLT.16.175869, 10.2471/blt.16.175869]; Kujawski SA, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-001002; Kyei NNA, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-151; Lassi ZS, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007754.pub2; Leonard K, 2006, SOC SCI MED, V63, P2330, DOI 10.1016/j.socscimed.2006.06.003; Leslie HH, 2016, HEALTH AFFAIR, V35, P1716, DOI 10.1377/hlthaff.2016.0261; Lidia Abou-Zahr Carla, 2003, ANAL TRENDS LEVELS D; McDonagh M, 1996, HEALTH POLICY PLANN, V11, P1, DOI 10.1093/heapol/11.1.1; Miltenburg AS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188279; Ministry of Health Community Development Gender Elderly and Children (MoHCDGEC) [Tanzania Mainland] Ministry of Health (MoH) [Zanzibar] National Bureau of Statistics (NBS) Office of the Chief Government Statistician (OCGS) and ICF, 2015, TANZ 2015 16 DEM HLT; MoHCDGEC, 2016, TANZ DEM HLTH SURV; MoHSW, 2008, NAT ROAD MAP STRAT P; Morris C, 2014, MEASURING HLTH CARE; Mosadeghrad AM, 2014, INT J HEALTH POLICY, V3, P77, DOI 10.15171/ijhpm.2014.65; Mrisho M, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-10; Mubyazi GM, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-135; Munuswamy Suresh, 2014, J Rural Med, V9, P10, DOI 10.2185/jrm.2877; Nikiema L, 2010, J HEALTH POPUL NUTR, V28, P67, DOI 10.3329/jhpn.v28i1.4525; Nyamtema AS, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-70; Osungbade K, 2008, INT J QUAL HEALTH C, V20, P346, DOI 10.1093/intqhc/mzn026; Oyerinde K., 2013, J COMMUNITY MED HLTH, V3; Papaevangelou V, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-84; Pembe AB, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-35; Pembe AB, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-12; Sarker Malabika, 2010, BMC Res Notes, V3, P209, DOI 10.1186/1756-0500-3-209; SMITH AM, 1986, LANCET, V1, P1331; Tafere TE, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192428; Tetui M, 2012, PAN AFR MED J, V13; The United Republic of Tanzania (URT), 2002, FOC ANT CAR MAL SYPH; UN, 2019, IMPROVING SUSTAINABL; Urassa DP, 2012, TANZAN J HLTH RES, V14; Villadsen SF, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1708-3; Villar J, 2001, LANCET, V357, P1551, DOI 10.1016/S0140-6736(00)04722-X; Vogel JP, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-19; von Both C FleaS, 2006, BMC PREGNANCY CHILDB, V6, P22, DOI [10.1186/1471-2393-6-22, DOI 10.1186/1471-2393-6-22]; Wang W, 2014, ASSESSING QUALITY CA; WHO, 2022, WHO RECOMMENDATIONS; WHO (World Health Organization), 2015, TRENDS MATERNAL MORT; 2010, OBSTET GYNECOL, V115, P1021, DOI DOI 10.1097/AOG.0B013E3181D9F4CD	83	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2019	14	5							e0216520	10.1371/journal.pone.0216520	http://dx.doi.org/10.1371/journal.pone.0216520			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HX9GC	31083696	Green Submitted, Green Published, gold			2023-01-03	WOS:000467714000027
J	Liebrecht, LK; Newton, J; Martin, EJ; Wickramaratne, N; Jayaraman, S; Han, JF; Aboutanos, M; Brophy, DF; Mangino, MJ				Liebrecht, Loren K.; Newton, Jason; Martin, Erika J.; Wickramaratne, Niluka; Jayaraman, Sudha; Han, Jinfeng; Aboutanos, Michel; Brophy, Donald F.; Mangino, Martin J.			Effects of a novel low volume resuscitation solutions on coagulation and platelet function	PLOS ONE			English	Article							HEMORRHAGIC-SHOCK; NORMAL RANGE; FACTOR-XIII; STRENGTH; SALINE	Background Novel crystalloid solutions containing polyethylene glycol polymers (PEG-20k) produce dramatic resuscitation effects but dose-dependently produce a hypocoagulative state. The objective of this study was to examine possible mechanisms of this effect. Based on previous thromboelastography data, we hypothesize the effect is largely due to platelet interactions with the polymers. Methods Whole citrated blood from healthy volunteers was diluted ex-vivo 10% with crystalloids and tested for coagulation and platelet function. The specific tests included prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen and von Willebrand factor (vWf) activity, thrombin generation, thromboelastography with and without platelet mapping, platelet flow cytometry, and erythrocyte sedimentation rate. Findings Fibrinogen and vWF activities, PT, and aPTT were not affected by PEG-20k dilutions. Thrombin activity was mildly suppressed with PEG-20k (TTP-20%). Platelet mapping demonstrated significantly greater % inhibition of both ADP and arachidonic acid-induced platelet aggregation with PEG-20k, but direct ADP-activated gpIIa/IIIb (PAC1) and P-selectin (CD62P) binding site expression was not altered. Mild dose-dependent suppression of TEG-MA was seen with PEG-20k using platelet poor plasma. Erythrocyte Sedimentation Rates (ESR) were dramatically accelerated after dilution with 10% PEG-20k, which was competitively blocked by smaller PEG polymers, suggesting nonspecific PEG-20k cell binding effects. Conclusions PEG-20k creates a mild hypocoagulative state in whole blood at concentrations. 10%, which may be due to platelet-PEG interactions at the IIb/IIIa interface with lesser effects on fibrin polymerization. This interaction may cause a functional thrombasthenia induced by nonspecific platelet surface passivation by the PEG polymer.	[Liebrecht, Loren K.; Wickramaratne, Niluka; Jayaraman, Sudha; Han, Jinfeng; Aboutanos, Michel; Mangino, Martin J.] Virginia Commonwealth Univ, Dept Surg, Div Acute Care Surg, Sch Med, Richmond, VA 23284 USA; [Newton, Jason] Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, Richmond, VA USA; [Martin, Erika J.; Brophy, Donald F.] Virginia Commonwealth Univ, Sch Med, Dept Pharmacotherapy & Outcomes Sci, Richmond, VA USA; [Mangino, Martin J.] Virginia Commonwealth Univ, Sch Med, Dept Physiol & Biophys, Richmond, VA 23284 USA; [Mangino, Martin J.] Virginia Commonwealth Univ, Sch Med, Dept Emergency Med, Richmond, VA 23284 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Mangino, MJ (corresponding author), Virginia Commonwealth Univ, Dept Surg, Div Acute Care Surg, Sch Med, Richmond, VA 23284 USA.; Mangino, MJ (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Physiol & Biophys, Richmond, VA 23284 USA.; Mangino, MJ (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Emergency Med, Richmond, VA 23284 USA.	martin.mangino@vcuhealth.org	Newton, Jason/AAN-8428-2020; Brophy, Donald F./AAJ-3805-2021; Jayaraman, Sudha/AAH-3059-2019	Brophy, Donald F./0000-0003-3447-8523; Jayaraman, Sudha/0000-0003-1094-5836; Mangino, Martin/0000-0003-2440-1952; Newton, Jason/0000-0003-2952-2008	Department of Defense [W81XWH-12-1-0599, W81XWH-16-2-0040, W81XWH-17-1-0602, W81XWH-18-1-0597, W81XWH-18-1-0759]	Department of Defense(United States Department of Defense)	This work was supported by grants from the Department of Defense (https://www.arl.army.mil/www/default.cfm?page=8) to Dr. Mangino (mjm): W81XWH-12-1-0599, W81XWH-16-20040, W81XWH-17-1-0602, W81XWH-18-1-0597, and W81XWH-18-1-0759. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by grants from the Department of Defense to Dr. Mangino (W81XWH-12-1-0599, W81XWH-16-2-0040, W81XWH-17-1-0602, W81XWH-18-1-0597, and W81XWH-18-1-0759)	Bakaltcheva I, 2000, CRYOBIOLOGY, V40, P283, DOI 10.1006/cryo.2000.2247; BLANN AD, 1990, BIOLOGICALS, V18, P351, DOI 10.1016/1045-1056(90)90041-W; Bochsen Louise, 2007, Thromb J, V5, P3, DOI 10.1186/1477-9560-5-3; Duchesne JC, 2010, J TRAUMA, V69, P976, DOI 10.1097/TA.0b013e3181f2abc9; Finkelstein E., 2006, INCIDENCE EC BURDEN, DOI [10.1093/acprof:oso/9780195179484.001.0001, DOI 10.1093/ACPROF:OSO/9780195179484.001.0001]; Franklin GA, 2000, J TRAUMA, V48, P1034, DOI 10.1097/00005373-200006000-00006; Gu JM, 2014, HAEMOPHILIA, V20, P593, DOI 10.1111/hae.12374; Heckbert SR, 1998, J TRAUMA, V45, P545, DOI 10.1097/00005373-199809000-00022; Hemker HC, 2003, PATHOPHYSIOL HAEMO T, V33, P4, DOI 10.1159/000071636; Hillarp A, 2017, HAEMOPHILIA, V23, P458, DOI 10.1111/hae.13168; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Kyluik-Price DL, 2016, BIOMATERIALS, V74, P167, DOI 10.1016/j.biomaterials.2015.09.047; Liebrecht LK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207147; Mangino MJ, 2017, HEMORRHAGIC SHOCK RE; McNamee CE, 2007, BIOPHYS J, V93, P324, DOI 10.1529/biophysj.106.102251; Murphy B, 2014, BLOOD COAGUL FIBRIN, V25, P876, DOI 10.1097/MBC.0000000000000176; Nielsen VG, 2005, ACTA ANAESTH SCAND, V49, P1163, DOI 10.1111/j.1399-6576.2005.00733.x; Nielsen VG, 2004, ANESTH ANALG, V99, P120, DOI 10.1213/01.ANE.0000123012.24871.62; OSWALD MW, 1983, AM J MED TECHNOL, V49, P57; Parrish D, 2016, ANN SURG, V263, P565, DOI 10.1097/SLA.0000000000001049; Parrish D, 2015, J TRAUMA ACUTE CARE, V79, P22, DOI 10.1097/TA.0000000000000682; Plant V, 2017, J PHARMACOL EXP THER, V361, P334, DOI 10.1124/jpet.116.239822; Plant V, 2016, J TRAUMA ACUTE CARE, V81, P1056, DOI 10.1097/TA.0000000000001155; Riha GM, 2013, J TRAUMA ACUTE CARE, V75, P129, DOI 10.1097/TA.0b013e3182984a9b; Riha GM, 2011, J TRAUMA, V71, P1755, DOI 10.1097/TA.0b013e3182367b1c; Sauter A, 2013, BIOINTERPHASES, V8, DOI 10.1186/1559-4106-8-14; Scarpelini S, 2009, BRAZ J MED BIOL RES, V42, P1210, DOI 10.1590/S0100-879X2009001200015; Schmitz G, 1998, THROMB HAEMOSTASIS, V79, P885; Solomon C, 2015, ANESTH ANALG, V121, P868, DOI 10.1213/ANE.0000000000000859; Stein Deborah M, 2012, Adv Surg, V46, P237; VANLAMBALGEN AA, 1990, INT J MICROCIRC, V9, P303; Walsh Mark, 2011, J Extra Corpor Technol, V43, P162; Wee YM, 2008, CELL TRANSPLANT, V17, P1257, DOI 10.3727/096368908787236657; 1997, P NATL ACAD SCI US, V94, P8378; 2006, SHOCK, V26, P115, DOI DOI 10.1097/01.SHK.0000209564.84822.F2	35	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2019	14	5							e0215386	10.1371/journal.pone.0215386	http://dx.doi.org/10.1371/journal.pone.0215386			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW0KS	31042735	Green Published, gold, Green Submitted			2023-01-03	WOS:000466370200032
J	Brayden, DJ; Baird, AW				Brayden, David J.; Baird, Alan W.			Stomaching Drug Delivery	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SYSTEMS		[Brayden, David J.] Univ Coll Dublin, Sch Vet Med, Dublin, Ireland; Univ Coll Dublin, Conway Inst Biotechnol, Dublin, Ireland	University College Dublin; University College Dublin	Brayden, DJ (corresponding author), Univ Coll Dublin, Sch Vet Med, Dublin, Ireland.		Brayden, David J/J-3215-2019	Brayden, David J/0000-0002-8781-8344				Abramson A, 2019, SCIENCE, V363, P611, DOI 10.1126/science.aau2277; [Anonymous], 2019, RANI THERAPEUTICS CO; Banerjee A, 2017, CURR OPIN PHARMACOL, V36, P58, DOI 10.1016/j.coph.2017.08.005; Lopes CM, 2016, INT J PHARMACEUT, V510, P144, DOI 10.1016/j.ijpharm.2016.05.016; Maher S, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11010041	5	5	5	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 25	2019	380	17					1671	1673		10.1056/NEJMcibr1901766	http://dx.doi.org/10.1056/NEJMcibr1901766			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HU9FC	31018074	Green Published			2023-01-03	WOS:000465598600016
J	Steinberg, DI				Steinberg, Daniel I.			In medical inpatients at nutritional risk, individualized nutritional support reduced adverse clinical outcomes	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Steinberg, Daniel I.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Steinberg, DI (corresponding author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA.							Bally MR, 2016, JAMA INTERN MED, V176, P43, DOI 10.1001/jamainternmed.2015.6587; Gomes F, 2018, CLIN NUTR, V37, P336, DOI 10.1016/j.clnu.2017.06.025	2	1	1	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 20	2019	171	4					JC18	JC18		10.7326/ACPJ201908200-018	http://dx.doi.org/10.7326/ACPJ201908200-018			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IR7TC	31426061				2023-01-03	WOS:000481642800008
J	Ahn, SS; Lee, B; Kim, D; Jung, SM; Lee, SW; Park, MC; Park, YB; Hwang, YG; Song, JJ				Ahn, Sung Soo; Lee, Byeori; Kim, Dam; Jung, Seung Min; Lee, Sang-Won; Park, Min-Chan; Park, Yong-Beom; Hwang, Yong Gil; Song, Jason Jungsik			Evaluation of macrophage activation syndrome in hospitalised patients with Kikuchi-Fujimoto disease based on the 2016 EULAR/ACR/PRINTO classification criteria	PLOS ONE			English	Article							HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; DIAGNOSIS; ARTHRITIS; MORTALITY; HSCORE	Background To evaluate the impact of macrophage activation syndrome (MAS) on clinical features in patients with Kikuchi-Fujimoto disease (KFD) and to compare the features of MAS in KFD with those of adult-onset Still's disease (AOSD) and systemic lupus erythematosus (SLE). Methods The medical records of febrile patients hospitalised with KFD between November 2005 and April 2017 were reviewed. Patients fulfilling the 2016 classification criteria for MAS were classified as having MAS. Clinical and laboratory features of patients with KFD with and without MAS were evaluated. Poor hospitalisation outcomes were defined as intensive care unit admission or in-hospital mortality. The treatment outcomes of MAS in KFD, AOSD, and SLE were also compared. Results Among 78 patients hospitalised with KFD, 24 (30.8%) patients had MAS during admission. Patients with KFD and MAS more frequently required glucocorticoid treatment (66.7% vs 40.7%, p = 0.036) and had longer hospital stays than patients with KFD without MAS (12.5 vs 8.5 days, p<0.001). In addition, patients with MAS had worse hospitalisation outcomes than patients without MAS (29.2% vs. 0.0%, p<0.001). Among patients with MAS in KFD, AOSD, and SLE, the number of patients requiring glucocorticoid treatment after 3 months was significantly lower among patients with MAS and KFD (KFD 33.3%, AOSD 88.9%, SLE 100%, p<0.001). Conclusions The presence of MAS in KFD was associated with adverse clinical outcomes including higher steroid usage and worse hospitalisation outcomes. However, compared to those with AOSD and SLE, patients with MAS and KFD were less likely to require long-term glucocorticoid treatment.	[Ahn, Sung Soo; Kim, Dam; Jung, Seung Min; Lee, Sang-Won; Park, Min-Chan; Park, Yong-Beom; Song, Jason Jungsik] Yonsei Univ, Coll Med, Dept Internal Med, Div Rheumatol, Seoul, South Korea; [Lee, Byeori] Albert Einstein Med Ctr Philadelphia, Dept Internal Med, Philadelphia, PA USA; [Hwang, Yong Gil] Univ Pittsburgh, Dept Med, Div Rheumatol & Clin Immunol, Pittsburgh, PA USA; [Song, Jason Jungsik] Yonsei Univ, Coll Med, Inst Immunol & Immunol Dis, Seoul, South Korea	Yonsei University; Yonsei University Health System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Yonsei University; Yonsei University Health System	Song, JJ (corresponding author), Yonsei Univ, Coll Med, Dept Internal Med, Div Rheumatol, Seoul, South Korea.; Song, JJ (corresponding author), Yonsei Univ, Coll Med, Inst Immunol & Immunol Dis, Seoul, South Korea.	jsksong@yuhs.ac	Ahn, Sung Soo/AAB-4945-2021	Ahn, Sung Soo/0000-0002-9002-9880; Song, Jason/0000-0003-0662-7704; Park, Min-Chan/0000-0003-1189-7637; Jung, Seung Min/0000-0003-3465-2181; Lee, Sang-Won/0000-0002-8038-3341	Korean Health Technology R&D Project through the Korean Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI18C0919]	Korean Health Technology R&D Project through the Korean Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea	This research was supported by a grant of the Korean Health Technology R&D Project through the Korean Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (Grant number: HI18C0919).	Agmon-Levin N, 2013, LUPUS, V22, P1327, DOI 10.1177/0961203313504633; Ahn SS, 2017, SEMIN ARTHRITIS RHEU, V47, P216, DOI 10.1016/j.semarthrit.2017.02.002; Ahn SS, 2017, J RHEUMATOL, V44, P996, DOI 10.3899/jrheum.161286; Barbat B, 2017, WORLD J CLIN CASES, V5, P35, DOI 10.12998/wjcc.v5.i2.35; Batu ED, 2017, SCAND J RHEUMATOL, V46, P44, DOI 10.3109/03009742.2016.1167951; Behrens EM, 2008, AUTOIMMUN REV, V7, P305, DOI 10.1016/j.autrev.2007.11.025; Bosch X, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-18; Chmait RH, 2000, OBSTET GYNECOL, V95, P1022, DOI 10.1016/S0029-7844(00)00834-6; Colafrancesco S, 2014, IMMUNOL RES, V60, P177, DOI 10.1007/s12026-014-8563-7; Crayne CB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00119; Deaver D, 2014, CANCER CONTROL, V21, P313, DOI 10.1177/107327481402100407; Dumas G, 2014, MEDICINE, V93, P372, DOI 10.1097/MD.0000000000000220; Fardet L, 2014, ARTHRITIS RHEUMATOL, V66, P2613, DOI 10.1002/art.38690; Fiorella ML, 2017, EUR ARCH OTO-RHINO-L, V274, P1761, DOI 10.1007/s00405-016-4147-6; Fujimoto Y, 1972, NAIKA, V20, P920; Grom AA, 2016, NAT REV RHEUMATOL, V12, P259, DOI 10.1038/nrrheum.2015.179; Grom AA, 2010, CURR OPIN RHEUMATOL, V22, P561, DOI 10.1097/01.bor.0000381996.69261.71; Hall LD, 2015, J AM ACAD DERMATOL, V72, P1, DOI 10.1016/j.jaad.2014.07.034; Hayden A, 2016, BLOOD REV, V30, P411, DOI 10.1016/j.blre.2016.05.001; Hutchinson CB, 2010, ARCH PATHOL LAB MED, V134, P289, DOI 10.1043/1543-2165-134.2.289; Jordan MB, 2011, BLOOD, V118, P4041, DOI 10.1182/blood-2011-03-278127; KIKUCHI M, 1972, Acta Haematologica Japonica, V35, P379; Kim YM, 2003, J KOREAN MED SCI, V18, P592, DOI 10.3346/jkms.2003.18.4.592; Kucukardali Y, 2007, CLIN RHEUMATOL, V26, P50, DOI 10.1007/s10067-006-0230-5; Lee HY, 2010, J MICROBIOL IMMUNOL, V43, P253, DOI 10.1016/S1684-1182(10)60040-0; Lerkvaleekul B, 2018, OPEN ACCESS RHEUMATO, V10, P117, DOI 10.2147/OARRR.S151013; Lim GY, 2008, PEDIATR RADIOL, V38, P756, DOI 10.1007/s00247-008-0894-x; Marsili M, 2015, SCAND J RHEUMATOL, V44, P429, DOI 10.3109/03009742.2015.1033009; Mathew LM, 2016, INT J DERMATOL, V55, P1069, DOI 10.1111/ijd.13314; Nayak Hemanta Kumar, 2013, BMJ Case Rep, V2013, DOI 10.1136/bcr-2012-008026; Nishiwaki M, 2016, ACTA MED OKAYAMA, V70, P383; Ramirez AL, 2001, OTOLARYNG HEAD NECK, V125, P651, DOI 10.1067/mhn.2001.120431; Ravelli A, 2016, ANN RHEUM DIS, V75, P481, DOI 10.1136/annrheumdis-2015-208982; Ravelli A, 2016, ARTHRITIS RHEUMATOL, V68, P566, DOI 10.1002/art.39332; Schulert GS, 2014, BEST PRACT RES CL RH, V28, P277, DOI 10.1016/j.berh.2014.03.002; Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402; Song Y, 2019, BRIT J HAEMATOL, V186, P717, DOI 10.1111/bjh.15988	37	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2019	14	7							e0219970	10.1371/journal.pone.0219970	http://dx.doi.org/10.1371/journal.pone.0219970			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IS7PC	31318961	Green Submitted, Green Published, gold			2023-01-03	WOS:000482340700078
J	Morishima, T; Miyashiro, I; Inoue, N; Kitasaka, M; Akazawa, T; Higeno, A; Idota, A; Sato, A; Ohira, T; Sakon, M; Matsuura, N				Morishima, Toshitaka; Miyashiro, Isao; Inoue, Norimitsu; Kitasaka, Mitsuko; Akazawa, Takashi; Higeno, Akemi; Idota, Atsushi; Sato, Akira; Ohira, Tetsuya; Sakon, Masato; Matsuura, Nariaki			Effects of laughter therapy on quality of life in patients with cancer: An open-label, randomized controlled trial	PLOS ONE			English	Article							EUROPEAN-ORGANIZATION; MIRTHFUL LAUGHTER; EXERCISE PROGRAM; CLINICAL-TRIALS; HUMOR; TRANSPLANTATION; COMPLEMENTARY; SURVIVORS; DISEASE; STRESS	Background Few randomized controlled trials have assessed the effects of laughter therapy on health-related quality of life (QOL) in cancer patients. This study aimed to evaluate these effects as an exploratory endpoint in cancer patients as part of a randomized controlled trial conducted at a single institution in Japan. Methods The Initiative On Smile And CAncer (iOSACA) study was an open-label randomized controlled trial conducted in 2017 in which participants aged 40-64 years with cancer were randomly assigned to either an intervention group (laughter therapy) or control group (no laughter therapy). Each participant in the intervention group underwent a laughter therapy session once every two weeks for seven weeks (total of four sessions). Each session involved a laughter yoga routine followed by Rakugo or Manzai traditional Japanese verbal comedy performances. We assessed QOL as a secondary endpoint in this intention-to-treat population using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The questionnaire was completed at baseline (Week 0) and at Weeks 3 and 7. Mixed-effects models for repeated measures were developed to compare time-dependent changes in each QOL domain from baseline between the intervention and control groups. Results Four participants retracted consent and one participant was retrospectively excluded from analysis due to unmet inclusion criteria. The analysis was conducted using 56 participants, with 26 in the intervention group and 30 in the control group. Questionnaire completion rates were high (> 90%), with similar QOL scores reported at baseline in both groups. The mixed-effects models showed that the intervention group had significantly better cognitive function and less pain than the control group for a short period. Conclusion Laughter therapy may represent a beneficial, noninvasive complementary intervention in the clinical setting. Further studies are needed to verify the hypotheses generated from this exploratory study.	[Morishima, Toshitaka; Miyashiro, Isao; Sato, Akira] Osaka Int Canc Inst, Canc Control Ctr, Osaka, Japan; [Inoue, Norimitsu] Osaka Int Canc Inst, Res Ctr, Dept Tumor Immunol, Osaka, Japan; [Inoue, Norimitsu] Wakayama Med Univ, Dept Mol Genet, Wakayama, Japan; [Kitasaka, Mitsuko] Osaka Int Canc Inst, Dept Nursing Serv, Osaka, Japan; [Akazawa, Takashi] Osaka Int Canc Inst, Dept Canc Drug Discovery & Dev, Res Ctr, Osaka, Japan; [Higeno, Akemi; Idota, Atsushi] Osaka Int Canc Inst, Dept Clin Lab, Osaka, Japan; [Ohira, Tetsuya] Fukushima Med Univ, Dept Epidemiol, Fukushima, Japan; [Sakon, Masato; Matsuura, Nariaki] Osaka Int Canc Inst, Osaka, Japan	Wakayama Medical University; Fukushima Medical University	Morishima, T (corresponding author), Osaka Int Canc Inst, Canc Control Ctr, Osaka, Japan.	morishima.t@oici.jp	Morishima, Toshitaka/AAB-3010-2019	Morishima, Toshitaka/0000-0002-0747-3287; Akazawa, Takashi/0000-0002-4155-9228	Foundation for Promotion of Cancer Research in Japan [H29]; Japan Society for the Promotion of Science [JP16K19291]	Foundation for Promotion of Cancer Research in Japan; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	TM and TO received a Grant for Cancer Survivorship Research H29 from the Foundation for Promotion of Cancer Research in Japan (https://www.fpcr.or.jp).TM received a Grant-in-Aid for Scientific Research (JSPS KAKENHI JP16K19291) from the Japan Society for the Promotion of Science (https://www.jsps.go.jp/english/e-grants).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3; Altman DG, 2005, BRIT MED J, V330, P843, DOI 10.1136/bmj.330.7495.843; [Anonymous], 2016, PDQ CANC INF SUMM; Bennett MP, 2003, ALTERN THER HEALTH M, V9, P38; BERK LS, 1989, AM J MED SCI, V298, P390, DOI 10.1097/00000441-198912000-00006; Borod M, 2006, J CANCER EDUC, V21, P30, DOI 10.1207/s15430154jce2101_11; Bukutu C, 2008, PEDIATR REV, V29, pE44, DOI 10.1542/pir.29-8-e44; Christie Wanda, 2005, Clin J Oncol Nurs, V9, P211, DOI 10.1188/05.CJON.211-218; COUSINS N, 1976, NEW ENGL J MED, V295, P1458, DOI 10.1056/NEJM197612232952605; Dolgoff-Kaspar R, 2012, ALTERN THER HEALTH M, V18, P61; Dunbar RIM, 2012, P ROY SOC B-BIOL SCI, V279, P1161, DOI 10.1098/rspb.2011.1373; Ellis L, 2006, PHYSIOL BEHAV, V88, P303, DOI 10.1016/j.physbeh.2006.03.034; Ernst E, 2000, Lancet Oncol, V1, P176, DOI 10.1016/S1470-2045(00)00031-0; Farifteh S, 2014, IRAN J CANCER PREV, V7, P179; Fayers P, 2001, EORTC QLQ C30 SCORIN, V3th; Findley PA, 2009, J CANCER SURVIV, V3, P43, DOI 10.1007/s11764-008-0074-x; Ghodsbin Fariba, 2015, Int J Community Based Nurs Midwifery, V3, P31; GOLDSTEIN JH, 1982, SCIENCES, V22, P21, DOI 10.1002/j.2326-1951.1982.tb02088.x; Gotay CC, 1998, JNCI-J NATL CANCER I, V90, P656, DOI 10.1093/jnci/90.9.656; Grob JJ, 2014, ANN ONCOL, V25, P1428, DOI 10.1093/annonc/mdu154; Hirosaki M, 2013, GERIATR GERONTOL INT, V13, P152, DOI 10.1111/j.1447-0594.2012.00877.x; Jansen L, 2010, EUR J CANCER, V46, P2879, DOI 10.1016/j.ejca.2010.06.010; Kim SH, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/864739; Kim SH, 2015, J ALTERN COMPLEM MED, V21, P217, DOI 10.1089/acm.2014.0152; Kobayashi K, 1998, EUR J CANCER, V34, P810, DOI 10.1016/S0959-8049(97)00395-X; Kong M, 2014, ONCOTARGETS THER, V7, P2053, DOI 10.2147/OTT.S72973; Lengacher Cecile A, 2002, Oncol Nurs Forum, V29, P1445, DOI 10.1188/02.ONF.1445-1452; Linge-Dahl LM, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00890; Lipscomb J, 2007, CA-CANCER J CLIN, V57, P278, DOI 10.3322/CA.57.5.278; Loge JH, 2000, J PAIN SYMPTOM MANAG, V19, P91, DOI 10.1016/S0885-3924(99)00148-7; McPhail S, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-65; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Penson RT, 2005, ONCOLOGIST, V10, P651, DOI 10.1634/theoncologist.10-8-651; Peppercorn JM, 2011, J CLIN ONCOL, V29, P755, DOI 10.1200/JCO.2010.33.1744; Phipps S, 2012, PEDIATRICS, V129, pE762, DOI 10.1542/peds.2011-1816; Phipps S, 2010, CANCER-AM CANCER SOC, V116, P3924, DOI 10.1002/cncr.25415; Reijneveld JC, 2016, LANCET ONCOL, V17, P1533, DOI 10.1016/S1470-2045(16)30305-9; Scott NW, 2002, CONTROL CLIN TRIALS, V23, P662, DOI 10.1016/S0197-2456(02)00242-8; Senn S, 2002, CROSS OVER TRIALS CL; Shahidi M, 2011, INT J GERIATR PSYCH, V26, P322, DOI 10.1002/gps.2545; Stark D, 2002, J CLIN ONCOL, V20, P3137, DOI 10.1200/JCO.2002.08.549; Takeda M, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-28; Tannock IF, 2004, J CLIN ONCOL, V22, P2233, DOI 10.1200/JCO.2004.08.094; Walter M, 2007, INT J GERIATR PSYCH, V22, P77, DOI 10.1002/gps.1658; WEISENBERG M, 1995, PAIN, V63, P207, DOI 10.1016/0304-3959(95)00046-U; Weisenberg M, 1998, PAIN, V76, P365, DOI 10.1016/S0304-3959(98)00069-4; Yoshino S, 1996, J RHEUMATOL, V23, P793; Zweyer K, 2004, HUMOR, V17, P85, DOI 10.1515/humr.2004.009	49	13	13	2	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2019	14	6							e0219065	10.1371/journal.pone.0219065	http://dx.doi.org/10.1371/journal.pone.0219065			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW3WH	31247017	Green Published, gold			2023-01-03	WOS:000484911900072
J	Erdogan, O; Abbak, M; Demirbolat, GM; Birtekocak, F; Aksel, M; Pasa, S; Cevik, O				Erdogan, Omer; Abbak, Muruvvet; Demirbolat, Gulen Melike; Birtekocak, Fatih; Aksel, Mehran; Pasa, Salih; Cevik, Ozge			Green synthesis of silver nanoparticles via Cynara scolymus leaf extracts: The characterization, anticancer potential with photodynamic therapy in MCF7 cells	PLOS ONE			English	Article							SKIN-CANCER; ARTICHOKE; ANTIOXIDANT; METAL	In this study, we report on the synthesis of silver nanoparticles (AgNPs) from the leaf extracts of Cynara scolymus (Artichoke) using microwave irradiation and the evaluation of its anti-cancer potential with photodynamic therapy (PDT). Silver nanoparticles formation was characterized by scanning electron microscopy with energy dispersive x-ray spectroscopy and Fourier transform infrared (FTIR) spectroscopy. Silver nanoparticles formation was also investigated the surface charge, particle size and distribution using zetasizer analysis. The cytotoxic effect of AgNPs and/or PDT was studied by MTT assay and migration by the scratch assay. The apoptotic inducing ability of the AgNPs and/or PDT was investigated by intracellular ROS analysis, antioxidant enzyme levels (SOD, CAT, GPx and GSH), Hoechst staining and Bax/Bcl-2 analysis using western blotting. The mean particle size of produced AgNPs was found 98.47 +/- 2.04 nm with low polydispersity (0.301 +/- 0.033). Zeta potential values of AgNPs show -32.3 +/- 0.8 mV. These results clearly indicate the successful formation of AgNPs for cellular uptake. Mitochondrial damage and intracellular ROS production were observed upon treatment with AgNPs (10 mu g/mL) and PDT (0.5 mJ/cm(2)) showed significant reducing cell migration, expression of Bax and suppression of Bcl-2. Significantly, biosynthesized AgNPs showed a broad-spectrum anti-cancer activity with PDT therapy and therefore represent promoting ROS generation by modulating mitochondrial apoptosis induction in MCF7 breast cancer cells.	[Erdogan, Omer; Birtekocak, Fatih; Cevik, Ozge] Adnan Menderes Univ, Sch Med, Dept Biochem, Aydin, Turkey; [Abbak, Muruvvet; Cevik, Ozge] Adnan Menderes Univ, Sci Technol Res & Applicat Ctr, Aydin, Turkey; [Demirbolat, Gulen Melike] Sivas Cumhuriyet Univ, Dept Pharmaceut Technol, Fac Pharm, Sivas, Turkey; [Aksel, Mehran] Aydin Adnan Univ, Sch Med, Dept Biophys, Aydin, Turkey; [Pasa, Salih] Afyon Kocatepe Univ, Dept Sci, Fac Educ, Afyon, Turkey	Adnan Menderes University; Adnan Menderes University; Cumhuriyet University; Afyon Kocatepe University	Cevik, O (corresponding author), Adnan Menderes Univ, Sch Med, Dept Biochem, Aydin, Turkey.; Cevik, O (corresponding author), Adnan Menderes Univ, Sci Technol Res & Applicat Ctr, Aydin, Turkey.	ozge.cevik@adu.edu.tr	Paşa, Salih/AAC-9404-2019; Erdogan, Omer/AAW-5497-2021; Cevik, Ozge/F-1326-2014	Paşa, Salih/0000-0002-4792-8821; Cevik, Ozge/0000-0002-9325-3757; DEMIRBOLAT, Gulen Melike/0000-0001-5621-5818; erdogan, omer/0000-0002-8327-7077; Aksel, Mehran/0000-0002-9510-8553; AKSEL, Mehran/0000-0002-3942-2257	Adnan Menderes University [ADU-MARL-18001, TPF-18012]; Scientific and Technological Research Council of Turkey (TUBITAK) [214Z057]	Adnan Menderes University(Adnan Menderes University); Scientific and Technological Research Council of Turkey (TUBITAK)(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK))	This work was supported by Adnan Menderes University Research Grant (ADU-MARL-18001, TPF-18012 to OC) and by a partly grant (214Z057 to OC) from the Scientific and Technological Research Council of Turkey (TUBITAK). The analysis conducted by the Adnan Menderes University Science and Technology Research Center (ADU-BILTEM) is gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abel F, 2005, EUR J CANCER, V41, P635, DOI 10.1016/j.ejca.2004.12.021; Agarwal Happy, 2017, Resource-Efficient Technologies, V3, P406, DOI 10.1016/j.reffit.2017.03.002; Agarwal H, 2019, BIOMED PHARMACOTHER, V109, P2561, DOI 10.1016/j.biopha.2018.11.116; Ahmed S, 2016, J ADV RES, V7, P17, DOI 10.1016/j.jare.2015.02.007; Antonenko YN, 2014, BBA-BIOMEMBRANES, V1838, P793, DOI 10.1016/j.bbamem.2013.11.012; Balasubramanian S, 2019, INT J NANOSCI, V18, DOI 10.1142/S0219581X18500114; Bendale Y, 2017, INTEGR MED RES, V6, P141, DOI [10.1016/j.imr.2017.01.006, 10.1016/j.imr.2017.01.006|]; Benov L, 2015, MED PRIN PRACT, V24, P14, DOI 10.1159/000362416; Bharathiraja S, 2016, NANOMATERIALS-BASEL, V6, DOI 10.3390/nano6040078; Braathen LR, 2007, J AM ACAD DERMATOL, V56, P125, DOI 10.1016/j.jaad.2006.06.006; Cao HQ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181018; Cevik O, 2017, J BIOL CHEM, V292, P21676, DOI [10.1074/jbc.M117.792721, 10.1074/jbc.m117.792721]; Chen J, 2015, J HAZARD MATER, V297, P173, DOI 10.1016/j.jhazmat.2015.04.077; Coruh I, 2018, ARCH PHARM, V351, DOI 10.1002/ardp.201700195; Demirbolat GM, 2018, J PHARM SCI-US, V107, P1398, DOI 10.1016/j.xphs.2018.01.006; dos Santos KC, 2012, NANOTECHNOL SCI APPL, V5, P37, DOI 10.2147/NSA.S32837; El-Hussein A, 2017, IET NANOBIOTECHNOL, V11, P173, DOI 10.1049/iet-nbt.2015.0083; Ferrin G, 2011, CURR PHARM DESIGN, V17, P2002, DOI 10.2174/138161211796904803; George BPA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32480-5; Huang Z, 2005, TECHNOL CANCER RES T, V4, P283, DOI 10.1177/153303460500400308; Jesus VPS, 2018, PHOTODIAGN PHOTODYN, V23, P212, DOI 10.1016/j.pdpdt.2018.06.011; Khan ST, 2016, COLLOID SURFACE B, V146, P70, DOI 10.1016/j.colsurfb.2016.05.046; Latha M, 2015, MICROB PATHOGENESIS, V82, P43, DOI 10.1016/j.micpath.2015.03.008; Li SK, 2007, GREEN CHEM, V9, P852, DOI 10.1039/b615357g; Logeswari P, 2013, SCI IRAN, V20, P1049, DOI 10.1016/j.scient.2013.05.016; Lombardo S, 2017, FOOD RES INT, V100, P95, DOI 10.1016/j.foodres.2017.08.028; Lopes CRB, 2018, J LUMIN, V199, P183, DOI 10.1016/j.jlumin.2018.03.030; Lucky SS, 2015, CHEM REV, V115, P1990, DOI 10.1021/cr5004198; Machado I., 2015, AM J FOOD SCI TECHNO, V3, P55, DOI DOI 10.12691/AJFST-3-3-1; Machado I, 2016, MICROCHEM J, V128, P128, DOI 10.1016/j.microc.2016.04.016; Mariselvam R, 2014, SPECTROCHIM ACTA A, V129, P537, DOI 10.1016/j.saa.2014.03.066; Mfouo-Tynga I, 2014, INT J NANOMED, V9, P3771, DOI 10.2147/IJN.S63371; Nassar MI, 2013, J SCI FOOD AGR, V93, P2494, DOI 10.1002/jsfa.6065; Oves M, 2018, MAT SCI ENG C-MATER, V89, P429, DOI 10.1016/j.msec.2018.03.035; Patil MJ, 2016, IEEE C ELECTR PERFOR, P79, DOI 10.1109/EPEPS.2016.7835422; Patil MP, 2018, MICROB PATHOGENESIS, V121, P184, DOI 10.1016/j.micpath.2018.05.040; Pereira C, 2013, IND CROP PROD, V49, P61, DOI 10.1016/j.indcrop.2013.04.032; Prabhu S, 2012, INT NANO LETT, V2, DOI 10.1186/2228-5326-2-32; Price M, 2009, PHOTOCHEM PHOTOBIOL, V85, P1177, DOI 10.1111/j.1751-1097.2009.00555.x; Pugazhendhi A, 2018, MICROB PATHOGENESIS, V114, P41, DOI 10.1016/j.micpath.2017.11.013; Pugazhendhi A, 2018, INT J PHARMACEUT, V539, P104, DOI 10.1016/j.ijpharm.2018.01.034; Rafique M, 2017, ARTIF CELL NANOMED B, V45, P1272, DOI 10.1080/21691401.2016.1241792; Saber MM, 2018, J DRUG DELIV SCI TEC, V47, P375, DOI 10.1016/j.jddst.2018.08.004; Saha J, 2017, SUSTAIN ENVIRON RES, V27, P245, DOI 10.1016/j.serj.2017.04.003; Saratale RG, 2018, COLLOID SURFACE B, V170, P20, DOI 10.1016/j.colsurfb.2018.05.045; Seelinger G, 2008, PLANTA MED, V74, P1667, DOI 10.1055/s-0028-1088314; Senthil B, 2017, J PHOTOCH PHOTOBIO B, V177, P1, DOI 10.1016/j.jphotobiol.2017.10.010; Shanmuganathan R, 2018, ENVIRON SCI POLLUT R, V25, P10362, DOI 10.1007/s11356-017-9367-9; Silva CO, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11010022; Dzul-Erosa MS, 2018, MAT SCI ENG C-MATER, V91, P838, DOI 10.1016/j.msec.2018.06.007; Sumitha S, 2019, PHARMACOGN MAG, V15, P52, DOI 10.4103/pm.pm_400_18; Tang XC, 2017, NUTRIENTS, V9, DOI 10.3390/nu9091000; Vijayan R, 2019, BIOPROC BIOSYST ENG, V42, P305, DOI 10.1007/s00449-018-2035-8; Wittemer SM, 2005, PHYTOMEDICINE, V12, P28, DOI 10.1016/j.phymed.2003.11.002; Yi G, 2018, QUANT IMAG MED SURG, V8, P433, DOI 10.21037/qims.2018.05.04; Zomorodian K, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/5435397	56	115	118	15	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2019	14	6							e0216496	10.1371/journal.pone.0216496	http://dx.doi.org/10.1371/journal.pone.0216496			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW3PH	31220110	Green Published, Green Submitted, gold			2023-01-03	WOS:000484893500007
J	Rourke, E				Rourke, Elizabeth			Blood Relations	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								The elderly woman has demand-related ischemia and needs a transfusion, but she's a Jehovah's Witness. Soon, her hospital room becomes the site of a fraught battle between her family members and representatives of her church, and it's up to the intern to intervene.	[Rourke, Elizabeth] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Rourke, Elizabeth] Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Rourke, E (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.; Rourke, E (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.								0	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 13	2019	380	24					2292	2293		10.1056/NEJMp1901351	http://dx.doi.org/10.1056/NEJMp1901351			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IC9JQ	31189034				2023-01-03	WOS:000471299100007
J	Promraksa, B; Phetcharaburanin, J; Namwat, N; Techasen, A; Boonsiri, P; Loilome, W				Promraksa, Bundit; Phetcharaburanin, Jutarop; Namwat, Nisana; Techasen, Anchalee; Boonsiri, Patcharee; Loilome, Watcharin			Evaluation of anticancer potential of Thai medicinal herb extracts against cholangiocarcinoma cell lines	PLOS ONE			English	Article							TOTAL PHENOLIC CONTENT; IN-VITRO EVALUATION; DRUG-RESISTANCE; ANTIOXIDANT ACTIVITY; CANCER-CELLS; DNA-DAMAGE; CYTOTOXICITY; METABOLOMICS; MECHANISMS; PREVENTION	Although cholangiocarcinoma ( CCA) has a low incidence globally, this is extremely high in Northeast Thailand. The lack of both early detection measures and effective therapeutic drugs is the major problem for the poor prognosis of CCA patients. Based on regional knowledge, it would be advantageous to search for effective natural phyto-products for the treatment of CCA. Cardiospermum halicacabum L., Gomphrena celosioides Mart. and Scoparia dulcis L., very well-known medicinal herbs in Asian countries, were selected for the investigation of inhibitory effects on CCA cells. Of the three different ethanolic extracts, S. dulcis L extract showed most inhibitory effects on cell growth of CCA cell lines KKU-100 and KKU-213, at percentages of 56.06 and 74.76, respectively, compared to the untreated group after treatment with 250 mu g/mL of extracts for 72 hrs. At 400 and 500 mu g/mL of the extracts, the inhibitory effect of KKU-213 was indicated by a significant increase in the BAX/Bcl-2 ratio and cell membrane permeability. Moreover, metabolic profiling-based screening employed in the current study revealed a significant positive association between the lignin compound and a decrease in CCA cell viability. Our study suggests, for the first time, that ESD has the ability to inhibit CCA cell growth through the induction of apoptosis.	[Promraksa, Bundit; Phetcharaburanin, Jutarop; Namwat, Nisana; Boonsiri, Patcharee; Loilome, Watcharin] Khon Kaen Univ, Dept Biochem, Fac Med, Khon Kaen, Thailand; [Promraksa, Bundit; Phetcharaburanin, Jutarop; Namwat, Nisana; Techasen, Anchalee; Loilome, Watcharin] Khon Kaen Univ, Cholangiocarcinoma Res Inst, Fac Med, Khon Kaen, Thailand; [Phetcharaburanin, Jutarop] Mahidol Univ, Ctr Excellence Innovat Chem, Bangkok, Thailand; [Techasen, Anchalee] Khon Kaen Univ, Fac Associated Med Sci, Khon Kaen, Thailand	Khon Kaen University; Khon Kaen University; Mahidol University; Khon Kaen University	Loilome, W (corresponding author), Khon Kaen Univ, Dept Biochem, Fac Med, Khon Kaen, Thailand.; Loilome, W (corresponding author), Khon Kaen Univ, Cholangiocarcinoma Res Inst, Fac Med, Khon Kaen, Thailand.	watloi@yahoo.com	Loilome, Watcharin/AAW-6203-2021; Promraksa, Bundit/AAI-5552-2021	Phetcharaburanin, Jutarop/0000-0003-4727-8395	Khon Kaen University (KKU) [592JH216]; Thailand Research Fund [RSA5980013]; Khon Kaen University through the Cholangiocarcinoma Screening Care Program (CASCAP) [CASCAP-09]; Khon Kaen University in Thailand	Khon Kaen University (KKU); Thailand Research Fund(Thailand Research Fund (TRF)); Khon Kaen University through the Cholangiocarcinoma Screening Care Program (CASCAP); Khon Kaen University in Thailand	This work was supported by the research fund for supporting lecturers to admit high potential students to study and research on the expert program, Khon Kaen University (KKU) (grant number 592JH216); the Thailand Research Fund (Grant No. RSA5980013); a grant from Khon Kaen University through the Cholangiocarcinoma Screening Care Program (CASCAP, Grant No. CASCAP-09); and a grant from Khon Kaen University in Thailand to WL.	Aishwarya V, 2014, INT J PHARM PHARM SC, V6, P263; Al-Sharif I, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-600; Anderson CD, 2004, ONCOLOGIST, V9, P43, DOI 10.1634/theoncologist.9-1-43; Ando H, 2004, TOXICOL IN VITRO, V18, P765, DOI 10.1016/j.tiv.2004.03.011; Barapatre A, 2016, INT J BIOL MACROMOL, V86, P443, DOI 10.1016/j.ijbiomac.2016.01.109; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Boeing H, 2012, EUR J NUTR, V51, P637, DOI 10.1007/s00394-012-0380-y; Butthongkomvong K, 2013, ASIAN PAC J CANCER P, V14, P3565, DOI 10.7314/APJCP.2013.14.6.3565; Bylesjo M, 2006, J CHEMOMETR, V20, P341, DOI 10.1002/cem.1006; Catalan U, 2017, GENOM PROTEOM BIOINF, V15, P236, DOI 10.1016/j.gpb.2016.12.007; Chassagne F, 2018, FITOTERAPIA, V127, P226, DOI 10.1016/j.fitote.2018.02.021; Cloarec O, 2005, ANAL CHEM, V77, P1282, DOI 10.1021/ac048630x; Vasconcelos PCD, 2017, J ETHNOPHARMACOL, V202, P85, DOI 10.1016/j.jep.2017.03.007; Do QD, 2014, J FOOD DRUG ANAL, V22, P296, DOI 10.1016/j.jfda.2013.11.001; Dudonne S, 2009, J AGR FOOD CHEM, V57, P1768, DOI 10.1021/jf803011r; Figueiredo P, 2017, BIOMATERIALS, V121, P97, DOI 10.1016/j.biomaterials.2016.12.034; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Graziani V, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23704-9; Gupta SC, 2012, ANTIOXID REDOX SIGN, V16, P1295, DOI 10.1089/ars.2011.4414; HASWELLELKINS MR, 1991, CLIN EXP IMMUNOL, V84, P213, DOI 10.1111/j.1365-2249.1991.tb08151.x; HAYASHI T, 1988, CHEM PHARM BULL, V36, P4849; Hientz K, 2017, ONCOTARGET, V8, P8921, DOI 10.18632/oncotarget.13475; Huang DJ, 2005, J AGR FOOD CHEM, V53, P1841, DOI 10.1021/jf030723c; Jaganathan SK, 2012, MOLECULES, V17, P6290, DOI 10.3390/molecules17066290; Jeong WS, 2006, ANTIOXID REDOX SIGN, V8, P99, DOI 10.1089/ars.2006.8.99; Johnson SR, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00022; Kankanamalage TNM, 2014, J ETHNOPHARMACOL, V155, P679, DOI 10.1016/j.jep.2014.06.016; Kerbel RS, 2001, CANCER METAST REV, V20, P1, DOI 10.1023/A:1013129128673; Khuntikeo N, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1475-7; Kim HK, 2010, PLANTA MED, V76, P1094, DOI 10.1055/s-0030-1249898; Liang WQ, 2017, ONCOTARGET, V8, P109094, DOI 10.18632/oncotarget.22618; Lundquist K., 1992, SPRINGER SERIES WOOD; Luo J, 2010, INT J BIOL SCI, V6, P784; Mahmood N, 2018, ONCOTARGET, V9, P5169, DOI 10.18632/oncotarget.23704; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Nakabayashi R, 2013, ANAL BIOANAL CHEM, V405, P5005, DOI 10.1007/s00216-013-6869-2; Nicholson JK, 1999, XENOBIOTICA, V29, P1181, DOI 10.1080/004982599238047; NISHINO H, 1993, ONCOLOGY, V50, P100; Njiojob CN, 2016, CHEM-EUR J, V22, P12506, DOI 10.1002/chem.201601592; Pinlaor S, 2005, WORLD J GASTROENTERO, V11, P4644, DOI 10.3748/wjg.v11.i30.4644; Poomphakwaen K, 2009, ASIAN PAC J CANCER P, V10, P251; Promraksa Bundit, 2015, Asian Pac J Cancer Prev, V16, P7155; Qader SW, 2011, MOLECULES, V16, P3433, DOI 10.3390/molecules16043433; Ralph John, 2004, Phytochemistry Reviews, V3, P29, DOI 10.1023/B:PHYT.0000047809.65444.a4; Ratnasooriya WD, 2005, FITOTERAPIA, V76, P220, DOI 10.1016/j.fitote.2004.06.012; Selma MV, 2009, J AGR FOOD CHEM, V57, P6485, DOI 10.1021/jf902107d; Semenas J, 2012, CURR DRUG TARGETS, V13, P1308, DOI 10.2174/138945012802429615; Singh K, 2018, SAUDI PHARM J, V26, P177, DOI 10.1016/j.jsps.2017.12.013; Tangkawattana S, 2008, ASIAN PAC J CANCER P, V9, P101; Verpoorte R., 2008, Phytochemistry Reviews, V7, P525, DOI 10.1007/s11101-008-9091-7; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Vogt T, 2010, MOL PLANT, V3, P2, DOI 10.1093/mp/ssp106; WOLD S, 1987, CHEMOMETR INTELL LAB, V2, P37, DOI 10.1016/0169-7439(87)80084-9; Worley B, 2016, CURR METABOL, V4, P97, DOI 10.2174/2213235X04666160613122429; Yongvanit P, 2012, PARASITOL INT, V61, P130, DOI 10.1016/j.parint.2011.06.011; Zhang YY, 2018, CELL RES, V28, P9, DOI 10.1038/cr.2017.133	56	17	17	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2019	14	5							e0216721	10.1371/journal.pone.0216721	http://dx.doi.org/10.1371/journal.pone.0216721			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ3VE	31120926	Green Published, gold, Green Submitted			2023-01-03	WOS:000468775700025
J	Cooper, DJ; Nichol, AD; McArthur, C				Cooper, D. James; Nichol, Alistair D.; McArthur, Colin			Prophylactic Hypothermia for Severe Traumatic Brain Injury	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Cooper, D. James; Nichol, Alistair D.; McArthur, Colin] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia	Monash University	Cooper, DJ (corresponding author), Monash Univ, ANZIC Res Ctr, 553 St Kilda Rd,Level 3, Melbourne, Vic 3004, Australia.	jamie.cooper@monash.edu	Cooper, D. James/G-7961-2013	Cooper, D. James/0000-0002-5872-9051; Nichol, Alistair/0000-0002-4689-1238				Cooper DJ, 2018, JAMA-J AM MED ASSOC, V320, P2211, DOI 10.1001/jama.2018.17075; Docherty A, 2018, JAMA-J AM MED ASSOC, V320, P2204, DOI 10.1001/jama.2018.17121; 2017, NEUROSURGERY, V80, P6, DOI DOI 10.1227/NEU.0000000000001432	3	1	1	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	2019	321	17					1726	1726		10.1001/jama.2019.1538	http://dx.doi.org/10.1001/jama.2019.1538			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX3TE	31063568				2023-01-03	WOS:000467314800026
J	Burgueno, JF; Lang, JK; Santander, AM; Fernandez, I; Fernandez, E; Zaias, J; Abreu, MT				Burgueno, Juan F.; Lang, Jessica K.; Santander, Ana M.; Fernandez, Irina; Fernandez, Ester; Zaias, Julia; Abreu, Maria T.			Fluid supplementation accelerates epithelial repair during chemical colitis	PLOS ONE			English	Article							DEXTRAN SULFATE SODIUM; INTESTINAL INFLAMMATION; GROWTH-FACTORS; MOUSE MODELS; CELL GROWTH; VAGUS NERVE; IN-VITRO; ACTIVATION; EXPRESSION; MUCOSAL	The dextran sulfate sodium (DSS) model of colitis is a common animal model of inflammatory bowel disease that causes pain and distress. In this study, we aimed to determine whether fluid supplementation can be used as a welfare-based intervention to minimize animal suffering. C57Bl/6 females undergoing acute colitis by administration of 3% DSS in drinking water were supplemented with 1 mL intraperitoneal injections of NaCl and compared to non-supplemented control mice. Mouse behavior and locomotive activity were assessed on days 5-6 after DSS initiation by means of tail suspension, novel object recognition and open field activity tests. Mice were euthanized after either the acute (day 7) or the recovery phase (day 12) of colitis and inflammation, epithelial proliferation, and differentiation were assessed by means of histology, immunohistochemistry, quantitative PCR, and western blot. We found that fluid-supplemented mice had reduced signs of colitis with no alterations in behavior or locomotive activity. Furthermore, we observed an accelerated epithelial repair response after fluid hydration during the acute phase of colitis, characterized by increased crypt proliferation, activation of ERK1/2, and modulation of TGF-beta 1 expression. Consistent with these findings, fluid-supplemented mice had increased numbers of goblet cells, upregulated expression of differentiation markers for absorptive enterocytes, and reduced inflammation during the recovery phase. Our results show that fluid hydration does not reduce stress in DSS-treated mice but alters colitis evolution by reducing clinical signs and accelerating epithelial repair. These results argue against the routine use of fluid supplementation in DSS-treated mice.	[Burgueno, Juan F.; Lang, Jessica K.; Santander, Ana M.; Fernandez, Irina; Abreu, Maria T.] Univ Miami, Leonard Miller Sch Med, Dept Med, Div Gastroenterol, Miami, FL 33136 USA; [Lang, Jessica K.] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA USA; [Fernandez, Ester] Univ Autonoma Barcelona, Dept Cell Biol Physiol & Immunol, Anim Physiol Unit, Barcelona, Spain; [Zaias, Julia] Univ Miami, Miller Sch Med, Div Vet Resources, Miami, FL 33136 USA; [Zaias, Julia] Univ Miami, Leonard Miller Sch Med, Dept Pathol & Lab Med, Miami, FL USA	University of Miami; Harvard University; Harvard T.H. Chan School of Public Health; Autonomous University of Barcelona; University of Miami; University of Miami	Burgueno, JF (corresponding author), Univ Miami, Leonard Miller Sch Med, Dept Med, Div Gastroenterol, Miami, FL 33136 USA.	J.Burgueno@med.miami.edu	Burgueno, Juan/AEW-2833-2022	Burgueno, Juan/0000-0002-7641-5136; Abreu, Maria T./0000-0002-7294-0574	National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases [R01DK099076]; National Institute of Allergy and Infectious Diseases [R21AI24058]; Micky & Madeleine Arison Family Foundation Crohn's & Colitis Discovery Laboratory; Martin Kalser Chair; American Association for Laboratory Animal Science (AALAS); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK099076] Funding Source: NIH RePORTER	National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Micky & Madeleine Arison Family Foundation Crohn's & Colitis Discovery Laboratory; Martin Kalser Chair; American Association for Laboratory Animal Science (AALAS); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from the National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases (R01DK099076 to MTA), the National Institute of Allergy and Infectious Diseases (R21AI24058 to MTA), the Micky & Madeleine Arison Family Foundation Crohn's & Colitis Discovery Laboratory, and Martin Kalser Chair. Additional funding was provided by Grants for Laboratory Animal Science (GLAS) from the American Association for Laboratory Animal Science (AALAS) to JKL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALTSCHULER SM, 1993, GASTROENTEROLOGY, V104, P502, DOI 10.1016/0016-5085(93)90419-D; Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; Bamias G, 2007, J IMMUNOL, V178, P1809, DOI 10.4049/jimmunol.178.3.1809; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; Beck PL, 2003, AM J PATHOL, V162, P597, DOI 10.1016/S0002-9440(10)63853-9; Bekkevold CM, 2013, J AM ASSOC LAB ANIM, V52, P233; Burkholder Tanya, 2012, Curr Protoc Mouse Biol, V2, P145; CAN A, 2012, JOVE J VIS EXP JAN, DOI DOI 10.3791/3769; Cattin AL, 2009, MOL CELL BIOL, V29, P6294, DOI 10.1128/MCB.00939-09; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COOPER HS, 1993, LAB INVEST, V69, P238; Dahlhamer JM, 2016, MMWR-MORBID MORTAL W, V65, P1166, DOI 10.15585/mmwr.mm6542a3; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; de Villiers WJS, 2000, CYTOKINE, V12, P1337, DOI 10.1006/cyto.2000.0716; Dieckgraefe BK, 1997, BIOCHEM BIOPH RES CO, V233, P389, DOI 10.1006/bbrc.1997.6469; Diehl KH, 2001, J APPL TOXICOL, V21, P15, DOI 10.1002/jat.727; DIGNASS AU, 1994, GASTROENTEROLOGY, V106, P1254, DOI 10.1016/0016-5085(94)90017-5; Dube PE, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27353-w; Emge JR, 2016, AM J PHYSIOL-GASTR L, V310, pG989, DOI 10.1152/ajpgi.00086.2016; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Erben U, 2014, INT J CLIN EXP PATHO, V7, P4557; Fukata M, 2006, GASTROENTEROLOGY, V131, P862, DOI 10.1053/j.gastro.2006.06.017; Fukata M, 2011, INFLAMM BOWEL DIS, V17, P1464, DOI 10.1002/ibd.21527; Goke M, 1998, GASTROENTEROLOGY, V114, P697, DOI 10.1016/S0016-5085(98)70583-9; Gupta J, 2014, BIOPROTOCOL, V4, pe1289, DOI DOI 10.21769/BI0PR0T0C.1289; Hashimoto T, 2012, NATURE, V487, P477, DOI 10.1038/nature11228; Hsu D, 2010, LAB INVEST, V90, P1295, DOI 10.1038/labinvest.2010.100; Iizuka M, 2011, WORLD J GASTROENTERO, V17, P2161, DOI 10.3748/wjg.v17.i17.2161; Jain P, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00177; Jain U, 2018, CELL HOST MICROBE, V24, P353, DOI 10.1016/j.chom.2018.07.019; Johansson MEV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012238; Kishida K, 2017, AM J PHYSIOL-GASTR L, V312, pG592, DOI 10.1152/ajpgi.00416.2016; Kitajima S, 2000, EXP ANIM TOKYO, V49, P9, DOI 10.1538/expanim.49.9; Ko WK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180673; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Li WL, 2009, CELL STEM CELL, V4, P16, DOI 10.1016/j.stem.2008.11.014; Lindemans CA, 2015, NATURE, V528, P560, DOI 10.1038/nature16460; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Matsubayashi Y, 2004, CURR BIOL, V14, P731, DOI 10.1016/j.cub.2004.03.060; Melgar S, 2005, AM J PHYSIOL-GASTR L, V288, pG1328, DOI 10.1152/ajpgi.00467.2004; Miyoshi H, 2012, SCIENCE, V338, P108, DOI 10.1126/science.1223821; Molodecky NA, 2012, GASTROENTEROLOGY, V142, P46, DOI 10.1053/j.gastro.2011.10.001; Nava P, 2010, IMMUNITY, V32, P392, DOI 10.1016/j.immuni.2010.03.001; Neufert C, 2013, J CLIN INVEST, V123, P1428, DOI 10.1172/JCI63748; Nyuyki KD, 2018, FRONT BEHAV NEUROSCI, V12, DOI 10.3389/fnbeh.2018.00058; Ordonez-Moran P, 2015, CANCER CELL, V28, P815, DOI 10.1016/j.ccell.2015.11.001; Pavlov VA, 2012, NAT REV ENDOCRINOL, V8, P743, DOI 10.1038/nrendo.2012.189; Pizarro TT, 2003, TRENDS MOL MED, V9, P218, DOI 10.1016/S1471-4914(03)00052-2; Sato T, 2013, SCIENCE, V340, P1190, DOI 10.1126/science.1234852; Sellon RK, 1998, INFECT IMMUN, V66, P5224, DOI 10.1128/IAI.66.11.5224-5231.1998; Seno H, 2009, P NATL ACAD SCI USA, V106, P256, DOI 10.1073/pnas.0803343106; Shimizu S, 2004, LAB MOUSE, P527, DOI DOI 10.1016/B978-012336425-8/50085-6; Song XY, 2015, IMMUNITY, V43, P488, DOI 10.1016/j.immuni.2015.06.024; Sturm A, 2008, WORLD J GASTROENTERO, V14, P348, DOI 10.3748/wjg.14.348; Tahiri H, 2016, SCI REP-UK, V6, DOI 10.1038/srep37391; Than BLN, 2014, ONCOGENE, V33, P3861, DOI 10.1038/onc.2013.350; Tillinger W, 2008, AM J PHYSIOL-REG I, V295, pR1839, DOI 10.1152/ajpregu.00412.2007; Verma-Gandhu M, 2007, GUT, V56, P358, DOI 10.1136/gut.2006.100016; Viennois Emilie, 2013, BMC Res Notes, V6, P360, DOI 10.1186/1756-0500-6-360; Wirtz S, 2007, ADV DRUG DELIVER REV, V59, P1073, DOI 10.1016/j.addr.2007.07.003; Yan YT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006073; Yarur AJ, 2017, INFLAMM BOWEL DIS, V23, P158, DOI 10.1097/MIB.0000000000000991; Zaias J, 2009, J AM ASSOC LAB ANIM, V48, P387	63	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2019	14	4							e0215387	10.1371/journal.pone.0215387	http://dx.doi.org/10.1371/journal.pone.0215387			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU1GG	31002683	Green Submitted, gold, Green Published			2023-01-03	WOS:000465019900020
J	Khazaee, R; McCaig, LA; Yamashita, C; Hardy, DB; Veldhuizen, RAW				Khazaee, Reza; McCaig, Lynda A.; Yamashita, Cory; Hardy, Daniel B.; Veldhuizen, Ruud A. W.			Maternal protein restriction during perinatal life affects lung mechanics and the surfactant system during early postnatal life in female rats	PLOS ONE			English	Article							INTRAUTERINE GROWTH RESTRICTION; PULMONARY SURFACTANT; ALVEOLAR SURFACTANT; ANIMAL-MODELS; FETAL LUNG; CONSEQUENCES; VENTILATION; EXPRESSION; MATURATION; PREGNANCY	Limited information is available on how fetal growth retardation (FGR) affects the lung in the neonatal period in males and females. This led us to test the hypothesis that FGR alters lung mechanics and the surfactant system during the neonatal period. To test this hypothesis a model of FGR was utilized in which pregnant rat dams were fed a low protein diet during both the gestation and lactation period. We subsequently analyzed lung mechanics using a FlexiVent ventilator in male and female pups at postnatal day 7 and 21. Lung lavage material was obtained at postnatal day 1, 7 and 21, and was used for analysis of the surfactant system which included measurement of the pool size of surfactant and its subfraction as well as the surface tension reducing ability of the surfactant. The main result of the study was a significantly lower lung compliance and higher tissue elastance which was observed in FGR female offspring at day 21 compared to control offspring. In addition, female LP offspring exhibited lower surfactant pool sizes at postnatal day 1compared to controls. These changes were not observed in the male offspring. It is concluded that FGR has a different impact on pulmonary function and on surfactant in female, as compared to male, offspring.	[Khazaee, Reza; Yamashita, Cory; Hardy, Daniel B.; Veldhuizen, Ruud A. W.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; [Khazaee, Reza] Univ Western Ontario, Biotron Res Ctr, London, ON, Canada; [McCaig, Lynda A.; Yamashita, Cory; Hardy, Daniel B.; Veldhuizen, Ruud A. W.] Lawson Hlth Res Inst, London, ON, Canada; [Yamashita, Cory; Veldhuizen, Ruud A. W.] Univ Western Ontario, Dept Med, London, ON, Canada; [Hardy, Daniel B.] Univ Western Ontario, Dept Obstet & Gynecol, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Veldhuizen, RAW (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada.; Veldhuizen, RAW (corresponding author), Lawson Hlth Res Inst, London, ON, Canada.; Veldhuizen, RAW (corresponding author), Univ Western Ontario, Dept Med, London, ON, Canada.	rveldhui@uwo.ca	Khazaee, Reza/AAL-5309-2021; Veldhuizen, Ruud/G-3352-2011; Yamashita, Cory/G-3359-2011; Hardy, Daniel/GYU-8976-2022	Khazaee, Reza/0000-0002-9681-023X; Veldhuizen, Ruud/0000-0002-8802-1580; Hardy, Daniel/0000-0001-5445-273X; Yamashita, Cory/0000-0003-2040-4996	Ontario Thoracic Society; Lawson Health Research Institute-Internal Research Fund; Women's Development Council of the London Health Sciences Centre; Western University Bridge funding	Ontario Thoracic Society; Lawson Health Research Institute-Internal Research Fund; Women's Development Council of the London Health Sciences Centre; Western University Bridge funding	Funding for the current studies were provided to RV by the Ontario Thoracic Society (https://lungontario.ca/research), Lawson Health Research Institute-Internal Research Fund (https://www.lawsonresearch.ca/), the Women's Development Council of the London Health Sciences Centre and Western University Bridge funding (https://www.uwo.ca/research/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADAMSON IYR, 1984, LAB INVEST, V50, P456; ADAMSON IYR, 1984, AM REV RESPIR DIS, V129, P130; Aiko Y, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-181; Albion CD, 2011, FETAL GROWTH RESTRIC; Bailey TC, 2008, CRIT CARE MED, V36, P2381, DOI 10.1097/CCM.0b013e318180b65c; BARTLETT JG, 1995, NEW ENGL J MED, V333, P1618, DOI 10.1056/NEJM199512143332408; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boe DM, 2009, J LEUKOCYTE BIOL, V86, P1097, DOI 10.1189/jlb.0209087; Broussard D, 2006, EXP LUNG RES, V32, P263, DOI 10.1080/01902140600817549; Chavatte-Palmer P, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13060586; Chen CM, 2004, PEDIATR RES, V56, P329, DOI 10.1203/01.PDR.0000134254.83113.8E; Dasinger JH, 2016, CLIN SCI, V130, P337, DOI 10.1042/CS20150611; Deng FT, 2015, J HUAZHONG U SCI-MED, V35, P122, DOI 10.1007/s11596-015-1400-y; Dickinson H, 2016, J DEV ORIG HLTH DIS, V7, P449, DOI 10.1017/S2040174416000477; DUCKCHONG CG, 1979, LIPIDS, V14, P492, DOI 10.1007/BF02533467; El Hajj N, 2014, REPRODUCTION, V148, pR111, DOI 10.1530/REP-14-0334; Goerke J, 1998, BBA-MOL BASIS DIS, V1408, P79, DOI 10.1016/S0925-4439(98)00060-X; GROSS NJ, 1992, AM J PHYSIOL, V262, pL446, DOI 10.1152/ajplung.1992.262.4.L446; Harding R, 2012, SEMIN FETAL NEONAT M, V17, P67, DOI 10.1016/j.siny.2012.01.005; Huang X, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-4518-z; Joss-Moore L, 2013, PEDIATR RES, V73, P612, DOI 10.1038/pr.2013.38; Joyce BJ, 2001, PEDIATR RES, V50, P641, DOI 10.1203/00006450-200111000-00018; Kim WY, 2016, TUBERC RESPIR DIS, V79, P53, DOI 10.4046/trd.2016.79.2.53; Martin EL, 2007, EXP LUNG RES, V33, P99, DOI 10.1080/01902140701198625; Maruscak AA, 2008, AM J PHYSIOL-LUNG C, V294, pL974, DOI 10.1152/ajplung.00528.2007; MCMILLAN EM, 1989, EXP LUNG RES, V15, P167, DOI 10.3109/01902148909087851; Milos S, 2017, AM J PHYSIOL-LUNG C, V313, pL524, DOI 10.1152/ajplung.00055.2017; Nawabi J, 2019, NOVEL FUNCTIONAL ROL, P623; Orgeig S, 2015, AM J PHYSIOL-LUNG C, V309, pL84, DOI 10.1152/ajplung.00275.2014; Orgeig S, 2010, AM J PHYSIOL-LUNG C, V298, pL575, DOI 10.1152/ajplung.00226.2009; Pike K, 2012, SEMIN FETAL NEONAT M, V17, P92, DOI 10.1016/j.siny.2012.01.003; Schouten LRA, 2015, ANESTHESIOLOGY, V123, P389, DOI 10.1097/ALN.0000000000000687; Schraufnagel DE, 2019, CHEST, V155, P409, DOI 10.1016/j.chest.2018.10.042; Sharma D, 2016, INTRAUTERINE GROWTH, P67; Shubert J, 2010, INHALATION INJURY; Smith CJ, 2015, DIABETES METAB SYNDR, V8, P295, DOI 10.2147/DMSO.S61296; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; Sohi G, 2015, ENDOCRINOLOGY, V156, P3069, DOI [10.1210/en.2015-1058, 10.1210/EN.2015-1058]; Sohi G, 2014, DRUG METAB DISPOS, V42, P221, DOI 10.1124/dmd.113.053538; SPAIN CL, 1987, PEDIATR RES, V21, P5, DOI 10.1203/00006450-198701000-00002; STEVENS PA, 1987, J APPL PHYSIOL, V63, P1049, DOI 10.1152/jappl.1987.63.3.1049; Sundrani DP, 2017, REPROD FERT DEVELOP, V29, P2085, DOI 10.1071/RD16265; Valle RP, 2015, ACS NANO, V9, P5413, DOI 10.1021/acsnano.5b01181; Veldhuizen RAW, 1996, AM J PHYSIOL-LUNG C, V270, pL152, DOI 10.1152/ajplung.1996.270.1.L152; Xu Y, 2006, FASEB J, V20, P1251, DOI 10.1096/fj.05-4917fje; Zana-Taieb E, 2015, J PATHOL, V235, P420, DOI 10.1002/path.4470; Zana-taieb E, 2013, EFFECT 2 MODELS INTR, V8	47	9	9	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2019	14	4							e0215611	10.1371/journal.pone.0215611	http://dx.doi.org/10.1371/journal.pone.0215611			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU1GG	31002676	gold, Green Published, Green Submitted			2023-01-03	WOS:000465019900037
J	Marins, LMS; Torres, TS; Leite, ID; Moreira, RI; Luz, PM; Hoagland, B; Kallas, EG; Madruga, JV; Liu, AY; Anderson, PL; Grinsztejn, B; Veloso, VG				Marins, Luana M. S.; Torres, Thiago S.; Leite, Iuri da C.; Moreira, Ronaldo I.; Luz, Paula M.; Hoagland, Brenda; Kallas, Esper G.; Madruga, Jose Valdez; Liu, Albert Y.; Anderson, Peter L.; Grinsztejn, Beatriz; Veloso, Valdilea G.			Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study	PLOS ONE			English	Article							SERODISCORDANT COUPLES; CLINICAL-TRIAL; PREVENTION; INFECTION; CONCORDANCE; SYSTEM; RISK	Introduction Efficacy of daily emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for PrEP is strongly dependent on the adherence. We examined the concordance between indirect adherence measures and protective drug levels among participants retained through 48 weeks in the PrEP Brasil Study. Methods PrEP Brasil was a prospective, multicenter, open-label demonstration project evaluating PrEP provision for men who have sex with men (MSM) and transgender women (TGW) at higher risk for HIV infection within the setting of Brazilian Public Health System. Three indirect adherence measures were obtained at week 48: medication possession ratio (MPR), pill count and self-report (30-days recall). Tenofovir diphosphate (TFV-DP) concentration in Dried Blood Spot (DBS) was measured at week 48. Areas under (AUC) the receiver operating characteristics (ROC) curve were used to evaluate the concordance between achieving protective drug levels (TFV-DP >= 700fmol/punch) and the indirect adherence measures. Youden's index and distance to corner were used to determine the optimal cutoff points for each indirect adherence measure. We calculated sensitivity, specificity, negative (NPV) and positive (PPV) predictive values for the found cutoff points. Finally, Delong test was used to compare AUCs. Results and discussion From April, 2014 to July, 2016, 450 participants initiated PrEP, 375(83.3%) were retained through 48 weeks. Of these, 74% (277/375) had TFV-DP >= 700fmol/punch. All adherence measures discriminated between participants with and without protective drug levels (AUC>0.5). High indirect adherence measure was predictive of protective drug levels (PPV>0.8) while low indirect adherence measure was not predictive of lack of protective drug levels (NPV<0.5). No significant differences were found between the adherence methods (p = 0.44). Conclusions Low-burden measurements such as MPR and self-report can be used to predict PrEP adherence in a public health context in Brazil for MSM and TGW retained through 48 weeks.	[Marins, Luana M. S.; Torres, Thiago S.; Moreira, Ronaldo I.; Luz, Paula M.; Hoagland, Brenda; Grinsztejn, Beatriz; Veloso, Valdilea G.] Inst Nacl Infectol Evandro Chagas INI Fiocruz, Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil; [Leite, Iuri da C.] Escola Nacl Saude Publ ENSP Fiocruz, Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil; [Kallas, Esper G.] Univ Sao Paulo, Escola Med, Sao Paulo, Brazil; [Madruga, Jose Valdez] Ctr Referencia & Treinamento DST AIDS, Sao Paulo, Brazil; [Liu, Albert Y.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA; [Anderson, Peter L.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA	Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Universidade de Sao Paulo; San Francisco Department of Public Health; University of Colorado System; University of Colorado Anschutz Medical Campus	Marins, LMS (corresponding author), Inst Nacl Infectol Evandro Chagas INI Fiocruz, Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.	luana.marins@ini.fiocruz.br	TORRES, THIAGO SILVA/D-6548-2014	TORRES, THIAGO SILVA/0000-0002-2557-601X; Kallas, Esper/0000-0003-2026-6925; Marins, Luana/0000-0003-0045-6764	Brazilian Ministry of Health (Brasilia, Brazil) [01/2013 BRA/K57]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [402004/2012-4, 454931/2014-0]; Secretaria de Vigilancia em Saude (SVS) [281/2013]; Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ) [E-26/110.261/2014]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/51743-0]; CNPq; FAPERJ; FAPESP; Secretaria de Vigilancia Sanitaria; Gilead Sciences; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI069476] Funding Source: NIH RePORTER	Brazilian Ministry of Health (Brasilia, Brazil); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Secretaria de Vigilancia em Saude (SVS); Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPERJ(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Secretaria de Vigilancia Sanitaria; Gilead Sciences(Gilead Sciences); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was sponsored by the Brazilian Ministry of Health (Brasilia, Brazil; #01/2013 BRA/K57), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; #402004/2012-4, #454931/2014-0), Secretaria de Vigilancia em Saude (SVS; #281/2013), Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ; #E-26/110.261/2014), and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP; #2012/51743-0). BG and PML are funded by the CNPq and FAPERJ. EGK is funded by FAPESP. Gilead Sciences donated the study drug and covered costs related to drug concentration assessment but had no role in study design, collection, analysis and interpretation of data, writing of the manuscript, or the decision to submit the manuscript for publication.; The authors would like to thank the following: the study participants; the PrEP Brasil Study Team; and the University of Colorado Antiviral Pharmacology Laboratory. The authors also acknowledge the support of our funders: CNPq; Secretaria de Vigilancia Sanitaria; FAPERJ; FAPESP; and Gilead Sciences.	Abaasa A, 2018, AIDS BEHAV, V22, P1165, DOI 10.1007/s10461-017-1951-y; Agot K, 2015, AIDS BEHAV, V19, P743, DOI 10.1007/s10461-014-0859-z; Amico KR, 2016, AIDS BEHAV, V20, P1535, DOI 10.1007/s10461-016-1360-7; Amico KR, 2014, JAIDS-J ACQ IMM DEF, V66, P530, DOI 10.1097/QAI.0000000000000216; Amico KR, 2012, CURR OPIN HIV AIDS, V7, P542, DOI 10.1097/COH.0b013e3283582d4a; Anderson PL, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.01710-17; Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006; [Anonymous], 2018, J Int AIDS Soc, V21 Suppl 6, pe25148, DOI 10.1002/jia2.25148; [Anonymous], SIST CONTR LOG MED S; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Baker Z, 2018, AIDS BEHAV, V22, P1174, DOI 10.1007/s10461-017-1958-4; Baxi SM, 2015, JAIDS-J ACQ IMM DEF, V68, P13, DOI 10.1097/QAI.0000000000000386; Berg KM, 2006, JAIDS-J ACQ IMM DEF, V43, pS79, DOI 10.1097/01.qai.0000248337.97814.66; Castillo-Mancilla JR, 2018, CURR HIV-AIDS REP, V15, P49, DOI 10.1007/s11904-018-0377-0; Cohen SE, 2015, JAIDS-J ACQ IMM DEF, V68, P439, DOI 10.1097/QAI.0000000000000479; Corneli AL, 2014, JAIDS-J ACQ IMM DEF, V66, P324, DOI 10.1097/QAI.0000000000000158; D'Alessandro A, 2010, BLOOD TRANSFUS-ITALY, V8, P82, DOI 10.2450/2009.0122-09; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Fluss R, 2005, BIOMETRICAL J, V47, P458, DOI 10.1002/bimj.200410135; Food and Drug Administration, 2012, TRUV PREP FACT SHEET; Galea JT, 2018, LANCET HIV, V5, pE110, DOI 10.1016/S2352-3018(18)30011-0; Grangeiro A, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009021; Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Grinsztejn B, 2018, LANCET HIV, V5, pE136, DOI 10.1016/S2352-3018(18)30008-0; Haberer JE, 2016, CURR OPIN HIV AIDS, V11, P10, DOI 10.1097/COH.0000000000000220; Haberer JE, 2015, AIDS, V29, P1277, DOI 10.1097/QAD.0000000000000647; Haberer JE, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001511; Hajian-Tilaki K, 2018, STAT METHODS MED RES, V27, P2374, DOI 10.1177/0962280216680383; Hajian-Tilaki K, 2013, CASP J INTERN MED, V4, P627; Hoagland B, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21472; Kabore Lassane, 2015, J Int Assoc Provid AIDS Care, V14, P156, DOI 10.1177/2325957414557263; Kebaabetswe PM, 2015, AIDS BEHAV, V19, P758, DOI 10.1007/s10461-014-0891-z; Liu AQ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0095291, 10.1371/journal.pone.0083736]; Liu AY, 2016, JAMA INTERN MED, V176, P75, DOI 10.1001/jamainternmed.2015.4683; Luz PM, 2018, MEDICINE, V97, pS75, DOI [10.1097/MD.0000000000010602, 10.1097/md.0000000000010602]; Marcus JL, 2016, JAIDS-J ACQ IMM DEF, V73, P540, DOI 10.1097/QAI.0000000000001129; McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2; Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273; Montgomery MC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157742; Musinguzi N, 2016, AIDS, V30, P1121, DOI 10.1097/QAD.0000000000001024; PAHO/ WHO, BRAZ IN IMPL PREP PR; Predhomme J, 2012, AIDS RES HUM RETROV; PrEP-O ESTADO DE IMPLEMENTACAO DA PREP NO BRASIL, 2019, B VAC ANT HIV AIDS, V32; Psaros C, 2014, JAIDS-J ACQ IMM DEF, V66, P522, DOI 10.1097/QAI.0000000000000212; Seifert SM, 2015, CLIN INFECT DIS, V60, P804, DOI 10.1093/cid/ciu916; Spinner CD, 2016, INFECTION, V44, P151, DOI 10.1007/s15010-015-0850-2; Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711; Torres T., 2019, JMIR PUBLIC HLTH SUR; Torres T. S., 2018, AIDS 2018; Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614; Williams AB, 2013, AIDS BEHAV, V17, P284, DOI 10.1007/s10461-012-0172-7; World Health Organization, 2014, CONS PREEXP PROPH PR; World Health Organization (WHO) WHO, 2017, BRAZ BEG PREP ROLL O; Zheng JH, 2016, J PHARMACEUT BIOMED, V122, P16, DOI 10.1016/j.jpba.2016.01.038	55	17	17	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2019	14	8							e0221281	10.1371/journal.pone.0221281	http://dx.doi.org/10.1371/journal.pone.0221281			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5OC	31430318	Green Published, gold, Green Submitted			2023-01-03	WOS:000485026800040
J	Peterson, JF; Roden, DM; Orlando, LA; Ramirez, AH; Mensah, GA; Williams, MS				Peterson, Josh F.; Roden, Dan M.; Orlando, Lori A.; Ramirez, Andrea H.; Mensah, George A.; Williams, Marc S.			Building evidence and measuring clinical outcomes for genomic medicine	LANCET			English	Review							FAMILIAL HYPERCHOLESTEROLEMIA; PRECISION MEDICINE; HEALTH; IMPLEMENTATION; RECOMMENDATIONS; CARE; REIMBURSEMENT; INTERVENTIONS; STATEMENT; GENETICS	Human genomic sequencing has potential diagnostic, prognostic, and therapeutic value across a wide breadth of clinical disciplines. One barrier to widespread adoption is the paucity of evidence for improved outcomes in patients who do not already have an indication for more focused testing. In this Series paper, we review clinical outcome studies in genomic medicine and discuss the important features and key challenges to building evidence for next generation sequencing in the context of routine patient care.	[Peterson, Josh F.; Roden, Dan M.] Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Nashville, TN USA; [Peterson, Josh F.; Roden, Dan M.; Ramirez, Andrea H.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA; [Roden, Dan M.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN USA; [Orlando, Lori A.] Duke Univ, Sch Med, Ctr Appl Genom & Precis Med, Durham, NC USA; [Mensah, George A.] NHLBI, Ctr Translat Res & Implementat Sci, NIH, Bethesda, MD USA; [Williams, Marc S.] Genom Med Inst, Danville, PA USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Duke University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Peterson, JF (corresponding author), Vanderbilt Univ, Med Ctr, Nashville, TN 37203 USA.	josh.peterson@vumc.org	Roden, Dan/ABD-5412-2021	Orlando, Lori/0000-0003-2534-7855	National Human Genome Institute, National Institutes of Health; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG009694, U01HG008701] Funding Source: NIH RePORTER	National Human Genome Institute, National Institutes of Health; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	JFP is a consultant for Color Genomics outside the submitted work. MSW reports grants from National Human Genome Institute, National Institutes of Health, during the conduct of the study. All other authors declare no competing interests.	Abul-Husn NS, 2016, SCIENCE, V354, DOI 10.1126/science.aaf7000; Alver M, 2019, GENET MED, V21, P1173, DOI 10.1038/s41436-018-0311-2; Amendola LM, 2015, GENOME RES, V25, P305, DOI 10.1101/gr.183483.114; Berg AO, 2009, GENET MED, V11, P35, DOI [10.1097/GIM.0b013e318181fa2ff, 10.1097/GIM.0b013e31818fa2ff]; Buchanan AH, 2018, GENET MED, V20, P554, DOI 10.1038/gim.2017.145; Bucholz EM, 2018, CIRCULATION, V137, P2218, DOI [10.1161/circulationaha.117.032321, 10.1161/CIRCULATIONAHA.117.032321]; Carey DJ, 2016, GENET MED, V18, P906, DOI 10.1038/gim.2015.187; Caswell-Jin JL, 2019, JNCI-J NATL CANCER I, V111, P95, DOI 10.1093/jnci/djy147; Cavallari LH, 2018, JACC-CARDIOVASC INTE, V11, P181, DOI 10.1016/j.jcin.2017.07.022; Centers for Disease Control and Prevention, 2017, ACCE MOD PROC EV GEN; Chambers DA, 2016, JAMA-J AM MED ASSOC, V315, P1941, DOI 10.1001/jama.2016.3867; Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Collins FS, 2014, J AM MED INFORM ASSN, V21, P576, DOI 10.1136/amiajnl-2014-002864; Daly MB, 2017, J NATL COMPR CANC NE, V15, P9, DOI 10.6004/jnccn.2017.0003; Eccles MP, 2006, IMPLEMENT SCI, V1, DOI 10.1186/1748-5908-1-28; Frueh FW, 2013, VALUE HEALTH, V16, pS27, DOI 10.1016/j.jval.2013.06.009; Gaziano JM, 2016, J CLIN EPIDEMIOL, V70, P214, DOI 10.1016/j.jclinepi.2015.09.016; Gidding SS, 2015, CIRCULATION, V132, P2167, DOI 10.1161/CIR.0000000000000297; Glasgow RE, 1999, AM J PUBLIC HEALTH, V89, P1322, DOI 10.2105/AJPH.89.9.1322; Gottesman O, 2013, GENET MED, V15, P761, DOI 10.1038/gim.2013.72; Gray SW, 2014, GENET MED, V16, P727, DOI 10.1038/gim.2014.26; Green ED, 2011, NATURE, V470, P204, DOI 10.1038/nature09764; Green RC, 2016, AM J HUM GENET, V98, P1051, DOI 10.1016/j.ajhg.2016.04.011; Harada-Shiba M, 2018, J ATHEROSCLER THROMB, V25, P751, DOI 10.5551/jat.CR003; Henry J, ADOPTION ELECT HLTH; Hosseini SM, 2018, CIRCULATION, V138, P1195, DOI 10.1161/CIRCULATIONAHA.118.035070; Hripcsak G, 2015, STUD HEALTH TECHNOL, V216, P574, DOI 10.3233/978-1-61499-564-7-574; Kalia SS, 2017, GENET MED, V19, P249, DOI 10.1038/gim.2016.190; Khera AV, 2018, NAT GENET, V50, P1219, DOI 10.1038/s41588-018-0183-z; Khera AV, 2016, NEW ENGL J MED, V375, P2349, DOI 10.1056/NEJMoa1605086; Khoury MJ, 2008, HEALTH AFFAIR, V27, P1600, DOI 10.1377/hlthaff.27.6.1600; Kirby JC, 2016, J AM MED INFORM ASSN, V23, P1046, DOI 10.1093/jamia/ocv202; Kullo IJ, 2016, CIRCULATION, V133, P1181, DOI 10.1161/CIRCULATIONAHA.115.020109; Landrum MJ, 2014, NUCLEIC ACIDS RES, V42, pD980, DOI 10.1093/nar/gkt1113; Lu CY, 2018, GENET MED, V20, P390, DOI 10.1038/gim.2017.122; Machens A, 2007, CLIN ENDOCRINOL, V67, P613, DOI 10.1111/j.1365-2265.2007.02934.x; Manolio TA, 2013, GENET MED, V15, P258, DOI 10.1038/gim.2012.157; Marian AJ, 2017, CIRC RES, V121, P749, DOI 10.1161/CIRCRESAHA.117.311059; Marteau TM, 2010, COCHRANE DB SYST REV, V2010, DOI DOI 10.1002/14651858; McMurry AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055811; McNally EM, 2017, CIRC RES, V121, P731, DOI 10.1161/CIRCRESAHA.116.309396; Natarajan P, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag2367; New JP, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.j5554; Nordestgaard BG, 2013, EUR HEART J, V34, P3478, DOI 10.1093/eurheartj/eht273; Olfson E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135193; Orlando LA, 2018, GENET MED, V20, P655, DOI 10.1038/gim.2017.144; Overhage JM, 2012, J AM MED INFORM ASSN, V19, P54, DOI 10.1136/amiajnl-2011-000376; Pagon R. A., 1993, GENEREVIEWS; Phillips M, 2017, GENET MED, V19, P834, DOI [10.1038/gim.2016.199, 10.1038/gim.2017.21]; Provenzale D, 2016, J NATL COMPR CANC NE, V14, P1010, DOI 10.6004/jnccn.2016.0108; Ramos EM, 2014, AM J MED GENET C, V166, P93, DOI 10.1002/ajmg.c.31386; Rehm HL, 2015, NEW ENGL J MED, V372, P2235, DOI 10.1056/NEJMsr1406261; Roberts MC, 2018, HEALTH AFFAIR, V37, P801, DOI 10.1377/hlthaff.2017.1630; Robinson JG, 2011, J CLIN LIPIDOL, V5, pS18, DOI 10.1016/j.jacl.2011.03.451; Roden DM, 2019, LANCET, V394, P521, DOI 10.1016/S0140-6736(19)31276-0; Schwartz MLB, 2018, AM J HUM GENET, V103, P328, DOI 10.1016/j.ajhg.2018.07.009; Schwiter R, 2018, CURR GENET MED REP, V6, P21, DOI 10.1007/s40142-018-0134-0; Taber JM, 2015, ANN BEHAV MED, V49, P616, DOI 10.1007/s12160-014-9679-7; Telenti A, 2016, P NATL ACAD SCI USA, V113, P11901, DOI 10.1073/pnas.1613365113; The National Patient-Centered Clinical Research Network, PCORNET COMM DAT MOD; Trosman JR, 2017, J NATL COMPR CANC NE, V15, P219, DOI 10.6004/jnccn.2017.0022; Turnbull C, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1687; Vassy JL, 2017, ANN INTERN MED, V167, P159, DOI 10.7326/M17-0188; Vozikis A, 2016, PUBLIC HEALTH GENOM, V19, P352, DOI 10.1159/000449152; Weitzel KW, 2016, BMC MED GENOMICS, V9, DOI 10.1186/s12920-015-0162-5; Wetterstrand K.A, DNA SEQUENCING COSTS; Williams JL, 2018, HEALTHCARE-BASEL, V6, DOI 10.3390/healthcare6030083; Wise AL, 2019, LANCET, V394, P533, DOI 10.1016/S0140-6736(19)31274-7; Wu RR, 2019, GENET MED, V21, P331, DOI 10.1038/s41436-018-0049-x; Yang YP, 2014, JAMA-J AM MED ASSOC, V312, P1870, DOI 10.1001/jama.2014.14601	70	22	22	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 17	2019	394	10198					604	610		10.1016/S0140-6736(19)31278-4	http://dx.doi.org/10.1016/S0140-6736(19)31278-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IR6ZT	31395443	Green Accepted			2023-01-03	WOS:000481590500043
J	Beargie, SM; Higgins, CR; Evans, DR; Laing, SK; Erim, D; Ozawa, S				Beargie, Sarah M.; Higgins, Colleen R.; Evans, Daniel R.; Laing, Sarah K.; Erim, Daniel; Ozawa, Sachiko			The economic impact of substandard and falsified antimalarial medications in Nigeria	PLOS ONE			English	Article							PLASMODIUM-FALCIPARUM MALARIA; SULFADOXINE-PYRIMETHAMINE; ARTEMETHER-LUMEFANTRINE; ARTESUNATE-AMODIAQUINE; AFRICAN CHILDREN; EFFICACY; QUALITY; CHLOROQUINE; LIMITATIONS; QUININE	Introduction Substandard and falsified medications pose significant risks to global health. Nearly one in five antimalarials circulating in low- and middle-income countries are substandard or falsified. We assessed the health and economic impact of substandard and falsified antimalarials on children under five in Nigeria, where malaria is endemic and poor-quality medications are commonplace. Methods We developed a dynamic agent-based SAFARI (Substandard and Falsified Antimalarial Research Impact) model to capture the impact of antimalarial use in Nigeria. The model simulated children with background characteristics, malaria infections, patient care-seeking, disease progression, treatment outcomes, and incurred costs. Using scenario analyses, we simulated the impact of substandard and falsified medicines, antimalarial resistance, as well as possible interventions to improve the quality of treatment, reduce stock-outs, and educate caregivers about antimalarial quality. Results We estimated that poor quality antimalarials are responsible for 12,300 deaths and $892 million ($890-$893 million) in costs annually in Nigeria. If antimalarial resistance develops, we simulated that current costs of malaria could increase by $839 million (11% increase, $837-$841 million). The northern regions of Nigeria have a greater burden as compared to the southern regions, with 9,700 deaths and $698 million ($697-$700 million) in total economic losses annually due to substandard and falsified antimalarials. Furthermore, our scenario analyses demonstrated that possible interventions-such as removing stock-outs in all facilities ($1.11 billion), having only ACTs available for treatment ($594 million), and 20% more patients seeking care ($469 million)-can save hundreds of millions in costs annually in Nigeria. Conclusions The results highlight the significant health and economic burden of poor quality antimalarials in Nigeria, and the impact of potential interventions to counter them. In order to reduce the burden of malaria and prevent antimalarials from developing resistance, policymakers and donors must understand the problem and implement interventions to reduce the impact of ineffective and harmful antimalarials.	[Beargie, Sarah M.; Higgins, Colleen R.; Laing, Sarah K.; Ozawa, Sachiko] Univ N Carolina, Div Practice Adv & Clin Educ, UNC Eshelman Sch Pharm, Chapel Hill, NC 27515 USA; [Evans, Daniel R.] Duke Univ, Sch Med, Durham, NC USA; [Erim, Daniel] RTI Int, Qual Measurement & Hlth Policy Grp, Res Triangle Pk, NC USA; [Ozawa, Sachiko] Univ N Carolina, Dept Maternal & Child Hlth, UNC Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University; Research Triangle Institute; University of North Carolina; University of North Carolina Chapel Hill	Ozawa, S (corresponding author), Univ N Carolina, Div Practice Adv & Clin Educ, UNC Eshelman Sch Pharm, Chapel Hill, NC 27515 USA.; Ozawa, S (corresponding author), Univ N Carolina, Dept Maternal & Child Hlth, UNC Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA.	ozawa@unc.edu	Ozawa, Sachiko/D-4399-2014	Ozawa, Sachiko/0000-0001-7608-9038; Evans, Daniel/0000-0002-9818-5001				ACTwatch Group SFH, 2015, ACTWATCH STUD REF DO; Adjuik M, 2002, LANCET, V359, P1365, DOI 10.1016/S0140-6736(02)08348-4; Affum AO, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-220; Aina BA, 2008, J INFECT DEV COUNTR, V2, P68, DOI 10.3855/jidc.325; ATTARAN A, 2012, BMJ-BRIT MED J, V345, DOI DOI 10.1136/BMJ.E7381; Atwine D, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001119; Bate R, 2010, RES REP TROP MED, V1, P19, DOI 10.2147/RRTM.S13242; Blackstone EA, 2014, AM HEALTH DRUG BENEF, V7, P216; Bruxvoort K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134275; Bruxvoort K, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0602-x; Buckley GJ, 2013, COUNTERING PROBLEM F, P351, DOI 10.17226/18272; Camponovo F, 2017, MALARIA J, V16, DOI 10.1186/s12936-016-1650-6; Central Bank of Nigeria, 2018, MONTHL AV EXCH RAT N; Dapel Z., 2018, POVERTY NIGERIA UNDE; Davis B, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-135; Dondorp AM, 2010, LANCET, V376, P1647, DOI 10.1016/S0140-6736(10)61924-1; Erhun WO., 2001, J HLTH POPULATION DE, V4, P23; Evans DR, 2019, HLTH POLICY PLANNING; Ezeoke OP, 2012, AM J TROP MED HYG, V86, P52, DOI 10.4269/ajtmh.2012.11-0090; Falade C, 2005, T ROY SOC TROP MED H, V99, P459, DOI 10.1016/j.trstmh.2004.09.013; Falade CO, 2014, MED PRIN PRACT, V23, P204, DOI 10.1159/000360578; Farrar J, 2014, MANSONS TROPICAL INF, pxi, DOI [10.1016/b978-0-7020-5101-2.00094-7, DOI 10.1016/B978-0-7020-5101-2.00094-7]; Fatokun O, 2016, LANCET, V388, P2603, DOI 10.1016/S0140-6736(16)32121-3; Faucher JF, 2009, J INFECT DIS, V200, P57, DOI 10.1086/599378; Gallup JL, 2001, AM J TROP MED HYG, V64, P85, DOI 10.4269/ajtmh.2001.64.85; Garuba HA, 2009, GLOBALIZATION HEALTH, V5, DOI 10.1186/1744-8603-5-14; Gomez-Ramirez J, 2013, PROG BIOPHYS MOL BIO, V113, P80, DOI 10.1016/j.pbiomolbio.2013.03.008; Grandesso F, 2006, T ROY SOC TROP MED H, V100, P419, DOI 10.1016/j.trstmh.2005.07.017; Idowu O A, 2006, Tanzan Health Res Bull, V8, P45; Ioset JR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007270; Kaur H, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1096-x; Kaur H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125577; Lubell Y, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-452; Lubell Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017439; Nahum A, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-37; National Malaria Elimination Programme-NMEP/ Nigeria National Population Commission-NPC/ Nigeria National Bureau of Statistics-NBS/ Nigeria ICF International, 2016, NIG MAL IND SURV 201; National Population Commission (NPC) [Nigeria] and ICF International, 2014, NIG DEM HLTH SURV 20; Nyarko Samuel Harrenson, 2014, Malar Res Treat, V2014, P304361, DOI 10.1155/2014/304361; Obieche OA, 2016, MWJ, V7; Ochekpe NA, 2010, INT J DRUG DEV RES, V2, P211; Onwujekwe O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078362; Onwujekwe O, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-22; Ozawa S, 2019, AM J TROP MED HYG, V100, P1149, DOI 10.4269/ajtmh.18-0334; Ozawa S, 2019, MALARIA J, V18, DOI 10.1186/s12936-018-2628-3; Ozawa S, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.1662; President's Malaria Initiative, 2019, NIG MAL OP PLAN FY 2; Ramharter M, 2005, CLIN INFECT DIS, V40, P1777, DOI 10.1086/430309; Renschler JP, 2015, AM J TROP MED HYG, V92, P119, DOI 10.4269/ajtmh.14-0725; Sabartova J, 2011, SURVEY QUALITY SELEC; Salihu O, 2013, J EC SUSTAINABLE DEV, V4; Taylor RB, 2001, LANCET, V357, P1933, DOI 10.1016/S0140-6736(00)05065-0; UNICEF, 2019, CHILD MORT EST NEW Y; Verret WJ, 2011, ANTIMICROB AGENTS CH, V55, P2629, DOI 10.1128/AAC.01727-10; White NJ, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-253; WHO, 2018, MAL CHILDR 5; WHO, 2018, WORLD MALARIA REPORT; WHO, 2017, DEPRESSION; World Health Organization, 2017, WHO PARTN TAK MAL TO; World Health Organization (WHO), 2017, 1 10 MED PROD DEV CO; Xie Y, 2011, RES SOC STRAT MOBIL, V29, P343, DOI 10.1016/j.rssm.2011.04.001; Yeka A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053772; Zongo I, 2005, AM J TROP MED HYG, V73, P826, DOI 10.4269/ajtmh.2005.73.826	62	19	19	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 15	2019	14	8							e0217910	10.1371/journal.pone.0217910	http://dx.doi.org/10.1371/journal.pone.0217910			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5KK	31415560	Green Submitted, gold, Green Published			2023-01-03	WOS:000485017200002
J	Tapp, A; Nancarrow, C; Morey, Y; Warren, S; Bowtell, N; Verne, J				Tapp, Alan; Nancarrow, Clive; Morey, Yvette; Warren, Stella; Bowtell, Nicola; Verne, Julia			Public responses to volunteer community care: Propositions for old age and end of life	PLOS ONE			English	Article							PALLIATIVE CARE; PEOPLE; PROJECTIONS; PROVISION	Background Funding shortages and an ageing population have increased pressures on state or insurance funded end of life care for older people. Across the world, policy debate has arisen about the potential role volunteers can play, working alongside health and social care professionals in the community to support and care for the ageing and dying. Aims The authors examined self-reported levels of care for the elderly by the public in England, and public opinions of community volunteering concepts to care for the elderly at the end of life. In particular, claimed willingness to help and to be helped by local people was surveyed. Methods A sample of 3,590 adults in England aged 45 or more from an online access panel responded to a questionnaire in late 2017. The survey data was weighted to be representative of the population within this age band. Key literature and formative qualitative research informed the design of the survey questionnaire, which was further refined after piloting. Results Preferences for different models of community volunteering were elicited. There was a preference for 'formal' models with increased wariness of 'informal' features. Whilst 32% of adults said they 'might join' depending on whom the group helped, unsurprisingly more personal and demanding types of help significantly reduced the claimed willingness to help. Finally, willingness to help (or be helped) by local community carers or volunteers was regarded as less attractive than care being provided by personal family, close friends or indeed health and care professionals. Conclusion Findings suggest that if community volunteering to care for elderly people at the end of life in England is to expand it may require considerable attention to the model including training for volunteers and protections for patients and volunteers as well as public education and promotion. Currently, in England, there is a clear preference for non-medical care to be delivered by close family or social care professionals, with volunteer community care regarded only as a back-up option.	[Tapp, Alan; Nancarrow, Clive; Morey, Yvette; Warren, Stella] Univ West England, Fac Business & Law, Bristol, Avon, England; [Bowtell, Nicola; Verne, Julia] Publ Hlth England, Natl End Life Care Intelligence Network, Bristol, Avon, England	University of West England; Public Health England	Tapp, A (corresponding author), Univ West England, Fac Business & Law, Bristol, Avon, England.	Alan.Tapp@uwe.ac.uk			Public Health England	Public Health England	This work was supported from Public Health England (https//www gov,uk/government/organisations/public-health-england) to AT. The funder JV (Public Health England) was involved in discussing initial project aims and research objectives. She was not involved in study design, data collection or analysis. She was party to the decision to publish. She was not involved in manuscript creation but has read the manuscript and is happy to be a co-author.	Abel J, 2018, BMJ SUPPORT PALLIAT, V1, P129; Abel Julian, 2011, BMJ Support Palliat Care, V1, P129, DOI 10.1136/bmjspcare-2011-000068; Alakeson V, 2016, BJPSYCH BULL, V40, P34, DOI 10.1192/pb.bp.114.048827; [Anonymous], 2016, MAK TIM GIVERS; [Anonymous], 2018, INDIVIDUALISM COLLEC; [Anonymous], 2015, AMBITIONS PALLIATIVE; Badrakalimuthu V, 2014, AGE AGEING, V43, P13, DOI 10.1093/ageing/aft151; Barry V., 2013, OVERVIEW COMPASSIONA; Blickem C, 2018, SAGE OPEN, V8, DOI 10.1177/2158244018787223; Bone AE, 2018, PALLIATIVE MED, V32, P329, DOI 10.1177/0269216317734435; Burbeck R, 2014, BMC PALLIAT CARE, V13, DOI 10.1186/1472-684X-13-3; Candy B, 2015, INT J NURS STUD, V52, P756, DOI 10.1016/j.ijnurstu.2014.08.007; CLARY EG, 1994, J APPL SOC PSYCHOL, V24, P1129, DOI 10.1111/j.1559-1816.1994.tb01548.x; Commonwealth of Australia, 2010, SUPP AUSTR LIV WELL; Correa Santiago, 2018, Ann Palliat Med, V7, pAB009, DOI 10.21037/apm.2018.s009; Costa V, 2016, BMC PALLIAT CARE, V15, DOI 10.1186/s12904-016-0077-8; CQC, 2017, STAT AD SOC CAR SERV; Cross B. R, ACT LON; Davies H. I, 2004, PALLIATIVE CARE SOLI; Economist Intelligence Unit, 2010, QUAL DEATH RANK END; England P. H, 2018, ATL VAR PALL END LIF; Etkind SN, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0860-2; Etkind SN, 2018, J AM GERIATR SOC, V66, P1031, DOI 10.1111/jgs.15272; Foot J., 2010, GLASS HALF FULL ASSE; French J., 2015, STRATEGIC SOCIAL MAR; Gaughan J, 2017, INT J HLTH EC M 0228; Gawende A, 2014, BEING MORTAL MED WHA; Glasgow Centre for Population Health, 2012, BRIEF PAP CONC SER; Goossensen A., 2018, CHANGING FACE VOLUNT, P69; Hanratty B, 2012, J PAIN SYMPTOM MANAG, V44, P74, DOI 10.1016/j.jpainsymman.2011.08.006; Hesse M, 2018, CHANGING FACE VOLUNT, P69; Higginson IJ, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0648-4; Holtgraves T, 1997, J APPL SOC PSYCHOL, V27, P1650, DOI 10.1111/j.1559-1816.1997.tb01618.x; Hospice Foundation, 2013, BRIEF HIST; KMIETOWICZ Z, 2013, BMJ-BRIT MED J, V346, P12871, DOI DOI 10.1136/BMJ.F1595; Krakowiak P., 2018, CHANGING FACE VOLUNT, P83; Kumar S, 2013, CURR OPIN SUPPORT PA, V7, P216, DOI 10.1097/SPC.0b013e3283610255; Flores SL, 2018, ANN PALLIAT MED, V7, pS15, DOI 10.21037/apm.2018.03.02; Linsi K, 2016, ROUT KEY THEME HEALT, P165; Mathie A., 2003, DEV PRACT, V13, P474, DOI [DOI 10.1080/0961452032000125857, 10.1080/0961452032000125857]; Molina Emilio Herrera, 2015, BMJ Support Palliat Care, V5 Suppl 1, pA9, DOI 10.1136/bmjspcare-2015-000906.29; Moorhouse P, 2010, CANADIAN REV ALZHEIM; Morris SM, 2017, HEALTH SOC CARE COMM, V25, P1704, DOI 10.1111/hsc.12232; Nancarrow C., 2014, ONLINE ACCESS PANELS; Nancarrow C., 2001, MARK REV, V2, P55, DOI [10.1362/1469347012569427, DOI 10.1362/1469347012569427]; Pelttari L., 2018, CHANGING FACE VOLUNT, P42; Phillips L.C., 2010, SAM ADV MANAGE J, V75, P12; Public Health England, 2015, WHAT WE KNOW NOW 201; Public Health England, 2014, NAT END LIF CAR INT; Qureshi H., 1989, CARING RELATIONSHIP; Rhodes R, 2018, CAMB Q HEALTHC ETHIC, V27, P137, DOI 10.1017/S0963180117000469; Sallnow L., 2018, CHANGING FACE VOLUNT, P185; Saunders C., 1990, HOSPICE PALLIATIVE C; Schneider W, 2017, BUNDESGESUNDHEITSBLA, V60, P69, DOI 10.1007/s00103-016-2472-y; Schuchter P., 2016, COMPASSIONATE COMMUN; Scott R., 2015, EUR J PALLIAT CARE, V22, P80; Scott R., 2018, CHANGING FACE VOLUNT; Smith Justin Davis, 1995, INTRO VOLUNTARY SECT; Sundstrom M, 2018, INT J QUAL STUD HEAL, V13, DOI 10.1080/17482631.2018.1474673; Tompkins B, 2018, ANN PALLIAT MED, V7, pS118, DOI 10.21037/apm.2018.03.16; Verne J, 2019, J PUBLIC HLTH; Wegleitner K, 2016, ROUT KEY THEME HEALT, P1; Whitehead P, 2014, CARING ELDERLY PERSO; Zaman S, 2018, MED HUMANIT, V44, DOI [10.1136/medhum-2016-010874, DOI 10.1136/MEDHUM-2016-010874]	65	2	2	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 1	2019	14	7							e0218597	10.1371/journal.pone.0218597	http://dx.doi.org/10.1371/journal.pone.0218597			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW3YW	31260482	Green Published, gold, Green Submitted			2023-01-03	WOS:000484918700017
J	Chami, N; Hauid, DK; Masoza, TS; Smart, LR; Kayange, NM; Hokororo, A; Ambrose, EE; Moschovis, PP; Wiens, MO; Peck, RN				Chami, Neema; Hauid, Duncan K.; Masoza, Tulla S.; Smart, Luke R.; Kayange, Neema M.; Hokororo, Adolfine; Ambrose, Emmanuela E.; Moschovis, Peter P.; Wiens, Matthew O.; Peck, Robert N.			Very severe anemia and one year mortality outcome after hospitalization in Tanzanian children: A prospective cohort study	PLOS ONE			English	Article							BLOOD-TRANSFUSION; YOUNG-CHILDREN; MALARIA; DISCHARGE; TRENDS	Background Africa has the highest rates of child mortality. Little is known about outcomes after hospitalization for children with very severe anemia. Objective To determine one year mortality and predictors of mortality in Tanzanian children hospitalized with very severe anemia. Methods We conducted a prospective cohort study enrolling children 2-12 years hospitalized from August 2014 to November 2014 at two public hospitals in northwestern Tanzania. Children were screened for anemia and followed until 12 months after discharge. The primary outcome measured was mortality. Predictors of mortality were determined using Cox regression analysis. Results Of the 505 children, 90 (17.8%) had very severe anemia and 415 (82.1%) did not. Mortality was higher for children with very severe anemia compared to children without over a one year period from admission, 27/90 (30.0%) vs. 59/415 (14.2%) respectively (Hazard Ratio (HR) 2.42, 95% Cl 1.53-3.83). In-hospital mortality was 11/90 (12.2%) and post-hospital mortality was 16/79 (20.2%) for children with very severe anemia. The strongest predictors of mortality were age (HR 1.01, 95% Cl 1.00-1.03) and decreased urine output (HR 4.30, 95% Cl 1.04-17.7). Conclusions Children up to 12 years of age with very severe anemia have nearly a 30% chance of mortality following admission over a one year period, with over 50% of mortality occurring after discharge. Post-hospital interventions are urgently needed to reduce mortality in children with very severe anemia, and should include older children.	[Chami, Neema; Masoza, Tulla S.; Kayange, Neema M.; Hokororo, Adolfine; Ambrose, Emmanuela E.; Peck, Robert N.] Catholic Univ Hlth & Allied Sci, Dept Pediat, Mwanza, Tanzania; [Hauid, Duncan K.] Weill Cornell Med Coll, Dept Pediat, New York, NY 10065 USA; [Smart, Luke R.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Hematol Oncol, Cincinnati, OH 45229 USA; [Moschovis, Peter P.] Massachusetts Gen Hosp, Dept Pediat, Div Pediat Global Hlth, Boston, MA 02114 USA; [Moschovis, Peter P.] Massachusetts Gen Hosp, Dept Pediat, Div Pulm Med, Boston, MA 02114 USA; [Wiens, Matthew O.] Mbarara Univ Sci & Technol, Fac Med, Mbarara, Uganda; [Wiens, Matthew O.] BC Childrens Hosp, Ctr Int Child Hlth, Vancouver, BC, Canada; [Wiens, Matthew O.] Univ British Columbia, Vancouver, BC, Canada; [Peck, Robert N.] Weill Cornell Med Coll, Ctr Global Hlth, New York, NY USA	Cornell University; Cincinnati Children's Hospital Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Mbarara University of Science & Technology; BC Childrens Hospital; University of British Columbia; University of British Columbia; Cornell University	Hauid, DK (corresponding author), Weill Cornell Med Coll, Dept Pediat, New York, NY 10065 USA.	dkh2001@med.cornell.edu	Moschovis, Peter/GRY-7498-2022; Smart, Luke R./AAI-1561-2020; Wiens, Matthew/J-9249-2019	Smart, Luke R./0000-0003-4083-0060; Wiens, Matthew/0000-0002-3287-5181; Peck, Robert/0000-0002-4526-2480	Weill Cornell Medical College Department of Pediatrics [87000213]; Medical Education Partnership Initiative Junior Faculty [D43TW010138]; Harvard Catalyst \ The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health Award) [UL 1TR002541]; National Institutes of Health [K01 TW010281]; FOGARTY INTERNATIONAL CENTER [D43TW010138, K01TW010281] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002541] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL124951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K23ES030399] Funding Source: NIH RePORTER	Weill Cornell Medical College Department of Pediatrics; Medical Education Partnership Initiative Junior Faculty; Harvard Catalyst \ The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health Award); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Funding was provided by a pilot award from the Weill Cornell Medical College Department of Pediatrics [#87000213] to DH. NK is supported by a grant Medical Education Partnership Initiative Junior Faculty [#D43TW010138]. PM is supported by a grant from Harvard Catalyst vertical bar The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health Award [UL 1TR002541]). RP is supported by a grant from the National Institutes of Health [#K01 TW010281]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdullahi, 2011, AFR J TRADIT COMPLEM, V8, P115, DOI 10.4314/ajtcam.v8i5S.5; Ahmed MM, 2016, BMC NUTR, V2, P49, DOI [10.1186/s40795-016-0090-6, DOI 10.1186/S40795-016-0090-6, DOI 10.1186/s40795-016-0090-6]; Ambrose EE, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.26735; BioMed Central, 2015, TRANSF TREATM SEV AN, DOI [10.1186/s13063-015-1112-4, DOI 10.1186/S13063-015-1112-4]; Bojang KA, 1997, ANN TROP PAEDIATR, V17, P355, DOI 10.1080/02724936.1997.11747910; Calis JCJ, 2008, NEW ENGL J MED, V358, P888, DOI 10.1056/NEJMoa072727; English L, 2016, AFR HEALTH SCI, V16, P883, DOI 10.4314/ahs.v16i4.2; English M, 2002, LANCET, V359, P494, DOI 10.1016/S0140-6736(02)07666-3; Hau DK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202334; Islam MA, 1996, J TROP PEDIATRICS, V42, P342, DOI 10.1093/tropej/42.6.342; Kagabo DM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190739; Kidney Disease Improving Global Outcomes, 2013, KIDNEY INT, V3, P43; Kiguli S, 2015, BMC MED, V13, DOI 10.1186/s12916-014-0246-7; Koram KA, 2000, AM J TROP MED HYG, V62, P670, DOI 10.4269/ajtmh.2000.62.670; Krumholz HM, 2013, NEW ENGL J MED, V368, P100, DOI 10.1056/NEJMp1212324; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O; MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102; Masquelier B, 2018, LANCET GLOB HEALTH, V6, pE1087, DOI 10.1016/s2214-109x(18)30353-x; Moschovis PP, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019654; Newton CRJC, 1997, TROP MED INT HEALTH, V2, P165, DOI 10.1046/j.1365-3156.1997.d01-238.x; Organization. WH, 2011, HAEM CONC DIAGN AN A; Patton GC, 2018, LANCET GLOB HEALTH, V6, pE1048, DOI 10.1016/S2214-109X(18)30417-0; Phiri KS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002903; ROY SK, 1983, BRIT MED J, V287, P1097, DOI 10.1136/bmj.287.6399.1097; Scott SP, 2014, NUTRIENTS, V6, P5915, DOI 10.3390/nu6125915; Simbauranga Rehema H, 2015, BMC Hematol, V15, P13, DOI 10.1186/s12878-015-0033-5; Smart LR, 2016, ACTA TROP, V159, P36, DOI 10.1016/j.actatropica.2016.03.019; Stevens GA, 2013, LANCET GLOB HEALTH, V1, pE16, DOI 10.1016/S2214-109X(13)70001-9; The United Republic of Tanzania, 2012, REPORT LAW MARRIAGE; Veirum JE, 2007, ACTA PAEDIATR, V96, P1832, DOI 10.1111/j.1651-2227.2007.00562.x; WHO. World Health Organization, 1992, INT STAT CLASS DIS R; Wiens MO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066698; World Health Organization, 2012, WHO STEPS INSTR; Zucker JR, 1996, AM J TROP MED HYG, V55, P655, DOI 10.4269/ajtmh.1996.55.655	34	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2019	14	6							e0214563	10.1371/journal.pone.0214563	http://dx.doi.org/10.1371/journal.pone.0214563			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW3PH	31220109	gold, Green Submitted, Green Published			2023-01-03	WOS:000484893500003
J	Tinetti, M; Dindo, L; Smith, CD; Blaum, C; Costello, D; Ouellet, G; Rosen, J; Hernandez-Bigos, K; Geda, M; Naik, A				Tinetti, Mary; Dindo, Lilian; Smith, Cynthia Daisy; Blaum, Caroline; Costello, Darce; Ouellet, Gregory; Rosen, Jonathan; Hernandez-Bigos, Kizzy; Geda, Mary; Naik, Aanand			Challenges and strategies in patients' health priorities-aligned decision-making for older adults with multiple chronic conditions	PLOS ONE			English	Article							SERIOUS ILLNESS; PRIMARY-CARE; MANAGEMENT; GOALS; CONTEXT; FOCUS	Objectives While patients' health priorities should inform healthcare, strategies for doing so are lacking for patients with multiple conditions. We describe challenges to, and strategies that support, patients' priorities-aligned decision-making. Design Participant observation qualitative study. Setting Primary care and cardiology practices in Connecticut. Participants Ten primary care clinicians, five cardiologists, and the Patient Priorities implementation team (four geriatricians, physician expert in clinician training, behavioral medicine expert). The patients discussed were >= 66 years with > 3 chronic conditions and. 10 medications or saw >= two specialists. Exposure Following initial training and experience in providing Patient Priorities Care, the clinicians and Patient Priorities implementation team participated in 21 case-based, group discussions (10 face-to-face; 11 telephonic). Using emergent learning (i.e. learning which arises from interactions among the participants), participants discussed challenges, posed solutions, and worked together to determine how to align care options with the health priorities of 35 patients participating in the Patient Priorities Care pilot. Main outcomes Challenges to, and strategies for, aligning decision-making with patient's health priorities. Results Categories of challenges discussed among participants included uncertainty, complexity, and multiplicity of problems and treatments; difficulty switching to patients' priorities as the focus of decision-making; and differing perspectives between patients and clinicians, and among clinicians. Strategies identified to support patient priorities-aligned decision-making included starting with one thing that matters most to each patient; conducting serial trials of starting, stopping, or continuing interventions; focusing on function (i. e. achieving patient's desired activities) rather than eliminating symptoms; basing communications, decision-making, and effectiveness on patients' priorities not solely on diseases; and negotiating shared decisions when there are differences in perspectives. Conclusions The discrete set of challenges encountered and the implementable strategies identified suggest that patient priorities-aligned decision-making in the care of patients with multiple chronic conditions is feasible, albeit complicated. Findings require replication in additional settings and determination of their effect on patient outcomes.	[Tinetti, Mary; Costello, Darce; Ouellet, Gregory; Geda, Mary] Yale Sch Med, Dept Med, New Haven, CT 06510 USA; [Tinetti, Mary] Yale Sch Publ Hlth, Dept Chron Dis Epidemiol, New Haven, CT 06510 USA; [Dindo, Lilian; Naik, Aanand] Michael E DeBakey VA Med Ctr, Houston Ctr Innovat Qual Effectiveness & Safety, Houston, TX USA; [Dindo, Lilian; Naik, Aanand] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA; [Smith, Cynthia Daisy] Amer Coll Physicians, Philadelphia, PA USA; [Smith, Cynthia Daisy] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Blaum, Caroline] NYU, Sch Med, Dept Internal Med, New York, NY USA; [Rosen, Jonathan; Hernandez-Bigos, Kizzy] Connecticut Ctr Primary Care, Hartford, CT USA; [Naik, Aanand] Baylor Coll Med, Alkek Dept Med, Houston, TX 77030 USA	Yale University; Yale University; Baylor College of Medicine; Baylor College of Medicine; American College of Physicians; University of Pennsylvania; Pennsylvania Medicine; New York University; Baylor College of Medicine	Tinetti, M (corresponding author), Yale Sch Med, Dept Med, New Haven, CT 06510 USA.; Tinetti, M (corresponding author), Yale Sch Publ Hlth, Dept Chron Dis Epidemiol, New Haven, CT 06510 USA.	mary.tinetti@yale.edu		Naik, Aanand/0000-0001-6936-7984; Tinetti, Mary/0000-0003-0940-9702	John A. Hartford Foundation; Patient Centered Outcomes Research Institute [2870]; Gordon and Betty Moore Foundation; Claude D. Pepper Older Americans Independence Center at Yale University School of Medicine [P30AG021342 NIH/NIA]; Houston VA Health Services Research and Development Center for Innovations in Quality, Effectiveness, and Safety [CIN 13-413]; Robert Wood Johnson Foundation; NATIONAL INSTITUTE ON AGING [P30AG021342] Funding Source: NIH RePORTER	John A. Hartford Foundation; Patient Centered Outcomes Research Institute(Patient-Centered Outcomes Research Institute - PCORI); Gordon and Betty Moore Foundation(Gordon and Betty Moore Foundation); Claude D. Pepper Older Americans Independence Center at Yale University School of Medicine; Houston VA Health Services Research and Development Center for Innovations in Quality, Effectiveness, and Safety; Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by The John A. Hartford Foundation -https://www.johnahartford.org/ - MT, CB; Patient Centered Outcomes Research Institute (2870) - https://www.pcori.org/ - CB; The Gordon and Betty Moore Foundation https://www.moore.org/ - MT, CB; The Robert Wood Johnson Foundation - https://www.rwjf.org/ - MT, CB; Claude D. Pepper Older Americans Independence Center at Yale University School of Medicine (#P30AG021342 NIH/NIA) - https://www.nia.nih.gov/ - MT, DC, MG; Houston VA Health Services Research and Development Center for Innovations in Quality, Effectiveness, and Safety (CIN 13-413) - https://www.houston.hsrd.research.va.gov/ - AN, LD. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Austin CA, 2015, JAMA INTERN MED, V175, P1213, DOI 10.1001/jamainternmed.2015.1679; Bayliss EA, 2014, ANN FAM MED, V12, P260, DOI 10.1370/afm.1643; Bayliss EA, 2012, ANN FAM MED, V10, P3, DOI 10.1370/afm.1352; Bernacki RE, 2014, JAMA INTERN MED, V174, P1994, DOI 10.1001/jamainternmed.2014.5271; Blaum CS, 2018, J AM GERIATR SOC, V66, P2009, DOI 10.1111/jgs.15465; Boyd CM, 2014, MED CARE, V52, pS118, DOI 10.1097/MLR.0b013e3182a977da; Brown VA, 2007, PATIENT EDUC COUNS, V69, P93, DOI 10.1016/j.pec.2007.07.006; Childers JW, 2017, J ONCOL PRACT, V13, P700, DOI 10.1200/JOP.2016.018796; Cole F L, 1988, Clin Nurse Spec, V2, P53, DOI 10.1097/00002800-198800210-00025; Coulter A, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010523.pub2; DeWitt KM, 2011, PARTICIPANT OBSERVAT; Elwyn G, 2014, PATIENT ED COUNS; Ferris R, 2018, J AGING HEALTH, V30, P778, DOI 10.1177/0898264317691166; Fram SM, 2013, QUAL REP, V18; Fraser SW, 2001, BRIT MED J, V323, P799, DOI 10.1136/bmj.323.7316.799; Fried TR, 2008, J AM GERIATR SOC, V56, P1839, DOI 10.1111/j.1532-5415.2008.01923.x; Fried TR, 2011, ARCH INTERN MED, V171, P1854, DOI 10.1001/archinternmed.2011.424; Harwood T., 2002, MARK INTELL PLAN, V20, P336, DOI [10.1108/02634500210445392, DOI 10.1108/02634500210445392]; Hess DW, 2015, J CONTIN EDUC HEALTH, V35, P71, DOI 10.1002/chp.21260; Institute of Medicine (IOM), 2001, CROSSING THE QUALITY; Limm B, 2012, J AM GERIATR SOC, V60, pS167; Lorgunpai SJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089447; Montori VM, 2013, JAMA-J AM MED ASSOC, V310, P2503, DOI 10.1001/jama.2013.281422; Naik AD, 2018, J AM GERIATR SOC, V66, P1872, DOI 10.1111/jgs.15437; Naik AD, 2016, J AM GERIATR SOC, V64, P625, DOI 10.1111/jgs.14027; O'Hare AM, 2014, JAMA INTERN MED, V174, P391, DOI 10.1001/jamainternmed.2013.13328; Pavlinich M, 2018, AM J PHYS MED REHAB, V97, P856, DOI 10.1097/PHM.0000000000001026; Rockwood K, 2000, J AM GERIATR SOC, V48, P1080, DOI 10.1111/j.1532-5415.2000.tb04783.x; Schreijenberg M, 2019, EXPERT REV CLIN PHAR, V12, P145, DOI 10.1080/17512433.2019.1565992; Soubhi H, 2010, ANN FAM MED, V8, P170, DOI 10.1370/afm.1056; Sudore RL, 2014, J PAIN SYMPTOM MANAG, V47, P674, DOI 10.1016/j.jpainsymman.2013.05.023; Tinetti ME, 2016, JAMA CARDIOL, V1, P9, DOI 10.1001/jamacardio.2015.0248; Tinetti ME, 2016, CLIN GERIATR MED, V32, P261, DOI 10.1016/j.cger.2016.01.012; Tinetti ME, 2012, JAMA-J AM MED ASSOC, V307, P2493, DOI 10.1001/jama.2012.5265; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Toto PE, 2015, ARCH GERONTOL GERIAT, V60, P16, DOI 10.1016/j.archger.2014.10.022; Uhlig K, 2014, J GEN INTERN MED, V29, P670, DOI 10.1007/s11606-013-2659-y; Tran VT, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-109; Wenger E., 2002, CULTIVATING COMMUNIT; Zulman DM, 2011, J GEN INTERN MED, V26, P783, DOI 10.1007/s11606-010-1629-x	40	27	27	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2019	14	6							e0218249	10.1371/journal.pone.0218249	http://dx.doi.org/10.1371/journal.pone.0218249			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IC3IS	31181117	Green Published, gold, Green Submitted			2023-01-03	WOS:000470854200056
J	Baugh, CW; Faridi, MK; Mueller, EL; Camargo, CA; Pallin, DJ				Baugh, Christopher W.; Faridi, Mohammad Kamal; Mueller, Emily L.; Camargo, Carlos A., Jr.; Pallin, Daniel J.			Near-universal hospitalization of US emergency department patients with cancer and febrile neutropenia	PLOS ONE			English	Article							MANAGEMENT; GUIDELINE; SOCIETY; CARE	Importance Febrile neutropenia (FN) is the most common oncologic emergency and is among the most deadly. Guidelines recommend risk stratification and outpatient management of both pediatric and adult FN patients deemed to be at low risk of complications or mortality, but our prior single-center research demonstrated that the vast majority (95%) are hospitalized. Objective From a nationwide perspective, to determine the proportion of cancer patients of all ages hospitalized after an emergency department (ED) visit for FN, and to analyze variability in hospitalization rates. Our a priori hypothesis was that >90% of US cancer-associated ED FN visits would end in hospitalization. Design Analysis of data from the Nationwide Emergency Department Sample, 2006-2014. Setting Stratified probability sample of all US ED visits. Participants Inclusion criteria were: (1) Clinical Classification Software code indicating cancer, (2) diagnostic code indicating fever, and (3) diagnostic code indicating neutropenia. We excluded visits ending in transfer. Exposure The hospital at which the visit took place. Main outcomes and measures Our main outcome is the proportion of ED FN visits ending in hospitalization, with an a priori hypothesis of >90%. Our secondary outcomes are: ( a) hospitalization rates among subsets, and ( b) proportion of variability in the hospitalization rate attributable to which hospital the patient visited, as measured by the intra-class correlation coefficient ( ICC). Results Of 348,868 visits selected to be representative of all US ED visits, 94% ended in hospitalization ( 95% Confidence Interval [CI] 93-94%). Each additional decade of age conferred 1.23x increased odds of hospitalization. Those with private ( 92%), self-pay ( 92%), and other ( 93%) insurance were less likely to be hospitalized than those with public insurance ( 95%, odds ratios [OR] 0.74-0.76). Hospitalization was least likely at non-metropolitan hospitals ( 84%, OR 0.15 relative to metropolitan teaching hospitals), and was also less likely at metropolitan non-teaching hospitals ( 94%, OR 0.64 relative to metropolitan teaching hospitals). The ICC adjusted for hospital random effects and patient and hospital characteristics was 26% ( 95% CI 23-29%), indicating that 26% of the variability in hospitalization rate was attributable to which hospital the patient visited. Conclusions and relevance Nearly all cancer-associated ED FN visits in the US end in hospitalization. Inter-hospital variation in hospitalization practices explains 26% of the limited variability in hospitalization decisions. Simple, objective tools are needed to improve risk stratification for ED FN patients.	[Baugh, Christopher W.; Pallin, Daniel J.] Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA; [Baugh, Christopher W.; Camargo, Carlos A., Jr.; Pallin, Daniel J.] Harvard Med Sch, Boston, MA 02115 USA; [Faridi, Mohammad Kamal; Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Mueller, Emily L.] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Indiana University System; Indiana University Bloomington	Baugh, CW (corresponding author), Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA.; Baugh, CW (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	cbaugh@bwh.harvard.edu	Baugh, Christopher William/AAJ-3688-2021; Camargo, Carlos A./C-2145-2008	Baugh, Christopher William/0000-0002-2360-1891; Camargo, Carlos A./0000-0002-5071-7654				Baugh CW, 2017, ACAD EMERG MED, V24, P83, DOI 10.1111/acem.13079; Baugh CWBG, 2016, NEW ENGL REG SAEM M; Baughmd CW, 2016, AM J EMERG MED, V34, P1704, DOI 10.1016/j.ajem.2016.05.047; Bitar Roger A, 2015, Perm J, V19, P37, DOI 10.7812/TPP/14-188; Brown J, 2016, ANN EMERG MED, V68, P706, DOI 10.1016/j.annemergmed.2016.01.021; Del Greco Maurizio, 2003, Ital Heart J, V4, P99; Flowers CR, 2013, J CLIN ONCOL, V31, P794, DOI 10.1200/JCO.2012.45.8661; Freifeld AG, 2011, CLIN INFECT DIS, V52, pE56, DOI 10.1093/cid/cir073; Greene J, 2015, ANN EMERG MED, V66, p13A, DOI 10.1016/j.annemergmed.2015.05.015; Klastersky J, 2000, J CLIN ONCOL, V18, P3038, DOI 10.1200/JCO.2000.18.16.3038; Lehrnbecher T, 2017, J CLIN ONCOL, V35, P2082, DOI 10.1200/JCO.2016.71.7017; Mueller EL, 2015, PEDIATR BLOOD CANCER, V62, P490, DOI 10.1002/pbc.25288; Rivera DR, 2017, JAMA ONCOL, V3, DOI 10.1001/jamaoncol.2017.2450; Weycker D, 2014, J ONCOL PHARM PRACT, V20, P190, DOI 10.1177/1078155213492450	14	9	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2019	14	5							e0216835	10.1371/journal.pone.0216835	http://dx.doi.org/10.1371/journal.pone.0216835			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ3VE	31120893	Green Published, gold			2023-01-03	WOS:000468775700031
J	Watts, G				Watts, Geoff			Mike Grocott: climbing high in critical care medicine	LANCET			English	Biographical-Item																			0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 11	2019	393	10184					1927	1927		10.1016/S0140-6736(19)30996-1	http://dx.doi.org/10.1016/S0140-6736(19)30996-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX9AE	31084955				2023-01-03	WOS:000467698100011
J	Henrikson, NB; Banegas, MP; Tuzzio, L; Lim, C; Schneider, JL; Walsh-Bailey, C; Scrol, A; Hodge, SM				Henrikson, Nora B.; Banegas, Matthew P.; Tuzzio, Leah; Lim, Catherine; Schneider, Jennifer L.; Walsh-Bailey, Callie; Scrol, Aaron; Hodge, Stephanie M.			Workflow Requirements for Cost-of-Care Conversations in Outpatient Settings Providing Oncology or Primary Care A Qualitative, Human-Centered Design Study	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL ONCOLOGY; AMERICAN SOCIETY; PROSTATE-CANCER; ECONOMIC BURDEN; PATIENT; HEALTH; SURVIVORS; ATTITUDES; COMMUNICATION; DISCUSSIONS	Background: Patients prefer to discuss costs in the clinical setting, but physicians and teams may be unprepared to incorporate cost discussions into existing workflows. Objective: To understand and improve clinical workflows related to cost-of-care conversations. Design: Qualitative human-centered design study. Setting: 2 integrated health systems in the U.S. Pacific Northwest: a system-wide oncology service line and a system-wide primary care service line. Participants: Clinicians, clinical team members, operations staff, and patients. Measurements: Ethnographic observations were made at the integrated health systems, assessing barriers to and facilitators of discussing costs with patients. Three unique patient experiences of having financial concerns addressed in the clinic were designed. These experiences were refined after in-person interviews with patients (n = 20). Data were synthesized into a set of clinical workflow requirements. Results: Most patient cost concerns take 1 of 3 pathways: informing clinical care decision making, planning and budgeting concerns, and addressing immediate financial hardship. Work-flow requirements include organizational recognition of the need for clinic-based cost-of-care conversations; access to cost and health plan benefit data to support each conversation pathway; clear team member roles and responsibilities for addressing cost-of-care concerns; a patient experience where cost questions are normal and each patient's preferences and privacy are respected; patients know who to go to with cost questions; patients' concerns are documented to minimize repetition to multiple team members; and patients learn their expected out-of-pocket costs before treatment begins. Limitation: Results may have limited generalizability to other health care settings, and the study did not test the effectiveness of the workflows developed. Conclusion: Clinic-based workflows for cost-of-care conversations that optimize patients' care experience require organizational commitment to addressing cost concerns, clear roles and responsibilities, appropriate and complete data access, and a team-based approach. Primary Funding Source: Robert Wood Johnson Foundation.	[Henrikson, Nora B.; Tuzzio, Leah; Lim, Catherine; Walsh-Bailey, Callie; Scrol, Aaron] Kaiser Permanente, Washington Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA; [Banegas, Matthew P.; Schneider, Jennifer L.; Hodge, Stephanie M.] Kaiser Permanente Northwest, Ctr Hlth Res, 3800 North Interstate Ave, Portland, OR 97227 USA	Kaiser Permanente; Kaiser Permanente	Henrikson, NB (corresponding author), Kaiser Permanente, Washington Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.	nora.b.henrikson@kp.org			Robert Wood Johnson Foundation [74123]	Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF))	By the Robert Wood Johnson Foundation (grant 74123).	American Soc Clinical Oncology, 2018, J ONCOL PRACT, V14, P187, DOI 10.1200/JOP.2017.027359; Balch A., 2018, J CLIN PATHW, V4, P32, DOI [10.25270/jcp.2018.08.00031, DOI 10.25270/JCP.2018.08.00031]; Banegas Matthew P, 2019, Perm J, V23, DOI 10.7812/TPP/18-084; Banegas MP, 2018, J CANCER SURVIV, V12, P28, DOI 10.1007/s11764-017-0640-1; Basch E, 2014, J CLIN ONCOL, V32, P3436, DOI 10.1200/JCO.2013.54.8404; Bestvina CM, 2014, J ONCOL PRACT, V10, P162, DOI 10.1200/JOP.2014.001406; Braveman P, 2014, PUBLIC HEALTH REP, V129, P19, DOI 10.1177/00333549141291S206; Brooks J, 2015, QUAL RES PSYCHOL, V12, P202, DOI 10.1080/14780887.2014.955224; Bullock AJ, 2012, J ONCOL PRACT, V8, pE50, DOI 10.1200/JOP.2011.000418; Claxton G, 2017, PETERSON KAISER HLTH; Cuckler GA, 2018, HEALTH AFFAIR, V37, P482, DOI 10.1377/hlthaff.2017.1655; DiJulio B., 2017, DATA NOTE AM CHALLEN; Doty MM, 2006, SQUEEZED WHY RISING; Ekberg K, 2017, INT J AUDIOL, V56, P854, DOI 10.1080/14992027.2017.1339128; Epstein RM, 2007, PATIENT CTR COMMUNIC; Fenn KM, 2014, J ONCOL PRACT, V10, P332, DOI 10.1200/JOP.2013.001322; Financial Toxicity and Cancer Treatment (PDQ ), 2018, FIN TOX CANC TREATM; Goldman AW, 2014, EVAL PROGRAM PLANN, V47, P9, DOI 10.1016/j.evalprogplan.2014.06.005; Guest G., 2012, APPL THEMATIC ANAL, DOI [10.4135/9781483384436, DOI 10.4135/9781483384436]; Guy GP, 2017, J CLIN ONCOL, V35, P2053, DOI 10.1200/JCO.2016.71.9716; Hardee JT, 2005, J GEN INTERN MED, V20, P666, DOI 10.1111/j.1525-1497.2005.0125.x; Henrikson NB, 2017, PERM J, V21, DOI [10.7812/TPP/16-070, DOI 10.7812/TPP/16-070]; Henrikson NB, 2016, J ONCOL PRACT, V12, P44, DOI 10.1200/JOP.2015.006171; Henrikson NB, 2014, SUPPORT CARE CANCER, V22, P961, DOI 10.1007/s00520-013-2050-x; Hunter WG, 2017, J ONCOL PRACT, V13, P757, DOI 10.1200/JOP.2017.022855; Institute of Medicine, 2014, ENS PAT ACC AFF CANC; International Organization for Standardization, 2010, HUM CTR DES EV METH; International Organization for Standardization, 2010, ERGONOMICS HUMAN SYS; Irwin B, 2014, ONCOLOGIST, V19, P1135, DOI 10.1634/theoncologist.2014-0117; Kochovska S, 2018, PALLIAT SUPPORT CARE, V16, P347, DOI 10.1017/S1478951517000979; Lathan CS, 2016, J CLIN ONCOL, V34, P1732, DOI 10.1200/JCO.2015.63.2232; Lin JT, 2016, FINANCIAL CAPABILITY, P1; Lincoln, 2018, SAGE HDB QUALITATIVE, DOI DOI 10.4135/9781849208550.N1; Marti J, 2016, PSYCHO-ONCOLOGY, V25, P77, DOI 10.1002/pon.3877; May Jessica H, 2004, Issue Brief Cent Stud Health Syst Change, P1; Meisenberg BR, 2015, ONCOLOGIST, V20, P1199, DOI 10.1634/theoncologist.2015-0168; Meropol NJ, 2009, J CLIN ONCOL, V27, P3868, DOI 10.1200/JCO.2009.23.1183; Harvard T. H., 2016, PUBL OP POLL SER, P1; Palinkas LA, 2015, ADM POLICY MENT HLTH, V42, P533, DOI 10.1007/s10488-013-0528-y; Peppercorn J, 2017, ONCOLOGIST, V22, P123, DOI 10.1634/theoncologist.2016-0301; Perecman E., 2006, HDB SOCIAL SCI FIELD; Rizzo JA, 2016, J OCCUP ENVIRON MED, V58, P351, DOI 10.1097/JOM.0000000000000621; Shankaran V, 2018, J ONCOL PRACT, V14, pE122, DOI 10.1200/JOP.2017.024927; Shigeoka H, 2014, AM ECON REV, V104, P2152, DOI 10.1257/aer.104.7.2152; Ubel PA, 2013, NEW ENGL J MED, V369, P1484, DOI 10.1056/NEJMp1306826; Winfield L, 2018, SOCIAL DETERMINANTS; Zafar SY, 2015, AM J MANAG CARE, V21, P607	47	14	15	4	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 7	2019	170	9		S			S70	U57		10.7326/M18-2227	http://dx.doi.org/10.7326/M18-2227			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IB1GA	31060061				2023-01-03	WOS:000470011700007
J	Gardiner, KM; Singleton, JA; Sheridan, J; Kyle, GJ; Nissen, LM				Gardiner, Kyle M.; Singleton, Judith A.; Sheridan, Janie; Kyle, Gregory J.; Nissen, Lisa M.			Health professional beliefs, knowledge, and concerns surrounding medicinal cannabis - A systematic review	PLOS ONE			English	Review							MEDICAL CANNABIS; MARIJUANA; ATTITUDES; PHARMACISTS; EXPERIENCE; PROVIDERS	Background The number of jurisdictions allowing access to medicinal cannabis has been steadily increasing since the state of California introduced legislation in 1996. Although there is a high degree of legislative heterogeneity across jurisdictions, the involvement of a health professional is common among all. This places health professionals at the forefront of therapy, yet no systematic review of literature has offered insight into the beliefs, knowledge, and concerns of health professionals regarding medicinal cannabis. Methods Using a predetermined study protocol, PubMed, EMBASE, PsycINFO, CINAHL, and Scopus databases were searched for studies indexed up to the 1st August 2018. Pre-defined inclusion and exclusion criteria were applied uniformly. Screening for relevancy, full-text review, data extraction, and risk of bias were completed by two independent investigators. Risk of bias was assessed using CASP criteria (qualitative) and a modified domain-based risk assessment tool (quantitative). Results Of the 15,775 studies retrieved, 106 underwent full-text review and of these, 26 were included. The overall risk of bias was considered low across all included studies. The general impression was that health professionals supported the use of medicinal cannabis in practice; however, there was a unanimous lack of self-perceived knowledge surrounding all aspects of medicinal cannabis. Health professionals also voiced concern regarding direct patient harms and indirect societal harms. Conclusion This systematic review has offered a lens through which to view the existing literature surrounding the beliefs, knowledge, and concerns of health professionals regarding medicinal cannabis. These results are limited, however, by the implicit common-sense models of behaviour utilised by the included studies. Before strategies can be developed and implemented to change health professional behaviour, a more thorough understanding of the factors that underpin the delivery of medicinal cannabis is necessary.	[Gardiner, Kyle M.; Singleton, Judith A.; Kyle, Gregory J.; Nissen, Lisa M.] Queensland Univ Technol, Sch Clin Sci, Discipline Pharm, Brisbane, Qld, Australia; [Sheridan, Janie] Univ Auckland, Fac Med & Hlth Sci, Sch Pharm, Auckland, New Zealand	Queensland University of Technology (QUT); University of Auckland	Gardiner, KM (corresponding author), Queensland Univ Technol, Sch Clin Sci, Discipline Pharm, Brisbane, Qld, Australia.	kyle.gardiner@qut.edu.au	Singleton, Judith Ann/AAC-8225-2022; Nissen, Lisa/N-9476-2019; Kyle, Greg/C-1320-2008	Singleton, Judith Ann/0000-0002-7715-6391; Nissen, Lisa/0000-0001-5826-4605; Kyle, Greg/0000-0003-4943-2077				Ablin JN, 2016, RAMBAM MAIMONIDES ME, V7, DOI 10.5041/RMMJ.10239; Ananth P, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-0559; [Anonymous], 2007, BMJ-BRIT MED J, V335, DOI [10.1136/bmj.39386.490150.94, DOI 10.1136/BMJ.39386.490150.94]; Atkins L, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0605-9; Balneaves LG, 2018, CANNABIS CANNABINOID, V3, P66, DOI 10.1089/can.2018.0002; Barnes M, 2016, CANNABIS EVIDENCE ME; Bega D, 2017, MOV DISORD CLIN PRAC, V4, P90, DOI 10.1002/mdc3.12359; Belackova V., 2015, MED CANNABIS AUSTR F; Braun IM, 2017, PSYCHO-ONCOLOGY, V26, P1087, DOI 10.1002/pon.4365; Braun IM, 2018, J CLIN ONCOL, V36, P1957, DOI 10.1200/JCO.2017.76.1221; Carlini BH, 2017, AM J HOSP PALLIAT ME, V34, P85, DOI 10.1177/1049909115604669; Chapman SA, 2016, SUBST USE MISUSE, V51, P1174, DOI 10.3109/10826084.2016.1160932; Charuvastra A, 2005, J ADDICT DIS, V24, P87, DOI 10.1300/J069v24n03_07; Crane NA, 2013, NEUROPSYCHOL REV, V23, P117, DOI 10.1007/s11065-012-9222-1; Crowley D, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-016-0129-7; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DOBLIN RE, 1991, J CLIN ONCOL, V9, P1314, DOI 10.1200/JCO.1991.9.7.1314; Draugalis JR, 2008, AM J PHARM EDUC, V72, DOI 10.5688/aj720111; Ebert T, 2015, ISR MED ASSOC J, V17, P437; Fitzcharles MA, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-258; Hazekamp A, 2013, J PSYCHOACTIVE DRUGS, V45, P199, DOI 10.1080/02791072.2013.805976; Hwang Joy, 2016, P T, V41, P716; Irvine G, 2006, J LAW MED, V14, P135; Isaac S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155113; Karanges EA, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022101; Kondrad E, 2013, J AM BOARD FAM MED, V26, P52, DOI 10.3122/jabfm.2013.01.120089; LI HL, 1974, ECON BOT, V28, P437; LITTLE PJ, 1988, J PHARMACOL EXP THER, V247, P1046; Luba R, 2018, J PSYCHOACTIVE DRUGS, V50, P411, DOI 10.1080/02791072.2018.1511877; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-10; Michie S, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-40; Mitchell F, 2016, CAN J HOSP PHARM, V69, P122; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Nutt D, 2007, LANCET, V369, P1047, DOI 10.1016/S0140-6736(07)60464-4; Robinson V, 1912, AM J PSYCHIAT, V70, P276, DOI [10.1176/ajp.70.1.276, DOI 10.1176/AJP.70.1.276]; Schwartz RH, 1997, SOUTH MED J, V90, P167, DOI 10.1097/00007611-199702000-00001; Schwartz Richard H., 1994, Journal of Addictive Diseases, V13, P53; Sideris A, 2018, CANNABIS CANNABINOID, V3, P74, DOI 10.1089/can.2017.0046; Uritsky TJ, 2011, J PALLIAT MED, V14, P1291, DOI 10.1089/jpm.2011.0113; van Hout MC, 2016, INT J MENT HEALTH AD, P1, DOI [10.1007/s11469-016-9710-2, DOI 10.1007/S11469-016-9710-2]; Whiting PF, 2015, JAMA-J AM MED ASSOC, V313, P2456, DOI 10.1001/jama.2015.6358; Ziemianski D, 2015, BMC MED EDUC, V15, DOI 10.1186/s12909-015-0335-0; Zolotov Y, 2018, INT J DRUG POLICY, V57, P4, DOI 10.1016/j.drugpo.2018.03.025; 1990, NEUROPHARMACOLOGY, V29, P161; 2006, REV BRAS PSIQUIATR, V28, P153; 2013, NEUROPSYCHOL REV, V23, P117, DOI DOI 10.1007/S11065-012-9222-1	47	55	55	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2019	14	5							e0216556	10.1371/journal.pone.0216556	http://dx.doi.org/10.1371/journal.pone.0216556			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HW7RE	31059531	Green Published, gold			2023-01-03	WOS:000466886300050
J	Choi, SR; Lee, YK; Cho, AJ; Park, HC; Han, CH; Choi, MJ; Koo, JR; Yoon, JW; Noh, JW				Choi, Sun Ryoung; Lee, Young-Ki; Cho, A. Jin; Park, Hayne Cho; Han, Chae Hoon; Choi, Myung-Jin; Koo, Ja-Ryong; Yoon, Jong-Woo; Noh, Jung Woo			Malnutrition, inflammation, progression of vascular calcification and survival: Inter-relationships in hemodialysis patients	PLOS ONE			English	Article							CORONARY-ARTERY CALCIFICATION; C-REACTIVE PROTEIN; BODY-MASS INDEX; CARDIOVASCULAR-DISEASE; DIALYSIS PATIENTS; SERUM-ALBUMIN; MORTALITY; OBESITY; RISK; INTERLEUKIN-6	Background and aims Malnutrition and inflammation are closely linked to vascular calcification (VC), the severity of which correlate with adverse outcome. However, there were few studies on the interplay between malnutrition, inflammation and VC progression, rather than VC presence per se. We aimed to determine the relationship of malnutrition, inflammation, abdominal aortic calcification (AAC) progression with survival in hemodialysis (HD) patients. Methods Malnutrition and inflammation were defined as low serum albumin (<40 g/L) and high hs-CRP (>= 28.57 nmol/L), respectively. We defined AAC progression as an increase in AAC score using lateral lumbar radiography at both baseline and one year later. Patients were followed up to investigate the impact of AAC progression on all-cause and cardiovascular mortality. Results AAC progressed in 54.6% of 97 patients (mean age 58.2 +/- 11.7 years, 41.2% men) at 1-year follow-up. Hypoalbuminemia (Odds ratio 3.296; 95% confidence interval 1.178-9.222), hsCRP (1.561; 1.038-2.348), low LDL-cholesterol (0.976; 0.955-0.996), and the presence of baseline AAC (10.136; 3.173-32.386) were significant risk factors for AAC progression. During the mean follow-up period of 5.9 years, 38(39.2%) patients died and 27(71.0%) of them died of cardiovascular disease. Multivariate Cox regression analysis adjusted for old age, diabetes, cardiovascular history, and hypoalbuminemia determined that AAC progression was an independent predictor of all-cause mortality (2.294; 1.054-4.994). Conclusions Malnutrition and inflammation were significantly associated with AAC progression. AAC progression is more informative than AAC presence at a given time-point as a predictor of all-cause mortality in patients on maintenance HD.	[Choi, Sun Ryoung; Koo, Ja-Ryong] Hallym Univ, Dongtan Sacred Heart Hosp, Dept Internal Med, Dongtan, South Korea; [Lee, Young-Ki; Cho, A. Jin; Park, Hayne Cho; Han, Chae Hoon; Noh, Jung Woo] Hallym Univ, Kangnam Sacred Heart Hosp, Dept Internal Med, Seoul, South Korea; [Choi, Myung-Jin; Yoon, Jong-Woo] Hallym Univ, Chuncheon Sacred Heart Hosp, Dept Internal Med, Chunchon, South Korea	Hallym University; Hallym University; Hallym University	Lee, YK (corresponding author), Hallym Univ, Kangnam Sacred Heart Hosp, Dept Internal Med, Seoul, South Korea.	km2071@hallym.or.kr	SR, Choi/GRJ-6326-2022; choi, sun ryoung/AGZ-1893-2022	choi, sun ryoung/0000-0002-9668-3349; Lee, Young-Ki/0000-0003-3464-6144; CHOI, MYUNG JIN/0000-0002-2761-7161				Abdelmalek JA, 2012, AM J KIDNEY DIS, V60, P990, DOI 10.1053/j.ajkd.2012.06.018; Block GA, 2005, KIDNEY INT, V68, P1815, DOI 10.1111/j.1523-1755.2005.00600.x; Chen HY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158789; Chiou TTY, 2016, INT J MED SCI, V13, P92, DOI 10.7150/ijms.13785; Cho A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185846; Choi MJ, 2012, NEPHRON CLIN PRACT, V122, P44, DOI 10.1159/000348509; Dai L, 2017, CONTRIB NEPHROL, V191, P32, DOI 10.1159/000479254; Daugirdas JT, 2009, AM J KIDNEY DIS, V54, P798, DOI 10.1053/j.ajkd.2009.06.033; Delgado C, 2017, AM J KIDNEY DIS, V70, P817, DOI 10.1053/j.ajkd.2017.06.028; Desjardins MP, 2018, J AM SOC HYPERTENS, V12, P5, DOI 10.1016/j.jash.2017.09.013; Disthabanchong Sinee, 2017, World J Nephrol, V6, P100, DOI 10.5527/wjn.v6.i3.100; Gross ML, 2007, CLIN J AM SOC NEPHRO, V2, P121, DOI 10.2215/CJN.01760506; Hamano T, 2018, SEMIN DIALYSIS, V31, P592, DOI 10.1111/sdi.12729; Henaut L, 2018, TOXINS, V10, DOI 10.3390/toxins10060218; Henaut L, 2018, SEMIN NEPHROL, V38, P233, DOI 10.1016/j.semnephrol.2018.02.004; Henaut L, 2016, EXPERT OPIN THER TAR, V20, P89, DOI 10.1517/14728222.2015.1081685; Honda H, 2006, AM J KIDNEY DIS, V47, P139, DOI 10.1053/j.ajkd.2005.09.014; Honkanen E, 2008, NEPHROL DIAL TRANSPL, V23, P4009, DOI 10.1093/ndt/gfn403; Hwang JH, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882-015-0108-3; Ishimura E, 2004, SEMIN NEPHROL, V24, P408, DOI 10.1016/j.semnephrol.2004.06.008; Jean G, 2015, NEPHRON, V130, P169, DOI 10.1159/000431288; Kaysen GA, 2001, KIDNEY INT, V60, P333, DOI 10.1046/j.1523-1755.2001.00804.x; Kaysen GA, 2009, CLIN J AM SOC NEPHRO, V4, pS56, DOI 10.2215/CJN.03090509; Kidney Dis Improving Global, 2017, KIDNEY INT SUPPL, V7, P1, DOI 10.1016/j.kisu.2017.04.001; Kim SJ, 2017, INT J CARDIOL, V243, P431, DOI 10.1016/j.ijcard.2017.05.008; Lee MS, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0035710, 10.1371/journal.pone.0040370]; Liu YM, 2004, JAMA-J AM MED ASSOC, V291, P451, DOI 10.1001/jama.291.4.451; Makki Kassem, 2013, ISRN Inflamm, V2013, P139239, DOI 10.1155/2013/139239; Moriyama Y, 2011, ASIA PAC J CLIN NUTR, V20, P109; Okamoto T, 2018, INT UROL NEPHROL, V50, P1713, DOI 10.1007/s11255-018-1957-z; Okamoto T, 2018, BMC NEPHROL, V19, DOI 10.1186/s12882-018-0872-y; Palmer SC, 2016, AM J KIDNEY DIS, V68, P691, DOI 10.1053/j.ajkd.2016.05.015; Shin DH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185296; Sigrist MK, 2007, CLIN J AM SOC NEPHRO, V2, P1241, DOI 10.2215/CJN.02190507; Stenvinkel P, 2005, KIDNEY INT, V67, P1216, DOI 10.1111/j.1523-1755.2005.00200.x; Sueta D, 2017, INT J CARDIOL, V230, P97, DOI 10.1016/j.ijcard.2016.12.072; Tentori F, 2007, J AM SOC NEPHROL, V18, P2377, DOI 10.1681/ASN.2006111250; Vashistha T, 2014, AM J KIDNEY DIS, V63, P612, DOI 10.1053/j.ajkd.2013.07.021; Yin TT, 2000, CIRCULATION, V102, P2636, DOI 10.1161/01.cir.102.21.2636; Zhang K, 2016, AM J PHYSIOL-RENAL, V311, pF663, DOI 10.1152/ajprenal.00189.2016; Zheng H, 2013, AM J EPIDEMIOL, V178, P1591, DOI 10.1093/aje/kwt179; 2004, CIRCULATION, V109, P1955, DOI DOI 10.1161/01.CIR.0000125690.80303.A8; 1997, ATHEROSCLEROSIS, V132, P245; 2018, DIABETES METAB SYND, V12, P91, DOI DOI 10.1016/J.DSX.2017.09.003; 2008, KIDNEY BLOOD PRESS R, V31, P10, DOI DOI 10.1159/000112542; 2014, CURRENT MED CHEM, V21, P2910; 2011, NEPHROL DIAL TRANSPL, V26, P1662, DOI DOI 10.1093/NDT/GFQ582	47	37	42	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2019	14	5							e0216415	10.1371/journal.pone.0216415	http://dx.doi.org/10.1371/journal.pone.0216415			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW2JY	31048884	gold, Green Submitted, Green Published			2023-01-03	WOS:000466511200084
J	Zappasodi, R; Sirard, C; Li, YY; Budhu, S; Abu-Akeel, M; Liu, CL; Yang, X; Zhong, H; Newman, W; Qi, JJ; Wong, P; Schaer, D; Koon, H; Velcheti, V; Hellmann, MD; Postow, MA; Callahan, MK; Wolchok, JD; Merghoub, T				Zappasodi, Roberta; Sirard, Cynthia; Li, Yanyun; Budhu, Sadna; Abu-Akeel, Mohsen; Liu, Cailian; Yang, Xia; Zhong, Hong; Newman, Walter; Qi, Jingjing; Wong, Phillip; Schaer, David; Koon, Henry; Velcheti, Vamsidhar; Hellmann, Matthew D.; Postow, Michael A.; Callahan, Margaret K.; Wolchok, Jedd D.; Merghoub, Taha			Rational design of anti-GITR-based combination immunotherapy	NATURE MEDICINE			English	Article							CD8(+) T-CELLS; COMBINED NIVOLUMAB; SOLID TUMORS; OPEN-LABEL; MODULATION; IPILIMUMAB; MELANOMA; COSTIMULATION; STIMULATION; MECHANISMS	Modulating T cell homeostatic mechanisms with checkpoint blockade can efficiently promote endogenous anti-tumor T cell responses(1-11). However, many patients still do not benefit from checkpoint blockade(12), highlighting the need for targeting of alternative immune pathways(13). Glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) is an attractive target for immunotherapy, owing to its capacity to promote effector T cell (T-eff) functions(14,15) and hamper regulatory T cell (T-reg) suppression(16-20). On the basis of the potent preclinical anti-tumor activity of agonist anti-GITR antibodies, reported by us and others(16,21,22), we initiated the first in-human phase 1 trial of GITR agonism with the anti-GITR antibody TRX518 (NCT01239134). Here, we report the safety profile and immune effects of TRX518 monotherapy in patients with advanced cancer and provide mechanistic preclinical evidence to rationally combine GITR agonism with checkpoint blockade in future clinical trials. We demonstrate that TRX518 reduces circulating and intratumoral T-reg cells to similar extents, providing an easily assessable biomarker of anti-GITR activity. Despite T-reg reductions and increased T-eff: T-reg ratios, substantial clinical responses were not seen. Similarly, in mice with advanced tumors, GITR agonism was not sufficient to activate cytolytic T cells due to persistent exhaustion. We demonstrate that T cell reinvigoration with PD-1 blockade can overcome resistance of advanced tumors to anti-GITR monotherapy. These findings led us to start investigating TRX518 with PD-1 pathway blockade in patients with advanced refractory tumors (NCT02628574).	[Zappasodi, Roberta; Li, Yanyun; Budhu, Sadna; Abu-Akeel, Mohsen; Liu, Cailian; Yang, Xia; Zhong, Hong; Schaer, David; Wolchok, Jedd D.; Merghoub, Taha] Mem Sloan Kettering Canc Ctr, Ludwig Collaborat & Swim Amer Lab, 1275 York Ave, New York, NY 10021 USA; [Zappasodi, Roberta; Li, Yanyun; Qi, Jingjing; Wong, Phillip; Hellmann, Matthew D.; Callahan, Margaret K.; Wolchok, Jedd D.; Merghoub, Taha] Mem Sloan Kettering Canc Ctr, Parker Inst Canc Immunotherapy, 1275 York Ave, New York, NY 10021 USA; [Sirard, Cynthia; Newman, Walter] Leap Therapeut, Cambridge, MA USA; [Qi, Jingjing; Wong, Phillip] Mem Sloan Kettering Canc Ctr, Immune Monitoring Core Facil, 1275 York Ave, New York, NY 10021 USA; [Koon, Henry] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Velcheti, Vamsidhar] NYU, Sch Med, Dept Hematol & Oncol, New York, NY USA; [Hellmann, Matthew D.; Postow, Michael A.; Callahan, Margaret K.; Wolchok, Jedd D.; Merghoub, Taha] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA; [Hellmann, Matthew D.; Postow, Michael A.; Callahan, Margaret K.; Wolchok, Jedd D.] Weill Cornell Med Coll, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Case Western Reserve University; New York University; Memorial Sloan Kettering Cancer Center; Cornell University	Wolchok, JD; Merghoub, T (corresponding author), Mem Sloan Kettering Canc Ctr, Ludwig Collaborat & Swim Amer Lab, 1275 York Ave, New York, NY 10021 USA.; Wolchok, JD; Merghoub, T (corresponding author), Mem Sloan Kettering Canc Ctr, Parker Inst Canc Immunotherapy, 1275 York Ave, New York, NY 10021 USA.; Wolchok, JD; Merghoub, T (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.; Wolchok, JD (corresponding author), Weill Cornell Med Coll, New York, NY 10065 USA.	wolchokj@mskcc.org; merghout@mskcc.org	Qi, Jingjing/AAP-8561-2021; Merghoub, Taha/ABD-8362-2021; Qi, Jingjing/AAL-7378-2021	Qi, Jingjing/0000-0002-9368-1882; 	NIH/NCI Cancer Center Support Grant [P30 CA008748]; NIH/NCI [R01 CA056821]; Swim Across America; Ludwig Institute for Cancer Research; Ludwig Center for Cancer Immunotherapy at Memorial Sloan Kettering; Cancer Research Institute; Parker Institute for Cancer Immunotherapy; Breast Cancer Research Foundation; Parker Institute for Cancer Immunotherapy scholar award; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NIH/NCI Cancer Center Support Grant; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Swim Across America; Ludwig Institute for Cancer Research; Ludwig Center for Cancer Immunotherapy at Memorial Sloan Kettering; Cancer Research Institute; Parker Institute for Cancer Immunotherapy; Breast Cancer Research Foundation; Parker Institute for Cancer Immunotherapy scholar award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Immune Monitoring, Flow Cytometry and Molecular Cytology Core Facilities at Memorial Sloan Kettering Cancer Center for technical assistance. This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748, NIH/NCI R01 CA056821, the Swim Across America, Ludwig Institute for Cancer Research, Ludwig Center for Cancer Immunotherapy at Memorial Sloan Kettering, Cancer Research Institute, Parker Institute for Cancer Immunotherapy and Breast Cancer Research Foundation. R.Z. was supported by the Parker Institute for Cancer Immunotherapy scholar award.	Brzezianska E, 2006, MUTAT RES-FUND MOL M, V599, P26, DOI 10.1016/j.mrfmmm.2005.12.013; Budhu S, 2010, J EXP MED, V207, P223, DOI 10.1084/jem.20091279; Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405; Cohen AD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010436; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gonzalez AM, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-3643; He R, 2016, NATURE, V537, P412, DOI 10.1038/nature19317; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Hellmann MD, 2017, LANCET ONCOL, V18, P31, DOI [10.1016/S1470-2045(16)30624-6, 10.1016/s1470-2045(16)30624-6]; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Huang AC, 2017, NATURE, V545, P60, DOI 10.1038/nature22079; Im SJ, 2016, NATURE, V537, P417, DOI 10.1038/nature19330; Kanamaru F, 2004, J IMMUNOL, V172, P7306, DOI 10.4049/jimmunol.172.12.7306; Ko K, 2005, J EXP MED, V202, P885, DOI 10.1084/jem.20050940; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lin YC, 2013, INT J CANCER, V132, P1341, DOI 10.1002/ijc.27784; Mahne AE, 2017, CANCER RES, V77, P1108, DOI 10.1158/0008-5472.CAN-16-0797; Mitsui J, 2010, CLIN CANCER RES, V16, P2781, DOI 10.1158/1078-0432.CCR-09-3243; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Nishikawa H, 2008, CANCER RES, V68, P5948, DOI 10.1158/0008-5472.CAN-07-5839; Nocentini G, 2012, BRIT J PHARMACOL, V165, P2089, DOI 10.1111/j.1476-5381.2011.01753.x; Quezada SA, 2006, J CLIN INVEST, V116, P1935, DOI 10.1172/JCI27745; R Core Team, 2021, R LANG ENV STAT COMP; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Ronchetti S, 2007, J IMMUNOL, V179, P5916, DOI 10.4049/jimmunol.179.9.5916; Rosenzweig M, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.e13028; Saito T, 2016, NAT MED, V22, P679, DOI 10.1038/nm.4086; Schaer DA, 2013, CANCER IMMUNOL RES, V1, P320, DOI 10.1158/2326-6066.CIR-13-0086; Schaer DA, 2012, CURR OPIN IMMUNOL, V24, P217, DOI 10.1016/j.coi.2011.12.011; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Sukumar S, 2017, CANCER RES, V77, P4378, DOI 10.1158/0008-5472.CAN-16-1439; Tigue NJ, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1280645; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Turk MJ, 2004, J EXP MED, V200, P771, DOI 10.1084/jem.20041130; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Valzasina B, 2005, BLOOD, V105, P2845, DOI 10.1182/blood-2004-07-2959; Weber JS, 2015, LANCET ONCOL, V16, P375, DOI 10.1016/S1470-2045(15)70076-8; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624; Yarilin D, 2015, SCI REP-UK, V5, DOI 10.1038/srep09534; Zappasodi R, 2018, CANCER CELL, V33, P581, DOI 10.1016/j.ccell.2018.03.005; 2018, CANCER CELL, V33, P1017, DOI DOI 10.1016/J.CCELL.2018.05.009	42	116	119	2	20	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2019	25	5					759	+		10.1038/s41591-019-0420-8	http://dx.doi.org/10.1038/s41591-019-0420-8			22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	HY6NU	31036879	Green Accepted			2023-01-03	WOS:000468247800019
J	Higuchi, K; Yanagawa, T				Higuchi, Kyouko; Yanagawa, Takashi			Evaluating dose of cisplatin responsible for causing nephrotoxicity	PLOS ONE			English	Article							CANCER-PATIENTS; MUSCLE MASS; TOXICITY; DISEASE; ORGAN; RISK	Nephrotoxicity is a well-known side effect of cisplatin for cancer treatment. Various regimens have been developed to treat cancer based on the type and severity of the tumor. We focus on the docetaxel, cisplatin, and 5-fluorouracil regimen, which is called the TPF regimen, where the standard dose of cisplatin is 60 mg/m(2). The aim of this study is to examine the relationship of the dosage of cisplatin that causes nephrotoxicity and back ground factors of patients using information about the dose of cisplatin actually administered to patients. It is shown that nephrotoxicity may be caused by a substantially smaller dosage than the standard dose of cisplatin in the TPF regimen, indicating the need for dose adjustment, taking into account the patient's background factors in the treatment of a cancer.	[Higuchi, Kyouko] Kurume Univ, Dept Biostat, Sch Med, Kurume, Fukuoka, Japan; [Higuchi, Kyouko] Kurume Univ Hosp, Dept Pharm, Kurume, Fukuoka, Japan; [Yanagawa, Takashi] Kurume Univ, Biostat Ctr, Kurume, Fukuoka, Japan	Kurume University; Kurume University; Kurume University	Higuchi, K (corresponding author), Kurume Univ, Dept Biostat, Sch Med, Kurume, Fukuoka, Japan.; Higuchi, K (corresponding author), Kurume Univ Hosp, Dept Pharm, Kurume, Fukuoka, Japan.	higuchi_kyouko@kurume-u.ac.jp						Ahmadzadeh A, 2015, J RENAL INJ PREV, V4, P87, DOI 10.12861/jrip.2015.17; [Anonymous], 2009, COMMON TERMINOLOGY C; Bhat ZY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142225; Blauwhoff-Buskermolen S, 2016, J CLIN ONCOL, V34, P1339, DOI 10.1200/JCO.2015.63.6043; CORNELISON TL, 1993, GYNECOL ONCOL, V50, P147, DOI 10.1006/gyno.1993.1184; de Jongh FE, 2003, BRIT J CANCER, V88, P1199, DOI 10.1038/sj.bjc.6600884; Hartmann JT, 1999, INT J CANCER, V83, P866, DOI 10.1002/(SICI)1097-0215(19991210)83:6<866::AID-IJC34>3.0.CO;2-9; Kaestner SA, 2007, CLIN ONCOL-UK, V19, P23, DOI 10.1016/j.clon.2006.10.010; Kidera Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101902; Kim SB, 2016, PLOS ONE, V11, DOI [10.1371/journal.pone.0147745, 10.1371/journal.pone.0164800]; Komaki K, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3135-6; Lichtman SM, 2007, EUR J CANCER, V43, P14, DOI 10.1016/j.ejca.2006.11.004; Lieffers JR, 2009, AM J CLIN NUTR, V89, P1173, DOI 10.3945/ajcn.2008.27273; Mathe C, 2011, EUR RESPIR J, V37, P888, DOI 10.1183/09031936.00055110; Miyoshi T, 2016, BIOL PHARM BULL, V39, P2009, DOI 10.1248/bpb.b16-00473; Muscaritoli M, 2010, CLIN NUTR, V29, P154, DOI 10.1016/j.clnu.2009.12.004; Ozkok A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/967826; Pabla N, 2008, KIDNEY INT, V73, P994, DOI 10.1038/sj.ki.5002786; Patel SS, 2013, J CACHEXIA SARCOPENI, V4, P19, DOI 10.1007/s13539-012-0079-1; Peres Luis Alberto Batista, 2013, Braz. J. Nephrol., V35, P332, DOI 10.5935/0101-2800.20130052; Prado CM, 2013, AM J CLIN NUTR, V98, P1012, DOI 10.3945/ajcn.113.060228; Sato K, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2271-8; Stewart DJ, 1997, CANCER CHEMOTH PHARM, V40, P293, DOI 10.1007/s002800050661; Wallengren O, 2015, SUPPORT CARE CANCER, V23, P79, DOI 10.1007/s00520-014-2332-y; WILLOX JC, 1986, BRIT J CANCER, V54, P19, DOI 10.1038/bjc.1986.147; Yao X, 2007, AM J MED SCI, V334, P115, DOI 10.1097/MAJ.0b013e31812dfe1e; Zarif Yeganeh M, 2016, IRAN J PUBLIC HEALTH, V45, P54; Zhang XY, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0673-8; 1988, CANC RES, V48, P3869; 2016, J ONCOL PRACT, V12, P1163, DOI DOI 10.1200/JOP.; 1995, CANC TREAT REV, V21, P33; 2010, TOXINS, V2, P2490, DOI DOI 10.3390/TOXINS2112490; 2012, ASIAN PAC J TROP BIO, V2, P640, DOI DOI 10.1016/S2221-1691(12)60112-9; 1998, JPN J CLIN ONCOL, V28, P168; 2012, ARCH TOXICOL, V86, P1233, DOI DOI 10.1007/S00204-012-0821-7; 1997, PHARMACOTHERAPY, V17, P1246	36	9	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2019	14	4							e0215757	10.1371/journal.pone.0215757	http://dx.doi.org/10.1371/journal.pone.0215757			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU8EY	31022233	Green Published, Green Submitted, gold			2023-01-03	WOS:000465519100048
J	Zawahir, S; Lekamwasam, S; Aslani, P				Zawahir, Shukry; Lekamwasam, Sarath; Aslani, Parisa			A cross-sectional national survey of community pharmacy staff: Knowledge and antibiotic provision	PLOS ONE			English	Article							PRESCRIPTION; RESISTANCE; ATTITUDES	Background Pharmacists' knowledge about the clinical and legal aspects of antibiotic supply has an impact on appropriate dispensing practice. There are limited studies evaluating community pharmacists' knowledge of antibiotic dispensing in low and middle-income countries, including Sri Lanka. We aimed (i) to evaluate community pharmacy staff's self-reported knowledge about antibiotics and dispensing behaviour of antibiotics without a prescription, and (ii) to identify possible factors impacting their antibiotic dispensing behaviour. Methods A cross-sectional survey was conducted among a random sample (n = 369) of community pharmacies across all nine provinces in Sri Lanka using a self-administered questionnaire on their antibiotic knowledge and dispensing practice. Data were analysed using descriptive and inferential statistics including; t-test, one-way ANOVA or chi-square test, and binary and multiple logistic regression. Results A total of 265 pharmacy staff (210 (79%) pharmacists and 55 (21%) assistants) responded. Overall mean antibiotic knowledge score was 26.1 (SD 3.9; range 1-33, max possible score 34). The overall mean knowledge score t(263) = 2.41, p = 0.017, specific knowledge about antibiotic resistance (ABR) t(262) = 4.98, p = 0.021 and legal aspects of antibiotic dispensing.2 (1, N = 265) = 8.55, p = 0.003) were significantly higher among pharmacists than assistants. One in every three pharmacy staff reported that they dispensed antibiotics without a prescription on patient request; however the proportion was close to half when the patient was known to them. About 30% of the staff reported to have supplied antibiotics for minor infections in the week prior to the survey. However, there was no significant difference in the supply between pharmacists and assistants except for acute sore throat (12% vs 23%, respectively; p = 0.040). Those pharmacists with higher ABR knowledge were less likely to give out antibiotics without a prescription for viral infections in adults (Adj. OR = 0.73, 95% CI: 0.55-0.96; p = 0.027) and children (Adj. OR = 0.55, 95% CI: 0.38-0.80; p = 0.002). Awareness of legal aspects of antibiotic supply reduced overall dispensing (Adj. OR = 0.47, 95% CI: 0.30-0.75; p = 0.001), and specifically for bacterial infections in adults (Adj. OR = 0.45, 95% CI: 0.20-0.99; p = 0.047). Knowledge about antibiotic use and misuse reduced the likelihood of illegal dispensing for common cold (Adj. OR = 0.75, 95% CI: 0.60-0.94; p = 0.011) and acute diarrhoea (Adj. OR = 0.76, 95% CI: 0.58-0.99; p = 0.048). Conclusion Despite the law prohibiting provision, antibiotic dispensing without a prescription continues in community pharmacies in Sri Lanka. Appropriate antibiotic dispensing was associated with high levels of pharmacists' legal and clinical knowledge about antibiotics. Strategies to change the current practice are urgently needed.	[Zawahir, Shukry; Aslani, Parisa] Univ Sydney, Sch Pharm, Sydney, NSW, Australia; [Lekamwasam, Sarath] Univ Ruhuna, Fac Med, Dept Med, Populat Hlth Res Ctr, Galle, Sri Lanka	University of Sydney; University Ruhuna	Zawahir, S (corresponding author), Univ Sydney, Sch Pharm, Sydney, NSW, Australia.	shukry2010@gmail.com	Lekamwasam, Sarath/ABG-4986-2020	Zawahir, Mohamed Shukry/0000-0002-2101-5952				Albrich WC, 2004, EMERG INFECT DIS, V10, P514, DOI 10.3201/eid1003.030252; Alhomoud F, 2017, INT J INFECT DIS, V57, P3, DOI 10.1016/j.ijid.2017.01.014; Ansari M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183907; Apisarnthanarak A, 2008, INFECT CONT HOSP EP, V29, P572, DOI 10.1086/587496; Awaisu A, 2014, INT J CLIN PHARM-NET, V36, P394, DOI 10.1007/s11096-013-9909-2; Ayukekbong JA, 2017, ANTIMICROB RESIST IN, V6, DOI 10.1186/s13756-017-0208-x; Barker AK, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013190; Ben-Nun P, 2008, ENCY SURVEY RES METH; Costelloe C, 2010, BMJ-BRIT MED J, V340, P1; Fiol F.S.D., 2015, J INFECT DEV COUNTR, V9, P5; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Gulen TA, 2015, INT J INFECT DIS, V38, P32, DOI [10.1016/j.ijid.2015.06.014, 10.1016/j.ijid.2015.06.01]; Hadi MA, 2016, INT J INFECT DIS, V47, P95, DOI 10.1016/j.ijid.2016.06.003; Jamshed SQ, 2014, J INFECT DEV COUNTR, V8, P780, DOI 10.3855/jidc.3833; Livermore DM, 2005, LANCET INFECT DIS, V5, P450, DOI 10.1016/S1473-3099(05)70166-3; Morgan DJ, 2011, LANCET INFECT DIS, V11, P692, DOI 10.1016/S1473-3099(11)70054-8; Napolitano F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084177; NMRA, 2016, PHARM DIR; Ocan M, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2109-3; Roque F, 2015, CLIN THER, V37, P168, DOI 10.1016/j.clinthera.2014.11.006; Roque F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090470; Vazquez-Lago J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015674; Wafula FN, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-223; World Health Organization, 2014, ANTIMICROBIAL RESIST; Zapata-Cachafeiro M, 2014, J ANTIMICROB CHEMOTH, V69, P3156, DOI 10.1093/jac/dku229; Zawahir S., 2016, PHARM PRACTICE DEV C, VVolume 1, P79; Zawahir S, 2019, ANTIMICROB RESIST IN, V8, DOI 10.1186/s13756-019-0510-x; Zawahir S, 2019, RES SOC ADMIN PHARM, V15, P584, DOI 10.1016/j.sapharm.2018.07.019; Zawahir S, 2013, NICOTINE TOB RES, V15, P482, DOI 10.1093/ntr/nts161; Zucco R, 2018, INT J MED INFORM, V111, P131, DOI 10.1016/j.ijmedinf.2017.12.005; 2010, ANTIMICROBIAL AGENTS, V54, P3564, DOI DOI 10.1128/AAC.00220-10	31	24	24	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2019	14	4							e0215484	10.1371/journal.pone.0215484	http://dx.doi.org/10.1371/journal.pone.0215484			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU8EY	31022197	Green Submitted, Green Published, gold			2023-01-03	WOS:000465519100026
J	Akdeniz, M; Hahnel, E; Ulrich, C; Blume-Peytavi, U; Kottner, J				Akdeniz, Merve; Hahnel, Elisabeth; Ulrich, Claas; Blume-Peytavi, Ulrike; Kottner, Jan			Prevalence and associated factors of skin cancer in aged nursing home residents: A multicenter prevalence study	PLOS ONE			English	Article							BASAL-CELL CARCINOMA; ACTINIC KERATOSIS; RISK-FACTORS; DNA-DAMAGE; NONMELANOMA; CARE; EXPOSURE; COHORT; NEVI	Non-melanoma-skin cancer is an emerging clinical problem in the elderly, fair skinned population which predominantly affects patients aged older than 70 years. Its steady increase in incidence rates and morbidity is paralleled by related medical costs. Despite the fact that many elderly patients are in need of care and are living in nursing homes, specific data on the prevalence of skin cancer in home care and the institutional long-term care setting is currently lacking. A representative multicenter prevalence study was conducted in a random sample of ten institutional long-term care facilities in the federal state of Berlin, Germany. In total, n = 223 residents were included. Actinic keratoses, the precursor lesions of invasive cutaneous squamous cell carcinoma were the most common epithelial skin lesions (21.1%, 95% CI 16.2 to 26.9). Non-melanoma skin cancer was diagnosed in 16 residents (7.2%, 95% CI 4.5 to 11.3). None of the residents had a malignant melanoma. Only few bivariate associations were detected between non-melanoma skin cancer and demographic, biographic and functional characteristics. Male sex was significantly associated with actinic keratosis whereas female sex was associated with non-melanoma skin cancer. Smoking was associated with an increased occurrence of non-melanoma skin cancer. Regular dermatology check-ups in nursing homes would be needed but already now due to financial limitations, lack of time in daily clinical practice and limited number of practising dermatologists, it is not the current standard. With respect to the worldwide growing aging population new programs and decisions are required. Overall, primary health care professionals should play a more active role in early diagnosis of skin cancer in nursing home residents. Dermoscopy courses, web-based or smartphone-based applications and teledermatology may support health care professionals to provide elderly nursing home residents an early diagnosis of skin cancer.	[Akdeniz, Merve; Hahnel, Elisabeth; Blume-Peytavi, Ulrike; Kottner, Jan] Charite Univ Med Berlin, Clin Res Ctr Hair & Skin Sci, Dept Dermatol & Allergy, Berlin, Germany; [Ulrich, Claas] Charite, Dept Dermatol & Allergy, Skin Canc Ctr, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Kottner, J (corresponding author), Charite Univ Med Berlin, Clin Res Ctr Hair & Skin Sci, Dept Dermatol & Allergy, Berlin, Germany.	jan.kottner@charite.de	Kottner, Jan/N-2365-2013	Kottner, Jan/0000-0003-0750-3818; Akdeniz, Merve/0000-0002-0992-8230; Blume-Peytavi, Ulrike/0000-0003-3528-3752	Galderma Pharma SA (Switzerland)	Galderma Pharma SA (Switzerland)	This investigator initiated clinical trial was supported by an unrestricted medical grant from Galderma Pharma SA (Switzerland). UBP received a consultancy honorary from Galderma Pharma SA (Switzerland). CU received a consultancy honorary from Beiersdorf, Germany, Galderma Pharma SA (Switzerland), Almirall, Germany, Meda, Germany. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Apalla Zoe, 2017, Dermatol Pract Concept, V7, P1, DOI 10.5826/dpc.0702a01; Beani JC, 2014, B ACAD NAT MED PARIS, V198, P273, DOI 10.1016/S0001-4079(19)31342-1; Blume-Peytavi U, 2016, GERONTOLOGIST, V56, pS230, DOI 10.1093/geront/gnw003; Cvitanovic H, 2010, COLLEGIUM ANTROPOL, V34, P247; Dejaco D, 2015, LARYNGO RHINO OTOL, V94, P467, DOI 10.1055/s-0035-1554655; Dodd AT, 2007, CANCER EPIDEM BIOMAR, V16, P2136, DOI 10.1158/1055-9965.EPI-07-0453; Ershler WB, 1997, JNCI-J NATL CANCER I, V89, P1489, DOI 10.1093/jnci/89.20.1489; Ferrandiz C, 2016, ACTAS DERMO-SIFILOGR, V107, P674, DOI 10.1016/j.ad.2016.05.016; Flohil SC, 2013, J INVEST DERMATOL, V133, P1971, DOI 10.1038/jid.2013.134; Fontaine J, 2008, ANN DERMATOL VENER, V135, P651, DOI 10.1016/j.annder.2008.06.005; Freedman M, 2003, CANCER EPIDEM BIOMAR, V12, P1540; Garcovich S, 2017, AGING DIS, V8, P643, DOI 10.14336/AD.2017.0503; Goulart JM, 2011, J GEN INTERN MED, V26, P1027, DOI 10.1007/s11606-011-1692-y; GREEN A, 1988, J AM ACAD DERMATOL, V19, P1045, DOI 10.1016/S0190-9622(88)70270-4; Grob JJ, 1998, ARCH DERMATOL, V134, P103, DOI 10.1001/archderm.134.1.103-a; Hahnel E, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018283; Hahnel E, 2017, J TISSUE VIABILITY, V26, P20, DOI 10.1016/j.jtv.2016.04.001; Hannuksela-Svahn A, 1999, ARCH DERMATOL, V135, P781, DOI 10.1001/archderm.135.7.781; Henderson MT, 2015, J AM ACAD DERMATOL, V72, P190, DOI 10.1016/j.jaad.2014.09.024; KARAGAS MR, 1992, JAMA-J AM MED ASSOC, V267, P3305, DOI 10.1001/jama.267.24.3305; Kottner J, 2015, INT J NURS STUD, V52, P598, DOI 10.1016/j.ijnurstu.2014.11.007; Lear JT, 2014, BRIT J CANCER, V111, P1476, DOI 10.1038/bjc.2014.270; Leonardi-Bee J, 2012, ARCH DERMATOL, V148, P939, DOI 10.1001/archdermatol.2012.1374; Li WQ, 2016, INT J CANCER, V139, P2671, DOI 10.1002/ijc.30395; Lichterfeld A, 2016, INT J NURS STUD, V56, P37, DOI 10.1016/j.ijnurstu.2016.01.003; Lubeek SFK, 2015, EUR J DERMATOL, V25, P606, DOI 10.1684/ejd.2015.2657; MAHONEY F I, 1965, Md State Med J, V14, P61; Pettan-Brewer C, 2012, PATHOBIOL AGING AGE, V2, DOI 10.3402/pba.v2i0.19182; Pfeifer GP, 2012, PHOTOCH PHOTOBIO SCI, V11, P90, DOI 10.1039/c1pp05144j; Que SKT, 2018, J AM ACAD DERMATOL, V78, P237, DOI 10.1016/j.jaad.2017.08.059; Sanderson WC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121922; Sanderson WC, 2005, NATURE, V435, P811, DOI 10.1038/nature03593; Skin Cancer Foundation, 2018, SKIN CANC FACTS STAT; Stern RS, 1998, JNCI-J NATL CANCER I, V90, P1278, DOI 10.1093/jnci/90.17.1278; Templier C, 2015, CLIN EXP DERMATOL, V40, P356, DOI 10.1111/ced.12562; Traianou A, 2012, BRIT J DERMATOL, V167, P36, DOI 10.1111/j.1365-2133.2012.11085.x; VITASA BC, 1990, CANCER, V65, P2811, DOI 10.1002/1097-0142(19900615)65:12<2811::AID-CNCR2820651234>3.0.CO;2-U; WHO, 2018, COMM IS SKIN CANC; Zink A, 2017, HAUTARZT, V68, P919, DOI [10.1007/s00105-017-4058-5, 10.1007/s00105-017-4049-6]	39	7	7	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2019	14	4							e0215379	10.1371/journal.pone.0215379	http://dx.doi.org/10.1371/journal.pone.0215379			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU2FT	31009466	Green Published, Green Submitted, gold			2023-01-03	WOS:000465087500022
J	Arbour, KC; Riely, GJ				Arbour, Kathryn C.; Riely, Gregory J.			Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer A Review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PHASE-III TRIAL; OPEN-LABEL; SINGLE-ARM; CLINICAL-PRACTICE; EGFR MUTATION; STAGE IV; CHEMOTHERAPY; CRIZOTINIB; ALK; MULTICENTER	IMPORTANCE Non-small cell lung cancer remains the leading cause of cancer death in the United States. Until the last decade, the 5-year overall survival rate for patients with metastatic non-small cell lung cancer was less than 5%. Improved understanding of the biology of lung cancer has resulted in the development of new biomarker-targeted therapies and led to improvements in overall survival for patients with advanced or metastatic disease. OBSERVATIONS Systemic therapy for metastatic non-small cell lung cancer is selected according to the presence of specific biomarkers. Therefore, all patients with metastatic non-small cell lung cancer should undergo molecular testing for relevant mutations and expression of the protein PD-L1 (programmed death ligand 1). Molecular alterations that predict response to treatment (eg, EGFR mutations, ALK rearrangements, ROS1 rearrangements, and BRAF V600E mutations) are present in approximately 30% of patients with non-small cell lung cancer. Targeted therapy for these alterations improves progression-free survival compared with cytotoxic chemotherapy. For example, somatic activating mutations in the EGFR gene are present in approximately 20% of patients with advanced non-small cell lung cancer. Tyrosine kinase inhibitors such as gefitinib, erlotinib, and afatinib improve progression-free survival in patients with susceptible EGFR mutations. In patients with overexpression of ALK protein, the response rate was significantly better with crizotinib (a tyrosine kinase inhibitor) than with the combination of pemetrexed and either cisplatin or carboplatin (platinum-based chemotherapy) (74% vs 45%, respectively; P < .001) and progression-free survival (median, 10.9 months vs 7.0 months; P < .001). Subsequent generations of tyrosine kinase inhibitors have improved these agents. For patients without biomarkers indicating susceptibility to specific targeted treatments, immune checkpoint inhibitor-containing regimens either as monotherapy or in combination with chemotherapy are superior vs chemotherapy alone. These advances in biomarker-directed therapy have led to improvements in overall survival. For example, the 5-year overall survival rate currently exceeds 25% among patients whose tumors have high PD-L1 expression (tumor proportion score of >= 50%) and 40% among patients with ALK-positive tumors. CONCLUSIONS AND RELEVANCE Improved understanding of the biology and molecular subtypes of non-small cell lung cancer have led to more biomarker-directed therapies for patients with metastatic disease. These biomarker-directed therapies and newer empirical treatment regimens have improved overall survival for patients with metastatic non-small cell lung cancer.	[Arbour, Kathryn C.; Riely, Gregory J.] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv,Div Solid Tumor, New York, NY USA	Cornell University; Memorial Sloan Kettering Cancer Center	Riely, GJ (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA.	rielyg@mskcc.org	Riely, Gregory/AAF-4300-2019		National Cancer Institute [P30 CA008748]; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was partially supported by grant P30 CA008748 from the National Cancer Institute awarded to Memorial Sloan Kettering Cancer Center.	Aggarwal C, 2019, JAMA ONCOL, V5, P173, DOI 10.1001/jamaoncol.2018.4305; Antonia SJ, 2018, NEW ENGL J MED, V379, P2342, DOI 10.1056/NEJMoa1809697; Brahmer JR, 2013, CANCER IMMUNOL RES, V1, P85, DOI 10.1158/2326-6066.CIR-13-0078; Camidge DR, 2018, NEW ENGL J MED, V379, P2027, DOI 10.1056/NEJMoa1810171; Camidge DR, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.TPS9111; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Chen VW, 2014, CANCER-AM CANCER SOC, V120, P3781, DOI 10.1002/cncr.29045; Couraud S, 2012, EUR J CANCER, V48, P1299, DOI 10.1016/j.ejca.2012.03.007; Curran WJ, 2011, J NATL CANCER I, V103, P1452, DOI 10.1093/jnci/djr325; Davar D, 2019, JAMA ONCOL, V5, P942, DOI 10.1001/jamaoncol.2019.0413; Dogan S, 2012, CLIN CANCER RES, V18, P6169, DOI 10.1158/1078-0432.CCR-11-3265; Drilon A, 2018, J THORAC ONCOL, V13, pS348, DOI 10.1016/j.jtho.2018.08.300; DRILON AE, 2018, J CLIN ONCOL S, V36; Drilon A, 2019, CANCER DISCOV, V9, P384, DOI 10.1158/2159-8290.CD-18-0839; Drilon A, 2018, CANCER DISCOV, V8, P1227, DOI 10.1158/2159-8290.CD-18-0484; Drilon A, 2016, LANCET ONCOL, V17, P1653, DOI 10.1016/S1470-2045(16)30562-9; Forde PM, 2018, NEW ENGL J MED, V378, P1976, DOI 10.1056/NEJMoa1716078; Gainor JF, 2013, ONCOLOGIST, V18, P865, DOI 10.1634/theoncologist.2013-0095; Galluzzi L, 2015, CANCER CELL, V28, P690, DOI 10.1016/j.ccell.2015.10.012; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Gautschi O, 2017, J CLIN ONCOL, V35, P1403, DOI 10.1200/JCO.2016.70.9352; Gervais R, 2005, ANN ONCOL, V16, P90, DOI 10.1093/annonc/mdi018; Gettinger SN, 2015, J THORAC ONCOL, V10, pS238; Govindan R, 2006, J CLIN ONCOL, V24, P4539, DOI 10.1200/JCO.2005.04.4859; Hellmann Matthew D, 2018, N Engl J Med, V378, P2093, DOI 10.1056/NEJMoa1801946; Huber KVM, 2014, NATURE, V508, P222, DOI 10.1038/nature13194; Husain H, 2017, JAMA-J AM MED ASSOC, V318, P1272, DOI 10.1001/jama.2017.12131; Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309; Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022; Johnson DB, 2018, JAMA-J AM MED ASSOC, V320, P1702, DOI 10.1001/jama.2018.13995; Jordan EJ, 2017, CANCER DISCOV, V7, P596, DOI 10.1158/2159-8290.CD-16-1337; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Langer CJ, 2016, LANCET ONCOL, V17, P1497, DOI 10.1016/S1470-2045(16)30498-3; Lee SH, 2017, ANN ONCOL, V28, P292, DOI 10.1093/annonc/mdw559; Leighl NB, 2019, CLIN CANCER RES, V25, P4691, DOI 10.1158/1078-0432.CCR-19-0624; Li BT, 2018, J CLIN ONCOL, V36, P2532, DOI 10.1200/JCO.2018.77.9777; Lim SM, 2017, J CLIN ONCOL, V35, P2613, DOI 10.1200/JCO.2016.71.3701; Lopes G, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.18_suppl.LBA4; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Mok Tony S, 2017, N Engl J Med, V376, P629, DOI 10.1056/NEJMoa1612674; Mok TS, 2018, J CLIN ONCOL, V36, P2244, DOI 10.1200/JCO.2018.78.7994; Mok TSK, 2019, LANCET, V393, P1819, DOI 10.1016/S0140-6736(18)32409-7; Moyer VA, 2014, ANN INTERN MED, V160, P330, DOI 10.7326/M13-2771; Naidoo J, 2017, J CLIN ONCOL, V35, P709, DOI 10.1200/JCO.2016.68.2005; National Cancer Institute, SURV EP END RES PROG; Oxnard GR, 2018, JAMA ONCOL, V4, P1527, DOI 10.1001/jamaoncol.2018.2969; Oxnard GR, 2011, CLIN CANCER RES, V17, P1616, DOI 10.1158/1078-0432.CCR-10-2692; Paik PK, 2015, CANCER DISCOV, V5, P842, DOI 10.1158/2159-8290.CD-14-1467; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Peng J, 2015, CANCER RES, V75, P5034, DOI 10.1158/0008-5472.CAN-14-3098; Pennell NA, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00356; Peters S, 2017, NEW ENGL J MED, V377, P829, DOI 10.1056/NEJMoa1704795; Planchard D, 2016, LANCET ONCOL, V17, P984, DOI 10.1016/S1470-2045(16)30146-2; Planchard D, 2016, LANCET ONCOL, V17, P642, DOI 10.1016/S1470-2045(16)00077-2; Ramalingam SS, 2018, J CLIN ONCOL, V36, P841, DOI 10.1200/JCO.2017.74.7576; Reck M, 2019, J CLIN ONCOL, V37, P537, DOI 10.1200/JCO.18.00149; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rizvi NA, 2018, ANN ONCOL, V29; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Sabari JK, 2019, JNCI-J NATL CANCER I, V111, P575, DOI 10.1093/jnci/djy156; Santini FC, 2018, CANCER IMMUNOL RES, V6, P1093, DOI 10.1158/2326-6066.CIR-17-0755; Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375; Sequist LV, 2013, J CLIN ONCOL, V31, P3327, DOI 10.1200/JCO.2012.44.2806; Shaw AT, 2017, LANCET ONCOL, V18, P1590, DOI 10.1016/S1470-2045(17)30680-0; Shaw AT, 2017, LANCET ONCOL, V18, P874, DOI 10.1016/S1470-2045(17)30339-X; Shaw AT, 2016, LANCET ONCOL, V17, P234, DOI 10.1016/S1470-2045(15)00488-X; Shaw AT, 2014, NEW ENGL J MED, V371, P1963, DOI 10.1056/NEJMoa1406766; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Shaw AT, 2011, LANCET ONCOL, V12, P1004, DOI 10.1016/S1470-2045(11)70232-7; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948; Solomon BJ, 2018, LANCET ONCOL, V19, P1654, DOI 10.1016/S1470-2045(18)30649-1; Solomon BJ, 2018, J CLIN ONCOL, V36, P2251, DOI 10.1200/JCO.2017.77.4794; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Spiro SG, 2007, CHEST, V132, p149S, DOI 10.1378/chest.07-1358; Thompson JA, 2019, J NATL COMPR CANC NE, V17, P255, DOI 10.6004/jnccn.2019.0013; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Travis WD, 2013, J CLIN ONCOL, V31, P992, DOI 10.1200/JCO.2012.46.9270; Wang YC, 2019, JAMA ONCOL, V5, P1008, DOI 10.1001/jamaoncol.2019.0393; Yu HA, 2015, JAMA ONCOL, V1, P981, DOI 10.1001/jamaoncol.2015.1066; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246; Zukin M, 2013, J CLIN ONCOL, V31, P2849, DOI 10.1200/JCO.2012.48.1911	84	471	489	34	174	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2019	322	8					764	774		10.1001/jama.2019.11058	http://dx.doi.org/10.1001/jama.2019.11058			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IU5UJ	31454018				2023-01-03	WOS:000483652500024
J	Li, YC				Li, Ying-Chun			Continuity of care for newly diagnosed diabetic patients: A population-based study	PLOS ONE			English	Article							PREVENTABLE HOSPITALIZATION; INTERPERSONAL CONTINUITY; AMBULATORY-CARE; OUTCOMES; IMPACT; MEDICATION; ASTHMA; COHORT; RISK; EXPENDITURES	This study explores whether continuity of care is associated with health care outcomes and medical care use among patients with newly diagnosed diabetes. A retrospective cohort analysis was performed using the Taiwanese National Health Insurance database, and cases were followed up from January 2010 to December 2012. Four thousand and seven patients with newly diagnosed diabetes were followed for 3 years. The continuity of care was measured using the continuity of care index (COCI) and the usual provider continuity score (UPCS) with high and low dichotomous categories. The probabilities of dementia, hospitalization, emergency room visits, and death were used as health care outcomes. Medical care use was defined as the number of hospital admissions, length of hospital stays, and number of emergency room visits. Adjusted odds ratios (ORs) were obtained using multivariate logistic regression; adjusted ORs for the probabilities of dementia, hospital admissions, and emergency room visits in the higher COCI patient group were 0.582 (p < 0.05), 0.623 (p < 0.001), and 0.650 (p < 0.001), respectively. Negative binomial regression models for medical resource use indicated that the group with higher COCI scores used fewer medical resources compared with the group with lower COCI scores. The findings of UPCS analysis showed that those in the high COCI group also fell into the high UPCS group. In this study, continuity of care was associated with favorable health care outcomes and less medical care uses among newly diagnosed diabetic patients. Long-term relationships between patients and health care providers should be enhanced to provide improved continuity of care.	[Li, Ying-Chun] Natl Sun Yat Sen Univ, Inst Hlth Care Management, Kaohsiung, Taiwan	National Sun Yat Sen University	Li, YC (corresponding author), Natl Sun Yat Sen Univ, Inst Hlth Care Management, Kaohsiung, Taiwan.	ycli@mail.nsysu.edu.tw		Li, Ying-Chun/0000-0001-8516-970X	Ministry of Science and Technology in Taiwan [MOST 103-2410-H-110-076]	Ministry of Science and Technology in Taiwan(Ministry of Science and Technology, Taiwan)	This study was supported by Ministry of Science and Technology (MOST 103-2410-H-110-076) in Taiwan to YCL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study was supported by the Ministry of Science and Technology (MOST 103-2410-H-110-076) of Taiwan. The funders had no role in study design, data collection, and analysis, the decision to publish, or preparation of the manuscript.	Aller MB, 2013, INT J QUAL HEALTH C, V25, P291, DOI 10.1093/intqhc/mzt010; Bentler SE, 2014, QUAL LIFE RES, V23, P185, DOI 10.1007/s11136-013-0472-z; BICE TW, 1977, MED CARE, V15, P347, DOI 10.1097/00005650-197704000-00010; BRESLAU N, 1975, J MED EDUC, V50, P965; Bynum JPW, 2004, J AM GERIATR SOC, V52, P187, DOI 10.1111/j.1532-5415.2004.52054.x; Charlson ME, 2008, J CLIN EPIDEMIOL, V61, P1234, DOI 10.1016/j.jclinepi.2008.01.006; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chen TJ, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-54; Cheng SH, 2014, MED CARE, V52, P149, DOI 10.1097/MLR.0000000000000042; Cho KH, 2016, INT J QUAL HEALTH C, V28, P478, DOI 10.1093/intqhc/mzw050; Cho KH, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0745-z; Chu HY, 2012, MED CARE, V50, P1002, DOI 10.1097/MLR.0b013e31826c870f; Coleman EA, 2004, ANN INTERN MED, V141, P533, DOI 10.7326/0003-4819-141-7-200410050-00009; Comino EJ, 2015, DIABETES RES CLIN PR, V108, P296, DOI 10.1016/j.diabres.2015.02.003; Crane PK, 2013, NEW ENGL J MED, V369, P540, DOI [10.1056/NEJMoa1215740, 10.1056/NEJMc1311765]; Dearinger AT, 2008, J GEN INTERN MED, V23, P937, DOI 10.1007/s11606-008-0654-5; Gill James M, 2003, Ann Fam Med, V1, P162, DOI 10.1370/afm.22; Gill JM, 1998, ARCH FAM MED, V7, P352, DOI 10.1001/archfami.7.4.352; Gill JM, 2000, ARCH FAM MED, V9, P333, DOI 10.1001/archfami.9.4.333; Gulliford MC, 2007, FAM PRACT, V24, P245, DOI 10.1093/fampra/cmm014; Haggerty JL, 2003, BRIT MED J, V327, P1219, DOI 10.1136/bmj.327.7425.1219; Hong JS, 2010, J KOREAN MED SCI, V25, P1259, DOI 10.3346/jkms.2010.25.9.1259; Hong JS, 2013, HEALTH POLICY, V109, P158, DOI 10.1016/j.healthpol.2012.09.009; Huang CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087095; HURLEY RE, 1991, INQUIRY-J HEALTH CAR, V28, P375; Jee SH, 2006, MED CARE RES REV, V63, P158, DOI 10.1177/1077558705285294; Kawamura T, 2012, J DIABETES INVEST, V3, P413, DOI 10.1111/j.2040-1124.2012.00234.x; Kristjansson E, 2013, BMC FAM PRACT, V14, DOI 10.1186/1471-2296-14-72; L'Heveder R, 2013, DIABETES RES CLIN PR, V101, P349, DOI 10.1016/j.diabres.2013.08.003; Lin W, 2010, INT J QUAL HEALTH C, V22, P3, DOI 10.1093/intqhc/mzp059; Lustman A, 2016, PRIM CARE DIABETES, V10, P165, DOI 10.1016/j.pcd.2015.10.001; Meurer JR, 1998, PEDIATRICS, V102, part. no., DOI 10.1542/peds.102.6.e70; Ministry of Health and Welfare, NAT HLTH INS STAT; Napolitano F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154940; Nyweide DJ, 2013, JAMA INTERN MED, V173, P1879, DOI 10.1001/jamainternmed.2013.10059; Raddish M, 1999, AM J MANAG CARE, V5, P727; Saultz John W, 2003, Ann Fam Med, V1, P134, DOI 10.1370/afm.23; Shin DW, 2014, ANN FAM MED, V12, P534, DOI 10.1370/afm.1685; SHORTELL SM, 1976, MED CARE, V14, P377, DOI 10.1097/00005650-197605000-00001; SKOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437, DOI 10.1001/jama.268.24.3437; Smith SR, 1999, HEALTH SERV RES, V34, P123; Sokol MC, 2005, MED CARE, V43, P521, DOI 10.1097/01.mlr.0000163641.86870.af; van den Berg E, 2006, DRUG TODAY, V42, P741, DOI 10.1358/dot.2006.42.11.1003542; Williams BA, 2006, TECHNICAL REPORT SER, V#79; Wolff JL, 2002, ARCH INTERN MED, V162, P2269, DOI 10.1001/archinte.162.20.2269; Wolinsky FD, 2007, J GERONTOL B-PSYCHOL, V62, pS160, DOI 10.1093/geronb/62.3.S160; Worrall G, 2011, CAN FAM PHYSICIAN, V57, pE16; Yang Hailin, 2011, Shengwu Jiagong Guocheng, V9, P1, DOI 10.3969/j.issn.1672-3678.2011.06.001	48	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2019	14	8							e0221327	10.1371/journal.pone.0221327	http://dx.doi.org/10.1371/journal.pone.0221327			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW5RZ	31437219	Green Published, Green Submitted, gold			2023-01-03	WOS:000485036900051
J	Di Cosimo, S; La Verde, N; Moretti, A; Cazzaniga, ME; Generali, D; Bianchi, GV; Mariani, L; Torri, V; Crippa, F; Paolini, B; Scaperrotta, G; De Santis, MC; Di Nicola, M; Apolone, G; Gulino, A; Tripodo, C; Colombo, MP; Folli, S; de Braud, F				Di Cosimo, Serena; La Verde, Nicla; Moretti, Anna; Cazzaniga, Marina Elena; Generali, Daniele; Bianchi, Giulia Valeria; Mariani, Luigi; Torri, Valter; Crippa, Flavio; Paolini, Biagio; Scaperrotta, Gianfranco; De Santis, Maria Carmen; Di Nicola, Massimo; Apolone, Giovanni; Gulino, Alessandro; Tripodo, Claudio; Colombo, Mario Paolo; Folli, Secondo; de Braud, Filippo			Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study	PLOS ONE			English	Article							HALICHONDRIN B ANALOG; PHASE-II; ADJUVANT CHEMOTHERAPY; NAB-PACLITAXEL; TUMOR RESPONSE; CLINICAL-TRIAL; OPEN-LABEL; WOMEN; CYCLOPHOSPHAMIDE; FLUOROURACIL	Background Eribulin mesylate (E) is indicated for metastatic breast cancer patients previously treated with anthracycline and taxane. We argued that E could also benefit patients eligible for neoadjuvant chemotherapy. Methods Patients with primary triple negative breast cancer >= 2 cm received doxorubicin 60 mg/m(2) and paclitaxel 200 mg/m(2) x 4 cycles (AT) followed by E 1.4 mg/m(2) x 4 cycles. Primary endpoint was pathological complete response (pCR) rate; secondary and explorative endpoints included clinical/metabolic response rates and safety, and biomarker analysis, respectively. Using a two-stage Simon design, 43 patients were to be included provided that 4 of 13 patients had achieved pCR in the first stage of the study. Results In stage I of the study 13 women were enrolled, median age 43 years, tumor size 2-5 cm in 9/13 (69%), positive nodal status in 8/13 (61%). Main grade 3 adverse event was neutropenia (related to AT and E in 4 and 2 cases, respectively). AT followed by E induced clinical complete + partial responses in 11/13 patients (85%), pCR in 3/13 (23%). Median measurements of maximum standardized uptake value (SUVmax) resulted 13, 3, and 1.9 at baseline, after AT and E, respectively. Complete metabolic response (CMR) occurred after AT and after E in 2 and 3 cases, respectively. Notably, 2 of the 5 (40%) patients with CMR achieved pCR at surgery. Immunostaining of paired pre-/post-treatment tumor specimens showed a reduction of beta-catenin, CyclinD1, Zeb-1, and c-myc expression, in the absence of N-cadherin modulation. The study was interrupted at stage I due to the lack of the required patients with pCR. Conclusions Despite the early study closure, preoperative E following AT showed clinical and biological activity in triple negative breast cancer patients. Furthermore, the modulation of beta-catenin pathway core proteins, supposedly outside the domain of epithelial-mesenchymal transition, claims for further investigation.	[Di Cosimo, Serena; Bianchi, Giulia Valeria; Mariani, Luigi; Crippa, Flavio; Paolini, Biagio; Scaperrotta, Gianfranco; De Santis, Maria Carmen; Di Nicola, Massimo; Apolone, Giovanni; Colombo, Mario Paolo; Folli, Secondo; de Braud, Filippo] Fdn IRCCS Ist Nazl Tumori Milano, Milan, Italy; [La Verde, Nicla] ASST Fatebenefratelli Sacco, PO Sacco, Milan, Italy; [Moretti, Anna] ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; [Cazzaniga, Marina Elena] ASST Monza, Ctr Ric Fase 1, Monza, Italy; [Generali, Daniele] ASST Cremona, Cremona, Italy; [Torri, Valter] IRCCS Ist Ric Farmacol Mario Negri, Milan, Italy; [Gulino, Alessandro; Tripodo, Claudio] Univ Palermo, Sch Med, Palermo, Italy; [de Braud, Filippo] Univ Milan, Sch Med, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Palermo; University of Milan	Di Cosimo, S (corresponding author), Fdn IRCCS Ist Nazl Tumori Milano, Milan, Italy.	serena.dicosimo@istitutotumori.mi.it	la verde, nicla/AAW-9398-2020; Torri, Valter/H-7550-2015; , Di Cosimo Serena/E-9418-2017; Mariani, Luigi/C-2580-2017; Colombo, Mario P./V-7166-2017; Folli, Secondo/AAB-2227-2020; cazzaniga, marina/AAB-9950-2022; Mariani, Luigi/AAB-9464-2019; Tripodo, Claudio/AAB-6004-2022; Apolone, Giovanni/R-9799-2016; BIANCHI, GIULIA VALERIA/C-4553-2017; Paolini, Biagio/E-9240-2017	la verde, nicla/0000-0002-2884-1632; Torri, Valter/0000-0001-9541-9354; , Di Cosimo Serena/0000-0002-4666-8052; Mariani, Luigi/0000-0001-6208-4084; Colombo, Mario P./0000-0003-0042-7955; Folli, Secondo/0000-0003-3465-3010; Tripodo, Claudio/0000-0002-0821-6231; GENERALI, DANIELE/0000-0003-2480-3855; Apolone, Giovanni/0000-0001-5179-104X; BIANCHI, GIULIA VALERIA/0000-0003-3630-4527; Paolini, Biagio/0000-0001-7535-7715	EISAI	EISAI(Eisai Co Ltd)	The HOPE study is an Investigator Initiated Trial supported by EISAI; Eribulin is an asset of EISAI. EISAI had no role in study design, enrollment, biological sample collection; data management, analysis, and interpretation, preparation, review, or approval of the manuscript and decision to submit the manuscript for publication.	Abraham J, 2015, BREAST CANCER RES TR, V152, P399, DOI 10.1007/s10549-015-3466-4; Albain K, 2012, LANCET, V379, P432, DOI 10.1016/S0140-6736(11)61625-5; Alberro JA, 2018, LANCET ONCOL, V19, P27, DOI 10.1016/S1470-2045(17)30777-5; [Anonymous], CLIN BREAST CANC; Byrski T, 2010, J CLIN ONCOL, V28, P375, DOI 10.1200/JCO.2008.20.7019; Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109; Chang HR, 2010, CANCER-AM CANCER SOC, V116, P4227, DOI 10.1002/cncr.25309; Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8; Cortes J, 2011, LANCET, V377, P914, DOI 10.1016/S0140-6736(11)60070-6; Cortes J, 2010, J CLIN ONCOL, V28, P3922, DOI 10.1200/JCO.2009.25.8467; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gianni L, 2005, CLIN CANCER RES, V11, P8715, DOI 10.1158/1078-0432.CCR-05-0539; Gianni L, 2018, JAMA ONCOL, V4, P302, DOI 10.1001/jamaoncol.2017.4612; Gianni L, 2009, J CLIN ONCOL, V27, P2474, DOI 10.1200/JCO.2008.19.2567; Gray R, 2018, CANCER RES, V78; Jordan MA, 2005, MOL CANCER THER, V4, P1086, DOI 10.1158/1535-7163.MCT-04-0345; Kaklamani VG, 2015, BREAST CANCER RES TR, V151, P629, DOI 10.1007/s10549-015-3435-y; Kuznetsov G, 2004, CANCER RES, V64, P5760, DOI 10.1158/0008-5472.CAN-04-1169; Locatelli MA, 2017, BREAST CARE, V12, P152, DOI 10.1159/000478087; Loibl S, 2018, LANCET ONCOL, V19, P497, DOI 10.1016/S1470-2045(18)30111-6; Malorni L, 2012, BREAST CANCER RES TR, V136, P795, DOI 10.1007/s10549-012-2315-y; Naito Y, EUR J CANC S3, V92, pS17; Okouneva T, 2008, MOL CANCER THER, V7, P2003, DOI 10.1158/1535-7163.MCT-08-0095; Shien T, 2016, ANN ONCOL, V27; Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725; Torrisi R, 2008, CANCER CHEMOTH PHARM, V62, P667, DOI 10.1007/s00280-007-0652-z; Twelves C, 2016, BREAST CANCER-BASIC, V10, P77, DOI 10.4137/BCBCR.S39615; Twelves C, 2014, BREAST CANCER RES TR, V148, P553, DOI 10.1007/s10549-014-3144-y; Untch M, 2016, LANCET ONCOL, V17, P345, DOI 10.1016/S1470-2045(15)00542-2; Vahdat LT, 2009, J CLIN ONCOL, V27, P2954, DOI 10.1200/JCO.2008.17.7618; Yardley DA, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.SABCS15-P1-12-04; Yardley DA, 2015 SAN ANT BREAST; Yoshida T, 2014, BRIT J CANCER, V110, P1497, DOI 10.1038/bjc.2014.80; Young H, 1999, EUR J CANCER, V35, P1773, DOI 10.1016/S0959-8049(99)00229-4; Zoltan D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106131	35	6	6	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 7	2019	14	8							e0220644	10.1371/journal.pone.0220644	http://dx.doi.org/10.1371/journal.pone.0220644			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5DR	31390375	Green Published, Green Submitted, gold			2023-01-03	WOS:000484999400025
J	Butler, CC; Gillespie, D; White, P; Bates, J; Lowe, R; Thomas-Jones, E; Wootton, M; Hood, K; Phillips, R; Melbye, H; Llor, C; Cals, JWL; Naik, G; Kirby, N; Gal, M; Riga, E; Francis, NA				Butler, Christopher C.; Gillespie, David; White, Patrick; Bates, Janine; Lowe, Rachel; Thomas-Jones, Emma; Wootton, Mandy; Hood, Kerenza; Phillips, Rhiannon; Melbye, Hasse; Llor, Carl; Cals, Jochen W. L.; Naik, Gurudutt; Kirby, Nigel; Gal, Micaela; Riga, Evgenia; Francis, Nick A.			C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; RESPIRATORY-TRACT INFECTION; OF-CARE; STREPTOCOCCUS-PNEUMONIAE; RESISTANCE; SUSCEPTIBILITY; PREDICTORS; BIOMARKERS; THERAPY; EUROPE	Background Point-of-care testing of C-reactive protein (CRP) may be a way to reduce unnecessary use of antibiotics without harming patients who have acute exacerbations of chronic obstructive pulmonary disease (COPD). Methods We performed a multicenter, open-label, randomized, controlled trial involving patients with a diagnosis of COPD in their primary care clinical record who consulted a clinician at 1 of 86 general medical practices in England and Wales for an acute exacerbation of COPD. The patients were assigned to receive usual care guided by CRP point-of-care testing (CRP-guided group) or usual care alone (usual-care group). The primary outcomes were patient-reported use of antibiotics for acute exacerbations of COPD within 4 weeks after randomization (to show superiority) and COPD-related health status at 2 weeks after randomization, as measured by the Clinical COPD Questionnaire, a 10-item scale with scores ranging from 0 (very good COPD health status) to 6 (extremely poor COPD health status) (to show noninferiority). Results A total of 653 patients underwent randomization. Fewer patients in the CRP-guided group reported antibiotic use than in the usual-care group (57.0% vs. 77.4%; adjusted odds ratio, 0.31; 95% confidence interval [CI], 0.20 to 0.47). The adjusted mean difference in the total score on the Clinical COPD Questionnaire at 2 weeks was -0.19 points (two-sided 90% CI, -0.33 to -0.05) in favor of the CRP-guided group. The antibiotic prescribing decisions made by clinicians at the initial consultation were ascertained for all but 1 patient, and antibiotic prescriptions issued over the first 4 weeks of follow-up were ascertained for 96.9% of the patients. A lower percentage of patients in the CRP-guided group than in the usual-care group received an antibiotic prescription at the initial consultation (47.7% vs. 69.7%, for a difference of 22.0 percentage points; adjusted odds ratio, 0.31; 95% CI, 0.21 to 0.45) and during the first 4 weeks of follow-up (59.1% vs. 79.7%, for a difference of 20.6 percentage points; adjusted odds ratio, 0.30; 95% CI, 0.20 to 0.46). Two patients in the usual-care group died within 4 weeks after randomization from causes considered by the investigators to be unrelated to trial participation. Conclusions CRP-guided prescribing of antibiotics for exacerbations of COPD in primary care clinics resulted in a lower percentage of patients who reported antibiotic use and who received antibiotic prescriptions from clinicians, with no evidence of harm. (Funded by the National Institute for Health Research Health Technology Assessment Program; PACE Current Controlled Trials number, .)	[Butler, Christopher C.; Riga, Evgenia] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Radcliffe Primary Care Bldg, Oxford OX2 6GG, England; [Gillespie, David; Bates, Janine; Lowe, Rachel; Thomas-Jones, Emma; Hood, Kerenza; Kirby, Nigel] Cardiff Univ, Ctr Trials Res, Cardiff, S Glam, Wales; [Phillips, Rhiannon; Naik, Gurudutt; Francis, Nick A.] Cardiff Univ, Div Populat Med, Cardiff, S Glam, Wales; [Gal, Micaela] Cardiff Univ, Sch Med, Wales Ctr Primary & Emergency Res, Cardiff, S Glam, Wales; [Wootton, Mandy] Univ Hosp Wales, Publ Hlth Wales, Specialist Antimicrobial Chemotherapy Unit, Cardiff, S Glam, Wales; [White, Patrick] Kings Coll London, Sch Populat Hlth & Environm Sci, London, England; [Melbye, Hasse] Univ Tromso Arctic Univ Norway, Dept Community Med, Gen Practice Res Unit, Tromso, Norway; [Llor, Carl] Univ Inst Primary Care Res Jordi Gol, Via Roma Hlth Ctr, Barcelona, Spain; [Cals, Jochen W. L.] Maastricht Univ, Dept Family Med, Care & Publ Hlth Res Inst, Maastricht, Netherlands	University of Oxford; Cardiff University; Cardiff University; Cardiff University; Cardiff University; University of London; King's College London; UiT The Arctic University of Tromso; Maastricht University; Maastricht University Medical Centre (MUMC)	Butler, CC (corresponding author), Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Radcliffe Primary Care Bldg, Oxford OX2 6GG, England.	christopher.butler@phc.ox.ac.uk	Phillips, Rhiannon/F-7733-2013; Lowe, Rachel/GXN-3278-2022; White, Patrick/AAN-7799-2020; Francis, Nick/B-7413-2009; Hood, Kerenza/C-2528-2008; Cals, Jochen/A-1262-2007	Phillips, Rhiannon/0000-0002-4256-4598; Francis, Nick/0000-0001-8939-7312; Butler, Christopher/0000-0002-0102-3453; Lowe, Rachel/0000-0002-7306-0085; Gal, Micaela/0000-0002-1326-190X; Gillespie, David/0000-0002-6934-2928; Hood, Kerenza/0000-0002-5268-8631; Thomas-Jones, Emma/0000-0001-7716-2786; Wootton, Mandy/0000-0002-2227-3355; Cals, Jochen/0000-0001-9550-5674; White, Patrick/0000-0002-2047-8787	National Institute for Health Research	National Institute for Health Research(National Institute for Health Research (NIHR))	Funded by the National Institute for Health Research Health Technology Assessment Program; PACE Current Controlled Trials number, ISRCTN24346473.	Aabenhus R, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010130.pub2; Al-ani S, 2013, FAM PRACT, V30, P621, DOI 10.1093/fampra/cmt055; Angrist JD, 1996, J AM STAT ASSOC, V91, P444, DOI 10.2307/2291629; ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196; Bafadhel M, 2012, AM J RESP CRIT CARE, V186, P48, DOI 10.1164/rccm.201108-1553OC; Bates J, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2144-8; Cals JWL, 2013, ANN FAM MED, V11, P157, DOI 10.1370/afm.1477; Cals JWL, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1374; Cosby JL, 2007, LANCET INFECT DIS, V7, P749, DOI 10.1016/S1473-3099(07)70263-3; Desai H, 2010, COPD, V7, P337, DOI 10.3109/15412555.2010.510162; Ferrante di Ruffano L, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e686; Fleming-Dutra KE, 2016, JAMA-J AM MED ASSOC, V315, P1864, DOI 10.1001/jama.2016.4151; Gillespie D, 2018, LANCET INFECT DIS, V18, P595, DOI 10.1016/S1473-3099(18)30289-5; Gonzales R, 2006, ACAD EMERG MED, V13, P288, DOI [10.1111/j.1553-2712.2006.tb01695.x, 10.1197/j.aem.2005.10.016]; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Goossens H, 2000, J ANTIMICROB CHEMOTH, V46, P39, DOI 10.1093/jac/46.suppl_2.39; Harries TH, 2014, NPJ PRIM CARE RESP M, V24, DOI 10.1038/npjpcrm.2014.6; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Hicks LA, 2015, CLIN INFECT DIS, V60, P1308, DOI 10.1093/cid/civ076; Horvath AR, 2014, CLIN CHIM ACTA, V427, P49, DOI 10.1016/j.cca.2013.09.018; Hurst JR, 2006, AM J RESP CRIT CARE, V174, P867, DOI 10.1164/rccm.200604-506OC; Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883; Kocks JWH, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-62; Lindenauer PK, 2006, ANN INTERN MED, V144, P894, DOI 10.7326/0003-4819-144-12-200606200-00006; Little P, 2013, LANCET INFECT DIS, V13, P123, DOI 10.1016/S1473-3099(12)70300-6; Llor C, 2013, THER ADV RESPIR DIS, V7, P131, DOI 10.1177/1753465812472387; Llor C, 2012, AM J RESP CRIT CARE, V186, P716, DOI 10.1164/rccm.201206-0996OC; Mathioudakis AG, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0073-2016; McNulty CAM, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009748; Minnaard MC, 2015, SCAND J CLIN LAB INV, V75, P291, DOI 10.3109/00365513.2015.1006136; Miravitlles M, 2002, EUR RESPIR J, V20, p9S, DOI 10.1183/09031936.02.00400302; Miravitlles M, 2013, CHEST, V144, P1571, DOI 10.1378/chest.13-0518; Nacul L, 2011, J PUBLIC HEALTH-UK, V33, P108, DOI 10.1093/pubmed/fdq031; Ni Hanyu, 2016, NCHS Data Brief, P1; O'Neill J, 2015, RAPID DIAGNOSTICS ST; Papi A, 2006, AM J RESP CRIT CARE, V173, P1114, DOI 10.1164/rccm.200506-859OC; Perez-Trallero E, 2005, CLIN INFECT DIS, V41, P560, DOI 10.1086/432062; Schroeck JL, 2015, ANTIMICROB AGENTS CH, V59, P3848, DOI 10.1128/AAC.00652-15; Schunemann HJ, 2003, CHEST, V124, P1421, DOI 10.1378/chest.124.4.1421; Schunemann HJ, 2005, COPD, V2, P81, DOI DOI 10.1081/C0PD-200050651; Strykowski DF, 2015, FAM PRACT, V32, P395, DOI 10.1093/fampra/cmv020; Thorpe KE, 2009, J CLIN EPIDEMIOL, V62, P464, DOI [10.1503/cmaj.090523, 10.1016/j.jclinepi.2008.12.011]; Tonkin-Crine SK, 2017, COCHRANE DB SYST REV, V9; van der Molen Thys, 2003, Health Qual Life Outcomes, V1, P13, DOI 10.1186/1477-7525-1-13; van Velzen P, 2017, LANCET RESP MED, V5, P492, DOI 10.1016/S2213-2600(17)30165-0; Verbakel JY, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015760; Vollenweider DJ, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010257; Wheaton AG, 2015, MMWR-MORBID MORTAL W, V64, P289	48	110	113	5	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 11	2019	381	2					111	120		10.1056/NEJMoa1803185	http://dx.doi.org/10.1056/NEJMoa1803185			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IJ1ON	31291514	Green Accepted, Bronze, Green Published			2023-01-03	WOS:000475668100006
J	Shehabi, Y; Howe, BD; Bellomo, R; Arabi, YM; Bailey, M; Bass, FE; Bin Kadiman, S; McArthur, CJ; Murray, L; Reade, MC; Seppelt, IM; Takala, J; Wise, MP; Webb, SA				Shehabi, Y.; Howe, B. D.; Bellomo, R.; Arabi, Y. M.; Bailey, M.; Bass, F. E.; Bin Kadiman, S.; McArthur, C. J.; Murray, L.; Reade, M. C.; Seppelt, I. M.; Takala, J.; Wise, M. P.; Webb, S. A.		ANZICS Clinical Trials Grp; SPICE III Investigators	Early Sedation with Dexmedetomidine in Critically Ill Patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MECHANICALLY VENTILATED PATIENTS; INTENSIVE-CARE-UNIT; LONG-TERM MORTALITY; STANDARD CARE; DELIRIUM; ADULTS; METAANALYSIS; RELIABILITY; MIDAZOLAM; VALIDITY	BackgroundDexmedetomidine produces sedation while maintaining a degree of arousability and may reduce the duration of mechanical ventilation and delirium among patients in the intensive care unit (ICU). The use of dexmedetomidine as the sole or primary sedative agent in patients undergoing mechanical ventilation has not been extensively studied. MethodsIn an open-label, randomized trial, we enrolled critically ill adults who had been undergoing ventilation for less than 12 hours in the ICU and were expected to continue to receive ventilatory support for longer than the next calendar day to receive dexmedetomidine as the sole or primary sedative or to receive usual care (propofol, midazolam, or other sedatives). The target range of sedation-scores on the Richmond Agitation and Sedation Scale (which is scored from -5 [unresponsive] to +4 [combative]) was -2 to +1 (lightly sedated to restless). The primary outcome was the rate of death from any cause at 90 days. ResultsWe enrolled 4000 patients at a median interval of 4.6 hours between eligibility and randomization. In a modified intention-to-treat analysis involving 3904 patients, the primary outcome event occurred in 566 of 1948 (29.1%) in the dexmedetomidine group and in 569 of 1956 (29.1%) in the usual-care group (adjusted risk difference, 0.0 percentage points; 95% confidence interval, -2.9 to 2.8). An ancillary finding was that to achieve the prescribed level of sedation, patients in the dexmedetomidine group received supplemental propofol (64% of patients), midazolam (3%), or both (7%) during the first 2 days after randomization; in the usual-care group, these drugs were administered as primary sedatives in 60%, 12%, and 20% of the patients, respectively. Bradycardia and hypotension were more common in the dexmedetomidine group. ConclusionsAmong patients undergoing mechanical ventilation in the ICU, those who received early dexmedetomidine for sedation had a rate of death at 90 days similar to that in the usual-care group and required supplemental sedatives to achieve the prescribed level of sedation. More adverse events were reported in the dexmedetomidine group than in the usual-care group.	[Shehabi, Y.] Monash Univ, Sch Clin Sci, Melbourne, Vic, Australia; [Howe, B. D.; Bellomo, R.; Bailey, M.; Murray, L.; Webb, S. A.] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Shehabi, Y.] Monash Hlth, Melbourne, Vic, Australia; [Bellomo, R.; Bailey, M.] Univ Melbourne, Fac Med, Melbourne, Vic, Australia; [Bellomo, R.] Austin Hosp, Heidelberg, Vic, Australia; [Shehabi, Y.] Univ New South Wales, Prince Wales Clin Sch Med, Royal North Shore Hosp, Sydney, NSW, Australia; [Bass, F. E.] Univ Sydney, Sydney Med Sch Nepean, George Inst Global Hlth, Sydney, NSW, Australia; [Seppelt, I. M.] Macquarie Univ, Dept Clin Med, Sydney, NSW, Australia; [Reade, M. C.] Univ Queensland, Royal Brisbane & Womens Hosp, Fac Med, Brisbane, Qld, Australia; [Reade, M. C.] Australian Def Force, Joint Hlth Command, Canberra, ACT, Australia; [Webb, S. A.] St John God Subiaco Hosp, Subiaco, WA, Australia; [Arabi, Y. M.] King Saud Bin Abdulaziz Univ Hlth Sci, Coll Med, Riyadh, Saudi Arabia; [Arabi, Y. M.] King Abdul Aziz Med City, King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia; [Bin Kadiman, S.] Natl Heart Inst, IJN UTM Cardiovasc Engn Ctr, Dept Anesthesiol & Intens Care, Kuala Lumpur, Malaysia; [McArthur, C. J.] Univ Auckland, Auckland City Hosp, Dept Crit Care Med, Auckland, New Zealand; [Takala, J.] Univ Bern, Bern Univ Hosp, Inselspital, Bern, Switzerland; [Wise, M. P.] Univ Hosp Wales, Adult Crit Care, Cardiff, S Glam, Wales	Monash University; Monash University; University of Melbourne; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Royal North Shore Hospital; University of New South Wales Sydney; George Institute for Global Health; University of Sydney; Macquarie University; Royal Brisbane & Women's Hospital; University of Queensland; St John of God Health Care; King Saud Bin Abdulaziz University for Health Sciences; King Abdulaziz Medical City; King Saud Bin Abdulaziz University for Health Sciences; King Abdulaziz Medical City - Riyadh; King Abdullah International Medical Research Center (KAIMRC); Institute Jantung Negara; Universiti Teknologi Malaysia; Auckland City Hospital; University of Auckland; University of Bern; University Hospital of Bern; Cardiff University	Shehabi, Y (corresponding author), Monash Univ, Sch Clin Sci, Monash Med Ctr, Level 5,E Block, Clayton, Vic 3168, Australia.	yahya.shehabi@monashhealth.org	Bailey, Michael J/A-4499-2012; Arabi, Yaseen/ABF-3316-2020; Mellinghoff, Johannes/V-4844-2019; Reade, Michael/G-7035-2012; Edgeworth, Cathrine/AAB-7428-2020; martin-loeches, Prof. Ignacio/Q-6645-2018	Bailey, Michael J/0000-0002-5551-1401; Arabi, Yaseen/0000-0001-5735-6241; Mellinghoff, Johannes/0000-0002-5455-8953; Reade, Michael/0000-0003-1570-0707; Hays, Leanne/0000-0002-6936-1459; Edgeworth, Cathrine/0000-0002-5190-9711; Al-Sheikh Hassan, Mohammed/0000-0001-7020-1156; Venkatesh, Bala/0000-0002-3234-5244; Young, Paul/0000-0002-3428-3083; Whitehead, Christina/0000-0003-4561-7082; LANDONI, Giovanni/0000-0002-8594-5980; SHEHABI, Yahya/0000-0003-4707-7462; Welters, Ingeborg/0000-0002-3408-8798; ZANGRILLO, Alberto/0000-0002-7687-7648; Deeb, Ahmad/0000-0002-3680-7338; Bass, Frances/0000-0003-3826-8558; Brealey, David/0000-0002-1982-3379; Nichol, Alistair/0000-0002-4689-1238; martin-loeches, Prof. Ignacio/0000-0002-5834-4063; Bercades, Georgia/0000-0002-5961-3149	National Health and Medical Research Council of Australia	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	Funded by the National Health and Medical Research Council of Australia and others; SPICE III ClinicalTrials.gov number, NCT01728558.	BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Carollo DS, 2008, CURR OPIN ANESTHESIO, V21, P457, DOI 10.1097/ACO.0b013e328305e3ef; Constantin JM, 2016, ANAESTH CRIT CARE PA, V35, P7, DOI 10.1016/j.accpm.2015.06.012; Devlin JW, 2013, SEMIN RESP CRIT CARE, V34, P201, DOI 10.1055/s-0033-1342983; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Fraser GL, 2013, CRIT CARE MED, V41, pS30, DOI 10.1097/CCM.0b013e3182a16898; Gelinas C, 2006, AM J CRIT CARE, V15, P420; Gommers D, 2008, CRIT CARE, V12, DOI 10.1186/cc6150; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Jakob SM, 2012, JAMA-J AM MED ASSOC, V307, P1151, DOI 10.1001/jama.2012.304; Jorm A, 2004, SHORT FORM INFORMANT; Kawazoe Y, 2017, JAMA-J AM MED ASSOC, V317, P1321, DOI 10.1001/jama.2017.2088; Keating GM, 2015, DRUGS, V75, P1119, DOI 10.1007/s40265-015-0419-5; Kim J, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/1471-2253-15-17; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Mangoni AA, 2004, BRIT J CLIN PHARMACO, V57, P6, DOI 10.1046/j.1365-2125.2003.02007.x; Mehta S, 2012, JAMA-J AM MED ASSOC, V308, P1985, DOI 10.1001/jama.2012.13872; Mehta S, 2009, CRIT CARE CLIN, V25, P471, DOI 10.1016/j.ccc.2009.04.001; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; Pandharipande PP, 2010, CRIT CARE, V14, DOI 10.1186/cc8916; Pun BT, 2019, CRIT CARE MED, V47, P3, DOI 10.1097/CCM.0000000000003482; Reade MC, 2016, JAMA-J AM MED ASSOC, V315, P1460, DOI 10.1001/jama.2016.2707; Reade MC, 2014, NEW ENGL J MED, V370, P444, DOI 10.1056/NEJMra1208705; Ren XY, 2016, J NEUROIMMUNE PHARM, V11, P238, DOI 10.1007/s11481-016-9658-9; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Roberts DJ, 2012, DRUGS, V72, P1881, DOI 10.2165/11636220-000000000-00000; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Shehabi Y, 2018, CRIT CARE MED, V46, P850, DOI 10.1097/CCM.0000000000003071; Shehabi Y, 2017, CRIT CARE RESUSC, V19, P318; Shehabi Y, 2013, CRIT CARE, V17, DOI 10.1186/cc12679; Shehabi Y, 2013, INTENS CARE MED, V39, P910, DOI 10.1007/s00134-013-2830-2; Shehabi Y, 2012, AM J RESP CRIT CARE, V186, P724, DOI 10.1164/rccm.201203-0522OC; Shehabi Y, 2010, CRIT CARE MED, V38, P2311, DOI 10.1097/CCM.0b013e3181f85759; Si YN, 2014, EUR REV MED PHARMACO, V18, P1843; Skrobik Y, 2018, AM J RESP CRIT CARE, V197, P1147, DOI 10.1164/rccm.201710-1995OC; Stephens RJ, 2018, CRIT CARE MED, V46, P471, DOI 10.1097/CCM.0000000000002885; Taniguchi T, 2004, CRIT CARE MED, V32, P1322, DOI 10.1097/01.CCM.0000128579.84228.2A; Ueki M, 2014, ANAESTHESIA, V69, P693, DOI 10.1111/anae.12636; Wunsch H, 2009, CRIT CARE MED, V37, P3031, DOI 10.1097/CCM.0b013e3181b02eff	40	196	201	8	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	2019	380	26					2506	2517		10.1056/NEJMoa1904710	http://dx.doi.org/10.1056/NEJMoa1904710			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IN7CS	31112380	Bronze			2023-01-03	WOS:000478840000007
J	Jung, L; Hogan, ME; Sun, YH; Liang, BM; Hayward, JA				Jung, Lawrence; Hogan, Michael E.; Sun, Yuhua; Liang, Benjamin Minghwa; Hayward, James A.			Rapid authentication of pharmaceuticals via DNA tagging and field detection	PLOS ONE			English	Article							IDENTIFICATION; ASSAY	A small PCR-generated DNA fragment was introduced into a pharmaceutical grade ink as a molecular taggant, and the DNA tagged ink was delivered onto the surface of capsules by standard high-speed offset printing. The amount of DNA in the ink on each capsule is roughly 10-12 fold lower than that allowed as safe by the United States Food and Drug Administration (FDA) and the WHO with regards to acceptable limits of residual DNA. The printed ink on the capsule surface was sampled by swabbing, followed by direct analysis of the DNA-swab complex, without subsequent DNA purification. It was shown that DNA recovered from the ink by swabbing was suitable for PCR-CE analysis-a widely used method in forensic science and was also suitable for qPCR and isothermal DNA amplification, when coupled with portable devices similar to those used for environmental sampling and food safety testing. The data set a precedent: A small DNA fragment could be introduced as an excipient into a pharmaceutical application, and thereafter tracked through the pharmaceutical supply chain via forensic DNA authentication.	[Jung, Lawrence; Hogan, Michael E.; Sun, Yuhua; Liang, Benjamin Minghwa; Hayward, James A.] Appl DNA Sci Inc, Stony Brook, NY 11790 USA		Jung, L; Hogan, ME (corresponding author), Appl DNA Sci Inc, Stony Brook, NY 11790 USA.	lawrence.jung@adnas.com; mike.hogan@adnas.com		Jung, Lawrence/0000-0002-9857-5480	Applied DNA Sciences, Inc.	Applied DNA Sciences, Inc.	This study was funded by Applied DNA Sciences, Inc.; a publicly traded company (NASDAQ: APDN) http://adnas.com/. Authors are employed by Applied DNA Sciences, Inc., which provided support in the form of salaries for all authors and decision to publish the results but did not have any additional role in the study design, data collection and analysis or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Alghafri R, 2015, FORENSIC SCI INT-GEN, V17, P91, DOI 10.1016/j.fsigen.2015.04.004; [Anonymous], 2007, ILLUSTRATM PURETAQ R; [Anonymous], 2018, ACG SIGNS MOU APPL D; [Anonymous], 2015, D005566 VIC; [Anonymous], 2010, BBC NEWS; [Anonymous], 2015, TWISTAMP MANUALS; [Anonymous], 2015, SOFTW MAN VER 1 1 0; [Anonymous], 2018, APPL DNA SIGNS DEFIN; Centers for Disease Control and Prevention, 2014, COUNT DRUGS; Daher RK, 2016, CLIN CHEM, V62, P947, DOI 10.1373/clinchem.2015.245829; Degardin K, 2015, FORENSIC SCI INT, V248, P15, DOI 10.1016/j.forsciint.2014.11.015; Gorog S, 2015, TRAC-TREND ANAL CHEM, V69, P114, DOI 10.1016/j.trac.2014.11.020; Hill-Cawthorne GA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101419; Interpol, 2015, OP; Lebron JA, 2006, DEV BIOLOGICALS, V123, P35; Lebron JA, 2006, DEV BIOL BASEL, V123, P55; Lynch M, 2003, ENDEAVOUR, V27, P93, DOI 10.1016/S0160-9327(03)00068-1; Mead BK, 2014, J FORENSIC SCI, V59, P264, DOI 10.1111/1556-4029.12280; Murray E, 2012, US Patent, Patent No. [8,163,489, 8163489]; National Research Council (US), 1992, DNA TECHN FOR SCI; Niemz A, 2011, TRENDS BIOTECHNOL, V29, P240, DOI 10.1016/j.tibtech.2011.01.007; NORTH ATLANTIC TREATY ORGANIZATION MILITARY AGENCY FOR STANDARDIZATION (MAS), 1996, NATO HDB MED ASP NBC; Nussbaumer C, 2006, FORENSIC SCI INT, V157, P181, DOI 10.1016/j.forsciint.2005.10.009; Patel P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004953; Piepenburg O, 2006, PLOS BIOL, V4, P1115, DOI 10.1371/journal.pbio.0040204; Stringer J, 2000, POINT CARE VIROLOGIC; TaqMan Fast Advanced Master Mix Product Insert, 2010, TAQMAN FAST ADV MAST; TaqMan&REG; Gene Expression Assays Protocol, 2010, TAQMAN GENE EXPRESSI; U. S. Food and Drug, 2003, ADM GUID IND 11; U. S. Food and Drug Administration, 2018, IN INGR SEARCH APPR; United States of America. U. S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2011, GUID IND INC PHYS CH; United States of America. U. S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2010, GUID IND CHAR QUAL C; Varsha, 2006, DNA CELL BIOL, V25, P181; WHO, 2010, WHO TECHN REP SER, V878; World Health Organization, 1991, ANN 3 WORLD TECHN RE, V814; Yang Harry, 2013, PDA J Pharm Sci Technol, V67, P155, DOI 10.5731/pdajpst.2013.00910; Zhang XA, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2016.134	37	3	3	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2019	14	6							e0218314	10.1371/journal.pone.0218314	http://dx.doi.org/10.1371/journal.pone.0218314			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IC8NN	31194827	gold, Green Published, Green Submitted			2023-01-03	WOS:000471238300086
J	Wangmo, K; Laven, R; Cliquet, F; Wasniewski, M; Yang, A				Wangmo, Karma; Laven, Richard; Cliquet, Florence; Wasniewski, Marine; Yang, Aaron			Comparison of antibody titres between intradermal and intramuscular rabies vaccination using inactivated vaccine in cattle in Bhutan	PLOS ONE			English	Article							DISEASE; IMMUNIZATION; PROPHYLAXIS; POPULATION; INFECTION; EFFICACY; IMPACT; DOGS	In developing countries, the cost of vaccination limits the use of prophylactic rabies vaccination, especially in cattle. Intradermal vaccination delivers antigen directly to an area with higher number of antigen-presenting cells. Therefore, it could produce equivalent or higher antibody titres than conventional intramuscular vaccination even when a lower dose is given. This study aimed to compare the antibody response in cattle vaccinated intramuscularly with 1mL of inactivated rabies vaccine (Raksharab, Indian Immunologicals) against intradermally vaccinated cattle with 0.2mL of the same vaccine. The study was conducted in Haa province of Bhutan where rabies is not endemic. One hundred cattle from 27 farms were selected for the study. Virus neutralising antibody (VNA) response was measured using the fluorescent antibody virus neutralisation test on the day of vaccination (day 0) and 14, 30, 60 and 90 days later. Overall, 71% of intradermally vaccinated cattle and 89% of the intramuscularly vaccinated cattle produced an adequate response (>= 0.5IU/mL). On days 14 and 30 post vaccination fewer cattle (P< 0.02) in the intradermal group had adequate titres with 36% and 58%, respectively, having titres >= 0.5 IU/mL compared to the equivalent figures of 78% and 77% in the intramuscular group. The mean VNA titres were lower for the intradermal group than intramuscular group (p< 0.001) with the mean difference being > 0.6 IU/mL. Although low dose intradermal vaccination did produce a detectable antibody response, it was inferior to intramuscular vaccination. Thus, although intradermal vaccination has the potential to reduce the cost of vaccination by reducing the dose required, this study showed that a single dose of 0.2 mL intradermally was inferior to an intramuscular dose of 1 mL. Further research evaluating dose and dose regimen is needed before intradermal vaccination using the Raksharab rabies vaccine can be recommended in cattle.	[Wangmo, Karma; Laven, Richard; Yang, Aaron] Massey Univ, Inst Vet Anim & Biomed Sci, Palmerston North, New Zealand; [Wangmo, Karma] Minist Agr & Forest, Dist Vet Hosp, Dept Livestock, Samtse, Bhutan; [Cliquet, Florence; Wasniewski, Marine] ANSES, European Union Reference Lab Rabies Serol, OIE Reference Lab Rabies,WHO Collaborating Ctr Re, Nancy Lab Rabies & Wildlife,European Union Refere, Paris, France	Massey University; Agence Nationale de Securite Sanitaire de l'Alimentation, de l'Environnement du Travail (ANSES); Technopole Agricole et Veterinaire	Wangmo, K (corresponding author), Massey Univ, Inst Vet Anim & Biomed Sci, Palmerston North, New Zealand.; Wangmo, K (corresponding author), Minist Agr & Forest, Dist Vet Hosp, Dept Livestock, Samtse, Bhutan.	karmazwank@yahoo.com	WASNIEWSKI, Marine/AAX-8945-2020; Yang, Danchen Aaron/AAC-4306-2019; Laven, Richard/ABG-4840-2020	Yang, Danchen Aaron/0000-0003-3893-9403; Wangmo, Karma/0000-0002-5306-4417	New Zealand development scholarship, Massey University; ANSES, Nancy Laboratory for Rabies and Wildlife, France	New Zealand development scholarship, Massey University; ANSES, Nancy Laboratory for Rabies and Wildlife, France	The study was funded by New Zealand development scholarship, Massey University and ANSES, Nancy Laboratory for Rabies and Wildlife, France. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson A, 2014, TRANSBOUND EMERG DIS, V61, P140, DOI 10.1111/tbed.12007; Asokkumar M., 2016, Indian Veterinary Journal, V93, P33; Aubert M F, 1992, Rev Sci Tech, V11, P735; Benisek Z, 2006, B VET I PULAWY, V50, P137; Bharti OK, 2018, WORLD, V8, P8; Cliquet F, 2000, VACCINE, V18, P3272, DOI 10.1016/S0264-410X(00)00127-4; Cliquet F, 1998, J IMMUNOL METHODS, V212, P79, DOI 10.1016/S0022-1759(97)00212-3; Cortes J A, 1993, Rev Sci Tech, V12, P941; Darkaoui S, 2016, CLIN EXP VACCINE RES, V5, P60, DOI 10.7774/cevr.2016.5.1.60; Dukpa K, 2011, NEW ZEAL VET J, V59, P51, DOI 10.1080/00480169.2011.552852; European directorate for the quality of medicines, EUROPEAN PHARMACOPOE, P949; Feng Y, 2016, ARCH VIROL, V161, P2851, DOI 10.1007/s00705-016-2982-9; Hammami S, 1999, VET RES, V30, P607; ITZCHAK S, 1992, VACCINE, V10, P217, DOI 10.1016/0264-410X(92)90155-D; Jibat T, 2016, PREV VET MED, V130, P67, DOI 10.1016/j.prevetmed.2016.06.005; Khawplod P, 2006, VACCINE, V24, P3084, DOI 10.1016/j.vaccine.2006.01.051; KOPROWSKI H, 1955, J Am Vet Med Assoc, V127, P363; LARGHI OP, 1985, ZBL VET MED B, V32, P609; Lodmell DL, 2006, VACCINE, V24, P412, DOI 10.1016/j.vaccine.2005.08.003; Madhusudana SN, 2014, EXPERT REV VACCINES, V13, P641, DOI 10.1586/14760584.2014.901893; Malissen B, 2014, NAT REV IMMUNOL, V14, P417, DOI 10.1038/nri3683; Mayen F, 2003, J VET MED B, V50, P469, DOI 10.1046/j.1439-0450.2003.00713.x; MoAF, 2016, LIV STAT; National Centre of Animal Health, 2017, NAT RAB PREV CONTR P; OIE, 2018, MAN DIAGN TESTS VACC, P35; Permpalung N, 2013, VACCINE, V31, P4079, DOI 10.1016/j.vaccine.2013.06.083; Ray NB, 1997, VACCINE, V15, P892, DOI 10.1016/S0264-410X(96)00281-2; Rinzin K, 2016, PREV VET MED, V126, P39, DOI 10.1016/j.prevetmed.2016.01.030; Roche JR, 2013, VET CLIN N AM-FOOD A, V29, P323, DOI 10.1016/j.cvfa.2013.03.003; Rodrigues da Silva Andrea De Cassia, 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P95, DOI 10.1590/S0036-46652000000200006; Rupprecht CE, 2002, LANCET INFECT DIS, V2, P327, DOI 10.1016/S1473-3099(02)00287-6; Sudarshan MK, 2011, ASIAN BIOMED, V5, P589, DOI 10.5372/1905-7415.0505.078; Tenzin, 2012, PREV VET MED, V107, P21, DOI 10.1016/j.prevetmed.2012.05.003; Tenzin, 2011, ZOONOSES PUBLIC HLTH, V58, P463, DOI 10.1111/j.1863-2378.2011.01393.x; Tenzin, 2011, EPIDEMIOL INFECT, V139, P220, DOI 10.1017/S0950268810001135; Thiptara A, 2011, AM J TROP MED HYG, V85, P138, DOI 10.4269/ajtmh.2011.10-0535; Vescovo P, 2017, VACCINE, V35, P1782, DOI 10.1016/j.vaccine.2016.09.069; Vos A, 2014, EPIDEMIOL INFECT, V142, P1925, DOI 10.1017/S0950268813002811; World Health Organization, 2013, WHO EXP CONS RAB 2 R; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	40	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2019	14	6							e0209946	10.1371/journal.pone.0209946	http://dx.doi.org/10.1371/journal.pone.0209946			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IC3IS	31181078	Green Published, Green Submitted, gold			2023-01-03	WOS:000470854200002
J	van den Tillaar, R; Andersen, V; Saeterbakken, AH				van den Tillaar, Roland; Andersen, Vidar; Saeterbakken, Atle Hole			Comparison of muscle activation and kinematics during free-weight back squats with different loads	PLOS ONE			English	Article							CLOSED KINETIC CHAIN; RESISTANCE; STRENGTH; INTENSITY; VELOCITY; SINGLE; PRESS; KNEE	Although several studies have examined the effects of performing resistance training with different percentages of one-repetition maximum (1-RM), little is known of the neuromuscular effects and kinematics of lifting low to heavy loads with maximal movement velocity. The aim of this study is to compare muscle activation and kinematics in free-weight back squats with different loads. Thirteen resistance-training males (aged 24.2 +/- 2.0 years, body mass 81.5 +/- 9.1 kg, height 1.78 +/- 0.06 m) with 6 +/- 3 years of resistance-training experience conducted squats with 30%-100% of 1-RM. Barbell kinematics and electromyographic (EMG) activity of the vastus lateralis, vastus medialis, rectus femoris, semitendinosus, biceps femoris, and gluteus maximus were measured in the upward phase of each load. With increasing loads, the barbell velocity decreased, the upward phase duration increased, and the peak velocity occurred later. The muscle activation in all muscles increased with increasing loads but was not linear. In general, similar muscle activation in the prime movers was observed for loads between 40% and 60% of 1-RM and between 70% and 90% of 1-RM, with 100% of 1-RM being superior to the other loads when the loads were lifted at maximal intended velocity. However, the timing of maximal muscle activations was not affected by the different loadings for the quadriceps, but the timing was sequential and independent of loading (rectus femoris before vastus medial before vastus lateral). Maximal activation in the gluteus and semitendinosus increased with increasing loads. This means that for muscle activation, maximal lifting velocity may compensate for increased loads, which may allow resistance-trained athletes and individuals in rehabilitation to avoid heavy loads but still get the same muscle activation.	[van den Tillaar, Roland] Nord Univ, Dept Sport Sci & Phys Educ, Levanger, Norway; [Andersen, Vidar; Saeterbakken, Atle Hole] Western Norway Univ, Fac Teacher Educ Culture & Sport, Dept Sport Food & Nat Sci, Sogndal, Sogn Og Fjordan, Norway	Nord University	van den Tillaar, R (corresponding author), Nord Univ, Dept Sport Sci & Phys Educ, Levanger, Norway.	roland.v.tillaar@nord.no						Aagaard P, 2002, J APPL PHYSIOL, V93, P1318, DOI 10.1152/japplphysiol.00283.2002; Andersen V, 2014, INT J SPORTS MED, V35, P1196, DOI 10.1055/s-0034-1382016; Aspe RR, 2014, J STRENGTH COND RES, V28, P2827, DOI 10.1519/JSC.0000000000000462; Bangalore S, 2006, J AM COLL CARDIOL, V48, P1471, DOI 10.1016/j.jacc.2006.07.011; Bloomquist K, 2013, EUR J APPL PHYSIOL, V113, P2133, DOI 10.1007/s00421-013-2642-7; Bosquet L, 2010, J SPORT SCI MED, V9, P459; Campos GER, 2002, EUR J APPL PHYSIOL, V88, P50, DOI 10.1007/s00421-002-0681-6; Clark DR, 2012, J STRENGTH COND RES, V26, P1169, DOI 10.1519/JSC.0b013e31822d533d; Cochrane DJ, 2015, RES SPORTS MED, V23, P179, DOI 10.1080/15438627.2015.1005299; Cohen J., 2013, STAT POWER ANAL BEHA; Drinkwater EJ, 2007, J STRENGTH COND RES, V21, P841; Ema R, 2016, EUR J APPL PHYSIOL, V116, P1031, DOI 10.1007/s00421-016-3363-5; Escamilla RF, 1998, MED SCI SPORT EXER, V30, P556, DOI 10.1097/00005768-199804000-00014; Escamilla RF, 2001, MED SCI SPORT EXER, V33, P984, DOI 10.1097/00005768-200106000-00019; Farahmand F, 1998, J ORTHOP RES, V16, P136, DOI 10.1002/jor.1100160123; Gomes WA, 2015, J STRENGTH COND RES, V29, P2482, DOI 10.1519/JSC.0000000000000922; Gonzalez-Badillo JJ, 2010, INT J SPORTS MED, V31, P347, DOI 10.1055/s-0030-1248333; Goodman CA, 2008, J STRENGTH COND RES, V22, P88, DOI 10.1519/JSC.0b013e31815ef6b3; Hermens HJ, 2000, J ELECTROMYOGR KINES, V10, P361, DOI 10.1016/S1050-6411(00)00027-4; Kaneko M, 1983, SCAND J SPORTS SCI, V5, P50; KOMI PV, 1987, INT J SPORTS MED, V8, P22; Marshall PWM, 2011, EUR J APPL PHYSIOL, V111, P3007, DOI 10.1007/s00421-011-1944-x; McBride JM, 2002, J STRENGTH COND RES, V16, P75, DOI 10.1519/00124278-200202000-00011; Newton RU, 1997, EUR J APPL PHYSL, V50, P311; Ratamess NA, 2009, MED SCI SPORT EXER, V41, P687, DOI 10.1249/MSS.0b013e3181915670; Saeterbakken AH, 2016, J STRENGTH COND RES, V30, P945, DOI 10.1519/JSC.0000000000001178; Saeterbakken AH, 2014, J STRENGTH COND RES, V28, P3056, DOI 10.1519/JSC.0000000000000516; Saeterbakken AH, 2013, J STRENGTH COND RES, V27, P130, DOI 10.1519/JSC.0b013e3182541d43; Sanchez Medina L., 2010, THESIS; Suchomel TJ, 2018, SPORTS MED, V48, P765, DOI 10.1007/s40279-018-0862-z; Van Cutsem M, 1998, J PHYSIOL-LONDON, V513, P295, DOI 10.1111/j.1469-7793.1998.295by.x; van den Tillaar R, 2014, KINESIOL SLOVENICA, V20, P5; van den Tillaar R, 2015, KINESIOL SLOVEN, V21, P15; van den Tillaar R, 2014, J HUM KINET, V42, P63, DOI 10.2478/hukin-2014-0061; van den Tillaar R, 2009, MED SCI SPORT EXER, V41, P2056, DOI 10.1249/MSS.0b013e3181a8c360; Yavuz HU, 2017, APPL BIONICS BIOMECH, V2017, DOI 10.1155/2017/9084725; 2002, CLIN ANAT, V15, P116; 2008, J BIOMECH, V41, P3127, DOI DOI 10.1016/J.JBIOMECH.2008.09.003; MED SCI SPORTS EXERC, V32, P459; 1981, EUR J APPL PHYSL OCC, V46, P221; 2010, INT J SPORT PHYSIOL, V5, P177	41	18	18	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2019	14	5							e0217044	10.1371/journal.pone.0217044	http://dx.doi.org/10.1371/journal.pone.0217044			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY3MG	31095625	Green Submitted, Green Published, gold			2023-01-03	WOS:000468030100070
J	Fernandez-Mendez, F; Otero-Agra, M; Abelairas-Gomez, C; Saez-Gallego, NM; Rodriguez-Nunez, A; Barcala-Furelos, R				Fernandez-Mendez, Felipe; Otero-Agra, Martin; Abelairas-Gomez, Cristian; Maria Saez-Gallego, Nieves; Rodriguez-Nunez, Antonio; Barcala-Furelos, Roberto			ABCDE approach to victims by lifeguards: How do they manage a critical patient? A cross sectional simulation study	PLOS ONE			English	Article							RESUSCITATION COUNCIL GUIDELINES; BASIC LIFE-SUPPORT; CARDIOPULMONARY-RESUSCITATION; CARDIAC-ARREST; TECHNOLOGY; EDUCATION; QUALITY	Introduction Decision-making in emergencies is a multifactorial process based on the rescuer, patient, setting and resources. The eye-tracking system is a proven method for assessing decision-making processes that have been used in different fields of science. Our aim was to evaluate the lifeguards' capacity to perform the ABCDE (Airway-Breathing-Circulation-Disability-Exposure) approach when facing a simulated critically ill-drowned victim. Methods A cross-sectional simulation study was designed to assess the skills and sequence of the ABCDE approach by 20 professional lifeguards. They had to assess a victim and act according to his/her clinical status by following the ABCDE primary assessment approach. The two kinds of variables were recorder: those related to the quality of each step of the ABCDE approach and the visual behaviour using a portable eye-movement system. The eye-tracking system was the Mobile Eye system (Bedford, USA). Results None of the study participants were able to complete correctly the ABCDE approach. Lifeguards spent more time in the Circulation step: Airway (15.5 +/- 11.1 s), Breathing (25.1 +/- 21.1 s), Circulation (44.6 +/- 29.5 s), Disability (38.5 +/- 0.7 s). Participants spent more time in viewpoints considered as important (65.5 +/- 17.4 s) compared with secondary ones (34.6 +/- 17.4 s, p = 0.008). This was also represented in the percentage of visual fixations (fixations in important viewpoints: 63.36 +/- 15.06; fixation in secondary viewpoints: 36.64 +/- 15.06; p = 0.008). Conclusion Professional lifeguards failed to fully perform the ABCDE sequence. Evaluation by experts with the help of eye-tracking technology detected the lifeguards' limitations in the assessment and treatment of an eventual critically ill victim. Such deficits should be considered in the design and implementation of lifeguards' training programmes.	[Fernandez-Mendez, Felipe; Abelairas-Gomez, Cristian; Rodriguez-Nunez, Antonio] Univ Santiago de Compostela, CLINURSID Res Grp, Santiago De Compostela, Spain; [Fernandez-Mendez, Felipe] Univ Vigo, Univ Coll Nursing, Pontevedra, Spain; [Otero-Agra, Martin; Barcala-Furelos, Roberto] Univ Vigo, REMOSS Network Res, Fac Educ & Sport Sci, Pontevedra, Spain; [Abelairas-Gomez, Cristian] Univ Santiago de Compostela, Fac Educ Sci, Santiago De Compostela, Spain; [Abelairas-Gomez, Cristian; Rodriguez-Nunez, Antonio; Barcala-Furelos, Roberto] Inst Hlth Res Santiago IDIS, Santiago De Compostela, Spain; [Maria Saez-Gallego, Nieves] Univ Castilla La Mancha, Fac Educ, Toledo, Spain; [Rodriguez-Nunez, Antonio] Univ Hosp Santiago De Compostela, Pediat Emergency & Crit Care Div, Pediat Area, Santiago De Compostela, Spain; [Rodriguez-Nunez, Antonio] Carlos III Hlth Inst, Mother Child Hlth & Dev Network Red SAMID, Madrid, Spain	Universidade de Santiago de Compostela; Universidade de Vigo; Universidade de Vigo; Universidade de Santiago de Compostela; Universidad de Castilla-La Mancha; Complexo Hospitalario Universitario de Santiago de Compostela	Abelairas-Gomez, C (corresponding author), Univ Santiago de Compostela, CLINURSID Res Grp, Santiago De Compostela, Spain.; Abelairas-Gomez, C (corresponding author), Univ Santiago de Compostela, Fac Educ Sci, Santiago De Compostela, Spain.; Abelairas-Gomez, C (corresponding author), Inst Hlth Res Santiago IDIS, Santiago De Compostela, Spain.	cristianabelairasgomez@gmail.com	Barcala-Furelos, Roberto/R-8396-2018; Gallego, Nieves María Sáez/R-3775-2019; Abelairas-Gomez, Cristian/K-3338-2017; Otero-Agra, Martín/AAE-3210-2021; Saez-Gallego, Nieves María/K-3536-2017	Barcala-Furelos, Roberto/0000-0002-7247-0509; Gallego, Nieves María Sáez/0000-0001-5052-5567; Abelairas-Gomez, Cristian/0000-0002-1056-7778; Saez-Gallego, Nieves María/0000-0001-5052-5567; Fernandez-Mendez, Felipe/0000-0002-9025-595X; Otero-Agra, Martin/0000-0003-1543-9780; Rodriguez-Nunez, Antonio/0000-0003-3414-2771				American College of Surgeons Committee on Trauma, 2012, ADV TRAUM LIF SUPP S; Ashraf H, 2018, MED TEACH, V40, P62, DOI 10.1080/0142159X.2017.1391373; Baldi E, 2017, CAN J EMERG MED, V19, P480, DOI 10.1017/cem.2016.410; Beaubien JM, 2004, QUAL SAF HEALTH CARE, V13, pI51, DOI 10.1136/qshc.2004.009845; Claesson A, 2011, AM J EMERG MED, V29, P1044, DOI 10.1016/j.ajem.2010.06.026; Cooke D, 2017, JAMA-J AM MED ASSOC, V306, P978; Cortegiani A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169591; Cortegiani A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125685; Damji O, 2019, CAN J EMERG MED, V21, P138, DOI 10.1017/cem.2018.450; Fernandez-Mendez F, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9837508; Finn JC, 2015, RESUSCITATION, V95, pE203, DOI 10.1016/j.resuscitation.2015.07.046; Garcia SL, 2019, RETOS, V36, P461; Grant VJ, 2018, MED TEACH, V40, P703, DOI 10.1080/0142159X.2018.1468558; Henneman EA, 2017, SIMUL HEALTHC, V12, P51, DOI 10.1097/SIH.0000000000000192; Jayaraman S, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004173.pub4; Mohamed MMG, 2018, SUDAN MED J, V54, P64; Mundell WC, 2013, RESUSCITATION, V84, P1174, DOI 10.1016/j.resuscitation.2013.04.016; National Association of Emergency Medical Technicians US (NAEMET), 2014, PHTLS PREH TRAUM LIF; Olgers TJ, 2017, NETH J MED, V75, P106; Roca Andre, 2018, PLoS One, V13, pe0199381, DOI 10.1371/journal.pone.0199381; Saez-Gallego NM, 2018, REV INT MED CIENC AC, V18, P135, DOI 10.15366/rimcafd2018.69.009; Soar J, 2015, RESUSCITATION, V95, P100, DOI 10.1016/j.resuscitation.2015.07.016; Soreide K, 2008, SCAND J TRAUMA RESUS, V16, P9; Szpilman D, 2017, INT J EMERG MENT HLT, V19, P1; Szpilman D, 2018, RESUSCITATION, V129, P103, DOI 10.1016/j.resuscitation.2018.06.018; Szpilman D, 2016, AM J EMERG MED, V34, P2224, DOI 10.1016/j.ajem.2016.07.063; Szpilman D, 2012, NEW ENGL J MED, V366, P2102, DOI 10.1056/NEJMra1013317; Szulewski A, 2014, SCI WORLD J, DOI 10.1155/2014/975752; Truhlar A, 2015, RESUSCITATION, V95, P148, DOI 10.1016/j.resuscitation.2015.07.017; White MR, 2018, ANN EMERG MED, V72, P289, DOI 10.1016/j.annemergmed.2018.03.005; World Health Organization, 2014, GLOB REP DROWN PREV, P58	33	5	5	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2019	14	4							e0212080	10.1371/journal.pone.0212080	http://dx.doi.org/10.1371/journal.pone.0212080			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW0IT	31039154	Green Published, gold, Green Submitted			2023-01-03	WOS:000466364800003
J	Lin, TK; You, KX; Hsu, CT; Li, YD; Lin, CL; Weng, CY; Koo, M				Lin, Tin-Kwang; You, Kai-Xun; Hsu, Chiu-Tien; Li, Yi-Da; Lin, Chin-Lon; Weng, Chia-Ying; Koo, Malcolm			Negative affectivity and social inhibition are associated with increased cardiac readmission in patients with heart failure: A preliminary observation study	PLOS ONE			English	Article							C-REACTIVE PROTEIN; D PERSONALITY; PREDICTIVE-VALUE; HEALTH-STATUS; DISEASE; DEPRESSION; HOSPITALIZATIONS; MORTALITY	Background Type D personality was hypothesized to influence clinical and patient-centered outcomes patients with heart failure. The aim of this study was to investigate the association between negative affectivity and social inhibition components of Type D personality and cardiac readmission in patients with heart failure. Methods A prospective observational study design was used. A total of 222 patients with heart failure were recruited from the department of cardiology in two regional hospitals in Taiwan. The 14-item Type D Scale-Taiwanese version was used to assess negative affectivity and social inhibition of the patients. Logistic regression analyses were conducted to determine the association of both Z-score transformed and dichotomized negative affectivity and social inhibition with 6-month and 18-month cardiac readmissions. Results A total of 55 patients (24.8%) and 89 patients (40.1%) had cardiac readmissions within 6 months and 18 months, respectively. Multiple logistic regression analyses of Z-score transformed negative affectivity and social inhibition were significantly associated with (1) 6-month cardiac readmission with odds ratios of 1.62 (P = 0.003) and 1.48 (P = 0.014), respectively and (2) 18-month cardiac readmission with odds ratios of 1.45 (P = 0.013) and 1.38 (P = 0.031), respectively. Similar findings were obtained when negative affectivity and social inhibition were analyzed as dichotomized scores. Conclusions Negative affectivity and social inhibition components of the Type D personality were significantly associated with a higher risk of cardiac readmission in both 6 months and 18 months after the initial hospitalization in patients with heart failure.	[Lin, Tin-Kwang; Li, Yi-Da; Lin, Chin-Lon] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Internal Med, Div Cardiol, Chiayi, Taiwan; [Lin, Tin-Kwang; Li, Yi-Da; Lin, Chin-Lon] Tzu Chi Univ, Sch Med, Hualien, Taiwan; [You, Kai-Xun; Weng, Chia-Ying] Natl Chung Cheng Univ, Dept Psychol, Chiayi, Taiwan; [Hsu, Chiu-Tien] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Clin Psychol Ctr, Chiayi, Taiwan; [Hsu, Chiu-Tien] Natl Chung Cheng Univ, Dept Adult & Continuing Educ, Chiayi, Taiwan; [Koo, Malcolm] Tzu Chi Univ Sci & Technol, Grad Inst Long Term Care, Hualien, Taiwan; [Koo, Malcolm] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada	Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Tzu Chi University; National Chung Cheng University; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; National Chung Cheng University; Tzu Chi University of Science & Technology; University of Toronto	Weng, CY (corresponding author), Natl Chung Cheng Univ, Dept Psychol, Chiayi, Taiwan.; Koo, M (corresponding author), Tzu Chi Univ Sci & Technol, Grad Inst Long Term Care, Hualien, Taiwan.; Koo, M (corresponding author), Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.	psycyw@ccu.edu.tw; m.koo@utoronto.ca	Koo, Malcolm/AAE-5822-2020	Koo, Malcolm/0000-0002-9242-9167				Aizawa H, 2015, BMC CARDIOVASC DISOR, V15, DOI 10.1186/s12872-015-0127-9; Alonso-Martinez JL, 2002, EUR J HEART FAIL, V4, P331, DOI 10.1016/S1388-9842(02)00021-1; Cao X, 2016, J GERIATR CARDIOL, V13, P401, DOI 10.11909/j.issn.1671-5411.2016.05.011; Chida Y, 2009, J AM COLL CARDIOL, V53, P936, DOI 10.1016/j.jacc.2008.11.044; Chun S, 2012, CIRC-HEART FAIL, V5, P414, DOI 10.1161/CIRCHEARTFAILURE.111.964791; De Fruyt F, 2002, PSYCHOL HEALTH, V17, P671, DOI 10.1080/08870440290025858; Denollet J, 2005, PSYCHOSOM MED, V67, P89, DOI 10.1097/01.psy.0000149256.81953.49; Denollet J, 2000, J PSYCHOSOM RES, V49, P255, DOI 10.1016/S0022-3999(00)00177-X; Denollet J, 2008, BRAIN BEHAV IMMUN, V22, P736, DOI 10.1016/j.bbi.2007.10.015; Denollet J, 2018, INT J CARDIOL, V259, P205, DOI 10.1016/j.ijcard.2018.02.064; Denollet J, 2013, PSYCHOSOM MED, V75, P873, DOI 10.1097/PSY.0000000000000001; Desai AS, 2012, CIRCULATION, V126, P501, DOI 10.1161/CIRCULATIONAHA.112.125435; Dulfer K, 2015, J PSYCHOSOM RES, V79, P214, DOI 10.1016/j.jpsychores.2015.05.014; Ferguson E, 2009, PSYCHOSOM MED, V71, P981, DOI 10.1097/PSY.0b013e3181bd888b; Floras JS, 2015, EUR HEART J, V36, P1974, DOI 10.1093/eurheartj/ehv087; Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad; Horwood S, 2015, PERS INDIV DIFFER, V83, P50, DOI 10.1016/j.paid.2015.03.041; Kilgore M, 2017, RISK MANAG HEALTHC P, V10, P63, DOI 10.2147/RMHP.S130341; Kim SY, 2016, J AFFECT DISORDERS, V203, P38, DOI 10.1016/j.jad.2016.05.071; Kumar A, 2007, AM J PHYSIOL-REG I, V292, pR1900, DOI 10.1152/ajpregu.00146.2006; Kupper N, 2007, J PERS ASSESS, V89, P265, DOI 10.1080/00223890701629797; Kupper N, 2013, INT J PSYCHOPHYSIOL, V90, P44, DOI 10.1016/j.ijpsycho.2013.01.011; Liguori I, 2018, J GERIATR CARDIOL, V15, P451, DOI 10.11909/j.issn.1671-5411.2018.06.014; Lin IM, 2017, INT J BEHAV MED, V24, P101, DOI 10.1007/s12529-016-9571-x; Mazzella F, 2010, ARCH GERONTOL GERIAT, V51, P323, DOI 10.1016/j.archger.2010.01.011; McLaren DP, 2016, CARDIOL J, V23, P155, DOI 10.5603/CJ.a2016.0005; Mommersteeg PMC, 2012, BRAIN BEHAV IMMUN, V26, P301, DOI 10.1016/j.bbi.2011.09.010; Mosterd A, 2007, HEART, V93, P1137, DOI 10.1136/hrt.2003.025270; Ross JS, 2008, ARCH INTERN MED, V168, P1371, DOI 10.1001/archinte.168.13.1371; Saito M, 2016, AM J CARDIOL, V117, P626, DOI 10.1016/j.amjcard.2015.11.048; Savarese Gianluigi, 2017, Card Fail Rev, V3, P7, DOI 10.15420/cfr.2016:25:2; Sharma Rajesh, 2002, Congest Heart Fail, V8, P165, DOI 10.1111/j.1527-5299.2002.00714.x; Son YJ, 2012, EUR J CARDIOVASC NUR, V11, P304, DOI 10.1016/j.ejcnurse.2011.04.004; Van Craenenbroeck EM, 2009, CLIN SCI, V117, P165, DOI 10.1042/CS20080564; Vukovic O, 2014, PSYCHIAT DANUB, V26, P46; Weng CY, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-46; Widdershoven Jos, 2013, Curr Heart Fail Rep, V10, P244, DOI 10.1007/s11897-013-0139-7; Wu JR, 2014, INT J BEHAV MED, V21, P833, DOI 10.1007/s12529-013-9366-2; Zaya M, 2012, WORLD J CARDIOL, V4, P23, DOI 10.4330/wjc.v4.i2.23	39	5	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2019	14	4							e0215726	10.1371/journal.pone.0215726	http://dx.doi.org/10.1371/journal.pone.0215726			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HU1GG	31002696	gold, Green Submitted, Green Published			2023-01-03	WOS:000465019900047
J	Roshandel, G; Khoshnia, M; Poustchi, H; Hemming, K; Kamangar, F; Gharavi, A; Ostovaneh, MR; Nateghi, A; Majed, M; Navabakhsh, B; Merat, S; Pourshams, A; Nalini, M; Malekzadeh, F; Sadeghi, M; Mohammadifard, N; Sarrafzadegan, N; Naemi-Tabiei, M; Fazel, A; Brennan, P; Etemadi, A; Boffetta, P; Thomas, N; Marshall, T; Cheng, KK; Malekzadeh, R				Roshandel, Gholamreza; Khoshnia, Masoud; Poustchi, Hossein; Hemming, Karla; Kamangar, Farin; Gharavi, Abdolsamad; Ostovaneh, Mohammad Reza; Nateghi, Alireza; Majed, Masoud; Navabakhsh, Behrooz; Merat, Shahin; Pourshams, Akram; Nalini, Mahdi; Malekzadeh, Fatemeh; Sadeghi, Masoumeh; Mohammadifard, Noushin; Sarrafzadegan, Nizal; Naemi-Tabiei, Mohammad; Fazel, Abdolreza; Brennan, Paul; Etemadi, Arash; Boffetta, Paolo; Thomas, Neil; Marshall, Tom; Cheng, Kar Keung; Malekzadeh, Reza			Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial	LANCET			English	Article							ADHERENCE; STRATEGY; DESIGN; GOLESTAN; RISK	Background A fixed-dose combination therapy (polypill strategy) has been proposed as an approach to reduce the burden of cardiovascular disease, especially in low-income and middle-income countries (LMICs). The PolyIran study aimed to assess the effectiveness and safety of a four-component polypill including aspirin, atorvastatin, hydrochlorothiazide, and either enalapril or valsartan for primary and secondary prevention of cardiovascular disease. Methods The PolyIran study was a two-group, pragmatic, cluster-randomised trial nested within the Golestan Cohort Study (GCS), a cohort study with 50 045 participants aged 40-75 years from the Golestan province in Iran. Clusters (villages) were randomly allocated (1:1) to either a package of non-pharmacological preventive interventions alone (minimal care group) or together with a once-daily polypill tablet (polypill group). Randomisation was stratified by three districts (Gonbad, Aq-Qala, and Kalaleh), with the village as the unit of randomisation. We used a balanced randomisation algorithm, considering block sizes of 20 and balancing for cluster size or natural log of the cluster size (depending on the skewness within strata). Randomisation was done at a fixed point in time (Jan 18, 2011) by statisticians at the University of Birmingham (Birmingham, UK), independent of the local study team. The non-pharmacological preventive interventions (including educational training about healthy lifestyle-eg, healthy diet with low salt, sugar, and fat content, exercise, weight control, and abstinence from smoking and opium) were delivered by the PolyIran field visit team at months 3 and 6, and then every 6 months thereafter. Two formulations of polypill tablet were used in this study. Participants were first prescribed polypill one (hydrochlorothiazide 12.5 mg, aspirin 81 mg, atorvastatin 20 mg, and enalapril 5 mg). Participants who developed cough during follow-up were switched by a trained study physician to polypill two, which included valsartan 40 mg instead of enalapril 5 mg. Participants were followed up for 60 months. The primary outcome-occurrence of major cardiovascular events (including hospitalisation for acute coronary syndrome, fatal myocardial infarction, sudden death, heart failure, coronary artery revascularisation procedures, and non-fatal and fatal stroke)-was centrally assessed by the GCS follow-up team, who were masked to allocation status. We did intention-to-treat analyses by including all participants who met eligibility criteria in the two study groups. The trial was registered with ClinicalTrials.gov, number NCT01271985. Findings Between Feb 22, 2011, and April 15, 2013, we enrolled 6838 individuals into the study-3417 (in 116 clusters) in the minimal care group and 3421 (in 120 clusters) in the polypill group. 1761 (51.5%) of 3421 participants in the polypill group were women, as were 1679 (49.1%) of 3417 participants in the minimal care group. Median adherence to polypill tablets was 80.5% (IQR 48.5-92.2). During follow-up, 301 (8.8%) of 3417 participants in the minimal care group had major cardiovascular events compared with 202 (5.9%) of 3421 participants in the polypill group (adjusted hazard ratio [HR] 0.66, 95% CI 0.55-0.80). We found no statistically significant interaction with the presence (HR 0.61, 95% CI 0.49-0.75) or absence of pre-existing cardiovascular disease (0.80; 0.51-1.12; p(interaction) = 0.19). When restricted to participants in the polypill group with high adherence, the reduction in the risk of major cardiovascular events was even greater compared with the minimal care group (adjusted HR 0.43, 95% CI 0.33-0.55). The frequency of adverse events was similar between the two study groups. 21 intracranial haemorrhages were reported during the 5 years of follow-up-ten participants in the polypill group and 11 participants in the minimal care group. There were 13 physicianconfirmed diagnoses of upper gastrointestinal bleeding in the polypill group and nine in the minimal care group. Interpretation Use of polypill was effective in preventing major cardiovascular events. Medication adherence was high and adverse event numbers were low. The polypill strategy could be considered as an additional effective component in controlling cardiovascular diseases, especially in LMICs.	[Roshandel, Gholamreza; Khoshnia, Masoud; Poustchi, Hossein; Gharavi, Abdolsamad; Ostovaneh, Mohammad Reza; Nateghi, Alireza; Majed, Masoud; Navabakhsh, Behrooz; Pourshams, Akram; Nalini, Mahdi; Malekzadeh, Fatemeh; Malekzadeh, Reza] Univ Tehran Med Sci, Digest Dis Res Inst, Shariati Hosp, Digest Dis Res Ctr, Tehran, Iran; [Poustchi, Hossein; Pourshams, Akram; Malekzadeh, Reza] Univ Tehran Med Sci, Digest Dis Res Inst, Shariati Hosp, Digest Oncol Res Ctr, Tehran, Iran; [Merat, Shahin; Malekzadeh, Reza] Univ Tehran Med Sci, Digest Dis Res Inst, Shariati Hosp, Liver & Pancreaticobiliary Dis Res Ctr, Tehran, Iran; [Roshandel, Gholamreza; Khoshnia, Masoud; Naemi-Tabiei, Mohammad; Fazel, Abdolreza] Golestan Univ Med Sci, Golestan Res Ctr Gastroenterol & Hepatol, Gorgan, Golestan, Iran; [Hemming, Karla; Thomas, Neil; Marshall, Tom; Cheng, Kar Keung] Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England; [Kamangar, Farin] Morgan State Univ, Dept Biol Sch Comp Math & Nat Sci, Baltimore, MD 21239 USA; [Sadeghi, Masoumeh] Isfahan Univ Med Sci, Cardiac Rehabil Res Ctr, Esfahan, Iran; [Mohammadifard, Noushin] Isfahan Univ Med Sci, Isfahan Cardiovasc Res Ctr, Esfahan, Iran; [Sarrafzadegan, Nizal] Isfahan Univ Med Sci, Cardiovasc Res Inst, Heart Failure Res Ctr, Esfahan, Iran; [Brennan, Paul] WHO, Int Agcy Res Canc, Genet Sect, Lyon, France; [Etemadi, Arash] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA; [Boffetta, Paolo] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA; [Boffetta, Paolo] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy	Tehran University of Medical Sciences; Tehran University of Medical Sciences; Tehran University of Medical Sciences; Golestan University of Medical Sciences; University of Birmingham; Morgan State University; Isfahan University Medical Science; Isfahan University Medical Science; Isfahan University Medical Science; World Health Organization; International Agency for Research on Cancer (IARC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Icahn School of Medicine at Mount Sinai; University of Bologna	Malekzadeh, R (corresponding author), Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, Iran.	malek@tums.ac.ir	Mohammadifard, Noushin/M-2244-2018; Cheng, Kar/AAL-8899-2021; Nalini/AAY-1099-2020; Fazel, Abdolreza/GON-4224-2022; Hemming, karla/AAB-3391-2021; Boffetta, Paolo/AAI-7767-2021; Sadeghi, Masoumeh/AAU-8493-2021; Ostovaneh, Mohammad/AAY-5728-2021; Merat, Shahin/A-5478-2009; Roshandel, Gholamreza/AAJ-9562-2021	Mohammadifard, Noushin/0000-0003-1776-1060; Cheng, Kar/0000-0002-1516-1857; Nalini/0000-0002-7464-9756; Hemming, karla/0000-0002-2226-6550; Boffetta, Paolo/0000-0002-3811-2791; Sadeghi, Masoumeh/0000-0001-7179-5558; Roshandel, Gholamreza/0000-0002-5494-0722; Marshall, Tom/0000-0001-9277-5214; Thomas, Graham Neil/0000-0002-2777-1847; Pourshams, Akram/0000-0002-7950-3983	Barakat Foundation; Digestive Disease Research Institute of Tehran University of Medical Sciences (Tehran, Iran); Golestan University of Medical Sciences (Gorgan, Iran); WHO; US National Institutes of Health or National Cancer Institute; Tehran University of Medical Sciences [81/15]; Cancer Research UK [C20/A5860]; NIHR Collaboration for Leadership in Applied Health Research and Care West Midlands	Barakat Foundation; Digestive Disease Research Institute of Tehran University of Medical Sciences (Tehran, Iran); Golestan University of Medical Sciences (Gorgan, Iran); WHO(World Health Organization); US National Institutes of Health or National Cancer Institute; Tehran University of Medical Sciences(Tehran University of Medical Sciences); Cancer Research UK(Cancer Research UK); NIHR Collaboration for Leadership in Applied Health Research and Care West Midlands	We thank Hamid Reza Jamshidi from the Barakat Foundation, Behrooz Abaie from the Digestive Disease Research Institute of Tehran University of Medical Sciences (Tehran, Iran), Akbar Fotouhi from the Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Golestan Cohort Study (GCS) centre staff, the local health networks and health workers (behvarz) in the study area, the Golestan University of Medical Sciences (Gorgan, Iran), and the chiefs of the Maraveh-Tappeh, Gonbad, Kalaleh, and Aq-Qala health districts for their assistance and support. We also thank the GCS participants who participated in this trial. We thank Kazem Kazempour for independent analysis of the data to verify the findings. The lead authors affirm that the manuscript is an honest, accurate, and transparent account of the study being reported, that no important aspects of the study have been omitted, and that any discrepancies from the study as originally planned have been explained. The authors alone are responsible for the views expressed in this Article and they do not necessarily represent the decisions, policies, or views of the International Agency for Research on Cancer (IARC), WHO, the US National Institutes of Health or National Cancer Institute, the National Institute for Health Research (NIHR), or the UK Department of Health and Social Care. The study was supported by the Barakat Foundation, Alborz Darou, and Tehran University of Medical Sciences. The GCS was supported by Cancer Research UK (grant no C20/A5860), Tehran University of Medical Sciences (grant no 81/15), and the IARC. TM is supported by the NIHR Collaboration for Leadership in Applied Health Research and Care West Midlands.	Altman DG, 1999, BRIT MED J, V319, P1492, DOI 10.1136/bmj.319.7223.1492; Bahiru E, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009868.pub3; Bramlage P, 2017, EUR J PREV CARDIOL, V24, P297, DOI 10.1177/2047487316674817; Castellano JM, 2014, J AM COLL CARDIOL, V64, P2071, DOI 10.1016/j.jacc.2014.08.021; Chow CK, 2019, NAT REV CARDIOL, V16, P602, DOI 10.1038/s41569-019-0209-y; FRIEDEWA WT, 1972, CLIN CHEM, V18, P499, DOI [10.1093/clinchem/18.6.499, DOI 10.1093/clinchem/18.6.499]; Grundy SM, 2019, J AM COLL CARDIOL, V73, P3168, DOI 10.1016/j.jacc.2018.11.002; Huffman MD, 2017, LANCET, V389, P1055, DOI 10.1016/S0140-6736(17)30553-6; Joseph P, 2018, AM HEART J, V206, P72, DOI 10.1016/j.ahj.2018.07.012; Khademi H, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2502; Kyu HH, 2018, LANCET, V392, P1859, DOI [10.1016/S0140-6736(18)32335-3, 10.1016/s0140-6736(18)32335-3]; Lonn EM, 2016, NEW ENGL J MED, V374, P2009, DOI 10.1056/NEJMoa1600175; Lozano R, 2018, LANCET, V392, P2091, DOI 10.1016/s0140-6736(18)32281-5; Malekzadeh F, 2010, INT J CLIN PRACT, V64, P1220, DOI 10.1111/j.1742-1241.2010.02412.x; Mokdad AH, 2018, INT J PUBLIC HEALTH, V63, P137, DOI 10.1007/s00038-017-1012-3; Nalini M, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-021479; Nalini M, 2018, ARCH IRAN MED, V21, P86; Ostovaneh MR, 2015, EUR J PREV CARDIOL, V22, P1609, DOI 10.1177/2047487314550803; Pourshams A, 2010, INT J EPIDEMIOL, V39, P52, DOI 10.1093/ije/dyp161; Republic of Slovenia, 1995, ZAK NAL BOL COMM DIS; Roth GA, 2017, J AM COLL CARDIOL, V70, P1, DOI 10.1016/j.jacc.2017.04.052; Sanz G, 2013, NAT REV CARDIOL, V10, P683, DOI 10.1038/nrcardio.2013.157; Selak V, 2011, CONTEMP CLIN TRIALS, V32, P909, DOI 10.1016/j.cct.2011.07.006; Singh K, 2018, INT J CARDIOL, V262, P71, DOI 10.1016/j.ijcard.2018.03.082; Thom S, 2013, JAMA-J AM MED ASSOC, V310, P918, DOI 10.1001/jama.2013.277064; United Nations Development Program, 2019, SUST DEV GOALS; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; Zheng SL, 2019, JAMA-J AM MED ASSOC, V321, P277, DOI 10.1001/jama.2018.20578	28	130	132	3	34	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 24	2019	394	10199					672	683		10.1016/S0140-6736(19)31791-X	http://dx.doi.org/10.1016/S0140-6736(19)31791-X			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IT6UU	31448738	Green Submitted			2023-01-03	WOS:000483011200031
J	Choi, CH; Kim, JH; Kim, JI; Park, JM				Choi, Chang Heon; Kim, Jin Ho; Kim, Jung-in; Park, Jong Min			Comparison of treatment plan quality among MRI-based IMRT with a linac, MRI-based IMRT with tri-Co-60 sources, and VMAT for spine SABR	PLOS ONE			English	Article							STEREOTACTIC BODY RADIOTHERAPY; MODULATED RADIATION-THERAPY; METASTASES; RADIOSURGERY; SBRT; MOTION; CORD	Purpose This study compares the plan quality of magnetic-resonance image (MRI)-based intensity modulated radiation therapy (IMRT) using a linac (MR-linac-IMRT), MRI-based IMRT using tri-Co-60 sources (MR-Co-60-IMRT), and volumetric modulated arc therapy (VMAT) for spine stereotactic ablative radiotherapy (SABR). Methods Twenty patients with thoracic spine metastasis were retrospectively selected for this study. For each patient, the MR-linac-IMRT, MR-Co-60-IMRT, and VMAT plans were generated using an identical CT image set and structures, except for the spinal cord and spinal cord planning organ-at-risk volume (PRV). Those two structures were contoured based on CT image sets for VMAT planning while those were contoured based on MR image sets for MR-linac-IMRT and MR-Co-60-IMRT planning. The initial prescription doses were 18 Gy in a single fraction for every plan in this study. If the tolerance level of the spinal cord was not met, the prescription doses were reduced to meet the tolerance level of the spinal cord. Dose-volumetric parameters of each plan were analyzed. Results The average spinal cord volumes contoured based on the CT and MR images were 3.8 +/- 1.6 cm(3) and 1.1 +/- 1.0 cm(3), respectively (p<0.001). For four patients, the prescription doses of VMAT plans were reduced to 16 Gy to satisfy the spinal cord tolerance level. For thirteen patients, the prescription doses of MR-Co-60-IMRT plans were reduced to be less than 16 Gy to meet the spinal cord tolerance level. However, for every MR-linac-IMRT plan, the initial prescription doses of 18 Gy could be delivered to the target volume while satisfying the spinal cord tolerance. The average values of D-10%, V-10Gy, and V-14Gy of the spinal cord PRV consistently indicated that the doses to the spinal cord PRV in the MR-linac-IMRT plans were the lowest among three types of plans in this study (all with p <= 0.003). Conclusion MR-linac-IMRT appears promising for spine SABR.	[Choi, Chang Heon; Kim, Jin Ho; Kim, Jung-in; Park, Jong Min] Seoul Natl Univ Hosp, Dept Radiat Oncol, Seoul, South Korea; [Choi, Chang Heon; Kim, Jin Ho; Kim, Jung-in; Park, Jong Min] Seoul Natl Univ, Inst Radiat Med, Med Res Ctr, Seoul, South Korea; [Choi, Chang Heon; Kim, Jin Ho; Kim, Jung-in; Park, Jong Min] Seoul Natl Univ Hosp, Biomed Res Inst, Seoul, South Korea; [Choi, Chang Heon] Sheikh Khalifa Specialty Hosp, Dept Radiat Oncol, Ras Al Khaymah, U Arab Emirates; [Park, Jong Min] Adv Inst Convergence Technol, Robot Res Lab Extreme Environm, Suwon, South Korea	Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital	Kim, JI; Park, JM (corresponding author), Seoul Natl Univ Hosp, Dept Radiat Oncol, Seoul, South Korea.; Kim, JI; Park, JM (corresponding author), Seoul Natl Univ, Inst Radiat Med, Med Res Ctr, Seoul, South Korea.; Kim, JI; Park, JM (corresponding author), Seoul Natl Univ Hosp, Biomed Res Inst, Seoul, South Korea.; Park, JM (corresponding author), Adv Inst Convergence Technol, Robot Res Lab Extreme Environm, Suwon, South Korea.	leodavinci@naver.com; madangin@gmail.com		Kim, Jin Ho/0000-0002-7918-1072; Park, Jong Min/0000-0003-3617-3870	Radiation Technology R&D program through the National Research Foundation of Korea - Ministry of Science and ICT [2017M2A2A7A02020640, 2017M2A2A7A02020641, 2017M2A2A7A02020643]	Radiation Technology R&D program through the National Research Foundation of Korea - Ministry of Science and ICT	This work was supported by: JHK: Radiation Technology R&D program through the National Research Foundation of Korea funded by the Ministry of Science and ICT (No. 2017M2A2A7A02020640). JMP: Radiation Technology R&D program through the National Research Foundation of Korea funded by the Ministry of Science and ICT (No. 2017M2A2A7A02020641). JIK: Radiation Technology R&D program through the National Research Foundation of Korea funded by the Ministry of Science and ICT (No. 2017M2A2A7A02020643). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by Radiation Technology R&D program through the National Research Foundation of Korea funded by the Ministry of Science and ICT (No. 2017M2A2A7A02020640, No. 2017M2A2A7A02020641, and No. 2017M2A2A7A02020643).	Bjerre T, 2013, PHYS MED BIOL, V58, P4943, DOI 10.1088/0031-9155/58/14/4943; Boda-Heggemann J, 2011, STRAHLENTHER ONKOL, V187, P284, DOI 10.1007/s00066-011-2236-4; Chang Z, 2010, RADIOTHER ONCOL, V95, P116, DOI 10.1016/j.radonc.2009.12.036; Choi CH, 2017, BRIT J RADIOL, V90, DOI 10.1259/bjr.20160652; Dahele M, 2011, INT J RADIAT ONCOL, V81, P321, DOI 10.1016/j.ijrobp.2011.04.039; Gallo JJ, 2015, J APPL CLIN MED PHYS, V16, P170, DOI 10.1120/jacmp.v16i1.5120; Katsoulakis E, 2017, SEMIN RADIAT ONCOL, V27, P209, DOI 10.1016/j.semradonc.2017.03.004; Keall PJ, 2018, INT J RADIAT ONCOL, V102, P922, DOI 10.1016/j.ijrobp.2018.04.016; Kim Jung-in, 2018, [Journal of Radiation Protection and Research, 방사선방어학회지], V43, P59, DOI 10.14407/jrpr.2018.43.2.59; Kishan AU, 2015, PRACT RADIAT ONCOL, V5, P330, DOI 10.1016/j.prro.2015.02.014; Li WN, 2012, INT J RADIAT ONCOL, V84, P520, DOI 10.1016/j.ijrobp.2011.12.039; Low DA, 2016, CANCER TREAT RES, V172, P41, DOI 10.1007/978-3-319-53235-6_3; Matsuo Y, 2015, RADIOTHER ONCOL, V115, P412, DOI 10.1016/j.radonc.2015.05.003; Murphy MJ, 2007, MED PHYS, V34, P4041, DOI 10.1118/1.2775667; Paddick I, 2006, J NEUROSURG, V105, P194, DOI 10.3171/sup.2006.105.7.194; Park JM, 2017, ONCOTARGET, V8, P91174, DOI 10.18632/oncotarget.20039; Park JM, 2017, PHYS MEDICA, V40, P11, DOI 10.1016/j.ejmp.2017.06.018; Park JM, 2016, RADIOTHER ONCOL, V120, P279, DOI 10.1016/j.radonc.2016.06.013; Pollard JM, 2017, BRIT J RADIOL, V90, DOI 10.1259/bjr.20160667; Ramey SJ, 2018, PRACT RADIAT ONCOL, V8, pE312, DOI 10.1016/j.prro.2018.02.010; Redmond KJ, 2016, INT J RADIAT ONCOL, V95, P1414, DOI 10.1016/j.ijrobp.2016.03.027; Ryu S, 2014, PRACT RADIAT ONCOL, V4, P76, DOI 10.1016/j.prro.2013.05.001; Sahgal A, 2008, INT J RADIAT ONCOL, V71, P652, DOI 10.1016/j.ijrobp.2008.02.060; SHAW E, 1993, INT J RADIAT ONCOL, V27, P1231, DOI 10.1016/0360-3016(93)90548-A; Son Jaeman, 2019, [Journal of Radiation Protection and Research, 방사선방어학회지], V44, P26, DOI 10.14407/jrpr.2019.44.1.26; Steiner E, 2013, RADIOTHER ONCOL, V109, P409, DOI 10.1016/j.radonc.2013.09.007; Thibault I, 2015, INT J RADIAT ONCOL, V93, P353, DOI 10.1016/j.ijrobp.2015.03.029; Tseng CL, 2015, INT J RADIAT ONCOL, V91, P995, DOI 10.1016/j.ijrobp.2014.12.037; Winey B, 2015, INT J RADIAT ONCOL, V93, pS159, DOI 10.1016/j.ijrobp.2015.07.382; Wooten HO, 2015, INT J RADIAT ONCOL, V92, P771, DOI 10.1016/j.ijrobp.2015.02.057; Wu QJ, 2009, INT J RADIAT ONCOL, V75, P1596, DOI 10.1016/j.ijrobp.2009.05.005; Yamada Y, 2008, INT J RADIAT ONCOL, V71, P484, DOI 10.1016/j.ijrobp.2007.11.046; Zhang PP, 2010, INT J RADIAT ONCOL, V76, P1456, DOI 10.1016/j.ijrobp.2009.03.033	33	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2019	14	7							e0220039	10.1371/journal.pone.0220039	http://dx.doi.org/10.1371/journal.pone.0220039			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4UB	31329641	Green Submitted, gold, Green Published			2023-01-03	WOS:000484974100042
J	Akizuki, K; Yamamoto, R; Yamaguchi, K; Yabuki, J; Ohashi, Y				Akizuki, Kazunori; Yamamoto, Ryohei; Yamaguchi, Kazuto; Yabuki, Jun; Ohashi, Yukari			The effects of feedback timing and frequency on the acquisition of cardiopulmonary resuscitation skills of health sciences undergraduate students: A 2 x 2 factorial quasi randomized study	PLOS ONE			English	Article							2015 INTERNATIONAL CONSENSUS; CARDIOVASCULAR CARE SCIENCE; BASIC LIFE-SUPPORT; CARDIAC-ARREST; VISUAL FEEDBACK; QUALITY; DEFIBRILLATION; KNOWLEDGE; TIME	Background High-quality training is required to improve the cardiopulmonary resuscitation (CPR) skills. Although it has been reported that the use of a feedback device is effective, the effects of feedback timing and frequency on CPR training have not been investigated. The aim of this study was to clarify the influence of feedback frequency and timing on the acquisition of CPR skills. Methods Sixty-eight undergraduates were first divided into female (n = 32) and male (n = 36) groups, and randomly assigned to one of four groups for each sex: concurrent-100%, concurrent50%, terminal-100%, and terminal-50% feedback groups. The randomization was performed using a lottery method. This study consisted of a pre-test, practice sessions, a post-test, and a follow-up test. In the practice sessions, the participants performed six 2-minute CPR sessions in accordance with the condition assigned using mannequins and feedback devices. The post-test was conducted 24 hours after the completion of the practice sessions and the follow-up test was conducted 3 months after the completion of the practice sessions. The primary outcome of the study was the overall score at the follow-up test. Results The results of the overall score at the follow-up test for each group were 88.2 +/- 9.6% for concurrent-100%, 92.2 +/- 6.4% for concurrent-50%, 82.6 +/- 16.4% for terminal-100%, and 85.2 +/- 16.9% for terminal-50%. We did not find any statistically significant difference for the overall score at the follow-up test among the four groups (p = 0.173). The ANOVA for the test sessions revealed that there were no significant main effects of feedback timing (p = 0.135) or frequency (p = 0.765), and no significant interaction between timing and frequency (p = 0.997). Conclusion The present study reveals that the use of feedback devices is an important factor for higher quality CPR training, regardless of the timing and frequency with which they are used.	[Akizuki, Kazunori] Kobe Int Univ, Dept Phys Therapy, Kobe, Hyogo, Japan; [Yamamoto, Ryohei] Kyushu Univ Nursing & Social Welf, Dept Rehabil, Tamana, Kumamoto, Japan; [Yamaguchi, Kazuto] Misato Cent Gen Hosp, Misato, Saitama, Japan; [Yabuki, Jun] Ibaraki Prefectural Univ Hlth Sci Hosp, Ami, Ibaraki, Japan; [Ohashi, Yukari] Ibaraki Prefectural Univ Hlth Sci, Dept Phys Therapy, Ami, Ibaraki, Japan		Akizuki, K (corresponding author), Kobe Int Univ, Dept Phys Therapy, Kobe, Hyogo, Japan.	akizuki@kobe-kiu.ac.jp		Yamaguchi, Kazuto/0000-0001-5592-767X; Akizuki, Kazunori/0000-0001-9576-9952				Abella BS, 2016, CURR OPIN CRIT CARE, V22, P218, DOI 10.1097/MCC.0000000000000296; American Heart Association, 2012, BAS LIF SUPP BLS REN; Baldi E, 2017, CAN J EMERG MED, V19, P480, DOI 10.1017/cem.2016.410; Brennan EE, 2016, CAN J EMERG MED, V18, P276, DOI 10.1017/cem.2015.104; Cheng A, 2018, CIRCULATION, V138, pE82, DOI 10.1161/CIR.0000000000000583; Cortegiani A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1740-z; Cortegiani A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169591; de Ruijter PA, 2014, MED EDUC ONLINE, V19, DOI 10.3402/meo.v19.24841; Go AS, 2013, CIRCULATION, V127, P143, DOI 10.1161/CIR.0b013e318282ab8f; Guadagnoli MA, 2004, J MOTOR BEHAV, V36, P212, DOI 10.3200/JMBR.36.2.212-224; Hasselqvist-Ax I, 2015, NEW ENGL J MED, V372, P2307, DOI 10.1056/NEJMoa1405796; Hazinski MF, 2015, CIRCULATION, V132, pS2, DOI 10.1161/CIR.0000000000000270; Japan Resuscitation Council, 2016, 2015 JAP GUID EM CAR; Kitamura T, 2016, NEW ENGL J MED, V375, P1649, DOI 10.1056/NEJMsa1600011; Kiyohara K, 2019, AM J CARDIOL, V123, P1060, DOI 10.1016/j.amjcard.2018.12.038; Kong SYJ, 2020, HONG KONG J EMERG ME, V27, P187, DOI 10.1177/1024907918825016; Marschall F, 2007, E J BEWEGUNG TRAININ, V1, P75; Nishiyama C, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.009436; Nolan JP, 2014, CURR OPIN CRIT CARE, V20, P227, DOI 10.1097/MCC.0000000000000083; Perkins GD, 2015, RESUSCITATION, V95, pE43, DOI 10.1016/j.resuscitation.2015.07.041; SALMONI AW, 1984, PSYCHOL BULL, V95, P355, DOI 10.1037/0033-2909.95.3.355; Sattelmayer M, 2016, BMC MED EDUC, V16, DOI 10.1186/s12909-016-0538-z; SCHMIDT RA, 1991, NATO ADV SCI I D-BEH, V62, P59; Schmidt RA, 1997, HUM FACTORS, V39, P509, DOI 10.1518/001872097778667979; Sigrist R, 2013, PSYCHON B REV, V20, P21, DOI 10.3758/s13423-012-0333-8; Spooner BB, 2007, RESUSCITATION, V73, P417, DOI 10.1016/j.resuscitation.2006.10.017; Wallace SK, 2013, CIRC-CARDIOVASC QUAL, V6, P148, DOI 10.1161/CIRCOUTCOMES.111.000041; Wulf G, 2002, PSYCHON B REV, V9, P185, DOI 10.3758/BF03196276; Wulf G, 2016, PSYCHON B REV, V23, P1382, DOI 10.3758/s13423-015-0999-9; Yang CW, 2012, RESUSCITATION, V83, P1055, DOI 10.1016/j.resuscitation.2012.02.027; Yudkowsky R, 2015, ACAD MED, V90, P1495, DOI 10.1097/ACM.0000000000000887	32	2	2	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2019	14	7							e0220004	10.1371/journal.pone.0220004	http://dx.doi.org/10.1371/journal.pone.0220004			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IS7LS	31314785	Green Published, Green Submitted, gold			2023-01-03	WOS:000482331900058
J	Bartlett, M				Bartlett, Molly			Finding hope in dying	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 17	2019	366								l2416	10.1136/bmj.l2416	http://dx.doi.org/10.1136/bmj.l2416			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IK8UP	31315818	Bronze			2023-01-03	WOS:000476871500001
J	Abe, Y; Konno, H; Yoshida, S; Yamauchi, T; Yamasaki, K; Denda, M; Nishizawa, M				Abe, Yuina; Konno, Hajime; Yoshida, Shotaro; Yamauchi, Takeshi; Yamasaki, Kenshi; Denda, Mitsuhiro; Nishizawa, Matsuhiko			Red light-promoted skin barrier recovery: Spatiotemporal evaluation by transepidermal potential	PLOS ONE			English	Article							WATER-LOSS; INDICATOR; LASER; TIME	The light-promoted recovery of epidermal barrier of skin was evaluated by the associated recovery of transepidermal potential (TEP), the potential difference between the surface and dermis of skin, by using porcine skin samples. An accelerated recovery of TEP was observed by irradiation of red light with the irradiance of 40 mW/cm(2) and a duration of >10 min. The influence of the light stimulation to the surroundings (similar to 20 mm) was also observed. The irradiations of blue and purple lights were ineffective in accelerating the barrier recovery. These characteristics of the light stimulation would be useful for the design of effective and safe phototherapy devices for skin. The present study proves that the TEP can serve as a spatiotemporal indicator of the epidermal barrier function.	[Abe, Yuina; Konno, Hajime; Yoshida, Shotaro; Nishizawa, Matsuhiko] Tohoku Univ, Dept Finemech, Grad Sch Engn, Sendai, Miyagi, Japan; [Yamauchi, Takeshi; Yamasaki, Kenshi] Tohoku Univ, Grad Sch Med, Dept Dermatol, Seiryo Machi, Sendai, Miyagi, Japan; [Denda, Mitsuhiro] Shiseido Res Ctr, Kanazawa Ku, Yokohama, Kanagawa, Japan	Tohoku University; Tohoku University; Shiseido Company, Limited	Nishizawa, M (corresponding author), Tohoku Univ, Dept Finemech, Grad Sch Engn, Sendai, Miyagi, Japan.	nishizawa@biomems.mech.tohoku.ac.jp	Yoshida, Shotaro/T-2672-2019; Yamasaki, Kenshi/C-8905-2018	Yoshida, Shotaro/0000-0002-7417-5722; Abe, Yuina/0000-0001-9249-1449; Yamasaki, Kenshi/0000-0002-5495-4956	Tohoku University Institute for Promoting Graduate Degree Programs Division for Interdisciplinary Advanced Research and Education (DIARE), Center of Innovation Program (COI-Stream); MIRAI Project of Japan Science and Technology Agency (JST) [17944087]; Ministry of Education, Culture, Sports, Science and Technology, Japan [17J03919, 18H04158, 18K19896]	Tohoku University Institute for Promoting Graduate Degree Programs Division for Interdisciplinary Advanced Research and Education (DIARE), Center of Innovation Program (COI-Stream); MIRAI Project of Japan Science and Technology Agency (JST); Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by Tohoku University Institute for Promoting Graduate Degree Programs Division for Interdisciplinary Advanced Research and Education (DIARE), Center of Innovation Program (COI-Stream), MIRAI Project (17944087) of Japan Science and Technology Agency (JST), and financially by Grand-in-Aid for JSPS Research Fellow (17J03919), Scientific Research A (18H04158) and Challenging Exploratory Research (18K19896) from the Ministry of Education, Culture, Sports, Science and Technology, Japan. Shiseido Research Center provided support in the form of salaries for an author MD, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the author are articulated in the "author contributions" section.	Abe Y, 2016, BIOMED MICRODEVICES, V18, DOI 10.1007/s10544-016-0080-0; BARKER AT, 1982, AM J PHYSIOL, V242, pR358, DOI 10.1152/ajpregu.1982.242.3.R358; Barolet D, 2008, SEMIN CUTAN MED SURG, V27, P227, DOI 10.1016/j.sder.2008.08.003; Brancaleon L, 2002, LASER MED SCI, V17, P173, DOI 10.1007/s101030200027; Chabert R, 2015, SKIN RES TECHNOL, V21, P426, DOI 10.1111/srt.12210; Denda M, 2001, BIOCHEM BIOPH RES CO, V284, P112, DOI 10.1006/bbrc.2001.4925; Denda M, 2008, J INVEST DERMATOL, V128, P1335, DOI 10.1038/sj.jid.5701168; Dube J, 2010, TISSUE ENG PT A, V16, P3055, DOI [10.1089/ten.tea.2010.0030, 10.1089/ten.TEA.2010.0030]; GRUBAUER G, 1989, J LIPID RES, V30, P323; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Kawai E, 2008, EXP DERMATOL, V17, P688, DOI 10.1111/j.1600-0625.2007.00692.x; Kawai E, 2011, EXP DERMATOL, V20, P757, DOI 10.1111/j.1600-0625.2011.01298.x; Lanzafame RJ, 2007, LASER SURG MED, V39, P534, DOI 10.1002/lsm.20519; Nouri Keyvan, 2006, J Cosmet Dermatol, V5, P14, DOI 10.1111/j.1473-2165.2006.00217.x; Papadavid E, 2003, INT J DERMATOL, V42, P480, DOI 10.1046/j.1365-4362.2003.01784.x; Peplow PV, 2010, PHOTOMED LASER SURG, V28, P291, DOI 10.1089/pho.2008.2446; PINNAGODA J, 1990, CONTACT DERMATITIS, V22, P164, DOI 10.1111/j.1600-0536.1990.tb01553.x; Silvestre MA, 2003, THERIOGENOLOGY, V59, P1469, DOI 10.1016/S0093-691X(02)01185-8; Tsutsumi M, 2009, CELL TISSUE RES, V338, P99, DOI 10.1007/s00441-009-0848-0; Tsutsumi M, 2009, EXP DERMATOL, V18, P567, DOI 10.1111/j.1600-0625.2009.00851.x	20	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2019	14	7							e0219198	10.1371/journal.pone.0219198	http://dx.doi.org/10.1371/journal.pone.0219198			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4JZ	31291308	gold, Green Published, Green Submitted			2023-01-03	WOS:000484947800056
J	Willett, M; Duda, J; Fenton, S; Gautrey, C; Greig, C; Rushton, A				Willett, Matthew; Duda, Joan; Fenton, Sally; Gautrey, Charlotte; Greig, Carolyn; Rushton, Alison			Effectiveness of behaviour change techniques in physiotherapy interventions to promote physical activity adherence in lower limb osteoarthritis patients: A systematic review	PLOS ONE			English	Review							LONG-TERM EFFECTIVENESS; KNEE OSTEOARTHRITIS; EXERCISE THERAPY; OLDER-ADULTS; MANUAL-THERAPY; HIP OSTEOARTHRITIS; TREATMENT FIDELITY; BOOSTER SESSIONS; SELF-MANAGEMENT; HOME EXERCISE	Background Lower limb osteoarthritis (OA) causes high levels of individual pain and disability and is an increasing socio-economic burden to global healthcare systems. Physical Activity interventions are commonly provided by physiotherapists to help patients with lower limb OA manage their clinical symptoms. Objective To identify and evaluate the effectiveness of behavioural change techniques (BCTs) within physiotherapy interventions to increase physical activity (PA) adherence in patients with lower limb OA. Design A systematic review was conducted, following Cochrane guidelines according to a published and registered protocol (CRD42016039932). Two independent researchers conducted searches, determined eligibility, assessed risk of bias (Cochrane tool), intervention fidelity (NIHBCC checklist), and coded randomised controlled trials (RCTs) for BCTs (V1 taxonomy). BCT effectiveness ratios were calculated and RCT risk of bias and intervention fidelity were summarised narratively. Data sources A highly sensitive search strategy was conducted on Medline, Embase, PsycINFO, CENTRAL, CINAHL and PEDro and grey literature databases from inception to January 2nd, 2018. Reference lists of included RCTs and relevant articles were reviewed, and a citation search was conducted using Web of Science. Eligibility criteria for selecting studies RCTs that evaluated the effectiveness of a physiotherapy intervention that incorporated >= 1 BCT that promoted home or community-based PA adherence in patients with lower limb osteoarthritis. Results Twenty-four RCTs (n = 2366 participants) of variable risk of bias (RoB) (5 low; 7 moderate; 12 high) and poor intervention reporting from 10 countries were included. Heterogeneity of intervention BCTs and PA adherence outcome measures precluded meta-analysis. Thirty-one distinct BCTs were identified in 31 interventions across RCTs. In general, BCTs demonstrated higher effectiveness ratios for short-term and long-term PA adherence compared with medium-term outcomes. The BCTs 'behavioural contract', 'non-specific reward', 'patient-led goal setting' (behaviour), 'self-monitoring of behaviour', and 'social support (unspecified) demonstrated the highest effectiveness ratios across time points to promote PA adherence. Conclusions BCTs demonstrate higher short and long-term than medium-term effectiveness ratios. Further research involving low RoB RCTs incorporating transparently reported interventions with pre-specified BCTs aimed at optimising lower limb OA patient PA adherence is required.	[Willett, Matthew; Rushton, Alison] Univ Birmingham, Sch Sport Exercise & Rehabil Sci, Ctr Precis Rehabil Spinal Pain CPR Spine, Birmingham, W Midlands, England; [Willett, Matthew; Duda, Joan; Fenton, Sally; Greig, Carolyn; Rushton, Alison] Univ Birmingham, Sch Sport Exercise & Rehabil Sci, Birmingham, W Midlands, England; [Duda, Joan; Fenton, Sally; Greig, Carolyn] Univ Birmingham, MRC Arthrit Res UK Ctr Musculoskeletal Ageing Res, Birmingham, W Midlands, England; [Gautrey, Charlotte] Univ Hertfordshire, Sch Life & Med Sci, Hatfield, Herts, England	University of Birmingham; University of Birmingham; University of Birmingham; University of Hertfordshire	Willett, M (corresponding author), Univ Birmingham, Sch Sport Exercise & Rehabil Sci, Ctr Precis Rehabil Spinal Pain CPR Spine, Birmingham, W Midlands, England.; Willett, M (corresponding author), Univ Birmingham, Sch Sport Exercise & Rehabil Sci, Birmingham, W Midlands, England.	M.j.willett.1@bham.ac.uk	Greig, Carolyn/AAN-5132-2020; Rushton, Alison/V-1260-2017; Fenton, Sally/AAC-3606-2022; Duda, Joan/ABA-5207-2020	Greig, Carolyn/0000-0003-1704-9997; Rushton, Alison/0000-0001-8114-7669; Fenton, Sally/0000-0002-3732-1348; Willett, Matthew/0000-0001-5107-1771; Gautrey, Charlotte/0000-0001-8909-2535	MRC [MR/K00414X/1] Funding Source: UKRI	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abbott JH, 2013, OSTEOARTHR CARTILAGE, V21, P525, DOI 10.1016/j.joca.2012.12.014; Abbott JH, 2015, J ORTHOP SPORT PHYS, V45, P975, DOI 10.2519/jospt.2015.6015; Alexanders J, 2015, PHYSIOTHERAPY, V101, P95, DOI 10.1016/j.physio.2014.03.008; Autier P, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4200; Bailey N, 2018, POVERTY AND SOCIAL EXCLUSION IN THE UK, VOL. 2: THE DIMENSIONS OF DISADVANTAGE, P1; Bandura A., 1986, SOCIAL FDNS THOUGHTS; Bennell KL, 2010, OSTEOARTHR CARTILAGE, V18, P621, DOI 10.1016/j.joca.2010.01.010; Bennell KL, 2017, ARTHRIT CARE RES, V69, P84, DOI 10.1002/acr.22915; Bennell KL, 2016, ARTHRIT CARE RES, V68, P590, DOI 10.1002/acr.22744; Bennell KL, 2014, ARTHRIT CARE RES, V66, P1680, DOI 10.1002/acr.22350; Bennell KL, 2014, BEST PRACT RES CL RH, V28, P93, DOI 10.1016/j.berh.2014.01.009; Bennell KL, 2014, JAMA-J AM MED ASSOC, V311, P1987, DOI 10.1001/jama.2014.4591; Bennell KL, 2005, ANN RHEUM DIS, V64, P906, DOI 10.1136/ard.2004.026526; Bird EL, 2013, HEALTH PSYCHOL, V32, P829, DOI 10.1037/a0032078; Bishop FL, 2015, PSYCHOL HEALTH, V30, P104, DOI 10.1080/08870446.2014.953529; Borrelli B, 2005, J CONSULT CLIN PSYCH, V73, P852, DOI 10.1037/0022-006X.73.5.852; Borrelli B, 2011, J PUBLIC HEALTH DENT, V71, pS52, DOI 10.1111/j.1752-7325.2011.00233.x; CARVER CS, 1982, PSYCHOL BULL, V92, P111, DOI 10.1037/0033-2909.92.1.111; CASPERSEN CJ, 1985, PUBLIC HEALTH REP, V100, P126; Colak TK, 2017, RHEUMATOL INT, V37, P399, DOI 10.1007/s00296-016-3646-5; Cradock KA, 2017, INT J BEHAV NUTR PHY, V14, DOI 10.1186/s12966-016-0436-0; Cramp F, 2013, MUSCULOSKELET CARE, V11, P238, DOI 10.1002/msc.1049; Crossley KM, 2015, OSTEOARTHR CARTILAGE, V23, P1457, DOI 10.1016/j.joca.2015.04.024; Deyle GD, 2000, ANN INTERN MED, V132, P173, DOI 10.7326/0003-4819-132-3-200002010-00002; Dincer U, 2016, TURK FIZ TIP REHAB D, V62, P28, DOI 10.5606/tftrd.2016.93899; Dombrowski SU, 2012, HEALTH PSYCHOL REV, V6, P7, DOI 10.1080/17437199.2010.513298; Dunlop DD, 2011, ARTHRITIS RHEUM-US, V63, P3372, DOI 10.1002/art.30562; Fransen M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007912; French DP, 2014, ANN BEHAV MED, V48, P225, DOI 10.1007/s12160-014-9593-z; French HP, 2013, ARCH PHYS MED REHAB, V94, P302, DOI 10.1016/j.apmr.2012.09.030; Ghogomu EAT, 2014, J RHEUMATOL, V41, P194, DOI 10.3899/jrheum.121306; Gilinsky AS, 2015, HEALTH PSYCHOL REV, V9, P244, DOI 10.1080/17437199.2014.899059; Hendrikx J, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen-2015-000114; Heron N, 2016, BRIT J GEN PRACT, V66, pE747, DOI 10.3399/bjgp16X686617; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Hiyama Y, 2012, CLIN REHABIL, V26, P403, DOI 10.1177/0269215511421028; Holden MA, 2012, ARTHRIT CARE RES, V64, P1554, DOI 10.1002/acr.21700; Hunt MA, 2013, KNEE, V20, P106, DOI 10.1016/j.knee.2012.07.008; Hurley MV, 2007, ARTHRIT RHEUM-ARTHR, V57, P1211, DOI 10.1002/art.22995; Jones A, 2012, ANN RHEUM DIS, V71, P172, DOI 10.1136/ard.2010.140178; Jordan JL, 2010, INTERVENTIONS IMPROV; Kadam UT, 2007, J RHEUMATOL, V34, P1899; Kanavaki AM, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017042; Kawasaki T, 2009, J ORTHOP SCI, V14, P182, DOI 10.1007/s00776-008-1312-9; Keogh A, 2015, MANUAL THER, V20, P727, DOI 10.1016/j.math.2015.03.014; Kinnafick FE, 2014, QUAL HEALTH RES, V24, P706, DOI 10.1177/1049732314528811; Kunstler BE, 2017, J SCI MED SPORT; Kwasnicka D, 2016, HEALTH PSYCHOL REV, V10, P277, DOI 10.1080/17437199.2016.1151372; Lefebvre C, 2011, COCHRANE HDB SYSTEMA; Lim BW, 2008, ARTHRIT RHEUM-ARTHR, V59, P943, DOI 10.1002/art.23823; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Marley J, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1836-2; Martin J, 2013, INT J OBESITY, V37, P1287, DOI 10.1038/ijo.2013.107; Michie S, 2014, BCT TAXONOMY STARTER; Michie S, 2013, ANN BEHAV MED, V46, P81, DOI 10.1007/s12160-013-9486-6; Michie S, 2009, HEALTH PSYCHOL, V28, P690, DOI 10.1037/a0016136; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; National Institute for Health and Care Excellence (NICE), 2014, OST CAR MAN AD; O'Brien N, 2015, HEALTH PSYCHOL REV, V9, P417, DOI 10.1080/17437199.2015.1012177; Odole AC, 2013, INT J TELEREHABILITA, V5, P11, DOI 10.5195/ijt.2013.6125; Olander Ellinor K, 2013, Int J Behav Nutr Phys Act, V10, P29, DOI 10.1186/1479-5868-10-29; Pereira D, 2011, OSTEOARTHR CARTILAGE, V19, P1270, DOI 10.1016/j.joca.2011.08.009; Pisters MF, 2010, OSTEOARTHR CARTILAGE, V18, P1019, DOI 10.1016/j.joca.2010.05.008; Pisters MF, 2010, ARTHRIT CARE RES, V62, P1087, DOI 10.1002/acr.20182; Plow MA, 2014, OBES REV, V15, P945, DOI 10.1111/obr.12223; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037//0022-006X.51.3.390; Schlenk EA, 2011, REHABIL NURS, V36, P32, DOI 10.1002/j.2048-7940.2011.tb00063.x; Segal NA, 2015, AM J PHYS MED REHAB, V94, P848, DOI 10.1097/PHM.0000000000000264; Smith AL, 2011, J SPORT EXERCISE PSY, V33, P124, DOI 10.1123/jsep.33.1.124; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; Teirlinck CH, 2016, OSTEOARTHR CARTILAGE, V24, P82, DOI 10.1016/j.joca.2015.07.023; Teixeira PJ, 2012, INT J BEHAV NUTR PHY, V9, DOI 10.1186/1479-5868-9-78; Tiffreau V., 2007, Annales de Readaptation et de Medecine Physique, V50, P741, DOI 10.1016/j.annrmp.2007.10.001; Toomey E, 2015, MANUAL THER, V20, P287, DOI 10.1016/j.math.2014.10.012; University of York Centre for Reviews and Dissemination, 2009, SYST REV CRDS GUID U; Van Baar ME, 1998, J RHEUMATOL, V25, P2432; van Dijk GM, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-95; Veenhof C, 2006, ARTHRIT RHEUM-ARTHR, V55, P925, DOI 10.1002/art.22341; Wallis JA, 2017, OSTEOARTHR CARTILAGE, V25, P1969, DOI 10.1016/j.joca.2016.12.017; Willett M, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-015833; Wood CE, 2016, IMPLEMENT SCI, V11, DOI 10.1186/s13012-016-0448-9	81	29	29	2	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2019	14	7							e0219482	10.1371/journal.pone.0219482	http://dx.doi.org/10.1371/journal.pone.0219482			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4JZ	31291326	Green Published, Green Submitted, gold			2023-01-03	WOS:000484947800095
J	Akata, K; Muratani, T; Yatera, K; Naito, K; Noguchi, S; Yamasaki, K; Kawanami, T; Kido, T; Mukae, H				Akata, Kentaro; Muratani, Tetsuro; Yatera, Kazuhiro; Naito, Keisuke; Noguchi, Shingo; Yamasaki, Kei; Kawanami, Toshinori; Kido, Takashi; Mukae, Hiroshi			Induction of plasmid-mediated AmpC beta-lactamase DHA-1 by piperacillin/tazobactam and other beta-lactams in Enterobacteriaceae	PLOS ONE			English	Article							RESISTANCE; PENICILLINS; EXPRESSION; MORGANII	Chromosomal AmpC beta-lactamase induction by several types of beta-lactams has been reported, but not enough data are available on DHA-1 beta-lactamase, a plasmid-mediated AmpC beta-lactamase. Therefore, we evaluated the DHA-1 beta-lactamase induction by various antibiotics including piperacillin/tazobactam (PIP/TZB) in this study. Six strains (Enterobacter cloacae 2 strains, Citrobacter freundii 1 strain, Serratia marcescens 2 strain, and Morganella morganii 1 strain) possessing chromosomal inducible AmpC beta-lactamase were used as controls. Four strains (Escherichia coli 2 strains, Klebsiella pneumoniae 1 strain, and C. koseri 1 strain) possessing DHA-1 beta-lactamase were used. The beta-lactamase activities were determined by a spectrophotometer using nitrocefin. beta-lactamase induction by PIP, PIP/TZB was not observed in any strains and beta-lactamase induction by third- and fourth-generation cephems was not observed in most strains. The induction ratios of the chromosomal AmpC beta-lactamase in the reference group by PIP/TZB were <1.51, and those of the DHA-1 beta-lactamase were <1.36, except for K. pneumoniae Rkp2004 (2.22). The beta-lactamase induction by first- and second-generation cephems, flomoxef, and carbapenem differed in each strain. Cefmetazole (CMZ) strongly induced beta-lactamase. This study demonstrated that the induction of DHA-1 beta-lactamase was similar to that of chromosomal AmpC using various Enterobacteriaceae, although the induction of beta-lactamase in both groups by PIP/TZB was low. We also reported that the induction of PIP/TZB, a beta-lactamase inhibitor combination antibiotic, against various AmpC-producing Enterobacteriaceae, including DHA-1 producers, was low.	[Akata, Kentaro; Yatera, Kazuhiro; Naito, Keisuke; Noguchi, Shingo; Yamasaki, Kei; Kawanami, Toshinori; Kido, Takashi] Univ Occupat & Environm Hlth, Dept Resp Med, Kitakyushu, Fukuoka, Japan; [Muratani, Tetsuro] Kyurin Med Lab, Dept Clin Microbiol, Kitakyushu, Fukuoka, Japan; [Mukae, Hiroshi] Nagasaki Univ, Sch Med, Dept Internal Med 2, Nagasaki, Nagasaki, Japan	University of Occupational & Environmental Health - Japan; Nagasaki University	Yatera, K (corresponding author), Univ Occupat & Environm Hlth, Dept Resp Med, Kitakyushu, Fukuoka, Japan.	yatera@med.uoeh-u.ac.jp		Yatera, Kazuhiro/0000-0002-2955-4432				AKOVA M, 1990, J ANTIMICROB CHEMOTH, V25, P199, DOI 10.1093/jac/25.2.199; AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; Barnaud G, 1998, ANTIMICROB AGENTS CH, V42, P2352, DOI 10.1128/AAC.42.9.2352; Bauernfeind A, 1997, ANTIMICROB AGENTS CH, V41, P2041, DOI 10.1128/AAC.41.9.2041; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; Clinical Laboratory Standard Institute, 2015, M07A10 CLIN LAB STAN, VTwelfth; Dietz H, 1997, ANTIMICROB AGENTS CH, V41, P2113, DOI 10.1128/AAC.41.10.2113; GOOTZ TD, 1983, ANTIMICROB AGENTS CH, V23, P91, DOI 10.1128/AAC.23.1.91; Hanson ND, 1999, CURR PHARM DESIGN, V5, P881; Hennequin C, 2018, J ANTIMICROB CHEMOTH, V73, P2981, DOI 10.1093/jac/dky285; Jacobs C, 1997, CELL, V88, P823, DOI 10.1016/S0092-8674(00)81928-5; Jacoby GA, 2009, CLIN MICROBIOL REV, V22, P161, DOI 10.1128/CMR.00036-08; Kadima TA, 1997, ANTIMICROB AGENTS CH, V41, P2177, DOI 10.1128/AAC.41.10.2177; Medeiros AA, 1997, CLIN INFECT DIS, V24, pS19, DOI 10.1093/clinids/24.Supplement_1.S19; MINAMI S, 1983, J ANTIBIOT, V36, P1387, DOI 10.7164/antibiotics.36.1387; MINAMI S, 1980, ANTIMICROB AGENTS CH, V18, P382, DOI 10.1128/AAC.18.3.382; Muratani T, 2006, INT J ANTIMICROB AG, V27, P491, DOI 10.1016/j.ijantimicag.2006.03.007; Philippon A, 2002, ANTIMICROB AGENTS CH, V46, P1, DOI 10.1128/AAC.46.1.1-11.2002; Poirel L, 1999, ANTIMICROB AGENTS CH, V43, P769, DOI 10.1128/AAC.43.4.769; SANDERS CC, 1987, ANNU REV MICROBIOL, V41, P573, DOI 10.1146/annurev.mi.41.100187.003041; SYKES R B, 1976, Journal of Antimicrobial Chemotherapy, V2, P115, DOI 10.1093/jac/2.2.115; Trepanier S, 1997, ANTIMICROB AGENTS CH, V41, P2399, DOI 10.1128/AAC.41.11.2399; WEBER DA, 1990, ANTIMICROB AGENTS CH, V34, P156, DOI 10.1128/AAC.34.1.156; YAGINUMA S, 1974, JPN J MICROBIOL, V18, P113, DOI 10.1111/j.1348-0421.1974.tb00798.x; Yamasaki K, 2010, J CLIN MICROBIOL, V48, P3267, DOI 10.1128/JCM.02111-09	25	6	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2019	14	7							e0218589	10.1371/journal.pone.0218589	http://dx.doi.org/10.1371/journal.pone.0218589			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4GX	31283769	Green Published, gold, Green Submitted			2023-01-03	WOS:000484939800009
J	Turnbull, AE; Ning, XJ; Rao, A; Tao, JJ; Needham, DM				Turnbull, Alison E.; Ning, Xuejuan; Rao, Anirudh; Tao, Jessica J.; Needham, Dale M.			Demonstrating the impact of POLST forms on hospital care requires information not contained in state registries	PLOS ONE			English	Article							PHYSICIAN ORDERS; LIFE; PREFERENCES; PREVALENCE	Background Physician Orders for Life-Sustaining Treatment (POLST) programs have expanded rapidly, but evaluating their impact on hospital care is challenging. Objectives To demonstrate how careful study design can reveal POLST's impact at hospital admission and why analyses of state registry data are unlikely to capture POLST's effects. Design Prospective cohort study. Setting and participants Adult in-patients with Do Not Intubate and/or Do Not Resuscitate (DNR/I) orders in the electronic medical record at the time of discharge from Johns Hopkins Hospital over 18 months. For patients with unplanned readmissions within 30 days, records were reviewed to determine if a Maryland Medical Order for Life-Sustaining Treatment (MOLST) form was presented and for the time from readmission to a DNR/I order in the EMR. Analyses were stratified by whether patients could communicate or were accompanied by a proxy at readmission. Results Among 1,507 patients with DNR/I orders at discharge, 124 (8%) had unplanned readmissions, 112 (90%) could communicate or were accompanied by a proxy at readmission, and 12 (10%) could not communicate and were unaccompanied. For patients who were unaccompanied and could not communicate, MOLST significantly decreased the median time from readmission to DNR/I order (1.2 vs 27.1 hours, P = .001), but this association was greatly attenuated among patients who could communicate or were accompanied by a proxy (16.4 vs 25.4 hours P = .10). Conclusion Among patients who wanted to avoid intubation and/or CPR, MOLST forms were protective when the patient was unaccompanied by a healthcare proxy at admission and could not communicate. Fewer than 10% of patients met these criteria during unplanned readmissions, and state registry data does not allow this sub-population to be identified.	[Turnbull, Alison E.; Needham, Dale M.] Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD 21218 USA; [Turnbull, Alison E.; Needham, Dale M.] Johns Hopkins Univ, Outcomes Crit Illness & Surg Grp OACIS, Baltimore, MD 21218 USA; [Turnbull, Alison E.; Ning, Xuejuan] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; [Rao, Anirudh] Medstar Washington Hosp, Washington, DC USA; [Tao, Jessica J.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Needham, Dale M.] Johns Hopkins Univ, Dept Phys Med & Rehabil, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; MedStar Washington Hospital Center; Memorial Sloan Kettering Cancer Center; Johns Hopkins University	Turnbull, AE (corresponding author), Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD 21218 USA.; Turnbull, AE (corresponding author), Johns Hopkins Univ, Outcomes Crit Illness & Surg Grp OACIS, Baltimore, MD 21218 USA.; Turnbull, AE (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA.	turnbull@jhmi.edu		NING, XUEJUAN/0000-0002-8523-0483; Turnbull, Alison/0000-0002-1564-6547	Johns Hopkins Hospital Department of Medical Affairs; NATIONAL CANCER INSTITUTE [T32CA009207] Funding Source: NIH RePORTER	Johns Hopkins Hospital Department of Medical Affairs; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	AET received financial support for this study from the Johns Hopkins Hospital Department of Medical Affairs.	Auriemma CL, 2014, JAMA INTERN MED, V174, P1085, DOI 10.1001/jamainternmed.2014.1183; Austin PC, 2009, COMMUN STAT-SIMUL C, V38, P1228, DOI 10.1080/03610910902859574; Clemency B, 2017, J AM MED DIR ASSOC, V18, P35, DOI 10.1016/j.jamda.2016.07.032; Fromme EK, 2012, JAMA-J AM MED ASSOC, V307, P34, DOI 10.1001/jama.2011.1956; Hart JL, 2015, JAMA INTERN MED, V175, P1019, DOI 10.1001/jamainternmed.2015.0372; Hernan MA, 2016, AM J EPIDEMIOL, V183, P758, DOI 10.1093/aje/kwv254; Heyland DK, 2016, BMJ QUAL SAF, V25, P671, DOI 10.1136/bmjqs-2015-004567; Heyland DK, 2013, JAMA INTERN MED, V173, P778, DOI 10.1001/jamainternmed.2013.180; Hickman SE, 2015, J AM GERIATR SOC, V63, P341, DOI 10.1111/jgs.13248; Hickman SE, 2011, J AM GERIATR SOC, V59, P2091, DOI 10.1111/j.1532-5415.2011.03656.x; Hickman SE, 2010, J AM GERIATR SOC, V58, P1241, DOI 10.1111/j.1532-5415.2010.02955.x; Mirarchi FL, 2015, J PATIENT SAF, V11, P9, DOI 10.1097/PTS.0000000000000164; Mirarchi FL, 2015, J PATIENT SAF, V11, P1, DOI 10.1097/PTS.0000000000000165; Moore KA, 2016, JAMA-J AM MED ASSOC, V315, P259, DOI 10.1001/jama.2015.17362; Richardson DK, 2014, ANN EMERG MED, V63, P375, DOI 10.1016/j.annemergmed.2013.09.004; Turnbull AE, 2016, ANN AM THORAC SOC, V13, P926, DOI 10.1513/AnnalsATS.201511-738OC; Waldrop DP, 2014, J PALLIAT MED, V17, P338, DOI 10.1089/jpm.2013.0442; Zive DM, 2015, J PAIN SYMPTOM MANAG, V50, P650, DOI 10.1016/j.jpainsymman.2015.06.004	18	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2019	14	6							e0217113	10.1371/journal.pone.0217113	http://dx.doi.org/10.1371/journal.pone.0217113			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW3OQ	31211788	gold, Green Submitted, Green Published			2023-01-03	WOS:000484891700007
J	Duranti, S; Mancabelli, L; Mancino, W; Anzalone, R; Longhi, G; Statello, R; Carnevali, L; Sgoifo, A; Bernasconi, S; Turroni, F; Ventura, M				Duranti, Sabrina; Mancabelli, Leonardo; Mancino, Walter; Anzalone, Rosaria; Longhi, Giulia; Statello, Rosario; Carnevali, Luca; Sgoifo, Andrea; Bernasconi, Sergio; Turroni, Francesca; Ventura, Marco			Exploring the effects of COLOSTRONONI on the mammalian gut microbiota composition	PLOS ONE			English	Article							MORINDA-CITRIFOLIA NONI; BOVINE COLOSTRUM; TNF-ALPHA; CELLS; CONSTITUENTS; THERAPY; FRUIT; JUICE	COLOSTRONONI is a dietary supplement consisting of bovine colostrum and Morinda citrifolia fruit (Noni). In this study, we tested the capability of COLOSTRONONI to influence gut microbiota composition using an in vivo evaluation in rats. Furthermore, we analyzed the effect of COLOSTRONONI on the systemic inflammatory responses as well as on the gut permeability of the animals. Altogether, our analyses supported the concept of COLOSTRONONI as a natural food supplement that doesn't affect (neither negatively nor positively) gut microbiota homeostasis in healthy conditions. Moreover, COLOSTRONONI highlighted a lower effect in the expression of genes coding for IL-10, Il-12 and TNF-alpha response allowing us to hypothesize an immunomodulatory activity of this dietary supplement.	[Duranti, Sabrina; Mancabelli, Leonardo; Mancino, Walter; Turroni, Francesca; Ventura, Marco] Univ Parma, Dept Chem Life Sci & Environm Sustainabil, Lab Probiogen, Parma, Italy; [Anzalone, Rosaria; Longhi, Giulia] GenProbio Srl Parma, Parma, Italy; [Statello, Rosario; Carnevali, Luca; Sgoifo, Andrea] Univ Parma, Dept Chem Life Sci & Environm Sustainabil, Stress Physiol Lab, Parma, Italy; [Sgoifo, Andrea; Bernasconi, Sergio; Turroni, Francesca; Ventura, Marco] Univ Parma, Microbiome Res Hub, Parma, Italy	University of Parma; University of Parma; University of Parma	Ventura, M (corresponding author), Univ Parma, Dept Chem Life Sci & Environm Sustainabil, Lab Probiogen, Parma, Italy.; Ventura, M (corresponding author), Univ Parma, Microbiome Res Hub, Parma, Italy.	marco.ventura@unipr.it	Duranti, Sabrina/AAI-7916-2020; Sgoifo, Andrea/AAC-6278-2022; Mancabelli, Leonardo/AAV-5147-2021; Turroni, Francesca/K-9660-2016; ventura, marco/M-8230-2015; Bernasconi, Sergio/AAA-9419-2021; Carnevali, Luca/E-5322-2017	Duranti, Sabrina/0000-0002-7724-5669; Sgoifo, Andrea/0000-0002-9428-6198; Mancabelli, Leonardo/0000-0002-1744-2214; Turroni, Francesca/0000-0001-5363-0231; Carnevali, Luca/0000-0001-9053-7976; Statello, Rosario/0000-0002-0644-2454	GenProbio srl	GenProbio srl	GenProbio srl supports the Laboratory of Probiogenomics. The funder provided support in the form of salaries for R.A. and G.L. and research materials, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abou Assi R, 2017, ARAB J CHEM, V10, P691, DOI 10.1016/j.arabjc.2015.06.018; Campbell HK, 2017, EXP CELL RES, V358, P39, DOI 10.1016/j.yexcr.2017.03.061; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Cardani D, 2014, Minerva Gastroenterol Dietol, V60, P71; Derrien M, 2017, MICROB PATHOGENESIS, V106, P171, DOI 10.1016/j.micpath.2016.02.005; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Ferrario C, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01749; Filipescu IE, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202929; Furusawa E, 2003, PHYTOTHER RES, V17, P1158, DOI 10.1002/ptr.1307; Gad M, 2011, FEMS IMMUNOL MED MIC, V63, P93, DOI 10.1111/j.1574-695X.2011.00835.x; Gorska S, 2016, SCI REP-UK, V6, DOI 10.1038/srep37613; Groschwitz KR, 2009, J ALLERGY CLIN IMMUN, V124, P3, DOI 10.1016/j.jaci.2009.05.038; Kamiya K, 2004, J AGR FOOD CHEM, V52, P5843, DOI 10.1021/jf040114k; Komarova Y, 2010, ANNU REV PHYSIOL, V72, P463, DOI 10.1146/annurev-physiol-021909-135833; Leppkes M, 2014, INT IMMUNOL, V26, P509, DOI 10.1093/intimm/dxu051; Lozupone C, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-371; Milani C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068739; Pakkanen R, 1997, INT DAIRY J, V7, P285, DOI 10.1016/S0958-6946(97)00022-8; Qiu XY, 2013, J CROHNS COLITIS, V7, pE558, DOI 10.1016/j.crohns.2013.04.002; Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219; Rathe M, 2014, NUTR REV, V72, P237, DOI 10.1111/nure.12089; Saludes JP, 2002, PHYTOTHER RES, V16, P683, DOI 10.1002/ptr.1003; Shen YJ, 2017, AM J PHYSIOL-GASTR L, V312, pG123, DOI 10.1152/ajpgi.00316.2016; Soini Y, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-70; Sponseller JK, 2015, J INFECT DIS, V211, P1334, DOI 10.1093/infdis/jiu605; Uruakpa FO, 2002, NUTR RES, V22, P755, DOI 10.1016/S0271-5317(02)00373-1; Yang J, 2007, FOOD CHEM, V102, P302, DOI 10.1016/j.foodchem.2006.05.020; Zin ZM, 2006, FOOD CHEM, V94, P169, DOI 10.1016/j.foodchem.2004.08.048	28	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2019	14	5							e0217609	10.1371/journal.pone.0217609	http://dx.doi.org/10.1371/journal.pone.0217609			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IA7TI	31150516	Green Published, Green Submitted, gold			2023-01-03	WOS:000469759100070
J	Khawagi, WY; Steinke, DT; Nguyen, J; Keers, RN				Khawagi, Wael Y.; Steinke, Douglas T.; Nguyen, Joanne; Keers, Richard N.			Identifying potential prescribing safety indicators related to mental health disorders and medications: A systematic review	PLOS ONE			English	Review							DRUG-RELATED MORBIDITY; OLDER PERSONS PRESCRIPTIONS; NORWEGIAN GENERAL-PRACTICE; INAPPROPRIATE MEDICATION; SCREENING TOOL; EXPLICIT CRITERIA; ELDERLY-PATIENTS; AMBULATORY-CARE; DEVELOPING CONSENSUS; QUALITY INDICATORS	Background Prescribing errors and medication related harm may be common in patients with mental illness. However, there has been limited research focusing on the development and application of prescribing safety indicators (PSIs) for this population. Objective Identify potential PSIs related to mental health (MH) medications and conditions. Methods Seven electronic databases were searched (from 1990 to February 2019), including the bibliographies of included studies and of relevant review articles. Studies that developed, validated or updated a set of explicit medication-specific indicators or criteria that measured prescribing safety or quality were included, irrespective of whether they contained MH indicators or not. Studies were screened to extract all MH related indicators before two MH clinical pharmacists screened them to select potential PSIs based on established criteria. All indicators were categorised into prescribing problems and medication categories. Results 79 unique studies were included, 70 of which contained at least one MH related indicator. No studies were identified that focused on development of PSIs for patients with mental illness. A total of 1386 MH indicators were identified (average 20 (SD = 25.1) per study); 245 of these were considered potential PSIs. Among PSIs the most common prescribing problem was 'Potentially inappropriate prescribing considering diagnoses or conditions' (n = 91, 37.1%) and the lowest was 'omission' (n = 5, 2.0%). 'Antidepressant' was the most common PSI medication category (n = 85, 34.7%). Conclusion This is the first systematic review to identify a comprehensive list of MH related potential PSIs. This list should undergo further validation and could be used as a foundation for the development of new suites of PSIs applicable to patients with mental illness.	[Khawagi, Wael Y.; Steinke, Douglas T.; Nguyen, Joanne; Keers, Richard N.] Univ Manchester, Div Pharm & Optometry, Sch Hlth Sci, Fac Biol Med & Hlth, Manchester, Lancs, England; [Khawagi, Wael Y.] Taif Univ, Coll Pharm, Clin Pharm Dept, At Taif, Saudi Arabia; [Nguyen, Joanne; Keers, Richard N.] Greater Manchester Mental Hlth NHS Fdn Trust, Pharm Dept, Manchester, Lancs, England	University of Manchester; Taif University	Khawagi, WY (corresponding author), Univ Manchester, Div Pharm & Optometry, Sch Hlth Sci, Fac Biol Med & Hlth, Manchester, Lancs, England.; Khawagi, WY (corresponding author), Taif Univ, Coll Pharm, Clin Pharm Dept, At Taif, Saudi Arabia.	wael.khawagi@postgrad.manchester.ac.uk	Khawagi, Wael/AAC-8343-2022; Keers, Richard/D-9136-2012	Keers, Richard/0000-0001-7854-8154; Khawagi, Wael/0000-0002-9489-1697	Taif University	Taif University	WK acknowledges Taif University for funding this systematic review as part of his PhD programme at The University of Manchester. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Taweel D, 2017, INT J CLIN PHARM-NET, V39, P897, DOI 10.1007/s11096-017-0498-3; Alshehri GH, 2017, DRUG SAFETY, V40, P871, DOI 10.1007/s40264-017-0557-7; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU; [Anonymous], 2016, FUND FACTS MENT HLTH; Avery AJ, 2012, LANCET, V379, P1310, DOI 10.1016/S0140-6736(11)61817-5; Avery AJ, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X588501; Avery AJ, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-28; Barnett KN, 2014, IMPLEMENT SCI, V9, DOI 10.1186/s13012-014-0133-9; Barry E, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012079; Basger BJ, 2008, DRUG AGING, V25, P777, DOI 10.2165/00002512-200825090-00004; Basger BJ, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001431; Bazire S., 2018, PSYCHOTROPIC DRUG DI; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; Beers MH, 1997, ARCH INTERN MED, V157, P1531, DOI 10.1001/archinte.157.14.1531; Boulkedid R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020476; British Medical Association, 2017, BREAK BARR THE CHALL; Campbell SM, 2000, BRIT MED J, V321, P425, DOI 10.1136/bmj.321.7258.425; Castillo-Paramo A, 2013, Semergen, V39, P413, DOI 10.1016/j.semerg.2013.01.017; Caughey GE, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004625; Center for Health Policy/ Center for Primary Care and Outcomes Research Battelle Memorial Institute, 2011, 290040020 CTR HLTH P; Chang CB, 2012, PHARMACOEPIDEM DR S, V21, P1269, DOI 10.1002/pds.3274; Chen YF, 2005, DRUG SAFETY, V28, P67, DOI 10.2165/00002018-200528010-00005; Clyne B, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-307; Constantine RJ, 2013, COMMUNITY MENT HLT J, V49, P33, DOI 10.1007/s10597-012-9497-y; Cooper JA, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0484-6; Department of Health and Social Care, MED SAF IND SAF PRES; Desnoyer A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016070; Desrochers JF, 2011, AM J KIDNEY DIS, V58, P527, DOI 10.1053/j.ajkd.2011.04.020; Dreischulte Tobias, 2012, BMC Clin Pharmacol, V12, P5, DOI 10.1186/1472-6904-12-5; Duerden M, 2011, QUALITY GP PRESCRIBI; Edwards P, 2002, STAT MED, V21, P1635, DOI 10.1002/sim.1190; Elliott Rohan A., 2001, Australian Journal of Hospital Pharmacy, V31, P19; Urrusuno RF, 2013, EUR J CLIN PHARMACOL, V69, P1845, DOI 10.1007/s00228-013-1542-4; Fialova D., 2013, KLIN FARMAKOL FARM, V27, P18; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; Fick D, 2012, J AM GERIATR SOC, V60, P616, DOI 10.1111/j.1532-5415.2012.03923.x; Fox A, 2016, BRIT J CLIN PHARMACO, V82, P451, DOI 10.1111/bcp.12954; Galán Retamal C., 2014, Farm Hosp., V38, P305, DOI [10.7399/fh.2014.38.4.1148, 10.7399/FH.2014.38.4.1148]; Gallagher P, 2008, INT J CLIN PHARM TH, V46, P72; Green H., 2005, J RES SPEC EDUC NEED; Guerreiro Mara Pereira, 2007, Acta Med Port, V20, P107; Guthrie B, 2011, BMJ-BRIT MED J, V342, P1; Guthrie B., 2015, HEALTH SERV DELIVERY, V3, P1, DOI [10.3310/hsdr03420, DOI 10.3310/HSDR03420]; Guthrie B, 2015, HLTH SERVICES DELIVE, DOI [10.3399/bjgp14X677806, DOI 10.3399/BJGP14X677806]; HANLON JT, 1992, J CLIN EPIDEMIOL, V45, P1045, DOI 10.1016/0895-4356(92)90144-C; Harper MB, 2014, J PATIENT SAF, V10, P59, DOI 10.1097/PTS.0000000000000050; Helmer-Hirschberg O., 1967, IN; Holmes HM, 2008, J AM GERIATR SOC, V56, P1306, DOI 10.1111/j.1532-5415.2008.01741.x; Holt S, 2010, DTSCH ARZTEBL INT, V107, P543, DOI 10.3238/arztebl.2010.0543; Humphrey-Murto S, 2017, MED TEACH, V39, P14, DOI 10.1080/0142159X.2017.1245856; Hurley JS, 2005, J GEN INTERN MED, V20, P331, DOI 10.1111/j.1525-1497.2005.40182.x; Ivers N, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000259.pub3; Jeffries M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205419; Joint Formulary Committee, 2018, BRIT NATL FORMULARY; Kaufmann CP, 2014, EUR J CLIN PHARMACOL, V70, P1, DOI 10.1007/s00228-013-1575-8; Keers RN, 2015, J CLIN PHARM THER, V40, P645, DOI 10.1111/jcpt.12328; Keers RN, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-005948; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Khodyakov D, 2017, J AM GERIATR SOC, V65, P586, DOI 10.1111/jgs.14689; Kim DS, 2010, HEALTHC INFORM RES, V16, P231, DOI 10.4258/hir.2010.16.4.231; Kim DS, 2015, INT J CLIN PHARM-NET, V37, P76, DOI 10.1007/s11096-014-0042-7; Kim MY, 2018, ANN GERIATR MED RES, V22, P121, DOI 10.4235/agmr.2018.22.3.121; Kim SO, 2015, INT J GERONTOL, V9, P136, DOI 10.1016/j.ijge.2015.05.013; Kojima T, 2016, GERIATR GERONTOL INT, V16, P983, DOI 10.1111/ggi.12890; Kroger E, 2015, J AM MED DIR ASSOC, V16, DOI 10.1016/j.jamda.2015.04.002; Kuhn-Thiel AM, 2014, DRUG AGING, V31, P131, DOI 10.1007/s40266-013-0146-0; Laroche ML, 2007, EUR J CLIN PHARMACOL, V63, P725, DOI 10.1007/s00228-007-0324-2; Lavan AH, 2016, CLIN INTERV AGING, V11, P857, DOI 10.2147/CIA.S80280; Lavan AH, 2017, AGE AGEING, V46, P600, DOI 10.1093/ageing/afx005; Lilford R, 2006, QUAL SAF HEALTH CARE, V15, P311, DOI 10.1136/qshc.2005.017178; Lindblad CI, 2006, CLIN THER, V28, P1133, DOI 10.1016/j.clinthera.2006.08.006; Mackinnon Neil J, 2002, J Manag Care Pharm, V8, P365; Maio V, 2010, J CLIN PHARM THER, V35, P219, DOI 10.1111/j.1365-2710.2009.01094.x; Malone Daniel C, 2004, J Am Pharm Assoc (2003), V44, P142, DOI 10.1331/154434504773062591; Mann E, 2012, WIEN KLIN WOCHENSCHR, V124, P160, DOI 10.1007/s00508-011-0061-5; Mann K, 2008, WORLD J BIOL PSYCHIA, V9, P24, DOI 10.1080/15622970601178056; Marzi Marta M, 2018, Value Health Reg Issues, V17, P38, DOI 10.1016/j.vhri.2017.10.002; Mast Ruth, 2015, BMC Res Notes, V8, P642, DOI 10.1186/s13104-015-1566-1; McDonnell J., 2001, RANDUCLA APPROPRIATE; McLeod PJ, 1997, CAN MED ASSOC J, V156, P385; McManus S, 2014, MENTAL HLTH WELLBEIN; Mitchell AJ, 2012, BRIT J PSYCHIAT, V201, P435, DOI 10.1192/bjp.bp.111.094532; Morris CJ, 2003, J CLIN PHARM THER, V28, P295, DOI 10.1046/j.1365-2710.2003.00496.x; Morris CJ, 2002, INT J QUAL HEALTH C, V14, P183, DOI 10.1093/oxfordjournals.intqhc.a002610; NICE, NICE GUID NAT I HLTH; NICE, 2015, MED OPT SAF EFF US M; Nyborg G, 2015, SCAND J PRIM HEALTH, V33, P134, DOI 10.3109/02813432.2015.1041833; O'Mahony D, 2015, AGE AGEING, V44, P213, DOI 10.1093/ageing/afu145; Oborne CA, 1997, BRIT J CLIN PHARMACO, V43, P91, DOI 10.1111/j.1365-2125.1997.tb00038.x; Oborne CA, 2003, AGE AGEING, V32, P102; Okechukwu I, 2006, BRIT J CLIN PHARMACO, V62, P218, DOI 10.1111/j.1365-2125.2006.02621.x; Onder G, 2014, J GERONTOL A-BIOL, V69, P430, DOI 10.1093/gerona/glt118; Onder G, 2014, DRUG AGING, V31, P33, DOI 10.1007/s40266-013-0134-4; Paton C, 2004, QUAL SAF HEALTH CARE, V13, P40, DOI 10.1136/qshc.2003.006338; Pazan F, 2018, DRUG AGING, V35, P61, DOI 10.1007/s40266-017-0514-2; Pazan F, 2016, DRUG AGING, V33, P447, DOI 10.1007/s40266-016-0371-4; Phansalkar S, 2012, J AM MED INFORM ASSN, V19, P735, DOI 10.1136/amiajnl-2011-000612; Pontefract SK, 2018, BMJ QUAL SAF, V27, P725, DOI 10.1136/bmjqs-2017-007135; Prot-Labarthe S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108007; Quintens C, 2019, BMC MED INFORM DECIS, V19, DOI 10.1186/s12911-019-0748-5; Radcliff S, 2015, J AM GERIATR SOC, V63, P2227, DOI 10.1111/jgs.13702; Raebel MA, 2006, PHARMACOTHERAPY, V26, P619, DOI 10.1592/phco.26.5.619; Raebel MA, 2007, J AM GERIATR SOC, V55, P977, DOI 10.1111/j.1532-5415.2007.01202.x; Rancourt Carol, 2004, BMC Geriatr, V4, P9, DOI 10.1186/1471-2318-4-9; Renom-Guiteras A, 2015, EUR J CLIN PHARMACOL, V71, P861, DOI 10.1007/s00228-015-1860-9; Robertson HA, 2002, CLIN THER, V24, P1595, DOI 10.1016/S0149-2918(02)80063-7; Rognstad S, 2009, SCAND J PRIM HEALTH, V27, P153, DOI 10.1080/02813430902992215; Ross M K, 2014, Yearb Med Inform, V9, P97, DOI 10.15265/IY-2014-0003; Royal Pharmaceutical Society, 2017, MEDICINESCOMPLETE RO; Ruths S, 2003, QUAL SAF HEALTH CARE, V12, P176, DOI 10.1136/qhc.12.3.176; Saverno KR, 2011, J AM MED INFORM ASSN, V18, P32, DOI 10.1136/jamia.2010.007609; Smits KPJ, 2017, INT J CLIN PRACT, V71, DOI 10.1111/ijcp.12922; Smits KPJ, 2016, NEPHROL DIAL TRANSPL, V31, P1876, DOI 10.1093/ndt/gfv420; Soerensen AL, 2016, NORD J PSYCHIAT, V70, P365, DOI 10.3109/08039488.2015.1127996; Solberg LI, 2004, AM J MANAG CARE, V10, P753; Song Jie, 2017, J Evid Based Med, V10, P222, DOI 10.1111/jebm.12244; Spencer R, 2014, BRIT J GEN PRACT, V64, pE181, DOI 10.3399/bjgp14X677806; Standage C., 2008, INT J PHARM PRACT, V16, P317, DOI [DOI 10.1211/ijpp.16.5.0007, 10.1211/ijpp.16.5.0007]; Steel Z, 2014, INT J EPIDEMIOL, V43, P476, DOI 10.1093/ije/dyu038; Stocks SJ, 2015, BMJ-BRIT MED J, P351; TAMBLYN RM, 1994, CAN MED ASSOC J, V150, P1801; Taylor DM, 2018, MAUDSLEY PRESCRIBING; The Medicines and Healthcare products Regulatory Agency (MHRA), 2018, DRUG SAFETY UPDATE, V11, P1; Thomas S, DEV ELECT DATA CAPTU; Thomas SK, 2013, BRIT J CLIN PHARMACO, V76, P797, DOI 10.1111/bcp.12087; Tjia J, 2010, AM J MANAG CARE, V16, P489; Tommelein E, 2016, J PUBLIC HEALTH-UK, V38, pE158, DOI 10.1093/pubmed/fdv090; Tully MP, 2005, PHARM WORLD SCI, V27, P407, DOI 10.1007/s11096-005-0340-1; University of Nottingham, PINCER TOOL; Van der Linden L, 2014, EUR GERIATR MED, V5, P175, DOI 10.1016/j.eurger.2013.12.005; van Dijk KN, 2003, ANN PHARMACOTHER, V37, P1136, DOI 10.1345/aph.1C073; Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4; Wenger NS, 2001, ANN INTERN MED, V135, P642, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00002; Wessell AM, 2010, QUAL SAF HEALTH CARE, V19, DOI 10.1136/qshc.2009.034678; WHO (World Health Organization), 2016, INT STAT CLASS DIS R, V5th; Williams D, 2005, EUR J CLIN PHARMACOL, V61, P127, DOI 10.1007/s00228-004-0876-3; Williams Richard, 2018, J Innov Health Inform, V25, P183, DOI 10.14236/jhi.v25i3.1015; Winit-Watjana W, 2008, ARCH GERONTOL GERIAT, V47, P35, DOI 10.1016/j.archger.2007.06.006; Yu SS, 2011, AM J HEALTH-SYST PH, V68, P407, DOI 10.2146/ajhp100215; Zhen CL, 2001, JAMA-J AM MED ASSOC, V286, P2823, DOI 10.1001/jama.286.22.2823	140	7	7	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 24	2019	14	5							e0217406	10.1371/journal.pone.0217406	http://dx.doi.org/10.1371/journal.pone.0217406			29	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HZ5BN	31125358	Green Published, gold, Green Submitted			2023-01-03	WOS:000468865700036
J	Han, HJ; Song, X; Yadav, D; Hwang, MS; Lee, JH; Lee, CH; Kim, TH; Lee, JJ; Kwon, J				Han, Hye-Ju; Song, Xinjie; Yadav, Dhananjay; Hwang, Mi Sun; Lee, Joo Hee; Lee, Chang Hoon; Kim, Tae Hee; Lee, Jeong Jun; Kwon, Jungkee			Ulmus macrocarpa Hance modulates lipid metabolism in hyperlipidemia via activation of AMPK pathway	PLOS ONE			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR-DISEASE; EXTRACT	Ulmus macrocarpa Hance as an oriental medicinal plant has shown enormous potential for the treatment of several metabolic disorders in Korea. Hyperlipidemia, which is characterized by the excess accumulation of lipid contents in the bloodstream, may lead to several cardiovascular diseases. Therefore, in this study, anti-hyperlipidemic potential of U. macrocarpa water extract (UME) was examined in vitro and in vivo using HepG2 cells and experimental rats, respectively. The hyperlipidemia in experimental rats was induced by the high-cholesterol diet (HCD) followed by oral administration of various concentrations (25, 50 and 100 mg/kg) of UME for 6 weeks. As a result, the UME significantly improved the biochemical parameters such as increased the level of triglyceride, total cholesterol, and low-density lipoprotein cholesterol as well as reduced the high-density lipoprotein cholesterol in the HCD-fed rats. In addition, UME also prevented lipid accumulation through regulating AMPK activity and lipid metabolism proteins (ACC, SREBP1 and HMGCR) in the HCD-fed rats as compared to the controls. Moreover, similar pattern of gene expression levels was confirmed in oleic acid (OA)-treated HepG2 cells. Taken together, our results indicate that UME prevents hyperlipidemia via activating the AMPK pathway and regulates lipid metabolism. Thus, based on the above findings, it is estimated that UME could be a potential therapeutic agent for preventing the hyperlipidemia.	[Han, Hye-Ju; Kwon, Jungkee] Chonbuk Natl Univ, Dept Lab Anim Med, Coll Vet Med, Iksan, South Korea; [Song, Xinjie] Yeungnam Univ, Dept Food Sci & Technol, Gyongsan, Gyeongsangbuk D, South Korea; [Yadav, Dhananjay] Yeungnam Univ, Dept Med Biotechnol, Gyongsan, Gyeongsangbuk D, South Korea; [Hwang, Mi Sun; Lee, Joo Hee; Lee, Chang Hoon] Pusan Natl Univ, Korea Nanotechnol Ctr, Busan, South Korea; [Hwang, Mi Sun; Lee, Joo Hee; Lee, Chang Hoon] Pusan Natl Univ, Ctr Antiaging Ind, Busan, South Korea; [Kim, Tae Hee; Lee, Jeong Jun] Naturetech Co Ltd, Jincheon Gun, Chungbuk, South Korea	Jeonbuk National University; Yeungnam University; Yeungnam University; Pusan National University; Pusan National University	Kwon, J (corresponding author), Chonbuk Natl Univ, Dept Lab Anim Med, Coll Vet Med, Iksan, South Korea.	jkwon@jbnu.ac.kr	Yadav, Dhananjay/AAZ-9435-2021	Yadav, Dhananjay/0000-0003-4047-7236; Kwon, Jungkee/0000-0001-6008-3918	Ministry of Trade, industry, and Energy (MOTIE) Korea, under the "Regional Specialized Industry Development Program (RD) [P0002747]	Ministry of Trade, industry, and Energy (MOTIE) Korea, under the "Regional Specialized Industry Development Program (RD)	This research was financially supported by the Ministry of Trade, industry, and Energy (MOTIE) Korea, under the "Regional Specialized Industry Development Program (R&D, P0002747)" supervised by the Korea Institute for Advancement of Technology (KIAT). Naturetech Co. Ltd. provided support in the form of research materials and salaries for authors THK and JJL. The specific roles of these authors are articulated in the 'author contributions' section. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anandhi R, 2013, J PHYSIOL BIOCHEM, V69, P313, DOI 10.1007/s13105-012-0215-6; Atkinson LL, 2003, AM J PHYSIOL-ENDOC M, V284, pE923, DOI 10.1152/ajpendo.00360.2002; Bauters C, 2018, ARCH CARDIOVASC DIS, V111, P634, DOI 10.1016/j.acvd.2017.07.007; Carling D, 2011, NAT CHEM BIOL, V7, P512, DOI [10.1038/nchembio.610, 10.1038/NCHEMBIO.610]; Choudhary MI, 2005, J ETHNOPHARMACOL, V98, P217, DOI 10.1016/j.jep.2005.01.013; Das PP, 2010, WORLD J BIOL PSYCHIA, V11, P321, DOI [10.1080/15622970902960889, 10.3109/15622970902960889]; Golomb BA, 2008, AM J CARDIOVASC DRUG, V8, P373, DOI 10.2165/0129784-200808060-00004; Guo P, 2010, J PHARMACOL SCI, V113, P395, DOI 10.1254/jphs.10041FP; Le NA, 2008, CURR OPIN LIPIDOL, V19, P545, DOI 10.1097/MOL.0b013e32830f4a57; Le Ngoc-Anh, 2007, Curr Atheroscler Rep, V9, P110, DOI 10.1007/s11883-007-0006-7; Lee I, 2014, J LIFE SCI, V24, P151; Lee MS, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1031-2; Leslie MA, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944-015-0049-7; Okerson T, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004909; 김경범, 2012, 한국식품저장유통학회지, V19, P909; Rho J, 2019, J ETHNOPHARMACOL, V233, P115, DOI 10.1016/j.jep.2018.11.042; Rosenson RS, 2006, AM HEART J, V151, P556, DOI 10.1016/j.ahj.2005.03.049; Shimano H, 2000, TRENDS CARDIOVAS MED, V10, P275, DOI 10.1016/S1050-1738(00)00079-7; Shin MS, 2004, CANCER RES, V64, P4419, DOI 10.1158/0008-5472.CAN-03-3885; Steinberg GR, 2009, PHYSIOL REV, V89, P1025, DOI 10.1152/physrev.00011.2008; Thomson DM, 2009, ACTA PHYSIOL, V196, P147, DOI 10.1111/j.1748-1716.2009.01973.x; Uddin MJ, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/652473; Watts GF, 2011, HEART, V97, P350, DOI 10.1136/hrt.2010.204990; Xiao CT, 2016, DIABETES, V65, P1767, DOI 10.2337/db16-0046; Yanai Hidekatsu, 2018, J Clin Med Res, V10, P281, DOI 10.14740/jocmr3362w	25	5	6	7	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2019	14	5							e0217112	10.1371/journal.pone.0217112	http://dx.doi.org/10.1371/journal.pone.0217112			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ3VE	31120956	Green Submitted, gold, Green Published			2023-01-03	WOS:000468775700057
J	Steinhubl, SR				Steinhubl, Steven R.			The future of individualized health maintenance	NATURE MEDICINE			English	Editorial Material								Multi-omics longitudinal profiling of individuals can detect subtle changes in health status at the earliest possible time point, allowing preemptive initiation of mechanism-appropriate disease-prevention strategies.	[Steinhubl, Steven R.] Scripps Res Translat Inst, La Jolla, CA 92037 USA		Steinhubl, SR (corresponding author), Scripps Res Translat Inst, La Jolla, CA 92037 USA.	steinhub@scripps.edu		Steinhubl, Steve/0000-0002-9256-7914				Catala A, 2018, METABOLOMICS, V14, DOI 10.1007/s11306-018-1395-z; Gigerenzer G, 2017, PSYCHOL REV, V124, P179, DOI 10.1037/rev0000055; Hall H, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005143; Hollands GJ, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1102; Huffaker MF, 2018, AM J RESP CRIT CARE, V198, P320, DOI 10.1164/rccm.201712-2606OC; Li L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa9364; Parikh RB, 2017, NEW ENGL J MED, V376, P1609, DOI 10.1056/NEJMp1613224; Schussler-Fiorenza Rose S. M., 2019, NAT MED, DOI [10.1038/s41591-019-0414-6, DOI 10.1038/S41591-019-0414-6]; Shilaih M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01433-9; Turnwald BP, 2019, NAT HUM BEHAV, V3, P48, DOI 10.1038/s41562-018-0483-4; Zeevi D, 2015, CELL, V163, P1079, DOI 10.1016/j.cell.2015.11.001	11	6	6	2	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2019	25	5					712	714		10.1038/s41591-019-0443-1	http://dx.doi.org/10.1038/s41591-019-0443-1			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	HY6NU	31068704				2023-01-03	WOS:000468247800011
J	Rosario, EVN; Gomes, MC; Brito, M; Costa, D				Nova Rosario, Edite Vila; Gomes, Manuel Carmo; Brito, Miguel; Costa, Diogo			Determinants of maternal health care and birth outcome in the Dande Health and Demographic Surveillance System area, Angola	PLOS ONE			English	Article							ANTENATAL CARE; DEVELOPING-COUNTRIES; COVERAGE; TRENDS; STILLBIRTHS; MORTALITY; FACILITY; AFRICA; WOMEN	Objectives Maternal health care improvement and reduction of maternal and child mortality are priorities of the global health agenda. In Angola, maternal mortality remains high and the risk of pregnancy-related death was 1 in 32 during 2015. This study aims to identify demographic and social factors influencing antenatal care and health facility delivery among women in Dande and to understand their impact on birth outcomes. Methods This study is based on community based longitudinal data collected by the Dande Health and Demographic Surveillance System between 2009 and 2015. Data on pregnancy outcomes (10,289 outcomes of 8,066 women) were collected for all reported pregnancies, including sociodemographic information, health services utilisation and women's reproductive history. Logistic regression was used to investigate the determinants of birth outcomes, antenatal care attendance and institutionalised delivery. Findings Of the 10,289 pregnancy outcomes, 98.5% resulted in live births, 96.8% attended antenatal care, and 82.5% had four or more visits. Yet, 50.7% of the women delivered outside a health facility. Antenatal care attendance was a determinant of birth outcomes (stillbirth: unadjusted OR = 0.34 95% CI = 0.16-0.70; abortion: OR = 0.07 95% CI = 0.04-0.12). Older women, with lower education, living at a greater distance of a health facility and in rural areas, were less likely to use maternal health care. Having had previous pregnancies, namely resulting in live births, also decreased the likelihood of health care utilization by pregnant women. Conclusions The study identifies relevant social determinants for the utilisation of antenatal care, place of delivery and their impact on birth outcome, thereby providing insight on how best to address inequities in health care utilization.	[Nova Rosario, Edite Vila; Brito, Miguel] CISA, Bengo, Angola; [Nova Rosario, Edite Vila; Costa, Diogo] ISPUP, Porto, Portugal; [Gomes, Manuel Carmo] Univ Lisbon, Fac Ciencias, Lisbon, Portugal; [Brito, Miguel] Inst Politecnico Lisboa, H&TRC, Escola Super Tecnol Saude Lisboa, Lisbon, Portugal	Universidade do Porto; Universidade de Lisboa; Universidade de Lisboa	Rosario, EVN (corresponding author), CISA, Bengo, Angola.; Rosario, EVN (corresponding author), ISPUP, Porto, Portugal.	edite.rosario@cisacaxito.org	Brito, Miguel/A-7970-2016; Gomes, Manuel/AFI-6075-2022; Costa, Diogo/AAN-5827-2021; Gomes, Manuel C/F-9633-2011	Brito, Miguel/0000-0001-6394-658X; Gomes, Manuel/0000-0002-2679-0974; Costa, Diogo/0000-0001-9696-7088; Gomes, Manuel C/0000-0002-2679-0974	Camoes - Portuguese Institute for Cooperation and Language; Calouste Gulbenkian Foundation; Angolan Ministry of Health; Bengo Province Government	Camoes - Portuguese Institute for Cooperation and Language; Calouste Gulbenkian Foundation; Angolan Ministry of Health; Bengo Province Government	The core funding of all CISA activities has been provided by Camoes - Portuguese Institute for Cooperation and Language, by the Calouste Gulbenkian Foundation, by the Angolan Ministry of Health and by the Bengo Province Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adewuyi EO, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197324; Adjiwanou V, 2013, SOC SCI MED, V86, P26, DOI 10.1016/j.socscimed.2013.02.047; Akowuah JA, 2018, J TROP MED-US, V2018, DOI 10.1155/2018/1673517; [Anonymous], 2014, ROAD DIGN 2030 END P; Arthur E, 2012, HEALTH ECON REV, V2, DOI 10.1186/2191-1991-2-14; Asseffa NA, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1151-1; Asundep NN, 2013, J EPIDEMIOL GLOB HEA, V3, P279, DOI 10.1016/j.jegh.2013.09.004; Babalola S, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-43; Bayou YT, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0930-z; BENOVA L, 2018, BMJ GLOB HEALTH, V3, DOI DOI 10.1136/BMJGH-2018-000779; Best RR, 2019, THE BRITISH STUDENT, V3, DOI [10.18573/bsdj.76, DOI 10.18573/BSDJ.76]; Blanc AK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059864; Boah M, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1749-6; Burgess C, 2008, SECRETS STOLEN, FORTUNES LOST: PREVENTING INTELLECTUAL PROPERTY THEFT AND ECONOMIC ESPIONAGE IN THE 21ST CENTURY, P3, DOI 10.1016/B978-1-59749-255-3.00001-0; Caliskan Z, 2015, INT J PUBLIC HEALTH, V60, P815, DOI 10.1007/s00038-015-0711-x; Campbell OMR, 2016, LANCET, V388, P2193, DOI 10.1016/S0140-6736(16)31528-8; Choulagai BP, 2015, GLOBAL HEALTH ACTION, V8, P1, DOI 10.3402/gha.v8.29396; de Camargo KR, 2011, GLOB PUBLIC HEALTH, V6, P102, DOI 10.1080/17441692.2010.514617; Dimbuene ZT, 2018, J BIOSOC SCI, V50, P725, DOI 10.1017/S0021932017000505; Doctor HV, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5695-z; Emelumadu OF, 2014, ANN MED HEALTH SCI R, V4, P374, DOI 10.4103/2141-9248.133463; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Gabriel SA, 2009, BE J ECON ANAL POLI, V9, DOI 10.1186/1471-2393-9-34; Graham W, 2016, LANCET, V388, P2164, DOI 10.1016/S0140-6736(16)31533-1; Heaman Maureen I, 2008, BMC Pregnancy Childbirth, V8, P15, DOI 10.1186/1471-2393-8-15; Heredia-Pi I, 2016, B WORLD HEALTH ORGAN, V94, P452, DOI 10.2471/BLT.15.168302; Hijazi HH, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0542-3; INE, 2008, POP WELL BEING INT S; Instituto Nacional de Estatistica (INE) Ministerio da Saude (MINSA) Ministerio do Planeamento e do Desenvolvimento Territorial (MINPLAN) e ICF, 2017, 2015 16 MULT IND HLT; Kadobera D, 2012, GLOBAL HEALTH ACTION, V5, P1, DOI 10.3402/gha.v5i0.19099; Kuhnt J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017122; Kujala S, 2017, TROP MED INT HEALTH, V22, P63, DOI 10.1111/tmi.12807; Lawn JE, 2011, LANCET, V377, P1448, DOI 10.1016/S0140-6736(10)62187-3; LUMBIGANON P, 1990, INT J EPIDEMIOL, V19, P997, DOI 10.1093/ije/19.4.997; Moller AB, 2017, LANCET GLOB HEALTH, V5, pE977, DOI 10.1016/S2214-109X(17)30325-X; Moses P., 2017, INT J INNOVATIVE RES, V6, P7; Moyer CA, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-40; Mwase T, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-018-0770-8; Nimi T, 2016, INT J GYNECOL OBSTET, V135, pS72, DOI 10.1016/j.ijgo.2016.08.013; Rosario EVN, 2017, INT J EPIDEMIOL, V46, P1094, DOI 10.1093/ije/dyx072; Nyongesa C, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1727-z; Odwe G, 2015, INT J POPUL RES, V2015, P1, DOI DOI 10.1155/2015/296437; Osamor PE, 2016, INT J WOMENS HEALTH, V8, P191, DOI 10.2147/IJWH.S105483; Pervin J, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-111; Raynes-Greenow C, 2017, LANCET GLOB HEALTH, V5, pE949, DOI 10.1016/S2214-109X(17)30346-7; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S0140-6736(06)69380-X; Rossier C, 2014, GLOBAL HEALTH ACTION, V7, P1, DOI 10.3402/gha.v7.24351; Rurangirwa AA, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1328-2; Simkhada B, 2008, J ADV NURS, V61, P244, DOI 10.1111/j.1365-2648.2007.04532.x; Tran TK, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-40; Udo IE, 2016, AFR J REPROD HEALTH, V20, P108, DOI 10.29063/ajrh2016/v20i3.15; Umar Abubakar Sadiq, 2016, Int J MCH AIDS, V5, P61; USAID, 2020, MAT NEON CHILD HLTH; Wang WJ, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0497-0; WHO, 2022, WHO RECOMMENDATIONS; WHO, 2015, THE MILLENNIUM DEVEL; Wilunda C, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0067-y; Woldegiorgis MA, 2018, INT J PUBLIC HEALTH, V63, P525, DOI 10.1007/s00038-018-1086-6; Yaya S, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1846-6	59	26	26	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2019	14	8							e0221280	10.1371/journal.pone.0221280	http://dx.doi.org/10.1371/journal.pone.0221280			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW5RZ	31437180	Green Published, Green Submitted, gold			2023-01-03	WOS:000485036900046
J	Carroll, AE				Carroll, Aaron E.			Averting Alert Fatigue to Prevent Adverse Drug Reactions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									[Carroll, Aaron E.] Indiana Univ Sch Med, Pediat, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington	Carroll, AE (corresponding author), Indiana Univ Sch Med, Pediat, Indianapolis, IN 46202 USA.	aaecarro@iu.edu							0	18	18	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2019	322	7					601	601		10.1001/jama.2019.11710	http://dx.doi.org/10.1001/jama.2019.11710			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IU5TU	31429887	Bronze			2023-01-03	WOS:000483651000003
J	Schakel, L; Veldhuijzen, DS; van Middendorp, H; Manai, M; Meeuwis, SH; Van Dessel, P; Evers, AWM				Schakel, Lemmy; Veldhuijzen, Dieuwke S.; van Middendorp, Henriet; Manai, Meriem; Meeuwis, Stefanie H.; Van Dessel, Pieter; Evers, Andrea W. M.			Can verbal suggestions strengthen the effects of a relaxation intervention?	PLOS ONE			English	Article							STRESS-MANAGEMENT INTERVENTION; RESPONSES; PLACEBO; REACTIVITY; REDUCTION; PANAS	Short stress management interventions such as relaxation therapy have demonstrated preliminary effectiveness in reducing stress-related problems. A promising tool to strengthen the effectiveness of relaxation-based interventions is the use of verbal suggestions, as previous research provided evidence that verbal suggestions can induce positive outcome expectancies, facilitate adaptive responses to stress and improve health outcomes. The present experimental proof-of-concept study aimed to investigate the effects of a brief relaxation intervention and specifically the role of verbal suggestions on stress-related outcomes assessed by self-report questionnaires and psychophysiological data. 120 participants (mean age = 22.1 years) were randomized to one of four intervention conditions: a brief relaxation intervention plus verbal suggestions condition, a brief relaxation intervention only condition, a verbal suggestions only condition, and a control condition. Afterwards, participants were subjected to a psychosocial stress challenge to assess reactivity to a stressful event. Immediately after both relaxation interventions (with and without verbal suggestions), lower self-reported state anxiety was found compared to the control condition, but no differences were observed in response to the stressor. The verbal suggestions only condition did not impact state anxiety. No significant effects were found for verbal suggestion interventions on cortisol, alpha amylase, heart rate and skin conductance. This is the first study investigating the role of verbal suggestions in the effectiveness of a brief relaxation intervention. Although this experimental proof-of-concept study provides support for the effectiveness of a brief relaxation intervention in lowering state anxiety directly after the intervention, the effects did not impact the response to a subsequent stressor and we did not observe any evidence for the add-on effectiveness of verbal suggestions. The effectiveness of brief relaxation interventions on stress responses should be investigated further in future research by incorporating interventions that are tailored to the specific stress challenge and various types of verbal suggestions.	[Schakel, Lemmy; Veldhuijzen, Dieuwke S.; van Middendorp, Henriet; Manai, Meriem; Meeuwis, Stefanie H.; Evers, Andrea W. M.] Leiden Univ, Inst Psychol, Fac Social & Behav Sci, Hlth Med & Neu Ropsychol Unit, Leiden, Netherlands; [Schakel, Lemmy; Veldhuijzen, Dieuwke S.; van Middendorp, Henriet; Manai, Meriem; Meeuwis, Stefanie H.; Evers, Andrea W. M.] Leiden Univ, Leiden Inst Brain & Cognit, Leiden, Netherlands; [Van Dessel, Pieter] Univ Ghent, Dept Expt Clin & Hlth Psychol, Ghent, Belgium; [Evers, Andrea W. M.] Leiden Univ, Dept Psychiat, Med Ctr, Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Ghent University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Schakel, L (corresponding author), Leiden Univ, Inst Psychol, Fac Social & Behav Sci, Hlth Med & Neu Ropsychol Unit, Leiden, Netherlands.; Schakel, L (corresponding author), Leiden Univ, Leiden Inst Brain & Cognit, Leiden, Netherlands.	l.schakel@fsw.leidenuniv.nl	Evers, Andrea/GWV-9705-2022; Van Dessel, Pieter/Q-1917-2019	Van Dessel, Pieter/0000-0002-3401-780X; Manai, Meriem/0000-0002-4684-9224; Veldhuijzen, Dieuwke S. (Judy)/0000-0001-9046-1019	European Research Council [ERC-2013-CoG-617700_EXPECT HEAL-TH]; NWO Vici Grant [016.Vici.170.152]	European Research Council(European Research Council (ERC)European Commission); NWO Vici Grant(Netherlands Organization for Scientific Research (NWO))	This study was funded by a European Research Council Consolidator Grant (ERC-2013-CoG-617700_EXPECT HEAL-TH) and a NWO Vici Grant (016.Vici.170.152), both granted to AWME. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen AP, 2014, NEUROSCI BIOBEHAV R, V38, P94, DOI 10.1016/j.neubiorev.2013.11.005; [Anonymous], 1982, TIJDSCHR PSYCHIAT; Bartels DJP, 2016, EUR J PAIN, V20, P8, DOI 10.1002/ejp.750; Blease C, 2016, BIOETHICS, V30, P407, DOI 10.1111/bioe.12245; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Cohen S, 2002, PSYCHOSOM MED, V64, P302, DOI 10.1097/00006842-200203000-00014; Cohen S., 1988, PERCEIVED STRESS PRO; Colloca L, 2011, PHILOS T R SOC B, V366, P1859, DOI 10.1098/rstb.2010.0398; Colloca L, 2011, CURR OPIN PSYCHIATR, V24, P149, DOI 10.1097/YCO.0b013e328343803b; Creswell JD, 2014, PSYCHONEUROENDOCRINO, V44, P1, DOI 10.1016/j.psyneuen.2014.02.007; Cruess DG, 2015, INT J STRESS MANAGE, V22, P270, DOI 10.1037/a0039130; Evers AWM, 2018, PSYCHOTHER PSYCHOSOM, V87, P204, DOI 10.1159/000490354; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Gaab J, 2003, PSYCHONEUROENDOCRINO, V28, P767, DOI 10.1016/S0306-4530(02)00069-0; Hartrick Craig T, 2003, Pain Pract, V3, P310; KERCHER K, 1992, RES AGING, V14, P131, DOI 10.1177/0164027592142001; KIRSCHBAUM C, 1993, NEUROPSYCHOBIOLOGY, V28, P76, DOI 10.1159/000119004; MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x; McRae AL, 2006, HUM PSYCHOPHARM CLIN, V21, P377, DOI 10.1002/hup.778; Nagele E, 2014, J HYPERTENS, V32, P1936, DOI 10.1097/HJH.0000000000000298; Peerdeman KJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139563; Pruessner JC, 2003, PSYCHONEUROENDOCRINO, V28, P916, DOI 10.1016/S0306-4530(02)00108-7; Richardson KM, 2008, J OCCUP HEALTH PSYCH, V13, P69, DOI 10.1037/1076-8998.13.1.69; Rohrmann S, 2002, PSYCHOL HEALTH, V17, P583, DOI 10.1080/08870440290025795; Rohrmann S, 1999, INT J PSYCHOPHYSIOL, V33, P149, DOI 10.1016/S0167-8760(99)00036-7; Schakel L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201309; Segerstrom SC, 2004, PSYCHOL BULL, V130, P601, DOI 10.1037/0033-2909.130.4.601; Sharma M, 2014, J EVID-BASED INTEGR, V19, P271, DOI 10.1177/2156587214543143; Sjak-Shie EE, 2016, PHYSIODATA TOOLBOX V; Skvortsova A, 2018, PSYCHOSOM MED, V80, P353, DOI 10.1097/PSY.0000000000000571; van Dixhoorn J J, 1999, J Cardiopulm Rehabil, V19, P178, DOI 10.1097/00008483-199905000-00005; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Yamakawa K, 2009, BIOL PSYCHOL, V82, P25, DOI 10.1016/j.biopsycho.2009.05.001	33	1	1	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 7	2019	14	8							e0220112	10.1371/journal.pone.0220112	http://dx.doi.org/10.1371/journal.pone.0220112			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW5DR	31390349	Green Published, gold			2023-01-03	WOS:000484999400011
J	Maxwell, SRJ; Webb, DJ				Maxwell, Simon R. J.; Webb, David J.			Improving medication safety: focus on prescribers and systems	LANCET			English	Editorial Material									[Maxwell, Simon R. J.; Webb, David J.] Univ Edinburgh, Western Gen Hosp, Clin Res Ctr, Clin Pharmacol Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Maxwell, SRJ (corresponding author), Univ Edinburgh, Western Gen Hosp, Clin Res Ctr, Clin Pharmacol Unit, Edinburgh EH4 2XU, Midlothian, Scotland.	s.maxwell@ed.ac.uk		Maxwell, Simon/0000-0002-3032-7237	Medical Schools Council; British Pharmacological Society; UK Department of Health and Social Care; NHS Education Scotland; Healthcare Education England	Medical Schools Council; British Pharmacological Society; UK Department of Health and Social Care; NHS Education Scotland; Healthcare Education England	We have an academic interest in the success of the Prescribing Safety Assessment; SRJM is Medical Director and DJW is Chair of the Prescribing Safety Assessment Executive. We declare no other competing interests. The development and delivery of the Prescribing Safety Assessment has been funded by the Medical Schools Council and British Pharmacological Society. The project has also been supported by grants from the UK Department of Health and Social Care, NHS Education Scotland, and Healthcare Education England.	Assiri GA, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019101; Davies S., 2017, CHIEF MED OFFICER AN; Dean B, 2002, LANCET, V359, P1373, DOI 10.1016/S0140-6736(02)08350-2; Elliott R, 2018, PREVALENCE EC BURDEN; General Medical Council, 2017, REP MED LIC ASS CONS; Maxwell SRJ, 2017, BRIT J CLIN PHARMACO, V83, P2249, DOI 10.1111/bcp.13319; Maxwell SRJ, 2015, LANCET, V385, P579, DOI 10.1016/S0140-6736(14)62339-4; Maxwell SRJ, 2006, LANCET, V367, P799, DOI 10.1016/S0140-6736(06)68316-5; McLachlan, 2019, INDEPENDENT REV PRES; O'Mahony D, 2015, AGE AGEING, V44, P213, DOI 10.1093/ageing/afu145; Royal Pharmaceutical Society, 2016, COMP FRAM ALL PRESCR; The Lancet, 2009, LANCET, V374, P1495; WHO, 2017, THIRD WHO GLOBAL PAT	13	11	11	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 27	2019	394	10195					283	285		10.1016/S0140-6736(19)31526-0	http://dx.doi.org/10.1016/S0140-6736(19)31526-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IL1QD	31272692	Green Submitted			2023-01-03	WOS:000477075200009
J	Nagai, M; Bellizzi, S; Murray, J; Kitong, J; Cabral, EI; Sobel, HL				Nagai, Mari; Bellizzi, Saverio; Murray, John; Kitong, Jacqueline; Cabral, Esperanza I.; Sobel, Howard L.			Opportunities lost: Barriers to increasing the use of effective contraception in the Philippines	PLOS ONE			English	Article							HEALTH-CARE PROVIDERS; QUALITY-OF-CARE; IMMUNIZATION SERVICES; COMMUNICATION; INTEGRATION; CHALLENGES; PREGNANCY; GHANA	Background In the Philippines, one in four pregnancies are unintended and 610 000 unsafe abortions are performed each year. This study explored the association between missed opportunities to provide family planning counseling, quality of counseling and its impact on utilization of effective contraception in the Philippines. Methods One-hundred-one nationally representative health facilities were randomly selected from five levels of the health system. Sexually-active women 18-49 years old, wanting to delay or limit childbearing, attending primary care clinics between April 24 and August 8, 2017 were included. Data on contraceptive use, counseling and availability were collected using interviews and facility assessments. Effective contraceptive methods were defined as those with rates of unintended pregnancy of less than 10 per 100 women in first year of typical use. Findings 849 women were recruited of whom 51.1% currently used effective contraceptive methods, 20.6% were former effective method users and 28.3% had never used an effective method. Of 1664 cumulative clinic visits reported by women in the previous year, 72.6% had a missed opportunity to receive family planning counseling at any visit regardless of level of facility, with 83.7% having a missed counseling opportunity on the day of the interview. Most women (55.9%) reported health concerns about modern contraception, with 2.9% receiving counseling addressing their concerns. Only 0.6% of former users and 2.1% never-users said they would consider starting a modern contraceptive in the future. Short and long acting reversible contraceptive methods were available in 93% and 68% of facilities respectively. Conclusions Missed opportunities to provide family planning counseling are widespread in the Philippines. Delivery of effective contraceptive methods requires that wider legal, policy, social, cultural, and structural barriers are addressed, coupled with systems approaches for improving availability and quality of counseling at all primary health care contacts.	[Nagai, Mari] Natl Ctr Global Hlth & Med, Bur Int Hlth Cooperat, Tokyo, Japan; [Bellizzi, Saverio] Partnership Maternal Newborn & Child Hlth, Geneva, Switzerland; [Murray, John] Maternal & Child Hlth, Iowa City, IA USA; [Kitong, Jacqueline] WHO, Philippines Country Off, Manila, Philippines; [Cabral, Esperanza I.] RP RH NIT, Dept Hlth, Manila, Philippines; [Sobel, Howard L.] WHO, Reg Off Western Pacific, Div NCD & Hlth Life Course Reprod Maternal Newbor, Manila, Philippines	National Center for Global Health & Medicine - Japan; WHO Western Pacific Regional Office; World Health Organization; Philippine Department Health; WHO Western Pacific Regional Office; World Health Organization	Nagai, M (corresponding author), Natl Ctr Global Hlth & Med, Bur Int Hlth Cooperat, Tokyo, Japan.	nagaimwho@gmail.com	Sobel, Howard L/M-8800-2018	Bellizzi, Saverio/0000-0002-4119-0803	World Health Organization (WHO) Regional Office of the Western Pacific	World Health Organization (WHO) Regional Office of the Western Pacific	Data collection was funded by World Health Organization (WHO) Regional Office of the Western Pacific. The funder was involved with study design, data analysis, and preparation of the manuscript. SB, JK, and HS are affiliated with WHO. The specific role of these authors is articulated in the 'author contributions' section.	Abdel-Tawab N, 2002, SOC SCI MED, V54, P1357, DOI 10.1016/S0277-9536(01)00101-0; Academy for Educational Development, 2003, SKETCH SOC ACC PROJ, V1; Akers AY, 2010, J WOMENS HEALTH, V19, P1163, DOI 10.1089/jwh.2009.1735; Alvarado R, 1999, STUD FAMILY PLANN, V30, P133, DOI 10.1111/j.1728-4465.1999.00133.x; [Anonymous], 2014, PHILIPPINES NATL DEM; [Anonymous], 2015, GLOB CONS STAT EXP C; Ayiasi RM, 2015, PAN AFR MED J, V21, DOI 10.11604/pamj.2015.21.138.7026; Bearak J, 2018, LANCET GLOB HEALTH, V6, pE380, DOI 10.1016/S2214-109X(18)30029-9; Becker D, 2007, PERSPECT SEX REPRO H, V39, P206, DOI 10.1363/3920607; Bellizzi S, 2015, HUM REPROD; Bongaarts J., 2014, 20134 UN POP DIV UN; Bowling A., 2006, HDB HLTH RES METHODS, V422; CEDAW, 2015, SUMM INQ PHIL ART 8; Darroch Jacqueline E, 2009, Issues Brief (Alan Guttmacher Inst), P1; DaVanzo J, 2007, BJOG-INT J OBSTET GY, V114, P1079, DOI 10.1111/j.1471-0528.2007.01338.x; Dehlendorf C, 2014, CLIN OBSTET GYNECOL, V57, P659, DOI 10.1097/GRF.0000000000000059; Dehlendorf C, 2010, CONTRACEPTION, V81, P292, DOI 10.1016/j.contraception.2009.11.006; Demographic Research and Development Foundation Inc. and University of the Philippines Population Institute, 2016, 2013 YOUNG AD FERT S; Fullerton J, 2003, MIDWIFERY, V19, P17, DOI 10.1054/midw.2002.0334; Guttmacher Institute, GUTTM I 2013 BRIEF S; Harper CC, 2008, OBSTET GYNECOL, V111, P1359, DOI 10.1097/AOG.0b013e318173fd83; Hounton S, 2015, GLOBAL HEALTH ACTION, V8, P64, DOI 10.3402/gha.v8.29738; HUNTINGTON D, 1994, STUD FAMILY PLANN, V25, P176, DOI 10.2307/2137943; Jain Anrudh K, 2013, Int Perspect Sex Reprod Health, V39, P133, DOI 10.1363/3913313; Jatlaoui TC, 2017, J WOMENS HEALTH, V26, P870, DOI 10.1089/jwh.2016.5930; Kim YM, 2001, PATIENT EDUC COUNS, V45, P59, DOI 10.1016/S0738-3991(01)00144-6; Kim YM, 1998, INT FAM PLAN PERSPEC, V24, P4, DOI 10.2307/2991913; Koenig MA, 1997, STUD FAMILY PLANN, V28, P278, DOI 10.2307/2137859; Kuhlmann AS, 2010, INT PERSPECT SEX R H, V36, P189, DOI 10.1363/3618910; Melgar JLD, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0638-9; Moore Z, 2015, CONTRACEPTION, V92, P31, DOI 10.1016/j.contraception.2015.03.007; Peremans L, 2005, CONTRACEPTION, V71, P421, DOI 10.1016/j.contraception.2004.12.007; Philippine Statistics Authority-PSA ICF, 2018, PHIL NAT DEM HLTH SU; RamaRao S, 2003, INT FAM PLAN PERSPEC, V29, P76, DOI 10.2307/3181061; Ross JA, 2001, INT FAM PLAN PERSPEC, V27, P20, DOI 10.2307/2673801; Sedgh G., 2016, UNMET NEED CONTRACEP; Starrs AM, 2018, LANCET, V391, P2642, DOI 10.1016/S0140-6736(18)30293-9; UN DESA, 2015, WORLD POP POL DAT; Vance G, 2014, HEALTH POLICY PLANN, V29, P359, DOI 10.1093/heapol/czt022; Venkataramani M, 2017, ACAD PEDIATR, V17, P476, DOI 10.1016/j.acap.2016.03.001; Wallace AS, 2012, J INFECT DIS, V205, pS6, DOI 10.1093/infdis/jir778; WHO, 2022, WHO RECOMMENDATIONS; WHO, 2013, PROGR STRAT POSTP FA; World Health Organization, 2017, PAP NEW GUIN ACT SCA; World Health Organization Department of Maternal N, 2013, WHO REC POSTN CAR MO; World Health Organization Department of Reproductive Health and Research, 2018, FAMILY PLANNING GLOB; Yee LM, 2011, J HEALTH CARE POOR U, V22, P1387, DOI 10.1353/hpu.2011.0144	47	10	10	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2019	14	7							e0218187	10.1371/journal.pone.0218187	http://dx.doi.org/10.1371/journal.pone.0218187			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4VN	31344054	Green Published, gold, Green Submitted			2023-01-03	WOS:000484977900007
J	Topkan, E; Ozdemir, Y; Kucuk, A; Besen, AA; Mertsoylu, H; Sezer, A; Selek, U				Topkan, Erkan; Ozdemir, Yurday; Kucuk, Ahmet; Besen, Ali Ayberk; Mertsoylu, Huseyin; Sezer, Ahmet; Selek, Ugur			Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients	PLOS ONE			English	Article							TREATMENT TIME; RADIATION-THERAPY; LOCAL-CONTROL; PHASE-III; SEQUENTIAL CHEMORADIOTHERAPY; RETROSPECTIVE ANALYSIS; THORACIC RADIOTHERAPY; CHEMOTHERAPY WORTH; ADVANCED HEAD; CANCER	Background To investigate the detrimental effects of prolonged overall radiotherapy duration (ORTD) on survival outcomes of stage IIIB/C NSCLC patients treated with concurrent chemoradiotherapy (C-CRT) Methods The study cohort consisted of 956 patients who underwent C-CRT for stage IIIB/C NSCLC. Primary endpoint was the association between the ORTD and overall survival (OS) with locoregional progression-free survival (LRPFS) and PFS comprising the secondary endpoints. Receiver operating characteristic (ROC) curve analysis was utilized for accessibility of the cut-off that interacts with survival outcomes. Multivariate Cox model was utilized to identify the independent associates of survival outcomes. Results The ROC curve analysis exhibited significance at 49 days of ORTD cut-off that dichotomized patients into ORTD<50 versus ORTD >= 50 days groups for OS [area under the curve (AUC): 82.8%; sensitivity: 81.1%; specificity: 74.8%], LRPFS (AUC: 91.9%; sensitivity: 90.6%; specificity: 76.3%), and PFS (AUC: 76.1%; sensitivity: 72.4%; specificity: 68.2%), respectively. Accordingly, ORTD >= 50 days group had significantly shorter median OS (P<0.001), LRPFS (P<0.001), and PFS (P<0.001); and 10-year actuarial locoregional control (P<0.001) and distant metastases-free (P<0.011) rates than the ORTD<50 days group. The ORTD retained its significant association with survival outcomes at multivariate analyses independent of the other favorable covariates (p<0.001, for OS, LRPFS, and PFS): Stage IIIB disease (versus IIIC), lymph node bulk <2 cm (versus >= 2 cm), and 2-3 chemotherapy cycles (versus 1). The higher sensitivity for LRPFS (90.6%) than PFS (72.4%) on ROC curve analysis suggested the prolonged ORTD-induced decrements in locoregional control rates as the major cause of the poor survival outcomes. Conclusions Longer ORTD beyond >= 50 days was associated with significantly poorer OS, LRPFS and PFS outcomes, where reduced locoregional control rates appeared to be the main causative.	[Topkan, Erkan; Ozdemir, Yurday] Baskent Univ, Med Fac, Dept Radiat Oncol, Adana, Turkey; [Kucuk, Ahmet] Mersin City Hosp, Radiat Oncol Clin, Mersin, Turkey; [Besen, Ali Ayberk; Mertsoylu, Huseyin; Sezer, Ahmet] Baskent Univ, Med Fac, Dept Med Oncol, Adana, Turkey; [Selek, Ugur] Koc Univ, Sch Med, Dept Radiat Oncol, Istanbul, Turkey; [Selek, Ugur] Univ Texas MD Anderson Canc Ctr, Div Radiat Oncol, Houston, TX 77030 USA	Baskent University; Baskent University; Koc University; University of Texas System; UTMD Anderson Cancer Center	Topkan, E (corresponding author), Baskent Univ, Med Fac, Dept Radiat Oncol, Adana, Turkey.	docdretopkan@gmail.com	Topkan, Erkan/AAG-2213-2021; Besen, Ali Ayberk/AAD-6910-2021; selek, ugur/O-5474-2014; SEZER, AHMET/AAD-2667-2020; Ozdemir, Yurday/AAG-5629-2021; Mertsoylu, Hüseyin/M-9530-2014; Kucuk, Ahmet/GQI-3022-2022	Topkan, Erkan/0000-0001-8120-7123; Besen, Ali Ayberk/0000-0002-7862-0192; selek, ugur/0000-0001-8087-3140; SEZER, AHMET/0000-0002-6445-1439; Ozdemir, Yurday/0000-0002-2218-2074; Mertsoylu, Hüseyin/0000-0002-1932-9784; Kucuk, Ahmet/0000-0002-5361-364X				Auperin A, 2010, J CLIN ONCOL, V28, P2181, DOI 10.1200/JCO.2009.26.2543; Bar-Ad V, 2012, REV RECENT CLIN TRIA, V7, P31, DOI 10.2174/157488712799363235; Baumann M, 1999, RADIOTHER ONCOL, V50, P107, DOI 10.1016/S0167-8140(98)00112-1; BAUMANN M, 1994, RADIOTHER ONCOL, V32, P137, DOI 10.1016/0167-8140(94)90100-7; Bradley JD, 2015, LANCET ONCOL, V16, P187, DOI 10.1016/S1470-2045(14)71207-0; Budach W, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-28; Chen M, 2000, LUNG CANCER-J IASLC, V28, P11, DOI 10.1016/S0169-5002(99)00113-0; Chun SG, 2017, J CLIN ONCOL, V35, P56, DOI 10.1200/JCO.2016.69.1378; COX JD, 1993, INT J RADIAT ONCOL, V27, P493, DOI 10.1016/0360-3016(93)90371-2; Curran WJ, 2011, J NATL CANCER I, V103, P1452, DOI 10.1093/jnci/djr325; De Ruysscher D, 2006, J CLIN ONCOL, V24, P1057, DOI 10.1200/JCO.2005.02.9793; Faivre-Finn C, 2017, LANCET ONCOL, V18, P1116, DOI 10.1016/S1470-2045(17)30318-2; Fesinmeyer MD, 2010, INT J RADIAT ONCOL, V78, P675, DOI 10.1016/j.ijrobp.2009.08.004; Fournel P, 2005, J CLIN ONCOL, V23, P5910, DOI 10.1200/JCO.2005.03.070; Fowler JF, 2008, INT J RADIAT ONCOL, V71, P326, DOI 10.1016/j.ijrobp.2008.01.052; Fowler JF, 2000, INT J RADIAT ONCOL, V46, P516; FOWLER JF, 1992, INT J RADIAT ONCOL, V23, P457, DOI 10.1016/0360-3016(92)90768-D; Furuse K, 1999, J CLIN ONCOL, V17, P2692, DOI 10.1200/JCO.1999.17.9.2692; Ferreira JAG, 2015, REP PRACT ONCOL RADI, V20, P328, DOI 10.1016/j.rpor.2015.05.010; Hong J, 2017, J ELECTROCHEM SCI TE, V8, P1, DOI 10.5229/JECST.2017.8.1.1; Jeremic B, 1996, J CLIN ONCOL, V14, P1065, DOI 10.1200/JCO.1996.14.4.1065; Kasibhatla M, 2007, INT J RADIAT ONCOL, V68, P1491, DOI 10.1016/j.ijrobp.2007.03.025; Koukourakis M, 1996, INT J RADIAT ONCOL, V34, P315, DOI 10.1016/0360-3016(95)02102-7; Machtay M, 2005, INT J RADIAT ONCOL, V63, P667, DOI 10.1016/j.ijrobp.2005.03.037; Machtay M, 2012, J THORAC ONCOL, V7, P716, DOI 10.1097/JTO.0b013e3182429682; Machtay M, 2012, INT J RADIAT ONCOL, V82, P425, DOI 10.1016/j.ijrobp.2010.09.004; Mauguen A, 2012, J CLIN ONCOL, V30, P2788, DOI 10.1200/JCO.2012.41.6677; McMillan MT, 2017, INT J RADIAT ONCOL, V98, P1142, DOI 10.1016/j.ijrobp.2017.04.004; Morimoto M, 2017, CLIN LUNG CANCER, V18, pE117, DOI 10.1016/j.cllc.2016.09.004; O'Rourke N, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002140.pub3; Overgaard Jens, 2000, Rays (Rome), V25, P313; PEREZ CA, 1995, INT J RADIAT ONCOL, V32, P1275, DOI 10.1016/0360-3016(95)00220-S; Pijls-Johannesma M, 2007, CANCER TREAT REV, V33, P461, DOI 10.1016/j.ctrv.2007.03.002; Rengan R, 2004, INT J RADIAT ONCOL, V60, P741, DOI 10.1016/j.ijrobp.2004.04.013; Suwinski R, 2003, INT J RADIAT BIOL, V79, P495, DOI 10.1080/09553000310001596986; Tarnawski R, 2002, INT J RADIAT ONCOL, V54, P229, DOI 10.1016/S0360-3016(02)02936-X; Topkan E, 2013, INT J RADIAT ONCOL, V87, P697, DOI 10.1016/j.ijrobp.2013.07.033; Topkan E, 2013, LUNG CANCER, V81, P226, DOI 10.1016/j.lungcan.2013.05.002; Wang L, 2009, INT J RADIAT ONCOL, V73, P1383, DOI 10.1016/j.ijrobp.2008.06.1935; Werner-Wasik M, 2000, INT J RADIAT ONCOL, V48, P689, DOI 10.1016/S0360-3016(00)00699-4; WITHERS HR, 1988, ACTA ONCOL, V27, P131, DOI 10.3109/02841868809090333; Zatloukal P, 2004, LUNG CANCER-J IASLC, V46, P87, DOI 10.1016/j.lungcan.2004.03.004; Zhao S, 2018, CANCER MED-US, V7, P4208, DOI 10.1002/cam4.1616	43	4	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2019	14	7							e0218627	10.1371/journal.pone.0218627	http://dx.doi.org/10.1371/journal.pone.0218627			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4UB	31329602	Green Submitted, gold, Green Published			2023-01-03	WOS:000484974100008
J	Egharevba, HO; Fatokun, O; Aboh, M; Kunle, OO; Nwaka, S; Gamaniel, KS				Egharevba, Henry Omoregie; Fatokun, Omolola; Aboh, Mercy; Kunle, Olobayo Olufunso; Nwaka, Solomon; Gamaniel, Karniyus Shingu			Piloting a smartphone-based application for tracking and supply chain management of medicines in Africa	PLOS ONE			English	Article							PLATFORM	A confounding factor for healthcare programmes in African countries is the inability of essential health tools to reach targeted locations and populations, due to poor Logistics Management Information System (LMIS). In a bid to contribute towards addressing these challenges, a pilot study was undertaken to evaluate the tracking ability, reliability and applicability of EASE App, a novel Smart Phone based Application. The App is designed to provide real-time tracking and tracing of commodities as well as curation of data in a cloud based database with restricted access which can be linked with other databases. In this study, NIPRIMAL was labelled with QR codes, and tracked within the Federal Capital Territory, Abuja, Nigeria, using the smartphone based EASE App. Data collected showed that the "EASE App" tracking had accuracy of 100% for date and time of scan, operators' codes and product identity; and 92.83 +/- 1.69% and 99.83 +/- 0.27% accuracy for GPS mapping label for the city and country, respectively. The GPS mapping label for specific streets, roads or districts, gave an accuracy of about 64.28 +/- 3.14%. The technology was able to provide realtime data on user unique identity, user location as well as date/time of use, and the feedback report indicated that it was readily deployable and easy to use. The results demonstrate that the "EASE App" is a promising technology that can support supply chain and related data management challenges in resource poor settings. The potential benefit of the EASE App in strengthening LMIS and distribution chain system in Africa as well as future optimization of the App are discussed.	[Egharevba, Henry Omoregie; Fatokun, Omolola; Aboh, Mercy; Kunle, Olobayo Olufunso; Gamaniel, Karniyus Shingu] NIPRD, Abuja, Fct, Nigeria; [Nwaka, Solomon] UNOPS, Africa Network Drugs & Diagnost Innovat ANDI, Addis Ababa, Ethiopia		Egharevba, HO (corresponding author), NIPRD, Abuja, Fct, Nigeria.	omoregieegharevba@yahoo.com		Egharevba, Henry/0000-0002-0200-326X	WHO	WHO(World Health Organization)	ANDI is the coordinator of a WHO funded project that resulted in the identification of the EASE App (developed by EASE Medtrend) as a useful tool for integration of rapid diagnostics tests and tracking of medicines in Africa. Note that EASE Medtrend and others are part of the WHO funded project and EASE Medrend received funds for further optimization of the APP and cloud database for use in Africa as part of the project. The authors and affiliated organizations have no financial interest on the product.	[Anonymous], 2009, INT J HLTH RES; Baccarelli E, 2016, IEEE NETWORK, P1; Bello SI, 2010, AFR J PHARM PHARMACO, V4, P158; DHIS 2, DHIS 2 OV; Federal Ministry of Health [Nigeria], 2012, NAT GUID DRUG DISTR, V2, P1; Fiandrino C, 2017, IEEE ACCESS, V5, P3490, DOI 10.1109/ACCESS.2017.2671678; GHAIN [Global HIV/AIDS Initiative Nigeria], 2011, GHAIN SUPP LOG MAN S; Gordon M., 2013, BAD GPS DATA WHAT WH; Griffis S., 2007, TRANSPORTATION, V18, P18, DOI [10.22237/jotm/1175385780, DOI 10.22237/JOTM/1175385780]; Mahmud M. Z., 2014, BUILDING REAL TIME L; Michael N., 2010, REMOTE TRACKING GPS; Mudanyali O, 2012, LAB CHIP, V12, P2678, DOI [10.1039/c21c40235a, 10.1039/c2lc40235a]; NOLD EG, 1985, AM J HOSP PHARM, V42, P2722, DOI 10.1093/ajhp/42.12.2722; Pedersen G., 2016, MOBILE PHONE ANTENNA; Tawalbeh LA, 2016, IEEE ACCESS, V4, P6171, DOI 10.1109/ACCESS.2016.2613278; Toloza J, TECHNIQUES DETERMINE; USAID, 2016, LINKING HUMAN RESOUR; WHO, 2011, WHO HARM MON EV IND; WHO, 2014, FOLL UP REP CONS EXP; Yadav P, 2015, HEALTH SYST REFORM, V1, P142, DOI 10.4161/23288604.2014.968005	20	4	4	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2019	14	7							e0217976	10.1371/journal.pone.0217976	http://dx.doi.org/10.1371/journal.pone.0217976			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IS7LS	31314809	Green Published, Green Submitted, gold			2023-01-03	WOS:000482331900005
J	Bylow, H; Karlsson, T; Lepp, M; Claesson, A; Lindqvist, J; Herlitz, J				Bylow, Helene; Karlsson, Thomas; Lepp, Margret; Claesson, Andreas; Lindqvist, Jonny; Herlitz, Johan			Effectiveness of web-based education in addition to basic life support learning activities: A cluster randomised controlled trial	PLOS ONE			English	Article							RESUSCITATION COUNCIL GUIDELINES; EMERGENCY CARDIOVASCULAR CARE; EUROPEAN RESUSCITATION; CARDIOPULMONARY-RESUSCITATION; IMPLEMENTATION; TECHNOLOGIES	Background Effective education in basic life support (BLS) may improve the early initiation of high-quality cardiopulmonary resuscitation and automated external defibrillation (CPR-AED). Aim To compare the learning outcome in terms of practical skills and knowledge of BLS after participating in learning activities related to BLS, with and without web-based education in cardiovascular diseases (CVD). Methods Laymen (n = 2,623) were cluster randomised to either BLS education or to web-based education in CVD before BLS training. The participants were assessed by a questionnaire for theoretical knowledge and then by a simulated scenario for practical skills. The total score for practical skills in BLS six months after training was the primary outcome. The total score for practical skills directly after training, separate variables and self-assessed knowledge, confidence and willingness, directly and six months after training, were the secondary outcomes. Results BLS with web-based education was more effective than BLS without web-based education and obtained a statistically significant higher total score for practical skills at six months (mean 58.8, SD 5.0 vs mean 58.0, SD 5.0; p = 0.03) and directly after training (mean 59.6, SD 4.8 vs mean 58.7, SD 4.9; p = 0.004). Conclusion A web-based education in CVD in addition to BLS training enhanced the learning outcome with a statistically significant higher total score for performed practical skills in BLS as compared to BLS training alone. However, in terms of the outcomes, the differences were minor, and the clinical relevance of our findings has a limited practical impact.	[Bylow, Helene; Herlitz, Johan] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Mol & Clin Med, Gothenburg, Sweden; [Karlsson, Thomas] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Hlth Metr Unit, Gothenburg, Sweden; [Lepp, Margret] Univ Gothenburg, Sahlgrenska Acad, Inst Hlth & Care Sci, Gothenburg, Sweden; [Lepp, Margret] Ostfold Univ Coll, Halden, Norway; [Lepp, Margret] Griffith Univ, Sch Nursing & Midwifery, Brisbane, Qld, Australia; [Claesson, Andreas] Karolinska Inst, Ctr Resuscitat Sci, Dept Med, Stockholm, Sweden; [Lindqvist, Jonny; Herlitz, Johan] Ctr Registers Vastra Gotaland, Gothenburg, Sweden; [Herlitz, Johan] Univ Boras, Prehospen Ctr Prehosp Res, Boras, Sweden; [Herlitz, Johan] Univ Boras, Fac Caring Sci Work Life & Social Welf, Boras, Sweden	University of Gothenburg; University of Gothenburg; University of Gothenburg; Ostfold University College; Griffith University; Karolinska Institutet; University of Boras; University of Boras	Bylow, H (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Mol & Clin Med, Gothenburg, Sweden.	helene.bylow@gu.se		Claesson, Andreas/0000-0002-0499-9929; Lepp, Margret/0000-0002-3324-0946	Swedish Heart-Lung Foundation [20130629]; Foundation for Cardiopulmonary Resuscitation in Sweden; Swedish Resuscitation Council; Swedish government; Swedish County Council	Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Foundation for Cardiopulmonary Resuscitation in Sweden; Swedish Resuscitation Council; Swedish government; Swedish County Council	This research was funded by the Swedish Heart-Lung Foundation (20130629), the Foundation for Cardiopulmonary Resuscitation in Sweden, the Swedish Resuscitation Council and the Swedish state under the agreement between the Swedish government and the County Council (the ALF agreement). The funders had no role in study design, data collection and analysis, decision, preparation of the manuscript or did not take any part in the research.	Abeysekera L, 2015, HIGH EDUC RES DEV, V34, P1, DOI 10.1080/07294360.2014.934336; Anderson R, 2019, RESUSCITATION, V135, P153, DOI 10.1016/j.resuscitation.2018.10.033; Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI 10.1161/CIR.0000000000000659; Bylow H., 2017, ED METHODS CARDIO PU, V06; Bylow H, 2019, RESUSCITATION; Castillo J, 2019, RESUSCITATION, V134, P127, DOI 10.1016/j.resuscitation.2018.11.008; Castillo J, 2018, NURS EDUC TODAY, V65, P232, DOI 10.1016/j.nedt.2018.03.008; Chamberlain DA, 2003, CIRCULATION, V108, P2575, DOI 10.1161/01.CIR.0000099898.11954.3B; Finn JC, 2015, RESUSCITATION, V95, pE203, DOI 10.1016/j.resuscitation.2015.07.046; Greif R, 2015, RESUSCITATION, V95, P288, DOI 10.1016/j.resuscitation.2015.07.032; Hansson L, 1992, Blood Press, V1, P113, DOI 10.3109/08037059209077502; Hasselqvist-Ax I, 2015, NEW ENGL J MED, V372, P2307, DOI 10.1056/NEJMoa1405796; Herlitz J., 2017, SWEDISH REGISTRY CAR; Hillman T, 2016, LEARN MEDIA TECHNOL, V41, P306, DOI 10.1080/17439884.2016.1167080; Hsieh MJ, 2018, RESUSCITATION, V128, P151, DOI 10.1016/j.resuscitation.2018.05.010; Isbye DL, 2007, RESUSCITATION, V74, P296, DOI 10.1016/j.resuscitation.2006.12.012; Jensen TW, 2019, RESUSCITATION, V134, P110, DOI 10.1016/j.resuscitation.2018.10.029; Kolb D.A., 2010, EXPERIENTIAL LEARNIN; Koster RW, 2010, RESUSCITATION, V81, P1277, DOI 10.1016/j.resuscitation.2010.08.009; Krammel M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198918; Lau Y, 2018, RESUSCITATION, V131, P14, DOI 10.1016/j.resuscitation.2018.07.033; Nielsen AM, 2010, ACQUISITION RETENTIO, V81, DOI [10.1016/j.resuscitation.2010.06.003, DOI 10.1016/J.RESUSCITATION.2010.06.003]; Nielsen AM, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-34; Nielsen AM, 2012, EMERG MED J, V29, P587, DOI 10.1136/emermed-2011-200098; Nord A, 2017, SCAND J TRAUMA RESUS, V25, DOI 10.1186/s13049-017-0439-0; Nord A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014230; Nordanstig A, 2017, ACTA NEUROL SCAND, V136, P345, DOI 10.1111/ane.12777; Nordanstig A, 2014, ACTA NEUROL SCAND, V130, P400, DOI 10.1111/ane.12293; Pedersen TH, 2018, RESUSCITATION, V126, P147, DOI 10.1016/j.resuscitation.2018.02.031; Perkins GD, 2012, ANN INTERN MED, V157, P19, DOI 10.7326/0003-4819-157-1-201207030-00005; Perkins GD, 2010, RESUSCITATION, V81, P877, DOI 10.1016/j.resuscitation.2010.03.019; Rumsfeld JS, 2016, CIRCULATION, V134, pE87, DOI 10.1161/CIR.0000000000000428; Saljo R, 2010, J COMPUT ASSIST LEAR, V26, P53, DOI 10.1111/j.1365-2729.2009.00341.x; Schulz KF, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000251; Soar J, 2010, NOTFALL RETTUNGSMED, V13, P723, DOI 10.1007/s10049-010-1375-y; Thorne CJ, 2017, RESUSCITATION, V114, P83, DOI 10.1016/j.resuscitation.2017.02.014; Thorne CJ, 2015, RESUSCITATION, V90, P79, DOI 10.1016/j.resuscitation.2015.02.026; Thuresson M., 2012, INITIAL PHASE ACUTE; Thuresson M, 2015, AM J EMERG MED, V33, P297, DOI 10.1016/j.ajem.2014.11.001; Whitfield RH, 2003, RESUSCITATION, V59, P291, DOI 10.1016/S0300-9572(03)00246-6	41	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2019	14	7							e0219341	10.1371/journal.pone.0219341	http://dx.doi.org/10.1371/journal.pone.0219341			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4LN	31295275	Green Published, gold			2023-01-03	WOS:000484951800027
J	Turunen, M; Hokkanen, L; Backman, L; Stigsdotter-Neely, A; Hanninen, T; Paajanen, T; Soininen, H; Kivipelto, M; Ngandu, T				Turunen, Merita; Hokkanen, Laura; Backman, Lars; Stigsdotter-Neely, Anna; Hanninen, Tuomo; Paajanen, Teemu; Soininen, Hilkka; Kivipelto, Miia; Ngandu, Tiia			Computer-based cognitive training for older adults: Determinants of adherence	PLOS ONE			English	Article							FINNISH GERIATRIC INTERVENTION; ALZHEIMERS-DISEASE; IMPAIRMENT; RISK; AGE; REHABILITATION; PARTICIPANTS; DEPRESSION; DEMENTIA; PEOPLE	The possibilities of computer-based cognitive training (CCT) in postponing the onset of dementia are currently unclear, but promising. Our aim is to investigate older adults ' adherence to a long-term CCT program, and which participant characteristics are associated with adherence to the CCT. This study was part of the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). Participants were 60-77-year-old individuals with increased dementia risk, recruited from previous population-based studies. The participants included in this study (n = 631) had been randomized to receive a multi-domain lifestyle intervention, including CCT. The measure of adherence was the number of completed CCT sessions (max = 144) as continuous measure. Due to a substantial proportion of participants with 0 sessions, the zero inflated negative binomial regression analyses were used to enable assessment of both predictors of starting the training and predictors of completing a higher number of training sessions. Several cognitive, demographic, lifestyle, and health-related variables were examined as potential predictors of adherence to CCT. Altogether, 63% of the participants participated in the CCT at least once, 20% completed at least half of the training, and 12% completed all sessions. Previous experience with computers, being married or cohabiting, better memory performance, and positive expectations toward the study predicted greater odds for starting CCT. Previous computer use was the only factor associated with a greater number of training sessions completed. Our study shows that there is a large variation in adherence to a long-lasting CCT among older adults with an increased risk of dementia. The results indicate that encouraging computer use, and taking into account the level of cognitive functioning, may help boost adherence to CCT.	[Turunen, Merita; Kivipelto, Miia; Ngandu, Tiia] Natl Inst Hlth & Welf THL, Publ Hlth Promot Unit, Helsinki, Finland; [Hokkanen, Laura] Univ Helsinki, Fac Med, Dept Psychol & Logoped, Helsinki, Finland; [Backman, Lars; Kivipelto, Miia] Stockholm Univ, Karolinska Inst, Aging Res Ctr, Stockholm, Sweden; [Stigsdotter-Neely, Anna] Umea Univ, Dept Psychol, Umea, Sweden; [Stigsdotter-Neely, Anna] Karlstad Univ, Dept Social & Psychol Sci, Karlstad, Sweden; [Hanninen, Tuomo; Soininen, Hilkka] Kuopio Univ Hosp, Neuroctr Neurol, Kuopio, Finland; [Paajanen, Teemu] Finnish Inst Occupat Hlth, Res & Serv Ctr Occupat Hlth, Helsinki, Finland; [Soininen, Hilkka; Kivipelto, Miia] Univ Eastern Finland, Inst Clin Med Neurol, Kuopio, Finland; [Kivipelto, Miia; Ngandu, Tiia] Karolinska Inst, NVS, Ctr Alzheimer Res, Div Clin Geriatr, Stockholm, Sweden	Finland National Institute for Health & Welfare; University of Helsinki; Karolinska Institutet; Stockholm University; Umea University; Karlstad University; Kuopio University Hospital; University of Eastern Finland; Finnish Institute of Occupational Health; University of Eastern Finland; Karolinska Institutet	Turunen, M (corresponding author), Natl Inst Hlth & Welf THL, Publ Hlth Promot Unit, Helsinki, Finland.	merita.turunen@thl.fi	Kivipelto, Miia/AAS-3557-2021	Ngandu, Tiia/0000-0002-3698-2021	Academy of Finland's Responding to Public Health Challenges Research Programme (SALVE); Academy of Finland [259615, 278457]; Academy of Finland for Joint Program of Neurodegenerative Disorders-prevention (MIND-AD); Finnish Medical Foundation; La Carita Foundation; Alzheimer Association [HAT-10-173121]; Juho Vainio Foundation; Novo Nordisk Foundation; Finnish Social Insurance Foundation; Ministry of Education and Culture Research Grant; University Hospital of Kuopio; Swedish Research Council; Alzheimer's Research & Prevention Foundation USA; AXA Research Found; Sheika Salama Bint Hamdan Alahyan Foundation; Swedish Research Council for Health, Working Life, and Welfare; Knut and Alice Wallenberg Foundation Sweden; Center for Innovative Medicine (CIMED) at Karolinska Institutet Sweden; Stiftelsen Stockholms sjukhem Sweden; Konung Gustaf V:s och Drottning Victorias Frimurarstiftelse Sweden; Finnish Cultural Foundation Central Found [00161052]; Finnish Cultural Foundation Satakunta Regional Fund [75142262]; University Hospital of Oulu; University Hospital of Turku; Seinajoki Central Hospital; Oulu City Hospital for FINGER project; Alexander von Humboldt Research award; Juho Vainio Foundation [201410050, 201610032]	Academy of Finland's Responding to Public Health Challenges Research Programme (SALVE)(Academy of Finland); Academy of Finland(Academy of Finland); Academy of Finland for Joint Program of Neurodegenerative Disorders-prevention (MIND-AD); Finnish Medical Foundation; La Carita Foundation; Alzheimer Association(Alzheimer's AssociationBrightFocus Foundation); Juho Vainio Foundation; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Finnish Social Insurance Foundation; Ministry of Education and Culture Research Grant; University Hospital of Kuopio; Swedish Research Council(Swedish Research CouncilEuropean Commission); Alzheimer's Research & Prevention Foundation USA; AXA Research Found(AXA Research Fund); Sheika Salama Bint Hamdan Alahyan Foundation; Swedish Research Council for Health, Working Life, and Welfare(Swedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte)); Knut and Alice Wallenberg Foundation Sweden(Knut & Alice Wallenberg Foundation); Center for Innovative Medicine (CIMED) at Karolinska Institutet Sweden; Stiftelsen Stockholms sjukhem Sweden; Konung Gustaf V:s och Drottning Victorias Frimurarstiftelse Sweden; Finnish Cultural Foundation Central Found; Finnish Cultural Foundation Satakunta Regional Fund; University Hospital of Oulu; University Hospital of Turku; Seinajoki Central Hospital; Oulu City Hospital for FINGER project; Alexander von Humboldt Research award(Alexander von Humboldt Foundation); Juho Vainio Foundation	This work was funded by the Academy of Finland's Responding to Public Health Challenges Research Programme (SALVE) grants; Academy of Finland 259615, 278457, projects; Academy of Finland for Joint Program of Neurodegenerative Disorders-prevention (MIND-AD); the Finnish Medical Foundation, La Carita Foundation, Alzheimer Association grant (HAT-10-173121); Juho Vainio Foundation; Novo Nordisk Foundation; Finnish Social Insurance Foundation; Ministry of Education and Culture Research Grant; EVO/VTR grants of University Hospitals of Kuopio, Oulu and Turku, Seinajoki Central Hospital and Oulu City Hospital for FINGER project; Swedish Research Council; Alzheimer's Research & Prevention Foundation USA; AXA Research Found; the Sheika Salama Bint Hamdan Alahyan Foundation; the Swedish Research Council, the Swedish Research Council for Health, Working Life, and Welfare, Knut and Alice Wallenberg Foundation Sweden; Center for Innovative Medicine (CIMED) at Karolinska Institutet Sweden; Stiftelsen Stockholms sjukhem Sweden, Konung Gustaf V:s och Drottning Victorias Frimurarstiftelse Sweden; an Alexander von Humboldt Research award, and a donation from the af Jochnick Foundation as well as personal grants from Finnish Cultural Foundation Central Found 00161052, Finnish Cultural Foundation Satakunta Regional Fund 75142262, and Juho Vainio Foundation 201410050, 201610032 to MT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Backman L, 2011, SCIENCE, V333, P718, DOI 10.1126/science.1204978; Bagwell DK, 2008, CLIN INTERV AGING, V3, P371; Belleville S, 2008, INT PSYCHOGERIATR, V20, P57, DOI 10.1017/S104161020700631X; Choi J, 2013, NEUROPSYCHOL REV, V23, P48, DOI 10.1007/s11065-013-9227-4; Clare L, 2004, NEUROPSYCHOL REHABIL, V14, P385, DOI 10.1080/09602010443000074; Dahlin E, 2008, PSYCHOL AGING, V720; De La Vega FA, 2005, MUTAT RES-FUND MOL M, V573, P111, DOI 10.1016/j.mrfmmm.2005.01.008; Double KS, 2016, PERS INDIV DIFFER, V102, P7, DOI 10.1016/j.paid.2016.04.101; Downey A., 2017, PREVENTING COGNITIVE; Edwards Jerri D, 2017, Alzheimers Dement (N Y), V3, P603, DOI 10.1016/j.trci.2017.09.002; Gavelin HM, 2015, STRESS, V18, P578, DOI 10.3109/10253890.2015.1064892; Golden S., 1978, STROOP COLOR WORD TE; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; Hachinski V, 2006, STROKE, V37, P2220, DOI 10.1161/01.STR.0000237236.88823.47; Hanninen Tuomo, 2010, Duodecim, V126, P2013; Harrison J, 2007, ARCH NEUROL-CHICAGO, V64, P1323, DOI 10.1001/archneur.64.9.1323; Hill NTM, 2017, AM J PSYCHIAT, V174, P329, DOI 10.1176/appi.ajp.2016.16030360; Huang CQ, 2011, INT PSYCHOGERIATR, V23, P516, DOI 10.1017/S1041610210000049; Kivipelto M, 2006, LANCET NEUROL, V5, P735, DOI 10.1016/S1474-4422(06)70537-3; Kivipelto M, 2013, ALZHEIMERS DEMENT, V9, P657, DOI 10.1016/j.jalz.2012.09.012; Kueider AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040588; Lam L. C., 2015, PLOS ONE, P1, DOI [10.1371/journal.pone.0118173, DOI 10.1371/JOURNAL.PONE.0118173]; MORRIS JC, 1988, PSYCHOPHARMACOL BULL, V24, P641; Ngandu T, 2015, LANCET, V385, P2255, DOI 10.1016/S0140-6736(15)60461-5; Ngandu T, 2014, INT J ENV RES PUB HE, V11, P9345, DOI 10.3390/ijerph110909345; Prince MJ., 2015, WORLD ALZHEIMER REPO; Rebok GW, 2014, J AM GERIATR SOC, V62, P16, DOI 10.1111/jgs.12607; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Saaristo T, 2007, INT J CIRCUMPOL HEAL, V66, P101, DOI 10.3402/ijch.v66i2.18239; Sabate E, 2003, ADHERENCE LONG TERM; Sandberg P, 2016, NEUROPSYCHOL REHABIL, V26, P761, DOI 10.1080/09602011.2015.1108205; Sandberg P, 2014, AGING NEUROPSYCHOL C, V21, P577, DOI 10.1080/13825585.2013.839777; Shah H, 2016, LANCET NEUROL, V15, P1283, DOI 10.1016/S1474-4422(16)30235-6; Shao YK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130831; Van der Elst W, 2006, PSYCHOL ASSESSMENT, V18, P424, DOI 10.1037/1040-3590.18.4.424; van der Elst W, 2006, J CLIN EXP NEUROPSYC, V28, P998, DOI 10.1080/13803390591004428; Vartiainen E, 2010, INT J EPIDEMIOL, V39, P504, DOI 10.1093/ije/dyp330; Wechler D., 1998, WMS 3 ADM SCORING MA; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	39	25	26	3	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2019	14	7							e0219541	10.1371/journal.pone.0219541	http://dx.doi.org/10.1371/journal.pone.0219541			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4JZ	31291337	gold, Green Published, Green Submitted			2023-01-03	WOS:000484947800109
J	Ferreira, JSSP; Sacco, ICN; Siqueira, AA; Almeida, MHM; Sartor, CD				Ferreira, Jane S. S. P.; Sacco, Isabel C. N.; Siqueira, Alisson A.; Almeida, Maria H. M.; Sartor, Cristina D.			Rehabilitation technology for self-care: Customised foot and ankle exercise software for people with diabetes	PLOS ONE			English	Article							PLANTAR PRESSURES; ADAPTATION; INSTRUMENT; MANAGEMENT; NEUROPATHY; THERAPY; MOTION; ULCER; RANGE	Aims To develop and validate the content of a free web-based software (desktop and mobile applications) for the self-management of and customised foot-ankle exercises for people with diabetes and diabetic neuropathy. Methods The development of the programme was based on gamification principles and addressed three main areas: foot care recommendations; self-assessment of feet according to the main complications of diabetic neuropathy; and customised foot-ankle exercises to strengthen muscles, increase the range of motion and improve functionality. The content was validated using the Delphi methodology and a quantitative approach in two rounds with diabetes specialists (n = 9) and users with diabetes (n = 20). A 70% approval rate was considered sufficient in the second round for final validation purposes. The data analysis was conducted using descriptive statistics, absolute and relative frequencies and the content-validity index (CVI). Results Among specialists, the CVI was 0.812 after the first round, and final approval was 100% after the second round. Among users, the CVI was 0.902 in the first round, and the final approval was 97%. Conclusion This free access web software was developed based on the high agreement rating between specialists and users and has the potential to prevent complications arising from diabetic polyneuropathy. It allows for self-monitoring and promotes personalised exercises, following a preventive model that can be applied in primary and secondary care services as a complementary treatment for chronic complications. However, further steps to validate the software in a larger population are recommended.	[Ferreira, Jane S. S. P.; Sacco, Isabel C. N.; Almeida, Maria H. M.; Sartor, Cristina D.] Univ Sao Paulo, Dept Fisioterapia Fonoaudiol & Terapia Ocupac, Fac Med FMUSP, Sao Paulo, Brazil; [Siqueira, Alisson A.] Univ Fed Vale Sao Francisco, Juazeiro, Pernanbuco, Brazil; [Sartor, Cristina D.] Univ Ibirapuera, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade Federal do Vale do Sao Francisco; Universidade Ibirapuera	Sacco, ICN (corresponding author), Univ Sao Paulo, Dept Fisioterapia Fonoaudiol & Terapia Ocupac, Fac Med FMUSP, Sao Paulo, Brazil.	icnsacco@usp.br	Sacco, Isabel/T-2630-2019; Ferreira, Jane S S P/C-3671-2019; Sacco, Isabel/D-7172-2011	Sacco, Isabel/0000-0003-1254-0007; Ferreira, Jane S S P/0000-0001-5302-4784; Sacco, Isabel/0000-0003-1254-0007	CAPES [001]; CNPq [304124/2018-4]; FAPESP agency [2015/14810-0]	CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPESP agency(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	J.S.S.P.F. received a scholarship during the period of his master's degree from CAPES (financial code 001). I.C.N.S. received a CNPq fellowship (304124/2018-4) and received funding for the laboratory from FAPESP agency (2015/14810-0).	Allet L, 2010, DIABETOLOGIA, V53, P458, DOI 10.1007/s00125-009-1592-4; Amer Diabet Assoc, 2016, DIABETES CARE, V39, pS6, DOI 10.2337/dc16-S004; Boyko EJ, 1999, DIABETES CARE, V22, P1036, DOI 10.2337/diacare.22.7.1036; Bus SA, 2015, IWGDF GUIDANCE PREVE, DOI [10.1002/dmrr.2696, DOI 10.1002/DMRR.2696]; Caetano LCG, 2017, BRAZ J PHYS THER, V21, P336, DOI 10.1016/j.bjpt.2016.08.001; Cerrahoglu L, 2016, J AM PODIAT MED ASSN, V106, P189, DOI 10.7547/14-095; Chaudhry B, 2006, ANN INTERN MED, V144, P742, DOI 10.7326/0003-4819-144-10-200605160-00125; Cheuy VA, 2013, CLIN BIOMECH, V28, P1055, DOI 10.1016/j.clinbiomech.2013.10.006; Alexandre NMC, 2011, CIENC SAUDE COLETIVA, V16, P3061, DOI 10.1590/S1413-81232011000800006; Deterding S., 2011, P 15 INT ACAD MINDTR, P9, DOI 10.1145/2181037.2181040; Diabetes atlas, 2017, IDF DIABETES ATLAS, V8; Dijs HM, 2000, J AM PODIAT MED ASSN, V90, P126, DOI 10.7547/87507315-90-3-126; FEBNMSHS A, 2016, INT J PHARMTECH RES, V9, P151; FEHRING RJ, 1987, HEART LUNG, V16, P625; Ferreira AFB, 2008, CLINICS, V63, P595, DOI 10.1590/S1807-59322008000500005; Goldsmith JR, 2002, J AM PODIAT MED ASSN, V92, P483, DOI 10.7547/87507315-92-9-483; Grant JS, 1997, RES NURS HEALTH, V20, P269, DOI 10.1002/(SICI)1098-240X(199706)20:3<269::AID-NUR9>3.0.CO;2-G; Horgas A.L., 2008, RES NURS HEALTH, V31, P341, DOI [10.1002/nur, DOI 10.1002/NUR, 10.1002/nur.20270, DOI 10.1002/NUR.20270]; Hunt CW, 2015, WORLD J DIABETES, V6, P225, DOI 10.4239/wjd.v6.i2.225; Kanchanasamut W, 2017, DIABET FOOT ANKLE, V8, DOI 10.1080/2000625X.2017.1287239; Kruse RL, 2010, PHYS THER, V90, P1568, DOI 10.2522/ptj.20090362; Moghtaderi A, 2006, CLIN NEUROL NEUROSUR, V108, P477, DOI 10.1016/j.clineuro.2005.08.003; Monteiro-Soares M, 2014, DIABETES-METAB RES, V30, P610, DOI 10.1002/dmrr.2535; Osheim DE, 2013, THIS COULD BE GAME D, P117; Pratskevich M. A, GAMIFICATION PROBLEM; Rodriguez DD, 2013, DIABETES-METAB RES, V29, P139, DOI 10.1002/dmrr.2366; Rossaneis MA, 2016, REV LAT-AM ENFERM, V24, DOI 10.1590/1518-8345.1203.2761; Sartor CD, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-137; Sartor CD, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-36; Schaper NC, 2016, DIABETES-METAB RES, V32, P7, DOI 10.1002/dmrr.2695; Solomon SD, 2017, DIABETES CARE, V40, P412, DOI 10.2337/dc16-2641; Van Schie CHM, 2004, DIABETES CARE, V27, P1668, DOI 10.2337/diacare.27.7.1668; Vianna Y., 2013, COMO REINVENTAR EMPR; WILLIAMS PL, 1994, J ADV NURS, V19, P180, DOI 10.1111/j.1365-2648.1994.tb01066.x; York RM, 2009, PM&R, V1, P434, DOI 10.1016/j.pmrj.2009.03.001	35	9	10	2	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2019	14	6							e0218560	10.1371/journal.pone.0218560	http://dx.doi.org/10.1371/journal.pone.0218560			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW3PH	31220155	Green Published, Green Submitted, gold			2023-01-03	WOS:000484893500065
J	Wolff, JL; Nicholas, LH; Willink, A; Mulcahy, J; Davis, K; Kasper, JD				Wolff, Jennifer L.; Nicholas, Lauren H.; Willink, Amber; Mulcahy, John; Davis, Karen; Kasper, Judith D.			Medicare Spending and the Adequacy of Support With Daily Activities in Community-Living Older Adults With Disability An Observational Study	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH-CARE EXPENDITURES; UNMET NEED; COST; HOME; SERVICES; READMISSIONS; SAVINGS; ELDERS; HELP	Background: Identifying factors that affect variation in health care spending among older adults with disability may reveal opportunities to better address their care needs while offsetting excess spending. Objective: To quantify differences in total Medicare spending among older adults with disability by whether they experience negative consequences due to inadequate support with household activities, mobility, or self-care. Design: Observational study of in-person interviews and linked Medicare claims. Setting: United States, 2015. Participants: 3716 community-living older adults who participated in the 2015 NHATS (National Health and Aging Trends Study) and survived for 12 months. Measurements: Total Medicare spending by spending quartile in multivariable regression models that adjusted for individual characteristics. Results: Negative consequences were experienced by 18.3% of participants with disability in household activities, 25.6% with mobility disability, and 20.0% with self-care disability. Median Medicare spending was higher for those who experienced negative consequences due to household ($4866 vs. $4095), mobility ($7266 vs. $4115), and self-care ($10 935 vs. $4436) disability versus those who did not. In regression-adjusted analyses, median spending did not differ appreciably for participants who experienced negative consequences in household activities ($338 [95% CI, -$768 to $1444]), but was higher for those with mobility ($2309[CI, $208 to $4409]) and self-care ($3187 [CI, $432 to $5942]) disability. In the bottom-spending quartile, differences were observed for self-care only ($1460 [CI, $358 to $2561]). No differences were observed in the top quartile. Limitation: This observational study could not establish causality. Conclusion: Inadequate support for mobility and self-care is associated with higher Medicare spending, especially in the middle and lower ends of the spending distribution. Better support for the care needs of older adults with disability could offset some Medicare spending. Primary Funding Source: The Commonwealth Fund.	[Wolff, Jennifer L.; Nicholas, Lauren H.; Willink, Amber; Mulcahy, John; Davis, Karen; Kasper, Judith D.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Wolff, Jennifer L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 North Broadway,Room 692, Baltimore, MD 21205 USA; [Nicholas, Lauren H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 North Broadway,Room 450, Baltimore, MD 21205 USA; [Willink, Amber] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 North Broadway,Room 698, Baltimore, MD 21205 USA; [Mulcahy, John] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 North Broadway,Room 696, Baltimore, MD 21205 USA; [Davis, Karen] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 North Broadway,Room 690, Baltimore, MD 21205 USA; [Kasper, Judith D.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 North Broadway,Room 641, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Wolff, JL (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 North Broadway,Room 692, Baltimore, MD 21205 USA.	jwolff2@jhu.edu; jmulcah2@jhu.edu			Commonwealth Fund; NATIONAL INSTITUTE ON AGING [R01AG047859, U01AG032947] Funding Source: NIH RePORTER	Commonwealth Fund; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The Commonwealth Fund.	Agency for Healthcare Research and Quality, 2017, NAT QUAL STRAT ANN R; Allen SM, 2014, J GERONTOL B-PSYCHOL, V69, pS51, DOI 10.1093/geronb/gbu124; Alley DE, 2016, NEW ENGL J MED, V374, P8, DOI 10.1056/NEJMp1512532; Ash AS, 2017, JAMA INTERN MED, V177, P1424, DOI 10.1001/jamainternmed.2017.3317; Auerbach AD, 2016, JAMA INTERN MED, V176, P484, DOI 10.1001/jamainternmed.2015.7863; Beach SR, 2017, J AM GERIATR SOC, V65, P560, DOI 10.1111/jgs.14547; Blumenthal D, 2016, NEW ENGL J MED, V375, P909, DOI 10.1056/NEJMp1608511; Boyd CM, 2018, ANN INTERN MED, V168, P695, DOI 10.7326/M17-2219; Bradley EH, 2016, HEALTH AFFAIR, V35, P760, DOI 10.1377/hlthaff.2015.0814; Centers for Medicare & Medicaid Services, 2018, MEAS MED MAN LONG TE; Chen J, 2014, HEALTH SERV RES, V49, P705, DOI 10.1111/1475-6773.12113; Counsell SR, 2009, J AM GERIATR SOC, V57, P1420, DOI 10.1111/j.1532-5415.2009.02383.x; DePalma G, 2013, GERONTOLOGIST, V53, P454, DOI 10.1093/geront/gns103; Eiken S., 2018, MED EXPENDITURES LON; Figueroa JF, 2017, ANN INTERN MED, V167, P706, DOI 10.7326/M17-0767; Freedman VA, 2014, MILBANK Q, V92, P509, DOI 10.1111/1468-0009.12076; Grabowski DC, 2007, MILBANK Q, V85, P579, DOI 10.1111/j.1468-0009.2007.00502.x; Hass Z, 2017, GERONTOLOGIST, V57, P206, DOI 10.1093/geront/gnv142; Hayes Susan L, 2016, Issue Brief (Commonw Fund), V26, P1; Hinton E., 2019, SECTION 1115 MEDICAI; Institute of Medicine, 2007, FUTURE DISABILITY AM, DOI [10.17226/11898, DOI 10.17226/11898]; Institute of Medicine, 2013, VARIATION HLTH CARE, DOI [10.17226/18393, DOI 10.17226/18393]; Jennings LA, 2019, JAMA INTERN MED, V179, P161, DOI 10.1001/jamainternmed.2018.5579; Joynt KE, 2017, HEALTHCARE-J DEL SCI, V5, P62, DOI 10.1016/j.hjdsi.2016.11.002; Joynt KE, 2013, JAMA-J AM MED ASSOC, V309, P2572, DOI 10.1001/jama.2013.7103; Jutkowitz Eric, 2012, J Aging Res, V2012, P680265, DOI 10.1155/2012/680265; Kasper JD, 2013, 5 J HOPK U SCH PUBL; Kaye HS, 2012, HEALTH AFFAIR, V31, P1195, DOI 10.1377/hlthaff.2011.1237; Kim H, 2019, MED CARE RES REV, V76, P661, DOI 10.1177/1077558717740206; Kindig DA, 2008, JAMA-J AM MED ASSOC, V299, P2081, DOI 10.1001/jama.299.17.2081; Lage DE, 2018, J AM GERIATR SOC, V66, P100, DOI 10.1111/jgs.15150; Lavelle B, 2014, 831 RDA DEP SOC HLTH; Lewis E., 2018, GROWTH MANAGED LONG; McWilliams JM, 2017, JAMA INTERN MED, V177, P518, DOI 10.1001/jamainternmed.2016.9115; Medicare Payment Advisory Commission (MedPAC) Medicaid and CHIP Payment and Access Commission (MACPAC), 2018, DAT BOOK BEN DUALL E; Mitra S, 2009, ARCH PHYS MED REHAB, V90, P1532, DOI 10.1016/j.apmr.2009.02.020; Mor V, 2010, HEALTH AFFAIR, V29, P57, DOI 10.1377/hlthaff.2009.0629; National Academies of Sciences Engineering and Medicine, 2016, FAM CAR AG AM; National Quality Forum, 2015, ADDR PERF MEAS GAPS; Nichols LO, 2017, J AM GERIATR SOC, V65, P931, DOI 10.1111/jgs.14716; Rosati RJ, 2014, HEALTH AFFAIR, V33, P946, DOI 10.1377/hlthaff.2013.1159; Samus QM, 2014, AM J GERIAT PSYCHIAT, V22, P398, DOI 10.1016/j.jagp.2013.12.175; Shugrue N, 2019, J APPL GERONTOL, V38, P1319, DOI 10.1177/0733464817733104; Szanton SL, 2018, J AM GERIATR SOC, V66, P614, DOI 10.1111/jgs.15143; Washington State Health Care Authority, IN 2 LONG TERM SERV; WEISSERT WG, 1985, HEALTH SERV RES, V20, P423; Werner RM, 2018, JAMA-J AM MED ASSOC, V319, P1616, DOI 10.1001/jama.2018.2408; Willink A, 2018, NEW ENGL J MED, V378, P2153, DOI 10.1056/NEJMp1803292; Wodchis WP, 2016, CAN MED ASSOC J, V188, P182, DOI 10.1503/cmaj.150064; Wolff JL, 2018, J AM GERIATR SOC, V66, P1887, DOI 10.1111/jgs.15447; World Health Organization (WHO), 2002, COMMON LANGUAGE FUNC; Xu HP, 2012, J AM GERIATR SOC, V60, P927, DOI 10.1111/j.1532-5415.2012.03926.x; Zuckerman RB, 2016, NEW ENGL J MED, V374, P1543, DOI 10.1056/NEJMsa1513024	53	13	13	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 18	2019	170	12					837	+		10.7326/M18-2467	http://dx.doi.org/10.7326/M18-2467			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ID7AO	31132789	Green Accepted			2023-01-03	WOS:000471834300013
J	Liotta, G; Gilardi, F; Orlando, S; Rocco, G; Proietti, MG; Asta, F; De Sario, M; Michelozzi, P; Mancinelli, S; Palombi, L; Marazzi, MC; Scarcella, P				Liotta, Giuseppe; Gilardi, Francesco; Orlando, Stefano; Rocco, Gennaro; Proietti, Maria Grazia; Asta, Federica; De Sario, Manuela; Michelozzi, Paola; Mancinelli, Sandro; Palombi, Leonardo; Marazzi, Maria Cristina; Scarcella, Paola			Cost of hospital care for the older adults according to their level of frailty. A cohort study in the Lazio region, Italy	PLOS ONE			English	Article							HEALTH-CARE; PREDICTIVE-VALIDITY; ELDERLY PERSONS; DISABILITY; COMORBIDITY; POPULATION; MULTIMORBIDITY; MORTALITY	Background The increasing burden of chronic diseases associated with the ageing of the European population constitutes one of the main challenges for the welfare systems in developed western countries, especially through its impact on the use of hospital services and the cost of care. This study aims at evaluating the cost of hospital care for older adults living in the Lazio Region, Italy, according to their level of frailty. Methods Since 2014 a longitudinal randomized cohort study has been carried out on a sample consisting of 1280 older adults aged over 64 years resident in the Lazio region (Italy), with their being evaluated for multidimensional frailty. Accesses to Hospital Services (acute care and Day Hospital care admissions and Emergency Room accesses) during the first year after enrolment, as well as the related costs have been recorded through a regional database. Costs have been stratified on the basis of the state of frailty. Results The analysis of hospital services and costs highlights the role played by pre-frail individuals who generated 49.3% of the hospital care cumulative costs. Hospital Admission (HA) costs arising from robust and pre-frail subjects are 70% of the total HA costs. Pre-frail individuals also showed the highest average HA cost per person/year (7062.89 Euros). The main determinant of the highest HA costs was given by the number of HAs during the follow-up (multivariate linear regression, beta coefficient = 0.319; p<0.001), which was higher among pre-frail individuals than in any other group of patients. Conclusions Pre-frail individuals generated the highest cost for hospital care in a sample of representative subjects living in an Italian Region with a low rate of community care services, as is the case in the Lazio region. Assessment of the multidimensional frailty of older adults permits a better definition of the important target of the pre-frail population as the main category within which interventions to prevent or mitigate frailty should be carried out.	[Liotta, Giuseppe; Gilardi, Francesco; Orlando, Stefano; Mancinelli, Sandro; Palombi, Leonardo; Scarcella, Paola] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy; [Rocco, Gennaro] IPASVI Ctr Excellence, Rome, Italy; [Proietti, Maria Grazia] OPI, Rome, Italy; [Asta, Federica; De Sario, Manuela; Michelozzi, Paola] Reg Lazio Dept Epidemiol, Rome, Italy; [Marazzi, Maria Cristina] LUMSA Univ, Rome, Italy	University of Rome Tor Vergata; Universita LUMSA	Gilardi, F (corresponding author), Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy.	francesco.gilardi@uniroma2.it	Orlando, Stefano/AAU-2937-2021; Gilardi, Francesco/AAA-1999-2020; Asta, Federica/J-3493-2018	Orlando, Stefano/0000-0001-9706-4075; Asta, Federica/0000-0001-5166-522X; Gilardi, Francesco/0000-0002-4038-6003				Apostolo Joao, 2018, JBI Database System Rev Implement Rep, V16, P140, DOI 10.11124/JBISRIR-2017-003382; Blakely T, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002716; Bock JO, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1360-3; Bottle A, 2019, AGE AGEING, V48, P347, DOI 10.1093/ageing/afy194; Brennan P, 2017, EUR J EPIDEMIOL, V32, P741, DOI 10.1007/s10654-017-0315-2; Comans TA, 2016, AGE AGEING, V45, P317, DOI 10.1093/ageing/afv196; Domagaa A., 2017, HLTH PROMOTION OLDER, P147; Fairhall N, 2015, J AM MED DIR ASSOC, V16, P41, DOI 10.1016/j.jamda.2014.07.006; Fitzpatrick T, 2015, AM J PREV MED, V49, P161, DOI 10.1016/j.amepre.2015.02.018; Fried LP, 2004, J GERONTOL A-BIOL, V59, P255; Garcia-Nogueras I, 2017, J NUTR HEALTH AGING, V21, P207, DOI 10.1007/s12603-016-0727-9; Gijsen R, 2001, J CLIN EPIDEMIOL, V54, P661, DOI 10.1016/S0895-4356(00)00363-2; Gilardi F, ANN IGIENE MED PREVE, V30, P128; Gilardi F, 2016, EUR J PUBLIC HEALTH, V26, P261; Gilardi F, 2018, EUR J PUBLIC HEALTH, V28, P842, DOI 10.1093/eurpub/cky006; Gill TM, 2006, ARCH INTERN MED, V166, P418, DOI 10.1001/.418; Gobbens RJJ, 2012, GERONTOLOGIST, V52, P619, DOI 10.1093/geront/gnr135; Hajek A, 2018, AGE AGEING, V47, P233, DOI 10.1093/ageing/afx157; Hoeck S, 2012, EUR J PUBLIC HEALTH, V22, P671, DOI 10.1093/eurpub/ckr133; Howdona D, 2018, J HLTH EC, V57, P6074; Ilinca S, 2015, HEALTH SERV RES, V50, P305, DOI 10.1111/1475-6773.12211; Illario M, 2017, ANN I SUPER SANITA, V53, P60, DOI 10.4415/ANN_17_01_12; Italian Government Health Ministry, HOSP DISCH CARDS REP; Joynt KE, 2017, HEALTHCARE-J DEL SCI, V5, P62, DOI 10.1016/j.hjdsi.2016.11.002; Larsen FB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169426; Lehnert T, 2011, MED CARE RES REV, V68, P387, DOI 10.1177/1077558711399580; Liotta G, 2016, ANN IG, V28, P1; Liotta G, 2018, INT J ENV RES PUBLIC, V15; Liotta G, 2017, ARCH GERONTOL GERIAT, V68, P1, DOI 10.1016/j.archger.2016.08.004; Liotta Giuseppe, 2012, Ig Sanita Pubbl, V68, P657; Manton KG, 2008, ANNU REV PUBL HEALTH, V29, P91, DOI 10.1146/annurev.publhealth.29.020907.090812; Manton KG, 2009, P NATL ACAD SCI USA, V106, P21080, DOI 10.1073/pnas.0911626106; Marazzi M. C., 2015, ADV AGING RES, V4, P187, DOI DOI 10.4236/AAR.2015.46020; Marengoni A, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/7029027; McPhail SM, 2016, RISK MANAG HEALTHC P, V9, P143, DOI 10.2147/RMHP.S97248; Morciano L, 2017, BIOMEDICINE PREVENTI, V2, DOI [10.19252/000000074, DOI 10.19252/000000074]; National Guideline Centre, 2016, MULT CLIN ASS MAN NG; Nunes BP, 2016, ARCH GERONTOL GERIAT, V67, P130, DOI 10.1016/j.archger.2016.07.008; Olaya B, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0586-1; Peters LL, 2015, J PSYCHOSOM RES, V79, P404, DOI 10.1016/j.jpsychores.2015.09.015; Ritt M, 2017, CLIN INTERV AGING, V12, P293, DOI 10.2147/CIA.S124342; Rolden HJA, 2014, SOC SCI MED, V120, P110, DOI 10.1016/j.socscimed.2014.09.020; Scarcella P, 2005, ARCH GERONTOL GERIAT, V40, P147, DOI 10.1016/j.archger.2004.07.004; Scitovsky AA, 2005, MILBANK Q, V83, P825, DOI 10.1111/j.1468-0009.2005.00402.x; Sirven N, 2017, EUR J HEALTH ECON, V18, P243, DOI 10.1007/s10198-016-0772-7; Skinner HG, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1304-y; Tarasuk V, 2015, CAN MED ASSOC J, V187, pE429, DOI 10.1503/cmaj.150234; Vetrano DL, 2019, J GERONTOL A-BIOL, V74, P659, DOI 10.1093/gerona/gly110; Villacampa-Fernandez P, 2017, MATURITAS, V95, P31, DOI 10.1016/j.maturitas.2016.10.008; Walker A., 2011, FUTURAGE A ROAD MAP; Yarnall AJ, 2017, AGE AGEING, V46, P882, DOI 10.1093/ageing/afx150; Zucchelli A, 2018, EUR J INTERN MED, V56, P53, DOI 10.1016/j.ejim.2018.06.012	52	13	13	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2019	14	6							e0217829	10.1371/journal.pone.0217829	http://dx.doi.org/10.1371/journal.pone.0217829			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IC4XB	31185033	gold, Green Submitted, Green Published			2023-01-03	WOS:000470970000019
J	Lobo, DN				Lobo, Dileep N.			Improving outcomes with a little EFFORT	LANCET			English	Editorial Material							OLDER; RISK; FOOD		[Lobo, Dileep N.] Univ Nottingham, Nottingham Digest Dis Ctr, Gastrointestinal Surg, Nottingham NG7 2UH, England; [Lobo, Dileep N.] Univ Nottingham, Sch Life Sci, MRC Arthrit Res UK Ctr Musculoskeletal Ageing Res, Nottingham, England	University of Nottingham; University of Nottingham	Lobo, DN (corresponding author), Univ Nottingham, Nottingham Digest Dis Ctr, Gastrointestinal Surg, Nottingham NG7 2UH, England.; Lobo, DN (corresponding author), Univ Nottingham, Sch Life Sci, MRC Arthrit Res UK Ctr Musculoskeletal Ageing Res, Nottingham, England.	dileep.lobo@nottingham.ac.uk	Lobo, Dileep/AAC-6207-2020	Lobo, Dileep/0000-0003-1187-5796				Bally MR, 2016, JAMA INTERN MED, V176, P43, DOI 10.1001/jamainternmed.2015.6587; Barton AD, 2000, CLIN NUTR, V19, P445, DOI 10.1054/clnu.2000.0150; Deutz NE, 2016, CLIN NUTR, V35, P18, DOI 10.1016/j.clnu.2015.12.010; Feinberg J, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011598.pub2; Hartwell HJ, 2016, APPETITE, V96, P293, DOI 10.1016/j.appet.2015.09.023; Hope K, 2017, MATURITAS, V97, P6, DOI 10.1016/j.maturitas.2016.12.001; Kondrup J, 2003, CLIN NUTR, V22, P321, DOI 10.1016/S0261-5614(02)00214-5; MCWHIRTER JP, 1994, BRIT MED J, V308, P945, DOI 10.1136/bmj.308.6934.945; Schuetz P, 2019, LANCET, V393, P2312, DOI 10.1016/S0140-6736(18)32776-4; Sprengell C, 1735, APHORISMS HIPPOCRATE; Studley HO, 1936, J AMER MED ASSOC, V106, P458, DOI 10.1001/jama.1936.02770060032009	11	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 8	2019	393	10188					2278	2280		10.1016/S0140-6736(18)32856-3	http://dx.doi.org/10.1016/S0140-6736(18)32856-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IB4SX	31030982	Green Submitted			2023-01-03	WOS:000470263400005
J	Hampton, T				Hampton, Tracy			Noninvasive Ultrasound May Help Treat Inflammation and Other Conditions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2019	321	21					2064	2065		10.1001/jama.2019.6653	http://dx.doi.org/10.1001/jama.2019.6653			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IB3HN	31162552				2023-01-03	WOS:000470158700004
J	Wang, XN; Dong, YL; Zhang, YY; Li, TZ; Xie, ZC				Wang, Xiaoning; Dong, Yuanlin; Zhang, Yiying; Li, Tianzuo; Xie, Zhongcong			Sevoflurane induces cognitive impairment in young mice via autophagy	PLOS ONE			English	Article							DEVELOPING BRAIN; APOPTOSIS; NEUROTOXICITY; ANESTHESIA; RAT; ISOFLURANE; EXPOSURE; ERYTHROPOIETIN; ABNORMALITIES; HIPPOCAMPUS	Background Anesthesia may induce neurotoxicity and neurocognitive impairment in young mice. However, the underlying mechanism remains largely to be determined. Meanwhile, autophagy is involved in brain development and contributes to neurodegenerative diseases. We, therefore, set out to determine the effects of sevoflurane on autophagy in the hippocampus of young mice and on cognitive function in the mice. Methods Six day-old mice received 3% sevoflurane, for two hours daily, on postnatal days (P) 6, 7 and 8. We then decapitated the mice and harvested the hippocampus of the young mice at P8. The level of LC3, the ratio of LC3-II to LC3-I, and SQSTM1/p62 level associated with the autophagy in the hippocampus of the mice were assessed by using Western blotting. We used different groups of mice for behavioral testing via the Morris Water Maze from P31 to P37. Results The anesthetic sevoflurane increased the level of LC3-II and ratio of LC3-II/LC3-I, decreased the p62 level in the hippocampus of the young mice, and induced cognitive impairment in the mice. 3-Methyladenine, the inhibitor of autophagy, attenuated the activation of autophagy and ameliorated the cognitive impairment induced by sevoflurane in the young mice. Conclusion These data showed that sevoflurane anesthesia might induce cognitive impairment in the young mice via activation of autophagy in the hippocampus of the young mice. These findings from the proof of concept studies have established a system and suggest the role of autophagy in anesthesia neurotoxicity and cognitive impairment in the young mice, pending further investigation.	[Wang, Xiaoning; Li, Tianzuo] Capital Med Univ, Beijing Shijitan Hosp, Dept Anesthesiol, Beijing, Peoples R China; [Wang, Xiaoning; Dong, Yuanlin; Zhang, Yiying; Xie, Zhongcong] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Charlestown, MA 02129 USA; [Wang, Xiaoning; Dong, Yuanlin; Zhang, Yiying; Xie, Zhongcong] Harvard Med Sch, Charlestown, MA 02129 USA	Capital Medical University; Harvard University; Massachusetts General Hospital	Xie, ZC (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Charlestown, MA 02129 USA.; Xie, ZC (corresponding author), Harvard Med Sch, Charlestown, MA 02129 USA.	zxie@mgh.harvard.edu		Dong, Yuanlin/0000-0002-4760-0519; wang, xiaoning/0000-0001-8175-766X	National Institutes of Health, Bethesda, Maryland [R01HD086977]; National Natural Science Foundation, Beijing, People's Republic of China [81571037]	National Institutes of Health, Bethesda, Maryland(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation, Beijing, People's Republic of China	This research was supported by grant R01HD086977 from the National Institutes of Health, Bethesda, Maryland (to Dr. Zhongcong Xie) and was partially supported by grant No. 81571037 (to Dr. Tianzuo Li) from the National Natural Science Foundation, Beijing, People's Republic of China. URL of each funder website: https://grants.nih.gov/funding/searchguide/index.html#/, https://isisn. nsfc. gov. cn/egrantindex/funcindex/prjsearchlist.; This research was supported by grant R01HD086977 from the National Institutes of Health, Bethesda, Maryland (to Dr. Zhongcong Xie) and was partially supported by grant No. 81571037 (to Dr. Tianzuo Li) from the National Natural Science Foundation, Beijing, People's Republic of China. The anesthetic sevoflurane was generously provided by the Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.	Amrock LG, 2015, ANESTHESIOLOGY, V122, P87, DOI 10.1097/ALN.0000000000000477; Andropoulos DB, 2018, FETAL DIAGN THER, V43, P1, DOI 10.1159/000475928; Bento CF, 2016, ANNU REV BIOCHEM, V85, P685, DOI 10.1146/annurev-biochem-060815-014556; Bianchi SL, 2008, NEUROBIOL AGING, V29, P1002, DOI 10.1016/j.neurobiolaging.2007.02.009; Booth LA, 2014, CELL SIGNAL, V26, P549, DOI 10.1016/j.cellsig.2013.11.028; Budini M, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00170; Bussi C, 2017, SCI REP-UK, V7, DOI 10.1038/srep43153; Chen G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057870; Cheng AB, 2019, EUR J PHARMACOL, V849, P84, DOI 10.1016/j.ejphar.2019.01.051; Chittaranjan Suganthi, 2015, Cold Spring Harb Protoc, V2015, P743, DOI 10.1101/pdb.prot086256; Cui YS, 2018, TOXICOL LETT, V297, P24, DOI 10.1016/j.toxlet.2018.08.020; DeFrances Carol J, 2007, Vital Health Stat 13, P1; Ghatge S, 2003, ACTA ANAESTH SCAND, V47, P917, DOI 10.1034/j.1399-6576.2003.00196.x; Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019; Huang R, 2015, AUTOPHAGY, V11, P852, DOI 10.1080/15548627.2015.1038016; Istaphanous GK, 2011, ANESTHESIOLOGY, V114, P578, DOI 10.1097/ALN.0b013e3182084a70; Ji MH, 2015, NEUROTOXICOLOGY, V46, P155, DOI 10.1016/j.neuro.2014.11.003; Katsuragi Y, 2015, FEBS J, V282, P4672, DOI 10.1111/febs.13540; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Ko GJ, 2016, HUM EXP TOXICOL, V35, P724, DOI 10.1177/0960327115604198; Komita M, 2013, ANESTH ANALG, V117, P1197, DOI 10.1213/ANE.0b013e3182a74773; Kvolik S, 2009, ACTA ANAESTH SCAND, V53, P1192, DOI 10.1111/j.1399-6576.2009.02036.x; Li YZ, 2017, AUTOPHAGY, V13, P1145, DOI 10.1080/15548627.2017.1320467; Liang G, 2010, ANESTHESIOLOGY, V112, P1325, DOI 10.1097/ALN.0b013e3181d94da5; Liao ZX, 2014, BRAIN RES BULL, V107, P69, DOI 10.1016/j.brainresbull.2014.07.001; Liu WW, 2017, BRIT J CANCER, V117, P1139, DOI 10.1038/bjc.2017.293; Liu YF, 2017, NEUROSCI LETT, V651, P21, DOI 10.1016/j.neulet.2017.04.040; Lu Y, 2010, ANESTHESIOLOGY, V112, P1404, DOI 10.1097/ALN.0b013e3181d94de1; Pellegrini L, 2014, PEDIATR ANESTH, V24, P749, DOI 10.1111/pan.12372; Periyasamy-Thandavan S, 2008, KIDNEY INT, V74, P631, DOI 10.1038/ki.2008.214; Qiu L, 2016, TOXICOL SCI, V149, P121, DOI 10.1093/toxsci/kfv219; Ramage TM, 2013, BRIT J ANAESTH, V110, P39, DOI 10.1093/bja/aet103; Ravikumar B, 2005, NAT GENET, V37, P771, DOI 10.1038/ng1591; Ren GY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11607-0; Shen X, 2013, ANESTHESIOLOGY, V118, P502, DOI 10.1097/ALN.0b013e3182834d77; Sun W, 2017, ENVIRON TOXICOL PHAR, V50, P151, DOI 10.1016/j.etap.2017.02.006; Tanida I, 2011, ANTIOXID REDOX SIGN, V14, P2201, DOI 10.1089/ars.2010.3482; Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4; Tao G, 2016, BIOMED RES INT BIOME, V2016, P2016, DOI DOI 10.1155/2016/7919640; Tao GR, 2014, ANESTHESIOLOGY, V121, P510, DOI 10.1097/ALN.0000000000000278; Valente MJ, 2017, ARCH TOXICOL, V91, P3663, DOI 10.1007/s00204-017-1984-z; Vutskits L, 2016, NAT REV NEUROSCI, V17, P705, DOI 10.1038/nrn.2016.128; Xie SN, 2017, J NEUROSCI RES, V95, P2367, DOI 10.1002/jnr.24118; Xie ZC, 2005, J MOL NEUROSCI, V25, P67, DOI 10.1385/JMN:25:1:067; Xu G, 2017, BRIT J ANAESTH, V119, P481, DOI 10.1093/bja/aex071; Yamamoto A, 2014, ANNU REV NEUROSCI, V37, P55, DOI 10.1146/annurev-neuro-071013-014149; Yang MR, 2017, NEUROTOXICOL TERATOL, V60, P59, DOI 10.1016/j.ntt.2016.11.004; Zhang DX, 2017, BIOMED PHARMACOTHER, V87, P332, DOI 10.1016/j.biopha.2016.12.115; Zhang J, 2015, MOL NEUROBIOL, V51, P853, DOI 10.1007/s12035-014-8746-1; Zhang L, 2014, MED GAS RES, V4, DOI 10.1186/2045-9912-4-5; Zhang XE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155490; Zhang YY, 2012, ANN NEUROL, V71, P687, DOI 10.1002/ana.23536; 2015, J CLIN INVEST, V125, P33, DOI DOI 10.1172/JCI73940; 2017, NEUROTOX RES, V31, P218, DOI DOI 10.1007/S12640-016-9671-Z; 2014, ANESTHESIOLOGY, V120, P626, DOI DOI 10.1097/ALN.0000000000000037	55	28	29	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2019	14	5							e0216372	10.1371/journal.pone.0216372	http://dx.doi.org/10.1371/journal.pone.0216372			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY7BF	31107909	Green Published, gold, Green Submitted			2023-01-03	WOS:000468285200008
J	Tefera, GM; Feyisa, BB; Kebede, TM				Tefera, Gosaye Mekonen; Feyisa, Beshadu Bedada; Kebede, Tsegaye Melaku			Antimicrobial use-related problems and their costs in surgery ward of Jimma University Medical Center: Prospective observational study	PLOS ONE			English	Article							SURGICAL SITE INFECTIONS; ANTIBIOTIC-PROPHYLAXIS; GUIDELINES; UPDATE	Introduction Antibiotics are among the most commonly misused of all drugs, which results in antibiotic resistance and waste of resources and it has not been studied in Ethiopia. Therefore, this study was carried out to assess antibiotic use-related problems and their costs among patients hospitalized at the surgical ward of Jimma University Medical Center. Methods Hospital-based prospective observational study was used to assess the prevalence, cost, and determinants of antibiotic use-related problems; multiple stepwise backward logistic regression analysis was done for a P value of <0.25 to look for predictors of antibiotic use-related problems. Written informed consent was obtained and confidentiality was secured. Results Among 300 participants, antibiotic use-related problems (ABURPs) were found in 69.3% of the study participants. The direct total cost attributed to these problems was approximated to a minimum of 2230.15 US$. Independent predictors for antibiotic use-related problems were: indication for antibiotic use like: use of antibiotic for prophylaxis; p < 0.0001, antibiotic use for both therapeutic & prophylaxis; p < 0.0001, CDC wound class I and II; p = 0.016 and; p = 0.002 respectively, overall poly-pharmacy and greater than 2 antibiotic exposure during hospital stay; p = 0.019and p = 0.006 respectively and hospital stay for >= 21 days; p = 0.007. Conclusion The prevalence of antibiotic use-related problems was high and resulted in extra cost. Antibiotic use for prophylaxis, prophylaxis, and treatment, poly-pharmacy, greater than 2 antibiotic exposures during the hospital stay, CDC wound class I and II, and duration of hospital stay of >= 21 days was found to be independent predictors of antibiotic use-related problems.	[Tefera, Gosaye Mekonen] Ambo Univ, Clin Pharm Course Unit, Dept Pharm, Ambo, Ethiopia; [Feyisa, Beshadu Bedada] Ambo Univ, Dept Publ Hlth, Nutr Course Unit, Ambo, Ethiopia; [Kebede, Tsegaye Melaku] Jimma Univ, Sch Pharm, Dept Clin Pharm, Jimma, Ethiopia	Ambo University; Ambo University; Jimma University	Tefera, GM (corresponding author), Ambo Univ, Clin Pharm Course Unit, Dept Pharm, Ambo, Ethiopia.	Gosi2010pharma@gmail.com	Melaku, Tsegaye/AAD-6981-2021; Mekonen, Gosaye/AAU-8435-2020	Melaku, Tsegaye/0000-0001-8373-5309; Mekonen, Gosaye/0000-0002-7534-2828	Jimma University	Jimma University	Gosaye Mekonen recieved funding for this study from Jimma University (www.ju.edu.et) as a research for post-graduate study. The funder has no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrha S., 2015, GLOB J MED RES B, V15, P1; Alemu T, 2009, LIT REV INFECT DIS A, P37; [Anonymous], 2015, REC FDA ANT APPR GOO; [Anonymous], 2014, OPEN SURG J, V8, P1; [Anonymous], 2014, WHO URG COUNTR TAK M; [Anonymous], 2016, GLOBAL GUIDELINES PR; [Anonymous], 2016, 1 NEW ANTIBIOTIC IN; Baiden F, 2010, LANCET, V375, P637, DOI 10.1016/S0140-6736(10)60265-6; Beique Lizanne, 2015, Can J Hosp Pharm, V68, P318; Boucher HW, 2009, CLIN INFECT DIS, V48, P1, DOI 10.1086/595011; Bratzler DW, 2013, SURG INFECT, V14, P73, DOI 10.1089/sur.2013.9999; Bratzler DW, 2005, ARCH SURG-CHICAGO, V140, P174, DOI 10.1001/archsurg.140.2.174; Burke JP, 2001, CLIN INFECT DIS, V33, pS78, DOI 10.1086/321861; Calbo Esther, 2013, Enferm Infecc Microbiol Clin, V31 Suppl 4, P12, DOI 10.1016/S0213-005X(13)70127-7; Carneiro M, 2011, REV ASSOC MED BRAS, V57, P421, DOI 10.1590/S0104-42302011000400016; Centers for Disease Control and Prevention US Department of Health and Human Services, 2013, ANTIBIOTIC RESISTANC; Cipolle R, 2006, GOOGLE PATENTS; Fehr J, 2006, CLIN MICROBIOL INFEC, V12, P1224, DOI 10.1111/j.1469-0691.2006.01551.x; FSe, 2006, ARCH SURG-CHICAGO, V141, P109; Godebo G, 2013, ANN CLIN MICROB ANTI, V12, DOI 10.1186/1476-0711-12-17; Golembiewski J, 2014, J PERIANESTH NURS, V29, P155, DOI 10.1016/j.jopan.2014.01.001; Harbarth S, 2000, CIRCULATION, V101, P2916, DOI 10.1161/01.CIR.101.25.2916; Heddini A, 2009, LANCET, V373, P30, DOI 10.1016/S0140-6736(08)61956-X; Howe LM, 2006, VET CLIN N AM-SMALL, V36, P1049, DOI 10.1016/j.cvsm.2006.05.001; Lim MK, 2015, J INFECT DEV COUNTR, V9, P1264, DOI 10.3855/jidc.6731; Ogbonna B, 2014, INT J INNOV RES DEV, V3, P494; Pollack LA, 2014, CLIN INFECT DIS, V59, pS97, DOI 10.1093/cid/ciu542; Rehan HS, 2009, INT J INFECT CONTROL, V6; Rice LB, 2009, CURR OPIN MICROBIOL, V12, P476, DOI 10.1016/j.mib.2009.08.001; Sahile T, 2016, INT J TROP DIS HLTH, V17, P1, DOI DOI 10.9734/IJTDH/2016/27253; Shrayteh ZM, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-717; Sileshi A, 2016, BMC PHARMACOL TOXICO, V17, DOI 10.1186/s40360-016-0057-x; Tigabu BM, 2013, FACTORS ASS UNNECESS; Tseng SH, 2011, J MICROBIOL IMMUNOL, V44, P157, DOI 10.1016/j.jmii.2011.03.001; Vessal C., 2011, Eastern Mediterranean Health Journal, V17, P663; Yadesa TM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138385; Yang Z., 2014, PLOS ONE, V9, P1, DOI [10.1371/journal.pone.011598925551561, DOI 10.1371/JOURNAL.PONE.011598925551561, DOI 10.1371/J0URNAL.P0NE.0115989]; Young B, 2011, ANTIMICROB AGENTS CH, V55, P4659, DOI 10.1128/AAC.00562-11; Zhang HX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088971	39	9	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 17	2019	14	5							e0216770	10.1371/journal.pone.0216770	http://dx.doi.org/10.1371/journal.pone.0216770			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY5OE	31100088	Green Published, Green Submitted, gold			2023-01-03	WOS:000468176600015
J	Grigoryan, B; Paulsen, SJ; Corbett, DC; Sazer, DW; Fortin, CL; Zaita, AJ; Greenfield, PT; Calafat, NJ; Gounley, JP; Ta, AH; Johansson, F; Randles, A; Rosenkrantz, JE; Louis-Rosenberg, JD; Galie, PA; Stevens, KR; Miller, JS				Grigoryan, Bagrat; Paulsen, Samantha J.; Corbett, Daniel C.; Sazer, Daniel W.; Fortin, Chelsea L.; Zaita, Alexander J.; Greenfield, Paul T.; Calafat, Nicholas J.; Gounley, John P.; Ta, Anderson H.; Johansson, Fredrik; Randles, Amanda; Rosenkrantz, Jessica E.; Louis-Rosenberg, Jesse D.; Galie, Peter A.; Stevens, Kelly R.; Miller, Jordan S.			BIOMEDICINE Multivascular networks and functional intravascular topologies within biocompatible hydrogels	SCIENCE			English	Article							LUNG STRUCTURE; HEART-VALVES; BLOOD-FLOW; MODEL; STEREOLITHOGRAPHY; NANOPARTICLES; PERFORMANCE; FABRICATION; EVOLUTION; SYSTEM	Solid organs transport fluids through distinct vascular networks that are biophysically and biochemically entangled, creating complex three-dimensional (3D) transport regimes that have remained difficult to produce and study. We establish intravascular andmultivascular design freedoms with photopolymerizable hydrogels by using food dye additives as biocompatible yet potent photoabsorbers for projection stereolithography. We demonstrate monolithic transparent hydrogels, produced in minutes, comprising efficient intravascular 3D fluid mixers and functional bicuspid valves. We further elaborate entangled vascular networks from space-filling mathematical topologies and explore the oxygenation and flow of human red blood cells during tidal ventilation and distension of a proximate airway. In addition, we deploy structured biodegradable hydrogel carriers in a rodent model of chronic liver injury to highlight the potential translational utility of this materials innovation.	[Grigoryan, Bagrat; Paulsen, Samantha J.; Sazer, Daniel W.; Zaita, Alexander J.; Greenfield, Paul T.; Calafat, Nicholas J.; Ta, Anderson H.; Miller, Jordan S.] Rice Univ, Dept Bioengn, Houston, TX 77005 USA; [Corbett, Daniel C.; Johansson, Fredrik; Stevens, Kelly R.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; [Corbett, Daniel C.; Fortin, Chelsea L.; Johansson, Fredrik; Stevens, Kelly R.] Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98195 USA; [Fortin, Chelsea L.; Stevens, Kelly R.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA; [Randles, Amanda] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA; [Rosenkrantz, Jessica E.; Louis-Rosenberg, Jesse D.] Nervous Syst, Somerville, MA 02143 USA; [Galie, Peter A.] Rowan Univ, Dept Biomed Engn, Glassboro, NJ 08028 USA; [Gounley, John P.] Oak Ridge Natl Lab, Computat Sci & Engn Div, Oak Ridge, TN 37830 USA	Rice University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Duke University; Rowan University; United States Department of Energy (DOE); Oak Ridge National Laboratory	Miller, JS (corresponding author), Rice Univ, Dept Bioengn, Houston, TX 77005 USA.; Stevens, KR (corresponding author), Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.; Stevens, KR (corresponding author), Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98195 USA.; Stevens, KR (corresponding author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.	ksteve@uw.edu; jmil@rice.edu	Fortin, Chelsea L./E-8972-2017	Fortin, Chelsea L./0000-0002-6931-0862; Paulsen, Samantha/0000-0003-4525-7697; Ta, Anderson/0000-0003-0433-6946; Gounley, John/0000-0001-8424-4982; Galie, Peter/0000-0001-5161-4924; Greenfield, MD, Paul T./0000-0003-4567-7173; Rosenkrantz, Jessica/0000-0002-3114-7422; Sazer, Daniel/0000-0002-1057-4353	Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation; U.S. National Science Foundation (NSF) [1728239]; NSF [1450681]; U.S. National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) via F31 NRSA Fellowship [HL134295]; NIH Director's New Innovator Award (NHLBI) [DP2HL137188]; John H. Tietze Foundation; NIH National Institute of Biomedical Imaging and Bioengineering (NIBIB) Cardiovascular Training Grant [T32EB001650]; NIH National Institute of General Medical Sciences (NIGMS) Molecular Medicine Training Grant [T32GM095421]; Office of the Director of the National Institutes of Health Early Independence Award [DP5OD019876]; Gulf Coast Consortia on the NSF IGERT: Neuroengineering from Cells to Systems [1250104]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [DP2HL137188, F31HL134295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [T32EB001650] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP5OD019876] Funding Source: NIH RePORTER	Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation; U.S. National Science Foundation (NSF)(National Science Foundation (NSF)); NSF(National Science Foundation (NSF)); U.S. National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) via F31 NRSA Fellowship; NIH Director's New Innovator Award (NHLBI); John H. Tietze Foundation; NIH National Institute of Biomedical Imaging and Bioengineering (NIBIB) Cardiovascular Training Grant; NIH National Institute of General Medical Sciences (NIGMS) Molecular Medicine Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Office of the Director of the National Institutes of Health Early Independence Award; Gulf Coast Consortia on the NSF IGERT: Neuroengineering from Cells to Systems; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported in part by the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation (J.S.M.), the U.S. National Science Foundation (NSF) (P.A.G., 1728239), an NSF Graduate Research Fellowship (B.G., 1450681), the U.S. National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) via F31 NRSA Fellowship (S.J.P., HL134295), the NIH Director's New Innovator Award (K.R.S., NHLBI, DP2HL137188), the John H. Tietze Foundation (K.R.S.), NIH National Institute of Biomedical Imaging and Bioengineering (NIBIB) Cardiovascular Training Grant (D.C.C., T32EB001650); NIH National Institute of General Medical Sciences (NIGMS) Molecular Medicine Training Grant (C.L.F., T32GM095421); Office of the Director of the National Institutes of Health Early Independence Award (A.R., DP5OD019876), and a training fellowship from the Gulf Coast Consortia on the NSF IGERT: Neuroengineering from Cells to Systems (D.W.S., 1250104). The content is solely the responsibility of the authors and does not necessarily represent the official views of any of the funding agencies.	Andrus L, 2011, HEPATOLOGY, V54, P1901, DOI 10.1002/hep.24557; Armeniades C. D., U. S. Patent, Patent No. [3,286,992 51, 3286992]; Bazigou E, 2013, CELL MOL LIFE SCI, V70, P1055, DOI 10.1007/s00018-012-1110-6; Bhattacharjee T, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500655; Brikov AV, 2016, DOKL PHYS CHEM, V469, P121, DOI 10.1134/S0012501616080030; Calderon GA, 2017, BIOMATER SCI-UK, V5, P1652, DOI 10.1039/c7bm00223h; Chen AA, 2011, P NATL ACAD SCI USA, V108, P11842, DOI 10.1073/pnas.1101791108; Chen S, 1998, ANNU REV FLUID MECH, V30, P329, DOI 10.1146/annurev.fluid.30.1.329; Coakley MF, 2014, 3D PRINT ADDIT MANUF, V1, P137, DOI 10.1089/3dp.2014.1503; DeForest CA, 2011, NAT CHEM, V3, P925, DOI [10.1038/NCHEM.1174, 10.1038/nchem.1174]; DeForest CA, 2009, NAT MATER, V8, P659, DOI [10.1038/NMAT2473, 10.1038/nmat2473]; DUNN JCY, 1991, BIOTECHNOL PROGR, V7, P237, DOI 10.1021/bp00009a007; Farmer CG, 2015, PHYSIOLOGY, V30, P260, DOI 10.1152/physiol.00056.2014; Fonovich TM, 2013, DRUG CHEM TOXICOL, V36, P343, DOI 10.3109/01480545.2012.710626; FREYER JP, 1989, CYTOMETRY, V10, P803, DOI 10.1002/cyto.990100620; FUNG YC, 1988, J APPL PHYSIOL, V64, P2132, DOI 10.1152/jappl.1988.64.5.2132; Ghanem A, 2014, CHEM ENG RES DES, V92, P205, DOI 10.1016/j.cherd.2013.07.013; Gormley J, 2017, PROCEDIA COMPUT SCI, V108, P175, DOI 10.1016/j.procs.2017.05.209; Griffith BE, 2009, INT J APPL MECH, V1, P137, DOI 10.1142/S1758825109000113; Hahn MS, 2006, ADV MATER, V18, P2679, DOI 10.1002/adma.200600647; Heintz KA, 2016, ADV HEALTHC MATER, V5, P2153, DOI 10.1002/adhm.201600351; Hinton TJ, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500758; Hofemeier P, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4027328; Hsia CCW, 2016, COMPR PHYSIOL, V6, P827, DOI 10.1002/cphy.c150028; Huh D, 2010, SCIENCE, V328, P1662, DOI 10.1126/science.1188302; Kang HW, 2016, NAT BIOTECHNOL, V34, P312, DOI 10.1038/nbt.3413; Kelly BE, 2019, SCIENCE, V363, P1075, DOI 10.1126/science.aau7114; Kim Y, 2009, ANN BIOMED ENG, V37, P927, DOI 10.1007/s10439-009-9669-2; Kolesky DB, 2016, P NATL ACAD SCI USA, V113, P3179, DOI 10.1073/pnas.1521342113; Koshy ST, 2016, ADV HEALTHC MATER, V5, P541, DOI 10.1002/adhm.201500757; Kumar S, 2008, NAT PROTOC, V3, P314, DOI 10.1038/nprot.2008.1; L'Heureux N, 2006, NAT MED, V12, P361, DOI 10.1038/nm1364; Li M, 2014, J AGR FOOD CHEM, V62, P12052, DOI 10.1021/jf5045052; Lin H, 2013, BIOMATERIALS, V34, P331, DOI 10.1016/j.biomaterials.2012.09.048; LINHARTOVA A, 1986, ANAT RECORD, V214, P266, DOI 10.1002/ar.1092140305; Lurie F, 2003, J VASC SURG, V38, P955, DOI 10.1016/S0741-5214(03)00711-0; Ma XY, 2016, P NATL ACAD SCI USA, V113, P2206, DOI 10.1073/pnas.1524510113; Madurantakam PA, 2009, BIOMATERIALS, V30, P5456, DOI 10.1016/j.biomaterials.2009.06.043; March S, 2009, HEPATOLOGY, V50, P920, DOI 10.1002/hep.23085; MEAD J, 1970, J APPL PHYSIOL, V28, P596, DOI 10.1152/jappl.1970.28.5.596; Miller J, 2019, Dataset for: Multivascular networks and functional intravascular topologies within biocompatible hydrogels, DOI [10.5281/zenodo.2614071, DOI 10.5281/ZENODO.2614071]; Miller J. S., 2019, DATASET MULTIVASCULA, DOI [10.5281/zenodo, DOI 10.5281/ZENODO]; Miller JS, 2012, NAT MATER, V11, P768, DOI [10.1038/NMAT3357, 10.1038/nmat3357]; Miller JS, 2010, BIOMATERIALS, V31, P3736, DOI 10.1016/j.biomaterials.2010.01.058; Monahan-Earley R, 2013, J THROMB HAEMOST, V11, P46, DOI 10.1111/jth.12253; Moriyama EH, 2008, PHOTOCH PHOTOBIO SCI, V7, P675, DOI 10.1039/b719231b; Nam KH, 2012, INT J CARDIOVAS IMAG, V28, P69, DOI 10.1007/s10554-010-9778-x; Neiman JAS, 2015, BIOTECHNOL BIOENG, V112, P777, DOI 10.1002/bit.25494; Oancea P, 2014, CHEM PAP, V68, P105, DOI 10.2478/s11696-013-0426-5; Pedron S, 2013, J BIOMED MATER RES A, V101, P3404, DOI 10.1002/jbm.a.34637; Peskin CS, 2002, ACT NUMERIC, V11, P479, DOI 10.1017/S0962492902000077; PESKIN CS, 1972, J COMPUT PHYS, V10, P252, DOI 10.1016/0021-9991(72)90065-4; Randles AP, 2013, INT PARALL DISTRIB P, P1063, DOI 10.1109/IPDPS.2013.109; Schachner ER, 2013, PEERJ, V1, DOI 10.7717/peerj.60; Scott GR, 2011, J EXP BIOL, V214, P2455, DOI 10.1242/jeb.052548; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Segur J. B., 1963, PHYS PROPERTIES GLYC; Shirahama H, 2016, SCI REP-UK, V6, DOI 10.1038/srep31036; Stevens KR, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah5505; Stevens LJ, 2015, CLIN PEDIATR, V54, P309, DOI 10.1177/0009922814530803; Stroock AD, 2002, SCIENCE, V295, P647, DOI 10.1126/science.1066238; Therriault D, 2003, NAT MATER, V2, P265, DOI 10.1038/nmat863; Theunissen R, 2007, MEAS SCI TECHNOL, V18, P275, DOI 10.1088/0957-0233/18/1/034; Tsang VL, 2007, FASEB J, V21, P790, DOI 10.1096/fj.06-7117com; Tumbleston JR, 2015, SCIENCE, V347, P1349, DOI 10.1126/science.aaa2397; WEAIRE D, 1994, PHIL MAG LETT, V69, P107, DOI 10.1080/09500839408241577; WEST JB, 1964, J APPL PHYSIOL, V19, P713, DOI 10.1152/jappl.1964.19.4.713; 2016, DOKL PHYS CHEM, V469, P121, DOI DOI 10.1134/S0012501616080030; 2013, J THROMB HAEMOST S1, V11, P46, DOI DOI 10.1111/JTH.12253; 2009, BIOMATERIALS, V30, P6702, DOI DOI 10.1016/J.BIOMATERIALS.2009.08.055; 2016, P NATL ACAD SCI USA, V113, P2206, DOI DOI 10.1073/PNAS.1524510113	71	596	616	87	948	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	2019	364	6439					458	+		10.1126/science.aav9750	http://dx.doi.org/10.1126/science.aav9750			46	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW6ON	31048486	Green Accepted, Green Submitted			2023-01-03	WOS:000466809600028
J	Berggren, KL; Cruz, SR; Hixon, MD; Cowan, AT; Keysar, SB; Craig, S; James, J; Barry, M; Ozbun, MA; Jimeno, A; McCance, DJ; Beswick, EJ; Gan, GN				Berggren, Kiersten L.; Cruz, Sebastian Restrepo; Hixon, Michael D.; Cowan, Andrew T.; Keysar, Stephen B.; Craig, Stephanie; James, Jacqueline; Barry, Marc; Ozbun, Michelle A.; Jimeno, Antonio; McCance, Dennis J.; Beswick, Ellen J.; Gan, Gregory N.			MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma	ONCOGENE			English	Article							HUMAN-PAPILLOMAVIRUS; ENDOTHELIAL-CELLS; NECROSIS-FACTOR; KINASE 2; CANCER; SMOKING; FIBROBLASTS; EXPRESSION; HSP27; IL-6	Radiation therapy (RT) is a cornerstone of treatment in the management of head and neck squamous cell carcinomas (HNSCC), yet treatment failure and disease recurrence are common. The p38/MK2 pathway is activated in response to cellular stressors, including radiation, and promotes tumor inflammation in a variety of cancers. We investigated MK2 pathway activation in HNSCC and the interaction of MK2 and RT in vitro and in vivo. We used a combination of an oropharyngeal SCC tissue microarray, HNSCC cell lines, and patient-derived xenograft (PDX) tumor models to study the effect of RT on MK2 pathway activation and to determine how inhibition of MK2 by pharmacologic (PF-3644022) and genetic (siRNA) methods impacts tumor growth. We show that high phosphorylated MK2 (p-MK2) levels are associated with worsened disease-specific survival in p16-negative HNSCC patients. RT increased p-MK2 in both p16-positive, HPV-positive and p16-negative, HPV-negative HNSCC cell lines. Pharmacologic inhibition or gene silencing of MK2 in vitro abrogated RT-induced increases in p-MK2; inflammatory cytokine expression and expression of the downstream MK2 target, heat shock protein 27 (HSP27); and markers of epithelial-to-mesenchymal transition. Mouse PDX models treated with a combination of RT and MK2 inhibitor experienced decreased tumor growth and increased survival. Our results suggest that MK2 is a potential prognostic biomarker for head and neck cancer and that MK2 pathway activation can mediate radiation resistance in HNSCC.	[Berggren, Kiersten L.; Cruz, Sebastian Restrepo; Hixon, Michael D.] Univ New Mexico, Dept Internal Med, Sect Radiat Oncol, Albuquerque, NM 87131 USA; [Berggren, Kiersten L.; Cruz, Sebastian Restrepo; Hixon, Michael D.] Univ New Mexico, Ctr Comprehens Canc, Canc Therapeut Program, Albuquerque, NM 87131 USA; [Cowan, Andrew T.] Univ New Mexico, Dept Surg, Div Otolaryngol, Albuquerque, NM 87131 USA; [Cowan, Andrew T.; Ozbun, Michelle A.] Univ New Mexico, Ctr Comprehens Canc, Canc Biol & Signaling Program, Albuquerque, NM 87131 USA; [Keysar, Stephen B.; Jimeno, Antonio] Univ Colorado Denver, Dept Med, Div Med Oncol, Aurora, CO USA; [Craig, Stephanie; James, Jacqueline] Queens Univ, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland; [Barry, Marc; McCance, Dennis J.] Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA; [Ozbun, Michelle A.] Univ New Mexico, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA; [Beswick, Ellen J.] Univ Utah, Dept Internal Med, Div Gastroenterol Hepataol & Nutr, Salt Lake City, UT 84112 USA; [Gan, Gregory N.] Univ Kansas, Med Ctr, Dept Radiat Oncol, Kansas City, KS 66103 USA	University of New Mexico; University of New Mexico; University of New Mexico; University of New Mexico; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Queens University Belfast; University of New Mexico; University of New Mexico; Utah System of Higher Education; University of Utah; University of Kansas; University of Kansas Medical Center	Gan, GN (corresponding author), Univ Kansas, Med Ctr, Dept Radiat Oncol, Kansas City, KS 66103 USA.	greg.gan@gmail.com	Ozbun, Michelle/AAN-2922-2021; Craig, Stephanie/AAX-2060-2020	Ozbun, Michelle/0000-0001-8551-4606; Craig, Stephanie/0000-0002-5476-751X; Gan, Gregory/0000-0001-5090-0064	RSNA Foundation Research Scholar Grant; ACS-IRG [IRG-14-187-19]; University of New Mexico School of Medicine; STI CRC [U19 AI 113187]; NIH P30 Grant NCI [P30CA118100]; Department of Pathology; University of New Mexico Comprehensive Cancer Center [NCI P30CA118100]; NCI [2P30 CA118100]; University of New Mexico Cancer Center Animal Shared Resource - NCI [2P30 CA118100]; NATIONAL CANCER INSTITUTE [R01CA207051, P30CA118100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI113187] Funding Source: NIH RePORTER	RSNA Foundation Research Scholar Grant; ACS-IRG(American Cancer Society); University of New Mexico School of Medicine; STI CRC; NIH P30 Grant NCI; Department of Pathology; University of New Mexico Comprehensive Cancer Center; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of New Mexico Cancer Center Animal Shared Resource - NCI; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Work supported in part by RSNA Foundation Research Scholar Grant, ACS-IRG (IRG-14-187-19), Dedicated Health Research Fund from the University of New Mexico School of Medicine (UNM RAC 2018), STI CRC (U19 AI 113187), and the NIH P30 Grant NCI P30CA118100. The research in this paper was supported by the Human Tissue Repository and Tissue Analysis Shared Resource, funded by the Department of Pathology and The University of New Mexico Comprehensive Cancer Center and NCI P30CA118100. Many of the images in this paper were generated in the University of New Mexico Cancer Center Fluorescence Microscopy Shared Resource with current funding from NCI 2P30 CA118100. Initial support with PDX generation was performed with the assistance from the University of New Mexico Cancer Center Animal Shared Resource funded by NCI 2P30 CA118100. We also wish to acknowledge UNM Cancer Center Biostatistics Core Facility for their statistical assistance.	An SS, 2005, AM J PHYSIOL-CELL PH, V289, pC521, DOI 10.1152/ajpcell.00429.2004; Argiris A, 2008, LANCET, V371, P1695, DOI 10.1016/S0140-6736(08)60728-X; Argiris A, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00072; Bae JY, 2014, NEOPLASIA, V16, P928, DOI 10.1016/j.neo.2014.09.003; Cheng JCH, 2014, ANN SURG ONCOL, V21, P2361, DOI 10.1245/s10434-014-3611-z; Duffy SA, 2008, CANCER-AM CANCER SOC, V113, P750, DOI 10.1002/cncr.23615; Gan GN, 2014, CANCER RES, V74, P7024, DOI 10.1158/0008-5472.CAN-14-1346; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Gorska MM, 2007, J EXP MED, V204, P1637, DOI 10.1084/jem.20062621; Gurgis FMS, 2015, ONCOGENE, V34, P2934, DOI 10.1038/onc.2014.225; Guttmann DM, 2013, INT J RADIAT ONCOL, V87, P168, DOI 10.1016/j.ijrobp.2013.05.028; Haigentz M, 2018, ADV THER, V35, P255, DOI 10.1007/s12325-018-0682-4; Jank BJ, 2019, EUR ARCH OTO-RHINO-L, V276, P1487, DOI 10.1007/s00405-019-05381-0; Jomrich G, 2018, J CANCER, V9, P460, DOI 10.7150/jca.22310; Keysar SB, 2013, MOL ONCOL, V7, P776, DOI 10.1016/j.molonc.2013.03.004; Keysar SB, 2013, CANCER RES, V73, P3381, DOI 10.1158/0008-5472.CAN-12-4047; Kim JY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22635-9; Klussmann JP, 2003, AM J PATHOL, V162, P747, DOI 10.1016/S0002-9440(10)63871-0; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kumar B, 2017, ONCOTARGET, V8, P14847, DOI 10.18632/oncotarget.14682; Leon X, 2015, ONCOTARGET, V6, P37407, DOI 10.18632/oncotarget.6054; Liskamp CP, 2016, HEAD NECK-J SCI SPEC, V38, P1780, DOI 10.1002/hed.24516; Liu TG, 2007, AM J RESP CELL MOL, V37, P507, DOI 10.1165/rcmb.2007-0077OC; Mirghani H, 2018, ORAL ONCOL, V82, P131, DOI 10.1016/j.oraloncology.2018.05.007; Morandell S, 2013, CELL REP, V5, P868, DOI 10.1016/j.celrep.2013.10.025; Munshi Anupama, 2013, Genes Cancer, V4, P401, DOI 10.1177/1947601913485414; Muschter D, 2018, CLIN ORAL INVEST, V22, P2251, DOI 10.1007/s00784-017-2323-8; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; Park KJ, 2003, J BIOL CHEM, V278, P35272, DOI 10.1074/jbc.M305095200; Pavan S, 2014, INT J CANCER, V134, P1289, DOI 10.1002/ijc.28464; Powrozek T, 2018, J CANCER RES CLIN, V144, P1423, DOI 10.1007/s00432-018-2679-4; Qin X, 2018, THERANOSTICS, V8, P921, DOI 10.7150/thno.22182; Ray AL, 2018, INT J CANCER, V142, P1702, DOI 10.1002/ijc.31191; Ray AL, 2016, INT J CANCER, V138, P770, DOI 10.1002/ijc.29716; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Schernberg A, 2019, HEAD NECK-J SCI SPEC, V41, P1441, DOI 10.1002/hed.25598; Seiwert TY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102112; Sharma RA, 2016, NAT REV CLIN ONCOL, V13, P627, DOI 10.1038/nrclinonc.2016.79; Shen BR, 2017, SCI REP-UK, V7, DOI 10.1038/srep46231; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Singh MK, 2017, J THERM BIOL, V69, P149, DOI 10.1016/j.jtherbio.2017.06.004; Singh RK, 2017, PHARMACOL REP, V69, P746, DOI 10.1016/j.pharep.2017.03.023; Stein AP, 2015, CANCER MED-US, V4, P699, DOI 10.1002/cam4.387; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Sumner WA, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1268-7; Thuraisingam T, 2010, J INVEST DERMATOL, V130, P278, DOI 10.1038/jid.2009.209; Tribius S, 2012, ORAL ONCOL, V48, P1178, DOI 10.1016/j.oraloncology.2012.05.022; Xu L, 2014, J MOL CELL CARDIOL, V77, P86, DOI 10.1016/j.yjmcc.2014.09.011; Yadav A, 2017, ONCOTARGET, V8, P66912, DOI 10.18632/oncotarget.11464; Yeung YT, 2012, J NEURO-ONCOL, V109, P35, DOI 10.1007/s11060-012-0875-7; Zheng GP, 2018, CLIN CANCER RES, V24, P1163, DOI 10.1158/1078-0432.CCR-17-2619	51	7	7	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2019	38	48					7329	7341		10.1038/s41388-019-0945-9	http://dx.doi.org/10.1038/s41388-019-0945-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JR4XX	31417185	Green Accepted			2023-01-03	WOS:000499631000004
J	Xu, CL; Wang, XR; Zhou, Y; Chen, FX; Wang, HW; Li, KN; Fan, HY; Tang, XM; Jiang, GJ; Zhang, J				Xu, Congling; Wang, Xinrui; Zhou, Yu; Chen, Fei Xavier; Wang, Haiwei; Li, Kening; Fan, Huiyong; Tang, Xiaomei; Jiang, Guojuan; Zhang, Ji			Synergy between arsenic trioxide and JQ1 on autophagy in pancreatic cancer	ONCOGENE			English	Article							CELL-DEATH; MEDIATED APOPTOSIS; UP-REGULATION; TUMOR-GROWTH; NRF2; P53; INHIBITION; ACTIVATION; SURVIVAL; BIOLOGY	Pancreatic cancer is a deadliest type of malignancy and lacks effective intervention. We here report a potential strategy for treatment of this malignancy by the combination of arsenic trioxide (ATO) and BET bromodomain inhibitor JQ1. These two agents synergistically modulate multistages of autophagy and thus induce apoptosis effectively in pancreatic cancer cells. Our genomic and biochemical data have demonstrated that crosstalks between ER stress and autophagy play crucial roles during ATO-induced apoptosis, in which NRF2 may stand at the crossroad between cell death and survival. This has been further strengthened by our finding that NRF2 depletion renders insensitive cells into sensitive ones in regard to ATO treatment-caused cell death. The knockdown of NRF2 and the addition of JQ1 result in similar molecular/cellular effects in promoting effective ATO-induced apoptosis in cells that are insensitive to ATO treatment alone. Thus, the combination of ATO and JQ1 may represent a new treatment strategy for pancreatic cancer.	[Xu, Congling; Wang, Xinrui; Li, Kening; Fan, Huiyong; Tang, Xiaomei; Jiang, Guojuan; Zhang, Ji] Shanghai Jiao Tong Univ, Rui Jin Hosp, Shanghai Inst Hematol, State Key Lab Med Genom,Sch Med, Shanghai, Peoples R China; [Xu, Congling; Chen, Fei Xavier] Fudan Univ, Sch Basic Med Sci, Dept Syst Biol Med, Key Lab Mol Med,Shanghai Med Coll,Minist Educ, Shanghai 200032, Peoples R China; [Zhou, Yu] Civil Aviat Hosp Shanghai, Dept Orthoped, Shanghai, Peoples R China; [Wang, Haiwei] Fujian Med Univ, Fujian Prov Matern & Childrens Hosp, Fujian Key Lab Prenatal Diag & Birth Defect, Affiliated Hosp, Fuzhou 350001, Fujian, Peoples R China	Chinese Academy of Sciences; Shanghai Jiao Tong University; Fudan University; Fujian Medical University	Zhang, J (corresponding author), Shanghai Jiao Tong Univ, Rui Jin Hosp, Shanghai Inst Hematol, State Key Lab Med Genom,Sch Med, Shanghai, Peoples R China.	Zj11222@rjh.com.cn	Wang, Xinrui/AAW-5405-2021	CHEN, FEI/0000-0002-7827-7988; Wang, Xinrui/0000-0002-7383-9128	National Natural Science Foundation [81370655]; Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University	This study is supported in part by the National Natural Science Foundation (no. 81370655), and by Distinguished Professorship (JZ) from Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University.	Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3; Antonucci L, 2015, P NATL ACAD SCI USA, V112, pE6166, DOI 10.1073/pnas.1519384112; Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137; Chen WM, 2009, MOL CELL, V34, P663, DOI 10.1016/j.molcel.2009.04.029; Cho HY, 2006, ANTIOXID REDOX SIGN, V8, P76, DOI 10.1089/ars.2006.8.76; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Du YZ, 2006, BLOOD, V107, P1582, DOI 10.1182/blood-2005-06-2318; Dunne RF, 2015, HEMATOL ONCOL CLIN N, V29, P595, DOI 10.1016/j.hoc.2015.04.003; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Garcia PL, 2016, ONCOGENE, V35, P833, DOI 10.1038/onc.2015.126; Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966; Ghaneh P, 2007, GUT, V56, P1134, DOI 10.1136/gut.2006.103333; Hayashi-Nishino M, 2009, NAT CELL BIOL, V11, P1433, DOI 10.1038/ncb1991; Hussong M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.157; Iacobuzio-Donahue CA, 2014, NEW ENGL J MED, V370, P1352, DOI 10.1056/NEJMcibr1400189; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kim J, 2013, CANCER CELL, V23, P23, DOI 10.1016/j.ccr.2012.11.017; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Ktistakis NT, 2016, TRENDS CELL BIOL, V26, P624, DOI 10.1016/j.tcb.2016.03.006; Kundu M, 2008, ANNU REV PATHOL-MECH, V3, P427, DOI 10.1146/annurev.pathmechdis.2.010506.091842; Langdon CG, 2017, MOL CANCER THER, V16, P1041, DOI 10.1158/1535-7163.MCT-16-0794; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Martina JA, 2016, EMBO J, V35, P479, DOI 10.15252/embj.201593428; Martina JA, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004754; Mazur PK, 2015, NAT MED, V21, P1163, DOI 10.1038/nm.3952; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Newman RA, 2007, INTEGR CANCER THER, V6, P354, DOI 10.1177/1534735407309623; Pietrocola F, 2013, SEMIN CANCER BIOL, V23, P310, DOI 10.1016/j.semcancer.2013.05.008; Piya S, 2017, AUTOPHAGY, V13, P214, DOI 10.1080/15548627.2016.1245263; Qian WB, 2007, LEUKEMIA RES, V31, P329, DOI 10.1016/j.leukres.2006.06.021; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Sakamaki JI, 2017, MOL CELL, V66, P517, DOI 10.1016/j.molcel.2017.04.027; Shah P, 2017, MOLECULES, V22, DOI 10.3390/molecules22020194; Sun H. D., 1992, CHIN J INTEGRAT CHIN, V12, P170; Sun XF, 2016, HEPATOLOGY, V63, P173, DOI 10.1002/hep.28251; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Wakabayashi N, 2010, ANTIOXID REDOX SIGN, V13, P1649, DOI 10.1089/ars.2010.3216; Wang KK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007538; Wen X, 2017, AUTOPHAGY, V13, P1801, DOI 10.1080/15548627.2017.1364334; Xia Y, 2013, EXP BIOL MED, V238, P932, DOI 10.1177/1535370213492689; Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Zhang T. D., 1973, HEILONGJIANG MED J, P66; Zhang YX, 2011, ANTIOXID REDOX SIGN, V15, P2867, DOI 10.1089/ars.2010.3685	53	14	15	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2019	38	47					7249	7265		10.1038/s41388-019-0930-3	http://dx.doi.org/10.1038/s41388-019-0930-3			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP0UL	31420604				2023-01-03	WOS:000497989400005
J	Wu, JY; Huang, QY; Li, PL; Wang, YX; Zheng, CH; Lei, XH; Li, ST; Gong, WQ; Yin, BH; Luo, CW; Xiao, J; Zhou, WD; Xu, ZZ; Chen, YH; Peng, FF; Long, HB				Wu, Jiayu; Huang, Qianyin; Li, Peilin; Wang, Yuxian; Zheng, Chenghao; Lei, Xianghong; Li, Shuting; Gong, Wangqiu; Yin, Bohui; Luo, Congwei; Xiao, Jing; Zhou, Weidong; Xu, Zhaozhong; Chen, Yihua; Peng, Fenfen; Long, Haibo			MicroRNA-145 promotes the epithelial-mesenchymal transition in peritoneal dialysis-associated fibrosis by suppressing fibroblast growth factor 10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						fibrosis; microRNA (miRNA); mRNA; translation regulation; epithelial-mesenchymal transition (EMT); fibroblast growth factor 10 (FGF10); peritoneal dialysis (PD); kidney disease; renal replacement therapy	MESOTHELIAL CELLS; RENAL FIBROSIS; PROGRESSION; ACTIVATION; TGF-BETA-1; DIFFERENTIATION; EXPRESSION; MEMBRANE; EXPOSURE; STRESS	Peritoneal fibrosis is a common complication of long-term peritoneal dialysis (PD) and the principal cause of ultrafiltration failure during PD. The initial and reversible step in PD-associated peritoneal fibrosis is the epithelial-mesenchymal transition (EMT). Although the mechanisms in the EMT have been the focus of many studies, only limited information is currently available concerning microRNA (miRNA) regulation in peritoneal fibrosis. In this study, we aimed to characterize the roles of microRNA-145 (miR-145) and fibroblast growth factor 10 (FGF10) in peritoneal fibrosis. After inducing EMT with transforming growth factor-?1 (TGF-?1) in vitro, we found that miR-145 is significantly up-regulated, whereas FGF10 is markedly down-regulated, suggesting a close link between miR-145 and FGF10 in peritoneal fibrosis, further confirmed in luciferase reporter experiments. Furthermore, in human peritoneal mesothelial cells (i.e. HMrSV5 cells), miR-145 mimics induced EMT, whereas miR-145 inhibition suppressed EMT, and we also observed that miR-145 suppressed FGF10 expression. In vivo, we found that the exogenous delivery of an miR-145 expression plasmid both blocked FGF10 and intensified the EMT, whereas miR-145 inhibition promoted the expression of FGF10 and reversed the EMT. In conclusion, miR-145 promotes the EMT during the development of peritoneal fibrosis by suppressing FGF10 activity, suggesting that miR-145 represents a potential therapeutic target for managing peritoneal fibrosis.	[Wu, Jiayu; Huang, Qianyin; Li, Peilin; Lei, Xianghong; Li, Shuting; Gong, Wangqiu; Yin, Bohui; Luo, Congwei; Xiao, Jing; Zhou, Weidong; Chen, Yihua; Peng, Fenfen; Long, Haibo] Southern Med Univ, Zhujiang Hosp, Dept Nephrol, Guangzhou 510280, Guangdong, Peoples R China; [Wang, Yuxian] Southern Med Univ, Zhujiang Hosp, Dept Gerontol, Guangzhou 510280, Guangdong, Peoples R China; [Xu, Zhaozhong] Southern Med Univ, Zhujiang Hosp, Dept Emergency, Guangzhou 510280, Guangdong, Peoples R China; [Zheng, Chenghao] Southern Med Univ, Clin Med Sch 2, Guangzhou 510280, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China	Chen, YH; Peng, FF; Long, HB (corresponding author), Southern Med Univ, Zhujiang Hosp, Dept Nephrol, Guangzhou 510280, Guangdong, Peoples R China.	13724005373@163.com; doctorpff@163.com; longhb1966@163.com			National Natural Science Foundation of China (NSFC) [81673792, 81600624, 81704134, 81873346, U1801288]; Natural Science Foundation of Guangdong Province, China [2017A030313708, 2014A030310065]; Science and Technology Planning Project of Guangdong Province, China [2014A020210011, 2015A020211012, 2017A020215158]; Science and Technology Planning Project of Guangzhou, China [201510010137, 201707010286]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province, China(National Natural Science Foundation of Guangdong Province); Science and Technology Planning Project of Guangdong Province, China; Science and Technology Planning Project of Guangzhou, China	This work was supported by the National Natural Science Foundation of China (NSFC) Grants 81673792, 81600624, 81704134, 81873346, and U1801288; Natural Science Foundation of Guangdong Province, China, Grants 2017A030313708 and 2014A030310065; Science and Technology Planning Project of Guangdong Province, China, Grants 2014A020210011, 2015A020211012, and 2017A020215158; and Science and Technology Planning Project of Guangzhou, China, Grants 201510010137 and 201707010286. The authors declare that they have no conflicts of interest with the contents of this article.	Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Chang HY, 2002, P NATL ACAD SCI USA, V99, P12877, DOI 10.1073/pnas.162488599; Che MW, 2017, J AM SOC NEPHROL, V28, P2459, DOI 10.1681/ASN.2016060663; Correll KA, 2018, PHYSIOL REP, V6, DOI 10.14814/phy2.13794; del Peso G, 2008, KIDNEY INT, V73, pS26, DOI 10.1038/sj.ki.5002598; Dhanakijcharoen Prateep, 2011, J Med Assoc Thai, V94 Suppl 4, pS153; Emoto H, 1997, J BIOL CHEM, V272, P23191, DOI 10.1074/jbc.272.37.23191; Gupte VV, 2009, AM J RESP CRIT CARE, V180, P424, DOI 10.1164/rccm.200811-1794OC; Itoh N, 2016, CYTOKINE GROWTH F R, V28, P63, DOI 10.1016/j.cytogfr.2015.10.001; Kabir FL, 2018, AM J RESP CRIT CARE, V197, P632, DOI 10.1164/rccm.201704-0732OC; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kokoroishi K, 2016, CLIN EXP NEPHROL, V20, P30, DOI 10.1007/s10157-015-1128-9; Li D, 2018, J CELL MOL MED, V22, P3452, DOI 10.1111/jcmm.13622; Liu H, 2014, CELL MOL BIOL LETT, V19, P315, DOI 10.2478/s11658-014-0199-z; Liu Y, 2015, PERITON DIALYSIS INT, V35, P14, DOI 10.3747/pdi.2014.00188; Lopez-Cabrera M, 2014, ADV MED, V2014; Ma YL, 2018, INT J MOL MED, V41, P1030, DOI 10.3892/ijmm.2017.3268; Margetts PJ, 2003, PERITON DIALYSIS INT, V23, P530; Men RT, 2017, SCI REP-UK, V7, DOI 10.1038/srep40468; Mutsaers SE, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00113; Ornitz DM, 2015, WIRES DEV BIOL, V4, P215, DOI 10.1002/wdev.176; Patel P, 2010, KIDNEY INT, V77, P319, DOI 10.1038/ki.2009.436; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Rivara MB, 2014, CURR OPIN NEPHROL HY, V23, P586, DOI 10.1097/MNH.0000000000000066; Rougier JP, 1997, KIDNEY INT, V51, P337, DOI 10.1038/ki.1997.42; Selgas R, 2006, NEPHROL DIAL TRANSPL, V21, DOI 10.1093/ndt/gfl183; Shang J, 2019, J CELL PHYSIOL, V234, P9746, DOI 10.1002/jcp.27660; Shin HS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05836-6; Shin HS, 2015, LAB INVEST, V95, P1157, DOI 10.1038/labinvest.2015.91; Shirakihara T, 2011, EMBO J, V30, P783, DOI 10.1038/emboj.2010.351; Skrypek N, 2018, EPIGENET CHROMATIN, V11, DOI 10.1186/s13072-018-0239-4; Stein JA, 2003, NEW ENGL J MED, V348, P2037; Strippoli R, 2015, EMBO MOL MED, V7, P102, DOI 10.15252/emmm.201404127; Sun WL, 2018, TOXICOL LETT, V282, P37, DOI 10.1016/j.toxlet.2017.09.009; Tulchinsky E, 2019, BBA-REV CANCER, V1871, P29, DOI 10.1016/j.bbcan.2018.10.003; Vargha R, 2008, NEPHROL DIAL TRANSPL, V23, P3494, DOI 10.1093/ndt/gfn353; Wang L, 2016, J AM SOC NEPHROL, V27, P2631, DOI 10.1681/ASN.2015030299; Watson J, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00500; Williams JD, 2002, J AM SOC NEPHROL, V13, P470, DOI 10.1681/ASN.V132470; Xiao L, 2015, LAB INVEST, V95, P817, DOI 10.1038/labinvest.2015.57; Yanez-Mo M, 2003, NEW ENGL J MED, V348, P403, DOI 10.1056/NEJMoa020809; Yang SZ, 2013, FASEB J, V27, P2382, DOI 10.1096/fj.12-219493; Yao LP, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1053-4; Yu JW, 2014, LAB INVEST, V94, P978, DOI 10.1038/labinvest.2014.91; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhao S, 2019, ECOTOX ENVIRON SAFE, V169, P266, DOI 10.1016/j.ecoenv.2018.10.073; Zhou DD, 2016, MOL IMMUNOL, V75, P151, DOI 10.1016/j.molimm.2016.05.018; Zhou Q, 2013, AM J PATHOL, V183, P808, DOI 10.1016/j.ajpath.2013.05.019	49	12	14	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2019	294	41					15052	15067		10.1074/jbc.RA119.007404	http://dx.doi.org/10.1074/jbc.RA119.007404			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JQ9JH	31431501	hybrid, Green Published			2023-01-03	WOS:000499253400018
J	Totsch, SK; Schlappi, C; Kang, KD; Ishizuka, AS; Lynn, GM; Fox, B; Beierle, EA; Whitley, RJ; Markert, JM; Gillespie, GY; Bernstock, JD; Friedman, GK				Totsch, Stacie K.; Schlappi, Charles; Kang, Kyung-Don; Ishizuka, Andrew S.; Lynn, Geoffrey M.; Fox, Brandon; Beierle, Elizabeth A.; Whitley, Richard J.; Markert, James M.; Gillespie, G. Yancey; Bernstock, Joshua D.; Friedman, Gregory K.			Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance	ONCOGENE			English	Review							INTRATUMORAL INJECTION; VIRAL REPLICATION; MALIGNANT GLIOMA; EXPRESSING IL-12; CANCER VACCINES; CLINICAL-TRIAL; ENTER CELLS; GLIOBLASTOMA; HSV-1; G207	Malignant tumors of the central nervous system (CNS) continue to be a leading cause of cancer-related mortality in both children and adults. Traditional therapies for malignant brain tumors consist of surgical resection and adjuvant chemoradiation; such approaches are often associated with extreme morbidity. Accordingly, novel, targeted therapeutics for neoplasms of the CNS, such as immunotherapy with oncolytic engineered herpes simplex virus (HSV) therapy, are urgently warranted. Herein, we discuss treatment challenges related to HSV virotherapy delivery, entry, replication, and spread, and in so doing focus on host anti-viral immune responses and the immune microenvironment. Strategies to overcome such challenges including viral re-engineering, modulation of the immunoregulatory microenvironment and combinatorial therapies with virotherapy, such as checkpoint inhibitors, radiation, and vaccination, are also examined in detail.	[Totsch, Stacie K.; Schlappi, Charles; Kang, Kyung-Don; Friedman, Gregory K.] Univ Alabama Birmingham, Dept Pediat, Div Pediat Hematol & Oncol, Birmingham, AL 35294 USA; [Ishizuka, Andrew S.; Lynn, Geoffrey M.; Bernstock, Joshua D.] Avidea Technol Inc, Baltimore, MD 21205 USA; [Fox, Brandon; Bernstock, Joshua D.] Univ Alabama Birmingham, Med Scientist Training Program, Birmingham, AL 35294 USA; [Beierle, Elizabeth A.; Friedman, Gregory K.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA; [Whitley, Richard J.] Univ Alabama Birmingham, Div Pediat Infect Dis, Dept Pediat, Birmingham, AL USA; [Markert, James M.; Gillespie, G. Yancey; Friedman, Gregory K.] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35294 USA; [Bernstock, Joshua D.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Friedman, GK (corresponding author), Univ Alabama Birmingham, Dept Pediat, Div Pediat Hematol & Oncol, Birmingham, AL 35294 USA.; Bernstock, JD (corresponding author), Avidea Technol Inc, Baltimore, MD 21205 USA.; Bernstock, JD (corresponding author), Univ Alabama Birmingham, Med Scientist Training Program, Birmingham, AL 35294 USA.; Friedman, GK (corresponding author), Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA.; Friedman, GK (corresponding author), Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35294 USA.; Bernstock, JD (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.	jdb82@uab.edu; gfriedman@peds.uab.edu		Fox, Brandon/0000-0003-2242-2477; Gillespie, George/0000-0001-6436-9542; Ishizuka, Andrew/0000-0002-3024-7536; Bernstock, Joshua/0000-0002-7814-3867; Friedman, Gregory/0000-0002-6653-7420	Food and Drug Administration Office of Orphan Products Development [R01FD005379]; Department of Defense [W81XWH-15-1-0108]; Rally Foundation for Childhood Cancer Research; Hyundai Hope on Wheels; Kaul Pediatric Research Institute; UAB Medical Scientist Training Program (MSTP); American Brain Tumor Association; National Cancer Institute of the National Institutes of Health [T32CA183926];  [R01CA217179]; FOOD AND DRUG ADMINISTRATION [R01FD005379] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA217179, T32CA183926] Funding Source: NIH RePORTER	Food and Drug Administration Office of Orphan Products Development; Department of Defense(United States Department of Defense); Rally Foundation for Childhood Cancer Research; Hyundai Hope on Wheels; Kaul Pediatric Research Institute; UAB Medical Scientist Training Program (MSTP); American Brain Tumor Association; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; FOOD AND DRUG ADMINISTRATION(United States Department of Health & Human Services); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported in part by grants from the Food and Drug Administration Office of Orphan Products Development (R01FD005379), the Department of Defense (W81XWH-15-1-0108) Rally Foundation for Childhood Cancer Research, Hyundai Hope on Wheels, and the Kaul Pediatric Research Institute to GKF and R01CA217179 to JMM and GYG. JDB was supported by the UAB Medical Scientist Training Program (MSTP) and an American Brain Tumor Association summer fellowship. SKT was supported by the National Cancer Institute of the National Institutes of Health under Award Number T32CA183926. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the U.S. FDA or the Department of Defense. The authors apologize to colleagues we couldn't cite given limitations on the number of references.	Aghi MK, 2009, MOL THER, V17, P51, DOI 10.1038/mt.2008.232; Aldape K, 2019, NAT REV CLIN ONCOL, V16, P509, DOI 10.1038/s41571-019-0177-5; Alvarez-Breckenridge CA, 2012, NAT MED, V18, P1827, DOI 10.1038/nm.3013; Alvarez-Breckenridge CA, 2012, J VIROL, V86, P4566, DOI 10.1128/JVI.05545-11; Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377; Banchereau J, 2018, NAT REV CLIN ONCOL, V15, P9, DOI 10.1038/nrclinonc.2017.149; Bernstock JD, 2019, WORLD NEUROSURG, V122, pE1592, DOI 10.1016/j.wneu.2018.11.122; Bookstaver ML, 2018, TRENDS IMMUNOL, V39, P135, DOI 10.1016/j.it.2017.10.002; Bradley JD, 1999, CLIN CANCER RES, V5, P1517; Brencicova E, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00037; Cassady KA, 2005, J VIROL, V79, P8707, DOI 10.1128/JVI.79.14.8707-8715.2005; Cheema TA, 2013, P NATL ACAD SCI USA, V110, P12006, DOI 10.1073/pnas.1307935110; Chesney J, 2018, J CLIN ONCOL, V36, P1658, DOI 10.1200/JCO.2017.73.7379; Currier MA, 2013, MOL THER, V21, P1014, DOI 10.1038/mt.2013.39; Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405; Dmitrieva N, 2011, CLIN CANCER RES, V17, P1362, DOI 10.1158/1078-0432.CCR-10-2213; Draper SJ, 2010, NAT REV MICROBIOL, V8, P62, DOI 10.1038/nrmicro2240; Evans SM, 2004, CLIN CANCER RES, V10, P8177, DOI 10.1158/1078-0432.CCR-04-1081; Facciabene A, 2012, CANCER RES, V72, P2162, DOI 10.1158/0008-5472.CAN-11-3687; Filley AC, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00106; Flingai S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00354; Foreman PM, 2017, NEUROTHERAPEUTICS, V14, P333, DOI 10.1007/s13311-017-0516-0; Friedman GK, 2015, GENE THER, V22, P348, DOI 10.1038/gt.2014.107; Friedman GK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32353-x; Friedman GK, 2012, TRANSL ONCOL, V5, P200, DOI 10.1593/tlo.12115; Friedman GK, 2009, MOL THER, V17, P1125, DOI 10.1038/mt.2009.73; Fukuhara H, 2016, CANCER SCI, V107, P1373, DOI 10.1111/cas.13027; Fulci G, 2007, CANCER RES, V67, P9398, DOI 10.1158/0008-5472.CAN-07-1063; Fulci G, 2006, P NATL ACAD SCI USA, V103, P12873, DOI 10.1073/pnas.0605496103; Ghonime MG, 2018, TRANSL ONCOL, V11, P86, DOI 10.1016/j.tranon.2017.10.005; Guo CQ, 2013, ADV CANCER RES, V119, P421, DOI 10.1016/B978-0-12-407190-2.00007-1; Han JF, 2015, CANCER RES, V75, P5273, DOI 10.1158/0008-5472.CAN-15-0894; Hardcastle J, 2010, MOL THER, V18, P285, DOI 10.1038/mt.2009.232; Harrow S, 2004, GENE THER, V11, P1648, DOI 10.1038/sj.gt.3302289; Herrera FG, 2017, CA-CANCER J CLIN, V67, P65, DOI 10.3322/caac.21358; Jackson JD, 2014, GENE THER, V21, P984, DOI 10.1038/gt.2014.72; Kambara H, 2005, CANCER RES, V65, P2832, DOI 10.1158/0008-5472.CAN-04-3227; Kamiyama H, 2006, GENE THER, V13, P621, DOI 10.1038/sj.gt.3302685; Kanai R, 2006, GENE THER, V13, P106, DOI 10.1038/sj.gt.3302636; Kaur B, 2009, CURR GENE THER, V9, P341, DOI 10.2174/156652309789753329; Kesari S, 1998, J GEN VIROL, V79, P525, DOI 10.1099/0022-1317-79-3-525; Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300; Krull KR, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2017.76.4696; Laquerre S, 1998, J VIROL, V72, P9683, DOI 10.1128/JVI.72.12.9683-9697.1998; Leddon JL, 2015, MOL THER-ONCOLYTICS, V2, DOI 10.1038/mto.2014.10; Leoni V, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007209; Liu R, 2005, GENE THER, V12, P647, DOI 10.1038/sj.gt.3302445; Liu ZQ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14754; Longo SL, 2011, CANCER GENE THER, V18, P123, DOI 10.1038/cgt.2010.62; Lynn GM, 2015, NAT BIOTECHNOL, V33, P1201, DOI 10.1038/nbt.3371; Markert JM, 2014, MOL THER, V22, P1048, DOI 10.1038/mt.2014.22; Markert JM, 2012, J VIROL, V86, P5304, DOI 10.1128/JVI.06998-11; Markert JM, 2009, MOL THER, V17, P199, DOI 10.1038/mt.2008.228; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; Maroun J, 2017, FUTURE VIROL, V12, P193, DOI 10.2217/fvl-2016-0129; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; Menotti L, 2008, J VIROL, V82, P10153, DOI 10.1128/JVI.01133-08; Miest TS, 2014, NAT REV MICROBIOL, V12, P23, DOI 10.1038/nrmicro3140; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Mitchell BM, 1996, J IMMUNOL, V156, P246; MITTNACHT S, 1988, VIROLOGY, V164, P201, DOI 10.1016/0042-6822(88)90637-X; Nakashima H, 2018, CLIN CANCER RES, V24, P2574, DOI 10.1158/1078-0432.CCR-17-2954; Nakashima H, 2015, J CLIN INVEST, V125, P4269, DOI 10.1172/JCI80713; Okemoto K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071932; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223; Papanastassiou V, 2002, GENE THER, V9, P398, DOI 10.1038/sj.gt.3301664; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Parker JN, 2000, P NATL ACAD SCI USA, V97, P2208, DOI 10.1073/pnas.040557897; Passaro C, 2019, CLIN CANCER RES, V25, P290, DOI 10.1158/1078-0432.CCR-18-2311; Patel DM, 2016, HUM GENE THER CL DEV, V27, P69, DOI 10.1089/humc.2016.031; POND SM, 1984, CLIN PHARMACOKINET, V9, P1, DOI 10.2165/00003088-198409010-00001; Pulluri B, 2017, PHARMACOL RES, V123, P95, DOI 10.1016/j.phrs.2017.07.006; Rampling R, 2000, GENE THER, V7, P859, DOI 10.1038/sj.gt.3301184; Rasmussen SB, 2007, J VIROL, V81, P13315, DOI 10.1128/JVI.01167-07; Ricklefs FL, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar2766; Ring EK, 2017, MOL THER-ONCOLYTICS, V7, P27, DOI 10.1016/j.omto.2017.09.003; Ring EK, 2017, CLIN CANCER RES, V23, P342, DOI 10.1158/1078-0432.CCR-16-1829; Roizman B, 1996, P NATL ACAD SCI USA, V93, P11307, DOI 10.1073/pnas.93.21.11307; Saha D, 2018, CLIN CANCER RES, V24, P3409, DOI 10.1158/1078-0432.CCR-17-1717; Saha D, 2017, CANCER CELL, V32, P253, DOI 10.1016/j.ccell.2017.07.006; Sarkaria JN, 2018, NEURO-ONCOLOGY, V20, P184, DOI 10.1093/neuonc/nox175; Shah AC, 2003, J NEURO-ONCOL, V65, P203, DOI 10.1023/B:NEON.0000003651.97832.6c; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Spear PG, 2004, CELL MICROBIOL, V6, P401, DOI 10.1111/j.1462-5822.2004.00389.x; Streby KA, 2017, CLIN CANCER RES, V23, P3566, DOI 10.1158/1078-0432.CCR-16-2900; Stronen E, 2016, SCIENCE, V352, P1337, DOI 10.1126/science.aaf2288; Sundaresan P, 2000, J VIROL, V74, P3832, DOI 10.1128/JVI.74.8.3832-3841.2000; Suschak JJ, 2017, HUM VACC IMMUNOTHER, V13, P2837, DOI 10.1080/21645515.2017.1330236; Tanaka T, 1997, NAT MED, V3, P437, DOI 10.1038/nm0497-437; Thorne AH, 2014, MOL THER, V22, P1678, DOI 10.1038/mt.2014.101; Trybala E, 2000, J VIROL, V74, P9106, DOI 10.1128/JVI.74.19.9106-9114.2000; Uchida H, 2013, MOL THER, V21, P561, DOI 10.1038/mt.2012.211; Wakimoto H, 2009, CANCER RES, V69, P3472, DOI 10.1158/0008-5472.CAN-08-3886; Wang PY, 2016, GENE THER, V23, P135, DOI 10.1038/gt.2015.105; Waters AM, 2017, HUM GENE THER CL DEV, V28, P7, DOI 10.1089/humc.2017.002; Yarchoan M, 2017, NAT REV CANCER, V17, DOI 10.1038/nrc.2017.74; Zhai LJ, 2018, CELL MOL IMMUNOL, V15, P447, DOI 10.1038/cmi.2017.143; Zhou GY, 2006, P NATL ACAD SCI USA, V103, P5508, DOI 10.1073/pnas.0601258103; Zhou GY, 2003, J VIROL, V77, P3759, DOI 10.1128/JVI.77.6.3759-3767.2003; Zhu H, 2007, CANCER BIOL THER, V6, P724, DOI 10.4161/cbt.6.5.3953	100	33	35	0	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2019	38	34					6159	6171		10.1038/s41388-019-0870-y	http://dx.doi.org/10.1038/s41388-019-0870-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IS5RM	31289361	Green Accepted			2023-01-03	WOS:000482210100001
J	Teychenne, M; Lamb, KE; Main, L; Miller, C; Hahne, A; Ford, J; Rosenbaum, S; Belavy, D				Teychenne, Megan; Lamb, Karen E.; Main, Luana; Miller, Clint; Hahne, Andrew; Ford, Jon; Rosenbaum, Simon; Belavy, Daniel			General strength and conditioning versus motor control with manual therapy for improving depressive symptoms in chronic low back pain: A randomised feasibility trial	PLOS ONE			English	Article							TREATMENT PROTOCOL; PHYSICAL-ACTIVITY; EXERCISE; OLDER; CLASSIFICATION; DISORDERS; QUALITY; ADULTS; WOMEN	Objectives Exercise can be used as a treatment for depressive symptoms in the general population. However, little is known as to whether exercise has mental health benefits for adults experiencing chronic low back pain (CLBP). The aim of this study was to examine the feasibility of two intervention protocols commonly used in clinical practice for treating chronic low back pain, but with differing exercise dose, on depressive symptoms. Methods Forty men and women (mean age = 35) experiencing chronic persistent (>3 months), nonspecific low back pain were recruited into a randomised clinical trial during 2015-2016. Participants were randomised to receive motor control (low-dose exercise) and manual therapy (n = 20), or general strength and conditioning training (moderate-dose exercise) (n = 20). Depressive symptoms were assessed fortnightly throughout a 6-month follow-up period using the Centre for Epidemiologic Studies Depression Scale (CES-D 10). Linear mixed models were used to examine within-group and between-group changes in depressive symptoms. Results Mean CES-D 10 score at baseline was 9.17 (SD = 4.32). There was evidence of a small decrease in average depressive symptoms over time (beta -0.19 per fortnight, 95% CI = -0.34, -0.02). However, there was no evidence that change over time was dependent on treatment group Conclusions Reduction in depressive symptoms amongst adults with CLBP occurred with both treatment methods (motor control [low-dose exercise] and manual therapy; or general strength and conditioning [moderate-dose exercise]). Further interventions including a true control group are needed to draw conclusions as to the effectiveness of each of these treatment methods on depressive symptoms amongst adults with CLBP.	[Teychenne, Megan; Lamb, Karen E.; Main, Luana; Belavy, Daniel] Deakin Univ, IPAN, Sch Exercise & Nutr Sci, Geelong, Vic, Australia; [Lamb, Karen E.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Lamb, Karen E.] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia; [Miller, Clint] Deakin Univ, Sch Exercise & Nutr Sci, Geelong, Vic, Australia; [Hahne, Andrew; Ford, Jon] La Trobe Univ, Melbourne, Vic, Australia; [Rosenbaum, Simon] Univ New South Wales, Sch Psychiat, Sydney, NSW, Australia; [Rosenbaum, Simon] Black Dog Inst, Sydney, NSW, Australia	Deakin University; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; Deakin University; La Trobe University; University of New South Wales Sydney; Black Dog Institute	Teychenne, M (corresponding author), Deakin Univ, IPAN, Sch Exercise & Nutr Sci, Geelong, Vic, Australia.	mteych@deakin.edu.au	Hahne, Andrew/AAK-5728-2021; Belavy, Daniel/P-4947-2016; Main, L.C./L-2359-2015	Belavy, Daniel/0000-0002-9307-832X; Main, L.C./0000-0002-9576-9466; Miller, Clint/0000-0001-7743-6986; Ford, Jon/0000-0001-5524-190X; Rosenbaum, Simon/0000-0002-8984-4941	Deakin University School of Exercise and Nutrition Sciences	Deakin University School of Exercise and Nutrition Sciences	This study was supported by internal institutional funding (Deakin University School of Exercise and Nutrition Sciences. ID number: Belavy 2014-2017) to DB. The funder played no role in the study design, data collection, analysis, decision to publish or prepare the manuscript.	Ahn C., 2015, SAMPLE SIZE CALCULAT; ANDRESEN EM, 1994, AM J PREV MED, V10, P77, DOI 10.1016/S0749-3797(18)30622-6; Ashworth NL, 2005, HOME VERSUS CTR BASE, V1; Bair MJ, 2003, ARCH INTERN MED, V163, P2433, DOI 10.1001/archinte.163.20.2433; Coulter ID, 2018, SPINE J, V18, P866, DOI 10.1016/j.spinee.2018.01.013; Dhar AK, 2016, FRONT PSYCHIATRY, V7, DOI 10.3389/fpsyt.2016.00033; Dishman RK, 1997, MED SCI SPORT EXER, V29, P63, DOI 10.1097/00005768-199701000-00010; Focht BC, 2004, J BEHAV MED, V27, P101, DOI 10.1023/B:JOBM.0000019847.80315.4d; Ford JJ, 2012, PHYS THER REV, V17, P55, DOI 10.1179/1743288X11Y.0000000037; Ford JJ, 2011, PHYS THER REV, V16, P168, DOI 10.1179/1743288X11Y.0000000005; Gordon BR, 2018, JAMA PSYCHIAT, V75, P566, DOI 10.1001/jamapsychiatry.2018.0572; Gorman J M, 1996, Depress Anxiety, V4, P160, DOI 10.1002/(SICI)1520-6394(1996)4:4<160::AID-DA2>3.0.CO;2-J; Gowans SE, 2004, ARTHRIT RHEUM-ARTHR, V51, P890, DOI 10.1002/art.20828; Hallgren M, 2016, FRONT PSYCHIATRY, V7, DOI 10.3389/fpsyt.2016.00036; Hoffman Martin D, 2007, Curr Pain Headache Rep, V11, P93; Laske C, 2010, INT J NEUROPSYCHOPH, V13, P595, DOI 10.1017/S1461145709991234; Maitland GD., 1987, CLIN PHYS THER, V13, P135; Mammen G, 2013, AM J PREV MED, V45, P649, DOI 10.1016/j.amepre.2013.08.001; Miller AH, 2009, BIOL PSYCHIAT, V65, P732, DOI 10.1016/j.biopsych.2008.11.029; Pinheiro MB, 2015, ARTHRIT CARE RES, V67, P1591, DOI 10.1002/acr.22619; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Richardson C A, 1995, Man Ther, V1, P2, DOI 10.1054/math.1995.0243; Schuch FB, 2018, AM J PSYCHIAT, V175, P631, DOI 10.1176/appi.ajp.2018.17111194; Schuch FB, 2016, J PSYCHIATR RES, V77, P42, DOI 10.1016/j.jpsychires.2016.02.023; Sculco A D, 2001, Spine J, V1, P95, DOI 10.1016/S1529-9430(01)00026-2; Simson KJ, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1913-8; Sivertsen H, 2015, DEMENT GERIATR COGN, V40, P311, DOI 10.1159/000437299; SULLIVAN MJL, 1992, PAIN, V50, P5, DOI 10.1016/0304-3959(92)90107-M; Teychenne M, 2017, PREV MED, V102, P72, DOI 10.1016/j.ypmed.2017.07.005; Espi-Lopez GV, 2016, INT J OSTEOPATH MED, V22, P11, DOI 10.1016/j.ijosm.2016.05.003; Wang PS, 2004, AM J PSYCHIAT, V161, P1885, DOI 10.1176/appi.ajp.161.10.1885; World Confederation for Physical Therapy, 2018, PROM INT EXC UN CLIN; World Health Organization, 2017, DEPRESSION OTHER COM; Zhang YQ, 2017, J CLIN EPIDEMIOL, V88, P67, DOI 10.1016/j.jclinepi.2017.05.016	34	6	7	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2019	14	8							e0220442	10.1371/journal.pone.0220442	http://dx.doi.org/10.1371/journal.pone.0220442			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4ZH	31369613	Green Published, gold			2023-01-03	WOS:000484987900047
J	Martinez, AC; Lima, AOD; Terol, JMM; Garcia, OJM; Rodriguez, CR; Mochon, LG; de la Nuez, PC; Fosalba, NA				Caro Martinez, Araceli; de Labry Lima, Antonio Olry; Munoz Terol, Jose Manuel; Mendoza Garcia, Oscar Javier; Remon Rodriguez, Cesar; Garcia Mochon, Leticia; Castro de la Nuez, Pablo; Areste Fosalba, Nuria			Optimal start in dialysis shows increased survival in patients with chronic kidney disease	PLOS ONE			English	Article							IMPACT; INITIATION; CARE	Objective To compare the survival among patients with chronic kidney disease who had optimal starts of renal replacement therapy, dialysis or hemodialysis, with patients who had suboptimal starts. Methods A retrospective cohort consisting of > 18 year-old patients who started renal replacement therapy, using peritoneal dialysis or hemodialysis, in any public hospital or associated center of the Andalusian Public Health System, between the 1st of January of 2006 and the 15th of March of 2017. The optimal start was defined when all the following criteria were met: a planned dialysis start, a minimum of six-month follow-up by a nephrologist, and a first dialysis method coinciding with the one registered at 90 days. The information was obtained from the registry of the Information System of the Transplant Autonomic Coordination of Andalusia. Results A total of 10,692 patients were studied. 4,377 (40.9%) of these patients died. A total of 4,937 patients (46.17%) achieved optimal starts of renal replacement therapy and showed higher survival rates (HR 0.669; 95% CI 0.628-0.712) in the multivariate analysis of Cox regression model. Conclusions Patients with an optimal start of renal replacement therapy have a greater survival than those who had a non-optimal start. Therefore, the necessary measures should be encouraged to increase the optimal start of the patient in dialysis.	[Caro Martinez, Araceli; de Labry Lima, Antonio Olry; Mendoza Garcia, Oscar Javier; Garcia Mochon, Leticia] Campus Univ Cartuja, EASP, Granada, Spain; [de Labry Lima, Antonio Olry; Garcia Mochon, Leticia] CIBERESP, Granada, Spain; [de Labry Lima, Antonio Olry; Garcia Mochon, Leticia] Univ Granada, Hosp Univ Granada, Inst Invest Biosanit Ibs, Granada, Spain; [Munoz Terol, Jose Manuel] Hosp Univ Virgen Rocio, Seville, Spain; [Remon Rodriguez, Cesar] Hosp Univ Puerto Real, Cadiz, Spain; [Castro de la Nuez, Pablo] CATA, Seville, Spain; [Areste Fosalba, Nuria] Hosp Univ Virgen Macarena, Seville, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Instituto de Investigacion Biosanitaria IBS Granada; University of Granada; Virgen del Rocio University Hospital; Universidad de Cadiz; Hospital Universitario Puerto Real; Hospital Universitario Virgen Macarena	Lima, AOD (corresponding author), Campus Univ Cartuja, EASP, Granada, Spain.; Lima, AOD (corresponding author), CIBERESP, Granada, Spain.; Lima, AOD (corresponding author), Univ Granada, Hosp Univ Granada, Inst Invest Biosanit Ibs, Granada, Spain.	antonio.olrylabry.easp@juntadeandalcia.es	Areste-Fosalba, Nuria/ABH-7097-2020; Garcia, Leticia/AGV-7679-2022; Olry, Antonio/AAR-7602-2020	ARESTE-FOSALBA, NURIA/0000-0003-3107-2253; Remon-Rodriguez, Cesar/0000-0001-8232-6060; Olry de Labry Lima, Antonio/0000-0001-5448-1370				Alcazar R, 2008, NEFROLOGIA, V28, P273; Brown PA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130080; Buck J, 2007, NEPHROL DIAL TRANSPL, V22, P3240, DOI 10.1093/ndt/gfm387; Castro de la Nuez P, 2016, SISTEMA INFORM COORD; Coentrao L, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-88; Couchoud C, 2007, NEPHROL DIAL TRANSPL, V22, P3246, DOI 10.1093/ndt/gfm400; Curtis BM, 2005, NEPHROL DIAL TRANSPL, V20, P147, DOI 10.1093/ndt/gfh585; Escobar EM, 2016, NEFROLOGIA, V36, P97, DOI 10.1016/j.nefro.2015.10.020; Gorriz JL, 2002, NEFROLOGIA, V22, P49; Henry SL, 2017, J RENAL CARE, V43, P143, DOI 10.1111/jorc.12202; Kessler M, 2003, AM J KIDNEY DIS, V42, P474, DOI 10.1016/S0272-6386(03)00805-9; Liu FX, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000293; Lopez-Vargas PA, 2016, AM J KIDNEY DIS, V68, P353, DOI 10.1053/j.ajkd.2016.01.022; Lorenzo-Sellares V, 2014, NEFROLOGIA, V34, P458, DOI 10.3265/Nefrologia.pre2014.Apr.12501; Machowska A, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-016-0419-z; Machowska A, 2016, PATIENT PREFER ADHER, V10, P2229, DOI 10.2147/PPA.S119243; Marron B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155987; Marron B, 2006, NEPHROL DIAL TRANSPL, V21, DOI 10.1093/ndt/gfl191; Mendelssohn DC, 2011, NEPHROL DIAL TRANSPL, V26, P2959, DOI 10.1093/ndt/gfq843; Mendelssohn DC, 2009, BMC NEPHROL, V10, DOI 10.1186/1471-2369-10-22; Mendelssohn DC, 2002, PERITON DIALYSIS INT, V22, P5; Metcalfe W, 2003, QJM-INT J MED, V96, P899, DOI 10.1093/qjmed/hcg155; Prieto-Velasco M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138811; Roca-Tey R, 2016, J VASC ACCESS, V17, P20, DOI 10.5301/jva.5000468; Seras M, 2015, SESION HEMODIALISIS, V5, P448	25	1	2	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2019	14	7							e0219037	10.1371/journal.pone.0219037	http://dx.doi.org/10.1371/journal.pone.0219037			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4WU	31361758	gold, Green Published			2023-01-03	WOS:000484981300009
J	Kurtz, DM; Esfahani, MS; Scherer, F; Soo, J; Jin, MC; Liu, CL; Newman, AM; Duhrsen, U; Huttmann, A; Casasnovas, O; Westin, JR; Ritgen, M; Bottcher, S; Langerak, AW; Roschewski, M; Wilson, WH; Gaidano, G; Rossi, D; Bahlo, J; Hallek, M; Tibshirani, R; Diehn, M; Alizadeh, AA				Kurtz, David M.; Esfahani, Mohammad S.; Scherer, Florian; Soo, Joanne; Jin, Michael C.; Liu, Chih Long; Newman, Aaron M.; Duehrsen, Ulrich; Huettmann, Andreas; Casasnovas, Olivier; Westin, Jason R.; Ritgen, Matthais; Boettcher, Sebastian; Langerak, Anton W.; Roschewski, Mark; Wilson, Wyndham H.; Gaidano, Gianluca; Rossi, Davide; Bahlo, Jasmin; Hallek, Michael; Tibshirani, Robert; Diehn, Maximilian; Alizadeh, Ash A.			Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction	CELL			English	Article							B-CELL LYMPHOMA; INTERNATIONAL PROGNOSTIC INDEX; CHRONIC LYMPHOCYTIC-LEUKEMIA; POSITRON-EMISSION-TOMOGRAPHY; MINIMAL RESIDUAL DISEASE; BREAST-CANCER; ADJUVANT CHEMOTHERAPY; LUNG-CANCER; OPEN-LABEL; INDEPENDENT PREDICTOR	Accurate prediction of long-term outcomes remains a challenge in the care of cancer patients. Due to the difficulty of serial tumor sampling, previous prediction tools have focused on pretreatment factors. However, emerging non-invasive diagnostics have increased opportunities for serial tumor assessments. We describe the Continuous Individualized Risk Index (CIRI), a method to dynamically determine outcome probabilities for individual patients utilizing risk predictors acquired over time. Similar to "win probability" models in other fields, CIRI provides a real-time probability by integrating risk assessments throughout a patient's course. Applying CIRI to patients with diffuse large B cell lymphoma, we demonstrate improved outcome prediction compared to conventional risk models. We demonstrate CIRI's broader utility in analogous models of chronic lymphocytic leukemia and breast adenocarcinoma and perform a proof-of-concept analysis demonstrating how CIRI could be used to develop predictive biomarkers for therapy selection. We envision that dynamic risk assessment will facilitate personalized medicine and enable innovative therapeutic paradigms.	[Kurtz, David M.; Esfahani, Mohammad S.; Scherer, Florian; Soo, Joanne; Jin, Michael C.; Liu, Chih Long; Newman, Aaron M.; Alizadeh, Ash A.] Stanford Univ, Dept Med, Div Oncol, Stanford, CA 94305 USA; [Kurtz, David M.; Alizadeh, Ash A.] Stanford Univ, Dept Med, Div Hematol, Stanford, CA 94305 USA; [Kurtz, David M.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Newman, Aaron M.; Diehn, Maximilian; Alizadeh, Ash A.] Stanford Univ, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA; [Duehrsen, Ulrich; Huettmann, Andreas] Univ Hosp Essen, Dept Hematol, Essen, Germany; [Casasnovas, Olivier] CHU Dijon, Hop F Mitterrand, Dept Hematol, Dijon, France; [Casasnovas, Olivier] INSERM 1231, Dijon, France; [Westin, Jason R.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA; [Ritgen, Matthais] Univ Schleswig Holstein, Dept Internal Med 2, Campus Kiel, Kiel, Germany; [Boettcher, Sebastian] Univ Hosp Rostock, Dept Internal Med 3, Rostock, Germany; [Langerak, Anton W.] Erasmus MC, Lab Med Immunol, Dept Immunol, Rotterdam, Netherlands; [Roschewski, Mark; Wilson, Wyndham H.] NCI, Lymphoid Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD USA; [Gaidano, Gianluca] Univ Piemonte Orientale, Dept Translat Med, Div Hematol, Novara, Italy; [Rossi, Davide] Oncol Inst Southern Switzerland, Hematol, Bellinzona, Switzerland; [Rossi, Davide] Inst Oncol Res, Bellinzona, Switzerland; [Bahlo, Jasmin; Hallek, Michael] Univ Hosp Cologne, Dept Internal Med 1, German CLL Study Grp, Cologne, Germany; [Bahlo, Jasmin; Hallek, Michael] Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, Cologne, Germany; [Hallek, Michael] Univ Cologne, Cologne Cluster Excellence Cellular Stress Respon, Cologne, Germany; [Tibshirani, Robert] Stanford Univ, Dept Stat, Stanford, CA 94305 USA; [Tibshirani, Robert] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA; [Diehn, Maximilian; Alizadeh, Ash A.] Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA; [Diehn, Maximilian] Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA; [Scherer, Florian] Albert Ludwigs Univ, Freiburg Univ Med Ctr, Dept Hematol Oncol & Stem Cell Transplantat, Freiburg, Germany	Stanford University; Stanford University; Stanford University; Stanford University; University of Duisburg Essen; CHU Dijon Bourgogne; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; University of Texas System; UTMD Anderson Cancer Center; University of Kiel; Schleswig Holstein University Hospital; University of Rostock; Erasmus University Rotterdam; Erasmus MC; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Eastern Piedmont Amedeo Avogadro; Institute of Oncology Research (IOR); Institute of Oncology Research (IOR); University of Cologne; University of Cologne; University of Cologne; Stanford University; Stanford University; Stanford Cancer Institute; Stanford University; Stanford University; University of Freiburg	Alizadeh, AA (corresponding author), Stanford Univ, Dept Med, Div Oncol, Stanford, CA 94305 USA.; Alizadeh, AA (corresponding author), Stanford Univ, Dept Med, Div Hematol, Stanford, CA 94305 USA.; Diehn, M; Alizadeh, AA (corresponding author), Stanford Univ, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA.; Diehn, M; Alizadeh, AA (corresponding author), Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA.; Diehn, M (corresponding author), Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA.	diehn@stanford.edu; arasha@stanford.edu	Huettmann, Andreas/AAH-6483-2019; Hüttmann, Andreas/W-6106-2019; Newman, Aaron M/ABE-1620-2021; Alizadeh, Ash A/C-5594-2009; Hallek, Michael/Y-3191-2019; Gaidano, Gianluca/AAW-2773-2021	Hüttmann, Andreas/0000-0003-2230-3873; Newman, Aaron M/0000-0002-1857-8172; Alizadeh, Ash A/0000-0002-5153-5625; Hallek, Michael/0000-0002-7425-4455; Gaidano, Gianluca/0000-0002-4681-0151; Kurtz, David/0000-0002-6382-4651; Casasnovas, Rene-Olivier/0000-0002-1156-8983; Shahrokh Esfahani, Mohammad/0000-0002-0950-3937; Westin, Jason/0000-0002-1824-2337	National Cancer Institute [R01CA188298, R01CA233975, R01CA229766, U01CA194389, R25CA180993]; Damon Runyon Cancer Research Foundation [71-14, 09-16]; American Society of Hematology Scholar Award; Leukemia and Lymphoma Society Scholar Award; V Foundation for Cancer Research Abeloff Scholar Award; Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator Award; Emerson Collective Cancer Research Fund; Stinehart/Reed Award; Shanahan Family Fund; NIH [1-DP2-CA186569]; Ludwig Institute for Cancer Research; NATIONAL CANCER INSTITUTE [R25CA180993, ZIABC011914, R01CA188298, R01CA233975, R01CA229766, U01CA194389] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Damon Runyon Cancer Research Foundation; American Society of Hematology Scholar Award; Leukemia and Lymphoma Society Scholar Award(Leukemia and Lymphoma Society); V Foundation for Cancer Research Abeloff Scholar Award; Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator Award; Emerson Collective Cancer Research Fund; Stinehart/Reed Award; Shanahan Family Fund; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ludwig Institute for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Cancer Institute (R01CA188298 and R01CA233975 to M.D. and A.A.A., R01CA229766 and U01CA194389 to A.A.A., and training grant R25CA180993 to M.S.E.), the Damon Runyon Cancer Research Foundation (DR-CI#71-14 to A.A.A. and PST#09-16 to D.M.K.), American Society of Hematology Scholar Award (to A.A.A.), Leukemia and Lymphoma Society Scholar Award (to A.A.A.), V Foundation for Cancer Research Abeloff Scholar Award (to A.A.A.), Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator Award (to D.M.K.), the Emerson Collective Cancer Research Fund (to A.A.A.), the Stinehart/Reed Award (to A.A.A.), the Shanahan Family Fund (to A.A.A.), the NIH Director's New Innovator Award Program (1-DP2-CA186569), and the Ludwig Institute for Cancer Research.	Alberro JA, 2018, LANCET ONCOL, V19, P27, DOI 10.1016/S1470-2045(17)30777-5; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Ballman KV, 2015, J CLIN ONCOL, V33, P3968, DOI 10.1200/JCO.2015.63.3651; Barrington SF, 2014, J CLIN ONCOL, V32, P3048, DOI 10.1200/JCO.2013.53.5229; Bedard PL, 2013, NATURE, V501, P355, DOI 10.1038/nature12627; Bottcher S, 2012, J CLIN ONCOL, V30, P980, DOI 10.1200/JCO.2011.36.9348; Cashen AF, 2011, J NUCL MED, V52, P386, DOI 10.2967/jnumed.110.082586; Chaudhuri AA, 2017, CANCER DISCOV, V7, P1394, DOI 10.1158/2159-8290.CD-17-0716; Chen MK, 2008, MANAGE SCI, V54, P1381, DOI 10.1287/mnsc.1080.0872; Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800; Chi KN, 2016, ANN ONCOL, V27, P454, DOI 10.1093/annonc/mdv594; Chiappella A, 2017, LANCET ONCOL, V18, P1076, DOI 10.1016/S1470-2045(17)30444-8; Crump M, 2014, J CLIN ONCOL, V32, P3490, DOI 10.1200/JCO.2013.53.9593; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Duhrsen U, 2018, J CLIN ONCOL, V36, P2024, DOI 10.1200/JCO.2017.76.8093; Duehrsen U, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.391.391; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Eichhorst B, 2016, LANCET ONCOL, V17, P928, DOI 10.1016/S1470-2045(16)30051-1; El-Galaly TC, 2015, J CLIN ONCOL, V33, P3993, DOI 10.1200/JCO.2015.62.0229; Esserman LJ, 2012, BREAST CANCER RES TR, V132, P1049, DOI 10.1007/s10549-011-1895-2; Fink AM, 2013, LEUKEMIA, V27, P1949, DOI 10.1038/leu.2013.190; Fink AM, 2017, LANCET HAEMATOL, V4, pE475, DOI 10.1016/S2352-3026(17)30171-0; Fisher LD, 1999, ANNU REV PUBL HEALTH, V20, P145, DOI 10.1146/annurev.publhealth.20.1.145; Foster JC, 2011, STAT MED, V30, P2867, DOI 10.1002/sim.4322; Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI [10.1126/scitranslmed.aab0021, 10.1126/scitranslmed.aac7551]; Goede V, 2014, NEW ENGL J MED, V370, P1101, DOI 10.1056/NEJMoa1313984; Gradishar WJ, 2018, J NATL COMPR CANC NE, V16, P310, DOI 10.6004/jnccn.2018.0012; Greenwood M., 1926, REPORT NATURAL DURAT; Hahnen E, 2017, JAMA ONCOL, V3, P1378, DOI 10.1001/jamaoncol.2017.1007; Hallek M, 2010, LANCET, V376, P1164, DOI 10.1016/S0140-6736(10)61381-5; Hallek M, 2016, LANCET ONCOL, V17, P779, DOI 10.1016/S1470-2045(16)30029-8; Hamlin PA, 2003, BLOOD, V102, P1989, DOI 10.1182/blood-2002-12-3837; Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593; Heagerty PJ, 2000, BIOMETRICS, V56, P337, DOI 10.1111/j.0006-341X.2000.00337.x; Hertzberg M, 2017, HAEMATOLOGICA, V102, P356, DOI 10.3324/haematol.2016.154039; Horwitz SM, 2016, J NATL COMPR CANC NE, V14, P1067, DOI 10.6004/jnccn.2016.0117; Ignatiadis M, 2019, JNCI-J NATL CANCER I, V111, P69, DOI 10.1093/jnci/djy076; Jongen-Lavrencic M, 2018, NEW ENGL J MED, V378, P1189, DOI 10.1056/NEJMoa1716863; Kovacs G, 2016, J CLIN ONCOL, V34, P3758, DOI 10.1200/JCO.2016.67.1305; Kurtz DM, 2018, J CLIN ONCOL, V36, P2845, DOI 10.1200/JCO.2018.78.5246; Kwok M, 2016, BLOOD, V128, P2770, DOI 10.1182/blood-2016-05-714162; Linzer DA, 2013, J AM STAT ASSOC, V108, P124, DOI 10.1080/01621459.2012.737735; Little RJ, 2012, NEW ENGL J MED, V367, P1355, DOI 10.1056/NEJMsr1203730; Lock D, 2014, J QUANT ANAL SPORTS, V10, P197, DOI 10.1515/jqas-2013-0100; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maurer MJ, 2014, J CLIN ONCOL, V32, P1066, DOI 10.1200/JCO.2013.51.5866; Micallef INM, 2011, BLOOD, V118, P4053, DOI 10.1182/blood-2011-02-336990; Moskowitz CH, 1999, BONE MARROW TRANSPL, V23, P561, DOI 10.1038/sj.bmt.1701624; Moskowitz CH, 2010, J CLIN ONCOL, V28, P1896, DOI 10.1200/JCO.2009.26.5942; Newman AM, 2014, NAT MED, V20, P552, DOI 10.1038/nm.3519; Nols N, 2014, LEUKEMIA LYMPHOMA, V55, P773, DOI 10.3109/10428194.2013.831848; Nowakowski GS, 2016, FUTURE ONCOL, V12, P1553, DOI 10.2217/fon-2016-0130; Ommen HB, 2016, THER ADV HEMATOL, V7, P3, DOI 10.1177/2040620715614529; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pencina MJ, 2010, CLIN CHEM LAB MED, V48, P1703, DOI 10.1515/CCLM.2010.340; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Pregno P, 2012, BLOOD, V119, P2066, DOI 10.1182/blood-2011-06-359943; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Safar V, 2012, J CLIN ONCOL, V30, P184, DOI 10.1200/JCO.2011.38.2648; Sargent DJ, 2017, ONCOLOGIST, V22, P1415, DOI 10.1634/theoncologist.2017-0177; Scherer F, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aai8545; Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066; Scott DW, 2015, J CLIN ONCOL, V33, P2848, DOI 10.1200/JCO.2014.60.2383; Sehn LH, 2007, BLOOD, V109, P1857, DOI 10.1182/blood-2006-08-038257; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sparano JA, 2015, NEW ENGL J MED, V373, P2005, DOI 10.1056/NEJMoa1510764; STERN H, 1991, AM STAT, V45, P179, DOI 10.2307/2684286; Stern HS, 2014, BAYESIAN DATA ANAL, V3rd; Steyerberg EW., 2009, CLIN PREDICTION MODE, DOI [10.1007/978-0-387-77244-8, DOI 10.1007/978-0-387-77244-8]; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Stiff PJ, 2013, NEW ENGL J MED, V369, P1681, DOI 10.1056/NEJMoa1301077; Symmans WF, 2007, J CLIN ONCOL, V25, P4414, DOI 10.1200/JCO.2007.10.6823; Symmans WF, 2017, J CLIN ONCOL, V35, P1049, DOI 10.1200/JCO.2015.63.1010; Thompson CA, 2014, J CLIN ONCOL, V32, P3506, DOI 10.1200/JCO.2014.55.7561; Tie J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6219; Wierda WG, 2017, J NATL COMPR CANC NE, V15, P293, DOI 10.6004/jnccn.2017.0030; Yang DH, 2011, EUR J CANCER, V47, P1312, DOI 10.1016/j.ejca.2010.12.027; Yoo C, 2011, ANN HEMATOL, V90, P797, DOI 10.1007/s00277-010-1135-6; Ziepert M, 2010, J CLIN ONCOL, V28, P2373, DOI 10.1200/JCO.2009.26.2493; Zinzani PL, 2011, CANCER-AM CANCER SOC, V117, P1010, DOI 10.1002/cncr.25579	82	91	92	1	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 25	2019	178	3					699	+		10.1016/j.cell.2019.06.011	http://dx.doi.org/10.1016/j.cell.2019.06.011			34	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	IL0GF	31280963	Green Accepted, Bronze			2023-01-03	WOS:000476973800017
J	Beetham, T; Saloner, B; Wakeman, SE; Gaye, M; Barnett, ML				Beetham, Tamara; Saloner, Brendan; Wakeman, Sarah E.; Gaye, Marema; Barnett, Michael L.			Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related Mortality An Audit Study	ANNALS OF INTERNAL MEDICINE			English	Article							CARE APPOINTMENT AVAILABILITY; MAINTENANCE TREATMENT; WAITING-LIST; METHADONE	Background: Improving access to treatment for opioid use disorder is a national priority, but little is known about the barriers encountered by patients seeking buprenorphine-naloxone ("buprenorphine") treatment. Objective: To assess real-world access to buprenorphine treatment for uninsured or Medicaid-covered patients reporting current heroin use. Design: Audit survey ("secret shopper" study). Setting: 6 U.S. jurisdictions with a high burden of opioid-related mortality (Massachusetts, Maryland, New Hampshire, West Virginia, Ohio, and the District of Columbia). Participants: From July to November 2018, callers contacted 546 publicly listed buprenorphine prescribers twice, posing as uninsured or Medicaid-covered patients seeking buprenorphine treatment. Measurements: Rates of new appointments offered, whether buprenorphine prescription was possible at the first visit, and wait times. Results: Among 1092 contacts with 546 clinicians, schedulers were reached for 849 calls (78% response rate). Clinicians offered new appointments to 54% of Medicaid contacts and 62% of uninsured-self-pay contacts, whereas 27% of Medicaid and 41% of uninsured-self-pay contacts were offered an appointment with the possibility of buprenorphine prescription at the first visit. The median wait time to the first appointment was 6 days (interquartile range [IQR], 2 to 10 days) for Medicaid contacts and 5 days (IQR, 1 to 9 days) for uninsured-self-pay contacts. These wait times were similar regardless of clinician type or payer status. The median wait time from first contact to possible buprenorphine induction was 8 days (IQR, 4 to 15 days) for Medicaid and 7 days (IQR, 3 to 14 days) for uninsured-self-pay contacts. Limitation: The survey sample included only publicly listed buprenorphine prescribers. Conclusion: Many buprenorphine prescribers did not offer new appointments or rapid buprenorphine access to callers reporting active heroin use, particularly those with Medicaid coverage. Nevertheless, wait times were not long, implying that opportunities may exist to increase access by using the existing prescriber workforce. Primary Funding Source: National Institute on Drug Abuse.	[Beetham, Tamara; Barnett, Michael L.] Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Saloner, Brendan] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Wakeman, Sarah E.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Gaye, Marema; Barnett, Michael L.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Barnett, Michael L.] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave,Kresge 411, Boston, MA 02115 USA; [Beetham, Tamara] Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, 677 Huntington Ave, Boston, MA 02115 USA; [Saloner, Brendan] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 North Broadway,Room 344, Baltimore, MD 21205 USA; [Wakeman, Sarah E.] Massachusetts Gen Hosp, Dept Med, 55 Fruit St, Boston, MA 02114 USA; [Gaye, Marema] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Barnett, ML (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave,Kresge 411, Boston, MA 02115 USA.	mbarnett@hsph.harvard.edu	Barnett, Michael/AAF-4017-2019; Beetham, Tamara/ABA-5858-2021; Barnett, Michael/ABA-4159-2021	Barnett, Michael/0000-0002-4884-6609; Beetham, Tamara/0000-0001-7746-7459; Barnett, Michael/0000-0002-4884-6609	National Institute on Drug Abuse [K01 DA042139]; NATIONAL INSTITUTE ON DRUG ABUSE [K01DA042139] Funding Source: NIH RePORTER	National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	By National Institute on Drug Abuse grant K01 DA042139 to Dr. Saloner.	American Society of Addiction Medicine, 2018, SUMM FIN RUL RAIS BU; American Society of Addiction Medicine, 2019, PUBL POL STAT REG OF; Andrilla CHA, 2019, J RURAL HEALTH, V35, P108, DOI 10.1111/jrh.12307; Bisgaier J, 2011, NEW ENGL J MED, V364, P2324, DOI 10.1056/NEJMsa1013285; Candon M, 2018, JAMA INTERN MED, V178, P145, DOI 10.1001/jamainternmed.2017.6302; Center for Behavioral Health Statistics and Quality, 2018, NAT MENT HLTH SERV S; Centers for Disease Control and Prevention National Center for Health Statistics, 1999, CDC WONDER UND CAUS; Clausen T, 2008, DRUG ALCOHOL DEPEN, V94, P151, DOI 10.1016/j.drugalcdep.2007.11.003; Connery HS, 2015, HARVARD REV PSYCHIAT, V23, P63, DOI 10.1097/HRP.0000000000000075; Creedon TB, 2016, HEALTH AFFAIR, V35, P1017, DOI 10.1377/hlthaff.2016.0098; George J., 2019, MEDPAGE TODAY; Henry J., OPIOID EPIDEMIC MED; Henry J Kaiser Family Foundation, 2019, OP OV DEATH RAT ALL; Hser YI, 2016, ADDICTION, V111, P695, DOI 10.1111/add.13238; Larochelle MR, 2018, ANN INTERN MED, V169, P137, DOI 10.7326/M17-3107; Lee JD, 2009, J GEN INTERN MED, V24, P226, DOI 10.1007/s11606-008-0866-8; Martin SA, 2018, ANN INTERN MED, V169, P628, DOI 10.7326/M18-1652; Medicaid and CHIP Payment and Access Commission, 2017, JUN 2017 REP C MED C; Morrill R, 2018, RURAL URBAN COMMUTIN; Parran TV, 2017, SUBST ABUS-RES TREAT, V11, DOI 10.1177/1178221817699247; Patrick SW, 2019, SUBST ABUS, V40, P356, DOI 10.1080/08897077.2018.1488336; Peles E, 2013, J ADDICT MED, V7, P177, DOI 10.1097/ADM.0b013e318287cfc9; Penn M, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.7096; Polsky D, 2015, NEW ENGL J MED, V372, P537, DOI 10.1056/NEJMsa1413299; Rhodes K, 2011, NEW ENGL J MED, V365, P484, DOI 10.1056/NEJMp1107779; Rinaldo SG, 2018, AVAILABILITY WITHOUT; Sandoe E, 2018, HLTH AFFAIRS BLOG, DOI [10.1377/hblog20180927.51221/fullon, DOI 10.1377/HBLOG20180927.51221/FULLON]; Schuckit MA, 2016, NEW ENGL J MED, V375, P357, DOI 10.1056/NEJMra1604339; Schulte F., 2018, KAISER HLTH NEWS; Schwartz RP, 2006, ARCH GEN PSYCHIAT, V63, P102, DOI 10.1001/archpsyc.63.1.102; Sigmon SC, 2016, NEW ENGL J MED, V375, P2504, DOI 10.1056/NEJMc1610047; Simon CB, 2017, DRUG ALCOHOL DEPEN, V181, P58, DOI 10.1016/j.drugalcdep.2017.09.017; Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550; Substance Abuse and Mental Health Services Administration, 2019, HHS PUBL; Tesema L, 2018, SUBST ABUS, V39, P434, DOI 10.1080/08897077.2018.1449047; Tipirneni R, 2015, HEALTH AFFAIR, V34, P1399, DOI 10.1377/hlthaff.2014.1425; U. S. Department of Health and Human Services, 2019, BUPR PRACT LOC; U. S. Department of Health and Human Services, 2019, BUPRENORPHINE; Volkow ND, 2014, NEW ENGL J MED, V370, P2063, DOI 10.1056/NEJMp1402780; Wakeman SE, 2018, NEW ENGL J MED, V379, P1, DOI 10.1056/NEJMp1802741; Williams A, 2017, HLTH AFFAIRS BLOG, DOI [10.1377/hblog20170313.059163/full, DOI 10.1377/HBLOG20170313.059163]	41	49	49	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 2	2019	171	1					1	+		10.7326/M18-3457	http://dx.doi.org/10.7326/M18-3457			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IF7KB	31158849	Green Accepted			2023-01-03	WOS:000473261600002
J	Huang, CN; Wang, CJ; Lin, CL; Yen, AT; Li, HH; Peng, CH				Huang, Chien-Ning; Wang, Chau-Jong; Lin, Chih-Li; Yen, An-Ting; Li, Hsin-Hua; Peng, Chiung-Huei			Abelmoschus esculentus subfractions attenuate beta amyloid-induced neuron apoptosis by regulating DPP-4 with improving insulin resistance signals	PLOS ONE			English	Article							ENDOPLASMIC-RETICULUM STRESS; DIPEPTIDYL PEPTIDASE-4; CELL APOPTOSIS; INHIBITOR; VILDAGLIPTIN; GLUCOSAMINE; ACTIVATION; DEMENTIA; SURVIVAL; RECEPTOR	The association of Alzheimer disease (AD) and Diabetes (DM) is less clear. Accumulation of beta amyloid (A beta) and presence of hyperphosphorylated tau (p-tau) are hallmarks of AD, spreading in the region where insulin receptors are also found. A beta exerts neuron toxicity, and could disturb insulin signaling of phosphatidylinositol 3-kinase (PI3K), glycogen synthase kinase (GSK)-3 beta and AMP-activated protein kinase (AMPK), but increase IRS-1-Ser307 phosphorylation which is viewed as insulin resistance marker. Previously we reported dipeptidyl peptidase-4 (DPP-4) mediate insulin resistance signals, and Abelmoschus esculentus (AE) subfractions F1 (rich in quercetin glucosides and triterpene ester) and F2 (containing large amount of polysaccharides) attenuate DPP-4-mediated apoptosis. In the present study, we aim to investigate if A beta induce neuron death by regulating DPP-4 and insulin resistance signals, and the putative effect of F1 and F2. By MTT, microscopy, and Western blotting, we demonstrate treatment of appropriate doses of AE subfractions prevent A beta-induced neuron apoptosis. F1 attenuate A beta-induced caspase 3 expression especially at 25 mu g/mL, while F2 attenuate caspase 3 activation even at the low dose of 1 mu g/mL. Both AE subfractions decrease A beta-enhanced DPP-4, but increase A beta-reduced p-AMPK and p-PI3K. The activity analysis reveals that F2 is more valid than F1 to reduce DPP-4 activity. The inhibition of DPP-4 demonstrates it plays the pivotal role in A beta-induced neuron apoptosis. Moreover, although both F1 and F2 are effective to inhibit p-IRS-1-Ser307, F2 takes advantage to reduce p-Tau while F1 is superior to enhance p-GSK-3 beta. This implies AE subfractions act on different targets, and could be developed respectively. In conclusion, we demonstrate AE is potential to prevent A beta-induced neuron damage by regulating DPP-4 and the insulin resistance cascades. AE could be an adjuvant to protect neuron degenerative disease related to A beta and insulin resistance.	[Huang, Chien-Ning] Chung Shan Med Univ Hosp, Dept Internal Med, Taichung, Taiwan; [Huang, Chien-Ning; Lin, Chih-Li; Li, Hsin-Hua] Chung Shan Med Univ, Inst Med, Taichung, Taiwan; [Wang, Chau-Jong; Yen, An-Ting] Chung Shan Med Univ, Inst Biochem Microbiol & Immunol, Taichung, Taiwan; [Peng, Chiung-Huei] Hungkuang Univ, Div Basic Med Sci, Taichung, Taiwan	Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University; Chung Shan Medical University; Hungkuang University	Peng, CH (corresponding author), Hungkuang Univ, Div Basic Med Sci, Taichung, Taiwan.	a222907@sunrise.hk.edu.tw	Lin, Chih-Li/H-9515-2019; Lin, Chih-Li/GQZ-6480-2022	Lin, Chih-Li/0000-0003-4553-3727; Peng, Chiung-Huei/0000-0003-1833-5522	Ministry of Science and Technology [MOST 107-2320-B-241-001]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea)	This work was supported by the Ministry of Science and Technology, grant MOST 107-2320-B-241-001 (https://www.most.gov.tw/) to CHP. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe TK, 2014, FEBS OPEN BIO, V4, P162, DOI 10.1016/j.fob.2014.01.008; Arancio O, 2004, EMBO J, V23, P4096, DOI 10.1038/sj.emboj.7600415; Chiu N, 1995, ILLUSTRATED MED PLAN, VI.; Choi Kangduk, 2010, Korean Journal of Internal Medicine, V25, P119, DOI 10.3904/kjim.2010.25.2.119; Choi YJ, 2005, J NUTR, V135, P707, DOI 10.1093/jn/135.4.707; Cole AR, 2007, NEUROSCI BIOBEHAV R, V31, P1046, DOI 10.1016/j.neubiorev.2007.04.004; Council NR, 2006, LOST CROPS AFR; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Fulop N, 2007, CARDIOVASC RES, V73, P288, DOI 10.1016/j.cardiores.2006.07.018; Han WP, 2010, P NATL ACAD SCI USA, V107, P6557, DOI 10.1073/pnas.1002555107; Hocher B, 2012, KIDNEY BLOOD PRESS R, V36, P65, DOI 10.1159/000339028; Huang CN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180285; Huang CN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189065; Huang CN, 2016, FOOD FUNCT, V7, P475, DOI [10.1039/C5FO00464K, 10.1039/c5fo00464k]; Huser CAM, 2008, OSTEOARTHR CARTILAGE, V16, P125, DOI 10.1016/j.joca.2007.05.021; Hwang HJ, 2014, MOL CELL ENDOCRINOL, V392, P1, DOI 10.1016/j.mce.2014.04.017; Isnaini Isnaini, 2019, Asian Pac J Cancer Prev, V20, P639, DOI 10.31557/APJCP.2019.20.2.639; Kopf D, 2009, J ALZHEIMERS DIS, V16, P677, DOI 10.3233/JAD-2009-1011; Kornelius E, 2015, CNS NEUROSCI THER, V21, P549, DOI 10.1111/cns.12404; Maher PA, 2009, EXPERT REV NEUROTHER, V9, P617, DOI [10.1586/ern.09.18, 10.1586/ERN.09.18]; Ng RCL, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0136-x; Ott A, 1999, NEUROLOGY, V53, P1937, DOI 10.1212/WNL.53.9.1937; Peng CH, 2019, J FOOD DRUG ANAL, V27, P135, DOI 10.1016/j.jfda.2018.07.004; Peng CH, 2016, FOOD FUNCT, V7, P728, DOI [10.1039/C5FO01214G, 10.1039/c5fo01214g]; Peterszegi G, 2003, BIOMED PHARMACOTHER, V57, P187, DOI 10.1016/S0753-3322(03)00031-3; Ruderman NB, 2013, J CLIN INVEST, V123, P2764, DOI 10.1172/JCI67227; Takeda S, 2011, MOL BIOSYST, V7, P1822, DOI 10.1039/c0mb00302f; Tseng HL, 2012, TOXICOL APPL PHARM, V264, P104, DOI 10.1016/j.taap.2012.07.022; Wang XM, 2015, CELL PHYSIOL BIOCHEM, V37, P1914, DOI 10.1159/000438552; Wu YJ, 2015, METABOLISM, V64, P226, DOI 10.1016/j.metabol.2014.08.006; Xie L, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-10-j0001.2002; Yao RQ, 2012, NEUROCHEM RES, V37, P2777, DOI 10.1007/s11064-012-0871-5; Zhang DD, 2018, EXP THER MED, V15, P5100, DOI 10.3892/etm.2018.6016; Zhao WQ, 2008, FASEB J, V22, P246, DOI 10.1096/fj.06-7703com	34	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2019	14	6							e0217400	10.1371/journal.pone.0217400	http://dx.doi.org/10.1371/journal.pone.0217400			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW3BT	31237881	gold, Green Published, Green Submitted			2023-01-03	WOS:000484856000007
J	Shifren, JL; Crandall, CJ; Manson, JE				Shifren, Jan L.; Crandall, Carolyn J.; Manson, Joann E.			Menopausal Hormone Therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MANAGEMENT; MORTALITY		[Shifren, Jan L.] Harvard Med Sch, Massachusetts Gen Hosp, Midlife Womens Hlth Ctr, Dept Obstet & Gynecol, Boston, MA 02115 USA; [Crandall, Carolyn J.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA; [Manson, Joann E.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Manson, Joann E.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Shifren, JL (corresponding author), Massachusetts Gen Hosp, Dept Obstet & Gynecol, Midlife Womens Hlth Ctr, 55 Fruit St,Yawkey 10A, Boston, MA 02114 USA.	jshifren@mgh.harvard.edu						Avis NE, 2015, JAMA INTERN MED, V175, P531, DOI 10.1001/jamainternmed.2014.8063; Kaunitz AM, 2015, OBSTET GYNECOL, V126, P859, DOI 10.1097/AOG.0000000000001058; Manson JE, 2017, JAMA-J AM MED ASSOC, V318, P927, DOI 10.1001/jama.2017.11217; Manson JE, 2015, MENOPAUSE, V22, P247, DOI [10.1097/gme.0000000000000373, 10.1097/GME.0000000000000373]; Manson JE, 2013, JAMA-J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040; Pinkerton JV, 2017, MENOPAUSE, V24, P728, DOI 10.1097/GME.0000000000000921; Rivera CM, 2009, MENOPAUSE, V16, P15, DOI 10.1097/gme.0b013e31818888f7; Shifren JL, 2018, CLIN OBSTET GYNECOL, V61, P508, DOI 10.1097/GRF.0000000000000380; VINOGRADOVA Y, 2019, BMJ-BRIT MED J, V364, DOI DOI 10.1136/BMJ.K4810	9	17	19	2	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	2019	321	24					2458	2459		10.1001/jama.2019.5346	http://dx.doi.org/10.1001/jama.2019.5346			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IF3UX	31145419				2023-01-03	WOS:000473009700024
J	Zhao, BL; Cui, YJ; Fan, XD; Qi, P; Liu, CC; Zhou, XS; Zhang, XW				Zhao, Bingli; Cui, Yujiao; Fan, Xiaodan; Qi, Ping; Liu, Chunchen; Zhou, Xuesong; Zhang, Xuewu			Anti-obesity effects of Spirulina platensis protein hydrolysate by modulating brain-liver axis in high-fat diet fed mice	PLOS ONE			English	Article							LIPOPROTEIN SUBFRACTIONS; 3T3-L1 PREADIPOCYTES; LIPID-ACCUMULATION; INSULIN-RESISTANCE; OBESE-PATIENTS; EXTRACT; ADIPOGENESIS; DIFFERENTIATION; ASSOCIATION; CHOLESTEROL	Spirulina platensis is a blue-green algae with potential anti-obesity effects. In this study, the anti-obesity effects of whole Spirulina platensis (WSP), Spirulina platensis protein (SPP) and Spirulina platensis protein hydrolysate (SPPH) were compared in high-fat diet fed mice, and the potential acting mechanism of SPPH was also investigated. Totally, SPPH exhibited good anti-obesity effects (reducing 39.8%+/- 9.7% of body weight), lowering 23.8%+/- 1.6% of serum glucose, decreasing 20.8%+/- 1.4% of total cholesterol, while positive drug Simvastatin had the corresponding values: 8.3%+/- 4.6%, 24.8%+/- 1.9% and -2.1%+/- 0.2%, respectively. Subsequently, PCR array was used to conduct gene expression analysis in brain and liver tissues of SPPH-treated mice, which displayed distinctly different expression pattern. The most markedly changed genes included: Acadm (-34.7 fold), Gcg (2.5 fold), Adra2b (2 fold) and Ghsr (2 fold) in brain; Retn (39 fold), Fabp4 (15.5 fold), Ppard (6 fold) and Slc27a1 (5.4 fold) in liver. Further network analysis demonstrated that the significantly expressed genes in brain and liver tissues were mapped into an interacting network, suggesting a modulatory effect on brain-liver axis, major pathways were involved in the axis: PPAR, adipocytokine, AMPK, non-alcoholic fatty liver disease and MAPK. This study showed that Spirulina platensis protein hydrolysate possessed anti-obesity effect in mice.	[Zhao, Bingli; Cui, Yujiao; Fan, Xiaodan; Zhou, Xuesong; Zhang, Xuewu] South China Univ Technol, Coll Food Sci & Engn, Guangzhou, Guangdong, Peoples R China; [Qi, Ping] Guangzhou Inst Food & Drug Control, Guangzhou, Guangdong, Peoples R China; [Liu, Chunchen] Zhongci Hlth Care Prod Technol Dev Co Ltd, Guangzhou, Guangdong, Peoples R China; [Zhou, Xuesong] Guangzhou Honsea Ind Co Ltd, Guangzhou, Guangdong, Peoples R China	South China University of Technology	Zhang, XW (corresponding author), South China Univ Technol, Coll Food Sci & Engn, Guangzhou, Guangdong, Peoples R China.; Qi, P (corresponding author), Guangzhou Inst Food & Drug Control, Guangzhou, Guangdong, Peoples R China.	gzsp2000@163.com; snow_dance@sina.com						Barter P, 2019, ATHEROSCLEROSIS, V283, P7, DOI 10.1016/j.atherosclerosis.2019.01.001; Beraza Naiara, 2008, Hepatology, V48, P1011, DOI 10.1002/hep.22478; Choi HS, 2015, MOL NUTR FOOD RES, V59, P1458, DOI 10.1002/mnfr.201500021; Ding YL, 2017, EXCLI J, V16, P328, DOI 10.17179/excli2016-638; Drotningsvik A, 2016, BRIT J NUTR, V116, P1336, DOI 10.1017/S0007114516003548; Fan XD, 2018, J FUNCT FOODS, V47, P350, DOI 10.1016/j.jff.2018.05.066; Filippatos TD, 2008, DIABETES OBES METAB, V10, P476, DOI 10.1111/j.1463-1326.2007.00733.x; de los Monteros LAGE, 2011, PLANT FOOD HUM NUTR, V66, P355, DOI 10.1007/s11130-011-0263-z; Hasumura T, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-73; Hwang HS, 2009, MAR BIOTECHNOL, V11, P531, DOI 10.1007/s10126-008-9171-0; Jung EY, 2012, ANN NUTR METAB, V61, P89, DOI 10.1159/000338441; Jung HA, 2014, ARCH PHARM RES, V37, P713, DOI 10.1007/s12272-013-0237-9; Kalogirou M, 2007, CURR MED RES OPIN, V23, P1169, DOI 10.1185/030079907X188062; Kang JH, 2017, NUTR RES PRACT, V11, P17, DOI 10.4162/nrp.2017.11.1.17; Kang MC, 2017, MAR DRUGS, V15, DOI 10.3390/md15040119; Kang MC, 2016, FOOD CHEM TOXICOL, V90, P36, DOI 10.1016/j.fct.2016.01.023; Keene D, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4379; Kim CH, 2016, ANIM CELLS SYST, V20, P335, DOI 10.1080/19768354.2016.1254110; Kim MR, 2017, INT J MOL MED, V40, P784, DOI 10.3892/ijmm.2017.3063; Lee JA, 2017, PHYTOTHER RES, V31, P1694, DOI 10.1002/ptr.5892; Lee YS, 2015, ASIAN PAC J TROP MED, V8, P276, DOI 10.1016/S1995-7645(14)60330-8; Mithieux G, 2010, DIABETES METAB, V36, pS50, DOI 10.1016/S1262-3636(10)70467-5; Moon J, 2013, FOOD CHEM TOXICOL, V58, P347, DOI 10.1016/j.fct.2013.05.006; Mopuri R, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0598-3; Nakou ES, 2008, EXPERT OPIN PHARMACO, V9, P3151, DOI 10.1517/14656560802548430 ; Oh IH, 2019, ATHEROSCLEROSIS, V283, P43, DOI 10.1016/j.atherosclerosis.2019.01.035; Ohashi A, 2004, J NUTR SCI VITAMINOL, V50, P416, DOI 10.3177/jnsv.50.416; Park HJ, 2016, NUTR RES PRACT, V10, P418, DOI 10.4162/nrp.2016.10.4.418; Sirtori CR, 2004, J NUTR, V134, P18, DOI 10.1093/jn/134.1.18; Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937; Tsai YC, 2017, PHYTOMEDICINE, V31, P11, DOI 10.1016/j.phymed.2017.05.005; Vitali C, 2017, CURR CARDIOL REP, V19, DOI 10.1007/s11886-017-0940-0; Voight BF, 2012, LANCET, V380, P572, DOI 10.1016/S0140-6736(12)60312-2; Wan-Loy C, 2016, MAR DRUGS, V14, DOI 10.3390/md14120222; Wang PYT, 2008, NATURE, V452, P1012, DOI 10.1038/nature06852; Wang ZJ, 2016, FOOD FUNCT, V7, P781, DOI [10.1039/c5fo01186h, 10.1039/C5FO01186H]; Waterman C, 2015, MOL NUTR FOOD RES, V59, P1013, DOI 10.1002/mnfr.201400679; Xu F, 2005, YUNNAN J TRADITIONAL, V26, P34; Xu XF, 2015, FOOD FUNCT, V6, P2068, DOI 10.1039/c4fo01192a; Yang L, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-24; Yang N, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-261; Yuan HD, 2010, J GINSENG RES, V34, P369, DOI 10.5142/jgr.2010.34.4.369; Zeinalian R, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1670-y	43	19	19	4	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2019	14	6							e0218543	10.1371/journal.pone.0218543	http://dx.doi.org/10.1371/journal.pone.0218543			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW3PH	31220177	Green Submitted, Green Published, gold			2023-01-03	WOS:000484893500062
J	Fuster-RuizdeApodaca, MJ; Castro-Granell, V; Garin, N; Laguia, A; Jaen, A; Iniesta, C; Cenoz, S; Galindo, MJ				Jose Fuster-RuizdeApodaca, Maria; Castro-Granell, Vanessa; Garin, Noe; Laguia, Ana; Jaen, Angeles; Iniesta, Carlos; Cenoz, Santiago; Galindo, Maria Jose			Prevalence and patterns of illicit drug use in people living with HIV in Spain: A cross-sectional study	PLOS ONE			English	Article							SEXUALLY-TRANSMITTED INFECTIONS; RISK BEHAVIORS; SUBSTANCE-USE; BISEXUAL MEN; POSITIVE MEN; SEX; ALCOHOL; ADHERENCE; CHEMSEX; GAY	This study assessed the prevalence and patterns of drug use among people living with HIV (PLHIV) in Spain. We conducted an observational cross-sectional study including 1401 PLHIV. Data were collected through 33 sites across Spain using an online computer-assisted self-administered interview. The survey measured use of illicit drugs and other substances, treatment adherence and health-related variables. To analyse patterns of drug use we performed cluster analysis in two stages. The most frequently consumed substances were: alcohol (86.7%), tobacco (55.0%), illicit drugs (49.5%), other substances (27.1%). The most prevalent illicit drugs used were cannabis (73.8%), cocaine powder (53.9%), and poppers (45.4%). Results found four clusters of PLHIV who used drugs. Two of them were composed mainly of heterosexuals (HTX): Cluster 1 (n = 172) presented the lowest polydrug use and they were mainly users of cannabis, and Cluster 2 (n = 84) grouped mostly men who used mainly heroin and cocaine; which had the highest percentage of people who inject drugs and presented the lowest level of treatment adherence (79.8 +/- 14.2; p<.0001). The other two clusters were composed mainly of men who have sex with men (MSM), who were mostly users of recreational drugs. Cluster 3 (n = 285) reported moderate consumption, both regarding frequency and diversity of drugs used, while Cluster 4 (n = 153) was characterized by the highest drug polyconsumption (7.4 +/- 2.2; p<.0001), and 4 grouped MSM who injected recreational drugs, and who reported the highest frequency of use of drugs in a sexual context (2.6 +/- 0.8; p<.0001) and rates of sexually transmitted infections (1.8 +/- 1.1; p<.01). This is the largest multi-centre cross-sectional study assessing the current prevalence and patterns of drug use among PLHIV in Spain. The highest prevalence of drug use was found among MSM, although HTX who used heroin and cocaine (Cluster 2) had the most problems with adherence to HIV treatment and the worst health status.	[Jose Fuster-RuizdeApodaca, Maria; Iniesta, Carlos; Galindo, Maria Jose] SEISIDA, Spanish Interdisciplinary Aids Soc, Madrid, Spain; [Castro-Granell, Vanessa] Granada Univ, Doctoral Programme Pharm, Granada, Spain; [Castro-Granell, Vanessa] Hosp Marina Baixa, Dept Pharm, Alicante, Spain; [Garin, Noe] Univ Autonoma Barcelona, Dept Pharm, Hosp Santa Creu & St Pau, Barcelona, Spain; [Garin, Noe] Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain; [Garin, Noe] Univ Ramon Llull, Sch Hlth Sci Blanquerna, Barcelona, Spain; [Laguia, Ana] UNED, Dept Social & Org Psychol, Fac Psicol, Madrid, Spain; [Jaen, Angeles] Univ Barcelona, Res Unit, Res Fdn MutuaTerrassa, Barcelona, Spain; [Iniesta, Carlos] Inst Salud Carlos III, Ctr Nacl Epidemiol, Madrid, Spain; [Cenoz, Santiago] ViiV Healthcare, Med Dept, Madrid, Spain; [Galindo, Maria Jose] Hosp Clin Univ, Dept Infect Dis, Valencia, Spain	University of Granada; Autonomous University of Barcelona; Hospital of Santa Creu i Sant Pau; CIBER - Centro de Investigacion Biomedica en Red; CIBERSAM; Instituto de Salud Carlos III; Universitat Ramon Llull; Universidad Nacional de Educacion a Distancia (UNED); University of Barcelona; Instituto de Salud Carlos III; Centro Nacional de Epidemiologia (CNE); Sanofi-Aventis; Hospital Clinic Universitari de Valencia	Fuster-RuizdeApodaca, MJ (corresponding author), SEISIDA, Spanish Interdisciplinary Aids Soc, Madrid, Spain.; Castro-Granell, V (corresponding author), Granada Univ, Doctoral Programme Pharm, Granada, Spain.; Castro-Granell, V (corresponding author), Hosp Marina Baixa, Dept Pharm, Alicante, Spain.	gerencia@seisida.net; vanemcg@hotmail.com	Fuster Ruiz de Apodaca, María José/K-4110-2017; Laguía, Ana/I-8651-2019; Jaen, Angeles/J-9780-2013	Fuster Ruiz de Apodaca, María José/0000-0003-4304-7194; Laguía, Ana/0000-0002-4634-3127; Jaen, Angeles/0000-0002-6815-2022; Garin, Noe/0000-0002-1559-9453; Iniesta, Carlos/0000-0002-0928-2679	ViiV Healthcare [SEISIDA 001/2016]	ViiV Healthcare	This study was funded by ViiV Healthcare (grant no : SEISIDA 001/2016). SC is Medical Manager at ViiV Healthcare. ViiV Healthcare was the promoter of the study but they did not play any role in data collection and analysis.	Allavena C, 2014, J INT AIDS SOC, V17, P176, DOI [10.7448/IAS.17.4.19780, 10.7448/IAS.17.4.19576]; Altice FL, 2010, LANCET, V376, P367, DOI 10.1016/S0140-6736(10)60829-X; Binford MC, 2012, CURR HIV-AIDS REP, V9, P287, DOI 10.1007/s11904-012-0134-8; Cashman SB, 2008, AM J PUBLIC HEALTH, V98, P1407, DOI 10.2105/AJPH.2007.113571; Chiu T., 2001, KDD-2001. Proceedings of the Seventh ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, P263, DOI 10.1145/502512.502549; Claborn K, 2018, ADDICT SCI CLIN PRAC, V13, DOI 10.1186/s13722-018-0113-5; Coll J, 2016, ENFERM EMERG, V15, P77; Daskalopoulou M, 2014, LANCET HIV, V1, pE22, DOI 10.1016/S2352-3018(14)70001-3; Dawson-Rose C, 2017, J ASSOC NURSE AIDS C, V28, P238, DOI 10.1016/j.jana.2015.12.001; de la Fuente L, 2006, REV ESP SALUD PUBLIC, V80, P505, DOI 10.1590/S1135-57272006000500009; Ding GJ, 2013, J HIGH ENERGY PHYS, DOI 10.1007/JHEP12(2013)006; Direccion General de Salud Publica Calidad e Innovacion, 2017, ENC HOSP PAC CON INF; Edmundson C, 2018, INT J DRUG POLICY, V55, P131, DOI 10.1016/j.drugpo.2018.02.002; Eignor DR, 2001, EUR J PSYCHOL ASSESS, V17, P157, DOI 10.1027//1015-5759.17.3.157; European Monitoring Centre for Drugs and Drug Addiction, SPAIN DRUG REP 2018; European Monitoring Centre for Drugs and Drug Addiction, EUR DRUG REP; Folch C, 2015, MED CLIN-BARCELONA, V145, P102, DOI 10.1016/j.medcli.2014.04.030; Folch C, 2010, EUR J PUBLIC HEALTH, V20, P139, DOI 10.1093/eurpub/ckp091; Garin N, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014105; Garin N, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00690; Glynn RW, 2018, INT J DRUG POLICY, V52, P9, DOI 10.1016/j.drugpo.2017.10.008; Gonzalez-Baeza A, 2018, AIDS PATIENT CARE ST, V32, P112, DOI 10.1089/apc.2017.0263; Grabovac I, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26413-5; Jose MAF., 2015, REV MULTIDISCIPLINAR, V3, P7; Korthuis PT, 2018, ADDICT SCI CLIN PRAC, V13, DOI 10.1186/s13722-018-0114-4; Kumar S, 2015, EXPERT OPIN DRUG MET, V11, P343, DOI 10.1517/17425255.2015.996546; Li J, 2014, SEX TRANSM INFECT, V90, P125, DOI 10.1136/sextrans-2013-051195; Lix LM, 1996, REV EDUC RES, V66, P579, DOI 10.2307/1170654; Maxwell S, 2019, INT J DRUG POLICY, V63, P74, DOI 10.1016/j.drugpo.2018.11.014; Network TE, 2013, EMIS 2010 EUR MEN WH; Norusis MJ, 2004, SPSS 12 0 STAT PROCE; Okazaki S, 2006, INFORM MANAGE-AMSTER, V43, P127, DOI 10.1016/j.im.2005.05.001; Ottaway Z, 2017, INT J STD AIDS, V28, P91, DOI 10.1177/0956462416666753; Perez C., 2004, TECNICAS ANALISIS MU; Pufall EL, 2018, HIV MED, V19, P261, DOI 10.1111/hiv.12574; Ramos C, 2019, REV MULTIDISCIP SIDA, V7, P48; Remor E, 2013, PATIENT, V6, P61, DOI 10.1007/s40271-013-0009-0; Revicki DA, 2007, QUAL LIFE RES, V16, P717, DOI 10.1007/s11136-006-9153-5; Saitz R, 2014, J STUD ALCOHOL DRUGS, V75, P153, DOI 10.15288/jsad.2014.75.153; Schmidt AJ, 2016, INT J DRUG POLICY, V38, P4, DOI 10.1016/j.drugpo.2016.09.007; Semple S, 2009, AM J ADDICTION, V18, P65, DOI 10.1080/10550490802544466; Staltari Orietta, 2014, Recent Pat CNS Drug Discov, V9, P153; Stardust Z, 2018, SEX HEALTH, V15, P179, DOI 10.1071/SH17145; Strathdee Steffanie A, 2010, Curr HIV/AIDS Rep, V7, P99, DOI 10.1007/s11904-010-0043-7; Stuart D., 2015, HIV NURS, V15, P24; UNAIDS, UNAIDS DAT 2017; *UNAIDS, UNAIDS DAT 2018; Vigilancia epidemiologica del VIH y SIDA en Espana, 2016, VIG EP VIH SIDA ESP; Wallerstein NB, 2006, HEALTH PROMOT PRACT, V7, P312, DOI 10.1177/1524839906289376; Williams EC, 2016, ALCOHOL CLIN EXP RES, V40, P2056, DOI 10.1111/acer.13204; Zaro I., 2016, CLOSER LOOK CHEMSEX	51	13	13	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2019	14	6							e0211252	10.1371/journal.pone.0211252	http://dx.doi.org/10.1371/journal.pone.0211252			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW3OC	31206550	Green Submitted, Green Published, gold			2023-01-03	WOS:000484890300002
J	Walter, J; Tufman, A; Holle, R; Schwarzkopf, L				Walter, Julia; Tufman, Amanda; Holle, Rolf; Schwarzkopf, Larissa			"Age matters"- German claims data indicate disparities in lung cancer care between elderly and young patients	PLOS ONE			English	Article							SURVIVAL; OCTOGENARIANS; DIAGNOSIS; OLDER; UNDERTREATMENT; PREVALENCE; MANAGEMENT; SOCIETY; NSCLC; PAIN	Background Although lung cancer is most commonly diagnosed in elderly patients, evidence about tumor-directed therapy in elderly patients is sparse, and it is unclear to what extent this affects treatment and care. Our study aimed to discover potential disparities in care between elderly patients and those under 65 years of age. Methods We studied claims from 13 283 German patients diagnosed with lung cancer in 2009 who survived for at least 90 days after diagnosis. We classified patients as "non-elderly" (<= 65), "young-old" (65-74), "middle-old" (75-84), and "old-old" (>= 85). We compared receipt of tumor-directed therapy (6 months after diagnosis), palliative care, opioids, antidepressants, and pathologic diagnosis confirmation via logistic regression. We used generalized linear regression (gamma distribution) to compare group-specific costs of care for 3 months after diagnosis. We adjusted all models by age, nursing home residency, nursing care need, comorbidity burden, and area of residence (urban, rural). The age group "non-elderly" served as reference group. Results Compared with the reference group "non-elderly", the likelihood of receiving any tumor-directed treatment was significantly lower in all age groups with a decreasing gradient with advancing age. Elderly lung cancer patients received significantly fewer resections and radiotherapy than non-elderly patients. In particular, treatment with antineoplastic therapy declined with increasing age ("young-old" (OR = 0.76, CI = [0.70,0.83]), "middle-old" (OR = 0.45, CI = [0.36,0.50]), and "old-old" (OR = 0.13, CI = [0.10,0.17])). Patients in all age groups were less likely to receive structured palliative care than "non-elderly" ("young-old" (OR = 0.84, CI = [0.76,0.92]), "middle-old" (OR = 0.71, CI = [0.63,0.79]), and "old-old" (OR = 0.57, CI = [0.44,0.73])). Moreover, increased age was significantly associated with reduced quotas for outpatient treatment with opioids and antidepressants. Costs of care decreased significantly with increasing age. Conclusion This study suggests the existence of age-dependent care disparities in lung cancer patients, where elderly patients are at risk of potential undertreatment. To support equal access to care, adjustments to public health policies seem to be urgently required.	[Walter, Julia; Holle, Rolf; Schwarzkopf, Larissa] Helmholtz Zentrum Munchen, Inst Hlth Econ & Hlth Care Management IGM, German Res Ctr Environm Hlth, Munich, Germany; [Walter, Julia; Tufman, Amanda; Schwarzkopf, Larissa] German Ctr Lung Res DZL, Giessen, Germany; [Tufman, Amanda] Ludwig Maximilians Univ Hosp LMU Munich, Med Clin Pneumol 5, Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Walter, J (corresponding author), Helmholtz Zentrum Munchen, Inst Hlth Econ & Hlth Care Management IGM, German Res Ctr Environm Hlth, Munich, Germany.; Walter, J (corresponding author), German Ctr Lung Res DZL, Giessen, Germany.	Julia.Walter@helmholtz-muenchen.de	Schwarzkopf, Larissa/O-5157-2015	Schwarzkopf, Larissa/0000-0002-9402-7700				Ambroggi M, 2015, ONCOLOGIST, V20, P1378, DOI 10.1634/theoncologist.2015-0110; Ashbury FD, 2003, SUPPORT CARE CANCER, V11, P278, DOI 10.1007/s00520-003-0446-8; Baimatova I, 2015, NEW ZEAL MED J, V128, P29; Barrera-Rodriguez R, 2012, LUNG CANCER-TARGETS, V3, P79, DOI 10.2147/LCTT.S37319; Bernabei R, 1998, JAMA-J AM MED ASSOC, V279, P1877, DOI 10.1001/jama.279.23.1877; Berry MF, 2013, J THORAC ONCOL, V8, P744, DOI 10.1097/JTO.0b013e31828916aa; Blanchard EM, 2010, J THORAC ONCOL, V5, P909, DOI 10.1097/JTO.0b013e3181d89b48; Cancer Research UK, 2016, MIDDL AG MOR LIK DIA; Cancer Research UK, 2017, LUNG CANC INC STAT; Cassidy RJ, 2018, CANCER-AM CANCER SOC, V124, P775, DOI 10.1002/cncr.31077; Clark D, 1999, SOC SCI MED, V49, P727, DOI 10.1016/S0277-9536(99)00098-2; Costa GJ, 2017, J CANCER RES CLIN, V143, P1469, DOI 10.1007/s00432-017-2412-8; Davidoff AJ, 2010, J CLIN ONCOL, V28, P2191, DOI 10.1200/JCO.2009.25.4052; Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419; Findley Patricia A, 2012, Depress Res Treat, V2012, P676784, DOI 10.1155/2012/676784; Gajra A, 2017, J GERIATR ONCOL, V8, P16, DOI 10.1016/j.jgo.2016.12.007; Girones R, 2012, CLIN TRANSL ONCOL, V14, P183, DOI 10.1007/s12094-012-0782-6; Goeckenjan G, 2010, Pneumologie, V64 Suppl 2, pe1, DOI 10.1055/s-0029-1243837; Graubard BI, 1999, BIOMETRICS, V55, P652, DOI 10.1111/j.0006-341X.1999.00652.x; Gridelli C, 2007, J CLIN ONCOL, V25, P1898, DOI 10.1200/JCO.2006.10.3085; Guerra M, 2013, INTERACT CARDIOV TH, V16, P673, DOI 10.1093/icvts/ivt020; Hopwood P, 2000, J CLIN ONCOL, V18, P893, DOI 10.1200/JCO.2000.18.4.893; Huang HL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101731; Hung MS, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006864; Hurria A, 2010, J GERIATR ONCOL, V1, P1, DOI 10.1016/j.jgo.2010.04.001; Lekka D, 2014, PAIN RES TREAT, V2014, DOI 10.1155/2014/312941; Lewis JH, 2003, J CLIN ONCOL, V21, P1383, DOI 10.1200/JCO.2003.08.010; Max Gordon TL, 2017, ADV FOR PLOT US GRID; National Cancer Equality Initiative/ Pharmaceutical Oncology Initiative, 2012, IMP PAT AG CLIN DEC; National Cancer Institute, 2017, SURV EP END RES PROG; Owonikoko TK, 2007, J CLIN ONCOL, V25, P5570, DOI 10.1200/JCO.2007.12.5435; Oxnard GR, 2007, J THORAC ONCOL, V2, P1029, DOI 10.1097/JTO.0b013e318158d4a2; Pallis AG, 2014, ANN ONCOL, V25, P1270, DOI 10.1093/annonc/mdu022; Palma DA, 2010, J THORAC ONCOL, V5, P818, DOI 10.1097/JTO.0b013e3181d6e052; Pang HH, 2016, J CLIN ONCOL, V34, P3992, DOI 10.1200/JCO.2016.67.7088; Postmus PE, 2017, ANN ONCOL, V28, P1, DOI 10.1093/annonc/mdx222; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Rao Arati, 2004, J Natl Cancer Inst Monogr, P150; Robert Koch Institut, 2019, KREBSR; Robert Koch Institut, 2012, KREBS DEUTSCHL 2011; Rothgang H, 2010, SOC POLICY ADMIN, V44, P436, DOI 10.1111/j.1467-9515.2010.00722.x; Schwarzkopf L, 2015, LUNG CANCER, V90, P274, DOI 10.1016/j.lungcan.2015.09.005; Shenoy Premnath, 2015, Perspect Clin Res, V6, P184, DOI 10.4103/2229-3485.167099; Statistisches Bundesamt der Bundesrepublik Deutschland, 2019, TOD DEUTSCHL 2016; Swart E, 2015, GESUNDHEITSWESEN, V77, DOI [10.1055/s-0034-1396815, 10.1055/s-0035-1562981]; Tabchi S, 2017, CURR ONCOL, V24, pE115, DOI 10.3747/co.24.3355; Tas F, 2013, ONCOL LETT, V6, P1507, DOI 10.3892/ol.2013.1566; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Thomas AA, 2017, J EPIDEMIOL COMMUN H, V71, P468, DOI 10.1136/jech-2016-208113; van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340; Walter J, 2018, SUPPORTIVE CARE CANC; Wisnivesky JP, 2007, J CLIN ONCOL, V25, P1705, DOI 10.1200/JCO.2006.08.1455	52	13	13	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2019	14	6							e0217434	10.1371/journal.pone.0217434	http://dx.doi.org/10.1371/journal.pone.0217434			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IC8MD	31188861	Green Submitted, gold, Green Published			2023-01-03	WOS:000471234500026
J	Jamieson, JJ; Gerecht, S				Jamieson, John J.; Gerecht, Sharon			Chipping Away at Blood-Brain-Barrier Modeling	CELL STEM CELL			English	Editorial Material							ENDOTHELIAL-CELLS	In this issue, Vatine et al. (2019) present a fully human blood-brain barrier chip that accurately predicts drug permeability and can be perfused with whole blood. Utilizing patient-derived tissue, they recapitulate disease-specific defects and establish a platform to advance drug screening and disease modeling.	[Jamieson, John J.; Gerecht, Sharon] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; [Jamieson, John J.; Gerecht, Sharon] Johns Hopkins Univ, Inst NanoBioTechnol, Baltimore, MD 21218 USA; [Gerecht, Sharon] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA; [Gerecht, Sharon] Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Gerecht, S (corresponding author), Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA.; Gerecht, S (corresponding author), Johns Hopkins Univ, Inst NanoBioTechnol, Baltimore, MD 21218 USA.; Gerecht, S (corresponding author), Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA.; Gerecht, S (corresponding author), Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA.	gerecht@jhu.edu	Gerecht, Sharon/HCH-8629-2022	Gerecht, Sharon/0000-0002-8542-4835				Campisi M, 2018, BIOMATERIALS, V180, P117, DOI 10.1016/j.biomaterials.2018.07.014; DeStefano JG, 2018, FLUIDS BARRIERS CNS, V15, DOI 10.1186/s12987-018-0117-2; Jamieson JJ, 2019, FLUIDS BARRIERS CNS, V16, DOI 10.1186/s12987-019-0136-7; Lim RG, 2017, CELL REP, V19, P1365, DOI 10.1016/j.celrep.2017.04.021; Linville RM, 2019, BIOMATERIALS, V190, P24, DOI 10.1016/j.biomaterials.2018.10.023; Smith Q, 2018, CELL REP, V24, P895, DOI [10.1016/j.celrep.2018.06.083, 10.1016/j.celrep.2018.08.005]; Stebbins MJ, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau7375; Vatine G.D., 2019, CELL STEM CELL, V24; Vatine GD, 2017, CELL STEM CELL, V20, P831, DOI 10.1016/j.stem.2017.04.002; Zhao Z, 2015, CELL, V163, P1064, DOI 10.1016/j.cell.2015.10.067	10	2	2	4	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	1934-5909	1875-9777		CELL STEM CELL	Cell Stem Cell	JUN 6	2019	24	6					831	832		10.1016/j.stem.2019.05.014	http://dx.doi.org/10.1016/j.stem.2019.05.014			2	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	IB5KH	31173708	Bronze			2023-01-03	WOS:000470309800001
J	Pfister, PB; de Bruin, ED; Bastiaenen, CHG; Maurer, B; Knols, RH				Pfister, Pierrette Baschung; de Bruin, Eling D.; Bastiaenen, Caroline H. G.; Maurer, Britta; Knols, Ruud H.			Reliability and validity of the German version of the Myositis Activities Profile (MAP) in patients with inflammatory myopathy	PLOS ONE			English	Article							CULTURAL-ADAPTATION; POLYMYOSITIS; ADULT; QUESTIONNAIRE; EPIDEMIOLOGY; TRANSLATION; VALIDATION	The Myositis Activity Profile (MAP) is the only disease-specific questionnaire to assess limitations in activities of daily living (ADL) in patients with inflammatory myopathy (IM). Because a German version does not currently exist, this study's aim was to translate the MAP and assess reliability and construct validity of the new version. Therefore, a cross-cultural adaptation was performed following international guidelines. Forty-eight patients with IM completed the German-MAP, twice within two weeks. They were also assessed using the Health Assessment Questionnaire (HAQ), 36-Item Short Form Survey (SF36), Manual Muscle Test (MMT8), Quantitative Muscle Testing (QMT) and Functional Index (FI-2). For discriminant validity, 48 age-and gender-matched healthy controls completed the German-MAP. Reliability was assessed using weighted kappa (K-w). Correlations between the MAP and the HAQ, the physical (PCM) and mental (MCS) component scores of SF36 and the MMT8 and QMT muscle tests were assessed using Spearman correlation analysis. Discriminative validity was assessed by calculating the Area under the Curve (AUC). The German-MAP showed substantial reliability for the four subscales (K-w: 0.65-0.71) and moderate to substantial reliability for the single items (K-w: 0.57-0.77). The MAP showed good construct validity (high correlations with HAQ and PCM, moderate with FI-2, QMT and MMT8 and poor with MCS and pain) and acceptable discrimination for three subscales and two single items (AUC: 0.65-0.79). In conclusion, the German-MAP appears to be a reliable and valid questionnaire to assess ADL-limitations in patients with IM. Further research is required, both to substantiate these results and to evaluate responsiveness.	[Pfister, Pierrette Baschung; Knols, Ruud H.] Univ Hosp Zurich, Directorate Res & Educ, Physiotherapy Occupat Therapy Res Ctr, Zurich, Switzerland; [Pfister, Pierrette Baschung; Bastiaenen, Caroline H. G.] Maastricht Univ, CAPHRI Sch Publ Hlth & Primary Care, Dept Epidemiol, Maastricht, Netherlands; [de Bruin, Eling D.] Swiss Fed Inst Technol, Inst Human Movement Sci & Sport, Dept Hlth Sci & Technol, Zurich, Switzerland; [de Bruin, Eling D.] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Div Physiotherapy, Huddinge, Sweden; [Bastiaenen, Caroline H. G.] Maastricht Univ, Dept Epidemiol, Caphri Res Inst, Res Line Functioning & Rehabil, Maastricht, Netherlands; [Maurer, Britta] Univ Hosp Zurich, Div Rheumatol, Zurich, Switzerland; [Maurer, Britta] Univ Hosp Zurich, Lab Syst Autoimmune Dis, Zurich, Switzerland	University of Zurich; University Zurich Hospital; Maastricht University; Swiss Federal Institutes of Technology Domain; ETH Zurich; Karolinska Institutet; Maastricht University; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	de Bruin, ED (corresponding author), Swiss Fed Inst Technol, Inst Human Movement Sci & Sport, Dept Hlth Sci & Technol, Zurich, Switzerland.; de Bruin, ED (corresponding author), Karolinska Inst, Dept Neurobiol Care Sci & Soc, Div Physiotherapy, Huddinge, Sweden.	eling.debruin@hest.ethz.ch	de Bruin, Eling D./A-4751-2011	de Bruin, Eling D./0000-0002-6542-7385				Alexanderson H, 2006, ARTHRIT RHEUM-ARTHR, V55, P114, DOI 10.1002/art.21715; Alexanderson H, 2002, J RHEUMATOL, V29, P2386; Alexanderson H, 2012, J RHEUMATOL, V39, P2134, DOI 10.3899/jrheum.120504; Alkotob ML, 2006, CHEST, V130, P176, DOI 10.1378/chest.130.1.176; Beaton DE, 2000, SPINE, V25, P3186, DOI 10.1097/00007632-200012150-00014; Bernatsky S, 2011, J RHEUMATOL, V38, P885, DOI 10.3899/jrheum.101083; BOHAN A, 1975, NEW ENGL J MED, V292, P403, DOI 10.1056/NEJM197502202920807; BULLINGER M, 1995, SOC SCI MED, V41, P1359, DOI 10.1016/0277-9536(95)00115-N; DALAKAS MC, 1991, NEW ENGL J MED, V325, P1487, DOI 10.1056/NEJM199111213252107; de Vet HC, 2011, MEASUREMENT MED PRAC; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; Furst DE, 2012, MUSCLE NERVE, V45, P676, DOI 10.1002/mus.23302; Greenberg SA, 2008, SEMIN NEUROL, V28, P241, DOI 10.1055/s-2008-1062267; Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543; Hosmer D. J., 2013, APPL LOGISTIC REGRES, DOI DOI 10.1002/9781118548387; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Mastaglia FL, 2002, RHEUM DIS CLIN N AM, V28, P723, DOI 10.1016/S0889-857X(02)00021-2; Mokkink LB, 2010, J CLIN EPIDEMIOL, V63, P737, DOI 10.1016/j.jclinepi.2010.02.006; Munro B., 1997, STAT METHODS HLTH CA; Rider LG, 2011, ARTHRIT CARE RES, V63, pS118, DOI 10.1002/acr.20532; Rider LG, 2010, ARTHRIT CARE RES, V62, P465, DOI 10.1002/acr.20035; Schonbrodt FD, 2013, J RES PERS, V47, P609, DOI 10.1016/j.jrp.2013.05.009; Vincze M, 2012, BEST PRACT RES CL RH, V26, P25, DOI 10.1016/j.berh.2012.01.013; Wild D, 2005, VALUE HEALTH, V8, P94, DOI 10.1111/j.1524-4733.2005.04054.x	24	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2019	14	6							e0217173	10.1371/journal.pone.0217173	http://dx.doi.org/10.1371/journal.pone.0217173			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IA9ZE	31158240	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000469915700010
J	Armstrong, MJ; Alliance, S; Taylor, A; Corsentino, P; Galvin, JE				Armstrong, Melissa J.; Alliance, Slande; Taylor, Angela; Corsentino, Pamela; Galvin, James E.			End-of-life experiences in dementia with Lewy bodies: Qualitative interviews with former caregivers	PLOS ONE			English	Article							PALLIATIVE CARE; BODY DEMENTIA; MANAGEMENT; DIAGNOSIS; SURVIVAL; DISEASE; RESIDENTS; MORTALITY; PEOPLE; NEEDS	Background Dementia caregivers describe knowing what to expect as an unmet need and many are unaware that dementia can be a terminal condition. Dementia with Lewy bodies (DLB) is a common neurodegenerative dementia with unique features which may affect the end of life (EOL). Given the paucity of data on EOL experiences in dementia and unique aspects of DLB affecting EOL, we investigated EOL experiences as reported by caregivers of individuals with DLB. Method We conducted telephone interviews with caregivers and family members of individuals who died with DLB in the last 5 years using a semi-structured questionnaire to identify and describe EOL experiences. We used a qualitative descriptive approach to analyze interview transcripts and identify common themes. Results Thirty individuals participated in interviews. Key themes included lack of knowledge regarding what to expect, end-of-life time course (including end-of-life symptoms, declines after hospitalization and falls, and varied EOL trajectories), advance care planning, lack of family understanding, hospice, views regarding right-to-die, medications at the end of life, approaching end of life, the death experience, and activities that enhanced end of life. Lack of communication between health care teams and families and difficulty predicting death timing were two frequently expressed challenges. Conclusions Study results emphasize the need for improved EOL counseling in DLB, recognition of EOL symptoms, earlier hospice involvement, tailoring EOL care to DLB-specific needs, and clinician-family communication. Suggestions for patient and family education are provided. Further research should confirm predictors of approaching EOL in DLB, identify strategies to improve physician recognition of EOL, and develop tools to aid communication and quality EOL care.	[Armstrong, Melissa J.; Alliance, Slande] Univ Florida, Coll Med, Dept Neurol, Gainesville, FL 32611 USA; [Armstrong, Melissa J.] Univ Florida, McKnight Brain Inst, Gainesville, FL 32611 USA; [Taylor, Angela; Corsentino, Pamela] Lewy Body Dementia Assoc, Lilburn, GA USA; [Galvin, James E.] Florida Atlantic Univ, Charles E Schmidt Coll Med, Comprehens Ctr Brain Hlth, Boca Raton, FL 33431 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; Florida Atlantic University	Armstrong, MJ (corresponding author), Univ Florida, Coll Med, Dept Neurol, Gainesville, FL 32611 USA.; Armstrong, MJ (corresponding author), Univ Florida, McKnight Brain Inst, Gainesville, FL 32611 USA.	melissa.armstrong@neurology.ufl.edu	Galvin, James/AAM-7492-2021	Armstrong, Melissa/0000-0002-2163-1907; Alliance, Slande/0000-0003-1290-8422	ARHQ K08 career development award [K08HS24159]; 1Florida ADRC pilot grant [AG047266]; Michael J. Fox Foundation; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS024159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS100610, R01NS088040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG057681, R01AG054425, R01AG056531, R01AG056610, R01AG040211] Funding Source: NIH RePORTER	ARHQ K08 career development award; 1Florida ADRC pilot grant; Michael J. Fox Foundation; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	MJA is supported by an ARHQ K08 career development award (K08HS24159), a 1Florida ADRC (AG047266) pilot grant, and as the local PI of a Lewy Body Dementia Association Research Center of Excellence. Staff from the LBDA participated in data collection, analysis, and preparation of the manuscript. MJA previously received research support from the Michael J. Fox Foundation. MJA receives royalties from the publication of the book Parkinson's Disease: Improving Patient Care. MJA receives compensation from the American Academy of Neurology for work as an evidence-based medicine methodology consultant and has participated as faculty in the annual meeting of the American Academy of Neurology and for Medscape CME. These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alzheimer's A., 2017, ALZHEIMERS DEMENT, V13, P325, DOI DOI 10.1016/J.JALZ.2017.02.001; Armstrong MJ, 2019, J AM GERIATR SOC, V67, P67, DOI 10.1111/jgs.15608; Barker WW, 2002, ALZ DIS ASSOC DIS, V16, P203, DOI 10.1097/00002093-200210000-00001; Beernaert K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137251; Biola H, 2007, J AM GERIATR SOC, V55, P846, DOI 10.1111/j.1532-5415.2007.01179.x; Bostrom F, 2007, ALZ DIS ASSOC DIS, V21, P150, DOI 10.1097/WAD.0b013e318065c4a9; Colorafi KJ, 2016, HERD-HEALTH ENV RES, V9, P16, DOI 10.1177/1937586715614171; de Beaufort ID, 2016, J NEUROL, V263, P1463, DOI 10.1007/s00415-016-8095-2; de Lau LML, 2005, ARCH NEUROL-CHICAGO, V62, P1265, DOI 10.1001/archneur.62.8.1265; Dionne-Odom JN, 2019, PALLIAT SUPPORT CARE, V17, P643, DOI 10.1017/S1478951519000154; Erel M, 2017, ANN PALLIAT MED, V6, P365, DOI 10.21037/apm.2017.06.13; Galvin JE, 2010, PARKINSONISM RELAT D, V16, P388, DOI 10.1016/j.parkreldis.2010.03.007; Galvin JE, 2010, ALZ DIS ASSOC DIS, V24, P177, DOI 10.1097/WAD.0b013e3181c72b5d; Garcia-Ptacek S, 2016, J AM GERIATR SOC, V64, pE137, DOI 10.1111/jgs.14421; Hely MA, 2008, MOVEMENT DISORD, V23, P837, DOI 10.1002/mds.21956; Hennings J, 2010, REV CLIN GERONTOL, V20, P114, DOI 10.1017/S0959259810000092; Jennings LA, 2015, J AM GERIATR SOC, V63, P282, DOI 10.1111/jgs.13251; Klapwijk MS, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-99; Lee RP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179355; Lewis LF, 2014, QUAL HEALTH RES, V24, P1221, DOI 10.1177/1049732314545888; MCKEITH I, 1992, BRIT MED J, V305, P673, DOI 10.1136/bmj.305.6855.673; McKeith IG, 2017, NEUROLOGY, V89, P88, DOI 10.1212/WNL.0000000000004058; McKeith IG, 2005, NEUROLOGY, V65, P1863, DOI 10.1212/01.wnl.0000187889.17253.b1; Millenaar JK, 2016, INT J GERIATR PSYCH, V31, P1261, DOI 10.1002/gps.4502; Mitchell SL, 2015, NEW ENGL J MED, V372, P2533, DOI [10.1056/NEJMcp1412652, 10.1056/NEJMc1509349]; Mitchell SL, 2010, JAMA-J AM MED ASSOC, V304, P1929, DOI 10.1001/jama.2010.1572; Moscovich M, 2017, PARKINSONISM RELAT D, V41, P99, DOI 10.1016/j.parkreldis.2017.05.022; Price A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017504; REISBERG B, 1982, AM J PSYCHIAT, V139, P1136; Sanders AE, 2017, NEUROLOGY, V88, P1951, DOI 10.1212/WNL.0000000000003917; Toles M, 2018, J AM MED DIR ASSOC, V19, P879, DOI 10.1016/j.jamda.2018.05.015; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; van der Steen JT, 2014, PALLIATIVE MED, V28, P197, DOI 10.1177/0269216313493685; van der Steen JT, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-105; Vandervoort A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091130; Walker Z, 2000, INT J GERIATR PSYCH, V15, P267, DOI 10.1002/(SICI)1099-1166(200003)15:3<267::AID-GPS107>3.0.CO;2-7; Williams MM, 2006, NEUROLOGY, V67, P1935, DOI 10.1212/01.wnl.0000247041.63081.98	37	17	17	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2019	14	5							e0217039	10.1371/journal.pone.0217039	http://dx.doi.org/10.1371/journal.pone.0217039			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IA2XG	31145749	gold, Green Published, Green Submitted			2023-01-03	WOS:000469425500008
J	Masese, RV; Bulgin, D; Douglas, C; Shah, N; Tanabe, P				Masese, Rita Vanessa; Bulgin, Dominique; Douglas, Christian; Shah, Nirmish; Tanabe, Paula			Barriers and facilitators to care for individuals with sickle cell disease in central North Carolina: The emergency department providers' perspective	PLOS ONE			English	Article							MANAGEMENT	Background Sickle cell disease (SCD) is an inherited blood disorder associated with acute pain crisis and other complications that lead to frequent emergency department (ED) visits. To improve outcomes, the National Heart, Lung and Blood Institute (NHLBI) published recommendations for management of acute pain crisis. NHLBI also funded eight centers across the United States to participate in the Sickle Cell Disease Implementation Consortium. This six-year effort consists of two phases. Phase one involved conducting needs assessments of barriers and facilitators to SCD care. The aim of this study was to describe challenges and facilitators to caring for SCD from the perspective of ED providers in central North Carolina (NC). Methods and findings We conducted a needs assessment survey with ED providers throughout NC. We also conducted focus groups and an interview with ED providers from three healthcare facilities in central NC. One hundred and eleven surveys (60.6% physicians, 26% registered nurses, 13.5% physician assistants) were completed and 13 providers participated in 3 focus groups and 1 interview. Slightly more than half (50.4%) utilized individualized dosing protocols to treat sickle cell pain. Only 32.4% of the providers were aware of the NHLBI SCD recommendations. Barriers to care from the survey included: patient behavior (67.57%), the opioid epidemic (67.57%), overcrowding (64.86%), and concern about addiction (49.55%). Perceived barriers to care identified in the focus groups and interview included: high patient volumes, lack of SCD care protocols, poor communication among providers and stigma. Facilitators to care included: individualized pain plans, comfort prescribing opioids and electronic medical records. Conclusion SCD care is influenced by many factors. Our results illuminate the need for increased use of the NHLBI SCD recommendations, individualized pain protocols, and use of electronic medical records and other care-interventions, specifically geared towards improving provider knowledge and mitigating provider bias.	[Masese, Rita Vanessa; Bulgin, Dominique; Tanabe, Paula] Duke Univ, Sch Nursing, Durham, NC 27708 USA; [Douglas, Christian] Duke Univ, Off Clin Res, Durham, NC USA; [Shah, Nirmish] Duke Univ, Med Ctr, Durham, NC USA	Duke University; Duke University; Duke University	Masese, RV (corresponding author), Duke Univ, Sch Nursing, Durham, NC 27708 USA.	rita.masese@duke.edu	Masese, Rita Vanessa/V-9852-2019	Masese, Rita Vanessa/0000-0002-1431-8840; Bulgin, Dominique/0000-0002-4030-0791	US Federal Government from the National Heart Lung and Blood Institute [HL133948, HL133964, HL133990, HL133996, HL133994, HL133997, HL134004, HL134007, HL134042]; National Institute on Minority Health and Health Disparities (Bethesda, MD); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL133964] Funding Source: NIH RePORTER	US Federal Government from the National Heart Lung and Blood Institute; National Institute on Minority Health and Health Disparities (Bethesda, MD); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The study is part of the Sickle Cell Disease Implementation Consortium which has been supported by US Federal Government cooperative agreements HL133948, HL133964, HL133990, HL133996, HL133994, HL133997, HL134004, HL134007, and HL134042 from the National Heart Lung and Blood Institute and the National Institute on Minority Health and Health Disparities (Bethesda, MD).	Beach MC, 2005, MED CARE, V43, P356, DOI 10.1097/01.mlr.0000156861.58905.96; Binding A, 2019, CAN J EMERG MED, V21, P55, DOI 10.1017/cem.2017.413; Bowers D, 2001, Proc (Bayl Univ Med Cent), V14, P347; Centers for Disease Control, 2018, DRUG OV DEATHS DRUG; Kato-Lin YC, 2014, INT J MED INFORM, V83, P814, DOI 10.1016/j.ijmedinf.2014.08.003; Kavanagh PL, 2015, PEDIATRICS, V136, pE1016, DOI 10.1542/peds.2014-3470; Lewin S, 2001, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003267/abstract, DOI 10.1002/14651858.CD003267/ABSTRACT]; Mager Amy, 2017, J Opioid Manag, V13, P143, DOI 10.5055/jom.2017.0382; Murnik M, FAM MED, V38, P5; Ozair Fouzia F, 2015, Perspect Clin Res, V6, P73, DOI 10.4103/2229-3485.153997; Saunders B, 2018, QUAL QUANT, V52, P1893, DOI 10.1007/s11135-017-0574-8; Schefft MR, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.27274; Scholl L., 2019, MMWR-MORBID MORTAL W, P67; Yawn BP, 2014, JAMA-J AM MED ASSOC, V312, P1033, DOI 10.1001/jama.2014.10517; 2014, PEDIAT BLOOD CANC, V61, P1747, DOI DOI 10.1002/PBC.25024; 2013, PUBLIC HLTH REP, V128, P110, DOI DOI 10.1177/003335491312800206; 2015, AM J HEMATOL, V90, P376, DOI DOI 10.1002/AJH.23961; 2007, ACAD EMERG MED, V14, P419, DOI DOI 10.1111/J.1553-2712.2007.TB01801.X; 2013, ANN EMERG MED, V62, P293, DOI DOI 10.1016/J.ANNEMERGMED.2013.02.004; 2018, PROF CASE MANAG, V23, P213, DOI DOI 10.1097/NCM.0000000000000260; 2009, J NATL MED ASSOC, V101, P1022; 2009, ANN EMERG MED, V54, P279, DOI DOI 10.1016/J.ANNEMERGMED.2008.10.030; 2010, CLIN J PAIN, V26, P199, DOI DOI 10.1097/AJP.0B013E3181BED10C; 2011, J MED LIBR ASSOC, V99, P15, DOI DOI 10.3163/1536-5050.99.1.005; 2005, ACAD EMERG MED, V12, P647, DOI DOI 10.1197/J.AEM.2005.02.015; 2018, AM J HEMATOL, V93, P159, DOI DOI 10.1002/AJH.24948; 2010, AM J HEMATOL, V85, P797, DOI DOI 10.1002/AJH.21807; 2016, ADV EMERG NURS J, V38, P199, DOI DOI 10.1097/TME.0000000000000106	28	19	19	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2019	14	5							e0216414	10.1371/journal.pone.0216414	http://dx.doi.org/10.1371/journal.pone.0216414			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX1JZ	31063506	Green Published, gold, Green Submitted			2023-01-03	WOS:000467148400029
J	Gimenes, FRE; Baysari, M; Walter, S; Moreira, LA; de Carvalho, REFL; Miasso, AI; Faleiros, F; Westbrook, J				Escobar Gimenes, Fernando Raphael; Baysari, Melissa; Walter, Scott; Moreira, Leticia Alves; Fontenele Lima de Carvalho, Rhanna Emanuela; Miasso, Adriana Inocenti; Faleiros, Fabiana; Westbrook, Johanna			Are patients with a nasally placed feeding tube at risk of potential drug-drug interactions? A multicentre cross-sectional study	PLOS ONE			English	Article							INTERNAL-MEDICINE WARD; INTENSIVE-CARE-UNIT; HOSPITALIZED-PATIENTS; GENERAL MEDICINE; PREVALENCE; POLYPHARMACY; MEDICATION; ERRORS	Aims The primary aims were to determine the rate of potential drug-drug interactions (pDDIs) in patients with nasally placed feeding tubes (NPFT) and the factors significantly associated with pDDIs. The secondary aim was to assess the change in pDDIs for patients between admission and discharge. Material and methods This multicentre study applied a cross-sectional design and was conducted in six Brazilian hospitals, from October 2016 to July 2018. Data from patients with NPFT were collected through electronic forms. All regular medications prescribed were recorded. Medications were classified according to the World Health Organization (WHO) Anatomical Therapeutic Chemical code. Drug-drug interaction screening software was used to screen patients' medications for pDDIs. Negative binomial regression was used to account for the over dispersed nature of the pDDI count. Since the number of pDDIs was closely related to the number of prescribed medications, we modelled the rate of pDDIs with the count of pDDIs as the numerator and the number of prescribed medications as the denominator; six variables were considered for inclusion: time (admission or discharge), patient age, patient gender, age-adjusted Charlson Comorbidity Index (CCI) score, type of prescription (electronic or handwritten) and patient care complexity. To account for correlation within the two time points (admission and discharge) for each patient a generalised estimating equations approach was used to adjust the standard error estimates. To test the change in pDDI rate between admission and discharge a full model of six variables was fitted to generate an adjusted estimate. Results In this study, 327 patients were included. At least one pDDI was found in more than 91% of patients on admission and discharge and most of these pDDIs were classified as major severity. Three factors were significantly associated with the rate of pDDIs per medication: patient age, patient care complexity and prescription type (handwritten vs electronic). There was no evidence of a difference in pDDI rate between admission and discharge. Conclusion Patients with a NPFT are at high risk of pDDIs. Drug interaction screening tools and computerized clinical decision support systems could be effective risk mitigation strategies for this patient group.	[Escobar Gimenes, Fernando Raphael; Moreira, Leticia Alves; Faleiros, Fabiana] Univ Sao Paulo Ribeirao Preto, Coll Nursing, Dept Gen & Specialized Nursing, Ribeirao Preto, SP, Brazil; [Baysari, Melissa; Walter, Scott; Westbrook, Johanna] Macquarie Univ, Australian Inst Hlth Innovat, Ctr Hlth Syst & Safety Res, Sydney, NSW, Australia; [Fontenele Lima de Carvalho, Rhanna Emanuela] Univ Estadual Ceara, Fortaleza, Ceara, Brazil; [Miasso, Adriana Inocenti] Univ Sao Paulo Ribeirao Preto, Coll Nursing, Dept Psychiat Nursing & Human Sci, Ribeirao Preto, SP, Brazil	Universidade de Sao Paulo; Macquarie University; Universidade Estadual do Ceara; Universidade de Sao Paulo	Gimenes, FRE (corresponding author), Univ Sao Paulo Ribeirao Preto, Coll Nursing, Dept Gen & Specialized Nursing, Ribeirao Preto, SP, Brazil.	fregimenes@eerp.usp.br	Westbrook, Johanna I/J-9045-2018; Faleiros, FABIANA/F-6038-2013; Gimenes, Fernanda Raphael Escobar/F-6692-2012; Miasso, Adriana I/H-2790-2012	Westbrook, Johanna I/0000-0003-1083-8192; Faleiros, FABIANA/0000-0003-3723-7944; Gimenes, Fernanda Raphael Escobar/0000-0002-5174-112X; Miasso, Adriana I/0000-0003-1726-7169; Baysari, Melissa/0000-0003-1645-9126	Scope Global PTY LTA [6396 2018]; Centre for Health Systems and Safety Research (CHSSR); Australian Institute for Health Innovation; Macquarie University	Scope Global PTY LTA; Centre for Health Systems and Safety Research (CHSSR); Australian Institute for Health Innovation; Macquarie University	FREG received the 2018 Australia Awards-Endeavour Research Fellowship (Recipient ID number: 6396 2018) from Scope Global PTY LTA. The Centre for Health Systems and Safety Research (CHSSR), Australian Institute for Health Innovation, from Macquarie University, supported the Research Fellowship Program. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The principal investigator wishes to thank the Centre for Health Systems and Safety Research (CHSSR), Australian Institute for Health Innovation, from Macquarie University, for supporting the Research Fellowship Program. We also wish to thank Thalyta Cardoso Alux Teixeira, Adriane Pinto de Medeiros, Ligia Menezes de Freitas and Patricia Rezende do Prado for supporting data collection at the hospital sites.	Ahmad A, 2015, J CLIN DIAGN RES, V9, pFC10, DOI 10.7860/JCDR/2015/11264.5608; Santos TRA, 2017, GERIATR GERONTOL INT, V17, P2336, DOI 10.1111/ggi.13070; Bajracharya N, 2018, J YOUNG PHARM, V10, P450, DOI 10.5530/jyp.2018.10.98; Bethi Y, 2018, EUR J HOSP PHARM, V25, P317, DOI 10.1136/ejhpharm-2017-001272; Bhagavathula Akshaya Srikanth, 2014, Asian Pacific Journal of Tropical Biomedicine, V4, pS204, DOI 10.12980/APJTB.4.2014C1172; Boullata JI, 2017, JPEN-PARENTER ENTER, V41, P15, DOI 10.1177/0148607116673053; Bucsa C, 2013, EUR J INTERN MED, V24, P27, DOI 10.1016/j.ejim.2012.09.011; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; de Melo DO, 2016, BRAZ J PHARM SCI, V52, P391, DOI [10.1590/S1984-82502016000300005, 10.1590/s1984-82502016000300005]; de Moura CS, 2012, REV SAUDE PUBL, V46, P1082, DOI 10.1590/S0034-89102013005000001; de Wit HAJM, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2376-1; Dookeeram D, 2017, INT J CLIN PHARM-NET, V39, P1119, DOI 10.1007/s11096-017-0520-9; Egger SS, 2003, EUR J CLIN PHARMACOL, V58, P773, DOI 10.1007/s00228-002-0557-z; Fokter N, 2010, WIEN KLIN WOCHENSCHR, V122, P81, DOI 10.1007/s00508-009-1251-2; Foroughinia F, 2016, J RES PHARM PRACT, V5, P285, DOI 10.4103/2279-042X.192455; Fugulin F, 2002, THESIS; GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340; Gujjarlamudi Hima Bindu, 2016, J Midlife Health, V7, P105; Heineck I, 2009, PHARM WORLD SCI, V31, P145, DOI 10.1007/s11096-008-9268-6; Huang YQ, 2014, J ZHEJIANG UNIV-SC B, V15, P58, DOI 10.1631/jzus.B1300109; Hurkens KPGM, 2017, INT J HOSP PHARM, V2, P1; Ismail M, 2016, INT J CLIN PHARM-NET, V38, P1052, DOI 10.1007/s11096-016-0340-3; Ismail M, 2013, INT J CLIN PHARM-NET, V35, P455, DOI 10.1007/s11096-013-9764-1; Jankovic SM, 2018, J CRIT CARE, V43, P1, DOI 10.1016/j.jcrc.2017.08.021; Jazbar J, 2018, RES SOC ADMIN PHARM, V14, P572, DOI 10.1016/j.sapharm.2017.07.004; Khandeparkar Akshay, 2017, Perspect Clin Res, V8, P180, DOI 10.4103/picr.PICR_132_16; Kovacevic M, 2017, INT J CLIN PRACT, V71, DOI 10.1111/ijcp.13005; Lonergan MT, 2010, AGE AGEING, V39, P495, DOI 10.1093/ageing/afq037; Lu Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep17357; McEvoy DS, 2017, J AM MED INFORM ASSN, V24, P331, DOI 10.1093/jamia/ocw114; Mitchell SL, 2003, JAMA-J AM MED ASSOC, V290, P73, DOI 10.1001/jama.290.1.73; Nuckols TK, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-56; Ojo O, 2015, NUTRIENTS, V7, P2524, DOI 10.3390/nu7042524; Onatade R, 2013, DRUG AGING, V30, P729, DOI 10.1007/s40266-013-0097-5; Pasina L, 2013, PHARMACOEPIDEM DR S, V22, P1054, DOI 10.1002/pds.3510; Radley DC, 2013, J AM MED INFORM ASSN, V20, P470, DOI 10.1136/amiajnl-2012-001241; Saleem A, 2017, INTEGR PHARM RES PRA, V6, P71, DOI 10.2147/IPRP.S128816; Shakeel F, 2018, SAUDI MED J, V39, P1207, DOI 10.15537/smj.2018.12.23430; Singh S, 2018, INT J BASIC CLIN PHA, V7, P655; Stoll P, 2015, INT J CLIN PHARM-NET, V37, P475, DOI 10.1007/s11096-015-0083-6; Straubhaar B, 2006, DRUG SAFETY, V29, P79, DOI 10.2165/00002018-200629010-00006; Tesfaye ZT, 2017, DRUG HEALTHC PATIENT, V9, P71, DOI 10.2147/DHPS.S126336; Thomson Reuters (Healthcare), 2018, IBM MICR US GUID; Thomson Reuters (Healthcare), 2011, MICR DRUG REAX SYST, V148; Viktil KK, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001461; Vonbach P, 2008, PHARM WORLD SCI, V30, P367, DOI 10.1007/s11096-008-9191-x; Westbrook JI, 2013, J AM MED INFORM ASSN, V20, P1159, DOI 10.1136/amiajnl-2013-001745; White R, 2015, HUM TECHN C IHTC2015, P1; Yasu T, 2018, GERIATR GERONTOL INT, V18, P187, DOI 10.1111/ggi.13181; Zheng WY, 2018, EUR J CLIN PHARMACOL, V74, P15, DOI 10.1007/s00228-017-2357-5	50	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2019	14	7							e0220248	10.1371/journal.pone.0220248	http://dx.doi.org/10.1371/journal.pone.0220248			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4XR	31365563	gold, Green Published, Green Submitted			2023-01-03	WOS:000484983600032
J	Wu, V; Yeerna, H; Nohata, N; Chiou, J; Harismendy, O; Raimondi, F; Inoue, A; Russell, RB; Tamayo, P; Gutkind, JS				Wu, Victoria; Yeerna, Huwate; Nohata, Nijiro; Chiou, Joshua; Harismendy, Olivier; Raimondi, Francesco; Inoue, Asuka; Russell, Robert B.; Tamayo, Pablo; Gutkind, J. Silvio			Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review						G protein-coupled receptor (GPCR); G protein; signal transduction; cancer; immunotherapy; drug repurposing; oncocrine signaling; precision therapies	SARCOMA-ASSOCIATED HERPESVIRUS; REGULATORY T-CELLS; HETEROTRIMERIC G-PROTEINS; EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER; COLON-CANCER; ACTIVATING MUTATIONS; CHEMOKINE RECEPTORS; SOMATIC MUTATIONS; SIGNALING PATHWAY	G protein-coupled receptors (GPCRs) are the largest gene family of cell membrane-associated molecules mediating signal transmission, and their involvement in key physiological functions is well-established. The ability of GPCRs to regulate a vast array of fundamental biological processes, such as cardiovascular functions, immune responses, hormone and enzyme release from endocrine and exocrine glands, neurotransmission, and sensory perception (e.g. vision, odor, and taste), is largely due to the diversity of these receptors and the layers of their downstream signaling circuits. Dysregulated expression and aberrant functions of GPCRs have been linked to some of the most prevalent human diseases, which renders GPCRs one of the top targets for pharmaceutical drug development. However, the study of the role of GPCRs in tumor biology has only just begun to make headway. Recent studies have shown that GPCRs can contribute to the many facets of tumorigenesis, including proliferation, survival, angiogenesis, invasion, metastasis, therapy resistance, and immune evasion. Indeed, GPCRs are widely dysregulated in cancer and yet are underexploited in oncology. We present here a comprehensive analysis of GPCR gene expression, copy number variation, and mutational signatures in 33 cancer types. We also highlight the emerging role of GPCRs as part of oncocrine networks promoting tumor growth, dissemination, and immune evasion, and we stress the potential benefits of targeting GPCRs and their signaling circuits in the new era of precision medicine and cancer immunotherapies.	[Wu, Victoria; Nohata, Nijiro; Gutkind, J. Silvio] UCSD Moores Canc Ctr, Dept Pharmacol, La Jolla, CA 92093 USA; [Yeerna, Huwate; Harismendy, Olivier; Tamayo, Pablo] UCSD Moores Canc Ctr, Dept Med, La Jolla, CA 92093 USA; [Chiou, Joshua] Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA; [Harismendy, Olivier] Univ Calif San Diego, Sch Med, Div Biomed Informat, La Jolla, CA 92093 USA; [Raimondi, Francesco; Russell, Robert B.] Heidelberg Univ, Bioquant, CellNetworks, Neuenheimer Feld 267, D-69120 Heidelberg, Germany; [Raimondi, Francesco; Russell, Robert B.] Heidelberg Univ, BZH, Neuenheimer Feld 328, D-69120 Heidelberg, Germany; [Inoue, Asuka] Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi 9808578, Japan; [Nohata, Nijiro] MSD KK, Oncol Sci Unit, Tokyo 1028667, Japan	University of California System; University of California San Diego; University of California System; University of California San Diego; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Tohoku University; Merck & Company	Gutkind, JS (corresponding author), UCSD Moores Canc Ctr, Dept Pharmacol, La Jolla, CA 92093 USA.	sgutkind@ucsd.edu	Russell, Robert/GWU-6389-2022; Harismendy, Olivier/AAM-2072-2021; Russell, Rob/AAH-9145-2019; Raimondi, Francesco/AAB-8586-2019; Nohata, Nijiro/H-5190-2011; Gutkind, J. Silvio/J-1201-2016	Russell, Robert/0000-0002-7213-1398; Harismendy, Olivier/0000-0002-8098-9888; Russell, Rob/0000-0002-1905-4717; Nohata, Nijiro/0000-0002-6816-2984; Gutkind, J. Silvio/0000-0002-5150-4482; Chiou, Joshua/0000-0002-4618-0647; RAIMONDI, Francesco/0000-0002-6891-3178	National Institutes of Health [R33CA225291, U54CA209891, U01-CA217885, P30-CA023100, R01-HG009285, R01-GM074024, R01-CA172513, U24-CA194107, U24-CA220341]; NCI [U01CA196406]; NIDCR [U01DE028227]; NATIONAL CANCER INSTITUTE [T32CA067754, U01CA196406, R33CA225291, U54CA209891, R01CA172513, U24CA194107, U24CA220341, U01CA217885, P30CA023100] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG009285] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [U01DE028227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074024] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by National Institutes of Health Grants R33CA225291 and U54CA209891 (to S. G. and V. W.) and U01CA196406 (to O. H.) from NCI, U01DE028227 from NIDCR (to S. G. and V. W.), and National Institutes of Health Grants U01-CA217885 and P30-CA023100 (to P. T. and H. Y.), and R01-HG009285, R01-GM074024, R01-CA172513, U24-CA194107, and U24-CA220341 (to P. T.). J. S. G. is a member of the Scientific Advisory Board of Oncoceutics Inc. and Domain Therapeutics. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Alakus H, 2014, GENOME MED, V6, DOI 10.1186/gm559; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Amano H, 2009, CANCER SCI, V100, P2318, DOI 10.1111/j.1349-7006.2009.01322.x; Amersi FF, 2008, CLIN CANCER RES, V14, P638, DOI 10.1158/1078-0432.CCR-07-2025; Anderson GR, 2017, CELL REP, V20, P999, DOI 10.1016/j.celrep.2017.07.006; Annala S, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aau5948; Antonioli L, 2016, TRENDS CANCER, V2, P95, DOI 10.1016/j.trecan.2016.01.003; Arrillaga-Romany I, 2017, ONCOTARGET, V8, P79298, DOI 10.18632/oncotarget.17837; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Aust G, 1997, CANCER RES, V57, P1798; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Ayturk UM, 2016, AM J HUM GENET, V98, P789, DOI 10.1016/j.ajhg.2016.03.009; Bais C, 2003, CANCER CELL, V3, P131, DOI 10.1016/S1535-6108(03)00024-2; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Baratelli F, 2005, J IMMUNOL, V175, P1483, DOI 10.4049/jimmunol.175.3.1483; Barker N, 2010, GASTROENTEROLOGY, V138, P1681, DOI 10.1053/j.gastro.2010.03.002; Bayin NS, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.63; BLACKMORE M, 1992, BRIT J CANCER, V66, P32, DOI 10.1038/bjc.1992.212; Borea PA, 2018, PHYSIOL REV, V98, P1591, DOI 10.1152/physrev.00049.2017; Carvajal RD, 2018, J CLIN ONCOL, V36, P1232, DOI 10.1200/JCO.2017.74.1090; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Cekic C, 2016, NAT REV IMMUNOL, V16, P177, DOI 10.1038/nri.2016.4; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan AT, 2007, NEW ENGL J MED, V356, P2131, DOI 10.1056/NEJMoa067208; Chatzistamou I, 2000, BRIT J CANCER, V83, P906, DOI 10.1054/bjoc.2000.1374; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chen EP, 2011, PROSTAG OTH LIPID M, V96, P14, DOI 10.1016/j.prostaglandins.2011.08.005; Chen X, 2017, CANCER CELL, V31, P685, DOI 10.1016/j.ccell.2017.04.002; Cheng KR, 2008, AM J PHYSIOL-GASTR L, V295, pG591, DOI 10.1152/ajpgi.00055.2008; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; Choi KY, 2011, P NATL ACAD SCI USA, V108, P15219, DOI 10.1073/pnas.1107304108; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Cowley GS, 2014, SCI DATA, V1, DOI 10.1038/sdata.2014.35; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; Darmoul D, 2004, J BIOL CHEM, V279, P20927, DOI 10.1074/jbc.M401430200; Dascal N, 2015, INT REV NEUROBIOL, V123, P27, DOI 10.1016/bs.irn.2015.06.001; Davies JQ, 2011, ONCOL REP, V25, P619, DOI 10.3892/or.2010.1117; De Giorgi V, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2017.2908; Devaud C, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.25961; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Drew DA, 2016, NAT REV CANCER, V16, P173, DOI 10.1038/nrc.2016.4; Du W, 2010, CANCER RES, V70, P772, DOI 10.1158/0008-5472.CAN-09-2722; DuhamelClerin E, 1997, ARTERIOSCL THROM VAS, V17, P1931, DOI 10.1161/01.ATV.17.10.1931; Dutra-Oliveira A, 2012, BIOCHEM BIOPH RES CO, V421, P221, DOI 10.1016/j.bbrc.2012.03.140; Ellrott K, 2018, CELL SYST, V6, P271, DOI 10.1016/j.cels.2018.03.002; Esapa C, 1997, J CLIN ENDOCR METAB, V82, P493, DOI 10.1210/jc.82.2.493; Facciabene A, 2011, NATURE, V475, P226, DOI 10.1038/nature10169; Fang XJ, 2000, ANN NY ACAD SCI, V905, P188; Feng XD, 2019, CANCER CELL, V35, P457, DOI 10.1016/j.ccell.2019.01.009; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Fischer SM, 2011, CANCER PREV RES, V4, P1728, DOI 10.1158/1940-6207.CAPR-11-0166; Forster R, 2008, NAT REV IMMUNOL, V8, P362, DOI 10.1038/nri2297; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gutierrez AN, 2017, CELL SIGNAL, V41, P65, DOI 10.1016/j.cellsig.2017.09.005; Gutkind JS, 2018, NAT REV MOL CELL BIO, V19, P615, DOI 10.1038/s41580-018-0041-y; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Halmos G, 1997, P NATL ACAD SCI USA, V94, P956, DOI 10.1073/pnas.94.3.956; Hauser AS, 2017, NAT REV DRUG DISCOV, V16, P829, DOI 10.1038/nrd.2017.178; Hayakawa Y, 2017, CANCER CELL, V31, P21, DOI 10.1016/j.ccell.2016.11.005; HERBERT JM, 1994, BIOCHEM J, V303, P227, DOI 10.1042/bj3030227; Hilger D, 2018, NAT STRUCT MOL BIOL, V25, P4, DOI 10.1038/s41594-017-0011-7; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Homey B, 2000, J IMMUNOL, V164, P3465, DOI 10.4049/jimmunol.164.7.3465; Hu Q, 2018, CELL, V173, P1254, DOI 10.1016/j.cell.2018.03.018; Husted AS, 2017, CELL METAB, V25, P777, DOI 10.1016/j.cmet.2017.03.008; Ideno N, 2018, GASTROENTEROLOGY, V155, P1593, DOI 10.1053/j.gastro.2018.08.006; Iglesias-Bartolome R, 2015, NAT CELL BIOL, V17, P793, DOI 10.1038/ncb3164; Iniguez MA, 1999, J IMMUNOL, V163, P111; Inoue A, 2019, CELL, V177, P1933, DOI 10.1016/j.cell.2019.04.044; Insel PA, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00431; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Itadani H, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-615; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Johnson-Holiday C, 2011, INT J ONCOL, V38, P1279, DOI 10.3892/ijo.2011.953; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Jung B, 2012, DEV CELL, V23, P600, DOI 10.1016/j.devcel.2012.07.015; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; Kawada K, 2007, ONCOGENE, V26, P4679, DOI 10.1038/sj.onc.1210267; Kelly P, 2006, J BIOL CHEM, V281, P26483, DOI 10.1074/jbc.M604376200; Kelly P, 2006, P NATL ACAD SCI USA, V103, P8173, DOI 10.1073/pnas.0510254103; Kerksiek KM, 2005, BLOOD, V105, P742, DOI 10.1182/blood-2004-05-1891; Kiberstis PA, 2017, SCIENCE, V355, P1143, DOI [10.1126/science.355.6321.144-d, 10.1126/science.355.6330.1142]; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kitamura T, 2015, J EXP MED, V212, P1043, DOI 10.1084/jem.20141836; Kline CLB, 2018, NEOPLASIA, V20, P80, DOI 10.1016/j.neo.2017.10.002; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; Konermann S, 2015, NATURE, V517, P583, DOI 10.1038/nature14136; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Lapadula D, 2019, MOL CANCER RES, V17, P963, DOI 10.1158/1541-7786.MCR-18-0574; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee RTH, 2016, DEVELOPMENT, V143, P367, DOI 10.1242/dev.120154; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Leone RD, 2015, COMPUT STRUCT BIOTEC, V13, P265, DOI 10.1016/j.csbj.2015.03.008; Li MH, 2018, CHEMSUSCHEM, V11, P171, DOI 10.1002/cssc.201701911; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Lin P, 2003, J BIOL CHEM, V278, P14379, DOI 10.1074/jbc.M209101200; Liu SC, 2009, CANCER RES, V69, P6122, DOI 10.1158/0008-5472.CAN-08-3435; Liu YL, 2006, CANCER BIOL THER, V5, P1320, DOI 10.4161/cbt.5.10.3162; Lohr JG, 2012, P NATL ACAD SCI USA, V109, P3879, DOI 10.1073/pnas.1121343109; Lopez-Giral S, 2004, J LEUKOCYTE BIOL, V76, P462, DOI 10.1189/jlb.1203652; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Love C, 2012, NAT GENET, V44, P1321, DOI 10.1038/ng.2468; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Maiga A, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.36; Mancini M, 2016, SEMIN CELL DEV BIOL, V50, P164, DOI 10.1016/j.semcdb.2015.09.018; Marin-Acevedo JA, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0582-8; Markwalder R, 1999, CANCER RES, V59, P1152; Martin D, 2011, CANCER CELL, V19, P805, DOI 10.1016/j.ccr.2011.05.005; Mathur P, 2015, BBA-MOL BASIS DIS, V1852, P406, DOI 10.1016/j.bbadis.2014.11.020; Maussang D, 2006, P NATL ACAD SCI USA, V103, P13068, DOI 10.1073/pnas.0604433103; McClanahan T, 2006, CANCER BIOL THER, V5, P419, DOI 10.4161/cbt.5.4.2521; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Monje M, 2017, CANCER CELL, V31, P1, DOI 10.1016/j.ccell.2016.12.008; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Montaner S, 2013, ANNU REV PHARMACOL, V53, P331, DOI 10.1146/annurev-pharmtox-010510-100608; MOODY TW, 1981, SCIENCE, V214, P1246, DOI 10.1126/science.6272398; Moore AR, 2016, NAT GENET, V48, P675, DOI 10.1038/ng.3549; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Muppidi JR, 2014, NATURE, V516, P254, DOI 10.1038/nature13765; Murphy PM, 2000, PHARMACOL REV, V52, P145; Nagahashi M, 2012, CANCER RES, V72, P726, DOI 10.1158/0008-5472.CAN-11-2167; Nagarsheth N, 2017, NAT REV IMMUNOL, V17, P559, DOI 10.1038/nri.2017.49; Nakayama J, 2002, ANN NEUROL, V52, P654, DOI 10.1002/ana.10347; Nazarko O, 2018, ISCIENCE, V3, P264, DOI 10.1016/j.isci.2018.04.019; Nilsson MB, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao4307; Nomura R, 2014, HUM PATHOL, V45, P2488, DOI 10.1016/j.humpath.2014.08.016; North TE, 2007, NATURE, V447, P1007, DOI 10.1038/nature05883; Novitskiy SV, 2008, BLOOD, V112, P1822, DOI 10.1182/blood-2008-02-136325; Nugent A, 2017, CELL SIGNAL, V39, P95, DOI 10.1016/j.cellsig.2017.08.002; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; O'Hayre M, 2016, ONCOGENE, V35, P3771, DOI 10.1038/onc.2015.442; O'Hayre M, 2014, CURR OPIN CELL BIOL, V27, P126, DOI 10.1016/j.ceb.2014.01.005; O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521; Obermajer N, 2012, ONCOIMMUNOLOGY, V1, P762, DOI 10.4161/onci.19681; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 2014, ANNU REV PHARMACOL, V54, P407, DOI 10.1146/annurev-pharmtox-011613-135945; Ohta A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00109; Onken MD, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aao6852; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Parish AJ, 2018, CANCER-AM CANCER SOC, V124, P4080, DOI 10.1002/cncr.31724; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Patra KC, 2018, NAT CELL BIOL, V20, P811, DOI 10.1038/s41556-018-0122-3; Paulsen SJ, 2005, J VIROL, V79, P536, DOI 10.1128/JVI.79.1.536-546.2005; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Pold M, 2004, CANCER RES, V64, P1853, DOI 10.1158/0008-5472.CAN-03-3262; Pollock PM, 2003, NAT GENET, V34, P108, DOI 10.1038/ng1148; Pukrop T, 2010, GLIA, V58, P1477, DOI 10.1002/glia.21022; Rafii S, 2016, NATURE, V529, P316, DOI 10.1038/nature17040; Raimondi F., 2019, ONCOGENE; Randolph GJ, 2005, NAT REV IMMUNOL, V5, P617, DOI 10.1038/nri1670; Ransohoff RM, 2009, IMMUNITY, V31, P711, DOI 10.1016/j.immuni.2009.09.010; Rasheed SAK, 2018, ONCOGENE, V37, P1340, DOI 10.1038/s41388-017-0038-6; Rasmussen JG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046087; Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361; Renz BW, 2018, CANCER CELL, V33, P75, DOI 10.1016/j.ccell.2017.11.007; Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449; Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144; Rybaczyk L, 2009, INFLAMM BOWEL DIS, V15, P971, DOI 10.1002/ibd.20893; Ryu Y, 2002, CIRC RES, V90, P325, DOI 10.1161/hh0302.104455; Sadeque A, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-59; Santos R, 2017, NAT REV DRUG DISCOV, V16, P19, DOI 10.1038/nrd.2016.230; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; Schioth HB, 2005, GEN COMP ENDOCR, V142, P94, DOI 10.1016/j.ygcen.2004.12.018; Schlecker E, 2012, J IMMUNOL, V189, P5602, DOI 10.4049/jimmunol.1201018; Schulte G, 2018, TRENDS PHARMACOL SCI, V39, P828, DOI 10.1016/j.tips.2018.07.001; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shi XL, 2004, MOL CANCER RES, V2, P395; Shirley MD, 2013, NEW ENGL J MED, V368, P1971, DOI 10.1056/NEJMoa1213507; Simonetti O, 2006, EUR J CANCER, V42, P1181, DOI 10.1016/j.ejca.2006.01.043; Sin WC, 2004, ONCOGENE, V23, P6299, DOI 10.1038/sj.onc.1207838; Singh R, 2011, INT J ONCOL, V39, P373, DOI 10.3892/ijo.2011.1059; Sivaraj KK, 2013, DEV CELL, V25, P427, DOI 10.1016/j.devcel.2013.04.008; SMITH JP, 1994, AM J PHYSIOL, V266, pR277, DOI 10.1152/ajpregu.1994.266.1.R277; Sodhi A, 2004, NAT REV MOL CELL BIO, V5, P998, DOI 10.1038/nrm1529; Song PF, 2003, CANCER RES, V63, P214; Sosa MS, 2010, MOL CELL, V40, P877, DOI 10.1016/j.molcel.2010.11.029; Speyer CL, 2012, BREAST CANCER RES TR, V132, P565, DOI 10.1007/s10549-011-1624-x; Sreeramkumar V, 2012, IMMUNOL CELL BIOL, V90, P579, DOI 10.1038/icb.2011.75; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Stein JV, 2005, IMMUNOLOGY, V116, P1, DOI 10.1111/j.1365-2567.2005.02183.x; Su S, 2009, ONCOGENE, V28, P3047, DOI 10.1038/onc.2009.163; Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200; Sun BD, 2000, PROSTATE, V42, P295; Tanese K, 2008, AM J PATHOL, V173, P835, DOI 10.2353/ajpath.2008.071091; Thal DM, 2018, NATURE, V559, P45, DOI 10.1038/s41586-018-0259-z; Thommen DS, 2018, CANCER CELL, V33, P547, DOI 10.1016/j.ccell.2018.03.012; Thompson MD, 2014, METHODS MOL BIOL, V1175, P153, DOI 10.1007/978-1-4939-0956-8_8; Trusolino L, 2012, CANCER DISCOV, V2, P876, DOI 10.1158/2159-8290.CD-12-0400; Umansky V, 2017, CANCER IMMUNOL IMMUN, V66, P1015, DOI 10.1007/s00262-017-1988-9; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0; van der Westhuizen ET, 2015, J PHARMACOL EXP THER, V353, P246, DOI 10.1124/jpet.114.221606; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Vaque JP, 2013, MOL CELL, V49, P94, DOI 10.1016/j.molcel.2012.10.018; Vazquez-Prado J, 2004, METHOD ENZYMOL, V390, P259; Veglia F, 2018, NAT IMMUNOL, V19, P108, DOI 10.1038/s41590-017-0022-x; Visser SS, 2000, BIOCHEM PHARMACOL, V60, P993, DOI 10.1016/S0006-2952(00)00414-7; von Bergwelt-Baildon MS, 2006, BLOOD, V108, P228, DOI 10.1182/blood-2005-08-3507; Wacker D, 2017, CELL, V170, P414, DOI 10.1016/j.cell.2017.07.009; Walter K, 2010, CLIN CANCER RES, V16, P1781, DOI 10.1158/1078-0432.CCR-09-1913; Wang DZ, 2006, J EXP MED, V203, P941, DOI 10.1084/jem.20052124; Wang JH, 2018, ONCOL LETT, V15, P552, DOI 10.3892/ol.2017.7279; Wang NT, 2016, STEM CELL REP, V6, P668, DOI 10.1016/j.stemcr.2016.04.007; Wang NT, 2015, CLIN CANCER RES, V21, P4676, DOI 10.1158/1078-0432.CCR-14-3163; WARD PA, 1965, J EXP MED, V122, P327, DOI 10.1084/jem.122.2.327; WARD PA, 1968, AM J PATHOL, V52, P725; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Wei SC, 2018, CANCER DISCOV, V8, P1069, DOI 10.1158/2159-8290.CD-18-0367; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; Whitehead IP, 2001, ONCOGENE, V20, P1547, DOI 10.1038/sj.onc.1204188; Wootten D, 2018, NAT REV MOL CELL BIO, V19, P638, DOI 10.1038/s41580-018-0049-3; Wu J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002543; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Xu L, 2006, P NATL ACAD SCI USA, V103, P9023, DOI 10.1073/pnas.0602681103; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Yang LQ, 2011, CANCER RES, V71, P5558, DOI 10.1158/0008-5472.CAN-10-4543; Yang L, 2018, IMMUNOPHARM IMMUNOT, V40, P91, DOI 10.1080/08923973.2017.1417997; Yoda A, 2015, NAT MED, V21, P71, DOI 10.1038/nm.3751; Young A, 2018, CANCER RES, V78, P1003, DOI 10.1158/0008-5472.CAN-17-2826; Young A, 2014, CANCER DISCOV, V4, P879, DOI 10.1158/2159-8290.CD-14-0341; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhang JX, 2016, ONCOTARGET, V7, P4414, DOI 10.18632/oncotarget.6780; Zhang JJ, 2016, BIOCHEM PHARMACOL, V114, P69, DOI 10.1016/j.bcp.2016.03.021; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X; Zlotnik A, 2011, NAT REV IMMUNOL, V11, P597, DOI 10.1038/nri3049; Zou LH, 2004, CANCER RES, V64, P8451, DOI 10.1158/0008-5472.CAN-04-1987	241	82	86	3	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2019	294	29					11062	11086		10.1074/jbc.REV119.005601	http://dx.doi.org/10.1074/jbc.REV119.005601			25	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	IN5LO	31171722	Green Published, hybrid			2023-01-03	WOS:000478717400003
J	Lin, YW; Zhou, YQ; Faghri, F; Shawl, MJ; Campbell, RH				Lin, Yu-Wei; Zhou, Yuqian; Faghri, Faraz; Shawl, Michael J.; Campbell, Roy H.			Analysis and prediction of unplanned intensive care unit readmission using recurrent neural networks with long shortterm memory	PLOS ONE			English	Article							ELECTRONIC HEALTH RECORD; HOSPITAL READMISSIONS; RISK-FACTORS; DISCHARGE; MODELS; SPECIFICITY; SENSITIVITY; PNEUMONIA; OUTCOMES	Background Unplanned readmission of a hospitalized patient is an indicator of patients' exposure to risk and an avoidable waste of medical resources. In addition to hospital readmission, intensive care unit (ICU) readmission brings further financial risk, along with morbidity and mortality risks. Identification of high-risk patients who are likely to be readmitted can provide significant benefits for both patients and medical providers. The emergence of machine learning solutions to detect hidden patterns in complex, multi-dimensional datasets provides unparalleled opportunities for developing an efficient discharge decision-making support system for physicians and ICU specialists. Methods and findings We used supervised machine learning approaches for ICU readmission prediction. We used machine learning methods on comprehensive, longitudinal clinical data from the MIMIC-III to predict the ICU readmission of patients within 30 days of their discharge. We incorporate multiple types of features including chart events, demographic, and ICD-9 embeddings. We have utilized recent machine learning techniques such as Recurrent Neural Networks (RNN) with Long Short-Term Memory (LSTM), by this we have been able to incorporate the multivariate features of EHRs and capture sudden fluctuations in chart event features (e.g. glucose and heart rate). We show that our LSTM-based solution can better capture high volatility and unstable status in ICU patients, an important factor in ICU readmission. Our machine learning models identify ICU readmissions at a higher sensitivity rate of 0.742 (95% CI, 0.718-0.766) and an improved Area Under the Curve of 0.791 (95% CI, 0.782-0.800) compared with traditional methods. We perform in-depth deep learning performance analysis, as well as the analysis of each feature contribution to the predictive model. Conclusion Our manuscript highlights the ability of machine learning models to improve our ICU decision-making accuracy and is a real-world example of precision medicine in hospitals. These data-driven solutions hold the potential for substantial clinical impact by augmenting clinical decision-making for physicians and ICU specialists. We anticipate that machine learning models will improve patient counseling, hospital administration, allocation of healthcare resources and ultimately individualized clinical care.	[Lin, Yu-Wei; Shawl, Michael J.] Univ Illinois, Dept Business Adm, Champaign, IL USA; [Zhou, Yuqian] Univ Illinois, Dept Elect & Comp Engn, Champaign, IL USA; [Faghri, Faraz; Campbell, Roy H.] Univ Illinois, Dept Comp Sci, Champaign, IL 61820 USA; [Faghri, Faraz] NIA, Lab Neurogenet, NIH, Bethesda, MD 20892 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Faghri, F (corresponding author), Univ Illinois, Dept Comp Sci, Champaign, IL 61820 USA.; Faghri, F (corresponding author), NIA, Lab Neurogenet, NIH, Bethesda, MD 20892 USA.	faghri2@illnois.edu	Campbell, Roy/O-1141-2019; Zhou, Yuqian/AGY-3776-2022	Campbell, Roy/0000-0002-3754-7777; Zhou, Yuqian/0000-0001-7100-113X				Alba AC, 2017, JAMA-J AM MED ASSOC, V318, P1377, DOI 10.1001/jama.2017.12126; [Anonymous], MULTITASK PREDICTION; [Anonymous], LEARNING DIAGNOSE LS; [Anonymous], 2017, FY2018 IPPS FINAL RU; Baillie CA, 2013, J HOSP MED, V8, P689, DOI 10.1002/jhm.2106; Berry C, 2008, HEART, V94, P296, DOI 10.1136/hrt.2006.110999; Brown SES, 2013, MED CARE, V51, P706, DOI 10.1097/MLR.0b013e318293c2fa; Calvert J, 2017, J MED ECON, V20, P646, DOI 10.1080/13696998.2017.1307203; Casalini F, 2017, INT J QUAL HEALTH C, V29, P256, DOI 10.1093/intqhc/mzx011; Chen LM, 1998, CRIT CARE MED, V26, P1834, DOI 10.1097/00003246-199811000-00025; Choi E, 2016, KDD'16: PROCEEDINGS OF THE 22ND ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P1495, DOI 10.1145/2939672.2939823; Choi Youngduck, 2016, AMIA Jt Summits Transl Sci Proc, V2016, P41; Curto S, 2016, IEEE INT FUZZY SYST; De Alba I, 2014, OCHSNER J, V14, P649; Desautels T, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017199; Dungan Kathleen M, 2012, J Diabetes Sci Technol, V6, P1045; elHassouni A, DATA DRIVEN MODELS M; Emons MF, 2016, BMJ OPEN DIAB RES CA, V4, DOI 10.1136/bmjdrc-2015-000160; Evans NR, 2012, CLIN MED, V12, P137, DOI 10.7861/clinmedicine.12-2-137; Guo T, 2016, PROCEEDINGS OF 3RD IEEE/ACM INTERNATIONAL CONFERENCE ON DATA SCIENCE AND ADVANCED ANALYTICS, (DSAA 2016), P816, DOI 10.1109/DSAA.2016.92; Halm EA, 2002, ARCH INTERN MED, V162, P1278, DOI 10.1001/archinte.162.11.1278; Hammill BG, 2011, CIRC-CARDIOVASC QUAL, V4, P60, DOI 10.1161/CIRCOUTCOMES.110.954693; Harutyunyan H., 2017, MULTITASK LEARNING B; He DN, 2014, J AM MED INFORM ASSN, V21, P272, DOI 10.1136/amiajnl-2013-002151; Hoogendoorn M, 2016, IEEE ENG MED BIO, P2464, DOI 10.1109/EMBC.2016.7591229; Hosein FS, 2013, CRIT CARE, V17, DOI 10.1186/cc12747; Hug C., 2009, DETECTING HAZARDOUS; Jamei M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181173; Johnson AEW, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.35; Kansagara D, 2011, JAMA-J AM MED ASSOC, V306, P1688, DOI 10.1001/jama.2011.1515; Keenan PS, 2008, CIRC-CARDIOVASC QUAL, V1, P29, DOI 10.1161/CIRCOUTCOMES.108.802686; Kennedy CE, 2011, THEOR BIOL MED MODEL, V8, DOI 10.1186/1742-4682-8-40; Kim H, 2010, AM J MANAG CARE, V16, P760; Kramer AA, 2013, CRIT CARE MED, V41, P24, DOI 10.1097/CCM.0b013e3182657b8a; Lee J, 2010, BIOMED ENG ONLINE, V9, DOI 10.1186/1475-925X-9-62; Mao QQ, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-017833; Mathew AT, 2015, KIDNEY INT, V88, P1250, DOI 10.1038/ki.2015.307; McAdams-DeMarco MA, 2013, AM J TRANSPLANT, V13, P2091, DOI 10.1111/ajt.12300; McIlvennan CK, 2015, CIRCULATION, V131, P1796, DOI 10.1161/CIRCULATIONAHA.114.010270; Nijhawan AE, 2015, AIDS PATIENT CARE ST, V29, P465, DOI 10.1089/apc.2015.0096; Parikh R, 2008, INDIAN J OPHTHALMOL, V56, P45, DOI 10.4103/0301-4738.37595; Pepe MS, 2016, CLIN CHEM, V62, P737, DOI 10.1373/clinchem.2015.252163; Ponzoni CR, 2017, ANN AM THORAC SOC, V14, P1312, DOI 10.1513/AnnalsATS.201611-851OC; Rajkomar A, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0029-1; RUBINS HB, 1988, AM J MED, V84, P863, DOI 10.1016/0002-9343(88)90064-2; Shadmi E, 2015, MED CARE, V53, P283, DOI 10.1097/MLR.0000000000000315; Shams I, 2015, HEALTH CARE MANAG SC, V18, P19, DOI 10.1007/s10729-014-9278-y; SINGER DE, 1981, NEW ENGL J MED, V304, P625, DOI 10.1056/NEJM198103123041101; Singh A, 2015, J BIOMED INFORM, V53, P220, DOI 10.1016/j.jbi.2014.11.005; Sood MM, 2011, CLIN J AM SOC NEPHRO, V6, P613, DOI 10.2215/CJN.01160210; VINSON JM, 1990, J AM GERIATR SOC, V38, P1290, DOI 10.1111/j.1532-5415.1990.tb03450.x; Wellner B, 2017, JMIR MED INF, V5, DOI 10.2196/medinform.8680; ZAGER RA, 1986, AM J PHYSIOL, V251, pF87, DOI 10.1152/ajprenal.1986.251.1.F87; Zhang M, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a2752; Zhang Y., 2015, ARXIV	55	42	43	3	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2019	14	7							e0218942	10.1371/journal.pone.0218942	http://dx.doi.org/10.1371/journal.pone.0218942			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4GX	31283759	Green Published, Green Submitted, gold			2023-01-03	WOS:000484939800014
J	Das, Q; Lepp, D; Yin, XH; Ross, K; McCallum, JL; Warriner, K; Marcone, MF; Diarra, MS				Das, Quail; Lepp, Dion; Yin, Xianhua; Ross, Kelly; McCallum, Jason L.; Warriner, Keith; Marcone, Massimo F.; Diarra, Moussa S.			Transcriptional profiling of Salmonella enterica serovar Enteritidis exposed to ethanolic extract of organic cranberry pomace	PLOS ONE			English	Article							ESCHERICHIA-COLI; TYPHIMURIUM INVASION; VIRULENCE GENES; EXPRESSION; RESISTANCE; PATHOGENESIS; INHIBITION; METABOLISM; MOTILITY; SEQUENCE	Non-typhoidal Salmonella enterica serovars continue to be an important food safety issue worldwide. Cranberry (Vaccinium macrocarpon Ait) fruits possess antimicrobial properties due to their various acids and phenolic compounds; however, the underlying mechanism of actions is poorly understood. We evaluated the effects of cranberry extracts on the growth rate of Salmonella enterica serovars Typhimurium, Enteritidis and Heidelberg and on the transcriptomic profile of Salmonella Enteritidis to gain insight into phenotypic and transcriptional changes induced by cranberry extracts on this pathogen. An ethanolic extract from cranberry pomaces (KCOH) and two of its sub-fractions, anthocyanins (CRFa20) and non-anthocyanin polyphenols (CRFp85), were used. The minimum inhibitory (MICs) and bactericidal (MBCs) concentrations of these fractions against tested pathogens were obtained using the broth micro-dilution method according to the Clinical Laboratory Standard Institute's guidelines. Transcriptional profiles of S. Enteritidis grown in cation-adjusted Mueller-Hinton broth supplemented with or without 2 or 4 mg/ml of KCOH were compared by RNA-Seq to reveal gene modulations serving as markers for biological activity. The MIC and MBC values of KCOH were 8 and 16 mg/mL, respectively, against all tested S. enterica isolates. The MIC value was 4 mg/mL for both CRFa20 and CRFp85 sub-fractions, and a reduced MBC value was obtained for CRFp85 (4 mg/ml). Treatment of S. Enteritidis with KCOH revealed a concentration-dependent transcriptional signature. Compared to the control, 2 mg/ml of KCOH exposure resulted in 89 differentially expressed genes (DEGs), of which 53 and 36 were downregulated and upregulated, respectively. The upregulated genes included those involved in citrate metabolism, enterobactin synthesis and transport, and virulence. Exposure to 4 mg/ml KCOH led to the modulated expression of 376 genes, of which 233 were downregulated and 143 upregulated, which is 4.2 times more DEGs than from exposure to 2 mg/ml KCOH. The downregulated genes were related to flagellar motility, Salmonella Pathogenicity Island-1 (SPI-1), cell wall/membrane biogenesis, and transcription. Moreover, genes involved in energy production and conversion, carbohydrate transport and metabolism, and coenzyme transport and metabolism were upregulated during exposure to 4 mg/ml KCOH. Overall, 57 genes were differentially expressed (48 downregulated and 9 upregulated) in response to both concentrations. Both concentrations of KCOH downregulated expression of hilA, which is a major SPI-1 transcriptional regulator. This study provides information on the response of Salmonella exposed to cranberry extracts, which could be used in the control of this important foodborne pathogen.	[Das, Quail; Warriner, Keith; Marcone, Massimo F.] Univ Guelph, Dept Food Sci, Guelph, ON, Canada; [Das, Quail; Lepp, Dion; Yin, Xianhua; Diarra, Moussa S.] Agr & Agri Food Canada, Guelph Res & Dev Ctr, Guelph, ON, Canada; [Ross, Kelly] Agr & Agri Food Canada, Summerland Res & Dev Ctr, Summerland, BC, Canada; [McCallum, Jason L.] Agr & Agri Food Canada, Charlottetown Res & Dev Ctr, Charlottetown, PE, Canada	University of Guelph; Agriculture & Agri Food Canada; Agriculture & Agri Food Canada; Agriculture & Agri Food Canada	Diarra, MS (corresponding author), Agr & Agri Food Canada, Guelph Res & Dev Ctr, Guelph, ON, Canada.	moussa.diarra@canada.ca			OMFRA HQP, Agriculture and Agri-Food Canada through the Organic Science Cluster II program [AIP CL-02 AGR-10383]; Canadian Federal Genomic Research and Development Initiative on Antimicrobial resistance (GRDI-AMR); OMFRA HQP program; Agriculture and Agri-Food Canada through the Organic Science Cluster II program [AIP CL-02 AGR-10383]	OMFRA HQP, Agriculture and Agri-Food Canada through the Organic Science Cluster II program; Canadian Federal Genomic Research and Development Initiative on Antimicrobial resistance (GRDI-AMR); OMFRA HQP program; Agriculture and Agri-Food Canada through the Organic Science Cluster II program	QD was supported by OMFRA HQP, Agriculture and Agri-Food Canada through the Organic Science Cluster II program (#AIP CL-02 AGR-10383); the Canadian Federal Genomic Research and Development Initiative on Antimicrobial resistance (GRDI-AMR) and OMFRA HQP program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was financially supported by Agriculture and Agri-Food Canada through the Organic Science Cluster II program (#AIP CL-02 AGR-10383), the Canadian Federal Genomic Research and Development Initiative on Antimicrobial resistance (GRDI-AMR) and OMFRA HQP program. The authors thank S. Chekabab and J. Tang for assistance and help.	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Bajaj V, 1995, MOL MICROBIOL, V18, P715, DOI 10.1111/j.1365-2958.1995.mmi_18040715.x; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Betancor L, 2010, J CLIN MICROBIOL, V48, P2413, DOI 10.1128/JCM.02137-09; Boddicker JD, 2003, J BACTERIOL, V185, P525, DOI 10.1128/JB.185.2.525-533.2003; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Bott M, 1997, ARCH MICROBIOL, V167, P78, DOI 10.1007/s002030050419; Boyd EF, 1997, J BACTERIOL, V179, P1985, DOI 10.1128/jb.179.6.1985-1991.1997; Chan M, 2013, COLLOID SURFACE B, V110, P275, DOI 10.1016/j.colsurfb.2013.03.047; Chekabab SM, 2019, J FOOD PROTECT, V82, P548, DOI 10.4315/0362-028X.JFP-18-371; Chiu CH, 1996, J CLIN MICROBIOL, V34, P2619, DOI 10.1128/JCM.34.10.2619-2622.1996; Dandekar T, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00164; Das Q, 2017, FOOD CONTROL, V73, P650, DOI 10.1016/j.foodcont.2016.09.019; Dhanani AS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128773; Diarra MS, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-90; Diarrassouba F, 2007, J FOOD PROTECT, V70, P1316, DOI 10.4315/0362-028X-70.6.1316; Ebraihimnejad H., 2014, RECENT ADV REDOX ACT, P211; Ellermeier JR, 2007, CURR OPIN MICROBIOL, V10, P24, DOI 10.1016/j.mib.2006.12.002; Encheva V, 2009, MICROBIOL-SGM, V155, P2429, DOI 10.1099/mic.0.026138-0; Eng SK, 2015, FRONT LIFE SCI, V8, P284, DOI 10.1080/21553769.2015.1051243; Frawley ER, 2013, P NATL ACAD SCI USA, V110, P12054, DOI 10.1073/pnas.1218274110; Gal-Mor O, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00088-18; Galperin MY, 2015, NUCLEIC ACIDS RES, V43, pD261, DOI 10.1093/nar/gku1223; Gonzalez-Lamothe R, 2009, INT J MOL SCI, V10, P3400, DOI 10.3390/ijms10083400; Harmidy K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027267; Harrison JE, 2013, J FOOD PROCESS PRES, V37, P356, DOI 10.1111/j.1745-4549.2011.00655.x; Hidalgo G, 2011, APPL ENVIRON MICROB, V77, P6852, DOI 10.1128/AEM.05561-11; Howell K, 2015, INTEGR FOOD NUTR MET, V2, P9, DOI [10.1016/j.mib.2006.12.002, DOI 10.1016/J.MIB.2006.12.002]; Huang JY, 2016, MMWR MORBIDITY MORTA, V65; ISHIGURO N, 1992, J BIOL CHEM, V267, P9559; Johnson TJ, 2018, APPL ENVIRON MICROB, V84, DOI [10.1128/aem.00362-18, 10.1128/AEM.00362-18]; Johny AK, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01828; Jones MA, 2007, AVIAN PATHOL, V36, P199, DOI 10.1080/03079450701264118; Kim W, 2004, MOL MICROBIOL, V54, P702, DOI 10.1111/j.1365-2958.2004.04295.x; Kirby CW, 2013, PHYTOCHEMISTRY, V94, P284, DOI 10.1016/j.phytochem.2013.06.017; Liu M, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00746-18; Maisuria VB, 2016, SCI REP-UK, V6, DOI 10.1038/srep30169; Mani-Lopez E, 2012, FOOD RES INT, V45, P713, DOI 10.1016/j.foodres.2011.04.043; Manon R, 2012, SALMONELLA DISTRIBUT; Martinez-Flores I, 2016, SCI REP-UK, V6, DOI 10.1038/srep37858; Mouttotou N, 2017, CURRENT TOPICS SALMO, P21, DOI 10.5772/67438; Negi PS, 2012, INT J FOOD MICROBIOL, V156, P7, DOI 10.1016/j.ijfoodmicro.2012.03.006; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; Porcheron G, 2013, FRONT CELL INFECT MI, V3, P90, DOI [DOI 10.3389/FCIMB.2013.00090, 10.3389/fcimb.2013.00090]; Public Health Agency of Canada, 2018, FOODNET CAN ANN REP; Raffatellu M, 2005, INFECT IMMUN, V73, P146, DOI 10.1128/IAI.73.1.146-154.2005; Ranfaing J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29082-6; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Vaquero MJR, 2010, J AGR FOOD CHEM, V58, P6048, DOI 10.1021/jf903966p; Rodriguez-Saona L.E., 2001, CURRENT PROTOCOLS FO, DOI DOI 10.1002/0471142913.FAF0101S00; Ross KA, 2017, INT J FRUIT SCI, V17, P202, DOI 10.1080/15538362.2017.1285264; Ryan D, 2015, APPL ENVIRON MICROB, V81, P8054, DOI 10.1128/AEM.02172-15; Salaheen S, 2016, INT J FOOD MICROBIOL, V237, P128, DOI 10.1016/j.ijfoodmicro.2016.08.027; Spector MP, 2012, FOOD RES INT, V45, P455, DOI 10.1016/j.foodres.2011.06.056; Vandeplas S, 2017, BURL DODDS AGR SCI, V13, P17, DOI 10.19103/AS.2016.0010.26; Wang D, 2013, METALLOMICS, V5, P372, DOI 10.1039/c3mt20217h; Wiedemann A, 2015, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00791; Wojnicz D, 2016, INT J FOOD SCI NUTR, V67, P1005, DOI 10.1080/09637486.2016.1211996	58	15	15	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 3	2019	14	7							e0219163	10.1371/journal.pone.0219163	http://dx.doi.org/10.1371/journal.pone.0219163			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4CE	31269043	Green Submitted, Green Published, gold			2023-01-03	WOS:000484927300047
J	Xue, YM; Xu, BZ; Su, CY; Han, QF; Wang, T; Tang, W				Xue, Yanmei; Xu, Baozhen; Su, Chunyan; Han, Qingfeng; Wang, Tao; Tang, Wen			Cardiorenal syndrome in incident peritoneal dialysis patients: What is its effect on patients' outcomes?	PLOS ONE			English	Article							CONGESTIVE-HEART-FAILURE; ULTRAFILTRATION; INITIATION; SURVIVAL	Background Peritoneal dialysis (PD) is increasingly used for long-term management of Cardiorenal Syndrome (CRS). We compared outcomes in incident PD patients according to their baseline heart failure status. Methods This retrospective cohort study evaluated all-cause and cardiovascular mortality in incident PD patients with different heart failure status (non-CRS, acute heart failure [AHF], type II CRS, type IV CRS) who started PD between 2006 and 2016 in the Peking University Third Hospital. Results Of 748 patients included in the study, there were 466 (62.3%), 214 (28.6%), 27 (3.6%), and 41 (5.5%) patients in the non-CRS, AHF, type II CRS and type IV CRS groups, respectively. Patients with CRS were older (p<0.001), with more diabetes mellitus (p<0.001), coronary heart history (p<0.001), higher estimated glomerular filtration rate (eGFR) (p<0.001), lower serum creatinine (p<0.001) and phosphorus levels (p = 0.003) compared to non-CRS patients. Respective all-cause survival rates for patients with non-CRS, AHF, type II CRS and type IV CRS were 90.6%, 87.1%, 85.2% and 84.8% at 1 year, and 63.1%, 47.7%, 27.3% and 35.1% at 5 years (p<0.001). The corresponding figures for cardiovascular survival were 93%, 92%, 84% and 81% at 1 year, and 67%, 59%, 55% and 54% at 5 years (p<0.001). However, after adjusting for confounding factors, the presence of CRS was not independently associated with all-cause mortality whereas type IV CRS (HR 2.10, 95% CI 1.03-4.28, p = 0.04) was associated with higher cardiovascular mortality as compared to without CRS. Conclusion Incident PD patients with different types of CRS had higher rates of both all-cause and cardiovascular mortality compared with patients without CRS. However, these observed adverse outcomes may be related to associated older age and higher prevalence of comorbidities, rather than CRS per se, except for type IV CRS, treatment strategies to reduce high cardiovascular CVD mortality may needed.	[Xue, Yanmei; Xu, Baozhen; Su, Chunyan; Han, Qingfeng; Wang, Tao; Tang, Wen] Peking Univ, Hosp 3, Dept Nephrol, Beijing, Peoples R China; [Xu, Baozhen] Hebei Med Univ, Sch Chinese Integrat Med, Shijiazhuang, Hebei, Peoples R China; [Xu, Baozhen] Hebei Med Univ, Dept Nephrol, Hosp 1, Shijiazhuang, Hebei, Peoples R China	Peking University; Hebei Medical University; Hebei Medical University	Tang, W (corresponding author), Peking Univ, Hosp 3, Dept Nephrol, Beijing, Peoples R China.	tanggwen@126.com		, Wen/0000-0002-2263-2979	Chinese Society of Nephrology [1405046058, BMU20160584]; National Natural Science Foundation of China [30900681]	Chinese Society of Nephrology; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by Chinese Society of Nephrology (No. 1405046058), Peking University Medical seeds for Fund interdisciplinary Research (BMU20160584) and grants from National Natural Science Foundation of China (Project 30900681). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bertoli SV, 2014, PERITON DIALYSIS INT, V34, P64, DOI 10.3747/pdi.2012.00290; Claudio R., 2010, EUROPEAN HEART J, V6; Courivaud C, 2014, PERITON DIALYSIS INT, V34, P100, DOI 10.3747/pdi.2012.00149; Feng L, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0590-x; GU DF, 2003, CHIN J CARDIOL, P6; HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; Jessup M, 2003, NEW ENGL J MED, V348, P2007, DOI 10.1056/NEJMra021498; Kazmi WH, 2005, AM J KIDNEY DIS, V46, P887, DOI 10.1053/j.ajkd.2005.08.005; Kunin M, 2013, BLOOD PURIFICAT, V35, P285, DOI 10.1159/000351202; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Lu RH, 2015, CARDIORENAL MED, V5, P145, DOI 10.1159/000380915; Maaroufi A, 2013, AM J NEPHROL, V37, P359, DOI 10.1159/000348822; McMurray J, 2013, REV PORTUGUESA CARDI, V32, P641, DOI [10.1016/j.repce.2013.10.001, DOI 10.1016/J.REPCE.2013.10.001]; Nakayama M, 2010, J CARDIOL, V55, P49, DOI 10.1016/j.jjcc.2009.08.003; Nodari S, 2011, HEART FAIL REV, V16, P583, DOI 10.1007/s10741-010-9202-6; Rangaswami J, 2018, ADV CHRONIC KIDNEY D, V25, P400, DOI 10.1053/j.ackd.2018.08.006; Ronco C, 2008, J AM COLL CARDIOL, V52, P1527, DOI 10.1016/j.jacc.2008.07.051; Ronco C, 2008, INTENS CARE MED, V34, P957, DOI 10.1007/s00134-008-1017-8; Ronco C, 2017, KIDNEY DIS-BASEL, V2, P151, DOI 10.1159/000448749; Rosansky SJ, 2011, ARCH INTERN MED, V171, P396, DOI 10.1001/archinternmed.2010.415; Sanchez JE, 2010, NEPHROL DIAL TRANSPL, V25, P605, DOI 10.1093/ndt/gfp484; Vallabhajosyula S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190965; Wright S, 2010, CLIN J AM SOC NEPHRO, V5, P1828, DOI 10.2215/CJN.06230909	23	3	4	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2019	14	6							e0218082	10.1371/journal.pone.0218082	http://dx.doi.org/10.1371/journal.pone.0218082			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IC0OB	31173609	Green Published, Green Submitted, gold			2023-01-03	WOS:000470658500032
J	Quanjel, TCC; Spreeuwenberg, MD; Struijs, JN; Baan, CA; Ruwaard, D				Quanjel, Tessa C. C.; Spreeuwenberg, Marieke D.; Struijs, Jeroen N.; Baan, Caroline A.; Ruwaard, Dirk			Substituting hospital-based outpatient cardiology care: The impact on quality, health and costs	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; QUADRUPLE AIM CARE; OUTREACH CLINICS; GENERAL-PRACTICE; SPECIALISTS; SYSTEMS; TRIPLE	Background Many Western countries face the challenge of providing high-quality care while keeping the healthcare system accessible and affordable. In an attempt to deal with this challenge a new healthcare delivery model called primary care plus (PC+) was introduced in the Netherlands. Within the PC+ model, medical specialists perform consultations in a primary care setting. PC+ aims to support the general practitioners in gatekeeping and prevent unnecessary referrals to hospital care. The aim of this study was to examine the effects of a cardiology PC+ intervention on the Triple Aim outcomes, which were operationalized by patient-perceived quality of care, health-related quality of life (HRQoL) outcomes, and healthcare costs per patient. Methods This is a quantitative study with a longitudinal observational design. The study population consisted of patients, with non-acute and low-complexity cardiology-related health complaints, who were referred to the PC+ centre (intervention group) or hospital-based outpatient care (control group; care-as-usual). Patient-perceived quality of care and HRQoL (EQ-5D-5L, EQ-VAS and SF-12) were measured through questionnaires at three different time points. Healthcare costs per patient were obtained from administrative healthcare data and patients were followed for nine months. Chi-square tests, independent t-tests and multilevel linear models were used to analyse the data. Results The patient-perceived quality of care was significantly higher within the intervention group for 26 out of 27 items. HRQoL outcomes did significantly increase in both groups (P < 0.05) but there was no significant interaction between group and time. At baseline and also at three, six and nine months' follow-up the healthcare costs per patient were significantly lower for patients in the intervention group (P<0.001). Conclusions While this study showed no improvements on HRQoL outcomes, PC+ seemed to be promising as it results in improved quality of care as experienced by patients and lower healthcare costs per patient.	[Quanjel, Tessa C. C.; Spreeuwenberg, Marieke D.; Ruwaard, Dirk] Maastricht Univ, Fac Hlth Med & Life Sci, Care & Publ Hlth Res Inst, Dept Hlth Serv Res, Maastricht, Netherlands; [Spreeuwenberg, Marieke D.] Zuyd Univ Appl Sci, Res Ctr Technol Care, Heerlen, Netherlands; [Struijs, Jeroen N.; Baan, Caroline A.] Natl Inst Publ Hlth & Environm, Prevent & Hlth Serv, Dept Qual Care & Hlth Econ, Ctr Nutr, Bilthoven, Netherlands; [Struijs, Jeroen N.] Leiden Univ, Dept Publ Hlth & Primary Care, Med Ctr, Leiden, Netherlands; [Baan, Caroline A.] Univ Tilburg, Sci Ctr Transformat Care & Welf Tranzo, Tilburg, Netherlands	Maastricht University; Maastricht University Medical Centre (MUMC); Netherlands National Institute for Public Health & the Environment; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Tilburg University	Quanjel, TCC (corresponding author), Maastricht Univ, Fac Hlth Med & Life Sci, Care & Publ Hlth Res Inst, Dept Hlth Serv Res, Maastricht, Netherlands.	t.quanjel@maastrichtuniversity.nl	Struijs, Jeroen/AAQ-9872-2020; Struijs, Jeroen/AAX-6827-2020; Struijs, Jeroen/AAA-8057-2022	Struijs, Jeroen/0000-0002-7493-6720; Ruwaard, Dirk/0000-0003-4887-8413; Quanjel, Tessa/0000-0001-6103-363X	Province of Limburg, the Netherlands; cooperative named: 'Versterking Eerstelijn Zuid-Nederland' (VEZN) (translated in English: 'Reinforcing Primary Care South of the Netherlands'); CZ; VGZ	Province of Limburg, the Netherlands(Netherlands Government); cooperative named: 'Versterking Eerstelijn Zuid-Nederland' (VEZN) (translated in English: 'Reinforcing Primary Care South of the Netherlands'); CZ; VGZ	We received funding from non-commercial companies, namely from the non-commercial private health insurers CZ and VGZ and the Province of Limburg, the Netherlands. The insurers funded this project via the cooperative named: 'Versterking Eerstelijn Zuid-Nederland' (VEZN) (translated in English: 'Reinforcing Primary Care South of the Netherlands'). VEZN is a cooperative for project funding, focused on regional projects which aim to keep healthcare sustainable and affordable. The funding sources of this study have been checked and approved by the Medical Research and Ethics Committee. They approved that there were no competing interests. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2018, OPEN DATA NEDERLANDS; Atun R, 2004, WHAT ARE ADVANTAGES; Berwick DM, 2008, HEALTH AFFAIR, V27, P759, DOI 10.1377/hlthaff.27.3.759; Black N, 2013, BMJ, V346, pf167, DOI [DOI 10.1136/BMJ.F167, 10.1136/bmj.f167]; Bodenheimer T, 2014, ANN FAM MED, V12, P573, DOI 10.1370/afm.1713; Bond M, 2000, J EPIDEMIOL COMMUN H, V54, P149, DOI 10.1136/jech.54.2.149; Bowling A, 2001, BRIT J GEN PRACT, V51, P264; Bowling A, 1997, J EPIDEMIOL COMMUN H, V51, P52, DOI 10.1136/jech.51.1.52; Gruen RL, 2003, COCHRANE DB SYST REV, P1; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Institute of Medicine, 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Kessler R, 2011, AM J PREV MED, V40, P637, DOI 10.1016/j.amepre.2011.02.023; Kringos DS, 2013, HEALTH AFFAIR, V32, P686, DOI 10.1377/hlthaff.2012.1242; Kringos DS, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-65; Ma X., 2010, INT ENCYCLOP ED, V3, P757, DOI [10.1016/B978-0-08-044894-7.01611-0, DOI 10.1016/B978-0-08-044894-7.01611-0]; Macinko J, 2003, HEALTH SERV RES, V38, P831, DOI 10.1111/1475-6773.00149; Maris E, 1998, PSYCHOL METHODS, V3, P309, DOI 10.1037/1082-989X.3.3.309; Meuwissen LE, 2008, CONSUMER QUALITY IND; Ministerie van Volksgezondheid Welzijn en Sport, 2013, OND MED SPEC ZORG 20; Ministerie van Volksgezondheid Welzijn en Sport, 2013, OND 1 LIJN 2014 MET; Mols F, 2009, QUAL LIFE RES, V18, P403, DOI 10.1007/s11136-009-9455-5; Ovretveit J, 2017, INT J QUAL HEALTH C, V29, P874, DOI 10.1093/intqhc/mzx108; Peiro S, 2015, EUR J PUBLIC HEALTH, V25, P1, DOI 10.1093/eurpub/cku223; Porter ME, 2013, HARVARD BUS REV, V91, P50; Powell John, 2002, J Health Serv Res Policy, V7, P177, DOI 10.1258/135581902760082490; Quanjel TCC, 2018, BMC FAM PRACT, V19, DOI 10.1186/s12875-018-0734-5; Quanjel TCC, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2580-x; Sandager M, 2016, J PATIENT EXP, V3, P63; Sanson-Fisher RW, 2007, AM J PREV MED, V33, P155, DOI 10.1016/j.amepre.2007.04.007; Schulpen GJC, 2003, ANN RHEUM DIS, V62, P159, DOI 10.1136/ard.62.2.159; Schut FT, 2017, HEALTH POLICY, V121, P126, DOI 10.1016/j.healthpol.2016.11.002; Sibbald B, 2008, J HEALTH SERV RES PO, V13, P233, DOI 10.1258/jhsrp.2008.008049; Sikka R, 2015, BMJ QUAL SAF, V24, P608, DOI 10.1136/bmjqs-2015-004160; Steenbakkers M., 2014, NIEUWE KIJK GEZONDHE; Van Breukelen GJP, 2006, J CLIN EPIDEMIOL, V59, P920, DOI 10.1016/j.jclinepi.2006.02.007; van Hoof SJM, 2016, BMC FAM PRACT, V17, DOI 10.1186/s12875-016-0498-8; van Hoof SJM, 2016, INT J INTEGR CARE, V16, DOI 10.5334/ijic.2446; van Poucke A, 2018, WIE DOET MET WIE TIJ; Versteegh MM, 2016, VALUE HEALTH, V19, P343, DOI 10.1016/j.jval.2016.01.003; Vlek JFM, 2003, BRIT J GEN PRACT, V53, P108; WHO, 2008, PHARMAFORUM 0121; Wiebe S, 2003, J CLIN EPIDEMIOL, V56, P52, DOI 10.1016/S0895-4356(02)00537-1; Wiering B, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2582-8; Winpenny EM, 2017, J HEALTH SERV RES PO, V22, P53, DOI 10.1177/1355819616648982; Zarbailov N, 2017, BMC FAM PRACT, V18, DOI 10.1186/s12875-017-0653-x	45	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2019	14	5							e0217923	10.1371/journal.pone.0217923	http://dx.doi.org/10.1371/journal.pone.0217923			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IA7TI	31150520	Green Submitted, Green Published, gold			2023-01-03	WOS:000469759100128
J	Facon, T; Kumar, S; Plesner, T; Orlowski, RZ; Moreau, P; Bahlis, N; Basu, S; Nahi, H; Hulin, C; Quach, H; Goldschmidt, H; O'Dwyer, M; Perrot, A; Venner, CP; Weisel, K; Mace, JR; Raje, N; Attal, M; Tiab, M; Macro, M; Frenzel, L; Leleu, X; Ahmadi, T; Chiu, C; Wang, J; Van Rampelbergh, R; Uhlar, CM; Kobos, R; Qi, M; Usmani, SZ				Facon, T.; Kumar, S.; Plesner, T.; Orlowski, R. Z.; Moreau, P.; Bahlis, N.; Basu, S.; Nahi, H.; Hulin, C.; Quach, H.; Goldschmidt, H.; O'Dwyer, M.; Perrot, A.; Venner, C. P.; Weisel, K.; Mace, J. R.; Raje, N.; Attal, M.; Tiab, M.; Macro, M.; Frenzel, L.; Leleu, X.; Ahmadi, T.; Chiu, C.; Wang, J.; Van Rampelbergh, R.; Uhlar, C. M.; Kobos, R.; Qi, M.; Usmani, S. Z.		MAIA Trial Investigators	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTIBODY DARATUMUMAB; OPEN-LABEL; BORTEZOMIB; CRITERIA; MONOTHERAPY; CD38	BackgroundLenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. We sought to determine whether the addition of daratumumab would significantly reduce the risk of disease progression or death in this population. MethodsWe randomly assigned 737 patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation to receive daratumumab plus lenalidomide and dexamethasone (daratumumab group) or lenalidomide and dexamethasone alone (control group). Treatment was to continue until the occurrence of disease progression or unacceptable side effects. The primary end point was progression-free survival. ResultsAt a median follow-up of 28.0 months, disease progression or death had occurred in 240 patients (97 of 368 patients [26.4%] in the daratumumab group and 143 of 369 patients [38.8%] in the control group). The estimated percentage of patients who were alive without disease progression at 30 months was 70.6% (95% confidence interval [CI], 65.0 to 75.4) in the daratumumab group and 55.6% (95% CI, 49.5 to 61.3) in the control group (hazard ratio for disease progression or death, 0.56; 95% CI, 0.43 to 0.73; P<0.001). The percentage of patients with a complete response or better was 47.6% in the daratumumab group and 24.9% in the control group (P<0.001). A total of 24.2% of the patients in the daratumumab group, as compared with 7.3% of the patients in the control group, had results below the threshold for minimal residual disease (1 tumor cell per 10(5) white cells) (P<0.001). The most common adverse events of grade 3 or 4 were neutropenia (50.0% in the daratumumab group vs. 35.3% in the control group), anemia (11.8% vs. 19.7%), lymphopenia (15.1% vs. 10.7%), and pneumonia (13.7% vs. 7.9%). ConclusionsAmong patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation, the risk of disease progression or death was significantly lower among those who received daratumumab plus lenalidomide and dexamethasone than among those who received lenalidomide and dexamethasone alone. A higher incidence of neutropenia and pneumonia was observed in the daratumumab group. (Funded by Janssen Research and Development; MAIA ClinicalTrials.gov number, NCT02252172.) The addition of daratumumab to lenalinomide and dexamethasone in patients with previously untreated myeloma who were not eligible for high-dose chemotherapy and hematopoietic stem-cell transplantation resulted in a higher response rate, an increased depth of response, and longer progression-free survival than lenalidomide and dexamethasone alone.	[Facon, T.] CHU Lille, Univ Lille, Serv Malad Sang, Lille, France; [Moreau, P.] Univ Hosp Hotel Dieu, Hematol Dept, Nantes, France; [Hulin, C.] Univ Hosp, Hosp Haut Leveq, Dept Hematol, Pessac, France; [Perrot, A.] Univ Hosp, Hematol Dept, Vandoeuvre Les Nancy, France; [Attal, M.] CHU Toulouse, Inst Univ Canc Toulouse Oncopole, Serv Hematol, Toulouse, France; [Tiab, M.] Vendee Hosp, Dept Hematol, La Roche Sur Yon, France; [Macro, M.] CHU Caen, Caen, France; [Frenzel, L.] Hop Necker Enfants Malad, AP HP, Dept Clin Hematol, Paris, France; [Leleu, X.] CHU La Miletrie, Dept Hematol, Poitiers, France; [Leleu, X.] INSERM CIC 1402, Poitiers, France; [Kumar, S.] Mayo Clin, Dept Hematol, Rochester, MN USA; [Plesner, T.] Vejle Hosp, Vejle, Denmark; [Plesner, T.] Univ Southern Denmark, Vejle, Denmark; [Orlowski, R. Z.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA; [Bahlis, N.] Univ Calgary, Arnie Charbonneau Canc Res Inst, Calgary, AB, Canada; [Venner, C. P.] Univ Alberta, Div Med Oncol, Edmonton, AB, Canada; [Basu, S.] Royal Wolverhampton & Hosp NHS Trust, Wolverhampton, W Midlands, England; [Nahi, H.] Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Med, Div Hematol, Stockholm, Sweden; [Quach, H.] Univ Melbourne, St Vincents Hosp, Melbourne, Vic, Australia; [Goldschmidt, H.] Univ Hosp Heidelberg, Heidelberg, Germany; [Goldschmidt, H.] Natl Ctr Tumor Dis NCT, Heidelberg, Germany; [Weisel, K.] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Sect Pneumol, Hamburg, Germany; [O'Dwyer, M.] Natl Univ Ireland, Dept Med Haematol, Galway, Ireland; [Mace, J. R.] Florida Canc Specialists & Res Inst, St Petersburg, FL USA; [Raje, N.] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA; [Ahmadi, T.] Genmab US, Princeton, NJ USA; [Wang, J.; Kobos, R.] Janssen Res & Dev, Raritan, NJ USA; [Chiu, C.; Uhlar, C. M.; Qi, M.] Janssen Res & Dev, Spring House, PA USA; [Van Rampelbergh, R.] Janssen Res & Dev, Beerse, Belgium; [Usmani, S. Z.] Levine Canc Inst Arrium Hlth, Charlotte, NC USA	Universite de Lille - ISITE; CHU Lille; Universite de Lille; Nantes Universite; CHU de Nantes; CHU Bordeaux; CHU de Nancy; CHU de Toulouse; CHD Vendee; CHU de Caen NORMANDIE; Universite de Caen Normandie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Poitiers; Universite de Poitiers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Poitiers; Mayo Clinic; University of Southern Denmark; Lillebaelt Hospital; University of Southern Denmark; University of Texas System; UTMD Anderson Cancer Center; University of Calgary; University of Alberta; Karolinska Institutet; Karolinska University Hospital; St Vincent's Hospital Melbourne; University of Melbourne; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ollscoil na Gaillimhe-University of Galway; Florida Cancer Specialists; Harvard University; Massachusetts General Hospital; Johnson & Johnson; Janssen Pharmaceuticals; Johnson & Johnson; Janssen Pharmaceuticals; Johnson & Johnson; Janssen Pharmaceuticals	Facon, T (corresponding author), CHRU, Rue Michel Polonovski, F-59037 Lille, France.	thierry.facon@chru-lille.fr	Goldschmidt, Hartmut/AAL-8069-2021; Kumar, Shaji K/A-9853-2008; Quach, Hang/AAB-8516-2020; nahi, hareth/AAA-3445-2020; Blimark, Cecilie Hveding/AAZ-6423-2021; Usmani, Saad Z/HCI-4676-2022	Kumar, Shaji K/0000-0001-5392-9284; Blimark, Cecilie Hveding/0000-0003-3297-6019; Usmani, Saad Z/0000-0002-5484-8731; Perrot, Aurore/0000-0003-0131-8689; Orlowski, Robert/0000-0002-5723-4129; gunsilius, eberhard/0000-0003-1327-2921; nahi, hareth/0000-0003-4711-5094; moreau, philippe/0000-0003-1780-8746; Ramasamy, Karthik/0000-0003-3385-3707; Chiu, Christopher W./0000-0001-9744-991X; QUACH, HANG/0000-0002-4796-3352	Janssen Research and Development	Janssen Research and Development	Funded by Janssen Research and Development; MAIA ClinicalTrials.gov number, NCT02252172.	Adams HC, 2019, CYTOM PART A, V95A, P279, DOI 10.1002/cyto.a.23693; BAHLIS N, 2018, BLOOD S, V132, DOI DOI 10.1182/BLOOD-2018-99-112697; Benboubker L, 2014, NEW ENGL J MED, V371, P906, DOI 10.1056/NEJMoa1402551; Chari A, 2017, BLOOD, V130, P974, DOI 10.1182/blood-2017-05-785246; de Weers M, 2011, J IMMUNOL, V186, P1840, DOI 10.4049/jimmunol.1003032; Department of Health and Human Services, 2009, COMMON TERMINOLOGY C; Dimopoulos MA, 2016, NEW ENGL J MED, V375, P1319, DOI 10.1056/NEJMoa1607751; Dimopoulos MA, 2018, HAEMATOLOGICA, V103, P2088, DOI 10.3324/haematol.2018.194282; Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284; Durie BGM, 2018, BLOOD S, V132, P1992, DOI DOI 10.1182/BLOOD-2018-99-117003; Durie BGM, 2017, LANCET, V389, P519, DOI 10.1016/S0140-6736(16)31594-X; Facon T, 2018, BLOOD, V131, P301, DOI 10.1182/blood-2017-07-795047; Krejcik J, 2016, BLOOD, V128, P384, DOI 10.1182/blood-2015-12-687749; Kumar S, 2016, LANCET ONCOL, V17, pE328, DOI 10.1016/S1470-2045(16)30206-6; Lokhorst HM, 2015, NEW ENGL J MED, V373, P1207, DOI 10.1056/NEJMoa1506348; Lonial S, 2016, LANCET, V387, P1551, DOI 10.1016/S0140-6736(15)01120-4; Mateos MV, 2018, NEW ENGL J MED, V378, P518, DOI 10.1056/NEJMoa1714678; MATEOS MV, 2018, BLOOD S, V132, DOI DOI 10.1182/BLOOD-2018-99-112554; McCudden C, 2016, CLIN CHEM LAB MED, V54, P1095, DOI 10.1515/cclm-2015-1031; Overdijk MB, 2016, J IMMUNOL, V197, P807, DOI 10.4049/jimmunol.1501351; Overdijk MB, 2015, MABS-AUSTIN, V7, P311, DOI 10.1080/19420862.2015.1007813; Palumbo A, 2016, NEW ENGL J MED, V375, P754, DOI 10.1056/NEJMoa1606038; Palumbo A, 2014, J CLIN ONCOL, V32, P587, DOI 10.1200/JCO.2013.48.7934; Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442; Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470-2045(14)70442-5; Rajkumar SV, 2011, BLOOD, V117, P4691, DOI 10.1182/blood-2010-10-299487; Rollig C, 2015, LANCET, V385, P2197, DOI 10.1016/S0140-6736(14)60493-1; Spencer A, 2018, HAEMATOLOGICA, V103, P2079, DOI 10.3324/haematol.2018.194118	28	485	495	2	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 30	2019	380	22					2104	2115		10.1056/NEJMoa1817249	http://dx.doi.org/10.1056/NEJMoa1817249			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IC6IF	31141632	Bronze, Green Published, Green Accepted			2023-01-03	WOS:000471074800008
J	Perez-Ruiz, E; Minute, L; Otano, I; Alvarez, M; Ochoa, MC; Belsue, V; de Andrea, C; Rodriguez-Ruiz, ME; Perez-Gracia, JL; Marquez-Rodas, I; Llacer, C; Alvarez, M; de Luque, V; Molina, C; Teijeira, A; Berraondo, P; Melero, I				Perez-Ruiz, Elisabeth; Minute, Luna; Otano, Itziar; Alvarez, Maite; Carmen Ochoa, Maria; Belsue, Virginia; de Andrea, Carlos; Esperanza Rodriguez-Ruiz, Maria; Luis Perez-Gracia, Jose; Marquez-Rodas, Ivan; Llacer, Casilda; Alvarez, Martina; de Luque, Vanesa; Molina, Carmen; Teijeira, Alvaro; Berraondo, Pedro; Melero, Ignacio			Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; T-CELLS; FACTOR-ALPHA; IPILIMUMAB; NIVOLUMAB; MELANOMA; TARGET	Combined PD-1 and CTLA-4-targeted immunotherapy with nivolumab and ipilimumab is effective against melanoma, renal cell carcinoma and non-small-cell lung cancer(1-3). However, this comes at the cost of frequent, serious immune-related adverse events, necessitating a reduction in the recommended dose of ipilimumab that is given to patients(4). In mice, co-treatment with surrogate anti-PD-1 and anti-CTLA-4 monoclonal antibodies is effective in transplantable cancer models, but also exacerbates autoimmune colitis. Here we show that treating mice with clinically available TNF inhibitors concomitantly with combined CTLA-4 and PD-1 immunotherapy ameliorates colitis and, in addition, improves anti-tumour efficacy. Notably, TNF is upregulated in the intestine of patients suffering from colitis after dual ipilimumab and nivolumab treatment. We created a model in which Rag2(-/-)Il2rg(-/-) mice were adoptively transferred with human peripheral blood mononuclear cells, causing graft-versus-host disease that was further exacerbated by ipilimumab and nivolumab treatment. When human colon cancer cells were xenografted into these mice, prophylactic blockade of human TNF improved colitis and hepatitis in xenografted mice, and moreover, immunotherapeutic control of xenografted tumours was retained. Our results provide clinically feasible strategies to dissociate efficacy and toxicity in the use of combined immune checkpoint blockade for cancer immunotherapy.	[Perez-Ruiz, Elisabeth; Minute, Luna; Otano, Itziar; Alvarez, Maite; Carmen Ochoa, Maria; Belsue, Virginia; Esperanza Rodriguez-Ruiz, Maria; Molina, Carmen; Teijeira, Alvaro; Berraondo, Pedro; Melero, Ignacio] Cima Univ Navarra, Program Immunol & Immunotherapy, Pamplona, Spain; [Perez-Ruiz, Elisabeth; Minute, Luna; Otano, Itziar; Alvarez, Maite; Carmen Ochoa, Maria; Belsue, Virginia; de Andrea, Carlos; Luis Perez-Gracia, Jose; Molina, Carmen; Teijeira, Alvaro; Berraondo, Pedro; Melero, Ignacio] Navarra Inst Hlth Res IDISNA, Pamplona, Spain; [Perez-Ruiz, Elisabeth; Esperanza Rodriguez-Ruiz, Maria; Luis Perez-Gracia, Jose; Melero, Ignacio] Clin Univ Navarra, Dept Oncol, Pamplona, Spain; [Perez-Ruiz, Elisabeth] Hosp Costa del Sol, Dept Oncol, Marbella, Spain; [Perez-Ruiz, Elisabeth; Alvarez, Martina; de Luque, Vanesa] Hosp Univ Reg & Virgen de la Victoria, Inst Invest Biomed Malaga IBIMA, Malaga, Spain; [Carmen Ochoa, Maria; Luis Perez-Gracia, Jose; Marquez-Rodas, Ivan; Teijeira, Alvaro; Berraondo, Pedro; Melero, Ignacio] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain; [de Andrea, Carlos] Clin Univ Navarra, Dept Pathol, Pamplona, Spain; [Marquez-Rodas, Ivan] Hosp Gen Univ Gregorio Maranon, Dept Oncol, Madrid, Spain; [Llacer, Casilda] Hosp Univ Virgen de la Victoria, Dept Oncol, Malaga, Spain; [Alvarez, Martina; de Luque, Vanesa] Univ Malaga, Ctr Invest Med Sanitarias CIMES, Lab Biol Mol Canc, Malaga, Spain; [Alvarez, Martina] Univ Malaga, Dept Pathol, Fac Med, Malaga, Spain; [Melero, Ignacio] Clin Univ Navarra, Dept Immunol & Immunotherapy, Pamplona, Spain	University of Navarra; University of Navarra; Universidad de Malaga; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; University of Navarra; General University Gregorio Maranon Hospital; Universidad de Malaga; Universidad de Malaga; Universidad de Malaga; University of Navarra	Berraondo, P; Melero, I (corresponding author), Cima Univ Navarra, Program Immunol & Immunotherapy, Pamplona, Spain.; Berraondo, P; Melero, I (corresponding author), Navarra Inst Hlth Res IDISNA, Pamplona, Spain.; Melero, I (corresponding author), Clin Univ Navarra, Dept Oncol, Pamplona, Spain.; Berraondo, P; Melero, I (corresponding author), Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain.; Melero, I (corresponding author), Clin Univ Navarra, Dept Immunol & Immunotherapy, Pamplona, Spain.	pberraondol@unav.es; imelero@unav.es	Otano, Itziar/N-1410-2016; Marquez-Rodas, Ivan/ABD-5532-2021; Rodriguez-Ruiz, Maria Esperanza/K-7227-2017; Alvarez, Maite/ABD-5806-2020; Ruiz, Elísabeth Pérez/ABI-5900-2020; Berraondo, Pedro/J-3154-2012; Teijeira, Alvaro/I-6903-2017; Melero, Ignacio/T-7600-2019; Ochoa, Maria C./K-4508-2017; Perez-Gracia, Jose Luis/I-8372-2017	Otano, Itziar/0000-0002-1433-1711; Marquez-Rodas, Ivan/0000-0002-2476-668X; Rodriguez-Ruiz, Maria Esperanza/0000-0002-9765-2499; Alvarez, Maite/0000-0002-5969-9181; Ruiz, Elísabeth Pérez/0000-0001-7204-0800; Berraondo, Pedro/0000-0001-7410-1865; Teijeira, Alvaro/0000-0002-7339-4464; Melero, Ignacio/0000-0002-1360-348X; Ochoa, Maria C./0000-0001-9920-2144; Perez-Gracia, Jose Luis/0000-0003-4941-9075; Minute, Luna/0000-0003-3174-112X	International Immuno-Oncology Network (II-ON) from Bristol-Myers Squibb; Worldwide Cancer Research Grant [15-1146]; Asociacion Espanola Contra el Cancer (AECC) Foundation [GCB15152947MELE]; Instituto Carlos III [PI14/01686, PI13/00207, PI16/00668]; FEDER funds; European Union [635122 PROCROP]; Miguel Servet II from Instituto de Salud Carlos III [CPII15/00004]; Carmen Lavigne training program of the Asociacion Espanola contra el Cancer; Consejeria de Salud de la Junta de Andalucia; la Caixa Banking Foundation [LCF/BQ/LR18/11640014]	International Immuno-Oncology Network (II-ON) from Bristol-Myers Squibb(Bristol-Myers Squibb); Worldwide Cancer Research Grant; Asociacion Espanola Contra el Cancer (AECC) Foundation; Instituto Carlos III(Instituto de Salud Carlos III); FEDER funds(European Commission); European Union(European Commission); Miguel Servet II from Instituto de Salud Carlos III(Instituto de Salud Carlos III); Carmen Lavigne training program of the Asociacion Espanola contra el Cancer; Consejeria de Salud de la Junta de Andalucia(Junta de Andalucia); la Caixa Banking Foundation(La Caixa Foundation)	We thank M. Fernandez de Sanmamed and I. Etxeberria for scientific discussion, P. Miller for English editing and X. Morales for ultrasound imaging. The figures contain elements from Servier Medical Art (https://smart.servier.com/), licensed under Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/).This work was supported by the International Immuno-Oncology Network (II-ON) from Bristol-Myers Squibb; a Worldwide Cancer Research Grant (15-1146); the Asociacion Espanola Contra el Cancer (AECC) Foundation under grant GCB15152947MELE; the Instituto Carlos III (under grants PI14/01686, PI13/00207 and PI16/00668) co-financed with FEDER funds; and the European Union's Horizon 2020 Program (grant agreement no. 635122 PROCROP). P.B. is supported by a Miguel Servet II (CPII15/00004) contract from Instituto de Salud Carlos III; E.P.-R is supported by the Carmen Lavigne training program of the Asociacion Espanola contra el Cancer and by Consejeria de Salud de la Junta de Andalucia; and A.T. has received financial support through la Caixa Banking Foundation (LCF/BQ/LR18/11640014).	Arakaki R, 2014, CRIT REV IMMUNOL, V34, P301, DOI 10.1615/CritRevImmunol.2014009988; Ascierto PA, 2017, LANCET ONCOL, V18, P611, DOI 10.1016/S1470-2045(17)30231-0; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Bertrand F, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02358-7; Blonski W, 2014, CURR OPIN GASTROEN, V30, P84, DOI 10.1097/MOG.0000000000000031; COOPER HS, 1993, LAB INVEST, V69, P238; Coward J, 2011, CLIN CANCER RES, V17, P6083, DOI 10.1158/1078-0432.CCR-11-0945; Curran MA, 2010, P NATL ACAD SCI USA, V107, P4275, DOI 10.1073/pnas.0915174107; Duraiswamy J, 2013, CANCER RES, V73, P3591, DOI 10.1158/0008-5472.CAN-12-4100; Eichele DD, 2017, WORLD J GASTROENTERO, V23, P6016, DOI 10.3748/wjg.v23.i33.6016; Harrison ML, 2007, J CLIN ONCOL, V25, P4542, DOI 10.1200/JCO.2007.11.2136; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Hettich M, 2016, THERANOSTICS, V6, P1629, DOI 10.7150/thno.15253; Jhaveri KD, 2018, NEW ENGL J MED, V378, P1163, DOI 10.1056/NEJMc1801663; Kurtulus S, 2019, IMMUNITY, V50, P181, DOI 10.1016/j.immuni.2018.11.014; Mace TA, 2018, GUT, V67, P320, DOI 10.1136/gutjnl-2016-311585; Madhusudan S, 2005, J CLIN ONCOL, V23, P5950, DOI 10.1200/JCO.2005.04.127; Mahler M, 1998, AM J PHYSIOL-GASTR L, V274, pG544, DOI 10.1152/ajpgi.1998.274.3.G544; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Ryu H, 2017, NEW ENGL J MED, V377, P2503, DOI 10.1056/NEJMc1714339; Sanmamed MF, 2015, CANCER RES, V75, P3466, DOI 10.1158/0008-5472.CAN-14-3510; Siddiqui I, 2019, IMMUNITY, V50, P195, DOI 10.1016/j.immuni.2018.12.021; Spranger S, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/2051-1426-2-3; Tang QY, 2014, INT J CLIN EXP PATHO, V7, P2019; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Wainwright DA, 2014, CLIN CANCER RES, V20, P5290, DOI 10.1158/1078-0432.CCR-14-0514; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Xiao YT, 2016, CYTOKINE, V83, P189, DOI 10.1016/j.cyto.2016.04.012; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	31	199	209	8	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 16	2019	569	7756					428	+		10.1038/s41586-019-1162-y	http://dx.doi.org/10.1038/s41586-019-1162-y			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY4UP	31043740	hybrid, Green Submitted			2023-01-03	WOS:000468123700043
J	Kim, MS; Park, JH; Lee, KY; Choi, SH; Jung, HH; Kim, JH; Lee, B				Kim, Min-Soo; Park, Jin Ha; Lee, Ki-Young; Choi, Seung Ho; Jung, Hwan Ho; Kim, Ji-Ho; Lee, Bora			Influence of head and neck position on the performance of supraglottic airway devices: A systematic review and meta-analysis	PLOS ONE			English	Review							LARYNGEAL MASK AIRWAY; OROPHARYNGEAL LEAK PRESSURE; CUFF POSITION; SEALING PRESSURE; TUBE; VENTILATION; FLEXION; SIZE; ANESTHESIA; I-GEL(TM)	Background Changes in head and neck position may significantly affect the performance of supraglottic airway devices (SADs) by altering the pharyngeal structure. Purpose This systematic review and meta-analysis aimed to elucidate the effect of changes in head and neck position on performance of SADs. Data source Bibliographic databases, including PubMed, EMBASE, the Cochrane library, and the Web of Science. Study eligibility criteria Prospective studies investigating the effects of head and neck positions on the performance of SADs. Methods A random effect model was applied in the all analyses. Subgroup analysis was performed according to the type of device and the age of patient. The oropharyngeal leak pressure was the primary outcome measure. Secondary outcome measures included peak inspiratory pressure, fibreoptic view, and ventilation score (PROSPERO, CRD42017076971). Results Seventeen studies met the eligibility criteria. Overall, the oropharyngeal leak pressure significantly increased (mean difference 4.07 cmH(2)O; 95% confidence interval 3.30 to 4.84) during neck flexion with adverse effects on ventilation and fibreoptic view. Conversely, the oropharyngeal leak pressure decreased (mean difference -4.05; 95% confidence interval -4.90 to -3.20) during neck extension with no significant effect on ventilation or fibreoptic view. Rotation of the head and neck did not significantly affect SAD performance. Conclusions The reduced oropharyngeal leak pressure in the extended neck position was not associated with impaired ventilation except with the air-Q self-pressurizing airway. The flexed neck position significantly worsens ventilation and the alignment between the SAD and glottis despite improving the seal except with the air-Q self-pressurizing airway and LMA Proseal.	[Kim, Min-Soo; Park, Jin Ha; Lee, Ki-Young; Choi, Seung Ho; Lee, Bora] Yonsei Univ, Coll Med, Severance Hosp, Dept Anesthesiol & Pain Med, Seoul, South Korea; [Kim, Min-Soo; Park, Jin Ha; Lee, Ki-Young; Choi, Seung Ho; Lee, Bora] Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Seoul, South Korea; [Jung, Hwan Ho; Kim, Ji-Ho] Ilsan Hosp, Natl Hlth Insurance Serv, Dept Anesthesiol & Pain Med, Goyang City, Gyeonggi Do, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; National Health Insurance Service; NHIS Ilsan Hospital	Lee, B (corresponding author), Yonsei Univ, Coll Med, Severance Hosp, Dept Anesthesiol & Pain Med, Seoul, South Korea.; Lee, B (corresponding author), Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Seoul, South Korea.	dreamkaist@yuhs.ac		Choi, Seung Ho/0000-0001-8442-4406; Kim, Min-Soo/0000-0001-8760-4568; Park, Jin Ha/0000-0002-1398-3304; Lee, Ki-Young/0000-0003-4893-3195				Biedler A, 2013, J ANESTH, V27, P657, DOI 10.1007/s00540-013-1583-y; BRIMACOMBE J, 1993, ANESTH ANALG, V76, P457; Brimacombe J, 1996, BRIT J ANAESTH, V77, P295, DOI 10.1093/bja/77.2.295-a; Buckham M, 1999, ANAESTH INTENS CARE, V27, P628, DOI 10.1177/0310057X9902700612; Cook TM, 2005, BRIT J ANAESTH, V95, P261, DOI 10.1093/bja/aei167; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ghai B, 2009, CURR OPIN ANESTHESIO, V22, P400, DOI 10.1097/ACO.0b013e3283294d06; Gupta Swati, 2017, Anesth Essays Res, V11, P647, DOI 10.4103/aer.AER_238_16; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Jain D, 2016, PEDIATR ANESTH, V26, P1136, DOI 10.1111/pan.13001; Jain D, 2015, PEDIATR ANESTH, V25, P1248, DOI 10.1111/pan.12748; Keller C, 1999, BRIT J ANAESTH, V82, P286, DOI 10.1093/bja/82.2.286; Keller C, 1999, ANESTH ANALG, V88, P913, DOI 10.1097/00000539-199904000-00042; Kim HJ, 2017, BRIT J ANAESTH, V118, P452, DOI 10.1093/bja/aew448; Kim JT, 2007, BRIT J ANAESTH, V99, P704, DOI 10.1093/bja/aem241; Kim JT, 2009, PEDIATR ANESTH, V19, P153, DOI 10.1111/j.1460-9592.2008.02861.x; Kim MS, 2015, PEDIATR ANESTH, V25, P405, DOI 10.1111/pan.12609; Mann V, NOTFALL RETTUNGSMED; Mishra SK, 2015, ANESTHESIOL RES PRAC, V2015, DOI 10.1155/2015/705869; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; NANDI PR, 1991, BRIT J ANAESTH, V66, P157, DOI 10.1093/bja/66.2.157; Okuda K, 2001, BRIT J ANAESTH, V86, P122, DOI 10.1093/bja/86.1.122; Park SH, 2009, ANESTH ANALG, V108, P112, DOI 10.1213/ane.0b013e318192376f; Sanuki T, 2011, EUR J ANAESTH, V28, P597, DOI 10.1097/EJA.0b013e32834698f4; Somri M, 2016, BMC ANESTHESIOL, V16, DOI 10.1186/s12871-016-0237-7; Wan X, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-135; Xue FS, 2008, ANAESTHESIA, V63, P979, DOI 10.1111/j.1365-2044.2008.05490.x; 2003, EUR J ANAESTH, V20, P65, DOI DOI 10.1017/S0265021503000127; 2007, ANAESTH INTENSIVE CA, V35, P957, DOI DOI 10.1177/	30	8	8	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2019	14	5							e0216673	10.1371/journal.pone.0216673	http://dx.doi.org/10.1371/journal.pone.0216673			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX6ZE	31071171	Green Published, gold, Green Submitted			2023-01-03	WOS:000467552100086
J	Wang, WM; Green, M; Choi, JE; Gijon, M; Kennedy, PD; Johnson, JK; Liao, P; Lang, XT; Kryczek, I; Sell, A; Xia, HJ; Zhou, JJ; Li, GP; Li, J; Li, W; Wei, S; Vatan, L; Zhang, HJ; Szeliga, W; Gu, W; Liu, R; Lawrence, TS; Lamb, C; Tanno, Y; Cieslik, M; Stone, E; Georgiou, G; Chan, TA; Chinnaiyan, A; Zou, WP				Wang, Weimin; Green, Michael; Choi, Jae Eun; Gijon, Miguel; Kennedy, Paul D.; Johnson, Jeffrey K.; Liao, Peng; Lang, Xueting; Kryczek, Ilona; Sell, Amanda; Xia, Houjun; Zhou, Jiajia; Li, Gaopeng; Li, Jing; Li, Wei; Wei, Shuang; Vatan, Linda; Zhang, Hongjuan; Szeliga, Wojciech; Gu, Wei; Liu, Rebecca; Lawrence, Theodore S.; Lamb, Candice; Tanno, Yuri; Cieslik, Marcin; Stone, Everett; Georgiou, George; Chan, Timothy A.; Chinnaiyan, Arul; Zou, Weiping			CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy	NATURE			English	Article							SENSITIVITY; DEATH	Cancer immunotherapy restores or enhances the effector function of CD8(+) T cells in the tumour microenvironment(1,2). CD8(+) T cells activated by cancer immunotherapy clear tumours mainly by inducing cell death through perforin-granzyme and Fas-Fas ligand pathways(3,4). Ferroptosis is a form of cell death that differs from apoptosis and results from iron-dependent accumulation of lipid peroxide(5,6). Although it has been investigated in vitro(7,8), there is emerging evidence that ferroptosis might be implicated in a variety of pathological scenarios(9,10). It is unclear whether, and how, ferroptosis is involved in T cell immunity and cancer immunotherapy. Here we show that immunotherapy-activated CD8(+) T cells enhance ferroptosis-specific lipid peroxidation in tumour cells, and that increased ferroptosis contributes to the antitumour efficacy of immunotherapy. Mechanistically, interferon gamma (IFN gamma) released from CD8(+) T cells downregulates the expression of SLC3A2 and SLC7A11, two subunits of the glutamate-cystine antiporter system x(c)(-), impairs the uptake of cystine by tumour cells, and as a consequence, promotes tumour cell lipid peroxidation and ferroptosis. In mouse models, depletion of cystine or cysteine by cyst(e)inase (an engineered enzyme that degrades both cystine and cysteine) in combination with checkpoint blockade synergistically enhanced T cell-mediated anti-tumour immunity and induced ferroptosis in tumour cells. Expression of system x(c)(- )was negatively associated, in cancer patients, with CD8(+) T cell signature, IFN gamma expression, and patient outcome. Analyses of human transcriptomes before and during nivolumab therapy revealed that clinical benefits correlate with reduced expression of SLC3A2 and increased IFN gamma and CD8. Thus, T cell-promoted tumour ferroptosis is an anti-tumour mechanism, and targeting this pathway in combination with checkpoint blockade is a potential therapeutic approach.	[Wang, Weimin; Liao, Peng; Lang, Xueting; Kryczek, Ilona; Sell, Amanda; Xia, Houjun; Zhou, Jiajia; Li, Gaopeng; Li, Jing; Li, Wei; Wei, Shuang; Vatan, Linda; Zhang, Hongjuan; Szeliga, Wojciech; Zou, Weiping] Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA; [Wang, Weimin; Green, Michael; Choi, Jae Eun; Liao, Peng; Lang, Xueting; Kryczek, Ilona; Sell, Amanda; Xia, Houjun; Zhou, Jiajia; Li, Gaopeng; Li, Jing; Li, Wei; Wei, Shuang; Vatan, Linda; Zhang, Hongjuan; Szeliga, Wojciech; Zou, Weiping] Univ Michigan, Sch Med, Rogel Canc Ctr, Ctr Excellence Canc Immunol & Immunotherapy, Ann Arbor, MI 48109 USA; [Green, Michael; Lang, Xueting; Lawrence, Theodore S.] Univ Michigan, Dept Radiat Oncol, Sch Med, Ann Arbor, MI 48109 USA; [Choi, Jae Eun; Cieslik, Marcin; Chinnaiyan, Arul; Zou, Weiping] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; [Choi, Jae Eun; Chinnaiyan, Arul] Univ Michigan, Sch Med, Michigan Ctr Translat Pathol, Ann Arbor, MI USA; [Gijon, Miguel; Kennedy, Paul D.; Johnson, Jeffrey K.] Cayman Chem Co, Ann Arbor, MI USA; [Gu, Wei] Columbia Univ, Coll Phys & Surg, Inst Canc Genet, Dept Pathol & Cell Biol, New York, NY USA; [Gu, Wei] Columbia Univ, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY USA; [Liu, Rebecca] Univ Michigan, Dept Obstet & Gynecol, Sch Med, Ann Arbor, MI 48109 USA; [Lamb, Candice; Tanno, Yuri; Stone, Everett; Georgiou, George] Univ Texas Austin, Dept Chem Engn, Austin, TX 78712 USA; [Lamb, Candice; Tanno, Yuri; Stone, Everett; Georgiou, George] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA; [Cieslik, Marcin] Univ Michigan, Sch Med, Dept Computat Med & Bioinformat, Ann Arbor, MI USA; [Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, Immunogen & Precis Oncol Platform, 1275 York Ave, New York, NY 10021 USA; [Chinnaiyan, Arul] Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; [Zou, Weiping] Univ Michigan, Sch Med, Grad Program Immunol, Ann Arbor, MI 48109 USA; [Zou, Weiping] Univ Michigan, Sch Med, Grad Program Canc Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Columbia University; Columbia University; University of Michigan System; University of Michigan; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Michigan System; University of Michigan; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Zou, WP (corresponding author), Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA.; Zou, WP (corresponding author), Univ Michigan, Sch Med, Rogel Canc Ctr, Ctr Excellence Canc Immunol & Immunotherapy, Ann Arbor, MI 48109 USA.; Zou, WP (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.; Zou, WP (corresponding author), Univ Michigan, Sch Med, Grad Program Immunol, Ann Arbor, MI 48109 USA.; Zou, WP (corresponding author), Univ Michigan, Sch Med, Grad Program Canc Biol, Ann Arbor, MI 48109 USA.	wzou@med.umich.edu	Choi, Jae Eun/AAZ-2305-2020; Lang, Xueting/ABI-3909-2020; Chan, Timothy A/ABD-5850-2021; Liao, Peng/Y-1896-2019	Liao, Peng/0000-0002-8409-5574; Green, Michael/0000-0003-4951-7118; Xia, Houjun/0000-0003-1045-1465	NIH/NCI R01 grants [CA217648, CA123088, CA099985, CA193136, CA152470]; NIH through the University of Michigan Rogel Cancer Center Support Grant [CA46592]; NIH/NCI [CA189623, CA205426]; Pershing Square Sohn Cancer Research; PaineWebber Chair; STARR Cancer Consortium; NCI R35 [CA232097]; NIH/NCI Cancer Center Support Grant [P30 CA008748]; NATIONAL CANCER INSTITUTE [R01CA189623, R01CA205426, R01CA190176, P30CA008748, R01CA217510, R01CA193136, R01CA211016, R35CA232097, P30CA046592] Funding Source: NIH RePORTER	NIH/NCI R01 grants; NIH through the University of Michigan Rogel Cancer Center Support Grant; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Pershing Square Sohn Cancer Research(Pershing Square Sohn Cancer Research Alliance); PaineWebber Chair; STARR Cancer Consortium; NCI R35; NIH/NCI Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank all members of the Zou laboratory for suggestions. This work was supported in part by NIH/NCI R01 grants (CA217648, CA123088, CA099985, CA193136 and CA152470), and the NIH through the University of Michigan Rogel Cancer Center Support Grant (CA46592) (W.Z.); the NIH/NCI (CA189623) (E.S. and G.G.); Pershing Square Sohn Cancer Research, the PaineWebber Chair, the NIH/NCI (CA205426), the STARR Cancer Consortium, NCI R35 (CA232097), and an NIH/NCI Cancer Center Support Grant (P30 CA008748) (T.A.C.).	Alvarez SW, 2017, NATURE, V551, P639, DOI 10.1038/nature24637; Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Braumuller H, 2013, NATURE, V494, P361, DOI 10.1038/nature11824; Buck MD, 2017, CELL, V169, P570, DOI 10.1016/j.cell.2017.04.004; Conrad M, 2016, NAT REV DRUG DISCOV, V15, P348, DOI 10.1038/nrd.2015.6; Cramer SL, 2017, NAT MED, V23, P120, DOI 10.1038/nm.4232; Dixon SJ, 2014, ELIFE, V3, DOI 10.7554/eLife.02523; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Doll S, 2017, NAT CHEM BIOL, V13, P91, DOI [10.1038/nchembio.2239, 10.1038/NCHEMBIO.2239]; Golstein P, 2018, NAT REV IMMUNOL, V18, P526, DOI 10.1038/s41577-018-0009-3; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Kagan VE, 2017, NAT CHEM BIOL, V13, P81, DOI [10.1038/NCHEMBIO.2238, 10.1038/nchembio.2238]; Khalil DN, 2016, NAT REV CLIN ONCOL, V13, P273, DOI 10.1038/nrclinonc.2016.25; Kim SE, 2016, NAT NANOTECHNOL, V11, P977, DOI 10.1038/nnano.2016.164; Linher-Melville K, 2015, MOL CELL BIOCHEM, V405, P205, DOI 10.1007/s11010-015-2412-4; Linkermann A, 2014, P NATL ACAD SCI USA, V111, P16836, DOI 10.1073/pnas.1415518111; O'Neill LAJ, 2016, NAT REV IMMUNOL, V16, P553, DOI 10.1038/nri.2016.70; Rees MG, 2016, NAT CHEM BIOL, V12, P109, DOI [10.1038/NCHEMBIO.1986, 10.1038/nchembio.1986]; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Tsoi J, 2018, CANCER CELL, V33, P890, DOI 10.1016/j.ccell.2018.03.017; Wang WM, 2016, CELL, V165, P1092, DOI 10.1016/j.cell.2016.04.009; Wu YM, 2018, CELL, V173, P1770, DOI 10.1016/j.cell.2018.04.034; Yamanaka K, 2012, RSC ADV, V2, P7894, DOI 10.1039/c2ra20816d; Yang WS, 2016, TRENDS CELL BIOL, V26, P165, DOI 10.1016/j.tcb.2015.10.014; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; 2016, SCI TRANSL MED, V8, P328, DOI DOI 10.1126/SCITRANSLMED.AAD7118	29	852	881	88	674	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 9	2019	569	7755					270	+		10.1038/s41586-019-1170-y	http://dx.doi.org/10.1038/s41586-019-1170-y			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX5VX	31043744	Green Accepted			2023-01-03	WOS:000467473600051
J	Colman, AM; Krockow, EM; Chattoe-Brown, E; Tarrant, C				Colman, Andrew M.; Krockow, Eva M.; Chattoe-Brown, Edmund; Tarrant, Carolyn			Medical prescribing and antibiotic resistance: A game-theoretic analysis of a potentially catastrophic social dilemma	PLOS ONE			English	Article							ANTIMICROBIAL RESISTANCE; EVOLUTION	The availability of antibiotics presents medical practitioners with a prescribing dilemma. On the one hand, antibiotics provide a safe and effective treatment option for patients with bacterial infections, but at a population level, over-prescription reduces their effectiveness by facilitating the evolution of bacteria that are resistant to antibiotic medication. A game-theoretic investigation, including analysis of equilibrium strategies, evolutionarily stability, and replicator dynamics, reveals that rational doctors, motivated to attain the best outcomes for their own patients, will prescribe antibiotics irrespective of the level of antibiotic resistance in the population and the behavior of other doctors, although they would achieve better long-term outcomes if their prescribing were more restrained. Ever-increasing antibiotic resistance may therefore be inevitable unless some means are found of modifying the payoffs of this potentially catastrophic social dilemma.	[Colman, Andrew M.] Univ Leicester, Dept Neurosci Psychol & Behav, Leicester, Leics, England; [Krockow, Eva M.; Tarrant, Carolyn] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England; [Chattoe-Brown, Edmund] Univ Leicester, Dept Media Commun & Sociol, Leicester, Leics, England	University of Leicester; University of Leicester; University of Leicester	Colman, AM (corresponding author), Univ Leicester, Dept Neurosci Psychol & Behav, Leicester, Leics, England.	amc@le.ac.uk	Colman, Andrew M./A-3322-2008; Colman, Andrew M./CBO-8743-2022	Colman, Andrew M./0000-0003-0499-3479; Colman, Andrew M./0000-0003-0499-3479; Krockow, Eva Maria/0000-0001-8748-9897; Tarrant, Carolyn/0000-0001-7356-5342	Global Challenges Research Fund - Economic and Social Research Council (ESRC) on behalf of the Research Councils UK (RCUK) [ES/P004784/1]; Leicester Judgment and Decision Making Endowment Fund [RM43G0176]; ESRC [ES/P004784/1] Funding Source: UKRI	Global Challenges Research Fund - Economic and Social Research Council (ESRC) on behalf of the Research Councils UK (RCUK); Leicester Judgment and Decision Making Endowment Fund; ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))	This research was funded by the Global Challenges Research Fund, Grant No. ES/P004784/1, awarded by the Economic and Social Research Council (ESRC) on behalf of the Research Councils UK (RCUK) to Carolyn Tarrant, Andrew M. Colman, and Edmund Chattoe-Brown, and by the Leicester Judgment and Decision Making Endowment Fund (Grant Number RM43G0176) awarded to Andrew M. Colman.	Arepeva M, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00352; Austin DJ, 1999, PHILOS T R SOC B, V354, P721, DOI 10.1098/rstb.1999.0425; Aveling Emma-Louise, 2012, J Health Organ Manag, V26, P158; Baquero F, 2003, Rev Esp Quimioter, V16, P11; Bauch CT, 2004, P NATL ACAD SCI USA, V101, P13391, DOI 10.1073/pnas.0403823101; Bernoulli D, 1766, MEM MATH PHY ACAD RO, P1; Broom A, 2014, SOC SCI MED, V110, P81, DOI 10.1016/j.socscimed.2014.03.030; Conlin PL, 2014, CURR OPIN MICROBIOL, V21, P35, DOI 10.1016/j.mib.2014.09.004; Davey P, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003543.pub4; Drake JW, 1998, GENETICS, V148, P1667; Dyar OJ, 2016, FUTURE MICROBIOL, V11, P1057, DOI 10.2217/fmb-2016-0041; Foster KR, 2006, PLOS MED, V3, P177, DOI 10.1371/journal.pmed.0030029; Gupta K, 1999, JAMA-J AM MED ASSOC, V281, P736, DOI 10.1001/jama.281.8.736; Hofbauer J., 1998, EVOLUTIONARY GAMES P, DOI [10.1017/CBO9781139173179, DOI 10.1017/CBO9781139173179]; Hulscher MEJL, 2017, CLIN MICROBIOL INFEC, V23, P799, DOI 10.1016/j.cmi.2017.07.017; KOCH AL, 1981, MICROBIOL REV, V45, P355, DOI 10.1128/MMBR.45.2.355-378.1981; Krockow EM, 2019, J HOSP INFECT, V101, P428, DOI 10.1016/j.jhin.2018.08.007; Kurutepe S, 2005, JPN J INFECT DIS, V58, P159; LANGLOIS BE, 1984, J ANIM SCI, V58, P666, DOI 10.2527/jas1984.583666x; Laxminarayan R, 2013, LANCET INFECT DIS, V13, P1057, DOI 10.1016/S1473-3099(13)70318-9; Livorsi D, 2015, INFECT CONT HOSP EP, V36, P1065, DOI 10.1017/ice.2015.136; Maynard Smith J., 1982, pi; NASH J, 1951, ANN MATH, V54, P286, DOI 10.2307/1969529; Nash J, 1950, THESIS; NASH JF, 1950, P NATL ACAD SCI USA, V36, P48, DOI 10.1073/pnas.36.1.48; O'Brien KS, 2014, COMPUT MATH METHOD M, V837929, P1; Okeke IN, 2009, CURR SCI INDIA, V97, P1564; Ostrom E., 2003, TRUST RECIPROCITY IN; Ostrom E., 1990, GOVERNING COMMONS EV, DOI [10.1017/cbo9780511807763, DOI 10.1017/CBO9780511807763, 10.1017/CBO9780511807763]; Porco TC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046505; Sandholm W. H., 2010, POPULATION GAMES EVO; SMITH JM, 1973, NATURE, V246, P15, DOI 10.1038/246015a0; SMITH JM, 1974, J THEOR BIOL, V47, P209, DOI 10.1016/0022-5193(74)90110-6; TAYLOR PD, 1978, MATH BIOSCI, V40, P145, DOI 10.1016/0025-5564(78)90077-9; Temime L, 2008, EPIDEMIOL INFECT, V136, P289, DOI 10.1017/S0950268807009442; von Neumann J., 2007, THEORY GAMES EC BEHA, DOI [10.1515/9781400829460, DOI 10.1515/9781400829460, 10.1515%2F9781400829460]; Weibull J.W., 1997, EVOLUTIONARY GAME TH; Young H.P., 1998, INDIVIDUAL STRATEGY, DOI DOI 10.1515/9780691214252	38	17	17	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2019	14	4							e0215480	10.1371/journal.pone.0215480	http://dx.doi.org/10.1371/journal.pone.0215480			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU1GG	31002685	Green Published, gold, Green Submitted			2023-01-03	WOS:000465019900025
J	Hardy, J; Baggott, C; Fingleton, J; Reddel, HK; Hancox, RJ; Harwood, M; Corin, A; Sparks, J; Hall, D; Sabbagh, D; Mane, S; Vohlidkova, A; Martindale, J; Williams, M; Shirtcliffe, P; Holliday, M; Weatherall, M; Beasley, R				Hardy, Jo; Baggott, Christina; Fingleton, James; Reddel, Helen K.; Hancox, Robert J.; Harwood, Matire; Corin, Andrew; Sparks, Jenny; Hall, Daniela; Sabbagh, Donah; Mane, Saras; Vohlidkova, Alexandra; Martindale, John; Williams, Mathew; Shirtcliffe, Philippa; Holliday, Mark; Weatherall, Mark; Beasley, Richard		PRACTICAL Study Team	Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial	LANCET			English	Article							EXACERBATIONS	Background In adults with mild asthma, a combination of an inhaled corticosteroid with a fast-onset long-acting beta-agonist (LABA) used as reliever monotherapy reduces severe exacerbations compared with short-acting beta-agonist (SABA) reliever therapy. We investigated the efficacy of combination budesonide-formoterol reliever therapy compared with maintenance budesonide plus as-needed terbutaline. Methods We did a 52-week, open-label, parallel-group, multicentre, superiority, randomised controlled trial at 15 primary care or hospital-based clinical trials units and primary care practices in New Zealand. Participants were adults aged 18-75 years with a self-reported doctor's diagnosis of asthma who were using SABA for symptom relief with or without maintenance low to moderate doses of inhaled corticosteroids in the previous 12 weeks. We randomly assigned participants (1:1) to either reliever therapy with budesonide 200 mu g-formoterol 6 mu g Turbuhaler (one inhalation as needed for relief of symptoms) or maintenance budesonide 200 mu g Turbuhaler (one inhalation twice daily) plus terbutaline 250 mu g Turbuhaler (two inhalations as needed). Participants and investigators were not masked to group assignment; the statistician was masked for analysis of the primary outcome. Six study visits were scheduled: randomisation, and weeks 4, 16, 28, 40, and 52. The primary outcome was the number of severe exacerbations per patient per year analysed by intention to treat (severe exacerbations defined as use of systemic corticosteroids for at least 3 days because of asthma, or admission to hospital or an emergency department visit because of asthma requiring systemic corticosteroids). Safety analyses included all participants who had received at least one dose of study treatment. This trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12616000377437. Findings Between May 4, 2016, and Dec 22, 2017, we assigned 890 participants to treatment and included 885 eligible participants in the analysis:437 assigned to budesonide-formoterol as needed and 448 to budesonide maintenance plus terbutaline as needed. Severe exacerbations per patient per year were lower with as-needed budesonide-formoterol than with maintenance budesonide plus terbutaline as needed (absolute rate per patient per year 0.119 vs 0.172; relative rate 0.69, 95% CI 0.48-1.00; p=0.049). Nasopharyngitis was the most common adverse event in both groups, occurring in 154 (35%) of 440 patients receiving as-needed budesonide-formoterol and 144 (32%) of 448 receiving maintenance budesonide plus terbutaline as needed. Interpretation In adults with mild to moderate asthma, budesonide-formoterol used as needed for symptom relief was more effective at preventing severe exacerbations than maintenance low-dose budesonide plus as-needed terbutaline. The findings support the 2019 Global Initiative for Asthma recommendation that inhaled corticosteroid-formoterol reliever therapy is an alternative regimen to daily low-dose inhaled corticosteroid for patients with mild asthma. Copyright (C) 2019 Elsevier Ltd. All rights reserved.	[Hardy, Jo; Baggott, Christina; Fingleton, James; Sparks, Jenny; Hall, Daniela; Sabbagh, Donah; Mane, Saras; Vohlidkova, Alexandra; Martindale, John; Williams, Mathew; Shirtcliffe, Philippa; Holliday, Mark; Beasley, Richard] Med Res Inst New Zealand, Wellington 6242, New Zealand; [Fingleton, James; Beasley, Richard] Capital & Coast Dist Hlth Board, Wellington, New Zealand; [Reddel, Helen K.] Univ Sydney, Woolcock Inst Med Res, Sydney, NSW, Australia; [Hancox, Robert J.] Waikato Hosp, Hamilton, New Zealand; [Hancox, Robert J.] Univ Otago, Dunedin, New Zealand; [Harwood, Matire] Univ Auckland, Auckland, New Zealand; [Corin, Andrew] Clin Horizons, Tauranga, New Zealand; [Weatherall, Mark] Univ Otago Wellington, Wellington, New Zealand	Medical Research Institute Of New Zealand; University of Sydney; Woolcock Institute of Medical Research; Waikato Hospital; University of Otago; University of Auckland; University of Otago	Beasley, R (corresponding author), Med Res Inst New Zealand, Wellington 6242, New Zealand.	richard.beasley@mrinz.ac.nz	Reddel, Helen/ABD-6338-2021; Reddel, Helen/AAC-3394-2020; Weatherall, Mark/Y-6824-2019	Reddel, Helen/0000-0002-6695-6350; Weatherall, Mark/0000-0002-0051-9107; Eathorne, Allie/0000-0002-0706-044X; Hassan, summer/0000-0002-6185-9906; Oldfield, Karen/0000-0003-4734-8488; Baggott, Christina/0000-0002-3581-4472; Ebmeier, Stefan/0000-0001-7570-7172; Fingleton, James/0000-0001-9148-196X; Mane, Saras/0000-0002-9977-2523	Health Research Council of New Zealand	Health Research Council of New Zealand(Health Research Council of New Zealand)	Health Research Council of New Zealand.	Bateman ED, 2018, NEW ENGL J MED, V378, P1877, DOI 10.1056/NEJMoa1715275; Beasley R, 2019, NEW ENGL J MED, V380, P2020, DOI 10.1056/NEJMoa1901963; Charles T, 2007, J ALLERGY CLIN IMMUN, V119, P811, DOI 10.1016/j.jaci.2006.11.700; Cochrane MG, 2000, CHEST, V117, P542, DOI 10.1378/chest.117.2.542; Dusser D, 2007, ALLERGY, V62, P591, DOI 10.1111/j.1398-9995.2007.01394.x; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Fingleton J, 2017, BMJ OPEN RESPIR RES, V4, DOI 10.1136/bmjresp-2017-000217; Fingleton J, 2012, THORAX, V67, P667, DOI 10.1136/thoraxjnl-2012-201966; Global Initiative for Asthma (GINA), GLOB STRAT ASTHM MAN; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; O'Byrne PM, 2018, NEW ENGL J MED, V378, P1865, DOI 10.1056/NEJMoa1715274; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; Papi A, 2007, NEW ENGL J MED, V356, P2040, DOI 10.1056/NEJMoa063861; Pavord ID, 2018, LANCET, V391, P350, DOI 10.1016/S0140-6736(17)30879-6; Pilcher J, 2015, BMJ OPEN RESPIR RES, V2, DOI 10.1136/bmjresp-2015-000097; Price D, 2014, NPJ PRIM CARE RESP M, V24, DOI 10.1038/npjpcrm.2014.9; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2; Reddel HK, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.01046-2019; Reddel HK, 2017, LANCET, V389, P157, DOI 10.1016/S0140-6736(16)31399-X; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Sobieraj DM, 2018, JAMA-J AM MED ASSOC, V319, P1485, DOI 10.1001/jama.2018.2769	23	127	130	1	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 14	2019	394	10202					919	928		10.1016/S0140-6736(19)31948-8	http://dx.doi.org/10.1016/S0140-6736(19)31948-8			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IX7CE	31451207				2023-01-03	WOS:000485840600023
J	van Bussel, IPG; Fazelzadeh, P; Frost, GS; Rundle, M; Afman, LA				van Bussel, Inge P. G.; Fazelzadeh, Parastoo; Frost, Gary S.; Rundle, Milena; Afman, Lydia A.			Measuring phenotypic flexibility by transcriptome time-course analyses during challenge tests before and after energy restriction	FASEB JOURNAL			English	Article						PBMCs; whole-genome gene expression; OGTT; mixed-meal test	BLOOD MONONUCLEAR-CELLS; GENE-EXPRESSION; CALORIC RESTRICTION; INSULIN SENSITIVITY; LIFE-SPAN; DIET; METABOLISM; INDEX; MEN	Metabolic challenge tests may be a valuable tool to magnify the effects of diet on health. The use of transcriptomics enables a more extensive characterization of the effects of diet. The question remains whether transcriptome time-course analyses during challenge tests will deliver more information on the effect of diet than a static fasting measurement. A dietary intervention known to improve health is energy restriction (ER). Seventy-two healthy, overweight men and women aged 50-65 were subjected to an oral glucose tolerance test (OGTT) and a mixed-meal test (MMT) before and after 12 wk of a 20% ER diet or control diet. Whole-genome gene expression of peripheral blood mononuclear cells was performed before and after the intervention. This was done during fasting, during the OGTT at 30, 60, and 120 min, and during the MMT at 60, 120, 240, and 360 min. Upon ER, the OGTT resulted in a faster and more pronounced down-regulation in gene expression of oxidative phosphorylation, cell adhesion, and DNA replication compared with the control. The MMT showed less-consistent effects. The OGTT combined with transcriptomics can be used to measure dynamic cellular adaptation upon an intervention that cannot be determined with a static fasting measurement.-Van Bussel, I. P. G., Fazelzadeh, P., Frost, G. S., Rundle, M., Afman, L. A. Measuring phenotypic flexibility by transcriptome time-course analyses during challenge tests before and after energy restriction.	[van Bussel, Inge P. G.; Fazelzadeh, Parastoo; Afman, Lydia A.] Wageningen Univ & Res Ctr, Div Human Nutr & Hlth, Wageningen, Netherlands; [Frost, Gary S.; Rundle, Milena] Imperial Coll London, Div Diabet Endocrinol & Metab, Dept Med, London, England	Wageningen University & Research; Imperial College London	Afman, LA (corresponding author), Wageningen Univ & Res Ctr, Div Human Nutr, POB 17,Stippeneng 4, NL-6700 AA Wageningen, Netherlands.	lydia.afman@wur.nl		Rundle, Milena/0000-0001-9908-5195; Frost, Gary/0000-0003-0529-6325	NutriTech - European Commission in the Seventh Framework Programme (FP7) [289511]	NutriTech - European Commission in the Seventh Framework Programme (FP7)	The authors thank the participants, Mechteld Grootte-Bromhaar, Jenny Jansen, and the nurses and dieticians (all from the Division of Human Nutrition and Health, Wageningen University and Research Centre, Wageningen, The Netherlands) for their practical work during the study. Furthermore, the authors thank Philip de Groot, Mark Boekschoten, and Guido Hooiveld Division of Human Nutrition and Health for helping with microarray analysis. Funding was provided by NutriTech, which is financed by the European Commission in the Seventh Framework Programme (FP7) (Grant 289511; 2012-11-30). Membership of the NutriTech Consortium is provided at http://nutrigenomics.topshare.com/nutritech/. The authors declare no conflicts of interest.	Alipour A, 2008, ARTERIOSCL THROM VAS, V28, P792, DOI 10.1161/ATVBAHA.107.159749; Backx EMP, 2016, INT J OBESITY, V40, P299, DOI 10.1038/ijo.2015.182; Blumenthal JA, 2010, HYPERTENSION, V55, P1199, DOI 10.1161/HYPERTENSIONAHA.109.149153; Boren J, 2014, CLIN CHIM ACTA, V431, P131, DOI 10.1016/j.cca.2014.01.015; Bouwens M, 2009, AM J CLIN NUTR, V90, P415, DOI 10.3945/ajcn.2009.27680; Cao SX, 2001, P NATL ACAD SCI USA, V98, P10630, DOI 10.1073/pnas.191313598; Chen CN, 2015, AM J PHYSIOL-ENDOC M, V308, pE942, DOI 10.1152/ajpendo.00508.2014; Colin S, 2014, IMMUNOL REV, V262, P153, DOI 10.1111/imr.12218; Crujeiras AB, 2008, OMICS, V12, P251, DOI 10.1089/omi.2008.0001; Davis LM, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-11; Esser D, 2015, MOL NUTR FOOD RES, V59, P1563, DOI 10.1002/mnfr.201400853; Esser D, 2013, J NUTR, V143, P843, DOI 10.3945/jn.113.174540; Ghosh S, 2011, OBESITY, V19, P457, DOI 10.1038/oby.2010.209; Hill AA, 2014, IMMUNOL REV, V262, P134, DOI 10.1111/imr.12216; Huber Machteld, 2011, BMJ, V343, pd4163, DOI 10.1136/bmj.d4163; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Katz A, 2000, J CLIN ENDOCR METAB, V85, P2402, DOI 10.1210/jc.85.7.2402; Larsen TM, 2010, NEW ENGL J MED, V363, P2102, DOI 10.1056/NEJMoa1007137; Leder L, 2016, GENES NUTR, V11, DOI 10.1186/s12263-016-0521-4; Lin K, 2011, J INTEGR BIOINFORMAT, V8, DOI 10.2390/biecoll-jib-2011-160; Loftus RM, 2016, J BIOL CHEM, V291, P1, DOI 10.1074/jbc.R115.693903; Martinez F. O., 2014, F1000PRIME REP, V6, P13; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; O'Neill LAJ, 2016, J EXP MED, V213, P15, DOI 10.1084/jem.20151570; Pirillo A, 2014, CURR MED RES OPIN, V30, P1489, DOI 10.1185/03007995.2014.909394; Ristow M, 2014, DOSE-RESPONSE, V12, P288, DOI 10.2203/dose-response.13-035.Ristow; Ristow M, 2011, FREE RADICAL BIO MED, V51, P327, DOI 10.1016/j.freeradbiomed.2011.05.010; Ristow M, 2010, EXP GERONTOL, V45, P410, DOI 10.1016/j.exger.2010.03.014; Sathananthan M, 2015, J NUTR, V145, P2046, DOI 10.3945/jn.115.210617; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Stroeve JHM, 2015, GENES NUTR, V10, DOI 10.1007/s12263-015-0459-1; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Van Bussel IPG, 2016, GENES NUTR, V11, DOI 10.1186/s12263-016-0528-0; van Dijk SJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041388; van Dijk SJ, 2012, J NUTR, V142, P1219, DOI 10.3945/jn.111.155283; van Ommen B, 2014, GENES NUTR, V9, DOI 10.1007/s12263-014-0423-5; Yang JY, 2014, BIOMARK RES, V2, DOI 10.1186/2050-7771-2-1	38	4	4	3	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2019	33	9					10280	10290		10.1096/fj.201900148R	http://dx.doi.org/10.1096/fj.201900148R			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	IS5TA	31238007	Bronze			2023-01-03	WOS:000482214200045
J	Alessandrini, V; Anselem, O; Girault, A; Mandelbrot, L; Luton, D; Launay, O; Goffinet, F				Alessandrini, Vivien; Anselem, Olivia; Girault, Aude; Mandelbrot, Laurent; Luton, Dominique; Launay, Odile; Goffinet, Francois			Does the availability of influenza vaccine at prenatal care visits and of immediate vaccination improve vaccination coverage of pregnant women?	PLOS ONE			English	Article							MATERNAL IMMUNIZATION; VIRUS-INFECTION; UNITED-STATES; PHASE 4; A H1N1; MOTHERS; PREDICTORS; ACCEPTABILITY; DETERMINANTS; DISPARITIES	Introduction Although vaccination against influenza is recommended for pregnant women in France because it exposes them to a risk of death and severe respiratory complications, their vaccination coverage in 2016 was estimated at 7%. This study's principal objective was to assess the association between the availability of influenza vaccination at prenatal care visits and vaccination coverage. Material and methods This multicenter survey took place in 3 Paris-area public hospital (AP-HP) maternity wards (A, B, and C). Only maternity ward A offered the vaccine and vaccination without charge at prenatal visits. Data were collected from parturients during 10 days in January 2017 by a self-administered anonymous questionnaire. Results Data from 248 women showed overall vaccination coverage of 19.4% (48/248): 35.4% (46/130) in maternity unit A, 2.7% (2/75) in B, and 0% (0/43) in C (P<0.01). After adjustment for socio-demographic characteristics, women at maternity ward A were significantly more likely to be vaccinated than those at B and C (aOR 25.52, 95% CI [5.76-113.10]). Other factors significantly associated with higher vaccination coverage were the mother's French birth (aOR 2.37 CI [1.03-5.46]) and previous influenza vaccination (aOR 3.13, 95% CI [1.25-7.86]). Vaccinated women generally considered they had received adequate information (aOR 4.15 CI [2.10-8.22]), principally from the professional providing their prenatal care. Nonvaccination was attributed to the absence of an offer of vaccination (81.5%), fear of fetal side effects (59.5%), and inadequate information (51.4%). Conclusion Our results show that availability of influenza vaccination, free of charge, at prenatal consultations at the maternity ward increases vaccination coverage significantly.	[Alessandrini, Vivien; Anselem, Olivia; Girault, Aude; Goffinet, Francois] Univ Paris 05, Grp Hosp Cochin Broca Hotel Dieu, AP HP, Maternite Port Royal, Paris, France; [Alessandrini, Vivien; Anselem, Olivia; Girault, Aude; Mandelbrot, Laurent; Luton, Dominique; Launay, Odile; Goffinet, Francois] PRES Sorbonne Paris Cite, DHU Risques & Grossesse, Paris, France; [Mandelbrot, Laurent] Univ Diderot Paris 7, Maternite Louis Mourier, Hop Univ Paris Nord Val de Seine, AP HP, Colombes, France; [Luton, Dominique] Univ Diderot Paris 7, Maternite Bichat Claude Bernard, Hop Univ Paris Nord Val de Seine, AP HP, Paris, France; [Launay, Odile] Univ Paris 05, Sorbonne Paris Cite, Ctr Invest Clin Cochin Pasteur, Grp Hosp Cochin Broca Hotel Dieu,AP HP,Inserm,CIC, Paris, France; [Goffinet, Francois] UPMC, Unite INSERM U953, Rech Epidemiol Sante Perinatale & Sante Femmes &, Paris, France	Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Hopital Universitaire Hotel-Dieu - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Alessandrini, V (corresponding author), Univ Paris 05, Grp Hosp Cochin Broca Hotel Dieu, AP HP, Maternite Port Royal, Paris, France.; Alessandrini, V (corresponding author), PRES Sorbonne Paris Cite, DHU Risques & Grossesse, Paris, France.	alessandrini.viven@hotmail.fr	Mandelbrot, Laurent/AAD-3554-2019	Mandelbrot, Laurent/0000-0002-5883-7597				Anselem O, 2013, PRESSE MED, V42, P1453, DOI 10.1016/j.lpm.2013.01.064; Bianco A, 2019, VACCINE, V37, P984, DOI 10.1016/j.vaccine.2018.12.062; Blanchard-Rohner G, 2012, J MATERN-FETAL NEO M, V25, P1800, DOI 10.3109/14767058.2012.663835; Bonmarin I, 2011, BEH, V37-38, P398; Bonville CA, 2015, HUM VACC IMMUNOTHER, V11, P713, DOI 10.1080/21645515.2015.1011999; Bratton KN, 2015, CLIN INFECT DIS, V60, pE11, DOI 10.1093/cid/ciu915; Cohen R, 2019, MED MALADIES INFECT, V49, P34, DOI 10.1016/j.medmal.2018.10.004; Creanga AA, 2010, OBSTET GYNECOL, V115, P717, DOI 10.1097/AOG.0b013e3181d57947; D'Alessandro A, 2018, HUM VACC IMMUNOTHER, V14, P1573, DOI 10.1080/21645515.2018.1483809; Danchin MH, 2018, VACCINE, V36, P6473, DOI 10.1016/j.vaccine.2017.08.003; Ding H, 2017, MMWR-MORBID MORTAL W, V66, P1016, DOI 10.15585/mmwr.mm6638a2; Eick AA, 2011, ARCH PEDIAT ADOL MED, V165, P104, DOI 10.1001/archpediatrics.2010.192; Endrich MM, 2009, VACCINE, V27, P4018, DOI 10.1016/j.vaccine.2009.04.029; Equipes de surveillance de la grippe, 2017, B EPIDEMIOL HEBD, P466; Freund R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020900; Fridman D, 2011, AM J OBSTET GYNECOL, V204, pS124, DOI 10.1016/j.ajog.2011.04.011; Gilkey MB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159087; Goldfarb I, 2011, AM J OBSTET GYNECOL, V204, pS112, DOI 10.1016/j.ajog.2011.01.007; Haberg SE, 2013, NEW ENGL J MED, V368, P333, DOI 10.1056/NEJMoa1207210; Harris JW, 1919, J AMER MED ASSOC, V72, P978, DOI 10.1001/jama.1919.02610140008002; Henninger ML, 2015, J WOMENS HEALTH, V24, P394, DOI 10.1089/jwh.2014.5105; Henrikson NB, 2017, PUBLIC HEALTH REP, V132, P451, DOI 10.1177/0033354917711175; Jamieson DJ, 2011, AM J OBSTET GYNECOL, V204, pS1, DOI 10.1016/j.ajog.2011.04.010; Krishnaswamy S, 2018, VACCINE, V36, P1796, DOI 10.1016/j.vaccine.2017.12.080; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Link MW, 2006, AM J EPIDEMIOL, V163, P571, DOI 10.1093/aje/kwj086; Linn ST, 2010, J AM GERIATR SOC, V58, P1333, DOI 10.1111/j.1532-5415.2010.02904.x; Loubet P, 2015, J DES ANTIINFECTIEUX, V17, P173; Loubet P, 2014, EXPERT OPIN DRUG SAF, V13, P1709, DOI 10.1517/14740338.2014.977252; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Madhi SA, 2014, NEW ENGL J MED, V371, P918, DOI 10.1056/NEJMoa1401480; Ministere des Solidarite &PRIME; s et de la Sante, ENQ NAT PER 2010; Ministere des Solidarites et de la Sante, ENQ NAT PER 2016; Mohammed H, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214538; Mohammed H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197867; Moro PL, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.047; Myers KL, 2016, VACCINE, V34, P3942, DOI 10.1016/j.vaccine.2016.06.042; Napolitano F, 2018, HUM VACC IMMUNOTHER, V14, P1558, DOI 10.1080/21645515.2018.1463943; Napolitano F, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2138-2; Nordin JD, 2013, OBSTET GYNECOL, V121, P519, DOI 10.1097/AOG.0b013e3182831b83; Omer SB, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000441; Pierce M, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d3214; Regan AK, 2016, WOMEN BIRTH, V29, P423, DOI 10.1016/j.wombi.2016.01.009; Sakaguchi S, 2011, J OBSTET GYNAECOL CA, V33, P460, DOI 10.1016/S1701-2163(16)34879-4; Siston AM, 2010, JAMA-J AM MED ASSOC, V303, P1517, DOI 10.1001/jama.2010.479; Steinhoff MC, 2017, LANCET INFECT DIS, V17, P981, DOI 10.1016/S1473-3099(17)30252-9; Steinhoff MC, 2010, NEW ENGL J MED, V362, P1644, DOI 10.1056/NEJMc0912599; Tapia MD, 2016, LANCET INFECT DIS, V16, P1026, DOI 10.1016/S1473-3099(16)30054-8; Tarrant M, 2013, MATERN CHILD HLTH J, V17, P23, DOI 10.1007/s10995-011-0943-1; van Lier A, 2012, VACCINE, V30, P2892, DOI 10.1016/j.vaccine.2012.02.030; Ward JK, 2018, VACCINE, V36, P1801, DOI 10.1016/j.vaccine.2018.02.095; Wilson RJ, 2015, VACCINE, V33, P6420, DOI 10.1016/j.vaccine.2015.08.046; Yates L, 2010, HEALTH TECHNOL ASSES, V14, P121; Yudin MH, 2010, J OBSTET GYNAECOL CA, V32, P745, DOI 10.1016/S1701-2163(16)34614-X; Yuen CYS, 2014, VACCINE, V32, P4602, DOI 10.1016/j.vaccine.2014.06.067; Yuen CYS, 2013, VACCINE, V31, P5281, DOI 10.1016/j.vaccine.2013.08.063; Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630	57	11	11	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2019	14	8							e0220705	10.1371/journal.pone.0220705	http://dx.doi.org/10.1371/journal.pone.0220705			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4ZH	31369626	Green Submitted, gold, Green Published			2023-01-03	WOS:000484987900080
J	Bergt, S; Grub, A; Mueller, M; Bajorat, R; Barilar, I; Vollmar, B; Roesner, JP; Wagner, NM				Bergt, Stefan; Grub, Andrea; Mueller, Melanie; Bajorat, Rika; Barilar, Ivan; Vollmar, Brigitte; Roesner, Jan Patrick; Wagner, Nana-Maria			Toll-like receptor 4 deficiency or inhibition does not modulate survival and neurofunctional outcome in a murine model of cardiac arrest and resuscitation	PLOS ONE			English	Article							CARDIOPULMONARY-RESUSCITATION; NEUROLOGICAL REHABILITATION; BRAIN-INJURY; MICE; MANAGEMENT; CARE	Background Patients experiencing cardiac arrest (CA) and cardiopulmonary resuscitation (CPR) often die or suffer from severe neurological impairment. Post resuscitation syndrome is characterized by a systemic inflammatory response. Toll-like receptor 4 (TLR4) is a major mediator of inflammation and TLR4 has been implicated in the pathogenesis of post-resuscitation encephalopathy. The aim of this study was to evaluate whether TLR4 deficiency or inhibition can modulate survival and neurofunctional outcome after CA/CPR. Methods Following intubation and central venous cannulation, CA was induced in wild type (C57Bl/6J, n = 38), TLR4 deficient (TLR4(-/-), n = 37) and TLR4 antibody treated mice (5mg/kg MTS510, n = 15) by high potassium. After 10min, CPR was performed using a modified sewing machine until return of spontaneous circulation (ROSC). Cytokines and cerebral TNFalpha levels were measured 8h after CA/CPR. Survival, early neurological recovery, locomotion, spatial learning and memory were assessed over a period of 28 days. Results Following CA/CPR, all mice exhibited ROSC and 31.5% of wild type mice survived until day 28. Compared to wild type mice, neither TLR4(-/-) nor MTS510 treated wild type mice had statistically significant altered survival following CA/ CPR (51.3 and 26.7%, P = 0.104 and P = 0.423 vs. WT, respectively). Antibody-treated but not TLR4(-/-) mice had higher IL-1 beta and IL-6 levels and TLR4(-/-) mice had higher IL-10 and cerebral TNFalpha levels. No differences existed between mice of all groups in early neurological recovery, locomotion, spatial learning ability or remembrance. Conclusion Therapeutic strategies targeting TLR4 may not be suitable for the reduction of mortality or neurofunctional impairment after CA/CPR.	[Bergt, Stefan; Grub, Andrea; Bajorat, Rika; Roesner, Jan Patrick] Rostock Univ, Clin Anesthesiol & Crit Care Med, Med Ctr, Rostock, Germany; [Mueller, Melanie; Wagner, Nana-Maria] Univ Hosp Muenster, Clin Anesthesiol Intens Care Med & Pain Therapy, Munster, Germany; [Barilar, Ivan] Res Ctr Borstel, Prior Area Infect, Mol & Expt Mycobacteriol, Borstel, Germany; [Vollmar, Brigitte] Rostock Univ, Inst Expt Surg, Med Ctr, Rostock, Germany	University of Rostock; University of Munster; Forschungszentrum Borstel; University of Rostock	Wagner, NM (corresponding author), Univ Hosp Muenster, Clin Anesthesiol Intens Care Med & Pain Therapy, Munster, Germany.	nmwagner@uni-muenster.de	Wagner, Nana-Maria/AAB-3953-2021	Wagner, Nana-Maria/0000-0002-4610-6666	departmental funds of the Clinic for Anesthesiology and Critical Care Medicine, Rostock, Germany	departmental funds of the Clinic for Anesthesiology and Critical Care Medicine, Rostock, Germany	The study was funded by departmental funds of the Clinic for Anesthesiology and Critical Care Medicine, Rostock, Germany. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abella BS, 2004, CIRCULATION, V109, P2786, DOI 10.1161/01.CIR.0000131940.19833.85; Andresen L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148428; Asmussen A, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1340-3; Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI 10.1161/CIR.0000000000000558; Bergt S, 2017, JACC BASIC TRANSLATI, V105; Bergt S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074944; DECKER MW, 1989, BRAIN RES, V477, P29, DOI 10.1016/0006-8993(89)91391-7; Dvoriantchikova G, 2010, MOL VIS, V16, P1907; Fertl E, 2000, RESUSCITATION, V47, P231, DOI 10.1016/S0300-9572(00)00239-2; Gesuete R, 2014, J NEUROPATH EXP NEUR, V73, P378, DOI 10.1097/NEN.0000000000000068; Grasner JT, 2016, RESUSCITATION, V105, P188, DOI 10.1016/j.resuscitation.2016.06.004; Hutchens MP, 2008, RESUSCITATION, V76, P89, DOI 10.1016/j.resuscitation.2007.06.031; Jiang H, 2017, CANCER IMMUNOL IMMUN, V66, P1037, DOI 10.1007/s00262-017-2003-1; Krupinski J, 2007, BIOMARK INSIGHTS, V2, P361; Laver S, 2004, INTENS CARE MED, V30, P2126, DOI 10.1007/s00134-004-2425-z; Liu FD, 2013, ACTA PHARMACOL SIN, V34, P1121, DOI 10.1038/aps.2013.89; Maramattom BV, 2005, NEUROLOGIST, V11, P234, DOI 10.1097/01.nrl.0000159985.07242.22; Miyamoto O, 2000, NEUROLOGY, V54, P362, DOI 10.1212/WNL.54.2.362; Neigh GN, 2004, EUR J NEUROSCI, V20, P1865, DOI 10.1111/j.1460-9568.2004.03649.x; Neigh GN, 2004, J CEREBR BLOOD F MET, V24, P372, DOI 10.1097/00004647-200404000-00002; Nicholson A, 2009, J AM ASSOC LAB ANIM, V48, P740; NIEMANN JT, 1984, ANN EMERG MED, V13, P849, DOI 10.1016/S0196-0644(84)80458-8; Oda Y, 2012, RESUSCITATION, V83, P1006, DOI 10.1016/j.resuscitation.2012.01.030; Orr JS, 2012, DIABETES; Packard AEB, 2012, J CEREBR BLOOD F MET, V32, P2193, DOI 10.1038/jcbfm.2012.140; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Pradillo JM, 2009, J NEUROCHEM, V109, P287, DOI 10.1111/j.1471-4159.2009.05972.x; Pusswald G, 2000, RESUSCITATION, V47, P241, DOI 10.1016/S0300-9572(00)00240-9; Puttgen HA, 2009, CURR OPIN CRIT CARE, V15, P118, DOI 10.1097/MCC.0b013e328326077c; Shi X, 2017, NEUROSCIENCE, V360, P128, DOI 10.1016/j.neuroscience.2017.07.052; Tang SC, 2007, P NATL ACAD SCI USA, V104, P13798, DOI 10.1073/pnas.0702553104; Thaete LG, 2013, REPRODUCTION; Wang Y, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/124614; Xu L, 2015, CHINESE MED J-PEKING, V128, P2646, DOI 10.4103/0366-6999.166024; Yang HZ, 2012, AM J PATHOL, V180, P275, DOI 10.1016/j.ajpath.2011.09.019	36	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2019	14	8							e0220404	10.1371/journal.pone.0220404	http://dx.doi.org/10.1371/journal.pone.0220404			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4ZH	31369614	Green Published, gold, Green Submitted			2023-01-03	WOS:000484987900046
J	Graham-Clarke, E; Rushton, A; Noblet, T; Marriott, J				Graham-Clarke, Emma; Rushton, Alison; Noblet, Timothy; Marriott, John			Non-medical prescribing in the United Kingdom National Health Service: A systematic policy review	PLOS ONE			English	Review								Introduction Non-medical prescribing was introduced into the United Kingdom (UK) to improve patient care, through extending healthcare professionals' roles. More recent government health service policy focuses on the increased demand and the need for efficiency. This systematic policy review aimed to describe any changes in government policy position and the role that non-medical prescribing plays in healthcare provision. Method The systematic policy review included policy and consultation documents that describe independent non-medical prescribing. A pre-defined protocol was registered with PROSPERO (CRD42015019786). Professional body websites, other relevant websites and the following databases were searched to identify relevant documents: HMIC, Lexis Nexis, UK Government Web Archive, UKOP, UK Parliamentary Papers and Web of Science. Documents published between 2006 and February 2018 were included. Results and discussion Following exclusions, 45 documents were selected for review; 23 relating to policy or strategy and 22 to consultations. Of the former, 13/23 were published 2006-2010 and the remainder since 2013. Two main themes were identified: chronological aspects and healthcare provision. In the former, a publication gap for policy documents resulted from a change in government and associated major healthcare service reorganisation. In the later, the role of non-medical prescribing was found to have evolved to support efficient service delivery, and cost reduction. For many professions, prescribing appears embedded into practice; however, the pharmacy profession continues to produce policy documents, suggesting that prescribing is not yet perceived as normal practice. Conclusion Prescribing appears to be more easily adopted into practice where it can form part of the overall care of the patient. Where new roles are required to be established, then prescribing takes longer to be universally adopted. While this review concerns policy and practice in the UK, the aspect of role adoption has wider potential implications.	[Graham-Clarke, Emma; Marriott, John] Univ Birmingham, Inst Clin Sci, Sch Pharm, Coll Med & Dent Sci, Birmingham, W Midlands, England; [Rushton, Alison; Noblet, Timothy] Univ Birmingham, Ctr Precis Rehabil Spinal Pain, Sch Sport Exercise & Rehabil Sci, Coll Life & Environm Sci, Birmingham, W Midlands, England; [Noblet, Timothy] St Georges Univ Hosp NHS Fdn Trust, Physiotherapy Dept, London, England	University of Birmingham; University of Birmingham	Graham-Clarke, E (corresponding author), Univ Birmingham, Inst Clin Sci, Sch Pharm, Coll Med & Dent Sci, Birmingham, W Midlands, England.	EMG315@bham.ac.uk	Graham-Clarke, Emma/GZG-8429-2022; Rushton, Alison/V-1260-2017; Noblet, Tim/AAK-9611-2021; Graham-Clarke, Emma/U-1559-2019	Rushton, Alison/0000-0001-8114-7669; Graham-Clarke, Emma/0000-0001-5657-778X				Advisory Council on the Misuse of Drugs, 2008, ANN REP ACC YEAR 200; Allied Health Professions Medicines Project Team, 2015, CONS PROP INTR IND P; Allied Health Professions Medicines Project Team, 2016, SUMM RESP PUBL CONS; [Anonymous], 1999, REV PRESCRIBING SUPP; [Anonymous], 2016, IND PRESCR THER RAD; [Anonymous], 2018, 2008 RECESSION 10 YE; [Anonymous], 2016, PRESCR SURV REP, P54; [Anonymous], 2019, COUNC M; Booth A., 2016, GUIDANCE CHOOSING QU; Commission for Healthcare Audit and Inspection, 2007, BEST MED MAN MED AC; Commission on Human Medicines, 2015, COMM HUM MED M HELD; Commission on Human Medicines, 2008, OUTC CONS EX PROP RE; Commission on Human Medicines, 2012, COMM HUM MED M HELD; Commission on Human Medicines, 2017, COMM HUM MED M HELD; Cordina Maria, 2015, Pharmacy Pract (Granada), V13, DOI 10.18549/PharmPract.2015.04.640; Crowther N, 2010, PROPOSALS INTRO PRES; Department of Health, 2011, PROP INTR IND PRESCR; Department of Health, 2000, NHS PLAN A PLAN INV; Department of Health, 2012, PROP INTR IND PRESCR; Department of Health, 2011, CONS PROP INTR IND P; Department of Health, 2000, CONS PROP EXT NURS P; Department of Health, 2006, MED MATT GUID MECH P; Department of Health, 2010, ENG EX SEEK VIEWS PO; Department of Health, 2006, CAR HOM IND PHARM PR; Department of Health, 2010, EQ EXC LIB NHS; Department of Health, 2008, PHARM ENGL BUILD STR; Department of Health, 2005, 4941 DEP HLTH; Department of Health, 2012, SUMM PUBL CONS PROP; Department of Health, 2005, TAK HEALTHC PAT TRAN; Department of Health and Social Security, 1986, NEIGHB NURS FOC CAR; Department of Health Social Services and Public Safety., 2006, 10406 DEP HLTH SOC S; Drug Strategy Unit, 2007, PUBL CONS IND PRESCR; Greengross P., 1999, HIST DEV UK NATL HLT, V2nd; Greenhalgh T, 2005, BRIT MED J, V331, P1064, DOI 10.1136/bmj.38636.593461.68; H M Treasury, 2010, BUDGET 2010; Health Education England, 2015, FUT PRIM CAR CREAT T; Health Education England, 2017, GEN PRACT NURS WORKF; Kroezen M, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-127; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Marks D, 2009, 12185 DEP HLTH; Mays Nicholas, 2005, J Health Serv Res Policy, V10 Suppl 1, P6, DOI 10.1258/1355819054308576; Medical Education England, 2010, PHARM PRESCR TRAIN W; Medicines & Healthcare Products Regulatory Agency, 2005, CONS OPT FUT IND PRE; Medicines & Healthcare Products Regulatory Agency, 2008, PUBL CONS MLX 334 PR; Medicines & Healthcare Products Regulatory Agency, 2005, CONS PROP INTR IND P; Medicines & Healthcare Products Regulatory Agency, 2006, CONS PROP INTR IND P; Moher D, 2015, STATEMENT SYST REV, V4, DOI [10.1186/2046-4053-4-1, DOI 10.1186/2046-4053-4-1, 10.1186/s13643-015-0163-7, DOI 10.14306/RENHYD.20.2.223]; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; National Institute for Mental Health in England National Workforce Programme, 2007, NEW WAYS WORK EV BES; National Institute for Mental Health in England National Workforce Programme, 2007, MENT HLTH NEW WAYS W; NHS England, 2013, NHS BEL PEOPL CALL A; NHS England, 2015, PROP INTR IND PRESCR; NHS England, 2014, 5 YEAR FORW VIEW2014; NHS England, 2013, HIGH QUAL CAR ALL NO; NHS England, 2015, IND PRESCR RAD IMP A; NHS England, 2016, 5764 NHS ENGL; NHS England, BETT TREATM PAT ADV; NHS Scotland, 2009, SAF PRESCR DEV NURS; NHS Scotland, 2006, GUID NURS IND PRESCR; NHS Wales, 2014, OUR PLAN PRIM CAR WA; Pharmaceutical Division, 2007, NONM PRESCR WAL GUID; Popay J, 2006, GUIDANCE CONDUCT NAR, DOI DOI 10.13140/2.1.1018.4643; Primary Care Division, 2007, CONS SAT PRESCR DEV; Public Health England, 2017, FAC FACTS SHAP FUT D; Royal Pharmaceutical Society, 2014, 7 DAY SERV HOSP PHAR; Royal Pharmaceutical Society, 2016, IMPR CAR PEOPL LONG; Royal Pharmaceutical Society Wales, 2014, YOUR CAR YOUR MED PH; Smith J, 2013, NOW NEVER SHAPING PH; Stoye G., 2018, DOES NHS NEED MORE M; The Health Foundation, 2016, STAFF MATT FUND COUN; The Scottish Government, 2013, PRESCR EXC	71	24	24	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2019	14	7							e0214630	10.1371/journal.pone.0214630	http://dx.doi.org/10.1371/journal.pone.0214630			29	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IV1OL	31356615	gold, Green Submitted, Green Published			2023-01-03	WOS:000484047000003
J	Rochoy, M; Bordet, R; Gautier, S; Chazard, E				Rochoy, Michael; Bordet, Regis; Gautier, Sophie; Chazard, Emmanuel			Factors associated with the onset of Alzheimer's disease: Data mining in the French nationwide discharge summary database between 2008 and 2014	PLOS ONE			English	Article							RISK-FACTOR; DEMENTIA; EPIDEMIOLOGY; BENZODIAZEPINE; METAANALYSIS; POPULATION; DEPRESSION; PSYCHOSIS; MIDLIFE; FRANCE	Introduction Identifying modifiable risk factors for Alzheimer's disease (AD) is critical for research. Data mining may be a useful tool for finding new AD associated factors. Methods We included all patients over 49 years of age, hospitalized in France in 2008 (without dementia) and in 2014. Dependent variable was AD or AD dementia diagnosis in 2014. We recoded the diagnoses of hospital stays (in ICD-10) into 137 explanatory variables. To avoid overweighting the "age" variable, we divided the population into 7 sub-populations of 5 years. Results We analyzed 1,390,307 patients in the PMSI in 2008 and 2014: 55,997 patients had coding for AD or AD dementia in 2014 (4.04%). We associated Alzheimer disease in 2014 with about 20 variables including male sex, stroke, diabetes mellitus, mental retardation, bipolar disorder, intoxication, Parkinson disease, depression, anxiety disorders, alcohol, undernutrition, fall and 3 less explored variables: intracranial hypertension (odd radio [95% confidence interval]: 1.16 [1.12-1.20] in 70-80 years group), psychotic disorder (OR: 1.09 [1.07-1.11] in 70-75 years group) and epilepsy (OR: 1.06 [1.05-1.07] after 70 years). Discussion We analyzed 137 variables in the PMSI identified some well-known risk factors for AD, and highlighted a possible association with intracranial hypertension, which merits further investigation. Better knowledge of associations could lead to better targeting (identifying) at-risk patients, and better prevention of AD, in order to reduce its impact.	[Rochoy, Michael; Bordet, Regis; Gautier, Sophie; Chazard, Emmanuel] Univ Lille, Lille, France; [Rochoy, Michael; Bordet, Regis; Gautier, Sophie] INSERM, U1171 Degenerat & Vasc Cognit Disorders, Lille, France; [Rochoy, Michael; Chazard, Emmanuel] Publ Hlth Dept, EA2694, Lille, France	Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille	Rochoy, M (corresponding author), Univ Lille, Lille, France.; Rochoy, M (corresponding author), INSERM, U1171 Degenerat & Vasc Cognit Disorders, Lille, France.; Rochoy, M (corresponding author), Publ Hlth Dept, EA2694, Lille, France.	michael.rochoy@gmail.com	Rochoy, Michaël/AAD-7340-2020	Rochoy, Michael/0000-0002-8865-3748				Agarwal R, 2014, AM J ALZHEIMERS DIS, V29, P575, DOI 10.1177/1533317514531443; Alosco ML, 2015, HEART FAIL REV, V20, P561, DOI 10.1007/s10741-015-9488-5; Alzheimer's Association, 2016, Alzheimers Dement, V12, P459; Anstey KJ, 2011, OBES REV, V12, pe426, DOI 10.1111/j.1467-789X.2010.00825.x; Barnes DE, 2011, LANCET NEUROL, V10, P819, DOI 10.1016/S1474-4422(11)70072-2; Bellou V, 2017, ALZHEIMERS DEMENT, V13, P406, DOI 10.1016/j.jalz.2016.07.152; Bennett DA, 2012, CURR ALZHEIMER RES, V9, P617; Berr C, 2007, PRESSE MED, V36, P1431, DOI 10.1016/j.lpm.2007.04.022; Beydoun MA, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-643; Bezin J, 2017, PHARMACOEPIDEM DR S, V26, P954, DOI 10.1002/pds.4233; Bomboi G, 2010, NEUROL SCI, V31, P1, DOI 10.1007/s10072-009-0151-6; Boudemaghe T, 2017, INT J EPIDEMIOL, V46, P392, DOI 10.1093/ije/dyw359; Bousquet Cedric, 2010, AMIA Annu Symp Proc, V2010, P61; Breiman L., 1984, CLASSIFICATION REGRE, DOI 10.1201/9781315139470; Breiman L., 2001, RANDOM FORESTS, V45, P5, DOI DOI 10.1023/A:1010933404324; BUXTON RL, 1970, LANCET, V2, P498; Cowppli-Bony Pascale, 2006, Psychol Neuropsychiatr Vieil, V4, P47; DEGAGE SB, 2012, BMJ-BRIT MED J, V345, DOI DOI 10.1136/BMJ.E6231; Diniz BS, 2017, AM J GERIAT PSYCHIAT, V25, P357, DOI 10.1016/j.jagp.2016.11.014; Dubois B, 2016, J ALZHEIMERS DIS, V49, P617, DOI 10.3233/JAD-150692; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Garre-Olmo J, 2018, REV NEUROLOGIA, V66, P377, DOI 10.33588/rn.6611.2017519; Garre-Olmo J, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-5; Harrington KD, 2015, AUST NZ J PSYCHIAT, V49, P36, DOI 10.1177/0004867414557161; Harris SA, 2015, J ALZHEIMERS DIS, V48, P319, DOI 10.3233/JAD-142853; Harvey RJ, 2003, J NEUROL NEUROSUR PS, V74, P1206, DOI 10.1136/jnnp.74.9.1206; Imfeld P, 2015, DRUG SAFETY, V38, P909, DOI 10.1007/s40264-015-0319-3; JENKINSON ML, 1989, BRIT J RHEUMATOL, V28, P86; Kao LT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168106; Kivipelto M, 2006, ACTA NEUROL SCAND, V114, P50, DOI 10.1111/j.1600-0404.2006.00685.x; LaRoia H, 2011, NEUROEPIDEMIOLOGY, V37, P1, DOI 10.1159/000328866; Mercy L, 2008, NEUROLOGY, V71, P1496, DOI 10.1212/01.wnl.0000334277.16896.fa; Mortimer JA, 2012, CURR ALZHEIMER RES, V9, P621; MYLLYKANGASLUOSUJARVI R, 1994, BRIT J RHEUMATOL, V33, P501; Nixon DW, 2017, CURR ALZHEIMER RES, V14, P883, DOI 10.2174/1567205014666170216152905; Norton S, 2014, LANCET NEUROL, V13, P788, DOI 10.1016/S1474-4422(14)70136-X; Ownby RL, 2006, ARCH GEN PSYCHIAT, V63, P530, DOI 10.1001/archpsyc.63.5.530; Panza F, 2015, NAT REV NEUROL, V11; R.C. Team Vienna Austria R.F. f.S. Computing, 2021, R LANG ENV STAT COMP; Rochoy M, 2019, JPAD-J PREV ALZHEIM, V6, P121, DOI 10.14283/jpad.2019.7; Rochoy M, 2019, JPAD-J PREV ALZHEIM, V6, P108, DOI 10.14283/jpad.2019.5; Rochoy M, 2019, Ann Cardiol Angeiol (Paris), V68, P150, DOI 10.1016/j.ancard.2018.10.011; Rochoy M, 2019, GERIATR PSYCHOL NEUR, P8; Rochoy M, 2019, AM J ALZHEIMERS DIS, V34, P188, DOI 10.1177/1533317518822043; Roubaud Baudron C, 2016, GERIATR PSYCHOL NEUR, V14, P86, DOI 10.1684/pnv.2016.0584; Schneider LS, 2004, J PSYCHIATR RES, V38, P105, DOI 10.1016/S0022-3956(03)00092-X; Schwarzinger M, 2016, ALZHEIMERS DEMENT J, V12, pP194; Serafini G, 2016, CURR ALZHEIMER RES, V13, P1083, DOI 10.2174/1567205013666160720112608; Shafi O, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0765-2; Subota A, 2017, EPILEPSIA, V58, P962, DOI 10.1111/epi.13744; Tolppanen AM, 2012, J ALZHEIMERS DIS, V32, P531, DOI 10.3233/JAD-2012-120802; Vagelatos NT, 2013, EPIDEMIOL REV, V35, P152, DOI 10.1093/epirev/mxs012; van de Rest O, 2015, ADV NUTR, V6, P154, DOI 10.3945/an.114.007617; Van der Mussele S, 2015, AGING MENT HEALTH, V19, P818, DOI 10.1080/13607863.2014.967170; Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]; World Health Organization, 2012, DEM PUBL HLTH PRIOR; WOSTYN P, 1994, MED HYPOTHESES, V43, P219, DOI 10.1016/0306-9877(94)90069-8; Wostyn P, 2008, CLIN NEUROL NEUROSUR, V110, P101, DOI 10.1016/j.clineuro.2007.10.011; Wu CS, 2009, AM J GERIAT PSYCHIAT, V17, P614, DOI 10.1097/JGP.0b013e3181a65210; Wyss-Coray T, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006346; Zhuo JM, 2011, TRENDS PHARMACOL SCI, V32, P562, DOI 10.1016/j.tips.2011.05.003	61	8	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2019	14	7							e0220174	10.1371/journal.pone.0220174	http://dx.doi.org/10.1371/journal.pone.0220174			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4VN	31344088	Green Published, Green Submitted, gold			2023-01-03	WOS:000484977900061
J	Santos, R; Ruza, D; Cunha, E; Tavares, L; Oliveira, M				Santos, Raquel; Ruza, Diana; Cunha, Eva; Tavares, Luis; Oliveira, Manuela			Diabetic foot infections: Application of a nisin-biogel to complement the activity of conventional antibiotics and antiseptics against Staphylococcus aureus biofilms	PLOS ONE			English	Article							HOST-DEFENSE PEPTIDES; IN-VITRO ACTIVITIES; CHLORHEXIDINE; RESISTANT; ENTEROCOCCUS; VANCOMYCIN; MECHANISMS; DIAGNOSIS	Background Diabetic foot infections (DFIs) are a frequent complication of Diabetes mellitus and a major cause of nontraumatic limb amputations. The Gram-positive bacterium Staphylococcus aureus, known for its resilient biofilms and antibiotic resistant profile, is the most frequent DFI pathogen. It is urgent to develop innovative treatments for these infections, being the antimicrobial peptide (AMP) nisin a potential candidate. We have previously proposed the use of a guar gum biogel as a delivery system for nisin. Here, we evaluated the potential of the nisin-biogel to enhance the efficacy of conventional antibiotics and antiseptics against DFIs S. aureus clinical isolates. Methods A collection of 23 S. aureus strains isolated from DFI patients, including multidrug- and methicillin-resistant strains, was used. The antimicrobial activity of the nisin-biogel was tested alone and in different combinations with the antiseptic chlorhexidine and the antibiotics clindamycin, gentamicin and vancomycin. Isolates' in vitro susceptibility to the different protocols was assessed using broth microdilution methods in order to determine their ability to inhibit and/or eradicate established S. aureus biofilms. Antimicrobials were added to the 96-well plates every 8 h to simulate a typical DFI treatment protocol. Statistical analysis was conducted using RCBD ANOVA in SPSS. Results The nisin-biogel showed a high antibacterial activity against biofilms formed by DFI S. aureus. The combined protocol using nisin-biogel and chlorhexidine presented the highest efficacy in biofilm formation inhibition, significantly higher (p<0.05) than the ones presented by the antibiotics-based protocols tested. Regarding biofilm eradication, there were no significant differences (p>0.05) between the activity of the combination nisin-biogel plus chlorhexidine and the conventional antibiotic-based protocols. Conclusions Results provide a valuable contribution for the development of complementary strategies to conventional antibiotics protocols. A combined protocol including chlorhexidine and nisinbiogel could be potentially applied in medical centres, contributing for the reduction of antibiotic administration, selection pressure on DFI pathogens and resistance strains dissemination.	[Santos, Raquel; Ruza, Diana; Cunha, Eva; Tavares, Luis; Oliveira, Manuela] Univ Lisbon, Fac Med Vet, CIISA, Lisbon, Portugal	Universidade de Lisboa	Oliveira, M (corresponding author), Univ Lisbon, Fac Med Vet, CIISA, Lisbon, Portugal.	moliveira@fmv.ulisboa.pt		Tavares, Luis/0000-0001-8671-6285; Oliveira, Manuela/0000-0002-3910-1525; Martins dos Santos, Tania Raquel/0000-0003-2215-0467; Cunha, Eva/0000-0002-5641-4400	FCT Fundacao para a Ciencia e a Tecnologia [PTDC/SAU-INF/28466/2017]; CIISA - Centro de Investigacao Interdisciplinar em Sanidade Animal, Faculdade de Medicina Veterinaria, Universidade de Lisboa [UID/CVT/276/2019]; FCT [SFRH/BD/100571/2014, SFRH/BD/131384/2017]	FCT Fundacao para a Ciencia e a Tecnologia(Portuguese Foundation for Science and Technology); CIISA - Centro de Investigacao Interdisciplinar em Sanidade Animal, Faculdade de Medicina Veterinaria, Universidade de Lisboa; FCT(Portuguese Foundation for Science and TechnologyEuropean Commission)	This work was supported by FCT Fundacao para a Ciencia e a Tecnologia (Project PTDC/SAU-INF/28466/2017) and by CIISA -Centro de Investigacao Interdisciplinar em Sanidade Animal, Faculdade de Medicina Veterina 'ria, Universidade de Lisboa (Project UID/CVT/276/2019). RS and EC acknowledge FCT for their PhD fellowships (SFRH/BD/100571/2014 and SFRH/BD/131384/2017, respectively).	Akhi MT, 2017, INT J DIABETES DEV C, V37, P58, DOI 10.1007/s13410-016-0492-7; Armstrong David G, 2011, J Diabetes Sci Technol, V5, P1591; Bader MS, 2008, AM FAM PHYSICIAN, V78, P71; Batoni G, 2016, BBA-BIOMEMBRANES, V1858, P1044, DOI 10.1016/j.bbamem.2015.10.013; Binda E, 2014, ANTIBIOTICS-BASEL, V3, P572, DOI 10.3390/antibiotics3040572; Bonez PC, 2013, AM J INFECT CONTROL, V41, pE119, DOI 10.1016/j.ajic.2013.05.002; Chambers HF, 2009, NAT REV MICROBIOL, V7, P629, DOI 10.1038/nrmicro2200; Choutet P, 2007, MED MAL INFECT, V37, P14, DOI [10.1016/j.medmal.2006.10.001, DOI 10.1016/J.MEDMAL.2006.10.001]; Climo MW, 2009, CRIT CARE MED, V37, P1858, DOI 10.1097/CCM.0b013e31819ffe6d; Clinical and Laboratory Standards Institute, 1999, M26A CLIN LAB STAND; CLSI, 2015, CLSI DOCUMENT M07 A1, V10th; Correia SS, 2015, CHALLENGES ANTIBIOTI, P178; Dang CN, 2003, DIABETIC MED, V20, P159, DOI 10.1046/j.1464-5491.2003.00860.x; Dickschat JS, 2010, NAT PROD REP, V27, P343, DOI 10.1039/b804469b; Duarte Nádia, 2011, Angiol Cir Vasc, V7, P65; French GL, 2006, J ANTIMICROB CHEMOTH, V58, P1107, DOI 10.1093/jac/dkl393; Hancock REW, 2006, NAT BIOTECHNOL, V24, P1551, DOI 10.1038/nbt1267; Henry-Stanley MJ, 2014, J MED MICROBIOL, V63, P861, DOI 10.1099/jmm.0.068130-0; Hobizal Kimberlee B, 2012, Diabet Foot Ankle, V3, DOI 10.3402/dfa.v3i0.18409; Huang HP, 2016, KOREAN J INTERN MED, V31, P1159, DOI 10.3904/kjim.2015.240; Kaplan JB, 2011, INT J ARTIF ORGANS, V34, P737, DOI 10.5301/ijao.5000027; Kluytmans J, 1997, CLIN MICROBIOL REV, V10, P505, DOI 10.1128/CMR.10.3.505; Kohanski MA, 2010, NAT REV MICROBIOL, V8, P423, DOI 10.1038/nrmicro2333; LaPlante KL, 2009, ANTIMICROB AGENTS CH, V53, P3166, DOI 10.1128/AAC.01642-08; Lim KS, 2008, ANAESTH INTENS CARE, V36, P502; Lipsky BA, 2014, COCHRANE DB SYST REV, V3; Lipsky BA, 2016, DIABETES-METAB RES, V32, P45, DOI 10.1002/dmrr.2699; Lipsky BA, 2012, CLIN INFECT DIS, V54, P1679, DOI [10.1093/cid/cis460, 10.1093/cid/cis346]; Lipsky BA, 2009, CLIN INFECT DIS, V49, P1541, DOI 10.1086/644732; Liu QZ, 2015, DIAGN MICR INFEC DIS, V82, P278, DOI 10.1016/j.diagmicrobio.2015.03.023; Main R C, 2008, J Wound Care, V17, P112; Malik A, 2013, DIABETES METAB SYND, V7, P101, DOI 10.1016/j.dsx.2013.02.006; Mataraci E, 2012, ANTIMICROB AGENTS CH, V56, P6366, DOI 10.1128/AAC.01180-12; McDonnell G, 1999, CLIN MICROBIOL REV, V12, P147, DOI 10.1128/CMR.12.1.147; Mendes JJ, 2012, DIABETES RES CLIN PR, V95, P153, DOI 10.1016/j.diabres.2011.10.001; Milstone AM, 2008, CLIN INFECT DIS, V46, P274, DOI 10.1086/524736; Mottola C, 2016, J BIOMED SCI, V23, DOI [10.1186/s12929-016-0250-7, 10.1186/ s12929-016-0250-7]; Mottola C, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0737-0; Mottola C, 2016, FOLIA MICROBIOL, V61, P35, DOI 10.1007/s12223-015-0401-3; O'Driscoll NH, 2013, CURR MICROBIOL, V66, P271, DOI 10.1007/s00284-012-0268-3; Okuda K, 2013, ANTIMICROB AGENTS CH, V57, P5572, DOI 10.1128/AAC.00888-13; Rosenfeld Y, 2006, J BIOL CHEM, V281, P1636, DOI 10.1074/jbc.M504327200; Santos R, 2016, J MED MICROBIOL, V65, P1092, DOI 10.1099/jmm.0.000329; Schlett CD, 2014, ANTIMICROB AGENTS CH, V58, P4404, DOI 10.1128/AAC.02419-14; Touzel RE, 2016, J HOSP INFECT, V92, P154, DOI 10.1016/j.jhin.2015.09.013; Vert M, 2012, PURE APPL CHEM, V84, P377, DOI 10.1351/PAC-REC-10-12-04; Wiedemann I, 2001, J BIOL CHEM, V276, P1772, DOI 10.1074/jbc.M006770200; World Health Organization, 2016, GLOB REP DIAB; Wound Healing & Management, 2017, WOUND PRACT RES, V25, P49; Yeaman MR, 2003, PHARMACOL REV, V55, P27, DOI 10.1124/pr.55.1.2; Younes M, 2017, EFSA J, V15, DOI 10.2903/j.efsa.2017.5049; Zhu M, 2017, CHINESE CHEM LETT, V28, P703, DOI 10.1016/j.cclet.2016.10.001	52	16	16	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2019	14	7							e0220000	10.1371/journal.pone.0220000	http://dx.doi.org/10.1371/journal.pone.0220000			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IS7NE	31339915	Green Submitted, Green Published, gold			2023-01-03	WOS:000482335700044
J	Campbell, BCV; Ma, H; Ringleb, PA; Parsons, MW; Churilov, L; Bendszus, M; Levi, CR; Hsu, C; Kleinig, TJ; Fatar, M; Leys, D; Molina, C; Wijeratne, T; Curtze, S; Dewey, HM; Barber, PA; Butcher, KS; De Silva, DA; Bladin, CF; Yassi, N; Pfaff, JAR; Sharma, G; Bivard, A; Desmond, PM; Schwab, S; Schellinger, PD; Yan, B; Mitchell, PJ; Serena, J; Toni, D; Thijs, V; Hacke, W; Davis, SM; Donnan, GA				Campbell, Bruce C., V; Ma, Henry; Ringleb, Peter A.; Parsons, Mark W.; Churilov, Leonid; Bendszus, Martin; Levi, Christopher R.; Hsu, Chung; Kleinig, Timothy J.; Fatar, Marc; Leys, Didier; Molina, Carlos; Wijeratne, Tissa; Curtze, Sami; Dewey, Helen M.; Barber, P. Alan; Butcher, Kenneth S.; De Silva, Deidre A.; Bladin, Christopher F.; Yassi, Nawaf; Pfaff, Johannes A. R.; Sharma, Gagan; Bivard, Andrew; Desmond, Patricia M.; Schwab, Stefan; Schellinger, Peter D.; Yan, Bernard; Mitchell, Peter J.; Serena, Joaquin; Toni, Danilo; Thijs, Vincent; Hacke, Werner; Davis, Stephen M.; Donnan, Geoffrey A.		EXTEND Investigator; ECASS-4 Investigator; EPITHET Investigator	Extending thrombolysis to 4.5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data	LANCET			English	Review							ACUTE ISCHEMIC-STROKE; REPERFUSION; DIFFUSION; ALTEPLASE; MULTICENTER; MISMATCH; ONSET; TIME	Background Stroke thrombolysis with alteplase is currently recommended 0-4.5 h after stroke onset. We aimed to determine whether perfusion imaging can identify patients with salvageable brain tissue with symptoms 4.5 h or more from stroke onset or with symptoms on waking who might benefit from thrombolysis. Methods In this systematic review and meta-analysis of individual patient data, we searched PubMed for randomised trials published in English between Jan 1, 2006, and March 1, 2019. We also reviewed the reference list of a previous systematic review of thrombolysis and searched ClinicalTrials. gov for interventional studies of ischaemic stroke. Studies of alteplase versus placebo in patients (aged =18 years) with ischaemic stroke treated more than 4.5 h after onset, or with wake-up stroke, who were imaged with perfusion-diffusion MRI or CT perfusion were eligible for inclusion. The primary outcome was excellent functional outcome (modified Rankin Scale [mRS] score 0-1) at 3 months, adjusted for baseline age and clinical severity. Safety outcomes were death and symptomatic intracerebral haemorrhage. We calculated odds ratios, adjusted for baseline age and National Institutes of Health Stroke Scale score, using mixed-effects logistic regression models. This study is registered with PROSPERO, number CRD42019128036. Findings We identified three trials that met eligibility criteria: EXTEND, ECASS4-EXTEND, and EPITHET. Of the 414 patients included in the three trials, 213 (51%) were assigned to receive alteplase and 201 (49%) were assigned to receive placebo. Overall, 211 patients in the alteplase group and 199 patients in the placebo group had mRS assessment data at 3 months and thus were included in the analysis of the primary outcome. 76 (36%) of 211 patients in the alteplase group and 58 (29%) of 199 patients in the placebo group had achieved excellent functional outcome at 3 months (adjusted odds ratio [OR] 1.86, 95% CI 1.15-2.99, p=0.011). Symptomatic intracerebral haemorrhage was more common in the alteplase group than the placebo group (ten [5%] of 213 patients vs one [< 1%] of 201 patients in the placebo group; adjusted OR 9.7, 95% CI 1.23-76.55, p=0.031). 29 (14%) of 213 patients in the alteplase group and 18 (9%) of 201 patients in the placebo group died (adjusted OR 1.55, 0.81-2.96, p=0.66). Interpretation Patients with ischaemic stroke 4.5-9 h from stroke onset or wake-up stroke with salvageable brain tissue who were treated with alteplase achieved better functional outcomes than did patients given placebo. The rate of symptomatic intracerebral haemorrhage was higher with alteplase, but this increase did not negate the overall net benefit of thrombolysis. Copyright (c) 2019 Elsevier Ltd. All rights reserved.	[Campbell, Bruce C., V; Parsons, Mark W.; Churilov, Leonid; Yassi, Nawaf; Sharma, Gagan; Bivard, Andrew; Yan, Bernard; Davis, Stephen M.; Donnan, Geoffrey A.] Univ Melbourne, Royal Melbourne Hosp, Dept Med & Neurol, Melbourne Brain Ctr, Melbourne, Vic 3050, Australia; [Desmond, Patricia M.; Yan, Bernard; Mitchell, Peter J.] Univ Melbourne, Dept Radiol, Royal Melbourne Hosp, Melbourne, Vic, Australia; [Campbell, Bruce C., V; Ma, Henry; Bladin, Christopher F.; Yassi, Nawaf; Thijs, Vincent; Donnan, Geoffrey A.] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Ma, Henry] Monash Univ, Dept Med, Sch Clin Sci, Melbourne, Vic, Australia; [Dewey, Helen M.; Bladin, Christopher F.] Monash Univ, Dept Neurosci, Eastern Hlth, Melbourne, Vic, Australia; [Dewey, Helen M.; Bladin, Christopher F.] Monash Univ, Eastern Hlth Clin Sch, Melbourne, Vic, Australia; [Ringleb, Peter A.; Hacke, Werner] Heidelberg Univ, Dept Neurol, Heidelberg, Germany; [Bendszus, Martin; Pfaff, Johannes A. R.] Heidelberg Univ, Dept Neuroradiol, Heidelberg, Germany; [Churilov, Leonid] Univ Melbourne, Dept Med, Austin Hlth, Melbourne, Vic, Australia; [Thijs, Vincent] Univ Melbourne, Dept Neurol, Austin Hlth, Melbourne, Vic, Australia; [Wijeratne, Tissa] Univ Melbourne, Dept Med, Western Hosp, Melbourne Med Sch, Melbourne, Vic, Australia; [Levi, Christopher R.] Univ Newcastle, John Hunter Hosp, Prior Res Ctr Brain & Mental Hlth Res, Dept Neurol, Newcastle, NSW, Australia; [Hsu, Chung] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan; [Kleinig, Timothy J.] Royal Adelaide Hosp, Dept Neurol, Adelaide, SA, Australia; [Fatar, Marc] Heidelberg Univ, Dept Neurol, Fac Med Mannheim, Mannheim, Germany; [Leys, Didier] Hosp CHU Lille, Dept Neurol, Lille, France; [Molina, Carlos] Univ Barcelona, Hosp Vall dHebron, Dept Neurol, Barcelona, Spain; [Wijeratne, Tissa] Sunshine Hosp, Dept Neurol, Western Hlth, Melbourne, Vic, Australia; [Curtze, Sami] Helsinki Univ Hosp, Dept Neurol, Helsinki, Finland; [Barber, P. Alan] Univ Auckland, Auckland City Hosp, Dept Neurol, Auckland, New Zealand; [Butcher, Kenneth S.] Univ New South Wales, Prince Wales Clin Sch, Sydney, NSW, Australia; [Butcher, Kenneth S.] Univ Alberta, Div Neurol, Edmonton, AB, Canada; [De Silva, Deidre A.] Singapore Gen Hosp, Natl Neurosci Inst, Dept Neurol, Singapore, Singapore; [Schwab, Stefan] Univ Erlangen Nurnberg, Dept Neurol, Erlangen, Germany; [Schellinger, Peter D.] Ruhr Univ Bochum, Johannes Wesling Med Ctr Minden, Dept Neurol & Neurogeriatry, Univ Hosp, Bochum, Germany; [Serena, Joaquin] Girona Univ Hosp, Biomed Res Inst Girona, Dept Neurol, Girona, Spain; [Toni, Danilo] Sapienza Univ Roma, Dept Neurol, Rome, Italy	Royal Melbourne Hospital; University of Melbourne; Royal Melbourne Hospital; University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Monash University; Monash University; Monash University; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Melbourne; Western Hospital; John Hunter Hospital; University of Newcastle; China Medical University Taiwan; Royal Adelaide Hospital; Ruprecht Karls University Heidelberg; Universite de Lille - ISITE; CHU Lille; Hospital Universitari Vall d'Hebron; University of Barcelona; University of Helsinki; Helsinki University Central Hospital; Auckland City Hospital; University of Auckland; University of New South Wales Sydney; University of Alberta; National Neuroscience Institute (NNI); Singapore General Hospital; University of Erlangen Nuremberg; Ruhr University Bochum; Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Institut d'Investigacio Biomedica de Girona (IDIBGI); Sapienza University Rome	Donnan, GA (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Dept Med & Neurol, Melbourne Brain Ctr, Melbourne, Vic 3050, Australia.	geoffrey.donnan@unimelb.edu.au	Pfaff, Johannes Alex Rolf/P-6272-2019; FRACP, Tissa Wijeratne MD PhD/I-2086-2019; Zhao, Henry/AAL-9919-2020; Toni, Danilo/K-3151-2016; Spratt, Neil J/K-4208-2012; Hankey, Graeme J/H-4968-2014; Campbell, Bruce/AGY-4147-2022; Campbell, Bruce/J-1220-2019; Hacke, Werner/ABE-8661-2020; Butcher, Ken/ABC-6632-2020; Thijs, Vincent/C-3647-2009; Butcher, Ken/AEP-3693-2022; Poli, Sven/ACY-0995-2022; Oppenheim, Catherine/N-1635-2018; Macleod, Malcolm Robert/B-2052-2010; Desmond, Patricia/D-1966-2014; Davis, Stephen/L-5260-2013; Clissold, Benjamin/X-3245-2018	Pfaff, Johannes Alex Rolf/0000-0003-0672-5718; FRACP, Tissa Wijeratne MD PhD/0000-0002-1701-7111; Zhao, Henry/0000-0002-4320-4287; Toni, Danilo/0000-0003-2735-8427; Spratt, Neil J/0000-0002-9023-6177; Hankey, Graeme J/0000-0002-6044-7328; Campbell, Bruce/0000-0003-3632-9433; Butcher, Ken/0000-0002-0590-7918; Thijs, Vincent/0000-0002-6614-8417; Butcher, Ken/0000-0002-0590-7918; Ng, Felix/0000-0001-6973-8677; Choi, Philip/0000-0003-0339-3439; Yassi, Nawaf/0000-0002-0685-0060; Alemseged, Fana/0000-0003-4001-1591; Poli, Sven/0000-0002-0286-8781; Blacker, David/0000-0003-0046-9776; Schultz, David/0000-0001-6319-7574; Oppenheim, Catherine/0000-0003-3410-0862; Tsai, Chia-Kuang/0000-0001-7693-1408; Macleod, Malcolm Robert/0000-0001-9187-9839; Mikulik, Robert/0000-0002-7458-5166; Balabanski, Anna/0000-0003-3209-3101; Muller, Claire/0000-0002-9250-936X; kleinig, Timothy/0000-0003-4430-3276; Yeh, Shin-Joe/0000-0003-1511-6295; Desmond, Patricia/0000-0002-4803-6323; Tsai, Li-Kai/0000-0001-8420-6951; Williams, Cameron/0000-0003-4952-8896; Davis, Stephen/0000-0003-0962-2300; Barber, P Alan/0000-0003-2469-9023; MA, HENRY/0000-0002-0510-8059; Levi, Christopher/0000-0002-9474-796X; Sobesky, Jan/0000-0001-5459-3655; Clissold, Benjamin/0000-0002-9747-9817; Wardlaw, Joanna/0000-0002-9812-6642; De Silva, Deidre Anne/0000-0002-7123-2381; Eschenfelder, Christoph/0000-0003-2766-2488	Australian National Health and Medical Research Council through the Commonwealth Scientific and Industrial Research Organization Flagship programme; Ministry of Health and Welfare [MOHW108-TDU-B-212-133004]; Ministry of Science and Technology Taiwan Clinical Trial Consortium for Stroke [MOST107-2321-B-039-004]; Boehringer Ingelheim (Ingelheim, Germany); Australian National Health and Medical Research Council	Australian National Health and Medical Research Council through the Commonwealth Scientific and Industrial Research Organization Flagship programme; Ministry of Health and Welfare(Ministry of Health, Labour and Welfare, Japan); Ministry of Science and Technology Taiwan Clinical Trial Consortium for Stroke; Boehringer Ingelheim (Ingelheim, Germany)(Boehringer Ingelheim); Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	EXTEND was funded by the Australian National Health and Medical Research Council through the Commonwealth Scientific and Industrial Research Organization Flagship programme. The EXTEND trial sites in Taiwan were supported in part by a Ministry of Health and Welfare grant (MOHW108-TDU-B-212-133004) and the Ministry of Science and Technology Taiwan Clinical Trial Consortium for Stroke (MOST107-2321-B-039-004). ECASS4-EXTEND was an investigator-initiated trial supported by a restricted grant from Boehringer Ingelheim (Ingelheim, Germany). EPITHET was funded by the Australian National Health and Medical Research Council. Investigational product for all three trials was supplied by Boehringer Ingelheim. RAPID imaging software was provided by iSchemaView.	Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973; Albers GW, 2006, ANN NEUROL, V60, P508, DOI 10.1002/ana.20976; Amiri H, 2016, INT J STROKE, V11, P260, DOI 10.1177/1747493015620805; Barow E, 2019, JAMA NEUROL, V76, P641, DOI 10.1001/jamaneurol.2019.0351; Campbell BCV, 2011, STROKE, V42, P3435, DOI 10.1161/STROKEAHA.111.618355; Campbell BCV, 2010, CEREBROVASC DIS, V29, P592, DOI 10.1159/000311080; Cao WJ, 2016, J CLIN NEUROSCI, V29, P70, DOI 10.1016/j.jocn.2016.01.001; Davis SM, 2008, LANCET NEUROL, V7, P299, DOI 10.1016/S1474-4422(08)70044-9; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Lansberg MG, 2017, ANN NEUROL, V81, P849, DOI 10.1002/ana.24953; Lansberg MG, 2012, LANCET NEUROL, V11, P860, DOI 10.1016/S1474-4422(12)70203-X; Ma H, 2019, NEW ENGL J MED, V380, P1795, DOI 10.1056/NEJMoa1813046; Ma H, 2012, INT J STROKE, V7, P74, DOI 10.1111/j.1747-4949.2011.00730.x; Nagakane Y, 2011, STROKE, V42, P59, DOI 10.1161/STROKEAHA.110.580464; Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442; Olivot JM, 2009, STROKE; Picanco MR, 2014, INT J STROKE, V9, P266, DOI 10.1111/ijs.12209; Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158; Purushotham A, 2015, INT J STROKE, V10, P348, DOI 10.1111/ijs.12068; Ringleb P, 2019, INT J STROKE, V14, P483, DOI 10.1177/1747493019840938; Thomalla G, 2018, NEW ENGL J MED, V379, P611, DOI 10.1056/NEJMoa1804355; Thomalla G, 2011, LANCET NEUROL, V10, P978, DOI 10.1016/S1474-4422(11)70192-2; Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4; Whiteley WN, 2016, LANCET NEUROL, V15, P925, DOI [10.1016/s1474-4422(16)30076-X, 10.1016/S1474-4422(16)30076-X]	24	216	227	8	62	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 13	2019	394	10193					139	147		10.1016/S0140-6736(19)31053-0	http://dx.doi.org/10.1016/S0140-6736(19)31053-0			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	II7TG	31128925	Green Published			2023-01-03	WOS:000475393900027
J	Mukai, N; Nakayama, Y; Ishi, S; Murakami, T; Ogawa, S; Kageyama, K; Murakami, S; Sasada, Y; Yoshioka, J; Nakajima, Y				Mukai, Nobuhiro; Nakayama, Yoshinobu; Ishi, Sachiyo; Murakami, Takayuki; Ogawa, Satoru; Kageyama, Kyoko; Murakami, Satoshi; Sasada, Yuji; Yoshioka, Jun; Nakajima, Yasufumi			Cold storage conditions modify microRNA expressions for platelet transfusion	PLOS ONE			English	Article							MESSENGER-RNA; APHERESIS PLATELETS; APOPTOSIS; BLOOD; TEMPERATURE; INFLAMMATION; BIOGENESIS; REACTIVITY	MicroRNAs (miRNAs) are small RNA molecules that modulate gene and protein expression in hematopoiesis. Platelets are known to contain a fully functional miRNA machinery. While platelets used for transfusion are normally stored at room temperature, recent evidence suggests more favorable effects under a cold-storage condition, including higher adhesion and aggregation properties. Thus, we sought to determine whether functional differences in platelets are associated with the differential profiling of platelet miRNA expressions. To obtain the miRNA expression profile, next-generation sequencing was performed on human platelets obtained from 10 healthy subjects. The miRNAs were quantified after being stored in three different conditions: 1) baseline (before storage), 2) stored at 22 degrees C with agitation for 72 h, and 3) stored at 4 degrees C for 72 h. Following the identification of miRNAs by sequencing, the results were validated at the level of mature miRNAs from 18 healthy subjects, by using quantitative polymerase chain reaction (qPCR). Differential expression was observed for 125 miRNAs that were stored at 4 degrees C and 9 miRNAs stored at 22 degrees C as compared to the baseline. The validation study by qPCR confirmed that storage at 4 degrees C increased the expression levels (fold change 95% CI) of mir-20a-5p (1.87, p<0.0001), mir-10a-3p (1.88, p<0.0001), mir-16-2-3p (1.54, p<0.01), and mir-223-5p (1.38, p<0.05), compared with those of the samples stored at 22 degrees C. These results show that miRNAs correlate with platelet quality under specific storage conditions. The data indicate that miRNAs could be potentially used as biomarkers of platelet quality.	[Mukai, Nobuhiro; Nakayama, Yoshinobu; Ishi, Sachiyo; Murakami, Takayuki; Ogawa, Satoru] Kyoto Prefectural Univ Med, Dept Anesthesiol & Crit Care, Kyoto, Japan; [Nakayama, Yoshinobu; Yoshioka, Jun] CUNY City Coll, Sch Med, Dept Mol Cellular & Biomed Sci, New York, NY 10031 USA; [Kageyama, Kyoko] Otokoyama Hosp, Dept Anesthesiol, Kyoto, Japan; [Murakami, Satoshi] Life Technol Japan Ltd, Life Solut Grp, Thermo Fisher Sci, Tokyo, Japan; [Sasada, Yuji] Kyoto Prefectural Univ Med, Dept Transfus Med & Cell Therapy, Kyoto, Japan; [Nakajima, Yasufumi] Kansai Med Univ, Dept Anesthesiol & Crit Care, Osaka, Japan; [Nakajima, Yasufumi] Outcomes Res Consortium, Cleveland, OH USA	Kyoto Prefectural University of Medicine; City University of New York (CUNY) System; City College of New York (CUNY); Thermo Fisher Scientific; Kyoto Prefectural University of Medicine; Kansai Medical University	Nakayama, Y (corresponding author), Kyoto Prefectural Univ Med, Dept Anesthesiol & Crit Care, Kyoto, Japan.; Nakayama, Y (corresponding author), CUNY City Coll, Sch Med, Dept Mol Cellular & Biomed Sci, New York, NY 10031 USA.	na-yoshi@koto.kpu-m.ac.jp	Nakayama, Yoshinobu/GNO-9970-2022	Nakayama, Yoshinobu/0000-0002-0818-4145	Japanese Ministry of Education, Culture, Sports, Science and Technology [17K11093, 18K16457]; Philip V. & Anna S Brown Foundation; LaRue S. Fisher and Walter F. Fisher Memorial Trust; Bank of America, N. A., Trustee; NIH [1R01HL130861]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL130861] Funding Source: NIH RePORTER	Japanese Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Philip V. & Anna S Brown Foundation; LaRue S. Fisher and Walter F. Fisher Memorial Trust; Bank of America, N. A., Trustee; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by Grants-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (Nos. 17K11093, 18K16457) to Y. Nakayama and S. Ishii. This work was also supported by awards from the Philip V. & Anna S Brown Foundation, the LaRue S. Fisher and Walter F. Fisher Memorial Trust, and Bank of America, N. A., Trustee, and a NIH grant 1R01HL130861 to J. Yoshioka.	Abdelmohsen K, 2012, AGEING RES REV, V11, P491, DOI 10.1016/j.arr.2012.01.003; Bauersachs J, 2011, CIRC RES, V109, P334, DOI 10.1161/CIRCRESAHA.110.228676; Beppu S, 2009, ANESTHESIOLOGY, V111, P1227, DOI 10.1097/ALN.0b013e3181c155ce; Bray PF, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-1; Brecher ME, 2013, TRANSFUSION, V53, P221, DOI 10.1111/j.1537-2995.2012.03708.x; Capocelli KE, 2014, CURR OPIN HEMATOL, V21, P491, DOI 10.1097/MOH.0000000000000081; Chen XJ, 2018, TRANSFUS MED HEMOTH, V45, P397, DOI 10.1159/000489321; Dahiya N, 2017, PLATELETS, V28, P74, DOI 10.1080/09537104.2016.1203405; Edelstein LC, 2013, NAT MED, V19, P1609, DOI 10.1038/nm.3385; Elgheznawy A, 2015, CIRC RES, V117, P157, DOI 10.1161/CIRCRESAHA.117.305784; Elling V, 2015, BULL INST MATH ACAD, V10; Frank D, 2012, J MOL CELL CARDIOL, V52, P711, DOI 10.1016/j.yjmcc.2011.12.001; Hoffmeister KM, 2003, CELL, V112, P87, DOI 10.1016/S0092-8674(02)01253-9; Kannan M, 2009, TRANSFUSION, V49, P1443, DOI 10.1111/j.1537-2995.2009.02140.x; Kato M, 2013, AGEING RES REV, V12, P429, DOI 10.1016/j.arr.2012.03.012; Knight JE, 2000, MOL CELL BIOL, V20, P6374, DOI 10.1128/MCB.20.17.6374-6379.2000; Krol J, 2010, CELL, V141, P618, DOI 10.1016/j.cell.2010.03.039; Landry P, 2009, NAT STRUCT MOL BIOL, V16, P961, DOI 10.1038/nsmb.1651; Leytin V, 2012, BLOOD REV, V26, P51, DOI 10.1016/j.blre.2011.10.002; Mestdagh P, 2014, NAT METHODS, V11, P809, DOI [10.1038/NMETH.3014, 10.1038/nmeth.3014]; Metcalfe C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163006; Montgomery RK, 2013, TRANSFUSION, V53, P1520, DOI 10.1111/j.1537-2995.2012.03917.x; Mukai N, 2018, CRIT CARE MED, V46, pE761, DOI 10.1097/CCM.0000000000003197; Mukai N, 2018, PEDIATR RES, V83, P866, DOI 10.1038/pr.2017.327; MURPHY S, 1969, NEW ENGL J MED, V280, P1094, DOI 10.1056/NEJM196905152802004; MURPHY S, 1976, TRANSFUSION, V16, P2; Nagalla S, 2011, BLOOD, V117, P5189, DOI 10.1182/blood-2010-09-299719; Nurden AT, 2011, THROMB HAEMOSTASIS, V105, pS13, DOI 10.1160/THS10-11-0720; Pidcoke HF, 2014, SHOCK, V41, P51, DOI 10.1097/SHK.0000000000000078; Pilotte J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028446; Pontes TB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129399; Pope CA, 2004, ENVIRON HEALTH PERSP, V112, P339, DOI 10.1289/ehp.6588; Reddoch KM, 2014, SHOCK, V41, P54, DOI 10.1097/SHK.0000000000000082; Sharma S, 2011, AM FAM PHYSICIAN, V83, P719; Stec DE, 2007, RENAL FAILURE, V29, P543, DOI 10.1080/08860220701391878; Stroncek DF, 2007, LANCET, V370, P427, DOI 10.1016/S0140-6736(07)61198-2; Sunderland N, 2017, CIRC RES, V120, P418, DOI 10.1161/CIRCRESAHA.116.309303; Teruel-Montoya R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102259; VALERI CR, 1974, NEW ENGL J MED, V290, P353, DOI 10.1056/NEJM197402142900702; van der Wal DE, 2010, J THROMB HAEMOST, V8, P2554, DOI 10.1111/j.1538-7836.2010.04043.x; van der Wal DE, 2012, HAEMATOL-HEMATOL J, V97, P1514, DOI 10.3324/haematol.2011.059956; Vojtechova Z, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179645; Yu SF, 2014, BLOOD TRANSFUS-ITALY, V12, P541, DOI 10.2450/2014.0291-13; Zhang ZP, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111873	44	9	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 3	2019	14	7							e0218797	10.1371/journal.pone.0218797	http://dx.doi.org/10.1371/journal.pone.0218797			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4CE	31269049	Green Published, Green Submitted, gold			2023-01-03	WOS:000484927300026
J	Zainal, H; Dahlui, M; Soelar, SA; Su, TT				Zainal, Hadzri; Dahlui, Maznah; Soelar, Shahrul Aiman; Su, Tin Tin			Cost of preterm birth during initial hospitalization: A care provider's perspective	PLOS ONE			English	Article							NEONATAL INTENSIVE-CARE; LENGTH-OF-STAY; GESTATIONAL-AGE; INFANTS; OUTCOMES; IMPACT	Preterm birth incidence has risen globally and remains a major cause of neonatal mortality despite improved survival. Demand and cost of initial hospitalization has also increased. This study assessed the cost of preterm birth during initial hospitalization from care provider perspective in neonatal intensive care units (NICU) of two hospitals in the state of Kedah, Malaysia. It utilized universal sampling and prospectively followed up preterm infants till discharge. Care provider cost was assessed using mixed method of top down approach and activity based costing. A total of 112 preterm infants were recruited from intensive care (93 infants) and minimal care (19 infants) units. Majority were from the moderate (23%) and late (36%) preterm groups followed by very preterm (32%) and extreme preterm (9%). Median cost per infant increased with level of care and degree of prematurity. Cost was dominated by overhead (fixed) costs for general (hospital), intermediate (clinical support services) and final (NICU) cost centers where it constituted at least three quarters of admission cost per infant while the remainder was consumables (variable) cost. Breakdown of overhead cost showed NICU specific overhead contributing at least two thirds of admission cost per infant. Personnel salary made up three quarters of NICU specific overhead. Laboratory investigation was the cost driver for consumables. Gender, birth weight and length of stay were significant factors and cost prediction was developed with these variables. This study demonstrated the inverse relation between resource utilization, cost and prematurity and identified personnel salary as the cost driver. Cost estimates and prediction provide in-depth understanding of provider cost and are applicable for further economic evaluations. Since gender is non-modifiable and reducing LOS alone is not effective, birth weight as a cost predictive factor in this study can be addressed through measures to prevent or delay preterm birth.	[Zainal, Hadzri; Dahlui, Maznah; Su, Tin Tin] Univ Malaya, Dept Social & Prevent Med, Fac Med, Kuala Lumpur, Malaysia; [Dahlui, Maznah] Univ Airlangga, Fac Publ Hlth, Surabaya, Indonesia; [Soelar, Shahrul Aiman] Minist Hlth, Clin Res Ctr, Alor Setar, Malaysia; [Su, Tin Tin] Monash Univ, South East Asia Community Observ, Jeffery Cheah Sch Med & Hlth Sci, Subang Jaya, Malaysia	Universiti Malaya; Airlangga University; Kementerian Kesihatan Malaysia; Monash University; Monash University Sunway	Zainal, H (corresponding author), Univ Malaya, Dept Social & Prevent Med, Fac Med, Kuala Lumpur, Malaysia.	hadzrizainal@gmail.com	Dahlui, Maznah/F-9665-2010; Dahlui, Maznah/B-8976-2010	Dahlui, Maznah/0000-0003-4923-9410; Su, Tin Tin/0000-0003-0387-6406				Akman I, 2002, TURK J MED SCI, V32, P159; [Anonymous], 2012, R J PRELIMINARY REPO; [Anonymous], 2017, MAL NAT NEON REG REP; Behrman RE, 2007, PRETERM BIRTH CAUSES; Blencowe H, 2012, LANCET, V379, P2162, DOI 10.1016/S0140-6736(12)60820-4; Cheah Irene Guat Sim, 2005, J Perinatol, V25, P47; Comert S, 2012, IRAN J PEDIATR, V22, P185; DeRienzo C, 2016, J PERINATOL, V36, P1128, DOI 10.1038/jp.2016.128; Elsmen E, 2004, ACTA PAEDIATR, V93, P529, DOI 10.1080/08035250410024998; Evans J, 2018, CAN J ANESTH, V65, P627, DOI 10.1007/s12630-018-1087-1; Foundation. MoD, BAB BOYS HIGH RISK D; Geitona Mary, 2007, Cost Eff Resour Alloc, V5, P9, DOI 10.1186/1478-7547-5-9; Gilbert WM, 2003, OBSTET GYNECOL, V102, P488, DOI 10.1016/S0029-7844(03)00617-3; Hodek JM, 2011, HEALTH ECON REV, V1, DOI 10.1186/2191-1991-1-6; Ingemarsson I, 2003, BJOG-INT J OBSTET GY, V110, P34, DOI 10.1016/S1470-0328(03)00022-3; Kent AL, 2012, PEDIATRICS, V129, P124, DOI 10.1542/peds.2011-1578; Kerlin MP, 2015, ANN AM THORAC SOC, V12, P1743, DOI 10.1513/AnnalsATS.201510-660ED; Kirkby Sharon, 2007, Adv Neonatal Care, V7, P80; Mangham LJ, 2009, PEDIATRICS, V123, pE312, DOI 10.1542/peds.2008-1827; Moran JL, 2004, ANAESTH INTENS CARE, V32, P787, DOI 10.1177/0310057X0403200610; Narang A, 2005, INDIAN PEDIATR, V42, P989; NEWNS B, 1984, ARCH DIS CHILD, V59, P1064, DOI 10.1136/adc.59.11.1064; Petrou S, 2003, PEDIATRICS, V112, P1290, DOI 10.1542/peds.112.6.1290; Petrou S, 2003, BJOG-INT J OBSTET GY, V110, P17, DOI 10.1016/S1470-0328(03)00013-2; Richardson D K, 2001, J Perinatol, V21, P121, DOI 10.1038/sj.jp.7200501; Roberts RR, 1999, JAMA-J AM MED ASSOC, V281, P644, DOI 10.1001/jama.281.7.644; Russell RB, 2007, PEDIATRICS, V120, pE1, DOI 10.1542/peds.2006-2386; St John EB, 2000, AM J OBSTET GYNECOL, V182, P170, DOI 10.1016/S0002-9378(00)70509-6; Tommiska Viena, 2003, Pediatr Crit Care Med, V4, P157, DOI 10.1097/01.PCC.0000059731.74435.02; Tucker J, 2004, BRIT MED J, V329, P675, DOI 10.1136/bmj.329.7467.675; Zisk JL, 2011, AM J PERINAT, V28, P241, DOI 10.1055/s-0030-1268239	31	15	15	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2019	14	6							e0211997	10.1371/journal.pone.0211997	http://dx.doi.org/10.1371/journal.pone.0211997			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW3BT	31237874	gold, Green Published, Green Submitted			2023-01-03	WOS:000484856000003
J	Martinez-Solanas, E; Basagana, X				Martinez-Solanas, Erica; Basagana, Xavier			Temporal changes in the effects of ambient temperatures on hospital admissions in Spain	PLOS ONE			English	Article							HEAT WAVES; EMERGENCY-DEPARTMENTS; CONTRASTING PATTERNS; GP CONSULTATIONS; PUBLIC-HEALTH; MORTALITY; COLD; IMPACT; MORBIDITY; WEATHER	Background The exposure to extreme ambient temperatures has been reported to increase mortality, although less is known about its impact on morbidity. The analysis of temporal changes in temperature-health associations has also focused on mortality with no studies on hospitalizations worldwide. Studies on temporal variations can provide insights on changes in susceptibility or on effectiveness of public health interventions. We aimed to analyse the effects of temperature on cause-specific hospital admissions in Spain and assess temporal changes using two periods, the second one characterized by the introduction of a heat health prevention plan. Methods Daily counts of non-scheduled hospital admissions for cardiovascular, cerebrovascular and respiratory diseases and daily maximum temperature were obtained for each Spanish province for the period 1997-2013. The relationship between temperature and hospitalizations was estimated using distributed lag non-linear models. We compared the risk of hospitalization due to temperatures (cold, heat and extreme heat) in two periods (1997-2002 and 2004-2013). Results Cold temperatures were associated with increased risk of cardiovascular, cerebrovascular and respiratory hospital admissions. Hot temperatures were only associated with higher hospital admissions for respiratory causes while hospitalizations for cardiovascular and cerebrovascular diseases did not increase with heat. There was a small reduction in heat-related respiratory admissions in period 2. Whereas cold-related hospitalizations for cardiovascular and cerebrovascular diseases increased in period 2, a significant reduction for respiratory hospitalizations was reported. Conclusions Our results suggested that heat had an adverse impact on hospital admissions for respiratory diseases, while cold increased the risk of the three studied cause-specific hospitalizations. Public health interventions should also focus on morbidity effects of temperature.	[Martinez-Solanas, Erica; Basagana, Xavier] ISGlobal, Barcelona, Spain; [Martinez-Solanas, Erica; Basagana, Xavier] UPF, Barcelona, Spain; [Martinez-Solanas, Erica; Basagana, Xavier] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain	ISGlobal; Pompeu Fabra University; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP	Basagana, X (corresponding author), ISGlobal, Barcelona, Spain.; Basagana, X (corresponding author), UPF, Barcelona, Spain.; Basagana, X (corresponding author), CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain.	xavier.basagana@isglobal.org	Basagaña, Xavier/C-3901-2017; Stefanadis, Christodoulos/ABH-2232-2020	Basagaña, Xavier/0000-0002-8457-1489; Stefanadis, Christodoulos/0000-0001-5974-6454	Instituto de Salud Carlos III - European Union [PI14/00421]	Instituto de Salud Carlos III - European Union	XB was supported by a grant awarded by the Instituto de Salud Carlos III and co-funded by European Union (Project "PI14/00421"). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Achebak H, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002617; Alessandrini E, 2011, ENVIRON RES, V111, P1192, DOI 10.1016/j.envres.2011.07.005; [Anonymous], 2019, ENVIRON RES, V169, P102, DOI [10.1016/j.envres.2018.11.006, DOI 10.1016/J.ENVRES.2018.11.006]; [Anonymous], 2015, LANCET, DOI DOI 10.1016/S0140-6736(15)60854-6; Bai L, 2016, SCI REP-UK, V6, DOI 10.1038/srep30283; Basu R, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-40; Benmarhnia T, REV ARTICLE VULNERAB; Benmarhnia T, 2016, ENVIRON HEALTH PERSP, V124, P1694, DOI 10.1289/EHP203; Bernal JL, 2017, INT J EPIDEMIOL, V46, P348, DOI 10.1093/ije/dyw098; Bhaskaran K, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3823; Boeckmann M, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1112; Bunker A, 2016, EBIOMEDICINE, V6, P258, DOI 10.1016/j.ebiom.2016.02.034; Carmona R, 2016, ENVIRON INT, V88, P103, DOI 10.1016/j.envint.2015.12.027; Davis RE, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15071436; de' Donato FK, 2015, INT J ENV RES PUB HE, V12, P15567, DOI 10.3390/ijerph121215006; Diaz J, 2015, TEMPERATURAS UMBRALE, VII; Ebi KL, 2004, INT J BIOMETEOROL, V49, P48, DOI 10.1007/s00484-004-0207-5; Gasparrini A, 2015, LANCET, V386, P369, DOI 10.1016/S0140-6736(14)62114-0; Gasparrini A, 2015, ENVIRON HEALTH PERSP, V123, P1200, DOI 10.1289/ehp.1409070; Gasparrini A, 2014, STAT MED, V33, P881, DOI 10.1002/sim.5963; Gasparrini A, 2011, EPIDEMIOLOGY, V22, P68, DOI 10.1097/EDE.0b013e3181fdcd99; Guo YM, 2017, ENVIRON HEALTH PERSP, V125, DOI 10.1289/EHP1026; Hajat S, 2004, EUR J EPIDEMIOL, V19, P959, DOI 10.1007/s10654-004-5731-4; Hajat S, 2002, INT J EPIDEMIOL, V31, P825, DOI 10.1093/ije/31.4.825; Hess JJ, 2014, ENVIRON HEALTH PERSP, V122, P1209, DOI 10.1289/ehp.1306796; Kenney WL, 2003, J APPL PHYSIOL, V95, P2598, DOI 10.1152/japplphysiol.00202.2003; Kingsley SL, 2016, ENVIRON HEALTH PERSP, V124, P460, DOI 10.1289/ehp.1408826; Kovats RS, 2008, ANNU REV PUBL HEALTH, V29, P41, DOI 10.1146/annurev.publhealth.29.020907.090843; Kovats RS, 2004, OCCUP ENVIRON MED, V61, P893, DOI 10.1136/oem.2003.012047; Lam HCY, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002612; Lavigne E, 2014, ENVIRON HEALTH-GLOB, V13, DOI 10.1186/1476-069X-13-5; Lee S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094070; Liang WM, 2008, INT J BIOMETEOROL, V52, P223, DOI 10.1007/s00484-007-0116-5; Lin S, 2009, EPIDEMIOLOGY, V20, P738, DOI 10.1097/EDE.0b013e3181ad5522; Linares C, 2008, EUR J PUBLIC HEALTH, V18, P317, DOI 10.1093/eurpub/ckm108; Marinacci C, 2009, EPIDEMIOL PREV, V33, P96; Marmot Review Team, 2011, HLTH IMPACTS COLD HO; Martinez-Solanas E, 2018, ENVIRON HEALTH PERSP, V126, DOI 10.1289/EHP2590; Mastrangelo G, 2006, MED HYPOTHESES, V66, P1025, DOI 10.1016/j.mehy.2005.09.053; Matthies F., 2008, HEAT HLTH ACTION PLA; Michelozzi P, 2009, AM J RESP CRIT CARE, V179, P383, DOI 10.1164/rccm.200802-217OC; Ministerio de Sanidad Consumo y Bienestar Social, 2004, PLAN NAC AC PREV EF; Ministerio de Sanidad Servicios Sociales e Igualdad. Informe sobre la hospitalizacion, 2014, INF HOSP 2014 REG AT; Misailidou M, 2006, EUR J CARDIOV PREV R, V13, P846, DOI 10.1097/01.hjr.0000221857.04168.06; Phung D, 2016, SCI TOTAL ENVIRON, V550, P1084, DOI 10.1016/j.scitotenv.2016.01.154; Ponjoan A, 2017, ENVIRON HEALTH-GLOB, V16, DOI 10.1186/s12940-017-0238-0; Reid CE, 2012, ENVIRON HEALTH PERSP, V120, P1627, DOI 10.1289/ehp.1205251; Robine JM, 2008, CR BIOL, V331, P171, DOI 10.1016/j.crvi.2007.12.001; Schifano P, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-58; Son JY, 2014, INT J BIOMETEOROL, V58, P1893, DOI 10.1007/s00484-014-0791-y; Song X, SCI TOTAL ENV; Song XP, 2018, SCI TOTAL ENVIRON, V615, P1499, DOI 10.1016/j.scitotenv.2017.09.108; Tobias A, 2014, ENVIRON HEALTH-GLOB, V13, DOI 10.1186/1476-069X-13-48; Tobias A, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-133; Toloo G, 2013, INT J PUBLIC HEALTH, V58, P667, DOI 10.1007/s00038-013-0465-2; Turner LR, 2012, EPIDEMIOLOGY, V23, P594, DOI 10.1097/EDE.0b013e3182572795; Vicedo-Cabrera AM, 2018, ENVIRON INT, V111, P239, DOI 10.1016/j.envint.2017.11.006; Vida S, 2012, PSYCHIAT SERV, V63, P1150, DOI 10.1176/appi.ps.201100485; Wichmann J, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-19; Wichmann J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022904; Ye XF, 2012, ENVIRON HEALTH PERSP, V120, P19, DOI [10.1289/ehp.1003198, 10.1289/ehp.120-a19]; Zhang AR, 2019, ENVIRON RES, V169, P196, DOI 10.1016/j.envres.2018.10.034	62	14	14	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2019	14	6							e0218262	10.1371/journal.pone.0218262	http://dx.doi.org/10.1371/journal.pone.0218262			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IC8NN	31194811	Green Published, gold, Green Submitted			2023-01-03	WOS:000471238300077
J	Partl, R; Lehner, J; Winkler, P; Kapp, KS				Partl, Richard; Lehner, Joerg; Winkler, Peter; Kapp, Karin Sigrid			Testing the feasibility of augmented digital skin imaging to objectively compare the efficacy of topical treatments for radiodermatitis	PLOS ONE			English	Article							DERMATITIS	Introduction Radiation-induced dermatitis (RID) is routinely graded by visual inspection. Inter-observer variability makes this approach inadequate for an objective assessment of the efficacy of different topical treatments. In this study we report on the first clinical application of a new image-analysis tool developed to measure the relevant effects quantitatively and to compare the effects of two different topical preparations used to treat RID. Materials and methods After completion of radiotherapy, RID was retrospectively assessed in 100 white female breast cancer patients who had received adjuvant breast irradiation. Of these patients, 34 were treated with R1&R2, a Lactokine-fluid derived from milk proteins, and 66 were treated with Bepanthen. In addition RID was graded independently by two experienced radiation oncologists in accordance with the Common Terminology Criteria for Adverse Events (CTCAE). For quantitative evaluation, the irradiated breast and the non-irradiated contralateral breast were photographed in a standardized manner including a color reference card. For analysis, all images were converted into the color space L*a*b* and mean values were calculated for each of the color parameters. Results The CTCAE-based grading revealed statistically significant inter-observer variability in the scoring of RID Grades 1, 2 and 3 (p<0.001). A difference between the two topical products could not be observed with visual inspection. By using augmented image analysis methods a statistically significant increase in a*-values (mean 4.15; 95% CI: 5.97-2.33, p<0.001) in patients treated with R1&R2 indicated more intense reddening. Digital subtraction was used to eliminate differences in individual baseline skin tone to generate a new, low-scatter parameter (Delta SEV). Conclusions Visual CTCAE-based evaluation of RID was not suitable for assessing the efficacy of the skin treatment products. In contrast, the novel image analysis enabled a quantitative evaluation independent of skin type and baseline skin tone in our cohort suggesting that augmented image analysis may be a suitable tool for this type of investigation. Prospective studies are needed to validate our findings.	[Partl, Richard; Lehner, Joerg; Winkler, Peter; Kapp, Karin Sigrid] Med Univ Graz, Comprehens Canc Ctr Graz, Dept Therapeut Radiol & Oncol, Graz, Austria	Medical University of Graz	Partl, R (corresponding author), Med Univ Graz, Comprehens Canc Ctr Graz, Dept Therapeut Radiol & Oncol, Graz, Austria.	richard.partl@medunigraz.at	Partl, Richard/AAM-3537-2020	Partl, Richard/0000-0001-9132-012X				[Anonymous], R1 R2 US GUID; [Anonymous], 1928, BRIT J RADIOL, V1, P442; BELISARIO JC, 1952, BRIT J RADIOL, V25, P326, DOI 10.1259/0007-1285-25-294-326; CHARDON A, 1991, INT J COSMETIC SCI, V13, P191, DOI 10.1111/j.1467-2494.1991.tb00561.x; Chin L, 2016, JOVE-J VIS EXP, DOI 10.3791/53573; Chin MS, 2017, CLIN TRANSL RAD ONCO, V4, P15, DOI 10.1016/j.ctro.2017.03.003; Commission Internationale de l'Eclairage, 2004, TECH REP; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; FITZPATRICK TB, 1988, ARCH DERMATOL, V124, P869, DOI 10.1001/archderm.124.6.869; McQuestion Maurene, 2006, Semin Oncol Nurs, V22, P163, DOI 10.1016/j.soncn.2006.04.004; Momm F, 2005, STRAHLENTHER ONKOL, V181, P392, DOI 10.1007/s00066-005-1345-3; Neubauer Andreas, 2016, Patent European Patent, Patent No. [2976013A1, 2976013]; Partl R, 2017, STUD HEALTH TECHNOL, V236, P363, DOI 10.3233/978-1-61499-759-7-363; Schollhammer M, 2019, EUR DERM C MARCH; Takiwaki Hirotsugu, 1998, Journal of Medical Investigation, V44, P121; Tanaka E, 2011, INT J RADIAT ONCOL, V81, P1098, DOI 10.1016/j.ijrobp.2010.07.035; Trattner H., CASE REPORT ANPRECHE; Wiala A, 2018, J INVEST DERMATOL, V138, pS92, DOI 10.1016/j.jid.2018.03.549; Yoshida K, 2010, STRAHLENTHER ONKOL, V186, P621, DOI 10.1007/s00066-010-2134-1	19	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2019	14	6							e0218018	10.1371/journal.pone.0218018	http://dx.doi.org/10.1371/journal.pone.0218018			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IC3IS	31181091	Green Published, Green Submitted, gold			2023-01-03	WOS:000470854200036
J	Schuetz, P; Fehr, R; Baechli, V; Geiser, M; Deiss, M; Gomes, F; Kutz, A; Tribolet, P; Bregenzer, T; Braun, N; Hoess, C; Pavlicek, V; Schmid, S; Bilz, S; Sigrist, S; Brandle, M; Benz, C; Henzen, C; Mattmann, S; Thomann, R; Brand, C; Rutishauser, J; Aujesky, D; Rodondi, N; Donze, J; Stanga, Z; Mueller, B				Schuetz, Philipp; Fehr, Rebecca; Baechli, Valerie; Geiser, Martina; Deiss, Manuela; Gomes, Filomena; Kutz, Alexander; Tribolet, Pascal; Bregenzer, Thomas; Braun, Nina; Hoess, Claus; Pavlicek, Vojtech; Schmid, Sarah; Bilz, Stefan; Sigrist, Sarah; Brandle, Michael; Benz, Carmen; Henzen, Christoph; Mattmann, Silvia; Thomann, Robert; Brand, Claudia; Rutishauser, Jonas; Aujesky, Drahomir; Rodondi, Nicolas; Donze, Jacques; Stanga, Zeno; Mueller, Beat			Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial	LANCET			English	Article							MANAGEMENT; OUTCOMES; MALNUTRITION; ASSOCIATION; GUIDELINES; CARE	Background Guidelines recommend the use of nutritional support during hospital stays for medical patients (patients not critically ill and not undergoing surgical procedures) at risk of malnutrition. However, the supporting evidence for this recommendation is insufficient, and there is growing concern about the possible negative effects of nutritional therapy during acute illness on recovery and clinical outcomes. Our aim was thus to test the hypothesis that protocol-guided individualised nutritional support to reach protein and caloric goals reduces the risk of adverse clinical outcomes in medical inpatients at nutritional risk. Methods The Effect of early nutritional support on Frailty, Functional Outcomes, and Recovery of malnourished medical inpatients Trial (EFFORT) is a pragmatic, investigator-initiated, open-label, multicentre study. We recruited medical patients at nutritional risk (nutritional risk screening 2002 [NRS 2002] score >= 3 points) and with an expected length of hospital stay of more than 4 days from eight Swiss hospitals. These participants were randomly assigned (1: 1) to receive either protocol-guided individualised nutritional support to reach protein and caloric goals (intervention group) or standard hospital food (control group). Randomisation was done with variable block sizes and stratification according to study site and severity of malnutrition using an interactive web-response system. In the intervention group, individualised nutritional support goals were defined by specialist dietitians and nutritional support was initiated no later than 48 h after admission. Patients in the control group received no dietary consultation. The composite primary endpoint was any adverse clinical outcome defined as all-cause mortality, admission to intensive care, non-elective hospital readmission, major complications, and decline in functional status at 30 days, and it was measured in all randomised patients who completed the trial. This trial is registered with ClinicalTrials.gov, number NCT02517476. Findings 5015 patients were screened, and 2088 were recruited and monitored between April 1, 2014, and Feb 28, 2018. 1050 patients were assigned to the intervention group and 1038 to the control group. 60 patients withdrew consent during the course of the trial (35 in the intervention group and 25 in the control group). During the hospital stay, caloric goals were reached in 800 (79%) and protein goals in 770 (76%) of 1015 patients in the intervention group. By 30 days, 232 (23%) patients in the intervention group experienced an adverse clinical outcome, compared with 272 (27%) of 1013 patients in the control group (adjusted odds ratio [OR] 0.79 [95% CI 0.64-0.97], p=0.023). By day 30, 73 [7%] patients had died in the intervention group compared with 100 [10%] patients in the control group (adjusted OR 0.65 [0.47-0.91], p=0.011). There was no difference in the proportion of patients who experienced side-effects from nutritional support between the intervention and the control group (162 [16%] vs 145 [14%], adjusted OR 1.16 [0.90-1.51], p=0.26). Interpretation In medical inpatients at nutritional risk, the use of individualised nutritional support during the hospital stay improved important clinical outcomes, including survival, compared with standard hospital food. These findings strongly support the concept of systematically screening medical inpatients on hospital admission regarding nutritional risk, independent of their medical condition, followed by a nutritional assessment and introduction of individualised nutritional support in patients at risk. Copyright (C) 2019 Elsevier Ltd. All rights reserved.	[Schuetz, Philipp; Fehr, Rebecca; Baechli, Valerie; Geiser, Martina; Deiss, Manuela; Gomes, Filomena; Kutz, Alexander; Mueller, Beat] Kantonsspital Aarau, Med Univ Dept, Div Gen Internal & Emergency Med, Aarau, Switzerland; [Tribolet, Pascal; Bregenzer, Thomas] Spital Lachen, Internal Med, Lachen, Switzerland; [Braun, Nina; Hoess, Claus; Pavlicek, Vojtech; Schmid, Sarah] Kantonsspital Munsterlingen, Internal Med, Munsterlingen, Switzerland; [Bilz, Stefan; Sigrist, Sarah; Brandle, Michael; Benz, Carmen] Kantonsspital St Gallen, Internal Med & Endocrinol, St Gallen, Switzerland; [Henzen, Christoph; Mattmann, Silvia] Kantonsspital Luzern, Internal Med, Luzern, Switzerland; [Thomann, Robert; Brand, Claudia] Burgerspital, Internal Med, Solothurn, Switzerland; [Rutishauser, Jonas] Kantonsspital Baselland, Internal Med, Standort Bruderholz, Switzerland; [Aujesky, Drahomir; Rodondi, Nicolas; Donze, Jacques] Univ Bern, Univ Hosp Bern, Inselspital, Dept Gen Internal Med, Bern, Switzerland; [Stanga, Zeno] Univ Bern, Univ Hosp Bern, Inselspital, Div Diabetol Endocrinol Nutr Med & Metab, Bern, Switzerland; [Schuetz, Philipp; Mueller, Beat] Univ Basel, Fac Med, Basel, Switzerland; [Rodondi, Nicolas] Univ Bern, Inst Primary Hlth Care BIHAM, Bern, Switzerland; [Donze, Jacques] Brigham & Womens Hosp, Div Gen Internal Med, 75 Francis St, Boston, MA 02115 USA; [Gomes, Filomena] New York Acad Sci, New York, NY USA; [Tribolet, Pascal] Bern Univ Appl Sci, Dept Hlth Profess, Bern, Switzerland	Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen; Lucerne Cantonal Hospital; Kantonsspital Baselland; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; University of Basel; University of Geneva; University of Bern; Harvard University; Brigham & Women's Hospital	Schuetz, P (corresponding author), Kantonsspital Aarau, Univ Dept Med, Tellstr, CH-5001 Aarau, Switzerland.	philipp.schuetz@unibas.ch	schuetz, philipp/C-8475-2013; Mueller, Beat/G-2662-2012; Stanga, Zeno/AAM-2244-2020	schuetz, philipp/0000-0001-6400-4949; Kaegi-Braun, Nina/0000-0003-4015-295X; Rodondi, Nicolas/0000-0001-9083-6896; Gomes, Filomena/0000-0003-1702-1433	Swiss National Science Foundation (SNSF) [PP00P3_150531, PP00P3_176972]; Research Council of the Kantonsspital Aarau, Switzerland [1410.000.058, 1410.000.044]	Swiss National Science Foundation (SNSF)(Swiss National Science Foundation (SNSF)); Research Council of the Kantonsspital Aarau, Switzerland	We thank all patients and hospital staff for support of our trial. The Swiss National Science Foundation (SNSF professorship, PP00P3_150531 and and PP00P3_176972) and the Research Council of the Kantonsspital Aarau, Switzerland (1410.000.058 and 1410.000.044) provided funding for the trial. We are grateful to Jeffrey Greenwald (Massachusetts General Hospital, Boston, MA, USA), Ulrich Keller (EndoNet Praxis, Basel, Switzerland), Peter E Ballmer (Kantonsspital Winterthur, Winterthur, Switzerland), Jeannie Wurz (Inselspital, Bern, Switzerland), and C Elizabeth Weekes (Guy's and St Thomas' National Health Service Foundation Trust, London, UK) for helpful scientific discussions.	Bally MR, 2016, JAMA INTERN MED, V176, P43, DOI 10.1001/jamainternmed.2015.6587; Baumann- Holzle R, 2006, SCHWEIZERISCHE ARZTE, V87, P33; Bounoure L, 2016, NUTRITION, V32, P790, DOI 10.1016/j.nut.2016.01.019; BROQVIST M, 1994, EUR HEART J, V15, P1641, DOI 10.1093/oxfordjournals.eurheartj.a060447; Casaer MP, 2014, NEW ENGL J MED, V370, P1227, DOI 10.1056/NEJMra1304623; Casaer MP, 2011, NEW ENGL J MED, V365, P506, DOI 10.1056/NEJMoa1102662; Deutz NE, 2016, CLIN NUTR, V35, P18, DOI 10.1016/j.clnu.2015.12.010; Feinberg J, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011598.pub2; Felder S, 2016, ANN NUTR METAB, V68, P164, DOI 10.1159/000444096; Felder S, 2015, NUTRITION, V31, P1385, DOI 10.1016/j.nut.2015.06.007; Friedli N, 2018, NUTRITION, V47, P13, DOI 10.1016/j.nut.2017.09.007; Genton L, 2011, INT J VITAM NUTR RES, V81, P143, DOI 10.1024/0300-9831/a000058; Gomes F, 2018, CLIN NUTR, V37, P336, DOI 10.1016/j.clnu.2017.06.025; Imoberdorf R, 2010, CLIN NUTR, V29, P38, DOI 10.1016/j.clnu.2009.06.005; Kalantar-Zadeh K, 2017, NEW ENGL J MED, V377, P1765, DOI [10.1056/NEJMra1700312, 10.1056/nejmra1700312]; Khalatbari-Soltani S, 2015, CLIN NUTR ESPEN, V10, pE89, DOI 10.1016/j.clnesp.2015.04.003; Kondrup J, 2003, CLIN NUTR, V22, P415, DOI 10.1016/S0261-5614(03)00098-0; Kondrup J, 2002, CLIN NUTR, V21, P461, DOI 10.1054/clnu.2002.0585; MacDonald A, 2003, NUTRITION, V19, P233, DOI 10.1016/S0899-9007(02)01033-X; MAHONEY F I, 1965, Md State Med J, V14, P61; Milne Anne C, 2009, Cochrane Database Syst Rev, pCD003288, DOI 10.1002/14651858.CD003288.pub3; Mueller C, 2011, JPEN-PARENTER ENTER, V35, P16, DOI 10.1177/0148607110389335; Potter JM, 2001, JPEN-PARENTER ENTER, V25, P323, DOI 10.1177/0148607101025006323; Russell RC, 2014, CELL RES, V24, P42, DOI 10.1038/cr.2013.166; Schetz M, 2013, CRIT CARE, V17, DOI 10.1186/cc11828; Schuetz P, 2018, INT J CLIN TRIALS, V5, P142, DOI [10.18203/2349-3259.ijct201, 10.18203/2349-3259.ijct20182085]; Schuetz P, 2015, SWISS MED WEEKLY, V145, DOI DOI 10.4414/SMW.2015.14132; Schuetz P, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0812-x; Schuetz P, 2014, SWISS MED WKLY, V144, DOI 10.4414/smw.2014.13957; Schuetz P, 2013, BMC EMERG MED, V13, DOI 10.1186/1471-227X-13-12; Somanchi M, 2011, JPEN-PARENTER ENTER, V35, P209, DOI 10.1177/0148607110392234; Starke J, 2011, CLIN NUTR, V30, P194, DOI 10.1016/j.clnu.2010.07.021	32	281	303	9	47	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 8	2019	393	10188					2312	2321		10.1016/S0140-6736(18)32776-4	http://dx.doi.org/10.1016/S0140-6736(18)32776-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IB4SX	31030981				2023-01-03	WOS:000470263400028
J	Callahan, RL; Brunie, A; Mackenzie, ACL; Wayack-Pambe, M; Guiella, G; Kibira, SPS; Makumbi, F				Callahan, Rebecca L.; Brunie, Aurelie; Mackenzie, Amelia C. L.; Wayack-Pambe, Madeleine; Guiella, Georges; Kibira, Simon P. S.; Makumbi, Fredrick			Potential user interest in new long-acting contraceptives: Results from a mixed methods study in Burkina Faso and Uganda	PLOS ONE			English	Article							ACCEPTABILITY; PREVENTION; HIV	Method-related concerns represent an important cause of contraceptive non-use and discontinuation. User preferences must be incorporated into the design of new contraceptive technologies to ensure product success and improve family planning outcomes. We assessed preferences among potential users in Burkina Faso and Uganda for six contraceptive methods currently under development or ready for introduction: a new copper intra-uterine device (IUD), a levonorgestrel intra-uterine system, a new single-rod implant, a biodegradable implant, a longer-acting injectable, and a method of non-surgical permanent contraception. Questions were added to nationally-representative PMA2020 household surveys that asked 2,743 and 2,403 women in Burkina Faso and Uganda, respectively, their interest in using each new method. We assessed factors associated with interest through multivariable logistic regression models. We conducted qualitative interviews and focus groups with 398 women, 78 men, and 52 family planning providers and key informants to explore perceived advantages and disadvantages of the methods. Respondents expressed interest in using all new methods, with greatest interest in the longer-acting injectable (77% in Burkina Faso, 61% in Uganda), followed by a new single-rod implant. Least interest was expressed in a new copper IUD (26% Burkina Faso, 15% in Uganda). In both countries, women with less education had higher odds of interest in a longer-acting injectable. Interest in most new methods was associated with desiring a method lasting longer than one year and acceptance of lack of menstrual bleeding as a contraceptive side effect. Perceived advantages and disadvantages were similar between countries, including concerns about menstrual side effects and fear of the biodegradable nature of the biodegradable implant. Potential users, their partners, and providers are interested in new longer-acting methods, however, familiar forms including the injectable and implant may be the most immediately acceptable. A biodegradable implant will require clear counseling messages to allay potential fears.	[Callahan, Rebecca L.; Mackenzie, Amelia C. L.] Contracept Technol Innovat, Durham, NC 27701 USA; [Brunie, Aurelie] Hlth Serv Res, Washington, DC USA; [Wayack-Pambe, Madeleine; Guiella, Georges] Univ Ouagadougou, Inst Super Sci Populat, Ouagadougou, Burkina Faso; [Kibira, Simon P. S.; Makumbi, Fredrick] Makerere Univ, Coll Hlth Sci, Sch Publ Hlth, Kampala, Uganda	Makerere University	Callahan, RL (corresponding author), Contracept Technol Innovat, Durham, NC 27701 USA.	rcallahan@fhi360.org		Mackenzie, Amelia/0000-0003-1721-805X; Kibira, Simon Peter Sebina/0000-0002-7385-423X; Brunie, Aurelie/0000-0002-9515-1420	Bill & Melinda Gates Foundation [OPP1055878]	Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation)	This research was funded by the Bill & Melinda Gates Foundation through grant #OPP1055878. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2018, POPULATION COUNCIL F; Bailey MJ, 2013, BROOKINGS PAP ECO AC, P341; Bill and Melinda Gates Foundation, FAM PLANN STRAT OV; Brauner-Otto SR, 2013, POPUL RES POLICY REV, V32, P1, DOI 10.1007/s11113-012-9261-6; Brunie A, DEV ACCEPTABLE CONTR; Casterline J, 2009, UNWANTED FERTILITY L; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P241; Darroch JE, 2011, NEW YORK GUTTMACHER, V201, P1; FHI 360, CONTR TECHN INN IN; Frost JJ, 2007, PERSPECT SEX REPRO H, V39, P90, DOI 10.1363/3909007; Guthrie KM, 2018, PHARM DEV TECHNOL, V23, P311, DOI 10.1080/10837450.2017.1339085; Heise L, 1997, ACCEPTABILITY USERS, P6; Moran M, 2014, REPROD HLTH R D DEV; Nass SJ, 2004, NAT REV DRUG DISCOV, V3, P885, DOI 10.1038/nrd1526; Performance Monitoring and Accountability 2020, SAMPL OV; Performance Monitoring and Accountability 2020, SURVEY METHODOLOGY; Performance Monitoring and Accountability 2020, UG ROUND 4 FAM PLANN; Performance Monitoring and Accountability 2020, BURK FAS ROUND 4 FAM; Polis CB, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0561-0; Ross J, 2013, GLOB HEALTH-SCI PRAC, V1, P203, DOI 10.9745/GHSP-D-13-00010; Sedgh G., 2016, UNMET NEED CONTRACEP; Singh S, 2015, ADD COSTS BEN INV SE; Starbird E, 2016, GLOB HEALTH-SCI PRAC, V4, P191, DOI 10.9745/GHSP-D-15-00374; Tolley EE, 2013, ANTIVIR RES, V100, pS54, DOI 10.1016/j.antiviral.2013.09.029; Van Lith LM, 2013, GLOB HEALTH-SCI PRAC, V1, P97, DOI 10.9745/GHSP-D-12-00036; Woodsong C, 2015, ADV DRUG DELIVER REV, V92, P146, DOI 10.1016/j.addr.2015.02.004	26	13	13	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2019	14	5							e0217333	10.1371/journal.pone.0217333	http://dx.doi.org/10.1371/journal.pone.0217333			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IA0CM	31136612	gold, Green Submitted, Green Published			2023-01-03	WOS:000469224300027
J	Chen, PM; Kwong, PWH; Lai, CKY; Ng, SSM				Chen, Pei-ming; Kwong, Patrick W. H.; Lai, Claudia K. Y.; Ng, Shamay S. M.			Comparison of bilateral and unilateral upper limb training in people with stroke: A systematic review and meta-analysis	PLOS ONE			English	Review							INDUCED MOVEMENT THERAPY; CONSTRAINT-INDUCED THERAPY; MOTOR FUNCTION-TEST; TRANSCRANIAL MAGNETIC STIMULATION; UPPER EXTREMITY FUNCTION; RESEARCH ARM TEST; POST-STROKE; INTERHEMISPHERIC FACILITATION; CORTEX ACTIVATION; RANDOMIZED-TRIAL	Background and objectives Bilateral upper limb training (BULT) and unilateral upper limb training (UULT) are two effective strategies for the recovery of upper limb motor function after stroke. This meta-analysis aimed to compare the improvements in motor impairment and functional performances of people with stroke after BULT and UULT. Research design and methods This systematic review and meta-analysis identified 21 randomized controlled trials (RCTs) met the eligibility criteria from CINAHL, Medline, Embase, Cochrane Library and PubMed. The outcome measures were the Fugl-Meyer Assessment of Upper Extremity (FMA-UE), Wolf Motor Function Test (WMFT), Action Research Arm Test (ARAT) and Box and Block Test (BBT), which are validated measures of upper limb function. Results Twenty-one studies involving 842 subjects with stroke were included. Compared with UULT, BULT yielded a significantly greater mean difference (MD) in the FMA-UE (MD = 2.21, 95% Confidence Interval (CI), 0.12 to 4.30, p = 0.04; l(2) = 86%, p<0.001). However, a comparison of BULT and UULT yielded insignificant mean difference (MD) in terms of the time required to complete the WMFT (MD = 0.44; 95%CI, -2.22 to 3.10, p = 0.75; l(2) = 55%, p = 0.06) and standard mean difference (SMD) in terms of the functional ability scores on the WMFT, ARAT and BBT (SMD = 0.25; 95%CI, -0.02 to 0.52, p = 0.07; l(2) = 54%, p = 0.02). Discussion and implications Compared to UULT, BULT yielded superior improvements in the improving motor impairment of people with stroke, as measured by the FMA-UE. However, these strategies did not yield significant differences in terms of the functional performance of people with stroke, as measured by the WMFT, ARAT and BBT. More comparative studies of the effects of BULT and UULT are needed to increase the reliability of these conclusions.	[Chen, Pei-ming; Kwong, Patrick W. H.; Ng, Shamay S. M.] Hong Kong Polytech Univ, Dept Rehabil Sci, Hong Kong, Peoples R China; [Lai, Claudia K. Y.] Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Peoples R China	Hong Kong Polytechnic University; Hong Kong Polytechnic University	Ng, SSM (corresponding author), Hong Kong Polytech Univ, Dept Rehabil Sci, Hong Kong, Peoples R China.	Shamay.Ng@polyu.edu.hk	Kwong, Patrick W.H./AAY-2084-2020; Kwong, Wai Hang/AAZ-5331-2020; NG, Sheung Mei Shamay/E-2731-2016	Kwong, Patrick W.H./0000-0002-1834-5715; Kwong, Wai Hang/0000-0002-1834-5715; Lai, Claudia KY/0000-0001-8503-5429; NG, Sheung Mei Shamay/0000-0003-1660-0548	Health and Medical Research Fund [12131821]; Food and Health Bureau, Hong Kong SAR Government	Health and Medical Research Fund; Food and Health Bureau, Hong Kong SAR Government	This study was supported by Health and Medical Research Fund 12131821 from the Food and Health Bureau, Hong Kong SAR Government, to Dr. Shamay Ng and her team.	Arya KN, 2012, TOP STROKE REHABIL, V19, P193, DOI 10.1310/tsr1903-193; Benjamin EJ, 2017, CIRCULATION, V135, pE146, DOI 10.1161/CIR.0000000000000485; Blanton S, 1999, PHYS THER, V79, P847, DOI 10.1093/ptj/79.9.847; Boddington LJ, 2017, BRAIN STIMUL, V10, P214, DOI 10.1016/j.brs.2017.01.006; Bohannon RW, 2007, J REHABIL MED, V39, P14, DOI 10.2340/16501977-0018; BONITA R, 1988, STROKE, V19, P1497, DOI 10.1161/01.STR.19.12.1497; Brogardh C, 2006, CONSTRAINT INDUCED M; Brunner IC, 2012, CLIN REHABIL, V26, P1078, DOI 10.1177/0269215512443138; Buchner DM, 1996, AGE AGEING, V25, P386, DOI 10.1093/ageing/25.5.386; Calautti C, 2003, STROKE, V34, P1553, DOI 10.1161/01.STR.0000071761.36075.A6; Carson RG, 2005, BRAIN RES REV, V49, P641, DOI 10.1016/j.brainresrev.2005.03.005; Carson RG, 2004, J PHYSIOL-LONDON, V560, P929, DOI 10.1113/jphysiol.2004.069088; Carson RG, 1999, HUM MOVEMENT SCI, V18, P307, DOI 10.1016/S0167-9457(99)00013-5; Cattaert D, 1999, BIOL CYBERN, V81, P343, DOI 10.1007/s004220050567; Cauraugh JH, 2008, CEREBROVASC DIS, V25, P115, DOI 10.1159/000112321; Cauraugh JH, 2010, HUM MOVEMENT SCI, V29, P853, DOI 10.1016/j.humov.2009.09.004; Cauraugh JH, 2005, PROG NEUROBIOL, V75, P309, DOI 10.1016/j.pneurobio.2005.04.001; Chang JJ, 2007, ARCH PHYS MED REHAB, V88, P1332, DOI 10.1016/j.apmr.2007.07.016; Chang YC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133192; Coupar F, 2010, COCHRANE DATABASE SY, V4; Desrosiers J, 2005, CLIN REHABIL, V19, P581, DOI 10.1191/0269215505cr896oa; Edwards DF, 2012, ARCH PHYS MED REHAB, V93, P660, DOI 10.1016/j.apmr.2011.10.005; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; FERBERT A, 1992, J NEUROL NEUROSUR PS, V55, P294, DOI 10.1136/jnnp.55.4.294; Green S, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005319; Grefkes C, 2014, NEUROSCIENTIST, V20, P56, DOI 10.1177/1073858413491147; Grotta JC, 2004, STROKE, V35, P2699, DOI 10.1161/01.STR.0000143320.64953.c4; Hallett M, 2001, BRAIN RES REV, V36, P169, DOI 10.1016/S0165-0173(01)00092-3; Hammer AM, 2009, PHYS THER, V89, P526, DOI 10.2522/ptj.20080017; Han Kyoung Ju, 2016, J Phys Ther Sci, V28, P2299, DOI 10.1589/jpts.28.2299; Hanajima R, 2001, J PHYSIOL-LONDON, V531, P849, DOI 10.1111/j.1469-7793.2001.0849h.x; Harris JE, 2007, PHYS THER, V87, P88, DOI 10.2522/ptj.20060065; Hesse S, 2005, STROKE, V36, P1960, DOI 10.1161/01.STR.0000177865.37334.ce; Hodics TM, 2012, ARCH PHYS MED REHAB, V93, P1963, DOI 10.1016/j.apmr.2012.05.002; Hsieh YW, 2017, CLIN REHABIL, V31, P225, DOI 10.1177/0269215516633275; Hubbard IJ, 2015, NEUROREHAB NEURAL RE, V29, P703, DOI 10.1177/1545968314562647; Ingram JN, 2008, EXP BRAIN RES, V188, P223, DOI 10.1007/s00221-008-1355-3; Kim H., 2013, T NEURAL SYSTEMS REH, V21, P153; Kwakkel G, 2003, STROKE, V34, P2181, DOI 10.1161/01.STR.0000087172.16305.CD; Kwakkel G, 2016, NEUROREHAB NEURAL RE, V30, P804, DOI 10.1177/1545968315624784; Latimer CP, 2010, DISABIL REHABIL, V32, P1221, DOI 10.3109/09638280903483877; Lee MJ, 2017, J STROKE CEREBROVASC, V26, P1020, DOI 10.1016/j.jstrokecerebrovasdis.2016.12.008; Lee Y, 2017, NEUROREHABILITATION, V40, P301, DOI 10.3233/NRE-161418; Liao WW, 2012, CLIN REHABIL, V26, P111, DOI 10.1177/0269215511416383; Lin KC, 2007, CLIN REHABIL, V21, P1075, DOI 10.1177/0269215507079843; Lin KC, 2010, NEUROREHAB NEURAL RE, V24, P42, DOI 10.1177/1545968309345268; Lin KC, 2009, NEUROREHAB NEURAL RE, V23, P441, DOI 10.1177/1545968308328719; Lin LF, 2018, J GEN INTERN MED, V33, P1260, DOI 10.1007/s11606-018-4425-7; Luft AR, 2004, JAMA-J AM MED ASSOC, V292, P1853, DOI 10.1001/jama.292.15.1853; Lum PS, 2006, J REHABIL RES DEV, V43, P631, DOI 10.1682/JRRD.2005.02.0044; MATHIOWETZ V, 1985, AM J OCCUP THER, V39, P386, DOI 10.5014/ajot.39.6.386; Meng GL, 2018, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00726; Miltner WHR, 1999, STROKE, V30, P586, DOI 10.1161/01.STR.30.3.586; Morris JH, 2008, ARCH PHYS MED REHAB, V89, P1237, DOI 10.1016/j.apmr.2007.11.039; Murase N, 2004, ANN NEUROL, V55, P400, DOI 10.1002/ana.10848; Netz J, 1997, BRAIN, V120, P1579, DOI 10.1093/brain/120.9.1579; Page SJ, 2002, CLIN REHABIL, V16, P55, DOI 10.1191/0269215502cr473oa; Page SJ, 2008, PHYS THER, V88, P333, DOI 10.2522/ptj.20060029; Platz T, 2005, CLIN REHABIL, V19, P404, DOI 10.1191/0269215505cr832oa; Richards LG, 2008, NEUROREHAB NEURAL RE, V22, P180, DOI 10.1177/1545968307305355; Salter K, 2005, DISABIL REHABIL, V27, P507, DOI 10.1080/0963828040008552; Santisteban L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154792; Shahine EM, 2014, EGYPT RHEUMATOL REHA, V41, P8, DOI [10.4103/1110-161X.128128, DOI 10.4103/1110-161X.128128]; Singer BJ, 2013, RESTOR NEUROL NEUROS, V31, P681, DOI 10.3233/RNN-130319; Stewart KC, 2006, J NEUROL SCI, V244, P89, DOI 10.1016/j.jns.2006.01.005; Stinear CM, 2008, BRAIN, V131, P1381, DOI 10.1093/brain/awn051; Stinear JW, 2004, J CLIN NEUROPHYSIOL, V21, P124, DOI 10.1097/00004691-200403000-00008; Stoykov ME, 2009, NEUROREHAB NEURAL RE, V23, P945, DOI 10.1177/1545968309338190; Summers JJ, 2007, J NEUROL SCI, V252, P76, DOI 10.1016/j.jns.2006.10.011; Suputtitada Areerat, 2004, Journal of the Medical Association of Thailand, V87, P1482; Swinnen S.P., 2012, NEUROBEHAVIORAL DETE; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; Taub E, 1999, J REHABIL RES DEV, V36, P237; Thielman GT, 2004, ARCH PHYS MED REHAB, V85, P1613, DOI 10.1016/j.apmr.2004.01.028; Turton A, 1996, ELECTROMYOGR MOTOR C, V101, P316, DOI 10.1016/0924-980X(96)95560-5; UGAWA Y, 1993, NEUROSCI LETT, V160, P153, DOI 10.1016/0304-3940(93)90401-6; van Delden AEQ, 2012, J REHABIL MED, V44, P106, DOI 10.2340/16501977-0928; van Delden AEQ, 2013, STROKE, V44, P2613, DOI 10.1161/STROKEAHA.113.001969; Van der Lee JH, 2001, ARCH PHYS MED REHAB, V82, P14, DOI 10.1053/apmr.2001.18668; van der Lee JH, 1999, STROKE, V30, P2369, DOI 10.1161/01.STR.30.11.2369; Waller SM, 2008, HUM MOVEMENT SCI, V27, P749, DOI 10.1016/j.humov.2008.03.006; Whitall J, 2000, STROKE, V31, P2390, DOI 10.1161/01.STR.31.10.2390; Whitall J, 2011, NEUROREHAB NEURAL RE, V25, P118, DOI 10.1177/1545968310380685; Wolf SL, 2001, STROKE, V32, P1635, DOI 10.1161/01.STR.32.7.1635; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; Wu CY, 2007, NEUROREHAB NEURAL RE, V21, P460, DOI 10.1177/1545968307303411; Wu CY, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-35; Wu CY, 2011, NEUROREHAB NEURAL RE, V25, P130, DOI 10.1177/1545968310380686; Yang CL, 2012, AM J OCCUP THER, V66, P198, DOI 10.5014/ajot.2012.003103; Ziemann U, 2001, CLIN NEUROPHYSIOL, V112, P107, DOI 10.1016/S1388-2457(00)00502-2	91	26	28	2	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2019	14	5							e0216357	10.1371/journal.pone.0216357	http://dx.doi.org/10.1371/journal.pone.0216357			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HZ3VE	31120910	Green Published, Green Submitted, gold			2023-01-03	WOS:000468775700014
J	Xu, HY; Zou, XD				Xu, Hongyi; Zou, Xiaodong			Absolute structure, at the nanoscale	SCIENCE			English	Editorial Material							ELECTRON-DIFFRACTION DATA; DATA-COLLECTION		[Xu, Hongyi; Zou, Xiaodong] Stockholm Univ, Dept Mat & Environm Chem, SE-10691 Stockholm, Sweden	Stockholm University	Zou, XD (corresponding author), Stockholm Univ, Dept Mat & Environm Chem, SE-10691 Stockholm, Sweden.	xzou@mmk.su.se		Xu, Hongyi/0000-0002-8271-3906	Swedish Research Council (VR) [2017-04321, 2017-05333]	Swedish Research Council (VR)(Swedish Research Council)	The authors acknowledge the financial support from the Swedish Research Council (VR, nos. 2017-04321to X.Z. and 2017-05333 to H.X.).	Brazda P, 2019, SCIENCE, V364, P667, DOI 10.1126/science.aaw2560; Flack HD, 2008, CHIRALITY, V20, P681, DOI 10.1002/chir.20473; Gemmi M, 2015, J APPL CRYSTALLOGR, V48, P718, DOI 10.1107/S1600576715004604; Gruene T, 2018, ANGEW CHEM INT EDIT, V57, P16313, DOI 10.1002/anie.201811318; Jones CG, 2018, ACS CENTRAL SCI, V4, P1587, DOI 10.1021/acscentsci.8b00760; Kolb U, 2007, ULTRAMICROSCOPY, V107, P507, DOI 10.1016/j.ultramic.2006.10.007; Nannenga BL, 2016, CURR OPIN STRUC BIOL, V40, P128, DOI 10.1016/j.sbi.2016.09.007; Nannenga BL, 2014, NAT METHODS, V11, P927, DOI [10.1038/NMETH.3043, 10.1038/nmeth.3043]; Nederlof I, 2013, ACTA CRYSTALLOGR D, V69, P1223, DOI 10.1107/S0907444913009700; Wang YC, 2018, J APPL CRYSTALLOGR, V51, P1094, DOI 10.1107/S1600576718007604; Yun YF, 2015, IUCRJ, V2, P267, DOI 10.1107/S2052252514028188; Zhang D., 2010, J APPL CRYSTALLOGR, V46, P1863	12	5	5	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 17	2019	364	6441					632	633		10.1126/science.aax5385	http://dx.doi.org/10.1126/science.aax5385			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HZ0SB	31097652				2023-01-03	WOS:000468551000012
J	Liu, CN; Chen, S; Chen, H; Yue, L; Ling, LQ; Chen, CW; Du, L; Zhou, J				Liu, Chao-Nan; Chen, Si; Chen, Hao; Yue, Li; Ling, Li-Qin; Chen, Chang-Wei; Du, Lei; Zhou, Jing			Peak urea level, leukocyte count and use of invasive ventilation as risk factors of mortality in acute pancreatitis: A retrospective study	PLOS ONE			English	Article							PREDICTION; NITROGEN	Background Acute pancreatitis (AP) is associated with high complications. Early, reliable prediction of mortality may improve patient management. Methods We retrospectively reviewed medical records of 1,599 patients with AP treated at a single large hospital in southwest China. Models to predict mortality were derived from a subset of 1,062 patients (development dataset), and the models were then validated in the remaining 537 patients (validation dataset). Independent risk factors and prediction models for mortality were identified using logistic regression. Results A total of 33 patients in the development dataset and 13 in the validation dataset died during hospitalization. Independent risk factors for mortality were found to be plasma urea levels, glucose levels and platelet counts at admission; as well as peak urea levels, leukocyte counts and use of invasive ventilation during hospitalization. Based on the development dataset, a mortality prediction model based only on urea level at admission gave an area under the curve (AUC) of 0.81, which did not significantly improve by incorporating glucose level or platelet count at admission. Significantly better was a model taking into account three in-hospital parameters: peak urea level, leukocyte count and use of invasive ventilation (AUC 0.97). Conclusions While mortality of AP patients can be predicted reasonably well based only on urea values at admission, predictions are more reliable when they take into account in-hospital data on peak urea level, leukocyte count and use of invasive ventilation.	[Liu, Chao-Nan; Chen, Si; Chen, Hao; Ling, Li-Qin; Zhou, Jing] Sichuan Univ, West China Hosp, Dept Lab Med, Chengdu, Sichuan, Peoples R China; [Yue, Li] Workpl Safety & Insurance Board, Toronto, ON, Canada; [Chen, Chang-Wei; Du, Lei] Sichuan Univ, West China Hosp, Dept Anesthesiol, Chengdu, Sichuan, Peoples R China; [Chen, Chang-Wei; Du, Lei] Sichuan Univ, West China Hosp, Translat Neurosci Ctr, Chengdu, Sichuan, Peoples R China	Sichuan University; Sichuan University; Sichuan University	Zhou, J (corresponding author), Sichuan Univ, West China Hosp, Dept Lab Med, Chengdu, Sichuan, Peoples R China.	zhoujinghuaxi@163.com		Chen, Si/0000-0003-3415-0974	National Natural Science Foundation of China [81371878, 81570374]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (81371878 and 81570374) awarded to Zhou Jing.	Banks PA, 2013, GUT, V62, P102, DOI 10.1136/gutjnl-2012-302779; Beckingham IJ, 2001, BRIT MED J, V322, P595, DOI 10.1136/bmj.322.7286.595; Harrison DA, 2007, CRIT CARE MED, V35, P1703, DOI 10.1097/01.CCM.0000269031.13283.C8; Johnson CD, 2005, GUT, V54, P1, DOI 10.1136/gut.200A.057026; Karakayali FY, 2014, WORLD J GASTROENTERO, V20, P13412, DOI 10.3748/wjg.v20.i37.13412; Rahimi RS, 2013, J INVEST MED, V61, P695, DOI 10.2310/JIM.0b013e318289e254; Spitzer AL, 2006, ANN SURG, V243, P380, DOI 10.1097/01.sla.0000202213.22389.36; Sundararajan K, 2017, EMERG MED AUSTRALAS, V29, P184, DOI 10.1111/1742-6723.12737; WILSON C, 1990, BRIT J SURG, V77, P1260, DOI 10.1002/bjs.1800771120; Wright SE, 2009, INTENS CARE MED, V35, P1974, DOI 10.1007/s00134-009-1616-z; Wu BU, 2011, ARCH INTERN MED, V171, P669, DOI 10.1001/archinternmed.2011.126; Wu BU, 2009, GASTROENTEROLOGY, V137, P129, DOI 10.1053/j.gastro.2009.03.056; 2008, GUT, V57, P1698, DOI DOI 10.1136/GUT.2008.152702	13	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2019	14	5							e0216562	10.1371/journal.pone.0216562	http://dx.doi.org/10.1371/journal.pone.0216562			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX7AR	31075129	gold, Green Published, Green Submitted			2023-01-03	WOS:000467556300030
J	Wiangkham, T; Duda, J; Haque, MS; Price, J; Rushton, A				Wiangkham, Taweewat; Duda, Joan; Haque, M. Sayeed; Price, Jonathan; Rushton, Alison			A cluster randomised, double-blind pilot and feasibility trial of an active behavioural physiotherapy intervention for acute whiplash-associated disorder (WAD)II	PLOS ONE			English	Article							FEAR-AVOIDANCE BELIEFS; NECK-DISABILITY-INDEX; QUALITY-OF-LIFE; CERVICAL RANGE; PSYCHOLOGICAL-FACTORS; VISUAL ANALOG; SAMPLE-SIZE; PAIN; HEALTH; SCALE	Whiplash-associated disorder (WAD) causes substantial social and economic burden, with >= 70% patients classified as WADII (neck complaint and musculoskeletal sign(s)). Effective management in the acute stage is required to prevent development of chronicity; an issue for 60% of patients. An Active Behavioural Physiotherapy Intervention (ABPI) was developed to address both physical and psychological components of WAD. The ABPI is a novel complex intervention designed through a rigorous sequential multiphase project to prevent transition of acute WAD to chronicity. An external pilot and feasibility cluster randomised double-blind (assessor, participants) parallel two-arm clinical trial was conducted in the UK private sector. The trial compared ABPI versus standard physiotherapy to evaluate trial procedures and feasibility of the ABPI for managing acute WADII in preparation for a future definitive trial. Six private physiotherapy clinics were recruited and cluster randomised using a computer-generated randomisation sequence. Twenty-eight (20 ABPI, 8 standard physiotherapy) participants [median age 38.00 (IQR = 21.50) years] were recruited. Data were analysed descriptively with a priori establishment of success criteria. Ninety-five percent of participants in the ABPI arm fully recovered (Neck Disability Index <= 4, compared to 17% in the standard physiotherapy arm); required fewer treatment sessions; and demonstrated greater improvement in all outcome measures (pain intensity, Cervical Range of Motion, Pressure Pain Threshold, EuroQol-5 Dimensions) except for the Impact of Events Scale and Fear Avoidance Beliefs Questionnaire. The findings support the potential value of the ABPI, and that an adequately powered definitive trial to evaluate effectiveness (clinical, cost) is feasible with minor modifications to procedures.	[Wiangkham, Taweewat; Rushton, Alison] Univ Birmingham, Ctr Precis Rehabil Spinal Pain CPR Spine, Birmingham, W Midlands, England; [Wiangkham, Taweewat; Duda, Joan; Rushton, Alison] Univ Birmingham, Sch Sport Exercise & Rehabil Sci, Birmingham, W Midlands, England; [Wiangkham, Taweewat] Naresuan Univ, Exercise & Rehabil Sci Res Unit, Phitsanulok, Thailand; [Wiangkham, Taweewat] Naresuan Univ, Dept Phys Therapy, Phitsanulok, Thailand; [Haque, M. Sayeed] Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England; [Price, Jonathan] Birmingham Community Healthcare NHS Fdn Trust, Physiotherapy Dept, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham; Naresuan University; Naresuan University; University of Birmingham	Rushton, A (corresponding author), Univ Birmingham, Ctr Precis Rehabil Spinal Pain CPR Spine, Birmingham, W Midlands, England.; Rushton, A (corresponding author), Univ Birmingham, Sch Sport Exercise & Rehabil Sci, Birmingham, W Midlands, England.	a.b.rushton@gham.ac.uk	Duda, Joan/ABA-5207-2020; Rushton, Alison/V-1260-2017; Price, Jonathan/B-5842-2016; Wiangkham, Taweewat/I-9818-2019; Haque, Mohammad S/B-9160-2018	Rushton, Alison/0000-0001-8114-7669; Price, Jonathan/0000-0002-5505-1564; Wiangkham, Taweewat/0000-0003-4115-704X; Haque, (Mohammad) Sayeed/0000-0002-2467-8575	Royal Thai Government; National Institute for Health Research [ICA-PCAF-2018-01-117] Funding Source: researchfish	Royal Thai Government; National Institute for Health Research(National Institute for Health Research (NIHR))	The lead author (TW) would like to thank the Royal Thai Government for the scholarship to support the trial research costs. This funding had no role in any process of this trial and publication.	Arain M, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-67; Ask T, 2009, CLIN REHABIL, V23, P812, DOI 10.1177/0269215509335639; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Bijur PE, 2003, ACAD EMERG MED, V10, P390, DOI 10.1111/j.1553-2712.2003.tb01355.x; Bijur PE, 2001, ACAD EMERG MED, V8, P1153, DOI 10.1111/j.1553-2712.2001.tb01132.x; Blincoe Lawrence, 2015, EC SOC IMPACT MOTOR; Borsbo B, 2008, J REHABIL MED, V40, P562, DOI 10.2340/16501977-0207; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Buitenhuis J, 2009, SPINE, V34, P262, DOI 10.1097/BRS.0b013e3181913d07; Buitenhuis J, 2006, J PSYCHOSOM RES, V61, P681, DOI 10.1016/j.jpsychores.2006.07.008; Buitenhuis J, 2011, SPINE, V36, pS238, DOI 10.1097/BRS.0b013e3182388400; Campbell MK, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5661; Carreon LY, 2010, SPINE J, V10, P469, DOI 10.1016/j.spinee.2010.02.007; Carroll LJ, 2008, SPINE, V33, pS214, DOI 10.1097/BRS.0b013e318164462c; Carstensen TBW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130298; Chappuis G, 2008, EUR SPINE J, V17, P1350, DOI 10.1007/s00586-008-0732-8; Childs JD, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-32; Cleland JA, 2008, AM J PHYS MED REHAB, V87, P109, DOI 10.1097/PHM.0b013e31815b61f1; Coffey CS, 2003, STAT MED, V22, P2469, DOI 10.1002/sim.1466; Cote P, 2007, ARTHRIT RHEUM-ARTHR, V57, P861, DOI 10.1002/art.22775; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Crawford JR, 2004, INJURY, V35, P891, DOI 10.1016/j.injury.2004.01.011; Dall'Alba PT, 2001, SPINE, V26, P2090, DOI 10.1097/00007632-200110010-00009; Edwards SJL, 1999, BMJ-BRIT MED J, V318, P1407, DOI 10.1136/bmj.318.7195.1407; Eldridge SM, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5239; Ellman L, 2013, COST MOTOR INSURANCE; Elvik M. R., 2007, SOCIAL EC CONSEQUENC; Financial Services Commission of Ontario, 2014, FIN SERV SUBM SUP SU; GOULD AL, 1995, STAT MED, V14, P1039, DOI 10.1002/sim.4780140922; Haywood KL, 2005, QUAL LIFE RES, V14, P1651, DOI 10.1007/s11136-005-1743-0; Hemming K, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-102; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Hole D E, 1995, Man Ther, V1, P36, DOI 10.1054/math.1995.0248; Holm LW, 2008, SPINE, V33, pS52, DOI 10.1097/BRS.0b013e3181643ece; Hyde Dan, 2013, TELEGRAPH; Jagnoor J, 2014, MOTOR ACCIDENTS AUTH; Jennum P, 2013, SPINE, V38, P449, DOI 10.1097/BRS.0b013e3182819203; Jull G., 2016, WHIPLASH CONTINUES I, P22134; Jull G, 2013, PAIN, V154, P1798, DOI 10.1016/j.pain.2013.05.041; Jull GA, 2011, SPINE, V36, pS173, DOI 10.1097/BRS.0b013e31823883e6; Kardouni JR, 2015, MANUAL THER, V20, P540, DOI 10.1016/j.math.2014.12.003; Katz J, 1999, SURG CLIN N AM, V79, P231, DOI 10.1016/S0039-6109(05)70381-9; Lamb SE, 2013, LANCET, V381, P546, DOI 10.1016/S0140-6736(12)61304-X; Lamb SE, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471-2474-8-7; Leth-Petersen S, 2009, J HEALTH ECON, V28, P996, DOI 10.1016/j.jhealeco.2009.06.013; Luo N, 2013, QUAL LIFE RES, V22, P2237, DOI 10.1007/s11136-012-0342-0; MacDermid JC, 2009, J ORTHOP SPORT PHYS, V39, P400, DOI 10.2519/jospt.2009.2930; Malmstrom EM, 2003, SPINE, V28, pE433, DOI 10.1097/01.BRS.0000090840.45802.D4; McPhail S, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-48; Merrick Daniel, 2010, BMC Res Notes, V3, P190, DOI 10.1186/1756-0500-3-190; Michaleff ZA, 2014, LANCET, V384, P133, DOI 10.1016/S0140-6736(14)60457-8; Mooney H., INSURANCE CO ARE REE; Moore A, 2005, CLIN GUIDELINES PHYS; Pietrobon B, 2002, SPINE, V27, P515, DOI 10.1097/00007632-200203010-00012; Price DD, 2008, PAIN, V140, P158, DOI 10.1016/j.pain.2008.07.028; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Richter M, 2004, J NEUROL NEUROSUR PS, V75, P758, DOI 10.1136/jnnp.2003.026963; Rosenfeld M, 2000, SPINE, V25, P1782, DOI 10.1097/00007632-200007150-00008; Rosenfeld M, 2003, SPINE, V28, P2491, DOI 10.1097/01.BRS.0000090822.96814.13; Rushton A, 2014, MANUAL THER, V19, P222, DOI 10.1016/j.math.2013.11.005; Siebers AG, 2009, JAMA-J AM MED ASSOC, V302, P1757, DOI 10.1001/jama.2009.1569; Spitzer WO, 1995, SPINE S8, V20, P1, DOI DOI 10.1097/00007632-199504151-00001; Sterling M, 2004, SPINE, V29, P182, DOI 10.1097/01.BRS.0000105535.12598.AE; Sterling M, 2004, MANUAL THER, V9, P60, DOI 10.1016/j.math.2004.01.006; Sterling M, 2015, PAIN, V156, P635, DOI 10.1097/01.j.pain.0000460359.40116.c1; Sterling M, 2014, J PHYSIOTHER, V60, P5, DOI 10.1016/j.jphys.2013.12.004; Sterling M, 2006, PAIN, V122, P102, DOI 10.1016/j.pain.2006.01.014; Stone AM, 2013, MANUAL THER, V18, P111, DOI 10.1016/j.math.2012.07.009; Stovner LJ, 1996, SPINE, V21, P2735, DOI 10.1097/00007632-199612010-00006; Sundin EC, 2002, BRIT J PSYCHIAT, V180, P205, DOI 10.1192/bjp.180.3.205; Teerenstra S, 2012, STAT MED, V31, P2169, DOI 10.1002/sim.5352; Thabane L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-1; Tough EA, 2010, MANUAL THER, V15, P529, DOI 10.1016/j.math.2010.05.010; TRACsa, 2008, CLIN GUID BEST PRACT; Vanderweeen L., 1996, Man Ther, V1, P258, DOI 10.1054/math.1996.0276; Vernon H, 2008, J MANIP PHYSIOL THER, V31, P491, DOI 10.1016/j.jmpt.2008.08.006; Vernon H, 2011, J MANIP PHYSIOL THER, V34, P506, DOI 10.1016/j.jmpt.2011.08.011; Walton DM, 2014, PHYS THER, V94, P827, DOI 10.2522/ptj.20130369; Walton DM, 2013, J ORTHOP SPORT PHYS, V43, P31, DOI 10.2519/jospt.2013.4507; Whitehead AL, 2014, CONTEMP CLIN TRIALS, V38, P130, DOI 10.1016/j.cct.2014.04.001; Wiangkham T, 2017, DEV EVALUATION NOVEL; Wiangkham T, 2015, PHYSIOTHERAPY, V101, pe1623, DOI [10.1016/j.physio.2015.03.1642, DOI 10.1016/J.PHYSIO.2015.03.1642, DOI 10.1016/J]; Wiangkham T, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011764; Wiangkham T, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011336; Wiangkham T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133415; Williams MA, 2012, EUR SPINE J, V21, P872, DOI 10.1007/s00586-011-2096-8; Williams MA, 2010, J MANIP PHYSIOL THER, V33, P138, DOI 10.1016/j.jmpt.2009.12.009; Woods MP, 2008, PAIN, V136, P271, DOI 10.1016/j.pain.2007.06.037; Wyatt JC, 1998, BMJ-BRIT MED J, V317, P1041; 2009, DISABIL REHABIL, V31, P1605, DOI DOI 10.1080/09638280903110079; 1991, J MANIPULATIVE PHYSL, V14, P409; 2010, J PHYS ACT HLTH, V7, P402; 2005, PAIN, V114, P408, DOI DOI 10.1016/J.PAIN.2005.01.006; 1979, PSYCHOSOM MED, V41, P209; 1981, AM J EPIDEMIOL, V114, P906; 2012, PAIN, V153, P113, DOI DOI 10.1016/J.PAIN.2011.09.023; 2005, PAIN, V114, P141, DOI DOI 10.1016/J.PAIN.2004.12.005; 2006, J PSYCHOSOM RES, V60, P387, DOI DOI 10.1016/J.JPSYCHORES.2005.08.016; 2011, CLIN J PAIN, V27, P502, DOI DOI 10.1097/AJP.0B013E31820D97B0; 2001, NEUROLOGY, V56, P1637; 2005, ANAESTH INTENSIVE CA, V33, P54, DOI DOI 10.1177/0310057X0503300108; 2004, J EVAL CLIN PRACT, V10, P307; 2012, J ORTHOP SPORT PHYS, V42, P634, DOI DOI 10.2519/JOSPT.2012.4117; 2010, PHYSIOTHER CAN, V62, P172, DOI DOI 10.3138/PHYSIO.62.3.172; 2003, PAIN, V104, P509, DOI DOI 10.1016/S0304-3959(03)00078-2; 2009, J STRENGTH COND RES, V23, P312, DOI DOI 10.1519/JSC.0B013E31818F051C; 1982, J CONSULT CLIN PSYCH, V50, P407; 2011, J ORTHOP SPORT PHYS, V41, P644, DOI DOI 10.1016/J.MATH.2014.12.003; 2008, RES NURS HLTH, V31, P180, DOI DOI 10.1002/NUR.20247; 2015, PHYSIOTHERAPY, V101, P34, DOI DOI 10.1016/J.PHYSIO.2014.04.004	110	7	7	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2019	14	5							e0215803	10.1371/journal.pone.0215803	http://dx.doi.org/10.1371/journal.pone.0215803			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HX6ZE	31071100	Green Published, Green Submitted, gold			2023-01-03	WOS:000467552100018
J	Phuong, JM; Penm, J; Chaar, B; Oldfield, LD; Moles, R				Phuong, Jonathan Minh; Penm, Jonathan; Chaar, Betty; Oldfield, Lachlan Daniel; Moles, Rebekah			The impacts of medication shortages on patient outcomes: A scoping review	PLOS ONE			English	Review							ONCOLOGY DRUG SHORTAGES; NATIONAL-SURVEY; CARE; DAUNORUBICIN; EXPERIENCES; STRATEGIES; MANAGEMENT; INDUCTION; AUSTRALIA; PROPOFOL	Background In recent years, medication shortages have become a growing worldwide issue. This scoping review aimed to systematically synthesise the literature to report on the economic, clinical, and humanistic impacts of medication shortages on patient outcomes. Methods Medline, Embase, Global Health, PsycINFO and International Pharmaceutical Abstracts were searched using the two key concepts of medicine shortage and patient outcomes. Articles were limited to the English language, human studies and there were no limits to the year of publication. Manuscripts included contained information regarding the shortage of a scheduled medication and had gathered data regarding the economic, clinical, and/or humanistic outcomes of drug shortages on human patients. Findings We found that drug shortages were predominantly reported to have adverse economic, clinical and humanistic outcomes to patients. Patients were more commonly reported to have increased out of pocket costs, rates of drug errors, adverse events, mortality, and complaints during times of shortage. There were also reports of equivalent and improved patient outcomes in some cases. Conclusions The results of this review provide valuable insights into the impact drug shortages have on patient outcomes. The majority of studies reported medication shortages resulted in negative patient clinical, economic and humanistic outcomes.	[Phuong, Jonathan Minh; Penm, Jonathan; Chaar, Betty; Oldfield, Lachlan Daniel; Moles, Rebekah] Univ Sydney, Sydney Pharm Sch, Fac Med & Hlth, Sydney, NSW, Australia	University of Sydney	Phuong, JM (corresponding author), Univ Sydney, Sydney Pharm Sch, Fac Med & Hlth, Sydney, NSW, Australia.	jphu0360@uni.sydney.edu.au	Oldfield, Lachlan/GPS-7785-2022; Penm, Jonathan/I-1555-2019	Penm, Jonathan/0000-0001-9606-7135; Phuong, Jonathan/0000-0002-0290-8229				AlRuthia YS, 2017, ANN SAUDI MED, V37, P375, DOI 10.5144/0256-4947.2017.375; [Anonymous], 2016, WHO Drug Information, V30, P180; Baumer AM, 2004, AM J HEALTH-SYST PH, V61, P2015, DOI 10.1093/ajhp/61.19.2015; Becker DJ, 2013, J ONCOL PRACT, V9, pE122, DOI 10.1200/JOP.2012.000799; Berger JL, 2014, ONCOTARGETS THER, V7, P1409, DOI 10.2147/OTT.S62881; Blaine KP, 2016, J CLIN ANESTH, V35, P516, DOI 10.1016/j.jclinane.2016.08.037; Caulder Celeste R, 2015, Hosp Pharm, V50, P279, DOI 10.1310/hpj5004-279; Cho S, 2016, ANN PHARMACOTHER, V50, P718, DOI 10.1177/1060028016653138; Dilworth TJ, 2014, J MANAG CARE SPEC PH, V20, P1246, DOI 10.18553/jmcp.2014.20.12.1246; Duan F, 2016, RADIOLOGY, V278, P612, DOI 10.1148/radiol.2015141417; Duong M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143654; Farid, 2016, B FACULTY PHARM, V54, P191, DOI DOI 10.1016/J.BFOPCU.2016.05.004; Fox ER, 2003, AM J HEALTH-SYST PH, V60, P245, DOI 10.1093/ajhp/60.3.245; Goldblatt J, 2011, BLOOD CELL MOL DIS, V46, P107, DOI 10.1016/j.bcmd.2010.05.002; Goldsack JC, 2014, AM J HEALTH-SYST PH, V71, P571, DOI 10.2146/ajhp130569; Gross AE, 2017, CLIN INFECT DIS, V65, P613, DOI 10.1093/cid/cix379; Gundlapalli AV, 2013, DIAGN MICR INFEC DIS, V75, P256, DOI 10.1016/j.diagmicrobio.2012.11.020; Hall R, 2013, CAN J ANESTH, V60, P539, DOI 10.1007/s12630-013-9920-z; Hayes MS, 2014, AM HEALTH DRUG BENEF, V7, P264; Holcombe B, 2018, NUTR CLIN PRACT, V33, P53, DOI 10.1002/ncp.10052; Kehl KL, 2015, J ONCOL PRACT, V11, pE154, DOI 10.1200/JOP.2014.000380; Ladha KS, 2015, ANESTH ANALG, V121, P404, DOI 10.1213/ANE.0000000000000809; Lukmanji S, 2018, EPILEPSIA, V59, P468, DOI 10.1111/epi.13974; Malone C, 2016, Ulster Med J, V85, P174; McBride A, 2013, AM J HEALTH-SYST PH, V70, P609, DOI 10.2146/ajhp120563; McLaughlin M, 2013, J MANAGE CARE PHARM, V19, P783, DOI 10.18553/jmcp.2013.19.9.783; McLaughlin MM, 2017, INFECT DIS THER, V6, P259, DOI 10.1007/s40121-017-0157-y; McLaughlin MM, 2014, INFECT DIS THER, V3, P349, DOI 10.1007/s40121-014-0040-z; Meloni ST, 2017, AIDS RES THER, V14, DOI 10.1186/s12981-017-0184-5; Mendez MN, 2006, PHARMACOTHERAPY, V26, P61, DOI 10.1592/phco.2006.26.1.61; Mohammed MA, 2016, ANN PHARMACOTHER, V50, P862, DOI 10.1177/1060028016656016; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Mori J, 2012, DRUG INF J, V46, P607, DOI 10.1177/0092861512448569; Nickel RS, 2014, PEDIATR BLOOD CANCER, V61, P810, DOI 10.1002/pbc.24892; Pauwels K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119322; Perumal-Pillay VA, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2385-y; Pirkle CM, 2012, INT J QUAL HEALTH C, V24, P564, DOI 10.1093/intqhc/mzs034; Price B, 2013, AM J EMERG MED, V31, P1124, DOI 10.1016/j.ajem.2013.03.041; Rider Anne Elise, 2013, J Pharm Pract, V26, P183, DOI 10.1177/0897190013482332; Roberts R, 2012, CRIT CARE MED, V40, P406, DOI 10.1097/CCM.0b013e31822f0af5; Romito Bryan, 2015, Hosp Pharm, V50, P798, DOI 10.1310/hpj5009-798; Salazar EG, 2015, PEDIATR BLOOD CANCER, V62, P940, DOI 10.1002/pbc.25445; SALKELD G, 1995, HEALTH POLICY, V31, P111, DOI 10.1016/0168-8510(94)00672-5; Shah S, 2015, OPHTHAL PHYSL OPT, V35, P236, DOI 10.1111/opo.12180; Sollaci LB, 2004, J MED LIBR ASSOC, V92, P364; Souliotis K, 2014, RHEUMATOL INT, V34, P25, DOI 10.1007/s00296-013-2866-1; Tan YX, 2016, INT J CLIN PHARM-NET, V38, P1133, DOI 10.1007/s11096-016-0342-1; Thoma BN, 2014, PHARMACOECONOMICS, V32, P149, DOI 10.1007/s40273-013-0116-8; Trifilio S, 2013, LEUKEMIA RES, V37, P868, DOI 10.1016/j.leukres.2013.04.009; Vail E, 2017, JAMA-J AM MED ASSOC, V317, P1433, DOI 10.1001/jama.2017.2841; Walker J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178429; Yan LD, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2063-0	52	61	61	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 3	2019	14	5							e0215837	10.1371/journal.pone.0215837	http://dx.doi.org/10.1371/journal.pone.0215837			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HW5AX	31050671	Green Published, gold, Green Submitted			2023-01-03	WOS:000466702600009
J	Gupta, R; Verma, R; Pradhan, D; Jain, AK; Umamaheswari, A; Rai, CS				Gupta, Reena; Verma, Rashi; Pradhan, Dibyabhaba; Jain, Arun Kumar; Umamaheswari, Amineni; Rai, Chandra Shekhar			An in silico approach towards identification of novel drug targets in pathogenic species of Leptospira	PLOS ONE			English	Article							LIPOPOLYSACCHARIDE BIOSYNTHESIS; PROTEIN; INTERROGANS; GENE; EPIDEMIOLOGY; PREDICTION; NETWORKS; FEATURES	Leptospirosis is one of the leading zoonotic infections worldwide. As with other infectious diseases, report of antimicrobial resistance to existing therapeutic arsenal poses challenges in the management of disease. Hence, identification of novel drug targets for the pathogen deems essential. Present study used combined approach of comparative and subtractive genomics to identify putative drug targets. Crucial genes of 16 pathogenic Leptospira strains were filtered and subjected to homology search via target identification tool "TiD". Thereafter, comparative analysis was performed for non-homologous, essential genes to accomplish the broad-spectrum drug target. Consequently, 37 essential genes were found to be conserved in at least 10 strains of Leptospira. Further, prioritization of resultant set of genes revealed 18 were hubs in protein-protein interaction network. Sixteen putative targets among the hub genes were conserved in all strains of Leptospira. Out of sixteen, fourteen were enzymes while 8 were novel and 4 were involved in virulence mechanism. In addition, genome scale metabolic network reconstruction and choke point analysis revealed cobA (porphyrin and chlorophyll metabolism) and thiL (thiamine metabolism) as chokepoints in their respective metabolic pathways. The proposed hub genes could act as putative broad-spectrum drug targets for Leptospira species, however, these putative targets should be validated to ensure them as real one prior to utilizing them for target based lead discovery.	[Gupta, Reena; Rai, Chandra Shekhar] Guru Gobind Singh Indraprastha Univ, Univ Sch Informat Commun & Technol, New Delhi, India; [Verma, Rashi; Jain, Arun Kumar] Indian Council Med Res, Natl Inst Pathol, Biomed Informat Ctr, New Delhi, India; [Pradhan, Dibyabhaba] Indian Council Med Res, Computat Genom Ctr, Campus All India Inst Med Sci, New Delhi, India; [Umamaheswari, Amineni] Sri Venkateswara Inst Med Sci, Dept Bioinformat, Tirupati, Andhra Pradesh, India	GGS Indraprastha University; Indian Council of Medical Research (ICMR); ICMR - National Institute of Pathology (IOP); Indian Council of Medical Research (ICMR)	Rai, CS (corresponding author), Guru Gobind Singh Indraprastha Univ, Univ Sch Informat Commun & Technol, New Delhi, India.; Pradhan, D (corresponding author), Indian Council Med Res, Computat Genom Ctr, Campus All India Inst Med Sci, New Delhi, India.	dbpinfo@gmail.com; csrai@ipu.ac.in	Pradhan, Dibyabhaba/AFO-4655-2022; Verma, Rashi/GQA-9121-2022; Umamaheswari, amineni/O-2944-2017	Pradhan, Dibyabhaba/0000-0002-2459-5032; Verma, Rashi/0000-0002-2989-4162; Umamaheswari, amineni/0000-0001-6092-1715				Amineni U, 2010, J Chem Biol, V3, P165, DOI 10.1007/s12154-010-0039-1; Anishetty S, 2005, COMPUT BIOL CHEM, V29, P368, DOI 10.1016/j.compbiolchem.2005.07.001; [Anonymous], 1999, Wkly Epidemiol Rec, V74, P237; Assenov Y, 2008, BIOINFORMATICS, V24, P282, DOI 10.1093/bioinformatics/btm554; Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2; Benkert P, 2011, BIOINFORMATICS, V27, P343, DOI 10.1093/bioinformatics/btq662; Bian J, 2011, J BACTERIOL, V193, P3912, DOI 10.1128/JB.00386-11; Bourhy P, 2014, INT J SYST EVOL MICR, V64, P4061, DOI 10.1099/ijs.0.066597-0; Bulach DM, 2000, J MOL MICROB BIOTECH, V2, P375; Caimi K, 2017, INFECT GENET EVOL, V54, P478, DOI 10.1016/j.meegid.2017.08.013; Chaemchuen S, 2011, VET MICROBIOL, V153, P178, DOI 10.1016/j.vetmic.2011.04.030; Charon NW, 2002, ANNU REV GENET, V36, P47, DOI 10.1146/annurev.genet.36.041602.134359; Cline MS, 2007, NAT PROTOC, V2, P2366, DOI 10.1038/nprot.2007.324; Costa F, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003898; Delano W.L, 2002, DELANO SCI; Fair RJ, 2014, PERSPECT MED CHEM, V6, P25, DOI 10.4137/PMC.S14459; Ferla MP, 2014, MICROBIOL-SGM, V160, P1571, DOI 10.1099/mic.0.077826-0; Fernandes LGV, 2012, INFECT IMMUN, V80, P3679, DOI 10.1128/IAI.00474-12; Fouts DE, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004403; Fu LM, 2012, BIOINFORMATICS, V28, P3150, DOI 10.1093/bioinformatics/bts565; Gamberini M, 2005, FEMS MICROBIOL LETT, V244, P305, DOI 10.1016/j.femsle.2005.02.004; Gupta R, 2017, GENOMICS, V109, P51, DOI 10.1016/j.ygeno.2016.11.005; Haake DA, 2015, CURR TOP MICROBIOL, V387, P65, DOI 10.1007/978-3-662-45059-8_5; Hema K, 2015, BIOCH ANAL BIOCH, V4; Himani D, 2013, J FOODBORNE ZOONOTIC, V1, P6; Izurieta Ricardo, 2008, J Emerg Trauma Shock, V1, P21, DOI 10.4103/0974-2700.40573; Kanehisa M, 2016, NUCLEIC ACIDS RES, V44, pD457, DOI 10.1093/nar/gkv1070; Karp PD, BRIEF BIOINFORM, DOI [10.1093/bib/bbx085/4084231, DOI 10.1093/BIB/BBX085/4084231]; Karp Peter D, 2002, Bioinformatics, V18 Suppl 1, pS225; Krieger E, 2009, PROTEINS, V77, P114, DOI 10.1002/prot.22570; La Scola B, 2006, FEMS MICROBIOL LETT, V263, P142, DOI 10.1111/j.1574-6968.2006.00377.x; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Levett PN, 2001, CLIN MICROBIOL REV, V14, P296, DOI 10.1128/CMR.14.2.296-326.2001; Liao SM, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-253; Moriya Y, 2007, NUCLEIC ACIDS RES, V35, pW182, DOI 10.1093/nar/gkm321; Nascimento ALTO, 2004, J BACTERIOL, V186, P2164, DOI 10.1128/JB.186.7.2164-2172.2004; Pal M., 2017, AIR WATER BORNE DIS, V6, P133, DOI 10.4172/2167-7719.1000133; Pandey M, 2015, INT J COMPUT APPL, V109, P29, DOI DOI 10.5120/19426-0455; Patra KP, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0581-7; Phimda K, 2007, ANTIMICROB AGENTS CH, V51, P3259, DOI 10.1128/AAC.00508-07; Plank R, 2000, MICROBES INFECT, V2, P1265, DOI 10.1016/S1286-4579(00)01280-6; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Ren SX, 2003, NATURE, V422, P888, DOI 10.1038/nature01597; Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316; Saint-Macary ME, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0111108; Rao R. Sambasiva, 2003, Braz J Infect Dis, V7, P178, DOI 10.1590/S1413-86702003000300003; Sethi S, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000579; Sivaprakasam Venkat, 2014, JMM Case Rep, V1, pe000003, DOI 10.1099/jmmcr.0.000003; TAYLOR J., 1931, INDIAN J MED RES, V20, P55, DOI 10.2307/3271745; Taylor PL, 2008, J BIOL CHEM, V283, P2835, DOI 10.1074/jbc.M706163200; Tian W, 2018, NUCLEIC ACIDS RES, V46, pW363, DOI 10.1093/nar/gky473; Victoriano AFB, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-147; Wang ZJ, 2007, MICROB CELL FACT, V6, DOI 10.1186/1475-2859-6-39; Webb B, 2014, METHODS MOL BIOL, V1137, P1, DOI 10.1007/978-1-4939-0366-5_1; Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290; Ye YN, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-769; Yeh W, 2004, GENOME RES, V14, P917, DOI 10.1101/gr.2050304; Yu CS, 2006, PROTEINS, V64, P643, DOI 10.1002/prot.21018; Yu NY, 2010, BIOINFORMATICS, V26, P1608, DOI 10.1093/bioinformatics/btq249	59	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2019	14	8							e0221446	10.1371/journal.pone.0221446	http://dx.doi.org/10.1371/journal.pone.0221446			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5OC	31430340	gold, Green Submitted, Green Published			2023-01-03	WOS:000485026800056
J	Akinleye, DD; McNutt, LA; Lazariu, V; McLaughlin, CC				Akinleye, Dean D.; McNutt, Louise-Anne; Lazariu, Victoria; McLaughlin, Colleen C.			Correlation between hospital finances and quality and safety of patient care	PLOS ONE			English	Article							ACUTE MYOCARDIAL-INFARCTION; PROSPECTIVE PAYMENT SYSTEM; OF-CARE; HEALTH-CARE; RACIAL DISPARITIES; MEDICAID; PERFORMANCE; MORTALITY; OUTCOMES; PAY	Background Hospitals under financial pressure may struggle to maintain quality and patient safety and have worse patient outcomes relative to well-resourced hospitals. Poor predictive validity may explain why previous studies on the association between finances and quality/safety have been equivocal. This manuscript employs principal component analysis to produce robust measures of both financial status and quality/safety of care, to assess our a priori hypothesis: hospital financial performance is associated with the provision of quality care, as measured by quality and safety processes, patient outcomes, and patient centered care. Methods This 2014 cross-sectional study investigated hospital financial condition and hospital quality and safety at acute care hospitals. The hospital financial data from the Centers for Medicare and Medicaid Services (CMS) cost report were used to develop a composite financial performance score using principal component analysis. Hospital quality and patient safety were measured with a composite quality/safety performance score derived from principal component analysis, utilizing a range of established quality and safety indicators including: risk-standardized inpatient mortality, 30-day mortality, 30-day readmissions for select conditions, patient safety indicators from inpatient admissions, process of care chart reviews, CMS value-based purchasing total performance score and patient experience of care surveys. The correlation between the composite financial performance score and the composite quality/safety performance score was calculated using linear regression adjusting for hospital characteristics. Results Among the 108 New York State acute care facilities for which data were available, there is a clear relationship between hospital financial performance and hospital quality/safety performance score (standardized correlation coefficient 0.34, p<0.001). The composite financial performance score is also positively associated with the CMS Value Based Purchasing Total Performance Score (standardized correlation coefficient 0.277, p = 0.002); while it is negatively associated with 30 day readmission for all outcomes (standardized correlation coefficient -0.236, p = 0.013), 30-day readmission for congestive heart failure (standardized correlation coefficient -0.23, p = 0.018), 30 day readmission for pneumonia (standardized correlation coefficient -0.209, p = 0.033), and a decrease in 30-day mortality for acute myocardial infarction (standardized correlation coefficient -0.211, p = 0.027). Used alone, operating margin and total margin are poor predictors of quality and safety outcomes. Conclusions Strong financial performance is associated with improved patient reported experience of care, the strongest component distinguishing quality and safety. These findings suggest that financially stable hospitals are better able to maintain highly reliable systems and provide ongoing resources for quality improvement.	[Akinleye, Dean D.; Lazariu, Victoria] SUNY Albany, Sch Publ Hlth, Albany, NY 12144 USA; [McNutt, Louise-Anne] SUNY Albany, Inst Hlth & Environm, Albany, NY 12222 USA; [McLaughlin, Colleen C.] Albany Coll Pharm & Hlth Sci, Albany, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Albany College of Pharmacy & Health Sciences	Akinleye, DD (corresponding author), SUNY Albany, Sch Publ Hlth, Albany, NY 12144 USA.	dean.akinleye@gmail.com	McLaughlin, Colleen/AAD-8604-2020	McLaughlin, Colleen/0000-0003-4172-8172				Allison JJ, 2000, JAMA-J AM MED ASSOC, V284, P1256, DOI 10.1001/jama.284.10.1256; [Anonymous], 2005, INQUIRY, DOI [10.5034/inquiryjrnl_41.4.401, DOI 10.5034/INQUIRYJRNL_41.4.401]; Baicker K, 2011, NEW ENGL J MED, V365, P683, DOI 10.1056/NEJMp1108222; Banks DA, 1997, HEALTH ECON, V6, P133; Barnato AE, 2005, MED CARE, V43, P308, DOI 10.1097/01.mlr.0000156848.62086.06; Bazzoli GJ, 2008, HEALTH ECON, V17, P977, DOI 10.1002/hec.1311; Bazzoli GJ, 2007, MED CARE RES REV, V64, P148, DOI 10.1177/1077558706298289; BRECHER C, 1985, HEALTH SERV RES, V20, P266; Breiman L, 2017, CLASSIFICATION REGRE, DOI DOI 10.1201/9781315139470; BURSTIN HR, 1993, JAMA-J AM MED ASSOC, V270, P845, DOI 10.1001/jama.270.7.845; Casalino LP, 2007, HEALTH AFFAIR, V26, pW405, DOI 10.1377/hlthaff.26.3.w405; Cefalu MS, 2019, HEALTH SERV RES, V54, P502, DOI 10.1111/1475-6773.13056; Chien AT, 2007, MED CARE RES REV, V64, p283S, DOI 10.1177/1077558707305426; Clement JP, 2007, MED CARE, V45, P131, DOI 10.1097/01.mlr.0000244636.54588.2b; Corrigan JM., 2005, CROSS QUAL CHASM; Davies SM, 2001, REFINEMENT HCUP QUAL; Davies SM, 2001, AHRQ TECHNICAL REV R; Dong GN, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0690-x; Dranove D, 1998, HEALTH SERV RES, V33, P163; DUFFY SQ, 1993, HEALTH AFFAIR, V12, P151, DOI 10.1377/hlthaff.12.2.151; Eddy DM, 2012, HEALTH AFFAIR, V31, P2441, DOI 10.1377/hlthaff.2011.1274; Eddy DM, 2011, ANN INTERN MED, V154, P627, DOI 10.7326/0003-4819-154-9-201105030-00008; Encinosa WE, 2005, INQUIRY-J HEALTH CAR, V42, P60, DOI 10.5034/inquiryjrnl_42.1.60; Epstein AM, 2004, NEW ENGL J MED, V350, P406, DOI 10.1056/NEJMsb035374; FEDER J, 1987, NEW ENGL J MED, V317, P867, DOI 10.1056/NEJM198710013171405; Forum NQ, 2014, DRAFT REP; Freedman D.A., 2009, STAT MODELS THEORY P; Gapenski LC, 2008, HEALTHCARE FINANCE I; Gaskin DJ, 2008, HEALTH AFFAIR, V27, P518, DOI 10.1377/hlthaff.27.2.518; Glasziou PP, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5047; Goldman LE, 2007, MED CARE, V45, P579, DOI 10.1097/MLR.0b013e318041f723; Grabowski DC, 2008, REV ECON STAT, V90, P754, DOI 10.1162/rest.90.4.754; Guthrie B, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6341; HADLEY J, 1989, INQUIRY-J HEALTH CAR, V26, P354; Hasnain-Wynia R, 2007, ARCH INTERN MED, V167, P1233, DOI 10.1001/archinte.167.12.1233; Health NYSDo, 2016, HOSP INP DISCH SPARC; Hibbard JH, 2005, HEALTH AFFAIR, V24, P1150, DOI 10.1377/hlthaff.24.4.1150; Hoehn RS, 2016, JAMA SURG, V151, P120, DOI 10.1001/jamasurg.2015.3209; Indicators AQ, 2002, GUID INP QUAL IND; Jha AK, 2005, NEW ENGL J MED, V353, P265, DOI 10.1056/NEJMsa051249; Jha AK, 2010, ANN INTERN MED, V153, P299, DOI 10.7326/0003-4819-153-5-201009070-00004; Kim TH, 2008, INQUIRY-J HEALTH CAR, V45, P215, DOI 10.5034/inquiryjrnl_45.02.215; Kim TH, 2010, HEALTH CARE MANAG, V29, P52, DOI 10.1097/HCM.0b013e3181cca2c5; Krumholz HM, 2013, JAMA-J AM MED ASSOC, V309, P587, DOI 10.1001/jama.2013.333; Landon BE, 2007, JAMA-J AM MED ASSOC, V298, P1674, DOI 10.1001/jama.298.14.1674; LANGA KM, 1993, NEW ENGL J MED, V329, P1784, DOI 10.1056/NEJM199312093292407; Laschober M, 2007, HEALTH CARE FINANC R, V28, P61; Leatherman S, 2003, HEALTH AFFAIR, V22, P17, DOI 10.1377/hlthaff.22.2.17; Lieberthal RD, 2014, RISK MANAGEMENT INSU, V17, P17; Lindrooth RC, 2007, SOUTH ECON J, V73, P575, DOI 10.2307/20111912; Loubeau Patricia R, 2005, J Health Care Finance, V31, P41; Loxterkamp D, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5539; Ly DP, 2011, J GEN INTERN MED, V26, P1291, DOI 10.1007/s11606-011-1815-5; Marshall MN, 2003, HEALTH AFFAIR, V22, P134, DOI 10.1377/hlthaff.22.3.134; Martsolf GR, 2014, MED CARE, V52, P982, DOI 10.1097/MLR.0000000000000248; MCCUE MJ, 1990, INQUIRY-J HEALTH CAR, V27, P242; MCCUE MJ, 1991, HOSP HEALTH SERV ADM, V36, P223; McGlynn EA, 2014, NEW ENGL J MED, V371, P2150, DOI 10.1056/NEJMp1407883; McShane M, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2540; Mor V, 2011, J AM GERIATR SOC, V59, P3, DOI 10.1111/j.1532-5415.2010.03230.x; Mouch CA, 2014, SURGERY, V155, P826, DOI 10.1016/j.surg.2013.12.006; Mueller SK, 2013, MED CARE, V51, P567, DOI 10.1097/MLR.0b013e3182902151; Nguyen OK, 2016, J HOSP MED, V11, P481, DOI 10.1002/jhm.2570; Pedhazur EJ., 1997, MULTIPLE REGRESSION, V3rd ed; Platt H.D., 2002, J EC FINANCE, V26, P184, DOI [https://doi.org/10.1007/BF02755985, DOI 10.1007/BF02755985]; Popescu I, 2009, CIRC-CARDIOVASC QUAL, V2, P221, DOI 10.1161/CIRCOUTCOMES.108.813790; Roby DH, 2018, SUPPORTING TRANSFORM; Rosenthal GE, 1997, JAMA-J AM MED ASSOC, V278, P485, DOI 10.1001/jama.278.6.485; Rosko MD, 2004, HEALTH CARE MANAGE R, V29, P229, DOI 10.1097/00004010-200407000-00008; Saver BG, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001902; Shen YC, 2003, J HEALTH ECON, V22, P243, DOI 10.1016/S0167-6296(02)00124-8; SHERLOCK DB, 1986, INQUIRY-J HEALTH CAR, V23, P261; Silow-Carroll S., 2007, HOSP QUALITY IMPROVE; Smedley BD, 2003, UNEQUAL TREATMENT CO, DOI [10.17226/12875, DOI 10.17226/12875]; Smith RB, 2012, HEALTH SERV RES, V47, P1621, DOI 10.1111/j.1475-6773.2012.01385.x; Swensen SJ, 2013, J PATIENT SAF, V9, P44, DOI 10.1097/PTS.0b013e3182753e33; TRASKA MR, 1988, HOSPITALS, V62, P38; Vogel W B, 1993, Health Care Manage Rev, V18, P15; Volpp KG, 2005, CIRCULATION, V112, P2268, DOI 10.1161/CIRCULATIONAHA.105.534164; Volpp KGM, 2004, AM J MANAG CARE, V10, P505; Weissman JS, 2013, MED CARE, V51, P389, DOI 10.1097/MLR.0b013e31827fef95; Werner RM, 2008, JAMA-J AM MED ASSOC, V299, P2180, DOI 10.1001/jama.299.18.2180	82	30	30	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2019	14	8							e0219124	10.1371/journal.pone.0219124	http://dx.doi.org/10.1371/journal.pone.0219124			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW5LL	31419227	Green Published, gold, Green Submitted			2023-01-03	WOS:000485019900009
J	de Rassenfosse, G; Jaffe, A; Raiteri, E				de Rassenfosse, Gaetan; Jaffe, Adam; Raiteri, Emilio			The procurement of innovation by the US government	PLOS ONE			English	Article							SCIENCE; IMPACT	The U.S. government invests more than $50 billion per year in R&D procurement but we know little about the outcomes of these investments. We have traced all the patents arising from government funding since the year 2000. About 1.5 percent of all R&D procurement contracts have led to at least one patent for a total of about 13,000 patents. However, contracts connected to patents account for 36 per cent of overall contract value. The gestation lag from the signing date of the contract to the patent filing is on average 33 months and does not depend on the type of R&D performed. Patents that are produced faster also seem to be more valuable. We find strong decreasing returns to contract size. Conditional on generating at least one patent, a 1-percent increase in the size of an R&D contract is associated with 0.12 percent more patents.	[de Rassenfosse, Gaetan; Raiteri, Emilio] Ecole Polytech Fed Lausanne, Coll Management Technol, Chair Innovat & IP Policy, Lausanne, Switzerland; [Jaffe, Adam] MIT, Sloan Sch Management, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Jaffe, Adam] Brandeis Univ, Waltham, MA USA; [Jaffe, Adam] Motu Econ & Publ Policy Res, Wellington, New Zealand; [Jaffe, Adam] Queensland Univ Technol, Brisbane, Qld, Australia; [Raiteri, Emilio] Eindhoven Univ Technol, Sch Innovat Sci, Eindhoven, Netherlands	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Massachusetts Institute of Technology (MIT); Brandeis University; Queensland University of Technology (QUT); Eindhoven University of Technology	de Rassenfosse, G (corresponding author), Ecole Polytech Fed Lausanne, Coll Management Technol, Chair Innovat & IP Policy, Lausanne, Switzerland.	gaetan.derassenfosse@epfl.ch	de Rassenfosse, Gaétan/HJB-1549-2022; Jaffe, Adam/R-8313-2019	de Rassenfosse, Gaétan/0000-0002-7862-0918; Jaffe, Adam/0000-0003-1337-1751; raiteri, emilio/0000-0002-2769-1660	Marie Sklodowska-Curie program [665667]	Marie Sklodowska-Curie program	E.R. was supported by Marie Sklodowska-Curie program for the project "Innovative Public Procurement as Innovation Policy" (Action: H2020-MSCA COFUND-2015, Grant Agreement Number: 665667). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arora A., 2005, ANN EC STAT, V79, P91, DOI [10.2307/20777571, DOI 10.2307/20777571]; Azoulay P, 2015, PUBLIC R D INVESTMEN; de Rassenfosse G, 2018, EUR ECON REV, V101, P625, DOI 10.1016/j.euroecorev.2017.11.005; GEROSKI P. A., 1990, INT REV APPL EC, V4, P182, DOI DOI 10.1080/758523673; Jacob BA, 2011, J PUBLIC ECON, V95, P1168, DOI 10.1016/j.jpubeco.2011.05.005; Jaffe AB, 2017, J ASSOC INF SCI TECH, V68, P1360, DOI 10.1002/asi.23731; Lane J, 2011, SCIENCE, V331, P678, DOI 10.1126/science.1201865; Lane J, 2010, NATURE, V464, P488, DOI 10.1038/464488a; Li D, 2017, SCIENCE, V356, P78, DOI 10.1126/science.aal0010; LICHTENBERG FR, 1988, AM ECON REV, V78, P550; Link AN, 2009, ECON INNOV NEW TECH, V18, P381, DOI 10.1080/10438590802208166; Mowery D. C., 2011, ACCELERATING ENERGY, P159; Raiteri E, 2018, RES POLICY, V47, P936, DOI 10.1016/j.respol.2018.02.017; Sampat BN, 2012, RES POLICY, V41, P1729, DOI 10.1016/j.respol.2012.05.013; Toole AA, 2007, J ECON BEHAV ORGAN, V63, P716, DOI 10.1016/j.jebo.2006.05.011	15	3	3	4	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 12	2019	14	8							e0218927	10.1371/journal.pone.0218927	http://dx.doi.org/10.1371/journal.pone.0218927			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW5GN	31404070	Green Published, Green Submitted, gold			2023-01-03	WOS:000485006800006
J	Ueno, K; Otani, Y; Yanagihara, N; Nakamura, T; Shimizu, K; Yamagoe, S; Miyazaki, Y				Ueno, Keigo; Otani, Yoshiko; Yanagihara, Nao; Nakamura, Takumi; Shimizu, Kiminori; Yamagoe, Satoshi; Miyazaki, Yoshitsugu			Cryptococcus gattii alters immunostimulatory potential in response to the environment	PLOS ONE			English	Article							C-TYPE LECTIN; PULMONARY INFECTION; DECTIN-1; RECOGNITION; NEOFORMANS; RECEPTOR; MATURATION; DEFENSE; GROWTH; YEAST	Cryptococcus gattii is a capsular fungal pathogen, which causes life-threatening cryptococcosis in immunocompetent individuals. This emerging pathogen is less likely to be recognized by innate immunity compared to traditional Cryptococcus neoformans strains. Previous studies indicate that C-type lectin receptors (CLRs), including dectin-1 and dectin-2, play a role in recognizing cryptococcal cells; however, it remains to be elucidated whether the receptors physically associate with C. gattii yeast cell surfaces. Based on the previous findings, we hypothesized that culture conditions influence the expression or exposure of CLR ligands on C. gattii. Therefore, in the present study, we first investigated the culture conditions that induce exposure of CLR ligands on C. gattii yeast cells via the binding assay using recombinant fusion proteins of mouse CLR and IgG Fc, Fc dectin-1 and Fc dectin-2. Common fungal culture media, such as yeast extract peptone dextrose (YPD) broth, Sabouraud broth, and potato dextrose agar, did not induce the exposure of dectin-1 ligands, including beta-1,3-glucan, on both capsular and acapsular C. gattiistrains, in contrast to Fc dectin-1 and Fc dectin-2 bound to C. gattii cells growing in the conventional synthetic dextrose (SD) medium [may also be referred to as a yeast nitrogen base with glucose medium]. The medium also induced the exposure of dectin-1 ligands on C. neoformans, whereas all tested media induced dectin-1 and dectin-2 ligands in a control fungus Candida albicans. Notably, C. gattii did not expose dectin-1 ligands in SD medium supplemented with yeast extract or neutral buffer. In addition, compared to YPD medium-induced C. gattii, SD medium-induced C. gattii more efficiently induced the phosphorylation of Syk, Akt, and Erk1/2 in murine dendritic cells (DCs). Afterwards, the cells were considerably engulfed by DCs and remarkably induced DCs to secrete the inflammatory cytokines. Overall, the findings suggest that C. gattii alters its immunostimulatory potential in response to the environment.	[Ueno, Keigo; Otani, Yoshiko; Yanagihara, Nao; Nakamura, Takumi; Yamagoe, Satoshi; Miyazaki, Yoshitsugu] Natl Inst Infect Dis, Dept Chemotherapy & Mycoses, Shinjuku Ku, Toyama, Tokyo, Japan; [Otani, Yoshiko; Yanagihara, Nao; Nakamura, Takumi; Shimizu, Kiminori] Tokyo Univ Sci, Dept Biol Sci & Technol, Fac Ind Sci & Technol, Katsushika Ku, Tokyo, Japan	National Institute of Infectious Diseases (NIID); Tokyo University of Science	Ueno, K (corresponding author), Natl Inst Infect Dis, Dept Chemotherapy & Mycoses, Shinjuku Ku, Toyama, Tokyo, Japan.	keigo-u@niid.go.jp		Ueno, Keigo/0000-0003-0671-0049; miyazaki, yoshitsugu/0000-0001-8942-0869	Ministry of Education, Culture, Sports, Science, and Technology of Japan [KAKENHI 17K10040, KAKENHI 17K18385]; Takeda Science Foundation; Tomy Digital Biology Co. Ltd; Japan Agency for Medical Research and Development, AMED [JP19fk0108045, JP19fk0108094]	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Tomy Digital Biology Co. Ltd; Japan Agency for Medical Research and Development, AMED(Japan Agency for Medical Research and Development (AMED))	This work was supported by: Ministry of Education, Culture, Sports, Science, and Technology of Japan [KAKENHI 17K18385], Takeda Science Foundation, Tomy Digital Biology Co. Ltd [LEGEND Research Grant Program 2015] to Keigo Ueno; and by Ministry of Education, Culture, Sports, Science, and Technology of Japan [KAKENHI 17K10040], Japan Agency for Medical Research and Development, AMED [JP19fk0108045 and JP19fk0108094] to Yoshitsugu Miyazaki. These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ariizumi K, 2000, J BIOL CHEM, V275, P20157, DOI 10.1074/jbc.M909512199; Ariizumi K, 2000, J BIOL CHEM, V275, P11957, DOI 10.1074/jbc.275.16.11957; Ballou ER, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2016.238; Blanco-Menendez N, 2015, J IMMUNOL, V195, P4466, DOI 10.4049/jimmunol.1402874; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Brown GD, 2018, NAT REV IMMUNOL, V18, P374, DOI 10.1038/s41577-018-0004-8; Campuzano A, 2018, J FUNGI, V4, DOI 10.3390/jof4010033; Cheng PY, 2009, INFECT IMMUN, V77, P4284, DOI 10.1128/IAI.00628-09; Chiba S, 2014, ELIFE, V3, DOI 10.7554/eLife.04177; CROSS CE, 1995, INFECT IMMUN, V63, P2604, DOI 10.1128/IAI.63.7.2604-2611.1995; Deng ZH, 2015, NAT IMMUNOL, V16, P642, DOI 10.1038/ni.3155; Esher SK, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007126; Farkas V, 2009, FEMS YEAST RES, V9, P311, DOI 10.1111/j.1567-1364.2008.00478.x; Frank D, 2018, MBIO, V9, DOI [10.1128/mBio.00782-18, 10.1128/mbio.00782-18]; Gantner BN, 2005, EMBO J, V24, P1277, DOI 10.1038/sj.emboj.7600594; Gilbert NM, 2012, MBIO, V3, DOI 10.1128/mBio.00007-12; Giles SS, 2009, INFECT IMMUN, V77, P3491, DOI 10.1128/IAI.00334-09; Goodridge HS, 2009, J IMMUNOL, V182, P1146, DOI 10.4049/jimmunol.182.2.1146; Graham LM, 2006, J IMMUNOL METHODS, V314, P164, DOI 10.1016/j.jim.2006.05.013; Huston SM, 2016, J IMMUNOL, V196, P1259, DOI 10.4049/jimmunol.1501089; JAMES PG, 1990, CARBOHYD RES, V198, P23, DOI 10.1016/0008-6215(90)84273-W; JOHNSON BF, 1967, J BACTERIOL, V94, P192, DOI 10.1128/JB.94.1.192-195.1967; Leongson K, 2013, INFECT IMMUN, V81, P1100, DOI 10.1128/IAI.01339-12; Lim J, 2018, J IMMUNOL, V200, P3539, DOI 10.4049/jimmunol.1700790; Ma J, 2014, J IMMUNOL, V192, P1356, DOI 10.4049/jimmunol.1302835; Matsuo Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059887; McGreal EP, 2006, GLYCOBIOLOGY, V16, P422, DOI 10.1093/glycob/cwj077; Mukaremera Liliane, 2018, Cell Surf, V1, P15, DOI 10.1016/j.tcsw.2017.12.001; Nakamura K, 2007, MICROBIOL IMMUNOL, V51, P1115, DOI 10.1111/j.1348-0421.2007.tb04007.x; Nakamura Y, 2015, INFECT IMMUN, V83, P671, DOI 10.1128/IAI.02835-14; Nishino K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141796; O'Meara TR, 2014, MOL CELL BIOL, V34, P673, DOI 10.1128/MCB.01359-13; O'Meara TR, 2013, MBIO, V4, DOI 10.1128/mBio.00522-12; Okubo Y, 2013, JPN J INFECT DIS, V66, P216, DOI 10.7883/yoken.66.216; Ostrop J, 2017, J IMMUNOL, V198, P1403, DOI 10.4049/jimmunol.1601665; Patin EC, 2019, SEMIN CELL DEV BIOL, V89, P24, DOI 10.1016/j.semcdb.2018.03.003; Rachini A, 2007, INFECT IMMUN, V75, P5085, DOI 10.1128/IAI.00278-07; Rapaka RR, 2007, J IMMUNOL, V178, P3702, DOI 10.4049/jimmunol.178.6.3702; Springer DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010978; Stanton BC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000860; Strijbis K, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003446; Tarumoto N, 2014, J INFECT DIS, V209, P799, DOI 10.1093/infdis/jit534; Thiagarajan PS, 2013, CARDIOVASC RES, V99, P494, DOI 10.1093/cvr/cvt117; Ueno K, 2019, MED MYCOL, V57, P1046, DOI 10.1093/mmy/myy153; Ueno K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35699-4; Ueno K, 2019, MUCOSAL IMMUNOL, V12, P265, DOI 10.1038/s41385-018-0094-4; Ueno K, 2015, INFECT IMMUN, V83, P1577, DOI 10.1128/IAI.02827-14; Ueno K, 2013, MED MYCOL, V51, P385, DOI 10.3109/13693786.2012.733892; Urai M, 2016, FRONT CELL INFECT MI, V5, DOI 10.3389/fcimb.2015.00101; Walsh NM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173866; Wang HF, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006568; Wright WF, 2011, LABMEDICINE, V42, P679, DOI 10.1309/LM8BW8QNV7NZBROG	52	5	5	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2019	14	8							e0220989	10.1371/journal.pone.0220989	http://dx.doi.org/10.1371/journal.pone.0220989			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5FL	31398236	Green Published, gold, Green Submitted			2023-01-03	WOS:000485004000036
J	Shakibfar, S; Krause, O; Lund-Andersen, C; Strycko, F; Moll, J; Andersen, TO; Petersen, HH; Svendsen, JH; Igel, C				Shakibfar, Saeed; Krause, Oswin; Lund-Andersen, Casper; Strycko, Filip; Moll, Jonas; Andersen, Tariq Osman; Petersen, Helen Hogh; Svendsen, Jesper Hastrup; Igel, Christian			Impact of device programming on the success of the first anti-tachycardia pacing therapy: An anonymized large-scale study	PLOS ONE			English	Article							IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; RAPID VENTRICULAR-TACHYCARDIA; SHOCKS	Background Antitachycardia pacing (ATP) is an effective treatment for ventricular tachycardia (VT). We evaluated the efficacy of different ATP programs based on a large remote monitoring data set from patients with implantable cardioverter-defibrillators (ICDs). Methods A dataset from 18,679 ICD patients was used to evaluate the first delivered ATP treatment. We considered all device programs that were used for at least 50 patients, leaving us with 7 different programs and a total of 32,045 episodes. We used the two-proportions z-test (alpha = 0.01) to compare the probability of success and the probability for acceleration in each group with the corresponding values of the default setting. Results Overall, the first ATP treatment terminated in 78.4%-97.5% of episodes with slow VT and 81.5%-91.1% of episodes with fast VT. The default setting of the ATP programs with the number of sequences S = 3 was applied to treat 30.1% of the slow and 36.6% of the fast episodes. Reducing the maximum number of sequences to S = 2 decreased the success rate for slow VT (P < 0.0001, h = 0.38), while the setting S = 4 resulted in the highest success rate of 97.5% (P < 0.0001, h = 0.27). Conclusion While the default programs performed well, we found that increasing the number of sequences from 3 to 4 was a promising option to improve the overall ATP performance.	[Shakibfar, Saeed; Krause, Oswin; Strycko, Filip; Moll, Jonas; Andersen, Tariq Osman; Igel, Christian] Univ Copenhagen, Dept Comp Sci, Copenhagen, Denmark; [Lund-Andersen, Casper; Petersen, Helen Hogh; Svendsen, Jesper Hastrup] Univ Copenhagen, Rigshosp, Heart Ctr, Dept Cardiol, Copenhagen, Denmark; [Svendsen, Jesper Hastrup] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark	University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Copenhagen	Igel, C (corresponding author), Univ Copenhagen, Dept Comp Sci, Copenhagen, Denmark.	igel@diku.dk	Svendsen, Jesper Hastrup/G-8573-2017; Lund-Andersen, Casper/AAV-9915-2021; Andersen, Tariq Osman/O-6884-2015; Shakibfar, Saeed/M-2613-2016	Svendsen, Jesper Hastrup/0000-0001-8466-8515; Lund-Andersen, Casper/0000-0003-1111-0734; Andersen, Tariq Osman/0000-0002-9342-5520; Shakibfar, Saeed/0000-0001-8399-0318; Krause, Oswin/0000-0002-0990-559X	Innovation Fund Denmark [72-2014-1]	Innovation Fund Denmark	This work was supported by the Innovation Fund Denmark under grant #72-2014-1. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chen TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099418; Cohen J., 1988, STAT POWER ANAL BEHA, V567; Grimm W, 2006, PACE, V29, P759, DOI 10.1111/j.1540-8159.2006.00431.x; Mansour F, 2011, PACE, V34, P506, DOI 10.1111/j.1540-8159.2011.03037.x; Nauffal V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175205; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Shakibfar S, 2019, EUROPACE, V21, P268, DOI 10.1093/europace/euy257; Wathen M, 2007, AM HEART J, V153, DOI 10.1016/j.ahj.2007.01.020; Wathen MS, 2004, CIRCULATION, V110, P2591, DOI 10.1161/01.CIR.0000145610.64014.E4; Wilkoff BL, 2008, J AM COLL CARDIOL, V52, P541, DOI 10.1016/j.jacc.2008.05.011; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019	11	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2019	14	8							e0219533	10.1371/journal.pone.0219533	http://dx.doi.org/10.1371/journal.pone.0219533			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5EW	31393871	Green Published, gold			2023-01-03	WOS:000485002500012
J	Kamali, AM; Saadi, ZK; Yahyavi, SS; Zarifkar, A; Aligholi, H; Nami, M				Kamali, Ali-Mohammad; Saadi, Zahra Kheradmand; Yahyavi, Seyedeh-Saeedeh; Zarifkar, Asadollah; Aligholi, Hadi; Nami, Mohammad			Transcranial direct current stimulation to enhance athletic performance outcome in experienced bodybuilders	PLOS ONE			English	Article							PRIMARY MOTOR CORTEX; ISOMETRIC STRENGTH; BRAIN-STIMULATION; WORKING-MEMORY; MODULATION; EXCITABILITY; ACTIVATION; TASK; TDCS; MECHANISMS	Transcranial direct current stimulation (tDCS) is currently under investigation as a promising technique for enhancement of athletic performance through modulating cortical excitability. Through consecutive randomization, 12 experienced bodybuilders were randomly assigned to two arms receiving either sham or real tDCS over the primary motor cortex (leg area) and left temporal cortex (T3) for 13 minutes in the first session. After 72 hours, both groups received the inverse stimulation. After the brain stimulation, cerebral hemodynamic response (using frontopolar hemoencephalography) was examined upon taking three computer-based cognitive tasks i.e. reasoning, memory and verbal ability using the Cambridge Brain Science-Cognitive Platform. Subsequently, the bodybuilders performed knee extension exercise while performance indicators including one-repetition maximum (1RM), muscular endurance (SEI), heart rate (ECG), motivation (VAS), surface electromyography over quadriceps femoris muscle (sEMG) and perceived exertion (RPE) were evaluated. The real tDCS vs. sham group showed decreased RPE and HR mean scores by 14.2% and 4.9%, respectively. Regarding muscular strength, endurance, and electrical activity, the 1RM, SEI, and sEMG factors improved by 4.4%, 16.9%, and % 5.8, respectively. Meanwhile, compared to sham, real tDCS did not affect the athletes' motivation. Incidentally, it turned out that subjects who underwent T3 anodal stimulation outperformed in memory (p = 0.02) and verbal functions (0.02) as well as their corresponding frontopolar hemodynamic response [(memory HEG (p = 0.001) and verbal HEG (p = 0.003)]. Our findings suggest that simultaneous tDCS-induced excitation over the M1 leg area and left temporal area may potentially improve the overall athletic performance in experienced bodybuilders.	[Kamali, Ali-Mohammad; Yahyavi, Seyedeh-Saeedeh; Zarifkar, Asadollah; Aligholi, Hadi; Nami, Mohammad] Shiraz Univ Med Sci, Sch Adv Med Sci & Technol, Dept Neurosci, Shiraz, Iran; [Kamali, Ali-Mohammad; Saadi, Zahra Kheradmand; Yahyavi, Seyedeh-Saeedeh; Aligholi, Hadi; Nami, Mohammad] Iranian Neurosci Soc, DANA Brain Hlth Inst, Fars Branch, Shiraz, Iran; [Kamali, Ali-Mohammad; Saadi, Zahra Kheradmand; Yahyavi, Seyedeh-Saeedeh; Nami, Mohammad] Shiraz Univ Med Sci, Sch Adv Med Sci & Technol, Dept Neurosci, Neurosci Lab,NSL Brain Cognit & Behav, Shiraz, Iran; [Kamali, Ali-Mohammad; Yahyavi, Seyedeh-Saeedeh] Shiraz Univ Med Sci, Student Res Comm, Shiraz, Iran; [Saadi, Zahra Kheradmand] Shiraz Univ, Dept Foreign Languages & Literature, Shiraz, Iran; [Zarifkar, Asadollah] Shiraz Univ Med Sci, Dept Physiol, Sch Med, Shiraz, Iran; [Nami, Mohammad] Senses Cultural Fdn, Acad Hlth, Sacramento, CA 95826 USA	Shiraz University of Medical Science; Shiraz University of Medical Science; Shiraz University of Medical Science; Shiraz University; Shiraz University of Medical Science	Nami, M (corresponding author), Shiraz Univ Med Sci, Sch Adv Med Sci & Technol, Dept Neurosci, Shiraz, Iran.; Nami, M (corresponding author), Iranian Neurosci Soc, DANA Brain Hlth Inst, Fars Branch, Shiraz, Iran.; Nami, M (corresponding author), Shiraz Univ Med Sci, Sch Adv Med Sci & Technol, Dept Neurosci, Neurosci Lab,NSL Brain Cognit & Behav, Shiraz, Iran.; Nami, M (corresponding author), Senses Cultural Fdn, Acad Hlth, Sacramento, CA 95826 USA.	torabinami@sums.ac.ir	zarifkar, asadollah/U-6873-2017; Nami, Mohammad/AAL-6280-2021	zarifkar, asadollah/0000-0002-2684-6712; Nami, Mohammad/0000-0003-1410-5340; Leo, TJ/0000-0002-9525-6572	Shiraz University of Medical Sciences [1396-01-74-14298]	Shiraz University of Medical Sciences	This work was supported by Shiraz University of Medical Sciences under the grant No. 1396-01-74-14298.	Angius L, 2016, NEUROSCIENCE, V339, P363, DOI 10.1016/j.neuroscience.2016.10.028; Angius L, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00090; Baudewig J, 2001, MAGN RESON MED, V45, P196, DOI 10.1002/1522-2594(200102)45:2<196::AID-MRM1026>3.0.CO;2-1; Bigliassi M, 2016, PHYSIOL BEHAV, V158, P128, DOI 10.1016/j.physbeh.2016.03.001; Boggio PS, 2006, J NEUROL SCI, V249, P31, DOI 10.1016/j.jns.2006.05.062; Borducchi DMM, 2016, FRONT PSYCHIATRY, V7, DOI 10.3389/fpsyt.2016.00183; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Cogiamanian F, 2007, EUR J NEUROSCI, V26, P242, DOI 10.1111/j.1460-9568.2007.05633.x; Colzato LS, 2017, J COGN ENHANCE, V1, P73, DOI 10.1007/s41465-016-0003-2; Davis NJ, 2013, SPORTS MED, V43, P649, DOI 10.1007/s40279-013-0027-z; Devinsky Orrin, 2004, Epilepsy Curr, V4, P43, DOI 10.1111/j.1535-7597.2004.42001.x; Dutta A, 2014, NEUROREHABILITATION, V34, P789, DOI 10.3233/NRE-141077; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Furley PA, 2012, J SPORT EXERCISE PSY, V34, P322, DOI 10.1123/jsep.34.3.322; Furuya S, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-35; Geiger M, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2219-6; Grospretre S, 2016, EUR J SPORT SCI, V16, P317, DOI 10.1080/17461391.2015.1024756; Hall JE, 2015, GUYTON HALL TXB MED; Hampshire A, 2012, NEURON, V76, P1225, DOI 10.1016/j.neuron.2012.06.022; Hazime FA, 2017, INT J SPORTS PHYS TH, V12, P402; Hermens H.J., 1999, EUROPEAN RECOMMENDAT, V8, P13; Hilz MJ, 2002, BRAIN, V125, P985, DOI 10.1093/brain/awf092; Jang SH, 2009, NEUROSCI LETT, V460, P117, DOI 10.1016/j.neulet.2009.05.037; Kamali A-M, 2018, CEREBELLUM, P1, DOI [10.1007/s12311-018-0919-4, DOI 10.1007/S12311-018-0919-4]; Kamali AM, 2019, CEREBELLUM, V18, P119, DOI 10.1007/s12311-018-0967-9; Kaminski E, 2016, CLIN NEUROPHYSIOL, V127, P2455, DOI 10.1016/j.clinph.2016.03.018; Kan B, 2013, APPL PHYSIOL NUTR ME, V38, P734, DOI 10.1139/apnm-2012-0412; Kaski D, 2014, NEUROSCI LETT, V568, P39, DOI 10.1016/j.neulet.2014.03.043; Kelsey JL, 1996, METHODS OBSERVATIONA; Krishnan C, 2014, BRAIN STIMUL, V7, P443, DOI 10.1016/j.brs.2014.01.057; Leibenluft E, 2004, BIOL PSYCHIAT, V56, P225, DOI 10.1016/j.biopsych.2004.05.017; LeSuer DA, 1997, J STRENGTH COND RES, V11, P211; Lewthwaite R, 2017, CURR OPIN PSYCHOL, V16, P38, DOI 10.1016/j.copsyc.2017.04.005; Medeiros L. F., 2012, NEUROBIOLOGICAL EFFE; Meinzer M, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00253; Montenegro RA, 2011, NEUROSCI LETT, V497, P32, DOI 10.1016/j.neulet.2011.04.019; Moran A.P., 2016, PSYCHOL CONCENTRATIO; Muthalib M, 2013, ADV EXP MED BIOL, V789, P73, DOI 10.1007/978-1-4614-7411-1_11; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2003, J COGNITIVE NEUROSCI, V15, P619, DOI 10.1162/089892903321662994; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Noakes TD, 2011, SPORTS MED, V41, P263, DOI 10.2165/11583950-000000000-00000; Okano AH, 2013, BRIT J SPORT MED; Okano AH, 2015, BRIT J SPORT MED, V49, P1213, DOI 10.1136/bjsports-2012-091658; Oki K, 2001, J GERIATRIC PHYS THE; Reis J, 2009, P NATL ACAD SCI USA, V106, P1590, DOI 10.1073/pnas.0805413106; Rroji O, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127270; Serra-Sala M., 2012, J NEUROTHER, V16, P183, DOI [10.1080/10874208.2012.705754, DOI 10.1080/10874208.2012.705754]; Simons HD, 1999, J COLL STUDENT DEV, V40, P151; Sloan RP, 2009, AM J PUBLIC HEALTH, V99, P921, DOI 10.2105/AJPH.2007.133165; Sohn MK, 2013, ANN REHABIL MED-ARM, V37, P759, DOI 10.5535/arm.2013.37.6.759; Soutschek A, 2018, BIOL PSYCHIAT, V84, P38, DOI 10.1016/j.biopsych.2017.11.007; Stagg CJ, 2011, J PHYSIOL-LONDON, V589, P5845, DOI 10.1113/jphysiol.2011.216978; Stagg CJ, 2011, CURR BIOL, V21, P480, DOI 10.1016/j.cub.2011.01.069; Stagg CJ, 2009, J NEUROSCI, V29, P5202, DOI 10.1523/JNEUROSCI.4432-08.2009; Tanaka S, 2009, EXP BRAIN RES, V196, P459, DOI 10.1007/s00221-009-1863-9; Toomim H., 2005, J NEUROTHER, V8, P5, DOI DOI 10.1300/J184V08N03_; Tulppo MP, 1998, AM J PHYSIOL-HEART C, V274, pH424, DOI 10.1152/ajpheart.1998.274.2.H424; Vitor-Costa M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144916; Williams PS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081418; Wulf G, 2016, PSYCHON B REV, V23, P1382, DOI 10.3758/s13423-015-0999-9; Zhou JH, 2014, EUR J NEUROSCI, V39, P1343, DOI 10.1111/ejn.12492; Zhou P, 2004, J NEUROPHYSIOL, V92, P2878, DOI 10.1152/jn.00367.2004; Zhu FF, 2015, BRAIN STIMUL, V8, P784, DOI 10.1016/j.brs.2015.02.005; Ziemann U, 1998, J NEUROSCI, V18, P7000	66	22	22	2	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2019	14	8							e0220363	10.1371/journal.pone.0220363	http://dx.doi.org/10.1371/journal.pone.0220363			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4ZH	31369607	gold, Green Submitted, Green Published			2023-01-03	WOS:000484987900043
J	Cassarino, M; Robinson, K; Quinn, R; Naddy, B; O'Regan, A; Ryan, D; Boland, F; Ward, ME; McNamara, R; O'Connor, M; McCarthy, G; Galvin, R				Cassarino, Marica; Robinson, Katie; Quinn, Rosie; Naddy, Breda; O'Regan, Andrew; Ryan, Damien; Boland, Fiona; Ward, Marie E.; McNamara, Rosa; O'Connor, Margaret; McCarthy, Gerard; Galvin, Rose			Impact of early assessment and intervention by teams involving health and social care professionals in the emergency department: A systematic review	PLOS ONE			English	Review							LENGTH-OF-STAY; DISCHARGE; OUTCOMES; MULTIDISCIPLINARY; QUALITY; MODELS	Background Dedicated Health and Social Care Professional (HSCP) teams have been proposed for emergency departments (EDs) in an effort to improve patient and process outcomes. This systematic review synthesises the totality of evidence relating to the impact of early assessment and intervention by HSCP teams on quality, safety and effectiveness of care in the ED. Methods A systematic literature search was conducted in April 2019 to identify experimental studies examining the effectiveness of ED-based HSCP teams providing services to adults aged. 18 years old and including two or more of the following disciplines: occupational therapist, physiotherapist, medical social worker, clinical pharmacist, or speech and language therapist. Data extraction and quality appraisal of each study were conducted independently by two reviewers. Results Six studies were included in the review (n = 273,886), all describing interdisciplinary Care Coordination Teams (CCTs) caring for adults aged. 65 years old. CCT care was associated with on average 2% reduced rates of hospital admissions (three studies), improved referrals to community services for falls (one study), increased satisfaction (two studies) with the safety of discharge (patients and staff), and with the distribution of workload (staff), improved health-related quality of care (one study). No statistically significant differences between intervention and control groups emerged in terms of rates of ED re-visits, ranging between 0.2% and 3% (two studies); hospital length of stay (one hour difference noted in one study) or mortality rates (0.5% difference in one study). Increased rates of unplanned hospitalisations following the intervention (13.9% difference) were reported in one study. The methodological quality of the studies was mixed. Discussion We found limited and heterogeneous evidence on the impact of HSCP teams in the ED, suggesting a reduction in hospital admissions as well as improved patient and staff satisfaction. More robust investigations including cost-effectiveness evaluations are needed.	[Cassarino, Marica; Robinson, Katie; Galvin, Rose] Univ Limerick, Ageing Res Cluster, Hlth Res Inst, Sch Allied Hlth,Fac Educ & Hlth Sci, Limerick, Ireland; [Quinn, Rosie] Our Lady Lourdes Hosp, Emergency Dept, Drogheda, Ireland; [Naddy, Breda] Royal Coll Surgeons Ireland, Clin Strategy & Programmes Div, Dublin, Ireland; [O'Regan, Andrew; Ryan, Damien; O'Connor, Margaret] Univ Limerick, Fac Educ & Hlth Sci, Grad Entry Med Sch, Limerick, Ireland; [Ryan, Damien] Univ Hosp Limerick, Emergency Dept, Retrieval Emergency & Disaster Med Res & Dev Unit, Limerick, Ireland; [Boland, Fiona] Royal Coll Surgeons Ireland, HRB Ctr Primary Care Res, Dublin, Ireland; [Ward, Marie E.] Univ Dublin, Trinity Coll, Sch Psychol, Dublin, Ireland; [McNamara, Rosa] St Vincents Univ Hosp, Emergency Dept, Dublin, Ireland; [O'Connor, Margaret] Univ Hosp Limerick, Dept Ageing & Therapeut, Limerick, Ireland; [McCarthy, Gerard] Cork Univ Hosp, Emergency Dept, Cork, Ireland	University of Limerick; Royal College of Surgeons - Ireland; University of Limerick; University of Limerick; Health Research Board - Ireland; Royal College of Surgeons - Ireland; Trinity College Dublin; University College Dublin; Saint Vincent's University Hospital; University of Limerick; University College Cork	Cassarino, M (corresponding author), Univ Limerick, Ageing Res Cluster, Hlth Res Inst, Sch Allied Hlth,Fac Educ & Hlth Sci, Limerick, Ireland.	marica.cassarino@ul.ie	O'Connor, Margaret/AAE-2673-2021; Cassarino, Marica/G-2332-2018; Galvin, Rose/AAL-6072-2020	Cassarino, Marica/0000-0002-1624-921X; O'Regan, Andrew/0000-0001-8470-2736; Ryan, Damien/0000-0001-7457-2640; Boland, Fiona/0000-0003-3228-0046; Ward, Marie Elizabeth/0000-0002-6638-8461; Robinson, Katie/0000-0003-1008-9857	Health Research Board of Ireland through the Research Collaborative for Quality and Patient Safety (RCQPS) 2017	Health Research Board of Ireland through the Research Collaborative for Quality and Patient Safety (RCQPS) 2017	This work is supported by the Health Research Board of Ireland (https://www.hrb.ie/) through the Research Collaborative for Quality and Patient Safety (RCQPS) 2017. The grant was awarded to Dr. Rose Galvin as Principal Investigator. The funder did not play any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arendts G, 2013, INT J CLIN PRACT, V67, P807, DOI 10.1111/ijcp.12153; Arendts G, 2013, EMERG MED AUSTRALAS, V25, P127, DOI 10.1111/1742-6723.12049; Arendts G, 2012, BMC GERIATR, V12, DOI 10.1186/1471-2318-12-8; Asplin BR, 2003, ANN EMERG MED, V42, P173, DOI 10.1067/mem.2003.302; Carter EJ, 2014, J NURS SCHOLARSHIP, V46, P106, DOI 10.1111/jnu.12055; Cassarino M, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-023464; Cohen V, 2009, AM J HEALTH-SYST PH, V66, P1353, DOI 10.2146/ajhp080304; Corbett Helen M, 2005, Aust Health Rev, V29, P43; Effective Practice and Organisation of Care (EPOC), 2017, EPOC RES REV AUTH OS, P1; Ferreira GE, 2019, EMERG MED AUSTRALAS, V31, P43, DOI 10.1111/1742-6723.12987; Flores-Mateo G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035903; Fogarty E, 2014, J EMERG MED, V46, P706, DOI 10.1016/j.jemermed.2013.08.111; Gardner G, 2018, AUST HEALTH REV, V42, P340, DOI 10.1071/AH16231; Haines TP, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002412; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Hoffmann TC, 2016, BETTER REPORTING INT, DOI [10.1055/s-0041-111066, DOI 10.1055/S-0041-111066]; Hoot NR, 2008, ANN EMERG MED, V52, P126, DOI 10.1016/j.annemergmed.2008.03.014; Innes K, 2016, INT EMERG NURS, V25, P27, DOI 10.1016/j.ienj.2015.07.003; James K, 2016, BRIT J OCCUP THER, V79, P459, DOI 10.1177/0308022616629168; Jarvis PRE, 2016, CLIN EXP EMERG MED, V3, P63, DOI 10.15441/ceem.16.127; Katz EB, 2012, ANN EMERG MED, V60, P12, DOI 10.1016/j.annemergmed.2012.02.025; Kilner E, 2011, J HEALTH SERV RES PO, V16, P51, DOI 10.1258/jhsrp.2010.009129; McGowan J, 2010, EVID BASED LIB INF P, V5, P149, DOI 10.18438/B8SG8R; Mitchell P, 2012, NAM PERSPECT, DOI DOI 10.31478/201210C; Moher D, 2009, PHYS THER, V89, P873, DOI 10.1093/ptj/89.9.873; Moore M, 2012, SOC WORK HEALTH CARE, V51, P140, DOI 10.1080/00981389.2011.610872; Moss JE, 2002, MED J AUSTRALIA, V177, P435, DOI 10.5694/j.1326-5377.2002.tb04884.x; Moy E, 2016, AM J EMERG MED, V34, P83, DOI 10.1016/j.ajem.2015.09.031; Naylor M. D., 2010, ABIM FDN M ADV UNPUB; NHS Improvement and NHS England, 2018, ALL HLTH PROF SUPP P; Oredsson S, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-43; Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4; Paw RC, 2008, EMERG MED J, V25, P420, DOI 10.1136/emj.2007.054197; Preen DB, 2005, INT J QUAL HEALTH C, V17, P43, DOI 10.1093/intqhc/mzi002; Saxon RL, 2014, J MULTIDISCIP HEALTH, V7, P479, DOI 10.2147/JMDH.S66746; Schrock JW, 2011, ACAD EMERG MED, V18, P584, DOI 10.1111/j.1553-2712.2011.01087.x; Schunemann H, 2013, GRADE HDB GRADING QU, DOI [10.1136/bmj.332.7549.1089, DOI 10.1136/BMJ.332.7549.1089]; Stapleton C, 2017, INT J INTEGR CARE, V17, DOI 10.5334/ijic.3900; Waldron N, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-6; Wylie K, 2015, EMERG MED AUSTRALAS, V27, P95, DOI 10.1111/1742-6723.12367; Yarmohammadian MH, 2017, J RES MED SCI, V22, DOI 10.4103/1735-1995.200277	41	13	13	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2019	14	7							e0220709	10.1371/journal.pone.0220709	http://dx.doi.org/10.1371/journal.pone.0220709			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4XR	31365575	gold, Green Published, Green Submitted			2023-01-03	WOS:000484983600065
J	Kumar, S; Rajkumar, SV				Kumar, Shaji; Rajkumar, S. Vincent			Surrogate endpoints in randomised controlled trials: a reality check	LANCET			English	Editorial Material							MULTIPLE-MYELOMA; DEXAMETHASONE; VENETOCLAX; BORTEZOMIB; EFFICACY		[Kumar, Shaji; Rajkumar, S. Vincent] Mayo Clin, Div Hematol, Rochester, MN 55905 USA	Mayo Clinic	Rajkumar, SV (corresponding author), Mayo Clin, Div Hematol, Rochester, MN 55905 USA.	rajkumar.vincent@mayo.edu	Rajkumar, S. Vincent/AAV-1834-2021; Kumar, Shaji K/A-9853-2008	Rajkumar, S. Vincent/0000-0002-5862-1833; Kumar, Shaji K/0000-0001-5392-9284				[Anonymous], 2019, LANCET ONCOL, V20, P601, DOI 10.1016/S1470-2045(19)30238-4; DiMasi JA, 2016, J HEALTH ECON, V47, P20, DOI 10.1016/j.jhealeco.2016.01.012; Dimopoulos MA, 2016, LANCET ONCOL, V17, P27, DOI 10.1016/S1470-2045(15)00464-7; Haslam A, 2019, EUR J CANCER, V106, P196, DOI 10.1016/j.ejca.2018.11.012; Krauss AC, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.8008; Kumar S, 2019, 24 C EUR HEM ASS AMS; Kumar S, 2017, BLOOD, V130, P2401, DOI 10.1182/blood-2017-06-788786; Kumar S, 2016, LANCET ONCOL, V17, pE328, DOI 10.1016/S1470-2045(16)30206-6; Moreau P, 2017, BLOOD, V130, P2392, DOI 10.1182/blood-2017-06-788323; Moreau P, 2016, LANCET, V388, P111, DOI 10.1016/S0140-6736(16)30954-0; Palumbo A, 2016, NEW ENGL J MED, V375, P754, DOI 10.1056/NEJMoa1606038; Rajkumar SV, 2011, BLOOD, V118, P3205, DOI 10.1182/blood-2011-06-297853; U.S. Food & Drug Administration, 2019, FDA WARNS RISKS ASS	13	19	19	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 27	2019	394	10195					281	283		10.1016/S0140-6736(19)31711-8	http://dx.doi.org/10.1016/S0140-6736(19)31711-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IL1QD	31354129				2023-01-03	WOS:000477075200008
J	Bitta, MA; Kariuki, SM; Gona, J; Abubakar, A; Newton, CRJC				Bitta, Mary A.; Kariuki, Symon M.; Gona, Joseph; Abubakar, Amina; Newton, Charles R. J. C.			Priority mental, neurological and substance use disorders in rural Kenya: Traditional health practitioners' and primary health care workers' perspectives	PLOS ONE			English	Article							EPILEPSY; HEALERS; PEOPLE; PROVISION; CHILDREN; AFRICA; BURDEN	Background Over 75% of people with mental neurological and substance use disorders (MNSD) live in low and middle-income countries with limited access to specialized care. The World Health Organization's Mental Health Gap Action Program (mhGAP) aims to address the human resource gap but it requires contextualization. Aims We conducted a qualitative study in rural coastal Kenya to explore the local terms, perceived causes and management modalities of priority MNSD listed in the mhGAP, to inform implementation in this setting. Methods We conducted 8 focus group discussions with primary health care providers and traditional health practitioners and used the framework method to conduct thematic analysis. We identified local terms, perceived causes and treatment options for MNSD. We also explored possibilities for collaboration between the traditional health practitioners and primary health care providers. Results We found local terms for depression, psychoses, epilepsy, disorders due to substance use and self-harm/suicide but none for dementia. Child and adolescent mental and behavioral problems were not regarded as MNSD but consequences of poor parenting. Self-harm/suicide was recognized in the context of other MNSD. Causes of MNSD were broadly either biological or supernatural. Treatment options were dependent on perceived cause of illness. Most traditional health practitioners were willing to collaborate with primary health care providers mainly through referring cases. Primary health care providers were unwilling to collaborate with traditional health practitioners because they perceived them to contribute to worsening of patients' prognoses. Conclusions Local terms and management modalities are available for some priority MNSD in this setting. Community level case detection and referral may be hindered by lack of collaboration between traditional health practitioners and primary health care providers. There is need for training on the recognition and management of all priority MNSD.	[Bitta, Mary A.; Kariuki, Symon M.; Gona, Joseph; Abubakar, Amina; Newton, Charles R. J. C.] Ctr Geog Med Res Coast, Trop Neurosci, KEMRI Wellcome Trust Res Programme, Kilifi, Kenya; [Bitta, Mary A.; Kariuki, Symon M.; Newton, Charles R. J. C.] Univ Oxford, Dept Psychiat, Oxford, England; [Abubakar, Amina] Aga Khan Univ, Nairobi, Kenya	University of Oxford; Aga Khan University	Bitta, MA (corresponding author), Ctr Geog Med Res Coast, Trop Neurosci, KEMRI Wellcome Trust Res Programme, Kilifi, Kenya.; Bitta, MA (corresponding author), Univ Oxford, Dept Psychiat, Oxford, England.	mbitta@kemri-wellcome.org	bitta, mary/GVU-6500-2022; Abubakar, Amina/F-1479-2017	bitta, mary/0000-0003-0258-9931; Kariuki, Symon/0000-0002-3934-5132; Abubakar, Amina/0000-0002-3686-7904	Wellcome Trust Public Engagement Fund [213763/Z/18/Z]; Wellcome Trust [203077/Z/16/Z, 107769/Z/10/Z]; MQ Fellows' Award	Wellcome Trust Public Engagement Fund; Wellcome Trust(Wellcome TrustEuropean Commission); MQ Fellows' Award	SK is supported by an MQ Fellows' Award. MB is supported by a Wellcome Trust Public Engagement Fund number 213763/Z/18/Z and by Wellcome Trust grants number 203077/Z/16/Z and 107769/Z/10/Z. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abubakar A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151030; Abubakar A, 2015, EPILEPSY BEHAV, V45, P74, DOI 10.1016/j.yebeh.2015.02.023; Ae-Ngibise K, 2010, INT REV PSYCHIATR, V22, P558, DOI 10.3109/09540261.2010.536149; Akol A, 2018, GLOB MENT HEALTH, V5, DOI 10.1017/gmh.2018.18; Awiti JO, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0560-y; Bitta MA, 2017, INT J MENT HEALTH SY, V11, DOI 10.1186/s13033-017-0135-5; BROWN F, 2019, EUR J PSYCHOTRAUM S1, V10; Burns JK, 2015, SOC PSYCH PSYCH EPID, V50, P867, DOI 10.1007/s00127-014-0989-7; Chibanda D, 2015, INT J MENT HEALTH SY, V9, DOI 10.1186/s13033-015-0013-y; Cohen A, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-1090-4; Gona JK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132729; Gureje O, 2019, LANCET GLOB HEALTH, V7, pE951, DOI 10.1016/S2214-109X(19)30148-2; Ibinda F, 2014, EPILEPSIA, V55, P344, DOI 10.1111/epi.12498; Kariuki SM, 2017, LANCET PSYCHIAT, V4, P136, DOI 10.1016/S2215-0366(16)30403-5; Kariuki SM, 2016, CHILD ADOL PSYCH MEN, V10, DOI 10.1186/s13034-015-0089-9; Kariuki SM, 2015, EPILEPSIA, V56, P577, DOI 10.1111/epi.12935; Keikelame MJ, 2015, TRANSCULT PSYCHIATRY, V52, P659, DOI 10.1177/1363461515571626; Kendall-Taylor NH, 2009, RURAL REMOTE HEALTH, V9; Kendall-Taylor N, 2008, EPILEPSIA, V49, P1638, DOI 10.1111/j.1528-1167.2008.01580_1.x; Kpanake L, 2018, TRANSCULT PSYCHIATRY, V55, P198, DOI 10.1177/1363461517749435; Mbwayo AW, 2013, AFR J PSYCHIATRY, V16, P134, DOI [http://dx.doi.org/10.4314/ajpsy.v16i2.17, 10.4314/ajpsy.v16i2.17]; Ofori-Atta A, 2010, INT REV PSYCHIATR, V22, P589, DOI 10.3109/09540261.2010.536150; Ouma PO, 2018, LANCET GLOB HEALTH, V6, pE342, DOI 10.1016/S2214-109X(17)30488-6; Srivastava A., 2009, JOAAG, V4; Ssewanyana D, 2020, J HEALTH PSYCHOL, V25, P1940, DOI 10.1177/1359105318782594; Tanywe Asahngwa, 2016, JBI Database System Rev Implement Rep, V14, P136, DOI 10.11124/JBISRIR-2016-002182; Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]; WHO Guidelines Approved by the Guidelines Review Committee, 2016, MHGAP INT GUID MENT	28	4	4	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2019	14	7							e0220034	10.1371/journal.pone.0220034	http://dx.doi.org/10.1371/journal.pone.0220034			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4UP	31335915	gold, Green Published, Green Submitted			2023-01-03	WOS:000484975500027
J	Hawryl, A; Hawryl, M; Waksmundzka-Hajnos, M				Hawryl, Anna; Hawryl, Miroslaw; Waksmundzka-Hajnos, Monika			Liquid chromatography fingerprint analysis and antioxidant activity of selected lavender species with chemometric calculations	PLOS ONE			English	Article							ESSENTIAL OILS; QUALITY; COMPONENTS; EXTRACTS; PREDICTION; ALIGNMENT	The extracts of seven Lavandulae species (Lavandula stoechas, Lavandula lanata, Lavandula viridis, Lavandula angustifolia "Rosea", Lavandula angustifolia "Afropurpurea", Lavandula angustifolia and one unknown) were analyzed using the reversed-phase-high performance liquid chromatography-diode array detection (RP-HPLC-DAD) with gradient elution technique to obtain the chromatographic fingerprint profiles. The HPLC analysis was performed using the Kinetex RP18 chromatographic column and eluent consisting of methanol-water-0.1% formic acid (5-100% (v/v)) at 30 degrees C with the run time of 60 min. and the detection wavelength 280 nm. The chromatograms were preliminary processed with the smoothing, noise reduction, background subtraction and alignment using the SpecAlign program (version 2.4.1). The presence of selected standards (apigenin, myricetin, luteolin, luteolin 7-glucoside, chlorogenic acid, caffeic acid, ferulic acid) in the extracts was confirmed. The chemical similarity between studied plants was evaluated using the Cluster Analysis (Pearson correlation coefficient, r, and Euclidean) and PCA. The preliminary antioxidant activity of studied extracts was evaluated based on the total phenolic content (Folin-Ciocalteu method), ferric ion reducing antioxidant parameter (FRAP) and alpha,alpha-diphenyl-beta-picrylhydrazyl (DPPH) free radical scavenging method using the spectrophotometric technique.	[Hawryl, Anna; Hawryl, Miroslaw; Waksmundzka-Hajnos, Monika] Med Univ Lublin, Fac Pharm, Dept Inorgan Chem, Lublin, Poland	Medical University of Lublin	Hawryl, A (corresponding author), Med Univ Lublin, Fac Pharm, Dept Inorgan Chem, Lublin, Poland.	anna.hawryl@umlub.pl	Hawrył, Mirosław/GLN-5484-2022	Hawryl, Miroslaw/0000-0003-3286-763X; Hawryl, Anna/0000-0002-8924-169X				Alexa E, 2018, ANAL CELL PATHOL, V2018, DOI 10.1155/2018/2678924; Aloglu AK, 2016, TALANTA, V161, P503, DOI 10.1016/j.talanta.2016.09.014; [Anonymous], 1991, GUID ASS HERB MED; Areias FM, 2000, J LIQ CHROMATOGR R T, V23, P2563, DOI 10.1081/JLC-100100510; BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25; Cavanagh HMA, 2002, PHYTOTHER RES, V16, P301, DOI 10.1002/ptr.1103; Celik SE, 2017, J CHROMATOGR SCI, V55, P291, DOI 10.1093/chromsci/bmw184; Chang YX, 2008, J CHROMATOGR A, V1208, P76, DOI 10.1016/j.chroma.2008.08.054; Ciesla L., 2012, CHROMATOGR RES INT, V9; Daszykowski M, 2007, J CHROMATOGR A, V1176, P1, DOI 10.1016/j.chroma.2007.10.099; Contreras MD, 2018, ELECTROPHORESIS, V39, P1284, DOI 10.1002/elps.201700393; Gabrieli C, 2003, PHARMAZIE, V58, P426; Gilani AH, 2000, J ETHNOPHARMACOL, V71, P161, DOI 10.1016/S0378-8741(99)00198-1; Gulcin I, 2004, FOOD CHEM, V87, P393, DOI 10.1016/j.foodchem.2003.12.008; Hawryl A, 2017, J LIQ CHROMATOGR R T, V40, P36, DOI 10.1080/10826076.2017.1282373; Hawryl AM, 2017, ANAL LETT, V50, P2078, DOI 10.1080/00032719.2016.1263645; Hawryl AM, 2016, J BRAZIL CHEM SOC, V27, P1736, DOI 10.5935/0103-5053.20160054; Jiang W, 2013, CHROMATOGRAPHIA, V76, P1067, DOI 10.1007/s10337-013-2513-8; Kirmizibekmez H, 2009, NAT PROD COMMUN, V4, P1001; Kovatcheva EG, 2001, FOOD CHEM, V72, P295, DOI 10.1016/S0308-8146(00)00229-6; Liu X, 2016, CHEMOMETR INTELL LAB, V152, P54, DOI 10.1016/j.chemolab.2016.01.006; Peng L, 2011, FOOD CHEM, V125, P1064, DOI 10.1016/j.foodchem.2010.09.079; Rodrigues MJ, 2019, S AFR J BOT, V120, P87, DOI 10.1016/j.sajb.2017.12.003; Sabara D., 2009, SCI B TU LODZ, V73, P33; Sosa S, 2005, PHYTOMEDICINE, V12, P271, DOI 10.1016/j.phymed.2004.02.007; Spiridon I, 2011, NAT PROD RES, V25, P1657, DOI 10.1080/14786419.2010.521502; Tang DQ, 2010, ANAL BIOANAL CHEM, V396, P3087, DOI 10.1007/s00216-010-3536-8; Turek C, 2012, FOOD RES INT, V46, P341, DOI 10.1016/j.foodres.2011.12.028; Turek C, 2011, J FOOD SCI, V76, pC1365, DOI 10.1111/j.1750-3841.2011.02416.x; Turek C, 2011, ANAL BIOANAL CHEM, V400, P3109, DOI 10.1007/s00216-011-4976-5; Wong CC, 2006, FOOD CHEM, V97, P705, DOI 10.1016/j.foodchem.2005.05.049; Wong JWH, 2005, BIOINFORMATICS, V21, P2088, DOI 10.1093/bioinformatics/bti300; Wu QY, 2011, INT J MOL SCI, V12, P8740, DOI 10.3390/ijms12128740; Yan SK, 2005, J CHROMATOGR A, V1090, P90, DOI 10.1016/j.chroma.2005.07.066; Yu YP, 2018, J CHROMATOGR B, V1095, P149, DOI 10.1016/j.jchromb.2018.07.031	35	12	12	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2019	14	7							e0218974	10.1371/journal.pone.0218974	http://dx.doi.org/10.1371/journal.pone.0218974			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IS7KI	31287826	gold, Green Submitted, Green Published			2023-01-03	WOS:000482328300008
J	Khurana, D; Kaul, S; Schneider, D; Csanyi, A; Adam, I; Ichaporia, NR; Griewing, B; Csiba, L; Valikovics, A; Puri, V; Diener, HC; Schwab, S; Hetzel, A; Bornstein, N				Khurana, Dheeraj; Kaul, Subhash; Schneider, Dietmar; Csanyi, Attila; Adam, Ilona; Ichaporia, Nasli R.; Griewing, Bernd; Csiba, Laszlo; Valikovics, Attila; Puri, Vinod; Diener, Hans Christoph; Schwab, Stefan; Hetzel, Andreas; Bornstein, Natan		ImpACT-Study Grp	Implant for Augmentation of Cerebral Blood Flow Trial-1 (ImpACT-1). A single-arm feasibility study evaluating the safety and potential benefit of the Ischemic Stroke System for treatment of acute ischemic stroke	PLOS ONE			English	Article							SPHENOPALATINE-GANGLION; STIMULATION; RELIABILITY; INFARCTION	Background The Ischemic Stroke System is a novel device designed to deliver stimulation to the sphenopalatine ganglion(SPG). The SPG sends parasympathetic innervations to the anterior cerebral circulation. In rat stroke models, SPG stimulation results in increased cerebral blood flow, reduced infarct volume, protects the blood brain barrier, and improved neurological outcome. We present here the results of a prospective, multinational, single-arm, feasibility study designed to assess the safety, tolerability, and potential benefit of SPG stimulation inpatients with acute ischemic stroke(AIS). Methods Patients with anterior AIS, baseline NIHSS 7-20 and ability to initiate treatment within 24h from stroke onset, were implanted and treated with the SPG stimulation. Patients were followed up for 90 days. Effect was assessed by comparing the patient outcome to a matched population from the NINDS rt-PA trial placebo patients. Results Ninety-eight patients were enrolled (mean age 57years, mean baseline NIHSS 12 and mean treatment time from stroke onset 19h). The observed mortality rate(12.2%), serious adverse events (SAE) incidence(23.5%) and nature of SAE were within the expected range for the population. The modified intention to treat cohort consisted of 84 patients who were compared to matched patients from the NINDS placebo arm. Patients treated with SPG stimulation had an average mRS lower by 0.76 than the historical controls(CMH test p = 0.001). Conclusion The implantation procedure and the SPG stimulation, initiated within 24hr from stroke onset, are feasible, safe, and tolerable.	[Khurana, Dheeraj] Postgrad Inst Med Educ & Res, Chandigarh, India; [Kaul, Subhash] Nizams Inst Med Sci, Hyderabad, India; [Schneider, Dietmar] Univ Leipzig, NICU, Leipzig, Germany; [Schneider, Dietmar] Stroke Unit, Leipzig, Germany; [Csanyi, Attila; Adam, Ilona] Aladar Petz Cty Teaching Hosp, Gyor, Hungary; [Adam, Ilona] Istvan Szechenyi Univ, Gyor, Hungary; [Ichaporia, Nasli R.] Jahangir Hosp, Pune, Maharashtra, India; [Griewing, Bernd] Neurol Klin GmbH, Bad Neustadt an der Saale, Germany; [Csiba, Laszlo] Univ Debrecen, Debrecen, Hungary; [Valikovics, Attila] BAZ Cty Hosp, Miskolc, Hungary; [Puri, Vinod] GB Pant Hosp, New Delhi, India; [Diener, Hans Christoph] Univ Hosp Essen, Dept Neurol, Essen, Germany; [Diener, Hans Christoph] Univ Hosp Essen, Stroke Ctr, Essen, Germany; [Schwab, Stefan] Univ Klinikum Erlangen, Erlangen, Germany; [Hetzel, Andreas] Univ Freiburg, Freiburg, Germany; [Bornstein, Natan] Tel Aviv Med Ctr & Sch Med, Tel Aviv, Israel	Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Nizam's Institute of Medical Sciences; Leipzig University; University of Istvan Szechenyi; University of Debrecen; Govind Ballabh Pant Institute of Postgraduate Medical Education & Research; University of Duisburg Essen; University of Duisburg Essen; University of Erlangen Nuremberg; University of Freiburg; Tel Aviv University; Sackler Faculty of Medicine	Khurana, D (corresponding author), Postgrad Inst Med Educ & Res, Chandigarh, India.	dherajk@yahoo.com		Csanyi, Attila/0000-0002-2368-3751; Khurana, Dheeraj/0000-0002-5379-3089	BrainsGate Ltd, Caesarea, Israel; Neurologische Klinic GmbH	BrainsGate Ltd, Caesarea, Israel; Neurologische Klinic GmbH	The study was funded by BrainsGate Ltd, Caesarea, Israel (www.brainsgate.com). N.B.and H.C.D. received contracted hourly payments from BrainsGate for service on the ImpACT trials steering committee providing guidance on rigorous trial conduct and design. The institutions of D.K., S.K., D. S., A.C., I.I., N.I., B.G., L.C., A.V., V.P., H.C.D., S.S., A.H., N.B. received payments for study services on the basis of clinical trial contracts with BrainsGate. The study was designed by an Academic Steering Committee and the sponsor, BrainsGate Ltd. Site management and data collection were coordinated by the sponsor. Data analysis and writing of the report were performed by the authors and the sponsor. Neurologische Klinic GmbH provided support in the form of salary for author BG, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section.	Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973; Bar-Shir A, 2010, J MAGN RESON IMAGING, V31, P1355, DOI 10.1002/jmri.22110; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Goldstein LB, 1997, STROKE, V28, P307, DOI 10.1161/01.STR.28.2.307; GOLDSTEIN LB, 1989, ARCH NEUROL-CHICAGO, V46, P660, DOI 10.1001/archneur.1989.00520420080026; Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905; Guenego A, 2018, ANN NEUROL, V84, P616, DOI 10.1002/ana.25320; Henninger N, 2007, STROKE, V38, P2779, DOI 10.1161/STROKEAHA.107.485581; Khurana D, 2009, INT J STROKE, V4, P480, DOI 10.1111/j.1747-4949.2009.00385.x; Laska AC, 2001, J INTERN MED, V249, P413, DOI 10.1046/j.1365-2796.2001.00812.x; Levi H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039636; Liebeskind DS, 2003, STROKE, V34, P2279, DOI 10.1161/01.STR.0000086465.41263.06; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Menon BK, 2018, JAMA-J AM MED ASSOC, V320, P1017, DOI 10.1001/jama.2018.12498; Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442; Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158; Saver JL, 2009, NEUROLOGY, V72, P1310, DOI 10.1212/01.wnl.0000341308.73506.b7; SEYLAZ J, 1988, J CEREBR BLOOD F MET, V8, P875, DOI 10.1038/jcbfm.1988.145; Shuaib A, 2011, LANCET NEUROL, V10, P909, DOI 10.1016/S1474-4422(11)70195-8; Su DS, 2010, NEUROL SCI, V31, P431, DOI 10.1007/s10072-010-0238-0; Subramaniam S, 2005, NEUROLOGIST, V11, P150, DOI 10.1097/01.nrl.0000159987.70461.d7	21	2	2	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 3	2019	14	7							e0217472	10.1371/journal.pone.0217472	http://dx.doi.org/10.1371/journal.pone.0217472			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4CE	31269025	Green Published, Green Submitted, gold			2023-01-03	WOS:000484927300005
J	Matei, D; Filiaci, V; Randall, ME; Mutch, D; Steinhoff, MM; DiSilvestro, PA; Moxley, KM; Kim, YM; Powell, MA; O'Malley, DM; Spirtos, NM; Small, W; Tewari, KS; Richards, WE; Nakayama, J; Matulonis, UA; Huang, HQ; Miller, DS				Matei, Daniela; Filiaci, Virginia; Randall, Marcus E.; Mutch, David; Steinhoff, Margaret M.; DiSilvestro, Paul A.; Moxley, Katherine M.; Kim, Yong M.; Powell, Matthew A.; O'Malley, David M.; Spirtos, Nick M.; Small, William, Jr.; Tewari, Krishnansu S.; Richards, William E.; Nakayama, John; Matulonis, Ursula A.; Huang, Helen Q.; Miller, David S.			Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-III TRIAL; POSITIVE PERITONEAL CYTOLOGY; EXTERNAL-BEAM RADIOTHERAPY; HIGH-RISK; INTERMEDIATE-RISK; INTRAVAGINAL RADIATION; OPEN-LABEL; CARCINOMA; CISPLATIN; SURGERY	Background Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence. Methods In this randomized phase 3 trial, we tested whether 6 months of platinum-based chemotherapy plus radiation therapy (chemoradiotherapy) is associated with longer relapse-free survival (primary end point) than six cycles of combination chemotherapy alone in patients with stage III or IVA endometrial carcinoma. Secondary end points included overall survival, acute and chronic toxic effects, and quality of life. Results Of the 813 patients enrolled, 736 were eligible and were included in the analysis of relapse-free survival; of those patients, 707 received the randomly assigned intervention (346 received chemoradiotherapy and 361 received chemotherapy only). The median follow-up period was 47 months. At 60 months, the Kaplan-Meier estimate of the percentage of patients alive and relapse-free was 59% (95% confidence interval [CI], 53 to 65) in the chemoradiotherapy group and 58% (95% CI, 53 to 64) in the chemotherapy-only group (hazard ratio, 0.90; 90% CI, 0.74 to 1.10). Chemoradiotherapy was associated with a lower 5-year incidence of vaginal recurrence (2% vs. 7%; hazard ratio, 0.36; 95% CI, 0.16 to 0.82) and pelvic and paraaortic lymph-node recurrence (11% vs. 20%; hazard ratio, 0.43; 95% CI, 0.28 to 0.66) than chemotherapy alone, but distant recurrence was more common in association with chemoradiotherapy (27% vs. 21%; hazard ratio, 1.36; 95% CI, 1.00 to 1.86). Grade 3, 4, or 5 adverse events were reported in 202 patients (58%) in the chemoradiotherapy group and 227 patients (63%) in the chemotherapy-only group. Conclusions Chemotherapy plus radiation was not associated with longer relapse-free survival than chemotherapy alone in patients with stage III or IVA endometrial carcinoma. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00942357.)	[Matei, Daniela] Northwestern Univ, Chicago, IL 60611 USA; [Small, William, Jr.] Loyola Univ, Chicago, IL 60611 USA; [Filiaci, Virginia; Huang, Helen Q.] Roswell Pk Comprehens Canc Ctr, NRG Oncol Stat & Data Ctr, Buffalo, NY USA; [Randall, Marcus E.] Univ Kentucky, Lexington, KY USA; [Mutch, David; Powell, Matthew A.] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA; [Steinhoff, Margaret M.; DiSilvestro, Paul A.] Brown Univ, Warren Alpert Med Sch, Women & Infants Hosp Rhode Isl, Providence, RI 02912 USA; [Moxley, Katherine M.] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Gynecol Canc Clin, Oklahoma City, OK USA; [Kim, Yong M.] Univ Ulsan, Asan Med Ctr, Seoul, South Korea; [O'Malley, David M.] Ohio State Univ, Columbus, OH 43210 USA; [Spirtos, Nick M.] Womens Canc Ctr Nevada, Las Vegas, NV USA; [Tewari, Krishnansu S.] Univ Calif Irvine, Med Ctr, Irvine, CA USA; [Richards, William E.] Lewis Canc & Res Pavil St Josephs Candler, Savannah, GA USA; [Nakayama, John] Case Western Reserve Univ Hosp, Cleveland, OH 44106 USA; [Matulonis, Ursula A.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Miller, David S.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA	Northwestern University; Loyola University Chicago; University of Kentucky; Siteman Cancer Center; Washington University (WUSTL); Brown University; Women & Infants Hospital Rhode Island; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Ulsan; University System of Ohio; Ohio State University; University of California System; University of California Irvine; Case Western Reserve University; Case Western Reserve University Hospital; Harvard University; Dana-Farber Cancer Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas	Matei, D (corresponding author), Northwestern Univ, Div Gynecol Oncol, 303 E Super St,Lurie 4-107, Chicago, IL 60610 USA.	daniela.matei@northwestern.edu	Miller, David Scott/H-4604-2011; Filiaci, Virginia/AAX-7329-2020; Small, William/AAI-9027-2020	Miller, David Scott/0000-0002-8215-5887; Filiaci, Virginia/0000-0002-0623-9667; Matei, Daniela/0000-0003-2169-5035; OMalley, David/0000-0002-2828-0177	National Cancer Institute (NCI) [CA 27469]; Gynecologic Oncology Group Statistical and Data Center [CA 37517]; NRG Oncology [1 U10 CA180822]; NRG Operations [U10 CA180868]; NCI Community Oncology Research Program (NCORP) [UG1 CA189867]; NATIONAL CANCER INSTITUTE [U10CA180798, U10CA180868, UG1CA189867, U10CA180822, UG1CA233193] Funding Source: NIH RePORTER	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Gynecologic Oncology Group Statistical and Data Center; NRG Oncology; NRG Operations; NCI Community Oncology Research Program (NCORP); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by grants from the National Cancer Institute (NCI) to the Gynecologic Oncology Group Administrative Office (CA 27469), the Gynecologic Oncology Group Statistical and Data Center (CA 37517), NRG Oncology (1 U10 CA180822), NRG Operations (U10 CA180868), and the NCI Community Oncology Research Program (NCORP) (UG1 CA189867).	AALDERS J, 1980, OBSTET GYNECOL, V56, P419; Alektiar KM, 2009, GYNECOL ONCOL, V112, P142, DOI 10.1016/j.ygyno.2008.10.006; Alektiar KM, 2002, INT J RADIAT ONCOL, V54, P79, DOI 10.1016/S0360-3016(02)02913-9; Blake P, 2009, LANCET, V373, P137, DOI 10.1016/S0140-6736(08)61767-5; Bruzzone M, 2004, GYNECOL ONCOL, V93, P345, DOI 10.1016/j.ygyno.2004.02.008; Creutzberg CL, 2000, LANCET, V355, P1404, DOI 10.1016/S0140-6736(00)02139-5; de Boer SM, 2018, LANCET ONCOL, V19, P295, DOI 10.1016/S1470-2045(18)30079-2; Fleming GF, 2004, J CLIN ONCOL, V22, P2159, DOI 10.1200/JCO.2004.07.184; Foerster R, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-141; Geller MA, 2011, GYNECOL ONCOL, V121, P112, DOI 10.1016/j.ygyno.2010.12.338; Greven K, 2006, GYNECOL ONCOL, V103, P155, DOI 10.1016/j.ygyno.2006.02.007; Havrilesky LJ, 2007, GYNECOL ONCOL, V104, P401, DOI 10.1016/j.ygyno.2006.08.027; Hogberg T, 2010, EUR J CANCER, V46, P2422, DOI 10.1016/j.ejca.2010.06.002; Homesley HD, 2009, GYNECOL ONCOL, V112, P543, DOI 10.1016/j.ygyno.2008.11.014; Keys HM, 2004, GYNECOL ONCOL, V92, P744, DOI 10.1016/j.ygyno.2003.11.048; Kiess AP, 2012, GYNECOL ONCOL, V127, P321, DOI 10.1016/j.ygyno.2012.07.112; Lewin SN, 2011, CLIN OBSTET GYNECOL, V54, P215, DOI 10.1097/GRF.0b013e3182185baa; Lu SM, 2015, GYNECOL ONCOL, V137, P28, DOI 10.1016/j.ygyno.2015.01.546; Maggi R, 2006, BRIT J CANCER, V95, P266, DOI 10.1038/sj.bjc.6603279; Mariani A, 2002, GYNECOL ONCOL, V87, P112, DOI 10.1006/gyno.2002.6789; Mariani A, 2002, GYNECOL ONCOL, V86, P38, DOI 10.1006/gyno.2002.6713; McMeekin DS, 2001, GYNECOL ONCOL, V82, P375, DOI 10.1006/gyno.2001.6278; McMeekin DS, 2001, GYNECOL ONCOL, V81, P273, DOI 10.1006/gyno.2001.6157; Meyer LA, 2015, J CLIN ONCOL, V33, P2908, DOI 10.1200/JCO.2015.62.5459; Miller D, 2012, GYNECOL ONCOL, V125, P771, DOI 10.1016/j.ygyno.2012.03.034; Mundt AJ, 2001, INT J RADIAT ONCOL, V50, P1145, DOI 10.1016/S0360-3016(01)01566-8; Mundt AJ, 2001, INT J RADIAT ONCOL, V50, P1154, DOI 10.1016/S0360-3016(01)01590-5; Nelson G, 1999, GYNECOL ONCOL, V75, P211, DOI 10.1006/gyno.1999.5569; Nout RA, 2010, LANCET, V375, P816, DOI 10.1016/S0140-6736(09)62163-2; Randall ME, 2006, J CLIN ONCOL, V24, P36, DOI 10.1200/JCO.2004.00.7617; Schorge JO, 1996, GYNECOL ONCOL, V63, P34, DOI 10.1006/gyno.1996.0274; Sood BM, 2003, INT J RADIAT ONCOL, V57, P208, DOI 10.1016/S0360-3016(03)00531-5; Stewart KD, 2002, INT J RADIAT ONCOL, V54, P527, DOI 10.1016/S0360-3016(02)02947-4; Susumu N, 2008, GYNECOL ONCOL, V108, P226, DOI 10.1016/j.ygyno.2007.09.029; Takeshima N, 2001, GYNECOL ONCOL, V82, P470, DOI 10.1006/gyno.2001.6301; Thigpen JT, 2004, J CLIN ONCOL, V22, P3902, DOI 10.1200/JCO.2004.02.088; Yost KJ, 2005, EVAL HEALTH PROF, V28, P172, DOI 10.1177/0163278705275340	37	188	195	5	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 13	2019	380	24					2317	2326		10.1056/NEJMoa1813181	http://dx.doi.org/10.1056/NEJMoa1813181			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IC9JQ	31189035	Green Accepted, Bronze			2023-01-03	WOS:000471299100010
J	Montgomery, JR; Cain-Nielsen, AH; Jenkins, PC; Regenbogen, SE; Hemmila, MR				Montgomery, John R.; Cain-Nielsen, Anne H.; Jenkins, Peter C.; Regenbogen, Scott E.; Hemmila, Mark R.			Prevalence and Payments for Traumatic Injury Compared With Common Acute Diseases by Episode of Care in Medicare Beneficiaries, 2008-2014	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Montgomery, John R.; Cain-Nielsen, Anne H.; Regenbogen, Scott E.; Hemmila, Mark R.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; [Jenkins, Peter C.] Indiana Univ, Dept Surg, Indianapolis, IN 46204 USA	University of Michigan System; University of Michigan; Indiana University System; Indiana University-Purdue University Indianapolis	Hemmila, MR (corresponding author), Univ Michigan Hlth Syst, Trauma Burn Ctr, 1B407 Univ Hosp,1500 E Med Ctr Dr,SPC 5033, Ann Arbor, MI 48109 USA.	mhemmila@umich.edu			Obesity Surgery Scientist Fellowship Award [T32-DK108740]; National Institute on Aging Mentored Career Development Award [K08-AG047252]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK108740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG047252] Funding Source: NIH RePORTER	Obesity Surgery Scientist Fellowship Award; National Institute on Aging Mentored Career Development Award; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Dr Montgomery is supported by Obesity Surgery Scientist Fellowship Award T32-DK108740, administered by the National Institute of Diabetes and Digestive and Kidney Diseases. Dr Regenbogen is supported by National Institute on Aging Mentored Career Development Award K08-AG047252.	American College of Surgeons, ACS TQIP GER TRAUM M; American College of Surgeons, NAT TRAUM DAT BANK 2; Colby SL, 2015, PROJECTIONS SIZE COM; DeGrauw X, 2016, J SAFETY RES, V56, P105, DOI 10.1016/j.jsr.2015.11.002; Hemmila MR, 2010, J TRAUMA, V68, P253, DOI 10.1097/TA.0b013e3181cfc8e6; Heron Melonie, 2018, Natl Vital Stat Rep, V67, P1	6	7	7	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2019	321	21					2129	2131		10.1001/jama.2019.1146	http://dx.doi.org/10.1001/jama.2019.1146			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IB3HN	31162560	Green Published, Bronze			2023-01-03	WOS:000470158700019
J	Thin, K; Prum, V; Johns, B				Thin, Kouland; Prum, Virak; Johns, Benjamin			The cost of HIV services at health facilities in Cambodia	PLOS ONE			English	Article								Background Donor funding for HIV/AIDS services is declining in Cambodia, and domestic resources need to be mobilized to sustain and expand these services. However, the cost of delivering HIV/AIDS services is not well studied in Cambodia. This study aims to assess the costs of delivering HIV/AIDS services, identify the major components of costs, and sources of funding. Methods Four of the six highest HIV burden provinces were selected at random for this study. Within each province, four health centers and two hospitals were selected for detailed data collection. A mix of top-down and bottom-up methods were used to assess the costs for HIV testing and antiretroviral therapy (ART) from the provider perspective. We assessed the differences in the quantity and prices of inputs between health facilities of the same type to identify cost-drivers. Results The average cost per visit for HIV testing was $8.92 at health centers and $14.03 at referral hospitals. Differences in the number of visits per staff were the primary determinant of differences in the cost per visit. First-line ART costed about $250 per patient per year, and the number of patients per staff was an important cost driver. Second-line ART costed from $500 to $716 per patient per year, on average, across the types of facilities, with the quantity and mix of second-line antiretroviral drugs being an important cost driver. Inpatient care at referral and provincial hospitals in total represented less than 2 percent of costs of outpatient ART. Discussion Costs are similar to neighboring countries, but over 50% of the costs of ART are financed by donors. Cambodia now is scaling up social health insurance coverage; the data from this study could serve as one input when setting reimbursement rates for HIV/AIDS services to help ensure that providers are adequately reimbursed for their services.	[Thin, Kouland] Swiss Dev Cooperat, Hlth Div, Phnom Penh, Cambodia; [Prum, Virak] Royal Univ Phnom Penh, Dept Geog, Phnom Penh, Cambodia; [Johns, Benjamin] ABT Associates Inc, Int Dev Div, Bethesda, MD USA	ABT Associates	Thin, K (corresponding author), Swiss Dev Cooperat, Hlth Div, Phnom Penh, Cambodia.	koulandthin@hotmail.com			United States Agency for International Development through the Health Finance and Governance Project [AID OAA-A-12-00080]	United States Agency for International Development through the Health Finance and Governance Project(United States Agency for International Development (USAID))	This study was funded by the United States Agency for International Development through the Health Finance and Governance Project (Cooperative Agreement No: AID OAA-A-12-00080). ABT Associates provided support in the form of salaries for authors KT and BJ. The staff at USAID provided comments on, for example, the sample design, although all final decisions were the responsibility of the authors. The funders did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Allinder SM, 2017, HIV INVESTMENT CAMBO; Anh DT, 2014, J ACQUIR IMMUNE DEFI; [Anonymous], 2004, MAN ACC SYST HOSP MA; Conteh L, 2004, HEALTH POLICY PLANN, V19, P127, DOI 10.1093/heapol/czh015; Dandona L, 2005, NATL MED J INDIA, V18, P26; Health Finance and Governance Project (HFG), 2017, CAMB 5 NAT AIDS SPEN; Ingun P., 2015, J THAI MED INFORM AS, V2, P137; Japan International Cooperation Agency (JICA) Global Link Management (GLM), 2016, DAT COLL SURV SOC HL; Kiet PHT, 2013, COSTING HIV AIDS SER; Menzies N, 2009, AIDS, V23, P395, DOI 10.1097/QAD.0b013e328321e40b; Ministry of Labour and Vacational Training (MLVT) and Ministry of Health (MoH), 2016, INT PRAK PROV PAYM M; Minstry of Health (MoH), 2006, NAT GUID COMPL PACK; Minstry of Health (MoH), 2008, NAT GUID MIN PACK AC; Minstry of Health (MoH), 2018, EST HLTH EXP CAMB NA; Nguyen QLT, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2464-0; Robin T, 2012, OXFORD POLICY MANAGE; Royal Government of Cambodia (RGC), 2016, NAT SOC PROT POL FRA; Samji H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081355; Slaymaker E, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.22789; Sweat M, 2000, LANCET, V356, P113, DOI 10.1016/S0140-6736(00)02447-8; UNAIDS, 2016, FAST TRACK UPD INV N; UNAIDS, 2017, GLOB AIDS UPD 2016; Vietnam Ministry of Health, 2021, INCR ACC TTREATM HIV; Ward WJ, 1994, HLTH CARE BUDGETING; Yi S, 2014, GLOBAL J MED PUBLIC, V3	25	3	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2019	14	5							e0216774	10.1371/journal.pone.0216774	http://dx.doi.org/10.1371/journal.pone.0216774			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IA1LO	31141514	Green Published, Green Submitted, gold			2023-01-03	WOS:000469323000022
J	Denham, AMJ; Wynne, O; Baker, AL; Spratt, NJ; Turner, A; Magin, P; Janssen, H; English, C; Loh, M; Bonevski, B				Denham, Alexandra M. J.; Wynne, Olivia; Baker, Amanda L.; Spratt, Neil J.; Turner, Alyna; Magin, Parker; Janssen, Heidi; English, Coralie; Loh, Madeleine; Bonevski, Billie			"This is our life now. Our new normal": A qualitative study of the unmet needs of carers of stroke survivors	PLOS ONE			English	Article							FAMILY CAREGIVERS; SUPPORT NEEDS; EXPERIENCES; INTERVENTION; INTERVIEWS; CONTINUUM	Many stroke survivors require care from informal carers such as family members and friends who may experience adverse impacts. This study aimed to qualitatively explore the unmet needs of carers of stroke survivors, and their preferences for interventions and support services. We conducted 24 semi-structured, qualitative interviews with carers of stroke survivors from the Hunter region, Australia. Inductive thematic analysis was used in the context of a needs-led framework to identify key themes of their unmet needs. Key unmet needs identified by carers of stroke survivors in this study centred on four main themes: (1) social relationships and support; (2) adequacy of information; (3) taking care of oneself; and (4) accessing appropriate services. Carers of stroke survivors desired the development of services which provide connectivity to information, training, education and community support; and inclusion in a community with social relationships and other carers of stroke survivors. Ongoing unmet needs often result in adverse health and quality of life outcomes for carers of stroke survivors. Co-designed programs and resources for carers, particularly relating to unmet needs in social, information, self-care and service access domains are needed.	[Denham, Alexandra M. J.; Wynne, Olivia; Baker, Amanda L.; Turner, Alyna; Magin, Parker; Loh, Madeleine; Bonevski, Billie] Univ Newcastle, Fac Hlth & Med, Sch Med & Publ Hlth, Callaghan, NSW, Australia; [Denham, Alexandra M. J.; Spratt, Neil J.; Janssen, Heidi; English, Coralie; Bonevski, Billie] Hunter Med Res Inst, Prior Res Ctr Stroke & Brain Injury, New Lambton Hts, NSW, Australia; [Spratt, Neil J.] Univ Newcastle, Fac Hlth & Med, Sch Biomed Sci & Pharm, Callaghan, NSW, Australia; [Spratt, Neil J.] John Hunter Hosp, Dept Neurol, Hunter New England Local Hlth Dist, New Lambton Hts, NSW, Australia; [Turner, Alyna] Deakin Univ, IMPACT Strateg Res Ctr, Sch Med, Barwon Hlth, Geelong, Vic, Australia; [Janssen, Heidi; English, Coralie] Univ Newcastle, Fac Hlth & Med, Sch Hlth Sci, Callaghan, NSW, Australia	University of Newcastle; Hunter Medical Research Institute; University of Newcastle; University of Newcastle; John Hunter Hospital; Deakin University; University of Newcastle	Denham, AMJ (corresponding author), Univ Newcastle, Fac Hlth & Med, Sch Med & Publ Hlth, Callaghan, NSW, Australia.; Denham, AMJ (corresponding author), Hunter Med Res Inst, Prior Res Ctr Stroke & Brain Injury, New Lambton Hts, NSW, Australia.	alexandra.denham@newcastle.edu.au	Baker, Amanda L/H-2966-2014; Spratt, Neil J/K-4208-2012; English, Coralie/D-4591-2009; Bonevski, Billie/G-7298-2013	Baker, Amanda L/0000-0002-3328-7146; Spratt, Neil J/0000-0002-9023-6177; English, Coralie/0000-0001-5910-7927; Denham, Alexandra/0000-0003-4512-3250; Bonevski, Billie/0000-0001-8505-622X; Janssen, Heidi/0000-0002-8612-0112; Turner, Alyna/0000-0001-7389-2546	Research Training Program (RTP), University of Newcastle PhD Scholarship; Hunter Medical Research Institute/Emlyn and Jennie Thomas Postgraduate Medical Research Scholarship; NHMRC [APP1135901, APP1063206]; National Health and Medical Research Council/National Heart Foundation Career Development/Future Leader Fellowship [APPS1110629/100827]; Faculty of Health and Medicine, University of Newcastle, Faculty of Health and Medicine Gladys M Brawn Career Development Fellowship	Research Training Program (RTP), University of Newcastle PhD Scholarship; Hunter Medical Research Institute/Emlyn and Jennie Thomas Postgraduate Medical Research Scholarship; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); National Health and Medical Research Council/National Heart Foundation Career Development/Future Leader Fellowship; Faculty of Health and Medicine, University of Newcastle, Faculty of Health and Medicine Gladys M Brawn Career Development Fellowship	AMJD is supported by a Research Training Program (RTP), University of Newcastle PhD Scholarship, https://www.newcastle.edu.au/and Hunter Medical Research Institute/Emlyn and Jennie Thomas Postgraduate Medical Research Scholarship, https://hmri.org.au/.ALB is supported by an NHMRC Senior Research Fellowship (APP1135901), https://nhmrc.gov.au/.NJS was the recipient of a co-funded National Health and Medical Research Council/National Heart Foundation Career Development/Future Leader Fellowship (APPS1110629/100827), https://nhmrc.gov.au/; https://www.heartfoundation.org.au/.BB is supported by an NHMRC Career Development Fellowship (APP1063206), https://nhmrc.gov.au/and a Faculty of Health and Medicine, University of Newcastle, Faculty of Health and Medicine Gladys M Brawn Career Development Fellowship, https://www.newcastle.edu.au/.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDERSON CS, 1995, STROKE, V26, P843, DOI 10.1161/01.STR.26.5.843; [Anonymous], 2018, NVIVO QUAL DAT AN SO; Australian Department of Health Services, 2018, DROP; Australian Government, CAR GAT 2018; Avent J, 2005, APHASIOLOGY, V19, P365, DOI 10.1080/02687030444000813; Bejot Y, 2016, RISING STROKE INCIDE; Berends L, 2005, ADDICT RES THEORY, V13, P373, DOI 10.1080/16066350500102237; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Bulley C, 2010, DISABIL REHABIL, V32, P1406, DOI 10.3109/09638280903531238; Buschenfeld K, 2009, DISABIL REHABIL, V31, P1643, DOI 10.1080/09638280902736338; Cameron JI, 2012, STROKE, V43, pE143; Cameron JI, 2008, PATIENT EDUC COUNS, V70, P305, DOI 10.1016/j.pec.2007.10.020; Cameron JI, 2013, DISABIL REHABIL, V35, P315, DOI 10.3109/09638288.2012.691937; Cancer Council, CAR SOME CANC CANC 2; Carers NSW, 2018, CAR NSW 2018 CAR SUR; Carers UK, 2018, STAT CAR 2018; Cecil R, 2013, J ADV NURS, V69, P1761, DOI 10.1111/jan.12037; Chow C, 2014, J ADULT PROT, V16, P276, DOI 10.1108/JAP-03-2014-0007; Cobley CS, 2013, CLIN REHABIL, V27, P750, DOI 10.1177/0269215512474030; Deloitte Access Economics, 2013, EC IMP STROK AUSTR; Garrett Dawne, 2005, Nurs Older People, V17, P14; Gillespie D, 2011, NURSING STANDARD, V26; Giorgi A, 2012, J PHENOMENOLOGICAL P, V43, P3, DOI [10.1163/156916212X632934, DOI 10.1163/156916212X632934]; Greenwood N, 2010, MATURITAS, V66, P268, DOI 10.1016/j.maturitas.2010.03.017; Greenwood N, 2009, INT J NURS STUD, V46, P1122, DOI 10.1016/j.ijnurstu.2009.02.011; Greenwood N, 2009, DISABIL REHABIL, V31, P337, DOI 10.1080/09638280802051721; Han B, 1999, STROKE, V30, P1478, DOI 10.1161/01.STR.30.7.1478; International Alliance of Carer Organizations, CAR FACTS 2017; International Alliance of Carer Organzations, 2018, GLOB STAT CAR; Kumar R., 2016, ADV PRACTICE NURS, V1, P2; Lifeline Australia, LIF 2018; Luker J, 2017, ARCH PHYS MED REHAB, V98, P1852, DOI 10.1016/j.apmr.2017.02.024; McKevitt C, 2004, STROKE, V35, P1499, DOI 10.1161/01.STR.0000127532.64840.36; National Academies of Sciences E and Medicine, 2016, 5 PROGR SUPP FAM CAR; Ocloo J, 2016, BMJ QUAL SAF, V25, P626, DOI 10.1136/bmjqs-2015-004839; Paul R, 2007, J DEV ED, V31, P36, DOI DOI 10.1007/S10804-014-9190-1; Pini S, 2017, GERONTOLOGIST; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Visser-Meily A, 2005, PATIENT EDUC COUNS, V56, P257, DOI 10.1016/j.pec.2004.02.013; White CL., 2015, CLIN NURS STUD, V3, P87, DOI DOI 10.5430/CNS.V3N3P87; Willig C., 2001, QUALITATIVE PSYCHOL	41	9	10	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 8	2019	14	5							e0216682	10.1371/journal.pone.0216682	http://dx.doi.org/10.1371/journal.pone.0216682			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HX4MT	31067286	Green Published, gold			2023-01-03	WOS:000467373000058
J	Kemp, L; Bruce, T; Elcombe, EL; Anderson, T; Vimpani, G; Price, A; Smith, C; Goldfeld, S				Kemp, Lynn; Bruce, Tracey; Elcombe, Emma L.; Anderson, Teresa; Vimpani, Graham; Price, Anna; Smith, Charlene; Goldfeld, Sharon			Quality of delivery of"right@home": Implementation evaluation of an Australian sustained nurse home visiting intervention to improve parenting and the home learning environment	PLOS ONE			English	Article							CHILD MALTREATMENT; VISITATION PROGRAM; ATTRITION; FIDELITY; ENGAGEMENT; OUTCOMES; HEALTH	Background Home visiting programs are implemented in high income countries to improve outcomes for families with young children. Significant resources are invested in such programs and high quality evaluations are important. In the context of research trials, implementation quality is often poorly reported and, when reported, is variable. This paper presents the quality of implementation of the right@home program, a sustained nurse home visiting intervention trialled in Australia, and delivered in a 'real world' context through usual child and family health services. right@home is structured around the core Maternal Early Childhood Sustained Home-visiting (MECSH) program, which is a salutogenic, child focused prevention model. Method At each visit right@home practitioners completed a checklist detailing the client unique identifier, date of contact and activities undertaken. These checklists were collated to provide data on intervention dose, retention to program completion at child age 2 years, and visit content, which were compared with the program schedule. Quality of family-provider relationship was measured using the Session Rating Scale. Exploratory factor analysis was conducted to identify clusters of activities and allow qualitative assessment of concordance between program aims and program delivery. Results Of 363 intervention families offered the program, 352 (97.0%) commenced the program and 304 (87.3%) completed the program to child age 2 years. 253 of 352 (71.9%) families who commenced the program received more than 75 percent of scheduled visits including at least one antenatal visit. Families rated the participant-practitioner relationship highly (mean 39.4/40). The factor analysis identified six antenatal and six postnatal components which were concordant with the program aims. Conclusions The right@home program was delivered with higher adherence to program dose, schedule and content, and retention than usually reported in other home visiting research. Program compliance may have resulted from program design (visit schedule, dose, content and delivery flexibility) that was consistent with family aims.	[Kemp, Lynn; Bruce, Tracey; Elcombe, Emma L.] Western Sydney Univ, Sch Nursing & Midwifery, Ingham Inst Appl Med Res, Liverpool, NSW, Australia; [Anderson, Teresa] Sydney Local Hlth Dist, Camperdown, NSW, Australia; [Vimpani, Graham] Univ Newcastle, Community Child & Family Hlth, Reg & Rural Hlth Serv, Hunter New England Local Hlth Dist, New Lambton, NSW, Australia; [Price, Anna; Goldfeld, Sharon] Royal Childrens Hosp, Ctr Community Child Hlth, Parkville, Vic, Australia; [Price, Anna; Goldfeld, Sharon] Murdoch Childrens Res Inst, Populat Hlth, Parkville, Vic, Australia; [Price, Anna; Goldfeld, Sharon] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia; [Smith, Charlene] Australian Res Alliance Children & Youth, Canberra, ACT, Australia	Ingham Institute for Applied Medical Research; Western Sydney University; University of Newcastle; Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; University of Melbourne	Kemp, L (corresponding author), Western Sydney Univ, Sch Nursing & Midwifery, Ingham Inst Appl Med Res, Liverpool, NSW, Australia.	lynn.kemp@westernsydney.edu.au		Goldfeld, Sharon/0000-0001-6520-7094; Kemp, Lynn/0000-0002-0348-1837; Price, Anna/0000-0002-8117-8059	Victorian Department of Education and Training; Tasmanian Department of Health and Human Services; Ian Potter Foundation; Sabemo Trust; Sidney Myer Fund; Vincent Fairfax Family Foundation; National Health and Medical Research Council (NHMRC) [1079418]	Victorian Department of Education and Training; Tasmanian Department of Health and Human Services; Ian Potter Foundation; Sabemo Trust; Sidney Myer Fund; Vincent Fairfax Family Foundation; National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia)	This work is supported by the Victorian Department of Education and Training, the Tasmanian Department of Health and Human Services, the Ian Potter Foundation, Sabemo Trust, Sidney Myer Fund, the Vincent Fairfax Family Foundation, and the National Health and Medical Research Council (NHMRC, 1079418). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson T, 1997, LEARNING TO COMMUNIC; [Anonymous], 2014, MAKING REPLICATION W; Australian Government Department of Health, 2009, GET GROW HLTH EAT PH; Avellar SA, 2013, PEDIATRICS, V132, pS90, DOI 10.1542/peds.2013-1021G; Azzi-Lessing L, 2011, EARLY CHILD RES Q, V26, P387, DOI 10.1016/j.ecresq.2011.03.005; Biggs J, 2018, CHILD YOUTH SERV REV, V94, P56, DOI 10.1016/j.childyouth.2018.09.021; Brand T, 2014, EARLY CHILD RES Q, V29, P155, DOI 10.1016/j.ecresq.2013.12.001; Buehlman, 2008, PROMOTING 1 RELATION; Casillas KL, 2016, CHILD ABUSE NEGLECT, V53, P64, DOI 10.1016/j.chiabu.2015.10.009; Damashek A, 2011, CHILD MALTREATMENT, V16, P9, DOI 10.1177/1077559510388507; Daro D., 2009, EMBEDDING HOME VISIT; Daro D, 2014, IMPLEMENTATION FIDEL; Davis H, 2010, WORKING PARTNERSHIP; Duncan B.L., 2003, J BRIEF THERAPY, V3, P3; Filene JH, 2013, PEDIATRICS, V132, pS100, DOI 10.1542/peds.2013-1021H; Goldberg J, 2016, EVAL PROGRAM PLANN, V55, P163, DOI 10.1016/j.evalprogplan.2015.12.007; Goldfeld S, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-1206; Goldfeld S, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013307; Gomby DS, 2007, CHILD ABUSE NEGLECT, V31, P793, DOI 10.1016/j.chiabu.2007.07.001; Gomby DS, 1999, FUTURE CHILD, V9, P27, DOI 10.2307/1602720; Hiscock H, 2007, ARCH DIS CHILD, V92, P952, DOI 10.1136/adc.2006.099812; Holland ML, 2014, JOGNN-J OBST GYN NEO, V43, P61, DOI 10.1111/1552-6909.12263; Kemp L, 2012, MATERNAL EARLY CHILD; Kemp L, 2016, PREV SCI, V17, P429, DOI 10.1007/s11121-016-0642-7; Kemp L, 2011, ARCH DIS CHILD, V96, P533, DOI 10.1136/adc.2010.196279; Kidsafe Child Accident Prevention Foundation of Australia, HOM SAF CHECKL 2016; Korfmacher J, 2007, INFANT MENT HEALTH J, V28, P459, DOI 10.1002/imhj.20148; Latimore AD, 2017, PREV SCI, V18, P577, DOI 10.1007/s11121-017-0767-3; McKelvey LM, 2018, MATERN CHILD HLTH J, V22, P33, DOI 10.1007/s10995-018-2533-y; McNaughton DB, 2004, PUBLIC HEALTH NURS, V21, P207, DOI 10.1111/j.0737-1209.2004.021303.x; Moore TG., 2012, SUSTAINED HOME VISIT; Mowbray CT, 2003, AM J EVAL, V24, P315, DOI 10.1177/109821400302400303; Parenting Research Centre, EARL HOM LEARN STUD; Paulsell D, 2014, AM J PUBLIC HEALTH, V104, P1624, DOI 10.2105/AJPH.2014.301962; Price A, 2019, WOMEN BIRTH, V32, pE351, DOI 10.1016/j.wombi.2018.08.162; Price AMH, 2017, J PAEDIATR CHILD H, V53, P572, DOI 10.1111/jpc.13510; Robling M, 2016, LANCET, V387, P146, DOI 10.1016/S0140-6736(15)00392-X; Saias T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036915; Segal L, 2012, MILBANK Q, V90, P47, DOI 10.1111/j.1468-0009.2011.00655.x; Sweet MA, 2004, CHILD DEV, V75, P1435, DOI 10.1111/j.1467-8624.2004.00750.x; Tabachnick B. G., 2007, USING MULTIVARIATE S, V5, P481	41	12	12	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2019	14	5							e0215371	10.1371/journal.pone.0215371	http://dx.doi.org/10.1371/journal.pone.0215371			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HW7RE	31059504	Green Published, gold			2023-01-03	WOS:000466886300008
J	Haddadin, RN; Alsous, M; Wazaify, M; Tahaineh, L				Haddadin, Randa N.; Alsous, Mervat; Wazaify, Mayyada; Tahaineh, Linda			Evaluation of antibiotic dispensing practice in community pharmacies in Jordan: A cross sectional study	PLOS ONE			English	Article							SELF-MEDICATION; ANTIMICROBIAL RESISTANCE; MISUSE; PRESCRIPTION; CRISIS; IMPACT; DRUGS; ABUSE	It is well known that the emergence of antibiotic resistance is linked to the misuse and overuse of antibiotics. Misuse includes self-medication and the inappropriate use of antibiotics because of improper dosage or improper duration than recommended. This study investigated three patterns of dispensing antibiotics in a sample of community pharmacies in Jordan. This included dispensing antibiotics by prescription or over-the-counter either by direct request or upon a pharmacist's recommendation. The antibiotics dispensed were evaluated in terms of indication, appropriateness of dose, and duration of treatment based on the empirical treatment suggested by selected references: Lexicomp (2017) and UptoDate (2017) and the manufacturer's recommendations. Of the 457 antibiotics dispensed, almost one third were without prescription. Of the antibiotics dispensed with prescription or without prescription, 31.5% and 24.6% respectively were appropriate dosage and duration (p = 0.002). In the three patterns of dispensing, beta lactam antibiotics were the most commonly dispensed. In addition, it was noticed that there was a tendency to prescribe or dispense higher generations of antibiotics to cases that could have been treated with lower generation or safer antibiotics. Furthermore, 12.2% of the antibiotics were dispensed to treat infections that are not indicated for them. In conclusion, a significant proportion of antibiotics are dispensed without prescription in Jordan. Moreover, a considerable proportion of prescribed antibiotics were inappropriate for the conditions concerned. This indicates the importance of enforcing the Jordanian regulations prohibiting the dispensing of nonprescription antibiotics and the implementation of continuous education to physicians and pharmacists to increase awareness about the emergence of antibiotic resistance.	[Haddadin, Randa N.] Univ Jordan, Sch Pharm, Pharmaceut & Pharmaceut Technol Dept, Amman, Jordan; [Alsous, Mervat] Yarmouk Univ, Sch Pharm, Dept Pharm Practice, Irbid, Jordan; [Wazaify, Mayyada] Univ Jordan, Sch Pharm, Clin Pharmm Dept, Amman, Jordan; [Tahaineh, Linda] Jordan Univ Sci & Technol, Clin Pharm Dept, Fac Pharm, Irbid, Jordan	University of Jordan; Yarmouk University; University of Jordan; Jordan University of Science & Technology	Haddadin, RN (corresponding author), Univ Jordan, Sch Pharm, Pharmaceut & Pharmaceut Technol Dept, Amman, Jordan.	r_haddadin@ju.edu.jo	Haddadin, Randa N/O-7565-2019; Alsous, Mervat/AAF-2470-2019; Wazaify, Mayyada/E-5910-2016	Haddadin, Randa N/0000-0002-1214-0129; Wazaify, Mayyada/0000-0001-8724-6027				Adorka M, 2014, J PUBLIC HEALTH AFR, V5, P57, DOI [10.4081/jphia.2014.354, 10.4081/jphia.2014.3549]; Albsoul-Younes A, 2010, SUBST USE MISUSE, V45, P1319, DOI 10.3109/10826080802490683; Burjaq S.Z., 2013, INT ARAB J ANTIMICRO, V3, P1; COLLIER P, 2018, J APPL MICROBIOL, V125, P308, DOI DOI 10.1111/JAM; Dror DM, 2016, INDIAN J MED RES, V143, P809, DOI 10.4103/0971-5916.192075; Emam D, 2016, THE JORDAN TIMES, P22; Ganguly NK, 2011, INDIAN J MED RES, V134, P281; Ghanem B, 2018, ANTIMICROB RESIST IN, V7, DOI 10.1186/s13756-018-0339-8; Grigoryan L, 2006, EMERG INFECT DIS, V12, P452, DOI 10.3201/eid1203.050992; Grigoryan L, 2008, J ANTIMICROB CHEMOTH, V61, P1172, DOI 10.1093/jac/dkn054; Lexicomp, 2017, DRUG INF HDB CLIN RE; Michael CA, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00145; O'Neill J., 2016, Review on antimicrobial resistance: tackling drug-resistant infections globally: final report and recommendations; Pope C, 2002, QUAL SAF HEALTH CARE, V11, P148, DOI 10.1136/qhc.11.2.148; Rather IA, 2017, SAUDI J BIOL SCI, V24, P808, DOI 10.1016/j.sjbs.2017.01.004; Sabry NA, 2014, RES SOC ADMIN PHARM, V10, P168, DOI 10.1016/j.sapharm.2013.03.004; Shah SJ, 2014, BMC PHARMACOL TOXICO, V15, DOI 10.1186/2050-6511-15-74; Shehabi AA, 2006, J CHEMOTHERAPY, V18, P468, DOI 10.1179/joc.2006.18.5.468; Shehadeh M, 2012, SAUDI PHARM J, V20, P125, DOI 10.1016/j.jsps.2011.11.005; Van Katwyk SR, 2018, HUM RESOUR HEALTH, V16, DOI 10.1186/s12960-018-0270-3; Vazquez-Lago J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015674; Wazaify M, 2017, J SUBST USE, V22, P656, DOI 10.1080/14659891.2016.1271041; Wazaify M, 2017, J SUBST USE, V22, P463, DOI 10.1080/14659891.2016.1235734; WHO,, 2020, WHO ANT RES; World Health Organization, 2001, WHO GLOBAL STRATEGY; World Health Organization, 2018, ANT RES; World Health Organization (WHO), 2018, WEIGHT FOR AG GIRLS; World Health Organization (WHO), 2018, WEIGHT FOR AG BOYS B; World Health Organization (WHO), 2015, WHO RAT US MED; Yousef AMM, 2008, PHARM WORLD SCI, V30, P24, DOI 10.1007/s11096-007-9135-x; Zoorob R, 2016, ANTIMICROB AGENTS CH, V60, P5527, DOI 10.1128/AAC.00528-16; 2006, HLTH POLICY NEW YORK, V75, P170, DOI DOI 10.1016/J.HEALTHPOL.2005.03.007	32	32	32	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2019	14	4							e0216115	10.1371/journal.pone.0216115	http://dx.doi.org/10.1371/journal.pone.0216115			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV6ZL	31034528	Green Published, Green Submitted, gold			2023-01-03	WOS:000466131200036
J	Stevens, ER; Nucifora, KA; Irvine, MK; Penrose, K; Robertson, M; Kulkarni, S; Robbins, R; Abraham, B; Nash, D; Braithwaite, RS				Stevens, Elizabeth R.; Nucifora, Kimberly A.; Irvine, Mary K.; Penrose, Katherine; Robertson, McKaylee; Kulkarni, Sarah; Robbins, Rebekkah; Abraham, Bisrat; Nash, Denis; Braithwaite, R. Scott			Cost-effectiveness of HIV care coordination scale-up among persons at high risk for sub-optimal HIV care outcomes	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; VIRAL LOAD; PREVALENCE; INFECTION; RETENTION; HIV/AIDS; SUPPRESSION; ADHERENCE; PEOPLE	Background A study of a comprehensive HIV Care Coordination Program (CCP) showed effectiveness in increasing viral load suppression (VLS) among PLWH in New York City (NYC). We evaluated the cost-effectiveness of a scale-up of the CCP in NYC. Methods We incorporated observed effects and costs of the CCP into a computer simulation of HIV in NYC, comparing strategy scale-up with no implementation. The simulation combined a deterministic compartmental model of HIV transmission with a stochastic microsimulation of HIV progression, and was calibrated to NYC HIV epidemiological data from 1997 to 2009. We assessed incremental cost-effectiveness from a health sector perspective using 2017 $US, a 20-year time horizon, and a 3% annual discount rate. We explored two scenarios: (1) two-year average enrollment and (2) continuous enrollment. Results In scenario 1, scale-up resulted in a cost-per-infection-averted of $898,104 and a cost-perQALY-gained of $423,721. In sensitivity analyses, scale-up achieved cost-effectiveness if effectiveness increased from RR1.11 to RR1.37 or costs decreased by 41.7%. Limiting the intervention to persons with unsuppressed viral load prior to enrollment (RR1.32) attenuated the cost reduction necessary to 11.5%. In scenario 2, scale-up resulted in a cost-per-infection- averted of $705,171 and cost-per-QALY-gained of $720,970. In sensitivity analyses, scale-up achieved cost-effectiveness if effectiveness increased from RR1.11 to RR1.46 or program costs decreased by 71.3%. Limiting the intervention to persons with unsuppressed viral load attenuated the cost reduction necessary to 38.7%. Conclusion Cost-effective CCP scale-up would require reduced costs and/or focused enrollment within NYC, but may be more readily achieved in cities with lower background VLS levels.	[Stevens, Elizabeth R.; Nucifora, Kimberly A.; Braithwaite, R. Scott] NYU, Sch Med, Dept Populat Hlth, New York, NY 10003 USA; [Irvine, Mary K.; Penrose, Katherine; Robbins, Rebekkah; Abraham, Bisrat] New York City Dept Hlth & Mental Hyg, Bur HIV AIDS Prevent & Control, New York, NY USA; [Robertson, McKaylee; Kulkarni, Sarah; Nash, Denis] CUNY, Inst Implementat Sci Populat Hlth, New York, NY 10021 USA; [Robertson, McKaylee; Nash, Denis] CUNY, Sch Publ Hlth, Dept Epidemiol & Biostat, New York, NY 10021 USA	New York University; New York City Department of Health & Mental Hygiene; City University of New York (CUNY) System; City University of New York (CUNY) System	Stevens, ER (corresponding author), NYU, Sch Med, Dept Populat Hlth, New York, NY 10003 USA.	Elizabeth.stevens@nyumc.org	Nash, Denis/AFI-7485-2022; Robertson, McKaylee/GLU-4343-2022	Robertson, McKaylee/0000-0002-8426-6572; Stevens, Elizabeth R./0000-0001-6063-1523; Nash, Denis/0000-0002-3280-5386; Braithwaite, Ronald Scott/0000-0001-7067-3655	National Institute of Mental Health (NIMH) [R01 MH101028]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH101028] Funding Source: NIH RePORTER	National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was funded by a grant from the National Institute of Mental Health (NIMH), grant number R01 MH101028. The grant was received by Mary Irvine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adimora AA, 2007, AM J PUBLIC HEALTH, V97, P2230, DOI 10.2105/AJPH.2006.099069; Aidala AA, 2016, AM J PUBLIC HEALTH, V106, pE1, DOI 10.2105/AJPH.2015.302905; Attia S, 2009, AIDS, V23, P1397, DOI 10.1097/QAD.0b013e32832b7dca; Bradley H, 2014, MMWR-MORBID MORTAL W, V63, P1113; Brady JE, 2008, J URBAN HEALTH, V85, P323, DOI 10.1007/s11524-007-9248-5; CDC (Centers for Disease Control and Prevention), 2021, MONITORING SELECTED; Celentano DD, 2007, CLIN INFECT DIS, V45, pS318, DOI 10.1086/522557; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Das M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011068; Dawson-Rose C, 2017, J ASSOC NURSE AIDS C, V28, P238, DOI 10.1016/j.jana.2015.12.001; Giordano TP, 2007, CLIN INFECT DIS, V44, P1493, DOI 10.1086/516778; Higa DH, 2012, CURR HIV-AIDS REP, V9, P313, DOI 10.1007/s11904-012-0136-6; Hughes E, 2016, LANCET PSYCHIAT, V3, P40, DOI 10.1016/S2215-0366(15)00357-0; International Advisory Panel on HIV Care Continuum Optimization, 2015, J Int Assoc Provid AIDS Care, V14 Suppl 1, pS3, DOI 10.1177/2325957415613442; Irvine MK, 2015, CLIN INFECT DIS, V60, P298, DOI 10.1093/cid/ciu783; Kessler J, 2014, EVALUATING IMPACT PR; Kessler J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073269; Lingappa JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012598; Machtinger EL, ADHERENCE HIV ANTIRE; Mahrer-Imhof R, 2002, HEART LUNG, V31, P368, DOI 10.1067/mhl.2002.126539; Mannheimer S, 2002, CLIN INFECT DIS, V34, P1115, DOI 10.1086/339074; Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1; Morin SF, 2011, JAIDS-J ACQ IMM DEF, V57, P175, DOI 10.1097/QAI.0b013e318222c0f9; Mosher William D., 2005, ADV DATA VITAL HLTH, P362, DOI DOI 10.1037/E609202007-001; Mugavero MJ, 2009, CLIN INFECT DIS, V48, P248, DOI 10.1086/595705; Neumann PJ, 2014, NEW ENGL J MED, V371, P796, DOI 10.1056/NEJMp1405158; New York City Department of Health and Mental Hygiene, HIV CAR COORD; New York City Department of Health and Mental Hygiene, COMM HLTH SURV 2009; New York City Department of Health and Mental Hygiene, 2016, CAR CLIN STAT PEOPL; New York City Department of Health and Mental Hygiene, HIV RISK PREV NEW YO; New York City Department of Health and Mental Hygiene Bureau of HIV/AIDS Prevention and Control Care and Treatment Program, 2017, CAR COORD PEOPL HIV; New York City Department of Mental Health and Hygiene, VIT STAT 2009; New York State Department of Health, BLUEPR END EP 2015; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Robertson MM, 2019, JAIDS-J ACQ IMM DEF, V80, P46, DOI 10.1097/QAI.0000000000001877; Robertson MM, 2018, AM J EPIDEMIOL, V187, P1980, DOI 10.1093/aje/kwy103; Salcuni P, 2017, ID WEEK         0202; Sanders GD, 2005, NEW ENGL J MED, V352, P570, DOI 10.1056/NEJMsa042657; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; Simoni Jane M, 2010, Curr HIV/AIDS Rep, V7, P44, DOI 10.1007/s11904-009-0037-5; Solem CT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098152; TOKARS JI, 1993, ANN INTERN MED, V118, P913, DOI 10.7326/0003-4819-118-12-199306150-00001; Torian LV, 2014, AM J PUBLIC HEALTH, V104, pE24, DOI 10.2105/AJPH.2014.302080; Wunsch-Hitzig R, 2003, PREVALENCE COST ESTI; XIA Q, 2016, J ACQ IMMUN DEF SYND, V73, pE5, DOI DOI 10.1097/QAI; Zaragoza-Macias E, 2010, AIDS RES HUM RETROV, V26, P133, DOI 10.1089/aid.2009.0001; 2007, ANN INTERN MED, V146, P564, DOI DOI 10.7326/0003-4819-146-8-200704170-00007; 1994, ANN INTERN MED, V121, P847, DOI DOI 10.7326/0003-4819-121-11-199412010-00004; 2012, ANN INTERN MED, V156, P817, DOI DOI 10.7326/0003-4819-156-11-201206050-00419; 2017, AIDS BEHAV, V21, P1572, DOI DOI 10.1007/S10461-016-1460-4; AIDS, V14, P357	51	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2019	14	4							e0215965	10.1371/journal.pone.0215965	http://dx.doi.org/10.1371/journal.pone.0215965			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HU8EY	31022280	Green Published, gold, Green Submitted			2023-01-03	WOS:000465519100074
J	Lucey, CR; Jones, L; Eastburn, A				Lucey, Catherine R.; Jones, Lee; Eastburn, Abigail			A Lethal Hidden Curriculum - Death of a Medical Student from Opioid Use Disorder	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Lucey, Catherine R.; Eastburn, Abigail] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA; [Jones, Lee] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lucey, CR (corresponding author), Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA.			Lucey, Catherine/0000-0002-8345-2795				Jalal H, 2018, SCIENCE, V361, P1218, DOI 10.1126/science.aau1184; McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689; Merlo LJ, 2011, J ADDICT MED, V5, P279, DOI 10.1097/ADM.0b013e31821852a0; Schuckit MA, 2016, NEW ENGL J MED, V375, P357, DOI 10.1056/NEJMra1604339; Warner DO, 2013, JAMA-J AM MED ASSOC, V310, P2289, DOI 10.1001/jama.2013.281954	5	4	4	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 29	2019	381	9					793	795		10.1056/NEJMp1901537	http://dx.doi.org/10.1056/NEJMp1901537			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IV7FE	31461592				2023-01-03	WOS:000484431200004
J	Islam, MM; Wollersheim, D				Islam, M. Mofizul; Wollersheim, Dennis			A comparison of opioids and benzodiazepines dispensing in Australia	PLOS ONE			English	Article							DRUG-MONITORING PROGRAM; PAIN; MISUSE; ABUSE	Background Inappropriate utilization of prescription opioids and benzodiazepines is a public health problem. This study examined and compared user-types and trends in dispensing of these medicines, and identified associated factors related to the duration of dispensing in Australia. Methods A random 10% sample of unit-record data of opioids and benzodiazepines dispensed nationally during 2013-2016 was analyzed. Users were categorized into four types: single quarter (i.e., three months), medium-episodic (dispensed 2-6 quarters), long-episodic (dispensed 7-11 quarters), chronic (dispensed 12-16 quarters). Dispensing quantity was computed in defined daily dose (DDD). Generalized multilevel ordinal models were developed to examine the factors associated with the duration of dispensing. Results There were similarities in terms of trends of dispensing of opioids and benzodiazepines in Australia. Overall, more people were dispensed opioids than benzodiazepines. Around 52% of opioids users and 46% of benzodiazepines users were dispensed these medicines for a single quarter. However, chronic users were dispensed 60% of opioids and 50% of benzodiazepines in DDD/1000 people/day, respectively. On average, 16.6 DDD/1000 people/day of opioids and 14.2 DDD/1000 people/day of benzodiazepines were dispensed in Australia during the study period. Tasmania was dispensed the highest quantity (in DDD/1000 people/day) of these medicines, followed by South Australia and Queensland. Women compared to men, and clients of age-group 20-44, 45-64 and 65+ compared to age-group 0-19, were significantly more likely to have dispensed opioids/benzodiazepine for a relatively long duration. Clients with a history of dispensing of one of these two medicines were significantly more likely to have dispensed the other for a relatively long period. Conclusions There were similarities in patterns of dispensing of opioids and benzodiazepines in terms of user characteristics and structural variables. Consistent use of real-time drug monitoring program and tailored intervention are recommended.	[Islam, M. Mofizul] La Trobe Univ, Dept Publ Hlth, Melbourne, Vic, Australia; [Wollersheim, Dennis] La Trobe Univ, Dept Publ Hlth, Hlth Informat Management, Melbourne, Vic, Australia	La Trobe University; La Trobe University	Islam, MM (corresponding author), La Trobe Univ, Dept Publ Hlth, Melbourne, Vic, Australia.	mofi.islam@latrobe.edu.au	Islam, M Mofizul/E-8160-2012	Islam, M Mofizul/0000-0003-1330-863X	La Trobe University	La Trobe University	This study received funding from La Trobe University's "Building Healthy Communities" Research Focus Area for paying the cost of the dataset.	Abbasi J, 2016, JAMA-J AM MED ASSOC, V316, P2343, DOI 10.1001/jama.2016.15029; Alessi-Severini S, 2016, PSYCHIAT SERV, V67, P1012, DOI 10.1176/appi.ps.201500380; Australian Government Department of Health, 2014, AUSTR STAT MED 2011; Australian Institute of Health and Welfare, 2017, AUSTR I HLTH WELF DR, V30; Berecki-Gisolf J, 2016, PAIN MED, V17, P304, DOI 10.1111/pme.12890; Boudreau D, 2009, PHARMACOEPIDEM DR S, V18, P1166, DOI 10.1002/pds.1833; Campbell G, 2019, MED J AUSTRALIA, V210, P6, DOI 10.5694/mja2.12047; Caughey GE, 2019, MED J AUSTRALIA, V210, P39, DOI 10.5694/mja2.12026; Chan GCK, 2019, DRUG ALCOHOL REV, V38, P151, DOI 10.1111/dar.12893; Currow DC, 2016, MED J AUSTRALIA, V204, P305, DOI 10.5694/mja16.00066; Dasgupta N, 2018, AM J PUBLIC HEALTH, V108, P182, DOI 10.2105/AJPH.2017.304187; Davies J, 2017, BRIT J GEN PRACT, V67, pE609, DOI 10.3399/bjgp17X691865; Day C, 2019, RES SOCIAL ADM PHARM; Degenhardt L, 2013, DRUG ALCOHOL REV; Department of Health and Human Services Tasmania, 2017, PHARM SERV BRANCH DA; Department of Infrastructure and Regional Development (DIRD), 2015, LOC GOV NAT REP 2013; Deyo RA, 2018, J PAIN, V19, P166, DOI 10.1016/j.jpain.2017.10.001; Fischer B, 2014, DRUG ALCOHOL REV, V33, P19, DOI 10.1111/dar.12089; Gisev N, 2018, PHARMACOEPIDEM DR S, V27, P550, DOI 10.1002/pds.4329; Gomes T, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3207; Graaff Bd, 2012, AUSTR DRUG TRENDS SE, V77; Hadlandsmyth K, 2018, J GEN INTERN MED, V33, P818, DOI 10.1007/s11606-017-4283-8; Hall WD, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002626; Hollingworth SA, 2013, AUST NZ J PUBL HEAL, V37, P132, DOI 10.1111/1753-6405.12030; Islam MM, 2019, J CLIN MED, V8, DOI 10.3390/jcm8030293; Islam MM, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11040116; Islam MM, 2018, BMC PHARMACOL TOXICO, V19, DOI 10.1186/s40360-018-0219-0; Kennedy-Hendricks A, 2016, AM J PUBLIC HEALTH, V106, P291, DOI 10.2105/AJPH.2015.302953; Kovitwanichkanont T, 2018, SUBST USE MISUSE, V53, P200, DOI 10.1080/10826084.2017.1305415; Levine M, 2018, ANN INTERN MED, V169, P712, DOI 10.7326/M18-1757; Mazumdar Soumya, 2015, Curr Drug Abuse Rev, V8, P104; Morley KI, 2017, PAIN, V158, P1138, DOI 10.1097/j.pain.0000000000000892; Nielsen S, 2011, DRUG ALCOHOL REV, V30, P233, DOI 10.1111/j.1465-3362.2011.00326.x; Novak SP, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0909-3; Nuckols TK, 2014, ANN INTERN MED, V160, P38, DOI 10.7326/0003-4819-160-1-201401070-00732; Ogeil RP, 2016, MED J AUSTRALIA, V204, P148, DOI 10.5694/mja15.00929; Pain Australia, 2019, REAL TIM MON AH; PEACOCK A, 2018, AUSTR DRUG TRENDS 20; Raebel MA, 2013, JAMA-J AM MED ASSOC, V310, P1369, DOI 10.1001/jama.2013.278344; Russolillo A, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002625; Schaffer AL, 2016, JAMA INTERN MED, V176, P1223, DOI 10.1001/jamainternmed.2016.2992; Schnell M, 2018, AM J HEALTH ECON, V4, P383, DOI 10.1162/ajhe_a_00113; Shah A, 2017, MMWR-MORBID MORTAL W, V66, P265, DOI 10.15585/mmwr.mm6610a1; Shand FL, 2013, MED J AUSTRALIA, V198, P80, DOI 10.5694/mja12.10785; Skurtveit S, 2010, PAIN MED, V11, P805, DOI 10.1111/j.1526-4637.2010.00870.x; StataCorp, 2013, STAT STAT SOFTW REL; Surratt HL, 2014, PHARMACOEPIDEM DR S, V23, P314, DOI 10.1002/pds.3553; Taylor LA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160217; The Australian National Audit Office, 2010, 39200910 AUSTR NAT A; Therapeutic Goods Administration of Australian Government Department of Health, 2018, CONSULTATION PAPER; Therapeutic Guidelines Limited, 2019, ETG COMPL PSYCH GUID; Viana MC, 2018, J PAIN, V19, P99, DOI 10.1016/j.jpain.2017.08.011; Vowles KE, 2015, PAIN, V156, P569, DOI 10.1097/01.j.pain.0000460357.01998.f1; WHO Collaborating Centre for Drug Statistics Methodology, 2017, GUID ATC CLASS DDD A; WHO Expert Committee, 2017, WHO MOD LIST ESS MED; Winstanley EL, 2018, DRUG ALCOHOL DEPEN, V188, P169, DOI 10.1016/j.drugalcdep.2018.03.036	56	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 19	2019	14	8							e0221438	10.1371/journal.pone.0221438	http://dx.doi.org/10.1371/journal.pone.0221438			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW5MK	31425552	gold, Green Published, Green Submitted			2023-01-03	WOS:000485022400045
J	Robert, C; Grob, JJ; Stroyakovskiy, D; Karaszewska, B; Hauschild, A; Levchenko, E; Sileni, VC; Schachter, J; Garbe, C; Bondarenko, I; Gogas, H; Mandala, M; Haanen, JBAG; Lebbe, C; Mackiewicz, A; Rutkowski, P; Nathan, PD; Ribas, A; Davies, MA; Flaherty, KT; Burgess, P; Tan, M; Gasal, E; Voi, M; Schadendorf, D; Long, GV				Robert, C.; Grob, J. J.; Stroyakovskiy, D.; Karaszewska, B.; Hauschild, A.; Levchenko, E.; Sileni, V. Chiarion; Schachter, J.; Garbe, C.; Bondarenko, I.; Gogas, H.; Mandala, M.; Haanen, J. B. A. G.; Lebbe, C.; Mackiewicz, A.; Rutkowski, P.; Nathan, P. D.; Ribas, A.; Davies, M. A.; Flaherty, K. T.; Burgess, P.; Tan, M.; Gasal, E.; Voi, M.; Schadendorf, D.; Long, G. V.			Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POOLED ANALYSIS; DOUBLE-BLIND; SURVIVAL; IPILIMUMAB; BRAF	Background Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation have prolonged progression-free survival and overall survival when receiving treatment with BRAF inhibitors plus MEK inhibitors. However, long-term clinical outcomes in these patients remain undefined. To determine 5-year survival rates and clinical characteristics of the patients with durable benefit, we sought to review long-term data from randomized trials of combination therapy with BRAF and MEK inhibitors. Methods We analyzed pooled extended-survival data from two trials involving previously untreated patients who had received BRAF inhibitor dabrafenib (at a dose of 150 mg twice daily) plus MEK inhibitor trametinib (2 mg once daily) in the COMBI-d and COMBI-v trials. The median duration of follow-up was 22 months (range, 0 to 76). The primary end points in the COMBI-d and COMBI-v trials were progression-free survival and overall survival, respectively. Results A total of 563 patients were randomly assigned to receive dabrafenib plus trametinib (211 in the COMBI-d trial and 352 in the COMBI-v trial). The progression-free survival rates were 21% (95% confidence interval [CI], 17 to 24) at 4 years and 19% (95% CI, 15 to 22) at 5 years. The overall survival rates were 37% (95% CI, 33 to 42) at 4 years and 34% (95% CI, 30 to 38) at 5 years. In multivariate analysis, several baseline factors (e.g., performance status, age, sex, number of organ sites with metastasis, and lactate dehydrogenase level) were significantly associated with both progression-free survival and overall survival. A complete response occurred in 109 patients (19%) and was associated with an improved long-term outcome, with an overall survival rate of 71% (95% CI, 62 to 79) at 5 years. Conclusions First-line treatment with dabrafenib plus trametinib led to long-term benefit in approximately one third of the patients who had unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. (Funded by GlaxoSmithKline and Novartis; COMBI-d ClinicalTrials.gov number, ; COMBI-v ClinicalTrials.gov number, .) In long-term follow-up of more than 500 patients with melanoma containing a BRAF V600E or V600K mutation, a combination of dabrafenib plus trametinib was associated with progression-free survival in 19% of the patients and overall survival in 34% at 5 years. A complete response to dabrafenib plus trametinib was the strongest predictor of long-term survival.	[Robert, C.] Inst Gustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif, France; [Robert, C.] Paris Sud Paris Saclay Univ, Villejuif, France; [Grob, J. J.] Aix Marseille Univ, Marseille, France; [Lebbe, C.] Univ Paris, Hop St Louis, AP HP, Dermatol & Clin Invest Ctr,Unite 976, Paris, France; [Stroyakovskiy, D.] Moscow City Oncol Hosp, Moscow, Russia; [Levchenko, E.] Petrov Res Inst Oncol, St Petersburg, Russia; [Karaszewska, B.] Przychodnia Lekarska Komed, Konin, Poland; [Mackiewicz, A.] Univ Med Sci, Poznan, Poland; [Rutkowski, P.] Maria Sklodowska Curie Inst, Oncol Ctr, Warsaw, Poland; [Hauschild, A.] Univ Hosp Schleswig Holstein, Kiel, Germany; [Garbe, C.] Univ Tubingen, Dept Dermatol, Tubingen, Germany; [Schadendorf, D.] Univ Hosp Essen, Essen, Germany; [Schadendorf, D.] German Canc Consortium, Heidelberg, Germany; [Sileni, V. Chiarion] Veneto Inst Oncol, Padua, Italy; [Mandala, M.] Papa Giovanni XXIII Hosp, Bergamo, Italy; [Schachter, J.] Sheba Med Ctr, Ella Lemelbaum Inst Immunooncol & Melanoma, Tel Hashomer, Israel; [Schachter, J.] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel; [Bondarenko, I.] Dnipropetrovsk State Med Acad, Dnepropetrovsk, Ukraine; [Gogas, H.] Univ Athens, Sch Med, Laiko Gen Hosp, Athens, Greece; [Haanen, J. B. A. G.] Netherlands Canc Inst, Amsterdam, Netherlands; [Nathan, P. D.] Mt Vernon Canc Ctr, Northwood, Middx, England; [Ribas, A.] Univ Calif Los Angeles, Los Angeles, CA USA; [Davies, M. A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Flaherty, K. T.] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA; [Flaherty, K. T.] Harvard Med Sch, Boston, MA 02115 USA; [Burgess, P.] Novartis Pharmaceut, Basel, Switzerland; [Tan, M.; Gasal, E.; Voi, M.] Novartis Pharmaceut, E Hanover, NJ USA; [Long, G. V.] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia; [Long, G. V.] Royal North Shore Hosp, Sydney, NSW, Australia; [Long, G. V.] Mater Hosp, Sydney, NSW, Australia	UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; N.N. Petrov Research Institute of Oncology; Maria Sklodowska-Curie National Research Institute of Oncology; University of Kiel; Schleswig Holstein University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); IRCCS Istituto Oncologico Veneto (IOV); ASST Papa Giovanni XXIII; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Dnipro State Medical University; Athens Medical School; Laiko General Hospital; National & Kapodistrian University of Athens; Netherlands Cancer Institute; Mount Vernon Cancer Centre; University of California System; University of California Los Angeles; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Novartis; Novartis; Melanoma Institute Australia; University of Sydney; Royal North Shore Hospital	Robert, C (corresponding author), Inst Gustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif, France.	caroline.robert@gustaveroussy.fr	Mandala', Mario/AAA-4258-2019; Davies, Michael/GWV-2527-2022; Bondarenko, Igor/W-9412-2019; Haanen, John/AAD-8578-2022; Haanen, John/AAD-8534-2022; Robert, Caroline/G-6157-2018; Rutkowski, Piotr/B-3907-2013; Schadendorf, Dirk/AAE-8206-2019; Levchenko, Evgeny/X-8697-2018; Bondarenko, Igor N/GQP-1497-2022; mandala, mario/AAB-8637-2022; sileni, vanna chiarion/B-9042-2018; Long, Georgina V/C-1771-2013	Bondarenko, Igor/0000-0002-7071-2471; Haanen, John/0000-0001-5884-7704; Robert, Caroline/0000-0002-9493-0238; Rutkowski, Piotr/0000-0002-8920-5429; Levchenko, Evgeny/0000-0003-3837-2515; Bondarenko, Igor N/0000-0002-7071-2471; sileni, vanna chiarion/0000-0001-9191-9124; Long, Georgina V/0000-0001-8894-3545; Stroyakovskiy, Daniil/0000-0003-1973-1092; Schadendorf, Dirk/0000-0003-3524-7858; Nathan, Paul/0000-0002-2327-3250	GlaxoSmithKline; Novartis	GlaxoSmithKline(GlaxoSmithKline); Novartis(Novartis)	Funded by GlaxoSmithKline and Novartis; COMBI-d ClinicalTrials.gov number, NCT01584648; COMBI-v ClinicalTrials.gov number, NCT01597908.	Ascierto PA, 2016, LANCET ONCOL, V17, P1248, DOI 10.1016/S1470-2045(16)30122-X; Conforti F, 2018, LANCET ONCOL, V19, P737, DOI 10.1016/S1470-2045(18)30261-4; Dummer R, 2018, LANCET ONCOL, V19, P1315, DOI 10.1016/S1470-2045(18)30497-2; Hamid O, 2018, J CLIN ONCOL S, V36; Hodi FS, 2018, LANCET ONCOL, V19, P1480, DOI 10.1016/S1470-2045(18)30700-9; Hodi FS, 2016, P AM ASS CANC RES S, V76, pCT001; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Long GV, 2018, J CLIN ONCOL, V36, P667, DOI 10.1200/JCO.2017.74.1025; Long GV, 2016, LANCET ONCOL, V17, P1743, DOI 10.1016/S1470-2045(16)30578-2; Long GV, 2015, LANCET, V386, P444, DOI 10.1016/S0140-6736(15)60898-4; Maio M, 2015, J CLIN ONCOL, V33, P1191, DOI 10.1200/JCO.2014.56.6018; McArthur GA, 2016, 13 INT C SOC MEL RES; Prieto PA, 2012, CLIN CANCER RES, V18, P2039, DOI 10.1158/1078-0432.CCR-11-1823; Robert C, 2019, AM ASS CANC RES ANN; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Schadendorf D, 2017, EUR J CANCER, V82, P45, DOI 10.1016/j.ejca.2017.05.033; Ugurel S, 2017, EUR J CANCER, V83, P247, DOI 10.1016/j.ejca.2017.06.028; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684	18	551	569	2	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 15	2019	381	7					626	636		10.1056/NEJMoa1904059	http://dx.doi.org/10.1056/NEJMoa1904059			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IR5HE	31166680	Bronze			2023-01-03	WOS:000481462800008
J	Carlos, MD; Cavaletti, ACL; Caldas, CP				Carlos, Marcelo de Jesus; Lima Cavaletti, Ana Carolina; Caldas, Celia Pereira			Hospitalization of the aged due to stroke: An ecological perspective	PLOS ONE			English	Article							HEALTH-CARE; GLOBAL BURDEN; RISK-FACTORS; BRAZIL; POPULATION; PREVALENCE; DETERMINANTS; DISEASES	Contextual variables have been associated with the incidence of stroke, but their association with hospitalization of older persons remains unclear. This study evaluated the association between social context variables and hospitalization of 60 years old and older patients due to stroke in Rio de Janeiro, Brazil. An ecological cross-sectional study was conducted, with secondary data from the Brazilian Hospital Information System from 2006 to 2014. Hospitalization rates were calculated and categorized by tertiles. For subsequent analyzes, the polar extremes method was used to select the groups with extremes values. After that, Student t or Mann-Whitney tests were used to compare the contextual variables and the hospitalization rates clusters. Then, a Binary Logistic Regression analysis was used to assess the association between hospitalization rates clusters and the contextual variables. The total number of hospitalizations was 82 796; the hospitalization rate varied in extremes groups from the lowest (3.49) to the highest (11.95) (p< 0.001). The highest rates group was positively associated with the proportion of elderly (p< 0.001), the illiteracy rate of the aged (p = 0.01), primary care coverage (p< 0.001) and ambulatory care for hypertension and diabetes, while the income ratio showed negative association with the highest rates of hospitalization (p = 0.01). In the multivariate analysis, only the proportion of elderly (OR = 1.55; 95% CI 1.07-2.25), primary care coverage (OR = 1.05; 95% CI 1.01-1.11) and income ratio (OR = 0.82; 95% CI 0.67-0.99) maintained the association. In conclusion, contextual variables in the three dimensions studied were associated with the rate of hospitalization of aged due to stroke in the municipalities in Rio de Janeiro State. Transitional care and other improvements in both the health care and social services are demanded.	[Carlos, Marcelo de Jesus; Lima Cavaletti, Ana Carolina; Caldas, Celia Pereira] Univ Estado Rio De Janeiro, Med Sci Coll, Postgrad Program Med Sci, Rio De Janeiro, RJ, Brazil; [Caldas, Celia Pereira] Univ Estado Rio De Janeiro, Nursing Sch, Dept Aging, Rio De Janeiro, RJ, Brazil	Universidade do Estado do Rio de Janeiro; Universidade do Estado do Rio de Janeiro	Carlos, MD (corresponding author), Univ Estado Rio De Janeiro, Med Sci Coll, Postgrad Program Med Sci, Rio De Janeiro, RJ, Brazil.	marcelojcarlos@gmail.com	Caldas, Celia/K-5370-2019	Caldas, Celia/0000-0001-6903-1778; Carlos, Marcelo/0000-0002-8810-3092				Adami F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152739; Afonso MPD, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015322; Bittencourt Sonia Azevedo, 2006, Cad. Saúde Pública, V22, P19, DOI 10.1590/S0102-311X2006000100003; Bousquat A, 2017, CIENC SAUDE COLETIVA, V22, P1141, DOI 10.1590/1413-81232017224.28632016; Cabral NL, 2011, NEUROEPIDEMIOLOGY, V36, P258, DOI 10.1159/000328865; Cavalini LT, 2008, INT J EPIDEMIOL, V37, P775, DOI 10.1093/ije/dyn088; Copstein L, 2013, ARQ NEURO-PSIQUIAT, V71, P294, DOI 10.1590/0004-282X20130024; da Rocha PR, 2015, REV ESC ENFERM USP, V49, P127, DOI 10.1590/S0080-623420150000100017; Silva AMD, 2017, REV SAUDE PUBL, V51, DOI [10.1590/S1518-8787.2017051000243, 10.1590/s1518-8787.2017051000243]; Campos GWD, 2016, CIENC SAUDE COLETIVA, V21, P2655, DOI 10.1590/1413-81232015219.18922016; Feigin VL, 2015, NEUROEPIDEMIOLOGY, V45, P161, DOI 10.1159/000441085; Lentsck MH, 2015, REV LAT-AM ENFERM, V23, P611, DOI 10.1590/0104-1169.0078.2595; Lima Cavaletti Ana Carolina, 2018, Value Health Reg Issues, V17, P8, DOI 10.1016/j.vhri.2017.12.002; Lopes Johnnatas Mikael, 2016, Rev. bras. epidemiol., V19, P122, DOI 10.1590/1980-5497201600010011; Lotufo PA, 2015, SAO PAULO MED J, V133, P457, DOI 10.1590/1516-3180.2015.13360510; Macinko James, 2018, Saúde debate, V42, P18, DOI 10.1590/0103-11042018s102; Marmot M, 2016, ANN EPIDEMIOL, V26, P238, DOI 10.1016/j.annepidem.2016.02.003; Marmot M, 2011, B WORLD HEALTH ORGAN, V89, P702, DOI 10.2471/BLT.11.094862; Marques AP, 2014, REV SAUDE PUBL, V48, P817, DOI 10.1590/S0034-8910.2014048005133; Melo Eduardo Alves, 2018, Saúde debate, V42, P38, DOI 10.1590/0103-11042018s103; Moffat K, 2015, BMC FAM PRACT, V16, DOI 10.1186/s12875-015-0344-4; de Andrade LOM, 2015, LANCET, V385, P1343, DOI 10.1016/S0140-6736(14)61494-X; Morosini Márcia Valéria Guimarães Cardoso, 2018, Saúde debate, V42, P11, DOI 10.1590/0103-1104201811601; Moura EC, 2009, REV PANAM SALUD PUBL, V26, P17, DOI 10.1590/S1020-49892009000700003; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Pereira ABCND, 2009, CAD SAUDE PUBLICA, V25, P1929, DOI 10.1590/S0102-311X2009000900007; Norrving B, 2013, NEUROLOGY, V80, pS5, DOI 10.1212/WNL.0b013e3182762397; Nunes BP, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2505-8; O'Cathain A, 2014, BMJ QUAL SAF, V23, P47, DOI 10.1136/bmjqs-2013-002003; Pedigo A, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-644; Perez LM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166304; Pickett KE, 2015, SOC SCI MED, V128, P316, DOI 10.1016/j.socscimed.2014.12.031; Pinto LF, 2018, CIENC SAUDE COLETIVA, V23, P1903, DOI 10.1590/1413-81232018236.05592018; Ribeiro IJS, 2018, J STROKE CEREBROVASC, V27, P1616, DOI 10.1016/j.jstrokecerebrovasdis.2018.01.013; Rocha Suelen Alves, 2016, Physis, V26, P87, DOI 10.1590/S0103-73312016000100007; Rodriguez F, 2013, J COMMUN HEALTH, V38, P451, DOI 10.1007/s10900-012-9640-2; Rolim Cristina Lúcia Rocha Cubas, 2012, Rev. bras. epidemiol., V15, P179, DOI 10.1590/S1415-790X2012000100016; Sacco RL, 2013, STROKE, V44, P2064, DOI 10.1161/STR.0b013e318296aeca; Stubbs B, 2017, PSYCHOL MED, V47, P2107, DOI 10.1017/S0033291717000551; Travassos Claudia, 2004, Cad. Saúde Pública, V20, pS190; World Health Organization, 2008, GUIA GLOB CID AM DO	41	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 7	2019	14	8							e0220833	10.1371/journal.pone.0220833	http://dx.doi.org/10.1371/journal.pone.0220833			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW5DR	31390380	Green Submitted, gold, Green Published			2023-01-03	WOS:000484999400031
J	Gaffney, A; McCormick, D; Bor, DH; Goldman, A; Woolhandler, S; Himmelstein, DU				Gaffney, Adam; McCormick, Danny; Bor, David H.; Goldman, Anna; Woolhandler, Steffie; Himmelstein, David U.			The Effects on Hospital Utilization of the 1966 and 2014 Health Insurance Coverage Expansions in the United States	ANNALS OF INTERNAL MEDICINE			English	Article							EARLY MEDICAID EXPANSION; LENGTH-OF-STAY; CARE UTILIZATION; IMPACT; MASSACHUSETTS; QUALITY; DEMAND; REFORM; RATES; ACA	Background: Persons with comprehensive health insurance use more hospital care than those who are uninsured or have high-deductible plans. Consequently, analysts generally assume that expanding coverage will increase society-wide use of inpatient services. However, a limited supply of beds might constrain this growth. Objective: To determine how the implementations of Medicare and Medicaid (1966) and the Patient Protection and Affordable Care Act (ACA) (2014) affected hospital use. Design: Repeated cross-sectional study. Setting: Nationally representative surveys. Participants: Respondents to the National Health Interview Survey (1962 to 1970) and Medical Expenditure Panel Survey (2008 to 2015). Measurements: Mean hospital discharges and days were measured, both society-wide and among subgroups defined by income, age, and health status. Changes between preexpansion and postexpansion periods were analyzed using multivariable negative binomial regression. Results: Overall hospital discharges averaged 12.8 per 100 persons in the 3 years before implementation of Medicare and Medicaid and 12.7 per 100 persons in the 4 years after (adjusted ;difference, 0.2 discharges [95% CI, -0.1 to 0.4 discharges] per 100 persons; P = 0.26). Hospital days did not change in the first 2 years after implementation but increased later. Effects differed by subpopulation: Adjusted discharges increased by 2.4 (CI, 1.7 to 3.1) per 100 persons among elderly compared with non-elderly persons (P < 0.001) and also increased among those with low incomes compared with high-income populations. For younger and higher-income persons, use decreased. Similarly, after the ACA's implementation, overall hospital use did not change: Society-wide rates of discharge were 9.4 per 100 persons before the ACA and 9.0 per 100 persons after the ACA (adjusted difference, -0.6 discharges [CI, -1.3 to 0.2 discharges] per 100 persons; P = 0.133), and hospital days were also stable. Trends differed for some subgroups, and rates decreased significantly in unadjusted (but not adjusted) analyses among persons reporting good or better health status and increased nonsignificantly among those in worse health. Limitation: Data sources relied on participant recall, surveys excluded institutionalized persons, and follow-up after the ACA was limited. Conclusion: Past coverage expansions were associated with little or no change in society-wide hospital use; increases in groups who gained coverage were offset by reductions among others, suggesting that bed supply limited increases in use. Reducing coverage may merely shift care toward wealthier and healthier persons. Conversely, universal coverage is unlikely to cause a surge in hospital use if growth in hospital capacity is carefully constrained. Primary Funding Source: None.	[Gaffney, Adam; McCormick, Danny; Bor, David H.; Woolhandler, Steffie; Himmelstein, David U.] Cambridge Hlth Alliance, 1493 Cambridge St, Cambridge, MA 02138 USA; [Gaffney, Adam; McCormick, Danny; Bor, David H.; Woolhandler, Steffie; Himmelstein, David U.] Harvard Med Sch, Cambridge, MA USA; [Goldman, Anna] Harvard TH Chan Sch Publ Hlth, 677 Huntington Ave,Kresge Room 430, Boston, MA 02115 USA; [Goldman, Anna] Cambridge Hlth Alliance, Cambridge, MA USA; [Woolhandler, Steffie; Himmelstein, David U.] CUNY Hunter Coll, New York, NY 10021 USA; [Woolhandler, Steffie; Himmelstein, David U.] 255 West 90th St, New York, NY 10024 USA	Harvard University; Cambridge Health Alliance; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Cambridge Health Alliance; City University of New York (CUNY) System; Hunter College (CUNY)	Gaffney, A (corresponding author), 1493 Cambridge St, Cambridge, MA 02138 USA.	agaffney@challiance.org		Gaffney, Adam/0000-0001-7326-0661				American Hospital Association, 1971, HOSP STAT, V1971; American Hospital Association, 2018, AHA HOSP STAT; American Hospital Association, 2013, AHA HOSP STAT; Anderson ME, 2016, J HOSP MED, V11, P847, DOI 10.1002/jhm.2649; Aron-Dine A, 2013, J ECON PERSPECT, V27, P197, DOI 10.1257/jep.27.1.197; Bond AM, 2013, HEALTH SERV RES, V48, P1826, DOI 10.1111/1475-6773.12103; Brot-Goldberg ZC, 2017, Q J ECON, V132, P1261, DOI 10.1093/qje/qjx013; Card D, 2008, AM ECON REV, V98, P2242, DOI 10.1257/aer.98.5.2242; Carey Colleen M, 2018, IMPACT INSURANCE EXP; Centers for Medicare & Medicaid Services, 2018, NAT HLTH EXP DAT HIS; Cheng SH, 1997, JAMA-J AM MED ASSOC, V278, P89, DOI 10.1001/jama.278.2.89; Cowan C, 2015, HIST HLTH SPENDING U; Cunningham P, 2017, MED CARE RES REV, V74, P705, DOI 10.1177/1077558716669433; Deb P, 2018, ANNU REV PUBL HEALTH, V39, P489, DOI 10.1146/annurev-publhealth-040617-013517; Delamater PL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054900; Finkelstein A, 2007, Q J ECON, V122, P1, DOI 10.1162/qjec.122.1.1; Finkelstein A, 2012, Q J ECON, V127, P1057, DOI 10.1093/qje/qjs020; Finkelstein AN, 2016, NEW ENGL J MED, V375, P1505, DOI 10.1056/NEJMp1609533; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Fisher LS, 2000, HEALTH SERV RES, V34, P1351; Freedman S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183616; Ginsburg P B, 1983, Health Care Financ Rev, V5, P87; Gleeson G A, 1966, Vital Health Stat 10, V10, P1; Glied S, 2018, J HEALTH ECON, V60, P165, DOI 10.1016/j.jhealeco.2018.05.001; Hellinger FJ, 2015, HEALTH AFFAIR, V34, P2061, DOI 10.1377/hlthaff.2015.0718; Holzmacher JL, 2017, JAMA SURG, V152, P960, DOI 10.1001/jamasurg.2017.1720; Joynt KE, 2015, HEALTH SERV RES, V50, P599, DOI 10.1111/1475-6773.12228; Kolstad JT, 2012, J PUBLIC ECON, V96, P909, DOI 10.1016/j.jpubeco.2012.07.003; LOEWENSTEIN R, 1971, SOC SECUR BULL, V34, P3; MANNING WG, 1987, AM ECON REV, V77, P251; Mazurenko O, 2018, HEALTH AFFAIR, V37, P944, DOI 10.1377/hlthaff.2017.1491; McDermott K, 2017, PATIENT TRENDS HOSP; McWilliams JM, 2007, NEW ENGL J MED, V357, P143, DOI 10.1056/NEJMsa067712; *NAT CTR HLTH STAT, 2002, 2000 NAT HLTH INT SU; National Health Interview Survey, 2008, TAB DAT FISC YEAR 19; Nikpay S, 2015, HEALTH AFFAIR, V34, P1170, DOI 10.1377/hlthaff.2015.0107; Nyman JA, 2007, J HEALTH POLIT POLIC, V32, P759, DOI 10.1215/03616878-2007-029; PETTENGILL JH, 1972, SOC SECUR BULL, V35, P3; Pickens G, 2018, HEALTH SERV RES, V53, P2446, DOI 10.1111/1475-6773.12734; SHAIN M, 1959, Mod Hosp, V92, P71; Shwartz M, 2011, MED CARE, V49, P1062, DOI 10.1097/MLR.0b013e3182353907; Statista, HOSP BEDS NUMB US 19; U. S. Census Bureau, 2011, TABL 1 INT EST RES P; U. S. Census Bureau, 2018, HIST NAT POP EST JUL; U.S. Census Bureau, 2018, HIST POV TABL PEOPL, DOI 10.1086/525035?origin=JSTOR-pdf&seq=1; US Census Bureau, 2019, ANN EST RES POP SING; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; Zhou M, 2018, J GEN INTERN MED, V33, P2127, DOI 10.1007/s11606-018-4638-9	48	5	5	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 6	2019	171	3					172	+		10.7326/M18-2806	http://dx.doi.org/10.7326/M18-2806			23	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IN6RQ	31330539				2023-01-03	WOS:000478809000004
J	Barnett, ML; Mehrotra, A; Grabowski, DC				Barnett, Michael L.; Mehrotra, Ateev; Grabowski, David C.			Postacute Care - The Piggy Bank for Savings in Alternative Payment Models?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								The shift away from fee-for-service payment puts pressure on hospitals to reduce low-value care and to manage care delivered outside their walls. Thus far, hospitals have found savings by using an unusually consistent strategy: reducing institutional postacute care.	[Barnett, Michael L.] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Barnett, Michael L.] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med & Primary Care, 75 Francis St, Boston, MA 02115 USA; [Mehrotra, Ateev; Grabowski, David C.] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA 02115 USA; [Mehrotra, Ateev] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Barnett, ML (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.; Barnett, ML (corresponding author), Brigham & Womens Hosp, Dept Med, Div Gen Internal Med & Primary Care, 75 Francis St, Boston, MA 02115 USA.		Mehrotra, Ateev/AAO-8454-2021; Barnett, Michael/ABA-4159-2021; Barnett, Michael/AAF-4017-2019	Mehrotra, Ateev/0000-0003-2223-1582; Barnett, Michael/0000-0002-4884-6609; Barnett, Michael/0000-0002-4884-6609; Grabowski, David/0000-0003-2915-5770	NATIONAL INSTITUTE ON AGING [K23AG058806] Funding Source: NIH RePORTER; NIA NIH HHS [K23 AG058806] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barnett ML, 2019, NEW ENGL J MED, V380, P252, DOI 10.1056/NEJMsa1809010; Curto V, 2017, HEALTHCARE SPENDING; Lewin Group, 2018, CMS BUNDL PAYM CAR I; McWilliams JM, 2017, JAMA INTERN MED, V177, P518, DOI 10.1001/jamainternmed.2016.9115; McWilliams JM, 2016, NEW ENGL J MED, V374, P2357, DOI 10.1056/NEJMsa1600142	5	24	24	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 25	2019	381	4					302	303		10.1056/NEJMp1901896	http://dx.doi.org/10.1056/NEJMp1901896			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IM4VO	31340092	Green Accepted			2023-01-03	WOS:000477993600004
J	Im, SA; Lu, YS; Bardia, A; Harbeck, N; Colleoni, M; Franke, F; Chow, L; Sohn, J; Lee, KS; Campos-Gomez, S; Villanueva-Vazquez, R; Jung, KH; Chakravartty, A; Hughes, G; Gounaris, I; Rodriguez-Lorenc, K; Taran, T; Hurvitz, S; Tripathy, D				Im, S. -A.; Lu, Y. -S.; Bardia, A.; Harbeck, N.; Colleoni, M.; Franke, F.; Chow, L.; Sohn, J.; Lee, K. -S.; Campos-Gomez, S.; Villanueva-Vazquez, R.; Jung, K. -H.; Chakravartty, A.; Hughes, G.; Gounaris, I.; Rodriguez-Lorenc, K.; Taran, T.; Hurvitz, S.; Tripathy, D.			Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							KINASE 4/6 INHIBITOR; FULVESTRANT; COMBINATION; PALBOCICLIB; TARGETS; WOMEN	BackgroundAn earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit with regard to progression-free survival than endocrine therapy alone in premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Here we report the results of a protocol-specified interim analysis of the key secondary end point of overall survival. MethodsWe randomly assigned patients to receive either ribociclib or placebo in addition to endocrine therapy (goserelin and either a nonsteroidal aromatase inhibitor or tamoxifen). Overall survival was evaluated with the use of a stratified log-rank test and summarized with the use of Kaplan-Meier methods. ResultsA total of 672 patients were included in the intention-to-treat population. There were 83 deaths among 335 patients (24.8%) in the ribociclib group and 109 deaths among 337 patients (32.3%) in the placebo group. The addition of ribociclib to endocrine therapy resulted in significantly longer overall survival than endocrine therapy alone. The estimated overall survival at 42 months was 70.2% (95% confidence interval [CI], 63.5 to 76.0) in the ribociclib group and 46.0% (95% CI, 32.0 to 58.9) in the placebo group (hazard ratio for death, 0.71; 95% CI, 0.54 to 0.95; P=0.00973 by log-rank test). The survival benefit seen in the subgroup of 495 patients who received an aromatase inhibitor was consistent with that in the overall intention-to-treat population (hazard ratio for death, 0.70; 95% CI, 0.50 to 0.98). The percentage of patients who received subsequent antineoplastic therapy was balanced between the groups (68.9% in the ribociclib group and 73.2% in the placebo group). The time from randomization to disease progression during receipt of second-line therapy or to death was also longer in the ribociclib group than in the placebo group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.55 to 0.87). ConclusionsThis trial showed significantly longer overall survival with a CDK4/6 inhibitor plus endocrine therapy than with endocrine therapy alone among patients with advanced hormone-receptor-positive, HER2-negative breast cancer. No new concerns regarding toxic effects emerged with longer follow-up.	[Im, S. -A.] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Canc Res Inst, Seoul, South Korea; [Sohn, J.] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea; [Jung, K. -H.] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea; [Lee, K. -S.] Natl Canc Ctr, Ctr Breast Canc, Gyeonggi Do, South Korea; [Lu, Y. -S.] Natl Taiwan Univ Hosp, Taipei, Taiwan; [Bardia, A.] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA; [Bardia, A.] Harvard Med Sch, Boston, MA 02115 USA; [Harbeck, N.] Ludwig Maximilians Univ Munchen, Breast Ctr, Dept Obstet & Gynecol, Munich, Germany; [Colleoni, M.] Ist Europeo Oncol, Div Med Senol, Milan, Italy; [Franke, F.] Hosp Caridade Ijui, CACON, Ijui, Brazil; [Chow, L.] Org Oncol & Translat Res, Hong Kong, Peoples R China; [Campos-Gomez, S.] Inst Seguridad Social Estado Mexico & Municipios, Ctr Oncol Estatal, Toluca, Mexico; [Villanueva-Vazquez, R.] Hosp St Joan Despi Moises Broggi, Inst Catala Oncol, Barcelona, Spain; [Chakravartty, A.; Rodriguez-Lorenc, K.; Taran, T.] Novartis Pharmaceut, E Hanover, NJ USA; [Hughes, G.; Gounaris, I.] Novartis, Basel, Switzerland; [Hurvitz, S.] UCLA, Ctr Comprehens Canc, Los Angeles, CA USA; [Tripathy, D.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	Seoul National University (SNU); Seoul National University Hospital; Yonsei University; Yonsei University Health System; University of Ulsan; National Cancer Center - Korea (NCC); National Taiwan University; National Taiwan University Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Munich; IRCCS European Institute of Oncology (IEO); Catalan Institute of Oncology; Novartis; University of California System; University of California Los Angeles; University of Texas System; UTMD Anderson Cancer Center	Tripathy, D (corresponding author), Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd,Unit 1354, Houston, TX 77030 USA.	dtripathy@mdanderson.org	Campos-Gomez, Saul/AAB-6496-2020	Campos-Gomez, Saul/0000-0002-1804-2589; Lu, Yen-Shen/0000-0001-7461-1291; Villanueva, Rafael/0000-0003-4730-6886	Novartis	Novartis(Novartis)	Supported by Novartis.	[Anonymous], 2018, KISQ RIB HIGHL PRESC; Azim HA, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0427-5; Azim HA, 2012, CLIN CANCER RES, V18, P1341, DOI 10.1158/1078-0432.CCR-11-2599; Bardia A, 2018, CLIN CANCER RES, V24, P5206, DOI 10.1158/1078-0432.CCR-18-0162; Bellet M, 2016, J CLIN ONCOL, V34, P1584, DOI 10.1200/JCO.2015.61.2259; Cardoso F, 2018, ANN ONCOL, V29, P1634, DOI 10.1093/annonc/mdy192; Chen P, 2016, MOL CANCER THER, V15, P2273, DOI 10.1158/1535-7163.MCT-16-0300; Cristofanilli M, 2016, LANCET ONCOL, V17, P425, DOI 10.1016/S1470-2045(15)00613-0; Dmitrienko A, 2018, NEW ENGL J MED, V378, P2115, DOI 10.1056/NEJMra1709701; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Gabriel CA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2647; Glimm E, 2010, STAT MED, V29, P219, DOI 10.1002/sim.3748; Hortobagyi GN, 2018, ANN ONCOL, V29, P1541, DOI 10.1093/annonc/mdy155; Hortobagyi GN, 2016, NEW ENGL J MED, V375, P1738, DOI 10.1056/NEJMoa1609709; Hosford SR, 2014, PHARMACOGEN PERS MED, V7, P203, DOI 10.2147/PGPM.S52762; Hurvitz SA, 2011, CANCER TREAT REV, V37, P495, DOI 10.1016/j.ctrv.2011.01.002; Inwald EC, 2013, BREAST CANCER RES TR, V139, P539, DOI 10.1007/s10549-013-2560-8; Kan ZY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04129-4; Kim Sunkyu, 2018, Oncotarget, V9, P35226, DOI 10.18632/oncotarget.26215; Liao S, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0618-8; Miller TW, 2011, CANCER DISCOV, V1, P338, DOI 10.1158/2159-8290.CD-11-0101; National Comprehensive Cancer Network, 2019, CLIN PRACTICE GUIDEL; Rugo HS, 2016, J CLIN ONCOL, V34, P3069, DOI 10.1200/JCO.2016.67.1487; Sammons SL, 2017, CURR CANCER DRUG TAR, V17, P637, DOI 10.2174/1568009617666170330120452; Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689; Slamon DJ, 2018, J CLIN ONCOL, V36, P2465, DOI 10.1200/JCO.2018.78.9909; Sledge GW, 2017, J CLIN ONCOL, V35, P2875, DOI 10.1200/JCO.2017.73.7585; Thangavel C, 2011, ENDOCR-RELAT CANCER, V18, P333, DOI 10.1530/ERC-10-0262; Tripathy D, 2018, LANCET ONCOL, V19, P904, DOI 10.1016/S1470-2045(18)30292-4; Tripathy D, 2017, CLIN CANCER RES, V23, P3251, DOI 10.1158/1078-0432.CCR-16-3157; Turner NC, 2018, NEW ENGL J MED, V379, P1926, DOI 10.1056/NEJMoa1810527	32	422	436	2	56	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 25	2019	381	4					307	316		10.1056/NEJMoa1903765	http://dx.doi.org/10.1056/NEJMoa1903765			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IM4VO	31166679	Bronze			2023-01-03	WOS:000477993600006
J	Fell, GL; Anez-Bustillos, L; Dao, DT; Baker, MA; Nandivada, P; Cho, BS; Pan, A; O'Loughlin, AA; Nose, V; Gura, KM; Puder, M				Fell, Gillian L.; Anez-Bustillos, Lorenzo; Dao, Duy T.; Baker, Meredith A.; Nandivada, Prathima; Cho, Bennet S.; Pan, Amy; O'Loughlin, Alison A.; Nose, Vania; Gura, Kathleen M.; Puder, Mark			Alpha-tocopherol in intravenous lipid emulsions imparts hepatic protection in a murine model of hepatosteatosis induced by the enteral administration of a parenteral nutrition solution	PLOS ONE			English	Article							FATTY-ACID DEFICIENCY; FISH-OIL; LIVER-DISEASE; GENE-EXPRESSION; PPAR-GAMMA; STEATOSIS; FAILURE; MICE; SUPPLEMENTATION; INFLAMMATION	Intestinal failure-associated liver disease (IFALD) is a risk of parenteral nutrition (PN)-dependence. Intravenous soybean oil-based parenteral fat can exacerbate the risk of IFALD while intravenous fish oil can minimize its progression, yet the mechanisms by which soybean oil harms and fish oil protects the liver are uncertain. Properties that differentiate soybean and fish oils include a-tocopherol and phytosterol content. Soybean oil is rich in phytosterols and contains little a-tocopherol. Fish oil contains abundant a-tocopherol and little phytosterols. This study tested whether a-tocopherol confers hepatoprotective properties while phytosterols confer hepatotoxicity to intravenous fat emulsions. Utilizing emulsions formulated in the laboratory, a soybean oil emulsion (SO) failed to protect from hepatosteatosis in mice administered a PN solution enterally. An emulsion of soybean oil containing alpha-tocopherol (SO+AT) preserved normal hepatic architecture. A fish oil emulsion (FO) and an emulsion of fish oil containing phytosterols (FO+P) protected from steatosis in this model. Expression of hepatic acetyl CoA carboxylase (ACC) and peroxisome proliferator-activated receptor gamma (PPAR gamma), was increased in animals administered SO. ACC and PPAR. levels were comparable to chow-fed controls in animals receiving SO+AT, FO, and FO+P. This study suggests a hepatoprotective role for alpha-tocopherol in liver injury induced by the enteral administration of a parenteral nutrition solution. Phytosterols do not appear to compromise the hepatoprotective effects of fish oil.	[Fell, Gillian L.; Anez-Bustillos, Lorenzo; Dao, Duy T.; Baker, Meredith A.; Cho, Bennet S.; Pan, Amy; O'Loughlin, Alison A.; Puder, Mark] Boston Childrens Hosp, Dept Surg, Vasc Biol Program, Boston, MA 02115 USA; [Nandivada, Prathima] Beth Israel Deaconess Med Ctr, Dept Surg, 330 Brookline Ave, Boston, MA 02215 USA; [Nose, Vania] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Gura, Kathleen M.] Boston Childrens Hosp, Dept Pharm, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital	Puder, M (corresponding author), Boston Childrens Hosp, Dept Surg, Vasc Biol Program, Boston, MA 02115 USA.	mark.puder@childrens.harvard.edu		Cho, Bennet/0000-0002-1440-0019; Dao, Duy/0000-0001-9915-7080	National Institutes of Health [1F32DK104525-01, 5T32HL007734, T35HL110843]; Howard Hughes Medical Institute Training Grant; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T35HL110843, T32HL007734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK104525] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute Training Grant; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by: GLF: National Institutes of Health, Grant 1F32DK104525-01; MAB and DTD: National Institutes of Health, Grant 5T32HL007734; BSC: National Institutes of Health, Grant T35HL110843, and Howard Hughes Medical Institute Training Grant (no number). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alwayn IPJ, 2005, PEDIATR RES, V57, P445, DOI 10.1203/01.PDR.0000153672.43030.75; Bagga D, 2003, P NATL ACAD SCI USA, V100, P1751, DOI 10.1073/pnas.0334211100; Bedoucha M, 2001, J HEPATOL, V35, P17, DOI 10.1016/S0168-8278(01)00066-6; Calkins KL, 2014, JPEN-PARENTER ENTER, V38, P682, DOI 10.1177/0148607113495416; Carter BA, 2007, PEDIATR RES, V62, P301, DOI 10.1203/PDR.0b013e3181256492; de Meijer VE, 2009, JPEN-PARENTER ENTER, V33, P541, DOI 10.1177/0148607109332773; Diamond IR, 2009, J PEDIATR GASTR NUTR, V48, P209, DOI 10.1097/MPG.0b013e318182c8f6; Driscoll DF, 2007, AM J HEALTH-SYST PH, V64, P2032, DOI 10.2146/ajhp070097; Driscoll DF, 2006, PHARM RES-DORDR, V23, P1959, DOI 10.1007/s11095-006-9092-4; El Kasmi KC, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006898; El-Basioni BMM, 2017, WIREL COMMUN MOB COM, P1, DOI 10.1155/2017/7493269; Fell GL, 2017, JPEN-PARENTER ENTER, V41, P181, DOI 10.1177/0148607116640275; Gupte AA, 2010, HEPATOLOGY, V52, P2001, DOI 10.1002/hep.23941; Gura KM, 2006, PEDIATRICS, V118, pE197, DOI 10.1542/peds.2005-2662; HOLMAN RT, 1960, J NUTR, V70, P405, DOI 10.1093/jn/70.3.405; Hosui A, 2017, HEPATOL RES, V47, P813, DOI 10.1111/hepr.12816; Hukkinen M, 2017, JPEN-PARENTER ENTER, V41, P1014, DOI 10.1177/0148607116637855; Jeppesen PB, 1998, AM J CLIN NUTR, V68, P126, DOI 10.1093/ajcn/68.1.126; Jia Y, 2016, J NUTR BIOCHEM, V28, P9, DOI [10.1016/j.jnutbio.2015.09.015, 10.20463/jenb.2016.0055]; Kalish BT, 2013, AM J PHYSIOL-GASTR L, V305, pG818, DOI 10.1152/ajpgi.00106.2013; Kurvinen A, 2012, J PEDIATR GASTR NUTR, V54, P803, DOI 10.1097/MPG.0b013e3182474118; Lam HS, 2014, NEONATOLOGY, V105, P290, DOI 10.1159/000358267; Le HD, 2012, JPEN-PARENTER ENTER, V36, P431, DOI 10.1177/0148607111414580; Maruyama H, 2016, INT J MED SCI, V13, P169, DOI 10.7150/ijms.13581; Mascioli EA, 1996, NUTRITION, V12, P245, DOI 10.1016/S0899-9007(96)90850-3; Meisel JA, 2011, J PEDIATR SURG, V46, P666, DOI 10.1016/j.jpedsurg.2010.08.018; Muto M, 2017, JPEN-PARENTER ENTER, V41, P575, DOI 10.1177/0148607115612030; Ng K, 2016, JPEN-PARENTER ENTER, V40, P656, DOI 10.1177/0148607114567900; Pharmacopoeia TUS, 2012, GLOB SIZ DISTR LIP I, P321; Puder M, 2009, ANN SURG, V250, P395, DOI 10.1097/SLA.0b013e3181b36657; Saboori S, 2015, EUR J CLIN NUTR, V69, P867, DOI 10.1038/ejcn.2014.296; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shing CM, 2014, CARDIOVASC THER, V32, P270, DOI 10.1111/1755-5922.12096; Sorrell M, 2016, J PEDIAT GASTROENTER, V1; Tahan V, 2007, DIGEST DIS SCI, V52, P3465, DOI 10.1007/s10620-007-9756-x; Teng J, 2015, J PEDIATR GASTR NUTR, V60, P702, DOI 10.1097/MPG.0000000000000739; Xu ZD, 2015, EUR J LIPID SCI TECH, V117, P15, DOI 10.1002/ejlt.201400182; Xu ZD, 2012, NUTRIENTS, V4, P904, DOI 10.3390/nu4080904; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200; Zheng JY, 2016, NUTRIENTS, V8, DOI 10.3390/nu8010055	40	9	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2019	14	7							e0217155	10.1371/journal.pone.0217155	http://dx.doi.org/10.1371/journal.pone.0217155			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4LN	31295333	Green Published, Green Submitted, gold			2023-01-03	WOS:000484951800004
J	Lundeen, T; Musange, S; Azman, H; Nzeyimana, D; Murindahabi, N; Butrick, E; Walker, D				Lundeen, Tiffany; Musange, Sabine; Azman, Hana; Nzeyimana, David; Murindahabi, Nathalie; Butrick, Elizabeth; Walker, Dilys			Nurses' and midwives' experiences of providing group antenatal and postnatal care at 18 health centers in Rwanda: A mixed methods study	PLOS ONE			English	Article								Background The East Africa Preterm Birth Initiative-Rwanda began a cluster randomized controlled trial of group antenatal care (ANC) and postnatal care (PNC) in Rwanda in 2017. That trial will report its primary outcome, gestational length at birth, after data collection concludes in 2019. This nested study includes providers of ANC and/or PNC at the 18 health centers randomized to provide the group model of ANC/PNC and the 18 health centers randomized to continue providing ANC/PNC in the traditional, individual visit model. The objective of this study is to understand the experiences of providers of group ANC/PNC and compare their job satisfaction and perceived stress with individual ANC/PNC providers. Methods We collected both quantitative and qualitative data from providers (nurses and midwives) who were recruited by health center directors to participate as group ANC and PNC facilitators at intervention sites and from a similar number of providers of standard ANC and PNC at control sites. Quantitative data was collected with questionnaires administered at baseline and approximately 9 months later (follow up). Qualitative data was collected in 3 focus groups of group ANC/PNC providers conducted one year after group care began. Results Eighty-six percent of nurses and midwives surveyed who implemented group ANC and PNC reported that they prefer group care to the traditional individual model of ANC and PNC. Perceived stress levels and job satisfaction results were similar between groups. Mixed focus group discussions among both nurses and midwives experienced in group ANC and PNC suggest that the group model of care has advantages for both service beneficiaries and providers. When providers described implementation challenges, their peers in the focus groups offered them suggestions to cope and improve service delivery. Discussion These results are consistent with studies of providers of group ANC and PNC in other LMIC contexts with respect to the perceived benefits of group care. This study adds new insights into the ways peer providers can help one another solve implementation problems. When given the opportunity to meet as a group, these study participants offered one another peer support and shared knowledge about best practices for successful implementation of group ANC/PNC.	[Lundeen, Tiffany; Azman, Hana; Butrick, Elizabeth; Walker, Dilys] Univ Calif San Francisco, Inst Global Hlth Sci, San Francisco, CA 94143 USA; [Musange, Sabine; Nzeyimana, David; Murindahabi, Nathalie] Univ Rwanda, Sch Publ Hlth, Kigali, Rwanda; [Walker, Dilys] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA	University of California System; University of California San Francisco; University of Rwanda; University of California System; University of California San Francisco	Lundeen, T (corresponding author), Univ Calif San Francisco, Inst Global Hlth Sci, San Francisco, CA 94143 USA.	tiffany.lundeen@gmail.com	Musange, Sabine F./AAC-3652-2019	Nzeyimana, David/0000-0002-1389-7107	East Africa Preterm Birth Initiative - Bill and Melinda Gates Foundation [OPP1107312]; East Africa Preterm Birth Initiative	East Africa Preterm Birth Initiative - Bill and Melinda Gates Foundation; East Africa Preterm Birth Initiative	This trial is supported by the East Africa Preterm Birth Initiative, a multi-year, multi-country effort generously funded by the Bill and Melinda Gates Foundation (OPP1107312). All the authors had some portion of their salary supported by the East Africa Preterm Birth Initiative.	Baldwin K, 2011, J PERINAT ED; Benediktsson I, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-S1-S5; Bloomfield J, 2013, J MIDWIFERY WOMENS H; Cohen S, 1983, J HLTH SOC BEHAV; Gaudion A., 2011, BRIT J MIDWIFERY, V19, P796, DOI DOI 10.12968/BJ0M.2011.19.12.796; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Kamugundu D, RWANDA MASTER FACILI; Kania-Richmond A, 2017, MATERN CHILD HLTH J, V21, P1327, DOI 10.1007/s10995-016-2236-1; Klima C, 2009, J MIDWIFERY WOMENS H; Lori JR, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1414-5; Mazzoni SE, 2017, AM J OBSTET GYNECOLO; McNeil DA, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-S1-S6; NISR Ministry of Finance Economic Planning/Rwanda Ministry of Health/Rwanda ICF International, 2016, RWAND DEM HLTH SURV; Novick G, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.03.026; Patil CL, 2017, INT J GYNECOL OBSTET, V139, P290, DOI 10.1002/ijgo.12324; Patil CL, 2013, MIDWIFERY, V29, P1190, DOI 10.1016/j.midw.2013.05.008; Pope C, 2000, BMJ; Rising SS, 2004, J MIDWIFERY WOM HEAL, V49, P398, DOI 10.1111/j.1542-2011.2004.tb04433.x; Sayinzoga F, 2018, J MIDWIFERY WOMENS H; Sayinzoga F, 2018, J MIDWIFER      0925; Teate A, 2013, WOMEN BIRTH; WHO, 2016, 2030A6938 WHO	22	9	9	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2019	14	7							e0219471	10.1371/journal.pone.0219471	http://dx.doi.org/10.1371/journal.pone.0219471			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4LN	31295335	Green Submitted, Green Published, gold			2023-01-03	WOS:000484951800036
J	Sandfort, TGM; Dominguez, K; Kayange, N; Ogendo, A; Panchia, R; Chen, YQ; Chege, W; Cummings, V; Guo, X; Hamilton, EL; Stirratt, M; Eshleman, SH				Sandfort, Theo G. M.; Dominguez, Karen; Kayange, Noel; Ogendo, Arthur; Panchia, Ravindre; Chen, Ying Q.; Chege, Wairimu; Cummings, Vanessa; Guo, Xu; Hamilton, Erica L.; Stirratt, Michael; Eshleman, Susan H.			HIV testing and the HIV care continuum among sub-Saharan African men who have sex with men and transgender women screened for participation in HPTN 075	PLOS ONE			English	Article							KEY POPULATIONS; HIGH PREVALENCE; INFECTION; RISK; INTERVENTIONS; STIGMA; PREVENTION; GAY; MSM; EPIDEMIOLOGY	Throughout the world, men who have sex with men (MSM) are at increased risk for HIV infection compared to heterosexual men. Little is known about awareness of HIV infection and other gaps in the HIV care continuum for MSM, especially in sub-Saharan Africa (SSA). This information is urgently needed to address the HIV epidemic in this population. This study assessed gaps in the HIV care continuum among persons screened for participation in a multi-country prospective study that evaluated the feasibility of recruiting and retaining MSM for HIV prevention studies in SSA (HIV Prevention Trials Network (HPTN) 075, conducted in four cities in Kenya, Malawi, and South Africa). Participants were recruited using site-specific strategies, that included outreach and informal networks. Transgender women (TW) were eligible to participate. During screening, 601 MSM and TW were tested for HIV infection and asked about prior HIV testing, HIV status, engagement in care, and HIV treatment. Viral load testing and retrospective antiretroviral (ARV) drug testing were performed for HIV-infected participants. Most participants (92.2%) had a prior HIV test; 42.1% were last tested >6 months earlier. HIV prevalence was 30.4%. HIV infection was associated with older age and identifying as female or transgender; 43.7% of the HIV-infected participants were newly diagnosed, especially younger persons and persons with a less recent HIV test. Almost a third of previously-diagnosed participants were not linked to care. Most participants (88.7%) in care were on ARV treatment (ART). Only about one-quarter of all HIV-infected participants were virally suppressed. These findings demonstrate substantial prevalence of undiagnosed HIV infection and sub-optimal HIV care engagement among MSM and TW in SSA. Increased HIV testing frequency and better linkage to care represent critical steps in preventing further HIV transmission in this population. Once in care, gaps in the HIV care continuum appear less critical.	[Sandfort, Theo G. M.] Columbia Univ, HIV Ctr Clin & Behav Studies, New York, NY 10027 USA; [Dominguez, Karen] UCT Med Sch, Desmond Tutu HIV Ctr, Cape Town, South Africa; [Kayange, Noel] Johns Hopkins Med Coll, Blantyre, Malawi; [Ogendo, Arthur] Kenya Med Res Inst KEMRI CDC, Kisumu, Kenya; [Panchia, Ravindre] Univ Witwatersrand, Perinatal HIV Res Unit, Soweto HPTN CRS, Soweto, South Africa; [Chen, Ying Q.; Guo, Xu] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA; [Chege, Wairimu] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Cummings, Vanessa; Eshleman, Susan H.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Hamilton, Erica L.] FHI, Sci Facilitat Dept, Durham, NC USA; [Stirratt, Michael] NIMH, Div AIDS Res, Bethesda, MD 20892 USA	Columbia University; University of Cape Town; Kenya Medical Research Institute; University of Witwatersrand; Fred Hutchinson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Sandfort, TGM (corresponding author), Columbia Univ, HIV Ctr Clin & Behav Studies, New York, NY 10027 USA.	tgs2001@cumc.columbia.edu	Sandfort, Theo/D-1796-2011	Sandfort, Theo/0000-0002-4986-1739; Chen, Ying Qing/0000-0002-2726-3391; Hamilton, Erica L./0000-0003-1174-9263	National Institute of Allergy and Infectious Diseases; National Institute of Mental Health of the National Institutes of Health [UM1AI068619, UM1AI068617, UM1AI068613]; National Institute of Mental Health [P30 MH43520]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI069518, UM1AI068617, UM1AI068613, UM1AI069453, UM1AI068619] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH043520] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Mental Health of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases and the National Institute of Mental Health of the National Institutes of Health under award number UM1AI068619 (HPTN Leadership and Operations Center), UM1AI068617 (HPTN Statistical and Data Management Center), and UM1AI068613 (HPTN Laboratory Center). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institute of Mental Health. Sandfort received additional support from the National Institute of Mental Health, P30 MH43520. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrinopoulos K, 2015, AIDS BEHAV, V19, P60, DOI 10.1007/s10461-014-0813-0; Arreola S, 2015, AIDS BEHAV, V19, P227, DOI 10.1007/s10461-014-0869-x; Baral S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004997; Baral SD, 2014, CURR OPIN HIV AIDS, V9, P156, DOI 10.1097/COH.0000000000000037; Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8; Beyrer C, 2012, LANCET, V380, P367, DOI 10.1016/S0140-6736(12)60821-6; Beyrer C, 2010, EPIDEMIOL REV, V32, P137, DOI 10.1093/epirev/mxq011; Bowring AL, 2016, AIDS BEHAV, V20, P2243, DOI 10.1007/s10461-015-1281-x; Cao BL, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.7997; Carroll A, 2017, STATE SPONSORED HOMO; Cock J, 2003, WOMEN STUD INT FORUM, V26, P35, DOI 10.1016/S0277-5395(02)00353-9; Cohen MS, 2012, CURR OPIN HIV AIDS, V7, P99, DOI 10.1097/COH.0b013e32834f5cf2; Crowell TA, 2019, ANN EPIDEMIOL, V31, P11, DOI 10.1016/j.annepidem.2018.12.004; Djomand G, 2014, CURR OPIN HIV AIDS, V9, P506, DOI 10.1097/COH.0000000000000090; Fay H, 2011, AIDS BEHAV, V15, P1088, DOI 10.1007/s10461-010-9861-2; Fogel JM, 2019, AIDS BEHAV, V23, P289, DOI 10.1007/s10461-018-2231-1; Freeland R, 2018, AIDS BEHAV, V22, P1614, DOI 10.1007/s10461-017-1975-3; Gelmon L, 2009, KENYA HIV PREVENTION; Gouws E, 2012, SEX TRANSM INFECT, V88, pI76, DOI 10.1136/sextrans-2012-050719; Grinsztejn B, 2014, LANCET INFECT DIS, V14, P281, DOI 10.1016/S1473-3099(13)70692-3; Hakim A, 2017, SEX TRANSM DIS, V44, P565, DOI 10.1097/OLQ.0000000000000655; Hergenrather KC, 2016, AIDS EDUC PREV, V28, P252, DOI 10.1521/aeap.2016.28.3.252; Hoad Neville Wallace, 2005, SEX POLITICS S AFRIC; Keane J, 2017, AIDS BEHAV, V21, P1745, DOI 10.1007/s10461-016-1532-5; Kellerman S, 2012, EPIDEMIOLOGY HIV EPI; Keshinro B, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.21270; Knox J, 2011, INT J STD AIDS, V22, P709, DOI 10.1258/ijsa.2011.010350; Kohut A, 2013, GLOBAL DIVIDE HOMOSE, P4; Krishnaratne S, 2016, LANCET HIV, V3, pE307, DOI 10.1016/S2352-3018(16)30038-8; Kunzweiler CP, 2017, JAIDS-J ACQ IMM DEF, V76, P241, DOI 10.1097/QAI.0000000000001512; Laar A, 2017, BMC INT HEALTH HUM R, V17, DOI 10.1186/s12914-017-0129-z; Lane T, 2016, JAIDS-J ACQ IMM DEF, V73, P609, DOI 10.1097/QAI.0000000000001162; Lane T, 2011, AIDS BEHAV, V15, P626, DOI 10.1007/s10461-009-9598-y; Logie CH, 2017, J INT AIDS SOC, V20, DOI [10.7448/IAS.20.01/21422, 10.7448/IAS.20.1.21385, 10.7448/IAS.20.1.21422]; Lyons CE, 2017, JAIDS-J ACQ IMM DEF, V74, pS52, DOI 10.1097/qai.0000000000001209; Maleke K, 2019, GLOB HEALTH PROMOT, V26, P6, DOI 10.1177/1757975917737509; Mishra S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050691; Mmbaga EJ, 2018, JAIDS-J ACQ IMM DEF, V77, P243, DOI [10.1097/qai.0000000000001593, 10.1097/QAI.0000000000001593]; Mumtaz GR, 2013, SEX TRANSM INFECT, V89, P49, DOI 10.1136/sextrans-2012-050844; Poteat T, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002422; Poteat T, 2016, GLOB PUBLIC HEALTH, V11, P835, DOI 10.1080/17441692.2015.1134615; Poteat T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028760; Reid G, 2010, SOC DYNAMICS, V36, P38, DOI 10.1080/02533950903561221; Reisner SL, 2016, CURR OPIN ENDOCRINOL, V23, P198, DOI 10.1097/MED.0000000000000229; Reisner SL, 2014, ARCH SEX BEHAV, V43, P1503, DOI 10.1007/s10508-014-0314-2; Rispel LC, 2011, JAIDS-J ACQ IMM DEF, V57, P69, DOI 10.1097/QAI.0b013e318211b40a; Sanders EJ, 2007, AIDS, V21, P2513, DOI 10.1097/QAD.0b013e3282f2704a; Sanders EJ, 2013, AIDS, V27, P437, DOI 10.1097/QAD.0b013e32835b0f81; Sandfort TGM, 2018, ARCH SEX BEHAV, V47, P2481, DOI 10.1007/s10508-018-1168-9; Sandfort TGM, 2015, AIDS BEHAV, V19, P561, DOI 10.1007/s10461-014-0843-7; Sandfort TGM, 2015, AIDS BEHAV, V19, P2270, DOI 10.1007/s10461-015-1067-1; Sevelius JM, 2016, GLOB PUBLIC HEALTH, V11, P1060, DOI 10.1080/17441692.2016.1154085; Smith AD, 2009, LANCET, V374, P416, DOI 10.1016/S0140-6736(09)61118-1; Stahlman S, 2016, J INT AIDS SOC, V19, P5, DOI 10.7448/IAS.19.3.20774; Tanser F, 2014, CURR OPIN HIV AIDS, V9, P115, DOI 10.1097/COH.0000000000000034; Thoreson R, 2011, NOWHERE TURN BLACKMA; Winter S, 2016, LANCET, V388, P390, DOI 10.1016/S0140-6736(16)00683-8; Wirtz AL, 2017, LANCET HIV, V4, pE260, DOI 10.1016/S2352-3018(17)30042-5; Zhang YF, 2018, AIDS, V32, P1301, DOI 10.1097/QAD.0000000000001839	59	18	18	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2019	14	5							e0217501	10.1371/journal.pone.0217501	http://dx.doi.org/10.1371/journal.pone.0217501			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IA7TI	31150447	Green Submitted, Green Published, gold			2023-01-03	WOS:000469759100060
J	Mckay, B; Castellanos, M; Ebell, M; Whalen, CC; Handel, A				Mckay, Brian; Castellanos, Maria; Ebell, Mark; Whalen, Christopher C.; Handel, Andreas			An attempt to reproduce a previous meta-analysis and a new analysis regarding the impact of directly observed therapy on tuberculosis treatment outcomes	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; OBSERVED TREATMENT DOT; VARIANCE ESTIMATORS; CLINICAL-TRIALS; HEALTH-WORKERS; EFFICACY; HETEROGENEITY; NONCOMPLIANCE; URBAN; BIAS	Directly observed therapy (DOT) is almost universally used for the treatment of TB. Several meta-analyses using different methods have assessed the effectiveness of DOT compared to self-administered therapy (SAT). The results of these meta-analyses often conflict with some concluding DOT is superior and others that there is little or no difference. Meta-analyses can guide policymaking, but such analyses must be reliable. To assess the validity of a previous meta-analysis, we tried to reproduce it. We encountered problems with the previous analysis that did not allow for a meaningful reproduction. We describe the issues we encountered here. We then performed a new meta-analysis comparing the treatment outcomes of adults given treatment with SAT versus DOT. Outcomes in the new analysis are loss to follow-up, treatment failure, cure, treatment completed, and all-cause mortality. All data, documentation, and code used to generate our results is provided. Our new analysis included four randomized and three observational studies with 1603 and 1626 individuals respectively. The pooled relative risks (RR) are as follows: Lost to follow-up (RR = 1.2, 95% CI 0.9, 1.7), Treatment Failure (RR = 1.1, 95% CI 0.6, 2), Cure (RR = 0.9, 95% CI 0.8, 1.1), Treatment Completion (RR = 1, 95% CI 0.9, 1.1), Mortality (RR = 0.9, 95% CI 0.6, 1.3). Based on data from our new meta-analysis, the magnitude of the difference between DOT and SAT for all reported outcomes is small, and none of the differences are statistically significant.	[Mckay, Brian; Castellanos, Maria; Ebell, Mark; Whalen, Christopher C.; Handel, Andreas] Univ Georgia, Dept Epidemiol & Biostat, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Mckay, B; Handel, A (corresponding author), Univ Georgia, Dept Epidemiol & Biostat, Athens, GA 30602 USA.	bmckay52@uga.edu; ahandel@uga.edu		Handel, Andreas/0000-0002-4622-1146; McKay, Brian/0000-0003-3859-7634; Castellanos, Maria Eugenia/0000-0002-8181-6321				Alipanah N, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002595; Alvarez-Gordillo GD, 1998, SALUD PUBLICA MEXICO, V40, P272, DOI 10.1590/S0036-36341998000300008; [Anonymous], 1997, Int J Tuberc Lung Dis, V1, P509; [Anonymous], R LANG ENV STAT COMP; Anuwatnonthakate A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003089; Borenstein M., 2009, INTRO METAANALYSIS, P69, DOI DOI 10.1002/9780470743386.CH12; de Steenwinkel JEM, 2012, ANTIMICROB AGENTS CH, V56, P4937, DOI 10.1128/AAC.00124-12; Deeks JJ, 2002, STAT MED, V21, P1575, DOI 10.1002/sim.1188; Denkinger CM, 2013, INT J TUBERC LUNG D, V17, P719, DOI 10.5588/ijtld.12.0638; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Freedman LP, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002165; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; Friedrich JO, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-5; Garner P, 2003, BRIT MED J, V327, P823, DOI 10.1136/bmj.327.7419.823; Glaziou P, 2013, SEMIN RESP CRIT CARE, V34, P3, DOI 10.1055/s-0032-1333467; Green S, 2008, COCHRANE HDB SYSTEMA, V5; Jackson D, 2010, J STAT PLAN INFER, V140, P961, DOI 10.1016/j.jspi.2009.09.017; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jasmer RM, 2004, AM J RESP CRIT CARE, V170, P561, DOI 10.1164/rccm.200401-095OC; Kamolratanakul P, 1999, T ROY SOC TROP MED H, V93, P552, DOI 10.1016/S0035-9203(99)90379-6; Karumbi J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003343.pub4; Kironde Samson, 2002, Afr Health Sci, V2, P16; Lwilla F, 2003, TROP MED INT HEALTH, V8, P204, DOI 10.1046/j.1365-3156.2003.00999.x; MacIntyre CR, 2003, INT J TUBERC LUNG D, V7, P848; Macq JCM, 2003, INT J TUBERC LUNG D, V7, P103; Mathema B, 2001, INT J TUBERC LUNG D, V5, P912; McLaren ZM, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1862-y; Mesirov JP, 2010, SCIENCE, V327, P415, DOI 10.1126/science.1179653; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Moonan PK, 2013, CLIN INFECT DIS, V57, P1062, DOI 10.1093/cid/cit431; Muller AM, 2018, INT J TUBERC LUNG D, V22, P731, DOI 10.5588/ijtld.17.0596; Nunn AJ, 2013, CLIN INFECT DIS, V57, P1064, DOI 10.1093/cid/cit433; Okanurak K, 2007, INT J TUBERC LUNG D, V11, P762; Ormerod LP, 2002, INT J TUBERC LUNG D, V6, P662; Orwin R. G., 1983, J EDUC STAT, V8, P157, DOI [10.3102/10769986008002157, DOI 10.2307/1164923]; Pasipanodya JG, 2013, CLIN INFECT DIS, V57, P1223, DOI 10.1093/cid/cit487; Peng RD, 2011, SCIENCE, V334, P1226, DOI 10.1126/science.1213847; Pungrassami P, 2002, TROP MED INT HEALTH, V7, P271, DOI 10.1046/j.1365-3156.2002.00849.x; Schwab M, 2000, COMPUT SCI ENG, V2, P61, DOI 10.1109/5992.881708; Seaworth BJ, 2013, CLIN INFECT DIS, V57, P1063, DOI 10.1093/cid/cit432; Sidik K, 2007, STAT MED, V26, P1964, DOI 10.1002/sim.2688; Srivastava S, 2011, J INFECT DIS, V204, P1951, DOI 10.1093/infdis/jir658; Tandon Monika, 2002, Indian J Med Sci, V56, P19; Thorlund K, 2011, RES SYNTH METHODS, V2, P238, DOI 10.1002/jrsm.53; Tian JH, 2014, INT J TUBERC LUNG D, V18, P1092, DOI 10.5588/ijtld.13.0867; Viechtbauer W, 2005, J EDUC BEHAV STAT, V30, P261, DOI 10.3102/10769986030003261; Viswanathan M., 2013, AHRQ METHODS EFFECTI; Volmink J., 2007, COCHRANE DATABASE SY, V4; Walley JD, 2001, LANCET, V357, P664, DOI 10.1016/S0140-6736(00)04129-5; Wandwalo E, 2004, INT J TUBERC LUNG D, V8, P1248; WHO, 2017, TREATMENT TUBERCULOS; World Health Organization, 1999, WHAT IS DOTS GUID UN; Wright J, 2004, TROP MED INT HEALTH, V9, P559, DOI 10.1111/j.1365-3156.2004.01230.x; Zwarenstein M, 2000, INT J TUBERC LUNG D, V4, P550; Zwarenstein M, 1998, LANCET, V352, P1340, DOI 10.1016/S0140-6736(98)04022-7	56	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2019	14	5							e0217219	10.1371/journal.pone.0217219	http://dx.doi.org/10.1371/journal.pone.0217219			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ3VE	31120965	gold, Green Published, Green Accepted			2023-01-03	WOS:000468775700071
J	Albuja, AF; Sanchez, DT; Lee, SJ; Lee, JY; Yadava, S				Albuja, Analia F.; Sanchez, Diana T.; Lee, Shawna J.; Lee, Joyce Y.; Yadava, Stacy			The effect of paternal cues in prenatal care settings on men's involvement intentions	PLOS ONE			English	Article							FATHER INVOLVEMENT; SOCIAL IDENTITY; PREGNANCY; BEHAVIOR; SUPPORT; HEALTH	A father's involvement in prenatal care engenders health benefits for both mothers and children. While this information can help practitioners improve family health, low paternal involvement in prenatal care remains a challenge. The present study tested a simple, easily scalable intervention to promote father involvement by increasing men's feelings of comfort and expectations of involvement in prenatal settings through three randomized control trials. Borrowing from social psychological theory on identity safety, the three studies tested whether the inclusion of environmental cues that represent men and fatherhood in prenatal care offices influenced men's beliefs and behavioral intentions during the perinatal period. Men in studies 1 and 3 viewed online videos of purported prenatal care offices, while men in study 2 visited the office in person. Those who viewed or were immersed in a father-friendly prenatal care office believed that doctors had higher expectations of father involvement compared to treatment-as-usual. This perception predicted greater parenting confidence, comfort, and behavioral intentions to learn about the pregnancy and engage in healthy habits, such as avoiding smoking and alcohol during their partner's pregnancy. Study 3 replicated these studies with an online sample of expectant fathers. The results suggest that shifting environment office cues can signal fathering norms to men in prenatal settings, with healthier downstream behavior intentions.	[Albuja, Analia F.; Sanchez, Diana T.] Rutgers State Univ, Dept Psychol, New Brunswick, NJ 08854 USA; [Lee, Shawna J.; Lee, Joyce Y.] Univ Michigan, Sch Social Work, Ann Arbor, MI 48109 USA; [Yadava, Stacy] Univ Med & Dent New Jersey, Dept Obstet Gynecol & Reprod Sci, New Brunswick, NJ USA	Rutgers State University New Brunswick; University of Michigan System; University of Michigan; Rutgers State University New Brunswick; Rutgers State University Medical Center	Albuja, AF (corresponding author), Rutgers State Univ, Dept Psychol, New Brunswick, NJ 08854 USA.	analia.albuja@rutgers.edu	Sanchez, Diana/GSD-6690-2022					Albuja AF, 2019, J STUD ALCOHOL DRUGS, V80, P129, DOI 10.15288/jsad.2019.80.129; Alio AP, 2011, MATERN CHILD HLTH J, V15, P425, DOI 10.1007/s10995-011-0781-1; Alio AP, 2010, MATERN CHILD HLTH J, V14, P931, DOI 10.1007/s10995-009-0531-9; Appleton PL, 1998, BRIT J HEALTH PSYCH, V3, P361, DOI 10.1111/j.2044-8287.1998.tb00580.x; Cabrera NJ, 2008, J MARRIAGE FAM, V70, P1094, DOI 10.1111/j.1741-3737.2008.00551.x; Cheng ER, 2016, J WOMENS HEALTH, V25, P672, DOI 10.1089/jwh.2015.5462; Cheryan S, 2011, COMPUT EDUC, V57, P1825, DOI 10.1016/j.compedu.2011.02.004; Cheryan S, 2009, J PERS SOC PSYCHOL, V97, P1045, DOI 10.1037/a0016239; Coltrane S, 2004, FAM RELAT, V53, P179; Cook J. L., 2005, FATHERING, V3, P165; Craig L, 2006, GENDER SOC, V20, P259, DOI 10.1177/0891243205285212; Croft A, 2014, PSYCHOL SCI, V25, P1418, DOI 10.1177/0956797614533968; Deave T, 2008, J ADV NURS, V63, P626, DOI 10.1111/j.1365-2648.2008.04748.x; Dover TL, 2016, J EXP SOC PSYCHOL, V62, P58, DOI 10.1016/j.jesp.2015.10.006; Draper H, 2013, MIDWIFERY, V29, P723, DOI 10.1016/j.midw.2013.02.007; Eagly AH, 1999, AM PSYCHOL, V54, P408, DOI 10.1037/0003-066X.54.6.408; Fagan J., 2003, FATHERING, V1, P283, DOI [DOI 10.3149/FTH.0103.283, https://doi.org/10.3149/fth.0103.283]; Hauser DJ, 2016, BEHAV RES METHODS, V48, P400, DOI 10.3758/s13428-015-0578-z; Hayes A.F., PROCESS VERSATILE CO; Johnson WE, 2001, CHILD YOUTH SERV REV, V23, P513, DOI 10.1016/S0190-7409(01)00146-3; Lamb ME, 2000, MARRIAGE FAM REV, V29, P23, DOI 10.1300/J002v29n02_03; Lee JY, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-0437; Lee SJ, 2018, MATERN CHILD HLTH J, V22, P1407, DOI 10.1007/s10995-018-2521-2; Martin LT, 2007, MATERN CHILD HLTH J, V11, P595, DOI 10.1007/s10995-007-0209-0; Park B, 2010, J EXP SOC PSYCHOL, V46, P809, DOI 10.1016/j.jesp.2010.04.009; Plantin L, 2011, FATHERING, V9, P87, DOI [10.3149/fth.0901.87, DOI 10.3149/FTH.0901.87, 10.4069/kjwhn.2020.06.12102]; Prentice DA, 2002, PSYCHOL WOMEN QUART, V26, P269, DOI 10.1111/1471-6402.t01-1-00066; Purdie-Vaughns V, 2008, J PERS SOC PSYCHOL, V94, P615, DOI 10.1037/0022-3514.94.4.615; Rouse SV, 2015, COMPUT HUM BEHAV, V43, P304, DOI 10.1016/j.chb.2014.11.004; Rudman LA, 2012, J EXP SOC PSYCHOL, V48, P165, DOI 10.1016/j.jesp.2011.10.008; Salzmann-Erikson M, 2013, HEALTH SOC CARE COMM, V21, P381, DOI 10.1111/hsc.12028; Schmader T, 2018, PERS SOC PSYCHOL REV, V22, P228, DOI 10.1177/1088868317734080; Steen M, 2012, MIDWIFERY, V28, P422, DOI 10.1016/j.midw.2011.06.009; Stout JG, 2011, J PERS SOC PSYCHOL, V100, P255, DOI 10.1037/a0021385; Wall G, 2007, GENDER SOC, V21, P508, DOI 10.1177/0891243207304973; Webb TL, 2006, PSYCHOL BULL, V132, P249, DOI 10.1037/0033-2909.132.2.249	36	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2019	14	5							e0216454	10.1371/journal.pone.0216454	http://dx.doi.org/10.1371/journal.pone.0216454			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HX6ZE	31071147	Green Submitted, Green Published, gold			2023-01-03	WOS:000467552100051
J	Silva, D; Moreira, R; Beltrao, M; Sokhatska, O; Montanha, T; Pizarro, A; Garcia-Larsen, V; Villegas, R; Delgado, L; Moreira, P; Carvalho, J; Moreira, A				Silva, Diana; Moreira, Rita; Beltrao, Marilia; Sokhatska, Oksana; Montanha, Tiago; Pizarro, Andreia; Garcia-Larsen, Vanessa; Villegas, Rodrigo; Delgado, Luis; Moreira, Pedro; Carvalho, Joana; Moreira, Andre			What is the effect of a Mediterranean compared with a Fast Food meal on the exercise induced adipokine changes? A randomized cross-over clinical trial	PLOS ONE			English	Article							BETA-CELL FUNCTION; PHYSICAL-ACTIVITY; POSTPRANDIAL ADIPONECTIN; AEROBIC EXERCISE; SERUM RESISTIN; HIGH-FAT; DIET; RESPONSES; ADIPSIN; METAANALYSIS	Background Adipose tissue-derived adipokines are pro-inflammatory cytokines involved in metabolic-related diseases and can be influenced by diet and exercise. We aimed to compare the effect of a Mediterranean (MdM) compared with Fast Food (FFM) meal on the exercise induced adipokines changes. Methods In a double blinded cross over trial, 46 participants were randomly assigned to one of two standardized iso-energy pre-exercise meals: FFM or MdM-type. Three hours after each meal, participants completed a treadmill exercise test (EC). Serum adiponectin, resistin, PAI-1, lipocalin-2/NGAL and adipsin were determined by Luminex magnetic bead immunoassay. Wilcoxon signed rank test compared changes before/after meal and before/after EC and a linear mixed model evaluated the effect of meals on the adipokine response to exercise, adjusted for confounders. Results Thirty-nine participants (mean age of 25, with a standard deviation of 5 years) completed the trial (56% females). For both interventions, a significant reduction of adipsin after each meal and a significant increase of lipocalin, PAI-1, adipsin and resistin, after exercise was observed. When exercise was preceded by a MdM meal a higher increase in adipsin levels was seen. Conclusion Acute exercise induced an increase of circulatory levels of adipsin, resistin, lipocalin and PAI-1, but not adiponectin. A pre-exercise Mediterranean meal potentiated the increase of adipsin after the exercise test, which possibly relates to the immune regulatory role of adipsin. These changes suggest a cross-talk between the immune and metabolic immediate response to exercise and its modulation by the pre-exercise diet composition.	[Silva, Diana; Beltrao, Marilia; Sokhatska, Oksana; Delgado, Luis; Moreira, Andre] Univ Porto, Fac Med, Dept Pathol, Basic & Clin Immunol, Porto, Portugal; [Silva, Diana; Delgado, Luis; Moreira, Andre] Ctr Hosp Sao Joao EPE, Serv Imunoalergol, Porto, Portugal; [Moreira, Rita; Moreira, Pedro] Univ Porto, Fac Nutr & Food Sci, Porto, Portugal; [Montanha, Tiago; Pizarro, Andreia; Carvalho, Joana] Fac Sports, Res Ctr Phys Act Hlth & Leisure, Porto, Portugal; [Garcia-Larsen, Vanessa] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; [Villegas, Rodrigo] Univ Chile, Sch Publ Hlth, Independencia 939, Santiago, Chile; [Moreira, Andre] Univ Porto, Inst Saude Publ, Epidemiol Res Unit, Porto, Portugal	Universidade do Porto; Sao Joao Hospital; Universidade do Porto; Universidade do Porto; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Universidad de Chile; Universidade do Porto	Silva, D (corresponding author), Univ Porto, Fac Med, Dept Pathol, Basic & Clin Immunol, Porto, Portugal.; Silva, D (corresponding author), Ctr Hosp Sao Joao EPE, Serv Imunoalergol, Porto, Portugal.	disolha@gmail.com	Moreira, André/AAH-9683-2020; Moreira, Pedro/U-2581-2019; Moreira, Pedro/U-3034-2019; Delgado, Luis/L-8035-2013; Silva, Diana/ABC-4233-2021	Moreira, André/0000-0002-7294-9296; Moreira, Pedro/0000-0002-7035-7799; Delgado, Luis/0000-0003-2375-9071; Silva, Diana/0000-0002-0656-7206; Carvalho, Maria Joana/0000-0001-6500-7543; Montanha, Tiago/0000-0003-0362-9771; Sokhatska, Oksana/0000-0003-3061-8066; Pizarro, Andreia/0000-0001-6518-5569; Villegas, Rodrigo/0000-0001-7878-5053	Health, Comfort and Energy in the Built Environment (HEBE) [NORTE-01-0145-FEDER-000010]; Programa Operacional Regional do Norte (NORTE2020), through Fundo Europeu de Desenvolvimento Regional (FEDER)	Health, Comfort and Energy in the Built Environment (HEBE); Programa Operacional Regional do Norte (NORTE2020), through Fundo Europeu de Desenvolvimento Regional (FEDER)	This work was supported by the Project NORTE-01-0145-FEDER-000010 - Health, Comfort and Energy in the Built Environment (HEBE), cofinanced by Programa Operacional Regional do Norte (NORTE2020), through Fundo Europeu de Desenvolvimento Regional (FEDER) (AM). The sponsors did not play any role in the study design, data collection, analysis, decision to publish or preparation of the manuscript.	Abella V, 2015, BIOMARKERS, V20, P565, DOI 10.3109/1354750X.2015.1123354; Abreu S, 2015, NUTR HOSP, V31, P1403, DOI 10.3305/nh.2015.31.3.8158; Adeghate E, 2004, CELL MOL LIFE SCI, V61, P2485, DOI 10.1007/s00018-004-4083-2; Asthma GIF, GLOB STRAT ASTHM MAN; Azizi M, 2017, INT J DIABETES DEV C, V37, P298, DOI 10.1007/s13410-016-0504-7; Baila-Rueda L, 2015, NUTR METAB CARDIOVAS, V25, P853, DOI 10.1016/j.numecd.2015.06.008; Bays HE, 2011, J AM COLL CARDIOL, V57, P2461, DOI 10.1016/j.jacc.2011.02.038; Bedard A, 2014, EUR J CLIN NUTR, V68, P561, DOI 10.1038/ejcn.2014.27; Bokarewa M, 2005, J IMMUNOL, V174, P5789, DOI 10.4049/jimmunol.174.9.5789; Bray GA, 2007, ANN NUTR METAB, V51, P163, DOI 10.1159/000103277; Bruce RA, 2004, ANN NONINVAS ELECTRO, V9, P291, DOI 10.1111/j.1542-474X.2004.93003.x; Campbell JP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00648; Chen YC, 2017, AM J PHYSIOL-ENDOC M, V313, pE84, DOI 10.1152/ajpendo.00006.2017; Christiansen T, 2013, EUR J APPL PHYSIOL, V113, P1635, DOI 10.1007/s00421-013-2592-0; Cooper JA, 2004, MED SCI SPORT EXER, V36, P1884, DOI 10.1249/01.MSS.0000145447.61736.ED; Corp I, 2016, IBM SPSS STAT WINDOW, V24; Damirchi Arsalan, 2011, Asian J Sports Med, V2, P44; Dinu M, 2018, EUR J CLIN NUTR, V72, P30, DOI 10.1038/ejcn.2017.58; Dordevic AL, 2015, NUTRIENTS, V7, P5347, DOI 10.3390/nu7075224; Ferguson MA, 2004, EUR J APPL PHYSIOL, V91, P324, DOI 10.1007/s00421-003-0985-1; Garcia-Hermoso A, 2017, INT J OBESITY, V41, P475, DOI 10.1038/ijo.2016.230; Gavriilaki E, 2014, J HUM HYPERTENS, V28, P606, DOI 10.1038/jhh.2014.18; Gorgens SW, 2015, PROG MOL BIOL TRANSL, V135, P313, DOI 10.1016/bs.pmbts.2015.07.002; Gruendel S, 2006, J ENDOCRINOL INVEST, V29, pRC27, DOI 10.1007/BF03349186; Heilbronn LK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078864; Heinzerling Lucie, 2013, Clin Transl Allergy, V3, P3, DOI 10.1186/2045-7022-3-3; INSA, 2017, PORTFIR NAT HLTH I D; Kaji H, 2016, COMPR PHYSIOL, V6, P1873, DOI 10.1002/cphy.c160004; Kennedy A, 2015, NUTRITION, V31, P863, DOI 10.1016/j.nut.2015.01.009; Kentish SJ, 2015, PHYSIOL BEHAV, V152, P354, DOI 10.1016/j.physbeh.2015.06.016; Liyanage T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159252; Lo JC, 2014, CELL, V158, P41, DOI 10.1016/j.cell.2014.06.005; Lozano A, 2013, NUTR RES, V33, P1012, DOI 10.1016/j.nutres.2013.08.010; Maiorino MI, 2016, ENDOCRINE, V54, P634, DOI 10.1007/s12020-016-0881-1; Martos-Moreno GA, 2010, CLIN CHEM LAB MED, V48, P1439, DOI 10.1515/CCLM.2010.276; McDermott BP, 2018, J SCI MED SPORT, V21, P1180, DOI 10.1016/j.jsams.2018.05.003; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Mortensen Lene S, 2010, Rev Diabet Stud, V7, P233, DOI 10.1900/RDS.2010.7.233; Nimmo MA, 2013, DIABETES OBES METAB, V15, P51, DOI 10.1111/dom.12156; Numao S, 2011, METABOLISM, V60, P186, DOI 10.1016/j.metabol.2009.12.011; Papamichael MM, 2019, J HUM NUTR DIET, V32, P185, DOI 10.1111/jhn.12609; Peake PW, 2005, INT J OBESITY, V29, P429, DOI 10.1038/sj.ijo.0802644; Racil G, 2016, BIOL SPORT, V33, P145, DOI 10.5604/20831862.1198633; Rossi FE, 2017, EUR J CLIN NUTR, V71, P638, DOI 10.1038/ejcn.2016.263; Roupas ND, 2013, HORM-INT J ENDOCRINO, V12, P275, DOI 10.14310/horm.2002.1411; Schwellnus M, 2016, BRIT J SPORT MED, V50, P1043, DOI 10.1136/bjsports-2016-096572; Silva D, 2018, CONT CLIN TRIAL COMM, V10, P177, DOI 10.1016/j.conctc.2018.05.010; Simpson KA, 2008, OBESITY, V16, P241, DOI 10.1038/oby.2007.53; Smith MM, 2012, J PHYSIOL-LONDON, V590, P1787, DOI 10.1113/jphysiol.2011.221036; StataCorp, 2017, STATA STAT SOFTWARE; Troiano RP, 2008, MED SCI SPORT EXER, V40, P181, DOI 10.1249/mss.0b013e31815a51b3; Vardar SA, 2018, ARCH PHYSIOL BIOCHEM, V124, P149, DOI 10.1080/13813455.2017.1369998; von Frankenberg AD, 2014, BRIT J NUTR, V112, P1235, DOI 10.1017/S0007114514002013; von Kanel R, 2007, AM J HYPERTENS, V20, P670, DOI 10.1016/j.amjhyper.2007.01.005; WHITE RT, 1992, J BIOL CHEM, V267, P9210; Wu Chung-Jung, 2004, Lipids Health Dis, V3, P17, DOI 10.1186/1476-511X-3-17; Yamauchi J, 2008, METABOLISM, V57, P149, DOI 10.1016/j.metabol.2007.08.018; Zhang X, 2018, ALLERGY ASTHMA PROC, V39, P43, DOI [10.2500/aap.2018.39.4096, 10.2500/aap.2017.38.4096]	58	3	3	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2019	14	4							e0215475	10.1371/journal.pone.0215475	http://dx.doi.org/10.1371/journal.pone.0215475			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU1EQ	30998792	Green Published, Green Submitted, gold			2023-01-03	WOS:000465015500064
J	Thornton, J				Thornton, Jacqui			Palliative care in Tajikistan	LANCET			English	Editorial Material																			0	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 24	2019	394	10199					624	626		10.1016/S0140-6736(19)31968-3	http://dx.doi.org/10.1016/S0140-6736(19)31968-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IT6UU	31448728				2023-01-03	WOS:000483011200017
J	Szczurek, L; Juszkat, R; Szczurek, J; Turek, I; Sosnowski, P				Szczurek, Lukasz; Juszkat, Robert; Szczurek, Jolanta; Turek, Ilona; Sosnowski, Piotr			Pre-treatment 2D and 3D dosimetric verification of volumetric arc therapy. A correlation study between gamma index passing rate and clinical dose volume histogram	PLOS ONE			English	Article							QUALITY-ASSURANCE; PER-BEAM; IMRT; QA; VALIDATION; ALGORITHM; SYSTEM; HEAD	Objectives To evaluate methods for the pre-treatment verification of volumetric modulated arc therapy (VMAT) based on the percentage gamma passing rate (%GP) and its correlation and sensitivity with percentage dosimetric errors (%DE). Methods A total of 25 patients with prostate cancer and 15 with endometrial cancer were analysed. The %GP values of 2D and 3D verifications with different acceptance criteria (1%/1 mm, 2%/2 mm, and 3%/3 mm) were obtained using OmniPro and Compass. The %DE was calculated using a planned dose volume histogram (DVH) created in Monaco's treatment planning system (TPS), which relates radiation dose to tissue and the patient's predicted dose volume histogram in Compass. Statistical correlation between %GP and %DE was verified using Pearson's correlation coefficient. Sensitivity was calculated based on the receiver operating characteristics (ROC) curve. Plans were calculated using Collapsed Cone Convolution and the Monte Carlo algorithm. Results The t-test results of the planned and estimated DVH showed that the mean values were comparable (P > 0.05). For the 3%/3 mm criterion, the average %GP was acceptable for the prostate and endometrial cancer groups, with average rates of 99.68 +/- 0.49% and 99.03 +/- 0.59% for 2D and 99.86 +/- 0.39% and 99.53 +/- 0.44% for 3D, respectively. The number of correlations was poor for all analysed data. The mean Pearson's R-values for prostate and endometrial cancer were < 0.45 and < 0.43, respectively. The area under the ROC curve for the prostate and endometrial cancer groups, was lower than 0.667. Conclusions Analysis of the %GP versus %DE values revealed only weak correlations between 2D and 3D verifications. DVH results obtained using the Compass system will be helpful in confirming that the analysed plans respect dosimetric constraints.	[Szczurek, Lukasz] Poznan Univ Med Sci, Dept Med 1, Poznan, Poland; [Szczurek, Lukasz] Int Oncol Ctr Affidea, Dept Med Phys, Poznan, Poland; [Juszkat, Robert; Sosnowski, Piotr] Poznan Univ Med Sci, Dept Gen & Intervent Radiol, Poznan, Poland; [Szczurek, Jolanta] Affidea, Dept Diagnost Imaging, Poznan, Poland; [Szczurek, Jolanta] Poznan Univ Med Sci, Dept Endocrinol Metab & Internal Med, Poznan, Poland; [Turek, Ilona] La Trobe Univ, Dept Pharm & Biomed Sci, Bendigo, Australia	Poznan University of Medical Sciences; Poznan University of Medical Sciences; Poznan University of Medical Sciences; La Trobe University	Juszkat, R (corresponding author), Poznan Univ Med Sci, Dept Gen & Intervent Radiol, Poznan, Poland.	radiol@ump.edu.pl		Turek, Ilona/0000-0001-6457-7456				AHNESJO A, 1989, MED PHYS, V16, P577, DOI 10.1118/1.596360; Bentzen SM, 2010, INT J RADIAT ONCOL, V76, pS3, DOI 10.1016/j.ijrobp.2009.09.040; Boggula R, 2010, PHYS MED BIOL, V55, P5619, DOI 10.1088/0031-9155/55/19/001; Carrasco P, 2012, MED PHYS, V39, P5040, DOI 10.1118/1.4736949; Clivio L, 2014, RADIOTHER ONCOL, V9, P286; Cozzolino M, 2014, PHYS MEDICA, V30, P462, DOI 10.1016/j.ejmp.2014.01.003; Crijns W, 2016, MED PHYS, V43, DOI 10.1118/1.4945024; Delaby N, 2017, PHYS MED, V44, P19, DOI [10.1016/j.ejmp.2017.10.065, DOI 10.1016/J.EJMP.2017.10.065]; ESTRO, 2008, GUIDELINES VERIFICAT; Ezzell GA, 2003, MED PHYS, V30, P2089, DOI 10.1118/1.1591194; Ezzell GA, 2009, MED PHYS, V36, P5359, DOI 10.1118/1.3238104; Fodor E, 2018, BIOMED J SCI TECH RE, V6, P2; Hussein M, 2013, RADIOTHER ONCOL, V109, P370, DOI 10.1016/j.radonc.2013.08.048; International Commission on Radiation Units and Measurements, 2010, J ICRU, V10, P1; Jin X, 2015, BRIT J RADIOL, V88, DOI 10.1259/bjr.20140577; Jornet N, 2014, RADIOTHER ONCOL, V112, P381, DOI 10.1016/j.radonc.2014.06.016; Korevaar EW, 2011, RADIOTHER ONCOL, V100, P446, DOI 10.1016/j.radonc.2011.09.007; Lawton CAF, 2009, INT J RADIAT ONCOL, V74, P383, DOI 10.1016/j.ijrobp.2008.08.002; Low DA, 2003, MED PHYS, V30, P2455, DOI 10.1118/1.1598711; Nelms BE, 2011, MED PHYS, V38, P1037, DOI 10.1118/1.3544657; Nisbet A, 2004, RADIOTHER ONCOL, V73, P79, DOI 10.1016/j.radonc.2004.06.007; Palanisamy M, 2019, REP PRACT ONCOL RADI, V24, P188, DOI 10.1016/j.rpor.2019.01.005; Pasler M, 2018, PHYS IMAG RADIAT ONC, V5, P76, DOI 10.1016/j.phro.2018.03.002; Pimthong J, 2015, J PHYS C SER, V694, P1; Schreibmann E, 2009, MED PHYS, V36, P4530, DOI 10.1118/1.3213085; Seema S, 2018, INT J CANC THER ONCO, V6; Stasi M, 2012, MED PHYS, V39, P7626, DOI 10.1118/1.4767763; Subcommittee Netherlands Commission on Radiation Dosimetry. IMRT QA, 2013, 22 NCS; Tanha K, 2014, J RADIOTHER PRACT, V13, P447, DOI 10.1017/S1460396914000211; Teoh M, 2011, BRIT J RADIOL, V84, P967, DOI 10.1259/bjr/22373346; The Radiation Therapy Oncology Group, 2011, RTOG 0822 PROT PHAS; The Radiation Therapy Oncology Group, 2014, RTOG 0126 PROT PHAS; Visser R, 2014, RADIOTHER ONCOL, V112, P389, DOI 10.1016/j.radonc.2014.08.002; Zhao YQ, 2014, RADIAT ONCOL, V9, DOI 10.1186/s13014-014-0287-2; Zhen HM, 2011, MED PHYS, V38, P5477, DOI 10.1118/1.3633904	35	7	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2019	14	8							e0221086	10.1371/journal.pone.0221086	http://dx.doi.org/10.1371/journal.pone.0221086			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5HO	31408486	Green Published, Green Submitted, gold			2023-01-03	WOS:000485009500037
J	Jarvis, JD; Woods, H; Bali, A; Oronsaye, E; Persaud, N				Jarvis, Jordan D.; Woods, Hannah; Bali, Anjli; Oronsaye, Efosa; Persaud, Nav			Selection of WHO-recommended essential medicines for non-communicable diseases on National Essential Medicines Lists	PLOS ONE			English	Article							COUNTRIES	Background Non-communicable diseases (NCDs) are the leading cause of death worldwide. Inadequate and inequitable access to essential NCD medicines is a major concern, particularly in low and middle-income countries. National Essential Medicines Lists (EMLs) are important policy tools that indicate which medicines are prioritized as essential within a country's health system. This study sought to analyze a wide range of national essential medicines lists (EMLs) for their inclusion of priority non communicable disease (NCD) interventions recommended by the World Health Organization (WHO). Methods Three lists of WHO endorsed priority NCD interventions were included. A database with 137 national EMLs and the WHO EML was created from the WHO Repository and these EMLs were compared for listing of priority NCD interventions. Results Across 137 countries with national EMLs, the median percentage of 20 Best Buys interventions listed was 90% (IQR 80-95) and 31 Package of essential noncommunicable disease interventions (PEN) interventions listed was 94% (IQR 90-97), of 9 HEARTS interventions was 100% (IQR 89-100), and of the 43 unique interventions across the three priority lists was 88% (IQR 84-93). Less than 80% of the 43 interventions were listed by 22 (16%) countries and less than half of the interventions were listed by 2 countries: Angola (35%) and Cambodia (23%). Interventions listed on the fewest number of national EMLs were: influenza vaccine, HPV vaccine, hepatitis B vaccine, cervical cancer chemotherapy, codeine, promethazine, senna, and oxygen. Conclusion Most NCD interventions have been prioritized in national policy in most cases. The majority of priority medicines for NCDs described within key WHO NCD technical packages are listed on nearly all national EMLs across 137 countries of all income levels. Most NCD interventions have been prioritized in national policy in most cases, but in some countries and for select interventions such as the HPV vaccine, prioritization may be reviewed.	[Jarvis, Jordan D.] London Sch Hyg & Trop Med, London, England; [Jarvis, Jordan D.; Woods, Hannah; Bali, Anjli; Oronsaye, Efosa; Persaud, Nav] St Michaels Hosp, Ctr Urban Hlth Solut, Toronto, ON, Canada; [Persaud, Nav] St Michaels Hosp, Dept Family & Community Med, Toronto, ON, Canada	University of London; London School of Hygiene & Tropical Medicine; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Persaud, N (corresponding author), St Michaels Hosp, Ctr Urban Hlth Solut, Toronto, ON, Canada.; Persaud, N (corresponding author), St Michaels Hosp, Dept Family & Community Med, Toronto, ON, Canada.	nav.persaud@utoronto.ca		Jarvis, Jordan/0000-0001-9994-1748	Canadian Institutes of Health Research [381409]; Ontario SPOR (Strategy for Patient Oriented Research) Support Unit	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario SPOR (Strategy for Patient Oriented Research) Support Unit	The authors received funding from Canadian Institutes of Health Research (grant 381409 to NP) and Ontario SPOR (Strategy for Patient Oriented Research) Support Unit (http://www.cihr-irsc.gc.ca/e/45859.html). The funding sources were all governmental. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors (JJ, HW, AB, EO, NP) have not entered into any agreement with the funder that may have limited their ability to complete the research as planned. The authors (JJ, HW, AB, EO, NP) have full access and control of all primary data.	[Anonymous], 2017, BAS LIN SURV REP SOI; [Anonymous], 2017, NAT ESS MED LISTS NE; Bazargani YT, 2014, THORAX, V69, P1149, DOI 10.1136/thoraxjnl-2014-205249; Bazargani YT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106072; Bazargani YT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087576; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cameron A, 2009, LANCET, V373, P240, DOI 10.1016/S0140-6736(08)61762-6; Chido-Amajuoyi OG, 2019, CALL INTRO GEN NEUTR, V7; Chivukula Meenakshi V, 2018, WHO South East Asia J Public Health, V7, P90, DOI 10.4103/2224-3151.239420; Cuomo RE, 2017, J Cancer Policy, V12, P49, DOI 10.1016/j.jcpo.2017.03.010; Ewen M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171284; Gallagher KE, 2018, VACCINE, V36, P4761, DOI 10.1016/j.vaccine.2018.02.003; Graham JE, 2011, INT J EQUITY HEALTH, V10, DOI 10.1186/1475-9276-10-27; Knaul FM, 2018, J GLOB ONCOL, V4, DOI 10.1200/JGO.17.00190; Mehrtash H, 2018, E MEDITERR HEALTH J, V24, P427, DOI 10.26719/2018.24.5.427; Neuzil KM, 2017, VACCINE, V35, P5734, DOI 10.1016/j.vaccine.2017.08.088; Parkhurst JO, 2019, CERVICAL CANC GLOBAL, V8, DOI [10.1080/17441692.2013.850524, DOI 10.1080/17441692.2013.850524]; Persaud N, 2019, B WHO; Persaud N, WHO B UNPUB; Rowlands A, 2016, BMJ GLOB HEALTH, V1, DOI 10.1136/bmjgh-2016-000114; Tsu VD, 2019, INVESTMENT CASE CERV, V138, P69; US Food and Drug Administration, 2009, GARD VACC SAF; WHO Collaborating Centre for Drugs Statistics Methodology, 2018, ATC DDD IND 2018; Wigle J, 2013, VACCINE, V31, P3811, DOI 10.1016/j.vaccine.2013.06.016; Wirtz VJ, 2017, LANCET, V389, P403, DOI 10.1016/S0140-6736(16)31599-9; World Health Organization, 2019, WORLD MED SITUATION; World Health Organization, 2019, GLOB ACT PLAN PREV C; World Health Organization, 2018, GLOB HLTH OBS GHO DA; World Health Organization, 2017, DEPR OTH COMM MENT D; World Health Organization, 2018, HLTH FIN UN COV, P1; World Health Organization, 2018, WORLD HLTH STAT 2018; World Health Organization, 2019, AFF VACC KEY SCAL HP; World Health Organization, 2019, PACK ESS NONC PEN DI; World Health Organization, 2018, ESS MED	34	10	10	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2019	14	8							e0220781	10.1371/journal.pone.0220781	http://dx.doi.org/10.1371/journal.pone.0220781			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5FL	31398195	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000485004000018
J	Roddy, P; Dalrymple, U; Jensen, TO; Dittrich, S; Rao, VB; Pfeffer, DA; Twohig, KA; Roberts, T; Bernal, O; Guillen, E				Roddy, Paul; Dalrymple, Ursula; Jensen, Tomas O.; Dittrich, Sabine; Rao, V. Bhargavi; Pfeffer, Daniel A.; Twohig, Katherine A.; Roberts, Teri; Bernal, Oscar; Guillen, Ethan			Quantifying the incidence of severe-febr-ileillness hospital admissions in sub-Saharan Africa	PLOS ONE			English	Article							BLOOD-STREAM INFECTIONS; MALARIA; MANAGEMENT; OVERDIAGNOSIS; TANZANIA; CHILDREN; ILLNESS; DISEASE; FEVER	Severe-febrile-illness (SFI) is a common cause of morbidity and mortality across sub-Saharan Africa (SSA). The burden of SFI in SSA is currently unknown and its estimation is fraught with challenges. This is due to a lack of diagnostic capacity for SFI in SSA, and thus a dearth of baseline data on the underlying etiology of SFI cases and scant SFI-specific causativeagent prevalence data. To highlight the public health significance of SFI in SSA, we developed a Bayesian model to quantify the incidence of SFI hospital admissions in SSA. Our estimates indicate a mean population-weighted SFI-inpatient-admission incidence rate of 18.4 (6.8-31.1, 68% CrI) per 1000 people for the year 2014, across all ages within areas of SSA with stable Plasmodium falciparum transmission. We further estimated a total of 16,200,337 (5,993,249-27,321,779, 68% CrI) SFI hospital admissions. This analysis reveals the significant burden of SFI in hospitals in SSA, but also highlights the paucity of pathogen-specific prevalence and incidence data for SFI in SSA. Future improvements in pathogen-specific diagnostics for causative agents of SFI will increase the abundance of SFI-specific prevalence and incidence data, aid future estimations of SFI burden, and enable clinicians to identify SFI-specific pathogens, administer appropriate treatment and management, and facilitate appropriate antibiotic use.	[Roddy, Paul; Jensen, Tomas O.; Roberts, Teri; Bernal, Oscar; Guillen, Ethan] Febrile Illness Diagnost Programme, Med Sans Frontieres, New York, NY USA; [Dalrymple, Ursula; Pfeffer, Daniel A.; Twohig, Katherine A.] Univ Oxford, Big Data Inst, Li Ka Shing Ctr Hlth Informat & Discovery, Oxford, England; [Dittrich, Sabine] FIND, Geneva, Switzerland; [Dittrich, Sabine] Univ Oxford, Nuffield Sch Med, Oxford, England; [Rao, V. Bhargavi] Med Sans Frontieres, Manson Unit MSF UK, London, England; [Pfeffer, Daniel A.] Menzies Sch Hlth Res, Darwin, NT, Australia; [Pfeffer, Daniel A.] Charles Darwin Univ, Darwin, NT, Australia; [Roberts, Teri] Med Sans Frontieres, Access Campaign, Geneva, Switzerland	University of Oxford; Foundation For Innovative New Diagnostics; University of Oxford; Doctors Without Borders; Charles Darwin University; Menzies School of Health Research; Charles Darwin University; Doctors Without Borders	Roddy, P (corresponding author), Febrile Illness Diagnost Programme, Med Sans Frontieres, New York, NY USA.	roddypd@gmail.com	Jensen, Tomas/AFN-5759-2022; Twohig, Katherine/AGK-7931-2022	Jensen, Tomas/0000-0003-0398-4431; Twohig, Katherine/0000-0001-9514-0097; Bernal, oscar/0000-0003-2514-3318; Pfeffer, Daniel A./0000-0002-2204-3488; Rao, V. Bhargavi/0000-0002-4406-1636				Ahorlu CK, 1997, TROP MED INT HEALTH, V2, P488, DOI 10.1046/j.1365-3156.1997.d01-298.x; Amexo M, 2004, LANCET, V364, P1896, DOI 10.1016/S0140-6736(04)17446-1; Baba M.M., 2009, J AM SCI, V5, P129; Bhatt S, 2015, NATURE, V526, P207, DOI 10.1038/nature15535; Biritwum RB, 2000, ANN TROP MED PARASIT, V94, P771, DOI 10.1080/00034980020013037; Bisoffi Z, 2013, LANCET GLOB HEALTH, V1, pE11, DOI 10.1016/S2214-109X(13)70013-5; Camponovo F, 2017, MALARIA J, V16, DOI 10.1186/s12936-016-1650-6; Chandler CIR, 2008, HEALTH POLICY PLANN, V23, P170, DOI 10.1093/heapol/czm046; Chandler CIR, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-53; Chandramohan D, 2002, TROP MED INT HEALTH, V7, P45, DOI 10.1046/j.1365-3156.2002.00827.x; Crump JA, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004040; Crump JA, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002324; Dailey PJ, 2019, DIAGNOSTICS, V9, DOI 10.3390/diagnostics9010010; Dalrymple U, 2017, ELIFE, V6, DOI [10.7554/elife.29198, 10.7554/eLife.29198]; Febrile Illness Evaluation in a Broad Range of Endemicities (FIEBRE), FEBR ILLN EV BROAD R; Feikin DR, 2014, LANCET, V383, P1762, DOI 10.1016/S0140-6736(13)61682-7; Font F, 2001, TROP MED INT HEALTH, V6, P423, DOI 10.1046/j.1365-3156.2001.00727.x; Guerra CA, 2008, PLOS MED, V5, P300, DOI 10.1371/journal.pmed.0050038; Koram KA, 2007, AM J TROP MED HYG, V77, P1; Kristensen K, 2016, J STAT SOFTW, V70, P1; Loonen AJM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087315; Malm K, 2012, P ANN M AM SPC TROP; Maze MJ, 2018, CLIN MICROBIOL INFEC, V24, P808, DOI 10.1016/j.cmi.2018.02.011; Nankabirwa J, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-66; Nkengasong JN, 2018, LANCET, V391, P1873, DOI 10.1016/S0140-6736(18)30308-8; Nonvignon J, 2012, TROP MED INT HEALTH, V17, P951, DOI 10.1111/j.1365-3156.2012.03018.x; ODEMPSEY TJD, 1993, T ROY SOC TROP MED H, V87, P662, DOI 10.1016/0035-9203(93)90279-Y; Oladosu O.O., 2013, ISRN INFECT DIS, V2013, P6, DOI DOI 10.5402/2013/914675; Ombelet S, 2018, LANCET INFECT DIS, V18, pE248, DOI 10.1016/S1473-3099(18)30093-8; Penno EC, 2015, AM J TROP MED HYG, V93, P850, DOI 10.4269/ajtmh.15-0083; Prasad N, 2015, AM J TROP MED HYG, V93, P178, DOI 10.4269/ajtmh.14-0646; Prasad N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127962; President's Malaria Initiative, 2014, GHAN MAL OP PLAN FY; Reddy EA, 2010, LANCET INFECT DIS, V10, P417, DOI 10.1016/S1473-3099(10)70072-4; Reyburn H, 2004, BMJ-BRIT MED J, V329, P1212, DOI 10.1136/bmj.38251.658229.55; Seale AC, 2014, LANCET INFECT DIS, V14, P731, DOI 10.1016/S1473-3099(14)70804-7; Sigauque B, 2009, PEDIATR INFECT DIS J, V28, P108, DOI 10.1097/INF.0b013e318187a87d; Stoler J, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-2025-x; United Nations Department of Economic and Social Affairs Population Division, 2017, ESAPWP248; Van Dillen J, 2007, TROP DOCT, V37, P185, DOI 10.1258/004947507781524845; WHO, 2017, DEPRESSION; World Health Organization (WHO), MULT MULT DIAGN PLAT; Ye Y, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-160; 2013, WORLD MAL REP 2013, P1	44	10	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2019	14	7							e0220371	10.1371/journal.pone.0220371	http://dx.doi.org/10.1371/journal.pone.0220371			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4VN	31344116	Green Published, Green Submitted, gold			2023-01-03	WOS:000484977900093
J	Nardi, R; Nozzoli, C; Berti, F; Bonizzoni, E; Fabbri, LM; Frasson, S; Gambacorta, M; Martini, M; Mazzone, A; Muzzulini, CL; Nobili, A; Campanini, M				Nardi, Roberto; Nozzoli, Carlo; Berti, Franco; Bonizzoni, Erminio; Fabbri, Leonardo M.; Frasson, Stefania; Gambacorta, Maurizia; Martini, Marilisa; Mazzone, Antonino; Muzzulini, Carlo Lorenzo; Nobili, Alessandro; Campanini, Mauro			Prognostic value for mortality of the new FADOI-COMPLIMED score(s) in patients hospitalized in medical wards	PLOS ONE			English	Article							OLDER-ADULTS; 1-YEAR MORTALITY; ELDERLY-PATIENTS; INDEX; VALIDATION; SURVIVAL; PREDICTION; FRAILTY; MODEL	Background Recently we defined a user-friendly tool (FADOI-COMPLIMED scores-FCS) to assess complexity of patients hospitalized in medical wards. FCS-1 is an average between the Barthel Index and the Exton-Smith score, while FCS-2 is obtained by using the Charlson score. The aim of this paper is to assess the ability of the FCS to predict mortality in-hospital and after 1-3-6-12-months. In this perspective, we performed comparisons with the validated Multidimensional Prognostic Index (MPI). Methods It is a multicenter, prospective observational study, enrolling patients aged over 40, suffering from at least two chronic diseases and consecutively admitted to Internal Medicine departments. For each patient, data from 13 questionnaires were collected. Survival follow-up was conducted at 1-3-6-12 months after discharge. The relationships between cumulative incidences of death with FCS were investigated with logistic regression analyses. ROC curve analyses were performed in order to compare the predictiveness of the logistic models based on FCS with respect to those with MPI taken as reference. Results A cohort of 541 patients was evaluated. A 10-point higher value for FCS-1 and FCS-2 leads to an increased risk of 1-year death equal to 25.0% and 27.1%, respectively. In case of in hospital mortality, the relevant percentages were 63.1% and 15.3%. The logistic model based on FCS is significantly more predictive than the model based on MPI (which requires an almost doubled number of items) for all the time-points considered. Conclusions Assessment of prognosis of patients has the potential to guide clinical decision-making and lead to better care. We propose a new, efficient and easy-to-use instrument based on FCS, which demonstrated a good predictive power for mortality in patients hospitalized in medical wards. This tool may be of interest for clinical practice, since it well balances feasibility (requiring the compilation of 34 items, taking around 10 minutes) and performance.	[Nardi, Roberto] Maggiore Hosp, Internal Med, Bologna, Italy; [Nozzoli, Carlo] Careggi Hosp, Dept Internal Med, Florence, Italy; [Berti, Franco] San Camillo Forlanini Hosp, Internal Med, Rome, Italy; [Bonizzoni, Erminio] Univ Milan, Fac Med & Surg, Sect Med Stat Biometry & Epidemiol, Inst Dept Clin Sci & Community, Milan, Italy; [Fabbri, Leonardo M.] Univ Modena & Reggio Emilia, Dept Internal & Resp Med, Modena, Italy; [Frasson, Stefania] FADOI Fdn, Res Dept, Milan, Italy; [Gambacorta, Maurizia] Hosp Media Valle Tevere, Internal Med, Todi, Italy; [Martini, Marilisa] San Bortolo Hosp, Internal Med, Vicenza, Italy; [Mazzone, Antonino] Civile Hosp, Dept Internal Med, Legnano, Italy; [Muzzulini, Carlo Lorenzo] Ceva Hosp, Internal Med, Ceva, Italy; [Nobili, Alessandro] IRCCS Ist Ric Farmacol Mario Negri, Dept Neurosci, Lab Qual Assessment Geriatr Therapies & Serv, Milan, Italy; [Campanini, Mauro] Hosp Maggiore Carita, Dept Internal Med, Novara, Italy	AUSL di Bologna; University of Florence; Azienda Ospedaliero Universitaria Careggi; Azienda Ospedaliera San Camillo-Forlanini; University of Milan; Universita di Modena e Reggio Emilia; ULSS 8 Berica; Ospedale San Bortolo di Vicenza; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Azienda Ospedaliera Maggiore della Carita di Novara	Frasson, S (corresponding author), FADOI Fdn, Res Dept, Milan, Italy.	stefania.frasson@fadoi.org	Alessandro, Nobili/AAA-7512-2020; nozzoli, carlo/AAW-9197-2020; Nobili, Alessandro/ABG-4516-2020; Fabbri, Leonardo/I-4055-2012	Nobili, Alessandro/0000-0002-7813-0572; Fabbri, Leonardo/0000-0001-8894-1689	FADOI Foundation, a not-for-profit organization (Italian Scientific Society of Hospital Internal Medicine)	FADOI Foundation, a not-for-profit organization (Italian Scientific Society of Hospital Internal Medicine)	The study was funded by FADOI Foundation, a not-for-profit organization (Italian Scientific Society of Hospital Internal Medicine).	Aguayo GA, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002543; American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity, 2012, J Am Geriatr Soc, V60, P1957, DOI 10.1111/j.1532-5415.2012.04187.x; Bernabeu-Wittel M, 2011, EUR J INTERN MED, V22, P311, DOI 10.1016/j.ejim.2010.11.012; Bogardus ST, 2001, J GEN INTERN MED, V16, P728, DOI 10.1046/j.1525-1497.2001.00625.x; Bonizzoni E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195805; Carey EC, 2004, J GEN INTERN MED, V19, P1027, DOI 10.1111/j.1525-1497.2004.40016.x; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Covinsky KE, 2003, J AM GERIATR SOC, V51, P451, DOI 10.1046/j.1532-5415.2003.51152.x; EVANS C, 1985, LANCET, V1, P1204; Fried LP, 2004, J GERONTOL A-BIOL, V59, P255; Guralnik JM, 2003, PRINCIPLES GERIATRIC, P53; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; Kulminski AM, 2007, J AM GERIATR SOC, V55, P935, DOI 10.1111/j.1532-5415.2007.01155.x; Levine SK, 2007, AM J MED, V120, P455, DOI 10.1016/j.amjmed.2006.09.021; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Marengoni A, 2010, REJUV RES, V13, P469, DOI 10.1089/rej.2009.1002; Morita T, 1999, JPN J CLIN ONCOL, V29, P156, DOI 10.1093/jjco/29.3.156; Muers MF, 1996, THORAX, V51, P894, DOI 10.1136/thx.51.9.894; Pilotto A, 2008, REJUV RES, V11, P151, DOI 10.1089/rej.2007.0569; Pilotto A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029090; Rockwood K, 2007, J GERONTOL A-BIOL, V62, P722, DOI 10.1093/gerona/62.7.722; Schonberg MA, 2009, J GEN INTERN MED, V24, P1115, DOI 10.1007/s11606-009-1073-y; Teno JM, 2000, J AM GERIATR SOC, V48, pS16, DOI 10.1111/j.1532-5415.2000.tb03126.x; Walter LC, 2001, JAMA-J AM MED ASSOC, V285, P2750, DOI 10.1001/jama.285.21.2750; Walter LC, 2001, JAMA-J AM MED ASSOC, V285, P2987, DOI 10.1001/jama.285.23.2987; Yourman LC, 2012, JAMA-J AM MED ASSOC, V307, P182, DOI 10.1001/jama.2011.1966	27	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2019	14	7							e0219767	10.1371/journal.pone.0219767	http://dx.doi.org/10.1371/journal.pone.0219767			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IS7NE	31339912	Green Published, Green Submitted, gold			2023-01-03	WOS:000482335700034
J	Wadhera, RK; Yeh, RW; Maddox, KEJ				Wadhera, Rishi K.; Yeh, Robert W.; Maddox, Karen E. Joynt			The Hospital Readmissions Reduction Program - Time for a Reboot	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MORTALITY; ASSOCIATION	Some policymakers have pushed for the HRRP to be expanded to cover all conditions treated in inpatient settings. Others, including many clinicians and researchers, have expressed skepticism regarding the program's effects and concerns about unintended consequences.	[Wadhera, Rishi K.; Yeh, Robert W.] Beth Israel Deaconess Med Ctr, Richard & Susan Smith Ctr Outcomes Res Cardiol, Div Cardiol, Boston, MA 02215 USA; [Wadhera, Rishi K.; Yeh, Robert W.] Harvard Med Sch, Boston, MA 02115 USA; [Wadhera, Rishi K.] Harvard Med Sch, Brigham & Womens Hosp, Heart & Vasc Ctr, Boston, MA 02115 USA; [Maddox, Karen E. Joynt] Washington Univ, Sch Med, Dept Med, Cardiovasc Div, St Louis, MO 63110 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Washington University (WUSTL)	Wadhera, RK (corresponding author), Beth Israel Deaconess Med Ctr, Richard & Susan Smith Ctr Outcomes Res Cardiol, Div Cardiol, Boston, MA 02215 USA.; Wadhera, RK (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Wadhera, RK (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Heart & Vasc Ctr, Boston, MA 02115 USA.		Yeh, Robert/AAJ-3463-2020	Wadhera, Rishi/0000-0003-1089-3896	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007604] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL007604] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Gupta A, 2018, JAMA CARDIOL, V3, P44, DOI 10.1001/jamacardio.2017.4265; Huckfeldt P, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0634; Huckfeldt P, 2018, J AM COLL CARDIOL, V72, P2539, DOI 10.1016/j.jacc.2018.08.2174; Khera R, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.2777; Wadhera RK, 2018, JAMA-J AM MED ASSOC, V320, P2542, DOI 10.1001/jama.2018.19232	5	51	51	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 13	2019	380	24					2289	2291		10.1056/NEJMp1901225	http://dx.doi.org/10.1056/NEJMp1901225			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IC9JQ	31091367	Green Published, Green Accepted			2023-01-03	WOS:000471299100006
J	Adedini, SA; Omisakin, OA; Somefun, OD				Adedini, Sunday A.; Omisakin, Olusola Akintoye; Somefun, Oluwaseyi Dolapo			Trends, patterns and determinants of long-acting reversible methods of contraception among women in sub-Saharan Africa	PLOS ONE			English	Article							UNMET NEED; FERTILITY; MORTALITY; PREGNANCIES; COUNTRIES; DEMAND; POOR	Background Method-specific contraceptive prevalence varies widely globally, as huge variations exist in the use of different types of contraception, with short-term methods being the most common methods in sub-Saharan Africa (SSA). Evidence is scanty on the trends, patterns and determinants of long-acting reversible contraceptive (LARC) methods in SSA. This study aimed to address this knowledge gap. Methods Using a pseudo longitudinal research design and descriptive and inferential statistics, we analysed Demographic and Health Survey data of eight countries selected on the basis of contraceptive prevalence rates across SSA. Multinomial logistic regression modelling was used to tease out the predictors of the uptake of LARC methods in the selected countries. Results Findings exhibit a steady but slow upward trend in LARC methods across selected countries, as a marginal increase was recorded in LARC uptake over a 10-year period in many of the selected countries. Results established significant predictors of LARC methods uptake, including fertility-related characteristics, age, level of education, work status, wealth index and exposure to mass media. This study underscored the need to address various barriers to the uptake of LARC methods in SSA. It is recommended that governments at different levels undertake to cover the costs of LARC methods in order to increase access and uptake.	[Adedini, Sunday A.] Univ Witwatersrand, Resp & Meningeal Pathogens Res Unit, Med Res Council, Johannesburg, South Africa; [Adedini, Sunday A.; Somefun, Oluwaseyi Dolapo] Univ Witwatersrand, Sch Publ Hlth, Programme Demog & Populat Studies, Johannesburg, South Africa; [Adedini, Sunday A.; Somefun, Oluwaseyi Dolapo] Univ Witwatersrand, Sch Social Sci, Programme Demog & Populat Studies, Johannesburg, South Africa; [Omisakin, Olusola Akintoye] Fed Univ, Demog & Social Stat Dept, Birnin Kebbi, Nigeria	South African Medical Research Council; University of Witwatersrand; University of Witwatersrand; University of Witwatersrand	Adedini, SA (corresponding author), Univ Witwatersrand, Resp & Meningeal Pathogens Res Unit, Med Res Council, Johannesburg, South Africa.; Adedini, SA (corresponding author), Univ Witwatersrand, Sch Publ Hlth, Programme Demog & Populat Studies, Johannesburg, South Africa.; Adedini, SA (corresponding author), Univ Witwatersrand, Sch Social Sci, Programme Demog & Populat Studies, Johannesburg, South Africa.	sunday.adedini@gmail.com	Adedini, Sunday/AAM-6790-2021; Adedini, Sunday/GZM-8362-2022	Adedini, Sunday/0000-0003-0378-1941; 				Adebowale SA, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-40; Adedini SA, 2015, J HEALTH POPUL NUTR, V33, P187; Adeyanju O., 2017, NIGERIAN URBAN REPRO; Akinyemi A, 2015, GLOBAL HEALTH ACTION, V8, P45, DOI 10.3402/gha.v8.29745; Alkema L, 2016, LANCET, V387, P462, DOI 10.1016/S0140-6736(15)00838-7; Alkema L, 2013, LANCET, V381, P1642, DOI 10.1016/S0140-6736(12)62204-1; [Anonymous], 2015, TRENDS CONTR US WORL; Babalola S, 2015, DEMOGR RES, V33, P211, DOI 10.4054/DemRes.2015.33.8; Bongaarts J, 2017, POPUL DEV REV, V43, P39, DOI 10.1111/j.1728-4457.2016.00164.x; Choi Y, 2015, GLOBAL HEALTH ACTION, V8, P3, DOI 10.3402/gha.v8.29734; Creanga AA, 2011, B WORLD HEALTH ORGAN, V89, P258, DOI 10.2471/BLT.10.083329; Darroch JE, 2013, LANCET, V381, P1756, DOI 10.1016/S0140-6736(13)60597-8; Ezeh AC, 2009, PHILOS T R SOC B, V364, P2991, DOI 10.1098/rstb.2009.0166; Fabic MS, 2015, LANCET, V385, P1928, DOI 10.1016/S0140-6736(14)61055-2; Fekadu H, 2017, J WOMENS HLTH CARE, V6, P2167; Gakidou E, 2007, PLOS MED, V4, P381, DOI 10.1371/journal.pmed.0040031; Gerland P, 2014, SCIENCE, V346, P234, DOI 10.1126/science.1257469; Gillespie D, 2007, B WORLD HEALTH ORGAN, V85, P100, DOI 10.2471/BLT.06.033829; Gribble J, 2008, POPULATION REFERENCE, P8; Gyimah SO, 2012, J RELIG HEALTH, V51, P1359, DOI 10.1007/s10943-011-9478-4; Hasselback L, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2316-y; Imasiku ENS, 2014, J BIOSOC SCI, V46, P294, DOI 10.1017/S0021932013000357; Lipetz C, 2009, J FAM PLAN REPROD H, V35, P75, DOI 10.1783/147118909787931555; Masquelier B, 2018, LANCET GLOB HEALTH, V6, pE1087, DOI 10.1016/s2214-109x(18)30353-x; Mbizvo MT, 2014, BEST PRACT RES CL OB, V28, P931, DOI 10.1016/j.bpobgyn.2014.04.014; Ngo TD, 2017, MATERN CHILD HLTH J, V21, P1734, DOI 10.1007/s10995-016-2014-0; Ochako R, 2016, BMC WOMENS HEALTH, V16, DOI 10.1186/s12905-016-0314-6; Okigbo C, 2017, WORLD MED HEALTH POL, V9, P65, DOI 10.1002/wmh3.215; Onarheim KH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150120; Oye-Adeniran Boniface A, 2006, Afr J Reprod Health, V10, P90; Payne JB, 2016, J MIDWIFERY WOM HEAL, V61, P482, DOI 10.1111/jmwh.12425; Secura GM, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.04.017; Sedgh G, 2014, STUD FAMILY PLANN, V45, P301, DOI 10.1111/j.1728-4465.2014.00393.x; Shoupe D, 2016, CONTRACEP REPROD MED, V1, DOI 10.1186/s40834-016-0011-8; Singh S., 2014, ADD COSTS BEN INV SE; Skiles MP, 2015, INT PERSPECT SEX R H, V41, P20, DOI 10.1363/4102015; Starbird E, 2016, GLOB HEALTH-SCI PRAC, V4, P191, DOI 10.9745/GHSP-D-15-00374; Stoddard A, 2011, DRUGS, V71, P969, DOI 10.2165/11591290-000000000-00000; Tibaijuka L, 2017, BMC WOMENS HEALTH, V17, DOI 10.1186/s12905-017-0382-2; United Nations, 2015, 241 ESAPWP UN; Waggoner MR, 2012, J CHILD ADOL PS NURS, V25, P96, DOI 10.1111/j.1744-6171.2012.00326.x	41	31	31	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2019	14	6							e0217574	10.1371/journal.pone.0217574	http://dx.doi.org/10.1371/journal.pone.0217574			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IB2FX	31163050	Green Published, gold, Green Submitted			2023-01-03	WOS:000470086200019
J	Liu-Ambrose, T; Davis, JC; Best, JR; Dian, L; Madden, K; Cook, W; Hsu, CL; Khan, KM				Liu-Ambrose, Teresa; Davis, Jennifer C.; Best, John R.; Dian, Larry; Madden, Kenneth; Cook, Wendy; Hsu, Chun Liang; Khan, Karim M.			Effect of a Home-Based Exercise Program on Subsequent Falls Among Community-Dwelling High-Risk Older Adults After a Fall A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREVENTING FALLS; TAI CHI; PEOPLE; IMPUTATION; WOMEN; SCALE	IMPORTANCE Whether exercise reduces subsequent falls in high-risk older adults who have already experienced a fall is unknown. OBJECTIVE To assess the effect of a home-based exercise program as a fall prevention strategy in older adults who were referred to a fall prevention clinic after an index fall. DESIGN, SETTING, AND PARTICIPANTS A 12-month, single-blind, randomized clinical trial conducted from April 22, 2009, to June 5, 2018, among adults aged at least 70 years who had a fall within the past 12 months and were recruited from a fall prevention clinic. INTERVENTIONS Participants were randomized to receive usual care plus a home-based strength and balance retraining exercise program delivered by a physical therapist (intervention group; n = 173) or usual care, consisting of fall prevention care provided by a geriatrician (usual care group; n = 172). Both were provided for 12 months. MAIN OUTCOMES AND MEASURES The primary outcome was self-reported number of falls over 12 months. Adverse event data were collected in the exercise group only and consisted of falls, injuries, or muscle soreness related to the exercise intervention. RESULTS Among 345 randomized patients (mean age, 81.6 [SD, 6.1] years; 67% women), 296 (86%) completed the trial. During a mean follow-up of 338 (SD, 81) days, a total of 236 falls occurred among 172 participants in the exercise group vs 366 falls among 172 participants in the usual care group. Estimated incidence rates of falls per person-year were 1.4 (95% CI, 0.1-2.0) vs 2.1 (95% CI, 0.1-3.2), respectively. The absolute difference in fall incidence was 0.74 (95% CI, 0.04-1.78; P = .006) falls per person-year and the incident rate ratio was 0.64 (95% CI, 0.46-0.90; P = .009). No adverse events related to the intervention were reported. CONCLUSIONS AND RELEVANCE Among older adults receiving care at a fall prevention clinic after a fall, a home-based strength and balance retraining exercise program significantly reduced the rate of subsequent falls compared with usual care provided by a geriatrician. These findings support the use of this home-based exercise program for secondary fall prevention but require replication in other clinical settings.	[Liu-Ambrose, Teresa; Best, John R.; Hsu, Chun Liang] Univ British Columbia, Fac Med, Dept Phys Therapy, Aging Mobil & Cognit Neurosci Lab, Vancouver, BC, Canada; [Liu-Ambrose, Teresa; Davis, Jennifer C.; Best, John R.; Madden, Kenneth; Hsu, Chun Liang; Khan, Karim M.] Univ British Columbia, Vancouver Coastal Hlth Res Inst, Ctr Hip Hlth & Mobil, Vancouver, BC, Canada; [Liu-Ambrose, Teresa; Best, John R.; Hsu, Chun Liang] Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC, Canada; [Davis, Jennifer C.] Univ British Columbia Okanagan, Fac Management, Kelowna, BC, Canada; [Dian, Larry; Madden, Kenneth; Cook, Wendy] Univ British Columbia, Fac Med, Div Geriatr Med, Dept Med, Vancouver, BC, Canada; [Khan, Karim M.] Univ British Columbia, Fac Med, Dept Family Practice, Vancouver, BC, Canada	University of British Columbia; University of British Columbia; Vancouver Coastal Health Research Institute; University of British Columbia; University of British Columbia; University of British Columbia Okanagan; University of British Columbia; University of British Columbia	Liu-Ambrose, T (corresponding author), Univ British Columbia, Fac Med, Dept Phys Therapy, 212-2177 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	teresa.ambrose@ubc.ca	Liu-Ambrose, Teresa/W-2332-2019; Hsu, Chun Liang/AAN-4254-2021	Liu-Ambrose, Teresa/0000-0002-8297-5308; Hsu, Chun Liang/0000-0003-2090-1001; Best, John R/0000-0001-5775-7053	Canadian Institutes for Health Research [MOP-110954, MAT-92025]	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR))	This study was funded by the Canadian Institutes for Health Research (MOP-110954 and MAT-92025). Dr Liu-Ambrose is a Canada Research Chair (Tier 2) in Physical Activity, Mobility, and Cognitive Neuroscience, Department of Physical Therapy, University of British Columbia. Dr Madden is the Allan M. McGavin Chair in Geriatric Medicine, Department of Medicine, University of British Columbia.	Austin PC, 2013, MED CARE, V51, P797, DOI 10.1097/MLR.0b013e31829a4fb4; Campbell AJ, 1999, AGE AGEING, V28, P513, DOI 10.1093/ageing/28.6.513; Campbell AJ, 1997, BMJ-BRIT MED J, V315, P1065, DOI 10.1136/bmj.315.7115.1065; Clayton D, 1994, Stat Methods Med Res, V3, P244, DOI 10.1177/096228029400300304; Cnaan A, 1997, STAT MED, V16, P2349, DOI 10.1002/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E; Davis JC, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020576; Duckham RL, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-133; Fitzmaurice GM, 1999, APPL LONGITUDINAL DA; Gautschi OP, 2017, NEUROSURGERY, V80, P380, DOI 10.1227/NEU.0000000000001320; GIBSON MJ, 1987, DAN MED BULL, V34, P1; Gillespie Lesley D, 2012, Cochrane Database Syst Rev, pCD007146, DOI 10.1002/14651858.CD007146.pub3; Graham JW, 2007, PREV SCI, V8, P206, DOI 10.1007/s11121-007-0070-9; Groll DL, 2005, J CLIN EPIDEMIOL, V58, P595, DOI 10.1016/j.jclinepi.2004.10.018; Guirguis-Blake JM, 2018, JAMA-J AM MED ASSOC, V319, P1705, DOI 10.1001/jama.2017.21962; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; Hwang HF, 2016, J AM GERIATR SOC, V64, P518, DOI 10.1111/jgs.13952; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Liu-Ambrose T, 2008, J AM GERIATR SOC, V56, P1821, DOI [10.1111/j.1532-5415.2008.01931.x, 10.1111/j.1532-5415.2008.01984.x]; Liu-Ambrose T, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0648-7; Logghe IHJ, 2009, J AM GERIATR SOC, V57, P70, DOI 10.1111/j.1532-5415.2008.02064.x; Lord S., 2001, FALLS OLDER PEOPLE R, P221; Lundebjerg N, 2001, J AM GERIATR SOC, V49, P664, DOI 10.1046/j.1532-5415.2001.49115.x; Luukinen H, 2007, PREV MED, V44, P265, DOI 10.1016/j.ypmed.2006.09.011; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Robertson MC, 2002, J AM GERIATR SOC, V50, P905, DOI 10.1046/j.1532-5415.2002.50218.x; Robertson MC, 2001, BRIT MED J, V322, P697, DOI 10.1136/bmj.322.7288.697; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Shumway-Cook A, 2000, PHYS THER, V80, P896, DOI 10.1093/ptj/80.9.896; Shumway-Cook A, 2007, J GERONTOL A-BIOL, V62, P1420, DOI 10.1093/gerona/62.12.1420; SIGNORINI DF, 1991, BIOMETRIKA, V78, P446; Spreen O., 1998, COMPENDIUM NEUROLOGI, V2nd ed.; Uusi-Rasi K, 2015, JAMA INTERN MED, V175, P703, DOI 10.1001/jamainternmed.2015.0225; van Buuren S, 2011, J STAT SOFTW, V45, P1; VANMARWIJK HWJ, 1995, BRIT J GEN PRACT, V45, P195; WASHBURN RA, 1993, J CLIN EPIDEMIOL, V46, P153, DOI 10.1016/0895-4356(93)90053-4; Wright AA, 2011, J ORTHOP SPORT PHYS, V41, P319, DOI 10.2519/jospt.2011.3515; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	37	74	79	2	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2019	321	21					2092	2100		10.1001/jama.2019.5795	http://dx.doi.org/10.1001/jama.2019.5795			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IB3HN	31162569	Bronze, Green Published			2023-01-03	WOS:000470158700014
J	Singh, S; Goodwin, JS; Zhou, J; Kuo, YF; Nattinger, AB				Singh, Siddhartha; Goodwin, James S.; Zhou, Jie; Kuo, Yong-Fang; Nattinger, Ann B.			Variation Among Primary Care Physicians in 30-Day Readmissions	ANNALS OF INTERNAL MEDICINE			English	Article							FOLLOW-UP; RATES; ASSOCIATION; ALGORITHMS	Background: Whether readmission rates vary by primary care physician (PCP) is unknown, although federal policy holds PCPs accountable for reducing readmissions. Objective: To determine whether 30-day readmission rates vary by PCP. Design: Retrospective cohort study using marginal models and multilevel logistic regression with 100% of data on Texas Medicare claims from 2008 to 2015. Setting: Texas. Participants: Patients discharged alive between 1 January 2008 and 30 November 2015 who had a PCP in the prior year and whose PCP had at least 50 admissions in the study period. Measurements: Readmission within 30 days of discharge. Follow-up visits with a PCP within 7 days of discharge were also measured. Results: Between 2012 and 2015, the mean risk-standardized rate of 30-day readmissions was 12.9%. Of 4230 PCPs, 1 had a readmission rate that was significantly higher than the mean and none had a significantly lower rate. The 10th and 90th percentiles of PCP readmission rates were 12.4% and 13.4%, respectively, each only 0.5 percentage point different from the mean. The 99th percentile of PCP readmission rates was 14.0%, 1.1-percentage points higher than the mean. Detecting a 1.1-percentage point difference from the mean adjusted readmission rate would require more than 3500 admissions per PCP per year. Limitations: Only fee-for-service Medicare patients in a single state were included. The authors could not account for confounders not included in Medicare databases or classify readmissions as avoidable. Conclusion: Variation in readmission rates among PCPs is very low. Programs holding PCPs accountable for readmissions may prove ineffective. Primary Funding Source: National Institutes of Health.	[Singh, Siddhartha; Nattinger, Ann B.] Med Coll Wisconsin, Collaborat Healthcare Delivery Sci, Milwaukee, WI 53226 USA; [Goodwin, James S.; Zhou, Jie; Kuo, Yong-Fang] Univ Texas Med Branch, Sealy Ctr Aging, Galveston, TX 77555 USA; [Singh, Siddhartha; Nattinger, Ann B.] Med Coll Wisconsin, 9200 West Wisconsin Ave, Milwaukee, WI 53226 USA; [Goodwin, James S.; Zhou, Jie; Kuo, Yong-Fang] Univ Texas Med Branch, 301 Univ Blvd, Galveston, TX 77555 USA	Medical College of Wisconsin; University of Texas System; University of Texas Medical Branch Galveston; Medical College of Wisconsin; University of Texas System; University of Texas Medical Branch Galveston	Singh, S (corresponding author), Med Coll Wisconsin, 9200 West Wisconsin Ave, Milwaukee, WI 53226 USA.	ssingh@mcw.edu; jiezhou@utmb.edu		Nattinger, Ann/0000-0002-8189-3300	National Institutes of Health [AG033134, K05CA134923, P30AG024832, UL1TR001439]; NATIONAL CANCER INSTITUTE [K05CA134923] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG024832, R01AG033134] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	By grants AG033134, K05CA134923, P30AG024832, and UL1TR001439 from the National Institutes of Health.	Albert NM, 2015, CIRC-HEART FAIL, V8, P384, DOI 10.1161/HHF.0000000000000006; Bloink Jacqueline, 2013, Fam Pract Manag, V20, P12; Centers for Medicare and Medicaid Services, HOSP READM RED PROGR; Centers for Medicare and Medicaid Services, MIPS OV; Epstein AM, 2011, NEW ENGL J MED, V365, P2287, DOI 10.1056/NEJMsa1101942; Feigenbaum P, 2012, MED CARE, V50, P599, DOI 10.1097/MLR.0b013e318249ce72; Goodwin JS, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2318-9; Goodwin JS, 2013, J GEN INTERN MED, V28, P370, DOI 10.1007/s11606-012-2255-6; Halfon P, 2006, MED CARE, V44, P972, DOI 10.1097/01.mlr.0000228002.43688.c2; Hernandez AF, 2010, JAMA-J AM MED ASSOC, V303, P1716, DOI 10.1001/jama.2010.533; Hess CN, 2013, CIRCULATION, V128, P1206, DOI 10.1161/CIRCULATIONAHA.113.004569; Horwitz L., 2011, HOSP WIDE ALL CAUSE; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Kuo YF, 2011, ANN INTERN MED, V155, P152, DOI 10.7326/0003-4819-155-3-201108020-00005; Kuo Y, 2009, NEW ENGL J MED, V360, P1102, DOI 10.1056/NEJMsa0802381; Leyland AH, 2001, MULTILEVEL MODELLING; McIlvennan CK, 2015, CIRCULATION, V131, P1796, DOI 10.1161/CIRCULATIONAHA.114.010270; Medicare Payment Advisory Commission, 2007, C PROM GREAT EFF MED; Morganti KG, 2013, EVOLVING ROLES EMERG; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Rabe-Hesketh Sophia, 2008, MULTILEVEL LONGITUDI; Shah BR, 2007, HEALTH SERV RES, V42, P1783, DOI 10.1111/j.1475-6773.2006.00681.x; Sharma G, 2010, ARCH INTERN MED, V170, P1664, DOI 10.1001/archinternmed.2010.345; Singh S, 2015, J HOSP MED, V10, P705, DOI 10.1002/jhm.2407; Tang N, 2014, J HOSP MED, V9, P688, DOI 10.1002/jhm.2243; United Health Foundation, TREND HOSP READM; van Walraven C, 2002, J GEN INTERN MED, V17, P186, DOI 10.1046/j.1525-1497.2002.10741.x; Zhu M, 2014, ANAL MULTILEVEL MODE	29	7	7	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 4	2019	170	11					749	+		10.7326/M18-2526	http://dx.doi.org/10.7326/M18-2526			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IB1HI	31108502	Green Accepted			2023-01-03	WOS:000470015600003
J	Webb, NJA; Woolley, RL; Lambe, T; Frew, E; Brettell, EA; Barsoum, EN; Trompeter, RS; Cummins, C; Deeks, JJ; Wheatley, K; Ives, NJ				Webb, Nicholas J. A.; Woolley, Rebecca L.; Lambe, Tosin; Frew, Emma; Brettell, Elizabeth A.; Barsoum, Emma N.; Trompeter, Richard S.; Cummins, Carole; Deeks, Jonathan J.; Wheatley, Keith; Ives, Natalie J.		PREDNOS Collaborative Grp	Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; THERAPY	OBJECTIVE To determine whether extending initial prednisolone treatment from eight to 16 weeks in children with idiopathic steroid sensitive nephrotic syndrome improves the pattern of disease relapse. DESIGN Double blind, parallel group, phase III randomised placebo controlled trial, including a cost effectiveness analysis. SETTING 125 UK National Health Service district general hospitals and tertiary paediatric nephrology centres. PARTICIPANTS 237 children aged 1-14 years with a first episode of steroid sensitive nephrotic syndrome. INTERVENTIONS Children were randomised to receive an extended 16 week course of prednisolone (total dose 3150 mg/m(2)) or a standard eight week course of prednisolone (total dose 2240 mg/m(2)). The drug was supplied as 5 mg tablets alongside matching placebo so that participants in both groups received the same number of tablets at any time point in the study. A minimisation algorithm ensured balanced treatment allocation by ethnicity (South Asian, white, or other) and age (5 years or less, 6 years or more). MAIN OUTCOME MEASURES The primary outcome measure was time to first relapse over a minimum follow-up of 24 months. Secondary outcome measures were relapse rate, incidence of frequently relapsing nephrotic syndrome and steroid dependent nephrotic syndrome, use of alternative immunosuppressive treatment, rates of adverse events, behavioural change using the Achenbach child behaviour checklist, quality adjusted life years, and cost effectiveness from a healthcare perspective. Analysis was by intention to treat. RESULTS No significant difference was found in time to first relapse (hazard ratio 0.87, 95% confidence interval 0.65 to 1.17, log rank P=0.28) or in the incidence of frequently relapsing nephrotic syndrome (extended course 60/114 (53%) vstandard course 55/109 (50%), P=0.75), steroid dependent nephrotic syndrome (48/114 (42%) v48/109 (44%), P=0.77), or requirement for alternative immunosuppressive treatment (62/114 (54%) v61/109 (56%), P=0.81). Total prednisolone dose after completion of the trial drug was 6674 mg for the extended course versus 5475 mg for the standard course (P=0.07). There were no statistically significant differences in serious adverse event rates (extended course 19/114 (17%) vstandard course 27/109 (25%), P=0.13) or adverse event rates, with the exception of behaviour, which was poorer in the standard course group. Scores on the Achenbach child behaviour checklist did not, however, differ. Extended course treatment was associated with a mean increase in generic quality of life (0.0162 additional quality adjusted life years, 95% confidence interval -0.005 to 0.037) and cost savings (difference -1673 pound ($2160; ((sic)1930), 95% confidence interval -3455 pound to 109) pound. CONCLUSIONS Clinical outcomes did not improve when the initial course of prednisolone treatment was extended from eight to 16 weeks in UK children with steroid sensitive nephrotic syndrome. However, evidence was found of a short term health economic benefit through reduced resource use and increased quality of life.	[Webb, Nicholas J. A.] Royal Manchester Childrens Hosp, Dept Paediat Nephrol, Manchester, Lancs, England; [Webb, Nicholas J. A.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester M13 9PL, Lancs, England; [Woolley, Rebecca L.; Brettell, Elizabeth A.; Barsoum, Emma N.; Deeks, Jonathan J.; Ives, Natalie J.] Univ Birmingham, Inst Appl Hlth Res, Birmingham Clin Trials Unit, Birmingham, W Midlands, England; [Lambe, Tosin; Frew, Emma] Univ Birmingham, Inst Appl Hlth Res, Hlth Econ Unit, Birmingham, W Midlands, England; [Trompeter, Richard S.] UCL, Ctr Nephrol, London, England; [Cummins, Carole] Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England; [Deeks, Jonathan J.] Univ Hosp Birmingham NHS Fdn Trust, NIHR Birmingham Biomed Res Ctr, Birmingham, W Midlands, England; [Deeks, Jonathan J.] Univ Birmingham, Birmingham, W Midlands, England; [Wheatley, Keith] Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England	Royal Manchester Children's Hospital; University of Manchester; University of Birmingham; University of Birmingham; University of London; University College London; University of Birmingham; University of Birmingham; University of Birmingham; Cancer Research UK; University of Birmingham	Webb, NJA (corresponding author), Royal Manchester Childrens Hosp, Dept Paediat Nephrol, Manchester, Lancs, England.; Webb, NJA (corresponding author), Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester M13 9PL, Lancs, England.	nicholas.webb@mft.nhs.uk	Tse, Yincent/AAJ-3332-2021; Deeks, Jon/AAV-5745-2020; Frew, Emma/AAO-5141-2021	Tse, Yincent/0000-0003-3175-1475; Deeks, Jon/0000-0002-8850-1971; Frew, Emma/0000-0002-5462-1158; webb, nicholas/0000-0001-8572-5446; Ives, Natalie/0000-0002-1664-7541; Saleem, Moin/0000-0002-9808-4518; Cummins, Carole/0000-0001-5464-1944	National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme (HTA grant) [08/53/31]; MRC [MR/P024297/1, MR/R013942/1, MR/L002418/1, MR/R003017/1, G0800200, G0800571] Funding Source: UKRI	National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme (HTA grant); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The PREDNOS study was funded by an investigator led grant from the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme (HTA grant reference No 08/53/31). This report presents independent research commissioned by the NIHR. The views and opinions expressed by the authors in this publication are those of the authors and do not necessarily reflect those of the UK National Health Service, the Medical Research Council, the NIHR Central Commissioning Facility, Evaluation, Trials and Studies Coordinating Centre, the HTA programme, or the Department of Health. The researchers in the PREDNOS study are independent of the funders. All authors had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.	ABRAMOWI.M, 1970, LANCET, V1, P959; Achenbach TM, 1983, MANUAL CHILD BEHAV C; [Anonymous], 1978, Kidney Int, V13, P159; Bagga A, 1999, PEDIATR NEPHROL, V13, P824, DOI 10.1007/s004670050708; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; EHRICH JHH, 1993, EUR J PEDIATR, V152, P357, DOI 10.1007/BF01956754; FEEHALLY J, 1985, ARCH DIS CHILD, V60, P1018, DOI 10.1136/adc.60.11.1018; Hodson EM, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001533.pub3; Jayantha UK, 2004, PEDIATR NEPHROL, V19, pC81; KSIAZEK J, 1995, ACTA PAEDIATR, V84, P889; Larkins N, 2016, ARCH DIS CHILD, V101, P404, DOI 10.1136/archdischild-2015-308924; MacNeill V, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002750; McCaffrey J, 2016, PEDIATR NEPHROL, V31, P1383, DOI 10.1007/s00467-015-3241-0; McKinney PA, 2001, PEDIATR NEPHROL, V16, P1040, DOI 10.1007/s004670100021; Norero C, 1996, REV MED CHILE, V124, P567; SHARPLES PM, 1985, ARCH DIS CHILD, V60, P1014, DOI 10.1136/adc.60.11.1014; Sinha A, 2015, KIDNEY INT, V87, P217, DOI 10.1038/ki.2014.240; Stevens K, 2012, PHARMACOECONOMICS, V30, P729, DOI 10.2165/11599120-000000000-00000; Takeda A, 2001, PEDIATR NEPHROL, V16, P888, DOI 10.1007/s004670100683; TROMPETER RS, 1985, LANCET, V1, P368; UEDA N, 1988, J PEDIATR-US, V112, P122, DOI 10.1016/S0022-3476(88)80136-7; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; Webb NJA, 2012, PEDIAT NEPHROLOGY; Yap HK, 2001, PEDIATR NEPHROL, V16, P1049, DOI 10.1007/s004670100024; Yoshikawa N, 2015, KIDNEY INT, V87, P225, DOI 10.1038/ki.2014.260; 1988, LANCET, V1, P380	26	34	36	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 23	2019	365								l1800	10.1136/bmj.l1800	http://dx.doi.org/10.1136/bmj.l1800			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IA1MV	31335316	Green Published, hybrid			2023-01-03	WOS:000469327000001
J	Lo, TH; Abadir, E; Gasiorowski, RE; Kabani, K; Ramesh, M; Orellana, D; Fromm, PD; Kupresanin, F; Newman, E; Cunningham, I; Hart, DNJ; Silveira, PA; Clark, GJ				Lo, Tsun-Ho; Abadir, Edward; Gasiorowski, Robin E.; Kabani, Karieshma; Ramesh, Murari; Orellana, Daniel; Fromm, Phillip D.; Kupresanin, Fiona; Newman, Elizabeth; Cunningham, Ilona; Hart, Derek N. J.; Silveira, Pablo A.; Clark, Georgina J.			Examination of CD302 as a potential therapeutic target for acute myeloid leukemia	PLOS ONE			English	Article							STEM-CELLS; ANTIBODY THERAPY; EXPRESS	Acute myeloid leukemia (AML) is the most common form of adult acute leukemia with similar to 20,000 new cases yearly. The disease develops in people of all ages, but is more prominent in the elderly, who due to limited treatment options, have poor overall survival rates. Monoclonal antibodies (mAb) targeting specific cell surface molecules have proven to be safe and effective in different haematological malignancies. However, AML target molecules are currently limited so discovery of new targets would be highly beneficial to patients. We examined the C-type lectin receptor CD302 as a potential therapeutic target for AML due to its selective expression in myeloid immune populations. In a cohort of 33 AML patients with varied morphological and karyotypic classifications, 88% were found to express CD302 on the surface of blasts and 80% on the surface of CD34(+) CD38 -population enriched with leukemic stem cells. A mAb targeting human CD302 was effective in mediating antibody dependent cell cytotoxicity and was internalised, making it amenable to toxin conjugation. Targeting CD302 with antibody limited in vivo engraftment of the leukemic cell line HL-60 in NOD/SCID mice. While CD302 was expressed in a hepatic cell line, HepG2, this molecule was not detected on the surface of HepG2, nor could HepG2 be killed using a CD302 antibody-drug conjugate. Expression was however found on the surface of haematopoietic stem cells suggesting that targeting CD302 would be most effective prior to haematopoietic transplantation. These studies provide the foundation for examining CD302 as a potential therapeutic target for AML.	[Lo, Tsun-Ho; Abadir, Edward; Fromm, Phillip D.; Kupresanin, Fiona; Hart, Derek N. J.; Silveira, Pablo A.; Clark, Georgina J.] ANZAC Res Inst, Dendrit Cell Res, Sydney, NSW, Australia; [Abadir, Edward; Gasiorowski, Robin E.; Ramesh, Murari; Fromm, Phillip D.; Hart, Derek N. J.; Silveira, Pablo A.; Clark, Georgina J.] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia; [Gasiorowski, Robin E.; Newman, Elizabeth; Cunningham, Ilona; Hart, Derek N. J.] Concord Repatriat Gen Hosp, Dept Haematol, Sydney, NSW, Australia; [Kabani, Karieshma; Orellana, Daniel; Hart, Derek N. J.] Royal Prince Alfred Hosp, Inst Haematol, Sydney, NSW, Australia	University of Sydney; ANZAC Research Institute; University of Sydney; Concord Repatriation General Hospital; University of Sydney	Clark, GJ (corresponding author), ANZAC Res Inst, Dendrit Cell Res, Sydney, NSW, Australia.; Clark, GJ (corresponding author), Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia.	georgina.clark@sydney.edu.au	Research Institute, ANZAC/CAE-9030-2022; Gasiorowski, Robin/AAO-6267-2020; Ekanayake, Kanchana/P-8817-2016; Silveira, Pablo A/A-7560-2008	Gasiorowski, Robin/0000-0003-1225-8757; Silveira, Pablo A/0000-0001-5074-8824; Clark, Georgina/0000-0001-7894-232X; LO, TSUN HO/0000-0003-0229-6004; Abadir, Edward/0000-0002-4152-5079	Australian Government National Health Medical Research Council [543727]; Cancer Institute New South Wales Translational Program [11/TPG/3-02]	Australian Government National Health Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute New South Wales Translational Program	This work was supported by Australian Government National Health Medical Research Council (https://nhmrc.gov.au/) Program Grant (543727) and Cancer Institute New South Wales (https://www.cancer.nsw.gov.au/) Translational Program Grant (11/TPG/3-02) awarded to GJC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We would like to acknowledge the ANZAC Research Institute Animal Facility staff for their help with mouse husbandry and Donna Bonnici for administrative assistance. This work was supported by Australian Government National Health Medical Research Council Program Grant (543727) and Cancer Institute New South Wales Translational Program Grant (11/TPG/3-02).	Burnett A, 2011, J CLIN ONCOL, V29, P487, DOI 10.1200/JCO.2010.30.1820; Clark GJ, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2015.40; Crews LA, 2013, CANCER LETT, V338, P15, DOI 10.1016/j.canlet.2012.08.006; Gasiorowski RE, 2014, BRIT J HAEMATOL, V164, P481, DOI 10.1111/bjh.12691; Hills RK, 2014, LANCET ONCOL, V15, P986, DOI 10.1016/S1470-2045(14)70281-5; Kato M, 2003, J BIOL CHEM, V278, P34035, DOI 10.1074/jbc.M303112200; Lichtenegger FS, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0505-0; Lutz C, 2013, CANCER LETT, V338, P10, DOI 10.1016/j.canlet.2012.07.014; Maloney DG, 2012, NEW ENGL J MED, V366, P2008, DOI 10.1056/NEJMct1114348; Palumbo A, 2016, NEW ENGL J MED, V375, P754, DOI 10.1056/NEJMoa1606038; Perna F, 2017, CANCER CELL, V32, P506, DOI 10.1016/j.ccell.2017.09.004; Rico JF, 2013, CANCER LETT, V338, P4, DOI 10.1016/j.canlet.2012.05.034; SHULTZ LD, 1995, J IMMUNOL, V154, P180; Taussig DC, 2005, BLOOD, V106, P4086, DOI 10.1182/blood-2005-03-1072; Topp MS, 2014, J CLIN ONCOL, V32, P4134, DOI 10.1200/JCO.2014.56.3247; 2009, BLOOD, V113, P3088, DOI DOI 10.1182/BLOOD-2008-09-179895; 2016, J IMMUNOL, V197, P885, DOI DOI 10.4049/JIMMUNOL.1600259; 2007, J IMMUNOL, V179, P6052	18	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2019	14	5							e0216368	10.1371/journal.pone.0216368	http://dx.doi.org/10.1371/journal.pone.0216368			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX7AR	31075107	Green Submitted, Green Published, gold			2023-01-03	WOS:000467556300023
J	Bergl, PA				Bergl, Paul A.			At Baseline	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DISCHARGE; READINESS		[Bergl, Paul A.] Med Coll Wisconsin, Dept Med, Div Pulm Crit Care & Sleep Med, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Bergl, PA (corresponding author), Med Coll Wisconsin, Dept Med, Div Pulm Crit Care & Sleep Med, Milwaukee, WI 53226 USA.							Galvin EC, 2017, J ADV NURS, V73, P2547, DOI 10.1111/jan.13324; Goldszmidt M, 2019, ACAD MED, V94, P594, DOI 10.1097/ACM.0000000000002510; Harrison JD, 2016, J HOSP MED, V11, P610, DOI 10.1002/jhm.2591	3	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 9	2019	380	19					1792	1793		10.1056/NEJMp1900543	http://dx.doi.org/10.1056/NEJMp1900543			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HX9ZZ	31067368				2023-01-03	WOS:000467769800004
J	Bosma, LBE; van Rein, N; Hunfeld, NGM; Steyerberg, EW; Melief, PHGJ; van den Bemt, PMLA				Bosma, Liesbeth B. E.; van Rein, Nienke; Hunfeld, Nicole G. M.; Steyerberg, Ewout W.; Melief, Piet H. G. J.; van den Bemt, Patricia M. L. A.			Development of a multivariable prediction model for identification of patients at risk for medication transfer errors at ICU discharge	PLOS ONE			English	Article							PHARMACIST; ADMISSION	Introduction Discharge from the intensive care unit (ICU) is a high-risk process, leading to numerous potentially harmful medication transfer errors (PH-MTE). PH-MTE could be prevented by medication reconciliation by ICU pharmacists, but resources are scarce, which renders the need for predicting which patients are at risk for PH-MTE. The aim of this study was to develop a prognostic multivariable model in patients discharged from the ICU to predict who is at increased risk for PH-MTE after ICU discharge, using predictors of PH-MTE that are readily available at the time of ICU discharge. Material and methods Data for this study were derived from the Transfer ICU Medication reconciliation study, which included ICU patients and scored MTE at discharge of the ICU. The potential harm of every MTE was estimated with a validated score, where after MTE with potential for harm were indicated as PH-MTE. Predictors for PH-MTE at ICU discharge were identified using LASSO regression. The c statisticprovided a measure of the overall discriminative ability of the prediction model and the prediction model was internally validated by bootstrap resampling. Based on sensitivity and specificity, the cut-off point of the prediction model was determined. Results The cohort contained 258 patients and six variables were identified as predictors for PHMTE: length of ICU admission, number of home medications and patient taking one of the following medication groups at home: vitamin/mineral supplements, cardiovascular medication, psycholeptic/analeptic medication and medication for obstructive airway disease. The c of the final prediction model was 0.73 (95% CI 0.67-0.79) and decreased to 0.62 according to bootstrap resampling. At a cut-off score of two the prediction model yielded a sensitivity of 70% and a specificity of 61%. Conclusions A multivariable prediction model was developed to identify patients at risk for PH-MTE after ICU discharge. The model contains predictors that are available on the day of ICU discharge. Once external validation and evaluation of this model in daily practice has been performed, its incorporation into clinical practice could potentially allow institutions to identify patients at risk for PH-MTE after ICU discharge, on the day of ICU discharge, thus allowing for efficient, patient-specific allocation of clinical pharmacy services.	[Bosma, Liesbeth B. E.; van Rein, Nienke] Haga Teaching Hosp, Dept Clin Pharm, The Hague, Netherlands; [Bosma, Liesbeth B. E.; Hunfeld, Nicole G. M.; van den Bemt, Patricia M. L. A.] Erasmus Univ, Med Ctr, Dept Hosp Pharm, Rotterdam, Netherlands; [van Rein, Nienke] Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, Leiden, Netherlands; [Hunfeld, Nicole G. M.] Erasmus Univ, Med Ctr, Dept Intens Care, Rotterdam, Netherlands; [Steyerberg, Ewout W.] Erasmus MC, Clin Biostat & Med Decis Making, Rotterdam, Netherlands; [Steyerberg, Ewout W.] Leiden Univ, Med Ctr, Leiden, Netherlands; [Melief, Piet H. G. J.] Haga Teaching Hosp, Dept Intens Care, The Hague, Netherlands	Haga Hospital; Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Haga Hospital	Bosma, LBE (corresponding author), Haga Teaching Hosp, Dept Clin Pharm, The Hague, Netherlands.; Bosma, LBE (corresponding author), Erasmus Univ, Med Ctr, Dept Hosp Pharm, Rotterdam, Netherlands.	l.bosma@hagaziekenhuis.nl		Van den Bemt, Patricia/0000-0003-1418-5520				Alshakrah MA, 2019, RES SOC ADMIN PHARM, V15, P767, DOI 10.1016/j.sapharm.2018.09.009; Bell CM, 2011, JAMA-J AM MED ASSOC, V306, P840, DOI 10.1001/jama.2011.1206; Bell CM, 2006, J GEN INTERN MED, V21, P937, DOI 10.1007/BF02743141; Bos JM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201645; Bosma BE, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2065-y; Bosma LBE, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-018-0361-2; Breuker C, 2021, J PATIENT SAF, V17, pE645, DOI 10.1097/PTS.0000000000000420; Daniels M, 2018, MEDISCH CONTACT; Falconer N, 2018, BRIT J CLIN PHARMACO, V84, P846, DOI 10.1111/bcp.13514; Gleason KM, 2010, J GEN INTERN MED, V25, P441, DOI 10.1007/s11606-010-1256-6; Hias J, 2017, EUR J CLIN PHARMACOL, V73, P1355, DOI 10.1007/s00228-017-2308-1; Jolivot PA, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0643-5; Lewis P, 2017, EUR J HOSP PHARM, V24, P314, DOI 10.1136/ejhpharm-2017-001395; Moons KGM, 2015, ANN INTERN MED, V162, pW1, DOI 10.7326/M14-0698; Mueller SK, 2012, ARCH INTERN MED, V172, P1057, DOI 10.1001/archinternmed.2012.2246; Nates JL, 2016, CRIT CARE MED, V44, P1553, DOI 10.1097/CCM.0000000000001856; Nesbit TW, 2001, AM J HEALTH-SYST PH, V58, P784, DOI 10.1093/ajhp/58.9.784; Niven DJ, 2014, CRIT CARE MED, V42, P179, DOI 10.1097/CCM.0b013e3182a272c0; Picone DM, 2008, AM J MED QUAL, V23, P115, DOI 10.1177/1062860607313143; Pippins JR, 2008, J GEN INTERN MED, V23, P1414, DOI 10.1007/s11606-008-0687-9; Robertson R, 2017, UNDERSTANDING NHS FI; Scales DC, 2016, J GEN INTERN MED, V31, P196, DOI 10.1007/s11606-015-3501-5; Stelfox HT, 2015, CHEST, V147, P317, DOI 10.1378/chest.13-2965; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Nguyen TL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171995; van Sluisveld N, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2139-x; Vincent JL, 2010, CRIT CARE, V14, DOI 10.1186/cc8204	27	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2019	14	4							e0215459	10.1371/journal.pone.0215459	http://dx.doi.org/10.1371/journal.pone.0215459			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW0IT	31039162	Green Published, gold, Green Submitted			2023-01-03	WOS:000466364800009
J	Cicaloni, V; Spiga, O; Dimitri, GM; Maiocchi, R; Millucci, L; Giustarini, D; Bernardini, G; Bernini, A; Marzocchi, B; Braconi, D; Santucci, A				Cicaloni, Vittoria; Spiga, Ottavia; Dimitri, Giovanna Maria; Maiocchi, Rebecca; Millucci, Lia; Giustarini, Daniela; Bernardini, Giulia; Bernini, Andrea; Marzocchi, Barbara; Braconi, Daniela; Santucci, Annalisa			Interactive alkaptonuria database: investigating clinical data to improve patient care in a rare disease	FASEB JOURNAL			English	Article						precision medicine; machine learning; biomarkers	THIOLATION INDEX PTI; SERUM AMYLOID-A; OXIDATIVE STRESS; ASCORBIC-ACID; CHITOTRIOSIDASE ACTIVITY; HOMOGENTISIC ACID; INFLAMMATION; BIOMARKER; HISTORY; PATHWAY	Alkaptonuria (AKU) is an ultrarare autosomal recessive disorder (MIM 203500) that is caused byby a complex set of mutations in homogentisate 1,2-dioxygenasegene and consequent accumulation of homogentisic acid (HGA), causing a significant protein oxidation. A secondary form of amyloidosis was identified in AKU and related to high circulating serum amyloid A (SAA) levels, which are linked with inflammation and oxidative stress and might contribute to disease progression and patients' poor quality of life. Recently, we reported that inflammatory markers (SAA and chitotriosidase) and oxidative stress markers (protein thiolation index) might be disease activity markers in AKU. Thanks to an international network, we collected genotypic, phenotypic, and clinical data from more than 200 patients with AKU. These data are currently stored in our AKU database, named ApreciseKUre. In this work, we developed an algorithm able to make predictions about the oxidative status trend of each patient with AKU based on 55 predictors, namely circulating HGA, body mass index, total cholesterol, SAA, and chitotriosidase. Our general aim is to integrate the data of apparently heterogeneous patients with AKUAKU by using specific bioinformatics tools, in order to identify pivotal mechanisms involved in AKU for a preventive, predictive, and personalized medicine approach to AKU.	[Cicaloni, Vittoria; Spiga, Ottavia; Maiocchi, Rebecca; Millucci, Lia; Giustarini, Daniela; Bernardini, Giulia; Bernini, Andrea; Marzocchi, Barbara; Braconi, Daniela; Santucci, Annalisa] Univ Siena, Dept Biotechnol Chem & Pharm, Via A Moro 2, I-53100 Siena, Italy; [Cicaloni, Vittoria; Maiocchi, Rebecca] Toscana Life Sci Fdn, Siena, Italy; [Dimitri, Giovanna Maria] Univ Cambridge, Dept Comp Sci, Cambridge, England; [Marzocchi, Barbara] Azienda Osped Senese, UOC, Patol Clin, Siena, Italy	University of Siena; University of Cambridge; University of Siena; University Hospital of Siena	Spiga, O (corresponding author), Univ Siena, Dept Biotechnol Chem & Pharm, Via A Moro 2, I-53100 Siena, Italy.	ottavia.spiga@unisi.it	Santucci, Annalisa/K-1932-2018; Bernini, Andrea/H-9412-2012; Dimitri, Giovanna Maria/AGG-4991-2022; Giustarini, Daniela/AAV-6629-2021; Bernardini, Giulia/ABG-2209-2020; Braconi, Daniela/J-9616-2018	Santucci, Annalisa/0000-0001-6976-9086; Bernini, Andrea/0000-0002-7528-2749; Dimitri, Giovanna Maria/0000-0002-2728-4272; Bernardini, Giulia/0000-0003-0016-0728; Braconi, Daniela/0000-0002-9657-4169; Cicaloni, Vittoria/0000-0002-8329-1565	Telethon Italy [GGP10058]; Toscana Life Sciences Orphan_1 Project; Associazione Italiana Malati di Alkaptonuria Alkaptonuria [ORPHA263402]; Tuscany Region Pegaso Ph.D. School in Biochemistry and Molecular Biology (Fondazione Vita Its Probits) [113195]	Telethon Italy(Fondazione Telethon); Toscana Life Sciences Orphan_1 Project; Associazione Italiana Malati di Alkaptonuria Alkaptonuria; Tuscany Region Pegaso Ph.D. School in Biochemistry and Molecular Biology (Fondazione Vita Its Probits)	The authors acknowledge support from Telethon Italy Grant GGP10058, the Toscana Life Sciences Orphan_1 Project, and Associazione Italiana Malati di Alkaptonuria Alkaptonuria (ORPHA263402). The authors thank the Toscana Life Sciences Foundation. V.C. was supported by a Ph.D. fellowship from the Tuscany Region Pegaso Ph.D. School in Biochemistry and Molecular Biology (Fondazione Vita Its Probits, 113195). The authors declare no conflicts of interest.	Albatayneh Eman M, 2019, J Clin Med Res, V11, P337, DOI 10.14740/jocmr3801; Ally MMTM, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/183653; Basok BI, 2014, J MED BIOCHEM, V33, P245, DOI 10.2478/jomb-2014-0010; Bernardini G, 2012, PROTEOMICS, V12, P708, DOI 10.1002/pmic.201100358; Braconi D, 2018, OSTEOARTHR CARTILAGE, V26, P1078, DOI 10.1016/j.joca.2018.05.017; Braconi D, 2016, INT J BIOCHEM CELL B, V81, P271, DOI 10.1016/j.biocel.2016.08.016; Braconi D, 2015, FREE RADICAL BIO MED, V88, P70, DOI 10.1016/j.freeradbiomed.2015.02.021; Braconi D, 2012, J CELL PHYSIOL, V227, P3333, DOI 10.1002/jcp.24033; Braconi D, 2011, J INHERIT METAB DIS, V34, P1163, DOI 10.1007/s10545-011-9377-6; Braconi D, 2010, J CELL BIOCHEM, V111, P922, DOI 10.1002/jcb.22780; Braconi D, 2010, RHEUMATOLOGY, V49, P1975, DOI 10.1093/rheumatology/keq175; Bruce B, 2003, J RHEUMATOL, V30, P167; Brunner JKH, 2008, RHEUMATOL INT, V28, P949, DOI 10.1007/s00296-008-0558-z; Calkins MJ, 2009, ANTIOXID REDOX SIGN, V11, P497, DOI [10.1089/ars.2008.2242, 10.1089/ARS.2008.2242]; Cantarini L, 2012, YONSEI MED J, V53, P1045, DOI 10.3349/ymj.2012.53.5.1045; Chambers J. M., 1992, STAT MMODELS S, V251; Cicaloni V., 2016, PEERJ PREPRINTS, V4, DOI DOI 10.7287/PEERJ.PREPRINTS.2174V1; Ciftci S, 2016, J CLIN LAB ANAL, V30, P1158, DOI 10.1002/jcla.21997; Cox TF, 2011, J INHERIT METAB DIS, V34, P1153, DOI 10.1007/s10545-011-9367-8; Davison AS, 2016, J INHERIT METAB DIS, V39, P203, DOI 10.1007/s10545-015-9902-0; de Seny D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066769; Duzova A, 2003, CLIN EXP RHEUMATOL, V21, P509; FernandezCanon JM, 1996, NAT GENET, V14, P19, DOI 10.1038/ng0996-19; Gillmore JD, 2001, LANCET, V358, P24, DOI 10.1016/S0140-6736(00)05252-1; Giustarini D, 2017, ANAL BIOCHEM, V538, P38, DOI 10.1016/j.ab.2017.09.010; Giustarini D, 2012, FREE RADICAL BIO MED, V53, P907, DOI 10.1016/j.freeradbiomed.2012.06.022; Guo YF, 1995, J INHERIT METAB DIS, V18, P717, DOI 10.1007/BF02436762; Hughes AT, 2015, ANN CLIN BIOCHEM, V52, P597, DOI 10.1177/0004563215571969; Jung SY, 2007, YONSEI MED J, V48, P218, DOI 10.3349/ymj.2007.48.2.218; Li JQ, 2009, EXPERT OPIN THER TAR, V13, P785, DOI 10.1517/14728220903025762; Manna P, 2015, METAB SYNDR RELAT D, V13, P423, DOI 10.1089/met.2015.0095; Maritim AC, 2003, J BIOCHEM MOL TOXIC, V17, P24, DOI 10.1002/jbt.10058; Marseglia L, 2015, INT J MOL SCI, V16, P378, DOI 10.3390/ijms16010378; Mayatepek E, 1998, EUR J PEDIATR, V157, P867, DOI 10.1007/s004310050956; Millucci L, 2015, J INHERIT METAB DIS, V38, P797, DOI 10.1007/s10545-015-9842-8; Millucci L, 2015, J CELL PHYSIOL, V230, P1148, DOI 10.1002/jcp.24850; Millucci L, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0185-9; Millucci L, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/258471; Millucci L, 2014, INT J CARDIOL, V172, pE121, DOI 10.1016/j.ijcard.2013.12.117; Millucci L, 2012, BBA-MOL BASIS DIS, V1822, P1682, DOI 10.1016/j.bbadis.2012.07.011; Mistry JB, 2013, RARE DIS, V1, DOI 10.4161/rdis.27475; Morava E, 2003, ANN CLIN BIOCHEM, V40, P108, DOI 10.1258/000456303321016268; Nemethova M, 2016, EUR J HUM GENET, V24, P66, DOI 10.1038/ejhg.2015.60; Phornphutkul C, 2002, NEW ENGL J MED, V347, P2111, DOI 10.1056/NEJMoa021736; Ramos LF, 2008, J AM SOC NEPHROL, V19, P593, DOI 10.1681/ASN.2007030355; Ranganath LR, 2016, ANN RHEUM DIS, V75, P362, DOI 10.1136/annrheumdis-2014-206033; Ranganath LR, 2013, J CLIN PATHOL, V66, P367, DOI 10.1136/jclinpath-2012-200877; Rencher A. C., 2008, LINEAR MMODELS SSTAT; Ruiz S, 2013, KIDNEY INT, V83, P1029, DOI 10.1038/ki.2012.439; Shimojima Y, 2005, INTERNAL MED, V44, P1009, DOI 10.2169/internalmedicine.44.1009; Spiga O, 2018, COMPUT BIOL MED, V103, P1, DOI 10.1016/j.compbiomed.2018.10.002; Spiga O, 2017, BMC MED INFORM DECIS, V17, DOI 10.1186/s12911-017-0438-0; Su XH, 2018, FREE RADICAL BIO MED, V115, P471, DOI 10.1016/j.freeradbiomed.2017.12.004; Team R.C., 2021, R FOUN DATION STAT C; Tharini Gk, 2011, Indian J Dermatol, V56, P194, DOI 10.4103/0019-5154.80415; Tinti L, 2010, J CELL PHYSIOL, V225, P84, DOI 10.1002/jcp.22199; Vilboux T, 2009, HUM MUTAT, V30, P1611, DOI 10.1002/humu.21120; WILKINSON GN, 1973, ROY STAT SOC C-APP, V22, P392; WOLFF JA, 1989, PEDIATR RES, V26, P140, DOI 10.1203/00006450-198908000-00015; Wu K., 2018, EUR J RHEUMATOL, V6, P1; Yang RL, 2008, J CLIN BIOCHEM NUTR, V43, P154, DOI 10.3164/jcbn.2008044	61	9	9	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2019	33	11					12696	12703		10.1096/fj.201901529R	http://dx.doi.org/10.1096/fj.201901529R			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KC8ZX	31462106	Green Published			2023-01-03	WOS:000507461600085
J	Persmark, A; Wemrell, M; Zettermark, S; Leckie, G; Subramanian, SV; Merlo, J				Persmark, Anna; Wemrell, Maria; Zettermark, Sofia; Leckie, George; Subramanian, S., V; Merlo, Juan			Precision public health: Mapping socioeconomic disparities in opioid dispensations at Swedish pharmacies by Multilevel Analysis of Individual Heterogeneity and Discriminatory Accuracy (MAIHDA)	PLOS ONE			English	Article							BRIEF CONCEPTUAL TUTORIAL; SOCIAL EPIDEMIOLOGY; MENTAL-HEALTH; INTERSECTIONALITY THEORY; USE DISORDERS; RISK-FACTORS; POPULATION; DETERMINANTS; ASSOCIATION; MORTALITY	Background In light of the opioid epidemic in the United States, there is growing concern about the use of opioids in Sweden as it may lead to misuse and overuse and, in turn, severe public health problems. However, little is known about the distribution of opioid use across different demographic and socioeconomic dimensions in the Swedish general population. Therefore, we applied an intersectional Multilevel Analysis of Individual Heterogeneity and Discriminatory Accuracy (MAIHDA), to obtain an improved mapping of the risk heterogeneity of and socioeconomic inequalities in opioid prescription receipt. Methods and findings Using data from 6,846,106 residents in Sweden aged 18 and above, we constructed 72 intersectional strata from combinations of gender, age, income, cohabitation status, and presence or absence of psychological distress. We modelled the absolute risk (AR) of opioid prescription receipt in a series of multilevel logistic regression models distinguishing between additive and interaction effects. By means of the Variance Partitioning Coefficient (VPC) and the area under the receiver operating characteristic curve (AUC), we quantified the discriminatory accuracy (DA) of the intersectional strata for discerning those who received opioid prescriptions from those who did not. The AR of opioid prescription receipt ranged from 2.77% (95% CI 2.69-2.86) among low-income men aged 18-34, living alone, without psychological distress, to 28.25% (95% CI 27.95-28.56) among medium-income women aged 65 and older, living alone, with psychological distress. In a model that conflated both additive and interaction effects, the intersectional strata had a fair DA for discerning opioid users from non-users (VPC = 13.2%, AUC = 0.68). However, in the model that decomposed total effects into additive and interaction effects, the VPC was very low (0.42%) indicating the existence of small interaction effects for a number of the intersectional strata. Conclusions The intersectional MAIHDA approach aligns with the aims of precision public health, through improving the evidence base for health policy by increasing understanding of both health inequalities and individual heterogeneity. This approach is particularly relevant for socioeconomically conditioned outcomes such as opioid prescription receipt. We have identified intersections of social position within the Swedish population at greater risk for opioid prescription receipt.	[Persmark, Anna; Wemrell, Maria; Zettermark, Sofia; Leckie, George; Merlo, Juan] Lund Univ, Fac Med, Unit Social Epidemiol, Malmo, Sweden; [Wemrell, Maria] Lund Univ, Fac Social Sci, Dept Gender Studies, Lund, Sweden; [Leckie, George] Univ Bristol, Ctr Multilevel Modelling, Bristol, Avon, England; [Subramanian, S., V] Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA USA; [Merlo, Juan] Ctr Primary Hlth Care Res, Malmo, Sweden	Lund University; Lund University; University of Bristol; Harvard University; Harvard T.H. Chan School of Public Health	Persmark, A; Wemrell, M (corresponding author), Lund Univ, Fac Med, Unit Social Epidemiol, Malmo, Sweden.; Wemrell, M (corresponding author), Lund Univ, Fac Social Sci, Dept Gender Studies, Lund, Sweden.	apersmark@gmail.com; maria.wemrell@med.lu.se	Zettermark, Sofia/AAD-1920-2021; Wemrell, Maria/AAO-4079-2021; Merlo, Juan/E-2136-2011	Zettermark, Sofia/0000-0003-3181-8609; Persmark, Anna/0000-0001-5446-1484; Wemrell, Maria/0000-0002-3186-9054; Merlo, Juan/0000-0001-8379-9708	Swedish Research Council (Vetenskapsradet) [2017-01321]; Faculty of Medicine, Lund University; Region Skane County Council	Swedish Research Council (Vetenskapsradet)(Swedish Research Council); Faculty of Medicine, Lund University; Region Skane County Council	This work was supported by Swedish Research Council (Vetenskapsradet), https://www.vr.se/inenglish.4.12fff4451215cbd83e4800015152.html, Grant #: 2017-01321, JM; Faculty of Medicine, Lund University, https://www.med.lu.se/english, JM; Region Skane County Council, http://www.researchweb.org/is/ssvr, JM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2017, USERS GUIDE MLWIN V3; Backryd E., 2017, LAKARTIDNINGEN, V114; Bauer GR, 2014, SOC SCI MED, V110, P10, DOI 10.1016/j.socscimed.2014.03.022; Bayer R, 2015, NEW ENGL J MED, V373, P499, DOI 10.1056/NEJMp1506241; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Bonnie RJ, 2017, JAMA-J AM MED ASSOC, V318, P423, DOI 10.1001/jama.2017.10046; Browne W.J., 2017, MCMC ESTIMATION MLWI; Browne WJ, 2017, MLWIN VERSION 301; Choo HY, 2010, SOCIOL THEOR, V28, P129, DOI 10.1111/j.1467-9558.2010.01370.x; Crenshaw K., 1989, UNIV CHICAGO LEG FOR, V1, P139, DOI [10.4324/9781315582924-10, DOI 10.4324/9780429500480-5]; CRUTCHFIELD RD, 1984, SOC SCI MED, V18, P503, DOI 10.1016/0277-9536(84)90008-X; Degenhardt L, 2014, ADDICTION, V109, P1320, DOI 10.1111/add.12551; Edlund MJ, 2010, CLIN J PAIN, V26, P1, DOI 10.1097/AJP.0b013e3181b99f35; Evans C. R, 2015, INNOVATIVE APPROACHE; Evans CR, 2019, SOC SCI MED, V220, P1, DOI 10.1016/j.socscimed.2018.10.019; Evans CR, 2018, SOC SCI MED, V203, P64, DOI 10.1016/j.socscimed.2017.11.011; Fisk SA, 2018, SSM-POPUL HLTH, V4, P334, DOI 10.1016/j.ssmph.2018.03.005; Frenk S.M., 2015, PRESCRIPTION OPIOID; Fugelstad A, 2015, SOCIALMEDICINSK TIDS, V92; Galea S, 2004, EPIDEMIOL REV, V26, P36, DOI 10.1093/epirev/mxh007; Galobardes B, 2007, BRIT MED BULL, V81-82, P21, DOI 10.1093/bmb/ldm001; Ghith N, 2016, PLOS ONE, V11; Goldstein H., 2002, Understanding Statistics, V1, P223, DOI 10.1207/S15328031US0104_02; Green MA, 2017, SOC SCI MED, V178, P214, DOI 10.1016/j.socscimed.2017.02.029; Gustafsson A, 2011, BERAKNINGSDEFINITION; Han B, 2017, ANN INTERN MED, V167, pI24, DOI 10.7326/P17-9042; Hancock A.M., 2013, UC IRVINE LAW REV, V3, P259; Hernandez-Yumar A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208624; Hudson TJ, 2008, J PAIN SYMPTOM MANAG, V36, P280, DOI 10.1016/j.jpainsymman.2007.10.003; Imtiaz S, 2014, SUBST ABUSE TREAT PR, V9, DOI 10.1186/1747-597X-9-43; Ivert AK, 2016, ETHNIC HEALTH, V21, P578, DOI 10.1080/13557858.2016.1143090; Jones K., 2016, METHODOL INNOV, V9, P1, DOI DOI 10.1177/2059799116672874; Juarez SP, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005388; Katz C, 2013, DRUG ALCOHOL DEPEN, V132, P107, DOI 10.1016/j.drugalcdep.2013.01.010; Khoury MJ, 2016, JAMA-J AM MED ASSOC, V316, P1357, DOI 10.1001/jama.2016.12260; Khoury MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/j.amepre.2015.08.031; King NB, 2014, AM J PUBLIC HEALTH, V104, pE32, DOI 10.2105/AJPH.2014.301966; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Leckie G, 2013, J STAT SOFTW, V52, P1; Link BG, 2006, LANCET, V367, P528, DOI 10.1016/S0140-6736(06)68184-1; Ludvigsson JF, 2016, EUR J EPIDEMIOL, V31, P125, DOI 10.1007/s10654-016-0117-y; Lynch J., 2000, SOCIAL EPIDEMIOLOGY; MANCHIKANTI L, 2012, PAIN PHYS S, V15, pES; McCall L, 2005, SIGNS, V30, P1771, DOI 10.1086/426800; Merlo J, 2005, MED CARE, V43, P1092, DOI 10.1097/01.mlr.0000182484.14608.b9; Merlo J, 2005, J EPIDEMIOL COMMUN H, V59, P729, DOI 10.1136/jech.2004.023929; Merlo J, 2004, AM J EPIDEMIOL, V159, P1168, DOI 10.1093/aje/kwh160; Merlo J, 2009, J EPIDEMIOL COMMUN H, V63, P1043, DOI 10.1136/jech.2009.088310; Merlo J, 2003, J EPIDEMIOL COMMUN H, V57, P550, DOI 10.1136/jech.57.8.550; Merlo J, 2006, J EPIDEMIOL COMMUN H, V60, P290, DOI 10.1136/jech.2004.029454; Merlo J, 2013, EUR J EPIDEMIOL, V28, P135; Merlo J, 2015, EC SALUD BOLETI INFO, V84; Merlo J, 2013, EUR J EPIDEMIOL S, V28, P148; Merlo J, 2018, SOC SCI MED, V203, P74, DOI 10.1016/j.socscimed.2017.12.026; Merlo J, 2017, SSM-POPUL HLTH, V3, P684, DOI 10.1016/j.ssmph.2017.08.005; Merlo J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153778; Merlo J, 2015, EUR J PUBLIC HEALTH, V25, P910, DOI 10.1093/eurpub/ckv209; Merlo J, 2014, AM J EPIDEMIOL, V180, P208, DOI 10.1093/aje/kwu108; Mulinari S, 2018, CRIT PUBLIC HEALTH, V28, P177, DOI 10.1080/09581596.2017.1316831; Mulinari S, 2015, EUR J PUBLIC HEALTH, V25, P911, DOI 10.1093/eurpub/ckv099; Ohlsson H, 2011, MED CARE, V49, P327, DOI 10.1097/MLR.0b013e31820325c5; Pepe MS, 2004, AM J EPIDEMIOL, V159, P882, DOI 10.1093/aje/kwh101; Rhodin A, 2014, LAKARTIDNINGEN, V111, pCZW3; Scherbaum N, 2008, INT J METH PSYCH RES, V17, pS39, DOI 10.1002/mpr.244; Seal KH, 2012, JAMA-J AM MED ASSOC, V307, P940, DOI 10.1001/jama.2012.234; Seng JS, 2012, SOC SCI MED, V75, P2437, DOI 10.1016/j.socscimed.2012.09.023; Shah A, 2017, J PAIN, V18, P1374, DOI 10.1016/j.jpain.2017.06.010; Socialstyrelsen, STAT LAK 2017; Socialstyrelsen, 2017, STAT LAK 2016; Subramanian SV, 2004, SOC SCI MED, V58, P1961, DOI 10.1016/S0277-9536(03)00415-5; Subramanian SV, 2007, MACROSOCIAL DETERMIN, P301, DOI DOI 10.1007/978-0-387-70812-6_15; Svendsen K, 2014, ACTA ANAESTH SCAND, V58, P437, DOI 10.1111/aas.12281; Tjaderborn M, 2009, PHARMACOEPIDEM DR S, V18, P1192, DOI 10.1002/pds.1838; VanderWeele T.J., 2014, TUTORIAL INTERACTION, V3, P33, DOI [10.1515/em-2013-0005, DOI 10.1515/EM-2013-0005]; Wagner P, 2015, INT J EPIDEMIOL, V44, P49; Wemrell M, 2017, SOC SCI MED, V178, P217, DOI 10.1016/j.socscimed.2017.02.040; Wemrell M, 2017, SOC SCI MED, V177, P213, DOI 10.1016/j.socscimed.2017.01.050; Wettermark B, 2007, PHARMACOEPIDEM DR S, V16, P726, DOI 10.1002/pds.1294	78	16	16	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2019	14	8							e0220322	10.1371/journal.pone.0220322	http://dx.doi.org/10.1371/journal.pone.0220322			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW5WO	31454361	Green Published, Green Submitted, gold			2023-01-03	WOS:000485049000005
J	Brown, TJ; Brainard, J; Song, F; Wang, X; Abdelhamid, A; Hooper, L; Ajabnoor, S; Alabdulghafoor, F; Brainard, J; Brown, TJ; Donaldson, D; Hooper, L; Jimoh, OF; O'Brien, A; Song, FJ; Wang, X; Winstanley, L; Alkhudairy, L; Rees, K; Biswas, P; Deane, K; Hanson, S; Thorpe, G; Bridges, C; Martin, N				Brown, Tracey J.; Brainard, Julii; Song, Fujian; Wang, Xia; Abdelhamid, Asmaa; Hooper, Lee; Ajabnoor, Sarah; Alabdulghafoor, Faye; Brainard, Julii; Brown, Tracey J.; Donaldson, Daisy; Hooper, Lee; Jimoh, Oluseyi Florence; O'Brien, Alex; Song, Fujian; Wang, Xia; Winstanley, Lauren; Alkhudairy, Lena; Rees, Karen; Biswas, Priti; Deane, Katherine; Hanson, Sarah; Thorpe, Gabrielle; Bridges, Charlene; Martin, Nicole		PUFAH Grp	Omega-3, omega-6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: systematic review and meta-analysis of randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Review							FISH CONSUMPTION; CARDIOVASCULAR OUTCOMES; EMPIRICAL-EVIDENCE; ACIDS; OMEGA-3-FATTY-ACIDS; SUPPLEMENTS; RISK; ASSOCIATION; MERCURY; DISEASE	OBJECTIVE To assess effects of increasing omega-3, omega-6, and total polyunsaturated fatty acids (PUFA) on diabetes diagnosis and glucose metabolism. DESIGN Systematic review and meta-analyses. DATA SOURCES Medline, Embase, Cochrane CENTRAL, WHO International Clinical Trials Registry Platform, Clinicaltrials.gov, and trials in relevant systematic reviews. ELIGIBILITY CRITERIA Randomised controlled trials of at least 24 weeks' duration assessing effects of increasing alpha-linolenic acid, long chain omega-3, omega-6, or total PUFA, which collected data on diabetes diagnoses, fasting glucose or insulin, glycated haemoglobin (HbA 1c), and/or homoeostatic model assessment for insulin resistance (HOMA-IR). DATA SYNTHESIS Statistical analysis included random effects meta-analyses using relative risk and mean difference, and sensitivity analyses. Funnel plots were examined and subgrouping assessed effects of intervention type, replacement, baseline risk of diabetes and use of antidiabetes drugs, trial duration, and dose. Risk of bias was assessed with the Cochrane tool and quality of evidence with GRADE. RESULTS 83 randomised controlled trials (mainly assessing effects of supplementary long chain omega-3) were included; 10 were at low summary risk of bias. Long chain omega-3 had little or no effect on likelihood of diagnosis of diabetes (relative risk 1.00, 95% confidence interval 0.85 to 1.17; 58 643 participants, 3.7% developed diabetes) or measures of glucose metabolism (HbA 1c mean difference-0.02%, 95% confidence interval-0.07% to 0.04%; plasma glucose 0.04, 0.02 to 0.07, mmol/L; fasting insulin 1.02, -4.34 to 6.37, pmol/L; HOMA-IR 0.06,-0.21 to 0.33). A suggestion of negative outcomes was observed when dose of supplemental long chain omega-3 was above 4.4 g/d. Effects of a-linolenic acid, omega-6, and total PUFA on diagnosis of diabetes were unclear (as the evidence was of very low quality), but little or no effect on measures of glucose metabolism was seen, except that increasing a-linolenic acid may increase fasting insulin (by about 7%). No evidence was found that the omega-3/omega-6 ratio is important for diabetes or glucose metabolism. CONCLUSIONS This is the most extensive systematic review of trials to date to assess effects of polyunsaturated fats on newly diagnosed diabetes and glucose metabolism, including previously unpublished data following contact with authors. Evidence suggests that increasing omega-3, omega-6, or total PUFA has little or no effect on prevention and treatment of type 2 diabetes mellitus.	[Brown, Tracey J.; Brainard, Julii; Song, Fujian; Wang, Xia; Abdelhamid, Asmaa; Hooper, Lee; Ajabnoor, Sarah; Alabdulghafoor, Faye; Brainard, Julii; Brown, Tracey J.; Donaldson, Daisy; Hooper, Lee; Jimoh, Oluseyi Florence; O'Brien, Alex; Song, Fujian; Wang, Xia; Winstanley, Lauren] Univ East Anglia, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England; [Alkhudairy, Lena; Rees, Karen] Univ Warwick, Warwick Med Sch, Coventry, W Midlands, England; [Biswas, Priti; Deane, Katherine; Hanson, Sarah; Thorpe, Gabrielle] Univ East Anglia, Hlth Sci, Norwich, Norfolk, England; [Bridges, Charlene; Martin, Nicole] UCL, Cochrane Heart Grp, London, England	University of East Anglia; University of Warwick; University of East Anglia; University of London; University College London	Hooper, L (corresponding author), Univ East Anglia, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England.	L.Hooper@uea.ac.uk	Ajabnoor, Sarah/ABA-7399-2020; Hooper, Lee/D-2795-2009	Ajabnoor, Sarah/0000-0003-0996-1484; Hooper, Lee/0000-0002-7904-3331; Brown, Tracey/0000-0003-4381-5974; Wang, Xia/0000-0001-6915-2588				ABDELHAMID AS, 2018, COCHRANE DB SYST REV, DOI DOI 10.1007/S12517-017-3380-7; Abdelhamid A, 2019, CALCIFIED TISSUE INT, V105, P353, DOI 10.1007/s00223-019-00584-3; Afshin A, 2019, LANCET, V393, P1958, DOI 10.1016/S0140-6736(19)30041-8; Alhazmi A, 2014, PUBLIC HEALTH NUTR, V17, P1587, DOI 10.1017/S1368980013001870; Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS67, DOI [10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc11-S062, 10.2337/dc10-S062]; American Heart Association, 2017, FISH OM 3 FATT AC; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Bonds DE, 2014, JAMA INTERN MED, V174, P763, DOI 10.1001/jamainternmed.2014.328; Bosch J, 2012, NEW ENGL J MED, V367, P309, DOI 10.1056/NEJMoa1203859; Bourdon JA, 2010, FOOD CHEM TOXICOL, V48, P3093, DOI 10.1016/j.fct.2010.07.051; Bowman L, 2018, NEW ENGL J MED, V379, P1540, DOI 10.1056/NEJMoa1804989; Brown T, 2017, DIETARY POLYUNSATURA; Browning LM, 2012, AM J CLIN NUTR, V96, P748, DOI 10.3945/ajcn.112.041343; Caldwell SH, 2011, J HEPATOL, V54, pS8, DOI 10.1016/S0168-8278(11)60019-6; Cefalu WT, 2019, DIABETES CARE, V42, pS13, DOI 10.2337/dc19-S002; Cefalu WT, 2019, DIABETES CARE, V42, pS46, DOI 10.2337/dc19-S005; Chen C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139565; Chen YW, 2006, DIABETES, V55, P1614, DOI 10.2337/db06-0029; Dangour AD, 2010, AM J CLIN NUTR, V91, P1725, DOI 10.3945/ajcn.2009.29121; Danthiir V, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-117; Derosa G, 2016, BIOFACTORS, V42, P316, DOI 10.1002/biof.1277; Djousse L, 2011, AM J CLIN NUTR, V93, P143, DOI 10.3945/ajcn.110.005603; Forouhi NG, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002094; Gakidou E, 2017, LANCET, V390, P1345, DOI 10.1016/S0140-6736(17)32366-8; GLAUBER H, 1988, ANN INTERN MED, V108, P663, DOI 10.7326/0003-4819-108-5-663; Hanson S, 2017, EFFECTS SUPPLEMENTAR; Harding AH, 2004, EUR J CLIN NUTR, V58, P277, DOI 10.1038/sj.ejcn.1601779; Hartweg J, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003205.pub2; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hooper L, 2018, COCHRANE DATABASE SY; Hooper L, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029554; Kromhout D, 2010, NEW ENGL J MED, V363, P2015, DOI 10.1056/NEJMoa1003603; Lee DH, 2006, DIABETES CARE, V29, P1638, DOI 10.2337/dc06-0543; Levine KE, 2005, J AUTOM METHOD MANAG, P211, DOI 10.1155/JAMMC.2005.211; Li D, 2015, ASIA PAC J CLIN NUTR, V24, P10, DOI 10.6133/apjcn.2015.24.1.21; McKenzie JE, 2016, RES SYNTH METHODS, V7, P371, DOI 10.1002/jrsm.1196; National Institute for Health and Care Excellence, 2016, CG181 NICE; National Institute for Health and Care Excellence, 2018, PREVENTING TYPE 2 DI; Nutrition Science Team, 2016, GOV DIET REC GOV REC; Papanikolaou Y, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-64; Patel PS, 2012, AM J CLIN NUTR, V95, P1445, DOI 10.3945/ajcn.111.029314; Proudman SM, 2015, BRIT J NUTR, V114, P885, DOI 10.1017/S0007114515002718; Public Health England, 2018, NATL DIET NUTR SURVE; Public Health England, 2019, STAT SUMM NAT DIET N; Ruidavets JB, 2007, J EPIDEMIOL COMMUN H, V61, P810, DOI 10.1136/jech.2006.052126; SACN, 2004, ADV FISH CONS BEN RI; Savovic J, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16350; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schwab U, 2014, FOOD NUTR RES, V58, DOI 10.3402/fnr.v58.25145; Scorletti E, 2014, DIABETIC MED, V31, P1; Seuring T, 2015, PHARMACOECONOMICS, V33, P811, DOI 10.1007/s40273-015-0268-9; Simopoulos AP, 2016, OPEN HEART, V3, DOI 10.1136/openhrt-2015-000385; Thorning TK, 2017, AM J CLIN NUTR, V105, P1033, DOI 10.3945/ajcn.116.151548; Thorpe G, 2017, DIETARY POLYUNSATURA; VESSBY B, 1992, DIABETIC MED, V9, P126, DOI 10.1111/j.1464-5491.1992.tb01748.x; Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]; Wallin A, 2012, DIABETES CARE, V35, P918, DOI 10.2337/dc11-1631; Wood L, 2008, BMJ-BRIT MED J, V336, P601, DOI 10.1136/bmj.39465.451748.AD; World Health Organization, 2016, GLOB REP PSOR; Wu JHY, 2017, LANCET DIABETES ENDO, V5, P965, DOI [10.1016/s2213-8587(17)30307-8, 10.1016/S2213-8587(17)30307-8]; Wu JHY, 2012, BRIT J NUTR, V107, pS214, DOI 10.1017/S0007114512001602; Zheng JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044525; Zhou YP, 2012, BRIT J NUTR, V108, P408, DOI 10.1017/S0007114512002036	64	113	113	8	50	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 21	2019	366								l4697	10.1136/bmj.l4697	http://dx.doi.org/10.1136/bmj.l4697			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IT5DG	31434641	Green Published, hybrid, Green Accepted			2023-01-03	WOS:000482882000003
J	Ferreira, NR; Junqueira, YN; Correa, NB; Fonseca, EO; Brito, NBM; Menezes, TA; Magini, M; Fidalgo, TKS; Ferreira, DMTP; de Lima, RL; Carvalho, AC; DosSantos, MF				Ferreira, Natalia R.; Junqueira, Ygor N.; Correa, Nathalia B.; Fonseca, Estevao O.; Brito, Nathalia B. M.; Menezes, Thayna A.; Magini, Marcio; Fidalgo, Tatiana K. S.; Ferreira, Daniele M. T. P.; de Lima, Rodrigo L.; Carvalho, Antonio C.; DosSantos, Marcos F.			The efficacy of transcranial direct current stimulation and transcranial magnetic stimulation for chronic orofacial pain: A systematic review	PLOS ONE			English	Review							BURNING MOUTH SYNDROME; NEUROSTIMULATION THERAPY; FIBROMYALGIA; GUIDELINES; METAANALYSIS; MECHANISMS; MANAGEMENT; TARGET; ART	Background Transcranial Direct Current Stimulation (tDCS) and Transcranial Magnetic Stimulation (TMS) have been described as promising alternatives to treat different pain syndromes. This study evaluated the effects of TMS and tDCS in the treatment of chronic orofacial pain, through a systematic review. Methods An electronic search was performed in major databases: MEDLINE, Scopus, Web of Science, Cochrane, Embase, LILACS, BBO, Open Gray and CINAHL. The eligibility criteria comprised randomized clinical trials (RCTs) that applied TMS or tDCS to treat chronic orofacial pain. The variables analyzed were pain, functional limitation, quality of life, tolerance to treatment, somatosensory changes, and adverse effects. The risk of bias was assessed through the Cochrane Collaboration tool, and the certainty of evidence was evaluated through GRADE. The protocol was registered in the PROSPERO database (CRD42018090774). Results The electronic search resulted in 636 studies. Thereafter, the eligibility criteria were applied and the duplicates removed, resulting in eight RCTs (four TMS and four tDCS). The findings of these studies suggest that rTMS applied to the Motor cortex (M1), the dorsolateral prefrontal cortex (DLPFC) and the secondary somatosensory cortex (S2) provide adequate orofacial pain relief. Two studies reported significant pain improvement with tDCS applied over M1 while the other two failed to demonstrate significant effects compared to placebo. Conclusions rTMS, applied to M1, DLPFC or S2, is a promising approach for the treatment of chronic orofacial pain. Moreover, tDCS targeting M1 seems to be also effective in chronic orofacial pain treatment. The included studies used a wide variety of therapeutic protocols. In addition, most of them used small sample sizes, with a high risk of biases in their methodologies, thus producing a low quality of evidence. The results indicate that further research should be carried out with caution and with better-standardized therapeutic protocols.	[Ferreira, Natalia R.; Fonseca, Estevao O.; Carvalho, Antonio C.; DosSantos, Marcos F.] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, LMC, Rio De Janeiro, Brazil; [Ferreira, Natalia R.; DosSantos, Marcos F.] Univ Fed Rio de Janeiro, Fac Med, Programa Posgrad Radiol, Rio De Janeiro, Brazil; [Junqueira, Ygor N.; Correa, Nathalia B.; Fonseca, Estevao O.; Brito, Nathalia B. M.; Menezes, Thayna A.] Univ Fed Rio de Janeiro, Campus Macae, Macae, RJ, Brazil; [Magini, Marcio] Univ Fed Rio de Janeiro, Lab Analise & Processamento Sinais, Campus Macae, Macae, RJ, Brazil; [Fidalgo, Tatiana K. S.] Univ Estado Rio De Janeiro, Dept Odontol Prevent & Comunitaria, Rio De Janeiro, Brazil; [Ferreira, Daniele M. T. P.] Univ Fed Rio de Janeiro, Biblioteca Ctr Ciencias Saude, Rio De Janeiro, Brazil; [de Lima, Rodrigo L.] Univ Fed Rio de Janeiro, Dept Ortodontia & Odontopediatria, Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade do Estado do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	DosSantos, MF (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, LMC, Rio De Janeiro, Brazil.; DosSantos, MF (corresponding author), Univ Fed Rio de Janeiro, Fac Med, Programa Posgrad Radiol, Rio De Janeiro, Brazil.	santosmfh@gmail.com	DosSantos, Marcos/E-8913-2014; carvalho, antonio carlos pires/M-6737-2013; DosSantos, Marcos/AAR-7308-2020; da Silva Fidalgo, Tatiana Kelly/I-4969-2014	DosSantos, Marcos/0000-0002-5997-9693; carvalho, antonio carlos pires/0000-0003-2447-7607; DosSantos, Marcos/0000-0002-5997-9693; da Silva Fidalgo, Tatiana Kelly/0000-0003-1340-9967; Lopes de Lima, Rodrigo/0000-0002-5628-9603				Aggarwal VR, 2019, EUR J PAIN, V23, P849, DOI 10.1002/ejp.1358; Aggarwal VR, 2006, INT J EPIDEMIOL, V35, P468, DOI 10.1093/ije/dyi265; Al-Ani MZ, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002778.PUB2; Batsikadze G, 2013, NEUROPSYCHOPHARMACOL, V38, P2260, DOI 10.1038/npp.2013.127; Bendtsen L, 2019, EUR J NEUROL, V26, P831, DOI 10.1111/ene.13950; Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658; Brandao Filho R, 2015, THESIS; Brandao RA, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0938-0; COHEN SP, 2014, BMJ-BRIT MED J, V348, DOI DOI 10.1136/BMJ.F7656; Cruccu G, 2007, EUR J NEUROL, V14, P952, DOI 10.1111/j.1468-1331.2007.01916.x; Cruccu G, 2016, EUR J NEUROL, V23, P1489, DOI 10.1111/ene.13103; DaSilva AF, 2015, FRONT NEUROANAT, V9, DOI 10.3389/fnana.2015.00089; de Andrade DC, 2014, PAIN, V155, P598, DOI 10.1016/j.pain.2013.12.022; de Andrade DC, 2011, PAIN, V152, P320, DOI 10.1016/j.pain.2010.10.032; De Laat A, 2003, J OROFAC PAIN, V17, P42; Donnell A, 2015, BRAIN STIMUL, V8, P1085, DOI 10.1016/j.brs.2015.06.008; DosSantos MF, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00018; DosSantos MF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102350; DosSantos Marcos Fabio, 2012, Front Psychiatry, V3, P93, DOI 10.3389/fpsyt.2012.00093; Fricova J, 2013, PHYSIOL RES, V62, pS125, DOI 10.33549/physiolres.932575; GALHARDONI R., 2014, THESIS, DOI [10.11606/T.5.2014.tde-12012015-130033, DOI 10.11606/T.5.2014.TDE-12012015-130033]; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Hagenacker T, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-78; Haggman-Henrikson B, 2017, J ORAL REHABIL, V44, P800, DOI 10.1111/joor.12539; Hou WH, 2016, RHEUMATOLOGY, V55, P1507, DOI 10.1093/rheumatology/kew205; Jaeaeskelaeinen S, 2014, CLIN NEUROPHYSIOL, pS229; Khedr EM, 2005, J NEUROL NEUROSUR PS, V76, P833, DOI 10.1136/jnnp.2004.055806; Klein MM, 2015, PAIN, V156, P1601, DOI 10.1097/j.pain.0000000000000210; Ledermann K, 2016, EUR NEUROPSYCHOPHARM, V26, P320, DOI 10.1016/j.euroneuro.2015.12.007; Lefaucheur JP, 2016, PAIN, V157, pS81, DOI 10.1097/j.pain.0000000000000401; Lefaucheur JP, 2014, CLIN NEUROPHYSIOL, V125, P2150, DOI 10.1016/j.clinph.2014.05.021; Lima MC, 2008, NEUROLOGY, V70, P2329, DOI 10.1212/01.wnl.0000314649.38527.93; Lindholm P, 2013, J NEUROL, V260, pS200; Lindholm P, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005231; Lindholm P, 2015, PAIN, V156, P1276, DOI 10.1097/j.pain.0000000000000175; List T, 2010, J ORAL REHABIL, V37, P430, DOI 10.1111/j.1365-2842.2010.02089.x; Liston C, 2014, BIOL PSYCHIAT, V76, P517, DOI 10.1016/j.biopsych.2014.01.023; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Macfarlane TV, 2002, COMMUNITY DENT ORAL, V30, P52, DOI 10.1034/j.1600-0528.2002.300108.x; Maltenfort M, 2015, J SPINAL DISORD TECH, V28, P189, DOI 10.1097/BSD.0000000000000285; Mao JR, 2012, TRENDS PHARMACOL SCI, V33, P568, DOI 10.1016/j.tips.2012.08.001; Marlow NM, 2013, PAIN PRACT, V13, P131, DOI 10.1111/j.1533-2500.2012.00562.x; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Nicholas M, 2019, PAIN, V160, P28, DOI 10.1097/j.pain.0000000000001390; O'Connell Neil E, 2018, Cochrane Database Syst Rev, V4, pCD008208, DOI 10.1002/14651858.CD008208.pub5; O'Connell NE, 2018, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008208.pub4, 10.1002/14651858.CD008208.pub5]; O'Connell NE, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008208.pub2; Obermann M, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00257; Oliveira LB, 2015, J ORAL REHABIL, V42, P723, DOI 10.1111/joor.12300; Pashut T, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002022; Patton LL, 2007, ORAL SURG ORAL MED O, V103, pS39, DOI 10.1016/j.tripleo.2006.11.009; Riley JL, 2001, PAIN, V90, P245, DOI 10.1016/S0304-3959(00)00408-5; Tremblay S, 2014, BRAIN STIMUL, V7, P773, DOI 10.1016/j.brs.2014.10.003; Tsubokawa T, 1991, Acta Neurochir Suppl (Wien), V52, P137; TSUBOKAWA T, 1991, PACE, V14, P131, DOI 10.1111/j.1540-8159.1991.tb04058.x; Umezaki Y, 2015, INT J ORAL MAX SURG, V44, P1048, DOI 10.1016/j.ijom.2015.04.008; Umezaki Y, 2016, BRAIN STIMUL, V9, P234, DOI 10.1016/j.brs.2015.10.005; Villamar MF, 2013, JOVE-J VIS EXP, DOI 10.3791/50309	58	9	9	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 15	2019	14	8							e0221110	10.1371/journal.pone.0221110	http://dx.doi.org/10.1371/journal.pone.0221110			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5KK	31415654	gold, Green Submitted, Green Published			2023-01-03	WOS:000485017200077
J	Taber, JM; Ellis, EM; Reblin, M; Ellington, L; Ferrer, RA				Taber, Jennifer M.; Ellis, Erin M.; Reblin, Maija; Ellington, Lee; Ferrer, Rebecca A.			Knowledge of and beliefs about palliative care in a nationally-representative US sample	PLOS ONE			English	Article							DONT KNOW RESPONSES; INFORMATION-SEEKING; ADVANCE DIRECTIVES; ADVANCED CANCER; HEALTH; DECISION; PERCEPTIONS; BARRIERS; OUTCOMES; INTEGRATION	Palliative care aims to improve quality of life for people with serious illness and their families. One potential barrier to palliative care uptake is inaccurate knowledge and/or negative beliefs among the general population, which may inhibit early interest in, communication about, and integration of palliative care following subsequent illness diagnosis. We explored knowledge and beliefs about palliative care among the general public using nationally-representative data collected in 2018 as part of the cross-sectional Health Information National Trends Survey. Only individuals who had heard of palliative care (n = 1,162, M-age = 51.8, 64% female) were queried on knowledge and beliefs. We examined whether self-assessed level of awareness of palliative care (i.e., knowing a little vs. enough to explain it) was associated with the relative likelihood of having accurate/positive beliefs, inaccurate/negative beliefs, or responding "don't know" to questions about palliative care. Respondents who indicated knowing a lot about palliative care had more accurate versus inaccurate knowledge than those who knew a little on only two of six items and more positive attitudes on only one of three items. In particular, respondents with greater awareness were equally likely to report that palliative care is the same as hospice and requires stopping other treatments, and equally likely to believe that palliative care means giving up and to associate palliative care with death. Those with higher awareness were less likely than those with lower awareness to respond "don't know," but greater awareness was not necessarily associated with having accurate or positive beliefs about palliative care as opposed to inaccurate or negative beliefs. Thus, even members of the general public who perceived themselves to know a lot about palliative care were often no less likely to report inaccurate knowledge or negative beliefs (versus accurate and positive, respectively). Findings suggest a need to improve awareness and attitudes about palliative care.	[Taber, Jennifer M.] Kent State Univ, Dept Psychol Sci, Kent, OH 44242 USA; [Ellis, Erin M.; Ferrer, Rebecca A.] NCI, Behav Res Program, Bethesda, MD 20892 USA; [Reblin, Maija] H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL USA; [Ellington, Lee] Univ Utah, Coll Nursing, Salt Lake City, UT 84112 USA	University System of Ohio; Kent State University; Kent State University Kent; Kent State University Salem; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); H Lee Moffitt Cancer Center & Research Institute; Utah System of Higher Education; University of Utah	Taber, JM (corresponding author), Kent State Univ, Dept Psychol Sci, Kent, OH 44242 USA.	jtaber1@kent.edu	Taber, Jennifer/AAT-6045-2021	Taber, Jennifer/0000-0003-3285-4871				Ahmed N, 2004, PALLIATIVE MED, V18, P525, DOI 10.1191/0269216304pm921oa; Akiyama M, 2016, SUPPORT CARE CANCER, V24, P347, DOI 10.1007/s00520-015-2788-4; Aldridge MD, 2016, PALLIATIVE MED, V30, P224, DOI 10.1177/0269216315606645; Barnato AE, 2009, J GEN INTERN MED, V24, P695, DOI 10.1007/s11606-009-0952-6; Barwise A, 2019, ANN PALLIAT MED; Center to Advance Palliative Care, 2011, 2011 PUBL OP RES PAL; Clark D, 2007, LANCET ONCOL, V8, P430, DOI 10.1016/S1470-2045(07)70138-9; Collins A, 2017, PALLIATIVE MED, V31, P825, DOI 10.1177/0269216317696420; Cutrona SL, 2015, J CANCER EDUC, V30, P12, DOI 10.1007/s13187-014-0701-3; Dans M, 2017, J NATL COMPR CANC NE, V15, P989, DOI 10.6004/jnccn.2017.0132; Denman DC, 2018, MED DECIS MAKING, V38, P673, DOI 10.1177/0272989X18785159; Ditto PH, 2005, MOTIV EMOTION, V29, P481, DOI 10.1007/s11031-006-9017-x; Dumanovsky T, 2016, J PALLIAT MED, V19, P8, DOI 10.1089/jpm.2015.0351; El-Jawahri A, 2016, JAMA-J AM MED ASSOC, V316, P2094, DOI 10.1001/jama.2016.16786; Ellis EM, 2018, J HEALTH COMMUN, V23, P967, DOI 10.1080/10810730.2018.1554729; Ellis EM, 2018, HEALTH PSYCHOL, V37, P394, DOI 10.1037/hea0000587; Fadul N, 2007, J PALLIAT MED, V10, P1146, DOI 10.1089/jpm.2006.0259; Fadul N, 2009, CANCER-AM CANCER SOC, V115, P2013, DOI 10.1002/cncr.24206; Feeg Veronica D, 2005, Am J Hosp Palliat Care, V22, P119, DOI 10.1177/104990910502200207; Ferrell BR, 2017, J ONCOL PRACT, V13, P119, DOI 10.1200/JOP.2016.017897; Ferris FD, 2009, J CLIN ONCOL, V27, P3052, DOI 10.1200/JCO.2008.20.1558; Flemming K, 2010, J PAIN SYMPTOM MANAG, V39, P139, DOI 10.1016/j.jpainsymman.2009.05.014; Gawande A, 2014, BEING MORTAL MED WHA; Goethals G. R., 1977, SOC COMP PROCESS THE; Halpern SD, 2013, HEALTH AFFAIR, V32, P408, DOI 10.1377/hlthaff.2012.0895; Hay JL, 2015, MED DECIS MAKING, V35, P436, DOI 10.1177/0272989X15572827; Hughes MT, 2014, ANNU REV PUBL HEALTH, V35, P459, DOI 10.1146/annurev-publhealth-032013-182406; Huo J, 2019, J PAIN SYMPTOM MANAG; Janssen E, 2018, BRIT J HEALTH PSYCH, V23, P407, DOI 10.1111/bjhp.12296; Kavalieratos D, 2016, JAMA-J AM MED ASSOC, V316, P2104, DOI 10.1001/jama.2016.16840; Kelley AS, 2015, NEW ENGL J MED, V373, P747, DOI 10.1056/NEJMra1404684; Klinger CA, 2014, PALLIATIVE MED, V28, P111, DOI 10.1177/0269216313493342; Koffman J, 2007, PALLIATIVE MED, V21, P145, DOI 10.1177/0269216306074639; Kozlov E, 2018, AM J HOSP PALLIAT ME, V35, P647, DOI 10.1177/1049909117725725; Loewenstein G, 2005, HEALTH PSYCHOL, V24, pS49, DOI 10.1037/0278-6133.24.4.S49; Love AW, 2014, PROG PALLIAT CARE, V22, P9, DOI 10.1179/1743291X13Y.0000000055; Lynch T, 2013, J PAIN SYMPTOM MANAG, V45, P1094, DOI 10.1016/j.jpainsymman.2012.05.011; McIlfatrick S, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-34; Meier DE, 2016, MESSAGING PALLIATIVE; Nelson DE, 2004, J HEALTH COMMUN, V9, P443, DOI 10.1080/10810730490504233; Orleans CT., 2008, THEORY REASONED ACTI, V4th, P68; Orom H, 2018, MED DECIS MAKING, V38, P1006, DOI 10.1177/0272989X18799999; Parker SM, 2013, J HOSP PALLIAT NURS, V15, P225, DOI 10.1097/NJH.0b013e318279f4ce; Reid CM, 2008, ANN ONCOL, V19, P44, DOI 10.1093/annonc/mdm462; Rogers M, 2017, WE WORK TREND INSIGH; Schallmo MK, 2019, J CARDIOVASC NURS, V34, pE9, DOI 10.1097/JCN.0000000000000556; Schenker Y, 2014, JAMA INTERN MED, V174, P1093, DOI 10.1001/jamainternmed.2014.1887; Schenker Y, 2014, J ONCOL PRACT, V10, pE37, DOI 10.1200/JOP.2013.001130; Shalev A, 2018, AM J HOSP PALLIAT ME, V35, P431, DOI 10.1177/1049909117715215; Shen M., 2018, P IEEE INT C RFID TE P IEEE INT C RFID TE, P1; Shin DW, 2017, PSYCHO-ONCOLOGY, V26, P770, DOI 10.1002/pon.4226; Silveira MJ, 2010, NEW ENGL J MED, V362, P1211, DOI 10.1056/NEJMsa0907901; Smith S, 2014, PALLIATIVE MED, V28, P130, DOI 10.1177/0269216313493466; Sudore RL, 2010, ANN INTERN MED, V153, P256, DOI 10.7326/0003-4819-153-4-201008170-00008; Suls J, 2014, OXFORD HDB HLTH COMM, P251; Temel JS, 2017, J CLIN ONCOL, V35, P834, DOI 10.1200/JCO.2016.70.5046; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Trivedi N, 2019, J PALLIAT MED, V22, P1578, DOI 10.1089/jpm.2018.0656; Van Dussen D, 2011, AM J HOSP PALLIAT ME, V28, P418, DOI 10.1177/1049909110394339; Waters EA, 2016, ANN BEHAV MED, V50, P784, DOI 10.1007/s12160-016-9789-5; Waters EA, 2013, MED DECIS MAKING, V33, P271, DOI 10.1177/0272989X12464435; Zimmermann C, 2016, CAN MED ASSOC J, V188, pE217, DOI 10.1503/cmaj.151171	62	35	36	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 15	2019	14	8							e0219074	10.1371/journal.pone.0219074	http://dx.doi.org/10.1371/journal.pone.0219074			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW5KK	31415570	Green Submitted, Green Published, gold			2023-01-03	WOS:000485017200003
J	Thomson, G; Balaam, MC				Thomson, Gill; Balaam, Marie-Clare			International insights into peer support in a neonatal context: A mixed-methods study	PLOS ONE			English	Article							PRETERM INFANTS; PREMATURE BIRTH; HEALTH; CARE; PARENTS; MOTHERS; IMPACT; EXPERIENCES; PROVIDERS; RECOMMENDATIONS	Peer support is a widely used intervention that offers information and emotional support to parents during their infant's admission to the neonatal unit and/or post-discharge. Despite its widespread use, there are no comprehensive insights into the nature and types of neonatal- related peer support, or the training and support offered to peer supporters. We aimed to bridge these knowledge gaps via an international study into neonatal peer support provision. A mixed-methods study comprising an online survey was issued to peer support services/organisations, and follow-up interviews held with a purposive sample of survey respondents. Survey/interview questions explored the funding, types of peer support and the recruitment, training and support for peer supporters. Descriptive and thematic analysis was undertaken. Thirty-one managers/coordinators/trainers and 77 peer supporters completed the survey from 48 peer support organisations/services in 16 different countries; with 26 interviews undertaken with 27 survey respondents. We integrated survey and interview findings into five themes: 'background and infrastructure of peer support services', 'timing, location and nature of peer support', 'recruitment and suitability of peer supporters', 'training provision' and 'professional and emotional support'. Findings highlight variations in the types of peer support provided, training and development opportunities, supervisory and mentoring arrangements and the methods of recruitment and support for peer supporters; with these differences largely related to the size, funding, multidisciplinary involvement, and level of integration of peer support within healthcare pathways and contexts. Despite challenges, promising strategies were reported across the different services to inform macro (e.g. to facilitate management and leadership support), meso (e.g. to help embed peer support in practice) and micro (e.g. to improve training, supervision and support of peer supporters) recommendations to underpin the operationalisation and delivery of PS provision.	[Thomson, Gill] Univ Cent Lancashire, Sch Community Hlth & Midwifery, MAINN, Preston, Lancs, England; [Thomson, Gill] Dalarna Univ, Sch Educ Hlth & Social Studies, Falun, Sweden; [Balaam, Marie-Clare] Univ Cent Lancashire, Sch Community Hlth & Midwifery, ReaCH, Preston, Lancs, England	University of Central Lancashire; Dalarna University; University of Central Lancashire	Thomson, G (corresponding author), Univ Cent Lancashire, Sch Community Hlth & Midwifery, MAINN, Preston, Lancs, England.; Thomson, G (corresponding author), Dalarna Univ, Sch Educ Hlth & Social Studies, Falun, Sweden.	gthomson@uclan.ac.uk		Balaam, Marie-Clare/0000-0003-4511-7352; Thomson, Gill/0000-0003-3392-8182	British Academy/Leverhulme Small Grants Award [SG152947]	British Academy/Leverhulme Small Grants Award	GT received a British Academy/Leverhulme Small Grants Award. Grant number (SG152947) -https://www.thebritishacademy.ac.uk/ba-leverhulme-small-research-grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed AO, 2015, COMMUNITY MENT HLT J, V51, P424, DOI 10.1007/s10597-015-9854-8; Aiken A, 2013, MIDWIFERY, V29, pE145, DOI 10.1016/j.midw.2012.12.014; Alam J, 2010, ARCH DIS CHILD, V95, pA104; Barlow JH, 2005, BRIT J HEALTH PSYCH, V10, P589, DOI 10.1348/135910705X26317; BC First Responders Mental Health, SUPP MENT HLTH 1 RES; BLISS, 2015, HANG BAL; Boukydis CFZ, 2000, CHILD HEALTH CARE, V29, P129, DOI 10.1207/S15326888CHC2902_5; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Cooper LG, 2007, J PERINATOL, V27, pS32, DOI 10.1038/sj.jp.7211840; Davis L, 2003, EARLY HUM DEV, V73, P61, DOI 10.1016/S0378-3782(03)00073-2; Dennis CL, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006309; Dennis CL, 2003, INT J NURS STUD, V40, P321, DOI 10.1016/S0020-7489(02)00092-5; Elklit A, 2007, J CLIN PSYCHOL MED S, V14, P238, DOI 10.1007/s10880-007-9077-4; Flacking R, 2007, SOC SCI MED, V64, P2405, DOI 10.1016/j.socscimed.2007.03.008; Forcada-Guex M, 2011, EARLY HUM DEV, V87, P21, DOI 10.1016/j.earlhumdev.2010.09.006; Franck LS, 2011, PEDIATRICS, V128, P510, DOI 10.1542/peds.2011-0272; Gale NK, 2018, SOC SCI MED, V196, P96, DOI 10.1016/j.socscimed.2017.11.012; Gillard SG, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-188; Gordon J., 2015, DECISION MAKERS BARR; Hall SL, 2015, J PERINATOL, V35, pS9, DOI 10.1038/jp.2015.143; Hall SL, 2016, NEWBORN INFANT NURS, V16, P69, DOI 10.1053/j.nainr.2016.03.008; Heermann Judith A, 2005, Pediatr Nurs, V31, P176; Hynan MT, 2015, J PERINATOL, V35, pS1, DOI 10.1038/jp.2015.141; Ingram J, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-192; Jarrett M H, 1996, Pediatr Nurs, V22, P142; Jolly K, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.d8287; Jones CCG, 2014, MIDWIFERY, V30, P491, DOI 10.1016/j.midw.2013.08.003; Jotzo M, 2005, PEDIATRICS, V115, P915, DOI 10.1542/peds.2004-0370; Kemp V, 2012, PSYCHIATR REHABIL J, V35, P337, DOI 10.2975/35.4.2012.337.340; Kerr SM, 2000, CHILD CARE HLTH DEV, V26, P309, DOI 10.1046/j.1365-2214.2000.00149.x; MacLellan J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141122; Major J, 2018, RURAL EXT INNOV SYST, V14, P1; McLeish J, 2018, PRACTISING MIDWIFE, V21, P25; McLeish J, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0685-y; Miles MS, 2007, J DEV BEHAV PEDIATR, V28, P36, DOI 10.1097/01.DBP.0000257517.52459.7a; MINDE K, 1980, J PEDIATR-US, V96, P933; Moran GS, 2012, QUAL HEALTH RES, V22, P304, DOI 10.1177/1049732311420578; Morgan J., 2011, INFANT, V7, P155; Mowbray CT, 1996, COMMUNITY MENT HLT J, V32, P47, DOI 10.1007/BF02249367; Mowbray CT, 1998, J BEHAV HEALTH SER R, V25, P397, DOI 10.1007/BF02287510; National Maternity Review, 2016, BETTER BIRTHS IMPROV; National Perinatal Association (NPA), 2016, START SUST PEER SUPP; Partnership for Maternal Newborn and Child Health (PMNCH), 2012, BORN TOO SOON GLOBAL; Peers for Progress, 2014, 2014 GLOBAL EVIDENCE; Preyde M, 2003, CAN MED ASSOC J, V168, P969; Preyde M, 2007, SOC WORK HEALTH CARE, V44, P65, DOI 10.1300/J010v44n04_05; Purdy IB, 2015, J PERINATOL, V35, pS24, DOI 10.1038/jp.2015.146; Rebeiro Gruhl K, 2015, J MENT HEALTH, V25, P1; Renfrew MJ, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001141.pub4; Repper J., 2010, USING PERSONAL EXPER; Repper J, 2011, J MENT HEALTH, V20, P392, DOI 10.3109/09638237.2011.583947; ROMAN LA, 1995, RES NURS HEALTH, V18, P385, DOI 10.1002/nur.4770180504; Sandall J, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004667.pub5, 10.1002/14651858.CD004667.pub3]; Schwartz C, 2003, PSYCHOSOM MED, V65, P778, DOI 10.1097/01.PSY.0000079378.39062.D4; Shaw RJ, 2006, PSYCHOSOMATICS, V47, P206, DOI 10.1176/appi.psy.47.3.206; Taft AJ, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-178; Thomson G, 2015, INT BREASTFEED J, V10, DOI 10.1186/s13006-015-0039-4; Thomson G, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-84; Thomson G, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-150; Trickey H, 2018, MATERN CHILD NUTR, V14, DOI 10.1111/mcn.12559; WHO, 2018, PRET BIRTH	61	7	7	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2019	14	7							e0219743	10.1371/journal.pone.0219743	http://dx.doi.org/10.1371/journal.pone.0219743			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4XR	31365559	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000484983600017
J	Guo, BY; Itami, J; Oikawa, K; Motoda, Y; Kigawa, T; Numata, K				Guo, Boyang; Itami, Jun; Oikawa, Kazusato; Motoda, Yoko; Kigawa, Takanori; Numata, Keiji			Native protein delivery into rice callus using ionic complexes of protein and cell-penetrating peptides	PLOS ONE			English	Article							GENE DELIVERY; TRANSFORMATION; AGROBACTERIUM; MUTATIONS; PLANTS	Direct protein delivery into intact plants remains a challenge for the agricultural and plant science fields. Cell-penetrating peptide (CPP)-mediated protein delivery requires the binding of CPPs to a protein to carry the protein into the cell through the cell wall and lipid bilayer. Thus, we prepared ionic complexes of a CPP-containing carrier peptide and a cargo protein, namely, Citrine yellow fluorescent protein, and subsequently studied their physicochemical properties. Two types of carrier peptides, BP100(KH)(9) and BP100CH(7), were investigated for delivery efficiency into rice callus. Both BP100(KH)(9) and BP100CH(7) successfully introduced Citrine protein into rice callus cells under pressure and vacuum treatment. Moreover, delivery efficiency varied at different growth stages of rice callus; 5-day rice callus was a more efficient recipient for Citrine than 21-day callus.	[Guo, Boyang; Itami, Jun; Oikawa, Kazusato; Motoda, Yoko; Numata, Keiji] RIKEN Ctr Sustainable Resource Sci, Biomacromol Res Team, Wako, Saitama, Japan; [Kigawa, Takanori] RIKEN Ctr Biosyst Dynam Res, Lab Cellular Struct Biol, Yokohama, Kanagawa, Japan	RIKEN; RIKEN	Numata, K (corresponding author), RIKEN Ctr Sustainable Resource Sci, Biomacromol Res Team, Wako, Saitama, Japan.	keiji.numata@riken.jp	Itami, Jun/AAB-1380-2022; Kigawa, Takanori/A-7679-2010; Numata, Keiji/H-9751-2012	Kigawa, Takanori/0000-0003-0146-9719; Numata, Keiji/0000-0003-2199-7420; Oikawa, Kazusato/0000-0002-1033-9089	BASF SE; Japan Science and Technology Agency Exploratory Research for Advanced Technology (JST-ERATO) [JPMJER1602]	BASF SE(BASF); Japan Science and Technology Agency Exploratory Research for Advanced Technology (JST-ERATO)	The present study was financially supported by BASF SE and grants from the Japan Science and Technology Agency Exploratory Research for Advanced Technology (JST-ERATO; Grant No. JPMJER1602). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Badosa E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085515; Bechara C, 2013, FEBS LETT, V587, P1693, DOI 10.1016/j.febslet.2013.04.031; Chuah JA, 2018, BIOMACROMOLECULES, V19, P1154, DOI 10.1021/acs.biomac.8b00016; Cosgrove DJ, 2005, NAT REV MOL CELL BIO, V6, P850, DOI 10.1038/nrm1746; Daniell H, 2002, NAT BIOTECHNOL, V20, P581, DOI 10.1038/nbt0602-581; Eggenberger K, 2011, CHEMBIOCHEM, V12, P132, DOI 10.1002/cbic.201000402; Endo M, 2015, PLANT CELL PHYSIOL, V56, P41, DOI 10.1093/pcp/pcu154; Hart SL, 1998, HUM GENE THER, V9, P575, DOI 10.1089/hum.1998.9.4-575; HIEI Y, 1994, PLANT J, V6, P271, DOI 10.1046/j.1365-313X.1994.6020271.x; Jiang W, 2013, NUCLEIC ACIDS RES, V41, P1; Kanchiswamy CN, 2016, PLANT CELL REP, V35, P1469, DOI 10.1007/s00299-016-1982-2; Kigawa Takanori, 2004, Journal of Structural and Functional Genomics, V5, P63, DOI 10.1023/B:JSFG.0000029204.57846.7d; Lakshmanan M, 2015, PLANT BIOTECHNOL-NAR, V32, P39, DOI 10.5511/plantbiotechnology.14.1210b; Lakshmanan M, 2013, BIOMACROMOLECULES, V14, P10, DOI 10.1021/bm301275g; Li W, 2013, NAT BIOTECHNOL, V31, P684, DOI 10.1038/nbt.2652; Liang Z., 2017, NAT PUBL GR, V8, P1, DOI DOI 10.1038/ncomms14261; LIU MJ, 2013, ADV STUD BIOL, V5, P71; MEINERT MC, 1977, PLANT PHYSIOL, V59, P1088, DOI 10.1104/pp.59.6.1088; Montesinos L, 2017, BMC PLANT BIOL, V17, DOI 10.1186/s12870-017-1011-9; Nadal A, 2012, BMC PLANT BIOL, V12, DOI 10.1186/1471-2229-12-159; Ng KM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0144798; Numata K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29298-6; Numata K, 2016, PLANT BIOTECHNOL-NAR, V33, P403, DOI 10.5511/plantbiotechnology.16.0929a; Numata K, 2014, PLANT BIOTECHNOL J, V12, P1027, DOI 10.1111/pbi.12208; Numata K, 2012, BIOMACROMOLECULES, V13, P3450, DOI 10.1021/bm301276k; Svitashev S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13274; Toki S, 2006, PLANT J, V47, P969, DOI 10.1111/j.1365-313X.2006.02836.x	27	14	14	5	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2019	14	7							e0214033	10.1371/journal.pone.0214033	http://dx.doi.org/10.1371/journal.pone.0214033			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4WU	31361745	Green Published, gold, Green Submitted			2023-01-03	WOS:000484981300004
J	Truong, MBT; Ngo, E; Ariansen, H; Tsuyuki, RT; Nordeng, H				Truong, Maria Bich-Thuy; Ngo, Elin; Ariansen, Hilde; Tsuyuki, Ross T.; Nordeng, Hedvig			Community pharmacist counseling in early pregnancy-Results from the SafeStart feasibility study	PLOS ONE			English	Article							MEDICATION; NAUSEA; CARE	Background Community pharmacists are available to counsel women in early pregnancy, but no studies have assessed the feasibility of such a service. Objective To test the feasibility of a pharmacist consultation in early pregnancy and to inform the design of a definitive trial. Setting Six community pharmacies in Norway from Oct. to Dec. 2017. Method We evaluated recruitment approaches and an automatic data preprocessing system (ADPS) to enroll, assign participants, and distribute questionnaires. Women (>= 18 years) in early pregnancy were eligible for inclusion. Participants were assigned to a pharmacist consultation (intervention group) or standard care (control group). The intervention aimed to address each woman's concerns and needs regarding medications and ailments in pregnancy, and was documented on a standard form. The women's acceptability of the intervention was measured by a questionnaire. Main outcome measures Appropriate recruitment approaches, workflow of the ADPS, and women's acceptability of the intervention. Results Of the 35 participants recruited, 19 were recruited through Facebook. The ADPS worked well. Treatment of nausea and vomiting (NVP) (10/11) and general information about medications (8/11) were frequently discussed during the consultations (n = 11). The women reported high satisfaction with the consultation. Having the option of telephone and follow-up consultations was important to the women. Conclusion It is feasible to provide community pharmacist consultations in early pregnancy. In a definitive study, the consultations should focus on NVP and general medication use and further explore social media as a recruiting tool. Both in-pharmacy and telephone consultations should be offered to deliver the intervention.	[Truong, Maria Bich-Thuy; Ngo, Elin; Ariansen, Hilde; Nordeng, Hedvig] Univ Oslo, Dept Pharm, Oslo, Norway; [Ariansen, Hilde] Norwegian Pharm Assoc, Oslo, Norway; [Tsuyuki, Ross T.] Univ Alberta, Dept Pharmacol, Edmonton, AB, Canada; [Nordeng, Hedvig] Norwegian Inst Publ Hlth, Dept Child Hlth & Dev, Oslo, Norway	University of Oslo; University of Alberta; Norwegian Institute of Public Health (NIPH)	Truong, MBT (corresponding author), Univ Oslo, Dept Pharm, Oslo, Norway.	b.t.h.truong@farmasi.uio.no			Norwegian Extra Foundation for Health and Rehabilitation through the Norwegian Women's Public Health Association; Norwegian Society of Pharmacy; Norwegian PhD School of Pharmacy; Norwegian Community Pharmacy Foundation	Norwegian Extra Foundation for Health and Rehabilitation through the Norwegian Women's Public Health Association; Norwegian Society of Pharmacy; Norwegian PhD School of Pharmacy; Norwegian Community Pharmacy Foundation	HN recieved funding from the Norwegian Extra Foundation for Health and Rehabilitation (https://www.extrastiftelsen.no/) through the Norwegian Women's Public Health Association. MT received funding from the Norwegian Society of Pharmacy (https://www.nfs.no/), the Norwegian PhD School of Pharmacy (https://www.mn.uio.no/farmasi/english/research/norwegian-phd-school/), and the Norwegian Community Pharmacy Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adam LM, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.6404; Admon L, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.6593; Alderliesten ML, 2007, BJOG-INT J OBSTET GY, V114, P1232, DOI 10.1111/j.1471-0528.2007.01438.x; Brueton VC, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-003821; Ebrahimi N, 2009, J OBSTET GYNAECOL CA, V31, P803, DOI 10.1016/S1701-2163(16)34298-0; Einarson TR, 2013, J POPUL THER CLIN PH, V20, pE171; Esposito G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145873; Froyland H., 2011, LEGEMIDDELSAMTALEN K; Froyland H., 2017, KLIN FARMASI LAEREBO, P79; Griffin BL, 2018, ANN PHARMACOTHER, V52, P810, DOI 10.1177/1060028018764447; Hameen-Anttila K, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002594; Holst L, 2009, J ALTERN COMPLEM MED, V15, P787, DOI 10.1089/acm.2008.0467; Irvine L, 2010, DRUG SAFETY, V33, P593, DOI 10.2165/11532330-000000000-00000; Kearney A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204886; Lupattelli A, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004365; Lupattelli A, 2014, INT J CLIN PHARM-NET, V36, P145, DOI 10.1007/s11096-013-9864-y; Lynch MM, 2018, MATERN CHILD HLTH J, V22, P92, DOI 10.1007/s10995-017-2358-0; Lynch MM, 2017, QUAL HEALTH RES, V27, P2071, DOI 10.1177/1049732317732027; Matsui D, 2012, OBSTET GYNECOL INT, V2012, DOI 10.1155/2012/796590; Milosavljevic A, 2018, INT J PHARM PRACT, V26, P387, DOI 10.1111/ijpp.12462; Moore CG, 2011, CTS-CLIN TRANSL SCI, V4, P332, DOI 10.1111/j.1752-8062.2011.00347.x; Muslim I, 2018, BMJ BEST PRACTICE; Navaro M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198618; Nordeng H, 2010, EUR J CLIN PHARMACOL, V66, P207, DOI 10.1007/s00228-009-0744-2; O'Cathain Alicia, 2015, Pilot Feasibility Stud, V1, P32; Odalovic M, 2016, MIDWIFERY, V40, P79, DOI 10.1016/j.midw.2016.06.003; Petersen I, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007390; Rengerink KO, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0641-x; Sinclair M, 2018, J ADV NURS, V74, P137, DOI 10.1111/jan.13387; van der Zande ISE, 2018, WOMEN BIRTH, V31, P350, DOI 10.1016/j.wombi.2017.12.009; Vikanes A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2050; Whitaker C, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.7071	32	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 19	2019	14	7							e0219424	10.1371/journal.pone.0219424	http://dx.doi.org/10.1371/journal.pone.0219424			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4SZ	31323048	gold, Green Published, Green Submitted			2023-01-03	WOS:000484971300008
J	Wedel, C; Moller, CM; Budtz-Lilly, J; Eldrup, N				Wedel, Charlotte; Moller, Cecilie M.; Budtz-Lilly, Jacob; Eldrup, Nikolaj			Red blood cell transfusion associated with increased morbidity and mortality in patients undergoing elective open abdominal aortic aneurysm repair	PLOS ONE			English	Article							CRITICALLY-ILL; PREOPERATIVE ANEMIA; SURGERY; IMMUNOMODULATION; INFECTION; TRIM	Background Red blood cell (RBC) transfusions are associated with increased mortality and morbidity. The aim of this analysis was to examine the association between RBC transfusions and long-term survival for patients undergoing elective open infrarenal abdominal aortic aneurysm (AAA) repair with up to 15 years of follow-up. Methods Prospective cohort study using data from The Danish Vascular Registry from 2000-2015. Primary endpoint was all-cause mortality. Secondary endpoints were in-hospital complications. Transfused patients were divided into subgroups based on received RBC transfusions (1, 2-3, 4-5 or >5). Using Cox regression multi-adjusted analysis, non-transfused patients were compared to transfused patients (1, 2-3, 4-5, >5 transfusions) for both primary and secondary endpoints. Results There were 3 876 patients included with a mean survival of 9.1 years. There were 801 patients who did not receive transfusions. Overall 30-day mortality was 3.1% (121 patients) and 3.6% (112) for all transfused patients. For the five subgroups 30-day mortality was: No transfusions 1.1% (9 patients), 1 RBC 1.2% (4 patients), 2-3 RBC 2.2% (26 patients), 4-5 RBC 1.9% (14 patients) and >5 RBC 7.9% (68 patients). After receiving RBCs, the hazard ratio for death was 1.54 (95% CI 1.27-1.85) compared to non-transfused patients. There was a significant increase in mortality when receiving 2-3 RBC: HR 1.32 (95% CI 1.07-1.62), 4-5 RBC: 1.64 (1.32-2.03) and >5 RBC: 1.96 (1.27-1.85) in a multi-adjusted model. Conclusion There is a dose-dependent association between RBC transfusions received during elective AAA repair and an increase in short-and long-term mortality. Approximately 25% of included patients had preoperative anemia. These findings should raise awareness regarding potentially unnecessary and harmful RBC transfusions.	[Wedel, Charlotte; Moller, Cecilie M.; Budtz-Lilly, Jacob; Eldrup, Nikolaj] Aarhus Univ Hosp, Dept Cardiothorac & Vasc Surg, Aarhus, Denmark; [Eldrup, Nikolaj] Aarhus Univ Hosp, Danish Vasc Registry, Aarhus, Denmark	Aarhus University; Aarhus University	Wedel, C (corresponding author), Aarhus Univ Hosp, Dept Cardiothorac & Vasc Surg, Aarhus, Denmark.	charlotte_wedel@hotmail.com		Budtz-Lilly, Jacob/0000-0002-6181-6391; Eldrup, Nikolaj/0000-0002-7980-5295				Aquina CT, 2016, DIS COLON RECTUM, V59, P411, DOI 10.1097/DCR.0000000000000588; Beattie WS, 2009, ANESTHESIOLOGY, V110, P574, DOI 10.1097/ALN.0b013e31819878d3; Blajchman MA, 2005, HEMATOLOGY, V10, P208, DOI 10.1080/10245330512331390447; Buddeberg F, 2008, BEST PRACT RES-CLIN, V22, P503, DOI 10.1016/j.bpa.2008.05.003; Bursi F, 2009, EUR J VASC ENDOVASC, V37, P311, DOI 10.1016/j.ejvs.2008.12.002; Carless Paul A, 2010, Cochrane Database Syst Rev, pCD001888, DOI 10.1002/14651858.CD001888.pub4; Carson JL, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002042.pub3; Carson JL, 1996, LANCET, V348, P1055, DOI 10.1016/S0140-6736(96)04330-9; Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79; French CJ, 2002, MED J AUSTRALIA, V177, P548, DOI 10.5694/j.1326-5377.2002.tb04950.x; Gombotz H, 2007, TRANSFUSION, V47, P1468, DOI 10.1111/j.1537-2995.2007.01286.x; Gunst MA, 2007, CURR OPIN CRIT CARE, V13, P428, DOI 10.1097/MCC.0b013e32826385ef; Hebert PC, 1999, CRIT CARE, V3, P57, DOI 10.1186/cc310; Henry DA, 2011, COCHRANE DB SYST REV, V1, P1, DOI DOI 10.1002/14651858.CD001886.PUB3; Holst LB, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1354; Konigstein M, 2016, CAN J CARDIOL, V32, DOI 10.1016/j.cjca.2015.10.032; Laustsen J, 2004, EUR J VASC ENDOVASC, V27, P216, DOI 10.1016/j.ejvs.2003.11.011; Leal-Noval SM, 2001, CHEST, V119, P1461, DOI 10.1378/chest.119.5.1461; Leal-Noval SR, 2000, CRIT CARE MED, V28, P935, DOI 10.1097/00003246-200004000-00004; Murphy GJ, 2007, CIRCULATION, V116, P2544, DOI 10.1161/CIRCULATIONAHA.107.698977; Obi AT, 2015, J VASC SURG, V61, P1000, DOI 10.1016/j.jvs.2014.10.106; Rao MP, 2002, ANAESTHESIA, V57, P530, DOI 10.1046/j.1365-2044.2002.02514.x; Seicean A, 2013, SPINE, V38, P1331, DOI 10.1097/BRS.0b013e3182912c6b; Smilowitz NR, 2016, AM J MED, V129, P315, DOI 10.1016/j.amjmed.2015.10.012; Tan TW, 2013, J AM COLL SURGEONS, V216, P1005, DOI 10.1016/j.jamcollsurg.2013.01.006; Vamvakas EC, 2007, BLOOD REV, V21, P327, DOI 10.1016/j.blre.2007.07.003; van de Watering LMG, 1998, CIRCULATION, V97, P562; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Walsh TS, 2004, TRANSFUSION, V44, P1405, DOI 10.1111/j.1537-2995.2004.04085.x; Westbrook A, 2010, INTENS CARE MED, V36, P1138, DOI 10.1007/s00134-010-1867-8	30	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2019	14	7							e0219263	10.1371/journal.pone.0219263	http://dx.doi.org/10.1371/journal.pone.0219263			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4LN	31295273	Green Published, gold, Green Submitted			2023-01-03	WOS:000484951800022
J	Rodgers, H; Bosomworth, H; Krebs, HI; van Wijck, F; Howel, D; Wilson, N; Aird, L; Alvarado, N; Andole, S; Cohen, DL; Dawson, J; Fernandez-Garcia, C; Finch, T; Ford, GA; Francis, R; Hogg, S; Hughes, N; Price, CI; Ternent, L; Turner, DL; Vale, L; Wilkes, S; Shaw, L				Rodgers, Helen; Bosomworth, Helen; Krebs, Hermano I.; van Wijck, Frederike; Howel, Denise; Wilson, Nina; Aird, Lydia; Alvarado, Natasha; Andole, Sreeman; Cohen, David L.; Dawson, Jesse; Fernandez-Garcia, Cristina; Finch, Tracy; Ford, Gary A.; Francis, Richard; Hogg, Steven; Hughes, Niall; Price, Christopher I.; Ternent, Laura; Turner, Duncan L.; Vale, Luke; Wilkes, Scott; Shaw, Lisa			Robot assisted training for the upper limb after stroke (RATULS): a multicentre randomised controlled trial	LANCET			English	Article							REHABILITATION; THERAPY; IMPAIRMENT; RECOVERY	Background Loss of arm function is a common problem after stroke. Robot-assisted training might improve arm function and activities of daily living. We compared the clinical effectiveness of robot-assisted training using the MIT-Manus robotic gym with an enhanced upper limb therapy (EULT) programme based on repetitive functional task practice and with usual care. Methods RATULS was a pragmatic, multicentre, randomised controlled trial done at four UK centres. Stroke patients aged at least 18 years with moderate or severe upper limb functional limitation, between 1 week and 5 years after their first stroke, were randomly assigned (1:1:1) to receive robot-assisted training, EULT, or usual care. Robot-assisted training and EULT were provided for 45 min, three times per week for 12 weeks. Randomisation was internet-based using permuted block sequences. Treatment allocation was masked from outcome assessors but not from participants or therapists. The primary outcome was upper limb function success (defined using the Action Research Arm Test [ARAT]) at 3 months. Analyses were done on an intention-to-treat basis. This study is registered with the ISRCTN registry, number ISRCTN69371850. Findings Between April 14, 2014, and April 30, 2018, 770 participants were enrolled and randomly assigned to either robot-assisted training (n= 257), EULT (n= 259), or usual care (n= 254). The primary outcome of ARAT success was achieved by 103 (44%) of 232 patients in the robot-assisted training group, 118 (50%) of 234 in the EULT group, and 85 (42%) of 203 in the usual care group. Compared with usual care, robot-assisted training (adjusted odds ratio [aOR] 1.17 [98.3% CI 0.70-1.96]) and EULT (aOR 1.51 [0.90-2.51]) did not improve upper limb function; the effects of robot-assisted training did not differ from EULT (aOR 0.78 [0.48-1.27]). More participants in the robot-assisted training group (39 [15%] of 257) and EULT group (33 [13%] of 259) had serious adverse events than in the usual care group (20 [8%] of 254), but none were attributable to the intervention. Interpretation Robot-assisted training and EULT did not improve upper limb function after stroke compared with usual care for patients with moderate or severe upper limb functional limitation. These results do not support the use of robot-assisted training as provided in this trial in routine clinical practice.	[Rodgers, Helen; Bosomworth, Helen; Ford, Gary A.; Francis, Richard; Hogg, Steven; Price, Christopher I.; Shaw, Lisa] Newcastle Univ, Stroke Res Grp, Inst Neurosci, Newcastle Upon Tyne NE2 4AE, Tyne & Wear, England; [Rodgers, Helen; Aird, Lydia; Price, Christopher I.] Northumbria Healthcare NHS Fdn Trust, Stroke Northumbria, North Tyneside, England; [Rodgers, Helen] Newcastle Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England; [Krebs, Hermano I.] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [van Wijck, Frederike] Glasgow Caledonian Univ, Sch Hlth & Life Sci, Glasgow, Lanark, Scotland; [Howel, Denise; Wilson, Nina; Fernandez-Garcia, Cristina; Ternent, Laura; Vale, Luke] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne, Tyne & Wear, England; [Alvarado, Natasha] Univ Leeds, Sch Healthcare, Leeds, W Yorkshire, England; [Andole, Sreeman] Barking Havering & Redbridge Univ Hosp NHS Trust, Romford, Essex, England; [Cohen, David L.] London North West Healthcare NHS Trust, Northwick Pk Hosp, Harrow, Middx, England; [Dawson, Jesse] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland; [Finch, Tracy] Northumbria Univ, Nursing Midwifery & Hlth, Newcastle Upon Tyne, Tyne & Wear, England; [Ford, Gary A.] Univ Oxford, Div Med Sci, Oxford, England; [Ford, Gary A.] Oxford Univ Hosp NHS Fdn Trust, Oxford, England; [Hughes, Niall] NHS Greater Glasgow & Clyde, Glasgow, Lanark, Scotland; [Turner, Duncan L.] Univ East London, Sch Hlth Sport & Biosci, London, England; [Wilkes, Scott] Univ Sunderland, Sch Med, Sunderland, Durham, England	Newcastle University - UK; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Massachusetts Institute of Technology (MIT); Glasgow Caledonian University; Newcastle University - UK; University of Leeds; Imperial College London; University of Glasgow; Northumbria University; University of Oxford; Oxford University Hospitals NHS Foundation Trust; University of East London; University of Sunderland	Rodgers, H (corresponding author), Newcastle Univ, Stroke Res Grp, Inst Neurosci, Newcastle Upon Tyne NE2 4AE, Tyne & Wear, England.	helen.rodgers@newcastle.ac.uk	Ford, Gary/AAY-6405-2020	Ford, Gary/0000-0001-8719-4968; Finch, Tracy/0000-0001-8647-735X; Vale, Luke/0000-0001-8574-8429; Shaw, Lisa/0000-0002-3435-9519; Price, Christopher/0000-0003-3566-3157; Francis, Richard/0000-0002-6568-1295; Cohen, David/0000-0001-7318-8567	National Institute for Health Research; National Institutes of Health Research (NIHR) [11/26/05]; NIHR Stroke Research Network; NIHR Clinical Research Network: Stroke	National Institute for Health Research(National Institute for Health Research (NIHR)); National Institutes of Health Research (NIHR)(National Institute for Health Research (NIHR)); NIHR Stroke Research Network; NIHR Clinical Research Network: Stroke	National Institute for Health Research Health Technology Assessment Programme.; This project was funded by the National Institutes of Health Research (NIHR) Health Technology Assessment (HTA) programme (project number 11/26/05). The views and opinions expressed here are those of the authors and do not necessarily reflect those of the HTA programme, NIHR, the UK National Health Service (NHS), or UK Department of Health. We would like to thank participants of this trial for their contribution to this research project. We thank staff at RATULS NHS study centres, including Jen Alexander, Elizabeth Colquhoun, Ozlem Dincarslan, Wendy Jackson, Pamela MacKenzie, and Karen Shields (Glasgow); Rebecca Davidson, Judith Murdy, Victoria Riddell, Anna Smith, Leanne Smith, Gail Storey, Marie Twentyman, Helen Walker, and Rebecca Watson (North Tyneside); Robert Ballantine, Daniel Brooks, Aberami Chandrakumar, Angela Chamberlain, Anette David, and Mushiya Mpelembue (Northwick Park); Evelyne Burssens, Karen Dunne, Janice Hastings, Louise Hinkins, and Sam King (Romford) and staff at all adjacent sites. We would like to thank staff who left the study centre teams before the end of the study; staff at Newcastle University who assisted with conducting the study, including Michael Adams, Clare Bowes, and Deborah Jones; Jenni Hislop for her input into the health economics analysis plan; Data Monitoring and Ethics Committee members (John Bamford [chair], Richard McManus, Rebecca Palmer, Philip Rowe, and Christopher Weir); Trial Steering Committee members (Jennifer Burr [chair], Jane Burridge, Nikola Sprigg, Sarah Tyson, and Judith Williamson); staff at Biosense Medical for their technical support; Brenda Hyland-Miller for staff training and support; the NIHR Stroke Research Network and NIHR Clinical Research Network: Stroke for their support and encouragement; and Jim Mackey for his support throughout.	[Anonymous], 2016, INT STROK WORK PART; Briggs AH, 2002, ANNU REV PUBL HEALTH, V23, P377, DOI 10.1146/annurev.publhealth.23.100901.140534; Brkic Lianne, 2016, Pilot Feasibility Stud, V2, P50; Cramer SC, 2017, STROKE, V48, P813, DOI 10.1161/STROKEAHA.116.015501; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; Duncan PW, 2003, ARCH PHYS MED REHAB, V84, P950, DOI 10.1016/S0003-9993(03)00035-2; French K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0169332; Harris JE, 2009, STROKE, V40, P2123, DOI 10.1161/STROKEAHA.108.544585; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Kind P., 1999, 172 U YORK YORK HLTH; Kwakkel G, 2017, INT J STROKE, V12, P451, DOI 10.1177/1747493017711813; Langhorne P, 2009, LANCET NEUROL, V8, P741, DOI 10.1016/S1474-4422(09)70150-4; Lo AC, 2010, NEW ENGL J MED, V362, P1772, DOI 10.1056/NEJMoa0911341; Lohse KR, 2014, STROKE, V45, P2053, DOI 10.1161/STROKEAHA.114.004695; Lundquist CB, 2017, DISABIL REHABIL, V39, P934, DOI 10.3109/09638288.2016.1163422; MAHONEY F I, 1965, Md State Med J, V14, P61; Mehrholz J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006185.pub2; Norouzi-Gheidari N, 2012, J REHABIL RES DEV, V49, P479, DOI 10.1682/JRRD.2010.10.0210; Peyre H, 2011, QUAL LIFE RES, V20, P287, DOI 10.1007/s11136-010-9740-3; Platz T, ARM ARM REHABILITATI; Pollock A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010820.pub2; Pollock A, 2014, INT J STROKE, V9, P313, DOI 10.1111/j.1747-4949.2012.00942.x; Remy-Neris O, 2018, ANN PHYS REHABIL MED, V61, pe21, DOI [DOI 10.1016/J.REHAB.2018.05.045, 10.1016/j.rehab.2018.05.045]; Rodgers H, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2083-4; Ryan S., 2016, REHABILITATION MEASU; Shaw LC, 2011, STROKE, V42, P1371, DOI 10.1161/STROKEAHA.110.582197; Stinear CM, 2017, ANN CLIN TRANSL NEUR, V4, P811, DOI 10.1002/acn3.488; van Hout B, 2012, VALUE HEALTH, V15, P708, DOI 10.1016/j.jval.2012.02.008; Veerbeek JM, 2017, NEUROREHAB NEURAL RE, V31, P107, DOI 10.1177/1545968316666957; Wagner TH, 2011, STROKE, V42, P2630, DOI 10.1161/STROKEAHA.110.606442; Willan AR, 2004, HEALTH ECON, V13, P461, DOI 10.1002/hec.843	33	152	156	30	123	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 6	2019	394	10192					51	62		10.1016/S0140-6736(19)31055-4	http://dx.doi.org/10.1016/S0140-6736(19)31055-4			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IH3AK	31128926	Green Published, Green Accepted, hybrid			2023-01-03	WOS:000474365500031
J	Kohler-Forsberg, O; Cusin, C; Nierenberg, AA				Kohler-Forsberg, Ole; Cusin, Cristina; Nierenberg, Andrew A.			Evolving Issues in the Treatment of Depression	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SYMPTOMS; THERAPY		[Kohler-Forsberg, Ole] Aarhus Univ Hosp Psychiat, Psychosis Res Unit, Aarhus, Denmark; [Kohler-Forsberg, Ole] Aarhus Univ Hosp, Dept Clin Med, Aarhus, Denmark; [Cusin, Cristina] Massachusetts Gen Hosp, Dept Psychiat, Depress Clin, Boston, MA 02114 USA; [Cusin, Cristina] Massachusetts Gen Hosp, Dept Psychiat, Res Program, Boston, MA 02114 USA; [Cusin, Cristina; Nierenberg, Andrew A.] Harvard Med Sch, Boston, MA 02115 USA; [Nierenberg, Andrew A.] Massachusetts Gen Hosp, Dept Psychiat, Dauten Family Ctr Bipolar Treatment Innovat, Boston, MA 02114 USA	Aarhus University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Nierenberg, AA (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.	anierenberg@mgh.harvard.edu		Kohler-Forsberg, Ole/0000-0001-5121-1287				Berk M, 2019, JAMA-J AM MED ASSOC, V321, P842, DOI 10.1001/jama.2019.0273; Bot M, 2019, JAMA-J AM MED ASSOC, V321, P858, DOI 10.1001/jama.2019.0556; Choi KW, 2019, JAMA PSYCHIAT, V76, P399, DOI 10.1001/jamapsychiatry.2018.4175; Cipriani A, 2018, LANCET, V391, P1357, DOI 10.1016/S0140-6736(17)32802-7; Gordon BR, 2018, JAMA PSYCHIAT, V75, P566, DOI 10.1001/jamapsychiatry.2018.0572; Jacka FN, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0791-y; Kohler-Forsherg O, 2019, ACTA PSYCHIAT SCAND, V139, P404, DOI 10.1111/acps.13016; Ma J, 2019, JAMA-J AM MED ASSOC, V321, P869, DOI 10.1001/jama.2019.0557; Pedersen CB, 2014, JAMA PSYCHIAT, V71, P573, DOI 10.1001/jamapsychiatry.2014.16; Sanacora G, 2017, JAMA PSYCHIAT, V74, P399, DOI 10.1001/jamapsychiatry.2017.0080	10	10	10	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	2019	321	24					2401	2402		10.1001/jama.2019.4990	http://dx.doi.org/10.1001/jama.2019.4990			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IF3UX	31125042				2023-01-03	WOS:000473009700014
J	Deng, H; Coumans, JV; Anderson, R; Houle, TT; Peterfreund, RA				Deng, Hao; Coumans, Jean-Valery; Anderson, Richard; Houle, Timothy T.; Peterfreund, Robert A.			Spinal anesthesia for lumbar spine surgery correlates with fewer total medications and less frequent use of vasoactive agents: A single center experience	PLOS ONE			English	Article							GENERAL-ANESTHESIA; BLOOD-PRESSURE; COST-ANALYSIS; DISC SURGERY; LAMINECTOMY; COMPLICATIONS; ERRORS	Study objective Anesthesiologists at our hospital commonly administer spinal anesthesia for routine lumbar spine surgeries. Anecdotal impressions suggested that patients received fewer anesthesia-administered intravenous medications, including vasopressors, during spinal versus general anesthesia. We hypothesized that data review would confirm these impressions. The objective was to test this hypothesis by comparing specific elements of spinal versus general anesthesia for 1-2 level open lumbar spine procedures. Design Retrospective single institutional study. Setting Academic medical center, operating rooms. Patients Consecutive patients (144 spinal and 619 general anesthesia) identified by automatic structured query of our electronic anesthesia record undergoing lumbar decompression, foraminotomy or microdiscectomy by one surgeon under general or spinal anesthesia. Interventions Spinal or general anesthesia. Measurements Numbers of medications administered during the case. Main results Anesthesiologists administered in the operating room a total of 10 +/- 2 intravenous medications for general anesthetics and 5 +/- 2 medications for spinal anesthetics (-5, 95% CI -5 to -4, p<0.001, univariate analysis). Multivariable analysis supported this finding (spinal versus general anesthesia: -4, 95% CI -5 to -4, p<0.001). Spinal anesthesia patients were less likely to receive ephedrine, or phenylephrine (by bolus or by infusion) (all p<0.001, Chi-squared test). Spinal anesthesia patients were also less likely to receive labetolol or esmolol (both p = 0.002, Fishers' Exact test). No neurologic injuries were attributed to, or masked by, spinal anesthesia. Three spinal anesthetics failed. Conclusions For routine lumbar surgery in our cohort, spinal compared to general anesthesia was associated with significantly fewer drugs administered during a case and less frequent use of vasoactive agents. Safety implications include greater hemodynamic stability with spinal anesthesia along with reduced risks for medication error and transmission of pathogens associated with medication administration.	[Deng, Hao; Anderson, Richard; Houle, Timothy T.; Peterfreund, Robert A.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA; [Coumans, Jean-Valery] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Peterfreund, RA (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.	RPeterfreund@Partners.org	Houle, Timothy T/I-7649-2019; Houle, Timothy T/CAF-5465-2022; Deng, Hao/I-8104-2019	Deng, Hao/0000-0002-0331-2427; Peterfreund, Robert/0000-0002-9075-5014				Agarwal P, 2016, WORLD NEUROSURG, V89, P266, DOI 10.1016/j.wneu.2016.02.022; Ard JL, 2016, J CLIN NEUROSCI, V34, P59, DOI 10.1016/j.jocn.2016.08.001; Attari MA, 2011, J RES MED SCI, V16, P524; Baenziger B, 2018, J NEUROSURG ANESTHES; Bates DM, 2004, J MULTIVARIATE ANAL, V91, P1, DOI 10.1016/j.jmva.2004.04.013; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Bijker JB, 2007, ANESTHESIOLOGY, V107, P213, DOI 10.1097/01.anes.0000270724.40897.8e; Chambers JM, 1993, STAT MODELS S, P95; Chang CC, 2010, ANESTHESIOLOGY, V113, P279, DOI 10.1097/ALN.0b013e3181e2c1c3; Chowdhury SRS. S., 2010, J BANGLADESH SOC ANA, V23, P47; Dagistan Y, 2015, TURK NEUROSURG, V25, P685, DOI 10.5137/1019-5149.JTN.10300-14.1; De Rojas JO, 2014, CLIN NEUROL NEUROSUR, V119, P39, DOI 10.1016/j.clineuro.2014.01.016; DITZLER J W, 1959, Anesth Analg, V38, P118; Drummond JC, 2013, J NEUROSURG ANESTH, V25, P154, DOI 10.1097/ANA.0b013e31827a0151; Duger C, 2012, J CLIN NEUROSCI, V19, P406, DOI 10.1016/j.jocn.2011.04.042; Finsterwald M, 2018, J CLIN ANESTH, V46, P3, DOI 10.1016/j.jclinane.2018.01.004; Forbes SS, 2013, CAN J ANESTH, V60, P176, DOI 10.1007/s12630-012-9858-6; Gargiulo DA, 2016, ANESTHESIOLOGY, V124, P785, DOI 10.1097/ALN.0000000000001041; Hopf HW, 2015, ANESTH ANALG, V120, P700, DOI 10.1213/ANE.0000000000000247; Hussain Z, 2015, PAFMJ, V65, P397; Jellish WS, 1996, ANESTH ANALG, V83, P559, DOI 10.1097/00000539-199609000-00021; Kahveci K, 2014, NEUROL NEUROCHIR POL, V48, P167, DOI 10.1016/j.pjnns.2014.05.005; Lessing NL, 2017, ORTHOPEDICS, V40, pE317, DOI 10.3928/01477447-20161219-01; Liu JB, 2013, ANESTH ANALG, V117, P1010, DOI 10.1213/ANE.0b013e3182a1bf1c; Llewellyn RL, 2009, ANAESTH INTENS CARE, V37, P93, DOI 10.1177/0310057X0903700105; McLain RF, 2005, J NEUROSURG-SPINE, V2, P17, DOI 10.3171/spi.2005.2.1.0017; McLain RF, 2004, SPINE, V29, P2542, DOI 10.1097/01.brs.0000144834.43115.38; McLain Robert F, 2007, J Surg Orthop Adv, V16, P5; Meng LZ, 2018, HYPERTENSION, V72, P806, DOI 10.1161/HYPERTENSIONAHA.118.11688; Meng T, 2017, ANAESTHESIA, V72, P391, DOI 10.1111/anae.13702; Mergeay M, 2015, ACTA ANAESTH BELG, V66, P1; Nanji KC, 2016, ANESTHESIOLOGY, V124, P25, DOI 10.1097/ALN.0000000000000904; Pierce JT, 2017, LOCAL REG ANESTH, V10, DOI 10.2147/LRA.S141233; Pinar HU, 2018, J CLIN ANESTH, V46, P54, DOI 10.1016/j.jclinane.2018.01.026; Rung GW, 1997, ANESTH ANALG, V84, P1165, DOI 10.1097/00000539-199705000-00045; Sadrolsadat SH, 2009, SURG NEUROL, V71, P60, DOI 10.1016/j.surneu.2008.08.003; Shafer SL, 2015, ANESTH ANALG, V120, P697, DOI 10.1213/ANE.0000000000000641; Tetzlaff JE, 1998, J CLIN ANESTH, V10, P666, DOI 10.1016/S0952-8180(98)00112-3; TETZLAFF JE, 1995, REGION ANESTH, V20, P533; Vural C, 2014, TURK NEUROSURG, V24, P380, DOI 10.5137/1019-5149.JTN.8575-13.0; Walcott BP, 2015, J CLIN NEUROSCI, V22, P539, DOI 10.1016/j.jocn.2014.08.024; Webster CS, 2001, ANAESTH INTENS CARE, V29, P494, DOI 10.1177/0310057X0102900508; Wittich CM, 2014, MAYO CLIN PROC, V89, P1116, DOI 10.1016/j.mayocp.2014.05.007; Yildirim Guclu C, 2014, J NEUROL SCI-TURK, V31, P586; Zorrilla-Vaca A, 2016, J NEUROSURG ANESTHES	45	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2019	14	6							e0217939	10.1371/journal.pone.0217939	http://dx.doi.org/10.1371/journal.pone.0217939			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IC8NN	31194777	Green Published, gold, Green Submitted			2023-01-03	WOS:000471238300031
J	Ose, D; Kamradt, M; Kiel, M; Freund, T; Besier, W; Mayer, M; Krisam, J; Wensing, M; Salize, HJ; Szecsenyi, J				Ose, Dominik; Kamradt, Martina; Kiel, Marion; Freund, Tobias; Besier, Werner; Mayer, Manfred; Krisam, Johannes; Wensing, Michel; Salize, Hans-Joachim; Szecsenyi, Joachim			Care management intervention to strengthen self-care of multimorbid patients with type 2 diabetes in a German primary care network: A randomized controlled trial	PLOS ONE			English	Article							CHRONIC ILLNESS CARE; MULTIPLE CHRONIC CONDITIONS; DISEASE MANAGEMENT; HEALTH-CARE; SUPPORT; QUALITY; PREVALENCE; PROGRAMS; IMPACT; STRATEGIES	Purpose This study aimed to assess the effectiveness of a care management intervention in improving self-management behavior in multimorbid patients with type 2 diabetes; care was delivered by medical assistants in the context of a primary care network (PCN) in Germany. Methods This study is an 18-month, multi-center, two-armed, open-label, patient-randomized parallel-group superiority trial (ISRCTN 83908315). The intervention group received the care management intervention in addition to the usual care. The control group received usual care only. The primary outcome was the change in self-care behavior at month 9 compared to baseline. The self-care behavior was measured with the German version of the Summary of Diabetes Self-Care Activities Measure (SDSCA-G). A multilevel regression analysis was applied. Results We assigned 495 patients to intervention (n = 252) and control (n = 243). At baseline, the mean age was 68 +/- 11 years, 47.8% of the patients were female and the mean HbA1c was 7.1 +/- 1.2%. The primary analysis showed no statistically significant effect, but a positive trend was observed (p = 0.206; 95%-CI = -0.084; 0.384). The descriptive analysis revealed a significantly increased sum score of the SDSCA-G in the intervention group over time (P = 0.012) but not in the control group (p = 0.1973). Conclusion The sum score for self-care behavior markedly improved in the intervention group over time. However, the results of our primary analysis showed no statistically significant effect. Possible reasons are the high baseline performance in our sample and the low intervention fidelity. The implementation of this care management intervention in PCNs has the potential to improve self-care behavior of multimorbid patients with type 2 diabetes.	[Ose, Dominik] Univ Utah, Dept Family & Prevent Med, Salt Lake City, UT 84112 USA; [Ose, Dominik; Kamradt, Martina; Kiel, Marion; Freund, Tobias; Wensing, Michel; Szecsenyi, Joachim] Marsilius Arkaden, Dept Gen Practice & Hlth Serv Res, Univ Hosp Heidelberg, Heidelberg, Germany; [Besier, Werner; Mayer, Manfred] Genossenschaft Gesundheitsprojekt Mannheim eG, Mannheim, Germany; [Krisam, Johannes] Marsilius Arkaden, Univ Heidelberg Hosp, Inst Med Biometry & Informat, Heidelberg, Germany; [Salize, Hans-Joachim] Heidelberg Univ, Med Fac Mannheim, Cent Inst Mental Hlth, Mannheim, Germany	Utah System of Higher Education; University of Utah; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Central Institute of Mental Health; Ruprecht Karls University Heidelberg	Ose, D (corresponding author), Univ Utah, Dept Family & Prevent Med, Salt Lake City, UT 84112 USA.; Ose, D (corresponding author), Marsilius Arkaden, Dept Gen Practice & Hlth Serv Res, Univ Hosp Heidelberg, Heidelberg, Germany.	dominik.ose@hsc.utah.edu	Wensing, Michel/H-8113-2014; Ose, Dominik/L-4250-2019	Wensing, Michel/0000-0001-6569-8137; Ose, Dominik/0000-0002-5079-2152; Kamradt, Martina/0000-0003-3603-5574	German Federal Ministry of Education and Research (Bundesministerium fuer Bildung und Forschung) [01KQ1003B]	German Federal Ministry of Education and Research (Bundesministerium fuer Bildung und Forschung)(Federal Ministry of Education & Research (BMBF))	This study was funded by the German Federal Ministry of Education and Research (Bundesministerium fuer Bildung und Forschung) (funding code: 01KQ1003B). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albright TL, 2001, FAM MED, V33, P354; Altenhofen L, 2006, DIS MANAGEMENT PROGR; Amelung Volker, 2012, Int J Integr Care, V12, pe16; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Bernhard G, 2017, DIABETES EDUCATOR, V43, P190, DOI 10.1177/0145721717697243; Bodenheimer T., 2009, CARE MANAGEMENT PATI; Bonds Denise E, 2004, BMC Fam Pract, V5, P26, DOI 10.1186/1471-2296-5-26; Bos-Touwen I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126400; Boult C, 2013, J GEN INTERN MED, V28, P612, DOI 10.1007/s11606-012-2287-y; Boult C, 2010, JAMA-J AM MED ASSOC, V304, P1936, DOI 10.1001/jama.2010.1623; Bozorgmehr K, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-243; Busse R, 2004, HEALTH AFFAIR, V23, P56, DOI 10.1377/hlthaff.23.3.56; Colhoun HM, 2004, LANCET, V364, P685, DOI 10.1016/S0140-6736(04)16895-5; Collins AE, 2014, PROF PSYCHOL-RES PR, V45, P20, DOI 10.1037/a0032604; Creber RM, 2016, PATIENT EDUC COUNS, V99, P256, DOI 10.1016/j.pec.2015.08.031; Duke SAS, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005268.pub2; Egginton JS, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-72; Eigenmann CA, 2009, DIABETIC MED, V26, P425, DOI 10.1111/j.1464-5491.2009.02697.x; Eisenstat SA, 2016, AM J MED QUAL; Federal Insurance Office Germany, 2016, ACT REP; Freund T, 2016, ANN INTERN MED, V164, P323, DOI 10.7326/M14-2403; Fuchs S, 2014, DTSCH ARZTEBL INT, V111, P453, DOI 10.3238/arztebl.2014.0453; Gensichen J, 2009, ANN INTERN MED, V151, P369, DOI 10.7326/0003-4819-151-6-200909150-00001; Glasgow RE, 2002, ANN BEHAV MED, V24, P80, DOI 10.1207/S15324796ABM2402_04; Halanych JH, 2007, DIABETES CARE, V30, P2999, DOI 10.2337/dc06-1836; Kamradt M, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/s12955-014-0185-1; Lee H, 2009, ASIAN NURS RES, V3, P139, DOI 10.1016/S1976-1317(09)60025-6; Manns BJ, 2012, CAN MED ASSOC J, V184, pE144, DOI 10.1503/cmaj.110755; Moher David, 2010, BMJ, V340, pc869, DOI [10.1016/j.jclinepi.2010.03.004, 10.1136/bmj.c869]; Muldoon Laura, 2006, Healthc Manage Forum, V19, P18; Norris SL, 2002, DIABETES CARE, V25, P1159, DOI 10.2337/diacare.25.7.1159; Norris SL, 2001, DIABETES CARE, V24, P561, DOI 10.2337/diacare.24.3.561; Nouwens E, 2012, NETH J MED, V70, P298; Ose D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051726; Ose D, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-179; Ose D, 2009, DIABETES CARE, V32, P1594, DOI 10.2337/dc08-2223; Peters-Klimm F, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-56; Piette JD, 2006, DIABETES CARE, V29, P725, DOI 10.2337/diacare.29.03.06.dc05-2078; Pillay J, 2015, ANN INTERN MED, V163, P848, DOI 10.7326/M15-1400; Rosemann T, 2007, ARTHRIT RHEUM-ARTHR, V57, P1390, DOI 10.1002/art.23080; Rosenthal TC, 2008, J AM BOARD FAM MED, V21, P427, DOI 10.3122/jabfm.2008.05.070287; Ruggiero L, 2014, WESTERN J NURS RES, V36, P1052, DOI 10.1177/0193945914522862; Salisbury C, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c5004; Sarayani A, 2018, INT J CLIN PHARM; Sheaff R, 2006, PRIMARY CARE DRIVERS, P129; Shrivastava SR, 2013, J DIABETES METAB DIS, V12, DOI 10.1186/2251-6581-12-14; Smith SM, 2007, BRIT J GEN PRACT, V57, P268; Szecsenyi J, 2008, DIABETES CARE, V31, P1150, DOI 10.2337/dc07-2104; Tamayo T, 2016, DTSCH ARZTEBL INT, V113, P177, DOI 10.3238/arztebl.2016.0177; Tang TS, 2012, DIABETES RES CLIN PR, V95, P85, DOI 10.1016/j.diabres.2011.04.003; Toobert DJ, 2000, DIABETES CARE, V23, P943, DOI 10.2337/diacare.23.7.943; Tricco AC, 2012, LANCET, V379, P2252, DOI 10.1016/S0140-6736(12)60480-2; Valderas JM, 2009, ANN FAM MED, V7, P357, DOI 10.1370/afm.983; Valent F, 2013, J DIABETES INVEST, V4, P355, DOI 10.1111/jdi.12043; van Buuren S, 2007, STAT METHODS MED RES, V16, P219, DOI 10.1177/0962280206074463; Vogeli C, 2007, J GEN INTERN MED, V22, P391, DOI 10.1007/s11606-007-0322-1; Von Korff M, 1997, ANN INTERN MED, V127, P1097, DOI 10.7326/0003-4819-127-12-199712150-00008; Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64; Wallace E, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h176; Wangberg SC, 2008, HEALTH EDUC RES, V23, P170, DOI 10.1093/her/cym014	60	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2019	14	6							e0214056	10.1371/journal.pone.0214056	http://dx.doi.org/10.1371/journal.pone.0214056			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IC8MD	31188825	Green Published, gold			2023-01-03	WOS:000471234500005
J	Lee, YS; Kim, SY; Chae, Y				Lee, Ye-Seul; Kim, Song-Yi; Chae, Younbyoung			Distribution of monetary incentives in health insurance scheme influences acupuncture treatment choices: An experimental study	PLOS ONE			English	Article							DECISION-MAKING; PAYMENT SYSTEMS; NEURAL BASIS; PROVISION; RESPONSES; BEHAVIOR; SERVICE; REWARD; WILL; PAIN	Background Understanding how doctors respond to occupational and monetary incentives in health care payment systems is important for determining the effectiveness of such systems. This study examined changes in doctors' behaviors in response to monetary incentives within health care payment systems in a ceteris paribus setting. Methods An online experiment was developed to analyze the effect of monetary incentives similar to fee-for-service (FFS) and capitation (CAP) on doctors' prescription patterns. In the first session, no monetary values were presented. In the second session conducted 1 week later, doctors were randomly assigned to one of two monetary incentive groups (FFS group: n = 25, CAP group: n = 25). In all sessions, doctors were presented with 10 cases and asked to determine the type and number of treatments. Results In the first session with no monetary incentives, there was no significant difference between the FFS and CAP groups in the number of treatments. When monetary incentives were provided, doctors in the CAP group prescribed fewer treatments than the FFS group. The perceived severity of the cases did not change significantly between sessions and between groups. linear mixed-effects regression model indicated the treatment choices were influenced by monetary incentives, but not by the perceived severity of the patient's symptoms. Conclusion The monetary values incentivized the doctors' treatment choices, but not their professional evaluation of patients. Monetary values designed within health care systems influence the doctor's decisions in the form of external rewards, in addition to occupational values, and can thus be adjusted by more effective incentives.	[Lee, Ye-Seul; Chae, Younbyoung] Kyung Hee Univ, Coll Korean Med, Acupuncture & Meridian Sci Res Ctr, Seoul, South Korea; [Lee, Ye-Seul; Kim, Song-Yi] Gachon Univ, Coll Korean Med, Dept Anat & Acupoint, Seongnam, South Korea	Kyung Hee University; Gachon University	Chae, Y (corresponding author), Kyung Hee Univ, Coll Korean Med, Acupuncture & Meridian Sci Res Ctr, Seoul, South Korea.	ybchae@khu.ac.kr	Chae, Younbyoung/AAM-1243-2020	Lee, Ye-Seul/0000-0001-6127-5401; Kim, Song-Yi/0000-0002-3512-2134; Chae, Younbyoung/0000-0001-6787-2215	National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning [2018R1D1A1B07042313]; Korea Institute of Oriental Medicine [K18181]	National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning; Korea Institute of Oriental Medicine	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (No. 2018R1D1A1B07042313) and the Korea Institute of Oriental Medicine (no. K18181). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albrecht L, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-52; Allard M, 2011, J HEALTH ECON, V30, P880, DOI 10.1016/j.jhealeco.2011.05.016; Aron-Dine A, 2015, REV ECON STAT, V97, P725, DOI 10.1162/REST_a_00518; Banuri S, 2018, SOC SCI MED, V213, P173, DOI 10.1016/j.socscimed.2018.07.046; Benabou R, 2003, REV ECON STUD, V70, P489, DOI 10.1111/1467-937X.00253; Britton JR, 2015, INT J HEALTH POLICY, V4, P549, DOI 10.15171/ijhpm.2015.93; Brosig-Koch J, 2017, HEALTH ECON, V26, P243, DOI 10.1002/hec.3292; Clemens J, 2014, AM ECON REV, V104, P1320, DOI 10.1257/aer.104.4.1320; Cox J, 2017, FIT FIDDLE SICK DOG, DOI [10.1007/s12062-016-9168-9, DOI 10.1007/S12062-016-9168-9]; Cox JC, 2016, J ECON BEHAV ORGAN, V131, pA1, DOI 10.1016/j.jebo.2016.10.011; Dumont E, 2008, J HEALTH ECON, V27, P1436, DOI 10.1016/j.jhealeco.2008.07.010; Einav L, 2013, AM ECON REV, V103, P178, DOI 10.1257/aer.103.1.178; Fehr E, 2004, SCAND J ECON, V106, P453, DOI 10.1111/j.0347-0520.2004.00372.x; FeldmanHall O, 2015, NEUROIMAGE, V105, P347, DOI 10.1016/j.neuroimage.2014.10.043; Flodgren G, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009255; Gottlieb AB, 2018, DERMATOLOGY THER, V8, P45, DOI 10.1007/s13555-017-0213-2; Green EP, 2014, J ECON BEHAV ORGAN, V106, P367, DOI 10.1016/j.jebo.2014.05.009; Hennig-Schmidt H, 2014, SOC SCI MED, V108, P156, DOI 10.1016/j.socscimed.2014.03.001; Hennig-Schmidt H, 2011, J HEALTH ECON, V30, P637, DOI 10.1016/j.jhealeco.2011.05.001; Izuma K, 2011, P NATL ACAD SCI USA, V108, P17302, DOI 10.1073/pnas.1107038108; Jeong Hyoung-Sun, 2012, J Prev Med Public Health, V45, P127, DOI 10.3961/jpmph.2012.45.3.127; Kwon S, 2003, HEALTH POLICY PLANN, V18, P84, DOI 10.1093/heapol/18.1.84; Kwon S, 2009, HEALTH POLICY PLANN, V24, P63, DOI 10.1093/heapol/czn037; Lagarde M, 2017, SOC SCI MED, V179, P147, DOI 10.1016/j.socscimed.2017.03.002; Lee YS, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213104; Lee YS, 2015, ACUPUNCT MED, V33, P129, DOI 10.1136/acupmed-2014-010661; Ludwig M, 2010, EUR J HEALTH ECON, V11, P291, DOI 10.1007/s10198-009-0176-z; Luft HS, 2015, HEALTH SERV RES, V50, P2187, DOI 10.1111/1475-6773.12423; Ma YN, 2011, NEUROIMAGE, V57, P1273, DOI 10.1016/j.neuroimage.2011.05.003; McPherson E, 2016, SYST REV, V5, DOI 10.1186/s13643-016-0341-2; Murayama K, 2010, P NATL ACAD SCI USA, V107, P20911, DOI 10.1073/pnas.1013305107; Oldenmenger WH, 2013, J PAIN SYMPTOM MANAG, V45, P1083, DOI 10.1016/j.jpainsymman.2012.06.007; PARSONS T, 1975, MILBANK FUND Q, V53, P257, DOI 10.2307/3349493; Rosenthal MB, 2007, JAMA-J AM MED ASSOC, V297, P740, DOI 10.1001/jama.297.7.740; Scott A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008451.pub2; Seong SC, 2017, INT J EPIDEMIOL, V46, P799, DOI 10.1093/ije/dyw253; Shih T, 2015, CIRCULATION, V131, P2151, DOI 10.1161/CIRCULATIONAHA.114.010393; Spiegel B, 2009, ALIMENT PHARM THER, V30, P1159, DOI 10.1111/j.1365-2036.2009.04144.x; Story GW, 2015, SCI REP-UK, V5, DOI 10.1038/srep15389; Sul S, 2015, P NATL ACAD SCI USA, V112, P7851, DOI 10.1073/pnas.1423895112; Tankersley D, 2007, NAT NEUROSCI, V10, P150, DOI 10.1038/nn1833; Tom SM, 2007, SCIENCE, V315, P515, DOI 10.1126/science.1134239; Vainieri M, 2018, INT J HEALTH PLAN M, V33, pE474, DOI 10.1002/hpm.2496; Zaki J, 2011, P NATL ACAD SCI USA, V108, P19761, DOI 10.1073/pnas.1112324108	44	0	0	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2019	14	6							e0218154	10.1371/journal.pone.0218154	http://dx.doi.org/10.1371/journal.pone.0218154			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IC3IS	31181131	gold, Green Published, Green Submitted			2023-01-03	WOS:000470854200047
J	Nordberg, P; Taccone, FS; Truhlar, A; Forsberg, S; Hollenberg, J; Jonsson, M; Cuny, J; Goldstein, P; Vermeersch, N; Higuet, A; Jimenes, FC; Ortiz, FR; Williams, J; Desruelles, D; Creteur, J; Dillenbeck, E; Busche, C; Busch, HJ; Ringh, M; Konrad, D; Peterson, J; Vincent, JL; Svensson, L				Nordberg, Per; Taccone, Fabio Silvio; Truhlar, Anatolij; Forsberg, Sune; Hollenberg, Jacob; Jonsson, Martin; Cuny, Jerome; Goldstein, Patrick; Vermeersch, Nick; Higuet, Adeline; Jimenes, Francisco Carmona; Ortiz, Fernando Rosell; Williams, Julia; Desruelles, Didier; Creteur, Jacques; Dillenbeck, Emelie; Busche, Caroline; Busch, Hans-Joerg; Ringh, Mattias; Konrad, David; Peterson, Johan; Vincent, Jean-Louis; Svensson, Leif			Effect of Trans-Nasal Evaporative Intra-arrest Cooling on Functional Neurologic Outcome in Out-of-Hospital Cardiac Arrest The PRINCESS Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THERAPEUTIC HYPOTHERMIA; CARDIOPULMONARY-RESUSCITATION; COLD SALINE; INDUCTION; SURVIVAL; GUIDELINES; INFUSION; IMPACT; CARE	IMPORTANCE Therapeutic hypothermia may increase survival with good neurologic outcome after cardiac arrest. Trans-nasal evaporative cooling is amethod used to induce cooling, primarily of the brain, during cardiopulmonary resuscitation (ie, intra-arrest). OBJECTIVE To determine whether prehospital trans-nasal evaporative intra-arrest cooling improves survival with good neurologic outcome compared with cooling initiated after hospital arrival. DESIGN, SETTING, AND PARTICIPANTS The PRINCESS trialwas an investigator-initiated, randomized, clinical, international multicenter study with blinded assessment of the outcome, performed by emergency medical services in 7 European countries from July 2010 to January 2018, with final follow-up on April 29, 2018. In total, 677 patients with bystander-witnessed out-of-hospital cardiac arrest were enrolled. INTERVENTIONS Patients were randomly assigned to receive trans-nasal evaporative intra-arrest cooling (n =343) or standard care (n =334). Patients admitted to the hospital in both groups received systemic therapeutic hypothermia at 32 degrees C to 34 degrees C for 24 hours. MAIN OUTCOMES AND MEASURES The primary outcomewas survival with good neurologic outcome, defined as Cerebral Performance Category (CPC) 1-2, at 90 days. Secondary outcomes were survival at 90 days and time to reach core body temperature less than 34 degrees C. RESULTS Among the 677 randomized patients (median age, 65 years; 172 [25%] women), 671 completed the trial. Median time to core temperature less than 34 degrees C was 105 minutes in the intervention group vs 182 minutes in the control group (P <.001). The number of patients with CPC 1-2 at 90 days was 56 of 337 (16.6%) in the intervention cooling group vs 45 of 334 (13.5%) in the control group (difference, 3.1%[95% CI, -2.3% to 8.5%]; relative risk [RR], 1.23 [95% CI, 0.86-1.72]; P =.25). In the intervention group, 60 of 337 patients (17.8%) were alive at 90 days vs 52 of 334 (15.6%) in the control group (difference, 2.2%[95% CI, -3.4% to 7.9%]; RR, 1.14 [95% CI, 0.81-1.57]; P =.44). Minor nosebleed was the most common device-related adverse event, reported in 45 of 337 patients (13%) in the intervention group. The adverse event rate within 7 days was similar between groups. CONCLUSIONS AND RELEVANCE Among patients with out-of-hospital cardiac arrest, trans-nasal evaporative intra-arrest cooling compared with usual care did not result in a statistically significant improvement in survival with good neurologic outcome at 90 days.	[Nordberg, Per; Forsberg, Sune; Hollenberg, Jacob; Jonsson, Martin; Dillenbeck, Emelie; Ringh, Mattias; Svensson, Leif] Karolinska Inst, Dept Med, Ctr Resuscitat Sci, Solna, Sweden; [Taccone, Fabio Silvio; Creteur, Jacques; Vincent, Jean-Louis] ULB, Erasme Hosp, Dept Intens Care, Brussels, Belgium; [Truhlar, Anatolij] Emergency Med Serv Hradec Kralove Reg, Hradec Kralove, Czech Republic; [Forsberg, Sune] Norrtalje Hosp, Dept Anesthesiol & Intens Care, Norrtalje, Sweden; [Cuny, Jerome; Goldstein, Patrick] Ctr Hosp Reg Univ Lille, Emergency Dept, Lille, France; [Cuny, Jerome; Goldstein, Patrick] Ctr Hosp Reg Univ Lille, SAMU, Lille, France; [Vermeersch, Nick; Higuet, Adeline] St Maria Hosp, Emergency Dept, Halle, Germany; [Jimenes, Francisco Carmona] Sistema Emergencies Med, Barcelona, Catalunya, Spain; [Ortiz, Fernando Rosell] Empresa Publ Emergencias Sanit, Almeria, Andalucia, Spain; [Williams, Julia] Univ Hertfordshire, Sch Hlth & Social Work, Hatfield, Herts, England; [Desruelles, Didier] Univ Hosp Leuven, Emergency Dept, Leuven, Belgium; [Busche, Caroline; Busch, Hans-Joerg] Univ Freiburg, Fac Med, Univ Hosp Freiburg, Dept Emergency Med, Freiburg, Germany; [Konrad, David; Peterson, Johan] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden; [Konrad, David; Peterson, Johan] Karolinska Univ Hosp, Perioperat Med & Intens Care, Stockholm, Sweden	Karolinska Institutet; Universite Libre de Bruxelles; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille; University of Hertfordshire; KU Leuven; University Hospital Leuven; University of Freiburg; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Nordberg, P (corresponding author), Soder Sjukhuset, Dept Cardiol, Sjukhusbacken 10, S-11883 Stockholm, Sweden.	per.nordberg@sll.se	Forsberg, Sune/U-7115-2019; Jonsson, Martin/AEF-9167-2022; Williams, Julia/AAQ-8655-2021	Forsberg, Sune/0000-0003-2684-5194; Williams, Julia/0000-0003-0796-5465; Carmona Jimenez, Francesc/0000-0001-6474-9860; Vincent, Jean-Louis/0000-0001-6011-6951; Jonsson, Martin/0000-0002-3539-8317; Rosell-Ortiz, Fernando/0000-0003-0260-9955	Swedish Heart-Lung Foundation; Laerdal Foundation	Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Laerdal Foundation	The study was funded by independent research grants from the Swedish Heart-Lung Foundation and the Laerdal Foundation. The cooling devices used at each study site were provided by the company BrainCool AB at no cost.	Abella BS, 2004, CIRCULATION, V109, P2786, DOI 10.1161/01.CIR.0000131940.19833.85; Abou-Chebl A, 2011, STROKE, V42, P2164, DOI 10.1161/STROKEAHA.110.613000; Bernard SA, 2016, CIRCULATION, V134, P797, DOI 10.1161/CIRCULATIONAHA.116.021989; Bernard SA, 2010, CIRCULATION, V122, P737, DOI 10.1161/CIRCULATIONAHA.109.906859; Busch HJ, 2010, RESUSCITATION, V81, P943, DOI 10.1016/j.resuscitation.2010.04.027; Callaway CW, 2015, CIRCULATION, V132, pS465, DOI 10.1161/CIR.0000000000000262; Castren M, 2010, CIRCULATION, V122, P729, DOI 10.1161/CIRCULATIONAHA.109.931691; Che DF, 2011, CRIT CARE MED, V39, P1423, DOI 10.1097/CCM.0b013e318212020a; Debaty G, 2014, INTENS CARE MED, V40, P1832, DOI 10.1007/s00134-014-3519-x; Froehler MT, 2007, J NEUROL SCI, V261, P118, DOI 10.1016/j.jns.2007.04.042; Holzer M, 2002, NEW ENGL J MED, V346, P549; JENNETT B, 1975, LANCET, V1, P480; Kim F, 2014, JAMA-J AM MED ASSOC, V311, P45, DOI 10.1001/jama.2013.282173; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Nolan JP, 2015, RESUSCITATION, V95, P202, DOI 10.1016/j.resuscitation.2015.07.018; Nolan JP, 2010, RESUSCITATION, V81, pE1, DOI 10.1016/j.resuscitation.2010.08.002; Nordberg P, 2013, BMC EMERG MED, V13, DOI 10.1186/1471-227X-13-21; Perkins GD, 2015, RESUSCITATION, V96, P328, DOI 10.1016/j.resuscitation.2014.11.002; Scolletta S, 2012, CRIT CARE, V16, DOI 10.1186/cc11235; Yu T, 2010, CRIT CARE MED, V38, P916, DOI 10.1097/CCM.0b013e3181cd1291; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	21	76	79	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	2019	321	17					1677	1685		10.1001/jama.2019.4149	http://dx.doi.org/10.1001/jama.2019.4149			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX3TE	31063573	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000467314800016
J	Matzkin, H; Chen, J; Agai, R; Ziv-Baran, T; Mabjeesh, NJ				Matzkin, Haim; Chen, Juza; Agai, Rubi; Ziv-Baran, Tomer; Mabjeesh, Nicola J.			Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification	PLOS ONE			English	Article							EXTERNAL-BEAM RADIOTHERAPY; PERMANENT INTERSTITIAL BRACHYTHERAPY; RADIATION-THERAPY; HORMONAL-THERAPY; OUTCOMES; IMPACT; IMPLANT; FAILURE; MEN	Introduction Brachytherapy is a well-established treatment of localized prostate cancer. Few studies have documented long-term results, specifically biochemical progression-free survival (bPFS) in men with brachytherapy alone, with or without short-term androgen deprivation therapy (ADT), or in combination with external beam radiotherapy (EBRT). Our aim was to analyze long-term bPFS of brachytherapy treated patients. Materials and methods Retrospective analysis of 1457 patients with low and intermediate risk prostate cancer treated with brachytherapy alone (1255) or combined with EBRT (202). Six-months ADT was administrated for all EBRT combined patients and for prostate volume downsizing when >55 cc (328). Failure was by the Phoenix definition. Kaplan-Meier analysis and multi-variate Cox regression estimated and compared 10-yr and 15-yr rates of bPFS. Results Median follow-up was 6.1 yr. Ten and 15-yr bPFS rates of the entire cohort were 93.2% and 89.2%, respectively. On multivariate analysis, PSA density (PSAD), ADT and clinical stage were significantly associated with failure. The most powerful independent factor was PSAD with a HR of 3.5 (95% CI, 1.7-7.4) for PSAD above 0.15. No significant difference was found between low and intermediate risks patients regardless of treatment regimen. However, comparison of two intermediate risk groups, Gleason score (GS) 7, PSA<20 ng/ml versus GS <= 6 and PSA = 10-20 ng/ml, revealed 10- and 15-yr bPFS rates of 94.2% and 94.2% compared to 88.2% and 79.9%, (P = 0.022), respectively. ADT improved bPFS rates in low risk patients. The ten and 15-yr bPFS rates were 97.6% and 94.6% compared to 92.3% and 88.2%, (P = 0.020), respectively. Conclusions Our retrospective large scale study suggests that brachytherapy provides excellent long-term bPFS rates in low and intermediate risk disease. Combination of brachytherapy with EBRT yields favorable outcomes in GS 7 intermediate risk patients and short-term ADT has a positive effect on outcomes in low risk patients. Further prospective studies are warranted to discriminate the role of adding either EBRT and/or ADT to brachytherapy protocols.	[Matzkin, Haim; Chen, Juza; Mabjeesh, Nicola J.] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Urol, Tel Aviv, Israel; [Agai, Rubi] Tel Aviv Sourasky Med Ctr, Dept Oncol, Inst Radiotherapy, Tel Aviv, Israel; [Ziv-Baran, Tomer] Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Mabjeesh, NJ (corresponding author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Urol, Tel Aviv, Israel.	nicolam@tlvmc.gov.il	Ziv-Baran, Tomer/AAA-8408-2022					Amini A, 2016, BRACHYTHERAPY, V15, P136, DOI 10.1016/j.brachy.2015.11.006; Ash D, 2005, RADIOTHER ONCOL, V75, P303, DOI 10.1016/j.radonc.2005.03.015; Beyer DC, 2005, INT J RADIAT ONCOL, V61, P1299, DOI 10.1016/j.ijrobp.2004.08.024; Bruner DW, 2018, ANN M AM SOC RAD ONC; Castle KO, 2013, INT J RADIAT ONCOL, V85, P693, DOI 10.1016/j.ijrobp.2012.06.030; Crook J, 2011, INT J RADIAT ONCOL, V80, P1323, DOI 10.1016/j.ijrobp.2010.04.038; D'Amico AV, 2004, JAMA-J AM MED ASSOC, V292, P821, DOI 10.1001/jama.292.7.821; Dickinson PD, 2014, BJU INT, V113, P748, DOI 10.1111/bju.12358; Frank SJ, 2007, BRACHYTHERAPY, V6, P2, DOI 10.1016/j.brachy.2006.09.004; Giberti C, 2017, CAN J UROL; Goldner G, 2012, RADIOTHER ONCOL, V103, P223, DOI 10.1016/j.radonc.2012.01.016; Grimm P, 2012, BJU INT, V109, P22, DOI 10.1111/j.1464-410X.2011.10827.x; HOLM HH, 1983, J UROLOGY, V130, P283, DOI 10.1016/S0022-5347(17)51108-8; Keyes M, 2017, BRACHYTHERAPY, V16, P245, DOI 10.1016/j.brachy.2016.11.017; Kibel AS, 2012, J UROLOGY, V187, P1259, DOI 10.1016/j.juro.2011.11.084; Matzkin H, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-288; Merrick GS, 2006, INT J RADIAT ONCOL, V65, P669, DOI 10.1016/j.ijrobp.2006.01.030; Merrick GS, 2002, INT J RADIAT ONCOL, V52, P664, DOI 10.1016/S0360-3016(01)02670-0; Morris WJ, 2017, INT J RADIAT ONCOL, V98, P275, DOI 10.1016/j.ijrobp.2016.11.026; Ohashi T, 2013, RADIOTHER ONCOL, V109, P241, DOI 10.1016/j.radonc.2013.09.022; Potters L, 2000, J CLIN ONCOL, V18, P1187, DOI 10.1200/JCO.2000.18.6.1187; Potters L, 2005, J UROLOGY, V173, P1562, DOI 10.1097/01.ju.0000154633.73092.8e; Prestidge BR, 2016, INT J RADIAT ONCOL, V96, pS4, DOI 10.1016/j.ijrobp.2016.06.026; Roach M, 2006, INT J RADIAT ONCOL, V65, P965, DOI 10.1016/j.ijrobp.2006.04.029; Shah C, 2012, BRACHYTHERAPY, V11, P441, DOI 10.1016/j.brachy.2012.04.002; Stock RG, 2006, INT J RADIAT ONCOL, V64, P527, DOI 10.1016/j.ijrobp.2005.07.981; STOCK RG, 1995, INT J RADIAT ONCOL, V32, P219, DOI 10.1016/0360-3016(95)00521-Y; Stock RG, 1998, INT J RADIAT ONCOL, V41, P101, DOI 10.1016/S0360-3016(98)00006-6; Stock RG, 2000, TECH UROL, DOI [10.1016/j.palaeo.2012.06.020, DOI 10.1016/J.PALAEO.2012.06.020]; Stone NN, 2014, J UROLOGY, V192, P754, DOI 10.1016/j.juro.2014.03.094; Stone NN, 1999, J UROLOGY, V162, P421, DOI 10.1016/S0022-5347(05)68574-6; Sylvester JE, 2007, INT J RADIAT ONCOL, V67, P57, DOI 10.1016/j.ijrobp.2006.07.1382; Taira AV, 2011, INT J RADIAT ONCOL, V79, P1336, DOI 10.1016/j.ijrobp.2010.01.005; Zelefsky MJ, 2007, RADIOTHER ONCOL, V84, P185, DOI 10.1016/j.radonc.2007.07.002	34	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2019	14	4							e0215582	10.1371/journal.pone.0215582	http://dx.doi.org/10.1371/journal.pone.0215582			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU1GG	31002732	Green Submitted, Green Published, gold			2023-01-03	WOS:000465019900031
J	Grigoryan, L; Germanos, G; Zoorob, R; Juneja, S; Raphael, JL; Paasche-Orlow, MK; Trautner, BW				Grigoryan, Larissa; Germanos, George; Zoorob, Roger; Juneja, Shivanki; Raphael, Jean L.; Paasche-Orlow, Michael K.; Trautner, Barbara W.			Use of Antibiotics Without a Prescription in the US Population A Scoping Review	ANNALS OF INTERNAL MEDICINE			English	Review							NONPRESCRIPTION ANTIMICROBIAL USE; INJECTION-DRUG USERS; SELF-MEDICATION; UNITED-STATES; LATINO COMMUNITY; ATTITUDES; CARE; KNOWLEDGE; AVAILABILITY; DETERMINANTS	Background: Use of antibiotics without a prescription may increase unnecessary and inappropriate drug use or doses as well as global risk for antimicrobial resistance. Purpose: To perform a scoping review of research on the prevalence of nonprescription antibiotic use in the United States and to examine the factors that influence it. Data Sources: Searches of PubMed, EMBASE, CINAHL, Scopus, and relevant Web sites without language restrictions from January 2000 to March 2019. Study Selection: Studies reporting nonprescription use of antibiotics, storage of antibiotics, intention to use antibiotics without a prescription, and factors influencing nonprescription use. Data Extraction: Two reviewers independently screened citations and full texts and performed data abstraction. Data Synthesis: Of 17 422 screened articles, 31 met inclusion criteria. Depending on population characteristics, prevalence of nonprescription antibiotic use varied from 1% to 66%, storage of antibiotics for future use varied from 14% to 48%, and prevalence of intention to use antibiotics without a prescription was 25%. Antibiotics were obtained without a prescription from various sources, including previously prescribed courses, local markets or stores, and family or friends. Reported factors contributing to nonprescription use included easy access through markets or stores that obtain antibiotics internationally for under-the-counter sales, difficulty accessing the health care system, costs of physician visits, long waiting periods in clinics, and transportation problems. Limitation: Scarce evidence and heterogeneous methods and outcomes. Conclusion: Nonprescription antibiotic use is a seemingly prevalent and understudied public health problem in the United States. An increased understanding of risk factors and pathways that are amenable to intervention is essential to decrease this unsafe practice.	[Grigoryan, Larissa; Germanos, George; Zoorob, Roger] Baylor Coll Med, Dept Family & Community Med, 3701 Kirby Dr,Suite 600, Houston, TX 77098 USA; [Juneja, Shivanki] Univ Penn, Philadelphia, PA 19104 USA; [Paasche-Orlow, Michael K.] Boston Univ, Sch Med, Dept Med, 801 Massachusetts Ave,2nd Floor, Boston, MA 02118 USA; [Raphael, Jean L.; Trautner, Barbara W.] Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effectiveness & Safety 152, 2002 Holcombe Blvd, Houston, TX 77030 USA; [Raphael, Jean L.; Trautner, Barbara W.] Baylor Coll Med, Houston, TX 77030 USA; [Juneja, Shivanki] 4105 Spruce St,Unit C3, Philadelphia, PA 19104 USA	Baylor College of Medicine; University of Pennsylvania; Boston University; Baylor College of Medicine; Baylor College of Medicine	Grigoryan, L (corresponding author), Baylor Coll Med, Dept Family & Community Med, 3701 Kirby Dr,Suite 600, Houston, TX 77098 USA.	grigorya@bcm.edu	Paasche-Orlow, Michael/ABF-7919-2020	Paasche-Orlow, Michael/0000-0002-9276-7190; Juneja, Shivanki/0000-0003-4797-8009; Zoorob, Roger/0000-0001-7311-6723	Health Resources and Services Administration, an agency of the U.S. Department of Health and Human Services [T32 HP1003]; Houston Veterans Affairs Health Services Research AMP; Development Center for Innovations in Quality, Effectiveness and Safety [CIN 13-413]; Department of Veterans Affairs [HSRD 16-025]	Health Resources and Services Administration, an agency of the U.S. Department of Health and Human Services; Houston Veterans Affairs Health Services Research AMP; Development Center for Innovations in Quality, Effectiveness and Safety; Department of Veterans Affairs(US Department of Veterans Affairs)	No grant support was received for this study. Dr. Germanos is supported in part by the Health Resources and Services Administration, an agency of the U.S. Department of Health and Human Services (grant number T32 HP1003). Dr. Trautner's work is supported in part by the Houston Veterans Affairs Health Services Research & Development Center for Innovations in Quality, Effectiveness and Safety (CIN 13-413) and by Department of Veterans Affairs funding (HSR&D 16-025).	Belongia EA, 2002, PREV MED, V34, P346, DOI 10.1006/pmed.2001.0992; Binswanger IA, 2000, CLIN INFECT DIS, V30, P579, DOI 10.1086/313703; Boucher HW, 2016, ANN INTERN MED, V165, P812, DOI 10.7326/M16-2079; Bryce A, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i939; Ceaser S, 2000, ANN INTERN MED, V133, P74, DOI 10.7326/0003-4819-133-1-200007040-00017; Cespedes A, 2006, AM J INFECT CONTROL, V34, P495, DOI 10.1016/j.ajic.2006.01.005; Coffman MJ, 2008, PUBLIC HEALTH NURS, V25, P203, DOI 10.1111/j.1525-1446.2008.00697.x; Edwards DJ, 2002, ACAD EMERG MED, V9, P22, DOI 10.1197/aemj.9.1.22; Eng JV, 2003, EMERG INFECT DIS, V9, P1128; Fink DS, 2013, SUBST USE MISUSE, V48, P523, DOI 10.3109/10826084.2013.787094; Goff BJ, 2002, NEW ENGL J MED, V347, P223, DOI 10.1056/NEJM200207183470319; Goldsworthy RC, 2008, AM J PUBLIC HEALTH, V98, P1115, DOI 10.2105/AJPH.2007.123257; Goldsworthy RC, 2009, J ADOLESCENT HEALTH, V45, P634, DOI 10.1016/j.jadohealth.2009.06.002; Grigoryan L, 2006, EMERG INFECT DIS, V12, P452, DOI 10.3201/eid1203.050992; Grigoryan L, 2008, J ANTIMICROB CHEMOTH, V61, P1172, DOI 10.1093/jac/dkn054; Grigoryan L, 2010, CURR DRUG SAF, V5, P329, DOI 10.2174/157488610792246046; Harris RE, 2018, DRUG ALCOHOL DEPEN, V187, P8, DOI 10.1016/j.drugalcdep.2018.01.029; Horton S, 2012, J IMMIGR MINOR HEALT, V14, P664, DOI 10.1007/s10903-011-9562-6; Hu J, 2014, INT J INFECT DIS, V26, P103, DOI 10.1016/j.ijid.2014.04.017; Huttner B, 2011, CLIN INFECT DIS, V53, P640, DOI 10.1093/cid/cir449; Kahan TF, 2018, AM AC PED C PHIL PEN; Landers TF, 2010, J AM ACAD NURSE PRAC, V22, P488, DOI 10.1111/j.1745-7599.2010.00539.x; Larson E, 2004, J URBAN HEALTH, V81, P498, DOI 10.1093/jurban/jth133; Larson EL, 2006, NURS RES, V55, P94, DOI 10.1097/00006199-200603000-00004; Mainous AG, 2005, EMERG INFECT DIS, V11, P883, DOI 10.3201/EID1106.040960; Mainous AG, 2008, J AM BOARD FAM MED, V21, P128, DOI 10.3122/jabfm.2008.02.070149; Mainous AG, 2009, ANN FAM MED, V7, P520, DOI 10.1370/afm.1061; Mainous AG, 2009, ANN FAM MED, V7, P431, DOI 10.1370/afm.999; McDonald MA, 2001, HEALTH EDUC BEHAV, V28, P624, DOI 10.1177/109019810102800508; McGowan J, 2016, J CLIN EPIDEMIOL, V75, P40, DOI 10.1016/j.jclinepi.2016.01.021; Morgan DJ, 2011, LANCET INFECT DIS, V11, P692, DOI 10.1016/S1473-3099(11)70054-8; Norris P, 2010, J IMMIGR MINOR HEALT, V12, P107, DOI 10.1007/s10903-008-9224-5; Peters MDJ, 2015, INT J EVID-BASED HEA, V13, P141, DOI 10.1097/XEB.0000000000000050; Richman PB, 2001, AM J EMERG MED, V19, P57, DOI 10.1053/ajem.2001.20035; Roose RJ, 2009, J ADDICT DIS, V28, P74, DOI 10.1080/10550880802545200; Sanchez J, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00108; Scanfeld D, 2010, AM J INFECT CONTROL, V38, P182, DOI 10.1016/j.ajic.2009.11.004; Shehab N, 2008, CLIN INFECT DIS, V47, P735, DOI 10.1086/591126; Starrels JL, 2009, J GEN INTERN MED, V24, P263, DOI 10.1007/s11606-008-0859-7; Summers PJ, 2018, DRUG ALCOHOL DEPEN, V190, P200, DOI 10.1016/j.drugalcdep.2018.06.010; Thorpe KE, 2018, HEALTH AFFAIR, V37, P662, DOI 10.1377/hlthaff.2017.1153; Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; Ward L, 2011, J URBAN HEALTH, V88, P997, DOI 10.1007/s11524-011-9589-y; Watkins LKF, 2015, MMWR-MORBID MORTAL W, V64, P767, DOI 10.15585/mmwr.mm6428a5; Wieczorkiewicz SM, 2013, ANN PHARMACOTHER, V47, P482, DOI 10.1345/aph.1R706; Zoorob R, 2016, ANTIMICROB AGENTS CH, V60, P5527, DOI 10.1128/AAC.00528-16	46	41	43	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 20	2019	171	4					257	+		10.7326/M19-0505	http://dx.doi.org/10.7326/M19-0505			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IR7TC	31330541				2023-01-03	WOS:000481642800017
J	Corrigan, AM; Karlsson, J; Wildenhain, J; Knerr, L; Olwegard-Halvarsson, M; Karlsson, M; Lunse, S; Wang, YH				Corrigan, Adam M.; Karlsson, Johan; Wildenhain, Jan; Knerr, Laurent; Olwegard-Halvarsson, Maria; Karlsson, Maria; Lunse, Svenja; Wang, Yinhai			IA-Lab: A MATLAB framework for efficient microscopy image analysis development, applied to quantifying intracellular transport of internalized peptide-drug conjugate	PLOS ONE			English	Article							SOFTWARE; DELIVERY; PLATFORM	This work presents a MATLAB-based software package for high-throughput microscopy image analysis development, making such development more accessible for a large user community. The toolbox provides a GUI and a number of analysis workflows, and can serve as a general framework designed to allow for easy extension. For a new application, only a minor part of the object-oriented code needs to be replaced by new components, making development efficient. This makes it possible to quickly develop solutions for analysis not available in existing tools. We show its use in making a tool for quantifying intracellular transport of internalized peptide-drug conjugates.	[Corrigan, Adam M.; Wildenhain, Jan; Wang, Yinhai] AstraZeneca, Discovery Sci R&D, Cambridge, England; [Karlsson, Johan; Lunse, Svenja] AstraZeneca, Discovery Sci R&D, Gothenburg, Sweden; [Knerr, Laurent; Olwegard-Halvarsson, Maria] AstraZeneca, Res & Early Dev Cardiovasc Renal & Metab BioPharm, Gothenburg, Sweden; [Karlsson, Maria] AstraZeneca, Res & Early Dev Resp Inflammat & Autoimmune BioPh, Gothenburg, Sweden; [Wildenhain, Jan] Syngenta, Jealotts Hill Res Ctr, Bracknell, Berks, England	AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Syngenta	Corrigan, AM (corresponding author), AstraZeneca, Discovery Sci R&D, Cambridge, England.	adam.corrigan@astrazeneca.com	Wildenhain, Jan/E-5597-2011	Wildenhain, Jan/0000-0002-5461-3828; Corrigan, Adam/0000-0001-5142-6579	AstraZeneca	AstraZeneca(AstraZeneca)	All authors are or were employees of AstraZeneca. AstraZeneca provided the funding for this research and provided support in the form of salaries for all authors, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Belevich I, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002340; Caicedo JC, 2017, NAT METHODS, V14, P849, DOI [10.1038/NMETH.4397, 10.1038/nmeth.4397]; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; de Chaumont F, 2012, NAT METHODS, V9, P690, DOI [10.1038/NMETH.2075, 10.1038/nmeth.2075]; Du C-J, 2011, BIOMEDICAL IMAGING N; Eliceiri KW, 2012, NAT METHODS, V9, P697, DOI [10.1038/NMETH.2084, 10.1038/nmeth.2084]; Georgescu W, 2012, BIOINFORMATICS, V28, P138, DOI 10.1093/bioinformatics/btr633; Gilad Y, 2016, BIOMEDICINES, V4, DOI 10.3390/biomedicines4020011; Hodneland E, 2013, SOURCE CODE BIOL MED, V8, DOI 10.1186/1751-0473-8-16; Kankaanpaa P, 2012, NAT METHODS, V9, P683, DOI [10.1038/nmeth.2047, 10.1038/NMETH.2047]; Kvarnstrom M, 2008, OPT EXPRESS, V16, P12943, DOI 10.1364/OE.16.012943; Lelle M, 2015, MOL PHARMACEUT, V12, P4290, DOI 10.1021/acs.molpharmaceut.5b00487; Li HY, 2002, MED RES REV, V22, P225, DOI 10.1002/med.10008; Linkert M, 2010, J CELL BIOL, V189, P777, DOI 10.1083/jcb.201004104; Majumdar S, 2012, MED RES REV, V32, P637, DOI 10.1002/med.20225; Ogier A, 2012, BIOINFORMATICS, V28, P1945, DOI 10.1093/bioinformatics/bts288; Rueden CT, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1934-z; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Valeur E, 2017, ANGEW CHEM INT EDIT, V56, P10294, DOI 10.1002/anie.201611914; Wang Q, 2005, CELLTRACER SOFTWARE; Williams E, 2017, NAT METHODS, V14, P775, DOI [10.1038/NMETH.4326, 10.1038/nmeth.4326]	21	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2019	14	8							e0220627	10.1371/journal.pone.0220627	http://dx.doi.org/10.1371/journal.pone.0220627			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4ZH	31369634	gold, Green Submitted, Green Published			2023-01-03	WOS:000484987900069
J	Clements, H; Valentin, S; Jenkins, N; Rankin, J; Baker, JS; Gee, N; Snellgrove, D; Sloman, K				Clements, Heather; Valentin, Stephanie; Jenkins, Nicholas; Rankin, Jean; Baker, Julien S.; Gee, Nancy; Snellgrove, Donna; Sloman, Katherine			The effects of interacting with fish in aquariums on human health and well-being: A systematic review	PLOS ONE			English	Review							ANIMAL-ASSISTED THERAPY; PET OWNERSHIP; COMPANION ANIMALS; ATTACHMENT THEORY; PUBLIC AQUARIUMS; MODERATING ROLE; STRESS; DOG; INTERVENTION; BENEFITS	Background Most research into the health benefits of human-animal interaction has focused on species that interact physically with humans, such as dogs. This may be unsuitable for certain populations for reasons including accessibility and the risk of negative consequences to both the person and the animal. However, some research has associated viewing fish in aquariums with positive well-being outcomes; as there is no physical contact with the animal, this form of interaction carries less risk. At present, little is known about the specific benefits of human-fish interaction. Objectives To explore current evidence relating to the psychological and physiological benefits of interacting with fish in aquariums. Methods Systematic searches were conducted to identify relevant primary research of any design. All forms of interaction were considered, including keeping fish as companion animals and fish aquarium-based interventions. "Non-live" alternatives, such as videos, were also considered. This review was conducted according to a registered protocol (PROSPERO ID: CRD42018090466). Results Nineteen studies were included. Two provided tentative evidence that keeping home aquaria is associated with relaxation. The remaining studies involved novel interactions with fish in home or public aquariums. Outcomes relating to anxiety, relaxation and/or physiological stress were commonly assessed; evidence was mixed with both positive and null findings. Preliminary support was found for effects on mood, pain, nutritional intake and body weight, but not loneliness. All studies had methodological issues and risk of bias was either high or unclear. Conclusions Review findings suggest that interacting with fish in aquariums has the potential to benefit human well-being, although research on this topic is currently limited. Future research should aim to address gaps in the evidence, such as whether and how the type of human-fish interaction can influence well-being outcomes. Researchers should also aim to address the methodological concerns highlighted in this review.	[Clements, Heather; Sloman, Katherine] Univ West Scotland, Sch Hlth & Life Sci, Inst Biomed & Environm Hlth Res, Paisley, Renfrew, Scotland; [Valentin, Stephanie; Baker, Julien S.] Univ West Scotland, Sch Hlth & Life Sci, Inst Clin Exercise & Hlth Sci, Glasgow, Lanark, Scotland; [Jenkins, Nicholas] Univ West Scotland, Sch Media Culture & Soc, Glasgow, Lanark, Scotland; [Rankin, Jean] Univ West Scotland, Sch Hlth & Life Sci, Paisley, Renfrew, Scotland; [Gee, Nancy; Snellgrove, Donna] WALTHAM Ctr Pet Nutr, Glasgow, Lanark, Scotland; [Gee, Nancy] SUNY Coll Fredonia, Dept Psychol, Fredonia, NY 14063 USA	University of West Scotland; University of West Scotland; State University of New York (SUNY) System; SUNY Fredonia	Clements, H; Sloman, K (corresponding author), Univ West Scotland, Sch Hlth & Life Sci, Inst Biomed & Environm Hlth Res, Paisley, Renfrew, Scotland.	heather.clements@uws.ac.uk; katherine.sloman@uws.ac.uk		Valentin, Stephanie/0000-0002-8568-3458	Mars Petcare UK; University of the West of Scotland	Mars Petcare UK; University of the West of Scotland	This systematic review was conducted as part of the first author's (HC) PhD. Partial funding for this PhD was secured by KS from Mars Petcare UK. Two authors (NG and DS) are employees of the WALTHAM Centre for Pet Nutrition, a Mars Petcare research centre. Neither NG or DS were involved in data collection or analysis, but both provided feedback on the protocol and earlier drafts of the manuscript. Mars Petcare UK played no role in study design, data collection, or analysis, but approved the final manuscript before publication. The remaining funding for the PhD was secured from the University of the West of Scotland.	Adams M, 2018, SOC PERSONAL PSYCHOL, V12, DOI 10.1111/spc3.12375; AINSWORTH MDS, 1989, AM PSYCHOL, V44, P709, DOI 10.1037/0003-066X.44.4.709; Allen K, 2001, HYPERTENSION, V38, P815, DOI 10.1161/hyp.38.4.815; Amiot C, 2016, BIOSCIENCE, V66, P552, DOI [10.1093/biosci/biw051, 10.1093/biosci/biw0]; Amiot CE, 2015, PSYCHOL BULL, V141, P6, DOI 10.1037/a0038147; Banks J. B., 2018, Human-Animal Interaction Bulletin, V6, P1; Banks MR, 2005, ANTHROZOOS, V18, P396, DOI 10.2752/089279305785593983; BANZIGER G, 1983, GERONTOLOGIST, V23, P527, DOI 10.1093/geront/23.5.527; Bao KJ, 2016, ANTHROZOOS, V29, P283, DOI 10.1080/08927936.2016.1152721; Barker RT, 2012, INT J WORKPLACE HEAL, V5, P15, DOI 10.1108/17538351211215366; Barker SB, 2016, ANTHROZOOS, V29, P35, DOI 10.1080/08927936.2015.1069988; Barker SB, 2003, ANTHROZOOS, V16, P229, DOI 10.2752/089279303786992071; Beck L, 2008, ANTHROZOOS, V21, P43, DOI 10.2752/089279308X274056; Beetz A, 2016, SOCIAL NEUROSCIENCE, P107; Beetz AM, 2017, APPL DEV SCI, V21, P139, DOI 10.1080/10888691.2016.1262263; Bell SL, 2018, LANDSCAPE RES, V43, P8, DOI 10.1080/01426397.2016.1267721; Bert F, 2016, EUR J INTEGR MED, V8, P695, DOI 10.1016/j.eujim.2016.05.005; Berto R, 2014, BEHAV SCI, V4, P394, DOI 10.3390/bs4040394; Bowlby J., 1980, LOSS SADNESS DEPRESS; Bowlby J., 1969, ATTACHMENT LOSS, V1; Bowlby J., 1973, SEPARATION ANXIETY A, V2; Bringslimark T, 2009, J ENVIRON PSYCHOL, V29, P422, DOI 10.1016/j.jenvp.2009.05.001; Brodie SJ, 2002, J CLIN NURS, V11, P444, DOI 10.1046/j.1365-2702.2002.00628.x; Brooks HL, 2018, BMC PSYCHIATRY, V18, DOI 10.1186/s12888-018-1613-2; Buttelmann D, 2014, ANTHROZOOS, V27, P267, DOI 10.2752/175303714X13903827487647; Chur-Hansen A, 2013, APPL TOPICS HLTH PSY, P134; Chur-Hansen A, 2010, INT J EVID-BASED HEA, V8, P140, DOI 10.1111/j.1744-1609.2010.00176.x; Cole K M, 2000, AACN Clin Issues, V11, P139, DOI 10.1097/00044067-200002000-00015; COLE KM, 1995, NURS CLIN N AM, V30, P529; Cox DTC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158717; Cracknell D, 2017, LANDSCAPE RES, V42, P18, DOI 10.1080/01426397.2016.1243236; Cracknell D, 2016, ENVIRON BEHAV, V48, P1242, DOI 10.1177/0013916515597512; Cracknell DL, 2018, HUM DIMENS WILDL, V23, P446, DOI 10.1080/10871209.2018.1449039; Crossman MK, 2018, J CLIN PSYCHOL, V74, P566, DOI 10.1002/jclp.22548; Charry-Sanchez JD, 2018, COMPLEMENT THER CLIN, V32, P169, DOI 10.1016/j.ctcp.2018.06.011; de Bell S, 2017, LANDSCAPE URBAN PLAN, V167, P118, DOI 10.1016/j.landurbplan.2017.06.003; DeSchriver M.M., 1990, ANTHROZODS, V4, P44, DOI [10.2752/089279391787057396, DOI 10.2752/089279391787057396]; Ding D, 2018, AM J PREV MED, V54, P289, DOI 10.1016/j.amepre.2017.09.012; Ebener J, 2017, ACT ADAPT AGING, V41, P107, DOI 10.1080/01924788.2017.1306380; Edwards NE, 2014, WESTERN J NURS RES, V36, P1309, DOI 10.1177/0193945914526647; Edwards NE, 2013, ALZ DIS ASSOC DIS, V27, P379, DOI 10.1097/WAD.0b013e3182769b34; Edwards NE, 2002, WESTERN J NURS RES, V24, P697, DOI 10.1177/019394502320555430; Ein N, 2018, STRESS HEALTH, V34, P477, DOI 10.1002/smi.2812; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; Friedmann E, 2018, GERONTOLOGIST, P1, DOI [10.1093/geront/gnx189, DOI 10.1093/GERONT/GNX189]; Friedmann E, 2013, ANTHROZOOS, V26, P535, DOI 10.2752/175303713X13795775536138; Galbraith JA, 2014, BIOL CONSERV, V180, P64, DOI 10.1016/j.biocon.2014.09.038; Glaser R, 2005, NAT REV IMMUNOL, V5, P243, DOI 10.1038/nri1571; Gough D, 2007, RES PAP EDUC, V22, P213, DOI [10.1080/02671520701296189, DOI 10.1080/02671520701296189]; Hatch A, 2007, ANTHROZOOS, V20, P37, DOI 10.2752/089279307780216632; HAZAN C, 1987, J PERS SOC PSYCHOL, V52, P511, DOI 10.1037/0022-3514.52.3.511; Herzog H, 2011, CURR DIR PSYCHOL SCI, V20, P236, DOI 10.1177/0963721411415220; Inzlicht M, 2018, TRENDS COGN SCI, V22, P337, DOI 10.1016/j.tics.2018.01.007; Joranson N, 2015, J AM MED DIR ASSOC, V16, P867, DOI 10.1016/j.jamda.2015.05.002; Joye Y, 2011, ENVIRON VALUE, V20, P189, DOI 10.3197/096327111X12997574391724; Julius H., 2013, ATTACHMENT PETS AN I; Kamioka H, 2014, COMPLEMENT THER MED, V22, P371, DOI 10.1016/j.ctim.2013.12.016; KATCHER A, 1984, AM J CLIN HYPN, V27, P14, DOI 10.1080/00029157.1984.10402583; Katcher A H, 1983, NEW PERSPECTIVES OUR, P351; Katcher AH, 2010, HANDBOOK ON ANIMAL-ASSISTED THERAPY: THEORETICAL FOUNDATIONS AND GUIDELINES FOR PRACTICE, 3RD EDITION, P49, DOI 10.1016/B978-0-12-381453-1.10004-2; Kazdin AE, 2017, APPL DEV SCI, V21, P150, DOI 10.1080/10888691.2016.1191952; Kellert S.R., 1993, BIOPHILIA HYPOTHESIS; Kidd AH, 1999, PSYCHOL REP, V84, P998, DOI 10.2466/PR0.84.3.998-1004; Krantz DS, 2002, ANNU REV PSYCHOL, V53, P341, DOI 10.1146/annurev.psych.53.100901.135208; KRUGER KA, 2018, HDB ANIMAL ASSISTED, DOI DOI 10.1007/978-3-319-75529-8_1; Langfield J, 2009, BRIT J OCCUP THER, V72, P349, DOI 10.1177/030802260907200805; Lefebvre SL, 2008, AM J INFECT CONTROL, V36, P78, DOI 10.1016/j.ajic.2007.09.005; Levine GN, 2013, CIRCULATION, V127, P2353, DOI 10.1161/CIR.0b013e31829201e1; Lin BYJ, 2013, HERD-HEALTH ENV RES, V6, P77, DOI 10.1177/193758671300600207; LoBue V, 2013, BRIT J DEV PSYCHOL, V31, P57, DOI 10.1111/j.2044-835X.2012.02078.x; Maranda L, 2015, DIABETES EDUCATOR, V41, P224, DOI 10.1177/0145721714567235; Maujean A, 2015, ANTHROZOOS, V28, P23, DOI 10.2752/089279315X14129350721812; Meehan M, 2017, ANTHROZOOS, V30, P273, DOI 10.1080/08927936.2017.1311050; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Mubanga M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16118-6; Mueller MK, 2018, BMC PUBLIC HEALTH, V18, DOI [10.1186/s12889-018-5188-0, 10.1186/s12889-018-5585-4]; Mullersdorf M, 2010, SCAND J PUBLIC HEALT, V38, P53, DOI 10.1177/1403494809344358; Murthy R, 2015, INFECT CONT HOSP EP, V36, P495, DOI 10.1017/ice.2015.15; National Institute for Health and Care Excellence (NICE), 2012, METH DEV NICE PUBL H, VThird; New J, 2007, P NATL ACAD SCI USA, V104, P16598, DOI 10.1073/pnas.0703913104; Nimer J, 2007, ANTHROZOOS, V20, P225, DOI 10.2752/089279307X224773; Palmer R, 2008, APPL ANIM BEHAV SCI, V109, P306, DOI 10.1016/j.applanim.2007.04.002; Parker GB, 2010, ACTA PSYCHIAT SCAND, V121, P65, DOI 10.1111/j.1600-0447.2009.01410.x; Pickard M. B., 2011, ANIMALS AFFECT US EX, P85, DOI [10.1037/12301-004, DOI 10.1037/12301-004]; Popay J, 2006, NARRATIVE SYNTHESIS, DOI [10.13140/2.1.1018.4643, DOI 10.13140/2.1.1018.4643]; Powell L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200276; Prato-Previde E, 2003, BEHAVIOUR, V140, P225, DOI 10.1163/156853903321671514; Pu LH, 2019, GERONTOLOGIST, V59, pE37, DOI 10.1093/geront/gny046; Riddick C.C., 1985, MARRIAGE FAM REV, V8, P163, DOI [10.1300/J002v08n03_12, DOI 10.1300/J002V08N03_12]; Sahrmann JM, 2016, ZOO BIOL, V35, P4, DOI 10.1002/zoo.21257; Sanchez M, 2015, PAIN RES MANAG, V20, pE28, DOI 10.1155/2015/419412; Sanders MJ, 2013, AM J OCCUP THER, V67, P91, DOI 10.5014/ajot.2013.005033; Saunders J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179494; Serpell J, 2017, APPL DEV SCI, V21, P223, DOI 10.1080/10888691.2016.1262775; Shapiro K, 2010, SOC ANIM, V18, P307, DOI 10.1163/156853010X510807; Simmons SF, 2000, J AM GERIATR SOC, V48, P209, DOI 10.1111/j.1532-5415.2000.tb03914.x; Staats S, 2008, SOC ANIM, V16, P279, DOI 10.1163/156853008X323411; Stanley IH, 2014, AGING MENT HEALTH, V18, P394, DOI 10.1080/13607863.2013.837147; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; Torske MO, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179832; Ulrich R. S., 1993, BIOPHILIA HYPOTHESIS, P73, DOI DOI 10.3389/FPSYG.2020.00511; Volkert D, 2015, CLIN NUTR, V34, P1052, DOI 10.1016/j.clnu.2015.09.004; Wells DL, 2009, J SOC ISSUES, V65, P523, DOI 10.1111/j.1540-4560.2009.01612.x; Wells DL, 2005, STRESS HEALTH, V21, P209, DOI 10.1002/smi.1057; Wilson E.O, 1984, BIOPHILIA, DOI DOI 10.2307/J.CTVK12S6H; Zilcha-Mano S, 2012, J RES PERS, V46, P571, DOI 10.1016/j.jrp.2012.06.005	106	10	10	3	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2019	14	7							e0220524	10.1371/journal.pone.0220524	http://dx.doi.org/10.1371/journal.pone.0220524			36	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IV1OL	31356652	Green Published, gold, Green Submitted			2023-01-03	WOS:000484047000038
J	Rocha, JVM; Nunes, C; Santana, R				Muniz Rocha, Joao Victor; Nunes, Carla; Santana, Rui			Avoidable hospitalizations in Brazil and Portugal: Identifying and comparing critical areas through spatial analysis	PLOS ONE			English	Article							CARE-SENSITIVE CONDITIONS; FAMILY HEALTH STRATEGY; GEOGRAPHIC-VARIATION; PROJECT-ICSAP; ADMISSION; TRENDS; RATES	Background Hospitalizations for ambulatory care sensitive conditions have been used to assess the performance of primary health care. Few studies have compared geographic variation in rates of avoidable hospitalizations and characteristics of high-risk areas within and between countries. The aim of this study was to identify and compare critical areas of avoidable hospitalizations in Brazil and Portugal, because these countries have reformed their primary health care systems in recent years and have similar organizational characteristics. Methods An ecological study on hospitalizations for ambulatory care sensitive conditions produced in Brazil and Portugal in 2015 was used. Geographic variation of rates were analyzed and compared at the municipal level. A spatial scan statistic was employed to identify clusters with higher risk of hospitalizations for acute and chronic conditions in each country separately. Socioeconomic and primary health care characteristics of critical areas were compared to non-critical areas. Results There were high variations in rates of avoidable hospitalizations within and between Brazil and Portugal, with higher variations found in Brazil. A more evident pattern of rates was found in Portugal. Rates and cluster distribution of acute and chronic conditions had significant agreement for both countries. The differences in primary health care and socioeconomic characteristics between areas identified as high risk clusters and non-clusters varied between category of conditions and between countries. Conclusion Brazil and Portugal presented expressive regional differences with respect to rates of avoidable hospitalizations, indicating that there is room to improve by reducing such events in both countries. Different areas presented distinct interactions between primary health care, socioeconomic characteristics, and avoidable hospitalizations. Results indicate that the primary health care reforms, with similar organizational characteristics in different contexts, did not produce similar results either between or within countries. Possible actions to reduce these events should be defined at a local level.	[Muniz Rocha, Joao Victor; Nunes, Carla; Santana, Rui] Univ Nova Lisboa, Escola Nacl Saude Publ, Lisbon, Portugal; [Muniz Rocha, Joao Victor; Nunes, Carla; Santana, Rui] Univ Nova Lisboa, Ctr Invest Saude Publ, Lisbon, Portugal	Universidade Nova de Lisboa; Universidade Nova de Lisboa	Rocha, JVM (corresponding author), Univ Nova Lisboa, Escola Nacl Saude Publ, Lisbon, Portugal.; Rocha, JVM (corresponding author), Univ Nova Lisboa, Ctr Invest Saude Publ, Lisbon, Portugal.	jv.rocha@ensp.unl.pt	Rocha, Joao/HII-9975-2022	Muniz Rocha, Joao Victor/0000-0002-8660-490X	Erasmus Mundus Joint Doctoral Program on Dynamics of Health and Welfare - Phoenix JDP Erasmus+ [2012-1727]	Erasmus Mundus Joint Doctoral Program on Dynamics of Health and Welfare - Phoenix JDP Erasmus+	JR has a PhD grant from Erasmus Mundus Joint Doctoral Program on Dynamics of Health and Welfare - Phoenix JDP Erasmus+. Grant Agreement no. 2012-1727. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adminstracao Central do Servico de Saude, 2016, PUBL PER NUM UT INSC; Agency for Healthcare Research and Quality, 2018, PREV QUAL IND OV; Alfradique ME, 2009, CAD SAUDE PUBLICA, V25, P1337, DOI 10.1590/S0102-311X2009000600016; Ansari Z, 2007, AUST J PRIM HEALTH, V13, P91, DOI 10.1071/PY07043; Bastos ML, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182336; Berlin C, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-289; Biscaia AR, 2017, CIENC SAUDE COLETIVA, V22, P701, DOI 10.1590/1413-81232017223.33152016; Busby J, 2017, BMC FAM PRACT, P1, DOI [10.1186/s12875-016-0573-1, DOI 10.1186/S12875-016-0573-1]; Ceccon Roger Flores, 2014, Rev. bras. epidemiol., V17, P968, DOI 10.1590/1809-4503201400040014; Conway R, 2016, CLIN MED, V16, P119, DOI 10.7861/clinmedicine.16-2-119; Couttolenc B, 2013, UNICO STUDIES SERIES; Dahlgren G., 2006, EUROPEAN STRATEGIE 2, V3; de Sa FD, 2016, FAM PRACT, V33, P243, DOI 10.1093/fampra/cmv096; Direc-Geral da Saude Institute for Health Metrics and Evaluation, 2018, PORT NAT HLTH 1990 2; Dourado I, 2011, MED CARE, V49, P577, DOI 10.1097/MLR.0b013e31820fc39f; Entidade Reguladora da Saude, 2016, EST UN SAUD FAM UN C; Falster MO, 2015, MED CARE, V53, P436, DOI 10.1097/MLR.0000000000000342; Freund T, 2013, ANN FAM MED, V11, P363, DOI 10.1370/afm.1498; Gervas J, 2007, REV ESP SALUD PUBLIC, V81, P7, DOI 10.1590/S1135-57272007000100002; Gibbons DC, 2012, J ROY SOC MED, V105, P422, DOI 10.1258/jrsm.2012.120178; Hossain M, 2009, INT J HEALTH GEOGR, V8, DOI 10.1186/1476-072X-8-51; Huntley A, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004746; Kulldorff M, 1997, COMMUN STAT-THEOR M, V26, P1481, DOI 10.1080/03610929708831995; Laditka JN, 2005, HEALTH SERV RES, V40, P1148, DOI 10.1111/j.1475-6773.2005.00403.x; Longman JM, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1137-0; Macinko J, 2015, NEW ENGL J MED, V372, P2177, DOI 10.1056/NEJMp1501140; Macinko J, 2011, AM J PUBLIC HEALTH, V101, P1963, DOI 10.2105/AJPH.2010.198887; Magan P, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-42; Malta DC, 2016, CIENC SAUDE COLETIVA, V21, P327, DOI 10.1590/1413-81232015212.23602015; Marinho F, 2018, LANCET, V6736, P1; Mendes EV, 2012, CUIDADO CONDICOES CR; Ministerio da Saude de Portugal, 2012, PLAN NAC SAUD 2012 2; National Cancer Institute, 2017, FOOD FREQUENCY QUEST; Nedel FB, 2011, CIENC SAUDE COLETIVA, V16, P1145, DOI 10.1590/S1413-81232011000700046; Noronha KVMD, 2005, REV PANAM SALUD PUBL, V17, P410, DOI 10.1590/S1020-49892005000500013; OECD, 2016, SOC GLANCE 2016 OECD, DOI [10.1787/eag-2016-en, DOI 10.1787/9789264261488-EN, 10.1787/9789264261488-en]; Pagotto V, 2013, CIENC SAUDE COLETIVA, V18, P3061, DOI 10.1590/S1413-81232013001000031; Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8; Payne RA, 2013, CAN MED ASSOC J, V185, P1; Purdy S, 2009, PUBLIC HEALTH, V123, P169, DOI 10.1016/j.puhe.2008.11.001; Rosano A, 2011, EPIDEMIOL BIOSTAT PU, V8, P77; Rosano A, 2013, J PUBLIC HEALTH-HEID, V21, P445, DOI 10.1007/s10389-013-0563-x; Rosychuk RJ., 2006, INT J HEALTH GEOGR, V11, P1; Sarmento J, 2015, ACTA MEDICA PORT, V28, P590, DOI 10.20344/amp.6324; Saxena S, 2006, J ROY SOC MED, V99, P81, DOI 10.1258/jrsm.99.2.81; Silva Miguel L, 2010, CUIDADOS SAUDE PRIMA; Simoes JD, 2017, HEALT SYST TRANSIT, V19, P1; Tello J, 2015, HLTH SERVICES DELIVE; Thygesen LC, 2015, EUR J PUBLIC HEALTH, V25, P35, DOI 10.1093/eurpub/cku227; Tian, 2012, DATA BRIEFING EMERGE; United Nations, 2015, STESASERA390 UN; Weeks WB, 2016, EUR J HEALTH ECON, V17, P453, DOI 10.1007/s10198-015-0692-y; World Health Organization, 2010, INCREASING ACCESS HL, V23; World Health Organization, 2016, ASS HLTH SERV DEL PE	54	8	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 12	2019	14	7							e0219262	10.1371/journal.pone.0219262	http://dx.doi.org/10.1371/journal.pone.0219262			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4NB	31299045	Green Published, gold, Green Submitted			2023-01-03	WOS:000484955800002
J	Warraich, HJ; Meier, DE				Warraich, Haider J.; Meier, Diane E.			Serious-Illness Care 2.0-Meeting the Needs of Patients with Heart Failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							OLDER-ADULTS		[Warraich, Haider J.] Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA; [Meier, Diane E.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY 10029 USA; [Meier, Diane E.] Icahn Sch Med Mt Sinai, Ctr Adv Palliat Care, New York, NY 10029 USA	Duke University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Warraich, HJ (corresponding author), Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA.							Bekelman DB, 2018, JAMA INTERN MED, V178, P511, DOI 10.1001/jamainternmed.2017.8667; Dabbouseh NM, 2018, AM J HOSP PALLIAT ME, V35, P284, DOI 10.1177/1049909117703728; Gelfman LP, 2018, JACC-HEART FAIL, V6, P780, DOI 10.1016/j.jchf.2018.04.009; Kelley AS, 2017, HEALTH SERV RES, V52, P113, DOI 10.1111/1475-6773.12479; Lum HD, 2016, CLIN GERIATR MED, V32, P247, DOI 10.1016/j.cger.2016.01.011	5	14	14	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	2019	380	26					2492	2494		10.1056/NEJMp1900584	http://dx.doi.org/10.1056/NEJMp1900584			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IN7CS	31242359				2023-01-03	WOS:000478840000004
J	Minnaar, CA; Kotzen, JA; Ayeni, OA; Naidoo, T; Tunmer, M; Sharma, V; Vangu, MD; Baeyens, A				Minnaar, Carrie Anne; Kotzen, Jeffrey Allan; Ayeni, Olusegun Akinwale; Naidoo, Thanushree; Tunmer, Mariza; Sharma, Vinay; Vangu, Mboyo-Di-Tamba; Baeyens, Ans			The effect of modulated electro-hyperthermia on local disease control in HIV-positive and -negative cervical cancer women in South Africa: Early results from a phase III randomised controlled trial	PLOS ONE			English	Article							WEEKLY SYSTEMIC CISPLATIN; LOCOREGIONAL HYPERTHERMIA; REGIONAL HYPERTHERMIA; HUMAN-PAPILLOMAVIRUS; DEEP HYPERTHERMIA; PLUS HYPERTHERMIA; INFECTED WOMEN; CLINICAL-TRIAL; RADIOTHERAPY; CARCINOMA	Background The global burden of cervical cancer remains high with the highest morbidity and mortality rates reported in developing countries. Hyperthermia as a chemo- and radiosensitiser has shown to improve treatment outcomes. This is an analysis of the local control results at six months post-treatment of patients enrolled in an ongoing study investigating the effects of the addition of modulated electro-hyperthermia (mEHT) to chemoradiotherapy for the treatment of HIV-positive and -negative cervical cancer patients in a low-resource setting. Methods This ongoing Phase III randomised controlled trial, conducted at a state hospital in Johannesburg, South Africa, was registered with the appropriate ethics committee. After signing an informed consent, participants with FIGO stages IIB to IIIB squamous cell carcinoma of the cervix were randomised to receive chemoradiotherapy with/without mEHT using a secure online random-sampling tool (stratum: HIV status) accounting for age and stage. Reporting physicians were blind to treatment allocation. HIV-positive participants on antiretroviral treatment, or with a CD4 count >200cell/mu L were included. mEHT was administered 2/weekly immediately before external beam radiation. The primary end point is local disease control (LDC) and secondary endpoints are toxicity; quality of life analysis; and two year survival. We report on six month LDC, including nodes visualised in the radiation field on F-18-FDG PET/CT (censored for six month survival), and six month local disease free survival (LDFS) (based on intention to treat). Trial status: Recruitment closed (ClinicalTrials. gov: NCT03332069). Results 271 participants were recruited between January 2014 and November 2017, of which 210 were randomised for trial and 202 were available for analysis at six months post-treatment (mEHT: n = 101; Control: n = 101). Six month LDFS was higher in the mEHT Group (n = 39 [38.6%]), than in the Control Group (n = 20[19.8%]); p = 0.003). LDC was also higher in the mEHT Group (n = 40[45.5%]) than the Control Group (n = 20[24.1%]); (p = 0.003). Conclusion Our results show that mEHT is effective as a chemo-radiosensitiser for cervical cancer, even in high risk a patients and resource-constrained settings.	[Minnaar, Carrie Anne; Baeyens, Ans] Univ Witwatersrand, Radiobiol, Dept Radiat Sci, Johannesburg, South Africa; [Kotzen, Jeffrey Allan; Naidoo, Thanushree; Tunmer, Mariza] Wits Donald Gordon Med Ctr, Dept Radiat Oncol, Johannesburg, South Africa; [Ayeni, Olusegun Akinwale; Vangu, Mboyo-Di-Tamba] Charlotte Maxeke Johannesburg Acad Hosp, Dept Nucl Med, Johannesburg, South Africa; [Tunmer, Mariza; Sharma, Vinay] Univ Witwatersrand, Radiat Oncol, Dept Radiat Sci, Johannesburg, South Africa; [Vangu, Mboyo-Di-Tamba] Univ Witwatersrand, Nucl Med, Dept Radiat Sci, Johannesburg, South Africa; [Baeyens, Ans] Univ Ghent, Radiobiol, Dept Human Struct & Repair, Ghent, Belgium	University of Witwatersrand; University of Witwatersrand; University of Witwatersrand; University of Witwatersrand; Ghent University	Baeyens, A (corresponding author), Univ Witwatersrand, Radiobiol, Dept Radiat Sci, Johannesburg, South Africa.; Baeyens, A (corresponding author), Univ Ghent, Radiobiol, Dept Human Struct & Repair, Ghent, Belgium.	Ans.Baeyens@Ugent.be		Baeyens, Ans/0000-0002-2578-7917; Ayeni, Olusegun Akinwale/0000-0001-6754-4553	National Research Foundation of South Africa (NRF) [TP12082710852]	National Research Foundation of South Africa (NRF)(National Research Foundation - South Africa)	The study was funded by the National Research Foundation of South Africa (NRF), URL: https://www.nrf.ac.za/, Grant number: TP12082710852, Awarded to J.A.Kotzen. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andocs G, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.39; Andocs G, 2015, CELL STRESS CHAPERON, V20, P37, DOI 10.1007/s12192-014-0523-6; Andocs G, 2009, STRAHLENTHER ONKOL, V185, P120, DOI 10.1007/s00066-009-1903-1; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen HW, 1997, ZHONGHUA ZHONG LIU Z, V24, P249; Chhabra S, 2016, CANC SURG, V1, P1; Coghill AE, 2013, AIDS, V27, P2933, DOI 10.1097/01.aids.0000433236.55937.cb; D'Ambrosio V, 2007, MED BIOL ENG COMPUT, V45, P459, DOI 10.1007/s11517-007-0177-y; Dani A., 2012, ONCOTHERMIA J, V6, P11; Datta N, 1987, INDIAN MED GAZETTE, V121, P68; Datta NR, 2016, INT J HYPERTHER, V32, P809, DOI 10.1080/02656736.2016.1195924; de Wit R, 1999, BRIT J CANCER, V80, P1387, DOI 10.1038/sj.bjc.6690533; Denny L, 2012, CANCER EPIDEM BIOMAR, V21, P1434, DOI 10.1158/1055-9965.EPI-12-0334; Dewhirst MW, 2005, INT J HYPERTHER, V21, P779, DOI 10.1080/02656730500271668; Dryden-Peterson S, 2016, J CLIN ONCOL, V34, P3749, DOI 10.1200/JCO.2016.67.9613; Einstein MH, 2019, GYNECOL ONCOL, V153, P20, DOI 10.1016/j.ygyno.2019.01.023; Elming PB, 2019, CANCERS, V11, DOI 10.3390/cancers11010060; Fatehi D, 2006, INT J HYPERTHER, V22, P353, DOI 10.1080/02656730600715796; Ferlay J, 2018, CANC TODAY POWERED P; Fiorentini G, 2013, OCOTHERMIA J, V7, P2013; Fiorentini Giammaria, 2006, J Cancer Res Ther, V2, P41; Firnhaber C, 2009, ACTA CYTOL, V53, P10, DOI 10.1159/000325079; Flameling B, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.e17023; Franckena M, 2008, INT J RADIAT ONCOL, V70, P1176, DOI 10.1016/j.ijrobp.2007.07.2348; Franckena M, 2007, INT J HYPERTHER, V23, P443, DOI 10.1080/02656730701549359; Franckena M, 2009, INT J RADIAT ONCOL, V73, P242, DOI 10.1016/j.ijrobp.2008.03.072; Frey B, 2012, CURR MED CHEM, V19, P1751, DOI 10.2174/092986712800099811; Ghebre RG, 2017, GYNECOL ONCOL REP, V21, P101, DOI 10.1016/j.gore.2017.07.009; Gichangi P, 2006, GYNECOL ONCOL, V100, P405, DOI 10.1016/j.ygyno.2005.10.006; Grover S, 2015, FRONT ONCOL, V4, P380, DOI [DOI 10.3389/fonc.2014.00380, DOI 10.3389/FONC.2014.00380]; Hansen HV, 2015, EUR J NUCL MED MOL I, V42, P1833, DOI 10.1007/s00259-015-3113-7; Harima Y, 2009, INT J HYPERTHER, V25, P338, DOI 10.1080/02656730903092018; Harima Y, 2016, INT J HYPERTHER, V32, P801, DOI 10.1080/02656736.2016.1213430; Herd O, 2016, MOL MED REP, V13, P130, DOI 10.3892/mmr.2015.4504; Huilgol N, 2014, ONCOTHERMIA J, V10, P64; Hurwitz M, 2014, SEMIN ONCOL, V41, P714, DOI 10.1053/j.seminoncol.2014.09.014; Hyun OJ, 2016, RADIOLOGY, V280, P576, DOI 10.1148/radiol.2016142043; de la Pena MJ, 2008, GYNECOL ONCOL, V110, pS49, DOI 10.1016/j.ygyno.2008.05.030; Kok HP, 2018, INT J HYPERTHER, V34, P714, DOI 10.1080/02656736.2018.1448119; Lee SY, 2017, ONCOL LETT, V14, P73, DOI 10.3892/ol.2017.6117; Lee SY, 2018, INT J HYPERTHER, V34, P953, DOI 10.1080/02656736.2018.1423709; Lutgens Ludy, 2010, Cochrane Database Syst Rev, pCD006377, DOI 10.1002/14651858.CD006377.pub2; Magne N, 2008, CANCER TREAT REV, V34, P671, DOI 10.1016/j.ctrv.2008.08.003; Marth C, 2017, ANN ONCOL, V28, P72, DOI 10.1093/annonc/mdx220; Moodley M, 2009, SOUTH AFR J GYNAECOL, V1, P11, DOI 10.1080/20742835.2009.11441128; Morkel M, 2018, INT J GYNECOL CANCER, V28, P379, DOI 10.1097/IGC.0000000000001174; National Cancer Registry, 2014, CANC S AFR 2013 FULL; Oei AL, 2015, CANCER RES, V75, P5120, DOI 10.1158/0008-5472.CAN-15-0816; Oei AL, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0462-0; Pandita TK, 2009, CRIT REV EUKAR GENE, V19, P235, DOI 10.1615/CritRevEukarGeneExpr.v19.i3.50; Papp E., 2017, OPEN J BIOPHYS, V7, P216, DOI [DOI 10.4236/OJBIPHY.2017.74016, 10.4236/ojbiphy.2017.74016]; Pecorelli S, 2009, INT J GYNECOL OBSTET, V105, P103, DOI 10.1016/j.ijgo.2009.02.012; Peeken JC, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00132; Pew Research Center, 2018, AUD PODC FACT SHEET; Potter R, 2018, CLIN TRANSL RAD ONCO, V9, P48, DOI 10.1016/j.ctro.2018.01.001; Rietbroek RC, 1996, INT J RADIAT ONCOL, V34, P887, DOI 10.1016/0360-3016(95)02152-3; Sapienza LG, 2017, GYNECOL ONCOL, V144, P312, DOI 10.1016/j.ygyno.2016.11.044; Sharma S, 1991, Asia Oceania J Obstet Gynaecol, V17, P5; Shrestha Aamod Dhoj, 2018, Asian Pac J Cancer Prev, V19, P319; Simonds HM, 2015, INT J GYNECOL CANCER, V25, P884, DOI 10.1097/IGC.0000000000000441; Sreenivasa G, 2006, INT J RADIAT ONCOL, V66, P1159, DOI 10.1016/j.ijrobp.2006.06.052; Szasz A, 2001, DTSCH Z ONKOLOGIE, V33, P91; Szasz A, 2011, PRINCIPLES PRACTICE, P194; Szasz Andras, 2014, Korean J Thorac Cardiovasc Surg, V47, P77, DOI 10.5090/kjtcs.2014.47.2.77; Szasz O., 2018, OPEN J BIOPHYS, V8, P31, DOI DOI 10.4236/ojbiphy.2018.81004; Szasz O, 2016, ONCOTHERMIA J, V17, P38; Szasz O, 2016, OPEN J BIOPHYS, V6, P53, DOI DOI 10.4236/ojbiphy.2016.63007; Szigeti GP, 2016, J CANC DIAGNOSIS, V1, P1; Testa AC, 2014, BEST PRACT RES CL OB, V28, P741, DOI 10.1016/j.bpobgyn.2014.04.009; Tsang YW, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1690-2; van der Zee J, 2000, LANCET, V355, P1119, DOI 10.1016/S0140-6736(00)02059-6; van der Zee J, 2002, ANN ONCOL, V13, P1173, DOI 10.1093/annonc/mdf280; van Leeuwen CM, 2017, RADIAT ONCOL, V12, DOI 10.1186/s13014-017-0813-0; Vasanthan A, 2005, INT J RADIAT ONCOL, V61, P145, DOI 10.1016/j.ijrobp.2004.04.057; Westermann AM, 2005, CANCER, V104, P763, DOI 10.1002/cncr.21128	75	37	39	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2019	14	6							e0217894	10.1371/journal.pone.0217894	http://dx.doi.org/10.1371/journal.pone.0217894			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IT5EM	31216321	Green Published, gold, Green Submitted			2023-01-03	WOS:000482885300026
J	Stephenson, J; Vogel, C; Hall, J; Hutchinson, J; Mann, S; Duncan, H; Woods-Townsend, K; de Lusignan, S; Poston, L; Cade, J; Godfrey, K; Hanson, M; Barrett, G; Barker, M; Conti, G; Shannon, G; Colbourn, T				Stephenson, Judith; Vogel, Christina; Hall, Jennifer; Hutchinson, Jayne; Mann, Sue; Duncan, Helen; Woods-Townsend, Kathryn; de Lusignan, Simon; Poston, Lucilla; Cade, Janet; Godfrey, Keith; Hanson, Mark; Barrett, Geraldine; Barker, Mary; Conti, Gabriella; Shannon, Geordan; Colbourn, Tim		Preconception Partnership	Preconception health in England: a proposal for annual reporting with core metrics	LANCET			English	Article							UK; PREVENTION; INFLUENZA	There is growing interest in preconception health as a crucial period for influencing not only pregnancy outcomes, but also future maternal and child health, and prevention of long-term medical conditions. Successive national and international policy documents emphasise the need to improve preconception health, but resources and action have not followed through with these goals. We argue for a dual intervention strategy at both the public health level (eg, by improving the food environment) and at the individual level (eg, by better identification of those planning a pregnancy who would benefit from support to optimise health before conception) in order to raise awareness of preconception health and to normalise the notion of planning and preparing for pregnancy. Existing strategies that target common risks factors, such as obesity and smoking, should recognise the preconception period as one that offers special opportunity for intervention, based on evidence from life-course epidemiology, developmental (embryo) programming around the time of conception, and maternal motivation. To describe and monitor preconception health in England, we propose an annual report card using metrics from multiple routine data sources. Such a report card should serve to hold governments and other relevant agencies to account for delivering interventions to improve preconception health.	[Stephenson, Judith; Hall, Jennifer; Barrett, Geraldine] UCL, Elizabeth Garrett Anderson Inst Womens Hlth, 74 Huntley St, London WC1E 6AU, England; [Conti, Gabriella] UCL, Dept Econ, London, England; [Conti, Gabriella] UCL, Dept Social Sci, London, England; [Shannon, Geordan; Colbourn, Tim] UCL, UCL Inst Global Hlth, Global Hlth Epidemiol & Evaluat, London, England; [Vogel, Christina; Barker, Mary] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, NY USA; [Hanson, Mark] Univ Southampton, Inst Dev Sci, Southampton, NY USA; [Hutchinson, Jayne; Cade, Janet] Univ Leeds, Sch Food Sci & Nutr, Nutr Epidemiol Grp, Leeds, W Yorkshire, England; [Mann, Sue; Duncan, Helen] Publ Hlth England, London, England; [Woods-Townsend, Kathryn] Univ Southampton, Southampton Educ Sch, Southampton, Hants, England; [Woods-Townsend, Kathryn] Univ Hosp Southampton, NIHR Southampton Biomed Res Ctr, Southampton, Hants, England; [de Lusignan, Simon] Univ Oxford, Nuffield Dept Primary Hlth Care Sci, Oxford, England; [de Lusignan, Simon] Royal Coll Gen Practitioners, London, England; [Poston, Lucilla] St Thomas Hosp, Kings Coll London, Fac Life Sci & Med, Sch Life Course Sci, London, England; [Godfrey, Keith] Univ Southampton, Univ Hosp Southampton, NIHR Southampton, Biomed Res Ctr,MRC Lifecourse Epidemiol Unit, Southampton, Hants, England	University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; University of Leeds; Public Health England; University of Southampton; University of Oxford; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Southampton	Stephenson, J (corresponding author), UCL, Elizabeth Garrett Anderson Inst Womens Hlth, 74 Huntley St, London WC1E 6AU, England.	judith.stephenson@ucl.ac.uk	Colbourn, Tim/AAE-6645-2019; Hanson, Mark/AAE-8236-2019; Cade, Janet/G-4250-2016	Colbourn, Tim/0000-0002-6917-6552; Hanson, Mark/0000-0002-6907-613X; Barker, Mary/0000-0003-2976-0217; Vogel, Christina/0000-0002-3897-3786; Poston, Lucilla/0000-0003-1100-2821; Barrett, Geraldine/0000-0002-9738-1051; Cade, Janet/0000-0003-3421-0121; Godfrey, Keith/0000-0002-4643-0618; Woods-Townsend, Kathryn/0000-0003-3376-6988; Conti, Gabriella/0000-0003-4699-2490	British Heart Foundation [RG/15/17/31749, PG/14/33/30827] Funding Source: Medline; Medical Research Council [MC_UU_12011/4, MR/N011848/1] Funding Source: Medline; Department of Health [DRF-2011-04-015, PHR/17/44/46, RP-PG-0216-20004] Funding Source: Medline; ESRC [ES/M001660/1] Funding Source: UKRI; MRC [MC_UU_12011/4, MR/N011848/1] Funding Source: UKRI	British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health; ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ahern AL, 2017, LANCET, V389, P2214, DOI 10.1016/S0140-6736(17)30647-5; American College of Obstetricians and Gynecologists, 2005, Obstet Gynecol, V106, P665; [Anonymous], 2018, LANCET SERIES PRECON; Barker M, 2018, LANCET, V391, P1853, DOI [10.1016/s0140-6736(18)30313-1, 10.1016/S0140-6736(18)30313-1]; Barrett G, 2004, J EPIDEMIOL COMMUN H, V58, P426, DOI 10.1136/jech.2003.014787; Black C, 2014, HEALTH PLACE, V27, P229, DOI 10.1016/j.healthplace.2013.09.015; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; Davies S., 2015, ANN REPORT CHIEF MED; de Lusignan S, 2006, FAM PRACT, V23, P253, DOI 10.1093/fampra/cmi106; de Lusignan S, 2017, BRIT J GEN PRACT, V67, P440, DOI 10.3399/bjgp17X692645; Department for Education, 2018, REL ED REL SEX ED HL; Department of Health, 1991, DIET REF VAL FOOD EN; Fleming TP, 2018, LANCET, V391, P1842, DOI [10.1016/s0140-6736(18)30312-x, 10.1016/S0140-6736(18)30312-X]; GOV. UK, 2018, PUBL HLTH OUTC FRAM; GOV. UK, 2018, GUID PREC CAR MAK CA; GOV. UK, 2018, STAT DAT SET FAM FOO; Hagell A, 2017, KEY DATA YOUNG PEOPL; Hall JA, 2016, J FAM PLAN REPROD H, V42, P75, DOI 10.1136/jfprhc-2015-101310; Hanson MA, 2015, INT J GYNECOL OBSTET, V131, pS213, DOI 10.1016/S0020-7292(15)30034-5; Herrett E, 2015, INT J EPIDEMIOL, V44, P827, DOI 10.1093/ije/dyv098; Korbin J., 2014, HDB CHILD WELL BEING, DOI DOI 10.1007/978-90-481-9063-8; Kousoulis AA, 2015, BRIT J GEN PRACT, V65, P54, DOI 10.3399/bjgp15X683353; Maguire ER, 2015, HEALTH PLACE, V33, P142, DOI 10.1016/j.healthplace.2015.02.012; Mastroiacovo P, 2011, BIOFACTORS, V37, P272, DOI 10.1002/biof.172; Maternal Newborn and Infant Clinical Outcome Review Programme, 2017, SAV LIV IMPR MOTH CA; Morris JK, 2016, ARCH DIS CHILD, V101, P604, DOI 10.1136/archdischild-2015-309226; Pathirannehelage S, 2018, STUD HEALTH TECHNOL, V247, P161, DOI 10.3233/978-1-61499-852-5-161; Penn-Newman D, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022062; Rennie KL, 2007, BRIT J NUTR, V97, P1169, DOI 10.1017/S0007114507433086; Rocca CH, 2019, MED CARE, V57, P152, DOI 10.1097/MLR.0000000000001048; Sacks G, 2013, OBES REV, V14, P38, DOI 10.1111/obr.12074; Scholes S., 2018, HLTH SURVEY ENGLAND; Shah R, 2019, INT COMP HLTH WELLBE; Stephenson J, 2018, LANCET, V391, P1830, DOI [10.1016/S0140-6736(18)30311-8, 10.1016/s0140-6736(18)30311-8]; The Schools and Students Health Education Unit, HLTH WELLB SURV CHIL; United Nations, 2015, SUSTAINABLE DEV GOAL; Vogel C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183700; WHO Policy Brief, 2013, PREC CAR MAX GAINS M; World Health Organisation, 2013, M DEV GLOB CONS PREC; World Health Organization, 2015, GLOB STRAT WOM CHILD; World Health Organization, 2016, 69 WORLD HLTH ASS FR; World Health Organization, 2014, 2 INT C NUTR ROM DEC; World Health Organization, 2018, COMM END CHILDH OB T; World Health Organization, 2014, COMPR IMPL PLAN MAT; World Health Organization Rotary International Centers for Disease Control and Prevention and UNICEF, 2013, GLOB ACT PLAN PREV C	45	34	34	2	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 1	2019	393	10187					2262	2271		10.1016/S0140-6736(19)30954-7	http://dx.doi.org/10.1016/S0140-6736(19)30954-7			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IB1HV	31162084	Green Accepted, Green Submitted			2023-01-03	WOS:000470017100029
J	Yang, CP; Cheng, HM; Lu, MC; Lang, HC				Yang, Chun-Pai; Cheng, Hao-Min; Lu, Mei-Chun; Lang, Hui-Chu			Association between continuity of care and long-term mortality in Taiwanese first-ever stroke survivors: An 8-year cohort study	PLOS ONE			English	Article							CHARLSON COMORBIDITY INDEX; POTENTIALLY INAPPROPRIATE MEDICATION; ACUTE ISCHEMIC-STROKE; PREVENTABLE HOSPITALIZATION; INTRACEREBRAL HEMORRHAGE; ELDERLY-PATIENTS; SEVERITY INDEX; RISK-FACTORS; OUTCOMES; HEALTH	Background Continuity of care is considered to be an important principle of stroke care; however, few analyses of empirically related outcomes have been reported. Objective This study examined the correlation between the continuity of care for outpatients after a stroke event and the survival of stroke patients over the year following hospital discharge. Research design Data from the Taiwan National Health Insurance Database were used in this study. We defined stroke as the ICD-9-CM codes 430 to 437, and all patients were followed up regarding their survival for at least one year. The modified modified continuity index (MMCI) was used as the indicator of continuity of care. Cox proportional hazard models with robust sandwich variance estimates were employed to analyze the correlation between continuity of care and stroke-related death. Results A total of 9,252 stroke patients were included in the analysis. Those patients who had a high and a completed COC had a higher percentage of survival (97.25% and 95.39%) compared to the other two groups. After controlling for other variables, compared with the low-level continuity of care group, the moderate-level, high-level and completed continuity of care groups still showed a significantly lower risk of death HR (95% CI) were: 0.63 (0.49-0.80), 0.56 (0.40-0.79) and 0.50 (0.39-0.63), respectively. Conclusion Continuity of care may increase the survival among stroke patients and therefore plays an important role in management of stroke after survival.	[Yang, Chun-Pai] Kuang Tien Gen Hosp, Dept Neurol, Taichung, Taiwan; [Yang, Chun-Pai; Lu, Mei-Chun] Kuang Tien Gen Hosp, Dept Med Res, Taichung, Taiwan; [Yang, Chun-Pai] Hung Kuang Univ, Dept Nutr, Taichung, Taiwan; [Yang, Chun-Pai] Hung Kuang Univ, Inst Biomed Nutr, Taichung, Taiwan; [Cheng, Hao-Min] Taipei Vet Gen Hosp, Dept Med Educ, Taipei, Taiwan; [Cheng, Hao-Min] Natl Yang Ming Univ, Div Cardiol, Taipei, Taiwan; [Cheng, Hao-Min] Natl Yang Ming Univ, Dept Publ Hlth, Taipei, Taiwan; [Cheng, Hao-Min] Taipei Vet Gen Hosp, Ctr Evidence Based Med, Taipei, Taiwan; [Lu, Mei-Chun] Hung Kuang Univ, Dept Nuring, Taichung, Taiwan; [Lang, Hui-Chu] Natl Yang Ming Univ, Inst Hosp & Hlth Care Adm, Taipei, Taiwan	Hungkuang University; Hungkuang University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; Hungkuang University; National Yang Ming Chiao Tung University	Lang, HC (corresponding author), Natl Yang Ming Univ, Inst Hosp & Hlth Care Adm, Taipei, Taiwan.	hclang@ym.edu.tw	Lang, Hui-Chu/GXG-4373-2022		Ministry of Science and Technology, Taiwan	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	This research was funded by the Ministry of Science and Technology, Taiwan to HC Lang and HM Cheng. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barker I, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j84; BENSIRA Z, 1980, J HEALTH SOC BEHAV, V21, P170, DOI 10.2307/2136736; BICE TW, 1977, MED CARE, V15, P347, DOI 10.1097/00005650-197704000-00010; Burge F, 2003, MED CARE, V41, P992, DOI 10.1097/00005650-200308000-00012; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chen CC, 2013, MED CARE, V51, P231, DOI 10.1097/MLR.0b013e31827da5b9; Cheng SH, 2014, MED CARE, V52, P149, DOI 10.1097/MLR.0000000000000042; Chiu HY, 2016, TAIWAN J PUBLIC HLTH, V35, P66; Cho KH, 2016, INT J QUAL HEALTH C, V28, P478, DOI 10.1093/intqhc/mzw050; Cho SF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139289; Chu HY, 2012, MED CARE, V50, P1002, DOI 10.1097/MLR.0b013e31826c870f; Denti L, 2015, J STROKE CEREBROVASC, V24, P330, DOI 10.1016/j.jstrokecerebrovasdis.2014.08.034; Falsetti L, 2016, NEUROL SCI, V37, P1443, DOI 10.1007/s10072-016-2602-1; Freeman GK, 2003, FAM PRACT, V20, P623, DOI 10.1093/fampra/cmg601; Haggerty JL, 2003, BRIT MED J, V327, P1219, DOI 10.1136/bmj.327.7425.1219; Hong JS, 2013, HEALTH POLICY, V109, P158, DOI 10.1016/j.healthpol.2012.09.009; Hsieh CY, 2017, J NEUROL SCI, V372, P21, DOI 10.1016/j.jns.2016.11.026; Hsieh FI, 2014, J STROKE, V16, P59, DOI 10.5853/jos.2014.16.2.59; Hsu CH, 2016, J EPIDEMIOL, V26, P413, DOI 10.2188/jea.JE20150045; Hung LC, 2017, J EPIDEMIOL, V27, P24, DOI 10.1016/j.je.2016.08.003; Jee SH, 2006, MED CARE RES REV, V63, P158, DOI 10.1177/1077558705285294; Caballero PEJ, 2013, J STROKE CEREBROVASC, V22, pE214, DOI 10.1016/j.jstrokecerebrovasdis.2012.11.014; Kao YH, 2017, J AM BOARD FAM MED, V30, P384, DOI 10.3122/jabfm.2017.03.160285; Lai YR, 2016, GERIATR GERONTOL INT, V16, P1117, DOI 10.1111/ggi.12606; Leleu H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071669; Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8; Lin HC, 2007, STROKE, V38, P1565, DOI 10.1161/STROKEAHA.106.474841; Lin IP, 2017, HEALTH POLICY, V121, P1001, DOI 10.1016/j.healthpol.2017.06.010; MAGILL MK, 1987, J FAM PRACTICE, V24, P165; Micieli G, 2002, STROKE, V33, P1341, DOI 10.1161/01.STR.0000013663.27776.DB; Napolitano F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154940; Nyweide DJ, 2013, JAMA INTERN MED, V173, P1879, DOI 10.1001/jamainternmed.2013.10059; PATTEN RC, 1980, J FAM PRACTICE, V11, P67; Pilotto LS, 1996, MED J AUSTRALIA, V164, P463, DOI 10.5694/j.1326-5377.1996.tb122121.x; Saultz John W, 2003, Ann Fam Med, V1, P134, DOI 10.1370/afm.23; Saultz JW, 2005, ANN FAM MED, V3, P159, DOI 10.1370/afm.285; Shin DW, 2014, ANN FAM MED, V12, P534, DOI 10.1370/afm.1685; Starfield B, 2005, MILBANK Q, V83, P457, DOI 10.1111/j.1468-0009.2005.00409.x; Sung SF, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1769-8; Sung SF, 2016, INT J CARDIOL, V215, P277, DOI 10.1016/j.ijcard.2016.04.069; Sung SF, 2015, J CLIN EPIDEMIOL, V68, P1292, DOI 10.1016/j.jclinepi.2015.01.009; van Walraven C, 2010, J EVAL CLIN PRACT, V16, P947, DOI 10.1111/j.1365-2753.2009.01235.x; Wolinsky FD, 2010, J GERONTOL A-BIOL, V65, P421, DOI 10.1093/gerona/glp188; Wu CY, 2012, JAMA-J AM MED ASSOC, V308, P1906, DOI 10.1001/2012.jama.11975	44	3	3	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2019	14	5							e0216495	10.1371/journal.pone.0216495	http://dx.doi.org/10.1371/journal.pone.0216495			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HZ1LE	31116786	Green Published, gold, Green Submitted			2023-01-03	WOS:000468607400023
J	Ferguson, L; Fried, S; Matsaseng, T; Ravindran, S; Gruskin, S				Ferguson, Laura; Fried, Susana; Matsaseng, Thabo; Ravindran, Sundari; Gruskin, Sofia			Human rights and legal dimensions of self care interventions for sexual and reproductive health	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							TRANSGENDER PERSONS; IDENTITY		[Ferguson, Laura; Gruskin, Sofia] Univ Southern Calif, Keck Sch Med, Inst Inequal Global Hlth, Los Angeles, CA 90007 USA; [Fried, Susana] Yale Law Sch, Global Hlth Justice Partnership, New Haven, CT USA; [Matsaseng, Thabo] Stellenbosch Univ, Reprod Med Unit, Stellenbosch, Western Cape, South Africa; [Ravindran, Sundari] Sree Chitra Tirunal Inst Med Sci & Technol, Thiruvananthapuram, Kerala, India	University of Southern California; Yale University; Stellenbosch University; Department of Science & Technology (India); Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)	Ferguson, L (corresponding author), Univ Southern Calif, Keck Sch Med, Inst Inequal Global Hlth, Los Angeles, CA 90007 USA.	laurafer@usc.edu	Ferguson, Laura/AAO-9694-2021	Ferguson, Laura/0000-0002-1340-793X				Aguayo-Romero RA, 2015, INT J TRANSGENDERISM, V16, P103, DOI 10.1080/15532739.2015.1075930; Beutel M, 1999, ANDROLOGIA, V31, P27, DOI 10.1046/j.1439-0272.1999.00231.x; Chen X, 2016, J MACH LEARN RES, V17; Elfin DA, 2018, BLOOMBERG LAW; Gibson BA, 2016, GLOB PUBLIC HEALTH, V11, P1010, DOI 10.1080/17441692.2015.1134614; Gruskin S, 2012, GLOB PUBLIC HEALTH, V7, P337, DOI 10.1080/17441692.2011.651733; Klitzman Robert, 2017, AJOB Empir Bioeth, V8, P253, DOI 10.1080/23294515.2017.1394927; Lawrence RE, 2010, OBSTET GYNECOL, V116, P127, DOI 10.1097/AOG.0b013e3181e2f27d; Metastasio A, 2018, BRAIN SCI, V8, DOI 10.3390/brainsci8050088; NARASIMHAN M, 2019, BMJ-BRIT MED J, V365, DOI DOI 10.1136/BMJ.L688; Robles R, 2016, LANCET PSYCHIAT, V3, P850, DOI 10.1016/S2215-0366(16)30165-1; Sanchez NF, 2009, AM J PUBLIC HEALTH, V99, P713, DOI 10.2105/AJPH.2007.132035; UN OHCHR, 2016, PATH BEING LESB GAY; UNFPA, 2010, GEND HUM RIGHTS CULT; White Hughto Jaclyn M, 2016, Transgend Health, V1, P21; WHO, 2014, FRAM ENS HUM RIGHTS; Wood BR, 2014, HIV AIDS-RES PALLIAT, V6, P117, DOI 10.2147/HIV.S49083; World Health Organization, 2018, MEDICAL MANAGEMENT A; World Health Organization (WHO), 2014, ENS HUM RIGHTS PROV	19	13	13	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 13	2019	365								l1941	10.1136/bmj.l1941	http://dx.doi.org/10.1136/bmj.l1941			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ1CS	31085551	Green Published, hybrid			2023-01-03	WOS:000468584200002
J	Engrand, N; Pharaboz, A; Dinkelacker, V				Engrand, Nicolas; Pharaboz, Alexandre; Dinkelacker, Vera			Prophylactic Hypothermia for Severe Traumatic Brain Injury	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Engrand, Nicolas] Fdn Ophtalmol Rothschild, Neurointens Care Unit, 29 Rue Manin, F-75019 Paris, France; [Pharaboz, Alexandre] Hop Lariboisiere, Dept Anesthesie Reanimat, Paris, France; [Dinkelacker, Vera] Fdn Ophtalmol Rothschild, Neurol Dept, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	Engrand, N (corresponding author), Fdn Ophtalmol Rothschild, Neurointens Care Unit, 29 Rue Manin, F-75019 Paris, France.	nengrand@for.paris	ENGRAND, Nicolas/AFV-5864-2022					Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Cooper DJ, 2018, JAMA-J AM MED ASSOC, V320, P2211, DOI 10.1001/jama.2018.17075; Vigue B, 2000, INTENS CARE MED, V26, P722, DOI 10.1007/s001340051238; 2015, J NEUROTRAUM, V32, P422, DOI DOI 10.1089/NEU.2013.3197	5	3	3	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	2019	321	17					1725	1726		10.1001/jama.2019.1534	http://dx.doi.org/10.1001/jama.2019.1534			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX3TE	31063565				2023-01-03	WOS:000467314800025
J	Allegretti, JR; Mullish, BH; Kelly, C; Fischer, M				Allegretti, Jessica R.; Mullish, Benjamin H.; Kelly, Colleen; Fischer, Monika			The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications	LANCET			English	Review							CLOSTRIDIUM-DIFFICILE INFECTION; INFLAMMATORY-BOWEL-DISEASE; ACTIVE ULCERATIVE-COLITIS; INTESTINAL MICROBIOTA; INSULIN SENSITIVITY; CONTROLLED-TRIAL; GUT MICROBIOTA; UNITED-STATES; HOST-DISEASE; DOUBLE-BLIND	Developments in high-throughput microbial genomic sequencing and other systems biology techniques have given novel insight into the potential contribution of the gut microbiota to health and disease. As a result, an increasing number of diseases have been characterised by distinctive changes in the composition and functionality of the gut microbiota; however, whether such changes are cause, consequence, or incidental to the disease in question remains largely uncertain. Restoration of the gut microbiota to a premorbid state is a key novel therapeutic approach of interest, and faecal microbiota transplantation-the transfer of prescreened stool from healthy donors into the gastrointestinal tract of patients-is gaining increasing importance in both the clinical and research settings. At present, faecal microbiota transplantation is only recommended in the treatment of recurrent Clostridioides difficile infection, although a large number of trials are ongoing worldwide exploring other potential therapeutic indications.	[Allegretti, Jessica R.] Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, 75 Francis St, Boston, MA 02115 USA; [Allegretti, Jessica R.] Harvard Med Sch, Boston, MA 02115 USA; [Mullish, Benjamin H.] Imperial Coll London, Div Integrat Syst Med & Digest Dis, Fac Med, London, England; [Kelly, Colleen] Brown Univ, Div Gastroenterol, Alpert Med Sch, Providence, RI 02912 USA; [Fischer, Monika] Indiana Univ, Div Gastroenterol & Hepatol, Indianapolis, IN 46204 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Imperial College London; Brown University; Indiana University System; Indiana University-Purdue University Indianapolis	Allegretti, JR (corresponding author), Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, 75 Francis St, Boston, MA 02115 USA.	jallegretti@bwh.harvard.edu	Mullish, Benjamin H/O-9524-2017	Mullish, Benjamin H/0000-0001-6300-3100	Medical Research Council Clinical Research Training Fellowship [MR/R000875/1]; National Institute of Health Research Imperial Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London; MRC [MC_PC_17162, MR/R000875/1] Funding Source: UKRI	Medical Research Council Clinical Research Training Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute of Health Research Imperial Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	BHM is the recipient of a Medical Research Council Clinical Research Training Fellowship (grant reference: MR/R000875/1). The Division of Integrative Systems Medicine and Digestive Disease at Imperial College receives financial support from the National Institute of Health Research Imperial Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London.	Allegretti JR, 2018, CLIN MICROBIOL INFEC, V24, DOI 10.1016/j.cmi.2017.10.022; Allegretti JR, 2020, CLIN GASTROENTEROL H, V18, P855, DOI 10.1016/j.cgh.2019.07.006; Allegretti JR, 2019, AM J GASTROENTEROL, V114, P1071, DOI 10.14309/ajg.0000000000000115; Allegretti JR, 2018, GASTROINTEST ENDOSC, V87, P18, DOI 10.1016/j.gie.2017.05.036; [Anonymous], 2017, Am J Gastroenterol, V112, pS45, DOI 10.1038/ajg.2017.296; Aroniadis OC, 2018, GASTROENTEROLOGY, V154, pS154; Backhed F, 2012, CELL HOST MICROBE, V12, P611, DOI 10.1016/j.chom.2012.10.012; Bajaj JS, 2019, HEPATOLOGY, V70, P1690, DOI 10.1002/hep.30690; Bajaj JS, 2019, GASTROENTEROLOGY, V156, P1921, DOI 10.1053/j.gastro.2019.01.033; Bajaj JS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060042; Bajaj JS, 2017, INT LIV C AMST NETH; Battaglioli EJ, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aam7019; Bilinski J, 2017, CLIN INFECT DIS, V65, P364, DOI 10.1093/cid/cix252; Buffie CG, 2015, NATURE, V517, P205, DOI 10.1038/nature13828; Burrello C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07359-8; Camacho-Ortiz A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189768; Cammarota G, 2015, ALIMENT PHARM THER, V41, P835, DOI 10.1111/apt.13144; Cammarota G, 2017, GUT, V66, P569, DOI 10.1136/gutjnl-2016-313017; Cammarota G, 2015, ANN INTERN MED, V163, P487, DOI 10.7326/L15-5139; Chilton CH, 2018, CLIN MICROBIOL INFEC, V24, P476, DOI 10.1016/j.cmi.2017.11.017; Costello SP, 2019, JAMA-J AM MED ASSOC, V321, P156, DOI 10.1001/jama.2018.20046; Davidovics ZH, 2019, J PEDIATR GASTR NUTR, V68, P130, DOI 10.1097/MPG.0000000000002205; De Leon LM, 2013, CLIN GASTROENTEROL H, V11, P1036, DOI 10.1016/j.cgh.2013.04.045; Draper LA, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0598-x; EISEMAN B, 1958, SURGERY, V44, P854; Ferreyra JA, 2014, CELL HOST MICROBE, V16, P770, DOI 10.1016/j.chom.2014.11.003; Fischer M, 2015, ALIMENT PHARM THER, V42, P470, DOI 10.1111/apt.13290; Fischer M, 2017, GUT MICROBES, V8, P289, DOI 10.1080/19490976.2016.1273998; Fischer M, 2016, INFLAMM BOWEL DIS, V22, P2402, DOI 10.1097/MIB.0000000000000908; Gratton J, 2016, ANAL CHEM, V88, P4661, DOI 10.1021/acs.analchem.5b04159; Halkjaer SI, 2018, GUT, V67, P2107, DOI 10.1136/gutjnl-2018-316434; Hoffmann D, 2017, SCIENCE, V358, P1390, DOI 10.1126/science.aaq0034; Hoffmann DE, 2017, GUT MICROBES, V8, P208, DOI 10.1080/19490976.2017.1293223; Holster S, 2019, CLIN TRANSL GASTROEN, V10, DOI 10.14309/ctg.0000000000000034; Holvoet T, 2017, GUT, V66, P980, DOI 10.1136/gutjnl-2016-312513; Human Tissue Authority, 2015, REG FAEC MICR TRANSL; Huttner BD, 2019, CLIN MICROBIOL INFEC, V25, P830, DOI 10.1016/j.cmi.2018.12.009; Hvas CL, 2019, GASTROENTEROLOGY, V156, P1324, DOI 10.1053/j.gastro.2018.12.019; Ianiro G, 2018, UNITED EUR GASTROENT, V6, P1232, DOI 10.1177/2050640618780762; Imdad A, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012774.pub2; Jalanka J, 2018, ALIMENT PHARM THER, V47, P371, DOI 10.1111/apt.14443; Jalanka J, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0698-z; Johnsen PH, 2018, LANCET GASTROENTEROL, V3, P17, DOI 10.1016/S2468-1253(17)30338-2; Juul FE, 2018, NEW ENGL J MED, V378, P2535, DOI 10.1056/NEJMc1803103; Kaito S, 2018, BLOOD ADV, V2, P3097, DOI 10.1182/bloodadvances.2018024968; Kakihana K, 2016, BLOOD, V128, P2083, DOI 10.1182/blood-2016-05-717652; Kang DW, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42183-0; Kang DW, 2017, MICROBIOME, V5, DOI 10.1186/s40168-016-0225-7; Kassam Z, 2013, AM J GASTROENTEROL, V108, P500, DOI 10.1038/ajg.2013.59; Kelly CR, 2016, ANN INTERN MED, V165, P609, DOI 10.7326/M16-0271; Kelly CR, 2014, AM J GASTROENTEROL, V109, P1065, DOI 10.1038/ajg.2014.133; Khan KJ, 2011, AM J GASTROENTEROL, V106, P661, DOI 10.1038/ajg.2011.72; Khoruts A, 2018, EXPERT REV GASTROENT, V12, P435, DOI 10.1080/17474124.2018.1465818; Khoruts A, 2016, CLIN GASTROENTEROL H, V14, P1433, DOI 10.1016/j.cgh.2016.02.018; Khoruts A, 2016, NAT REV GASTRO HEPAT, V13, DOI 10.1038/nrgastro.2016.98; Ko CW, 2019, GASTROENTEROLOGY, V156, P748, DOI 10.1053/j.gastro.2018.12.009; Kootte RS, 2017, CELL METAB, V26, P611, DOI 10.1016/j.cmet.2017.09.008; Kummen M, 2017, GUT, V66, P611, DOI 10.1136/gutjnl-2015-310500; Lau JT, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0327-7; Lee CH, 2016, JAMA-J AM MED ASSOC, V315, P142, DOI 10.1001/jama.2015.18098; Lessa FC, 2015, NEW ENGL J MED, V372, P2369, DOI [10.1056/NEJMc1505190, 10.1056/NEJMoa1408913]; Ma GK, 2017, ANN INTERN MED, V167, P152, DOI [10.7326/M16-2733, 10.7326/m16-2733]; McDonald JAK, 2018, GASTROENTEROLOGY, V155, P1495, DOI 10.1053/j.gastro.2018.07.014; McDonald LC, 2018, CLIN INFECT DIS, V66, pE1, DOI [10.1093/cid/cix1085, 10.1093/cid/ciy149]; McDonald LC, 2006, EMERG INFECT DIS, V12, P409, DOI 10.3201/eid1203.051064; Millan B, 2016, CLIN INFECT DIS, V62, P1479, DOI 10.1093/cid/ciw185; Moayyedi P, 2015, GASTROENTEROLOGY, V149, P102, DOI 10.1053/j.gastro.2015.04.001; Mullish BH, 2018, J HOSP INFECT, V100, P130, DOI 10.1016/j.jhin.2018.07.028; Mullish BH, 2019, GUT, V68, P1791, DOI 10.1136/gutjnl-2018-317842; Mullish BH, 2018, GUT, V67, P1920, DOI [10.1016/j.jhin.2018.07.037, 10.1136/gutjnl-2018-316818]; Neal MD, 2011, ANN SURG, V254, P423, DOI 10.1097/SLA.0b013e31822ade48; Newman KM, 2017, GUT MICROBES, V8, P303, DOI 10.1080/19490976.2017.1279377; Ng KM, 2013, NATURE, V502, P96, DOI 10.1038/nature12503; Ogden CL, 2014, JAMA-J AM MED ASSOC, V311, P806, DOI 10.1001/jama.2014.732; Ott SJ, 2017, GASTROENTEROLOGY, V152, P799, DOI 10.1053/j.gastro.2016.11.010; Papanicolas LE, 2019, EBIOMEDICINE, V41, P509, DOI 10.1016/j.ebiom.2019.02.023; Paramsothy S, 2017, J CROHNS COLITIS, V11, P1180, DOI 10.1093/ecco-jcc/jjx063; Paramsothy S, 2017, LANCET, V389, P1218, DOI 10.1016/S0140-6736(17)30182-4; Peng ZY, 2016, ENDOSC INT OPEN, V4, pE610, DOI 10.1055/s-0042-105205; Petrof EO, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-3; Qi XF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02195; Quraishi MN, 2017, ALIMENT PHARM THER, V46, P479, DOI 10.1111/apt.14201; Rabot S, 2010, FASEB J, V24, P4948, DOI 10.1096/fj.10-164921; Rossen NG, 2015, GASTROENTEROLOGY, V149, P110, DOI 10.1053/j.gastro.2015.03.045; Satokari R, 2015, ALIMENT PHARM THER, V41, P46, DOI 10.1111/apt.13009; Schirmer M, 2018, NAT MICROBIOL, V3, P337, DOI 10.1038/s41564-017-0089-z; Sidhu M, 2017, AUST FAM PHYSICIAN, V46, P206; Smith M, 2014, NAT BIOTECHNOL, V32, P867, DOI 10.1038/nbt.3006; Smits LP, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008342; Spindelboeck W, 2017, HAEMATOLOGICA, V102, pE210, DOI 10.3324/haematol.2016.154351; Staley C, 2017, AM J GASTROENTEROL, V112, P940, DOI 10.1038/ajg.2017.6; Stewart DB, 2013, COLORECTAL DIS, V15, P798, DOI 10.1111/codi.12134; Surawicz CM, 2013, AM J GASTROENTEROL, V108, P478, DOI 10.1038/ajg.2013.4; U.S. food and drug administration, 2016, GUID IND ENF POL REG; US Food and Drug Administration, 2019, IMP SAF AL REG US FE; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Vrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031; Wang SA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161174; Weingarden A, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0070-0; Weingarden AR, 2014, AM J PHYSIOL-GASTR L, V306, pG310, DOI 10.1152/ajpgi.00282.2013; Weingarden AR, 2013, J CLIN GASTROENTEROL, V47, P735, DOI 10.1097/MCG.0b013e31829004ae; Zar FA, 2007, CLIN INFECT DIS, V45, P302, DOI 10.1086/519265; Zuo T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06103-6; Zuo T, 2018, GUT, V67, P634, DOI 10.1136/gutjnl-2017-313952	104	143	158	3	63	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 3	2019	394	10196					420	431		10.1016/S0140-6736(19)31266-8	http://dx.doi.org/10.1016/S0140-6736(19)31266-8			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IN5EI	31379333	Green Submitted			2023-01-03	WOS:000478698300027
J	Coletta, AM; Marquez, G; Thomas, P; Thoman, W; Bevers, T; Brewster, AM; Hawk, E; Basen-Engquist, K; Gilchrist, SC				Coletta, Adriana M.; Marquez, Guillermo; Thomas, Parijatham; Thoman, Whittney; Bevers, Therese; Brewster, Abenaa M.; Hawk, Ernest; Basen-Engquist, Karen; Gilchrist, Susan C.			Clinical factors associated with adherence to aerobic and resistance physical activity guidelines among cancer prevention patients and survivors	PLOS ONE			English	Article							BREAST-CANCER; CARDIORESPIRATORY FITNESS; RISK; MORTALITY; EXERCISE; HEALTH; STRENGTH; PARADIGM; PROSTATE	Physical activity (PA) is a known behavior to reduce cancer risk and improve cancer survivorship, yet adherence to PA guidelines is poor among the general population and cancer survivors. The purpose of this study was to determine the extent to which patients referred for exercise consultation within a clinical cancer prevention setting were meeting aerobic and resistance physical activity (PA) guidelines and to identify factors associated with guideline adherence. Between 2013 and 2015, cancer prevention patients and cancer survivors were interviewed by an exercise physiologist within an Integrative Health Program at The University of Texas MD Anderson Cancer Prevention Center. PA adherence was defined as at least 150-minutes of moderate-intensity or 75-minutes of vigorous-intensity PA per week, along with resistance training at least 2 days per week. Logistic regression was used to determine factors associated with meeting or not meeting PA guidelines for aerobic exercise, resistance exercise, and aerobic and resistance exercise combined. Among 1,024 cancer prevention patients and survivors, 9% of patients adhered to guideline-based PA. Adherence to aerobic and resistance guidelines were 20% and 12%, respectively. Overweight or obesity was associated with not meeting guideline-based PA in both cancer prevention patients and cancer survivors. Among breast cancer survivors, combination treatment with surgery, radiation, and chemotherapy ('multimodal therapy') was robustly associated with not meeting aerobic guidelines (OR 2.20, 95% CI: 1.17 to 4.16). BMI and breast cancer treatment history are key determinants of PA behavior among cancer prevention patients and survivors. Poor adherence to PA guidelines is a key issue for cancer prevention patients and survivors, particularly obese patients and women who receive multimodal therapy for breast cancer. Identifying and connecting patients at highest risk of poor PA adherence with exercise programs is needed to improve PA, a key modifiable cancer risk factor.	[Coletta, Adriana M.] Huntsman Canc Inst, Canc Control & Populat Sci Program, Salt Lake City, UT USA; [Coletta, Adriana M.] Univ Utah, Dept Hlth Kinesiol & Recreat, Salt Lake City, UT USA; [Marquez, Guillermo; Thomas, Parijatham; Thoman, Whittney; Bevers, Therese; Brewster, Abenaa M.; Gilchrist, Susan C.] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; [Hawk, Ernest] Univ Texas MD Anderson Canc Ctr, Div OVP Canc Prevent & Populat Sci, Houston, TX 77030 USA; [Basen-Engquist, Karen] Univ Texas MD Anderson Canc Ctr, Dept Behav Sci, Houston, TX 77030 USA; [Gilchrist, Susan C.] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Gilchrist, SC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA.; Gilchrist, SC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA.	sgilchrist@mdanderson.org		Coletta, Adriana/0000-0002-2503-2792	Duncan Family; Center for Energy Balance in Cancer Prevention and Survivorship, Duncan Family Institute; National Cancer Institute of the National Institutes of Health [R25CA057730]; NATIONAL CANCER INSTITUTE [P30CA016672, R25CA057730] Funding Source: NIH RePORTER	Duncan Family; Center for Energy Balance in Cancer Prevention and Survivorship, Duncan Family Institute; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by a gift from the Duncan Family to the University of Texas MD Anderson Cancer Center Duncan Family Institute for Cancer Prevention and Risk Assessment. This study was also supported by the Center for Energy Balance in Cancer Prevention and Survivorship, Duncan Family Institute. We would like to thank the National Cancer Institute of the National Institutes of Health under Award Number R25CA057730 (PI: Shine Chang, PhD) for supporting AMC. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All funders had not role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abioye AI, 2015, BRIT J SPORT MED, V49, P224, DOI 10.1136/bjsports-2013-092778; ALBANES D, 1989, AM J PUBLIC HEALTH, V79, P744, DOI 10.2105/AJPH.79.6.744; [Anonymous], 2018, 2018 PHYSICAL ACTIVI; Crawford JJ, 2016, SUPPORT CARE CANCER, V24, P3533, DOI 10.1007/s00520-016-3173-7; Farrell SW, 2007, OBESITY, V15, P3140, DOI 10.1038/oby.2007.374; Fisher A, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006853; Fong DYT, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e70; Forbes CC, 2015, ONCOL NURS FORUM, V42, P118, DOI 10.1188/15.ONF.42-02AP; Friedenreich CM, 2016, EUR UROL, V70, P576, DOI 10.1016/j.eururo.2015.12.032; Inoue-Choi M, 2013, CANCER EPIDEM BIOMAR, V22, P792, DOI 10.1158/1055-9965.EPI-13-0054; Irwin ML, 2008, J CLIN ONCOL, V26, P3958, DOI 10.1200/JCO.2007.15.9822; Irwin ML, 2004, MED SCI SPORT EXER, V36, P1484, DOI 10.1249/01.MSS.0000074670.03001.98; Jones LW, 2004, ANN BEHAV MED, V28, P105, DOI 10.1207/s15324796abm2802_5; Kabat GC, 2015, AM J CLIN NUTR, V101, P558, DOI 10.3945/ajcn.114.094854; Lahart IM, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011292.pub2; Lakoski SG, 2015, JAMA ONCOL, V1, P231, DOI 10.1001/jamaoncol.2015.0226; Lakoski SG, 2013, BREAST CANCER RES TR, V138, P909, DOI 10.1007/s10549-013-2478-1; Lauby-Secretan B, 2016, NEW ENGL J MED, V375, P794, DOI 10.1056/NEJMsr1606602; Loprinzi P, 2014, N AM J MED SCI, V6, P295, DOI 10.4103/1947-2714.136901; Mazzilli KM, 2019, MED SCI SPORT EXER, V51, P1845, DOI 10.1249/MSS.0000000000001987; McCullough ML, 2011, CANCER EPIDEM BIOMAR, V20, P1089, DOI 10.1158/1055-9965.EPI-10-1173; McTiernan A, 2003, JAMA-J AM MED ASSOC, V290, P1331, DOI 10.1001/jama.290.10.1331; Mishra SI, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007566.pub2; Nayak P, 2014, PREV CHRONIC DIS, V11, DOI 10.5888/pcd11.140067; Ottenbacher A, 2015, J PHYS ACT HEALTH, V12, P675, DOI 10.1123/jpah.2014-0003; Peel AB, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000432; Pescatello LS, 2013, ACSMS GUIDELINES FOR; Sanchis-Gomar F, 2015, CANCER PREV RES, V8, P105, DOI 10.1158/1940-6207.CAPR-14-0320; Short CE, 2014, SUPPORT CARE CANCER, V22, P2757, DOI 10.1007/s00520-014-2273-5; Smith SG, 2010, AM SURGEON, V76, P962; Tarasenko YN, 2018, CANCER CAUSE CONTROL, V29, P475, DOI 10.1007/s10552-018-1017-0; Tarasenko YN, 2017, PREV MED, V99, P211, DOI 10.1016/j.ypmed.2017.01.010; Thune I, 1997, NEW ENGL J MED, V336, P1269, DOI 10.1056/NEJM199705013361801; Thune I, 2001, MED SCI SPORT EXER, V33, pS530, DOI 10.1097/00005768-200106001-00025; Trinh L, 2018, PSYCHO-ONCOLOGY, V27, P2419, DOI 10.1002/pon.4844; Vallerand JR, 2017, INT J BEHAV NUTR PHY, V14, DOI 10.1186/s12966-017-0498-7; van Vulpen JK, 2016, MATURITAS, V85, P104, DOI 10.1016/j.maturitas.2015.12.007; Wu YL, 2013, BREAST CANCER RES TR, V137, P869, DOI 10.1007/s10549-012-2396-7	38	23	23	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2019	14	8							e0220814	10.1371/journal.pone.0220814	http://dx.doi.org/10.1371/journal.pone.0220814			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4ZH	31369653	Green Published, Green Submitted, gold			2023-01-03	WOS:000484987900087
J	Du, TF; Xiao, JF; Qiu, ZL; Wu, KS				Du, Taifeng; Xiao, Jiefeng; Qiu, Zhaolong; Wu, Kusheng			The effectiveness of intensity-modulated radiation therapy versus 2D-RT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis	PLOS ONE			English	Review							CONVENTIONAL 2-DIMENSIONAL RADIOTHERAPY; NECK CANCERS; HEAD; TRISMUS; OUTCOMES; CHEMOTHERAPY; XEROSTOMIA; TOXICITIES; ONCOLOGY; TRIAL	Background At present, the management of nasopharyngeal carcinoma (NPC) is mainly based on radiotherapy, but there are many radiation delivery techniques such as intensity-modulated radiotherapy (IMRT) and 2-dimensional radiotherapy (2D-RT). Materials and methods We searched all the eligible studies through the PubMed, Cochrane Library, Medline, and Embase. The endpoint events in meta-analysis were overall survival (OS), tumor local control including local-regional free survival (LRFS), progression-free survival (PFS), and distant metastasis-free survival (DMFS), and late toxicities. Results A total of ten publications met the criteria and were identified through searches of the data-bases and references. We included 13304 patients in the meta-analysis, of whom 5212 received IMRT and 8092 were allocated to 2D-RT alone group. Compared with 2D-RT treatment, the IMRT group was associated with a better 5-year OS (OR = 1.70; 95% CI = 1.362.12), LRFS (OR = 2.08; 95% CI = 1.82-2.37), and PFS (OR = 1.40; 95% CI = 1.26-1.56). Additionally, the incidence of late toxicities such as late xerostomia (OR = 0.21; 95% CI = 0.09-0.51), trismus (OR = 0.16; 95% CI = 0.04-0.60), and temporal lobe neuropathy (TLN) (OR = 0.40; 95% CI = 0.24-0.67) for NPC patients in IMRT group were significantly lower than 2D-RT. Conclusions The meta-analysis demonstrates that IMRT provides improved long-term tumor overall survival and local control including LRFS and PFS. Additionally, IMRT yields a lower incidence of late toxicities induced by irradiation in NPC patients. Compared to 2D-RT, IMRT may be an effective treatment for patients with NPC. Further intensive studies should be pursued to examine the association.	[Du, Taifeng; Xiao, Jiefeng; Qiu, Zhaolong; Wu, Kusheng] Shantou Univ, Med Coll, Dept Prevent Med, Shantou, Guangdong, Peoples R China	Shantou University	Wu, KS (corresponding author), Shantou Univ, Med Coll, Dept Prevent Med, Shantou, Guangdong, Peoples R China.	kswu@stu.edu.cn	Wu, Kusheng/O-5141-2019	Wu, Kusheng/0000-0001-5163-2524; , Taifeng Du/0000-0002-0783-6092	Natural Science Foundation of Guangdong Province [2014A030313474, 2016A030313071]	Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province)	This work was supported by the Natural Science Foundation of Guangdong Province (No. 2014A030313474, 2016A030313071).	Bucci MK, 2005, CA-CANCER J CLIN, V55, P117, DOI 10.3322/canjclin.55.2.117; Chen QY, 2011, JNCI-J NATL CANCER I, V103, P1761, DOI 10.1093/jnci/djr432; Chen YJ, 2016, EUR J CANCER CARE, V25, P440, DOI 10.1111/ecc.12270; Chen YY, 2011, CANCER-AM CANCER SOC, V117, P2910, DOI 10.1002/cncr.25773; Co J, 2016, HEAD NECK-J SCI SPEC, V38, pE2130, DOI 10.1002/hed.23977; Dieste O, 2011, RISK USING Q HETEROG; Dijkstra PU, 2006, INT J ORAL MAX SURG, V35, P337, DOI 10.1016/j.ijom.2005.08.001; Dijkstra PU, 2004, ORAL ONCOL, V40, P879, DOI 10.1016/j.oraloncology.2004.04.003; Gluckman J L, 1995, Cancer Treat Res, V74, P159; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kam MKM, 2007, J CLIN ONCOL, V25, P4873, DOI 10.1200/JCO.2007.11.5501; Kam MKM, 2003, INT J RADIAT ONCOL, V56, P145, DOI 10.1016/S0360-3016(03)00075-0; Kwong DLW, 1999, CANCER, V85, P1446, DOI 10.1002/(SICI)1097-0142(19990401)85:7<1446::AID-CNCR4>3.0.CO;2-3; Lai SZ, 2011, INT J RADIAT ONCOL, V80, P661, DOI 10.1016/j.ijrobp.2010.03.024; Lee AWM, 2014, RADIOTHER ONCOL, V110, P377, DOI 10.1016/j.radonc.2014.02.003; Lee AWM, 2010, JNCI-J NATL CANCER I, V102, P1188, DOI 10.1093/jnci/djq258; Lee AWM, 2002, INT J RADIAT ONCOL, V53, P75, DOI 10.1016/S0360-3016(02)02711-6; Lee N, 2002, INT J RADIAT ONCOL, V53, P12, DOI 10.1016/S0360-3016(02)02724-4; Lee N, 2007, HEAD NECK-J SCI SPEC, V29, P387, DOI 10.1002/hed.20332; Lee N, 2009, J CLIN ONCOL, V27, P3684, DOI 10.1200/JCO.2008.19.9109; Lin SJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-39; Macaskill P, 2001, STAT MED, V20, P641, DOI 10.1002/sim.698; Melsen WG, 2014, CLIN MICROBIOL INFEC, V20, P123, DOI 10.1111/1469-0691.12494; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Moon SH, 2016, STRAHLENTHER ONKOL, V192, P377, DOI 10.1007/s00066-016-0959-y; Pan XB, 2017, ONCOTARGET, V8, P46211, DOI 10.18632/oncotarget.17582; Peng G, 2012, RADIOTHER ONCOL, V104, P286, DOI 10.1016/j.radonc.2012.08.013; Pfister DG, 2013, J NATL COMPR CANC NE, V11, P917, DOI 10.6004/jnccn.2013.0113; Pow EHN, 2006, INT J RADIAT ONCOL, V66, P981, DOI 10.1016/j.ijrobp.2006.06.013; Qiu WZ, 2017, J CANCER RES CLIN, V143, P1563, DOI 10.1007/s00432-017-2401-y; SHAM J, 1994, INT J RADIAT ONCOL, V29, P699, DOI 10.1016/0360-3016(94)90556-8; Shuster J.J, 2011, RES SYNTH METHODS, V2, P126, DOI [DOI 10.1002/JRSM.38, 10.1002/jrsm.38]; Steelman R, 1986, Mo Dent J, V66, P21; Su SF, 2012, INT J RADIAT ONCOL, V82, P327, DOI 10.1016/j.ijrobp.2010.09.011; Tang LL, 2015, RADIOTHER ONCOL, V116, P167, DOI 10.1016/j.radonc.2015.07.038; THOMAS F, 1988, INT J RADIAT ONCOL, V15, P1097, DOI 10.1016/0360-3016(88)90190-3; Toledano I, 2012, RADIOTHER ONCOL, V103, P57, DOI 10.1016/j.radonc.2011.12.010; Wong FCS, 2010, INT J RADIAT ONCOL, V76, P138, DOI 10.1016/j.ijrobp.2009.01.084; Xiao WW, 2011, CANCER-AM CANCER SOC, V117, P1874, DOI 10.1002/cncr.25754; Zhang BL, 2015, ORAL ONCOL, V51, P1041, DOI 10.1016/j.oraloncology.2015.08.005; Zhang MX, 2015, EUR J CANCER, V51, P2587, DOI 10.1016/j.ejca.2015.08.006; Zhong Hailin, 2013, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V27, P462; Zhou GQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067488	43	32	35	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2019	14	7							e0219611	10.1371/journal.pone.0219611	http://dx.doi.org/10.1371/journal.pone.0219611			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4JZ	31291379	Green Published, Green Submitted, gold			2023-01-03	WOS:000484947800126
J	Zeiger, JS; Silvers, WS; Fleegler, EM; Zeiger, RS				Zeiger, Joanna S.; Silvers, William S.; Fleegler, Edward M.; Zeiger, Robert S.			Cannabis use in active athletes: Behaviors related to subjective effects	PLOS ONE			English	Article							CLUSTER-ANALYSIS; PAIN MANAGEMENT; MARIJUANA; TOBACCO; SUGGESTIONS; PERFORMANCE; PREVALENCE; EXERCISE; EFFICACY; ALCOHOL	Cannabis use has not been well characterized in athletes. Studies primarily examine problematic use or its categorization by anti-doping bodies as a banned substance. Patterns of use, reasons for use, and responses to cannabis consumption have not been studied in a community-based sample of adult athletes. The Athlete PEACE Survey examined cannabis use patterns and subjective effects to cannabis in a community-based cohort of adult athletes. We used mainly social media and email blasts to recruit and SurveyGizmo to collect data. 1,161 ( 91.1%) of the 1,274 athletes taking the survey completed it. Current cannabis use was evaluated by asking "In the past two weeks, have you used marijuana ( including THC and/or CBD)?" and cannabis type used was assessed by asking "What do you primarily use THC, CBD, or both?". Cannabis benefits and adverse effects ( i.e. subjective effects) and patterns of use were reported. 302 athletes ( 26%) currently use cannabis of whom 301 had complete data for cluster analysis. Cluster analysis was used to determine cannabis user phenotypes and exploratory factor analysis ( EFA) was used to create subjective effects factors. Associations between cannabis user phenotype clusters and the subjective effects factors were explored using multivariate analysis. Cluster analysis identified three statistically distinct cannabis user phenotypes: ( 1) older athletes who primarily use medical CBD, ( 2) mixed age athletes who use cannabis mainly recreationally with both THC and CBD use, and ( 3) mixed age athletes who used cannabis the longest with primary THC and CBD use. EFA showed three subjective effects factors: ( 1) Well-being, ( 2) Calm, and ( 3) Adverse. Mean positive subjective were higher than mean adverse subjective effects ( p<0.001). The cluster using THC and CBD showed the highest mean scores for all three subjective effects factors ( p<0.001). Athletes who use a combination of THC and CBD exhibited the most benefit to well-being and calm with minimal adverse effects. Our methodology can be used to develop real-world evidence to inform future use of medical cannabis products.	[Zeiger, Joanna S.; Silvers, William S.; Fleegler, Edward M.; Zeiger, Robert S.] Canna Res Grp, Boulder, CO 80302 USA; [Silvers, William S.] Univ Colorado, Sch Med, Aurora, CO USA; [Fleegler, Edward M.] To Life Peace LLC, Wheat Ridge, CO USA; [Zeiger, Robert S.] Kaiser Permanente Southern Calif, San Diego, CA USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Kaiser Permanente	Zeiger, JS (corresponding author), Canna Res Grp, Boulder, CO 80302 USA.	joanna@cannaresearchgroup.net		Zeiger, Joanna/0000-0002-2421-2206				Agrawal A, 2014, ADDICTION, V109, P663, DOI 10.1111/add.12449; Ambrose KR, 2015, BEST PRACT RES CL RH, V29, P120, DOI 10.1016/j.berh.2015.04.022; [Anonymous], 2017, 2017 NATL RUNNER SUR; Aviram J, 2017, Pain Physician, V20, pE755; Bacher J., 2004, SPSS TWOSTEP CLUSTER; Berman JS, 2004, PAIN, V112, P299, DOI 10.1016/j.pain.2004.09.013; Bhatnagar R., 2014, AM J ED RES, V2, P683, DOI [10.12691/education-2-8-18, DOI 10.12691/EDUCATION-2-8-18, 10.12691/ education- 2-8-18]; Blackwell DL, 2008, STATE VARIATION M 20; Boehnke KF, 2019, ANN INTERN MED, V170, P118, DOI 10.7326/M18-2972; Bousquet PJ, 2015, INT ARCH ALLERGY IMM, V166, P231, DOI 10.1159/000381339; Brisola-Santos MB, 2016, AM J ADDICTION, V25, P518, DOI 10.1111/ajad.12425; Bryan AD, 2018, DOES CANNABIS USE FA, P48; Cook PF., 2010, PERFORM MANOVA SPSS; Corroon J, 2018, CANNABIS CANNABINOID, V3, P152, DOI 10.1089/can.2018.0006; Curran HV, 2002, PSYCHOPHARMACOLOGY, V164, P61, DOI 10.1007/s00213-002-1169-0; Dietrich A, 2004, BRIT J SPORT MED, V38, P536, DOI 10.1136/bjsm.2004.011718; Dolnicar S, 2014, J TRAVEL RES, V53, P296, DOI 10.1177/0047287513496475; Ehlert K. M., 2017, P AM SOC ENGG ED C A, P1; Fiz J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018440; Geneen LJ, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011279.pub3; Gillman AS, 2015, SPORTS MED, V45, P1357, DOI 10.1007/s40279-015-0362-3; Goldenberg M, 2017, DRUG ALCOHOL DEPEN, V174, P80, DOI 10.1016/j.drugalcdep.2016.12.030; Green B, 2003, DRUG ALCOHOL REV, V22, P453, DOI 10.1080/09595230310001613976; Hainline B, 2017, BRIT J SPORT MED, V51, P1245, DOI 10.1136/bjsports-2017-097884; Hainline B, 2017, BRIT J SPORT MED, V51, P1259, DOI 10.1136/bjsports-2017-097890; Hair J.F., 2010, MULTIVARIATE DATA AN, V7th ed., P785; Hair J.F., 2014, 7 EDITION MULTIVARIA, Vseventh; Haroutounian S, 2016, CLIN J PAIN, V32, P1036, DOI 10.1097/AJP.0000000000000364; Haug NA, 2017, ADDICT BEHAV, V72, P14, DOI 10.1016/j.addbeh.2017.03.006; Heishman SJ, PHARM BIOCH BEHAV, V37; Henry D, 2015, PREV SCI, V16, P1007, DOI 10.1007/s11121-015-0561-z; Hill KP, 2017, CANNABIS CANNABINOID, V2, P96, DOI 10.1089/can.2017.0017; Huestis MA, 2011, SPORTS MED, V41, P949, DOI 10.2165/11591430-000000000-00000; Kline P., 2000, HDB PSYCHOL TESTING, V2nd; Lin LA, 2016, ADDICT BEHAV, V61, P99, DOI 10.1016/j.addbeh.2016.05.015; Morean ME, 2019, ADDICT BEHAV, V93, P233, DOI 10.1016/j.addbeh.2019.02.003; Parker R, 2017, SOUTH AFR J PHYSIOTH, V73, DOI 10.4102/sajp.v73i1.323; Peretti-Watel P, 2003, ADDICTION; Polaski AM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210418; Primack BA, 2012, J AM COLL HEALTH, V60, P374, DOI 10.1080/07448481.2012.663840; PUNJ G, 1983, J MARKETING RES, V20, P134, DOI 10.2307/3151680; Rice SM, 2016, SPORTS MED, V46, P1333, DOI 10.1007/s40279-016-0492-2; Rog DJ, 2005, NEUROLOGY, V65, P812, DOI 10.1212/01.wnl.0000176753.45410.8b; Russo E.B., 2013, COMPREHENSIVE TREATM, P181, DOI [10.1007/978-1-4614-1560-2_18, DOI 10.1007/978-1-4614-1560-2_18]; Russo EB, 2011, BRIT J PHARMACOL, V163, P1344, DOI 10.1111/j.1476-5381.2011.01238.x; Scherrer JF, 2009, DRUG ALCOHOL DEPEN, V105, P76, DOI 10.1016/j.drugalcdep.2009.06.014; Schilling L, LICIT ILLICIT SUBSTA, DOI [10.1186/s13011-017-0128-z, DOI 10.1186/S13011-017-0128-Z]; Schwope DM, 2012, J ANAL TOXICOL, V36, P405, DOI 10.1093/jat/bks044; Shuer ML, 1997, WESTERN J MED, V166, P104; Stith SS, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00916; Stockings E, 2018, PAIN, V159, P1932, DOI 10.1097/j.pain.0000000000001293; The Official Website-USA Cycling, 2018, ACT MEMB REP; Trompeter K, 2018, GER J SPORT MED Z SP, V7-8, P240; USA Triathlon, 2016, US TRIATHL MEMB REP, P1; Vigil JM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187795; Wade DT, 2003, CLIN REHABIL, V17, P21, DOI 10.1191/0269215503cr581oa; Ware MA, 2018, CLIN J SPORT MED, V28, P480, DOI 10.1097/JSM.0000000000000650; Whiting PF, 2015, JAMA-J AM MED ASSOC, V313, P2456, DOI 10.1001/jama.2015.6358; Williams B., 2010, AUSTRALAS J PARAMED, V8; Windgassen S, 2018, J MENT HEALTH, V27, P94, DOI 10.1080/09638237.2018.1437615; Zeiger JS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193071; Zeiger JS, 2012, DRUG ALCOHOL DEPEN, V123, pS52, DOI 10.1016/j.drugalcdep.2012.02.014; Zeiger JS, 2010, DRUG ALCOHOL DEPEN, V109, P161, DOI 10.1016/j.drugalcdep.2009.12.026; Zhornitsky S, 2012, PHARMACEUTICALS, V5, P529, DOI 10.3390/ph5050529	64	23	23	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2019	14	6							e0218998	10.1371/journal.pone.0218998	http://dx.doi.org/10.1371/journal.pone.0218998			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW3XM	31251769	Green Published, Green Submitted, gold			2023-01-03	WOS:000484915000033
J	Khazneh, E; Qaddumi, J; Hamdan, Z; Qudaimat, F; Sbitany, A; Jebrin, K; Sawalmeh, O; Abuiram, Y; Shraim, M				Khazneh, Emad; Qaddumi, Jamal; Hamdan, Zakaria; Qudaimat, Falasteen; Sbitany, Asmaa; Jebrin, Kamel; Sawalmeh, Osama; Abuiram, Yousef; Shraim, Mujahed			The effects of Ramadan fasting on clinical and biochemical markers among hemodialysis patients: A prospective cohort study	PLOS ONE			English	Article							ISLAMIC MONTH; PARAMETERS; GLUCOSE; WEIGHT	Background Ramadan fasting is compulsory for all healthy adult Muslims. Although sick people are exempted from Ramadan fasting, some patients such as hemodialysis patients prefer to fast during Ramadan. The effect of Ramadan fasting on clinical outcomes and biochemical markers among hemodialysis patients is not clear. The aim of this study was to examine the effects of daily Ramadan fasting and partial Ramadan fasting on key biochemical and clinical markers among hemodialysis patients as compared to hemodialysis patients who chose not to fast during Ramadan. Methods A prospective cohort study of 269 end stage renal disease patients were recruited from the hemodialysis unit in An-Najah National University Hospital, Nablus, Palestine. The participants were divided into three cohorts based on their plans for fasting during Ramadan in May 2018; Ramadan fasting group (RFG), Ramadan partial fasting group (RPFG) and Ramadan not-fasting group (RNFG). Key clinical and biochemical markers were measured before, during and after Ramadan. Results After adjustment for diabetic and hypertension status and other sociodemographic variables, RFG had higher mean inter-dialytic weight gain (IDWG) by 0.62 kg than RNFG (95% confidence interval (CI) 0.26, 0.99). RPFG also had slight increase in mean IDWG than RNFG by 0.35 kg (95% CI 0.11, 0.60). Additionally, RFG and RPFG had significant increase in mean serum potassium as compared to RNFG. Diabetes was independently associated with increased IDWG by 0.48 kg (0.25, 0.72). Diabetes and hypertension were associated with some independent changes in biochemical markers, but these were clinically negligible. Conclusion Our findings suggest that Ramadan fasting (fully or partially) is tolerable by hemodialysis patients and is not associated with important clinical complications. However, these patients should be made aware of the potential risk of fluid overload and hyperkalemia, if they decide to fast during Ramadan. Thus, they should be closely monitored and instructed to adhere to their dietary and fluid intake allowances. Further prospective cohort studies with comprehensive dietary measures and information on adverse clinical outcomes may provide more evidence about the tolerability and safety of Ramadan fasting by hemodialysis patients.	[Khazneh, Emad; Hamdan, Zakaria; Jebrin, Kamel; Abuiram, Yousef] An Najah Natl Univ, An Najah Natl Univ Hosp, Dept Nephrol, Nablus, Palestine; [Qaddumi, Jamal] An Najah Natl Univ, Fac Med & Hlth Sci, Dept Publ Hlth, Nablus, Palestine; [Qudaimat, Falasteen; Sbitany, Asmaa] An Najah Natl Univ, Fac Med & Hlth Sci, Dept Med, Nablus, Palestine; [Sawalmeh, Osama] An Najah Natl Univ, An Najah Natl Univ Hosp, Dept Internal Med, Nablus, Palestine; [Shraim, Mujahed] Qatar Univ, Dept Publ Hlth, Coll Hlth Sci, Doha, Qatar	An Najah National University; An Najah National University; An Najah National University; An Najah National University; Qatar University	Shraim, M (corresponding author), Qatar Univ, Dept Publ Hlth, Coll Hlth Sci, Doha, Qatar.	mshraim@qu.edu.qa	Shraim, Mujahed/AAD-4647-2020; Qaddumi, Jamal A.S./AAF-9553-2020	Shraim, Mujahed/0000-0001-7972-8210; Sawalmeh, Osama/0000-0002-5733-2589; KHAZNEH, Emad/0000-0001-6803-1848	Qatar National Library	Qatar National Library(Qatar National Research Fund (QNRF))	The publication of this article was funded by the Qatar National Library. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdalla AH, 1998, AM J NEPHROL, V18, P101, DOI 10.1159/000013316; Adnan WAHWM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114262; Al Suwaidi J, 2005, SAUDI MED J, V26, P1579; Al Wakeel JS, 2014, IRAN J KIDNEY DIS, V8, P321; Alkandari JR, 2012, J SPORT SCI, V30, pS9, DOI 10.1080/02640414.2012.698298; ALKHADER AA, 1991, SAUDI MED J, V12, P30; Alshamsi S, 2016, HEMODIAL INT, V20, P270, DOI 10.1111/hdi.12369; Azizi F, 2002, ANN SAUDI MED, V22, P186, DOI 10.5144/0256-4947.2002.186; Azizi F, 2010, ANN NUTR METAB, V56, P273, DOI 10.1159/000295848; CHEAH SH, 1990, BRIT J NUTR, V63, P329, DOI 10.1079/BJN19900119; DUMBAULD SL, 1983, KIDNEY INT, V24, P222, DOI 10.1038/ki.1983.147; Einollahi B, 2017, IRAN J KIDNEY DIS, V11, P168; GIFFORD JD, 1989, KIDNEY INT, V35, P90, DOI 10.1038/ki.1989.12; Imtiaz S, 2015, JCPSP-J COLL PHYSICI, V25, P189, DOI 03.2015/JCPSP.189192; Imtiaz S, 2016, IRAN J KIDNEY DIS, V10, P75; KORDY MT, 1991, ANN SAUDI MED, V11, P23, DOI 10.5144/0256-4947.1991.23; Kul S, 2014, J RELIG HEALTH, V53, P929, DOI 10.1007/s10943-013-9687-0; LAAJAM MA, 1990, E AFR MED J, V67, P732; Matter YE, 2018, J EGYPTIAN SOC NEPHR, V18, P1; Megahed AF, 2019, SAUDI J KIDNEY DIS T, V30, P339, DOI 10.4103/1319-2442.256841; Miladipour AH, 2012, IRAN J KIDNEY DIS, V6, P33; NOMANI MZ, 1989, AM J CLIN NUTR, V49, P1141, DOI 10.1093/ajcn/49.6.1141; Palestinian Health Information Center, 2017, HLTH ANN REP PAL 201; PRENTICE AM, 1983, HUM NUTR-CLIN NUTR, V37, P283; RASHED AH, 1992, BRIT MED J, V304, P521, DOI 10.1136/bmj.304.6826.521; Sliman NA, 1998, NUTR REP INT, V38, P1299; Sung JM, 2006, NEPHROL DIAL TRANSPL, V21, P2521, DOI 10.1093/ndt/gfl236; Trepanowski JF, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-57	28	9	9	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2019	14	6							e0218745	10.1371/journal.pone.0218745	http://dx.doi.org/10.1371/journal.pone.0218745			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW3QN	31233556	Green Published, Green Submitted, gold			2023-01-03	WOS:000484896700036
J	Hulzebos, CV; Vader-van Imhoff, DE; Bos, AF; Dijk, PH				Hulzebos, Christian V.; Vader-van Imhoff, Deirdre E.; Bos, Arend F.; Dijk, Peter H.			Should transcutaneous bilirubin be measured in preterm infants receiving phototherapy? The relationship between transcutaneous and total serum bilirubin in preterm infants with and without phototherapy	PLOS ONE			English	Article							TRANS-CUTANEOUS BILIRUBINOMETRY; TERM; RELIABILITY; BILICHECK; NEWBORNS; JAUNDICE; DEVICES	Our objective was to analyze the relationship between transcutaneous bilirubin (TcB) measured on an unexposed area of skin and total serum bilirubin (TSB) in preterm infants before, during, and after phototherapy (PT). For this purpose paired TSB and TcB levels were measured daily during the first ten days after birth in preterm infants of less than 32 weeks' gestation. TcB was measured with a Drager Jaundice Meter JM-103 on the covered hipbone. Agreement between TSB and TcB levels was assessed before, during, and after PT. True negative and corresponding false negative percentages were calculated using different TcB cut-off levels. Data are presented as mean (+/- SD). We obtained 856 paired TcB and TSB levels in 109 preterm infants (66 boys, gestational age 29.4 +/- 1.6 weeks and birth weight 1282 g +/- 316 g). We found that the difference between TSB and TcB before PT was significantly lower, 44 (+/- 36) mu mol/L, than the difference during and after PT, 61 (+/- 29) mu mol/L and 63 (+/- 25) mu mol/L, respectively; P < 0.01. Blood sampling could be reduced by 42%, with 2% false negatives, when 50 mu mol/L was added to the TcB level at 70% of the PT threshold. Our conclusion is that phototherapy enhances underestimation of TSB by TcB in preterms, even if measured on unexposed skin. The use of specific TcB cut-off levels substantially reduces the need for TSB measurements.	[Hulzebos, Christian V.; Vader-van Imhoff, Deirdre E.; Bos, Arend F.; Dijk, Peter H.] Univ Med Ctr Groningen, Beatrix Childrens Hosp, Div Neonatol, Dept Pediat, Groningen, Netherlands	University of Groningen	Hulzebos, CV (corresponding author), Univ Med Ctr Groningen, Beatrix Childrens Hosp, Div Neonatol, Dept Pediat, Groningen, Netherlands.	c.v.hulzebos@umcg.nl	Hulzebos, Christian Victor/AAY-6803-2021	Hulzebos, Christian Victor/0000-0002-8159-7501				BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Cucuy M, 2017, J MATERN-FETAL NEO M, V24, P1; Cucuy M, 2018, J MATERN-FETAL NEO M, V31, P1323, DOI 10.1080/14767058.2017.1315662; Ebbesen F, 2002, ACTA PAEDIATR, V91, P203, DOI 10.1080/080352502317285225; Ebbesen F, 2012, ACTA PAEDIATR, V101, P1128, DOI 10.1111/j.1651-2227.2012.02797.x; Fonseca R, 2012, J PERINATOL, V32, P129, DOI 10.1038/jp.2011.66; Grabenhenrich J, 2014, PEDIATRICS, V134, pE1324, DOI 10.1542/peds.2014-1677; Hulzebos CV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099466; Jangaard Ka, 2006, Paediatr Child Health, V11, P79; Jnah A, 2018, ADV NEONAT CARE, V18, P144, DOI 10.1097/ANC.0000000000000469; Juster-Reicher A, 2014, J MATERN-FETAL NEO M, V30, P1; Knupfer M, 2001, ACTA PAEDIATR, V90, P899; Lucanova LC, 2016, J PERINATOL, V36, P858, DOI 10.1038/jp.2016.91; Maisels J, 2009, PEDIATRICS, V124, P1193, DOI 10.1542/peds.2009-0329; Maisels MJ, 2015, J PERINATOL, V35, P739, DOI 10.1038/jp.2015.34; Maisels MJ, 2004, PEDIATRICS, V114, P297; Mreihil K, 2018, ACTA PAEDIATR, V107, P611, DOI 10.1111/apa.14141; Mukherjee D, 2018, J PERINATOL, V38, P1246, DOI 10.1038/s41372-018-0153-4; Nagar G, 2016, NEONATOLOGY, V109, P203, DOI 10.1159/000442195; Nagar G, 2013, PEDIATRICS, V132, P871, DOI 10.1542/peds.2013-1713; Nanjundaswamy S, 2005, AM J PERINAT, V22, P127, DOI 10.1055/s-2005-863785; National Institute for Health and Clinical Excellence, 2010, NEON JAUND CLIN GUID; Ozkan H, 2003, ACTA PAEDIATR, V92, P577, DOI 10.1080/08035320310001563; Stillova L, 2009, INDIAN PEDIATR, V46, P405; Tan KL, 2003, ACTA PAEDIATR, V92, P327; van Imhoff DE, 2011, EARLY HUM DEV, V87, P521, DOI 10.1016/j.earlhumdev.2011.04.004; Willems W A, 2004, J Matern Fetal Neonatal Med, V16, P209; YAMANOUCHI I, 1980, PEDIATRICS, V65, P195, DOI 10.1542/peds.65.2.195; Yasuda S, 2003, J PERINAT MED, V31, P81, DOI 10.1515/JPM.2003.012; Zecca E, 2009, EARLY HUM DEV, V85, P537, DOI 10.1016/j.earlhumdev.2009.05.010	30	11	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 14	2019	14	6							e0218131	10.1371/journal.pone.0218131	http://dx.doi.org/10.1371/journal.pone.0218131			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ID3OU	31199817	Green Published, Green Submitted, gold			2023-01-03	WOS:000471587000027
J	Nazari, G; MacDermid, JC; Bryant, D; Athwal, GS				Nazari, Goris; MacDermid, Joy C.; Bryant, Dianne; Athwal, George S.			The effectiveness of surgical vs conservative interventions on pain and function in patients with shoulder impingement syndrome. A systematic review and meta-analysis	PLOS ONE			English	Review							ROTATOR CUFF TENDINOPATHY; STAGE-II IMPINGEMENT; SUBACROMIAL IMPINGEMENT; ARTHROSCOPIC ACROMIOPLASTY; FOLLOW-UP; PREVALENCE; QUALITY; DECOMPRESSION; EXERCISES; COMMUNITY	Objective To assess the effectiveness of surgical vs conservative interventions on pain and function in patients with subacromial impingement syndrome. Design Systematic review and meta-analysis of randomized controlled trials. Setting Clinical setting. Participants Patients 18 years and older with subacromial impingement syndrome. Intervention/Comparison Surgical intervention plus postoperative physiotherapy / placebo surgery plus physiotherapy or physiotherapy only. Main outcome measures Pain and function. Results 11 RCTs (n = 919) were included. The pooled results displayed no statistically or clinically different between surgery plus physiotherapy vs physiotherapy alone on pain levels at 3-, 6-months, 5- and 10 years follow up (moderate quality, 3 RCTs, 300 patients, WMD -0.39, 95% CI: -1.02 to 0.23, p = 0.22; moderate quality, 3 RCTs, 310 patients, WMD -0.36, 95% CI: -1.02 to 0.29, p = 0.27; low quality, 1 RCT, 109 patients, WMD -0.30, 95% CI: -1.54 to 0.94, p = 0.64; low quality, 1 RCT, 90 patients, WMD -1.00, 95% CI: -0.24 to 2.24, p = 0.11) respectively. Similarly, the pooled results were not statistically or clinically different between groups for function at 3-, 6-month and 1-year follow ups (very low quality, 2 RCTs, 184 patients, SMD 0.11, 95% CI: -0.57 to 0.79, p = 0.75; moderate quality, 3 RCTs, 310 patients, SMD 0.15, 95% CI: -0.14 to 0.43, p = 0.31; very low quality, 2 RCTs, 197 patients, SMD 0.11, 95% CI: -0.46 to 0.69, p = 0.70) respectively. Conclusion The effects of surgery plus physiotherapy compared to physiotherapy alone on improving pain and function are too small to be clinically important at 3-, 6-months, 1-, 2-, 5- and >= 10-years follow up.	[Nazari, Goris; MacDermid, Joy C.; Bryant, Dianne] Western Univ, Fac Hlth Sci, Sch Phys Therapy, London, ON, Canada; [Nazari, Goris; Bryant, Dianne; Athwal, George S.] Western Univ, Bone & Joint Inst, Collaborat Program Musculoskeletal Hlth Res, London, ON, Canada; [MacDermid, Joy C.; Athwal, George S.] St Josephs Hosp, Roth McFarlane Hand & Upper Limb Ctr, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); McGill University; Western University (University of Western Ontario)	Nazari, G (corresponding author), Western Univ, Fac Hlth Sci, Sch Phys Therapy, London, ON, Canada.; Nazari, G (corresponding author), Western Univ, Bone & Joint Inst, Collaborat Program Musculoskeletal Hlth Res, London, ON, Canada.	gnazari@uwo.ca	Bryant, Dianne M/K-6766-2013; Athwal, George S/H-1762-2015; MacDermid, Joy C/H-7837-2013	Bryant, Dianne M/0000-0002-7535-8707; MacDermid, Joy C/0000-0001-9311-7379				Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015; Beard DJ, 2018, LANCET, V391, P329, DOI 10.1016/S0140-6736(17)32457-1; Bossuyt FM, 2018, DISABIL REHABIL, V40, P798, DOI 10.1080/09638288.2016.1276974; Brox JI, 1999, J SHOULDER ELB SURG, V8, P102, DOI 10.1016/S1058-2746(99)90001-0; Farfaras S, 2018, AM J SPORT MED, V46, P1397, DOI 10.1177/0363546518755759; Farfaras S, 2016, KNEE SURG SPORT TR A, V24, P2181, DOI 10.1007/s00167-014-3416-4; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Haahr JP, 2006, SCAND J RHEUMATOL, V35, P224, DOI 10.1080/03009740600556167; Haahr JP, 2005, ANN RHEUM DIS, V64, P760, DOI 10.1136/ard.2004.021188; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hill CL, 2010, INT J RHEUM DIS, V13, P215, DOI 10.1111/j.1756-185X.2010.01475.x; Johannes CB, 2010, J PAIN, V11, P1230, DOI 10.1016/j.jpain.2010.07.002; Ketola S, 2017, BONE JOINT J, V99B, P799, DOI 10.1302/0301-620X.99B6.BJJ-2016-0569.R1; Ketola S, 2013, BONE JOINT RES, V2, P132, DOI 10.1302/2046-3758.27.2000163; Ketola S, 2009, J BONE JOINT SURG BR, V91B, P1326, DOI 10.1302/0301-620X.91B10.22094; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Norman Geoffrey R, 2004, Expert Rev Pharmacoecon Outcomes Res, V4, P581, DOI 10.1586/14737167.4.5.581; Paavola M, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k2860; Rahme H, 1998, SCAND J REHABIL MED, V30, P253; Saltychev M, 2015, DISABIL REHABIL, V37, P1, DOI 10.3109/09638288.2014.907364; Schopflocher D, 2011, PAIN RES MANAG, V16, P445, DOI 10.1155/2011/876306; Steuri R, 2017, BRIT J SPORT MED, V51, P1340, DOI 10.1136/bjsports-2016-096515; Tashjian RZ, 2009, J SHOULDER ELB SURG, V18, P927, DOI 10.1016/j.jse.2009.03.021; Toliopoulos P, 2014, CLIN RHEUMATOL, V33, P1373, DOI 10.1007/s10067-014-2563-9; Urwin M, 1998, ANN RHEUM DIS, V57, P649, DOI 10.1136/ard.57.11.649; Yeldan I, 2009, DISABIL REHABIL, V31, P935, DOI 10.1080/09638280802377985	27	17	17	2	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2019	14	5							e0216961	10.1371/journal.pone.0216961	http://dx.doi.org/10.1371/journal.pone.0216961			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IA1LO	31141546	Green Submitted, Green Published, gold			2023-01-03	WOS:000469323000032
J	Gershon, AS; Thiruchelvam, D; Aaron, S; Stanbrook, M; Vozoris, N; Tan, WC; Cho, E; To, T				Gershon, Andrea S.; Thiruchelvam, Deva; Aaron, Shawn; Stanbrook, Matthew; Vozoris, Nicholas; Tan, Wan C.; Cho, Eunice; To, Teresa			Socioeconomic status (SES) and 30-day hospital readmissions for chronic obstructive pulmonary (COPD) disease: A population-based cohort study	PLOS ONE			English	Article							RISK; REHOSPITALIZATIONS; EXACERBATIONS; ICD-9-CM	Background Patients with chronic obstructive pulmonary disease (COPD) are more likely to be readmitted than patients with other chronic medical conditions, yet knowledge regarding such readmissions is limited. We aimed to determine factors associated with readmission within 30 days of a COPD hospitalization or death with an emphasis on examining aspects of socioeconomic status and specific comorbidities. Methods A population-based cohort study was conducted using health administrative data from Ontario, Canada. All hospitalizations for COPD between 2004 and 2014 were considered. The primary exposures were socioeconomic status as measured by residential instability (an ecologic variable), and comorbidities such as cardiovascular disease and cancer. Other domains of socioeconomic status were considered as secondary exposures. Logistic regression with generalized estimating equations was used to examine the effect of exposures, adjusting for other patient factors, on 30-day readmission or death. Results There were 126,013 patients contributing to 252,756 index COPD hospitalizations from 168 Ontario hospitals. Of these hospitalizations, 19.4% resulted in a readmission and 2.8% resulted in death within 30 days. After adjusting for other factors, readmissions or death were modestly more likely among people with the highest residential instability compared to the lowest (OR 1.05, 95% CI 1.01-1.09). Comorbidities such as cardiovascular disease and cancer, as well as other aspects of low socioeconomic status also increased readmission or death risk. Interpretation Socioeconomic status, measured in various ways, and many comorbidities predict 30-day readmission or death in patients hospitalized for COPD. Strategies that address these factors may help reduce readmissions and death.	[Gershon, Andrea S.; Thiruchelvam, Deva] Sunnybrook Hlth Sci Ctr, Dept Med, Toronto, ON, Canada; [Gershon, Andrea S.; Thiruchelvam, Deva; To, Teresa] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Aaron, Shawn] Ottawa Hosp, Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; [Stanbrook, Matthew] Toronto Western Hosp, Asthma & Airway Ctr, Toronto, ON, Canada; [Vozoris, Nicholas] St Michaels Hosp, Dept Med, Toronto, ON, Canada; [Tan, Wan C.] Univ British Columbia, Ctr Heart Lung Innovat, Vancouver, BC, Canada; [Cho, Eunice] Univ Toronto, Dept Med, Toronto, ON, Canada; [To, Teresa] Hosp Sick Children, Child Hlth Evaluat Sci, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of British Columbia; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Gershon, AS (corresponding author), Sunnybrook Hlth Sci Ctr, Dept Med, Toronto, ON, Canada.; Gershon, AS (corresponding author), Inst Clin Evaluat Sci, Toronto, ON, Canada.	andrea.gershon@ices.on.ca			Health Service Research Fund Capacity Grant from the Province of Ontario; ICES - Ontario Ministry of Health and Long-Term Care (MOHLTC); Canadian Institutes of Health Research New Investigator Award; Physicians' Services Incorporated Foundation, Toronto, Ontario	Health Service Research Fund Capacity Grant from the Province of Ontario; ICES - Ontario Ministry of Health and Long-Term Care (MOHLTC)(Ministry of Health and Long-Term Care, Ontario); Canadian Institutes of Health Research New Investigator Award(Canadian Institutes of Health Research (CIHR)); Physicians' Services Incorporated Foundation, Toronto, Ontario	Funding for this project was made available from a Health Service Research Fund Capacity Grant from the Province of Ontario. This study was also supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). Dr. Gershon is supported by a Canadian Institutes of Health Research New Investigator Award and was supported by a Fellowship for Translational Health Research from the Physicians' Services Incorporated Foundation, Toronto, Ontario, while working on this study. The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred.	Adeloye D, 2015, J GLOB HEALTH, V5, P186, DOI 10.7189/jogh.05.020415; Alter DA, 2004, JAMA-J AM MED ASSOC, V291, P1100, DOI 10.1001/jama.291.9.1100; [Anonymous], 2013, LANCET RESP MED, V1, P347, DOI 10.1016/S2213-2600(13)70153-X; [Anonymous], 2017, GLOB STRAT DIAGN MAP; Bahadori Katayoun, 2009, Can Respir J, V16, pe43; Baker CL, 2013, INT J CHRONIC OBSTR, V8, P551, DOI 10.2147/COPD.S51507; Canadian Institute for Health Information, CAN COD STAND VERS 2; Chan FWK, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-186; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Echevarria C, 2017, THORAX; Eisner MD, 2010, J EPIDEMIOLOGY COMMU; Feemster LC, 2014, AM J RESP CRIT CARE, V189, P634, DOI 10.1164/rccm.201308-1541PP; Gershon AS, 2009, COPD, V6, P388, DOI 10.1080/15412550903140865; Gershon N, 2019, COST EFFECT RESOUR A, V17, DOI 10.1186/s12962-019-0174-7; Jacobs DM, 2018, ANN AM THORAC SOC, V15, P837, DOI 10.1513/AnnalsATS.201712-913OC; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Jennings JH, 2015, CHEST, V147, P1227, DOI 10.1378/chest.14-1123; Joynt KE, 2013, NEW ENGL J MED, V368, P1175, DOI 10.1056/NEJMp1300122; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Kristensen SR, 2015, HEALTH POLICY, V119, P264, DOI 10.1016/j.healthpol.2014.12.009; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Matheson FI, 2012, CAN J PUBLIC HEALTH, V103, pS12, DOI 10.1007/BF03403823; McIlvennan CK, 2015, CIRCULATION, V131, P1796, DOI 10.1161/CIRCULATIONAHA.114.010270; Press VG, 2018, ANN AM THORAC SOC, V15, P801, DOI 10.1513/AnnalsATS.201804-246ED; Prieto-Centurion Valentin, 2014, Ann Am Thorac Soc, V11, P417, DOI 10.1513/AnnalsATS.201308-254OC; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Richardson D, 2001, CURR CONTR TRIALS C, V2, P115; Roberts MH, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0231-3; Rosenberg SR, 2015, SEMIN RESP CRIT CARE, V36, P457, DOI 10.1055/s-0035-1555607; Shah T, 2015, CHEST, V147, P1219, DOI 10.1378/chest.14-2181; Simmering JE, 2016, CHRON OBSTR PULM DIS, V3, P729, DOI 10.15326/jcopdf.3.4.2016.0136; Soriano JB, 2009, LANCET, V374, P721, DOI 10.1016/S0140-6736(09)61290-3; Yu TC, 2015, CLINICOECONOMIC OUTC, V7, P37, DOI 10.2147/CEOR.S74181	33	16	16	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2019	14	5							e0216741	10.1371/journal.pone.0216741	http://dx.doi.org/10.1371/journal.pone.0216741			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HY9HS	31112573	Green Submitted, Green Published, gold			2023-01-03	WOS:000468451000021
J	Moors, A; Fini, C; Everaert, T; Bardi, L; Bossuyt, E; Kuppens, P; Brass, M				Moors, Agnes; Fini, Chiara; Everaert, Tom; Bardi, Lara; Bossuyt, Evelien; Kuppens, Peter; Brass, Marcel			The role of stimulus-driven versus goal-directed processes in fight and flight tendencies measured with motor evoked potentials induced by Transcranial Magnetic Stimulation	PLOS ONE			English	Article							IMPLEMENTATION INTENTIONS; EMOTION; POWER; EXCITABILITY; AGGRESSION; APPRAISAL; METAANALYSIS; ACHIEVEMENT; ANGER; PAIN	This study examines two contrasting explanations for early tendencies to fight and flee. According to a stimulus-driven explanation, goal-incompatible stimuli that are easy/difficult to control lead to the tendency to fight/flee. According to a goal-directed explanation, on the other hand, the tendency to fight/flee occurs when the expected utility of fighting/fleeing is the highest. Participants did a computer task in which they were confronted with goal-incompatible stimuli that were (a) easy to control and fighting had the highest expected utility, (b) easy to control and fleeing had the highest expected utility, and (c) difficult to control and fleeing and fighting had zero expected utility. After participants were trained to use one hand to fight and another hand to flee, they either had to choose a response or merely observe the stimuli. During the observation trials, single-pulse Transcranial Magnetic Stimulation (TMS) was applied to the primary motor cortex 450 ms post-stimulus onset and motor evoked potentials (MEPs) were measured from the hand muscles. Results showed that participants chose to fight/flee when the expected utility of fighting/fleeing was the highest, and that they responded late when the expected utility of both responses was low. They also showed larger MEPs for the right/left hand when the expected utility of fighting/fleeing was the highest. This result can be interpreted as support for the goal-directed account, but only if it is assumed that we were unable to override the presumed natural mapping between hand (right/left) and response (fight/flight).	[Moors, Agnes; Kuppens, Peter] Katholieke Univ Leuven, Res Grp Quantitat Psychol & Individual Difference, Leuven, Belgium; [Moors, Agnes] Katholieke Univ Leuven, Ctr Social & Cultural Psychol, Leuven, Belgium; [Moors, Agnes; Everaert, Tom; Bossuyt, Evelien] Univ Ghent, Dept Expt Clin & Hlth Psychol, Ghent, Belgium; [Fini, Chiara] State Univ Roma La Sapienza, Dept Dynam & Clin Psychol, Rome, Italy; [Bardi, Lara; Brass, Marcel] Univ Ghent, Dept Expt Psychol, Ghent, Belgium	KU Leuven; KU Leuven; Ghent University; Sapienza University Rome; Ghent University	Moors, A (corresponding author), Katholieke Univ Leuven, Res Grp Quantitat Psychol & Individual Difference, Leuven, Belgium.; Moors, A (corresponding author), Katholieke Univ Leuven, Ctr Social & Cultural Psychol, Leuven, Belgium.; Moors, A (corresponding author), Univ Ghent, Dept Expt Clin & Hlth Psychol, Ghent, Belgium.	agnes.moors@kuleuven.be	Moors, Agnes/C-6342-2008; kuppens, peter/DHG-5268-2022; Brass, Marcel/J-7082-2012; Fini, Chiara/ABC-5055-2021	Moors, Agnes/0000-0002-5137-557X; Brass, Marcel/0000-0002-3364-4019; fini, chiara/0000-0002-9939-4745; Bardi, Lara/0000-0002-1678-647X; kuppens, peter/0000-0002-2363-2356	Research Foundation - Flanders (FWO) [G073317N, G022313N]; Research Fund of KU Leuven [C14/17/047]	Research Foundation - Flanders (FWO)(FWO); Research Fund of KU Leuven	Preparation of this article was supported by Research Program G073317N to AM and PK and G022313N to AM and MB of the Research Foundation - Flanders (FWO; http://fwo.be) and Grant C14/17/047 to AM of the Research Fund of KU Leuven (https://admin.kuleuven.be/raden/en/research-council). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arnold M.B., 1960, EMOTION PERSONALITY; Avenanti A, 2009, CORTEX, V45, P1072, DOI 10.1016/j.cortex.2008.10.004; BARON RA, 1971, J PERS SOC PSYCHOL, V18, P48, DOI 10.1037/h0030643; BINDRA D, 1969, ANN NY ACAD SCI, V159, P1071, DOI 10.1111/j.1749-6632.1969.tb12998.x; Borgomaneri S, 2015, BRAIN STRUCT FUNCT, V220, P2765, DOI 10.1007/s00429-014-0825-6; Bossuyt E, 2014, PSYCHOL REC, V64, P841, DOI 10.1007/s40732-014-0065-4; CARLSON M, 1990, J PERS SOC PSYCHOL, V58, P622, DOI 10.1037/0022-3514.58.4.622; Chen S, 2001, J PERS SOC PSYCHOL, V80, P173, DOI 10.1037//0022-3514.80.2.173; Chorpita BF, 1998, PSYCHOL BULL, V124, P3, DOI 10.1037/0033-2909.124.1.3; Coelho CM, 2010, NEUROSCI LETT, V481, P135, DOI 10.1016/j.neulet.2010.03.027; DICKINSON A, 1994, ANIM LEARN BEHAV, V22, P1, DOI 10.3758/BF03199951; Dickinson A., 1993, CONSCIOUSNESS PSYCHO, P105; DONNERSTEIN E, 1976, J PERS SOC PSYCHOL, V34, P774, DOI 10.1037/0022-3514.34.5.774; Ellsworth PC, 2003, SER AFFECTIVE SCI, P572; Fast NJ, 2009, PSYCHOL SCI, V20, P1406, DOI 10.1111/j.1467-9280.2009.02452.x; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Frijda N. H., 2004, FEELINGS EMOTIONS AM, P158; FRIJDA NH, 1989, J PERS SOC PSYCHOL, V57, P212, DOI 10.1037/0022-3514.57.2.212; FRIJDA NH, 1988, AM PSYCHOL, V43, P349, DOI 10.1037/0003-066X.43.5.349; Galea JM, 2013, J NEUROSCI, V33, P3981, DOI 10.1523/JNEUROSCI.1294-12.2013; Galinsky AD, 2003, J PERS SOC PSYCHOL, V85, P453, DOI 10.1037/0022-3514.85.3.453; Gollwitzer PM, 2006, ADV EXP SOC PSYCHOL, V38, P69, DOI 10.1016/S0065-2601(06)38002-1; Gollwitzer PM, 1999, AM PSYCHOL, V54, P493, DOI 10.1037//0003-066X.54.7.493; Gough PM, 2013, BRAIN LANG, V125, P54, DOI 10.1016/j.bandl.2013.01.012; Gross JJ, 2007, HDB EMOTION REGULATI, P3, DOI DOI 10.1080/00140130600971135; Hajcak G, 2007, PSYCHOPHYSIOLOGY, V44, P91, DOI 10.1111/j.1469-8986.2006.00487.x; Kapogiannis D, 2008, EUR J NEUROSCI, V27, P1836, DOI 10.1111/j.1460-9568.2008.06147.x; Keltner D, 2003, PSYCHOL REV, V110, P265, DOI 10.1037/0033-295X.110.2.265; Keltner D, 2001, PSYCHOL BULL, V127, P229, DOI 10.1037//0033-2909.127.2.229; KIPNIS D, 1972, J PERS SOC PSYCHOL, V24, P33, DOI 10.1037/h0033390; Langner O, 2010, COGNITION EMOTION, V24, P1377, DOI 10.1080/02699930903485076; Lazarus R. S., 1991, EMOTION ADAPTATION; Mandler G, 1966, ANXIETY BEHAV, P263; Mirabella G, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.01334; Mirabella G, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00206; Moors A, 2007, COGNITION EMOTION, V21, P1238, DOI 10.1080/02699930701438061; Moors A, 2017, EMOT REV, V9, P310, DOI 10.1177/1754073916669595; Moors A, 2017, PSYCHOL INQ, V28, P1, DOI 10.1080/1047840X.2017.1235900; Moors A, 2016, ANNU REV PSYCHOL, V67, P263, DOI 10.1146/annurev-psych-122414-033550; Murphy FC, 2003, COGN AFFECT BEHAV NE, V3, P207, DOI 10.3758/CABN.3.3.207; Parkinson B, 2001, BRIT J PSYCHOL, V92, P507, DOI 10.1348/000712601162310; Pekrun R, 2006, EDUC PSYCHOL REV, V18, P315, DOI 10.1007/s10648-006-9029-9; Phaf RH, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00378; RICHARDSON DR, 1986, J RES PERS, V20, P402, DOI 10.1016/0092-6566(86)90122-4; Ridderinkhof KR, 2017, EMOT REV, V9, P319, DOI 10.1177/1754073916661765; Roseman IJ, 1996, COGNITION EMOTION, V10, P241, DOI 10.1080/026999396380240; Rossini PM, 2015, CLIN NEUROPHYSIOL, V126, P1071, DOI 10.1016/j.clinph.2015.02.001; Rutherford HJV, 2011, EMOT REV, V3, P333, DOI 10.1177/1754073911402392; Scherer KR, 2009, COGNITION EMOTION, V23, P1307, DOI 10.1080/02699930902928969; Scherer KR, 2001, APPRAISAL PROCESSES, P369; Schutter DJLG, 2008, PSYCHOPHYSIOLOGY, V45, P345, DOI 10.1111/j.1469-8986.2007.00635.x; Sheeran P, 2005, PERS SOC PSYCHOL B, V31, P87, DOI 10.1177/0146167204271308; Spruyt A, 2018, EMOTION, V18, P332, DOI 10.1037/emo0000361; Spruyt A, 2010, EXP PSYCHOL, V57, P36, DOI 10.1027/1618-3169/a000005; Suzuki M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090773; Thabit MN, 2011, CLIN NEUROPHYSIOL, V122, P1764, DOI 10.1016/j.clinph.2011.02.021; van Loon AM, 2010, COGN AFFECT BEHAV NE, V10, P174, DOI 10.3758/CABN.10.2.174; Vicario CM, 2015, CORTEX, V65, P139, DOI 10.1016/j.cortex.2014.12.017; Wager TD, 2003, NEUROIMAGE, V19, P513, DOI 10.1016/S1053-8119(03)00078-8; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Zheng X, 2012, NEUROPSYCHOLOGIA, V50, P1451, DOI 10.1016/j.neuropsychologia.2012.02.030; 2012, J NEUROSCI, V32, P8373, DOI DOI 10.1523/JNEUROSCI.0270-12.2012; 2002, DEV REV, V22, P117	63	17	17	3	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2019	14	5							e0217266	10.1371/journal.pone.0217266	http://dx.doi.org/10.1371/journal.pone.0217266			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY7BF	31107906	Green Submitted, Green Published, gold			2023-01-03	WOS:000468285200042
J	Cooper, C; Heinzle, B; Reitmaier, T				Cooper, Christine; Heinzle, Bernd; Reitmaier, Thomas			Evidence of infectious disease, trauma, disability and deficiency in skeletons from the 19th/20th century correctional facility and asylum "Realta" in Cazis, Switzerland	PLOS ONE			English	Article							ARCHAEOLOGICAL SITES; ENAMEL HYPOPLASIA; STICKLER-SYNDROME; AGE ESTIMATION; PHASE-ANALYSIS; RIB FRACTURES; MENTAL-HEALTH; SCURVY; LESIONS; BONE	As a reaction to widespread poverty, a system of coercive welfare developed in Switzerland during the 19th century. Poverty was often thought to result from an individual's misconduct rather than from structural, economic or political circumstances. People whose lifestyle deviated from the desired norm or who were unable to make a living for themselves were subjected to so-called administrative detention at institutions such as workhouses and poorhouses. The excavation of the cemetery of the correctional facility/workhouse and asylum Realta in Cazis offered the opportunity to gain insight into the living conditions of a marginalized group of people and to shed light on aspects of coercive welfare that have hardly been addressed in historical studies. A comprehensive study of pathological alterations was used to assess possible physical causes and effects of administrative detention. Skeletal samples from regular contemporaneous cemeteries provided data for the general population and thus allowed us to detect peculiarities in the "Realta assemblage. Possible cases of Stickler Syndrome, microcephaly, congenital syphilis, endemic hypothyroidism and disabilities secondary to trauma may have been the reason for the affected individuals' institutionalisation. The high prevalence of tuberculosis was linked to the socioeconomic status and the living conditions at the facility. Several cases of scurvy and osteomalacia may have resulted from various risk factors such as poverty, alcoholism, mental illness or institutionalisation. The fracture rates, especially of ribs, were extremely high. A large proportion of the fractures were incompletely healed and most likely occurred during detention due to interpersonal violence. Underlying diseases further contributed to the high fracture rates. This first study on skeletons from an institution of administrative detention in Switzerland demonstrated how pre-existing health conditions and the socioeconomic background contributed to the chance of being detained, and how detention led to further deterioration of health.	[Cooper, Christine; Heinzle, Bernd; Reitmaier, Thomas] Archaeol Serv Canton Grisons, Chur, Switzerland; [Cooper, Christine] Off Culture, Dept Archaeol, Triesen, Liechtenstein		Cooper, C (corresponding author), Archaeol Serv Canton Grisons, Chur, Switzerland.; Cooper, C (corresponding author), Off Culture, Dept Archaeol, Triesen, Liechtenstein.	christine.cooper@llv.li		Heinzle, Bernd/0000-0003-4559-0377; Cooper, Christine/0000-0001-7904-808X				Acsadi G., 1970, HIST HUMAN LIFESPAN; AlQahtani SJ, 2010, AM J PHYS ANTHROPOL, V142, P481, DOI 10.1002/ajpa.21258; Alterauge A, 2017, JB ARCHAOLOGIE SCHWE, V100, P295; [Anonymous], 1980, J HUM EVOL, V9, P517; [Anonymous], 2017, INTRO FORENSIC ANTHR; Anson C, 2012, ADV ANTHR, V2, P57, DOI [10.4236/aa.2012.22007, DOI 10.4236/AA.2012.22007]; Aufderheide A.C., 1998, HUMAN PALEOPATHOLOGY; Blondiaux J, 2012, INT J PALEOPATHOL, V2, P223, DOI 10.1016/j.ijpp.2012.10.002; Breitinger E., 1938, ANTHROPOL ANZ, V14, P249; Brickley M, 2006, INT J OSTEOARCHAEOL, V16, P61, DOI 10.1002/oa.809; Brickley M, 2006, AM J PHYS ANTHROPOL, V129, P163, DOI 10.1002/ajpa.20265; Brickley M, 2005, INT J OSTEOARCHAEOL, V15, P389, DOI 10.1002/oa.794; Brooks S., 1990, HUM EVOL, V5, P227; Buikstra J. E., 1994, STANDARDS DATA COLLE; Bulger EM, 2000, J TRAUMA, V48, P1040, DOI 10.1097/00005373-200006000-00007; Byrnes JF, 2015, PAUPERS SHAME BIOCUL; Carlichi-Witjes NMP, 2015, IDENTIFIKATION TOTEN; Chu A., 2017, NEOREVIEWS, V18, pE44; Corti F, 2013, HIST LEXIKON SCHWEIZ, P539; Crist TA, 2014, INT J PALEOPATHOL, V5, P95, DOI 10.1016/j.ijpp.2014.04.002; Dam K, 2001, J UROLOGIE UROGYNAKO, V8, P25; Debrunner HU, 2003, ORTHOPADISCHES DIAGN; DeWitte SN, 2014, INT J PALEOPATHOL, V7, P38, DOI 10.1016/j.ijpp.2014.06.001; DiGangia EA, 2017, INT J OSTEOARCHAEOL, V27, P155, DOI 10.1002/oa.2526; Drew N, 2011, LANCET, V378, P1664, DOI 10.1016/S0140-6736(11)61458-X; Francomano CA, 2010, MANAGEMENT GENETIC S, P787; Galloway A., 2014, BROKEN BONES ANTHR A, P133; Galloway A., 2014, BROKEN BONES ANTHR A, V2nd, P47; Galloway A., 2014, BROKEN BONES ANTHR A, P161; Galloway A., 2014, BROKEN BONES ANTHR A, P195; Galloway A., 2014, BROKEN BONES ANTHR A, P245; Geber J, 2014, AM J PHYS ANTHROPOL, V155, P149, DOI 10.1002/ajpa.22567; Geber J, 2012, AM J PHYS ANTHROPOL, V148, P512, DOI 10.1002/ajpa.22066; Germann U, 2014, ADM ANSTALTSVERSORGU; Gowland RL, 2016, INT J OSTEOARCHAEOL, V26, P514, DOI 10.1002/oa.2442; Hackett C., 1976, DIAGNOSTIC CRITERIA, V1st; Hagg AC, 2017, INT J PALEOPATHOL, V17, P42, DOI 10.1016/j.ijpp.2017.04.001; Henderson RC, 2014, AM J PHYS ANTHROPOL, V154, P585, DOI 10.1002/ajpa.22554; Herrmann B., 1990, PRAHISTORISCHE ANTHR; Hershkovitz I, 2002, AM J PHYS ANTHROPOL, V118, P201, DOI 10.1002/ajpa.10077; Hill RMF, 2001, J BONE JOINT SURG BR, V83B, P1141, DOI 10.1302/0301-620X.83B8.11709; Hillson S, 1998, AM J PHYS ANTHROPOL, V107, P25, DOI 10.1002/(SICI)1096-8644(199809)107:1<25::AID-AJPA3>3.0.CO;2-C; Hillson S, 1997, AM J PHYS ANTHROPOL, V104, P89, DOI 10.1002/(SICI)1096-8644(199709)104:1<89::AID-AJPA6>3.0.CO;2-8; Hitz F, 2017, HIST LEXIKON SCHWEIZ; Huonker T., 1990, FAHRENDES VOLK VERFO; ISCAN MY, 1985, J FORENSIC SCI, V30, P853; ISCAN MY, 1984, J FORENSIC SCI, V29, P1094; Johannesen M, 2013, AGE AGEING, V42, P292, DOI 10.1093/ageing/afs195; Jordana X, 2006, INT J OSTEOARCHAEOL, V16, P366, DOI 10.1002/oa.829; Kaufmann A, 2008, ENTWICKLUNG ARMENFUR; KELLEY MA, 1980, AM J PHYS ANTHROPOL, V52, P153, DOI 10.1002/ajpa.1330520202; KELLEY MA, 1984, AM J PHYS ANTHROPOL, V65, P381, DOI 10.1002/ajpa.1330650407; Kimmerle EH, 2008, SKELETAL TRAUMA: IDENTIFICATION OF INJURIES RESULTING FROM HUMAN RIGHTS ABUSE AND ARMED CONFLICT, P1, DOI 10.1201/9781420009118; Knecht S, 2015, ZWANGSVERSORGUNGEN A; Koppel BS, 2005, ACTA NEUROL SCAND, V111, P225, DOI 10.1111/j.1600-0404.2005.00399.x; Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047; LANPHEAR KM, 1990, AM J PHYS ANTHROPOL, V81, P35, DOI 10.1002/ajpa.1330810106; Larsen ClarkS., 2015, BIOARCHAEOLOGY INTER; Leavitt-Reynolds AA, 2011, BIOCULTURAL EXAMINAT; Lewis ME, 2004, INT J OSTEOARCHAEOL, V14, P82, DOI 10.1002/oa.713; Lewis ME, 2003, SCI JUSTICE, V43, P201, DOI 10.1016/S1355-0306(03)71777-8; Liberfarb RM, 2003, GENET MED, V5, P21, DOI 10.1097/00125817-200301000-00004; Lippuner S, 2005, THURGAUISCHEN ZWANGS; LOVEJOY CO, 1985, AM J PHYS ANTHROPOL, V68, P15, DOI 10.1002/ajpa.1330680103; Lovell NC, 1997, YEARB PHYS ANTHROPOL, V40, P139; Lynch LG, 2014, THESIS; Mann R. W., 1990, REGIONAL ATLAS BONE; MANSILLA J, 1995, AM J PHYS ANTHROPOL, V97, P187, DOI 10.1002/ajpa.1330970208; Maples W. R., 1986, FORENSIC OSTEOLOGY A, P218; Matos V, 2006, AM J PHYS ANTHROPOL, V130, P190, DOI 10.1002/ajpa.20309; Mays S, 2008, INT J OSTEOARCHAEOL, V18, P178, DOI 10.1002/oa.930; Mays S., 2008, ADV HUMAN PALAEOPATH, P215; Meier A, 1997, ESCHNER FAMILIENBUCH; Miles AEW, 2000, INT J OSTEOARCHAEOL, V10, P125, DOI 10.1002/(SICI)1099-1212(200003/04)10:2<125::AID-OA515>3.0.CO;2-#; Mittlmeier T, 2008, TRAUMATOLOGISCHE PAT, P17; Molleson T, 1993, ANTHR MIDDLING SORT; Muller JL, 2017, BIOARCHAEOL SOC THEO, P119, DOI 10.1007/978-3-319-56949-9_7; Nerlich AG, 1998, HOMO, V49, P156; NIETHARD FU, 2003, ORTHOPADIE; Ortner D.J., 2003, IDENTIFICATION PATHO, V2nd, DOI DOI 10.1016/B978-0-12-528628-2.X5037-6; Ortner DJ, 1997, INT J OSTEOARCHAEOL, V7, P212, DOI 10.1002/(SICI)1099-1212(199705)7:3<212::AID-OA346>3.0.CO;2-5; Ortner DJ, 1999, AM J PHYS ANTHROPOL, V108, P321, DOI 10.1002/(SICI)1096-8644(199903)108:3&lt;321::AID-AJPA7&gt;3.0.CO;2-7; Ortner DJ, 2001, AM J PHYS ANTHROPOL, V114, P343, DOI 10.1002/ajpa.1046; Papageorgopoulou C, 2008, THESIS; Pimentel L, 2003, AM J EMERG MED, V21, P328, DOI 10.1016/S0735-6757(03)00083-4; Posa A, 2013, ANTHROPOL ANZ, V70, P83, DOI 10.1127/0003-5548/2012/0260; Quatrehomme G, 1997, FORENSIC SCI INT, V89, P155, DOI 10.1016/S0379-0738(97)00113-8; Reitmaier T, 2017, FORUM TOTENKULT KULT, P54; RESNICK D, 1995, DIAGNOSIS BONE JOINT, P2448; Rietmann T, 2017, FURSORGERISCHE ZWANG; Rietmann T, 2013, ADM ANSTALTSVERSORGU; Ritzmann I, 2011, HIST LEXIKON SCHWEIZ, P64; ROBERTS C, 1994, AM J PHYS ANTHROPOL, V95, P169, DOI 10.1002/ajpa.1330950205; Roberts C, 2007, ARCHAEOLOGY DIS, P2; Roberts C.A., 2003, BIOARCHAEOLOGY TUBER; Rodriguez-Martin C, 2006, FORENSIC ANTHROPOLOGY AND MEDICINE: COMPLEMENTARY SCIENCES FROM RECOVERY TO CAUSE OF DEATH, P197, DOI 10.1007/978-1-59745-099-7_8; Rose PS, 2005, AM J MED GENET A, V138A, P199, DOI 10.1002/ajmg.a.30955; Rose PS, 2001, SPINE, V26, P403, DOI 10.1097/00007632-200102150-00017; Rose PS, 2001, J PEDIATR ORTHOPED, V21, P657, DOI 10.1097/00004694-200109000-00020; Ruttimann D, 2012, HOMO, V63, P50, DOI 10.1016/j.jchb.2011.11.001; Saenger JED, 2009, THESIS; Sauer NJ, 1997, FORENSIC OSTEOLOGY A, P321; Schubert M, 2012, OP J, V28, P228; Schultz M, 2001, YEARB PHYS ANTHROPOL, V44, P106, DOI 10.1002/ajpa.10024; Schultz M., 1999, TUBERCULOSIS PRESENT, P503; Schultz M, 2015, TUBERCULOSIS, V95, pS80, DOI 10.1016/j.tube.2015.02.035; Sele R, 2017, ARCHIVRECHERCHE ANST, DOI [10.1016/j.ijpp.2017.04.001, DOI 10.1016/J.IJPP.2017.04.001]; Snoddy AME, 2018, AM J PHYS ANTHROPOL, V167, P876, DOI 10.1002/ajpa.23699; Somers J, 2017, INT J OSTEOARCHAEOL, V27, P958, DOI 10.1002/oa.2607; Somers J, 2016, PALEOPATHOLOGY NEWSL, V176, P15; Souverein PC, 2005, EPILEPSIA, V46, P304, DOI 10.1111/j.0013-9580.2005.23804.x; STEEGMANN AT, 1991, AM J PHYS ANTHROPOL, V85, P261, DOI 10.1002/ajpa.1330850304; Steinbock R.T., 1976, PALEOPATHOLOGICAL DI; Steyn M, 2013, TUBERCULOSIS, V93, P467, DOI 10.1016/j.tube.2013.04.003; STINI WA, 1995, ANNU REV ANTHROPOL, V24, P397; Szilvassy J, 1977, Beitr Gerichtl Med, V35, P343; Tuffli F, 1932, ASYLE REALTA ROTHENB; Tuli S., 2016, TUBERCULOSIS SKELETA, V5th; Ubelaker D. H., 1978, HUMAN SKELETAL REMAI; Ulrich-Bochsler S, 2016, BERNER Z GESCH HEIMA, V78, P3; Uzkeser M, 2012, EUR J TRAUMA EMERG S, V38, P157, DOI 10.1007/s00068-011-0139-9; Von Eiselsberg A, 1930, LEHRBUCH CHIRURG; von Oertzen J., 2004, Intensivmedizin und Notfallmedizin, V41, P331; Waldron T, 2009, CAMB MAN ARCHAEOL, P1; Weston DA, 2008, AM J PHYS ANTHROPOL, V137, P48, DOI 10.1002/ajpa.20839; Zhao DM, 2016, INT J CLIN EXP MED, V9, P564; 2013, INT ORTHOP, V37, P659, DOI DOI 10.1007/S00264-013-1778-8; 2009, SOC SCI MED, V68, P2240, DOI DOI 10.1016/J.SOCSCIMED.2009.03.041	128	3	3	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 8	2019	14	5							e0216483	10.1371/journal.pone.0216483	http://dx.doi.org/10.1371/journal.pone.0216483			42	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HX4MT	31067285	Green Published, Green Submitted, gold			2023-01-03	WOS:000467373000044
J	Horvath, JC; Anderson, GF				Horvath, Jane C.; Anderson, Gerard F.			The States as Important Laboratories for Federal Prescription Drug Cost-Containment Efforts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Horvath, Jane C.] Horvath Hlth Policy, POB 196, College Pk, MD 20741 USA; [Anderson, Gerard F.] Johns Hopkins Ctr Hosp Finance & Management, Johns Hopkins Sch Med, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Medicine	Horvath, JC (corresponding author), Horvath Hlth Policy, POB 196, College Pk, MD 20741 USA.	horvathhealthpolicy@gmail.com						[Anonymous], 2018, CULTIVATING VIBRANT; Crisp E, 2019, LOUISIANA MAKES ANOT; Department of Health and Human Services CfMaMS, 2018, FED REGISTER, P54546; Greene JA, 2016, JAMA-J AM MED ASSOC, V315, P461, DOI 10.1001/jama.2015.18720; Kaiser Family Foundation, 2018, PUBL OP PRESCR DRUGS; McClellan M, 2017, FORMER FDA COMMISSIO; Trusheim MR, 2018, JAMA-J AM MED ASSOC, V320, P1977, DOI 10.1001/jama.2018.15782; Willingham E, WHY DID MYLAN HIKE E	8	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	2019	321	16					1561	1562		10.1001/jama.2019.2189	http://dx.doi.org/10.1001/jama.2019.2189			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV7BZ	31012941				2023-01-03	WOS:000466137800006
J	Anabire, NG; Aryee, PA; Abdul-Karim, A; Quaye, O; Awandare, GA; Helegbe, GK				Anabire, Nsoh Godwin; Aryee, Paul Armah; Abdul-Karim, Abass; Quaye, Osbourne; Awandare, Gordon Akanzuwine; Helegbe, Gideon Kofi			Impact of malaria and hepatitis B co-infection on clinical and cytokine profiles among pregnant women	PLOS ONE			English	Article							LIVER-DISEASE; VIRUS-INFECTION; CARRIER STATUS; ERYTHROPOIETIN; OUTCOMES	Background The overlap of malaria and chronic hepatitis B (CHB) is common in endemic regions, however, it is not known if this co-infection could adversely influence clinical and immunological responses. This study investigated these interactions in pregnant women reporting to antenatal clinics in Ghana. Methods Clinical parameters (hemoglobin, liver function biomarker, peripheral malaria parasitemia, and hepatitis B viremia) and cytokine profiles were assayed and compared across four categories of pregnant women: un-infected, mono-infected with Plasmodium falciparum (Malaria group), mono-infected with chronic hepatitis B virus (CHB group) and co-infected (Malaria +CHB group). Results Women with Malaria+CHB maintained appreciably normal hemoglobin levels (mean +/- SEM = 10.3 +/- 0.3 g/dL). That notwithstanding, Liver function test showed significantly elevated levels of alanine aminotransferase, aspartate aminotransferase and total bilirubin [P<0.001 for all comparisons]. Similarly, the Malaria+CHB group had significantly elevated pro-inflammatory cytokines, including tumour necrosis factor alpha (TNF-alpha), interleukin (IL)-1 beta, and IL-6 [P<0.05 for all comparisons]. In women with Malaria+CHB, correlation analysis showed significant negative association of the pro-inflammatory cytokines responses with malaria parasitemia [IL-1 beta (P<0.001; r = -0.645), IL-6 (P = 0.046; r = -0.394) and IL-12 (P = 0.011; r = -0.49)]. On the other hand, the pro-inflammatory cytokine levels positively correlated with HBV viremia [TNF-alpha (P = 0.004; r = 0.549), IL-1 beta (P<0.001; r = 0.920), IL-6 (P<0.001; r = 0.777), IFN-gamma (P = 0.002; r = 0.579), IL-2 (P = 0.008; r = 0.512) and IL-12 (P<0.001; r = 0.655)]. Also, for women in the Malaria+CHB group, parasitemia was observed to diminish HBV viremia [P = 0.003, r = -0.489]. Conclusion Put together the findings suggests that Malaria+CHB could exacerbate inflammatory cytokine responses and increase susceptibility to liver injury among pregnant women in endemic settings.	[Anabire, Nsoh Godwin; Quaye, Osbourne; Awandare, Gordon Akanzuwine; Helegbe, Gideon Kofi] Univ Ghana, WACCBIP, Legon, Ghana; [Anabire, Nsoh Godwin; Quaye, Osbourne; Awandare, Gordon Akanzuwine] Univ Ghana, Dept Biochem Cell & Mol Biol, Legon, Ghana; [Anabire, Nsoh Godwin; Helegbe, Gideon Kofi] Univ Dev Studies, Sch Med & Hlth Sci, Dept Biochem & Mol Med, Amale, Ghana; [Aryee, Paul Armah] Univ Dev Studies, Sch Allied Hlth Sci, Dept Nutr Sci, Tamale, Ghana; [Abdul-Karim, Abass] Tamale Teaching Hosp, Zonal Publ Hlth Lab, Tamale, Ghana	University of Ghana; University of Ghana; University for Development Studies; University for Development Studies	Helegbe, GK (corresponding author), Univ Ghana, WACCBIP, Legon, Ghana.; Helegbe, GK (corresponding author), Univ Dev Studies, Sch Med & Hlth Sci, Dept Biochem & Mol Med, Amale, Ghana.	ghelegbe@uds.edu.gh		Anabire, Nsoh/0000-0002-1459-2559; Quaye, Osbourne/0000-0002-0621-876X; Awandare, Gordon/0000-0002-8793-3641	Nsoh Godwin Anabire's MPhil fellowship from a World Bank African Centres of Excellence Grant [ACE02-WACCBIP]; University for Development Studies, Tamale	Nsoh Godwin Anabire's MPhil fellowship from a World Bank African Centres of Excellence Grant; University for Development Studies, Tamale	This work was supported by Nsoh Godwin Anabire's MPhil fellowship from a World Bank African Centres of Excellence Grant (ACE02-WACCBIP: Awandare) and funds from the University for Development Studies, Tamale. Views expressed in this publication are those of the author(s) and not necessarily the funders.	Anabire NG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210365; Azizieh F, 2018, AM J REPROD IMMUNOL, V79, DOI 10.1111/aji.12818; Azizieh FY, 2015, MED PRIN PRACT, V24, P165, DOI 10.1159/000369363; Baheti R., 2003, J INDIAN ACAD CLIN M, V4, P34; Boeuf P, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003153; Bostrom S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048763; BROWN AE, 1992, J INFECT DIS, V166, P1465, DOI 10.1093/infdis/166.6.1465; Dunn C, 2007, J EXP MED, V204, P667, DOI 10.1084/jem.20061287; Eldaim N, 2012, J PHYSIOBIOCHEMICAL; Elefsiniotis IS, 2013, ANN GASTROENTEROL, V26, P59; Gao B, 2009, J LEUKOCYTE BIOL, V86, P513, DOI [10.1189/jlb.0309135, 10.1189/JLB.0309135]; Garson JA, 2005, J VIROL METHODS, V126, P207, DOI 10.1016/j.jviromet.2005.03.001; Harinasuta T., 1988, Malaria: principles and practice of malariology. Volume 1., P709; Helegbe GK, 2018, CANADIAN J INFECT DI, V2018; Holz LE, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.60; Ifeanyichukwu M O, 2017, Afr J Infect Dis, V11, P54, DOI 10.21010/ajid.v11i2.7; Ifudu O, 2001, ASAIO J, V47, P569, DOI 10.1097/00002480-200109000-00035; Jonas MM, 2009, LIVER INT, V29, P133, DOI 10.1111/j.1478-3231.2008.01933.x; Joshi D, 2010, LANCET, V375, P594, DOI 10.1016/S0140-6736(09)61495-1; Kabyemela ER, 2008, J INFECT DIS, V198, P163, DOI 10.1086/589512; Kfutwah A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008114; KLASSEN DK, 1990, AM J MED, V89, P684, DOI 10.1016/0002-9343(90)90190-O; Mackillop L, 2010, POSTGRAD MED J, V86, P160, DOI 10.1136/pgmj.2009.089631; Mahtab MA, 2008, HEPATOB PANCREAT DIS, V7, P161; Mor G, 2011, ANN NY ACAD SCI, V1221, P80, DOI 10.1111/j.1749-6632.2010.05938.x; Nmorsi OPG, 2010, ASIAN PAC J TROP MED, V3, P731, DOI 10.1016/S1995-7645(10)60175-7; Nsobya SL, 2004, J INFECT DIS, V189, P2220, DOI 10.1086/421281; Nwosu DC, 2015, INT J CURRENT RES AC, V3, P376; Pasquetto V, 2000, J EXP MED, V192, P529, DOI 10.1084/jem.192.4.529; Raghupathy R, 2008, FRONT BIOSCI-LANDMRK, V13, P985, DOI 10.2741/2737; Safir A, 2010, LIVER INT, V30, P765, DOI 10.1111/j.1478-3231.2010.02218.x; Saito S, 2010, AM J REPROD IMMUNOL, V63, P601, DOI 10.1111/j.1600-0897.2010.00852.x; Sarin Shiv K, 2011, Gastroenterology, V141, P1522, DOI 10.1053/j.gastro.2011.08.016; Saxena R, 2014, INDIAN J MED RES, V139, P737; Sharma L, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00117; SIMON P, 1982, NOUV PRESSE MED, V11, P1401; SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V58, P283, DOI 10.1016/0166-6851(93)90050-8; Suguitan AL, 2003, AM J TROP MED HYG, V69, P574, DOI 10.4269/ajtmh.2003.69.574; Tan HH, 2008, HEPATOL INT, V2, P370, DOI 10.1007/s12072-008-9063-4; Tse KY, 2005, J HEPATOL, V43, P771, DOI 10.1016/j.jhep.2005.05.023; Westbrook RH, 2010, AM J TRANSPLANT, V10, P2520, DOI 10.1111/j.1600-6143.2010.03301.x; Woodford J, 2018, AM J TROP MED HYG; World Health Organisation, 2010, BAS MAL MICR LEARN G, P69; World Health Organization, 2011, SER FERR CONC ASS IR	44	2	2	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2019	14	4							e0215550	10.1371/journal.pone.0215550	http://dx.doi.org/10.1371/journal.pone.0215550			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU1GG	31002731	Green Submitted, Green Published, gold			2023-01-03	WOS:000465019900029
J	Munday, D; Boyd, K; Jeba, J; Kimani, K; Moine, S; Grant, L; Murray, S				Munday, Daniel; Boyd, Kirsty; Jeba, Jenifer; Kimani, Kellen; Moine, Sebastien; Grant, Liz; Murray, Scott			Defining primary palliative care for universal health coverage	LANCET			English	Editorial Material									[Munday, Daniel; Boyd, Kirsty; Moine, Sebastien; Grant, Liz; Murray, Scott] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Primary Palliat Care Grp, Edinburgh EH8 9AG, Midlothian, Scotland; [Jeba, Jenifer] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India; [Kimani, Kellen] Hlth Serv Dept, Kiambu, Kiambu County, Kenya	University of Edinburgh; Christian Medical College & Hospital (CMCH) Vellore	Munday, D (corresponding author), Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Primary Palliat Care Grp, Edinburgh EH8 9AG, Midlothian, Scotland.	daniel.munday@ed.ac.uk		MOINE, Sebastien/0000-0003-3960-9422				Bloom G, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l2107; CHARLTON R, 2002, PRIMARY PALLIATIVE C; Das J, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1716; European Association For Palliative Care, 2019, TOOLK DEV PALL CAR P; Knaul FM, 2018, LANCET, V391, P1391, DOI 10.1016/S0140-6736(17)32513-8; Munday D, 2019, BMJ SUPPORT PALLIAT, V9, DOI 10.1136/bmjspcare-2018-001579; Murray SA, 2004, BMJ-BRIT MED J, V329, P1056, DOI 10.1136/bmj.329.7474.1056; Quill TE, 2013, NEW ENGL J MED, V368, P1173, DOI 10.1056/NEJMp1215620; Sleeman KE, 2019, LANCET GLOB HEALTH, V7, pE883, DOI 10.1016/S2214-109X(19)30172-X; Stjernsward J, 2007, J PAIN SYMPTOM MANAG, V33, P486, DOI 10.1016/j.jpainsymman.2007.02.016; Weissman D. E, 2010, J PALLIAT MED, V14, P17; WHO, 2017, UN HLTH COV FACTSH; World Health Organization, 2018, INT PALL CAR SYMPT R	13	7	7	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 24	2019	394	10199					621	622		10.1016/S0140-6736(19)31830-6	http://dx.doi.org/10.1016/S0140-6736(19)31830-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IT6UU	31448727	Green Accepted			2023-01-03	WOS:000483011200015
J	Martens, RJH; Broers, NJH; Canaud, B; Christiaans, MHL; Cornelis, T; Gauly, A; Hermans, MMH; Konings, CJAM; van Der Sande, FM; Scheijen, JLJM; Stifft, F; Wirtz, JJJM; Kooman, JP; Schalkwijk, CG				Martens, Remy J. H.; Broers, Natascha J. H.; Canaud, Bernard; Christiaans, Maarten H. L.; Cornelis, Tom; Gauly, Adelheid; Hermans, Marc M. H.; Konings, Constantijn J. A. M.; van Der Sande, Frank M.; Scheijen, Jean L. J. M.; Stifft, Frank; Wirtz, Joris J. J. M.; Kooman, Jeroen P.; Schalkwijk, Casper G.			Relations of advanced glycation endproducts and dicarbonyls with endothelial dysfunction and low-grade inflammation in individuals with end-stage renal disease in the transition to renal replacement therapy: A cross-sectional observational study	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; INTERCELLULAR-ADHESION MOLECULE-3; C-REACTIVE PROTEIN; SKIN-AUTOFLUORESCENCE; PLASMA-LEVELS; CARDIOVASCULAR-DISEASE; HEMODIALYSIS-PATIENTS; MEMBRANE-PROTEIN; PRODUCTS; DIALYSIS	Background Cardiovascular disease (CVD) related mortality and morbidity are high in end-stage renal disease (ESRD). The pathophysiology of CVD in ESRD may involve non-traditional CVD risk factors, such as accumulation of advanced glycation endproducts (AGEs), dicarbonyls, endothelial dysfunction (ED) and low-grade inflammation (LGI). However, detailed data on the relation of AGEs and dicarbonyls with ED and LGI in ESRD are limited. Methods We examined cross-sectional Spearman's rank correlations of AGEs and dicarbonyls with serum biomarkers of ED and LGI in 43 individuals with chronic kidney disease (CKD) stage 5 not on dialysis (CKD5-ND). Free and protein-bound serum AGEs (N-is an element of-(carboxymethyl) lysine (CML), N-is an element of-(carboxyethyl) lysine (CEL), N-delta-(5-hydro-5-methyl-4-imidazolon-2-yl)ornithine (MG-H1)) and serum dicarbonyls (glyoxal, methylglyoxal, 3-deoxyglucosone) were analyzed with tandem mass spectrometry, and tissue AGE accumulation was estimated by skin autofluorescence (SAF). Further, serum biomarkers of ED and LGI included sVCAM-1, sE-selectin, sP-selectin, sThrombomodulin, sICAM-1, sICAM-3, hs-CRP, SAA, IL-6, IL-8 and TNF-alpha. Results After adjustment for age, sex and diabetes status, protein-bound CML was positively correlated with sVCAM-1; free CEL with sVCAM-1 and sThrombomodulin; glyoxal with sThrombomodulin; and methylglyoxal with sVCAM-1 (correlation coefficients ranged from 0.36 to 0.44). In addition, free CML was positively correlated with SAA; protein-bound CML with IL-6; free CEL with hs-CRP, SAA and IL-6; free MG-H1 with SAA; protein-bound MG-H1 with IL-6; and MGO with hs-CRP and IL-6 (correlation coefficients ranged from 0.33 to 0.38). Additional adjustment for eGFR attenuated partial correlations of serum AGEs and serum dicarbonyls with biomarkers of ED and LGI. Conclusions In individuals with CKD5-ND, higher levels of serum AGEs and serum dicarbonyls were related to biomarkers of ED and LGI after adjustment for age, sex and diabetes mellitus. Correlations were attenuated by eGFR, suggesting that eGFR confounds and/or mediates the relation of serum AGEs and dicarbonyls with ED and LGI.	[Martens, Remy J. H.; Broers, Natascha J. H.; Christiaans, Maarten H. L.; van Der Sande, Frank M.; Kooman, Jeroen P.] Maastricht Univ, Dept Internal Med, Div Nephrol, Med Ctr, Maastricht, Netherlands; [Martens, Remy J. H.; Scheijen, Jean L. J. M.; Schalkwijk, Casper G.] Maastricht Univ, CARIM Sch Cardiovasc Dis, Maastricht, Netherlands; [Broers, Natascha J. H.; Kooman, Jeroen P.] Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Maastricht, Netherlands; [Canaud, Bernard; Gauly, Adelheid] Fresenius Med Care, Med Off EMEA, Bad Homburg, Germany; [Canaud, Bernard] Montpellier Univ, Sch Med, Montpellier, France; [Cornelis, Tom] Jessa Hosp, Dept Nephrol, Hasselt, Belgium; [Hermans, Marc M. H.] Viecuri Med Ctr, Dept Internal Med, Div Nephrol, Venlo, Netherlands; [Konings, Constantijn J. A. M.] Catharina Hosp, Dept Internal Med, Div Nephrol, Eindhoven, Netherlands; [Scheijen, Jean L. J. M.; Schalkwijk, Casper G.] Maastricht Univ, Dept Internal Med, Med Ctr, Maastricht, Netherlands; [Stifft, Frank] Zuyderland Med Ctr, Dept Internal Med, Div Nephrol, Sittard Geleen, Netherlands; [Wirtz, Joris J. J. M.] St Laurentius Hosp, Div Nephrol, Dept Internal Med, Roermond, Netherlands	Maastricht University; Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC); Universite de Franche-Comte; Universite de Montpellier; VieCuri Medical Center; Catharina Hospital; Maastricht University	Kooman, JP (corresponding author), Maastricht Univ, Dept Internal Med, Div Nephrol, Med Ctr, Maastricht, Netherlands.; Schalkwijk, CG (corresponding author), Maastricht Univ, CARIM Sch Cardiovasc Dis, Maastricht, Netherlands.; Kooman, JP (corresponding author), Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Maastricht, Netherlands.; Schalkwijk, CG (corresponding author), Maastricht Univ, Dept Internal Med, Med Ctr, Maastricht, Netherlands.	jeroen.kooman@mumc.nl; c.schalkwijk@maastrichtuniversity.nl	Gauly, Adelheid/X-7273-2019; Martens, Remy J.H./K-2765-2019; Scheijen, Jean/AAY-3799-2020	Martens, Remy J.H./0000-0003-4632-6412; Schalkwijk, Casper G/0000-0003-0190-2690	Fresenius Medical Care Deutschland GmbH [NL33129.068.10, NL43381.068.13]; Baxter International extramural grant [NL35039.068.10, 11CECHHDEU1004]; Dutch Kidney Foundation [NL35039.068.10, SB166]	Fresenius Medical Care Deutschland GmbH; Baxter International extramural grant; Dutch Kidney Foundation	The studies included in this article were supported by an unrestricted grant from Fresenius Medical Care Deutschland GmbH to JPK (study NL33129.068.10 and NL43381.068.13), a Baxter International extramural grant (study NL35039.068.10; grant reference number 11CECHHDEU1004 to TC) and the Dutch Kidney Foundation (study NL35039.068.10; grant reference number SB166 to TC). BC and AG, who are employees of Fresenius Medical Care, reviewed the manuscript. However, the funding sources had no role in the preparation or analysis of data, and the decision to publish.	Agalou S, 2005, J AM SOC NEPHROL, V16, P1471, DOI 10.1681/ASN.2004080635; Ando R, 2013, DIABETES VASC DIS RE, V10, P436, DOI 10.1177/1479164113486662; Bradbury BD, 2007, CLIN J AM SOC NEPHRO, V2, P89, DOI 10.2215/CJN.01170905; Broers NJH, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1299-9; Broers NJH, 2017, NEPHRON, V137, P47, DOI 10.1159/000476072; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Carrero JJ, 2010, SEMIN DIALYSIS, V23, P498, DOI 10.1111/j.1525-139X.2010.00784.x; Cornelis T, 2015, NEPHROL DIAL TRANSPL, V30, P1395, DOI 10.1093/ndt/gfv038; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DiagnOptics Technologies BV Groningen, AGE READ CU US MAN I; Gansevoort RT, 2013, LANCET, V382, P339, DOI 10.1016/S0140-6736(13)60595-4; Goldin A, 2006, CIRCULATION, V114, P597, DOI 10.1161/CIRCULATIONAHA.106.621854; Hanssen NMJ, 2019, CURR OPIN NEPHROL HY, V28, P26, DOI 10.1097/MNH.0000000000000465; Hanssen NMJ, 2014, EUR HEART J, V35, P1137, DOI 10.1093/eurheartj/eht402; Hanssen NMJ, 2013, J CLIN ENDOCR METAB, V98, pE1369, DOI 10.1210/jc.2013-1068; Hartog JWL, 2008, J CARD FAIL, V14, P596, DOI 10.1016/j.cardfail.2008.03.008; Horner DV, 2019, J RENAL NUTR, V29, P149, DOI 10.1053/j.jrn.2018.07.004; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; Lapolla A, 2005, ANN NY ACAD SCI, V1043, P217, DOI 10.1196/annals.1333.027; le Poole CY, 2012, PERITON DIALYSIS INT, V32, P45, DOI 10.3747/pdi.2010.00101; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Linden E, 2008, CLIN J AM SOC NEPHRO, V3, P691, DOI 10.2215/CJN.04291007; Maessen DE, 2016, DIABETOLOGIA, V59, P2013, DOI 10.1007/s00125-016-4009-1; Maessen DEM, 2015, CLIN SCI, V128, P839, DOI 10.1042/CS20140683; MAKITA Z, 1994, LANCET, V343, P1519, DOI 10.1016/S0140-6736(94)92935-1; Malyszko J, 2010, CLIN CHIM ACTA, V411, P1412, DOI 10.1016/j.cca.2010.06.019; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; Meerwaldt R, 2005, ANN NY ACAD SCI, V1043, P290, DOI 10.1196/annals.1333.036; Meerwaldt R, 2005, J AM SOC NEPHROL, V16, P3687, DOI 10.1681/ASN.2005020144; Mukai H, 2019, NEPHROL DIAL TRANSPL, V34, P442, DOI 10.1093/ndt/gfx371; Nagano M, 2011, NEPHROLOGY, V16, P299, DOI 10.1111/j.1440-1797.2010.01419.x; Nienhuis HL, 2008, RHEUMATOLOGY, V47, P1554, DOI 10.1093/rheumatology/ken302; Odetti P, 2006, HORM METAB RES, V38, P817, DOI 10.1055/s-2006-956501; Padilla J, 2011, PHYSIOLOGY, V26, P132, DOI 10.1152/physiol.00052.2010; Patey N, 1996, AM J PATHOL, V148, P465; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; R Core Team, 2021, R LANG ENV STAT COMP; Rabbani N, 2018, KIDNEY INT, V93, P803, DOI 10.1016/j.kint.2017.11.034; Rabbani N, 2015, BIOCHEM BIOPH RES CO, V458, P221, DOI 10.1016/j.bbrc.2015.01.140; Raj DSC, 2000, AM J KIDNEY DIS, V35, P365, DOI 10.1016/S0272-6386(00)70189-2; RStudio Team, 2016, RSTUDIO INT DEV R, DOI [10.2215/CJN.04291007, DOI 10.2215/CJN.04291007]; Sack GH, 2018, MOL MED, V24, DOI 10.1186/s10020-018-0047-0; Schalkwijk CG, 2015, DIABETOLOGIA, V58, P1715, DOI 10.1007/s00125-015-3597-5; Scheijen JLJM, 2014, CLIN CHEM LAB MED, V52, P85, DOI 10.1515/cclm-2012-0878; Schiffrin EL, 2007, CIRCULATION, V116, P85, DOI 10.1161/CIRCULATIONAHA.106.678342; Schisterman EF, 2009, EPIDEMIOLOGY, V20, P488, DOI 10.1097/EDE.0b013e3181a819a1; Schwedler SB, 2002, KIDNEY INT, V62, P301, DOI 10.1046/j.1523-1755.2002.00423.x; Sebekova K, 2001, CLIN NEPHROL, V56, pS21; Shafi T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126048; Suliman ME, 2003, J AM SOC NEPHROL, V14, P1614, DOI 10.1097/01.ASN.0000067413.32377.CF; Tonelli M, 2007, ANNU REV MED, V58, P123, DOI 10.1146/annurev.med.58.071105.111123; Uchimura T, 2002, NEPHRON, V90, P401, DOI 10.1159/000054727; Ueno H, 2011, METABOLISM, V60, P453, DOI 10.1016/j.metabol.2010.04.001; von Scholten BJ, 2016, J DIABETES COMPLICAT, V30, P248, DOI 10.1016/j.jdiacomp.2015.11.005; Wang CH, 2016, PLOS ONE, V11, DOI [10.1371/journal.pone.0148017, 10.1371/journal.pone.0151633]; Weiss MF, 2000, KIDNEY INT, V57, P2571, DOI 10.1046/j.1523-1755.2000.00117.x; Witko-Sarsat V, 1998, J IMMUNOL, V161, P2524; Yudkin JS, 1999, ARTERIOSCL THROM VAS, V19, P972, DOI 10.1161/01.ATV.19.4.972	58	15	15	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2019	14	8							e0221058	10.1371/journal.pone.0221058	http://dx.doi.org/10.1371/journal.pone.0221058			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5HO	31408493	gold, Green Submitted, Green Published			2023-01-03	WOS:000485009500035
J	Nadal-Serrano, JM; de la Pedrosa, EGG; Lopez-Vallejo, M; Gonzalez, ADF; Lopez-Barrio, C				Nadal-Serrano, Jose M.; de la Pedrosa, Elia Gomez G.; Lopez-Vallejo, Marisa; Fernandez Gonzalez, Alvaro de Guzman; Lopez-Barrio, Carlos			Simple method to generate calibrated synthetic smoke-like atmospheres at microscopic scale	PLOS ONE			English	Article							FRACTAL AGGREGATE; SOOT; SCATTERING; PARTICLES; VESSEL; MODEL	Artificial smokes focusing on macroscopic or fluid properties of smoke have been available for a long time. This paper presents a simple method to generate fully customizable smoke-like atmospheres at microscopic scale (i.e. considering their constituent particles as discrete elements) using a different approach. Synthetic, reproducible media can be generated combining monodisperse microspheres with known geometrical and optical properties conveniently parameterized. The method is presented as a proof-of-concept, highlighting the design decisions along with their implications. Practical issues such as aerosol nebulization, particle carrier selection or the features of the medium chamber where the smoke-like atmosphere is to be tested are analyzed. A comparison between methanol and ethanol as carriers for polystyrene microsphere nebulization is also made. The method could be the seed for the obtention of standard reference media for calibration or standardized characterization of not only smoke detectors and exhaust smoke sensors but also other instruments relying on optical properties of dispersive media (dust in PV panels, public lighting, etc.).	[Nadal-Serrano, Jose M.; Lopez-Vallejo, Marisa; Fernandez Gonzalez, Alvaro de Guzman; Lopez-Barrio, Carlos] Univ Politecn Madrid, ETSI Telecomunicac, Madrid, Spain; [de la Pedrosa, Elia Gomez G.] Hosp Univ Ramon y Cajal, Madrid, Spain	Universidad Politecnica de Madrid; Hospital Universitario Ramon y Cajal	Nadal-Serrano, JM (corresponding author), Univ Politecn Madrid, ETSI Telecomunicac, Madrid, Spain.	jmnadal@ieee.org	Lopez-Vallejo, Marisa/K-9456-2014; Barrio, Carlos A. López/I-1311-2015	Lopez-Vallejo, Marisa/0000-0002-3833-524X; Barrio, Carlos A. López/0000-0002-2423-5272				BANKSTON CP, 1981, COMBUST FLAME, V41, P273, DOI 10.1016/0010-2180(81)90062-6; Baumgardner D, 2012, ATMOS MEAS TECH, V5, P1869, DOI 10.5194/amt-5-1869-2012; Black JD, 2017, SOOT GENERATING DEVI; Brandrup J., 1975, POLYM HDB; Bryan JL, SMOKE DETERMINANT HU; CHRISTOFORIDIS AJ, 1971, CHEST, V59, P629, DOI 10.1378/chest.59.6.629; Davies NW, 2018, ACCURACY AEROSOL PHO; Deng XY, 2004, APPL OPTICS, V43, P2925, DOI 10.1364/AO.43.002925; Di Sarli V, 2014, J LOSS PREVENT PROC, V27, P8, DOI 10.1016/j.jlp.2013.10.015; DOBBINS RA, 1994, ATMOS ENVIRON, V28, P889, DOI 10.1016/1352-2310(94)90247-X; Doner N, 2017, J QUANT SPECTROSC RA, V187, P10, DOI 10.1016/j.jqsrt.2016.09.005; Frank SR, 2004, RESP INFECT TREATMEN; Hinds W.C, 1999, AEROSOL TECHNOLOGY P; Hull P, 2004, APPL OPTICS, V43, P3433, DOI 10.1364/AO.43.003433; Ishii K, 1998, APPL OPTICS, V37, P5014, DOI 10.1364/AO.37.005014; Jiang H, 2014, SCI REP-UK, V4, DOI 10.1038/srep07114; Kashef A, 2004, 5 INT C TUNN FIR LON, P185; Kobes M, 2010, FIRE SAFETY J, V45, P1, DOI 10.1016/j.firesaf.2009.08.005; Kou L., 1996, BLACK CARBON ATMOSPH; Labs B, 2013, MICR AGGR; Labs B, 2013, DRYING RES MICR; Ma XY, 2003, PHYS MED BIOL, V48, P4165, DOI 10.1088/0031-9155/48/24/013; MERCER TT, 1968, AM IND HYG ASSOC J, V29, P66, DOI 10.1080/00028896809342983; Middleton N, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9061053; Moallemi A, 2019, J AEROSOL SCI, V135, P46, DOI 10.1016/j.jaerosci.2019.05.004; Mulholland GW, 1995, SFPE HDB FIRE PROTEC; Nadal-Serrano JM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187219; Nadal-Serrano JM, 2015, FIRE SAFETY J, V71, P299, DOI 10.1016/j.firesaf.2014.11.029; NIST, 2013, SRM 2975 DIES PART M; OCallaghan C, 1997, THORAX, V52, pS31, DOI 10.1136/thx.52.2008.S31; PHIPPS PR, 1990, CHEST, V97, P1327, DOI 10.1378/chest.97.6.1327; Prahl S., 2012, MIE SCATTERING; Runyan CW, 2005, AM J PREV MED, V28, P73, DOI 10.1016/j.amepre.2004.09.010; Seinfeld J.H., 2016, ENVIRONMENT, DOI [10.1080/00139157.1999.10544295, DOI 10.1080/00139157.1999.10544295]; SPANNER G, 1994, J AEROSOL SCI, V25, P265, DOI 10.1016/0021-8502(94)90078-7; Tan S, 2019, RELIAB ENG SYST SAFE, V188, P233, DOI 10.1016/j.ress.2019.03.012; Tumolva L, 2010, AEROSOL SCI TECH, V44, P202, DOI 10.1080/02786820903518907; Webb AK, 2006, FDS MODELLING HOT SM; Weinert D. W., 2002, FIR SAF SCI P 7 INT, P209; Wu WW, 2017, J LOSS PREVENT PROC, V49, P299, DOI 10.1016/j.jlp.2017.07.012	40	1	1	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 2	2019	14	8							e0220700	10.1371/journal.pone.0220700	http://dx.doi.org/10.1371/journal.pone.0220700			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5AR	31374105	gold, Green Published, Green Submitted			2023-01-03	WOS:000484991500027
J	Fahrni, ML; Azmy, MT; Usir, E; Abd Aziz, N; Hassan, Y				Fahrni, Mathumalar Loganathan; Azmy, Mohd Taufiq; Usir, Ezlina; Abd Aziz, Noorizan; Hassan, Yahaya			Inappropriate prescribing defined by STOPP and START criteria and its association with adverse drug events among hospitalized older patients: A multicentre, prospective study	PLOS ONE			English	Article							SCREENING TOOL; STOPP/START CRITERIA; MEDICATION USE; BEERS CRITERIA; ALERT DOCTORS; POLYPHARMACY; IMPACT; RISK; PEOPLE; PRESCRIPTIONS	Objectives To provide baseline information on inappropriate prescribing (IP), and to evaluate whether potentially inappropriate medications (PIMs), as defined by STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions) criteria, were associated with preventable adverse drug events (ADEs) and/or hospitalization. Methods We prospectively studied older patients (n = 301) admitted to three urban, public-funded hospitals. We scrutinized their medical records and used STOPP-START (Screening Tool to Alert Prescribers to Right Treatment) criteria to determine PIM and potential prescribing omissions (PPO) respectively-together these constitute IP. Prescriptions with PIM(s) were subjected to a pharmacist medication review, aimed at detecting cases of ADE(s). The vetted cases were further assessed by an expert consensus panel to ascertain: i) causality between the ADE and hospitalization, using, the World Health Organization Uppsala Monitoring Centre criteria, and, ii) whether the ADEs were avoidable (using Hallas criteria). Finally, percentages of PIM-associated ADEs that were both preventable and linked to hospitalization were calculated. Results IP prevalence was 58.5% (n = 176). A majority (49.5%, n = 150) had moderate to severe degree of comorbidities (Charlson Comorbidity Index score >= 3). Median age was 72 years. Median number of medications was 6 and 30.9% (n = 93) had >= 8 medications. PIM prevalence was 34.9% (117 PIMs, n = 105) and PPO 37.9% (191 PPOs, n = 114). Most PIMs and PPOs involved overuse of aspirin and underuse of both antiplatelets and statins respectively. With every increase in the number of medications prescribed, the likelihood of PIM occurrence increased by 20%, i.e. 1.2 fold (OR 1.20, 95% CI: 1.1-1.3). Among the 105 patients with PIMs, 33 ADEs (n = 33); 31 ADEs (n = 31) considered "causal" or "contributory" to hospitalization; 27 ADEs (n = 27) deemed "avoidable" or "potentially avoidable"; and 25 PIM-associated ADEs, preventable, and that induced hospitalization (n = 25), were identified: these equated to prevalence of 31.4%, 29.5%, 25.7%, and 23.8% respectively. The most common ADEs were masked hypoglycemia and gastrointestinal bleed. With every additional PIM prescribed, the odds for ADE occurrence increased by 12 folds (OR 11.8, 95% CI 5.20-25.3). Conclusion The majority of the older patients who were admitted to secondary care for acute illnesses were potentially exposed to IP. Approximately a quarter of the patients were prescribed with PIMs, which were plausibly linked with preventable ADEs that directly caused or contributed to hospitalization.	[Fahrni, Mathumalar Loganathan; Azmy, Mohd Taufiq; Usir, Ezlina] Univ Teknol MARA UiTM, Fac Pharm, Dept Clin Pharm & Pharm Practice, Selangor Branch, Puncak Alam Campus, Selangor Darul Ehsan, Malaysia; [Fahrni, Mathumalar Loganathan] Univ Teknol MARA UiTM, Communities Res Pharmaceut & Life Sci, Collaborat Drug Discovery Res CDDR Grp, Selangor Darul Ehsan, Malaysia; [Abd Aziz, Noorizan; Hassan, Yahaya] Management & Sci Univ, Shah Alam, Selangor, Malaysia	Management Science University	Fahrni, ML (corresponding author), Univ Teknol MARA UiTM, Fac Pharm, Dept Clin Pharm & Pharm Practice, Selangor Branch, Puncak Alam Campus, Selangor Darul Ehsan, Malaysia.; Fahrni, ML (corresponding author), Univ Teknol MARA UiTM, Communities Res Pharmaceut & Life Sci, Collaborat Drug Discovery Res CDDR Grp, Selangor Darul Ehsan, Malaysia.	mathumalar@gmail.com	Usir, EZLINA/AAU-3392-2020; Fahrni, Mathumalar Loganathan/F-6421-2015; Fahrni, Mathumalar/GRO-4323-2022	Usir, EZLINA/0000-0001-6510-2049; Fahrni, Mathumalar Loganathan/0000-0002-9042-4290; 	UiTM Cawangan Selangor Grant [(DUCS) 600-UiTMSEL (PI. 5/4) (059/2018) EU]	UiTM Cawangan Selangor Grant	This project was funded by the UiTM Cawangan Selangor Grant (DUCS) 600-UiTMSEL (PI. 5/4) (059/2018) EU. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almeida TA, 2018, RES SOCIAL ADM PHARM; Anathhanam S, 2012, THER ADV DRUG SAF, V3, P165, DOI 10.1177/2042098612443848; Barry PJ, 2007, AGE AGEING, V36, P632, DOI 10.1093/ageing/afm118; Beers MH, 1997, ARCH INTERN MED, V157, P1531, DOI 10.1001/archinte.157.14.1531; Boparai MK, 2011, MT SINAI J MED, V78, P613, DOI 10.1002/msj.20278; Bradley MC, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-72; Cadogan CA, 2016, DRUG SAFETY, V39, P109, DOI 10.1007/s40264-015-0378-5; Chang CB, 2012, PHARMACOEPIDEM DR S, V21, P1269, DOI 10.1002/pds.3274; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chen LL, 2012, INT J CLIN PHARM-NET, V34, P596, DOI 10.1007/s11096-012-9651-1; Coupland CA, NIHR HEALTH TECHNOLO; Dalleur O, 2012, DRUG AGING, V29, P829, DOI 10.1007/s40266-012-0016-1; Gallagher P, 2008, INT J CLIN PHARM TH, V46, P72; Gallagher P, 2007, J CLIN PHARM THER, V32, P113, DOI 10.1111/j.1365-2710.2007.00793.x; Gallagher P, 2008, AGE AGEING, V37, P673, DOI 10.1093/ageing/afn197; Gallagher P, 2011, EUR J CLIN PHARMACOL, V67, P1175, DOI 10.1007/s00228-011-1061-0; Garcia-Gollarte F, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2011.02.009; Gates PJ, 2019, DRUG SAFETY, V42, P13, DOI 10.1007/s40264-018-0715-6; Ghadimi H, 2011, PHARMACOEPIDEM DR S, V20, P482, DOI 10.1002/pds.2106; HALLAS J, 1990, J INTERN MED, V228, P83, DOI 10.1111/j.1365-2796.1990.tb00199.x; Hamilton H, 2011, ARCH INTERN MED, V171, P1013, DOI 10.1001/archinternmed.2011.215; Hamilton Hilary J, 2009, BMC Geriatr, V9, P5, DOI 10.1186/1471-2318-9-5; Henschel Frank, 2015, Drugs Real World Outcomes, V2, P249; Hiance-Delahaye A, 2018, INT PSYCHOGERIATR, V30, P715, DOI 10.1017/S1041610217002290; Hill-Taylor B, 2013, J CLIN PHARM THER, V38, P360, DOI 10.1111/jcpt.12059; Hughes CM, 2016, INT J PHARMACEUT, V512, P360, DOI 10.1016/j.ijpharm.2016.02.035; Jano E, 2007, ANN PHARMACOTHER, V41, P438, DOI 10.1345/aph.1H473; Karani MV, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00250; Katzung B.G., 2010, BASIC CLIN PHARM; Kaufmann CP, 2014, EUR J CLIN PHARMACOL, V70, P1, DOI 10.1007/s00228-013-1575-8; Kim DS, 2010, HEALTHC INFORM RES, V16, P231, DOI 10.4258/hir.2010.16.4.231; Kuijpers MAJ, 2008, BRIT J CLIN PHARMACO, V65, P130, DOI 10.1111/j.1365-2125.2007.02961.x; Lam MPS, 2012, EXPERT REV CLIN PHAR, V5, P187, DOI [10.1586/ecp.12.6, 10.1586/ECP.12.6]; Lao CK, 2013, INT J CLIN PHARM-NET, V35, P805, DOI 10.1007/s11096-013-9811-y; Lehnert T, 2011, MED CARE RES REV, V68, P387, DOI 10.1177/1077558711399580; Lindquist M, 2001, J RHEUMATOL, V28, P1180; Liu CL, 2012, ARCH GERONTOL GERIAT, V55, P148, DOI 10.1016/j.archger.2011.07.001; Loganathan M, 2011, AGE AGEING, V40, P150, DOI 10.1093/ageing/afq161; Lonnbro J, 2017, EUR J CLIN PHARMACOL, V73, P499, DOI 10.1007/s00228-016-2188-9; Meyboom R., 1992, PHARMACOEPIDEM DR S, V1, P87; Miller GE, 2017, HEALTH SERV RES, V52, P1534, DOI 10.1111/1475-6773.12562; Morin L, 2016, J AM MED DIR ASSOC, V17, DOI 10.1016/j.jamda.2016.06.011; Vishwas H, 2012, GERIATR GERONTOL INT, V12, P506, DOI 10.1111/j.1447-0594.2011.00806.x; Naing L, 2006, ARCH OROFAC SCI, V1, P9; Noelker LS, 2014, GERONTOLOGIST, V54, P13, DOI 10.1093/geront/gnt086; O'Mahony D, 2015, AGE AGEING, V44, P213, DOI 10.1093/ageing/afu145; Parfitt K, 2009, MARTINDALE COMPLETE; PETTY DR, 2001, PHARM J, V267, P863; Projovic I, 2016, EUR J CLIN PHARMACOL, V72, P93, DOI 10.1007/s00228-015-1957-1; Ryan C, 2009, ANN PHARMACOTHER, V43, P1239, DOI 10.1345/aph.1M157; Silva RDS, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210312; Sheikh A, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.010422; Spinewine A, 2007, LANCET, V370, P173, DOI 10.1016/S0140-6736(07)61091-5; Stausberg J, 2010, DTSCH ARZTEBL INT, V107, P23, DOI 10.3238/arztebl.2010.0023; Steinman MA, 2006, J AM GERIATR SOC, V54, P1516, DOI 10.1111/j.1532-5415.2006.00889.x; Stevens GA, 2011, LANCET, V378, P31; Thevelin S, 2019, DRUGS AGING, V29, P1; Thevelin S, 2018, BRIT J CLIN PHARMACO, V84, P2600, DOI 10.1111/bcp.13716; Wauters M, 2016, BRIT J CLIN PHARMACO, V82, P1382, DOI 10.1111/bcp.13055; Weng MC, 2013, QJM-INT J MED, V106, P1009, DOI 10.1093/qjmed/hct141; WHO, US WHO UMC SYST STAN; Winit-Watjana W, 2008, ARCH GERONTOL GERIAT, V47, P35, DOI 10.1016/j.archger.2007.06.006; World Health Organization, 2002, IMP PHARM SAF MON ME, P52	63	14	14	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 26	2019	14	7							e0219898	10.1371/journal.pone.0219898	http://dx.doi.org/10.1371/journal.pone.0219898			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4WC	31348784	Green Published, gold, Green Submitted			2023-01-03	WOS:000484979500013
J	Arienti, C; Lazzarini, SG; Pollock, A; Negrini, S				Arienti, Chiara; Lazzarini, Stefano G.; Pollock, Alex; Negrini, Stefano			Rehabilitation interventions for improving balance following stroke: An overview of systematic reviews	PLOS ONE			English	Article							WHOLE-BODY VIBRATION; VIRTUAL-REALITY; SITTING BALANCE; MOTOR FUNCTION; WALKING SPEED; NINTENDO WII; GAIT SPEED; TAI CHI; EXERCISE; POSTSTROKE	Background The aim of this study was to synthesize evidence from systematic reviews, to summarise the effects of rehabilitation interventions for improving balance in stroke survivors. Methods We conducted an overview of systematic reviews (SRs). We included Cochrane Systematic Reviews and non-Cochrane Systematic Reviews of randomized-controlled clinical trials and not-randomized clinical trials, in all types of stroke, comparing the effects of interventions, control interventions and no interventions on balance-related outcomes. We conducted a comprehensive search of electronic databases, from inception to December 2017. Data extracted included: number and type of participants, type of intervention, control intervention, method of assessing risk of bias of primary studies, balance outcome measures and results of statistical meta-analyses. Methodological quality of included reviews was assessed using AMSTAR 2. A narrative description of the characteristics of the SRs was provided and results of meta-analyses summarised with reference to their methodological quality. Results 51 SRs (248 primary studies and 10,638 participants) met the inclusion criteria and were included in the overview. All participants were adults with stroke. A wide variety of different balance and postural control outcomes were included. 61% of SRs focussed on the effectiveness of physical therapy, 20% virtual reality, 6% electromechanical devices, 4% Tai-Chi, whole body vibration and circuit training intervention, and 2% cognitive rehabilitation. The methodology of 54% of SRs were judged to be of a "low or critically low" quality, 23% "moderate" quality and 22% "high" quality. Conclusions There are 51 SRs of evidence relating to the effectiveness of interventions to improve balance in people with stroke, but the majority of these are of poor methodological quality, limiting our ability to draw clear implications. Only 22% of these SRs were judged to be of high quality, highlighting the need to address important methodological issues within rehabilitation research.	[Arienti, Chiara; Lazzarini, Stefano G.; Negrini, Stefano] IRCCS Fdn Don Carlo Gnocchi, Milan, Italy; [Pollock, Alex] Glasgow Caledonian Univ, Nursing Midwifery & Allied Hlth Profess Res Unit, Glasgow, Lanark, Scotland; [Negrini, Stefano] Univ Brescia, Dept Clin & Expt Sci, Brescia, Italy	IRCCS Fondazione Don Carlo Gnocchi Onlus; Glasgow Caledonian University; University of Brescia	Arienti, C (corresponding author), IRCCS Fdn Don Carlo Gnocchi, Milan, Italy.	carienti@dongnocchi.it	Negrini, Stefano/B-6667-2013; Lazzarini, Stefano Giuseppe/AHC-0043-2022	Negrini, Stefano/0000-0002-1878-2747; Lazzarini, Stefano Giuseppe/0000-0002-9576-2459; Todhunter-Brown, Alex/0000-0003-4941-7985				Dos Santos LRA, 2015, J STROKE CEREBROVASC, V24, P2298, DOI 10.1016/j.jstrokecerebrovasdis.2015.06.010; An MJ, 2011, J NEUROSCI NURS, V43, P298, DOI 10.1097/JNN.0b013e318234ea24; [Anonymous], 2007, WORLD CONF PHYS THER; Armijo-Olivo S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132634; Armijo-Olivo S, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-116; Bank J, 2016, TOP STROKE REHABIL, V23, P33, DOI 10.1179/1945511915Y.0000000005; Banzi R, 2018, J CLIN EPIDEMIOL, V99, P24, DOI 10.1016/j.jclinepi.2018.02.024; Barclay-Goddard R., 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004129.PUB2; Beyaert C, 2015, NEUROPHYSIOL CLIN, V45, P335, DOI 10.1016/j.neucli.2015.09.005; Boehm WL, 2016, TRANSL STROKE RES, V7, P3, DOI 10.1007/s12975-015-0435-5; Bonini-Rocha AC, 2018, PM&R, V10, P398, DOI 10.1016/j.pmrj.2017.09.014; Bowen A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003586.pub3; Broderick P, 2018, GAIT POSTURE, V63, P208, DOI 10.1016/j.gaitpost.2018.05.017; Cabanas-Valdes R, 2013, NEUROREHABILITATION, V33, P575, DOI 10.3233/NRE-130996; Chen BL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135932; Chen J, 2015, J STROKE CEREBROVASC, V24, P2660, DOI 10.1016/j.jstrokecerebrovasdis.2015.09.014; CHEN L, 2016, BIOMED RES INT, V2016, DOI DOI 10.1155/2016/7309272; Chen LH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163351; Cheok G, 2015, J AM MED DIR ASSOC, V16, P923, DOI 10.1016/j.jamda.2015.06.010; Corbetta D, 2015, J PHYSIOTHER, V61, P117, DOI 10.1016/j.jphys.2015.05.017; da Costa BR, 2013, J CLIN EPIDEMIOL, V66, P75, DOI 10.1016/j.jclinepi.2012.08.003; de Rooij IJM, 2016, PHYS THER, V96, P1905, DOI 10.2522/ptj.20160054; English C, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007513.pub3; Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4; Fisher A, 2014, J STROKE CEREBROVASC, V23, P759, DOI 10.1016/j.jstrokecerebrovasdis.2013.06.035; French B, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006073.pub2; Ge L, 2017, COMPLEMENT THER CLIN, V29, P35, DOI 10.1016/j.ctcp.2017.08.005; Gillespie DC, 2015, CLIN REHABIL, V29, P120, DOI 10.1177/0269215514538982; GREEN S, 2008, COCHRANE HDB SYSTEMA, pCH1; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Hammer A, 2008, EUR J PHYSIOTHER, V10, P163, DOI 10.1080/14038190701757656; Hancock NJ, 2012, INT J STROKE, V7, P47, DOI 10.1111/j.1747-4949.2011.00728.x; Herbert R, 1998, Health Inf Manag, V28, P186; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Hunt H, 2018, SYST REV-LONDON, V7, DOI 10.1186/s13643-018-0695-8; Iruthayarajah J, 2017, TOP STROKE REHABIL, V24, P68, DOI 10.1080/10749357.2016.1192361; Ko DS, 2014, J PHYS THER SCI, V26, P1993, DOI 10.1589/jpts.26.1993; Kollen BJ, 2009, STROKE, V40, pE89, DOI 10.1161/STROKEAHA.108.533828; Langhorne P, 2009, LANCET NEUROL, V8, P741, DOI 10.1016/S1474-4422(09)70150-4; Laver KE, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008349.pub2, 10.1002/14651858.CD008349.pub3, 10.1002/14651858.CD008349.pub4]; Lawrence M, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011483.pub2; Li GY, 2018, J REHABIL MED, V50, P582, DOI 10.2340/16501977-2346; Li Z, 2016, CLIN REHABIL, V30, P432, DOI 10.1177/0269215515593611; Lin SQ, 2018, J REHABIL MED, V50, P3, DOI 10.2340/16501977-2266; Louie DR, 2019, J STROKE CEREBROVASC, V28, P107, DOI 10.1016/j.jstrokecerebrovasdis.2018.09.017; Lu J, 2015, TOP STROKE REHABIL, V22, P161, DOI 10.1179/1074935714Z.0000000005; Lubetzky-Vilnai A, 2010, J NEUROL PHYS THER, V34, P127, DOI 10.1097/NPT.0b013e3181ef764d; Lunny C, 2018, SYST REV-LONDON, V7, DOI 10.1186/s13643-018-0784-8; Lunny C, 2017, SYST REV-LONDON, V6, DOI 10.1186/s13643-017-0617-1; Lunny C, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-015-0178-0; Luque-Moreno C, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/342529; Mehrholz J, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008186.pub2; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Murad MH, 2014, JAMA-J AM MED ASSOC, V312, P171, DOI 10.1001/jama.2014.5559; Olivo SA, 2008, PHYS THER, V88, P156, DOI 10.2522/ptj.20070147; Ovbiagele B, 2011, NEUROTHERAPEUTICS, V8, P319, DOI 10.1007/s13311-011-0053-1; Petro B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185188; Pieper D, 2019, J CLIN EPIDEMIOL, V108, P26, DOI 10.1016/j.jclinepi.2018.12.004; Pin-Barre C, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/608581; Pollock A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001920.pub2; Pollock Alex, 2011, Cochrane Database Syst Rev, pCD008389, DOI 10.1002/14651858.CD008389.pub2; Pollock A, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008388.pub3; Pollock A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001920.pub3; Pollock A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008388.pub2; Pollock M., 2018, COCHRANE HDB SYSTEMA; Saunders DH, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003316.pub6; Schroder J, 2018, TOP STROKE REHABIL, V25, P312, DOI 10.1080/10749357.2018.1440694; Shea BJ, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j4008; Sorinola IO, 2014, NEUROREHABILITATION, V35, P205, DOI 10.3233/NRE-141123; Stoller O, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-45; Swinnen E, 2014, TOP STROKE REHABIL, V21, P87, DOI 10.1310/tsr2102-87; Tally Z, 2017, TOP STROKE REHABIL, V24, P539, DOI 10.1080/10749357.2017.1345445; Tang A, 2015, CLIN REHABIL, V29, P1168, DOI 10.1177/0269215515570380; The Stroke Association, 2018, STATE NATION STROKE; Tyson SF, 2013, ARCH PHYS MED REHAB, V94, P1377, DOI 10.1016/j.apmr.2012.12.025; Van Criekinge T, 2018, DISABIL REHABIL, V40, P1981, DOI 10.1080/09638288.2017.1323030; van Duijnhoven HJR, 2016, STROKE, V47, P2603, DOI 10.1161/STROKEAHA.116.013839; Van Peppen RPS, 2006, J REHABIL MED, V38, P3, DOI 10.1080/16501970500344902; Van Peppen RPS, 2004, CLIN REHABIL, V18, P833, DOI 10.1191/0269215504cr843oa; Veerbeek JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087987; Vloothuis JDM, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011058.pub2; Walker MF, 2017, NEUROREHAB NEURAL RE, V31, P877, DOI 10.1177/1545968317732686; Wang XQ, 2015, EUR J NEUROL, V22, P555, DOI 10.1111/ene.12616; Wevers L, 2009, STROKE, V40, P2450, DOI 10.1161/STROKEAHA.108.541946; Whiting P, 2016, J CLIN EPIDEMIOL, V69, P225, DOI 10.1016/j.jclinepi.2015.06.005; Winstein CJ, 2016, STROKE, V47, pE98, DOI 10.1161/STR.0000000000000098; Wist S, 2016, ANN PHYS REHABIL MED, V59, P114, DOI 10.1016/j.rehab.2016.02.001; Wonsetler EC, 2017, TOP STROKE REHABIL, V24, P394, DOI 10.1080/10749357.2017.1282413; Wu SZ, 2018, MED SCI MONIT BASIC, V24, P210, DOI 10.12659/MSMBR.911951; Yang XT, 2015, CLIN REHABIL, V29, P627, DOI 10.1177/0269215514552829; Zou LY, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15061292	91	32	38	2	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 19	2019	14	7							e0219781	10.1371/journal.pone.0219781	http://dx.doi.org/10.1371/journal.pone.0219781			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4SZ	31323068	Green Submitted, Green Published, gold			2023-01-03	WOS:000484971300018
J	Garrouste-Orgeas, M; Flahault, C; Vinatier, I; Rigaud, JP; Thieulot-Rolin, N; Mercier, E; Rouget, A; Grand, H; Lesieur, O; Tamion, F; Hamidfar, R; Renault, A; Parmentier-Decrucq, E; Monseau, Y; Argaud, L; Bretonniere, C; Lautrette, A; Badie, J; Boulet, E; Floccard, B; Forceville, X; Kipnis, E; Soufir, L; Valade, S; Bige, N; Gaffinel, A; Hamzaoui, O; Simon, G; Thirion, M; Bouadma, L; Large, A; Mira, JP; Amdjar-Badidi, N; Jourdain, M; Jost, PH; Maxime, V; Santoli, F; Ruckly, S; Vioulac, C; Leborgne, MA; Bellalou, L; Fasse, L; Misset, B; Bailly, S; Timsit, JF				Garrouste-Orgeas, Maite; Flahault, Cecile; Vinatier, Isabelle; Rigaud, Jean-Philippe; Thieulot-Rolin, Nathalie; Mercier, Emmanuelle; Rouget, Antoine; Grand, Hubert; Lesieur, Olivier; Tamion, Fabienne; Hamidfar, Rebecca; Renault, Anne; Parmentier-Decrucq, Erika; Monseau, Yannick; Argaud, Laurent; Bretonniere, Cedric; Lautrette, Alexandre; Badie, Julio; Boulet, Eric; Floccard, Bernard; Forceville, Xavier; Kipnis, Eric; Soufir, Lilia; Valade, Sandrine; Bige, Naike; Gaffinel, Alain; Hamzaoui, Olfa; Simon, Georges; Thirion, Marina; Bouadma, Lila; Large, Audrey; Mira, Jean-Paul; Amdjar-Badidi, Nora; Jourdain, Merce; Jost, Paul-Henri; Maxime, Virginie; Santoli, Francois; Ruckly, Stephane; Vioulac, Christel; Leborgne, Marie Annick; Bellalou, Lucie; Fasse, Leonor; Misset, Benoit; Bailly, Sebastien; Timsit, Jean-Francois			Effect of an ICU Diary on Posttraumatic Stress Disorder Symptoms Among Patients Receiving Mechanical Ventilation A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE-UNIT SURVIVORS; HOSPITAL ANXIETY; CRITICAL ILLNESS; DEPRESSION; REHABILITATION; COMMUNICATION; DISCHARGE; RELATIVES; DISTRESS; MEMORY	Importance Keeping a diary for patients while they are in the intensive care unit (ICU) might reduce their posttraumatic stress disorder (PTSD) symptoms. Objectives To assess the effect of an ICU diary on the psychological consequences of an ICU hospitalization. Design, Setting, and Participants Assessor-blinded, multicenter, randomized clinical trial in 35 French ICUs from October 2015 to January 2017, with follow-up until July 2017. Among 2631 approached patients, 709 adult patients (with 1 family member each) who received mechanical ventilation within 48 hours after ICU admission for at least 2 days were eligible, 657 were randomized, and 339 were assessed 3 months after ICU discharge. Interventions Patients in the intervention group (n = 355) had an ICU diary filled in by clinicians and family members. Patients in the control group (n = 354) had usual ICU care without an ICU diary. Main Outcomes and Measures The primary outcome was significant PTSD symptoms, defined as an Impact Event Scale-Revised (IES-R) score greater than 22 (range, 0-88; a higher score indicates more severe symptoms), measured in patients 3 months after ICU discharge. Secondary outcomes, also measured at 3 months and compared between groups, included significant PTSD symptoms in family members; significant anxiety and depression symptoms in patients and family members, based on a Hospital Anxiety and Depression Scale score greater than 8 for each subscale (range, 0-42; higher scores indicate more severe symptoms; minimal clinically important difference, 2.5); and patient memories of the ICU stay, reported with the ICU memory tool. Results Among 657 patients who were randomized (median [interquartile range] age, 62 [51-70] years; 126 women [37.2%]), 339 (51.6%) completed the trial. At 3 months, significant PTSD symptoms were reported by 49 of 164 patients (29.9%) in the intervention group vs 60 of 175 (34.3%) in the control group (risk difference, -4% [95% CI, -15% to 6%]; P = .39). The median (interquartile range) IES-R score was 12 (5-25) in the intervention group vs 13 (6-27) in the control group (difference, -1.47 [95% CI, -1.93 to 4.87]; P = .38). There were no significant differences in any of the 6 prespecified comparative secondary outcomes. Conclusions and Relevance Among patients who received mechanical ventilation in the ICU, the use of an ICU diary filled in by clinicians and family members did not significantly reduce the number of patients who reported significant PTSD symptoms at 3 months. These findings do not support the use of ICU diaries for preventing PTSD symptoms.	[Garrouste-Orgeas, Maite; Bouadma, Lila; Bailly, Sebastien; Timsit, Jean-Francois] Paris Diderot Univ, Bichat Univ Hosp, AP HP, IAME,UMR 1137,INSERM,Dept Biostat,HUPNVS,UFR Med, Paris, France; [Garrouste-Orgeas, Maite; Ruckly, Stephane; Timsit, Jean-Francois] Outcomerea, Dept Biostat, Paris, France; [Garrouste-Orgeas, Maite] French British Hosp, Med Unit, Levallois Perret, France; [Flahault, Cecile; Vioulac, Christel; Leborgne, Marie Annick; Bellalou, Lucie; Fasse, Leonor] Paris Descartes Univ, LPPS, EA4057, Lab Psychopathol & Hlth Proc, Paris, France; [Vinatier, Isabelle] Les Oudaries Hosp, Med ICU, La Roche Sur Yon, Vendee, France; [Rigaud, Jean-Philippe] Dieppe Gen Hosp, Dept Intens Care, Dieppe, France; [Thieulot-Rolin, Nathalie] Gen Hosp, Med Surg ICU, Melun, France; [Mercier, Emmanuelle] Tours Univ Hosp, Med Surg ICU, CRICS TRIGGERSEP Grp, Tours, France; [Rouget, Antoine] Rangueil Univ Hosp, Med Surg ICU, Toulouse, France; [Grand, Hubert] Hosp Robert Boulin, Med Surg ICU, Libourne, France; [Lesieur, Olivier] Gen Hosp, Med Surg ICU, La Rochelle, France; [Tamion, Fabienne; Misset, Benoit] Univ Med Ctr, Med ICU, Rouen, France; [Tamion, Fabienne] Univ Rouen, INSERM, U1096, Rouen, France; [Hamidfar, Rebecca] Albert Michallon Univ Hosp, Med ICU, Grenoble, France; [Renault, Anne] La Cavale Blanche Univ Hosp, Med ICU, Brest, France; [Parmentier-Decrucq, Erika; Jourdain, Merce] Lille Univ Hosp, Grp Med ICUs, Lille, France; [Monseau, Yannick] Gen Hosp, Med Surg ICU, Perigueux, France; [Argaud, Laurent] Edouard Herriot Univ Hosp, Med ICU, Lyon, France; [Bretonniere, Cedric] Nantes Univ Hosp, Med ICU, Nantes, France; [Bretonniere, Cedric] Univ Nantes, Lab Clin & Expt Therapeut Infect, EA3826, Nantes, France; [Lautrette, Alexandre] Gabriel Montpied Univ Hosp, Med ICU, Clermont Ferrand, France; [Lautrette, Alexandre] Univ Clermont Ferrand, LMGE, UMR CNRS 6023, Clermont Ferrand, France; [Badie, Julio] Gen Hosp, Med Surg ICU, Belfort Montbeliard, Belfort, France; [Boulet, Eric] Beaumont Gen Hosp, Med ICU, Beaumont, France; [Floccard, Bernard] Edouard Herriot Univ Hosp, Hosp Civils Lyon, Med ICU, Lyon, France; [Forceville, Xavier] Great Hosp East Francilien, Med Surg ICU, Meaux, France; [Kipnis, Eric] Lille Univ Hosp, Surg ICU, Lille, France; [Soufir, Lilia] St Joseph Hosp Network, Med Surg ICU, Paris, France; [Valade, Sandrine] St Louis Univ Hosp, Med ICU, Paris, France; [Bige, Naike] St Antoine Univ Hosp, Med ICU, Paris, France; [Gaffinel, Alain] Gustave Roussy Canc Campus, Med Surg ICU, Villejuif, France; [Hamzaoui, Olfa] Beciere Univ Hosp, Univ Hosp Paris Sud, Med Surg ICU, Clamart, France; [Simon, Georges] Gen Hosp, Med Surg ICU, Troyes, France; [Thirion, Marina] Gen Hosp Victor Dupouy, Med Surg ICU, Argenteuil, France; [Bouadma, Lila; Timsit, Jean-Francois] Hop Xavier Bichat, Med ICU, Paris, France; [Large, Audrey] Francois Mitterrand Univ Hosp, Med ICU, Dijon, France; [Mira, Jean-Paul] Cochin Univ Hosp, AP HP, Paris Ctr Hosp Grp, Med ICU, Paris, France; [Amdjar-Badidi, Nora] Gen Hosp Rene Dubos, Med Surg ICU, Pontoise, France; [Jourdain, Merce] Lille Univ, INSERM, U1190, Lille, France; [Jost, Paul-Henri] Henri Mondor Univ Hosp, Surg ICU, Creteil, France; [Maxime, Virginie] Raymond Poincare Univ Hosp, Med ICU, Garches, France; [Santoli, Francois] Gen Hosp Robert Ballanger, Med ICU, Aulnay Sous Bois, France; [Bailly, Sebastien] Grenoble Alpes Univ, Univ Hosp Grenoble Alpes, INSERM, HP2, Grenoble, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; CHD Vendee; CHU Tours; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie; CHU Grenoble Alpes; CHU Brest; Universite de Lille - ISITE; CHU Lille; CHU Lyon; Nantes Universite; CHU de Nantes; Nantes Universite; CHU Clermont Ferrand; Centre National de la Recherche Scientifique (CNRS); Universite Clermont Auvergne (UCA); CHU Lyon; Universite de Lille - ISITE; CHU Lille; Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm)	Garrouste-Orgeas, M (corresponding author), Hop Franco Britannique, Serv Med Interne, 4 Rue Kleber, F-92300 Levallois Perret, France.	maite.garrouste@ihfb.org	BAILLY, Sébastien SB/H-4648-2013; Carmen, Team3/Y-7384-2019; Kipnis, Eric/C-6286-2016; Misset, Benoit/P-7817-2018	BAILLY, Sébastien SB/0000-0002-2179-4650; Carmen, Team3/0000-0002-3614-0924; Kipnis, Eric/0000-0001-8887-7330; Lab, Carmen/0000-0002-5935-3236; vioulac, christel/0000-0002-8759-4563; Garrouste-Orgeas, Maite/0000-0003-4250-1666; Parmentier-Decrucq, Erika/0000-0002-5836-5956; lesieur, olivier/0000-0001-9135-2041; Misset, Benoit/0000-0001-6466-0065	Fondation de France [ENG 5032]; Saint Joseph Hospital Network	Fondation de France(Fondation de France); Saint Joseph Hospital Network	This study was funded through a grant from the Fondation de France (ENG 5032) and was sponsored by the Saint Joseph Hospital Network.	Adhikari NKJ, 2009, CHEST, V135, P678, DOI 10.1378/chest.08-0974; Aitken LM, 2013, CRIT CARE, V17, DOI 10.1186/cc13164; Azoulay E, 2000, CRIT CARE MED, V28, P3044, DOI 10.1097/00003246-200008000-00061; Chan KS, 2016, GEN HOSP PSYCHIAT, V42, P32, DOI 10.1016/j.genhosppsych.2016.07.004; Combe Denise, 2005, Nurs Crit Care, V10, P31, DOI 10.1111/j.1362-1017.2005.00093.x; Cox CE, 2018, AM J RESP CRIT CARE, V197, P66, DOI 10.1164/rccm.201704-0720OC; Curtis JR, 2016, AM J RESP CRIT CARE, V193, P154, DOI 10.1164/rccm.201505-0900OC; de Miranda S, 2011, CRIT CARE MED, V39, P112, DOI 10.1097/CCM.0b013e3181feb824; Egerod Ingrid, 2010, Intensive Crit Care Nurs, V26, P278, DOI 10.1016/j.iccn.2010.07.002; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Engstrom A, 2009, NURS CRIT CARE, V14, P61, DOI 10.1111/j.1478-5153.2008.00312.x; Ewens B, 2014, AUST CRIT CARE, V27, P28, DOI 10.1016/j.aucc.2013.07.001; Garrouste-Orgeas M, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2283-y; Garrouste-Orgeas M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110146; Garrouste-Orgeas M, 2012, CRIT CARE MED, V40, P2033, DOI 10.1097/CCM.0b013e31824e1b43; Jackson JC, 2012, CRIT CARE MED, V40, P1088, DOI 10.1097/CCM.0b013e3182373115; Jones C, 2003, CRIT CARE MED, V31, P2456, DOI 10.1097/01.CCM.0000089938.56725.33; Jones C, 2001, CRIT CARE MED, V29, P573, DOI 10.1097/00003246-200103000-00019; Jones C, 2004, INTENS CARE MED, V30, P456, DOI 10.1007/s00134-003-2149-5; Jones C., 2000, CLIN INTENSIVE CARE, V11, P251, DOI [10.3109/tcic.11.5.251.255, DOI 10.3109/TCIC.11.5.251.255]; Jones C, 2010, CRIT CARE, V14, DOI 10.1186/cc9260; Kentish-Barnes N, 2017, INTENS CARE MED, V43, P473, DOI 10.1007/s00134-016-4669-9; Kentish-Barnes N, 2015, EUR RESPIR J, V45, P1341, DOI 10.1183/09031936.00160014; Knowles RE, 2009, CRIT CARE MED, V37, P184, DOI 10.1097/CCM.0b013e31819287f7; Kredentser MS, 2018, CRIT CARE MED, V46, P1914, DOI 10.1097/CCM.0000000000003367; McAdam JL, 2012, AM J CRIT CARE, V21, P386, DOI 10.4037/ajcc2012582; Needham DM, 2012, CRIT CARE MED, V40, P502, DOI 10.1097/CCM.0b013e318232da75; Nydahl P, 2019, MED KLIN-INTENSIVMED, V114, P68, DOI 10.1007/s00063-018-0456-4; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Parker AM, 2015, CRIT CARE MED, V43, P1121, DOI 10.1097/CCM.0000000000000882; Peris A, 2011, CRIT CARE, V15, DOI 10.1186/cc10003; Rash CJ, 2008, ADDICT BEHAV, V33, P1039, DOI 10.1016/j.addbeh.2008.04.006; Roberts MB, 2018, CRIT CARE MED, V46, P1328, DOI 10.1097/CCM.0000000000003222; Timsit JF, 2009, JAMA-J AM MED ASSOC, V301, P1231, DOI 10.1001/jama.2009.376; White DB, 2018, NEW ENGL J MED, V378, P2365, DOI 10.1056/NEJMoa1802637; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	36	60	70	2	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	2019	322	3					229	239		10.1001/jama.2019.9058	http://dx.doi.org/10.1001/jama.2019.9058			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IK7OO	31310299	Green Published, Bronze			2023-01-03	WOS:000476780400014
J	Brett, L; Noblet, T; Jorgensen, M; Georgiou, A				Brett, Lindsey; Noblet, Tim; Jorgensen, Mikaela; Georgiou, Andrew			The use of physiotherapy in nursing homes internationally: A systematic review	PLOS ONE			English	Review							TERM-CARE FACILITIES; OLDER-ADULTS; HEALTH-CARE; REHABILITATION; PROVISION; RESIDENTS; EXERCISE	Background Physiotherapy can improve functional ability, prevent falls and reduce pain for older adults in nursing homes. However, there are no legislations or guidelines that specify the parameters of physiotherapy required in nursing homes. With the increasing healthcare demands of ageing populations worldwide, it is important to understand the current use of physiotherapy services to ensure they are both evidence-based and promote equity. Objectives (1) When and how are physiotherapy services used by older adults living in nursing homes? (2) What are the factors associated with use of physiotherapy services in nursing homes? (3) How are physiotherapy services in nursing homes documented and monitored? Methods Several databases and grey literature (including MEDLINE, PubMed, Pedro and EMBASE) were searched following PRISMA guidelines in March 2018. Searches were limited to English language publications from 1997. Assessment for inclusion, data extraction and quality assessment were completed by two investigators independently using standardised forms. Studies were included if they considered any type of physiotherapy service that involved a qualified physiotherapist (such as exercise, massage and staff education) with older adults (aged 60 years and older) that were primarily permanent residents of a nursing home. Data extracted included proportion of clients that used physiotherapy services, type, frequency and duration of physiotherapy services, and factors associated with physiotherapy service use. Results Eleven studies were included. Between 10% and 67% of nursing home clients used physiotherapy services. Factors associated with greater use of physiotherapy services included larger size facilities, and if clients had a physical impairment and mild or no cognitive impairment. Types of physiotherapy services reported were pain management and pressure ulcer management. Conclusions Physiotherapy service use in nursing homes varied widely. The development of physiotherapy benchmarks and quality standards are needed to support older adults in nursing homes.	[Brett, Lindsey; Noblet, Tim] Macquarie Univ, Dept Hlth Profess, Sydney, NSW, Australia; [Brett, Lindsey; Jorgensen, Mikaela; Georgiou, Andrew] Macquarie Univ, Australian Inst Hlth Innovat, Sydney, NSW, Australia; [Noblet, Tim] Univ Birmingham, Dept Sports & Rehabil Sci, Birmingham, W Midlands, England; [Noblet, Tim] St Georges Univ Hosp NHS Fdn Trust, London, England	Macquarie University; Macquarie University; University of Birmingham	Brett, L (corresponding author), Macquarie Univ, Dept Hlth Profess, Sydney, NSW, Australia.; Brett, L (corresponding author), Macquarie Univ, Australian Inst Hlth Innovat, Sydney, NSW, Australia.	lindsey.brett@mq.edu.au	Georgiou, Andrew/A-5525-2011	Georgiou, Andrew/0000-0002-7619-3668; Brett, Lindsey/0000-0002-1141-2030; Jorgensen, Mikaela/0000-0002-5490-0819				Andersen R.M., 2001, CHANGING US HLTH CAR, P3; Andersen R. M, 1968, THESIS; Aromataris E, 2017, J BRIGGS I REV MANUA; [Australian Government DoS S], 2014, QUAL CAR PRINC 2014; Australian Institute of Health and Welfare, 2010, RES AG CAR FAC ID DE; Australian Physiotherapy Association, 2014, ACFI SURV 2014; Barodawala S, 2001, CLIN REHABIL, V15, P607, DOI 10.1191/0269215501cr454oa; Barreto PD, 2016, J AM MED DIR ASSOC, V17, P381, DOI 10.1016/j.jamda.2016.01.021; Berg K, 1997, AGE AGEING, V26, P37, DOI 10.1093/ageing/26.suppl_2.37; Bhuyan SS, 2017, ARCH PHYS MED REHAB, V98, P1203, DOI 10.1016/j.apmr.2016.11.021; Brett L, 2018, AUST NZ J PUBLIC HLT, V42; Brett L, 2018, ARE QUALIFIED PHYSIO; Brett L, 2016, J AM MED DIR ASSOC, V17, P104, DOI 10.1016/j.jamda.2015.08.016; Buchanan RJ, 2004, J REHABIL RES DEV, V41, P847, DOI 10.1682/JRRD.2003.05.0082; Colombo F., 2011, OECD HLTH POLICY STU, DOI [10.1787/9789264097759-en, DOI 10.1787/9789264097759-EN]; De Boer ME, 2007, DISABIL REHABIL, V29, P665, DOI 10.1080/09638280600926561; Drucker AM, 2016, J INVEST DERMATOL, V136, pE109, DOI 10.1016/j.jid.2016.08.021; Frandin K, 2016, GERONTOLOGY, V62, P571, DOI 10.1159/000443611; Godin K, 2015, SYST REV-LONDON, V4, DOI 10.1186/s13643-015-0125-0; Harrison FG, 2004, J GERIATR PHYS THER, V27, P88, DOI DOI 10.1519/00139143-200412000-00003; Hewitt J, 2018, J AM MED DIR ASSOC, V19, P361, DOI 10.1016/j.jamda.2017.12.014; Hoek JF, 2000, J AM GERIATR SOC, V48, P214, DOI 10.1111/j.1532-5415.2000.tb03915.x; Kinley J, 2014, AGE AGEING, V43, P375, DOI 10.1093/ageing/aft158; Klauber M., 2001, 1987 NURSING REFORM; Kloth Luther C, 2009, J Am Col Certif Wound Spec, V1, P4, DOI 10.1016/j.jcws.2008.08.001; Leemrijse Chantal J, 2007, BMC Geriatr, V7, P7, DOI 10.1186/1471-2318-7-7; McArthur C, 2015, PHYSIOTHER CAN, V67, P113, DOI 10.3138/ptc.2014-27; Ministry of health and long-term care, 2010, LONG TERM CAR HOM AC; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; New Zealand Government, 2000, NZ PUBL HLTH DIS ACT; Noblet T, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3300-x; Noblet T, 2017, J PHYSIOTHER, V63, P221, DOI 10.1016/j.jphys.2017.09.001; O'Dea G, 2000, HEALTH SOC CARE COMM, V8, P180, DOI 10.1046/j.1365-2524.2000.00238.x; Roberts K., 2017, INT AGED CARE QUICK; Roche E, 2014, BRIT J GEN PRACT, V64, P591, DOI 10.3399/bjgp14X682501; Seitz D, 2010, INT PSYCHOGERIATR, V22, P1025, DOI 10.1017/S1041610210000608; Tse Mimi M Y, 2013, Pain Manag Nurs, V14, pe10, DOI 10.1016/j.pmn.2011.01.004; UK Government, 2000, CAR STAND ACT 2000; White C, 2002, HEALTH CARE FINANC R, V24, P7	39	15	15	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2019	14	7							e0219488	10.1371/journal.pone.0219488	http://dx.doi.org/10.1371/journal.pone.0219488			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4LN	31295297	Green Submitted, Green Published, gold			2023-01-03	WOS:000484951800038
J	Niriayo, YL; Ibrahim, S; Kassa, TD; Asgedom, SW; Atey, TM; Gidey, K; Demoz, GT; Kahsay, D				Niriayo, Yirga Legesse; Ibrahim, Seid; Kassa, Tesfaye Dessale; Asgedom, Solomon Weldegebreal; Atey, Tesfay Mahari; Gidey, Kidu; Demoz, Gebre Teklemariam; Kahsay, Desalegn			Practice and predictors of self-care behaviors among ambulatory patients with hypertension in Ethiopia	PLOS ONE			English	Article							BODY-MASS INDEX; BLOOD-PRESSURE; HEALTH-CARE; AFRICAN-AMERICANS; ILLNESS BELIEFS; PREVALENCE; MANAGEMENT; ADHERENCE; ACCESS; RISK	Background Despite the benefits of evidence-based self-care behaviors in the management of hypertension, hypertensive patients have low rate of adherence to the recommended self-care behaviors. Studies related to self-care behaviors among hypertensive patients are limited in Ethiopia. Objective To assess the rate of adherence to self-care behaviors and associated factors among hypertensive patients. Method A cross-sectional study was conducted at the cardiac clinic of Ayder comprehensive specialized hospital among ambulatory hypertensive patients. Self-care behaviors were assessed using an adopted Hypertension Self-Care Activity Level Effects (H-SCALE). Data were collected through patient interview and review of medical records. Binary logistic regression analysis was performed to identify predictors of self-care behaviors. Result A total of 276 patients were included in the study. The majority of the participants were nonsmokers (89.9%) and alcohol abstainers (68.8%). Less than half of the participants were adherent to the prescribed antihypertensive medications (48.2%) and recommended physical activity level (44.9%). Moreover, only 21.45% and 29% were adherent to weight management and low salt diet recommendations, respectively. Our finding indicated that rural resident (adjusted odds ratio [AOR]: 0.45, 95% confidence interval [CI]: 0.21-0.97), comorbidity (AOR: 0.16, 95% CI: 0.08-0.31), and negative medication belief (AOR: 0.25, 95% CI: 0.14-0.46) were significantly associated with medication adherence. Female sex (AOR: 0.46, 95% CI: 0.23-0.92), old age (AOR: 0.19, 95% CI: 0.06-0.60) and lack of knowledge on self-care behaviors (AOR: 0.13, 95% CI: 0.03-0.57) were significantly associated with adherence to weight management. Female sex (AOR: 1.97, 95% CI: 1.03-3.75) and lack of knowledge on self-care (AOR: 0.07, 95% CI: 0.03-0.16) were significantly associated with adherence to alcohol abstinence. Female sex (AOR: 6.33, 95% CI: 1.80-22.31) and khat chewing (AOR: 0.08, 95% CI: 0.03-0.24) were significantly associated with non-smoking behavior. There was also a significant association between female sex and physical activity (AOR: 0.22, 95% CI: 0.12-0.40). Conclusion The rate of adherence to self-care behaviors particularly weight management, low salt intake, physical exercise, and medication intake was low in our study. Elders, females, khat chewers, rural residents, and patients with negative medication belief, comorbidity, and inadequate knowledge of SCBs were less adherent to self-care behaviors compared to their counterparts. Therefore, health care providers should pay more emphasis to patients at risk of having low self-care behaviors.	[Niriayo, Yirga Legesse; Ibrahim, Seid; Kassa, Tesfaye Dessale; Asgedom, Solomon Weldegebreal; Atey, Tesfay Mahari; Gidey, Kidu; Kahsay, Desalegn] Mekelle Univ, Coll Hlth Sci, Sch Pharm, Dept Clin Pharm, Mekelle, Tigray, Ethiopia; [Demoz, Gebre Teklemariam] Aksum Univ, Coll Hlth Sci, Dept Pharm, Clin Pharm & Pharm Practice Unit, Aksum, Tigray, Ethiopia	Mekelle University	Niriayo, YL (corresponding author), Mekelle Univ, Coll Hlth Sci, Sch Pharm, Dept Clin Pharm, Mekelle, Tigray, Ethiopia.	yirga.pharma@gmail.com	Demoz, Gebre Teklemariam/K-6986-2019	Demoz, Gebre Teklemariam/0000-0002-2534-821X; Gidey, kidu/0000-0002-7363-1327; Atey, Tesfay Mehari/0000-0002-6483-2258; Niriayo, yirga/0000-0002-6943-753X				Adisa R, 2018, BMC CARDIOVASC DISOR, V18, DOI 10.1186/s12872-018-0934-x; Agyemang C, 2006, J HUM HYPERTENS, V20, P67, DOI 10.1038/sj.jhh.1001923; Al-Sutari MM, 2017, INT J EVID-BASED HEA, V15, P178, DOI 10.1097/XEB.0000000000000108; Alhalaiqa F, 2017, TURK J MED SCI, V47, P273, DOI 10.3906/sag-1508-18; Alsanosy RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065504; Alwan A, 2011, GLOBAL STATUS REPORT ON NONCOMMUNICABLE DISEASES 2010, P9; Ambaw AD, 2012, BMC PUBLIC HEALTH, V12, P1471; Asmah EE, 2017, AM J HEALTH EDUC, V48, P374, DOI 10.1080/19325037.2017.1358120; Beigi MAB, 2014, INT CARDIOVASC RES J, V8, P94; Bibbins-Domingo K, 2010, NEW ENGL J MED, V362, P590, DOI 10.1056/NEJMoa0907355; Boima V, 2015, INT J HYPERTENS, V2015, DOI 10.1155/2015/205716; Bonsa F, 2014, ETHIOP J HEALTH SCI, V24, P21, DOI 10.4314/ejhs.v24i1.3; Bradley E, 2011, INT J QUAL HEALTH C, V23, P222, DOI 10.1093/intqhc/mzr013; Buda Eyasu Siyum, 2017, Clin Hypertens, V23, P26, DOI 10.1186/s40885-017-0081-1; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Danaei G, 2014, LANCET DIABETES ENDO, V2, P634, DOI 10.1016/S2213-8587(14)70102-0; de Vijver SV, 2013, PAN AFR MED J, V16, DOI 10.11604/pamj.2013.16.38.3100; Douglas K, 2018, NIGERIAN J MED, V27, P234; Egenasi C, 2015, S AFR FAM PRACT, V57, P326, DOI 10.1080/20786190.2015.1078152; Elbur A.I., 2015, INT J PHARM PHARM SC, V7, P168; Erku DA, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/6987636; Flynn SJ, 2013, PATIENT PREFER ADHER, V7, P741, DOI 10.2147/PPA.S46517; Forouzanfar MH, 2017, JAMA-J AM MED ASSOC, V317, P165, DOI 10.1001/jama.2016.19043; Gelaw Y, 2004, ETHIOP J HEALTH DEV, V18, P179; Girma F, 2014, J HYPERTENS, V3, P1, DOI DOI 10.4172/2167-1095.1000174; Guessous I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039877; Gupta S, 2016, ASIAN J MULTIDISCIPL, V4, P2348; Hacihasanoglu R, 2011, J CLIN NURS, V20, P692, DOI 10.1111/j.1365-2702.2010.03534.x; Hekler EB, 2008, J BEHAV MED, V31, P391, DOI 10.1007/s10865-008-9165-4; Heymann AD, 2011, ISR MED ASSOC J, V13, P553; Hien HA, 2018, INT J HYPERTENS, V2018, DOI 10.1155/2018/6326984; Hu G, 2004, HYPERTENSION, V43, P25, DOI 10.1161/01.HYP.0000107400.72456.19; Hu H, 2013, INT J ANTENN PROPAG, V2013, DOI 10.1155/2013/416096; Hyman DJ, 2001, NEW ENGL J MED, V345, P479, DOI 10.1056/NEJMoa010273; James PA, 2014, JAMA-J AM MED ASSOC, V311, P1809, DOI 10.1001/jama.2013.284427; Kayima J, 2013, BMC CARDIOVASC DISOR, V13, DOI 10.1186/1471-2261-13-54; Khanam MA, 2014, GLOBAL HEALTH ACTION, V7, P1, DOI 10.3402/gha.v7.25028; Kibret KT, 2015, PUBLIC HEALTH REV, V36, DOI 10.1186/s40985-015-0014-z; Kressin NR, 2010, CIRC-CARDIOVASC QUAL, V3, P173, DOI 10.1161/CIRCOUTCOMES.109.860841; Kumar PN, 2010, INT J BIOL MED RES, V1, P248; Lee E, 2017, CONTEMP NURSE, V53, P607, DOI 10.1080/10376178.2017.1368401; Liwa AC, 2014, CURR HYPERTENS REP, V16, DOI 10.1007/s11906-014-0437-9; Lulebo Aimee M, 2015, BMC Res Notes, V8, P526, DOI 10.1186/s13104-015-1519-8; Mallat SG, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1142; McClintock H, 2017, LANCET GLOB HEALTH, V5, P18; Mills KT, 2016, CIRCULATION, V134, P441, DOI 10.1161/CIRCULATIONAHA.115.018912; Mohamed SF, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6052-y; Mostafavi Firoozeh, 2016, Mater Sociomed, V28, P298; Motlagh SFZ, 2016, IRAN RED CRESCENT ME, V18, DOI 10.5812/ircmj.35805; Niriayo YL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206120; Ogah OS, 2013, HEART, V99, P1390, DOI 10.1136/heartjnl-2012-303227; Opie LH, 2005, CIRCULATION, V112, P3562, DOI 10.1161/CIRCULATIONAHA.105.539569; Peltzer K, 2004, Curationis, V27, P15; Peters DH, 2008, ANN NY ACAD SCI, V1136, P161, DOI 10.1196/annals.1425.011; Pickett S, 2014, WESTERN J NURS RES, V36, P152, DOI 10.1177/0193945913491837; Reda AA, 2012, HARM REDUCT J, V9, DOI 10.1186/1477-7517-9-39; Reda AA, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-213; Ross S, 2004, J HUM HYPERTENS, V18, P607, DOI 10.1038/sj.jhh.1001721; Saleem F, 2012, J YOUNG PHARM, V4, P101, DOI 10.4103/0975-1483.96624; Schrauben SJ, 2017, HEALTH PROMOT INT, V32, P475, DOI 10.1093/heapro/dav108; Sharma G., 2013, J IND ENG INT, V9, P1; Shihab HM, 2012, CIRCULATION, V126, P2983, DOI 10.1161/CIRCULATIONAHA.112.117333; Shiri Clarris, 2007, Cardiovasc J Afr, V18, P353; Strasser R, 2016, ANNU REV PUBL HEALTH, V37, P395, DOI 10.1146/annurev-publhealth-032315-021507; Teshome DF, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196535; van der Hoeven M, 2012, INT J EQUITY HEALTH, V11, DOI 10.1186/1475-9276-11-31; Venkatachalam J, 2015, Indian J Community Med, V40, P33, DOI 10.4103/0970-0218.149267; Warren-Findlow J, 2013, J CLIN HYPERTENS, V15, P637, DOI 10.1111/jch.12157; Warren-Findlow J, 2011, J NATL MED ASSOC, V103, P503, DOI 10.1016/S0027-9684(15)30365-5; Webber D., 2013, SELFCARE, V4, P101; Weber MA, 2014, J HYPERTENS, V32, P3, DOI [10.1097/HJH.0000000000000065, 10.1111/jch.12237]; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; Yigzaw Kebede, 2002, Ethiopian Journal of Health Development, V16, P9; Zhou B, 2017, LANCET, V389, P37, DOI 10.1016/S0140-6736(16)31919-5	74	12	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 26	2019	14	6							e0218947	10.1371/journal.pone.0218947	http://dx.doi.org/10.1371/journal.pone.0218947			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IT5DV	31242265	gold, Green Published, Green Submitted			2023-01-03	WOS:000482883600070
J	Schroder, J; Bouaziz, O; Agner, BR; Martinussen, T; Madsen, PL; Li, D; Dixen, U				Schroder, Jakob; Bouaziz, Olivier; Agner, Bue Ross; Martinussen, Torben; Madsen, Per Lav; Li, Dana; Dixen, Ulrik			Recurrent event survival analysis predicts future risk of hospitalization in patients with paroxysmal and persistent atrial fibrillation	PLOS ONE			English	Article							ELECTRICAL CARDIOVERSION; TEMPORAL PATTERNS; DYSFUNCTION	Background In patients with paroxysmal atrial fibrillation (PAF) or persistent atrial fibrillation (PeAF) symptom burden and fear of hospital readmission are major causes of reduced quality of life. We attempted to develop a prediction model for future atrial fibrillation hospitalization (AFH) risk in PAF and PeAF patients including all previously experienced AFHs in the analysis, as opposed to time to first event. Methods Recurrent event survival analysis was used to model the impact of past AFHs on the risk of future AFHs. A recurrent event was defined as a hospitalization due to a new episode of AF. Death or progression to permanent AF were included as competing risks. Results We enrolled 174 patients with PAF or PeAF, mean follow up duration was 1279 days, and 325 AFHs were observed. Median patient age was 63.0 (IQR 52.2-68.0), 29% had PAF, and 71% were male. Highly significant predictors of future AFH risk were PeAF (HR 3.20, CI 2.01-5.11) and number of past AFHs observed (HR for 1 event: 2.97, CI 2.04-4.32, HR for >= 2 events: 7.54, CI 5.47-10.40). Conclusion In PAF and PeAF patients, AF type and observed AFH frequency are highly significant predictors of future AFH risk. The developed model enables risk prediction in individual patients based on AFH history and baseline characteristics, utilizing all events experienced by the patient. This is the first time recurrent event survival analysis has been used in AF patients.	[Schroder, Jakob] Bispebjerg Hosp, Dept Cardiol, Copenhagen, Denmark; [Bouaziz, Olivier] Univ Paris 05, Lab MAP5, Paris, France; [Bouaziz, Olivier] Sorbonne Paris Cite, CNRS, Paris, France; [Agner, Bue Ross; Li, Dana; Dixen, Ulrik] Hvidovre Univ Hosp, Dept Cardiol, Copenhagen, Denmark; [Martinussen, Torben] Univ Copenhagen, Dept Biostat, Inst Publ Hlth, Copenhagen, Denmark; [Madsen, Per Lav] Herlev Univ Hosp, Dept Cardiol, Copenhagen, Denmark	University of Copenhagen; Bispebjerg Hospital; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); University of Copenhagen; University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital	Schroder, J (corresponding author), Bispebjerg Hosp, Dept Cardiol, Copenhagen, Denmark.	jakobschroder@gmail.com	Bouaziz, Olivier/ABG-9841-2020; Madsen, Per Lav/AAX-6087-2020	Bouaziz, Olivier/0000-0003-3556-9531; 				Amorim LDAF, 2015, INT J EPIDEMIOL, V44, P324, DOI 10.1093/ije/dyu222; Andersen PK, 2002, STAT METHODS MED RES, V11, P91, DOI 10.1191/0962280202SM276ra; Bertaglia E, 2005, INT J CARDIOL, V102, P219, DOI 10.1016/j.ijcard.2004.05.013; Blanche C, 2014, ANN NONINVAS ELECTRO, V19, P266, DOI 10.1111/anec.12131; Bouaziz O, 2018, CLIN INFECT DIS, V66, P930, DOI 10.1093/cid/cix899; Charitos EI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089022; Chong JJH, 2006, EUROPACE, V8, P341, DOI 10.1093/europace/eul008; Cook RJ, 2007, STAT BIOL HEALTH, P1, DOI 10.1007/978-0-387-69810-6; Fornengo C, 2015, EUR HEART J-CARD IMG, V16, P335, DOI 10.1093/ehjci/jeu193; GERAETS DR, 1993, CLIN PHARMACY, V12, P721; Gillis AM, 2000, AM J CARDIOL, V85, P1445, DOI 10.1016/S0002-9149(00)00792-X; Gonna H, 2014, ANN NONINVAS ELECTRO, V19, P57, DOI 10.1111/anec.12087; GREER GS, 1989, AM J CARDIOL, V64, P339, DOI 10.1016/0002-9149(89)90531-6; Kiliszek M, 2015, CARDIOL J, V22, P453, DOI 10.5603/CJ.a2015.0006; Kirchhof P, 2016, EUROPACE, V18, DOI [10.1093/europace/euw295, 10.5603/KP.2016.0172, 10.1016/j.rec.2016.11.033]; Lafuente-Lafuente C, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005049.pub4; Latouche A, 2013, J CLIN EPIDEMIOL, V66, P648, DOI 10.1016/j.jclinepi.2012.09.017; LAWLESS JF, 1995, TECHNOMETRICS, V37, P158, DOI 10.2307/1269617; Luong C, 2015, CAN J CARDIOL, V31, P29, DOI 10.1016/j.cjca.2014.10.009; Mukherjee R, 2013, J CARDIOVASC TRANSL, V6, P528, DOI 10.1007/s12265-013-9471-2; Nishino M, 2000, AM J CARDIOL, V85, P1451, DOI 10.1016/S0002-9149(00)00793-1; Rizzo MR, 2015, J DIABETES COMPLICAT, V29, P88, DOI 10.1016/j.jdiacomp.2014.09.002; Rondano E, 2010, J CARDIOVASC MED, V11, P499, DOI 10.2459/JCM.0b013e32833757b5; Schoen T, 2012, J AM COLL CARDIOL, V60, P1421, DOI 10.1016/j.jacc.2012.06.030; Shehadeh LA, 2002, J CARDIOVASC ELECTR, V13, P303, DOI 10.1046/j.1540-8167.2002.00303.x; WIJFFELS MCEF, 1995, CIRCULATION, V92, P1954, DOI 10.1161/01.CIR.92.7.1954; Wolpert C, 2003, PACE, V26, P1691, DOI 10.1046/j.1460-9592.2003.t01-1-00254.x	27	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2019	14	6							e0217983	10.1371/journal.pone.0217983	http://dx.doi.org/10.1371/journal.pone.0217983			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IC0OB	31173602	gold, Green Published, Green Submitted			2023-01-03	WOS:000470658500026
J	Tsutsumi-Arai, C; Takakusaki, K; Arai, Y; Terada-Ito, C; Takebe, Y; Imamura, T; Ide, S; Tatehara, S; Tokuyama-Toda, R; Wakabayashi, N; Satomura, K				Tsutsumi-Arai, Chiaki; Takakusaki, Kensuke; Arai, Yuki; Terada-Ito, Chika; Takebe, Yusuke; Imamura, Takahiro; Ide, Shinji; Tatehara, Seiko; Tokuyama-Toda, Reiko; Wakabayashi, Noriyuki; Satomura, Kazuhito			Grapefruit seed extract effectively inhibits the Candida albicans biofilms development on polymethyl methacrylate denture-base resin	PLOS ONE			English	Article							ANTIBACTERIAL AGENT; ANTIFUNGAL ACTIVITY; ADHESION; POLYPHENOLS; FLAVONOIDS	This study aimed to investigate the cleansing effects of grapefruit seed extract (GSE) on biofilms of Candida albicans (C. albicans) formed on denture-base resin and the influence of GSE on the mechanical and surface characteristics of the resin. GSE solution diluted with distilled water to 0.1% (0.1% GSE) and 1% (1% GSE) and solutions with Polident (R) denture cleansing tablet dissolved in distilled water (Polident) or in 0.1% GSE solution (0.1% G+P) were prepared as cleansing solutions. Discs of acrylic resin were prepared, and the biofilm of C. albicans was formed on the discs. The discs with the biofilm were treated with each solution for 5 min at 25 degrees C. After the treatment, the biofilm on the discs was analyzed using a colony forming unit (CFU) assay, fluorescence microscopy, and scanning electron microscopy (SEM). In order to assess the persistent cleansing effect, the discs treated with each solution for 5 min were aerobically incubated in Yeast Nitrogen Base medium for another 24 h. After incubation, the persistent effect was assessed by CFU assay. Some specimens of acrylic resin were immersed in each solution for 7 days, and changes in surface roughness (Ra), Vickers hardness (VH), flexural strength (FS), and flexural modulus (FM) were evaluated. As a result, the treatment with 1% GSE for 5 min almost completely eliminated the biofilm formed on the resin; whereas, the treatment with 0.1% GSE, Polident, and 0.1% G+P for 5 min showed a statistically significant inhibitory effect on biofilms. In addition, 0.1% GSE and 0.1% G+P exerted a persistent inhibitory effect on biofilms. Fluorescence microscopy indicated that Polident mainly induced the death of yeast, while the cleansing solutions containing at least 0.1% GSE induced the death of hyphae as well as yeast. SEM also revealed that Polident caused wrinkles, shrinkage, and some deep craters predominantly on the cell surfaces of yeast, while the solutions containing at least 0.1% GSE induced wrinkles, shrinkage, and some damage on cell surfaces of not only yeasts but also hyphae. No significant changes in Ra, VH, FS, or FM were observed after immersion in any of the solutions. Taken together, GSE solution is capable of cleansing C. albicans biofilms on denture-base resin and has a persistent inhibitory effect on biofilm development, without any deteriorations of resin surface.	[Tsutsumi-Arai, Chiaki; Terada-Ito, Chika; Takebe, Yusuke; Imamura, Takahiro; Ide, Shinji; Tatehara, Seiko; Tokuyama-Toda, Reiko; Satomura, Kazuhito] Tsurumi Univ, Dept Oral Med & Stomatol, Sch Dent Med, Tsurumi Ku, Yokohama, Kanagawa, Japan; [Takakusaki, Kensuke; Arai, Yuki; Wakabayashi, Noriyuki] Tokyo Med & Dent Univ, Dept Removable Partial Prosthodont, Grad Sch, Tokyo, Japan	Tsurumi University; Tokyo Medical & Dental University (TMDU)	Tsutsumi-Arai, C (corresponding author), Tsurumi Univ, Dept Oral Med & Stomatol, Sch Dent Med, Tsurumi Ku, Yokohama, Kanagawa, Japan.	Tsutsumi-c@tsurumi-u.ac.jp	Wakabayashi, N./ABA-2063-2020		JSPS KAKENHI [17K17156]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by the JSPS KAKENHI, Grant numbers: 17K17156 (https://www.jsps.go.jp/j-grantsinaid/) to CT. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali I, 2016, SCI REP-UK, V6, DOI 10.1038/srep37867; Alsteens D, 2013, LANGMUIR, V29, P13473, DOI 10.1021/la403237f; Andrae-Marobela K, 2013, CURR DRUG METAB, V14, P392, DOI 10.2174/13892002113149990095; Bahrin LG, 2014, BIOORG MED CHEM LETT, V24, P2315, DOI 10.1016/j.bmcl.2014.03.071; Belofsky G, 2013, J NAT PROD, V76, P915, DOI 10.1021/np4000763; Cao SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032943; Chen M, 2015, MED MYCOL, V53, P194, DOI 10.1093/mmy/myu073; Choi JS, 2014, J FOOD SCI, V79, pM1159, DOI 10.1111/1750-3841.12469; Coulthwaite L, 2007, BRIT J BIOMED SCI, V64, P180, DOI 10.1080/09674845.2007.11732784; Kammers ACE, 2015, J CLIN DIAGN RES, V9, pZC94, DOI 10.7860/JCDR/2015/11261.5975; Felipucci DNB, 2011, J APPL ORAL SCI, V19, P483, DOI 10.1590/S1678-77572011000500008; Felton D, 2011, J PROSTHODONT, V20, pS1, DOI 10.1111/j.1532-849X.2010.00683.x; Freitas-Fernandes FS, 2014, J PROSTHET DENT, V112, P1349, DOI 10.1016/j.prosdent.2014.07.004; Gleiznys Alvydas, 2015, Stomatologija, V17, P54; Hariri BM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185203; Heggers JP, 2002, J ALTERN COMPLEM MED, V8, P333, DOI 10.1089/10755530260128023; Hirasawa M, 2018, ARCH ORAL BIOL, V87, P143, DOI 10.1016/j.archoralbio.2017.12.024; Jackson S, 2014, J PROSTHET DENT, V112, P988, DOI 10.1016/j.prosdent.2014.02.003; JAGGER DC, 1995, BRIT DENT J, V178, P413, DOI 10.1038/sj.bdj.4808788; Jung S, 2018, FOOD SCI BIOTECHNOL, V27, P261, DOI 10.1007/s10068-017-0198-8; Kang ST, 2017, KOREAN J FOOD SCI AN, V37, P429, DOI 10.5851/kosfa.2017.37.3.429; Kim JH, 2018, INT J BIOL MACROMOL, V120, P1468, DOI 10.1016/j.ijbiomac.2018.09.160; Kurt A, 2018, J PROSTHODONT, V27, P577, DOI 10.1111/jopr.12539; Lee H, 2015, BBA-BIOMEMBRANES, V1848, P634, DOI 10.1016/j.bbamem.2014.11.016; Liu WF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108474; Manoharan RK, 2018, MICROB BIOTECHNOL, V11, P1060, DOI 10.1111/1751-7915.13268; Mayahara M, 2014, J INVESTIG CLIN DENT, V5, DOI 10.1111/jicd.12055; Moussa A. R., 2016, J MED SCI, V4, P476, DOI DOI 10.3889/0AMJMS.2016.089; Paranhos HFO, 2007, J ORAL REHABIL, V34, P606, DOI 10.1111/j.1365-2842.2007.01753.x; RADFORD DR, 1993, J DENT, V21, P87, DOI 10.1016/0300-5712(93)90151-F; Reagor L, 2002, J ALTERN COMPLEM MED, V8, P325, DOI 10.1089/10755530260128014; Saito H, 2013, MICROB PATHOGENESIS, V56, P16, DOI 10.1016/j.micpath.2013.01.002; Seleem D, 2017, ARCH ORAL BIOL, V76, P76, DOI 10.1016/j.archoralbio.2016.08.030; Serpa R, 2012, J MED MICROBIOL, V61, P1704, DOI 10.1099/jmm.0.047852-0; Shankar S, 2018, INT J BIOL MACROMOL, V120, P846, DOI 10.1016/j.ijbiomac.2018.09.004; Shankar S, 2018, CARBOHYD POLYM, V196, P92, DOI 10.1016/j.carbpol.2018.04.128; Sharma A, 2014, FUNGAL BIOL-UK, V118, P264, DOI 10.1016/j.funbio.2013.12.006; Sitheeque MAM, 2009, CHEMOTHERAPY, V55, P189, DOI 10.1159/000216836; Tripathi P, 2018, J INDIAN PROSTHODONT, V18, P291, DOI 10.4103/jips.jips_335_17; Tsang PWK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050866; Tsutsumi C, 2016, J DENT, V44, P37, DOI 10.1016/j.jdent.2015.11.010; Xie YX, 2015, CURR MED CHEM, V22, P132; Zhou SD, 2011, BIOTECHNOL J, V6, P513, DOI 10.1002/biot.201000254; Zoric N, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1773-5; Zuzarte M, 2012, EUR J CLIN MICROBIOL, V31, P1359, DOI 10.1007/s10096-011-1450-4	45	9	11	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2019	14	5							e0217496	10.1371/journal.pone.0217496	http://dx.doi.org/10.1371/journal.pone.0217496			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IA0CM	31136636	Green Submitted, Green Published, gold			2023-01-03	WOS:000469224300044
J	Alemanno, F; Houdayer, E; Emedoli, D; Locatelli, M; Mortini, P; Mandelli, C; Raggi, A; Iannaccone, S				Alemanno, Federica; Houdayer, Elise; Emedoli, Daniele; Locatelli, Matteo; Mortini, Pietro; Mandelli, Carlo; Raggi, Alberto; Iannaccone, Sandro			Efficacy of virtual reality to reduce chronic low back pain: Proof-of-concept of a non-pharmacological approach on pain, quality of life, neuropsychological and functional outcome	PLOS ONE			English	Article							HEALTH SURVEY SF-36; CORTICAL REORGANIZATION; NORMATIVE DATA; PERSONALITY; ADULTS; RELIABILITY; PERCEPTION; COLLEGE	Objectives Chronic pain, such as low-back pain, can be a highly disabling condition degrading people's quality of life ( QoL). Not every patient responds to pharmacological therapies, thus alternative treatments have to be developed. The chronicity of pain can lead to a somatic dysperception, meaning a mismatch between patients' own body perception and its actual physical state. Since clinical evaluation of pain relies on patients' subjective reports, a body image disruption can be associated with an incorrect pain rating inducing incorrect treatment and a possible risk of drug abuse. Our aim was to reduce chronic low-back pain through a multi-modal neurorehabilitative strategy using innovative technologies to help patients regain a correct body image. Methods Twenty patients with chronic low-back pain were included. Before and after treatment, patients underwent: a neurological exam; a neuro-psychological evaluation testing cognitive functions ( memory, attention, executive functions) and personality traits, QoL and mood; pain ratings; sensorimotor functional abilities' testing. Patients underwent a 6 week-neurorehabilitative treatment ( total 12 sessions) using virtual reality ( VRRS system, Khymeia, Italy). Treatment consisted on teaching patients to execute correct movements with the painful body parts to regain a correct body image, based on the augmented multisensory feedback ( auditory, visual) provided by the VRRS. Results Our data showed significant reductions in all pain rating scale scores ( p<0.05); significant improvements of QoL in the domains of physical functioning, physical role functioning, bodily pain, vitality, and social role functioning; improvements in cognitive functions ( p<0.05); improvements in functional scales ( p<0.05) and mood ( p = 0.04). Conclusion This non-pharmacological approach was able to act on the multi-dimensional aspects of pain and improved patients' QoL, pain intensity, mood and patient's functional abilities.	[Alemanno, Federica; Houdayer, Elise; Emedoli, Daniele; Locatelli, Matteo; Iannaccone, Sandro] IRCCS San Raffaele Hosp, Dept Rehabil & Funct Recovery, Milan, Italy; [Alemanno, Federica; Houdayer, Elise; Emedoli, Daniele; Locatelli, Matteo; Iannaccone, Sandro] Univ Vita Salute San Raffaele, Milan, Italy; [Mortini, Pietro; Mandelli, Carlo] IRCCS San Raffaele Hosp, Dept Neurosurg & Gamma Knife Radiosurg, Milan, Italy; [Mortini, Pietro; Mandelli, Carlo] Univ Vita Salute San Raffaele, Milan, Italy; [Raggi, Alberto] GB Morgagni L Pierantoni Hosp, Neurol Unit, Forli, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University	Alemanno, F (corresponding author), IRCCS San Raffaele Hosp, Dept Rehabil & Funct Recovery, Milan, Italy.	alemanno.federica@hsr.it	mortini, pietro/AAB-1292-2019; Locatelli, Matteo/S-2424-2019; Iannaccone, sandro/K-4252-2018	Locatelli, Matteo/0000-0002-7266-0679; Emedoli, Daniele/0000-0002-7904-1803; Iannaccone, sandro/0000-0002-8333-3972; MORTINI, Pietro/0000-0003-2320-2281	Italian Ministry of Health (Bando Conto capitale 2015)	Italian Ministry of Health (Bando Conto capitale 2015)	This work was provided by the Italian Ministry of Health (Bando Conto capitale 2015) to SI. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Applegate KL, 2005, J PAIN, V6, P92, DOI 10.1016/j.jpain.2004.11.001; Baykara RA, 2013, J BACK MUSCULOSKELET, V26, P367, DOI 10.3233/BMR-130393; Beck A.T., 1996, MANUAL BDI 2, DOI [10.1037/t00742-000, DOI 10.1037/T00742-000]; Carlesimo GA, 1996, EUR NEUROL, V36, P378, DOI 10.1159/000117297; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Cohen JP, 2018, CLIN THER, V40, P334, DOI 10.1016/j.clinthera.2018.01.003; Corsi P.M., 1972, DISS ABSTR INT, V34; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Ehrsson HH, 2007, SCIENCE, V317, P1048, DOI 10.1126/science.1142175; Ekman U, 2018, ACTA NEUROL SCAND, V138, P284, DOI 10.1111/ane.12955; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Flor H, 1997, NEUROSCI LETT, V224, P5, DOI 10.1016/S0304-3940(97)13441-3; FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Forderreuther S, 2004, PAIN, V110, P756, DOI 10.1016/j.pain.2004.05.019; Harstall C, 2003, PAIN CLIN UPDATES, V11, P1, DOI DOI 10.1016/S1070-7212(03)00004-6; Hartrick Craig T, 2003, Pain Pract, V3, P310; Harvie DS, 2017, PEERJ, V5, DOI 10.7717/peerj.3023; Heaton P.D.R.K., 1993, WISCONSIN CARD SORTI, Vsecond; Ito M, 2011, CURR OPIN NEUROBIOL, V21, P368, DOI 10.1016/j.conb.2011.04.001; Jack D, 2001, IEEE T NEUR SYS REH, V9, P308, DOI 10.1109/7333.948460; JENSEN AR, 1966, ACTA PSYCHOL, V25, P36, DOI 10.1016/0001-6918(66)90004-7; Jones T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167523; Juottonen K, 2002, PAIN, V98, P315, DOI 10.1016/S0304-3959(02)00119-7; Kaplan E., 1983, BOSTON NAMING TEST; Kato F, 2017, BIOPSYCHOSOC MED, V11, DOI 10.1186/s13030-017-0098-4; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kizony R, 2003, J VISUAL COMP ANIMAT, V14, P261, DOI 10.1002/vis.323; Kommalapati R, 2016, IEEE ENG MED BIO, P5849, DOI 10.1109/EMBC.2016.7592058; LAWTON MP, 1969, GERONTOLOGIST, V9, P9, DOI 10.1093/geront/9.1.9; Leadley RM, 2014, PAIN PRACT, V14, P547, DOI 10.1111/papr.12125; Lenggenhager B, 2007, SCIENCE, V317, P1096, DOI 10.1126/science.1143439; Lewis JS, 2007, PAIN, V133, P111, DOI 10.1016/j.pain.2007.03.013; Macedo LG, 2012, PHYS THER, V92, P363, DOI 10.2522/ptj.20110290; Maihofner C, 2004, NEUROLOGY, V63, P693, DOI 10.1212/01.WNL.0000134661.46658.B0; Maughan EF, 2010, EUR SPINE J, V19, P1484, DOI 10.1007/s00586-010-1353-6; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Miceli G., 1994, BATTERIA LANALISI DE; Mongini F, 2000, HEADACHE, V40, P466, DOI 10.1046/j.1526-4610.2000.00070.x; Mongini F, 2005, NEUROL SCI, V26, P203, DOI 10.1007/s10072-005-0462-1; Mongini F, 2009, PAIN, V144, P125, DOI 10.1016/j.pain.2009.03.026; Moore RA, 2014, PAIN PRACT, V14, P79, DOI 10.1111/papr.12050; Moriarty O, 2011, PROG NEUROBIOL, V93, P385, DOI 10.1016/j.pneurobio.2011.01.002; Moseley GL, 2008, PAIN, V140, P239, DOI 10.1016/j.pain.2008.08.001; Moseley GL, 2012, NEUROSCI BIOBEHAV R, V36, P34, DOI 10.1016/j.neubiorev.2011.03.013; NOVELLI G, 1986, Archivio di Psicologia Neurologia e Psichiatria, V47, P477; ORSINI A, 1987, ITAL J NEUROL SCI, V8, P539; Pamment J, 2017, EUR J PAIN, V21, P334, DOI 10.1002/ejp.927; Park J, 2012, J AM GERIATR SOC, V60, P555, DOI 10.1111/j.1532-5415.2011.03846.x; Raven J, 2003, HANDBOOK OF NONVERBAL ASSESSMENT, P223; REITAN R M, 1955, AMA Arch Neurol Psychiatry, V73, P28; Rizzo A. S. K., 2005, PRESENCE-TELEOP VIRT, V14, P119, DOI DOI 10.1162/1054746053967094; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; Roosink M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120251; Sato K, 2010, PAIN MED, V11, P622, DOI 10.1111/j.1526-4637.2010.00819.x; Sellbom M, 2008, J PERS DISORD, V22, P291, DOI 10.1521/pedi.2008.22.3.291; Simons LE, 2014, NEUROSCI BIOBEHAV R, V39, P61, DOI 10.1016/j.neubiorev.2013.12.006; Slesinger D, 2002, ASSESSMENT, V9, P406, DOI 10.1177/1073191102238153; Solouki S, 2016, CEREBELLUM, V15, P299, DOI 10.1007/s12311-015-0695-3; Thornton M, 2005, BRAIN INJURY, V19, P989, DOI 10.1080/02699050500109944; Treede RD, 2015, PAIN, V156, P1003, DOI 10.1097/j.pain.0000000000000160; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Weiss AL, 2017, CURR PAIN HEADACHE R, V21, DOI 10.1007/s11916-017-0609-9; Willigenburg NW, 2013, GAIT POSTURE, V38, P625, DOI 10.1016/j.gaitpost.2013.02.010; YANG TT, 1994, NATURE, V368, P592, DOI 10.1038/368592b0; Yelvar GDY, 2017, EUR SPINE J, V26, P538, DOI 10.1007/s00586-016-4892-7	69	26	28	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2019	14	5							e0216858	10.1371/journal.pone.0216858	http://dx.doi.org/10.1371/journal.pone.0216858			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HZ3VE	31120892	Green Published, gold, Green Submitted			2023-01-03	WOS:000468775700033
J	Vigneshwari, A; Rakk, D; Nemeth, A; Kocsube, S; Kiss, N; Csupor, D; Papp, T; Skrbic, B; Vagvolgyi, C; Szekeres, A				Vigneshwari, Aruna; Rakk, David; Nemeth, Aniko; Kocsube, Sandor; Kiss, Noemi; Csupor, Dezso; Papp, Tamas; Skrbic, Biljana; Vagvolgyi, Csaba; Szekeres, Andras			Host metabolite producing endophytic fungi isolated from Hypericum perforatum	PLOS ONE			English	Article							ST-JOHNS-WORT; SECONDARY METABOLITES; ALTERNARIA-ALTERNATA; TAXOL PRODUCTION; IDENTIFICATION; EMODIN; PSEUDOHYPERICIN; PLANTS	In the present study, endophytic fungi have been isolated from various parts of the medicinal herb Hypericum perforatum (St. John's Wort), which is known as a source of medically important metabolites. The isolated strains were cultured in liquid media and their ability to synthesize hypericin, the secondary metabolite of the host and its suspected precursor, emodin was tested analyzing the extracts of the fermentation broth and the mycelia. The HPLC-UV analysis of the chloroform/methanol extracts of the mycelia revealed that three isolates were able to produce emodin (SZMC 23771, 19.9 ng/mg; SZMC 23772, 20.8 ng/mg; SZMC 23769, 427.9 ng/mg) and one of them also could synthesize hypericin (SZMC 23769, 320.4 ng/mg). These results were also confirmed via UHPLC-HRMS technique both in full scan and MS/MS mode. The strains producing only emodin belong to the section Alternata of the genus Alternaria, while the isolate producing both metabolites was identified as Epicoccum nigrum. The mycelial extracts of E. nigrum and the Alternaria sp. SZMC 23772 showed higher inhibitory activities in the antimicrobial tests against the six selected bacteria compared to the hypericin and emodin standards in the applied concentration (100 mu g/mL), while in case of the Alternaria sp. SZMC 23771 lower inhibition activities were observed on Staphylococcus aureus and Streptomyces albus than the pure compounds.	[Vigneshwari, Aruna; Rakk, David; Kocsube, Sandor; Kiss, Noemi; Papp, Tamas; Vagvolgyi, Csaba; Szekeres, Andras] Univ Szeged, Fac Sci & Informat, Dept Microbiol, Szeged, Hungary; [Vigneshwari, Aruna] Univ Szeged, Doctoral Sch Biol, Fac Sci & Informat, Szeged, Hungary; [Nemeth, Aniko] Univ Szeged, Bot Garden, Szeged, Hungary; [Csupor, Dezso] Univ Szeged, Dept Pharmacognosy, Fac Pharm, Szeged, Hungary; [Papp, Tamas] Univ Szeged, Hungarian Acad Sci, MTA SZTE Fungal Pathogen Mech Res Grp, Szeged, Hungary; [Skrbic, Biljana] Univ Novi Sad, Fac Technol, Novi Sad, Serbia; [Vagvolgyi, Csaba; Szekeres, Andras] Univ Szeged, Interdisciplinary Ctr Nat Prod, Szeged, Hungary	Szeged University; Szeged University; Szeged University; Szeged University; Hungarian Academy of Sciences; Szeged University; University of Novi Sad; Szeged University	Szekeres, A (corresponding author), Univ Szeged, Fac Sci & Informat, Dept Microbiol, Szeged, Hungary.; Szekeres, A (corresponding author), Univ Szeged, Interdisciplinary Ctr Nat Prod, Szeged, Hungary.	andras.j.szekeres@gmail.com	Skrbic, Biljana/ABE-9412-2020; Csupor, Dezső/ABE-1830-2021; Vagvolgyi, Csaba/L-8497-2018; Skrbic, Biljana/T-1660-2019; Szekeres, Andras/I-8956-2012	Csupor, Dezső/0000-0002-4088-3333; Vagvolgyi, Csaba/0000-0003-0009-7773; Skrbic, Biljana/0000-0002-8615-8989; Papp, Tamas/0000-0001-8211-5431; Kocsube, Sandor/0000-0001-7839-0510; RAMASAMY, ARUNA VIGNESHWARI/0000-0002-8131-1518; Szekeres, Andras/0000-0003-1651-4623	Hungarian Government; European Union [GINOP-2.3.2-15-2016-00012]; Szechenyi 2020 Programme [GINOP-2.3.3-15-2016-00006]; National Research, Development and Innovation Fund of Hungary [TET_16-1-2016-0148]; Hungarian Academy of Sciences [LP2016-8/2016];  [PD 116609]	Hungarian Government; European Union(European Commission); Szechenyi 2020 Programme; National Research, Development and Innovation Fund of Hungary; Hungarian Academy of Sciences(Hungarian Academy of Sciences); 	This work was supported by the Hungarian Government and the European Union within the frames of the Szechenyi 2020 Programme through grant GINOP-2.3.2-15-2016-00012. The infrastructural background was established with the support of GINOP-2.3.3-15-2016-00006 grant (Szechenyi 2020 Programme). The research was carried out with the contribution of the project TET_16-1-2016-0148 (National Research, Development and Innovation Fund of Hungary). TP was supported by the LP2016-8/2016 project of the Hungarian Academy of Sciences and SK was supported by the PD 116609 grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agapouda A, 2019, J PHARM PHARMACOL, V71, P15, DOI 10.1111/jphp.12711; AGOSTI G, 1962, BIOCHEM J, V85, P528, DOI 10.1042/bj0850528; Agostinis P, 2002, INT J BIOCHEM CELL B, V34, P221, DOI 10.1016/S1357-2725(01)00126-1; Andrew M, 2009, MYCOLOGIA, V101, P95, DOI 10.3852/08-135; Armitage AD, 2015, FUNGAL BIOL-UK, V119, P994, DOI 10.1016/j.funbio.2015.06.012; Arnold A. Elizabeth, 2007, Fungal Biology Reviews, V21, P51, DOI 10.1016/j.fbr.2007.05.003; Ayan AK, 2008, PHARM BIOL, V46, P288, DOI 10.1080/13880200701741211; BAMFORD PHILIP C., 1961, TRANS BRIT MYCOL SOC, V44, P354; BAUTE MA, 1978, J ANTIBIOT, V31, P1099, DOI 10.7164/antibiotics.31.1099; Birt DF, 2009, PHARM BIOL, V47, P774, DOI 10.1080/13880200902988645; Butterweck V, 2003, CNS DRUGS, V17, P539, DOI 10.2165/00023210-200317080-00001; Chen Q, 2017, STUD MYCOL, P105, DOI 10.1016/j.simyco.2017.06.002; Crockett Sara L, 2011, Med Aromat Plant Sci Biotechnol, V5, P1; Cui YN, 2012, FITOTERAPIA, V83, P913, DOI 10.1016/j.fitote.2012.04.009; Devari S, 2014, PHYTOCHEMISTRY, V98, P183, DOI 10.1016/j.phytochem.2013.12.001; Dewick P.M., 2009, MED NATURAL PRODUCTS; Dong XX, 2016, PHYTOTHER RES, V30, P1207, DOI 10.1002/ptr.5631; Fatima N, 2016, ACTA POL PHARM, V73, P13; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Garnica S, 2003, MYCOL RES, V107, P1143, DOI 10.1017/S0953756203008414; Garyali S, 2013, J MICROBIOL BIOTECHN, V23, P1372, DOI 10.4014/jmb.1305.05070; Holscher D, 2009, PLANT J, V60, P907, DOI 10.1111/j.1365-313X.2009.04012.x; Huang LF, 2014, CHIN J NAT MEDICINES, V12, P81, DOI 10.1016/S1875-5364(14)60014-5; IKAWA M, 1978, J ANTIBIOT, V31, P159, DOI 10.7164/antibiotics.31.159; Karioti A, 2010, INT J MOL SCI, V11, P562, DOI 10.3390/ijms11020562; Kaul S, 2008, ANN MICROBIOL, V58, P443, DOI 10.1007/BF03175541; Kaul S, 2013, 3 BIOTECH, V3, P335, DOI 10.1007/s13205-012-0106-0; Kaul S, 2012, PHYTOCHEM REV, V11, P487, DOI 10.1007/s11101-012-9260-6; Kharwar RN, 2011, NAT PROD REP, V28, P1208, DOI 10.1039/c1np00008j; Kitanov GM, 2001, BIOCHEM SYST ECOL, V29, P171, DOI 10.1016/S0305-1978(00)00032-6; Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]; Kusari P, 2015, APPL MICROBIOL BIOT, V99, P5383, DOI 10.1007/s00253-015-6660-8; Kusari S, 2009, J APPL MICROBIOL, V107, P1019, DOI 10.1111/j.1365-2672.2009.04285.x; Kusari S, 2008, J NAT PROD, V71, P159, DOI 10.1021/np070669k; Kusari S, 2015, ANAL BIOANAL CHEM, V407, P4779, DOI 10.1007/s00216-015-8682-6; Lawrence DP, 2016, MYCOL PROG, V15, DOI 10.1007/s11557-015-1144-x; Lawrence DP, 2013, MYCOLOGIA, V105, P530, DOI 10.3852/12-249; Li MJ, 2014, MYCOBIOLOGY, V42, P412, DOI 10.5941/MYCO.2014.42.4.412; Li WK, 2001, J CHROMATOGR B, V765, P99, DOI 10.1016/S0378-4347(01)00404-2; Lu P, 2010, AFR J BIOTECHNOL, V9, P512; Martonfi P, 2006, BIOLOGIA, V61, P473, DOI 10.2478/s11756-006-0079-8; Mims CW, 2005, CAN J BOT, V83, P1354, DOI 10.1139/b05-137; Nei M., 2000, MOL EVOLUTION PHYLOG; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schulz B, 2002, MYCOL RES, V106, P996, DOI 10.1017/S0953756202006342; Silva BA, 2005, FOOD CHEM, V90, P157, DOI 10.1016/j.foodchem.2004.03.049; Singh U. P., 1992, Fitopatologia Brasileira, V17, P420; Somjaipeng S, 2015, FUNGAL BIOL-UK, V119, P1022, DOI 10.1016/j.funbio.2015.07.007; Sotak M, 2016, FRONT PLANT SCI, V7, DOI [10.3389/fpls.2010.01039, 10.3389/fpls.2016.01039]; Southwell IA, 2001, PHYTOCHEMISTRY, V56, P437, DOI 10.1016/S0031-9422(00)00411-8; Strobel G, 2003, MICROBIOL MOL BIOL R, V67, P491, DOI 10.1128/MMBR.67.4.491-502.2003; Stuart RM, 2010, ARCH MICROBIOL, V192, P307, DOI 10.1007/s00203-010-0557-9; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Thunig J, 2011, ANAL CHEM, V83, P3256, DOI 10.1021/ac2004967; Wayne P.A., 2015, METHODS DILUTION ANT, DOI 10.1109/bsn.2015.7299391; WELLS JM, 1975, APPL MICROBIOL, V30, P26, DOI 10.1106/0U8J-DK8P-MUER-FCKG; White TJ, 1990, PCR PROTOCOLS GUIDE, P315, DOI DOI 10.1016/B978-0-12-372180-8.50042-1; Woudenberg JHC, 2013, STUD MYCOL, P171, DOI 10.3114/sim0015; Yin H, 2011, PHYTOMEDICINE, V18, P802, DOI 10.1016/j.phymed.2011.01.005; Zhang YG, 2007, J NAT PROD, V70, P1522, DOI 10.1021/np070239u; Zhao J, 2010, CURRENT RES TECHNOLO, P567, DOI DOI 10.1016/J.PHYTOCHEM.2012.07.021; 2015, PLANT CELL TISS ORG, V122, P45, DOI DOI 10.1007/S11240-015-0748-9; 2009, J NAT PRODUCTS, V72, P1825, DOI DOI 10.1021/NP9002977; 2007, ORG BIOMOL CHEM, V5, P1702, DOI DOI 10.1039/B702378B; 1925, LIEBIGS ANN CHEM, V444, P1, DOI DOI 10.1002/JLAC.19254440102; 2005, FUNGAL GENET BIOL, V42, P813, DOI DOI 10.1016/J.FGB.2005.06.007; 2017, APPL MICROBIOL BIOT, V101, P5831, DOI DOI 10.1007/S00253-017-8354-X	67	16	19	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2019	14	5							e0217060	10.1371/journal.pone.0217060	http://dx.doi.org/10.1371/journal.pone.0217060			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY9HS	31112560	Green Published, gold, Green Accepted, Green Submitted			2023-01-03	WOS:000468451000037
J	Yadav, KN; Josephs, M; Gabler, NB; Detsky, ME; Halpern, SD; Hart, JL				Yadav, Kuldeep N.; Josephs, Michael; Gabler, Nicole B.; Detsky, Michael E.; Halpern, Scott D.; Hart, Joanna L.			What's behind the white coat: Potential mechanisms of physician-attributable variation in critical care	PLOS ONE			English	Article							OF-LIFE CARE; DECISION-MAKING; ADVANCE DIRECTIVES; REGIONAL-VARIATION; PATIENT; VARIABILITY; UNIT; ASSOCIATION; PREFERENCES; QUALITY	Background Critical care intensity is known to vary across regions and centers, yet the mechanisms remain unidentified. Physician behaviors have been implicated in the variability of intensive care near the end of life, but physician characteristics that may underlie this association have not been determined. Purpose We sought to identify behavioral attributes that vary among intensivists to generate hypotheses for mechanisms of intensivist-attributable variation in critical care delivery. Methods We administered a questionnaire to intensivists who participated in a prior cohort study in which intensivists made prognostic estimates. We evaluated the degree to which scores on six attribute measures varied across intensivists. Measures were selected for their relevance to preference-sensitive critical care: a modified End-of-Life Preferences (EOLP) scale, Life Orientation Test-Revised (LOT-R), Jefferson Scale of Empathy (JSE), Physicians' Reactions to Uncertainty (PRU) scale, Collett-Lester Fear of Death (CLFOD) scale, and a test of omission bias. We conducted regression analyses assessing relationships between intensivists' attribute scores and their prognostic accuracy, as physicians' prognostic accuracy may influence preference-sensitive decisions. Results 20 of 25 eligible intensivists (80%) completed the questionnaire. Intensivists' scores on the EOLP, LOT-R, PRU, CLFOD, and omission bias measures varied considerably, while their responses on the JSE scale did not. There were no consistent associations between attribute scores and prognostic accuracy. Conclusions Intensivists vary in feasibly measurable attributes relevant to preference-sensitive critical care delivery. These attributes represent candidates for future research aimed at identifying mechanisms of clinician-attributable variation in critical care and developing effective interventions to reduce undue variation.	[Yadav, Kuldeep N.; Josephs, Michael; Gabler, Nicole B.; Detsky, Michael E.; Halpern, Scott D.; Hart, Joanna L.] Univ Penn, Palliat & Adv Illness Res Ctr, Philadelphia, PA 19104 USA; [Yadav, Kuldeep N.; Josephs, Michael; Gabler, Nicole B.; Detsky, Michael E.; Halpern, Scott D.; Hart, Joanna L.] Univ Penn, Fostering Improvement End Of Life Decis Sci Progr, Philadelphia, PA 19104 USA; [Yadav, Kuldeep N.; Josephs, Michael; Halpern, Scott D.; Hart, Joanna L.] Univ Penn, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA; [Yadav, Kuldeep N.; Halpern, Scott D.; Hart, Joanna L.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Detsky, Michael E.] UHN Mt Sinai Hosp, Div Crit Care Med, Toronto, ON, Canada; [Detsky, Michael E.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Halpern, Scott D.; Hart, Joanna L.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; [Halpern, Scott D.; Hart, Joanna L.] Univ Penn, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA; [Halpern, Scott D.; Hart, Joanna L.] Univ Penn, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University Health Network Toronto; University of Toronto; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Hart, JL (corresponding author), Univ Penn, Palliat & Adv Illness Res Ctr, Philadelphia, PA 19104 USA.; Hart, JL (corresponding author), Univ Penn, Fostering Improvement End Of Life Decis Sci Progr, Philadelphia, PA 19104 USA.; Hart, JL (corresponding author), Univ Penn, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.; Hart, JL (corresponding author), Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.; Hart, JL (corresponding author), Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.; Hart, JL (corresponding author), Univ Penn, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA.; Hart, JL (corresponding author), Univ Penn, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA.	joanna.hart@uphs.upenn.edu		Yadav, Kuldeep/0000-0002-7661-6229	Otto Haas Charitable Trust; National Heart, Lung, and Blood Institute [K12HL109009]	Otto Haas Charitable Trust; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by: Otto Haas Charitable Trust to SDH, and by K12HL109009 (National Heart, Lung, and Blood Institute) to JLH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ASCH DA, 1994, MED DECIS MAKING, V14, P118, DOI 10.1177/0272989X9401400204; Baker LC, 2014, HEALTH AFFAIR, V33, P957, DOI 10.1377/hlthaff.2013.1184; Barnato AE, 2007, MED CARE, V45, P386, DOI 10.1097/01.mlr.0000255248.79308.41; Curtis JR, 2017, INTENS CARE MED, V43, P94, DOI 10.1007/s00134-016-4340-5; Cutler D, 2013, PHYS BELIEFS PATIENT; Detsky ME, 2017, JAMA-J AM MED ASSOC, V317, P2187, DOI 10.1001/jama.2017.4078; Frakt A, 2017, NY TIMES; Gallo JJ, 2003, J AM GERIATR SOC, V51, P961, DOI 10.1046/j.1365-2389.2003.51309.x; Garland A, 2006, AM J RESP CRIT CARE, V174, P1206, DOI 10.1164/rccm.200511-1810OC; GERRITY MS, 1990, MED CARE, V28, P724, DOI 10.1097/00005650-199008000-00005; Goodman DC, 2013, TRENDS CANC CARE NEA; Hart JL, 2017, ANN AM THORAC SOC, V14, P491, DOI 10.1513/AnnalsATS.201701-094ED; Hart JL, 2015, JAMA INTERN MED, V175, P1019, DOI 10.1001/jamainternmed.2015.0372; Hojat M, 2002, AM J PSYCHIAT, V159, P1563, DOI 10.1176/appi.ajp.159.9.1563; Hojat M, 2011, ACAD MED, V86, P359, DOI 10.1097/ACM.0b013e3182086fe1; Kelley AS, 2011, ANN INTERN MED, V154, P235, DOI 10.7326/0003-4819-154-4-201102150-00004; Lester D, 2003, DEATH STUD, V27, P81, DOI 10.1080/07481180302873; Mark NM, 2015, INTENS CARE MED, V41, P1572, DOI 10.1007/s00134-015-3810-5; McKenzie MS, 2015, CRIT CARE MED, V43, P1660, DOI 10.1097/CCM.0000000000001084; Mohan D, 2010, J PALLIAT MED, V13, P949, DOI 10.1089/jpm.2010.0053; Nicholas LH, 2011, JAMA-J AM MED ASSOC, V306, P1447, DOI 10.1001/jama.2011.1410; Obermeyer Z, 2015, HEALTH AFFAIR, V34, P993, DOI 10.1377/hlthaff.2014.1055; Pollack CE, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.6550; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Quill CM, 2014, CHEST, V146, P573, DOI 10.1378/chest.13-2529; SCHEIER MF, 1994, J PERS SOC PSYCHOL, V67, P1063, DOI 10.1037/0022-3514.67.6.1063; Teno JM, 2005, J AM GERIATR SOC, V53, P1905, DOI 10.1111/j.1532-5415.2005.53563.x; Teno JM, 2007, J AM GERIATR SOC, V55, P189, DOI 10.1111/j.1532-5415.2007.01045.x; Weeks William Brinson, 2011, Front Health Serv Manage, V27, P17; Wilkinson DJC, 2013, INTENS CARE MED, V39, P1128, DOI 10.1007/s00134-013-2871-6	30	5	5	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2019	14	5							e0216418	10.1371/journal.pone.0216418	http://dx.doi.org/10.1371/journal.pone.0216418			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HY3MG	31095596	gold, Green Published, Green Submitted			2023-01-03	WOS:000468030100024
J	Brodsky, RA				Brodsky, Robert A.			Warm Autoimmune Hemolytic Anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; DRUG-INDUCED IMMUNE; RITUXIMAB; ADULTS; CYCLOPHOSPHAMIDE; COMPLEMENT; MANAGEMENT; DIAGNOSIS; EFFICACY; INSIGHTS	Warm autoimmune hemolytic anemia is a chronic, relapsing disease characterized by anemia, reticulocytosis, other evidence of hemolysis, and a positive direct antiglobulin test. First-line therapy (after prompt transfusion of ABO- and RhD-matched blood in patients with severe anemia) involves glucocorticoids and rituximab.	[Brodsky, Robert A.] Johns Hopkins Univ, Sch Med, Dept Med, Div Hematol, Baltimore, MD 21205 USA	Johns Hopkins University	Brodsky, RA (corresponding author), Ross Res Bldg,Rm 1025,720 Rutland Ave, Baltimore, MD 21205 USA.	brodsro@jhmi.edu						ALLGOOD JW, 1967, AM J MED, V43, P254, DOI 10.1016/0002-9343(67)90168-4; Audia S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207218; Barbar S, 2010, J THROMB HAEMOST, V8, P2450, DOI 10.1111/j.1538-7836.2010.04044.x; Barcellini W, 2015, TRANSFUS MED HEMOTH, V42, P287, DOI 10.1159/000439002; Barcellini W, 2014, BLOOD, V124, P2930, DOI 10.1182/blood-2014-06-583021; Berentsen S, 2018, SEMIN HEMATOL, V55, P141, DOI 10.1053/j.seminhematol.2018.04.002; Birgens H, 2013, BRIT J HAEMATOL, V163, P393, DOI 10.1111/bjh.12541; Bride Karen, 2017, F1000Res, V6, P1928, DOI 10.12688/f1000research.11545.1; Bride KL, 2016, BLOOD, V127, P17, DOI 10.1182/blood-2015-07-657981; Brodsky RA, 2015, BLOOD, V126, P2459, DOI 10.1182/blood-2015-06-640995; Bussel J, 2018, AM J HEMATOL, V93, P921, DOI 10.1002/ajh.25125; CONLEY CL, 1982, NEW ENGL J MED, V306, P281, DOI 10.1056/NEJM198202043060507; Crowther M, 2011, BLOOD, V118, P4036, DOI 10.1182/blood-2011-05-347708; Dierickx D, 2015, BLOOD, V125, P3223, DOI 10.1182/blood-2015-01-588392; Eaton WW, 2007, J AUTOIMMUN, V29, P1, DOI 10.1016/j.jaut.2007.05.002; Garbe E, 2011, BRIT J HAEMATOL, V154, P644, DOI 10.1111/j.1365-2141.2011.08784.x; Go RS, 2017, BLOOD, V129, P2971, DOI 10.1182/blood-2016-11-693689; Hill A, 2018, HEMATOL-AM SOC HEMAT, P382, DOI 10.1182/asheducation-2018.1.382; Hill A, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.28; Hill QA, 2017, BRIT J HAEMATOL, V177, P208, DOI 10.1111/bjh.14654; Hill QA, 2017, BRIT J HAEMATOL, V176, P395, DOI 10.1111/bjh.14478; Kalfa TA, 2016, HEMATOL-AM SOC HEMAT, P690, DOI 10.1182/asheducation-2016.1.690; Kamesaki T, 2009, AM J HEMATOL, V84, P98, DOI 10.1002/ajh.21336; KIPPS TJ, 1993, BLOOD, V81, P2475; Lechner K, 2010, BLOOD, V116, P1831, DOI 10.1182/blood-2010-03-259325; LIESVELD JL, 1987, BLOOD, V69, P820; Maung SW, 2013, BRIT J HAEMATOL, V163, P118, DOI 10.1111/bjh.12486; Mauro FR, 2000, BLOOD, V95, P2786, DOI 10.1182/blood.V95.9.2786.009k30_2786_2792; MCCANN EL, 1992, ACTA HAEMATOL-BASEL, V88, P120; Miano M, 2015, BRIT J HAEMATOL, V171, P247, DOI 10.1111/bjh.13533; Michel M, 2017, AM J HEMATOL, V92, P23, DOI 10.1002/ajh.24570; Moyo VM, 2002, BLOOD, V100, P704, DOI 10.1182/blood-2002-01-0087; Podjasek JC, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00189; Ravindran A, 2017, AM J HEMATOL, V92, pE164, DOI 10.1002/ajh.24765; Reynaud Q, 2015, AUTOIMMUN REV, V14, P304, DOI 10.1016/j.autrev.2014.11.014; Rother RP, 2005, JAMA-J AM MED ASSOC, V293, P1653, DOI 10.1001/jama.293.13.1653; Roumier M, 2014, AM J HEMATOL, V89, pE150, DOI 10.1002/ajh.23767; SHULMAN IA, 1985, JAMA-J AM MED ASSOC, V253, P1746, DOI 10.1001/jama.253.12.1746; Tanios GE, 2019, EUR J HAEMATOL, V102, P157, DOI 10.1111/ejh.13187; Thabet AF, 2014, INDIAN J HEMATOL BLO, V30, P313, DOI 10.1007/s12288-013-0290-z; Woolley AE, 2017, NEW ENGL J MED, V376, P939, DOI [10.1056/NEJMoa1612165, 10.1056/nejmoa1612165]; Yurek S, 2015, BLOOD TRANSFUS-ITALY, V13, P616, DOI 10.2450/2015.0326-14	42	54	59	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 15	2019	381	7					647	654		10.1056/NEJMcp1900554	http://dx.doi.org/10.1056/NEJMcp1900554			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IR5HE	31412178				2023-01-03	WOS:000481462800010
J	Ding, L; Chen, F				Ding, Li; Chen, Feng			Predicting Tumor Response to PD-1 Blockade	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Immune checkpoint inhibitors have efficacy in persons who have tumors with microsatellite instability (MSI). A recent study using a mouse model suggests that a specific type of mutation related to MSI drives the response.	[Ding, Li; Chen, Feng] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Ding, Li] Washington Univ, Sch Med, McDonnell Genome Inst, St Louis, MO 63110 USA; [Ding, Li] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; [Ding, Li; Chen, Feng] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63110 USA; [Chen, Feng] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); Washington University (WUSTL)	Ding, L (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.; Ding, L (corresponding author), Washington Univ, Sch Med, McDonnell Genome Inst, St Louis, MO 63110 USA.; Ding, L (corresponding author), Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA.; Ding, L (corresponding author), Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63110 USA.							Baretti M, 2018, PHARMACOL THERAPEUT, V189, P45, DOI 10.1016/j.pharmthera.2018.04.004; Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Mandal R, 2019, SCIENCE, V364, P485, DOI 10.1126/science.aau0447; Niu BF, 2014, BIOINFORMATICS, V30, P1015, DOI 10.1093/bioinformatics/btt755	5	14	15	4	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 1	2019	381	5					477	479		10.1056/NEJMcibr1906340	http://dx.doi.org/10.1056/NEJMcibr1906340			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IM5WH	31365807	Green Published			2023-01-03	WOS:000478064200014
J	Nguyen, C; Yamazaki, T; Kovalenko, A; Case, DA; Gilson, MK; Kurtzman, T; Luchko, T				Nguyen, Crystal; Yamazaki, Takeshi; Kovalenko, Andriy; Case, David A.; Gilson, Michael K.; Kurtzman, Tom; Luchko, Tyler			A molecular reconstruction approach to site-based 3D-RISM and comparison to GIST hydration thermodynamic maps in an enzyme active site	PLOS ONE			English	Article							INHOMOGENEOUS FLUID APPROACH; SOLVATION THERMODYNAMICS; FREE-ENERGIES; PARTITION-COEFFICIENT; SPATIAL DECOMPOSITION; INTEGRAL-EQUATION; WATER; ENTROPY; DENSITY; SOLVENT	Computed, high-resolution, spatial distributions of solvation energy and entropy can provide detailed information about the role of water in molecular recognition. While grid inhomogeneous solvation theory (GIST) provides rigorous, detailed thermodynamic information from explicit solvent molecular dynamics simulations, recent developments in the 3D reference interaction site model (3D-RISM) theory allow many of the same quantities to be calculated in a fraction of the time. However, 3D-RISM produces atomic-site, rather than molecular, density distributions, which are difficult to extract physical meaning from. To overcome this difficulty, we introduce a method to reconstruct molecular density distributions from atomic-site density distributions. Furthermore, we assess the quality of the resulting solvation thermodynamics density distributions by analyzing the binding site of coagulation Factor Xa with both GIST and 3D-RISM. We find good qualitative agreement between the methods for oxygen and hydrogen densities as well as direct solute-solvent energetic interactions. However, 3D-RISM predicts lower energetic and entropic penalties for moving water from the bulk to the binding site.	[Nguyen, Crystal; Gilson, Michael K.] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA; [Yamazaki, Takeshi] Vancouver Prostate Ctr, Vancouver, BC, Canada; [Kovalenko, Andriy] Natl Res Council Canada, Natl Inst Nanotechnol, Edmonton, AB, Canada; [Kovalenko, Andriy] Univ Alberta, Dept Mech Engn, Edmonton, AB, Canada; [Case, David A.] CUNY, Lehman Coll, Dept Chem, Bronx, NY USA; [Kurtzman, Tom] Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA; [Luchko, Tyler] Calif State Univ Northridge, Dept Phys & Astron, Northridge, CA 91330 USA; [Yamazaki, Takeshi] 1QB Informat Technol 1QBit, Vancouver, BC, Canada	University of California System; University of California San Diego; National Research Council Canada; University of Alberta; City University of New York (CUNY) System; Lehman College (CUNY); Rutgers State University New Brunswick; California State University System; California State University Northridge	Gilson, MK (corresponding author), Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA.; Kurtzman, T (corresponding author), Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA.; Luchko, T (corresponding author), Calif State Univ Northridge, Dept Phys & Astron, Northridge, CA 91330 USA.	mgilson@ucsd.edu; simpleliquid@gmail.com; tluchko@csun.edu	Yamazaki, Takeshi/A-5785-2018	Yamazaki, Takeshi/0000-0002-5714-764X; Luchko, Tyler/0000-0001-6737-6019; Kurtzman, Tom/0000-0003-0900-772X	National Science Foundation (NSF) [1566638]; Research Corporation for Science Advancement (RCSA) Cottrell Scholar Award [23967]; National Institutes of Health (NIH) [GM122086, GM061300, GM100946]	National Science Foundation (NSF)(National Science Foundation (NSF)); Research Corporation for Science Advancement (RCSA) Cottrell Scholar Award; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This material is based upon work supported by the National Science Foundation (NSF) under Grant No. 1566638 and the Research Corporation for Science Advancement (RCSA) Cottrell Scholar Award #23967 awarded to T. L. Additional support came from National Institutes of Health (NIH) Grant GM122086 (D.A.C.), GM061300 (M.K.G), and GM100946 (M.K.G. and T. K.). The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the NIH, NSF, or RCSA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abel R, 2008, J AM CHEM SOC, V130, P2817, DOI 10.1021/ja0771033; Beglov D, 1997, J PHYS CHEM B, V101, P7821, DOI 10.1021/jp971083h; Case D. A., 2014, AMBER 14, V14; Fujita T, 2017, J CHEM PHYS, V147, DOI 10.1063/1.4990502; Giambasu GM, 2014, BIOPHYS J, V106, P883, DOI 10.1016/j.bpj.2014.01.021; Green HS, 1952, THE MOLECULAR THEORY; Gussregen S, 2017, J CHEM INF MODEL, V57, P1652, DOI 10.1021/acs.jcim.6b00765; Haider K, SOLVATION STRUCTURE; Hansen J.-P., 2006, THEORY OF SIMPLE LIQ; Hornak V, 2006, PROTEINS, V65, P712, DOI 10.1002/prot.21123; Huang WJ, 2015, J PHYS CHEM B, V119, P5588, DOI 10.1021/acs.jpcb.5b01291; Huggins DJ, 2014, J CHEM THEORY COMPUT, V10, P3617, DOI 10.1021/ct500415g; Johnson J, 2016, J PHYS-CONDENS MAT, V28, DOI 10.1088/0953-8984/28/34/344002; Johnson J, SMALL MOLECULE SOLVA; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Joung IS, 2013, J CHEM PHYS, V138, DOI 10.1063/1.4775743; Kast SM, 2008, J CHEM PHYS, V129, DOI 10.1063/1.3041709; Kovalenko A, 2000, J CHEM PHYS, V112, P10391, DOI 10.1063/1.481676; Kovalenko A, 2003, UNDERS CH R, V24, P169; Kovalenko A, 1999, J CHEM PHYS, V110, P10095, DOI 10.1063/1.478883; Kovalenko A, 1999, J COMPUT CHEM, V20, P928, DOI 10.1002/(SICI)1096-987X(19990715)20:9<928::AID-JCC4>3.0.CO;2-X; Kovalenko A, 2000, J CHEM PHYS, V113, P2793, DOI 10.1063/1.1305885; Kovalenko A, 2017, SPRINGER HANDBOOK OF ELECTROCHEMICAL ENERGY, P95; Lazaridis T, 1996, J CHEM PHYS, V105, P4294, DOI 10.1063/1.472247; Lazaridis T, 1998, J PHYS CHEM B, V102, P3531, DOI 10.1021/jp9723574; Lazaridis T, 1998, J PHYS CHEM B, V102, P3542, DOI 10.1021/jp972358w; Li Z, 2012, METHODS MOL BIOL, V819, P393, DOI 10.1007/978-1-61779-465-0_24; Luchko T, 2016, J COMPUT AID MOL DES, V30, P1115, DOI 10.1007/s10822-016-9947-7; Luchko T, 2010, J CHEM THEORY COMPUT, V6, P607, DOI 10.1021/ct900460m; Misin M, 2016, J PHYS CHEM B, V120, P5724, DOI 10.1021/acs.jpcb.6b05352; Misin M, 2016, J PHYS CHEM B, V120, P975, DOI 10.1021/acs.jpcb.5b10809; Misin M, 2015, J CHEM PHYS, V142, DOI 10.1063/1.4914315; MORITA T, 1958, PROG THEOR PHYS, V20, P920, DOI 10.1143/PTP.20.920; NETTLETON RE, 1958, J CHEM PHYS, V29, P1365, DOI 10.1063/1.1744724; Nguyen C, 2011, ARXIV11084876 PHYS Q; Nguyen CN, 2016, J CHEM THEORY COMPUT, V12, P414, DOI 10.1021/acs.jctc.5b00939; Nguyen CN, 2012, J CHEM PHYS, V137, DOI 10.1063/1.4733951; Ornstein LS, 1914, P K AKAD WET-AMSTERD, V17, P793; Palmer DS, 2010, J PHYS-CONDENS MAT, V22, DOI 10.1088/0953-8984/22/49/492101; Palmer DS, 2010, J CHEM PHYS, V133, DOI 10.1063/1.3458798; PERKYNS J, 1992, J CHEM PHYS, V97, P7656, DOI 10.1063/1.463485; Ramsey S, 2016, J COMPUT CHEM, V37, P2029, DOI 10.1002/jcc.24417; Ratkova EL, 2010, J PHYS CHEM B, V114, P12068, DOI 10.1021/jp103955r; Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p; Salomon-Ferrer R, 2013, WIRES COMPUT MOL SCI, V3, P198, DOI 10.1002/wcms.1121; Sergiievskyi V, 2015, J CHEM PHYS, V143, DOI 10.1063/1.4935065; Sindhikara DJ, 2013, J PHYS CHEM B, V117, P6718, DOI 10.1021/jp4046116; Singh H., 2003, American Journal of Mathematical and Management Sciences, V23, P301; Stumpe MC, 2011, J PHYS CHEM B, V115, P319, DOI 10.1021/jp102587q; Tielker N, 2016, J COMPUT AID MOL DES, V30, P1035, DOI 10.1007/s10822-016-9939-7; Truchon JF, 2014, J CHEM THEORY COMPUT, V10, P934, DOI 10.1021/ct4009359; Vega C, 2011, PHYS CHEM CHEM PHYS, V13, P19663, DOI 10.1039/c1cp22168j; Wang L, 2009, J CHEM THEORY COMPUT, V5, P1462, DOI 10.1021/ct900078k; Yamazaki T, 2009, J CHEM THEORY COMPUT, V5, P1723, DOI 10.1021/ct9000729; Young T, 2007, P NATL ACAD SCI USA, V104, P808, DOI 10.1073/pnas.0610202104; YU HA, 1990, J CHEM PHYS, V92, P5020, DOI 10.1063/1.458538; Zielkiewicz J, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2018637	57	18	18	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2019	14	7							e0219473	10.1371/journal.pone.0219473	http://dx.doi.org/10.1371/journal.pone.0219473			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4JZ	31291328	Green Submitted, Green Published, gold			2023-01-03	WOS:000484947800094
J	Liu, FY; Zhang, Z; Levit, A; Levring, J; Touhara, KK; Shoichet, BK; Chen, J				Liu, Fangyu; Zhang, Zhe; Levit, Anat; Levring, Jesper; Touhara, Kouki K.; Shoichet, Brian K.; Chen, Jue			Structural identification of a hotspot on CFTR for potentiation	SCIENCE			English	Article							CYSTIC-FIBROSIS; STRUCTURE VALIDATION; ATOM CONTACTS; IN-VITRO; PHOSPHORYLATION; IVACAFTOR; VX-770; MODEL; REFINEMENT; MOLPROBITY	Cystic fibrosis is a fatal disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR). Two main categories of drugs are being developed: correctors that improve folding of CFTR and potentiators that recover the function of CFTR. Here, we report two cryo-electron microscopy structures of human CFTR in complex with potentiators: one with the U.S. Food and Drug Administration (FDA)-approved drug ivacaftor at 3.3-angstrom resolution and the other with an investigational drug, GLPG1837, at 3.2-angstrom resolution. These two drugs, although chemically dissimilar, bind to the same site within the transmembrane region. Mutagenesis suggests that in both cases, hydrogen bonds provided by the protein are important for drug recognition. The molecular details of how ivacaftor and GLPG1837 interact with CFTR may facilitate structure-based optimization of therapeutic compounds.	[Liu, Fangyu; Zhang, Zhe; Levring, Jesper; Chen, Jue] Rockefeller Univ, Lab Membrane Biophys & Biol, New York, NY 10065 USA; [Liu, Fangyu] Rockefeller Univ, Triinst Training Program Chem Biol, New York, NY 10065 USA; [Levit, Anat; Shoichet, Brian K.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA; [Touhara, Kouki K.] Rockefeller Univ, Lab Mol Neurobiol & Biophys, New York, NY 10065 USA; [Chen, Jue] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA; [Touhara, Kouki K.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	Rockefeller University; Rockefeller University; University of California System; University of California San Francisco; Rockefeller University; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Chen, J (corresponding author), Rockefeller Univ, Lab Membrane Biophys & Biol, New York, NY 10065 USA.; Chen, J (corresponding author), Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.	juechen@rockefeller.edu		Touhara, Kouki/0000-0003-3167-9784; Levring, Jesper/0000-0002-8916-4241; Liu, Fangyu/0000-0001-5022-0106	Howard Hughes Medical Institute; Cystic Fibrosis Foundation Therapeutics; Charles H. Revson fellowship in Biomedical Science;  [R35GM122481]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R35GM122481] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); Cystic Fibrosis Foundation Therapeutics(Italian Cystic Fibrosis Research Foundation); Charles H. Revson fellowship in Biomedical Science; ; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work is supported by the Howard Hughes Medical Institute (to J.C), the Cystic Fibrosis Foundation Therapeutics (to J.C), the Charles H. Revson fellowship in Biomedical Science (to Z.Z), and R35GM122481 (to B.K.S).	Balius TE, 2017, P NATL ACAD SCI USA, V114, pE6839, DOI 10.1073/pnas.1703287114; Barrett RDH, 2019, SCIENCE, V363, P499, DOI 10.1126/science.aav3824; Brown A, 2015, ACTA CRYSTALLOGR D, V71, P136, DOI 10.1107/S1399004714021683; Case D. A., 2015, AMBER 2015; Chambers CC, 1996, J PHYS CHEM-US, V100, P16385, DOI 10.1021/jp9610776; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; Coleman RG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075992; Davies JC, 2018, NEW ENGL J MED, V379, P1599, DOI 10.1056/NEJMoa1807119; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; Eckford PDW, 2012, J BIOL CHEM, V287, P36639, DOI 10.1074/jbc.M112.393637; Elborn JS, 2016, LANCET, V388, P2519, DOI 10.1016/S0140-6736(16)00576-6; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Gallagher K, 1998, BIOPHYS J, V75, P769, DOI 10.1016/S0006-3495(98)77566-6; Goehring A, 2014, NAT PROTOC, V9, P2574, DOI 10.1038/nprot.2014.173; Grant T, 2015, ELIFE, V4, DOI 10.7554/eLife.06980; Grigorieff N, 2016, METHOD ENZYMOL, V579, P191, DOI 10.1016/bs.mie.2016.04.013; Hadida S, 2014, J MED CHEM, V57, P9776, DOI 10.1021/jm5012808; Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x; Heymann JB, 2007, J STRUCT BIOL, V157, P3, DOI 10.1016/j.jsb.2006.06.006; Jih KY, 2013, P NATL ACAD SCI USA, V110, P4404, DOI 10.1073/pnas.1215982110; Keating D, 2018, NEW ENGL J MED, V379, P1612, DOI 10.1056/NEJMoa1807120; Kimanius D, 2016, ELIFE, V5, DOI 10.7554/eLife.18722; Li JB, 1998, J PHYS CHEM A, V102, P1820, DOI 10.1021/jp972682r; Liu FY, 2017, CELL, V169, P85, DOI 10.1016/j.cell.2017.02.024; Liu HT, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-91; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Mysinger MM, 2010, J CHEM INF MODEL, V50, P1561, DOI 10.1021/ci100214a; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Ramsey BW, 2011, NEW ENGL J MED, V365, P1663, DOI 10.1056/NEJMoa1105185; Rohou A, 2015, J STRUCT BIOL, V192, P216, DOI 10.1016/j.jsb.2015.08.008; Rubinstein JL, 2015, J STRUCT BIOL, V192, P188, DOI 10.1016/j.jsb.2015.08.007; Scheres SHW, 2012, J STRUCT BIOL, V180, P519, DOI 10.1016/j.jsb.2012.09.006; SHARP KA, 1995, BIOPOLYMERS, V36, P227, DOI 10.1002/bip.360360210; Taylor-Cousar JL, 2017, NEW ENGL J MED, V377, P2013, DOI 10.1056/NEJMoa1709846; Van der Plas SE, 2018, J MED CHEM, V61, P1425, DOI 10.1021/acs.jmedchem.7b01288; Van Goor F, 2011, P NATL ACAD SCI USA, V108, P18843, DOI 10.1073/pnas.1105787108; Van Goor F, 2009, P NATL ACAD SCI USA, V106, P18825, DOI 10.1073/pnas.0904709106; Wainwright CE, 2015, NEW ENGL J MED, V373, P1783, DOI 10.1056/NEJMc1510466; WANG ZX, 1995, FEBS LETT, V360, P111, DOI 10.1016/0014-5793(95)00062-E; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Word JM, 1999, J MOL BIOL, V285, P1735, DOI 10.1006/jmbi.1998.2401; Yeh HI, 2017, J GEN PHYSIOL, V149, P1105, DOI 10.1085/jgp.201711886; Yu YC, 2016, J PHYSIOL-LONDON, V594, P3227, DOI 10.1113/JP271723; Zhang K, 2016, J STRUCT BIOL, V193, P1, DOI 10.1016/j.jsb.2015.11.003; Zhang Z, 2018, P NATL ACAD SCI USA, V115, P12757, DOI 10.1073/pnas.1815287115; Zhang Z, 2017, CELL, V170, P483, DOI 10.1016/j.cell.2017.06.041; Zhang Z, 2016, CELL, V167, P1586, DOI 10.1016/j.cell.2016.11.014; Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193	50	101	103	8	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	2019	364	6446			SI		1184	+		10.1126/science.aaw7611	http://dx.doi.org/10.1126/science.aaw7611			34	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IE1VY	31221859	Green Accepted			2023-01-03	WOS:000472175100042
J	Phillips, CT; Wang, JM; Celi, LA; Zhang, ZB; Feng, ML				Phillips, Colin T.; Wang, Junmei; Celi, Leo Anthony; Zhang, Zhengbo; Feng, Mengling			Association of hypokalemia with an increased risk for medically treated arrhythmias	PLOS ONE			English	Article							ACUTE MYOCARDIAL-INFARCTION; SERUM POTASSIUM LEVELS; VENTRICULAR-FIBRILLATION; GUIDELINES; MORTALITY; LEVEL	Background Potassium replenishment protocols are often employed across broad patient populations to prevent cardiac arrhythmias. Tailoring potassium thresholds to specific patient populations would reduce unnecessary tasks and cost. The objective of this retrospective cohort study was to determine the threshold at which hypokalemia increases the risk for medically treated arrhythmias in cardiac versus medical and surgical intensive care units. Methods Patients captured in the publicly available Philips eICU database were assessed for initiation of either intravenous amiodarone, adenosine, ibutilide, isoproterenol, or lidocaine as a surrogate for a clinically significant arrhythmia. A landmark time-to-event analysis was conducted to investigate the association of serum potassium values and time-marked administration of an antiarrhythmic drug. Analysis was adjusted for comorbidities, the use of vasopressor agents, diuretics, as well as age, gender and severity of illness. Results Among 20,665 admissions to cardiac intensive care units, 1,371 (6.6%) were treated with either amiodarone, adenosine, ibutilide, isoproterenol, or lidocaine. For potassium values of >= 3.0<3.5mEq/L, antiarrhythmic treatment occurred at an increased rate compared to a baseline of >= 4.0.5.0mEq/L (HR 1.23, 95% CI 1.01-1.51; P = 0.04). For admissions to medical and surgical intensive care units, 2,100 of 69,714 patients (3.0%) were treated with either amiodarone, adenosine, ibutilide, isoproterenol, or lidocaine. Potassium values of >= 3.0<3.5mEq/L were also associated with an increased hazard of treatment (HR 1.26, 95% CI 1.09-1.45; P = 0.002). In both cohorts, worsening hypokalemia was associated with an increased risk of antiarrhythmic drug treatment. In neither cohort were there statistically significant differences for serum potassium values of >= 3.5<4.0 and a baseline of >= 4.0<5.0mEq/L. The proportion of patients initiated on vasopressors or inotropes was over four-fold higher in those treated with one of the antiarrhythmic drugs in both cohorts. Conclusions Serum potassium levels <3.5mEq/L were associated with an increased hazard for treatment with specific antiarrhythmic drugs in a large cohort of patients admitted to both a cardiac as well as medical and surgical intensive care units. Potassium thresholds may be individualized further based on risk of relevant outcomes.	[Phillips, Colin T.] Maine Med Ctr, Cardiovasc Div, Portland, ME 04102 USA; [Phillips, Colin T.] Beth Israel Deaconess Med Ctr, Cardiovasc Div, 330 Brookline Ave, Boston, MA 02215 USA; [Wang, Junmei] Beihang Univ, Sch Biol Sci & Med Engn, Beijing, Peoples R China; [Wang, Junmei] Ping An Hlth Technol, Beijing, Peoples R China; [Celi, Leo Anthony] MIT, Lab Computat Physiol, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Celi, Leo Anthony] Beth Israel Deaconess Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA 02215 USA; [Zhang, Zhengbo] Chinese Peoples Liberat Army Gen Hosp, Dept Biomed Engn, Beijing, Peoples R China; [Zhang, Zhengbo] Chinese Peoples Liberat Army Gen Hosp, Med Big Data Ctr, Beijing, Peoples R China; [Feng, Mengling] Natl Univ Singapore, Natl Univ Hlth Syst, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore	Maine Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Beihang University; Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital; National University of Singapore	Phillips, CT (corresponding author), Maine Med Ctr, Cardiovasc Div, Portland, ME 04102 USA.; Phillips, CT (corresponding author), Beth Israel Deaconess Med Ctr, Cardiovasc Div, 330 Brookline Ave, Boston, MA 02215 USA.	cphillips@mmc.org		Phillips, Colin/0000-0002-6543-0234	National Institutes of Health through the R01 grant [EB017205]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB017205] Funding Source: NIH RePORTER	National Institutes of Health through the R01 grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	LAC is funded by the National Institutes of Health through the R01 grant EB017205, https://grants.nih.gov/grants/funding/r01.htm. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BROWN MJ, 1983, NEW ENGL J MED, V309, P1414, DOI 10.1056/NEJM198312083092303; Chen S, 2015, JAMA INTERN MED, V175, P894, DOI 10.1001/jamainternmed.2015.0837; Choi JS, 2014, AM J CARDIOL, V113, P1285, DOI 10.1016/j.amjcard.2014.01.402; Cohn JN, 2000, ARCH INTERN MED, V160, P2429, DOI 10.1001/archinte.160.16.2429; Couture J, 2013, CJHP, V66; Goyal A, 2012, JAMA-J AM MED ASSOC, V307, P157, DOI 10.1001/jama.2011.1967; Hoekstra M, 2016, AM HEART J, V172, P45, DOI 10.1016/j.ahj.2015.10.020; HULTING J, 1981, ACTA MED SCAND, P109; KAFKA H, 1987, ARCH INTERN MED, V147, P465, DOI 10.1001/archinte.147.3.465; Link MS, 2015, CIRCULATION, V132, pS444, DOI 10.1161/CIR.0000000000000261; Macdonald JE, 2004, J AM COLL CARDIOL, V43, P155, DOI 10.1016/j.jacc.2003.06.021; Madias JE, 2000, CHEST, V118, P904, DOI 10.1378/chest.118.4.904; Manrai AK, 2018, JAMA-J AM MED ASSOC, V319, P1981, DOI 10.1001/jama.2018.2009; Mattsson N, 2018, AM J MED, V131, DOI 10.1016/j.amjmed.2017.09.026; NORDREHAUG JE, 1983, BRIT HEART J, V50, P525; Paltiel O, 2001, ARCH INTERN MED, V161, P1089, DOI 10.1001/archinte.161.8.1089; Patel RB, 2017, EUR HEART J-ACUTE CA, V6, P18, DOI 10.1177/2048872615624241; Pezhouman A, 2015, CIRCULATION, V132, P1528, DOI 10.1161/CIRCULATIONAHA.115.016217; Pollard TJ, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.178; Scirica BM, 2012, JAMA-J AM MED ASSOC, V307, P195, DOI 10.1001/jama.2011.2003; STRUTHERS AD, 1983, LANCET, V1, P1358; Vandenbroucke JP, 2007, EPIDEMIOLOGY, V18, P805, DOI 10.1097/EDE.0b013e3181577511; Viera AJ, 2015, AM FAMILY PHYS, V92	23	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2019	14	6							e0217432	10.1371/journal.pone.0217432	http://dx.doi.org/10.1371/journal.pone.0217432			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW3OC	31206521	gold, Green Published, Green Submitted			2023-01-03	WOS:000484890300014
J	Crow, D				Crow, Diana			Could iPSCs Enable "Off-the-Shelf'' Cell Therapy?	CELL			English	Editorial Material								An "off-the-shelf'' cell therapy derived from induced pluripotent stem cells (iPSCs) has entered clinical trials in the United States. Other companies are following suit, harnessing iPSCs' self-renewal ability to manufacture cell therapies that don't require customization for each patient. But some experts aren't sure such therapies are a good idea.											0	9	10	2	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	2019	177	7					1667	1669		10.1016/j.cell.2019.05.043	http://dx.doi.org/10.1016/j.cell.2019.05.043			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	IC8UG	31199910	Bronze			2023-01-03	WOS:000471256800002
J	Jablonska, PA; Diez-Valle, R; Perez-Larraya, JG; Moreno-Jimenez, M; Idoate, MA; Arbea, L; Tejada, S; de Eulate, MRG; Ramos, L; Arbizu, J; Dominguez, P; Aristu, JJ				Anna Jablonska, Paola; Diez-Valle, Ricardo; Gallego Perez-Larraya, Jaime; Moreno-Jimenez, Marta; Angel Idoate, Miguel; Arbea, Leire; Tejada, Sonia; Garcia de Eulate, Maria Reyes; Ramos, Luis; Arbizu, Javier; Dominguez, Pablo; Javier Aristu, Jose			Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience	PLOS ONE			English	Article							RANDOMIZED PHASE-III; ADJUVANT TEMOZOLOMIDE; RADIOTHERAPY; CONCOMITANT; OLDER	Background Hypofractionated radiation therapy is a feasible and safe treatment option in elderly and frail patients with glioblastoma. The aim of this study was to evaluate the effectiveness of hypofractionated radiation therapy with concurrent temozolomide in terms of feasibility and disease control in primary glioblastoma patients with poor prognostic factors other than advanced age, such as post-surgical neurological complications, high tumor burden, unresectable or multifocal lesions, and potential low treatment compliance due to social factors or rapidly progressive disease. Material and methods GTV included the surgical cavity plus disease visible in T1WI-MRI, FLAIR-MRI and in the MET-uptake. The CTV was defined as the GTV plus 1.5-2 cm margin; the PTV was the CTV+0.3 cm margin. Forty, fourty-five, and fifty grays in 15 fractions were prescribed to 95% of PTV, CTV, and GTV, respectively. Treatment was delivered using IMRT or the VMAT technique. Simultaneously, 75 mg/m(2)/day of temozolomide were administered. Results Between January 2010 and November 2017, we treated a total of 17 patients. The median age at diagnosis was 68-years; median KPS was 50-70%. MGMT-methylation status was negative in 5 patients, and 8 patients were IDH-wildtype. Eight of 18 patients were younger than 65-years. Median tumor volume was 26.95cc; median PTV volume was 322cc. Four lesions were unresectable; 6 patients underwent complete surgical resection. Median residual volume was 1.14cc. Progression-free survival was 60% at 6 months, 33% at 1-year and 13% at 2-years (median OS = 7 months). No acute grade 3-5 toxicities were documented. Symptomatic grade 3 radiation necrosis was observed in one patient. Conclusions Patients with poor clinical factors other than advanced age can be selected for hypofractionated radiotherapy. The OS and PFS rates obtained in our series are similar to those in patients treated with standard fractionation, assuring good treatment adherence, low rates of toxicity and probable improved cost-effectiveness.	[Anna Jablonska, Paola; Moreno-Jimenez, Marta; Arbea, Leire; Ramos, Luis; Javier Aristu, Jose] Clin Univ Navarra, Dept Radiat Oncol, Pamplona, Spain; [Diez-Valle, Ricardo; Tejada, Sonia] Clin Univ Navarra, Dept Neurosurg, Pamplona, Spain; [Gallego Perez-Larraya, Jaime] Clin Univ Navarra, Dept Neurol, Pamplona, Spain; [Angel Idoate, Miguel] Clin Univ Navarra, Dept Anat Pathol, Pamplona, Spain; [Garcia de Eulate, Maria Reyes; Dominguez, Pablo] Clin Univ Navarra, Dept Radiol, Pamplona, Spain; [Arbizu, Javier] Clin Univ Navarra, Dept Nucl Med, Pamplona, Spain	University of Navarra; University of Navarra; University of Navarra; University of Navarra; University of Navarra; University of Navarra	Jablonska, PA (corresponding author), Clin Univ Navarra, Dept Radiat Oncol, Pamplona, Spain.	pjablonska@unav.es	Dominguez, Pablo D./K-9067-2014; Arbizu, Javier/H-9255-2017; Idoate, Miguel-Ángel/D-8502-2019; Jablonska, Paola Anna/AAN-2063-2021; Aristu, Javier J/D-7594-2019; de Eulate, Maria Reyes Garcia/H-3031-2017	Dominguez, Pablo D./0000-0002-9692-3808; Arbizu, Javier/0000-0002-8370-5510; Idoate, Miguel-Ángel/0000-0002-1596-1192; Aristu, Javier J/0000-0002-0382-2363; de Eulate, Maria Reyes Garcia/0000-0002-2039-6634; Jablonska, Paola/0000-0001-5830-8321; Moreno Jimenez, Marta/0000-0001-5614-4589; Ramos Garcia, Luis Isaac/0000-0003-0491-5841; Gallego Perez-Larraya, Jaime/0000-0003-2969-0116				Arvold ND, 2015, INT J RADIAT ONCOL, V92, P384, DOI 10.1016/j.ijrobp.2015.01.017; BAUMAN GS, 1994, INT J RADIAT ONCOL, V29, P835, DOI 10.1016/0360-3016(94)90573-8; Chalmers AJ, 2009, INT J RADIAT ONCOL, V75, P1511, DOI 10.1016/j.ijrobp.2009.07.1703; CURRAN WJ, 1993, J NATL CANCER I, V85, P704, DOI 10.1093/jnci/85.9.704; Keime-Guibert F, 2007, NEW ENGL J MED, V356, P1527, DOI 10.1056/NEJMoa065901; Mallick S, 2018, J NEURO-ONCOL, V140, P75, DOI 10.1007/s11060-018-2932-3; Malmstrom A, 2012, LANCET ONCOL, V13, P916, DOI 10.1016/S1470-2045(12)70265-6; Navarria P, 2018, RADIOTHER ONCOL, V127, P108, DOI 10.1016/j.radonc.2017.12.006; Perry JR, 2017, NEW ENGL J MED, V376, P1027, DOI 10.1056/NEJMoa1611977; Roa W, 2015, J CLIN ONCOL, V33, P4145, DOI 10.1200/JCO.2015.62.6606; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Thakkar JP, 2014, EPIDEMIOLOGIC MOL PR, V23, P707; Van Nifterik KA, 2007, INT J RADIAT ONCOL, V69, P1246, DOI 10.1016/j.ijrobp.2007.07.2366; Wen PY, 2010, J CLIN ONCOL, V28, P1963, DOI 10.1200/JCO.2009.26.3541; Wick W, 2012, LANCET ONCOL, V13, P707, DOI 10.1016/S1470-2045(12)70164-X; Zhou XF, 2016, MOL CLIN ONCOL, V5, P289, DOI 10.3892/mco.2016.936	17	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2019	14	6							e0217881	10.1371/journal.pone.0217881	http://dx.doi.org/10.1371/journal.pone.0217881			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IB4TA	31170245	Green Published, gold, Green Submitted			2023-01-03	WOS:000470263700077
J	Ascierto, PA; Ferrucci, PF; Fisher, R; Del Vecchio, M; Atkinson, V; Schmidt, H; Schachter, J; Queirolo, P; Long, GV; Di Giacomo, AM; Svane, IM; Lotem, M; Bar-Sela, G; Couture, F; Mookerjee, B; Ghori, R; Ibrahim, N; Moreno, BH; Ribas, A				Ascierto, Paolo Antonio; Ferrucci, Pier Francesco; Fisher, Rosalie; Del Vecchio, Michele; Atkinson, Victoria; Schmidt, Henrik; Schachter, Jacob; Queirolo, Paola; Long, Georgina V.; Di Giacomo, Anna Maria; Svane, Inge Marie; Lotem, Michal; Bar-Sela, Gil; Couture, Felix; Mookerjee, Bijoyesh; Ghori, Razi; Ibrahim, Nageatte; Moreno, Blanca Homet; Ribas, Antoni			Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma	NATURE MEDICINE			English	Article							MEK INHIBITION; POOLED ANALYSIS; T-CELL; COMBINATION; SURVIVAL; VEMURAFENIB; PROGRESSION; IPILIMUMAB; NIVOLUMAB; OUTCOMES	Blocking programmed death 1 (PD-1) may enhance the durability of anti-tumor responses that are induced by the combined inhibition of BRAF and MEK1. Here we performed a randomized phase 2 trial (NCT02130466), in which patients with treatment-naive BRAF(V600E/K)-mutant, advanced melanoma received the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib together with the PD-1-blocking antibody pembrolizumab (triplet; n = 60) or placebo (doublet; n = 60). The primary end point of progression-free survival was numerically improved in the triplet group-16.0 months-compared with 10.3 months in the doublet group (hazard ratio, 0.66; P = 0.043); however, the trial did not reach the planned benefit for a statistically significant improvement. Median duration of response was 18.7 months (95% confidence interval, 10.1-22.1) and 12.5 months (95% confidence interval, 6.0-14.1); 59.8 and 27.8% of responses were estimated to have lasted for more than 18 months for triplet and doublet treatment, respectively. Grade 3-5 treatment-related adverse events occurred in 58.3 and 26.7% of patients treated with triplet and doublet therapies, respectively, which were most commonly fever, increased transaminase levels and rash. One patient who received triplet therapy died of pneumonitis. In summary, triplet therapy with dabrafenib, trametinib and pembrolizumab conferred numerically longer progressionfree survival and duration of response with a higher rate of grade 3/4 adverse events compared with the doublet therapy of dabrafenib, trametinib and placebo.	[Ascierto, Paolo Antonio] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy; [Ferrucci, Pier Francesco] European Inst Oncol IRCCS, Milan, Italy; [Fisher, Rosalie] Auckland City Hosp, Auckland, New Zealand; [Del Vecchio, Michele] Fdn IRCCS Ist Nazl Tumori, Milan, Italy; [Atkinson, Victoria] Greenslopes Private Hosp, Gallipoli Med Res Fdn, Brisbane, Qld, Australia; [Schmidt, Henrik] Aarhus Univ Hosp, Aarhus, Denmark; [Schachter, Jacob] Sheba Med Ctr Tel HaShomer, Ella Lemelbaum Inst Melanoma, Canc Ctr Oncol Inst, Ramat Gan, Israel; [Queirolo, Paola] IRCCS San Martino IST, Genoa, Italy; [Long, Georgina V.] Melanoma Inst Australia, Sydney, NSW, Australia; [Long, Georgina V.] Univ Sydney, Mater Hosp, Sydney, NSW, Australia; [Long, Georgina V.] Univ Sydney, Royal North Shore Hosp, Sydney, NSW, Australia; [Di Giacomo, Anna Maria] Univ Hosp Siena, Ctr Immunooncol, Siena, Italy; [Svane, Inge Marie] Univ Copenhagen, Herlev Hosp, Herlev, Denmark; [Lotem, Michal] Hadassah Hebrew Med Ctr, Sharett Inst Oncol, Jerusalem, Israel; [Bar-Sela, Gil] Rambam Hlth Care Campus, Haifa, Israel; [Couture, Felix] Laval Univ, Ctr Hosp Univ Quebec, Res Ctr, Quebec City, PQ, Canada; [Mookerjee, Bijoyesh] Novartis, E Hanover, NJ USA; [Ghori, Razi; Ibrahim, Nageatte; Moreno, Blanca Homet] Merck & Co Inc, Kenilworth, NJ USA; [Ribas, Antoni] Univ Calif Los Angeles, Los Angeles, CA USA; [Ribas, Antoni] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA	IRCCS Fondazione Pascale; IRCCS European Institute of Oncology (IEO); Auckland City Hospital; Fondazione IRCCS Istituto Nazionale Tumori Milan; Aarhus University; Chaim Sheba Medical Center; University of Genoa; IRCCS AOU San Martino IST; Melanoma Institute Australia; University of Sydney; Royal North Shore Hospital; University of Sydney; University of Siena; University Hospital of Siena; University of Copenhagen; Herlev & Gentofte Hospital; Hebrew University of Jerusalem; Hadassah University Medical Center; Rambam Health Care Campus; Laval University; Novartis; Merck & Company; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center	Ascierto, PA (corresponding author), Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy.; Ferrucci, PF (corresponding author), European Inst Oncol IRCCS, Milan, Italy.	paolo.ascierto@gmail.com; pier.ferrucci@ieo.it; aribas@mednet.ucla.edu	Ascierto, Paolo A/J-9106-2016; Schmidt, Henrik/A-1753-2008; Di Giacomo, Anna Maria/AAY-5625-2020; Ferrucci, Pier Francesco/AAQ-9002-2020; Long, Georgina V/C-1771-2013	Ascierto, Paolo A/0000-0002-8322-475X; Long, Georgina V/0000-0001-8894-3545; Bar-Sela, Gil/0000-0001-6579-1841; Ferrucci, Pier Francesco/0000-0001-6255-5851; Svane, Inge Marie/0000-0002-9451-6037; Melucci, Maria Teresa/0000-0002-1677-3345	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Parker Institute for Cancer Immunotherapy; NIH [R35 CA197633, P01 CA168585]	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Parker Institute for Cancer Immunotherapy; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank the patients and their families; S. Ebbinghaus for clinical study design, oversight and initiation of this collaborative study with Novartis; S. Diede for clinical study design and oversight; M. Bucci, J. Siegel and N. Cote for data acquisition; J. Anderson for statistical analysis and study oversight; and R. Yadav Baddula for data analysis. Medical writing and/or editorial assistance was provided by D. Mitra of the ApotheCom pembrolizumab team. This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Study drug was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and Novartis. A.R. is supported by the Parker Institute for Cancer Immunotherapy and NIH grants R35 CA197633 and P01 CA168585. The sponsor collaborated with academic advisors to design the study, acquire and analyze data, and interpret the results. All authors had access to all study data and reviewed and approved the final version of the manuscript for publication.	Ascierto PA, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1468955; Deken MA, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1238557; DUMMER R, 2018, J CLIN ONCOL S, V36; Ebert PJR, 2016, IMMUNITY, V44, P609, DOI 10.1016/j.immuni.2016.01.024; Frederick DT, 2013, CLIN CANCER RES, V19, P1225, DOI 10.1158/1078-0432.CCR-12-1630; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; Hu-Lieskovan S, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4691; Johnson DB, 2014, J CLIN ONCOL, V32, P3697, DOI 10.1200/JCO.2014.57.3535; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Long G. V., 2018, P 2018 C SOC MEL RES; Long GV, 2016, LANCET ONCOL, V17, P1743, DOI 10.1016/S1470-2045(16)30578-2; Long GV, 2016, J CLIN ONCOL, V34, P871, DOI 10.1200/JCO.2015.62.9345; Long GV, 2015, LANCET, V386, P444, DOI 10.1016/S0140-6736(15)60898-4; Luke JJ, 2017, NAT REV CLIN ONCOL, V14, P463, DOI 10.1038/nrclinonc.2017.43; Moreno BH, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1052212; National Comprehensive Cancer Network (NCCN), 2018, NCCN CLIN PRACT GUID; Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI [10.1056/NEJMc1801663, 10.1056/NEJMra1703481]; Ribas A., NAT MED; Ribas A, 2016, JAMA-J AM MED ASSOC, V315, P1600, DOI 10.1001/jama.2016.4059; Ribas A, 2013, NEW ENGL J MED, V368, P1365, DOI 10.1056/NEJMc1302338; Robert C, 2015, EUR J CANCER, V51, pS663, DOI 10.1016/S0959-8049(16)31820-2; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Rozeman E. A., 2018, ANN ONCOL, V29; Schadendorf D, 2017, EUR J CANCER, V82, P45, DOI 10.1016/j.ejca.2017.05.033; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Vella LJ, 2014, CANCER IMMUNOL RES, V2, P351, DOI 10.1158/2326-6066.CIR-13-0181; Weide B, 2016, CLIN CANCER RES, V22, P5487, DOI 10.1158/1078-0432.CCR-16-0127; Wilmott JS, 2012, CLIN CANCER RES, V18, P1386, DOI 10.1158/1078-0432.CCR-11-2479; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684	31	163	162	5	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2019	25	6					941	+		10.1038/s41591-019-0448-9	http://dx.doi.org/10.1038/s41591-019-0448-9			15	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	IC3FK	31171878				2023-01-03	WOS:000470844400025
J	Cui, Y; Cao, R; Li, G; Gong, TQ; Ou, YY; Huang, J				Cui, Yu; Cao, Rong; Li, Gen; Gong, Tianqing; Ou, Yingyu; Huang, Jing			The effect of lung recruitment maneuvers on post-operative pulmonary complications for patients undergoing general anesthesia: A meta-analysis	PLOS ONE			English	Article							END-EXPIRATORY PRESSURE; RESPIRATORY-DISTRESS-SYNDROME; LOW-TIDAL-VOLUME; PROTECTIVE-VENTILATION; MECHANICAL VENTILATION; OBESE-PATIENTS; ATELECTASIS; OXYGENATION; PARALYSIS; SURGERY	Background Respiratory function would be impaired during general anesthesia period. Researchers devoted their energies to finding effective strategies for protecting respiratory function. Low tidal volume, positive end-expiratory pressure (PEEP), and lung recruitment maneuvers (LRMs) were recommended for patients under mechanical ventilation. However, based on the current evidence, there was no consensus on whether LRMs should be routinely used for anesthetized patients with healthy lungs, and the benefits of them remained to be determined. Materials and methods To evaluate the benefits of LRMs on patients undergoing surgery with general anesthesia, we searched relevant studies in PubMed, EMBASE, Ovid Medline and the Cochrane Library up to June 30, 2018. The primary outcome was postoperative pulmonary complications (PPCs). Results Twelve trials involving 2756 anesthetized patients were included. The results of our study showed a significant benefit of LRMs for reducing the incidence of PPCs (RR = 0.67; 95% CI, 0.49 to 0.90; P< 0.05; Chi(2) = 32.94, p for heterogeneity = 0.0005, I-2 = 67%). After subgroup analyses, we found LRMs combining with lung protective ventilation strategy and sustained recruitment maneuvers were associated with reducing the occurrence of PPCs. The results also revealed that the use of LRMs improved PaO2/ FiO(2) in non-obese patients, but with extremely high heterogeneity (I-2 = 95%). Conclusion According to the findings from contemporary meta-analysis, LRMs combining with lung protective ventilation strategy may have an association with decreasing in the incidence of PPCs and improvement of oxygenation on non-obese patients. However, the conclusions must be interpreted cautiously as the outcome may be influenced dramatically due to varied LRMs and ventilation patterns.	[Cui, Yu; Cao, Rong; Gong, Tianqing; Ou, Yingyu; Huang, Jing] Chengdu Womens & Childrens Cent Hosp, Dept Anesthesiol, Chengdu, Sichuan, Peoples R China; [Li, Gen] Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Nashville, TN USA	Vanderbilt University	Cui, Y (corresponding author), Chengdu Womens & Childrens Cent Hosp, Dept Anesthesiol, Chengdu, Sichuan, Peoples R China.	cuiyu19831001@163.com		Cui, Yu/0000-0002-1481-9389; LI, GEN/0000-0002-8417-6569				Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Aretha D, 2017, INT J OBSTET ANESTH, V30, P30, DOI 10.1016/j.ijoa.2016.12.004; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Choi ES, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183311; de Jong MAC, 2016, ANN SURG, V264, P362, DOI 10.1097/SLA.0000000000001499; Ferrando C, 2018, LANCET RESP MED, V6, P193, DOI 10.1016/S2213-2600(18)30024-9; Fichtner F, 2018, DTSCH ARZTEBL INT, V115, P840, DOI 10.3238/arztebl.2018.0840; Futier E, 2013, NEW ENGL J MED, V369, P428, DOI 10.1056/NEJMoa1301082; Ge Yeying, 2013, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V38, P81, DOI 10.3969/j.issn.1672-7347.2013.01.015; Goligher EC, 2017, ANN AM THORAC SOC, V14, pS304, DOI 10.1513/AnnalsATS.201704-340OT; Gu WJ, 2015, CAN MED ASSOC J, V187, pE101, DOI 10.1503/cmaj.141005; Hartland BL, 2015, RESP CARE, V60, P609, DOI 10.4187/respcare.03488; Hartog A, 2000, CRIT CARE MED, V28, P1450, DOI 10.1097/00003246-200005000-00032; Hedenstierna G, 2015, ANESTHESIOLOGY, V123, P501, DOI 10.1097/ALN.0000000000000755; Hemmes SNT, 2014, LANCET, V384, P495, DOI 10.1016/S0140-6736(14)60416-5; Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13; Jiang GQ, 2008, HEPATOB PANCREAT DIS, V7, P367; KRAYER S, 1989, ANESTHESIOLOGY, V70, P891, DOI 10.1097/00000542-198906000-00002; Kuchnicka K, 2013, ANAESTH INTENSIVE TH, V45, P164, DOI 10.5603/AIT.2013.0034; Martin Jennifer Bourgeois, 2015, JBI Database System Rev Implement Rep, V13, P211, DOI 10.11124/jbisrir-2015-1410; Mills GH, 2018, ANAESTHESIA, V73, P25, DOI 10.1111/anae.14137; Miskovic A, 2017, BRIT J ANAESTH, V118, P317, DOI 10.1093/bja/aex002; Nestler C, 2017, BRIT J ANAESTH, V119, P1194, DOI 10.1093/bja/aex192; Neto AS, 2016, LANCET RESP MED, V4, P272, DOI 10.1016/S2213-2600(16)00057-6; Neto AS, 2015, CRIT CARE MED, V43, P2155, DOI 10.1097/CCM.0000000000001189; Parameswaran Krishnan, 2006, Can Respir J, V13, P203; Pereira SM, 2018, ANESTHESIOLOGY, V129, P1070, DOI 10.1097/ALN.0000000000002435; Pi X, 2015, INT J CLIN EXP PATHO, V8, P14305; Pirrone M, 2016, CRIT CARE MED, V44, P300, DOI 10.1097/CCM.0000000000001387; Reinius H, 2009, ANESTHESIOLOGY, V111, P979, DOI 10.1097/ALN.0b013e3181b87edb; Schunemann HJ, 2008, BMJ-BRIT MED J, V336, P1106, DOI 10.1136/bmj.39500.677199.AE; [沈子珒 Shen Zijin], 2015, [上海交通大学学报. 医学版, Journal of Shanghai Jiaotong University .Medical Science], V35, P1632; Sulemanji DS, 2014, AM J RESP CRIT CARE, P189; TOKICS L, 1987, ANESTHESIOLOGY, V66, P157, DOI 10.1097/00000542-198702000-00009; Tusman G, 2012, CURR OPIN ANESTHESIO, V25, P1, DOI 10.1097/ACO.0b013e32834dd1eb; VANEEDEN AF, 1980, S AFR MED J, V58, P349; Villar J, 2010, CRIT CARE, V14, DOI 10.1186/cc8842; Weingarten TN, 2010, BRIT J ANAESTH, V104, P16, DOI 10.1093/bja/aep319; Whalen FX, 2006, ANESTH ANALG, V102, P298, DOI 10.1213/01.ane.0000183655.57275.7a; Xiong Wei, 2016, Nan Fang Yi Ke Da Xue Xue Bao, V36, P215	40	23	25	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2019	14	5							e0217405	10.1371/journal.pone.0217405	http://dx.doi.org/10.1371/journal.pone.0217405			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IA1LO	31141541	Green Published, gold, Green Submitted			2023-01-03	WOS:000469323000055
J	Li, F; Dong, YZ; Zhang, D; Zhang, XM; Lin, ZJ; Zhang, B				Li, Fan; Dong, Yi-Zhu; Zhang, Dan; Zhang, Xiao-Meng; Lin, Zhi-Jian; Zhang, Bing			Molecular mechanisms involved in drug-induced liver injury caused by urate-lowering Chinese herbs: A network pharmacology study and biology experiments	PLOS ONE			English	Article							URIC-ACID; TARGET IDENTIFICATION; METABOLIC SYNDROME; UCSF CHIMERA; WEB SERVER; HYPERURICEMIA; VISUALIZATION; UPDATE; TOOL; PROLIFERATION	As an important part of the comprehensive treatment methods, the urate-lowering Chinese herbs could provide favorable clinical effects on hyperuricemia in its ability to invigorate spleen and remove dampness. Owing to the long-term duration, it brought up the potential adverse reactions (ADRs) and concerns about the drug-induced liver injury from these herbs. To address this problem, the bioinformatics approaches which combined the network pharmacology, computer simulation and molecular biology experiments were undertaken to elucidate the underlying drug-induced liver injury molecular mechanisms of urate-lowering Chinese herbs. Several electronic databases were searched to identify the potential liver injury compounds in published research. Then, the putative target profile of liver injury was predicted, and the interaction network was constructed based on the links between the compounds, corresponding targets and core pathways. Accordingly, the molecular docking simulation was performed to recognize the representative compounds with hepatotoxicity. Finally, the cell experiments were conducted to investigate the biochemical indicators and expression of the crucial protein that were closely associated with liver injury. In conclusion, the current research revealed that the compounds with potential liver injury including diosgenin, baicalin, saikosaponin D, tetrandrine, rutaecarpine and evodiamine from urate-lowering Chinese herbs, could lead to decline the survival rate of L-02 cell, increase the activities of aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH) and alkaline phosphatase (ALP) in cell-culture medium, enhance the expression of p-p38/p38, while the p38 inhibitor could achieve the trend of regulating and controlling liver injury. These research findings bring further support to the growing evidence that the mechanism of the liver injury induced by the compounds from urate-lowering Chinese herbs may be associated with the activation of p38 alpha.	[Li, Fan; Dong, Yi-Zhu; Zhang, Dan; Zhang, Xiao-Meng; Lin, Zhi-Jian; Zhang, Bing] Beijing Univ Chinese Med, Sch Chinese Materia Med, Dept Clin Chinese Pharm, Beijing, Peoples R China	Beijing University of Chinese Medicine	Zhang, B (corresponding author), Beijing Univ Chinese Med, Sch Chinese Materia Med, Dept Clin Chinese Pharm, Beijing, Peoples R China.	zhangb@bucm.edu.cn						Barbarino JM, 2018, WIRES SYST BIOL MED, V10, DOI 10.1002/wsbm.1417; Bateman A, 2017, NUCLEIC ACIDS RES, V45, pD158, DOI 10.1093/nar/gkw1099; Becker KG, 2004, NAT GENET, V36, P431, DOI 10.1038/ng0504-431; Becker MA, 2005, NEW ENGL J MED, V353, P2450, DOI 10.1056/NEJMoa050373; Billiet Laura, 2014, ISRN Rheumatol, V2014, P852954, DOI 10.1155/2014/852954; Boezio B, 2017, MOL INFORM, V36, DOI 10.1002/minf.201700048; Burley SK, 2017, METHODS MOL BIOL, V1606, P627, DOI 10.1007/978-1-4939-7000-1_26; Cai QY, 2014, MOLECULES, V19, P21168, DOI 10.3390/molecules191221168; Calogiuri Gianfranco, 2013, Inflammation & Allergy Drug Targets, V12, P19; Cao J, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14010067; Ceol A, 2010, NUCLEIC ACIDS RES, V38, pD532, DOI 10.1093/nar/gkp983; Chatterjee B, 2016, SKELET MUSCLE, V6, DOI 10.1186/s13395-016-0100-z; Chen MF, 2013, J MED FOOD, V16, P793, DOI [10.1091/jmf.2013.2762, 10.1089/jmf.2013.2762]; Chen X, 2002, NUCLEIC ACIDS RES, V30, P412, DOI 10.1093/nar/30.1.412; Corre I, 2017, ONCOTARGET, V8, P55684, DOI 10.18632/oncotarget.18264; Dai CS, 2016, MOLECULES, V21, DOI 10.3390/molecules21081061; Ford ES, 2007, CIRCULATION, V115, P2526, DOI 10.1161/CIRCULATIONAHA.106.657627; Gilbert D, 2005, BRIEF BIOINFORM, V6, P194, DOI 10.1093/bib/6.2.194; Goddard TD, 2005, STRUCTURE, V13, P473, DOI 10.1016/j.str.2005.01.006; Godyn J, 2017, ELECTROPHORESIS, V38, P1268, DOI 10.1002/elps.201600473; Goel R, 2012, MOL BIOSYST, V8, P453, DOI 10.1039/c1mb05340j; Gonzalez-Teran B, 2016, EMBO J, V35, P536, DOI 10.15252/embj.201591857; Hamosh A, 2005, NUCLEIC ACIDS RES, V33, pD514; Haw R, 2011, PROTEOMICS, V11, P3598, DOI 10.1002/pmic.201100066; Hong M, 2017, MOLECULES, V22, DOI 10.3390/molecules22040632; Hu YY, 2015, MOLECULES, V20, P6443, DOI 10.3390/molecules20046443; Huang J, 2017, J NANOMATER, V2017, P1, DOI DOI 10.1155/2017/2084621; Jiang Y, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1834-9; Jiang Y, 2017, ONCOL LETT, V13, P4035, DOI 10.3892/ol.2017.6015; Jiao XL, 2012, BIOINFORMATICS, V28, P1805, DOI 10.1093/bioinformatics/bts251; Kaufmann P, 2005, HEPATOLOGY, V41, P925, DOI 10.1002/hep.20634; Kerrien S, 2012, NUCLEIC ACIDS RES, V40, pD841, DOI 10.1093/nar/gkr1088; Kojima S, 2017, J CARDIOL, V69, P169, DOI 10.1016/j.jjcc.2016.02.015; Korashy HM, 2011, CHEM RES TOXICOL, V24, P1540, DOI 10.1021/tx200141p; Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u; Lee Y, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.00080; Li CG, 2013, CURR OPIN RHEUMATOL, V25, P210, DOI 10.1097/BOR.0b013e32835d951e; Li L, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-122; [李丽玉 Li Liyu], 2015, [中药新药与临床药理, Traditional Chinese Drug Research and Clinical Plarmacology], V26, P284; Li S, 2016, SCI REP-UK, V6, DOI 10.1038/srep33082; Li XX, 2013, CLIN RHEUMATOL, V32, P943, DOI 10.1007/s10067-013-2274-7; Liu XF, 2010, NUCLEIC ACIDS RES, V38, pW609, DOI 10.1093/nar/gkq300; Luo X, 2018, BRAIN BEHAV IMMUN, V72, P34, DOI 10.1016/j.bbi.2017.11.007; Maharani N, 2016, INT HEART J, V57, P395, DOI 10.1536/ihj.16-192; Malik UZ, 2011, FREE RADICAL BIO MED, V51, P179, DOI 10.1016/j.freeradbiomed.2011.04.004; Martin A, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-91; McGill MR, 2016, EXCLI J, V15, P817, DOI 10.17179/excli2016-800; Meng AH, 2016, INT J CHRONIC OBSTR, V11, P909, DOI 10.2147/COPD.S99810; Merriman TR, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0609-2; Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Multi-Disciplinary Expert Task Force on Hyperuricemia and Its Related Diseases, 2017, Zhonghua Nei Ke Za Zhi, V56, P235, DOI 10.3760/cma.j.issn.0578-1426.2017.03.021; Okamoto K, 2003, J BIOL CHEM, V278, P1848, DOI 10.1074/jbc.M208307200; Oughtred Rose, 2016, Cold Spring Harb Protoc, V2016, DOI 10.1101/pdb.top080754; Pathak Ashish, 2016, Central Nervous System Agents in Medicinal Chemistry, V16, P143, DOI 10.2174/1871524916666151210143347; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Qi XM, 2013, ACTA PHARMACOL SIN, V34, P1229, DOI 10.1038/aps.2013.62; Qiu L, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-664; Rigsby RE, 2016, BIOCHEM MOL BIOL EDU, V44, P433, DOI 10.1002/bmb.20966; Robinson PC, 2015, EXPERT OPIN PHARMACO, V16, P533, DOI 10.1517/14656566.2015.997213; Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13; Sato H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030124; Seeliger D, 2010, J COMPUT AID MOL DES, V24, P417, DOI 10.1007/s10822-010-9352-6; Senior JR, 2012, CLIN PHARMACOL THER, V92, P332, DOI 10.1038/clpt.2012.108; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sreekanth GP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149486; Stamp LK, 2016, INTERN MED J, V46, P1075, DOI 10.1111/imj.13173; Su J, 2010, J TRAUMA, V68, P1317, DOI 10.1097/TA.0b013e3181bb9cd3; Sun HL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00661-3; Tang Y, 2015, BIOSYSTEMS, V127, P67, DOI 10.1016/j.biosystems.2014.11.005; Thornton C. E., 2010, BMC BIOINFORMATICS, V11, P91, DOI DOI 10.1186/1471-2105-11-91; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; van Tonder Alet, 2015, BMC Res Notes, V8, P47, DOI 10.1186/s13104-015-1000-8; Vilar S, 2017, CURR MED CHEM, V24, P4340, DOI 10.2174/0929867324666170724101448; Wang JB, 2015, FRONT MED-PRC, V9, P457, DOI 10.1007/s11684-015-0417-8; Wang L, 2018, MOL MED REP, V17, P789, DOI 10.3892/mmr.2017.7958; Wang X, 2017, NUCLEIC ACIDS RES, V45, pW356, DOI 10.1093/nar/gkx374; Wang Y, 2017, NUTR METAB, V14, DOI 10.1186/s12986-017-0190-6; Wen B, 2014, DRUG METAB DISPOS, V42, P1044, DOI 10.1124/dmd.114.057414; Xenarios I, 2002, NUCLEIC ACIDS RES, V30, P303, DOI 10.1093/nar/30.1.303; Xiao YT, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.523; Yang ZH, 2016, INT J MED SCI, V13, P783, DOI 10.7150/ijms.16663; Zhang ZX, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0678-6; Zhou Q, 2014, PLANTA MED, V80, P1259, DOI 10.1055/s-0034-1383048; Zhu JJ, 2014, ANIMAL, V8, P1469, DOI 10.1017/S1751731114001323; Zuo T, 2016, BMC CARDIOVASC DISOR, V16, DOI 10.1186/s12872-016-0379-z	87	12	17	3	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2019	14	5							e0216948	10.1371/journal.pone.0216948	http://dx.doi.org/10.1371/journal.pone.0216948			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IA1LO	31141540	Green Submitted, Green Published, gold			2023-01-03	WOS:000469323000031
J	Jimenez-Reyes, P; Samozino, P; Morin, JB				Jimenez-Reyes, Pedro; Samozino, Pierre; Morin, Jean-Benoit			Optimized training for jumping performance using the force-velocity imbalance: Individual adaptation kinetics	PLOS ONE			English	Article							MAXIMAL POWER; BALLISTIC-POWER; STRENGTH; LOAD; RESISTANCE; EXERCISE; COUNTERMOVEMENT; PROGRAM; PROFILE; OUTPUT	Aims We analysed the changes in force-velocity-power variables and jump performance in response to an individualized training program based on the force-velocity imbalance (FVimb). In particular, we investigated (i) the individual adaptation kinetics to reach the optimal profile and (ii) de-training kinetics over the three weeks following the end of the training program. Methods Sixty subjects were assigned to four sub-groups according to their initial FVimb: high or low force-deficit (FD) and high or low velocity-deficit (VD). The duration of training intervention was set so that each individual reached their "Optimal force-velocity (F-v) profile". Mechanical and performance variables were measured every 3 weeks during the program, and every week after the end of the individualized program. Results All subjects in the FD sub-groups showed extremely large increases in maximal theoretical force output (+30 +/- 16.6% Mean +/- SD; ES = 2.23 +/- 0.28), FVimb reduction (-74.3 +/- 54.7%; ES = 2.17 +/- 0.27) and large increases in jump height (+12.4 +/- 7.6%; ES = 1.45 +/- 0.23). For the VD sub-groups, we observed moderate to extremely large increases in maximal theoretical velocity (+15.8 +/- 5.1%; ES = 2.72 +/- 0.29), FVimb reduction (-19.2 +/- 6.9%; ES = 2.36 +/- 0.35) and increases in jump height (+10.1 +/- 2.7%; ES = 0.93 +/- 0.09). The number of weeks needed to reach the optimal F-v profile (12.6 +/- 4.6) was correlated to the magnitude of initial FVimb (r = 0.82, p<0.01) for all participants regardless of their initial subgroup. No significant change in mechanical variables or jump performance was observed over the 3-week de-training period. Conclusions Collectively, these results provide useful insights into a more specific, individualized (i.e. based on the type and magnitude of FVimb) and accurate training prescription for jumping performance. Considering both training content and training duration together with FVimb may enable more individualized, specific and effective training monitoring and periodization.	[Jimenez-Reyes, Pedro] Rey Juan Carlos Univ, Ctr Sport Studies, Madrid, Spain; [Samozino, Pierre] Univ Savoie Mt Blanc, Lab Interuniv Biol Motricite, Chambery, France; [Morin, Jean-Benoit] Univ Cote Azur, LAMHESS, Nice, France; [Morin, Jean-Benoit] Auckland Univ Technol, SPRINZ, Auckland, New Zealand	Universidad Rey Juan Carlos; UDICE-French Research Universities; Universite Cote d'Azur; Auckland University of Technology	Jimenez-Reyes, P (corresponding author), Rey Juan Carlos Univ, Ctr Sport Studies, Madrid, Spain.	peterjr49@hotmail.com	Jimenez-Reyes, Pedro/P-1075-2016	Jimenez-Reyes, Pedro/0000-0002-8156-243X; Morin, Jean-Benoit/0000-0003-3808-6762	Spanish Ministry of Education, Culture and Sport [CAS15/00171]; National Program for "Mobility stays abroad "Jose Castillejo" for young doctors"	Spanish Ministry of Education, Culture and Sport; National Program for "Mobility stays abroad "Jose Castillejo" for young doctors"	This study was funded by the Spanish Ministry of Education, Culture and Sport (National Plan 2015; grant reference CAS15/00171) with the National Program for "Mobility stays abroad "Jose Castillejo" for young doctors". The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study was funded by the Spanish Ministry of Education, Culture and Sport (National Plan 2015; grant reference CAS15/00171) with the National Program for "Mobility stays abroad "Jose Castillejo" for young doctors". The experimenters would like to thank Matt Brughelli for his contribution in the publication of the first part of this study and Adrian Castano- Zambudio, Victor Cuadrado-Penafiel, Antonio Del Aguila, Salustiano Campuzano, and Pete Griffith for their technical support, and the subjects for having performed this demanding experiment with enthusiasm. We also thank the numerous colleagues and students who have discussed these issues with us in recent years. These discussions were a very important source of reflection in our writing process. Some of these results were presented at the 2018 European Congress of Sport Science.	Argus CK, 2011, J STRENGTH COND RES, V25, P2219, DOI 10.1519/JSC.0b013e3181f6b0f4; Barnes C, 2014, INT J SPORTS MED, V35, P1095, DOI 10.1055/s-0034-1375695; Batterham AM, 2006, INT J SPORT PHYSIOL, V1, P50, DOI 10.1123/ijspp.1.1.50; Chelly MS, 2009, J STRENGTH COND RES, V23, P2241, DOI 10.1519/JSC.0b013e3181b86c40; Cormie P, 2007, MED SCI SPORT EXER, V39, P996, DOI 10.1097/mss.0b013e3180408e0c; Cormie P, 2007, MED SCI SPORT EXER, V39, P340, DOI 10.1249/01.mss.0000246993.71599.bf; Cormie P, 2010, MED SCI SPORT EXER, V42, P1582, DOI 10.1249/MSS.0b013e3181d2013a; Cormie P, 2010, MED SCI SPORT EXER, V42, P1566, DOI 10.1249/MSS.0b013e3181cf818d; Cronin J, 2005, SPORTS MED, V35, P213, DOI 10.2165/00007256-200535030-00003; de Lacey J, 2014, J STRENGTH COND RES, V28, P3567, DOI 10.1519/JSC.0000000000000572; Faude O, 2012, J SPORT SCI, V30, P625, DOI 10.1080/02640414.2012.665940; Garcia-Ramos A, 2021, SPORT BIOMECH, V20, P274, DOI 10.1080/14763141.2018.1545044; Giroux C, 2016, J APPL BIOMECH, V32, P59, DOI 10.1123/jab.2015-0070; Harris GR, 2000, J STRENGTH COND RES, V14, P14; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; Jimenez-Reyes P, 2018, PEERJ, V6, DOI 10.7717/peerj.5937; Jimenez-Reyes P, 2017, INT J SPORT PHYSIOL, V12, P36, DOI [10.1123/ijspp.2015-0484, 10.1123/IJSPP.2015-0484]; Jimenez-Reyes P, 2017, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00677; Jimenez-Reyes P, 2014, EUR J APPL PHYSIOL, V114, P2281, DOI 10.1007/s00421-014-2947-1; KANEHISA H, 1983, EUR J APPL PHYSIOL O, V52, P104, DOI 10.1007/BF00429034; Kaneko M, 1983, SCAND J SPORTS SCI, V5, P50; Kenney L., 2015, PHYSL SPORT EXERCISE; Kotzamanidis C, 2005, J STRENGTH COND RES, V19, P369; Markovic G, 2011, INT J SPORTS MED, V32, P365, DOI 10.1055/s-0031-1271678; Marrier B, 2017, INT J SPORT PHYSIOL, V12, P1163, DOI 10.1123/ijspp.2016-0607; McBride JM, 2002, J STRENGTH COND RES, V16, P75, DOI 10.1519/00124278-200202000-00011; Morin JB, 2016, INT J SPORT PHYSIOL, V11, P267, DOI 10.1123/ijspp.2015-0638; Newton RU, 1996, J APPL BIOMECH, V12, P31, DOI 10.1123/jab.12.1.31; Paddon-Jones D, 2001, EUR J APPL PHYSIOL, V85, P466, DOI 10.1007/s004210100467; Veliz RR, 2014, J STRENGTH COND RES, V28, P1007, DOI 10.1519/JSC.0000000000000240; Ronnestad BR, 2017, J SPORT SCI, V35, P1435, DOI 10.1080/02640414.2016.1215499; Ronnestad BR, 2008, J STRENGTH COND RES, V22, P773, DOI 10.1519/JSC.0b013e31816a5e86; de Villarreal ESS, 2011, J STRENGTH COND RES, V25, P3274, DOI 10.1519/JSC.0b013e3182163085; SALE DG, 1988, MED SCI SPORT EXER, V20, pS135, DOI 10.1249/00005768-198810001-00009; Samozino P, 2014, INT J SPORTS MED, V35, P505, DOI 10.1055/s-0033-1354382; Samozino P, 2008, J BIOMECH, V41, P2940, DOI 10.1016/j.jbiomech.2008.07.028; Samozino P, 2012, MED SCI SPORT EXER, V44, P313, DOI 10.1249/MSS.0b013e31822d757a; Sheppard JM, 2011, J SCI MED SPORT, V14, P85, DOI 10.1016/j.jsams.2010.07.006; Smilios I, 2013, J STRENGTH COND RES, V27, P1223, DOI 10.1519/JSC.0b013e3182654a1c; Toii H, 2004, J STRENGTH COND RES, V18, P792; Toji H, 1997, CAN J APPL PHYSIOL, V22, P328, DOI 10.1139/h97-021; VANDEWALLE H, 1987, SPORTS MED, V4, P268, DOI 10.2165/00007256-198704040-00004; WILSON GJ, 1993, MED SCI SPORT EXER, V25, P1279; Yamauchi J, 2007, J STRENGTH COND RES, V21, P703, DOI 10.1519/00124278-200708000-00009; Zaras N, 2013, J SPORT SCI MED, V12, P130; 1999, EUR J APPL PHYSL OCC, V80, P485, DOI DOI 10.1007/S004210050622; 2018, INT J SPORT PHYSIOL, V13, P910, DOI DOI 10.1123/IJSPP.2017-0499; 2012, EUR J APPL PHYSL, V112, P2341, DOI DOI 10.1007/S00421-011-2204-9; 2011, SCAND J MED SCI SPOR, V21, P389, DOI DOI 10.1111/J.1600-0838.2009.01074.X	49	42	42	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2019	14	5							e0216681	10.1371/journal.pone.0216681	http://dx.doi.org/10.1371/journal.pone.0216681			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY2KH	31091259	gold, Green Published, Green Submitted			2023-01-03	WOS:000467949100035
J	Rose, SMSF; Contrepois, K; Moneghetti, KJ; Zhou, WY; Mishra, T; Mataraso, S; Dagan-Rosenfeld, O; Ganz, AB; Dunn, J; Hornburg, D; Rego, S; Perelman, D; Ahadi, S; Sailani, MR; Zhou, YJ; Leopold, SR; Chen, JM; Ashland, M; Christle, JW; Avina, M; Limcaoco, P; Ruiz, C; Tan, M; Butte, AJ; Weinstock, GM; Slavich, GM; Sodergren, E; McLaughlin, TL; Haddad, F; Snyder, MP				Rose, Sophia Miryam Schussler-Fiorenza; Contrepois, Kevin; Moneghetti, Kegan J.; Zhou, Wenyu; Mishra, Tejaswini; Mataraso, Samson; Dagan-Rosenfeld, Orit; Ganz, Ariel B.; Dunn, Jessilyn; Hornburg, Daniel; Rego, Shannon; Perelman, Dalia; Ahadi, Sara; Sailani, M. Reza; Zhou, Yanjiao; Leopold, Shana R.; Chen, Jieming; Ashland, Melanie; Christle, Jeffrey W.; Avina, Monika; Limcaoco, Patricia; Ruiz, Camilo; Tan, Marilyn; Butte, Atul J.; Weinstock, George M.; Slavich, George M.; Sodergren, Erica; McLaughlin, Tracey L.; Haddad, Francois; Snyder, Michael P.			A longitudinal big data approach for precision health	NATURE MEDICINE			English	Article							CORONARY-HEART-DISEASE; BETA-CELL FUNCTION; INSULIN-RESISTANCE; AMERICAN-COLLEGE; UNDETERMINED SIGNIFICANCE; CARDIOVASCULAR-DISEASE; MONOCLONAL GAMMOPATHY; GLUCOSE-TOLERANCE; RISK PREDICTION; ARTERY CALCIUM	Precision health relies on the ability to assess disease risk at an individual level, detect early preclinical conditions and initiate preventive strategies. Recent technological advances in omics and wearable monitoring enable deep molecular and physiological profiling and may provide important tools for precision health. We explored the ability of deep longitudinal profiling to make health-related discoveries, identify clinically relevant molecular pathways and affect behavior in a prospective longitudinal cohort (n = 109) enriched for risk of type 2 diabetes mellitus. The cohort underwent integrative personalized omics profiling from samples collected quarterly for up to 8 years (median, 2.8 years) using clinical measures and emerging technologies including genome, immunome, transcriptome, proteome, metabolome, microbiome and wearable monitoring. We discovered more than 67 clinically actionable health discoveries and identified multiple molecular pathways associated with metabolic, cardiovascular and oncologic pathophysiology. We developed prediction models for insulin resistance by using omics measurements, illustrating their potential to replace burdensome tests. Finally, study participation led the majority of participants to implement diet and exercise changes. Altogether, we conclude that deep longitudinal profiling can lead to actionable health discoveries and provide relevant information for precision health.	[Rose, Sophia Miryam Schussler-Fiorenza; Contrepois, Kevin; Zhou, Wenyu; Mishra, Tejaswini; Dagan-Rosenfeld, Orit; Ganz, Ariel B.; Dunn, Jessilyn; Hornburg, Daniel; Rego, Shannon; Perelman, Dalia; Ahadi, Sara; Sailani, M. Reza; Ashland, Melanie; Avina, Monika; Limcaoco, Patricia; Snyder, Michael P.] Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; [Rose, Sophia Miryam Schussler-Fiorenza] Vet Affairs Palo Alto Hlth Care Syst, Spinal Cord Injury Serv, Palo Alto, CA USA; [Rose, Sophia Miryam Schussler-Fiorenza] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA USA; [Moneghetti, Kegan J.; Christle, Jeffrey W.; Haddad, Francois; Snyder, Michael P.] Stanford Univ, Stanford Cardiovasc Inst, Stanford, CA 94305 USA; [Moneghetti, Kegan J.; Christle, Jeffrey W.; Haddad, Francois] Stanford Univ, Sch Med, Dept Med, Div Cardiovasc Med, Stanford, CA 94305 USA; [Moneghetti, Kegan J.] Univ Melbourne, St Vincents Hosp, Dept Med, Melbourne, Vic, Australia; [Mataraso, Samson] Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Berkeley, CA 94720 USA; [Mataraso, Samson] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA; [Dunn, Jessilyn] Stanford Univ, Mobilize Ctr, Stanford, CA 94305 USA; [Zhou, Yanjiao; Leopold, Shana R.; Weinstock, George M.; Sodergren, Erica] Jackson Lab Genom Med, Farmington, CT USA; [Zhou, Yanjiao] Univ Connecticut Hlth, Dept Med, Farmington, CT USA; [Chen, Jieming; Butte, Atul J.] Univ Calif San Francisco, Bakar Computat Hlth Sci Inst, San Francisco, CA 94143 USA; [Chen, Jieming; Butte, Atul J.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Ruiz, Camilo] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Tan, Marilyn; McLaughlin, Tracey L.] Stanford Univ, Sch Med, Div Endocrinol, Stanford, CA USA; [Slavich, George M.] Univ Calif Los Angeles, Cousins Ctr Psychoneuroimmunol, Los Angeles, CA USA; [Slavich, George M.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; Stanford University; Stanford University; St Vincent's Hospital Melbourne; University of Melbourne; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Stanford University; Jackson Laboratory; University of Connecticut; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University; Stanford University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Snyder, MP (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.; Haddad, F; Snyder, MP (corresponding author), Stanford Univ, Stanford Cardiovasc Inst, Stanford, CA 94305 USA.; Haddad, F (corresponding author), Stanford Univ, Sch Med, Dept Med, Div Cardiovasc Med, Stanford, CA 94305 USA.	fhaddad@stanford.edu; mpsnyder@stanford.edu	Leopold, Shana/ABA-2797-2020; Slavich, George M/C-6208-2008; Mishra, Tejaswini/D-3528-2018; Slavich, George/ABD-5450-2021; Schussler-Fiorenza Rose, Sophia Miryam/E-6411-2013	Leopold, Shana/0000-0001-5830-1955; Slavich, George M/0000-0001-5710-3818; Mishra, Tejaswini/0000-0001-9931-1260; Mataraso, Samson/0000-0003-3146-2243; Schussler-Fiorenza Rose, Sophia Miryam/0000-0002-6311-6671; Moneghetti, Kegan/0000-0001-9503-6660; Ashland, Melanie/0000-0002-3340-3573; Snyder, Michael/0000-0003-0784-7987; Tan, Marilyn/0000-0002-6651-4691; Zhou, Wenyu/0000-0002-8447-8815	National Institutes of Health (NIH) Human Microbiome Project (HMP) [1U54DE02378901]; NIH [R01 DK110186-03, S10OD020141, P30DK116074, K08 MH103443]; NIH National Center for Advancing Translational Science Clinical and Translational Science Award [UL1TR001085]; Stanford Center for Genomics and Personalized Medicine Sequencing Center; Diabetes Genomics Analysis Core; Clinical and Translational Core of the Stanford Diabetes Research Center (NIH) [P30DK116074]; Department of Veteran Affairs Office of Academic Affiliations Advanced Fellowship in Spinal Cord Injury Medicine; NIH Career Development Award [K08 ES028825]; Stanford School of Medicine Dean's Postdoctoral Fellowship; Stanford Center for Computational, Evolutionary and Human Genomics Fellowship [P300PA_161005, P2GEP3_151825]; Swiss National Science Foundation (SNSF); SNSF; NATIONAL CANCER INSTITUTE [P30CA124435] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK116074, R01DK110186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K08ES028825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K08MH103443] Funding Source: NIH RePORTER	National Institutes of Health (NIH) Human Microbiome Project (HMP)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH National Center for Advancing Translational Science Clinical and Translational Science Award; Stanford Center for Genomics and Personalized Medicine Sequencing Center; Diabetes Genomics Analysis Core; Clinical and Translational Core of the Stanford Diabetes Research Center (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veteran Affairs Office of Academic Affiliations Advanced Fellowship in Spinal Cord Injury Medicine; NIH Career Development Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Stanford School of Medicine Dean's Postdoctoral Fellowship; Stanford Center for Computational, Evolutionary and Human Genomics Fellowship; Swiss National Science Foundation (SNSF)(Swiss National Science Foundation (SNSF)); SNSF(Swiss National Science Foundation (SNSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Our work was supported by grants from the National Institutes of Health (NIH) Human Microbiome Project (HMP) 1U54DE02378901 (G.M.W. and M.P.S.), an NIH grant no. R01 DK110186-03 (T.L.M.), a NIH National Center for Advancing Translational Science Clinical and Translational Science Award (no. UL1TR001085). This work used the Genome Sequencing Service Center by the Stanford Center for Genomics and Personalized Medicine Sequencing Center (supported by NIH grant no. S10OD020141), the Diabetes Genomics Analysis Core and the Clinical and Translational Core of the Stanford Diabetes Research Center (NIH grant no. P30DK116074). S.M.S.-F.R. was supported by a Department of Veteran Affairs Office of Academic Affiliations Advanced Fellowship in Spinal Cord Injury Medicine and a NIH Career Development Award no. K08 ES028825. G.M.S. was supported by NIH grant no. K08 MH103443. D.H. was supported by a Stanford School of Medicine Dean's Postdoctoral Fellowship and a Stanford Center for Computational, Evolutionary and Human Genomics Fellowship. M.R.S. was supported by grant nos. P300PA_161005 and P2GEP3_151825 from the Swiss National Science Foundation (SNSF). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, the Department of Veteran Affairs, or the SNSF. We thank S. Chen and B. Lee for their work in metabolomics data production. A. Breschi generously shared her code for the ISR calculations. Finally, we thank the iPOP participants who generously gave their time and biological samples.	Ahlqvist E, 2018, LANCET DIABETES ENDO, V6, P361, DOI 10.1016/S2213-8587(18)30051-2; Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393; [Anonymous], 2018, LUMINEX MULTIPLEX AN; Apostolopoulou M, 2018, DIABETES CARE, V41, P1235, DOI 10.2337/dc17-1318; Arena R, 2003, CHEST, V124, P720, DOI 10.1378/chest.124.2.720; Bell EJ, 2016, STROKE, V47, P2689, DOI 10.1161/STROKEAHA.116.014172; Berry CE, 2004, J PHYSIOL-LONDON, V555, P589, DOI 10.1113/jphysiol.2003.055913; Bokulich NA, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0470-z; Buhr S., 2018, APPLES WATCH ISNT 1; Callahan BJ, 2017, ISME J, V11, P2639, DOI 10.1038/ismej.2017.119; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/NMETH.3869, 10.1038/nmeth.3869]; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Cauwenberghs N, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008315; Cersosimo E, 2014, CURR DIABETES REV, V10, P2, DOI 10.2174/1573399810666140214093600; Chang CC, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0047-8; Charbonneau B, 2012, CYTOKINE, V60, P882, DOI 10.1016/j.cyto.2012.08.028; Chen R, 2012, CELL, V148, P1293, DOI 10.1016/j.cell.2012.02.009; Chen XP, 2014, METAB SYNDR RELAT D, V12, P362, DOI 10.1089/met.2014.0017; COHEN S, 1988, CLAR SYMP, P31; Contrepois K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35807-4; Contrepois K, 2015, MOL CELL PROTEOMICS, V14, P1684, DOI 10.1074/mcp.M114.046508; Cross DS, 2012, CURR MED RES OPIN, V28, P1819, DOI 10.1185/03007995.2012.742878; Ding Q, 2016, CANCER MED-US, V5, P3246, DOI 10.1002/cam4.934; DINNEEN S, 1992, NEW ENGL J MED, V327, P707, DOI 10.1056/NEJM199209033271007; Douglas PS, 2016, JACC-CARDIOVASC IMAG, V9, P1211, DOI 10.1016/j.jcmg.2016.02.027; Elkind MS, 2005, ATHEROSCLEROSIS, V180, P181, DOI 10.1016/j.atherosclerosis.2004.11.015; FRUCHTERMAN TMJ, 1991, SOFTWARE PRACT EXPER, V21, P1129, DOI 10.1002/spe.4380211102; Go RS, 2015, CL LYMPH MYELOM LEUK, V15, P177, DOI 10.1016/j.clml.2014.09.004; Godsland IF, 2004, DIABETOLOGIA, V47, P1157, DOI 10.1007/s00125-004-1454-z; Goff DC, 2014, CIRCULATION, V129, pS49, DOI 10.1161/01.cir.0000437741.48606.98; Gomez-Arango LF, 2016, DIABETES, V65, P2214, DOI 10.2337/db16-0278; Guasch-Ferre M, 2016, DIABETES CARE, V39, P833, DOI 10.2337/dc15-2251; Haabeth OAW, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1239; Hall H, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005143; Hall KT, 2014, ARTERIOSCL THROM VAS, V34, P2160, DOI 10.1161/ATVBAHA.114.303845; Hamilton JA, 2002, TRENDS IMMUNOL, V23, P403, DOI 10.1016/S1471-4906(02)02260-3; Hovorka R, 1996, COMPUT METH PROG BIO, V50, P253, DOI 10.1016/0169-2607(96)01755-5; Hu FB, 2002, DIABETES CARE, V25, P1129, DOI 10.2337/diacare.25.7.1129; Iikuni Noriko, 2008, Current Immunology Reviews, V4, P70, DOI 10.2174/157339508784325046; Johnson LDS, 2014, ANTICANCER RES, V34, P593; Kalia SS, 2017, GENET MED, V19, P249, DOI 10.1038/gim.2016.190; Kamburov A, 2011, BIOINFORMATICS, V27, P2917, DOI 10.1093/bioinformatics/btr499; Kaminsky LA, 2017, MAYO CLIN PROC, V92, P228, DOI 10.1016/j.mayocp.2016.10.003; Kanat M, 2011, DIABETES CARE, V34, P1006, DOI 10.2337/dc10-1352; Klok MD, 2007, OBES REV, V8, P21, DOI 10.1111/j.1467-789X.2006.00270.x; Kuznetsova T, 2016, CIRC-CARDIOVASC IMAG, V9, DOI 10.1161/CIRCIMAGING.116.004661; Kwo PY, 2017, AM J GASTROENTEROL, V112, P18, DOI 10.1038/ajg.2016.517; Lagani V., 2017, J STAT SOFTWARE ARTI, V80, P1; Lam HYK, 2012, NAT BIOTECHNOL, V30, P226, DOI 10.1038/nbt.2134; Lang RM, 2015, EUR HEART J-CARD IMG, V16, P233, DOI 10.1093/ehjci/jev014; Lee KK, 2010, CIRCULATION, V122, P1478, DOI 10.1161/CIRCULATIONAHA.110.947960; Lee PH, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-115; Li JJ, 2018, CELL, V174, P1361, DOI 10.1016/j.cell.2018.07.021; Li X, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2001402; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Ma H, 2002, ATHEROSCLEROSIS, V164, P79, DOI 10.1016/S0021-9150(02)00062-X; Malik R, 2018, NAT GENET, V50, P524, DOI 10.1038/s41588-018-0058-3; Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462; McClelland RL, 2015, J AM COLL CARDIOL, V66, P1643, DOI 10.1016/j.jacc.2015.08.035; McConnell MV, 2017, JAMA CARDIOL, V2, P67, DOI 10.1001/jamacardio.2016.4395; McLaughlin T, 2003, ANN INTERN MED, V139, P802, DOI 10.7326/0003-4819-139-10-200311180-00007; Mitchell GF, 2010, CIRCULATION, V121, P505, DOI 10.1161/CIRCULATIONAHA.109.886655; Moneghetti KJ, 2018, INT J CARDIOL, V263, P75, DOI 10.1016/j.ijcard.2018.02.102; Montagna P. A., 2014, S CENTR SAS US GROUP; Mothe-Satney I, 2012, DIABETES, V61, P2311, DOI 10.2337/db11-1455; Myers J, 2001, AM HEART J, V142, P1041, DOI 10.1067/mhj.2001.118740; National Research Council (US), 2012, PREC MED BUILD KNOWL; Nowak C, 2016, DIABETES, V65, P276, DOI 10.2337/db15-0881; Oliveira AG, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00503; Omer W, 2016, GENET TEST MOL BIOMA, V20, P685, DOI 10.1089/gtmb.2016.0108; Pearson ER, 2003, LANCET, V362, P1275, DOI 10.1016/S0140-6736(03)14571-0; PEI D, 1994, DIABETOLOGIA, V37, P843, DOI 10.1007/BF00404344; Perkins BA, 2018, P NATL ACAD SCI USA, V115, P3686, DOI 10.1073/pnas.1706096114; Piening BD, 2018, CELL SYST, V6, P157, DOI 10.1016/j.cels.2017.12.013; Porez G, 2012, J LIPID RES, V53, P1723, DOI 10.1194/jlr.R024794; Price ND, 2017, NAT BIOTECHNOL, V35, P747, DOI 10.1038/nbt.3870; Proctor LM, 2014, CELL HOST MICROBE, V16, P276, DOI 10.1016/j.chom.2014.08.014; Przewoznik M, 2012, J IMMUNOTHER, V35, P217, DOI 10.1097/CJI.0b013e318247440a; Rego S, 2018, CSH MOL CASE STUD, V4, DOI 10.1101/mcs.a003178; Reidy SP, 2000, COMP BIOCHEM PHYS A, V125, P285, DOI 10.1016/S1095-6433(00)00159-8; Rolny C, 2011, CANCER CELL, V19, P31, DOI 10.1016/j.ccr.2010.11.009; Sane DC, 2007, FRONT BIOSCI-LANDMRK, V12, P2530, DOI 10.2741/2253; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Slavich GM, 2018, PSYCHOSOM MED, V80, P17, DOI 10.1097/PSY.0000000000000534; Smith DA, 2016, ANN INTERN MED, V164, pJC35, DOI 10.7326/ACPJC-2016-164-6-035; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Tsamardinos I, 2006, MACH LEARN, V65, P31, DOI 10.1007/s10994-006-6889-7; Turesson I, 2014, BLOOD, V123, P338, DOI 10.1182/blood-2013-05-505487; Twig G, 2013, DIABETES CARE, V36, P276, DOI 10.2337/dc11-2298; VANCAUTER E, 1992, DIABETES, V41, P368, DOI 10.2337/diabetes.41.3.368; Varghese RT, 2016, J CLIN ENDOCR METAB, V101, P4816, DOI 10.1210/jc.2016-1998; Wang TJ, 2003, CIRCULATION, V108, P572, DOI 10.1161/01.CIR.0000081764.35431.DE; Whirl-Carrillo M, 2012, CLIN PHARMACOL THER, V92, P414, DOI 10.1038/clpt.2012.96; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Wollert KC, 2017, CLIN CHEM, V63, P140, DOI 10.1373/clinchem.2016.255174; Zhou W, NATURE	97	166	166	10	105	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2019	25	5					792	+		10.1038/s41591-019-0414-6	http://dx.doi.org/10.1038/s41591-019-0414-6			24	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	HY6NU	31068711	Green Accepted, Green Submitted			2023-01-03	WOS:000468247800023
J	Jinno, N; Hori, Y; Naitoh, I; Miyabe, K; Yoshida, M; Natsume, M; Kato, A; Asano, G; Sano, H; Hayashi, K				Jinno, Naruomi; Hori, Yasuki; Naitoh, Itaru; Miyabe, Katsuyuki; Yoshida, Michihiro; Natsume, Makoto; Kato, Akihisa; Asano, Go; Sano, Hitoshi; Hayashi, Kazuki			Predictive factors for the mortality of acute pancreatitis on admission	PLOS ONE			English	Article							AMERICAN-COLLEGE; EARLY-STAGE; CT; CLASSIFICATION; NECROSIS; DEFINITIONS; SEVERITY; ATLANTA	Background and aims The revised Atlanta classification is widely used for the evaluation of acute pancreatitis (AP) severity. However, this classification cannot be used within 48 hours of AP onset. The aim of this study was to investigate the predictive factors of mortality in patients with AP on admission. Methods We evaluated the association between AP mortality and clinical parameters at the time of admission in patients with AP from April 2013 to December 2017 at one university hospital and one tertiary care referral center. Results A total of 203 consecutive patients were enrolled. Nine patients (4.4%) died despite multidisciplinary treatment. In a multivariable analysis, hematocrit >= 40% (odds ratio [OR], 1.07; 95% confidence interval [CI], 1.01-1.13; P = 0.021), blood urea nitrogen (BUN) >= 40 mg/dL (OR, 1.26; 95% CI, 1.11-1.42; P<0.001), base excess < -3.0 mmol/L (OR, 1.15; 95% CI, 1.04-1.26; P = 0.004), and inflammation extending to the rectovesical excavation (OR, 1.19; 95% CI, 1.10-1.30; P<0.001) on admission were significantly associated with mortality. Conclusion Among the imaging findings, inflammation extending to the rectovesical excavation was the only independent predictive factor for mortality in AP. This simple finding, obtained on computed tomography without contrast agent on admission, might be a promising prognostic factor for AP.	[Jinno, Naruomi; Hori, Yasuki; Naitoh, Itaru; Miyabe, Katsuyuki; Yoshida, Michihiro; Natsume, Makoto; Kato, Akihisa; Asano, Go; Hayashi, Kazuki] Nagoya City Univ, Grad Sch Med Sci, Dept Gastroenterol & Metab, Nagoya, Aichi, Japan; [Sano, Hitoshi] Toyokawa City Hosp, Dept Gastroenterol, Toyokawa, Japan	Nagoya City University	Hori, Y (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Gastroenterol & Metab, Nagoya, Aichi, Japan.	yhori@med.nagoya-cu.ac.jp	Naitoh, Itaru/AAB-7252-2020	Naitoh, Itaru/0000-0001-8342-886X; Miyabe, Katsuyuki/0000-0002-4915-9835				BALTHAZAR EJ, 1990, RADIOLOGY, V174, P331, DOI 10.1148/radiology.174.2.2296641; Banks PA, 2013, GUT, V62, P102, DOI 10.1136/gutjnl-2012-302779; Besselink M, 2013, PANCREATOLOGY, V13, pE1, DOI 10.1016/j.pan.2013.07.063; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; BRADLEY EL, 1993, ARCH SURG-CHICAGO, V128, P586; Casas JD, 2004, AM J ROENTGENOL, V182, P569, DOI 10.2214/ajr.182.3.1820569; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Dellinger EP, 2012, ANN SURG, V256, P875, DOI 10.1097/SLA.0b013e318256f778; Forsmark CE, 2016, NEW ENGL J MED, V375, P1972, DOI 10.1056/NEJMra1505202; Hori Y, 2019, PANCREATOLOGY, V19, P224, DOI 10.1016/j.pan.2019.02.004; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Pienkowska J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146965; Spanier BWM, 2010, PANCREATOLOGY, V10, P222, DOI 10.1159/000243731; Stimac D, 2007, AM J GASTROENTEROL, V102, P997, DOI 10.1111/j.1572-0241.2007.01164.x; Takeda K, 2010, J HEPATO-BIL-PAN SCI, V17, P37, DOI 10.1007/s00534-009-0213-4; Tenner S, 2013, AM J GASTROENTEROL, V108, P1400, DOI 10.1038/ajg.2013.218; Tsuji Y, 2007, CLIN GASTROENTEROL H, V5, P1484, DOI 10.1016/j.cgh.2007.07.014; Tsuji Y, 2014, AM J ROENTGENOL, V202, pW349, DOI 10.2214/AJR.13.10957; van Santvoort HC, 2010, NEW ENGL J MED, V362, P1491, DOI 10.1056/NEJMoa0908821; Yadav AK, 2015, ABDOM IMAGING, V40, P488, DOI 10.1007/s00261-014-0226-6	20	11	12	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2019	14	8							e0221468	10.1371/journal.pone.0221468	http://dx.doi.org/10.1371/journal.pone.0221468			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5RZ	31437218	gold, Green Published, Green Submitted			2023-01-03	WOS:000485036900077
J	Zhang, S; Morgenstern, H; Albertus, P; Nallamothu, BK; He, K; Saran, R				Zhang, Sai; Morgenstern, Hal; Albertus, Patrick; Nallamothu, Brahmajee K.; He, Kevin; Saran, Rajiv			Emergency department visits and hospitalizations among hemodialysis patients by day of the week and dialysis schedule in the United States	PLOS ONE			English	Article							PRACTICE PATTERNS; INTRADIALYTIC HYPOTENSION; MORTALITY; OUTCOMES; ULTRAFILTRATION; TIME	Background and objective Previous reports indicated that patients on thrice-weekly hemodialysis (HD) had higher mortality rates after the 3-day interdialytic interval. However, day-of-the-week patterns of emergency department (ED) visits and hospitalizations remain under-investigated. Methods We conducted a retrospective cohort study of HD patients on thrice-weekly dialysis, using 2013 data from the United States Renal Data System (USRDS). We estimated crude incidence rates of ED visits and hospitalizations by day of the week and dialysis schedule (Monday, Wednesday, Friday or Tuesday, Thursday, Saturday). Using Poisson regression, we estimated case-mix adjusted rate ratios of all-cause ED visits and hospitalizations, and adjusted rates of cause-specific ED visits and hospitalizations. Results We identified 241,093 eligible HD patients in 2013, who had 514,773 ED visits and 301,674 hospitalizations that year. Three distinct but related patterns of outcome events were observed. Crude and adjusted incidence rates of all-cause, cardiovascular, and infection-related ED visits and hospitalizations, but not vascular-access-related events, were higher on all three HD treatment days ("dialysis-day effect"). Rates for ED visits and hospitalizations were lower on weekends than weekdays, rising appreciably from Sunday to Monday for both dialysis schedules ("post-weekend effect"); and rates were highest after the long 3-day interval between dialysis sessions for both dialysis schedules ("interdialytic-gap effect"). In contrast, rates of hospitalizations not preceded by an ED visit were nearly the same Monday through Friday and lower on weekends for both dialysis schedules. Conclusions Higher rates of ED visits and hospitalizations on the days of HD sessions and early in the week are a public-health concern that should stimulate research to explain these patterns and reduce the excessive morbidity and associated costs among patients on thrice-weekly HD, while improving quality of care and patient experience with dialysis.	[Zhang, Sai; Albertus, Patrick; He, Kevin; Saran, Rajiv] Univ Michigan, Sch Publ Hlth, Kidney Epidemiol & Cost Ctr, Ann Arbor, MI 48109 USA; [Zhang, Sai; Morgenstern, Hal; He, Kevin; Saran, Rajiv] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA; [Morgenstern, Hal] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA; [Morgenstern, Hal] Univ Michigan, Dept Urol, Med Sch, Ann Arbor, MI 48109 USA; [Morgenstern, Hal; Nallamothu, Brahmajee K.; Saran, Rajiv] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA; [Albertus, Patrick; Saran, Rajiv] Univ Michigan, Dept Internal Med, Med Sch, Ann Arbor, MI 48109 USA; [Albertus, Patrick] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Nallamothu, Brahmajee K.] Ann Arbor VA Ctr Clin Management & Res, Ann Arbor, MI USA; [Nallamothu, Brahmajee K.] Univ Michigan Hlth Syst, Ann Arbor, MI USA; [Nallamothu, Brahmajee K.] Univ Michigan, Dept Internal Med, Michigan Integrated Ctr Hlth Analyt & Med Predict, Ann Arbor, MI 48109 USA; [He, Kevin] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University System of Ohio; University of Cincinnati; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Saran, R (corresponding author), Univ Michigan, Sch Publ Hlth, Kidney Epidemiol & Cost Ctr, Ann Arbor, MI 48109 USA.; Saran, R (corresponding author), Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.; Saran, R (corresponding author), Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA.; Saran, R (corresponding author), Univ Michigan, Dept Internal Med, Med Sch, Ann Arbor, MI 48109 USA.	rsaran@med.umich.edu		Saran, Rajiv/0000-0001-7317-8756	National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services [HHSN276201400001C]; University of Michigan [HHSN276201400001C]	National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); University of Michigan(University of Michigan System)	Funding for this research was provided through a contract (HHSN276201400001C) between the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, and the University of Michigan. The interpretation and reporting of findings and data reported in this manuscript are the responsibility of the authors, and in no way should be seen as an official policy of or interpretation by the US government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Assimon MM, 2016, AM J KIDNEY DIS, V68, P911, DOI 10.1053/j.ajkd.2016.06.020; Banshodani M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180577; Bell CM, 2001, NEW ENGL J MED, V345, P663, DOI 10.1056/NEJMsa003376; Chou JA, 2017, SEMIN DIALYSIS, V30, P473, DOI 10.1111/sdi.12627; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Foley RN, 2011, NEW ENGL J MED, V365, P1099, DOI 10.1056/NEJMoa1103313; Fotheringham J, 2019, NEPHROL DIAL TRANSPL; Fotheringham J, 2015, KIDNEY INT, V88, P569, DOI 10.1038/ki.2015.141; Freemantle N, 2012, J ROY SOC MED, V105, P74, DOI 10.1258/jrsm.2012.120009; Freemantle N, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4843; Kjellstrand Carl M, 2004, Hemodial Int, V8, P24, DOI 10.1111/j.1492-7535.2004.00083.x; Lopot F, 1998, NEPHROL DIAL TRANSPL, V13, P74, DOI 10.1093/ndt/13.suppl_6.74; Lovasik BP, 2016, JAMA INTERN MED, V176, P1563, DOI 10.1001/jamainternmed.2016.4975; McDonough Matthew J, 2008, Nephrol News Issues, V22, P48; Ok E, 2017, SEMIN DIALYSIS, V30, P420, DOI 10.1111/sdi.12612; Rayner HC, 2014, AM J KIDNEY DIS, V64, P86, DOI 10.1053/j.ajkd.2014.01.014; Rothman JK, 2008, MODERN EPIDEMIOLOGY, V3rd; Sakhuja A, 2013, AM J KIDNEY DIS, V62, P763, DOI 10.1053/j.ajkd.2013.03.014; Sands JJ, 2014, HEMODIAL INT, V18, P415, DOI 10.1111/hdi.12138; Saran R, 2006, KIDNEY INT, V69, P1222, DOI 10.1038/sj.ki.5000186; Saran R, 2017, AM J KIDNEY DIS, V69, DOI 10.1053/j.ajkd.2016.12.004; Scribner Belding H, 2004, Hemodial Int, V8, P188, DOI 10.1111/j.1492-7535.2004.01094.x; Tentori F, 2012, NEPHROL DIAL TRANSPL, V27, P4180, DOI 10.1093/ndt/gfs021; Varney J, 2014, INT J EVID-BASED HEA, V12, P128, DOI 10.1097/XEB.0000000000000011; Zhang H, 2012, KIDNEY INT, V81, P1108, DOI 10.1038/ki.2011.481	25	4	4	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 15	2019	14	8							e0220966	10.1371/journal.pone.0220966	http://dx.doi.org/10.1371/journal.pone.0220966			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5KK	31415609	Green Published, gold, Green Submitted			2023-01-03	WOS:000485017200053
J	Manolio, TA; Rowley, R; Williams, MS; Roden, D; Ginsburg, GS; Bult, C; Chisholm, RL; Deverka, PA; McLeod, HL; Mensah, GA; Relling, MV; Rodriguez, LL; Tamburro, C; Green, ED				Manolio, Teri A.; Rowley, Robb; Williams, Marc S.; Roden, Dan; Ginsburg, Geoffrey S.; Bult, Carol; Chisholm, Rex L.; Deverka, Patricia A.; McLeod, Howard L.; Mensah, George A.; Relling, Mary V.; Rodriguez, Laura Lyman; Tamburro, Cecelia; Green, Eric D.			Opportunities, resources, and techniques for implementing genomics in clinical care	LANCET			English	Article							GENETIC COUNSELORS; MEDICAL GENETICS; AMERICAN-COLLEGE; RISK-ASSESSMENT; FAMILY-HISTORY; HEALTH-CARE; RETURN; GUIDELINES; EXOME; ASSOCIATION	Advances in technologies for assessing genomic variation and an increasing understanding of the effects of genomic variants on health and disease are driving the transition of genomics from the research laboratory into clinical care. Genomic medicine, or the use of an individual's genomic information as part of their clinical care, is increasingly gaining acceptance in routine practice, including in assessing disease risk in individuals and their families, diagnosing rare and undiagnosed diseases, and improving drug safety and efficacy. We describe the major types and measurement tools of genomic variation that are currently of clinical importance, review approaches to interpreting genomic sequence variants, identify publicly available tools and resources for genomic test interpretation, and discuss several key barriers in using genomic information in routine clinical practice.	[Manolio, Teri A.; Rowley, Robb; Rodriguez, Laura Lyman; Tamburro, Cecelia; Green, Eric D.] NHGRI, NIH, Bethesda, MD 20892 USA; [Williams, Marc S.] Geisinger, Genom Med Inst, Danville, PA USA; [Roden, Dan] Vanderbilt Univ, Med Ctr, Dept Med, Dept Pharmacol, Nashville, TN USA; [Roden, Dan] Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Nashville, TN USA; [Ginsburg, Geoffrey S.] Duke Univ, Duke Ctr Appl Genom & Precis Med, Durham, NC USA; [Bult, Carol] Jackson Lab Mammalian Genet, Bar Harbor, ME USA; [Chisholm, Rex L.] Northwestern Univ, Ctr Genet Med, Feinberg Sch Med, Chicago, IL 60611 USA; [Deverka, Patricia A.] Amer Inst Res, Washington, DC USA; [McLeod, Howard L.] H Lee Moffitt Canc Ctr & Res Inst, DeBartolo Family Personalized Med Inst, Tampa, FL USA; [Mensah, George A.] NHLBI, Ctr Translat Res & Implementat Sci, NIH, Bldg 10, Bethesda, MD 20892 USA; [Relling, Mary V.] St Jude Childrens Res Hosp, Pharmaceut Sci Dept, 332 N Lauderdale St, Memphis, TN 38105 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Vanderbilt University; Vanderbilt University; Duke University; Jackson Laboratory; Northwestern University; Feinberg School of Medicine; American Institutes for Research; H Lee Moffitt Cancer Center & Research Institute; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); St Jude Children's Research Hospital	Manolio, TA (corresponding author), NHGRI, Div Genom Med, Bethesda, MD 20892 USA.	manolio@nih.gov	Roden, Dan/ABD-5412-2021; McLeod, Howard/ABD-8364-2021; Chisholm, Rex/B-3418-2009	McLeod, Howard/0000-0002-9004-9232; Chisholm, Rex/0000-0002-5638-3990				1000 Genomes Project Consortium, 2015, Nature, V526, P68, DOI 10.1038/nature15393; Abul-Husn NS, 2016, SCIENCE, V354, DOI 10.1126/science.aaf7000; Acuna-Hidalgo R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1110-1; Aronson SJ, 2012, GENET MED, V14, P713, DOI 10.1038/gim.2012.19; Bentley SD, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2015.0488; Caudle KE, 2017, GENET MED, V19, P215, DOI 10.1038/gim.2016.87; Cavallari LH, 2018, JACC-CARDIOVASC INTE, V11, P181, DOI 10.1016/j.jcin.2017.07.022; Ceyhan-Birsoy O, 2019, AM J HUM GENET, V104, P76, DOI 10.1016/j.ajhg.2018.11.016; Chisholm C, 2018, GENET MED, V20, P365, DOI 10.1038/gim.2017.191; Cline MS, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007752; Crews KR, 2014, CLIN PHARMACOL THER, V95, P376, DOI 10.1038/clpt.2013.254; Cummings BB, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal5209; Damodaran Senthilkumar, 2015, Am Soc Clin Oncol Educ Book, pe175, DOI 10.14694/EdBook_AM.2015.35.e175; de Almeida RM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182946; Dzau VJ, 2016, REALIZING FULL POTEN; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Fullerton SM, 2012, GENET MED, V14, P424, DOI 10.1038/gim.2012.15; GAFF CL, 2017, NPJ GENOM MED, V2, DOI DOI 10.1038/S41525-017-0017-4; Ginsburg GS, 2019, LANCET, V394, P596, DOI 10.1016/S0140-6736(19)31275-9; Ginsburg GS, 2018, HEALTH AFFAIR, V37, P694, DOI 10.1377/hlthaff.2017.1624; Gonorazky H, 2016, ANN CLIN TRANSL NEUR, V3, P55, DOI 10.1002/acn3.267; Green ED, 2011, NATURE, V470, P204, DOI 10.1038/nature09764; Hindorff LA, 2018, NAT REV GENET, V19, P175, DOI 10.1038/nrg.2017.89; Hollands GJ, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1102; Holm IA, 2019, PEDIATRICS, V143, pS37, DOI 10.1542/peds.2018-1099H; Horowitz CR, 2016, CONTEMP CLIN TRIALS, V47, P101, DOI 10.1016/j.cct.2015.12.020; Human Genome Variation Society, 2019, DAT TOOLS; Hunter JE, 2016, GENET MED, V18, P1258, DOI 10.1038/gim.2016.40; Kalia SS, 2017, GENET MED, V19, P249, DOI 10.1038/gim.2016.190; Khera AV, 2018, NAT GENET, V50, P1219, DOI 10.1038/s41588-018-0183-z; Khoury MJ, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002631; Knoppers BM, 2015, NAT REV GENET, V16, P553, DOI 10.1038/nrg3960; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Lynch John, 2016, AJOB Empir Bioeth, V7, P160, DOI 10.1080/23294515.2015.1053008; MacArthur J, 2017, NUCLEIC ACIDS RES, V45, pD896, DOI 10.1093/nar/gkw1133; Manolio TA, 2016, ATHEROSCLEROSIS, V253, P225, DOI 10.1016/j.atherosclerosis.2016.08.034; Manolio TA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab0194; Manolio TA, 2013, GENET MED, V15, P258, DOI 10.1038/gim.2012.157; Manrai AK, 2016, NEW ENGL J MED, V375, P655, DOI 10.1056/NEJMsa1507092; Marteau TM, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007275.pub2; Matthijs G, 2016, EUR J HUM GENET, V24, P2, DOI 10.1038/ejhg.2015.226; McDonald-McGinn DM, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.71; Mester JL, 2012, CLEV CLIN J MED, V79, P560, DOI 10.3949/ccjm.79a.11091; Meynert AM, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-247; Nakagawa H, 2018, CANCER SCI, V109, P513, DOI 10.1111/cas.13505; National Academies of Sciences Engineering and Medicine, 2018, RET IND RES RES PART; National Cancer Institute, NCI DICT GEN TERMS S; National Society of Genetic Counselors, 2018, WHO AR GEN COUNS; Obeng AO, 2018, J PERS MED, V8, DOI 10.3390/jpm8030024; Orlando LA, 2016, GENET MED, V18, P1020, DOI 10.1038/gim.2015.210; Orlando Lori A, 2013, N C Med J, V74, P287; Owusu-Obeng A, 2014, PHARMACOTHERAPY, V34, P1102, DOI 10.1002/phar.1481; Pena LDM, 2018, GENET MED, V20, P464, DOI 10.1038/gim.2017.128; Peterson JF, 2019, LANCET, V394, P604, DOI 10.1016/S0140-6736(19)31278-4; Petrikin JE, 2018, NPJ GENOM MED, V3, DOI 10.1038/s41525-018-0045-8; Petrikin JE, 2015, SEMIN PERINATOL, V39, P623, DOI 10.1053/j.semperi.2015.09.009; Pyeritz RE, 2012, GENET MED, V14, P3, DOI 10.1038/gim.0b013e3182310bcf; Qureshi N, 2012, ANN INTERN MED, V156, P253, DOI 10.7326/0003-4819-156-4-201202210-00002; Ramoni RB, 2017, AM J HUM GENET, V100, P185, DOI 10.1016/j.ajhg.2017.01.006; Ramos EM, 2014, AM J MED GENET C, V166, P93, DOI 10.1002/ajmg.c.31386; Rasmussen LV, 2016, APPL CLIN INFORM, V7, P870, DOI 10.4338/ACI-2016-04-RA-0060; Rehm HL, 2013, GENET MED, V15, P733, DOI 10.1038/gim.2013.92; Reuter C, 2018, J GENET COUNS, V27, P751, DOI 10.1007/s10897-017-0175-7; Reuter JA, 2015, MOL CELL, V58, P586, DOI 10.1016/j.molcel.2015.05.004; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Roberts MC, 2018, HEALTH AFFAIR, V37, P801, DOI 10.1377/hlthaff.2017.1630; Roberts MC, 2017, GENET MED, V19, P858, DOI 10.1038/gim.2016.210; Roden DM, 2019, LANCET, V394, P521, DOI 10.1016/S0140-6736(19)31276-0; Senecal K, 2015, GENOME, V58, P541, DOI 10.1139/gen-2015-0092; Stark Z, 2019, AM J HUM GENET, V104, P13, DOI 10.1016/j.ajhg.2018.11.014; Turnbull C, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1687; Valdez R, 2010, ANNU REV PUBL HEALTH, V31, P69, DOI 10.1146/annurev.publhealth.012809.103621; van Dijk EL, 2018, TRENDS GENET, V34, P666, DOI 10.1016/j.tig.2018.05.008; Volpi S, 2018, CLIN PHARMACOL THER, V103, P778, DOI 10.1002/cpt.1048; Vrecar I, 2017, J MED SYST, V41, DOI 10.1007/s10916-016-0666-3; Wauters A, 2016, J HUM GENET, V61, P275, DOI 10.1038/jhg.2015.151; Welch BM, 2018, J GENET COUNS, V27, P381, DOI 10.1007/s10897-018-0235-7; Williams MS, 2018, HEALTH AFFAIR, V37, P757, DOI 10.1377/hlthaff.2017.1557; Wise AL, 2019, LANCET, V394, P533, DOI 10.1016/S0140-6736(19)31274-7; Wu RR, 2015, POSTGRAD MED J, V91, P508, DOI 10.1136/postgradmedj-2014-133195; Xue Y, 2015, GENET MED, V17, P444, DOI 10.1038/gim.2014.122; Yu JH, 2014, AM J HUM GENET, V95, P77, DOI 10.1016/j.ajhg.2014.06.004	82	40	40	1	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 10	2019	394	10197					511	520		10.1016/S0140-6736(19)31140-7	http://dx.doi.org/10.1016/S0140-6736(19)31140-7			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IP9VH	31395439	Green Accepted			2023-01-03	WOS:000480398100032
J	Scott, RH; Fowler, TA; Caulfield, M				Scott, Richard H.; Fowler, Tom A.; Caulfield, Mark			Genomic medicine: time for health-care transformation	LANCET			English	Editorial Material									[Scott, Richard H.; Fowler, Tom A.; Caulfield, Mark] Queen Mary Univ London, Genom England, London, England; [Scott, Richard H.] Great Ormond St Hosp Children NHS Fdn Trust, London, England; [Fowler, Tom A.; Caulfield, Mark] Queen Mary Univ London, William Harvey Res Inst, London EC1M 6BQ, England	University of London; Queen Mary University London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; Queen Mary University London	Caulfield, M (corresponding author), Queen Mary Univ London, Genom England, London, England.; Caulfield, M (corresponding author), Queen Mary Univ London, William Harvey Res Inst, London EC1M 6BQ, England.	m.j.caulfield@qmul.ac.uk	Fowler, Tom/AGT-1933-2022	Fowler, Tom/0000-0002-7258-2279	MRC [MC_PC_14089, MR/M009203/1, G9521010, MC_EX_MR/M009203/1] Funding Source: UKRI	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Davies, 2016, CHIEF MED OFFICER AN; Genomics England, 2019, PUBL DIAL GEN MED TI; Ginsburg GS, 2019, LANCET, V394, P596, DOI 10.1016/S0140-6736(19)31275-9; Gov UK, 2018, MATT HANC ANN AMB MA; IQVIA, 2019, GLOB ONC TRENDS 2019; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lord J, 2019, GENOME RES, V29, P159, DOI 10.1101/gr.238444.118; Manolio TA, 2019, LANCET, V394, P511, DOI 10.1016/S0140-6736(19)31140-7; Peterson JF, 2019, LANCET, V394, P604, DOI 10.1016/S0140-6736(19)31278-4; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; RAJAGOPAL D, 2019, ECONOMIC TIMES; Roden DM, 2019, LANCET, V394, P521, DOI 10.1016/S0140-6736(19)31276-0; Turnbull C, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1687; Wise AL, 2019, LANCET, V394, P533, DOI 10.1016/S0140-6736(19)31274-7	14	10	12	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 10	2019	394	10197					454	456		10.1016/S0140-6736(19)31796-9	http://dx.doi.org/10.1016/S0140-6736(19)31796-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IP9VH	31395438				2023-01-03	WOS:000480398100011
J	Guo, J; Xiao, Y; Iyer, R; Lu, X; Lake, M; Ladror, U; Harlan, J; Samanta, T; Tomlinson, M; Bukofzer, G; Donawho, C; Shoemaker, A; Huang, TH				Guo, Jun; Xiao, Yu; Iyer, Ramesh; Lu, Xin; Lake, Marc; Ladror, Uri; Harlan, John; Samanta, Tanushree; Tomlinson, Medha; Bukofzer, Gail; Donawho, Cherrie; Shoemaker, Alex; Huang, Tzu-Hsuan			Empowering therapeutic antibodies with IFN-alpha for cancer immunotherapy	PLOS ONE			English	Article							INTERFERON-ALPHA	Type 1 IFNs stimulate secretion of IP-10 (CXCL10) which is a critical chemokine to recruit effector T cells to the tumor microenvironment and IP-10 knockout mice exhibit a phenotype with compromised effector T cell generation and trafficking. Type 1 IFNs also induce MHC class 1 upregulation on tumor cells which can enhance anti-tumor CD8 T cell effector response in the tumor microenvironment. Although type 1 IFNs show great promise in potentiating anti-tumor immune response, systemic delivery of type 1 IFNs is associated with toxicity thereby limiting clinical application. In this study, we fused tumor targeting antibodies with IFN-alpha and showed that the fusion proteins can be produced with high yields and purity. IFN fusions selectively induced IP-10 secretion from antigen positive tumor cells, which was critical in recruiting the effector T cells to the tumor microenvironment. Further, we found that treatment with the anti-PDL1-IFN-alpha fusion at concentrations as low as 1 pM exhibited potent activity in mediating OT1 CD8(+) T cell killing against OVA expressing tumor cells, while control IFN fusion did not exhibit any activity at the same concentration. Furthermore, the IFN-alpha fusion antibody was well tolerated in vivo and demonstrated anti-tumor efficacy in an anti-PD-L1 resistant syngeneic mouse tumor model. One of the potential mechanisms for the enhanced CD8 T cell killing by anti-PD-L1 IFN fusion was up-regulation of MHC class I/tumor antigen complex. Our data supports the hypothesis of targeting type 1 IFN to the tumor microenvironment may enhance effector T cell functions for anti-tumor immune response.	[Guo, Jun; Xiao, Yu; Samanta, Tanushree; Bukofzer, Gail; Donawho, Cherrie; Shoemaker, Alex; Huang, Tzu-Hsuan] AbbVie Inc, Oncol Discovery, N Chicago, IL 60064 USA; [Iyer, Ramesh; Lake, Marc; Ladror, Uri; Harlan, John] AbbVie Inc, Global Prot Sci, N Chicago, IL USA; [Lu, Xin] AbbVie Inc, Genom Res Ctr, N Chicago, IL USA; [Tomlinson, Medha] AbbVie Biores Ctr, Global Biol, Worcester, MA USA	AbbVie; AbbVie; AbbVie; AbbVie	Huang, TH (corresponding author), AbbVie Inc, Oncol Discovery, N Chicago, IL 60064 USA.	leon.huang@abbvie.com			AbbVie	AbbVie(AbbVie)	JG, YX, RI, XL, ML, UL, JH, TS, GB, AS, and TH are employees of AbbVie. MT & CD were AbbVie employees at the time of the study. The specific roles of these authors are articulated in the ` author contributions' section. The design, study conduct, and financial support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication.	Bazhin AV, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02129; Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019; Dong YN, 2017, ONCOTARGET, V8, P2171, DOI 10.18632/oncotarget.13895; Farrar JD, 2000, NAT IMMUNOL, V1, P65, DOI 10.1038/76932; Fuertes MB, 2011, J EXP MED, V208, P2005, DOI 10.1084/jem.20101159; Guo J, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-2783; Huang TH, 2007, J IMMUNOL, V179, P6881, DOI 10.4049/jimmunol.179.10.6881; Jennings RN, 2014, J VIROL, V88, P14040, DOI 10.1128/JVI.02360-14; Knudson KM, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1426519; Kwok G, 2016, HUM VACC IMMUNOTHER, V12, P2777, DOI 10.1080/21645515.2016.1199310; Liang Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06890-y; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Papageorgiou A, 2007, CANCER BIOL THER, V6, P872, DOI 10.4161/cbt.6.6.4088; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Schiavoni G, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00483; Sistigu A, 2014, NAT MED, V20, P1301, DOI 10.1038/nm.3708; Trinchieri G, 2010, J EXP MED, V207, P2053, DOI 10.1084/jem.20101664; Woo SR, 2015, TRENDS IMMUNOL, V36, P250, DOI 10.1016/j.it.2015.02.003; Xuan CY, 2010, BLOOD, V115, P2864, DOI 10.1182/blood-2009-10-250555; Yang XM, 2014, CANCER CELL, V25, P37, DOI 10.1016/j.ccr.2013.12.004; Zhang HC, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0397-y; Zhang L, 2017, EXP HEMATOL ONCOL, V6, DOI 10.1186/s40164-017-0081-6; Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118	24	11	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2019	14	8							e0219829	10.1371/journal.pone.0219829	http://dx.doi.org/10.1371/journal.pone.0219829			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5EW	31393905	Green Submitted, gold, Green Published			2023-01-03	WOS:000485002500018
J	Vaughn, VM; Flanders, SA; Snyder, A; Conlon, A; Rogers, MAM; Malani, AN; McLaughlin, E; Bloemers, S; Srinivasan, A; Nagel, J; Kaatz, S; Osterholzer, D; Thyagarajan, R; Hsaiky, L; Chopra, V; Gandhi, TN				Vaughn, Valerie M.; Flanders, Scott A.; Snyder, Ashley; Conlon, Anna; Rogers, Mary A. M.; Malani, Anurag N.; McLaughlin, Elizabeth; Bloemers, Sarah; Srinivasan, Arjun; Nagel, Jerod; Kaatz, Scott; Osterholzer, Danielle; Thyagarajan, Rama; Hsaiky, Lama; Chopra, Vineet; Gandhi, Tejal N.			Excess Antibiotic Treatment Duration and Adverse Events in Patients Hospitalized With Pneumonia A Multihospital Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; INFECTIOUS-DISEASES-SOCIETY; VENTILATOR-ASSOCIATED PNEUMONIA; STEWARDSHIP INTERVENTION; VENOUS THROMBOEMBOLISM; THERAPY; GUIDELINES; ADULTS; MANAGEMENT; ASSOCIATION	Background: Randomized trials demonstrate no benefit from antibiotic treatment exceeding the shortest effective duration. Objective: To examine predictors and outcomes associated with excess duration of antibiotic treatment. Design: Retrospective cohort study. Setting: 43 hospitals in the Michigan Hospital Medicine Safety Consortium. Patients: 6481 general care medical patients with pneumonia. Measurements: The primary outcome was the rate of excess antibiotic treatment duration (excess days per 30-day period). Excess days were calculated by subtracting each patient's shortest effective (expected) treatment duration (based on time to clinical stability, pathogen, and pneumonia classification [community-acquired vs. health care-associated]) from the actual duration. Negative binomial generalized estimating equations (GEEs) were used to calculate rate ratios to assess predictors of 30-day rates of excess duration. Patient outcomes, assessed at 30 days via the medical record and telephone calls, were evaluated using logit GEEs that adjusted for patient characteristics and probability of treatment. Results: Two thirds (67.8% [4391 of 6481]) of patients received excess antibiotic therapy. Antibiotics prescribed at discharge accounted for 93.2% of excess duration. Patients who had respiratory cultures or nonculture diagnostic testing, had a longer stay, received a high-risk antibiotic in the prior 90 days, had community-acquired pneumonia, or did not have a total antibiotic treatment duration documented at discharge were more likely to receive excess treatment. Excess treatment was not associated with lower rates of any adverse outcomes, including death, readmission, emergency department visit, or Clostridioides difficile infection. Each excess day of treatment was associated with a 5% increase in the odds of antibiotic-associated adverse events reported by patients after discharge. Limitation: Retrospective design; not all patients could be contacted to report 30-day outcomes. Conclusion: Patients hospitalized with pneumonia often receive excess antibiotic therapy. Excess antibiotic treatment was associated with patient-reported adverse events. Future interventions should focus on whether reducing excess treatment and improving documentation at discharge improves outcomes. Primary Funding Source: Blue Cross Blue Shield of Michigan (BCBSM) and Blue Care Network as part of the BCBSM Value Partnerships program.	[Vaughn, Valerie M.; Flanders, Scott A.; Snyder, Ashley; Conlon, Anna; Rogers, Mary A. M.; McLaughlin, Elizabeth; Bloemers, Sarah; Chopra, Vineet; Gandhi, Tejal N.] Univ Michigan, Sch Med, Ann Arbor, MI USA; [Vaughn, Valerie M.; Rogers, Mary A. M.; Chopra, Vineet] VA Ann Arbor Hlth Syst, Ann Arbor, MI USA; [Malani, Anurag N.] St Joseph Mercy Hlth Syst, Ann Arbor, MI USA; [Srinivasan, Arjun] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS H16-2, Atlanta, GA 30306 USA; [Nagel, Jerod] Michigan Med, 1111 East Catherine St, Ann Arbor, MI 48109 USA; [Kaatz, Scott] Henry Ford Hosp, OFP 413,2799 West Grand Blvd, Detroit, MI 48202 USA; [Osterholzer, Danielle] Hurley Med Ctr, 2 Hurley Plaza,Suite 212, Flint, MI 48503 USA; [Osterholzer, Danielle] Michigan State Univ, Coll Human Med, E Lansing, MI 48824 USA; [Thyagarajan, Rama; Hsaiky, Lama] Beaumont Hosp, Dearborn, MI USA; [Vaughn, Valerie M.] Michigan Med, Div Hosp Med, Med, North Campus Res Complex,2800 Plymouth Rd,Bldg 16, Ann Arbor, MI 48109 USA; [Flanders, Scott A.] Univ Michigan, Med, 2800 Plymouth Rd, Ann Arbor, MI 48109 USA; [Flanders, Scott A.] Univ Michigan, 2800 Plymouth Rd, Ann Arbor, MI 48109 USA; [Flanders, Scott A.; Snyder, Ashley; Conlon, Anna; Rogers, Mary A. M.; McLaughlin, Elizabeth; Bloemers, Sarah; Chopra, Vineet; Gandhi, Tejal N.] Univ Michigan, Sch Med, Dept Internal Med, Taubman Ctr 3110, SPC 5368,1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA; [Malani, Anurag N.] St Joseph Mercy Hlth Syst, IHA Infect Dis Consultants, 5333 McAuley Dr,Suite 6109, Ypsilanti, MI 48197 USA; [Thyagarajan, Rama] Beaumont Infect Dis Dearborn, Pharm Adm Dearborn, 18181 Oakwood Blvd,Suite 101, Dearborn, MI 48124 USA; [Hsaiky, Lama] Beaumont Infect Dis Dearborn, Pharm Adm Dearborn, 18101 Oakwood Blvd,Suite 101, Dearborn, MI 48124 USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; Saint Joseph Mercy Health System (SJMHS); Centers for Disease Control & Prevention - USA; Henry Ford Health System; Henry Ford Hospital; Michigan State University; Michigan State University College of Human Medicine; Beaumont Health; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Saint Joseph Mercy Health System (SJMHS)	Vaughn, VM (corresponding author), Michigan Med, Div Hosp Med, Med, North Campus Res Complex,2800 Plymouth Rd,Bldg 16, Ann Arbor, MI 48109 USA.	valmv@med.umich.edu; amsn@med.umich.edu	Gandhi, Tejal/AAY-3423-2020	Rogers, Mary/0000-0001-5519-3223; Vaughn, Valerie/0000-0003-4362-7842	Blue Cross Blue Shield of Michigan (BCBSM); Blue Care Network as part of the BCBSM Value Partnerships program	Blue Cross Blue Shield of Michigan (BCBSM); Blue Care Network as part of the BCBSM Value Partnerships program	Support for the Michigan Hospital Medicine Safety Consortium is provided by Blue Cross Blue Shield of Michigan (BCBSM) and Blue Care Network as part of the BCBSM Value Partnerships program.	[Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Avdic E, 2012, CLIN INFECT DIS, V54, P1581, DOI 10.1093/cid/cis242; Barlam TF, 2016, CLIN INFECT DIS, V62, pE51, DOI 10.1093/cid/ciw118; Buckland ST, 1997, BIOMETRICS, V53, P603, DOI 10.2307/2533961; Chastre J, 2003, JAMA-J AM MED ASSOC, V290, P2588, DOI 10.1001/jama.290.19.2588; Costelloe C, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2096; Drahos J, 2013, ANN EPIDEMIOL, V23, P291, DOI 10.1016/j.annepidem.2013.02.005; Field TS, 2004, J AM GERIATR SOC, V52, P1349, DOI 10.1111/j.1532-5415.2004.52367.x; File TM, 2007, J ANTIMICROB CHEMOTH, V60, P112, DOI 10.1093/jac/dkm119; Flanders SA, 2014, JAMA INTERN MED, V174, P1577, DOI 10.1001/jamainternmed.2014.3384; Freedberg DE, 2016, JAMA INTERN MED, V176, P1801, DOI 10.1001/jamainternmed.2016.6193; Fridkin S, 2014, MMWR-MORBID MORTAL W, V63, P194; Garcia-Vazquez E, 2004, ARCH INTERN MED, V164, P1807, DOI 10.1001/archinte.164.16.1807; Gouliouris T, 2018, J ANTIMICROB CHEMOTH, V73, P1692, DOI 10.1093/jac/dky075; GRASELA TH, 1990, DICP ANN PHARMAC, V24, P1220, DOI 10.1177/106002809002401215; Greene MT, 2015, AM J MED, V128, P986, DOI 10.1016/j.amjmed.2015.03.028; Haas MK, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw186; Kalil AC, 2016, CLIN INFECT DIS, V63, pE61, DOI 10.1093/cid/ciw353; Lautenbach E, 2001, CLIN INFECT DIS, V33, P1288, DOI 10.1086/322667; Lee JS, 2016, JAMA-J AM MED ASSOC, V316, P2544, DOI 10.1001/jama.2016.17589; Li DX, 2016, INFECT CONT HOSP EP, V37, P1243, DOI 10.1017/ice.2016.165; Li JZ, 2007, AM J MED, V120, P783, DOI 10.1016/j.amjmed.2007.04.023; Madaras-Kelly KJ, 2016, J HOSP MED, V11, P832, DOI 10.1002/jhm.2648; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; McCollum DL, 2012, CLIN GASTROENTEROL H, V10, P581, DOI 10.1016/j.cgh.2012.03.008; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418; Pollack LA, 2016, CLIN INFECT DIS, V63, P443, DOI 10.1093/cid/ciw323; Pollack LA, 2014, CLIN INFECT DIS, V59, pS97, DOI 10.1093/cid/ciu542; Rhee C, 2017, JAMA-J AM MED ASSOC, V318, P1241, DOI 10.1001/jama.2017.13836; Royer S, 2018, J HOSP MED, V13, P336, DOI 10.12788/jhm.2905; Rubin Donald B., 1978, P SURV RES METH SECT, P20, DOI DOI 10.1631/JZUS.C10B0359; Schrag SJ, 2001, JAMA-J AM MED ASSOC, V286, P49, DOI 10.1001/jama.286.1.49; Schuler CL, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-1223; Singh N, 2000, AM J RESP CRIT CARE, V162, P505, DOI 10.1164/ajrccm.162.2.9909095; Tamma PD, 2017, JAMA INTERN MED, V177, P1308, DOI 10.1001/jamainternmed.2017.1938; Uranga A, 2016, JAMA INTERN MED, V176, P1257, DOI 10.1001/jamainternmed.2016.3633; Vassallo A, 2014, EXPERT REV ANTI-INFE, V12, P1087, DOI 10.1586/14787210.2014.942284; Vaughn VM, 2019, CLIN INFECT DIS, V69, P1269, DOI 10.1093/cid/ciy1102; Vaughn VM, 2016, ANN INTERN MED, V165, pHO2, DOI 10.7326/M16-2043; Yi SH, 2018, CLIN INFECT DIS, V66, P1333, DOI 10.1093/cid/cix986	41	87	87	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 6	2019	171	3					153	+		10.7326/M18-3640	http://dx.doi.org/10.7326/M18-3640			21	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IN6RQ	31284301				2023-01-03	WOS:000478809000002
J	Lea, M; Mowe, M; Mathiesen, L; Kvernrod, K; Skovlund, E; Molden, E				Lea, Marianne; Mowe, Morten; Mathiesen, Liv; Kvernrod, Kristin; Skovlund, Eva; Molden, Espen			Prevalence and risk factors of drug-related hospitalizations in multimorbid patients admitted to an internal medicine ward	PLOS ONE			English	Article							INAPPROPRIATE MEDICATION; CREATININE CLEARANCE; ELDERLY-PATIENTS; PRIMARY-CARE; ADMISSIONS; EVENTS; POPULATION; PEOPLE; FREQUENCY	Background Knowledge of risk factors for drug-related hospitalizations (DRHs) is limited. Aim To examine the prevalence of DRHs and the relationships between DRHs and various variables in multimorbid patients admitted to an internal medicine ward. Methods Multimorbid patients >= 18 years, using minimum of four regular drugs from minimum two therapeutic classes, were included from the Internal Medicine ward, Oslo University Hospital, Norway, from August 2014 to March 2016. Clinical pharmacists prospectively conducted medicines reconciliations and reviews to reveal drug-related problems (DRPs). Blinded for identified DRPs, an interdisciplinary group retrospectively made comprehensive, clinical assessments of each patient case to classify hospitalizations as drug-related (DRH) or nondrug- related (non-DRH). Age, sex distribution, Charlson Comorbidity Index (CCI), renal function, aberrant genotype frequencies, body-mass index, number of drugs, proportion of patients which received assistance for drug administration from the home care service, and/ or through multidose-dispensed drugs, and occurrence of specific DRP subgroups, were compared separately between patients with DRHs versus non-DRHs, followed by multiple logistic regression analysis. Results Hospitalizations were classified as drug-related in 155 of the 404 included patients (38%). Factors significantly associated with DRHs were occurrence of adverse effect DRPs adjusted odds ratio (OR) 3.3, 95% confidence interval (CI) 1.4-8.0), adherence issues (OR 2.9, 1.1-7.2), home care (OR 1.9, 1.1-3.5), drug monitoring DRPs (OR 1.9, 1.2-3.0), and CCI score. 6 (OR 0.33, 0.14-0.77). Frequencies of aberrant genotypes did not differ between the patient groups, but in 41 patients with DRHs (26.5%), gene-drug interactions influenced the assessments of DRHs. Conclusion DRHs are prevalent in multimorbid patients with adverse effect DRPs and adherence issues as the most important risk factors.	[Lea, Marianne; Kvernrod, Kristin] Oslo Hosp Pharm, Hosp Pharm Enterprise, Dept Pharmaceut Serv, South Eastern Norway, Oslo, Norway; [Mowe, Morten] Oslo Univ Hosp, Med Clin, Gen Internal Med Ward, Oslo, Norway; [Mowe, Morten] Univ Oslo, Fac Med, Oslo, Norway; [Mathiesen, Liv] South Eastern Norway, Hosp Pharm Enterprise, Oslo, Norway; [Mathiesen, Liv; Molden, Espen] Univ Oslo, Dept Pharm, Sect Pharmacol & Pharmaceut Biosci, Oslo, Norway; [Skovlund, Eva] Norwegian Univ Sci & Technol, Fac Med & Hlth Sci, Dept Publ Hlth & Nursing, NTNU, Trondheim, Norway; [Molden, Espen] Diakonhjemmet Hosp, Ctr Psychopharmacol, Oslo, Norway	University of Oslo; University of Oslo; Norwegian University of Science & Technology (NTNU); Diakonhjemmet Hospital	Lea, M (corresponding author), Oslo Hosp Pharm, Hosp Pharm Enterprise, Dept Pharmaceut Serv, South Eastern Norway, Oslo, Norway.	marianne.lea@sykehusapotekene.no	Mathiesen, Liv/AAI-1095-2020	Mathiesen, Liv/0000-0002-6598-2215	South-Eastern Norway Regional Health Authority [12/00718]; Hospital Pharmacies Enterprise, South Eastern Norway; Oslo University Hospital; Diakonhjemmet Hospital	South-Eastern Norway Regional Health Authority; Hospital Pharmacies Enterprise, South Eastern Norway; Oslo University Hospital; Diakonhjemmet Hospital	The study was funded by South-Eastern Norway Regional Health Authority (PhD grant number 12/00718 to author ML, https://www.helse-sorost.no/south-eastern-norway-regionalhealth-authority), Hospital Pharmacies Enterprise, South Eastern Norway (https://sykehusapotekene.no/), Oslo University Hospital (https://oslouniversitetssykehus.no/oslo-university-hospital) and Diakonhjemmet Hospital (http://diakonhjemmetsykehus.no/#!/diakon/forside/omsykehuset/brief-information-in-english).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al Hamid A, 2014, BRIT J CLIN PHARMACO, V78, P202, DOI 10.1111/bcp.12293; Alassaad A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111797; Alexopoulou A, 2008, EUR J INTERN MED, V19, P505, DOI 10.1016/j.ejim.2007.06.030; Aubert CE, 2016, EUR J INTERN MED, V35, P35, DOI 10.1016/j.ejim.2016.05.022; Bao YH, 2012, J GEN INTERN MED, V27, P304, DOI 10.1007/s11606-011-1905-4; Blix HS, 2004, EUR J CLIN PHARMACOL, V60, P651, DOI 10.1007/s00228-004-0830-4; Brody AA, 2016, J AM GERIATR SOC, V64, pE166, DOI 10.1111/jgs.14457; Cassell A, 2018, BRIT J GEN PRACT, V68, pE245, DOI 10.3399/bjgp18X695465; Chan A, 2014, SUPPORT CARE CANCER, V22, P1875, DOI 10.1007/s00520-014-2160-0; Chan M, 2001, INTERN MED J, V31, P199, DOI 10.1046/j.1445-5994.2001.00044.x; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cheng PY, 2001, CURR DRUG METAB, V2, P165, DOI 10.2174/1389200013338676; Claydon-Platt K, 2012, DIABETES RES CLIN PR, V97, P223, DOI 10.1016/j.diabres.2012.03.003; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Easton KL, 2004, BRIT J CLIN PHARMACO, V57, P611, DOI 10.1111/j.1365-2125.2003.02052.x; Elliott LS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170905; Franciosa JA, 1999, CORONARY ARTERY DIS, V10, P369, DOI 10.1097/00019501-199909000-00004; Glynn LG, 2011, FAM PRACT, V28, P516, DOI 10.1093/fampra/cmr013; Griese-Mammen N, 2018, INT J CLIN PHARM-NET, V40, P1199, DOI 10.1007/s11096-018-0696-7; Gustafsson M, 2016, EUR J CLIN PHARMACOL, V72, P1143, DOI 10.1007/s00228-016-2084-3; Howard RL, 2007, BRIT J CLIN PHARMACO, V63, P136, DOI 10.1111/j.1365-2125.2006.02698.x; Hubbard RE, 2008, EUR J CLIN PHARMACOL, V64, P895, DOI 10.1007/s00228-008-0499-1; Jureviciene E, 2018, HEALTH POLICY, V122, P681, DOI 10.1016/j.healthpol.2018.03.003; Leendertse AJ, 2008, ARCH INTERN MED, V168, P1890, DOI 10.1001/archinternmed.2008.3; Lohman MC, 2017, J GEN INTERN MED, V32, P1301, DOI 10.1007/s11606-017-4157-0; Marcum ZA, 2012, J GERONTOL A-BIOL, V67, P867, DOI 10.1093/gerona/gls001; Mercer S., 2014, ABC MULTIMORBIDITY; Muth C, 2019, J INTERN MED, V285, P272, DOI 10.1111/joim.12842; Navickas R, 2015, EUR J INTERN MED, V26, P160, DOI 10.1016/j.ejim.2015.02.015; Nivya K, 2015, SAUDI PHARM J, V23, P1, DOI 10.1016/j.jsps.2013.05.006; Onder G, 2002, J AM GERIATR SOC, V50, P1962, DOI 10.1046/j.1532-5415.2002.50607.x; Oscanoa TJ, 2017, EUR J CLIN PHARMACOL, V73, P759, DOI 10.1007/s00228-017-2225-3; Pattanaik S, 2009, BRIT J CLIN PHARMACO, V67, P363, DOI 10.1111/j.1365-2125.2008.03346.x; Pedros C, 2014, EUR J CLIN PHARMACOL, V70, P361, DOI 10.1007/s00228-013-1630-5; Peyriere H, 2003, ANN PHARMACOTHER, V37, P5, DOI 10.1345/aph.1C126; Philips BJ, 2014, EXPERT OPIN DRUG MET, V10, P11, DOI 10.1517/17425255.2013.835802; Picker D, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0950-9; SALAZAR DE, 1988, AM J MED, V84, P1053, DOI 10.1016/0002-9343(88)90310-5; Samoy LJ, 2006, PHARMACOTHERAPY, V26, P1578, DOI 10.1592/phco.26.11.1578; Schneeweiss S, 2002, EUR J CLIN PHARMACOL, V58, P285, DOI 10.1007/s00228-002-0467-0; Schwab C, 2018, J CLIN PHARM THER, V43, P393, DOI 10.1111/jcpt.12670; Scullin C, 2007, J EVAL CLIN PRACT, V13, P781, DOI 10.1111/j.1365-2753.2006.00753.x; Sehgal Vishal, 2013, J Family Med Prim Care, V2, P194, DOI 10.4103/2249-4863.117423; Smith SM, 2010, BRIT J GEN PRACT, V60, DOI 10.3399/bjgp10X514756; Sondergaard E, 2015, SCAND J PRIM HEALTH, V33, P121, DOI 10.3109/02813432.2015.1041828; Uijen Annemarie A, 2008, Eur J Gen Pract, V14 Suppl 1, P28, DOI 10.1080/13814780802436093; Varga S, 2017, BRIT J CLIN PHARMACO, V83, P2572, DOI 10.1111/bcp.13365; Warwick J, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0328-1; Winterstein AG, 2002, ANN PHARMACOTHER, V36, P1238, DOI 10.1345/aph.1A225; Zhang M, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a2752	50	10	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2019	14	7							e0220071	10.1371/journal.pone.0220071	http://dx.doi.org/10.1371/journal.pone.0220071			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4UB	31329634	Green Published, gold, Green Submitted			2023-01-03	WOS:000484974100045
J	Davis, ID; Martin, AJ; Stockler, MR; Begbie, S; Chi, KN; Chowdhury, S; Coskinas, X; Frydenberg, M; Hague, WE; Horvath, LG; Joshua, AM; Lawrence, NJ; Marx, G; McCaffrey, J; McDermott, R; McJannett, M; North, SA; Parnis, F; Parulekar, W; Pook, DW; Reaume, MN; Sandhu, SK; Tan, A; Tan, TH; Thomson, A; Tu, E; Vera-Badillo, F; Williams, SG; Yip, S; Zhang, AY; Zielinski, RR; Sweeney, CJ				Davis, Ian D.; Martin, Andrew J.; Stockler, Martin R.; Begbie, Stephen; Chi, Kim N.; Chowdhury, Simon; Coskinas, Xanthi; Frydenberg, Mark; Hague, Wendy E.; Horvath, Lisa G.; Joshua, Anthony M.; Lawrence, Nicola J.; Marx, Gavin; McCaffrey, John; McDermott, Ray; McJannett, Margaret; North, Scott A.; Parnis, Francis; Parulekar, Wendy; Pook, David W.; Reaume, M. Neil; Sandhu, Shahneen K.; Tan, Alvin; Tan, T. Hsiang; Thomson, Alastair; Tu, Emily; Vera-Badillo, Francisco; Williams, Scott G.; Yip, Sonia; Zhang, Alison Y.; Zielinski, Robert R.; Sweeney, Christopher J.		ENZAMET Trial Investigators; Australian New Zealand Urogenital	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOCETAXEL; MITOXANTRONE; SURVIVAL	Background Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men with castration-resistant prostate cancer. It is not known whether adding enzalutamide to testosterone suppression, with or without early docetaxel, will improve survival in men with metastatic, hormone-sensitive prostate cancer. Methods In this open-label, randomized, phase 3 trial, we assigned patients to receive testosterone suppression plus either open-label enzalutamide or a standard nonsteroidal antiandrogen therapy (standard-care group). The primary end point was overall survival. Secondary end points included progression-free survival as determined by the prostate-specific antigen (PSA) level, clinical progression-free survival, and adverse events. Results A total of 1125 men underwent randomization; the median follow-up was 34 months. There were 102 deaths in the enzalutamide group and 143 deaths in the standard-care group (hazard ratio, 0.67; 95% confidence interval [CI], 0.52 to 0.86; P=0.002). Kaplan-Meier estimates of overall survival at 3 years were 80% (based on 94 events) in the enzalutamide group and 72% (based on 130 events) in the standard-care group. Better results with enzalutamide were also seen in PSA progression-free survival (174 and 333 events, respectively; hazard ratio, 0.39; P<0.001) and in clinical progression-free survival (167 and 320 events, respectively; hazard ratio, 0.40; P<0.001). Treatment discontinuation due to adverse events was more frequent in the enzalutamide group than in the standard-care group (33 events and 14 events, respectively). Fatigue was more common in the enzalutamide group; seizures occurred in 7 patients in the enzalutamide group (1%) and in no patients in the standard-care group. Conclusions Enzalutamide was associated with significantly longer progression-free and overall survival than standard care in men with metastatic, hormone-sensitive prostate cancer receiving testosterone suppression. The enzalutamide group had a higher incidence of seizures and other toxic effects, especially among those treated with early docetaxel. (Funded by Astellas Scientific and Medical Affairs and others; ENZAMET (ANZUP 1304) ANZCTR number, ; ClinicalTrials.gov number, ; and EU Clinical Trials Register number, .)	[Davis, Ian D.; Frydenberg, Mark; Pook, David W.] Monash Univ, Melbourne, Vic, Australia; [Davis, Ian D.] Eastern Hlth, Melbourne, Vic, Australia; [Frydenberg, Mark] Australian Urol Associates, Melbourne, Vic, Australia; [Pook, David W.] Monash Hlth, Melbourne, Vic, Australia; [Sandhu, Shahneen K.; Williams, Scott G.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Sandhu, Shahneen K.; Williams, Scott G.] Univ Melbourne, Melbourne, Vic, Australia; [Martin, Andrew J.; Stockler, Martin R.; Coskinas, Xanthi; Hague, Wendy E.; Tu, Emily; Yip, Sonia; Zhang, Alison Y.] Univ Sydney, Natl Hlth & Med Res Council Clin Trials Ctr, Sydney, NSW, Australia; [Stockler, Martin R.; Horvath, Lisa G.; Zhang, Alison Y.] Chris OBrien Lifehouse, Sydney, NSW, Australia; [Horvath, Lisa G.; Marx, Gavin] Univ Sydney, Sydney, NSW, Australia; [Horvath, Lisa G.] Royal Prince Alfred Hosp, Sydney, NSW, Australia; [Joshua, Anthony M.] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia; [Joshua, Anthony M.] Garvan Inst Med Res, Sydney, NSW, Australia; [Zhang, Alison Y.] Macquarie Univ, Sydney, NSW, Australia; [Zielinski, Robert R.] Western Sydney Univ, Sydney, NSW, Australia; [Stockler, Martin R.] Concord Repatriat Gen Hosp, Concord Canc Ctr, Concord, NSW, Australia; [Begbie, Stephen] Port Macquarie Base Hosp, Port Macquarie, NSW, Australia; [Begbie, Stephen] Mid North Coast Canc Inst Port Macquarie, Port Macquarie, NSW, Australia; [Marx, Gavin] Sydney Adventist Hosp, Wahroonga, NSW, Australia; [McJannett, Margaret] ANZUP Canc Trials Grp, Camperdown, NSW, Australia; [Parnis, Francis] Adelaide Canc Ctr, Adelaide, SA, Australia; [Parnis, Francis] Univ Adelaide, Adelaide, SA, Australia; [Tan, T. Hsiang] Royal Adelaide Hosp, Adelaide, SA, Australia; [Zielinski, Robert R.] Cent West Canc Care Ctr, Orange Hlth Serv, Orange, NSW, Australia; [Chi, Kim N.] BC Canc, Vancouver, BC, Canada; [Chi, Kim N.] Univ British Columbia, Vancouver, BC, Canada; [North, Scott A.] Cross Canc Inst, Edmonton, AB, Canada; [North, Scott A.] Univ Alberta, Edmonton, AB, Canada; [Parulekar, Wendy; Vera-Badillo, Francisco] Queens Univ, Canadian Canc Trials Grp, Kingston, ON, Canada; [Vera-Badillo, Francisco] Kingston Hlth Sci Ctr, Kingston, ON, Canada; [Reaume, M. Neil] Univ Ottawa, Ottawa, ON, Canada; [Reaume, M. Neil] Ottawa Hosp Res Inst, Ottawa, ON, Canada; [Chowdhury, Simon] Guys & St Thomas NHS Fdn Trust, Biomed Res Ctr, Canc Res UK, London, England; [Chowdhury, Simon] Kings Coll London, London, England; [Chowdhury, Simon] Sarah Cannon Res UK, London, England; [Thomson, Alastair] Royal Cornwall Hosp, Truro, England; [Lawrence, Nicola J.] Auckland City Hosp, Auckland, New Zealand; [Tan, Alvin] Waikato Dist Hlth Board, Hamilton, New Zealand; [McCaffrey, John; McDermott, Ray] Canc Trials Ireland, Dublin, Ireland; [McCaffrey, John] Mater Misericordiae Univ Hosp, Dublin, Ireland; [McDermott, Ray] St Vincents Univ Hosp, Dublin, Ireland; [McDermott, Ray] Univ Coll Dublin, Dublin, Ireland; [Sweeney, Christopher J.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Sweeney, Christopher J.] Harvard Med Sch, Boston, MA 02115 USA	Monash University; Peter Maccallum Cancer Center; University of Melbourne; University of Sydney; University of Sydney; University of Sydney; University of Sydney; St Vincents Hospital Sydney; Garvan Institute of Medical Research; Macquarie University; Western Sydney University; Concord Repatriation General Hospital; Sydney Adventist Hospital; University of Adelaide; Royal Adelaide Hospital; University of British Columbia; University of Alberta; University of Alberta; Queens University - Canada; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Royal Cornwall Hospital; Auckland City Hospital; Mater Misericordiae University Hospital; University College Dublin; University College Dublin; Saint Vincent's University Hospital; University College Dublin; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Davis, ID (corresponding author), Level 2,5 Arnold St, Box Hill, Vic 3128, Australia.	ian.davis@monash.edu	Reaume, Martin/AAA-2621-2021; Coskinas, Xanthi/GYV-5271-2022; Davis, Ian D/A-1430-2012	Davis, Ian D/0000-0002-9066-8244; McDermott, Ray/0000-0002-8952-4315; Sandhu, Shahneen/0000-0002-8660-4475; Zhang, Alison/0000-0002-1902-6863; Joshua, Anthony/0000-0001-5159-4580; Horvath, Lisa/0000-0001-6842-9223; North, scott/0000-0003-4427-5439; Martin, Andrew/0000-0001-5804-2295; Morris, Michelle/0000-0002-0246-0786; Pook, David/0000-0002-1744-3022	Astellas Scientific and Medical Affairs; ENZAMET ANZCTR [ANZUP 1304, ACTRN12614000110684]; EU	Astellas Scientific and Medical Affairs; ENZAMET ANZCTR; EU(European Commission)	Funded by Astellas Scientific and Medical Affairs and others; ENZAMET (ANZUP 1304) ANZCTR number, ACTRN12614000110684; ClinicalTrials.gov number, NCT02446405; and EU Clinical Trials Register number, 2014-003190-42.	Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Berthold DR, 2008, ANN ONCOL, V19, P1749, DOI 10.1093/annonc/mdn288; Dalesio O, 2000, LANCET, V355, P1491; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Fizazi K, 2017, NEW ENGL J MED, V377, P352, DOI 10.1056/NEJMoa1704174; Gravis G, 2018, EUR UROL, V73, P847, DOI 10.1016/j.eururo.2018.02.001; Gravis G, 2016, EUR UROL, V70, P256, DOI 10.1016/j.eururo.2015.11.005; Gravis G, 2013, LANCET ONCOL, V14, P149, DOI 10.1016/S1470-2045(12)70560-0; Hoyle AP, 2018, ANN ONCOL, V29, P722; James ND, 2017, NEW ENGL J MED, V377, P338, DOI 10.1056/NEJMoa1702900; James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140-6736(15)01037-5; Kyriakopoulos CE, 2018, J CLIN ONCOL, V36, P1080, DOI 10.1200/JCO.2017.75.3657; Piccirillo JF, 2004, JAMA-J AM MED ASSOC, V291, P2441, DOI 10.1001/jama.291.20.2441; POCOCK SJ, 1989, CONTROL CLIN TRIALS, V10, pS209; Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747; Sydes MR, 2018, ANN ONCOL, V29, P1235, DOI 10.1093/annonc/mdy072; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Vale CL, 2016, LANCET ONCOL, V17, P243, DOI 10.1016/S1470-2045(15)00489-1	20	609	618	7	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 11	2019	381	2					121	131		10.1056/NEJMoa1903835	http://dx.doi.org/10.1056/NEJMoa1903835			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IJ1ON	31157964	Bronze			2023-01-03	WOS:000475668100007
J	Lopez-Maya, E; Olmstead, R; Irwin, MR				Lopez-Maya, Eric; Olmstead, Richard; Irwin, Michael R.			Mindfulness meditation and improvement in depressive symptoms among Spanish- and English speaking adults: A randomized, controlled, comparative efficacy trial	PLOS ONE			English	Article							BREAST-CANCER SURVIVORS; COGNITIVE-BEHAVIORAL THERAPY; LATE-LIFE INSOMNIA; TAI CHI; PSYCHOMETRIC PROPERTIES; INFLAMMATION; STRESS; INVENTORY; ACCULTURATION; AMERICAN	Objective Latino immigrants experience acculturative stress and increased depression risk. Mindfulness meditation improves depressive symptoms, yet the vast majority of research has focused on English speaking populations. Methods In this randomized clinical trial with 2 parallel treatment groups, adults with moderate levels of perceived stress (n = 76) were recruited from the Los Angeles community from October 2015 to March 2016, stratified into Spanish- (n = 36) and English speaking (n = 40) language groups, and randomized for 6 weeks of treatment with standardized mindful awareness practices (MAPs) or health education (HE). Main outcome measure was depressive symptoms, measured by the Beck Depression Inventory. Results Using an intent-to-treat analysis, the primary outcome, depressive symptoms as indexed by the Beck Depression Inventory, showed greater improvement in MAPs vs. HE, with a between-group post-intervention mean difference of -2.2 (95% CI -4.4 - -0.07) and effect size of 0.28; similar effect sizes were found in the the Spanish- (0.29) and English speaking (0.30) groups. MAPs showed significant improvement relative to HE on secondary outcome of mindfulness with between group difference of 10.7 (95% CI4.5-16.9), but not perceived stress. Conclusion The comparable efficacy of Spanish and English formats of mindfulness meditation in improving depressive symptoms suggests that this community based intervention may mitigate depression risk in Latino adults who are experiencing social adversity.	[Lopez-Maya, Eric; Olmstead, Richard; Irwin, Michael R.] Univ Calif Los Angeles, Geffen Sch Med, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav,Mindful Awarene, Los Angeles, CA 90095 USA; [Lopez-Maya, Eric; Olmstead, Richard; Irwin, Michael R.] Univ Calif Los Angeles, Geffen Sch Med, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav,Cousins Ctr Psy, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Irwin, MR (corresponding author), Univ Calif Los Angeles, Geffen Sch Med, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav,Mindful Awarene, Los Angeles, CA 90095 USA.	mirwin1@ucla.edu	Irwin, Michael/H-4870-2013	Irwin, Michael/0000-0002-1502-8431; Lopez-Maya, Eric/0000-0003-1978-0302	Petit Foundation; Mindful Awareness Research Center at the UCLA Semel Institute; Mexican National Council for Science and Technology (CONACYT)	Petit Foundation; Mindful Awareness Research Center at the UCLA Semel Institute; Mexican National Council for Science and Technology (CONACYT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	The funding for this study was provided by Petit Foundation to MRI; Mindful Awareness Research Center at the UCLA Semel Institute to MRI; and Mexican National Council for Science and Technology (CONACYT) to EL.	Alegria M, 2007, AM J PUBLIC HEALTH, V97, P68, DOI 10.2105/AJPH.2006.087205; Azocar F, 2001, J CLIN PSYCHOL, V57, P355, DOI 10.1002/jclp.1017; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Berry JW, 2006, INT CUL PSY, P287; Black DS, 2015, JAMA INTERN MED, V175, P494, DOI 10.1001/jamainternmed.2014.8081; Bohlmeijer E, 2011, ASSESSMENT, V18, P308, DOI 10.1177/1073191111408231; Bower JE, 2016, BRAIN BEHAV IMMUN, V51, P1, DOI 10.1016/j.bbi.2015.06.012; Bower JE, 2015, CANCER-AM CANCER SOC, V121, P1231, DOI 10.1002/cncr.29194; Bower JE, 2014, PSYCHONEUROENDOCRINO, V43, P20, DOI 10.1016/j.psyneuen.2014.01.019; BROWN C, 1995, PSYCHOL ASSESSMENT, V7, P59; Brown KW, 2003, J PERS SOC PSYCHOL, V84, P822, DOI 10.1037/0022-3514.84.4.822; BUMBERRY W, 1978, J CONSULT CLIN PSYCH, V46, P150, DOI 10.1037/0022-006X.46.1.150; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Cobb CL, 2017, CULT DIVERS ETHN MIN, V23, P258, DOI 10.1037/cdp0000118; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Farley Tillman, 2005, J Immigr Health, V7, P213, DOI 10.1007/s10903-005-3678-5; Fournier JC, 2010, JAMA-J AM MED ASSOC, V303, P47, DOI 10.1001/jama.2009.1943; FRANCESCHI C, 2014, J GERONTOL A BIOL S1, V69, pS4, DOI [10.1093/gerona/glu057, DOI 10.1093/GER0NA/GLU057, DOI 10.1093/GERONA/GLU057]; Fuligni AJ, 2009, BRAIN BEHAV IMMUN, V23, P803, DOI 10.1016/j.bbi.2009.02.021; Fuligni AJ, 2009, PSYCHOSOM MED, V71, P329, DOI 10.1097/PSY.0b013e3181921b1f; Garcia-Campayo J, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01161; Goyal M, 2014, JAMA INTERN MED, V174, P357, DOI 10.1001/jamainternmed.2013.13018; Irwin MR, 2017, J CLIN ONCOL, V35, P2656, DOI 10.1200/JCO.2016.71.0285; Irwin MR, 2015, BIOL PSYCHIAT, V78, P721, DOI 10.1016/j.biopsych.2015.01.010; Irwin Michael R., 2014, Journal of the National Cancer Institute Monographs, P295, DOI 10.1093/jncimonographs/lgu028; Irwin MR, 2014, SLEEP, V37, P1543, DOI 10.5665/sleep.4008; Irwin MR, 2011, NAT REV IMMUNOL, V11, P625, DOI 10.1038/nri3042; KENDLER KS, 1995, AM J PSYCHIAT, V152, P833; Kennedy BK, 2014, CELL, V159, P708, DOI 10.1016/j.cell.2014.10.039; Kiecolt-Glaser JK, 2014, J CLIN ONCOL, V32, P1040, DOI 10.1200/JCO.2013.51.8860; Lorenzo-Blanco EI, 2012, J YOUTH ADOLESCENCE, V41, P1350, DOI 10.1007/s10964-012-9774-7; Manotas M, 2014, INT J STRESS MANAGE, V21, P207, DOI 10.1037/a0035150; Mazure CM, 1998, CLIN PSYCHOL-SCI PR, V5, P291, DOI 10.1111/j.1468-2850.1998.tb00151.x; Miller AH, 2016, NAT REV IMMUNOL, V16, P22, DOI 10.1038/nri.2015.5; Morgan N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100903; Nair RL, 2018, J YOUTH ADOLESCENCE, V47, P105, DOI 10.1007/s10964-017-0753-x; Proulx J, 2018, MINDFULNESS, V9, P361, DOI 10.1007/s12671-017-0785-z; Raison CL, 2013, JAMA PSYCHIAT, V70, P31, DOI 10.1001/2013.jamapsychiatry.4; Romero A.J., 2017, OXFORD HDB ACCULTURA, P119, DOI [10.1093/oxfordhb/9780190215217.013.8, DOI 10.1093/OXFORDHB/9780190215217.013.8]; Ryan D, 2018, J BEHAV HEALTH SER R, V45, P280, DOI 10.1007/s11414-017-9582-7; Slavich GM, 2014, PSYCHOL BULL, V140, P774, DOI 10.1037/a0035302; Smalley S.L., 2010, FULLY PRESENT SCI AR; Steiger JH, 2004, PSYCHOL METHODS, V9, P164, DOI 10.1037/1082-989X.9.2.164	43	10	10	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 5	2019	14	7							e0219425	10.1371/journal.pone.0219425	http://dx.doi.org/10.1371/journal.pone.0219425			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4FP	31276540	Green Submitted, Green Published, gold			2023-01-03	WOS:000484936300077
J	Steenland, MW; Pace, LE; Sinaiko, AD; Cohen, JL				Steenland, Maria W.; Pace, Lydia E.; Sinaiko, Anna D.; Cohen, Jessica L.			Association Between South Carolina Medicaid's Change in Payment for Immediate Post partum Long-cActing Reversible Contraception and Birth Intervals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Steenland, Maria W.] Brown Univ, Populat Studies & Training Ctr, 68 Waterman St, Providence, RI 02912 USA; [Pace, Lydia E.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Sinaiko, Anna D.] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA; [Cohen, Jessica L.] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA USA	Brown University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Steenland, MW (corresponding author), Brown Univ, Populat Studies & Training Ctr, 68 Waterman St, Providence, RI 02912 USA.	maria_steenland@brown.edu			Eric M. Mindich Research Fund for the Foundations of Human Behavior; National Institutes of Health (NIH) [T32 HD007338]; NIH [P2C HD041020]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P2CHD041020, T32HD007338] Funding Source: NIH RePORTER	Eric M. Mindich Research Fund for the Foundations of Human Behavior; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	The Eric M. Mindich Research Fund for the Foundations of Human Behavior provided funding to acquire the data used in this study. Dr Steenland was supported by National Institutes of Health (NIH) training grant T32 HD007338 and by other NIH support (P2C HD041020).	Ahrens KA, 2019, PAEDIATR PERINAT EP, V33, pO25, DOI 10.1111/ppe.12503; American College of Obstetricians and Gynecologists Committee on Obstetric Practice, 2016, Obstet Gynecol, V128, pe32, DOI 10.1097/AOG.0000000000001587; Moniz M. H., 2018, REIMBURSEMENT IMMEDI; Wachino V, 2016, STATE MED PAYMENT AP; White K, 2015, OBSTET GYNECOL, V125, P1471, DOI 10.1097/AOG.0000000000000841	5	18	18	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	2019	322	1					76	78		10.1001/jama.2019.6854	http://dx.doi.org/10.1001/jama.2019.6854			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IH7AA	31158852	Bronze, Green Published			2023-01-03	WOS:000474655200023
J	Sasaki, K; Ben Othman, M; Ferdousi, F; Yoshida, M; Watanabe, M; Tominaga, K; Isoda, H				Sasaki, Kazunori; Ben Othman, Mahmoud; Ferdousi, Farhana; Yoshida, Masaki; Watanabe, Makoto; Tominaga, Kenichi; Isoda, Hiroko			Modulation of the neurotransmitter systems through the anti-inflammatory and antidepressant-like effects of squalene from Aurantiochytrium sp.	PLOS ONE			English	Article							SEROTONERGIC NEUROTRANSMISSION; DOCOSAHEXAENOIC ACID; CHEMOKINE RECEPTORS; DEPRESSION; STRAIN; BDNF; DIFFERENTIATION; GLUTAMATE; 18W-13A; FEMALE	Although algae have been the focal point of biofuel research, studies on their biological activities have been limited. In recent years, however, the importance of algae as sources of functional ingredients has been recognized due to their health beneficial effects. In this study, we evaluated the antidepressant-like activities of ethanol extract of Aurantiochytrium sp. ( EEA) in the forced swimming test ( FST)-induced depression in ICR mice. Imipramine, a commercially available tricyclic antidepressant drug, was used as positive control. Animals were administered EEA orally for 14 consecutive days and were subjected to the locomotor activity testing. Additionally, changes in gene expression in mice brain were assessed by real-time PCR and microarray assays to understand the molecular mechanisms underlying the effect of EEA. We found that the immobility time in FST was significantly reduced in the EEA-treated mice compared to that of in the control mice. Microarray and real-time PCR results revealed that EEA treatment induced changes in several genes in mice brain associated with pro-inflammation and dopaminergic, cholinergic, glutamatergic, and serotonergic synapses. It has previously been reported that several cytokines, such as IL-6 and TNF-alpha, which mediate neuroinflammation, are also responsible for indirectly altering brain neurotransmitter levels in neuropsychiatric disorders. Therefore, the regulation of the expression of pro-inflammatory genes in EEA-administered mice brain is considered to contribute to the enhancement of neurotransmitter systems-related gene expression in our study. Moreover, our in vitro study suggested that squalene, a component produced by Aurantiochytrium, was one of the active substances in EEA. In conclusion, our study provides the first evidence that Aurantiochytrium sp. can reduce neuroinflammation that may contribute to the modulation of the neurotransmitter systems, which could underlie its antistress and antidepressant effects.	[Sasaki, Kazunori; Ben Othman, Mahmoud; Ferdousi, Farhana; Tominaga, Kenichi; Isoda, Hiroko] Univ Tsukuba, ARENA, Tsukuba, Ibaraki, Japan; [Sasaki, Kazunori; Isoda, Hiroko] Natl Inst Adv Ind Sci & Technol, Interdisciplinary Res Ctr Catalyt Chem, Tsukuba, Ibaraki, Japan; [Sasaki, Kazunori] Univ Tsukuba, Fac Pure & Appl Sci, Tsukuba, Ibaraki, Japan; [Yoshida, Masaki; Watanabe, Makoto] Univ Tsukuba, Algal Biomass & Energy Syst R&D Ctr ABES, Tsukuba, Ibaraki, Japan; [Yoshida, Masaki] Univ Tsukuba, Fac Life & Environm Sci, Tsukuba, Ibaraki, Japan	University of Tsukuba; National Institute of Advanced Industrial Science & Technology (AIST); University of Tsukuba; University of Tsukuba; University of Tsukuba	Isoda, H (corresponding author), Univ Tsukuba, ARENA, Tsukuba, Ibaraki, Japan.; Isoda, H (corresponding author), Natl Inst Adv Ind Sci & Technol, Interdisciplinary Res Ctr Catalyt Chem, Tsukuba, Ibaraki, Japan.	isoda.hiroko.ga@u.tsukuba.ac.jp		Ferdousi, Farhana/0000-0003-2816-9118; Isoda, Hiroko/0000-0002-1399-9541; Tominaga, Ken-ichi/0000-0002-6078-2169	Japan Science and Technology Agency (JST); Technology Research Partnership for Sustainable Development (SATREPS) [JPMJSA1506]	Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST)); Technology Research Partnership for Sustainable Development (SATREPS)	This study was partially supported by the Japan Science and Technology Agency (JST) and by the Technology Research Partnership for Sustainable Development (SATREPS) grant no. JPMJSA1506 to HI.	Adzic M, 2015, BEHAV BRAIN RES, V291, P130, DOI 10.1016/j.bbr.2015.05.029; Aguilera Y, 2005, EXP EYE RES, V80, P535, DOI 10.1016/j.exer.2004.11.003; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; Ben Othman M, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/737401; Can A, 2012, JOVE-J VIS EXP, DOI 10.3791/3638; Falkowski PG, 2004, SCIENCE, V305, P354, DOI 10.1126/science.1095964; Fehling Johanna, 2007, P75, DOI 10.1016/B978-012370518-1/50007-2; Fujii T, 1998, J NEUROIMMUNOL, V82, P101, DOI 10.1016/S0165-5728(97)00195-1; GRANDO SA, 1993, J INVEST DERMATOL, V101, P32, DOI 10.1111/1523-1747.ep12358588; Hlavacova N, 2018, PROG NEURO-PSYCHOPH, V82, P332, DOI 10.1016/j.pnpbp.2017.07.008; Huang D, 2018, GENES DIS; Kaur K, 2017, J NEUROL SCI, V381, P308, DOI 10.1016/j.jns.2017.08.3251; Kaya K, 2011, BIOSCI BIOTECH BIOCH, V75, P2246, DOI 10.1271/bbb.110430; Kelly G S, 1999, Altern Med Rev, V4, P29; KIM JS, 1982, ARCH PSYCHIAT NERVEN, V232, P299, DOI 10.1007/BF00345492; Liao L, 2017, INT IMMUNOPHARMACOL, V49, P178, DOI 10.1016/j.intimp.2017.05.036; Maes M, 1995, J AFFECT DISORDERS, V36, P29, DOI 10.1016/0165-0327(95)00049-6; Mao LM, 2010, NEURON, V67, P679, DOI 10.1016/j.neuron.2010.08.036; Massana R, 2006, ENVIRON MICROBIOL, V8, P1515, DOI 10.1111/j.1462-2920.2006.01042.x; Furlan VJM, 2017, BRAZ J MICROBIOL, V48, P359, DOI 10.1016/j.bjm.2017.01.001; MIETTINEN TA, 1994, AM J CLIN NUTR, V59, P356, DOI 10.1093/ajcn/59.2.356; Milledge JJ, 2011, REV ENVIRON SCI BIO, V10, P31, DOI 10.1007/s11157-010-9214-7; Miller AH, 2016, NAT REV IMMUNOL, V16, P22, DOI 10.1038/nri.2015.5; Nakazawa A, 2012, BIORESOURCE TECHNOL, V109, P287, DOI 10.1016/j.biortech.2011.09.127; Nunes SOV, 2002, BRAZ J MED BIOL RES, V35, P581, DOI 10.1590/S0100-879X2002000500011; Parada E, 2013, ANTIOXID REDOX SIGN, V19, P1135, DOI 10.1089/ars.2012.4671; PORSOLT RD, 1978, EUR J PHARMACOL, V51, P291, DOI 10.1016/0014-2999(78)90414-4; Qi F, 2017, BIORESOURCE TECHNOL, V227, P221, DOI 10.1016/j.biortech.2016.12.011; Ransohoff RM, 2007, INT REV NEUROBIOL, V82, P187, DOI 10.1016/S0074-7742(07)82010-1; Reichenberg A, 2001, BIOORG MED CHEM LETT, V11, P833, DOI 10.1016/S0960-894X(01)00075-0; Ren J, 2014, J BIOL CHEM, V289, P9013, DOI 10.1074/jbc.M113.515957; Revathikumar P, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0725-1; Richmond A., 2013, Handbook of microalgal culture: applied phycology and biotechnology; Sanacora G, 2004, ARCH GEN PSYCHIAT, V61, P705, DOI 10.1001/archpsyc.61.7.705; Sasaki K, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00900; Shabbir F, 2013, NEUROCHEM INT, V62, P324, DOI 10.1016/j.neuint.2012.12.014; Sijtsma L, 2004, APPL MICROBIOL BIOT, V64, P146, DOI 10.1007/s00253-003-1525-y; Skolnick P, 1996, PHARMACOPSYCHIATRY, V29, P23, DOI 10.1055/s-2007-979537; Stern RF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013991; STORM HM, 1993, LIPIDS, V28, P555, DOI 10.1007/BF02536088; Stuart MJ, 2014, NEUROSCI BIOBEHAV R, V42, P93, DOI 10.1016/j.neubiorev.2014.02.001; Stuart MJ, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00357; Sultana J, 2014, EUR J CLIN PHARMACOL, V70, P469, DOI 10.1007/s00228-013-1636-z; Sung M, 2018, BIORESOURCE TECHNOL, V261, P117, DOI 10.1016/j.biortech.2018.03.099; Takahashi S, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01205; Takahashi T, 2014, FEBS J, V281, P4672, DOI 10.1111/febs.12974; Toffali L, 2017, J IMMUNOL, V198, P708, DOI 10.4049/jimmunol.1600933; VENTIMIGLIA R, 1995, EUR J NEUROSCI, V7, P213, DOI 10.1111/j.1460-9568.1995.tb01057.x; World Health Organization, 2017, DEPR OTH COMM MENT D; Zhang XY, 2016, BRAIN BEHAV IMMUN, V51, P169, DOI 10.1016/j.bbi.2015.09.014	50	10	10	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2019	14	6							e0218923	10.1371/journal.pone.0218923	http://dx.doi.org/10.1371/journal.pone.0218923			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW3XM	31251788	Green Published, Green Submitted, gold			2023-01-03	WOS:000484915000030
J	Shatz, W; Hass, PE; Peer, N; Paluch, MT; Blanchette, C; Han, GH; Sandoval, W; Morando, A; Loyet, KM; Bantseev, V; Booler, H; Crowell, S; Kamath, A; Scheer, JM; Kelley, RF				Shatz, Whitney; Hass, Philip E.; Peer, Nikhil; Paluch, Maciej T.; Blanchette, Craig; Han, Guanghui; Sandoval, Wendy; Morando, Ashley; Loyet, Kelly M.; Bantseev, Vladimir; Booler, Helen; Crowell, Susan; Kamath, Amrita; Scheer, Justin M.; Kelley, Robert F.			Identification and characterization of an octameric PEG-protein conjugate system for intravitreal long-acting delivery to the back of the eye	PLOS ONE			English	Article							MACULAR DEGENERATION; PHARMACOKINETICS; RANIBIZUMAB; IMPAIRMENT; BLINDNESS	Innovative protein engineering and chemical conjugation technologies have yielded an impressive number of drug candidates in clinical development including > 80 antibody drug conjugates, > 60 bispecific antibodies, > 35 Fc-fusion proteins and > 10 immuno-cytokines. Despite these innovations, technological advances are needed to address unmet medical needs with new pharmacological mechanisms. Age-related eye diseases are among the most common causes of blindness and poor vision in the world. Many such diseases affect the back of the eye, where the inaccessibility of the site of action necessitates therapeutic delivery via intravitreal ( IVT) injection. Treatments administered via this route typically have vitreal half-lives < 10 days in humans, requiring frequent administration. Since IVT injection is burdensome to patients, there exists a strong need to develop therapeutics with prolonged residence time in the eye. We report here a strategy to increase retention of a therapeutic fragment antibody ( Fab) in the eye, using an anti-complement factor D Fab previously optimized for ocular delivery. Polyethylene glycol structures, varying in length, geometry and degree of branching, were coupled to the Fab via maleimide-activated termini. A screening strategy was developed to allow for key determinants of ocular half-life to be measured in vitro. After compound selection, a scalable process was established to enable tolerability and pharmacokinetic studies in cynomolgus monkeys, demonstrating an increase in vitreal half-life with no associated adverse events. Further, we show that the technique for compound selection, analytical characterization, and scalable production is general for a range of antibody fragments. The application of the technology has broad impact in across many therapeutic areas with the first major advancement in the treatment of an important ocular disease.	[Shatz, Whitney; Hass, Philip E.; Peer, Nikhil; Paluch, Maciej T.; Blanchette, Craig; Scheer, Justin M.] Genentech Inc, Prot Chem, San Francisco, CA 94080 USA; [Han, Guanghui; Sandoval, Wendy] Genentech Inc, Microchem Prote & Lipid, San Francisco, CA 94080 USA; [Morando, Ashley; Loyet, Kelly M.] Genentech Inc, Biochem & Cellular Pharmacol, San Francisco, CA 94080 USA; [Bantseev, Vladimir; Booler, Helen] Genentech Inc, Safety Assessment, San Francisco, CA 94080 USA; [Crowell, Susan; Kamath, Amrita] Genentech Inc, Preclin & Translat Pharmacokinet, San Francisco, CA 94080 USA; [Kelley, Robert F.] Genentech Inc, Drug Delivery, San Francisco, CA 94080 USA; [Peer, Nikhil] Genentech Inc, Purificat Dev, San Francisco, CA 94080 USA; [Han, Guanghui] BGI Amer, Mass Spectrometry Ctr, San Jose, CA USA; [Scheer, Justin M.] Boehringer Ingelheim GmbH & Co KG, Antibody Engn, Ridgefield, CT USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Boehringer Ingelheim	Shatz, W (corresponding author), Genentech Inc, Prot Chem, San Francisco, CA 94080 USA.	Shatz.whitney@gene.com	Loyet, Kelly/AAD-7544-2021; Han, Guanghui/N-8573-2013	Han, Guanghui/0000-0002-9893-9168; Loyet, Kelly M./0000-0002-3733-099X; Shatz-Binder, Whitney/0000-0003-2996-501X	Genentech	Genentech(Roche HoldingGenentech)	The study was funded by Genentech, which provided indirect support to the study in the form of salaries to authors: W.S., P. E.H., N.P., M.T.P., C.B., G.H., W.S., A.M., K.M.L., V.B., H.B., S.C., A.K., J.M.S., and R.F.K. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section.	ABUCHOWSKI A, 1984, CANCER BIOCHEM BIOPH, V7, P175; Aguirre SA, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-018-2450-1; Bantseev V, 2018, J OCUL PHARMACOL TH, V34, P204, DOI 10.1089/jop.2017.0063; Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X; Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140; Campagne MVL, COCRYSTAL STRUCTURE, P1; CDC (Centers for Disease Control and Prevention), 2011, SEX TRANSM DIS SURV; Ehlken C, 2018, CLIN OPHTHALMOL, V12, P11, DOI 10.2147/OPTH.S151611; Gadkar K, 2015, INVEST OPHTH VIS SCI, V56, P5390, DOI 10.1167/iovs.15-17108; Ghate Deepta, 2006, Expert Opin Drug Deliv, V3, P275, DOI 10.1517/17425247.3.2.275; Greenwald RB, 2003, ADV DRUG DELIVER REV, V55, P217, DOI 10.1016/S0169-409X(02)00180-1; Haller JA, 2011, OPHTHALMOLOGY, V118, P2453, DOI 10.1016/j.ophtha.2011.05.014; Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544; Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023; Jevsevar S, 2010, BIOTECHNOL J, V5, P113, DOI 10.1002/biot.200900218; Johnston RL, 2016, OPHTHALMOLOGY, V123, P2386, DOI 10.1016/j.ophtha.2016.07.037; Le KN, 2015, CPT-PHARMACOMET SYST, V4, P595, DOI 10.1002/psp4.12031; Loyet KM, 2014, J PHARMACOL EXP THER, V351, P527, DOI 10.1124/jpet.114.215921; Maurice D, 2001, J OCUL PHARMACOL TH, V17, P393, DOI 10.1089/108076801753162807; Miyake T, 2010, INVEST OPHTH VIS SCI, V51, P1606, DOI 10.1167/iovs.09-4140; Nucci ML, 1991, ADV DRUG DELIV REV; PEYMAN GA, 1975, DOC OPHTHALMOL, V39, P183, DOI 10.1007/BF00578762; Rajagopal K, 2013, J PHARM SCI-US, V102, P2655, DOI 10.1002/jps.23634; Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889; Rostron E, 2012, EYE, V26, P933, DOI 10.1038/eye.2012.61; Saylor M, 2009, ARCH OPHTHALMOL-CHIC, V127, P402, DOI 10.1001/archophthalmol.2009.9; Shatz W, 2019, EXPERT OPIN DRUG DEL, V16, P43, DOI 10.1080/17425247.2019.1553953; Shatz W, 2016, MOL PHARMACEUT, V13, P2996, DOI 10.1021/acs.molpharmaceut.6b00345; Tesar D, 2017, PROTEIN ENG INCREASE, V5, DOI [10.1080/19420862.2017.1372078, DOI 10.1080/19420862.2017.1372078]; Welp A, 2016, MAKING EYE HLTH POPU, DOI [10.17226/23471, DOI 10.17226/23471]; Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1; Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260; Zarzar J, 2018, BIOPHYS CHEM, V236, P22, DOI 10.1016/j.bpc.2017.10.003; Zhao H, 2008, BIOCONJUGATE CHEM, V19, P849, DOI 10.1021/bc700333s	34	19	20	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2019	14	6							e0218613	10.1371/journal.pone.0218613	http://dx.doi.org/10.1371/journal.pone.0218613			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW3XM	31251757	Green Published, gold, Green Submitted			2023-01-03	WOS:000484915000015
J	Zimmermann, M; Zimmermann-Kogadeeva, M; Wegmann, R; Goodman, AL				Zimmermann, Michael; Zimmermann-Kogadeeva, Maria; Wegmann, Rebekka; Goodman, Andrew L.			Mapping human microbiome drug metabolism by gut bacteria and their genes	NATURE			English	Article							CLOSTRIDIUM-SCINDENS; EXPRESSION; DILTIAZEM; PHARMACOKINETICS; DETERMINANTS; COMMENSALS; SYMBIONT; IMPACT	Individuals vary widely in their responses to medicinal drugs, which can be dangerous and expensive owing to treatment delays and adverse effects. Although increasing evidence implicates the gut microbiome in this variability, the molecular mechanisms involved remain largely unknown. Here we show, by measuring the ability of 76 human gut bacteria from diverse clades to metabolize 271 orally administered drugs, that many drugs are chemically modified by microorganisms. We combined high-throughput genetic analyses with mass spectrometry to systematically identify microbial gene products that metabolize drugs. These microbiome-encoded enzymes can directly and substantially affect intestinal and systemic drug metabolism in mice, and can explain the drug-metabolizing activities of human gut bacteria and communities on the basis of their genomic contents. These causal links between the gene content and metabolic activities of the microbiota connect interpersonal variability in microbiomes to interpersonal differences in drug metabolism, which has implications for medical therapy and drug development across multiple disease indications.	[Zimmermann, Michael; Zimmermann-Kogadeeva, Maria; Wegmann, Rebekka; Goodman, Andrew L.] Yale Univ, Sch Med, Dept Microbial Pathogenesis, 333 Cedar St, New Haven, CT 06520 USA; [Zimmermann, Michael; Zimmermann-Kogadeeva, Maria; Wegmann, Rebekka; Goodman, Andrew L.] Yale Univ, Sch Med, Microbial Sci Inst, 333 Cedar St, New Haven, CT 06520 USA; [Wegmann, Rebekka] Swiss Fed Inst Technol, Inst Mol Syst Biol, Dept Biol, Zurich, Switzerland	Yale University; Yale University; Swiss Federal Institutes of Technology Domain; ETH Zurich	Goodman, AL (corresponding author), Yale Univ, Sch Med, Dept Microbial Pathogenesis, 333 Cedar St, New Haven, CT 06520 USA.; Goodman, AL (corresponding author), Yale Univ, Sch Med, Microbial Sci Inst, 333 Cedar St, New Haven, CT 06520 USA.	andrew.goodman@yale.edu		Zimmermann-Kogadeeva, Maria/0000-0001-6021-1246; Zimmermann, Michael/0000-0002-5797-3589	NIH [GM118159, GM105456, AI124275, DK114793]; Center for Microbiome Informatics and Therapeutics; Burroughs Wellcome Fund; Yale Cancer Center; Swiss National Science Foundation [P2EZP3_162256, P300PA_177915]; European Molecular Biology Organization [ALTF 670-2016]; Early Postdoc Mobility Fellowship from the Swiss National Science Foundation [P2EZP3_178482]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI124275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK114793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [DP2GM105456, R35GM118159] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for Microbiome Informatics and Therapeutics; Burroughs Wellcome Fund(Burroughs Wellcome Fund); Yale Cancer Center; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); European Molecular Biology Organization(European Molecular Biology Organization (EMBO)); Early Postdoc Mobility Fellowship from the Swiss National Science Foundation(Swiss National Science Foundation (SNSF)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the Goodman laboratory for helpful discussions and N. A. Barry, L. Valle, D. Lazo, W. B. Schofield, P. H. Degnan, T. Wu and the Yale Center for Molecular Discovery for technical assistance. This work was supported by NIH grants GM118159, GM105456, AI124275, DK114793, the Center for Microbiome Informatics and Therapeutics, the Burroughs Wellcome Fund, the Yale Cancer Center, and the HHMI Faculty and Pew Scholars Programs to A.L.G. M.Z. received Early and Advanced Postdoc Mobility Fellowships from the Swiss National Science Foundation (P2EZP3_162256 and P300PA_177915, respectively) and a Long-Term Fellowship (ALTF 670-2016) from the European Molecular Biology Organization. M.Z.-K. received an Early Postdoc Mobility Fellowship from the Swiss National Science Foundation (P2EZP3_178482).	Aziz RK, 2018, EXPERT OPIN DRUG MET, V14, P1043, DOI 10.1080/17425255.2018.1530216; Bjorkholm B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006958; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; BOYD RA, 1989, CLIN PHARMACOL THER, V46, P408, DOI 10.1038/clpt.1989.159; Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Clayton TA, 2009, P NATL ACAD SCI USA, V106, P14728, DOI 10.1073/pnas.0904489106; Cullen TW, 2015, SCIENCE, V347, P170, DOI 10.1126/science.1260580; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Forsberg KJ, 2012, SCIENCE, V337, P1107, DOI 10.1126/science.1220761; Goodman AL, 2011, NAT PROTOC, V6, P1969, DOI 10.1038/nprot.2011.417; Goodman AL, 2011, P NATL ACAD SCI USA, V108, P6252, DOI 10.1073/pnas.1102938108; Goodman AL, 2009, CELL HOST MICROBE, V6, P279, DOI 10.1016/j.chom.2009.08.003; Haiser HJ, 2013, SCIENCE, V341, P295, DOI 10.1126/science.1235872; Holdeman L.V., 1975, ANAEROBE LAB MANUAL; Kaminski J, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004557; Klatt NR, 2017, SCIENCE, V356, P938, DOI 10.1126/science.aai9383; Koropatkin NM, 2008, STRUCTURE, V16, P1105, DOI 10.1016/j.str.2008.03.017; Lim B, 2017, CELL, V169, P547, DOI 10.1016/j.cell.2017.03.045; Maier L, 2018, NATURE, V555, P623, DOI 10.1038/nature25979; McIver LJ, 2018, BIOINFORMATICS, V34, P1235, DOI 10.1093/bioinformatics/btx754; Molden E, 2002, DRUG METAB DISPOS, V30, P1, DOI 10.1124/dmd.30.1.1; MORRIS GN, 1985, INT J SYST BACTERIOL, V35, P478, DOI 10.1099/00207713-35-4-478; Obach RS, 2013, PHARMACOL REV, V65, P578, DOI 10.1124/pr.111.005439; Okuda H, 1998, J PHARMACOL EXP THER, V287, P791; Petersen TN, 2011, NAT METHODS, V8, P785, DOI 10.1038/nmeth.1701; Ridlon JM, 2013, J LIPID RES, V54, P2437, DOI 10.1194/jlr.M038869; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sousa T, 2014, J PHARM SCI-US, V103, P3171, DOI 10.1002/jps.24103; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suzek BE, 2015, BIOINFORMATICS, V31, P926, DOI 10.1093/bioinformatics/btu739; Truong DT, 2015, NAT METHODS, V12, P902, DOI 10.1038/nmeth.3589; Wallace BD, 2010, SCIENCE, V330, P831, DOI 10.1126/science.1191175; Warrens AN, 1997, GENE, V186, P29, DOI 10.1016/S0378-1119(96)00674-9; Whitaker WR, 2017, CELL, V169, P538, DOI 10.1016/j.cell.2017.03.041; Wilson ID, 2017, TRANSL RES, V179, P204, DOI 10.1016/j.trsl.2016.08.002; WINTER J, 1984, J LIPID RES, V25, P1124; Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037; Wu H, 2017, NAT MED, V23, P850, DOI 10.1038/nm.4345; YEUNG PKF, 1993, EUR J DRUG METAB PH, V18, P199, DOI 10.1007/BF03188796; Zimmermann M, 2019, SCIENCE, V363, P600, DOI 10.1126/science.aat9931	41	393	406	24	378	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 27	2019	570	7762					462	+		10.1038/s41586-019-1291-3	http://dx.doi.org/10.1038/s41586-019-1291-3			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IF1TD	31158845	Green Accepted			2023-01-03	WOS:000472860000039
J	Finnerup, NB				Finnerup, Nanna B.			Nonnarcotic Methods of Pain Management	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							NEUROPATHIC PAIN; PREGABALIN; GABAPENTIN; PLACEBO; TRIAL	Narcotic treatment of pain can lead to addiction, dependence, and tolerance, underscoring the need for alternative treatments. The roles of NSAIDs, antidepressants, antiepileptic drugs, local agents, and complementary therapies are summarized in this review.	[Finnerup, Nanna B.] Aarhus Univ, Dept Clin Med, Danish Pain Res Ctr, Aarhus, Denmark; [Finnerup, Nanna B.] Aarhus Univ Hosp, Dept Neurol, Aarhus, Denmark	Aarhus University; Aarhus University	Finnerup, NB (corresponding author), Aarhus Univ, Dept Clin Med, Danish Pain Res Ctr, Aarhus, Denmark.; Finnerup, NB (corresponding author), Aarhus Univ Hosp, Dept Neurol, Aarhus, Denmark.	finnerup@clin.au.dk	Finnerup, Nanna Brix/ABA-8219-2020	Finnerup, Nanna Brix/0000-0001-5541-0240				[Anonymous], 2017, CR PHYS, V18, P479; [Anonymous], 1994, IASP TASK FORCE TAXO; Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030; Ballantyne J, 2018, IASP STATEMENT OPIOI; Ballantyne JC, 2018, PAIN, V159, pS24, DOI 10.1097/j.pain.0000000000001270; Ballantyne JC, 2015, NEW ENGL J MED, V373, P2098, DOI 10.1056/NEJMp1507136; Becker WJ, 2015, CAN FAM PHYSICIAN, V61, P670; Berman BM, 2010, NEW ENGL J MED, V363, P454, DOI 10.1056/NEJMct0806114; Bouhassira D, 2018, PAIN, V159, P576, DOI 10.1097/j.pain.0000000000001136; Chang DS, 2015, CURR OPIN ANESTHESIO, V28, P379, DOI 10.1097/ACO.0000000000000216; Chen L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1284; Chou R, 2017, ANN INTERN MED, V166, P480, DOI 10.7326/M16-2458; Cordell WH, 2002, AM J EMERG MED, V20, P165, DOI 10.1053/ajem.2002.32643; Cruccu G, 2016, EUR J NEUROL, V23, P1489, DOI 10.1111/ene.13103; Demant DT, 2014, PAIN, V155, P2263, DOI 10.1016/j.pain.2014.08.014; Derry S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011790.pub2; Di Stefano G, 2018, DRUGS, V78, P1433, DOI 10.1007/s40265-018-0964-9; Eccleston Christopher, 2017, F1000Res, V6, P461, DOI 10.12688/f1000research.10612.1; Edwards RR, 2016, J PAIN, V17, pT70, DOI 10.1016/j.jpain.2016.01.001; Fabritius ML, 2017, BRIT J ANAESTH, V119, P775, DOI 10.1093/bja/aex227; Finnerup NB, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0; Food and Drug Administration, FDA DRUG SAF COMM FD; Food and Drug Administration, FDA DRUG SAF COMM PR; Gillman PK, 2007, BRIT J PHARMACOL, V151, P737, DOI 10.1038/sj.bjp.0707253; Goldstein DJ, 2005, PAIN, V116, P109, DOI 10.1016/j.pain.2005.03.029; Goodman CW, 2017, NEW ENGL J MED, V377, P411, DOI 10.1056/NEJMp1704633; Gordon DB, 2005, ARCH INTERN MED, V165, P1574, DOI 10.1001/archinte.165.14.1574; Hauser W, 2016, DTSCH ARZTEBL INT, V113, P289, DOI 10.3238/arztebl.2016.0289; Heiskanen T, 2012, SCAND J PAIN, V3, P201, DOI 10.1016/j.sjpain.2012.05.073; Ho KY, 2018, J PAIN RES, V11, P1937, DOI 10.2147/JPR.S168188; Holbech JV, 2015, PAIN, V156, P958, DOI 10.1097/j.pain.0000000000000143; Jordan KP, 2019, PAIN, V160, P281, DOI 10.1097/j.pain.0000000000001374; Kamper SJ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000963.pub3; Kremer M, 2018, J NEUROSCI, V38, P9934, DOI 10.1523/JNEUROSCI.1004-18.2018; Markozannes Georgios, 2017, BMC Psychol, V5, P31, DOI 10.1186/s40359-017-0200-5; Martel MO, 2015, PAIN, V156, P1092, DOI 10.1097/j.pain.0000000000000154; Mathieson S, 2017, NEW ENGL J MED, V376, P1111, DOI 10.1056/NEJMoa1614292; National Institute for Health and Care Excellence, 2016, CLIN GUID LOW BACK P; NCCN Clinical Practice, 2018, ACUTE MYELOID LEUKEM, VV2, pMS28; Pitchon Darsi N, 2018, Anesthesiol Clin, V36, P361, DOI 10.1016/j.anclin.2018.05.001; Qaseem A, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16-2367; Rice ASC, 2016, PAIN, V157, P791, DOI 10.1097/j.pain.0000000000000454; Rintala DH, 2007, ARCH PHYS MED REHAB, V88, P1547, DOI 10.1016/j.apmr.2007.07.038; Scascighini L, 2008, RHEUMATOLOGY, V47, P670, DOI 10.1093/rheumatology/ken021; Sinatra R, 2010, PAIN MED, V11, P1859, DOI 10.1111/j.1526-4637.2010.00983.x; Taylor SL, 2019, J ALTERN COMPLEM MED, V25, P32, DOI 10.1089/acm.2018.0276; The Interagency Pain Research Coordinating Committee, 2018, NAT PAIN STRAT COMPR; Themistocleous AC, 2018, PAIN, V159, pS31, DOI 10.1097/j.pain.0000000000001301; Todd KH, 2017, PAIN THER, V6, P193, DOI 10.1007/s40122-017-0090-5; Treede RD, 2019, PAIN, V160, P19, DOI 10.1097/j.pain.0000000000001384	50	47	50	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 20	2019	380	25					2440	2448		10.1056/NEJMra1807061	http://dx.doi.org/10.1056/NEJMra1807061			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IE2LF	31216399	Green Published, Bronze			2023-01-03	WOS:000472215000009
J	Trefan, L; Gartner, A; Alcock, A; Farewell, D; Morgan, J; Fone, D; Paranjothy, S				Trefan, Laszlo; Gartner, Andrea; Alcock, Amy; Farewell, Daniel; Morgan, Jennifer; Fone, David; Paranjothy, Shantini			Epidemiology of alcohol-related emergency hospital admissions in children and adolescents: An e-cohort analysis in Wales in 2006-2011	PLOS ONE			English	Article							INTOXICATED ADOLESCENTS; SOCIOECONOMIC-STATUS; BINGE DRINKING; CONSUMPTION; AGE; LEVEL; ONSET; HARM; VICTIMIZATION; BEHAVIORS	Objective Harmful levels of alcohol consumption in young people are prevalent and of increasing public concern in the western world. Rates of alcohol-related emergency hospital admissions in children and young people between 10 to 17 years were described, and the reasons for these admissions and their association with socio-demographic factors were examined. Methods E-cohort data were extracted from the Secure Anonymised Information Linkage Databank, which contained alcohol-related emergency hospital admissions (N = 2968) from 2006 to 2011 in children and adolescents aged 10 to 17 years in Wales. A generalised linear mixed model was fitted using a log-link with a population offset to the data to calculate incident rate ratios (IRRSs). Results There was a general decreasing trend from 2006 to 2011 in the number and rate of alcohol-related emergency hospital admissions; the mean age of admission was 15.4 (standard deviation 1.4) years. In each of the four youngest age groups (10-13,14,15,16 years), females had higher IRRs than males. Males had slightly higher IRR compared to females only in the oldest age group (17 years). IRRs increased with increasing deprivation. The majority (92%) of the admissions lasted one day and most of the admissions (70%) occured during the last three days of the week with a peak on Saturday. The length of stay in hospital was longer in cases when self-harm were present. Multiple admissions showed high prevalance of serious self-harm cases in females. The number of admissions with injuries and falls were higher for males than females. Conclusion Female children and adolescents were more likely to be admitted to hospital for alcohol-related reasons. These data illustrate the significant burden of alcohol-related harm in young people and highlight the need for interventions and policies that promote safe drinking practices among young people to prevent future alcohol-related harm during the life-course.	[Trefan, Laszlo; Gartner, Andrea; Farewell, Daniel; Fone, David; Paranjothy, Shantini] Cardiff Univ, Sch Med, Div Populat Med, Cardiff, S Glam, Wales; [Alcock, Amy] Royal Gwent Hosp, Newport, Gwent, Wales; [Morgan, Jennifer] NHS Wales Delivery Unit, Pencoed, Wales	Cardiff University; Royal Gwent Hospital	Trefan, L (corresponding author), Cardiff Univ, Sch Med, Div Populat Med, Cardiff, S Glam, Wales.	TrefanL@cardiff.ac.uk		Paranjothy, Shantini/0000-0002-0528-3121; Farewell, Daniel/0000-0002-8871-1653	Economic and Social Research Council; Medical Research Council; Alcohol Research UK [ES/L015471/1]; ESRC [ES/L015471/1] Funding Source: UKRI; MRC [MR/K023233/1] Funding Source: UKRI	Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Alcohol Research UK; ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by funds from the Economic and Social Research Council, the Medical Research Council and Alcohol Research UK to the ELAStiC Project (ES/L015471/1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bouthoorn SH, 2011, EUR J PEDIATR, V170, P1023, DOI 10.1007/s00431-011-1394-9; Calabria B, 2011, ADDICTION, V106, P1406, DOI 10.1111/j.1360-0443.2011.03418.x; Champion HLO, 2004, J ADOLESCENT HEALTH, V35, P321, DOI 10.1016/j.jadohealth.2003.09.023; Dawson DA, 2008, ALCOHOL CLIN EXP RES, V32, P2149, DOI 10.1111/j.1530-0277.2008.00806.x; de Looze M, 2015, EUR J PUBLIC HEALTH, V25, P69, DOI 10.1093/eurpub/ckv031; Diestelkamp S, 2015, ADDICT BEHAV, V50, P51, DOI 10.1016/j.addbeh.2015.06.009; Dobson A.J., 1990, INTRO GEN LINEAR MOD; Fone D, 2016, PUBLIC HLTH RES, V4, P1, DOI [DOI 10.3310/PHR04030, 10.3310/phr04030]; Fone D, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-428; Ford D, 2009, BMC HEALTH SERV RES, V9, P24; Gartner A., 2014, ALCOHOL HLTH WALES 2; Green MA, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4265-0; Healey C, 2014, INT J DRUG POLICY, V25, P124, DOI 10.1016/j.drugpo.2013.07.008; Hibell B, 2009, ESPAD REPORT 2007 SU; Hibell B., 2012, ESPAD REPORT 2011 SU; Hingson RW, 2006, ARCH PEDIAT ADOL MED, V160, P739, DOI 10.1001/archpedi.160.7.739; Holdcraft LC, 2002, ADDICTION, V97, P1025, DOI 10.1046/j.1360-0443.2002.00142.x; Huckle T, 2008, ADDICTION, V103, P1614, DOI 10.1111/j.1360-0443.2008.02318.x; Jefferis BJMH, 2005, ADDICTION, V100, P543, DOI 10.1111/j.1360-0443.2005.01034.x; Jones KH, 2014, J BIOMED INFORM, V50, P196, DOI 10.1016/j.jbi.2014.01.003; Katikireddi SV, 2017, LANCET PUBLIC HEALTH, V2, pE267, DOI 10.1016/S2468-2667(17)30078-6; KIRKWOOD BR, 2003, ESSENTIAL MED STAT, P315; Livingston W, 2018, REV WORKING TOGETHER; Loxley WM, 2005, MED J AUSTRALIA, V182, P54, DOI 10.5694/j.1326-5377.2005.tb06574.x; Lyons RA, 2009, BMC MED INFORM DECIS, V9, DOI 10.1186/1472-6947-9-3; Measham F, 2008, HEALTH EDUC, V108, P207, DOI 10.1108/09654280810867088; Moore GF, 2015, J SCHOOL HEALTH, V85, P267, DOI 10.1111/josh.12242; Moore GF, 2010, SUBST ABUSE TREAT PR, V5, DOI 10.1186/1747-597X-5-6; Nienhuis K., 2019, Nederlands Tijdschrift voor Geneeskunde, V163, pD2384; Pawlowska-Kamieniak A, 2018, ANN AGR ENV MED, V25, P1, DOI 10.5604/12321966.1228397; Peng M, 2018, INT J POPUL DATA SCI, V3, P1; Pitkanen T, 2005, ADDICTION, V100, P652, DOI 10.1111/j.1360-0443.2005.01053.x; Rowland B, 2014, ADDICT BEHAV, V39, P282, DOI 10.1016/j.addbeh.2013.10.001; Shepherd JP, 2006, J ADOLESCENCE, V29, P539, DOI 10.1016/j.adolescence.2006.06.005; Simons-Morton BG, 2009, INT J PUBLIC HEALTH, V54, P199, DOI 10.1007/s00038-009-5411-y; Sindelar H A, 2004, Minerva Pediatr, V56, P291; Swahn MH, 2004, ADDICT BEHAV, V29, P959, DOI 10.1016/j.addbeh.2004.02.043; Team R.C., 2021, R FOUN DATION STAT C; Toumbourou JW, 2007, LANCET, V369, P1391, DOI 10.1016/S0140-6736(07)60369-9; van Hoof JJ, 2015, J CHILD ADOLES SUBST, V24, P191, DOI 10.1080/1067828X.2013.803943; van Hoof JJ, 2011, J ADOLESCENT HEALTH, V48, P212, DOI 10.1016/j.jadohealth.2010.06.001; van Hoof JJ, 2010, J STUD ALCOHOL DRUGS, V71, P366, DOI 10.15288/jsad.2010.71.366; Van Zanten E, 2013, ALCOHOL CLIN EXP RES, V37, P1188, DOI 10.1111/acer.12090; Wachtel T, 2010, J CLIN NURS, V19, P605, DOI 10.1111/j.1365-2702.2009.03060.x; Warner LA, 2003, SUBST USE MISUSE, V38, P1983, DOI 10.1081/JA-120025123; WHO. World Health Organization, 1992, INT STAT CLASS DIS R; Williams S, 2005, BRIT MED J, V330, p115A	47	6	6	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2019	14	6							e0217598	10.1371/journal.pone.0217598	http://dx.doi.org/10.1371/journal.pone.0217598			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IB2FX	31163052	Green Published, Green Accepted, gold, Green Submitted			2023-01-03	WOS:000470086200024
J	Chou, R; Ballantyne, J; Lembke, A				Chou, Roger; Ballantyne, Jane; Lembke, Anna			Rethinking Opioid Dose Tapering, Prescription Opioid Dependence, and Indications for Buprenorphine	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CHRONIC PAIN; THERAPY		[Chou, Roger] Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA; [Ballantyne, Jane] Univ Washington, Sch Med, Dept Anesthesiol & Pain Med, 1959 NE Pacific St,Mail Code BB 1421, Seattle, WA 98195 USA; [Lembke, Anna] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, 401 Quarry Rd, Stanford, CA 94305 USA	Oregon Health & Science University; University of Washington; University of Washington Seattle; Stanford University	Chou, R (corresponding author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	chour@ohsu.edu						Busse JW, 2018, JAMA-J AM MED ASSOC, V320, P2448, DOI 10.1001/jama.2018.18472; Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559; Darnall BD, 2018, JAMA INTERN MED, V178, P707, DOI 10.1001/jamainternmed.2017.8709; Dowell D, 2017, ANN INTERN MED, V167, P208, DOI 10.7326/M17-1402; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Frank JW, 2017, ANN INTERN MED, V167, P181, DOI 10.7326/M17-0598; Oregon Pain Guidance Clinical Advisory Group Tapering Workgroup, 2019, TAP GUID TOOLS CLIN; Stanford Center for Continuing Medical Education, 2019, TAP PAT CHRON OP THE; Vowles KE, 2015, PAIN, V156, P569, DOI 10.1097/01.j.pain.0000460357.01998.f1; White JM, 2004, ADDICT BEHAV, V29, P1311, DOI 10.1016/j.addbeh.2004.06.007	10	23	23	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 17	2019	171	6					427	+		10.7326/M19-1488	http://dx.doi.org/10.7326/M19-1488			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IY0RW	31450240				2023-01-03	WOS:000486101400017
J	Berhe, A; Bayray, A; Berhe, Y; Teklu, A; Desta, A; Araya, T; Zielinski, R; Roosevelt, L				Berhe, Almaz; Bayray, Alemayehu; Berhe, Yibrah; Teklu, Alula; Desta, Amanuel; Araya, Tsige; Zielinski, Ruth; Roosevelt, Lee			Determinants of postnatal care utilization in Tigray, Northern Ethiopia: A community based cross-sectional study	PLOS ONE			English	Article							DISTRICT; MOTHERS	Introduction Globally, 289,000 women die from complications related to pregnancy, childbirth, or the postnatal period every year. Two-thirds of all maternal deaths occur during the first six weeks following birth and more than two thirds of newborn deaths occur during the first week of life, These statistics underscore the importance of postnatal care, an often neglected service according to the World Health Organization (WHO). The purpose of this study was to assess the factors associated with postnatal service utilization in the Tigray region of Ethiopia. Methods The study was a community-based, cross-sectional study. A multi-stage sampling method was used to select study districts randomly from the entire region. A total of 1,690 participants were selected using systematic random sampling. Participants were 18-49 years old, had given birth within the last six months, and were residents of the district for at least six months. Using SPSS version 20 means, frequencies, and percentages were calculated for the sub-group of participants who did attend postnatal care. Barriers to non-attendance of postatal care were analyzed using descriptive statistics. Bivariate analysis was undertaken to assess the association between demographic, obstetric, and knowledge regarding PNC and attendance at antenatal care. Variables with a P value, <0.05 were included in the multi-variate logistic regression analysis to identify the determinant factors of postnatal care utilization. Result Of the women surveyed, 132 (8%) obtained postnatal care. Women who did not receive postnatal care reported lack of awareness of the services (n = 1110, 73.3%). Most mothers who received postnatal care reported that they were aware of the service prior to the birth of their child (n = 101, 76.5%). Women were more likely to receive postnatal services if they lived in an urban area (odds ratio 1.96, 95% confidence interval 1.07, 3.59), had greater than a secondary education (OR 3.60, 95% CI 1.32,9.83), delivered by cesarean section (OR 2.88 95% CI 1.32,6.29), had four or more antenatal visits (OR 4.84, 95% CI 1.57,14.9), or had a planned pregnancy (OR 6.47, 95% CI 2.04,20.5). Conclusion Postnatal care service utilization is very low in Tigray region. Interventions targeted at increasing women's awareness of the importance of postnatal services and improving accessibility, particularly in rural areas, is needed.	[Berhe, Almaz; Bayray, Alemayehu; Berhe, Yibrah; Araya, Tsige] Mekelle Univ, Sch Med & Hlth Sci, Addis Adaba, Ethiopia; [Teklu, Alula] St Pauls Hosp, Millennium Med Coll, Addis Adaba, Ethiopia; [Desta, Amanuel] Ctr Int Reprod Hlth Training, Ann Arbor, MI USA; [Zielinski, Ruth; Roosevelt, Lee] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA	Mekelle University; University of Michigan System; University of Michigan	Roosevelt, L (corresponding author), Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA.	morgaine@umich.edu			Center for International Reproductive Health Training (CIRHT) at the University of Michigan [N018416]	Center for International Reproductive Health Training (CIRHT) at the University of Michigan	This work was financially supported by an anonymous donor through the Center for International Reproductive Health Training (CIRHT) at the University of Michigan [Project Grant number N018416]. The funding source did not have any involvement in the study design, data collection, analysis and interpretation of data, writing of the manuscript and the decision to submit the article for publication.	Afework MF, 2010, ETHIOP J HEALTH DEV, V24, P87; [Anonymous], POP HOUS CENS 2007; [Anonymous], 2014, SCI J PUBLIC HLTH, DOI [DOI 10.11648/j.sjph.20140203.15, DOI 10.11648/J.SJPH.20140203.15]; Darega B, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0940-x; Expanded Programme on Immunization, WHOIVB0423; Gabriel SA, 2009, BE J ECON ANAL POLI, V9, DOI 10.1186/1471-2393-9-34; Khanal V, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-19; Lawn JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7; Li C, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-31; Limenih Miteku Andualem, 2016, Int J Reprod Med, V2016, P7095352, DOI 10.1155/2016/7095352; Matijasevich A, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-335; Miller S, 2016, LANCET, V388, P2176, DOI 10.1016/S0140-6736(16)31472-6; Rahman M, 2011, HEALTH SOC CARE COMM, V19, P138, DOI 10.1111/j.1365-2524.2010.00953.x; Regassa N, 2011, AFR HEALTH SCI, V11, P390; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S0140-6736(06)69380-X; Say L, 2007, B WORLD HEALTH ORGAN, V85, P812, DOI 10.2471/BLT.06.035659; Sines E., 2015, POSTNATAL CARE CRITI; Tesfahun F, 2014, MATERN CHILD HLTH J, V18, P2341, DOI 10.1007/s10995-014-1474-3; Tigray regional health bureau annual profile 2007 Ethiopian fiscal year, 1997, REFUGEE HLTH APPROAC; WHO, 2014, TRENDS MAT MORT 1990; Winch PJ, 2005, LANCET, V366, P478, DOI 10.1016/S0140-6736(05)66836-5; World Health Organization, 2014, WHO REC POSTN CAR MO; World Health Organization (WHO), 2012, TRENDS MAT MORT 1990	23	20	20	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2019	14	8							e0221161	10.1371/journal.pone.0221161	http://dx.doi.org/10.1371/journal.pone.0221161			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5OC	31430356	gold, Green Published, Green Submitted			2023-01-03	WOS:000485026800031
J	Mohnen, SM; van Oosten, MJM; Los, J; Leegte, MJH; Jager, KJ; Hemmelder, MH; Logtenberg, SJJ; Stel, VS; Hakkaart-van Roijen, L; de Wit, GA				Mohnen, Sigrid M.; van Oosten, Manon J. M.; Los, Jeanine; Leegte, Martijn J. H.; Jager, Kitty J.; Hemmelder, Marc H.; Logtenberg, Susan J. J.; Stel, Vianda S.; Hakkaart-van Roijen, Leona; de Wit, G. Ardine			Healthcare costs of patients on different renal replacement modalities - Analysis of Dutch health insurance claims data	PLOS ONE			English	Article							ECONOMIC-EVALUATION; HEMODIALYSIS; DIALYSIS; DISEASE	Background The aim of this study is to present average annual healthcare costs for Dutch renal replacement therapy (RRT) patients for 7 treatment modalities. Methods Health insurance claims data from 2012-2014 were used. All patients with a 2014 claim for dialysis or kidney transplantation were selected. The RRT related and RRT unrelated average annual healthcare costs were analysed for 5 dialysis modalities (in-centre haemodialysis (CHD), home haemodialysis (HHD), continuous ambulatory peritoneal dialysis (CAPD), automated peritoneal dialysis (APD) and multiple dialysis modalities in a year (Mix group)) and 2 transplant modalities (kidney from living and deceased donor, respectively). Results The total average annual healthcare costs in 2014 ranged from (sic)77,566 (SD = (sic)27,237) for CAPD patients to (sic)105,833 (SD = (sic)30,239) for patients in the Mix group. For all dialysis modalities, the vast majority (72-84%) of costs was RRT related. Patients on haemodialysis >= 4x/week had significantly higher average annual costs compared to those dialyzing 3x/week (Delta(sic)19,122). Costs for kidney transplant recipients were (sic)85,127 (SD = (sic)39,679) in the year of transplantation and rapidly declined in the first and second year after successful transplantation (resp. (sic)29,612 (SD = (sic)34,099) and (sic)15,018 (SD = (sic)16,186)). Transplantation with a deceased donor kidney resulted in higher costs ((sic)99,450, SD = (sic)36,036)) in the year of transplantation compared to a living donor kidney transplantation ((sic)73,376, SD = (sic)38,666). Conclusions CAPD patients have the lowest costs compared to other dialysis modalities. Costs in the year of transplantation are 25% lower for patients with kidneys from living vs. deceased donor. After successful transplantation, annual costs decline substantially to a level that is approximately 14-19% of annual dialysis costs.	[Mohnen, Sigrid M.; de Wit, G. Ardine] Natl Inst Publ Hlth & Environm, Ctr Nutr Prevent & Hlth Serv, Bilthoven, Netherlands; [van Oosten, Manon J. M.; Jager, Kitty J.; Stel, Vianda S.] Univ Amsterdam, Amsterdam Publ Hlth Res Inst, Amsterdam UMC, Dept Med Informat, Amsterdam, Netherlands; [Los, Jeanine; Hakkaart-van Roijen, Leona] Erasmus Univ, iMTA, ESHPM, Rotterdam, Netherlands; [Leegte, Martijn J. H.; Hemmelder, Marc H.] Nefrovisie Fdn, Dutch Renal Registry Renine, Utrecht, Netherlands; [Logtenberg, Susan J. J.] Diakonessenhuis Utrecht, Dept Internal Med, Utrecht, Netherlands; [de Wit, G. Ardine] Univ Med Ctr Utrecht, Juliusctr Hlth Sci & Primary Care, Utrecht, Netherlands	Netherlands National Institute for Public Health & the Environment; University of Amsterdam; Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Diakonessenhuis; Utrecht University; Utrecht University Medical Center	Mohnen, SM (corresponding author), Natl Inst Publ Hlth & Environm, Ctr Nutr Prevent & Hlth Serv, Bilthoven, Netherlands.	sigrid.mohnen@rivm.nl	Hemmelder, Marc/AFQ-0383-2022	Hakkaart-van Roijen, Leona/0000-0003-0635-7388; de Wit, G. Ardine/0000-0002-1375-7657; Mohnen, Sigrid Mechthild/0000-0002-1537-8706; Jager, Kitty/0000-0003-0444-8569; Stel, Vianda S/0000-0002-0007-1947	Dutch Kidney Foundation; Institute of Medical Technology Assessment of Erasmus University Rotterdam	Dutch Kidney Foundation; Institute of Medical Technology Assessment of Erasmus University Rotterdam	This work is financed by a grant from the Dutch Kidney Foundation to National Institute of Public Health and the Environment and the Institute of Medical Technology Assessment of Erasmus University Rotterdam.	Agar JW, 2005, NEPHROLOGY, V10, P557, DOI 10.1111/j.1440-1797.2005.00471.x; Boo A., 2011, TIJDSCHRIFT GEZONDHE, V89, P358; Chertow GM, 2010, NEW ENGL J MED, V363, P2287, DOI 10.1056/NEJMoa1001593; Couillerot-Peyrondet A-L, 2016, EUR J HEALTH ECON, P1; de Wit GA, 1998, HEALTH POLICY, V44, P215, DOI 10.1016/S0168-8510(98)00017-7; ERA-EDTA Registry, 2017, ERA EDTA REG ANN REP; Hakkaart-van Roijen L, 2015, COSTING MANUAL METHO; Hoekstra T., 2018, RENINE ANN REPORT 20; Icks A, 2010, NEPHROL DIAL TRANSPL, V25, P1647, DOI 10.1093/ndt/gfp672; Jaar BG, 2009, BMC NEPHROL, V10, DOI 10.1186/1471-2369-10-3; Kitazawa T, 2017, TRANSPL P, V49, P4, DOI 10.1016/j.transproceed.2016.10.007; Klarenbach SW, 2014, NAT REV NEPHROL, V10, P644, DOI 10.1038/nrneph.2014.145; Kroeker A, 2003, AM J KIDNEY DIS, V42, pS49, DOI 10.1016/S0272-6386(03)00538-9; Lamb KE, 2011, AM J TRANSPLANT, V11, P450, DOI 10.1111/j.1600-6143.2010.03283.x; Lee H, 2002, AM J KIDNEY DIS, V40, P611, DOI 10.1053/ajkd.2002.34924; Legendre C, 2014, TRANSPL INT, V27, P19, DOI 10.1111/tri.12217; Li B, 2015, NDT; Mazairac AHA, 2013, NEPHROL DIAL TRANSPL, V28, P1865, DOI 10.1093/ndt/gft045; McFarlane PA, 2004, SEMIN DIALYSIS, V17, P118, DOI 10.1111/j.0894-0959.2004.17208.x; Murray CJL, 2015, LANCET, V386, P2145, DOI 10.1016/S0140-6736(15)61340-X; NZa, 2016, SCAN HLTH INS MARK 2; Oostenbrink JB, 2005, TRANSPLANT INT, V18, P437, DOI 10.1111/j.1432-2277.2004.00063.x; Pippias M, 2015, NDT; RIVM, DIS ORD COSTS; van Oosten MJM, 2020, NEPHROL DIAL TRANSPL, V35, P2138, DOI 10.1093/ndt/gfz146; Vanholder R, 2017, NAT REV NEPHROL, V13, P393, DOI 10.1038/nrneph.2017.63; Vanholder R, 2016, NEPHROL DIAL TRANSPL, V31, P1251, DOI 10.1093/ndt/gfv233; Vanholder R, 2012, J AM SOC NEPHROL, V23, P1291, DOI 10.1681/ASN.2011111094; Villa G, 2011, NEPHROL DIAL TRANSPL, V26, P3709, DOI 10.1093/ndt/gfr088	29	34	34	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 15	2019	14	8							e0220800	10.1371/journal.pone.0220800	http://dx.doi.org/10.1371/journal.pone.0220800			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5KK	31415578	gold, Green Published, Green Submitted			2023-01-03	WOS:000485017200033
J	Ruben, MD; Smith, DF; FitzGerald, GA; Hogenesch, JB				Ruben, Marc D.; Smith, David F.; FitzGerald, Garret A.; Hogenesch, John B.			Dosing time matters	SCIENCE			English	Editorial Material							GENE-EXPRESSION		[Ruben, Marc D.; Hogenesch, John B.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Ctr Chronobiol, Div Human Genet, 240 Albert Sabin Way, Cincinnati, OH 45229 USA; [Ruben, Marc D.; Hogenesch, John B.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Ctr Chronobiol, Div Immunobiol, 240 Albert Sabin Way, Cincinnati, OH 45229 USA; [Smith, David F.] Cincinnati Childrens Hosp Med Ctr, Div Pediat Otolaryngol, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Smith, David F.] Cincinnati Childrens Hosp Med Ctr, Div Pulm & Sleep Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Smith, David F.] Univ Cincinnati, Sch Med, Dept Otolaryngol Head & Neck Surg, 231 Albert Sabin Way, Cincinnati, OH 45267 USA; [FitzGerald, Garret A.] Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA; [FitzGerald, Garret A.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA; [FitzGerald, Garret A.] Univ Penn, Perelman Sch Med, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	FitzGerald, GA (corresponding author), Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA.; FitzGerald, GA (corresponding author), Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.; FitzGerald, GA (corresponding author), Univ Penn, Perelman Sch Med, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA.	garret@upenn.edu; john.hogenesch@cchmc.org	Ruben, Marc/GQI-4245-2022	Smith, David/0000-0002-0048-4012	National Institute of Neurological Disorders and Stroke [5R01NS05479413]; American Heart Association	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); American Heart Association(American Heart Association)	M.D.R. and J.B.H. are supported by the National Institute of Neurological Disorders and Stroke (5R01NS05479413). G.A.F. is the recipient of a MERIT award from the American Heart Association. J.B.H. is an advisor to Synchronicity Pharma. G.A.F. is an advisor to Calico Laboratories.	Anati R. C., 2017, P NATL ACAD SCI USA, V114, P5312; Bobin P, 2016, ARCH CARDIOVASC DIS, V109, P431, DOI 10.1016/j.acvd.2016.02.004; Chen CY, 2016, P NATL ACAD SCI USA, V113, P206, DOI 10.1073/pnas.1508249112; DALONZO GE, 1995, CHEST, V107, P406, DOI 10.1378/chest.107.2.406; Fagard RH, 2008, HYPERTENSION, V51, P55, DOI 10.1161/HYPERTENSIONAHA.107.100727; HAMPRECHT B, 1969, FEBS LETT, V4, P117, DOI 10.1016/0014-5793(69)80210-3; Hendel J, 1995, ALIMENT PHARM THERAP, V9, P693; LEVI FA, 1994, JNCI-J NATL CANCER I, V86, P1608, DOI 10.1093/jnci/86.21.1608; Montaigne D, 2018, LANCET, V391, P59, DOI 10.1016/S0140-6736(17)32132-3; Ruben MD, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat8806; Schork NJ, 2015, NATURE, V520, P609, DOI 10.1038/520609a; Skarke C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17362-6; Takahashi JS, 2017, NAT REV GENET, V18, P164, DOI 10.1038/nrg.2016.150; Zhang R, 2014, P NATL ACAD SCI USA, V111, P16219, DOI 10.1073/pnas.1408886111; Zhang SL, 2018, CELL, V173, P130, DOI 10.1016/j.cell.2018.02.017	15	93	94	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	2019	365	6453					547	+		10.1126/science.aax7621	http://dx.doi.org/10.1126/science.aax7621			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IT9IY	31395773	Green Accepted, Green Submitted			2023-01-03	WOS:000483195200026
J	Jones, CM; Compton, W; Vythilingam, M; Giroir, B				Jones, Christopher M.; Compton, Wilson; Vythilingam, Meena; Giroir, Brett			Naloxone Co-prescribing to Patients Receiving Prescription Opioids in the Medicare Part D Program, United States, 2016-2017	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter								This study uses Medicare Part D data to compare US national and state rates of co-prescribing of naloxone with opioids and benzodiazepines in 2016-2017.	[Jones, Christopher M.] Ctr Dis Control & Prevent, Atlanta, GA USA; [Compton, Wilson] NIH, Bldg 10, Bethesda, MD 20892 USA; [Vythilingam, Meena; Giroir, Brett] US Dept HHS, Washington, DC 20201 USA	Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA	Jones, CM (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4700 Buford Hwy, Atlanta, GA 30341 USA.	fjr0@cdc.gov						Centers for Medicare & Medicaid Services, OP OR MORPH MILL EQ; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Oliva EM, 2017, J AM PHARM ASSOC, V57, pS168, DOI 10.1016/j.japh.2017.01.022; U.S. Department of Health and Human Services, 2018, NAL OP REV DRUG SAV; Vermont Department of Health, 2019, RUL GOV PRESCR OP PA; Virginia Department of Health Professions Board of Medicine, 2017, BOARD MED REG OP PRE	6	31	31	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	2019	322	5					462	464		10.1001/jama.2019.7988	http://dx.doi.org/10.1001/jama.2019.7988			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IP8JR	31386124	Green Published, Bronze			2023-01-03	WOS:000480293200022
J	Arteaga-Marrero, N; Villa, E; Gonzalez-Fernandez, J; Martin, Y; Ruiz-Alzola, J				Arteaga-Marrero, Natalia; Villa, Enrique; Gonzalez-Fernandez, Javier; Martin, Yolanda; Ruiz-Alzola, Juan			Polyvinyl alcohol cryogel phantoms of biological tissues for wideband operation at microwave frequencies	PLOS ONE			English	Article							DEPENDENT DIELECTRIC-PROPERTIES; PERMITTIVITY; MODEL	The aim of this work is to provide a methodology to model the dielectric properties of human tissues based on phantoms prepared with an aqueous solution, in a semi-solid form, by using off-the-shelf components. Polyvinyl alcohol cryogel (PVA-C) has been employed as a novel gelling agent in the fabrication of phantoms for microwave applications in a wide frequency range, from 500 MHz to 20 GHz. Agar-based and deionized water phantoms have also been manufactured for comparison purposes. Mathematical models dependent on frequency and sucrose concentration are proposed to obtain the complex permittivity of the desired mimicked tissues. These models have been validated in the referred bandwidth showing a good agreement to experimental data for different sucrose concentrations. The PVA-C model provides a great performance as compared to agar, increasing the shelf-life of the phantoms and improving their consistency for contact-required devices. In addition, the feasibility of fabricating a multilayer phantom has been demonstrated with a two-layer phantom that exhibits a clear interface between each layer and its properties. Thus, the use of PVA-C extends the option for producing complex multilayer and multimodal phantoms.	[Arteaga-Marrero, Natalia; Villa, Enrique; Martin, Yolanda; Ruiz-Alzola, Juan] IAC, IACTec Med Technol Grp, San Cristobal la Laguna, Santa Cruz De T, Spain; [Gonzalez-Fernandez, Javier] ITC, Dept Ingn Biomed, San Cristobal la Laguna, Santa Cruz De T, Spain; [Ruiz-Alzola, Juan] Univ Palmas Gran Canaria, IUIBS, Dept Senales & Comunicac, Las Palmas Gran Canaria, Las Palmas, Spain	Instituto de Astrofisica de Canarias; Universidad de Las Palmas de Gran Canaria	Arteaga-Marrero, N (corresponding author), IAC, IACTec Med Technol Grp, San Cristobal la Laguna, Santa Cruz De T, Spain.	narteaga@iac.es	Villa, Enrique/H-9796-2015; Arteaga Marrero, Natalia/AAC-6524-2022	Villa, Enrique/0000-0003-1028-6957; Arteaga Marrero, Natalia/0000-0002-1645-0810; Ruiz-Alzola, Juan/0000-0002-3545-2328	IACTec Technological Training program (TF INNOVA 2016-2021); European Union [MAC/1.1.b/098]	IACTec Technological Training program (TF INNOVA 2016-2021); European Union(European Commission)	This work was supported by the IACTec Technological Training program (TF INNOVA 2016-2021) and European Union Interreg-Mac funding program under grant MAC/1.1.b/098 (MACbioIDi project). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ATHEY TW, 1982, IEEE T MICROW THEORY, V30, P82, DOI 10.1109/TMTT.1982.1131021; Beck BL, 2004, CONCEPT MAGN RESON B, V20B, P30, DOI 10.1002/cmr.b.20002; Bindu G, 2006, J MATER SCI, V41, P7419, DOI 10.1007/s10853-006-0793-1; Castello-Palacios S, 2017, IEEE ENG MED BIO, P3032, DOI 10.1109/EMBC.2017.8037496; Castello-Palacios S, 2017, INT SYM MED INFORM, P27, DOI 10.1109/ISMICT.2017.7891760; Chew KM, ADV MAT RES, V646; Cole KS, 1941, J CHEM PHYS, V9, P341, DOI 10.1063/1.1750906; Dabbagh A, 2014, ULTRASONIC IMAGING, V36, P291, DOI 10.1177/0161734614526372; Di Meo S, 2018, EUR MICROW CONF, P320; Di Meo S, 2019, PHYS MED BIOL, V64, DOI 10.1088/1361-6560/aafeec; Duan Q, 2014, MED PHYS, V41, DOI 10.1118/1.4895823; Fromageau J, 2007, IEEE T ULTRASON FERR, V54, P498, DOI 10.1109/TUFFC.2007.273; Gabriel C, 2006, PHYS MED BIOL, V51, P6033, DOI 10.1088/0031-9155/51/23/006; Gabriel S, 1996, PHYS MED BIOL, V41, P2251, DOI 10.1088/0031-9155/41/11/002; Goharian M, 2007, NUCL INSTRUM METH B, V263, P239, DOI 10.1016/j.nimb.2007.04.111; Hellerbach A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070343; Ianniello C, 2018, MAGN RESON MED, V80, P413, DOI 10.1002/mrm.27005; Iravani A, 2014, J BIOMAT SCI-POLYM E, V25, P181, DOI 10.1080/09205063.2013.848327; Karacolak T, 2013, MICROW OPT TECHN LET, V55, P1160, DOI 10.1002/mop.27515; Keysight Technologies Inc., KEYS N1501A DIEL PRO; Kotsuka Y., 2006, RF MICROWAVE INTERAC, V181; La Gioia A, 2018, DIAGNOSTICS, V8, DOI 10.3390/diagnostics8020040; Lazebnik M, 2006, PHYS MED BIOL, V51, P1941, DOI 10.1088/0031-9155/51/7/022; Lazebnik M, 2005, PHYS MED BIOL, V50, P4245, DOI 10.1088/0031-9155/50/18/001; Liu YL, 2013, IEEE INT WORKS GENET, P1, DOI 10.1109/GEFS.2013.6601048; Maccabi A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191919; Maher A, 2011, 8 INT MULT SYST SIGN; Melia G., 2013, ELECTROMAGNETIC ABSO; Millon LE, 2006, J BIOMED MATER RES B, V79B, P305, DOI 10.1002/jbm.b.30543; NYSHADHAM A, 1992, IEEE T MICROW THEORY, V40, P305, DOI 10.1109/22.120103; Ohta Makoto, 2004, Technol Health Care, V12, P225; Oliveira BL, 2018, BIOMED PHYS ENG EXPR, V4, DOI 10.1088/2057-1976/aaaaff; Pavlov ND, 2015, J PHYS CONF SER, V643, DOI 10.1088/1742-6596/643/1/012047; Porter E, 2010, PROCEEDINGS OF THE FOURTH EUROPEAN CONFERENCE ON ANTENNAS AND PROPAGATION; Romeo S, 2011, MICROW OPT TECHN LET, V53, P1276, DOI 10.1002/mop.26001; RStudio Team, 2015, INT DEV ENV R; Said T, 2009, IEEE MTT S INT MICR, P1445, DOI 10.1109/MWSYM.2009.5165979; Takahashi R, 2017, 2017 IEEE INTERNATIONAL CONFERENCE ON CYBORG AND BIONIC SYSTEMS (CBS), P150; Yu CH, 2015, TECHNOL HEALTH CARE, V23, pS301, DOI 10.3233/THC-150966	39	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2019	14	7							e0219997	10.1371/journal.pone.0219997	http://dx.doi.org/10.1371/journal.pone.0219997			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4VN	31344092	gold, Green Submitted, Green Published			2023-01-03	WOS:000484977900047
J	Geng, EH				Geng, Elvin H.			Implementation Science for the Bedside	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								The man knew he had life-threatening renal failure, but he didn't believe dialysis would help, especially in achieving his goal of returning to his home country to reunite with his wife. Understanding his perspective was the only way to help him take a step forward.	[Geng, Elvin H.] Washington Univ, Dept Med, Div Infect Dis, St Louis, MO 63110 USA; [Geng, Elvin H.] Washington Univ, Ctr Disseminat & Implementat, Inst Publ Hlth, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Geng, EH (corresponding author), Washington Univ, Dept Med, Div Infect Dis, St Louis, MO 63110 USA.; Geng, EH (corresponding author), Washington Univ, Ctr Disseminat & Implementat, Inst Publ Hlth, St Louis, MO 63110 USA.								0	1	1	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 25	2019	381	4					304	305		10.1056/NEJMp1902898	http://dx.doi.org/10.1056/NEJMp1902898			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IM4VO	31340093	Green Published			2023-01-03	WOS:000477993600005
J	Won, DO; Lee, BR; Seo, KS; Kim, HJ; Lee, SW				Won, Dong-Ok; Lee, Bo-Ram; Seo, Kwang-Suk; Kim, Hyun Jeong; Lee, Seong-Whan			Alteration of coupling between brain and heart induced by sedation with propofol and midazolam	PLOS ONE			English	Article							MEDIAL PREFRONTAL CORTEX; GRANGER CAUSALITY; RATE-VARIABILITY; FUNCTIONAL CONNECTIVITY; CENTRAL NUCLEUS; NETWORK; EEG; OSCILLATIONS; POTENTIALS; AMYGDALA	For a comprehensive understanding of the nervous system, several previous studies have examined the network connections between the brain and the heart in diverse conditions. In this study, we identified coupling between the brain and the heart along the continuum of sedation levels, but not in discrete sedation levels (e.g., wakefulness, conscious sedation, and deep sedation). To identify coupling between the brain and the heart during sedation, we induced several depths of sedation using patient-controlled sedation with propofol and midazolam. We performed electroencephalogram (EEG) spectral analysis and extracted the instantaneous heart rate (HR) from the electrocardiogram (ECG). EEG spectral power dynamics and mean HR were compared along the continuum of sedation levels. We found that EEG sigma power was the parameter most sensitive to changes in the sedation level and was correlated with the mean HR under the effect of sedative agents. Moreover, we calculated the Granger causality (GC) value to quantify brain-heart coupling at each sedation level. Additionally, the GC analysis revealed noticeably different strengths and directions of causality among different sedation levels. In all the sedation levels, GC values from the brain to the heart (GC(b -> h)) were higher than GC values from the heart to the brain (GC(h -> b)). Moreover, the mean GC(b -> h) increased as the sedation became deeper, resulting in higher GC(b -> h) values in deep sedation (1.97 +/- 0.18 in propofol, 2.02 +/- 0.15 in midazolam) than in pre-sedation (1.71 +/- 0.13 in propofol, 1.75 +/- 0.11 in midazolam; p < 0.001). These results show that coupling between brain and heart activities becomes stronger as sedation becomes deeper, and that this coupling is more attributable to the brain-heart direction than to the heart-brain direction. These findings provide a better understanding of the relationship between the brain and the heart under specific conditions, namely, different sedation states.	[Won, Dong-Ok; Lee, Bo-Ram; Lee, Seong-Whan] Korea Univ, Dept Brain & Cognit Engn, Seoul 02841, South Korea; [Lee, Seong-Whan] Korea Univ, Dept Artificial Intelligence, Seoul 02841, South Korea; [Seo, Kwang-Suk; Kim, Hyun Jeong] Seoul Natl Univ, Dent Hosp, Dept Dent Anesthesiol, Seoul 03080, South Korea	Korea University; Korea University; Seoul National University (SNU)	Lee, SW (corresponding author), Korea Univ, Dept Brain & Cognit Engn, Seoul 02841, South Korea.; Lee, SW (corresponding author), Korea Univ, Dept Artificial Intelligence, Seoul 02841, South Korea.	sw.lee@korea.ac.kr		Kim, Hyun Jeong/0000-0002-9265-7549; Seo, Kwang-Suk/0000-0001-5906-0639	Institute for Information & Communications Technology Planning & Evaluation (IITP) - Korea government [2017-0-00451]; Defense Acquisition Program Administration (DAPA); Agency for Defense Development (ADD) of Korea [06-201-305-001]; Seoul National University Dental Hospital (SNUDH) Research Fund [01-2015-0007]	Institute for Information & Communications Technology Planning & Evaluation (IITP) - Korea government; Defense Acquisition Program Administration (DAPA); Agency for Defense Development (ADD) of Korea; Seoul National University Dental Hospital (SNUDH) Research Fund	This work was supported by the Institute for Information & Communications Technology Planning & Evaluation (IITP) grant funded by the Korea government (No. 2017-0-00451 to SWL; Development of BCI based Brain and Cognitive Computing Technology for Recognizing User's Intentions using Deep Learning), Defense Acquisition Program Administration (DAPA) and Agency for Defense Development (ADD) of Korea (06-201-305-001 to SWL, A Study on Human-Computer Interaction Technology for the Pilot Status Recognition), and grant No. 01-2015-0007 to KSS from the Seoul National University Dental Hospital (SNUDH) Research Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by the Institute for Information & Communications Technology Planning & Evaluation (IITP) grant funded by the Korea government (No. 2017-0-00451; Development of BCI based Brain and Cognitive Computing Technology for Recognizing User's Intentions using Deep Learning), Defense Acquisition Program Administration (DAPA) and Agency for Defense Development (ADD) of Korea (06-201-305-001, A Study on Human-Computer Interaction Technology for the Pilot Status Recognition), and grant No. 01-2015-0007 from the Seoul National University Dental Hospital (SNUDH) Research Fund.	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; AMASSIAN VE, 1951, J NEUROPHYSIOL, V14, P433, DOI 10.1152/jn.1951.14.6.433; Barnett L, 2014, J NEUROSCI METH, V223, P50, DOI 10.1016/j.jneumeth.2013.10.018; Bashan A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1705; Beissner F, 2013, J NEUROSCI, V33, P10503, DOI 10.1523/JNEUROSCI.1103-13.2013; BENARROCH EE, 1993, MAYO CLIN PROC, V68, P988, DOI 10.1016/S0025-6196(12)62272-1; Benarroch EE., 1997, CENTRAL AUTONOMIC NE; Blayney MR, 2012, BJA EDUC, V12, P176, DOI 10.1093/bjaceaccp/mks016; Brown EN, 2011, ANNU REV NEUROSCI, V34, P601, DOI 10.1146/annurev-neuro-060909-153200; CHEUNG YW, 1993, OXFORD B ECON STAT, V55, P313, DOI 10.1111/j.1468-0084.1993.mp55003003.x; Critchley HD, 2013, NEURON, V77, P624, DOI 10.1016/j.neuron.2013.02.008; DOWNMAN CBB, 1951, J PHYSIOL-LONDON, V113, P434, DOI 10.1113/jphysiol.1951.sp004586; Evans MS, 1996, NEUROPHARMACOLOGY, V35, P347, DOI 10.1016/0028-3908(95)00182-4; Faes L, 2015, PHYSIOL MEAS, V36, P683, DOI 10.1088/0967-3334/36/4/683; Faes L, 2016, PHILOS T R SOC A, V374, DOI 10.1098/rsta.2015.0177; Gili T, 2013, J NEUROSCI, V33, P4024, DOI 10.1523/JNEUROSCI.3480-12.2013; GRANGER CWJ, 1969, ECONOMETRICA, V37, P424, DOI 10.2307/1912791; Gray MA, 2007, P NATL ACAD SCI USA, V104, P6818, DOI 10.1073/pnas.0609509104; Hesse W, 2003, J NEUROSCI METH, V124, P27, DOI 10.1016/S0165-0270(02)00366-7; Hyvarinen A, 2010, NEUROIMAGE, V49, P257, DOI 10.1016/j.neuroimage.2009.08.028; Immanuel SA, 2014, AM J RESP CRIT CARE, V190, P1149, DOI 10.1164/rccm.201405-0920OC; Ito SI, 2003, J NEUROPHYSIOL, V90, P143, DOI 10.1152/jn.01054.2002; Janig W., 2006, THE INTERGATIVE ACTI; Jurysta F, 2003, CLIN NEUROPHYSIOL, V114, P2146, DOI 10.1016/S1388-2457(03)00215-3; Kern M, 2013, NEUROIMAGE, V81, P178, DOI 10.1016/j.neuroimage.2013.05.042; KESELMAN HJ, 1977, PSYCHOL BULL, V84, P1050; Kwak NS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172578; Lee MH, 2018, IEEE T NEUR SYS REH, V26, P1443, DOI 10.1109/TNSRE.2018.2839116; Lee M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15082-5; Lin AJ, 2016, PHILOS T R SOC A, V374, DOI 10.1098/rsta.2015.0182; MCALLEN RM, 1978, J PHYSIOL-LONDON, V282, P353, DOI 10.1113/jphysiol.1978.sp012468; MELLER ST, 1992, NEUROSCIENCE, V48, P501, DOI 10.1016/0306-4522(92)90398-L; Nalatore H, 2014, PHYS REV E, V90, DOI 10.1103/PhysRevE.90.062127; Ng JM, 2001, GASTROINTEST ENDOSC, V54, P8, DOI 10.1067/mge.2001.116110; Ohsuga M, 2011, LECT NOTES ARTIF INT, V6781, P176, DOI 10.1007/978-3-642-21741-8_20; PAHLM O, 1984, MED BIOL ENG COMPUT, V22, P289, DOI 10.1007/BF02442095; Park HD, 2014, NAT NEUROSCI, V17, P612, DOI 10.1038/nn.3671; Pigarev I.N., 2014, NEUROSCI BEHAV PHYSI, V44, P421, DOI [10.1007/s11055-014-9928-z, DOI 10.1007/S11055-014-9928-Z]; Pigarev IN, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00139; Pigarev IN, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00075; Purdon PL, 2013, P NATL ACAD SCI USA, V110, pE1142, DOI 10.1073/pnas.1221180110; Ramshur JT, 2010, DESIGN EVALUATION AP; Rempel-Clower NL, 2007, ANN NY ACAD SCI, V1121, P72, DOI 10.1196/annals.1401.026; Resstel LBM, 2006, AUTON NEUROSCI-BASIC, V126, P130, DOI 10.1016/j.autneu.2006.02.022; Rothenberger SD, 2015, PSYCHOPHYSIOLOGY, V52, P572, DOI 10.1111/psyp.12383; Saha S, 2005, CLIN EXP PHARMACOL P, V32, P450, DOI 10.1111/j.1440-1681.2005.04210.x; Saha S, 2000, NEUROSCIENCE, V99, P613, DOI 10.1016/S0306-4522(00)00240-2; Schandry R, 1996, BIOL PSYCHOL, V42, P75, DOI 10.1016/0301-0511(95)05147-3; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; Seth AK, 2015, J NEUROSCI, V35, P3293, DOI 10.1523/JNEUROSCI.4399-14.2015; Shekhar A, 2003, ANN NY ACAD SCI, V985, P308; Shiogai Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044634; Sollis, 2003, APPL TIME SERIES MOD; Stankovski T, 2016, PHILOS T R SOC A, V374, DOI 10.1098/rsta.2015.0186; Steriade M, 1999, TRENDS NEUROSCI, V22, P337, DOI 10.1016/S0166-2236(99)01407-1; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; Stevenson IH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009206; Tarvainen MP, 2012, ANN BIOMED ENG, V40, P1802, DOI 10.1007/s10439-012-0544-1; Ter Horst GJ, 1997, AM J PHYSIOL-HEART C, V273, pH2926, DOI 10.1152/ajpheart.1997.273.6.H2926; Thayer JF, 2000, J AFFECT DISORDERS, V61, P201, DOI 10.1016/S0165-0327(00)00338-4; Traub RD, 2005, J NEUROPHYSIOL, V93, P2194, DOI 10.1152/jn.00983.2004; Tu Y, 2011, PHARMACOLOGY, V88, P322, DOI 10.1159/000334168; van Eden CG, 2000, PROG BRAIN RES, V126, P49; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; Won DO, 2018, IEEE T NEUR SYS REH, V26, P334, DOI 10.1109/TNSRE.2017.2736600; Won DO, 2016, J NEURAL ENG, V13, DOI 10.1088/1741-2560/13/1/016014; Wong SW, 2007, NEUROIMAGE, V35, P698, DOI 10.1016/j.neuroimage.2006.12.027; Yeom SK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187743; Zachariadis T., 2006, EXPLORATION CAUSAL R; Ziegler G, 2009, EUR J NEUROSCI, V30, P2205, DOI 10.1111/j.1460-9568.2009.07008.x	70	5	5	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2019	14	7							e0219238	10.1371/journal.pone.0219238	http://dx.doi.org/10.1371/journal.pone.0219238			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IS7LS	31314775	Green Published, Green Submitted, gold			2023-01-03	WOS:000482331900025
J	Campisi, J; Kapahi, P; Lithgow, GJ; Melov, S; Newman, JC; Verdin, E				Campisi, Judith; Kapahi, Pankaj; Lithgow, Gordon J.; Melov, Simon; Newman, John C.; Verdin, Eric			From discoveries in ageing research to therapeutics for healthy ageing	NATURE			English	Review							EXTENDS LIFE-SPAN; ONCOGENE-INDUCED SENESCENCE; GLYCATION END-PRODUCTS; CALORIE RESTRICTION; CELLULAR SENESCENCE; DIETARY RESTRICTION; BETA-HYDROXYBUTYRATE; METABOLIC DISEASES; NAD(+) METABOLISM; DEPENDENT CHANGES	For several decades, understanding ageing and the processes that limit lifespan have challenged biologists. Thirty years ago, the biology of ageing gained unprecedented scientific credibility through the identification of gene variants that extend the lifespan of multicellular model organisms. Here we summarize the milestones that mark this scientific triumph, discuss different ageing pathways and processes, and suggest that ageing research is entering a new era that has unique medical, commercial and societal implications. We argue that this era marks an inflection point, not only in ageing research but also for all biological research that affects the human healthspan.	[Campisi, Judith; Kapahi, Pankaj; Lithgow, Gordon J.; Melov, Simon; Newman, John C.; Verdin, Eric] Buck Inst Res Aging, Novato, CA 94945 USA	Buck Institute for Research on Aging	Verdin, E (corresponding author), Buck Inst Res Aging, Novato, CA 94945 USA.	EVerdin@buckinstitute.org	Verdin, Eric/AAB-7999-2019; Newman, John C/L-8112-2013; Melov, Simon/AAC-9469-2020	Melov, Simon/0000-0001-8554-2834	NIA NIH HHS [K08 AG048354, R01 AG029631] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anisimov VN, 2011, CELL CYCLE, V10, P4230, DOI 10.4161/cc.10.24.18486; Baker DJ, 2016, NATURE, V530, P184, DOI 10.1038/nature16932; Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600; Bannister CA, 2014, DIABETES OBES METAB, V16, P1165, DOI 10.1111/dom.12354; Bansal A, 2015, P NATL ACAD SCI USA, V112, pE277, DOI 10.1073/pnas.1412192112; Bartke A, 2008, AGING CELL, V7, P285, DOI 10.1111/j.1474-9726.2008.00387.x; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Barzilai N, 2016, CELL METAB, V23, P1060, DOI 10.1016/j.cmet.2016.05.011; Barzilai N, 2012, DIABETES, V61, P1315, DOI 10.2337/db11-1300; Belenky P, 2007, TRENDS BIOCHEM SCI, V32, P12, DOI 10.1016/j.tibs.2006.11.006; Belsky DW, 2018, J GERONTOL A-BIOL, V73, P4, DOI 10.1093/gerona/glx096; Bitto A, 2016, ELIFE, V5, DOI 10.7554/eLife.16351; Bonkowski MS, 2016, NAT REV MOL CELL BIO, V17, P679, DOI 10.1038/nrm.2016.93; Brand MD, 2010, EXP GERONTOL, V45, P466, DOI 10.1016/j.exger.2010.01.003; Brandhorst S, 2015, CELL METAB, V22, P86, DOI 10.1016/j.cmet.2015.05.012; Brown RT, 2017, GERONTOLOGIST, V57, P757, DOI 10.1093/geront/gnw011; Bussian TJ, 2018, NATURE, V562, P578, DOI 10.1038/s41586-018-0543-y; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Carrico C, 2018, CELL METAB, V27, P497, DOI 10.1016/j.cmet.2018.01.016; Chakravarty EF, 2008, ARCH INTERN MED, V168, P1638, DOI 10.1001/archinte.168.15.1638; Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010; Chaudhuri J, 2018, CELL METAB, V28, P337, DOI 10.1016/j.cmet.2018.08.014; Chen D, 2008, GENE DEV, V22, P1753, DOI 10.1101/gad.1650608; Chen D, 2013, CELL REP, V5, P1600, DOI 10.1016/j.celrep.2013.11.018; Childs BG, 2017, NAT REV DRUG DISCOV, V16, P718, DOI 10.1038/nrd.2017.116; Childs BG, 2016, SCIENCE, V354, P472, DOI 10.1126/science.aaf6659; Chinta SJ, 2018, CELL REP, V22, P930, DOI 10.1016/j.celrep.2017.12.092; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Costford SR, 2010, AM J PHYSIOL-ENDOC M, V298, pE117, DOI 10.1152/ajpendo.00318.2009; Dai DF, 2009, CIRCULATION, V119, P2789, DOI 10.1161/CIRCULATIONAHA.108.822403; Dai H, 2018, PHARMACOL THERAPEUT, V188, P140, DOI 10.1016/j.pharmthera.2018.03.004; David DC, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000450; Demaria M, 2017, CANCER DISCOV, V7, P165, DOI 10.1158/2159-8290.CD-16-0241; di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Dong X, 2016, NATURE, V538, P257, DOI 10.1038/nature19793; Duggal NA, 2018, AGING CELL, V17, DOI 10.1111/acel.12750; Durieux J, 2011, CELL, V144, P79, DOI 10.1016/j.cell.2010.12.016; Fabbri E, 2015, J AM MED DIR ASSOC, V16, P640, DOI 10.1016/j.jamda.2015.03.013; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385; Ferrucci L, 2018, NAT REV CARDIOL, V15, P505, DOI 10.1038/s41569-018-0064-2; Fischer KE, 2016, AGING-US, V8, P2370, DOI 10.18632/aging.101059; Floreani A, 2016, CLIN REV ALLERG IMMU, V50, P287, DOI 10.1007/s12016-015-8493-8; Flynn JM, 2013, AGING CELL, V12, P851, DOI 10.1111/acel.12109; Fontana L, 2009, EXP GERONTOL, V44, P41, DOI 10.1016/j.exger.2008.04.005; Franceschi C, 2000, ANN NY ACAD SCI, V908, P244; Franceschi C, 2007, MECH AGEING DEV, V128, P92, DOI 10.1016/j.mad.2006.11.016; Franceschi C, 2018, ANNU REV NUTR, V38, P329, DOI 10.1146/annurev-nutr-082117-051637; Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; FRIEDMAN DB, 1988, GENETICS, V118, P75; Fuhrmann-Stroissnigg H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00314-z; Fulco M, 2008, DEV CELL, V14, P661, DOI 10.1016/j.devcel.2008.02.004; Garatachea N, 2014, EXP GERONTOL, V53, P16, DOI 10.1016/j.exger.2014.02.004; Goncalves RLS, 2015, J BIOL CHEM, V290, P209, DOI 10.1074/jbc.M114.619072; Guarente L, 2008, CELL, V132, P171, DOI 10.1016/j.cell.2008.01.007; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Harper JM, 2006, AGING CELL, V5, P441, DOI 10.1111/j.1474-9726.2006.00236.x; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Hatori M, 2012, CELL METAB, V15, P848, DOI 10.1016/j.cmet.2012.04.019; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Horvath S, 2018, NAT REV GENET, V19, P371, DOI 10.1038/s41576-018-0004-3; Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115; Houtkooper RH, 2013, NATURE, V497, P451, DOI 10.1038/nature12188; Ickowicz E, 2012, J AM GERIATR SOC, V60, pE1, DOI 10.1111/j.1532-5415.2012.04188.x; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Ismail K, 2016, J AM GERIATR SOC, V64, P1583, DOI 10.1111/jgs.14222; Jeon OH, 2017, NAT MED, V23, P775, DOI 10.1038/nm.4324; Justice J, 2016, J GERONTOL A-BIOL, V71, P1415, DOI 10.1093/gerona/glw126; Justice JN, 2018, GEROSCIENCE, V40, P419, DOI 10.1007/s11357-018-0042-y; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Kane AE, 2018, CIRC RES, V123, P868, DOI 10.1161/CIRCRESAHA.118.312498; Kanfi Y, 2012, NATURE, V483, P218, DOI 10.1038/nature10815; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; Kapahi P, 2017, AGEING RES REV, V39, P3, DOI 10.1016/j.arr.2016.12.005; Kapahi P, 2010, CELL METAB, V11, P453, DOI 10.1016/j.cmet.2010.05.001; Kaplan-Lewis E, 2017, SEMIN DIAGN PATHOL, V34, P384, DOI 10.1053/j.semdp.2017.04.002; Katewa SD, 2016, CELL METAB, V23, P143, DOI 10.1016/j.cmet.2015.10.014; Katz DL, 2014, ANNU REV PUBL HEALTH, V35, P83, DOI 10.1146/annurev-publhealth-032013-182351; Kaushik S, 2015, NAT MED, V21, P1406, DOI 10.1038/nm.4001; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; Kennedy BK, 2014, CELL, V159, P708, DOI 10.1016/j.cell.2014.10.039; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kim SW, 2014, JAMA SURG, V149, P633, DOI 10.1001/jamasurg.2014.241; Kirkland JL, 2017, J AM GERIATR SOC, V65, P2297, DOI 10.1111/jgs.14969; Klaips CL, 2018, J CELL BIOL, V217, P51, DOI 10.1083/jcb.201709072; Kleinstreuer NC, 2014, NAT BIOTECHNOL, V32, P583, DOI 10.1038/nbt.2914; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kondratov RV, 2007, AGEING RES REV, V6, P12, DOI 10.1016/j.arr.2007.02.003; Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049; Lai JC, 2017, HEPATOLOGY, V66, P564, DOI 10.1002/hep.29219; Lee DC, 2017, PROG CARDIOVASC DIS, V60, P45, DOI 10.1016/j.pcad.2017.03.005; Lee HY, 2017, DIABETES, V66, P2072, DOI 10.2337/db16-1334; Lee SJ, 2010, CURR BIOL, V20, P2131, DOI 10.1016/j.cub.2010.10.057; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Levine ME, 2018, AGING-US, V10, P573, DOI 10.18632/aging.101414; Liao CY, 2010, AGING CELL, V9, P92, DOI 10.1111/j.1474-9726.2009.00533.x; Lin AL, 2013, J CEREBR BLOOD F MET, V33, P1412, DOI 10.1038/jcbfm.2013.82; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin YF, 2016, MOL CELL, V61, P677, DOI 10.1016/j.molcel.2016.02.004; Longo VD, 2016, CELL METAB, V23, P1048, DOI 10.1016/j.cmet.2016.06.001; Longo VD, 2014, CELL METAB, V19, P181, DOI 10.1016/j.cmet.2013.12.008; Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039; Lucanic M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14256; Makary MA, 2010, J AM COLL SURGEONS, V210, P901, DOI 10.1016/j.jamcollsurg.2010.01.028; Mannick JB, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaq1564; Mannick JB, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009892; Martens CR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03421-7; Martin-Montalvo A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3192; Mattison JA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14063; Mattison JA, 2012, NATURE, V489, P318, DOI 10.1038/nature11432; McCay CM, 1939, J NUTR, V18, P1; Medawar P., 1952, UNSOLVED PROBLEM BIO; Melis R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103120; Mercken EM, 2014, AGING CELL, V13, P787, DOI 10.1111/acel.12220; Mitchell SJ, 2014, CELL REP, V6, P836, DOI 10.1016/j.celrep.2014.01.031; Moore SC, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001335; Mouchiroud L, 2013, CELL, V154, P430, DOI 10.1016/j.cell.2013.06.016; Nadon NL, 2017, EBIOMEDICINE, V21, P3, DOI 10.1016/j.ebiom.2016.11.038; Nakahata Y, 2009, SCIENCE, V324, P654, DOI 10.1126/science.1170803; Newman JC, 2017, CELL METAB, V26, P547, DOI 10.1016/j.cmet.2017.08.004; Newman JC, 2017, ANNU REV NUTR, V37, P51, DOI 10.1146/annurev-nutr-071816-064916; Niccoli T, 2012, CURR BIOL, V22, pR741, DOI 10.1016/j.cub.2012.07.024; North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ogrodnik M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15691; OLSHANSKY SJ, 1990, SCIENCE, V250, P634, DOI 10.1126/science.2237414; Olson MV, 2012, ANNU REV GENOM HUM G, V13, P1, DOI 10.1146/annurev-genom-090711-163825; Omodei D, 2011, FEBS LETT, V585, P1537, DOI 10.1016/j.febslet.2011.03.015; Partridge L, 2018, NATURE, V561, P45, DOI 10.1038/s41586-018-0457-8; Patel SA, 2016, FASEB J, V30, P1634, DOI 10.1096/fj.15-282475; Perez VI, 2009, AGING CELL, V8, P73, DOI 10.1111/j.1474-9726.2008.00449.x; Perez VI, 2009, P NATL ACAD SCI USA, V106, P3059, DOI 10.1073/pnas.0809620106; Pifferi F, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0024-8; Pincus Z, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002306; Pollock RD, 2018, AGING CELL, V17, DOI 10.1111/acel.12735; Ramsey KM, 2009, SCIENCE, V324, P651, DOI 10.1126/science.1171641; Reis-Rodrigues P, 2012, AGING CELL, V11, P120, DOI 10.1111/j.1474-9726.2011.00765.x; Renz H, 2017, J ALLERGY CLIN IMMUN, V140, P24, DOI 10.1016/j.jaci.2017.05.015; Richardson A, 2016, J GERONTOL A-BIOL, V71, P427, DOI 10.1093/gerona/glv080; Ristow M, 2011, FREE RADICAL BIO MED, V51, P327, DOI 10.1016/j.freeradbiomed.2011.05.010; Ristow M, 2010, EXP GERONTOL, V45, P410, DOI 10.1016/j.exger.2010.03.014; Roberts MN, 2017, CELL METAB, V26, P539, DOI 10.1016/j.cmet.2017.08.005; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; ROSE M, 1980, NATURE, V287, P141, DOI 10.1038/287141a0; Sato S, 2017, CELL, V170, P664, DOI 10.1016/j.cell.2017.07.042; Satoh A, 2013, CELL METAB, V18, P416, DOI 10.1016/j.cmet.2013.07.013; Savji N, 2013, J AM COLL CARDIOL, V61, P1736, DOI 10.1016/j.jacc.2013.01.054; Schafer MJ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14532; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Semba RD, 2010, J GERONTOL A-BIOL, V65, P963, DOI 10.1093/gerona/glq074; Shah PP, 2013, GENE DEV, V27, P1787, DOI 10.1101/gad.223834.113; Shay JW, 2000, NAT REV MOL CELL BIO, V1, P72, DOI 10.1038/35036093; Shimazu T, 2013, SCIENCE, V339, P211, DOI 10.1126/science.1227166; Shinohara M, 2016, ANN NEUROL, V79, P758, DOI 10.1002/ana.24628; Sly PD, 2016, ANN GLOB HEALTH, V82, P3, DOI 10.1016/j.aogh.2016.01.004; Someya S, 2010, CELL, V143, P802, DOI 10.1016/j.cell.2010.10.002; St Sauver JL, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006413; Steinman MA, 2016, JAMA INTERN MED, V176, P482, DOI 10.1001/jamainternmed.2015.8597; Strandberg TE, 2007, LANCET, V369, P1328, DOI 10.1016/S0140-6736(12)62167-9; Studenski S, 2011, JAMA-J AM MED ASSOC, V305, P50, DOI 10.1001/jama.2010.1923; Sun JT, 2002, GENETICS, V161, P661; Sun N, 2016, MOL CELL, V61, P654, DOI 10.1016/j.molcel.2016.01.028; Swindell WR, 2012, AGEING RES REV, V11, P254, DOI 10.1016/j.arr.2011.12.006; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; TenNapel MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115616; Tower J, 2000, MECH AGEING DEV, V118, P1, DOI 10.1016/S0047-6374(00)00152-4; Treaster S. B., 2013, AGE, V36, P9597; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Urfer SR, 2017, GEROSCIENCE, V39, P117, DOI 10.1007/s11357-017-9972-z; Verdin E, 2015, SCIENCE, V350, P1208, DOI 10.1126/science.aac4854; Wallace LMK, 2019, LANCET NEUROL, V18, P177, DOI 10.1016/S1474-4422(18)30371-5; Wang YY, 2016, AGING-US, V8, P2915, DOI 10.18632/aging.101100; Wiley CD, 2016, CELL METAB, V23, P303, DOI 10.1016/j.cmet.2015.11.011; Wilicox BJ, 2008, P NATL ACAD SCI USA, V105, P13987, DOI 10.1073/pnas.0801030105; Wilson K. A., 2018, GENOME WIDE ANAL REV, DOI [10.1101/153791v2, DOI 10.1101/153791V2]; Xia Xian, 2017, F1000Res, V6, P860, DOI 10.12688/f1000research.10692.1; Xu M, 2018, NAT MED, V24, P1246, DOI 10.1038/s41591-018-0092-9; Yosef R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11190; Yun J, 2014, CELL METAB, V19, P757, DOI 10.1016/j.cmet.2014.01.011; Zaseck LW, 2016, J GERONTOL A-BIOL, V71, P858, DOI 10.1093/gerona/glv307; Zhang WB, 2016, CELL SYST, V3, P333, DOI 10.1016/j.cels.2016.09.003; Zid BM, 2009, CELL, V139, P149, DOI 10.1016/j.cell.2009.07.034	193	358	369	70	268	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 11	2019	571	7764					183	192		10.1038/s41586-019-1365-2	http://dx.doi.org/10.1038/s41586-019-1365-2			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IH9RF	31292558	Green Accepted, Bronze			2023-01-03	WOS:000474843400026
J	Volkow, ND; Han, B; Compton, WM; McCance-Katz, EF				Volkow, Nora D.; Han, Beth; Compton, Wilson M.; McCance-Katz, Elinore F.			Self-reported Medical and Nonmedical Cannabis Use Among Pregnant Women in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							MARIJUANA USE		[Volkow, Nora D.; Compton, Wilson M.] NIDA, NIH, Bethesda, MD 20892 USA; [Han, Beth; McCance-Katz, Elinore F.] Subst Abuse & Mental Hlth Serv Adm, 5600 Fishers Ln,15E17B, Rockville, MD 20857 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Han, B (corresponding author), Subst Abuse & Mental Hlth Serv Adm, 5600 Fishers Ln,15E17B, Rockville, MD 20857 USA.	beth.han@samhsa.hhs.gov			National Institute on Drug Abuse of the National Institutes of Health; Substance Abuse and Mental Health Services Administration of the US Department of Health and Human Services; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000550] Funding Source: NIH RePORTER	National Institute on Drug Abuse of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Substance Abuse and Mental Health Services Administration of the US Department of Health and Human Services; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This study was jointly sponsored by the National Institute on Drug Abuse of the National Institutes of Health and the Substance Abuse and Mental Health Services Administration of the US Department of Health and Human Services.	Brown QL, 2017, JAMA-J AM MED ASSOC, V317, P207, DOI 10.1001/jama.2016.17383; Center for Behavioral Health Statistics and Quality, 2017, 2017 NAT SURV DRUG U; O'Connor M, 2018, J LAW MED, V25, P634; Volkow ND, 2017, ANN INTERN MED, V166, P763, DOI 10.7326/L17-0067; 2017, OBSTET GYNECOL, V130, pE20, DOI DOI 10.1097/AOG.0000000000002354SSSS	5	140	140	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	2019	322	2					167	169		10.1001/jama.2019.7982	http://dx.doi.org/10.1001/jama.2019.7982			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IK7NZ	31211824	Green Published, Bronze			2023-01-03	WOS:000476778700021
J	Fischer, K; Al-Sawaf, O; Bahlo, J; Fink, AM; Tandon, M; Dixon, M; Robrecht, S; Warburton, S; Humphrey, K; Samoylova, O; Liberati, AM; Pinilla-Ibarz, J; Opat, S; Sivcheva, L; Du, KL; Fogliatto, LM; Niemann, CU; Weinkove, R; Robinson, S; Kipps, TJ; Boettcher, S; Tausch, E; Humerickhouse, R; Eichhorst, B; Wendtner, CM; Langerak, AW; Kreuzer, KA; Ritgen, M; Goede, V; Stilgenbauer, S; Mobasher, M; Hallek, M				Fischer, K.; Al-Sawaf, O.; Bahlo, J.; Fink, A. -M.; Tandon, M.; Dixon, M.; Robrecht, S.; Warburton, S.; Humphrey, K.; Samoylova, O.; Liberati, A. M.; Pinilla-Ibarz, J.; Opat, S.; Sivcheva, L.; Du, K. Le; Fogliatto, L. M.; Niemann, C. U.; Weinkove, R.; Robinson, S.; Kipps, T. J.; Boettcher, S.; Tausch, E.; Humerickhouse, R.; Eichhorst, B.; Wendtner, C. -M.; Langerak, A. W.; Kreuzer, K. -A.; Ritgen, M.; Goede, V.; Stilgenbauer, S.; Mobasher, M.; Hallek, M.			Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; IBRUTINIB; GUIDELINES	Background The BCL2 inhibitor venetoclax has shown activity in patients with chronic lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with CLL and coexisting conditions is not known. Methods In this open-label, phase 3 trial, we investigated fixed-duration treatment with venetoclax and obinutuzumab in patients with previously untreated CLL and coexisting conditions. Patients with a score of greater than 6 on the Cumulative Illness Rating Scale (scores range from 0 to 56, with higher scores indicating more impaired function of organ systems) or a calculated creatinine clearance of less than 70 ml per minute were randomly assigned to receive venetoclax-obinutuzumab or chlorambucil-obinutuzumab. The primary end point was investigator-assessed progression-free survival. The safety of each regimen was also evaluated. Results In total, 432 patients (median age, 72 years; median Cumulative Illness Rating Scale score, 8; median creatinine clearance, 66.4 ml per minute) underwent randomization, with 216 assigned to each group. After a median follow-up of 28.1 months, 30 primary end-point events (disease progression or death) had occurred in the venetoclax-obinutuzumab group and 77 had occurred in the chlorambucil-obinutuzumab group (hazard ratio, 0.35; 95% confidence interval [CI], 0.23 to 0.53; P<0.001). The Kaplan-Meier estimate of the percentage of patients with progression-free survival at 24 months was significantly higher in the venetoclax-obinutuzumab group than in the chlorambucil-obinutuzumab group: 88.2% (95% CI, 83.7 to 92.6) as compared with 64.1% (95% CI, 57.4 to 70.8). This benefit was also observed in patients with TP53 deletion, mutation, or both and in patients with unmutated immunoglobulin heavy-chain genes. Grade 3 or 4 neutropenia occurred in 52.8% of patients in the venetoclax-obinutuzumab group and in 48.1% of patients in the chlorambucil-obinutuzumab group, and grade 3 or 4 infections occurred in 17.5% and 15.0%, respectively. All-cause mortality was 9.3% in the venetoclax-obinutuzumab group and 7.9% in the chlorambucil-obinutuzumab group. These differences were not significant. Conclusions Among patients with untreated CLL and coexisting conditions, venetoclax-obinutuzumab was associated with longer progression-free survival than chlorambucil-obinutuzumab. (Funded by F. Hoffmann-La Roche and AbbVie; ClinicalTrials.gov number, NCT02242942.)	[Fischer, K.; Al-Sawaf, O.; Bahlo, J.; Fink, A. -M.; Robrecht, S.; Eichhorst, B.; Kreuzer, K. -A.; Hallek, M.] Univ Hosp Cologne, Dept Internal Med 1, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Cologne, Germany; [Fischer, K.; Al-Sawaf, O.; Bahlo, J.; Fink, A. -M.; Robrecht, S.; Eichhorst, B.; Kreuzer, K. -A.; Hallek, M.] Univ Cologne, Cologne, Germany; [Goede, V.] St Marien Hosp, Dept Geriatr Med, Oncogeriatr Unit, Cologne, Germany; [Hallek, M.] CECAD Ctr Excellence Cellular Stress Responses Ag, Cologne, Germany; [Hallek, M.] Ctr Mol Med Cologne, Cologne, Germany; [Boettcher, S.] Univ Hosp Rostock, Dept Internal Med 3, Rostock, Germany; [Tausch, E.; Stilgenbauer, S.] Ulm Univ, Dept Internal Med 3, Ulm, Germany; [Wendtner, C. -M.] Klinikum Schwabing, Dept Hematol, Munich, Germany; [Wendtner, C. -M.] Klinikum Schwabing, Dept Oncol, Munich, Germany; [Wendtner, C. -M.] Klinikum Schwabing, Dept Immunol, Munich, Germany; [Wendtner, C. -M.] Klinikum Schwabing, Dept Palliat Care, Munich, Germany; [Wendtner, C. -M.] Klinikum Schwabing, Dept Infect Dis, Munich, Germany; [Wendtner, C. -M.] Klinikum Schwabing, Dept Trop Med, Munich, Germany; [Ritgen, M.] Univ Schleswig Holstein, Dept Internal Med 2, Campus Kiel, Kiel, Germany; [Stilgenbauer, S.] Saarland Univ, Med Sch, Dept Hematol Oncol & Rheumatol, Homburg, Germany; [Tandon, M.; Dixon, M.; Warburton, S.; Humphrey, K.] Roche Prod, Welwyn Garden City, Herts, England; [Samoylova, O.] Reg Clin Hosp NA Semashko, Nizhnii Novgorod, Russia; [Liberati, A. M.] Univ Perugia, Santa Maria Terni Hosp, Div Oncohematol, Perugia, Italy; [Pinilla-Ibarz, J.] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA; [Opat, S.] Monash Univ, Monash Hlth, Sch Clin Sci, Haematol Dept, Clayton, Vic, Australia; [Sivcheva, L.] Multiprofile Hosp Act Treatment Hristo Botev, Internal Dept 1, Vratsa, Bulgaria; [Du, K. Le] Clin Victor Hugo, Hematol Dept, Le Mans, France; [Fogliatto, L. M.] Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil; [Niemann, C. U.] Copenhagen Univ Hosp, Dept Hematol, Rigshosp, Copenhagen, Denmark; [Weinkove, R.] Wellington Blood & Canc Ctr, Capital & Coast Dist Hlth Board, Wellington, New Zealand; [Weinkove, R.] Malaghan Inst Med Res, Wellington, New Zealand; [Robinson, S.] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada; [Kipps, T. J.] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA; [Mobasher, M.] Genentech Inc, San Francisco, CA USA; [Humerickhouse, R.] AbbVie, N Chicago, IL USA; [Langerak, A. W.] Erasmus MC, Dept Immunol, Lab Med Immunol, Rotterdam, Netherlands	University of Cologne; University of Cologne; St. Marien Hospital; University of Cologne; University of Cologne; University of Rostock; Ulm University; Munchen Klinik; Munchen Klinik; Munchen Klinik; Munchen Klinik; Munchen Klinik; Munchen Klinik; University of Kiel; Schleswig Holstein University Hospital; Universitatsklinikum des Saarlandes; Roche Holding; University of Perugia; H Lee Moffitt Cancer Center & Research Institute; Monash University; Rigshospitalet; University of Copenhagen; Malaghan Institute; Victoria University Wellington; Queen Elizabeth II Health Sciences Centre; University of California System; University of California San Diego; Roche Holding; Genentech; AbbVie; Erasmus University Rotterdam; Erasmus MC	Hallek, M (corresponding author), Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, Dept Internal Med, Kerpener Str 62, D-50937 Cologne, Germany.	michael.-hallek@-uni-koeln.-de	Fogliatto, Laura/W-3787-2019; Weinkove, Robert/S-4457-2019; Hallek, Michael/Y-3191-2019; Stilgenbauer, Stephan/ABE-6609-2020; Al-Sawaf, Othman/AAU-3737-2021; Opat, Stephen/AFR-0783-2022; Weinkove, Robert/I-6991-2012	Fogliatto, Laura/0000-0002-0610-7971; Weinkove, Robert/0000-0003-3645-7988; Hallek, Michael/0000-0002-7425-4455; Al-Sawaf, Othman/0000-0001-9895-0570; Opat, Stephen/0000-0002-0308-6458; Weinkove, Robert/0000-0003-3645-7988; Fink, Anna Maria/0000-0002-7669-7890; Wendtner, Clemens-Martin/0000-0003-2866-2260	F. Hoffmann-La Roche; AbbVie; Gardiner-Caldwell Communications; NATIONAL CANCER INSTITUTE [P30CA076292] Funding Source: NIH RePORTER	F. Hoffmann-La Roche(Hoffmann-La Roche); AbbVie(AbbVie); Gardiner-Caldwell Communications; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by F. Hoffmann-La Roche and AbbVie. Third-party editing and administrative support was provided by Gardiner-Caldwell Communications and was funded by F. Hoffmann-La Roche.	[Anonymous], 2016, SEER CANC STAT REV 1; [Anonymous], 2018, BLOOD, V132, pe1; Barr PM, 2018, HAEMATOLOGICA, V103, P1502, DOI 10.3324/haematol.2018.192328; Burger JA, 2015, NEW ENGL J MED, V373, P2425, DOI 10.1056/NEJMoa1509388; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Cory S, 2016, TRENDS CANCER, V2, P443, DOI 10.1016/j.trecan.2016.07.001; Cramer P, 2018, LANCET ONCOL, V19, P1215, DOI 10.1016/S1470-2045(18)30414-5; Davids MS, 2017, BLOOD, V130; Dmitrienko A, 2013, STAT MED, V32, P5172, DOI 10.1002/sim.5990; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Eichhorst B, 2016, Ann Oncol, V27, pv143; Fischer K, 2017, BLOOD, V129, P2702, DOI 10.1182/blood-2017-01-761973; Goede V, 2018, HEMASPHERE, V2, P30; Goede V, 2014, NEW ENGL J MED, V370, P1101, DOI 10.1056/NEJMoa1313984; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Hallek M, 2018, LANCET, V391, P1524, DOI 10.1016/S0140-6736(18)30422-7; Howard SC, 2011, NEW ENGL J MED, V364, P1844, DOI 10.1056/NEJMra0904569; Mato AR, 2018, AM J HEMATOL, V93, P1394, DOI 10.1002/ajh.25261; Mato AR, 2018, HAEMATOLOGICA, V103, P874, DOI 10.3324/haematol.2017.182907; MATO AR, 2016, BLOOD, V128; Moreno C, 2019, LANCET ONCOL, V20, P43, DOI 10.1016/S1470-2045(18)30788-5; National Comprehensive Cancer Network, 2019, CHRON LYMPH LEUK SMA; Piccirillo JF, 2008, CRIT REV ONCOL HEMAT, V67, P124, DOI 10.1016/j.critrevonc.2008.01.013; Rawstron AC, 2007, LEUKEMIA, V21, P956, DOI 10.1038/sj.leu.2404584; Rawstron AC, 2013, LEUKEMIA, V27, P142, DOI 10.1038/leu.2012.216; Salvi F, 2008, J AM GERIATR SOC, V56, P1926, DOI 10.1111/j.1532-5415.2008.01935.x; Seymour JF, 2018, NEW ENGL J MED, V378, P1107, DOI 10.1056/NEJMoa1713976; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Stilgenbauer S, 2016, LANCET ONCOL, V17, P768, DOI 10.1016/S1470-2045(16)30019-5; UK CLL Forum, 2016, HAEMATOLOGICA, V101, P1563, DOI 10.3324/haematol.2016.147900; Winqvist M, 2016, HAEMATOLOGICA, V101, P1573, DOI 10.3324/haematol.2016.144576; Woyach JA, 2018, NEW ENGL J MED, V379, P2517, DOI 10.1056/NEJMoa1812836	32	406	413	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 6	2019	380	23					2225	2236		10.1056/NEJMoa1815281	http://dx.doi.org/10.1056/NEJMoa1815281			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IC4KH	31166681	Bronze			2023-01-03	WOS:000470933900009
J	van Leersum, CM; Moser, A; van Steenkiste, B; Wolf, JRLM; van der Weijden, T				van Leersum, Catharina M.; Moser, Albine; van Steenkiste, Ben; Wolf, Judith R. L. M.; van der Weijden, Trudy			Getting to grips with the process of decision-making in long-term care. Descriptive cases illustrate the chaotic reality of the construction of preferences	PLOS ONE			English	Article							MENTAL-CAPACITY; LIFE	Background Clients facing decision-making for long-term care are in need of support and accessible information. Construction of preferences, including context and calculations, for clients in long-term care is challenging because of the variability in supply and demand. This study considers clients in four different sectors of long-term care: the nursing and care of the elderly, mental health care, care of people with disabilities, and social care. The aim is to understand the construction of preferences in real-life situations. Method Client choices were investigated by qualitative descriptive research. Data were collected from 16 in-depth interviews and 79 client records. Interviews were conducted with clients and relatives or informal caregivers from different care sectors. The original client records were explored, containing texts, letters, and comments of clients and caregivers. All data were analyzed using thematic analysis. Results Four cases showed how preferences were constructed during the decision-making process. Clients discussed a wide range of challenging aspects that have an impact on the construction of preferences, e.g. previous experiences, current treatment or family situation. This study describes two main characteristics of the construction of preferences: context and calculation. Conclusion Clients face diverse challenges during the decision-making process on long-term care and their construction of preferences is variable. A well-designed tool to support the elicitation of preferences seems beneficial.	[van Leersum, Catharina M.; Moser, Albine; van Steenkiste, Ben; van der Weijden, Trudy] Maastricht Univ, CAPHRI Sch Publ Hlth & Primary Care, Dept Family Med, Med Ctr, Maastricht, Netherlands; [Moser, Albine] Zuyd Univ Appl Sci, Res Ctr Auton & Participat Persons Chron Illness, Heerlen, Netherlands; [Wolf, Judith R. L. M.] Radboud Univ Nijmegen, Impuls Netherlands Ctr Social Care Res, Radboud Inst Hlth Sci, Med Ctr, Nijmegen, Netherlands	Maastricht University; Radboud University Nijmegen	van Leersum, CM (corresponding author), Maastricht Univ, CAPHRI Sch Publ Hlth & Primary Care, Dept Family Med, Med Ctr, Maastricht, Netherlands.	karin.vanleersum@maastrichtuniversity.nl	Wolf, Judith/H-8122-2014	Wolf, Judith/0000-0001-7106-9142; van Leersum, Catharina/0000-0002-1003-0794; van der weijden, trudy/0000-0002-7469-3781	ZonMw, The Hague, The Netherlands [516012502]	ZonMw, The Hague, The Netherlands(Netherlands Organization for Health Research and DevelopmentNetherlands Government)	TvdW received a fund by ZonMw, The Hague, The Netherlands (516012502). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Boot AWA, 2017, WETEN IS NOG GEEN DO; Bosselaar H., 2013, BOUWPLAATS LOKALE VE; Carter G, 2017, DEMENTIA-LONDON, V16, P79, DOI 10.1177/1471301215581227; Chatfield DA, 2018, NURS CRIT CARE, V23, P82, DOI 10.1111/nicc.12290; Elo S, 2008, J ADV NURS, V62, P107, DOI 10.1111/j.1365-2648.2007.04569.x; Elwyn G, 2012, J GEN INTERN MED, V27, P1361, DOI 10.1007/s11606-012-2077-6; Friesen-Storms JHHM, 2015, INT J NURS STUD, V52, P393, DOI 10.1016/j.ijnurstu.2014.06.012; Guo L, 2016, MANAGE SCI, V62, P2977, DOI 10.1287/mnsc.2015.2290; Habermas Jurgen, THEORY COMMUNICATIVE, P368; Hendrinks M, 2017, VERSLAG TWEEDAAGSE B; Iederin NPCF, 2017, ALS ZORG ONDERSTEUNI; Kahneman D, 2011, ONS FEILBARE DENKEN; Kane RA, 2001, GERONTOLOGIST, V41, P293, DOI 10.1093/geront/41.3.293; Lincoln Y.S., 1985, NATURALISTIC INQUIRY; Lindquist LA, 2017, PATIENT EDUC COUNS, V100, P1996, DOI 10.1016/j.pec.2017.06.028; McCall N, 2001, WHO WILL PAY LONG TE, P3; Mulley AG, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6572; Nicholson TRJ, 2008, BRIT MED J, V336, P322, DOI 10.1136/bmj.39457.485347.80; Oosterkamp E, 2016, SOCIAALBESTEK, V78, P3, DOI DOI 10.1007/S41196-016-0064-X; SLOVIC P, 1995, AM PSYCHOL, V50, P364, DOI 10.1037/0003-066X.50.5.364; Stiggelbout AM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e256; Tinetti ME, 2016, CLIN GERIATR MED, V32, P261, DOI 10.1016/j.cger.2016.01.012; Turnpenny A, 2015, HEALTH SOC CARE COMM, V23, P349, DOI 10.1111/hsc.12133; Warren C, 2011, WIRES COGN SCI, V2, P193, DOI 10.1002/wcs.98	24	4	4	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 24	2019	14	5							e0217338	10.1371/journal.pone.0217338	http://dx.doi.org/10.1371/journal.pone.0217338			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HZ5BN	31125374	Green Published, gold, Green Submitted			2023-01-03	WOS:000468865700029
J	Zadeh, NS; Mohammadi, F; Rarani, MA; Javadi, M; Mohammadzade, M; Yazdi-Feyzabadi, V				Zadeh, Nasrin Shaarbafchi; Mohammadi, Farzaneh; Rarani, Mostafa Amini; Javadi, Marzieh; Mohammadzade, Mohammadjavad; Yazdi-Feyzabadi, Vahid			How the service delivery works in the Iranian specialised burns hospitals? A qualitative approach	PLOS ONE			English	Article							CARE; EPIDEMIOLOGY; PREVENTION	As burn injuries are a major cause of death and infirmity, successful service delivery is vital in health systems. In Iran, a few specialised burns hospitals (SBHs) located in big provinces provide burn services in which burn patients with more severe conditions are referred to. However, SBHs are faced with several challenges for delivering due treatment for burn patients. So, for the first time in Iran, the main aim of the study was to identify the challenges of delivering burn services in SBHs. For this purpose, we conducted a qualitative study during February 2017 to April 2018. Key informants were purposefully selected and interviewed at national and provincial levels from the Ministry of Health, medical universities, and informants working in eight SBHs. The saturation point was reached at 21 face-to-face semi-structured interviews. A thematic analysis approach was employed to analyse transcribed documents assisted by MAXQDA Plus version 12. Our results reveal four themes and twelve subthemes on the challenges of delivering services in SBHs. Themes and (subthemes) including burn care continuum (preventive care, pre-hospital care, hospital care, follow-up, and home care), regionalisation of burning services (access to other specialties and medical services, access to specialized care in provinces without a SBH, standardised regionalisation system for burn related services (BRSs), costs of providing BRSs (expensive services and supplies and long hospitalisation), and non-compliance with standardised care (guidelines to provide burn care and physical space to provide BRSs). Results suggest that improving BRSs delivery in Iran may be reached by strengthening burn care continuum, regionalising burn care, allocating sufficient budgets to burn services and formulating burn care guidelines. These policy actions can be better addressed via intra-sectoral collaborations.	[Zadeh, Nasrin Shaarbafchi; Mohammadzade, Mohammadjavad] Isfahan Univ Med Sci, Social Determinants Hlth Res Ctr, Esfahan, Iran; [Mohammadi, Farzaneh; Rarani, Mostafa Amini; Javadi, Marzieh] Isfahan Univ Med Sci, Hlth Management & Econ Res Ctr, Esfahan, Iran; [Yazdi-Feyzabadi, Vahid] Kerman Univ Med Sci, Hlth Serv Management Res Ctr, Inst Futures Studies Hlth, Kerman, Iran	Isfahan University Medical Science; Isfahan University Medical Science; Kerman University of Medical Sciences	Rarani, MA (corresponding author), Isfahan Univ Med Sci, Hlth Management & Econ Res Ctr, Esfahan, Iran.	m.amini@mng.mui.ac.ir	Yazdi-Feyzabadi, Vahid/H-9647-2017; zadeh, Nasrin Shaarbafchi/ABF-1943-2020; Amini-Rarani, Mostafa/O-3651-2018	Yazdi-Feyzabadi, Vahid/0000-0002-8009-470X; Amini-Rarani, Mostafa/0000-0002-4809-2237	Isfahan University of Medical Sciences, Isfahan, Iran [295292]	Isfahan University of Medical Sciences, Isfahan, Iran	This study was funded by Isfahan University of Medical Sciences, Isfahan, Iran with research code No. 295292. MAR is author who received study fund.	Adams O., 2003, HLTH SYSTEMS PERFORM, P235; Atiyeh B, 2010, Ann Burns Fire Disasters, V23, P13; Atiyeh BS, 2009, BURNS, V35, P181, DOI 10.1016/j.burns.2008.06.002; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Dowling Maura, 2006, Nurse Res, V13, P7; Gallaher JR, 2015, INT J SURG, V19, P116, DOI 10.1016/j.ijsu.2015.05.015; Hewitt-Taylor Jaquelina, 2002, Nurs Stand, V16, P33; Hodgins P, 2011, BURNS, V37, P1354, DOI 10.1016/j.burns.2011.07.001; Holmes JH, 2011, J AM COLL SURGEONS, V212, P487, DOI 10.1016/j.jamcollsurg.2010.12.044; Jagnoor J, 2018, BMC Res Notes, V11, P224, DOI 10.1186/s13104-018-3314-9; Jagnoor J, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020045; Karimi H, 2012, Ann Burns Fire Disasters, V25, P115; Lincoln Y.S., 1985, NATURALISTIC INQUIRY; Mock C, 2008, WHO PLAN BURN PREVEN, P3; Outwater AH, 2013, INT J BURNS TRAUMA, V3, P18; Peck MD, 2011, BURNS, V37, P1087, DOI 10.1016/j.burns.2011.06.005; Rode H, 2015, SAMJ, S. Afr. med. j., V105, P853, DOI [10.7196/SAMJnew.8187, 10.7196/SAMJNEW.8187]; Smolle C, 2017, BURNS, V43, P249, DOI 10.1016/j.burns.2016.08.013; Wang Y, 2018, ADV DRUG DELIVER REV, V123, P3, DOI 10.1016/j.addr.2017.09.018; Warden GD, 2003, REGIONALIZATION BURN; WHO, 2014, WORLD HLTH STAT 2014; World Bank, 2013, ENH SERV DEL IMPR EF; World Health Organization, 2000, WORLD HLTH REP 2000; Yurt RW, 2009, SURG INFECT, V10, P441, DOI 10.1089/sur.2009.050; Zia N, 2018, J BURN CARE RES, V39, pS208, DOI [10.1093/jbcr/iry006.393, DOI 10.1093/JBCR/IRY006.393]	25	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2019	14	5							e0216489	10.1371/journal.pone.0216489	http://dx.doi.org/10.1371/journal.pone.0216489			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY9HS	31112548	Green Submitted, Green Published, gold			2023-01-03	WOS:000468451000015
J	Karol, SE; Janke, LJ; Panetta, JC; Ramsey, LB; Cai, XJ; Payton, MA; Jenkins, DA; Evans, WE; Relling, MV				Karol, Seth E.; Janke, Laura J.; Panetta, John C.; Ramsey, Laura B.; Cai, Xiangjun; Payton, Monique A.; Jenkins, David A.; Evans, William E.; Relling, Mary, V			Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models	PLOS ONE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; YOUNG-ADULTS; CHILDREN; RISK; ANTIBODIES	Introduction Combination therapy for acute lymphoblastic leukemia (ALL) is highly effective but results in significant toxicity including osteonecrosis. Asparaginase is known to potentiate both the antileukemic and osteonecrosis-inducing effects of dexamethasone. The schedule of dexamethasone alters osteonecrosis risk. However, the effects of the interaction with asparaginase are unknown when dexamethasone is given on a discontinuous schedule. Methods Using the murine model of osteonecrosis, we compared the frequency of osteonecrosis in mice receiving discontinuous dexamethasone (3.5 days/ week) with mice receiving asparaginase and discontinuous dexamethasone. We then tested the effect on antileukemic efficacy using six pediatric ALL xenografts. Results The addition of asparaginase to discontinuous dexamethasone did not alter the rate of osteonecrosis compared to dexamethasone alone (7/35 in dexamethasone with asparaginase combination vs. 10/36 in dexamethasone alone, p = 0.62) despite increasing steadystate plasma dexamethasone levels (103.9 nM vs. 33.4 nM, p = 9.2x10(-7)). Combination therapy with asparaginase and dexamethasone demonstrated synergistic antileukemic effects across all six xenografts studied. Conclusions When discontinuous dexamethasone was given, its anti-leukemic activity synergized with asparaginase but the osteonecrosis-worsening effects of asparaginase (above dexamethasone alone) were not observed. Thus, there is a favorable drug interaction (unchanged toxicity, synergistic efficacy) between discontinuous dexamethasone and asparaginase.	[Karol, Seth E.] St Jude Childrens Res Hosp, Dept Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Janke, Laura J.] St Jude Childrens Res Hosp, Dept Pathol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Panetta, John C.; Ramsey, Laura B.; Cai, Xiangjun; Payton, Monique A.; Jenkins, David A.; Evans, William E.; Relling, Mary, V] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA; [Ramsey, Laura B.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Clin Pharmacol, Cincinnati, OH 45229 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Cincinnati Children's Hospital Medical Center	Karol, SE (corresponding author), St Jude Childrens Res Hosp, Dept Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	seth.karol@stjude.org	Karol, Seth/N-2102-2018; Ramsey, Laura/ABD-6113-2020; Panetta, John/AAY-3850-2021	Karol, Seth/0000-0001-8113-8180; Ramsey, Laura/0000-0001-6417-3961; Panetta, John/0000-0003-1308-7208	National Institutes of Health [CA142665, GM115279, CA21765]; Hyundai Hope on Wheels; American Lebanese Syrian Associated Charities; Servier; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA036401, R01CA142665] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM115279] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Hyundai Hope on Wheels; American Lebanese Syrian Associated Charities(American Lebanese Syrian Associated Charities (ALSAC)); Servier(Servier); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Research supported by the National Institutes of Health [CA142665 (MVR), GM115279 (MVR), CA21765 (Institutional)], Hyundai Hope on Wheels (SEK), and the American Lebanese Syrian Associated Charities. Dr. Relling reports research funding from Servier. No sponsors were involved in the design or administration of the study and played no role in the decision to publish or preparation of the manuscript.	Boissel N, 2018, BLOOD, V132, P351, DOI 10.1182/blood-2018-02-778530; Fernandez CA, 2013, INT J CLIN EXP MED, V6, P478; GRECO WR, 1995, PHARMACOL REV, V47, P331; Henriksen LT, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26686; Holleman A, 2004, NEW ENGL J MED, V351, P533, DOI 10.1056/NEJMoa033513; Karol SE, 2015, BLOOD, V126, P1770, DOI 10.1182/blood-2015-05-643601; Kawedia JD, 2012, COMPARATIVE MED, V62, P466; Larsen EC, 2016, J CLIN ONCOL, V34, P2380, DOI 10.1200/JCO.2015.62.4544; Liu C, 2012, LEUKEMIA, V26, P2303, DOI 10.1038/leu.2012.102; Liu CC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151433; Mattano LA, 2013, J CLIN ONCOL S, V31; Mattano LAJ, 2012, BLOOD; Mattano LA, 2012, LANCET ONCOL, V13, P906, DOI 10.1016/S1470-2045(12)70274-7; Mogensen SS, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.27300; Patel B, 2008, LEUKEMIA, V22, P308, DOI 10.1038/sj.leu.2405032; Paugh SW, 2015, NAT GENET, V47, P607, DOI 10.1038/ng.3283; Pui CH, 2013, SEMIN HEMATOL, V50, P185, DOI 10.1053/j.seminhematol.2013.06.007; Pui CH, 2009, NEW ENGL J MED, V360, P2730, DOI 10.1056/NEJMoa0900386; Ramsey LB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135134; Schmiegelow K, 2010, LEUKEMIA, V24, P345, DOI 10.1038/leu.2009.251; Schrappe M, 2013, KLIN PADIATR, V225, pS62, DOI 10.1055/s-0033-1337966; Team RDC, 2006, R LANG ENV STAT COMP; Toft N, 2018, LEUKEMIA, V32, P606, DOI 10.1038/leu.2017.265; Tong WH, 2014, BLOOD, V123, P2026, DOI 10.1182/blood-2013-10-534347; Vora A, 2013, LANCET ONCOL, V14, P199, DOI 10.1016/S1470-2045(12)70600-9; [No title captured], DOI DOI 10.1182/BLOOD-2010-10-311969; [No title captured], DOI DOI 10.1182/BLOOD-2011-09-381731; [No title captured], DOI DOI 10.1016/J.AJPATH.2013.03.004; [No title captured], DOI DOI 10.1002/JOR.20733; [No title captured], DOI DOI 10.1182/BLOOD-2015-09-670729	30	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2019	14	5							e0216328	10.1371/journal.pone.0216328	http://dx.doi.org/10.1371/journal.pone.0216328			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW7RE	31059548	Green Published, gold, Green Submitted			2023-01-03	WOS:000466886300039
J	Pan, KC; Hung, SY; Chen, CI; Lu, CY; Shih, ML; Huang, CY				Pan, Kuei-Ching; Hung, Shih-Yuan; Chen, Chun-I; Lu, Chu-Yun; Shih, Mei-Ling; Huang, Chiung-Yu			Social support as a mediator between sleep disturbances, depressive symptoms, and health-related quality of life in patients undergoing hemodialysis	PLOS ONE			English	Article							STAGE RENAL-DISEASE; DIALYSIS; ADULTS; DISORDERS; MODERATOR; OUTCOMES; CANCER; BURDEN	Background The hemodialysis regimen is an inevitable and mandatory treatment for patients with end-stage renal disease (ESRD). During the dialysis journey, patients may experience maladaptation in terms of sleep disturbances, depressive symptoms, and reduced health-related quality of life (HRQOL). Psychosocial resources such as social support may have beneficial influences on health outcomes, but studies have rarely analyzed the integrated relationships among risk factors which include pain, sleep disturbances, duration since diagnosis and various health outcomes in Taiwan. This study aimed to bridge this gap by investigating the relationships among related risk factors, social support, sleep disturbances, depressive symptoms, and HRQOL, which is composed of physical quality of life (PQOL) and mental quality of life (MQOL), in ESRD patients. Method A correlational design was used, and 178 patients aged 20 years or older were recruited via convenience sample. The relationships among the risk factors, the mediators, depressive symptoms, PQOL, and MQOL were analyzed using structural equation modeling. Results The findings showed that more than 70% of the participants reported poor sleep quality, and 32% reported depressive symptoms. When participants had greater pain and more sleep disorders, they were more likely to be depressed. When participants had more appraisal support; they had better PQOL and fewer depressive symptoms. Overall, the structural equation model explained 31.8% of the variance in self-reported depressive symptoms, 29.4% of the variance in PQOL, and 5.7% of the variance in MQOL. Moreover, appraisal support enhanced PQOL and reduced depressive symptoms by exerting its two mediating effects on sleep disturbances. Conclusion Our findings indicate that patients with ESRD who have more social support have better PQOL and MQOL and fewer depressive symptoms than those with less social support.	[Pan, Kuei-Ching] Nanjing Med Univ, Affiliated BenQ Hosp, BenQ Med Ctr, Dept Nursing, Nanjing, Jiangsu, Peoples R China; [Hung, Shih-Yuan] E Da Hosp, Dept Nephrol, Kaohsiung, Taiwan; [Hung, Shih-Yuan] I Shou Univ, Coll Med, Kaohsiung, Taiwan; [Chen, Chun-I] I Shou Univ, Dept Ind Management, Kaohsiung, Taiwan; [Lu, Chu-Yun; Huang, Chiung-Yu] I Shou Univ, Dept Nursing, Kaohsiung, Taiwan; [Shih, Mei-Ling] E Da Hosp, Dept Nursing, Kaohsiung, Taiwan	Nanjing Medical University; E-Da Hospital; I Shou University; I Shou University; I Shou University; E-Da Hospital	Huang, CY (corresponding author), I Shou Univ, Dept Nursing, Kaohsiung, Taiwan.	chyh@isu.edu.tw	Huang, Chiung-Yu/T-9577-2019; Chen, ChunI/T-8983-2019	Huang, Chiung-Yu/0000-0002-0660-1101; Chen, ChunI/0000-0002-6295-1720				Abdel-Kader K, 2009, CLIN J AM SOC NEPHRO, V4, P1057, DOI 10.2215/CJN.00430109; Araujo SMHA, 2012, INT UROL NEPHROL, V44, P1229, DOI 10.1007/s11255-011-0032-9; BARNES GE, 1984, CAN J PSYCHIAT, V29, P2, DOI 10.1177/070674378402900102; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; BARRERA M, 1981, AM J COMMUN PSYCHOL, V9, P435, DOI 10.1007/BF00918174; Bossola M, 2010, GEN HOSP PSYCHIAT, V32, P125, DOI 10.1016/j.genhosppsych.2009.10.009; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Chang CP, 2001, J NURS, V48, P37, DOI [10.6224/JN.48.2.37, DOI 10.6224/JN.48.2.37]; Chen SS, 2016, BLOOD PURIFICAT, V41, P218, DOI 10.1159/000441462; De Leeuw JRJ, 2000, PSYCHO-ONCOL, V9, P20, DOI 10.1002/(SICI)1099-1611(200001/02)9:1<20::AID-PON425>3.3.CO;2-P; Ellis AA, 2009, BRIT J CLIN PSYCHOL, V48, P347, DOI 10.1348/014466508X401894; Fallon M, 2011, J PSYCHOSOC NURS MEN, V49, P30, DOI 10.3928/02793695-20110705-02; Freyd M, 1923, J EDUC PSYCHOL, V14, P83, DOI 10.1037/h0074329; GOGINENI A, 1995, SOC WORK RES, V19, P57; Haefeli M, 2006, EUR SPINE J, V15, pS17, DOI 10.1007/s00586-005-1044-x; Ho YF, 2016, PSYCHOL HEALTH, V31, P1435, DOI 10.1080/08870446.2016.1226307; Huang CY, 2015, OSTEOPOROSIS INT, V26, P875, DOI 10.1007/s00198-014-2963-3; Huang CY, 2015, SPINAL CORD, V53, P413, DOI 10.1038/sc.2014.158; Huang CY, 2008, J CLIN NURS, V17, P1795, DOI 10.1111/j.1365-2702.2008.02310.x; Huang CY, 2013, EUR J ONCOL NURS, V17, P767, DOI 10.1016/j.ejon.2013.03.011; Jhamb M, 2013, AM J NEPHROL, V38, P489, DOI 10.1159/000356939; Kannan S., 2016, SOCIAL SCI, V11, P264, DOI [10.1053/j.ackd.2007.04.007, DOI 10.1053/J.ACKD.2007.04.007]; Kao YY, 2016, ARCH PSYCHIAT NURS, V30, P607, DOI 10.1016/j.apnu.2016.02.002; Kline R. B., 2015, PRINCIPLES PRACTICE, V4th; KRAUSE N, 1990, INT J AGING HUM DEV, V30, P37, DOI 10.2190/CY26-XCKW-WY1V-VGK3; Liu S. H., 2002, J NURSING, V49, P54; Locking-Cusolito H, 2001, NEPHROL NURS J, V28, P40; Lu SC, 2010, J NURSING HEALTHCARE, V6, P33; Ma L.C., 2010, J TAIWAN NEPHROLOGY, V9, P1; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; Perales-Montilla CM, 2012, NEFROLOGIA, V32, P622, DOI 10.3265/Nefrologia.pre2012.Jun.11447; Perl J, 2006, KIDNEY INT, V70, P1687, DOI 10.1038/sj.ki.5001791; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Son YJ, 2009, AM J NEPHROL, V29, P36, DOI 10.1159/000150599; Spiegel BMR, 2008, CLIN J AM SOC NEPHRO, V3, P1759, DOI 10.2215/CJN.00820208; Thaden H, 2018, AM STAT, V72, P239, DOI 10.1080/00031305.2017.1305290; Untas A, 2011, CLIN J AM SOC NEPHRO, V6, P142, DOI 10.2215/CJN.02340310; Yang F, 2015, QUAL LIFE RES, V24, P2163, DOI 10.1007/s11136-015-0964-0; Yong DSP, 2009, PALLIATIVE MED, V23, P111, DOI 10.1177/0269216308101099	39	18	20	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2019	14	4							e0216045	10.1371/journal.pone.0216045	http://dx.doi.org/10.1371/journal.pone.0216045			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HV6ZL	31034497	Green Published, gold, Green Submitted			2023-01-03	WOS:000466131200029
J	Egilman, AC; Zhang, AD; Wallach, JD; Ross, JS				Egilman, Alexander C.; Zhang, Audrey D.; Wallach, Joshua D.; Ross, Joseph S.			Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors	ANNALS OF INTERNAL MEDICINE			English	Letter									[Egilman, Alexander C.] Yale New Haven Hlth Syst, Ctr Outcomes Res & Evaluat, New Haven, CT USA; [Egilman, Alexander C.; Wallach, Joshua D.] Yale Law Sch, Collaborat Res Integr & Transparency, New Haven, CT USA; [Zhang, Audrey D.] NYU, Sch Med, New York, NY USA; [Wallach, Joshua D.] Yale Sch Publ Hlth, New Haven, CT USA; [Ross, Joseph S.] Yale Sch Med, New Haven, CT 06510 USA; [Ross, Joseph S.] Yale Sch Publ Hlth, New Haven, CT 06510 USA; [Ross, Joseph S.] Yale New Haven Hlth Syst, Ctr Outcomes Res & Evaluat, New Haven, CT 06519 USA	Yale University; Yale University; New York University; Yale University; Yale University; Yale University; Yale University	Ross, JS (corresponding author), Yale Sch Med, New Haven, CT 06510 USA.; Ross, JS (corresponding author), Yale Sch Publ Hlth, New Haven, CT 06510 USA.; Ross, JS (corresponding author), Yale New Haven Hlth Syst, Ctr Outcomes Res & Evaluat, New Haven, CT 06519 USA.	joseph.ross@yale.edu		Ross, Joseph/0000-0002-9218-3320; Wallach, Joshua/0000-0002-2816-6905; Zhang, Audrey/0000-0001-9753-4276	Laura and John Arnold Foundation	Laura and John Arnold Foundation	This project was conducted as part of the Collaboration for Research Integrity and Transparency at Yale Law School, funded by the Laura and John Arnold Foundation, which supports Mr. Egilman, Ms. Zhang, and Drs. Wallach and Ross. The Laura and John Arnold Foundation played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The authors assume full responsibility for the accuracy and completeness of the ideas presented, which do not represent the views of any supporting institutions.	Asghar W, 2015, DARU, V23, DOI 10.1186/s40199-015-0133-6; Centers for Medicare and Medicaid Services, 2019, MED D; Egilman AC, 2018, JAMA INTERN MED, V178, P567, DOI 10.1001/jamainternmed.2017.8016; Gellad WF, 2014, AM J MANAG CARE, V20, pE90; Sacks CA, 2018, JAMA-J AM MED ASSOC, V320, P650, DOI 10.1001/jama.2018.11439	5	4	4	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	2019	171	7					521	+		10.7326/M19-1085	http://dx.doi.org/10.7326/M19-1085			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB4LK	31404926				2023-01-03	WOS:000488527900012
J	Alfaro, A; Leon, A; Guajardo-Correa, E; Reuquen, P; Torres, F; Mery, M; Segura, R; Zapata, PA; Orihuela, PA				Alfaro, Aline; Leon, Andrea; Guajardo-Correa, Emanuel; Reuquen, Patricia; Torres, Francisco; Mery, Mario; Segura, Rodrigo; Zapata, Paula A.; Orihuela, Pedro A.			MgO nanoparticles coated with polyethylene glycol as carrier for 2-Methoxyestradiol anticancer drug	PLOS ONE			English	Article							PROSTATE-CANCER; PACLITAXEL; BREAST	Novel Magnesium Oxide (MgO) nanoparticles (NPs) modified with the polymer polyethylene glycol (PEG) were synthesized as carrier for the anticancer drug 2-Methoxyestradiol (2ME) to improve its clinical application. The functionalized NPs were characterized by Infrared spectroscopy with Fourier transform to elucidate the vibration modes of this conjugate, indicating the formation of the MgO-PEG-2ME nanocomposite. The studies of absorption and liberation determined that MgO-PEG-2ME NPs incorporated 98.51% of 2ME while liberation of 2ME was constant during 7 days at pH 2, 5 and 7.35. Finally, the MgO-PEG-2ME NPs decreased the viability of the prostate cancer cell line LNCap suggesting that this nanocomposite is suitable as a drug delivery system for anticancer prostate therapy.	[Alfaro, Aline; Guajardo-Correa, Emanuel; Reuquen, Patricia; Orihuela, Pedro A.] Univ Santiago Chile, Lab Inmunol Reprod, Fac Quim & Biol, Santiago, Chile; [Alfaro, Aline; Leon, Andrea; Guajardo-Correa, Emanuel; Reuquen, Patricia; Orihuela, Pedro A.] Ctr Desarrollo Nanociencia & Nanotecnol CEDENNA, Santiago, Chile; [Leon, Andrea] Max Planck Inst Chem Phys Solids, D-01068 Dresden, Germany; [Torres, Francisco] Univ Atacama, Fac Ciencias Nat, Dept Fis, Copayapu 485, Copiapo, Chile; [Mery, Mario] Univ Tecn Federico Santa Maria, Ctr Cient Tecnol Valparaiso CCTVal, Valparaiso, Chile; [Segura, Rodrigo] Univ Valparaiso, Inst Quim & Bioquim, Fac Ciencias, Valparaiso, Chile; [Zapata, Paula A.] Univ Santiago Chile, Grp Polimeros, Fac Quim Biol, Santiago, Chile	Universidad de Santiago de Chile; Max Planck Society; Universidad de Atacama; Universidad Tecnica Federico Santa Maria; Universidad de Valparaiso; Universidad de Santiago de Chile	Orihuela, PA (corresponding author), Univ Santiago Chile, Lab Inmunol Reprod, Fac Quim & Biol, Santiago, Chile.; Orihuela, PA (corresponding author), Ctr Desarrollo Nanociencia & Nanotecnol CEDENNA, Santiago, Chile.	pedro.orihuela@usach.cl	Segura, Rodrigo A./P-2005-2016	Segura, Rodrigo A./0000-0003-0928-0021; Guajardo-Correa, Emanuel/0000-0002-6091-6745	Basal Program for Centers of Excellence [DICYT 021743OD-DAS]; CONICYT [FB0807 CEDENNA]; DGIIP-USM; Proyecto Basal [FB0821 - CONICYT]; FONDECYT Regular; CONICYT Becas Chile Postdoctorado Grant [N 1170226];  [74190099]	Basal Program for Centers of Excellence; CONICYT(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)); DGIIP-USM; Proyecto Basal(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT PIA/BASAL); FONDECYT Regular(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); CONICYT Becas Chile Postdoctorado Grant; 	This work received financial support from grants DICYT 021743OD-DAS and Basal Program for Centers of Excellence, Grant FB0807 CEDENNA, CONICYT and the DGIIP-USM. Proyecto Basal FB0821 - CONICYT. P. A. Zapata acknowledges the financial support of FONDECYT Regular N 1170226. A. Leon acknowledges the financial support of CONICYT Becas Chile Postdoctorado Grant No. 74190099.	Akram MW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23105-y; Behzadi E, 2019, INT J NANOMED, V14, P257, DOI 10.2147/IJN.S186428; Bunker A, 2012, PHYSCS PROC, V34, P24, DOI 10.1016/j.phpro.2012.05.004; Chang AJ, 2014, NAT REV CLIN ONCOL, V11, P308, DOI 10.1038/nrclinonc.2014.68; Di DR, 2012, NANOMED-NANOTECHNOL, V8, P1233, DOI 10.1016/j.nano.2012.02.010; Haume Kaspar, 2016, Cancer Nanotechnol, V7, P8, DOI 10.1186/s12645-016-0021-x; Ireson CR, 2004, BRIT J CANCER, V90, P932, DOI 10.1038/sj.bjc.6601591; Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437; Jokerst JV, 2011, NANOMEDICINE-UK, V6, P715, DOI [10.2217/NNM.11.19, 10.2217/nnm.11.19]; Kumar R, 2015, J NANOSCI NANOTECHNO, V15, P1543, DOI 10.1166/jnn.2015.8915; Leon A, 2017, APPL SCI-BASEL, V7, DOI 10.3390/app7010049; Li YC, 2012, J PHYS CHEM B, V116, P7334, DOI 10.1021/jp300301z; Lowes LE, 2015, PROSTATE CANCER P D, V18, P358, DOI 10.1038/pcan.2015.36; Mahmoud A, 2016, INT J TOXICOL, V35, P429, DOI 10.1177/1091581816648624; Mano SS, 2012, INT J MOL SCI, V13, P3703, DOI 10.3390/ijms13033703; Mastuli MS, 2012, APCBEE PROC, V3, P93, DOI 10.1016/j.apcbee.2012.06.052; Mueck AO, 2010, STEROIDS, V75, P625, DOI 10.1016/j.steroids.2010.02.016; Naghibi S, 2014, CERAM INT, V40, P5481, DOI 10.1016/j.ceramint.2013.10.136; Ranathunge TA, 2019, NANOMATERIALS-BASEL, V9, DOI 10.3390/nano9020208; Saslow D, 2007, CA-CANCER J CLIN, V57, P75, DOI 10.3322/canjclin.57.2.75; Shi JJ, 2017, NAT REV CANCER, V17, P20, DOI 10.1038/nrc.2016.108; Somanathan T, 2016, J NANOSCI NANOTECHNO, V16, P9421, DOI 10.1166/jnn.2016.12164; Tang ZX, 2014, BRAZ J CHEM ENG, V31, P591, DOI 10.1590/0104-6632.20140313s00002813; Venkatasubbu GD, 2013, ADV POWDER TECHNOL, V24, P947, DOI 10.1016/j.apt.2013.01.008; Verenich S, 2010, MOL PHARMACEUT, V7, P2030, DOI 10.1021/mp100190f; Vilos C, 2013, BIOMATERIALS, V34, P4098, DOI 10.1016/j.biomaterials.2013.02.034; Wang Y, 2011, BIOMATERIALS, V32, P3322, DOI 10.1016/j.biomaterials.2010.12.060; Welch HG, 2015, NEW ENGL J MED, V373, P1685, DOI 10.1056/NEJMp1510443; Wu Y, 2014, J CONTROL RELEASE, V190, P485; Yameen B, 2014, J CONTROL RELEASE, V190, P485, DOI 10.1016/j.jconrel.2014.06.038	30	23	23	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 15	2019	14	8							e0214900	10.1371/journal.pone.0214900	http://dx.doi.org/10.1371/journal.pone.0214900			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5KK	31415561	Green Published, gold, Green Submitted			2023-01-03	WOS:000485017200001
J	Liu, G; Khanna, V; Kirtane, A; Grill, A; Panyam, J				Liu, Garvey; Khanna, Vidhi; Kirtane, Ameya; Grill, Alex; Panyam, Jayanth			Chemopreventive efficacy of oral curcumin: a prodrug hypothesis	FASEB JOURNAL			English	Article						curcumin glucuronide; beta-glucuronidase; cancer prevention	BETA-GLUCURONIDASE; IN-VITRO; CANCER; VIVO; EXPRESSION; STABILITY; BIOTRANSFORMATION; PHARMACOKINETICS; DOXORUBICIN; ACTIVATION	Oral consumption of curcumin, a natural polyphenol, is associated with reduced incidence of cancer. Yet, a significant amount of the orally dosed compound is eliminated in the feces, and a major fraction of the absorbed compound is metabolized to inactive glucuronides, resulting in poor bioavailability (<1%). It is not known how oral curcumin exhibits chemopreventive activity. We propose curcumin glucuronide is an inflammation-responsive natural prodrug that is converted back to curcumin on demand at the site of action. Our studies show elevated levels of beta-glucuronidase, an enzyme that hydrolyzes the glycosidic bond of glucuronides to generate the parent compound, in human breast cancer. Oral administration of curcumin in mouse tumor models generated significant tumor levels of the polyphenol. Intravenous administration of the glucuronide resulted in the formation of curcumin in the tumor tissue. Chronic daily oral curcumin dosing led to tumor accumulation of curcumin and inhibition of tumor growth in tumor models with high beta-glucuronidase activity. Overall, the study presented here provides preliminary evidence for a novel mechanism of action for orally administered curcumin.-Liu, G., Khanna, V., Kirtane, A., Grill, A., Panyam, J. Chemopreventive efficacy of oral curcumin: a prodrug hypothesis.	[Liu, Garvey; Khanna, Vidhi; Kirtane, Ameya; Grill, Alex; Panyam, Jayanth] Univ Minnesota, Coll Pharm, Dept Pharmaceut, 308 Harvard St SE,Weaver Densford Hall, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Panyam, J (corresponding author), Univ Minnesota, Coll Pharm, Dept Pharmaceut, 308 Harvard St SE,Weaver Densford Hall, Minneapolis, MN 55455 USA.	jpanyam@umn.edu	Kirtane, Ameya/Y-8203-2019	Kirtane, Ameya/0000-0002-3779-0363; Panyam, Jayanth/0000-0002-8656-2244	University of Minnesota; U.S. National Institutes of Health, National Cancer Institute [CA 141996]	University of Minnesota(University of Minnesota System); U.S. National Institutes of Health, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors acknowledge Prof. Yu-Lin Leu of Chia Nan University of Pharmacy and Science (Tainan, Taiwan) for providing us with near-infrared fluorescent difluoromethylphenol-glucuronide probe. The authors thank Brenda Koniar (University of Minnesota, Minneapolis, MN, USA) for assistance with the animal studies and Jim Fischer (University of Minnesota) for assistance with liquid chromatography-mass spectrometry. Supported by a grant-in-aid award from the University of Minnesota and U.S. National Institutes of Health, National Cancer Institute Grant CA 141996 (to J.P.). The authors declare no conflicts of interest.	Arroo RRJ, 2014, PHYTOCHEM REV, V13, P853, DOI 10.1007/s11101-014-9355-3; Bachmeier BE, 2007, CELL PHYSIOL BIOCHEM, V19, P137, DOI 10.1159/000099202; Bertolini F, 2003, CANCER RES, V63, P4342; Bharti AC, 2003, J IMMUNOL, V171, P3863, DOI 10.4049/jimmunol.171.7.3863; Boggio K, 1998, J EXP MED, V188, P589, DOI 10.1084/jem.188.3.589; Bosslet K, 1998, CANCER RES, V58, P1195; Brusselbach S, 2004, METH MOLEC MED, V90, P303; Calogero RA, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1745; Cheng TC, 2012, J AM CHEM SOC, V134, P3103, DOI 10.1021/ja209335z; Choi C, 2014, ONCOGENE, V33, P3668, DOI 10.1038/onc.2013.341; Cummings J, 2004, BIOCHEM PHARMACOL, V67, P31, DOI 10.1016/j.bcp.2003.07.019; Dhillon N, 2008, CLIN CANCER RES, V14, P4491, DOI 10.1158/1078-0432.CCR-08-0024; Di Carlo E, 1999, LAB INVEST, V79, P1261; Dodds HM, 2002, J PHARMACOL EXP THER, V303, P649, DOI 10.1124/jpet.102.039040; Grill AE, 2014, DRUG DELIV TRANSL RE, V4, P344, DOI 10.1007/s13346-014-0199-6; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Juan TY, 2009, CLIN CANCER RES, V15, P4600, DOI 10.1158/1078-0432.CCR-09-0090; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kazemi-Lomedasht F, 2013, ADV PHARM BULL, V3, P127, DOI 10.5681/apb.2013.021; Kerbel RS, 2004, NAT REV CANCER, V4, P423, DOI 10.1038/nrc1369; Li L, 2005, CANCER-AM CANCER SOC, V104, P1322, DOI 10.1002/cncr.21300; Liang GA, 2009, BIOORGAN MED CHEM, V17, P2623, DOI 10.1016/j.bmc.2008.10.044; Lin JK, 2007, ADV EXP MED BIOL, V595, P227; MINERS JO, 1991, PHARMACOL THERAPEUT, V51, P347, DOI 10.1016/0163-7258(91)90065-T; Mohanty C, 2010, BIOMATERIALS, V31, P6597, DOI 10.1016/j.biomaterials.2010.04.062; Murdter TE, 2002, J PHARMACOL EXP THER, V301, P223, DOI 10.1124/jpet.301.1.223; Murdter TE, 1997, CANCER RES, V57, P2440; Nanni P, 2001, J EXP MED, V194, P1195, DOI 10.1084/jem.194.9.1195; Nelson KM, 2017, J MED CHEM, V60, P1620, DOI 10.1021/acs.jmedchem.6b00975; Pal A, 2014, BIOORGAN MED CHEM, V22, P435, DOI 10.1016/j.bmc.2013.11.006; Pan MH, 1999, DRUG METAB DISPOS, V27, P486; Prasad, 1997, J Cardiovasc Pharmacol Ther, V2, P309, DOI 10.1177/107424849700200409; Prijovich ZM, 2009, MOL CANCER THER, V8, P940, DOI 10.1158/1535-7163.MCT-08-0812; RAVINDRANATH V, 1980, TOXICOLOGY, V16, P259, DOI 10.1016/0300-483X(80)90122-5; RAVINDRANATH V, 1981, TOXICOLOGY, V22, P337, DOI 10.1016/0300-483X(81)90027-5; Sabolovic N, 2006, BIOPHARM DRUG DISPOS, V27, P181, DOI 10.1002/bdd.498; Sharan S, 2012, DRUG METAB DISPOS, V40, P1993, DOI 10.1124/dmd.112.046417; Sherwood RF, 1996, ADV DRUG DELIVER REV, V22, P269, DOI 10.1016/S0169-409X(96)00450-4; Shimoi K, 2005, METHOD ENZYMOL, V400, P263, DOI 10.1016/S0076-6879(05)00015-7; Shoji M, 2014, FOOD CHEM, V151, P126, DOI 10.1016/j.foodchem.2013.11.021; Sperker B, 2000, N-S ARCH PHARMACOL, V362, P110, DOI 10.1007/s002100000260; Thompson KJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188873; Tomren MA, 2007, INT J PHARM, V338, P27, DOI 10.1016/j.ijpharm.2007.01.013; Vareed SK, 2008, CANCER EPIDEM BIOMAR, V17, P1411, DOI 10.1158/1055-9965.EPI-07-2693; Yuan L, 2003, MUTAT RES-FUND MOL M, V523, P55, DOI 10.1016/S0027-5107(02)00321-4	45	5	5	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2019	33	8					9453	9465		10.1096/fj.201900166R	http://dx.doi.org/10.1096/fj.201900166R			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	IN7AA	31136203	Green Published			2023-01-03	WOS:000478832900058
J	Berard, A; Abbas-Chorfa, F; Kassai, B; Vial, T; Nguyen, KA; Sheehy, O; Schott, AM				Berard, Anick; Abbas-Chorfa, Fatima; Kassai, Behrouz; Vial, Thierry; Kim An Nguyen; Sheehy, Odile; Schott, Anne-Marie			The French Pregnancy Cohort: Medication use during pregnancy in the French population	PLOS ONE			English	Article							DRUG PRESCRIPTION; CLAIMS DATABASES; FRANCE; PREVALENCE; PREDICTORS; TRENDS; BIRTHS; WOMEN	Purpose We described the medication use during pregnancy in the French population using the French Pregnancy Cohort (FPC). Methods The FPC was built with the sampling of all pregnant women included in the French Echantillon generaliste des beneficiaires (EGB), which is a 1/97th representative sample of the population covered by the French health insurance. The EGB includes anonymized information on the socio-demographic and medical characteristics of beneficiaries, and the health care services they have received such as diagnoses and procedure codes as well as data on filled reimbursed medication; EGB also includes data on hospital stays in all public and private French health facilities. Each filled prescription record contains information on drug brand and generic names, date of prescription and date of dispensing, quantity dispensed, mode of administration, duration of prescription, dosage, and prescribing physician specialty. FPC includes data on all pregnancies of women in the EGB (2010-2013). Date of entry in the FPC is the first day of pregnancy regardless of pregnancy outcome (spontaneous abortions or planned abortions (with or without medical reasons), deliveries), and data on women are collected retrospectively for a period of one year before pregnancy, and prospectively during pregnancy, and up to one year after delivery. The prevalence of prescribed medications before, during and after pregnancy was compared; comparison was also done between trimesters. Pregnancy outcomes are described and include spontaneous and planned abortions, livebirths, and stillbirths. Results FPC includes data on 36,065 pregnancies. Among them, 27,253 (75.6%) resulted in a delivery including 201 stillbirths (0.7%). The total number of spontaneous abortions was 6,718 (18.6%), and planned abortions 2,094 (5.8%). The prevalence of filled medication use was 91.1%, 89.9%, and 95.6% before, during and after pregnancy, respectively. Although there was a statistically significant decrease in the proportion of use once the pregnancy was diagnosed (first trimester exposure, 76.4% vs. exposure in the year prior to pregnancy, 91.1% (p<.01)), post-pregnancy medication use was above the pre-pregnancy level (95.6%). Maternal depression was the most prevalent comorbidity during pregnancy (20%), and post-partum depression was higher in those who delivered a stillborn infant (38.8%) as well as in those with a spontaneous (19.5%) or planned abortion (22.4%) compared to those with a liveborn (12.0%). Conclusion FPC is an excellent tool for the study of the risk and benefit of drug use during the perinatal period. FPC has the advantage of including a representative sample of French pregnant women, and study medications only available in France in addition to others available worldwide.	[Berard, Anick; Sheehy, Odile] CHU St Justine, Res Ctr, Montreal, PQ, Canada; [Berard, Anick] Univ Montreal, Fac Pharm, Montreal, PQ, Canada; [Berard, Anick; Kassai, Behrouz; Vial, Thierry; Kim An Nguyen] CHU Lyon, EPICIME CIC 1407 Lyon, INSERM, Pharmacotoxicol Dept, Bron, France; [Berard, Anick; Kassai, Behrouz; Vial, Thierry; Kim An Nguyen] Univ Lyon 1, Lyon, France; [Berard, Anick; Kassai, Behrouz; Kim An Nguyen] Univ Lyon 1, CNRS, UMR 5558, Lab Biometrie & Biol Evolut, Villeurbanne, France; [Abbas-Chorfa, Fatima] Hosp Civils Lyon, Serv Biostat Bioinformat, Pole Sante Publ, Lyon, France; [Vial, Thierry] CHU Lyon, Serv Hosp Univ Pharmacotoxicol, Lyon, France; [Schott, Anne-Marie] Hosp Civils Lyon, Pole Sante Publ, Lyon, France; [Schott, Anne-Marie] Univ Lyon Claude Bernard 1, HeSPeR, Lyon, France	Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; VetAgro Sup; CHU Lyon; CHU Lyon; CHU Lyon	Berard, A (corresponding author), CHU St Justine, Res Ctr, Montreal, PQ, Canada.; Berard, A (corresponding author), Univ Montreal, Fac Pharm, Montreal, PQ, Canada.; Berard, A (corresponding author), CHU Lyon, EPICIME CIC 1407 Lyon, INSERM, Pharmacotoxicol Dept, Bron, France.; Berard, A (corresponding author), Univ Lyon 1, Lyon, France.; Berard, A (corresponding author), Univ Lyon 1, CNRS, UMR 5558, Lab Biometrie & Biol Evolut, Villeurbanne, France.	anick.berard@univ-lyon1.fr	NGUYEN, Kim An/AGT-1300-2022; Schott, Anne-Marie/V-7580-2018	NGUYEN, Kim An/0000-0001-7594-504X; Schott, Anne-Marie/0000-0003-3337-4474; Kassai, Behrouz/0000-0002-1712-120X	"Fonds de la recherche en sante du Quebec" (FRSQ) [30962]	"Fonds de la recherche en sante du Quebec" (FRSQ)(Fonds de la Recherche en Sante du Quebec)	The "Fonds de la recherche en sante du Quebec" (FRSQ, AB, grant number 30962). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1992, LANCET, V339, P1600, DOI DOI 10.1016/0140-6736(92)91856-4; Bakker MK, 2006, BJOG-INT J OBSTET GY, V113, P559, DOI 10.1111/j.1471-0528.2006.00927.x; Benard-Laribiere A, 2018, BRIT J CLIN PHARMACO, V84, P1764, DOI 10.1111/bcp.13608; Berard A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093870; BERTHIER M, 1993, THERAPIE, V48, P43; Beyens MN, 2003, THERAPIE, V58, P505, DOI 10.2515/therapie:2003082; Bezin J, 2017, PHARMACOEPIDEM DR S, V26, P954, DOI 10.1002/pds.4233; Blotiere PO, 2018, PHARMACOEPIDEM DR S, V27, P763, DOI 10.1002/pds.4556; BOTTING BJ, 1987, ARCH DIS CHILD, V62, P941, DOI 10.1136/adc.62.9.941; Damase-Michel C, 2014, THERAPIE, V69, P91, DOI 10.2515/therapie/2014005; de Jonge L, 2015, DRUG SAFETY, V38, P737, DOI 10.1007/s40264-015-0302-z; de La Rochebrochard E, 2002, HUM REPROD, V17, P1649, DOI 10.1093/humrep/17.6.1649; Demailly R, 2017, PHARMACOEPIDEM DR S, V26, P1126, DOI 10.1002/pds.4265; Egen-Lappe V, 2004, EUR J CLIN PHARMACOL, V60, P659, DOI 10.1007/s00228-004-0817-1; Heude B, 2019, PAEDIATR PERINAT EP, V33, P47, DOI 10.1111/ppe.12526; Hurault-Delarue C, 2018, EUR ARCH PSYCHIAT CL; Institut de la statistique du Quebec, 2013, NAISS SEL TYP SIMPL, P1988; Jones RK, 2008, PERSPECT SEX REPRO H, V40, P6, DOI 10.1363/4000608; Keirse MJNC, 2009, PAEDIATR PERINAT EP, V23, P522, DOI 10.1111/j.1365-3016.2009.01067.x; Koren G, 1998, NEW ENGL J MED, V338, P1128, DOI 10.1056/NEJM199804163381607; Lacroix I, 2000, LANCET, V356, P1735, DOI 10.1016/S0140-6736(00)03209-8; Lacroix I, 2009, EUR J CLIN PHARMACOL, V65, P839, DOI 10.1007/s00228-009-0647-2; Le Meur N, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0857-5; Macklin R, 2010, LANCET, V375, P632, DOI 10.1016/S0140-6736(10)60257-7; Moulis G, 2015, REV MED INTERNE, V36, P411, DOI 10.1016/j.revmed.2014.11.009; Nybo, 2000, West J Med, V173, P331, DOI 10.1136/ewjm.173.5.331; Quantin C, 2014, J GYNECOL OBST BIO R, V43, P680, DOI 10.1016/j.jgyn.2013.09.004; Ramos E, 2007, BJOG-INT J OBSTET GY, V114, P1055, DOI 10.1111/j.1471-0528.2007.01387.x; Salvatore S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0190101; Santos F, 2010, PHARMACOEPIDEM DR S, V19, P418, DOI 10.1002/pds.1915; Tuppin P, 2010, REV EPIDEMIOL SANTE, V58, P286, DOI 10.1016/j.respe.2010.04.005; Wenzel A, 2005, J ANXIETY DISORD, V19, P295, DOI 10.1016/j.janxdis.2004.04.001; Zhao JP, 2017, BIRTH DEFECTS RES, V109, P423, DOI 10.1002/bdra.23604	33	25	26	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2019	14	7							e0219095	10.1371/journal.pone.0219095	http://dx.doi.org/10.1371/journal.pone.0219095			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IS7LS	31314794	gold, Green Published, Green Submitted			2023-01-03	WOS:000482331900022
J	Hillier, D				Hillier, Debra			Whooping Cough in a Young Infant	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								An 8-week-old girl was admitted to the hospital with 2 weeks of worsening cough associated with a whooping sound (shown in a video), along with episodes of apnea. Bordetella pertussis infection was diagnosed.	[Hillier, Debra] Boston Childrens Hosp, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital	Hillier, D (corresponding author), Boston Childrens Hosp, Boston, MA 02115 USA.	debra.hillier@childrens.harvard.edu							0	1	2	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 11	2019	381	2							e4	10.1056/NEJMicm1814607	http://dx.doi.org/10.1056/NEJMicm1814607			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IJ1ON	31291519				2023-01-03	WOS:000475668100001
J	Cardona, AF; Ruiz-Patino, A; Zatarain-Barron, ZL; Hakim, F; Jimenez, E; Mejia, JA; Ramon, JF; Useche, N; Bermudez, S; Pineda, D; Cifuentes, H; Rojas, L; Ricaurte, L; Pino, LE; Balana, C; Arrieta, O				Cardona, Andres F.; Ruiz-Patino, Alejandro; Lucia Zatarain-Barron, Zyanya; Hakim, Fernando; Jimenez, Enrique; Mejia, Juan Armando; Fernando Ramon, Juan; Useche, Nicolas; Bermudez, Sonia; Pineda, Diego; Cifuentes, Hernando; Rojas, Leonardo; Ricaurte, Luisa; Eduardo Pino, Luis; Balana, Carmen; Arrieta, Oscar			Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib	PLOS ONE			English	Article							CENTRAL-NERVOUS-SYSTEM; PHASE-II TRIAL; RECURRENT; THERAPY; EXPRESSION; TUMORS	Purpose To compare the effectiveness of octreotide/everolimus vs. sunitinib for the systemic treatment of recurrent aggressive meningiomas. Methods 31 patients with recurrent or refractory WHO II or WHO III meningiomas were examined in two reference centers in Colombia. Patients who had systemic treatment (sunitinib, everolimus/octreotide) and a complete follow-up were included. Overall survival (OS), progression-free survival (PFS) and toxicities were evaluated. Additionally, tissue samples were examined for PDGFR beta and VEGFR2, their expression was correlated with outcomes. Results Twenty-two patients (72%) were female with a median age of 55 years (SD +/- 15.3). The most prevalent histology was anaplastic meningioma in 20 patients (65%) with 48% of patients suffering from three previous relapses before the start of systemic treatment. A total of 14 patients received combination therapy with octreotide/everolimus, 11 received sunitinib and the remaining 6 received other second-line agents. Median OS was 37.3 months (95% CI 28.5-42.1) and the PFS during the treatment with everolimus/octreotide (EO) and sunitinib (Su) was 12.1 months (95% CI 9.2-21.1) and 9.1 months (95% CI 6.8-16.8); p = 0.43), respectively. The OS of the group treated with the EO -> Su -> Bev sequence (1st/2nd/3rd line) was 6.5 months longer than the Su -> EO -> Bev sequence (36.0 vs. 29.5 months) (p = 0.0001). When analyzing molecular markers, the positive PDGFR beta and negative VEGFR2 expression were associated with longer survival both in OS and PFS. Conclusion Sunitinib and octreotide/everolimus have similar efficacy and safety in the systemic management of refractory meningioma. VEGFR2 and PDGFR beta expression are associated with better outcomes.	[Cardona, Andres F.; Pineda, Diego; Rojas, Leonardo] Clin Country, Brain Tumor Sect, Clin & Translat Oncol Grp, Bogota, Colombia; [Cardona, Andres F.; Ruiz-Patino, Alejandro; Rojas, Leonardo; Ricaurte, Luisa] Fdn Clin & Appl Canc Res FICMAC, Bogota, Colombia; [Cardona, Andres F.] Univ El Bosque, Mol Oncol & Biol Syst Grp G FOX, Bogota, Colombia; [Lucia Zatarain-Barron, Zyanya; Arrieta, Oscar] Inst Nacl Cancerol INCaN, Expt Oncol Lab, Mexico City, DF, Mexico; [Hakim, Fernando; Jimenez, Enrique; Mejia, Juan Armando; Fernando Ramon, Juan] Fdn Santa Fe Bogota, Dept Neurosurg, Bogota, Colombia; [Hakim, Fernando; Jimenez, Enrique; Mejia, Juan Armando; Fernando Ramon, Juan; Useche, Nicolas; Bermudez, Sonia] Univ El Bosque, Dept Neurosci, Bogota, Colombia; [Useche, Nicolas; Bermudez, Sonia] Fdn Santa Fe Bogota, Neuroradiol Sect, Dept Radiol, Bogota, Colombia; [Pineda, Diego] Clin Country, Neuroradiol Sect, Bogota, Colombia; [Cifuentes, Hernando] Clin Country, Dept Neurosurg, Bogota, Colombia; [Rojas, Leonardo] Clin Colsanitas, Dept Clin Oncol, Bogota, Colombia; [Eduardo Pino, Luis] Fdn Santa Fe Bogota, Clin Oncol Grp, Bogota, Colombia; [Balana, Carmen] Hosp Badalona Germans Trias & Pujol, Neurooncol Sect, Dept Oncol, ICO, Barcelona, Spain	Clinica del Country - Unidad Medica; Universidad El Bosque; Instituto Nacional de Cancerologia (INCAN); Universidad El Bosque; Clinica del Country - Unidad Medica; Clinica del Country - Unidad Medica; Hospital Germans Trias i Pujol	Cardona, AF (corresponding author), Clin Country, Brain Tumor Sect, Clin & Translat Oncol Grp, Bogota, Colombia.; Cardona, AF (corresponding author), Fdn Clin & Appl Canc Res FICMAC, Bogota, Colombia.; Cardona, AF (corresponding author), Univ El Bosque, Mol Oncol & Biol Syst Grp G FOX, Bogota, Colombia.	andres.cardona@clinicadelcountry.com	Arrieta, Oscar/ABH-6022-2020	Balana, Carmen/0000-0003-0771-0390	Foundation for Clinical and Applied Cancer Research - FICMAC (Bogota Colombia) research grant [011-2017SD]	Foundation for Clinical and Applied Cancer Research - FICMAC (Bogota Colombia) research grant	Supported by the Foundation for Clinical and Applied Cancer Research - FICMAC (Bogota Colombia) research grant 011-2017SD awarded to Andres F. Cardona. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amatya VJ, 2001, HUM PATHOL, V32, P970, DOI 10.1053/hupa.2001.27119; Chamberlain MC, 2007, NEUROLOGY, V69, P969, DOI 10.1212/01.wnl.0000271382.62776.b7; Silva CBD, 2015, INT J CLIN EXP PATHO, V8, P13185; Goldbrunner R, 2016, LANCET ONCOL, V17, pE383, DOI 10.1016/S1470-2045(16)30321-7; Graillon T, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.2011; Graillon T, 2015, J NEURO-ONCOL, V124, P33, DOI 10.1007/s11060-015-1812-3; Kaley T, 2014, NEURO-ONCOLOGY, V16, P829, DOI 10.1093/neuonc/not330; Kaley TJ, 2015, NEURO-ONCOLOGY, V17, P116, DOI 10.1093/neuonc/nou148; Le Rhun E, 2016, EXPERT REV NEUROTHER, V16, P889, DOI 10.1080/14737175.2016.1184087; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Nassehi D, 2013, DAN MED J, V60; Norden AD, 2015, NEUROLOGY, V84, P280, DOI 10.1212/WNL.0000000000001153; Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI [10.1093/neuonc/noab200, 10.1093/neuonc/nov189, 10.1093/neuonc/noaa200]; Pearson BE, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/5/E3; Perry A, 1999, CANCER, V85, P2046, DOI 10.1002/(SICI)1097-0142(19990501)85:9<2046::AID-CNCR23>3.0.CO;2-M; Perry A, 1997, AM J SURG PATHOL, V21, P1455, DOI 10.1097/00000478-199712000-00008; Rogers L, 2015, J NEUROSURG, V122, P4, DOI 10.3171/2014.7.JNS131644; Simo M, 2014, CANCER CHEMOTH PHARM, V73, P919, DOI 10.1007/s00280-014-2422-z; Wang N, 2018, SEMIN NEUROL, V38, P112, DOI 10.1055/s-0038-1636502; Wiemels J, 2010, J NEURO-ONCOL, V99, P307, DOI 10.1007/s11060-010-0386-3	20	11	11	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2019	14	6							e0217340	10.1371/journal.pone.0217340	http://dx.doi.org/10.1371/journal.pone.0217340			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW3PH	31220093	Green Published, Green Submitted, gold			2023-01-03	WOS:000484893500009
J	Wu, PH; Lin, MY; Huang, TH; Lin, YT; Hung, CC; Yeh, YC; Kuo, HT; Chiu, YW; Hwang, SJ; Tsai, JC; Carrero, JJ				Wu, Ping-Hsun; Lin, Ming-Yen; Huang, Teng-Hui; Lin, Yi-Ting; Hung, Chi-Chih; Yeh, Yi-Chun; Kuo, Hung-Tien; Chiu, Yi-Wen; Hwang, Shang-Jyh; Tsai, Jer-Chia; Carrero, Juan-Jesus			Depression amongst patients commencing maintenance dialysis is associated with increased risk of death and severe infections: A nationwide cohort study	PLOS ONE			English	Article							STAGE RENAL-DISEASE; INSURANCE RESEARCH DATABASE; CORONARY-HEART-DISEASE; QUALITY-OF-LIFE; CARDIOVASCULAR-DISEASE; CHRONIC-HEMODIALYSIS; COLLABORATIVE CARE; IMMUNE FUNCTION; HEALTH; SYMPTOMS	Background Depression is common in dialysis patients, but the clinical impact of this condition is poorly defined. Methods Out of 57,703 patients starting dialysis during 2000-2007 recorded in the National Health Insurance Research Database of Taiwan, we identified 2,475 patients with a clinical diagnosis of depression, and compared them with 1: 5 age-and sex-matched patients without a depression diagnosis (n = 12,375). Patients were followed up for hospitalisation due to severe infections, major adverse cardiovascular events (MACE) and death. Multivariable Cox regression and competing risk analyses (accounting for death when appropriate) were used to estimate risk associations. Results Patients with depression had a higher frequency of comorbidities. During a mean follow-up of 3.2 years, 1,140 severe infections, 806 MACE, and 1,121 deaths were recorded. Compared to controls, patients with depression were at increased risk of death (adjusted hazard ratio 1.24; 95% CI 1.16-1.33). Patients with depression were also at higher risk of severe (1.14; 1.06-1.22) and fatal infections (death within 30 days, 1.22; 1.09-1.35), attributed mainly to sepsis (1.19; 1.08-1.31), septic shock (1.36; 1.13-1.62) and pneumonia (1.19; 1.07-1.33). Conversely, no association was observed between depression and the MACE risk (1.04; 0.94-1.15). Conclusion Dialysis patients with depression are associated with increased risk of infections and death.	[Wu, Ping-Hsun; Lin, Ming-Yen; Huang, Teng-Hui; Hung, Chi-Chih; Kuo, Hung-Tien; Chiu, Yi-Wen; Hwang, Shang-Jyh; Tsai, Jer-Chia] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Div Nephrol, Dept Internal Med, Kaohsiung, Taiwan; [Wu, Ping-Hsun] Kaohsiung Med Univ, Inst Clin Med, Coll Med, Kaohsiung, Taiwan; [Lin, Ming-Yen; Hung, Chi-Chih; Kuo, Hung-Tien; Chiu, Yi-Wen; Hwang, Shang-Jyh; Tsai, Jer-Chia] Kaohsiung Med Univ, Fac Renal Care, Coll Med, Kaohsiung, Taiwan; [Lin, Ming-Yen] Natl Taiwan Univ, Coll Publ Hlth, Master Publ Hlth Degree Program, Taipei, Taiwan; [Lin, Yi-Ting] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Family Med, Kaohsiung, Taiwan; [Lin, Yi-Ting] Kaohsiung Municipal Hsiaokang Hosp, Dept Family Med, Kaohsiung, Taiwan; [Yeh, Yi-Chun] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Psychiat, Kaohsiung, Taiwan; [Yeh, Yi-Chun] Kaohsiung Med Univ, Dept Psychiat, Coll Med, Kaohsiung, Taiwan; [Carrero, Juan-Jesus] Karolinska Inst, Dept Med Epidemiol & Biostat MEB, Stockholm, Sweden	Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; National Taiwan University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Municipal Siao-Gang Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Karolinska Institutet	Kuo, HT; Tsai, JC (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Div Nephrol, Dept Internal Med, Kaohsiung, Taiwan.; Kuo, HT; Tsai, JC (corresponding author), Kaohsiung Med Univ, Fac Renal Care, Coll Med, Kaohsiung, Taiwan.	hutiku@kmu.edu.tw; jerchia.tsai@gmail.com	Wu, Ping-Hsun/S-8746-2017; Lin, Ming Yen/A-8637-2010	Wu, Ping-Hsun/0000-0003-1021-8161; Lin, Ming Yen/0000-0002-8194-4833; Kuo, Hung-Tien/0000-0002-9931-4354	Kaohsiung Medical University Hospital [KMUH103-3M09, KMUH103-3M50, KMUH104-4M05, KMUH104-4M08, KMUH104-4M07, KMUH104-4R10, KMUH105-5R18, KMUH106-6R18, KMUH107-7R17]; intramural grants from the Kaohsiung Medical University Hospital [KMUH103-3M09, KMUH103-3M50, KMUH104-4M05, KMUH104-4M08, KMUH104-4M07, KMUH104-4R10, KMUH105-5R18, KMUH106-6R18, KMUH107-7R17]	Kaohsiung Medical University Hospital; intramural grants from the Kaohsiung Medical University Hospital	This work was supported in part by grants from the intramural grants from the Kaohsiung Medical University Hospital (KMUH103-3M09, KMUH103-3M50, KMUH104-4M05, KMUH104-4M08, KMUH104-4M07, KMUH104-4R10, KMUH105-5R18, KMUH106-6R18, and KMUH107-7R17). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study is based in part on data from the NHIRD provided by the Bureau of National Health Insurance, Department of Health, and managed by the National Health Research Institutes (Registered number 99324). This work was supported in part by grants from the intramural grants from the Kaohsiung Medical University Hospital (KMUH103-3M09, KMUH103-3M50, KMUH104-4M05, KMUH104-4M08, KMUH104-4M07, KMUH104-4R10, KMUH105-5R18, KMUH106-6R18, and KMUH107-7R17). The interpretation and conclusions contained herein do not represent the views of the Bureau of National Health Insurance, Department of Health or National Health Research Institutes. The authors thank the help from the Statistical Analysis Laboratory, Department of Internal Medicine, Kaohsiung Medical University Hospital.	Abdel-Kader K, 2009, CLIN J AM SOC NEPHRO, V4, P1057, DOI 10.2215/CJN.00430109; Akman B, 2007, TRANSPL INT, V20, P682, DOI 10.1111/j.1432-2277.2007.00495.x; Boulware LE, 2006, CLIN J AM SOC NEPHRO, V1, P496, DOI 10.2215/CJN.00030505; Chang CH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135417; Chen JL, 2013, CLIN J AM SOC NEPHRO, V8, P51, DOI 10.2215/CJN.05140512; Cheng CL, 2014, J EPIDEMIOL, V24, P500, DOI 10.2188/jea.JE20140076; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; Chilcot J, 2010, SEMIN DIALYSIS, V23, P74, DOI 10.1111/j.1525-139X.2009.00628.x; Chonchol M, 2006, SEMIN DIALYSIS, V19, P291, DOI 10.1111/j.1525-139X.2006.00175.x; Cuijpers P, 2002, J AFFECT DISORDERS, V72, P227, DOI 10.1016/S0165-0327(01)00413-X; Cukor D, 2008, CLIN J AM SOC NEPHRO, V3, P1752, DOI 10.2215/CJN.01120308; Cukor D, 2009, KIDNEY INT, V75, P1223, DOI 10.1038/ki.2009.51; Dalrymple LS, 2008, CLIN J AM SOC NEPHRO, V3, P1487, DOI 10.2215/CJN.01290308; Davydow DS, 2014, J PSYCHOSOM RES, V77, P528, DOI 10.1016/j.jpsychores.2014.08.002; Davydow DS, 2013, AM J MED, V126, P615, DOI 10.1016/j.amjmed.2012.12.006; DIMATTEO MR, ARCH INTERNAL MED, V160, P2101; Einwohner R, 2004, PERITON DIALYSIS INT, V24, P256; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Gerra G, 2003, PSYCHIAT RES, V121, P145, DOI 10.1016/S0165-1781(03)00255-5; Glaser R, 2003, ARCH GEN PSYCHIAT, V60, P1009, DOI 10.1001/archpsyc.60.10.1009; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Godbout JP, 2006, J NEUROIMMUNE PHARM, V1, P421, DOI 10.1007/s11481-006-9036-0; Goldstein BI, 2015, CIRCULATION, V132, P965, DOI 10.1161/CIR.0000000000000229; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Hedayati SS, 2008, KIDNEY INT, V74, P930, DOI 10.1038/ki.2008.311; HERBERT TB, 1993, PSYCHOL BULL, V113, P472, DOI 10.1037/0033-2909.113.3.472; Katon WJ, 2010, NEW ENGL J MED, V363, P2611, DOI 10.1056/NEJMoa1003955; Khanfer R, 2011, BRAIN BEHAV IMMUN, V25, P1182, DOI 10.1016/j.bbi.2011.03.008; Kiecolt-Glaser JK, 2002, J PSYCHOSOM RES, V53, P873, DOI 10.1016/S0022-3999(02)00309-4; Kiecolt-Glaser JK, 2002, J CONSULT CLIN PSYCH, V70, P537, DOI 10.1037//0022-006X.70.3.537; Koo JR, 2003, AM J KIDNEY DIS, V41, P1037, DOI 10.1016/S0272-6386(03)00201-4; Lichtman JH, 2008, CIRCULATION, V118, P1768, DOI 10.1161/CIRCULATIONAHA.108.190769; Manns B, 2014, CLIN J AM SOC NEPHRO, V9, P1813, DOI 10.2215/CJN.01610214; McDougall KA, 2018, CLIN KIDNEY J, V11, P123, DOI 10.1093/ckj/sfx054; Miller GE, 2002, AM J CARDIOL, V90, P1279, DOI 10.1016/S0002-9149(02)02863-1; Moussavi S, 2007, LANCET, V370, P851, DOI 10.1016/S0140-6736(07)61415-9; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; Murtagh FEM, 2007, ADV CHRONIC KIDNEY D, V14, P82, DOI 10.1053/j.ackd.2006.10.001; Palmer SC, 2013, AM J KIDNEY DIS, V62, P493, DOI 10.1053/j.ajkd.2013.02.369; Penninx BWJH, 2003, BIOL PSYCHIAT, V54, P566, DOI 10.1016/S0006-3223(02)01811-5; Perng CL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088721; Rugulies R, 2002, AM J PREV MED, V23, P51, DOI 10.1016/S0749-3797(02)00439-7; Saglimbene V, 2017, NEPHROL DIAL TRANSPL, V32, P377, DOI 10.1093/ndt/gfw016; Slavich GM, 2014, PSYCHOL BULL, V140, P774, DOI 10.1037/a0035302; Troidle L, 2003, AM J KIDNEY DIS, V42, P350, DOI 10.1016/S0272-6386(03)00661-9; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; Van der Kooy K, 2007, INT J GERIATR PSYCH, V22, P613, DOI 10.1002/gps.1723; Wu CS, 2011, AM J PSYCHIAT, V168, P511, DOI 10.1176/appi.ajp.2010.10071064	48	7	8	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2019	14	6							e0218335	10.1371/journal.pone.0218335	http://dx.doi.org/10.1371/journal.pone.0218335			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IC8NN	31194838	Green Published, Green Submitted, gold			2023-01-03	WOS:000471238300090
J	Marrie, RA; O'Mahony, J; Maxwell, CJ; Ling, V; Yeh, EA; Arnold, DL; Bar-Or, A; Banwell, B; Wambera, K; Connolly, MB; Yager, J; Mah, JK; Sebire, G; Callen, D; Meaney, B; Dilenge, ME; Lortie, A; Pohl, D; Doja, A; Venkateswaran, S; Meek, D; Wood, E; Buckley, D; Awuku, M; Baird, JB; Bhan, V				Marrie, Ruth Ann; O'Mahony, Julia; Maxwell, Colleen J.; Ling, Vicki; Yeh, E. Ann; Arnold, Douglas L.; Bar-Or, Amit; Banwell, Brenda; Wambera, Katherine; Connolly, Mary B.; Yager, Jerome; Mah, Jean K.; Sebire, Giullaume; Callen, David; Meaney, Brandon; Dilenge, Marie-Emmanuelle; Lortie, Anne; Pohl, Daniela; Doja, Asif; Venkateswaran, Sunita; Meek, David; Wood, Ellen; Buckley, David; Awuku, Mark; Baird, J. Burke; Bhan, Virender		Canadian Pediat Demyelinating Dis	High rates of health care utilization in pediatric multiple sclerosis: A Canadian population-based study	PLOS ONE			English	Article							CHILDREN	We aimed to compare health care utilization of children with pediatric-onset multiple sclerosis to that of age, sex and geographically-matched children without multiple sclerosis. Using population-based administrative data from Ontario, Canada for the period 2003-2014, we applied a validated case definition to identify persons aged. 18 years with multiple sclerosis. We identified up to 5 children without multiple sclerosis matched on sex, age, and region of residence. In each cohort, we determined annual rates of any hospitalization and physician services use. Using general linear models we compared utilization rates adjusting for age, sex, region, socioeconomic status and year. Subsequently, we limited the analysis to incident cases of multiple sclerosis and their matches, and compared rates of utilization in the year of multiple sclerosis diagnosis, and the three years thereafter. We identified 659 youth with multiple sclerosis (428 incident cases), and 3,294 matched controls. Two-thirds of both cohorts were female. After adjustment for sociodemographic factors and year, the multiple sclerosis cohort was more likely to be hospitalized than the matched cohort (odds ratio 15.2; 95% CI: 12.0, 19.1), and had higher rates of ambulatory physician visits (rate ratio 4.58; 95% CI: 4.26, 4.92). The odds of hospitalization (odds ratio 40.1; 95% CI: 27.1, 59.5) and physician visits (rate ratio 5.14; 95% CI: 4.63, 5.71) were markedly elevated in the year of MS diagnosis, declining thereafter but remaining elevated versus the matched cohort. Children with multiple sclerosis have substantially elevated rates of health care utilization as compared to matched children without multiple sclerosis, over calendar time and throughout the early disease course.	[Marrie, Ruth Ann] Univ Manitoba, Max Rady Coll Med, Rady Fac Hlth Sci, Dept Internal Med, Winnipeg, MB, Canada; [Marrie, Ruth Ann] Univ Manitoba, Rady Fac Hlth Sci, Max Rady Coll Med, Dept Community Hlth Sci, Winnipeg, MB, Canada; [O'Mahony, Julia] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [O'Mahony, Julia] Hosp Sick Children, Div Neurol, Toronto, ON, Canada; [Maxwell, Colleen J.] Univ Waterloo, Sch Pharm, Waterloo, ON, Canada; [Maxwell, Colleen J.] Univ Waterloo, Sch Publ Hlth & Hlth Syst, Waterloo, ON, Canada; [Maxwell, Colleen J.; Ling, Vicki] ICES, Toronto, ON, Canada; [Yeh, E. Ann] Univ Toronto, Div Neurol, Dept Pediat, Toronto, ON, Canada; [Yeh, E. Ann] SickKids Res Inst, Neurosci & Mental Hlth, Toronto, ON, Canada; [Arnold, Douglas L.] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada; [Bar-Or, Amit] Univ Penn, Perelman Sch Med, Ctr Neuroinflammat & Expt Therapeut, Philadelphia, PA 19104 USA; [Bar-Or, Amit; Banwell, Brenda] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; [Banwell, Brenda] Childrens Hosp Philadelphia, Div Child Neurol, Dept Pediat, Philadelphia, PA 19104 USA; [Banwell, Brenda] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Bar-Or, Amit] Univ Penn, Philadelphia, PA 19104 USA; [Yeh, E. Ann] Hosp Sick Children, Toronto, ON, Canada; [Arnold, Douglas L.] McGill Univ, Montreal, PQ, Canada; [Wambera, Katherine] Victoria Gen Hosp, Victoria, BC, Canada; [Connolly, Mary B.] Childrens Hosp British Columbia, Vancouver, BC, Canada; [Yager, Jerome] Childrens Stollery Hosp, Edmonton, AB, Canada; [Mah, Jean K.] Alberta Childrens Prov Gen Hosp, Calgary, AB, Canada; [Sebire, Giullaume; Dilenge, Marie-Emmanuelle] Montreal Childrens Hosp, Montreal, PQ, Canada; [Callen, David; Meaney, Brandon] Hamilton Hlth Sci Ctr, Hamilton, ON, Canada; [Lortie, Anne] Hop St Justine, Montreal, PQ, Canada; [Pohl, Daniela; Doja, Asif; Venkateswaran, Sunita] Childrens Hosp Eastern Ontario, Ottawa, ON, Canada; [Meek, David] St John Reg Hosp Facil, Oxnard, CA USA; [Wood, Ellen; Bhan, Virender] Dalhousie Univ, Halifax, NS B3H 3J5, Canada; [Buckley, David] Janeway Childrens Hlth & Rehabil Ctr, St John, NF, Canada; [Awuku, Mark] Univ Windsor, Windsor, ON, Canada; [Baird, J. Burke] McMaster Univ, Hamilton, ON, Canada	University of Manitoba; University of Manitoba; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Waterloo; University of Waterloo; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University; University of Victoria; University of British Columbia; Alberta Childrens Hospital; University of Calgary; McGill University; McMaster University; Universite de Montreal; University of Ottawa; Children's Hospital of Eastern Ontario; Dalhousie University; University of Windsor; McMaster University	Marrie, RA (corresponding author), Univ Manitoba, Max Rady Coll Med, Rady Fac Hlth Sci, Dept Internal Med, Winnipeg, MB, Canada.; Marrie, RA (corresponding author), Univ Manitoba, Rady Fac Hlth Sci, Max Rady Coll Med, Dept Community Hlth Sci, Winnipeg, MB, Canada.	rmarrie@hsc.mb.ca	Bar-Or, Amit/AIC-1416-2022	Arnold, Douglas/0000-0003-4266-0106; Marrie, Ruth Ann/0000-0002-1855-5595	Multiple Sclerosis Scientific Research Foundation; Waugh Family Chair in Multiple Sclerosis; Manitoba Research Chair from Research Manitoba	Multiple Sclerosis Scientific Research Foundation; Waugh Family Chair in Multiple Sclerosis; Manitoba Research Chair from Research Manitoba	This study was funded by the Multiple Sclerosis Scientific Research Foundation (BB, RAM, ABO, EAY, DA). RAM is supported by the Waugh Family Chair in Multiple Sclerosis and a Manitoba Research Chair from Research Manitoba. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amato MP, 2008, NEUROLOGY, V70, P1891, DOI 10.1212/01.wnl.0000312276.23177.fa; Amato MP, 2016, NEUROLOGY, V87, pS82, DOI 10.1212/WNL.0000000000002883; Andersen RM, 2008, MED CARE, V46, P647, DOI 10.1097/MLR.0b013e31817f4d48; Evans C, 2012, AM J MANAG CARE, V18, P735; Goretti B, 2010, NEUROL SCI, V31, P467, DOI 10.1007/s10072-010-0281-x; Gorman MP, 2009, ARCH NEUROL-CHICAGO, V66, P54, DOI 10.1001/archneurol.2008.505; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Lavery AM, 2016, MULT SCLER RELAT DIS, V9, P5, DOI 10.1016/j.msard.2016.05.018; Marrie RA, 2018, NEUROLOGY, V91, pE1579, DOI [10.1212/WNL.0000000000006395, 10.1212/wnl.0000000000006395]; Marrie RA, 2014, NEUROLOGY, V83, P929, DOI 10.1212/WNL.0000000000000753; Marrie RA, 2013, MULT SCLER J, V19, P1113, DOI 10.1177/1352458512471877; Minkovitz CS, 2005, PEDIATRICS, V115, P306, DOI 10.1542/peds.2004-0341; Mustard CA, 1999, HEALTH PLACE, V5, P157, DOI 10.1016/S1353-8292(99)00008-8; Newacheck PW, 2005, ARCH PEDIAT ADOL MED, V159, P10, DOI 10.1001/archpedi.159.1.10; O'Mahony J, 2015, PEDIATRICS, V136, pE115, DOI 10.1542/peds.2015-0028; Ralston SL, 2015, PEDIATRICS, V136, P860, DOI 10.1542/peds.2014-3920; RILEY AW, 1993, MED CARE, V31, P767, DOI 10.1097/00005650-199309000-00002; Rotstein DL, 2018, NEUROLOGY, V90, pE1435, DOI 10.1212/WNL.0000000000005331; Sinay V, 2015, MULT SCLER J, V21, P945, DOI 10.1177/1352458514554054; Wijnands JMA, 2017, LANCET NEUROL, V16, P445, DOI 10.1016/S1474-4422(17)30076-5; Wright MA, 2017, NEUROL-NEUROIMMUNOL, V4, DOI 10.1212/NXI.0000000000000314	21	10	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2019	14	6							e0218215	10.1371/journal.pone.0218215	http://dx.doi.org/10.1371/journal.pone.0218215			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IC4XB	31185042	Green Published, Green Submitted, gold			2023-01-03	WOS:000470970000047
J	Babu, KM; Brent, J; Juurlink, DN				Babu, Kavita M.; Brent, Jeffrey; Juurlink, David N.			Prevention of Opioid Overdose	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INDUCED RESPIRATORY DEPRESSION; CHRONIC PAIN; PRESCRIBING PATTERNS; MISUSE MEASURE; UNITED-STATES; RISK INDEX; BACK-PAIN; PRESCRIPTION; THERAPY; NALOXONE	This review explains harm-reduction strategies for three groups of patients: those who have not received previous opioid therapy, those receiving long-term opioid therapy, and those with an opioid use disorder. It explains both risk assessment and the current approach to the use of medications for opioid use disorder.	[Babu, Kavita M.] Univ Massachusetts, Div Med Toxicol, Med Sch, Worcester, MA 01605 USA; [Babu, Kavita M.] Univ Massachusetts, Dept Emergency Med, Med Sch, Worcester, MA 01605 USA; [Brent, Jeffrey] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA; [Brent, Jeffrey] Univ Colorado, Sch Med, Dept Emergency Med, Aurora, CO USA; [Brent, Jeffrey] Colorado Sch Publ Hlth, Dept Med, Aurora, CO USA; [Juurlink, David N.] Univ Toronto, Div Gen Internal Med, Toronto, ON, Canada; [Juurlink, David N.] Univ Toronto, Dept Clin Pharmacol, Toronto, ON, Canada; [Juurlink, David N.] Univ Toronto, Dept Toxicol & Med, Toronto, ON, Canada	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Colorado School of Public Health; University of Toronto; University of Toronto; University of Toronto	Babu, KM (corresponding author), Univ Massachusetts, Med Sch, 55 Lake Ave N, Worcester, MA 01655 USA.	kavita.babu@umassmemorial.org			Alkermes	Alkermes	Dr. Babu reports receiving fees for medicolegal consulting, paid to her institution, from CRICO and Traveler's Insurance, fees for medicolegal consulting from Stryker, Bayer, and Johnson & Johnson, and grant support from Alkermes Investigator Sponsored Studies; Dr. Brent, receiving consulting fees and providing expert testimony for Bayer Pharmaceuticals, Forest Laboratories, Auxilium Pharmaceuticals, and the Coca-Cola Company and consulting fees from Pfizer Pharmaceuticals; and Dr. Juurlink, receiving lecture fees and fees for medicolegal consulting from Dutton Brock and from Pfaff, Gill, and Ports. No other potential conflict of interest relevant to this article was reported.	Abstracts from The Academy of Breastfeeding Medicine, 2015, BREASTFEED MED, V10, pS1; Aiyer R, 2018, ANESTH ANALG, V127, P529, DOI 10.1213/ANE.0000000000002718; Alam A, 2012, ARCH INTERN MED, V172, P425, DOI 10.1001/archinternmed.2011.1827; [Anonymous], 2018, BUPR WAIV MAN; [Anonymous], 2018, SURG GEN REL ADV NAL; [Anonymous], 2017, BUPR CHRON PAIN REV; [Anonymous], 2016, PAIN MAN OP TAP DEC; [Anonymous], [No title captured]; Bachhuber MA, 2018, PAIN MED, V19, P1952, DOI 10.1093/pm/pny053; Behar E, 2017, J GEN INTERN MED, V32, P291, DOI 10.1007/s11606-016-3911-z; Behar E, 2016, ANN FAM MED, V14, P431, DOI 10.1370/afm.1972; Bershad AK, 2018, INT J NEUROPSYCHOPH, V21, P120, DOI 10.1093/ijnp/pyx077; Bicket MC, 2017, JAMA SURG, V152, P1066, DOI 10.1001/jamasurg.2017.0831; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Boyer EW, 2012, NEW ENGL J MED, V367, P146, DOI 10.1056/NEJMra1202561; Brummett CM, 2017, JAMA SURG, V152, DOI 10.1001/jamasurg.2017.0504; Busse JW, 2017, CAN MED ASSOC J, V189, pE659, DOI 10.1503/cmaj.170363; Butler SF, 2010, CLIN J PAIN, V26, P770, DOI 10.1097/AJP.0b013e3181f195ba; Carroll JJ, 2018, J ADDICT MED, V12, P459, DOI 10.1097/ADM.0000000000000436; Chen KY, 2014, ANESTHESIOLOGY, V120, P1262, DOI 10.1097/ALN.0000000000000170; Chiu AS, 2018, JAMA SURG, V153, P1012, DOI 10.1001/jamasurg.2018.2083; Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559; Coffin PO, 2016, ANN INTERN MED, V165, P245, DOI 10.7326/M15-2771; Cunningham JL, 2016, PAIN MED, V17, P1676, DOI 10.1093/pm/pnv079; D'Onofrio G, 2015, JAMA-J AM MED ASSOC, V313, P1636, DOI 10.1001/jama.2015.3474; Daitch D, 2014, PAIN MED, V15, P2087, DOI 10.1111/pme.12520; Darnall BD, 2018, JAMA INTERN MED, V178, P707, DOI 10.1001/jamainternmed.2017.8709; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMsa1406143, 10.1056/NEJMc1501822]; Delgado MK, 2018, ANN EMERG MED, V72, P389, DOI 10.1016/j.annemergmed.2018.06.003; Deyo RA, 2017, J GEN INTERN MED, V32, P21, DOI 10.1007/s11606-016-3810-3; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI [10.1001/jama.2016.1464, 10.15585/mmwr.rr7103a1]; Duber HC, 2018, ANN EMERG MED, V72, P420, DOI 10.1016/j.annemergmed.2018.04.007; Expert Panel on Neurologic Imaging, 2017, J AM COLL RADIOL, V14, pS550; Freye Enno, 2007, Pain Pract, V7, P123, DOI 10.1111/j.1533-2500.2007.00119.x; Friedmann PD, 2018, J SUBST ABUSE TREAT, V85, P45, DOI 10.1016/j.jsat.2017.04.010; Garg RK, 2017, MED CARE, V55, P661, DOI 10.1097/MLR.0000000000000738; Gomes T, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.0217; Gomes T, 2018, ANN INTERN MED, V169, P732, DOI 10.7326/M18-1136; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Gray JA, 2012, ARCH INTERN MED, V172, P1186, DOI 10.1001/archinternmed.2012.2374; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; Harbaugh CM, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-2439; Hasak JM, 2018, J AM COLL SURGEONS, V226, P235, DOI 10.1016/j.jamcollsurg.2017.11.023; Hayes Corey J, 2017, J Opioid Manag, V13, P95, DOI 10.5055/jom.2017.0373; Hill MV, 2018, J AM COLL SURGEONS, V226, P996, DOI 10.1016/j.jamcollsurg.2017.10.012; Hill MV, 2017, ANN SURG, V265, P709, DOI 10.1097/SLA.0000000000001993; JUNE HL, 1995, CLIN PHARMACOL THER, V57, P270, DOI 10.1016/0009-9236(95)90152-3; Just JM, 2018, BMC FAM PRACT, V19, DOI 10.1186/s12875-018-0775-9; Juurlink DN, 2017, CAN MED ASSOC J, V189, pE1222, DOI 10.1503/cmaj.170628; Kennedy MC, 2017, CURR HIV-AIDS REP, V14, P161, DOI 10.1007/s11904-017-0363-y; Krebs EE, 2018, JAMA-J AM MED ASSOC, V319, P872, DOI 10.1001/jama.2018.0899; Larochelle MR, 2018, ANN INTERN MED, V169, P137, DOI 10.7326/M17-3107; Ma J., 2018, MOL PSYCHIATR; Manhapra A, 2017, SUBST ABUS; Massachusetts Department of Public Health, 2017, DAT BRIEF ASS OP REL; Mattick RP, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub4; McCaffrey SA, 2019, PAIN MED, V20, P113, DOI 10.1093/pm/pnx311; McClellan C, 2018, ADDICT BEHAV, V86, P90, DOI 10.1016/j.addbeh.2018.03.014; McPherson S, 2018, PAIN, V159, P2097, DOI 10.1097/j.pain.0000000000001315; Miech R, 2015, PEDIATRICS, V136, pE1169, DOI 10.1542/peds.2015-1364; Mundkur ML, 2018, PHARMACOEPIDEM DR S, V27, P495, DOI 10.1002/pds.4322; Murphy L, 2018, CAN PHARM J, V151, P114, DOI 10.1177/1715163518754918; Oquendo MA, 2018, NEW ENGL J MED, V378, P1567, DOI 10.1056/NEJMp1801417; Park TW, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2698; Potier C, 2014, DRUG ALCOHOL DEPEN, V145, P48, DOI 10.1016/j.drugalcdep.2014.10.012; PrescribeToPrevent. org, 2015, PRIMARY CHRONIC PAIN; Rose AJ, 2018, J GEN INTERN MED, V33, P1512, DOI 10.1007/s11606-018-4532-5; Scholl L, 2019, MMWR-MORBID MORTAL W, V67, P1419; Schuckit MA, 2016, NEW ENGL J MED, V375, P1596, DOI 10.1056/NEJMc1610830; Shah A, 2017, MMWR-MORBID MORTAL W, V66, P265, DOI 10.15585/mmwr.mm6610a1; Smith PC, 2010, ARCH INTERN MED, V170, P1155, DOI 10.1001/archinternmed.2010.140; Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550; Srivastava A, 2017, CAN FAM PHYSICIAN, V63, P200; Strang J, 2003, BMJ-BRIT MED J, V326, P959, DOI 10.1136/bmj.326.7396.959; Strang J, 2015, BRIT J PSYCHIAT, V207, P5, DOI 10.1192/bjp.bp.114.149195; Substance Abuse and Mental Health Services Administration, 2018, KEY SUBSTANCE USE ME; Substance Abuse and Mental Health Services Administration, 2018, MED OP US DIS TREATM, V63; Vowles KE, 2015, PAIN, V156, P569, DOI 10.1097/01.j.pain.0000460357.01998.f1; Webster BS, 2007, SPINE, V32, P2127, DOI 10.1097/BRS.0b013e318145a731; Wheeler E, 2015, MMWR-MORBID MORTAL W, V64, P631; Wickersham JA, 2015, J CORRECT HEALTH CAR, V21, P12, DOI 10.1177/1078345814557513; Wu PE, 2014, CAN MED ASSOC J, V186, P815, DOI 10.1503/cmaj.140222; Zedler B, 2015, PAIN MED, V16, P1566, DOI 10.1111/pme.12777; Zedler BK, 2018, PAIN MED, V19, P68, DOI 10.1093/pm/pnx009	84	50	50	1	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 6	2019	380	23					2246	2255		10.1056/NEJMra1807054	http://dx.doi.org/10.1056/NEJMra1807054			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IC4KH	31167053	Green Published			2023-01-03	WOS:000470933900011
J	Saleh, ME; Gadalla, R; Hassan, H; Afifi, A; Gotte, M; El-Shinawi, M; Mohamed, MM; Ibrahim, SA				Saleh, Moshira Ezzat; Gadalla, Ramy; Hassan, Hebatallah; Afifi, Ahmed; Goette, Martin; El-Shinawi, Mohamed; Mohamed, Mona Mostafa; Ibrahim, Sherif Abdelaziz			The immunomodulatory role of tumor Syndecan-1 (CD138) on ex vivo tumor microenvironmental CD4(+) T cell polarization in inflammatory and non-inflammatory breast cancer patients	PLOS ONE			English	Article							LATENT TGF-BETA; SULFATE BINDING; TH17 CELLS; PROMOTES; EXPRESSION; ACTIVATION; CARCINOMA; IL-17; DIFFERENTIATION; PROTEOGLYCAN	Herein, we aimed to identify the immunomodulatory role of tumor Syndecan-1 (CD138) in the polarization of CD4(+) T helper (Th) subsets isolated from the tumor microenvironment of inflammatory breast cancer (IBC) and non-IBC patients. Lymphocytes and mononuclear cells isolated from the axillary tributaries of non-IBC and IBC patients during modified radical mastectomy were either stimulated with the secretome as indirect co-culture or directly co-cultured with control and Syndecan-1-silenced SUM-149 IBC cells. In addition, peripheral blood mononuclear cells (PBMCs) of normal subjects were used for the direct co-culture. Employing flow cytometry, we analyzed the expression of the intracellular IFN-gamma, IL-4, IL-17, and Foxp3 markers as readout for basal and co-cultured Th-1, Th-2, Th-17, and T-reg CD4(+) subsets, respectively. Our data revealed that IBC displayed a lower basal frequency of Th1 and Th-2 subsets than non-IBC. Syndecan-1-silenced SUM-149 cells significantly upregulated only T-reg subset polarization of normal subjects relative to controls. However, Syndecan-1 silencing significantly enhanced the polarization of Th-17 and T-reg subsets of non-IBC under both direct and indirect conditions and induced only Th1 subset polarization under indirect conditions compared to control. Interestingly, qPCR revealed that there was a negative correlation between Syndecan-1 and each of IL-4, IL-17, and Foxp3 mRNA expression in carcinoma tissues of IBC and that the correlation was reversed in non-IBC. Mechanistically, Syndecan-1 knockdown in SUM-149 cells promoted Th17 cell expansion via upregulation of IL-23 and the Notch ligand DLL4. Overall, this study indicates a low frequency of the circulating antitumor Th1 subset in IBC and suggests that tumor Syndecan-1 silencing enhances ex vivo polarization of CD4(+) Th-17 and T-reg cells of non-IBC, whereby Th17 polarization is possibly mediated via upregulation of IL-23 and DLL4. These findings suggest the immunoregulatory role of tumor Syndecan-1 expression in Th cell polarization that may have therapeutic implications for breast cancer.	[Saleh, Moshira Ezzat; Gadalla, Ramy; Hassan, Hebatallah; Afifi, Ahmed; Mohamed, Mona Mostafa; Ibrahim, Sherif Abdelaziz] Cairo Univ, Dept Zool, Fac Sci, Giza, Egypt; [Goette, Martin] Munster Univ Hosp, Dept Gynecol & Obstet, Munster, Germany; [El-Shinawi, Mohamed] Ain Shams Univ, Fac Med, Dept Gen Surg, Cairo, Egypt	Egyptian Knowledge Bank (EKB); Cairo University; University of Munster; Egyptian Knowledge Bank (EKB); Ain Shams University	Ibrahim, SA (corresponding author), Cairo Univ, Dept Zool, Fac Sci, Giza, Egypt.	isherif@sci.cu.edu.eg	Gotte, M/Z-5878-2019; Götte, Martin/G-2254-2018	Gotte, M/0000-0003-2360-2496; Götte, Martin/0000-0003-2360-2496; El-Shinawi, Mohamed/0000-0003-3645-2343; Ibrahim, Sherif Abdelaziz/0000-0001-6403-7345	Science and Technology Development Funds (STDF), Egypt [6309]; German Academic Exchange Service (DAAD) [56808461]; H2020 Marie Sklodowska-Curie Actions [645756]	Science and Technology Development Funds (STDF), Egypt(Science and Technology Development Fund (STDF)); German Academic Exchange Service (DAAD)(Deutscher Akademischer Austausch Dienst (DAAD)); H2020 Marie Sklodowska-Curie Actions	This work was supported by Science and Technology Development Funds (STDF), Egypt, Reintegration project ID#6309 (to SAI and HH), German Academic Exchange Service (DAAD) #56808461 Al Tawasul (to SAI and MG), and H2020 Marie Sklodowska-Curie Actions #645756 (to MG and SAI). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; Ahrends T, 2017, IMMUNITY, V47, P848, DOI 10.1016/j.immuni.2017.10.009; Al Absi A, 2018, CANCER RES, V78, P5631, DOI 10.1158/0008-5472.CAN-18-0441; Baba F, 2006, BREAST CANCER RES TR, V98, P91, DOI 10.1007/s10549-005-9135-2; Barbareschi M, 2003, CANCER-AM CANCER SOC, V98, P474, DOI 10.1002/cncr.11515; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen Q, 2007, J BIOL CHEM, V282, P26418, DOI 10.1074/jbc.M703341200; Cochaud S, 2013, SCI REP-UK, V3, DOI 10.1038/srep03456; Coutaz M, 2016, SCI REP-UK, V6, DOI 10.1038/srep39117; Dagur Pradeep K, 2015, Curr Protoc Cytom, V73, DOI 10.1002/0471142956.cy0501s73; Dai H, 2015, EUR J IMMUNOL, V45, P3045, DOI 10.1002/eji.201545532; DAUBENER W, 1995, EUR J IMMUNOL, V25, P688, DOI 10.1002/eji.1830250309; DeNardo DG, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1746; DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018; Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9; Dydensborg AB, 2009, ONCOGENE, V28, P2634, DOI 10.1038/onc.2009.126; El-Shinawi M, 2010, ANN SURG ONCOL, V17, P2677, DOI 10.1245/s10434-010-1029-9; Fluhr H, 2011, FERTIL STERIL, V95, P1272, DOI 10.1016/j.fertnstert.2010.04.061; Fu S, 2004, AM J TRANSPLANT, V4, P1614, DOI 10.1111/j.1600-6143.2004.00566.x; Gao ZM, 2012, INT J CLIN EXP PATHO, V5, P626; Gong GQ, 2017, J HUAZHONG U SCI-MED, V37, P412, DOI 10.1007/s11596-017-1749-1; Gotte M, 2003, FASEB J, V17, P575, DOI 10.1096/fj.02-0739rev; Gupta S, 2007, ACTA ONCOL, V46, P792, DOI 10.1080/02841860701233443; Hassan H, 2013, FEBS J, V280, P2216, DOI 10.1111/febs.12111; Heijink IH, 2002, IMMUNOLOGY, V107, P316, DOI 10.1046/j.1365-2567.2002.01501.x; Hollmen M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09188; Ibrahim AS, 2014, J CANCER EPIDEMIOL, V2014, DOI 10.1155/2014/437971; Ibrahim SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085737; Ibrahim SA, 2012, INT J CANCER, V131, pE884, DOI 10.1002/ijc.27629; Ibrahim SA, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0621-z; Jiang XG, 2014, MOL CELL ENDOCRINOL, V382, P673, DOI 10.1016/j.mce.2013.06.003; Kaminska K, 2015, J CELL MOL MED, V19, P283, DOI 10.1111/jcmm.12408; Kennedy R, 2008, IMMUNOL REV, V222, P129, DOI 10.1111/j.1600-065X.2008.00616.x; Li J, 2017, ONCOTARGET, V8, P66656, DOI 10.18632/oncotarget.19105; Lim B, 2018, NAT REV CANCER, V18, P485, DOI 10.1038/s41568-018-0010-y; Maniati E, 2010, ONCOGENE, V29, P5653, DOI 10.1038/onc.2010.367; Masouleh BK, 2009, J IMMUNOL, V182, P4985, DOI 10.4049/jimmunol.0800574; Mukherjee S, 2009, J IMMUNOL, V182, P7381, DOI 10.4049/jimmunol.0804322; Mumm JB, 2008, ONCOGENE, V27, P5913, DOI 10.1038/onc.2008.275; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; Nikolova V, 2009, CARCINOGENESIS, V30, P397, DOI 10.1093/carcin/bgp001; Regos E, 2018, MATRIX BIOL, V68-69, P474, DOI 10.1016/j.matbio.2018.02.008; Ren Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0758-4; Rider CC, 2006, BIOCHEM SOC T, V34, P458, DOI 10.1042/BST0340458; Rider CC, 2017, MOLECULES, V22, DOI 10.3390/molecules22050713; Sadir R, 1998, J BIOL CHEM, V273, P10919, DOI 10.1074/jbc.273.18.10919; Shiao SL, 2015, CANCER IMMUNOL RES, V3, P518, DOI 10.1158/2326-6066.CIR-14-0232; Smeets RL, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-12; Sousa S, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0621-0; Stanley MJ, 1999, AM J CLIN PATHOL, V112, P377; Stepp MA, 2007, J CELL SCI, V120, P2851, DOI 10.1242/jcs.03480; Stepp MA, 2015, ADV WOUND CARE, V4, P235, DOI 10.1089/wound.2014.0555; Su XM, 2010, J IMMUNOL, V184, P1630, DOI 10.4049/jimmunol.0902813; Tanaka A, 2017, CELL RES, V27, P109, DOI 10.1038/cr.2016.151; Tindemans I, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00419; Usui T, 2006, J EXP MED, V203, P755, DOI 10.1084/jem.20052165; Wan YSY, 2010, IMMUNOLOGY, V130, P166, DOI 10.1111/j.1365-2567.2010.03289.x; Welte T, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/804347; Xiao J, 2011, ARTERIOSCL THROM VAS, V31, P2261, DOI 10.1161/ATVBAHA.111.229609; Xu J, 2005, J IMMUNOL, V174, P5758, DOI 10.4049/jimmunol.174.9.5758; Xu L, 2010, CLIN IMMUNOL, V135, P466, DOI 10.1016/j.clim.2010.01.014; Yoon NK, 2010, HUM PATHOL, V41, P1794, DOI 10.1016/j.humpath.2010.06.010; Zhang XL, 2013, J IMMUNOL, V191, P4551, DOI 10.4049/jimmunol.1300931; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878; Zhou M, 2003, IMMUNOL RES, V28, P25, DOI 10.1385/IR:28:1:25; zu Horste GM, 2016, CELL REP, V16, P392, DOI 10.1016/j.celrep.2016.05.088	66	16	17	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2019	14	5							e0217550	10.1371/journal.pone.0217550	http://dx.doi.org/10.1371/journal.pone.0217550			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IA2XG	31145753	Green Submitted, Green Published, gold			2023-01-03	WOS:000469425500021
J	Ahn, J; Kim, SA; Kim, KW; Oh, JH; Kim, SJ				Ahn, Jiyong; Kim, Seon Ae; Kim, Ki Won; Oh, Joon Hyuck; Kim, Seok Jung			Optimization of TGF-beta 1-transduced chondrocytes for cartilage regeneration in a 3D printed knee joint model	PLOS ONE			English	Article							MESENCHYMAL STEM-CELLS; IMPLANTATION; MICROFRACTURE; MATRIX; TISSUE; TRIAL; OUTCOMES; DEFECT	A cell therapy product of transforming growth factor (TGF)-beta 1-transduced chondrocytes has been commercialized to treat osteoarthritis of the knee via intra-articular injection. The need for arthroscopic application of the cells to simultaneously treat intra-articular pathologies of knee osteoarthritis is increasingly urgent. The purpose of this study was to optimize TGF-beta 1-transduced chondrocytes for arthroscopic application. The optimal composition of chondrocytes and thrombin was initially determined by measuring the consolidation time of a diverse ratio of chondrocytes and thrombin mixed with 1 ml of fibrinogen. The consolidation time of the diverse ratio of fibrinogen and atelocollagen mixed with the determined optimal ratio of chondrocytes and thrombin was evaluated. The mixture of the determined optimal ratio of TGF-beta 1-transduced chondrocytes, atelocollagen, fibrinogen, and thrombin was applied to the cartilage defect of the 3D printed knee joint model arthroscopically. The status of the mixture in the defect was then evaluated. Chondrogenic activities of TGF-beta 1-transduced chondrocytes mixed with atelocollagen were evaluated. The determined ratio of TGF-beta 1-transduced chondrocytes to thrombin was 8: 2 and that of fibrin to atelocollagen was also 8: 2. Excellent maintenance of conformation of the mixture of TGF-beta 1-transduced chondrocytes, atelocollagen, fibrinogen, and thrombin in the cartilage defect of the 3D printed knee joint model was observed arthroscopically. Increased chondrogenic activities were observed in the group of TGF-beta 1-transduced chondrocytes mixed with atelocollagen. TGF-beta 1-transduced chondrocytes can be applied arthroscopically to treat cartilage defects of the knee at an optimized mixing ratio of atelocollagen, fibrinogen, and thrombin.	[Ahn, Jiyong; Kim, Seon Ae; Kim, Ki Won; Oh, Joon Hyuck; Kim, Seok Jung] Catholic Univ Korea, Coll Med, Dept Orthopaed Surg, Uijenong Bu Si, Gyeonggi Do, South Korea	Catholic University of Korea	Kim, SJ (corresponding author), Catholic Univ Korea, Coll Med, Dept Orthopaed Surg, Uijenong Bu Si, Gyeonggi Do, South Korea.	peter@catholic.ac.kr			Global High-tech Biomedicine Technology Development Program of the National Research Foundation (NRF); Korea Health Industry Development Institute(KHIDI) - Korean government (MSIP) [2015M3D6A1065464]; Korea Health Industry Development Institute(KHIDI) - Korean government (MOHW) [2015M3D6A1065464]	Global High-tech Biomedicine Technology Development Program of the National Research Foundation (NRF); Korea Health Industry Development Institute(KHIDI) - Korean government (MSIP); Korea Health Industry Development Institute(KHIDI) - Korean government (MOHW)	This research was co-supported by the Global High-tech Biomedicine Technology Development Program of the National Research Foundation (NRF) & Korea Health Industry Development Institute(KHIDI) funded by the Korean government (MSIP&MOHW) (No. 2015M3D6A1065464). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aae TF, 2018, KNEE SURG SPORT TR A, V26, P1044, DOI 10.1007/s00167-017-4802-5; Abbas M, 2018, TISSUE ENG REGEN MED, V15, P661, DOI 10.1007/s13770-018-0131-0; Belluzzi E, 2017, J CELL PHYSIOL, V232, P1971, DOI 10.1002/jcp.25716; Benthien JP, 2010, CARTILAGE, V1, P65, DOI 10.1177/1947603509360044; BROWER TD, 1969, CLIN ORTHOP RELAT R, P9; Buldu MT, 2016, J KNEE SURG, V29, P396, DOI 10.1055/s-0035-1564592; Cho J, 2016, CYTOTHERAPY, V18, pS10, DOI 10.1016/j.jcyt.2016.03.024; CHOI H, 2016, OSTEOARTHR CARTILAGE, V24, pS33; Cvetanovich GL, 2017, AM J SPORT MED, V45, P70, DOI 10.1177/0363546516663711; de Windt TS, 2017, STEM CELLS, V35, P256, DOI 10.1002/stem.2475; Doyle AD, 2016, CURR PROTOC CELL BIO, V72, P10, DOI DOI 10.20.1; Ebert JR, 2017, AM J SPORT MED, V45, P59, DOI 10.1177/0363546516663493; Erggelet Christoph, 2016, J Clin Orthop Trauma, V7, P145, DOI 10.1016/j.jcot.2016.06.015; Finnson Kenneth W, 2012, Front Biosci (Schol Ed), V4, P251; Frappier Julie, 2014, J Med Econ, V17, P266, DOI 10.3111/13696998.2014.897626; Gillogly SD, 1998, J ORTHOP SPORT PHYS, V28, P241, DOI 10.2519/jospt.1998.28.4.241; Gobbi A, 2011, CARTILAGE, V2, P286, DOI 10.1177/1947603510392023; Gracitelli GC, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010675.pub2; Huri Pinar Yilgor, 2018, Knee Surg Relat Res, V30, P179, DOI 10.5792/ksrr.17.061; Irawan V, 2018, TISSUE ENG REGEN MED, V15, P673, DOI 10.1007/s13770-018-0135-9; Knutsen G, 2016, J BONE JOINT SURG AM, V98, P1332, DOI 10.2106/JBJS.15.01208; Lee MC, 2015, BONE JOINT J, V97B, P924, DOI 10.1302/0301-620X.97B7.35852; Meyer M, 2019, BIOMED ENG ONLINE, V18, DOI 10.1186/s12938-019-0647-0; Nawaz SZ, 2014, J BONE JOINT SURG AM, V96A, P824, DOI 10.2106/JBJS.L.01695; Niethammer T, 2015, INT ORTHOP, V39, P1615, DOI 10.1007/s00264-015-2792-9; Ning L, 2011, INT ORTHOP, V35, P831, DOI 10.1007/s00264-010-1045-1; Ogura T, 2017, AM J SPORT MED, V45, P1066, DOI 10.1177/0363546516682492; Pareek A, 2016, ARTHROSCOPY, V32, P2118, DOI 10.1016/j.arthro.2016.05.038; Pestka JM, 2016, AM J SPORT MED, V44, P370, DOI 10.1177/0363546515614578; Schrock JB, 2017, ORTHOP J SPORTS MED, V5, DOI 10.1177/2325967117704634; Shen J, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.2; Shetty Asode Ananthram, 2016, J Clin Orthop Trauma, V7, P164, DOI 10.1016/j.jcot.2016.05.003; Shin Young-Soo, 2018, Knee Surg Relat Res, V30, P206, DOI 10.5792/ksrr.17.201; Tuan RS, 2013, J AM ACAD ORTHOP SUR, V21, P303, DOI 10.5435/JAAOS-21-05-303; van der Kraan PM, 2014, BIO-MED MATER ENG, V24, pS75, DOI 10.3233/BME-140976; Wang X, 2017, J RHEUMATOL, V44, P1644, DOI 10.3899/jrheum.161596; Widuchowski W, 2011, SCAND J MED SCI SPOR, V21, P106, DOI 10.1111/j.1600-0838.2009.01062.x; Wondrasch B, 2015, AM J SPORT MED, V43, P146, DOI 10.1177/0363546514554910; Zantop T, 2009, ARTHROSCOPY, V25, P1354, DOI 10.1016/j.arthro.2009.04.077; Zhai GJ, 2015, RHEUMATOL INT, V35, P1283, DOI 10.1007/s00296-015-3251-z	40	6	7	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2019	14	5							e0217601	10.1371/journal.pone.0217601	http://dx.doi.org/10.1371/journal.pone.0217601			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ3VE	31120999	Green Published, gold, Green Submitted			2023-01-03	WOS:000468775700113
J	Andre, F; Ciruelos, E; Rubovszky, G; Campone, M; Loibl, S; Rugo, HS; Iwata, H; Conte, P; Mayer, IA; Kaufman, B; Yamashita, T; Lu, YS; Inoue, K; Takahashi, M; Papai, Z; Longin, AS; Mills, D; Wilke, C; Hirawat, S; Juric, D				Andre, Fabrice; Ciruelos, Eva; Rubovszky, Gabor; Campone, Mario; Loibl, Sibylle; Rugo, Hope S.; Iwata, Hiroji; Conte, Pierfranco; Mayer, Ingrid A.; Kaufman, Bella; Yamashita, Toshinari; Lu, Yen-Shen; Inoue, Kenichi; Takahashi, Masato; Papai, Zsuzsanna; Longin, Anne-Sophie; Mills, David; Wilke, Celine; Hirawat, Samit; Juric, Dejan		SOLAR-1 Study Grp	Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESTROGEN	PIK3CA mutations occur in approximately 40% of patients with hormone receptor-positive breast cancer. A PI3K inhibitor, alpelisib, combined with fulvestrant led to a median progression-free survival of 11 months, as compared with 5.7 months with placebo plus fulvestrant. Hyperglycemia, rash, and diarrhea were more common with alpelisib. Background PIK3CA mutations occur in approximately 40% of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The PI3K alpha-specific inhibitor alpelisib has shown antitumor activity in early studies. Methods In a randomized, phase 3 trial, we compared alpelisib (at a dose of 300 mg per day) plus fulvestrant (at a dose of 500 mg every 28 days and once on day 15) with placebo plus fulvestrant in patients with HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. Patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation status. The primary end point was progression-free survival, as assessed by the investigator, in the cohort with PIK3CA-mutated cancer; progression-free survival was also analyzed in the cohort without PIK3CA-mutated cancer. Secondary end points included overall response and safety. Results A total of 572 patients underwent randomization, including 341 patients with confirmed tumor-tissue PIK3CA mutations. In the cohort of patients with PIK3CA-mutated cancer, progression-free survival at a median follow-up of 20 months was 11.0 months (95% confidence interval [CI], 7.5 to 14.5) in the alpelisib-fulvestrant group, as compared with 5.7 months (95% CI, 3.7 to 7.4) in the placebo-fulvestrant group (hazard ratio for progression or death, 0.65; 95% CI, 0.50 to 0.85; P<0.001); in the cohort without PIK3CA-mutated cancer, the hazard ratio was 0.85 (95% CI, 0.58 to 1.25; posterior probability of hazard ratio <1.00, 79.4%). Overall response among all the patients in the cohort without PIK3CA-mutated cancer was greater with alpelisib-fulvestrant than with placebo-fulvestrant (26.6% vs. 12.8%); among patients with measurable disease in this cohort, the percentages were 35.7% and 16.2%, respectively. In the overall population, the most frequent adverse events of grade 3 or 4 were hyperglycemia (36.6% in the alpelisib-fulvestrant group vs. 0.7% in the placebo-fulvestrant group) and rash (9.9% vs. 0.3%). Diarrhea of grade 3 occurred in 6.7% of patients in the alpelisib-fulvestrant group, as compared with 0.3% of those in the placebo-fulvestrant group; no diarrhea of grade 4 was reported. The percentages of patients who discontinued alpelisib and placebo owing to adverse events were 25.0% and 4.2%, respectively. Conclusions Treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously.	[Andre, Fabrice] Univ Paris Sud, Inst Gustave Roussy, INSERM, U981, Villejuif, France; [Campone, Mario] Inst Cancarol Ouest, St Herblain, France; [Longin, Anne-Sophie] Novartis Pharmaceut, Paris, France; [Ciruelos, Eva] Hosp Univ 12 Octubre, Madrid, Spain; [Rubovszky, Gabor] Natl Inst Oncol, Budapest, Hungary; [Papai, Zsuzsanna] Duna Med Ctr, Budapest, Hungary; [Loibl, Sibylle] German Breast Grp, Neu Isenburg, Germany; [Loibl, Sibylle] Ctr Hematol & Oncol Bethanien, Frankfurt, Germany; [Rugo, Hope S.] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA; [Iwata, Hiroji] Aichi Canc Ctr, Nagoya, Aichi, Japan; [Yamashita, Toshinari] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan; [Inoue, Kenichi] Saitama Canc Ctr, Saitama, Japan; [Takahashi, Masato] Natl Hosp Org Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan; [Conte, Pierfranco] Ist Oncol Veneto, Padua, Italy; [Conte, Pierfranco] Univ Padua, Dept Surg, Padua, Italy; [Conte, Pierfranco] Univ Padua, Dept Oncol, Padua, Italy; [Conte, Pierfranco] Univ Padua, Dept Gastroenterol, Padua, Italy; [Mayer, Ingrid A.] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA; [Kaufman, Bella] Chaim Sheba Med Ctr, Tel Hashomer, Israel; [Lu, Yen-Shen] Natl Taiwan Univ Hosp, Taipei, Taiwan; [Mills, David; Wilke, Celine] Novartis Pharmaceut, Basel, Switzerland; [Hirawat, Samit] Novartis Pharmaceut, E Hanover, NJ USA; [Juric, Dejan] Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St, Boston, MA 02114 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Novartis; Hospital Universitario 12 de Octubre; National Institute of Oncology Hungary; German Breast Group; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Aichi Cancer Center; Kanagawa Prefectural Cancer Center; IRCCS Istituto Oncologico Veneto (IOV); University of Padua; University of Padua; University of Padua; Vanderbilt University; Chaim Sheba Medical Center; National Taiwan University; National Taiwan University Hospital; Novartis; Novartis; Harvard University; Massachusetts General Hospital	Andre, F (corresponding author), Inst Gustave Roussy, 114 Rue Edouard Vaillant, F-94805 Villejuif, France.; Juric, D (corresponding author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St, Boston, MA 02114 USA.	fabrice.andre@gustaveroussy.fr; juric.dejan@mgh.harvard.edu	Akewanlop, Charuwan/AFU-5176-2022; ANDRE, Fabrice/AAL-2683-2020; Takahashi, Masato/ABC-2223-2020; Mills, David/GXF-1821-2022; Rubovszky, Gabor/AAE-6486-2022; Yamashita, Toshinari/GZN-0536-2022; Romero, Jose Luis Alonso/AAC-3782-2020; CONTE, PIERFRANCO/F-7418-2014	Akewanlop, Charuwan/0000-0003-1022-3745; ANDRE, Fabrice/0000-0001-5795-8357; Romero, Jose Luis Alonso/0000-0001-8746-2096; Rubovszky, Gabor/0000-0003-1723-5589; ARNEDOS, MONICA/0000-0001-5269-1251; Yamashita, Toshinari/0000-0002-6479-1660; Lopez Lopez, Rafael/0000-0003-1315-655X; CONTE, PIERFRANCO/0000-0002-5210-5344; Lu, Yen-Shen/0000-0001-7461-1291	Novartis Pharmaceuticals	Novartis Pharmaceuticals(Novartis)	Funded by Novartis Pharmaceuticals; SOLAR-1 ClinicalTrials.gov number, NCT02437318.	Baselga J, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.18_suppl.LBA1006; Baselga J, 2017, LANCET ONCOL, V18, P904, DOI 10.1016/S1470-2045(17)30376-5; Bosch A, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4442; Cardoso F, 2018, ANN ONCOL, V29, P1634, DOI 10.1093/annonc/mdy192; Di Leo A, 2018, LANCET ONCOL, V19, P87, DOI 10.1016/S1470-2045(17)30688-5; Fritsch C, 2014, MOL CANCER THER, V13, P1117, DOI 10.1158/1535-7163.MCT-13-0865; Goncalves MD, 2018, NEW ENGL J MED, V379, P2052, DOI 10.1056/NEJMra1704560; Howlader N, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju055; Juric D, 2018, JAMA ONCOL; Juric D, PRESENTED AT THE SAN; Juric D, 2018, J CLIN ONCOL, V36, P1291, DOI 10.1200/JCO.2017.72.7107; Juric D, 2015, NATURE, V518, P240, DOI 10.1038/nature13948; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Liu CY, 2017, J STEROID BIOCHEM, V172, P166, DOI 10.1016/j.jsbmb.2017.07.001; Miller TW, 2010, J CLIN INVEST, V120, P2406, DOI 10.1172/JCI41680; Mollon L, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-1207; National Comprehensive Cancer Network (NCCN), 2018, NCCN CLIN PRACT GUID; O'Leary B, 2018, CANCER DISCOV, V8, P1390, DOI 10.1158/2159-8290.CD-18-0264; Rugo HS, 2016, J CLIN ONCOL, V34, P3069, DOI 10.1200/JCO.2016.67.1487; Setiawan VW, 2009, AM J EPIDEMIOL, V169, P1251, DOI 10.1093/aje/kwp036; Shah Payal D, 2014, Clin Adv Hematol Oncol, V12, P214; Turner NC, 2017, LANCET, V389, P2403, DOI 10.1016/S0140-6736(16)32419-9; Vora SR, 2014, CANCER CELL, V26, P136, DOI 10.1016/j.ccr.2014.05.020	23	989	1014	8	82	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 16	2019	380	20					1929	1940		10.1056/NEJMoa1813904	http://dx.doi.org/10.1056/NEJMoa1813904			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY3WU	31091374	Bronze, Green Published			2023-01-03	WOS:000468059200011
J	Sakuma, S; Yasuoka, J; Phongluxa, K; Jimba, M				Sakuma, Saki; Yasuoka, Junko; Phongluxa, Khampheng; Jimba, Masamine			Determinants of continuum of care for maternal, newborn, and child health services in rural Khammouane, Lao PDR	PLOS ONE			English	Article							ANTENATAL CARE; QUALITY; AREAS	Introduction The concept of continuum of care has gained attention as measures to improve maternal, newborn, and child health. However, little is known about the factors associated with the coverage level of continuum of care in Lao PDR. Therefore, this study was conducted 1) to investigate the coverage level of continuum of care and 2) to identify barriers and promoting factors that are associated with mothers' continuation in receiving services in rural Lao PDR. Methods A community-based, cross sectional study was conducted in a rural district in Khammouane Province, Lao PDR, using a structured questionnaire. The outcome to the express continuum of care was assessed by the modified composite coverage index (CCI) that reflects ten maternal and child health services. Results In total, 263 mothers were included in the final analyses. Only 6.8% of mothers continued to receive all MNCH services. Five factors were shown to have statistically significant associations with modified CCI score: higher educational attainment (B = 0.070, p<0.001), being a farmer (B = -0.078, p = 0.003), receiving the first antenatal care within the first trimester (B = 0.109, p<0.001), longer distance from district hospital (B = -0.012, p<0.001), and discussion with husband or family members (B = 0.057, p = 0.022). Conclusions In this study, we introduced the modified CCI to better explain the utilization of preventive maternal and child health services along with the continuum of care. By utilizing the modified CCI, we identified five factors as determinants of continuum of care. Furthermore, new and modifiable promoting factors were identified for continuum of care: receiving the first antenatal care within the first trimester and family and male involvement. Such demand side actions should be encouraged to improve the continuity of MNCH service use.	[Sakuma, Saki; Jimba, Masamine] Univ Tokyo, Grad Sch Med, Dept Community & Global Hlth, Tokyo, Japan; [Sakuma, Saki] Tokyo Womens Med Univ, Dept Int Affairs & Trop Med, Tokyo, Japan; [Yasuoka, Junko] Tokyo Univ Agr & Technol, Res & Educ Ctr Prevent Global Infect Dis Anim, Fuchu, Tokyo, Japan; [Phongluxa, Khampheng] Minist Hlth, Natl Inst Publ Hlth, Viangchan, Laos	University of Tokyo; Tokyo Women's Medical University; Tokyo University of Agriculture & Technology	Jimba, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Community & Global Hlth, Tokyo, Japan.	mjimba@m.u-tokyo.ac.jp	Jimba, Masamine/AAF-5630-2020; Yasuoka, Junko/GVT-8950-2022					Acuin CS, 2011, LANCET, V377, P516, DOI 10.1016/S0140-6736(10)62049-1; Alvesson HM, 2013, REPROD HEALTH MATTER, V21, P203, DOI 10.1016/S0968-8080(13)42748-9; Ampt F, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0561-9; [Anonymous], 2008, MILL DEV GOALS; Barros AJD, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001390; Berhan Y, 2014, ETHIOP J HEALTH SCI, V24, P93, DOI 10.4314/ejhs.v24i0.9S; Black RE, 2016, LANCET; Darmstadt GL, 2008, HEALTH POLICY PLANN, V23, P101, DOI 10.1093/heapol/czn001; Gilmore B, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-847; Graham WJ, 2012, LANCET, V379, pE5, DOI 10.1016/S0140-6736(10)62267-2; Jacobs B, 2012, REPROD HEALTH MATTER, V20, P112, DOI 10.1016/S0968-8080(12)40649-8; Kerber KJ, 2007, LANCET, V370, P1358, DOI 10.1016/S0140-6736(07)61578-5; Kinney MV, 2010, PLOS MED, V21, DOI [10.1371/journal.pmed.01000294, DOI 10.1371/JOURNAL.PMED.01000294]; Lao PDR-Ministry of Health, 2009, STRAT PLANN FRAM INT; Lao PDR-Ministry of Health, 2014, NAT HLTH STAT REP FY; Lao PDR-Ministry of Health, 2012, LAO SOC IND SURV 201; Lao Statistic Bureau, 2015, 4 POP HOUS CENS 2015; Lewis S, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0599-8; Manithip C, 2013, MIDWIFERY, V29, P195, DOI 10.1016/j.midw.2011.12.010; Owili PO, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3075-0; Phathammavong O, 2010, SE ASIAN J TROP MED, V41, P705; Sychareun V, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-243; Sychareun V, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-86; Tinker A, 2005, LANCET, V365, P822, DOI 10.1016/S0140-6736(05)71016-3; Wang WJ, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0497-0; Way C., 2015, MILLENIUM DEV GOALS, P38; WHO, 2015, WHO REC HLTH PROM IN; WHO, 2022, WHO RECOMMENDATIONS; WHO, 2006, CONC I FRAM PARTN MA; WHO, MOV UN COV HLTH LAO; WHO UNICEF. The World Bank, 2010, TRENDS MAT MORT 1990; Xaybouthong District Health Office, 2014, DISTR HLTH STAT REP; Yeji F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142849; Zegeye Amtatachew M, 2013, Afr J Reprod Health, V17, P130	34	37	37	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2019	14	4							e0215635	10.1371/journal.pone.0215635	http://dx.doi.org/10.1371/journal.pone.0215635			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU4DH	31013303	Green Published, gold, Green Submitted			2023-01-03	WOS:000465223900029
J	Fukui, S; Fujita, J; Ikezaki, S; Nakatani, E; Tsujimura, M				Fukui, Sakiko; Fujita, Junko; Ikezaki, Sumie; Nakatani, Eiji; Tsujimura, Mayuko			Effect of a multidisciplinary end-of-life educational intervention on health and social care professionals: A cluster randomized controlled trial	PLOS ONE			English	Article							PALLIATIVE CARE; IDENTITY; COMMUNICATION; NURSES; VIEWS; JAPAN; COLLABORATION; SOCIALIZATION; QUESTIONNAIRE; CHALLENGES	Background The aging of populations is rapidly accelerating worldwide. Especially, Japan has maintained the highest rate of population aging worldwide. As countermeasures, the Japanese government prioritized the promotion of local comprehensive care systems and collaboration in medical care and social (long-term) care. Development of a system to connect medical and social services in the community is necessary for the increasing older people, especially for the people in the stage of end of life. Objective This study aimed to assess the effect of a multidisciplinary end-of-life educational intervention program on confidence in inter-professional collaboration and job satisfaction among health and social care professionals. Design a cluster-randomized controlled trial Setting/Participants Three professional groups (home care nurses, care managers, and heads of care workers) in an urban area participated in this trial. Intervention We implemented a multidisciplinary end-of-life educational intervention program comprising two educational workshops and an educational booklet to support multidisciplinary care for end-of-life patients during the 7-month study period. Main outcome measure Confidence in improved interactions among professionals and job satisfaction were assessed with the Face-to-Face Cooperative Confidence Questionnaire and the Minnesota Satisfaction Questionnaire at T1 (before intervention) and T2 (7 months after the intervention). Results In total, 291 professionals participated in this study (experimental group n = 156; control group n = 135). Multivariate regression analyses showed significant between-group increases on all of seven subscales in participants' face-to-face cooperative confidence over the study period; no effect was evident regarding job satisfaction. Conclusions A multidisciplinary end-of-life educational intervention program increased confidence in multidisciplinary collaboration among health and social care professionals.	[Fukui, Sakiko] Osaka Univ, Dept Nursing, Sch Allied Hlth Sci, Osaka, Japan; [Fujita, Junko] Juntendo Univ, Sch Nursing, Chiba, Japan; [Ikezaki, Sumie; Tsujimura, Mayuko] Chiba Univ, Sch Nursing, Chiba, Japan; [Nakatani, Eiji] Shizuoka Prefectural Gen Hosp, Res Support Ctr, Div Stat Anal, Shizuoka, Japan	Osaka University; Juntendo University; Chiba University; Shizuoka General Hospital	Fukui, S (corresponding author), Osaka Univ, Dept Nursing, Sch Allied Hlth Sci, Osaka, Japan.	sfukui@sahs.med.osaka-u.ac.jp	Nakatani, Eiji/O-2782-2013; Ikezaki, Sumie/AAE-7841-2019	Nakatani, Eiji/0000-0002-4876-446X; Fukui, Sakiko/0000-0003-2113-8124	Japan Society for the Promotion of Science by the Japanese government [26293481]	Japan Society for the Promotion of Science by the Japanese government(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This study was supported by a Grant-in-Aid for Scientific Research (B) from the Japan Society for the Promotion of Science by the Japanese government (no. 26293481) (URL is https://www.jsps.go.jp/english/index.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams K., 2006, LEARNING HLTH SOCIAL, V5, P55, DOI [DOI 10.1111/J.1473-6861.2006.00119.X, 10.1111/j.1473-6861.2006.00119.x]; AIKEN LH, 1997, RES SOCIOL HEALTH CA, V14, P3; [Anonymous], 2011, GLOBAL HLTH AGING; Arai H, 2015, GERIATR GERONTOL INT, V15, P673, DOI 10.1111/ggi.12450; Banner D, 2018, DEATH STUD; Baycan A.F., 1985, THESIS BOGAZICI U I; Bernacki RE, 2014, JAMA INTERN MED, V174, P1994, DOI 10.1001/jamainternmed.2014.5271; Brighton LJ, 2017, J PAIN SYMPTOM MANAG, V54, P417, DOI 10.1016/j.jpainsymman.2017.04.008; Cabinet Office, 2017, WHIT PAP AG SOC JAP, P10; Chung HO, 2016, BMC MED EDUC, V16, DOI 10.1186/s12909-016-0653-x; Clark PG, 1997, GERONTOLOGIST, V37, P441, DOI 10.1093/geront/37.4.441; Clayton JM, 2013, PALLIATIVE MED, V27, P236, DOI 10.1177/0269216312449683; Crossley J, 2009, MED TEACH, V31, pE603, DOI 10.3109/01421590903193547; Deppoliti D, 2008, J CONTIN EDUC NURS, V39, P255, DOI 10.3928/00220124-20080601-03; Eddy Kylie, 2016, JBI Database System Rev Implement Rep, V14, P96, DOI 10.11124/JBISRIR-2016-1843; Eguchi K., 2013, OPTIM REPORT 2012 OU; Fujita J, 2015, J HLTH WELFARE STAT, V6, P1; Fukui S, 2014, JPN ACAD HOME CARE P, V16, P5; Fukui S, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0644-8; Fukui S, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-11; Hirakawa Y, 2017, NAGOYA J MED SCI, V79, P229, DOI 10.18999/nagjms.79.2.229; Howard M, 2018, CAN FAM PHYSICIAN, V64, pE190; Ikai S, 2010, THEORY CENTURY HOSP, P205; Japan national health insurance clinics and hospitals association, 2014, ANN REP 2013 SUPP PA; Karam M, 2018, INT J NURS STUD, V79, P70, DOI 10.1016/j.ijnurstu.2017.11.002; Khalili H, 2013, J INTERPROF CARE, V27, P448, DOI 10.3109/13561820.2013.804042; Kobayashi Y, 2014, J MATER RES TECHNOL, V3, P114, DOI 10.1016/j.jmrt.2013.12.003; Leutz WN, 1999, MILBANK Q, V77, P77, DOI 10.1111/1468-0009.00125; Martins H, 2012, MINNESOTA SATISFACTI; Matsui M, 2013, INT J PALLIAT NURS, V19, P606, DOI 10.12968/ijpn.2013.19.12.606; Mickan Sharon M, 2005, Aust Health Rev, V29, P211; Morikawa Mie, 2014, Int J Integr Care, V14, pe005; Murayama H, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-178; Nan JKM, 2018, AM J HOSP PALLIAT CA; Nedjat-Haiem FR, 2017, AM J HOSP PALLIAT ME, V34, P308, DOI 10.1177/1049909115627773; Oishi A, 2014, PALLIATIVE MED, V28, P1081, DOI 10.1177/0269216314531999; Plack M., 2006, J PHYS THERAPY ED, V20, P38; Sabanciogullari S, 2015, INT J NURS PRACT, V21, P847, DOI 10.1111/ijn.12330; Sarre S, 2018, INT J NURS STUD, V79, P145, DOI 10.1016/j.ijnurstu.2017.11.010; Seow H, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3496; Siebens K, 2006, INT J NURS STUD, V43, P71, DOI 10.1016/j.ijnurstu.2005.04.004; Spector P.E., 1997, JOB SATISFACTION APP; Takahashi K, 1997, AMINO ACIDS, V13, P1, DOI 10.1007/BF01373044; Tsutsui T, 2007, J AM GERIATR SOC, V55, P1458, DOI 10.1111/j.1532-5415.2007.01281.x; Weiss DJ, 1967, MANUAL MINNESOTTA SA; World Health Organization, 2010, FRAMEWORK ACTION INT; World Health Organization, 2015, AG HLTH	47	5	5	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 19	2019	14	8							e0219589	10.1371/journal.pone.0219589	http://dx.doi.org/10.1371/journal.pone.0219589			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW5MK	31425538	Green Published, Green Submitted, gold			2023-01-03	WOS:000485022400009
J	van Hoof, SJM; Quanjel, TCC; Kroese, MEAL; Spreeuwenberg, MD; Ruwaard, D				van Hoof, Sofie J. M.; Quanjel, Tessa C. C.; Kroese, Marielle E. A. L.; Spreeuwenberg, Marieke D.; Ruwaard, Dirk			Substitution of outpatient hospital care with specialist care in the primary care setting: A systematic review on quality of care, health and costs	PLOS ONE			English	Review							GENERAL-PRACTITIONERS; OUTREACH CLINICS; COMMUNITY; DISEASE; PROGRAMS	Rationale, aims and objective Substituting outpatient hospital care with primary care is seen as a solution to decrease unnecessary referrals to outpatient hospital care and decrease rising healthcare costs. This systematic review aimed to evaluate the effects on quality of care, health and costs outcomes of substituting outpatient hospital care with primary care-based interventions, which are performed by medical specialists in face-to-face consultations in a primary care setting. Method The systematic review was performed using the PICO framework. Original papers in which the premise of the intervention was to substitute outpatient hospital care with primary care through the involvement of a medical specialist in a primary care setting were eligible. Results A total of 14 papers were included. A substitution intervention in general practitioner (GP) practices was described in 11 papers, three described a joint consultation intervention in which GPs see patients together with a medical specialist. This study showed that substitution initiatives result mostly in favourable outcomes compared to outpatient hospital care. The initiatives resulted mostly in shorter waiting lists, shorter clinic waiting times and higher patient satisfaction. Costs for treating one extra patient seemed to be higher in the intervention settings. This was mainly caused by inefficient planning of consultation hours and lower patient numbers. Conclusions Despite the fact that internationally a lot has been written about the importance of performing substitution interventions in which preventing unnecessary referrals to outpatient hospital care was the aim, only 14 papers were included. Future systematic reviews should focus on the effects on the Triple Aim of substitution initiatives in which other healthcare professions than medical specialists are involved along with new technologies, such as e-consults. Additionally, to gain more insight into the effects of substitution initiatives operating in a dynamic healthcare context, it is important to keep evaluating the interventions in a longitudinal study design.	[van Hoof, Sofie J. M.; Quanjel, Tessa C. C.; Kroese, Marielle E. A. L.; Spreeuwenberg, Marieke D.; Ruwaard, Dirk] Maastricht Univ, Fac Hlth Med & Life Sci, Care & Publ Hlth Res Inst CAPHRI, Dept Hlth Serv Res, Maastricht, Netherlands; [Spreeuwenberg, Marieke D.] Zuyd Univ Appl Sci, Res Ctr Technol Care, Heerlen, Netherlands	Maastricht University	van Hoof, SJM; Quanjel, TCC (corresponding author), Maastricht Univ, Fac Hlth Med & Life Sci, Care & Publ Hlth Res Inst CAPHRI, Dept Hlth Serv Res, Maastricht, Netherlands.	s.vanhoof@maastrichtuniversity.nl; t.quanjel@maastrichtuniversity.nl		Ruwaard, Dirk/0000-0003-4887-8413				Berwick DM, 2008, HEALTH AFFAIR, V27, P759, DOI 10.1377/hlthaff.27.3.759; Black M, 1997, BRIT J GEN PRACT, V47, P558; Bond M, 2000, J EPIDEMIOL COMMUN H, V54, P149, DOI 10.1136/jech.54.2.149; Bowling A, 2001, BRIT J GEN PRACT, V51, P264; Bowling A, 1997, J EPIDEMIOL COMMUN H, V51, P52, DOI 10.1136/jech.51.1.52; Clements B., 2012, EC PUBLIC HLTH CARE; DART JKG, 1986, BRIT MED J, V293, P1477, DOI 10.1136/bmj.293.6560.1477; Deeks J J, 2003, Health Technol Assess, V7, piii; Faulkner A, 2003, BRIT J GEN PRACT, V53, P878; GILLAM SJ, 1995, BRIT J GEN PRACT, V45, P649; Gosden T, 1997, J Health Serv Res Policy, V2, P174; Gruen R L, 2004, Cochrane Database Syst Rev, pCD003798, DOI 10.1002/14651858.CD003798.pub2; Helliwell PS, 1996, BRIT J RHEUMATOL, V35, P385; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS8, DOI 10.1016/j.apmr.2005.08.116; Institute of Medicine, 2001, CROSSING QUALITY CHA; Korda H, 2011, INQUIRY-J HEALTH CAR, V48, P277, DOI 10.5034/inquiryjrnl_48.04.01; Kringos D, 2013, BRIT J GEN PRACT, V63, pE742, DOI 10.3399/bjgp13X674422; Laurant M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001271.pub2; LITTLE BC, 1993, EYE, V7, P180, DOI 10.1038/eye.1993.38; Martinez-Gonzalez NA, 2015, MED CARE RES REV, V72, P395, DOI 10.1177/1077558715586297; Martinez-Gonzalez NA, 2014, INT J QUAL HEALTH C, V26, P561, DOI 10.1093/intqhc/mzu071; Methley AM, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0579-0; Norris SL, 2002, AM J PREV MED, V22, P15, DOI 10.1016/S0749-3797(02)00423-3; OECD, 2015, FISCAL SUSTAINABILIT; Ouwens M, 2005, INT J QUAL HEALTH C, V17, P141, DOI 10.1093/intqhc/mzi016; Powell John, 2002, J Health Serv Res Policy, V7, P177, DOI 10.1258/135581902760082490; Prisma, 2017, PRISM TRANSP REP SYS; Schulpen G J C, 2003, Ned Tijdschr Geneeskd, V147, P447; Schut FT, 2017, HEALTH POLICY, V121, P126, DOI 10.1016/j.healthpol.2016.11.002; Sibbald B, 2008, J HEALTH SERV RES PO, V13, P233, DOI 10.1258/jhsrp.2008.008049; Struijs JN, 2011, NEW ENGL J MED, V364, P990, DOI 10.1056/NEJMp1011849; Suris X, 2007, J RHEUMATOL, V34, P1328; Thomas B H, 2004, Worldviews Evid Based Nurs, V1, P176, DOI 10.1111/j.1524-475X.2004.04006.x; Tsiachristas A, 2014, COST EFFECT RESOUR A, V12, DOI 10.1186/1478-7547-12-17; van Hoof SJM, 2016, BMC FAM PRACT, V17, DOI 10.1186/s12875-016-0498-8; van Hoof SJM, 2016, INT J INTEGR CARE, V16, DOI 10.5334/ijic.2446; VIERHOUT WPM, 1995, LANCET, V346, P990, DOI 10.1016/S0140-6736(95)91686-5; Villagra V, 2004, MED CARE, V42, P24, DOI 10.1097/01.mlr.0000119395.13327.e9; Wallace PG, 2002, J TELEMED TELECARE, V8, P94, DOI 10.1258/135763302320302208; Warner MM, 1997, REDESIGNING HLTH SER; Westra D, 2017, Ned Tijdschr Geneeskd, V161, pD1354; WHO, 2010, WOR HEALT REP, P1; Winpenny EM, 2017, J HEALTH SERV RES PO, V22, P53, DOI 10.1177/1355819616648982	43	15	15	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2019	14	8							e0219957	10.1371/journal.pone.0219957	http://dx.doi.org/10.1371/journal.pone.0219957			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4ZH	31369567	Green Published, gold, Green Submitted			2023-01-03	WOS:000484987900019
J	Buenestado-Fernandez, M; Alvarez-Castillo, JL; Gonzalez-Gonzalez, H; Espino-Diaz, L				Buenestado-Fernandez, Mariana; Luis Alvarez-Castillo, Jose; Gonzalez-Gonzalez, Hugo; Espino-Diaz, Luis			Evaluating the institutionalisation of diversity outreach in top universities worldwide	PLOS ONE			English	Article							HIGHER-EDUCATION; PARTICIPATION; INCLUSION; DISCOURSE; STUDENTS; ADAPTATION; EQUALITY; EQUITY	The participation of diverse demographics in higher education has risen over the last half-century; meanwhile, different political and social tiers have been assigning a more active role to institutions in terms of equality and social justice. This change in circumstances has led to the roll out of processes to institutionalise diversity outreach. This study was conducted for the clear purpose of assessing the current institutionalisation status of diversity outreach in 127 key universities from the Academic Ranking of World Universities based on the opinions of diversity outreach managers and the information published on institutional websites, in turn measuring compliance with various indicators. A qualitative analysis of the institutional statements, the goals sought through strategic plans and the definitions of diversity itself was also conducted. The evidence reveals the early stage of the institutionalisation process in universities on account of the low percentage obtained for the proposed indicators. Furthermore, the study failed to exhibit significant differences in this process in terms of the institutional ownership or position held in the ranking; however, more prominent progress was noted in the North-American region when geographical differences were taken into account, likely as a result of the historical background in the advocacy for equal opportunities. Lastly, a change of approach to the conceptualisation of diversity is suggested in favour of equality and social justice.	[Buenestado-Fernandez, Mariana; Luis Alvarez-Castillo, Jose; Gonzalez-Gonzalez, Hugo; Espino-Diaz, Luis] Univ Cordoba, Fac Educ Sci, Dept Educ, Cordoba, Spain	Universidad de Cordoba	Buenestado-Fernandez, M (corresponding author), Univ Cordoba, Fac Educ Sci, Dept Educ, Cordoba, Spain.	m62bufem@uco.es	Álvarez-Castillo, José-Luis/F-6467-2015; González-González, Hugo/AAF-7240-2020; Espino-Díaz, Luis/J-8241-2017	Álvarez-Castillo, José-Luis/0000-0001-7493-4664; González-González, Hugo/0000-0002-7537-1514; Espino-Díaz, Luis/0000-0002-9929-6889; Buenestado-Fernandez, Mariana/0000-0002-3242-5332	Spain's Ministry of Science, Innovation and Universities, State Plan for RD [EDU201782862-R]	Spain's Ministry of Science, Innovation and Universities, State Plan for RD	This study was supported by the Spain's Ministry of Science, Innovation and Universities, State Plan for R&D (Grant number EDU201782862-R). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed S, 2007, ETHNIC RACIAL STUD, V30, P590, DOI 10.1080/01419870701356015; [Anonymous], 2012, PUTT HIGH ED WORK SK; [Anonymous], 2010, DEV EMBEDDING INCLUS; [Anonymous], 2011, J EMERGING TRENDS ED; Aponte E., 2015, RESPONSABILIDAD SOCI; Araujo-Olivera SS, 2012, RIE, V58, P1; Archer L, 2007, TEACH HIGH EDUC, V12, P635, DOI 10.1080/13562510701595325; Association of American Colleges & Universities (AAC& U), 2015, COMM EQ INCL EXC CAM; Bell M., 2012, DIVERSITY ORG; Bergan S., 2018, COUNCIL EUROPE HIGHE, V22; Biewer G, 2015, ALTER, V9, P278, DOI 10.1016/j.alter.2015.02.001; Booth T., 2011, INDEX INCLUSION DEV, Vthird; Bowles TV, 2017, HIGH EDUC RES DEV, V36, P903, DOI 10.1080/07294360.2016.1264927; Carvajal Z., 2013, GUIA INTEGRADA, V2013; Chang MJ, 2002, REV HIGH EDUC, V25, P125, DOI 10.1353/rhe.2002.0003; Dawkins J., 1988, HIGHER ED POLICY STA; Dill D., 2010, NATL INNOVATION ACAD; Dovigo F, 2017, GOOD PRACTICES EQUIT; European Commission, 2019, ER PROGR GUID; Fajardo M. Stella, 2017, Rev. latinoam. educ. inclusiva, V11, P171; Ferreira C, 2014, EUR J EDUC, V49, P575, DOI 10.1111/ejed.12098; Gale T, 2011, CRIT STUD EDUC, V52, P109, DOI 10.1080/17508487.2011.572825; Gasman M, 2015, J DIVERS HIGH EDUC, V8, P1, DOI 10.1037/a0038872; Gause CP, 2010, QUEST, V62, P61, DOI 10.1080/00336297.2010.10483632; Gomez-Mejia L, 2012, MANAGING HUMAN RESOU; Gonzalez J., 2005, TUNING ED STRUCTURES; Griggs L., 1995, VALUING DIVERSITY NE, P1; Hazelkorn E, 2015, RANKINGS AND THE RESHAPING OF HIGHER EDUCATION: THE BATTLE FOR WORLD-CLASS EXCELLENCE, 2ND EDITION, P1, DOI 10.1057/9781137446671; Hazelkorn E, 2014, EUR J EDUC, V49, P12, DOI 10.1111/ejed.12059; Heagney M, 2017, J HIGH EDUC POLICY M, V39, P216, DOI 10.1080/1360080X.2017.1300986; Heng TT, 2018, STUD HIGH EDUC, V43, P22, DOI 10.1080/03075079.2016.1152466; Hode MG, 2017, J DIVERS HIGH EDUC, V10, P162, DOI 10.1037/dhe0000014; Hou YW, 2017, INT EDUC J, V16, P29; Killough A, 2019, DIVERS HIGH EDUC, V21, P43, DOI 10.1108/S1479-364420180000021004; Koshy P., 2014, STUDENT EQUITY PERFO; LePeau LA, 2018, INNOV HIGH EDUC, V43, P125, DOI 10.1007/s10755-017-9412-0; Lloyd MW, 2011, RANKINGS INT U IMPAC; Luque-Martinez T, 2020, STUD HIGH EDUC, V45, P819, DOI 10.1080/03075079.2018.1564260; Marginson S., 2018, HIGH PARTICIPATION S, P3; Marginson S, 2016, HIGH EDUC, V72, P413, DOI 10.1007/s10734-016-0016-x; Michael S., 2007, DIVERSITY COMPETENT; Mirza HS, 2003, KEYNOTE ADDRESS LAUN; National Center for Education Statistics (NCES), 2016, DIG ED STAT 2015; New England Resource Center for Higher Education, 2016, SELF ASS RUBR INST D; Opesade AO, 2017, J HIGH EDUC POLICY M, V39, P341, DOI 10.1080/1360080X.2017.1306907; Organizacion de Estados Iberoamericanos para la Educacion la Ciencia y la Cultura (OEI, 2016, AV MET ED 2021; Organization for Economic Co-operation and Development (OECD), 2008, HIGHER ED 2030, V1; Pereyra PJ, 2014, BIOINVASIONS REC, V3, P65, DOI 10.3391/bir.2014.3.2.02; Pitman T, 2015, CAMB J EDUC, V45, P281, DOI 10.1080/0305764X.2014.970514; Pitsoe V, 2018, INNOV HIGH EDUC TEAC, V12, P113, DOI 10.1108/S2055-364120180000012009; Mesa MS, 2015, INTANG CAP, V11, P508, DOI 10.3926/ic.647; Scales B., 2008, REV AUSTR HIGHER ED; Smith D. G., 2014, DIVERSITY INCLUSION; Smith JA, 2015, LEARN COMMUNITIES, P12, DOI 10.18793/LCJ2015.17.02; Stephens NM, 2018, CYTOPATHOLOGY, P1, DOI DOI 10.1111/CYT.125284; Temple P., 2012, HIGHER ED RES POLICY, P199; Tienda M, 2013, EDUC RESEARCHER, V42, P467, DOI 10.3102/0013189X13516164; Tomlinson M, 2016, HIGH EDUC POLICY, V29, P149, DOI 10.1057/hep.2015.17; UNESCO, 2012, WORLD ATL GEND EQ ED; Hanne AV, 2018, ALTERIDAD, V13, P14, DOI 10.17163/alt.v13n1.2018.01; van Breda AD, 2018, HIGH EDUC, V75, P1109, DOI 10.1007/s10734-017-0188-z; Wallenstein P., 2009, HIGHER ED CIVIL RIGH; Warikoo N., 2015, VERTOVEC STEVEN ROUT, P302; Warikoo NK, 2014, SOCIOL FORUM, V29, P959, DOI 10.1111/socf.12128; Wentling RoseMary., 1998, HUM RESOUR DEV Q, V9, P235, DOI [10.1002/HRDQ.3920090304/FORMAT/PDF, DOI 10.1002/HRDQ.3920090304/FORMAT/PDF, 10.1037/0021-9010.92.5.1414, DOI 10.1002/HRDQ.3920090304]; Wilson JL, 2012, INNOV HIGH EDUC, V37, P125, DOI 10.1007/s10755-011-9194-8; Yu BH, 2016, TERT EDUC MANAG, V22, P300, DOI 10.1080/13583883.2016.1226944; Yu BH, 2016, TERT EDUC MANAG, V22, P49, DOI 10.1080/13583883.2015.1127405; Zanoni P, 2010, ORGANIZATION, V17, P9, DOI 10.1177/1350508409350344	69	14	14	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2019	14	7							e0219525	10.1371/journal.pone.0219525	http://dx.doi.org/10.1371/journal.pone.0219525			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IS7NE	31339930	gold, Green Published, Green Submitted			2023-01-03	WOS:000482335700026
J	Casey, SE; Gallagher, MC; Dumas, EF; Kakesa, J; Katsongo, JM; Muselemu, JB				Casey, Sara E.; Gallagher, Meghan C.; Dumas, Erin Files; Kakesa, Jessica; Katsongo, Justin Mumbere; Muselemu, Jean-Baptiste			Meeting the demand of women affected by ongoing crisis: Increasing contraceptive prevalence in North and South Kivu, Democratic Republic of the Congo	PLOS ONE			English	Article							REPRODUCTIVE HEALTH; METHOD MIX; DENOMINATION; QUALITY; ACCESS; AREAS	Context Over 20 years of conflict in the DRC, North and South Kivu have experienced cycles of stability and conflict, resulting in a compromised health system and poor sexual and reproductive health outcomes. Modern contraceptive use is low (7.5%) and maternal mortality is high (846 deaths per 100,000 live births). Program partners have supported the Ministry of Health (MOH) in North and South Kivu to provide good quality contraceptive services in public health facilities since 2011. Methods Cross-sectional population-based surveys were conducted in the program areas using a two-stage cluster sampling design to ensure representation in each of six rural health zones. Using MOH population estimates for villages in the catchment areas of supported health facilities, 25 clusters in each zone were selected using probability proportional to size. Within each cluster, 22 households were systematically selected, and one woman of reproductive age (15-49 years) was randomly selected from all eligible women in each household. Results Modern contraceptive prevalence among women in union ranged from 8.4% to 26.7% in the six health zones; current use of long-acting or permanent method (LAPM) ranged from 2.5% to 19.8%. The majority of women (58.9% to 90.2%) reported receiving their current method for the first time at a health facility supported by the program partners. Over half of women in four health zones reported wanting to continue their method for five years or longer. Conclusion Current modern contraceptive use and LAPM use were high in these six health zones compared to DRC Demographic and Health Survey data nationally and provincially. These results were accomplished across all six health zones despite their varied socio-demographic characteristics and different experiences of conflict and displacement. These findings demonstrate that women in these conflict-affected areas want contraception and will choose to use it when good quality services are available to them.	[Casey, Sara E.] Columbia Univ, Mailman Sch Publ Hlth, Heilbrunn Dept Populat & Family Hlth, RAISE Initiat, New York, NY 10027 USA; [Gallagher, Meghan C.] Save Children US, Washington, DC USA; [Dumas, Erin Files] CARE USA, Atlanta, GA USA; [Kakesa, Jessica] Int Rescue Comm, Kinshasa, DEM REP CONGO; [Katsongo, Justin Mumbere] CARE, Goma, DEM REP CONGO; [Muselemu, Jean-Baptiste] Save Children, Goma, DEM REP CONGO	Columbia University; Save the Children; Save the Children	Casey, SE (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Heilbrunn Dept Populat & Family Hlth, RAISE Initiat, New York, NY 10027 USA.	sec42@columbia.edu		Casey, Sara/0000-0002-8476-0327				Agadjanian V, 2013, STUD FAMILY PLANN, V44, P259, DOI 10.1111/j.1728-4465.2013.00357.x; Al Gasseer N, 2004, J MIDWIFERY WOM HEAL, V49, P7, DOI 10.1016/j.jmwh.2004.05.001; [Anonymous], 2014, ENQ DEM SANT REP DEM; Austin J, 2008, REPROD HEALTH MATTER, V16, P10, DOI 10.1016/S0968-8080(08)31351-2; BENNETT S, 1991, World Health Statistics Quarterly, V44, P98; BRUCE J, 1990, STUD FAMILY PLANN, V21, P61, DOI 10.2307/1966669; Brunie Aurelie, 2013, Int J Gynaecol Obstet, V123 Suppl 1, pe11, DOI 10.1016/j.ijgo.2013.07.005; Casey SE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182744; Casey SE, 2017, CONFL HEALTH, V11, DOI 10.1186/s13031-017-0104-2; Casey SE, 2015, CONFL HEALTH, V9, DOI 10.1186/1752-1505-9-S1-S3; Casey SE, 2015, CONFL HEALTH, V9, DOI 10.1186/1752-1505-9-S1-S1; Chynoweth SK, 2015, CONFL HEALTH, V9, DOI 10.1186/1752-1505-9-S1-I1; Cleland J, 2006, LANCET, V368, P1810, DOI 10.1016/S0140-6736(06)69480-4; Cleland J, 2012, LANCET, V380, P149, DOI 10.1016/S0140-6736(12)60609-6; Foster AM, 2017, REPROD HEALTH MATTER, V25, P18, DOI 10.1080/09688080.2017.1403277; Gilda Sedgh, 2007, WOMEN UNMET NEED CON; Ho LS, 2018, GLOB HEALTH-SCI PRAC, V6, P161, DOI 10.9745/GHSP-D-17-00365; Internal Displacement Monitoring Center, 2018, GLOB REP INT DISPL 2; KISH L, 1949, J AM STAT ASSOC, V44, P380, DOI 10.2307/2280236; Kruk ME, 2010, SOC SCI MED, V70, P89, DOI 10.1016/j.socscimed.2009.09.042; Kwete D, 2018, GLOB HEALTH-SCI PRAC, V6, P40, DOI 10.9745/GHSP-D-17-00346; McGinn Therese, 2011, Confl Health, V5, P11, DOI 10.1186/1752-1505-5-11; Mpunga D, 2017, GLOB HEALTH-SCI PRAC, V5, P274, DOI 10.9745/GHSP-D-16-00205; Muanda MF, 2017, CULT HEALTH SEX, V19, P1011, DOI 10.1080/13691058.2017.1286690; Mukaba T, 2015, GLOB HEALTH, V3, P163, DOI 10.9745/GHSP-D-14-00244; Mwaikambo L, 2011, STUD FAMILY PLANN, V42, P67, DOI 10.1111/j.1728-4465.2011.00267.x; Prata N, 2009, PHILOS T R SOC B, V364, P3093, DOI 10.1098/rstb.2009.0172; Rattan J, 2016, GLOB HEALTH-SCI PRAC, V4, pS5, DOI 10.9745/GHSP-D-15-00315; Ross J, 2013, GLOB HEALTH-SCI PRAC, V1, P203, DOI 10.9745/GHSP-D-13-00010; Ross J, 2013, J BIOSOC SCI, V45, P761, DOI 10.1017/S0021932012000715; Snow RC, 2015, GLOB PUBLIC HEALTH, V10, P149, DOI 10.1080/17441692.2014.986178; United Nations High Commissioner for Refugees, 2018, GLOB TRENDS FORC DIS; Ward D, 2015, GLOB HEALTH-SCI PRAC, DOI [10.9745/GHSP-D-14-00164, DOI 10.9745/GHSP-D-14-00164]; Warren N, 2017, HEALTH CARE WOMEN IN, V38, P796, DOI 10.1080/07399332.2017.1329307; Yeatman SE, 2008, DEMOGR RES, V19, P1851, DOI 10.4054/DemRes.2008.19.55	35	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 19	2019	14	7							e0219990	10.1371/journal.pone.0219990	http://dx.doi.org/10.1371/journal.pone.0219990			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW4SZ	31323055	Green Submitted, Green Published, gold			2023-01-03	WOS:000484971300032
J	Choi, C; Son, A; Lee, GH; Shin, SW; Park, S; Ahn, SH; Chung, Y; Yu, JI; Park, HC				Choi, Changhoon; Son, Arang; Lee, Ga-Haeng; Shin, Sung-Won; Park, Sohee; Ahn, Sang Hee; Chung, Yoonsun; Yu, Jeong Il; Park, Hee Chul			Targeting DNA-dependent protein kinase sensitizes hepatocellular carcinoma cells to proton beam irradiation through apoptosis induction	PLOS ONE			English	Article							RELATIVE BIOLOGICAL EFFECTIVENESS; CHARGED-PARTICLE THERAPY; RADIATION; PATHWAY; PKCS; END; HEPATOCARCINOGENESIS; RADIOTHERAPY; INHIBITION	Recent studies have highlighted the implications of genetic variations in the relative biological effectiveness (RBE) of proton beam irradiation over conventional X-ray irradiation. Proton beam radiotherapy is a reasonable radiotherapy option for hepatocellular carcinoma (HCC), but the impact of genetic difference on the HCC RBE remains unknown. Here, we determined proton RBE in human HCC cells by exposing them to various doses of either 6-MV X-rays or 230-MeV proton beams. Clonogenic survival assay revealed variable radiosensitivity of human HCC cell lines with survival fraction at 2 Gy ranging from 0.38 to 0.83 and variable proton RBEs with 37% survival fraction ranging from 1.00 to 1.48. HCC cells appeared more sensitive to proton irradiation than X-rays, with more persistent activation of DNA damage repair proteins over time. Depletion of a DNA damage repair gene, DNA=PKcs, by siRNA dramatically increased the sensitivity of HCC cells to proton beams with a decrease in colony survival and an increase in apoptosis. Our findings suggest that there are large variations in proton RBE in HCC cells despite the use of a constant RBE of 1.1 in the clinic and targeting DNA-PKcs in combination with proton beam therapy may be a promising regimen for treating HCC.	[Choi, Changhoon; Son, Arang; Lee, Ga-Haeng; Shin, Sung-Won; Park, Sohee; Yu, Jeong Il; Park, Hee Chul] Samsung Med Ctr, Dept Radiat Oncol, Seoul, South Korea; [Shin, Sung-Won; Ahn, Sang Hee; Park, Hee Chul] Sungkyunkwan Univ, Sch Med, Seoul, South Korea; [Chung, Yoonsun] Hanyang Univ, Dept Nucl Engn, Seoul, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Hanyang University	Park, HC (corresponding author), Samsung Med Ctr, Dept Radiat Oncol, Seoul, South Korea.; Park, HC (corresponding author), Sungkyunkwan Univ, Sch Med, Seoul, South Korea.	hee.ro.park@gmail.com		Park, Hee Chul/0000-0003-0385-9681	Samsung Medical Center grant [SMX1180141]; Marine Biotechnology Program - Ministry of Oceans and Fisheries [20150220]	Samsung Medical Center grant(Samsung); Marine Biotechnology Program - Ministry of Oceans and Fisheries	This work is supported by a Samsung Medical Center grant (SMX1180141 to CC) and by a grant from the Marine Biotechnology Program (20150220 to HCP) funded by the Ministry of Oceans and Fisheries. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	정윤선, 2017, [PROGRESS in MEDICAL PHYSICS, 의학물리], V28, P11, DOI 10.14316/pmp.2017.28.1.11; Aoki-Nakano M, 2014, J RADIAT RES, V55, P812, DOI 10.1093/jrr/rru003; Baek HJ, 2008, J RADIAT RES, V49, P509, DOI 10.1269/jrr.08017; Chung K, 2015, RADIAT ONCOL J, V33, P337, DOI 10.3857/roj.2015.33.4.337; Cornell L, 2015, CLIN CANCER RES, V21, P925, DOI 10.1158/1078-0432.CCR-14-0842; Dionisi F, 2014, RADIOTHER ONCOL, V111, P1, DOI 10.1016/j.radonc.2014.02.001; Dong J, 2018, ONCOL REP, V39, P912, DOI 10.3892/or.2018.6217; Dong J, 2017, ONCOTARGET, V8, P22662, DOI 10.18632/oncotarget.15153; Evert M, 2013, BRIT J CANCER, V109, P2654, DOI 10.1038/bjc.2013.606; Ezzoukhry Z, 2012, INT J CANCER, V131, P2961, DOI 10.1002/ijc.27604; Fontana AO, 2015, RADIOTHER ONCOL, V116, P374, DOI 10.1016/j.radonc.2015.08.014; Gerelchuluun A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020496; Girdhani S, 2013, RADIAT RES, V179, P257, DOI 10.1667/RR2839.1; Held KD, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00023; Hirai T, 2016, BIOCHEM BIOPH RES CO, V478, P234, DOI 10.1016/j.bbrc.2016.07.062; Kalogeridi MA, 2015, WORLD J HEPATOL, V7, P101, DOI 10.4254/wjh.v7.i1.101; Klein J, 2013, INT J RADIAT ONCOL, V87, P22, DOI 10.1016/j.ijrobp.2012.08.043; Lin Z, 2016, SCI REP-UK, V6, DOI 10.1038/srep25999; Ling TC, 2012, CHINESE J CANCER RES, V24, P361, DOI [10.1007/s11670-012-0276-7, 10.3978/j.issn.1000-9604.2012.10.09]; Liu Q, 2016, INT J RADIAT ONCOL, V95, P78, DOI 10.1016/j.ijrobp.2016.01.046; Liu Q, 2015, INT J RADIAT ONCOL, V91, P1081, DOI 10.1016/j.ijrobp.2014.12.046; Matsumoto Y, 2014, J RADIAT RES, V55, P816, DOI 10.1093/jrr/rrt230; McNamara AL, 2015, PHYS MED BIOL, V60, P8399, DOI 10.1088/0031-9155/60/21/8399; Mizumoto M, 2011, INT J RADIAT ONCOL, V81, P1039, DOI 10.1016/j.ijrobp.2010.07.015; Paganetti H, 2015, INT J RADIAT ONCOL, V91, P892, DOI 10.1016/j.ijrobp.2014.11.021; Palagyi A, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-127; Pascale RM, 2016, DNA REPAIR, V47, P12, DOI 10.1016/j.dnarep.2016.10.004; Qi WX, 2015, RADIOTHER ONCOL, V114, P289, DOI 10.1016/j.radonc.2014.11.033; Rim CH, 2016, RADIAT ONCOL J, V34, P160, DOI 10.3857/roj.2016.01970; Skinner HD, 2011, SEMIN RADIAT ONCOL, V21, P278, DOI 10.1016/j.semradonc.2011.05.007; Wang L, 2017, HEAD NECK-J SCI SPEC, V39, P708, DOI 10.1002/hed.24673; Woodward WA, 2016, INT J RADIAT ONCOL, V95, P59, DOI 10.1016/j.ijrobp.2015.10.022; Yang CJ, 2016, CELL PHYSIOL BIOCHEM, V38, P1897, DOI 10.1159/000445551; Yang LN, 2015, ONCOL LETT, V10, P2856, DOI 10.3892/ol.2015.3730; Yang SF, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/153867; Yoo GS, 2018, WORLD J GASTROENTERO, V24, P3090, DOI 10.3748/wjg.v24.i28.3090; Zhang JX, 2012, HEPATOLOGY, V55, P1840, DOI 10.1002/hep.25566; Zhang YB, 2018, INT J ONCOL, V52, P1455, DOI 10.3892/ijo.2018.4327; Zhou X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072641	39	12	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2019	14	6							e0218049	10.1371/journal.pone.0218049	http://dx.doi.org/10.1371/journal.pone.0218049			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IC8NN	31194786	Green Published, Green Submitted, gold			2023-01-03	WOS:000471238300039
J	Sugano, N; Maruyama, Y; Kidoguchi, S; Ohno, I; Wada, A; Shigematsu, T; Masakane, I; Yokoo, T				Sugano, Naoki; Maruyama, Yukio; Kidoguchi, Satoshi; Ohno, Iwao; Wada, Atsushi; Shigematsu, Takashi; Masakane, Ikuto; Yokoo, Takashi			Effect of hyperuricemia and treatment for hyperuricemia in Japanese hemodialysis patients: A cohort study	PLOS ONE			English	Article							SERUM URIC-ACID; CARDIOVASCULAR-DISEASE; OXIDATIVE STRESS; KIDNEY-DISEASE; RENAL-DISEASE; ALLOPURINOL; MORTALITY; RISK; FEBUXOSTAT	Whether higher serum uric acid (UA) values comprise a risk factor for death and whether treatment for high UA is effective in patients undergoing hemodialysis (HD) are essentially unknown. To determine associations between UA and all-cause or cardiovascular (CV) mortality, interactions between UA or medication and effects on mortality, and significance of treatment for hyperuricemia in patients undergoing hemodialysis (HD). We collected the baseline data of 222,434 patients undergoing three HD sessions per week, extracted from a nationwide dialysis registry at the end of 2011 in Japan. Then we evaluated the interaction between serum uric acid level and all-cause and cardiovascular (CV) mortality by the end of 2012. Univariate and multivariate logistic regression and Cox regression analyses found higher all-cause and CV mortality rates among patients with lower, than higher UA values. Hazard ratios (HR) for all-cause and CV mortality were significantly lower in a group with, than without medication for hyperuricemia (HR, 0.837; 95% confidence interval (CI), 0.789-0.889 and HR, 0.830; 95%CI0.758-0.909, respectively). Lower UA values remained associated with all-cause and CV mortality rates even when in patients taking medication for hyperuricemia. The chief interacting factors for higher mortality rates due to lower UA were higher BMI and diabetes mellitus. In conclusion, lower UA levels were independently associated with higher all-cause and CV mortality among Japanese patients undergoing HD. Intervention for hyperuricemia is considered to improve patient outcomes.	[Sugano, Naoki; Maruyama, Yukio; Kidoguchi, Satoshi; Yokoo, Takashi] Jikei Univ, Sch Med, Dept Internal Med, Div Nephrol & Hypertens, Tokyo, Japan; [Ohno, Iwao] Jikei Univ, Sch Med, Dept Internal Med, Div Gen Med, Tokyo, Japan; [Wada, Atsushi; Shigematsu, Takashi; Masakane, Ikuto] Japanese Soc Dialysis Therapy, Comm Renal Data Registry, Tokyo, Japan	Jikei University; Jikei University	Sugano, N (corresponding author), Jikei Univ, Sch Med, Dept Internal Med, Div Nephrol & Hypertens, Tokyo, Japan.	n-sugano@jikei.ac.jp						Afshari M, 2004, BIOMED PHARMACOTHER, V58, P546, DOI 10.1016/j.biopha.2004.09.012; Beberashvili I, 2016, CLIN J AM SOC NEPHRO, V11, P1015, DOI 10.2215/CJN.10400915; Bellomo G, 2010, AM J KIDNEY DIS, V56, P264, DOI 10.1053/j.ajkd.2010.01.019; Culleton BF, 1999, ANN INTERN MED, V131, P7, DOI 10.7326/0003-4819-131-1-199907060-00003; Domrongkitchaiporn S, 2005, J AM SOC NEPHROL, V16, P791, DOI 10.1681/ASN.2004030208; FANG J, JAMA, V283, P2404; Glantzounis GK, 2005, CURR PHARM DESIGN, V11, P4145, DOI 10.2174/138161205774913255; Go AS, 2014, NEW ENGL J MED, V351, P1296; Gondouin B, 2015, NEPHRON, V131, P167, DOI 10.1159/000441091; Gouri A, 2014, CLIN LAB, V60, P751, DOI 10.7754/Clin.Lab.2013.130310; Higgins P, 2012, CARDIOVASC THER, V30, P217, DOI 10.1111/j.1755-5922.2011.00277.x; Hsu CY, 2009, ARCH INTERN MED, V169, P342, DOI 10.1001/archinternmed.2008.605; Kang Duk-Hee, 2014, Electrolyte Blood Press, V12, P1, DOI 10.5049/EBP.2014.12.1.1; Kuriyama S, 2015, CLIN EXP NEPHROL, V19, P1127, DOI 10.1007/s10157-015-1120-4; Kurra V, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882-015-0033-5; Latif W, 2011, CLIN J AM SOC NEPHRO, V6, P2470, DOI 10.2215/CJN.00670111; Madero M, 2009, AM J KIDNEY DIS, V53, P796, DOI 10.1053/j.ajkd.2008.12.021; Mortada I, 2017, CURR HYPERTENS REP, V19, DOI 10.1007/s11906-017-0770-x; Nakai S, 2013, THER APHER DIAL, V17, P567, DOI 10.1111/1744-9987.12147; Obermayr RP, 2008, J AM SOC NEPHROL, V19, P2407, DOI 10.1681/ASN.2008010080; Sagor MAT, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/478039; Sautin YY, 2008, NUCLEOS NUCLEOT NUCL, V27, P608, DOI 10.1080/15257770802138558; Siu YP, 2006, AM J KIDNEY DIS, V47, P51, DOI 10.1053/j.ajkd.2005.10.006; Sueta D, 2017, INT J CARDIOL, V230, P97, DOI 10.1016/j.ijcard.2016.12.072; Tausche AK, 2014, RHEUMATOL INT, V34, P101, DOI 10.1007/s00296-013-2857-2; Tsai CW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170393; Tsuda H, 2012, BIOCHEM BIOPH RES CO, V427, P266, DOI 10.1016/j.bbrc.2012.09.032; Weiner DE, 2008, J AM SOC NEPHROL, V19, P1204, DOI 10.1681/ASN.2007101075	28	7	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2019	14	6							e0217859	10.1371/journal.pone.0217859	http://dx.doi.org/10.1371/journal.pone.0217859			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IB4TA	31170241	Green Published, gold, Green Submitted			2023-01-03	WOS:000470263700070
J	Kubuga, CK; Abizari, AR; Song, WO				Kubuga, Clement Kubreziga; Abizari, Abdul-Razak; Song, Won O.			Iodine status of reproductive age women and their toddlers in northern Ghana improved through household supply of iodized salt and weekly indigenous meal consumption	PLOS ONE			English	Article							URINARY IODINE; DEFICIENCY; DIGESTION; NUTRITION; TRENDS; MILK	Iodine deficiency (ID) during pregnancy results in pregnancy losses, intrauterine growth retardation, and lower IQ in the offspring. Even after two decades of universal salt iodization (USI) implementation, the efficacy of USI has not been reported in high risk groups in vulnerable regions in Ghana. We aimed to assess and improve ID status in childbearing age women (all lactating women) and their toddlers in northern Ghana, a geographically and socioeconomically vulnerable region. We provided weekly supply of household iodized salt and community-based feeding of native Hibiscus Sabdariffaa leaves meal (HSM) prepared with iodized salt to women and their toddlers in intervention (n = 60) vs. control group (n = 60). At baseline, ID was prevalent in women (36%) and their toddlers (29%). For women, both median UIC values for intervention (57.4 ug/l) and control group (65.1 ug/l) were below the recommended UIC value of 100 ug/l with no significant differences between the two groups (p = 0.2778). At the endpoint, median UIC for the intervention group (123.6 ug/l) was significantly higher (p = 0.008) than the control group (59.7 ug/l). Our results suggest that weekly supply of iodized salt along with the feeding HSM is an effective channel for improving iodine status of economically disadvantaged groups in communities remote from coastal lands. Furthermore, our results suggest that decreased median UIC among lactating mothers does not necessarily imply lower iodine status for their breastfed toddlers. And finally, the observed median UIC<100 ug/l may point to a non-improvement in iodine status for the past decade for Ghana. There is a need to revisit, assess, and ascertain the challenges in preventing populations from attaining the intended benefits of the USI policy in Ghana.	[Kubuga, Clement Kubreziga; Abizari, Abdul-Razak] Univ Dev Studies, Nutr Sci Dept, Tamale, Ghana; [Song, Won O.] Michigan State Univ, Food Sci & Human Nutr Dept, E Lansing, MI 48824 USA	University for Development Studies; Michigan State University	Song, WO (corresponding author), Michigan State Univ, Food Sci & Human Nutr Dept, E Lansing, MI 48824 USA.	song@msu.edu		Song, Won/0000-0002-4372-4215	G Borlaug LEAP; BHEARD	G Borlaug LEAP; BHEARD	This project was mainly funded by G Borlaug LEAP and BHEARD, https://borlaugleap.org/; http://www.canr.msu.edu/bheard/received by CKK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abizari A.-R., 2016, PUBLIC HEALTH NUTR, P1; Andersson M, 2007, PUBLIC HEALTH NUTR, V10, P1606, DOI 10.1017/S1368980007361004; Andersson M, 2012, J NUTR, V142, P744, DOI 10.3945/jn.111.149393; [Anonymous], 2008, DEMOGRAPHIC HLTH RES; Bath S., 2008, Journal of Human Nutrition and Dietetics, V21, P379, DOI 10.1111/j.1365-277X.2008.00881_9.x; Bath S, 2008, J HUM NUTR DIET, V21, P280; Cappuccio F, 2014, 20 IEA WORLD C EP 17; Cogill B, 2003, ANTHROPOMETRIC INDIC; de Benoist B, 2008, FOOD NUTR BULL, V29, P195, DOI 10.1177/156482650802900305; DELANGE F, 1994, THYROID, V4, P107, DOI 10.1089/thy.1994.4.107; Dewey Kathryn G., 2003, Food and Nutrition Bulletin, V24, P5; Diosady L. L., 1997, Food and Nutrition Bulletin, V18, P388; Ghana Statistical Service, 2014, GHANA DEMOGRAPHIC HL; Haldimann M, 2015, PUBLIC HEALTH NUTR, V18, P1333, DOI 10.1017/S1368980014002018; Hedayati M, 2007, J CLIN LAB ANAL, V21, P286, DOI 10.1002/jcla.20185; Hedayati M, 2011, CLIN CHEM LAB MED, V49, P281, DOI 10.1515/CCLM.2011.053; Hess S. Y., 2016, PUBLIC HEALTH NUTR, P1; Hollowell JG, 1998, J CLIN ENDOCR METAB, V83, P3401, DOI 10.1210/jc.83.10.3401; Hurrell RF, 1997, EUR J CLIN NUTR, V51, pS9; Kennedy GL, 2007, J NUTR, V137, P472, DOI 10.1093/jn/137.2.472; Konig F, 2011, J NUTR, V141, P2049, DOI 10.3945/jn.111.144071; Kubuga CK, 2019, NUTRIENTS, V11, DOI 10.3390/nu11010198; Lee KW, 2016, NUTRIENTS, V8, DOI 10.3390/nu8060325; Lee KW, 2016, INT J FOOD SCI NUTR, V67, P184, DOI 10.3109/09637486.2016.1144717; Li M, 2006, MED J AUSTRALIA, V184, P307, DOI 10.5694/j.1326-5377.2006.tb00248.x; Lynch SR, 2011, J NUTR, V141, p763S, DOI 10.3945/jn.110.130609; Nazeri P, 2017, NUTRIENTS, V9, DOI 10.3390/nu9020180; Nyumuah RO, 2012, FOOD NUTR BULL, V33, pS293, DOI 10.1177/15648265120334S305; Pearce EN, 2013, THYROID, V23, P523, DOI 10.1089/thy.2013.0128; Ross AC, 2014, MODERN NUTR HLTH DIS, V11; Simpong DL, 2016, ARCH PUBLIC HEALTH, V74, DOI 10.1186/s13690-016-0119-y; Spybrook J, OPTIMAL DESIGN PLUS, V5, P2012; Vanderpump MPJ, 2012, INT J EPIDEMIOL, V41, P601, DOI 10.1093/ije/dys059; Vanderpump MPJ, 2011, LANCET, V377, P2007, DOI 10.1016/S0140-6736(11)60693-4; WHO, 2007, ASS IOD DEF DIS MON, V3rd; World Health Organization, 2004, VIT MIN REQ HUM NUTR; World Health Organization, 2017, ABN DEV IOD DEF; World Health Organization, 2013, UR IOD CONC DET IOD; Zhao JK, 1999, PUBLIC HEALTH NUTR, V2, P173, DOI 10.1017/S1368980099000221; Zimmermann MB, 2009, ENDOCR REV, V30, P376, DOI 10.1210/er.2009-0011	40	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2019	14	5							e0216931	10.1371/journal.pone.0216931	http://dx.doi.org/10.1371/journal.pone.0216931			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IA7TI	31150410	Green Submitted, gold, Green Published			2023-01-03	WOS:000469759100027
J	Tura, H; Licoze, A				Tura, Halkeno; Licoze, Armando			Women's experience of intimate partner violence and uptake of Antenatal Care in Sofala, Mozambique	PLOS ONE			English	Article							HEALTH CONSEQUENCES; PREVALENCE; PREGNANCY; SYMPTOMS; HIV	Intimate partner violence (IPV) is associated with negative physical and mental health outcomes. Although maternal health services, especially antenatal care (ANC), can act as a link to IPV resources, women experiencing IPV likely have reduced uptake of ANC due to social and emotional barriers. Poor ANC uptake can also further exacerbate adverse pregnancy outcomes. However, there is limited research examining the association between IPV and ANC within the context of Mozambique. Using data from a study conducted to assess the impact of membership in savings groups on maternal health service utilization in Mozambique (N = 205), we investigated the association between IPV and uptake of ANC. Pearson chi-square and logistic regression were employed to examine the association between IPV and ANC service utilization. The mean age of the participants was 33.4 years (SD = 11.88). Overall, 47.3%, 83.4%, and 51.7% of the participants reported experiencing IPV, receiving at least one ANC, and four or more ANC, respectively. Women who reported experience of IPV had lower odds of receiving both at least one (AOR 0.31 [95% CI: 0.12-0.82]) and four or more ANC (AOR 0.50 [95% CI: 0.27-0.92]). Women who reported experience of IPV also had lower odds of receiving ANC from skilled personnel (AOR 0.32 [95% CI: 0.10-0.90]). Experience of IPV showed significant association with reduced ANC service utilization among women in the study area. Further study is needed to assess whether the negative association between IPV and ANC service utilization is also a causal relationship, the evidence which will then help guide a comprehensive intervention effort to improve maternal health services use.	[Tura, Halkeno] Univ Iowa, Coll Publ Hlth, Dept Community & Behav Hlth, Iowa City, IA 52242 USA; [Licoze, Armando] Oasis Mozambique, Sofala, Mozambique	University of Iowa	Tura, H (corresponding author), Univ Iowa, Coll Publ Hlth, Dept Community & Behav Hlth, Iowa City, IA 52242 USA.	halkeno-tura@uiowa.edu	Zweigenthal, Virginia/AAW-6425-2021; Tura, Halkeno T/AAN-4939-2021	Zweigenthal, Virginia/0000-0003-3914-2156; Tura, Robsan/0000-0003-1245-6673	Oasis Mozambique	Oasis Mozambique	This project is funded by Oasis Mozambique The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript..	Allendorf K, 2010, STUD FAMILY PLANN, V41, P263, DOI 10.1111/j.1728-4465.2010.00252.x; [Anonymous], VIOLENCE AGAINST WOM; Antai D, 2011, BMC WOMENS HEALTH, V11, DOI 10.1186/1472-6874-11-56; Betron M., 2015, RECOGNIZING GENDER B; Borwankar R., 2008, GENDER BASED VIOLENC; Campbell J, 2002, ARCH INTERN MED, V162, P1157, DOI 10.1001/archinte.162.10.1157; Cebola B., 2013, DOMESTIC VIOLENCE BE; Dunkle KL, 2004, LANCET, V363, P1415, DOI 10.1016/S0140-6736(04)16098-4; Garcia-Moreno C, 2005, WHO MULTICOUNTRY STU; Garcia-Moreno C, 2006, LANCET, V368, P1260, DOI 10.1016/S0140-6736(06)69523-8; Hatcher AM, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.19233; Jewkes R, 2002, LANCET, V359, P1423, DOI 10.1016/S0140-6736(02)08357-5; Khan MN, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198833; Koski AD, 2011, J HEALTH POPUL NUTR, V29, P245, DOI 10.3329/jhpn.v29i3.7872; Krug EG, 2002, LANCET, V360, P1083, DOI 10.1016/S0140-6736(02)11133-0; Mozambique demographic and health survey, 2011, MOZ DEM HLTH SURV 20; Omer K, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/s12884-014-0380-4; Pallitto CC, 2013, INT J GYNECOL OBSTET, V120, P3, DOI 10.1016/j.ijgo.2012.07.003; Peltzer K, 2013, GEN HOSP PSYCHIAT, V35, P545, DOI 10.1016/j.genhosppsych.2013.04.001; Rees K, 2014, AFR J PRIM HEALTH CA, V6, DOI 10.4102/phcfm.v6i1.712; Rutherford A, 2007, J EPIDEMIOL COMMUN H, V61, P676, DOI 10.1136/jech.2005.043711; Sharps PW, 2007, TRAUMA VIOLENCE ABUS, V8, P105, DOI 10.1177/1524838007302594; Stephenson R, 2006, INT FAM PLAN PERSPEC, V32, P201, DOI 10.1363/3220106; Stephenson R, 2016, VIOLENCE AGAINST WOM, V22, P1642, DOI 10.1177/1077801216630148; Sugg N, 2015, MED CLIN N AM, V99, P629, DOI 10.1016/j.mcna.2015.01.012; WHO Department of Reproductive Health and Research London School of Hygiene and Tropical Medicine South African Medical Research Council, 2013, GLOB REG EST VIOL WO, P51; Winter A, 2013, INT J GYNECOL OBSTET, V121, P218, DOI 10.1016/j.ijgo.2012.12.018; World Health Organization, 2013, GLOB REG EST VIOL WO; World Health Organization , 2002, WHO ANT CAR RAND TRA; Zacarias AE, 2012, BMC INT HEALTH HUM R, V12, DOI 10.1186/1472-698X-12-35	30	16	16	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 24	2019	14	5							e0217407	10.1371/journal.pone.0217407	http://dx.doi.org/10.1371/journal.pone.0217407			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HZ5BN	31125370	Green Published, gold, Green Submitted			2023-01-03	WOS:000468865700037
J	McCoy, J; Ullman, T				McCoy, John; Ullman, Tomer			Judgments of effort for magical violations of intuitive physics	PLOS ONE			English	Article								People spend much of their time in imaginary worlds, and have beliefs about the events that are likely in those worlds, and the laws that govern them. Such beliefs are likely affected by people's intuitive theories of the real world. In three studies, people judged the effort required to cast spells that cause physical violations. People ranked the actions of spells congruently with intuitive physics. For example, people judge that it requires more effort to conjure up a frog than to levitate it one foot off the ground. A second study manipulated the target and extent of the spells, and demonstrated with a continuous measure that people are sensitive to this manipulation even between participants. A pre-registered third study replicated the results of Study 2. These results suggest that people's intuitive theories partly account for how they think about imaginary worlds.	[McCoy, John] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA; [Ullman, Tomer] Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA	University of Pennsylvania; Harvard University	Ullman, T (corresponding author), Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA.	tullman@wjh.harvard.edu		/0000-0003-1722-2382	Center for Brains, Minds, and Machines (National Science Foundation STC Award) [CCF-1231216]	Center for Brains, Minds, and Machines (National Science Foundation STC Award)	TDU was supported by the Center for Brains, Minds, and Machines (funded by National Science Foundation STC Award CCF-1231216). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baillargeon R, 1998, ADVANCES IN PSYCHOLOGICAL SCIENCE, VOL 2, P503; Baillargeon R., 2002, BLACKWELL HDB CHILDH, P47, DOI DOI 10.1002/9780470996652.CH3; Battaglia PW, 2013, P NATL ACAD SCI USA, V110, P18327, DOI 10.1073/pnas.1306572110; Byrne RMJ, 2005, RATIONAL IMAGINATION: HOW PEOPLE CREATE ALTERNATIVES TO REALITY, P1; Cacciari C., 1997, CREATIVE THOUGHT INV; Carey S., 1985, CONCEPTUAL CHANGE CH; Carey S., 2009, ORIGIN CONCEPTS; Feigenson L, 2004, TRENDS COGN SCI, V8, P307, DOI 10.1016/j.tics.2004.05.002; Forbus K. D., 1988, EXPLORING ARTIFICIAL, P239, DOI DOI 10.1016/B978-0-934613-67-5.50011-3; Gelman S. A., 2007, ESSENTIAL CHILD ORIG; Gelman SA, 2004, TRENDS COGN SCI, V8, P404, DOI 10.1016/j.tics.2004.07.001; Gopnik A., 1997, WORDS THOUGHTS THEOR; Griffiths TL, 2015, COGNITION, V136, P43, DOI 10.1016/j.cognition.2014.10.019; Hegarty M, 2004, TRENDS COGN SCI, V8, P280, DOI 10.1016/j.tics.2004.04.001; KELLY MH, 1985, COGNITIVE SCI, V9, P403, DOI 10.1207/s15516709cog0904_2; Lombrozo T., 2012, OXFORD HDB THINKING, P260, DOI DOI 10.1093/OXFORDHB/9780199734689.013.0014; MEDIN DL, 1989, AM PSYCHOL, V44, P1469, DOI 10.1037/0003-066X.44.12.1469; Sanborn AN, 2013, PSYCHOL REV, V120, P411, DOI 10.1037/a0031912; Shtulman A, 2017, PSYCHON B REV, V24, P1573, DOI 10.3758/s13423-016-1206-3; Skolnick D., 2006, ARCHITECTURE IMAGINA, P73, DOI [DOI 10.1093/ACPROF:OSO/9780199275731.001.0001, DOI 10.1093/ACPROF:OSO/9780199275731.003.0005]; Skolnick D, 2006, COGNITION, V101, pB9, DOI 10.1016/j.cognition.2005.10.001; Spelke ES, 2007, DEVELOPMENTAL SCI, V10, P89, DOI 10.1111/j.1467-7687.2007.00569.x; SPELKE ES, 1992, PSYCHOL REV, V99, P605, DOI 10.1037/0033-295X.99.4.605; SPELKE ES, 1993, PERCEPTION, V22, P1483, DOI 10.1068/p221483; Ullman TD, 2017, TRENDS COGN SCI, V21, P649, DOI 10.1016/j.tics.2017.05.012; WARD TB, 1994, COGNITIVE PSYCHOL, V27, P1, DOI 10.1006/cogp.1994.1010; Ward TB, 1997, J CREATIVE BEHAV, V31, P245, DOI 10.1002/j.2162-6057.1997.tb00797.x; Weisberg DS, 2009, J COGN CULT, V9, P69, DOI 10.1163/156853709X414647; WELLMAN HM, 1992, ANNU REV PSYCHOL, V43, P337, DOI 10.1146/annurev.ps.43.020192.002005; Xu F, 1999, COGNITION, V70, P137, DOI 10.1016/S0010-0277(99)00007-4	31	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2019	14	5							e0217513	10.1371/journal.pone.0217513	http://dx.doi.org/10.1371/journal.pone.0217513			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HZ3VE	31120990	Green Published, gold, Green Submitted			2023-01-03	WOS:000468775700109
J	Thapa, NR; Adhikari, S; Budhathoki, PK				Thapa, Naba Raj; Adhikari, Sunil; Budhathoki, Pawan Kumar			Influence of internal migration on the use of reproductive and maternal health services in Nepal: An analysis of the Nepal Demographic and Health Survey 2016	PLOS ONE			English	Article							URBAN MIGRATION; FERTILITY; DISRUPTION; HYPOTHESES; ADAPTATION	Background Internal migration has been an integral part of socioeconomic transformation in a country. Migrants are a vulnerable group for access to the reproductive and maternal health services. Very little is known regarding the role of internal migration on the use of reproductive and maternal health services in Nepal. This study examines the effect of internal migration on the use of reproductive and maternal health services in Nepal. Methods The data for this study were extracted from the 2016 Nepal Demographic and Health Survey (2016 NDHS). The study population is women age 15-49. The sample population is different for modern contraceptive use than for Antenatal care (ANC) visits and place of delivery. The sample population for modern contraceptive use is restricted to the 8,811 (weighted) women who are currently married. The total analytic sampled population for ANC visits and place of delivery is 3,220 (weighted) women. The study used descriptive and logistic regression analysis, with three outcome measures: current use of modern contraception; at least four ANC visits; and place of delivery. Results Sixty-eight percent women were internal migrants. Forty-four percent of eligible women reported current use of modern contraception, 71% of women made at least four ANC visits, about 9% of women made 8 or more ANC visits and 58% of women delivered in a health facility. Our findings show that modern contraceptive use is significantly higher among urban non-migrant women and urban-to-urban migrants. Urban-to-urban migrant women and rural-to-urban migrant women have significantly higher odds of attending at least four ANC visits for the most recent birth compared with rural-to-rural migrant women. Women who moved between urban areas, women who moved from an urban to a rural area, women who moved from a rural area to an urban area and urban non-migrants are significantly more likely to deliver in a health facility compared with women who moved between rural areas. Conclusion The differentials of use of reproductive and maternal health services by migration status may need consideration during program planning to improve women's reproductive and maternal health services in Nepal.	[Thapa, Naba Raj; Adhikari, Sunil; Budhathoki, Pawan Kumar] Tribhuvan Univ, Dept Populat Studies, Ratna Rajya Laxmi Campus, Kathmandu, Nepal	Tribhuvan University	Thapa, NR (corresponding author), Tribhuvan Univ, Dept Populat Studies, Ratna Rajya Laxmi Campus, Kathmandu, Nepal.	nabarthapa@gmail.com		Thapa, Naba Raj/0000-0001-6656-7497	USAID; ICF	USAID(United States Agency for International Development (USAID)); ICF	The authors would like to thank USAID and ICF for their financial and technical support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adanu RMK, 2009, INT J GYNECOL OBSTET, V106, P179, DOI 10.1016/j.ijgo.2009.03.036; BROCKERHOFF M, 1990, DEMOGRAPHY, V27, P601, DOI 10.2307/2061573; Chattopadhyay A, 2006, POP STUD-J DEMOG, V60, P189, DOI 10.1080/00324720600646287; Dahiru T, 2015, PAN AFR MED J, V21, DOI 10.11604/pamj.2015.21.321.6527; Deshingkar P., 2005, INTERNAL MIGRATION D, DOI 10.18356/00e90d72-en; Dickson KS, 2016, INT J REPROD MED, V2016, P1; Evans J., 1987, INT MIGR REV, V21, px; HERVITZ HM, 1985, INT MIGR REV, V19, P293, DOI 10.2307/2545774; Islam MS, 2016, BMC PLANT BIOL, V16, DOI 10.1186/s12870-016-0727-2; KC, 2003, POPULATION MONOGRAPH, V2, P121; Kitui J, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-40; Kulu H, 2005, EUR J POPUL, V21, P51, DOI 10.1007/s10680-005-3581-8; Lindstrom DP, 2006, INT FAM PLAN PERSPEC, V32, P146, DOI 10.1363/3214606; Lindstrom DP, 2003, POPUL RES POLICY REV, V22, P351, DOI 10.1023/A:1027336615298; Macro International Inc, 2007, TRENDS DEMPGR REOOD; McKay L., 2003, MIGRATION HLTH REV I; Mehata S, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5079234; Ministry of Health, 2017, NAT HLTH SECT STRAT; Ministry of Health New ERA and I, 2017, NEP DEM HLTH SURV 20; Mishra P, 2014, INTERNATIONAL HANDBOOK ON MIGRATION AND ECONOMIC DEVELOPMENT, P241; Ochako R, 2016, REPROD HLTH, V13, P1, DOI [10.1186/s12978-015-0112-x, DOI 10.1186/S12978-015-0112-X]; Santelli JS, 2009, J ADOLESCENT HEALTH, V44, P3, DOI 10.1016/j.jadohealth.2008.10.135; Sharma V., 2015, MIGRATION S ASIA REV; Subaiya L., 2007, INTERNAL MIGRATION U; Sudhinaraset M, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0942-8; SUWAL B.R., 2014, POPULATION MONOGRAPH, V1, P241; UNFPA Nepal, 2017, POP SIT AN NEP; World Health Organization, 1994, ANT CAR REP TECHN WO; Zhan SK, 2002, HEALTH POLICY PLANN, V17, P47, DOI 10.1093/heapol/17.suppl_1.47; Zhao Q, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1012	30	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2019	14	5							e0216587	10.1371/journal.pone.0216587	http://dx.doi.org/10.1371/journal.pone.0216587			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HX6ZE	31071179	Green Published, Green Submitted, gold			2023-01-03	WOS:000467552100068
J	Baroli, B; Loi, E; Solari, P; Kasture, A; Moi, L; Muroni, P; Kasture, S; Setzu, MD; Liscia, A; Zavattari, P				Baroli, Biancamaria; Loi, Eleonora; Solari, Paolo; Kasture, Ameya; Moi, Loredana; Muroni, Patrizia; Kasture, Sanjay; Setzu, Maria Dolores; Liscia, Anna; Zavattari, Patrizia			Evaluation of oxidative stress mechanisms and the effects of phytotherapic extracts on Parkinson's disease Drosophila PINK1(B9) model	FASEB JOURNAL			English	Article						Drosophila melanogaster; PINK1(B9) mutants; phytotherapic preparations; telomere length	AGING-ASSOCIATED ALTERATION; TELOMERE LENGTH; MITOCHONDRIAL DYSFUNCTION; MELANOGASTER; GLUTATHIONE; MUTATIONS; APOPTOSIS; MUTANTS; MUSCLE; RISK	Oxidative stress is commonly observed in both idiopathic and genetic cases of Parkinson's disease (PD). It plays an important role in the degeneration of dopaminergic neurons, and it has been associated with altered telomere length (TL). There is currently no cure for PD, and extracts of antioxidative plant, such as Mucuna pruriens and Withania somnifera, are commonly used in Ayurveda to treat patients with PD. In this study, we evaluated 2 enzymatic markers of oxidative stress, glutathione (GSH) system and superoxide dismutase (SOD), and TL in a Drosophila melanogaster model for PD [phosphatase and tensin homolog-induced putative kinase 1 (PINK1)(B9)]. This evaluation was also performed after treatment with the phytoextracts. PINK1(B9) mutants showed a decrease in GSH amount and SOD activity and unexpected longer telomeres compared with wild-type flies. M. pruriens treatment seemed to have a beneficial effect on the oxidative stress conditions. On the other hand, W. somnifera treatment did not show any improvements in the studied oxidative stress mechanisms and even seemed to favor the selection of flies with longer telomeres. In summary, our study suggests the importance of testing antioxidant phytoextracts in a PINK1(B9) model to identify beneficial effects for PD.-Baroli, B., Loi, E., Solari, P., Kasture, A., Moi, L., Muroni, P., Kasture, S., Setzu, M. D., Liscia, A., Zavattari, P. Evaluation of oxidative stress mechanisms and the effects of phytotherapic extracts on Parkinson's disease Drosophila PINK1(B9) model.	[Baroli, Biancamaria] Univ Cagliari, Dept Life & Environm Sci, Cagliari, Italy; [Loi, Eleonora; Solari, Paolo; Moi, Loredana; Muroni, Patrizia; Setzu, Maria Dolores; Liscia, Anna; Zavattari, Patrizia] Univ Cagliari, Dept Biomed Sci, Univ Campus,SP 8, I-09042 Cagliari, Italy; [Kasture, Ameya] Univ Vienna, Dept Neurobiol, Vienna, Austria; [Kasture, Sanjay] Pinnacle Biomed Res Inst, Bhopal, India	University of Cagliari; University of Cagliari; University of Vienna	Liscia, A (corresponding author), Univ Cagliari, Dept Biomed Sci, Univ Campus,SP 8, I-09042 Cagliari, Italy.	liscia@unica.it	Loi, Eleonora/Y-2968-2019	Loi, Eleonora/0000-0001-6437-4763; Kasture, Ameya/0000-0002-2947-4803; /0000-0001-8785-1438				Ahmed S, 1998, GENETICS, V150, P643; Alam N, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-175; Alviano DS, 2009, CURR PHARM BIOTECHNO, V10, P106, DOI 10.2174/138920109787048607; Bharath S, 2002, BIOCHEM PHARMACOL, V64, P1037, DOI 10.1016/S0006-2952(02)01174-7; Bjorklund A, 2010, PROG BRAIN RES, V184, P3, DOI 10.1016/S0079-6123(10)84001-4; Cai ZY, 2013, NEUROMOL MED, V15, P25, DOI 10.1007/s12017-012-8207-9; Celotto AM, 2005, MOL INTERV, V5, P292, DOI 10.1124/mi.5.5.9; De Rose F, 2017, SCI REP-UK, V7, DOI 10.1038/srep41059; De Rose F, 2016, PARKINSONS DIS-US, V2016, DOI 10.1155/2016/3508073; De Rose F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146140; Degerman S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113387; Deocaris CC, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-14; Dutta K, 2018, EXP NEUROL, V309, P193, DOI 10.1016/j.expneurol.2018.08.008; Forero DA, 2016, EXP GERONTOL, V75, P53, DOI 10.1016/j.exger.2016.01.002; Frydrychova RC, 2008, CYTOGENET GENOME RES, V122, P356, DOI 10.1159/000167823; Gautier CA, 2008, P NATL ACAD SCI USA, V105, P11364, DOI 10.1073/pnas.0802076105; Gonzalez-Ebsen AC, 2017, FRONT BIOSCI-LANDMRK, V22, P117, DOI 10.2741/4475; Ichikawa H, 2006, MOL CANCER THER, V5, P1434, DOI 10.1158/1535-7163.MCT-06-0096; Jenner P, 1996, NEUROLOGY, V47, pS161, DOI 10.1212/WNL.47.6_Suppl_3.161S; Kasture S, 2013, ORIENTAL PHARM EXP M, V13, P165, DOI 10.1007/s13596-013-0126-2; Keller MF, 2012, HUM MOL GENET, V21, P4996, DOI 10.1093/hmg/dds335; Korandova M, 2018, J INSECT PHYSIOL, V104, P1, DOI 10.1016/j.jinsphys.2017.11.002; Liu ZH, 2011, PHARMACOL RES, V63, P439, DOI 10.1016/j.phrs.2011.01.004; Maeda T, 2012, J NEUROGENET, V26, P245, DOI 10.3109/01677063.2011.651665; Maeda T, 2009, J GERONTOL A-BIOL, V64, P949, DOI 10.1093/gerona/glp070; Manyam BV, 2004, PHYTOTHER RES, V18, P706, DOI 10.1002/ptr.1514; Misra L, 2007, INDIAN J BIOCHEM BIO, V44, P56; Morais VA, 2009, EMBO MOL MED, V1, P99, DOI 10.1002/emmm.200900006; Nalls MA, 2014, NAT GENET, V46, P989, DOI 10.1038/ng.3043; Park J, 2006, NATURE, V441, P1157, DOI 10.1038/nature04788; Pickrell AM, 2015, NEURON, V87, P371, DOI 10.1016/j.neuron.2015.06.034; Poddighe S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110802; Poddighe S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073156; Pridgeon JW, 2007, PLOS BIOL, V5, P1494, DOI 10.1371/journal.pbio.0050172; Raffa G D, 2013, Tsitologiia, V55, P204; Raffa GD, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00112; Roberts RO, 2014, MECH AGEING DEV, V141, P64, DOI 10.1016/j.mad.2014.10.002; Salim S, 2017, J PHARMACOL EXP THER, V360, P201, DOI 10.1124/jpet.116.237503; Savage Sharon A, 2018, F1000Res, V7, DOI 10.12688/f1000research.14068.1; Senthil V, 2007, CHEM-BIOL INTERACT, V167, P19, DOI 10.1016/j.cbi.2007.01.004; Solari P, 2018, J INSECT PHYSIOL, V111, P32, DOI 10.1016/j.jinsphys.2018.10.007; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Vasantharaja Raguraman, 2016, Advances in Bioscience and Biotechnology, V7, P199, DOI 10.4236/abb.2016.74018; von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2; Walter MF, 2007, CHROMOSOMA, V116, P41, DOI 10.1007/s00412-006-0081-5; Whitworth AJ, 2005, P NATL ACAD SCI USA, V102, P8024, DOI 10.1073/pnas.0501078102; Wu DF, 2018, STAT PUBLIC POLICY, V5, P1, DOI 10.1080/2330443X.2018.1438939; Yang YF, 2006, P NATL ACAD SCI USA, V103, P10793, DOI 10.1073/pnas.0602493103	48	7	8	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2019	33	10					11028	11034		10.1096/fj.201901010	http://dx.doi.org/10.1096/fj.201901010			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JC3GG	31291788	Green Submitted			2023-01-03	WOS:000489166300038
J	Jordan, S; Tung, N; Casanova-Acebes, M; Chang, C; Cantoni, C; Zhang, DC; Wirtz, TH; Naik, S; Rose, SA; Brocker, CN; Gainullina, A; Hornburg, D; Horng, S; Maier, BB; Cravedi, P; LeRoith, D; Gonzalez, FJ; Meissner, F; Ochando, J; Rahman, A; Chipuk, JE; Artyomov, MN; Frenette, PS; Piccio, L; Berres, ML; Gallagher, EJ; Merad, M				Jordan, Stefan; Tung, Navpreet; Casanova-Acebes, Maria; Chang, Christie; Cantoni, Claudia; Zhang, Dachuan; Wirtz, Theresa H.; Naik, Shruti; Rose, Samuel A.; Brocker, Chad N.; Gainullina, Anastasiia; Hornburg, Daniel; Horng, Sam; Maier, Barbara B.; Cravedi, Paolo; LeRoith, Derek; Gonzalez, Frank J.; Meissner, Felix; Ochando, Jordi; Rahman, Adeeb; Chipuk, Jerry E.; Artyomov, Maxim N.; Frenette, Paul S.; Piccio, Laura; Berres, Marie-Luise; Gallagher, Emily J.; Merad, Miriam			Dietary Intake Regulates the Circulating Inflammatory Monocyte Pool	CELL			English	Article							WEIGHT-LOSS; BONE-MARROW; VEGETARIAN DIET; LOW-CALORIE; OVERWEIGHT; AUTOIMMUNITY; PROTEIN; STEM; PARAMETERS; EMIGRATION	Caloric restriction is known to improve inflammatory and autoimmune diseases. However, the mechanisms by which reduced caloric intake modulates inflammation are poorly understood. Here we show that short-term fasting reduced monocyte metabolic and inflammatory activity and drastically reduced the number of circulating monocytes. Regulation of peripheral monocyte numbers was dependent on dietary glucose and protein levels. Specifically, we found that activation of the low-energy sensor 5'-AMP-activated protein kinase (AMPK) in hepato-cytes and suppression of systemic CCL2 production by peroxisome proliferator-activator receptor alpha (PPAR alpha) reduced monocyte mobilization from the bone marrow. Importantly, we show that fasting improves chronic inflammatory diseases without compromising monocyte emergency mobilization during acute infectious inflammation and tissue repair. These results reveal that caloric intake and liver energy sensors dictate the blood and tissue immune tone and link dietary habits to inflammatory disease outcome.	[Jordan, Stefan; Tung, Navpreet; Casanova-Acebes, Maria; Chang, Christie; Maier, Barbara B.; Ochando, Jordi; Chipuk, Jerry E.; Merad, Miriam] Icahn Sch Med Mt Sinai, Dept Ontol Sci, 1 Gustave L Levy Pl, New York, NY 10029 USA; [Jordan, Stefan; Tung, Navpreet; Casanova-Acebes, Maria; Chang, Christie; Maier, Barbara B.; Cravedi, Paolo; Merad, Miriam] Icahn Sch Med Mt Sinai, Precis Immunol Inst, 1 Gustave L Levy Pl, New York, NY 10029 USA; [Jordan, Stefan; Tung, Navpreet; Casanova-Acebes, Maria; Chang, Christie; Maier, Barbara B.; Rahman, Adeeb; Chipuk, Jerry E.; Merad, Miriam] Icahn Sch Med Mt Sinai, Tisch Canc Inst, 1 Gustave L Levy Pl, New York, NY 10029 USA; [Rose, Samuel A.; Rahman, Adeeb] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, 1 Gustave L Levy Pl, New York, NY 10029 USA; [LeRoith, Derek; Gallagher, Emily J.] Icahn Sch Med Mt Sinai, Div Endocrinol Diabet & Bone Dis, 1 Gustave L Levy Pl, New York, NY 10029 USA; [Horng, Sam] Icahn Sch Med Mt Sinai, Dept Neurol & Neurosci, 1 Gustave L Levy Pl, New York, NY 10029 USA; [Rahman, Adeeb] Icahn Sch Med Mt Sinai, Human Immune Monitoring Ctr, 1 Gustave L Levy Pl, New York, NY 10029 USA; [Zhang, Dachuan; Frenette, Paul S.] Albert Einstein Coll Med, Ruth L & David S Gottesman Inst Stem Cell & Regen, Dept Cell Biol, 1301 Morris Pk Ave, Bronx, NY 10461 USA; [Wirtz, Theresa H.; Berres, Marie-Luise] Rhein Westfal TH Aachen, Dept Internal Med 3, Univ Hosp, Pauwelsstr 30, D-52074 Aachen, Germany; [Naik, Shruti] NYU, Dept Pathol, Sch Med, 240 East 38th St, New York, NY 10016 USA; [Naik, Shruti] NYU, Ronald O Perelman Dept Dermatol, Sch Med, 240 East 38th St, New York, NY 10016 USA; [Brocker, Chad N.; Gonzalez, Frank J.] NCI, Lab Metab, Ctr Canc Res, NIH, Bldg 37, Bethesda, MD 20892 USA; [Gainullina, Anastasiia; Artyomov, Maxim N.] Washington Univ, Sch Med, Dept Pathol & Immunol, 660 South Euclid Ave, St Louis, MO 63110 USA; [Cantoni, Claudia; Piccio, Laura] Washington Univ, Dept Neurol, Sch Med, 660 S Euclid Ave, St Louis, MO 63110 USA; [Gainullina, Anastasiia] ITMO Univ, Comp Technol Dept, Kronverksky 49, St Petersburg, Russia; [Hornburg, Daniel; Meissner, Felix] Max Planck Inst Biochem, Klopferspitz 18, D-82152 Martinsried, Germany; [Piccio, Laura] Univ Sydney, Brain & Mind Ctr, 94 Mallett St, Camperdown, NSW 2050, Australia	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Yeshiva University; Albert Einstein College of Medicine; RWTH Aachen University; RWTH Aachen University Hospital; New York University; New York University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Washington University (WUSTL); Washington University (WUSTL); ITMO University; Max Planck Society; University of Sydney	Jordan, S; Merad, M (corresponding author), Icahn Sch Med Mt Sinai, Dept Ontol Sci, 1 Gustave L Levy Pl, New York, NY 10029 USA.; Jordan, S; Merad, M (corresponding author), Icahn Sch Med Mt Sinai, Precis Immunol Inst, 1 Gustave L Levy Pl, New York, NY 10029 USA.; Jordan, S; Merad, M (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, 1 Gustave L Levy Pl, New York, NY 10029 USA.	stefan.jordan@mssm.edu; miriam.merad@mssm.edu	Berres, Marie-Luise/AAN-5351-2021; Acebes, Maria Casanova/AAH-1929-2019; Ochando, jordi/ABE-2358-2020; Jordan, Stefan/AAH-8261-2021; Zhang, Dachuan/GZA-8781-2022; Jordan, Stefan/AAI-1073-2021; Gainullina, Anastasiia/O-4727-2019; Meissner, Felix/C-8767-2015	Acebes, Maria Casanova/0000-0002-5790-1163; Ochando, jordi/0000-0001-7037-1681; Jordan, Stefan/0000-0001-9330-1715; Jordan, Stefan/0000-0001-9330-1715; Gainullina, Anastasiia/0000-0003-3796-2337; Cravedi, Paolo/0000-0001-7837-0923; Maier, Barbara/0000-0002-7359-6576; Brocker, Chad/0000-0003-4262-3567; Zhang, Dachuan/0000-0002-1746-275X; Piccio, Laura/0000-0002-8760-109X; Chang, Christie/0000-0002-7651-7220; Meissner, Felix/0000-0003-1000-7989	NIH [R01 CA154947, U24 AI118644, U19 AI128949, K08CA190770]; Tisch Cancer Institute; German Research Council (DFG) [SFB-TRR57 P07, JO 1216/1-1]; NATIONAL CANCER INSTITUTE [K08CA190770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Tisch Cancer Institute; German Research Council (DFG)(German Research Foundation (DFG)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank J. Agudo, S. Offermanns, C. Buettner, S. Fried, T. E. McGraw, A. W. Ferrante and the Merad laboratory for helpful discussions. We thank J. LeBerichel for technical assistance, A. Lansky for submission of the IRB application, the Flow Cytometry facility for technical support, the Human immune monitoring core for assistance with the multiplex assay, M. Davila for processing CyTOF data, M. Serasinghe for help with metabolic measurements in monocytes, the Stable Isotope & Metabolomics core at Albert Einstein College of Medicine for assistance with blood metabolite measurements, S. Hatem for assistance with phlebotomy and all participants of the human fasting experiment. We are grateful to Y. Belkaid for giving us the opportunity to use her laboratory at NIH and N. Bouladoux for assistance. We thank Wiegand von Hartmann GBR for designing the graphical abstract. Supported by the NIH (R01 CA154947, U24 AI118644, U19 AI128949 to M. M. and K08CA190770 to E.J.G),The Tisch Cancer Institute (Junior Scientist Award to E. J. G), and the German Research Council (DFG) (SFB-TRR57 P07 to M.-L. B, JO 1216/1-1 to S. J.).	Ajami B, 2011, NAT NEUROSCI, V14, P1142, DOI 10.1038/nn.2887; Aksungar FB, 2007, ANN NUTR METAB, V51, P88, DOI 10.1159/000100954; Boniakowski AE, 2018, EUR J IMMUNOL, V48, P1445, DOI 10.1002/eji.201747400; Brandhorst S, 2013, EXP GERONTOL, V48, P1120, DOI 10.1016/j.exger.2013.02.016; Brocker CN, 2017, AM J PHYSIOL-GASTR L, V312, pG283, DOI 10.1152/ajpgi.00205.2016; Choi IY, 2017, MOL CELL ENDOCRINOL, V455, P4, DOI 10.1016/j.mce.2017.01.042; Choi IY, 2016, CELL REP, V15, P2136, DOI 10.1016/j.celrep.2016.05.009; Chong SZ, 2016, J EXP MED, V213, P2293, DOI 10.1084/jem.20160800; Cignarella F, 2018, CELL METAB, V27, P1222, DOI 10.1016/j.cmet.2018.05.006; Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591; Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; DARLINGTON LG, 1986, LANCET, V1, P236; Decker M, 2018, SCIENCE, V360, P106, DOI 10.1126/science.aap8861; Faris E, 2012, NUTR RES, V32, P947, DOI 10.1016/j.nutres.2012.06.021; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1; Ho TP, 2015, HORM METAB RES, V47, P289, DOI 10.1055/s-0034-1382011; Hughes CS, 2014, MOL SYST BIOL, V10, DOI 10.15252/msb.20145625; Imayama I, 2012, CANCER RES, V72, P2314, DOI 10.1158/0008-5472.CAN-11-3092; Jensen P, 2016, AM J CLIN NUTR, V104, P259, DOI 10.3945/ajcn.115.125849; Jensen TL, 2013, LAB ANIM-UK, V47, P225, DOI 10.1177/0023677213501659; Johnson JB, 2007, FREE RADICAL BIO MED, V42, P665, DOI 10.1016/j.freeradbiomed.2006.12.005; Kani AH, 2017, HORM METAB RES, V49, P687, DOI 10.1055/s-0042-118707; King IL, 2009, BLOOD, V113, P3190, DOI 10.1182/blood-2008-07-168575; KJELDSENKRAGH J, 1991, LANCET, V338, P899, DOI 10.1016/0140-6736(91)91770-U; Lips MA, 2016, METABOLISM, V65, P1614, DOI 10.1016/j.metabol.2016.07.013; Loria-Kohen V, 2013, CLIN NUTR, V32, P511, DOI 10.1016/j.clnu.2012.10.015; Lumeng CN, 2011, J CLIN INVEST, V121, P2111, DOI 10.1172/JCI57132; Ma EH, 2017, CELL METAB, V25, P482, DOI 10.1016/j.cmet.2017.01.014; Manzel A, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-013-0404-6; Mendez-Ferrer S, 2008, NATURE, V452, P442, DOI 10.1038/nature06685; Mildner A, 2009, BRAIN, V132, P2487, DOI 10.1093/brain/awp144; Moro T, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1044-0; Oh EG, 2013, BIOL RES NURS, V15, P48, DOI 10.1177/1099800411416637; Orr JS, 2013, JOVE-J VIS EXP, DOI 10.3791/50707; Ott B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12109-9; Picca A, 2017, CLIN INTERV AGING, V12, P1887, DOI 10.2147/CIA.S126458; Piccio L, 2008, J LEUKOCYTE BIOL, V84, P940, DOI 10.1189/jlb.0208133; Poitou C, 2011, ARTERIOSCL THROM VAS, V31, P2322, DOI 10.1161/ATVBAHA.111.230979; Ramel A, 2010, EUR J CLIN NUTR, V64, P987, DOI 10.1038/ejcn.2010.99; Serbina NV, 2012, ADV IMMUNOL, V113, P119, DOI 10.1016/B978-0-12-394590-7.00003-8; Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309; Sergushichev AA, 2016, NUCLEIC ACIDS RES, V44, pW194, DOI 10.1093/nar/gkw266; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Shi C, 2011, IMMUNITY, V34, P590, DOI 10.1016/j.immuni.2011.02.016; SKOLDSTAM L, 1979, SCAND J RHEUMATOL, V8, P249, DOI 10.3109/03009747909114631; Tajik N, 2013, J ENDOCRINOL INVEST, V36, P211, DOI 10.3275/8465; Ulland TK, 2017, CELL, V170, P649, DOI 10.1016/j.cell.2017.07.023; Wang A, 2016, CELL, V166, P1512, DOI 10.1016/j.cell.2016.07.026; Wei M, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai8700; Yamanashi T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08055-1; Youm YH, 2015, NAT MED, V21, P263, DOI 10.1038/nm.3804; Zubrzycki A, 2018, J PHYSIOL PHARMACOL, V69, P663, DOI 10.26402/jpp.2018.5.02	54	154	159	4	60	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	2019	178	5					1102	+		10.1016/j.cell.2019.07.050	http://dx.doi.org/10.1016/j.cell.2019.07.050			30	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	IS5KJ	31442403	Bronze, Green Submitted, Green Accepted			2023-01-03	WOS:000482191000009
J	Luna, RB; Olombrada, MVD				Bermudez Luna, Rocio; de Torres Olombrada, Maria Victoria			mARC preoperative rectal cancer treatments vs. 3D conformal radiotherapy. A dose distribution comparative study	PLOS ONE			English	Article							VOLUMETRIC MODULATED ARC; SMALL-BOWEL TOXICITY; RADIATION-THERAPY; QUALITY-ASSURANCE; CHEMORADIOTHERAPY; DELIVERY; IMRT; IMPLEMENTATION; CHEMOTHERAPY; IRRADIATION	Purpose mARC (modulated arc) is the arc therapy technique provided by Siemens. The present study analyses the dose distributions and treatment times corresponding to preoperative rectal cancer mARC treatments. The results are compared to those corresponding to 3D-CRT plans. Methods The plans of 30 patients, each having one mARC and one 3D-CRT plan, were evaluated. Every plan was calculated on a sequential two-phase treatment scheme with prescription doses of 45 Gy in the initial phase and 5.4 Gy in the boost phase. Dosimetric parameters and mean DVHs corresponding to the PTVs and OARs were assessed for both techniques. Results All mARC plans were considered valid for treatment and yielded a highly significant improvement in the CI over 3D-CRT plans (p < 0.001). They also showed statistically significant advantage on the parameters D98%, D95% and D2% of the high dose PTV. Regarding the OARs, mARC plans showed reductions in the mean dose of 3.5 Gy in the bladder and greater than 4 Gy in the femoral heads. Considering the small bowel, the mARC plans resulted in a 2.7 Gy mean reduction in the mean dose and lower irradiated volumes over the entire dose range. Conclusions Arc therapy plans with the mARC technique for preoperative rectal cancer treatment in a sequential two-phase treatment scheme provide important advantages in the PTVs and OARs. mARC plans show superior protection of the femoral heads, bladder and small bowel, similar to the results found with other more widespread arc therapy techniques.	[Bermudez Luna, Rocio] Hosp Univ Fuenlabrada, Med Phys Dept, Madrid, Spain; [de Torres Olombrada, Maria Victoria] Hosp Univ Fuenlabrada, Radiat Oncol Dept, Madrid, Spain	Hospital Universitario Fuenlabrada; Hospital Universitario Fuenlabrada	Luna, RB (corresponding author), Hosp Univ Fuenlabrada, Med Phys Dept, Madrid, Spain.	rocio.bermudez@salud.madrid.org						[Anonymous], 2010, J ICRU, V10, DOI [10.1016/0360-3016(93)90548-A, DOI 10.1016/0360-3016(93)90548-A]; Baglan KL, 2002, INT J RADIAT ONCOL, V52, P176, DOI 10.1016/S0360-3016(01)01820-X; Bedford JL, 2009, INT J RADIAT ONCOL, V73, P537, DOI 10.1016/j.ijrobp.2008.08.055; Bell K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164616; Bell K, 2016, PHYS MEDICA, V32, P474, DOI 10.1016/j.ejmp.2016.02.011; Bonnetain F, 2012, EUR J CANCER, V48, P1781, DOI 10.1016/j.ejca.2012.03.016; Cilla S, 2012, CLIN ONCOL-UK, V24, P261, DOI 10.1016/j.clon.2011.07.001; Droge LH, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1812-x; Duthoy W, 2004, INT J RADIAT ONCOL, V60, P794, DOI 10.1016/j.ijrobp.2004.04.016; Dzierma Y., 2013, MODULATED ARC MARC P; Dzierma Y, 2014, RADIAT ONCOL, V9, DOI 10.1186/s13014-014-0250-2; GALLAGHER MJ, 1986, INT J RADIAT ONCOL, V12, P1565, DOI 10.1016/0360-3016(86)90279-8; Gerard JP, 2006, J CLIN ONCOL, V24, P4620, DOI 10.1200/JCO.2006.06.7629; HEALD RJ, 1986, LANCET, V1, P1479; Joye I, 2015, ACTA ONCOL, V54, P1677, DOI 10.3109/0284186X.2015.1064159; Kainz K, 2011, MED PHYS, V38, P5104, DOI 10.1118/1.3622612; Kaurin Darryl Gl, 2012, J Appl Clin Med Phys, V13, P3725, DOI 10.1120/jacmp.v13i2.3725; Kavanagh BD, 2010, INT J RADIAT ONCOL, V76, pS101, DOI 10.1016/j.ijrobp.2009.05.071; Ling CC, 2008, INT J RADIAT ONCOL, V72, P575, DOI 10.1016/j.ijrobp.2008.05.060; Myerson RJ, 2001, INT J RADIAT ONCOL, V50, P1299, DOI 10.1016/S0360-3016(01)01540-1; Myerson RJ, 2009, INT J RADIAT ONCOL, V74, P824, DOI 10.1016/j.ijrobp.2008.08.070; Otto K, 2008, MED PHYS, V35, P310, DOI 10.1118/1.2818738; Richetti A, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-14; Robertson JM, 2008, INT J RADIAT ONCOL, V70, P413, DOI 10.1016/j.ijrobp.2007.06.066; Salter BJ, 2011, PHYS MED BIOL, V56, P1931, DOI 10.1088/0031-9155/56/7/002; Samuelian JM, 2012, INT J RADIAT ONCOL, V82, P1981, DOI 10.1016/j.ijrobp.2011.01.051; Sarkar V, 2015, J APPL CLIN MED PHYS, V16, P458, DOI 10.1120/jacmp.v16i2.5351; Sauer R, 2012, J CLIN ONCOL, V30, P1926, DOI 10.1200/JCO.2011.40.1836; SHAW E, 1993, INT J RADIAT ONCOL, V27, P1231, DOI 10.1016/0360-3016(93)90548-A; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Teoh M, 2011, BRIT J RADIOL, V84, P967, DOI 10.1259/bjr/22373346; Tho LM, 2006, INT J RADIAT ONCOL, V66, P505, DOI 10.1016/j.ijrobp.2006.05.005; Valentini V, 2016, RADIOTHER ONCOL, V120, P195, DOI 10.1016/j.radonc.2016.07.017; Wolff HA, 2012, RADIOTHER ONCOL, V102, P30, DOI 10.1016/j.radonc.2011.10.018	34	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2019	14	8							e0221262	10.1371/journal.pone.0221262	http://dx.doi.org/10.1371/journal.pone.0221262			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5LL	31419263	Green Published, gold			2023-01-03	WOS:000485019900034
J	Wadhera, RK; Maddox, KEJ; Kazi, DS; Shen, C; Yeh, RW				Wadhera, Rishi K.; Maddox, Karen E. Joynt; Kazi, Dhruv S.; Shen, Changyu; Yeh, Robert W.			Hospital revisits within 30 days after discharge for medical conditions targeted by the Hospital Readmissions Reduction Program in the United States: national retrospective analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; HEART-FAILURE; ASSOCIATION; MORTALITY; OUTCOMES; QUALITY; CARE	OBJECTIVE To determine any changes in total hospital revisits within 30 days of discharge after a hospital stay for medical conditions targeted by the Hospital Readmissions Reduction Program (HRRP). DESIGN Retrospective cohort study. SETTING Hospital stays among Medicare patients for heart failure, acute myocardial infarction, or pneumonia between 1 January 2012 and 1 October 2015. PARTICIPANTS Medicare fee-for-service patients aged 65 or over. MAIN OUTCOMES Total hospital revisits within 30 days of discharge after hospital stays for medical conditions targeted by the HRRP, and by type of revisit: treat-and-discharge visit to an emergency department, observation stay (not leading to inpatient readmission), and inpatient readmission. Patient subgroups (age, sex, race) were also evaluated for each type of revisit. RESULTS Our study cohort included 3 038 740 total index hospital stays from January 2012 to September 2015: 1 357 620 for heart failure, 634 795 for acute myocardial infarction, and 1 046 325 for pneumonia. Counting all revisits after discharge, the total number of hospital revisits per 100 patient discharges for target conditions increased across the study period (monthly increase 0.023 visits per 100 patient discharges (95% confidence interval 0.010 to 0.035)). This change was due to monthly increases in treat-and-discharge visits to an emergency department (0.023 (0.015 to 0.032) and observation stays (0.022 (0.020 to 0.025)), which were only partly offset by declines in readmissions (-0.023 (-0.035 to -0.012)). Increases in observation stay use were more pronounced among non-white patients than white patients. No significant change was seen in mortality within 30 days of discharge for target conditions (-0.0034 (-0.012 to 0.0054)). CONCLUSIONS In the United States, total hospital revisits within 30 days of discharge for conditions targeted by the HRRP increased across the study period. This increase was due to a rise in post-discharge emergency department visits and observation stays, which exceeded the decline in readmissions. Although reductions in readmissions have been attributed to improvements in discharge planning and care transitions, our findings suggest that these declines could instead be because hospitals and clinicians have intensified efforts to treat patients who return to a hospital within 30 days of discharge in emergency departments and as observation stays.	[Wadhera, Rishi K.; Kazi, Dhruv S.; Shen, Changyu; Yeh, Robert W.] Beth Israel Deaconess Med, Div Cardiol, Richard A & Susan F Smith Ctr Outcomes Res Cardio, 185 Pilgrim Rd, Boston, MA 02215 USA; [Wadhera, Rishi K.; Kazi, Dhruv S.; Shen, Changyu; Yeh, Robert W.] Harvard Med Sch, 185 Pilgrim Rd, Boston, MA 02215 USA; [Maddox, Karen E. Joynt] Washington Univ, Sch Med, Dept Med Cardiovasc, St Louis, MO 63110 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Washington University (WUSTL)	Wadhera, RK (corresponding author), Beth Israel Deaconess Med, Div Cardiol, Richard A & Susan F Smith Ctr Outcomes Res Cardio, 185 Pilgrim Rd, Boston, MA 02215 USA.; Wadhera, RK (corresponding author), Harvard Med Sch, 185 Pilgrim Rd, Boston, MA 02215 USA.	rwadhera@bidmc.harvard.edu	Yeh, Robert/AAJ-3463-2020	Wadhera, Rishi/0000-0003-1089-3896	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL143421, K23HL148525, R01HL136708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG060935] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 2010, EQ EXC LIB NHS; [Anonymous], 2017, PRIC FRAM AUSTR PUBL; [Anonymous], 2019, MED CLAIMS PROCESS B; Dharmarajan K, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j2616; Fonarow GC, 2018, JAMA-J AM MED ASSOC, V320, P2539, DOI 10.1001/jama.2018.19325; Fonarow GC, 2017, J AM COLL CARDIOL, V70, P1931, DOI 10.1016/j.jacc.2017.08.046; Gupta A, 2018, JACC-HEART FAIL, V6, P607, DOI 10.1016/j.jchf.2018.02.012; Gupta A, 2018, EUR J HEART FAIL, V20, P1169, DOI 10.1002/ejhf.1212; Gupta A, 2018, JAMA CARDIOL, V3, P44, DOI 10.1001/jamacardio.2017.4265; Huckfeldt P, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0634; Huckfeldt P, 2018, J AM COLL CARDIOL, V72, P2539, DOI 10.1016/j.jacc.2018.08.2174; Ibrahim AM, 2018, JAMA INTERN MED, V178, P290, DOI 10.1001/jamainternmed.2017.6148; Jha AK, 2018, JAMA-J AM MED ASSOC, V319, P431, DOI 10.1001/jama.2017.21623; Jha AK, 2015, JAMA-J AM MED ASSOC, V314, P1681, DOI 10.1001/jama.2015.13254; Joynt KE, 2012, NEW ENGL J MED, V366, P1366, DOI 10.1056/NEJMp1201598; Kangovi S, 2015, J HOSP MED, V10, P718, DOI 10.1002/jhm.2436; Kristensen SR, 2015, HEALTH POLICY, V119, P264, DOI 10.1016/j.healthpol.2014.12.009; Obermeyer Z, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j239; Ody C, 2019, HEALTH AFFAIR, V38, P36, DOI 10.1377/hlthaff.2018.05178; Pandey A, 2017, JAMA CARDIOL, V2, P723, DOI 10.1001/jamacardio.2017.1143; Pandey A, 2016, JACC-HEART FAIL, V4, P935, DOI 10.1016/j.jchf.2016.07.003; Ross Michael A, 2012, Crit Pathw Cardiol, V11, P128; Sheehy AM, 2013, JAMA INTERN MED, V173, P1991, DOI 10.1001/jamainternmed.2013.8185; Tsugawa Y, 2019, JAMA INTERN MED, V179, P1287, DOI 10.1001/jamainternmed.2019.1005; Venkatesh AK, 2016, MED CARE, V55, P1070, DOI 10.1097/MLR.0000000000000601; Wadhera RK, 2019, NEW ENGL J MED, V380, P2289, DOI 10.1056/NEJMp1901225; Wadhera RK, 2018, JAMA-J AM MED ASSOC, V320, P2542, DOI 10.1001/jama.2018.19232; Wadhera RK, 2018, NEW ENGL J MED, V379, P2193, DOI 10.1056/NEJMp1806260; Wasfy JH, 2017, ANN INTERN MED, V166, P324, DOI 10.7326/M16-0185	29	42	42	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 12	2019	366								l4563	10.1136/bmj.l4563	http://dx.doi.org/10.1136/bmj.l4563			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IS5WH	31405902	Green Published, hybrid			2023-01-03	WOS:000482223100001
J	Kansiime, S; Mwesigire, D; Mugerwa, H				Kansiime, Sheila; Mwesigire, Doris; Mugerwa, Henry			Prevalence of non-communicable diseases among HIV positive patients on antiretroviral therapy at joint clinical research centre, Lubowa, Uganda	PLOS ONE			English	Article								Introduction Antiretroviral therapy (ART) has changed the course of HIV/AIDs by enabling patients to live longer, raising concern of the co-existence of HIV with other chronic illnesses, notably non-communicable diseases (NCDs). NCDs are on the rise in developing countries and evidence shows higher occurrence among people living with HIV (PLHIV). In Uganda, the burden of NCDs among PLHIV remains largely unquantified. Objective To determine the prevalence of hypertension, osteoporosis, diabetes mellitus, renal impairment, asthma, cardiomyopathy and multi-morbidity among HIV positive patients, receiving Anti-Retroviral Therapy at Joint Clinical Research Centre, Lubowa, Uganda. Methods This was a cross-sectional study conducted among 387 systematically sampled patients, receiving ART at the Joint Clinical Research Centre, Lubowa, between March and April 2017. The study used data extracted from routine care patient files to identify individuals with non-communicable diseases. Prevalence of the NCDs was estimated and reported with 95% confidence intervals. Prevalence was also reported at various levels of socio-demographic, behavioural and clinical factors. Results The overall prevalence of having at least one NCD was 20.7% (95% CI: 16.7-24.5). The prevalence of hypertension was 12.4% (95% CI: 9.1-15.7), osteoporosis 6.5% (95% CI: 4.0-8.9), diabetes mellitus 4.7% (95% CI: 2.6-6.8), renal impairment 1.6% (95% CI: 0.3-2.8), asthma 1.6% (95% CI: 0.3-2.8), and cardiomyopathy 1.3% (95% CI: 0.2-2.4). Prevalence of multi-morbidity was 4.7% (95% CI: 2.6-6.8). Prevalence was significantly higher among older participants, widowed participants and individuals with an opportunistic infection. Conclusion Non-communicable diseases are common among people living with HIV. There is need to encourage early diagnosis and treatment of non-communicable diseases in PLHIV in Uganda.	[Kansiime, Sheila; Mwesigire, Doris] Makerere Univ, Coll Hlth Sci, Kampala, Uganda; [Kansiime, Sheila] MRC UVRI Uganda Res Unit AIDS, Entebbe, Uganda; [Mugerwa, Henry] Joint Clin Res Ctr, Luboowa, Uganda	Makerere University	Kansiime, S (corresponding author), Makerere Univ, Coll Hlth Sci, Kampala, Uganda.; Kansiime, S (corresponding author), MRC UVRI Uganda Res Unit AIDS, Entebbe, Uganda.	Kansiimesheila@yahoo.com		Kansiime, Sheila/0000-0003-3700-1501	NIMH NIH HHS [R25 MH064712, R25 MH123256] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alvarez E, 2016, CURR OPIN HIV AIDS, V11, P268, DOI 10.1097/COH.0000000000000269; Cailhol J, 2011, BMC NEPHROL, V12, DOI 10.1186/1471-2369-12-40; CDC, 2013, BACKGR BRIEF PREV BE; Dimala CA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148100; Edwards J. K. B., 2015, T ROYAL SOC TROPICAL; Haregu T. N., 2012, EPIDEMIOLOGY COMORBI, V2; Hernandez-Romieu, 2016, IS DIABETES PREVALEN; Isa SE, 2016, CLIN INFECT DIS, V63, P830, DOI 10.1093/cid/ciw381; Kavishe B, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0357-9; Kotwani P, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1151; Kwarisiima D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156309; Magafu MGMD, 2013, PAN AFR MED J, V16, DOI 10.11604/pamj.2013.16.84.2831; Magodoro Itai M, 2016, BMC Res Notes, V9, P379, DOI 10.1186/s13104-016-2187-z; Musoke D., 2006, UGANDAS HIV RESPONSE; Narayan K, 2014, HIV NONCOMMUNICABLE, DOI [10.1097/QAI.0000000000000267, DOI 10.1097/QAI.0000000000000267]; Onyia, 2014, PREVALENCE COMORBIDI; Struik GM, 2011, INT J STD AIDS, V22, P457, DOI 10.1258/ijsa.2011.010521; Uganda M. o. H., 2014, HIV AIDS UG COUNTR P; UNODC, 2016, HIV AIDS E AFR; Wandera B., 2014, LOW BONE MINERAL DEN; World_Health_Organization, 2018, 2018 NCVRW RES GUID	21	14	14	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2019	14	8							e0221022	10.1371/journal.pone.0221022	http://dx.doi.org/10.1371/journal.pone.0221022			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW5FL	31398244	Green Submitted, Green Published, gold			2023-01-03	WOS:000485004000042
J	Anderson, DJ				Anderson, Deborah J.			Population and the Environment - Time for Another Contraception Revolution	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								As the world population continues to grow, pressures on the environment will become more critical. The time seems ripe for another contraception revolution to provide options for the diverse populations that are not currently being served by modern contraception.	[Anderson, Deborah J.] Boston Univ, Sch Med, Dept Obstet & Gynecol, Boston, MA 02215 USA; [Anderson, Deborah J.] Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; [Anderson, Deborah J.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Boston University; Boston University; Boston University	Anderson, DJ (corresponding author), Boston Univ, Sch Med, Dept Obstet & Gynecol, Boston, MA 02215 USA.; Anderson, DJ (corresponding author), Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA.; Anderson, DJ (corresponding author), Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.							Bongaarts J, 2018, SCIENCE, V361, P650, DOI 10.1126/science.aat8680; Crist E, 2017, SCIENCE, V356, P260, DOI 10.1126/science.aal2011; Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services, 2019, IPBES UN GLOB ASS RE; Universal Ecological Fund, 2018, EC CAS CLIM ACT US	4	15	15	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 1	2019	381	5					397	399		10.1056/NEJMp1906733	http://dx.doi.org/10.1056/NEJMp1906733			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IM5WH	31365795				2023-01-03	WOS:000478064200002
J	Tarazanova, M; Huppertz, T; Starrenburg, M; Todt, T; van Hijum, S; Kok, J; Bachmann, H				Tarazanova, Mariya; Huppertz, Thom; Starrenburg, Marjo; Todt, Tilman; van Hijum, Sacha; Kok, Jan; Bachmann, Herwig			Transcriptional response of Lactococcus lactis during bacterial emulsification	PLOS ONE			English	Article							CELL-SURFACE PROPERTIES; GRAM-POSITIVE BACTERIA; ACID BACTERIA; WATER EMULSIONS; MICROBIAL-CELLS; ADHESION; FOOD; CODY; PARTICLES; PROTEINS	Microbial surface properties are important for interactions with the environment in which cells reside. Surface properties of lactic acid bacteria significantly vary and some strains can form strong emulsions when mixed with a hydrocarbon. Lactococcus lactis NCDO712 forms oil-in-water emulsions upon mixing of a cell suspension with petroleum. In the emulsion the bacteria locate at the oil-water interphase which is consistent with Pickering stabilization. Cells of strain NCDO712 mixed with sunflower seed oil did not stabilize the oil droplets. This study shows that the addition of either ethanol or ammonium sulfate led to cell aggregation, which subsequently allowed stabilizing oil-in-water emulsions. From this, we conclude that bacterial cell aggregation is important for emulsion droplet stabilization. To determine how bacterial emulsification influences the microbial transcriptome RNAseq analysis was performed on lactococci taken from the oil-water interphase. In comparison to cells in suspension 72 genes were significantly differentially expressed with a more than 4-fold difference. The majority of these genes encode proteins involved in transport processes and the metabolism of amino acids, carbohydrates and ions. Especially the proportion of genes belonging to the CodY regulon was high. Our results also point out that in a complex environment such as food fermentations a heterogeneous response of microbes might be caused by microbe-matrix interactions. In addition, microdroplet technologies are increasingly used in research. The understanding of interactions between bacterial cells and oil-water interphases is of importance for conducting and interpreting such experiments.	[Tarazanova, Mariya; Huppertz, Thom; Starrenburg, Marjo; van Hijum, Sacha; Kok, Jan; Bachmann, Herwig] TI Food & Nutr, Wageningen, Netherlands; [Tarazanova, Mariya; Huppertz, Thom; Starrenburg, Marjo; van Hijum, Sacha; Bachmann, Herwig] NIZO, Ede, Netherlands; [Tarazanova, Mariya; Starrenburg, Marjo; Kok, Jan] Univ Groningen, Mol Genet, Groningen, Netherlands; [Todt, Tilman; van Hijum, Sacha] Radboud Univ Nijmegen, Med Ctr CMBI, Geert Grootepl, Nijmegen, Netherlands; [Todt, Tilman] Univ Appl Sci, PGL, HAN, Nijmegen, Netherlands; [Huppertz, Thom] FrieslandCampina, Amersfoort, Netherlands	Top Institute Food & Nutrition; NIZO Food Research; University of Groningen; Radboud University Nijmegen	Bachmann, H (corresponding author), TI Food & Nutr, Wageningen, Netherlands.; Bachmann, H (corresponding author), NIZO, Ede, Netherlands.	Herwig.Bachmann@nizo.com	Bachmann, Herwig/ABE-6301-2021	Bachmann, Herwig/0000-0002-8224-0993	Top Institute Food & Nutrition (TIFN, Wageningen, The Netherlands) [FF001]	Top Institute Food & Nutrition (TIFN, Wageningen, The Netherlands)	This study was funded by the Top Institute Food & Nutrition (TIFN, Program FF001, Wageningen, The Netherlands). MS, TH, SvH and HB are also employed by NIZO Food Research. TIFN provided support in the form of salaries for authors MT, MS, TH, SvH, JK and HB. The specific roles of these authors are articulated in the ' author contributions' section. Neither NIZO food research nor TIFN had an additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	An YH, 1998, J BIOMED MATER RES, V43, P338, DOI 10.1002/(SICI)1097-4636(199823)43:3<338::AID-JBM16>3.0.CO;2-B; ATLAS RM, 1991, J CHEM TECHNOL BIOT, V52, P149; Azeredo J, 1999, COLLOID SURFACE B, V14, P141, DOI 10.1016/S0927-7765(99)00031-4; Bachmann H, 2013, P NATL ACAD SCI USA, V110, P14302, DOI 10.1073/pnas.1308523110; Bayoudh S, 2009, COLLOID SURFACE B, V73, P1, DOI 10.1016/j.colsurfb.2009.04.030; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boonaert CJP, 2000, APPL ENVIRON MICROB, V66, P2548, DOI 10.1128/AEM.66.6.2548-2554.2000; Burgain J, 2014, ADV COLLOID INTERFAC, V213, P21, DOI 10.1016/j.cis.2014.09.005; Burgain J, 2015, COLLOID SURFACE B, V134, P332, DOI 10.1016/j.colsurfb.2015.06.068; Chambellon E, 2003, APPL ENVIRON MICROB, V69, P3061, DOI 10.1128/AEM.69.6.3061-3068.2003; Chapot-Chartier MP, 2014, MICROB CELL FACT, V13, DOI 10.1186/1475-2859-13-S1-S9; Das N, 2011, BIOTECHNOL RES INT, V2011, P1, DOI [10.4061/2011/941810, DOI 10.4061/2011/941810]; Decho AW, 2000, CONT SHELF RES, V20, P1257, DOI 10.1016/S0278-4343(00)00022-4; Delcour J, 1999, ANTON LEEUW INT J G, V76, P159, DOI 10.1023/A:1002089722581; den Hengst CD, 2006, J BACTERIOL, V188, P3280, DOI 10.1128/JB.188.9.3280-3289.2006; den Hengst CD, 2005, J BIOL CHEM, V280, P34332, DOI 10.1074/jbc.M502349200; den Hengst CD, 2005, J BACTERIOL, V187, P512, DOI 10.1128/JB.187.2.512-521.2005; Dickinson E, 2010, CURR OPIN COLLOID IN, V15, P40, DOI 10.1016/j.cocis.2009.11.001; Donlan RM, 2002, EMERG INFECT DIS, V8, P881, DOI 10.3201/eid0809.020063; Dorobantu LS, 2004, APPL ENVIRON MICROB, V70, P6333, DOI 10.1128/AEM.70.10.6333-6336.2004; Ercan O, 2015, APPL ENVIRON MICROB, V81, P2554, DOI 10.1128/AEM.03748-14; Feehily C, 2013, J APPL MICROBIOL, V114, P11, DOI 10.1111/j.1365-2672.2012.05434.x; Firoozmand H, 2016, FOOD RES INT, V81, P66, DOI 10.1016/j.foodres.2015.10.018; Firoozmand H, 2014, FOOD HYDROCOLLOID, V42, P204, DOI 10.1016/j.foodhyd.2014.04.040; Garrett TR, 2008, PROG NAT SCI-MATER, V18, P1049, DOI 10.1016/j.pnsc.2008.04.001; Guedon E, 2005, MICROBIOL-SGM, V151, P3895, DOI 10.1099/mic.0.28186-0; Heeres AS, 2014, TRENDS BIOTECHNOL, V32, P221, DOI 10.1016/j.tibtech.2014.02.002; Hermansson M, 1999, COLLOID SURFACE B, V14, P105, DOI 10.1016/S0927-7765(99)00029-6; Jeanson S, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01284; JENSEN PR, 1993, APPL ENVIRON MICROB, V59, P4363, DOI 10.1128/AEM.59.12.4363-4366.1993; Kaczorek E, 2011, BIODEGRADATION, V22, P359, DOI 10.1007/s10532-010-9406-4; Kankainen M, 2009, P NATL ACAD SCI USA, V106, P17193, DOI 10.1073/pnas.0908876106; Katsikogianni M, 2004, Eur Cell Mater, V8, P37; Larsen N, 2007, INT J FOOD MICROBIOL, V114, P113, DOI 10.1016/j.ijfoodmicro.2006.10.033; Le-Tien C, 2004, BIOTECHNOL APPL BIOC, V39, P347, DOI 10.1042/BA20030158; Leroy F, 2004, TRENDS FOOD SCI TECH, V15, P67, DOI 10.1016/j.tifs.2003.09.004; LIN L, 1995, COLLOID SURFACE B, V5, P127, DOI 10.1016/0927-7765(95)01189-P; Ly MH, 2008, FOOD HYDROCOLLOID, V22, P742, DOI 10.1016/j.foodhyd.2007.03.001; Ly MH, 2006, COLLOID SURFACE B, V52, P149, DOI 10.1016/j.colsurfb.2006.04.015; Ly MH, 2006, INT J FOOD MICROBIOL, V112, P26, DOI 10.1016/j.ijfoodmicro.2006.05.022; Ly-Chatain MH, 2010, FOOD RES INT, V43, P1594, DOI 10.1016/j.foodres.2010.04.019; Mandlik A, 2008, TRENDS MICROBIOL, V16, P33, DOI 10.1016/j.tim.2007.10.010; Millsap KW, 1996, J MICROBIOL METH, V27, P239, DOI 10.1016/S0167-7012(96)00937-2; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; Neu T R, 1990, J Biomater Appl, V5, P107, DOI 10.1177/088532829000500203; Neu TR, 1996, MICROBIOL REV, V60, P151, DOI 10.1128/MMBR.60.1.151-166.1996; Ong YL, 1999, LANGMUIR, V15, P2719, DOI 10.1021/la981104e; Pelletier C, 1997, APPL ENVIRON MICROB, V63, P1725, DOI 10.1128/AEM.63.5.1725-1731.1997; Poortinga AT, 2002, SURF SCI REP, V47, P3, DOI 10.1016/S0167-5729(02)00032-8; Price CE, 2019, BMC EVOL BIOL, V19, DOI 10.1186/s12862-018-1331-x; Rayner M, 2014, COLLOID SURFACE A, V458, P48, DOI 10.1016/j.colsurfa.2014.03.053; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; ROSENBERG M, 1980, FEMS MICROBIOL LETT, V9, P29, DOI 10.1016/0378-1097(80)90106-8; ROSENBERG M, 1984, FEMS MICROBIOL LETT, V22, P289; Rutter PR, MICROBIAL ADHESION A, DOI [10.1016/j.colsurfb.2009.04.030, DOI 10.1016/J.COLSURFB.2009.04.030]; STARRENBURG MJC, 1991, APPL ENVIRON MICROB, V57, P3535, DOI 10.1128/AEM.57.12.3535-3540.1991; Tadros T., 2013, EMULSION FORMATION S, P1; Tarazanova M, 2018, MICROB BIOTECHNOL, V11, P770, DOI 10.1111/1751-7915.13278; Tarazanova M, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01691; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; van der Mei HC, 2001, J COLLOID INTERF SCI, V241, P327, DOI 10.1006/jcis.2001.7768; VANLOOSDRECHT MCM, 1987, APPL ENVIRON MICROB, V53, P1893, DOI 10.1128/AEM.53.8.1893-1897.1987; VANLOOSDRECHT MCM, 1987, APPL ENVIRON MICROB, V53, P1898, DOI 10.1128/AEM.53.8.1898-1901.1987; Vestergaard M, 2017, MBIO, V8, P1, DOI DOI 10.1128/MBI0.00526-17; Wongkongkatep P, 2012, LANGMUIR, V28, P5729, DOI 10.1021/la300660x; Xiao J, 2016, TRENDS FOOD SCI TECH, V55, P48, DOI 10.1016/j.tifs.2016.05.010; Yvon M, 2011, INT DAIRY J, V21, P335, DOI 10.1016/j.idairyj.2010.11.010	67	3	2	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2019	14	7							e0220048	10.1371/journal.pone.0220048	http://dx.doi.org/10.1371/journal.pone.0220048			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4VN	31344087	Green Submitted, gold, Green Published			2023-01-03	WOS:000484977900050
J	Muntingh, ADT; Hoogendoorn, AW; Van Schaik, DJF; Van Straten, A; Stolk, EA; Van Balkom, AJLM; Batelaan, NM				Muntingh, Anna D. T.; Hoogendoorn, Adriaan W.; Van Schaik, Digna J. F.; Van Straten, Annemieke; Stolk, Elly A.; Van Balkom, Anton J. L. M.; Batelaan, Neeltje M.			Patient preferences for a guided self-help programme to prevent relapse in anxiety or depression: A discrete choice experiment	PLOS ONE			English	Article							COGNITIVE-BEHAVIORAL THERAPY; MENTAL-DISORDERS; HEALTH-CARE; RECURRENCE; IMPACT; INTERVENTION; PREVALENCE; STRATEGIES; INVENTORY; CHECKLIST	Background Anxiety and depressive disorders are increasingly being viewed as chronic conditions with fluctuating symptom levels. Relapse prevention programmes are needed to increase self-management and prevent relapse. Fine-tuning relapse prevention programmes to the needs of patients may increase uptake and effectiveness. Materials and methods A discrete choice experiment (DCE) was conducted amongst patients with a partially or fully remitted anxiety or depressive disorder. Patients were presented 20 choice tasks with two hypothetical treatment scenarios for relapse prevention, plus a "no treatment" option. Each treatment scenario was based on seven attributes of a hypothetical but realistic relapse prevention programme. Attributes considered professional contact frequency, treatment type, delivery mode, programme flexibility, a personal relapse prevention plan, time investment and effectiveness. Choice models were estimated to analyse the data. Results A total of 109 patients with a partially or fully remitted anxiety or depressive disorder completed the DCE. Attributes with the strongest impact on choice were high effectiveness, regular contact with a professional, low time investment and the inclusion of a personal prevention plan. A high heterogeneity in preferences was observed, related to both clinical and demographic characteristics: for example, a higher number of previous treatment episodes was related to a preference for a higher frequency of contact with a professional, while younger age was related to a stronger preference for high effectiveness. Conclusions This study using a DCE provides insights into preferences for a relapse prevention programme for anxiety and depressive disorders that can be used to guide the development of such a programme.	[Muntingh, Anna D. T.; Van Schaik, Digna J. F.; Van Straten, Annemieke; Van Balkom, Anton J. L. M.; Batelaan, Neeltje M.] Vrije Univ, Amsterdam UMC, Amsterdam Publ Hlth Res Inst, Psychiat, Amsterdam, Netherlands; [Muntingh, Anna D. T.; Hoogendoorn, Adriaan W.; Van Schaik, Digna J. F.; Van Straten, Annemieke; Van Balkom, Anton J. L. M.; Batelaan, Neeltje M.] GGZ Geest Specialised Mental Hlth Care, Amsterdam, Netherlands; [Van Straten, Annemieke] Vrije Univ Amsterdam, Fac Behav & Movement Sci, Amsterdam, Netherlands; [Stolk, Elly A.] EuroQol Off, Rotterdam, Netherlands	University of Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Muntingh, ADT (corresponding author), Vrije Univ, Amsterdam UMC, Amsterdam Publ Hlth Res Inst, Psychiat, Amsterdam, Netherlands.; Muntingh, ADT (corresponding author), GGZ Geest Specialised Mental Hlth Care, Amsterdam, Netherlands.	a.muntingh@ggzingeest.nl	van Straten, Annemieke/P-8495-2019	van Straten, Annemieke/0000-0001-6875-2215; Batelaan, Neeltje/0000-0001-6444-3781; van Schaik, Anneke/0000-0002-7169-9600	Netherlands Organisation for Health Research and Development (ZonMw) [430000003]	Netherlands Organisation for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development)	Funding was received from the Netherlands Organisation for Health Research and Development (ZonMw) (projectnr. 430000003). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alonso J, 2004, ACTA PSYCHIAT SCAND, V109, P21; Andersen P, 2016, BEHAV COGN PSYCHOTH, V44, P673, DOI 10.1017/S1352465816000229; [Anonymous], 2011, GEN ANXIETY DISORDER; [Anonymous], 2013, MULTIDISCIPLINAIRE R; Apolinario-Hagen J, 2017, JMIR MENT HEALTH, V4, DOI 10.2196/mental.6186; Barratt A, 2008, PATIENT EDUC COUNS, V73, P407, DOI 10.1016/j.pec.2008.07.054; Batelaan NM, 2010, ACTA PSYCHIAT SCAND, V122, P56, DOI 10.1111/j.1600-0447.2009.01488.x; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Biesheuvel-Leliefeld KEM, 2015, J AFFECT DISORDERS, V174, P400, DOI 10.1016/j.jad.2014.12.016; Bockting CLH, 2005, J CONSULT CLIN PSYCH, V73, P647, DOI 10.1037/0022-006X.73.4.647; Bolier L, 2013, J MED INTERNET RES, V15, P209, DOI 10.2196/jmir.2603; Bridges JFP, 2011, VALUE HEALTH, V14, P403, DOI 10.1016/j.jval.2010.11.013; Casey LM, 2013, CYBERPSYCH BEH SOC N, V16, P593, DOI 10.1089/cyber.2012.0515; ChoiceMetrics, 2014, NGEN 1 1 2 US MAN RE; Cuijpers P, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-181; de Bekker-Grob EW, 2015, PATIENT, V8, P373, DOI 10.1007/s40271-015-0118-z; de Bekker-Grob EW, 2012, HEALTH ECON, V21, P145, DOI 10.1002/hec.1697; de Graaf LE, 2009, BRIT J PSYCHIAT, V195, P73, DOI 10.1192/bjp.bp.108.054429; de Graaf LE, 2009, J AFFECT; de Jonge M, 2015, BMC PSYCHIATRY, V15, DOI 10.1186/s12888-015-0508-8; FRANK E, 1991, ARCH GEN PSYCHIAT, V48, P851, DOI 10.1001/archpsyc.1991.01810330075011; Godfrin KA, 2010, BEHAV RES THER, V48, P738, DOI 10.1016/j.brat.2010.04.006; Guidi J, 2011, PSYCHOL MED, V41, P321, DOI 10.1017/S0033291710000826; Hardeveld F, 2013, J AFFECT DISORDERS, V147, P225, DOI 10.1016/j.jad.2012.11.008; Hendriks SM, 2015, J AFFECT DISORDERS, V178, P121, DOI 10.1016/j.jad.2015.03.004; Hensher DA, 2015, APPL CHOICE ANAL, V2, DOI [10.1007/9781316136232, DOI 10.1007/9781316136232]; HISS H, 1994, J CONSULT CLIN PSYCH, V62, P801, DOI 10.1037/0022-006X.62.4.801; Hoek W, 2012, EUR CHILD ADOLES PSY, V21, P593, DOI 10.1007/s00787-012-0295-4; Hollandare F, 2013, BEHAV RES THER, V51, P719, DOI 10.1016/j.brat.2013.08.002; Johansson R, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-268; Johnson FR, 2007, MED CARE, V45, P545, DOI 10.1097/MLR.0b013e318040ad90; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kok G, 2015, PSYCHOTHER PSYCHOSOM, V84, P90, DOI 10.1159/000369469; Lancsar E, 2008, PHARMACOECONOMICS, V26, P661, DOI 10.2165/00019053-200826080-00004; Lancsar E, 2007, SOC SCI MED, V64, P1738, DOI 10.1016/j.socscimed.2006.12.007; Lindhiem O, 2014, CLIN PSYCHOL REV, V34, P506, DOI 10.1016/j.cpr.2014.06.002; McKay D, 1997, BEHAV RES THER, V35, P367, DOI 10.1016/S0005-7967(96)00105-2; Newby JM, 2016, J AFFECT DISORDERS, V199, P30, DOI 10.1016/j.jad.2016.03.018; Penninx BWJH, 2011, J AFFECT DISORDERS, V133, P76, DOI 10.1016/j.jad.2011.03.027; Pots WTM, 2016, BRIT J PSYCHIAT, V208, P69, DOI 10.1192/bjp.bp.114.146068; REISS S, 1986, BEHAV RES THER, V24, P1, DOI 10.1016/0005-7967(86)90143-9; Rhebergen D, 2011, ACTA PSYCHIAT SCAND, V123, P297, DOI 10.1111/j.1600-0447.2011.01677.x; Ride J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156629; Rush AJ, 1996, PSYCHOL MED, V26, P477, DOI 10.1017/S0033291700035558; Rycroft-Malone J, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-62; Scholten WD, 2018, REASONS NONPAR UNPUB; Scholten WD, 2018, PSYCHOTHER PSYCHOSOM, V87, P240, DOI 10.1159/000489498; Scholten WD, 2016, J AFFECT DISORDERS, V195, P185, DOI 10.1016/j.jad.2016.02.025; Scholten WD, 2013, PSYCHOTHER PSYCHOSOM, V82, P399, DOI 10.1159/000350450; Scholten WD, 2013, J AFFECT DISORDERS, V147, P180, DOI 10.1016/j.jad.2012.10.031; SWAIT J, 1993, J MARKETING RES, V30, P305, DOI 10.2307/3172883; ten Have M, 2010, SOC PSYCH PSYCH EPID, V45, P153, DOI 10.1007/s00127-009-0050-4; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Trevena LJ, 2006, J EVAL CLIN PRACT, V12, P13, DOI 10.1111/j.1365-2753.2005.00596.x; Ustun B., 2010, MEASURING HLTH DISAB; van Beljouw I, 2010, PSYCHIAT SERV, V61, P250, DOI 10.1176/ps.2010.61.3.250; Van der Maat M.J.P., 2010, EIGEN RISICO ZORGVER; van der Weele GM, 2012, INT PSYCHOGERIATR, V24, P270, DOI 10.1017/S1041610211001530; van Schaik DJF, 2004, GEN HOSP PSYCHIAT, V26, P184, DOI 10.1016/j.genhosppsych.2003.12.001; Warmerdam L, 2008, J MED INTERNET RES, V10, DOI [10.2196/jmir.1094, 10.2196/jmir.954]; Wright J, 2000, J ANXIETY DISORD, V14, P483, DOI 10.1016/S0887-6185(00)00035-9; Yap MBH, 2012, J AFFECT DISORDERS, V136, P940, DOI 10.1016/j.jad.2011.09.003	62	4	4	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2019	14	7							e0219588	10.1371/journal.pone.0219588	http://dx.doi.org/10.1371/journal.pone.0219588			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IS7PC	31318918	gold, Green Published, Green Submitted			2023-01-03	WOS:000482340700033
J	Li, JL; Chattopadhyay, K; Xu, M; Chen, YS; Hu, FF; Wang, XZ; Li, L				Li, Jialin; Chattopadhyay, Kaushik; Xu, Miao; Chen, Yanshu; Hu, Fangfang; Wang, Xingzhen; Li, Li			Prevalence and predictors of polypharmacy prescription among type 2 diabetes patients at a tertiary care department in Ningbo, China: A retrospective database study	PLOS ONE			English	Article							ADVERSE DRUG-REACTIONS; OLDER-ADULTS; RISK; PHARMACOKINETICS; COMPLICATIONS; GLYBURIDE; DIAGNOSIS; COST; AGE	Objectives To determine the prevalence of polypharmacy prescription among type 2 diabetes (T2DM) patients at a tertiary care department in Ningbo, China, and to determine factors that independently predict this polypharmacy prescription. Methods A retrospective cross-sectional study was conducted using an existing computerised medical records database. This database was screened from 2012 to 2017 for adult patients with T2DM and parameters like prescribed medicines and socio-demographic, behavioural and other medical information. Polypharmacy prescription was defined as the simultaneous prescription of. 5 medicines by the clinician at the time of discharge for daily usage by the patient as part of his/her long-term treatment plan. Results The study inclusion criteria were satisfied by 3370 T2DM patients. Over a 5-year period, 72.2% (n = 2432) of T2DM patients were prescribed polypharmacy. On an average, eight medicines were prescribed to them. The odds of polypharmacy prescription increased with patients' age (18-39 years: 1; 40-59 years: OR 1.86, 95% CI 1.28-2.71; and >= 60 years: 2.42, 1.65-3.55), duration of T2DM (<= 1 year: 1; > 5-10 years: 1.70, 1.10-2.62; and > 10 years: 2.55, 1.68-3.89), and length of hospital stay (<= 5 days: 1; > 5-10 days: 2.43, 1.86-3.17; and > 10 days: 2.99, 2.24-3.99), and were higher in those with poor blood glucose level (2.09, 1.67-2.62) and with comorbidities like other endocrine, nutritional and metabolic diseases (2.24, 1.76-2.85), circulatory system diseases (4.35, 3.62-5.23), skin and subcutaneous tissue diseases (1.64, 1.04-2.59), and musculoskeletal system and connective tissue diseases (1.61, 1.27-2.03). The odds of polypharmacy prescription were lower in those with comorbidities like neoplasms (0.51, 0.36-0.70) and during pregnancy, childbirth and the puerperium (0.06, 0.01-0.49). Conclusions Around three fourth of T2DM patients at the tertiary care department were prescribed polypharmacy, and the predictors were identified. The study findings could be taken into consideration in future interventional studies aimed at supporting medicines optimisation (and deprescribing) among these patients.	[Li, Jialin; Xu, Miao; Chen, Yanshu; Hu, Fangfang; Wang, Xingzhen; Li, Li] Ningbo First Hosp, Dept Endocrinol & Metab, Ningbo, Zhejiang, Peoples R China; [Chattopadhyay, Kaushik] Univ Nottingham, Sch Med, Div Epidemiol & Publ Hlth, Nottingham, England	University of Nottingham	Li, L (corresponding author), Ningbo First Hosp, Dept Endocrinol & Metab, Ningbo, Zhejiang, Peoples R China.	lilyningbo@163.com	Li, Jialin/B-3046-2018; li, jia/GVT-7587-2022	Li, Jialin/0000-0001-6930-9530; 				Abolhassani N, 2017, EUR J CLIN PHARMACOL, V73, P1187, DOI 10.1007/s00228-017-2288-1; Alwhaibi M, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020852; Alzner R, 2016, WIEN MED WOCHENSCHR, V166, P161, DOI 10.1007/s10354-015-0428-8; [Anonymous], INT STAT CLASS DIS; Bauer S, 2014, DIABETIC MED, V31, P1078, DOI 10.1111/dme.12497; Blanco-Reina E, 2015, EUR J CLIN PHARMACOL, V71, P199, DOI 10.1007/s00228-014-1780-0; Chinese Diabetes Society, 2018, CHIN J DIABETES, V10, P4; Chinese Diabetes Society, 2014, CHIN J ENDOCRINOL ME, V30, P893, DOI [10.3760/cma.j.issn.1000-6699.2014.10.020, DOI 10.3760/CMA.J.ISSN.1000-6699.2014.10.020]; da Silva Córralo Vanessa, 2018, Rev. salud pública, V20, P366, DOI [10.15446/rsap.v20n3.50304, 10.15446/rsap.V20n3.50304]; Doan J, 2013, ANN PHARMACOTHER, V47, P324, DOI 10.1345/aph.1R621; Dong LF, 2010, J EPIDEMIOL COMMUN H, V64, P549, DOI 10.1136/jech.2008.085415; Field TS, 2004, J AM GERIATR SOC, V52, P1349, DOI 10.1111/j.1532-5415.2004.52367.x; Gibson TB, 2005, AM J MANAG CARE, V11, P730; Gnjidic D, 2012, J CLIN EPIDEMIOL, V65, P989, DOI 10.1016/j.jclinepi.2012.02.018; Goldberg RM, 1996, AM J EMERG MED, V14, P447, DOI 10.1016/S0735-6757(96)90147-3; Grant RW, 2003, DIABETES CARE, V26, P1408, DOI 10.2337/diacare.26.5.1408; Han CY, 2017, J DIABETES, V9, P450, DOI 10.1111/1753-0407.12440; Harugeri A, 2010, AM J GERIATR PHARMAC, V8, P271, DOI 10.1016/j.amjopharm.2010.06.004; Hirota T, 2015, EXPERT OPIN DRUG MET, V11, P1435, DOI 10.1517/17425255.2015.1056149; Huang DJ, 2016, EXP CLIN ENDOCR DIAB, V124, P5, DOI 10.1055/s-0035-1565059; Indu Rania, 2018, Perspect Clin Res, V9, P139, DOI 10.4103/picr.PICR_81_17; International Diabetes Federation, 2017, DIABETES ATLAS, Veighth; Ito S, 2016, CLIN PHARMACOL THER, V100, P8, DOI 10.1002/cpt.383; Jyrkka J, 2011, PHARMACOEPIDEM DR S, V20, P514, DOI 10.1002/pds.2116; Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224; Klotz U, 2009, DRUG METAB REV, V41, P67, DOI 10.1080/03602530902722679; Kubacka RT, 1996, ANN PHARMACOTHER, V30, P20, DOI 10.1177/106002809603000103; Leslie TA, 2016, CURR PROBL DERMATOL, V50, P192, DOI 10.1159/000446094; Li JL, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019697; Lin W, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0333-z; Little MO, 2018, CURR OPIN CLIN NUTR, V21, P4, DOI 10.1097/MCO.0000000000000425; Lu J, 2014, INTERN MED J, V44, P1193, DOI 10.1111/imj.12534; Makrantonaki E, 2016, REV ENDOCR METAB DIS, V17, P269, DOI 10.1007/s11154-016-9373-0; Carmona-Torres JM, 2018, J CLIN NURS, V27, P2942, DOI 10.1111/jocn.14371; Marcum ZA, 2012, J AM GERIATR SOC, V60, P34, DOI 10.1111/j.1532-5415.2011.03772.x; Marengoni A, 2014, EUR J INTERN MED, V25, P843, DOI 10.1016/j.ejim.2014.10.001; Marengoni A, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1059; Maria Garcia AL, 2015, REV MED CHILE, V143, P606, DOI 10.4067/S0034-98872015000500008; Masnoon N, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0621-2; McCracken R, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017430; Ministry of Health of the People's Republic of China, 1989, MEAS ADM HOSP GRAD; MONTIELLUQUE A, 2017, PLOS ONE, V12, DOI DOI 10.1371/JOURNAL.PONE.0171320; Muhlberg W, 1999, GERONTOLOGY, V45, P243, DOI 10.1159/000022097; Noale M, 2016, ACTA DIABETOL, V53, P323, DOI 10.1007/s00592-015-0790-4; Onoue H, 2018, J AM GERIATR SOC, V66, P2267, DOI 10.1111/jgs.15569; da Silva MRR, 2018, CIENC SAUDE COLETIVA, V23, P2565, DOI 10.1590/1413-81232018238.10222016; Rochon PA, 2017, LANCET, V389, P1778, DOI 10.1016/S0140-6736(17)31188-1; Teljeur C, 2013, EUR J GEN PRACT, V19, P17, DOI 10.3109/13814788.2012.714768; Triplitt C., 2006, DIABETES SPECTR, V19, P202, DOI [10.2337/diaspect.19.4.202, DOI 10.2337/DIASPECT.19.4.202]; Valdes-Rodriguez R, 2015, DRUG AGING, V32, P201, DOI 10.1007/s40266-015-0246-0; White JR, 2000, ENDOCRIN METAB CLIN, V29, P789, DOI 10.1016/S0889-8529(05)70164-X; Willey CJ, 2006, AM J MANAG CARE, V12, P435; Wolff JL, 2002, ARCH INTERN MED, V162, P2269, DOI 10.1001/archinte.162.20.2269; Yang M, 2015, ARCH GERONTOL GERIAT, V60, P322, DOI 10.1016/j.archger.2014.11.004; Yao DZ., 2016, MOD PRACT MED, V28, P1343; Yu Dongwei, 2011, ADVERSE DRUG REACT, V13, P114; Zoungas S, 2014, DIABETOLOGIA, V57, P2465, DOI 10.1007/s00125-014-3369-7	57	11	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2019	14	7							e0220047	10.1371/journal.pone.0220047	http://dx.doi.org/10.1371/journal.pone.0220047			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IS7LS	31314797	Green Published, gold, Green Submitted			2023-01-03	WOS:000482331900059
J	Hwang, TJ; Dusetzina, SB; Feng, J; Maini, L; Kesselheim, AS				Hwang, Thomas J.; Dusetzina, Stacie B.; Feng, Josh; Maini, Luca; Kesselheim, Aaron S.			Price Increases of Protected-Class Drugs in Medicare Part D, Relative to Inflation, 2012-2017	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter								This study characterizes price increases exceeding inflation between 2012 and 2017 for protected-class drugs (antineoplastics, antiretrovirals, antidepressants, antipsychotics, anticonvulsants, and immunosuppressants for transplant patients) that would lead to their exclusion from Medicare Part D coverage based on excessive cost under a 2018 CMS rule intended to facilitate more effective price negotiations.	[Hwang, Thomas J.] Harvard Med Sch, Boston, MA 02115 USA; [Dusetzina, Stacie B.] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN 37212 USA; [Feng, Josh] Natl Bur Econ Res, Boston, MA USA; [Maini, Luca] Univ N Carolina, Chapel Hill, NC 27515 USA; [Kesselheim, Aaron S.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Vanderbilt University; National Bureau of Economic Research; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Brigham & Women's Hospital	Kesselheim, AS (corresponding author), Harvard Med Sch, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law PORTAL, Dept Med,Brigham & Womens Hosp, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.	akesselheim@bwh.harvard.edu		Hwang, Thomas/0000-0003-0717-1497	National Institute on Aging [T32-AG000186]; Arnold Ventures, Engelberg Foundation; Harvard-MIT Center for Regulatory Science; NATIONAL INSTITUTE ON AGING [T32AG000186] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Arnold Ventures, Engelberg Foundation; Harvard-MIT Center for Regulatory Science; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Dr Feng was supported by a grant from the National Institute on Aging (T32-AG000186). Dr Kesselheim was supported by grants from Arnold Ventures, Engelberg Foundation, and the Harvard-MIT Center for Regulatory Science.	Centers for Medicare & Medicaid Services, CMS DRUG SPEND MED D; Centers for Medicare & Medicaid Services, PRESCR DRUG PLAN FOR; Centers for Medicare Medicaid Services HHS, 2018, FED REGISTER, V83, P62152; Health SSR LLC, US PRESCR BRAND NET; Medicare Payment Advisory Commission (MedPAC), 2016, REP C MED HLTH CAR D	5	18	17	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	2019	322	3					267	269		10.1001/jama.2019.7521	http://dx.doi.org/10.1001/jama.2019.7521			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IK7OO	31310287	Green Published, Bronze			2023-01-03	WOS:000476780400020
J	Chi, KN; Agarwal, N; Bjartell, A; Chung, BH; Gomes, AJPD; Given, R; Soto, AJ; Merseburger, AS; Ozguroglu, M; Uemura, H; Ye, DW; Deprince, K; Naini, V; Li, JH; Cheng, S; Yu, MK; Zhang, K; Larsen, JS; McCarthy, S; Chowdhury, S				Chi, Kim N.; Agarwal, Neeraj; Bjartell, Anders; Chung, Byung Ha; Pereira de Santana Gomes, Andrea J.; Given, Robert; Juarez Soto, Alvaro; Merseburger, Axel S.; Ozguroglu, Mustafa; Uemura, Hirotsugu; Ye, Dingwei; Deprince, Kris; Naini, Vahid; Li, Jinhui; Cheng, Shinta; Yu, Margaret K.; Zhang, Ke; Larsen, Julie S.; McCarthy, Sharon; Chowdhury, Simon		TITAN Investigators	Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; FUNCTIONAL ASSESSMENT; THERAPY; ANTIANDROGEN; DOCETAXEL; SURVIVAL	Background Apalutamide is an inhibitor of the ligand-binding domain of the androgen receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would prolong radiographic progression-free survival and overall survival as compared with placebo plus ADT among patients with metastatic, castration-sensitive prostate cancer has not been determined. Methods In this double-blind, phase 3 trial, we randomly assigned patients with metastatic, castration-sensitive prostate cancer to receive apalutamide (240 mg per day) or placebo, added to ADT. Previous treatment for localized disease and previous docetaxel therapy were allowed. The primary end points were radiographic progression-free survival and overall survival. Results A total of 525 patients were assigned to receive apalutamide plus ADT and 527 to receive placebo plus ADT. The median age was 68 years. A total of 16.4% of the patients had undergone prostatectomy or received radiotherapy for localized disease, and 10.7% had received previous docetaxel therapy; 62.7% had high-volume disease, and 37.3% had low-volume disease. At the first interim analysis, with a median of 22.7 months of follow-up, the percentage of patients with radiographic progression-free survival at 24 months was 68.2% in the apalutamide group and 47.5% in the placebo group (hazard ratio for radiographic progression or death, 0.48; 95% confidence interval [CI], 0.39 to 0.60; P<0.001). Overall survival at 24 months was also greater with apalutamide than with placebo (82.4% in the apalutamide group vs. 73.5% in the placebo group; hazard ratio for death, 0.67; 95% CI, 0.51 to 0.89; P=0.005). The frequency of grade 3 or 4 adverse events was 42.2% in the apalutamide group and 40.8% in the placebo group; rash was more common in the apalutamide group. Conclusions In this trial involving patients with metastatic, castration-sensitive prostate cancer, overall survival and radiographic progression-free survival were significantly longer with the addition of apalutamide to ADT than with placebo plus ADT, and the side-effect profile did not differ substantially between the two groups. (Funded by Janssen Research and Development; TITAN ClinicalTrials.gov number, .) A randomized trial tested whether the addition of apalutamide, an androgen receptor blocker, to androgen-deprivation therapy might improve radiographic (including MRI-detected) progression-free survival and overall survival. Apalutamide was significantly more effective than placebo for both end points.	[Chi, Kim N.] BC Canc, 600 W 10th Ave, Vancouver, BC V5Z 1L3, Canada; [Chi, Kim N.] Vancouver Prostate Ctr, Vancouver, BC, Canada; [Agarwal, Neeraj] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA; [Bjartell, Anders] Lund Univ, Skane Univ Hosp, Malmo, Sweden; [Chung, Byung Ha] Yonsei Univ, Coll Med, Seoul, South Korea; [Chung, Byung Ha] Gangnam Severance Hosp, Seoul, South Korea; [Pereira de Santana Gomes, Andrea J.] Liga Norte Riograndense Canc, Natal, RN, Brazil; [Given, Robert] Eastern Virginia Med Sch, Urol Virginia, Norfolk, VA 23501 USA; [Juarez Soto, Alvaro] Hosp Univ Jerez Frontera, Cadiz, Spain; [Merseburger, Axel S.] Univ Hosp Schleswig Holstein, Campus Lubeck, Lubeck, Germany; [Ozguroglu, Mustafa] Istanbul Univ Cerrahpasa, Cerrahpasa Sch Med, Istanbul, Turkey; [Uemura, Hirotsugu] Kindai Univ Hosp, Fac Med, Osaka, Japan; [Ye, Dingwei] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China; [Deprince, Kris] Janssen Res & Dev, Beerse, Belgium; [Naini, Vahid; Li, Jinhui; Zhang, Ke] Janssen Res & Dev, San Diego, CA USA; [Yu, Margaret K.; Larsen, Julie S.] Janssen Res & Dev, Los Angeles, CA USA; [Cheng, Shinta; McCarthy, Sharon] Janssen Res & Dev, Raritan, NJ USA; [Chowdhury, Simon] Guys Hosp, London, England; [Chowdhury, Simon] Kings Hosp, London, England; [Chowdhury, Simon] St Thomas Hosp, London, England; [Chowdhury, Simon] Sarah Cannon Res Inst, London, England	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Lund University; Skane University Hospital; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Eastern Virginia Medical School; University of Kiel; Schleswig Holstein University Hospital; Istanbul University - Cerrahpasa; Fudan University; Johnson & Johnson; Janssen Pharmaceuticals; Johnson & Johnson; Janssen Pharmaceuticals; Johnson & Johnson; Janssen Pharmaceuticals; Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust	Chi, KN (corresponding author), BC Canc, 600 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.; Chi, KN (corresponding author), Vancouver Prostate Ctr, Vancouver Ctr, 600 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	kchi@bccancer.bc.ca	Smirnov, Alexey/AAB-2521-2020; MUSTAFA, ÖZGÜROĞLU/A-8234-2016; CARCANO, FLAVIO M/B-3293-2010; Mosca, Alessandra/O-7975-2016; SCIARRA, ALESSANDRO/AAC-8088-2021; Li, Jin/GYQ-5363-2022	Smirnov, Alexey/0000-0001-5361-8232; MUSTAFA, ÖZGÜROĞLU/0000-0002-8417-8628; CARCANO, FLAVIO M/0000-0002-0002-3507; Mosca, Alessandra/0000-0003-2538-8411; Chung, Byung Ha/0000-0001-9817-3660; Sciarra, Alessandro/0000-0002-7899-8056; MORELLI, FRANCO/0000-0003-2378-9094; Fradet, Yves/0000-0002-7581-2500	Janssen Research and Development	Janssen Research and Development	Funded by Janssen Research and Development; TITAN ClinicalTrials.gov number, NCT02489318.	Cella D, 2009, VALUE HEALTH, V12, P124, DOI 10.1111/j.1524-4733.2008.00409.x; Clegg NJ, 2012, CANCER RES, V72, P1494, DOI 10.1158/0008-5472.CAN-11-3948; Esper P, 1997, UROLOGY, V50, P920, DOI 10.1016/S0090-4295(97)00459-7; FACIT, 2007, FUNCT ASS CANC THER; Feyerabend S, 2018, EUR J CANCER, V103, P78, DOI 10.1016/j.ejca.2018.08.010; Fizazi K, 2015, ANN ONCOL, V26, P1660, DOI 10.1093/annonc/mdv245; Fizazi K, 2017, NEW ENGL J MED, V377, P352, DOI 10.1056/NEJMoa1704174; Gillessen S, 2018, EUR UROL, V73, P178, DOI 10.1016/j.eururo.2017.06.002; James ND, 2017, NEW ENGL J MED, V377, P338, DOI 10.1056/NEJMoa1702900; James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140-6736(15)01037-5; Kassem L, 2018, CURR MED RES OPIN, V34, P903, DOI 10.1080/03007995.2018.1447450; Kyriakopoulos CE, 2018, J CLIN ONCOL, V36, P1080, DOI 10.1200/JCO.2017.75.3657; Maia MC, 2017, J GLOB ONCOL, V4, DOI 10.1200/JGO.2016.007807; Mathias Susan D, 2011, J Support Oncol, V9, P72; National Comprehensive Cancer Network, 2019, NCCN GUID PROST CANC; Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487; Smith MR, 2018, NEW ENGL J MED, V378, P1408, DOI 10.1056/NEJMoa1715546; Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Wiens BL, 2005, J BIOPHARM STAT, V15, P929, DOI 10.1080/10543400500265660	20	570	578	5	50	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 4	2019	381	1					13	24		10.1056/NEJMoa1903307	http://dx.doi.org/10.1056/NEJMoa1903307			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IG9DT	31150574	Bronze, Green Published			2023-01-03	WOS:000474094900008
J	Sanvicente-Vieira, B; Rovaris, DL; Ornell, F; Sordi, A; Rothmann, LM; Niederauer, JPO; Schuch, JB; von Diemen, L; Kessler, FHP; Grassi-Oliveira, R				Sanvicente-Vieira, Breno; Rovaris, Diego Luiz; Ornell, Felipe; Sordi, Anne; Rothmann, Leonardo Melo; Ottolia Niederauer, Joao Paulo; Schuch, Jaqueline Bohrer; von Diemen, Lisia; Paim Kessler, Felix Henrique; Grassi-Oliveira, Rodrigo			Sex-based differences in multidimensional clinical assessments of early-abstinence crack cocaine users	PLOS ONE			English	Article							ADDICTION SEVERITY INDEX; CHILDHOOD-TRAUMA-QUESTIONNAIRE; GENDER-DIFFERENCES; DRUG-USE; SUBSTANCE-USE; ABUSE; WOMEN; DEPENDENCE; NEGLECT; HEALTH	Crack cocaine use disorder (CUD) has been related to sex differences. This work aimed to compare the severity of drug use and the severity of other negative related outcomes in males and females with CUD. A total of 1344 inpatients (798 males and 546 females) with crack cocaine use disorder (CUD) were evaluated by a detailed multidimensional clinical assessment, including addiction severity and trauma exposure. Linear regression predicted higher drug use severity (beta = 0.273, p < 0.001) and more problems in domains related to childcare issues (beta = 0.321), criminal involvement (beta = 0.108), work-related problems (beta = 0.281) and social support impairments (beta = 0.142) for females, all with p < 0.001. Alcohol problems were predicted to be higher in males (beta = -0.206, P < 0.001). Females had higher rates of other mental disorders, particularly trauma and stress-related disorders (OR: 3.206, CI: 2.22, 4.61). Important sex differences also emerged in trauma history and HIV infection prevalence. CUD has a more severe clinical presentation among females facing early abstinence. Sex differences in the CUD course indicate the need for consideration of sex-specific interventions and research.	[Sanvicente-Vieira, Breno; Rothmann, Leonardo Melo; Ottolia Niederauer, Joao Paulo; Grassi-Oliveira, Rodrigo] Pontificia Univ Catolica Rio Grande do Sul, Dev Cognit Neurosci Lab, Sch Hlth Sci, Porto Alegre, RS, Brazil; [Sanvicente-Vieira, Breno; Rothmann, Leonardo Melo; Ottolia Niederauer, Joao Paulo; Grassi-Oliveira, Rodrigo] Pontificia Univ Catolica Rio Grande do Sul, Brain Inst Rio Grande Sul, Porto Alegre, RS, Brazil; [Rovaris, Diego Luiz] Univ Fed Rio Grande do Sul, Fac Med, Dept Psychiat, Porto Alegre, RS, Brazil; [Rovaris, Diego Luiz] Hosp Clin Porto Alegre, Attent Deficit Disorder Outpatient Program, Porto Alegre, RS, Brazil; [Ornell, Felipe; Sordi, Anne; Schuch, Jaqueline Bohrer; von Diemen, Lisia; Paim Kessler, Felix Henrique] Univ Fed Rio Grande do Sul, Ctr Drug & Alcohol Res, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil; [Schuch, Jaqueline Bohrer] Pontificia Univ Catolica Rio Grande do Sul, Grad Program Biomed Gerontol, Lab Immunosenescence, Porto Alegre, RS, Brazil	Pontificia Universidade Catolica Do Rio Grande Do Sul; Pontificia Universidade Catolica Do Rio Grande Do Sul; Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul; Pontificia Universidade Catolica Do Rio Grande Do Sul	Grassi-Oliveira, R (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Dev Cognit Neurosci Lab, Sch Hlth Sci, Porto Alegre, RS, Brazil.; Grassi-Oliveira, R (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Brain Inst Rio Grande Sul, Porto Alegre, RS, Brazil.	rodrigo.grassi@pucrs.br	Schuch, Jaqueline Bohrer/L-1249-2015; KESSLER, FELIX HENRIQUE P/C-3798-2018; Kessler, Felix Henrique/AAO-1722-2020; Grassi-Oliveira, R/G-2623-2012; Rovaris, Diego/I-1133-2013; von Diemen, Lisia/D-5452-2015; von Diemen, Lisia/GSE-1795-2022; ornell, felipe/AAC-8207-2019; Sanvicente-Vieira, Breno/H-5530-2013	Schuch, Jaqueline Bohrer/0000-0002-2195-4407; KESSLER, FELIX HENRIQUE P/0000-0001-7059-2564; Grassi-Oliveira, R/0000-0001-9911-5921; Rovaris, Diego/0000-0002-8910-4927; von Diemen, Lisia/0000-0001-9228-7114; ornell, felipe/0000-0002-3881-4283; sordi, Anne/0000-0002-4629-1646; Sanvicente-Vieira, Breno/0000-0002-9922-966X	MCT/CT-Saude-DECIT/SCTIE/MS, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [466802/2014-5, 478492/2013-8]; Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS) [11/1302-7]; Secretaria Nacional de Politicas sobre Drogas (SENAD)/Ministerio da Justica [822647/2015]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil (CAPES) [001]; National Institutes of Health (NIH) [R01DA044859]; Fundo de Incentivo a pesquisa (FIPE) - Hospital de Clinicas de Porto Alegre/Universidade Federal do Rio Grande do Sul [2015-0234]	MCT/CT-Saude-DECIT/SCTIE/MS, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF)); Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS)(Fundacao de Amparo a Ciencia e Tecnologia do Estado do Rio Grande do Sul (FAPERGS)); Secretaria Nacional de Politicas sobre Drogas (SENAD)/Ministerio da Justica; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fundo de Incentivo a pesquisa (FIPE) - Hospital de Clinicas de Porto Alegre/Universidade Federal do Rio Grande do Sul	This study was supported by MCT/CT-Saude-DECIT/SCTIE/MS, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [Grant number 466802/2014-5] to RG-O and [Grant number 478492/2013-8] to LVD; Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS) [Grant number 11/1302-7]; Secretaria Nacional de Politicas sobre Drogas (SENAD)/Ministerio da Justica [Grant number 822647/2015]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil (CAPES) [Finance Code 001] to BS-V and JBS; National Institutes of Health (NIH) [Grant number R01DA044859]; and Fundo de Incentivo a pesquisa (FIPE) - Hospital de Clinicas de Porto Alegre/Universidade Federal do Rio Grande do Sul [Grant number 2015-0234] to LVD. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdalla RR, 2014, ADDICT BEHAV, V39, P297, DOI 10.1016/j.addbeh.2013.10.019; American Psychiatric Association, 2013, DSM 5 TASK FORC DIAG, V5th; Andersen SL, 2009, NEUROSCI BIOBEHAV R, V33, P516, DOI 10.1016/j.neubiorev.2008.09.009; Becker AE, 2013, NEW ENGL J MED, V369, P66, DOI 10.1056/NEJMra1110827; Becker JB, 2016, DIALOGUES CLIN NEURO, V18, P395; Becker JB, 2017, J NEUROSCI RES, V95, P136, DOI 10.1002/jnr.23963; Becker JB, 2016, ADDICT BIOL, V21, P1052, DOI 10.1111/adb.12383; Becker JB, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-14; Beltz AM, 2015, EXP CLIN PSYCHOPHARM, V23, P247, DOI 10.1037/pha0000033; Benjamini Y, 2001, ANN STAT, V29, P1165; Bernstein DP, 2003, CHILD ABUSE NEGLECT, V27, P169, DOI 10.1016/S0145-2134(02)00541-0; Bertoni N, 2014, INT J EQUITY HEALTH, V13, DOI 10.1186/s12939-014-0070-x; Bobzean SAM, 2014, EXP NEUROL, V259, P64, DOI 10.1016/j.expneurol.2014.01.022; Cacciola JS, 2011, ADDICTION, V106, P1588, DOI 10.1111/j.1360-0443.2011.03482.x; Vernaglia TVC, 2017, HEALTH CARE WOMEN IN, V38, P1170, DOI 10.1080/07399332.2017.1367001; Chilcoat HD, 1998, ADDICT BEHAV, V23, P827, DOI 10.1016/S0306-4603(98)00069-0; Clayton JA, 2016, JAMA-J AM MED ASSOC, V316, P1863, DOI 10.1001/jama.2016.16405; Courtwright DT, 2012, ADDICTION, V107, P486, DOI 10.1111/j.1360-0443.2011.03723.x; Degenhardt L, 2014, DRUG ALCOHOL DEPEN, V137, P36, DOI 10.1016/j.drugalcdep.2013.12.025; Dias AC, 2011, J SUBST ABUSE TREAT, V41, P273, DOI 10.1016/j.jsat.2011.03.008; Diaz-Mesa EM, 2016, ADICCIONES, V28, P221, DOI 10.20882/adicciones.829; Edinburgh Laurel, 2006, J Sch Nurs, V22, P278, DOI 10.1622/1059-8405(2006)022[0278:GDIESA]2.0.CO;2; Evans SM, 2007, EXP CLIN PSYCHOPHARM, V15, P418, DOI 10.1037/1064-1297.15.5.418; Falck RS, 2004, J NERV MENT DIS, V192, P503, DOI 10.1097/01.nmd.0000131913.94916.d5; Fattore L, 2016, FRONT PSYCHIATRY, V7, DOI 10.3389/fpsyt.2016.00019; First M.B., 1997, STRUCTURED CLIN INTE; Fox HC, 2009, HARVARD REV PSYCHIAT, V17, P103, DOI 10.1080/10673220902899680; Francke ID, 2013, CHILD ABUSE NEGLECT, V37, P883, DOI 10.1016/j.chiabu.2013.04.008; Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642; Grassi-Oliveira R, 2006, REV SAUDE PUBL, V40, P249, DOI 10.1590/S0034-89102006000200010; Guimaraes RA, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1569-7; Hatsukami DK, 1996, JAMA-J AM MED ASSOC, V276, P1580; Herrmann ES, 2015, EXP CLIN PSYCHOPHARM, V23, P415, DOI 10.1037/pha0000053; Hyman SM, 2008, DRUG ALCOHOL DEPEN, V92, P208, DOI 10.1016/j.drugalcdep.2007.08.006; Imtiaz S, 2016, J SUBST USE, V21, P22, DOI 10.3109/14659891.2014.949315; Kamakura WA, 2013, ESTRATIFICACAO SOCIO; Kessler F, 2012, REV BRAS PSIQUIATR, V34, P24, DOI 10.1590/S1516-44462012000100006; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Lejuez CW, 2007, EXP CLIN PSYCHOPHARM, V15, P165, DOI 10.1037/1064-1297.15.2.165; Marshal MP, 2008, ADDICTION, V103, P546, DOI 10.1111/j.1360-0443.2008.02149.x; Martel ML, 2018, AM J EMERG MED, V36, P18, DOI 10.1016/j.ajem.2017.06.043; McHugh RK, 2018, CLIN PSYCHOL REV, V66, P12, DOI 10.1016/j.cpr.2017.10.012; McLellan AT, 2006, AM J ADDICTION, V15, P113, DOI 10.1080/10550490500528316; Milivojevic V, 2014, HUM PSYCHOPHARM CLIN, V29, P589, DOI 10.1002/hup.2446; Minutillo Adele, 2016, Ann Ist Super Sanita, V52, P176, DOI 10.4415/ANN_16_02_08; Najavits LM, 2008, DRUG ALCOHOL DEPEN, V97, P190, DOI 10.1016/j.drugalcdep.2008.04.012; Narvaez JCM, 2014, COMPR PSYCHIAT, V55, P1369, DOI 10.1016/j.comppsych.2014.04.021; Padyab M, 2018, J DUAL DIAGN, V14, P187, DOI 10.1080/15504263.2018.1466086; Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8; Pedraz M, 2015, FRONT PSYCHIATRY, V6, DOI [10.3389/fpsyt.2015.00017, 10.3389/fmicb.2015.00449]; PIAZZA NJ, 1989, INT J ADDICT, V24, P19, DOI 10.3109/10826088909047272; Pinsky I, 2018, REV BRAS PSIQUIATR, V40, P320, DOI 10.1590/1516-4446-2017-2235; Pope SK, 2011, AM J DRUG ALCOHOL AB, V37, P491, DOI 10.3109/00952990.2011.600380; Quinones-Jenab V, 2012, ILAR J, V53, P14, DOI 10.1093/ilar.53.1.14; Scheidell JD, 2018, ADDICTION, V113, P44, DOI 10.1111/add.13921; SCHEIN S, 2013, PROBLEMS PSYCHOL 21, V6, P55; Thompson MP, 2004, AM J PUBLIC HEALTH, V94, P599, DOI 10.2105/AJPH.94.4.599; UNODOC, 2016, WORLD DRUG REP; Vergara-Moragues E, 2012, PSYCHIAT RES, V200, P734, DOI 10.1016/j.psychres.2012.07.043; Viola TW, 2016, CHILD ABUSE NEGLECT, V51, P1, DOI 10.1016/j.chiabu.2015.11.019; Viola TW, 2014, J PSYCHIATR NEUROSCI, V39, P206, DOI 10.1503/jpn.130027; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Vsevolozhskaya OA, 2016, NEUROPSYCHOPHARMACOL, V41, P869, DOI 10.1038/npp.2015.213; Wilson HW, 2009, J YOUTH ADOLESCENCE, V38, P340, DOI 10.1007/s10964-008-9331-6	64	11	11	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 21	2019	14	6							e0218334	10.1371/journal.pone.0218334	http://dx.doi.org/10.1371/journal.pone.0218334			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW3PT	31226126	Green Published, Green Submitted, gold			2023-01-03	WOS:000484894700013
J	Candilis, PJ; Kim, DT; Sulmasy, LS; Bledsoe, TA; Atiq, OT; Bundrick, JB; Chang, B; Dugdale, LS; Dunn, A; Hartzell, JD; Huddle, TS; Jokela, JA; Jung, D; Levine, MA; Lopez, AM; Mohan, N; Mueller, PS				Candilis, Philip J.; Kim, Daniel T.; Sulmasy, Lois Snyder; Bledsoe, Thomas A.; Atiq, Omar T.; Bundrick, John B.; Chang, Betty; Dugdale, Lydia S.; Dunn, Andrew; Hartzell, Joshua D.; Huddle, Thomas S.; Jokela, Janet A.; Jung, Diana; Levine, Mark A.; Lopez, Ana Maria; Mohan, Neena; Mueller, Paul S.		ACP Ethics; Professionalism Human Rights Comm	Physician Impairment and Rehabilitation: Reintegration Into Medical Practice While Ensuring Patient Safety: A Position Paper From the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Review							SUBSTANCE USE DISORDERS; HEALTH; PREVALENCE; PROGNOSIS; PERCEPTIONS; RECOVERY; DOCTORS; BURNOUT; CARE	Physician impairment, the inability to carry out patient care responsibilities safely and effectively, is a problem of functioning. However, the presence or treatment of a potentially impairing illness or other condition does not necessarily imply impairment. This American College of Physicians position paper examines the professional duties and principles that should guide the response of colleagues and the profession to physician impairment. The physician should be rehabilitated and reintegrated into medical practice whenever possible without compromising patient safety. At the same time, physicians have a duty to seek help when they are unable to provide safe care. When identifying and assisting colleagues who might be impaired, physicians should act on collegial concern as well as ethical and legal guidelines that require reporting of behavior that puts patients at risk. Health care institutions and the profession should support practice environments in which patient safety is prioritized and physician wellness and well-being are addressed. Physician health programs should be committed to best practices that safeguard patient safety and the rights of physician-patients.	[Candilis, Philip J.] St Elizabeth Hosp, Washington, DC USA; [Candilis, Philip J.] George Washington Univ, Sch Med, Washington, DC USA; [Kim, Daniel T.; Sulmasy, Lois Snyder] Amer Coll Physicians, Philadelphia, PA USA; [Kim, Daniel T.; Sulmasy, Lois Snyder] Amer Coll Physicians, ACP Ctr Eth & Professionalism, 190 N Independence Mall West, Philadelphia, PA 19106 USA; [Candilis, Philip J.] St Elizabeth Hosp, Med Affairs, 1100 Alabama Ave SE, Washington, DC 20032 USA	George Washington University; American College of Physicians; American College of Physicians	Sulmasy, LS (corresponding author), Amer Coll Physicians, ACP Ctr Eth & Professionalism, 190 N Independence Mall West, Philadelphia, PA 19106 USA.	lsnyder@acponline.org			ACP operating budget	ACP operating budget	Financial support for the development of this paper comes exclusively from the ACP operating budget.	Accreditation Council for Graduate Medical Education, 2017, ACGME PROGR REQ GRAD; American College of Surgeons Board of Governors Physician Competency and Health Workgroup, 2016, Bull Am Coll Surg, V101, P42; American Medical Association, 2 AM MED ASS COUNC S; American Medical Association, 2016, PHYS HLTH PROGR ACT; American Medical Association, 2016, ACC CONF HLTH SERV M; American Medical Association, 2015, 5 AM MED ASS COUNC M; American Society of Addiction Medicine, 2011, PUBL POL DISCR ADD P; [Anonymous], 1973, JAMA, V223, P684; Benkhadra K, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1728-4; Bonnie RJ, 2004, INT J FORENSIC MENT, V3, P131, DOI [10.2139/ssrn.1758874, DOI 10.2139/SSRN.1758874]; Brooks E, 2013, OCCUP MED-OXFORD, V63, P274, DOI 10.1093/occmed/kqt036; Buhl A, 2011, ARCH SURG-CHICAGO, V146, P1286, DOI 10.1001/archsurg.2011.271; Carr GD., 2017, PHYS MENTAL HLTH WEL, P265; Chiu YL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0130690; Coyle SL, 2002, ANN INTERN MED, V136, P396, DOI 10.7326/0003-4819-136-5-200203050-00014; Dellinger EP, 2017, JAMA SURG, V152, P967, DOI 10.1001/jamasurg.2017.2342; DesRoches CM, 2010, JAMA-J AM MED ASSOC, V304, P187, DOI 10.1001/jama.2010.921; DuPont RL, 2009, J SUBST ABUSE TREAT, V37, P1, DOI 10.1016/j.jsat.2009.03.010; Dyrbye LN, 2017, MAYO CLIN PROC, V92, P1486, DOI 10.1016/j.mayocp.2017.06.020; Dyrbye LN, 2014, ACAD MED, V89, P443, DOI 10.1097/ACM.0000000000000134; Earley PH, 2018, ASAM PRINCIPLES ADDI; Federation of State Medical Boards, 2013, REP SPEC COMM REENTR; Federation of State Medical Boards, 2011, POL PHYS IMP; Federation of State Medical Boards, 2018, PHYS WELLN BURN; Federation of State Physician Health Programs, STAT PROGR; Federation of State Physician Health Programs, 2016, PERF ENH REV PER GUI; Federation of State Physician Health Programs, 2005, PHYS HLTH PROGR GUID; Federation of State Physician Health Programs, 2018, MEMB UPD PERF ENH EF; John PR, 2018, J HOSP MED, V13, P210, DOI 10.12788/jhm.2945; Knight John R, 2007, J Psychiatr Pract, V13, P25, DOI 10.1097/00131746-200701000-00004; Leape LL, 2006, ANN INTERN MED, V144, P107, DOI 10.7326/0003-4819-144-2-200601170-00008; Lemaire JB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196888; Mata DA, 2015, JAMA-J AM MED ASSOC, V314, P2373, DOI 10.1001/jama.2015.15845; Mathes M, AGING COLLEAGUE SEEM; McLellan AT, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2038; Merlo LJ, 2016, JAMA-J AM MED ASSOC, V316, P2489, DOI 10.1001/jama.2016.10339; Merlo LJ, 2013, J ADDICT MED, V7, P349, DOI 10.1097/ADM.0b013e31829da074; MORSE RM, 1984, JAMA-J AM MED ASSOC, V251, P743, DOI 10.1001/jama.251.6.743; Mueller P, DEALING DISRUPTIVE P; Oreskovich MR, 2015, AM J ADDICTION, V24, P30, DOI 10.1111/ajad.12173; Oreskovich MR, 2012, ARCH SURG-CHICAGO, V147, P168, DOI 10.1001/archsurg.2011.1481; Reynolds NT, 2012, J MED LICENS DISCIP, V98, P8; Rose JS, 2017, J ADDICT MED, V11, P93, DOI 10.1097/ADM.0000000000000278; Rose JS, 2014, WEST J EMERG MED, V15, P20, DOI 10.5811/westjem.2013.7.17871; Ruitenburg MM, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-292; Sanchez LT, 2016, J PSYCHIATR PRACT, V22, P56, DOI 10.1097/PRA.0000000000000121; Schneck SA, 1998, JAMA-J AM MED ASSOC, V280, P2039, DOI 10.1001/jama.280.23.2039; Shanafelt T, 2017, JAMA INTERN MED, V177, P1826, DOI 10.1001/jamainternmed.2017.4340; Shojania KG, 2013, BMJ QUAL SAF, V22, P528, DOI 10.1136/bmjqs-2013-002138; SHORE JH, 1987, JAMA-J AM MED ASSOC, V257, P2931; Skipper GE, 2009, ANESTH ANALG, V109, P891, DOI 10.1213/ane.0b013e3181adc39d; Steffen MW, 2015, OCCUP MED-OXFORD, V65, P49, DOI 10.1093/occmed/kqu145; Sulmasy LS, 2019, ANN INTERN MED, V170, pS1, DOI 10.7326/M18-2160; Thomas LR, 2018, JAMA-J AM MED ASSOC, V319, P1541, DOI 10.1001/jama.2018.1331; Wood B.A., 2014, PERFORMANCE AUDIT N; Worley LLM, 2008, ACAD PSYCHIATR, V32, P8, DOI 10.1176/appi.ap.32.1.8; Wynia MK, 1999, NEW ENGL J MED, V341, P1612, DOI 10.1056/NEJM199911183412112; Yellowlees PM, 2014, PSYCHIAT SERV, V65, P1492, DOI 10.1176/appi.ps.201300472; Zwack J, 2013, ACAD MED, V88, P382, DOI 10.1097/ACM.0b013e318281696b	59	15	15	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 18	2019	170	12					871	+		10.7326/M18-3605	http://dx.doi.org/10.7326/M18-3605			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ID7AO	31158847				2023-01-03	WOS:000471834300017
J	Edgren, G; Murphy, EL; Brambilla, DJ; Westlake, M; Rostgaard, K; Lee, C; Cable, RG; Triulzi, D; Bruhn, R; St Lezin, EM; Erikstrup, C; Ullum, H; Glynn, SA; Kleinman, S; Hjalgrim, H; Roubinian, NH; Mast, AE; Gottschall, JL; Triulzi, DJ; Kiss, JE; Murphy, EL; St Lezin, E; Snyder, EL; Cable, RG; Brambilla, DJ; Sullivan, MT; Busch, MP; Norris, PJ; Dodd, RY; Kleinman, SH; Glynn, SA; Malkin, K				Edgren, Gustaf; Murphy, Edward L.; Brambilla, Don J.; Westlake, Matt; Rostgaard, Klaus; Lee, Catherine; Cable, Ritchard G.; Triulzi, Darrell; Bruhn, Roberta; St Lezin, Elizabeth M.; Erikstrup, Christian; Ullum, Henrik; Glynn, Simone A.; Kleinman, Steve; Hjalgrim, Henrik; Roubinian, Nareg H.; Mast, A. E.; Gottschall, J. L.; Triulzi, D. J.; Kiss, J. E.; Murphy, E. L.; St Lezin, E.; Snyder, E. L.; Cable, R. G.; Brambilla, D. J.; Sullivan, M. T.; Busch, M. P.; Norris, P. J.; Dodd, R. Y.; Kleinman, S. H.; Glynn, S. A.; Malkin, K.		NHLBI Recipient Epidemiology Donor	Association of Blood Donor Sex and Prior Pregnancy With Mortality Among Red Blood Cell Transfusion Recipients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE LUNG INJURY; SURVIVAL; AGE	IMPORTANCE Evidence regarding associations of blood donor sex with mortality among red blood cell transfusion recipients is conflicting. OBJECTIVE To study associations of donor sex and prior pregnancy with mortality of transfusion recipients. DESIGN, SETTING, AND PARTICIPANTS Data from 3 retrospective cohorts of transfusion recipients (the Kaiser Permanente Northern California [KPNC] and Recipient Epidemiology and Donor Evaluation Study-III [REDS-III] databases of data from January 2013 to December 2016 and the Scandinavian Donations and Transfusions [SCANDAT] database with data from January 2003 to December 2012) were analyzed. Final dates of follow-up were December 31, 2016, for the KPNC and REDS-III cohorts and December 31, 2012, for the SCANDAT cohort. Stratified Cox regression models were used to estimate associations between donor exposure groups with risk of mortality, adjusting for the number of red blood cell unit transfusions. EXPOSURES The number of transfused red blood cell units from female donors, previously pregnant donors, and sex-discordant donors (male donor and female recipient or female donor and male recipient). MAIN OUTCOMES AND MEASURES In-hospital mortality. RESULTS The study population included 34 662 patients (mean age, 69 years; 18 652 [54%] women) from the KPNC cohort, 93 724 patients (mean age, 61 years; 48 348 [52%] women) from the REDS-III cohort, and 918 996 patients (mean age, 72 years; 522 239 [57%] women) from the SCANDAT cohort. The median number of red blood cell transfusions per patient was 3 in the KPNC cohort, 2 in the REDS-III cohort, and 3 in the SCANDAT cohort. The percentage of transfusions from previously pregnant or parous donors was 9% in the KPNC cohort, 18% in the REDS-III cohort, and 25% in the SCANDAT cohort. The percentage of transfusions in the 3 cohorts from female donors ranged from 39% to 43%, from previously pregnant or parous donors ranged from 9% to 25%, and from sex-discordant donors ranged from 44% to 50%. There were 3217 in-hospital deaths in the KPNC cohort, 8519 in the REDS-III cohort, and 198 537 in the SCANDAT cohort. There were no statistically significant associations between any of the 3 donor exposures and in-hospital mortality in the 3 cohorts. Hazard ratios for in-hospital mortality per transfused unit from female donors were 0.99 (95% CI, 0.96-1.03) for the KPNC cohort, 1.00 (95% CI, 0.99-1.01) for the REDS-III cohort, and 1.00 (95% CI, 0.99-1.00) for the SCANDAT cohort. For units from previously pregnant or parous female donors, hazard ratios were 1.00 (95% CI, 1.00-1.01) for the KPNC cohort, 1.01 (95% CI, 0.98-1.03) for the REDS-III cohort, and 1.00 (95% CI, 1.00-1.01) for the SCANDAT cohort. For units from sex-discordant transfusions, hazard ratios were 1.02 (95% CI, 0.99-1.05) for the KPNC cohort, 0.99 (95% CI, 0.98-1.00) for the REDS-III cohort, and 1.00 (95% CI, 0.99-1.00) for the SCANDAT cohort. CONCLUSIONS AND RELEVANCE Among red blood cell transfusion recipients, transfusions from female, previously pregnant, or sex-discordant donors were not significantly associated with increased mortality.	[Edgren, Gustaf] Karolinska Univ Hosp, Dept Med Solna, Div Clin Epidemiol, SE-17176 Stockholm, Sweden; [Edgren, Gustaf] Soder Sjukhuset, Dept Cardiol, Stockholm, Sweden; [Murphy, Edward L.; Bruhn, Roberta; Roubinian, Nareg H.; Busch, M. P.; Norris, P. J.] Vitalant Res Inst, San Francisco, CA USA; [Murphy, Edward L.; St Lezin, Elizabeth M.; Roubinian, Nareg H.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Brambilla, Don J.; Westlake, Matt; Brambilla, D. J.; Sullivan, M. T.] RTI Int, Rockville, MD USA; [Rostgaard, Klaus; Hjalgrim, Henrik] Statens Serum Inst, Dept Epidemiol Res, Copenhagen, Denmark; [Lee, Catherine; Roubinian, Nareg H.] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA; [Cable, Ritchard G.] Amer Red Cross, Connecticut Reg, Farmington, CT USA; [Triulzi, Darrell] Inst Transfus Med, Pittsburgh, PA USA; [St Lezin, Elizabeth M.] Vet Affairs Healthcare Syst, San Francisco, CA USA; [Erikstrup, Christian] Aarhus Univ Hosp, Dept Clin Immunol, Aarhus, Denmark; [Ullum, Henrik] Univ Hosp Copenhagen, Rigshosp, Blood Bank, Dept Clin Immunol, Copenhagen, Denmark; [Glynn, Simone A.; Glynn, S. A.; Malkin, K.] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA; [Kleinman, Steve; Kleinman, S. H.] Univ British Columbia, Victoria, BC, Canada; [Hjalgrim, Henrik] Copenhagen Univ Hosp, Dept Hematol, Copenhagen, Denmark; [Mast, A. E.; Gottschall, J. L.] Versity Inc, Milwaukee, WI USA; [Triulzi, D. J.; Kiss, J. E.] Inst Transfus Med ITXM, Pittsburgh, PA USA; [Murphy, E. L.; St Lezin, E.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Snyder, E. L.] Yale Univ, Sch Med, New Haven, CT USA; [Cable, R. G.] Amer Red Cross Blood Serv, Farmington, CT USA; [Dodd, R. Y.] Amer Red Cross, Holland Lab, Rockville, MD USA	Karolinska Institutet; Karolinska University Hospital; Sodersjukhuset Hospital; Vitalant; Vitalant Research Institute; University of California System; University of California San Francisco; Research Triangle Institute; Statens Serum Institut; Kaiser Permanente; American Red Cross; Institute for Transfusion Medicine; Aarhus University; Rigshospitalet; University of Copenhagen; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of British Columbia; University of Copenhagen; Institute for Transfusion Medicine; University of California System; University of California San Francisco; Yale University; American Red Cross; American Red Cross	Edgren, G (corresponding author), Karolinska Univ Hosp, Dept Med Solna, Div Clin Epidemiol, SE-17176 Stockholm, Sweden.	gustaf.edgren@ki.se	Hjalgrim, Henrik/AAG-4973-2021; Edgren, Gustaf/F-4013-2014; Bruhn, Roberta/GPS-4534-2022	Edgren, Gustaf/0000-0002-2198-4745; Bruhn, Roberta/0000-0002-5898-8168; Erikstrup, Christian/0000-0001-6551-6647; Brambilla, Donald/0000-0002-7276-4689; Lee, Catherine/0000-0003-0008-9052; Westlake, Matthew/0000-0002-3063-734X; Rostgaard, Klaus/0000-0001-6220-9414; Ullum, Henrik/0000-0001-7306-9058	National Heart, Lung, and Blood Institute (NHLBI) [HHSN2682011000002I, HHSN2682011000003I, HHSN2682011000004I, HHSN2682011000005I, HHSN268201100006I]; NHLBI [R01HL126130]; Swedish Research Council [2017-01954]; Nordic Cancer Union [14-11675-1]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL126130] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Swedish Research Council(Swedish Research CouncilEuropean Commission); Nordic Cancer Union; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by funding from the National Heart, Lung, and Blood Institute (NHLBI contracts HHSN2682011000002I, HHSN2682011000003I, HHSN2682011000004I, HHSN2682011000005I, and HHSN268201100006I for the Recipient Epidemiology and Donor Evaluation Study-III and NHLBI grant R01HL126130). The creation of the SCANDAT database was supported by grants to Dr Edgren from the Swedish Research Council (2017-01954) and to Dr Hjalgrim from the Nordic Cancer Union (14-11675-1).	ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; ANDREWS AT, 1976, AM J CLIN PATHOL, V66, P483; Cable RG, 2017, JAMA-J AM MED ASSOC, V318, P1445, DOI 10.1001/jama.2017.15095; Caram-Deelder C, 2017, JAMA-J AM MED ASSOC, V318, P1471, DOI 10.1001/jama.2017.14825; Chasse M, 2016, JAMA INTERN MED, V176, P1307, DOI 10.1001/jamainternmed.2016.3324; Edgren G, 2017, JAMA INTERN MED, V177, P854, DOI 10.1001/jamainternmed.2017.0890; Edgren G, 2015, TRANSFUSION, V55, P1600, DOI 10.1111/trf.12986; Holzmann MJ, 2016, CIRCULATION, V134, P1692, DOI 10.1161/CIRCULATIONAHA.116.025087; Karafin MS, 2017, TRANSFUSION, V57, P2903, DOI 10.1111/trf.14370; Rostgaard Klaus, 2008, Epidemiol Perspect Innov, V5, P7, DOI 10.1186/1742-5573-5-7; Roubinian NH, 2014, TRANSFUSION, V54, P2678, DOI 10.1111/trf.12825; Roubinian NH, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-213; Rubin DB, 1996, J AM STAT ASSOC, V91, P473, DOI 10.1080/01621459.1996.10476908; Sundararajan V, 2004, J CLIN EPIDEMIOL, V57, P1288, DOI 10.1016/j.jclinepi.2004.03.012; Triulzi DJ, 2009, TRANSFUSION, V49, P1825, DOI 10.1111/j.1537-2995.2009.02206.x; Vlaar APJ, 2013, LANCET, V382, P984, DOI 10.1016/S0140-6736(12)62197-7	16	16	16	1	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2019	321	22					2183	2192		10.1001/jama.2019.7084	http://dx.doi.org/10.1001/jama.2019.7084			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IC6HB	31184739	Green Published, Bronze			2023-01-03	WOS:000471071200015
J	Leshner, AI; Dzau, VJ				Leshner, Alan I.; Dzau, Victor J.			Medication-Based Treatment to Address Opioid Use Disorder	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Leshner, Alan I.] Amer Assoc Advancement Sci, Potomac, MD USA; [Dzau, Victor J.] Natl Acad Med, 500 Fifth St NW, Washington, DC 20001 USA	National Academies of Sciences, Engineering & Medicine	Dzau, VJ (corresponding author), Natl Acad Med, 500 Fifth St NW, Washington, DC 20001 USA.	vdzau@nas.edu						Bukten A, 2012, ADDICTION, V107, P393, DOI 10.1111/j.1360-0443.2011.03637.x; Centers for Disease Control and Prevention, OP OV UND EP; National Academies of Sciences Engineering and Medicine, 2019, MED OP US DIS SAV LI; Park -Lee E., 2017, RECEIPT SERVICES SUB; Schuckit MA, 2016, NEW ENGL J MED, V375, P357, DOI 10.1056/NEJMra1604339	5	29	29	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2019	321	21					2071	2072		10.1001/jama.2019.5523	http://dx.doi.org/10.1001/jama.2019.5523			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IB3HN	31046072				2023-01-03	WOS:000470158700008
J	Marandi, RZ; Madeleine, P; Omland, O; Vuillerme, N; Samani, A				Marandi, Ramtin Zargari; Madeleine, Pascal; Omland, Oyvind; Vuillerme, Nicolas; Samani, Afshin			An oculometrics-based biofeedback system to impede fatigue development during computer work: A proof-of-concept study	PLOS ONE			English	Article							TRAPEZIUS MUSCLE-ACTIVITY; REST BREAKS; MAIN-SEQUENCE; PATTERN; SLEEPINESS; EEG; CLASSIFICATION; RECOGNITION; VARIABILITY; PERFORMANCE	A biofeedback system may objectively identify fatigue and provide an individualized timing plan for micro-breaks. We developed and implemented a biofeedback system based on oculometrics using continuous recordings of eye movements and pupil dilations to moderate fatigue development in its early stages. Twenty healthy young participants (10 males and 10 females) performed a cyclic computer task for 31-35 min over two sessions: 1) self-triggered micro-breaks (manual sessions), and 2) biofeedback-triggered micro-breaks (automatic sessions). The sessions were held with one-week inter-session interval and in a counterbalanced order across participants. Each session involved 180 cycles of the computer task and after each 20 cycles (a segment), the task paused for 5-s to acquire perceived fatigue using Karolinska Sleepiness Scale (KSS). Following the pause, a 25-s microbreak involving seated exercises was carried out whether it was triggered by the biofeed-back system following the detection of fatigue (KSS >= 5) in the automatic sessions or by the participants in the manual sessions. National Aeronautics and Space Administration Task Load Index (NASA-TLX) was administered after sessions. The functioning core of the biofeed-back system was based on a Decision Tree Ensemble model for fatigue classification, which was developed using an oculometrics dataset previously collected during the same computer task. The biofeedback system identified fatigue with a mean accuracy of approx. 70%. Perceived workload obtained from NASA-TLX was significantly lower in the automatic sessions compared with the manual sessions, p = 0.01 Cohen's d(z) = 0.89. The results give support to the effectiveness of integrating oculometrics-based biofeedback in timing plan of micro-breaks to impede fatigue development during computer work.	[Marandi, Ramtin Zargari; Madeleine, Pascal; Omland, Oyvind; Vuillerme, Nicolas; Samani, Afshin] Aalborg Univ, Dept Hlth Sci & Technol, Sport Sci, Aalborg, Denmark; [Marandi, Ramtin Zargari; Vuillerme, Nicolas] Univ Grenoble Alpes, AGEIS, Grenoble, France; [Omland, Oyvind] Aalborg Univ Hosp, Danish Ramazzini Ctr, Clin Occupat Med, Aalborg, Denmark; [Vuillerme, Nicolas] Inst Univ France, Paris, France	Aalborg University; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Aalborg University; Aalborg University Hospital; Institut Universitaire de France	Samani, A (corresponding author), Aalborg Univ, Dept Hlth Sci & Technol, Sport Sci, Aalborg, Denmark.	afsamani@hst.aau.dk	Madeleine, Pascal/AAD-3201-2021; Zargari Marandi, Ramtin/J-6868-2019; VUILLERME, Nicolas/U-5767-2019	Zargari Marandi, Ramtin/0000-0001-9233-1656; VUILLERME, Nicolas/0000-0003-3773-393X	VELUX FONDEN [00010912]	VELUX FONDEN(Velux Fonden)	This project was funded by the VELUX FONDEN (project number: 00010912). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelall Esraa S., 2018, Proceedings of the Human Factors and Ergonomics Society Annual Meeting, V62, P1042, DOI 10.1177/1541931218621240; Ackerman P.L., 2011, COGNITIVE FATIGUE MU, P11, DOI [10.1037/12343-001, DOI 10.1037/12343-001]; Ahn S, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00219; AKERSTEDT T, 1990, INT J NEUROSCI, V52, P29, DOI 10.3109/00207459008994241; Akerstedt T, 2014, J SLEEP RES, V23, P240, DOI 10.1111/jsr.12158; Al Shalabi L, 2006, DEPCOS-RELCOMEX 2006, P207; Arch JJ, 2006, BEHAV RES THER, V44, P1849, DOI 10.1016/j.brat.2005.12.007; Bailey BP, 2000, IEEE SYS MAN CYBERN, P757, DOI 10.1109/ICSMC.2000.885940; Barredo RDV, 2007, J PHYS THER SCI, V19, P151, DOI 10.1589/jpts.19.151; Benchetrit G, 2000, RESP PHYSIOL, V122, P123, DOI 10.1016/S0034-5687(00)00154-7; Bouchard S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036169; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Burg JM, 2011, COGNITIVE THER RES, V35, P179, DOI 10.1007/s10608-010-9343-x; Caffier PP, 2003, EUR J APPL PHYSIOL, V89, P319, DOI 10.1007/s00421-003-0807-5; Cao A, 2009, BEHAV RES METHODS, V41, P113, DOI 10.3758/BRM.41.1.113; Cazzoli D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087146; Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199; Chuang CH, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00181; Clemes SA, 2004, INFLUENCE MENSTRUAL; Cohen J., 2013, STAT POWER ANAL BEHA; Colligan TW, 2006, J WORKPLACE BEHAV HE, V21, P89, DOI 10.1300/J490v21n02_07; Combrisson E, 2015, J NEUROSCI METH, V250, P126, DOI 10.1016/j.jneumeth.2015.01.010; Comision Nacional Evaluadora de la Actividad Investigadora (CNEAI), 2011, PATTERN CLASSIFICATI, DOI DOI 10.1007/BF01237942; Cook DB, 2007, NEUROIMAGE, V36, P108, DOI 10.1016/j.neuroimage.2007.02.033; Dawson D, 2011, ACCIDENT ANAL PREV, V43, P549, DOI 10.1016/j.aap.2009.12.030; Deschodt-Arsac V, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201388; Di Stasi LL, 2013, EUR REV APPL PSYCHOL, V63, P335, DOI 10.1016/j.erap.2013.09.001; Di Stasi LL, 2015, EXP BRAIN RES, V233, P599, DOI 10.1007/s00221-014-4139-y; Di Stasi LL, 2014, ANN SURG, V259, P824, DOI 10.1097/SLA.0000000000000260; Di Stasi LL, 2013, EUR J NEUROSCI, V38, P2389, DOI 10.1111/ejn.12248; Di Stasi LL, 2013, NEUROSCI BIOBEHAV R, V37, P968, DOI 10.1016/j.neubiorev.2013.03.011; Di Stasi LL, 2012, TRANSPORT RES C-EMER, V21, P122, DOI 10.1016/j.trc.2011.07.002; Enoka RM, 2016, MED SCI SPORT EXER, V48, P2228, DOI 10.1249/MSS.0000000000000929; Epling SL, 2016, EXP BRAIN RES, V234, P2979, DOI 10.1007/s00221-016-4700-y; Esposito G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106705; Evers F.T., 1999, FUZZY CLUSTER ANAL M; Fan RE, 2005, J MACH LEARN RES, V6, P1889; Farina D, 2008, J ELECTROMYOGR KINES, V18, P16, DOI 10.1016/j.jelekin.2006.08.005; Feldman G, 2010, BEHAV RES THER, V48, P1002, DOI 10.1016/j.brat.2010.06.006; Felton EA, 2012, ERGONOMICS, V55, P526, DOI 10.1080/00140139.2012.662526; Ferguson DP, 2019, MED SCI SPORTS EXERC; Fogelton A, 2016, COMPUT VIS IMAGE UND, V148, P23, DOI 10.1016/j.cviu.2016.03.011; Freund Y, 2009, ARXIV09052138; Ftouni S, 2013, J SLEEP RES, V22, P58, DOI 10.1111/j.1365-2869.2012.01038.x; Gergelyfi M, 2015, FRONT BEHAV NEUROSCI, V9, DOI [10.3389/fnbeh.2015.00176, 10.3389/fnbeh.2015,00176]; Giggins OM, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-60; Grohn M, 2012, P 18 INT C AUD DISP, P18; Hallbeck MS, 2017, APPL ERGON, V60, P334, DOI 10.1016/j.apergo.2016.12.006; Harris CM, 2006, BIOL CYBERN, V95, P21, DOI 10.1007/s00422-006-0064-x; Hart S. G., 2006, P HUM FACT ERG SOC A, V50, P904, DOI 10.1177/154193120605000909.No.9; Helton WS, 2017, HUM FACTORS, V59, P91, DOI 10.1177/0018720816683509; Henderson JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064937; HEUER H, 1989, Z EXP ANGEW PSYCHOL, V36, P538; James G., 1998, MAJORITY VOTE CLASSI; Januario LB, 2016, J ELECTROMYOGR KINES, V30, P196, DOI 10.1016/j.jelekin.2016.07.009; Kaida K, 2006, CLIN NEUROPHYSIOL, V117, P1574, DOI 10.1016/j.clinph.2006.03.011; Katnani HA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051843; Kawczynski A, 2007, SCAND J MED SCI SPOR, V17, P172, DOI 10.1111/j.1600-0838.2006.00551.x; Kelso D, 2001, EFFECTS FREQUENT ACT; Kim S, 2017, J ORGAN BEHAV, V38, P28, DOI [10.1002/job.2109, 10.9728/dcs.2016.17.1.1]; KOTHARI SC, 1993, ADV COMPUT, V37, P119, DOI 10.1016/S0065-2458(08)60404-0; Kouchaki S, 2018, BIOMED ENG-APP BAS C, V30, DOI 10.4015/S1016237218500230; Krejtz K, 2016, ACM T APPL PERCEPT, V13, DOI 10.1145/2896452; Krolak A, 2012, UNIVERSAL ACCESS INF, V11, P409, DOI 10.1007/s10209-011-0256-6; Kuhnel J, 2017, EUR J WORK ORGAN PSY, V26, P481, DOI 10.1080/1359432X.2016.1269750; Laring J, 2002, INT J IND ERGONOM, V30, P135, DOI 10.1016/S0169-8141(02)00091-4; Lee KE, 2015, J ENVIRON PSYCHOL, V42, P182, DOI 10.1016/j.jenvp.2015.04.003; Liu CC, 2009, J SAFETY RES, V40, P239, DOI 10.1016/j.jsr.2009.04.005; Madeleine P, 2010, ACTA PHYSIOL, V199, P1, DOI 10.1111/j.1748-1716.2010.02145.x; Madeleine P, 2008, EUR J APPL PHYSIOL, V102, P325, DOI 10.1007/s00421-007-0589-2; Madeleine P, 2006, ERGONOMICS, V49, P921, DOI 10.1080/00140130600665828; Madeleine P, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-226; Mahachandra M., 2011, INT J BASIC APPL SCI, V11, P87; Marandi Ramtin Zargari, 2019, Proceedings of the 20th Congress of the International Ergonomics Association (IEA 2018). Volume IX: Aging, Gender and Work, Anthropometry, Ergonomics for Children and Educational Environments. Advances in Intelligent Systems and Computing (AISC 826), P104, DOI 10.1007/978-3-319-96065-4_14; Marandi RZ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31577-1; Marandi RZ, 2018, IEEE ACCESS, V6, P17500, DOI 10.1109/ACCESS.2018.2819211; Marandi RZ, 2015, BEHAV RES METHODS, V47, P1404, DOI 10.3758/s13428-014-0549-9; Marandi RZ, 2014, BASIC CLIN NEUROSCI, V5, P55; Marandi RZ., 2019, WAME1 0 STANDARDIZED, DOI [10.17605/OSF.IO/2FC7S, DOI 10.17605/OSF.IO/2FC7S]; McKee MG., 2008, CLEVE CLIN J MED, V2, pS31, DOI [10.3949/ccjm.75.Suppl_2.S31, DOI 10.3949/CCJM.75.SUPPL_2.S31]; McLean L, 2001, APPL ERGON, V32, P225, DOI 10.1016/S0003-6870(00)00071-5; Michaelis J, 2013, RESTORATIVE EFFECTS; Michielsen HJ, 2003, J PSYCHOSOM RES, V54, P345, DOI 10.1016/S0022-3999(02)00392-6; Morris D, 2008, CHI 2008: 26TH ANNUAL CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS VOLS 1 AND 2, CONFERENCE PROCEEDINGS, P1817; Nakanishi M, 2014, IEICE P SERIES, P114, DOI [10.15248/proc.1.114, DOI 10.15248/PROC.1.114]; Nystrom M, 2010, BEHAV RES METHODS, V42, P188, DOI 10.3758/BRM.42.1.188; Ogino M, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18124477; Pimenta A, 2016, NEUROCOMPUTING, V172, P413, DOI 10.1016/j.neucom.2015.03.105; Poole A., 2006, ENCY HUMAN COMPUTER, P211, DOI [DOI 10.4018/978-1-59140-562-7.CH034, DOI 10.1016/B978-044451020-4/50031-1]; Powers DM, 2011, J MACHINE LEARNING T, V2, P37; Prinsloo GE, 2013, APPL PSYCHOPHYS BIOF, V38, P45, DOI 10.1007/s10484-012-9207-0; PUDIL P, 1994, PATTERN RECOGN LETT, V15, P1119, DOI 10.1016/0167-8655(94)90127-9; Puspasari MA, 2018, INT CONF INTEL INFOR, P66, DOI 10.1109/ICIIBMS.2018.8549999; Raudys S, 1998, PATTERN RECOGN LETT, V19, P385, DOI 10.1016/S0167-8655(98)00016-6; Ren Q, 2017, AIP CONF PROC, V1820, DOI 10.1063/1.4977376; RIGGS LA, 1987, INVEST OPHTH VIS SCI, V28, P334; Roy RN, 2014, BIOMED SIGNAL PROCES, V14, P256, DOI 10.1016/j.bspc.2014.08.007; Samani A, 2017, EXP BRAIN RES, V235, P389, DOI 10.1007/s00221-016-4798-y; Samani A, 2010, EUR J APPL PHYSIOL, V110, P415, DOI 10.1007/s00421-010-1515-6; Samani A, 2010, MED BIOL ENG COMPUT, V48, P865, DOI 10.1007/s11517-010-0651-9; Samani A, 2009, J ELECTROMYOGR KINES, V19, pE430, DOI 10.1016/j.jelekin.2008.11.011; Sampei K, 2016, MICROMACHINES-BASEL, V7, DOI 10.3390/mi7020020; Satterfield BC, 2013, FATIGUE, V1, P118, DOI 10.1080/21641846.2013.798923; Schalen L, 1983, ACTA OTO-LARYNGOL, V96, P212, DOI [10.3109/00016488309123036, DOI 10.3109/00016488309123036]; Schleicher R, 2008, ERGONOMICS, V51, P982, DOI 10.1080/00140130701817062; Schmidt C, 2007, COGN NEUROPSYCHOL, V24, P755, DOI 10.1080/02643290701754158; Shahid A, 2010, J PSYCHOSOM RES, V69, P81, DOI 10.1016/j.jpsychores.2010.04.001; Silvian S. Paul, 2011, International Journal of Enterprise Network Management, V4, P247; Solomon SR, 2009, J MOD APPL STAT METH, V8, P448, DOI 10.22237/jmasm/1257034080; Steinborn MB, 2016, APPL COGNITIVE PSYCH, V30, P795, DOI 10.1002/acp.3255; Swaen GMH, 2003, OCCUP ENVIRON MED, V60, P88; Szegletes L, 2014, 2014 5TH IEEE CONFERENCE ON COGNITIVE INFOCOMMUNICATIONS (COGINFOCOM), P295, DOI 10.1109/CogInfoCom.2014.7020465; Temple JL, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00080; Tucker P, 2003, WORK STRESS, V17, P123, DOI 10.1080/0267837031000155949; Vlemincx E, 2011, PSYCHOPHYSIOLOGY, V48, P117, DOI 10.1111/j.1469-8986.2010.01043.x; Waersted Morten, 2010, BMC Musculoskelet Disord, V11, P79, DOI 10.1186/1471-2474-11-79; Wakui Hideki, 2014, JAPANESE SOC MED BIO, V51, P328; Wascher E, 2014, BIOL PSYCHOL, V96, P57, DOI 10.1016/j.biopsycho.2013.11.010; Wells R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046597; Wickens C.D., 1991, MULTIPLE TASK PERFOR, V1991, P3, DOI [10.1201/9781003069447-2, DOI 10.1201/9781003069447-2]; Wilhelm B, 2010, SOMNOLOGIE, V14, P200, DOI DOI 10.1007/; Williamson A, 2013, FATIGUE, V1, P81, DOI 10.1080/21641846.2012.744581; Xiong JS, 2012, PHYSCS PROC, V33, P2011, DOI 10.1016/j.phpro.2012.05.316; Xu R, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00915; Yamada Y., 2018, United States patent application, Patent No. [US15/345,876, 15345876]; Yamada Y, 2018, ARTIF INTELL MED, V91, P39, DOI 10.1016/j.artmed.2018.06.005; Yang GS, 2010, INFORM SCIENCES, V180, P1942, DOI 10.1016/j.ins.2010.01.011; Yorzinski JL, 2016, SCI REP-UK, V6, DOI 10.1038/srep32471; Yung M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188468; Zhang C, 2009, EXPERT SYST APPL, V36, P4664, DOI 10.1016/j.eswa.2008.06.022; Zhang C, 2010, POL J MED PHYS ENG, V16, P67, DOI 10.2478/v10013-010-0007-7; Zheng YL, 2014, IEEE T BIO-MED ENG, V61, P2179, DOI 10.1109/TBME.2014.2318779	132	8	8	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2019	14	5							e0213704	10.1371/journal.pone.0213704	http://dx.doi.org/10.1371/journal.pone.0213704			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IA7TI	31150405	Green Published, gold, Green Submitted			2023-01-03	WOS:000469759100007
J	Ooms, G; Hanefeld, J				Ooms, Gorik; Hanefeld, Johanna			Threat of compulsory licences could increase access to essential medicines	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PUBLIC-HEALTH; BRAZIL; DRUGS		[Ooms, Gorik] London Sch Hyg & Trop Med, Dept Global Hlth & Dev, Fac Publ Hlth & Policy, Global Hlth Law & Governance, London, England; [Hanefeld, Johanna] London Sch Hyg & Trop Med, Dept Global Hlth & Dev, Fac Publ Hlth & Policy, Hlth Policy & Syst, London, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Ooms, G (corresponding author), London Sch Hyg & Trop Med, Dept Global Hlth & Dev, Fac Publ Hlth & Policy, Global Hlth Law & Governance, London, England.	gorik.ooms@lshtm.ac.uk	Ooms, Gorik/A-2537-2015	Ooms, Gorik/0000-0002-9804-0128				Abbas MZ, 2017, J INTELLECTUAL PROPE, V12, P451; Abbott FM, 2007, J INT ECON LAW, V10, P921, DOI 10.1093/jiel/jgm040; Attaran A, 2001, JAMA-J AM MED ASSOC, V286, P1886, DOI 10.1001/jama.286.15.1886; Cohen-Kohler JC, 2007, GLOBALIZATION HEALTH, V3, DOI 10.1186/1744-8603-3-12; Drahos P., 2002, J WORLD INTELLECTUAL, V5, P765, DOI DOI 10.1111/J.1747-1796.2002.TB00181.X; Elliott R, 2007, MCGILL INT J SUSTAIN, V3, P23; Ford N, 2007, AIDS, V21, pS21, DOI 10.1097/01.aids.0000279703.78685.a6; Galvao J, 2005, AM J PUBLIC HEALTH, V95, P1110, DOI 10.2105/AJPH.2004.044313; Gervais D., 2012, TRIPS AGREEMENT DRAF; Goodwin PE, 2008, AM J LAW MED, V34, P567, DOI 10.1177/009885880803400404; Greenbaum Jessica L, 2008, J Contemp Health Law Policy, V25, P142; Hestermeyer Holger, 2007, HUMAN RIGHTS WTO CAS; Iyengar S, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002032; Matthews D, 2004, J INT ECON LAW, V7, P73, DOI 10.1093/jiel/7.1.73; Medecins Sans Frontieres, 2006, UNT WEB PRIC RED PRI; Mullin T. F., 2002, ILSA J INT COMP L, V9, P185; Ooms G, 2014, BMC INT HEALTH HUM R, V14, DOI 10.1186/s12914-014-0037-4; Reichman JH, 2009, J LAW MED ETHICS, V37, P247, DOI 10.1111/j.1748-720X.2009.00369.x; Rimmer M, 2008, PUBLIC HEALTH ETH-UK, V1, P89, DOI 10.1093/phe/phn011; Saez C, 2017, MALAYSIA GRANTS COMP; Sekalala S, 2017, SOFT LAW AND GLOBAL HEALTH PROBLEMS: LESSONS FROM RESPONSES TO HIV/AIDS, MALARIA AND TUBERCULOSIS, P1, DOI 10.1017/9781107278950; Sell S., 2010, J INTELLECTUAL PROPE, V18, P447; 't Hoen Ellen, 2002, Chic J Int Law, V3, P27; UN secretary-general's high-level panel on access to medicines, 2015, UN SECR GEN HIGH LEV; United Nations, 2018, TRANSF OUR WORLD 203	25	9	9	2	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 28	2019	365								l2098	10.1136/bmj.l2098	http://dx.doi.org/10.1136/bmj.l2098			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IB3EJ	31138530	hybrid, Green Published, Green Accepted			2023-01-03	WOS:000470150500001
J	Arefian, H; Hagel, S; Fischer, D; Scherag, A; Brunkhorst, FM; Maschmann, J; Hartmann, M				Arefian, Habibollah; Hagel, Stefan; Fischer, Dagmar; Scherag, Andre; Brunkhorst, Frank Martin; Maschmann, Jens; Hartmann, Michael			Estimating extra length of stay due to healthcare-associated infections before and after implementation of a hospital-wide infection control program	PLOS ONE			English	Article							HAND HYGIENE COMPLIANCE; TIME-DEPENDENT BIAS; GUIDELINES; COST	Introduction Healthcare-associated infections (HAIs) are a major health concern and have substantial effects on morbidity and mortality and increase healthcare costs. We investigated the effect of a hospital-wide program for the prevention of HAIs on additional length of stay (LOS). Methods We analyzed data from a prospective, single-center, quasi-experimental study with two surveillance periods before and after implementation of an infection prevention intervention program. HAI diagnosis was made according to surveillance definition criteria established by the US Centers for Disease Control and Prevention. A multistate model was used to estimate additional LOS for patients with HAI in both surveillance periods. Results During the first and second periods, 1,568 and 2,336 HAIs were identified among 26,943 and 35,211 patients, respectively. For HAI patients exclusively treated in a general ward, additional LOS was 8.4 (95% confidence interval, CI: 6.8-10.0) days in the first period and 9.6 (95% CI: 8.3-11.0) days in the second period (p = 0.26). For HAI patients treated in both an intensive care unit (ICU) and a general ward, additional LOS was 8.1 (95% CI: 6.3-9.9) days in the first period to 7.3 (95% CI: 6.1-8.5) days in the second period (p = 0.47). Conclusions Healthcare-associated infections prolong LOS. A hospital-wide infection control program did not alter the prolongation of LOS.	[Arefian, Habibollah; Hagel, Stefan; Scherag, Andre; Brunkhorst, Frank Martin; Hartmann, Michael] Jena Univ Hosp, CSCC, Jena, Germany; [Arefian, Habibollah; Fischer, Dagmar] Friedrich Schiller Univ Jena, Dept Pharmaceut Technol & Biopharm, Jena, Germany; [Arefian, Habibollah; Hartmann, Michael] Jena Univ Hosp, Hosp Pharm, Jena, Germany; [Hagel, Stefan] Jena Univ Hosp, Inst Infect Dis & Infect Control, Jena, Germany; [Scherag, Andre] Jena Univ Hosp, Inst Med Stat Comp & Data Sci, Jena, Germany; [Brunkhorst, Frank Martin] Jena Univ Hosp, Ctr Clin Studies, Jena, Germany; [Brunkhorst, Frank Martin] Jena Univ Hosp, Dept Anesthesiol & Intens Care Med, Paul Martini Clin Sepsis Res Unit, Jena, Germany; [Maschmann, Jens] Jena Univ Hosp, Jena, Germany	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena	Arefian, H (corresponding author), Jena Univ Hosp, CSCC, Jena, Germany.; Arefian, H (corresponding author), Friedrich Schiller Univ Jena, Dept Pharmaceut Technol & Biopharm, Jena, Germany.; Arefian, H (corresponding author), Jena Univ Hosp, Hosp Pharm, Jena, Germany.	Habibollah.Arefian@med.uni-jena.de	Hartmann, Michael/Y-2331-2019; Arefian, Habib/AAK-3701-2020; Hagel, Stefan/AAE-1174-2022	Arefian, Habib/0000-0002-8838-084X; Hagel, Stefan/0000-0003-2999-6131; Hartmann, Michael/0000-0002-6777-4540	German Ministry of Education and Research (BMBF) [FKZ 01EO1002, 01EO1502]	German Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	The CSCC and this research were supported by the German Ministry of Education and Research (BMBF) under grants FKZ 01EO1002 and 01EO1502.	AALEN OO, 1978, SCAND J STAT, V5, P141; Allegranzi B, 2009, J HOSP INFECT, V73, P305, DOI 10.1016/j.jhin.2009.04.019; Allignol A, 2011, COMPUTATION STAT, V26, P181, DOI 10.1007/s00180-010-0200-x; ANDERSON JR, 1983, J CLIN ONCOL, V1, P710, DOI 10.1200/JCO.1983.1.11.710; Arefian H, 2016, AM J INFECT CONTROL, V44, P160, DOI 10.1016/j.ajic.2015.09.005; Barnett AG, 2011, VALUE HEALTH, V14, P381, DOI 10.1016/j.jval.2010.09.008; Beyersmann J, 2006, INFECT CONT HOSP EP, V27, P493, DOI 10.1086/503375; Beyersmann J, 2011, COMPETING RISKS MULT; Beyersmann J, 2011, BIOMETRICAL J, V53, P332, DOI 10.1002/bimj.201000146; Dasta JF, 2005, CRIT CARE MED, V33, P1266, DOI 10.1097/01.CCM.0000164543.14619.00; Erasmus V, 2010, INFECT CONT HOSP EP, V31, P283, DOI 10.1086/650451; Graves N, 2010, CLIN INFECT DIS, V50, P1017, DOI 10.1086/651110; Hagel S, CLIN MICROBIOLOGY IN; Hagel S, 2015, INFECT CONT HOSP EP, V36, P957, DOI 10.1017/ice.2015.93; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; Macedo-Vinas M, 2013, J HOSP INFECT, V84, P132, DOI 10.1016/j.jhin.2013.02.015; McGuckin M, 2009, AM J MED QUAL, V24, P205, DOI 10.1177/1062860609332369; Nelson RE, 2015, INFECT CONT HOSP EP, V36, P1089, DOI 10.1017/ice.2015.129; Pittet D, 2000, LANCET, V356, P1307, DOI 10.1016/S0140-6736(00)02814-2; Pittet D, 2009, INFECT CONT HOSP EP, V30, P611, DOI 10.1086/600379; Schulgen G, 1996, Lifetime Data Anal, V2, P219, DOI 10.1007/BF00128975; Sickbert-Bennett EE, 2016, EMERG INFECT DIS, V22, P1628, DOI 10.3201/eid2209.151440; Stewardson AJ, 2016, EURO SURVEILL, V21; Umscheid CA, 2011, INFECT CONT HOSP EP, V32, P101, DOI 10.1086/657912	24	10	10	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 17	2019	14	5							e0217159	10.1371/journal.pone.0217159	http://dx.doi.org/10.1371/journal.pone.0217159			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY5OE	31100094	Green Published, Green Submitted, gold			2023-01-03	WOS:000468176600032
J	Peters, L; Olson, L; Khu, DTK; Linnros, S; Le, NK; Hanberger, H; Hoang, NTB; Tran, DM; Larsson, M				Peters, Lynn; Olson, Linus; Khu, Dung T. K.; Linnros, Sofia; Le, Ngai K.; Hanberger, Hakan; Hoang, Ngoc T. B.; Tran, Dien M.; Larsson, Mattias			Multiple antibiotic resistance as a risk factor for mortality and prolonged hospital stay: A cohort study among neonatal intensive care patients with hospital-acquired infections caused by gram-negative bacteria in Vietnam	PLOS ONE			English	Article							BLOOD-STREAM INFECTIONS; VENTILATOR-ASSOCIATED PNEUMONIA; ACINETOBACTER-BAUMANNII BACTEREMIA; PSEUDOMONAS-AERUGINOSA BACTEREMIA; ANTIMICROBIAL RESISTANCE; CLINICAL CHARACTERISTICS; NOSOCOMIAL INFECTIONS; OUTCOMES; UNIT; SPECTRUM	Background Antibiotic resistance (ABR) is an increasing burden for global health. The prevalence of ABR in Southeast Asia is among the highest worldwide, especially in relation to hospital acquired infections (HAI) in intensive care units (ICU). However, little is known about morbidity and mortality attributable to ABR in neonates. Aim This study aimed to assess mortality and the length of hospitalization attributable to ABR in gram-negative bacteria (GNB) causing HAI in a Vietnamese neonatal ICU (NICU). Methods We conducted a prospective cohort study (n = 296) in a NICU in Hanoi, Vietnam, from March 2016 to October 2017. Patients isolated with HAI caused by GNB were included. The exposure was resistance to multiple antibiotic classes, the two outcomes were mortality and length of hospital stay (LOS). Data were analysed using two regression models, controlling for confounders and effect modifiers such as co-morbidities, time at risk, severity of illness, sex, age, and birthweight. Results The overall case fatality rate was 44.3% and the 30 days mortality rate after infection was 31.8%. For every additional resistance to an antibiotic class, the odds of a fatal outcome increased by 27% and LOS increased by 2.1 days. These results were statistically significant (p < 0.05). Conclusion ABR was identified as a significant risk factor for adverse outcomes in neonates with HAI. These findings are generally in line with previous research in children and adults. However, heterogeneous study designs, the neglect of important confounders and varying definitions of ABR impair the validity, reliability, and comparability of results.	[Peters, Lynn; Linnros, Sofia] Karolinska Inst, Global Hlth program, Stockholm, Sweden; [Olson, Linus; Larsson, Mattias] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden; [Olson, Linus; Khu, Dung T. K.; Le, Ngai K.; Larsson, Mattias] Karolinska Inst, Training & Res Acad Collaborat Sweden Vietnam, Stockholm, Sweden; [Khu, Dung T. K.] Vietnam Natl Childrens Hosp, Dept Neonatol, Hanoi, Vietnam; [Le, Ngai K.; Hoang, Ngoc T. B.] Vietnam Natl Childrens Hosp, Dept Microbiol, Hanoi, Vietnam; [Hanberger, Hakan] Linkoping Univ, Fac Med & Hlth Sci, Dept Clin & Expt Med, Linkoping, Sweden; [Tran, Dien M.] Res Inst Child Hlth, Hanoi, Vietnam; [Tran, Dien M.] Vietnam Natl Childrens Hosp, Dept Surg, Hanoi, Vietnam	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Linkoping University	Larsson, M (corresponding author), Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden.; Larsson, M (corresponding author), Karolinska Inst, Training & Res Acad Collaborat Sweden Vietnam, Stockholm, Sweden.	mattias.larsson@ki.se	Olson, Linus O/A-5604-2011		Swedish Foundation for International Cooperation in Research and Higher Education (STINT); ReAct; Karolinska Institutet; TRAC (Training and Research Academic Collaboration) Sweden-Vietnam	Swedish Foundation for International Cooperation in Research and Higher Education (STINT); ReAct; Karolinska Institutet(Karolinska Institutet); TRAC (Training and Research Academic Collaboration) Sweden-Vietnam	No authors have financial disclosure to report. This work was supported by: Swedish Foundation for International Cooperation in Research and Higher Education (STINT) (All Authors), ReAct, and Karolinska Institutet (LP, SL doing their Master theses). The sponsors supported the study financially through the TRAC (Training and Research Academic Collaboration) Sweden-Vietnam. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Ethical considerations. The study was approved by the ethical board of the Vietnam Children's Hospital in 2015. All caretakers were informed about the study procedure and gave their consent prior to enrollment in the study. Caretakers could withdraw their children at any time from the study without justification.	Abdel-Hady H, 2008, J PERINATOL, V28, P685, DOI 10.1038/jp.2008.73; Al Jarousha AMK, 2009, INT J INFECT DIS, V13, P623, DOI 10.1016/j.ijid.2008.08.029; Al-Taiar A, 2013, ARCH DIS CHILD-FETAL, V98, pF249, DOI 10.1136/archdischild-2012-301767; Allegranzi B, 2011, LANCET, V377, P228, DOI 10.1016/S0140-6736(10)61458-4; Aloush V, 2006, ANTIMICROB AGENTS CH, V50, P43, DOI 10.1128/AAC.50.1.43-48.2006; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; [Anonymous], 2017, LEVELS TRENDS CHILD; Apisarnthanarak A, 2004, INFECT CONT HOSP EP, V25, P735, DOI 10.1086/502469; Bas AY, 2010, TURKISH J PEDIATR, V52, P464; Basra P, 2018, GENOME BIOL EVOL, V10, P667, DOI 10.1093/gbe/evy030; Bin T, 2014, AM J INFECT CONTROL, V42, P902, DOI 10.1016/j.ajic.2014.05.007; Cassini A, 2019, LANCET INFECT DIS, V19, P56, DOI 10.1016/S1473-3099(18)30605-4; CDC, CDC ANT RES ATL; CDC, 2013, PREV CFDCA; Chaurasia S, 2016, LANCET GLOB HEALTH, V4, pE752, DOI 10.1016/S2214-109X(16)30148-6; Chereau F, 2017, BMJ-BRIT MED J, V358, P2, DOI 10.1136/bmj.j3393; Cosgrove SE, 2002, ARCH INTERN MED, V162, P185, DOI 10.1001/archinte.162.2.185; Cosgrove SE, 2003, CLIN INFECT DIS, V36, P1433, DOI 10.1086/375081; Dantas RC, 2014, J MED MICROBIOL, V63, P1679, DOI 10.1099/jmm.0.073262-0; Dorling JS, 2005, ARCH DIS CHILD-FETAL, V90, pF11, DOI 10.1136/adc.2003.048488; ECDC, 2016, CONTR ECFDPA, P22; Evans SR, 2017, VIRULENCE, V8, P453, DOI 10.1080/21505594.2016.1213473; Falagas ME, 2006, J HOSP INFECT, V64, P7, DOI 10.1016/j.jhin.2006.04.015; Foglia EE, 2007, INFECT CONT HOSP EP, V28, P299, DOI 10.1086/512628; Folgori L, 2016, INFECT CONT HOSP EP, V37, P1302, DOI 10.1017/ice.2016.185; Garg B, 2018, J MATERN-FETAL NEO M, V31, P1373, DOI 10.1080/14767058.2017.1315665; GREEN SB, 1991, MULTIVAR BEHAV RES, V26, P499, DOI 10.1207/s15327906mbr2603_7; Hyle EP, 2005, ARCH INTERN MED, V165, P1375, DOI 10.1001/archinte.165.12.1375; Ivady B, 2016, INFECTION, V44, P309, DOI 10.1007/s15010-015-0857-8; Johnson PJ, 2012, NEONATAL NETW, V31, P109, DOI 10.1891/0730-0832.31.2.109; Juan C, 2005, CLIN MICROBIOL INFEC, V11, P887, DOI 10.1111/j.1469-0691.2005.01251.x; Kaye KS, 2015, PHARMACOTHERAPY, V35, P949, DOI 10.1002/phar.1636; Kollef MH, 2001, ANN INTERN MED, V134, P298, DOI 10.7326/0003-4819-134-4-200102200-00014; Kumar A, 2014, J INFECT DEV COUNTR, V8, P1049, DOI 10.3855/jidc.4248; Leblebicioglu H, 2013, ANN CLIN MICROB ANTI, V12, DOI 10.1186/1476-0711-12-10; Lin MF, 2014, WORLD J CLIN CASES, V2, P787, DOI 10.12998/wjcc.v2.i12.787; Magiorakos AP, 2012, CLIN MICROBIOL INFEC, V18, P268, DOI 10.1111/j.1469-0691.2011.03570.x; Maragakis LL, 2008, EXPERT REV ANTI-INFE, V6, P751, DOI 10.1586/14787210.6.5.751; Mauldin PD, 2010, ANTIMICROB AGENTS CH, V54, P109, DOI 10.1128/AAC.01041-09; Melnyk AH, 2015, EVOL APPL, V8, P273, DOI 10.1111/eva.12196; Morkel G, 2014, PAEDIATR INT CHILD H, V34, P108, DOI 10.1179/2046905513Y.0000000082; Nakwan N, 2011, PEDIATR PULM, V46, P60, DOI 10.1002/ppul.21324; Newgard CD, 2007, ACAD EMERG MED, V14, P669, DOI 10.1197/j.aem.2006.11.038; Le NK, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004099; Nikkhoo B, 2015, ITAL J PEDIATR, V41, DOI 10.1186/s13052-015-0136-4; O'Grady NP, 2011, AM J INFECT CONTROL, V39, pS1, DOI 10.1016/j.ajic.2011.01.003; Ozgur ES, 2014, AM J INFECT CONTROL, V42, P206, DOI 10.1016/j.ajic.2013.09.003; Paphitou NI, 2013, INT J ANTIMICROB AG, V42, pS25, DOI 10.1016/j.ijantimicag.2013.04.007; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Plano LRW, 2010, J PERINATOL, V30, pS16, DOI 10.1038/jp.2010.92; Prata-Rocha ML, 2012, BRAZ J INFECT DIS, V16, P237, DOI 10.1590/S1413-86702012000300004; Punpanich W, 2012, INT J INFECT DIS, V16, pE811, DOI 10.1016/j.ijid.2012.07.006; Review on Antimicrobial Resistance, 2014, REV ANTIMICROB RESIS; Saleem AF, 2010, J INFECT DEV COUNTR, V4, P30, DOI 10.3855/jidc.533; Salehi B, 2018, J INFECT CHEMOTHER; Schechner V, 2013, CLIN MICROBIOL REV, V26, P289, DOI 10.1128/CMR.00001-13; Schwaber MJ, 2006, CRIT CARE, V10, DOI 10.1186/cc5019; Schwaber MJ, 2009, CRIT CARE, V13, DOI 10.1186/cc7136; Sehgal R, 2007, ANN TROP PAEDIATR, V27, P45, DOI 10.1179/146532807X170501; Shitaye Demissie, 2010, Ethiop Med J, V48, P11; Song JH, 2015, DVNAMICS WAAARAGH; Sonmezer MC, 2016, CAN J INFECT DIS MED, V2016, DOI 10.1155/2016/1321487; Teerawattanapong N, 2018, INFECT CONT HOSP EP, V39, P525, DOI 10.1017/ice.2018.58; Thatrimontrichai A, 2016, J INFECT CHEMOTHER, V22, P444, DOI 10.1016/j.jiac.2016.03.013; Thatrimontrichai A, 2013, PEDIATR INFECT DIS J, V32, P140, DOI 10.1097/INF.0b013e318270b108; Tiskumara R, 2009, ARCH DIS CHILD-FETAL, V94, pF144, DOI 10.1136/adc.2008.139865; UNICEF, 2018, EV CHILD AL URG NEED; Viswanathan R, 2012, ARCH DIS CHILD-FETAL, V97, pF182, DOI 10.1136/archdischild-2011-300097; Wei HM, 2015, J MICROBIOL IMMUNOL, V48, P531, DOI 10.1016/j.jmii.2014.08.025; [WHO Organisation WH], 2015, WORLDW COUNTN SIT AN; Wilson R., 2007, UNDERSTANDING POWER; Xu XF, 2010, J PERINAT MED, V38, P431, DOI [10.1515/JPM.2010.063, 10.1515/jpm.2010.063]; Yang MA, 2011, J KOREAN MED SCI, V26, P612, DOI 10.3346/jkms.2011.26.5.612; Zaidi AKM, 2005, LANCET, V365, P1175, DOI 10.1016/S0140-6736(05)71881-X; Zaoutis TE, 2005, PEDIATRICS, V115, P942, DOI 10.1542/peds.2004-1289; Zhang Tong-qiang, 2011, Zhonghua Er Ke Za Zhi, V49, P545; DRUG RESIST UPDATE, V3, P237, DOI DOI 10.1054/DRUP.2000.0147; 2017, J INFECT PUBLIC HEAL, V10, P608, DOI DOI 10.1016/J.JIPH.2017.01.014	78	43	45	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 8	2019	14	5							e0215666	10.1371/journal.pone.0215666	http://dx.doi.org/10.1371/journal.pone.0215666			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX4MT	31067232	Green Published, gold, Green Submitted			2023-01-03	WOS:000467373000015
J	Yang, W; Lee, KW; Srivastava, RM; Kuo, FS; Krishna, C; Chowell, D; Makarov, V; Hoen, D; Dalin, MG; Wexler, L; Ghossein, R; Katabi, N; Nadeem, Z; Cohen, MA; Tian, SK; Robine, N; Arora, K; Geiger, H; Agius, P; Bouvier, N; Huberman, K; Vanness, K; Havel, JJ; Sims, JS; Samstein, RM; Mandal, R; Tepe, J; Ganly, I; Ho, AL; Riaz, N; Wong, RJ; Shukla, N; Chan, TA; Morris, LGT				Yang, Wei; Lee, Ken-Wing; Srivastava, Raghvendra M.; Kuo, Fengshen; Krishna, Chirag; Chowell, Diego; Makarov, Vladimir; Hoen, Douglas; Dalin, Martin G.; Wexler, Leonard; Ghossein, Ronald; Katabi, Nora; Nadeem, Zaineb; Cohen, Marc A.; Tian, S. Ken; Robine, Nicolas; Arora, Kanika; Geiger, Heather; Agius, Phaedra; Bouvier, Nancy; Huberman, Kety; Vanness, Katelynd; Havel, Jonathan J.; Sims, Jennifer S.; Samstein, Robert M.; Mandal, Rajarsi; Tepe, Justin; Ganly, Ian; Ho, Alan L.; Riaz, Nadeem; Wong, Richard J.; Shukla, Neerav; Chan, Timothy A.; Morris, Luc G. T.			Immunogenic neoantigens derived from gene fusions stimulate T cell responses	NATURE MEDICINE			English	Article							TUMOR-ANTIGENS; SOMATIC MUTATIONS; BCR-ABL; CANCER; LANDSCAPE; IMMUNOTHERAPY; INDUCTION; PEPTIDES; BLOCKADE; PROTEIN	Anti-tumor immunity is driven by self versus non-self discrimination. Many immunotherapeutic approaches to cancer have taken advantage of tumor neoantigens derived from somatic mutations. Here, we demonstrate that gene fusions are a source of immunogenic neoantigens that can mediate responses to immunotherapy. We identified an exceptional responder with metastatic head and neck cancer who experienced a complete response to immune checkpoint inhibitor therapy, despite a low mutational load and minimal pre-treatment immune infiltration in the tumor. Using whole-genome sequencing and RNA sequencing, we identified a novel gene fusion and demonstrated that it produces a neoantigen that can specifically elicit a host cytotoxic T cell response. In a cohort of head and neck tumors with low mutation burden, minimal immune infiltration and prevalent gene fusions, we also identified gene fusion-derived neoantigens that generate cytotoxic T cell responses. Finally, analyzing additional datasets of fusion-positive cancers, including checkpoint-inhibitor-treated tumors, we found evidence of immune surveillance resulting in negative selective pressure against gene fusion-derived neoantigens. These findings highlight an important class of tumor-specific antigens and have implications for targeting gene fusion events in cancers that would otherwise be less poised for response to immunotherapy, including cancers with low mutational load and minimal immune infiltration.	[Yang, Wei; Lee, Ken-Wing; Havel, Jonathan J.; Chan, Timothy A.; Morris, Luc G. T.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA; [Yang, Wei; Srivastava, Raghvendra M.; Kuo, Fengshen; Chowell, Diego; Makarov, Vladimir; Hoen, Douglas; Havel, Jonathan J.; Sims, Jennifer S.; Mandal, Rajarsi; Riaz, Nadeem; Chan, Timothy A.; Morris, Luc G. T.] Mem Sloan Kettering Canc Ctr, Immunogen & Precis Oncol Platform, 1275 York Ave, New York, NY 10021 USA; [Krishna, Chirag] Mem Sloan Kettering Canc Ctr, Computat & Syst Biol Program, 1275 York Ave, New York, NY 10021 USA; [Dalin, Martin G.] Univ Gothenburg, Inst Clin Sci, Dept Pediat, Gothenburg, Sweden; [Wexler, Leonard] Mem Sloan Kettering Canc Ctr, Dept Pediat, 1275 York Ave, New York, NY 10021 USA; [Ghossein, Ronald; Katabi, Nora; Shukla, Neerav] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Nadeem, Zaineb; Cohen, Marc A.; Mandal, Rajarsi; Tepe, Justin; Ganly, Ian; Wong, Richard J.; Morris, Luc G. T.] Mem Sloan Kettering Canc Ctr, Dept Surg, Head & Neck Serv, New York, NY 10021 USA; [Tian, S. Ken; Robine, Nicolas; Arora, Kanika; Geiger, Heather; Agius, Phaedra] New York Genome Ctr, New York, NY USA; [Bouvier, Nancy; Huberman, Kety; Vanness, Katelynd] Mem Sloan Kettering Canc Ctr, Integrated Genom Operat, 1275 York Ave, New York, NY 10021 USA; [Samstein, Robert M.; Riaz, Nadeem; Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA; [Ho, Alan L.] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Gothenburg; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Chan, TA; Morris, LGT (corresponding author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA.; Chan, TA; Morris, LGT (corresponding author), Mem Sloan Kettering Canc Ctr, Immunogen & Precis Oncol Platform, 1275 York Ave, New York, NY 10021 USA.; Morris, LGT (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, Head & Neck Serv, New York, NY 10021 USA.; Chan, TA (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA.	chant@mskcc.org; morrisl@mskcc.org	Arora, Kanika/ABC-8522-2021; Chan, Timothy A/ABD-5850-2021	Arora, Kanika/0000-0001-9537-8708; Robine, Nicolas/0000-0001-5698-8183; Riaz, Nadeem/0000-0001-9873-5862; Kuo, Fengshen/0000-0003-1797-2896; Samstein, Robert/0000-0001-6860-2401	NIH/NCI Cancer Center Support Grant [P30 CA008748]; Cycle for Survival; Frederick Adler Chair at MSKCC; Jayme Flowers Fund; Damon Runyon Cancer Research Foundation; NIH [K08 DE024774, R01 DE027738, R01 CA205426, R35 CA232097]; Adenoid Cystic Carcinoma Cancer Research Foundation; Geoffrey Beene Junior Faculty Chair; Pershing Square Sohn Cancer Research Alliance; STARR Cancer Consortium; PaineWebber Chair at MSKCC; Sebastian Nativo Fund; NATIONAL CANCER INSTITUTE [R01CA205426, P30CA008748, T32CA160001, R35CA232097] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE027738, K08DE024774] Funding Source: NIH RePORTER	NIH/NCI Cancer Center Support Grant; Cycle for Survival; Frederick Adler Chair at MSKCC; Jayme Flowers Fund; Damon Runyon Cancer Research Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Adenoid Cystic Carcinoma Cancer Research Foundation; Geoffrey Beene Junior Faculty Chair; Pershing Square Sohn Cancer Research Alliance(Pershing Square Sohn Cancer Research Alliance); STARR Cancer Consortium; PaineWebber Chair at MSKCC; Sebastian Nativo Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	The authors wish to acknowledge our patients and their families who selflessly contributed time and samples to support this research, the patients and investigators who contributed to the TCGA studies analyzed here, McKenzy and Beth Hupke, members of the Timothy Chan Laboratory for insightful discussions, members of the MSKCC Immunogenomics and Precision Oncology Platform and the Molecular Cytology Core Facility of MSKCC. This work was supported by the NIH/NCI Cancer Center Support Grant no. P30 CA008748 (to MSKCC), Cycle for Survival (R.J.W., L.G.T.M. and T.A.C.), the Frederick Adler Chair at MSKCC, the Jayme Flowers Fund, the Sebastian Nativo Fund, the Damon Runyon Cancer Research Foundation, NIH grant nos. K08 DE024774 and NIH R01 DE027738 (L.G.T.M.), the Adenoid Cystic Carcinoma Cancer Research Foundation, (T.A.C., A.L.H. and L.G.T.M.), The Geoffrey Beene Junior Faculty Chair (A.L.H.), NIH grant nos. R01 CA205426 and NIH R35 CA232097, the Pershing Square Sohn Cancer Research Alliance, the STARR Cancer Consortium and the PaineWebber Chair at MSKCC (T.A.C.).	Adams AK, 2015, ONCOGENE, V34, P868, DOI 10.1038/onc.2014.15; Angelova M, 2018, CELL, V175, P751, DOI 10.1016/j.cell.2018.09.018; Buzyn A, 1997, EUR J IMMUNOL, V27, P2066, DOI 10.1002/eji.1830270834; Chowell D, 2018, SCIENCE, V359, P582, DOI 10.1126/science.aao4572; Coulie PG, 2014, NAT REV CANCER, V14, P135, DOI 10.1038/nrc3670; Dalin MG, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01178-z; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; GAMBACORTIPASSERINI C, 1993, BLOOD, V81, P1369; Gao QS, 2018, CELL REP, V23, P227, DOI 10.1016/j.celrep.2018.03.050; Ho AS, 2013, NAT GENET, V45, P791, DOI 10.1038/ng.2643; Ilyas S, 2015, J IMMUNOL, V195, P5117, DOI 10.4049/jimmunol.1501657; Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Makita M, 2002, LEUKEMIA, V16, P2400, DOI 10.1038/sj.leu.2402742; Mandal R, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89829; Marty R, 2017, CELL, V171, P1272, DOI 10.1016/j.cell.2017.09.050; McGranahan N, 2017, CELL, V170, P825, DOI 10.1016/j.cell.2017.08.012; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Qin H, 2016, ONCOGENE, V35, P5686, DOI 10.1038/onc.2016.118; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Rosenberg SA, 2015, SCIENCE, V348, P62, DOI 10.1126/science.aaa4967; Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8; Sato Y, 2002, J IMMUNOL, V169, P1611, DOI 10.4049/jimmunol.169.3.1611; Scheper W, 2019, NAT MED, V25, P89, DOI 10.1038/s41591-018-0266-5; Scholtalbers J, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0240-5; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Senbabaoglu Y, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1092-z; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shen RL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw520; Shukla SA, 2018, CELL, V173, P624, DOI 10.1016/j.cell.2018.03.026; Shukla SA, 2015, NAT BIOTECHNOL, V33, P1152, DOI 10.1038/nbt.3344; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Stevanovic S, 2017, SCIENCE, V356, P200, DOI 10.1126/science.aak9510; Stronen E, 2016, SCIENCE, V352, P1337, DOI 10.1126/science.aaf2288; Thorsson V, 2018, IMMUNITY, V48, P812, DOI [10.1016/j.immuni.2018.03.023, 10.1016/j.immuni.2019.08.004]; Tran E, 2015, SCIENCE, V350, P1387, DOI 10.1126/science.aad1253; van den Broeke LT, 2006, CANCER RES, V66, P1818, DOI 10.1158/0008-5472.CAN-05-2549; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yotnda P, 1998, J CLIN INVEST, V102, P455, DOI 10.1172/JCI3126	44	156	158	2	59	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2019	25	5					767	+		10.1038/s41591-019-0434-2	http://dx.doi.org/10.1038/s41591-019-0434-2			23	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	HY6NU	31011208	Green Accepted			2023-01-03	WOS:000468247800020
J	Gonzalez-Galvez, N; Gea-Garcia, GM; Marcos-Pardo, PJ				Gonzalez-Galvez, Noelia; Gea-Garcia, Gemma M.; Marcos-Pardo, Pablo J.			Effects of exercise programs on kyphosis and lordosis angle: A systematic review and meta-analysis	PLOS ONE			English	Review							LOW-BACK-PAIN; THORACIC KYPHOSIS; SAGITTAL ALIGNMENT; INTERRATER RELIABILITY; SPINAL CURVATURES; LUMBAR LORDOSIS; POSTURE; VALIDITY; MOTION; PLAYERS	Many authors are interested in the effects that a specific exercise program could have on sagittal spinal curvatures. The purpose of this study was to determine the effects of different exercise programs on thoracic kyphosis and lumbar lordotic angle. This meta-analysis adhered to the PRISMA guideline and it was registered at PROSPERO. Five electronic databases (Pub Med, Cochrane, WOS, PEDro and EBSCO) were searched up to 31 July 2018. Eligible studies were randomized controlled trials that applied an exercise intervention and measured a kyphosis and/or lordotic angle. Study quality was performance by PEDro score. Risk of bias was assessed using the SIGN 50 checklist for randomized controlled trials. External validity was assessed using the EVAT. Ten randomized controlled trials were included for systematic review and meta-analysis. Meta-analysis with a random effect model was performed to infer the pooled estimated standardized mean difference. All studies were RCTs and they involved a total of 284 cases and 255 controls. Seven studies measured kyphosis angle. A large significant effect of the exercise on kyphosis was identified (SMD = -1.400 (95% CI-2.150 a -0.660), p = 0.000). Four studies assessed lordotic angle and moderate but not significant improvement was shown (SMD = -0.530 (95% CI-1.760 a -0.700), p = 0.401). The results suggest that exercise programs may have a positive effect on thoracic kyphosis angle, but no clear effect on lordotic angle. This systematic review suggests that strengthening rather than stretching could be more relevant for kyphosis and both qualities are important for lordosis. It is necessary to conduct more randomized controlled trials to assess the effects of strengthening and/or stretching program on kyphosis and lordotic angle and to establish the type of the exercise that is better for maintaining the sagittal disposition within normal ranges.	[Gonzalez-Galvez, Noelia; Gea-Garcia, Gemma M.; Marcos-Pardo, Pablo J.] Univ Catolica Murcia, Fac Sport, Murcia, Spain	Universidad Catolica de Murcia	Marcos-Pardo, PJ (corresponding author), Univ Catolica Murcia, Fac Sport, Murcia, Spain.	pmarcos@ucam.edu	Marcos-Pardo, Pablo J./X-7529-2018; GEA, GEMMA/AAB-8579-2019; GONZALEZ-GALVEZ, NOELIA/I-5832-2018	Marcos-Pardo, Pablo J./0000-0003-1624-5013; Gea Garcia/0000-0002-7467-8223; GONZALEZ-GALVEZ, NOELIA/0000-0002-7291-3306				Alricsson M, 2006, PHYS THER SPORT, V7, P181, DOI 10.1016/j.ptsp.2006.06.003; Andreotti L, 1989, ATLAS SEMIOLOGIA REU; Andujar P., 1996, SELECCION, V5, P37; Azadinia Fatemeh, 2014, J Spinal Disord Tech, V27, pE212, DOI 10.1097/BSD.0b013e31829a3574; BADO J L, 1964, An Fac Med Univ Repub Montev Urug, V49, P328; Bansal S, 2014, ARCH PHYS MED REHAB, V95, P129, DOI 10.1016/j.apmr.2013.06.022; Barrett E, 2018, PHYSIOTHER THEOR PR, V34, P301, DOI 10.1080/09593985.2017.1394411; Barrett E, 2014, MANUAL THER, V19, P10, DOI 10.1016/j.math.2013.09.003; BERGENUDD H, 1989, SPINE, V14, P577, DOI 10.1097/00007632-198906000-00005; Borghuis J, 2008, SPORTS MED, V38, P893, DOI 10.2165/00007256-200838110-00002; Briggs AM, 2007, SKELETAL RADIOL, V36, P761, DOI 10.1007/s00256-007-0284-8; Cohen J., 2013, STAT POWER ANAL BEHA; Collins H, 2018, SPORT MED, V4, P1; Coulter ID, 2018, SPINE J, V18, P866, DOI 10.1016/j.spinee.2018.01.013; Czaprowski D, 2018, SCOLIOSIS SPINAL DIS, V13, DOI 10.1186/s13013-018-0151-5; de Oliveira TS, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/186156; Diebo BG, 2015, CLIN NEUROL NEUROSUR, V139, P295, DOI 10.1016/j.clineuro.2015.10.024; Edmondston SJ, 2012, J MANIP PHYSIOL THER, V35, P203, DOI 10.1016/j.jmpt.2012.01.008; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Endo K, 2016, J ORTHOP SURG-HONG K, V24, P92, DOI 10.1177/230949901602400121; Fadaee E., 2017, J SHAHREKORD U MED, V19, P137; Fatemi R, 2015, J BACK MUSCULOSKELET, V28, P591, DOI 10.3233/BMR-150585; Ferrer V., 1998, THESIS; FON GT, 1980, AM J ROENTGENOL, V134, P979, DOI 10.2214/ajr.134.5.979; Garmabi S, 2013, J REHABILATION, V13, P8; Gomez S., 2002, SELECCION, V11, P274; Grabara M, 2015, BIOL SPORT, V32, P79, DOI 10.5604/20831862.1127286; Grabara M, 2014, J BACK MUSCULOSKELET, V27, P85, DOI 10.3233/BMR-130423; Greendale GA, 2011, OSTEOPOROSIS INT, V22, P1897, DOI 10.1007/s00198-010-1422-z; Harrison D E, 2001, Spine (Phila Pa 1976), V26, pE227, DOI 10.1097/00007632-200106010-00002; Higgins JPT, 2004, STAT MED, V23, P1663, DOI 10.1002/sim.1752; Hosseinifar M, 2017, ANN TROP MED PUBLIC, V10, P1779, DOI [10.4103/atmph.atmph_654_17, 10.4103/ATMPH.ATMPH_654_17]; Ioannidis JPA, 2008, J EVAL CLIN PRACT, V14, P951, DOI 10.1111/j.1365-2753.2008.00986.x; Junges S, 2017, FISIOTER BRAS, V18, P643; Kamali F, 2016, PHYSIOTHER THEOR PR, V32, P92, DOI 10.3109/09593985.2015.1110739; Karimi B, 2016, INT J MED RES HEALTH, V5, P673; Katzman WB, 2017, OSTEOPOROSIS INT, V28, P2831, DOI 10.1007/s00198-017-4109-x; Katzman WB, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1862-0; Kellis E, 2008, J MANIP PHYSIOL THER, V31, P570, DOI 10.1016/j.jmpt.2008.09.001; Khorsan R, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/694804; Kim TW, 2015, J PHYS THER SCI, V27, P383, DOI 10.1589/jpts.27.383; Knapp G, 2003, STAT MED, V22, P2693, DOI 10.1002/sim.1482; Korovessis P, 2001, J SPINAL DISORD, V14, P67, DOI 10.1097/00002517-200102000-00010; Kums T, 2007, J BACK MUSCULOSKELET, V20, P87, DOI 10.3233/BMR-2007-202-306; Kwang-Jun K, 2018, J PHYS THER SCI, V30, P1, DOI [10.1589/jpts.30.1, DOI 10.1589/JPTS.30.1]; Lang-Tapia M, 2011, J APPL BIOMECH, V27, P143, DOI 10.1123/jab.27.2.143; Leroux MA, 2000, SPINE, V25, P1689, DOI 10.1097/00007632-200007010-00012; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Livanelioglu A, 2016, EUR SPINE J, V25, P476, DOI 10.1007/s00586-015-3945-7; Lopez-Minarro PA, 2012, EUR J SPORT SCI, V12, P469, DOI 10.1080/17461391.2011.575476; Lundon KMA, 1998, SPINE, V23, P1978, DOI 10.1097/00007632-199809150-00013; Macedo RB, 2015, J PEDIAT-BRAZIL, V91, P263, DOI 10.1016/j.jped.2014.08.011; Magee D. J., 2020, ORTHOPEDIC PHYS ASSE, V7th; Mannion AF, 2004, EUR SPINE J, V13, P122, DOI 10.1007/s00586-003-0618-8; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Moher D, 2015, STATEMENT SYST REV, V4, DOI [10.1186/2046-4053-4-1, DOI 10.1186/2046-4053-4-1, 10.1186/s13643-015-0163-7, DOI 10.14306/RENHYD.20.2.223]; Moore KL., 2013, CLIN ORIENTED ANATOM; Moseley AM, 2011, J CLIN EPIDEMIOL, V64, P594, DOI 10.1016/j.jclinepi.2010.08.009; Muyor JM, 2017, J BACK MUSCULOSKELET, V30, P1319, DOI [10.3233/BMR-170606, 10.3233/BMR-169750]; Muyor JM, 2013, J SPORT SCI MED, V12, P588; Muyor JM, 2012, J BACK MUSCULOSKELET, V25, P161, DOI 10.3233/BMR-2012-0323; Ng JKF, 2001, SPINE, V26, P53, DOI 10.1097/00007632-200101010-00011; Nilsson C, 1993, Knee Surg Sports Traumatol Arthrosc, V1, P206, DOI 10.1007/BF01560208; Park J, 2017, MOL CELL TOXICOL, V13, P1, DOI 10.1007/s13273-017-0001-1; Rajabi R, 2008, BRIT J SPORT MED, V42, P229, DOI 10.1136/bjsm.2006.033639; Ripani M, 2008, J SPORT MED PHYS FIT, V48, P488; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; Sainz de Baranda P, 2009, COLECCION VERTEBRIN; Sangtarash F, 2014, J SPINE, V3, P1; Santonja F, 2003, SELECCION, V12, P150; Santonja F., 1993, EXPLORACION CLIN RAD; Santonja P, 2000, NATACION Y COLUMNA; Scottish Intercollegiate Guidelines Network (SIGN), 2015, SIGN 50 GUID DEV HDB; Seidi F, 2014, J BACK MUSCULOSKELET, V27, P7, DOI 10.3233/BMR-130411; Sinaki M, 2005, OSTEOPOROSIS INT, V16, P1004, DOI 10.1007/s00198-004-1791-2; Solomonow M, 2003, CLIN BIOMECH, V18, P890, DOI 10.1016/S0268-0033(03)00173-6; Standring S., 2021, GRAYS ANATOMY ANATOM; Teixeira FA, 2007, REV BRAS FISIOTER, V11, P199, DOI 10.1590/S1413-35552007000300005; Tooth L, 2005, J EVAL CLIN PRACT, V11, P547, DOI 10.1111/j.1365-2753.2005.00574.x; Tuzun C, 1999, CLIN RHEUMATOL, V18, P308, DOI 10.1007/s100670050107; Van Blommestein AS, 2012, OPEN SPINE J, V4, P10, DOI 10.2174/1876532701204010010; VOUTSINAS SA, 1986, CLIN ORTHOP RELAT R, P235; Wilke HJ, 1999, SPINE, V24, P755, DOI 10.1097/00007632-199904150-00005; WILLNER S, 1981, ACTA ORTHOP SCAND, V52, P525, DOI 10.3109/17453678108992142; Wodecki P, 2002, REV CHIR ORTHOP, V88, P328; Wojtys EM, 2000, AM J SPORT MED, V28, P490, DOI 10.1177/03635465000280040801; Yeh KT, 2018, CLIN ORTHOP RELAT R, V476, P1010, DOI 10.1007/s11999.0000000000000140; Zazulak B, 2008, J AM ACAD ORTHOP SUR, V16, P497, DOI 10.5435/00124635-200809000-00002; 1989, SPINE, V14, P580; 2009, REV INT MED CIENC AC, V9, P379; 2010, REV INT MED CIENC AC, V10, P138; 2012, J BODYW MOV THER, V16, P210, DOI DOI 10.1016/J.JBMT.2011.03.005	92	20	20	3	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2019	14	4							e0216180	10.1371/journal.pone.0216180	http://dx.doi.org/10.1371/journal.pone.0216180			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV6ZL	31034509	Green Submitted, Green Published, gold			2023-01-03	WOS:000466131200044
J	Migliaccio, V; Scudiero, R; Sica, R; Lionetti, L; Putti, R				Migliaccio, Vincenzo; Scudiero, Rosaria; Sica, Raffaella; Lionetti, Lilla; Putti, Rosalba			Oxidative stress and mitochondrial uncoupling protein 2 expression in hepatic steatosis induced by exposure to xenobiotic DDE and high fat diet in male Wistar rats	PLOS ONE			English	Article							BROWN ADIPOSE-TISSUE; SERUM CONCENTRATION; SUPEROXIDE; CELLS; APOPTOSIS; OBESITY; GENE; OVEREXPRESSION; DYSFUNCTION; DEFICIENCY	Oxidative stress plays a key role in steatohepatitis induced by both xenobiotic agents and high fat diet (HFD). The present study aimed to evaluate hepatic oxidative stress and antioxidant systems response in rats exposed to HFD and/or non-toxic dose of dichlorodiphenyldichloroethylene (DDE), the first metabolite of dichlorodiphenyltrichloroethane. Groups of 8 rats were so treated for 4 weeks: 1-standard diet (N group); 2-standard diet plus DDE (10 mg/kg b.w.) (N+DDE group); 3- HFD (D group); 4- HFD plus DDE (D+DDE group). Oxidative stress was analyzed by determining malondialdehyde as lipid peroxidation product, while the anti-oxidant systems were evaluating by measuring the levels of the principal cytosolic and mitochondrial antioxidant proteins and enzymes, namely superoxide dismutase 1 and 2 (SOD1, SOD2), glutathione peroxidase 1 (GPx1) and uncoupling protein 2 (UCP2) involved in the control of hepatic reactive oxygens species (ROS) accumulation. The results showed malondialdehyde accumulation in livers of all groups, confirming the pro-oxidant effects of both HFD and DDE, but with a greater effect of DDE in absence of HFD. In addition, we found different levels of the analyzed anti-oxidant systems in the different groups. DDE mainly induced UCP2 and SOD2, while HFD mainly induced GPx1. Noteworthy, in the condition of simultaneous exposure to DDE and HFD, the anti-oxidant response was more similar to the one induced by HFD than to the response induced by DDE. Present findings confirmed that both HFD and xenobiotic exposure induced hepatic oxidative stress and showed that the anti-oxidant defense response was not the same in the diverse groups, suggesting that UCP2 induction could be an adaptive response to limit excessive ROS damage, mainly in condition of xenobiotic exposure.	[Migliaccio, Vincenzo; Scudiero, Rosaria; Sica, Raffaella; Putti, Rosalba] Univ Naples Federico II, Dept Biol, Naples, Italy; [Migliaccio, Vincenzo; Lionetti, Lilla] Univ Salerno, Dept Chem & Biol Adolfo Zambelli, Fisciano, Italy	University of Naples Federico II; University of Salerno	Lionetti, L (corresponding author), Univ Salerno, Dept Chem & Biol Adolfo Zambelli, Fisciano, Italy.	llionetti@unisa.it	Scudiero, Rosaria/AAI-2119-2020; Lionetti, Lilla/AAM-1756-2021	Lionetti, Lilla/0000-0002-4059-8030; MIGLIACCIO, Vincenzo/0000-0002-8820-4694				Agrawal A, 2010, INT J BIOL MED RES, V1, P90; ALEXSON SEH, 1988, J BIOL CHEM, V263, P13564; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Baffy G, 2011, BRIT J CANCER, V105, P469, DOI 10.1038/bjc.2011.245; Berardi MJ, 2011, NATURE, V476, P109, DOI 10.1038/nature10257; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034; Brand MD, 2005, CELL METAB, V2, P85, DOI 10.1016/j.cmet.2005.06.002; BRAND MD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P128, DOI 10.1016/0005-2728(90)90232-S; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; Collins P, 2005, LIVER INT, V25, P880, DOI 10.1111/j.1478-3231.2005.01104.x; Derdak Z, 2008, CANCER RES, V68, P2813, DOI 10.1158/0008-5472.CAN-08-0053; Dowling V, 2006, AQUAT TOXICOL, V77, P11, DOI 10.1016/j.aquatox.2005.10.011; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Fanucchi M.V., 2014, LUNG, P223, DOI 10.1016/B978-0-12-799941-8.00011-0; Fedorenko A, 2012, CELL, V151, P400, DOI 10.1016/j.cell.2012.09.010; Fleury C, 1999, INT J BIOCHEM CELL B, V31, P1261, DOI 10.1016/S1357-2725(99)00049-7; FOLCH J, 1957, J BIOL CHEM, V226, P497; Glynn A, 2011, ENVIRON INT, V37, P71, DOI 10.1016/j.envint.2010.07.003; Grimalt S, 2016, J CHROMATOGR A, V1433, P1, DOI 10.1016/j.chroma.2015.12.076; Harada T, 2016, TOX RESEARCH, V32, P21, DOI 10.5487/TR.2016.32.1.021; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; Heindel JJ, 2017, REPROD TOXICOL, V68, P3, DOI 10.1016/j.reprotox.2016.10.001; Horimoto M, 2004, HEPATOLOGY, V39, P386, DOI 10.1002/hep.20047; Hsu WW, 2014, ENVIRON RES, V132, P384, DOI 10.1016/j.envres.2014.03.009; Indo HP, 2007, MITOCHONDRION, V7, P106, DOI 10.1016/j.mito.2006.11.026; Joshi-Barve S, 2015, CELL MOL GASTROENTER, V1, P356, DOI 10.1016/j.jcmgh.2015.05.006; KLINGENBERG M, 1989, EUR J BIOCHEM, V180, P123, DOI 10.1111/j.1432-1033.1989.tb14622.x; Koek GH, 2011, CLIN CHIM ACTA, V412, P1297, DOI 10.1016/j.cca.2011.04.013; Kokoszka JE, 2001, P NATL ACAD SCI USA, V98, P2278, DOI 10.1073/pnas.051627098; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larrouy D, 1997, BIOCHEM BIOPH RES CO, V235, P760, DOI 10.1006/bbrc.1997.6852; Leamy AK, 2013, PROG LIPID RES, V52, P165, DOI 10.1016/j.plipres.2012.10.004; Ledesma A., 2002, GENOME BIOL, V3, p3015.1, DOI DOI 10.1186/gb-2002-3-12-reviews3015; Lionetti L, 2004, CELL MOL LIFE SCI, V61, P1366, DOI 10.1007/s00018-004-4073-4; Lionetti L, 2014, PLOS ONE, V9, P1; Liu YH, 2013, BIOCHEM BIOPH RES CO, V438, P78, DOI 10.1016/j.bbrc.2013.07.029; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LIVERINI G, 1991, COMP BIOCHEM PHYS B, V98, P583, DOI 10.1016/0305-0491(91)90258-F; Longnecker MP, 2001, LANCET, V358, P110, DOI 10.1016/S0140-6736(01)05329-6; Makita Y, 2005, BASIC CLIN PHARMACOL, V97, P364, DOI 10.1111/j.1742-7843.2005.pto_199.x; Marouani N, 2017, REPROD BIOL ENDOCRIN, V15, DOI 10.1186/s12958-017-0259-0; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Migliaccio V, 2018, ENVIRON TOXICOL, P1; Mota PC, 2011, REPROD TOXICOL, V31, P80, DOI 10.1016/j.reprotox.2010.09.010; Motoori S, 2001, CANCER RES, V61, P5382; Mrema EJ, 2013, TOXICOLOGY, V307, P74, DOI 10.1016/j.tox.2012.11.015; Murray K., 2012, PHYSL GASTROINTESTIN, P1507, DOI DOI 10.1016/B978-0-12-382026-6.00055-5; Nassir F, 2014, INT J MOL SCI, V15, P8713, DOI 10.3390/ijms15058713; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Nicholls D G, 1978, Experientia Suppl, V32, P89; Orrenius S, 2007, DRUG METAB REV, V39, P443, DOI 10.1080/03602530701468516; Ott M, 2007, APOPTOSIS, V12, P913, DOI 10.1007/s10495-007-0756-2; Putti R, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00109; Ramsden DB, 2012, BRAIN BEHAV, V2, P468, DOI 10.1002/brb3.55; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Sechi S, 1998, ANAL CHEM, V70, P5150, DOI 10.1021/ac9806005; Shi YQ, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/181282; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Spagnuolo MS, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00479; Strassburger M, 2005, FREE RADICAL BIO MED, V38, P1458, DOI 10.1016/j.freeradbiomed.2005.02.009; Suzuki K, 2002, CIRCULATION, V106, pI270, DOI 10.1161/01.cir.0000032880.55215.92; United Nations Environment Programme (UNEP), 2009, C PART STOCKH CONV P, P1; van den Berg H, 2009, ENVIRON HEALTH PERSP, V117, P1656, DOI 10.1289/ehp.0900785; You L, 1998, TOXICOL SCI, V45, P162, DOI 10.1006/toxs.1998.2515; Zelko IN, 2002, FREE RADICAL BIO MED, V33, P337, DOI 10.1016/S0891-5849(02)00905-X; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6; 2008, TOXICOLOGY, V253, P53, DOI DOI 10.1016/J.TOX.2008.08.013; 2008, FREE RADIC BIOL MED, V45, P231, DOI DOI 10.1016/J.FREERADBIOMED.2008.04.029; 2003, MOL PHARM, V64, P474, DOI DOI 10.1124/MOL.64.2.474	72	17	17	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2019	14	4							e0215955	10.1371/journal.pone.0215955	http://dx.doi.org/10.1371/journal.pone.0215955			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU8EY	31022254	Green Submitted, Green Published, gold			2023-01-03	WOS:000465519100070
J	Xu, BS; Chen, HY; Que, Y; Xiao, W; Zeng, MS; Zhang, X				Xu, Bu-Shu; Chen, Huo-Ying; Que, Yi; Xiao, Wei; Zeng, Mu-Sheng; Zhang, Xing			ALK(ATI) interacts with c-Myc and promotes cancer stem cell-like properties in sarcoma	ONCOGENE			English	Article							CASSETTE TRANSPORTER GENES; SOFT-TISSUE SARCOMAS; LUNG-CANCER; ALK; EXPRESSION; PHENOTYPE; MUTATIONS; RECEPTOR; PATHWAY; TUMORS	Soft tissue sarcoma (STS) is a highly malignant tumor with limited targeted therapies. A novel anaplastic lymphoma kinase (ALK) transcript, ALK(ATI), was identified recently and could be targeted by ALK inhibitors in melanoma. However, the clinical and functional role of aberrant ALK(ATI) expression in STS remains unknown. Here we demonstrate that as a new ALK transcript, ALK(ATI) is frequently found in STS. ALK(ATI) expression correlates with a lower probability of progression-free survival in STS patients. Compared with the other ALK isoforms, ALK(ATI) expresses not only in the cytoplasm, but also in the nucleus of sarcoma cells. Functionally, overexpression of ALK(ATI) promoted cancer stem cell (CSC)-like properties in sarcoma cells by promoting sphere formation and upregulating the expression of stem cell markers. Moreover, the ALK inhibitors not only suppressed the oncogenic functions of ALK(ATI) but also attenuated ALK(ATI)-induced CSC-like properties by reducing the expression of stem cell markers such as c-Myc, ABCG2, BMI1, and OCT4 both in vitro and in vivo. Furthermore, ALK(ATI) interacted with c-Myc and increased the binding of c-Myc to the ABCG2 promoter, resulting in the induction of stem cell-like properties. Together, these findings indicate that ALK(ATI) may be a potential prognostic marker and therapeutic target for STS patients harboring such ALK aberrations.	[Xu, Bu-Shu; Chen, Huo-Ying; Que, Yi; Xiao, Wei; Zhang, Xing] Sun Yat Sen Univ, Melanoma & Sarcoma Med Oncol Unit, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China; [Chen, Huo-Ying] Guilin Med Univ, Affiliated Hosp 2, Dept Lab Med, Guilin 541100, Peoples R China; [Zeng, Mu-Sheng] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Guilin Medical University; State Key Lab Oncology South China; Sun Yat Sen University	Zhang, X (corresponding author), Sun Yat Sen Univ, Melanoma & Sarcoma Med Oncol Unit, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China.	zhangxing@sysucc.org.cn		zeng, musheng/0000-0003-3509-5591	National Key Research and Development Program [2017YFA0505600]; National Natural Science Foundation of China Programs [81772863, 81572403]	National Key Research and Development Program; National Natural Science Foundation of China Programs(National Natural Science Foundation of China (NSFC))	This work was supported by the National Key Research and Development Program (2017YFA0505600) and the National Natural Science Foundation of China Programs (Grant Nos 81772863 and 81572403). We thank Dr Deng Xianming (Principal Investigator for Chemical Biology and Medicinal Chemistry School of Life Sciences, Xiamen University, China) for generously providing the plasmids.	[Anonymous], 2013, FDA APPR PAZ HYDR; [Anonymous], 2016, FDA APPR 1 DRUG SHOW; Armstrong F, 2007, EUR J CANCER, V43, P640, DOI 10.1016/j.ejca.2006.12.005; Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597; Bonvini P, 2013, BRIT J CANCER, V109, P3084, DOI 10.1038/bjc.2013.653; Brown HK, 2017, CANCER LETT, V386, P189, DOI 10.1016/j.canlet.2016.11.019; Busam KJ, 2016, AM J SURG PATHOL, V40, P786, DOI 10.1097/PAS.0000000000000611; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Dandawate PR, 2016, SEMIN CANCER BIOL, V40-41, P192, DOI 10.1016/j.semcancer.2016.09.001; Deshmukh A, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0555-x; FDA, 2015, LAB CHANG REQ SOFT T; FDA, 2016, FDA GRANTS ACC APPR; Feng BH, 2013, ONCOL REP, V30, P815, DOI 10.3892/or.2013.2486; Fujiwara T, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2603092; Grande E, 2011, MOL CANCER THER, V10, P569, DOI 10.1158/1535-7163.MCT-10-0615; Gravina GL, 2016, RADIAT RES, V185, P411, DOI 10.1667/RR14237.1; Haldar M, 2007, CANCER CELL, V11, P375, DOI 10.1016/j.ccr.2007.01.016; Huang FF, 2013, CANCER LETT, V336, P96, DOI 10.1016/j.canlet.2013.04.006; Ishibashi Y, 2015, ONCOL REP, V33, P1667, DOI 10.3892/or.2015.3806; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Jiang Q, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0647-8; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Kimbara S, 2014, JPN J CLIN ONCOL, V44, P868, DOI 10.1093/jjco/hyu069; Kuo CY, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0317-9; Lee JC, 2017, J PATHOL, V241, P316, DOI 10.1002/path.4836; Lewis JJ, 1997, J CLIN ONCOL, V15, P646, DOI 10.1200/JCO.1997.15.2.646; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Mansfield AS, 2016, ANN ONCOL, V27, P2111, DOI 10.1093/annonc/mdw405; Pisters PWT, 1996, J CLIN ONCOL, V14, P1679, DOI 10.1200/JCO.1996.14.5.1679; Porro A, 2011, MOL CANCER RES, V9, P1054, DOI 10.1158/1541-7786.MCR-10-0510; Porro A, 2010, J BIOL CHEM, V285, P19532, DOI 10.1074/jbc.M109.078584; Riggi N, 2005, CANCER RES, V65, P11459, DOI 10.1158/0008-5472.CAN-05-1696; Schulte JH, 2011, CLIN CANCER RES, V17, P5082, DOI 10.1158/1078-0432.CCR-10-2809; Shaw AT, 2009, J CLIN ONCOL, V27, P4247, DOI 10.1200/JCO.2009.22.6993; Sheng JY, 2016, SURG CLIN N AM, V96, P1141, DOI 10.1016/j.suc.2016.06.006; Subbiah V, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0160-2; Todaro M, 2010, GASTROENTEROLOGY, V138, P2151, DOI 10.1053/j.gastro.2009.12.063; Toro JR, 2006, INT J CANCER, V119, P2922, DOI 10.1002/ijc.22239; Van Roosbroeck K, 2010, HAEMATOL-HEMATOL J, V95, P509, DOI 10.3324/haematol.2009.014761; Wang YW, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0307-y; Wiesner T, 2015, NATURE, V526, P453, DOI 10.1038/nature15258; Xia P, 2015, AM J CANCER RES, V5, P1602; Xie XK, 2013, MOL MED REP, V8, P168, DOI 10.3892/mmr.2013.1484; Zhou JX, 2013, ANN ONCOL, V24, P1319, DOI 10.1093/annonc/mds626	44	9	9	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					151	163		10.1038/s41388-019-0973-5	http://dx.doi.org/10.1038/s41388-019-0973-5			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31462708				2023-01-03	WOS:000509849200010
J	Fernandez-Alvarez, I; Zapata-Cachafeiro, M; Vazquez-Lago, J; Lopez-Vazquez, P; Pineiro-Lamas, M; Rodriguez, RG; Figueiras, A; Gestal, AE; Caamano, F; Gestal-Otero, JJ; Taracido, M; Lopez-Duran, A; Salgado, A; Gonzalez, EL; Sastre, I				Fernandez-Alvarez, Iria; Zapata-Cachafeiro, Maruxa; Vazquez-Lago, Juan; Lopez-Vazquez, Paula; Pineiro-Lamas, Maria; Garcia Rodriguez, Raquel; Figueiras, Adolfo; Estany Gestal, Ana; Caamano, Francisco; Gestal-Otero, Juan J.; Taracido, Margarita; Lopez-Duran, Ana; Salgado, Angel; Lopez Gonzalez, Elena; Sastre, Isabel		GREPHEPI Grp	Pharmaceutical companies information and antibiotic prescription patterns: A follow-up study in Spanish primary care	PLOS ONE			English	Article							RESPIRATORY-TRACT INFECTIONS; ANTIMICROBIAL RESISTANCE; PRESCRIBING BEHAVIOR; DRUG INFORMATION; PHYSICIAN; INDUSTRY; GUIDELINES; DETERMINANTS; ATTITUDES; QUALITY	Objectives To assess the impact of sources of drug information on antibiotic prescribing patterns (quantity and quality) among primary care physicians. Methods We conducted a cohort study on primary care physicians who were actively engaged in medical practice in 2010 in a region in north-west Spain (Galicia), fulfilling inclusion criteria (n = 2100). As the independent variable, we took the perceived utility of 6 sources of information on antibiotics, as measured by the validated KAAR-11 questionnaire. As dependent variables, we used: (1) a quality indicator (appropriate quality, defined as any case where 6 of the 12 indicators proposed by the European Surveillance of Antimicrobial Consumption Network [ESAC-Net] were better than the mean values for Spain); and, (2) a quantity indicator (high prescribing), defined as any case where defined daily doses (DDD) per 1 000 inhabitants per day of antibacterials for systemic use were higher than the mean values for Spain. The adjusted odds ratio for a change in the interquartile range (IqOR) for each sources of information on antibiotics was calculated using Generalized Linear Mixed Models. Results The questionnaire response rate was 68%. Greater perceived utility of pharmaceutical sales representatives increases the risk of having high prescribing (1/IqOR = 2.50 [95%CI: 1.63-3.66]) and reduces the probability of having appropriate quality (1/IqOR = 2.28 [95%CI: 1.77-3.01]). Greater perceived utility of clinical guidelines increases the probability of having appropriate quality (1/IqOR = 1.25 [95%CI: 1.02-1.54]) and reduces the probability of high prescribing (1/IqOR = 1.25 [95%CI: 1.02-1.54]). Conclusions Sources of information on antibiotics are an important determinant of the quantity and quality of antibiotic prescribing in primary care. Commercial sources of information influence prescribing negatively, and clinical guidelines are associated with better indicators.	[Fernandez-Alvarez, Iria] Santiago De Compostela Univ, Teaching Hosp, Prevent Med Serv, Santiago De Compostela, Spain; [Zapata-Cachafeiro, Maruxa; Vazquez-Lago, Juan; Lopez-Vazquez, Paula; Figueiras, Adolfo; Caamano, Francisco; Gestal-Otero, Juan J.; Taracido, Margarita; Lopez Gonzalez, Elena] Univ Santiago de Compostela, Dept Prevent Med & Publ Hlth, Santiago De Compostela, Spain; [Zapata-Cachafeiro, Maruxa; Pineiro-Lamas, Maria; Figueiras, Adolfo] CIBER Epidemiol & Salud Publ CIBERESP, Consortium Biomed Res Epidemiol & Publ Hlth, Santiago De Compostela, Spain; [Pineiro-Lamas, Maria; Figueiras, Adolfo] Hlth Res Inst Santiago De Compostela IDIS, Santiago De Compostela, Spain; [Garcia Rodriguez, Raquel] Univ A Coruna, Teaching Hosp, Prevent Med Serv, Coruna, Spain; [Estany Gestal, Ana] Hlth Res Inst Santiago De Compostela FIDIS, Unit Methodol Res, Santiago De Compostela, Spain; [Lopez-Duran, Ana] Univ Santiago de Compostela, Dept Clin Psychol & Psychobiol, Santiago De Compostela, Spain; [Salgado, Angel] Univ Hosp Alvaro Cunqueiro, Unit Supporting Res, Vigo, Spain; [Sastre, Isabel] Hlth Care Ctr San Jose A, Primary Care Pharm Unit, La Coruna, Spain	Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Complexo Hospitalario Universitario de Santiago de Compostela; Universidade da Coruna; Universidade de Santiago de Compostela; Complejo Hospitalario Universitario A Coruna	Figueiras, A (corresponding author), Univ Santiago de Compostela, Dept Prevent Med & Publ Hlth, Santiago De Compostela, Spain.; Figueiras, A (corresponding author), CIBER Epidemiol & Salud Publ CIBERESP, Consortium Biomed Res Epidemiol & Publ Hlth, Santiago De Compostela, Spain.; Figueiras, A (corresponding author), Hlth Res Inst Santiago De Compostela IDIS, Santiago De Compostela, Spain.	adolfo.figueiras@usc.es	lopez-duran, ana/ABE-1205-2021; /AAD-1740-2020; Caamano-Isorna, Francisco/AAL-3770-2020; lopez-duran, ana/N-1645-2014; Vazquez-Lago, Juan/M-2632-2016; Figueiras Guzman, Adolfo/K-8563-2015	lopez-duran, ana/0000-0001-7661-8972; lopez-duran, ana/0000-0001-7661-8972; Vazquez-Lago, Juan/0000-0003-3457-9957; Pineiro-Lamas, Maria/0000-0003-3655-100X; Zapata Cachafeiro, Maruxa/0000-0002-0648-7716; Figueiras Guzman, Adolfo/0000-0002-5766-8672; Lopez-Vazquez, Paula M/0000-0002-6836-2863	Institute de Salud Carlos III [PI081239, PI09/90609]; Spanish State Plan for Scientific and Technical Research and Innovation 2012-2016; European Regional Development Fund (ERDF); Mutua Madrilena insurance company	Institute de Salud Carlos III(Instituto de Salud Carlos III); Spanish State Plan for Scientific and Technical Research and Innovation 2012-2016; European Regional Development Fund (ERDF)(European Commission); Mutua Madrilena insurance company	This work was supported in part by the Institute de Salud Carlos III (PI081239, PI09/90609) Spanish State Plan for Scientific and Technical Research and Innovation 2012-2016, The European Regional Development Fund (ERDF) and the Mutua Madrilena insurance company. The funders had no role in study design, data-collection and -analysis, decision to publish, or preparation of the manuscript.	Abdelhamid A, 2014, BRIT J GEN PRACT, V64, pE719, DOI 10.3399/bjgp14X682309; Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS), 2015, PLAN ESTR ACCION RED; Aiello AE, 2006, AM J PUBLIC HEALTH, V96, P1910, DOI 10.2105/AJPH.2005.077214; [Anonymous], 2008, PERIODICO ARAGON; [Anonymous], 1941, NOTICIAS CATOLICAS, V25; Arnold SR, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003539.pub2; Bates D., 2014, R PACKAGE VERSION, DOI 10.18637/jss.v067.i01; Bell BG, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-13; Bharathiraja R., 2005, Indian Journal of Pediatrics, V72, P877, DOI 10.1007/BF02731121; Brax H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175493; Brenner PS, 2016, SOC PSYCHOL QUART, V79, P333, DOI 10.1177/0190272516628298; Caamano F, 2002, EUR J PUBLIC HEALTH, V12, P187, DOI 10.1093/eurpub/12.3.187; Carlsen B, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-218; Chimonas S, 2007, J GEN INTERN MED, V22, P184, DOI 10.1007/s11606-006-0041-z; CLEARY J D, 1992, Journal of Pharmacy Technology, V8, P27; Coenen S, 2007, QUAL SAF HEALTH CARE, V16, P440, DOI 10.1136/qshc.2006.021121; Costelloe Ceire, 2010, BMJ, V340, pc2096, DOI 10.1136/bmj.c2096; DeJong C, 2016, JAMA INTERN MED, V176, P1114, DOI 10.1001/jamainternmed.2016.2765; Dyar OJ, 2016, EXPERT REV ANTI-INFE, V14, P403, DOI 10.1586/14787210.2016.1151353; ECDC, 2017, PROP EU GUID PRUD US; European Centre for Disease Prevention and Control, 2016, QUAL IND ANT CONS CO; Fadlallah R, 2018, EUR J PUBLIC HEALTH, V28, P224, DOI 10.1093/eurpub/ckx204; Farmaindustria, 2016, COD BUEN PRACT; Fickweiler F, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016408; Figueiras A, 2001, MED CARE, V39, P158, DOI 10.1097/00005650-200102000-00006; Figueiras A, 2000, EUR J CLIN PHARMACOL, V56, P747, DOI 10.1007/s002280000217; Gagnon MA, 2008, PLOS MED, V5, P29, DOI 10.1371/journal.pmed.0050001; Galan Herrera S, 2004, Aten Primaria, V34, P231, DOI 10.1157/13066401; Garcés Redondo Guillermo, 2010, Rev Clin Med Fam, V3, P5, DOI 10.4321/s1699-695x2010000100003; Gonzalez-Gonzalez C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141820; Hagen TL, 2017, DAN MED J, V64; Ioannidis JPA, 2018, CIRC-CARDIOVASC QUAL, V11, DOI 10.1161/CIRCOUTCOMES.118.004889; Klein EY, 2018, P NATL ACAD SCI USA, V115, pE3463, DOI 10.1073/pnas.1717295115; Livermore DM, 2005, LANCET INFECT DIS, V5, P450, DOI 10.1016/S1473-3099(05)70166-3; Lobo E, 2012, GAC SANIT, V26, P336, DOI 10.1016/j.gaceta.2011.11.003; Lopez-Vazquez P, 2016, J ANTIMICROB CHEMOTH, V71, P2972, DOI 10.1093/jac/dkw238; Lopez-Vazquez P, 2012, J EVAL CLIN PRACT, V18, P473, DOI 10.1111/j.1365-2753.2010.01610.x; Mackinnon A, 1992, INT J METH PSYCH RES, V2, P233; Malo S, 2016, FAM PRACT, V33, P471, DOI 10.1093/fampra/cmw037; Malo S, 2015, BASIC CLIN PHARMACOL, V116, P337, DOI 10.1111/bcpt.12316; Mather C, 2005, SOC SCI MED, V60, P1323, DOI 10.1016/j.socscimed.2004.07.011; Moliner Javier, 2009, Rev Calid Asist, V24, P72, DOI 10.1016/S1134-282X(09)70656-6; Muijrers PEM, 2005, FAM PRACT, V22, P624, DOI 10.1093/fampra/cmi074; Napti P. R., 2016, J BUSINESS SOCIAL SC, V1, P201; Petersen I, 2007, BMJ-BRIT MED J, V335, P982, DOI 10.1136/bmj.39345.405243.BE; Pokorny AMJ, 2015, INTERN MED J, V45, P1085, DOI 10.1111/imj.12855; Rodrigues AT, 2016, CURR MED RES OPIN, V32, P949, DOI 10.1185/03007995.2016.1154520; Rodrigues AT, 2013, INT J ANTIMICROB AG, V41, P203, DOI 10.1016/j.ijantimicag.2012.09.003; Rothman JK, 2008, MODERN EPIDEMIOLOGY, V3rd; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; Sintchenko V, 2004, J AM MED INFORM ASSN, V11, P71, DOI 10.1197/jamia.M1166; Spurling GK, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000352; Strama, 2000, GUID TREATM RHIN PHA; van der Velden AW, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X659268; Vazquez-Lago JM, 2012, FAM PRACT, V29, P352, DOI 10.1093/fampra/cmr084; Wood S, 2017, PLOS ONE, V12, DOI [10.1371/journal.pone.0183168, 10.1371/journal.pone.0186060]; Zapata-Cachafeiro M, 2019, J ANTIMICROB CHEMOTH, V74, P511, DOI 10.1093/jac/dky440; Zapata-Cachafeiro M, 2014, J ANTIMICROB CHEMOTH, V69, P3156, DOI 10.1093/jac/dku229; ZIEGLER MG, 1995, JAMA-J AM MED ASSOC, V273, P1296, DOI 10.1001/jama.273.16.1296	59	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2019	14	8							e0221326	10.1371/journal.pone.0221326	http://dx.doi.org/10.1371/journal.pone.0221326			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW5RZ	31437201	gold, Green Published, Green Submitted			2023-01-03	WOS:000485036900050
J	Armour, M; Parry, K; Al-Dabbas, MA; Curry, C; Holmes, K; MacMillan, F; Ferfolja, T; Smith, CA				Armour, Mike; Parry, Kelly; Al-Dabbas, Mahmoud A.; Curry, Christina; Holmes, Kathryn; MacMillan, Freya; Ferfolja, Tania; Smith, Caroline A.			Self-care strategies and sources of knowledge on menstruation in 12,526 young women with dysmenorrhea: A systematic review and meta-analysis	PLOS ONE			English	Review							ADOLESCENT GIRLS; UNIVERSITY-STUDENTS; PREVALENCE; MANAGEMENT; ATTITUDES; IMPACT; SCHOOL; SYMPTOMS; EPIDEMIOLOGY; EXPERIENCES	Introduction: Dysmenorrhea (period pain) is common and affects around three quarters of all young women under the age of 25. The majority of young women, for a variety of reasons, think of period pain as 'normal' and something to be managed or endured. This normalisation of pain often is reinforced by family and friends and results in young women using self care strategies to manage their pain rather than seeking medical advice. This systematic review and meta-analysis examined observational studies reporting on the prevalence of different types of self-care, both pharmaceutical and non-pharmaceutical, self-rated effectiveness of self-care and the sources of information on menstruation in young women under 25 Methods: A search of Medline, Psychl NFO, EMBASE and CINAHL in English was carried out from 1980 to December 2018. Studies that reported on menstrual self-care strategies in young women were included. Results: Nine hundred and forty-seven articles were screened. Twenty-four studies including 12,526 young women were eligible and included in the meta-analysis. Fifteen studies were from low, lower-middle or upper-middle-income countries (LMIC) and nine studies were from high income countries (HIC). Self-care was used by over half of all young women (55%, 95%CI 34.1-74.3) with both pharmaceutical (48%, 95%CI 40.0-57.0) and non-pharmaceutical (51.8%, 95%CI 31.3-71.7) options used. Paracetamol was the most common analgesic used (28.7%, 95%CI 19.6-39.9) but did not always provide sufficient pain relief in almost half of those using it. Contraceptive use was significantly higher (P<0.001) in HIC (22%) compared to LMIC (1%). Only 11% (95%CI 8.4-15.2) of young women reported seeing a medical doctor for their period pain. Conclusions: Self-care usage, both pharmaceutical and non-pharmaceutical, was common, but young women were not necessarily choosing the most effective options for pain management. High-quality information on self-care for period pain is urgently needed.	[Armour, Mike; Parry, Kelly; Al-Dabbas, Mahmoud A.; Smith, Caroline A.] Western Sydney Univ, NICM Hlth Res Inst, Sydney, NSW, Australia; [Armour, Mike; Smith, Caroline A.] Western Sydney Univ, Translat Hlth Res Inst, Sydney, NSW, Australia; [Curry, Christina; Holmes, Kathryn; Ferfolja, Tania] Western Sydney Univ, Ctr Educ Res, Sydney, NSW, Australia; [MacMillan, Freya] Western Sydney Univ, Sch Sci & Hlth, Sydney, NSW, Australia	Western Sydney University; Western Sydney University; Western Sydney University; Western Sydney University	Armour, M (corresponding author), Western Sydney Univ, NICM Hlth Res Inst, Sydney, NSW, Australia.; Armour, M (corresponding author), Western Sydney Univ, Translat Hlth Res Inst, Sydney, NSW, Australia.	m.armour@westernsydney.edu.au	Macmillan, Freya/AAT-2472-2021; Holmes, Kathryn/Y-9362-2019; Armour, Mike/I-4853-2016	Macmillan, Freya/0000-0003-3176-2465; Holmes, Kathryn/0000-0002-5576-9656; Curry, Dr Christina/0000-0002-9405-0302; Armour, Mike/0000-0001-7539-9851; Parry, Kelly/0000-0003-3692-7361				Abidoye RO, 1994, INT J ADOLESC YOUTH, V4, P271; ABRAHAM S, 1985, MED J AUSTRALIA, V142, P247, DOI 10.5694/j.1326-5377.1985.tb113322.x; Adinma Echendu Dolly, 2008, Afr J Reprod Health, V12, P74; Alsaleem Mohammed Abadi, 2018, J Family Med Prim Care, V7, P769, DOI 10.4103/jfmpc.jfmpc_113_18; Ameade EPK, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-018-0532-1; Armour M, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/3467067; Armour M, 2019, J WOMENS HEALTH, V28, P1161, DOI 10.1089/jwh.2018.7615; Armour M, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2433-8; Banikarim C, 2000, ARCH PEDIAT ADOL MED, V154, P1226, DOI 10.1001/archpedi.154.12.1226; Brantelid IE, 2014, HEALTH CARE WOMEN IN, V35, P600, DOI 10.1080/07399332.2013.868465; Campbell MA, 1997, ARCH PEDIAT ADOL MED, V151, P905, DOI 10.1001/archpedi.1997.02170460043007; Chang SF, 2012, INT J NURS PRACT, V18, P117, DOI 10.1111/j.1440-172X.2012.02007.x; Chen Chung-Hey, 2006, Health Care Women Int, V27, P418, DOI 10.1080/07399330600629583; Chia CF, 2013, HONG KONG MED J, V19, P222, DOI 10.12809/hkmj133807; Chiou Miin-Huey, 2008, J Nurs Res, V16, P17; Coco AS, 1999, AM FAM PHYSICIAN, V60, P489; CRONJE HS, 1991, INT J GYNECOL OBSTET, V35, P147, DOI 10.1016/0020-7292(91)90818-P; Devi UT, 2014, ASIAN J NURS ED RES, V4, P220, DOI DOI 10.1097/AOG.0000000000000735; French Linda, 2008, Paediatr Drugs, V10, P1, DOI 10.2165/00148581-200810010-00001; Ghaderi Fariba, 2016, Int J Adolesc Med Health, V29, DOI 10.1515/ijamh-2016-0017; Grandi Giovanni, 2012, J Pain Res, V5, P169, DOI 10.2147/JPR.S30602; Hawkey AJ, 2017, QUAL HEALTH RES, V27, P1473, DOI 10.1177/1049732316672639; Hendrix SL, 2002, CONTRACEPTION, V66, P393, DOI 10.1016/S0010-7824(02)00414-6; Hillen TIJ, 1999, J ADOLESCENT HEALTH, V25, P40, DOI 10.1016/S1054-139X(98)00147-5; JOHNSON J, 1988, J ADOLESCENT HEALTH, V9, P398, DOI 10.1016/0197-0070(88)90036-8; KLEIN JR, 1981, PEDIATRICS, V68, P661; Kumar A, 2011, SOC WORK PUBLIC HLTH, V26, P594, DOI 10.1080/19371918.2010.525144; Latthe P, 2006, BMJ-BRIT MED J, V332, P749, DOI 10.1136/bmj.38748.697465.55; MacKichan F, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-53; Marjoribanks J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001751.pub3; Marjoribanks J, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001751.pub2; Matthewman G, 2018, AM J OBSTET GYNECOL, DOI [10.1016/j.jclinepi.2009.06.005, DOI 10.1016/J.JCLINEPI.2009.06.005]; Metusela C, 2017, INT J BEHAV MED, V24, P836, DOI 10.1007/s12529-017-9662-3; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Moronkola O A, 2006, Afr J Reprod Health, V10, P84; O'Connell Katharine, 2006, J Pediatr Adolesc Gynecol, V19, P285, DOI 10.1016/j.jpag.2006.05.004; O'Connell K, 2007, CONTRACEPTION, V75, P299, DOI 10.1016/j.contraception.2006.09.008; Ortiz Mario I, 2007, Proc West Pharmacol Soc, V50, P165; Ortiz MI, 2009, INT J GYNECOL OBSTET, V107, P240, DOI 10.1016/j.ijgo.2009.07.031; Pitangui ACR, 2013, J PEDIATR ADOL GYNEC, V26, P148, DOI 10.1016/j.jpag.2012.12.001; Poureslami M, 2002, ARCH IRAN MED, V5, P219; Proctor M, 2006, BMJ-BRIT MED J, V332, P1134, DOI 10.1136/bmj.332.7550.1134; Resurreccion DM, 2017, J WOMENS HEALTH, V26, P849, DOI 10.1089/jwh.2016.6249; Rostami M, 2007, PAK J MED SCI, V23, P928; Ryan A, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-96; Saka J OO-M, 2018, NURSING PRACTICE TOD, V5, P395; Santer M, 2005, J CLIN EPIDEMIOL, V58, P1206, DOI 10.1016/j.jclinepi.2005.02.026; SCAMBLER A, 1985, SOC SCI MED, V20, P1065, DOI 10.1016/0277-9536(85)90264-3; Schoep ME, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026186; Singh Amita, 2008, Indian J Physiol Pharmacol, V52, P389; Soderman L, 2019, ACTA OBSTET GYN SCAN, V98, P215, DOI 10.1111/aogs.13480; Ssewanyana D, 2019, GLOB HEALTH PROMOT, V26, P105, DOI 10.1177/1757975917694597; Subasinghe AK, 2016, AUST FAM PHYSICIAN, V45, P829; Sule ST, 2007, J TURK-GER GYNECOL A, V8, P7; Twyman L, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006414; Wijesiri HSMSK, 2013, NURS HEALTH SCI, V15, P58, DOI 10.1111/j.1442-2018.2012.00736.x; Wong CL, 2015, J NURS SCHOLARSHIP, V47, P219, DOI 10.1111/jnu.12134; WONG CL, 2009, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD002120.PUB3; Wong LP, 2011, AUST J RURAL HEALTH, V19, P218, DOI 10.1111/j.1440-1584.2011.01213.x; Wong LP, 2010, INT J GYNECOL OBSTET, V108, P139, DOI 10.1016/j.ijgo.2009.09.018; Wood JM, 2007, WOMEN HEALTH, V46, P41, DOI 10.1300/J013v46n01_04; Yagnik AS, 2014, HEALTH CARE WOMEN IN, V35, P617, DOI 10.1080/07399332.2013.838246; Yesuf TA., 2018, INT J REPROD MED, DOI 10.1155/2018/9730328; Zahradnik HP, 2010, CONTRACEPTION, V81, P185, DOI 10.1016/j.contraception.2009.09.014; Zhang WY, 1998, BRIT J OBSTET GYNAEC, V105, P780, DOI 10.1111/j.1471-0528.1998.tb10210.x; Zhu XS, 2010, J OBSTET GYNAECOL RE, V36, P1093, DOI 10.1111/j.1447-0756.2010.01250.x	66	41	41	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2019	14	7							e0220103	10.1371/journal.pone.0220103	http://dx.doi.org/10.1371/journal.pone.0220103			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IS7NE	31339951	Green Submitted, Green Published, gold			2023-01-03	WOS:000482335700054
J	Drabarek, D; Anh, NT; Nhung, NV; Hoa, NB; Fox, GJ; Bernays, S				Drabarek, Dorothy; Nguyen T Anh; Nguyen V Nhung; Nguyen B Hoa; Fox, Greg J.; Bernays, Sarah			Implementation of Medication Event Reminder Monitors among patients diagnosed with drug susceptible tuberculosis in rural Viet Nam: A qualitative study	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; RISK-FACTORS; ADHERENCE; DEFAULT; HIV	Background Despite the criticality of adherence to tuberculosis treatment, there is paucity of rigorous experimental research exploring the efficacy of interventions to promote adherence and a greater lack of inquiry addressing the integral role of adherence behaviour. The aim of this formative study was to examine the way in which the Wisepill evriMED Medication Event Reminder Monitor (MERM) was used among outpatients with drug susceptible pulmonary tuberculosis. Methods In depth interviews were conducted with 20 outpatients receiving treatment from two public healthcare facilities in Thanh Hoa, a rural province in northern Viet Nam. Patients had been enrolled in a randomized controlled trial evaluating the effect of using the MERM device upon adherence for between 1-3 months. The control group used the device without an alert, while the intervention group used the device with a daily alert and scheduled dosing history review. Findings All 20 patients interviewed were supportive of using the MERM device. Those able to be at home at the time that their treatment was due (50%) used the device as intended. Patients who worked all reported separating the time when the box was opened from the time at which they ingested their medication. Patients expressed fidelity to the prescribed medication taking time and concerns regarding the portability of the device. Limitations of the study surround the inclusion of a small sample population that did not experience factors that further compromise adherence. Conclusions Data recorded by the box did not always accurately reflect usage patterns. The alert in the intervention arm was able to support adherence only in patients who did not work while completing their treatment. MERM implementation can be improved by better aligning prescriber instructions with patients' daily routines, and increasing the use of adherence data to guide adherence support practices. Healthcare staff need to be aware of potential barriers to optimal use of MERM devices. A rigorous qualitative approach to formative assessment is essential to inform the scale up of new digital technologies.	[Drabarek, Dorothy; Fox, Greg J.; Bernays, Sarah] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia; [Nguyen T Anh; Fox, Greg J.] Univ Sydney, Woolcock Inst Med Res, Sydney, NSW, Australia; [Nguyen V Nhung; Nguyen B Hoa] Natl Lung Hosp, Hanoi, Vietnam; [Bernays, Sarah] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, London, England	University of Sydney; University of Sydney; Woolcock Institute of Medical Research; University of London; London School of Hygiene & Tropical Medicine	Drabarek, D (corresponding author), Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia.	dorothy.drabarek@sydney.edu.au	Bernays, Sarah/AFT-0369-2022; B, Hoa/AAF-4933-2020; Anh, Nguyễn/HGU-8434-2022	Bernays, Sarah/0000-0001-7628-8408; Nguyen, Thu Anh/0000-0002-2089-2902; Drabarek, Dorothy/0000-0003-2893-5863	Harry Windsor Grant of the Australian Respiratory Council (ARC)	Harry Windsor Grant of the Australian Respiratory Council (ARC)	The work was funded by a Harry Windsor Grant of the Australian Respiratory Council (ARC) (grant awarded to GF). www.thearc.org.au The funder had no role in the study design, collection, analysis and interpretation of data, writing of the report, or in the decision to submit this article for publication. All authors were independent of the funder.	Ailinger Rita L, 2008, Clin Nurs Res, V17, P89, DOI 10.1177/1054773808316941; Allenet B., 2013, ANNALES PHARMACEUTIQUES FRANCAISES, V71, P135, DOI 10.1016/j.pharma.2012.10.001; Alobu I, 2014, ASIAN PAC J TROP MED, V7, P977, DOI 10.1016/S1995-7645(14)60172-3; ALWOOD K, 1994, AIDS, V8, P1103, DOI 10.1097/00002030-199408000-00010; [Anonymous], TB ADH DEV DEPL INT; [Anonymous], 2015, WHOHTMTB201521; Bionghi N, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3080-2; Castillo-Mancilla JR, 2018, CURR HIV-AIDS REP, V15, P49, DOI 10.1007/s11904-018-0377-0; Chaudhry LA, 2012, INT J MYCOBACT, V1, P99, DOI 10.1016/j.ijmyco.2012.05.003; Dusing R, 2001, NEPHROL DIAL TRANSPL, V16, P1317, DOI 10.1093/ndt/16.7.1317; Farmer P, 1997, SOC SCI MED, V44, P347, DOI 10.1016/S0277-9536(96)00143-8; Fox GJ, 2018, NEW ENGL J MED, V378, P221, DOI 10.1056/NEJMoa1700209; Franke MF, 2008, CLIN INFECT DIS, V46, P1844, DOI 10.1086/588292; Garrison LE, 2017, CURR OPIN HIV AIDS, V12, P467, DOI 10.1097/COH.0000000000000393; Liu Xiaoqiu, 2017, Int J Environ Res Public Health, V14, DOI 10.3390/ijerph14101115; Liu XQ, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001876; Munro SA, 2007, PLOS MED, V4, P1230, DOI 10.1371/journal.pmed.0040238; Nguyen BH, 2010, B WORLD HEALTH ORGAN, V88, P273, DOI 10.2471/BLT.09.067801; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Smith T, 2014, CURR TOP MICROBIOL, V374, P53, DOI 10.1007/82_2012_279; Strauss A. L., 1990, GROUNDED THEORY PROC; van den Boogaard J, 2011, B WORLD HEALTH ORGAN, V89, P632, DOI 10.2471/BLT.11.086462; van den Boogaard J, 2011, TROP MED INT HEALTH, V16, P693, DOI 10.1111/j.1365-3156.2011.02755.x; WHO, 2017, TREATMENT TUBERCULOS; WHO, 2017, ANN 2 COUNTR PROF 30; WHO, 2017, US HIGH BURD COUNTR; Williams AB, 2013, AIDS BEHAV, V17, P284, DOI 10.1007/s10461-012-0172-7	27	13	13	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2019	14	7							e0219891	10.1371/journal.pone.0219891	http://dx.doi.org/10.1371/journal.pone.0219891			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4UB	31329610	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000484974100029
J	Sandset, EC; Ford, GA				Sandset, Else Charlotte; Ford, Gary A.			Sphenopalatine ganglion stimulation after stroke, promising but not yet ready for adoption	LANCET			English	Editorial Material							ISCHEMIC-STROKE; THROMBECTOMY; METAANALYSIS		[Sandset, Else Charlotte] Oslo Univ Hosp, Stroke Unit, Dept Neurol, Oslo, Norway; [Ford, Gary A.] Univ Oxford, Radcliffe Dept Med, Oxford OX4 4GA, England	University of Oslo; University of Oxford	Ford, GA (corresponding author), Univ Oxford, Radcliffe Dept Med, Oxford OX4 4GA, England.	gary.ford@rdm.ox.ac.uk	Ford, Gary/AAY-6405-2020	Ford, Gary/0000-0001-8719-4968				Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973; Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Bornstein NM, 2019, LANCET, V394, P219, DOI 10.1016/S0140-6736(19)31192-4; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Flynn D, 2017, EUR STROKE J, V2, P308, DOI 10.1177/2396987317719362; Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X; Thomalla G, 2018, NEW ENGL J MED, V379, P611, DOI 10.1056/NEJMoa1804355; US Food and Drug Administration Center for Drug Evaluation and Research, 2003, GUID IND EXP RESP RE	8	0	0	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 20	2019	394	10194					189	190		10.1016/S0140-6736(19)31412-6	http://dx.doi.org/10.1016/S0140-6736(19)31412-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	IJ6CC	31327352				2023-01-03	WOS:000475988700005
J	Benzekri, NA; Sambou, JF; Tamba, IT; Diatta, JP; Sall, I; Cisse, O; Thiam, M; Bassene, G; Badji, NM; Faye, K; Sall, F; Malomar, JJ; Seydi, M; Gottlieb, GS				Benzekri, Noelle A.; Sambou, Jacques F.; Tamba, Ibrahima Tito; Diatta, Jean Philippe; Sall, Ibrahima; Cisse, Ousseynou; Thiam, Makhtar; Bassene, Gaetan; Badji, Ndeye Maguette; Faye, Khadim; Sall, Fatima; Malomar, Jean Jacques; Seydi, Moussa; Gottlieb, Geoffrey S.			Nutrition support for HIV-TB co-infected adults in Senegal, West Africa: A randomized pilot implementation study	PLOS ONE			English	Article							NEWLY-DIAGNOSED TUBERCULOSIS; CONTROLLED-TRIAL; FOOD; SUPPLEMENTATION; MALNUTRITION	Background Food insecurity can contribute to poor adherence to both tuberculosis treatment and HIV antiretroviral therapy (ART). Interventions that target food insecurity have the potential to increase treatment adherence, improve clinical outcomes, and decrease mortality. The goals of this study were to compare the feasibility, acceptability, and potential impact of implementing two different forms of nutrition support for HIV-TB co-infected adults in the Casamance region of Senegal. Methods We conducted a randomized pilot implementation study among HIV-TB co-infected adults initiating treatment for TB (ClinicalTrials.gov Identifier: NCT03711721). Subjects received nutrition support in the form of a local food basket or Ready-to-Use Therapeutic Food (RUTF), distributed on a monthly basis for six months. Results A total of 178 monthly study encounters were completed by 26 HIV-TB co-infected adults; 14 received food baskets and 12 received RUTF. For both the food basket and RUTF, 100% of subjects obtained the supplement at every study encounter, transferred the supplement from the clinic to their household, and consumed the supplement. The food basket had greater acceptability and was more likely to be shared with members of the household. Adherence to TB treatment and ART exceeded 95%, and all outcomes, including CD4 cell count, hemoglobin, nutritional status, and food security, improved over the study period. All subjects completed TB treatment and were smear negative at treatment completion. The total cost of the local food basket was approximately $0.68 per day versus $0.99 for the RUTF. Conclusion The implementation of nutrition support for HIV-TB co-infected adults in Senegal is feasible and may provide an effective strategy to improve adherence, treatment completion, and clinical outcomes for less than 1 USD per day. Further studies to determine the impact of nutrition support among a larger population of HIV-TB co-infected individuals are indicated.	[Benzekri, Noelle A.; Gottlieb, Geoffrey S.] Univ Washington, Dept Med, Seattle, WA 98195 USA; [Sambou, Jacques F.; Diatta, Jean Philippe; Sall, Ibrahima; Cisse, Ousseynou; Thiam, Makhtar; Bassene, Gaetan; Malomar, Jean Jacques] Ctr Sante Ziguinchor, Ziguinchor, Senegal; [Tamba, Ibrahima Tito; Badji, Ndeye Maguette] Ctr Sante Bignona, Bignona, Senegal; [Faye, Khadim; Sall, Fatima; Seydi, Moussa] Ctr Hosp Natl Univ Fann, Serv Malad Infect & Trop, Dakar, Senegal; [Gottlieb, Geoffrey S.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Benzekri, NA (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.	benezekri@uw.edu			Firland Foundation [20150056]; US National Institutes of Health, University of Washington; Bill & Melinda Gates Foundation; Gilead Sciences; Merck Co, Inc; Alere Technologies; Janssen Pharmaceutica; Cerus Corporation; ViiV Healthcare; Bristol-Myers Squibb; Abbott Molecular Diagnostics	Firland Foundation; US National Institutes of Health, University of Washington(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Gilead Sciences(Gilead Sciences); Merck Co, Inc(Merck & Company); Alere Technologies; Janssen Pharmaceutica(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Cerus Corporation; ViiV Healthcare; Bristol-Myers Squibb(Bristol-Myers Squibb); Abbott Molecular Diagnostics	This study was supported by research grant #20150056 awarded to NAB from the Firland Foundation (www.firland.org, Shoreline, WA, USA). GSG has received research grants and support from the US National Institutes of Health, University of Washington, Bill & Melinda Gates Foundation, Gilead Sciences, Alere Technologies, Merck & Co, Inc, Janssen Pharmaceutica, Cerus Corporation, ViiV Healthcare, Bristol-Myers Squibb, and Abbott Molecular Diagnostics. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Benzekri NA, 2017, AIDS CARE, V29, P1510, DOI 10.1080/09540121.2017.1338652; Benzekri NA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141819; Cantalice JP, 2009, J BRAS PNEUMOL, V35, P992, DOI 10.1590/S1806-37132009001000008; Claros JM, 2014, AIDS BEHAV, V18, pS459, DOI 10.1007/s10461-014-0870-4; Coates J., 2007, FOOD NUTR TECHNICAL, V3, DOI 10.1007/s13398-014-0173-7.2; de Pee S, 2014, AIDS BEHAV, V18, pS531, DOI 10.1007/s10461-014-0730-2; Grobler L, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006086.pub4; Hane F, 2007, INT J TUBERC LUNG D, V11, P539; Ivers LC, 2014, CLIN INFECT DIS, V58, P1176, DOI 10.1093/cid/ciu028; Jahnavi G, 2010, SINGAP MED J, V51, P957; Jeremiah K, 2014, ANTIMICROB AGENTS CH, V58, P3468, DOI 10.1128/AAC.02307-13; Martins N, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4248; Ndekha MJ, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1867; Osendarp S, 2015, FOOD NUTR BULL, V36, pS59, DOI 10.1177/15648265150361S110; Paton NI, 2004, AM J CLIN NUTR, V80, P460, DOI 10.1093/ajcn/80.2.460; PrayGod G, 2011, J NUTR, V141, P685, DOI 10.3945/jn.110.131672; Sudarsanam TD, 2011, TROP MED INT HEALTH, V16, P699, DOI 10.1111/j.1365-3156.2011.02761.x; The PLOS Medicine Editors, 2007, PLOS MED, V4, pe147, DOI 10.1371/journal.pmed.0040147; Thiam S, 2005, Med Trop (Mars), V65, P43; Thiam S, 2007, JAMA-J AM MED ASSOC, V297, P380, DOI 10.1001/jama.297.4.380; UNAIDS, 2014, GUID NOT FOOD NUTR; WHO, 2010, GUID TREATM TUB; World Food Program, 2014, ANALYSE GLOBALE DE L; World Health Organisation, 2007, WHO CAS DEF HIV SURV; World Health Organization, 2013, NUTR CAR SUPP PAT TU; World Health Organization, 2016, STAT PROF	26	9	9	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2019	14	7							e0219118	10.1371/journal.pone.0219118	http://dx.doi.org/10.1371/journal.pone.0219118			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IN4ZB	31318879	gold, Green Published			2023-01-03	WOS:000478684600001
J	Hoffman, MR				Hoffman, Melissa Red			The Sound of Silence-When There Are No Words	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Hoffman, Melissa Red] Mission Hosp, Dept Surg, 509 Biltmore Ave, Asheville, NC 28801 USA		Hoffman, MR (corresponding author), Mission Hosp, Dept Surg, 509 Biltmore Ave, Asheville, NC 28801 USA.	redhoffman@gmail.com	Hoffman, Melissa Red/ABH-8742-2020					Kaye, 1989, NICE JEWISH GIRLS LE; Sacks J., BAMIDBAR	2	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	2019	322	2					117	118		10.1001/jama.2019.8385	http://dx.doi.org/10.1001/jama.2019.8385			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IK7NZ	31287526				2023-01-03	WOS:000476778700011
J	Machado, AAV; Negrao, FJ; Croda, J; de Medeiros, ES; Pires, MAD				Vieira Machado, Alessandra Aparecida; Negrao, Fabio Juliano; Croda, Julio; de Medeiros, Elias Silva; dos Santos Pires, Maria Aparecida			Safety and costs of blood transfusion practices in dengue cases in Brazil	PLOS ONE			English	Article							PROPHYLACTIC PLATELET TRANSFUSION; ECONOMIC BURDEN; PLASMA; ADULTS; FEVER; THROMBOCYTOPENIA; ANTIGEN; IMPACT; TIME	Background Dengue is a public health problem, and noncompliance with World Health Organization (WHO) recommendations for blood transfusion components is frequently reported. Moreover, economic impact studies of the WHO recommendations on the use of blood transfusion are scarce. Methods We compared the cost and hospitalization time in a prospective observational study, by following hospitalised patients and analysing their medical records from 2010 and March 2016 to December 2017. We divided the patients into two groups: transfused (with or without WHO criteria for transfusion) and not transfused (with or without WHO criteria for transfusion). Generalised linear modelling was performed to identify the variable that could increase the costs and hospital stay. Results Among 323 patients, 52 were transfused, of whom 52% without criteria (n = 27), and 271 were not transfused, of which 4.4% (n = 12) with criteria. Hospitalisation costs were 41% higher in the transfused group without criteria than in those with criteria (median US$674.3 vs US$478 p = 0.293). Patients who were not transfused but met the WHO criteria for transfusion (n = 12) had longer mean hospitalisation time than did those who were not transfused (3.8 +/- 3.4 days versus 3.6 +/- 3.1 days; p = 0.022). The GLM analysis using hospital stay and costs as the dependent variable explained approximately 33.4% (R-2 = 0.334) of the hospitalisation time and 79.3% (R-2 = 0.793) of costs. Receiving a transfusion increased the hospitalization time by 1.29 days (p = 0.0007; IRR = 1.29), and the costs were 5.1 times higher than those without receiving blood components (IRR = 5.1; p<0.001; median US$ 504.4 vs US$ 170.7). In contrast, patients who were transfused according to WHO criteria had a reduction in costs of approximately 96% (IRR = 0.044; p<0.001; beta = -3.12) compared to that for those who were not transfused according to WHO criteria (without criteria). Conclusion Transfusion without following WHO recommendations increased the time and cost of hospitalisation.	[Vieira Machado, Alessandra Aparecida; Negrao, Fabio Juliano; dos Santos Pires, Maria Aparecida] Fed Univ Grande Dourados, Hlth Sci Coll, Dourados, MS, Brazil; [Negrao, Fabio Juliano; dos Santos Pires, Maria Aparecida] Fed Univ Grande Dourados, Univ Hosp, Dourados, MS, Brazil; [Croda, Julio] Univ Fed Mato Grosso do Sul, Sch Med, Dourados, MS, Brazil; [Croda, Julio] Fundacao Oswaldo Cruz, Campo Grande, MS, Brazil; [de Medeiros, Elias Silva] Fed Univ Grande Dourados, Fac Exact Sci & Technol, Campo Grande, MS, Brazil	Universidade Federal da Grande Dourados; Universidade Federal da Grande Dourados; Universidade Federal de Mato Grosso do Sul; Fundacao Oswaldo Cruz; Universidade Federal da Grande Dourados	Machado, AAV; Negrao, FJ (corresponding author), Fed Univ Grande Dourados, Hlth Sci Coll, Dourados, MS, Brazil.; Negrao, FJ (corresponding author), Fed Univ Grande Dourados, Univ Hosp, Dourados, MS, Brazil.	Alessandra.uems@gmail.com; fabionegrao@ugd.edu.br	Croda, Julio/I-5172-2013	Croda, Julio/0000-0002-6665-6825; A. Vieira Machado, Alessandra/0000-0002-4257-8885	Fundacao de Apoio ao Desenvolvimento do Ensino, Ciencia e Tecnologia do Estado de Mato Grosso do Sul [FUNDECT outorga 111/2016 -SIAFEM 25868]	Fundacao de Apoio ao Desenvolvimento do Ensino, Ciencia e Tecnologia do Estado de Mato Grosso do Sul(Fundacao de Apoio ao Desenvolvimento do Ensino Ciencia e Tecnologia do Estado de Mato Grosso do Sul (FUNDECT MS))	This work was supported by the Fundacao de Apoio ao Desenvolvimento do Ensino, Ciencia e Tecnologia do Estado de Mato Grosso do Sul. (FUNDECT outorga 111/2016 -SIAFEM 25868; fundect.ledes.net). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahluwalia G, 2004, J Assoc Physicians India, V52, P561; Alcon S, 2002, J CLIN MICROBIOL, V40, P376, DOI 10.1128/JCM.40.02.376-381.2002; [Anonymous], 2010, VALORES MEDIOS INTER; [Anonymous], 2017, CENS DEM BRAS EST 20; Assir MZK, 2017, LANCET, V389, P1583, DOI 10.1016/S0140-6736(17)30545-7; Assir MZK, 2013, TRANSFUS MED HEMOTH, V40, P362, DOI 10.1159/000354837; Beatty ME, 2011, AM J TROP MED HYG, V84, P473, DOI 10.4269/ajtmh.2011.10-0521; Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; Brady OJ, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001760; Brasil, 2012, CAD INF SAUD SUPL BE; Brasil, 2016, DENG DIAGN MAN CLIN; Castro Marcia C, 2017, Lancet Infect Dis, V17, pe70, DOI 10.1016/S1473-3099(16)30545-X; Chaudhary R, 2006, TRANSFUS APHER SCI, V35, P239, DOI 10.1016/j.transci.2006.08.007; Chaurasia R, 2015, TRANSFUS MED HEMOTH, V42, P227, DOI 10.1159/000371500; de Azeredo EL, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/313842; Deen JL, 2006, LANCET, V368, P170, DOI 10.1016/S0140-6736(06)69006-5; Dhanoa A, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1731-8; DOURADOS, 2011, AGR DENG; Drummond MF., 2005, METHODS EC EVALUATIO, P55; Grosse SD, 2011, J FORENSIC EC, V22, P43, DOI DOI 10.5085/JFE.22.1.43; Halasa YA, 2012, AM J TROP MED HYG, V86, P745, DOI 10.4269/ajtmh.2012.11-0784; IBGE, 2016, CENS DEM BRAS 2010; Inaba K, 2010, J AM COLL SURGEONS, V210, P957, DOI 10.1016/j.jamcollsurg.2010.01.031; Kalayanarooj S, 2017, J INFECT DIS, V215, pS79, DOI 10.1093/infdis/jiw609; Kapoor Pawan, 2011, Med J Armed Forces India, V67, P206, DOI 10.1016/S0377-1237(11)60040-3; Kaur Paramjit, 2014, Int J Appl Basic Med Res, V4, pS8, DOI 10.4103/2229-516X.140708; Kumar N D, 2000, Indian J Pathol Microbiol, V43, P55; Kumarasamy V, 2007, SMJ Singapore Medical Journal, V48, P669; Kurukularatne C, 2011, ANN ACAD MED SINGAP, V40, P539; Lee TH, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004576; Lye DC, 2017, LANCET, V389, P1611, DOI 10.1016/S0140-6736(17)30269-6; Lye DC, 2009, CLIN INFECT DIS, V48, P1262, DOI 10.1086/597773; Makary MA, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2139; Pallavi P, 2011, INDIAN J HEMATOL BLO, V27, P70, DOI 10.1007/s12288-011-0059-1; Pan American Health Organization (PAHO), 2016, DENGUE GUIDELINES PA; Pandey S, 2012, TRANSFUSION, V52, p65S, DOI 10.1111/j.1537-2995.2012.03663.x; Tam PT, 2012, AM J TROP MED HYG, V87, P554, DOI 10.4269/ajtmh.2012.12-0101; Prashantha B, 2014, INDIAN J HEMATOL BLO, V30, P126, DOI 10.1007/s12288-013-0242-7; Rajapakse S, 2017, T ROY SOC TROP MED H, V111, P433, DOI 10.1093/trstmh/trx079; Shepard DS, 2016, LANCET INFECT DIS, V16, P935, DOI 10.1016/S1473-3099(16)00146-8; Shepard DS, 2011, AM J TROP MED HYG, V84, P200, DOI 10.4269/ajtmh.2011.10-0503; Slichter SJ, 2010, NEW ENGL J MED, V362, P600, DOI 10.1056/NEJMoa0904084; Stanworth SJ, 2011, TRANSFUSION, V51, P62, DOI 10.1111/j.1537-2995.2010.02798.x; Suaya JA, 2009, AM J TROP MED HYG, V80, P846, DOI 10.4269/ajtmh.2009.80.846; Tan VPK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200698; Martelli CMT, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004042; Machado AAV, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003104; Whitehorn J, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001716; WHO, 2009, DENGUE GUIDELINES FO; World Health Organization, 2017, PAT SAF MAK HLTH CAR	50	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2019	14	7							e0219287	10.1371/journal.pone.0219287	http://dx.doi.org/10.1371/journal.pone.0219287			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IW4GX	31283788	Green Published, Green Submitted, gold			2023-01-03	WOS:000484939800027
J	Rahmalia, A; Price, MH; Hartantri, Y; Alisjahbana, B; Wisaksana, R; van Crevel, R; van der Ven, AJAM				Rahmalia, Annisa; Price, Michael Holton; Hartantri, Yovita; Alisjahbana, Bachti; Wisaksana, Rudi; van Crevel, Reinout; van der Ven, Andre J. A. M.			Are there differences in HIV retention in care between female and male patients in Indonesia? A multi-state analysis of a retrospective cohort study	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY INITIATION; FOLLOW-UP; GENDER-DIFFERENCES; TREATMENT OUTCOMES; INFECTED ADULTS; SEX-DIFFERENCES; CD4 COUNT; MORTALITY; IMPACT; SURVIVAL	Background Little is known about HIV treatment outcomes in Indonesia, which has one of the most rapidly growing HIV epidemics worldwide. Methods We examined possible differences in loss to follow-up (LTFU) and survival between HIV-infected females and males over a 7-year period in an HIV clinic in Bandung, West Java. Data imputation was performed on missing covariates and a multi-state Cox regression was used to investigate the effects of sex and other covariates on patient transitions among four states: (1) clinic enrollment with HIV, (2) initiation/continuation/re-initiation of antiretroviral therapy (ART), (3) LTFU, and (4) death. Results We followed 3215 patients (33% females), for a total of 8430 person-years. ART was used by 59% of patients at some point. One-year retention was 73% for females and 77% for males (p = 0.06). One-year survival was 98% for both females and males (p = 0.15). Females experienced a higher relative hazard to transition from HIV to LTFU (adjusted hazard ratio 1.21; 95% confidence interval 1.00-1.45), but this decreased after adjustments for clinical variables (aHR 0.94; 95% CI 0.79-1.11). Similarly, a lower relative hazard in females to transition from ART to death (aHR 0.59; 95% CI 0.35-0.99) decreased after adjustments for demographic variables. Conclusion This Indonesian cohort has low ART uptake and poor overall pre- and post-ART retention. Female-male differences in survival and retention were gone after adjusting for clinical and sociodemographic factors such as CD4 count and education level. Efforts should be made to improve retention among patients with lower education.	[Rahmalia, Annisa; Hartantri, Yovita; Alisjahbana, Bachti; Wisaksana, Rudi] Univ Padjadjaran, Fac Med, Infect Dis Res Ctr, Bandung, Indonesia; [Rahmalia, Annisa; van Crevel, Reinout; van der Ven, Andre J. A. M.] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Nijmegen, Netherlands; [Price, Michael Holton] Penn State Univ, Dept Anthropol, University Pk, PA 16802 USA; [Price, Michael Holton] Santa Fe Inst, Santa Fe, NM 87501 USA; [Hartantri, Yovita; Alisjahbana, Bachti; Wisaksana, Rudi] Hasan Sadikin Gen Hosp, Dept Internal Med, Bandung, Indonesia	Universitas Padjadjaran; Radboud University Nijmegen; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; The Santa Fe Institute; Dr Hasan Sadikin General Hospital	Rahmalia, A (corresponding author), Univ Padjadjaran, Fac Med, Infect Dis Res Ctr, Bandung, Indonesia.; Rahmalia, A (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Nijmegen, Netherlands.	Annisa.Rahmalia@radboudumc.nl	van Crevel, reinout/A-6636-2010	van Crevel, reinout/0000-0002-6233-6410; Rahmalia, Annisa/0000-0001-8154-2765	European Commission [SANTE/2005/105-033]; Netherlands Fellowship Programme; Radboud University; Royal Dutch Academy of Arts and Science (KNAW); VIDI from the Netherlands Foundation of Scientific Research (NWO)	European Commission(European CommissionEuropean Commission Joint Research Centre); Netherlands Fellowship Programme; Radboud University; Royal Dutch Academy of Arts and Science (KNAW); VIDI from the Netherlands Foundation of Scientific Research (NWO)	Data collection was partially supported by 'IMPACT' (Integrated management of Prevention And Care and Treatment of HIV/AIDS), a collaborative research and implementation program of Padjadjaran University, Bandung, Indonesia; Maastrict University and Radboud University Nijmegen, The Netherlands; and University of Antwerp, Belgium. The European Commission (SANTE/2005/105-033) funded IMPACT. AR received PhD funding from Netherlands Fellowship Programme and conducted this study as part of her PhD, https://www.studyinholland.nl/study/scholarships/highlighted-scholarships/orangeknowledge-programme/netherlands-fellowship-programmes; RW has a fellowship from Radboud University; BA has a post-doc fellowship from the Royal Dutch Academy of Arts and Science (KNAW); RvC has a VIDI grant from the Netherlands Foundation of Scientific Research (NWO). No other authors received specific funding for this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abgrall S, 2016, CURR OPIN HIV AIDS, V11, P501, DOI 10.1097/COH.0000000000000301; Afriandi Irvan, 2009, Acta Med Indones, V41 Suppl 1, P75; Alvarez-Uria G, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.19251; Andersen PK, 2002, STAT METHODS MED RES, V11, P91, DOI 10.1191/0962280202SM276ra; Bateganya MH, 2015, JAIDS-J ACQ IMM DEF, V68, pS368, DOI 10.1097/QAI.0000000000000519; Beckham SW, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.21106; Beer L, 2014, AIDS EDUC PREV, V26, P521, DOI 10.1521/aeap.2014.26.6.521; Berg KM, 2004, J GEN INTERN MED, V19, P1111, DOI 10.1111/j.1525-1497.2004.30445.x; Bezabhe WM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097353; Burch LS, 2016, LANCET PUBLIC HEALTH, V1, pE26, DOI 10.1016/S2468-2667(16)30002-0; Burkey MD, 2014, JAIDS-J ACQ IMM DEF, V66, P41, DOI 10.1097/QAI.0000000000000094; Carriquiry G, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20016; de Oliveira RDC, 2013, CAD SAUDE PUBLICA, V29, P801, DOI [10.1590/S0102-311X2013000800017, 10.1590/S0102-311X2013000400017]; Castilho JL, 2014, AIDS RES HUM RETROV, V30, P446, DOI [10.1089/aid.2013.0208, 10.1089/AID.2013.0208]; Coelho L, 2016, LANCET HIV, V3, pE490, DOI 10.1016/S2352-3018(16)30052-2; Cornell M, 2014, JAIDS-J ACQ IMM DEF, V67, pE67, DOI 10.1097/QAI.0000000000000269; Cornell M, 2009, TROP MED INT HEALTH, V14, P722, DOI 10.1111/j.1365-3156.2009.02290.x; Culbert GJ, 2017, RES REP TROP MED, V8, P25, DOI [10.2147/RRTM.S126131, 10.2147/rrtm.s126131]; da Silva M, 2015, AIDS BEHAV, V19, P666, DOI 10.1007/s10461-014-0874-0; Dalhatu I, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165528; de Wreede LC, 2010, COMPUT METH PROG BIO, V99, P261, DOI 10.1016/j.cmpb.2010.01.001; Donders ART, 2006, J CLIN EPIDEMIOL, V59, P1087, DOI 10.1016/j.jclinepi.2006.01.014; Eguzo KN, 2014, AIDS RES TREAT, V2014, DOI 10.1155/2014/867827; Farahani M, 2010, LANCET, V2, P44; Farewell VT, 2014, LIFETIME DATA ANAL, V20, P51, DOI 10.1007/s10985-012-9236-2; Flynn AG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189055; Fox M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069300; Ganiem AR, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.18821; Graham SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059480; Grimsrud A, 2016, J EPIDEMIOL COMMUN H, V70, P549, DOI 10.1136/jech-2015-206629; Grimsrud AT, 2013, J CLIN EPIDEMIOL, V66, P1006, DOI 10.1016/j.jclinepi.2013.03.013; Guy R, 2013, AIDS PATIENT CARE ST, V27, P681, DOI 10.1089/apc.2012.0439; Gwynn RC, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0898-9; Hegdahl HK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148502; Hickey MD, 2016, AIDS CARE, V28, P1386, DOI 10.1080/09540121.2016.1179253; Hill T, 2010, J CLIN EPIDEMIOL, V63, P1101, DOI 10.1016/j.jclinepi.2009.12.007; Hull MW, 2012, CURR OPIN HIV AIDS, V7, P579, DOI 10.1097/COH.0b013e3283590617; Indonesia D and ICM of H, 2014, HIV AIDS SITUATION A; Inguane CA, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.5.20846; Januraga PP., 2018, LANCET HIV, V3018, P1; Jespersen S, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20243; Jiamsakul A, 2016, TROP MED INT HEALTH, P1; Jiamsakul A, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.18911; Kempf MC, 2009, JAIDS-J ACQ IMM DEF, V52, P336, DOI 10.1097/QAI.0b013e3181b628be; Koenig SP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142101; Lanoy E, 2006, J CLIN EPIDEMIOL, V59, P829, DOI 10.1016/j.jclinepi.2005.11.024; Lee MP, 2015, AIDS PATIENT CARE ST, V29, P229, DOI 10.1089/apc.2014.0232; Lodi S, 2014, AIDS, V28, P2297, DOI 10.1097/QAD.0000000000000410; Maskew M, 2013, J WOMENS HEALTH, V22, P113, DOI 10.1089/jwh.2012.3585; Matsumoto S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139594; Meira-Machado L, 2008, STAT METHODS MED RES, P1; Meloni ST, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu055; Menzaghi B, 2014, BIOMED PHARMACOTHER, V68, P385, DOI 10.1016/j.biopha.2014.01.007; Morgan R, 2016, HEALTH POLICY PLANN, V31, P1069, DOI 10.1093/heapol/czw037; Mosha F, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-38; Murray CJL, 2014, LANCET, V384, P1005, DOI 10.1016/S0140-6736(14)60844-8; Nelwan EJ, 2015, SE ASIAN J TROP MED, V46, P880; Nugroho A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191255; Plazy M, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006927; Podlekareva DN, 2009, AIDS, V23, P2485, DOI 10.1097/QAD.0b013e3283326879; Pontororing GJ, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-362; Poudel KC, 2018, LANCET HIV, V3018, P1; R Core Team R, 2013, R LANGUAGE ENV STAT; Rahmalia Annisa, 2015, BMC Res Notes, V8, P757, DOI 10.1186/s13104-015-1748-x; Rana AI, 2015, AIDS CARE, V27, P679, DOI 10.1080/09540121.2015.1005002; Republic of Indonesia Ministry of Health, 2014, EST PROJ HIV AIDS IN; Riono P, 2004, AIDS EDUC PREV, V16, P78, DOI 10.1521/aeap.16.3.5.78.35531; Santiago-rodriguez EJ, 2014, ANEMIA COHORT HIV IN, P1; Schoni-Affolter F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027919; Shepherd BE, 2013, AM J EPIDEMIOL, V178, P819, DOI 10.1093/aje/kwt030; Sia D, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3783-5; Simard EP, 2012, ARCH INTERN MED, V172, P1591, DOI 10.1001/archinternmed.2012.4508; Siregar AYM, 2016, ACTA MED INDONES, V48, P207; Smith LR, 2012, AIDS PATIENT CARE ST, V26, P344, DOI 10.1089/apc.2011.0388; Sri Utami, 2017, INT J STD AIDS, V28, P1199, DOI 10.1177/0956462417692942; Takarinda KC, 2015, INT J INFECT DIS, V30, P98, DOI 10.1016/j.ijid.2014.11.009; Teasdale CA, 2015, JAIDS-J ACQ IMM DEF, V68, P314, DOI 10.1097/QAI.0000000000000432; Umeh OC, 2006, EXPERT OPIN DRUG MET, V2, P273, DOI 10.1517/17425255.2.2.273; UNAIDS, 90 90 90 AMB TREATM; UNAIDS, 2017, ENDING AIDS PROGRESS; UNAIDS, 2017, COUNTR FACTSH IND 20, P1; UNESCO, 2012, INT STAND CLASS ED; van Buuren S, 2011, J STAT SOFTW, V45, P1; Vinikoor MJ, 2014, AIDS RES HUM RETROV, V30, P949, DOI [10.1089/aid.2014.0046, 10.1089/AID.2014.0046]; Westergaard RP, 2013, AIDS, V27, P2559, DOI 10.1097/QAD.0b013e328363bff2; WHO, 2011, WHO TECH REP SER, V959, P1; WHO, 2012, RET HIV PROGR; Wisaksana R, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-213; Wisaksana Rudi, 2009, Acta Med Indones, V41 Suppl 1, P45; Wisaksana R, 2010, ADDICTION, V105, P1055, DOI 10.1111/j.1360-0443.2010.02898.x; Yang GLL, 2015, ASIA-PAC J PUBLIC HE, V27, p86S, DOI 10.1177/1010539514548758; Yehia BR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129376; Zhou JL, 2012, AIDS RES TREAT, V2012, DOI 10.1155/2012/375217; Zwiener I, 2011, DTSCH ARZTEBL INT, V108, P163, DOI [10.3238/arztebl.2010.0163, 10.3238/arztebl.2011.0163]	94	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2019	14	6							e0218781	10.1371/journal.pone.0218781	http://dx.doi.org/10.1371/journal.pone.0218781			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW3BT	31237899	Green Published, Green Submitted, gold			2023-01-03	WOS:000484856000040
J	Marashi, A; Pour, SG; Li, V; Rissel, C; Girosi, F				Marashi, Amir; Pour, Shima Ghassem; Li, Vincy; Rissel, Chris; Girosi, Federico			The association between physical activity and hospital payments for acute admissions in the Australian population aged 45 and over	PLOS ONE			English	Article							HEALTH-CARE EXPENDITURE; RETRANSFORMATION; MODELS; PROFILE; COSTS; ADO	Physical activity (PA) is a key component of a healthy life, and it is hypothesised that individuals with higher levels of PA utilise fewer hospital resources. Quantifying the association between PA and hospital resource use is of interest to both payers and planners but estimates of its size in the general population are rare. In this paper we provide estimates of the association between PA and payments to hospitals in the Australian population over age 45. We use data from 45 and Up Study, a survey that contains health and lifestyle factors information about approximately 260,000 individuals over age 45 living in NSW, linked to hospital and death data. The linked data set allows to define a unique indicator for the level of PA over the week prior to the survey interview and to calculate payments to hospitals over the next year. We use Coarsened Exact Matching and multivariate analysis to study the relationship between PA and hospital payments, controlling for chronic health conditions, risk factors, standard socioeconomic variables and death. Our results clearly indicate that there is a statistically significant association between PA and lower hospital payments. While the size of the association depends to some extent on the covariates used in the model the conclusions are robust to changes in model specification. We also perform a sub-group analysis and show that the cost savings associated with PA are significantly larger for older and lower income populations. This study shows that if one is interested in lowering hospital expenditures then increasing PA levels is a policy that has the potential of being effective. It also shows that one does not need to target the entire population to achieve cost savings but can limit the intervention to the older population and/or the one in the lowest socioeconomic status.	[Marashi, Amir; Girosi, Federico] Western Sydney Univ, Translat Hlth Res Inst, Sydney, NSW, Australia; [Marashi, Amir; Girosi, Federico] Capital Markets CRC, Sydney, NSW, Australia; [Marashi, Amir; Girosi, Federico] Digital Hlth CRC, Sydney, NSW, Australia; [Pour, Shima Ghassem] Univ Sydney, Charles Perkins Ctr, Sydney, NSW, Australia; [Li, Vincy; Rissel, Chris] NSW Minist Hlth, Off Prevent Hlth, Sydney, NSW, Australia	Western Sydney University; University of Sydney	Marashi, A (corresponding author), Western Sydney Univ, Translat Hlth Res Inst, Sydney, NSW, Australia.; Marashi, A (corresponding author), Capital Markets CRC, Sydney, NSW, Australia.; Marashi, A (corresponding author), Digital Hlth CRC, Sydney, NSW, Australia.	amarashi@cmcrc.com	Rissel, Chris/ABA-5881-2020; Rissel, Chris/AAH-2423-2019	Rissel, Chris/0000-0002-2156-8581; Girosi, Federico/0000-0003-3937-2285	Capital Markets Cooperative Research Centre (CMCRC) Limited; Capital Markets CRC; NSW Health	Capital Markets Cooperative Research Centre (CMCRC) Limited; Capital Markets CRC(Australian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme); NSW Health	This research is funded by the Capital Markets Cooperative Research Centre (CMCRC) Limited with the following URL: https://www.cmcrc.com. The recipient of the award is AM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.r We also thank Capital Markets CRC and NSW Health for their generous support for this research.	Ai CR, 2000, J HEALTH ECON, V19, P697, DOI 10.1016/S0167-6296(00)00046-1; Amarasinghe Anura K, 2010, Cost Eff Resour Alloc, V8, P10, DOI 10.1186/1478-7547-8-10; Andreyeva Tatiana, 2006, J Phys Act Health, V3, pS6, DOI 10.1123/jpah.3.s1.s6; [Anonymous], 2018, HEALTHCARE COSTS UNS; Banks E, 2008, INT J EPIDEMIOL, V37, P941, DOI 10.1093/ije/dym184; Bishop Y. M., 2007, DISCRETE MULTIVARIAT; Buntin MB, 2004, J HEALTH ECON, V23, P525, DOI 10.1016/j.jhealeco.2003.10.005; Cobiac LJ, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000110; Diehr P, 1999, ANNU REV PUBL HEALTH, V20, P125, DOI 10.1146/annurev.publhealth.20.1.125; Ding D, 2016, LANCET, V388, P1311, DOI 10.1016/S0140-6736(16)30383-X; ELLEY CR, 2004, NZ MED J, V117, P8; Ellis RP, 2013, HEALTH ECON, V22, P1093, DOI 10.1002/hec.2916; Felder S, 2001, CARDIOVASC DRUG THER, V15, P345, DOI 10.1023/A:1012714800014; Fisher Koren L, 2015, J Aging Res, V2015, P425354, DOI 10.1155/2015/425354; Frew EJ, 2014, BRIT J SPORT MED, V48, P207, DOI 10.1136/bjsports-2012-091202; Iacus SM, 2012, POLIT ANAL, V20, P1, DOI 10.1093/pan/mpr013; Iacus SM, 2011, J AM STAT ASSOC, V106, P345, DOI 10.1198/jasa.2011.tm09599; Independent Hospital Pricing Authority, 2012, NAT EFF PRIC DET 201; Irvine KA, 2011, HETEROSKEDASTICITY R, V22, DOI 10.1071/NB10061; Irvine Katie A, 2011, N S W Public Health Bull, V22, P17, DOI 10.1071/NB10061; JENKINSON C, 1993, BRIT MED J PUBLISHIN, V306; Jones A.M., 2009, MODELS HLTH CARE; Jones AM, 2000, HANDB ECON, V17, P265; Kang SW, 2017, PREV MED, V96, P101, DOI 10.1016/j.ypmed.2016.12.043; Kardamanidis K, 2007, MED J AUSTRALIA, V187, P383, DOI 10.5694/j.1326-5377.2007.tb01306.x; Khoo J, 2018, AUST HEALTH REV, V42, P600, DOI 10.1071/AH17046; Manning WG, 2001, J HEALTH ECON, V20, P461, DOI 10.1016/S0167-6296(01)00086-8; Manning WG, 1998, J HEALTH ECON, V17, P283, DOI 10.1016/S0167-6296(98)00025-3; Manning WG, 2005, J HEALTH ECON, V24, P465, DOI 10.1016/j.jhealeco.2004.09.011; Mealing NM, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-26; Min JY, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13010136; Moran JL, 2007, J EVAL CLIN PRACT, V13, P381, DOI 10.1111/j.1365-2753.2006.00711.x; Muller-Riemenschneider F, 2009, BRIT J SPORT MED, V43, P70, DOI 10.1136/bjsm.2008.053728; Mullahy J, 1998, J HEALTH ECON, V17, P247, DOI 10.1016/S0167-6296(98)00030-7; Neuman P, 2015, HEALTH AFFAIR, V34, P335, DOI 10.1377/hlthaff.2014.1371; Peeters GMEE, 2018, J SCI MED SPORT, V21, P604, DOI 10.1016/j.jsams.2017.10.022; Productivity Commission, 2009, RES REPORT; QIN S, 2011, COMP MATCHING PROPER; Qin S., 2011, BRIT J SPORT MED; Rocca P, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2079-5; Sari N, 2011, MATURITAS, V70, P285, DOI 10.1016/j.maturitas.2011.08.004; SHAW KM, 2016, PREVENTING CHRONIC D; SIMS J, 2006, NATL PHYS ACTIVITY R, P1; Venables W.N., 2002, MODERN APPL STAT S, V4th ed., DOI [10.1007/978-0-387-21706-2, DOI 10.1007/978-0-387-21706-2]; 2003, ACTIVE AUSTR SURVEY; 2017, 6401 0 CONSUMER PRIC	46	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2019	14	6							e0218394	10.1371/journal.pone.0218394	http://dx.doi.org/10.1371/journal.pone.0218394			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW3QN	31233519	Green Submitted, Green Published, gold			2023-01-03	WOS:000484896700016
J	Godard-Sebillotte, C; Le Berre, M; Schuster, T; Trottier, M; Vedel, I				Godard-Sebillotte, Claire; Le Berre, Melanie; Schuster, Tibor; Trottier, Miguel; Vedel, Isabelle			Impact of health service interventions on acute hospital use in community-dwelling persons with dementia: A systematic literature review and meta-analysis	PLOS ONE			English	Review							EMERGENCY-DEPARTMENT USE; SELF-MANAGEMENT GROUPS; OLDER-ADULTS; ALZHEIMERS-DISEASE; RANDOMIZED-TRIAL; CARE MANAGEMENT; PEOPLE; OUTCOMES; PROGRAM; COSTS	Background Persons with dementia have twice the acute hospital use as older persons without dementia. In addition to straining overburdened healthcare systems, acute hospital use impacts patient and caregiver quality of life and is associated with increased risk of adverse outcomes including death. Reducing avoidable acute hospital use in persons with dementia is thus a global healthcare priority. However, evidence regarding the impact of health service interventions as defined by the Effective Practice and Organization of Care Cochrane Group on acute hospital use is scant and inconclusive. The aim of this systematic review and meta-analysis was to synthesize available evidence on the impact of health service interventions on acute hospital use in community-dwelling persons with dementia compared to usual care. Methods Data Sources: MEDLINE, EMBASE, CINAHL and Cochrane CENTRAL (from 01/1995 to 08/2017). Study eligibility criteria: Randomised controlled trials measuring the impact of health service interventions on acute hospital use (proportion and mean number of emergency department visits and hospitalisations, mean number of hospital days, measured at 12 months, and at longest follow-up) in community-dwelling persons with dementia, compared to usual care. Study selection, appraisal and synthesis methods: Reviewers independently identified studies, extracted data, and assessed the risk of bias, with the Cochrane risk of bias tool. Authors of relevant trials were queried about unpublished data. Random effects model was used for meta-analyses. Effect heterogeneity was assessed through prediction intervals, and explored using sub-group analyses. Findings Seventeen trials provided data on 4,549 persons. Unpublished data were obtained for 13 trials, representing 65% of synthesized data. Most interventions included a case management or a self-management component. None of the outcome comparisons provided conclusive evidence supporting the hypothesis that these interventions would lead to a decrease in acute hospital use. Furthermore, prediction intervals indicated possible and important increased service use associated with these interventions, such as emergency department visits, hospital admissions, and hospital days. Subgroup analyses did not favour any type of intervention. A limitation of this study is the inclusion of any type of health service intervention, which may have increased the observed heterogeneity. Conclusion Despite a comprehensive systematic review and meta-analysis, including predominantly unpublished data, no health service intervention beyond usual care was found to reduce acute hospital use in community-dwelling persons with dementia. An important increase in service use may be associated with these interventions. Further research is urgently needed to identify effective interventions for this vulnerable population to limit rising acute hospital use, associated costs and adverse outcomes.	[Godard-Sebillotte, Claire; Le Berre, Melanie; Schuster, Tibor; Trottier, Miguel; Vedel, Isabelle] McGill Univ, Dept Family Med, Montreal, PQ, Canada; [Le Berre, Melanie; Vedel, Isabelle] Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ, Canada; [Le Berre, Melanie] Univ Montreal, Ctr Rech Inst Univ Geriatrie Montreal, Montreal, PQ, Canada	McGill University; Lady Davis Institute; McGill University; Universite de Montreal	Godard-Sebillotte, C (corresponding author), McGill Univ, Dept Family Med, Montreal, PQ, Canada.	claire.godard-sebillotte@mail.mcgill.ca		Godard-Sebillotte, Claire/0000-0003-1477-7489; Le Berre, Melanie/0000-0002-8461-4274	Canadian Institutes of Health Research: Vanier Canada Graduate Scholarship (Vanier CGS); Canadian Institutes of Health Research: The Canadian Consortium for Neurodegeneration and Aging (CCNA); Tier II Canada Research Chair from the Canadian Institutes of Health Research	Canadian Institutes of Health Research: Vanier Canada Graduate Scholarship (Vanier CGS)(Canadian Institutes of Health Research (CIHR)); Canadian Institutes of Health Research: The Canadian Consortium for Neurodegeneration and Aging (CCNA)(Canadian Institutes of Health Research (CIHR)); Tier II Canada Research Chair from the Canadian Institutes of Health Research	Claire Godard-Sebillotte received support through a Doctoral Research Award from the Canadian Institutes of Health Research: Vanier Canada Graduate Scholarship (Vanier CGS). The work of Melanie Le Berre, Muriel Gueriton and Rebecca Rupp was funded through a research grant from the Canadian Institutes of Health Research: The Canadian Consortium for Neurodegeneration and Aging (CCNA). "Assessing care models implemented in primary health care for persons with Alzheimer's disease and related disorders". 2014-2019. Tibor Schuster received funding through a Tier II Canada Research Chair from the Canadian Institutes of Health Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alzheimer's Association, 2017, ALZHEIMERS DEMENT, V13, P325, DOI [10.1016/j.jalz.2017.02.001, DOI 10.1016/J.JALZ.2017.02.001]; Amjad H, 2018, HEALTH SERV RES, V53, P556, DOI 10.1111/1475-6773.12647; Amjad H, 2016, JAMA INTERN MED, V176, P1371, DOI 10.1001/jamainternmed.2016.3553; Bass DM, 2003, GERONTOLOGIST, V43, P73, DOI 10.1093/geront/43.1.73; Belle SH, 2006, ANN INTERN MED, V145, P727, DOI 10.7326/0003-4819-145-10-200611210-00005; Callahan CM, 2017, J AM GERIATR SOC, V65, P892, DOI 10.1111/jgs.14808; Callahan CM, 2006, JAMA-J AM MED ASSOC, V295, P2148, DOI 10.1001/jama.295.18.2148; Challis D, 2004, AGE AGEING, V33, P25, DOI 10.1093/ageing/afh007; Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457; Chien WT, 2008, PSYCHIAT SERV, V59, P433, DOI 10.1176/ps.2008.59.4.433; Chien WT, 2011, J ADV NURS, V67, P774, DOI 10.1111/j.1365-2648.2010.05537.x; Clark PA, 2004, AGING MENT HEALTH, V8, P40, DOI 10.1080/13607860310001613329; Costa AP., 2014, CLIN PRACTICE, V11, P763, DOI [DOI 10.2217/CPR.14.66, 10.2217/cpr.14.66]; Dreier A, 2016, NURS EDUC TODAY, V36, P310, DOI 10.1016/j.nedt.2015.07.024; Duru OK, 2009, AM J MANAG CARE, V15, P521; Dwan K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066844; Eloniemi-Sulkava U, 2009, J AM GERIATR SOC, V57, P2200, DOI 10.1111/j.1532-5415.2009.02564.x; Feng ZL, 2014, HEALTH AFFAIR, V33, P683, DOI 10.1377/hlthaff.2013.1179; Godard-Sebillotte C, INTERVENTIONS AIMED; Gomes B, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007760.pub2, 10.1590/1516-3180.20161341T2]; Gruneir A, 2011, MED CARE RES REV, V68, P131, DOI 10.1177/1077558710379422; Hanson LC, 2017, JAMA INTERN MED, V177, P24, DOI 10.1001/jamainternmed.2016.7031; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Holle R, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-91; IntHout J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010247; Joling KJ, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-305; Joling KJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030936; Joling Karlijn J, 2008, BMC Geriatr, V8, P2, DOI 10.1186/1471-2318-8-2; Khanassov V, 2014, ANN FAM MED, V12, P456, DOI 10.1370/afm.1677; Khanassov V, 2014, CLIN INTERV AGING, V9, P915, DOI 10.2147/CIA.S64723; Laakkonen ML, 2013, EUR GERIATR MED, V4, P389, DOI 10.1016/j.eurger.2013.09.006; Laakkonen ML, 2016, J AM GERIATR SOC, V64, P752, DOI 10.1111/jgs.14055; LaMantia MA, 2016, ALZ DIS ASSOC DIS, V30, P35, DOI 10.1097/WAD.0000000000000118; Ledgerd R, 2016, INT J GERIATR PSYCH, V31, P638, DOI 10.1002/gps.4371; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lin JS, 2012, J AM GERIATR SOC, V60, P2157, DOI 10.1111/j.1532-5415.2012.04214.x; Lin PJ, 2016, J AM GERIATR SOC, V64, P1549, DOI 10.1111/jgs.14227; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Meeuwsen EJ, 2009, J NUTR HEALTH AGING, V13, P242, DOI 10.1007/s12603-009-0066-1; Meeuwsen E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079797; Meeuwsen EJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3086; Menn P, 2012, VALUE HEALTH, V15, P851, DOI 10.1016/j.jval.2012.06.007; Mullan RJ, 2009, J CLIN EPIDEMIOL, V62, P138, DOI 10.1016/j.jclinepi.2008.08.002; Newcomer R, 1999, HEALTH CARE FINANC R, V20, P45; Nichols LO, 2017, J AM GERIATR SOC, V65, P931, DOI 10.1111/jgs.14716; Nici Linda, 2014, Ann Am Thorac Soc, V11, P101, DOI 10.1513/AnnalsATS.201306-150FR; Page MJ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000035.pub2; Pedder H, 2016, SYST REV, V5, DOI 10.1186/s13643-016-0368-4; Phelan EA, 2015, MED CARE, V53, P207, DOI 10.1097/MLR.0000000000000294; Phelan EA, 2012, JAMA-J AM MED ASSOC, V307, P165, DOI 10.1001/jama.2011.1964; Pimouguet C, 2010, J NUTR HEALTH AGING, V14, P669, DOI 10.1007/s12603-010-0314-4; Prince M., 2016, WORLD ALZHEIMER REPO; R Core Team, 2021, R LANG ENV STAT COMP; Reilly S, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008345.pub2; Richardson M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151818; Rubenstein LZ, 2007, J AM GERIATR SOC, V55, P166, DOI 10.1111/j.1532-5415.2007.01044.x; Rudolph JL, 2010, J AM GERIATR SOC, V58, P1542, DOI 10.1111/j.1532-5415.2010.02924.x; Samus QM, 2014, AM J GERIAT PSYCHIAT, V22, P398, DOI 10.1016/j.jagp.2013.12.175; Schwarzkopf L, 2011, VALUE HEALTH, V14, P827, DOI 10.1016/j.jval.2011.04.005; Shah H, 2016, LANCET NEUROL, V15, P1283, DOI 10.1016/S1474-4422(16)30235-6; Sloane PD, 2017, J AM GERIATR SOC, V65, P808, DOI 10.1111/jgs.14672; Smith SM, 2016, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006560.pub4, 10.1002/14651858.CD006560.pub3]; Sogaard R, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004105; Sogaard R, 2014, DEMENT GERIATR COGN, V37, P141, DOI 10.1159/000355368; Somme D, 2012, ALZHEIMERS DEMENT, V8, P426, DOI 10.1016/j.jalz.2011.06.004; Tam-Tham H, 2013, INT J GERIATR PSYCH, V28, P889, DOI 10.1002/gps.3906; Thyrian JR, 2017, JAMA PSYCHIAT, V74, P996, DOI 10.1001/jamapsychiatry.2017.2124; Thyrian JR, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-56; Toot S, 2013, J AM MED DIR ASSOC, V14, P463, DOI 10.1016/j.jamda.2013.01.011; Toot S, 2013, AGING MENT HEALTH, V17, P328, DOI 10.1080/13607863.2012.732037; Vickrey BG, 2006, ANN INTERN MED, V145, P713, DOI 10.7326/0003-4819-145-10-200611210-00004; Waldemar G, 2011, NEUROEPIDEMIOLOGY, V36, P52, DOI 10.1159/000322942; Wishart L, 2000, Can J Nurs Res, V31, P57; World Health Organization, 2017, WHO GLOB ACT PLAN PU; World Health Organization, 2012, DEM PUBL HLTH PRIOR; World Health Organization, 2015, EP IMP DEM CURR STAT; Wray LO, 2010, GERONTOLOGIST, V50, P623, DOI 10.1093/geront/gnq040; Zhao Y, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-108	78	11	11	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 21	2019	14	6							e0218426	10.1371/journal.pone.0218426	http://dx.doi.org/10.1371/journal.pone.0218426			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IW3PT	31226138	Green Published, gold, Green Submitted			2023-01-03	WOS:000484894700017
J	He, P; Sun, Q; Shi, LZ; Meng, QY				He, Ping; Sun, Qiang; Shi, Lizheng; Meng, Qingyue			Rational use of antibiotics in the context of China's health system reform	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							POLICY; RESISTANCE; PROVINCE; IMPACT		[He, Ping; Meng, Qingyue] Peking Univ, China Ctr Hlth Dev Studies, Beijing 100191, Peoples R China; [Sun, Qiang] Shandong Univ, Sch Hlth Care Management, Jinan 250012, Shandong, Peoples R China; [Shi, Lizheng] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA 70112 USA	Peking University; Shandong University; Tulane University	He, P (corresponding author), Peking Univ, China Ctr Hlth Dev Studies, Beijing 100191, Peoples R China.	phe@pku.edu.cn			Peking University Health Science Center	Peking University Health Science Center(Peking University)	This article is part of a series proposed by Peking University China Center for Health Development Studies and commissioned by The BMJ. The BMJ retained full editorial control over external peer review, editing, and publication of these articles. Article handling fees (including printing, distribution, and open access fees) are funded by Peking University Health Science Center.	[Anonymous], 2016, ADM CLIN US ANT AG S; Bao LD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118868; Chen MS, 2014, PHARMACOECONOMICS, V32, P245, DOI 10.1007/s40273-013-0068-z; China MoHo, 2011, NAT SPEC RECT ACT PR; Commission NHaFP, 2018, STAT REP ANT ANT RES; Cui D, 2017, J INT MED RES, V45, P1768, DOI 10.1177/0300060516686230; Dellit TH, 2007, CLIN INFECT DIS, V44, P159, DOI 10.1086/510393; Fletcher-Lartey S, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012244; Fu HQ, 2018, SOC SCI MED, V211, P114, DOI 10.1016/j.socscimed.2018.06.007; Holloway K, 2011, WORLD MED SITUATION; Liu GG, 2017, ANNU REV PUBL HEALTH, V38, P431, DOI 10.1146/annurev-publhealth-031816-044247; Lu Y, 2011, WORLD MED SITUATION; Ma XC, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l2406; Mao W, 2015, ZERO MARK UP POLICY; Mao WH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117710; Meng QY, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l2349; Qu XY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196668; Sun Q, 2008, HEALTH AFFAIR, V27, P1042, DOI 10.1377/hlthaff.27.4.1042; Sun XY, 2009, SOC SCI MED, V68, P1775, DOI 10.1016/j.socscimed.2009.02.043; Tang YQ, 2018, PHARMACOECONOMICS, V36, P995, DOI 10.1007/s40273-018-0654-1; Wang MG, 2018, CLIN INFECT DIS, V67, pS127, DOI 10.1093/cid/ciy702; Wei XL, 2017, TROP MED INT HEALTH, V22, P1166, DOI 10.1111/tmi.12922; World Health Organization, 2002, ANTITB OTHER MED PRE; World Health Organization, 2014, ANTIMICROBIAL RESIST; Xiao YH, 2018, CLIN INFECT DIS, V67, pS135, DOI 10.1093/cid/ciy641; Xiao YH, 2013, LANCET INFECT DIS, V13, P189, DOI 10.1016/S1473-3099(13)70011-2; Xie XF, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3614-8; Xue H, 2019, J ANTIMICROB CHEMOTH, V74, P256, DOI 10.1093/jac/dky390; Yang CJ, 2017, TROP MED INT HEALTH, V22, P180, DOI 10.1111/tmi.12817; Yang LP, 2013, HEALTH POLICY PLANN, V28, P750, DOI 10.1093/heapol/czs116; Yin J, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01396; Yin J, 2018, J ANTIMICROB CHEMOTH, V73, P814, DOI 10.1093/jac/dkx469; Yin XX, 2013, J ANTIMICROB CHEMOTH, V68, P2445, DOI 10.1093/jac/dkt223	33	28	31	3	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 21	2019	365								l4016	10.1136/bmj.l4016	http://dx.doi.org/10.1136/bmj.l4016			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	IF1PQ	31227479	Green Published, hybrid			2023-01-03	WOS:000472850900006
J	Awad, A; Hanna, O				Awad, Abdelmoneim; Hanna, Olivia			Potentially inappropriate medication use among geriatric patients in primary care setting: A cross-sectional study using the Beers, STOPP, FORTA and MAI criteria	PLOS ONE			English	Article							DWELLING OLDER-PEOPLE; ELDERLY-PATIENTS; SCREENING TOOL; PREVALENCE; POPULATION; OUTPATIENTS; MEDICINES; RISK; LIST; FIT	Inappropriate prescribing is a risk factor for adverse drug reactions and hospitalizations in the elderly and places a considerable burden on the healthcare system. Hence, it is imperative to identify irrational prescribing and implement interventions to improve prescribing appropriateness in geriatric clinical practice. This study aimed to determine: (i) the prevalence of potentially inappropriate medications (PIMs) according to Beers STOPP, FORTA, and the Medication Appropriateness Index (MAI) criteria; (ii) the prevalence of potential prescribing omissions (PPOs) according to START criteria; and (iii) the predictors for PIMs and PPOs. A cross-sectional study was performed among elderly outpatients of 10 primary healthcare centers with specialized geriatric clinics in Kuwait. Four-hundred and seventy-eight patients were selected randomly, 420 (87.9%) agreed to participate. Data about chronic diseases and prescribed medications were obtained from the physicians by accessing the patients' medical records. Descriptive and multivariable logistic regression were used for data analysis. A total of 2645 medications were prescribed to all patients; mean (SD) number of medicines per patient was 6.3 (3.0). PIMs were present in 53.1%, 55.7%, and 44.3% of respondents, according to Beers, STOPP, and FORTA criteria, respectively. Almost 74% of respondents had one or more inappropriate ratings among their medications in the MAI criteria. According to START criteria, 19.8% of patients had at least one PPO. Respondents taking. 5 medications were found to be using more PIMs according to Beers (OR: 6.3), STOPP (OR: 3.3), FORTA (OR: 6.0) and MAI (OR: 3.9) criteria in comparison to those taking. 4 medications (p<0.001). The MAI revealed a significantly higher number of medications with inappropriate ratings compared to the Beers, STOPP and FORTA criteria (p<0.001). Taking the MAI as reference standard, STOPP criteria had the highest sensitivity (68.6%) and measure of agreement (Kappa index = 0.40) to detect PIMs compared with Beers and FORTA criteria. Inappropriate prescribing is common among the elderly in the primary geriatric clinics. This necessitates further evaluation of its impact on clinical outcomes and warrants efforts to implement interventions to improve prescribing practice in these settings.	[Awad, Abdelmoneim; Hanna, Olivia] Kuwait Univ, Dept Pharm Practice, Fac Pharm, Kuwait, Kuwait; [Awad, Abdelmoneim; Hanna, Olivia] Kuwait Univ, Dept Pharm Practice, Fac Pharm, Kuwait, Kuwait	Kuwait University; Kuwait University	Awad, A (corresponding author), Kuwait Univ, Dept Pharm Practice, Fac Pharm, Kuwait, Kuwait.; Awad, A (corresponding author), Kuwait Univ, Dept Pharm Practice, Fac Pharm, Kuwait, Kuwait.	amoneim@hsc.edu.kw	Awad, Abdelmoneim Ismail/AAU-1963-2020	Awad, Abdelmoneim Ismail/0000-0002-2266-3687; Hanna, Olivia/0000-0003-2807-5912				Al Odhayani A, 2017, SAUDI J BIOL SCI, V24, P200, DOI 10.1016/j.sjbs.2016.05.006; Al-Omar HA, 2013, GERIATR GERONTOL INT, V13, P616, DOI 10.1111/j.1447-0594.2012.00951.x; Alhmoud E, 2015, INT J CLIN PHARM-NET, V37, P815, DOI 10.1007/s11096-015-0125-0; Bahlas SM., 2017, INT J ADV RES IJAR, V5, P540, DOI [10.21474/IJAR01/5799, DOI 10.21474/IJAR01/5799]; Baldoni AD, 2014, INT J CLIN PHARM-NET, V36, P316, DOI 10.1007/s11096-013-9880-y; Blanco-Reina E, 2014, J AM GERIATR SOC, V62, P1217, DOI 10.1111/jgs.12891; Bregnhoj L, 2007, PHARM WORLD SCI, V29, P109, DOI 10.1007/s11096-007-9108-0; Buck MD, 2009, AM J GERIATR PHARMAC, V7, P84, DOI 10.1016/j.amjopharm.2009.03.001; Castelino RL, 2010, ANN PHARMACOTHER, V44, P1922, DOI 10.1345/aph.1P373; Chen LL, 2012, INT J CLIN PHARM-NET, V34, P596, DOI 10.1007/s11096-012-9651-1; Miguel MDC, 2010, EUR GERIATR MED, V1, P9, DOI 10.1016/j.eurger.2009.12.002; Di Giorgio C, 2016, INT J CLIN PHARM-NET, V38, P462, DOI 10.1007/s11096-016-0284-7; Faustino CG, 2013, SAO PAULO MED J, V131, P19, DOI 10.1590/S1516-31802013000100004; Fu AZ, 2007, MED CARE, V45, P472, DOI 10.1097/01.mlr.0000254571.05722.34; Gallagher P, 2008, AGE AGEING, V37, P673, DOI 10.1093/ageing/afn197; Gallagher P, 2011, EUR J CLIN PHARMACOL, V67, P1175, DOI 10.1007/s00228-011-1061-0; Grina D, 2017, J CLIN PHARM THER, V42, P195, DOI 10.1111/jcpt.12494; Hamilton H, 2011, ARCH INTERN MED, V171, P1013, DOI 10.1001/archinternmed.2011.215; Hanlon J, 2013, DRUG AGING, V30, P893, DOI 10.1007/s40266-013-0118-4; Komagamine J, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021152; Kuhn-Thiel AM, 2014, DRUG AGING, V31, P131, DOI 10.1007/s40266-013-0146-0; Lai HY, 2009, CLIN THER, V31, P1859, DOI 10.1016/j.clinthera.2009.08.023; Liu CL, 2012, ARCH GERONTOL GERIAT, V55, P148, DOI 10.1016/j.archger.2011.07.001; Martins SDO, 2006, PHARM WORLD SCI, V28, P296, DOI 10.1007/s11096-006-9046-2; Michalek C, 2014, EUR J CLIN PHARMACOL, V70, P1261, DOI 10.1007/s00228-014-1731-9; Morgan Steven G, 2016, CMAJ Open, V4, pE346, DOI 10.9778/cmajo.20150131; Mucalo I, 2017, EUR J CLIN PHARMACOL, V73, P991, DOI 10.1007/s00228-017-2246-y; National Institute on Aging, 2018, WORLDS OLD POP GROWS; Nishtala PS, 2014, GERIATR GERONTOL INT, V14, P89, DOI 10.1111/ggi.12059; O'Mahony D, 2010, EUR GERIATR MED, V1, P45, DOI 10.1016/j.eurger.2010.01.007; O'Mahony D, 2015, AGE AGEING, V44, P213, DOI 10.1093/ageing/afu145; O'Sullivan DP, 2013, DRUG AGING, V30, P39, DOI 10.1007/s40266-012-0039-7; Pazan F, 2018, DRUG AGING, V35, P61, DOI 10.1007/s40266-017-0514-2; Radcliff S, 2015, J AM GERIATR SOC, V63, P2227, DOI 10.1111/jgs.13702; Raosoft, 2018, SAMPL SIZ CALC; Ryan C, 2009, BRIT J CLIN PHARMACO, V68, P936, DOI 10.1111/j.1365-2125.2009.03531.x; Saab YB, 2006, DRUG AGING, V23, P743, DOI 10.2165/00002512-200623090-00004; Sheikh-Taha M, 2017, BMC CARDIOVASC DISOR, V17, DOI 10.1186/s12872-017-0623-1; Somers A, 2013, CLIN INTERV AGING, V8, P703, DOI 10.2147/CIA.S42162; Spinewine A, 2007, LANCET, V370, P173, DOI 10.1016/S0140-6736(07)61091-5; Steinman MA, 2007, MED CARE, V45, P95, DOI 10.1097/01.mlr.0000241111.11991.62; Tommelein E, 2015, EUR J CLIN PHARMACOL, V71, P1415, DOI 10.1007/s00228-015-1954-4; Ubeda Amalia, 2012, Pharmacy Pract (Granada), V10, P83, DOI 10.4321/s1886-36552012000200004; Wawruch M, 2006, PHARMACOEPIDEM DR S, V15, P829, DOI 10.1002/pds.1290; Wickop Beate, 2016, Drugs Real World Outcomes, V3, P317; World Population Review, 2018, WORLD POP PROSP; Zeenny R, 2017, CLIN INTERV AGING, V12, P65, DOI 10.2147/CIA.S87564; Zhang XL, 2017, CLIN INTERV AGING, V12, P1697, DOI 10.2147/CIA.S146009	48	34	37	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2019	14	6							e0218174	10.1371/journal.pone.0218174	http://dx.doi.org/10.1371/journal.pone.0218174			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IC8NN	31194800	Green Published, gold, Green Submitted			2023-01-03	WOS:000471238300060
J	Herman, PM; Yuan, AH; Cefalu, MS; Chu, K; Zeng, Q; Marshall, N; Lorenz, KA; Taylor, SL				Herman, Patricia M.; Yuan, Anita H.; Cefalu, Matthew S.; Chu, Karen; Zeng, Qing; Marshall, Nell; Lorenz, Karl A.; Taylor, Stephanie L.			The use of complementary and integrative health approaches for chronic musculoskeletal pain in younger US Veterans: An economic evaluation	PLOS ONE			English	Article							LOW-BACK-PAIN; ALTERNATIVE MEDICINE USE; HIERARCHICAL LINEAR-MODELS; CARE EXPENDITURES; PROPENSITY SCORE; MASSAGE THERAPY; METAANALYSIS; COSTS; MANIPULATION; ACUPUNCTURE	Objectives To estimate the cost-effectiveness to the US Veterans Health Administration (VA) of the use of complementary and integrative health (CIH) approaches by younger Veterans with chronic musculoskeletal disorder (MSD) pain. Perspective VA healthcare system. Methods We used a propensity score-adjusted hierarchical linear modeling (HLM), and 2010-2013 VA administrative data to estimate differences in VA healthcare costs, pain intensity (0-10 numerical rating scale), and opioid use between CIH users and nonusers. We identified CIH use in Veterans' medical records through Current Procedural Terminology, VA workload tracking, and provider-type codes. Results We identified 30,634 younger Veterans with chronic MSD pain as using CIH and 195,424 with no CIH use. CIH users differed from nonusers across all baseline covariates except the Charlson comorbidity index. They also differed on annual pre-CIH-start healthcare costs ($10,729 versus $5,818), pain (4.33 versus 3.76), and opioid use (66.6% versus 54.0%). The HLM results indicated lower annual healthcare costs (-$637; 95% CI: -$1,023, -$247), lower pain (-0.34; -0.40, -0.27), and slightly higher (less than a percentage point) opioid use (0.8; 0.6, 0.9) for CIH users in the year after CIH start. Sensitivity analyses indicated similar results for three most-used CIH approaches (acupuncture, chiropractic care, and massage), but higher costs for those with eight or more CIH visits. Conclusions On average CIH use appears associated with lower healthcare costs and pain and slightly higher opioid use in this population of younger Veterans with chronic musculoskeletal pain. Given the VA's growing interest in the use of CIH, further, more detailed analyses of its impacts are warranted.	[Herman, Patricia M.; Cefalu, Matthew S.] RAND Corp, Santa Monica, CA 90401 USA; [Yuan, Anita H.; Chu, Karen; Taylor, Stephanie L.] VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Innovat Implementat & Policy, Los Angeles, CA USA; [Zeng, Qing] VA Washington DC Healthcare Syst, Ctr Hlth & Aging, Washington, DC USA; [Zeng, Qing] George Washington Univ, Biomed Informat Ctr, Washington, DC USA; [Marshall, Nell; Lorenz, Karl A.] VA Palo Alto Healthcare Syst, Ctr Study Innovat Implementat, Menlo Pk, CA USA; [Lorenz, Karl A.] Stanford Sch Med, Palo Alto, CA USA; [Taylor, Stephanie L.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90024 USA	RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; George Washington University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; University of California System; University of California Los Angeles	Herman, PM (corresponding author), RAND Corp, Santa Monica, CA 90401 USA.	pherman@rand.org	TAYLOR, STEPHANIE/GYV-4768-2022	Taylor, Stephanie/0000-0002-3266-1132; Herman, Patricia/0000-0001-5579-5654	Department of Veterans Affairs, Health Services Research and Development Service [1 R01 HX001704-1]	Department of Veterans Affairs, Health Services Research and Development Service(US Department of Veterans Affairs)	All authors were funded under a grant provided by the Department of Veterans Affairs, Health Services Research and Development Service, 1 R01 HX001704-1, Principal Investigator: Dr. Stephanie L Taylor. https://www.research.va.gov/services/hsrd.cfm. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agency for Healthcare Research and Quality, 2016, APP C CLIN CLASS SOF; [Anonymous], 2018, AHRQ PUB, V18-0033-EF; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; Avogo W, 2008, HEALTH EDUC J, V67, P258, DOI 10.1177/0017896908097069; Bolton JE, 1998, J MANIP PHYSIOL THER, V21, P1; Boyd C, 2016, PAIN MED, V17, P1553, DOI 10.1093/pm/pnw100; Bureau of Labor Statistics, 2013, CONS PRIC IND; Caspi O, 2004, MED DECIS MAKING, V24, P64, DOI 10.1177/0272989X03261567; Chou R, 2017, ANN INTERN MED, V166, P493, DOI 10.7326/M16-2459; Clare HA, 2004, AUST J PHYSIOTHER, V50, P209, DOI 10.1016/S0004-9514(14)60110-0; Coulter ID, 2018, SPINE J, V18, P866, DOI 10.1016/j.spinee.2018.01.013; Coulter ID, 2018, PAIN PHYS; Cramer H, 2013, CLIN J PAIN, V29, P450, DOI 10.1097/AJP.0b013e31825e1492; Crawford C, 2016, PAIN MED, V17, P1353, DOI 10.1093/pm/pnw099; Cui DW, 2014, PROCEEDINGS OF THE 21ST INTERNATIONAL CONFERENCE ON NUCLEAR ENGINEERING - 2013, VOL 3; Denneson LM, 2011, J REHABIL RES DEV, V48, P1119, DOI 10.1682/JRRD.2010.12.0243; Diagnosis and Treatment of Low Back Pain Work Group, 2017, VA DOD CLIN PRACT GU; DOWNIE WW, 1978, ANN RHEUM DIS, V37, P378, DOI 10.1136/ard.37.4.378; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; FELDMAN HA, 1988, J APPL PHYSIOL, V64, P1721, DOI 10.1152/jappl.1988.64.4.1721; Furlan AD, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/953139; Furlan AD, 2009, SPINE, V34, P1669, DOI 10.1097/BRS.0b013e3181ad7bd6; Gironda RJ, 2007, J REHABIL RES DEV, V44, P223, DOI 10.1682/JRRD.2006.06.0058; Goulet JL, 2016, PAIN, V157, P1696, DOI 10.1097/j.pain.0000000000000567; Grieves B, 2009, J MANIP PHYSIOL THER, V32, P734, DOI 10.1016/j.jmpt.2009.10.001; Haas M, 2014, SPINE J, V14, P1106, DOI 10.1016/j.spinee.2013.07.468; Hadlandsmyth K, 2018, J GEN INTERN MED, V33, P818, DOI 10.1007/s11606-017-4283-8; Haskell SG, 2006, J WOMENS HEALTH, V15, P862, DOI 10.1089/jwh.2006.15.862; Healthcare Analysis & Information Group, 2015, FY 2015 VHA COMPL IN; Healthcare Analysis & Information Group, 2011, 2011 COMPL ALT MED S; Healthcare Analysis & Information Group, 2002, SURV COMPL ALT MED; Heo M, 2003, STAT MED, V22, P1911, DOI 10.1002/sim.1218; Herman PM, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001046; Hilton L, 2017, ANN BEHAV MED, V51, P199, DOI 10.1007/s12160-016-9844-2; Imai K, 2014, J R STAT SOC B, V76, P243, DOI 10.1111/rssb.12027; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; Johnson ML, 2009, VALUE HEALTH, V12, P1062, DOI 10.1111/j.1524-4733.2009.00602.x; Kerns RD, 2003, J REHABIL RES DEV, V40, P371, DOI 10.1682/JRRD.2003.09.0371; Kerns RD, 2009, PAIN MED, V10, P1161, DOI 10.1111/j.1526-4637.2009.00722.x; Lam M, 2013, SPINE, V38, P2124, DOI 10.1097/01.brs.0000435025.65564.b7; Legorreta AP, 2004, ARCH INTERN MED, V164, P1985, DOI 10.1001/archinte.164.18.1985; Lind BK, 2010, J ALTERN COMPLEM MED, V16, P411, DOI 10.1089/acm.2009.0261; Lorenz KA, 2009, J AM BOARD FAM MED, V22, P291, DOI 10.3122/jabfm.2009.03.080162; Macey TA, 2011, PAIN MED, V12, P1502, DOI 10.1111/j.1526-4637.2011.01226.x; Machlin SR, 2018, CHARACTERISTICS HLTH; Martin BI, 2012, MED CARE, V50, P1029, DOI 10.1097/MLR.0b013e318269e0b2; McCaffrey DF, 2004, PSYCHOL METHODS, V9, P403, DOI 10.1037/1082-989X.9.4.403; McEachrane-Gross F Patricia, 2006, BMC Complement Altern Med, V6, P34, DOI 10.1186/1472-6882-6-34; Midboe AM, 2012, TRANSL BEHAV MED, V2, P57, DOI 10.1007/s13142-011-0104-5; Moritz S, 2011, J ALTERN COMPLEM MED, V17, P1015, DOI 10.1089/acm.2010.0619; National Pain Management Coordinating Committee, 2000, PAIN 5 VIT SIGN TOOL; O'Connell AA, 2004, EVAL HEALTH PROF, V27, P119, DOI 10.1177/0163278704264049; Owens JE, 1999, J ALTERN COMPLEM MED, V5, P529, DOI 10.1089/acm.1999.5.529; Perlman AI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030248; Phibbs CS, 2003, MED CARE RES REV, V60, p54S, DOI 10.1177/1077558703256725; Posadzki P, 2011, CLIN RHEUMATOL, V30, P1257, DOI 10.1007/s10067-011-1764-8; Qaseem A, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16-2367; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Raudenbush S. W., 2002, HIERARCHICAL LINEAR; Rickhi B, 2003, CAN J PSYCHIAT, V48, P475, DOI 10.1177/070674370304800708; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Schwehr NA, 2018, ACUPUNCT MED; Sherman KJ, 2014, ANN FAM MED, V12, P112, DOI 10.1370/afm.1602; Singer JD, 1998, J EDUC BEHAV STAT, V23, P323; Sirois FM, 2002, J ALTERN COMPLEM MED, V8, P127, DOI 10.1089/107555302317371415; Smith M.W., 2010, FEE BASIS DATA GUIDE; Sparber A, 2002, J ALTERN COMPLEM MED, V8, P93, DOI 10.1089/107555302753507230; Swartzman LC, 2002, MED DECIS MAKING, V22, P431, DOI 10.1177/027298902236943; Taylor SL, 2019, J ALTERN COMPLEM MED, V25, P32, DOI 10.1089/acm.2018.0276; Thorne S, 2002, INT J NURS STUD, V39, P671, DOI 10.1016/S0020-7489(02)00005-6; Tian TY, 2013, J AM MED INFORM ASSN, V20, pE275, DOI 10.1136/amiajnl-2013-001856; VA Health Care, 2017, WHOL HLTH LIF EXP VA; VA Health Care, 2018, ENR PRIOR GROUPS WHA; Veterans Health Administration (VHA), 2017, CORP DAT WAR CDW; VHA Office of Patient Centered Care and Cultural Transformation, 2017, WHOL HLTH ITS ALL YO; Wagner TH, 2003, MED CARE RES REV, V60, p15S, DOI 10.1177/1077558703256485; Williamson E, 2012, STAT METHODS MED RES, V21, P273, DOI 10.1177/0962280210394483; Wootton JC, 2001, J ALTERN COMPLEM MED, V7, P715, DOI 10.1089/10755530152755270; Yu W, 2003, MED CARE RES REV, V60, p146S, DOI 10.1177/1077558703257000	79	13	13	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 5	2019	14	6							e0217831	10.1371/journal.pone.0217831	http://dx.doi.org/10.1371/journal.pone.0217831			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IB2GN	31167005	Green Published, Green Submitted, gold			2023-01-03	WOS:000470087800042
J	Kaplan, WA; Cardenas, J; Mansilla, C; Tobar, T; Wirtz, VJ				Kaplan, Warren A.; Cardenas, Jorge; Mansilla, Cristian; Tobar, Tatiana; Wirtz, Veronika J.			The implementation of the bioequivalence certification policy in Chile: An analysis of market authorization data	PLOS ONE			English	Article							GENERIC MEDICINES; COUNTRIES	Background Affordability is a key barrier to access to medicines. Generic medicines policies can address this barrier and promote access. Successful uptake of generic medicines depends, in part, on ensuring that these products are interchangeable with reference products. Typically, bioequivalence certification is established in order to demonstrate such interchangeability. Objective To study the implementation of the bioequivalence certification policy in Chile. Methods We used Chilean Market Regulatory Authority data for analysis to study the number of products that obtained bioequivalence certification, the time until bioequivalence certification and associated factors to obtain bioequivalence. Results As of January 2017, out of 2,336 products with a valid market authorization containing at least one of the 167 APIs that required BE certification, 1,026 products actually have BE certification (1,026/ 2,336, 43.9% compliance). Where data were available, the time between submission of the market authorization as a bioequivalent product to final authorization by the national medicine regulatory authority for most products varied between 4-6 months. The fraction of all BE products containing a given API out of the total marketed products containing that API varies considerably, e.g. for the API olmesartan there was only a single BE product marketed, the API diclofenac had none. Conclusions Although the implementation of Chile's bioequivalence policy increased the number of bioequivalent products, over 50% of generic products requiring bioequivalence that did not obtain this certification. Also for some of the API none or very few BE products are marketed which limits the success of a substitution policy. Further studies are required to identify the apparent lack of incentives to obtain bioequivalence certification. Studies of sales volumes and prices of the products are needed to identify whether generic products without bioequivalence certification either become bioequivalent or eventually exit the market.	[Kaplan, Warren A.; Wirtz, Veronika J.] Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA 02215 USA; [Cardenas, Jorge; Mansilla, Cristian; Tobar, Tatiana] Minist Hlth Santiago, Santiago, Chile	Boston University	Wirtz, VJ (corresponding author), Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA 02215 USA.	vwirtz@bu.edu	Wirtz, Veornika/AAG-9712-2019	Kaplan, Warren/0000-0001-6127-4820; Wirtz, Veronika J./0000-0002-0863-8768; Mansilla, Cristian/0000-0003-2377-0094	Pan American Health Organization (PAHO); Alliance for Health Policy and Systems Research; Norwegian Government Agency for Development Cooperation (Norad); Swedish International Development Cooperation Agency (Sida); UK Department for International Development (DFID)	Pan American Health Organization (PAHO); Alliance for Health Policy and Systems Research; Norwegian Government Agency for Development Cooperation (Norad); Swedish International Development Cooperation Agency (Sida); UK Department for International Development (DFID)	This is work undertaken under the auspices of the embedded implementation research initiative supported by the Pan American Health Organization (PAHO) and the Alliance for Health Policy and Systems Research, an international partnership hosted by the World Health Organization (WHO), with support from the Norwegian Government Agency for Development Cooperation (Norad: https://norad.no/en/front/), the Swedish International Development Cooperation Agency (Sidahttps://www.sida.se/English/) and the UK Department for International Development (DFID: https://www.gov.uk/government/organisations/department-for-international-development).The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cameron A, 2009, LANCET, V373, P240, DOI 10.1016/S0140-6736(08)61762-6; Cristian Mansilla, BMJ GLOB HEALTH, DOI [10.1136/bmjgh-2018-000922, DOI 10.1136/BMJGH-2018-000922]; da Fonseca EM, 2015, REV PANAM SALUD PUBL, V37, P113; da Fonseca EM, 2014, POLICY SOC, V33, P65, DOI 10.1016/j.polsoc.2014.03.004; Dylst P, 2013, EXPERT REV PHARM OUT, V13, P59, DOI [10.1586/ERP.12.83, 10.1586/erp.12.83]; European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP), 2010, CPMPEWPQWP140198; Fiscalia Nacional Economica Santiago Chile, 2013, STUD EFF BIOEQ PEN G; Fonseca EM, 2016, REV PANAM SALUD PUBL, V41, P1; Gomes Barra AC, 2011, J GENERIC MED, V2, P72, DOI DOI 10.1177/1741134311411266; Gonzalez C., 2008, J GENERIC MED, V6, P43; Gonzalez PE, 2011, WORKING HLTH POPULAT; Hill S., 2004, EMERGING CHALLENGES; Homedes N, 2005, B WORLD HEALTH ORGAN, V83, P64; Kaplan WA, 2012, HEALTH POLICY, V106, P211, DOI 10.1016/j.healthpol.2012.04.015; Moise P, 2007, OECD HLTH WORKING PA; Moye-Holz D, 2017, GLOBALIZATION HEALTH, V13, DOI 10.1186/s12992-017-0281-1; Organisation for Economic Co-operation and Development, 2014, DAFCOMPGFWD20143 ORG, P3; Shadlen KC, 2013, POLIT SOC, V41, P561, DOI 10.1177/0032329213507552; Storpirtis S, 2014, PHARM POLICY LAW, V16, P22; US Food and Drug Administration, 2018, APPR PROD THER EQ OR; Vogler S, 2012, GABI J, V1, P93, DOI 10.5639/gabij.2012.0102.020; WHO Expert Committee on Specifications for Pharmaceutical Preparations, 40 WHO; World Health Organization, QUAL ASS MED TERM DA; 2006, WHO TECHN REP SER, V936, P1	24	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2019	14	5							e0217334	10.1371/journal.pone.0217334	http://dx.doi.org/10.1371/journal.pone.0217334			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IA1LO	31141565	Green Published, gold, Green Submitted			2023-01-03	WOS:000469323000050
J	Banierink, H; ten Duis, K; de Vries, R; Wendt, K; Heineman, E; Reininga, I; IJpma, F				Banierink, Hester; ten Duis, Kaj; de Vries, Rob; Wendt, Klaus; Heineman, Erik; Reininga, Inge; IJpma, Frank			Pelvic ring injury in the elderly: Fragile patients with substantial mortality rates and long-term physical impairment	PLOS ONE			English	Article							FUNCTION ASSESSMENT QUESTIONNAIRE; FRACTURES; EPIDEMIOLOGY; VALIDITY	Background Pelvic ring injuries in the elderly often occur after low-energy accidents. They may result in prolonged immobilization, complications and an intense rehabilitation process. The aim of this study was to assess mortality, physical functioning and quality of life (QoL) in elderly patients with pelvic ring injuries. Methods A cross-sectional study was performed including all elderly patients (. 65 years) admitted for a pelvic ring injury between 2007-2016. Mortality and survival were evaluated and patient reported outcome measures (PROMs) were used to assess physical functioning (SMFA) and QoL (EQ-5D). These were compared to age-matched normative data from the general Dutch population. Results A total of 153 patients, with a mean age of 79 years (SD 8) at the time of injury, were included in this study. The mortality rate was 20% at 30 days, 27% at 1 year and 41% at 3 years of follow-up. All six patients with a type C fracture died within 30 days. Analyses of the 153 patients showed that increasing age, fracture type C and Injury Severity Score (ISS) were all independent risk factors for mortality. Eventually, after excluding patients that died (N = 78) or were unable to contact (N = 2), 73 patients were eligible for follow-up, of which 53 patients (73%) responded. Mean Short Musculoskeletal Function Assessment (SMFA) scores were respectively 67.4 (function index), 65.2 (bother index), 66.5 (lower extremity), 60.4 (activities of daily living) and 68.2 (emotion). Mean EuroQuol-5D (EQ-5D) score was 0.72. Overall, physical functioning and quality of life were significantly decreased in comparison with normative data from the general population. Conclusion Elderly people who sustain a pelvic ring injury should be considered as a fragile population with substantial mortality rates. The patients who survived demonstrated a substantially lower level of physical functioning and quality of life in comparison with their age-matched peers from the general population.	[Banierink, Hester; ten Duis, Kaj; de Vries, Rob; Wendt, Klaus; Reininga, Inge; IJpma, Frank] Univ Groningen, Univ Med Ctr Groningen, Dept Trauma Surg, Groningen, Netherlands; [Wendt, Klaus; Reininga, Inge] Northern Netherlands Trauma Registry, Emergency Care Network Northern Netherlands AZNN, Groningen, Netherlands; [Heineman, Erik] Univ Groningen, Univ Med Ctr Groningen, Dept Surg, Groningen, Netherlands	University of Groningen; University of Groningen	Banierink, H (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Trauma Surg, Groningen, Netherlands.	h.banierink@umcg.nl	Heineman, Erik/ABG-9592-2021; IJpma, Frank/AAH-6350-2019; Reininga, Inge H.F./H-4250-2013	Reininga, Inge H.F./0000-0003-1341-845X				AO/OTA, 2018, J ORTHOP TRAUMA, V32; Balogh Z, 2007, J TRAUMA, V63, P1066, DOI 10.1097/TA.0b013e3181589fa4; Bible JE, 2013, ORTHOPEDICS, V36, P760, DOI 10.3928/01477447-20130523-21; Butler M, 2011, J BONE JOINT SURG AM, V93A, P1104, DOI [10.2106/JBJSJ.00296, 10.2106/JBJS.J.00296]; Centraal Bureau voor de Statistiek, 2018, LEV GESL LEEFT JAAR; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Clement Nicholas D, 2014, Eur J Orthop Surg Traumatol, V24, P1431, DOI 10.1007/s00590-014-1439-7; Court-Brown CM, 2006, INJURY, V37, P691, DOI 10.1016/j.injury.2006.04.130; de Graaf MW, 2015, QUAL LIFE RES, V24, P2015, DOI 10.1007/s11136-015-0929-3; de Vries R., 2018, AV TECHN INT OP C 20, P1; Dechert TA, 2009, AM SURGEON, V75, P291; Forni C, 2018, INT ORTHOP, P15; Giesbers H, 2013, WAT ZIJN BELANGRIJKS; Kannus P, 2000, OSTEOPOROSIS INT, V11, P443, DOI 10.1007/s001980070112; MELTON LJ, 1981, CLIN ORTHOP RELAT R, P43; Morris RO, 2000, POSTGRAD MED J, V76, P646, DOI 10.1136/pmj.76.900.646; Mundi S, 2014, ACTA ORTHOP, V85, P54, DOI 10.3109/17453674.2013.878831; Osterhoff G, 1994, PRAXIS, V40, P1195; Reininga IHF, 2012, INJURY, V43, P726, DOI 10.1016/j.injury.2011.07.013; Schmitz P, 2018, INT ORTHOP; Soles GLS, 2012, CURR REV MUSCULOSKE, V5, P222, DOI 10.1007/s12178-012-9128-9; Studer P, 2013, SWISS MED WKLY, V143, DOI 10.4414/smw.2013.13859; Swiontkowski MF, 1999, J BONE JOINT SURG AM, V81A, P1245, DOI 10.2106/00004623-199909000-00006; Tile M., 2015, THIEME; van Dijk WA, 2010, INJURY, V41, P411, DOI 10.1016/j.injury.2009.12.014; Verbeek Diederik O, 2018, Eur J Orthop Surg Traumatol, V28, P197, DOI 10.1007/s00590-017-2044-3; Versteegh MM, 2016, VALUE HEALTH, V19, P343, DOI 10.1016/j.jval.2016.01.003	27	17	22	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2019	14	5							e0216809	10.1371/journal.pone.0216809	http://dx.doi.org/10.1371/journal.pone.0216809			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IA0CM	31136589	Green Published, Green Submitted, gold			2023-01-03	WOS:000469224300010
J	Thee, S; Kruger, R; von Bernuth, H; Meisel, C; Kolsch, U; Kirchberger, V; Feiterna-Sperling, C				Thee, Stephanie; Krueger, Renate; von Bernuth, Horst; Meisel, Christian; Koelsch, Uwe; Kirchberger, Valerie; Feiterna-Sperling, Cornelia			Screening and treatment for tuberculosis in a cohort of unaccompanied minor refugees in Berlin, Germany	PLOS ONE			English	Article							LATENT TUBERCULOSIS; PREVENTIVE THERAPY; ISONIAZID HEPATOTOXICITY; CHRONIC HEPATITIS; SEEKING ASYLUM; LIVER-INJURY; INFECTION; RIFAMPIN; CHEMOPROPHYLAXIS; CHILDHOOD	Introduction In 2015, 4062 unaccompanied minor refugees were registered in Berlin, Germany. According to national policies, basic clinical examination and tuberculosis (TB) screening is a prerequisite to admission to permanent accommodation and schooling for every refugee. This article evaluates the use of an interferon-gamma-release-assay (IGRA) during the initial examination and TB screening of 970 unaccompanied minor refugees. Results IGRA test were obtained during TB screening for 301 (31.0%) of 970 adolescents not previously screened for TB. Positive IGRA results were obtained in 13.9% (42/301). Most of the 42 IGRA-positive refugees originated from Afghanistan or Syria (n?20 and 10 respectively). Two IGRA-positive adolescents were lost to follow-up, 2 were diagnosed with TB and the remaining 38 diagnosed with latent TB infection (LTBI). Demographic features of the 40 patients with positive IGRA result were as follows: 39 male, median age 16.8 years (IQR 16.0-17.2y), none meeting underweight criteria (median BMI 21.3kg/m(2)). On initial chest X-ray 2/40 participants had signs of active TB, while in 38 active disease was excluded and the diagnosis of latent TB infection (LTBI) made. Active hepatitis B-co-infection was diagnosed in 3/38 patients. All patients with LTBI received Isoniazid and Rifampicin for 3 months without occurrence of severe adverse events. The most frequently observed side effect was transient upper abdominal pain (n = 5). Asymptomatic elevation of liver transaminases was seen in 2 patients. 29 patients completed treatment with no signs of TB disease at the end of chemoprevention and 9 were lost to follow up. Conclusion Screening for TB infection in minor refugees was feasible in our setting with a relatively high rate of TB infection detected. Chemopreventive treatment was tolerated well regardless of underlying hepatitis-B-status. Minor refugees migrating to Germany should be screened for TB infection, instead of TB disease only, regardless of the background TB incidence.	[Thee, Stephanie; Krueger, Renate; von Bernuth, Horst; Kirchberger, Valerie; Feiterna-Sperling, Cornelia] Charite, Dept Pediat, Div Pneumonol & Immunol Intens Med, Berlin, Germany; [von Bernuth, Horst; Meisel, Christian; Koelsch, Uwe] Charite Vivantes GmbH, Dept Immunol, Lab Berlin, Berlin, Germany; [von Bernuth, Horst] Charite, Berlin Ctr Regenerat Therapies, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Labor Berlin - Charite Vivantes GmbH; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Thee, S (corresponding author), Charite, Dept Pediat, Div Pneumonol & Immunol Intens Med, Berlin, Germany.	Stephanie.thee@charite.de	von Bernuth, Horst/AAQ-9797-2021; von Bernuth, Horst/ABD-7779-2020	von Bernuth, Horst/0000-0002-5812-7675; Feiterna-Sperling, Cornelia/0000-0003-4171-1098; Thee, Stephanie/0000-0001-9090-7869; Meisel, Christian/0000-0003-0222-991X	Department of Immunology, Labor Berlin, Charite Vivantes GmbH, Germany	Department of Immunology, Labor Berlin, Charite Vivantes GmbH, Germany	The funder (Department of Immunology, Labor Berlin, Charite Vivantes GmbH, Germany) provided support in the form of salaries for authors [HvB, CM, UK], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abubakar I, 2008, ARCH DIS CHILD, V93, P1017, DOI 10.1136/adc.2008.139543; [Anonymous], 2017, FUBALL TALENTE DEUTS; BEAUDRY PH, 1974, AM REV RESPIR DIS, V110, P581; Bennet R, 2017, INFECT DIS-NOR, V49, P501, DOI 10.1080/23744235.2017.1292540; Bliven EE, 2009, INT J TUBERC LUNG D, V13, P1054; Borrell S, 2010, CLIN MICROBIOL INFEC, V16, P568, DOI 10.1111/j.1469-0691.2009.02886.x; Cookson ST, 2015, CONFL HEALTH, V9, DOI 10.1186/s13031-015-0044-7; DASH LA, 1980, AM REV RESPIR DIS, V121, P1039; Donald PR, 2011, PEDIATRIC REP, V3, P51, DOI 10.4081/pr.2011.e16; Ena J, 2005, CLIN INFECT DIS, V40, P670, DOI 10.1086/427802; Feiterna-Sperling C, 2017, PNEUMOLOGIE, V71, P629, DOI 10.1055/s-0043-116545; Gray EL, 2016, INTERN MED J, V46, P281, DOI 10.1111/imj.12979; Greenaway C, 2018, EUROSURVEILLANCE, V23, P24, DOI 10.2807/1560-7917.ES.2018.23.14.17-00543; Kunst H, 2017, INT J TUBERC LUNG D, V21, P840, DOI 10.5588/ijtld.17.0036; LITT IF, 1976, J PEDIATR-US, V89, P133, DOI 10.1016/S0022-3476(76)80949-3; Menzies D, 2018, NEW ENGL J MED, V379, P440, DOI 10.1056/NEJMoa1714283; Miyazawa S, 2015, INTERNAL MED, V54, P591, DOI 10.2169/internalmedicine.54.3669; Mueller-Hermelink M, 2018, EUROSURVEILLANCE, V23, P4, DOI 10.2807/1560-7917.ES.2018.23.12.17-00536; RAPP RS, 1978, AM REV RESPIR DIS, V118, P794, DOI 10.1164/arrd.1978.118.4.794; Rendon A, 2018, PULMONOLOGY, V24, P99, DOI 10.1016/j.rppnen.2017.11.007; Ritz N, 2015, LANCET, V386, P2475, DOI 10.1016/S0140-6736(15)01241-6; Ritz N, 2015, MONATSSCHR KINDERH, V163, P1287, DOI 10.1007/s00112-015-0007-5; SPYRIDIS P, 1979, ARCH DIS CHILD, V54, P65, DOI 10.1136/adc.54.1.65; Thee S., 2015, 33 ANN M EUR SOC PAE; Theuring S, 2016, EUR J EPIDEMIOL, V31, P707, DOI 10.1007/s10654-016-0187-x; Usemann J, 2018, 40 JAHR GES PAD PNEU; Villarino ME, 1997, AM J RESP CRIT CARE, V155, P1735, DOI 10.1164/ajrccm.155.5.9154885; Wang NT, 2016, J CHIN MED ASSOC, V79, P368, DOI 10.1016/j.jcma.2015.12.006; World Health Organization, 2011, ANNEX C WHO REG GROU; World Health Organization, GROWTH REF 5 19 YEAR; World Health Organization, TUB COUNTR PROF 2018; World Health Organization, 2018, LAT TB INF UPD CONS; Zenner D, 2017, INT J TUBERC LUNG D, V21, P965, DOI 10.5588/ijtld.16.0935; Zenner D, 2017, ANN INTERN MED, V167, P248, DOI 10.7326/M17-0609; Zenner D, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02505-2016; Zenner D, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.TNMI7-0031-2016	36	12	12	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2019	14	5							e0216234	10.1371/journal.pone.0216234	http://dx.doi.org/10.1371/journal.pone.0216234			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY9HS	31112542	Green Published, gold, Green Submitted			2023-01-03	WOS:000468451000013
J	Butowski, CF; Thomas, DG; Young, W; Cave, NJ; McKenzie, CM; Rosendale, DI; Bermingham, EN				Butowski, Christina F.; Thomas, David G.; Young, Wayne; Cave, Nick J.; McKenzie, Catherine M.; Rosendale, Douglas I.; Bermingham, Emma N.			Addition of plant dietary fibre to a raw red meat high protein, high fat diet, alters the faecal bacteriome and organic acid profiles of the domestic cat (Felis catus)	PLOS ONE			English	Article							BUTYRATE-PRODUCING BACTERIA; END-PRODUCT CONCENTRATIONS; GUT MICROBIOTA; NUTRIENT DIGESTIBILITY; ENERGY; FERMENTATION; POPULATIONS; METABOLISM; DOGS; NUTRITION	Commercial diets high in animal protein and fat are increasingly being developed for pets, however little is understood about the impacts of feeding such diets to domestic cats. The carbohydrate content of these diets is typically low, and dietary fibre is often not included. Dietary fibre is believed to be important in the feline gastrointestinal tract, promoting stool formation and providing a substrate for the hindgut microbiome. Therefore, we aimed to determine the effects of adding plant-based dietary fibre to a high animal protein and fat diet. Twelve domestic short hair cats were fed three complete and balanced diets in a crossover design for blocks of 21 days: raw meat (Raw), raw meat plus fibre (2%, 'as is' inclusion of inulin and cellulose; Raw+Fibre) and a commercially available Kibble diet. A commercially available canned diet was fed for 21 days as a washout phase. Apparent macronutrient digestibility, faecal output, score, pH, organic acid concentrations and bacteriome profiles were determined. Diet significantly affected all faecal parameters measured. The addition of dietary fibre to the raw meat diet was found to reduce apparent macronutrient digestibility, increase faecal output, pH and score. Thirty one bacterial taxa were significantly affected by diet. Prevotella was found to dominate in the Kibble diet, Clostridium and Fusobacterium in the Raw diet, and Prevotella and a group of unclassified Peptostreptococcaceae in the Raw +Fibre diet. Our results show that diets of different macronutrient proportions can strongly influence the faecal microbiome composition and metabolism, as shown by altered organic acid concentrations and faecal pH, in the domestic cat. The addition of 2% of each fibre to the Raw diet shifted faecal parameters closer to those produced by feeding a Kibble diet. These results provide a basis for further research assessing raw red meat diets to domestic cats.	[Butowski, Christina F.; Young, Wayne; Bermingham, Emma N.] AgRes Grasslands, Food & Biobased Prod, Palmerston North, New Zealand; [Butowski, Christina F.; Thomas, David G.; Cave, Nick J.] Massey Univ, Ctr Feline Nutr, Palmerston North, New Zealand; [Young, Wayne] Massey Univ, Riddet Inst, Palmerston North, New Zealand; [Young, Wayne; Bermingham, Emma N.] High Value Nutr Natl Sci Challenge, Auckland, New Zealand; [McKenzie, Catherine M.] AgRes Grasslands, Knowledge & Analyt, Palmerston North, New Zealand; [Rosendale, Douglas I.] New Zealand Inst Plant & Food Res Ltd, Palmerston North, New Zealand	AgResearch - New Zealand; Massey University; Massey University; AgResearch - New Zealand; New Zealand Institute for Plant & Food Research Ltd	Bermingham, EN (corresponding author), AgRes Grasslands, Food & Biobased Prod, Palmerston North, New Zealand.; Bermingham, EN (corresponding author), High Value Nutr Natl Sci Challenge, Auckland, New Zealand.	emma.bermingham@agresearch.co.nz	Cave, Nick/AAQ-9789-2021; Rosendale, Doug/E-4938-2010	Rosendale, Doug/0000-0001-9561-335X; Young, Wayne/0000-0003-0464-2062; Butowski, Christina/0000-0002-3165-5988	New Zealand Government (Ministry of Business, Innovation and Employment) [C10X1501]; New Zealand Premium Pet Food Alliance (K9 Natural); New Zealand Premium Pet Food Alliance (ZiwiPeak); New Zealand Premium Pet Food Alliance (Bombay PetFoods(TM) Ltd)	New Zealand Government (Ministry of Business, Innovation and Employment); New Zealand Premium Pet Food Alliance (K9 Natural); New Zealand Premium Pet Food Alliance (ZiwiPeak); New Zealand Premium Pet Food Alliance (Bombay PetFoods(TM) Ltd)	This project was funded by the New Zealand Government (Ministry of Business, Innovation and Employment: C10X1501), awarded to ENB and co-funded by the New Zealand Premium Pet Food Alliance (K9 Natural, ZiwiPeak and Bombay PetFoods (TM) Ltd). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Association of Cereal Chemists, 2001, DEF DIET FIBR, V46; Barcenilla A, 2000, APPL ENVIRON MICROB, V66, P1654, DOI 10.1128/AEM.66.4.1654-1661.2000; Barry KA, 2010, J ANIM SCI, V88, P2978, DOI 10.2527/jas.2009-2464; Barry KA, 2012, J PROTEOME RES, V11, P5924, DOI 10.1021/pr3006809; Beloshapka AN, 2013, FEMS MICROBIOL ECOL, V84, P532, DOI 10.1111/1574-6941.12081; Bermingham EN, 2013, J ANIM PHYSIOL AN N, V97, P522, DOI 10.1111/j.1439-0396.2012.01293.x; Bermingham EN, 2017, PEERJ, V5, DOI 10.7717/peerj.3019; Bermingham EN, 2013, MICROBIOLOGYOPEN, V2, P173, DOI 10.1002/mbo3.60; Blake AB, 2016, ANIM FRONT, V6, P37, DOI 10.2527/af.2016-0032; Bourriaud C, 2005, J APPL MICROBIOL, V99, P201, DOI 10.1111/j.1365-2672.2005.02605.x; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; CHERBUT C, 1998, AM J PHYSIOL-GASTR L, V275, pG141; CLARKE KR, 1993, AUST J ECOL, V18, P117, DOI 10.1111/j.1442-9993.1993.tb00438.x; Crissey SD, 1997, J ANIM SCI, V75, P2154; De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107; De Vadder F, 2016, CELL METAB, V24, P151, DOI 10.1016/j.cmet.2016.06.013; den Besten G, 2013, J LIPID RES, V54, P2325, DOI 10.1194/jlr.R036012; Den Hond E, 2000, NUTR RES, V20, P731, DOI 10.1016/S0271-5317(00)00162-7; Depauw S, 2013, J ANIM PHYSIOL AN N, V97, P146, DOI 10.1111/j.1439-0396.2011.01252.x; Deusch O, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144881; DeVries JW, 2003, P NUTR SOC, V62, P37, DOI 10.1079/PNS2002234; Donohoe DR, 2011, CELL METAB, V13, P517, DOI 10.1016/j.cmet.2011.02.018; Duncan SH, 2004, BRIT J NUTR, V91, P915, DOI 10.1079/BJN20041150; Duncan SH, 2004, APPL ENVIRON MICROB, V70, P5810, DOI 10.1128/AEM.70.10.5810-5817.2004; Earle K E, 1998, J Nutr, V128, p2798S, DOI 10.1093/jn/128.12.2798S; Fadrosh DW, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-6; FEDIAF, 2016, SCI IND 2016; Felix AP, 2013, ANIM FEED SCI TECH, V184, P86, DOI 10.1016/j.anifeedsci.2013.05.013; Flint HJ, 2012, NAT REV GASTRO HEPAT, V9, P577, DOI 10.1038/nrgastro.2012.156; GenStat, 2020, GENSTAT WINDOWS, V9th ed.; Gibson GR, 2004, NUTR RES REV, V17, P259, DOI 10.1079/NRR200479; GIBSON GR, 1995, GASTROENTEROLOGY, V108, P975, DOI 10.1016/0016-5085(95)90192-2; Hamper BA, 2016, J FELINE MED SURG, V18, P991, DOI 10.1177/1098612X15605535; Heimann E, 2016, ADIPOCYTE, V5, P359, DOI 10.1080/21623945.2016.1252011; HILLMAN L, 1983, BRIT J NUTR, V50, P189, DOI 10.1079/BJN19830088; Hooda S, 2013, BRIT J NUTR, V109, P1637, DOI 10.1017/S0007114512003479; Kageyama A, 2000, INT J SYST EVOL MICR, V50, P1595, DOI 10.1099/00207713-50-4-1595; Kanakupt K, 2011, J ANIM SCI, V89, P1376, DOI 10.2527/jas.2010-3201; Kerr KR, 2014, J NUTR SCI, V3, DOI 10.1017/jns.2014.21; Kerr KR, 2013, J ANIM SCI, V91, P2199, DOI 10.2527/jas.2012-5702; Kerr KR, 2012, J ANIM SCI, V90, P515, DOI 10.2527/jas.2010-3266; Kienzle E, 1998, J ANIM PHYSIOL AN N, V79, P46, DOI 10.1111/j.1439-0396.1998.tb00628.x; Kimura I, 2011, P NATL ACAD SCI USA, V108, P8030, DOI 10.1073/pnas.1016088108; Kruse HP, 1999, BRIT J NUTR, V82, P375, DOI 10.1017/S0007114599001622; Le Cao K.H., 2016, MIXOMICS OMICS DATA; Levine UY, 2013, APPL ENVIRON MICROB, V79, P3879, DOI 10.1128/AEM.00589-13; Louis P, 2007, J APPL MICROBIOL, V102, P1197, DOI 10.1111/j.1365-2672.2007.03322.x; Loureiro BA, 2016, J ANIMAL PHYSL ANIMA; Lubbs DC, 2009, J ANIM PHYSIOL AN N, V93, P113, DOI 10.1111/j.1439-0396.2007.00788.x; MEAD GC, 1971, J GEN MICROBIOL, V67, P47, DOI 10.1099/00221287-67-1-47; Middelbos IS, 2007, J ANIM SCI, V85, P3033, DOI 10.2527/jas.2007-0080; Moxham G., 2001, WALTHAM FOCUS, V11, P24; National Research Council, 2006, NUTR REQ DOGS CATS; Pet Food Industry, 2016, PET FOOD TRENDS UPD; Plantinga EA, 2011, BRIT J NUTR, V106, pS35, DOI 10.1017/S0007114511002285; R-Core-Team, 2016, LANG ENV STAT COMP; Reichardt N, 2014, ISME J, V8, P1323, DOI 10.1038/ismej.2014.14; RICHARDSON AJ, 1989, LETT APPL MICROBIOL, V9, P5, DOI 10.1111/j.1472-765X.1989.tb00278.x; Ritchie LE, 2010, VET MICROBIOL, V144, P140, DOI 10.1016/j.vetmic.2009.12.045; Rochus K, 2014, NUTR RES REV, V27, P295, DOI 10.1017/S0954422414000213; ROGOSA M, 1971, International Journal of Systematic Bacteriology, V21, P234; ROGOSA M, 1971, International Journal of Systematic Bacteriology, V21, P187; Salvetti E, 2011, INT J SYST EVOL MICR, V61, P2520, DOI 10.1099/ijs.0.029231-0; Scott KP, 2008, NUTR BULL, V33, P201, DOI 10.1111/j.1467-3010.2008.00706.x; Shetty SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079353; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; SUNVOLD GD, 1995, J ANIM SCI, V73, P2329; Van Soest P.J., 1994, NUTR ECOLOGY RUMINAN; Verbeke KA, 2015, NUTR RES REV, V28, P42, DOI 10.1017/S0954422415000037; Vital M, 2014, MBIO, V5, DOI 10.1128/mBio.00889-14	70	23	23	1	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2019	14	5							e0216072	10.1371/journal.pone.0216072	http://dx.doi.org/10.1371/journal.pone.0216072			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW0KS	31042730	Green Published, gold, Green Submitted			2023-01-03	WOS:000466370200053
J	Assalin, HB; Gontijo, JAR; Boer, PA				Assalin, Heloisa Balan; Rocha Gontijo, Jose Antonio; Boer, Patricia Aline			miRNAs, target genes expression and morphological analysis on the heart in gestational protein-restricted offspring	PLOS ONE			English	Article							KETONE-BODY METABOLISM; BARDET-BIEDL-SYNDROME; RECEPTOR KINASE 2; CATCH-UP GROWTH; MATERNAL UNDERNUTRITION; INSULIN-RESISTANCE; PRENATAL EXPOSURE; MICRORNA TARGETS; CARDIAC FIBROSIS; BLOOD-PRESSURE	Gestational protein restriction was associated with low birth weight, hypertension and higher prevalence of cardiac disorders in adults. Several mechanisms, including epigenetics, could be related with the cardiovascular phenotype on protein-restricted offspring. Thus, we investigated the morphological cardiac effects of gestational protein restriction and left ventricle miRNAs and target genes expression pattern in both 12-day and 16-week old gestational protein-restricted male offspring. Pregnant Wistar rats were allocated into two groups, according to protein supply during pregnancy: NP (normal protein diet-17%) or LP (low protein diet-6%). Dams on the gestational protein-restricted diet had lower body weight gain and higher food intake. Gestational protein-restricted offspring had low birth weight, followed by rapidly body weight recovery, hypertension, and increased myocytes cross-sectional area and collagen fraction at 16-week old age. At 12-days old, miR-184, miR-192, miR-376c, miR-380-3p, miR-380-5p, miR-451, and miR-582-3p had increased expression, and miR-547 and miR-743a had decreased expression in the gestational protein-restricted left ventricle. At 16-week old, let-7b, miR-125a-3p, miR-142-3p, miR-182 and miR-188-5p had increased expression and let-7g, miR-107, miR-127, miR-181a, miR-181c, miR-184, miR-324-5p, miR-383, miR-423-5p and miR-484 had decreased expression in gestational protein-restricted left ventricle. Target predicted gene expression analysis showed higher expression of Dnmt3a, Oxct1, Rictor and Trps1 and lower expression of Bbs1 and Calml3 in 12-day old protein-restricted offspring. 16-week old protein-restricted offspring had higher expression of Adrbk1, Bbs1, Dnmt3a, Gpr22, Inppl1, and Oxct1 genes. In conclusion, gestational protein restriction was related to offspring low birth weight, increased systolic blood pressure and morphological heart alterations that could be related to early heart miRNA expression changes that perpetuate into adulthood and which are associated with the regulation of essential genes involved in cardiovascular development, heart morphology, function, and metabolism.	[Assalin, Heloisa Balan; Rocha Gontijo, Jose Antonio; Boer, Patricia Aline] Univ Estadual Campinas, Sch Med, Internal Med Dept, Sao Paulo, Brazil	Universidade Estadual de Campinas	Boer, PA (corresponding author), Univ Estadual Campinas, Sch Med, Internal Med Dept, Sao Paulo, Brazil.	alineboer@yahoo.com.br	Boer, Patricia Aline/E-2551-2013; Assalin, Heloisa Balan H/F-5933-2016; Boer, Patrícia A/P-4435-2014; Gontijo, José/AAW-2644-2021	Boer, Patricia Aline/0000-0002-1196-2606; Assalin, Heloisa Balan H/0000-0003-1269-9624; Gontijo, Jose/0000-0002-4658-385X	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [2013/12486-5]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [9128/12-3]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (2013/12486-5); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES; 9128/12-3); and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq).	Ahuja P, 2007, PHYSIOL REV, V87, P521, DOI 10.1152/physrev.00032.2006; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Badano JL, 2006, ANNU REV GENOM HUM G, V7, P125, DOI 10.1146/annurev.genom.7.080505.115610; Barker DJP, 2010, EUR J HEART FAIL, V12, P819, DOI 10.1093/eurjhf/hfq069; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brenner B M, 1993, Curr Opin Nephrol Hypertens, V2, P691; Briffa JF, 2015, AM J PHYSIOL-ENDOC M, V308, pE335, DOI 10.1152/ajpendo.00312.2014; Bubb KJ, 2007, J PHYSIOL-LONDON, V578, P871, DOI 10.1113/jphysiol.2006.121160; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Catalucci D, 2009, CIRC-CARDIOVASC GENE, V2, P402, DOI 10.1161/CIRCGENETICS.109.857425; Chamson-Reig A, 2009, EXP BIOL MED, V234, P1425, DOI 10.3181/0902-RM-69; Chang TC, 2007, ANNU REV GENOM HUM G, V8, P215, DOI 10.1146/annurev.genom.8.080706.092351; Cheema KK, 2005, BRIT J NUTR, V93, P471, DOI 10.1079/BJN20041392; Chomczynski P, 2006, NAT PROTOC, V1, P581, DOI 10.1038/nprot.2006.83; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Corstius HB, 2005, PEDIATR RES, V57, P796, DOI 10.1203/01.PDR.0000157726.65492.CD; Cotter DG, 2013, AM J PHYSIOL-HEART C, V304, pH1060, DOI 10.1152/ajpheart.00646.2012; Cotter DG, 2011, J BIOL CHEM, V286, P6902, DOI 10.1074/jbc.M110.192369; de Franca SA, 2009, NUTRITION, V25, P1186, DOI 10.1016/j.nut.2009.03.011; Desai M, 1996, BRIT J NUTR, V76, P591, DOI 10.1079/BJN19960065; Dyson JM, 2005, INT J BIOCHEM CELL B, V37, P2260, DOI 10.1016/j.biocel.2005.05.003; Dyson JM, 2001, J CELL BIOL, V155, P1065, DOI 10.1083/jcb.200104005; ELBEDOUR K, 1994, AM J MED GENET, V52, P164, DOI 10.1002/ajmg.1320520208; Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427; Fagerberg B, 2004, J INTERN MED, V256, P254, DOI 10.1111/j.1365-2796.2004.01361.x; Fernandez-Twinn DS, 2006, AM J PHYSIOL-REG I, V291, pR429, DOI 10.1152/ajpregu.00608.2005; Gambacciani C, 2014, MICRORNA DIAGN THER, DOI [10.2478/micrnat-2013-0004, DOI 10.2478/MICRNAT-2013-0004]; Garcia-Guerra L, 2010, DIABETES, V59, P2407, DOI 10.2337/db10-0771; Gilsbach R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6288; GIRARD J, 1992, PHYSIOL REV, V72, P507, DOI 10.1152/physrev.1992.72.2.507; Haggarty P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068896; Hemachandra AH, 2007, PEDIATRICS, V119, pE1264, DOI 10.1542/peds.2005-2486; HOLSON RR, 1995, NEUROTOXICOL TERATOL, V17, P393, DOI 10.1016/0892-0362(94)00074-N; Huang ZM, 2014, ANTIOXID REDOX SIGN, V21, P2032, DOI 10.1089/ars.2014.5876; Izzo R, 2008, CTS-CLIN TRANSL SCI, V1, P215, DOI 10.1111/j.1752-8062.2008.00050.x; Jackson AA, 2002, CLIN SCI, V103, P633, DOI 10.1042/cs1030633; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Lall S, 2006, CURR BIOL, V16, P460, DOI 10.1016/j.cub.2006.01.050; LangleyEvans SC, 1997, J HYPERTENS, V15, P537, DOI 10.1097/00004872-199715050-00010; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LEVER AF, 1992, J HYPERTENS, V10, P101, DOI 10.1097/00004872-199202000-00001; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim KJ, 2006, PEDIATR RES, V60, P83, DOI 10.1203/01.pdr.0000220361.08181.c3; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Menendez-Castro C, 2014, PEDIATR RES, V75, P697, DOI 10.1038/pr.2014.27; Mesquita FF, 2010, BRAZ J MED BIOL RES, V43, P1010, DOI [10.1590/S0100-879X2010007500113, 10.1590/S0100-879X2010001100001]; Mesquita FF, 2010, NEPHROL DIAL TRANSPL, V25, P380, DOI 10.1093/ndt/gfp505; NAKAZONO K, 1991, P NATL ACAD SCI USA, V88, P10045, DOI 10.1073/pnas.88.22.10045; Nilsen TW, 2007, TRENDS GENET, V23, P243, DOI 10.1016/j.tig.2007.02.011; ONG KK, BMJ, V320, P967; Pang WW, 2017, J NUTR, V147, P653, DOI 10.3945/jn.116.243881; Prasad N, 2001, MOL CELL BIOL, V21, P1416, DOI 10.1128/MCB.21.4.1416-1428.2001; Reczko M, 2012, BIOINFORMATICS, V28, P771, DOI 10.1093/bioinformatics/bts043; Romaine SPR, 2015, HEART, V101, P921, DOI 10.1136/heartjnl-2013-305402; Roseboom TJ, 2000, HEART, V84, P595, DOI 10.1136/heart.84.6.595; Schugar RC, 2014, MOL METAB, V3, P754, DOI 10.1016/j.molmet.2014.07.010; Sene LD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071310; Seo SJ, 2009, HUM MOL GENET, V18, P1323, DOI 10.1093/hmg/ddp031; Small EM, 2011, NATURE, V469, P336, DOI 10.1038/nature09783; Starks RD, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005311; Stewart PM, 1995, J STEROID BIOCHEM, V55, P465, DOI 10.1016/0960-0760(95)00195-6; Tao H, 2014, TOXICOLOGY, V323, P42, DOI 10.1016/j.tox.2014.06.006; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; van Rooij E, 2008, P NATL ACAD SCI USA, V105, P13027, DOI 10.1073/pnas.0805038105; van Rooij E, 2006, P NATL ACAD SCI USA, V103, P18255, DOI 10.1073/pnas.0608791103; VANDERVUSSE GJ, 1992, PHYSIOL REV, V72, P881, DOI 10.1152/physrev.1992.72.4.881; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Vlachos IS, 2013, CLIN BIOCHEM, V46, P879, DOI 10.1016/j.clinbiochem.2013.03.006; VOMSAAL FS, 1981, J REPROD FERTIL, V62, P633, DOI [10.1530/jrf.0.0620633, 10.1530/jrf.0.0620033]; WEBER KT, 1993, CARDIOVASC RES, V27, P341, DOI 10.1093/cvr/27.3.341; WHITE BD, 1994, J NUTR, V124, P1152, DOI 10.1093/jn/124.8.1152; Woodall MC, 2014, CIRC RES, V114, P1661, DOI 10.1161/CIRCRESAHA.114.300513; Xu Y, 2006, FASEB J, V20, P1251, DOI 10.1096/fj.05-4917fje; Zhang YJ, 2014, RNA, V20, P1878, DOI 10.1261/rna.045633.114; Zhao Y, 2007, TRENDS BIOCHEM SCI, V32, P189, DOI 10.1016/j.tibs.2007.02.006; Zohdi V, 2015, NUTRIENTS, V7, P119, DOI 10.3390/nu7010119; [No title captured], DOI DOI 10.1210/JC.2002-030031; 2011, CARDIOGENETICS, V1, P24, DOI DOI 10.1038/EJHG.2012.145	82	9	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2019	14	4							e0210454	10.1371/journal.pone.0210454	http://dx.doi.org/10.1371/journal.pone.0210454			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV6ZL	31034522	Green Submitted, Green Published, gold			2023-01-03	WOS:000466131200004
J	Matsuno, AK; Gagliardi, TB; Paula, FE; Luna, LKS; Jesus, BLS; Stein, RT; Aragon, DC; Carlotti, APCP; Arruda, E				Matsuno, Alessandra K.; Gagliardi, Talita B.; Paula, Flavia E.; Luna, Luciano K. S.; Jesus, Bruna L. S.; Stein, Renato T.; Aragon, Davi C.; Carlotti, Ana P. C. P.; Arruda, Eurico			Human coronavirus alone or in co-infection with rhinovirus C is a risk factor for severe respiratory disease and admission to the pediatric intensive care unit: A one-year study in Southeast Brazil	PLOS ONE			English	Article							SYNCYTIAL VIRUS; CHILDREN; INFECTIONS	Objective We aimed to assess the profile of respiratory viruses in young children hospitalized for acute lower respiratory tract infection (ALRI) and its association with disease severity, defined as need for pediatric intensive care unit (PICU) admission. Design Prospective observational cohort study. Setting A tertiary-care university hospital in Brazil. Patients Children younger than three years attending the pediatric emergency room with ALRI who were admitted to the hospital. Interventions None. Measurements and main results Nasopharyngeal aspirates were collected from patients from June 1 st, 2008 to May 31 st, 2009within the first 48 hours of hospitalization. Nasopharyngeal aspirates were tested for 17humanrespiratory viruses by molecular and immunofluorescence based assays. Simple and multiple log-binomial regression models were constructed to assess associations of virus type with a need for PICU admission. Age, prematurity, the presence of an underlying disease and congenital heart disease were covariates. Nasopharyngeal aspirates were positive for at least one virus in 236 patients. Rhinoviruses were detected in 85.6% of samples, with a preponderance of rhinovirus C (RV-C) (61.9%). Respiratory syncytial virus was detected in 59.8% and human coronavirus (HCoV) in 11% of the samples. Co-detections of two to five viruses were found in 78% of the patients. The detection of HCoV alone (adjusted relative risk (RR) 2.18; 95% CI 1.15-4.15) or in co-infection with RV-C (adjusted RR 2.37; 95% CI 1.23-4.58) was independently associated with PICU admission. Conclusions The detection of HCoV alone or in co-infection with RV-C was independently associated with PICU admission in young children hospitalized for ALRI.	[Matsuno, Alessandra K.; Aragon, Davi C.; Carlotti, Ana P. C. P.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Ribeirao Preto, Brazil; [Gagliardi, Talita B.; Paula, Flavia E.; Luna, Luciano K. S.; Jesus, Bruna L. S.; Arruda, Eurico] Univ Sao Paulo, Dept Cell Biol, Ribeirao Preto Med Sch, Ribeirao Preto, Brazil; [Gagliardi, Talita B.; Paula, Flavia E.; Luna, Luciano K. S.; Jesus, Bruna L. S.; Arruda, Eurico] Univ Sao Paulo, Virol Res Ctr, Ribeirao Preto Med Sch, Ribeirao Preto, Brazil; [Stein, Renato T.] Pontificia Univ Catolica Rio Grande do Sul, Dept Pediat, Sch Med, Porto Alegre, RS, Brazil	Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); Universidade de Sao Paulo; Universidade de Sao Paulo; Pontificia Universidade Catolica Do Rio Grande Do Sul	Matsuno, AK (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Ribeirao Preto, Brazil.	matsuno@fmrp.usp.br	Carlotti, Ana PCP/G-4893-2012; de Souza Luna, Luciano Kleber/L-1213-2013; de Souza Luna, Luciano Kleber/AAG-6418-2019; Matsuno, Alessandra Kimie/H-9507-2012; Casale Aragon, Davi/R-6604-2016	Carlotti, Ana PCP/0000-0003-2760-8801; de Souza Luna, Luciano Kleber/0000-0002-3552-5507; de Souza Luna, Luciano Kleber/0000-0002-3552-5507; Matsuno, Alessandra Kimie/0000-0002-3491-1641; Arruda, Eurico/0000-0002-0978-410X; STEIN, RENATO/0000-0003-0269-0757; Sasahara, Kazutoshi/0000-0003-2572-0648; MATSUO, Akiko/0000-0002-6293-5501; Casale Aragon, Davi/0000-0003-1019-3654	Abbott Laboratorios do Brasil Ltda; Sao Paulo State Research Foundation (FAPESP); FAEPA - Fundacao de Apoio ao Ensino Pesquisa e Assistencia" ("Foundation of Support to Teaching Research and Assistance) of the University of Sao Paulo Hospital of Ribeirao Preto; Brazilian Research Council (CNPq)	Abbott Laboratorios do Brasil Ltda; Sao Paulo State Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); FAEPA - Fundacao de Apoio ao Ensino Pesquisa e Assistencia" ("Foundation of Support to Teaching Research and Assistance) of the University of Sao Paulo Hospital of Ribeirao Preto; Brazilian Research Council (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	AKM and EAN supported mainly by an academic grant from Abbott Laboratorios do Brasil Ltda based on an unrestricted investigatorgenerated proposal. EAN Additional funding was provided by a grant from the Sao Paulo State Research Foundation (FAPESP) and by FAEPA - Fundacao de Apoio ao Ensino Pesquisa e Assistencia"(in English would be "Foundation of Support to Teaching Research and Assistance) of the University of Sao Paulo Hospital of Ribeirao Preto. EA has long standing scholarship support from the Brazilian Research Council (CNPq). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arruda E, 2014, PEDIATR INFECT DIS J, V33, P997, DOI 10.1097/INF.0000000000000349; Cebey-Lopez M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152481; Chu HY, 2016, J PEDIAT INF DIS SOC, V5, P29, DOI 10.1093/jpids/piu099; Cintra OAL, 2001, J MED VIROL, V65, P408, DOI 10.1002/jmv.2049; Costa LF, 2014, PEDIATRICS, V133, pE312, DOI 10.1542/peds.2013-2216; De Luca M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154662; Luna LKD, 2007, J CLIN MICROBIOL, V45, P1049, DOI 10.1128/JCM.02426-06; Fawkner-Corbett DW, 2016, J MED VIROL, V88, P58, DOI 10.1002/jmv.24300; Kelesidis T, 2016, INFECT CONT HOSP EP, V37, P70, DOI 10.1017/ice.2015.226; Lauinger IL, 2013, J CLIN VIROL, V58, P216, DOI 10.1016/j.jcv.2013.06.042; Lee WM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000966; Lee WM, 2012, AM J RESP CRIT CARE, V186, P886, DOI 10.1164/rccm.201202-0330OC; Legg JP, 2005, PEDIATR INFECT DIS J, V24, P611, DOI 10.1097/01.inf.0000168747.94999.aa; Do LAH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160606; Miyaji Y, 2013, MICROBIOL IMMUNOL, V57, P811, DOI 10.1111/1348-0421.12102; Nathan AM, 2017, PEDIAT RESPIROL CRIT, V1, P46, DOI DOI 10.4103/PRCM.PRCM_2_17; Proenca-Modena JL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042136; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Renwick N, 2007, J INFECT DIS, V196, P1754, DOI 10.1086/524312; Scotta MC, 2016, J CLIN VIROL, V80, P45, DOI 10.1016/j.jcv.2016.04.019; Sonego M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116380; Varghese L, 2018, J PEDIAT INF DIS SOC, V7, P151, DOI 10.1093/jpids/pix027; Walsh EE., 2015, MANDELL BENNETTS PRI, V8th ed., P1948; Wishaupt JO, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2118-6; Zhang SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033773	26	29	31	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2019	14	6							e0217744	10.1371/journal.pone.0217744	http://dx.doi.org/10.1371/journal.pone.0217744			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IA9ZE	30908489	gold, Green Published, Green Submitted			2023-01-03	WOS:000469915700024
J	Matsuoi, A; Sasahara, K; Taguchi, Y; Karasawa, M				Matsuoi, Akiko; Sasahara, Kazutoshi; Taguchi, Yasuhiro; Karasawa, Minoru			Development and validation of the Japanese Moral Foundations Dictionary	PLOS ONE			English	Article								The Moral Foundations Dictionary (MFD) is a useful tool for applying the conceptual framework developed in Moral Foundations Theory and quantifying the moral meanings implicated in the linguistic information people convey. However, the applicability of the MFD is limited because it is available only in English. Translated versions of the MFD are therefore needed to study morality across various cultures, including non-Western cultures. The contribution of this paper is two-fold. We developed the first Japanese version of the MFD (referred to as the J-MFD) using a semi-automated method-this serves as a reference when translating the MFD into other languages. We next tested the validity of the J-MFD by analyzing open-ended written texts about the situations that Japanese participants thought followed and violated the five moral foundations. We found that the J-MFD correctly categorized the Japanese participants' descriptions into the corresponding moral foundations, and that the Moral Foundations Questionnaire (MFQ) scores correlated with the frequency of situations, of total words, and of J-MFD words in the participants' descriptions for the Harm and Fairness foundations. The J-MFD can be used to study morality unique to the Japanese and also multicultural comparisons in moral behavior.	[Matsuoi, Akiko] Nagoya Univ, Grad Sch Environm Studies, Dept Psychol, Nagoya, Aichi, Japan; [Sasahara, Kazutoshi] Nagoya Univ, Grad Sch Informat, Dept Complex Syst Sci, Nagoya, Aichi, Japan; [Taguchi, Yasuhiro] Aichi Univ, Sch Letters, Dept Humanities & Social Sci, Toyohashi, Aichi, Japan; [Karasawa, Minoru] Nagoya Univ, Grad Sch Informat, Dept Cognit & Psychol Sci, Nagoya, Aichi, Japan; [Sasahara, Kazutoshi] JST, PRESTO, Kawaguchi, Saitama, Japan	Nagoya University; Nagoya University; Nagoya University; Japan Science & Technology Agency (JST)	Sasahara, K (corresponding author), Nagoya Univ, Grad Sch Informat, Dept Complex Syst Sci, Nagoya, Aichi, Japan.; Sasahara, K (corresponding author), JST, PRESTO, Kawaguchi, Saitama, Japan.	sasahara@nagoya-u.jp	Carlotti, Ana PCP/G-4893-2012; de Souza Luna, Luciano Kleber/L-1213-2013; de Souza Luna, Luciano Kleber/AAG-6418-2019; Matsuno, Alessandra Kimie/H-9507-2012; Casale Aragon, Davi/R-6604-2016	Carlotti, Ana PCP/0000-0003-2760-8801; de Souza Luna, Luciano Kleber/0000-0002-3552-5507; de Souza Luna, Luciano Kleber/0000-0002-3552-5507; Matsuno, Alessandra Kimie/0000-0002-3491-1641; Arruda, Eurico/0000-0002-0978-410X; STEIN, RENATO/0000-0003-0269-0757; Sasahara, Kazutoshi/0000-0003-2572-0648; MATSUO, Akiko/0000-0002-6293-5501; Casale Aragon, Davi/0000-0003-1019-3654	JSPS/MEXT KAKENHI [15H03446, JP17H06383, 4903]; JST PRESTO [JPMJPR16D6]; JST CREST [JPMJCR17A4]	JSPS/MEXT KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); JST PRESTO(Japan Science & Technology Agency (JST)); JST CREST(Japan Science & Technology Agency (JST)Core Research for Evolutional Science and Technology (CREST))	This research was supported by JSPS/MEXT KAKENHI Grant Numbers 15H03446 and JP17H06383 in #4903, JST PRESTO Grant Number JPMJPR16D6, and JST CREST Grant Number JPMJCR17A4. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bulbulia J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080224; Clifford S, 2015, BEHAV RES METHODS, V47, P1178, DOI 10.3758/s13428-014-0551-2; Davis D, 2015, J PERS SOC PSYCHOL, V110, P56; Dehghani M, 2017, BEHAV RES METHODS, V49, P538, DOI 10.3758/s13428-016-0722-4; Dehghani M, 2016, J EXP PSYCHOL GEN, V145, P366, DOI 10.1037/xge0000139; Fulgoni D, 2016, LREC 2016 - TENTH INTERNATIONAL CONFERENCE ON LANGUAGE RESOURCES AND EVALUATION, P3730; GOOLSBY JR, 1992, J MARKETING, V56, P55, DOI 10.2307/1252132; Graham J, 2011, J PERS SOC PSYCHOL, V101, P366, DOI 10.1037/a0021847; Graham J, 2009, J PERS SOC PSYCHOL, V96, P1029, DOI 10.1037/a0015141; Haidt J, 2001, PSYCHOL REV, V108, P814, DOI 10.1037//0033-295X.108.4.814; Haidt J., 2015, VOLKSWAGEN MORAL PSY; Haidt J, 2008, PERSPECT PSYCHOL SCI, V3, P65, DOI 10.1111/j.1745-6916.2008.00063.x; Henrich J, 2010, NATURE, V466, P29, DOI 10.1038/466029a; Honda S., 2017, B FACULTY ED YAMAGUC, V66, P95; Ji QH, 2015, MEDIA PSYCHOL, V18, P221, DOI 10.1080/15213269.2014.956939; Johnson KA, 2016, PERS INDIV DIFFER, V100, P56, DOI 10.1016/j.paid.2015.12.037; Jones D, 2010, SCIENCE, V328, P1627, DOI 10.1126/science.328.5986.1627; Kanai R., 2013, NOU NI KIZAMARETA MO; Kaur R, 2016, 2016 IEEE INTERNATIONAL CONFERENCE ON BIG DATA (BIG DATA), P2505, DOI 10.1109/BigData.2016.7840889; LaBouff JP, 2017, ARCH PSYCHOL RELIG, V39, P263, DOI 10.1163/15736121-12341343; Maekawa K, 2014, LANG RESOUR EVAL, V48, P345, DOI 10.1007/s10579-013-9261-0; Matsumoto K, 2005, P ASS NAT LANG PROC, P145; Mooijman M, 2017, J PERSONALITY SOCIAL; Pennebaker J. W., 2001, MAHWAY LAWRENCE ERLB; Piazza J, 2018, SOCIAL PSYCHOL PERSO, P1; Reed A, 2007, J MARKETING, V71, P178, DOI 10.1509/jmkg.71.1.178; Sagi E, 2014, SOC SCI COMPUT REV, V32, P132, DOI 10.1177/0894439313506837; Takamatsu R., 2017, JPN J INTERPERS SOC, V17, P93; Yilmaz O, 2016, PERS INDIV DIFFER, V99, P149, DOI 10.1016/j.paid.2016.04.090	29	29	31	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2019	14	3							e0213343	10.1371/journal.pone.0213343	http://dx.doi.org/10.1371/journal.pone.0213343			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HQ1KV	30908489	Green Submitted, Green Published, gold			2023-01-03	WOS:000462157600010
